

<++++NEW DOCUMENT++++>
DOCUMENT URI:file:/Users/phyllis/git/hw1-mpzhu/hw1-mpzhu/src/main/resources/data/sample.in

P00001606T0076 |0 10|ComparisonP00001606T
P00001606T0076 |42 56|5-nucleotidaseosphatases and
P00001606T0076 |16 37|alkaline phosphatasesomparison with alkali
P00008171T0000 |34 52|hyperbilirubinemiaaline phosphatases
P00008171T0000 |14 21|aspects Compar
P00008997A0472 |169 174|slope3-] i
P00008997A0472 |75 79|rats0081
P00008997A0472 |31 39|functionalkaline
P00008997A0472 |10 14|HCO30076
P00008997A0472 |56 60|data 5-n
P00008997A0472 |121 129|controlshyperbil
P00008997A0472 |43 51|CSF PCO2sphatase
P00008997A0472 |5 8|CSF160
P00010943A0733 |0 10|FlurazepamP00001606T
P00010943A0733 |122 127|nightyperb
P00010943A0733 |74 78|dose0008
P00010943A0733 |83 86|use000
P00010943A0733 |52 56|drug and
P00010943A0733 |98 106|practiceic aspec
P00010943A0733 |116 118|mgat
P00012653T0045 |0 4|BetaP000
P00012653T0045 |14 20|agents Compa
P00013683A0210 |20 31|CO2 removalrison with 
P00013683A0210 |61 65|VCO2cleo
P00013683A0210 |45 59|CO2 productionhatases and 5-
P00013683A0210 |77 88|ventilation8171T0000 P
P00015731A0090 |102 118|dichlorphenamidespects of neonat
P00015731A0090 |158 162|riseen C
P00015731A0090 |219 220|p 
P00015731A0090 |265 270|bloodcompa
P00015731A0090 |120 129|sulthiame hyperbil
P00015731A0090 |31 36|mg/kgalkal
P00015731A0090 |250 252|pHdi
P00015731A0090 |228 233|p CO2ed ra
P00015731A0090 |72 85|acetazolamideP00008171T000
P00015731A0090 |50 70|anhydrase inhibitorses and 5-nucleotidas
P00015731A0090 |87 100|methazolamidePharmacologic
P00015731A0090 |12 26|administration76 Comparison 
P00015731A0090 |207 215|increase the dat
P00015731A0090 |175 176|p 
P00015731A0090 |238 246|decreasee no lon
P00022143T0000 |50 56|rabbites and
P00022143T0000 |14 19|study Comp
P00022143T0000 |42 45|ratosp
P00022143T0000 |23 34|etoperidoneon with alk
P00023348A0601 |11 17|polyps076 Co
P00024600A0522 |103 117|dosage regimenpects of neona
P00024600A0522 |13 31|HMG dosage regimen6 Comparison with 
P00024600A0522 |54 64|advantagesnd 5-nucle
P00025557A0100 |34 35|%a
P00025557A0100 |40 47|animalsphospha
P00025557A0100 |72 83|body weightP00008171T0
P00025557A0100 |9 20|CO2 contentT0076 Compa
P00027739T0000 |0 31|Serum gamma glutamyltransferaseP00001606T0076 Comparison with 
P00027739T0000 |39 48|diagnosis phosphat
P00027739T0000 |52 65|liver disease and 5-nucleo
P00027739T0000 |69 75|cattlese P00
P00027967A0207 |117 126|formationtal hyper
P00027967A0207 |149 159|antibodies7A0472 Whe
P00027967A0207 |75 82|illness008171T
P00027967A0207 |23 36|HI antibodieson with alkal
P00027967A0207 |97 105|patientsgic aspe
P00027967A0207 |176 182|levelsshown 
P00027967A0207 |192 196|daysion 
P00027967A0207 |212 219|illnessdata of
P00027967A0207 |203 208|onsetPCO2 
P00027967A0207 |66 71|onsetidase
P00027967A0207 |3 11|contrast001606T0
P00029555A0861 |38 50|quantitatione phosphatas
P00029555A0861 |9 18|exceptionT0076 Com
P00029555A0861 |122 157|shellfish microbiology laboratoriesyperbilirubinemia. P00008997A0472 W
P00029555A0861 |58 65|methods-nucleo
P00029555A0861 |22 33|virus assayson with al
P00029953T0045 |0 15|CharacteristicsP00001606T0076 
P00029953T0045 |19 34|lipase activityarison with alk
P00030183T0000 |0 8|TakayasuP0000160
P00030183T0000 |11 18|disease076 Com
P00030183T0000 |37 43|HLA-B5ne pho
P00030183T0000 |20 31|associationrison with 
P00030937A0119 |0 4|SGPTP000
P00030937A0119 |6 10|SGOT606T
P00030937A0119 |83 91|subjects000 Phar
P00030937A0119 |16 51|alkaline phosphatase concentrationsomparison with alkaline phosphatase
P00033873T0001 |0 29|Gamma glutamyl transpeptidaseP00001606T0076 Comparison wit
P00033873T0001 |31 35|GGTPalka
P00033873T0001 |61 66|fluidcleot
P00033873T0001 |37 45|activityne phosp
P00034935A0545 |0 8|PatientsP0000160
P00034935A0545 |14 23|Parkinson Comparis
P00034935A0545 |26 33|diseasewith al
P00034935A0545 |89 103|drug treatmentarmacologic as
P00034935A0545 |72 81|psychosesP00008171
P00034935A0545 |59 68|incidencenucleotid
P00034935A0545 |110 111|%f
P00038408T0000 |33 52|alpha-autoreceptorskaline phosphatases
P00038408T0000 |63 72|treatmenteotidase 
P00038408T0000 |78 94|alpha-methyldopa171T0000 Pharmac
P00038408T0000 |10 21|stimulation0076 Compar
P00038408T0000 |99 102|FLAc a
P00039271T0000 |55 66|applicationd 5-nucleot
P00039271T0000 |13 19|action6 Comp
P00039271T0000 |74 77|rat000
P00039271T0000 |23 31|diazepamon with 
P00041512T0067 |0 9|AbstractsP00001606
P00048373A0377 |0 7|RemovalP000016
P00048373A0377 |92 102|epitheliumacologic a
P00048373A0377 |72 79|absenceP000081
P00048373A0377 |38 44|mucoase phos
P00050628A0202 |85 96|proteinuria0 Pharmacol
P00050628A0202 |112 119|patientneonata
P00050628A0202 |59 67|patientsnucleoti
P00050628A0202 |18 28|gammopathyparison wi
P00050628A0202 |3 6|IgG001
P00050628A0202 |48 53|serumases 
P00052597T0000 |0 7|StudiesP000016
P00052597T0000 |45 52|sojournhatases
P00052597T0000 |58 74|Professor Dan H.-nucleotidase P0
P00052597T0000 |11 27|immunoglobulin E076 Comparison w
P00052597T0000 |33 39|impactkaline
P00054900A0226 |56 64|esterase 5-nucle
P00054900A0226 |11 26|reaction stains076 Comparison 
P00055040A0000 |4 16|out-patients01606T0076 C
P00055040A0000 |159 179|degradation productsn CSF [HCO3-] is sho
P00055040A0000 |261 269|fractionhen comp
P00055040A0000 |300 317|plasma fibrinogen a significantly 
P00055040A0000 |271 274|HPFed 
P00055040A0000 |181 191|FR-antigen as a func
P00055040A0000 |119 129|depositionl hyperbil
P00055040A0000 |220 224|skinK-de
P00055040A0000 |81 99|immunofluorescenceT0000 Pharmacologi
P00055040A0000 |22 41|pustulosis palmarisson with alkaline p
P00055040A0000 |325 330|bloodslope
P00055040A0000 |133 143|fibrinogeninemia. P0
P00055040A0000 |105 114|techniquects of ne
P00055040A0000 |277 289|cryoglobulincontrols but
P00056837A0000 |116 125|carcinomaatal hype
P00056837A0000 |89 100|operabilityarmacologic
P00056837A0000 |7 24|mediastinoscopies06T0076 Compariso
P00056901A0308 |34 54|hydroxy-ethyl-starchaline phosphatases a
P00056901A0308 |28 29|%t
P00056901A0308 |2 9|mixture0001606
P00056901A0308 |82 90|dilution0000 Pha
P00056901A0308 |19 26|albuminarison 
P00056901A0308 |69 77|solutionse P0000
P00060529A0695 |137 147|percentageia. P00008
P00060529A0695 |203 207|yearPCO2
P00060529A0695 |172 191|practice population is shown as a func
P00060529A0695 |110 111|%f
P00060529A0695 |151 156|women0472 
P00060529A0695 |15 28|control groupComparison wi
P00060529A0695 |33 49|acquisition-ratekaline phosphata
P00060529A0695 |115 121|figurenatal 
P00060529A0695 |87 98|0acteriuriaPharmacolog
P00060529A0695 |252 256|A.B.spla
P00061478T0000 |54 63|nutritionnd 5-nucl
P00061478T0000 |22 37|catheterisationson with alkali
P00061478T0000 |5 18|complications1606T0076 Com
P00063680T0000 |22 35|galactosaemiason with alka
P00063680T0000 |9 18|diagnosisT0076 Com
P00064414A1098 |0 5|SingsP0000
P00064414A1098 |42 56|erythropoiesisosphatases and
P00066874T0000 |102 109|resultsspects 
P00066874T0000 |24 54|fluid alpha fetoprotein levelsn with alkaline phosphatases a
P00066874T0000 |95 100|bloodlogic
P00066874T0000 |116 126|experimentatal hyper
P00066874T0000 |70 83|contaminatione P00008171T0
P00072928T0000 |0 14|Serum-ferritinP00001606T0076
P00072928T0000 |31 47|haemochromatosisalkaline phospha
P00072928T0000 |18 27|diagnosisparison w
P00073344A0367 |49 60|lymphocytesses and 5-n
P00073344A0367 |5 13|subjects1606T007
P00073344A0367 |80 89|treatment1T0000 Ph
P00073344A0367 |18 41|phytomitogen reactivityparison with alkaline p
P00074758T0000 |0 8|PatientsP0000160
P00074758T0000 |12 16|risk76 C
P00074758T0000 |20 34|hypothyroidismrison with alk
P00083846T0000 |0 7|AlbuminP000016
P00083846T0000 |44 50|fluidsphatas
P00083846T0000 |58 63|child-nucl
P00083846T0000 |19 29|AMP levelsarison wit
P00084275T0063 |0 7|PrefaceP000016
P00086313A0000 |102 108|groupsspects
P00086313A0000 |12 19|strains76 Comp
P00086313A0000 |37 53|disease bacteriane phosphatases 
P00086313A0000 |125 133|findingsrbilirub
P00086313A0000 |167 183|antibody testingCO3-] is shown a
P00086313A0000 |23 35|Legionnaireson with alka
P00086313A0000 |116 121|basisatal 
P00088391A0181 |87 94|antigenPharmac
P00088391A0181 |13 24|hand factor6 Compariso
P00088391A0181 |28 36|activityth alkal
P00088391A0181 |77 83|factor8171T0
P00088391A0181 |53 71|coumarin treatmentand 5-nucleotidase
P00089778A0000 |342 359|cataract patients.23 vs. P00010943
P00089778A0000 |126 129|FDPbil
P00089778A0000 |148 156|activity97A0472 
P00089778A0000 |213 221|patientsata of K
P00089778A0000 |186 192|humour funct
P00089778A0000 |21 42|alpha 2-macroglobulinison with alkaline ph
P00089778A0000 |260 268|patientswhen com
P00089778A0000 |295 303|cataract have a 
P00089778A0000 |93 124|fibrinogen degradation productscologic aspects of neonatal hyp
P00089778A0000 |246 255|dystrophyger displ
P00089778A0000 |78 91|C3-complement171T0000 Phar
P00089778A0000 |227 232|Fuchsted r
P00089778A0000 |44 63|alpha 1-antitrypsinphatases and 5-nucl
P00089778A0000 |65 76|plasminogentidase P000
P00089778A0000 |197 202|serumf CSF
P00089778A0000 |4 17|concentration01606T0076 Co
P00092689A0352 |16 24|patientsompariso
P00092689A0352 |44 49|timesphata
P00092689A0352 |7 8|%0
P00094639A0313 |0 8|PrazosinP0000160
P00094639A0313 |82 84|mg00
P00094639A0313 |32 38|volumelkalin
P00094639A0313 |64 68|doseotid
P00094639A0313 |50 58|patientses and 5
P00096241A0087 |0 2|T4P0
P00096241A0087 |46 52|groupsatases
P00096241A0087 |74 78|days0008
P00096241A0087 |30 37|courses alkali
P00096241A0087 |188 189|Pu
P00096241A0087 |7 11|FT4I06T0
P00096241A0087 |93 99|valuescologi
P00096241A0087 |162 165|EGASF 
P00096241A0087 |138 145|infantsa. P000
P00096241A0087 |174 186|term infantss shown as a
P00096241A0087 |155 160|weeks When
P00097989A0106 |50 58|patientses and 5
P00097989A0106 |15 23|analysisComparis
P00097989A0106 |27 42|treatment plansith alkaline ph
P00100540T0000 |0 19|Aspirin intoleranceP00001606T0076 Comp
P00100540T0000 |31 45|susceptibilityalkaline phosp
P00100540T0000 |77 87|inhibition8171T0000 
P00100540T0000 |91 98|aspirinmacolog
P00100540T0000 |49 73|platelet cyclo-oxygenaseses and 5-nucleotidase P
P00100791A0425 |101 115|rhesus monkeysaspects of neo
P00100791A0425 |28 46|cynomolgus monkeysth alkaline phosph
P00100791A0425 |6 13|results606T007
P00100791A0425 |147 154|effects997A047
P00100791A0425 |158 168|norcocaineen CSF [HC
P00101300A0257 |51 53|T3s 
P00101300A0257 |43 45|T1sp
P00101300A0257 |122 128|monthsyperbi
P00101300A0257 |47 49|T2ta
P00101300A0257 |110 115|yearsf neo
P00101300A0257 |93 98|yearscolog
P00101300A0257 |59 61|N1nu
P00101300A0257 |77 85|followup8171T000
P00101300A0257 |3 8|cases00160
P00101300A0257 |55 57|N0d 
P00101300A0257 |34 41|cancersaline p
P00105401A0635 |238 241|FT4e n
P00105401A0635 |46 58|interferenceatases and 5
P00105401A0635 |91 94|TBGmac
P00105401A0635 |14 17|CBZ Co
P00105401A0635 |144 158|clearance rate008997A0472 Wh
P00105401A0635 |162 178|thyroid hormonesSF [HCO3-] is sh
P00105401A0635 |214 234|premedication levelsta of K-depleted rat
P00105401A0635 |199 210|maintenanceCSF PCO2 th
P00105401A0635 |4 10|effect01606T
P00105401A0635 |246 249|FT3ger
P00105401A0635 |22 25|DPHson
P00105401A0635 |64 87|thyroid hormone bindingotidase P00008171T0000 
P00105903A0288 |35 46|possibilityline phosph
P00105903A0288 |12 20|research76 Compa
P00105903A0288 |77 80|PEG817
P00105903A0288 |52 71|polyethylene glycol and 5-nucleotidase
P00111174A0351 |171 178|stimuli] is sh
P00111174A0351 |125 129|eyesrbil
P00111174A0351 |108 115|stimuli of neo
P00111174A0351 |135 142|neuronsemia. P
P00111174A0351 |30 40|properties alkaline 
P00111174A0351 |52 59|neurons and 5-
P00111174A0351 |212 219|stimulidata of
P00111174A0351 |86 93|neurons Pharma
P00111174A0351 |184 191|neurons a func
P00112627A0542 |171 176|mg/kg] is 
P00112627A0542 |183 191|fentanyls a func
P00112627A0542 |60 71|combinationucleotidase
P00112627A0542 |122 127|mg/kgyperb
P00112627A0542 |197 202|mg/kgf CSF
P00112627A0542 |93 98|dosescolog
P00112627A0542 |146 151|mg/kg8997A
P00112627A0542 |130 141|anileridinerubinemia. 
P00112627A0542 |0 13|PentobarbitalP00001606T007
P00112627A0542 |154 166|alphaprodine2 When CSF [
P00112627A0542 |34 39|mg/kgaline
P00112627A0542 |102 115|normeperidinespects of neo
P00113657A0628 |0 7|Pb foilP000016
P00113657A0628 |14 19|gcm-2 Comp
P00113657A0628 |47 58|improvementtases and 5
P00114144A0189 |258 271|enzyme defectd when compar
P00114144A0189 |188 196|Andersenunction 
P00114144A0189 |67 82|result emphasisdase P00008171T
P00114144A0189 |162 186|glycogen storage diseaseSF [HCO3-] is shown as a
P00114144A0189 |199 206|diseaseCSF PCO
P00114144A0189 |154 158|Type2 Wh
P00114144A0189 |32 37|studylkali
P00114144A0189 |136 148|similaritiesmia. P000089
P00114144A0189 |102 112|hypothesesspects of 
P00115974A0576 |71 75|days P00
P00115974A0576 |79 82|age71T
P00115974A0576 |42 46|mazeosph
P00115974A0576 |4 10|groups01606T
P00117748T0000 |17 39|clindamycin resistancemparison with alkaline
P00117748T0000 |43 70|Corynebacterium diphtheriaesphatases and 5-nucleotidas
P00117748T0000 |76 88|skin lesions08171T0000 P
P00117748T0000 |0 12|ErythromycinP00001606T00
P00118044A0000 |137 149|EMG activityia. P0000899
P00118044A0000 |97 99|M2gi
P00118044A0000 |42 47|wristospha
P00118044A0000 |77 85|activity8171T000
P00118044A0000 |167 174|musclesCO3-] i
P00118044A0000 |105 113|M3 peakscts of n
P00118044A0000 |87 95|terms M1Pharmaco
P00118044A0000 |33 39|monkeykaline
P00118044A0000 |16 29|displacementsomparison wit
P00118044A0000 |68 73|peaksase P
P00118810T0001 |10 17|disease0076 Co
P00119339A0400 |171 183|degeneration] is shown a
P00119339A0400 |92 107|T. cruzi stocksacologic aspect
P00119339A0400 |189 196|lesionsnction 
P00119339A0400 |144 155|myocarditis008997A0472
P00119339A0400 |8 14|animal6T0076
P00119339A0400 |115 121|strainnatal 
P00119339A0400 |204 214|oesophagusCO2 the da
P00122718A0500 |16 25|MRF unitsomparison
P00122718A0500 |4 12|majority01606T00
P00122718A0500 |89 93|casearma
P00122718A0500 |141 149|behaviorP0000899
P00122718A0500 |101 109|activityaspects 
P00129659T0000 |0 11|VariabilityP00001606T0
P00129659T0000 |36 46|trisomy-21ine phosph
P00129659T0000 |26 34|syndromewith alk
P00129659T0000 |89 92|IQsarm
P00129659T0000 |19 23|Downaris
P00129659T0000 |70 85|sex differencese P00008171T000
P00130573T0054 |0 3|VIIP00
P00131739T0001 |55 65|Uzbekistand 5-nucleo
P00131739T0001 |40 51|populationsphosphatase
P00131739T0001 |20 27|indicesrison w
P00133214T0064 |4 12|concepts01606T00
P00133214T0064 |31 39|functionalkaline
P00133214T0064 |47 51|USSRtase
P00136175A1137 |50 57|densityes and 
P00136175A1137 |77 83|amount8171T0
P00136175A1137 |133 137|weekinem
P00136175A1137 |183 186|ECAs a
P00136175A1137 |168 179|enlargementO3-] is sho
P00136175A1137 |4 15|maintenance01606T0076 
P00136175A1137 |112 113|hn
P00136175A1137 |87 95|exercisePharmaco
P00136175A1137 |117 125|exercisetal hype
P00137671A0896 |118 129|coagulational hyperbil
P00137671A0896 |60 70|VIII-ratioucleotidas
P00137671A0896 |91 100|indicatormacologic
P00137671A0896 |6 18|observations606T0076 Com
P00139624A0318 |6 11|hours606T0
P00139624A0318 |40 50|colchicinephosphatas
P00139624A0318 |56 81|serum ceruloplasmin level 5-nucleotidase P00008171
P00139624A0318 |134 138|ratsnemi
P00139624A0318 |22 36|administrationson with alkal
P00139624A0318 |112 116|ratsneon
P00139827A0000 |0 17|RadioimmunoassaysP00001606T0076 Co
P00139827A0000 |113 121|cortisoleonatal 
P00139827A0000 |73 76|DHA000
P00139827A0000 |49 71|dehydroepiandrosteroneses and 5-nucleotidase
P00139827A0000 |222 230|deliverydepleted
P00139827A0000 |155 157|ml W
P00139827A0000 |21 33|pregnenoloneison with al
P00139827A0000 |81 98|alpha-hydroxy-DHAT0000 Pharmacolog
P00139827A0000 |168 174|plasmaO3-] i
P00139827A0000 |142 147|total00008
P00139827A0000 |197 203|coursef CSF 
P00139827A0000 |100 107|estriol aspect
P00139827A0000 |35 47|progesteroneline phospha
P00142718A0156 |137 154|chest radiographsia. P00008997A047
P00142718A0156 |111 121|99mTc-EHDP neonatal 
P00142718A0156 |12 20|patients76 Compa
P00142718A0156 |81 91|metastasesT0000 Phar
P00142718A0156 |49 56|changesses and
P00146327A0147 |118 125|tracheaal hype
P00146327A0147 |76 86|incidences08171T0000
P00146327A0147 |130 142|stem bronchirubinemia. P
P00146327A0147 |45 53|cavitieshatases 
P00146327A0147 |4 12|majority01606T00
P00146327A0147 |110 116|larynxf neon
P00146327A0147 |16 22|tumorsompari
P00149899T0001 |0 10|PredictionP00001606T
P00149899T0001 |18 23|timesparis
P00149899T0001 |35 46|developmentline phosph
P00150066A0100 |39 50|coagulation phosphatas
P00150066A0100 |61 69|thrombincleotida
P00150066A0100 |13 23|fibrinogen6 Comparis
P00150066A0554 |18 30|haemorrhagesparison with
P00150066A0554 |40 50|prosthesesphosphatas
P00154430A0906 |86 99|transcription Pharmacologi
P00154430A0906 |41 53|localizationhosphatases 
P00154430A0906 |61 67|regioncleoti
P00154430A0906 |126 134|fragmentbilirubi
P00154430A0906 |109 111|kbof
P00154430A0906 |4 22|Southern technique01606T0076 Compari
P00155973A0387 |187 188|%f
P00155973A0387 |233 238|min-1ts ar
P00155973A0387 |95 101|systemlogic 
P00155973A0387 |29 35|limitsh alka
P00155973A0387 |183 186|vols a
P00155973A0387 |285 290|min-1 but 
P00155973A0387 |140 168|carbon dioxide concentration P00008997A0472 When CSF [HC
P00155973A0387 |65 66|%t
P00155973A0387 |248 253|ranger dis
P00155973A0387 |257 275|minute ventilationed when compared t
P00155973A0387 |206 220|gas flow rates2 the data of 
P00155973A0387 |49 55|errorsses an
P00159600A0871 |0 2|SVP0
P00159600A0871 |66 76|complianceidase P000
P00159600A0871 |146 151|shift8997A
P00159600A0871 |107 116|ventricles of neon
P00159600A0871 |21 24|SHRiso
P00159600A0871 |174 179|curves sho
P00159600A0871 |98 101|SHRic 
P00163384A0000 |35 51|Bubo virginianusline phosphatase
P00163384A0000 |30 33|owl al
P00163384A0000 |96 103|Ontarioogic as
P00163384A0000 |123 131|necropsyperbilir
P00163384A0000 |4 11|carcass01606T0
P00167544A0067 |185 211|surface specimen techniquea function of CSF PCO2 the
P00167544A0067 |75 82|regions008171T
P00167544A0067 |10 14|ears0076
P00167544A0067 |31 46|microdissectionalkaline phosph
P00167544A0067 |131 150|electron microscopyubinemia. P00008997
P00168176A0000 |0 7|PatulinP000016
P00168176A0000 |163 169|eluantF [HCO
P00168176A0000 |26 46|apple butter sampleswith alkaline phosph
P00168176A0000 |74 81|extract0008171
P00168176A0000 |140 147|acetate P00008
P00168176A0000 |52 65|ethyl acetate and 5-nucleo
P00168176A0000 |101 118|silica gel columnaspects of neonat
P00168431T0000 |0 20|Steroid glucuronidesP00001606T0076 Compa
P00168431T0000 |42 46|termosph
P00168431T0000 |33 38|fluidkalin
P00172199A0270 |118 134|cross striationsal hyperbilirubi
P00172199A0270 |27 35|clustersith alka
P00172199A0270 |4 10|matrix01606T
P00172199A0270 |59 69|morphologynucleotida
P00172199A0270 |87 97|appearancePharmacolo
P00173860A0475 |0 10|RiboflavinP00001606T
P00173860A0475 |166 177|eliminationHCO3-] is s
P00173860A0475 |62 69|animalsleotida
P00173860A0475 |150 162|disturbancesA0472 When C
P00173860A0475 |30 40|percentage alkaline 
P00173860A0475 |92 110|excretion patternsacologic aspects o
P00173860A0475 |133 142|magnitudeinemia. P
P00173860A0475 |207 212|acids the 
P00176742T0000 |0 11|PolyglactinP00001606T0
P00176742T0000 |59 66|enzymesnucleot
P00176742T0000 |42 46|roleosph
P00176742T0000 |16 33|suture absorptionomparison with al
P00183063A0300 |138 146|patientsa. P0000
P00183063A0300 |17 31|DNCB reactionsmparison with 
P00183063A0300 |117 122|Stagetal h
P00183063A0300 |219 225|cancer K-dep
P00183063A0300 |52 57|Stage and 
P00183063A0300 |127 133|cancerilirub
P00183063A0300 |209 214|Stagehe da
P00183063A0300 |97 101|centgic 
P00183063A0300 |43 47|centspha
P00183063A0300 |79 87|patinets71T0000 
P00183063A0300 |160 164|cent CSF
P00183063A0300 |4 13|incidence01606T007
P00183063A0300 |67 74|cancersdase P0
P00183063A0300 |168 176|patientsO3-] is 
P00188387A0975 |0 7|StudiesP000016
P00188387A0975 |11 23|lipoproteins076 Comparis
P00188387A0975 |89 91|FHar
P00188387A0975 |52 60|children and 5-n
P00188387A0975 |110 123|heart diseasef neonatal hy
P00188387A0975 |66 74|familiesidase P0
P00193088A0196 |21 29|subjectsison wit
P00193088A0196 |42 52|Metyraponeosphatases
P00193088A0196 |62 71|responsesleotidase
P00193088A0196 |37 38|gn
P00193587T0000 |34 43|phenomenaaline pho
P00193587T0000 |58 66|analysis-nucleot
P00193587T0000 |47 53|reviewtases 
P00193587T0000 |0 15|EEG theta wavesP00001606T0076 
P00196255A0000 |0 17|REM dream contentP00001606T0076 Co
P00196255A0000 |133 146|verbalizationinemia. P0000
P00196255A0000 |194 202|saliencen of CSF
P00196255A0000 |33 43|categorieskaline pho
P00196255A0000 |93 103|hemispherecologic as
P00196255A0000 |179 184|musicwn as
P00196255A0000 |161 171|hemisphereCSF [HCO3-
P00196255A0000 |116 119|egoata
P00196255A0000 |71 80|influence P0000817
P00196255A0000 |204 215|bizarrenessCO2 the dat
P00198510T0000 |0 11|InnervationP00001606T0
P00198510T0000 |27 36|diaphragmith alkal
P00198510T0000 |44 50|locustphatas
P00198510T0000 |52 70|Locusta migratoria and 5-nucleotidas
P00199012T0000 |36 53|thyroid carcinomaine phosphatases 
P00199012T0000 |8 21|ACTH syndrome6T0076 Compar
P00201881A0487 |33 40|studieskaline 
P00201881A0487 |88 100|MSH contentsharmacologic
P00201881A0487 |56 67|correlation 5-nucleoti
P00201881A0487 |11 18|finding076 Com
P00201881A0487 |76 83|PI ACTH08171T0
P00205074A0000 |64 71|ricketsotidase
P00205074A0000 |44 48|typephat
P00205074A0000 |8 24|hypophosphatemia6T0076 Compariso
P00209664A0836 |33 41|serum LHkaline p
P00209664A0836 |13 24|correlation6 Compariso
P00209664A0836 |159 177|parallel phenomenan CSF [HCO3-] is s
P00209664A0836 |63 71|bone ageeotidase
P00209664A0836 |80 89|age group1T0000 Ph
P00209664A0836 |115 126|correlationnatal hyper
P00210220X0000 |38 43|drugse pho
P00210220X0000 |10 24|neurochemistry0076 Compariso
P00211881A0602 |152 155|PBB472
P00211881A0602 |134 138|sitenemi
P00211881A0602 |45 49|timehata
P00211881A0602 |142 148|action000089
P00211881A0602 |63 77|kidney lesionseotidase P0000
P00211881A0602 |35 41|amountline p
P00211881A0602 |0 7|EffortsP000016
P00216939T0001 |0 6|EffectP00001
P00216939T0001 |26 35|intensitywith alka
P00216939T0001 |89 94|brainarmac
P00216939T0001 |126 134|chloridebilirubi
P00216939T0001 |10 18|succimer0076 Com
P00216939T0001 |53 81|acid dehydrogenase reactionsand 5-nucleotidase P00008171
P00216939T0001 |98 102|ratsic a
P00219533T0001 |17 29|correlationsmparison wit
P00219533T0001 |89 92|menarm
P00219533T0001 |69 80|populationsse P0000817
P00219533T0001 |33 48|serum uric-acidkaline phosphat
P00219533T0001 |103 108|womenpects
P00219533T0001 |0 12|DistributionP00001606T00
P00219565A0172 |17 36|hepatitis B antigenmparison with alkal
P00219565A0172 |47 58|transfusiontases and 5
P00219565A0172 |77 81|cent8171
P00219565A0172 |4 13|incidence01606T007
P00219674A0000 |0 14|Technetium-99mP00001606T0076
P00219674A0000 |130 135|rangerubin
P00219674A0000 |123 128|weeksperbi
P00219674A0000 |49 60|scintigramsses and 5-n
P00219674A0000 |24 37|pyrophosphaten with alkali
P00219674A0000 |100 108|patients aspects
P00219674A0000 |169 179|infarction3-] is sho
P00221136A0984 |48 54|humansases a
P00221136A0984 |10 20|phenomenon0076 Compa
P00221725A0523 |51 61|peroxidases and 5-nu
P00221725A0523 |131 139|decreaseubinemia
P00221725A0523 |73 86|lipid content00008171T0000
P00221725A0523 |31 49|cytochrome oxidasealkaline phosphata
P00221725A0523 |4 11|decline01606T0
P00221725A0523 |158 166|activityen CSF [
P00221725A0523 |101 112|neutrophilsaspects of 
P00221725A0523 |19 27|activityarison w
P00222102A0227 |152 160|response472 When
P00222102A0227 |29 58|pseudohypoparathyroidism typeh alkaline phosphatases and 5
P00222102A0227 |166 172|regardHCO3-]
P00222102A0227 |180 193|normalisationn as a functi
P00222102A0227 |15 23|patientsComparis
P00222102A0227 |66 77|vitamin-D-3idase P0000
P00222102A0227 |197 210|serum-calciumf CSF PCO2 th
P00222102A0227 |84 112|alpha-Hydroxycholecalciferol00 Pharmacologic aspects of 
P00222102A0227 |0 9|TreatmentP00001606
P00222827A0000 |68 73|depthase P
P00222827A0000 |52 55|TDI an
P00222827A0000 |125 140|hyperreactivityrbilirubinemia.
P00222827A0000 |14 25|sensitivity Comparison
P00222827A0000 |38 50|diisocyanatee phosphatas
P00222827A0000 |80 87|attempt1T0000 
P00222827A0000 |101 111|mechanismsaspects of
P00222827A0000 |0 7|WorkersP000016
P00224013A0661 |32 38|groupslkalin
P00224013A0661 |391 399|pressure be an e
P00224013A0661 |303 307|limbsign
P00224013A0661 |467 481|vasodilatationtice being 15 
P00224013A0661 |107 112|groups of 
P00224013A0661 |257 268|utilizationed when com
P00224013A0661 |353 370|extraction ratios010943A0733 Flura
P00224013A0661 |114 124|beta-Blockonatal hyp
P00224013A0661 |157 161|limbhen 
P00224013A0661 |53 60|hypoxiaand 5-n
P00224013A0661 |455 459|partgene
P00224013A0661 |335 339|body1 +/
P00224013A0661 |173 183|resistanceis shown a
P00224013A0661 |501 508|hypoxia53T0045
P00224013A0661 |199 206|hypoxiaCSF PCO
P00224013A0661 |281 289|deliveryrols but
P00224013A0661 |401 427|beta-Vasodilator receptorsective hypnotic drug with 
P00224013A0661 |311 321|comparisonantly grea
P00224013A0661 |6 9|VO2606
P00224013A0661 |65 73|limb VO2tidase P
P00224013A0661 |139 143|fall. P0
P00225352T0000 |22 33|alterationsson with al
P00225352T0000 |56 58|3H 5
P00225352T0000 |41 51|metabolismhosphatase
P00225352T0000 |95 104|rat liverlogic asp
P00225352T0000 |59 69|vitamin D3nucleotida
P00227393T0000 |0 10|ModulationP00001606T
P00227393T0000 |14 49|25-hydroxyvitamin D3-24-hydroxylase Comparison with alkaline phosphata
P00227393T0000 |53 66|aminophyllineand 5-nucleot
P00227393T0000 |70 107|cytochrome P-450 monooxygenase systeme P00008171T0000 Pharmacologic aspect
P00227610A1593 |65 75|messengerstidase P00
P00227610A1593 |88 103|polyoma virusesharmacologic as
P00227610A1593 |14 22|respects Compari
P00227610A1593 |79 83|SV4071T0
P00227610A1593 |37 45|DBP mRNAne phosp
P00231555T0001 |0 6|EffectP00001
P00231555T0001 |91 110|cortisol productionmacologic aspects o
P00231555T0001 |82 86|ACTH0000
P00231555T0001 |50 67|combination drugses and 5-nucleoti
P00232354A0286 |0 10|Serum ACTHP00001606T
P00232354A0286 |30 37|insulin alkali
P00232354A0286 |42 52|metyraponeosphatases
P00232456T0000 |102 110|leukemiaspects o
P00232456T0000 |15 18|RNACom
P00232456T0000 |145 150|class08997
P00232456T0000 |126 134|evidencebilirubi
P00232456T0000 |40 44|MC29phos
P00232456T0000 |167 172|genesCO3-]
P00232456T0000 |74 87|tumor viruses0008171T0000 
P00232456T0000 |115 124|carcinomanatal hyp
P00232456T0000 |23 36|gene productson with alkal
P00232456T0000 |49 52|MH2ses
P00232456T0000 |0 7|AnatomyP000016
P00234206T0000 |0 8|BertiogaP0000160
P00234206T0000 |10 21|Guama group0076 Compar
P00234206T0000 |63 74|arboviruseseotidase P0
P00234206T0000 |36 52|Bunyamwera groupine phosphatases
P00234206T0000 |27 34|Anhembiith alk
P00234206T0000 |98 104|Brazilic asp
P00234206T0000 |87 96|Sao PauloPharmacol
P00234264A0164 |0 38|Gamma glutamyl transpeptidase activityP00001606T0076 Comparison with alkalin
P00234264A0164 |123 134|aminopyrineperbilirubi
P00234264A0164 |62 67|timesleoti
P00234264A0164 |91 96|limitmacol
P00234264A0164 |143 148|weeks00089
P00234264A0164 |100 108|children aspects
P00234626T0036 |0 3|XXIP00
P00239014A0000 |102 114|blood plasmaspects of ne
P00239014A0000 |88 92|CPIBharm
P00239014A0000 |44 57|determinationphatases and 
P00239014A0000 |29 35|methodh alka
P00239014A0000 |94 98|acidolog
P00239169T0000 |68 73|studyase P
P00239169T0000 |35 47|neurolepticsline phospha
P00239169T0000 |0 26|Dopamine receptor blockadeP00001606T0076 Comparison 
P00240016T0033 |0 2|V.P0
P00240518A0000 |21 30|procedureison with
P00240518A0000 |60 86|fungicide 5-fluorocytosineucleotidase P00008171T0000
P00240518A0000 |90 95|serumrmaco
P00240518A0000 |39 52|determination phosphatases
P00242427T0001 |5 10|field1606T
P00242427T0001 |14 20|stress Compa
P00242427T0001 |41 46|nursehosph
P00254537T0000 |39 47|programs phospha
P00254537T0000 |30 35|types alka
P00254537T0000 |59 71|state boardsnucleotidase
P00254537T0000 |7 16|graduates06T0076 C
P00261981A0434 |69 73|ratsse P
P00261981A0434 |88 95|littersharmaco
P00261981A0434 |20 39|serum somatomedin Arison with alkaline
P00264240A1843 |137 147|T clustersia. P00008
P00264240A1843 |104 112|residuesects of 
P00264240A1843 |4 13|sequences01606T007
P00264240A1843 |59 67|5S genesnucleoti
P00264240A1843 |28 46|X. borealis oocyteth alkaline phosph
P00264240A1843 |175 181|region shown
P00264240A1843 |185 208|X. laevis oocyte 5S DNAa function of CSF PCO2 
P00265964A0562 |5 14|mechanism1606T0076
P00265964A0562 |42 56|grain boundaryosphatases and
P00267764A0651 |49 67|treatment failuresses and 5-nucleoti
P00267764A0651 |109 119|managementof neonata
P00267764A0651 |88 98|philosophyharmacolog
P00267764A0651 |37 44|reasonsne phos
P00267764A0651 |5 11|report1606T0
P00294502T0001 |0 9|DiagnosisP00001606
P00294502T0001 |14 32|treatment planning Comparison with a
P00294502T0001 |46 54|divisionatases a
P00294502T0001 |36 44|Class IIine phos
P00300314A0132 |19 29|infectionsarison wit
P00300314A0132 |105 107|mmct
P00300314A0132 |179 197|calcium leucovorinwn as a function o
P00300314A0132 |245 257|methotrexatenger displac
P00300314A0132 |208 213|mg/m2the d
P00300314A0132 |31 36|feveralkal
P00300314A0132 |164 172|patients [HCO3-]
P00300314A0132 |115 130|hospitalizationnatal hyperbili
P00300314A0132 |234 238|dayss ar
P00300314A0132 |65 88|degrees F. granulocytestidase P00008171T0000 P
P00300314A0132 |138 148|drug deatha. P000089
P00300314A0132 |272 288|treatment cyclesd to controls bu
P00303189A0247 |18 21|waypar
P00303189A0247 |148 155|process97A0472
P00303189A0247 |46 53|patientatases 
P00303189A0247 |31 36|drugsalkal
P00303189A0247 |56 71|serum chemistry 5-nucleotidase
P00303189A0247 |98 106|efficacyic aspec
P00304240A0369 |51 59|presences and 5-
P00304240A0369 |77 84|disease8171T00
P00304240A0369 |22 27|testsson w
P00304310A0000 |4 13|end-stage01606T007
P00304310A0000 |30 35|phase alka
P00304310A0000 |62 73|retinopathyleotidase P
P00304310A0000 |121 128|periodshyperbi
P00304310A0000 |105 111|visioncts of
P00304310A0000 |88 101|stabilizationharmacologic 
P00304310A0000 |132 136|timebine
P00304806A0760 |16 43|serum alpha1AT quantitationomparison with alkaline pho
P00304806A0760 |159 162|mg%n C
P00304806A0760 |7 12|basis06T00
P00304806A0760 |125 139|concentrationsrbilirubinemia
P00304806A0760 |53 60|infantsand 5-n
P00304806A0760 |87 93|groupsPharma
P00313766A0666 |100 107|control aspect
P00313766A0666 |63 73|depressioneotidase P
P00313766A0666 |122 123|%y
P00313766A0666 |125 126|pr
P00313766A0666 |95 96|%l
P00313766A0666 |109 114|rangeof ne
P00313766A0666 |77 85|function8171T000
P00313766A0666 |3 11|patients001606T0
P00316723A0558 |0 7|ChangesP000016
P00316723A0558 |11 22|body weight076 Compari
P00316723A0558 |37 45|behaviorne phosp
P00321261A0104 |220 225|womenK-dep
P00321261A0104 |183 188|cycles a f
P00321261A0104 |120 126|routes hyper
P00321261A0104 |42 46|PGE2osph
P00321261A0104 |24 40|prostaglandin E2n with alkaline 
P00321261A0104 |12 20|response76 Compa
P00321261A0104 |52 73|prostaglandin F2alpha and 5-nucleotidase P
P00321261A0104 |159 165|phasesn CSF 
P00330364A0132 |273 285|laboratories to controls
P00330364A0132 |243 250|strainslonger 
P00330364A0132 |90 93|BCGrma
P00330364A0132 |151 159|children0472 Whe
P00330364A0132 |166 181|BCG-vaccinationHCO3-] is shown
P00330364A0132 |14 25|BCG strains Comparison
P00330364A0132 |116 123|strainsatal hy
P00330364A0132 |55 62|strainsd 5-nuc
P00330364A0132 |188 195|strainsunction
P00330364A0132 |219 234|BCG-vaccination K-depleted rat
P00330364A0132 |138 147|abscessesa. P00008
P00330364A0132 |78 86|cultures171T0000
P00330364A0132 |107 112|batchs of 
P00330364A0132 |207 212|cases the 
P00330364A0132 |2 7|total00016
P00331128A0000 |5 11|levels1606T0
P00331128A0000 |15 31|serum calcitoninComparison with 
P00331128A0000 |74 81|failure0008171
P00331128A0000 |46 54|patientsatases a
P00331936T0000 |0 9|DetectionP00001606
P00331936T0000 |29 39|antibodiesh alkaline
P00331936T0000 |50 87|immunoperoxidase antiglobulin technices and 5-nucleotidase P00008171T0000 
P00336354A0543 |16 24|serum GHompariso
P00336354A0543 |28 45|arginine infusionth alkaline phosp
P00336354A0543 |88 100|hypoglycemiaharmacologic
P00336354A0543 |4 12|response01606T00
P00336547A0000 |273 282|C57/BL/6J to contr
P00336547A0000 |303 309|BALB/csignif
P00336547A0000 |284 301|New Zealand Blacks but still have 
P00336547A0000 |324 330|C3H/eB slope
P00336547A0000 |250 263|mouse strainsdisplaced whe
P00336547A0000 |157 171|C3H/eB originshen CSF [HCO3-
P00336547A0000 |53 72|Nocardia asteroidesand 5-nucleotidase 
P00336547A0000 |149 152|ICR7A0
P00336547A0000 |77 109|Nocardia brasiliensis infections8171T0000 Pharmacologic aspects 
P00336547A0000 |41 49|featureshosphata
P00336547A0000 |228 232|miceed r
P00336547A0000 |311 318|CBA/LACantly g
P00336547A0000 |141 145|miceP000
P00336547A0000 |4 18|mortality rate01606T0076 Com
P00337102T0058 |0 8|WilliamsP0000160
P00337102T0058 |12 18|August76 Com
P00339289T0049 |0 3|UseP00
P00339289T0049 |19 27|isotopesarison w
P00339289T0049 |48 56|proteinsases and
P00339289T0049 |35 44|chemistryline phos
P00340692T0033 |1 9|Emeritus00001606
P00340692T0033 |11 42|John Henri Roosegaarde Bisschop076 Comparison with alkaline ph
P00342623A0228 |101 111|reactivityaspects of
P00342623A0228 |23 43|whole-virus vaccineson with alkaline pho
P00342623A0228 |10 18|vaccines0076 Com
P00342623A0228 |55 69|type B antigend 5-nucleotida
P00350465T0000 |38 47|disorderse phospha
P00350465T0000 |10 19|diagnosis0076 Comp
P00352569A0000 |35 51|blood parametersline phosphatase
P00352569A0000 |123 132|endotoxinperbiliru
P00352569A0000 |81 86|ratesT0000
P00352569A0000 |8 21|oxygen supply6T0076 Compar
P00352569A0000 |100 105|mg/kg aspe
P00354315T0000 |23 31|patientson with 
P00354315T0000 |8 19|dysfunction6T0076 Comp
P00354315T0000 |37 58|ataxia telangiectasiane phosphatases and 5
P00358945A0225 |83 88|weeks000 P
P00358945A0225 |12 18|period76 Com
P00358945A0225 |22 31|treatmentson with 
P00361059T0000 |2 7|study00016
P00361059T0000 |27 35|efficacyith alka
P00361059T0000 |107 117|% ointments of neona
P00361059T0000 |39 62|diflucortolone valerate phosphatases and 5-nuc
P00361059T0000 |66 76|% ointmentidase P000
P00361059T0000 |81 102|clobetasol propionateT0000 Pharmacologic a
P00361340A0529 |35 49|osteodystrophyline phosphata
P00361340A0529 |134 163|1,25-dihydroxycholecalciferolnemia. P00008997A0472 When CS
P00361340A0529 |120 130|deficiency hyperbili
P00361340A0529 |109 118|conditionof neonat
P00361340A0529 |182 194|significanceas a functio
P00361340A0529 |12 21|phenomena76 Compar
P00361340A0529 |76 96|vitamin D deficiency08171T0000 Pharmacol
P00361340A0529 |245 252|failurenger di
P00361340A0529 |216 235|hyperparathyroidism of K-depleted rats
P00369397A0280 |6 9|FSH606
P00369397A0280 |105 114|LH valuescts of ne
P00369397A0280 |52 59|addicts and 5-
P00369397A0280 |88 95|addictsharmaco
P00369397A0280 |14 23|LH levels Comparis
P00369397A0280 |97 100|FSHgic
P00369397A0280 |67 83|GnRH stimulationdase P00008171T0
P00369397A0280 |159 167|controlsn CSF [H
P00369683T0000 |0 10|AdriamycinP00001606T
P00369683T0000 |12 22|comparison76 Compari
P00369683T0000 |74 83|treatment0008171T0
P00369683T0000 |87 100|breast cancerPharmacologic
P00369683T0000 |58 66|schedule-nucleot
P00369683T0000 |35 43|scheduleline pho
P00377466A0188 |34 41|hormonealine p
P00377466A0188 |178 191|healing phaseown as a func
P00377466A0188 |95 99|HPRLlogi
P00377466A0188 |133 134|Pi
P00377466A0188 |164 173|catabolic [HCO3-] 
P00377466A0188 |119 131|progesteronel hyperbilir
P00377466A0188 |84 93|prolactin00 Pharma
P00377466A0188 |154 155|T2
P00377466A0188 |48 76|follicle stimulating hormoneases and 5-nucleotidase P000
P00377466A0188 |114 116|E2on
P00377466A0188 |43 45|LHsp
P00377466A0188 |10 18|controls0076 Com
P00377466A0188 |78 81|FSH171
P00377466A0188 |200 207|diseaseSF PCO2
P00377466A0188 |140 152|testosterone P00008997A0
P00377466A0188 |102 112|oestradiolspects of 
P00378492A0475 |0 13|Renin studiesP00001606T007
P00378492A0475 |61 74|control groupcleotidase P0
P00378492A0475 |43 51|patientssphatase
P00378492A0475 |146 170|plasma aldosterone level8997A0472 When CSF [HCO3
P00378492A0475 |104 113|elevationects of n
P00378492A0475 |117 138|plasma renin activitytal hyperbilirubinemi
P00378492A0475 |81 91|recipientsT0000 Phar
P00378492A0475 |237 252|artery stenosisre no longer di
P00378735A0000 |307 315|carriersificantl
P00378735A0000 |151 166|dosage schedule0472 When CSF [
P00378735A0000 |134 145|amoxycillinnemia. P000
P00378735A0000 |224 239|chloramphenicolpleted rats are
P00378735A0000 |320 333|relapse ratesater slope (1
P00378735A0000 |22 27|trialson w
P00378735A0000 |296 303|respecthave a 
P00378735A0000 |245 251|regardnger d
P00378735A0000 |268 288|temperature responsepared to controls bu
P00378735A0000 |79 84|fever71T00
P00378735A0000 |106 120|marrow culturets of neonatal
P00378735A0000 |47 55|patientstases an
P00378735A0000 |203 207|daysPCO2
P00378735A0000 |172 173|g 
P00378735A0000 |96 101|bloodogic 
P00381783T0000 |0 32|Bone marrow transplantation-1979P00001606T0076 Comparison with a
P00383169A0000 |137 158|rye-ergot derivativesia. P00008997A0472 Wh
P00383169A0000 |228 238|propertiesed rats ar
P00383169A0000 |181 186|basis as a
P00383169A0000 |30 37|actions alkali
P00383169A0000 |93 104|apomorphinecologic asp
P00383169A0000 |8 15|article6T0076 
P00383169A0000 |126 135|piribedilbilirubin
P00383169A0000 |55 72|dopamine receptord 5-nucleotidase 
P00383169A0000 |113 124|derivativeseonatal hyp
P00383169A0000 |85 91|agents0 Phar
P00384744T0000 |26 38|hypofunctionwith alkalin
P00385457A0187 |103 110|healingpects o
P00385457A0187 |10 20|inhibition0076 Compa
P00385457A0187 |123 128|ulcerperbi
P00385457A0187 |48 53|juiceases 
P00385457A0187 |24 30|pepsinn with
P00385457A0187 |86 95|influence Pharmaco
P00386251A0899 |32 41|detectionlkaline p
P00386251A0899 |126 130|milkbili
P00386251A0899 |88 97|detectionharmacolo
P00386251A0899 |45 55|penicillinhatases an
P00386251A0899 |4 23|IDF standard method01606T0076 Comparis
P00386251A0899 |59 63|milknucl
P00386251A0899 |101 122|sulphonamide residuesaspects of neonatal h
P00390932T0001 |9 17|antigensT0076 Co
P00393598A0198 |55 58|ALSd 5
P00393598A0198 |14 29|endotoxin fever Comparison wit
P00393598A0198 |4 10|course01606T
P00397806T0039 |6 20|Algerian cases606T0076 Compa
P00401521A0138 |23 31|patientson with 
P00401521A0138 |45 56|ticarcillinhatases and
P00401521A0138 |12 19|percent76 Comp
P00401676A0414 |81 93|radiotherapyT0000 Pharma
P00401676A0414 |20 27|stagingrison w
P00401676A0414 |39 47|patients phospha
P00406585T0001 |9 19|hematologyT0076 Comp
P00406585T0001 |27 30|ageith
P00409927A0570 |0 8|NeomycinP0000160
P00409927A0570 |37 50|staphylococcine phosphatas
P00409927A0570 |75 87|streptococci008171T0000 
P00409927A0570 |143 152|organisms0008997A0
P00411465A0142 |34 41|sectionaline p
P00411465A0142 |105 113|cavitiescts of n
P00411465A0142 |83 90|contact000 Pha
P00411465A0142 |52 56|cent and
P00411465A0142 |64 74|trabeculaeotidase P0
P00413854A0958 |0 7|ChangesP000016
P00413854A0958 |11 22|tissue PCO2076 Compari
P00413854A0958 |103 108|bloodpects
P00414575T0000 |11 21|evaluation076 Compar
P00414575T0000 |31 38|calculialkalin
P00415543A0320 |0 11|RecognitionP00001606T0
P00415543A0320 |113 118|filmseonat
P00415543A0320 |124 132|patientserbiliru
P00415543A0320 |104 109|filmsects 
P00415543A0320 |15 24|emphysemaCompariso
P00415543A0320 |65 72|qualitytidase 
P00415543A0320 |39 50|radiographs phosphatas
P00415543A0320 |155 167|lung disease When CSF [H
P00416758T0001 |0 9|IsolationP00001606
P00416758T0001 |13 33|T. gambiense strains6 Comparison with al
P00416758T0001 |67 85|laboratory animalsdase P00008171T000
P00416758T0001 |37 42|Zairene ph
P00416758T0001 |53 63|adaptationand 5-nucl
P00417166T0000 |16 23|profileomparis
P00417166T0000 |41 55|rhesus monkeyshosphatases an
P00417166T0000 |27 37|clonazepamith alkali
P00417301T0001 |34 45|brucellosisaline phosp
P00417301T0001 |12 22|mechanisms76 Compari
P00417301T0001 |49 55|humansses an
P00418341T0000 |36 41|partsine p
P00418341T0000 |11 21|adaptation076 Compar
P00420460A0291 |3 11|patients001606T0
P00420460A0291 |57 91|log baseline plasma renin activity5-nucleotidase P00008171T0000 Phar
P00420460A0291 |41 55|drug treatmenthosphatases an
P00420460A0291 |167 168|rC
P00420460A0291 |132 134|SQbi
P00420460A0291 |178 179|Po
P00420460A0291 |111 125|blood pressure neonatal hype
P00420460A0291 |96 102|changeogic a
P00423649A0259 |69 74|claimse P0
P00423649A0259 |40 46|peoplephosph
P00423649A0259 |56 61|years 5-nu
P00423649A0259 |6 16|techniques606T0076 C
P00423649A0259 |97 107|innovationgic aspect
P00423649A0259 |116 122|regardatal h
P00425547A0000 |3 11|patients001606T0
P00425547A0000 |104 114|cephalexinects of ne
P00425547A0000 |130 135|weeksrubin
P00425547A0000 |56 58|os 5
P00425547A0000 |25 38|osteomyelitis with alkalin
P00427715A0000 |153 163|University72 When CS
P00427715A0000 |28 35|Hodgkinth alka
P00427715A0000 |14 22|patients Compari
P00427715A0000 |67 76|diaphragmdase P000
P00427715A0000 |78 84|Stages171T00
P00427715A0000 |167 174|FloridaCO3-] i
P00427715A0000 |122 139|radiation therapyyperbilirubinemia
P00427715A0000 |101 102|Ba
P00427715A0000 |38 45|diseasee phosp
P00427715A0000 |2 7|total00016
P00429151T0000 |51 55|units an
P00429151T0000 |71 83|Glasgow area P00008171T0
P00429151T0000 |30 42|practitioner alkaline ph
P00429151T0000 |0 4|YearP000
P00429893A0000 |34 46|round windowaline phosph
P00429893A0000 |91 97|systemmacolo
P00429893A0000 |160 166|trauma CSF [
P00429893A0000 |56 68|implantation 5-nucleotid
P00429893A0000 |149 156|minimum7A0472 
P00429893A0000 |195 206|stimulation of CSF PCO
P00429893A0000 |128 141|scala tympanilirubinemia. 
P00429893A0000 |24 29|arrayn wit
P00429893A0000 |115 117|mmna
P00429949A0000 |239 248|prolactin no longe
P00429949A0000 |225 228|IRPlet
P00429949A0000 |104 115|preparationects of neo
P00429949A0000 |188 223|International Reference Preparationunction of CSF PCO2 the data of K-d
P00429949A0000 |52 68|Expert Committee and 5-nucleotid
P00429949A0000 |125 134|prolactinrbilirubi
P00429949A0000 |72 98|Biological StandardizationP00008171T0000 Pharmacolog
P00429949A0000 |138 146|ampoulesa. P0000
P00429949A0000 |21 46|World Health Organizationison with alkaline phosph
P00429949A0000 |253 264|immunoassayplaced when
P00430889T0001 |16 24|fistulasompariso
P00431832T0001 |0 18|Plasma ion changesP00001606T0076 Com
P00431832T0001 |29 34|bloodh alk
P00431832T0001 |50 72|beta receptor blockerses and 5-nucleotidase 
P00432615A0541 |154 166|interference2 When CSF [
P00432615A0541 |193 197|RISTon o
P00432615A0541 |12 23|differences76 Comparis
P00432615A0541 |104 117|gammaglobulinects of neona
P00432615A0541 |54 64|literaturend 5-nucle
P00432615A0541 |66 88|heterophile antibodiesidase P00008171T0000 P
P00432615A0541 |174 189|Sephadex systems shown as a fu
P00435187T0000 |17 30|flowers bloommparison with
P00437749A0242 |49 56|contextses and
P00437749A0242 |90 100|physiologyrmacologic
P00437749A0242 |8 28|treatment modalities6T0076 Comparison wi
P00437749A0242 |123 127|painperb
P00437749A0242 |64 74|psychologyotidase P0
P00439618T0001 |0 17|Lethal TachmalcorP00001606T0076 Co
P00439618T0001 |56 64|ajmaline 5-nucle
P00439618T0001 |41 54|hydroxypropylhosphatases a
P00439618T0001 |25 39|diethylamino-2 with alkaline
P00439618T0001 |79 88|childhood71T0000 P
P00439618T0001 |66 75|poisoningidase P00
P00439716T0001 |35 54|blood flow velocityline phosphatases a
P00439716T0001 |75 82|fistula008171T
P00439716T0001 |21 31|evaluationison with 
P00445259T0000 |0 28|Serum ferritin concentrationP00001606T0076 Comparison wi
P00445259T0000 |33 56|bone marrow iron storeskaline phosphatases and
P00445720A0263 |32 35|SPGlka
P00445720A0263 |78 84|atrium171T00
P00445720A0263 |13 30|pressure gradient6 Comparison with
P00445720A0263 |54 63|ventriclend 5-nucl
P00445720A0263 |108 142|high-fidelity pressure transducers of neonatal hyperbilirubinemia. P
P00445720A0263 |65 67|LVti
P00445720A0263 |86 88|LA P
P00450367T0000 |102 114|hysterectomyspects of ne
P00450367T0000 |14 19|trail Comp
P00450367T0000 |90 96|radiumrmacol
P00450367T0000 |30 42|hysterectomy alkaline ph
P00450367T0000 |138 147|carcinomaa. P00008
P00450367T0000 |44 56|hysterectomyphatases and
P00450367T0000 |70 76|radiume P000
P00450367T0000 |118 123|stageal hy
P00450559A0269 |18 25|patientparison
P00450559A0269 |28 34|reportth alk
P00450559A0269 |53 62|Clinitempand 5-nuc
P00450559A0269 |7 12|basis06T00
P00450559A0269 |96 104|accuracyogic asp
P00450559A0269 |113 124|thermometereonatal hyp
P00450760T0001 |0 16|CryoglobulinemiaP00001606T0076 C
P00450760T0001 |30 38|syndrome alkalin
P00450760T0001 |20 27|Raynaudrison w
P00451192A0248 |0 4|DataP000
P00451192A0248 |42 58|computer programosphatases and 5
P00451192A0248 |93 98|curvecolog
P00451192A0248 |116 137|LV region-of-interestatal hyperbilirubinem
P00453780A0430 |17 35|serum IgA responsemparison with alka
P00453780A0430 |181 184|IgA as
P00453780A0430 |159 165|sourcen CSF 
P00453780A0430 |52 70|patient population and 5-nucleotidas
P00453780A0430 |115 121|tissuenatal 
P00453780A0430 |138 142|lunga. P
P00454780A0340 |0 19|Ultimate strengthesP00001606T0076 Comp
P00454780A0340 |43 61|cast cobalt alloyssphatases and 5-nu
P00454780A0340 |122 135|fatigue limityperbilirubin
P00454780A0340 |96 98|Taog
P00454780A0340 |142 151|corrosion00008997A
P00454780A0340 |71 86|titanium alloys P00008171T0000
P00454780A0340 |101 102|Va
P00456424A0000 |103 113|heart ratepects of n
P00456424A0000 |30 39|injection alkaline
P00456424A0000 |52 61|clonidine and 5-nu
P00456424A0000 |41 47|i.c.i.hospha
P00456424A0000 |182 196|cisterna magnaas a function 
P00456424A0000 |166 174|catheterHCO3-] i
P00456424A0000 |140 147|rabbits P00008
P00456424A0000 |65 79|microgram kg-1tidase P000081
P00456424A0000 |4 11|effects01606T0
P00456424A0000 |84 98|blood pressure00 Pharmacolog
P00463973A0000 |137 140|ageia.
P00463973A0000 |147 154|infants997A047
P00463973A0000 |165 170|women[HCO3
P00463973A0000 |142 145|SGA000
P00463973A0000 |58 67|trimester-nucleoti
P00463973A0000 |176 183|infantsshown a
P00463973A0000 |198 211|birth weights CSF PCO2 the
P00463973A0000 |71 80|pregnancy P0000817
P00463973A0000 |20 29|life spanrison wit
P00463973A0000 |87 92|womenPharm
P00463973A0000 |0 15|Platelet numberP00001606T0076 
P00464387A1185 |71 87|disease activity P00008171T0000 
P00464387A1185 |62 67|indexleoti
P00464387A1185 |91 95|ABPAmaco
P00464387A1185 |29 38|serum IgEh alkalin
P00464387A1185 |7 19|measurements06T0076 Comp
P00465223A0373 |70 78|delta PUe P00008
P00465223A0373 |9 17|patientsT0076 Co
P00465223A0373 |60 66|valuesucleot
P00465223A0373 |112 114|SDne
P00465223A0373 |22 41|difference betweentson with alkaline p
P00465223A0373 |83 91|delta PM000 Phar
P00465223A0373 |116 120|mmHgatal
P00465681A0000 |87 98|blood serumPharmacolog
P00465681A0000 |194 197|atmn o
P00465681A0000 |181 186|state as a
P00465681A0000 |75 79|iron0081
P00465681A0000 |108 112|mice of 
P00465681A0000 |10 34|hemoglobin concentration0076 Comparison with alk
P00465681A0000 |210 215|statee dat
P00465681A0000 |150 153|atmA04
P00465681A0000 |129 144|oxygen pressureirubinemia. P00
P00465681A0000 |161 165|hourCSF 
P00465681A0000 |53 61|increaseand 5-nu
P00465681A0000 |2 6|rise0001
P00465829T0000 |0 6|NernstP00001
P00465829T0000 |47 61|state membranetases and 5-nu
P00465829T0000 |8 31|Planck analog equations6T0076 Comparison with 
P00465829T0000 |71 81|potentials P00008171
P00473229T0000 |0 7|EffectsP000016
P00473229T0000 |121 134|chick embryoshyperbilirubi
P00473229T0000 |91 98|toluenemacolog
P00473229T0000 |31 46|trichloroethanealkaline phosph
P00473229T0000 |11 29|methylene chloride076 Comparison wit
P00473229T0000 |106 117|developmentts of neona
P00473229T0000 |67 86|tetrachloroethylenedase P00008171T0000
P00473229T0000 |48 65|trichloroethyleneases and 5-nucleo
P00473249T0000 |0 6|EffectP00001
P00473249T0000 |91 98|rabbitsmacolog
P00473249T0000 |45 59|streptolysin Ohatases and 5-
P00473249T0000 |27 41|administrationith alkaline p
P00473249T0000 |67 87|electroencephalogramdase P00008171T0000 
P00474064A0205 |136 149|phenoperidinemia. P0000899
P00474064A0205 |92 104|mg.kg-1 I.V.acologic asp
P00474064A0205 |214 218|I.V.ta o
P00474064A0205 |177 187|sufentanilhown as a 
P00474064A0205 |122 130|morphineyperbili
P00474064A0205 |194 195|Rn
P00474064A0205 |153 154|R7
P00474064A0205 |53 63|substancesand 5-nucl
P00474064A0205 |22 42|convlusion thresholdson with alkaline ph
P00474064A0205 |106 117|piritramidets of neona
P00474064A0205 |165 173|fentanyl[HCO3-] 
P00474064A0205 |79 88|pethidine71T0000 P
P00474064A0205 |8 17|situation6T0076 Co
P00476020T0000 |51 57|growths and 
P00476020T0000 |29 34|fluidh alk
P00476020T0000 |4 16|biochemistry01606T0076 C
P00476572A0139 |109 114|casesof ne
P00476572A0139 |132 144|radiodensitybinemia. P00
P00476572A0139 |148 153|cases97A04
P00476572A0139 |26 32|lesionwith a
P00477794T0000 |0 7|EffectsP000016
P00477794T0000 |30 40|tractotomy alkaline 
P00477794T0000 |48 65|response patternsases and 5-nucleo
P00477794T0000 |95 113|nuclei principalislogic aspects of n
P00477794T0000 |69 76|neuronsse P000
P00477794T0000 |118 124|oralisal hyp
P00478714T0000 |0 8|EfficacyP0000160
P00478714T0000 |40 65|alcohol treatment programphosphatases and 5-nucleo
P00479222A0682 |0 10|ResistanceP00001606T
P00479222A0682 |99 109|propertiesc aspects 
P00479222A0682 |163 167|PECFF [H
P00479222A0682 |40 51|environmentphosphatase
P00479222A0682 |75 84|retention008171T00
P00479222A0682 |175 184|degrees C shown as
P00479222A0682 |156 161|fluidWhen 
P00479222A0682 |116 131|immersion timesatal hyperbilir
P00479222A0682 |206 211|years2 the
P00479246T0000 |31 44|osteomyelitisalkaline phos
P00481612A1121 |68 77|ventriclease P0000
P00481612A1121 |28 37|receptorsth alkali
P00481612A1121 |128 136|fentanyllirubine
P00481612A1121 |118 124|actional hyp
P00483716A0366 |48 55|carotidases an
P00483716A0366 |67 81|carotid arterydase P00008171
P00483716A0366 |114 125|anastomosisonatal hype
P00483716A0366 |3 7|case0016
P00484177A0242 |117 120|VT.tal
P00484177A0242 |90 98|CT valuermacolog
P00484177A0242 |108 113|range of n
P00484177A0242 |31 51|laminar flow regimenalkaline phosphatase
P00484177A0242 |59 69|expirationnucleotida
P00484177A0242 |5 15|expression1606T0076 
P00485615A0935 |137 145|syndromeia. P000
P00485615A0935 |149 154|order7A047
P00485615A0935 |23 32|existenceon with a
P00485615A0935 |6 10|data606T
P00485615A0935 |59 65|crisisnucleo
P00485615A0935 |106 116|importancets of neon
P00485615A0935 |209 220|performancehe data of 
P00485615A0935 |260 267|surgerywhen co
P00485615A0935 |188 200|pancreatitisunction of C
P00485615A0935 |80 86|entity1T0000
P00485615A0935 |168 178|occurrenceO3-] is sh
P00488534A0308 |3 11|addition001606T0
P00488534A0308 |26 56|Treatment X Strain interactionwith alkaline phosphatases and
P00488534A0308 |132 139|MR ratsbinemia
P00488534A0308 |79 97|defecation numbers71T0000 Pharmacolo
P00488534A0308 |172 179|MR rats is sho
P00490336A0181 |51 56|m/secs and
P00490336A0181 |58 65|group C-nucleo
P00490336A0181 |6 25|conduction velocity606T0076 Comparison
P00493818A0422 |4 12|failures01606T00
P00493818A0422 |79 82|fit71T
P00493818A0422 |131 137|monthsubinem
P00493818A0422 |40 59|patient intolerancephosphatases and 5-
P00493818A0422 |144 153|insertion008997A04
P00493818A0422 |113 117|dayseona
P00494659A0391 |18 29|metabolitesparison wit
P00494659A0391 |108 118|toloxatone of neonat
P00494659A0391 |57 86|hydroxymethyl-2-oxazolidinone5-nucleotidase P00008171T0000
P00494659A0391 |93 104|glucuronidecologic asp
P00494659A0391 |38 53|3-carboxyphenyle phosphatases 
P00495097A0663 |117 123|tissuetal hy
P00495097A0663 |95 101|matrixlogic 
P00495097A0663 |47 55|activitytases an
P00495097A0663 |6 21|characteristics606T0076 Compar
P00495097A0663 |71 86|fiber synthesis P00008171T0000
P00497494A0112 |38 43|PACO2e pho
P00497494A0112 |4 15|ventilation01606T0076 
P00499588T0000 |0 23|Carbohydrate metabolismP00001606T0076 Comparis
P00499588T0000 |56 63|insulin 5-nucl
P00499588T0000 |47 54|glucosetases a
P00499588T0000 |32 45|semen profilelkaline phosp
P00499588T0000 |69 82|sperm studiesse P00008171T
P00503336A0285 |102 122|alkaline phosphatasespects of neonatal h
P00503336A0285 |44 48|CIECphat
P00503336A0285 |196 205|diagnosisof CSF PC
P00503336A0285 |92 98|levelsacolog
P00503336A0285 |77 82|fever8171T
P00503336A0285 |58 65|attacks-nucleo
P00503336A0285 |148 153|serum97A04
P00503336A0285 |37 39|CCne
P00503336A0285 |127 140|transaminasesilirubinemia.
P00503336A0285 |21 25|CAECison
P00503336A0285 |170 178|findings-] is sh
P00506559A0000 |37 45|furfuralne phosp
P00506559A0000 |75 83|hamsters008171T0
P00506559A0000 |14 33|inhalation toxicity Comparison with al
P00506649T0000 |0 7|ChangesP000016
P00506649T0000 |22 46|serum protein componentsson with alkaline phosph
P00506649T0000 |66 72|stressidase 
P00509703A0581 |6 17|differences606T0076 Co
P00509703A0581 |63 72|textbookseotidase 
P00510341T0036 |2 7|study00016
P00510341T0036 |15 25|E.O.R.T.C.Comparison
P00512215A0000 |68 69|La
P00512215A0000 |156 158|f1Wh
P00512215A0000 |178 180|L2ow
P00512215A0000 |95 105|parameterslogic aspe
P00512215A0000 |122 127|inputyperb
P00512215A0000 |31 41|dependencealkaline p
P00512215A0000 |161 163|L1CS
P00512215A0000 |12 17|study76 Co
P00512215A0000 |133 138|f2/f1inemi
P00512215A0000 |165 167|L2[H
P00512215A0000 |45 66|difference tone levelhatases and 5-nucleot
P00512215A0000 |173 175|L1is
P00512215A0000 |129 131|f1ir
P00512215A0000 |140 142|f2 P
P00512215A0000 |70 75|f2-f1e P00
P00513284A0000 |170 186|pediatrics field-] is shown as a
P00513284A0000 |261 263|mlhe
P00513284A0000 |127 140|drip infusionilirubinemia.
P00513284A0000 |267 283|glucose solutionmpared to contro
P00513284A0000 |147 153|series997A04
P00513284A0000 |61 67|Pfizercleoti
P00513284A0000 |30 41|doxycycline alkaline p
P00513284A0000 |224 228|DOTCplet
P00513284A0000 |49 59|Vibramycinses and 5-
P00513284A0000 |86 98|tetracycline Pharmacolog
P00513284A0000 |293 298|mg/kgll ha
P00513284A0000 |157 162|studyhen C
P00513284A0000 |196 203|resultsof CSF 
P00513284A0000 |15 26|preparationComparison 
P00513284A0000 |43 47|DOTCspha
P00513284A0000 |234 236|mgs 
P00513284A1255 |18 22|dayspari
P00513284A1255 |44 60|laboratory testsphatases and 5-n
P00513284A1255 |95 100|bloodlogic
P00513284A1255 |29 42|DOTC infusionh alkaline ph
P00513284A1255 |65 70|livertidas
P00513284A1255 |81 90|functionsT0000 Pha
P00516545T0001 |34 54|erythrocyte membranealine phosphatases a
P00516545T0001 |56 78|peroxidation processes 5-nucleotidase P00008
P00516545T0001 |11 26|characteristics076 Comparison 
P00516545T0001 |107 115|childrens of neo
P00516545T0001 |95 103|functionlogic as
P00516545T0001 |129 147|glomerulonephritisirubinemia. P00008
P00517890A0468 |85 91|levels0 Phar
P00517890A0468 |149 157|jaundice7A0472 W
P00517890A0468 |60 71|hepatitis Aucleotidase
P00517890A0468 |43 55|transmissionsphatases an
P00517890A0468 |95 122|hepatitis A virus excretionlogic aspects of neonatal h
P00517890A0468 |12 17|route76 Co
P00517890A0468 |140 145|onset P000
P00517890A0468 |35 39|modeline
P00519173A0126 |34 42|evidencealine ph
P00519173A0126 |46 58|oesophagitisatases and 5
P00519173A0126 |7 15|patients06T0076 
P00521732T0000 |21 29|oestroneison wit
P00521732T0000 |93 122|steroid sulphatase deficiencycologic aspects of neonatal h
P00521732T0000 |8 17|excretion6T0076 Co
P00521732T0000 |31 49|oestradiol-17 betaalkaline phosphata
P00521732T0000 |66 77|pregnanciesidase P0000
P00521732T0000 |54 62|oestriolnd 5-nuc
P00524451A0136 |220 223|ratK-d
P00524451A0136 |124 137|hexobarbitoneerbilirubinem
P00524451A0136 |73 78|death00008
P00524451A0136 |47 51|micetase
P00524451A0136 |165 174|depletion[HCO3-] i
P00524451A0136 |104 112|toxicityects of 
P00524451A0136 |178 192|catecholaminesown as a funct
P00524451A0136 |25 43|locomotor activity with alkaline pho
P00524451A0136 |147 151|time997A
P00524451A0136 |206 212|organs2 the 
P00524451A0136 |84 95|amphetamine00 Pharmaco
P00528144T0000 |34 40|uptakealine 
P00528144T0000 |44 51|galliumphatase
P00528144T0000 |15 26|transferrinComparison 
P00528144T0000 |7 11|role06T0
P00528144T0000 |55 66|tumor cellsd 5-nucleot
P00534613A0000 |0 11|IrradiationP00001606T0
P00534613A0000 |42 46|UV-Aosph
P00534613A0000 |21 36|blood plateletsison with alkal
P00534613A0000 |112 120|collagenneonatal
P00534613A0000 |97 106|challengegic aspec
P00534613A0000 |81 90|aggregateT0000 Pha
P00534613A0000 |70 77|abilitye P0000
P00535520A0239 |86 101|cholangiography Pharmacologic 
P00535520A0239 |13 23|exceptions6 Comparis
P00535520A0239 |28 34|methodth alk
P00540707A0255 |68 81|complicationsase P00008171
P00540707A0255 |151 166|pouch haematoma0472 When CSF [
P00540707A0255 |241 249|approacho longer
P00540707A0255 |51 58|accounts and 5
P00540707A0255 |119 124|casesl hyp
P00540707A0255 |254 270|PMK implantationlaced when compa
P00540707A0255 |293 296|usell 
P00540707A0255 |27 34|resultsith alk
P00540707A0255 |130 146|tip displacementrubinemia. P0000
P00540707A0255 |195 202|Authors of CSF
P00540707A0255 |224 230|methodpleted
P00540707A0255 |108 112|rate of 
P00540707A0255 |304 318|vena cephalicaignificantly g
P00541752A1032 |156 158|SDWh
P00541752A1032 |104 110|valuesects o
P00541752A1032 |91 98|Octobermacolog
P00541752A1032 |45 52|sampleshatases
P00541752A1032 |160 165|ng/ml CSF 
P00541752A1032 |147 151|mean997A
P00541752A1032 |56 62|plasma 5-nuc
P00541752A1032 |9 23|determinationsT0076 Comparis
P00541752A1032 |81 87|adultsT0000 
P00550399A0615 |18 24|causespariso
P00550399A0615 |61 67|groupscleoti
P00550399A0615 |28 33|deathth al
P00553858A0000 |17 26|operationmparison 
P00553858A0000 |9 14|GriceT0076
P00553858A0000 |133 145|publicationsinemia. P000
P00553858A0000 |192 197|termsion o
P00553858A0000 |75 82|account008171T
P00553858A0000 |159 168|techniquen CSF [HC
P00553858A0000 |231 241|principlesrats are n
P00553858A0000 |111 121|literature neonatal 
P00553858A0000 |54 59|worldnd 5-
P00553858A0000 |255 264|operationaced when
P00555492A1034 |51 61|blood flows and 5-nu
P00555492A1034 |181 195|blood pressure as a function
P00555492A1034 |145 149|flow0899
P00555492A1034 |126 135|injectionbilirubin
P00555492A1034 |88 97|injectionharmacolo
P00555492A1034 |7 14|changes06T0076
P00555492A1034 |101 111|cimetidineaspects of
P00555495T0000 |0 5|StudyP0000
P00555495T0000 |29 38|ovulationh alkalin
P00555495T0000 |74 83|treatment0008171T0
P00555495T0000 |45 56|terminationhatases and
P00555495T0000 |156 164|deliveryWhen CSF
P00555495T0000 |9 25|re-establishmentT0076 Comparison
P00555495T0000 |133 141|abortioninemia. 
P00555495T0000 |100 113|re-appearance aspects of n
P00555495T0000 |117 126|ovulationtal hyper
P00555583T0000 |0 16|PharmacokineticsP00001606T0076 C
P00555583T0000 |44 50|reviewphatas
P00555583T0000 |37 40|manne 
P00555583T0000 |20 33|Carbamazepinerison with al
P00557559A0170 |171 180|organisms] is show
P00557559A0170 |57 84|N-methylnitrone 1,4-dioxide5-nucleotidase P00008171T00
P00557559A0170 |109 114|agentof ne
P00557559A0170 |25 30|alpha with
P00557559A0170 |7 16|compounds06T0076 C
P00564032A0724 |17 24|contentmpariso
P00564032A0724 |82 90|pressure0000 Pha
P00564032A0724 |108 112|duct of 
P00564032A0724 |120 125|gland hype
P00564032A0724 |64 74|mechanismsotidase P0
P00564032A0724 |0 7|ChangesP000016
P00564943A0444 |0 6|CalvesP00001
P00564943A0444 |78 79|T1
P00564943A0444 |11 19|MCT-milk076 Comp
P00564943A0444 |44 61|blood cholesterolphatases and 5-nu
P00564943A0444 |67 73|calvesdase P
P00564943A0444 |84 92|SBO-milk00 Pharm
P00565136T0000 |71 77|SO2Cl2 P0000
P00565136T0000 |56 61|doses 5-nu
P00565136T0000 |83 86|Br2000
P00565136T0000 |36 46|inhalationine phosph
P00565136T0000 |8 17|mortality6T0076 Co
P00565136T0000 |65 69|CH2Otida
P00565136T0000 |21 25|miceison
P00565314A0293 |0 11|Guinea pigsP00001606T0
P00565314A0293 |43 44|gs
P00569989A0239 |119 125|dPn/dtl hype
P00569989A0239 |177 193|pneumotachographhown as a functi
P00569989A0239 |150 155|apneaA0472
P00569989A0239 |86 115|acceleration pneumocardiogram Pharmacologic aspects of neo
P00569989A0239 |55 59|PnCGd 5-
P00569989A0239 |6 26|halothane anesthesia606T0076 Comparison 
P00569989A0239 |32 53|flow pneumocardiogramlkaline phosphatases 
P00569989A0239 |69 73|timese P
P00574222T0000 |35 46|developmentline phosph
P00574222T0000 |58 68|prostheses-nucleotid
P00574222T0000 |8 16|kindling6T0076 C
P00574222T0000 |18 30|implicationsparison with
P00574956A0304 |141 152|equilibriumP00008997A0
P00574956A0304 |269 280|developmentared to con
P00574956A0304 |194 201|systemsn of CS
P00574956A0304 |58 62|case-nuc
P00574956A0304 |94 98|toneolog
P00574956A0304 |300 313|manifestation a significan
P00574956A0304 |232 240|dopamineats are 
P00574956A0304 |21 31|stereotypyison with 
P00575231A0422 |0 4|NoneP000
P00575231A0422 |47 68|detrusor contractionstases and 5-nucleotid
P00575231A0422 |12 27|cystometrograms76 Comparison w
P00577440A0298 |49 53|doseses 
P00577440A0298 |73 95|3H-alpha-acetyldigoxin00008171T0000 Pharmaco
P00577440A0298 |24 28|partn wi
P00577440A0298 |7 15|duodenum06T0076 
P00578648T0048 |38 52|administratione phosphatases
P00578648T0048 |11 18|effects076 Com
P00580106T0000 |0 9|TreatmentP00001606
P00580106T0000 |13 19|Graves6 Comp
P00580106T0000 |21 28|diseaseison wi
P00580151A0706 |220 227|effectsK-deple
P00580151A0706 |74 86|testosterone0008171T0000
P00580151A0706 |241 246|doseso lon
P00580151A0706 |197 201|costf CS
P00580151A0706 |160 167|patient CSF [H
P00580151A0706 |130 135|rangerubin
P00580151A0706 |99 110|se-T levelsc aspects o
P00580151A0706 |141 152|convenienceP00008997A0
P00583004A0445 |69 93|1,8-diacetoxy-9-anthronese P00008171T0000 Pharma
P00583004A0445 |126 133|lesionsbilirub
P00583004A0445 |176 180|skinshow
P00583004A0445 |12 36|1,8-dihydroxy-9-anthrone76 Comparison with alkal
P00583004A0445 |38 64|1,8,9-triacetoxyanthracenee phosphatases and 5-nucle
P00583004A0445 |155 168|inflammations When CSF [HC
P00583522T0001 |33 41|problemskaline p
P00583522T0001 |59 71|inflammationnucleotidase
P00587791T0054 |0 7|NursingP000016
P00587791T0054 |11 19|patients076 Comp
P00587791T0054 |39 47|diseases phospha
P00589073A0000 |205 216|infertilityO2 the data
P00589073A0000 |194 201|historyn of CS
P00589073A0000 |164 172|patients [HCO3-]
P00589073A0000 |120 127|control hyperb
P00589073A0000 |99 104|phasec asp
P00589073A0000 |54 61|samplesnd 5-nu
P00589073A0000 |129 134|womenirubi
P00589073A0000 |18 49|plasma prolactin concentrationsparison with alkaline phosphata
P00589073A0000 |152 157|group472 W
P00590594T0000 |8 27|allotransplantation6T0076 Comparison w
P00592887T0000 |21 39|Patent Blue Violetison with alkaline
P00592887T0000 |47 59|lymphographytases and 5-
P00592887T0000 |9 17|reactionT0076 Co
P00593119T0001 |0 9|ScreeningP00001606
P00593119T0001 |60 73|comprehensionucleotidase P
P00593119T0001 |77 85|spectrum8171T000
P00593119T0001 |13 28|asthma patients6 Comparison wi
P00593119T0001 |105 119|IgE antibodiescts of neonata
P00593119T0001 |32 45|determinationlkaline phosp
P00593119T0001 |49 52|IgEses
P00594466T0001 |17 25|seizuresmparison
P00594466T0001 |53 65|allylglycineand 5-nucleo
P00594466T0001 |78 89|combination171T0000 Ph
P00594466T0001 |30 41|Papio papio alkaline p
P00594466T0001 |4 13|induction01606T007
P00594466T0001 |115 126|stimulationnatal hyper
P00594617A0192 |102 105|FDPspe
P00594617A0192 |300 305|fever a si
P00594617A0192 |270 275|signsred t
P00594617A0192 |150 163|insufficiencyA0472 When CS
P00594617A0192 |21 32|correlationison with a
P00594617A0192 |55 63|presenced 5-nucl
P00594617A0192 |115 124|incidencenatal hyp
P00594617A0192 |80 100|degradation products1T0000 Pharmacologic
P00594617A0192 |217 222|Godalof K-
P00594617A0192 |188 196|presenceunction 
P00594617A0192 |319 322|ESReat
P00594617A0192 |225 250|ethanol-gelification testleted rats are no longer 
P00594617A0192 |291 298|diseasetill ha
P00594617A0192 |128 139|nephropathylirubinemia
P00594617A0192 |207 215|monomers the dat
P00597715A0256 |17 20|menmpa
P00597715A0256 |26 37|azoospermiawith alkali
P00597715A0256 |47 60|sperm densitytases and 5-n
P00597715A0256 |150 156|othersA0472 
P00597715A0256 |184 193|prognosis a functi
P00597715A0256 |96 109|FSH elevationogic aspects 
P00597715A0256 |142 146|work0000
P00597715A0256 |118 128|experienceal hyperbi
P00597715A0256 |0 9|One-thirdP00001606
P00598012A0174 |34 39|stagealine
P00598012A0174 |77 81|boys8171
P00598012A0174 |94 100|changeologic
P00598012A0174 |104 120|prolactin levelsects of neonatal
P00598012A0174 |64 72|menarcheotidase 
P00598012A0174 |3 25|girls prolactin levels001606T0076 Comparison
P00599601A0260 |154 164|physiology2 When CSF
P00599601A0260 |122 133|alterationsyperbilirub
P00599601A0260 |45 55|procedureshatases an
P00599601A0260 |193 196|raton 
P00599601A0260 |77 89|pinealectomy8171T0000 Ph
P00600943T0001 |17 36|lymphomononucleosismparison with alkal
P00600943T0001 |2 7|cases00016
P00601401A0181 |69 75|oxygense P00
P00601401A0181 |8 27|hemoglobin solution6T0076 Comparison w
P00601401A0181 |56 64|affinity 5-nucle
P00601401A0181 |86 97|Bohr effect Pharmacolo
P00601401A0181 |117 145|delta log Po2/delta pH ratiotal hyperbilirubinemia. P000
P00602622A0362 |138 146|activitya. P0000
P00602622A0362 |30 38|atropine alkalin
P00602622A0362 |52 57|Roter and 
P00602622A0362 |43 50|Vikalinsphatas
P00602622A0362 |11 24|ulcer therapy076 Compariso
P00602622A0362 |99 108|reductionc aspects
P00602622A0362 |81 82|pT
P00602702A0309 |100 108|function aspects
P00602702A0309 |128 149|estriol concentrationlirubinemia. P0000899
P00602702A0309 |40 61|estriol concentrationphosphatases and 5-nu
P00602702A0309 |27 35|diarrheaith alka
P00602702A0309 |65 70|serumtidas
P00602702A0309 |7 14|patient06T0076
P00602702A0309 |175 183|diarrhea shown a
P00603783A0647 |0 12|Serum levelsP00001606T00
P00603783A0647 |24 27|IgMn w
P00603783A0647 |16 19|IgGomp
P00603783A0647 |66 74|findingsidase P0
P00603783A0647 |84 104|observers IgA levels00 Pharmacologic asp
P00606849T0000 |65 72|rabbitstidase 
P00606849T0000 |47 61|thromboxane A2tases and 5-nu
P00606849T0000 |22 35|heart diseaseson with alka
P00614915T0001 |0 10|VitrectomyP00001606T
P00614915T0001 |21 33|traumatologyison with al
P00616575A0000 |103 118|decimeter wavespects of neonat
P00616575A0000 |165 178|unit activity[HCO3-] is sh
P00616575A0000 |120 123|EMF hy
P00616575A0000 |94 99|fieldologi
P00616575A0000 |41 57|brain structureshosphatases and 
P00616575A0000 |13 24|sensitivity6 Compariso
P00616575A0000 |65 71|actiontidase
P00616575A0000 |127 129|DWil
P00616575A0000 |141 154|investigationP00008997A047
P00617815A0215 |14 29|L-R differences Comparison wit
P00618078A0367 |2 10|decrease0001606T
P00618078A0367 |64 75|improvementotidase P00
P00618078A0367 |93 103|meningitiscologic as
P00618078A0367 |18 35|lysozyme activityparison with alka
P00619305A0759 |85 95|dimensions0 Pharmaco
P00619305A0759 |58 67|dimension-nucleoti
P00619305A0759 |22 28|groupsson wi
P00619782A0058 |87 108|ultraviolet radiationPharmacologic aspects
P00619782A0058 |110 114|UV-Af ne
P00619782A0058 |41 51|volunteershosphatase
P00619782A0058 |5 9|tans1606
P00619782A0058 |66 74|exposureidase P0
P00619782A0058 |32 37|backslkali
P00619948A0000 |343 345|mg23
P00619948A0000 |373 384|propranololam thus app
P00619948A0000 |237 243|scalesre no 
P00619948A0000 |173 176|CNVis 
P00619948A0000 |162 171|variationSF [HCO3-
P00619948A0000 |107 109|mgs 
P00619948A0000 |50 54|dosees a
P00619948A0000 |292 302|depressionill have a
P00619948A0000 |114 127|nortriptylineonatal hyperb
P00619948A0000 |248 257|alertnessr displac
P00619948A0000 |354 356|mg10
P00619948A0000 |179 192|reaction timewn as a funct
P00619948A0000 |58 65|Motival-nucleo
P00619948A0000 |362 369|placebo33 Flur
P00619948A0000 |259 266|anxiety when c
P00619948A0000 |24 32|subjectsn with a
P00619948A0000 |331 339|diazepam(1.21 +/
P00619948A0000 |389 391|mgto
P00619948A0000 |268 275|tensionpared t
P00619948A0000 |90 102|fluphenazinermacologic a
P00619948A0000 |277 287|detachmentcontrols b
P00619948A0000 |131 133|mgub
P00619948A0000 |194 204|heart raten of CSF P
P00619948A0000 |206 220|blood pressure2 the data of 
P00619948A0000 |6 13|effects606T007
P00619948A0000 |71 77|tablet P0000
P00621626T0000 |0 14|Stress effectsP00001606T0076
P00621626T0000 |72 76|typeP000
P00621626T0000 |18 41|affiliation preferencesparison with alkaline p
P00621626T0000 |94 110|behavior patternologic aspects o
P00621626T0000 |48 56|subjectsases and
P00622556A0111 |20 28|collagenrison wi
P00622556A0111 |78 84|tendon171T00
P00622556A0111 |37 43|tissuene pho
P00623361A0221 |34 46|contributionaline phosph
P00623361A0221 |60 71|dysfunctionucleotidase
P00623361A0221 |0 7|SmokingP000016
P00626014T0001 |4 13|malignity01606T007
P00626014T0001 |24 31|lentigon with 
P00627039T0000 |0 11|EliminationP00001606T0
P00627039T0000 |15 25|bagassosisComparison
P00627039T0000 |29 72|Louisiana paper manufacturing plant workersh alkaline phosphatases and 5-nucleotidase 
P00627129A0944 |205 223|beta-adrenoceptorsO2 the data of K-d
P00627129A0944 |183 191|blockades a func
P00627129A0944 |6 15|responses606T0076 
P00627129A0944 |146 155|labetalol8997A0472
P00627129A0944 |78 88|conditions171T0000 P
P00627129A0944 |35 41|othersline p
P00627129A0944 |54 62|subjectsnd 5-nuc
P00627129A0944 |136 142|effectmia. P
P00627202T0000 |0 9|DiureticsP00001606
P00627202T0000 |26 38|pharmacologywith alkalin
P00627202T0000 |55 58|used 5
P00628990A0000 |38 43|unitse pho
P00628990A0000 |97 116|ureteroureterostomygic aspects of neon
P00628990A0000 |133 153|ureteroneocystostomyinemia. P00008997A04
P00628990A0000 |72 86|reconstructionP00008171T0000
P00628990A0000 |6 14|patients606T0076
P00628990A0000 |189 201|ureterostomynction of CS
P00628990A0000 |174 178|loops sh
P00630713T0000 |0 10|EvaluationP00001606T
P00630713T0000 |18 47|Du Pont aca ammonia procedureparison with alkaline phospha
P00633909A0000 |49 72|Internal-External Locusses and 5-nucleotidase 
P00633909A0000 |30 36|scores alkal
P00633909A0000 |197 204|controlf CSF P
P00633909A0000 |76 89|Control Scale08171T0000 Ph
P00633909A0000 |40 46|Rotterphosph
P00633909A0000 |20 28|patientsrison wi
P00633909A0000 |113 122|treatmenteonatal h
P00633909A0000 |156 164|patientsWhen CSF
P00635143T0001 |0 6|ActionP00001
P00635143T0001 |27 35|metaphosith alka
P00635143T0001 |10 22|strontium-900076 Compari
P00635143T0001 |39 54|Cyprinus carpio phosphatases a
P00635194A0093 |0 15|Kodak XV-2 filmP00001606T0076 
P00635194A0093 |77 94|dose distribution8171T0000 Pharmac
P00636526T0033 |0 9|DiagnosisP00001606
P00636526T0033 |27 36|diagnosisith alkal
P00637637T0000 |66 78|hypertensionidase P00008
P00637637T0000 |31 52|plasma renin activityalkaline phosphatases
P00637637T0000 |13 20|factors6 Compa
P00639410T0000 |51 72|lipid clearing agentss and 5-nucleotidase 
P00639410T0000 |18 30|bone changesparison with
P00639410T0000 |39 47|response phospha
P00639410T0000 |0 9|CortisoneP00001606
P00640584A0250 |55 64|stabilityd 5-nucle
P00640584A0250 |20 29|principlerison wit
P00641395A0441 |174 191|extraction methods shown as a func
P00641395A0441 |104 115|fluorimeterects of neo
P00641395A0441 |145 151|levels08997A
P00641395A0441 |92 95|ZPPaco
P00641395A0441 |77 88|measurement8171T0000 P
P00641395A0441 |36 54|hyperbilirubinemiaine phosphatases a
P00641395A0441 |22 30|patientsson with
P00641395A0441 |5 18|blood samples1606T0076 Com
P00644314T0000 |33 40|effectskaline 
P00644314T0000 |8 24|hypersensitivity6T0076 Compariso
P00644314T0000 |28 31|manth 
P00644314T0000 |53 68|anticoagulationand 5-nucleotid
P00644539A0783 |49 55|salineses an
P00644539A0783 |133 140|subjectinemia.
P00644539A0783 |88 89|%h
P00644539A0783 |143 152|reactions0008997A0
P00644539A0783 |23 33|inhalationon with al
P00644539A0783 |160 174|test solutions CSF [HCO3-] i
P00644539A0783 |65 69|FEV1tida
P00644539A0783 |39 41|ml p
P00644539A0783 |81 82|%T
P00646023T0058 |58 70|transmission-nucleotidas
P00646023T0058 |13 20|studies6 Compa
P00646023T0058 |24 39|virus excretionn with alkaline
P00646193T0000 |0 7|PotencyP000016
P00646193T0000 |60 70|isofluraneucleotidas
P00646193T0000 |30 40|comparison alkaline 
P00646193T0000 |11 20|enflurane076 Compa
P00646193T0000 |46 55|halothaneatases an
P00646193T0000 |24 28|dogsn wi
P00656008T0000 |0 10|PreventionP00001606T
P00656008T0000 |20 37|paraquat toxicityrison with alkali
P00656008T0000 |41 45|ratshosp
P00656008T0000 |49 69|superoxide dismutaseses and 5-nucleotida
P00657551T0000 |0 11|MeasurementP00001606T0
P00657551T0000 |15 35|magnesium absorptionComparison with alka
P00657551T0000 |66 72|traceridase 
P00657551T0000 |56 60|26Mg 5-n
P00657551T0000 |39 42|man ph
P00659962T0000 |18 38|riboflavin excretionparison with alkalin
P00659962T0000 |60 74|acid ingestionucleotidase P0
P00663166A0000 |205 227|Eisenmenger physiologyO2 the data of K-deple
P00663166A0000 |195 198|PDA of
P00663166A0000 |93 105|particulatescologic aspe
P00663166A0000 |42 54|body imagingosphatases a
P00663166A0000 |13 24|angiography6 Compariso
P00663166A0000 |155 163|patients When CS
P00663166A0000 |143 151|shunting0008997A
P00663166A0000 |169 193|patent ductus arteriosus3-] is shown as a functi
P00664320T0000 |38 45|pathwaye phosp
P00664320T0000 |8 17|detectors6T0076 Co
P00665053A0276 |80 95|group affection1T0000 Pharmaco
P00665053A0276 |45 50|06a6bhatas
P00665053A0276 |52 55|K13 an
P00665053A0276 |57 59|H15-
P00665053A0276 |39 43|type pho
P00665214A0374 |4 10|method01606T
P00665214A0374 |78 83|cycle171T0
P00665214A0374 |54 64|physiologynd 5-nucle
P00665336A0908 |51 66|EEG-informations and 5-nucleot
P00665336A0908 |12 16|time76 C
P00668122A0414 |0 8|AnalysisP0000160
P00668122A0414 |79 88|variation71T0000 P
P00668122A0414 |12 34|liver biopsy specimens76 Comparison with alk
P00668122A0414 |121 145|liver ferritin moleculeshyperbilirubinemia. P000
P00668122A0414 |96 113|mean iron contentogic aspects of n
P00668122A0414 |40 48|patientsphosphat
P00668122A0414 |54 63|hepatitisnd 5-nucl
P00669800A0579 |49 58|infectionses and 5
P00669800A0579 |7 11|mice06T0
P00669800A0579 |64 69|malesotida
P00676416A0320 |50 64|liver biopsieses and 5-nucle
P00676416A0320 |27 32|yearsith a
P00676790T0000 |0 18|Angiotensin effectP00001606T0076 Com
P00676790T0000 |32 38|kidneylkalin
P00681550A0000 |0 7|ProcionP000016
P00681550A0000 |107 119|relationships of neonata
P00681550A0000 |180 191|terminationn as a func
P00681550A0000 |78 86|goldfish171T0000
P00681550A0000 |208 214|maculathe da
P00681550A0000 |132 145|response typebinemia. P000
P00681550A0000 |172 176|site is 
P00681550A0000 |59 74|auditory fibersnucleotidase P0
P00681550A0000 |155 161|fibers When 
P00681571T0028 |27 36|epidermisith alkal
P00681571T0028 |63 87|eccrine sweat duct unitseotidase P00008171T0000 
P00681571T0028 |11 19|findings076 Comp
P00682762T0001 |0 19|Silicosis mortalityP00001606T0076 Comp
P00685922A0451 |83 86|IHB000
P00685922A0451 |31 41|stricturesalkaline p
P00685922A0451 |77 81|tree8171
P00686836A0000 |0 7|PentaneP000016
P00686836A0000 |167 171|dietCO3-
P00686836A0000 |106 120|breath samplests of neonatal
P00686836A0000 |12 18|ethane76 Com
P00686836A0000 |209 229|IU vitamin E acetatehe data of K-deplete
P00686836A0000 |39 57|lipid peroxidation phosphatases and 
P00686836A0000 |147 154|vitamin997A047
P00686836A0000 |124 128|ratserbi
P00686836A0000 |139 144|weeks. P00
P00686836A0000 |234 236|kgs 
P00686836A0000 |84 102|gas chromatography00 Pharmacologic a
P00693987T0001 |0 14|ThromboplasticP00001606T0076
P00693987T0001 |123 133|infarctionperbilirub
P00693987T0001 |151 155|life0472
P00693987T0001 |60 74|administrationucleotidase P0
P00693987T0001 |143 147|year0008
P00693987T0001 |92 95|menaco
P00693987T0001 |78 88|intralipid171T0000 P
P00693987T0001 |101 108|historyaspects
P00693987T0001 |48 53|bloodases 
P00693987T0001 |32 40|activitylkaline 
P00696680A0000 |84 101|rhabdomyosarcomas00 Pharmacologic 
P00696680A0000 |125 136|endometriumrbilirubine
P00696680A0000 |41 49|findingshosphata
P00696680A0000 |73 78|women00008
P00696680A0000 |140 146|cervix P0000
P00696680A0000 |58 63|cases-nucl
P00696680A0000 |4 11|authors01606T0
P00696858A0000 |136 152|porcine pancreasmia. P00008997A0
P00696858A0000 |47 56|endocrinetases and
P00696858A0000 |4 10|effect01606T
P00696858A0000 |27 43|porcine secretinith alkaline pho
P00696858A0000 |81 90|secretionT0000 Pha
P00701144T0000 |34 44|lens poweraline phos
P00701144T0000 |10 18|analysis0076 Com
P00701144T0000 |92 100|implantsacologic
P00701144T0000 |77 84|results8171T00
P00701144T0000 |65 75|emmetropiatidase P00
P00701462A0722 |0 16|Urine antibodiesP00001606T0076 C
P00701462A0722 |56 61|cases 5-nu
P00702773A0327 |0 11|Althoug RBFP00001606T0
P00702773A0327 |104 107|GFRect
P00702773A0327 |120 126|output hyper
P00702773A0327 |41 48|therapyhosphat
P00702773A0327 |89 95|changearmaco
P00702773A0327 |99 102|RBFc a
P00703350A0418 |34 39|99mTcaline
P00703350A0418 |49 56|sulfideses and
P00703350A0418 |15 28|198Au colloidComparison wi
P00703350A0418 |0 13|99mTc phytateP00001606T007
P00703932A0000 |18 36|glomerulonephritisparison with alkal
P00703932A0000 |40 51|associationphosphatase
P00703932A0000 |123 130|therapyperbili
P00703932A0000 |114 119|modesonata
P00703932A0000 |78 83|shunt171T0
P00703932A0000 |4 12|patients01606T00
P00704675A0199 |154 161|trachea2 When 
P00704675A0199 |142 146|mass0000
P00704675A0199 |108 118|inhalation of neonat
P00704675A0199 |56 67|bifurcation 5-nucleoti
P00704675A0199 |12 15|UO276 
P00704675A0199 |38 45|bronchie phosp
P00704675A0199 |4 8|mass0160
P00704675A0199 |100 101|d 
P00710217T0001 |22 31|hip jointson with 
P00710217T0001 |9 14|cystsT0076
P00710372A0302 |71 79|function P000081
P00710372A0302 |25 36|dysfunction with alkal
P00710372A0302 |94 107|GH deficiencyologic aspect
P00710372A0302 |143 151|features0008997A
P00712117A0521 |48 52|baseases
P00712117A0521 |60 68|Februaryucleotid
P00712117A0521 |146 155|prototpye8997A0472
P00712117A0521 |130 142|A/Victoria/3rubinemia. P
P00712117A0521 |106 111|virusts of
P00712117A0521 |88 97|A/Texas/1harmacolo
P00712117A0521 |20 31|influenza Arison with 
P00712117A0521 |8 16|outbreak6T0076 C
P00712117A0521 |115 122|variantnatal h
P00713525A0268 |81 93|presentationT0000 Pharma
P00713525A0268 |162 167|modelSF [H
P00713525A0268 |107 121|stimulus wordss of neonatal 
P00713525A0268 |45 55|stutterershatases an
P00713525A0268 |25 41|disfluency rates with alkaline p
P00713525A0268 |8 17|decreases6T0076 Co
P00713525A0268 |127 131|datailir
P00715180T0074 |0 6|EffectP00001
P00715180T0074 |27 38|alterationsith alkalin
P00715180T0074 |10 14|time0076
P00715180T0074 |63 92|plutonium-239 dioxide aerosoleotidase P00008171T0000 Pharm
P00715180T0074 |19 23|dosearis
P00715180T0074 |96 99|ratogi
P00715180T0074 |49 59|inhalationses and 5-
P00715753A0241 |138 143|CK-MBa. P0
P00715753A0241 |57 58|%5
P00715753A0241 |124 134|% fractionerbilirubi
P00715753A0241 |47 50|CPKtas
P00715753A0241 |3 26|biopsies CK-MB fraction001606T0076 Comparison 
P00715753A0241 |64 82|total-CPK activityotidase P00008171T
P00715753A0241 |101 108|musclesaspects
P00716366T0001 |0 5|ValueP0000
P00716366T0001 |121 136|liver cirrhosishyperbilirubine
P00716366T0001 |75 84|diagnosis008171T00
P00716366T0001 |9 22|determinationT0076 Compari
P00716366T0001 |26 57|alkaline phosphatase isoenzymeswith alkaline phosphatases and 
P00716366T0001 |100 108|jaundice aspects
P00722298A0619 |305 310|malesgnifi
P00722298A0619 |75 86|differences008171T0000
P00722298A0619 |187 194|femalesfunctio
P00722298A0619 |22 30|varianceson with
P00722298A0619 |57 60|men5-n
P00722298A0619 |146 158|significance8997A0472 Wh
P00722298A0619 |121 137|field dependencehyperbilirubinem
P00722298A0619 |110 116|groupsf neon
P00722298A0619 |10 18|analysis0076 Com
P00722298A0619 |281 287|groupsrols b
P00722298A0619 |160 163|rho CS
P00722298A0619 |235 240|field are 
P00722298A0619 |65 70|womentidas
P00722298A0619 |205 211|famaleO2 the
P00722652A0118 |136 141|cecummia. 
P00722652A0118 |121 128|surfacehyperbi
P00722652A0118 |80 90|micrometer1T0000 Pha
P00722652A0118 |13 37|2nd-generation schizonts6 Comparison with alkali
P00722652A0118 |55 63|diameterd 5-nucl
P00725257A0452 |50 53|DHEes 
P00725257A0452 |66 68|M.id
P00725257A0452 |15 25|pD2 valuesComparison
P00725257A0452 |39 40|E 
P00725336T0000 |0 36|Newcastle disease virus surveillanceP00001606T0076 Comparison with alkal
P00725336T0000 |72 79|poultryP000081
P00725336T0000 |40 49|Hong Kongphosphata
P00725534A0888 |34 43|challengealine pho
P00725534A0888 |47 56|M. lepraetases and
P00725534A0888 |165 179|IgA deficiency[HCO3-] is sho
P00725534A0888 |269 276|leprosyared to
P00725534A0888 |80 95|IgA immunocytes1T0000 Pharmaco
P00725534A0888 |144 153|tolerance008997A04
P00725534A0888 |230 235|villi rats
P00725534A0888 |243 251|patientslonger d
P00725534A0888 |64 72|antigensotidase 
P00725534A0888 |114 124|epitheliumonatal hyp
P00725534A0888 |204 211|atrophyCO2 the
P00725752T0001 |0 9|TreatmentP00001606
P00725752T0001 |88 95|obsidanharmaco
P00725752T0001 |13 25|hypertension6 Comparison
P00725752T0001 |105 116|vasodilatorcts of neon
P00725752T0001 |33 44|combinationkaline phos
P00725752T0001 |63 86|beta receptor blockadereotidase P00008171T0000
P00725752T0001 |118 126|apressinal hyper
P00726581T0122 |0 6|OrthopP00001
P00728718T0000 |0 15|Thyroid diseaseP00001606T0076 
P00728718T0000 |20 29|pregnancyrison wit
P00729003A1182 |0 8|ResiduesP0000160
P00729003A1182 |22 33|transcriptsson with al
P00729003A1182 |37 45|splicingne phosp
P00733067A0188 |34 38|loopalin
P00733067A0188 |291 310|spiral introflexiontill have a signifi
P00733067A0188 |156 168|constructionWhen CSF [HC
P00733067A0188 |176 187|anastomosisshown as a 
P00733067A0188 |214 222|creationta of K-
P00733067A0188 |245 257|valve systemnger displac
P00733067A0188 |391 396|lumen be a
P00733067A0188 |62 67|stepsleoti
P00733067A0188 |108 115|section of neo
P00733067A0188 |131 136|stumpubine
P00733067A0188 |12 18|reflux76 Com
P00733067A0188 |318 324|mucosareater
P00733067A0188 |276 287|anastomosis controls b
P00733067A0188 |42 48|numberosphat
P00733067A0188 |342 350|stitches.23 vs. 
P00736376A0371 |33 42|mortalitykaline ph
P00736376A0371 |121 126|skillhyper
P00736376A0371 |104 113|operationects of n
P00736376A0371 |8 13|stage6T007
P00736376A0371 |89 96|urgencyarmacol
P00736376A0371 |52 60|ischemia and 5-n
P00737422A0832 |0 9|PathogensP00001606
P00737422A0832 |156 163|numbersWhen CS
P00737422A0832 |112 119|numbersneonata
P00737422A0832 |97 102|staffgic a
P00737422A0832 |169 177|patients3-] is s
P00737422A0832 |87 93|memberPharma
P00737422A0832 |50 57|bacillies and 
P00740409A0000 |51 70|cerebellar depositss and 5-nucleotidas
P00740409A0000 |4 18|histochemistry01606T0076 Com
P00740409A0000 |23 37|ultrastructureon with alkali
P00740409A0000 |84 89|Tonge00 Ph
P00741476A0000 |54 61|mg p.d.nd 5-nu
P00741476A0000 |75 79|days0081
P00741476A0000 |30 49|Ergotamine Tartrate alkaline phosphata
P00741476A0000 |14 19|woman Comp
P00741476A0000 |90 98|abortionrmacolog
P00741476A0000 |108 113|birth of n
P00743335T0001 |0 14|Reaction timesP00001606T0076
P00743335T0001 |47 54|stimulitases a
P00743335T0001 |58 67|diabetics-nucleoti
P00745775A0170 |152 154|M.47
P00745775A0170 |53 66|arteriographyand 5-nucleot
P00745775A0170 |125 134|injectionrbilirubi
P00745775A0170 |100 113|complications aspects of n
P00745775A0170 |138 147|Urografina. P00008
P00745775A0170 |16 24|patientsompariso
P00747722A0486 |85 94|injection0 Pharmac
P00747722A0486 |144 147|sec008
P00747722A0486 |106 110|dropts o
P00747722A0486 |62 67|Phaseleoti
P00747722A0486 |47 59|B1 injectiontases and 5-
P00747722A0486 |32 40|reactionlkaline 
P00747722A0486 |4 8|data0160
P00747722A0486 |118 128|parametersal hyperbi
P00748978T0000 |0 20|Serum relaxin levelsP00001606T0076 Compa
P00748978T0000 |24 40|prostaglandin E2n with alkaline 
P00748978T0000 |49 58|abortionsses and 5
P00753237A0000 |548 559|prophylaxisen extracor
P00753237A0000 |539 543|cure3A02
P00753237A0000 |211 222|combination data of K-
P00753237A0000 |509 526|blood circulationBeta blocking age
P00753237A0000 |432 443|compressionptimum dose
P00753237A0000 |312 319|effectsntly gr
P00753237A0000 |380 396|PNEUMATIC INSOLE appears to be a
P00753237A0000 |108 112|PAIN of 
P00753237A0000 |377 378|Dh
P00753237A0000 |226 239|INSENSITIVITYeted rats are
P00753237A0000 |44 49|levelphata
P00753237A0000 |191 194|PPUtio
P00753237A0000 |485 494|attritiont night. 
P00753237A0000 |179 189|ulcerationwn as a fu
P00753237A0000 |57 61|ends5-nu
P00753237A0000 |244 253|TRAUMATISonger dis
P00753237A0000 |123 127|roleperb
P00753237A0000 |300 310|traumatism a signifi
P00753237A0000 |563 566|PPUal 
P00753237A0000 |156 157|BW
P00753237A0000 |159 166|Plantarn CSF [
P00753237A0000 |25 35|phenomenon with alka
P00753237A0000 |266 273|patientompared
P00753237A0000 |92 103|body weightacologic as
P00753237A0000 |451 455|ends in 
P00753237A0000 |568 571|fig2 r
P00753237A0000 |131 140|outsentryubinemia.
P00753237A0000 |287 298|body weightut still ha
P00753237A0000 |345 352|process vs. P0
P00753237A0000 |259 260|C 
P00753237A0000 |471 475|arcs bei
P00753237A0000 |77 81|arcs8171
P00753237A0000 |142 145|fig000
P00755245A0000 |85 95|chloralose0 Pharmaco
P00755245A0000 |10 19|indoramin0076 Comp
P00755245A0000 |109 113|catsof n
P00755245A0000 |29 34|dosesh alk
P00755245A0000 |50 64|vasomotor locies and 5-nucle
P00755245A0000 |146 151|sites8997A
P00755245A0000 |0 6|EffectP00001
P00755671A0485 |17 24|heparinmpariso
P00755671A0485 |77 88|development8171T0000 P
P00755671A0485 |47 68|recalcification timestases and 5-nucleotid
P00755671A0485 |116 125|hematomasatal hype
P00755869A0216 |0 23|Contingency contractingP00001606T0076 Comparis
P00755869A0216 |32 39|clientslkaline
P00755869A0216 |112 127|self-monitoringneonatal hyperb
P00755869A0216 |145 151|intake08997A
P00755869A0216 |89 101|consequencesarmacologic 
P00755869A0216 |153 164|weight loss72 When CSF
P00755869A0216 |50 68|parents/caregiverses and 5-nucleotid
P00755869A0216 |170 178|exercise-] is sh
P00756511T0036 |0 9|DieteticsP00001606
P00756511T0036 |13 22|childhood6 Compari
P00756511T0036 |37 45|diabetesne phosp
P00757244A0000 |4 11|results01606T0
P00757244A0000 |73 82|placentas00008171T
P00757244A0000 |30 35|study alka
P00757244A0000 |56 65|membranes 5-nucleo
P00759049A0185 |51 60|ferrozines and 5-n
P00759049A0185 |106 110|ICSHts o
P00759049A0185 |21 34|microcuvettesison with alk
P00759049A0185 |4 15|micromethod01606T0076 
P00759049A0185 |69 98|bathophenanthroline chromogense P00008171T0000 Pharmacolog
P00759400T0000 |0 18|Platelet serotoninP00001606T0076 Com
P00759400T0000 |45 51|factorhatase
P00759400T0000 |30 34|5-HT alk
P00759400T0000 |20 24|5-HTriso
P00759400T0000 |76 84|patients08171T00
P00759400T0000 |55 61|plasmad 5-nu
P00762763A0253 |54 60|birthsnd 5-n
P00762763A0253 |12 21|incidence76 Compar
P00762763A0253 |25 29|SIDS wit
P00764737X0000 |4 18|vigilance task01606T0076 Com
P00764737X0000 |27 38|measurementith alkalin
P00764737X0000 |54 62|deficitsnd 5-nuc
P00767155T0001 |19 25|revoltarison
P00767155T0001 |56 65|personnel 5-nucleo
P00767155T0001 |29 35|Moscowh alka
P00767155T0001 |4 12|December01606T00
P00767161A0837 |139 144|hours. P00
P00767161A0837 |106 120|administrationts of neonatal
P00767161A0837 |12 21|increases76 Compar
P00767161A0837 |30 52|serum E2 concentration alkaline phosphatases
P00767161A0837 |94 99|hoursologi
P00767161A0837 |148 151|day97A
P00767161A0837 |124 127|dayerb
P00767161A0837 |65 70|pg/mltidas
P00768220X0000 |4 14|motor unit01606T0076
P00771729X0000 |19 25|systemarison
P00771729X0000 |60 68|hormonesucleotid
P00771729X0000 |47 56|responsestases and
P00771729X0000 |33 43|variationskaline pho
P00775582T0000 |25 34|sumithion with alk
P00775582T0000 |11 21|properties076 Compar
P00779272T0001 |50 55|viruses an
P00779272T0001 |12 19|studies76 Comp
P00779272T0001 |23 33|antibodieson with al
P00779272T0001 |70 83|mononucleosise P00008171T0
P00780639X0000 |17 24|antigenmpariso
P00780639X0000 |31 41|proceduresalkaline p
P00780639X0000 |26 29|CEAwit
P00780639X0000 |55 65|evaluationd 5-nucleo
P00792847A0000 |85 90|agent0 Pha
P00792847A0000 |94 100|humansologic
P00792847A0000 |25 48|antilymphocyte globulin with alkaline phosphat
P00792847A0000 |50 53|ALGes 
P00799988A0554 |113 120|placeboeonatal
P00799988A0554 |135 142|therapyemia. P
P00799988A0554 |88 98|imipramineharmacolog
P00799988A0554 |73 83|preference00008171T0
P00799988A0554 |25 44|assessment patients with alkaline phos
P00799988A0554 |7 12|basis06T00
P00803867A0315 |0 8|PatientsP0000160
P00803867A0315 |151 158|disease0472 Wh
P00803867A0315 |45 51|groupshatase
P00803867A0315 |73 79|cancer000081
P00803867A0315 |121 129|patientshyperbil
P00803867A0315 |96 102|cancerogic a
P00803867A0315 |174 180|monthss show
P00806295A0193 |119 127|subjectsl hyperb
P00806295A0193 |40 44|centphos
P00806295A0193 |79 83|cent71T0
P00806295A0193 |58 68|absorption-nucleotid
P00806295A0193 |0 10|AbsorptionP00001606T
P00807356T0001 |33 41|activitykaline p
P00807356T0001 |45 66|hydroxy-9 ellipticinehatases and 5-nucleot
P00808266T0000 |0 8|AdvancesP0000160
P00808266T0000 |42 48|cancerosphat
P00808266T0000 |16 26|managementomparison 
P00808266T0000 |50 67|radiation therapyes and 5-nucleoti
P00808898A0000 |81 88|failureT0000 P
P00808898A0000 |90 94|IPRFrmac
P00808898A0000 |25 29|data wit
P00808898A0000 |37 44|patientne phos
P00811852T0001 |70 78|patientse P00008
P00811852T0001 |9 21|satisfactionT0076 Compar
P00811852T0001 |25 32|nursing with a
P00811852T0001 |37 46|encounterne phosph
P00812183T0000 |11 26|transfer factor076 Comparison 
P00818380A0239 |34 48|antibody testsaline phosphat
P00818380A0239 |11 17|factor076 Co
P00818380A0239 |149 160|populations7A0472 When
P00818380A0239 |79 88|reactions71T0000 P
P00818380A0239 |92 104|gold therapyacologic asp
P00819176T0001 |117 138|Pontella mediterraneatal hyperbilirubinemi
P00819176T0001 |94 115|Anomalocera patersoniologic aspects of neo
P00819176T0001 |26 34|pressurewith alk
P00819176T0001 |83 92|crustacea000 Pharm
P00819176T0001 |42 59|swimming activityosphatases and 5-
P00819176T0001 |140 161|Labidocera wollastoni P00008997A0472 When 
P00819176T0001 |4 10|effect01606T
P00821833A0000 |141 147|PanamaP00008
P00821833A0000 |46 56|repertoireatases and
P00821833A0000 |60 74|howler monkeysucleotidase P0
P00821833A0000 |76 93|Alouatta palliata08171T0000 Pharma
P00821833A0000 |24 32|analysisn with a
P00821833A0000 |113 124|field studyeonatal hyp
P00821833A0000 |5 11|report1606T0
P00822611A0467 |71 78|persons P00008
P00822611A0467 |14 20|number Compa
P00822611A0467 |24 32|patientsn with a
P00822611A0467 |93 106|binephrectomycologic aspec
P00823087A0608 |34 42|patientsaline ph
P00823087A0608 |0 8|DefluniaP0000160
P00825571T0031 |0 3|IIIP00
P00827364A0000 |71 79|material P000081
P00827364A0000 |6 16|instrument606T0076 C
P00827364A0000 |94 100|vacuumologic
P00827364A0000 |83 88|ultra000 P
P00827364A0000 |39 56|freeze-fracturing phosphatases and
P00830568A0000 |238 246|patientse no lon
P00830568A0000 |114 121|personsonatal 
P00830568A0000 |23 32|secretionon with a
P00830568A0000 |83 86|LTM000
P00830568A0000 |260 268|vagotomywhen com
P00830568A0000 |126 134|patientsbilirubi
P00830568A0000 |149 160|gastrectomy7A0472 When
P00830568A0000 |166 184|gastroduodenostomyHCO3-] is shown as
P00830568A0000 |45 59|emptying rateshatases and 5-
P00830568A0000 |186 192|STG-BI funct
P00830568A0000 |221 228|STG-BII-deplet
P00830568A0000 |287 290|V&Put 
P00830568A0000 |72 81|test mealP00008171
P00830568A0000 |202 219|gastrojejunostomy PCO2 the data of
P00830568A0000 |273 285|pyloroplasty to controls
P00832096T0000 |9 27|calcium metabolismT0076 Comparison w
P00832096T0000 |46 57|sarcoidosisatases and 
P00833472A0907 |20 27|patientrison w
P00833472A0907 |63 74|institutioneotidase P0
P00833472A0907 |104 120|gallbladder bileects of neonatal
P00833472A0907 |90 100|saturationrmacologic
P00833472A0907 |126 137|cholesterolbilirubinem
P00833472A0907 |78 88|colestipol171T0000 P
P00833472A0907 |42 52|gallstonesosphatases
P00833472A0907 |173 177|drugis s
P00836637A0000 |155 167|EMR children When CSF [H
P00836637A0000 |106 116|reinforcerts of neon
P00836637A0000 |13 23|experiment6 Comparis
P00836637A0000 |75 90|music-listening008171T0000 Pha
P00836637A0000 |247 257|reinforcerer displac
P00836637A0000 |227 237|preferenceted rats a
P00836637A0000 |129 151|arithmetic performanceirubinemia. P00008997A
P00836637A0000 |200 213|reinforcementSF PCO2 the d
P00837262A0000 |155 161|rabbit When 
P00837262A0000 |135 146|stimulationemia. P0000
P00837262A0000 |108 120|conditioning of neonatal
P00837262A0000 |130 133|OFFrub
P00837262A0000 |29 35|cortexh alka
P00837262A0000 |122 124|ONyp
P00837262A0000 |66 68|SCid
P00837262A0000 |37 39|VCne
P00837262A0000 |54 64|colliculusnd 5-nucle
P00837262A0000 |4 18|responsiveness01606T0076 Com
P00837811A0675 |68 99|fluid gamma globulin elevationsase P00008171T0000 Pharmacologi
P00837811A0675 |15 17|MSCo
P00837811A0675 |54 59|signsnd 5-
P00837811A0675 |105 118|abnormalitiescts of neonat
P00837811A0675 |141 148|testingP000089
P00837811A0675 |2 11|diagnosis0001606T0
P00838152A0863 |17 38|mean temperature risemparison with alkalin
P00838152A0863 |181 195|triplet groups as a function
P00838152A0863 |208 220|predominancethe data of 
P00838152A0863 |74 83|degrees C0008171T0
P00838152A0863 |269 275|groupsared t
P00838152A0863 |241 255|qualificationso longer displ
P00838152A0863 |131 144|disappearanceubinemia. P00
P00838152A0863 |56 65|degrees C 5-nucleo
P00838152A0863 |93 102|selectioncologic a
P00838152A0863 |159 173|qualificationsn CSF [HCO3-] 
P00839378A0649 |102 109|diseasespects 
P00839378A0649 |120 127|therapy hyperb
P00839378A0649 |27 36|RDS groupith alkal
P00839378A0649 |13 19|Viso V6 Comp
P00839378A0649 |67 84|airway resistancedase P00008171T00
P00839378A0649 |49 57|increaseses and 
P00842406A0771 |68 91|visuomotor coordinationase P00008171T0000 Phar
P00842406A0771 |98 114|recognition taskic aspects of ne
P00842406A0771 |59 63|testnucl
P00842406A0771 |18 23|testsparis
P00842406A0771 |51 55|tasks an
P00842522T0000 |86 95|emphysema Pharmaco
P00842522T0000 |20 30|intubationrison with
P00842522T0000 |38 48|managemente phosphat
P00843232A0100 |69 78|characterse P00008
P00843232A0100 |96 106|epitheliumogic aspec
P00843232A0100 |82 88|lesion0000 P
P00843232A0100 |54 60|factornd 5-n
P00843232A0100 |4 14|background01606T0076
P00843670T0000 |4 9|sense01606
P00843670T0000 |13 17|self6 Co
P00846559A0000 |206 214|capacity2 the da
P00846559A0000 |97 104|speciesgic asp
P00846559A0000 |7 14|strains06T0076
P00846559A0000 |224 233|T-2 toxinpleted ra
P00846559A0000 |157 163|U.S.A.hen CS
P00846559A0000 |80 87|strains1T0000 
P00846559A0000 |65 73|U.S.S.R.tidase P
P00846559A0000 |36 55|F. sporotrichioidesine phosphatases an
P00846559A0000 |18 31|Fusarium poaeparison with 
P00846559A0000 |141 151|tricinctumP00008997A
P00846559A0000 |116 139|F. sporotrichioides varatal hyperbilirubinemia
P00846559A0000 |168 174|FranceO3-] i
P00847967T0000 |19 23|usesaris
P00847967T0000 |63 71|medicineeotidase
P00847967T0000 |40 50|tomographyphosphatas
P00851041A0000 |48 55|anomalyases an
P00851041A0000 |12 17|study76 Co
P00851041A0000 |24 32|patientsn with a
P00851041A0000 |38 45|Ebsteine phosp
P00851286A0375 |0 6|DeathsP00001
P00851286A0375 |89 97|distressarmacolo
P00851286A0375 |72 75|ppmP00
P00851286A0375 |30 51|copper concentrations alkaline phosphatase
P00851286A0375 |146 151|hours8997A
P00851286A0375 |167 172|deathCO3-]
P00851286A0375 |80 85|signs1T000
P00851286A0375 |18 23|hoursparis
P00857024A0888 |0 10|RecurrenceP00001606T
P00857024A0888 |92 108|properdin levelsacologic aspects
P00857024A0888 |14 28|bladder tumors Comparison wi
P00857024A0888 |128 134|medianlirubi
P00857024A0888 |50 55|caseses an
P00863184T0043 |68 72|loadase 
P00863184T0043 |27 44|transport maximumith alkaline phos
P00863184T0043 |80 83|rat1T0
P00863184T0043 |0 10|AdaptationP00001606T
P00863773T0000 |0 7|DangersP000016
P00863773T0000 |11 14|use076
P00863773T0000 |18 37|live-virus vaccinesparison with alkali
P00866577A0579 |68 74|agentsase P0
P00866577A0579 |24 46|plasminogen activatorsn with alkaline phosph
P00866577A0579 |108 116|function of neon
P00866577A0579 |15 22|heparinCompari
P00866577A0579 |155 159|term Whe
P00866577A0579 |179 186|therapywn as a
P00866577A0579 |139 146|patient. P0000
P00866577A0579 |0 9|TreatmentP00001606
P00868301A0043 |51 83|2-benzylidenamio-1-phenylpropanes and 5-nucleotidase P00008171T0
P00868301A0043 |120 127|minutes hyperb
P00868301A0043 |3 25|diethyl ether solution001606T0076 Comparison
P00868301A0043 |97 111|retention timegic aspects of
P00868301A0043 |138 147|conditiona. P00008
P00868301A0043 |35 39|peakline
P00868903A0000 |0 8|AmikacinP0000160
P00868903A0000 |63 73|infectionseotidase P
P00868903A0000 |25 34|treatment with alk
P00868903A0000 |80 88|patients1T0000 P
P00870859A0121 |85 98|recirculation0 Pharmacolog
P00870859A0121 |57 64|account5-nucle
P00870859A0121 |72 81|directionP00008171
P00870859A0121 |127 133|factorilirub
P00870859A0121 |4 8|data0160
P00871237A0601 |7 15|activity06T0076 
P00871237A0601 |43 49|anginasphata
P00871237A0601 |25 32|patient with a
P00872442T0000 |0 10|EstimationP00001606T
P00872442T0000 |27 32|serumith a
P00872442T0000 |14 23|L-alanine Comparis
P00872442T0000 |36 42|plasmaine ph
P00872442T0000 |53 79|LKB reaction rate analyserand 5-nucleotidase P000081
P00872922A0204 |4 9|acids01606
P00872922A0204 |27 37|hydrolysisith alkali
P00872922A0204 |95 103|activitylogic as
P00872922A0204 |59 65|estersnucleo
P00874942T0000 |55 61|reportd 5-nu
P00874942T0000 |13 23|amnionitis6 Comparis
P00874942T0000 |28 39|prematurityth alkaline
P00875778T0000 |0 10|EvaluationP00001606T
P00875778T0000 |22 45|Gravigard IUCD inserterson with alkaline phosp
P00876722T0000 |34 41|abscessaline p
P00876722T0000 |10 20|meningitis0076 Compa
P00876722T0000 |55 61|septumd 5-nu
P00877857A0763 |0 13|Serum amylaseP00001606T007
P00877857A0763 |46 55|CU/100 mlatases an
P00877857A0763 |86 95|mEq/liter Pharmaco
P00877857A0763 |69 78|serum FFAse P00008
P00879329A0176 |34 40|weightaline 
P00879329A0176 |133 140|colloidinemia.
P00879329A0176 |149 157|pressure7A0472 W
P00879329A0176 |165 171|plasma[HCO3-
P00879329A0176 |91 99|pressuremacologi
P00879329A0176 |173 176|IIpis 
P00879329A0176 |7 26|control preparation06T0076 Comparison 
P00879329A0176 |101 104|Pciasp
P00879329A0176 |117 121|mmHgtal 
P00879829A0564 |0 7|InfantsP000016
P00879829A0564 |45 48|IVHhat
P00879829A0564 |149 155|apnoea7A0472
P00879829A0564 |75 89|birth asphyxia008171T0000 Ph
P00879829A0564 |127 134|symptomilirubi
P00879829A0564 |33 38|hourskalin
P00881630A0000 |222 226|ratsdepl
P00881630A0000 |150 157|N. najaA0472 W
P00881630A0000 |164 169|venom [HCO
P00881630A0000 |59 72|A. piscivorusnucleotidase 
P00881630A0000 |126 135|compoundsbilirubin
P00881630A0000 |109 124|Phospholipase-Aof neonatal hyp
P00881630A0000 |192 196|lungion 
P00881630A0000 |47 54|N. najatases a
P00881630A0000 |201 218|cremaster vesselsF PCO2 the data o
P00881630A0000 |98 104|Factoric asp
P00881630A0000 |18 25|effectsparison
P00881630A0000 |33 45|snake venomskaline phosp
P00885562A0281 |19 29|componentsarison wit
P00885562A0281 |142 155|GAG synthesis00008997A0472
P00885562A0281 |93 107|osteoarthrosiscologic aspect
P00885562A0281 |111 117|method neona
P00885562A0281 |6 10|GAGs606T
P00885562A0281 |159 166|culturen CSF [
P00885562A0281 |55 64|depletiond 5-nucle
P00885562A0281 |33 49|cartilage matrixkaline phosphata
P00890028A0507 |170 187|Kolmogoroff scale-] is shown as a 
P00890028A0507 |93 103|macroscalecologic as
P00890028A0507 |25 35|turbulence with alka
P00890028A0507 |126 143|Taylor microscalebilirubinemia. P0
P00890028A0507 |62 77|Reynolds numberleotidase P0000
P00890028A0507 |158 160|mmen
P00890028A0507 |202 204|mm P
P00890028A0507 |4 17|length scales01606T0076 Co
P00890028A0507 |118 120|mmal
P00891370A0000 |16 28|arteriogramsomparison wi
P00891370A0000 |165 173|patients[HCO3-] 
P00891370A0000 |61 76|xeroradiographycleotidase P000
P00891370A0000 |109 124|contrast-mediumof neonatal hyp
P00891370A0000 |133 141|arm veininemia. 
P00891370A0000 |36 41|limbsine p
P00891370A0000 |96 105|injectionogic aspe
P00892353A0686 |84 94|degrees C.00 Pharmac
P00892353A0686 |42 49|toxemiaosphata
P00892353A0686 |28 36|patientsth alkal
P00892353A0686 |67 72|feverdase 
P00892353A0686 |3 14|hypotension001606T0076
P00898500A0246 |171 192|IgE antibody activity] is shown as a funct
P00898500A0246 |37 45|patientsne phosp
P00898500A0246 |196 201|mitesof CS
P00898500A0246 |131 135|testubin
P00898500A0246 |74 89|mites skin test0008171T0000 Ph
P00898500A0246 |19 29|secretionsarison wit
P00898500A0246 |4 8|sera0160
P00898500A0246 |68 70|HDas
P00898500A0246 |137 141|RASTia. 
P00903772A0359 |0 8|WhereverP0000160
P00903772A0359 |13 17|site6 Co
P00903772A0359 |106 109|legts 
P00903772A0359 |89 98|ischaemiaarmacolog
P00903772A0359 |57 70|modifications5-nucleotidas
P00903772A0359 |25 49|conditioning stimulation with alkaline phosphata
P00909114A0000 |0 18|DiallylnitrosamineP00001606T0076 Com
P00909114A0000 |91 100|neoplasmsmacologic
P00909114A0000 |179 187|hamsterswn as a 
P00909114A0000 |124 133|incidenceerbilirub
P00909114A0000 |41 53|nitrosamineshosphatases 
P00909114A0000 |149 161|tract tumors7A0472 When 
P00909114A0000 |104 108|ratsects
P00909114A0000 |20 23|DANris
P00909114A0000 |196 198|scof
P00909114A0000 |234 242|compounds are no
P00909114A0000 |221 226|doses-depl
P00910823A0196 |100 111|blood flows aspects of
P00910823A0196 |30 40|conditions alkaline 
P00910823A0196 |74 76|pH00
P00910823A0196 |61 72|blood gasescleotidase 
P00910823A0196 |78 85|uterine171T000
P00910823A0196 |5 9|term1606
P00911590T0000 |40 56|bocurarine blockphosphatases and
P00911590T0000 |62 90|atropine-neostigmine mixtureleotidase P00008171T0000 Pha
P00911590T0000 |13 22|responses6 Compari
P00911590T0000 |26 36|antagonismwith alkal
P00911590T0000 |94 102|childrenologic a
P00913623A0242 |102 115|pyrophosphatespects of neo
P00913623A0242 |52 65|diphosphonate and 5-nucleo
P00913623A0242 |145 149|bone0899
P00913623A0242 |130 141|capillariesrubinemia. 
P00913623A0242 |29 38|moleculesh alkalin
P00913623A0242 |4 13|mechanism01606T007
P00913623A0242 |80 84|EHDP1T00
P00913623A0242 |156 173|passive diffusionWhen CSF [HCO3-] 
P00913623A0242 |117 121|passtal 
P00915090A0536 |70 74|radse P0
P00915090A0536 |94 100|numberologic
P00915090A0536 |12 16|days76 C
P00915090A0536 |47 53|Tc-99mtases 
P00915090A0536 |135 142|controlemia. P
P00915090A0536 |104 114|sperm hadsects of ne
P00915090A0536 |40 43|mCipho
P00915090A0536 |130 131|%r
P00915090A0536 |82 88|testis0000 P
P00915090A0536 |23 32|injectionon with a
P00916099A0000 |0 17|Self-emasculationP00001606T0076 Co
P00916099A0000 |62 70|disorderleotidas
P00916099A0000 |106 115|treatmentts of neo
P00916099A0000 |25 35|end result with alka
P00917572T0001 |0 11|PossibilityP00001606T0
P00917572T0001 |31 37|methodalkali
P00917572T0001 |42 51|detectionosphatase
P00917572T0001 |55 69|hypothyroidismd 5-nucleotida
P00917721A0484 |5 13|analysis1606T007
P00917721A0484 |60 80|presleep suggestionsucleotidase P0000817
P00917721A0484 |106 119|dream contentts of neonata
P00917721A0484 |36 44|evidenceine phos
P00918556A0000 |18 45|hepatitis B surface antigenparison with alkaline phosp
P00918556A0000 |58 66|anti-HBs-nucleot
P00918556A0000 |146 152|series8997A0
P00918556A0000 |47 52|HBsAgtases
P00918556A0000 |113 140|radio-immunoassay techniqueeonatal hyperbilirubinemia.
P00918556A0000 |178 192|liver diseasesown as a funct
P00918556A0000 |4 14|prevalence01606T0076
P00918556A0000 |156 164|patientsWhen CSF
P00918965A0728 |200 204|PAO2SF P
P00918965A0728 |104 116|componenentsects of neon
P00918965A0728 |134 139|shuntnemia
P00918965A0728 |22 30|patientsson with
P00918965A0728 |145 153|parallel08997A04
P00918965A0728 |83 94|ventilation000 Pharmac
P00918965A0728 |54 61|failurend 5-nu
P00920381T0000 |48 57|injectionases and 
P00920381T0000 |107 111|ratss of
P00920381T0000 |18 26|glycogenparison 
P00921032T0000 |50 56|Beaglees and
P00921032T0000 |11 21|evaluation076 Compar
P00921032T0000 |25 35|mibolerone with alka
P00921911A0159 |0 6|LevelsP00001
P00921911A0159 |147 152|onset997A0
P00921911A0159 |79 85|labour71T000
P00921911A0159 |15 18|PGFCom
P00921911A0159 |23 27|PGFMon w
P00921911A0159 |127 129|cmil
P00921911A0159 |156 162|labourWhen C
P00921911A0159 |101 111|dilatationaspects of
P00926272A0000 |16 21|causeompar
P00926272A0000 |72 79|patientP000081
P00926272A0000 |31 44|deteriorationalkaline phos
P00926272A0000 |111 117|reflux neona
P00926272A0000 |59 63|cordnucl
P00926604A0504 |152 158|effect472 Wh
P00926604A0504 |95 100|heartlogic
P00926604A0504 |78 87|apparatus171T0000 
P00926604A0504 |40 44|dosephos
P00926604A0504 |183 197|strophanthin Ks a function o
P00926604A0504 |13 20|Inderal6 Compa
P00926604A0504 |114 125|developmentonatal hype
P00926604A0504 |232 242|myocardiumats are no
P00926604A0504 |174 179|dosess sho
P00926604A0504 |0 11|PropranololP00001606T0
P00926751A0000 |87 96|irritancyPharmacol
P00926751A0000 |30 40|rat larynx alkaline 
P00926751A0000 |73 83|evaluation00008171T0
P00926751A0000 |60 65|organucleo
P00926751A0000 |108 117|materials of neona
P00926751A0000 |7 14|studies06T0076
P00927633T0001 |85 98|Rattus rattus0 Pharmacolog
P00927633T0001 |30 44|investigations alkaline phos
P00927633T0001 |76 81|fiber08171
P00927633T0001 |9 17|electronT0076 Co
P00927633T0001 |52 61|formation and 5-nu
P00927633T0001 |65 73|Reissnertidase P
P00928529T0001 |0 16|Feeding behaviorP00001606T0076 C
P00928529T0001 |29 40|body weighth alkaline 
P00928529T0001 |45 64|hibernation rhythmshatases and 5-nucle
P00928529T0001 |77 85|hamsters8171T000
P00928529T0001 |126 133|bundlesbilirub
P00929418T0001 |0 4|RoleP000
P00929418T0001 |74 83|incidence0008171T0
P00929418T0001 |12 41|infectious-disease specialist76 Comparison with alkaline p
P00929418T0001 |100 108|diseases aspects
P00930947A0629 |137 143|effectia. P0
P00930947A0629 |79 88|secretion71T0000 P
P00930947A0629 |208 212|drugthe 
P00930947A0629 |193 199|effecton of 
P00930947A0629 |15 32|drug interactionsComparison with a
P00930947A0629 |59 69|probenecidnucleotida
P00930947A0629 |92 95|PZAaco
P00930947A0629 |155 160|drugs When
P00930947A0629 |49 55|effectses an
P00931089T0001 |26 40|operating roomwith alkaline 
P00931089T0001 |12 18|arrest76 Com
P00932738A0116 |119 121|BPl 
P00932738A0116 |30 32|BP a
P00932738A0116 |46 64|C02 responsivenessatases and 5-nucle
P00932738A0116 |14 28|blood pressure Comparison wi
P00932738A0116 |109 115|levelsof neo
P00932738A0116 |40 44|mmHgphos
P00932817A0499 |102 112|MTF valuesspects of 
P00932817A0499 |89 93|turnarma
P00932817A0499 |59 78|pinhole collimatorsnucleotidase P00008
P00932817A0499 |146 151|99mTc8997A
P00932817A0499 |0 10|Iodine-123P00001606T
P00932817A0499 |51 54|MECs a
P00933251T0000 |22 28|plaqueson wi
P00933251T0000 |58 67|ear tumor-nucleoti
P00933251T0000 |8 18|meningioma6T0076 Com
P00935526A0000 |168 170|ngO3
P00935526A0000 |107 118|sensitivitys of neonat
P00935526A0000 |62 76|chromatographyleotidase P000
P00935526A0000 |28 42|prostaglandinsth alkaline ph
P00935526A0000 |44 46|PGph
P00935526A0000 |188 198|resolutionunction of
P00935526A0000 |213 220|columnsata of 
P00935526A0000 |99 103|lackc as
P00935526A0000 |4 16|difficulties01606T0076 C
P00938594A0149 |16 31|steroid therapyomparison with 
P00938594A0149 |122 125|HOAype
P00938594A0149 |73 87|manifestations00008171T0000 
P00938594A0149 |104 120|osteoarthropathyects of neonatal
P00938594A0149 |151 170|laboratory features0472 When CSF [HCO3
P00938594A0149 |36 43|patientine pho
P00938594A0149 |196 198|RAof
P00938594A0149 |3 12|cessation001606T00
P00938594A0149 |185 194|arthritisa functio
P00941050T0000 |4 10|effect01606T
P00941050T0000 |14 18|food Com
P00941050T0000 |22 45|procainamide absorptionson with alkaline phosp
P00947327A0000 |341 354|sulfanilamide0.23 vs. P000
P00947327A0000 |522 529|TMP/SMZ agents
P00947327A0000 |255 261|agentsaced w
P00947327A0000 |187 198|combinationfunction of
P00947327A0000 |357 368|sulfamoxole43A0733 Flu
P00947327A0000 |426 438|trimethoprim the optimum
P00947327A0000 |53 63|resistanceand 5-nucl
P00947327A0000 |297 308|combinationave a signi
P00947327A0000 |182 185|TMPas 
P00947327A0000 |145 161|sulfamethoxazole08997A0472 When 
P00947327A0000 |267 274|resultsmpared 
P00947327A0000 |29 38|situationh alkalin
P00947327A0000 |389 412|3,4,5-trimethoxy-benzylto be an effective hypn
P00947327A0000 |90 97|Bavariarmacolo
P00947327A0000 |511 516|teststa bl
P00947327A0000 |168 180|trimethoprimO3-] is show
P00947327A0000 |374 387|2,4-diamino-5m thus appear
P00947327A0000 |445 450|ratioor us
P00947327A0000 |312 314|N1nt
P00947327A0000 |163 166|SMZF [
P00947327A0000 |468 473|Nevinice b
P00947327A0000 |131 139|activityubinemia
P00947327A0000 |15 21|surveyCompar
P00947327A0000 |222 233|antibioticsdepleted ra
P00947327A0000 |459 461|CNra
P00947327A0000 |475 484|Supristolng 15 mg 
P00947327A0000 |278 283|testsontro
P00947327A0000 |414 424|pyrimidineic drug wi
P00947327A0000 |71 77|region P0000
P00947834X0000 |0 7|RESULTSP000016
P00947834X0000 |15 25|IgE levelsComparison
P00947834X0000 |35 43|tendencyline pho
P00951909X0001 |68 77|diagnosisase P0000
P00951909X0001 |14 27|loop syndrome Comparison w
P00951909X0001 |161 184|Billroth-II gastrectomyCSF [HCO3-] is shown as
P00951909X0001 |95 108|loop syndromelogic aspects
P00951909X0001 |46 52|authoratases
P00951909X0001 |55 62|opiniond 5-nuc
P00951909X0001 |139 147|patients. P00008
P00952734T0000 |0 6|LetterP00001
P00952734T0000 |92 102|cutis laxaacologic a
P00952734T0000 |27 33|damageith al
P00952734T0000 |104 108|PECLects
P00952734T0000 |76 87|elastolysis08171T0000 
P00952734T0000 |48 53|causeases 
P00954819A1041 |152 165|AChE activity472 When CSF 
P00954819A1041 |142 148|return000089
P00954819A1041 |110 115|Sarinf neo
P00954819A1041 |83 95|intoxication000 Pharmaco
P00954819A1041 |36 44|recoveryine phos
P00954819A1041 |6 10|data606T
P00954819A1041 |101 106|Somanaspec
P00954819A1041 |68 76|functionase P000
P00956364A0138 |0 14|Batch culturesP00001606T0076
P00956364A0138 |65 73|MSB agartidase P
P00956364A0138 |55 61|growthd 5-nu
P00956364A0138 |18 36|S. mutans serotypeparison with alkal
P00956554A0414 |17 22|serummpari
P00956554A0414 |6 13|samples606T007
P00956554A0414 |112 126|IgE antibodiesneonatal hyper
P00956554A0414 |54 75|solid-phase allergensnd 5-nucleotidase P00
P00956554A0414 |84 94|reactivity00 Pharmac
P00958550T0001 |0 6|CrisisP00001
P00958550T0001 |45 52|Britainhatases
P00958550T0001 |26 35|communitywith alka
P00959656A0250 |48 60|antithrombinases and 5-n
P00959656A0250 |9 14|womenT0076
P00959656A0250 |38 44|levelse phos
P00959656A0250 |18 22|termpari
P00961711T0000 |0 18|Hematology problemP00001606T0076 Com
P00961711T0000 |26 31|monthwith 
P00961711T0000 |41 44|seghos
P00961711T0000 |33 37|bandkali
P00962222A0633 |70 77|changese P0000
P00962222A0633 |41 54|heme turnoverhosphatases a
P00962222A0633 |120 138|progesterone phase hyperbilirubinemi
P00962222A0633 |27 37|variationsith alkali
P00962222A0633 |81 108|erythrocyte characteristicsT0000 Pharmacologic aspects
P00962277T0000 |0 13|HaemodilutionP00001606T007
P00962277T0000 |72 79|primingP000081
P00962277T0000 |33 39|bypasskaline
P00962277T0000 |48 67|gelatine derivativeases and 5-nucleoti
P00964758T0001 |35 48|parotid glandline phosphat
P00964758T0001 |15 27|plasmacytomaComparison w
P00967223T0059 |0 2|I.P0
P00968181A0264 |87 91|daysPhar
P00968181A0264 |108 117|infection of neona
P00968181A0264 |14 20|calves Compa
P00968181A0264 |37 45|immunityne phosp
P00968181A0264 |67 76|challengedase P000
P00970320A0000 |4 15|performance01606T0076 
P00970320A0000 |74 77|SO2000
P00970320A0000 |105 115|conditionscts of neo
P00970320A0000 |121 135|copper smelterhyperbilirubin
P00970320A0000 |39 69|chemical cartridge respirators phosphatases and 5-nucleotida
P00970488A0105 |169 175|effect3-] is
P00970488A0105 |88 108|DA receptor blockingharmacologic aspects
P00970488A0105 |44 55|DA turnoverphatases an
P00970488A0105 |60 69|indicatorucleotida
P00970488A0105 |179 191|neurolepticswn as a func
P00970488A0105 |24 32|increasen with a
P00970488A0105 |78 84|degree171T00
P00970488A0105 |233 241|symptomsts are n
P00970488A0105 |200 211|developmentSF PCO2 the
P00970839A0118 |0 13|Rainbow troutP00001606T007
P00970839A0118 |108 115|pellets of neo
P00970839A0118 |46 56|trout farmatases and
P00970839A0118 |74 79|water00081
P00970839A0118 |127 132|weeksiliru
P00970839A0118 |84 91|feeding00 Phar
P00974901A0080 |0 11|StimulationP00001606T0
P00974901A0080 |45 71|Bordetella pertussis cellshatases and 5-nucleotidase
P00974901A0080 |15 34|macrophage functionComparison with alk
P00974901A0080 |123 137|susceptibilityperbilirubinem
P00974901A0080 |100 106|effect aspec
P00975314T0001 |65 74|karyotypetidase P0
P00975314T0001 |79 81|xy71
P00975314T0001 |8 19|amenorrhoea6T0076 Comp
P00975314T0001 |96 110|gonadoblastomaogic aspects o
P00975540T0000 |16 23|methodsomparis
P00975540T0000 |62 82|mass fragmentographyleotidase P00008171T
P00975540T0000 |47 58|applicationtases and 5
P00975540T0000 |36 45|chemistryine phosp
P00975540T0000 |86 108|high-accuracy analyses Pharmacologic aspects
P00980255T0000 |51 59|couplings and 5-
P00980255T0000 |19 43|2-deoxy-D-glucose methodarison with alkaline pho
P00980255T0000 |72 82|metabolismP00008171T
P00980255T0000 |87 97|blood flowPharmacolo
P00980255T0000 |0 11|ApplicationP00001606T0
P00984209A0614 |0 20|Serum gastrin levelsP00001606T0076 Compa
P00984209A0614 |46 51|groupatase
P00984209A0614 |62 101|background serum gastrin concentrationsleotidase P00008171T0000 Pharmacologic 
P00984209A0614 |151 163|V&A patients0472 When CS
P00984209A0614 |133 145|V&P patientsinemia. P000
P00984209A0614 |179 184|studywn as
P00985110T0001 |51 58|putamens and 5
P00985110T0001 |97 104|regionsgic asp
P00985110T0001 |9 20|projectionsT0076 Compa
P00985110T0001 |125 131|cortexrbilir
P00985110T0001 |112 115|catneo
P00985110T0001 |36 43|portionine pho
P00985276A0000 |0 9|PreflightP00001606
P00985276A0000 |147 157|evaluation997A0472 W
P00985276A0000 |11 19|inflight076 Comp
P00985276A0000 |123 129|Skylabperbil
P00985276A0000 |107 121|Skylab missions of neonatal 
P00985276A0000 |82 92|astronauts0000 Pharm
P00985276A0000 |25 59|postflight exercise response tests with alkaline phosphatases and 5-
P00985276A0000 |199 213|weightlessnessCSF PCO2 the d
P00985276A0000 |175 185|adaptation shown as 
P00985276A0000 |136 140|partmia.
P00985279A0493 |17 42|hemoglobin concentrationsmparison with alkaline ph
P00985279A0493 |66 67|hi
P00985279A0493 |95 101|groupslogic 
P00985279A0493 |107 116|CO2 groups of neon
P00985279A0493 |136 144|decreasemia. P00
P00985279A0493 |0 4|MeanP000
P00986800A0325 |139 146|body Cu. P0000
P00986800A0325 |128 134|valueslirubi
P00986800A0325 |111 120|exception neonatal
P00986800A0325 |160 164|dams CSF
P00986800A0325 |88 101|mug Cu/g dietharmacologic 
P00986800A0325 |66 82|saturation levelidase P00008171T
P00986800A0325 |189 192|daynct
P00986800A0325 |196 204|deliveryof CSF P
P00986800A0325 |4 13|Cu values01606T007
P00986800A0325 |32 38|organslkalin
P00986925A0002 |34 40|amountaline 
P00986925A0002 |95 127|plasma 47Ca radioactivity curveslogic aspects of neonatal hyperb
P00986925A0002 |44 51|calciumphatase
P00986925A0002 |14 24|calcitonin Compariso
P00986925A0002 |83 91|glucagon000 Phar
P00986925A0002 |66 78|pentagastrinidase P00008
P00986925A0002 |131 139|subjectsubinemia
P00986925A0002 |4 10|effect01606T
P00986925A0002 |156 160|47CaWhen
P00987649T0001 |0 5|StateP0000
P00987649T0001 |56 63|rhythms 5-nucl
P00987649T0001 |13 17|body6 Co
P00987649T0001 |78 89|hypokinesia171T0000 Ph
P00987649T0001 |21 30|disordersison with
P00988572A0000 |220 226|oxygenK-depl
P00988572A0000 |198 202|data CSF
P00988572A0000 |56 72|rabbit hind limb 5-nucleotidase 
P00988572A0000 |28 41|lymph vesselsth alkaline p
P00988572A0000 |210 216|sourcee data
P00988572A0000 |234 239|lymphs are
P00988572A0000 |145 174|catheter-tip oxygen electrode08997A0472 When CSF [HCO3-] i
P00988572A0000 |43 47|PLO2spha
P00988572A0000 |117 124|chambertal hyp
P00988572A0000 |0 14|Oxygen tensionP00001606T0076
P00989973A0000 |4 12|response01606T00
P00989973A0000 |229 237|busulfand rats a
P00989973A0000 |125 134|endotoxinrbilirubi
P00989973A0000 |78 88|turpentine171T0000 P
P00989973A0000 |173 180|rabbitsis show
P00989973A0000 |158 165|rabbitsen CSF 
P00989973A0000 |112 121|injectionneonatal 
P00989973A0000 |20 43|plasma fibrinogen levelrison with alkaline pho
P00989973A0000 |65 74|injectiontidase P0
P00992316A0178 |55 65|activitiesd 5-nucleo
P00992316A0178 |144 153|gravidity008997A04
P00992316A0178 |112 120|criterianeonatal
P00992316A0178 |23 38|pressure curveson with alkalin
P00993176A0066 |138 148|hemoglobina. P000089
P00993176A0066 |94 101|portionologic 
P00993176A0066 |41 51|hemoglobinhosphatase
P00993176A0066 |164 177|2SO4 solution [HCO3-] is s
P00993176A0066 |59 72|heme pigmentsnucleotidase 
P00993176A0066 |160 163|NH4 CS
P00993176A0066 |109 116|extractof neon
P00993176A0066 |6 15|myoglobin606T0076 
P00993176A0066 |157 158|%h
P00996272A0397 |119 131|instructionsl hyperbilir
P00996272A0397 |47 58|variabilitytases and 5
P00996272A0397 |74 87|investigation0008171T0000 
P00996272A0397 |29 34|errorh alk
P00996272A0397 |18 25|sourcesparison
P00996364X0000 |0 1|EP
P00999494A0000 |70 75|dosese P00
P00999494A0000 |108 125|agent propranolol of neonatal hype
P00999494A0000 |41 46|maniahosph
P00999494A0000 |22 31|diagnosisson with 
P00999494A0000 |4 12|patients01606T00
P01000378T0000 |0 6|EffectP00001
P01000378T0000 |40 62|insulin concentrationsphosphatases and 5-nuc
P01000378T0000 |10 16|trauma0076 C
P01000378T0000 |66 71|sheepidase
P01000378T0000 |20 35|plasma glucagonrison with alka
P01003819A0498 |49 59|refractionses and 5-
P01003819A0498 |82 99|corneal curvature0000 Pharmacologi
P01003819A0498 |9 13|helpT007
P01003819A0498 |66 77|axis lengthidase P0000
P01003819A0498 |19 31|nomogram onearison with 
P01004298A0744 |70 71|%e
P01004298A0744 |90 98|studentsrmacolog
P01004298A0744 |126 131|levelbilir
P01004298A0744 |29 34|scoreh alk
P01004298A0744 |104 110|scoresects o
P01004298A0744 |42 54|CA componentosphatases a
P01004298A0744 |5 15|up-grading1606T0076 
P01009451A0728 |34 42|OCS ratsaline ph
P01009451A0728 |89 98|reductionarmacolog
P01009451A0728 |12 20|controls76 Compa
P01009451A0728 |122 130|drinkingyperbili
P01009451A0728 |106 118|nocturnalityts of neonat
P01009451A0728 |27 29|UBit
P01009739T0001 |0 6|EffectP00001
P01009739T0001 |58 61|ECG-nu
P01009739T0001 |10 22|indomethacin0076 Compari
P01009739T0001 |48 54|effectases a
P01009739T0001 |35 46|circulationline phosph
P01009841T0001 |35 48|trunk musclesline phosphat
P01009841T0001 |25 31|fibers with 
P01009841T0001 |52 66|lamprey larvae and 5-nucleot
P01009841T0001 |5 16|innervation1606T0076 C
P01010638A0161 |4 8|feed0160
P01010638A0161 |41 42|%h
P01012640T0001 |83 89|Sipple000 Ph
P01012640T0001 |92 100|syndromeacologic
P01012640T0001 |27 38|eye changesith alkalin
P01012640T0001 |56 72|pheochromocytoma 5-nucleotidase 
P01012640T0001 |8 23|characteristics6T0076 Comparis
P01012640T0001 |42 50|patientsosphatas
P01012904A0333 |141 147|sampleP00008
P01012904A0333 |164 170|format [HCO3
P01012904A0333 |15 34|interference effectComparison with alk
P01012904A0333 |94 105|Stroop testologic aspe
P01012904A0333 |67 78|populationsdase P00008
P01019207A0232 |119 124|rangel hyp
P01019207A0232 |37 47|conditionsne phospha
P01019207A0232 |57 67|dependence5-nucleoti
P01019207A0232 |104 107|lgCect
P01019207A0232 |87 99|betaI% valuePharmacologi
P01019207A0232 |136 150|mug ruscogeninmia. P00008997
P01021091T0000 |115 126|vasopressinnatal hyper
P01021091T0000 |75 85|rabbit ear008171T000
P01021091T0000 |42 50|responseosphatas
P01021091T0000 |128 139|Octapressinlirubinemia
P01021091T0000 |28 34|nervesth alk
P01021091T0000 |54 67|blood vesselsnd 5-nucleoti
P01021091T0000 |4 13|influence01606T007
P01027644T0001 |11 15|test076 
P01030985T0090 |0 2|I.P0
P01035457A0623 |55 65|importanced 5-nucleo
P01035457A0623 |88 97|treatmentharmacolo
P01035457A0623 |74 83|diagnosis0008171T0
P01035457A0623 |25 41|nipple discharge with alkaline p
P01035457A0623 |7 13|tumour06T007
P01036714A0072 |0 7|StudiesP000016
P01036714A0072 |41 48|changeshosphat
P01036714A0072 |134 138|lungnemi
P01036714A0072 |96 106|chrysotileogic aspec
P01036714A0072 |144 159|cell population008997A0472 Whe
P01036714A0072 |77 84|animals8171T00
P01036714A0072 |185 191|levelsa func
P01036714A0072 |118 126|increaseal hyper
P01044338A0240 |49 58|estimatesses and 5
P01044338A0240 |9 21|measurementsT0076 Compar
P01044338A0240 |25 44|temperature changes with alkaline phos
P01044338A0240 |66 73|heatingidase P
P01047417T0000 |10 37|National Health Dis-service0076 Comparison with alkali
P01047895T0001 |119 131|patient carel hyperbilir
P01047895T0001 |16 28|patient careomparison wi
P01047895T0001 |3 12|criticism001606T00
P01047895T0001 |75 83|Patients008171T0
P01047895T0001 |68 73|valuease P
P01047895T0001 |85 94|criticism0 Pharmac
P01048020T0000 |0 8|CritiqueP0000160
P01048020T0000 |25 32|Effects with a
P01048020T0000 |133 151|Course Informationinemia. P00008997A
P01048020T0000 |73 92|A-F Grade Condition00008171T0000 Pharm
P01048020T0000 |36 48|Test Anxietyine phosphat
P01048020T0000 |53 69|Credit/No Creditand 5-nucleotida
P01048968A0152 |85 97|penicillin G0 Pharmacolo
P01048968A0152 |53 66|staphylococciand 5-nucleot
P01048968A0152 |6 13|studies606T007
P01048968A0152 |126 140|beta-lactamasebilirubinemia.
P01048968A0152 |99 111|erythromycinc aspects of
P01048968A0152 |34 42|majorityaline ph
P01050144A0297 |136 147|83A complexmia. P00008
P01050144A0297 |36 42|numberine ph
P01050144A0297 |46 53|strainsatases 
P01050144A0297 |121 128|strainshyperbi
P01050144A0297 |20 28|decreaserison wi
P01050144A0297 |81 92|antibioticsT0000 Pharm
P01050400T0000 |0 11|ImprovementP00001606T0
P01050400T0000 |54 58|timend 5
P01050400T0000 |62 71|dischargeleotidase
P01050400T0000 |15 34|nursing instructionComparison with alk
P01050400T0000 |81 85|wardT000
P01050400T0000 |100 107|infants aspect
P01057137A0192 |3 13|difference001606T007
P01057137A0192 |30 43|acceptability alkaline pho
P01057137A0192 |81 87|groupsT0000 
P01064124A0560 |49 55|lesionses an
P01064124A0560 |13 23|subsurface6 Comparis
P01064124A0560 |9 10|dT
P01064124A0560 |76 85|specimens08171T000
P01067493A0119 |33 38|womenkalin
P01067493A0119 |61 68|percentcleotid
P01067493A0119 |92 99|methodsacologi
P01067493A0119 |18 25|patternparison
P01071715A0903 |17 26|techniquemparison 
P01071715A0903 |40 65|blood pressure recordingsphosphatases and 5-nucleo
P01075075T0038 |0 2|I.P0
P01078982A0227 |81 104|antilymphocyte globulinT0000 Pharmacologic asp
P01078982A0227 |62 78|cyclophosphamideleotidase P00008
P01078982A0227 |176 192|cyclophosphamideshown as a funct
P01078982A0227 |106 109|ALGts 
P01078982A0227 |166 172|dosageHCO3-]
P01078982A0227 |111 120|treatment neonatal
P01078982A0227 |127 145|ALG administrationilirubinemia. P000
P01080374A0709 |102 106|formspec
P01080374A0709 |44 62|aneurysm retinitisphatases and 5-nuc
P01080374A0709 |81 87|entityT0000 
P01080374A0709 |110 115|Coatsf neo
P01080374A0709 |27 32|Leberith a
P01080374A0709 |117 124|diseasetal hyp
P01080374A0709 |0 8|EvidenceP0000160
P01081904A0198 |51 59|patientss and 5-
P01081904A0198 |26 34|catheterwith alk
P01081904A0198 |129 137|symptomsirubinem
P01081904A0198 |71 93|pull-out arteriography P00008171T0000 Pharma
P01082726A0248 |55 61|DC-ERGd 5-nu
P01082726A0248 |26 31|pupilwith 
P01082726A0248 |39 47|response phospha
P01082726A0248 |4 13|influence01606T007
P01082833A0000 |171 182|guinea pigs] is shown 
P01082833A0000 |95 107|indomethacinlogic aspect
P01082833A0000 |130 138|responserubinemi
P01082833A0000 |109 111|IMof
P01082833A0000 |287 291|ratsut s
P01082833A0000 |75 85|inhibition008171T000
P01082833A0000 |45 51|Y-8004hatase
P01082833A0000 |272 283|peritonitisd to contro
P01082833A0000 |38 43|agente pho
P01082833A0000 |159 167|erytheman CSF [H
P01082833A0000 |184 201|carrageenin edema a function of CS
P01082833A0000 |238 247|pleuritise no long
P01083321X0000 |136 148|productivitymia. P000089
P01083321X0000 |53 56|ageand
P01083321X0000 |58 71|subalpine fir-nucleotidase
P01083321X0000 |3 9|stands001606
P01083321X0000 |21 30|dominanceison with
P01083321X0000 |114 119|ratesonata
P01083321X0000 |155 161|stands When 
P01083321X0000 |185 190|yearsa fun
P01083375T0000 |0 19|Alpha-1 antitrypsinP00001606T0076 Comp
P01083375T0000 |31 50|childhood cirrhosisalkaline phosphatas
P01083784T0000 |68 76|patientsase P000
P01083784T0000 |27 36|serum IgEith alkal
P01083784T0000 |47 64|eosinophil countstases and 5-nucle
P01083784T0000 |92 98|asthmaacolog
P01083784T0000 |0 25|Lymphocyte subpopulationsP00001606T0076 Comparison
P01084413A0271 |51 54|EMIs a
P01084413A0271 |30 42|measurements alkaline ph
P01084413A0271 |2 7|range00016
P01087288T0000 |2 12|comparison0001606T00
P01087288T0000 |94 104|iodine-131ologic asp
P01087288T0000 |41 50|estimateshosphatas
P01087288T0000 |72 80|patientsP0000817
P01087288T0000 |109 126|thyroid carcinomaof neonatal hyper
P01087288T0000 |54 68|radiation dosend 5-nucleotid
P01088654T0001 |0 9|TechniqueP00001606
P01088654T0001 |52 56|mass and
P01088654T0001 |32 40|ceramicslkaline 
P01090210A0417 |0 4|MeanP000
P01090210A0417 |11 24|lung capacity076 Compariso
P01090210A0417 |287 293|cm H20ut sti
P01090210A0417 |270 281|differencesred to cont
P01090210A0417 |46 54|capacityatases a
P01090210A0417 |226 232|cm H20eted r
P01090210A0417 |134 145|lung volumenemia. P000
P01090210A0417 |161 167|volumeCSF [H
P01090210A0417 |177 182|phasehown 
P01090210A0417 |109 128|mean closing volumeof neonatal hyperbi
P01090210A0417 |253 268|airway pressureplaced when com
P01090210A0417 |69 75|volumese P00
P01092248T0000 |18 33|zinc deficiencyparison with al
P01092248T0000 |106 115|disordersts of neo
P01092248T0000 |41 53|pathogenesishosphatases 
P01092248T0000 |8 14|status6T0076
P01093055T0000 |0 7|CalciumP000016
P01093055T0000 |45 51|uremiahatase
P01093055T0000 |12 33|phosphorus metabolism76 Comparison with al
P01093845A0208 |0 14|Modern studiesP00001606T0076
P01093845A0208 |109 117|identityof neona
P01093845A0208 |149 157|cannabis7A0472 W
P01093845A0208 |31 42|Delta-9-THCalkaline ph
P01093845A0208 |173 178|dreamis sh
P01093845A0208 |163 168|sleepF [HC
P01093845A0208 |125 138|modificationsrbilirubinemi
P01093845A0208 |55 66|voluntariesd 5-nucleot
P01093845A0208 |86 96|comparison Pharmacol
P01093847A0000 |25 50|tropatepine hydrochloride with alkaline phosphatas
P01093847A0000 |75 82|effects008171T
P01093847A0000 |15 21|actionCompar
P01093847A0000 |94 106|neurolepticsologic aspec
P01093847A0000 |146 152|states8997A0
P01096741X0000 |34 41|animalsaline p
P01096741X0000 |63 77|chickpea haulmeotidase P0000
P01096741X0000 |11 17|growth076 Co
P01096741X0000 |96 111|supplementationogic aspects of
P01097100A0217 |4 12|patients01606T00
P01097100A0217 |36 44|regimensine phos
P01098179A0167 |85 103|dissolution curves0 Pharmacologic as
P01098179A0167 |142 157|chloramphenicol00008997A0472 W
P01098179A0167 |209 215|creamshe dat
P01098179A0167 |194 202|activityn of CSF
P01098179A0167 |237 246|ointmentsre no lon
P01098179A0167 |48 60|preparationsases and 5-n
P01098179A0167 |175 182|release shown 
P01098179A0167 |118 124|assaysal hyp
P01098179A0167 |0 7|ResultsP000016
P01098592A0567 |102 107|onsetspect
P01098592A0567 |57 64|samples5-nucle
P01098592A0567 |78 82|days171T
P01098592A0567 |0 10|IgG levelsP00001606T
P01099693T0000 |0 6|LetterP00001
P01099693T0000 |24 51|bone marrow transplantationn with alkaline phosphatase
P01099693T0000 |8 20|Perspectives6T0076 Compa
P01101272T0000 |51 60|sweetnerss and 5-n
P01101272T0000 |80 95|cyclohexylamine1T0000 Pharmaco
P01101272T0000 |65 75|Cyclamatestidase P00
P01101272T0000 |18 33|carcinogenicityparison with al
P01101272T0000 |0 10|AssessmentP00001606T
P01103390A0149 |103 108|phasepects
P01103390A0149 |15 24|behaviourCompariso
P01103390A0149 |83 90|animals000 Pha
P01103390A0149 |123 131|increaseperbilir
P01103390A0149 |44 48|micephat
P01103390A0149 |64 74|occurrenceotidase P0
P01103390A0149 |139 150|parasitemia. P00008997
P01107226A0808 |101 117|mg/ml dose levelaspects of neona
P01107226A0808 |44 49|fecesphata
P01107226A0808 |57 61|mice5-nu
P01107226A0808 |9 23|amphotericin BT0076 Comparis
P01113908A0475 |51 53|hrs 
P01113908A0475 |109 119|experimentof neonata
P01113908A0475 |73 79|values000081
P01113908A0475 |62 68|tabletleotid
P01113908A0475 |37 48|transferrinne phosphat
P01113908A0475 |19 27|increasearison w
P01116254A0000 |204 214|myocardiumCO2 the da
P01116254A0000 |183 196|concentrations a function 
P01116254A0000 |91 103|potassium-43macologic as
P01116254A0000 |241 250|potassiumo longer 
P01116254A0000 |220 221|%K
P01116254A0000 |259 260|% 
P01116254A0000 |53 66|concentrationand 5-nucleot
P01116254A0000 |22 36|administrationson with alkal
P01116254A0000 |146 154|thallium8997A047
P01116254A0000 |265 273|rubidiumcompared
P01116254A0000 |140 144|mice P00
P01116254A0000 |280 287|minutestrols b
P01116254A0000 |109 120|rubidium-81of neonatal
P01116254A0000 |235 236|% 
P01116254A0000 |70 89|tracer thallium-201e P00008171T0000 Ph
P01116466A0185 |0 19|Thromboplastin timeP00001606T0076 Comp
P01116466A0185 |109 125|clotting factorsof neonatal hype
P01116466A0185 |133 137|VIIIinem
P01116466A0185 |29 48|thromboplastin timeh alkaline phosphat
P01116466A0185 |88 103|clot retractionharmacologic as
P01116466A0185 |80 86|fibrin1T0000
P01116466A0185 |143 144|X0
P01116466A0185 |130 131|Vr
P01116466A0185 |154 168|platelet count2 When CSF [HC
P01116466A0185 |50 63|thrombin timees and 5-nucl
P01118293A0150 |103 107|eyespect
P01118293A0150 |21 27|notionison w
P01118293A0150 |4 8|data0160
P01118293A0150 |72 79|rivalryP000081
P01118293A0150 |33 44|suppressionkaline phos
P01118293A0150 |48 54|imagesases a
P01119586A0337 |119 125|heartsl hype
P01119586A0337 |40 53|tissue levelsphosphatases 
P01119586A0337 |143 147|flow0008
P01119586A0337 |77 80|ATP817
P01119586A0337 |57 75|creatine phosphate5-nucleotidase P00
P01119586A0337 |86 93|lactate Pharma
P01119586A0337 |0 20|Glycogen utilizationP00001606T0076 Compa
P01119658A0000 |239 242|N2A no
P01119658A0000 |157 168|hypopharynxhen CSF [HC
P01119658A0000 |113 119|cavityeonata
P01119658A0000 |247 250|N2Ber 
P01119658A0000 |63 71|patientseotidase
P01119658A0000 |270 284|neck treatmentred to control
P01119658A0000 |121 131|oropharynxhyperbilir
P01119658A0000 |146 152|larynx8997A0
P01119658A0000 |4 11|records01606T0
P01119658A0000 |235 237|N1 a
P01119658A0000 |86 100|cell carcinoma Pharmacologic
P01119658A0000 |206 227|lymph node metastases2 the data of K-deple
P01119658A0000 |307 324|radiation therapyificantly greater
P01122015A0467 |51 58|mumol/1s and 5
P01122015A0467 |65 74|mg/100 mltidase P0
P01122015A0467 |9 12|volT00
P01122015A0467 |14 15|% 
P01122015A0467 |35 41|valuesline p
P01122015A0467 |98 107|mg/100 mlic aspect
P01122015A0467 |84 91|mumol/100 Phar
P01123658A0000 |153 158|spine72 Wh
P01123658A0000 |73 78|spine00008
P01123658A0000 |164 167|L-4 [H
P01123658A0000 |99 110|descriptionc aspects o
P01123658A0000 |25 34|technique with alk
P01123658A0000 |124 131|anatomyerbilir
P01123658A0000 |55 65|tomographyd 5-nucleo
P01123658A0000 |4 11|authors01606T0
P01123658A0000 |175 181|sacrum shown
P01124944A0830 |34 46|protein dietaline phosph
P01124944A0830 |52 56|g/kg and
P01124944A0830 |18 26|attitudeparison 
P01125117A0183 |138 144|groupsa. P00
P01125117A0183 |25 32|attacks with a
P01125117A0183 |92 99|changesacologi
P01125117A0183 |40 44|typephos
P01125117A0183 |18 22|typepari
P01125117A0183 |3 7|none0016
P01125117A0183 |48 55|attacksases an
P01128985A0000 |118 126|patientsal hyper
P01128985A0000 |88 95|periodsharmaco
P01128985A0000 |31 37|methodalkali
P01128985A0000 |99 104|apneac asp
P01130186A0568 |85 96|tolbutamide0 Pharmacol
P01130186A0568 |24 31|patientn with 
P01130186A0568 |73 81|response00008171
P01130186A0568 |54 69|insulin releasend 5-nucleotida
P01130531A0224 |0 17|Nerve stimulationP00001606T0076 Co
P01130531A0224 |65 75|reductionstidase P00
P01130531A0224 |79 82|CBF71T
P01130531A0224 |26 34|cycles/swith alk
P01130531A0224 |101 108|percentaspects
P01130531A0224 |86 94|decrease Pharmac
P01130531A0224 |136 145|frequencymia. P000
P01131946T0001 |0 6|EffectP00001
P01131946T0001 |10 19|ingestion0076 Comp
P01131946T0001 |23 33|Norbiogeston with al
P01131946T0001 |77 83|organs8171T0
P01131946T0001 |55 61|periodd 5-nu
P01138215T0001 |0 4|RiskP000
P01138215T0001 |25 34|treatment with alk
P01138215T0001 |8 17|infection6T0076 Co
P01138215T0001 |38 47|fracturese phospha
P01138330A0204 |85 91|% NaC10 Phar
P01138330A0204 |135 157|acetylcholine chlorideemia. P00008997A0472 W
P01138330A0204 |120 131|% solutions hyperbilir
P01138330A0204 |7 14|pouches06T0076
P01138330A0204 |72 81|% glucoseP00008171
P01138330A0204 |63 68|N HC1eotid
P01138330A0204 |50 57|% Na C1es and 
P01138330A0204 |99 108|% peptonec aspects
P01138330A0204 |34 43|solutionsaline pho
P01140184A0342 |0 16|Liver microsomesP00001606T0076 C
P01140184A0342 |59 83|epoxide hydrase activitynucleotidase P00008171T0
P01140184A0342 |126 134|capacitybilirubi
P01140184A0342 |164 167|rat [H
P01140184A0342 |50 51|%e
P01140184A0342 |138 154|liver microsomesa. P00008997A047
P01140184A0342 |103 104|%p
P01141114A0188 |68 72|mmHgase 
P01141114A0188 |161 168|effectsCSF [HC
P01141114A0188 |94 98|PH-volog
P01141114A0188 |123 129|Pv-CO2perbil
P01141114A0188 |206 207|H2
P01141114A0188 |33 41|increasekaline p
P01141114A0188 |189 200|temperaturenction of C
P01141114A0188 |84 87|P5000 
P01141114A0188 |16 20|workompa
P01141114A0188 |103 114|degrees C-vpects of ne
P01145884T0028 |39 44|study phos
P01147436T0000 |42 57|progress reportosphatases and 
P01147436T0000 |13 38|Burkitt Lymphoma Registry6 Comparison with alkalin
P01147502T0000 |0 10|VitrectomyP00001606T
P01147502T0000 |31 48|instrument systemalkaline phosphat
P01148868A0284 |32 44|progesteronelkaline phos
P01148868A0284 |61 65|S.E.cleo
P01148868A0284 |14 28|clearance rate Comparison wi
P01148868A0284 |67 72|1/daydase 
P01150658A0683 |65 72|hormonetidase 
P01150658A0683 |82 84|M.00
P01150658A0683 |74 80|Sairam000817
P01150658A0683 |5 13|sequence1606T007
P01156631A0658 |68 74|mEq/kgase P0
P01156631A0658 |91 100|treatmentmacologic
P01156631A0658 |178 179|Po
P01156631A0658 |59 61|SDnu
P01156631A0658 |161 163|SDCS
P01156631A0658 |136 145|treatmentmia. P000
P01156631A0658 |4 36|mean plasma sodium concentration01606T0076 Comparison with alkal
P01156631A0658 |170 176|mEq/kg-] is 
P01156814T0000 |0 9|EditorialP00001606
P01156814T0000 |36 46|preventionine phosph
P01156814T0000 |57 79|thromboembolic disease5-nucleotidase P000081
P01156814T0000 |20 27|heparinrison w
P01157191A0536 |17 28|dose levelsmparison wi
P01157191A0536 |130 145|bladder tumoursrubinemia. P000
P01157191A0536 |56 72|sodium cyclamate 5-nucleotidase 
P01157191A0536 |183 190|tumourss a fun
P01157191A0536 |223 228|weekseplet
P01157191A0536 |92 103|carcinogensacologic as
P01157191A0536 |35 51|sodium saccharinline phosphatase
P01157614T0000 |0 7|EffectsP000016
P01157614T0000 |22 30|salienceson with
P01157614T0000 |88 96|childrenharmacol
P01157614T0000 |38 61|matrix task performancee phosphatases and 5-nu
P01158512T0000 |35 41|G-6-PDline p
P01158512T0000 |43 53|deficiencysphatases 
P01158512T0000 |20 33|dehydrogenaserison with al
P01158838A0438 |57 66|flow rate5-nucleot
P01158838A0438 |74 80|ml/min000817
P01159822A0353 |171 175|size] is
P01159822A0353 |119 123|tiltl hy
P01159822A0353 |82 96|ultrastructure0000 Pharmacol
P01159822A0353 |144 152|increase008997A0
P01159822A0353 |179 188|lysosomeswn as a f
P01159822A0353 |271 279|granulesed to co
P01159822A0353 |210 216|bodiese data
P01159822A0353 |104 117|invaginationsects of neona
P01159822A0353 |135 139|axesemia
P01159822A0353 |45 52|animalshatases
P01159822A0353 |160 166|number CSF [
P01159822A0353 |14 23|epithelia Comparis
P01159822A0353 |232 239|numbersats are
P01168607A0672 |100 116|prothrombin time aspects of neon
P01168607A0672 |12 26|administration76 Comparison 
P01168607A0672 |121 135|serum vitaminshyperbilirubin
P01168607A0672 |42 50|vitaminsosphatas
P01168607A0672 |147 156|intervals997A0472 
P01168607A0672 |142 143|E0
P01168908A0000 |0 16|Prostaglandins FP00001606T0076 C
P01168908A0000 |82 93|vein plasma0000 Pharma
P01168908A0000 |62 68|arteryleotid
P01168908A0000 |168 173|cycleO3-] 
P01168908A0000 |48 52|veinases
P01168908A0000 |18 21|PGFpar
P01168908A0000 |207 233|plasma progesterone levels the data of K-depleted ra
P01168908A0000 |117 124|tissuestal hyp
P01168908A0000 |136 141|timesmia. 
P01168956A0552 |186 187|h 
P01168956A0552 |177 182|organhown 
P01168956A0552 |12 16|date76 C
P01168956A0552 |145 168|maximum weight decrease08997A0472 When CSF [HC
P01168956A0552 |125 128|dayrbi
P01168956A0552 |95 103|placentalogic as
P01168956A0552 |22 26|drugson 
P01168956A0552 |76 87|sensitivity08171T0000 
P01168956A0552 |51 62|weight gains and 5-nuc
P01170143A0247 |0 6|GroupsP00001
P01170143A0247 |86 96|conditions Pharmacol
P01170143A0247 |121 130|cylindershyperbili
P01170143A0247 |32 43|saline micelkaline pho
P01171020A0711 |4 11|effects01606T0
P01171020A0711 |31 54|nucleus accumbens septialkaline phosphatases a
P01171935A0313 |51 57|humanss and 
P01171935A0313 |29 47|movement disordersh alkaline phospha
P01171935A0313 |120 133|manifestation hyperbilirub
P01171935A0313 |99 110|amphetaminec aspects o
P01171935A0313 |80 83|use1T0
P01171935A0313 |203 211|striatumPCO2 the
P01171935A0313 |4 14|appearance01606T0076
P01171935A0313 |157 191|dopamine receptor site sensitivityhen CSF [HCO3-] is shown as a func
P01171935A0313 |87 95|levodopaPharmaco
P01172734T0035 |0 11|AssociationP00001606T0
P01172734T0035 |22 26|W-27son 
P01172917T0000 |0 6|LetterP00001
P01172917T0000 |37 46|predictorne phosph
P01172917T0000 |8 31|Lactose tolerance tests6T0076 Comparison with 
P01172917T0000 |50 64|milk tolerancees and 5-nucle
P01174873T0000 |0 14|RetinoblastomaP00001606T0076
P01174873T0000 |47 56|prognosistases and
P01174873T0000 |18 23|studyparis
P01174873T0000 |64 69|casesotida
P01174873T0000 |35 42|historyline ph
P01176905A0094 |51 59|mid-darks and 5-
P01176905A0094 |23 38|serum melatoninon with alkalin
P01176905A0094 |12 21|melatonin76 Compar
P01176905A0094 |71 80|mid-light P0000817
P01178153A0056 |0 2|D.P0
P01178637T0001 |0 15|AtherosclerosisP00001606T0076 
P01185956A0722 |98 105|changesic aspe
P01185956A0722 |4 11|authors01606T0
P01185956A0722 |113 126|stroke volumeeonatal hyper
P01185956A0722 |38 58|Doppler-cardiographye phosphatases and 5
P01186344A0303 |171 174|ova] i
P01186344A0303 |179 189|end-pointswn as a fu
P01186344A0303 |160 167|release CSF [H
P01186344A0303 |147 154|pattern997A047
P01186344A0303 |63 78|characteristicseotidase P00008
P01186344A0303 |211 218|process data o
P01186344A0303 |4 14|attainment01606T0076
P01186344A0303 |37 42|termsne ph
P01186344A0303 |25 33|maturity with al
P01186344A0303 |117 121|maletal 
P01186344A0303 |98 109|spermatozoaic aspects 
P01186344A0303 |84 94|production00 Pharmac
P01190120A0832 |17 30|% lengtheningmparison with
P01190120A0832 |95 102|storagelogic a
P01190120A0832 |46 65|thromboplastin timeatases and 5-nucleo
P01190120A0832 |86 91|hours Phar
P01190251A0335 |0 7|CautionP000016
P01190251A0335 |48 52|dyesases
P01190251A0335 |57 68|lymphograms5-nucleotid
P01190251A0335 |35 38|uselin
P01191955A0077 |87 94|varicesPharmac
P01191955A0077 |44 56|incompetencephatases and
P01191955A0077 |124 130|refluxerbili
P01191955A0077 |79 83|cent71T0
P01191955A0077 |19 23|testaris
P01191964A0000 |70 76|Gravese P000
P01191964A0000 |303 335|serum thyrotrophin concentrationsignificantly greater slope (1.2
P01191964A0000 |256 265|subgroupsced when 
P01191964A0000 |157 162|yearshen C
P01191964A0000 |191 206|serum thyroxinetion of CSF PCO
P01191964A0000 |52 65|thyroidectomy and 5-nucleo
P01191964A0000 |213 218|levelata o
P01191964A0000 |208 211|T-4the
P01191964A0000 |79 86|disease71T0000
P01191964A0000 |107 113|goitres of n
P01191964A0000 |16 24|patientsompariso
P01191964A0000 |141 147|goitreP00008
P01191964A0000 |6 12|groups606T00
P01191964A0000 |273 278|basis to c
P01193458T0001 |103 109|refluxpects 
P01193458T0001 |60 69|detectionucleotida
P01193458T0001 |8 27|isotope cystography6T0076 Comparison w
P01193458T0001 |74 83|follow-up0008171T0
P01193458T0001 |38 55|Tc sulfur colloide phosphatases an
P01193770T0000 |0 14|Air ion actionP00001606T0076
P01193770T0000 |18 26|bacteriaparison 
P01194673A0652 |3 11|evidence001606T0
P01194673A0652 |43 54|chemographysphatases a
P01201977T0000 |33 51|disc sensitivitieskaline phosphatase
P01201977T0000 |4 18|interpretation01606T0076 Com
P01202616A0466 |103 117|lamina propriapects of neona
P01202616A0466 |10 23|retransfusion0076 Comparis
P01202616A0466 |140 144|loss P00
P01202616A0466 |159 165|detailn CSF 
P01202616A0466 |49 55|liningses an
P01206772T0000 |2 7|study00016
P01206772T0000 |11 22|chromosomes076 Compari
P01206772T0000 |43 51|patientssphatase
P01206772T0000 |26 37|lymphocyteswith alkali
P01206772T0000 |65 75|hycanthonetidase P00
P01206896T0001 |51 73|emergency lung surgerys and 5-nucleotidase P
P01206896T0001 |0 15|CharacteristicsP00001606T0076 
P01206896T0001 |19 29|anesthesiaarison wit
P01206896T0001 |34 47|resuscitationaline phospha
P01208811T0001 |0 5|StudyP0000
P01208811T0001 |58 87|citrate solution-blood system-nucleotidase P00008171T0000 
P01208811T0001 |30 35|state alka
P01208811T0001 |39 52|plutonium-239 phosphatases
P01209618A0409 |119 125|actionl hype
P01209618A0409 |45 51|effecthatase
P01209618A0409 |92 111|potentiating effectacologic aspects of
P01209618A0409 |57 66|dibecacin5-nucleot
P01209618A0409 |14 16|mg C
P01209618A0409 |71 73|mg P
P01209618A0409 |129 143|d-tubocurarineirubinemia. P0
P01209618A0409 |0 10|TobramycinP00001606T
P01211754A0192 |137 145|deafnessia. P000
P01211754A0192 |90 98|patientsrmacolog
P01211754A0192 |26 31|caseswith 
P01211754A0192 |74 85|improvement0008171T000
P01211754A0192 |37 46|operationne phosph
P01215067A0000 |87 100|conductometryPharmacologic
P01215067A0000 |56 61|fluid 5-nu
P01215067A0000 |107 112|casess of 
P01215067A0000 |150 167|meningitis serosaA0472 When CSF [H
P01215067A0000 |181 193|encephalitis as a functi
P01215067A0000 |212 220|subjectsdata of 
P01215067A0000 |24 34|resistancen with alk
P01215067A0000 |78 83|means171T0
P01215067A0000 |141 146|casesP0000
P01215067A0000 |172 177|cases is s
P01215067A0000 |116 136|meningitis purulentaatal hyperbilirubine
P01217450A0295 |64 69|blockotida
P01217450A0295 |93 97|dogscolo
P01217450A0295 |4 22|Chemical occlusion01606T0076 Compari
P01224116A0576 |152 158|family472 Wh
P01224116A0576 |94 99|Buseyologi
P01224116A0576 |73 76|IgG000
P01224116A0576 |104 111|Barbeauects of
P01224116A0576 |23 31|patientson with 
P01224116A0576 |42 63|serum immunoglobulinsosphatases and 5-nucl
P01224116A0576 |87 92|RussePharm
P01225339A0590 |48 52|timeases
P01225339A0590 |60 70|infarctionucleotidas
P01225339A0590 |21 31|occlusionsison with 
P01228258A0000 |119 130|combinationl hyperbili
P01228258A0000 |149 153|5-FU7A04
P01228258A0000 |62 67|agentleoti
P01228258A0000 |14 25|preparation Comparison
P01228258A0000 |42 46|typeosph
P01228258A0000 |27 33|OK-432ith al
P01228258A0000 |109 115|cancerof neo
P01228258A0000 |86 94|patients Pharmac
P01228258A0000 |158 178|Cytosine arabinosideen CSF [HCO3-] is sh
P01228258A0000 |136 147|Mitomycin-Cmia. P00008
P01228882A0437 |190 198|diseasesction of
P01228882A0437 |129 137|responseirubinem
P01228882A0437 |72 91|CSF immunoglobulinsP00008171T0000 Phar
P01228882A0437 |13 24|correlation6 Compariso
P01228882A0437 |158 167|componenten CSF [H
P01228882A0437 |96 102|degreeogic a
P01228882A0437 |54 68|concentrationsnd 5-nucleotid
P01233561T0001 |9 18|lactationT0076 Com
P01235347T0001 |13 27|cardiotoxicity6 Comparison w
P01235347T0001 |31 41|adriamycinalkaline p
P01236224T0001 |9 18|pathologyT0076 Com
P01237206A0199 |0 13|DemonstrationP00001606T007
P01237206A0199 |172 188|Coxiella content is shown as a f
P01237206A0199 |97 104|methodsgic asp
P01237206A0199 |147 165|antibody technique997A0472 When CSF 
P01237206A0199 |106 111|Stampts of
P01237206A0199 |21 26|agentison 
P01237206A0199 |66 74|day p.i.idase P0
P01237206A0199 |232 235|henats
P01237206A0199 |207 216|titration the data
P01237206A0199 |116 133|auramine stainingatal hyperbilirub
P01237206A0199 |238 242|eggse no
P01241437A0152 |85 93|morphine0 Pharma
P01241437A0152 |97 104|Micorengic asp
P01241437A0152 |73 83|nalorphine00008171T0
P01241437A0152 |33 39|groupskaline
P01241437A0152 |4 12|patients01606T00
P01241437A0152 |50 56|NLA IIes and
P01241588A1470 |68 73|brainase P
P01241588A1470 |122 126|IDPNyper
P01241588A1470 |28 41|5-HIAA levelsth alkaline p
P01241588A1470 |53 60|regionsand 5-n
P01241588A1470 |129 142|neurotoxicityirubinemia. P
P01241588A1470 |177 185|neuroneshown as 
P01241588A1470 |19 23|5-HTaris
P01241588A1470 |4 15|alterations01606T0076 
P01241588A1470 |84 94|conditions00 Pharmac
P01241866A0682 |70 75|serume P00
P01241866A0682 |104 111|phase-2ects of
P01241866A0682 |90 96|rabbitrmacol
P01241866A0682 |52 66|administration and 5-nucleot
P01241866A0682 |7 15|increase06T0076 
P01241866A0682 |19 35|leukocyte-countsarison with alka
P01242636A0678 |64 70|systemotidas
P01242636A0678 |94 113|beryllium retentionologic aspects of n
P01242636A0678 |4 11|results01606T0
P01243628A0286 |81 85|COHbT000
P01243628A0286 |56 79|blood carboxyhemoglobin 5-nucleotidase P000081
P01243628A0286 |29 37|exposureh alkali
P01243628A0286 |47 52|leveltases
P01243628A0286 |22 25|endson
P01243628A0286 |8 13|cases6T007
P01243628A0286 |96 97|%o
P01244236A1122 |4 11|results01606T0
P01244236A1122 |254 260|amountlaced 
P01244236A1122 |288 297|thicknesst still h
P01244236A1122 |116 125|gestationatal hype
P01244236A1122 |322 329|vesselser slop
P01244236A1122 |271 277|muscleed to 
P01244236A1122 |301 307|musclea sign
P01244236A1122 |90 100|resistancermacologic
P01244236A1122 |162 168|numberSF [HC
P01244236A1122 |46 56|blood flowatases and
P01244236A1122 |194 214|vasomotor reactivityn of CSF PCO2 the da
P01244236A1122 |172 179|vessels is sho
P01244236A1122 |232 240|increaseats are 
P01244236A1122 |140 148|increase P000089
P01245162A0262 |0 9|ReductionP00001606
P01245162A0262 |13 19|dosage6 Comp
P01245162A0262 |77 81|drug8171
P01245162A0262 |132 151|transaminase levelsbinemia. P00008997A
P01245162A0262 |36 47|taste senseine phospha
P01246210A0648 |116 117|%a
P01246210A0648 |67 70|mendas
P01246210A0648 |58 62|TBCa-nuc
P01246210A0648 |88 89|%h
P01246210A0648 |4 17|calcium ratio01606T0076 Co
P01246210A0648 |97 102|womengic a
P01246210A0648 |18 28|mean ratioparison wi
P01247475A0000 |99 112|deteriorationc aspects of 
P01247475A0000 |56 60|fact 5-n
P01247475A0000 |120 127|outlook hyperb
P01247475A0000 |7 16|diagnosis06T0076 C
P01247475A0000 |77 83|growth8171T0
P01247475A0000 |20 34|retinoblastomarison with alk
P01248124A0281 |83 92|gestation000 Pharm
P01248124A0281 |43 49|fluidssphata
P01248124A0281 |73 79|stages000081
P01248124A0281 |6 17|cholesterol606T0076 Co
P01249198A1097 |4 27|serum FT3 concentration01606T0076 Comparison w
P01249198A1097 |63 69|rangeseotida
P01249198A1097 |96 108|GTD patientsogic aspects
P01249198A1097 |126 141|hyperthyroidismbilirubinemia. 
P01249198A1097 |80 89|pregnancy1T0000 Ph
P01252223A0347 |119 124|Winchl hyp
P01252223A0347 |147 162|complementarity997A0472 When C
P01252223A0347 |107 115|contrasts of neo
P01252223A0347 |140 144|type P00
P01252223A0347 |127 136|principleilirubine
P01252223A0347 |43 52|pugnacitysphatases
P01252223A0347 |70 88|trait correlationse P00008171T0000 P
P01252223A0347 |4 11|authors01606T0
P01252223A0347 |34 38|fearalin
P01253191T0000 |2 6|note0001
P01253191T0000 |14 50|phase-plane technique representation Comparison with alkaline phosphatas
P01253191T0000 |62 79|action potentialsleotidase P000081
P01256410T0001 |2 12|activities0001606T00
P01256410T0001 |30 38|molecule alkalin
P01256410T0001 |54 60|infantnd 5-n
P01256410T0001 |20 26|factorrison 
P01256410T0001 |64 68|termotid
P01259027A0416 |289 297|approach still h
P01259027A0416 |243 250|conceptlonger 
P01259027A0416 |225 234|extensionleted rat
P01259027A0416 |318 332|design problemreater slope (
P01259027A0416 |92 108|model parametersacologic aspects
P01259027A0416 |27 42|identifiabilityith alkaline ph
P01259027A0416 |182 186|dataas a
P01259027A0416 |4 11|concept01606T0
P01259027A0416 |203 212|procedurePCO2 the 
P01259027A0416 |64 72|analysisotidase 
P01261005A0711 |34 43|variationaline pho
P01261005A0711 |90 98|bandpassrmacolog
P01261005A0711 |108 135|bandpass spectrophotometers of neonatal hyperbilirubin
P01261005A0711 |63 74|performanceeotidase P0
P01261005A0711 |48 59|differencesases and 5-
P01262596T0000 |13 23|compromise6 Comparis
P01264640T0028 |19 25|Saigonarison
P01264640T0028 |2 6|case0001
P01265443A0159 |171 178|stomach] is sh
P01265443A0159 |11 18|glucose076 Com
P01265443A0159 |213 219|effectata of
P01265443A0159 |128 142|acid secretionlirubinemia. P
P01265443A0159 |199 205|salineCSF PC
P01265443A0159 |50 71|Heidenhain pouch dogses and 5-nucleotidase
P01265443A0159 |93 103|inhibitioncologic as
P01265443A0159 |152 157|pouch472 W
P01265887T0001 |49 57|patientsses and 
P01265887T0001 |9 30|factor VIII inhibitorT0076 Comparison with
P01267446A0210 |0 16|BiohydrogenationP00001606T0076 C
P01267446A0210 |29 33|acidh al
P01267446A0210 |52 56|acid and
P01272816A0000 |118 122|47Caal h
P01272816A0000 |80 88|controls1T0000 P
P01272816A0000 |52 60|children and 5-n
P01272816A0000 |13 31|calcium metabolism6 Comparison with 
P01272816A0000 |155 165|absorption When CSF 
P01272816A0000 |4 9|study01606
P01272816A0000 |100 114|administration aspects of ne
P01275335A0158 |79 84|phase71T00
P01275335A0158 |41 46|semenhosph
P01275335A0158 |11 17|agents076 Co
P01275335A0158 |56 59|end 5-
P01275541A0405 |153 161|delivery72 When 
P01275541A0405 |25 37|CPK activity with alkali
P01275541A0405 |141 146|weeksP0000
P01275541A0405 |54 62|newbornsnd 5-nuc
P01275541A0405 |101 110|dystrophyaspects o
P01276105A0313 |17 33|insulin responsemparison with al
P01276105A0313 |67 72|valuedase 
P01276105A0313 |3 11|contrast001606T0
P01276105A0313 |98 108|puerperiumic aspects
P01276105A0313 |87 90|dayPha
P01278251A0000 |87 96|materialsPharmacol
P01278251A0000 |127 147|tetraphenylbutadieneilirubinemia. P00008
P01278251A0000 |149 152|TPB7A0
P01278251A0000 |60 65|testsucleo
P01278251A0000 |36 42|seriesine ph
P01278251A0000 |23 30|resultson with
P01278251A0000 |189 199|sensitizernction of 
P01278251A0000 |4 11|authors01606T0
P01278251A0000 |234 243|materialss are no 
P01278251A0000 |98 110|polyethyleneic aspects o
P01279197T0000 |33 48|homology regionkaline phosphat
P01279197T0000 |88 110|saturation mutagenesisharmacologic aspects o
P01279197T0000 |52 77|Mason-Pfizer monkey virus and 5-nucleotidase P0000
P01279197T0000 |11 19|analysis076 Comp
P01279197T0000 |81 84|useT00
P01279352A0297 |4 8|site0160
P01279352A0297 |10 13|PAL007
P01279352A0297 |36 58|bp sequence GGGGAGGAGGine phosphatases and 5
P01279352A0473 |186 194|proteins functio
P01279352A0473 |147 151|PROX997A
P01279352A0473 |107 115|proteinss of neo
P01279352A0473 |8 16|extracts6T0076 C
P01279352A0473 |58 68|cell lines-nucleotid
P01279352A0473 |215 231|target sequencesa of K-depleted 
P01279352A0473 |70 81|mouse braine P00008171
P01279352A0473 |156 169|PAL sequencesWhen CSF [HCO
P01279352A0473 |87 98|mouse liverPharmacolog
P01279352A1197 |87 98|developmentPharmacolog
P01279352A1197 |26 34|promoterwith alk
P01279352A1197 |73 79|manner000081
P01279352A1197 |110 114|micef ne
P01279352A1197 |57 63|tissue5-nucl
P01279352A1197 |130 145|promoter regionrubinemia. P000
P01279352A1197 |158 190|beta-galactosidase reporter geneen CSF [HCO3-] is shown as a fun
P01279352A1197 |23 24|Ho
P01279352A1197 |20 22|NFri
P01279374A0396 |137 143|PET122ia. P0
P01279374A0396 |123 133|truncationperbilirub
P01279374A0396 |74 85|suppressors0008171T000
P01279374A0396 |38 43|genese pho
P01279696A0862 |71 80|Kishimoto P0000817
P01279696A0862 |29 37|Hisanagah alkali
P01279696A0862 |82 84|T.00
P01279696A0862 |43 51|Kusubatasphatase
P01279696A0862 |9 16|studiesT0076 C
P01279696A0862 |57 64|Okumura5-nucle
P01279696A0862 |66 68|E.id
P01279696A0862 |53 55|M.an
P01279696A0862 |39 41|S. p
P01280413T0001 |0 9|TreatmentP00001606
P01280413T0001 |63 77|microorganismseotidase P0000
P01280413T0001 |14 22|staining Compari
P01280413T0001 |37 45|sectionsne phosp
P01280413T0001 |26 32|smearswith a
P01280413T0001 |50 59|detectiones and 5-
P01280807A0575 |23 49|MetRS/CAU operator complexon with alkaline phosphata
P01280807A0575 |57 72|order magnitude5-nucleotidase 
P01280807A0575 |13 15|Kd6 
P01280807A0575 |97 123|ThrRS/CGU operator complexgic aspects of neonatal hy
P01281322A0604 |136 145|flow ratemia. P000
P01281322A0604 |90 96|musclermacol
P01281322A0604 |59 79|percent area densitynucleotidase P000081
P01281322A0604 |105 119|percent changects of neonata
P01281322A0604 |21 33|relationshipison with al
P01281472T0000 |0 6|RabbitP00001
P01281472T0000 |16 33|muscle glycogeninomparison with al
P01281771T0000 |0 16|CharacterizationP00001606T0076 C
P01281771T0000 |44 55|cytokeratinphatases an
P01281771T0000 |30 34|gene alk
P01281771T0000 |67 85|expression patterndase P00008171T000
P01282014A0275 |0 7|AnimalsP000016
P01282014A0275 |59 73|motor recoverynucleotidase P
P01282014A0275 |92 104|saline groupacologic asp
P01282014A0275 |22 27|DSP-4son w
P01282638A0934 |4 20|prophylactic use01606T0076 Compa
P01282638A0934 |211 215|life dat
P01282638A0934 |354 361|patient10943A0
P01282638A0934 |249 261|continuation displaced w
P01282638A0934 |296 308|interruptionhave a signi
P01282638A0934 |126 135|estimatesbilirubin
P01282638A0934 |331 346|life expectancy(1.21 +/- 0.23 
P01282638A0934 |28 38|medicationth alkalin
P01282638A0934 |90 102|chemotherapyrmacologic a
P01282638A0934 |162 179|health care costsSF [HCO3-] is sho
P01282638A0934 |107 116|agreements of neon
P01282638A0934 |225 233|patientsleted ra
P01282638A0934 |81 86|cycleT0000
P01282638A0934 |200 207|qualitySF PCO2
P01282638A0934 |43 51|patientssphatase
P01282638A0934 |279 287|schedulentrols b
P01284032A0213 |0 2|APP0
P01284032A0213 |91 95|acidmaco
P01284032A0213 |105 109|mmolcts 
P01284032A0213 |30 38|infusion alkalin
P01284032A0213 |97 101|GDOCgic 
P01284032A0213 |56 70|concentrations 5-nucleotidas
P01284032A0213 |117 121|mmoltal 
P01284595A0102 |102 111|sequencesspects of
P01284595A0102 |66 78|Y-231 cosmididase P00008
P01284595A0102 |22 26|geneson 
P01284595A0102 |93 96|CpGcol
P01284595A0102 |44 58|identificationphatases and 5
P01284595A0102 |4 13|isolation01606T007
P01284595A0102 |113 124|HTF islandseonatal hyp
P01284595A0102 |139 145|insert. P000
P01284828T0001 |68 80|fibrinolysisase P0000817
P01284828T0001 |139 147|prostate. P00008
P01284828T0001 |54 64|parametersnd 5-nucle
P01284828T0001 |93 101|patientscologic 
P01284828T0001 |120 131|hypertrophy hyperbilir
P01284828T0001 |0 28|Tissue plasminogen activatorP00001606T0076 Comparison wi
P01284828T0001 |84 89|blood00 Ph
P01284828T0001 |34 43|inhibitoraline pho
P01285009A0000 |0 15|Gene constructsP00001606T0076 
P01285009A0000 |214 217|cBAta 
P01285009A0000 |271 282|medaka eggsed to contr
P01285009A0000 |157 160|vTKhen
P01285009A0000 |219 223|gene K-d
P01285009A0000 |52 55|hGH an
P01285009A0000 |127 130|mMTili
P01285009A0000 |247 256|cytoplasmer displa
P01285009A0000 |92 100|sequenceacologic
P01285009A0000 |57 61|gene5-nu
P01285009A0000 |104 125|mouse metallothioneinects of neonatal hype
P01285009A0000 |194 212|chicken beta-actinn of CSF PCO2 the 
P01285009A0000 |184 188|rCCK a f
P01285009A0000 |291 300|micropyletill have
P01285009A0000 |36 50|growth hormoneine phosphatas
P01285009A0000 |163 182|rat cholecystokininF [HCO3-] is shown 
P01285009A0000 |139 155|thymidine kinase. P00008997A0472
P01285358A0396 |0 13|Serum gastrinP00001606T007
P01285358A0396 |80 88|interest1T0000 P
P01285358A0396 |42 51|evolutionosphatase
P01285358A0396 |117 124|diseasetal hyp
P01285358A0396 |18 28|AFP levelsparison wi
P01285358A0396 |103 109|coursepects 
P01285554T0000 |34 41|systemsaline p
P01285554T0000 |0 9|ProspectsP00001606
P01285807A0365 |18 22|PaO2pari
P01285807A0365 |180 181|Pn
P01285807A0365 |14 16|SD C
P01285807A0365 |96 104|infusionogic asp
P01285807A0365 |52 56|mmHg and
P01285807A0365 |124 129|PaCO2erbil
P01285807A0365 |106 107|Pt
P01285807A0365 |4 8|mean0160
P01285807A0365 |174 178|mmHgs sh
P01285807A0365 |81 85|mmHgT000
P01286732A0572 |203 215|complicationPCO2 the dat
P01286732A0572 |29 38|elevationh alkalin
P01286732A0572 |122 127|liveryperb
P01286732A0572 |107 118|involvements of neonat
P01286732A0572 |97 105|patientsgic aspe
P01286732A0572 |7 19|hepatomegaly06T0076 Comp
P01286732A0572 |42 49|enzymesosphata
P01286732A0572 |145 154|hepatitis08997A047
P01286732A0572 |83 93|proportion000 Pharma
P01286732A0572 |219 240|P. falciparum malaria K-depleted rats are 
P01286732A0572 |158 177|liver cell necrosisen CSF [HCO3-] is s
P01287197A0761 |137 143|mmol/lia. P0
P01287197A0761 |164 169|group [HCO
P01287197A0761 |45 61|plasma potassiumhatases and 5-nu
P01287197A0761 |179 188|decrementwn as a f
P01287197A0761 |74 84|salbutamol0008171T00
P01287197A0761 |14 19|group Comp
P01287197A0761 |241 247|mmol/lo long
P01287197A0761 |33 41|decreasekaline p
P01287197A0761 |260 262|powh
P01287197A0761 |256 258|ivce
P01292230A0283 |51 58|fillings and 5
P01292230A0283 |27 31|rateith 
P01292230A0283 |8 13|drugs6T007
P01294345A0591 |51 65|administrations and 5-nucleo
P01294345A0591 |180 187|tensionn as a 
P01294345A0591 |120 136|overreactiveness hyperbilirubine
P01294345A0591 |196 207|weight gainof CSF PCO2
P01294345A0591 |95 103|symptomslogic as
P01294345A0591 |147 163|prolactin levels997A0472 When CS
P01294345A0591 |28 39|improvementth alkaline
P01294345A0591 |189 194|edemanctio
P01294345A0591 |212 229|breast tendernessdata of K-deplete
P01294345A0591 |69 78|Bromergonse P00008
P01295373A0651 |50 51|%e
P01295373A0651 |27 35|responseith alka
P01295373A0651 |147 148|p9
P01295373A0651 |124 125|%e
P01295373A0651 |73 77|mean0000
P01295373A0651 |113 114|Be
P01295373A0651 |82 84|SE00
P01295373A0651 |58 71|% baseline RL-nucleotidase
P01295373A0651 |131 132|Cu
P01295373A0651 |4 13|magnitude01606T007
P01295373A0651 |143 144|%0
P01295373A0651 |55 56|Ad
P01295500A0366 |103 111|Deficitspects of
P01295500A0366 |12 20|patients76 Compa
P01295500A0366 |55 62|Attacksd 5-nuc
P01295500A0366 |66 67|%i
P01295500A0366 |115 116|%n
P01296815A0059 |71 88|sequence analysis P00008171T0000 P
P01296815A0059 |122 132|pseudogeneyperbiliru
P01296815A0059 |52 62|LD78 gamma and 5-nuc
P01296815A0059 |26 30|genewith
P01296815A0059 |39 43|LD78 pho
P01297332A0983 |118 126|proposalal hyper
P01297332A0983 |189 196|elementnction 
P01297332A0983 |52 56|SCBs and
P01297332A0983 |31 44|considerationalkaline phos
P01297332A0983 |140 158|consensus sequence P00008997A0472 Wh
P01297332A0983 |5 13|analysis1606T007
P01297332A0983 |98 103|genesic as
P01297332T0000 |81 91|cell cycleT0000 Phar
P01297332T0000 |58 73|gene expression-nucleotidase P
P01297332T0000 |11 19|analysis076 Comp
P01297332T0000 |25 37|DNA sequence with alkali
P01298173A0153 |171 181|modalities] is shown
P01298173A0153 |12 19|history76 Comp
P01298173A0153 |149 154|death7A047
P01298173A0153 |197 204|measuref CSF P
P01298173A0153 |129 137|survivalirubinem
P01298173A0153 |79 89|treatments71T0000 Ph
P01298173A0153 |29 36|lesionsh alkal
P01298173A0153 |100 104|part asp
P01298173A0153 |115 127|chemotherapynatal hyperb
P01298173A0153 |51 61|efficiencys and 5-nu
P01298398A0461 |48 66|nadolol racemate Aases and 5-nucleot
P01298398A0461 |31 44|determinationalkaline phos
P01298398A0461 |89 106|phase compositionarmacologic aspec
P01298398A0461 |72 78|changeP00008
P01298398A0461 |4 10|method01606T
P01299489A0788 |102 113|performancespects of n
P01299489A0788 |26 31|studywith 
P01299489A0788 |149 153|RDIs7A04
P01299489A0788 |74 89|supplementation0008171T0000 Ph
P01299489A0788 |48 56|evidenceases and
P01299489A0788 |64 70|effectotidas
P01299489A0788 |118 126|athletesal hyper
P01300914A1066 |202 207|walls PCO2
P01300914A1066 |713 729|RV abnormalitiesc anhydrase inhi
P01300914A1066 |103 110|resultspects o
P01300914A1066 |372 374|VTpa
P01300914A1066 |524 541|amplification ECGgents. P00013683A
P01300914A1066 |501 511|potentials53T0045 Be
P01300914A1066 |797 805|vaultingnduced a
P01300914A1066 |226 230|ACRVeted
P01300914A1066 |429 440|sensitivitye optimum d
P01300914A1066 |596 607|sensitivityroduction (
P01300914A1066 |125 132|dangersrbiliru
P01300914A1066 |419 425|degreeug wit
P01300914A1066 |300 308|criteria a signi
P01300914A1066 |483 492|existence at night
P01300914A1066 |396 403|featuren effec
P01300914A1066 |812 818|stasis impor
P01300914A1066 |455 466|stimulationgeneral pra
P01300914A1066 |213 222|diagnosisata of K-
P01300914A1066 |88 99|variabilityharmacologi
P01300914A1066 |31 39|criteriaalkaline
P01300914A1066 |151 157|biopsy0472 W
P01300914A1066 |621 626|fromsr ven
P01300914A1066 |322 333|arrhythmiaser slope (1
P01300914A1066 |561 565|signreal
P01300914A1066 |261 270|existencehen compa
P01300914A1066 |76 80|view0817
P01300914A1066 |468 476|exerciseice bein
P01300914A1066 |7 14|absence06T0076
P01301171A0979 |21 29|enhancerison wit
P01301171A0979 |46 69|c-myc bearing sequencesatases and 5-nucleotida
P01301171A0979 |73 83|chromosome00008171T0
P01301171A0979 |10 15|cases0076 
P01302765A0999 |119 121|adl 
P01302765A0999 |130 140|componentsrubinemia.
P01302765A0999 |66 69|R2sida
P01302765A0999 |6 16|components606T0076 C
P01302765A0999 |35 37|R2li
P01304515A0178 |65 75|volunteerstidase P00
P01304515A0178 |13 20|results6 Compa
P01304515A0178 |40 53|control groupphosphatases 
P01304809T0001 |4 9|years01606
P01304809T0001 |13 22|dentistry6 Compari
P01304809T0001 |30 59|Friedrich Schiller University alkaline phosphatases and 5-
P01304809T0001 |63 67|Jenaeoti
P01309244A0798 |136 143|contextmia. P0
P01309244A0798 |53 57|actsand 
P01309244A0798 |162 170|promoterSF [HCO3
P01309244A0798 |29 38|positionsh alkalin
P01309244A0798 |75 86|orientation008171T0000
P01309244A0798 |101 111|cell typesaspects of
P01309244A0798 |4 10|target01606T
P01309244A0798 |116 123|speciesatal hy
P01309587A0715 |118 127|Z proteinal hyperb
P01309587A0715 |57 76|Z/c-myb combination5-nucleotidase P000
P01309587A0715 |12 27|transactivation76 Comparison w
P01309587A0715 |35 49|BMRF1 promoterline phosphata
P01309587A0715 |140 153|c-myb protein P00008997A04
P01309587A0715 |103 110|bindingpects o
P01309593A0095 |4 21|UCR core sequence01606T0076 Compar
P01309593A0095 |90 100|regulationrmacologic
P01309593A0095 |104 126|MuLV promoter activityects of neonatal hyper
P01309593A0095 |61 67|factorcleoti
P01309593A0095 |23 32|CGCCATTTTon with a
P01309593A1092 |236 249|protein genesare no longer
P01309593A1092 |47 60|target motifstases and 5-n
P01309593A1092 |120 137|virus P5 promoter hyperbilirubinem
P01309593A1092 |196 201|genesof CS
P01309593A1092 |24 29|UCRBPn wit
P01309593A1092 |214 222|elementsta of K-
P01309593A1092 |88 97|UCR motifharmacolo
P01309593A1092 |6 13|studies606T007
P01309593A1092 |142 150|elements00008997
P01309593A1092 |158 178|immunoglobulin lighten CSF [HCO3-] is sh
P01309815A0972 |141 147|arrestP00008
P01309815A0972 |14 29|scr1-1 mutation Comparison wit
P01309815A0972 |151 164|AEP synthesis0472 When CSF
P01309815A0972 |82 88|arrest0000 P
P01309815A0972 |46 64|signal recognitionatases and 5-nucle
P01309815A0972 |112 123|maintenanceneonatal hy
P01309860A0559 |171 180|sequences] is show
P01309860A0559 |13 22|sequences6 Compari
P01309860A0559 |74 84|% identity0008171T00
P01309860A0559 |96 105|sequencesogic aspe
P01309860A0559 |123 138|mouse L1 familyperbilirubinemi
P01309860A0559 |39 55|integration site phosphatases an
P01309894A0807 |69 79|nucleotidese P000081
P01309894A0807 |15 20|Rep68Compa
P01309894A0807 |5 10|Rep781606T
P01309894A0807 |63 67|siteeoti
P01309894A0807 |38 50|AAV sequencee phosphatas
P01309910A0428 |0 28|Nucleotide sequence analysisP00001606T0076 Comparison wi
P01309910A0428 |55 62|proteind 5-nuc
P01309910A0428 |86 99|CREB2 protein Pharmacologi
P01310154A0879 |85 100|transrepression0 Pharmacologic
P01310154A0879 |104 115|FBR proteinects of neo
P01310154A0879 |188 208|protein modificationunction of CSF PCO2 
P01310154A0879 |6 13|results606T007
P01310154A0879 |145 154|mutations08997A047
P01310154A0879 |215 230|gene regulationa of K-depleted
P01310154A0879 |33 34|Nk
P01310154A0879 |234 245|FBR proteins are no lo
P01310154A0879 |51 60|mutationss and 5-n
P01310178A0876 |48 59|amber codonases and 5-
P01310178A0876 |36 39|gp0ine
P01310178A0876 |130 141|polypeptiderubinemia. 
P01310178A0876 |180 186|domainn as a
P01310178A0876 |4 32|JS78 mutation changes Gln24301606T0076 Comparison with a
P01310178A0876 |80 90|production1T0000 Pha
P01310178A0876 |190 217|host transcription shut-offction of CSF PCO2 the data 
P01310879A0000 |2 19|patient suffering0001606T0076 Comp
P01310879A0000 |62 65|HATleo
P01310879A0000 |44 60|thrombocytopeniaphatases and 5-n
P01310879A0000 |151 158|heparin0472 Wh
P01310879A0000 |127 136|treatmentilirubine
P01310879A0000 |78 95|arteriothromboses171T0000 Pharmaco
P01310879A0000 |113 120|failureeonatal
P01310899A0339 |101 121|transmembrane domainaspects of neonatal 
P01310899A0339 |14 32|receptor structure Comparison with a
P01310899A0339 |151 181|serine/threonine kinase domain0472 When CSF [HCO3-] is shown
P01310899A0339 |72 78|domainP00008
P01310935T0000 |66 72|enzymeidase 
P01310935T0000 |11 16|UbcD1076 C
P01310935T0000 |95 114|protein degradationlogic aspects of ne
P01312005A0600 |343 354|replication23 vs. P000
P01312005A0600 |295 300|bases have
P01312005A0600 |59 63|MDP1nucl
P01312005A0600 |265 275|structurescompared t
P01312005A0600 |208 213|tractthe d
P01312005A0600 |31 40|mt genomealkaline 
P01312005A0600 |328 334|originpe (1.
P01312005A0600 |85 96|chick mtDNA0 Pharmacol
P01312005A0600 |153 165|target sites72 When CSF 
P01312005A0600 |115 116|Hn
P01312005A0600 |189 190|An
P01312005A0600 |336 338|OH +
P01312005A0600 |73 81|cleavage00008171
P01312005A0600 |0 8|AnalysisP0000160
P01313715A0461 |100 108|rp47phox aspects
P01313715A0461 |185 190|virusa fun
P01313715A0461 |24 29|studyn wit
P01313715A0461 |125 129|U937rbil
P01313715A0461 |150 160|cell linesA0472 When
P01313715A0461 |269 280|CGD patientared to con
P01313715A0461 |227 234|EBV-BCLted rat
P01313715A0461 |51 62|feasibilitys and 5-nuc
P01313715A0461 |86 96|expression Pharmacol
P01313715A0461 |116 120|HL60atal
P01313715A0461 |66 76|retrovirusidase P000
P01313715A0461 |203 225|B-lymphocyte cell linePCO2 the data of K-dep
P01313715A0461 |4 8|goal0160
P01313846A0850 |152 170|melanoma Ag MUC-18472 When CSF [HCO3
P01313846A0850 |172 179|members is sho
P01313846A0850 |76 107|immunoglobulin gene superfamily08171T0000 Pharmacologic aspect
P01313846A0850 |62 68|memberleotid
P01313846A0850 |49 56|Tactileses and
P01313846A0850 |114 124|similarityonatal hyp
P01313846A0850 |20 38|sequence databanksrison with alkalin
P01313846A0850 |219 238|poliovirus receptor K-depleted rats ar
P01313846A0850 |255 277|cell adhesion moleculeaced when compared to 
P01313846A0850 |204 213|Ag familyCO2 the d
P01313846A0850 |0 10|ComparisonP00001606T
P01313894A1179 |17 24|patternmpariso
P01313894A1179 |93 104|transcriptscologic asp
P01313894A1179 |177 183|levelshown a
P01313894A1179 |132 138|subsetbinemi
P01313894A1179 |28 35|resultsth alka
P01313894A1179 |54 61|respectnd 5-nu
P01313894A1179 |142 148|tumors000089
P01313894A1179 |65 86|LMP2B mRNA expressiontidase P00008171T0000
P01313909A0526 |137 145|sequenceia. P000
P01313909A0526 |93 98|viruscolog
P01313909A0526 |167 182|nonsense mutantCO3-] is shown 
P01313909A0526 |4 14|phenotypes01606T0076
P01313909A0526 |22 43|ICP0 nonsense mutantsson with alkaline pho
P01313909A0526 |216 225|phenotype of K-dep
P01314457T0000 |85 90|L-DNA0 Pha
P01314457T0000 |12 31|nucleotide sequence76 Comparison with 
P01314457T0000 |166 171|virusHCO3-
P01314457T0000 |52 55|kbp an
P01314457T0000 |59 78|herpesvirus saimirinucleotidase P00008
P01314457T0000 |145 148|HVS089
P01314457T0000 |124 136|organizationerbilirubine
P01314457T0000 |100 112|conservation aspects of 
P01314457T0000 |80 83|HVS1T0
P01314457T0000 |0 8|AnalysisP0000160
P01314841A0724 |0 9|TreatmentP00001606
P01314841A0724 |77 81|drop8171
P01314841A0724 |57 60|EEG5-n
P01314841A0724 |124 132|pressureerbiliru
P01314841A0724 |15 21|MK-801Compar
P01314841A0724 |96 101|mm Hgogic 
P01314841A0724 |110 114|meanf ne
P01314841A0724 |32 49|burst suppressionlkaline phosphata
P01314953A1266 |136 145|complexesmia. P000
P01314953A1266 |93 99|domaincologi
P01314953A1266 |79 83|HAP371T0
P01314953A1266 |13 43|gel mobility shift experiments6 Comparison with alkaline pho
P01314953A1266 |3 11|contrast001606T0
P01314953A1266 |110 124|hap3 mutationsf neonatal hyp
P01314953A1266 |71 75|HAP2 P00
P01315706A0000 |49 71|adenovirus E1a proteinses and 5-nucleotidase
P01315706A0000 |79 102|rat L6 muscle cell line71T0000 Pharmacologic a
P01315706A0000 |9 24|differentiationT0076 Compariso
P01316125A0176 |168 171|1O2O3-
P01316125A0176 |115 118|aidnat
P01316125A0176 |188 192|BHPDunct
P01316125A0176 |247 251|BHPDer d
P01316125A0176 |147 154|ability997A047
P01316125A0176 |63 71|radicalseotidase
P01316125A0176 |122 126|YHPDyper
P01316125A0176 |79 81|OH71
P01316125A0176 |44 47|1O2pha
P01316125A0176 |225 227|OHle
P01316125A0176 |86 90|YHPD Pha
P01316125A0176 |173 177|YHPDis s
P01316125A0176 |229 233|YHPDd ra
P01316125A0176 |4 14|experiment01606T0076
P01316125A0382 |138 142|YHPDa. P
P01316125A0382 |115 123|radicalsnatal hy
P01316125A0382 |353 355|OH01
P01316125A0382 |293 298|yieldll ha
P01316125A0382 |53 59|damageand 5-
P01316125A0382 |147 153|second997A04
P01316125A0382 |63 67|YHPDeoti
P01316125A0382 |302 305|1O2 si
P01316125A0382 |194 198|YHPDn of
P01316125A0382 |224 228|BHPDplet
P01316125A0382 |254 260|damagelaced 
P01316125A0382 |184 190|damage a fun
P01316125A0382 |96 99|1O2ogi
P01316125A0382 |131 133|OHub
P01316125A0382 |4 10|points01606T
P01316459A0311 |0 4|AcadP000
P01316461A1083 |51 59|peptidess and 5-
P01316461A1083 |195 205|expression of CSF PC
P01316461A1083 |214 221|proteinta of K
P01316461A1083 |26 36|S2 proteinwith alkal
P01316461A1083 |148 154|horses97A047
P01316461A1083 |183 191|evidences a func
P01316461A1083 |234 241|animalss are n
P01316461A1083 |77 79|S281
P01316461A1083 |115 119|seranata
P01316476A0842 |82 93|start sites0000 Pharma
P01316476A0842 |15 29|TATA sequencesComparison wit
P01316476A0842 |62 65|VZVleo
P01316476A1428 |49 52|ORFses
P01316476A1428 |56 60|gene 5-n
P01316476A1428 |74 83|induction0008171T0
P01316476A1428 |90 95|genesrmaco
P01316476A1428 |128 137|inductionlirubinem
P01316476A1428 |10 14|gene0076
P01316476A1428 |4 7|ORF016
P01316680A0643 |19 26|IR5 ORFarison 
P01316680A0643 |151 167|C-X2-4-C-X2-15-C0472 When CSF [H
P01316680A0643 |30 35|EHV-1 alka
P01316680A0643 |177 178|Hh
P01316680A0643 |109 114|matchof ne
P01316680A0643 |63 74|amino acidseotidase P0
P01316680A0643 |122 149|consensus zinc finger motifyperbilirubinemia. P0000899
P01316680A0643 |48 56|sequenceases and
P01316680A0643 |76 89|CAYWCCLGHAFAC08171T0000 Ph
P01316680A0643 |168 176|H-X2-4-CO3-] is 
P01316900A0000 |71 75|K-12 P00
P01316900A0000 |24 48|sulfate activation locusn with alkaline phosphat
P01316900A0000 |4 16|DNA sequence01606T0076 C
P01316903A0296 |21 25|formison
P01316903A0296 |61 64|IIAcle
P01316903A0296 |93 97|formcolo
P01316903A0296 |29 43|RNA polymeraseh alkaline pho
P01316903A0296 |112 115|IIOneo
P01316903A1040 |0 18|RNA polymerase IIAP00001606T0076 Com
P01316903A1040 |61 70|complexescleotidas
P01316903A1040 |97 109|input enzymegic aspects 
P01316903A1040 |74 83|reactions0008171T0
P01316903A1040 |114 132|RNA polymerase IIAonatal hyperbiliru
P01317376A0981 |0 21|Fructokinase activityP00001606T0076 Compar
P01317376A0981 |77 85|fructose8171T000
P01317376A0981 |131 139|increaseubinemia
P01317376A0981 |53 63|Z. mobilisand 5-nucl
P01317376A0981 |97 104|glucosegic asp
P01317376A0981 |143 158|frk mRNA levels0008997A0472 Wh
P01318310A0000 |0 16|Plasma membranesP00001606T0076 C
P01318310A0000 |76 95|density lipoprotein08171T0000 Pharmaco
P01318310A0000 |125 132|removalrbiliru
P01318310A0000 |29 34|cellsh alk
P01318310A0000 |157 168|cholesterolhen CSF [HC
P01318310A0000 |97 100|HDLgic
P01318310A0000 |48 66|affinity receptorsases and 5-nucleot
P01318739A0410 |68 73|VM-26ase P
P01318739A0410 |82 95|neurotoxicity0000 Pharmaco
P01318739A0410 |56 66|teniposide 5-nucleot
P01318739A0410 |19 39|patients vincristinearison with alkaline
P01320255A0795 |139 146|element. P0000
P01320255A0795 |197 199|L1f 
P01320255A0795 |162 166|roleSF [
P01320255A0795 |89 100|L1 sequencearmacologic
P01320255A0795 |46 53|elementatases 
P01320255A0795 |174 187|transcriptions shown as a 
P01320255A0795 |6 13|results606T007
P01320255A0795 |117 131|factor bindingtal hyperbilir
P01320640A0336 |0 11|Tumor cellsP00001606T0
P01320640A0336 |60 67|enolaseucleoti
P01320640A0336 |78 86|glucagon171T0000
P01320640A0336 |91 94|VIPmac
P01320640A0336 |69 76|insulinse P000
P01321277A0342 |118 121|CEFal 
P01321277A0342 |73 76|ROS000
P01321277A0342 |90 116|chicken embryo fibroblastsrmacologic aspects of neon
P01321277A0342 |67 70|SRCdas
P01321277A0342 |128 152|spindle shape morphologylirubinemia. P00008997A0
P01321277A0342 |24 27|endn w
P01321277A0342 |46 49|endata
P01321277A0342 |55 58|rosd 5
P01321277A0342 |172 175|UR2 is
P01321277A0342 |33 36|srckal
P01321277A0664 |0 3|ROSP00
P01321277A0664 |105 108|roscts
P01321277A0664 |95 101|domainlogic 
P01321277A0664 |11 12|R0
P01321277A0664 |6 9|SRC606
P01321277A0664 |39 47|deletion phospha
P01321280A0494 |205 223|E7 fusion proteinsO2 the data of K-d
P01321280A0494 |46 62|E7 gene productsatases and 5-nuc
P01321280A0494 |192 200|BPV-1 E6ion of C
P01321280A0494 |14 20|number Compa
P01321280A0494 |151 159|antisera0472 Whe
P01321280A0494 |25 31|nature with 
P01321280A0494 |94 99|cellsologi
P01321280A0494 |39 41|E6 p
P01321280A0494 |114 145|immunoprecipitation experimentsonatal hyperbilirubinemia. P000
P01321332A0970 |258 265|amountsd when 
P01321332A0970 |215 230|transactivationa of K-depleted
P01321332A0970 |198 200|RA C
P01321332A0970 |123 133|apoAI geneperbilirub
P01321332A0970 |158 178|hepatoma HepG2 cellsen CSF [HCO3-] is sh
P01321332A0970 |283 288|ARP-1ls bu
P01321332A0970 |42 48|site Aosphat
P01321332A0970 |10 29|transfection assays0076 Comparison wit
P01321332A0970 |81 84|RXRT00
P01321332A0970 |140 148|promoter P000089
P01321332A0970 |100 115|transactivation aspects of neo
P01321332A0970 |186 194|presence functio
P01321336A0000 |34 48|leukemia virusaline phosphat
P01321336A0000 |62 85|sequence motif ACAGATGGleotidase P00008171T000
P01321336A0000 |23 26|Akvon 
P01321336A0000 |4 19|enhancer region01606T0076 Comp
P01321336A0731 |102 110|proteinsspects o
P01321336A0731 |23 32|ALF1 cDNAon with a
P01321336A0731 |126 137|amino acidsbilirubinem
P01321336A0731 |4 19|splice variants01606T0076 Comp
P01321336A0731 |71 80|insertion P0000817
P01321337A0318 |102 109|abilityspects 
P01321337A0318 |58 61|kDa-nu
P01321337A0318 |193 204|calcineurinon of CSF P
P01321337A0318 |262 273|calcineurinen compared
P01321337A0318 |80 90|properties1T0000 Pha
P01321337A0318 |172 179|subunit is sho
P01321337A0318 |230 239|antiserum rats are
P01321337A0318 |169 170|B3
P01321337A0318 |18 27|componentparison w
P01321337A0318 |50 54|masses a
P01321337A0318 |118 123|45Ca2al hy
P01321337A1161 |53 60|mutantsand 5-n
P01321337A1161 |104 111|abilityects of
P01321337A1161 |31 45|MATa cna1 cna2alkaline phosp
P01321337A1161 |62 79|MATa cnb1 mutantsleotidase P000081
P01321337A1161 |149 162|growth arrest7A0472 When C
P01324172A0880 |0 10|AntibodiesP00001606T
P01324172A0880 |58 70|mitochondria-nucleotidas
P01324172A0880 |33 40|proteinkaline 
P01324172A0880 |50 54|RIM1es a
P01324385A0329 |0 7|METHODSP000016
P01324385A0329 |262 275|control groupen compared t
P01324385A0329 |113 125|seronegativeeonatal hype
P01324385A0329 |27 32|HHV-6ith a
P01324385A0329 |176 181|stageshown
P01324385A0329 |150 155|HIV-1A0472
P01324385A0329 |78 96|immunofluorescence171T0000 Pharmacol
P01324385A0329 |104 108|IVDAects
P01324385A0329 |195 200|IV-C1 of C
P01324385A0329 |257 260|ageed 
P01324385A0329 |235 243|subjects are no 
P01324385A0329 |9 23|IgG antibodiesT0076 Comparis
P01324385A0329 |204 207|CDCCO2
P01324385A0329 |34 48|anti-HHV-6-IgGaline phosphat
P01324404A0813 |153 164|amino acids72 When CSF
P01324404A0813 |108 125|carboxyl terminus of neonatal hype
P01324404A0813 |133 151|HNF-3 beta proteininemia. P00008997A
P01324404A0813 |67 74|regionsdase P0
P01324404A0813 |23 40|activation domainon with alkaline 
P01324404A1208 |0 10|HNF-3 betaP00001606T
P01324404A1208 |108 114|region of ne
P01324404A1208 |57 63|region5-nucl
P01324404A1208 |26 35|sequenceswith alka
P01324404A1208 |140 153|participation P00008997A04
P01324404A1208 |161 181|region II-III domainCSF [HCO3-] is shown
P01324404A1208 |87 102|transactivationPharmacologic a
P01324404A1208 |118 126|activityal hyper
P01324406A1250 |153 162|sequences72 When C
P01324406A1250 |111 116|rates neon
P01324406A1250 |9 14|rolesT0076
P01324406A1250 |120 131|instability hyperbilir
P01324406A1250 |18 22|RAD5pari
P01324406A1250 |64 74|DNA repairotidase P0
P01324406A1250 |86 97|maintenance Pharmacolo
P01324406A1250 |32 60|ATPase/DNA helicase activitylkaline phosphatases and 5-n
P01324639T0000 |0 16|SusceptibilitiesP00001606T0076 C
P01324639T0000 |72 87|amoxicillin-BRLP00008171T0000 
P01324639T0000 |120 132|temafloxacin hyperbiliru
P01324639T0000 |59 70|amoxicillinnucleotidas
P01324639T0000 |95 118|amoxicillin-clavulanatelogic aspects of neonat
P01324639T0000 |48 55|bacilliases an
P01324639T0000 |138 149|clindamycina. P0000899
P01325221A0870 |55 64|detectiond 5-nucle
P01325221A0870 |89 99|MBP kinasearmacologi
P01325221A0870 |11 17|arrest076 Co
P01325221A0870 |123 137|p41 MAP kinaseperbilirubinem
P01325221A0870 |157 171|chromatographyhen CSF [HCO3-
P01325221A0870 |21 32|DU249 cellsison with a
P01325386A0766 |4 19|hit1-1 mutation01606T0076 Comp
P01325386A0766 |60 78|heat shock proteinucleotidase P00008
P01325386A0766 |29 35|defecth alka
P01325386A0766 |39 48|synthesis phosphat
P01326329A0703 |233 265|glucocorticoid response elementsts are no longer displaced when 
P01326329A0703 |191 208|activator proteintion of CSF PCO2 
P01326329A0703 |53 61|CAP siteand 5-nu
P01326329A0703 |218 223|sitesf K-d
P01326329A0703 |178 189|CCAAT boxesown as a fu
P01326329A0703 |212 216|Ap-2data
P01326329A0703 |267 271|GREsmpar
P01326329A0703 |122 130|presenceyperbili
P01326329A0703 |134 143|sequencesnemia. P0
P01326329A0703 |86 90|lack Pha
P01326329A0703 |155 163|GC boxes When CS
P01326329A0703 |293 314|AMP response elementsll have a significant
P01326329A0703 |165 176|CACCC boxes[HCO3-] is 
P01326329A0703 |105 113|TATA boxcts of n
P01326329A0703 |316 320|CREs gre
P01326329A0703 |8 24|base pair region6T0076 Compariso
P01326557T0000 |0 7|CloningP000016
P01326557T0000 |20 29|structurerison wit
P01326557T0000 |120 125|brain hype
P01326557T0000 |33 41|neurocankaline p
P01326557T0000 |84 116|chondroitin sulfate proteoglycan00 Pharmacologic aspects of neon
P01327280A0000 |69 71|pHse
P01327280A0000 |29 39|chloraloseh alkaline
P01327280A0000 |149 159|electrodes7A0472 Whe
P01327280A0000 |132 133|Kb
P01327280A0000 |44 51|changesphatase
P01327280A0000 |125 127|pHrb
P01327280A0000 |89 105|cord dorsal hornarmacologic aspe
P01327280A0000 |76 77|K0
P01327280A0000 |3 7|rats0016
P01327758A0000 |0 11|ReplicationP00001606T0
P01327758A0000 |47 50|DNAtas
P01327758A0000 |120 130|E2 protein hyperbili
P01327758A0000 |40 45|BPV-1phosp
P01327758A0000 |89 99|E1 proteinarmacologi
P01327758A0000 |22 38|papillomavirus-1son with alkalin
P01327758A0000 |70 83|gene productse P00008171T0
P01327967A0668 |139 145|serine. P000
P01327967A0668 |12 24|inactivation76 Compariso
P01327967A0668 |28 31|smsth 
P01327967A0668 |79 108|agent methylmethane sulfonate71T0000 Pharmacologic aspects
P01327967A0668 |123 134|requirementperbilirubi
P01327967A0668 |155 166|metabolites When CSF [
P01327967A0668 |49 60|sensitivityses and 5-n
P01328197A0985 |32 70|MAP kinase activator/MAP kinase systemlkaline phosphatases and 5-nucleotidas
P01328197A0985 |107 139|ras signal transduction pathwayss of neonatal hyperbilirubinemia
P01328197A0985 |93 103|componentscologic as
P01328197A0985 |6 14|findings606T0076
P01328219A1397 |0 6|NSCL-1P00001
P01328219A1397 |48 58|cell linesases and 5
P01328219A1397 |32 38|numberlkalin
P01328681A0149 |102 115|transcriptionspects of neo
P01328681A0149 |192 202|inhibitionion of CSF
P01328681A0149 |225 227|A.le
P01328681A0149 |150 158|proteinsA0472 Wh
P01328681A0149 |55 76|c-myc hyperexpressiond 5-nucleotidase P000
P01328681A0149 |124 134|activitieserbilirubi
P01328681A0149 |206 223|protein synthesis2 the data of K-d
P01328681A0149 |19 27|proteinsarison w
P01328681A0348 |0 7|RuddellP000016
P01328681A0348 |9 11|M.T0
P01328854T0000 |51 58|elements and 5
P01328854T0000 |183 195|muscle cellss a function
P01328854T0000 |109 116|subunitof neon
P01328854T0000 |72 85|transcriptionP00008171T000
P01328854T0000 |130 158|phosphoglycerate mutase generubinemia. P00008997A0472 Wh
P01328854T0000 |9 19|MEF-2 siteT0076 Comp
P01328884T0000 |0 19|Truncation variantsP00001606T0076 Comp
P01328884T0000 |77 92|sequence motifs8171T0000 Pharm
P01328884T0000 |46 55|MHC classatases an
P01328884T0000 |59 68|moleculesnucleotid
P01328884T0000 |23 31|peptideson with 
P01329039A0239 |153 161|proteins72 When 
P01329039A0239 |74 85|nucleotides0008171T000
P01329039A0239 |125 130|genesrbili
P01329039A0239 |13 28|E-box consensus6 Comparison wi
P01329039A0239 |53 59|CANNTGand 5-
P01329039A0239 |100 107|E-boxes aspect
P01329039A0951 |137 154|Ig kappa E2 E-boxia. P00008997A047
P01329039A0951 |23 36|gene activityon with alkal
P01329039A0951 |105 108|MCKcts
P01329039A0951 |114 124|E-box siteonatal hyp
P01329039A0951 |80 87|E-boxes1T0000 
P01329039A0951 |55 68|TnI enhancersd 5-nucleotid
P01329039A0951 |0 19|Intermediate levelsP00001606T0076 Comp
P01330077A0000 |0 20|T-cell receptor betaP00001606T0076 Compa
P01330077A0000 |105 114|leukemiascts of ne
P01330077A0000 |22 30|TCR betason with
P01330077A0000 |78 84|B-cell171T00
P01330077A0000 |116 120|ALLsatal
P01330077A0000 |32 51|gene rearrangementslkaline phosphatase
P01330309A1134 |4 17|CANNTG motifs01606T0076 Co
P01330309A1134 |135 143|myotubesemia. P0
P01330309A1134 |92 100|proteinsacologic
P01330309A1134 |46 70|myogenin fusion proteinsatases and 5-nucleotidas
P01330309A1134 |37 41|MyoDne p
P01330309A1134 |112 120|extractsneonatal
P01330975T0000 |51 58|myelomas and 5
P01330975T0000 |11 25|polyneuropathy076 Comparison
P01331057A0000 |48 52|geneases
P01331057A0000 |29 34|COX12h alk
P01331057A0000 |57 68|subunit VIb5-nucleotid
P01331057A0000 |97 117|cytochrome c oxidasegic aspects of neona
P01331060A0768 |21 39|calcineurin A geneison with alkaline
P01331060A0768 |88 102|cDNA sequencesharmacologic a
P01331060A0768 |58 68|comparison-nucleotid
P01331060A0768 |4 13|structure01606T007
P01331086T0000 |70 74|genee P0
P01331086T0000 |10 27|promoter elements0076 Comparison w
P01331086T0000 |106 116|ets motifsts of neon
P01331086T0000 |143 164|transcription factors0008997A0472 When CSF
P01331086T0000 |38 66|cytochrome c oxidase subunite phosphatases and 5-nucleot
P01331292A1425 |117 124|variolatal hyp
P01331292A1425 |75 82|repeats008171T
P01331292A1425 |27 36|instancesith alkal
P01331292A1425 |91 97|regionmacolo
P01331292A1425 |128 142|vaccinia viruslirubinemia. P
P01331292A1425 |52 67|oligonucleotide and 5-nucleoti
P01331501A0397 |34 42|peptidesaline ph
P01331501A0397 |123 127|p107perb
P01331501A0397 |106 117|interactionts of neona
P01331501A0397 |83 86|E1A000
P01331501A0397 |129 137|cyclin Airubinem
P01331501A0397 |143 147|p1300008
P01331501A0397 |70 79|sequencese P000081
P01331516A0103 |136 148|C2 myoblastsmia. P000089
P01331516A0103 |109 132|coinfection experimentsof neonatal hyperbiliru
P01331516A0103 |31 57|3T6 mouse fibroblast cellsalkaline phosphatases and 
P01331516A0103 |6 13|mutants606T007
P01331516A0103 |100 105|virus aspe
P01332589A0666 |17 25|compoundmparison
P01332589A0666 |91 100|S. aureusmacologic
P01332589A0666 |47 56|organismstases and
P01332589A0666 |150 163|micrograms/mlA0472 When CS
P01332589A0666 |36 37|%i
P01332589A0666 |4 8|MICs0160
P01332964A0247 |82 90|elements0000 Pha
P01332964A0247 |28 41|RII beta geneth alkaline p
P01332964A0247 |12 20|promoter76 Compa
P01333035T0000 |0 7|MappingP000016
P01333035T0000 |88 102|RNA polymeraseharmacologic a
P01333035T0000 |12 46|cAMP receptor protein contact site76 Comparison with alkaline phosph
P01333035T0000 |54 67|alpha subunitnd 5-nucleoti
P01333047A0404 |185 203|threonine residuesa function of CSF 
P01333047A0404 |148 159|Nck protein97A0472 Whe
P01333047A0404 |62 87|growth factor stimulationleotidase P00008171T0000 
P01333047A0404 |28 41|growth factorth alkaline p
P01333047A0404 |163 171|tyrosineF [HCO3-
P01333047A0404 |129 144|phosphorylationirubinemia. P00
P01333047A0404 |173 179|serineis sho
P01333047A0404 |114 119|cellsonata
P01333053A0110 |140 144|ACTH P00
P01333053A0110 |123 138|peptide hormoneperbilirubinemi
P01333053A0110 |161 165|cAMPCSF 
P01333053A0110 |26 64|steroid hydroxylase gene transcriptionwith alkaline phosphatases and 5-nucle
P01333053A0110 |8 17|mechanism6T0076 Co
P01333053A0110 |93 99|cortexcologi
P01333125A0000 |152 158|region472 Wh
P01333125A0000 |110 128|structure elementsf neonatal hyperbi
P01333125A0000 |160 163|UTR CS
P01333125A0000 |29 46|sequence analysish alkaline phosph
P01333125A0000 |192 204|rhinovirusesion of CSF P
P01333125A0000 |174 187|enterovirusess shown as a 
P01333125A0000 |65 72|methodstidase 
P01333125A0000 |2 13|combination0001606T007
P01333125A0000 |85 97|conservation0 Pharmacolo
P01333317A1008 |68 75|proteinase P00
P01333317A1008 |107 108|ss
P01333317A1008 |44 47|Sp1pha
P01333317A1008 |76 77|s0
P01333317A1008 |12 18|region76 Com
P01333317A1008 |113 118|PRF-Ieonat
P01333317A1008 |100 106|factor aspec
P01334428A1102 |0 2|KmP0
P01334428A1102 |61 64|Glucle
P01334428A1102 |44 51|peptidephatase
P01334428A1102 |7 11|Vmax06T0
P01334428A1102 |124 126|mMer
P01334428A1102 |56 60|poly 5-n
P01334428A1102 |135 151|mumol min-1 mg-1emia. P00008997A
P01334428A1102 |20 30|substratesrison with
P01334428A1102 |66 69|Tyrida
P01334428A1102 |98 114|mumol min-1 mg-1ic aspects of ne
P01334428A1102 |87 89|mMPh
P01334493A0289 |119 127|receptorl hyperb
P01334493A0289 |31 36|sHGFralkal
P01334493A0289 |13 17|form6 Co
P01334493A0289 |44 47|HGFpha
P01334493A0289 |56 64|affinity 5-nucle
P01334493A0289 |25 29|HGFr wit
P01334518T0000 |0 10|StrategiesP00001606T
P01334518T0000 |75 97|immunodeficiency virus008171T0000 Pharmacolo
P01334518T0000 |15 30|blood screeningComparison with
P01334518T0000 |106 117|risk groupsts of neona
P01334518T0000 |39 56|hepatitis C virus phosphatases and
P01337142A2043 |16 51|glycoprotein alpha-subunit promoteromparison with alkaline phosphatase
P01337142A2043 |75 78|FSK008
P01337142A2043 |133 138|WORDSinemi
P01337142A2043 |107 115|ABSTRACTs of neo
P01337142A2043 |82 89|GH4 rat0000 Ph
P01337142A2043 |100 105|cells aspe
P01338867A0503 |0 10|ComparisonP00001606T
P01338867A0503 |14 18|data Com
P01338867A0503 |178 184|extentown as
P01338867A0503 |198 208|activation CSF PCO2 
P01338867A0503 |130 138|blockaderubinemi
P01338867A0503 |56 65|treatment 5-nucleo
P01338867A0503 |82 92|antagonist0000 Pharm
P01338867A0503 |37 44|resultsne phos
P01338867A0503 |219 225|system K-dep
P01338867A0503 |153 166|fatiguability72 When CSF [
P01339125A0153 |0 18|Laboratory studiesP00001606T0076 Com
P01339125A0153 |133 145|bleach teethinemia. P000
P01339125A0153 |123 129|enamelperbil
P01339125A0153 |25 29|Ca45 wit
P01339125A0153 |94 104|dentifriceologic asp
P01339125A0153 |38 43|teethe pho
P01339125A0153 |69 74|teethse P0
P01339373T0000 |0 9|StructureP00001606
P01339373T0000 |30 34|gene alk
P01339373T0000 |91 110|SNF1 protein kinasemacologic aspects o
P01339373T0000 |14 24|expression Compariso
P01339373T0000 |72 79|proteinP000081
P01339373T0000 |40 60|Arabidopsis thalianaphosphatases and 5-n
P01339391A0000 |51 72|DNA surrounding HRAS1s and 5-nucleotidase 
P01339391A0000 |41 47|regionhospha
P01339468A0272 |186 194|proteins functio
P01339468A0272 |94 98|ORF2olog
P01339468A0272 |133 142|analoguesinemia. P
P01339468A0272 |114 122|proteinsonatal h
P01339468A0272 |67 92|potexvirus RNA replicasesdase P00008171T0000 Pharm
P01339468A0272 |4 16|ORF1 protein01606T0076 C
P01339468A0272 |153 158|potex72 Wh
P01339773A0000 |2 7|total00016
P01339773A0000 |149 157|analysis7A0472 W
P01339773A0000 |15 23|patientsComparis
P01339773A0000 |77 86|diagnosis8171T0000
P01339773A0000 |124 134|spirometryerbilirubi
P01339773A0000 |111 122|capnography neonatal h
P01339773A0000 |42 48|groupsosphat
P01339773A0778 |139 166|ventilation-perfusion ratio. P00008997A0472 When CSF [
P01339773A0778 |123 131|increaseperbilir
P01339773A0778 |4 17|relationships01606T0076 Co
P01339773A0778 |58 61|CO2-nu
P01339773A0778 |38 47|pressurese phospha
P01339773A0778 |87 96|gradientsPharmacol
P01339815A1545 |68 73|testsase P
P01339815A1545 |15 27|correlationsComparison w
P01339815A1545 |31 39|peak VO2alkaline
P01340470A0000 |77 98|RNA recognition motif8171T0000 Pharmacolog
P01340470A0000 |15 27|protein geneComparison w
P01340470A0000 |29 33|rbp1h al
P01340470A0000 |120 122|RS h
P01340470A0000 |106 113|Arg-Serts of n
P01340470A0000 |124 130|domainerbili
P01341119A0450 |70 79|ingestione P000081
P01341119A0450 |40 44|kindphos
P01341119A0450 |5 21|research studies1606T0076 Compar
P01341119A0450 |83 96|H2 inhibitors000 Pharmacol
P01341119A0450 |48 54|tumorsases a
P01341119A0450 |101 115|others antacidaspects of neo
P01346262A0377 |204 211|proteinCO2 the
P01346262A0377 |14 19|study Comp
P01346262A0377 |93 97|UC21colo
P01346262A0377 |63 81|S. entomophila UC9eotidase P00008171
P01346262A0377 |33 49|protein profileskaline phosphata
P01346262A0377 |154 161|protein2 When 
P01346534T0000 |0 16|CharacterizationP00001606T0076 C
P01346534T0000 |24 31|regulonn with 
P01346534T0000 |80 87|protein1T0000 
P01347476T0000 |0 7|MappingP000016
P01347476T0000 |15 30|mouse ornithineComparison with
P01347476T0000 |53 68|sequence familyand 5-nucleotid
P01347664A1026 |87 93|mutantPharma
P01347664A1026 |59 67|CAD mRNAnucleoti
P01347664A1026 |72 79|proteinP000081
P01347664A1026 |5 13|mutation1606T007
P01347664A1026 |49 55|levelsses an
P01347908T0000 |71 80|Parkinson P0000817
P01347908T0000 |42 53|stimulationosphatases 
P01347908T0000 |57 65|patients5-nucleo
P01347908T0000 |83 90|disease000 Pha
P01347908T0000 |4 13|rationale01606T007
P01347944A0964 |108 118|regulation of neonat
P01347944A0964 |44 68|homeodomain binding sitephatases and 5-nucleotid
P01347944A0964 |72 80|sequenceP0000817
P01347944A0964 |11 18|studies076 Com
P01348504A0757 |81 89|distanceT0000 Ph
P01348504A0757 |10 35|pol alpha-primase complex0076 Comparison with alka
P01348508A0313 |69 79|comparisonse P000081
P01348508A0313 |245 252|intronsnger di
P01348508A0313 |228 232|dateed r
P01348508A0313 |130 140|activitiesrubinemia.
P01348508A0313 |89 94|genesarmac
P01348508A0313 |158 168|literatureen CSF [HC
P01348508A0313 |178 187|TGM1 geneown as a 
P01348508A0313 |38 45|intronse phosp
P01348508A0313 |19 28|positionsarison wi
P01348590A0000 |175 184|diagnosis shown as
P01348590A0000 |81 87|cohortT0000 
P01348590A0000 |216 222|agents of K-
P01348590A0000 |260 267|outcomewhen co
P01348590A0000 |123 128|stageperbi
P01348590A0000 |149 152|CD47A0
P01348590A0000 |31 35|dataalka
P01348590A0000 |132 143|HIV-diseasebinemia. P0
P01348590A0000 |44 49|casesphata
P01348590A0000 |194 197|usen o
P01348590A0000 |19 27|analysisarison w
P01348590A0000 |167 171|timeCO3-
P01348590A0000 |226 238|radiotherapyeted rats ar
P01348590A0000 |109 117|patientsof neona
P01348590A0000 |65 73|lymphomatidase P
P01349705T0000 |0 7|EffectsP000016
P01349705T0000 |11 18|dioxins076 Com
P01349705T0000 |22 38|thyroid functionson with alkalin
P01349705T0000 |50 56|babieses and
P01349837T0000 |0 11|cDNA clonesP00001606T0
P01349837T0000 |134 144|heat shocknemia. P00
P01349837T0000 |90 105|gene expressionrmacologic aspe
P01349837T0000 |113 129|seed germinationeonatal hyperbil
P01349837T0000 |46 54|Zea maysatases a
P01349837T0000 |21 41|Arabidopsis thalianaison with alkaline p
P01349837T0000 |69 85|chaperonin HSP60se P00008171T000
P01350780A0184 |0 30|Amino acid sequence comparisonP00001606T0076 Comparison with
P01350780A0184 |52 60|homology and 5-n
P01350780A0184 |73 78|yeast00008
P01350780A0184 |140 147|lengths P00008
P01350780A0184 |100 122|gamma-glutamyl kinases aspects of neonatal h
P01350932A1123 |137 154|disulphide bridgeia. P00008997A047
P01350932A1123 |127 131|partilir
P01350932A1123 |95 106|Asn-Cys-Serlogic aspec
P01350932A1123 |11 15|site076 
P01350932A1123 |71 93|N-glycosylation sequon P00008171T0000 Pharma
P01350932A1123 |53 63|C-terminusand 5-nucl
P01350932A1123 |19 32|glycosylationarison with a
P01350932A1123 |117 120|Cystal
P01352113A0002 |114 130|inhalation modelonatal hyperbili
P01352113A0002 |62 64|NOle
P01352113A0002 |44 60|nitrogen dioxidephatases and 5-n
P01352113A0002 |96 99|ratogi
P01352113A0002 |67 75|exposuredase P00
P01352113A0002 |158 166|measuresen CSF [
P01352113A0002 |20 26|eventsrison 
P01352113A0231 |118 121|ppmal 
P01352113A0231 |125 132|ppm NO2rbiliru
P01352113A0231 |14 21|effects Compar
P01352113A0231 |140 150|mg m-3 NO2 P00008997
P01352113A0231 |188 191|minunc
P01352113A0231 |156 170|exposure timesWhen CSF [HCO3
P01352113A0231 |71 89|NO2 concentrations P00008171T0000 Ph
P01353478T0000 |0 11|InteractionP00001606T0
P01353478T0000 |15 20|H-2EbCompa
P01353478T0000 |29 48|IAP retrotransposonh alkaline phosphat
P01353478T0000 |56 78|A20/2J B cell lymphoma 5-nucleotidase P00008
P01354506T0000 |118 125|historyal hype
P01354506T0000 |90 104|histopathologyrmacologic asp
P01354506T0000 |43 51|advancessphatase
P01354506T0000 |26 34|diseaseswith alk
P01354506T0000 |59 72|understandingnucleotidase 
P01354506T0000 |76 88|cytogenetics08171T0000 P
P01357190A0726 |154 159|cells2 Whe
P01357190A0726 |132 138|fusionbinemi
P01357190A0726 |88 101|glycoproteinsharmacologic 
P01357190A0726 |9 18|exceptionT0076 Com
P01357190A0726 |46 68|membrane anchor domainatases and 5-nucleotid
P01357190A0726 |22 29|mutantsson wit
P01357190A0726 |115 122|abilitynatal h
P01357528A0084 |250 264|enterobacteriadisplaced when
P01357528A0084 |166 175|strain 3bHCO3-] is
P01357528A0084 |88 103|subunit proteinharmacologic as
P01357528A0084 |58 72|amino terminus-nucleotidase 
P01357528A0084 |199 205|fibresCSF PC
P01357528A0084 |125 133|fimbriaerbilirub
P01357528A0084 |228 246|surface organellesed rats are no lon
P01357528A0084 |219 224|class K-de
P01357528A0084 |76 82|SEF-1708171T
P01357528A0084 |23 28|curlion wi
P01357528A0084 |4 19|subunit protein01606T0076 Comp
P01358190A0654 |0 12|SubstitutionP00001606T00
P01358190A0654 |91 115|alpha chain substitutionmacologic aspects of neo
P01358190A0654 |134 140|effectnemia.
P01358190A0654 |78 89|recognition171T0000 Ph
P01358190A0654 |40 51|H-2E beta kphosphatase
P01358190A0654 |20 34|DR1 beta chainrison with alk
P01358190A0654 |70 74|losse P0
P01358592A0752 |66 75|cell fateidase P00
P01358592A0752 |133 139|regioninemia
P01358592A0752 |104 109|stateects 
P01358592A0752 |147 153|embryo997A04
P01358592A0752 |25 32|pathway with a
P01358758A0000 |141 152|combinationP00008997A0
P01358758A0000 |11 18|portion076 Com
P01358758A0000 |74 91|sequence elements0008171T0000 Phar
P01358758A0000 |105 118|FLAT elementscts of neonat
P01358758A0000 |57 60|DNA5-n
P01358758A0000 |26 44|rat insulin I genewith alkaline phos
P01358758A0000 |214 222|enhancerta of K-
P01358758A0000 |97 100|Fargic
P01358880A0251 |77 102|transglutaminase sequence8171T0000 Pharmacologic a
P01358880A0251 |44 54|% identityphatases a
P01358880A0251 |12 31|amino acid sequence76 Comparison with 
P01359588A0375 |85 93|elements0 Pharma
P01359588A0375 |44 51|networkphatase
P01359588A0375 |5 16|computation1606T0076 C
P01360180A0513 |100 112|recombinants aspects of 
P01360180A0513 |40 53|baculovirusesphosphatases 
P01360180A0513 |164 170|domain [HCO3
P01360180A0513 |77 83|kinase8171T0
P01360180A0513 |9 16|effortsT0076 C
P01360180A0513 |140 146|kinase P0000
P01360180A0513 |174 182|mutations shown 
P01360180A1568 |32 50|P68 amino terminuslkaline phosphatas
P01360180A1568 |161 182|reporter gene productCSF [HCO3-] is shown 
P01360180A1568 |209 212|RNAhe 
P01360180A1568 |145 155|properties08997A0472
P01360180A1568 |97 102|dsRNAgic a
P01360294A0000 |69 77|subjectsse P0000
P01360294A0000 |124 136|antithrombinerbilirubine
P01360294A0000 |106 112|plasmats of 
P01360294A0000 |150 158|activityA0472 Wh
P01360294A0000 |5 11|August1606T0
P01360294A0000 |96 102|levelsogic a
P01360294A0000 |20 27|Octoberrison w
P01360294A0000 |54 59|womennd 5-
P01363080A0710 |141 150|diureticsP00008997
P01363080A0710 |165 185|anhydrase inhibitors[HCO3-] is shown as 
P01363080A0710 |44 51|changesphatase
P01363080A0710 |7 13|acuity06T007
P01363080A0710 |111 130|agent metronidazole neonatal hyperbili
P01363080A0710 |82 94|sulfonamides0000 Pharmac
P01363080A0710 |66 71|erroridase
P01363166T0001 |51 60|treatments and 5-n
P01363166T0001 |20 43|H2 receptor antagonistsrison with alkaline pho
P01363166T0001 |64 70|ulcersotidas
P01363166T0001 |0 16|Currents aspectsP00001606T0076 C
P01364100A0377 |3 11|addition001606T0
P01364100A0377 |22 41|subrepeat structureson with alkaline p
P01364100A0377 |66 70|unitidas
P01370281A0461 |0 10|SequencingP00001606T
P01370281A0461 |67 74|proteindase P0
P01370281A0461 |35 48|reading frameline phosphat
P01370446A0818 |6 11|sites606T0
P01370446A0818 |31 63|keratan sulfate attachment sitesalkaline phosphatases and 5-nucl
P01371181A0688 |103 118|characteristicspects of neonat
P01371181A0688 |52 59|pADB201 and 5-
P01371181A0688 |127 137|regulationilirubinem
P01371181A0688 |147 159|copy numbers997A0472 Whe
P01371181A0688 |45 50|pE194hatas
P01371181A0688 |71 76|share P000
P01371181A0688 |65 69|pLB4tida
P01371181A0688 |32 43|pLS1 familylkaline pho
P01371181A0688 |16 24|plasmidsompariso
P01371272A1167 |0 12|PerturbationP00001606T00
P01371272A1167 |45 64|frameshift fidelityhatases and 5-nucle
P01371272A1167 |16 26|dNTP poolsomparison 
P01371272A1167 |84 110|yeast DNA polymerase alpha00 Pharmacologic aspects o
P01371275T0000 |35 42|subunitline ph
P01371275T0000 |13 23|expression6 Comparis
P01371275T0000 |64 70|ATPaseotidas
P01371275T0000 |59 60|Hn
P01371275T0000 |81 88|tissuesT0000 P
P01371275T0000 |32 33|Bl
P01371413A0742 |17 28|hGCSFR genemparison wi
P01371413A0742 |90 109|segregation patternrmacologic aspects 
P01371413A0742 |60 82|Southern blot analysisucleotidase P00008171T
P01371413A0742 |172 182|cDNA probe is shown 
P01371413A0742 |124 148|rodent-human hybrid DNAserbilirubinemia. P000089
P01371413A0742 |115 120|panelnatal
P01371413A0742 |3 11|addition001606T0
P01371863A0000 |81 110|protozoan parasite LeishmaniaT0000 Pharmacologic aspects o
P01371863A0000 |62 73|gene familyleotidase P
P01372365A1202 |69 70|Ms
P01372365A1202 |46 60|concentrationsatases and 5-n
P01372365A1202 |15 17|%TCo
P01372365A1202 |8 13|sites6T007
P01372365A1202 |130 140|conditionsrubinemia.
P01372365A1202 |42 44|Clos
P01372365A1202 |87 95|sites %TPharmaco
P01372456A0426 |0 8|NecrosisP0000160
P01372456A0426 |89 90|ha
P01372456A0426 |55 61|extentd 5-nu
P01372456A0426 |127 137|% necrosisilirubinem
P01372456A0426 |95 102|animalslogic a
P01372456A0426 |78 79|%1
P01372456A0426 |27 38|TA infusionith alkalin
P01372456A0426 |71 72|h 
P01372456A0426 |115 119|areanata
P01372456A0426 |19 20|ha
P01372456A0426 |50 51|%e
P01372802A1481 |274 282|residuesto contr
P01372802A1481 |256 264|segmentsced when
P01372802A1481 |429 436|proteine optim
P01372802A1481 |320 328|epitopesater slo
P01372802A1481 |127 128|Di
P01372802A1481 |179 191|C3 fragmentswn as a func
P01372802A1481 |124 126|C3er
P01372802A1481 |28 30|C3th
P01372802A1481 |314 316|C3ly
P01372802A1481 |46 65|amino acid residuesatases and 5-nucleo
P01372802A1481 |317 318|Dg
P01372802A1481 |16 24|segmentsompariso
P01372802A1481 |222 242|fluid-phase fragmentdepleted rats are no
P01372802A1481 |371 373|C3ep
P01372802A1481 |130 138|epitopesrubinemi
P01372802A1481 |412 421|fragmentsotic drug
P01372802A1481 |3 10|summary001606T
P01372900A0448 |35 40|exonsline 
P01372900A0448 |110 135|alpha s1-casein variant Af neonatal hyperbilirubin
P01372900A0448 |79 98|amino acid residues71T0000 Pharmacolog
P01372900A0448 |159 161|F.n 
P01372900A0448 |6 11|exons606T0
P01372900A1017 |118 155|polymerase chain reaction experimentsal hyperbilirubinemia. P00008997A0472
P01372900A1017 |44 56|organizationphatases and
P01372900A1017 |64 103|goat alpha s1-casein transcription unitotidase P00008171T0000 Pharmacologic as
P01373374A0735 |0 10|HomodimersP00001606T
P01373374A0735 |60 71|G-box motifucleotidase
P01373374A0735 |78 82|GBF1171T
P01373374A0735 |134 142|sequencenemia. P
P01373374A0735 |24 32|proteinsn with a
P01373374A0735 |87 99|GBF3 bindingPharmacologi
P01374331A0636 |50 60|start sitees and 5-n
P01374331A0636 |73 93|nuclease S1 analysis00008171T0000 Pharma
P01374331A0636 |8 12|gene6T00
P01374392A0341 |70 75|NHE-2e P00
P01374392A0341 |60 65|NHE-1ucleo
P01374392A0341 |27 32|NHE-3ith a
P01374392A0341 |4 23|hydrophobicity plot01606T0076 Comparis
P01374398A0951 |131 135|acidubin
P01374398A0951 |47 51|cDNAtase
P01374398A0951 |164 183|amino acid residues [HCO3-] is shown a
P01374398A0951 |149 150|%7
P01374398A0951 |62 65|kDaleo
P01374398A0951 |12 31|translation protein76 Comparison with 
P01374398A0951 |94 116|amino acid compositionologic aspects of neon
P01374688A0471 |115 130|micrograms/kg/0natal hyperbili
P01374688A0471 |58 71|% pentastarch-nucleotidase
P01374688A0471 |40 55|% pentafractionphosphatases an
P01374688A0471 |133 138|hr E.inemi
P01374688A0471 |23 28|ml/kgon wi
P01374688A0471 |76 82|plasma08171T
P01374688A0471 |96 101|hoursogic 
P01374688A0471 |5 10|group1606T
P01375224A0152 |170 187|growth regulation-] is shown as a 
P01375224A0152 |149 157|proteins7A0472 W
P01375224A0152 |47 52|v-Crktases
P01375224A0152 |128 136|activitylirubine
P01375224A0152 |24 32|evidencen with a
P01375224A0152 |82 108|chicken embryo fibroblasts0000 Pharmacologic aspects
P01375224A0152 |64 78|transformationotidase P00008
P01375913A0484 |168 175|plasmidO3-] is
P01375913A0484 |61 75|U14 snRNA genecleotidase P00
P01375913A0484 |111 142|T7 RNA polymerase promoter site neonatal hyperbilirubinemia. P
P01375913A0484 |37 57|DNA oligonucleotidesne phosphatases and 
P01376319T0000 |0 4|GeneP000
P01376319T0000 |27 32|mouseith a
P01376319T0000 |9 19|pseudogeneT0076 Comp
P01376319T0000 |50 78|mannose 6-phosphate receptores and 5-nucleotidase P00008
P01377696A0000 |4 9|chick01606
P01377696A0000 |26 58|surface glycoprotein neurofascinwith alkaline phosphatases and 5
P01377696A0000 |123 156|antibody perturbation experimentsperbilirubinemia. P00008997A0472 
P01377696A0000 |94 107|fasciculationologic aspect
P01377696A0000 |83 89|growth000 Ph
P01377764A0309 |71 76|layer P000
P01377764A0309 |105 110|layercts o
P01377764A0309 |40 50|epitheliumphosphatas
P01377764A0309 |4 13|carcinoma01606T007
P01377818A0468 |3 11|addition001606T0
P01377818A0468 |13 23|C/EBP beta6 Comparis
P01377818A0468 |28 39|C/EBP gammath alkaline
P01377818A0468 |95 106|C/EBP alphalogic aspec
P01377962A1012 |3 11|contrast001606T0
P01377962A1012 |13 25|tobacco GS-26 Comparison
P01377962A1012 |75 81|organs008171
P01377962A1012 |63 67|sizeeoti
P01377962A1012 |41 49|subunitshosphata
P01378052A0594 |102 105|N18spe
P01378052A0594 |80 88|symmetry1T0000 P
P01378052A0594 |189 193|NifAncti
P01378052A0594 |127 130|N14ili
P01378052A0594 |95 98|N11log
P01378052A0594 |180 184|NtrCn as
P01378052A0594 |90 93|CACrma
P01378052A0594 |120 123|N10 hy
P01378052A0594 |132 135|ACAbin
P01378052A0594 |17 24|acoXABCmpariso
P01378052A0594 |49 58|sequencesses and 5
P01378052A0594 |155 164|sequences When CSF
P01378052A0594 |115 118|TGTnat
P01378052A0594 |40 45|typesphosp
P01378052A0594 |107 110|GTGs o
P01378052A0594 |8 12|acoR6T00
P01378052A0594 |203 222|activator sequencesPCO2 the data of K-
P01378127A0841 |50 68|calcium antagonistes and 5-nucleotid
P01378127A0841 |13 20|effects6 Compa
P01378127A0841 |28 46|calcium supplementth alkaline phosph
P01378127A0841 |110 119|responsesf neonata
P01378431A0202 |0 2|C.P0
P01378431A0202 |13 16|Hsu6 C
P01378431A0202 |42 44|J.os
P01378431A0202 |25 40|Vallejo-Ramirez with alkaline 
P01378431A0202 |9 11|J.T0
P01378431A0202 |46 52|Inouyeatases
P01378431A0202 |62 68|Inouyeleotid
P01378431A0202 |4 7|Sun016
P01378431A0202 |54 56|S.nd
P01378431A0202 |18 23|M.-Y.paris
P01378431A0202 |70 72|M.e 
P01378506A0884 |18 38|full-deletion mutantparison with alkalin
P01378506A0884 |113 127|virus assemblyeonatal hyperb
P01378506A0884 |95 97|NClo
P01378506A0884 |55 60|blockd 5-n
P01378506A0884 |64 77|virus releaseotidase P0000
P01378526A0535 |34 53|FK506 plasma levelsaline phosphatases 
P01378526A0535 |78 88|appearance171T0000 P
P01378526A0535 |97 103|effectgic as
P01379032A0495 |136 146|prednisonemia. P0000
P01379032A0495 |130 132|mgru
P01379032A0495 |94 99|groupologi
P01379032A0495 |74 86|steroid dose0008171T0000
P01379032A0495 |151 154|day047
P01379032A0495 |113 121|steroidseonatal 
P01379032A0495 |7 14|percent06T0076
P01379032A0495 |18 26|patientsparison 
P01379032A0495 |48 56|steroidsases and
P01379150A0996 |184 200|risk arrhythmias a function of C
P01379150A0996 |167 174|therapyCO3-] i
P01379150A0996 |148 156|patients97A0472 
P01379150A0996 |89 96|profilearmacol
P01379150A0996 |6 17|cibenzoline606T0076 Co
P01379150A0996 |131 136|classubine
P01379150A0996 |49 54|agentses a
P01379150A0996 |139 144|drugs. P00
P01380062A0097 |51 63|T lymphocytes and 5-nucl
P01380062A0097 |142 145|Y-5000
P01380062A0097 |112 126|CTL clones Y-1neonatal hyper
P01380062A0097 |128 131|Y-2lir
P01380062A0097 |133 136|Y-3ine
P01380062A0097 |70 90|recognition epitopese P00008171T0000 Pha
P01380062A0097 |65 68|CTLtid
P01380062A0097 |100 107|targets aspect
P01380062A0097 |0 9|T antigenP00001606
P01380076A0165 |50 70|paired-ion techniquees and 5-nucleotidas
P01380076A0165 |37 43|columnne pho
P01380076A0165 |110 120|componentsf neonatal
P01380076A0165 |83 98|docusate sodium000 Pharmacolog
P01380076A0165 |4 10|method01606T
P01380454A0451 |102 122|Fos-Jun heterodimersspects of neonatal h
P01380454A0451 |271 286|ATF/CREB familyed to controls 
P01380454A0451 |52 62|ref-1 gene and 5-nuc
P01380454A0451 |78 98|DNA binding activity171T0000 Pharmacolog
P01380454A0451 |147 170|Hela cell AP-1 proteins997A0472 When CSF [HCO3
P01380454A0451 |124 142|Jun-Jun homodimerserbilirubinemia. P
P01380454A0451 |29 44|protein producth alkaline phos
P01380454A0451 |236 246|NF-kappa Bare no lon
P01380454A0451 |248 251|Mybr d
P01380454A0451 |256 263|membersced whe
P01380454A0451 |204 225|transcription factorsCO2 the data of K-dep
P01380716A0174 |11 18|tissues076 Com
P01380716A0174 |91 106|calcium hydratemacologic aspec
P01380716A0174 |47 53|molarstases 
P01380825A0622 |0 22|Northern blot analysesP00001606T0076 Compari
P01380825A0622 |60 65|mRNAsucleo
P01380825A0622 |193 201|functionon of CS
P01380825A0622 |150 157|proteinA0472 W
P01380825A0622 |112 119|tissuesneonata
P01380825A0622 |87 91|cDNAPhar
P01383690A1023 |4 18|ARG SH2 domain01606T0076 Com
P01383690A1023 |45 53|affinityhatases 
P01383690A1023 |58 61|BCR-nu
P01383690A1023 |126 140|ABL SH2 domainbilirubinemia.
P01383695A0100 |68 74|embryoase P0
P01383695A0100 |109 119|IgM lambdaof neonata
P01383695A0100 |15 31|EBV B-cell cloneComparison with 
P01383695A0100 |95 104|IgM kappalogic asp
P01383695A0100 |33 38|E29.1kalin
P01384040A1043 |140 145|pCF10 P000
P01384040A1043 |95 106|orientationlogic aspec
P01384040A1043 |20 30|activationrison with
P01384040A1043 |54 61|regionsnd 5-nu
P01384165A0000 |85 92|trachea0 Pharm
P01384165A0000 |157 162|stagehen C
P01384165A0000 |25 31|effect with 
P01384165A0000 |128 138|epitheliumlirubinemi
P01384165A0000 |62 77|vascularizationleotidase P0000
P01384165A0000 |38 45|omentume phosp
P01384165A0000 |174 191|tracheal graftings shown as a func
P01384165A0000 |3 7|rats0016
P01384165A0000 |100 112|regeneration aspects of 
P01384229A0175 |274 278|geneto c
P01384229A0175 |269 272|CATare
P01384229A0175 |198 216|herpes TK promoter CSF PCO2 the data
P01384229A0175 |124 134|BF-IV geneerbilirubi
P01384229A0175 |107 116|sequencess of neon
P01384229A0175 |180 186|copiesn as a
P01384229A0175 |31 35|rolealka
P01384229A0175 |53 64|chicken ICSand 5-nucle
P01384229A0175 |280 287|pBLCAT2trols b
P01384229A0175 |233 267|chloramphenicol acetyl transferasets are no longer displaced when co
P01384229A0175 |69 84|oligonucleotidese P00008171T00
P01385462A0151 |152 165|determination472 When CSF 
P01385462A0151 |173 183|monoaminesis shown a
P01385462A0151 |65 69|runstida
P01385462A0151 |117 135|acid determinationtal hyperbilirubin
P01386210A0293 |119 137|GM2 gangliosidosisl hyperbilirubinem
P01386210A0293 |104 107|manect
P01386210A0293 |25 28|use wi
P01386210A0293 |62 71|treatmentleotidase
P01386210A0293 |82 92|depression0000 Pharm
P01386210A0293 |50 57|therapyes and 
P01386897A0000 |68 72|formase 
P01386897A0000 |80 92|CDC28 kinase1T0000 Pharm
P01386897A0000 |145 149|CLN10899
P01386897A0000 |126 133|cyclinsbilirub
P01386897A0000 |9 20|yeast cellsT0076 Compa
P01386897A0000 |160 163|ref CS
P01386897A0000 |154 158|CLN22 Wh
P01386897A0000 |38 48|cell cyclee phosphat
P01386897A0000 |50 55|Startes an
P01386897A0000 |0 5|EntryP0000
P01387105A0933 |34 37|DNAali
P01387105A0933 |177 186|sequenceshown as a
P01387105A0933 |243 260|mouse chromosomeslonger displaced 
P01387105A0933 |90 97|strainsrmacolo
P01387105A0933 |111 123|cell hybrids neonatal hy
P01387105A0933 |199 213|loci Cycb1-rs1CSF PCO2 the d
P01387105A0933 |285 286|X 
P01387105A0933 |217 226|Cycb1-rs9of K-depl
P01387105A0933 |159 165|cyclinn CSF 
P01387105A0933 |8 30|Southern blot analyses6T0076 Comparison with
P01387105A0933 |43 52|backcrosssphatases
P01387105A0933 |65 69|micetida
P01387105A0933 |137 141|lociia. 
P01388160A1102 |185 192|Ser-107a funct
P01388160A1102 |127 143|peptide sequenceilirubinemia. P0
P01388160A1102 |25 29|beta wit
P01388160A1102 |176 183|Ser-106shown a
P01388160A1102 |165 172|choices[HCO3-]
P01388160A1102 |82 97|epsilon peptide0000 Pharmacolo
P01388160A1102 |197 204|Ser-108f CSF P
P01388160A1102 |6 21|residue Glu-381606T0076 Compar
P01388160A1102 |65 72|residuetidase 
P01389362T0000 |0 9|PorcelainP00001606
P01389362T0000 |41 56|dentin adhesivehosphatases and
P01389362T0000 |20 33|bond strengthrison with al
P01389573A1071 |102 104|P2sp
P01389573A1071 |37 47|differencene phospha
P01389573A1071 |76 87|measurement08171T0000 
P01389573A1071 |89 93|TBPfarma
P01389573A1071 |107 109|A1s 
P01389573A1071 |112 114|A2ne
P01389573A1071 |97 99|P1gi
P01389573A1071 |21 29|quotientison wit
P01389573A1071 |0 4|TBPfP000
P01389585A0825 |115 121|choicenatal 
P01389585A0825 |89 111|dentine bonding agentsarmacologic aspects of
P01389585A0825 |22 32|Scotchbondson with a
P01389585A0825 |39 60|Prisma Universal Bond phosphatases and 5-n
P01391001A0583 |117 124|methodstal hyp
P01391001A0583 |59 60|%n
P01391001A0583 |30 44|yeasts species alkaline phos
P01391001A0583 |80 90|ATB method1T0000 Pha
P01391001A0583 |48 53|totalases 
P01392012A0228 |21 32|vasopressinison with a
P01392012A0228 |166 170|HaysHCO3
P01392012A0228 |151 161|van Dongen0472 When 
P01392012A0228 |123 131|activityperbilir
P01392012A0228 |72 86|pressor effectP00008171T0000
P01392012A0228 |37 53|oxytocin contentne phosphatases 
P01392012A0228 |97 105|Dekanskigic aspe
P01392277A0000 |34 40|statusaline 
P01392277A0000 |44 55|regulationsphatases an
P01392277A0000 |178 186|standardown as a
P01392277A0000 |76 90|swimming pools08171T0000 Pha
P01392277A0000 |95 100|bathslogic
P01392277A0000 |193 196|No.on 
P01392277A0000 |132 147|KOK regulationsbinemia. P00008
P01392277A0000 |112 122|connectionneonatal h
P01392277A0000 |67 72|waterdase 
P01392277A0000 |188 191|DINunc
P01392277A0000 |0 8|CommentsP0000160
P01392358A0389 |6 11|reply606T0
P01392358A0389 |47 58|home visitstases and 5
P01392358A0389 |26 43|telephone contactwith alkaline pho
P01394200A0592 |100 121|rebound lymphocytosis aspects of neonatal 
P01394200A0592 |40 57|T-cell activationphosphatases and 
P01394200A0592 |167 178|interleukinCO3-] is sh
P01394200A0592 |195 201|CD45RO of CS
P01394200A0592 |74 85|lymphopenia0008171T000
P01394200A0592 |181 189|receptor as a fu
P01394200A0592 |126 138|upregulationbilirubinemi
P01394200A0592 |146 165|subset markers CD258997A0472 When CSF 
P01394200A0592 |212 217|cellsdata 
P01394200A0592 |4 19|treatment group01606T0076 Comp
P01394655A0615 |103 107|tubepect
P01394655A0615 |42 60|ammonia productionosphatases and 5-n
P01394655A0615 |125 146|Jack bean meal ureaserbilirubinemia. P0000
P01394655A0615 |109 112|S/Nof 
P01394655A0615 |96 98|ngog
P01394655A0615 |66 70|ureaidas
P01394655A0615 |32 38|amountlkalin
P01394655A0615 |1 16|Urease activity00001606T0076 C
P01395755A1023 |96 109|oxygen uptakeogic aspects 
P01395755A1023 |214 220|ml/minta of 
P01395755A1023 |26 37|differenceswith alkali
P01395755A1023 |122 128|ml/minyperbi
P01395755A1023 |151 152|p0
P01395755A1023 |74 81|methods0008171
P01395755A1023 |222 223|pd
P01395755A1023 |294 295|pl
P01395755A1023 |246 252|outputger di
P01395755A1023 |266 271|L/minompar
P01395755A1023 |287 292|L/minut st
P01395755A1023 |192 198|ml/minion of
P01395755A1023 |163 178|oxygen deliveryF [HCO3-] is sh
P01395755A1023 |143 149|ml/min000899
P01396432A0388 |35 44|functionsline phos
P01396432A0388 |112 130|memory performanceneonatal hyperbili
P01396432A0388 |74 81|seizure0008171
P01396432A0388 |98 108|assessmentic aspects
P01396432A0388 |16 21|rangeompar
P01396444A0934 |152 160|activity472 When
P01396444A0934 |203 211|recoveryPCO2 the
P01396444A0934 |36 47|micromilieuine phospha
P01396444A0934 |193 199|degreeon of 
P01396444A0934 |88 90|AMha
P01396444A0934 |4 15|experiments01606T0076 
P01396444A0934 |114 131|activation statesonatal hyperbilir
P01396444A0934 |55 62|alveolid 5-nuc
P01396444A0934 |71 80|condition P0000817
P01396572A0320 |85 98|plasmid pUC190 Pharmacolog
P01396572A0320 |131 138|segmentubinemi
P01396572A0320 |123 128|dG-dCperbi
P01396572A0320 |23 36|plasmid pUC19on with alkal
P01396572A0320 |146 152|Z-form8997A0
P01396572A0320 |99 101|CGc 
P01396572A0320 |170 180|competitor-] is show
P01396583A0204 |2 14|cDNA library0001606T0076
P01396583A0204 |52 63|interleukin and 5-nucl
P01396583A0204 |80 85|probe1T000
P01396583A0204 |18 30|tumour cellsparison with
P01396592A1113 |51 57|targets and 
P01396592A1113 |178 193|differentiationown as a functi
P01396592A1113 |76 103|transcription factor GATA-108171T0000 Pharmacologic as
P01396592A1113 |33 41|SCL genekaline p
P01396592A1113 |4 15|experiments01606T0076 
P01396592A1113 |155 164|regulator When CSF
P01396592A1113 |117 133|SCL gene producttal hyperbilirub
P01396601A0986 |119 127|homologyl hyperb
P01396601A0986 |25 32|domains with a
P01396601A0986 |44 49|Stl1pphata
P01396601A0986 |36 42|Sec12pine ph
P01396601A0986 |82 86|size0000
P01396601A0986 |54 59|Stl2pnd 5-
P01396601A0986 |3 11|contrast001606T0
P01398068A0948 |0 9|ComplexesP00001606
P01398068A0948 |52 58|his273 and 5
P01398068A0948 |42 48|his175osphat
P01398068A0948 |66 78|p53 proteinsidase P00008
P01398068A0948 |116 132|RGC DNA sequenceatal hyperbiliru
P01398071A0526 |139 147|activity. P00008
P01398071A0526 |89 102|BRF1 activityarmacologic a
P01398071A0526 |151 166|RNA polymerases0472 When CSF [
P01398071A0526 |67 75|extractsdase P00
P01398071A0526 |178 181|IIIown
P01398071A0526 |6 17|temperature606T0076 Co
P01398071A0526 |38 45|strainse phosp
P01398073A0986 |103 114|stimulationpects of ne
P01398073A0986 |126 144|activation domainsbilirubinemia. P00
P01398073A0986 |166 174|promoterHCO3-] i
P01398073A0986 |6 13|results606T007
P01398073A0986 |64 77|TFIID proteinotidase P0000
P01398074A0697 |51 54|RNAs a
P01398074A0697 |90 119|RNase MRP enzyme preparationsrmacologic aspects of neonata
P01398074A0697 |4 17|gene sequence01606T0076 Co
P01398074A0697 |64 73|yeast RNAotidase P
P01398074A1081 |50 61|replacementes and 5-nu
P01398074A1081 |142 146|role0000
P01398074A1081 |151 160|RNase MRP0472 When
P01398074A1081 |4 22|RNase MRP RNA gene01606T0076 Compari
P01398074A1081 |101 110|viabilityaspects o
P01398098A0770 |0 20|Clone pSRc200 hybridP00001606T0076 Compa
P01398098A0770 |56 67|translation 5-nucleoti
P01398098A0770 |33 37|mRNAkali
P01398098A0770 |86 97|polypeptide Pharmacolo
P01398104A0834 |71 78|protein P00008
P01398104A0834 |120 126|factor hyper
P01398104A0834 |37 45|CArG boxne phosp
P01398104A0834 |11 18|results076 Com
P01398104A0834 |20 25|CBF-Arison
P01398104A0834 |48 53|ssDNAases 
P01398106A0754 |0 8|CleavageP0000160
P01398106A0754 |56 58|bp 5
P01398106A0754 |31 37|enzymealkali
P01398106A0754 |39 45|I-CreI phosp
P01398106A0754 |111 115|exon neo
P01398106A0754 |78 99|intron insertion site171T0000 Pharmacologi
P01398106A0754 |147 154|strands997A047
P01398106A0754 |124 127|toperb
P01398106A0754 |222 232|OH terminidepleted r
P01398106A0754 |65 67|bpti
P01398106A0754 |136 142|bottommia. P
P01398106A0754 |204 213|overhangsCO2 the d
P01398140A0488 |102 104|bpsp
P01398140A0488 |149 157|location7A0472 W
P01398140A0488 |123 126|PSEper
P01398140A0488 |72 78|motifsP00008
P01398140A0488 |173 175|bpis
P01398140A0488 |18 33|Xenopus U7 geneparison with al
P01399206A0375 |4 11|results01606T0
P01399206A0375 |28 35|reportsth alka
P01399206A0375 |90 107|blister formationrmacologic aspect
P01399206A0375 |132 153|epidermolysis bullosabinemia. P00008997A04
P01399206A0375 |41 63|collagenase inhibitorshosphatases and 5-nucl
P01400217T0000 |85 96|involvement0 Pharmacol
P01400217T0000 |76 80|traG0817
P01400217T0000 |108 125|phage sensitivity of neonatal hype
P01400217T0000 |11 19|analysis076 Comp
P01400217T0000 |33 71|IncP alpha plasmid transfer genes traFkaline phosphatases and 5-nucleotidase
P01400217T0000 |100 104|traF asp
P01400396A1265 |4 12|promoter01606T00
P01400396A1265 |41 55|phorbol estershosphatases an
P01400396A1265 |125 146|protein kinase C betarbilirubinemia. P0000
P01400396A1265 |111 121|activation neonatal 
P01400401A0065 |50 56|musclees and
P01400401A0065 |162 170|criteriaSF [HCO3
P01400401A0065 |78 80|E217
P01400401A0065 |62 67|liverleoti
P01400401A0065 |47 48|Mt
P01400401A0065 |121 128|varietyhyperbi
P01400401A0065 |3 9|humans001606
P01400401A0065 |82 93|erythrocyte0000 Pharma
P01400401A0065 |59 60|Ln
P01400401A0065 |70 72|E1e 
P01400401A0065 |16 38|AMP deaminase variantsomparison with alkalin
P01400401A0854 |119 129|expressionl hyperbil
P01400401A0854 |145 155|AMPD3 cDNA08997A0472
P01400401A0854 |45 61|immunoreactivityhatases and 5-nu
P01400401A0854 |83 91|extracts000 Phar
P01400401A0854 |0 21|Western blot analysesP00001606T0076 Compar
P01400775A0435 |6 13|results606T007
P01400775A0435 |108 113|brain of n
P01400775A0435 |75 93|N-methylsalsolinol008171T0000 Pharma
P01400775A0435 |42 55|N-methylationosphatases an
P01400775A0435 |59 69|salsolinolnucleotida
P01402647A0114 |0 13|DR1 moleculesP00001606T007
P01402647A0114 |128 141|phage surfacelirubinemia. 
P01402647A0114 |93 110|peptide sequencescologic aspects o
P01402647A0114 |49 59|cell linesses and 5-
P01403222A0391 |85 99|blood donation0 Pharmacologi
P01403222A0391 |53 58|womanand 5
P01403222A0391 |41 45|carehosp
P01403222A0391 |5 12|article1606T00
P01403222A0391 |117 128|transfusiontal hyperbi
P01403391T0000 |8 19|hepatitis B6T0076 Comp
P01403391T0000 |40 48|childrenphosphat
P01404401A0740 |102 118|chloroplast genespects of neonat
P01404401A0740 |11 25|ATPase cluster076 Comparison
P01404401A0740 |36 50|reading framesine phosphatas
P01404612A0303 |83 91|proteins000 Phar
P01404612A0303 |60 63|HIVucl
P01404612A0303 |107 125|vaccine candidatess of neonatal hype
P01404612A0303 |29 32|Adsh a
P01406630A0545 |0 9|AlignmentP00001606
P01406630A0545 |243 251|proteinslonger d
P01406630A0545 |192 205|DNA sequencesion of CSF PC
P01406630A0545 |60 78|consensus sequenceucleotidase P00008
P01406630A0545 |215 235|sequence specificitya of K-depleted rats
P01406630A0545 |26 35|sequenceswith alka
P01406630A0545 |133 141|proteinsinemia. 
P01406630A0545 |159 175|binding analysisn CSF [HCO3-] is
P01406630A0545 |83 90|binding000 Pha
P01406630A0965 |136 143|bindingmia. P0
P01406630A0965 |15 18|p50Com
P01406630A0965 |36 49|kappa B motifine phosphata
P01406630A0965 |93 100|respectcologic
P01406630A0965 |180 198|NF-kappa B complexn as a function of
P01406630A0965 |80 87|binding1T0000 
P01406630A0965 |114 121|proteinonatal 
P01406656A1075 |117 120|DNAtal
P01406656A1075 |63 67|geneeoti
P01406656A1075 |46 57|mouse alphaatases and 
P01406656A1075 |194 197|rasn o
P01406656A1075 |99 101|kbc 
P01406656A1075 |83 85|kb00
P01406656A1075 |147 153|levels997A04
P01406656A1075 |157 168|fibroblastshen CSF [HC
P01406656A1075 |18 23|cloneparis
P01406677A0000 |171 191|nucleotide positions] is shown as a func
P01406677A0000 |26 42|control elementswith alkaline ph
P01406677A0000 |75 85|expression008171T000
P01406677A0000 |99 113|myoglobin genec aspects of n
P01406677A0000 |267 282|luciferase genempared to contr
P01406677A0000 |160 169|sequences CSF [HCO
P01406677A0000 |235 245|start site are no lo
P01406677A0000 |139 147|analysis. P00008
P01406688A0898 |0 19|Sequencing analysisP00001606T0076 Comp
P01406688A0898 |64 81|nonsense mutationotidase P00008171
P01406688A0898 |40 52|rap1t allelephosphatases
P01406688A0898 |115 126|amino acidsnatal hyper
P01406688A0898 |100 106|region aspec
P01406703A1435 |71 79|H-2RIIBP P000081
P01406703A1435 |177 182|cellshown 
P01406703A1435 |88 109|hormone receptor cDNAharmacologic aspects 
P01406703A1435 |15 35|Y1 cell cDNA libraryComparison with alka
P01406703A1435 |57 63|region5-nucl
P01406703A1435 |125 129|cDNArbil
P01407286A0427 |119 125|tracesl hype
P01407286A0427 |92 97|brainacolo
P01407286A0427 |26 34|survivalwith alk
P01407286A0427 |71 82|integration P00008171T
P01407286A0427 |55 60|cellsd 5-n
P01407286A0427 |157 165|reactionhen CSF 
P01407286A0427 |170 190|tyrosine hydroxylase-] is shown as a fun
P01407286A0427 |0 7|AutopsyP000016
P01408090A0572 |64 72|arteriesotidase 
P01408090A0572 |4 13|technique01606T007
P01408090A0572 |21 38|TEE visualizationison with alkalin
P01408137A0974 |137 142|% G+Cia. P
P01408137A0974 |123 133|mRNA startperbilirub
P01408137A0974 |4 12|sequence01606T00
P01408137A0974 |54 55|%n
P01408137A0974 |39 50|G+C content phosphatas
P01408137A0974 |21 27|regionison w
P01408137A0974 |102 104|bpsp
P01408219A0670 |119 127|analysisl hyperb
P01408219A0670 |13 21|patients6 Compar
P01408219A0670 |101 106|nodesaspec
P01408219A0670 |77 86|nontender8171T0000
P01408219A0670 |146 157|hyperplasia8997A0472 W
P01408219A0670 |50 66|lymph-adenopathyes and 5-nucleot
P01408219A0670 |68 71|PGLase
P01408474A0531 |0 14|PaO2 thresholdP00001606T0076
P01408474A0531 |41 51|indwellinghosphatase
P01408474A0531 |55 70|sensor catheterd 5-nucleotidas
P01409581A0206 |116 120|siteatal
P01409581A0206 |41 46|v-etshosph
P01409581A0206 |79 88|factor PU71T0000 P
P01409581A0206 |23 26|E26on 
P01409643A0618 |171 178|protein] is sh
P01409643A0618 |9 31|lambda gt11 expressionT0076 Comparison with 
P01409643A0618 |265 271|factorcompar
P01409643A0618 |89 111|immunodeficiency virusarmacologic aspects of
P01409643A0618 |241 253|TATA elemento longer dis
P01409643A0618 |45 61|oligonucleotideshatases and 5-nu
P01409643A0618 |114 126|TATA elementonatal hyper
P01409643A0618 |219 222|kDa K-
P01409643A0618 |142 156|identification00008997A0472 
P01409643A0618 |207 211|mass the
P01409643A0618 |273 276|TMF to
P01410071T0000 |0 12|Blood levelsP00001606T00
P01410071T0000 |27 36|serotoninith alkal
P01410071T0000 |91 97|rhythmmacolo
P01410071T0000 |38 46|cortisole phosph
P01410071T0000 |65 73|relationtidase P
P01410071T0000 |52 61|prolactin and 5-nu
P01410071T0000 |101 126|platelet serotonin uptakeaspects of neonatal hyper
P01410071T0000 |16 25|melatoninomparison
P01413984A0737 |168 180|antithrombinO3-] is show
P01413984A0737 |112 118|apo A1neonat
P01413984A0737 |334 348|blood pressure21 +/- 0.23 vs
P01413984A0737 |127 132|HbA1Ciliru
P01413984A0737 |95 110|LDL cholesterollogic aspects o
P01413984A0737 |301 305|timea si
P01413984A0737 |120 122|Lp h
P01413984A0737 |186 217|plasminogen activator inhibitor function of CSF PCO2 the data 
P01413984A0737 |252 287|von Willebrand factor concentrationsplaced when compared to controls b
P01413984A0737 |155 166|factor VIII When CSF [
P01413984A0737 |23 29|effecton wit
P01413984A0737 |219 247|tissue plasminogen activator K-depleted rats are no long
P01413984A0737 |37 55|FA supplementationne phosphatases an
P01413984A0737 |78 93|HDL cholesterol171T0000 Pharma
P01413984A0737 |134 141|glucosenemia. 
P01413984A0737 |143 153|fibrinogen0008997A04
P01413984A0737 |65 76|cholesteroltidase P000
P01414219A0319 |50 61|differenceses and 5-nu
P01414219A0319 |132 135|OXCbin
P01414219A0319 |13 23|volunteers6 Comparis
P01414219A0319 |65 68|AUCtid
P01414219A0319 |113 126|concentrationeonatal hyper
P01414219A0319 |176 179|ERYsho
P01414219A0319 |70 96|peak plasma concentrationse P00008171T0000 Pharmacol
P01414219A0319 |100 104|time asp
P01418272A1072 |48 51|CEAase
P01418272A1072 |8 13|ng/mL6T007
P01418272A1072 |58 59|%-
P01418272A1072 |21 27|cutoffison w
P01418272A1072 |33 44|sensitivitykaline phos
P01418494T0000 |9 15|spikesT0076 
P01418494T0000 |30 38|function alkalin
P01418542A0000 |4 10|effect01606T
P01418542A0000 |44 47|SGApha
P01418542A0000 |14 20|sodium Compa
P01418542A0000 |24 42|beta-glycyrrhetaten with alkaline ph
P01418542A0000 |65 75|arrhythmiatidase P00
P01418834A0987 |50 51|Pe
P01418834A0987 |45 46|Hh
P01418834A0987 |176 177|Ps
P01418834A0987 |78 82|fall171T
P01418834A0987 |14 33|hematocrit decrease Comparison with al
P01418834A0987 |86 100|blood pressure Pharmacologic
P01418834A0987 |155 160|mm Hg When
P01418860A0797 |86 95|diltiazem Pharmaco
P01418860A0797 |226 230|roleeted
P01418860A0797 |240 252|interactionsno longer di
P01418860A0797 |15 24|diltiazemCompariso
P01418860A0797 |162 171|diltiazemSF [HCO3-
P01418860A0797 |56 68|potentiation 5-nucleotid
P01418860A0797 |193 217|calcium channel blockadeon of CSF PCO2 the data 
P01418860A0797 |129 134|casesirubi
P01418860A0797 |4 11|effects01606T0
P01419945A1386 |0 12|LocalizationP00001606T00
P01419945A1386 |90 102|interscalenermacologic a
P01419945A1386 |45 61|nerve stimulatorhatases and 5-nu
P01419945A1386 |134 139|sitesnemia
P01419945A1386 |29 35|plexush alka
P01420177A1065 |51 54|Sers a
P01420177A1065 |162 170|activitySF [HCO3
P01420177A1065 |128 134|enzymelirubi
P01420177A1065 |41 46|Gly28hosph
P01420177A1065 |99 114|protein kinasesc aspects of ne
P01420177A1065 |83 91|residues000 Phar
P01420177A1065 |23 28|Val33on wi
P01420177A1065 |33 36|Glykal
P01420177A1065 |0 12|SubstitutionP00001606T00
P01420223T0000 |0 12|SignificanceP00001606T00
P01420223T0000 |67 79|fiber typingdase P000081
P01420223T0000 |20 31|biopsy siterison with 
P01420223T0000 |39 62|latissimus dorsi muscle phosphatases and 5-nuc
P01420363A0818 |170 183|consensus TRE-] is shown a
P01420363A0818 |132 139|bindingbinemia
P01420363A0818 |210 217|factorse data 
P01420363A0818 |61 76|c-Fos/c-Jun AP1cleotidase P000
P01420363A0818 |44 49|motifphata
P01420363A0818 |151 162|AP1 factors0472 When C
P01420363A0818 |4 8|TIMP0160
P01420363A0818 |249 262|consensus TRE displaced wh
P01420363A0818 |192 200|additionion of C
P01420363A0818 |18 26|AP1 siteparison 
P01420363A0818 |117 127|competitortal hyperb
P01420363T0000 |0 11|InvolvementP00001606T0
P01420363T0000 |90 110|metalloproteinases-1rmacologic aspects o
P01420363T0000 |15 18|AP1Com
P01420363T0000 |23 41|PEA3 binding siteson with alkaline p
P01420363T0000 |112 118|TIMP-1neonat
P01420363T0000 |120 133|transcription hyperbilirub
P01420363T0000 |49 59|regulationses and 5-
P01420363T0000 |70 86|tissue inhibitore P00008171T0000
P01420579A0292 |153 164|vaccination72 When CSF
P01420579A0292 |27 29|SNit
P01420579A0292 |31 39|antibodyalkaline
P01420579A0292 |60 61|%u
P01420579A0292 |112 117|monthneona
P01420579A0292 |7 25|serum neutralizing06T0076 Comparison
P01420579A0292 |78 79|%1
P01420579A0292 |98 109|SN antibodyic aspects 
P01420579A0292 |49 55|calvesses an
P01421145A1190 |0 13|FractionationP00001606T007
P01421145A1190 |43 73|heparin-agarose chromatographysphatases and 5-nucleotidase P
P01421145A1190 |89 95|PCAT-1armaco
P01421145A1190 |31 39|extractsalkaline
P01421145A1190 |117 125|extractstal hype
P01421145A1190 |154 165|leaf tissue2 When CSF 
P01421390T0000 |101 117|body irradiationaspects of neona
P01421390T0000 |210 218|leukemiae data o
P01421390T0000 |82 88|factor0000 P
P01421390T0000 |129 141|chemotherapyirubinemia. 
P01421390T0000 |13 18|trial6 Com
P01421390T0000 |232 240|lymphomaats are 
P01421390T0000 |158 185|bone marrow transplantationen CSF [HCO3-] is shown as 
P01421609A1067 |64 70|traumaotidas
P01421609A1067 |76 79|CPB081
P01421609A1067 |28 32|DMVAth a
P01421609A1067 |127 134|supportilirubi
P01421609A1067 |6 10|data606T
P01422265A0263 |136 140|IgG4mia.
P01422265A0263 |157 166|magnitudehen CSF [
P01422265A0263 |129 133|IgG3irub
P01422265A0263 |93 101|controlscologic 
P01422265A0263 |122 126|IgG2yper
P01422265A0263 |185 203|subclass responsesa function of CSF 
P01422265A0263 |38 53|coeliac diseasee phosphatases 
P01422265A0263 |4 24|IgG subclass profile01606T0076 Compariso
P01422265A0263 |223 239|coeliac patientsepleted rats are
P01422265A0263 |103 107|IgG1pect
P01423454A0309 |102 112|vasculitisspects of 
P01423454A0309 |126 135|indicatorbilirubin
P01423454A0309 |46 58|contributionatases and 5
P01423454A0309 |183 196|effectivenesss a function 
P01423454A0309 |15 19|ANCAComp
P01423454A0309 |143 151|activity0008997A
P01423454A0309 |83 92|diagnosis000 Pharm
P01423454A0309 |159 166|diseasen CSF [
P01423454A0309 |218 227|treatmentf K-deple
P01423454A0309 |0 11|ExaminationP00001606T0
P01423738A0639 |141 148|rhythmsP000089
P01423738A0639 |121 133|decelerationhyperbilirub
P01423738A0639 |25 37|pinealectomy with alkali
P01423738A0639 |13 17|hand6 Co
P01423738A0639 |150 164|mean delta tauA0472 When CSF
P01423738A0639 |173 174|hi
P01423738A0639 |80 87|rabbits1T0000 
P01424674A0000 |49 56|diseaseses and
P01424674A0000 |12 22|pemphigoid76 Compari
P01424674A0000 |95 108|cicatrizationlogic aspects
P01425653T0000 |103 108|womenpects
P01425653T0000 |4 11|effects01606T0
P01425653T0000 |29 47|caffeine ingestionh alkaline phospha
P01425653T0000 |71 89|oxygen consumption P00008171T0000 Ph
P01425653T0000 |19 25|levelsarison
P01425921A1286 |186 190|V1J1 fun
P01425921A1286 |43 61|amino acid changessphatases and 5-nu
P01425921A1286 |176 182|regionshown 
P01425921A1286 |120 138|consensus sequence hyperbilirubinemi
P01425921A1286 |82 97|lysine deletion0000 Pharmacolo
P01425921A1286 |19 27|featuresarison w
P01426635A0496 |23 28|ZFH-2on wi
P01426635A0496 |43 46|CNSsph
P01426635A0496 |12 19|profile76 Comp
P01426635A0496 |107 123|dopamine neuronss of neonatal hy
P01426635A0496 |77 80|DDC817
P01426635A0496 |93 102|serotonincologic a
P01427034A0440 |49 62|protein genesses and 5-nuc
P01427034A0440 |105 114|S13 genescts of ne
P01427034A0440 |174 180|lengths show
P01427034A0440 |11 18|introns076 Com
P01427034A0440 |194 201|intronsn of CS
P01427034A0440 |141 154|DNA sequencesP00008997A047
P01427034A0440 |168 170|bpO3
P01427457A0000 |153 167|sodium heparin72 When CSF [H
P01427457A0000 |219 222|DVT K-
P01427457A0000 |88 90|SCha
P01427457A0000 |60 68|efficacyucleotid
P01427457A0000 |175 184|treatment shown as
P01427457A0000 |38 43|triale pho
P01427457A0000 |114 115|ho
P01427457A0000 |117 132|calcium heparintal hyperbiliru
P01427457A0000 |207 217|thrombosis the data 
P01428490A0671 |187 191|pastfunc
P01428490A0671 |82 91|shortness0000 Phar
P01428490A0671 |95 101|breathlogic 
P01428490A0671 |56 61|cough 5-nu
P01428490A0671 |63 69|wheezeeotida
P01428490A0671 |12 22|prevalence76 Compari
P01428490A0671 |71 78|attacks P00008
P01428490A0671 |175 179|pets sho
P01428490A0671 |158 166|childrenen CSF [
P01428490A0671 |138 144|asthmaa. P00
P01428490A0671 |35 46|pet allergyline phosph
P01428513A0440 |53 60|personsand 5-n
P01429596A1669 |103 139|18K agglutination-aggregation factorpects of neonatal hyperbilirubinemia
P01429596A1669 |7 12|basis06T00
P01429596A1669 |29 39|propertiesh alkaline
P01429596A1669 |65 78|hemagglutinintidase P00008
P01429596A1669 |141 148|18K-LAFP000089
P01429624A0328 |101 109|activityaspects 
P01429624A0328 |113 128|adenylylcyclaseeonatal hyperbi
P01429624A0328 |73 79|guanyl000081
P01429624A0328 |31 42|temperaturealkaline ph
P01429624A0328 |65 69|losstida
P01429624A0328 |4 9|shift01606
P01429714A0730 |0 4|ClinP000
P01429724A0664 |98 104|Gly451ic asp
P01429724A0664 |45 51|domainhatase
P01429724A0664 |80 85|Ile591T000
P01429724A0664 |107 113|Leu455s of n
P01429724A0664 |88 93|Phe96harma
P01429724A0664 |4 8|data0160
P01429724A0664 |55 60|Nmt1pd 5-n
P01429740A1065 |80 86|domain1T0000
P01429740A1065 |45 56|presequencehatases and
P01429740A1065 |107 112|exonss of 
P01429740A1065 |144 151|E2 gene008997A
P01429768T0000 |70 75|alloye P00
P01429768T0000 |40 48|exposurephosphat
P01429768T0000 |52 56|F-75 and
P01429768T0000 |6 25|neutrophil response606T0076 Comparison
P01429836A0457 |0 10|DisruptionP00001606T
P01429836A0457 |14 26|microtubules Comparison 
P01429836A0457 |147 159|microtubules997A0472 Whe
P01429836A0457 |79 94|protein sorting71T0000 Pharmac
P01429836A0457 |46 54|fidelityatases a
P01429836A0457 |58 66|kinetics-nucleot
P01429836A0457 |112 126|Vps1p functionneonatal hyper
P01429836A1205 |17 22|Vps1pmpari
P01429836A1205 |54 60|domainnd 5-n
P01429836A1205 |9 13|formT007
P01429836A1205 |115 120|cellsnatal
P01429836A1205 |86 101|protein sorting Pharmacologic 
P01431380A0244 |338 346|antibody/- 0.23 
P01431380A0244 |268 279|rickettsiaepared to co
P01431380A0244 |256 264|findingsced when
P01431380A0244 |292 304|patient seraill have a s
P01431380A0244 |491 496|glandt. P0
P01431380A0244 |397 405|electron effecti
P01431380A0244 |127 132|ticksiliru
P01431380A0244 |386 391|ticksrs to
P01431380A0244 |214 218|miceta o
P01431380A0244 |177 194|group rickettsiaehown as a functio
P01431380A0244 |420 432|observationsg with the o
P01431380A0244 |362 377|hemolymph cells33 Flurazepam t
P01431380A0244 |240 254|tick emulsionsno longer disp
P01431380A0244 |196 200|SFGRof C
P01431380A0244 |78 82|area171T
P01431380A0244 |436 440|SFGRum d
P01431380A0244 |17 31|field researchmparison with 
P01431380A0244 |461 467|organsl prac
P01431380A0244 |202 210|antibody PCO2 th
P01431380A0244 |500 505|ticks653T0
P01431380A0244 |350 354|JSFRP000
P01431380A0244 |37 47|tick faunane phospha
P01431380A0244 |140 147|vectors P00008
P01431602A0229 |24 29|macron wit
P01431602A0229 |74 95|micrograms phosphorus0008171T0000 Pharmaco
P01431602A0229 |44 61|sensitivity rangephatases and 5-nu
P01431602A0229 |31 36|assayalkal
P01431602A0229 |11 17|method076 Co
P01431602A0229 |109 126|microliters HClO4of neonatal hyper
P01431809T0000 |0 19|Nucleotide sequenceP00001606T0076 Comp
P01431809T0000 |56 71|polyhedrin gene 5-nucleotidase
P01431809T0000 |75 92|Spodoptera exigua008171T0000 Pharm
P01431809T0000 |40 48|analysisphosphat
P01431809T0000 |101 119|polyhedrosis virusaspects of neonata
P01432453T0000 |0 10|ValidationP00001606T
P01432453T0000 |24 31|systemsn with 
P01432453T0000 |33 50|system definitionkaline phosphatas
P01433391A0594 |119 124|valuel hyp
P01433391A0594 |198 202|area CSF
P01433391A0594 |79 83|area71T0
P01433391A0594 |48 55|densityases an
P01433391A0594 |5 16|consequence1606T0076 C
P01433391A0594 |25 32|rearing with a
P01433391A0594 |153 160|kittens72 When
P01433391A0594 |68 75|neuronsase P00
P01433502A1163 |83 88|cells000 P
P01433502A1163 |164 170|factor [HCO3
P01433502A1163 |45 62|enhancer activityhatases and 5-nuc
P01433502A1163 |193 202|repressoron of CSF
P01433502A1163 |133 139|levelsinemia
P01433502A1163 |106 110|partts o
P01433502A1163 |37 42|classne ph
P01433502A1163 |6 13|results606T007
P01433524A0788 |110 120|activitiesf neonatal
P01433524A0788 |47 58|amino acidstases and 5
P01433524A0788 |62 65|IE1leo
P01433524A0788 |9 15|domainT0076 
P01435698A0000 |3 8|order00160
P01435698A0000 |28 47|blood compatibilityth alkaline phospha
P01435698A0000 |91 103|prostacyclinmacologic as
P01435698A0000 |74 77|AVG000
P01435698A0000 |105 109|PGI2cts 
P01435698A0000 |111 121|production neonatal 
P01435698A0000 |132 142|harvestingbinemia. P
P01435698A0000 |62 72|vein graftleotidase 
P01435698A0000 |80 87|changes1T0000 
P01435698A0000 |156 168|implantationWhen CSF [HC
P01436261A0145 |152 165|disappearance472 When CSF 
P01436261A0145 |176 188|incontinenceshown as a f
P01436261A0145 |123 134|improvementperbilirubi
P01436261A0145 |74 84|micrograms0008171T00
P01436261A0145 |206 223|calcitonin levels2 the data of K-d
P01436261A0145 |138 147|diarrhoeaa. P00008
P01436261A0145 |58 68|octreotide-nucleotid
P01436261A0145 |35 56|somatostatin analogueline phosphatases and
P01436261A0145 |0 27|Subcutaneous administrationP00001606T0076 Comparison w
P01437562A0462 |152 156|gene472 
P01437562A0462 |46 54|extractsatases a
P01437562A0462 |75 84|agreement008171T00
P01437562A0462 |58 71|C.fasciculata-nucleotidase
P01437562A0462 |9 19|antibodiesT0076 Comp
P01437562A0462 |94 98|sizeolog
P01437562A0462 |35 42|proteinline ph
P01437562A0462 |118 137|nucleotide sequenceal hyperbilirubinem
P01438224A0749 |57 59|J.5-
P01438287T0000 |65 70|genestidas
P01438287T0000 |15 30|vaccinia vectorComparison with
P01441120T0000 |0 3|UseP00
P01441120T0000 |19 27|mineralsarison w
P01441818T0001 |0 15|Interferon typeP00001606T0076 
P01441818T0001 |66 86|Klebsiella infectionidase P00008171T0000
P01441818T0001 |32 46|body reactionslkaline phosph
P01443047A0773 |34 56|differentiation statusaline phosphatases and
P01443047A0773 |74 85|association0008171T000
P01443047A0773 |91 108|Id-SCL expressionmacologic aspects
P01443047A0773 |9 16|changesT0076 C
P01443745T0000 |66 75|midazolamidase P00
P01443745T0000 |12 23|interaction76 Comparis
P01443745T0000 |37 47|anesthesiane phospha
P01443745T0000 |52 60|sedation and 5-n
P01443748A1190 |4 12|pressure01606T00
P01443748A1190 |151 160|movements0472 When
P01443748A1190 |30 37|atm abs alkali
P01443748A1190 |72 80|tadpolesP0000817
P01443748A1190 |52 64|excitability and 5-nucle
P01446132A0328 |4 16|air embolism01606T0076 C
P01446132A0328 |45 51|filterhatase
P01446132A0328 |74 86|complication0008171T0000
P01446828A1088 |17 21|ADH5mpar
P01446828A1088 |31 54|consensus binding sitesalkaline phosphatases a
P01446828A1088 |134 139|NF-E1nemia
P01446828A1088 |105 108|AP2cts
P01446828A1088 |90 98|proteinsrmacolog
P01446828A1088 |7 13|region06T007
P01446828A1088 |110 115|LF-A1f neo
P01446828A1088 |123 128|NF-A2perbi
P01446828A1088 |100 103|Sp1 as
P01446828A1088 |117 121|NF-1tal 
P01447139A0208 |0 2|V.P0
P01447189A1546 |102 110|granulesspects o
P01447189A1546 |129 140|lymphocytesirubinemia.
P01447189A1546 |25 34|RNK-Met-1 with alk
P01447189A1546 |40 55|serine proteasephosphatases an
P01447189A1546 |6 10|data606T
P01447189A1546 |68 76|activityase P000
P01447189T0000 |17 24|cloningmpariso
P01447189T0000 |73 81|granules00008171
P01447189T0000 |99 119|killer cell leukemiac aspects of neonata
P01447189T0000 |53 62|RNK-Met-1and 5-nuc
P01447189T0000 |36 51|serine proteaseine phosphatase
P01447189T0000 |87 90|ratPha
P01447189T0000 |0 12|PurificationP00001606T00
P01448107A0361 |96 103|absenceogic as
P01448107A0361 |107 128|amino acid starvations of neonatal hyperbi
P01448107A0361 |73 88|GCN4 expression00008171T0000 P
P01448107A0361 |29 43|GCN2 mutationsh alkaline pho
P01448107A0361 |57 69|derepression5-nucleotida
P01448806A0135 |0 14|AdministrationP00001606T0076
P01448806A0135 |73 88|bone maturation00008171T0000 P
P01448806A0135 |18 32|growth hormoneparison with a
P01448806A0135 |49 55|growthses an
P01448917A0775 |373 383|polymeraseam thus ap
P01448917A0775 |185 194|CPSMV RNAa functio
P01448917A0775 |253 272|proteinase cofactorplaced when compare
P01448917A0775 |55 75|sequence informationd 5-nucleotidase P00
P01448917A0775 |334 338|RNAs21 +
P01448917A0775 |297 300|VPgave
P01448917A0775 |146 169|clover mottle virus RNA8997A0472 When CSF [HCO
P01448917A0775 |94 102|CPMV RNAologic a
P01448917A0775 |360 363|87K073
P01448917A0775 |31 49|amino acid residuealkaline phosphata
P01448917A0775 |403 417|cleavage sitestive hypnotic 
P01448917A0775 |130 138|sequencerubinemi
P01448917A0775 |287 295|helicaseut still
P01448917A0775 |105 113|sequencects of n
P01448917A0775 |51 53|aas 
P01448917A0775 |220 223|setK-d
P01448917A0775 |274 277|58Kto 
P01448917A0775 |340 354|24K proteinase 0.23 vs. P000
P01448917A0775 |311 318|proteinantly g
P01448917A0775 |239 247|proteins no long
P01448917A0775 |0 11|ComparisonsP00001606T0
P01448932T0000 |0 47|Rice dwarf phytoreovirus segment S12 transcriptP00001606T0076 Comparison with alkaline phospha
P01449183A0795 |17 24|utilitympariso
P01449183A0795 |3 11|addition001606T0
P01449183A0795 |28 32|betath a
P01449183A0795 |60 69|diagnosisucleotida
P01449183A0795 |87 101|fluid otorrheaPharmacologic 
P01449183A0795 |35 52|transferrin assayline phosphatases
P01449301A0710 |0 17|Cold cardioplegiaP00001606T0076 Co
P01449301A0710 |41 46|mm Hghosph
P01449301A0710 |56 63|minutes 5-nucl
P01449301A0710 |70 75|hourse P00
P01450815A0337 |35 39|IPRKline
P01450815A0337 |73 79|change000081
P01450815A0337 |91 94|GFRmac
P01450815A0337 |83 86|RPF000
P01450815A0337 |177 185|decreasehown as 
P01450815A0337 |133 141|increaseinemia. 
P01450815A0337 |4 12|addition01606T00
P01450815A0337 |16 27|diatrizoateomparison w
P01451771A0619 |220 228|husbandsK-deplet
P01451771A0619 |177 180|MDShow
P01451771A0619 |79 83|data71T0
P01451771A0619 |133 136|PCAine
P01451771A0619 |15 23|analysesComparis
P01451771A0619 |202 215|health scores PCO2 the dat
P01451771A0619 |159 175|scaling analysisn CSF [HCO3-] is
P01451771A0619 |112 131|components analysisneonatal hyperbilir
P01451771A0619 |33 49|family variableskaline phosphata
P01451771A0619 |237 242|wivesre no
P01452037A0000 |304 320|gap amber mutantignificantly gre
P01452037A0000 |30 70|glyceraldehyde-3-phosphate dehydrogenase alkaline phosphatases and 5-nucleotidas
P01452037A0000 |107 110|PGKs o
P01452037A0000 |166 169|TIMHCO
P01452037A0000 |15 20|genesCompa
P01452037A0000 |187 213|Bacillus megaterium DSM319function of CSF PCO2 the d
P01452037A0000 |250 260|gap operondisplaced 
P01452037A0000 |265 280|complementationcompared to con
P01452037A0000 |99 105|kinasec aspe
P01452037A0000 |131 135|partubin
P01452037A0000 |72 77|GAPDHP0000
P01452037A0000 |236 248|gene clusterare no longe
P01452037A0000 |139 164|triosephosphate isomerase. P00008997A0472 When CSF
P01452584T0000 |86 100|Lindberg Award Pharmacologic
P01452584T0000 |62 75|wound healingleotidase P00
P01452584T0000 |47 58|retardationtases and 5
P01452584T0000 |23 33|exotoxin Aon with al
P01452584T0000 |39 43|role pho
P01452703A0782 |0 18|Laboratory studiesP00001606T0076 Com
P01452703A0782 |241 243|mlo 
P01452703A0782 |164 166|ml [
P01452703A0782 |230 236|bodies rats 
P01452703A0782 |179 189|ELISA kitswn as a fu
P01452703A0782 |63 67|kitseoti
P01452703A0782 |101 105|caseaspe
P01452703A0782 |153 159|bodies72 Whe
P01454518A0336 |102 109|homologspects 
P01454518A0336 |13 25|significance6 Comparison
P01454518A0336 |224 234|ERCC3 cDNApleted rat
P01454518A0336 |159 184|stringency hybridizationsn CSF [HCO3-] is shown as
P01454518A0336 |92 96|geneacol
P01454518A0336 |72 84|conservationP00008171T00
P01454518A0336 |35 42|domainsline ph
P01454518A0336 |204 210|probesCO2 th
P01454819A0000 |0 21|Mono-ADP-ribosylationP00001606T0076 Compar
P01454819A0000 |193 202|reactionson of CSF
P01454819A0000 |209 231|ADP-ribosylation cyclehe data of K-depleted 
P01454819A0000 |107 109|ECs 
P01454819A0000 |73 105|arginine ADP-ribosyltransferases00008171T0000 Pharmacologic aspe
P01454819A0000 |38 50|modificatione phosphatas
P01454819A0000 |54 62|proteinsnd 5-nuc
P01454819A0000 |144 154|hydrolases008997A047
P01454819A0000 |156 158|ECWh
P01454819A0000 |69 72|NADse 
P01456888A0074 |305 313|sequencegnifican
P01456888A0074 |329 359|myristylation consensus signale (1.21 +/- 0.23 vs. P00010943
P01456888A0074 |21 29|particleison wit
P01456888A0074 |157 175|expression systemshen CSF [HCO3-] is
P01456888A0074 |189 197|bacterianction o
P01456888A0074 |213 226|baculovirusesata of K-depl
P01456888A0074 |264 280|core protein p55 compared to con
P01456888A0074 |90 110|core antigen p55 gagrmacologic aspects o
P01456888A0074 |9 15|reasonT0076 
P01456888A0074 |199 207|vacciniaCSF PCO2
P01456888A0074 |50 61|derivativeses and 5-nu
P01456888A0074 |38 46|capacitye phosph
P01456888A0074 |69 80|HIV-1 groupse P0000817
P01457380A0000 |118 132|ttk transcriptal hyperbiliru
P01457380A0000 |20 24|generiso
P01457380A0000 |94 102|splicingologic a
P01457380A0000 |15 18|ttkCom
P01457380A0000 |65 73|proteinstidase P
P01457380A0000 |4 13|tramtrack01606T007
P01457695T0000 |1 8|Removal0000160
P01457695T0000 |53 67|hemofiltrationand 5-nucleoti
P01457695T0000 |36 48|hemodialysisine phosphat
P01457695T0000 |76 80|year0817
P01457695T0000 |12 32|beta 2-microglobulin76 Comparison with a
P01457695T0000 |76 80|year0817
P01457695T0000 |12 32|beta 2-microglobulin76 Comparison with a
P01457695T0000 |1 8|Removal0000160
P01457695T0000 |36 48|hemodialysisine phosphat
P01457695T0000 |53 67|hemofiltrationand 5-nucleoti
P01458170A0155 |0 10|AdapromineP00001606T
P01458170A0155 |178 186|increaseown as a
P01458170A0155 |148 154|cortex97A047
P01458170A0155 |243 249|cortexlonger
P01458170A0155 |254 263|hippocamplaced whe
P01458170A0155 |116 129|power spectraatal hyperbil
P01458170A0155 |54 63|amplitudend 5-nucl
P01458170A0155 |80 84|peak1T00
P01458170A0155 |217 221|betaof K
P01458170A0155 |159 168|hippocampn CSF [HC
P01458170A0155 |98 112|theta-activityic aspects of 
P01458170A0155 |196 209|wave activityof CSF PCO2 t
P01458170A0155 |224 229|rangeplete
P01458170A0155 |38 46|decreasee phosph
P01458170A0155 |137 140|EEGia.
P01459447A0484 |34 39|clonealine
P01459447A0484 |6 15|sequences606T0076 
P01459447A0484 |56 61|genes 5-nu
P01459447A0484 |83 90|library000 Pha
P01459447A0484 |69 74|yeastse P0
P01459451A0478 |19 33|antirepressionarison with al
P01459451A0478 |56 62|factor 5-nuc
P01459451A0478 |77 93|co-antirepressor8171T0000 Pharma
P01459451A0478 |140 147|embryos P00008
P01459885A0705 |17 38|haloperidol treatmentmparison with alkalin
P01459885A0705 |125 133|decreaserbilirub
P01459885A0705 |74 79|delta00081
P01459885A0705 |142 146|beta0000
P01459885A0705 |110 115|alphaf neo
P01459885A0705 |9 13|daysT007
P01459885A0705 |98 106|increaseic aspec
P01459885A0705 |48 55|changesases an
P01459921A0000 |233 240|cis C18ts are 
P01459921A0000 |225 230|C18:2leted
P01459921A0000 |150 167|calcium linoleateA0472 When CSF [H
P01459921A0000 |125 145|linoleoyl methioninerbilirubinemia. P000
P01459921A0000 |41 58|Hampshire wethershosphatases and 5
P01459921A0000 |192 196|flowion 
P01459921A0000 |93 103|experimentcologic as
P01459921A0000 |218 223|acidsf K-d
P01460054A0478 |85 88|ICS0 P
P01460054A0478 |127 145|DNA binding domainilirubinemia. P000
P01460054A0478 |10 15|ICSBP0076 
P01460054A0478 |183 197|amino terminuss a function o
P01460054A0478 |52 63|amino acids and 5-nucl
P01460054A0478 |115 119|partnata
P01460054A0968 |101 106|genesaspec
P01460054A0968 |75 83|activity008171T0
P01460054A0968 |11 16|ICSBP076 C
P01460054A0968 |124 129|cellserbil
P01460772T0001 |2 6|case0001
P01460772T0001 |43 57|hypothyroidismsphatases and 
P01460772T0001 |76 96|interferon treatment08171T0000 Pharmacol
P01460772T0001 |18 29|hepatitis Cparison wit
P01462786T0000 |0 23|Dynamic decision makingP00001606T0076 Comparis
P01462786T0000 |31 38|controlalkalin
P01462786T0000 |42 57|complex systemsosphatases and 
P01464329T0000 |71 91|prophase chromosomes P00008171T0000 Phar
P01464329T0000 |22 29|proteinson wit
P01464329T0000 |52 59|regions and 5-
P01464606A0344 |71 76|cells P000
P01464606A0344 |176 183|elutionshown a
P01464606A0344 |147 171|fragment affinity column997A0472 When CSF [HCO3-
P01464606A0344 |11 18|amounts076 Com
P01464606A0344 |122 133|fibronectinyperbilirub
P01464606A0344 |30 34|beta alk
P01464606A0344 |189 193|EDTAncti
P01464606A0344 |37 45|integrinne phosp
P01464606A0344 |22 27|alphason w
P01464606A0344 |80 94|chromatography1T0000 Pharmac
P01464606A0344 |98 116|detergent extractsic aspects of neon
P01467088T0075 |0 9|AbstractsP00001606
P01467828A0542 |34 45|involvementaline phosp
P01467828A0542 |91 98|effectsmacolog
P01467828A0542 |60 75|opioid peptidesucleotidase P00
P01467828A0542 |6 13|results606T007
P01467828A0542 |163 172|receptorsF [HCO3-]
P01467828A0542 |131 142|reperfusionubinemia. P
P01467828A0542 |188 198|antagonismunction of
P01467828A0542 |117 126|ischaemiatal hyper
P01468625A0282 |19 23|LEU2aris
P01468625A0282 |10 17|library0076 Co
P01468625A0282 |109 114|casesof ne
P01468625A0282 |28 38|HIS3 cDNAsth alkalin
P01468625A0282 |161 167|mannerCSF [H
P01468625A0282 |59 68|frequencynucleotid
P01468625A1080 |36 41|timesine p
P01468625A1080 |13 17|ACT16 Co
P01468625A1080 |47 51|NSR1tase
P01468625A1080 |58 63|times-nucl
P01469042A0355 |87 117|mouse centromere satellite DNAPharmacologic aspects of neona
P01469042A0355 |210 214|kinde da
P01469042A0355 |44 51|speciesphatase
P01469042A0355 |125 134|satelliterbilirubi
P01469042A0355 |56 68|CENP-B boxes 5-nucleotid
P01469042A0355 |225 244|centromere functionleted rats are no l
P01469042A0355 |172 183|interaction is shown a
P01469042A0355 |6 17|CENP-B gene606T0076 Co
P01469047A1606 |17 24|portionmpariso
P01469047A1606 |62 68|sharesleotid
P01469047A1606 |45 47|aaha
P01469047A1606 |71 101|% amino acid sequence identity P00008171T0000 Pharmacologic 
P01469047A1606 |129 140|mouse brainirubinemia.
P01469047A1606 |167 185|acid decarboxylaseCO3-] is shown as 
P01469047A1606 |116 123|proteinatal hy
P01469047A1606 |32 43|tail domainlkaline pho
P01470243A0871 |274 279|meansto co
P01470243A0871 |322 338|viscosity effecter slope (1.21 +
P01470243A0871 |114 123|mortalityonatal hy
P01470243A0871 |218 219|%f
P01470243A0871 |53 54|na
P01470243A0871 |261 270|viscosityhen compa
P01470243A0871 |244 253|reductiononger dis
P01470243A0871 |360 365|group0733 
P01470243A0871 |302 309|albumin signif
P01470243A0871 |210 211|%e
P01470243A0871 |150 151|%A
P01470243A0871 |283 296|haemodilutionls but still 
P01470243A0871 |132 138|monthsbinemi
P01470243A0871 |186 198|independence function of
P01470243A0871 |16 24|subgroupompariso
P01470243A0871 |48 51|l/lase
P01470243A0871 |86 95|reduction Pharmaco
P01470243A0871 |97 98|pg
P01470243A0871 |142 143|%0
P01470243A0871 |202 206|home PCO
P01470243A0871 |37 39|Htne
P01470243A0871 |174 182|increases shown 
P01470741T0062 |0 12|DistributionP00001606T00
P01470741T0062 |40 46|coursephosph
P01471602A0362 |16 19|useomp
P01471602A0362 |266 271|drugsompar
P01471602A0362 |129 136|HMG-CoAirubine
P01471602A0362 |24 32|benefitsn with a
P01471602A0362 |245 256|conjunctionnger displa
P01471602A0362 |226 236|approacheseted rats 
P01471602A0362 |164 172|probucol [HCO3-]
P01471602A0362 |138 158|reductase inhibitorsa. P00008997A0472 Wh
P01471602A0362 |83 88|acids000 P
P01471602A0362 |36 58|bile acid sequestrantsine phosphatases and 5
P01471602A0362 |70 74|acide P0
P01471602A0362 |117 127|coenzyme Atal hyperb
P01473196A1016 |24 36|reabsorptionn with alkal
P01473196A1016 |61 70|clearancecleotidas
P01473207A0582 |71 81|hypoplasia P00008171
P01473207A0582 |23 31|findingson with 
P01473207A0582 |53 66|prematurationand 5-nucleot
P01473207A0582 |39 47|placenta phospha
P01473234A1001 |0 12|Green pepperP00001606T00
P01473234A1001 |106 110|acidts o
P01473234A1001 |70 84|acid formatione P00008171T00
P01474990A0000 |17 22|pTt21mpari
P01474990A0000 |177 191|trypomastigotehown as a func
P01474990A0000 |164 171|library [HCO3-
P01474990A0000 |196 213|epimastigote cDNAof CSF PCO2 the d
P01474990A0000 |78 89|Trypanosoma171T0000 Ph
P01474990A0000 |10 15|clone0076 
P01474990A0000 |96 111|trypomastigotesogic aspects of
P01474990A0000 |35 38|DNAlin
P01475381T0001 |0 11|BrucellosisP00001606T0
P01476376T0000 |0 5|AssayP0000
P01476376T0000 |62 70|pH-meterleotidas
P01476376T0000 |29 35|ureaseh alka
P01476376T0000 |9 13|ureaT007
P01477021A0394 |51 80|serum prolactin concentrations and 5-nucleotidase P0000817
P01477021A0394 |110 119|gestationf neonata
P01477021A0394 |135 136|Pe
P01477021A0394 |121 122|Ph
P01477021A0394 |16 25|AGA groupomparison
P01477021A0394 |0 7|RESULTSP000016
P01478672A0795 |4 15|phage clone01606T0076 
P01478672A0795 |44 63|alpha satellite DNAphatases and 5-nucl
P01478672A0795 |94 102|sequenceologic a
P01478672A0795 |27 35|junctionith alka
P01480183A0000 |16 22|regionompari
P01480183A0000 |97 104|librarygic asp
P01480183A0000 |36 52|lactoferrin geneine phosphatases
P01480183A1689 |118 123|mouseal hy
P01480183A1689 |75 102|lactoferrin gene expression008171T0000 Pharmacologic a
P01480183A1689 |43 58|estrogen actionsphatases and 5
P01480183A1689 |25 35|mechanisms with alka
P01480470A0323 |0 6|BiP670P00001
P01480470A0323 |30 39|ionophore alkaline
P01480470A0323 |57 67|activities5-nucleoti
P01480470A0323 |25 28|Ca2 wi
P01482912A0617 |17 37|registration updatesmparison with alkali
P01482912A0617 |45 56|HL7 messagehatases and
P01482912A0617 |92 97|rulesacolo
P01482912A0617 |122 141|relational databaseyperbilirubinemia. 
P01482912A0617 |105 114|interfacects of ne
P01482912A0617 |4 7|CEM016
P01482912A0617 |71 88|data dependencies P00008171T0000 P
P01483755A0000 |152 158|muscle472 Wh
P01483755A0000 |81 91|techniquesT0000 Phar
P01483755A0000 |42 49|imagingosphata
P01483755A0000 |9 31|resonance spectroscopyT0076 Comparison with 
P01483755A0000 |139 148|structure. P000089
P01483755A0000 |100 105|study aspe
P01483755A0000 |33 36|MRSkal
P01483755A0000 |118 128|metabolismal hyperbi
P01483755A0000 |51 54|MRIs a
P01483771A1335 |25 27|NA w
P01483771A1335 |46 52|changeatases
P01483771A1335 |56 83|plasma epinephrine response 5-nucleotidase P00008171T0
P01485648A0000 |118 124|Swedenal hyp
P01485648A0000 |109 116|Uppsalaof neon
P01485648A0000 |148 159|measurement97A0472 Whe
P01485648A0000 |225 231|groupsleted 
P01485648A0000 |61 81|Pharmacia CAP Systemcleotidase P00008171
P01485648A0000 |31 36|valuealkal
P01485648A0000 |181 195|IgE antibodies as a function
P01485648A0000 |83 107|Pharmacia Diagnostics AB000 Pharmacologic aspect
P01485648A0000 |199 209|comparisonCSF PCO2 t
P01485648A0000 |215 219|RASTa of
P01485648A0000 |55 59|testd 5-
P01485648A0000 |235 243|patients are no 
P01486836A0774 |0 8|PatientsP0000160
P01486836A0774 |56 78|visuomotor performance 5-nucleotidase P00008
P01486836A0774 |30 41|differences alkaline p
P01486836A0774 |135 157|visuomotor performanceemia. P00008997A0472 W
P01486836A0774 |45 54|attentionhatases a
P01486836A0774 |187 189|T3fu
P01486836A0774 |19 22|VPAari
P01486836A0774 |87 91|spanPhar
P01486836A0774 |179 183|spanwn a
P01486836A0774 |128 130|T1li
P01486836A0774 |161 163|T2CS
P01486836A0774 |104 124|discrimination tasksects of neonatal hyp
P01486836A0774 |231 233|T4ra
P01486836A0774 |202 213|differences PCO2 the d
P01487144A0505 |18 30|gene segmentparison with
P01487144A0505 |56 57|A 
P01487144A0505 |46 55|mu m polyatases an
P01487144A0505 |181 199|L cell fibroblasts as a function of 
P01487144A0505 |59 66|signalsnucleot
P01487144A0505 |130 154|transcription terminatorrubinemia. P00008997A047
P01487144A0505 |109 117|sequenceof neona
P01487144A0505 |163 176|myeloma cellsF [HCO3-] is 
P01487144A0505 |83 85|bp00
P01490493A0416 |84 103|triglyceride levels00 Pharmacologic as
P01490493A0416 |5 9|part1606
P01490493A0416 |74 79|lipid00081
P01490493A0416 |21 32|examinationison with a
P01490493A0416 |49 66|serum cholesterolses and 5-nucleot
P01492463T0001 |0 5|AlenaP0000
P01492463T0001 |77 82|ocean8171T
P01492463T0001 |11 16|nurse076 C
P01492463T0001 |61 65|tripcleo
P01492463T0001 |20 26|Praguerison 
P01492463T0001 |49 54|wagesses a
P01493864A0619 |68 81|pre-treatmentase P00008171
P01493864A0619 |20 28|subjectsrison wi
P01493864A0619 |43 49|6-OHDAsphata
P01493864A0619 |87 96|GBR-12909Pharmacol
P01493864A0619 |0 16|Dopamine neuronsP00001606T0076 C
P01495069A0392 |0 4|DIBAP000
P01495069A0392 |61 66|valuecleot
P01495069A0392 |94 104|percentageologic asp
P01495069A0392 |110 114|DFATf ne
P01496348A0000 |0 6|CariesP00001
P01496348A0000 |11 23|parodontitis076 Comparis
P01496348A0000 |57 65|diseases5-nucleo
P01496348A0000 |69 76|mankindse P000
P01496784A0939 |68 73|causease P
P01496784A0939 |20 25|studyrison
P01496784A0939 |43 59|strongyloidiasissphatases and 5-
P01496784A0939 |4 11|results01606T0
P01496784A0939 |84 89|death00 Ph
P01497582A0593 |153 161|placenta72 When 
P01497582A0593 |104 113|pathogensects of n
P01497582A0593 |60 67|effectsucleoti
P01497582A0593 |15 20|groupCompa
P01497582A0593 |37 46|pregnancyne phosph
P01497582A0593 |24 33|disordersn with al
P01497582A0593 |89 95|motherarmaco
P01497582A0593 |71 81|infections P00008171
P01497582A0593 |139 145|embryo. P000
P01498607A0000 |33 38|boxeskalin
P01498607A0000 |72 86|responsivenessP00008171T0000
P01498607A0000 |11 31|nucleotide sequences076 Comparison with 
P01498607A0000 |94 128|parsley chalcone synthase promoterologic aspects of neonatal hyperbi
P01499213A0185 |119 123|falll hy
P01499213A0185 |79 100|hyperextension injury71T0000 Pharmacologic
P01499213A0185 |44 47|manpha
P01499213A0185 |140 148|fracture P000089
P01499213A0185 |53 63|ochronosisand 5-nucl
P01499213A0185 |108 113|spine of n
P01499213A0185 |4 8|case0160
P01499213A0185 |170 186|L2-L3 disk space-] is shown as a
P01499616A0136 |34 42|foreskinaline ph
P01499616A0136 |131 141|anesthesiaubinemia. 
P01499616A0136 |167 168|%C
P01499616A0136 |106 107|%t
P01499616A0136 |77 78|g8
P01499616A0136 |9 19|blood flowT0076 Comp
P01499616A0136 |176 179|tipsho
P01499616A0136 |206 219|foreskin flap2 the data of
P01499616A0136 |118 127|inductional hyperb
P01502157A0000 |0 5|ME1a1P0000
P01502157A0000 |135 146|P2 activityemia. P0000
P01502157A0000 |30 49|factor binding site alkaline phosphata
P01502157A0000 |71 79|c-MYC P1 P000081
P01502157A0000 |84 117|P2 transcription initiation sites00 Pharmacologic aspects of neona
P01504178T0000 |16 21|yearsompar
P01504178T0000 |25 35|prevention with alka
P01504178T0000 |46 53|countryatases 
P01504178T0000 |66 73|complexidase P
P01504178T0000 |55 64|visionaryd 5-nucle
P01504853A0299 |70 77|speciese P0000
P01504853A0299 |10 14|LHRH0076
P01504853A0299 |43 58|mating behaviorsphatases and 5
P01505488A0231 |48 51|EVLase
P01505488A0231 |91 95|Julymaco
P01505488A0231 |75 81|August008171
P01505488A0231 |63 69|periodeotida
P01505488A0231 |26 34|patientswith alk
P01505516A0928 |69 83|valine residuese P00008171T0
P01505516A0928 |92 101|formationacologic 
P01505516A0928 |58 65|alanine-nucleo
P01505516A0928 |122 128|dimersyperbi
P01505516A0928 |23 27|acidon w
P01505516A0928 |35 41|lysineline p
P01506705A0282 |19 31|hemodynamicsarison with 
P01506705A0282 |7 17|V-A bypass06T0076 Co
P01506746A0476 |0 21|Greater rupture forceP00001606T0076 Compar
P01506746A0476 |48 52|pigsases
P01506746A0476 |71 75|pigs P00
P01509798A0520 |84 85|%0
P01509798A0520 |46 47|%a
P01509798A0520 |64 66|ATot
P01509798A0520 |77 80|UEA817
P01509798A0520 |40 42|UTph
P01509798A0520 |3 11|rest AFF001606T0
P01509798A0520 |70 71|%e
P01511231A0085 |50 54|yeares a
P01511231A0085 |20 34|smoking habitsrison with alk
P01511231A0085 |105 113|nicotinects of n
P01511231A0085 |75 98|smoking cessation trial008171T0000 Pharmacolog
P01511231A0085 |38 47|relapserse phospha
P01511231A0085 |117 132|placebo patchestal hyperbiliru
P01511950T0000 |152 162|population472 When C
P01511950T0000 |59 67|Hisayamanucleoti
P01511950T0000 |12 29|hepatitis B virus76 Comparison wit
P01511950T0000 |45 55|populationhatases an
P01511950T0000 |101 109|antibodyaspects 
P01511950T0000 |113 140|hepatitis B surface antigeneonatal hyperbilirubinemia.
P01511950T0000 |76 88|significance08171T0000 P
P01511950T0000 |69 74|Japanse P0
P01511950T0000 |0 8|ExposureP0000160
P01512259A0867 |168 173|furinO3-] 
P01512259A0867 |124 131|Dfurin2erbilir
P01512259A0867 |73 87|cysteine motif00008171T0000 
P01512259A0867 |23 33|phenomenonon with al
P01512259A0867 |115 120|timesnatal
P01512654A0503 |87 101|KLH challengesPharmacologic 
P01512654A0503 |46 62|saline injectionatases and 5-nuc
P01512654A0503 |13 17|hand6 Co
P01512654A0503 |27 36|phosphateith alkal
P01512654A0503 |109 111|ESof
P01512654A0503 |72 74|ESP0
P01512654A0503 |142 157|threshold level00008997A0472 W
P01512654A0503 |175 182|latency shown 
P01512941A0000 |118 128|comparisonal hyperbi
P01512941A0000 |177 188|norfloxacinhown as a f
P01512941A0000 |167 171|OFLXCO3-
P01512941A0000 |149 153|CPFX7A04
P01512941A0000 |134 147|ciprofloxacinnemia. P00008
P01512941A0000 |190 194|NFLXctio
P01512941A0000 |156 165|ofloxacinWhen CSF 
P01512941A0000 |64 68|LVFXotid
P01512941A0000 |70 77|DR-3355e P0000
P01512941A0000 |50 62|levofloxacines and 5-nuc
P01513114A1133 |68 71|KTAase
P01513114A1133 |109 114|WORDSof ne
P01513114A1133 |76 80|mg/d0817
P01513114A1133 |59 62|SPKnuc
P01513114A1133 |9 32|serum creatinine levelsT0076 Comparison with a
P01513114A1133 |53 57|yearand 
P01513114A1133 |83 91|ABSTRACT000 Phar
P01513213A0231 |0 17|Model predictionsP00001606T0076 Co
P01513213A0231 |126 131|womenbilir
P01513213A0231 |26 32|accordwith a
P01513213A0231 |75 80|women00817
P01513213A0231 |88 97|HIP trialharmacolo
P01513213A0231 |174 182|survivals shown 
P01513213A0231 |113 122|exceptioneonatal h
P01513213A0231 |52 71|survival experience and 5-nucleotidase
P01513213A0231 |138 143|yearsa. P0
P01513213A0231 |154 162|HIP data2 When C
P01516427T0000 |64 76|tuberculosisotidase P000
P01516427T0000 |43 52|diagnosissphatases
P01516427T0000 |25 35|tomography with alka
P01516829A0113 |136 143|complexmia. P0
P01516829A0113 |27 31|SNF2ith 
P01516829A0113 |93 103|activationcologic as
P01516829A0113 |43 56|SNF6 functionsphatases and
P01516829A0113 |33 37|SNF5kali
P01516829A0460 |102 112|activationspects of 
P01516829A0460 |13 22|LexA-GAL46 Compari
P01516829A0460 |83 87|SNF5000 
P01516829A0460 |93 97|SNF6colo
P01516829A0460 |77 81|SNF28171
P01516829A0460 |156 170|lexA operatorsWhen CSF [HCO3
P01516829A0460 |39 54|fusion proteins phosphatases a
P01516829A0460 |116 128|target genesatal hyperbi
P01518396T0000 |0 9|George T.P00001606
P01518833A0397 |2 26|lambda gt10 cDNA library0001606T0076 Comparison 
P01518833A0397 |76 82|leaves08171T
P01518833A0397 |57 60|RNA5-n
P01518833A0397 |48 52|polyases
P01518833A0397 |53 54|Aa
P01518833A0397 |86 93|spinach Pharma
P01518849A0165 |0 2|NEP0
P01518849A0165 |150 160|activitiesA0472 When
P01518849A0165 |25 36|destruction with alkal
P01518849A0165 |108 123|protein elastin of neonatal hy
P01518849A0165 |215 231|elastin peptidesa of K-depleted 
P01518849A0165 |172 210|alpha 1-proteinase inhibitor complexes is shown as a function of CSF PCO2 th
P01518849A0165 |7 10|PR306T
P01518849A0165 |53 67|microorganismsand 5-nucleoti
P01518926T0000 |9 15|topicsT0076 
P01518926T0000 |29 44|ultrasonographyh alkaline phos
P01522699A0092 |0 7|MethodsP000016
P01522699A0092 |59 74|recipe analysisnucleotidase P0
P01522699A0092 |41 53|menu weightshosphatases 
P01522699A0092 |33 39|recallkaline
P01523111A0769 |0 7|FactorsP000016
P01523111A0769 |63 74|temperatureeotidase P0
P01523111A0769 |43 46|agesph
P01523111A0769 |24 33|afterdropn with al
P01523111A0769 |97 106|body massgic aspec
P01524549A0241 |118 129|associational hyperbil
P01524549A0241 |180 190|GH therapyn as a fun
P01524549A0241 |135 148|GH deficiencyemia. P000089
P01524549A0241 |66 73|statureidase P
P01524549A0241 |161 165|timeCSF 
P01524549A0241 |107 114|pubertys of ne
P01524549A0241 |39 45|growth phosp
P01524549A0241 |5 18|GH deficiency1606T0076 Com
P01524549A0241 |87 97|occurrencePharmacolo
P01525153A0359 |155 162|Gilbert When C
P01525153A0359 |29 34|T2G4Th alk
P01525153A0359 |149 151|D.7A
P01525153A0359 |13 14|d6
P01525153A0359 |164 166|W. [
P01525153A0359 |15 21|T2AG3TCompar
P01525153A0359 |144 147|Sen008
P01525153A0359 |27 28|di
P01525153A0359 |63 81|monomer structureseotidase P00008171
P01525153A0359 |36 40|formine 
P01525153A0359 |97 119|K cation concentrationgic aspects of neonata
P01525153A0359 |3 11|contrast001606T0
P01525966T0000 |28 34|stonesth alk
P01526658A0454 |0 3|IFIP00
P01526658A0454 |78 88|cell lines171T0000 P
P01526658A0454 |107 117|B lineagess of neona
P01526658A0454 |65 70|cellstidas
P01526658A0454 |7 11|mRNA06T0
P01526658A0454 |101 102|Ta
P01526690T0000 |19 25|actionarison
P01526690T0000 |29 37|warfarinh alkali
P01526690T0000 |41 52|lymphocyteshosphatases
P01527020A0511 |137 141|geneia. 
P01527020A0511 |110 115|exonsf neo
P01527020A0511 |12 21|junctions76 Compar
P01527020A0511 |88 97|positionsharmacolo
P01527020A0511 |39 69|rat AdoMet decarboxylase genes phosphatases and 5-nucleotida
P01527020A0511 |158 162|exonen C
P01527020A0511 |170 178|rat gene-] is sh
P01529530T0000 |67 73|effectdase P
P01529530T0000 |106 133|ISGF3 transcription complexts of neonatal hyperbilirub
P01529530T0000 |88 98|activationharmacolog
P01529530T0000 |25 40|gene expression with alkaline 
P01529530T0000 |77 84|ouabain8171T00
P01529530T0000 |42 50|evidenceosphatas
P01531086A0127 |21 34|reading frameison with alk
P01531086A0127 |83 90|protein000 Pha
P01531086A0127 |42 53|amino acidsosphatases 
P01531086A0127 |4 8|cDNA0160
P01531214A0885 |86 100|administration Pharmacologic
P01531214A0885 |26 32|RP-170with a
P01531214A0885 |46 50|i.v.atas
P01531214A0885 |73 77|g/kg0000
P01531214A0885 |38 42|g/kge ph
P01531214A0885 |10 14|LD500076
P01531214A0885 |18 22|micepari
P01531632A0000 |86 94|proteins Pharmac
P01531632A0000 |41 50|nucleolushosphatas
P01531632A0000 |107 118|fibrillarins of neonat
P01531632A0000 |14 22|proteins Compari
P01531632A0000 |120 124|SSB1 hyp
P01531632A0000 |163 168|motifF [HC
P01531632A0000 |129 133|NSR1irub
P01531632A0000 |215 232|arginine residuesa of K-depleted r
P01531632A0000 |203 210|glycinePCO2 th
P01531632A0000 |96 105|nucleolinogic aspe
P01531632A0000 |174 184|GAR domains shown as
P01532229A1264 |102 107|MEF-2spect
P01532229A1264 |26 34|evidencewith alk
P01532229A1264 |11 16|study076 C
P01532229A1264 |60 66|factorucleot
P01532229A1264 |173 183|expressionis shown a
P01532229A1264 |96 101|HF-1bogic 
P01532229A1264 |145 152|pathway08997A0
P01532229A1264 |207 219|muscle cells the data of
P01532229A1264 |81 94|muscle factorT0000 Pharmac
P01532229A1264 |68 73|HF-1aase P
P01532796A0107 |85 90|alpha0 Pha
P01532796A0107 |126 138|mitochondriabilirubinemi
P01532796A0107 |95 108|beta subunitslogic aspects
P01532796A0107 |57 65|assembly5-nucleo
P01532796A0107 |151 161|aggregates0472 When 
P01532796A0107 |20 24|generiso
P01532796A0107 |173 175|S.is
P01532796A0107 |163 171|AckermanF [HCO3-
P01532796A0107 |69 71|F1se
P01532796A0107 |49 53|stepses 
P01532796A0107 |0 9|MutationsP00001606
P01532914A0067 |0 7|ExpenseP000016
P01532914A0067 |122 130|strategyyperbili
P01532914A0067 |73 85|immunization00008171T000
P01532914A0067 |143 150|studies0008997
P01532914A0067 |26 46|hepatitis B vaccineswith alkaline phosph
P01532914A0067 |19 22|useari
P01533760T0000 |0 28|Estrogen replacement therapyP00001606T0076 Comparison wi
P01533760T0000 |41 54|breast cancerhosphatases a
P01533760T0000 |33 37|riskkali
P01533760T0000 |56 63|results 5-nucl
P01533760T0000 |71 84|meta-analyses P00008171T00
P01535242A0557 |51 57|GM-CSFs and 
P01535242A0557 |79 90|degradation71T0000 Pha
P01535242A0557 |122 138|factor switchingyperbilirubinemi
P01535242A0557 |42 47|M-CSFospha
P01535242A0557 |10 16|FDC-P10076 C
P01535242A0557 |94 104|c-fms mRNAologic asp
P01535242A0557 |32 38|growthlkalin
P01535242A0557 |114 115|ho
P01535242A0557 |17 26|MAC cellsmparison 
P01536153A0574 |34 44|differencealine phos
P01536153A0574 |150 160|skin testsA0472 When
P01536153A0574 |181 191|fish flour as a func
P01536153A0574 |248 255|dyspnear displ
P01536153A0574 |232 235|IgEats
P01536153A0574 |52 62|prevalence and 5-nuc
P01536153A0574 |103 122|animal food workerspects of neonatal h
P01536153A0574 |86 94|symptoms Pharmac
P01536153A0574 |170 174|dust-] i
P01536575A1213 |207 213|CYPIA1 the d
P01536575A1213 |225 230|genesleted
P01536575A1213 |292 304|hydrocarbonsill have a s
P01536575A1213 |148 157|induction97A0472 W
P01536575A1213 |182 205|cytochrome P450IA1 geneas a function of CSF PC
P01536575A1213 |243 268|detoxification/activationlonger displaced when com
P01536575A1213 |30 38|presence alkalin
P01536575A1213 |161 174|transcriptionCSF [HCO3-] i
P01536575A1213 |107 115|sequences of neo
P01536575A1213 |14 21|finding Compar
P01536575A1213 |42 50|positionosphatas
P01536575A1213 |78 84|dioxin171T00
P01536575A1213 |96 103|elementogic as
P01537334A0507 |32 48|mouse chromosomelkaline phosphat
P01537334A0507 |60 66|regionucleot
P01537334A0507 |4 8|gene0160
P01537334A0507 |74 100|coat colour mutation slaty0008171T0000 Pharmacologic
P01537334A0507 |18 28|TRP-2 mapsparison wi
P01537845A0571 |55 59|rated 5-
P01537845A0571 |63 87|c-myb gene transcriptioneotidase P00008171T0000 
P01537845A0571 |91 105|mRNA stabilitymacologic aspe
P01537845A0571 |130 140|cell cyclerubinemia.
P01537845A0571 |41 47|changehospha
P01537845A0571 |24 36|c-myb clonesn with alkal
P01538401A1244 |119 126|bindingl hyper
P01538401A1244 |40 51|nucleotidesphosphatase
P01538401A1244 |72 82|S RNA geneP00008171T
P01538401A1244 |141 147|latterP00008
P01538401A1244 |5 30|base-pair oligonucleotide1606T0076 Comparison with
P01538401A1244 |187 200|DNA fragmentsfunction of C
P01538403A1058 |186 203|complex formation function of CSF 
P01538403A1058 |56 79|transcription complexes 5-nucleotidase P000081
P01538403A1058 |14 28|reconstitution Comparison wi
P01538403A1058 |246 254|TATA-boxger disp
P01538403A1058 |212 233|H5 promoter mutationsdata of K-depleted ra
P01538403A1058 |94 111|protein fractionsologic aspects of
P01538403A1058 |32 36|eUSFlkal
P01538403A1058 |138 143|TFIIDa. P0
P01538403A1058 |153 157|eUSF72 W
P01539996A0588 |136 146|similaritymia. P0000
P01539996A0588 |241 247|enzymeo long
P01539996A0588 |20 39|amino acid sequencerison with alkaline
P01539996A0588 |157 169|conservationhen CSF [HCO
P01539996A0588 |296 304|presencehave a s
P01539996A0588 |334 344|C terminus21 +/- 0.2
P01539996A0588 |126 127|%b
P01539996A0588 |177 188|Ser residuehown as a f
P01539996A0588 |104 110|enzymeects o
P01539996A0588 |318 326|residuesreater s
P01539996A0588 |352 374|T. thermophilus enzyme0010943A0733 Flurazepa
P01539996A0588 |272 280|sequenced to con
P01539996A0588 |47 69|T. thermophilus enzymetases and 5-nucleotida
P01539996A0588 |2 12|comparison0001606T00
P01541556A1040 |84 102|lipid modification00 Pharmacologic a
P01541556A1040 |62 69|proteinleotida
P01541556A1040 |14 23|palmitate Comparis
P01541556A1040 |117 131|Cys-22 residuetal hyperbilir
P01541577A0000 |71 88|Stanford Hypnotic P00008171T0000 P
P01541577A0000 |105 109|SHCScts 
P01541577A0000 |114 120|Morganonatal
P01541577A0000 |43 63|volunteer hearing Sssphatases and 5-nucl
P01541577A0000 |125 127|J.rb
P01541577A0000 |3 12|volunteer001606T00
P01541577A0000 |98 103|Scaleic as
P01541577A0000 |18 20|Sspa
P01542565A0220 |70 84|protein L7/L12e P00008171T00
P01542565A0220 |7 26|tobacco L12 protein06T0076 Comparison 
P01542565A0220 |33 54|% amino acid identitykaline phosphatases a
P01542565T0000 |38 49|protein L12e phosphata
P01542565T0000 |183 192|precursors a funct
P01542565T0000 |146 157|cDNA clones8997A0472 W
P01542565T0000 |125 142|sequence analysisrbilirubinemia. P
P01542565T0000 |72 88|characterizationP00008171T0000 P
P01542565T0000 |53 70|Nicotiana tabacumand 5-nucleotidas
P01542565T0000 |111 120|isolation neonatal
P01542565T0000 |99 106|proteinc aspec
P01542667A0125 |18 27|IFN-gammaparison w
P01542667A0125 |125 133|activityrbilirub
P01542667A0125 |72 88|enhancer elementP00008171T0000 P
P01542667A0125 |158 168|expressionen CSF [HC
P01542667A0125 |202 206|gene PCO
P01542667A0125 |4 8|gene0160
P01542686A0000 |141 144|p65P00
P01542686A0000 |146 153|subunit8997A04
P01542686A0000 |10 17|cloning0076 Co
P01542686A0000 |72 97|p75 nucleoprotein complexP00008171T0000 Pharmacolo
P01542686A0000 |157 168|NF-kappa B.hen CSF [HC
P01542686A0000 |25 46|polypeptide component with alkaline phosph
P01542686A0000 |115 123|identitynatal hy
P01542730A1982 |238 245|devicese no lo
P01542730A1982 |302 310|ABSTRACT signifi
P01542730A1982 |85 89|risk0 Ph
P01542730A1982 |115 123|AV blocknatal hy
P01542730A1982 |292 300|patientsill have
P01542730A1982 |218 230|dual-chamberf K-depleted
P01542730A1982 |62 69|patientleotida
P01542730A1982 |328 333|WORDSpe (1
P01542730A1982 |276 282|number contr
P01542730A1982 |128 138|DDD pacinglirubinemi
P01542730A1982 |44 50|pacingphatas
P01542730A1982 |169 176|support3-] is 
P01542730A1982 |232 236|DDDRats 
P01542730A1982 |100 111|development aspects of
P01543909A0787 |51 53|Lgs 
P01543909A0787 |213 217|geneata 
P01543909A0787 |167 177|pseudogeneCO3-] is s
P01543909A0787 |62 67|cloneleoti
P01543909A0787 |136 151|characteristicsmia. P00008997A
P01543909A0787 |236 252|ferritin subunitare no longer di
P01543909A0787 |34 44|K562 cellsaline phos
P01544854A0699 |34 43|WR-168643aline pho
P01544854A0699 |57 66|protector5-nucleot
P01544854A0699 |74 77|DMF000
P01544854A0699 |7 12|drugs06T00
P01544918A1240 |0 16|CharacterizationP00001606T0076 C
P01544918A1240 |244 257|subunit sizesonger displac
P01544918A1240 |26 36|R subunitswith alkal
P01544918A1240 |86 102|immunoreactivity Pharmacologic a
P01544918A1240 |223 231|SDS-PAGEepleted 
P01544918A1240 |292 315|RII alpha dephosphoformill have a significantl
P01544918A1240 |320 323|kDaate
P01544918A1240 |261 269|RII betahen comp
P01544918A1240 |146 160|mobility shift8997A0472 When
P01544918A1240 |351 354|kDa000
P01544918A1240 |46 81|8-azido-cAMP photoaffinity labelingatases and 5-nucleotidase P00008171
P01544918A1240 |164 178|sodium dodecyl [HCO3-] is sh
P01544918A1240 |338 346|RI alpha/- 0.23 
P01544918A1240 |202 221|gel electrophoresis PCO2 the data of K
P01544918A1240 |274 277|kDato 
P01544928A1252 |0 10|ComparisonP00001606T
P01544928A1252 |98 109|transcriptsic aspects 
P01544928A1252 |161 169|pre-mRNACSF [HCO
P01544928A1252 |26 38|DNA sequencewith alkalin
P01544928A1252 |138 146|splicinga. P0000
P01544928A1252 |71 76|mRNAs P000
P01544928A1252 |185 199|cassette modela function of 
P01545523A0000 |119 137|antistreptolysin Ol hyperbilirubinem
P01545523A0000 |56 64|testings 5-nucle
P01545523A0000 |88 95|proteinharmaco
P01545523A0000 |77 78|C8
P01545523A0000 |108 114|factor of ne
P01545523A0000 |19 34|quantificationsarison with alk
P01545787A0345 |85 90|DNase0 Pha
P01545787A0345 |93 103|footprintscologic as
P01545787A0345 |105 111|NFAT-1cts of
P01545787A0345 |116 123|NFIL-2Batal hy
P01545787A0345 |37 42|sitesne ph
P01545787A0345 |17 25|enhancermparison
P01545792A0000 |34 39|MLC-2aline
P01545792A0000 |12 32|myosin light chain-276 Comparison with a
P01545792A0000 |105 114|sequencescts of ne
P01545792A0000 |158 168|expressionen CSF [HC
P01545792A0000 |41 54|gene promoterhosphatases a
P01545792A0000 |140 150|regulation P00008997
P01545792A0492 |0 20|Deletion mutagenesisP00001606T0076 Compa
P01545792A0492 |49 57|elementsses and 
P01545792A0492 |101 125|MLC-2 gene transcriptionaspects of neonatal hype
P01545792A0492 |87 97|regulationPharmacolo
P01545797A0587 |0 20|Disruption mutationsP00001606T0076 Compa
P01545797A0587 |97 106|degrees Cgic aspec
P01545797A0587 |150 160|degrees C.A0472 When
P01545797A0587 |61 65|slk1cleo
P01545797A0587 |117 122|cellstal h
P01545797A0587 |71 78|mutants P00008
P01545797A0587 |50 59|SLK1 genees and 5-
P01545806T0000 |38 43|yeaste pho
P01545806T0000 |58 84|recombination genes REC102-nucleotidase P00008171T00
P01545806T0000 |89 100|REC107/MER2armacologic
P01545806T0000 |22 30|analysisson with
P01545818A0696 |187 203|v-Src SH2 domainfunction of CSF 
P01545818A0696 |105 110|v-Srccts o
P01545818A0696 |41 49|proteinshosphata
P01545818A0696 |132 143|Rat-2 cellsbinemia. P0
P01545818A0696 |13 16|p626 C
P01545818A0696 |65 74|v-Src SH2tidase P0
P01545818A0696 |158 165|bindingen CSF 
P01545818A0696 |4 8|p1300160
P01546522A0000 |0 8|ProbableP0000160
P01546522A0000 |97 104|picturegic asp
P01546522A0000 |79 84|basis71T00
P01546522A0000 |173 182|remissionis shown 
P01546522A0000 |53 56|PMLand
P01546522A0000 |202 210|lymphoma PCO2 th
P01546522A0000 |118 135|resonance imagingal hyperbilirubin
P01546522A0000 |32 51|leukoencephalopathylkaline phosphatase
P01546522A0000 |153 156|man72 
P01547775A1024 |200 230|ORF2a/ORF2b transframe proteinSF PCO2 the data of K-depleted
P01547775A1024 |61 71|frameshiftcleotidase
P01547775A1024 |41 53|significancehosphatases 
P01547775A1024 |89 97|positionarmacolo
P01547775A1024 |166 170|siteHCO3
P01547775A1024 |178 192|PLRV replicaseown as a funct
P01547775A1024 |145 148|RNA089
P01547775A1024 |6 10|data606T
P01547787A0548 |0 21|Proprotein processingP00001606T0076 Compar
P01547942A0120 |34 53|dimerization domainaline phosphatases 
P01547942A0120 |91 96|clonemacol
P01547942A0120 |14 17|LAP Co
P01547942A0120 |142 149|CHOP-100000899
P01547942A0120 |133 140|proteininemia.
P01547942A0120 |55 67|zipper probed 5-nucleoti
P01547957A1083 |138 144|regiona. P00
P01547957A1083 |156 163|portionWhen CS
P01547957A1083 |295 298|PCR ha
P01547957A1083 |176 180|CYP2show
P01547957A1083 |210 216|genomee data
P01547957A1083 |268 293|polymerase chain reactionpared to controls but sti
P01547957A1083 |328 337|substratepe (1.21 
P01547957A1083 |167 171|CYP1CO3-
P01547957A1083 |319 322|DNAeat
P01547957A1083 |19 43|oligodeoxyribonucleotidearison with alkaline pho
P01547957A1083 |234 246|DNA fragments are no lon
P01547957A1083 |76 87|aa sequence08171T0000 
P01547957A1083 |306 310|GL81nifi
P01548756A1102 |84 94|EHS-1 loci00 Pharmac
P01548756A1102 |10 23|hybridization0076 Comparis
P01548756A1102 |183 200|rhesus monkey DNAs a function of C
P01548756A1102 |111 114|DNA ne
P01548756A1102 |57 60|DNA5-n
P01548756A1102 |27 32|EHS-1ith a
P01548756A1102 |129 141|band patternirubinemia. 
P01548756A1102 |145 159|chimpanzee DNA08997A0472 Whe
P01548756A1102 |174 179|locuss sho
P01548891A0635 |118 126|patientsal hyper
P01548891A0635 |43 50|hormonesphatas
P01548891A0635 |72 89|thyroid carcinomaP00008171T0000 Ph
P01548891A0635 |135 152|thyroid carcinomaemia. P00008997A0
P01548891A0635 |4 9|level01606
P01548891A0635 |58 66|patients-nucleot
P01548891A0635 |154 155|P2
P01549118A0000 |4 45|Caenorhabditis elegans vitellogenin genes01606T0076 Comparison with alkaline phosp
P01549118A0000 |61 64|sexcle
P01549118A0000 |146 169|hermaphrodite intestine8997A0472 When CSF [HCO
P01549118A0000 |95 105|regulationlogic aspe
P01549118A0000 |67 72|stagedase 
P01549123A0480 |34 42|sequencealine ph
P01549123A0480 |92 98|familyacolog
P01549123A0480 |106 110|bZIPts o
P01549123A0480 |4 13|MET4 gene01606T007
P01549123A0480 |127 137|activatorsilirubinem
P01549123A0480 |69 76|proteinse P000
P01549125A0140 |51 55|IAPPs an
P01549125A0140 |111 121|expression neonatal 
P01549125A0140 |26 34|portionswith alk
P01549125A0140 |61 78|beta GK promoterscleotidase P00008
P01549125A0140 |42 49|insulinosphata
P01549125A0140 |126 144|DNA binding assaysbilirubinemia. P00
P01549125A0140 |4 13|functions01606T007
P01549129A0356 |87 99|interactionsPharmacologi
P01549129A0356 |125 136|functioningrbilirubine
P01549129A0356 |26 33|domainswith al
P01549129A0356 |140 143|Src P0
P01549346A0000 |4 23|c-Ets-1 oncoprotein01606T0076 Comparis
P01549346A0000 |29 52|transcription activatorh alkaline phosphatases
P01549346A0000 |80 83|DNA1T0
P01549465A0122 |100 103|Ser as
P01549465A0122 |108 111|Val of
P01549465A0122 |95 98|Glylog
P01549465A0122 |151 165|discrimination0472 When CSF 
P01549465A0122 |58 69|amino acids-nucleotida
P01549465A0122 |9 36|transactivation experimentsT0076 Comparison with alkal
P01549465A0122 |87 93|regionPharma
P01551176A0000 |0 8|GR63178AP0000160
P01551176A0000 |40 51|mitoquidonephosphatase
P01551176A0000 |28 36|analogueth alkal
P01551176A0000 |67 81|pyrroloquinonedase P00008171
P01551568A1476 |0 22|Marker rescue analysisP00001606T0076 Compari
P01551568A1476 |62 69|segmentleotida
P01551568A1476 |95 105|Rif domainlogic aspe
P01551568A1476 |73 77|rpoB0000
P01551568A1476 |37 40|ts8ne 
P01551898A1084 |152 166|culture medium472 When CSF [
P01551898A1084 |104 111|proteinects of
P01551898A1084 |5 11|vector1606T0
P01551898A1084 |72 82|expressionP00008171T
P01551898A1084 |132 134|mgbi
P01551898A1084 |33 38|yeastkalin
P01551898A1084 |115 121|levelsnatal 
P01551898A1084 |138 148|LAPP/litera. P000089
P01551910A0313 |0 20|Competition analysisP00001606T0076 Compa
P01551910A0313 |24 58|gel mobility shift electrophoresisn with alkaline phosphatases and 5
P01551910A0313 |91 102|interactionmacologic a
P01551910A0313 |136 157|transcription factorsmia. P00008997A0472 W
P01551910A0978 |50 58|sequencees and 5
P01551910A0978 |5 14|DNA motif1606T0076
P01552052A0139 |137 146|mg/kg/dayia. P0000
P01552052A0139 |150 162|cyclosporineA0472 When C
P01552052A0139 |15 20|studyCompa
P01552052A0139 |81 97|serum creatinineT0000 Pharmacolo
P01552052A0139 |66 77|alterationsidase P0000
P01552052A0139 |53 62|frequencyand 5-nuc
P01552052A0139 |101 109|patientsaspects 
P01552052A0139 |115 124|psoriasisnatal hyp
P01552052A0139 |0 9|OBJECTIVEP00001606
P01552457T0000 |34 47|periodontitisaline phospha
P01552457T0000 |79 85|insert71T000
P01552457T0000 |97 106|ofloxacingic aspec
P01552457T0000 |108 113|PT-01 of n
P01552457T0000 |0 24|Intrapocket chemotherapyP00001606T0076 Compariso
P01552662A0398 |16 26|blood flowomparison 
P01552662A0398 |90 93|LADrma
P01552662A0398 |82 88|artery0000 P
P01552662A0398 |28 30|BFth
P01552662A0398 |32 37|probelkali
P01552853A1377 |70 81|yop regulone P00008171
P01552853A1377 |6 17|temperature606T0076 Co
P01552853A1377 |22 26|virFson 
P01552853A1377 |53 62|inductionand 5-nuc
P01553407T0000 |0 8|ProblemsP0000160
P01553407T0000 |59 74|risk assessmentnucleotidase P0
P01553407T0000 |38 42|areae ph
P01554334A0000 |152 161|Committee472 When 
P01554334A0000 |73 82|diagnosis00008171T
P01554334A0000 |165 176|Agriculture[HCO3-] is 
P01554334A0000 |181 184|use as
P01554334A0000 |93 105|tuberculosiscologic aspe
P01554334A0000 |109 115|cattleof neo
P01554334A0000 |41 50|IFN-gammahosphatas
P01554334A0000 |23 39|gamma-interferonon with alkaline
P01554334A0000 |52 64|assay system and 5-nucle
P01554334A0000 |188 197|Australiaunction o
P01555556A0565 |0 15|Control TmuscleP00001606T0076 
P01555556A0565 |76 78|SD08
P01555556A0565 |60 63|maxucl
P01555556A0565 |49 59|control Wises and 5-
P01555556A0565 |33 42|degrees Ckaline ph
P01555556A0565 |84 90|W.kg-100 Pha
P01556068A0000 |4 34|Klebsiella aerogenes gene maoA01606T0076 Comparison with alk
P01556068A0000 |133 142|compoundsinemia. P
P01556068A0000 |74 91|monoamine oxidase0008171T0000 Phar
P01556068A0000 |61 70|synthesiscleotidas
P01556068A0000 |172 195|ammonium ion repression is shown as a function
P01556068A0000 |108 116|tyramine of neon
P01556068A0000 |157 167|catabolitehen CSF [H
P01556111A0241 |30 37|plasmid alkali
P01556111A0241 |15 22|regionsCompari
P01557217A0272 |39 46|lesions phosph
P01557217A0272 |88 94|h p.i.harmac
P01557411A1282 |16 24|D1A geneompariso
P01557411A1282 |40 48|categoryphosphat
P01557411A1282 |79 84|genes71T00
P01557411A1282 |113 122|promoterseonatal h
P01558942A1369 |8 20|observations6T0076 Compa
P01558942A1369 |57 62|genes5-nuc
P01559209T0000 |17 29|CNS studentsmparison wit
P01559209T0000 |46 51|studyatase
P01559209T0000 |0 13|PreceptorshipP00001606T007
P01560021A0379 |39 50|differences phosphatas
P01560021A0379 |25 30|basis with
P01560021A0379 |75 93|brain AE3 variants008171T0000 Pharma
P01560021A0379 |129 137|rat geneirubinem
P01560774A0885 |18 26|fragmentparison 
P01560774A0885 |73 82|fliA gene00008171T
P01560774A0885 |8 10|kb6T
P01562659A0676 |0 11|InstitutionP00001606T0
P01562659A0676 |51 65|administrations and 5-nucleo
P01562659A0676 |354 357|CNS109
P01562659A0676 |212 222|C. immitisdata of K-
P01562659A0676 |246 258|encephalitisger displace
P01562659A0676 |121 135|administrationhyperbilirubin
P01562659A0676 |303 315|confirmationsignificantl
P01562659A0676 |197 208|associationf CSF PCO2 
P01562659A0676 |228 242|CNS vasculitised rats are no
P01562659A0676 |319 339|C. immitis infectioneater slope (1.21 +/
P01562659A0676 |139 152|dexamethasone. P00008997A0
P01562659A0676 |173 183|situationsis shown a
P01562659A0676 |69 83|amphotericin Bse P00008171T0
P01563343A0548 |0 13|Lac operatorsP00001606T007
P01563343A0548 |95 102|plasmidlogic a
P01563343A0548 |64 76|CAB promoterotidase P000
P01563343A0548 |43 52|positionssphatases
P01563343A0548 |115 122|controlnatal h
P01563635T0000 |0 14|OverproductionP00001606T0076
P01563635T0000 |53 78|M.HinfI methyltransferaseand 5-nucleotidase P00008
P01563635T0000 |87 102|deletion mutantPharmacologic a
P01563635T0000 |33 49|characterizationkaline phosphata
P01563635T0000 |16 28|purificationomparison wi
P01564653A0307 |39 43|lens pho
P01564653A0307 |31 35|typealka
P01564653A0307 |8 17|companies6T0076 Co
P01565093A0179 |118 126|hospitalal hyper
P01565093A0179 |163 190|disease surveillance systemF [HCO3-] is shown as a fun
P01565093A0179 |209 227|Alabama Departmenthe data of K-deple
P01565093A0179 |45 52|personshatases
P01565093A0179 |82 99|blood lead levels0000 Pharmacologi
P01565093A0179 |246 250|ADPHger 
P01565093A0179 |231 244|Public Healthrats are no l
P01565093A0179 |21 28|Octoberison wi
P01565093A0179 |5 10|March1606T
P01565093A0179 |101 105|BLLsaspe
P01565882A0737 |274 275|%t
P01565882A0737 |28 45|perfusion defectsth alkaline phosp
P01565882A0737 |183 184|%s
P01565882A0737 |268 270|Iapa
P01565882A0737 |120 136|perfusion defect hyperbilirubine
P01565882A0737 |186 190|Type fun
P01565882A0737 |290 292|Ibst
P01565882A0737 |112 116|Typeneon
P01565882A0737 |296 297|%h
P01565882A0737 |144 152|RD image008997A0
P01565882A0737 |212 221|subgroupsdata of K
P01565882A0737 |58 60|RD-n
P01565882A0737 |230 246|perfusion defect rats are no lon
P01565882A0737 |105 110|typescts o
P01565882A0737 |17 24|changesmpariso
P01565882A0737 |65 75|ReI imagestidase P00
P01565882A0737 |174 179|images sho
P01565882A0737 |306 314|RD imagenificant
P01566576A0605 |0 4|KeckP000
P01566576A0605 |6 10|C.J.606T
P01567649A0139 |152 159|infancy472 Whe
P01567649A0139 |132 142|evaluationbinemia. P
P01567649A0139 |104 109|palsyects 
P01567649A0139 |20 27|infantsrison w
P01567649A0139 |52 62|hemorrhage and 5-nuc
P01567649A0139 |17 18|%m
P01568960A1129 |111 125|corner vessels neonatal hype
P01568960A1129 |11 20|mechanism076 Compa
P01568960A1129 |47 55|pressuretases an
P01568960A1129 |78 84|output171T00
P01568960A1129 |147 159|VA/Q regions997A0472 Whe
P01568960A1129 |95 105|blood flowlogic aspe
P01569015A0120 |16 21|FRAMEompar
P01569015A0120 |130 139|directionrubinemia
P01569015A0120 |60 74|reading framesucleotidase P0
P01569015A0120 |23 31|analysison with 
P01569015A0120 |76 80|ORFs0817
P01569015A0120 |96 105|directionogic aspe
P01569102A0708 |0 6|DomainP00001
P01569102A0708 |90 102|conservationrmacologic a
P01569102A0708 |38 50|LDL receptore phosphatas
P01569102A0708 |124 133|cysteineserbilirub
P01569102A0708 |69 76|repeatsse P000
P01569344A0404 |113 133|HTLV-I/II prevalenceeonatal hyperbilirub
P01569344A0404 |79 94|New Orleans age71T0000 Pharmac
P01569344A0404 |26 36|prevalencewith alkal
P01569344A0404 |183 184|Ps
P01569344A0404 |172 181|Baltimore is shown
P01569344A0404 |8 14|cities6T0076
P01569344A0404 |66 69|ageida
P01569581A0482 |17 25|evidencemparison
P01569581A0482 |47 51|mRNAtase
P01569581A0482 |165 194|translation initiation region[HCO3-] is shown as a functio
P01569581A0482 |111 122|start codon neonatal h
P01569581A0482 |130 134|foldrubi
P01569581A0482 |79 90|nucleotides71T0000 Pha
P01569581A0482 |219 251|translation initiation frequency K-depleted rats are no longer d
P01569581A0482 |144 153|base-pair008997A04
P01569581A0482 |32 37|modellkali
P01569584A0672 |0 18|Hybridization dataP00001606T0076 Com
P01569584A0672 |108 113|6F6.1 of n
P01569584A0672 |167 172|genesCO3-]
P01569584A0672 |133 138|6F6.2inemi
P01569584A0672 |33 38|6F6.2kalin
P01569584A0672 |83 98|m6F6 cDNA clone000 Pharmacolog
P01569584A0672 |118 123|6F6.3al hy
P01569945A0529 |118 121|kDaal 
P01569945A0529 |45 58|reading framehatases and 5
P01569945A0529 |108 112|mass of 
P01569945A0529 |89 96|proteinarmacol
P01569945A0529 |4 13|SEN1 gene01606T007
P01572549A0000 |119 127|productsl hyperb
P01572549A0000 |197 220|growth factor receptorsf CSF PCO2 the data of 
P01572549A0000 |26 30|PTKswith
P01572549A0000 |224 234|componentspleted rat
P01572549A0000 |105 115|appearancects of neo
P01572549A0000 |65 76|cell growthtidase P000
P01572549A0000 |54 61|controlnd 5-nu
P01572549A0000 |142 151|oncogenes00008997A
P01572549A0000 |170 188|signal transducers-] is shown as a f
P01572549A0000 |80 86|virtue1T0000
P01572549A0000 |0 24|Protein tyrosine kinasesP00001606T0076 Compariso
P01573270A0000 |84 96|immunization00 Pharmacol
P01573270A0000 |151 157|killer0472 W
P01573270A0000 |45 55|antibodieshatases an
P01573270A0000 |159 162|LAKn C
P01573270A0000 |176 197|EBV-B lymphocyte lineshown as a function o
P01573270A0000 |107 116|HLA classs of neon
P01573270A0000 |4 11|IA4 mAb01606T0
P01573270A0000 |66 77|BALB/c miceidase P0000
P01573270A0000 |35 41|seriesline p
P01577056A0178 |69 81|theophyllinese P00008171
P01577056A0178 |51 59|subjectss and 5-
P01577056A0178 |119 121|mgl 
P01577056A0178 |84 91|mg.kg-100 Phar
P01577056A0178 |222 226|daysdepl
P01577056A0178 |126 129|daybil
P01577056A0178 |181 185|days as 
P01577056A0178 |162 169|periodsSF [HCO
P01577056A0178 |40 45|studyphosp
P01577056A0178 |105 115|omeprazolects of neo
P01577056A0178 |143 150|placebo0008997
P01577056A0178 |202 216|washout period PCO2 the data
P01577056A0178 |96 99|dayogi
P01577740A1111 |0 16|Primer extensionP00001606T0076 C
P01577740A1111 |74 104|transcription initiation sites0008171T0000 Pharmacologic asp
P01577740A1111 |21 30|mung beanison with
P01577740A1111 |130 147|Northern analysesrubinemia. P00008
P01577740A1111 |35 54|S1 nuclease mappingline phosphatases a
P01577819A0709 |69 75|numberse P00
P01577819A0709 |12 33|PRP-precursor alleles76 Comparison with al
P01577819A0709 |90 99|domain C.rmacologi
P01577819A0709 |79 86|repeats71T0000
P01579472A1018 |87 93|mannerPharma
P01579472A1018 |42 48|regionosphat
P01579472A1018 |19 35|enhancer elementarison with alka
P01579537A0000 |38 42|usese ph
P01579537A0000 |46 61|botulinum toxinatases and 5-nu
P01579537A0000 |15 20|yearsCompa
P01579537A0000 |72 82|neurotoxinP00008171T
P01580738T0001 |0 9|AllagilleP00001606
P01580738T0001 |47 54|ascitestases a
P01580738T0001 |12 20|syndrome76 Compa
P01581409A0398 |119 126|resultsl hyper
P01581409A0398 |134 138|skinnemi
P01581409A0398 |81 99|DPC AlaSTAT SystemT0000 Pharmacologi
P01581409A0398 |52 72|Pharmacia CAP System and 5-nucleotidase 
P01581409A0398 |145 149|test0899
P01581409A0398 |103 113|comparisonpects of n
P01581409A0398 |16 27|specificityomparison w
P01581409A0398 |0 11|SensitivityP00001606T0
P01581577A1186 |0 5|PSI-GP0000
P01581577A1186 |10 15|PSI-K0076 
P01581577A1186 |45 61|gene duplicationhatases and 5-nu
P01581577A1186 |78 82|gene171T
P01581965A0388 |38 44|domaine phos
P01581965A0388 |104 142|breakpoint cluster region gene productects of neonatal hyperbilirubinemia. P
P01581965A0388 |241 248|GTPaseso longe
P01581965A0388 |59 68|sequencesnucleotid
P01581965A0388 |25 32|protein with a
P01581965A0388 |160 167|rho GAP CSF [H
P01581965A0388 |7 17|C-terminus06T0076 Co
P01581965A0388 |144 154|n-chimerin008997A047
P01581965A0388 |219 231|GAP activity K-depleted 
P01582413A0192 |201 212|DNA bindingF PCO2 the 
P01582413A0192 |14 25|mutagenesis Comparison
P01582413A0192 |126 133|helicesbilirub
P01582413A0192 |62 73|amino acidsleotidase P
P01582413A0192 |44 52|clustersphatases
P01582413A0192 |99 105|regionc aspe
P01582413A0192 |158 164|domainen CSF
P01582413A0192 |217 239|hetero-oligomerizationof K-depleted rats are
P01582413A0759 |0 12|DimerizationP00001606T00
P01582413A0759 |94 102|affinityologic a
P01582413A0759 |107 110|DNAs o
P01582413A0759 |164 175|DNA binding [HCO3-] is
P01582413A0759 |59 70|protein E12nucleotidas
P01582413A0759 |131 146|transactivationubinemia. P0000
P01582413A0759 |16 21|Myf-5ompar
P01582500A0178 |29 34|sleeph alk
P01582500A0178 |14 25|rhythmicity Comparison
P01583819A0377 |68 70|Hzas
P01583819A0377 |77 90|Simson method8171T0000 Pha
P01583819A0377 |54 56|HZnd
P01583819A0377 |36 43|filtersine pho
P01583819A0377 |0 3|SEAP00
P01584812T0000 |16 26|expressionomparison 
P01584812T0000 |63 75|localizationeotidase P00
P01584812T0000 |83 87|gene000 
P01584812T0000 |36 45|structureine phosp
P01584812T0000 |113 140|transcription factor NGFI-Ceonatal hyperbilirubinemia.
P01585014A0000 |411 415|I.U.noti
P01585014A0000 |236 247|lupin grainare no long
P01585014A0000 |38 47|treatmente phospha
P01585014A0000 |497 502|FSH-P01265
P01585014A0000 |165 174|treatment[HCO3-] i
P01585014A0000 |186 192|spring funct
P01585014A0000 |425 449|mare serum gonadotrophinh the optimum dose for u
P01585014A0000 |118 119|ha
P01585014A0000 |252 258|autumnsplace
P01585014A0000 |359 370|Merino ewesA0733 Flura
P01585014A0000 |293 297|daysll h
P01585014A0000 |53 66|gonadotrophinand 5-nucleot
P01585014A0000 |126 152|progestagen sponge removalbilirubinemia. P00008997A0
P01585014A0000 |176 182|autumnshown 
P01585014A0000 |155 161|season When 
P01585014A0000 |392 403|combinationbe an effec
P01585014A0000 |335 344|ovulation1 +/- 0.2
P01585014A0000 |27 34|effectsith alk
P01585014A0000 |451 455|PMSG in 
P01585014A0000 |90 105|micrograms GnRHrmacologic aspe
P01585014A0000 |304 318|sponge removalignificantly g
P01585014A0000 |199 205|effectCSF PC
P01585014A0000 |464 495|mg follicle stimulating hormoneractice being 15 mg at night. P
P01585014A0000 |327 331|timeope 
P01585014A0000 |3 13|experiment001606T007
P01585014A0000 |77 84|hormone8171T00
P01585014A0000 |273 277|days to 
P01586901A0000 |137 143|windowia. P0
P01586901A0000 |79 90|medications71T0000 Pha
P01586901A0000 |100 105|drugs aspe
P01586901A0000 |10 22|interactions0076 Compari
P01586901A0000 |51 59|patientss and 5-
P01587267A1144 |102 108|enzymespects
P01587267A1144 |62 67|X-rayleoti
P01587267A1144 |194 205|mutagenesisn of CSF PC
P01587267A1144 |159 163|genen CS
P01587267A1144 |129 139|expressionirubinemia
P01587267A1144 |40 54|interpretationphosphatases a
P01587267A1144 |117 124|cloningtal hyp
P01587267A1144 |4 17|sequence data01606T0076 Co
P01587267A1144 |85 94|structure0 Pharmac
P01587763A0402 |70 76|schemee P000
P01587763A0402 |130 134|daysrubi
P01587763A0402 |109 112|dayof 
P01587763A0402 |83 92|fractions000 Pharm
P01587763A0402 |6 22|body irradiation606T0076 Compari
P01587763A0402 |115 117|hrna
P01588270A1029 |118 120|.9al
P01588270A1029 |15 29|blood pressureComparison wit
P01588270A1029 |66 71|studyidase
P01588270A1029 |129 133|mmHgirub
P01588270A1029 |135 136|Pe
P01588270A1029 |156 159|DBPWhe
P01588270A1029 |55 58|endd 5
P01588270A1029 |2 11|reduction0001606T0
P01588315A0356 |239 243|maps no 
P01588315A0356 |93 103|polyhedrincologic as
P01588315A0356 |199 208|directionCSF PCO2 
P01588315A0356 |130 145|polyhedrin generubinemia. P000
P01588315A0356 |11 36|Orgyia pseudotsugata MNPV076 Comparison with alkal
P01588315A0356 |61 66|termscleot
P01588315A0356 |38 44|OpMNPVe phos
P01588315A0356 |112 120|sequenceneonatal
P01588315A0356 |212 220|relationdata of 
P01588315A0356 |154 161|viruses2 When 
P01588315A0356 |70 88|promoter structuree P00008171T0000 P
P01588315A0356 |0 6|AgMNPVP00001
P01588913A0000 |153 162|P. putida72 When C
P01588913A0000 |97 110|transcriptiongic aspects o
P01588913A0000 |42 51|dnaA geneosphatase
P01588913A0000 |2 6|gene0001
P01588961A0000 |0 4|STP1P000
P01588961A0000 |73 82|sequences00008171T
P01588961A0000 |151 160|pre-tRNAs0472 When
P01588961A0000 |23 33|yeast geneon with al
P01588961A0000 |107 115|familiess of neo
P01588961A0000 |50 57|removales and 
P01588963A1153 |51 61|conditionss and 5-nu
P01588963A1153 |91 104|Cdc25 proteinmacologic asp
P01588963A1153 |12 22|antibodies76 Compari
P01588965A0000 |0 18|GCR1 gene functionP00001606T0076 Com
P01588965A0000 |57 72|gene expression5-nucleotidase 
P01589576A0170 |171 173|T3] 
P01589576A0170 |147 149|ps99
P01589576A0170 |164 166|ps [
P01589576A0170 |151 153|T204
P01589576A0170 |134 136|T1ne
P01589576A0170 |4 16|decay curves01606T0076 C
P01589576A0170 |54 67|superpositionnd 5-nucleoti
P01589576A0170 |20 44|chlorophyll fluorescencerison with alkaline phos
P01589576A0170 |100 110|components aspects o
P01589576A0170 |116 130|time constantsatal hyperbili
P01589576A0170 |184 186|ns a
P01592545A0726 |100 101|p 
P01592545A0726 |123 124|%p
P01592545A0726 |47 54|averagetases a
P01592545A0726 |60 61|%u
P01592545A0726 |24 38|blood pressuren with alkalin
P01592545A0726 |148 156|patients97A0472 
P01592545A0726 |65 73|patientstidase P
P01594554A0845 |153 161|function72 When 
P01594554A0845 |6 13|results606T007
P01594554A0845 |57 75|trypsin inhibitors5-nucleotidase P00
P01594554A0845 |38 43|rolese pho
P01594554A0845 |113 129|feedback controleonatal hyperbil
P01594554A0845 |49 52|CCKses
P01596007A0908 |35 41|Stagesline p
P01596007A0908 |56 59|REM 5-
P01596007A0908 |227 230|SWSted
P01596007A0908 |148 163|control studies97A0472 When CS
P01596007A0908 |12 18|events76 Com
P01596007A0908 |194 195|%n
P01596007A0908 |101 115|gamma OH studyaspects of neo
P01596007A0908 |246 254|ABSTRACTger disp
P01596007A0908 |129 130|%i
P01596007A0908 |272 277|WORDSd to 
P01596007A0908 |236 244|gamma OHare no l
P01596007A0908 |70 80|proportione P0000817
P01597170A0000 |102 110|group Cospects o
P01597170A0000 |211 217|months data 
P01597170A0000 |184 187|air a 
P01597170A0000 |113 115|Creo
P01597170A0000 |189 202|control groupnction of CSF
P01597170A0000 |92 94|Crac
P01597170A0000 |95 98|NO3log
P01597170A0000 |56 61|CoCl2 5-nu
P01597170A0000 |151 159|group Co0472 Whe
P01597170A0000 |42 51|mg/m3 Co2osphatase
P01597170A0000 |78 87|mg/m3 Cr3171T0000 
P01597170A0000 |221 230|days/week-depleted
P01597170A0000 |139 148|mg/m3 Co2. P000089
P01597170A0000 |6 13|rabbits606T007
P01597170A0000 |238 244|hr/daye no l
P01597272A0077 |48 67|withdrawal symptomsases and 5-nucleoti
P01597272A0077 |27 36|methadoneith alkal
P01597272A0077 |3 8|women00160
P01597462A0457 |51 55|genes an
P01597462A0457 |29 34|CDC14h alk
P01597462A0457 |0 10|DisruptionP00001606T
P01600531A0483 |65 66|%t
P01600531A0483 |31 32|%a
P01600531A0483 |40 55|phosphocreatinephosphatases an
P01600531A0483 |74 87|control group0008171T0000 
P01600531A0483 |9 13|flowT007
P01601181A0842 |98 106|mesodermic aspec
P01601181A0842 |24 31|proteinn with 
P01601181A0842 |124 133|germ banderbilirub
P01601181A0842 |67 79|gastrulationdase P000081
P01601181A0842 |58 63|onset-nucl
P01601181A0842 |4 19|60A transcripts01606T0076 Comp
P01601869A1389 |70 75|E-boxe P00
P01601869A1389 |9 16|segmentT0076 C
P01601869A1389 |124 130|regionerbili
P01601869A1389 |36 42|regionine ph
P01601869A1389 |202 217|BC3H1 myoblasts PCO2 the data 
P01601869A1389 |174 184|activations shown as
P01603088A1121 |50 52|TRes
P01603088A1121 |78 88|activation171T0000 P
P01603088A1121 |127 133|mannerilirub
P01603088A1121 |93 103|repressioncologic as
P01603088A1121 |6 13|results606T007
P01605038T0001 |0 9|InfluenceP00001606
P01605038T0001 |61 65|GABAcleo
P01605038T0001 |50 57|effectses and 
P01605038T0001 |20 30|regulationrison with
P01605038T0001 |69 73|ratsse P
P01607223A0000 |170 179|liposomes-] is sho
P01607223A0000 |52 69|release technique and 5-nucleotida
P01607223A0000 |7 21|investigations06T0076 Compar
P01607223A0000 |90 101|laser lightrmacologic 
P01607223A0000 |81 86|pulseT0000
P01607223A0000 |114 121|releaseonatal 
P01607223A0000 |207 218|vasculature the data o
P01608239T0001 |16 24|barriersompariso
P01611699A0000 |6 28|pyridoxine derivatives606T0076 Comparison wi
P01611699A0000 |63 72|stem barkeotidase 
P01611699A0000 |76 103|Albizzia julibrissin DURAZZ08171T0000 Pharmacologic as
P01612085A0624 |153 159|U.ml-172 Whe
P01612085A0624 |75 81|U.ml-1008171
P01612085A0624 |130 146|distance runnersrubinemia. P0000
P01612085A0624 |26 29|EPOwit
P01612085A0624 |31 45|concentrationsalkaline phosp
P01612085A0624 |161 162|PC
P01612085A0624 |57 68|triathletes5-nucleotid
P01612085A0624 |4 24|serum erythropoietin01606T0076 Compariso
P01613640A0158 |4 21|coating materials01606T0076 Compar
P01613640A0158 |95 99|Brijlogi
P01613640A0158 |27 37|poloxamineith alkali
P01613640A0158 |59 69|poloxaminenucleotida
P01613640A0158 |43 53|poloxaminesphatases 
P01613640A0158 |76 85|poloxamer08171T000
P01615049A0000 |4 10|eating01606T
P01615049A0000 |94 99|cycleologi
P01615049A0000 |15 32|drinking patternsComparison with a
P01615049A0000 |76 88|h light/12 h08171T0000 P
P01615049A0000 |42 47|goatsospha
P01615049A0000 |52 58|ad lib and 5
P01615182A0206 |119 121|mgl 
P01615182A0206 |182 187|amoxyas a 
P01615182A0206 |89 107|combination tabletarmacologic aspect
P01615182A0206 |12 17|study76 Co
P01615182A0206 |192 194|mgio
P01615182A0206 |75 81|levels008171
P01615182A0206 |141 143|mgP0
P01615182A0206 |127 138|bromhexeineilirubinemi
P01615182A0206 |109 114|amoxyof ne
P01615182A0206 |48 66|sputum amoxycillinases and 5-nucleot
P01615182A0206 |33 44|improvementkaline phos
P01615182A0206 |68 73|amoxyase P
P01615493A0408 |4 6|HC01
P01615493A0408 |78 86|daughter171T0000
P01615493A0408 |10 18|activity0076 Com
P01615493A0408 |45 46|%h
P01615493A0408 |23 37|antigen levelson with alkali
P01615493A0408 |111 117|levels neona
P01615493A0408 |53 54|%a
P01615493A0975 |0 10|ArgatrobanP00001606T
P01615493A0975 |82 92|inhibition0000 Pharm
P01615493A0975 |43 45|HCsp
P01615493A0975 |135 146|wall damageemia. P0000
P01615493A0975 |49 59|conditionsses and 5-
P01615493A0975 |96 113|thrombin activityogic aspects of n
P01615493A0975 |117 122|sitestal h
P01616475A0756 |102 116|family historyspects of neon
P01616475A0756 |177 204|panic disorder presentationhown as a function of CSF P
P01616475A0756 |120 134|panic disorder hyperbilirubi
P01616475A0756 |37 45|validityne phosp
P01616475A0756 |146 154|patients8997A047
P01616475A0756 |57 72|CP/NCA patients5-nucleotidase 
P01616475A0756 |49 53|NFPDses 
P01616475A0756 |6 13|results606T007
P01616475A0756 |87 95|patientsPharmaco
P01617242T0000 |0 15|FDA regulationsP00001606T0076 
P01617242T0000 |47 55|productstases an
P01617242T0000 |20 34|growth factorsrison with alk
P01617776A0343 |205 211|systemO2 the
P01617776A0343 |57 68|arrhythmias5-nucleotid
P01617776A0343 |245 249|daysnger
P01617776A0343 |215 222|reentrya of K-
P01617776A0343 |31 37|systemalkali
P01617776A0343 |173 177|roleis s
P01617776A0343 |127 138|innervationilirubinemi
P01617776A0343 |146 151|heart8997A
P01617776A0343 |256 266|infarctionced when c
P01617776A0343 |237 242|heartre no
P01617776A0343 |84 94|infarction00 Pharmac
P01617801A0088 |0 6|DESIGNP00001
P01617801A0088 |8 25|Serum aldosterone6T0076 Comparison
P01617801A0088 |131 133|mgub
P01617801A0088 |30 51|plasma renin activity alkaline phosphatase
P01617801A0088 |98 105|minutesic aspe
P01617801A0088 |66 72|supineidase 
P01617801A0088 |117 126|captopriltal hyper
P01618027A1108 |16 27|transcriptsomparison w
P01618027A1108 |40 44|sizephos
P01618027A1108 |79 86|profile71T0000
P01618027A1108 |123 135|E10 fragmentperbilirubin
P01618027A1108 |175 184|remainder shown as
P01618027A1108 |199 205|regionCSF PC
P01618027A1108 |155 161|probes When 
P01618243T0000 |43 53|volunteerssphatases 
P01618243T0000 |12 31|amine pressor tests76 Comparison with 
P01618256A0521 |138 152|micrograms.l-1a. P00008997A0
P01618256A0521 |93 94|%c
P01618256A0521 |59 66|regimennucleot
P01618256A0521 |30 43|concentration alkaline pho
P01618256A0521 |4 8|mean0160
P01618256A0521 |127 133|regimeilirub
P01618256A0521 |71 85|micrograms.l-1 P00008171T000
P01619114A0383 |83 104|Mini Speech Processor000 Pharmacologic asp
P01619114A0383 |14 19|study Comp
P01619114A0383 |24 35|performancen with alka
P01619114A0383 |106 109|MSPts 
P01619114A0383 |43 47|SMSPspha
P01619642A0131 |5 12|parents1606T00
P01620118A0470 |205 212|chickenO2 the 
P01620118A0470 |13 21|proteins6 Compar
P01620118A0470 |101 111|activationaspects of
P01620118A0470 |162 168|repeatSF [HC
P01620118A0470 |125 147|immunodeficiency virusrbilirubinemia. P00008
P01620118A0470 |35 42|abilityline ph
P01620118A0470 |222 227|cellsdeple
P01620118A0470 |68 73|kappaase P
P01620129A0417 |169 171|J.3-
P01620129A0417 |123 133|cell cycleperbilirub
P01620129A0417 |106 119|H4-FO108 genets of neonata
P01620129A0417 |45 58|factor HiNF-Dhatases and 5
P01620129A0417 |22 33|interactionson with al
P01620129A0417 |162 167|cellsSF [H
P01620129A0417 |82 98|promoter element0000 Pharmacolog
P01620610A1070 |185 194|sequencesa functio
P01620610A1070 |120 126|vector hyper
P01620610A1070 |53 72|expression problemsand 5-nucleotidase 
P01620610A1070 |37 39|TIne
P01620610A1070 |149 158|mutations7A0472 Wh
P01620610A1070 |201 205|ruleF PC
P01620610A1070 |217 230|MTI subregionof K-depleted
P01620610A1070 |3 13|conclusion001606T007
P01620781A0611 |170 177|stimuli-] is s
P01620781A0611 |19 27|subjectsarison w
P01620781A0611 |49 58|sequencesses and 5
P01620781A0611 |117 119|A3ta
P01620781A0611 |253 258|classplace
P01620781A0611 |219 227|sequence K-deple
P01620781A0611 |92 97|wordsacolo
P01620781A0611 |123 125|B4pe
P01620781A0611 |129 131|A5ir
P01620781A0611 |77 84|control8171T00
P01620781A0611 |111 113|B2 n
P01620781A0611 |105 107|A1ct
P01620781A0611 |233 240|membersts are 
P01620781A0611 |202 210|position PCO2 th
P01620781A0611 |140 148|reversal P000089
P01621584A0183 |0 6|UF-021P00001
P01621584A0183 |82 89|rabbits0000 Ph
P01621584A0183 |40 41|%p
P01621584A0183 |74 78|eyes0008
P01621584A0183 |164 172|IOP rise [HCO3-]
P01621584A0183 |18 26|solutionparison 
P01621584A0183 |113 126|IOP reductioneonatal hyper
P01621584A0183 |139 143|mmHg. P0
P01623900A0670 |102 111|excretionspects of
P01623900A0670 |224 239|blood pressurespleted rats are
P01623900A0670 |115 129|norepinephrinenatal hyperbil
P01623900A0670 |158 166|Pl groupen CSF [
P01623900A0670 |182 186|dropas a
P01623900A0670 |361 366|month733 F
P01623900A0670 |61 68|changescleotid
P01623900A0670 |370 387|dF administrationzepam thus appear
P01623900A0670 |310 334|norepinephrine excretioncantly greater slope (1.
P01623900A0670 |76 89|plasma levels08171T0000 Ph
P01623900A0670 |194 200|supinen of C
P01623900A0670 |39 47|activity phospha
P01623900A0670 |6 20|blood pressure606T0076 Compa
P01623900A0670 |274 294|norepinephrine levelto controls but stil
P01624425A0907 |78 99|consensus amino acids171T0000 Pharmacologi
P01624425A0907 |120 129|azido-ATP hyperbil
P01624425A0907 |10 17|protein0076 Co
P01624425A0907 |44 51|mutantsphatase
P01624425A0907 |57 70|substitutions5-nucleotidas
P01625131A0452 |34 44|stoma sitealine phos
P01625131A0452 |78 87|rejection171T0000 
P01625131A0452 |56 60|risk 5-n
P01625131A0452 |18 24|biopsypariso
P01625527A0000 |201 226|maintenance haemodialysisF PCO2 the data of K-depl
P01625527A0000 |52 65|control group and 5-nucleo
P01625527A0000 |145 162|treatment regimen08997A0472 When C
P01625527A0000 |125 126|nr
P01625527A0000 |181 190|treatment as a fun
P01625527A0000 |269 270|na
P01625527A0000 |107 123|failure patientss of neonatal hy
P01625527A0000 |192 193|ni
P01625527A0000 |84 89|group00 Ph
P01625527A0000 |252 267|transplantationsplaced when co
P01625527A0000 |67 68|nd
P01625527A0000 |228 229|ne
P01625527A0000 |6 28|blood serotonin levels606T0076 Comparison wi
P01626372T0000 |0 7|TissuesP000016
P01626372T0000 |123 152|trimethoprim-sulfamethoxazoleperbilirubinemia. P00008997A0
P01626372T0000 |12 20|exudates76 Compa
P01626372T0000 |74 82|bacteria0008171T
P01626372T0000 |90 98|presencermacolog
P01626372T0000 |113 119|levelseonata
P01626372T0000 |40 49|thymidinephosphata
P01626372T0000 |54 60|growthnd 5-n
P01626430A1112 |102 107|yeastspect
P01626430A1112 |40 44|SNF2phos
P01626430A1112 |30 35|RAD54 alka
P01626430A1112 |23 28|RAD16on wi
P01626430A1112 |112 128|Drosophila genesneonatal hyperbi
P01626430A1112 |4 14|homologies01606T0076
P01626440A0449 |33 57|instrument disinfectantskaline phosphatases and 
P01626440A0449 |8 29|application solutions6T0076 Comparison wit
P01626440A0449 |93 96|daycol
P01626631A0557 |171 180|elevation] is show
P01626631A0557 |198 203|level CSF 
P01626631A0557 |74 84|brain stem0008171T00
P01626631A0557 |7 20|Rett syndrome06T0076 Compa
P01626631A0557 |144 150|system008997
P01626631A0557 |54 66|disturbancesnd 5-nucleot
P01627106A0320 |153 172|isolation frequency72 When CSF [HCO3-]
P01627106A0320 |123 134|differencesperbilirubi
P01627106A0320 |13 23|experiment6 Comparis
P01627106A0320 |71 95|S. enteritidis challenge P00008171T0000 Pharmaco
P01627106A0320 |38 66|nitrofurazone administratione phosphatases and 5-nucleot
P01627106A0320 |138 140|S.a.
P01627828A0475 |32 40|blottinglkaline 
P01627828A0475 |183 191|SmN genes a func
P01627828A0475 |122 132|pseudogeneyperbiliru
P01627828A0475 |44 53|mouse DNAphatases 
P01627828A0475 |59 69|SmN probesnucleotida
P01627828A0475 |78 83|bands171T0
P01627828A0475 |3 12|agreement001606T00
P01627830A0000 |100 104|CKI2 asp
P01627830A0000 |61 79|yeast cDNA librarycleotidase P000081
P01627830A0000 |4 9|cDNAs01606
P01627830A0000 |91 95|CKI1maco
P01627830A0000 |19 34|casein kinase-1arison with alk
P01628201A0824 |0 14|Incidence rateP00001606T0076
P01628201A0824 |108 116|datasets of neon
P01628201A0824 |64 68|yearotid
P01628201A0824 |43 47|yearspha
P01628201A0824 |81 88|minimumT0000 P
P01628806A1347 |119 134|helicase regionl hyperbilirubi
P01628806A1347 |13 31|sequence variation6 Comparison with 
P01628806A1347 |92 95|ORFaco
P01628806A1347 |63 64|Ye
P01628806A1347 |51 54|ORFs a
P01628904A0386 |51 59|kilobases and 5-
P01628904A0386 |30 35|clone alka
P01628904A0386 |10 19|screening0076 Comp
P01628904A0386 |61 63|kbcl
P01628904A0386 |65 71|inserttidase
P01629768A0131 |0 7|LesionsP000016
P01629768A0131 |105 123|glass micropipettects of neonatal hy
P01629768A0131 |64 67|SOCoti
P01629768A0131 |21 39|pressure injectionison with alkaline
P01629768A0131 |50 54|acides a
P01630454A0635 |54 63|regulatornd 5-nucl
P01630454A0635 |13 18|dA-dT6 Com
P01630454A0635 |67 89|Act1 promoter activitydase P00008171T0000 Ph
P01630454A0635 |8 12|poly6T00
P01630454A0635 |20 26|regionrison 
P01630455A0448 |16 23|proteinomparis
P01630455A0448 |192 207|IL-1 beta genesion of CSF PCO2
P01630455A0448 |47 56|NF beta Atases and
P01630455A0448 |98 110|DNA sequenceic aspects o
P01630455A0448 |148 162|TATA box motif97A0472 When C
P01630455A0448 |32 45|NFIL-1 beta Alkaline phosp
P01630569A0605 |35 44|remissionline phos
P01630569A0605 |25 28|AmB wi
P01630569A0605 |9 23|amphotericin BT0076 Comparis
P01630569A0605 |52 57|tumor and 
P01631229T0000 |0 13|Cutis aplasiaP00001606T007
P01633435A0743 |138 145|Gossetta. P000
P01633435A0743 |97 103|factorgic as
P01633435A0743 |123 131|Hauschkaperbilir
P01633435A0743 |105 110|MEF-2cts o
P01633435A0743 |30 45|characteristics alkaline phosp
P01633435A0743 |4 9|DRF-201606
P01633435A0743 |112 118|Buskinneonat
P01633435A0743 |18 25|proteinparison
P01633816A0667 |68 73|exonsase P
P01633816A0667 |15 20|cloneCompa
P01633816A0667 |82 84|kb00
P01633816A0667 |166 176|start siteHCO3-] is 
P01633816A0667 |28 42|EcoRI fragmentth alkaline ph
P01633816A0667 |104 110|regionects o
P01633816A0667 |118 126|opn geneal hyper
P01633816A0667 |191 216|primer extension analysistion of CSF PCO2 the data
P01633816A0667 |221 240|S1 nuclease mapping-depleted rats are 
P01634308A0191 |0 27|Cardiovascular risk factorsP00001606T0076 Comparison w
P01634308A0191 |58 68|techniques-nucleotid
P01634400A1101 |0 16|Production costsP00001606T0076 C
P01634400A1101 |26 30|feedwith
P01634400A1101 |63 86|replacement stock costseotidase P00008171T0000
P01634400A1101 |41 50|operatinghosphatas
P01634464A0163 |113 117|riseeona
P01634464A0163 |12 19|patient76 Comp
P01634464A0163 |31 51|factor VII inhibitoralkaline phosphatase
P01634464A0163 |127 138|haemorrhageilirubinemi
P01634464A0163 |78 103|penicillin administration171T0000 Pharmacologic as
P01634464A0163 |66 74|reactionidase P0
P01634861A1336 |103 120|lactate clearancepects of neonatal
P01634861A1336 |40 62|oxygen debt hypothesisphosphatases and 5-nuc
P01634861A1336 |11 19|contrast076 Comp
P01634861A1336 |87 98|oxygen debtPharmacolog
P01636339A0200 |0 7|AccountP000016
P01636339A0200 |116 129|pollen grainsatal hyperbil
P01636339A0200 |106 114|crystalsts of ne
P01636339A0200 |46 54|elementsatases a
P01636339A0200 |62 68|smearsleotid
P01636339A0200 |84 89|mucus00 Ph
P01636339A0200 |139 148|fragments. P000089
P01636339A0200 |153 158|fungi72 Wh
P01636714A0845 |169 172|CLP3-]
P01636714A0845 |46 51|areasatase
P01636714A0845 |88 94|spleenharmac
P01636714A0845 |67 72|liverdase 
P01636714A0845 |161 162|hC
P01636714A0845 |130 133|MBFrub
P01636714A0845 |56 59|MBF 5-
P01636714A0845 |4 11|results01606T0
P01636714A0845 |80 86|cortex1T0000
P01636714A0845 |117 123|serosatal hy
P01637758A0532 |3 11|addition001606T0
P01637758A0532 |127 138|examinationilirubinemi
P01637758A0532 |58 63|group-nucl
P01637758A0532 |95 97|cmlo
P01637758A0532 |146 157|labour ward8997A0472 W
P01637758A0532 |182 183|%a
P01637758A0532 |79 89|dilatation71T0000 Ph
P01637758A0532 |186 188|OR f
P01637758A0532 |217 218|Po
P01637758A0532 |22 32|proportionson with a
P01637758A0532 |36 41|womenine p
P01637758A0532 |197 201|% CIf CS
P01637758A0532 |168 169|%O
P01639092A0776 |0 5|LewisP0000
P01639092A0776 |7 9|N.06
P01639724A0452 |2 15|control group0001606T0076 
P01639724A0452 |72 83|Nordette-28P00008171T0
P01639724A0452 |122 132|pill cycleyperbiliru
P01639724A0452 |107 112|timess of 
P01639724A0452 |31 34|agealk
P01639724A0452 |56 70|contraceptives 5-nucleotidas
P01639724A0452 |41 46|yearshosph
P01639724A0452 |24 29|womenn wit
P01640778A0485 |24 30|methodn with
P01640778A0485 |89 98|screeningarmacolog
P01640778A0485 |41 50|MLPA testhosphatas
P01641628A0869 |81 87|groupsT0000 
P01641628A0869 |57 65|subjects5-nucleo
P01641628A0869 |130 138|researchrubinemi
P01641628A0869 |120 126|points hyper
P01641628A0869 |188 204|reference valuesunction of CSF P
P01641628A0869 |25 41|reference values with alkaline p
P01641628A0869 |4 14|modalities01606T0076
P01642060A0471 |84 92|patients00 Pharm
P01642060A0471 |13 24|application6 Compariso
P01642060A0471 |139 147|FIGO III. P00008
P01642060A0471 |128 137|carcinomalirubinem
P01642060A0471 |50 64|Phthalocyaninees and 5-nucle
P01643943A0300 |66 69|TFRida
P01643943A0300 |14 33|lung cancer tissues Comparison with al
P01643943A0300 |46 50|67Gaatas
P01644751A0590 |117 134|msgB gene producttal hyperbilirubi
P01644751A0590 |79 96|sequence analysis71T0000 Pharmacol
P01644751A0590 |10 23|reading frame0076 Comparis
P01644796A0374 |8 13|study6T007
P01644796A0374 |104 109|cellsects 
P01644796A0374 |61 66|furincleot
P01644796A0374 |88 94|mediumharmac
P01644814A0068 |86 93|T cells Pharma
P01644814A0068 |27 34|proteinith alk
P01644814A0068 |36 39|taxine
P01644814A0068 |67 82|immortalizationdase P00008171T
P01644814A0068 |4 9|virus01606
P01644821A1259 |258 275|butyrate responsed when compared t
P01644821A1259 |173 182|sequencesis shown 
P01644821A1259 |9 17|butyrateT0076 Co
P01644821A1259 |229 240|PSG1-I gened rats are 
P01644821A1259 |214 221|regionsta of K
P01644821A1259 |84 96|fusion genes00 Pharmacol
P01644821A1259 |117 126|sequencestal hyper
P01644821A1259 |68 80|CAT activityase P0000817
P01644831A0824 |34 51|carboxyl terminusaline phosphatase
P01644831A0824 |229 237|activityd rats a
P01644831A0824 |146 155|receptors8997A0472
P01644831A0824 |89 97|activityarmacolo
P01644831A0824 |173 181|portionsis shown
P01644831A0824 |66 72|NGFI-Bidase 
P01644831A0824 |189 206|carboxyl terminusnction of CSF PCO
P01644831A0824 |22 26|roleson 
P01644831A0824 |3 14|examination001606T0076
P01644831A0824 |157 164|mutantshen CSF
P01644831A0824 |116 126|accordanceatal hyper
P01645902A1462 |136 138|TKmi
P01645902A1462 |17 24|resultsmpariso
P01645902A1462 |49 54|locusses a
P01645902A1462 |216 224|activity of K-de
P01645902A1462 |149 154|genes7A047
P01645902A1462 |91 93|gHma
P01645902A1462 |120 128|portions hyperbi
P01645902A1462 |202 212|expression PCO2 the 
P01645902A1462 |43 46|Synsph
P01645902A1462 |228 230|TKed
P01645902A1462 |75 79|gene0081
P01645902A1462 |169 181|syn mutation3-] is shown
P01645902A1462 |143 145|UL00
P01645902A1462 |100 106|region aspec
P01645905A0341 |0 13|NucleoproteinP00001606T007
P01645905A0341 |15 16|NC
P01645905A0341 |188 206|breakdown productsunction of CSF PCO
P01645905A0341 |159 169|C-terminusn CSF [HCO
P01645905A0341 |97 101|massgic 
P01645905A0341 |67 71|TGEVdase
P01645905A0341 |48 62|vaccinia virusases and 5-nuc
P01645905A0341 |140 151|degradation P00008997A
P01645905A0341 |103 105|Mrpe
P01646157A0414 |102 112|nucleotidespects of 
P01646157A0414 |229 233|cDNAd ra
P01646157A0414 |161 162|%C
P01646157A0414 |193 214|alpha-galactosidase Aon of CSF PCO2 the da
P01646157A0414 |216 227|alpha-Gal A of K-deple
P01646157A0414 |127 146|amino acid homologyilirubinemia. P0000
P01646157A0414 |33 59|alpha-GalNAc cDNA sequencekaline phosphatases and 5-
P01646487A0874 |0 8|PatientsP0000160
P01646487A0874 |87 90|IgAPha
P01646487A0874 |217 225|activityof K-dep
P01646487A0874 |92 95|IgGaco
P01646487A0874 |27 35|activityith alka
P01646487A0874 |180 188|patientsn as a f
P01646487A0874 |60 68|decreaseucleotid
P01646487A0874 |42 43|Xo
P01646487A0874 |76 83|content08171T0
P01646487A0874 |108 121|B lymphocytes of neonatal 
P01646487A0874 |153 164|neutrophils72 When CSF
P01646487A0874 |141 149|activityP0000899
P01646487A0874 |97 100|IgMgic
P01646487A0874 |102 103|Ts
P01646753A0336 |4 10|reason01606T
P01646753A0336 |47 64|hydroxyl radicalstases and 5-nucle
P01646753A0336 |104 122|reduction proceedsects of neonatal h
P01646753A0336 |194 196|EOn 
P01646753A0336 |134 137|N2Onem
P01646753A0336 |215 217|V.a 
P01646753A0336 |198 205|N2O/N2O CSF PC
P01646753A0336 |24 29|oxiden wit
P01647070A0232 |35 38|JCVlin
P01647070A0232 |43 55|SV40 originssphatases an
P01647070A0232 |11 25|JCV T antigens076 Comparison
P01647070A0232 |59 74|DNA replicationnucleotidase P0
P01647656A0000 |207 220|regurgitation the data of 
P01647656A0000 |159 177|LV volume overloadn CSF [HCO3-] is s
P01647656A0000 |110 118|patientsf neonat
P01647656A0000 |79 81|LV71
P01647656A0000 |134 139|yearsnemia
P01647656A0000 |4 12|relation01606T00
P01647656A0000 |83 91|function000 Phar
P01647656A0000 |48 56|receptorases and
P01647813A0512 |49 56|proteinses and
P01647813A0512 |63 73|complexityeotidase P
P01647813A0512 |90 94|needrmac
P01647813A0512 |145 152|control08997A0
P01647813A0512 |11 21|transcript076 Compar
P01647813A0512 |156 166|expressionWhen CSF [
P01648142A1170 |170 171|P-
P01648142A1170 |104 112|survivalects of 
P01648142A1170 |120 127|CAV arm hyperb
P01648142A1170 |129 130|Pi
P01648142A1170 |25 32|disease with a
P01648142A1170 |162 168|PE armSF [HC
P01648142A1170 |146 154|survival8997A047
P01648142A1170 |38 46|survivale phosph
P01648142A1170 |66 69|armida
P01648142A1170 |3 11|patients001606T0
P01648530A0000 |17 25|M regionmparison
P01648530A0000 |159 190|actin-beta-globin reporter genen CSF [HCO3-] is shown as a fun
P01648530A0000 |135 145|expressionemia. P000
P01648530A0000 |216 220|eggs of 
P01648530A0000 |66 85|actin gene promoteridase P00008171T000
P01648530A0000 |50 57|Xenopuses and 
P01649173A0160 |84 95|nucleotides00 Pharmaco
P01649173A0160 |127 151|transcription start siteilirubinemia. P00008997A
P01649173A0160 |59 69|attenuatornucleotida
P01649173A0160 |162 172|attenuatorSF [HCO3-]
P01649173A0160 |200 211|nucleotidesSF PCO2 the
P01649173A0160 |174 184|attenuators shown as
P01649173A0160 |3 11|addition001606T0
P01649318A0734 |0 6|EBNA-2P00001
P01649318A0734 |88 145|herpes simplex virus TK promoter transcription start siteharmacologic aspects of neonatal hyperbilirubinemia. P000
P01649318A0734 |61 65|mRNAcleo
P01649318A0734 |26 38|CD23 elementwith alkalin
P01649318A1222 |6 17|experiments606T0076 Co
P01649318A1222 |91 99|evidencemacologi
P01649318A1222 |105 111|EBNA-2cts of
P01649318A1222 |127 140|transcriptionilirubinemia.
P01649318A1222 |56 73|cell DNA fragment 5-nucleotidase P
P01649318A1222 |144 154|cell genes008997A047
P01649539T0000 |0 16|Plasma vitamin EP00001606T0076 C
P01649539T0000 |24 30|lipidsn with
P01649539T0000 |72 79|surgeryP000081
P01649539T0000 |35 57|myeloperoxidase levelsline phosphatases and 
P01649835A0822 |171 179|affinity] is sho
P01649835A0822 |126 128|3Hbi
P01649835A0822 |31 43|PBR/IBP cDNAalkaline pho
P01649835A0822 |49 60|COS-7 cellsses and 5-n
P01649835A0822 |138 151|binding sitesa. P00008997A
P01649835A0822 |116 124|affinityatal hyp
P01649835A0822 |129 131|PKir
P01649835A0822 |184 192|Ro5-4864 a funct
P01649835A0822 |100 107|density aspect
P01649835A0822 |84 92|increase00 Pharm
P01650524A0837 |171 177|A63162] is s
P01650524A0837 |40 52|permeabilityphosphatases
P01650524A0837 |12 17|phase76 Co
P01650524A0837 |183 186|ICIs a
P01650524A0837 |206 219|dexamethasone2 the data of
P01650524A0837 |71 77|cavity P0000
P01650524A0837 |82 97|LTB4 production0000 Pharmacolo
P01650524A0837 |163 169|BW A4CF [HCO
P01650524A0837 |136 161|5-LO inhibitors phenidonemia. P00008997A0472 When 
P01650524A0837 |223 233|colchicineepleted ra
P01650524A0837 |102 106|dosespec
P01650557T0000 |115 132|transplant donorsnatal hyperbiliru
P01650557T0000 |72 103|cytomegalovirus antibody statusP00008171T0000 Pharmacologic as
P01650557T0000 |26 50|latex agglutination testwith alkaline phosphatas
P01650557T0000 |11 18|results076 Com
P01650557T0000 |58 68|assessment-nucleotid
P01651232A0152 |101 104|UTPasp
P01651232A0152 |90 97|mixturermacolo
P01651232A0152 |109 117|thio-UTPof neona
P01651232A0152 |41 57|uridine residueshosphatases and 
P01651232A0152 |5 9|mRNA1606
P01651918A0000 |171 185|bisphosphatase] is shown as 
P01651918A0000 |47 61|cDNA fragmentstases and 5-nu
P01651918A0000 |151 157|kinase0472 W
P01651918A0000 |158 168|fructose-2en CSF [HC
P01651918A0000 |94 113|amino acid sequenceologic aspects of n
P01651918A0000 |117 148|rat testis fructose-6-phosphatetal hyperbilirubinemia. P000089
P01652372A0153 |34 53|localization signalaline phosphatases 
P01652372A0153 |55 58|NLSd 5
P01652372A0153 |88 92|cellharm
P01652372A0153 |19 23|SWI5aris
P01652372A0153 |141 148|proteinP000089
P01652372A0153 |117 122|entrytal h
P01652515A0379 |136 138|DAmi
P01652515A0379 |26 35|deviationwith alka
P01652515A0379 |148 153|level97A04
P01652515A0379 |165 176|neostriatum[HCO3-] is 
P01652515A0379 |75 86|haloperidol008171T0000
P01652515A0379 |3 11|contrast001606T0
P01652515A0379 |41 63|avoidance conditioninghosphatases and 5-nucl
P01652515A0379 |101 116|microinjectionsaspects of neon
P01652755A1492 |343 352|promoters23 vs. P0
P01652755A1492 |199 204|c-fosCSF P
P01652755A1492 |285 289|IL-6 but
P01652755A1492 |61 75|overexpressioncleotidase P00
P01652755A1492 |224 234|beta-actinpleted rat
P01652755A1492 |21 45|transfection experimentsison with alkaline phosp
P01652755A1492 |251 260|promotersisplaced 
P01652755A1492 |179 183|IL-6wn a
P01652755A1492 |92 134|retinoblastoma susceptibility gene productacologic aspects of neonatal hyperbilirubi
P01652755A1492 |49 59|HeLa cellsses and 5-
P01652755A1492 |325 328|MHCslo
P01652755A1492 |136 138|RBmi
P01653173A0619 |255 276|preinitiation complexaced when compared to
P01653173A0619 |37 44|bindingne phos
P01653173A0619 |149 162|preincubation7A0472 When C
P01653173A0619 |217 224|extractof K-de
P01653173A0619 |5 15|repression1606T0076 
P01653173A0619 |67 71|sitedase
P01653173A0619 |52 54|E2 a
P01653173A0619 |170 199|HPV-18 P105 promoter template-] is shown as a function of 
P01653173A0619 |100 122|P105 promoter TATA box aspects of neonatal h
P01653173A0619 |238 247|formatione no long
P01653236A0895 |49 72|glucocorticoid receptorses and 5-nucleotidase 
P01653236A0895 |25 36|association with alkal
P01653236A0895 |145 164|hamster ovary cells08997A0472 When CSF
P01653236A0895 |110 133|glucocorticoid receptorf neonatal hyperbilirub
P01653236A0895 |76 83|L cells08171T0
P01653236A0895 |18 21|p50par
P01653238A1062 |258 273|promoter regiond when compared
P01653238A1062 |150 168|consensus sequenceA0472 When CSF [HC
P01653238A1062 |104 109|sitesects 
P01653238A1062 |52 55|TPA an
P01653238A1062 |57 74|response elements5-nucleotidase P0
P01653238A1062 |209 217|TGF-betahe data 
P01653238A1062 |13 50|12-O-tetradecanoyl-phorbol-13-acetate6 Comparison with alkaline phosphatas
P01653238A1062 |118 143|transcription factor AP-1al hyperbilirubinemia. P0
P01653238A1062 |232 239|elementats are
P01653238A1062 |187 205|growth factor betafunction of CSF PC
P01653238A1715 |0 3|TPAP00
P01653238A1715 |72 78|enzymeP00008
P01653238A1715 |47 57|activitiestases and 
P01653238A1715 |8 16|TGF-beta6T0076 C
P01653918A0286 |84 91|corneas00 Phar
P01653918A0286 |127 149|corneal pain thresholdilirubinemia. P0000899
P01653918A0286 |66 72|corneaidase 
P01653918A0286 |97 105|strengthgic aspe
P01653918A0286 |38 46|pressuree phosph
P01654349A0327 |119 120|Kl
P01654349A0327 |89 93|gainarma
P01654349A0327 |47 69|NaHCO3 supplementationtases and 5-nucleotida
P01654349A0327 |157 163|NaHCO3hen CS
P01654349A0327 |40 43|KClpho
P01654349A0327 |0 11|Feed intakeP00001606T0
P01655126T0000 |0 20|Extraction procedureP00001606T0076 Compa
P01655126T0000 |29 40|measurementh alkaline 
P01655126T0000 |91 98|toluenemacolog
P01655126T0000 |44 62|butyltin compoundsphatases and 5-nuc
P01655126T0000 |77 84|tissues8171T00
P01655126T0000 |109 118|tropoloneof neonat
P01655126T0000 |100 103|HBr as
P01655713A0294 |32 38|regionlkalin
P01655713A0294 |131 134|Tn1ubi
P01655713A0294 |95 101|strainlogic 
P01655713A0294 |147 155|mutation997A0472
P01655713A0294 |106 110|exs1ts o
P01655713A0294 |82 91|phenotype0000 Phar
P01655713A0294 |8 13|study6T007
P01655713A0294 |112 115|Tn1neo
P01656220T0000 |0 3|axlP00
P01656220T0000 |93 117|receptor tyrosine kinasecologic aspects of neona
P01656220T0000 |61 75|leukemia cellscleotidase P00
P01656220T0000 |20 24|generiso
P01656221A1319 |119 136|tyrosine residuesl hyperbilirubine
P01656221A1319 |77 84|regions8171T00
P01656221A1319 |94 99|FGFRsologi
P01656221A1319 |165 176|FGFR family[HCO3-] is 
P01656221A1319 |150 157|membersA0472 W
P01656221A1319 |0 9|AlignmentP00001606
P01656221A1319 |50 57|Tyr-766es and 
P01656221A1319 |17 37|amino acid sequencesmparison with alkali
P01656235A0946 |98 109|CCAAT motific aspects 
P01656235A0946 |26 33|elementwith al
P01656235A0946 |75 81|region008171
P01656235A0946 |54 62|analysisnd 5-nuc
P01656675A0236 |0 18|Capnography curvesP00001606T0076 Com
P01656675A0236 |105 113|controlscts of n
P01656675A0236 |25 37|HVS patients with alkali
P01656675A0236 |79 89|complaints71T0000 Ph
P01656675A0236 |50 58|patientses and 5
P01657246A0325 |4 33|transcription initiation site01606T0076 Comparison with al
P01657246A0325 |61 63|bpcl
P01657246A0325 |91 94|Metmac
P01657249A1019 |139 157|region determinant. P00008997A0472 W
P01657249A1019 |57 63|chains5-nucl
P01657249A1019 |166 174|VH4-HV2aHCO3-] i
P01657249A1019 |47 50|VH4tas
P01657249A1019 |22 24|CAso
P01657249A1019 |78 80|CA17
P01657249A1019 |114 117|VH4ona
P01657415A0837 |0 16|Intron K1 cox1.2P00001606T0076 C
P01657415A0837 |72 80|locationP0000817
P01657415A0837 |84 93|K. lactis00 Pharma
P01657594A0472 |82 86|cgs10000
P01657594A0472 |47 69|complementation groupstases and 5-nucleotida
P01657594A0472 |28 35|mutantsth alka
P01657594A0472 |92 96|cgs2acol
P01657969A1420 |154 160|enzyme2 When
P01657969A1420 |88 112|amino acid substitutionsharmacologic aspects of 
P01657969A1420 |181 199|calmodulin binding as a function of 
P01657969A1420 |54 66|interactionsnd 5-nucleot
P01657969A1420 |9 20|alterationsT0076 Compa
P01657969A1420 |140 146|change P0000
P01658356A1369 |102 108|FeLV-Cspects
P01658356A1369 |65 75|generationtidase P00
P01658356A1369 |23 35|coexpressionon with alka
P01658356A1369 |79 96|FeLV recombinants71T0000 Pharmacol
P01658356A1369 |225 230|mRNAsleted
P01658356A1369 |190 196|levelsction 
P01658356A1369 |4 11|results01606T0
P01658356A1369 |139 154|3201B cell line. P00008997A047
P01658356T0000 |137 144|virusesia. P00
P01658356T0000 |29 54|leukemia virus subgroup Bh alkaline phosphatases a
P01658356T0000 |75 87|env elements008171T0000 
P01658356T0000 |0 13|RecombinationP00001606T007
P01658356T0000 |58 59|C-
P01658356T0000 |119 129|activitiesl hyperbil
P01658375A0854 |139 144|genes. P00
P01658375A0854 |167 177|differenceCO3-] is s
P01658375A0854 |192 195|endion
P01658375A0854 |203 213|LAT intronPCO2 the d
P01658375A0854 |42 46|endsosph
P01658375A0854 |94 105|transcriptsologic aspe
P01658375A0854 |56 63|introns 5-nucl
P01658375A0854 |4 24|nucleotide sequences01606T0076 Compariso
P01658375A0854 |217 219|GCof
P01658375A0854 |235 256|consensus sequence GT are no longer displa
P01658468A0123 |84 92|hamsters00 Pharm
P01658468A0123 |36 45|isolationine phosp
P01658468A0123 |178 183|sitesown a
P01658468A0123 |76 82|cavity08171T
P01658468A0123 |15 21|monthsCompar
P01658468A0123 |138 145|culturea. P000
P01658468A0123 |116 124|attemptsatal hyp
P01658468A0123 |49 61|C. kutscherises and 5-nu
P01658741A1047 |115 120|locusnatal
P01658741A1047 |44 53|kilobasesphatases 
P01658741A1047 |57 76|nucleotide sequence5-nucleotidase P000
P01658741A1047 |109 112|ADEof 
P01658741A1047 |4 12|strategy01606T00
P01659685T0000 |16 25|promotersomparison
P01659685T0000 |53 60|regionsand 5-n
P01659685T0000 |91 104|Dictyosteliummacologic asp
P01659685T0000 |70 87|Dd ras expressione P00008171T0000 
P01660486A1756 |238 253|gene expressione no longer dis
P01660486A1756 |224 234|activationpleted rat
P01660486A1756 |80 105|aminoglycoside resistance1T0000 Pharmacologic aspe
P01660486A1756 |58 73|gene cotransfer-nucleotidase P
P01660486A1756 |122 128|markeryperbi
P01660486A1756 |47 56|cell typetases and
P01660486A1756 |201 212|PKC pathwayF PCO2 the 
P01660486A1756 |4 11|results01606T0
P01660486A1756 |170 188|control mechanisms-] is shown as a f
P01660925T0000 |0 18|Transfer RNA genesP00001606T0076 Com
P01660925T0000 |91 99|elementsmacologi
P01660925T0000 |112 127|consensus boxesneonatal hyperb
P01660925T0000 |24 48|Dictyostelium discoideumn with alkaline phosphat
P01660925T0000 |156 163|regionsWhen CS
P01661369A0825 |137 145|moietiesia. P000
P01661369A0825 |60 66|probesucleot
P01661369A0825 |15 19|strDComp
P01661369A0825 |110 118|capacityf neonat
P01661369A0825 |24 34|strE genesn with alk
P01661369A0825 |85 93|presence0 Pharma
P01662609A0398 |86 93|R.HgiCI Pharma
P01662609A0398 |56 63|M.HgiCI 5-nucl
P01662609A0398 |73 84|amino acids00008171T00
P01662609A0398 |8 13|genes6T007
P01662609A0398 |43 54|amino acidssphatases a
P01662609A0398 |23 35|polypeptideson with alka
P01662794A0640 |0 10|ExpressionP00001606T
P01662794A0640 |57 68|COS-1 cells5-nucleotid
P01662794A0640 |41 53|transfectionhosphatases 
P01662794A0640 |83 94|kDa protein000 Pharmac
P01662794A0640 |172 180|antisera is show
P01662794A0640 |18 26|wt1 geneparison 
P01662807A1182 |4 10|factor01606T
P01662807A1182 |61 77|SV40 chromosomescleotidase P0000
P01662807A1182 |30 41|TR promoter alkaline p
P01662807A1182 |96 105|infectionogic aspe
P01662884A1029 |17 26|mg b.i.d.mparison 
P01662884A1029 |91 100|treatmentmacologic
P01662884A1029 |54 58|daysnd 5
P01662884A1029 |123 134|prostatitisperbilirubi
P01662884A1029 |0 12|TemafloxacinP00001606T00
P01664192A1577 |50 59|ED90 dosees and 5-
P01664192A1577 |63 73|vecuroniumeotidase P
P01664192A1577 |18 25|effectsparison
P01669611A0142 |118 126|diseasesal hyper
P01669611A0142 |72 77|aortaP0000
P01669611A0142 |29 34|feverh alk
P01669611A0142 |4 11|patient01606T0
P01669611A0142 |56 64|aneurysm 5-nucle
P01669611A0142 |86 101|pleuropneumonia Pharmacologic 
P01671675A0483 |84 91|pCAD14200 Phar
P01671675A0483 |147 164|sequence analysis997A0472 When CSF
P01671675A0483 |121 142|hybridization methodshyperbilirubinemia. P
P01671675A0483 |14 25|clone pKB11 Comparison
P01671675A0483 |99 101|bpc 
P01671675A0483 |219 228|amino end K-deplet
P01671675A0483 |197 210|cDNA sequencef CSF PCO2 th
P01671675A0483 |59 70|cDNA insertnucleotidas
P01671675A0483 |236 251|CAD polypeptideare no longer d
P01671675A0483 |55 57|bpd 
P01671675A0483 |49 53|pairses 
P01671675A0905 |33 59|Northern blotting analysiskaline phosphatases and 5-
P01671675A0905 |79 85|region71T000
P01671675A0905 |89 97|CAD genearmacolo
P01671675A0905 |5 15|conclusion1606T0076 
P01673220A0578 |80 91|bol3 allele1T0000 Phar
P01673220A0578 |76 78|Sn08
P01673220A0578 |14 23|isolation Comparis
P01673220A0578 |39 50|cDNA clones phosphatas
P01674177T0001 |0 20|Histamine-2 blockadeP00001606T0076 Compa
P01674177T0001 |24 33|psoriasisn with al
P01674242A0358 |68 69|%a
P01674242A0358 |419 430|ticlopidineug with the
P01674242A0358 |243 249|T-3262longer
P01674242A0358 |304 313|verapamilignifican
P01674242A0358 |505 515|interferon045 Beta b
P01674242A0358 |446 459|thiabendazoler use in gene
P01674242A0358 |97 109|erythromycingic aspects 
P01674242A0358 |432 444|idrocilamideptimum dose 
P01674242A0358 |111 125|troleandomycin neonatal hype
P01674242A0358 |315 324|diltiazemy greater
P01674242A0358 |521 529|caffeineg agents
P01674242A0358 |166 174|enoxacinHCO3-] i
P01674242A0358 |291 302|propranololtill have a
P01674242A0358 |488 503|BCG-vaccinationight. P00012653
P01674242A0358 |191 201|pefloxacintion of CS
P01674242A0358 |531 549|half-life increaseP00013683A0210 Whe
P01674242A0358 |127 148|triacetyloleandomycinilirubinemia. P000089
P01674242A0358 |176 189|ciprofloxacinshown as a fu
P01674242A0358 |326 336|nifedipinelope (1.21
P01674242A0358 |394 404|viloxazine an effect
P01674242A0358 |461 471|disulfiraml practice
P01674242A0358 |216 225|ofloxacin of K-dep
P01674242A0358 |261 265|acidhen 
P01674242A0358 |267 277|cimetidinempared to 
P01674242A0358 |386 392|agentsrs to 
P01674242A0358 |151 164|roxithromycin0472 When CSF
P01674242A0358 |203 214|norfloxacinPCO2 the da
P01674242A0358 |473 482|influenzaeing 15 m
P01674242A0358 |350 359|frusemideP00010943
P01674242A0358 |406 417|allopurinole hypnotic 
P01674242A0358 |279 289|etintidinentrols but
P01674242A0358 |338 348|furosemide/- 0.23 vs
P01674242A0358 |4 13|clearance01606T007
P01674369A0417 |64 80|restriction siteotidase P0000817
P01674369A0417 |90 97|cloningrmacolo
P01674369A0417 |21 28|elementison wi
P01674662A0000 |138 139|na
P01674662A0000 |257 264|factorsed when
P01674662A0000 |191 202|progressiontion of CSF
P01674662A0000 |82 83|n0
P01674662A0000 |219 226|complex K-depl
P01674662A0000 |121 136|lymphadenopathyhyperbilirubine
P01674662A0000 |228 231|ARCed 
P01674662A0000 |73 80|disease0000817
P01674662A0000 |164 169|study [HCO
P01674662A0000 |288 297|relevancet still h
P01674662A0000 |236 240|AIDSare 
P01674662A0000 |38 52|heroin addictse phosphatases
P01674662A0000 |206 210|AIDS2 th
P01674817A0862 |3 11|homology001606T0
P01674817A0862 |73 81|proteins00008171
P01674817A0862 |30 35|RNA14 alka
P01674817A0862 |57 62|RNA145-nuc
P01674817A0862 |40 45|RNA15phosp
P01674817A0862 |95 105|data bankslogic aspe
P01674817T0000 |17 28|yeast RNA14mparison wi
P01674817T0000 |33 44|RNA15 geneskaline phos
P01674817T0000 |67 82|mRNA decay ratedase P00008171T
P01674817T0000 |125 131|domainrbilir
P01674817T0000 |84 101|sequence analysis00 Pharmacologic 
P01674817T0000 |139 152|RNA15 protein. P00008997A0
P01674817T0000 |0 9|MutationsP00001606
P01675154T0000 |48 62|bypass surgeryases and 5-nuc
P01675154T0000 |11 21|infarction076 Compar
P01675154T0000 |25 33|patients with al
P01675424A0991 |48 61|H-NR sequenceases and 5-nu
P01675424A0991 |79 96|NADH-NR sequences71T0000 Pharmacol
P01675424A0991 |123 142|pyridine nucleotideperbilirubinemia. P
P01675424A0991 |46 47|Pa
P01675424A0991 |151 155|site0472
P01675424A0991 |65 75|comparisontidase P00
P01675424A0991 |42 45|NADosp
P01675424A0991 |18 28|differenceparison wi
P01675637T0033 |85 93|activity0 Pharma
P01675637T0033 |98 122|receptor dimer formationic aspects of neonatal h
P01675637T0033 |9 30|amino acid differenceT0076 Comparison with
P01675637T0033 |49 55|regionses an
P01675763A1389 |8 16|benefits6T0076 C
P01675763A1389 |45 48|CD4hat
P01675763A1389 |88 93|entryharma
P01675763A1389 |31 39|childrenalkaline
P01675763A1389 |79 84|liter71T00
P01678287A1308 |18 44|Antp TATAA binding proteinparison with alkaline phos
P01678287A1308 |120 133|homeobox gene hyperbilirub
P01678287A1308 |188 196|functionunction 
P01678287A1308 |92 97|cellsacolo
P01678287A1308 |218 223|cellsf K-d
P01678392A0648 |119 130|cmH2O l-1 sl hyperbili
P01678392A0648 |40 46|changephosph
P01678392A0648 |27 30|2SDith
P01678392A0648 |6 25|% confidence values606T0076 Comparison
P01678392A0648 |82 93|variability0000 Pharma
P01678392A0648 |50 53|Roses 
P01679068A0000 |184 194|Klebsiella a functio
P01679068A0000 |65 70|valuetidas
P01679068A0000 |10 17|infants0076 Co
P01679068A0000 |198 214|Enterobacter spp CSF PCO2 the da
P01679068A0000 |72 77|rangeP0000
P01679068A0000 |33 43|care unitskaline pho
P01679068A0000 |55 56|%d
P01679068A0000 |155 162|strains When C
P01679124A1368 |71 77|dorsal P0000
P01679124A1368 |113 120|animalseonatal
P01679124A1368 |178 196|dorsal hippocampusown as a function 
P01679124A1368 |242 247|WORDS long
P01679124A1368 |90 100|hippocampirmacologic
P01679124A1368 |151 165|norepinephrine0472 When CSF 
P01679124A1368 |12 19|studies76 Comp
P01679124A1368 |167 169|NECO
P01679124A1368 |50 63|ChAT activityes and 5-nucl
P01679124A1368 |216 224|ABSTRACT of K-de
P01679124A1368 |200 214|MS/HSI animalsSF PCO2 the da
P01679124A1368 |42 46|lossosph
P01679124A1368 |141 147|levelsP00008
P01679749A1171 |4 16|localization01606T0076 C
P01679749A1171 |72 84|availabilityP00008171T00
P01679749A1171 |110 115|toolsf neo
P01679749A1171 |25 43|proteoglycan locus with alkaline pho
P01679749A1171 |92 97|RFLPsacolo
P01679749A1171 |57 63|genome5-nucl
P01679749A1171 |144 152|diseases008997A0
P01679749A1171 |127 134|studiesilirubi
P01679749A1171 |163 186|HSPG2 proteoglycan geneF [HCO3-] is shown as a
P01681075A0429 |119 132|determinationl hyperbiliru
P01681075A0429 |183 206|carbohydrate metabolisms a function of CSF PCO
P01681075A0429 |15 35|dobutamine injectionComparison with alka
P01681075A0429 |172 178|energy is sh
P01681075A0429 |82 92|myocardium0000 Pharm
P01681075A0429 |8 11|min6T0
P01681075A0429 |56 76|pimobendan injection 5-nucleotidase P000
P01681075A0429 |157 168|metaboliteshen CSF [HC
P01681075A0429 |140 153|tissue levels P00008997A04
P01681075A0429 |49 52|minses
P01682484A0680 |16 24|stenosisompariso
P01682484A0680 |178 190|hemodynamicsown as a fun
P01682484A0680 |161 169|LCX flowCSF [HCO
P01682484A0680 |57 67|procaterol5-nucleoti
P01682484A0680 |132 143|dysfunctionbinemia. P0
P01682484A0680 |80 84|dose1T00
P01682484A0680 |203 221|lactate metabolismPCO2 the data of K
P01682484A0680 |33 41|contrarykaline p
P01682509A0539 |118 129|T-cell lineal hyperbil
P01682509A0539 |39 52|proteins IE86 phosphatases
P01682509A0539 |131 137|HUT-78ubinem
P01682509A0539 |105 112|HIV LTRcts of 
P01682509A0539 |64 68|IE55otid
P01682509A0539 |54 58|IE72nd 5
P01682509A0539 |16 24|evidenceompariso
P01682542A0690 |85 93|location0 Pharma
P01682542A0690 |5 12|country1606T00
P01682542A0690 |27 41|HIV prevalenceith alkaline p
P01682542A0690 |98 109|counsellingic aspects 
P01682542A0690 |54 62|strategynd 5-nuc
P01682542A0690 |138 149|individualsa. P0000899
P01684791A0000 |68 101|chicken glutamine synthetase genease P00008171T0000 Pharmacologic 
P01684791A0000 |15 22|elementCompari
P01684791A0000 |33 60|glucocorticoid inducibilitykaline phosphatases and 5-n
P01686909A0299 |33 42|excretionkaline ph
P01686909A0299 |13 21|increase6 Compar
P01686909A0299 |135 141|kidneyemia. 
P01686909A0299 |78 89|elimination171T0000 Ph
P01686909A0299 |122 126|acidyper
P01686909A0299 |93 102|bretyliumcologic a
P01687050T0000 |34 56|fluid immunoglobulin Galine phosphatases and
P01687050T0000 |11 16|value076 C
P01687050T0000 |89 97|diseasesarmacolo
P01687050T0000 |58 61|IgG-nu
P01688841A0430 |0 10|ExpressionP00001606T
P01688841A0430 |31 35|ipaCalka
P01688841A0430 |59 63|invKnucl
P01688841A0430 |25 29|ipaB wit
P01688841A0430 |43 47|invGspha
P01688841A0430 |106 120|regulator virFts of neonatal
P01688841A0430 |18 23|genesparis
P01688841A0430 |37 41|invEne p
P01688841A0430 |49 53|invJses 
P01688972A0803 |10 12|VT00
P01688972A0803 |44 51|patientphatase
P01690703A0285 |0 10|VenkatesanP00001606T
P01690703A0285 |16 18|D.om
P01690728A1166 |4 12|presence01606T00
P01690728A1166 |67 81|kilobase pairsdase P00008171
P01690728A1166 |41 57|mRNA transcriptshosphatases and 
P01690728A1166 |150 178|S1 nuclease protection assayA0472 When CSF [HCO3-] is sh
P01690728A1166 |121 148|Northern blot hybridizationhyperbilirubinemia. P000089
P01690728A1166 |96 107|fibroblastsogic aspect
P01690728A1166 |83 85|kb00
P01690728A1166 |188 213|polymerase chain reactionunction of CSF PCO2 the d
P01690812A0000 |35 38|DNAlin
P01690812A0000 |131 146|gene insertionsubinemia. P0000
P01690812A0000 |40 44|rDNAphos
P01690812A0000 |148 152|type97A0
P01690812A0000 |46 51|unitsatase
P01690812A0000 |115 120|S RNAnatal
P01690812A0000 |159 163|typen CS
P01690812A0000 |16 17|%o
P01691184A0995 |152 169|precursor protein472 When CSF [HCO
P01691184A0995 |129 144|disulfide bondsirubinemia. P00
P01691184A0995 |43 45|Mrsp
P01691184A0995 |98 115|cleavage productsic aspects of neo
P01691184A0995 |23 41|polypeptide chainson with alkaline p
P01691184A0995 |0 6|Gap b3P00001
P01692135A0783 |204 209|mouseCO2 t
P01692135A0783 |92 97|mRNAsacolo
P01692135A0783 |149 157|Fc gamma7A0472 W
P01692135A0783 |13 42|rtFc gamma R alpha cDNA clone6 Comparison with alkaline ph
P01692135A0783 |218 230|killer cellsf K-depleted
P01692135A0783 |111 124|CRNK-16 cells neonatal hyp
P01692135A0783 |168 180|mRNA speciesO3-] is show
P01692837A0390 |153 162|kilobases72 When C
P01692837A0390 |127 131|mRNAilir
P01692837A0390 |95 109|kilobase pairslogic aspects 
P01692837A0390 |26 31|exonswith 
P01692837A0390 |83 89|region000 Ph
P01692837A0390 |37 44|intronsne phos
P01692837A0390 |5 10|genes1606T
P01692962A0980 |34 39|alphaaline
P01692962A0980 |127 141|cAMP synthesisilirubinemia. 
P01692962A0980 |161 184|protein kinase activityCSF [HCO3-] is shown as
P01692962A0980 |46 59|s polypeptideatases and 5-
P01692962A0980 |91 96|cellsmacol
P01692962A0980 |71 84|hamster ovary P00008171T00
P01692962A0980 |7 17|expression06T0076 Co
P01692962A0980 |86 89|CHO Ph
P01694009A0112 |116 127|polypeptideatal hyperb
P01694009A0112 |93 108|signal sequencecologic aspects
P01694009A0112 |67 73|regiondase P
P01694009A0112 |22 26|exonson 
P01694009A0112 |5 9|exon1606
P01694014A0716 |0 9|TreatmentP00001606
P01694014A0716 |91 94|PMAmac
P01694014A0716 |126 132|levelsbiliru
P01694014A0716 |58 89|phorbol 12-myristate 13-acetate-nucleotidase P00008171T0000 Ph
P01694014A0716 |27 43|cell lines HL-60ith alkaline pho
P01694014A0716 |160 169|LD78 cDNA CSF [HCO
P01694014A0716 |115 116|hn
P01694014A0716 |140 156|RNA hybridizable P00008997A0472 
P01694014A0716 |48 52|U937ases
P01694280A0000 |87 95|cisternsPharmaco
P01694280A0000 |27 42|ventriculoscopeith alkaline ph
P01694280A0000 |47 58|observationtases and 5
P01694280A0000 |66 76|ventriclesidase P000
P01694525A0000 |0 25|Isopenicillin N isomeraseP00001606T0076 Comparison
P01694525A0000 |27 36|epimeraseith alkal
P01694525A0000 |123 133|N-terminusperbilirub
P01694525A0000 |96 115|amino acid sequenceogic aspects of neo
P01695098A1116 |0 9|Serum IgGP00001606
P01695098A1116 |38 46|patientse phosph
P01695116A0078 |51 54|CR1s a
P01695116A0078 |74 86|chemotherapy0008171T0000
P01695116A0078 |108 114|months of ne
P01695116A0078 |40 49|remissionphosphata
P01695116A0078 |4 11|patient01606T0
P01695314A0762 |18 20|NSpa
P01695314A0762 |11 16|mg/dl076 C
P01695314A0762 |23 37|glucose levelson with alkali
P01695314T0000 |0 20|Platelet aggregationP00001606T0076 Compa
P01695314T0000 |63 91|calcium antagonist treatmenteotidase P00008171T0000 Phar
P01695314T0000 |35 42|controlline ph
P01695314T0000 |95 99|typelogi
P01695314T0000 |103 120|diabetes mellituspects of neonatal
P01695322A0000 |0 5|Wnt-1P0000
P01695322A0000 |56 65|insertion 5-nucleo
P01695322A0000 |89 94|mousearmac
P01695322A0000 |28 36|oncogeneth alkal
P01695322A0000 |7 12|int-106T00
P01695322A0000 |78 81|DNA171
P01695322A0000 |103 114|tumor viruspects of ne
P01695378A1406 |0 9|InductionP00001606
P01695378A1406 |29 36|T cellsh alkal
P01695378A1406 |107 112|levels of 
P01695378A1406 |13 19|Jurkat6 Comp
P01695378A1406 |42 73|phorbol 12-myristate 13-acetateosphatases and 5-nucleotidase P
P01695378A1406 |78 87|ionomycin171T0000 
P01695378A1406 |116 125|FKBP mRNAatal hype
P01695905A0480 |51 60|intestines and 5-n
P01695905A0480 |79 85|levels71T000
P01695905A0480 |106 112|musclets of 
P01695905A0480 |89 95|kidneyarmaco
P01695905A0480 |118 132|adipose tissueal hyperbiliru
P01695905A0480 |35 41|levelsline p
P01695905A0480 |0 10|GLUT5 mRNAP00001606T
P01697611A0738 |70 77|growthse P0000
P01697611A0738 |24 30|tumorsn with
P01697683T0000 |0 14|IdentificationP00001606T0076
P01697683T0000 |43 51|promotersphatase
P01697683T0000 |60 75|cytotactin geneucleotidase P00
P01697683T0000 |19 35|characterizationarison with alka
P01697928A1214 |259 268|promoters when com
P01697928A1214 |26 43|sequence homologywith alkaline pho
P01697928A1214 |227 237|alpha/betated rats a
P01697928A1214 |133 149|response elementinemia. P0000899
P01697928A1214 |93 102|consensuscologic a
P01697928A1214 |57 63|region5-nucl
P01697928A1214 |67 72|Ly-6Edase 
P01698761A1059 |205 211|mucoidO2 the
P01698761A1059 |229 238|phenotyped rats ar
P01698761A1059 |75 82|repeats008171T
P01698761A1059 |113 120|histoneeonatal
P01698761A1059 |172 179|strains is sho
P01698761A1059 |142 146|AlgP0000
P01698761A1059 |129 138|structureirubinemi
P01698761A1059 |49 55|regionses an
P01698761A1059 |185 195|conversiona function
P01698761A1059 |17 35|DNA rearrangementsmparison with alka
P01698772A0238 |7 9|J.06
P01699944A1538 |136 152|promoter elementmia. P00008997A0
P01699944A1538 |6 13|results606T007
P01699944A1538 |160 164|VLC1 CSF
P01699944A1538 |191 202|c-fos genestion of CSF
P01699944A1538 |174 185|alpha-actins shown as 
P01699944A1538 |69 94|CArG box binding proteinsse P00008171T0000 Pharmac
P01700272A0838 |0 15|PolyadenylationP00001606T0076 
P01700272A0838 |88 96|residuesharmacol
P01700272A0838 |151 162|recruitment0472 When C
P01700272A0838 |113 119|numbereonata
P01700272A0838 |58 68|maturation-nucleotid
P01700272A0838 |19 25|B4 RNAarison
P01701088A1335 |0 12|Co-existenceP00001606T00
P01701088A1335 |75 87|AP-2 element008171T0000 
P01701088A1335 |53 61|elementsand 5-nu
P01701088A1335 |91 100|CCAAT boxmacologic
P01701088A1335 |33 41|elementskaline p
P01702361A0621 |100 123|angiogenesis inhibitors aspects of neonatal hy
P01702361A0621 |41 59|collagen synthesishosphatases and 5-
P01702361A0621 |21 27|agentsison w
P01702361A0621 |10 17|studies0076 Co
P01702361A0621 |64 74|depositionotidase P0
P01702426A0196 |37 41|genene p
P01702426A0196 |91 101|expressionmacologic 
P01702426A0196 |163 181|acid synthase geneF [HCO3-] is shown
P01702426A0196 |73 83|regulation00008171T0
P01702426A0196 |22 28|regionson wi
P01702426A1006 |6 9|set606
P01702426A1006 |13 24|cDNA clones6 Compariso
P01702426A1006 |75 110|lambda-ZAP goose liver cDNA library008171T0000 Pharmacologic aspects o
P01702426A1006 |145 153|fragment08997A04
P01702426A1006 |177 186|DNA clonehown as a
P01702426A1006 |52 54|kb a
P01702432A1296 |0 26|Northern blotting analysisP00001606T0076 Comparison 
P01702432A1296 |60 65|genesucleo
P01702432A1296 |111 124|pollen tissue neonatal hyp
P01702432A1296 |89 95|clonesarmaco
P01702432A1296 |42 52|expressionosphatases
P01702972A0613 |137 142|cDNAsia. P
P01702972A0613 |194 199|genesn of 
P01702972A0613 |66 75|subfamilyidase P00
P01702972A0613 |8 26|cDNA hybridization6T0076 Comparison 
P01702972A0613 |111 116|bands neon
P01702972A0613 |79 90|G0S19 genes71T0000 Pha
P01702972A0613 |38 47|DNA blotse phospha
P01702972A0613 |99 107|patternsc aspect
P01702972A0613 |154 164|G0S30 cDNA2 When CSF
P01703335T0000 |20 29|disordersrison wit
P01703335T0000 |44 61|immunosuppressionphatases and 5-nu
P01703335T0000 |67 69|FKda
P01703335T0000 |107 128|transplant populations of neonatal hyperbi
P01703335T0000 |83 95|observations000 Pharmaco
P01703632T0000 |50 61|polypeptidees and 5-nu
P01703632T0000 |15 25|suppressorComparison
P01703632T0000 |67 74|regionsdase P0
P01703632T0000 |107 115|proteinss of neo
P01703632T0000 |35 39|geneline
P01707659A0458 |70 77|HLA-5.4e P0000
P01707659A0458 |107 111|Ch28s of
P01707659A0458 |90 105|chimpanzee genermacologic aspe
P01707659A0458 |64 68|geneotid
P01707800A0354 |171 174|N20] i
P01707800A0354 |144 159|onset latencies008997A0472 Whe
P01707800A0354 |95 100|peakslogic
P01707800A0354 |13 39|N13-N20 interpeak interval6 Comparison with alkaline
P01707800A0354 |114 129|conduction timeonatal hyperbil
P01707800A0354 |163 166|N11F [
P01707800A0354 |71 85|parallel shift P00008171T000
P01708098A0922 |50 56|serieses and
P01708098A0922 |72 100|alpha promoter DNA sequencesP00008171T0000 Pharmacologic
P01708098A0922 |181 192|control GRE as a funct
P01708098A0922 |120 129|basepairs hyperbil
P01708098A0922 |20 46|complex DNA binding assaysrison with alkaline phosph
P01708098A0922 |167 169|GRCO
P01708098A0922 |206 214|receptor2 the da
P01708771A1215 |0 22|Sequence determinationP00001606T0076 Compari
P01708771A1215 |142 148|others000089
P01708771A1215 |93 99|Asn109cologi
P01708771A1215 |59 65|Asn120nucleo
P01708771A1215 |121 130|moleculeshyperbili
P01708771A1215 |154 159|Asn722 Whe
P01708771A1215 |83 88|Asn65000 P
P01708771A1215 |35 43|peptidesline pho
P01708774A0203 |70 85|promoter regione P00008171T000
P01708774A0203 |28 41|AP-1 activityth alkaline p
P01708774A0203 |4 16|DNA sequence01606T0076 C
P01709486A0000 |58 72|proto-oncogene-nucleotidase 
P01709486A0000 |45 46|Wh
P01709486A0000 |74 79|c-kit00081
P01709486A0000 |11 19|mutation076 Comp
P01709933T0000 |0 9|IsolationP00001606
P01709933T0000 |78 81|pS1171
P01709933T0000 |14 30|characterization Comparison with
P01709933T0000 |54 58|genend 5
P01709933T0000 |108 114|statin of ne
P01709933T0000 |65 76|polypeptidetidase P000
P01709933T0000 |38 41|rate p
P01710766A0349 |86 108|amino acids C terminal Pharmacologic aspects
P01710766A0349 |130 146|initiation codonrubinemia. P0000
P01710766A0349 |66 74|sequenceidase P0
P01710766A0349 |27 35|presenceith alka
P01710766A0349 |39 46|absence phosph
P01710766A0349 |4 12|proteins01606T00
P01710768A1172 |100 107|pattern aspect
P01710768A1172 |30 39|existence alkaline
P01710768A1172 |43 52|sequencessphatases
P01710768A1172 |73 75|kb00
P01710768A1172 |165 172|ability[HCO3-]
P01710768A1172 |181 185|gene as 
P01710768A1172 |127 137|expressionilirubinem
P01710768A1172 |145 156|HLA-B7 gene08997A0472 
P01710768A1172 |200 216|gamma interferonSF PCO2 the data
P01710768A1172 |4 11|results01606T0
P01710979T0000 |49 60|associationses and 5-n
P01710979T0000 |12 23|SH3 domains76 Comparis
P01710979T0000 |90 103|proteins p130rmacologic as
P01710979T0000 |108 112|p110 of 
P01710979T0000 |27 34|pp60srcith alk
P01710979T0000 |66 74|tyrosineidase P0
P01710979T0000 |4 7|SH2016
P01710985A0315 |0 4|ChemP000
P01711041A0348 |101 102|%a
P01711041A0348 |6 12|clones606T00
P01711041A0348 |110 120|beta-chainf neonatal
P01711041A0348 |53 57|geneand 
P01711041A0348 |80 94|C5 alpha-chain1T0000 Pharmac
P01711041A0962 |101 110|kilobasesaspects o
P01711041A0962 |61 66|exonscleot
P01711041A0962 |125 130|exonsrbili
P01711041A0962 |72 82|beta-chainP00008171T
P01711041A0962 |37 46|kilobasesne phosph
P01711041A0962 |4 18|C5 alpha-chain01606T0076 Com
P01711048T0000 |136 159|osteogenesis imperfectamia. P00008997A0472 Whe
P01711048T0000 |29 30|Gh
P01711048T0000 |62 71|pro-alphaleotidase
P01711048T0000 |13 21|mutation6 Compar
P01711048T0000 |45 51|intronhatase
P01711048T0000 |112 124|RNA splicingneonatal hyp
P01711048T0000 |77 81|gene8171
P01711048T0000 |83 89|COL1A2000 Ph
P01711048T0000 |33 41|positionkaline p
P01712296A0157 |34 39|genesaline
P01712296A0157 |60 69|positionsucleotida
P01712296A0157 |90 112|amino acid differencesrmacologic aspects of 
P01712296A0157 |4 24|nucleotide sequences01606T0076 Compariso
P01713213A0000 |51 78|pim-1 proto-oncogene sharess and 5-nucleotidase P00008
P01713213A0000 |89 97|homologyarmacolo
P01713213A0000 |29 37|sequenceh alkali
P01713213A0000 |161 173|Pim-1 enzymeCSF [HCO3-] 
P01713213A0000 |109 141|serine/threonine protein kinasesof neonatal hyperbilirubinemia. 
P01713213A0000 |214 246|protein tyrosine kinase activityta of K-depleted rats are no lon
P01713213A0000 |4 11|protein01606T0
P01713213A0488 |87 100|Pim-1 proteinPharmacologic
P01713213A0488 |146 171|glutathione S-transferase8997A0472 When CSF [HCO3-
P01713213A0488 |20 30|pim-1 cDNArison with
P01713213A0488 |173 176|GSTis 
P01713213A0488 |64 78|vector pGEX-2Totidase P00008
P01713213A0488 |116 130|fusion productatal hyperbili
P01714322A0969 |54 62|kDa hspsnd 5-nuc
P01714322A0969 |110 115|genesf neo
P01714322A0969 |76 84|products08171T00
P01714322A0969 |66 71|maizeidase
P01714322A0969 |5 11|report1606T0
P01714358A0990 |65 90|wheat etioplast membranestidase P00008171T0000 Pha
P01714358A0990 |108 111|ATP of
P01714358A0990 |7 22|kDa polypeptide06T0076 Compari
P01714358A0990 |97 106|gamma 32Pgic aspec
P01714452A0559 |137 142|sitesia. P
P01714452A0559 |58 71|repeat domain-nucleotidase
P01714452A0559 |24 31|proteinn with 
P01714452A0559 |88 100|conservationharmacologic
P01714452A0559 |104 111|serinesects of
P01714452A0559 |116 126|threoninesatal hyper
P01714452A0559 |42 43|%o
P01714452A0559 |155 178|carbohydrate attachment When CSF [HCO3-] is sh
P01714452A0559 |0 8|HomologyP0000160
P01714902A0221 |186 201|TCR stimulation function of CS
P01714902A0221 |104 116|cell surfaceects of neon
P01714902A0221 |45 96|Ti alpha-beta CD3 gamma delta epsilon TCR complexeshatases and 5-nucleotidase P00008171T0000 Pharmacol
P01714902A0221 |155 179|interleukin-2 production When CSF [HCO3-] is sho
P01714902A0221 |3 11|addition001606T0
P01714902A0221 |118 126|CD3 zetaal hyper
P01714902A0221 |221 247|histocompatibility complex-depleted rats are no long
P01715593A0838 |33 36|hrskal
P01715593A0838 |5 16|desipramine1606T0076 C
P01715593A0838 |43 63|fluoxetine injectionsphatases and 5-nucl
P01715593A0838 |65 77|brain levelstidase P0000
P01715593A0838 |81 92|desipramineT0000 Pharm
P01715975A0885 |20 24|CYP1riso
P01715975A0885 |9 16|effectsT0076 C
P01715975A0885 |66 71|cellsidase
P01716292A0000 |220 228|DR alphaK-deplet
P01716292A0000 |12 20|analysis76 Compa
P01716292A0000 |134 144|cell linesnemia. P00
P01716292A0000 |232 242|H-2E alphaats are no
P01716292A0000 |112 118|seriesneonat
P01716292A0000 |43 50|HLA-DR1sphatas
P01716292A0000 |160 168|products CSF [HC
P01716292A0000 |64 86|T cell allorecognitionotidase P00008171T0000
P01716292A0000 |191 199|Eb genestion of 
P01716292A0000 |32 39|regionslkaline
P01716292A0000 |184 189|DRB/H a fu
P01716629A0000 |17 28|cDNA clonesmparison wi
P01716629A0000 |60 87|matrix glycoprotein undulinucleotidase P00008171T0000 
P01717718A1255 |171 178|Gag-Pol] is sh
P01717718A1255 |106 108|PRts
P01717718A1255 |14 29|point mutations Comparison wit
P01717718A1255 |213 215|RTat
P01717718A1255 |199 209|activationCSF PCO2 t
P01717718A1255 |79 81|RT71
P01717718A1255 |182 194|prerequisiteas a functio
P01717718A1255 |158 167|PR domainen CSF [H
P01717718A1255 |37 54|Gag-Pol PR domainne phosphatases a
P01717718A1255 |65 75|activationtidase P00
P01717718A1255 |138 150|conformationa. P00008997
P01717833A1223 |86 101|granulosa cells Pharmacologic 
P01717833A1223 |123 135|CREB proteinperbilirubin
P01717833A1223 |73 82|forskolin00008171T
P01717833A1223 |4 26|alpha inhibin promoter01606T0076 Comparison 
P01717833A1223 |48 51|CREase
P01717833T0000 |0 10|RegulationP00001606T
P01717833T0000 |47 56|adenosinetases and
P01717833T0000 |83 95|transfection000 Pharmaco
P01717833T0000 |63 76|monophosphateeotidase P000
P01717833T0000 |18 36|alpha inhibin geneparison with alkal
P01717833T0000 |101 120|rat granulosa cellsaspects of neonatal
P01717925A0477 |152 158|region472 Wh
P01717925A0477 |88 107|sequence similarityharmacologic aspect
P01717925A0477 |18 38|nucleotide sequencesparison with alkalin
P01717925A0477 |122 124|bpyp
P01717925A0477 |0 10|ComparisonP00001606T
P01717925A0477 |68 71|DNAase
P01717994T0000 |0 7|CloningP000016
P01717994T0000 |58 73|complementation-nucleotidase P
P01717994T0000 |48 54|kinaseases a
P01717994T0000 |99 107|mutationc aspect
P01717994T0000 |19 23|cDNAaris
P01717994T0000 |87 92|yeastPharm
P01718043A0384 |17 30|osteomyelitismparison with
P01718043A0384 |193 194|%o
P01718043A0384 |58 70|PMN elastase-nucleotidas
P01718043A0384 |147 177|erythrocyte sedimentation rate997A0472 When CSF [HCO3-] is s
P01718043A0384 |94 95|%o
P01718043A0384 |41 48|empyemahosphat
P01718043A0384 |179 190|sensitivitywn as a fun
P01718043A0384 |77 88|sensitivity8171T0000 P
P01718043A0384 |3 11|patients001606T0
P01718043A0384 |50 51|ne
P01718983A1640 |102 106|Cellspec
P01718983A1640 |17 21|Goffmpar
P01718983A1640 |50 52|R.es
P01718983A1640 |54 60|Newmannd 5-n
P01718983A1640 |23 25|D.on
P01718983A1640 |27 36|Griffithsith alkal
P01718983A1640 |62 64|B.le
P01718983A1640 |91 93|R.ma
P01718983A1640 |42 48|Tizardosphat
P01718983A1640 |77 79|G.81
P01718983A1640 |13 15|C.6 
P01718983A1640 |85 89|Lobb0 Ph
P01718983A1640 |38 40|B.e 
P01718983A1640 |66 75|Chi-Rossoidase P00
P01718983A1640 |4 11|Hession01606T0
P01718983A1640 |0 2|E.P0
P01719684A0494 |171 189|sphincter function] is shown as a fu
P01719684A0494 |10 17|results0076 Co
P01719684A0494 |61 70|receptorscleotidas
P01719684A0494 |81 89|prostateT0000 Ph
P01719684A0494 |32 40|increaselkaline 
P01720555A1087 |63 77|alfalfa organseotidase P0000
P01720555A1087 |28 41|B2 transcriptth alkaline p
P01720843A1506 |32 48|sulfhydryl grouplkaline phosphat
P01720843A1506 |60 71|angiotensinucleotidase
P01720843A1506 |147 168|nitrovasodilator EDRF997A0472 When CSF [HC
P01720843A1506 |122 128|effectyperbi
P01720843A1506 |6 13|results606T007
P01720843A1506 |83 100|enzyme inhibitors000 Pharmacologic
P01721261T0000 |0 16|PharmacokineticsP00001606T0076 C
P01721261T0000 |30 49|transplant patients alkaline phosphata
P01721261T0000 |20 22|FKri
P01721884A0962 |312 337|RNase H crystal structurently greater slope (1.21 
P01721884A0962 |249 252|Pol di
P01721884A0962 |88 102|ribonuclease Hharmacologic a
P01721884A0962 |31 36|matchalkal
P01721884A0962 |269 270|Pa
P01721884A0962 |303 304|Ds
P01721884A0962 |255 264|helices Oaced when
P01721884A0962 |289 296|helices still 
P01721884A0962 |53 59|regionand 5-
P01721884A0962 |113 119|domaineonata
P01721884A0962 |224 231|RNase Hpleted 
P01721884A0962 |152 158|region472 Wh
P01721884A0962 |104 111|RNase Hects of
P01721884A0962 |193 206|investigatorson of CSF PCO
P01722319A0849 |0 8|AnalysisP0000160
P01722319A0849 |177 178|Nh
P01722319A0849 |183 192|C terminis a funct
P01722319A0849 |58 72|CHIP28 protein-nucleotidase 
P01722319A0849 |24 43|amino acid sequencen with alkaline pho
P01722319A0849 |103 110|domainspects o
P01722319A0849 |136 157|N-glycosylation sitesmia. P00008997A0472 W
P01722479A0302 |34 37|HCGali
P01722479A0302 |44 55|sensitivityphatases an
P01722479A0302 |89 90|%a
P01722479A0302 |63 64|%e
P01722479A0302 |71 82|specificity P00008171T
P01722479A0302 |16 30|concentrationsomparison with
P01723619A0766 |155 164|intestine When CSF
P01723619A0766 |194 206|F absorptionn of CSF PCO
P01723619A0766 |127 134|passageilirubi
P01723619A0766 |12 16|rate76 C
P01723619A0766 |104 112|emptyingects of 
P01723619A0766 |44 48|risephat
P01723619A0766 |52 74|plasma F concentration and 5-nucleotidase P0
P01723619A0766 |178 184|factorown as
P01723619A0766 |20 32|F absorptionrison with a
P01723619A0766 |138 139|Fa
P01723962A0165 |102 103|hs
P01723962A0165 |110 119|injectionf neonata
P01723962A0165 |123 128|Na-Tcperbi
P01723962A0165 |88 95|maximumharmaco
P01723962A0165 |4 12|activity01606T00
P01723962A0165 |67 68|hd
P01723962A0165 |33 40|amylasekaline 
P01723962A0165 |16 28|serum lipaseomparison wi
P01724982A0237 |50 61|HCV EIA kites and 5-nu
P01724982A0237 |91 93|ILma
P01724982A0237 |63 74|Abbott Lab.eotidase P0
P01724982A0237 |76 89|North Chicago08171T0000 Ph
P01725547A0354 |102 112|blood flowspects of 
P01725547A0354 |126 127|pb
P01725547A0354 |123 124|%p
P01725547A0354 |72 73|%P
P01725547A0354 |75 76|p0
P01725547A0354 |36 44|increaseine phos
P01725547A0354 |59 67|diameternucleoti
P01725547A0354 |114 117|CBFona
P01725547A0354 |0 9|DiltiazemP00001606
P01725622A0292 |68 71|CCIase
P01725622A0292 |61 66|Gpt/lcleot
P01725622A0292 |10 21|transfusion0076 Compar
P01725622A0292 |36 54|platelet incrementine phosphatases a
P01726211A0502 |118 125|factorsal hype
P01726211A0502 |75 82|factors008171T
P01726211A0502 |6 18|risk factors606T0076 Com
P01726211A0502 |41 47|groupshospha
P01726211A0502 |55 61|vesseld 5-nu
P01726211A0502 |101 107|actionaspect
P01726631T0001 |17 27|preventionmparison w
P01726631T0001 |109 119|resistanceof neonata
P01726631T0001 |79 86|Sassari71T0000
P01726631T0001 |88 95|profileharmaco
P01726631T0001 |31 50|hospital infectionsalkaline phosphatas
P01726631T0001 |138 144|agentsa. P00
P01726631T0001 |58 75|Local Health Unit-nucleotidase P00
P01726631T0001 |154 159|usage2 Whe
P01726631T0001 |0 12|EpidemiologyP00001606T00
P01727488A1146 |18 23|cDNAsparis
P01727488A1146 |95 110|gene expressionlogic aspects o
P01727488A1146 |42 53|stimulationosphatases 
P01727494A0000 |51 57|natures and 
P01727494A0000 |130 134|hostrubi
P01727494A0000 |89 99|activationarmacologi
P01727494A0000 |61 72|VV proteinscleotidase 
P01727494A0000 |32 41|immunogenlkaline p
P01727494A0000 |114 122|responseonatal h
P01727494A0000 |16 18|VVom
P01727494A0000 |0 14|Vaccinia virusP00001606T0076
P01730412T0000 |0 3|MaxP00
P01730412T0000 |45 50|c-Mychatas
P01730412T0000 |28 39|interactionth alkaline
P01730412T0000 |16 23|domainsomparis
P01730747A0205 |33 39|Reillykaline
P01730747A0205 |41 43|C.ho
P01730747A0205 |24 31|S phasen with 
P01730747A0205 |18 20|G1pa
P01731107A0928 |0 13|SubstitutionsP00001606T007
P01731107A0928 |79 95|pRNA replication71T0000 Pharmaco
P01731107A0928 |193 199|strandon of 
P01731107A0928 |167 176|structureCO3-] is 
P01731107A0928 |28 33|basesth al
P01731107A0928 |213 219|genomeata of
P01731107A0928 |128 139|maintenancelirubinemia
P01731107A0928 |50 60|ICR2 motifes and 5-n
P01731107A0928 |69 75|levelsse P00
P01731933T0000 |50 57|proteines and 
P01731933T0000 |1 3|Zn00
P01731933T0000 |39 46|T4 gene phosph
P01731933T0000 |8 35|coordination domain mutants6T0076 Comparison with alka
P01731933T0000 |8 35|coordination domain mutants6T0076 Comparison with alka
P01731933T0000 |50 57|proteines and 
P01731933T0000 |39 46|T4 gene phosph
P01731933T0000 |1 3|Zn00
P01731979A1408 |4 22|tissue specificity01606T0076 Compari
P01731979A1408 |26 41|gene expressionwith alkaline p
P01731979A1408 |93 127|CaMV 35S domain B enhancer elementcologic aspects of neonatal hyperb
P01732033A0000 |69 76|infancyse P000
P01732033A0000 |127 139|brain injuryilirubinemia
P01732033A0000 |145 150|model08997
P01732033A0000 |4 19|pathophysiology01606T0076 Comp
P01732033A0000 |53 65|brain injuryand 5-nucleo
P01732033A0000 |81 90|childhoodT0000 Pha
P01732033A0000 |33 43|managementkaline pho
P01732736A1076 |0 11|TranscriptsP00001606T0
P01732736A1076 |43 49|Oct-25sphata
P01732736A1076 |26 41|POU-domain genewith alkaline p
P01732736A1076 |81 88|oocytesT0000 P
P01732736A1076 |99 106|embryosc aspec
P01732736A1076 |71 77|levels P0000
P01732736A1076 |154 166|gastrulation2 When CSF [
P01732752A0156 |68 84|pre-B-cell linesase P00008171T00
P01732752A0156 |26 33|Abelsonwith al
P01732752A0156 |14 21|B cells Compar
P01732752A0156 |41 49|leukemiahosphata
P01732752A0156 |86 93|LT mRNA Pharma
P01733105A0127 |4 10|genome01606T
P01733105A0127 |14 27|Thogoto virus Comparison w
P01733105A0127 |42 50|segmentsosphatas
P01733105A0127 |80 89|sense RNA1T0000 Ph
P01733358A0240 |103 117|adenocarcinomapects of neona
P01733358A0240 |123 139|mucin productionperbilirubinemia
P01733358A0240 |46 52|groupsatases
P01733358A0240 |74 92|cystadenocarcinoma0008171T0000 Pharm
P01733358A0240 |6 12|tumors606T00
P01733358A0240 |57 68|cystadenoma5-nucleotid
P01733358A0240 |157 161|cysthen 
P01733358A0240 |98 101|IIIic 
P01734020A1318 |0 14|ImmunostainingP00001606T0076
P01734020A1318 |47 57|constructstases and 
P01734020A1318 |18 23|cellsparis
P01734020A1318 |142 148|nuclei000089
P01734020A1318 |116 123|mutantsatal hy
P01734020A1318 |168 177|PKC alphaO3-] is s
P01734283A0817 |32 45|RAP74 proteinlkaline phosp
P01734283A0817 |120 139|translation product hyperbilirubinemia
P01734283A0817 |60 70|HeLa cellsucleotidas
P01734283A0817 |97 100|DNAgic
P01734283A0817 |158 163|RAP30en CS
P01734570T0000 |0 7|EffectsP000016
P01734570T0000 |11 44|thromboxane synthetase inhibition076 Comparison with alkaline phos
P01734570T0000 |96 100|rateogic
P01734570T0000 |77 87|resistance8171T0000 
P01734570T0000 |114 127|translocationonatal hyperb
P01734570T0000 |141 154|porcine modelP00008997A047
P01735347A0482 |152 161|extension472 When 
P01735347A0482 |122 133|developmentyperbilirub
P01735347A0482 |180 188|necrosisn as a f
P01735347A0482 |61 70|treatmentcleotidas
P01735347A0482 |23 29|insulton wit
P01735347A0482 |92 96|riseacol
P01735347A0482 |100 113|plasma lipase aspects of n
P01735347A0482 |137 144|ascitesia. P00
P01735447A0271 |86 103|pre-super-pro-PrB Pharmacologic as
P01735447A0271 |121 134|sec61 mutantshyperbilirubi
P01735447A0271 |75 84|precursor008171T00
P01735447A0271 |23 31|moleculeon with 
P01735447A0271 |176 185|reticulumshown as 
P01735447A0271 |4 8|size0160
P01735447A0271 |141 154|translocationP00008997A047
P01735447A0833 |154 163|reticulum2 When CS
P01735447A0833 |107 110|PrBs o
P01735447A0833 |94 103|precursorologic as
P01735447A0833 |123 134|kDa pro-PrBperbilirubi
P01735447A0833 |10 30|active-site mutation0076 Comparison with
P01735447A0833 |54 64|processingnd 5-nucle
P01735721A0185 |68 101|Bacillus stearothermophilus TyrTSase P00008171T0000 Pharmacologic 
P01735721A0185 |46 56|% identityatases and
P01735721A0185 |180 202|B. subtilis TyrTS genen as a function of CSF
P01735721A0185 |14 33|amino acid sequence Comparison with al
P01735721A0185 |151 159|identity0472 Whe
P01735721A0185 |108 118|% identity of neonat
P01735721A0185 |215 219|tyrZa of
P01735721A0185 |232 233|%a
P01735721A0185 |138 143|TyrTSa. P0
P01736093A0731 |85 93|promoter0 Pharma
P01736093A0731 |15 27|CAT activityComparison w
P01736093A0731 |111 122|CCAAT boxes neonatal h
P01736093A0731 |160 173|constructions CSF [HCO3-] 
P01736093A0731 |59 68|sequencesnucleotid
P01736093A0731 |136 139|HSEmia
P01736651A0104 |16 23|Infantsomparis
P01736651A0104 |29 45|Children clinicsh alkaline phosp
P01736651A0104 |62 67|Minn.leoti
P01736651A0104 |9 14|WomenT0076
P01736651A0104 |49 60|Minneapolisses and 5-n
P01736844T0000 |186 194|function functio
P01736844T0000 |95 109|androgen indexlogic aspects 
P01736844T0000 |198 201|men CS
P01736844T0000 |72 84|testosteroneP00008171T00
P01736844T0000 |117 141|testosterone measurementtal hyperbilirubinemia. 
P01736844T0000 |19 31|testosteronearison with 
P01736844T0000 |207 215|epilepsy the dat
P01736844T0000 |0 12|TestosteroneP00001606T00
P01737741A0000 |0 10|BACKGROUNDP00001606T
P01737741A0000 |63 68|MAOIseotid
P01737741A0000 |93 103|depressioncologic as
P01737741A0000 |148 153|study97A04
P01737741A0000 |33 61|monoamine oxidase inhibitorskaline phosphatases and 5-nu
P01737741A0000 |16 29|effectivenessomparison wit
P01737789A0800 |172 178|intron is sh
P01737789A0800 |25 35|breakpoint with alka
P01737789A0800 |61 68|repeatscleotid
P01737789A0800 |76 96|acceptor splice site08171T0000 Pharmacol
P01737789A0800 |110 144|down-stream alpha-delta breakpointf neonatal hyperbilirubinemia. P00
P01738470A0441 |102 120|recognition memoryspects of neonatal
P01738470A0441 |23 28|PDDATon wi
P01738470A0441 |57 66|positions5-nucleot
P01738470A0441 |84 89|order00 Ph
P01738470A0441 |0 8|PatientsP0000160
P01738653T0014 |0 4|BoneP000
P01738653T0014 |9 14|bonesT0076
P01738936A0292 |17 33|plasma C-peptidemparison with al
P01738936A0292 |4 12|patients01606T00
P01738936A0292 |49 51|pMse
P01738936A0292 |84 92|analysis00 Pharm
P01739439A0257 |0 7|ComplexP000016
P01739439A0257 |162 174|control miceSF [HCO3-] i
P01739439A0257 |58 66|mdx mice-nucleot
P01739439A0257 |47 54|musclestases a
P01739439A0257 |74 81|complex0008171
P01739439A0257 |144 151|muscles008997A
P01739439A0257 |93 103|dischargescologic as
P01739439A0257 |113 126|abnormalitieseonatal hyper
P01739439A0257 |19 29|dischargesarison wit
P01739956A0638 |0 10|ManagementP00001606T
P01739956A0638 |61 66|drugscleot
P01739956A0638 |93 98|drugscolog
P01739956A0638 |26 30|betawith
P01739956A0638 |36 51|calcium channeline phosphatase
P01739956A0638 |70 77|type ICe P0000
P01740121A0136 |17 24|problemmpariso
P01740121A0136 |64 105|baculovirus/insect cell expression systemotidase P00008171T0000 Pharmacologic aspe
P01740121A0136 |48 53|Kex2pases 
P01740330A0329 |0 2|J.P0
P01740437A0851 |17 29|core proteinmparison wit
P01740437A0851 |145 151|domain08997A
P01740437A0851 |91 99|antibodymacologi
P01740437A0851 |37 59|liver HSPG preparationne phosphatases and 5-
P01740437A0851 |155 166|fibroglycan When CSF [
P01740448A1735 |17 38|transmembrane regionsmparison with alkalin
P01740448A1735 |224 233|membranespleted ra
P01740448A1735 |196 206|attachmentof CSF PCO
P01740448A1735 |210 220|precursorse data of 
P01740448A1735 |82 102|amino acid stretches0000 Pharmacologic a
P01740448A1735 |155 161|region When 
P01740682A0703 |0 8|ToxicityP0000160
P01740682A0703 |90 100|leukopeniarmacologic
P01740682A0703 |104 129|World Health Organizationects of neonatal hyperbil
P01740682A0703 |152 153|%4
P01740682A0703 |50 51|%e
P01740682A0703 |216 217|% 
P01740682A0703 |80 87|courses1T0000 
P01740682A0703 |59 67|patientsnucleoti
P01740682A0703 |245 252|coursesnger di
P01740682A0703 |182 189|coursesas a fu
P01740682A0703 |196 212|thrombocytopeniaof CSF PCO2 the 
P01740682A0703 |40 46|emesisphosph
P01740682A0703 |161 169|patientsCSF [HCO
P01740682A0703 |225 233|patientsleted ra
P01740682A0703 |71 72|% 
P01740682A0703 |173 174|%i
P01740682A0703 |236 237|%a
P01740682A0703 |136 141|grademia. 
P01741249A0177 |0 4|W.G.P000
P01742341A0499 |102 110|stressorspects o
P01742341A0499 |41 49|reactionhosphata
P01742341A0499 |75 89|transportation008171T0000 Ph
P01742341A0499 |5 10|study1606T
P01742341A0499 |115 126|Beagle dogsnatal hyper
P01742606A0000 |100 108|antibody aspects
P01742606A0000 |31 35|cDNAalka
P01742606A0000 |60 90|lambda Gt11 expression libraryucleotidase P00008171T0000 Pha
P01742606A0000 |147 172|kDa spectrin beta-subunit997A0472 When CSF [HCO3-]
P01742606A0000 |2 27|mouse brain beta-spectrin0001606T0076 Comparison w
P01742879A0471 |0 7|RESULTSP000016
P01742879A0471 |41 52|stimulationhosphatases
P01742879A0471 |134 148|water drinkingnemia. P000089
P01742879A0471 |9 29|Plasma AVP responsesT0076 Comparison wit
P01742879A0471 |109 117|patientsof neona
P01742879A0471 |70 80|inhibitione P0000817
P01742879A0471 |84 92|drinking00 Pharm
P01744039A0511 |4 13|fragments01606T007
P01744039A0511 |89 108|gel electrophoresisarmacologic aspects
P01744039A0511 |47 72|polymerase chain reactiontases and 5-nucleotidase 
P01744039A0511 |133 158|conformation polymorphisminemia. P00008997A0472 Wh
P01744039A0511 |22 28|regionson wi
P01744042A1355 |64 69|phaseotida
P01744042A1355 |73 78|cells00008
P01744042A1355 |129 140|% glutamineirubinemia.
P01744042A1355 |88 99|Luria brothharmacologi
P01744042A1355 |112 121|% glucoseneonatal 
P01744042A1355 |4 15|csbA fusion01606T0076 
P01744119A0757 |171 175|gene] is
P01744119A0757 |211 220|templates data of 
P01744119A0757 |232 240|sequenceats are 
P01744119A0757 |178 185|proteinown as 
P01744119A0757 |127 156|oligoribonucleotide synthesisilirubinemia. P00008997A0472 
P01744119A0757 |93 100|effectscologic
P01744119A0757 |115 123|proteinsnatal hy
P01744119A0757 |4 15|constraints01606T0076 
P01744119A0757 |19 48|primase recognition sequencesarison with alkaline phosphat
P01744119A0757 |50 83|nucleotide substrate requirementses and 5-nucleotidase P00008171T0
P01747972T0000 |13 20|therapy6 Compa
P01747972T0000 |45 62|artery dissectionhatases and 5-nuc
P01748067A0000 |67 70|mendas
P01748067A0000 |54 62|patientsnd 5-nuc
P01748067A0000 |159 170|replacementn CSF [HCO3
P01748067A0000 |149 152|hip7A0
P01748067A0000 |240 244|neckno l
P01748067A0000 |211 220|arthritis data of 
P01748067A0000 |224 232|fracturepleted r
P01748067A0000 |118 123|yearsal hy
P01748067A0000 |252 257|femursplac
P01748067A0000 |86 91|years Phar
P01748067A0000 |109 112|ageof 
P01748067A0000 |14 19|trial Comp
P01748067A0000 |77 80|age817
P01748067A0000 |97 102|womengic a
P01748194A0767 |143 159|cord transection0008997A0472 Whe
P01748194A0767 |40 52|hemisectionsphosphatases
P01748194A0767 |10 17|lesions0076 Co
P01748194A0767 |161 162|NC
P01748194A0767 |93 101|recoverycologic 
P01748287T0000 |18 26|proteinsparison 
P01748287T0000 |40 50|propertiesphosphatas
P01748287T0000 |76 83|targets08171T0
P01748292A0000 |17 22|cDNAsmpari
P01748292A0000 |47 70|G protein alpha subunittases and 5-nucleotidas
P01748292A0000 |109 111|cvof
P01748292A0000 |29 33|geneh al
P01748292A0000 |76 82|tomato08171T
P01748292A0000 |84 107|Lycopersicon esculentum00 Pharmacologic aspect
P01748630A0125 |0 25|Growth factor stimulationP00001606T0076 Comparison
P01748630A0125 |112 117|Ser62neona
P01748630A0125 |178 185|membersown as 
P01748630A0125 |214 216|E.ta
P01748630A0125 |245 247|F.ng
P01748630A0125 |29 34|cellsh alk
P01748630A0125 |91 108|activation domainmacologic aspects
P01748630A0125 |229 233|I.C.d ra
P01748630A0125 |46 61|phosphorylationatases and 5-nu
P01748630A0125 |193 203|Myc familyon of CSF 
P01748630A0125 |218 227|Northwoodf K-deple
P01748630A0125 |235 243|Gonzalez are no 
P01748630A0125 |140 146|region P0000
P01748630A0125 |69 74|c-Mycse P0
P01748630A0125 |205 212|AlvarezO2 the 
P01751163A0000 |51 64|complicationss and 5-nucle
P01751163A0000 |26 35|potentialwith alka
P01751163A0000 |123 135|Sarns/3M-VADperbilirubin
P01751163A0000 |145 151|calves08997A
P01751163A0000 |78 90|implantation171T0000 Pha
P01751163A0000 |4 11|authors01606T0
P01751163A0000 |115 121|devicenatal 
P01751255A0529 |16 18|COom
P01751255A0529 |73 83|MBBF group00008171T0
P01751255A0529 |46 47|pa
P01751255A0529 |8 14|output6T0076
P01751970A0209 |0 19|Amino acid residuesP00001606T0076 Comp
P01751970A0209 |55 63|sequenced 5-nucl
P01751970A0209 |84 92|residues00 Pharm
P01752441A0000 |137 164|TAR RNA stem-loop structureia. P00008997A0472 When CSF
P01752441A0000 |110 129|trinucleotide bulgef neonatal hyperbil
P01752441A0000 |214 225|transcriptsta of K-dep
P01752441A0000 |194 200|leadern of C
P01752441A0000 |70 78|residuese P00008
P01752441A0000 |86 105|hexanucleotide loop Pharmacologic aspe
P01752441A0000 |16 26|activationomparison 
P01752441A0000 |34 51|HIV-1 Tat proteinaline phosphatase
P01752792A0000 |116 123|neuronsatal hy
P01752792A0000 |95 102|stimulilogic a
P01752792A0000 |41 47|codinghospha
P01752792A0000 |62 78|time differencesleotidase P00008
P01752792A0000 |163 174|albino ratsF [HCO3-] i
P01752792A0000 |25 33|evidence with al
P01752792A0000 |80 84|ITDs1T00
P01752792A0000 |140 146|cortex P0000
P01753317A0879 |6 13|results606T007
P01753317A0879 |134 146|bone defectsnemia. P0000
P01753317A0879 |59 70|combinationnucleotidas
P01753317A0879 |94 108|bone formationologic aspects
P01753317A0879 |76 80|FDBA0817
P01753317A0879 |52 55|TTC an
P01754381A0000 |170 181|Trypanozoon-] is shown
P01754381A0000 |31 47|characterizationalkaline phospha
P01754381A0000 |14 18|step Com
P01754381A0000 |219 239|DNA polymerase alpha K-depleted rats are
P01754381A0000 |82 94|trypanosomes0000 Pharmac
P01754381A0000 |197 201|genef CS
P01754381A0000 |63 78|DNA polymeraseseotidase P00008
P01754381A0000 |250 254|coredisp
P01754381A0000 |157 168|Trypanosomahen CSF [HC
P01754381A0000 |139 149|expression. P0000899
P01754381A0000 |256 265|pol alphaced when 
P01756195A1117 |119 120|rl
P01756195A1117 |76 90|concentrations08171T0000 Pha
P01756195A1117 |96 99|ageogi
P01756195A1117 |37 45|increasene phosp
P01756195A1117 |3 11|addition001606T0
P01756195A1117 |101 102|pa
P01756539A0354 |119 129|infarctionl hyperbil
P01756539A0354 |10 22|hypertension0076 Compari
P01756539A0354 |58 67|narrowing-nucleoti
P01756539A0354 |82 91|condition0000 Phar
P01757341A0591 |102 106|areaspec
P01757341A0591 |41 43|Naho
P01757341A0591 |29 39|number/mm2h alkaline
P01757341A0591 |151 171|alkaline phosphatase0472 When CSF [HCO3-
P01757341A0591 |52 63|capillaries and 5-nucl
P01757341A0591 |110 115|brainf neo
P01757341A0591 |4 19|volume fraction01606T0076 Comp
P01757341A0591 |21 23|Vvis
P01758750A0000 |0 15|Airway pressureP00001606T0076 
P01758750A0000 |74 82|children0008171T
P01758750A0000 |63 67|tubeeoti
P01758750A0000 |88 95|varietyharmaco
P01758750A0000 |20 28|air flowrison wi
P01758750A0000 |99 110|ventilatorsc aspects o
P01759052A0786 |0 4|ApplP000
P01759282A0000 |137 145|positionia. P000
P01759282A0000 |57 63|object5-nucl
P01759282A0000 |10 22|distribution0076 Compari
P01759282A0000 |149 161|biomechanics7A0472 When 
P01759282A0000 |74 93|contact interaction0008171T0000 Pharma
P01759282A0000 |99 103|headc as
P01759282A0000 |111 117|impact neona
P01759282A0000 |0 6|IssuesP00001
P01759282A0000 |34 40|energyaline 
P01760166A0963 |0 10|CONCLUSIONP00001606T
P01760166A0963 |41 52|septum sitehosphatases
P01760166A0963 |123 131|patientsperbilir
P01760166A0963 |23 27|SpO2on w
P01760166A0963 |96 107|finger siteogic aspect
P01761736A0158 |186 187|P 
P01761736A0158 |240 246|volumeno lon
P01761736A0158 |30 44|body clearance alkaline phos
P01761736A0158 |179 184|hourswn as
P01761736A0158 |229 236|changesd rats 
P01761736A0158 |79 85|mL/min71T000
P01761736A0158 |123 144|elimination half-lifeperbilirubinemia. P00
P01761736A0158 |206 216|antipyrine2 the data
P01761736A0158 |250 262|distributiondisplaced wh
P01761736A0158 |87 88|PP
P01761736A0158 |0 9|DiltiazemP00001606
P01762053A0557 |32 40|materiallkaline 
P01762053A0557 |88 97|particlesharmacolo
P01762053A0557 |4 12|granules01606T00
P01762053A0557 |64 69|spaceotida
P01762914A1218 |101 123|translation start siteaspects of neonatal hy
P01762914A1218 |88 90|kbha
P01762914A1218 |11 23|uPA promoter076 Comparis
P01762914A1218 |58 66|elements-nucleot
P01762917A0615 |34 37|Gluali
P01762917A0615 |42 45|Lysosp
P01762917A0615 |131 142|DNA bindingubinemia. P
P01762917A0615 |123 127|lossperb
P01762917A0615 |15 18|SerCom
P01762917A0615 |66 83|TGEK tetrapeptideidase P00008171T0
P01762917A0615 |23 28|Gly69on wi
P01762917A0615 |87 93|fingerPharma
P01762917A0615 |100 106|TFIIIA aspec
P01763065A0913 |0 2|P.P0
P01763106A0070 |99 111|test sessionc aspects of
P01763106A0070 |58 68|locomotion-nucleotid
P01763106A0070 |42 46|holeosph
P01763106A0070 |20 28|behaviorrison wi
P01764899A0399 |137 149|cavity levelia. P0000899
P01764899A0399 |72 89|caries prevalenceP00008171T0000 Ph
P01764899A0399 |114 120|cariesonatal
P01764899A0399 |40 46|effectphosph
P01764899A0399 |4 9|model01606
P01764899A0399 |50 68|water fluoridationes and 5-nucleotid
P01765095A0680 |0 36|12-O-Tetradecanoylphorbol 13-acetateP00001606T0076 Comparison with alkal
P01765095A0680 |127 142|regulators CMD1ilirubinemia. P
P01765095A0680 |147 155|myogenin997A0472
P01765095A0680 |97 102|mRNAsgic a
P01765095A0680 |83 93|expression000 Pharma
P01765266A0000 |3 17|Xenopus laevis001606T0076 Co
P01765266A0000 |132 139|oocytesbinemia
P01765266A0000 |150 157|embryosA0472 W
P01765266A0000 |75 87|EF-1 alpha O008171T0000 
P01765266A0000 |95 96|Ol
P01765266A0000 |41 66|elongation factor 1-alphahosphatases and 5-nucleot
P01765266A0000 |108 114|oocyte of ne
P01765266A0000 |23 27|geneon w
P01765269A0308 |6 13|introns606T007
P01765269A0308 |28 33|classth al
P01765269A0308 |45 61|pre-mRNA intronshatases and 5-nu
P01765269A0308 |132 140|featuresbinemia.
P01765269A0308 |93 112|consensus sequencescologic aspects of 
P01765375A0290 |87 98|transcriptsPharmacolog
P01765375A0290 |210 215|chaine dat
P01765375A0290 |195 203|clathrin of CSF 
P01765375A0290 |181 187|weight as a 
P01765375A0290 |120 122|kb h
P01765375A0290 |167 170|kDaCO3
P01765375A0290 |63 77|clathrin cloneeotidase P0000
P01765375A0290 |4 8|mRNA0160
P01765375A0290 |38 47|rat cellse phospha
P01765386A0305 |86 90|gene Pha
P01765386A0305 |105 109|exoncts 
P01765386A0305 |145 147|bp08
P01765386A0305 |126 135|junctionsbilirubin
P01765386A0305 |73 75|bp00
P01765386A0305 |31 43|DNA sequencealkaline pho
P01765386A0305 |25 27|kb w
P01765386A0305 |8 14|report6T0076
P01765386A0305 |158 162|geneen C
P01765386A0305 |99 101|kbc 
P01765407A0866 |113 122|excretioneonatal h
P01765407A0866 |130 137|mumol/lrubinem
P01765407A0866 |63 83|plasma concentrationeotidase P00008171T0
P01765407A0866 |145 164|mmol/mol creatinine08997A0472 When CSF
P01765407A0866 |92 104|postexposureacologic asp
P01765407A0866 |7 15|exposure06T0076 
P01765407A0866 |22 32|mg DMEA/m3son with a
P01766666A0788 |0 10|AntibodiesP00001606T
P01766666A0788 |95 100|siteslogic
P01766666A0788 |147 154|factors997A047
P01766666A0788 |48 71|nucleoprotein complexesases and 5-nucleotidase
P01766666A0788 |23 27|rE12on w
P01766666A0788 |32 39|rNFIL-6lkaline
P01766666A0788 |117 128|interactiontal hyperbi
P01766876A0000 |186 204|replacement vector function of CSF P
P01766876A0000 |131 145|point mutationubinemia. P000
P01766876A0000 |95 108|co-conversionlogic aspects
P01766876A0000 |164 170|marker [HCO3
P01766876A0000 |45 51|eventshatase
P01766876A0000 |113 124|co-exchangeeonatal hyp
P01766876A0000 |59 61|munu
P01766876A0000 |2 8|method000160
P01766876A0000 |68 78|chain genease P00008
P01766999A0000 |84 94|volunteers00 Pharmac
P01766999A0000 |11 19|activity076 Comp
P01766999A0000 |122 130|allergenyperbili
P01766999A0000 |58 60|AE-n
P01766999A0000 |23 56|allergen extract Ambrosia elatioron with alkaline phosphatases and
P01767060A0000 |258 262|headd wh
P01767060A0000 |124 132|durationerbiliru
P01767060A0000 |240 250|carcinomasno longer 
P01767060A0000 |181 189|patients as a fu
P01767060A0000 |110 119|frequencyf neonata
P01767060A0000 |42 62|c-DDP administrationosphatases and 5-nuc
P01767060A0000 |267 271|neckmpar
P01767060A0000 |146 155|responses8997A0472
P01767060A0000 |5 10|study1606T
P01767060A0000 |82 94|radiotherapy0000 Pharmac
P01767060A0000 |168 176|survivalO3-] is 
P01767060A0000 |221 227|stages-deple
P01767592A0682 |102 142|HAP2/HAP3 consensus recognition sequencespects of neonatal hyperbilirubinemia. P
P01767592A0682 |146 160|nucleotide-1548997A0472 When
P01767592A0682 |167 202|BAF1 consensus recognition sequenceCO3-] is shown as a function of CSF
P01767592A0682 |25 34|sequences with alk
P01767592A0682 |92 98|regionacolog
P01767592A0682 |39 59|DNA binding proteins phosphatases and 5-
P01767592A0682 |206 220|nucleotide-1362 the data of 
P01767899A0136 |103 122|thromboplastin timepects of neonatal h
P01767899A0136 |25 34|depletion with alk
P01767899A0136 |162 169|minutesSF [HCO
P01767899A0136 |188 200|envenomationunction of C
P01767899A0136 |7 23|thrombocytopenia06T0076 Comparis
P01767899A0136 |38 54|serum fibrinogene phosphatases a
P01767899A0136 |69 80|prothrombinse P0000817
P01768648A0853 |95 102|domainslogic a
P01768648A0853 |29 49|LexA fusion proteinsh alkaline phosphata
P01768648A0853 |15 25|propertiesComparison
P01768648A0853 |63 75|dimerizationeotidase P00
P01768648A0853 |106 110|cRelts o
P01769189A0000 |0 12|Plasma lipidP00001606T00
P01769189A0000 |296 302|VO2maxhave a
P01769189A0000 |269 274|yearsared 
P01769189A0000 |241 246|womeno lon
P01769189A0000 |211 213|SD d
P01769189A0000 |132 149|training distancebinemia. P0000899
P01769189A0000 |105 110|yearscts o
P01769189A0000 |17 37|lipoprotein profilesmparison with alkali
P01769189A0000 |187 200|ml kg-1 min-1function of C
P01769189A0000 |252 253|ns
P01769189A0000 |293 294|%l
P01769189A0000 |248 250|UTr 
P01769189A0000 |83 84|n0
P01769189A0000 |112 116|bodyneon
P01769189A0000 |129 130|%i
P01769189A0000 |312 325|ml kg-1 min-1ntly greater 
P01769189A0000 |79 81|RU71
P01769189A0000 |160 169|km week-1 CSF [HCO
P01769189A0000 |276 280|body con
P01769189A0000 |202 206|mean PCO
P01769189A0000 |70 77|runnerse P0000
P01769189A0000 |171 177|VO2max] is s
P01769919A0393 |9 25|threshold shiftsT0076 Comparison
P01769919A0393 |62 80|brainstem responseleotidase P0000817
P01769919A0393 |122 125|kHzype
P01770651T0001 |115 124|thyroxinenatal hyp
P01770651T0001 |61 84|radioimmunoassay systemcleotidase P00008171T00
P01770651T0001 |89 100|measurementarmacologic
P01770651T0001 |104 109|serumects 
P01770651T0001 |25 35|evaluation with alka
P01770651T0001 |39 59|equilibrium dialysis phosphatases and 5-
P01771593A1152 |17 19|TAmp
P01771593A1152 |92 95|PCDaco
P01771593A1152 |57 59|GD5-
P01771593A1152 |38 46|decreasee phosph
P01771593A1152 |50 53|AGDes 
P01771593A1232 |17 23|adultsmparis
P01771593A1232 |27 32|weeksith a
P01771593A1232 |76 85|offspring08171T000
P01771593A1232 |52 61|genitalia and 5-nu
P01771959A0442 |69 70|ps
P01771959A0442 |53 54|%a
P01771959A0442 |245 254|deviationnger disp
P01771959A0442 |150 159|deviationA0472 Whe
P01771959A0442 |211 219|segments data of
P01771959A0442 |167 171|PTCACO3-
P01771959A0442 |192 196|PTCAion 
P01771959A0442 |285 289|PTCA but
P01771959A0442 |262 266|PTCAen c
P01771959A0442 |66 67|%i
P01771959A0442 |12 29|ejection fraction76 Comparison wit
P01771959A0442 |6 10|PTCA606T
P01771959A0442 |100 108|function aspects
P01772201T0001 |40 52|subjectivityphosphatases
P01772201T0001 |60 66|perioducleot
P01772201T0001 |14 21|patient Compar
P01772201T0001 |27 31|workith 
P01772341A0852 |200 205|agentSF PC
P01772341A0852 |93 124|thromboxane receptor antagonistcologic aspects of neonatal hyp
P01772341A0852 |162 182|digoxin intoxicationSF [HCO3-] is shown 
P01772341A0852 |6 10|data606T
P01772341A0852 |37 46|treatmentne phosph
P01772341A0852 |143 153|protection0008997A04
P01772341A0852 |54 86|thromboxane synthetase inhibitornd 5-nucleotidase P00008171T0000
P01774062A0257 |39 53|HLA-DQA1 locus phosphatases 
P01774062A0257 |108 110|kb o
P01774062A0257 |14 20|A148A7 Compa
P01774062A0257 |126 135|YAC B1D12bilirubin
P01774062A0257 |9 12|YACT00
P01774062A0257 |76 81|locus08171
P01774062A0257 |66 73|Y3/Ringidase P
P01774063A0161 |220 230|chromosomeK-depleted
P01774063A0161 |14 32|backcross analysis Comparison with a
P01774063A0161 |134 153|thrombospondin genenemia. P00008997A04
P01774063A0161 |60 67|matingsucleoti
P01774063A0161 |96 98|F1og
P01774063A0161 |179 183|Fshbwn a
P01774063A0161 |72 94|C57BL/6J x Mus spretusP00008171T0000 Pharmac
P01774063A0161 |192 195|Ltkion
P01774063A0161 |201 209|B2M lociF PCO2 t
P01774063A0161 |39 46|progeny phosph
P01774063A0161 |101 114|C57BL/6J miceaspects of ne
P01774063A0161 |185 190|Actcla fun
P01774093T0000 |35 38|IgMlin
P01774093T0000 |15 22|outcomeCompari
P01774093T0000 |83 92|pregnancy000 Pharm
P01774093T0000 |48 79|Chlamydia trachomatis infectionases and 5-nucleotidase P000081
P01774822A0289 |101 106|cycleaspec
P01774822A0289 |45 67|LV time-density curveshatases and 5-nucleoti
P01774822A0289 |26 34|computerwith alk
P01776306A0572 |24 26|VTn 
P01776306A0572 |12 19|patient76 Comp
P01776715A0489 |86 90|loss Pha
P01776715A0489 |120 126|sample hyper
P01776715A0489 |30 44|centrifugation alkaline phos
P01776715A0489 |53 64|measurementand 5-nucle
P01776715A0489 |163 167|PCO2F [H
P01776715A0489 |94 97|CO2olo
P01776715A0489 |134 145|gas mixturenemia. P000
P01776715A0489 |174 177|kPas s
P01776715A0489 |99 112|equilibrationc aspects of 
P01776715A0489 |191 202|measurementtion of CSF
P01776715A0489 |3 8|delay00160
P01777841A0744 |35 46|differencesline phosph
P01777841A0744 |13 23|mechanisms6 Comparis
P01777841A0744 |121 129|neonateshyperbil
P01777841A0744 |76 82|muscle08171T
P01777841A0744 |63 70|effectseotidas
P01777841A0744 |110 116|adultsf neon
P01777841A0744 |97 106|afferentsgic aspec
P01779299A0000 |48 57|cockroachases and 
P01779299A0000 |23 34|alterationson with alk
P01779299A0000 |59 78|Periplaneta brunneanucleotidase P00008
P01779299A0000 |98 113|acanthocephalanic aspects of n
P01779299A0000 |115 140|Moniliformis moniliformisnatal hyperbilirubinemia.
P01779433A0694 |34 51|Alu family repeataline phosphatase
P01779433A0694 |59 67|junctionnucleoti
P01779433A0694 |332 335|end1.2
P01779433A0694 |124 129|alphaerbil
P01779433A0694 |148 152|unit97A0
P01779433A0694 |242 250|position longer 
P01779433A0694 |88 95|block Iharmaco
P01779433A0694 |302 319|Alu family repeat significantly gr
P01779433A0694 |359 376|Alu family repeatA0733 Flurazepam 
P01779433A0694 |115 116|Yn
P01779433A0694 |156 162|rhesusWhen C
P01779433A0694 |216 219|Alu of
P01779433A0694 |197 214|Alu family repeatf CSF PCO2 the da
P01779433A0694 |11 18|finding076 Com
P01779433A0694 |277 286|insertioncontrols 
P01779433A0694 |100 108|homology aspects
P01779769A0000 |154 165|kDa protein2 When CSF 
P01779769A0000 |126 139|reading framebilirubinemia
P01779769A0000 |77 84|phi C318171T00
P01779769A0000 |47 59|Streptomycestases and 5-
P01779769A0000 |20 35|repressor locusrison with alka
P01779769A0000 |37 38|cn
P01779769A0000 |4 12|sequence01606T00
P01779769A0000 |70 75|phagee P00
P01780235A0094 |48 59|transfusionases and 5-
P01780235A0094 |106 117|transfusionts of neona
P01780235A0094 |4 14|EPO levels01606T0076
P01781923A0744 |101 109|rightingaspects 
P01781923A0744 |225 230|linesleted
P01781923A0744 |60 73|concentrationucleotidase P
P01781923A0744 |93 97|losscolo
P01781923A0744 |145 149|rate0899
P01781923A0744 |77 79|DB81
P01781923A0744 |167 197|barbiturate brain distributionCO3-] is shown as a function o
P01781923A0744 |113 115|LSeo
P01781923A0744 |202 213|elimination PCO2 the d
P01781923A0744 |18 29|sensitivityparison wit
P01781923A0744 |33 35|DBka
P01782424A0278 |17 41|threshold concentrationsmparison with alkaline p
P01782424A0278 |108 117|sentinels of neona
P01782424A0278 |63 72|phenomenaeotidase 
P01782424A0278 |4 13|existence01606T007
P01782424A0278 |100 104|role asp
P01782669A0496 |55 63|additiond 5-nucl
P01782669A0496 |67 73|A23187dase P
P01782669A0496 |36 48|temperaturesine phosphat
P01782982A0155 |0 10|FelodipineP00001606T
P01782982A0155 |29 42|baseline FEV1h alkaline ph
P01782982A0155 |112 115|AMPneo
P01782982A0155 |124 143|bronchoconstrictionerbilirubinemia. P0
P01782982A0155 |98 107|histamineic aspect
P01782982A0155 |86 92|effect Pharm
P01783088A1136 |152 163|fibronectin472 When CS
P01783088A1136 |271 278|diseaseed to c
P01783088A1136 |91 92|%m
P01783088A1136 |14 22|patients Compari
P01783088A1136 |280 288|ABSTRACTtrols bu
P01783088A1136 |94 104|hyaluronanologic asp
P01783088A1136 |193 207|micrograms.l-1on of CSF PCO2
P01783088A1136 |133 147|micrograms.l-1inemia. P00008
P01783088A1136 |52 62|mast cells and 5-nuc
P01783088A1136 |40 47|diseasephospha
P01783088A1136 |236 244|patientsare no l
P01783088A1136 |306 311|WORDSnific
P01783375A1066 |4 11|mapping01606T0
P01783375A1066 |133 158|translocation breakpointsinemia. P00008997A0472 Wh
P01783375A1066 |90 99|disordersrmacologi
P01783375A1066 |56 60|gene 5-n
P01783375A1066 |36 47|involvementine phospha
P01784589A0000 |49 72|5-HT2 receptor activityses and 5-nucleotidase 
P01784589A0000 |41 45|rolehosp
P01784589A0000 |92 100|behavioracologic
P01784589A0000 |81 84|ratT00
P01785749A0695 |84 90|weight00 Pha
P01785749A0695 |44 49|groupphata
P01785749A0695 |59 67|childrennucleoti
P01785749A0695 |6 13|changes606T007
P01786094T0001 |8 16|contents6T0076 C
P01786094T0001 |27 33|copperith al
P01787085A0331 |47 59|control ratstases and 5-
P01787085A0331 |74 81|colloid0008171
P01787085A0331 |13 24|experiments6 Compariso
P01788002T0001 |34 35|Ba
P01788002T0001 |39 47|children phospha
P01788002T0001 |18 29|hepatitis Aparison wit
P01788002T0001 |0 14|MagnetotherapyP00001606T0076
P01791363A0208 |101 108|testingaspects
P01791363A0208 |43 51|patientssphatase
P01791363A0208 |6 13|results606T007
P01791363A0208 |81 88|suturesT0000 P
P01791754T0000 |87 103|secretion signalPharmacologic as
P01791754T0000 |31 35|rolealka
P01791754T0000 |60 68|featuresucleotid
P01791754T0000 |11 19|analysis076 Comp
P01791754T0000 |124 134|haemolysinerbilirubi
P01792580A0198 |71 86|blood donations P00008171T0000
P01792580A0198 |178 190|blood donorsown as a fun
P01792580A0198 |92 102|percentageacologic a
P01792580A0198 |26 34|Republicwith alk
P01792580A0198 |61 67|numbercleoti
P01792580A0198 |6 18|blood donors606T0076 Com
P01792580A0198 |159 169|percentagen CSF [HCO
P01792580A0198 |113 119|donorseonata
P01792580A0198 |38 44|Serbiae phos
P01792914T0000 |26 44|childhood leukemiawith alkaline phos
P01792914T0000 |15 22|relapseCompari
P01797459A0103 |0 10|MycoplasmaP00001606T
P01797459A0103 |52 57|fluid and 
P01797459A0103 |66 73|patientidase P
P01797467A0000 |0 5|RU486P0000
P01797467A0000 |89 98|pregnancyarmacolog
P01797467A0000 |74 85|termination0008171T000
P01797467A0000 |10 13|ONO007
P01797467A0000 |21 32|combinationison with a
P01798407A1011 |69 79|hypothesisse P000081
P01798407A1011 |133 137|lobeinem
P01798407A1011 |89 95|cortexarmaco
P01798407A1011 |44 52|patientsphatases
P01798407A1011 |172 189|laughing seizures is shown as a fu
P01798407A1011 |22 35|abnormalitiesson with alka
P01798407A1011 |158 164|originen CSF
P01798407A1011 |4 12|presence01606T00
P01804671A1001 |34 39|QS/QCaline
P01804671A1001 |45 52|resultshatases
P01804671A1001 |23 29|valueson wit
P01804671A1001 |129 133|lungirub
P01804671A1001 |111 121|air spaces neonatal 
P01804671A1001 |264 270|mmHg-1 compa
P01804671A1001 |167 201|ventilation/perfusion distributionCO3-] is shown as a function of CS
P01804671A1001 |236 242|CDCSF6are no
P01804671A1001 |3 7|line0016
P01804671A1001 |222 230|gas datadepleted
P01804671A1001 |255 263|ml.min-1aced whe
P01806314A0322 |5 10|cells1606T
P01806314A0322 |90 98|antibodyrmacolog
P01806314A0322 |107 119|muscle actins of neonata
P01806314A0322 |46 53|markersatases 
P01808049A0262 |0 16|CT abnormalitiesP00001606T0076 C
P01808049A0262 |26 37|term babieswith alkali
P01808049A0262 |122 123|%y
P01808049A0262 |150 151|%A
P01808049A0262 |211 212|% 
P01808049A0262 |96 97|%o
P01808049A0262 |47 57|hemorrhagetases and 
P01808049A0262 |75 76|%0
P01808049A0262 |154 165|hypodensity2 When CSF 
P01808049A0262 |185 186|%a
P01808049A0262 |138 139|%a
P01808049A0262 |200 207|atrophySF PCO2
P01808049A0262 |100 111|hypodensity aspects of
P01808049A0262 |171 181|hemorrhage] is shown
P01808136T0000 |33 55|coagulation factor XIIkaline phosphatases an
P01808136T0000 |15 29|contrast mediaComparison wit
P01808136T0000 |4 11|effects01606T0
P01808186A0984 |0 4|PigsP000
P01808186A0984 |77 80|Exp817
P01808186A0984 |53 57|dietand 
P01808186A0984 |71 73|kg P
P01808602A0000 |103 108|serumpects
P01808602A0000 |11 19|patients076 Comp
P01808602A0000 |61 68|effectscleotid
P01808602A0000 |44 56|hypertensionphatases and
P01808602A0000 |147 151|acid997A
P01808602A0000 |79 99|nifedipine treatment71T0000 Pharmacologi
P01808602A0000 |129 138|excretionirubinemi
P01808602A0000 |114 118|acidonat
P01808829A0510 |0 4|TPTAP000
P01808829A0510 |14 30|brain congestion Comparison with
P01808829A0510 |84 95|hemorrhages00 Pharmaco
P01809854A0106 |0 8|ExamplesP0000160
P01809854A0106 |24 32|subjectsn with a
P01809854A0106 |106 119|meta-analysists of neonata
P01809854A0106 |76 96|consensus statements08171T0000 Pharmacol
P01809854A0106 |48 63|research designases and 5-nucl
P01810108A0000 |70 82|inactivatione P00008171T
P01810108A0000 |30 44|heat exchanger alkaline phos
P01810108A0000 |129 133|milkirub
P01810108A0000 |145 149|cows0899
P01810108A0000 |6 21|phase slug flow606T0076 Compar
P01810108A0000 |86 108|Listeria monocytogenes Pharmacologic aspects
P01810154A0491 |10 18|children0076 Com
P01811243A0000 |137 142|yearsia. P
P01811243A0000 |227 234|ratingsted rat
P01811243A0000 |30 34|rCBF alk
P01811243A0000 |191 196|studytion 
P01811243A0000 |65 72|ratingstidase 
P01811243A0000 |36 48|measurementsine phosphat
P01811243A0000 |126 129|agebil
P01811243A0000 |111 119|patients neonata
P01811243A0000 |169 174|years3-] i
P01811243A0000 |18 28|blood flowparison wi
P01811243A0000 |252 266|rCBF techniquesplaced when c
P01811243A0000 |0 8|RegionalP0000160
P01811948A0289 |204 206|bpCO
P01811948A0289 |94 96|bpol
P01811948A0289 |193 195|bpon
P01811948A0289 |132 140|sequencebinemia.
P01811948A0289 |104 122|LpS1 beta promoterects of neonatal h
P01811948A0289 |15 20|studyCompa
P01811948A0289 |173 184|cis-elementis shown as
P01811948A0289 |142 143|G0
P01811948A0289 |69 76|elementse P000
P01811948A0289 |84 86|bp00
P01812102A0101 |152 163|NPN complex472 When CS
P01812102A0101 |120 125|women hype
P01812102A0101 |219 224|state K-de
P01812102A0101 |189 198|responsesnction of
P01812102A0101 |130 137|changesrubinem
P01812102A0101 |63 79|pattern reversaleotidase P000081
P01812102A0101 |12 25|study reports76 Comparison
P01812102A0101 |141 148|latencyP000089
P01812102A0101 |81 86|VEP-PT0000
P01812102A0101 |101 110|trimesteraspects o
P01812102A0101 |50 59|responseses and 5-
P01812690A0475 |3 7|case0016
P01812690A0475 |47 53|growthtases 
P01812690A0475 |11 14|SMF076
P01814182A0000 |102 109|heifersspects 
P01814182A0000 |10 15|doses0076 
P01814182A0000 |89 96|oestrusarmacol
P01814182A0000 |132 135|daybin
P01814182A0000 |74 84|luteolysis0008171T00
P01814182A0000 |19 39|15-methyl-PGF2 alphaarison with alkaline
P01814182A0000 |157 162|cyclehen C
P01814182A0000 |50 52|mges
P01814182A0000 |118 128|treatmentsal hyperbi
P01816655T0000 |0 6|ReviewP00001
P01816655T0000 |29 35|reporth alka
P01816655T0000 |14 24|literature Compariso
P01816655T0000 |41 45|casehosp
P01816655T0000 |59 63|cystnucl
P01817497A0715 |0 10|ResolutionP00001606T
P01817497A0715 |45 53|decreasehatases 
P01817497A0715 |57 64|Delta T5-nucle
P01817497A0715 |28 37|asymmetryth alkali
P01817497A0715 |125 135|populationrbilirubin
P01817497A0715 |101 102|%a
P01822581A0533 |85 92|reading0 Pharm
P01822581A0533 |7 16|instances06T0076 C
P01822581A0533 |30 47|alcohol responses alkaline phospha
P01822581A0533 |98 113|microgram/100mlic aspects of n
P01822581A0533 |118 132|breath samplesal hyperbiliru
P01822995T0000 |0 28|Maize rbcS promoter activityP00001606T0076 Comparison wi
P01822995T0000 |40 57|sequence elementsphosphatases and 
P01822995T0000 |71 91|dicot rbcS promoters P00008171T0000 Phar
P01823520A0183 |0 12|MeasurementsP00001606T00
P01823520A0183 |107 124|haematocrit values of neonatal hyp
P01823520A0183 |41 70|haematofluorometer Buchler ZFhosphatases and 5-nucleotidas
P01823524A0238 |154 161|factors2 When 
P01823524A0238 |242 262|xenobiotics toxicity longer displaced wh
P01823524A0238 |209 220|differenceshe data of 
P01823524A0238 |180 189|influencen as a fu
P01823524A0238 |74 81|variety0008171
P01823524A0238 |224 238|susceptibilitypleted rats ar
P01823524A0238 |22 28|numberson wi
P01823524A0238 |109 117|exposureof neona
P01823524A0238 |86 96|complexity Pharmacol
P01823524A0238 |32 40|exampleslkaline 
P01824713A0964 |101 105|lackaspe
P01824713A0964 |109 120|stimulationof neonatal
P01824713A0964 |78 83|c-jun171T0
P01824713A0964 |40 52|TRE sequencephosphatases
P01824713A0964 |58 72|cotransfection-nucleotidase 
P01824713A0964 |4 19|12S E1A product01606T0076 Comp
P01824944A0988 |118 121|IgEal 
P01824944A0988 |83 95|polypeptides000 Pharmaco
P01824944A0988 |6 15|treatment606T0076 
P01824944A0988 |21 32|tunicamycinison with a
P01824944A0988 |38 51|transfectantse phosphatase
P01825027T0000 |102 109|ATPasesspects 
P01825027T0000 |8 18|yeast gene6T0076 Com
P01825027T0000 |65 71|membertidase
P01825027T0000 |83 89|family000 Ph
P01825027T0000 |32 53|peroxisome biogenesislkaline phosphatases 
P01825027T0000 |0 4|PAS1P000
P01826003A0694 |118 123|exonsal hy
P01826003A0694 |56 63|members 5-nucl
P01826003A0694 |30 32|bp a
P01826003A0694 |18 28|base pairsparison wi
P01826003A0694 |4 8|gene0160
P01826003A0694 |71 81|SIG family P00008171
P01826003A0694 |87 99|beta TG genePharmacologi
P01826043A0431 |257 272|protein kinasesed when compare
P01826043A0431 |52 62|rsk-kinase and 5-nuc
P01826043A0431 |106 140|signal transducing protein kinasests of neonatal hyperbilirubinemia.
P01826043A0431 |240 243|Ca2no 
P01826043A0431 |191 198|memberstion of
P01826043A0431 |174 189|protein kinasess shown as a fu
P01826043A0431 |4 35|pp90rsk-protein kinase activity01606T0076 Comparison with alka
P01826043A0431 |206 229|protein kinase C family2 the data of K-deplete
P01827068T0000 |35 55|transcription factorline phosphatases an
P01827068T0000 |75 85|expression008171T000
P01827068T0000 |93 119|T cell receptor alpha genecologic aspects of neonata
P01827068T0000 |6 12|GATA-3606T00
P01827203A0136 |50 58|proteinses and 5
P01827203A0136 |74 80|dimers000817
P01827203A0136 |67 70|DNAdas
P01827203A0136 |21 42|transcription factorsison with alkaline ph
P01828248A0189 |17 29|UvrA proteinmparison wit
P01828248A0189 |146 159|UvrAB complex8997A0472 Whe
P01828248A0189 |131 134|DNAubi
P01828248A0189 |78 88|activities171T0000 P
P01828248A0189 |114 125|associationonatal hype
P01828248A0189 |172 189|helicase activity is shown as a fu
P01828248A0189 |98 106|solutionic aspec
P01828248A0189 |49 61|UvrB proteinses and 5-nu
P01829060A0649 |69 75|valuesse P00
P01829060A0649 |105 110|mg/kgcts o
P01829060A0649 |79 89|nifedipine71T0000 Ph
P01829060A0649 |91 93|EDma
P01829060A0649 |4 15|ED30 values01606T0076 
P01829060A0649 |33 38|mg/kgkalin
P01829460A0329 |0 26|Southwestern blot analysisP00001606T0076 Comparison 
P01829460A0329 |78 93|kappa B element171T0000 Pharma
P01829460A0329 |50 64|phosphoproteines and 5-nucle
P01830114A1587 |19 25|effectarison
P01830114A1587 |63 77|P4 transcriptseotidase P0000
P01830114A1587 |29 32|NS1h a
P01830114A1587 |135 144|integrityemia. P00
P01830114A1587 |93 106|amplificationcologic aspec
P01830114A1587 |161 168|repeatsCSF [HC
P01830114A1587 |110 126|gene copy numberf neonatal hyper
P01830114A1587 |53 59|levelsand 5-
P01830928A0361 |23 41|microtubule motorson with alkaline p
P01830928A0361 |133 151|attachment domainsinemia. P00008997A
P01830928A0361 |47 54|dyneinstases a
P01830928A0361 |78 89|superfamily171T0000 Ph
P01830928A0361 |110 118|proteinsf neonat
P01832019A0265 |102 107|weeksspect
P01832019A0265 |77 84|animals8171T00
P01832152A0000 |51 89|Agrobacterium tumefaciens oncogenicitys and 5-nucleotidase P00008171T0000 Ph
P01832152A0000 |91 93|J.ma
P01832152A0000 |4 39|incompatibility group W plasmid pSa01606T0076 Comparison with alkaline
P01832152A0902 |54 58|ORF1nd 5
P01832152A0902 |63 67|ORF2eoti
P01832152A0902 |24 37|start signalsn with alkali
P01832197T0001 |0 7|ImagingP000016
P01832197T0001 |11 31|D2 dopamine receptor076 Comparison with 
P01833185A0547 |118 124|Thr161al hyp
P01833185A0547 |39 48|phenotype phosphat
P01833185A0547 |230 241|cytokinesis rats are n
P01833185A0547 |56 69|fission yeast 5-nucleotida
P01833185A0547 |167 182|phosphorylationCO3-] is shown 
P01833185A0547 |209 216|mitosishe data
P01833185A0547 |4 22|Thr161Val mutation01606T0076 Compari
P01833185A0547 |191 205|uncoordinationtion of CSF PC
P01833185A0547 |139 143|acid. P0
P01833185A0547 |103 114|replacementpects of ne
P01833637A0531 |17 28|transcriptsmparison wi
P01833637A0531 |129 140|temperatureirubinemia.
P01833637A0531 |161 171|transcriptCSF [HCO3-
P01833637A0531 |182 192|HSP82 geneas a funct
P01833637A0531 |89 94|cellsarmac
P01833637A0531 |74 81|cdc68-10008171
P01833637A0531 |218 225|fashionf K-dep
P01833637A0531 |52 57|genes and 
P01833637A0531 |4 13|abundance01606T007
P01833637A0531 |101 109|transferaspects 
P01833716A0990 |0 12|DeregulationP00001606T00
P01833716A0990 |61 75|transformationcleotidase P00
P01833716A0990 |92 108|HTLV-1 infectionacologic aspects
P01833716A0990 |22 32|expressionson with a
P01837787T0000 |53 65|organizationand 5-nucleo
P01837787T0000 |11 22|Mov-34 gene076 Compari
P01837787T0000 |36 40|cDNAine 
P01837842A1410 |34 52|protein componentsaline phosphatases
P01837842A1410 |115 118|CREnat
P01837842A1410 |71 90|gel shift complexes P00008171T0000 Pha
P01837842A1410 |0 4|CREBP000
P01839414T0000 |51 60|neoplasmss and 5-n
P01839414T0000 |4 12|spectrum01606T00
P01839414T0000 |64 69|Sabahotida
P01840513A1019 |186 195|induction function
P01840513A1019 |125 133|increaserbilirub
P01840513A1019 |210 214|acide da
P01840513A1019 |75 77|bp00
P01840513A1019 |45 57|pCAT plasmidhatases and 
P01840513A1019 |33 43|SL-2 cellskaline pho
P01840513A1019 |93 99|regioncologi
P01840513A1019 |222 234|8-bromo-cAMPdepleted rat
P01840513A1019 |137 179|chloramphenicol acetyltransferase activityia. P00008997A0472 When CSF [HCO3-] is sho
P01840607A0294 |81 83|bpT0
P01840607A0294 |46 50|typeatas
P01840607A0294 |29 33|UTRsh al
P01840607A0294 |57 61|type5-nu
P01840607A0294 |126 129|PFPbil
P01840608A0823 |98 102|nifBic a
P01840608A0823 |63 67|nifAeoti
P01840608A0823 |31 44|reading framealkaline phos
P01840608A0823 |106 136|amino acid sequence comparisonts of neonatal hyperbilirubine
P01840608A0823 |4 14|N-terminus01606T0076
P01840711A0000 |18 24|rabbitpariso
P01840711A0000 |37 50|disease virusne phosphatas
P01840711A0000 |52 56|RHDV and
P01840711A0000 |4 14|RNA genome01606T0076
P01840902A1089 |68 74|plantsase P0
P01840902A1089 |147 155|monocots997A0472
P01840902A1089 |31 37|systemalkali
P01840902A1089 |160 166|dicots CSF [
P01840902A1089 |113 132|transport machineryeonatal hyperbiliru
P01842498A0000 |154 166|Jurkat cells2 When CSF [
P01842498A0000 |8 18|cDNA clone6T0076 Com
P01842498A0000 |230 247|blood lymphocytes rats are no long
P01842498A0000 |92 110|phytohemagglutininacologic aspects o
P01842498A0000 |57 70|hybridization5-nucleotidas
P01842498A0000 |26 28|R2wi
P01842498A0000 |112 115|PHAneo
P01842498A0000 |76 88|cDNA library08171T0000 P
P01842498A0000 |188 200|cDNA libraryunction of C
P01842498A0000 |117 134|phorbol myristatetal hyperbilirubi
P01842867A0696 |35 55|regeneration abilityline phosphatases an
P01842867A0696 |77 83|injury8171T0
P01842867A0696 |97 103|mucosagic as
P01842867A0696 |3 13|conclusion001606T007
P01844017A0410 |49 53|dropses 
P01844017A0410 |147 155|duration997A0472
P01844017A0410 |109 124|vitamin E levelof neonatal hyp
P01844017A0410 |133 137|handinem
P01844017A0410 |24 36|relationshipn with alkal
P01844017A0410 |57 101|glucose-6-phosphatase dehydrogenase activity5-nucleotidase P00008171T0000 Pharmacologic 
P01844017A0410 |159 168|poisoningn CSF [HC
P01844017A0410 |174 188|sodium nitrites shown as a f
P01844878A0000 |153 166|DNA fragments72 When CSF [
P01844878A0000 |104 122|promoter sequencesects of neonatal h
P01844878A0000 |80 84|gene1T00
P01844878A0000 |130 134|poolrubi
P01844878A0000 |2 8|vector000160
P01844878A0000 |49 76|neomycin phosphotransferaseses and 5-nucleotidase P000
P01844982A0324 |0 6|ChagasP00001
P01844982A0324 |62 77|schistosomiasisleotidase P0000
P01844982A0324 |90 96|factorrmacol
P01844982A0324 |108 116|controls of neon
P01844982A0324 |26 39|leishmaniasiswith alkaline
P01844982A0324 |8 15|disease6T0076 
P01844982A0324 |54 60|factornd 5-n
P01845829A0158 |118 125|factorsal hype
P01845829A0158 |79 86|domains71T0000
P01845829A0158 |31 39|sequencealkaline
P01845829A0158 |9 17|analysisT0076 Co
P01845829A0158 |143 154|brain cells0008997A047
P01845885A1003 |221 255|UL26 transcription initiation site-depleted rats are no longer displ
P01845885A1003 |90 101|amino acidsrmacologic 
P01845885A1003 |75 82|protein008171T
P01845885A1003 |365 369|unitFlur
P01845885A1003 |125 133|proteinsrbilirub
P01845885A1003 |27 31|unitith 
P01845885A1003 |44 48|UL26phat
P01845885A1003 |344 348|UL263 vs
P01845885A1003 |159 163|mRNAn CS
P01845885A1003 |283 310|methionine initiation codonls but still have a signifi
P01845885A1003 |115 121|familynatal 
P01845885A1003 |322 330|positioner slope
P01845899A0000 |33 41|rep genekaline p
P01845899A0000 |79 84|Rep5271T00
P01845899A0000 |72 77|Rep68P0000
P01845899A0000 |28 31|AAVth 
P01845899A0000 |134 153|AAV gene regulationnemia. P00008997A04
P01845899A0000 |90 95|Rep40rmaco
P01845899A0000 |65 70|Rep78tidas
P01845899A0000 |110 129|AAV DNA replicationf neonatal hyperbil
P01845899A0000 |21 26|virusison 
P01845899A0000 |55 63|proteinsd 5-nucl
P01846206A0665 |34 41|CMV dbpaline p
P01846206A0665 |56 67|replication 5-nucleoti
P01846206A0665 |9 15|regionT0076 
P01846206A0665 |81 87|assaysT0000 
P01846489A1119 |76 92|protease domains08171T0000 Pharm
P01846489A1119 |40 55|protease domainphosphatases an
P01846491A0459 |259 269|divergence when comp
P01846491A0459 |124 127|SFVerb
P01846491A0459 |284 292|ancestors but st
P01846491A0459 |189 192|DNAnct
P01846491A0459 |22 31|positionsson with 
P01846491A0459 |231 238|virusesrats ar
P01846491A0459 |163 185|complex rearrangementsF [HCO3-] is shown as 
P01846491A0459 |129 149|genus Leporipoxvirusirubinemia. P0000899
P01846491A0459 |200 206|genomeSF PCO
P01846491A0459 |39 47|VV genes phospha
P01846491A0459 |116 120|ORFsatal
P01846491A0459 |49 68|genus Orthopoxvirusses and 5-nucleotid
P01846803A0688 |103 107|linepect
P01846803A0688 |26 41|phosphorylationwith alkaline p
P01846803A0688 |135 143|residuesemia. P0
P01846803A0688 |164 180|ATP binding site [HCO3-] is show
P01846803A0688 |75 98|p34cdc2 kinase activity008171T0000 Pharmacolog
P01846803A0688 |45 48|Thrhat
P01846803A0688 |188 194|kinaseunctio
P01846803A0688 |59 62|Tyrnuc
P01846803A0688 |5 11|result1606T0
P01846803A0688 |117 125|locationtal hype
P01847464A0856 |239 244|c-myc no l
P01847464A0856 |126 131|ori-Pbilir
P01847464A0856 |195 206|amino acids of CSF PCO
P01847464A0856 |91 101|EBV originmacologic 
P01847464A0856 |14 29|cotransfections Comparison wit
P01847464A0856 |105 124|plasmid replicationcts of neonatal hyp
P01847464A0856 |174 193|EBNA-1 constructions shown as a functi
P01847464A0856 |76 81|sites08171
P01847464A0856 |33 49|pFRTK-CAT targetkaline phosphata
P01847464A0856 |253 272|localization signalplaced when compare
P01847665A1079 |51 56|geness and
P01847665A1079 |37 41|ideane p
P01847665A1079 |212 230|glia cell lineagesdata of K-depleted
P01847665A1079 |144 154|expression008997A047
P01847665A1079 |133 138|genesinemi
P01847665A1079 |194 201|programn of CS
P01847665A1079 |114 121|concertonatal 
P01847665A1079 |66 80|PDGF receptorsidase P0000817
P01847665A1079 |4 12|findings01606T00
P01847665A1079 |84 96|glioma cells00 Pharmacol
P01848300A0910 |38 42|cstAe ph
P01848300A0910 |11 19|evidence076 Comp
P01848300A0910 |58 77|peptide utilization-nucleotidase P0000
P01848871A0392 |273 284|tachycardia to control
P01848871A0392 |62 67|drugsleoti
P01848871A0392 |194 206|prolongationn of CSF PCO
P01848871A0392 |219 228|potential K-deplet
P01848871A0392 |142 149|portion0000899
P01848871A0392 |97 106|potentialgic aspec
P01848871A0392 |22 32|hypothesisson with a
P01848871A0392 |124 140|amplitude signalerbilirubinemia.
P01848871A0392 |5 10|study1606T
P01848871A0392 |173 184|QRS complexis shown as
P01848871A0392 |38 52|sodium channele phosphatases
P01848871A0392 |250 257|slowingdisplac
P01849509T0000 |119 130|transposasel hyperbili
P01849509T0000 |191 196|IS256tion 
P01849509T0000 |142 147|ISRm300008
P01849509T0000 |42 85|Rhizobium meliloti insertion sequence ISRm3osphatases and 5-nucleotidase P00008171T000
P01849509T0000 |19 38|nucleotide sequencearison with alkalin
P01849509T0000 |201 231|Thiobacillus ferrooxidans IST2F PCO2 the data of K-depleted 
P01849509T0000 |87 97|similarityPharmacolo
P01849509T0000 |0 14|IdentificationP00001606T0076
P01849675A0167 |17 29|relationshipmparison wit
P01849675A0167 |77 79|KV81
P01849675A0167 |61 73|DNA sequencecleotidase P
P01849675A0167 |39 46|viruses phosph
P01849675A0167 |99 101|bpc 
P01849734A1063 |68 74|levelsase P0
P01849734A1063 |10 30|PR55 beta transcript0076 Comparison with
P01849734A1063 |104 120|cell line LA-N-1ects of neonatal
P01849734A1063 |44 46|kbph
P01849734A1063 |126 131|levelbilir
P01849734A1063 |176 186|cell linesshown as a
P01849734A1063 |82 95|neuroblastoma0000 Pharmaco
P01849734A1063 |139 143|mRNA. P0
P01850096A0662 |137 142|startia. P
P01850096A0662 |72 92|restriction fragmentP00008171T0000 Pharm
P01850096A0662 |46 49|E12ata
P01850096A0662 |29 32|E12h a
P01850096A0662 |154 179|alpha-actin transcription2 When CSF [HCO3-] is sho
P01850096A0662 |37 41|MyoDne p
P01850096A0662 |16 24|myogeninompariso
P01850096A0662 |0 12|HeterodimersP00001606T00
P01850105A1093 |139 161|muscle differentiation. P00008997A0472 When 
P01850105A1093 |60 65|c-mycucleo
P01850105A1093 |15 20|c-mycCompa
P01850105A1093 |111 113|Id n
P01850105A1093 |78 93|differentiation171T0000 Pharma
P01850105A1093 |126 135|regulatorbilirubin
P01850105A1093 |4 11|effects01606T0
P01850127A0000 |116 123|proteinatal hy
P01850127A0000 |40 60|branchpoint sequencephosphatases and 5-n
P01850127A0000 |74 83|pre-mRNAs0008171T0
P01850127A0000 |93 100|bindingcologic
P01850127A0000 |131 151|polypyrimidine tractubinemia. P00008997A
P01850127A0000 |7 18|association06T0076 Com
P01850127A0000 |22 30|U2 snRNPson with
P01850893A0286 |19 29|antibodiesarison wit
P01850893A0286 |56 63|rabbits 5-nucl
P01850893A0286 |83 88|farms000 P
P01851386T0092 |36 43|FONICAPine pho
P01851386T0092 |12 34|Lung Cancer Task Force76 Comparison with alk
P01851527T0000 |85 88|APP0 P
P01851527T0000 |29 33|geneh al
P01851527T0000 |110 116|blocksf neon
P01851527T0000 |43 83|Alzheimer beta-amyloid precursor proteinsphatases and 5-nucleotidase P00008171T0
P01851527T0000 |129 138|sequencesirubinemi
P01851527T0000 |4 21|promoter activity01606T0076 Compar
P01851756A0743 |0 4|BiolP000
P01851862A0273 |0 20|Nucleotide sequencesP00001606T0076 Compa
P01851862A0273 |57 62|SFV-15-nuc
P01851862A0273 |33 41|env genekaline p
P01851862A0273 |50 53|LTRes 
P01851876A0129 |35 46|EMBL3 mouseline phosph
P01851876A0129 |5 12|element1606T00
P01851876A0129 |55 62|libraryd 5-nuc
P01852438A0928 |50 54|casees a
P01852438A0928 |37 42|levelne ph
P01852438A0928 |4 13|MVV-value01606T007
P01852438A0928 |64 71|percentotidase
P01852603A0000 |119 128|radiationl hyperbi
P01852603A0000 |40 53|fission yeastphosphatases 
P01852603A0000 |13 30|DNA repair mutant6 Comparison with
P01852603A0000 |4 8|rad90160
P01852603A0000 |103 105|UVpe
P01853796T0000 |0 6|ReviewP00001
P01853796T0000 |57 61|role5-nu
P01853796T0000 |25 42|glucose tolerance with alkaline ph
P01853796T0000 |8 21|deterioration6T0076 Compar
P01853796T0000 |65 83|insulin resistancetidase P00008171T0
P01853796T0000 |48 51|agease
P01854339A0221 |67 86|consensus promotersdase P00008171T0000
P01854339A0221 |134 140|levelsnemia.
P01854339A0221 |108 117|sequences of neona
P01854339A0221 |27 46|sequence similarityith alkaline phosph
P01854339A0221 |144 154|expression008997A047
P01854339A0221 |7 13|region06T007
P01855255T0000 |35 40|yeastline 
P01855255T0000 |10 20|initiation0076 Compa
P01855255T0000 |72 78|GTPaseP00008
P01855255T0000 |24 31|mitosisn with 
P01855255T0000 |49 53|RCC1ses 
P01856021A0577 |4 10|method01606T
P01856021A0577 |161 168|tolueneCSF [HC
P01856021A0577 |125 132|controlrbiliru
P01856021A0577 |149 157|exposure7A0472 W
P01856021A0577 |42 52|laboratoryosphatases
P01856021A0577 |176 182|xyleneshown 
P01856021A0577 |59 63|yearnucl
P01856021A0577 |96 105|procedureogic aspe
P01857143A0351 |69 78|diagnosisse P00008
P01857143A0351 |43 55|skin lesionssphatases an
P01857143A0351 |30 34|male alk
P01857143A0351 |82 95|myelofibrosis0000 Pharmaco
P01857143A0351 |4 11|patient01606T0
P01857326A0160 |0 10|Oculus-500P00001606T
P01857326A0160 |30 55|resolution imaging boards alkaline phosphatases an
P01857326A0160 |91 100|computersmacologic
P01857326A0160 |60 63|useucl
P01857326A0160 |16 21|groupompar
P01857326A0160 |69 75|IBM-ATse P00
P01860846A0663 |96 121|MARCKS gene transcriptionogic aspects of neonatal 
P01860846A0663 |44 71|tumor necrosis factor-alphaphatases and 5-nucleotidase
P01860846A0663 |149 172|leukemia cell line HL607A0472 When CSF [HCO3-]
P01860846A0663 |10 14|cDNA0076
P01861034A0798 |32 40|fragmentlkaline 
P01861034A0798 |72 80|pressureP0000817
P01861034A0798 |104 121|scaphoid fragmentects of neonatal 
P01861034A0798 |6 15|resection606T0076 
P01861034A0798 |55 67|contact aread 5-nucleoti
P01861188A0000 |152 157|plate472 W
P01861188A0000 |132 143|screw headsbinemia. P0
P01861188A0000 |60 64|PMMAucle
P01861188A0000 |174 183|stabilitys shown a
P01861188A0000 |196 204|fixationof CSF P
P01861188A0000 |265 270|bonescompa
P01861188A0000 |330 353|ASIF compression plates (1.21 +/- 0.23 vs. P00
P01861188A0000 |89 94|platearmac
P01861188A0000 |16 25|techniqueomparison
P01861188A0000 |291 302|osteotomiestill have a
P01861188A0000 |103 107|bonepect
P01861188A0000 |0 12|Plate lutingP00001606T00
P01862027A0212 |49 58|diagnosisses and 5
P01862027A0212 |62 87|Rothmund-Thomson syndromeleotidase P00008171T0000 
P01862027A0212 |6 14|features606T0076
P01862455T0000 |0 16|Thyroid lymphomaP00001606T0076 C
P01862455T0000 |25 35|management with alka
P01863768A0649 |55 61|domaind 5-nu
P01863768A0649 |23 29|ORF113on wit
P01863768A0649 |4 11|protein01606T0
P01863887A0174 |0 17|Space limitationsP00001606T0076 Co
P01863887A0174 |63 78|pharmaceuticalseotidase P00008
P01863887A0174 |88 106|tissue plasminogenharmacologic aspec
P01863887A0174 |129 137|hormonesirubinem
P01863887A0174 |196 212|clotting factorsof CSF PCO2 the 
P01863887A0174 |179 193|erythropoietinwn as a functi
P01863887A0174 |145 152|thyroid08997A0
P01863887A0174 |40 46|reviewphosph
P01863887A0174 |218 232|blood productsf K-depleted r
P01863887A0174 |163 177|growth hormoneF [HCO3-] is s
P01863887A0174 |154 161|insulin2 When 
P01863887A0174 |118 127|substanceal hyperb
P01864510A0946 |34 44|starvationaline phos
P01864510A0946 |29 30|hh
P01864510A0946 |71 76|cells P000
P01864510A0946 |0 10|Dd PK1 RNAP00001606T
P01864821A0000 |204 217|blood vesselsCO2 the data 
P01864821A0000 |189 200|obstructionnction of C
P01864821A0000 |58 65|feature-nucleo
P01864821A0000 |133 140|hypoxiainemia.
P01864821A0000 |12 17|forms76 Co
P01864821A0000 |28 40|cell diseaseth alkaline 
P01864821A0000 |114 124|conditionsonatal hyp
P01864821A0000 |173 184|blood cellsis shown as
P01864821A0000 |157 165|sicklinghen CSF 
P01864821A0000 |81 93|globin chainT0000 Pharma
P01864837A1029 |64 74|% homologyotidase P0
P01864837A1029 |88 104|mouse contrapsinharmacologic asp
P01864837A1029 |150 180|rat alpha 1-protease inhibitorA0472 When CSF [HCO3-] is show
P01864837A1029 |109 117|contrastof neona
P01864837A1029 |12 21|structure76 Compar
P01864837A1029 |43 51|proteinssphatase
P01864837A1029 |126 136|% homologybilirubine
P01865010A0000 |171 177|manner] is s
P01865010A0000 |285 288|rat bu
P01865010A0000 |141 150|diamidinoP00008997
P01865010A0000 |125 136|Fluoro-Goldrbilirubine
P01865010A0000 |245 253|auditorynger dis
P01865010A0000 |12 23|connections76 Comparis
P01865010A0000 |271 277|cortexed to 
P01865010A0000 |116 123|tracersatal hy
P01865010A0000 |201 216|representationsF PCO2 the data
P01865010A0000 |50 61|integrationes and 5-nu
P01865010A0000 |0 8|PatternsP0000160
P01867069A0000 |154 160|effect2 When
P01867069A0000 |6 15|CD-1 mice606T0076 
P01867069A0000 |77 81|days8171
P01867069A0000 |43 61|% nicotine sulfatesphatases and 5-nu
P01867069A0000 |133 136|ageine
P01867069A0000 |116 120|pupsatal
P01867069A0000 |200 206|molarsSF PCO
P01867069A0000 |168 179|developmentO3-] is sho
P01867069A0000 |19 23|daysaris
P01869565A1254 |0 3|USFP00
P01869565A1254 |86 98|ADH promoter Pharmacolog
P01869565A1254 |31 44|transcriptionalkaline phos
P01869565A1254 |49 67|translation systemses and 5-nucleoti
P01869565A1254 |117 120|MLPtal
P01869907A2146 |32 41|responseslkaline p
P01869907A2146 |120 123|H2O hy
P01869907A2146 |125 133|ABSTRACTrbilirub
P01869907A2146 |151 156|WORDS0472 
P01869907A2146 |4 24|across-fiber pattern01606T0076 Compariso
P01869907A2146 |55 69|NaCl solutionsd 5-nucleotida
P01869968A0000 |71 76|HMPAO P000
P01869968A0000 |9 30|radioactivity contentT0076 Comparison with
P01869968A0000 |92 100|subjectsacologic
P01869968A0000 |53 67|administrationand 5-nucleoti
P01869968A0673 |114 118|rCBFonat
P01869968A0673 |131 143|significanceubinemia. P0
P01869968A0673 |91 96|HMPAOmacol
P01869968A0673 |59 65|resultnucleo
P01869968A0673 |145 146|p0
P01869968A0673 |7 26|regression analysis06T0076 Comparison 
P01869968A0673 |80 89|clearance1T0000 Ph
P01870194A0302 |100 111|homogeneity aspects of
P01870194A0302 |37 42|HIV-1ne ph
P01870194A0302 |6 33|immunodeficiency virus type606T0076 Comparison with al
P01870428A0677 |0 11|Thigh girthP00001606T0
P01870428A0677 |47 53|HDL2-Ctases 
P01870428A0677 |58 62|mass-nuc
P01870428A0677 |73 90|LDL particle size00008171T0000 Pha
P01870428A0677 |97 102|womengic a
P01870428A0677 |39 42|HDL ph
P01870500A0276 |102 107|tumorspect
P01870500A0276 |39 61|target volume elements phosphatases and 5-nu
P01870500A0276 |189 194|tumornctio
P01870500A0276 |242 261|reciprocity theorem longer displaced w
P01870500A0276 |28 34|sourceth alk
P01870500A0276 |150 160|host organA0472 When
P01870500A0276 |19 24|pairsariso
P01870500A0276 |81 89|S valuesT0000 Ph
P01870500A0276 |221 231|host organ-depleted 
P01870500A0276 |0 13|ContributionsP00001606T007
P01871033A0434 |0 5|TestsP0000
P01871033A0434 |29 39|impressionh alkaline
P01871033A0434 |47 52|forcetases
P01871033A0434 |86 107|laboratory simulation Pharmacologic aspect
P01871033A0434 |179 185|methodwn as 
P01871033A0434 |138 152|testing cementa. P00008997A0
P01871033A0434 |118 133|clearing cemental hyperbilirub
P01871135A0295 |84 95|amino acids00 Pharmaco
P01871135A0295 |161 182|rat liver glucokinaseCSF [HCO3-] is shown 
P01871135A0295 |27 40|reading frameith alkaline 
P01871135A0295 |147 157|% identity997A0472 W
P01871135A0295 |133 140|proteininemia.
P01871135A0295 |123 126|kDaper
P01871135A0295 |4 8|cDNA0160
P01871135A0295 |112 116|massneon
P01871135A0295 |49 51|bpse
P01871135A0295 |69 76|proteinse P000
P01871971A0836 |68 80|binding sitease P0000817
P01871971A0836 |56 65|NFIII/OCT 5-nucleo
P01871971A0836 |142 148|growth000089
P01871971A0836 |97 106|ATF motifgic aspec
P01871971A0836 |18 25|mutantsparison
P01871971A0836 |0 8|AnalysisP0000160
P01872856A0277 |0 8|RecoveryP0000160
P01872856A0277 |127 132|liveriliru
P01872856A0277 |26 28|BAwi
P01872856A0277 |63 64|%e
P01872856A0277 |90 91|%r
P01872856A0277 |46 47|%a
P01872856A0277 |75 78|hrs008
P01872856A0277 |187 194|animalsfunctio
P01872856A0277 |53 59|faecesand 5-
P01872856A0277 |158 166|recoveryen CSF [
P01872856A0277 |172 173|% 
P01872856A0277 |110 123|radioactivityf neonatal hy
P01872856A0277 |37 42|urinene ph
P01872856A0277 |137 143|testisia. P0
P01873999A0000 |187 191|hostfunc
P01873999A0000 |56 68|model system 5-nucleotid
P01873999A0000 |227 235|proteinsted rats
P01873999A0000 |135 150|gene expressionemia. P00008997
P01873999A0000 |159 176|secretion processn CSF [HCO3-] is 
P01873999A0000 |124 131|detailserbilir
P01873999A0000 |200 210|productionSF PCO2 th
P01873999A0000 |256 264|interestced when
P01874195A0139 |70 89|sequence similaritye P00008171T0000 Ph
P01874195A0139 |28 39|GH receptorth alkaline
P01874195A0139 |52 57|liver and 
P01874195A0139 |93 102|receptorscologic a
P01874195A0139 |114 144|signal transduction mechanismsonatal hyperbilirubinemia. P00
P01874195A0139 |190 214|tyrosine kinase activityction of CSF PCO2 the da
P01874752A0948 |71 79|cdc2/p62 P000081
P01874752A0948 |47 66|conditions cdc2/p58tases and 5-nucleot
P01874752A0948 |128 136|activitylirubine
P01874752A0948 |97 108|differencesgic aspects
P01875922A0770 |0 17|Mutation analysisP00001606T0076 Co
P01875922A0770 |111 117|effect neona
P01875922A0770 |38 46|segmentse phosph
P01875922A0770 |70 76|regione P000
P01876836T0000 |0 14|IdentificationP00001606T0076
P01876836T0000 |41 49|subunitshosphata
P01876836T0000 |53 71|GA binding proteinand 5-nucleotidase
P01876836T0000 |18 21|Etspar
P01878489A0959 |42 51|monocytesosphatase
P01878489A0959 |165 174|monocytes[HCO3-] i
P01878489A0959 |14 22|response Compari
P01878489A0959 |94 116|NADPH oxidase activityologic aspects of neon
P01878489A0959 |26 37|neutrophilswith alkali
P01878489A0959 |77 86|magnitude8171T0000
P01878489A0959 |145 156|neutrophils08997A0472 
P01878755A0496 |136 147|chloroquinemia. P00008
P01878755A0496 |63 64|Pe
P01878755A0496 |14 25|enterotoxin Comparison
P01878755A0496 |96 112|blood appearanceogic aspects of 
P01878755A0496 |7 12|ileum06T00
P01878755A0496 |114 115|Po
P01878755A0496 |48 61|disappearanceases and 5-nu
P01881595A0476 |0 8|FormalinP0000160
P01881595A0476 |75 86|NS neurones008171T0000
P01881595A0476 |173 174|ni
P01881595A0476 |196 197|no
P01881595A0476 |126 134|activitybilirubi
P01881595A0476 |24 30|SNO NSn with
P01881595A0476 |88 89|nh
P01881595A0476 |141 153|NnS neuronesP00008997A04
P01881595A0476 |188 194|phasesunctio
P01881595A0476 |117 122|phasetal h
P01881595A0476 |35 47|NnS neuronesline phospha
P01881671T0001 |0 6|UptakeP00001
P01881671T0001 |10 19|ofloxacin0076 Comp
P01882240A0526 |100 104|AIDS asp
P01882240A0526 |132 143|communitiesbinemia. P0
P01882240A0526 |88 96|researchharmacol
P01882240A0526 |77 84|quality8171T00
P01882240A0526 |40 46|issuesphosph
P01882240A0526 |113 122|behaviorseonatal h
P01882240A0526 |21 30|attentionison with
P01882386A0000 |175 179|lead sho
P01882386A0000 |125 136|combinationrbilirubine
P01882386A0000 |73 109|N-benzyl-N-dithiocarboxy-D-glucamine00008171T0000 Pharmacologic aspects 
P01882386A0000 |42 49|2-furylosphata
P01882386A0000 |162 171|excretionSF [HCO3-
P01882386A0000 |145 157|mobilization08997A0472 W
P01882386A0000 |111 114|NaB ne
P01882386A0000 |58 62|acid-nuc
P01882386A0000 |4 17|effectiveness01606T0076 Co
P01882386A0000 |200 204|ratsSF P
P01882386A0000 |21 40|alpha-mercapto-betaison with alkaline 
P01882386A0000 |64 67|MFAoti
P01883992A0922 |141 156|maize endospermP00008997A0472 
P01883992A0922 |94 104|expressionologic asp
P01883992A0922 |77 86|regulator8171T0000
P01883992A0922 |27 33|beta-1ith al
P01883992A0922 |112 126|beta-zein geneneonatal hyper
P01883992A0922 |6 13|results606T007
P01884435A0088 |68 72|ptO2ase 
P01884435A0088 |158 172|microelectrodeen CSF [HCO3-]
P01884435A0088 |77 94|ptH distributions8171T0000 Pharmac
P01884435A0088 |24 31|effectsn with 
P01884435A0088 |226 229|ptHete
P01884435A0088 |107 119|tissue sitess of neonata
P01884435A0088 |217 221|ptO2of K
P01884435A0088 |5 10|study1606T
P01884435A0088 |201 213|measurementsF PCO2 the d
P01884435A0088 |35 46|hypovolemialine phosph
P01884998A1135 |51 64|transcriptions and 5-nucle
P01884998A1135 |109 113|siteof n
P01884998A1135 |4 11|members01606T0
P01884998A1135 |70 79|promoterse P000081
P01885006A0995 |55 61|subsetd 5-nu
P01885006A0995 |104 114|activationects of ne
P01885006A0995 |24 39|superactivationn with alkaline
P01885006A0995 |4 11|domains01606T0
P01885613A1298 |0 11|InformationP00001606T0
P01885613A1298 |91 100|pro alphamacologic
P01885613A1298 |107 120|collagen genes of neonatal
P01885613A1298 |73 83|regulation00008171T0
P01885613A1298 |58 65|studies-nucleo
P01885613A1298 |35 44|sequencesline phos
P01885752A0198 |0 21|Chlamydia trachomatisP00001606T0076 Compar
P01885752A0198 |26 44|Chlamydia psittaciwith alkaline phos
P01885752A0198 |66 83|methanol fixationidase P00008171T0
P01885915A0000 |119 133|P. haemolytical hyperbilirub
P01885915A0000 |90 102|endocarditisrmacologic a
P01885915A0000 |15 25|infectionsComparison
P01885915A0000 |31 42|bacteraemiaalkaline ph
P01885915A0000 |50 71|Pasteurella multocidaes and 5-nucleotidase
P01886043A0380 |51 53|pHs 
P01886043A0380 |74 80|effect000817
P01886043A0380 |25 32|complex with a
P01886043A0380 |58 62|HPCD-nuc
P01886043A0380 |11 13|pH07
P01886043A0380 |88 98|solubilityharmacolog
P01886043A0380 |121 124|SMXhyp
P01886043A0380 |159 168|moleculesn CSF [HC
P01886043A0380 |178 197|inclusion complexesown as a function o
P01886043A0380 |4 7|SMX016
P01886043A0380 |207 211|HPCD the
P01886368A0000 |0 16|PO2 measurementsP00001606T0076 C
P01886368A0000 |121 125|pigshype
P01886368A0000 |129 137|normoxiairubinem
P01886368A0000 |42 69|recess type microelectrodesosphatases and 5-nucleotida
P01886368A0000 |97 107|nerve headgic aspect
P01886368A0000 |142 151|hyperoxia00008997A
P01886774A0000 |119 135|octamer sequencel hyperbilirubin
P01886774A0000 |60 75|Echerichia coliucleotidase P00
P01886774A0000 |80 96|characterization1T0000 Pharmacol
P01886774A0000 |27 34|domainsith alk
P01886774A0000 |38 42|Oct3e ph
P01886774A0000 |100 111|DNA binding aspects of
P01888896A0505 |2 17|deletion series0001606T0076 Co
P01888896A0505 |37 43|regionne pho
P01888896A0505 |61 69|positioncleotida
P01888896A0505 |115 130|initiation sitenatal hyperbili
P01888896A0505 |168 175|tobaccoO3-] is
P01889753A0441 |16 18|ntom
P01889753A0441 |56 66|boundaries 5-nucleot
P01889753A0441 |37 42|exonsne ph
P01889753A0441 |95 102|regionslogic a
P01889753A0441 |20 29|sequencesrison wit
P01889753A0441 |4 14|nucleotide01606T0076
P01890362A0305 |84 92|patients00 Pharm
P01890362A0305 |122 127|yearsyperb
P01890362A0305 |47 64|eye complicationstases and 5-nucle
P01890362A0305 |72 79|leprosyP000081
P01890362A0305 |10 18|patients0076 Com
P01890989A1392 |117 127|amphibianstal hyperb
P01890989A1392 |95 100|geneslogic
P01890989A1392 |104 112|chickensects of 
P01890989A1392 |36 44|elementsine phos
P01890989A1392 |65 83|estrogen inductiontidase P00008171T0
P01892680A0907 |0 8|ToxicityP0000160
P01892680A0907 |52 60|sedation and 5-n
P01892680A0907 |89 94|arm Barmac
P01892680A0907 |96 97|po
P01892680A0907 |33 41|regimenskaline p
P01893195A0000 |119 134|virus Issyk-Kull hyperbilirubi
P01893195A0000 |40 48|hamstersphosphat
P01893195A0000 |59 63|micenucl
P01893195A0000 |24 31|monkeysn with 
P01893195A0000 |99 109|propertiesc aspects 
P01893195A0000 |68 75|authorsase P00
P01893927A0704 |152 158|output472 Wh
P01893927A0704 |130 140|reductionsrubinemia.
P01893927A0704 |63 69|levelseotida
P01893927A0704 |25 33|pressure with al
P01893927A0704 |108 111|NNA of
P01893927A0704 |37 59|phenylephrine infusionne phosphatases and 5-
P01893927A0704 |100 103|NMA as
P01894696A0301 |0 2|J.P0
P01895358A0000 |0 6|LimitsP00001
P01895358A0000 |197 212|energy turnoverf CSF PCO2 the 
P01895358A0000 |129 147|training programmeirubinemia. P00008
P01895358A0000 |10 25|energy turnover0076 Comparison
P01895358A0000 |29 37|relationh alkali
P01895358A0000 |105 110|limitcts o
P01895358A0000 |80 85|terms1T000
P01895358A0000 |112 119|changesneonata
P01895358A0000 |168 182|energy balanceO3-] is shown 
P01895358A0000 |50 61|performancees and 5-nu
P01895370A0199 |119 127|parallell hyperb
P01895370A0199 |14 24|reductions Compariso
P01895370A0199 |76 110|maximum shifted-frequency envelope08171T0000 Pharmacologic aspects o
P01895370A0199 |59 60|Dn
P01895370A0199 |62 68|pointsleotid
P01895370A0199 |28 32|flowth a
P01895370A0199 |44 45|Sp
P01895370A0199 |38 42|peake ph
P01895370A0199 |140 147|fashion P00008
P01895370A0199 |154 155|D2
P01895370A0199 |51 57|troughs and 
P01895384A0746 |101 109|promoteraspects 
P01895384A0746 |45 57|IE1 promoterhatases and 
P01895384A0746 |77 87|expression8171T0000 
P01895384A0746 |4 20|IE0 gene product01606T0076 Compa
P01895393A0745 |103 111|TATA boxpects of
P01895393A0745 |10 19|promoters0076 Comp
P01895393A0745 |73 82|Sp1 sites00008171T
P01895393A0745 |90 97|absencermacolo
P01895393A0745 |60 69|Sp1 sitesucleotida
P01895393A0745 |33 41|TATA boxkaline p
P01895393A0745 |174 182|promoters shown 
P01895393A0745 |155 169|RNA polymerase When CSF [HCO
P01895393A0745 |49 56|absenceses and
P01895555T0001 |0 10|EvaluationP00001606T
P01895555T0001 |31 39|functionalkaline
P01895555T0001 |83 94|Tc-99m-MIBI000 Pharmac
P01895555T0001 |70 77|imaginge P0000
P01896777T0000 |0 17|Ivermectin uptakeP00001606T0076 Co
P01896777T0000 |107 126|Onchocerca volvuluss of neonatal hyper
P01896777T0000 |22 34|distributionson with alk
P01896777T0000 |42 48|plasmaosphat
P01896777T0000 |53 59|tissueand 5-
P01896777T0000 |84 92|patients00 Pharm
P01897515A0348 |0 25|Bone marrow abnormalitiesP00001606T0076 Comparison
P01897515A0348 |29 36|Hodgkinh alkal
P01897515A0348 |110 120|mechanismsf neonatal
P01897515A0348 |76 89|understanding08171T0000 Ph
P01897515A0348 |39 46|disease phosph
P01897515A0348 |141 147|anemiaP00008
P01898113A0265 |35 49|clearance rateline phosphata
P01898113A0265 |12 23|uptake rate76 Comparis
P01898113A0265 |72 75|BCFP00
P01898113A0265 |80 93|SWA killifish1T0000 Pharma
P01898164A0839 |117 121|archtal 
P01898164A0839 |135 156|aorta diameter ratiosemia. P00008997A0472 
P01898164A0839 |37 43|repairne pho
P01898164A0839 |77 82|group8171T
P01898164A0839 |158 170|arch indicesen CSF [HCO3
P01898164A0839 |86 93|infants Pharma
P01898928A0260 |102 111|DNA locusspects of
P01898928A0260 |147 155|fur gene997A0472
P01898928A0260 |73 78|cells00008
P01898928A0260 |82 84|Y.00
P01898928A0260 |0 26|DNA hybridization analysisP00001606T0076 Comparison 
P01899209A0883 |17 31|perfusate PCO2mparison with 
P01899209A0883 |47 58|perfusate Htases and 5
P01899209A0883 |135 153|oxygen consumptionemia. P00008997A04
P01899209A0883 |155 157|r2 W
P01899209A0883 |88 97|decreasesharmacolo
P01899209A0883 |117 130|contractilitytal hyperbili
P01899209A0883 |0 9|IncreasesP00001606
P01899287A0726 |0 10|ExpressionP00001606T
P01899287A0726 |15 25|cell cycleComparison
P01899287A0726 |133 138|cellsinemi
P01899287A0726 |56 66|RNA levels 5-nucleot
P01899409T0000 |1 13|Determinants00001606T007
P01899409T0000 |106 134|tissue plasminogen activatorts of neonatal hyperbilirubi
P01899409T0000 |27 36|ischaemiaith alkal
P01899409T0000 |41 69|revascularisation procedureshosphatases and 5-nucleotida
P01899409T0000 |76 88|thrombolysis08171T0000 P
P01899409T0000 |155 164|occlusion When CSF
P01899846A0862 |77 86|condition8171T0000
P01899846A0862 |15 30|rbcL-rbcS locusComparison with
P01899846A0862 |108 114|growth of ne
P01900194T0000 |0 12|RelationshipP00001606T00
P01900194T0000 |90 101|hydrogenasermacologic 
P01900194T0000 |35 60|NADH-ubiquinone reductaseline phosphatases and 5-n
P01901405A0694 |0 8|AnalysisP0000160
P01901405A0694 |82 89|tissues0000 Ph
P01901405A0694 |12 27|mRNA expression76 Comparison w
P01901405A0694 |39 45|AT-BP1 phosp
P01901405A0694 |50 56|AT-BP2es and
P01901443A0297 |33 54|maintenance valproatekaline phosphatases a
P01901443A0297 |14 22|patients Compari
P01901443A0297 |131 142|hepatitis Cubinemia. P
P01901443A0297 |209 217|O stainshe data 
P01901443A0297 |81 92|hepatitis CT0000 Pharm
P01901443A0297 |175 184|steatosis shown as
P01901664T0064 |2 7|cases00016
P01901859A0000 |0 7|UDP-GalP000016
P01901859A0000 |194 198|apesn of
P01901859A0000 |8 16|Gal beta6T0076 C
P01901859A0000 |176 185|exceptionshown as 
P01901859A0000 |79 98|glycosyltransferase71T0000 Pharmacolog
P01901859A0000 |41 64|3-galactosyltransferasehosphatases and 5-nucle
P01901859A0000 |150 157|speciesA0472 W
P01901859A0000 |22 35|4GlcNAc alphason with alka
P01901859A0000 |129 136|varietyirubine
P01901859A0000 |189 192|mannct
P01901859A0000 |204 221|Old World monkeysCO2 the data of K
P01901946A0243 |255 278|affinity chromatographyaced when compared to c
P01901946A0243 |43 55|SRE sequencesphatases an
P01901946A0243 |182 194|Southwesternas a functio
P01901946A0243 |12 27|oligonucleotide76 Comparison w
P01901946A0243 |209 217|blottinghe data 
P01901946A0243 |143 148|probe00089
P01901946A0243 |196 207|DNA-proteinof CSF PCO2
P01901946A0243 |65 90|mouse c-fos gene promotertidase P00008171T0000 Pha
P01901946A0243 |157 177|mobility shift assayhen CSF [HCO3-] is s
P01901950T0000 |0 21|Sequence requirementsP00001606T0076 Compar
P01901950T0000 |74 80|intron000817
P01901950T0000 |88 104|mouse c-fos geneharmacologic asp
P01901950T0000 |36 56|transcription arrestine phosphatases and
P01903404A0688 |17 34|ejection fractionmparison with alk
P01903404A0688 |175 176|p 
P01903404A0688 |276 292|perfusion status controls but st
P01903404A0688 |59 60|%n
P01903404A0688 |128 134|patentlirubi
P01903404A0688 |229 246|ejection fractiond rats are no lon
P01903404A0688 |84 91|studies00 Phar
P01903404A0688 |117 123|arterytal hy
P01903404A0688 |153 154|%7
P01903404A0688 |187 194|changesfunctio
P01903841A0125 |114 120|eIF-5Aonatal
P01903841A0125 |91 103|modificationmacologic as
P01903841A0125 |61 69|hypusinecleotida
P01903841A0125 |11 26|lysine residues076 Comparison 
P01903841A0125 |42 52|spermidineosphatases
P01903841A1449 |119 130|yeast cellsl hyperbili
P01903841A1449 |4 29|plasmid shuffle technique01606T0076 Comparison wit
P01903841A1449 |104 111|failureects of
P01903841A1449 |64 68|geneotid
P01903841A1449 |85 89|form0 Ph
P01904154A0164 |81 88|Ig lociT0000 P
P01904154A0164 |60 71|transcriptsucleotidase
P01904154A0164 |15 19|caseComp
P01904154A0164 |40 56|characterizationphosphatases and
P01904154A0164 |133 159|gene rearrangement processinemia. P00008997A0472 Whe
P01904154A0164 |112 125|understandingneonatal hype
P01904154A0164 |21 35|identificationison with alka
P01904437A0000 |0 13|TranscriptionP00001606T007
P01904437A0000 |109 126|metR gene productof neonatal hyper
P01904437A0000 |130 149|DNA binding proteinrubinemia. P0000899
P01904437A0000 |21 30|metH geneison with
P01904546A0671 |0 10|DisruptionP00001606T
P01904546A0671 |30 39|AAR1 gene alkaline
P01904546A0671 |43 48|alphasphat
P01904546A0671 |91 100|phenotypemacologic
P01904546A0671 |110 126|a/alpha diploidsf neonatal hyper
P01904546A0671 |53 66|a/alpha cellsand 5-nucleot
P01905199A0210 |87 90|WBHPha
P01905199A0210 |198 216|modality treatment CSF PCO2 the data
P01905199A0210 |79 82|ADR71T
P01905199A0210 |132 143|alterationsbinemia. P0
P01905199A0210 |14 22|ICRF-187 Compari
P01905199A0210 |30 48|antitumor response alkaline phosphat
P01905199A0210 |4 10|effect01606T
P01905199A0210 |163 168|indexF [HC
P01905199A0210 |64 75|combinationotidase P00
P01905199A0210 |116 121|orderatal 
P01905517A1076 |102 112|homologiesspects of 
P01905517A1076 |46 54|featuresatases a
P01905517A1076 |4 7|ORF016
P01905517A1076 |64 83|sequence data basesotidase P00008171T0
P01906111A1295 |5 10|study1606T
P01906111A1295 |135 151|toxicity profileemia. P00008997A
P01906111A1295 |44 51|regimenphatase
P01906111A1295 |94 97|useolo
P01906111A1295 |108 114|marrow of ne
P01906166A0119 |0 11|Mitomycin-CP00001606T0
P01906166A0119 |29 37|necrosish alkali
P01906166A0119 |104 111|tissuesects of
P01906166A0119 |90 94|skinrmac
P01906166A0119 |125 144|drug administrationrbilirubinemia. P00
P01906166A0119 |42 52|ulcerationosphatases
P01906509A0072 |66 78|nidogen geneidase P00008
P01906509A0072 |46 52|regionatases
P01906509A0072 |8 13|study6T007
P01906692A0321 |0 13|INTERVENTIONSP00001606T007
P01906692A0321 |40 47|heparinphospha
P01906692A0321 |15 23|PatientsComparis
P01906692A0321 |53 60|aspirinand 5-n
P01906692A0321 |33 38|rt-PAkalin
P01907265A0670 |83 95|cell extract000 Pharmaco
P01907265A0670 |28 34|resultth alk
P01907265A0670 |56 69|endonucleases 5-nucleotida
P01907265A0670 |126 147|DNA cleavage activitybilirubinemia. P00008
P01907941A0275 |85 88|Rel0 P
P01907941A0275 |74 81|binding0008171
P01907941A0275 |14 28|I kappa B beta Comparison wi
P01907941A0275 |96 108|kappa B siteogic aspects
P01907941A0275 |38 53|I kappa B alphae phosphatases 
P01909027A0922 |0 17|Sequence analysisP00001606T0076 Co
P01909027A0922 |57 60|ILF5-n
P01909027A0922 |193 199|familyon of 
P01909027A0922 |72 80|homologyP0000817
P01909027A0922 |107 135|fork head DNA binding domains of neonatal hyperbilirubin
P01909027A0922 |169 186|protein fork head3-] is shown as a
P01909027A0922 |203 213|hepatocytePCO2 the d
P01909027A0922 |231 236|HNF-3rats 
P01909027A0922 |222 229|factorsdeplete
P01909027A0922 |35 53|DNA binding domainline phosphatases 
P01909621A0119 |21 33|hemodialysesison with al
P01909621A0119 |57 65|lithemia5-nucleo
P01909621A0119 |78 84|ranges171T00
P01909960A0134 |186 195|NA levels function
P01909960A0134 |105 106|%c
P01909960A0134 |43 48|mg/kgsphat
P01909960A0134 |199 200|%C
P01909960A0134 |161 164|NMNCSF
P01909960A0134 |62 75|noradrenalineleotidase P00
P01909960A0134 |14 23|injection Comparis
P01909960A0134 |144 159|normetanephrine008997A0472 Whe
P01909960A0134 |127 140|concentrationilirubinemia.
P01909960A0134 |77 79|NA81
P01909960A0134 |81 93|biosynthesisT0000 Pharma
P01909960A0134 |169 170|%3
P01910505A0000 |84 94|leukopenia00 Pharmac
P01910505A0000 |7 25|wuzi yanzong pills06T0076 Comparison
P01910505A0000 |59 75|cyclophosphamidenucleotidase P00
P01910505A0000 |98 102|miceic a
P01910505A0000 |49 55|effectses an
P01911767T0000 |34 66|ribulosebisphosphate carboxylasealine phosphatases and 5-nucleot
P01911767T0000 |94 103|catalysisologic as
P01911767T0000 |74 89|subunit binding0008171T0000 Ph
P01911767T0000 |23 30|subuniton with
P01911767T0000 |0 9|MutationsP00001606
P01913955A0177 |441 445|typese f
P01913955A0177 |252 256|wallspla
P01913955A0177 |320 331|hypertrophyater slope 
P01913955A0177 |82 88|number0000 P
P01913955A0177 |159 168|pericytesn CSF [HC
P01913955A0177 |416 424|collagen drug wi
P01913955A0177 |267 278|muscle cellmpared to c
P01913955A0177 |298 302|wallve a
P01913955A0177 |123 138|muscularizationperbilirubinemi
P01913955A0177 |448 456|collagenuse in g
P01913955A0177 |382 394|accumulationppears to be
P01913955A0177 |406 412|amounte hypn
P01913955A0177 |15 22|changesCompari
P01913955A0177 |186 191|cells func
P01913955A0177 |358 370|muscle cells3A0733 Flura
P01913955A0177 |39 45|artery phosp
P01913955A0177 |336 347|hyperplasia +/- 0.23 v
P01913955A0177 |142 157|precursor cells00008997A0472 W
P01913955A0177 |101 107|arteryaspect
P01913955A0177 |70 78|increasee P00008
P01915580A0889 |137 159|airway hyperreactivityia. P00008997A0472 Whe
P01915580A0889 |63 72|treatmenteotidase 
P01915580A0889 |86 92|asthma Pharm
P01915580A0889 |6 13|results606T007
P01915580A0889 |27 33|NZ-107ith al
P01915580A0889 |116 132|airway responsesatal hyperbiliru
P01915580A0889 |50 54|druges a
P01916168A0969 |16 40|correlation coefficientsomparison with alkaline 
P01916168A0969 |127 133|mucosailirub
P01916168A0969 |208 216|learnersthe data
P01916168A0969 |3 8|study00160
P01916168A0969 |53 70|ISO2 measurementsand 5-nucleotidas
P01916168A0969 |178 186|observerown as a
P01916168A0969 |87 99|ulcer marginPharmacologi
P01916168A0969 |139 149|delta ISO2. P0000899
P01916405A0242 |70 78|aerosolse P00008
P01916405A0242 |135 141|stagesemia. 
P01916405A0242 |30 37|persons alkali
P01916405A0242 |110 112|PCf 
P01916405A0242 |125 133|diseasesrbilirub
P01916405A0242 |10 26|mucosa tattooing0076 Comparison 
P01916405A0242 |114 116|DBon
P01916405A0242 |101 106|formsaspec
P01916632A0431 |23 27|PBMCon w
P01916632A0431 |60 64|caseucle
P01916632A0431 |9 19|productionT0076 Comp
P01917943A0621 |1 18|Sequence analysis00001606T0076 Com
P01917943A0621 |49 58|sequencesses and 5
P01917943A0621 |101 111|base pairsaspects of
P01917943A0621 |201 209|plasmidsF PCO2 t
P01917943A0621 |113 115|bpeo
P01917943A0621 |219 261|chloramphenicol acetyltransferase reporter K-depleted rats are no longer displaced w
P01917943A0621 |178 188|expressionown as a f
P01917943A0621 |126 150|transfection experimentsbilirubinemia. P00008997
P01917943A0621 |77 86|TATAA box8171T0000
P01917943A0621 |26 31|sMtCKwith 
P01917943A0621 |178 188|expressionown as a f
P01917943A0621 |126 150|transfection experimentsbilirubinemia. P00008997
P01917943A0621 |77 86|TATAA box8171T0000
P01917943A0621 |26 31|sMtCKwith 
P01917943A0621 |1 18|Sequence analysis00001606T0076 Com
P01917943A0621 |201 209|plasmidsF PCO2 t
P01917943A0621 |113 115|bpeo
P01917943A0621 |219 261|chloramphenicol acetyltransferase reporter K-depleted rats are no longer displaced w
P01917943A0621 |101 111|base pairsaspects of
P01917943A0621 |49 58|sequencesses and 5
P01917962A0152 |186 193|control functi
P01917962A0152 |201 214|SV40 promoterF PCO2 the da
P01917962A0152 |98 110|cDNA segmentic aspects o
P01917962A0152 |4 16|cDNA segment01606T0076 C
P01917962A0152 |35 85|immunoglobulin gene recombination signal sequencesline phosphatases and 5-nucleotidase P00008171T000
P01917962A0152 |136 149|IL-2R L chainmia. P0000899
P01918010A0000 |0 18|Lipoprotein lipaseP00001606T0076 Com
P01918010A0000 |129 139|expressionirubinemia
P01918010A0000 |32 38|enzymelkalin
P01918010A0000 |98 108|regulationic aspects
P01918010A0000 |20 23|LPLris
P01918010A0000 |49 71|lipoprotein metabolismses and 5-nucleotidase
P01918010A0000 |87 94|patternPharmac
P01918010A1730 |0 8|DeletionP0000160
P01918010A1730 |189 206|3T3-L1 adipocytesnction of CSF PCO
P01918010A1730 |163 173|expressionF [HCO3-] 
P01918010A1730 |25 45|octanucleotide motif with alkaline phosp
P01918010A1730 |211 228|HepG2 hepatocytes data of K-deplet
P01918010A1730 |55 62|plasmidd 5-nuc
P01918010A1730 |99 111|LPL promoterc aspects of
P01918010A1730 |83 91|fragment000 Phar
P01918010A1730 |154 159|level2 Whe
P01918010A1730 |136 146|% decreasemia. P0000
P01918070A0281 |16 23|bindingomparis
P01918070A0281 |193 200|potencyon of C
P01918070A0281 |148 156|rGH T3RE97A0472 
P01918070A0281 |36 53|T3 receptor alphaine phosphatases 
P01918070A0281 |131 140|mutationsubinemia.
P01918070A0281 |228 239|T3R bindinged rats are
P01918070A0281 |217 224|changesof K-de
P01918070A0281 |55 64|T3R alphad 5-nucle
P01918073A0150 |0 10|ComparisonP00001606T
P01918073A0150 |179 223|protein kinase A phosphorylation target sitewn as a function of CSF PCO2 the data of K-d
P01918073A0150 |484 487|TnIat 
P01918073A0150 |418 421|TnCrug
P01918073A0150 |539 556|actin/TnC-binding3A0210 When extra
P01918073A0150 |303 306|TnIsig
P01918073A0150 |606 625|sequence divergence(VCO2), alveolar ve
P01918073A0150 |519 529|TnIcardiacing agents
P01918073A0150 |39 70|TnIcardiac amino acid sequences phosphatases and 5-nucleotidas
P01918073A0150 |581 587|domainroxima
P01918073A0150 |641 661|TnIcardiac sequences ceased. P00015731A0
P01918073A0150 |118 126|presenceal hyper
P01918073A0150 |492 495|TnC. P
P01918073A0150 |253 260|segmentplaced 
P01918073A0150 |292 299|featureill hav
P01918073A0150 |431 444|site sequenceoptimum dose 
P01918073A0150 |354 364|divergence10943A0733
P01918073A0150 |765 772|mammals, dichl
P01918073A0150 |82 95|TnI sequences0000 Pharmaco
P01918073A0150 |144 162|extension sequence008997A0472 When C
P01918073A0150 |758 761|TnIola
P01918073A0150 |690 718|protein kinase C target siten (25 mg/kg) of carbonic anh
P01918073A0150 |558 579|actomyosin-inhibitoryrporeal CO2 removal a
P01918073A0150 |677 684|absenceadminis
P01918073A0150 |406 416|troponin Ce hypnotic
P01918073A0150 |470 480|adaptatione being 15
P01918073A0150 |747 754|featureide, me
P01919831T0000 |12 31|management casebook76 Comparison with 
P01921463T0000 |3 20|ASSEMBLER routine001606T0076 Compa
P01921463T0000 |94 107|microcomputerologic aspect
P01921463T0000 |41 48|displayhosphat
P01921463T0000 |53 62|averagingand 5-nuc
P01921463T0000 |66 70|dataidas
P01922082A0149 |0 10|ExpressionP00001606T
P01922082A0149 |56 60|rise 5-n
P01922082A0149 |73 78|mRNAs00008
P01922082A0149 |115 121|regionnatal 
P01922082A0149 |18 37|mouse TSH beta geneparison with alkali
P01922734T0000 |0 11|HabituationP00001606T0
P01922734T0000 |57 62|snail5-nuc
P01922734T0000 |77 88|stimulation8171T0000 P
P01922734T0000 |35 42|neuronsline ph
P01922739A0336 |273 280|average to con
P01922739A0336 |22 26|ROSPson 
P01922739A0336 |147 153|course997A04
P01922739A0336 |245 249|ROSPnger
P01922739A0336 |360 370|electrodes0733 Flura
P01922739A0336 |91 101|directionsmacologic 
P01922739A0336 |388 393|level to b
P01922739A0336 |181 190|operation as a fun
P01922739A0336 |401 410|pia materective hy
P01922739A0336 |130 139|amplituderubinemia
P01922739A0336 |284 294|electrodess but stil
P01922739A0336 |49 61|fluctuationsses and 5-nu
P01922739A0336 |325 335|dura materslope (1.2
P01922739A0336 |350 356|valuesP00010
P01922739A0336 |162 166|daysSF [
P01922739A0336 |312 317|levelntly 
P01922739A0336 |231 237|valuesrats a
P01922739A0336 |39 45|number phosp
P01923167A0000 |0 29|Blood flow velocity waveformsP00001606T0076 Comparison wit
P01923167A0000 |54 73|Doppler examinationnd 5-nucleotidase P
P01923167A0000 |96 103|carotidogic as
P01923167A0000 |124 132|arterieserbiliru
P01923167A0000 |206 214|approach2 the da
P01923167A0000 |170 175|route-] is
P01923628T0001 |35 49|flow cytometryline phosphata
P01923628T0001 |73 81|findings00008171
P01923628T0001 |13 21|analysis6 Compar
P01923628T0001 |105 112|myxomascts of 
P01923628T0001 |88 93|casesharma
P01923628T0001 |25 28|DNA wi
P01923766A0485 |0 17|Sequence analysisP00001606T0076 Co
P01923766A0485 |63 70|varianteotidas
P01923766A0485 |226 230|exoneted
P01923766A0485 |150 159|exclusionA0472 Whe
P01923766A0485 |202 204|nt P
P01923766A0485 |189 200|nucleotidesnction of C
P01923766A0485 |124 132|splicingerbiliru
P01923766A0485 |81 93|mRNA speciesT0000 Pharma
P01923766A0485 |35 43|additionline pho
P01923803A0609 |0 8|PositionP0000160
P01923803A0609 |45 68|SsoL12 protein sequencehatases and 5-nucleotid
P01923803A0609 |82 91|AUA codon0000 Phar
P01923803A0609 |18 28|isoleucineparison wi
P01923985A0111 |0 8|SymptomsP0000160
P01923985A0111 |30 49|mastocyte mediators alkaline phosphata
P01923985A0111 |20 26|actionrison 
P01924315A0158 |81 86|levelT0000
P01924315A0158 |7 12|yeast06T00
P01924315A0158 |90 105|SOD1 expressionrmacologic aspe
P01924315A0158 |39 52|copper levels phosphatases
P01924315A0158 |64 71|controlotidase
P01924920A0115 |136 144|agar RLKmia. P00
P01924920A0115 |13 20|samples6 Compa
P01924920A0115 |60 61|%u
P01924920A0115 |159 169|atmospheren CSF [HCO
P01924920A0115 |22 35|Mobiluncus SPson with alka
P01924920A0115 |106 119|microorganismts of neonata
P01924920A0115 |98 99|%i
P01924920A0115 |69 82|Gram stainingse P00008171T
P01925092A0000 |115 123|meshworknatal hy
P01925092A0000 |9 22|investigatorsT0076 Compari
P01925092A0000 |72 78|retinaP00008
P01925092A0000 |82 86|part0000
P01925092A0000 |54 59|bloodnd 5-
P01925092A0304 |100 128|tissue plasminogen activator aspects of neonatal hyperbi
P01925092A0304 |164 170|saline [HCO3
P01925092A0304 |67 76|treatmentdase P000
P01925092A0304 |29 36|animalsh alkal
P01925092A0304 |12 17|hours76 Co
P01925092A0304 |142 148|volume000089
P01925092A0304 |86 96|micrograms Pharmacol
P01927421A0181 |17 29|examinationsmparison wit
P01927421A0181 |60 69|nystagmusucleotida
P01927421A0181 |108 117|nystagmus of neona
P01927421A0181 |86 95|nystagmus Pharmaco
P01927845A0107 |70 79|disorderse P000081
P01927845A0107 |89 96|diseasearmacol
P01927845A0107 |28 35|lesionsth alka
P01927845A0107 |10 20|morphology0076 Compa
P01927845A0107 |81 86|BowenT0000
P01928923A0000 |186 193|portion functi
P01928923A0000 |210 216|horsese data
P01928923A0000 |165 171|wounds[HCO3-
P01928923A0000 |201 206|limbsF PCO
P01928923A0000 |140 149|treatment P0000899
P01928923A0000 |23 44|yeast cell derivativeon with alkaline phos
P01928923A0000 |0 13|Equine amnionP00001606T007
P01928923A0000 |102 118|wound medicamentspects of neonat
P01930470A0337 |170 177|markers-] is s
P01930470A0337 |26 35|incidencewith alka
P01930470A0337 |193 198|unitson of
P01930470A0337 |107 111|AABBs of
P01930470A0337 |52 55|PTH an
P01930470A0337 |125 132|testingrbiliru
P01930470A0337 |94 105|Blood Banksologic aspe
P01930470A0337 |202 207|blood PCO2
P01930470A0337 |70 90|American Associatione P00008171T0000 Pha
P01930660T0000 |13 26|growth factor6 Comparison 
P01930660T0000 |30 35|IGF-1 alka
P01930660T0000 |45 53|patientshatases 
P01931966A0490 |0 6|FusionP00001
P01931966A0490 |23 29|pADPRPon wit
P01931966A0490 |10 19|ubiquitin0076 Comp
P01931966A0490 |44 49|yieldphata
P01931966A0490 |53 59|pADPRPand 5-
P01931966A0490 |114 120|enzymeonatal
P01932650A0435 |86 91|hours Phar
P01932650A0435 |14 22|patients Compari
P01932650A0435 |98 107|operationic aspect
P01932650A0435 |59 73|drainage bloodnucleotidase P
P01932650A0435 |146 150|MBRS8997
P01932650A0435 |115 128|concentrationnatal hyperbi
P01932650A0435 |3 8|group00160
P01932695A1155 |4 15|suppression01606T0076 
P01932695A1155 |93 110|barley endospermscologic aspects o
P01932695A1155 |53 69|expression assayand 5-nucleotida
P01933614A0406 |70 82|osteoporosise P00008171T
P01933614A0406 |47 52|womentases
P01933614A0406 |14 31|salmon calcitonin Comparison with 
P01933614A0406 |4 10|effect01606T
P01933614A0406 |38 43|spraye pho
P01934378A1219 |9 40|muscle metaboreceptor responsesT0076 Comparison with alkaline 
P01934378A1219 |57 70|heart failure5-nucleotidas
P01934378T0000 |68 81|heart failurease P00008171
P01934378T0000 |9 49|muscle metaboreceptor exercise responsesT0076 Comparison with alkaline phosphata
P01936213T0000 |0 10|EvaluationP00001606T
P01936213T0000 |28 39|drug effectth alkaline
P01936213T0000 |43 60|membrane fluiditysphatases and 5-n
P01936348A0155 |71 75|resp P00
P01936348A0155 |59 67|AmF/SnF2nucleoti
P01936348A0155 |39 45|groups phosp
P01936348A0155 |4 16|examinations01606T0076 C
P01936997A0795 |0 19|RNA gel retardationP00001606T0076 Comp
P01936997A0795 |104 126|TAR RNA loop sequencesects of neonatal hyper
P01936997A0795 |24 44|competition analysesn with alkaline phos
P01936997A0795 |59 74|TRP-185 bindingnucleotidase P0
P01937790A0292 |68 74|adultsase P0
P01937790A0292 |4 11|vaccine01606T0
P01937790A0292 |55 63|childrend 5-nucl
P01937989A0383 |65 69|testtida
P01937989A0383 |77 79|R281
P01937989A0383 |36 45|inductionine phosp
P01937989A0383 |5 11|groups1606T0
P01938178T0000 |34 42|analysisaline ph
P01938178T0000 |59 63|P300nucl
P01938178T0000 |0 12|ApplicationsP00001606T00
P01939131A0871 |34 40|BW2001aline 
P01939131A0871 |42 48|xth-11osphat
P01939131A0871 |57 69|strain cells5-nucleotida
P01939131A0871 |4 13|construct01606T007
P01939131A0871 |50 55|nfo-2es an
P01939199A0588 |185 198|transcriptiona function of
P01939199A0588 |45 58|transcriptionhatases and 5
P01939199A0588 |83 91|extracts000 Phar
P01939199A0588 |176 181|levelshown
P01939199A0588 |121 135|TFIID fractionhyperbilirubin
P01939199A0588 |141 151|HeLa cellsP00008997A
P01939199A0588 |18 23|TFIIDparis
P01939827A0150 |204 206|pHCO
P01939827A0150 |156 168|mmol/L CaCl2When CSF [HC
P01939827A0150 |190 202|mmol/L Hepesction of CSF
P01939827A0150 |114 127|precipitationonatal hyperb
P01939827A0150 |299 312|mmol/L KH2PO4e a significa
P01939827A0150 |331 333|pH(1
P01939827A0150 |226 239|precipitationeted rats are
P01939827A0150 |345 355|degrees C. vs. P0001
P01939827A0150 |74 89|titanium powder0008171T0000 Ph
P01939827A0150 |50 69|oxide surface layeres and 5-nucleotida
P01939827A0150 |256 265|solutionsced when 
P01939827A0150 |317 329|mmol/L Hepesgreater slop
P01939827A0150 |133 142|solutionsinemia. P
P01939827A0150 |13 25|pretreatment6 Comparison
P01939827A0150 |281 293|mmol/L CaCl2rols but sti
P01939827A0150 |172 185|mmol/L KH2PO4 is shown as 
P01939878A0765 |68 74|caseinase P0
P01939878A0765 |126 134|patientsbilirubi
P01939878A0765 |158 165|acidityen CSF 
P01939878A0765 |17 31|solidificationmparison with 
P01939899A2043 |119 125|amountl hype
P01939899A2043 |66 73|effectsidase P
P01939899A2043 |129 141|perturbationirubinemia. 
P01939899A2043 |8 13|model6T007
P01939899A2043 |109 114|tonesof ne
P01939899A2043 |86 95|variables Pharmaco
P01939899A2043 |99 105|numberc aspe
P01939899A2043 |143 151|ABSTRACT0008997A
P01939899A2043 |169 174|WORDS3-] i
P01939899A2043 |51 58|accounts and 5
P01939906A0233 |258 277|parameter landscaped when compared to 
P01939906A0233 |224 243|optimization methodpleted rats are no 
P01939906A0233 |76 89|cost function08171T0000 Ph
P01939906A0233 |145 151|source08997A
P01939906A0233 |109 121|search spaceof neonatal 
P01939906A0233 |183 196|wave equations a function 
P01939906A0233 |166 175|solutionsHCO3-] is
P01939906A0233 |5 19|generalization1606T0076 Comp
P01939906A0233 |23 26|MFPon 
P01939906A0233 |129 140|environmentirubinemia.
P01939906A0233 |293 300|minimumll have
P01939906A0233 |308 321|cost functionficantly grea
P01942033T0000 |0 13|DeterminationP00001606T007
P01942033T0000 |46 65|splicing inhibitionatases and 5-nucleo
P01942033T0000 |20 33|RNA structurerison with al
P01942033T0000 |87 91|exonPhar
P01943184A1050 |95 96|%l
P01943184A1050 |30 40|University alkaline 
P01943184A1050 |121 122|ph
P01943184A1050 |104 111|% cellsects of
P01943184A1050 |44 62|Wisconsin solutionphatases and 5-nuc
P01943184A1050 |12 17|cells76 Co
P01943184A1050 |72 78|trypanP00008
P01945430A0660 |154 170|neuroma suspects2 When CSF [HCO3
P01945430A0660 |72 81|ear fluidP00008171
P01945430A0660 |13 22|technique6 Compari
P01945430A0660 |126 140|labyrinthotomybilirubinemia.
P01945430A0660 |98 107|procedureic aspect
P01947449A0191 |239 242|PO2 no
P01947449A0191 |53 58|termsand 5
P01947449A0191 |232 235|PO2ats
P01947449A0191 |128 132|arealiru
P01947449A0191 |14 34|diffusion limitation Comparison with alk
P01947449A0191 |75 96|uptake/O2 requirement008171T0000 Pharmacol
P01947449A0191 |100 108|fraction aspects
P01947449A0191 |4 10|effect01606T
P01947449A0191 |66 71|ratioidase
P01947449A0191 |170 181|requirement-] is shown
P01947449A0191 |186 197|unit volume function o
P01947449A1082 |221 238|cylinder diameter-depleted rats ar
P01947449A1082 |46 56|model setsatases and
P01947449A1082 |192 198|modelsion of
P01947449A1082 |74 91|requirement value0008171T0000 Phar
P01947449A1082 |4 24|Diffusion limitation01606T0076 Compariso
P01947449A1082 |141 152|requirementP00008997A0
P01948783A0000 |100 108|patients aspects
P01948783A0000 |31 38|Estulicalkalin
P01948783A0000 |73 79|period000081
P01948783A0000 |21 27|effectison w
P01952827A0215 |32 39|patientlkaline
P01952827A0215 |60 71|test phraseucleotidase
P01952827A0215 |7 11|time06T0
P01952827A0215 |19 26|seizurearison 
P01954355A0997 |0 19|Monitoring patientsP00001606T0076 Comp
P01954355A0997 |44 48|IL-1phat
P01954355A0997 |31 39|leukemiaalkaline
P01954355A0997 |127 133|causesilirub
P01954355A0997 |145 153|episodes08997A04
P01954355A0997 |88 94|courseharmac
P01954355A0997 |53 63|TNF levelsand 5-nucl
P01954355A0997 |98 105|diseaseic aspe
P01954835A0000 |0 23|Echinococcus granulosusP00001606T0076 Comparis
P01954835A0000 |108 114|female of ne
P01954835A0000 |78 87|lung cyst171T0000 
P01954835A0000 |126 134|Missouribilirubi
P01954835A0000 |53 72|aspiration cytologyand 5-nucleotidase 
P01956285A0000 |4 12|sequence01606T00
P01956285A0000 |127 158|choline-glycine betaine pathwayilirubinemia. P00008997A0472 Wh
P01956285A0000 |36 47|nucleotidesine phospha
P01956285A0000 |65 74|bet genestidase P0
P01956491A0095 |257 261|ratsed w
P01956491A0095 |92 107|filtration rateacologic aspect
P01956491A0095 |109 112|GFRof 
P01956491A0095 |227 237|comparisonted rats a
P01956491A0095 |148 168|creatinine clearance97A0472 When CSF [HC
P01956491A0095 |134 143|clearancenemia. P0
P01956491A0095 |295 301|ml/min have 
P01956491A0095 |202 208|ml/min PCO2 
P01956491A0095 |8 17|treatment6T0076 Co
P01956491A0095 |39 48|mg/kg/day phosphat
P01956491A0095 |21 35|amphotericin Bison with alka
P01958368A0556 |102 128|vitelliform classificationspects of neonatal hyperbi
P01958368A0556 |88 94|stagesharmac
P01958368A0556 |13 20|lesions6 Compa
P01958368A0556 |58 69|progression-nucleotida
P01958368A0556 |0 9|EvolutionP00001606
P01958821T0000 |43 55|cell biologysphatases an
P01958821T0000 |9 32|fluorescence microscopyT0076 Comparison with a
P01960974A0000 |51 56|casess and
P01960974A0000 |15 23|chemicalComparis
P01960974A0000 |76 84|solvents08171T00
P01960974A0000 |0 7|TolueneP000016
P01961213A0150 |51 62|breast milks and 5-nuc
P01961213A0150 |79 84|years71T00
P01961213A0150 |27 37|HCB-levelsith alkali
P01961747A0000 |102 108|enzymespects
P01961747A0000 |142 161|transfection assays00008997A0472 When 
P01961747A0000 |113 128|substrate geneseonatal hyperbi
P01961747A0000 |2 33|herpesvirus proteinase activity0001606T0076 Comparison with al
P01961996A0522 |17 18|Rm
P01961996A0522 |45 55|preferencehatases an
P01961996A0522 |77 88|opportunity8171T0000 P
P01961996A0522 |0 7|Adult HP000016
P01963419A0501 |137 149|13N reactionia. P0000899
P01963419A0501 |57 68|MeV protons5-nucleotid
P01963419A0501 |124 127|16Oerb
P01963419A0501 |182 183|pa
P01963419A0501 |154 157|18F2 W
P01963419A0501 |185 186|na
P01963419A0501 |113 116|13Neon
P01963419A0501 |158 170|fluoride ionen CSF [HCO3
P01963419A0501 |178 181|18Oown
P01963419A0501 |131 136|alphaubine
P01963419A0501 |72 77|waterP0000
P01963419A0501 |187 199|18F reactionfunction of 
P01963419A0501 |128 129|pl
P01963419A0501 |9 30|silver liquid chamberT0076 Comparison with
P01963438T0000 |35 47|cytochrome cline phospha
P01963438T0000 |63 74|polypyrroleeotidase P0
P01963438T0000 |14 31|electron transfer Comparison with 
P01963438T0000 |120 130|electrodes hyperbili
P01963438T0000 |79 88|methylene71T0000 P
P01963438T0000 |94 110|polypyrrole filmologic aspects o
P01963858T0001 |96 109|microdialysisogic aspects 
P01963858T0001 |24 44|adrenaline secretionn with alkaline phos
P01963858T0001 |10 20|activation0076 Compa
P01963858T0001 |52 55|rat an
P01963858T0001 |67 82|neuroglycopeniadase P00008171T
P01964989A0145 |171 178|vinegar] is sh
P01964989A0145 |180 199|potassium hydroxiden as a function of 
P01964989A0145 |230 237|ammonia rats a
P01964989A0145 |214 224|2-propanolta of K-de
P01964989A0145 |146 161|sodium chloride8997A0472 When 
P01964989A0145 |208 212|soapthe 
P01964989A0145 |106 110|acidts o
P01964989A0145 |49 52|PCPses
P01964989A0145 |112 122|9-THC-COOHneonatal h
P01964989A0145 |163 169|bleachF [HCO
P01964989A0145 |0 15|Urine specimensP00001606T0076 
P01964989A0145 |34 47|phencyclidinealine phospha
P01967130A0645 |49 61|acid proteinses and 5-nu
P01967130A0645 |14 28|pair EFIA cDNA Comparison wi
P01967130A0645 |122 142|DNA binding proteinsyperbilirubinemia. P
P01968043A0908 |66 72|insertidase 
P01968043A0908 |74 80|pASB-1000817
P01968043A0908 |104 116|orientationsects of neon
P01968043A0908 |23 34|cDNA cloneson with alk
P01968061A0371 |0 3|SciP00
P01968156T0000 |0 20|Dose standardisationP00001606T0076 Compa
P01968156T0000 |24 39|botulinum toxinn with alkaline
P01968224A0119 |137 138|%i
P01968224A0119 |95 101|intronlogic 
P01968224A0119 |120 122|bp h
P01968224A0119 |41 60|residue polypeptidehosphatases and 5-n
P01968224A0119 |192 196|PCNAion 
P01968224A0119 |284 291|leucines but s
P01968224A0119 |154 173|amino acid sequence2 When CSF [HCO3-] 
P01968224A0119 |218 221|ratf K
P01968224A0119 |232 249|PCNA polypeptidesats are no longer
P01968224A0119 |310 316|regioncantly
P01968224A0119 |108 118|base pairs of neonat
P01968224A0119 |4 19|coding sequence01606T0076 Comp
P01968224A0119 |273 280|repeats to con
P01970560A1024 |306 315|organismsnificantl
P01970560A1024 |333 343|efficiency.21 +/- 0.
P01970560A1024 |29 33|aroFh al
P01970560A1024 |45 52|regionshatases
P01970560A1024 |186 196|regulation function 
P01970560A1024 |288 297|operatorst still h
P01970560A1024 |247 261|TyrR repressorer displaced w
P01970560A1024 |56 60|lacZ 5-n
P01970560A1024 |108 112|copy of 
P01970560A1024 |130 140|chromosomerubinemia.
P01970560A1024 |14 21|fusions Compar
P01970560A1024 |142 167|beta-Galactosidase assays00008997A0472 When CSF [H
P01970560A1024 |200 220|aroF-lacZ expressionSF PCO2 the data of 
P01970801A0925 |116 119|armata
P01970801A0925 |29 34|genesh alk
P01970801A0925 |195 200|mouse of C
P01970801A0925 |60 64|OSBPucle
P01970801A0925 |45 49|Ly-1hata
P01970801A0925 |54 58|CD20nd 5
P01970801A0925 |167 170|endCO3
P01970801A0925 |123 133|chromosomeperbilirub
P01970801A0925 |174 184|chromosomes shown as
P01970801A0925 |98 103|groupic as
P01970926A0000 |69 88|concentration risesse P00008171T0000 P
P01970926A0000 |59 67|plasma Knucleoti
P01970926A0000 |7 17|exercise K06T0076 Co
P01970926A0000 |48 54|muscleases a
P01970984A0668 |70 71|Te
P01970984A0668 |76 77|E0
P01970984A0668 |59 67|groups Enucleoti
P01970984A0668 |10 19|treatment0076 Comp
P01970984A0668 |21 43|serum estradiol levelsison with alkaline pho
P01970984A0668 |86 94|group C. Pharmac
P01971191A1271 |184 190|agents a fun
P01971191A1271 |72 81|influenceP00008171
P01971191A1271 |46 59|isoproterenolatases and 5-
P01971191A1271 |150 168|outflow resistanceA0472 When CSF [HC
P01971191A1271 |125 129|dogsrbil
P01971191A1271 |109 121|liver volumeof neonatal 
P01971191A1271 |94 105|capacitanceologic aspe
P01971191A1271 |199 208|histamineCSF PCO2 
P01971191A1271 |37 44|agonistne phos
P01972379T0042 |34 44|CPS domainaline phos
P01972379T0042 |83 94|protein CAD000 Pharmac
P01972379T0042 |59 66|hamsternucleot
P01972379T0042 |0 12|DNA sequenceP00001606T00
P01972379T0042 |17 26|evolutionmparison 
P01973384A0206 |34 47|binding sitesaline phospha
P01973384A0206 |145 152|embryos08997A0
P01973384A0206 |84 91|ability00 Phar
P01973384A0206 |103 116|transcriptionpects of neon
P01974550A0362 |16 19|CBFomp
P01974550A0362 |73 92|ipratropium bromide00008171T0000 Pharm
P01974550A0362 |62 70|mg/kg ivleotidas
P01974550A0362 |37 58|hexamethonium bromidene phosphatases and 5
P01974550A0362 |161 169|% salineCSF [HCO
P01974550A0362 |132 140|mg/kg ivbinemia.
P01974550A0362 |98 113|microgram/kg ivic aspects of n
P01974550A0362 |116 128|indomethacinatal hyperbi
P01974876A1051 |17 57|restriction fragment length polymorphismmparison with alkaline phosphatases and 
P01974876A1051 |121 133|enzyme BglIIhyperbilirub
P01974876A1051 |77 80|DNA817
P01974876A1051 |99 110|individualsc aspects o
P01975157A0836 |53 60|resultsand 5-n
P01975157A0836 |30 32|pH a
P01975157A0836 |12 26|transformation76 Comparison 
P01975428A0151 |0 9|TelomeresP00001606
P01975428A0151 |29 36|fusionsh alkal
P01975428A0151 |80 83|end1T0
P01975428A0151 |129 137|functionirubinem
P01975428A0151 |56 67|degradation 5-nucleoti
P01975428A0151 |98 110|DNA moleculeic aspects o
P01975428A0151 |141 154|cell divisionP00008997A047
P01976638A1135 |81 90|sequencesT0000 Pha
P01976638A1135 |47 53|regiontases 
P01977585A0222 |153 167|protein kinase72 When CSF [H
P01977585A0222 |121 129|subunitshyperbil
P01977585A0222 |11 17|enzyme076 Co
P01977585A0222 |70 75|cellse P00
P01977856A1036 |103 109|extentpects 
P01977856A1036 |79 88|diagnosis71T0000 P
P01977856A1036 |63 66|AMIeot
P01977856A1036 |90 98|locationrmacolog
P01977856A1036 |5 10|study1606T
P01977856A1036 |25 30|BSPMs with
P01977856A1036 |124 131|infarcterbilir
P01977856A1036 |49 59|assessmentses and 5-
P01977856A1036 |70 75|termse P00
P01978834A0076 |102 132|rabbit H,K-ATPase beta subunitspects of neonatal hyperbiliru
P01978834A0076 |74 82|antibody0008171T
P01978834A0076 |9 42|abomasum lambda gt11 cDNA libraryT0076 Comparison with alkaline ph
P01978857A0504 |17 35|laboratory testingmparison with alka
P01978857A0504 |61 76|CD4 cell countscleotidase P000
P01978857A0504 |47 57|monitoringtases and 
P01978857A0504 |10 13|use007
P01982061A0615 |12 20|TATA box76 Compa
P01982061A0615 |60 89|transcription initiation siteucleotidase P00008171T0000 Ph
P01982061T0000 |0 16|CharacterizationP00001606T0076 C
P01982061T0000 |62 78|hamster CAD geneleotidase P00008
P01982061T0000 |27 30|endith
P01982190T0001 |6 15|cirrhosis606T0076 
P01982190T0001 |61 70|hepatitiscleotidas
P01982190T0001 |26 34|modalitywith alk
P01982190T0001 |42 51|evolutionosphatase
P01982997A1104 |186 196|expression function 
P01982997A1104 |135 145|expressionemia. P000
P01982997A1104 |74 85|MDI regimen0008171T000
P01982997A1104 |31 62|transcription factor expressionalkaline phosphatases and 5-nuc
P01982997A1104 |200 205|c-FosSF PC
P01982997A1104 |149 159|c-Jun mRNA7A0472 Whe
P01982997A1104 |210 221|Jun-B mRNAse data of K
P01982997A1104 |100 102|RA a
P01982997A1104 |0 11|ExaminationP00001606T0
P01983026A0483 |102 119|CA concentrationsspects of neonata
P01983026A0483 |75 85|intubation008171T000
P01983026A0483 |144 156|study period008997A0472 
P01983026A0483 |9 19|heart rateT0076 Comp
P01983026A0483 |56 62|degree 5-nuc
P01983026A0483 |65 68|mintid
P01983026A0483 |34 42|pressurealine ph
P01984665T0000 |0 10|ProcessingP00001606T
P01984665T0000 |150 163|baculovirusesA0472 When CS
P01984665T0000 |27 43|immunoreactivityith alkaline pho
P01984665T0000 |12 21|secretion76 Compar
P01984665T0000 |47 54|carboxytases a
P01984665T0000 |76 108|dengue-2 virus envelope proteins08171T0000 Pharmacologic aspects
P01984665T0000 |129 134|cellsirubi
P01985301T0000 |71 83|brain damage P00008171T0
P01985301T0000 |22 28|MK-801son wi
P01985301T0000 |9 16|therapyT0076 C
P01985301T0000 |33 43|nimodipinekaline pho
P01985301T0000 |48 58|protectionases and 5
P01985920A0156 |140 155|pair cDNA clone P00008997A0472
P01985920A0156 |93 118|rat SCP2 protein sequencecologic aspects of neonat
P01985920A0156 |8 17|screening6T0076 Co
P01985920A0156 |180 201|SCP2 protein sequencen as a function of CS
P01985920A0156 |23 45|rat liver cDNA libraryon with alkaline phosp
P01985920A0156 |54 75|oligonucleotide probend 5-nucleotidase P00
P01985920T0000 |0 7|CloningP000016
P01985920T0000 |25 44|nucleotide sequence with alkaline phos
P01985920T0000 |9 19|expressionT0076 Comp
P01985920T0000 |83 88|cDNAs000 P
P01985920T0000 |48 80|rat liver sterol carrier proteinases and 5-nucleotidase P0000817
P01985924A0554 |102 112|holoenzymespects of 
P01985924A0554 |196 215|initiation activityof CSF PCO2 the dat
P01985924A0554 |95 98|pollog
P01985924A0554 |29 36|complexh alkal
P01985924A0554 |226 231|deltaeted 
P01985924A0554 |151 159|presence0472 Whe
P01985924A0554 |219 222|pol K-
P01985924A0554 |163 167|ureaF [H
P01985924A0554 |129 143|chromatographyirubinemia. P0
P01985924A0554 |4 12|addition01606T00
P01985924A0554 |71 79|subunits P000081
P01986225A0250 |19 33|identificationarison with al
P01986225A0250 |37 40|HSFne 
P01986225A0250 |48 61|fission yeastases and 5-nu
P01986241A0117 |102 111|CUP1 genespects of
P01986241A0117 |23 40|ACE1 gene producton with alkaline 
P01986241A0117 |79 94|promoter region71T0000 Pharmac
P01986241A0117 |66 71|sitesidase
P01986241A0117 |0 9|InductionP00001606
P01986254A0452 |0 25|Gel mobility shift assaysP00001606T0076 Comparison
P01986254A0452 |44 52|E6 motifphatases
P01986254A0452 |147 157|HeLa cells997A0472 W
P01986254A0452 |135 142|T cellsemia. P
P01986254A0452 |91 99|additionmacologi
P01986254A0452 |80 87|complex1T0000 
P01986254A0452 |116 120|bandatal
P01986360A0000 |259 264|probe when
P01986360A0000 |182 187|mouseas a 
P01986360A0000 |195 253|oligoadenylate synthetase gene interferon response element of CSF PCO2 the data of K-depleted rats are no longer dis
P01986360A0000 |22 65|interferon response element binding factorsson with alkaline phosphatases and 5-nucleo
P01986360A0000 |145 148|32P089
P01986360A0000 |92 133|mouse fibroblast lambda gt11 cDNA libraryacologic aspects of neonatal hyperbilirub
P01986360A0000 |6 12|clones606T00
P01986360A0000 |168 174|trimerO3-] i
P01988041A0281 |21 27|clonesison w
P01988041A0281 |66 84|BAL cDNA structureidase P00008171T00
P01988041A0281 |4 12|sequence01606T00
P01989561A0100 |204 211|ventingCO2 the
P01989561A0100 |94 111|perfusion cannulaologic aspects of
P01989561A0100 |44 53|occlusionphatases 
P01989561A0100 |157 162|hearthen C
P01989561A0100 |25 36|instruments with alkal
P01989561A0100 |145 149|apex0899
P01989561A0100 |4 15|application01606T0076 
P01989561A0100 |71 76|aorta P000
P01989999A0000 |17 27|synthetasemparison w
P01989999A0000 |161 164|IMPCSF
P01989999A0000 |147 157|conversion997A0472 W
P01989999A0000 |29 32|IMPh a
P01989999A0000 |90 94|rolermac
P01989999A0000 |98 117|purine biosynthesisic aspects of neona
P01989999A0000 |53 56|GDPand
P01989999A0000 |59 61|ECnu
P01989999A0000 |33 51|L-aspartate ligasekaline phosphatase
P01989999A0000 |168 171|AMPO3-
P01990254A0791 |0 17|ImmunophenotypingP00001606T0076 Co
P01990254A0791 |90 101|cell originrmacologic 
P01990254A0791 |26 31|caseswith 
P01990254A0791 |59 70|cell originnucleotidas
P01990266A0678 |186 194|proteins functio
P01990266A0678 |93 107|sodium dodecylcologic aspect
P01990266A0678 |213 221|promoterata of K
P01990266A0678 |12 36|UV cross-linking studies76 Comparison with alkal
P01990266A0678 |81 89|mobilityT0000 Ph
P01990266A0678 |52 57|UHF-1 and 
P01990266A0678 |127 131|gelsilir
P01990266A0678 |236 240|siteare 
P01990266A0678 |152 155|kDa472
P01991521A0481 |4 11|results01606T0
P01991521A0481 |27 37|conclusionith alkali
P01991521A0481 |88 98|G4 contentharmacolog
P01991521A0481 |125 132|musclesrbiliru
P01991521A0481 |65 73|activitytidase P
P01992459A0000 |252 256|mRNAspla
P01992459A0000 |281 290|cytoplasmrols but 
P01992459A0000 |214 220|exportta of 
P01992459A0000 |13 24|interaction6 Compariso
P01992459A0000 |104 107|RREect
P01992459A0000 |75 102|immunodeficiency virus mRNA008171T0000 Pharmacologic a
P01992459A0000 |113 133|Rev response elementeonatal hyperbilirub
P01992459A0000 |266 273|nucleusompared
P01992459A0000 |196 206|regulationof CSF PCO
P01992459A0000 |54 61|elementnd 5-nu
P01992459A0000 |157 168|protein Revhen CSF [HC
P01992742A0000 |51 59|neuritiss and 5-
P01992742A0000 |31 39|patientsalkaline
P01992742A0000 |88 94|periodharmac
P01992742A0000 |16 23|recordsomparis
P01992953A0247 |102 106|testspec
P01992953A0247 |8 14|levels6T0076
P01992953A0247 |27 38|abnormalityith alkalin
P01992953A0247 |129 137|patientsirubinem
P01992953A0247 |83 94|specificity000 Pharmac
P01992953T0000 |0 24|Alanine aminotransferaseP00001606T0076 Compariso
P01992953T0000 |37 45|practicene phosp
P01993181T0000 |0 28|Nucleotide sequence analysisP00001606T0076 Comparison wi
P01993181T0000 |89 93|nahGarma
P01993181T0000 |55 87|PpG7 salicylate hydroxylase gened 5-nucleotidase P00008171T0000 
P01993181T0000 |115 121|regionnatal 
P01993656A1860 |84 91|guanine00 Phar
P01993656A1860 |111 119|proteins neonata
P01993656A1860 |8 17|ARF cDNAs6T0076 Co
P01995951A0000 |68 71|HIVase
P01995951A0000 |126 136|factor Sp1bilirubine
P01995951A0000 |26 29|LTRwit
P01995951A0000 |44 66|immunodeficiency virusphatases and 5-nucleot
P01995951A0000 |96 101|sitesogic 
P01995951A0000 |18 24|repeatpariso
P01996312A0454 |0 3|DNAP00
P01996312A0454 |109 120|Dd kinase-2of neonatal
P01996312A0454 |9 12|PCRT00
P01996312A0454 |53 76|lambda gt11 cDNA clonesand 5-nucleotidase P000
P01997465A0276 |100 105|weeks aspe
P01997465A0276 |41 48|alveolihosphat
P01997465A0276 |18 25|changesparison
P01997465A0276 |53 58|septaand 5
P01997465A0276 |112 123|irradiationneonatal hy
P01997465A0276 |33 37|areakali
P01997465A0276 |70 86|collagen contente P00008171T0000
P01999035A0383 |119 129|IHD eventsl hyperbil
P01999035A0383 |45 53|intervalhatases 
P01999035A0383 |10 19|follow-up0076 Comp
P01999035A0383 |89 94|yearsarmac
P01999035A0383 |61 66|yearscleot
P01999035A0383 |98 107|Speedwellic aspect
P01999035A0383 |70 80|Caerphillye P0000817
P01999459A0795 |0 2|A.P0
P01999999T0001 |70 79|treatmente P000081
P01999999T0001 |31 37|injuryalkali
P01999999T0001 |10 18|luxation0076 Com
P02000093A0794 |0 9|LandsbergP00001606
P02000093A0794 |11 15|La-O076 
P02000093A0794 |21 23|cvis
P02001033A1907 |137 142|drugsia. P
P02001033A1907 |30 44|concentrations alkaline phos
P02001033A1907 |215 223|activitya of K-d
P02001033A1907 |242 250|decrease longer 
P02001033A1907 |46 56|desfluraneatases and
P02001033A1907 |166 174|reflexesHCO3-] i
P02001033A1907 |61 71|isofluranecleotidase
P02001033A1907 |263 271|pressuren compar
P02001033A1907 |126 133|absencebilirub
P02001033A1907 |176 186|desfluraneshown as a
P02001033A1907 |3 10|summary001606T
P02001033A1907 |101 108|effectsaspects
P02002051A0276 |19 28|isolationarison wi
P02002051A0276 |46 56|cDNA cloneatases and
P02002051A0276 |92 99|isoformacologi
P02002051A0276 |114 123|C-subunitonatal hy
P02002051T0000 |0 14|Isoform C betaP00001606T0076
P02002051T0000 |29 33|formh al
P02002051T0000 |58 65|subunit-nucleo
P02002051T0000 |84 98|protein kinase00 Pharmacolog
P02002511A0637 |86 94|examples Pharmac
P02002511A0637 |56 64|problems 5-nucle
P02002511A0637 |24 38|PB-PK modelingn with alkalin
P02002511A0637 |8 20|applications6T0076 Compa
P02004521A0266 |0 8|PatientsP0000160
P02004521A0266 |31 47|CT abnormalitiesalkaline phospha
P02004521A0266 |78 85|disease171T000
P02004705A0686 |119 121|Mrl 
P02004705A0686 |75 83|fragment008171T0
P02004705A0686 |45 56|amino acidshatases and
P02004705A0686 |4 17|cdr1 sequence01606T0076 Co
P02004705A0686 |98 105|productic aspe
P02005547A0121 |186 198|practitioner function of
P02005547A0121 |265 272|illnesscompare
P02005547A0121 |106 117|developmentts of neona
P02005547A0121 |134 152|hyperbilirubinemianemia. P00008997A0
P02005547A0121 |233 239|familyts are
P02005547A0121 |172 180|jaundice is show
P02005547A0121 |57 65|pathways5-nucleo
P02005547A0121 |257 262|childed wh
P02005547A0121 |19 32|understandingarison with a
P02006558A0000 |0 23|Displacement thresholdsP00001606T0076 Comparis
P02006558A0000 |63 69|visioneotida
P02006558A0000 |38 43|sitese pho
P02007045A0092 |118 126|distressal hyper
P02007045A0092 |21 25|caseison
P02007045A0092 |4 11|authors01606T0
P02007045A0092 |64 74|brain cystotidase P0
P02007045A0092 |48 58|irrigationases and 5
P02008982A0463 |0 5|ELISAP0000
P02008982A0463 |46 55|diagnosisatases an
P02008982A0463 |91 103|sputum smearmacologic as
P02008982A0463 |26 38|contributionwith alkalin
P02008982A0463 |59 71|tuberculosisnucleotidase
P02010912A0366 |49 58|structureses and 5
P02010912A0366 |90 108|MalT binding sitesrmacologic aspects
P02010912A0366 |8 13|paper6T007
P02010912A0366 |78 82|role171T
P02010912A0366 |147 152|pulAp997A0
P02010912A0366 |36 41|studyine p
P02010912A0366 |157 172|pulCp promotershen CSF [HCO3-]
P02011924A0729 |101 110|alpha-IFNaspects o
P02011924A0729 |28 36|patientsth alkal
P02011924A0729 |91 97|MU/daymacolo
P02011924A0729 |45 50|basishatas
P02011924A0729 |59 65|reportnucleo
P02011924A0729 |126 135|treatmentbilirubin
P02011924A0729 |160 173|cell leukemia CSF [HCO3-] 
P02011924A0729 |140 148|patients P000089
P02011924A0729 |18 24|numberpariso
P02012097T0000 |51 80|Plasmodium falciparum malarias and 5-nucleotidase P0000817
P02012097T0000 |11 23|fluctuations076 Comparis
P02012097T0000 |36 47|parasitemiaine phospha
P02012789A0051 |12 26|family history76 Comparison 
P02014928T0000 |49 59|inhalationses and 5-
P02014928T0000 |13 19|asthma6 Comp
P02014928T0000 |24 43|rhinoconjunctivitisn with alkaline pho
P02014928T0000 |82 102|serum albumin powder0000 Pharmacologic a
P02015921A0523 |70 74|nodee P0
P02015921A0523 |10 21|subdivision0076 Compar
P02015921A0523 |80 84|pN1b1T00
P02015921A0523 |25 37|Category pN1 with alkali
P02015921A0523 |43 47|pN1aspha
P02015921A0523 |98 103|nodesic as
P02015921A0523 |49 59|metastasisses and 5-
P02016053A0752 |0 31|Amino acid sequence comparisonsP00001606T0076 Comparison with 
P02016053A0752 |89 95|regionarmaco
P02016053A0752 |195 215|DNA binding activity of CSF PCO2 the dat
P02016053A0752 |39 51|E74A protein phosphatase
P02016053A0752 |118 137|amino acid residuesal hyperbilirubinem
P02016769A0720 |80 88|contexts1T0000 P
P02016769A0720 |44 53|promotersphatases 
P02016769A0720 |27 36|strengthsith alkal
P02017159A0646 |0 6|GrassoP00001
P02017159A0646 |12 14|A.76
P02017271A0502 |102 106|nonespec
P02017271A0502 |25 36|improvement with alkal
P02017271A0502 |8 14|months6T0076
P02017271A0502 |40 48|strengthphosphat
P02017271A0502 |112 120|controlsneonatal
P02017271A0502 |86 94|patients Pharmac
P02017414A0307 |68 75|Line F.ase P00
P02017414A0307 |7 10|POI06T
P02017414A0307 |15 24|asymptoteCompariso
P02017414A0307 |49 58|Line RBC2ses and 5
P02017414A0307 |0 3|AgeP00
P02019572A0000 |103 108|genespects
P02019572A0000 |112 118|seriesneonat
P02019572A0000 |364 384|hepatoma HepG2 cells Flurazepam thus app
P02019572A0000 |246 256|base pairsger displa
P02019572A0000 |454 465|C2C12 cells general pr
P02019572A0000 |386 401|rat hepatocytesrs to be an eff
P02019572A0000 |146 194|chloramphenicol acetyltransferase reporter genes8997A0472 When CSF [HCO3-] is shown as a functio
P02019572A0000 |122 132|constructsyperbiliru
P02019572A0000 |422 436|fibroblast LTKwith the optim
P02019572A0000 |329 339|expressione (1.21 +/
P02019572A0000 |438 443|cells dose
P02019572A0000 |224 233|fragmentspleted ra
P02019572A0000 |258 260|bpd 
P02019572A0000 |16 29|DNA sequencesomparison wit
P02019572A0000 |52 62|expression and 5-nuc
P02019572A0000 |283 296|gene cap sitels but still 
P02019572A0000 |471 480|CHO cells being 15
P02019572A0000 |346 358|introductionvs. P0001094
P02019572A0000 |413 420|culturetic dru
P02019572A0000 |70 95|rat liver pyruvate kinasee P00008171T0000 Pharmaco
P02020082A0356 |116 127|dysfunctionatal hyperb
P02020082A0356 |224 234|differencepleted rat
P02020082A0356 |76 81|AaDO208171
P02020082A0356 |199 209|parametersCSF PCO2 t
P02020082A0356 |133 138|AaDO2inemi
P02020082A0356 |29 41|gas exchangeh alkaline p
P02020082A0356 |243 257|plasma colloidlonger displac
P02020082A0356 |158 170|relationshipen CSF [HCO3
P02020082A0356 |67 72|valuedase 
P02020082A0356 |266 274|pressureompared 
P02020082A0356 |4 15|disturbance01606T0076 
P02020082A0356 |279 282|PCWntr
P02020314A1290 |221 227|future-deple
P02020314A1290 |67 78|neutropeniadase P00008
P02020314A1290 |182 194|chemotherapyas a functio
P02020314A1290 |106 147|carboplatin-cyclophosphamide chemotherapyts of neonatal hyperbilirubinemia. P00008
P02020314A1290 |18 42|micrograms/kg/day GM-CSFparison with alkaline ph
P02020314A1290 |55 63|severityd 5-nucl
P02020314A1290 |83 99|thrombocytopenia000 Pharmacologi
P02020314A1290 |2 6|dose0001
P02020314A1290 |207 213|cancer the d
P02021630A1104 |153 164|alterations72 When CSF
P02021630A1104 |89 92|DNAarm
P02021630A1104 |104 120|guanine N7 sitesects of neonatal
P02021630A1104 |211 226|protein binding data of K-depl
P02021630A1104 |134 140|groovenemia.
P02021630A1104 |52 64|interactions and 5-nucle
P02021630A1104 |144 147|DNA008
P02021630A1104 |77 84|protein8171T00
P02021630A1104 |6 17|differences606T0076 Co
P02021630A1104 |168 199|DNA phosphodiester conformationO3-] is shown as a function of 
P02022188A0112 |188 211|mobility group proteinsunction of CSF PCO2 the
P02022188A0112 |74 85|nucleosomes0008171T000
P02022188A0112 |120 126|agents hyper
P02022188A0112 |12 20|analysis76 Compa
P02022188A0112 |107 116|chromatins of neon
P02022188A0112 |150 153|DNAA04
P02022188A0112 |43 54|BJ1 proteinsphatases a
P02022188A0112 |213 217|HMGsata 
P02022188A1463 |119 131|prerequisitel hyperbilir
P02022188A1463 |148 163|gene expression97A0472 When CS
P02022188A1463 |47 56|chromatintases and
P02022188A1463 |21 34|gene productsison with alk
P02022188A1463 |98 113|order structureic aspects of n
P02022920A0334 |84 95|nucleotides00 Pharmaco
P02022920A0334 |106 109|UTRts 
P02022920A0334 |4 19|C4BP alpha gene01606T0076 Comp
P02022920A0334 |55 65|exon codesd 5-nucleo
P02023097A0000 |48 59|Rev proteinases and 5-
P02023097A0000 |124 139|gene expressionerbilirubinemia
P02023097A0000 |94 103|regulatorologic as
P02023097A0000 |41 46|HIV-1hosph
P02023097A0000 |10 37|immunodeficiency virus type0076 Comparison with alkali
P02023097A0000 |158 175|virus replicationen CSF [HCO3-] is
P02023421A0343 |98 106|strengthic aspec
P02023421A0343 |120 126|effect hyper
P02023421A0343 |75 83|increase008171T0
P02023421A0343 |9 22|proliferationT0076 Compari
P02023421A0343 |130 143|wound healingrubinemia. P0
P02023421A0343 |26 37|fibroblastswith alkali
P02023421A0343 |42 60|collagen synthesisosphatases and 5-n
P02023421A0343 |197 203|agentsf CSF 
P02023904A0120 |4 13|CDC7 gene01606T007
P02023904A0120 |31 41|AUG codonsalkaline p
P02023904A0120 |54 77|translation start sitesnd 5-nucleotidase P0000
P02023904A0120 |114 122|proteinsonatal h
P02024252A0000 |84 96|municipality00 Pharmacol
P02024252A0000 |122 128|Norwayyperbi
P02024252A0000 |40 47|personsphospha
P02024252A0000 |27 32|totalith a
P02024252A0000 |11 16|years076 C
P02024252A0000 |57 76|disability pensions5-nucleotidase P000
P02024252A0000 |100 109|Nordreisa aspects 
P02024488A0506 |0 4|HeLaP000
P02024488A0506 |63 75|CMV promotereotidase P00
P02024488A0506 |126 145|neomycin resistancebilirubinemia. P000
P02024488A0506 |9 26|Jurkat cell linesT0076 Comparison 
P02024488A0506 |40 48|nef genephosphat
P02024488A0506 |110 121|coselectionf neonatal 
P02024488A0506 |83 92|HIV-1 LTR000 Pharm
P02024625A0202 |102 114|similaritiesspects of ne
P02024625A0202 |77 82|cases8171T
P02024625A0202 |28 40|presentationth alkaline 
P02024625A0202 |134 142|featuresnemia. P
P02024625A0202 |55 65|appearanced 5-nucleo
P02024625A0202 |0 11|DifferencesP00001606T0
P02024791A0582 |17 29|MAIN RESULTSmparison wit
P02024791A0582 |77 82|study8171T
P02024791A0582 |123 135|L atropine/0perbilirubin
P02024791A0582 |62 67|entryleoti
P02024791A0582 |157 158|Ph
P02024791A0582 |99 116|FEV1 measurementsc aspects of neon
P02024791A0582 |39 45|groups phosp
P02024791A0582 |139 155|L metaproterenol. P00008997A0472
P02024791A0582 |0 12|MEASUREMENTSP00001606T00
P02024816A0521 |87 105|pneumonia patientsPharmacologic aspe
P02024816A0521 |41 50|protein Ahosphatas
P02024816A0521 |9 14|ELISAT0076
P02024816A0521 |52 56|SP-A and
P02025515A0979 |3 7|view0016
P02025515A0979 |41 50|doses/dayhosphatas
P02025515A0979 |21 25|t1/2ison
P02026144A0741 |115 119|NRS2nata
P02026144A0741 |9 16|controlT0076 C
P02026144A0741 |160 171|domain UAS1 CSF [HCO3-
P02026144A0741 |91 95|NRS1maco
P02026144A0741 |20 34|GUS expressionrison with alk
P02026144A0741 |80 89|sequences1T0000 Ph
P02026147A0000 |119 129|propertiesl hyperbil
P02026147A0000 |31 34|CaMalk
P02026147A0000 |14 17|Ca2 Co
P02026147A0000 |151 155|type0472
P02026147A0000 |159 170|CaM kinasesn CSF [HCO3
P02026147A0000 |46 60|protein kinaseatases and 5-n
P02026147A0000 |62 72|CaM kinaseleotidase 
P02026147A0000 |83 88|yeast000 P
P02026147A0000 |19 29|calmodulinarison wit
P02026461A0760 |49 60|individualsses and 5-n
P02026461A0760 |89 94|panelarmac
P02026461A0760 |8 13|cases6T007
P02026461A0760 |98 104|probesic asp
P02026491A0399 |35 42|effectsline ph
P02026491A0399 |122 126|painyper
P02026491A0399 |73 80|seizure0000817
P02026491A0399 |4 12|patients01606T00
P02026491A0399 |48 51|NMFase
P02027839A0250 |4 11|muscles01606T0
P02027839A0250 |124 135|fiber ratioerbilirubin
P02027839A0250 |61 62|Pc
P02027839A0250 |30 35|group alka
P02027839A0250 |111 120|capillary neonatal
P02027839A0250 |176 184|distanceshown as
P02027839A0250 |78 84|values171T00
P02027839A0250 |212 217|groupdata 
P02027839A0250 |99 106|densityc aspec
P02028125A0101 |32 41|infectionlkaline p
P02028125A0101 |180 188|examplesn as a f
P02028125A0101 |104 119|tumour responseects of neonata
P02028125A0101 |197 206|functionsf CSF PCO
P02028125A0101 |58 71|AIDS patients-nucleotidase
P02028125A0101 |130 144|cancer therapyrubinemia. P00
P02028125A0101 |80 91|probability1T0000 Phar
P02028125A0101 |4 14|prevalence01606T0076
P02029468A0296 |0 24|Serum TNF concentrationsP00001606T0076 Compariso
P02029468A0296 |107 111|weeks of
P02029468A0296 |42 51|diagnosisosphatase
P02029468A0296 |87 103|reference limitsPharmacologic as
P02030910A0000 |38 47|ETS1 genee phospha
P02030910A0000 |8 14|clones6T0076
P02030910A0000 |99 111|organizationc aspects of
P02030910A1070 |0 34|Polymerase chain reaction analysisP00001606T0076 Comparison with alk
P02030910A1070 |77 85|products8171T000
P02030910A1070 |110 118|splicingf neonat
P02030910A1070 |38 47|ETS1 cDNAe phospha
P02033038A0309 |85 91|pellet0 Phar
P02033038A0309 |127 129|E3il
P02033038A0309 |28 43|E3 polypeptidesth alkaline pho
P02033038A0309 |155 163|fraction When CS
P02033038A0309 |50 55|bandses an
P02033062A1169 |80 93|chicken IGF-I1T0000 Pharma
P02033062A1169 |8 25|promotor function6T0076 Comparison
P02033062A1169 |128 144|reporter plasmidlirubinemia. P00
P02033062A1169 |106 109|DNAts 
P02033062A1169 |67 76|fragmentsdase P000
P02033062A1169 |36 41|genesine p
P02034655A1224 |4 9|alpha01606
P02034655A1224 |12 16|gene76 C
P02034655A1224 |47 55|promotertases an
P02034655A1224 |29 35|regionh alka
P02034655A1224 |59 78|transfection assaysnucleotidase P00008
P02034655T0000 |0 16|CharacterizationP00001606T0076 C
P02034655T0000 |24 29|alphan wit
P02034655T0000 |32 54|integrin gene promoterlkaline phosphatases a
P02034669A0293 |68 78|expressionase P00008
P02034669A0293 |49 56|tissuesses and
P02034669A0293 |16 26|transcriptomparison 
P02034669A0293 |136 142|systemmia. P
P02034676A0267 |4 14|homologues01606T0076
P02034676A0267 |22 36|rhombotin geneson with alkal
P02035805T0000 |0 28|Angina haemorrhagica bullosaP00001606T0076 Comparison wi
P02035805T0000 |49 60|obstructionses and 5-n
P02036066A0000 |16 23|effectsomparis
P02036066A0000 |104 107|PHPect
P02036066A0000 |129 137|functionirubinem
P02036066A0000 |109 117|solutionof neona
P02036066A0000 |150 160|rat heartsA0472 When
P02036066A0000 |37 46|perfusionne phosph
P02036066A0000 |66 102|hemoglobin polyoxyethylene conjugateidase P00008171T0000 Pharmacologic a
P02038293A0919 |0 10|ConclusionP00001606T
P02038293A0919 |12 26|inlet type VSD76 Comparison 
P02038293A0919 |104 110|bundleects o
P02038293A0919 |151 162|VSD closure0472 When C
P02038293A0919 |46 54|type TOFatases a
P02038293A0919 |69 77|featuresse P0000
P02038326A0538 |216 233|43S-48S particles of K-depleted ra
P02038326A0538 |246 251|shiftger d
P02038326A0538 |94 101|couplesologic 
P02038326A0538 |167 196|translation initiation factorCO3-] is shown as a function 
P02038326A0538 |271 282|temperatureed to contr
P02038326A0538 |107 119|accumulations of neonata
P02038326A0538 |47 53|runofftases 
P02038326A0538 |200 211|eIF-2 alphaSF PCO2 the
P02038326A0538 |80 83|80S1T0
P02038326A0538 |143 151|subunits0008997A
P02038326A0538 |4 21|gcd2-503 mutation01606T0076 Compar
P02038326A0538 |55 67|accumulationd 5-nucleoti
P02038784A0317 |34 41|failurealine p
P02038784A0317 |6 14|patients606T0076
P02038784A0317 |20 23|ARCris
P02041088A1053 |207 219|39K promoter the data of
P02041088A1053 |15 32|enhancer activityComparison with a
P02041088A1053 |92 96|DR60acol
P02041088A1053 |44 60|reporter plasmidphatases and 5-n
P02041088A1053 |120 167|reporter chloramphenicol acetyltransferase gene hyperbilirubinemia. P00008997A0472 When CSF [H
P02041088A1053 |178 185|controlown as 
P02041088A1053 |36 40|DR60ine 
P02044785A0000 |119 123|cystl hy
P02044785A0000 |9 13|caseT007
P02044785A0000 |78 82|cyst171T
P02044785A0000 |20 34|adenocarcinomarison with alk
P02044785A0000 |49 64|retroperitonealses and 5-nucle
P02044950A0258 |53 65|U6 RNA genesand 5-nucleo
P02044950A0258 |72 81|organismsP00008171
P02044950A0258 |10 35|polymerase chain reaction0076 Comparison with alka
P02044975A0380 |154 165|application2 When CSF 
P02044975A0380 |108 120|instillation of neonatal
P02044975A0380 |10 16|volume0076 C
P02044975A0380 |26 30|flowwith
P02044975A0380 |63 64|Pe
P02044975A0380 |183 184|%s
P02044975A0380 |191 195|flowtion
P02044975A0380 |172 178|volume is sh
P02044975A0380 |144 147|min008
P02044975A0380 |200 201|%S
P02044975A0380 |100 101|h 
P02045366A1149 |0 23|Hydrophobicity analysisP00001606T0076 Comparis
P02045366A1149 |108 124|KlaC polypeptide of neonatal hyp
P02045366A1149 |180 187|domainsn as a 
P02045366A1149 |43 47|KlaAspha
P02045366A1149 |52 69|KlaB polypeptides and 5-nucleotida
P02045524A0000 |152 159|ratings472 Whe
P02045524A0000 |217 228|conferencesof K-deplet
P02045524A0000 |114 123|mid-1970sonatal hy
P02045524A0000 |72 76|FoodP000
P02045524A0000 |183 188|drugss a f
P02045524A0000 |60 66|agentsucleot
P02045524A0000 |201 213|end-of-phaseF PCO2 the d
P02045524A0000 |81 100|Drug AdministrationT0000 Pharmacologic
P02045524A0000 |234 247|drug sponsorss are no long
P02045524A0000 |18 30|availabilityparison with
P02045524A0000 |102 105|FDAspe
P02045809A0331 |136 145|reductionmia. P000
P02045809A0331 |73 79|powder000081
P02045809A0331 |30 52|B. sphaericus products alkaline phosphatases
P02045809A0331 |21 26|ratesison 
P02045809A0331 |99 110|concentratec aspects o
P02045809A0331 |54 62|ABG-6184nd 5-nuc
P02045809A0331 |3 11|contrast001606T0
P02045809A0331 |84 89|BSP-200 Ph
P02046202A0625 |19 20|%a
P02046202A0625 |31 46|IgA nephropathyalkaline phosph
P02046202A0625 |4 13|remainder01606T007
P02047597A0149 |77 85|bacteria8171T000
P02047597A0149 |26 34|vulvitiswith alk
P02047597A0149 |56 71|field condition 5-nucleotidase
P02047597A0149 |124 131|strainserbilir
P02052544A0641 |17 31|DNA polymerasemparison with 
P02052544A0641 |191 202|replicationtion of CSF
P02052544A0641 |72 78|dpb2-1P00008
P02052544A0641 |118 132|DNA polymeraseal hyperbiliru
P02052544A0641 |35 42|complexline ph
P02052544A0641 |86 91|cells Phar
P02052544A0641 |136 143|complexmia. P0
P02052544A0641 |153 157|DPB272 W
P02052592A0000 |275 286|interleukino controls 
P02052592A0000 |48 56|productsases and
P02052592A0000 |86 99|bone turnover Pharmacologi
P02052592A0000 |262 271|secretionen compar
P02052592A0000 |485 490|cellst nig
P02052592A0000 |300 327|tumor necrosis factor alpha a significantly greater sl
P02052592A0000 |122 133|developmentyperbilirub
P02052592A0000 |183 190|effectss a fun
P02052592A0000 |329 338|TNF-alphae (1.21 +
P02052592A0000 |467 472|bloodtice 
P02052592A0000 |75 82|changes008171T
P02052592A0000 |194 206|oophorectomyn of CSF PCO
P02052592A0000 |152 164|osteoporosis472 When CSF
P02052592A0000 |222 242|estrogen replacementdepleted rats are no
P02052592A0000 |290 294|IL-1stil
P02052592A0000 |351 369|phytohemagglutinin00010943A0733 Flur
P02052592A0000 |380 389|secretion appears 
P02052592A0000 |435 441|factormum do
P02052592A0000 |33 37|cellkali
P02052592A0000 |443 449|GM-CSF for u
P02053289A0701 |102 116|nt differencesspects of neon
P02053289A0701 |20 34|nt differencesrison with alk
P02053289A0701 |138 145|strainsa. P000
P02053289A0701 |70 76|groupse P000
P02054754A0919 |118 127|disordersal hyperb
P02054754A0919 |77 88|Sandostatin8171T0000 P
P02054754A0919 |13 23|principles6 Comparis
P02054754A0919 |36 46|managementine phosph
P02054754A0919 |98 106|patientsic aspec
P02055484A0538 |35 44|mutationsline phos
P02055484A0538 |60 64|ATG2ucle
P02055484A0538 |12 24|PCR products76 Compariso
P02055484A0538 |48 52|ATG1ases
P02056553T0000 |51 62|swine models and 5-nuc
P02056553T0000 |12 17|shock76 Co
P02056553T0000 |32 45|translocationlkaline phosp
P02060052A0954 |50 58|radicalses and 5
P02060052A0954 |93 105|mitochondriacologic aspe
P02060052A0954 |77 88|hepatocytes8171T0000 P
P02060052A0954 |28 34|levelsth alk
P02060052A0954 |6 10|data606T
P02060052A0954 |38 44|oxygene phos
P02061282A0447 |116 127|orientationatal hyperb
P02061282A0447 |161 167|middleCSF [H
P02061282A0447 |106 108|bpts
P02061282A0447 |60 66|regionucleot
P02061282A0447 |20 33|pMxL1 plasmidrison with al
P02061282A0447 |143 153|pilin gene0008997A04
P02061282A0447 |93 99|repeatcologi
P02061282A0447 |4 12|sequence01606T00
P02061282A0447 |175 202|recombination junction site shown as a function of CSF
P02061333A0784 |51 60|acvA genes and 5-n
P02061333A0784 |20 28|presencerison wi
P02061333A0784 |3 11|evidence001606T0
P02061333A0784 |32 39|intronslkaline
P02061333A1359 |170 187|reaction sequence-] is shown as a 
P02061333A1359 |6 18|observations606T0076 Com
P02061333A1359 |199 209|productionCSF PCO2 t
P02061333A1359 |64 99|phosphopantetheine-attachment sitesotidase P00008171T0000 Pharmacologi
P02061333A1359 |38 48|occurrencee phosphat
P02061333A1359 |217 231|ACV tripeptideof K-depleted 
P02061333A1359 |115 132|thioesterase sitenatal hyperbiliru
P02061333A1359 |153 162|reference72 When C
P02062116A0688 |0 9|PargylineP00001606
P02062116A0688 |13 40|monoamine oxidase inhibitor6 Comparison with alkaline 
P02062116A0688 |70 73|maxe P
P02062933A0738 |117 125|controlstal hype
P02062933A0738 |15 21|choiceCompar
P02062933A0738 |82 85|AOF000
P02062933A0738 |146 153|partner8997A04
P02062933A0738 |41 47|femalehospha
P02062933A0738 |70 74|malee P0
P02062933A0738 |87 104|flutamide femalesPharmacologic asp
P02064119A1172 |137 145|ABSTRACTia. P000
P02064119A1172 |127 135|subjectsilirubin
P02064119A1172 |56 62|% SaO2 5-nuc
P02064119A1172 |105 111|% SaO2cts of
P02064119A1172 |99 104|L/minc asp
P02064119A1172 |20 29|responsesrison wit
P02064119A1172 |163 168|WORDSF [HC
P02064119A1172 |70 79|relativese P000081
P02064119A1172 |50 55|L/mines an
P02065022A0747 |70 91|transforming activitye P00008171T0000 Phar
P02065022A0747 |11 20|deletions076 Compa
P02065022A0747 |141 147|regionP00008
P02065022A0747 |42 48|regionosphat
P02065022A0747 |95 98|dbllog
P02065022A0747 |116 124|deletionatal hyp
P02065022A0747 |155 161|effect When 
P02066246A0258 |49 54|filesses a
P02066246A0258 |62 91|Massachusetts Cancer Registryleotidase P00008171T0000 Phar
P02066246A0258 |96 101|casesogic 
P02066246A0258 |18 22|listpari
P02068085A1273 |51 58|elements and 5
P02068085A1273 |78 84|region171T00
P02068085A1273 |107 126|activation sequences of neonatal hyper
P02068085A1273 |92 95|Mluaco
P02068085A1273 |16 24|evidenceompariso
P02069738A0000 |2 8|method000160
P02069738A0000 |46 53|ethanolatases 
P02069738A0000 |26 42|stimulus controlwith alkaline ph
P02069873X0000 |0 9|MechanismP00001606
P02069873X0000 |13 23|activation6 Comparis
P02069873X0000 |31 48|vav protooncogenealkaline phosphat
P02069873X0000 |116 121|cellsatal 
P02069873X0000 |65 70|locustidas
P02069873X0000 |166 189|differentiation lineageHCO3-] is shown as a fu
P02069873X0000 |139 145|origin. P000
P02069873X0000 |50 53|vaves 
P02070227T0000 |12 24|cell seeding76 Compariso
P02072238T0000 |0 17|Menetrier diseaseP00001606T0076 Co
P02072238T0000 |23 28|childon wi
P02072798A0330 |87 92|ulcerPharm
P02072798A0330 |72 78|chanceP00008
P02072798A0330 |45 52|therapyhatases
P02072798A0330 |37 41|goalne p
P02072798A0330 |18 31|stabilizationparison with 
P02073222A0269 |137 147|conditionsia. P00008
P02073222A0269 |13 21|patients6 Compar
P02073222A0269 |45 58|moclobemide nhatases and 5
P02073222A0269 |23 38|amitriptyline non with alkalin
P02073222A0269 |83 96|week protocol000 Pharmacol
P02075876A0408 |71 80|amplitude P0000817
P02075876A0408 |56 65|variation 5-nucleo
P02075876A0408 |27 30|EERith
P02075876A0408 |4 22|stimulus threshold01606T0076 Compari
P02075876T0001 |0 8|AnalysisP0000160
P02075876T0001 |81 88|pathwayT0000 P
P02075876T0001 |96 99|catogi
P02075876T0001 |42 45|EERosp
P02075876T0001 |32 40|responselkaline 
P02075876T0001 |50 58|relationes and 5
P02076620A0548 |100 111|gemfibrozil aspects of
P02076620A0548 |13 37|plasma fibrinogen levels6 Comparison with alkali
P02076620A0548 |90 96|effectrmacol
P02076620A0548 |53 57|meanand 
P02076620A0548 |65 66|%t
P02076620T0000 |0 11|GemfibrozilP00001606T0
P02076620T0000 |31 39|patientsalkaline
P02076620T0000 |92 99|actionsacologi
P02076620T0000 |65 72|diseasetidase 
P02076816T0000 |32 51|sporulation controllkaline phosphatase
P02076816T0000 |93 121|IME1 transcript accumulationcologic aspects of neonatal 
P02076816T0000 |20 27|pathwayrison w
P02077560T0000 |4 8|role0160
P02077560T0000 |28 37|profilingth alkali
P02077560T0000 |41 58|safety assessmenthosphatases and 5
P02078080T0040 |19 29|Madagascararison wit
P02078080T0040 |31 41|advantagesalkaline p
P02078080T0040 |46 59|disadvantagesatases and 5-
P02078080T0040 |4 15|application01606T0076 
P02078570A0287 |7 12|cases06T00
P02078570A0287 |25 35|expression with alka
P02078570A0287 |59 68|integrinsnucleotid
P02079811A0407 |34 42|efficacyaline ph
P02079811A0407 |79 88|operation71T0000 P
P02079811A0407 |46 53|EMB AZSatases 
P02079811A0407 |121 126|levelhyper
P02079811A0407 |67 72|ulcerdase 
P02079811A0407 |176 184|bleedingshown as
P02079811A0407 |130 145|acid productionrubinemia. P000
P02079811A0407 |96 103|stomachogic as
P02079811A0407 |4 11|authors01606T0
P02080902A0183 |19 23|ratsaris
P02080902A0183 |64 82|avoidance responseotidase P00008171T
P02080902A0183 |98 106|controlsic aspec
P02080902A0183 |3 12|adulthood001606T00
P02081463A0110 |19 29|regulationarison wit
P02081463A0110 |75 80|Spec100817
P02081463A0110 |57 63|region5-nucl
P02081463A0110 |130 135|sitesrubin
P02081463A0110 |151 162|interaction0472 When C
P02081463A0110 |97 112|initiation sitegic aspects of 
P02081463A0110 |33 51|Spec gene activitykaline phosphatase
P02083199A1175 |0 22|Phosphopeptide mappingP00001606T0076 Compari
P02083199A1175 |120 124|EGFR hyp
P02083199A1175 |41 66|autophosphorylation siteshosphatases and 5-nucleot
P02083199A1175 |79 86|EGFR-IC71T0000
P02083230A0938 |185 191|domaina func
P02083230A0938 |121 142|N-glycosylation siteshyperbilirubinemia. P
P02083230A0938 |160 166|domain CSF [
P02083230A0938 |12 20|sequence76 Compa
P02083230A0938 |88 113|amino acid residue domainharmacologic aspects of n
P02083230A0938 |198 209|amino acids CSF PCO2 t
P02083230A0938 |40 54|signal peptidephosphatases a
P02083253A1512 |51 78|TCR alpha enhancer activitys and 5-nucleotidase P00008
P02083253A1512 |164 175|TCF-1 alpha [HCO3-] is
P02083253A1512 |197 217|transcription factorf CSF PCO2 the data 
P02083253A1512 |107 115|extractss of neo
P02083253A1512 |121 127|Jurkathyperb
P02083253A1512 |4 28|TCF-1 alpha binding site01606T0076 Comparison wi
P02083253A1512 |136 146|HeLa cellsmia. P0000
P02083546A0000 |238 245|diseasee no lo
P02083546A0000 |62 68|uptakeleotid
P02083546A0000 |328 349|motor neurone diseasepe (1.21 +/- 0.23 vs.
P02083546A0000 |120 131|99mTc-HMPAO hyperbilir
P02083546A0000 |21 27|methodison w
P02083546A0000 |250 258|patientsdisplace
P02083546A0000 |159 184|photon emission tomogramsn CSF [HCO3-] is shown as
P02083546A0000 |212 220|patientsdata of 
P02083546A0000 |264 272|dementia compare
P02083546A0000 |300 308|patients a signi
P02083546A0000 |107 118|amine oximes of neonat
P02083546A0000 |226 235|Alzheimereted rats
P02083546A0000 |284 293|lobe types but sti
P02083546A0000 |314 322|dementialy great
P02083546A0000 |199 207|subjectsCSF PCO2
P02088781A0653 |156 168|compensationWhen CSF [HC
P02088781A0653 |125 133|accuracyrbilirub
P02088781A0653 |56 59|fog 5-
P02088781A0653 |46 50|baseatas
P02088781A0653 |75 88|density units008171T0000 P
P02088781A0653 |97 106|influencegic aspec
P02088781A0653 |37 42|levelne ph
P02088781A0653 |24 27|fogn w
P02088781A0653 |4 11|results01606T0
P02088781A0653 |141 148|absenceP000089
P02089054A0121 |0 3|IdBP00
P02089054A0121 |193 204|UV detectoron of CSF P
P02089054A0121 |63 71|extractseotidase
P02089054A0121 |121 127|columnhyperb
P02089054A0121 |144 154|conditions008997A047
P02089054A0121 |32 54|liquid-solid partitionlkaline phosphatases a
P02091890A0614 |117 128|interactiontal hyperbi
P02091890A0614 |133 144|explorationinemia. P00
P02091890A0614 |73 80|profile0000817
P02091890A0614 |15 26|eltoprazineComparison 
P02091890A0614 |196 203|measureof CSF 
P02091890A0614 |208 216|sedationthe data
P02091890A0614 |182 192|inactivityas a funct
P02091890A0614 |8 13|model6T007
P02091890A0614 |93 103|aggressioncologic as
P02092131T0000 |50 66|hypersensitivityes and 5-nucleot
P02092131T0000 |30 38|transfer alkalin
P02092131T0000 |79 94|transfer factor71T0000 Pharmac
P02092131T0000 |6 12|method606T00
P02093033T0001 |0 6|EffectP00001
P02093033T0001 |124 128|ratserbi
P02093033T0001 |58 77|hexachlorobutadiene-nucleotidase P0000
P02093033T0001 |43 56|plutonium-239sphatases and
P02093033T0001 |108 120|thymus gland of neonatal
P02093033T0001 |82 100|tributyl phosphate0000 Pharmacologic
P02093033T0001 |32 39|effectslkaline
P02093741A0211 |0 15|Data collectionP00001606T0076 
P02093741A0211 |52 65|data analysis and 5-nucleo
P02093741A0211 |130 137|MAXITABrubinem
P02093741A0211 |124 128|toolerbi
P02093741A0211 |172 190|analysis technique is shown as a fun
P02093741A0211 |32 46|query languagelkaline phosph
P02093888A0293 |0 5|ARPIAP0000
P02093888A0293 |98 107|computersic aspect
P02093888A0293 |49 53|DBMSses 
P02094221A0247 |34 42|drinkingaline ph
P02094221A0247 |46 49|teaata
P02094221A0247 |55 59|ml/hd 5-
P02094221A0247 |0 8|DiuresisP0000160
P02094257T0000 |64 73|effusionsotidase P
P02094257T0000 |11 16|value076 C
P02094257T0000 |20 48|adenosine deaminase activityrison with alkaline phosphat
P02095150T0000 |38 53|hip replacemente phosphatases 
P02095150T0000 |57 67|comparison5-nucleoti
P02095150T0000 |91 110|ingrowth componentsmacologic aspects o
P02095150T0000 |8 25|strain adaptation6T0076 Comparison
P02095150T0000 |114 121|caninesonatal 
P02099622A1046 |0 20|Immuno-cytochemistryP00001606T0076 Compa
P02099622A1046 |181 190|structure as a fun
P02099622A1046 |45 65|Campylobacter jejunihatases and 5-nucleo
P02099622A1046 |92 100|stainingacologic
P02099622A1046 |123 128|cellsperbi
P02099622A1046 |28 36|antiserath alkal
P02099622A1046 |162 171|organismsSF [HCO3-
P02099622A1046 |202 219|Campylobacter spp PCO2 the data of
P02102823A0492 |0 19|Promoter activitiesP00001606T0076 Comp
P02102823A0492 |41 59|beta-glucuronidasehosphatases and 5-
P02102823A0492 |95 116|reporter gene systemslogic aspects of neon
P02102823A0492 |64 91|neomycin phosphotransferaseotidase P00008171T0000 Phar
P02102831A1282 |69 77|featuresse P0000
P02102831A1282 |28 47|soybean actin genesth alkaline phospha
P02102831A1282 |110 119|stretchesf neonata
P02102831A1282 |93 100|repeatscologic
P02102831A1282 |89 91|CTar
P02102831A1282 |7 14|regions06T0076
P02102831A1282 |139 142|DNA. P
P02103140A1088 |173 190|retransplantationis shown as a fun
P02103140A1088 |10 11|%0
P02103140A1088 |13 21|patients6 Compar
P02103140A1088 |45 52|failurehatases
P02103140A1088 |125 131|graftsrbilir
P02103140A1088 |66 72|graftsidase 
P02103403A0149 |17 24|historympariso
P02103403A0149 |3 10|patient001606T
P02103403A0149 |64 70|intakeotidas
P02103403A0149 |96 104|steroidsogic asp
P02103403A0149 |86 91|drugs Phar
P02103403A0149 |35 49|alcohol intakeline phosphata
P02105497A1092 |102 111|BiP genesspects of
P02105497A1092 |57 71|HSP70 proteins5-nucleotidase
P02105497A1092 |194 204|eukaryotesn of CSF P
P02105497A1092 |30 50|amino acid sequences alkaline phosphatas
P02105497A1092 |80 87|species1T0000 
P02105497A1092 |163 174|HSP70 genesF [HCO3-] i
P02105497A1092 |127 135|ancestorilirubin
P02105497A1092 |184 188|time a f
P02105497A1092 |16 26|comparisonomparison 
P02106287A0478 |0 13|Spore inoculaP00001606T007
P02106287A0478 |59 65|0.5-innucleo
P02106287A0478 |35 41|couponline p
P02107073A0584 |174 179|STE18s sho
P02107073A0584 |88 106|pheromone responseharmacologic aspec
P02107073A0584 |164 170|levels [HCO3
P02107073A0584 |45 59|STE18 proteinshatases and 5-
P02107073A0584 |112 126|overexpressionneonatal hyper
P02107073A0584 |9 23|overexpressionT0076 Comparis
P02107073A0584 |130 134|STE4rubi
P02107073A0584 |142 150|presence00008997
P02107073A0584 |36 40|STE4ine 
P02107548A0727 |69 72|RNAse 
P02107548A0727 |43 48|clonesphat
P02107548A0727 |124 131|psi ARFerbilir
P02107548A0727 |60 64|polyucle
P02107548A0727 |113 120|homologeonatal
P02107548A0727 |8 25|transcription-PCR6T0076 Comparison
P02107548A0727 |77 81|cDNA8171
P02107548A0727 |65 66|At
P02107548A0727 |156 159|ARFWhe
P02109544A0000 |239 247|antibody no long
P02109544A0000 |268 274|optionpared 
P02109544A0000 |156 194|leukocyte esterase urine dipstick testWhen CSF [HCO3-] is shown as a functio
P02109544A0000 |249 252|DFA di
P02109544A0000 |295 304|treatment have a s
P02109544A0000 |25 33|benefits with al
P02109544A0000 |93 98|malescolog
P02109544A0000 |57 78|Chlamydia trachomatis5-nucleotidase P00008
P02109544A0000 |281 290|screeningrols but 
P02109544A0000 |16 20|costompa
P02109544A0000 |115 138|decision analysis modelnatal hyperbilirubinemi
P02109544A0000 |37 52|screening testsne phosphatases
P02109544A0000 |200 207|cultureSF PCO2
P02110145T0000 |0 10|SequencingP00001606T
P02110145T0000 |149 179|Bacillus cereus beta-lactamase7A0472 When CSF [HCO3-] is sho
P02110145T0000 |121 131|similarityhyperbilir
P02110145T0000 |15 19|geneComp
P02110145T0000 |66 70|CfiAidas
P02110145T0000 |77 88|Bacteroides8171T0000 P
P02110145T0000 |58 64|enzyme-nucle
P02110145T0000 |140 144|CfiA P00
P02110145T0000 |98 105|TAL2480ic aspe
P02110148A0423 |288 291|IF2t s
P02110148A0423 |95 99|halflogi
P02110148A0423 |11 27|HindIII fragment076 Comparison w
P02110148A0423 |107 130|B. subtilis IF2 proteins of neonatal hyperbili
P02110148A0423 |240 244|ClaIno l
P02110148A0423 |303 307|genesign
P02110148A0423 |211 216|clone data
P02110148A0423 |48 69|DNA sequence analysisases and 5-nucleotida
P02110148A0423 |202 207|probe PCO2
P02110148A0423 |163 171|sequenceF [HCO3-
P02110148A0423 |257 265|fragmented when 
P02110148A0423 |139 141|kb. 
P02111015A0574 |68 74|domainase P0
P02111015A0574 |96 115|sequence similarityogic aspects of neo
P02111015A0574 |166 171|IRF-2HCO3-
P02111015A0574 |134 154|IFN response factorsnemia. P00008997A047
P02111015A0574 |156 161|IRF-1When 
P02111015A0574 |19 30|amino acidsarison with
P02113015A0295 |38 47|pregnancye phospha
P02113015A0295 |9 17|seizuresT0076 Co
P02113015A0295 |58 62|cent-nuc
P02113174A0064 |69 93|transcription factor Sp1se P00008171T0000 Pharma
P02113174A0064 |13 20|protein6 Compa
P02113174A0064 |32 44|zinc fingerslkaline phos
P02113174A0957 |0 7|Krox-24P000016
P02113174A0957 |57 66|activator5-nucleot
P02113455A0207 |64 77|considerationotidase P0000
P02113455A0207 |111 127|threshold levels neonatal hyperb
P02113455A0207 |20 31|variabilityrison with 
P02113455A0207 |39 49|parameters phosphata
P02113699A0372 |33 42|subgroupskaline ph
P02113699A0372 |179 180|Nw
P02113699A0372 |146 151|spots8997A
P02113699A0372 |121 129|patientshyperbil
P02113699A0372 |254 255|Nl
P02113699A0372 |221 226|spots-depl
P02113699A0372 |50 51|Ne
P02113699A0372 |118 119|Na
P02113699A0372 |80 85|spots1T000
P02113699A0372 |53 61|patientsand 5-nu
P02113699A0372 |193 194|No
P02113699A0372 |107 109|IMs 
P02113699A0372 |104 105|Ne
P02113699A0372 |196 204|patientsof CSF P
P02113699A0372 |4 12|patients01606T00
P02113901A0000 |34 38|hypoalin
P02113901A0000 |104 111|tensionects of
P02113901A0000 |113 117|PaO2eona
P02113901A0000 |43 54|normocapniasphatases a
P02113901A0000 |9 12|CO2T00
P02113901A0000 |21 28|changesison wi
P02113901A0000 |154 164|difference2 When CSF
P02115111T0000 |68 82|reading framesase P00008171T
P02115111T0000 |90 105|nif gene regionrmacologic aspe
P02115111T0000 |12 31|nucleotide sequence76 Comparison with 
P02115111T0000 |122 136|strain PCC7120yperbilirubine
P02115111T0000 |47 55|analysistases an
P02115111T0000 |109 120|Anabaena spof neonatal
P02115111T0000 |0 10|ExpressionP00001606T
P02115115A1053 |152 163|yeast genes472 When CS
P02115115A1053 |78 86|CAR1 URS171T0000
P02115115A1053 |122 129|regionsyperbil
P02115115A1053 |54 59|sitesnd 5-
P02115115A1053 |38 48|suggestione phosphat
P02115116A1137 |50 59|enhancerses and 5-
P02115116A1137 |72 89|promoter elementsP00008171T0000 Ph
P02115116A1137 |27 41|sequence matchith alkaline p
P02115116A1137 |4 11|results01606T0
P02115118A0565 |70 84|sodium dodecyle P00008171T00
P02115118A0565 |132 176|sucrose density gradient ultracentrifugationbinemia. P00008997A0472 When CSF [HCO3-] is 
P02115118A0565 |44 56|smg p25A GDIphatases and
P02115118A0565 |108 127|gel electrophoresis of neonatal hyperb
P02115118A0565 |5 7|Mr16
P02115121A0000 |0 13|Yeast mutantsP00001606T007
P02115121A0000 |209 216|complexhe data
P02115121A0000 |192 201|componention of CS
P02115121A0000 |30 60|pet complementation group G104 alkaline phosphatases and 5-n
P02115121A0000 |155 185|dihydrolipoyl transsuccinylase When CSF [HCO3-] is shown as 
P02115121A0000 |138 147|mutationsa. P00008
P02115121A0000 |128 134|resultlirubi
P02115121A0000 |100 122|dehydrogenase activity aspects of neonatal h
P02115121A0000 |187 190|KE2fun
P02115122A0562 |143 148|c-Fos00089
P02115122A0562 |31 41|repressionalkaline p
P02115122A0562 |94 99|c-Fosologi
P02115122A0562 |79 90|amino acids71T0000 Pha
P02115122A0562 |107 112|v-Foss of 
P02115122A0562 |9 17|residuesT0076 Co
P02115122A0562 |128 139|truncationslirubinemia
P02115572A1323 |49 61|psi V lambdases and 5-nu
P02115572A1323 |67 69|kbda
P02115572A1323 |21 40|V lambda pseudogeneison with alkaline 
P02115572A1323 |86 102|U266 lambda gene Pharmacologic a
P02115889A0436 |64 72|Gx alphaotidase 
P02115889A0436 |36 45|structureine phosp
P02115889A0436 |8 13|paper6T007
P02115889A0436 |99 108|kilobasesc aspects
P02115889A0436 |55 59|gened 5-
P02116071A0000 |204 207|IgECO2
P02116071A0000 |217 221|seraof K
P02116071A0000 |296 302|amounthave a
P02116071A0000 |365 371|amountFluraz
P02116071A0000 |389 392|IgGto 
P02116071A0000 |181 186|titer as a
P02116071A0000 |160 167|antigen CSF [H
P02116071A0000 |326 330|bodylope
P02116071A0000 |17 22|studympari
P02116071A0000 |50 64|stage childrenes and 5-nucle
P02116071A0000 |256 263|attacksced whe
P02116071A0000 |80 87|potency1T0000 
P02116071A0000 |311 318|antigenantly g
P02116071A0000 |348 357|reduction. P000109
P02116071A0000 |109 139|type hypersensitivity reactionof neonatal hyperbilirubinemia
P02116071A0000 |143 151|exposure0008997A
P02116071A0000 |279 288|reductionntrols bu
P02116537A1237 |70 73|AMKe P
P02116537A1237 |63 66|MICeot
P02116537A1237 |7 16|influence06T0076 C
P02116537A1237 |39 53|concentrations phosphatases 
P02117799T0000 |1 5|Uses0000
P02117799T0000 |29 40|prophylaxish alkaline 
P02117799T0000 |44 53|rejectionphatases 
P02117799T0000 |44 53|rejectionphatases 
P02117799T0000 |1 5|Uses0000
P02117799T0000 |58 67|induction-nucleoti
P02117799T0000 |9 24|orthoclone OKT3T0076 Compariso
P02117799T0000 |94 116|kidney transplantationologic aspects of neon
P02117799T0000 |79 90|nonfunction71T0000 Pha
P02117799T0000 |94 116|kidney transplantationologic aspects of neon
P02117799T0000 |79 90|nonfunction71T0000 Pha
P02117799T0000 |29 40|prophylaxish alkaline 
P02117799T0000 |9 24|orthoclone OKT3T0076 Compariso
P02117799T0000 |58 67|induction-nucleoti
P02118519A0516 |37 53|consensus motifsne phosphatases 
P02118519A0516 |167 188|neurofilament proteinCO3-] is shown as a f
P02118519A0516 |123 151|nerve growth factor receptorperbilirubinemia. P00008997A
P02118519A0516 |109 114|genesof ne
P02118519A0516 |92 101|positionsacologic 
P02118525A0737 |85 93|enhancer0 Pharma
P02118525A0737 |29 37|fragmenth alkali
P02118525A0737 |45 57|CCK promoterhatases and 
P02118525A0737 |190 198|positionction of
P02118525A0737 |115 128|transcriptionnatal hyperbi
P02118525A0737 |228 234|mannered rat
P02118525A0737 |3 11|addition001606T0
P02118525A0737 |138 184|herpes simplex virus thymidine kinase promotera. P00008997A0472 When CSF [HCO3-] is shown as
P02118612A0629 |18 34|supine restraintparison with alk
P02118612A0629 |146 154|exposure8997A047
P02118612A0629 |45 65|DOPAC concentrationshatases and 5-nucleo
P02118612A0629 |158 163|etheren CS
P02118612A0629 |7 14|minutes06T0076
P02118612A0629 |178 184|effectown as
P02118612A0629 |80 88|eminence1T0000 P
P02118612A0629 |99 103|ratsc as
P02119530T0000 |68 80|fibrinolysisase P0000817
P02119530T0000 |13 33|metoprolol treatment6 Comparison with al
P02119530T0000 |54 64|activationnd 5-nucle
P02119530T0000 |0 9|InfluenceP00001606
P02119626A0471 |58 68|dimensions-nucleotid
P02119626A0471 |46 47|%a
P02119626A0471 |11 16|scars076 C
P02119946T0000 |49 61|introductionses and 5-nu
P02119946T0000 |9 18|dysphagiaT0076 Com
P02119946T0000 |32 44|care settinglkaline phos
P02120707A0594 |87 97|V elementsPharmacolo
P02120707A0594 |58 66|proteins-nucleot
P02120707A0594 |123 152|HLA-DRA X-box oligonucleotideperbilirubinemia. P00008997A0
P02120707A0594 |45 49|Rajihata
P02120707A0594 |81 82|WT
P02120707A0594 |19 25|assaysarison
P02120833A0000 |68 76|TAH-NANBase P000
P02120833A0000 |113 117|caseeona
P02120833A0000 |52 66|hepatitis NANB and 5-nucleot
P02120833A0000 |130 135|unitsrubin
P02120833A0000 |20 25|casesrison
P02120833A0000 |3 10|Denmark001606T
P02121371T0000 |4 13|NF1 locus01606T007
P02121371T0000 |74 92|yeast IRA proteins0008171T0000 Pharm
P02121371T0000 |24 31|proteinn with 
P02121371T0000 |66 69|GAPida
P02122454A1042 |84 90|lambda00 Pha
P02122454A1042 |26 32|Phe-62with a
P02122454A1042 |11 22|replacement076 Compari
P02122454A1042 |65 76|determinanttidase P000
P02122454A1042 |163 171|moleculeF [HCO3-
P02122454A1042 |145 154|transport08997A047
P02122454A1042 |99 104|chainc asp
P02122454A1042 |38 41|Sere p
P02123029A0478 |153 159|probes72 Whe
P02123029A0478 |46 57|chain genesatases and 
P02123029A0478 |91 110|spleen cDNA librarymacologic aspects o
P02123029A0478 |212 219|isotypedata of
P02123029A0478 |127 134|Raja VHilirubi
P02123029A0478 |9 16|isotypeT0076 C
P02123029A0478 |189 196|regionsnction 
P02123029A0478 |20 39|Raja immunoglobulinrison with alkaline
P02123293A0227 |0 5|PetkoP0000
P02123293A0227 |11 13|S.07
P02123295A0645 |0 10|DisruptionP00001606T
P02123295A0645 |14 18|ARF2 Com
P02123295A0645 |40 49|phenotypephosphata
P02123300T0000 |86 99|hemophilia A. Pharmacologi
P02123300T0000 |73 82|treatment00008171T
P02123300T0000 |45 51|factorhatase
P02123300T0000 |112 135|Factor VIII Study Groupneonatal hyperbilirubin
P02123300T0000 |53 59|factorand 5-
P02123466A0272 |137 148|DNA bindingia. P000089
P02123466A0272 |77 83|domain8171T0
P02123466A0272 |27 33|familyith al
P02123466A0272 |11 18|members076 Com
P02123466A0272 |39 43|AP-4 pho
P02123466A0272 |48 53|motifases 
P02123467A0811 |103 106|Sp1pec
P02123467A0811 |209 212|Sp1he 
P02123467A0811 |13 23|expression6 Comparis
P02123467A0811 |31 39|promoteralkaline
P02123467A0811 |93 98|MyoD1colog
P02123467A0811 |77 82|cells8171T
P02123467A0811 |176 184|presenceshown as
P02123467A0811 |142 147|sites00008
P02123467A0811 |217 222|MyoD1of K-
P02123820A0000 |102 110|deprenylspects o
P02123820A0000 |42 45|MAOosp
P02123820A0000 |147 156|nialamide997A0472 
P02123820A0000 |209 212|FIAhe 
P02123820A0000 |132 145|MAO inhibitorbinemia. P000
P02123820A0000 |61 71|clorgylinecleotidase
P02123820A0000 |224 228|ratsplet
P02123820A0000 |50 59|inhibitores and 5-
P02123820A0000 |23 40|monoamine oxidaseon with alkaline 
P02123820A0000 |197 207|aggressionf CSF PCO2
P02123820A0000 |0 7|EffectsP000016
P02123820A0000 |85 100|MAO-B inhibitor0 Pharmacologic
P02123875A0223 |35 43|residuesline pho
P02123875A0223 |112 137|signal peptidase cleavageneonatal hyperbilirubinem
P02123875A0223 |266 270|coreompa
P02123875A0223 |57 65|c-region5-nucleo
P02123875A0223 |302 314|NH2 terminus significant
P02123875A0223 |329 335|regione (1.2
P02123875A0223 |407 414|apoA-II hypnot
P02123875A0223 |166 179|translocationHCO3-] is sho
P02123875A0223 |85 93|fidelity0 Pharma
P02123875A0223 |359 364|modelA0733
P02123875A0223 |397 406|delta pro effectiv
P02123875A0223 |23 31|featureson with 
P02123875A0223 |233 246|COOH terminusts are no lon
P02123875A0223 |199 223|amino acid substitutionsCSF PCO2 the data of K-d
P02123875A0223 |281 294|substitutionsrols but stil
P02123875A0223 |98 108|efficiencyic aspects
P02123875A0223 |341 352|+1 position0.23 vs. P0
P02123877A1452 |256 270|gene inductionced when compa
P02123877A1452 |23 28|c-foson wi
P02123877A1452 |112 117|fra-1neona
P02123877A1452 |92 103|liver cellsacologic as
P02123877A1452 |123 128|egr-2perbi
P02123877A1452 |226 236|regulationeted rats 
P02123877A1452 |105 110|fos-Bcts o
P02123877A1452 |71 77|levels P0000
P02123877A1452 |33 44|egr-1 mRNAskaline phos
P02123877A1452 |158 165|factorsen CSF 
P02123877A1452 |185 206|serum response factora function of CSF PCO
P02123877A1452 |169 177|addition3-] is s
P02124433A0235 |102 109|surgeryspects 
P02124433A0235 |21 26|casesison 
P02124433A0235 |157 164|surgeryhen CSF
P02124433A0235 |112 115|MMCneo
P02124433A0235 |93 100|Group Acologic
P02124433A0235 |56 63|patient 5-nucl
P02124433A0235 |123 135|chemotherapyperbilirubin
P02124433A0235 |148 155|group B97A0472
P02124433A0235 |180 186|OK-432n as a
P02124433A0235 |41 52|descriptionhosphatases
P02124433A0235 |167 170|MMCCO3
P02124433A0235 |194 212|immunochemotherapyn of CSF PCO2 the 
P02124433A0235 |118 122|5-FUal h
P02124433A0235 |222 229|group Cdeplete
P02124433A0235 |190 193|PSKcti
P02124433A0235 |66 76|backgroundidase P000
P02124433A0235 |7 15|patients06T0076 
P02124433A0235 |231 238|surgeryrats ar
P02124433A0235 |173 177|5-FUis s
P02124433A0235 |141 146|casesP0000
P02124710A0193 |116 148|osteoblast phenotype developmentatal hyperbilirubinemia. P000089
P02124710A0193 |46 66|c-jun protooncogenesatases and 5-nucleot
P02124710A0193 |12 20|proteins76 Compa
P02124710A0193 |92 112|proliferation periodacologic aspects of 
P02124710A0193 |36 41|c-fosine p
P02124710A1624 |102 119|collagen promoterspects of neonata
P02124710A1624 |72 81|AP-1 siteP00008171
P02124710A1624 |35 42|bindingline ph
P02124710A1624 |5 10|model1606T
P02124710A1624 |89 99|type alphaarmacologi
P02124710A1624 |50 65|Fos-Jun complexes and 5-nucleo
P02124710A1624 |170 174|VDRE-] i
P02125016A0145 |0 4|PBSXP000
P02125016A0145 |43 55|SOS responsesphatases an
P02125016A0145 |19 25|agentsarison
P02125153A0410 |118 129|Z5 patientsal hyperbil
P02125153A0410 |82 84|R300
P02125153A0410 |109 110|%o
P02125153A0410 |89 90|%a
P02125153A0410 |73 74|%0
P02125153A0410 |135 144|organismsemia. P00
P02125153A0410 |60 65|yearsucleo
P02125153A0410 |158 170|streptomycinen CSF [HCO3
P02125153A0410 |36 45|treatmentine phosp
P02125153A0410 |97 99|R5gi
P02125153A0410 |175 184|isoniazid shown as
P02125153A0410 |18 25|relapseparison
P02126417A0408 |141 150|advantageP00008997
P02126417A0408 |7 15|controls06T0076 
P02126417A0408 |129 139|hemisphereirubinemia
P02126417A0408 |113 116|VHFeon
P02126417A0408 |81 97|control subjectsT0000 Pharmacolo
P02126504A0602 |55 64|mechanismd 5-nucle
P02126504A0602 |91 100|Rh-systemmacologic
P02126504A0602 |12 25|Rh-antibodies76 Comparison
P02129338A0568 |49 57|homologyses and 
P02129338A0568 |61 62|%c
P02129338A0568 |12 31|amino acid sequence76 Comparison with 
P02129338A0568 |77 114|alga Scenedemus obliquus plastocyanin8171T0000 Pharmacologic aspects of ne
P02131652A0883 |169 179|ng.l-1 min3-] is sho
P02131652A0883 |15 42|serum gastrin concentrationComparison with alkaline ph
P02131652A0883 |126 134|AUC0-120bilirubi
P02131652A0883 |109 124|gastrin releaseof neonatal hyp
P02131652A0883 |75 81|ng.l-1008171
P02131652A0883 |219 226|VTP-Cas K-depl
P02131652A0883 |201 207|VTP-HMF PCO2
P02131666A0483 |17 22|groupmpari
P02131666A0483 |72 81|anomaliesP00008171
P02131666A0483 |39 59|examinees class II/2 phosphatases and 5-
P02131902A0000 |152 161|ventricle472 When 
P02131902A0000 |135 139|viewemia
P02131902A0000 |40 48|locationphosphat
P02131902A0000 |94 104|transducerologic asp
P02131902A0000 |89 92|TEEarm
P02131902A0000 |163 167|S-LVF [H
P02131902A0000 |5 10|study1606T
P02132636A0188 |0 8|SubjectsP0000160
P02132636A0188 |30 44|schizophrenics alkaline phos
P02132636A0188 |61 76|DST suppressorscleotidase P000
P02132636A0188 |83 97|nonsuppressors000 Pharmacolo
P02133731A1572 |19 20|%a
P02133731A1572 |25 27|S5 w
P02133731A1572 |58 61|1/T-nu
P02133731A1572 |9 12|CBFT00
P02133731A1572 |109 123|control levelsof neonatal hy
P02133731A1572 |29 32|CBFh a
P02133731A1572 |5 7|S316
P02133731A1572 |129 130|pi
P02133731A1572 |42 46|%WThosph
P02133731A1572 |38 39|%e
P02133731A1572 |48 53|1/TPCases 
P02135343A0131 |98 110|maloclusionsic aspects o
P02135343A0131 |198 219|ANGLE3 classification CSF PCO2 the data of
P02135343A0131 |177 182|archshown 
P02135343A0131 |8 15|article6T0076 
P02135343A0131 |145 157|relationship08997A0472 W
P02135343A0131 |43 53|percentagesphatases 
P02135343A0131 |82 94|distribution0000 Pharmac
P02135343A0131 |64 73|occlusionotidase P
P02135536A0621 |138 140|Hka.
P02135536A0621 |27 41|brush abrasionith alkaline p
P02135536A0621 |228 238|degrees C.ed rats ar
P02135536A0621 |123 131|hardnessperbilir
P02135536A0621 |164 178|micrograms/mm3 [HCO3-] is sh
P02135536A0621 |105 108|MPacts
P02135536A0621 |80 88|strength1T0000 P
P02135536A0621 |142 158|water absorption00008997A0472 Wh
P02135536A0621 |8 12|case6T00
P02135536A0621 |191 212|expansion coefficienttion of CSF PCO2 the 
P02135536A0621 |18 23|ratioparis
P02137704A0000 |200 201|hS
P02137704A0000 |487 495|diameternight. P
P02137704A0000 |182 196|blood pressureas a function 
P02137704A0000 |151 152|h0
P02137704A0000 |239 253|blood pressure no longer dis
P02137704A0000 |446 454|diameterr use in
P02137704A0000 |507 521|wall thickness5 Beta blockin
P02137704A0000 |381 388|indicesappears
P02137704A0000 |314 326|office visitly greater s
P02137704A0000 |590 594|mass CO2
P02137704A0000 |119 146|blood pressure measurementsl hyperbilirubinemia. P0000
P02137704A0000 |532 546|wall thickness00013683A0210 
P02137704A0000 |48 56|patientsases and
P02137704A0000 |666 680|diameter rationtravenous adm
P02137704A0000 |599 609|mass indexuction (VC
P02137704A0000 |19 24|groupariso
P02137704A0000 |223 230|morningepleted
P02137704A0000 |624 643|wall thickness/leftentilation almost c
P02137704A0000 |335 349|blood pressure1 +/- 0.23 vs.
P02137704A0000 |264 276|office visit compared to
P02137704A0000 |91 102|associationmacologic a
P02137704A0000 |79 87|strength71T0000 
P02137704A0000 |557 571|wall thicknessorporeal CO2 r
P02137704A0000 |285 299|blood pressure but still hav
P02137704A0000 |473 476|endein
P02137704A0000 |413 432|target organ damagetic drug with the o
P02138707A0198 |239 260|transcription element no longer displaced 
P02138707A0198 |46 76|lambda gt11 expression libraryatases and 5-nucleotidase P000
P02138707A0198 |180 225|histocompatibility complex A alpha gene X boxn as a function of CSF PCO2 the data of K-dep
P02138707A0198 |165 170|class[HCO3
P02138707A0198 |292 297|genesill h
P02138707A0198 |283 288|classls bu
P02138707A0198 |147 150|end997
P02138707A0198 |116 124|sequenceatal hyp
P02138707A0198 |85 97|protein mXBP0 Pharmacolo
P02138915A1060 |152 157|WORDS472 W
P02138915A1060 |58 66|sequence-nucleot
P02138915A1060 |28 30|kbth
P02138915A1060 |120 124|gene hyp
P02138915A1060 |4 12|p36 gene01606T00
P02138915A1060 |126 134|ABSTRACTbilirubi
P02138915A1060 |111 112|% 
P02138915A1060 |86 88|kb P
P02138915A1060 |34 40|lengthaline 
P02138992A0911 |119 123|workl hy
P02138992A0911 |62 68|tumorsleotid
P02138992A0911 |91 103|modificationmacologic as
P02138992A0911 |19 28|treatmentarison wi
P02138992A0911 |139 147|approach. P00008
P02139473A1603 |187 210|Shine-Dalgarno sequencefunction of CSF PCO2 th
P02139473A1603 |142 148|region000089
P02139473A1603 |61 65|sitecleo
P02139473A1603 |98 116|Fur concentrationsic aspects of neon
P02139473A1603 |69 73|entCse P
P02139891A0532 |155 165|EIIF sites When CSF 
P02139891A0532 |79 82|EIV71T
P02139891A0532 |209 222|ATF/CREB sitehe data of K-
P02139891A0532 |60 74|activators EIAucleotidase P0
P02139891A0532 |113 123|TAGA motifeonatal hy
P02139891A0532 |189 200|orientationnction of C
P02139891A0532 |10 18|promoter0076 Com
P02139891A0532 |141 149|TATA boxP0000899
P02139891A0532 |101 109|elementsaspects 
P02141425A0175 |103 115|measurementspects of neo
P02141425A0175 |167 172|floorCO3-]
P02141425A0175 |72 77|stoolP0000
P02141425A0175 |132 140|patientsbinemia.
P02141425A0175 |44 50|methodphatas
P02141425A0175 |38 42|MFTFe ph
P02141425A0175 |52 60|patients and 5-n
P02141425A0175 |193 198|levelon of
P02141425A0175 |18 36|fingertip-to-floorparison with alkal
P02141425A0175 |206 211|floor2 the
P02142240A0506 |115 123|presencenatal hy
P02142240A0506 |44 58|response ratesphatases and 5
P02142240A0506 |15 26|differencesComparison 
P02142240A0506 |93 111|estrogen receptorscologic aspects of
P02142240A0506 |76 89|concentration08171T0000 Ph
P02142240A0506 |166 174|patientsHCO3-] i
P02142240A0506 |127 148|progesteron receptorsilirubinemia. P000089
P02142240A0506 |157 162|grouphen C
P02142486A0367 |0 11|TeicoplaninP00001606T0
P02142486A0367 |126 131|casesbilir
P02142486A0367 |107 116|one-thirds of neon
P02142486A0367 |55 60|feverd 5-n
P02142486A0367 |86 97|bacteraemia Pharmacolo
P02142921T0000 |85 92|results0 Pharm
P02142921T0000 |73 81|analysis00008171
P02142921T0000 |147 156|goserelin997A0472 
P02142921T0000 |12 52|hormone-releasing hormone analog therapy76 Comparison with alkaline phosphatases
P02142921T0000 |107 116|buserelins of neon
P02142921T0000 |198 203|depot CSF 
P02142921T0000 |64 71|fibroidotidase
P02142955A0248 |170 176|delays-] is 
P02142955A0248 |89 94|basisarmac
P02142955A0248 |107 117|appearances of neona
P02142955A0248 |74 81|objects0008171
P02142955A0248 |38 44|adultse phos
P02142955A0248 |188 192|daysunct
P02142955A0248 |24 31|infantsn with 
P02142955A0248 |3 14|Experiments001606T0076
P02142955A0248 |153 162|exemplars72 When C
P02142993A0176 |153 161|patterns72 When 
P02142993A0176 |13 20|picture6 Compa
P02142993A0176 |172 183|L. infantum is shown a
P02142993A0176 |93 106|leishmaniasiscologic aspec
P02142993A0176 |28 35|diseaseth alka
P02142993A0176 |230 236|France rats 
P02142993A0176 |206 213|pattern2 the d
P02142993A0176 |117 127|L. tropicatal hyperb
P02143023A0729 |99 112|transcriptionc aspects of 
P02143023A0729 |46 63|adenovirus genomeatases and 5-nucl
P02143023A0729 |163 179|repeat sequencesF [HCO3-] is sho
P02143023A0729 |124 140|octamer elementserbilirubinemia.
P02143023A0729 |22 38|octamer elementsson with alkalin
P02143186A0867 |102 108|regionspects
P02143186A0867 |122 128|intronyperbi
P02143186A0867 |26 33|intronswith al
P02143186A0867 |72 78|intronP00008
P02143186A0867 |46 50|AHA3atas
P02143186A0867 |52 56|AHA2 and
P02143186A0867 |147 160|coding region997A0472 When
P02143186A0867 |3 13|comparison001606T007
P02143186A1306 |0 22|Northern blot analysisP00001606T0076 Compari
P02143186A1306 |126 137|root tissuebilirubinem
P02143186A1306 |75 78|RNA008
P02143186A1306 |116 122|levelsatal h
P02143186A1306 |38 47|AHA2 mRNAe phospha
P02143186A1306 |155 167|shoot tissue When CSF [H
P02143768T0000 |0 9|ImpactionP00001606
P02143768T0000 |13 29|gastrostomy tube6 Comparison wit
P02143768T0000 |47 51|walltase
P02143961A0400 |34 48|pain thresholdaline phosphat
P02143961A0400 |107 116|analgesias of neon
P02143961A0400 |5 20|antidepressants1606T0076 Compa
P02143961A0400 |82 86|pCPA0000
P02143961A0400 |64 76|pretreatmentotidase P000
P02144290A1444 |0 3|SciP00
P02144558A1022 |2 18|needs assessment0001606T0076 Com
P02144558A1022 |28 36|familiesth alkal
P02144610A1306 |0 9|TCR alphaP00001606
P02144610A1306 |177 185|proteinshown as 
P02144610A1306 |148 160|AMP response97A0472 When
P02144610A1306 |271 286|decamer elemented to controls 
P02144610A1306 |86 94|proteins Pharmac
P02144610A1306 |116 123|elementatal hy
P02144610A1306 |223 230|elementepleted
P02144610A1306 |213 220|T alphaata of 
P02144610A1306 |244 262|TCR alpha enhanceronger displaced wh
P02144610A1306 |333 351|TCR beta promoters.21 +/- 0.23 vs. P
P02144610A1306 |107 113|T betas of n
P02144610A1306 |14 34|beta gene expression Comparison with alk
P02144610A1306 |134 137|setnem
P02144610A1306 |71 77|T-cell P0000
P02144610A1306 |64 67|setoti
P02144610A1306 |306 312|numbernifica
P02145195A0253 |118 129|Sm proteinsal hyperbil
P02145195A0253 |56 63|species 5-nucl
P02145195A0253 |7 16|stem-loop06T0076 C
P02145195A0253 |40 49|structurephosphata
P02145195A0253 |101 113|binding siteaspects of n
P02145268A0746 |171 182|COL3A1 gene] is shown 
P02145268A0746 |12 31|nucleotide sequence76 Comparison with 
P02145268A0746 |82 94|organization0000 Pharmac
P02145268A0746 |67 74|analogydase P0
P02145268A0746 |109 123|collagen genesof neonatal hy
P02145268A0746 |48 57|sequencesases and 
P02145268A0746 |156 160|exonWhen
P02145268A0746 |102 106|typespec
P02145268A1454 |6 12|losses606T00
P02145268A1454 |62 78|cyanogen bromideleotidase P00008
P02145268A1454 |43 58|EDS-IV collagensphatases and 5
P02145268A1454 |29 39|resistanceh alkaline
P02145268A1454 |93 114|collagenase digestioncologic aspects of ne
P02146266A0000 |187 214|deoxyoligonucleotide probesfunction of CSF PCO2 the da
P02146266A0000 |161 168|libraryCSF [HC
P02146266A0000 |15 37|BamHI-HindIII fragmentComparison with alkali
P02146266A0000 |126 131|sod-1bilir
P02146266A0000 |58 106|Neurospora crassa CuZn superoxide dismutase gene-nucleotidase P00008171T0000 Pharmacologic aspec
P02146266A0000 |246 275|N. crassa amino acid sequenceger displaced when compared t
P02146495A0706 |136 142|dimersmia. P
P02146495A0706 |166 169|CREHCO
P02146495A0706 |66 72|regionidase 
P02146495A0706 |10 18|peptides0076 Com
P02146495A0706 |100 121|leucine zipper domain aspects of neonatal 
P02147223A1047 |34 48|c-fos promoteraline phosphat
P02147223A1047 |3 11|contrast001606T0
P02147223A1047 |95 98|E1alog
P02147223A1047 |107 111|HeLas of
P02147223A1047 |116 126|PC12 cellsatal hyper
P02147223A1047 |86 90|cAMP Pha
P02147223A1047 |17 20|CREmpa
P02147422A0000 |35 39|geneline
P02147422A0000 |59 79|U1-70K snRNP proteinnucleotidase P000081
P02148219A0508 |154 161|muscles2 When 
P02148219A0508 |92 100|rigidityacologic
P02148219A0508 |73 78|facts00008
P02148219A0508 |22 32|hypothesisson with a
P02148219A0508 |126 132|flexorbiliru
P02148219A0508 |113 121|extensoreonatal 
P02148291A0173 |87 106|HSE binding domainsPharmacologic aspec
P02148291A0173 |28 48|HSE oligonucleotidesth alkaline phosphat
P02148291A0173 |180 189|screeningn as a fu
P02148291A0173 |128 165|tomato lambda gt11 expression librarylirubinemia. P00008997A0472 When CSF 
P02148291A0173 |56 61|types 5-nu
P02148291A0173 |65 71|clonestidase
P02148508A0374 |0 5|FluidP0000
P02148508A0374 |7 11|AVLF06T0
P02148508A1478 |51 54|TCMs a
P02148508A1478 |112 120|patternsneonatal
P02148508A1478 |4 11|results01606T0
P02148508A1478 |65 73|patientstidase P
P02148508A1478 |38 47|principlee phospha
P02148799A0000 |221 228|circuit-deplet
P02148799A0000 |165 175|expression[HCO3-] is
P02148799A0000 |146 151|genes8997A
P02148799A0000 |208 213|genesthe d
P02148799A0000 |46 50|geneatas
P02148799A0000 |4 12|nmr gene01606T00
P02148799A0000 |58 82|nitrogen control circuit-nucleotidase P00008171T
P02148799A0000 |86 103|Neurospora crassa Pharmacologic as
P02149487A0348 |6 41|days dexamethasone suppression test606T0076 Comparison with alkaline p
P02149487A0348 |61 74|% suppressioncleotidase P0
P02149487A0348 |164 186|androstenedione levels [HCO3-] is shown as a
P02149487A0348 |134 143|reductionnemia. P0
P02149487A0348 |78 109|dehydroepiandrosterone-sulphate171T0000 Pharmacologic aspects 
P02149487A0348 |147 159|testosterone997A0472 Whe
P02149487A0348 |131 132|%u
P02149566A0478 |4 9|ratio01606
P02149566A0478 |61 76|phosphocreatinecleotidase P000
P02149566A0478 |120 131|LVH baboons hyperbilir
P02149566A0478 |78 81|PCr171
P02149566A0478 |13 23|P-31 NMR-S6 Comparis
P02149566A0478 |180 181|Pn
P02149566A0478 |112 116|restneon
P02149566A0478 |42 52|phosphatesosphatases
P02149566A0478 |54 56|Pind
P02149570T0000 |35 55|protein S deficiencyline phosphatases an
P02149570T0000 |10 18|necrosis0076 Com
P02150473T0067 |9 14|studyT0076
P02151229A0000 |0 8|RegionalP0000160
P02151229A0000 |214 217|ageta 
P02151229A0000 |265 271|mmol/Lcompar
P02151229A0000 |180 197|diabetes mellitusn as a function o
P02151229A0000 |118 128|tomographyal hyperbi
P02151229A0000 |18 28|blood flowparison wi
P02151229A0000 |48 80|N-isopropyl-123I-iodoamphetamineases and 5-nucleotidase P0000817
P02151229A0000 |223 228|yearseplet
P02151229A0000 |293 301|subjectsll have 
P02151229A0000 |145 153|patients08997A04
P02151229A0000 |199 204|NIDDMCSF P
P02151229A0000 |130 132|CTru
P02151229A0000 |319 325|mmol/Leater 
P02151229A0000 |100 108|emission aspects
P02151229A0000 |308 313|yearsfican
P02151229A0000 |238 260|fasting plasma glucosee no longer displaced 
P02151229A0921 |0 18|Mean ROI-A/B ratioP00001606T0076 Com
P02151229A0921 |129 130|pi
P02151229A0921 |122 127|groupyperb
P02151229A0921 |101 102|%a
P02151229A0921 |53 58|groupand 5
P02151229A0921 |35 36|%l
P02153243A0965 |143 149|factor000899
P02153243A0965 |56 66|int-2 gene 5-nucleot
P02153243A0965 |41 48|producthosphat
P02153243A0965 |92 123|fibroblast growth factor familyacologic aspects of neonatal hy
P02153243A0965 |177 183|tumorshown a
P02153243A0965 |6 10|data606T
P02153683A1579 |115 121|ATPasenatal 
P02153683A1579 |75 81|fodrin008171
P02153683A1579 |108 110|Na o
P02153683A1579 |94 104|uvomorulinologic asp
P02153683A1579 |63 70|ankyrineotidas
P02153683A1579 |36 45|complexesine phosp
P02153683A1579 |112 113|Kn
P02153683A1579 |5 11|result1606T0
P02153977A0364 |85 90|mRNAs0 Pha
P02153977A0364 |107 111|peaks of
P02153977A0364 |66 77|developmentidase P0000
P02153977A0364 |6 11|genes606T0
P02153977A0364 |52 62|initiation and 5-nuc
P02153977A0364 |139 150|culmination. P00008997
P02153977A0364 |39 44|hours phos
P02153977A0364 |118 120|hral
P02154467A0709 |33 43|similaritykaline pho
P02154467A0709 |75 83|sequence008171T0
P02154467A0709 |97 115|furin gene productgic aspects of neo
P02154467A0709 |160 168|molecule CSF [HC
P02154467A0709 |4 15|PC2 protein01606T0076 
P02154474A1504 |25 34|sequences with alk
P02154474A1504 |46 65|cAMP responsivenessatases and 5-nucleo
P02154474A1504 |91 99|P-450sccmacologi
P02154474A1504 |128 139|P-450 geneslirubinemia
P02154599A0382 |23 35|footprintingon with alka
P02154599A0382 |166 172|motifsHCO3-]
P02154599A0382 |180 183|DSLn a
P02154599A0382 |111 130|Zta fusion proteins neonatal hyperbili
P02154599A0382 |40 71|gel mobility retardation assaysphosphatases and 5-nucleotidase
P02154599A0382 |8 13|study6T007
P02154599T0000 |35 44|inductionline phos
P02154599T0000 |107 118|lymphocytess of neonat
P02154599T0000 |54 75|cycle gene expressionnd 5-nucleotidase P00
P02154599T0000 |142 151|ZRE sites00008997A
P02154599T0000 |133 137|AP-1inem
P02154599T0000 |175 191|enhancer regions shown as a func
P02154599T0000 |4 22|zta transactivator01606T0076 Compari
P02154599T0000 |155 170|target promoter When CSF [HCO3
P02154602A0092 |16 23|homologomparis
P02154602A0092 |31 47|mouse Mx proteinalkaline phospha
P02154602A0092 |60 70|resistanceucleotidas
P02154602A0092 |74 89|influenza virus0008171T0000 Ph
P02154686A0185 |0 9|FragmentsP00001606
P02154686A0185 |57 65|enhancer5-nucleo
P02154686A0185 |113 141|beta-galactosidase synthesiseonatal hyperbilirubinemia. 
P02154686A0185 |172 200|polyomavirus enhancer region is shown as a function of C
P02154686A0185 |76 81|virus08171
P02154686A0185 |153 162|fragments72 When C
P02154686A0185 |38 51|repeat regione phosphatase
P02154686A0185 |221 227|levels-deple
P02154885A0153 |139 160|substrate recognition. P00008997A0472 When
P02154885A0153 |36 44|residuesine phos
P02154885A0153 |23 34|mutagenesison with alk
P02154885A0153 |4 9|sites01606
P02154885A0153 |99 113|loop structurec aspects of n
P02154885A0153 |168 174|enzymeO3-] i
P02155017A1106 |221 234|complications-depleted rat
P02155017A1106 |46 55|frequencyatases an
P02155017A1106 |13 21|benefits6 Compar
P02155017A1106 |165 183|observation period[HCO3-] is shown a
P02155017A1106 |59 67|bleedingnucleoti
P02155017A1106 |25 36|LMW heparin with alkal
P02155017A1106 |196 205|incidenceof CSF PC
P02155017A1106 |69 80|alleviationse P0000817
P02155017A1106 |246 254|dialysesger disp
P02155017A1106 |84 104|hypertriglyceridemia00 Pharmacologic asp
P02156828A0164 |50 58|residueses and 5
P02156828A0164 |111 118|cofilin neonat
P02156828A0164 |12 31|amino acid sequence76 Comparison with 
P02156828A0164 |87 88|%P
P02156828A0164 |172 179|protein is sho
P02156828A0164 |35 42|destrinline ph
P02157067A0610 |0 7|SummersP000016
P02157067A0610 |9 17|VirologyT0076 Co
P02157141A0923 |102 111|sequencesspects of
P02157141A0923 |172 179|changes is sho
P02157141A0923 |217 227|base pairsof K-deple
P02157141A0923 |83 86|DNA000
P02157141A0923 |36 44|presenceine phos
P02157141A0923 |19 28|T antigenarison wi
P02157141A0923 |48 61|topoisomeraseases and 5-nu
P02157141A0923 |153 156|DNA72 
P02157764A1115 |50 57|peptidees and 
P02157764A1115 |89 96|portionarmacol
P02157764A1115 |122 135|cDNA sequenceyperbilirubin
P02157764A1115 |2 18|rabbit antiserum0001606T0076 Com
P02157882T0000 |85 99|transformation0 Pharmacologi
P02157882T0000 |52 55|abl an
P02157882T0000 |73 81|proteins00008171
P02157882T0000 |16 24|functionompariso
P02157882T0000 |113 118|cellseonat
P02157882T0000 |0 12|ConservationP00001606T00
P02158099A0487 |69 76|pM1 DNAse P000
P02158099A0487 |149 173|pSV2CAT reporter plasmid7A0472 When CSF [HCO3-] 
P02158099A0487 |13 34|cotransfection assays6 Comparison with alk
P02158099A0487 |60 63|CCLucl
P02158099A0487 |131 141|expressionubinemia. 
P02158099A0487 |41 58|Chang liver cellshosphatases and 5
P02158099A0487 |117 123|effecttal hy
P02158927A0000 |170 182|chromosome X-] is shown 
P02158927A0000 |62 73|COR segmentleotidase P
P02158927A0000 |121 125|UTR1hype
P02158927A0000 |190 195|yeastction
P02158927A0000 |115 119|CYC1nata
P02158927A0000 |23 33|nucleotideon with al
P02158927A0000 |93 100|clustercologic
P02158927A0000 |127 131|UTR3ilir
P02158927A0000 |144 147|Gly008
P02158927A0000 |108 113|genes of n
P02158927A0000 |133 137|OSM1inem
P02158927A0000 |153 157|RAD772 W
P02158927A0000 |139 143|tRNA. P0
P02158927A0000 |39 47|sequence phospha
P02158927A0000 |35 37|ntli
P02159470A1432 |153 166|transcription72 When CSF [
P02159470A1432 |193 201|subunitson of CS
P02159470A1432 |47 52|sitestases
P02159470A1432 |135 145|regulationemia. P000
P02159470A1432 |24 39|protein factorsn with alkaline
P02159470A1432 |9 16|bindingT0076 C
P02159470A1432 |242 257|phosphorylation longer displac
P02159470A1432 |178 183|genesown a
P02159470A1432 |76 88|Mt sequences08171T0000 P
P02159470A1432 |112 116|roleneon
P02159559A0779 |56 73|DNA amplification 5-nucleotidase P
P02159559A0779 |26 38|interferencewith alkalin
P02160502A0471 |68 87|recombination pointase P00008171T0000 
P02160502A0471 |3 33|recombination signal sequences001606T0076 Comparison with al
P02160622A0000 |186 197|combination function o
P02160622A0000 |91 104|motor effectsmacologic asp
P02160622A0000 |203 211|morphinePCO2 the
P02160622A0000 |66 81|hot-plate testsidase P00008171
P02160622A0000 |229 233|ratsd ra
P02160622A0000 |138 170|benzodiazepine agonist midazolama. P00008997A0472 When CSF [HCO3
P02160622A0000 |20 30|propertiesrison with
P02160622A0000 |51 61|tail-flicks and 5-nu
P02160955A0899 |0 10|ConstructsP00001606T
P02160955A0899 |120 122|bp h
P02160955A0899 |56 62|region 5-nuc
P02160955A0899 |89 98|distancesarmacolog
P02160955A0899 |33 39|AATAAAkaline
P02162049A0291 |16 21|issueompar
P02162049A0291 |36 44|factor Yine phos
P02162049A0291 |27 31|geneith 
P02162049A0291 |81 93|DNA sequenceT0000 Pharma
P02162103A0000 |205 206|AO
P02162103A0000 |123 128|PIV-2perbi
P02162103A0000 |28 33|cDNAsth al
P02162103A0000 |183 189|lengths a fu
P02162103A0000 |269 277|proteinsared to 
P02162103A0000 |155 158|RNA Wh
P02162103A0000 |293 304|amino acidsll have a s
P02162103A0000 |83 84|P0
P02162103A0000 |58 62|mRNA-nuc
P02162103A0000 |95 113|parainfluenza typelogic aspects of n
P02162103A0000 |245 259|reading framesnger displaced
P02162103A0000 |131 141|cDNA cloneubinemia. 
P02162103A0000 |50 53|RNAes 
P02162103A0000 |116 121|virusatal 
P02162103A0000 |200 204|polySF P
P02162103A0000 |67 81|phosphoproteindase P00008171
P02162103A0000 |168 179|nucleotidesO3-] is sho
P02162467A0311 |13 28|cytR expression6 Comparison wi
P02162467A0311 |105 121|cAMP/CAP complexcts of neonatal 
P02162467A0311 |61 73|CytR proteincleotidase P
P02162754A0339 |18 23|sitesparis
P02162754A0339 |37 56|amino acid sequencene phosphatases and
P02162754A0339 |105 110|mousects o
P02162754A0339 |64 97|3T3-L1 adipocyte insulin receptorotidase P00008171T0000 Pharmacolo
P02162754A0801 |0 3|PAOP00
P02162754A0801 |47 51|pp15tase
P02162754A0801 |112 131|signal transmissionneonatal hyperbilir
P02162754A0801 |27 43|phosphoryl groupith alkaline pho
P02162754A0801 |11 19|turnover076 Comp
P02162754A0801 |157 181|glucose-transport systemhen CSF [HCO3-] is shown
P02162754A0801 |65 77|accumulationtidase P0000
P02162754A0801 |141 149|receptorP0000899
P02162835A0989 |152 159|enzymes472 Whe
P02162835A0989 |123 142|copper binding siteperbilirubinemia. P
P02162835A0989 |22 43|sequence similaritiesson with alkaline pho
P02162835A0989 |95 113|heme binding siteslogic aspects of n
P02162835A0989 |71 83|architecture P00008171T0
P02163347A0472 |100 101|% 
P02163347A0472 |37 50|reading framene phosphatas
P02163347A0472 |73 92|amino acid sequence00008171T0000 Pharm
P02163347A0472 |165 178|ets-1 protein[HCO3-] is sh
P02163347A0472 |140 151|amino acids P00008997A
P02163347A0472 |52 55|ORF an
P02163347A0472 |4 17|cDNA sequence01606T0076 Co
P02163382A0169 |51 66|cosmids pJHCV31s and 5-nucleot
P02163382A0169 |166 176|lac operonHCO3-] is 
P02163382A0169 |225 232|fusionsleted r
P02163382A0169 |99 121|transposon mutagenesisc aspects of neonatal 
P02163382A0169 |20 33|O7-LPS regionrison with al
P02163382A0169 |127 135|Tn3HoHo1ilirubin
P02163382A0169 |204 208|lacZCO2 
P02163382A0169 |71 78|pJHCV32 P00008
P02163382A0169 |238 258|target DNA sequencese no longer displace
P02163394T0000 |4 13|sacT gene01606T007
P02163394T0000 |45 69|Bacillus subtilis shareshatases and 5-nucleotida
P02163394T0000 |29 41|sacPA operonh alkaline p
P02163394T0000 |107 122|antiterminatorss of neonatal h
P02163394T0000 |77 85|homology8171T000
P02164585A0416 |4 16|TraD protein01606T0076 C
P02164585A0416 |25 27|Da w
P02164585A0416 |56 63|regions 5-nucl
P02164585A0416 |114 120|regiononatal
P02164585A0814 |69 73|traXse P
P02164585A0814 |133 140|alanineinemia.
P02164585A0814 |53 61|tra geneand 5-nu
P02164585A0814 |23 27|orfDon w
P02164585A0814 |145 152|leucine08997A0
P02164585A0814 |101 112|amino acidsaspects of 
P02164585A0814 |4 19|protein product01606T0076 Comp
P02164585A0814 |87 88|%P
P02164588A0266 |187 202|HN glycoproteinfunction of CSF
P02164588A0266 |15 23|HN genesComparis
P02164588A0266 |143 151|assembly0008997A
P02164588A0266 |56 60|role 5-n
P02164588A0266 |134 138|tailnemi
P02164588A0266 |100 106|domain aspec
P02164588A0266 |64 72|residuesotidase 
P02164588A0266 |170 179|transport-] is sho
P02164604A0399 |103 112|promoterspects of 
P02164604A0399 |52 75|E2 transactivation gene and 5-nucleotidase P00
P02164604A0399 |25 33|findings with al
P02164604A0399 |4 11|studies01606T0
P02164604A1574 |172 185|E2 expression is shown as 
P02164604A1574 |13 21|analysis6 Compar
P02164604A1574 |90 103|BPV-1 mutantsrmacologic as
P02164604A1574 |60 70|cell linesucleotidas
P02164604A1574 |124 139|acceptor mutanterbilirubinemia
P02164604A1574 |29 40|E2 proteinsh alkaline 
P02164604A1574 |163 168|modesF [HC
P02164637A0515 |0 10|DisruptionP00001606T
P02164637A0515 |177 189|cdc25 mutanthown as a fu
P02164637A0515 |160 169|lethality CSF [HCO
P02164637A0515 |141 152|suppressionP00008997A0
P02164637A0515 |54 65|sensitivitynd 5-nucleo
P02164637A0515 |110 129|sporulation defectsf neonatal hyperbil
P02164637A0515 |69 79|heat shockse P000081
P02164637A0515 |18 27|IRA2 geneparison w
P02164637A0515 |84 103|nitrogen starvation00 Pharmacologic as
P02165181A0299 |5 11|cohort1606T0
P02165181A0299 |44 49|basisphata
P02165181A0299 |15 23|patientsComparis
P02165181A0299 |62 67|stageleoti
P02165589A0000 |119 125|memberl hype
P02165589A0000 |149 177|hormone receptor superfamily7A0472 When CSF [HCO3-] is s
P02165589A0000 |61 66|2C1-3cleot
P02165589A0000 |81 88|portionT0000 P
P02165589A0000 |96 108|X-chromosomeogic aspects
P02165589A0000 |2 6|gene0001
P02165589A0888 |139 162|heterodimerization site. P00008997A0472 When C
P02165589A0888 |183 199|fos oncoproteinss a function of 
P02165589A0888 |13 22|Region II6 Compari
P02165589A0888 |38 42|parte ph
P02165589A0888 |76 90|leucine zipper08171T0000 Pha
P02165589A0888 |56 73|c-jun oncoprotein 5-nucleotidase P
P02165589A0888 |101 105|turnaspe
P02165589A0888 |175 178|jun sh
P02165589A0888 |2 9|portion0001606
P02166040A0385 |410 418|leukemiapnotic d
P02166040A0385 |256 274|phosphotransferaseced when compared 
P02166040A0385 |116 125|deletionsatal hype
P02166040A0385 |21 29|vanadateison wit
P02166040A0385 |431 441|retrovirusoptimum do
P02166040A0385 |485 499|neo expressiont night. P0001
P02166040A0385 |365 372|methodsFluraze
P02166040A0385 |149 171|carboxykinase promoter7A0472 When CSF [HCO3-
P02166040A0385 |91 96|genesmacol
P02166040A0385 |44 68|PEPCK gene transcriptionphatases and 5-nucleotid
P02166040A0385 |284 317|chloramphenicol acetyltransferases but still have a significantly 
P02166040A0385 |378 387|infectionus appear
P02166040A0385 |395 402|Moloneyan effe
P02166040A0385 |532 566|chloroamphenicol acetyltransferase00013683A0210 When extracorporeal 
P02166040A0385 |222 227|genesdeple
P02166040A0385 |276 279|neo co
P02166040A0385 |471 480|selection being 15
P02166040A0385 |72 78|seriesP00008
P02166040A0385 |338 352|hepatoma cells/- 0.23 vs. P0
P02166040A0385 |447 459|transfection use in gene
P02166040A0385 |518 528|expressionking agent
P02166416A0419 |4 13|diagnosis01606T007
P02166416A0419 |25 37|tuberculosis with alkali
P02166416A0419 |77 81|ARDS8171
P02166416A0419 |93 99|origincologi
P02166825A0198 |136 154|promoter mutationsmia. P00008997A047
P02166825A0198 |40 48|elementsphosphat
P02166825A0198 |56 64|promoter 5-nucle
P02166825A0198 |208 217|mutationsthe data 
P02166825A0198 |115 122|signalsnatal h
P02166825A0198 |126 132|numberbiliru
P02166825A0198 |78 81|way171
P02166825A0198 |185 188|seta f
P02166825A0198 |3 8|order00160
P02166825A0198 |236 251|promoter regionare no longer d
P02167321T0000 |220 233|phorbol esterK-depleted ra
P02167321T0000 |99 103|sitec as
P02167321T0000 |43 50|elementsphatas
P02167321T0000 |2 11|DNA motif0001606T0
P02167321T0000 |206 216|activation2 the data
P02167321T0000 |71 90|activator protein-2 P00008171T0000 Pha
P02167321T0000 |184 194|expression a functio
P02167321T0000 |117 164|tissue-type plasminogen activator gene promotertal hyperbilirubinemia. P00008997A0472 When CSF
P02167321T0000 |238 242|cAMPe no
P02167467T0000 |4 20|26S rRNA binding01606T0076 Compa
P02167467T0000 |63 74|protein L11eotidase P0
P02167467T0000 |31 49|protein equivalentalkaline phosphata
P02167467T0000 |110 115|genesf neo
P02167784A0109 |69 70|%s
P02167784A0109 |61 62|%c
P02167784A0109 |36 39|airine
P02167784A0109 |108 111|min of
P02167784A0109 |47 50|mintas
P02167784A0109 |81 84|minT00
P02167784A0109 |157 172|CO2 measurementhen CSF [HCO3-]
P02167784A0109 |18 26|subjectsparison 
P02168640A0268 |152 158|ground472 Wh
P02168640A0268 |47 54|changestases a
P02168640A0268 |58 62|SSEP-nuc
P02168640A0268 |89 97|presencearmacolo
P02168640A0268 |12 24|correlations76 Compariso
P02168640A0268 |66 74|responseidase P0
P02168640A0268 |127 139|disturbancesilirubinemia
P02168640A0268 |175 184|disorders shown as
P02169887A0360 |68 80|capstructurease P0000817
P02169887A0360 |149 159|initiation7A0472 Whe
P02169887A0360 |4 15|transcripts01606T0076 
P02169887A0360 |123 128|mRNAsperbi
P02169887A0360 |100 108|EMCV-RNA aspects
P02170687A0000 |100 118|transforming genes aspects of neonat
P02170687A0000 |76 86|expression08171T0000
P02170687A0000 |40 56|papillomavirusesphosphatases and
P02170687A0000 |4 18|E6/E7 promoter01606T0076 Com
P02172672T0001 |2 6|case0001
P02172672T0001 |10 21|Goodpasture0076 Compar
P02172672T0001 |24 32|syndromen with a
P02173399A0333 |140 141|% 
P02173399A0333 |124 135|specificityerbilirubin
P02173399A0333 |53 59|blocksand 5-
P02173399A0333 |76 94|tissue radiographs08171T0000 Pharmac
P02173399A0333 |27 35|controlsith alka
P02173399A0333 |143 154|sensitivity0008997A047
P02173399A0333 |96 100|STRsogic
P02173399A0333 |158 159|%e
P02173405A0270 |58 64|period-nucle
P02173405A0270 |15 26|abnormalityComparison 
P02173405A0270 |88 102|calcificationsharmacologic a
P02174105A1232 |86 91|cells Phar
P02174105A1232 |40 50|rat organsphosphatas
P02174105A1232 |63 71|stainingeotidase
P02174105A1232 |20 28|analysisrison wi
P02174427A1574 |64 78|carbon sourcesotidase P00008
P02174427A1574 |124 170|ubiquinol-cytochrome c oxidoreductase activityerbilirubinemia. P00008997A0472 When CSF [HCO3
P02174427A1574 |109 110|%o
P02174427A1574 |5 12|strains1606T00
P02174861A0736 |0 10|RegulationP00001606T
P02174861A0736 |122 130|sequenceyperbili
P02174861A0736 |107 111|dyads of
P02174861A0736 |14 18|irgA Com
P02174861A0736 |30 41|V. cholerae alkaline p
P02174861A0736 |22 26|ironson 
P02174861A0736 |197 202|sitesf CSF
P02174861A0736 |72 77|levelP0000
P02174861A0736 |185 188|Fura f
P02174861A0736 |138 146|vicinitya. P0000
P02174861A0736 |154 162|promoter2 When C
P02174974A0000 |0 13|TranscriptionP00001606T007
P02174974A0000 |27 33|operonith al
P02174974A0000 |79 90|TOL plasmid71T0000 Pha
P02174974A0000 |133 150|xylR gene productinemia. P00008997
P02174974A0000 |64 71|enzymesotidase
P02174974A0000 |158 166|presenceen CSF [
P02174974A0000 |170 178|m-xylene-] is sh
P02175433A0575 |113 119|copieseonata
P02175433A0575 |67 71|genedase
P02175433A0575 |76 96|Ylp vector sequences08171T0000 Pharmacol
P02175433A0575 |36 54|beta A-globin geneine phosphatases a
P02175908A0805 |138 145|elementa. P000
P02175908A0805 |90 95|locusrmaco
P02175908A0805 |60 75|Ulysses elementucleotidase P00
P02175908A0805 |173 181|mutationis shown
P02175908A0805 |12 21|mutations76 Compar
P02175908A0805 |48 52|copyases
P02176021T0000 |51 87|electron spin resonance spectroscopys and 5-nucleotidase P00008171T0000 
P02176021T0000 |0 13|DeterminationP00001606T007
P02176021T0000 |38 47|materialse phospha
P02176021T0000 |17 23|diquatmparis
P02176152A0896 |51 59|activitys and 5-
P02176152A0896 |92 95|TPAaco
P02176152A0896 |107 123|AP1 binding sites of neonatal hy
P02176152A0896 |18 20|RApa
P02176152A0896 |65 78|reporter genetidase P00008
P02176152A0896 |136 151|HSV tk promotermia. P00008997A
P02176209A0954 |51 55|rises an
P02176209A0954 |134 144|cell typesnemia. P00
P02176209A0954 |97 105|extractsgic aspe
P02176209A0954 |37 45|CBF DNAsne phosp
P02176209A0954 |28 32|NF-Yth a
P02176209A0954 |113 120|varietyeonatal
P02176209A0954 |23 26|EFIon 
P02176209A0954 |69 93|gel retardation patternsse P00008171T0000 Pharma
P02176232T0001 |68 73|stagease P
P02176232T0001 |25 47|lymph nodes metastasis with alkaline phospha
P02176232T0001 |0 12|Risk factorsP00001606T00
P02176232T0001 |83 87|IIIA000 
P02176232T0001 |51 62|lung cancers and 5-nuc
P02176822A0000 |32 36|MFPKlkal
P02176822A0000 |187 204|glycogen synthasefunction of CSF P
P02176822A0000 |112 121|threonineneonatal 
P02176822A0000 |126 132|serinebiliru
P02176822A0000 |148 157|inhibitor97A0472 W
P02176822A0000 |208 213|sitesthe d
P02176822A0000 |91 96|sitesmacol
P02176822A0000 |74 83|peptide B0008171T0
P02176822A0000 |105 107|BSct
P02176822A0000 |16 30|protein kinaseomparison with
P02176822A0000 |65 70|lyasetidas
P02176822A0000 |174 181|residues shown
P02176822A0000 |98 100|BTic
P02179052A1044 |18 19|Yp
P02179052A1044 |30 47|sequence families alkaline phospha
P02179052A1044 |72 78|systemP00008
P02179052A1044 |134 143|evolutionnemia. P0
P02179052A1044 |97 118|sequence interactionsgic aspects of neonat
P02179188A1223 |69 77|presencese P0000
P02179188A1223 |81 94|dinitrophenolT0000 Pharmac
P02179188A1223 |25 41|motile responses with alkaline p
P02179188A1223 |98 113|cytochalasin B.ic aspects of n
P02179815A0582 |200 208|sequenceSF PCO2 
P02179815A0582 |92 100|p68c-relacologic
P02179815A0582 |177 182|cellshown 
P02179815A0582 |124 127|CEFerb
P02179815A0582 |47 50|CEFtas
P02179815A0582 |61 79|immunofluorescencecleotidase P000081
P02179815A0582 |7 15|p59v-rel06T0076 
P02179815A0582 |266 274|sequenceompared 
P02179815A0582 |212 220|p68c-reldata of 
P02179815A0582 |36 43|proteinine pho
P02179815A0582 |321 329|p59v-relter slop
P02179815A0582 |158 167|cytoplasmen CSF [H
P02180935A0535 |101 112|HL-60 cellsaspects of 
P02180935A0535 |121 123|Mrhy
P02180935A0535 |44 47|minpha
P02180935A0535 |8 19|experiments6T0076 Comp
P02180935A0535 |146 191|chondroitin sulfate proteoglycan intermediate8997A0472 When CSF [HCO3-] is shown as a func
P02180935A0535 |66 83|precursor proteinidase P00008171T0
P02181760A0311 |0 10|Blood flowP00001606T
P02181760A0311 |123 132|directionperbiliru
P02181760A0311 |180 184|foldn as
P02181760A0311 |15 23|velocityComparis
P02181760A0311 |87 95|diastolePharmaco
P02181760A0311 |40 58|Doppler ultrasoundphosphatases and 5
P02181760A0311 |136 156|cotyledon resistancemia. P00008997A0472 
P02182240A0355 |85 91|period0 Phar
P02182240A0355 |15 23|patientsComparis
P02182240A0355 |133 141|symptomsinemia. 
P02182240A0355 |106 109|mints 
P02182240A0355 |63 70|heparineotidas
P02182240A0355 |33 45|anistreplasekaline phosp
P02182240A0355 |124 129|onseterbil
P02182240A0355 |2 7|total00016
P02182323A0121 |102 119|growth conditionsspects of neonata
P02182323A0121 |47 50|Valtas
P02182323A0121 |42 46|tRNAosph
P02182323A0121 |57 61|gene5-nu
P02182323A0121 |124 133|degrees Cerbilirub
P02182323A0121 |174 180|regions show
P02182323A0121 |52 55|UAC an
P02182323A0121 |17 28|transcriptsmparison wi
P02182618A0168 |137 153|deletion mutantsia. P00008997A04
P02182618A0168 |173 179|regionis sho
P02182618A0168 |66 99|chloramphenicol acetyltransferaseidase P00008171T0000 Pharmacologi
P02182618A0168 |106 110|genets o
P02182618A0168 |101 104|CATasp
P02182618A0168 |4 21|promoter activity01606T0076 Compar
P02182618A0168 |50 60|expressiones and 5-n
P02183467A0668 |101 111|similarityaspects of
P02183467A0668 |242 243|Y 
P02183467A0668 |151 154|vif047
P02183467A0668 |49 52|BIVses
P02183467A0668 |223 227|ORFseple
P02183467A0668 |156 159|tatWhe
P02183467A0668 |144 149|genes00899
P02183467A0668 |179 191|lentiviruseswn as a func
P02183467A0668 |264 269|exons comp
P02183467A0668 |280 285|genestrols
P02183467A0668 |165 168|rev[HC
P02183467A0668 |19 23|ORFsaris
P02183467A0668 |39 45|region phosp
P02183467A0668 |77 85|location8171T000
P02183467A0668 |236 237|Wa
P02185140A0000 |49 75|cytochrome P450 lanosterolses and 5-nucleotidase P00
P02185140A0000 |148 155|strains97A0472
P02185140A0000 |29 38|14DM geneh alkalin
P02185140A0000 |166 173|controlHCO3-] 
P02185140A0000 |268 275|controlpared t
P02185140A0000 |241 245|pGPDo lo
P02185140A0000 |247 252|pPHO5er di
P02185140A0000 |79 96|alpha-demethylase71T0000 Pharmacol
P02185140A0000 |287 295|promoterut still
P02185140A0000 |234 239|pADC1s are
P02185140A0000 |203 232|yeast transcription promotersPCO2 the data of K-depleted r
P02185140A0000 |98 102|14DMic a
P02185250A0726 |34 45|amino acidsaline phosp
P02185250A0726 |87 105|reticulum membranePharmacologic aspe
P02185250A0726 |111 124|translocation neonatal hyp
P02185250A0726 |0 11|TruncationsP00001606T0
P02187091A0721 |19 29|resistancearison wit
P02187091A0721 |167 168|PC
P02187091A0721 |47 64|ejection fractiontases and 5-nucle
P02187091A0721 |99 116|relaxation periodc aspects of neon
P02187871T0000 |55 97|protein synthesis initiation factor eIF-4Dd 5-nucleotidase P00008171T0000 Pharmacolo
P02187871T0000 |4 14|ANB1 locus01606T0076
P02188096A0955 |34 49|splicing eventsaline phosphata
P02188096A0955 |53 69|c-myb expressionand 5-nucleotida
P02188096A0955 |82 96|c-myb function0000 Pharmacol
P02188096A0955 |4 16|contribution01606T0076 C
P02188168A0000 |0 10|Serum betaP00001606T
P02188168A0000 |153 161|carriers72 When 
P02188168A0000 |222 227|serumdeple
P02188168A0000 |190 205|lymphadenopathyction of CSF PC
P02188168A0000 |27 33|levelsith al
P02188168A0000 |120 136|HIV-1 antibodies hyperbilirubine
P02188168A0000 |303 308|yearssigni
P02188168A0000 |237 245|patientsre no lo
P02188168A0000 |65 77|drug addictstidase P0000
P02188168A0000 |278 287|communityontrols b
P02188168A0000 |103 111|carrierspects of
P02188168A0000 |207 213|P.G.L. the d
P02188168A0000 |35 43|beta-2-Mline pho
P02190122A0633 |5 17|emancipation1606T0076 Co
P02190122A0633 |125 131|matingrbilir
P02190122A0633 |89 99|motivationarmacologi
P02190122A0633 |135 143|primatesemia. P0
P02190122A0633 |59 68|influencenucleotid
P02190122A0633 |25 32|ability with a
P02190122A0633 |112 121|regulatorneonatal 
P02190134A0572 |34 45|progressionaline phosp
P02190134A0572 |79 88|exception71T0000 P
P02190134A0572 |224 235|hemorrhagespleted rats
P02190134A0572 |196 209|complicationsof CSF PCO2 t
P02190134A0572 |179 186|attemptwn as a
P02190134A0572 |92 124|laser photocoagulation treatmentacologic aspects of neonatal hyp
P02190134A0572 |53 60|diseaseand 5-n
P02190134A0572 |163 172|membranesF [HCO3-]
P02190134A0572 |3 10|therapy001606T
P02193033A0195 |0 2|R.P0
P02194273A0913 |34 43|pathogensaline pho
P02194273A0913 |9 30|hyperimmune globulinsT0076 Comparison with
P02194273A0913 |79 92|Streptococcus71T0000 Pharm
P02194273A0913 |64 74|influenzaeotidase P0
P02194972T0000 |34 36|HRal
P02194972T0000 |126 130|micebili
P02194972T0000 |12 19|effects76 Comp
P02194972T0000 |80 101|Enterococcus faecalis1T0000 Pharmacologic 
P02194972T0000 |23 32|cefpiromeon with a
P02194972T0000 |64 74|infectionsotidase P0
P02195025T0000 |0 10|RegulationP00001606T
P02195025T0000 |14 24|yeast LEU2 Compariso
P02195715A0143 |103 114|individualspects of ne
P02195715A0143 |60 68|newbornsucleotid
P02195715A0143 |11 22|individuals076 Compari
P02195715A0143 |148 158|thrombosis97A0472 Wh
P02195715A0143 |132 136|riskbine
P02195715A0143 |173 181|embolismis shown
P02195715A0143 |83 90|protein000 Pha
P02195715A0143 |39 56|purpura fulminans phosphatases and
P02195715T0000 |23 43|protein C deficiencyon with alkaline pho
P02195715T0000 |9 15|strokeT0076 
P02196176A0749 |0 5|TREB7P0000
P02196176A0749 |10 16|TREB360076 C
P02196176A0749 |63 68|TREB5eotid
P02196176A0749 |37 44|repeatsne phos
P02196176A0749 |95 101|repeatlogic 
P02196176A0749 |55 57|bpd 
P02196311A1034 |102 105|RNLspe
P02196311A1034 |29 37|KE X 3/Wh alkali
P02196311A1034 |6 13|results606T007
P02196311A1034 |57 64|regimen5-nucle
P02196311A1034 |80 98|antitumor immunity1T0000 Pharmacolog
P02196450A0870 |0 8|AnalysisP0000160
P02196450A0870 |198 201|QBP CS
P02196450A0870 |56 77|sequence requirements 5-nucleotidase P0000
P02196450A0870 |20 36|deletion mutantsrison with alkal
P02196450A0870 |82 89|binding0000 Ph
P02196450A0870 |93 96|QBPcol
P02196450A0870 |256 264|promoterced when
P02196450A0870 |222 230|functiondepleted
P02196450A0870 |153 163|Q activity72 When CS
P02196565A0606 |85 89|RAP10 Ph
P02196565A0606 |280 294|gal11 mutationtrols but stil
P02196565A0606 |41 81|repressor/activator site binding proteinhosphatases and 5-nucleotidase P00008171
P02196565A0606 |91 102|translationmacologic a
P02196565A0606 |241 254|GRFI/RAP1/TUFo longer disp
P02196565A0606 |120 123|TUF hy
P02196565A0606 |112 118|factorneonat
P02196565A0606 |25 33|factor I with al
P02196565A0606 |146 155|activator8997A0472
P02196565A0606 |201 205|PYK1F PC
P02196565A0606 |159 179|MAT alpha expressionn CSF [HCO3-] is sho
P02196565A0606 |35 39|GRFIline
P02196565T0000 |0 19|Yeast Gal11 proteinP00001606T0076 Comp
P02196565T0000 |133 196|factor I/repressor/activator site binding protein 1/translationinemia. P00008997A0472 When CSF [HCO3-] is shown as a function 
P02196565T0000 |105 109|Gal4cts 
P02196565T0000 |206 212|factor2 the 
P02196565T0000 |96 103|factorsogic as
P02196565T0000 |49 66|activation signalses and 5-nucleot
P02198259A0685 |0 8|DeletionP0000160
P02198259A0685 |25 26|N 
P02198259A0685 |66 72|codonsidase 
P02198259A0685 |142 151|initiator00008997A
P02198259A0685 |42 46|endsosph
P02198259A0685 |175 183|activity shown a
P02198259A0685 |114 127|reading frameonatal hyperb
P02198259A0685 |50 54|repAes a
P02198289A0436 |139 142|DNA. P
P02198289A0436 |40 51|amino acidsphosphatase
P02198289A0436 |120 128|solution hyperbi
P02198289A0436 |15 23|peptidesComparis
P02198289A0436 |110 116|dimersf neon
P02198289A0436 |161 166|dimerCSF [
P02198289A0436 |83 94|amino acids000 Pharmac
P02199311A0620 |85 118|transcription termination signals0 Pharmacologic aspects of neonat
P02199311A0620 |166 180|tRNA templatesHCO3-] is show
P02199311A0620 |135 145|RET1 cellsemia. P000
P02199311A0620 |37 49|ret1-1 cellsne phosphata
P02199311A0620 |9 31|transcription extractsT0076 Comparison with 
P02199311A0620 |155 162|variety When C
P02200150A1381 |68 72|teamase 
P02200150A1381 |120 131|pathologist hyperbilir
P02200150A1381 |24 32|decisionn with a
P02200150A1381 |108 118|geneticist of neonat
P02200150A1381 |133 148|psychotherapistinemia. P000089
P02200150A1381 |96 106|oncologistogic aspec
P02200150A1381 |8 16|patients6T0076 C
P02200150A1381 |153 168|plastic surgeon72 When CSF [HC
P02200315A0278 |0 3|IgGP00
P02200315A0278 |63 71|dilutioneotidase
P02200315A0278 |75 80|serum00817
P02200315A0278 |84 90|plates00 Pha
P02200315A0278 |8 29|IgM antibody activity6T0076 Comparison wit
P02200315A0278 |103 114|A60 antigenpects of ne
P02200736A1003 |84 88|MLTF00 P
P02200736A1003 |133 142|sequencesinemia. P
P02200736A1003 |107 121|CACCTGTC motifs of neonatal 
P02200736A1003 |75 79|AP-40081
P02200736A1003 |6 13|factors606T007
P02200736A1003 |26 29|setwit
P02200736A1003 |54 63|moleculesnd 5-nucl
P02201770A0188 |50 65|Anomiopsyllinaees and 5-nucleo
P02201770A0188 |29 48|genus Anomiopsyllush alkaline phosphat
P02201770A0188 |12 23|flea larvae76 Comparis
P02201770A0188 |127 133|adultsilirub
P02201770A0188 |111 115|form neo
P02201770A0188 |67 81|Anomiopsyllinidase P00008171
P02201901A0229 |70 82|SSN6 proteine P00008171T
P02201901A0229 |28 36|antibodyth alkal
P02201905A1004 |80 89|sequences1T0000 Ph
P02201905A1004 |13 20|results6 Compa
P02201905A1004 |60 72|RAP1 proteinucleotidase 
P02201905A1004 |146 161|gene expression8997A0472 When 
P02201905A1004 |132 142|regulationbinemia. P
P02201905A1004 |37 49|ABFI proteinne phosphata
P02202496T0000 |9 18|nutritionT0076 Com
P02202496T0000 |28 34|horsesth alk
P02203672A1542 |24 38|cytocentrifugen with alkalin
P02204029A0184 |0 23|RNase protection assaysP00001606T0076 Comparis
P02204029A0184 |41 45|genehosp
P02204029A0184 |47 50|unrtas
P02204029A0184 |163 168|pointF [HC
P02204029A0184 |92 97|N-rasacolo
P02204029A0184 |79 88|direction71T0000 P
P02204029A0184 |138 148|base pairsa. P000089
P02204029A0184 |114 117|endona
P02204029A0184 |184 197|transcription a function o
P02204621T0000 |0 9|IsolationP00001606
P02204621T0000 |107 111|genes of
P02204621T0000 |121 148|tRNA nucleotidyltransferasehyperbilirubinemia. P000089
P02204621T0000 |60 87|tRNA nucleotidyltransferaseucleotidase P00008171T0000 
P02204621T0000 |37 43|mutantne pho
P02204621T0000 |92 99|cloningacologi
P02204621T0000 |156 161|yeastWhen 
P02204623A0000 |205 215|substratesO2 the dat
P02204623A0000 |289 293|J.M. sti
P02204623A0000 |50 52|IRes
P02204623A0000 |257 261|M.F.ed w
P02204623A0000 |250 255|Whitedispl
P02204623A0000 |54 66|beta-subunitnd 5-nucleot
P02204623A0000 |263 273|Livingstonn compared
P02204623A0000 |113 119|Tyr960eonata
P02204623A0000 |295 301|Lauris have 
P02204623A0000 |328 330|A.pe
P02204623A0000 |303 305|V.si
P02204623A0000 |96 111|tyrosyl residueogic aspects of
P02204623A0000 |336 340|Kahn +/-
P02204623A0000 |313 317|T.J.tly 
P02204623A0000 |162 185|tyrosyl phosphorylationSF [HCO3-] is shown as 
P02204623A0000 |281 287|Backerrols b
P02204623A0000 |319 326|Ullricheater s
P02204623A0000 |307 311|Dullific
P02204623A0000 |32 48|insulin receptorlkaline phosphat
P02204623A0000 |4 24|juxtamembrane region01606T0076 Compariso
P02204623A0000 |275 279|J.N.o co
P02204623A0000 |342 346|C.R..23 
P02204623A0000 |239 248|responses no longe
P02204625A1130 |20 25|grouprison
P02204625A1130 |106 114|mitogensts of ne
P02204625A1130 |29 34|genesh alk
P02204625A1130 |88 95|insulinharmaco
P02204625A1130 |76 84|response08171T00
P02204625A1130 |41 48|membershosphat
P02204625A1130 |5 9|gene1606
P02204810A1080 |7 13|region06T007
P02204810A1080 |15 18|GA2Com
P02204810A1080 |45 55|expressionhatases an
P02206430A0197 |0 4|PupsP000
P02206430A0197 |27 38|environmentith alkalin
P02206430A0197 |50 57|motherses and 
P02206430A0197 |93 104|DA turnovercologic asp
P02206430A0197 |84 89|level00 Ph
P02206789A0002 |17 23|safetymparis
P02206789A0002 |142 153|environment00008997A04
P02206789A0002 |81 92|amethocaineT0000 Pharm
P02206789A0002 |4 12|efficacy01606T00
P02206789A0002 |48 71|anaesthetic preparationases and 5-nucleotidase
P02206858A0000 |66 70|girlidas
P02206858A0000 |149 154|years7A047
P02206858A0000 |75 78|boy008
P02206858A0000 |11 20|protein C076 Compa
P02206858A0000 |123 127|agesperb
P02206858A0000 |106 115|diagnosests of neo
P02206858A0000 |56 64|siblings 5-nucle
P02206858A0000 |26 36|deficiencywith alkal
P02206858A0000 |22 24|PCso
P02208762A0228 |116 119|earata
P02208762A0228 |47 55|microtiatases an
P02208762A0228 |24 37|granddaughtern with alkali
P02208762A0228 |161 171|appendagesCSF [HCO3-
P02208762A0228 |88 96|daughterharmacol
P02208762A0228 |140 146|meatus P0000
P02208762A0228 |67 74|atresiadase P0
P02208762A0228 |4 15|grandfather01606T0076 
P02209237A0239 |34 37|IPSali
P02209237A0239 |62 67|casesleoti
P02209237A0239 |95 103|scanninglogic as
P02209237A0239 |109 118|99mTc-MAAof neonat
P02209237A0239 |167 182|liver cirrhosisCO3-] is shown 
P02209237A0239 |24 32|shuntingn with a
P02209237A0239 |146 151|cause8997A
P02209237A0239 |155 163|cyanosis When CS
P02209243A0237 |21 34|serum albuminison with alk
P02209243A0237 |44 47|SCrpha
P02209243A0237 |12 19|protein76 Comp
P02209243A0237 |73 84|improvement00008171T00
P02209243A0237 |36 39|BUNine
P02209540A1362 |16 20|Ets1ompa
P02209540A1362 |25 29|Ets2 wit
P02209540A1362 |45 58|transcriptionhatases and 5
P02209540A1362 |71 76|genes P000
P02209605A0510 |153 157|mass72 W
P02209605A0510 |25 34|MSAS gene with alk
P02209605A0510 |12 20|sequence76 Compa
P02209605A0510 |73 86|reading frame00008171T0000
P02209605A0510 |116 127|amino acidsatal hyperb
P02209605A0510 |140 142|Da P
P02209605A0510 |100 107|protein aspect
P02209811T0000 |59 69|rat caudalnucleotida
P02209811T0000 |28 47|permeability markerth alkaline phospha
P02209811T0000 |74 88|iliac arteries0008171T0000 P
P02209811T0000 |12 22|peroxidase76 Compari
P02212540A0473 |68 74|ulcersase P0
P02212540A0473 |45 49|areahata
P02212540A0473 |21 35|wall specimensison with alka
P02212540A0473 |142 174|transmission electron microscopy00008997A0472 When CSF [HCO3-] i
P02212540A0473 |118 134|light microscopyal hyperbilirubi
P02213566A0000 |118 122|ratsal h
P02213566A0000 |62 70|capacityleotidas
P02213566A0000 |15 27|coenzyme Q10Comparison w
P02213566A0000 |89 97|survivalarmacolo
P02213566A0000 |72 84|hemodynamicsP00008171T00
P02213566A0000 |29 32|CoQh a
P02213566A0000 |38 47|captoprile phospha
P02213566A0000 |4 11|effects01606T0
P02213566A0000 |168 178|infarctionO3-] is sh
P02217307T0000 |0 8|EvidenceP0000160
P02217307T0000 |26 37|alterationswith alkali
P02217307T0000 |72 89|emptying responseP00008171T0000 Ph
P02217307T0000 |53 59|rhythmand 5-
P02217741T0001 |35 50|glucocorticoidsline phosphatas
P02217741T0001 |25 31|levels with 
P02217741T0001 |90 97|animalsrmacolo
P02217741T0001 |55 62|insulind 5-nuc
P02217741T0001 |4 17|interrelation01606T0076 Co
P02217741T0001 |70 75|bloode P00
P02218094A0395 |19 25|tissuearison
P02218094A0395 |29 37|transferh alkali
P02218094A0395 |39 41|Ft p
P02218094A0395 |78 80|Fm17
P02218094A0395 |65 76|utilizationtidase P000
P02219751A0517 |84 89|speed00 Ph
P02219751A0517 |63 67|FEMseoti
P02219751A0517 |75 80|basis00817
P02219751A0517 |10 18|saccades0076 Com
P02220102A0271 |68 75|diseasease P00
P02220102A0271 |44 55|hygiene undphatases an
P02220102A0271 |30 35|grade alka
P02220102A0271 |0 9|IncidenceP00001606
P02220304A0501 |187 193|Europefuncti
P02220304A0501 |25 29|area wit
P02220304A0501 |44 65|medium MS risk regionphatases and 5-nucleo
P02220304A0501 |83 89|thesis000 Ph
P02220304A0501 |159 174|MS distributionn CSF [HCO3-] i
P02220304A0501 |93 99|Kurzkecologi
P02220304A0501 |115 123|MS areasnatal hy
P02220304A0501 |4 9|study01606
P02220304A0501 |33 38|Alcoykalin
P02223652A0939 |86 88|UH P
P02223652A0939 |42 44|CYos
P02223652A0939 |31 33|CYal
P02223652A0939 |6 29|antithrombin unit basis606T0076 Comparison wit
P02223773A0000 |0 39|Chick brain actin depolymerizing factorP00001606T0076 Comparison with alkaline
P02223773A0000 |104 118|actin monomersects of neonat
P02223773A0000 |78 93|actin filaments171T0000 Pharma
P02223773A0000 |41 44|ADFhos
P02223773A0000 |58 65|protein-nucleo
P02223928T0069 |8 18|experience6T0076 Com
P02223928T0069 |26 43|serotonin agonistwith alkaline pho
P02225687A0546 |0 18|Comprehensive careP00001606T0076 Com
P02225687A0546 |26 33|patientwith al
P02225687A0546 |135 163|pregnancy management optionsemia. P00008997A0472 When CS
P02225687A0546 |80 90|discussion1T0000 Pha
P02225687A0546 |53 62|teratogenand 5-nuc
P02225687A0546 |114 124|proceduresonatal hyp
P02227438A0492 |0 25|Primer extension analysisP00001606T0076 Comparison
P02227438A0492 |145 154|A residue08997A047
P02227438A0492 |124 126|nter
P02227438A0492 |30 44|RNA sequencing alkaline phos
P02227438A0492 |67 92|transcription start pointdase P00008171T0000 Pharm
P02227438A0492 |162 173|start codonSF [HCO3-] 
P02227438A0492 |96 108|rat ODC mRNAogic aspects
P02228615A0974 |136 145|formationmia. P000
P02228615A0974 |149 168|metal-oxyhydroxides7A0472 When CSF [HC
P02228615A0974 |31 56|distribution coefficientsalkaline phosphatases and
P02228615A0974 |105 115|indicationcts of neo
P02228615A0974 |78 100|desorption experiments171T0000 Pharmacologic
P02228615A0974 |183 191|reactions a func
P02228615A0974 |4 8|85Sr0160
P02229068A0156 |0 15|Gene constructsP00001606T0076 
P02229068A0156 |50 53|tates 
P02229068A0156 |55 58|revd 5
P02229068A0156 |145 147|SU08
P02229068A0156 |179 190|rev proteinwn as a fun
P02229068A0156 |148 150|TM97
P02229068A0156 |120 135|precursor SU-TM hyperbilirubin
P02229068A0156 |45 48|revhat
P02229068A0156 |105 116|COS-1 cellscts of neon
P02229068A0156 |152 159|gp120 x472 Whe
P02229068A0156 |65 74|env genestidase P0
P02229068A0156 |40 43|tatpho
P02229068A0156 |137 142|gp160ia. P
P02229072A1012 |51 57|mediums and 
P02229072A1012 |91 96|cellsmacol
P02229072A1012 |67 77|conditionsdase P0000
P02229072A1012 |133 143|metabolisminemia. P0
P02229072A1012 |5 18|growth arrest1606T0076 Com
P02229282A0454 |0 8|PatientsP0000160
P02229282A0454 |25 41|serum TNF levels with alkaline p
P02229282A0454 |126 132|levelsbiliru
P02229282A0454 |66 89|serum T3 concentrationsidase P00008171T0000 Ph
P02229541T0000 |17 26|carcinomamparison 
P02229541T0000 |28 34|reportth alk
P02229541T0000 |39 45|review phosp
P02229541T0000 |53 63|literatureand 5-nucl
P02229541T0000 |0 5|GiantP0000
P02231162T0000 |50 63|tooth contactes and 5-nucl
P02231162T0000 |30 38|movement alkalin
P02231162T0000 |8 15|studies6T0076 
P02231479A0585 |51 54|sons a
P02231479A0585 |58 66|daughter-nucleot
P02231479A0585 |148 161|task activity97A0472 When 
P02231479A0585 |5 11|parent1606T0
P02231479A0585 |82 95|conversations0000 Pharmaco
P02231479A0585 |118 130|conversational hyperbili
P02233626T0000 |34 42|symptomsaline ph
P02233626T0000 |70 88|strabismus surgerye P00008171T0000 P
P02233680A1115 |171 175|gene] is
P02233680A1115 |6 13|results606T007
P02233680A1115 |144 146|kb00
P02233680A1115 |47 55|elementstases an
P02233680A1115 |98 122|HaG3-A helianthinin geneic aspects of neonatal h
P02233680A1115 |83 90|control000 Pha
P02233680A1115 |156 162|regionWhen C
P02233715A0914 |17 35|pseudorabies virusmparison with alka
P02233715A0914 |72 85|IL-6 TATA boxP00008171T000
P02233715A0914 |183 186|Dexs a
P02233715A0914 |150 160|MRE regionA0472 When
P02233715A0914 |194 202|presencen of CSF
P02233715A0914 |42 56|IL-6 constructosphatases and
P02233715A0914 |111 120|initiator neonatal
P02233715A0914 |94 108|RNA start siteologic aspects
P02233715A0914 |4 13|induction01606T007
P02233715A0914 |129 136|elementirubine
P02233715A0914 |216 218|GR o
P02233729A1065 |5 14|mutations1606T0076
P02233729A1065 |109 125|Dhfr transcriptsof neonatal hype
P02233729A1065 |46 52|manneratases
P02233729A1065 |151 160|abundance0472 When
P02233729A1065 |24 28|Dhfrn wi
P02233729A1065 |78 88|startpoint171T0000 P
P02233729A1065 |178 194|Dhfr transcriptsown as a functio
P02234345A0215 |33 37|partkali
P02234345A0215 |63 73|epitheliumeotidase P
P02234345A0215 |10 19|cyst wall0076 Comp
P02234731A0503 |102 110|findingsspects o
P02234731A0503 |114 125|condylomataonatal hype
P02234731A0503 |66 78|inflammationidase P00008
P02234731A0503 |35 41|smearsline p
P02234731A0503 |139 148|dysplasia. P000089
P02234731A0503 |17 22|classmpari
P02236002A0958 |119 127|elementsl hyperb
P02236002A0958 |131 153|chicken TCR beta cDNAsubinemia. P00008997A04
P02236002A0958 |28 48|nucleotide diversityth alkaline phosphat
P02236002A0958 |96 105|diversityogic aspe
P02236002A0958 |6 13|mammals606T007
P02236002A0958 |69 78|junctionsse P00008
P02236022A0000 |4 23|protooncogene c-myb01606T0076 Comparis
P02236022A0000 |130 143|transcriptionrubinemia. P0
P02236022A0000 |104 110|mannerects o
P02236022A0000 |42 62|transcription factorosphatases and 5-nuc
P02236022A0000 |77 80|DNA817
P02236022A0000 |174 179|geness sho
P02236060A1671 |0 12|ModificationP00001606T00
P02236060A1671 |63 69|amounteotida
P02236060A1671 |28 36|compoundth alkal
P02236060A1671 |109 116|proteinof neon
P02236064A1178 |0 20|S6 kinase activationP00001606T0076 Compa
P02236064A1178 |62 69|segmentleotida
P02236064A1178 |30 42|displacement alkaline ph
P02236064A1178 |125 140|phosphorylationrbilirubinemia.
P02236276T0000 |0 4|RatsP000
P02236276T0000 |59 64|narisnucle
P02236276T0000 |24 28|bulbn wi
P02236276T0000 |83 88|odors000 P
P02237431A0000 |0 10|ExpressionP00001606T
P02237431A0000 |107 115|enhancers of neo
P02237431A0000 |75 76|T0
P02237431A0000 |147 149|kb99
P02237431A0000 |41 44|TCRhos
P02237431A0000 |46 56|alpha geneatases and
P02237431A0000 |24 39|T cell receptorn with alkaline
P02237431A0000 |161 181|C alpha gene segmentCSF [HCO3-] is shown
P02237431A0000 |136 145|kilobasesmia. P000
P02237431A0833 |50 54|paires a
P02237431A0833 |56 58|bp 5
P02237431A0833 |60 66|regionucleot
P02237431A0833 |4 22|Ets-1 binding site01606T0076 Compari
P02237431A0833 |79 82|end71T
P02237431A0833 |86 93|T alpha Pharma
P02241742A0766 |18 28|resistanceparison wi
P02241742A0766 |58 60|HD-n
P02241742A0766 |9 13|flowT007
P02241742A0766 |42 52|reductionsosphatases
P02241892A0681 |0 11|UtilizationP00001606T0
P02241892A0681 |177 184|regionshown as
P02241892A0681 |121 123|kbhy
P02241892A0681 |145 151|length08997A
P02241892A0681 |27 50|polyadenylation signalsith alkaline phosphatas
P02241892A0681 |100 105|mRNAs aspe
P02242222T0000 |46 50|coldatas
P02242222T0000 |13 20|address6 Compa
P02243093A0000 |69 76|proteinse P000
P02243093A0000 |78 81|Tax171
P02243093A0000 |133 137|pairinem
P02243093A0000 |143 150|repeats0008997
P02243093A0000 |36 42|HTLV-Iine ph
P02243093A0000 |6 32|T-cell leukemia virus type606T0076 Comparison with a
P02243093A0000 |100 113|transcription aspects of n
P02243093A0000 |158 167|U3 regionen CSF [H
P02243093A0000 |139 141|bp. 
P02243386A0113 |50 58|passageses and 5
P02243386A0113 |62 65|MHVleo
P02243386A0113 |75 81|DI RNA008171
P02243386A0113 |83 88|DIssF000 P
P02243386A0113 |125 132|virionsrbiliru
P02243386A0113 |33 39|serialkaline
P02246362T0000 |101 107|traitsaspect
P02246362T0000 |57 65|evidence5-nucleo
P02246362T0000 |94 98|typeolog
P02246362T0000 |4 27|Jenkins Activity Survey01606T0076 Comparison w
P02246447A0460 |33 50|regression slopeskaline phosphatas
P02246447A0460 |160 173|portion sizes CSF [HCO3-] 
P02246447A0460 |133 142|r2 valuesinemia. P
P02246447A0460 |111 122|food groups neonatal h
P02246447A0460 |10 18|evidence0076 Com
P02246447A0460 |81 94|portion sizesT0000 Pharmac
P02246803A0692 |4 10|result01606T
P02246803A0692 |43 53|TTD methodsphatases 
P02246803A0692 |126 132|outputbiliru
P02247069A0261 |32 38|screenlkalin
P02247069A0261 |63 74|mating typeeotidase P0
P02247069A0261 |76 80|V.L.0817
P02247069A0261 |43 48|genessphat
P02247069A0261 |4 13|TUP1 gene01606T007
P02247072A0794 |4 29|SUP44 suppressor mutation01606T0076 Comparison wit
P02247072A0794 |135 148|ram mutationsemia. P000089
P02247072A0794 |44 50|regionphatas
P02247072A0794 |58 65|protein-nucleo
P02247072A0794 |109 120|alterationsof neonatal
P02247072A0794 |96 105|positionsogic aspe
P02247081A0223 |155 161|growth When 
P02247081A0223 |179 198|growth temperatureswn as a function of
P02247081A0223 |15 25|disruptionComparison
P02247081A0223 |33 44|VPS34 locuskaline phos
P02247081A0223 |81 94|growth defectT0000 Pharmac
P02247081A0223 |116 126|VPS34 geneatal hyper
P02247924A0078 |36 43|abscessine pho
P02247924A0078 |57 71|amphotericin B5-nucleotidase
P02247924A0078 |14 18|case Com
P02247924A0078 |76 87|nephrectomy08171T0000 
P02248732A1113 |170 178|turnover-] is sh
P02248732A1113 |125 126|%r
P02248732A1113 |182 184|NAas
P02248732A1113 |111 119|LC cells neonata
P02248732A1113 |43 54|haloperidolsphatases a
P02248732A1113 |24 28|datan wi
P02248732A1113 |80 88|increase1T0000 P
P02248732A1113 |96 107|firing rateogic aspect
P02248732A1113 |201 214|DOPAC changesF PCO2 the da
P02249872A1051 |136 141|phasemia. 
P02249872A1051 |180 185|phasen as 
P02249872A1051 |105 115|microC/cm2cts of neo
P02249872A1051 |66 80|charge densityidase P0000817
P02249872A1051 |36 41|rangeine p
P02249872A1051 |125 131|chargerbilir
P02249872A1051 |169 175|microC3-] is
P02249872A1051 |5 16|interaction1606T0076 C
P02249872A1051 |50 60|parameterses and 5-n
P02250919A0404 |0 11|PerceptionsP00001606T0
P02250919A0404 |194 203|headachesn of CSF 
P02250919A0404 |90 107|headache symptomsrmacologic aspect
P02250919A0404 |15 36|illness intrusivenessComparison with alkal
P02250919A0404 |177 190|muscle crampshown as a fun
P02250919A0404 |73 85|muscle cramp00008171T000
P02250919A0404 |136 156|assessment intervalsmia. P00008997A0472 
P02251119A0319 |0 7|ResultsP000016
P02251119A0319 |78 85|regions171T000
P02251119A0319 |57 60|U145-n
P02251119A0319 |104 111|intronsects of
P02251119A0319 |145 166|hsc70 heat shock gene08997A0472 When CSF [
P02251119A0319 |131 136|mouseubine
P02251119A0319 |39 47|presence phospha
P02252891T0000 |99 104|sitesc asp
P02252891T0000 |14 21|protein Compar
P02252891T0000 |129 134|sitesirubi
P02252891T0000 |40 51|interleukinphosphatase
P02252891T0000 |54 65|stimulationnd 5-nucleo
P02252953A0300 |205 221|eating behaviourO2 the data of K
P02252953A0300 |164 171|effects [HCO3-
P02252953A0300 |22 27|girlsson w
P02252953A0300 |128 142|susceptibilitylirubinemia. P
P02252953A0300 |89 94|girlsarmac
P02252953A0300 |184 195|mood states a function
P02252953A0300 |55 64|EAT scored 5-nucle
P02252953A0300 |118 125|mothersal hype
P02253274A0000 |153 166|mtDNA introns72 When CSF [
P02253274A0000 |134 149|characteristicsnemia. P0000899
P02253274A0000 |179 187|elementswn as a 
P02253274A0000 |106 108|kbts
P02253274A0000 |88 92|DNAsharm
P02253274A0000 |4 16|Mauriceville01606T0076 C
P02253274A0000 |42 50|plasmidsosphatas
P02253274A0000 |21 27|Varkudison w
P02253663A0687 |115 135|serum concentrationsnatal hyperbilirubin
P02253663A0687 |75 82|minimum008171T
P02253663A0687 |56 66|difference 5-nucleot
P02253663A0687 |14 20|rhythm Compa
P02253663A0687 |90 91|hr
P02253663A0687 |97 104|maximumgic asp
P02253663A0687 |144 145|%0
P02253663A0687 |112 113|hn
P02254282T0000 |102 120|glucose metabolismspects of neonatal
P02254282T0000 |91 98|enzymesmacolog
P02254282T0000 |21 33|organizationison with al
P02254282T0000 |39 69|Zymomonas mobilis gene cluster phosphatases and 5-nucleotida
P02254282T0000 |0 8|SequenceP0000160
P02254418A0641 |16 17|%o
P02254418A0641 |95 102|specieslogic a
P02254418A0641 |106 109|CNSts 
P02254418A0641 |5 12|strains1606T00
P02254418A0641 |22 36|S. lugdunensisson with alkal
P02254418A0641 |48 63|delta hemolysinases and 5-nucl
P02254749A0133 |70 79|sequencese P000081
P02254749A0133 |107 122|ATG start codons of neonatal h
P02254749A0133 |50 62|170K proteines and 5-nuc
P02254749A0133 |187 192|codonfunct
P02254749A0133 |178 181|TAAown
P02254749A0133 |31 34|60Kalk
P02254749A0133 |151 154|60K047
P02254749A0133 |10 15|cDNAs0076 
P02254749A0133 |131 135|cDNAubin
P02254749A0133 |41 45|110Khosp
P02254749A0133 |162 170|sequenceSF [HCO3
P02254749A0133 |230 238|sequence rats ar
P02254749A0133 |36 39|87Kine
P02256678A1224 |152 169|protein complexes472 When CSF [HCO
P02256678A1224 |63 69|regioneotida
P02256678A1224 |25 46|footprinting analysis with alkaline phosph
P02256678A1224 |125 133|presencerbilirub
P02256678A1224 |102 112|HSC82 genespects of 
P02257251T0000 |0 15|PathophysiologyP00001606T0076 
P02257251T0000 |42 49|animalsosphata
P02257251T0000 |19 28|bone lossarison wi
P02257899T0000 |35 45|generationline phosp
P02257899T0000 |49 57|saccadesses and 
P02257899T0000 |61 64|mancle
P02257899T0000 |16 27|interactionomparison w
P02258918A0242 |108 125|sampling fraction of neonatal hype
P02258918A0242 |12 16|lung76 C
P02258918A0242 |30 36|slices alkal
P02258918A0242 |57 66|disectors5-nucleot
P02259334A0205 |51 59|sequences and 5-
P02259334A0205 |13 21|promoter6 Compar
P02259334A0205 |104 106|Mrec
P02259334A0205 |75 79|gene0081
P02259334A0205 |93 100|proteincologic
P02259334A0205 |125 133|functionrbilirub
P02259334A0205 |110 113|kDaf n
P02259795A0570 |68 80|calculationsase P0000817
P02259795A0570 |122 127|mm Hgyperb
P02259795A0570 |162 168|uptakeSF [HC
P02259795A0570 |40 44|skinphos
P02259795A0570 |12 23|consumption76 Comparis
P02259795A0570 |98 107|water PO2ic aspect
P02259795A0570 |189 193|skinncti
P02259795A0570 |138 139|%a
P02261254A0168 |34 40|arrestaline 
P02261254A0168 |132 143|developmentbinemia. P0
P02261254A0168 |54 65|circulationnd 5-nucleo
P02261254A0168 |147 155|ischemia997A0472
P02261254A0168 |72 82|conditionsP00008171T
P02261254A0168 |185 191|tissuea func
P02261254A0168 |101 112|circulationaspects of 
P02261254A0168 |0 11|ExperimentsP00001606T0
P02262439A0508 |0 12|MCh infusionP00001606T00
P02262439A0508 |46 54|increaseatases a
P02262439A0508 |88 91|QBAhar
P02262439A0508 |58 75|airway resistance-nucleotidase P00
P02264601A0000 |0 22|Taste reactivity testsP00001606T0076 Compari
P02264601A0000 |94 98|ratsolog
P02264601A0000 |91 92|Pm
P02264601A0000 |151 158|alcohol0472 Wh
P02264601A0000 |126 128|NPbi
P02264601A0000 |58 67|responses-nucleoti
P02264601A0000 |130 134|ratsrubi
P02264601A0000 |71 78|alcohol P00008
P02264601A0000 |142 147|taste00008
P02264601A0000 |103 124|alcohol nonpreferringpects of neonatal hyp
P02265055A0417 |0 21|Plasma concentrationsP00001606T0076 Compar
P02265055A0417 |149 160|laudanosine7A0472 When
P02265055A0417 |25 35|atracurium with alka
P02265055A0417 |128 145|CSF concentrationlirubinemia. P000
P02265055A0417 |40 51|laudanosinephosphatase
P02265055A0417 |97 112|micrograms ml-1gic aspects of 
P02265055A0417 |67 82|micrograms ml-1dase P00008171T
P02265055A0417 |172 179|ng ml-1 is sho
P02266679A0740 |0 9|Plasma AlP00001606
P02266679A0740 |48 59|drug courseases and 5-
P02266679A0740 |35 43|baselineline pho
P02268461A0224 |34 42|patientsaline ph
P02268461A0224 |20 24|caseriso
P02268461A0224 |60 65|yearsucleo
P02268461A0224 |4 12|survival01606T00
P02269281A1276 |118 128|structuresal hyperbi
P02269281A1276 |165 173|location[HCO3-] 
P02269281A1276 |181 187|region as a 
P02269281A1276 |191 206|control signalstion of CSF PCO
P02269281A1276 |147 155|relation997A0472
P02269281A1276 |41 52|involvementhosphatases
P02269281A1276 |71 80|sequences P0000817
P02269281A1276 |4 14|occurrence01606T0076
P02269281A1276 |16 27|maintenanceomparison w
P02269426A0428 |0 3|ISTP00
P02269426A0428 |106 113|factorsts of n
P02269426A0428 |243 258|mRNA expressionlonger displace
P02269426A0428 |209 220|requirementhe data of 
P02269426A0428 |15 25|RNA targetComparison
P02269426A0428 |162 173|RNA targetsSF [HCO3-] 
P02269426A0428 |128 131|ISTlir
P02269426A0428 |27 30|TARith
P02269426A0428 |36 56|Tat trans-activationine phosphatases and
P02269426A0428 |178 198|Tat trans-activationown as a function of
P02269426A0428 |118 126|activityal hyper
P02270096T0000 |10 18|activity0076 Com
P02270096T0000 |41 52|nitrosaminehosphatases
P02270587A0000 |67 76|magnitudedase P000
P02270587A0000 |15 29|treatment needComparison wit
P02270587A0000 |58 63|order-nucl
P02270834A0123 |9 15|methodT0076 
P02270834A0123 |26 36|HML methodwith alkal
P02272095A0832 |86 94|patients Pharmac
P02272095A0832 |109 125|cluster headacheof neonatal hype
P02272095A0832 |26 37|involvementwith alkali
P02272095A0832 |67 82|pain modulationdase P00008171T
P02272095A0832 |52 63|enkephalins and 5-nucl
P02272095A0832 |6 13|results606T007
P02273690T0001 |0 7|EffectsP000016
P02273690T0001 |11 20|cisapride076 Compa
P02273690T0001 |47 55|motilitytases an
P02273690T0001 |70 78|hormonese P00008
P02274343A0064 |69 77|clawtoesse P0000
P02274343A0064 |124 140|nail pathologieserbilirubinemia.
P02274343A0064 |79 86|bunions71T0000
P02274343A0064 |88 102|hallux rigidusharmacologic a
P02274343A0064 |28 37|heel painth alkali
P02274343A0064 |104 109|cornsects 
P02274343A0064 |39 52|metatarsalgia phosphatases
P02274343A0064 |142 151|arthritis00008997A
P02274343A0064 |7 23|foot pathologies06T0076 Comparis
P02274343A0064 |114 122|callusesonatal h
P02274343A0064 |54 64|hammertoesnd 5-nucle
P02274343A0064 |157 169|neuropathieshen CSF [HCO
P02274509A0623 |0 17|Liver dysfunctionP00001606T0076 Co
P02274509A0623 |89 97|activityarmacolo
P02274509A0623 |120 143|indicator liver enzymes hyperbilirubinemia. P0
P02274509A0623 |105 116|blood serumcts of neon
P02274509A0623 |25 33|presence with al
P02274509A0623 |177 185|functionhown as 
P02274509A0623 |55 64|reactionsd 5-nucle
P02276891T0000 |0 12|Coenzyme Q10P00001606T00
P02276891T0000 |14 26|blood levels Comparison 
P02276891T0000 |41 47|demandhospha
P02277005A0227 |4 22|CT characteristics01606T0076 Compari
P02277005A0227 |52 62|literature and 5-nuc
P02277319A0211 |100 117|product sterility aspects of neona
P02277319A0211 |121 137|bioburden levelshyperbilirubinem
P02277319A0211 |75 81|assays008171
P02277319A0211 |21 34|preservativesison with alk
P02277452A0116 |68 77|PSP/LVESVase P0000
P02277452A0116 |52 56|LVEF and
P02277452A0116 |58 63|LVESV-nucl
P02277452A0116 |198 201|ECG CS
P02277452A0116 |41 48|changeshosphat
P02277452A0116 |106 115|detectionts of neo
P02277452A0116 |168 178|chest painO3-] is sh
P02277452A0116 |20 35|angina pectorisrison with alka
P02277452A0116 |6 14|patients606T0076
P02277452A0116 |136 144|ischemiamia. P00
P02277452A0116 |154 164|appearance2 When CSF
P02277452A0116 |187 194|changesfunctio
P02278217A0372 |50 57|therapyes and 
P02278217A0372 |104 116|section leadects of neon
P02278217A0372 |120 128|delivery hyperbi
P02278217A0372 |79 89|medication71T0000 Ph
P02278217A0372 |28 46|management failureth alkaline phosph
P02278217A0372 |8 14|groups6T0076
P02278474A0000 |0 33|Serum Fibrin Degradation ProductsP00001606T0076 Comparison with al
P02278474A0000 |130 139|treatmentrubinemia
P02278474A0000 |122 126|kindyper
P02278474A0000 |97 108|individualsgic aspects
P02278474A0000 |67 82|cancer patientsdase P00008171T
P02278474A0000 |35 38|FDPlin
P02280777T0000 |69 76|elementse P000
P02280777T0000 |4 24|uteroglobin promoter01606T0076 Compariso
P02280777T0000 |49 57|estrogenses and 
P02281118A1191 |0 34|Prostaglandin synthesis inhibitorsP00001606T0076 Comparison with alk
P02281118A1191 |96 107|limitationsogic aspect
P02281118A1191 |60 67|healingucleoti
P02281118A1191 |71 75|bone P00
P02281118A1191 |140 150|situations P00008997
P02281118A1191 |117 120|usetal
P02281330A0556 |16 36|oxygen concentrationomparison with alkal
P02281330A0556 |148 154|trauma97A047
P02281330A0556 |45 49|FiO2hata
P02281330A0556 |110 116|mannerf neon
P02281330A0556 |59 76|Horowitz quotientnucleotidase P000
P02281330A0556 |138 141|daya. 
P02281948A0245 |4 8|corn0160
P02281948A0245 |13 34|mineral oil emulsions6 Comparison with alk
P02281948A0245 |104 105|Me
P02281948A0245 |63 67|milkeoti
P02281948A0245 |122 131|ingestionyperbilir
P02281948A0245 |92 99|sucroseacologi
P02282815T0000 |0 12|SignificanceP00001606T00
P02282815T0000 |64 72|childrenotidase 
P02282815T0000 |32 50|basement membraneslkaline phosphatas
P02283148T0000 |0 12|SignificanceP00001606T00
P02283148T0000 |71 86|immunopathology P00008171T0000
P02283148T0000 |40 58|adhesion moleculesphosphatases and 5
P02283148T0000 |16 35|cytokine productionomparison with alka
P02283378A0385 |114 134|ultrafiltration tubeonatal hyperbilirubi
P02283378A0385 |11 20|procedure076 Compa
P02283378T0000 |18 31|determinationparison with 
P02283378T0000 |75 81|fluids008171
P02283378T0000 |7 13|method06T007
P02283378T0000 |109 123|chromatographyof neonatal hy
P02283378T0000 |39 60|cephalosporin DQ-2556 phosphatases and 5-n
P02283873A0308 |19 30|adolescentsarison with
P02283873A0308 |151 159|enhancer0472 Whe
P02283873A0308 |75 88|parents smoke008171T0000 P
P02283873A0308 |99 110|involvementc aspects o
P02283873A0308 |10 15|group0076 
P02283873A0308 |114 132|smoking preventiononatal hyperbiliru
P02284393A0751 |87 120|EE/low EE research classificationPharmacologic aspects of neonatal
P02284393A0751 |8 16|research6T0076 C
P02284393A0751 |48 61|coping stylesases and 5-nu
P02284573A0943 |17 21|MoABmpar
P02284573A0943 |31 40|BAL fluidalkaline 
P02284573A0943 |120 123|TBB hy
P02284573A0943 |128 145|brushing materiallirubinemia. P000
P02284573A0943 |91 111|methenamine stainingmacologic aspects of
P02284573A0943 |115 118|BALnat
P02287860T0001 |33 38|studykalin
P02287860T0001 |95 109|X-ray exposurelogic aspects 
P02287860T0001 |74 78|mice0008
P02287860T0001 |54 70|parenchyma cellsnd 5-nucleotidas
P02289102A0114 |32 42|headphoneslkaline ph
P02289102A0114 |63 77|hallucinationseotidase P0000
P02289102A0114 |47 55|durationtases an
P02289102A0114 |9 27|audiotape cassetteT0076 Comparison w
P02289639A0989 |119 120|pl
P02289639A0989 |9 15|changeT0076 
P02289639A0989 |95 96|%l
P02289639A0989 |104 117|control groupects of neona
P02289639A0989 |19 23|HbA1aris
P02289639A0989 |65 66|%t
P02289639A0989 |50 55|valuees an
P02290216T0001 |34 45|cholangitisaline phosp
P02290216T0001 |49 67|serum SPan-1 levelses and 5-nucleoti
P02290216T0001 |18 29|obstructionparison wit
P02290216T0001 |0 6|EffectP00001
P02291144A0493 |137 142|MCHCHia. P
P02291144A0493 |72 73|HP
P02291144A0493 |107 124|reference methodss of neonatal hyp
P02291144A0493 |91 98|machinemacolog
P02291144A0493 |10 18|accuracy0076 Com
P02291144A0493 |147 161|basophil count997A0472 When 
P02291144A0493 |20 21|rr
P02291628A0264 |49 61|applicationsses and 5-nu
P02291628A0264 |134 144|literaturenemia. P00
P02291628A0264 |75 82|aspects008171T
P02291628A0264 |109 117|examplesof neona
P02291628A0264 |11 15|part076 
P02291628A0264 |182 195|endocrinologyas a function
P02291628A0264 |96 100|helpogic
P02291628A0264 |24 29|papern wit
P02291628A0264 |86 89|NMR Ph
P02292272T0000 |0 22|Interlimb coordinationP00001606T0076 Compari
P02292272T0000 |65 68|cattid
P02292272T0000 |38 48|locomotione phosphat
P02293019A0000 |0 19|AntileukoproteinaseP00001606T0076 Comp
P02293019A0000 |132 138|serinebinemi
P02293019A0000 |60 67|proteinucleoti
P02293019A0000 |174 185|cathepsin-Gs shown as 
P02293019A0000 |106 116|activitiests of neon
P02293019A0000 |149 169|proteinases elastase7A0472 When CSF [HCO
P02293019A0000 |35 38|mollin
P02293019A0000 |21 24|ALPiso
P02293019A0000 |84 91|tissues00 Phar
P02293664A0946 |17 23|seriesmparis
P02293664A0946 |89 98|sequencesarmacolog
P02293664A0946 |44 61|vimentin promoterphatases and 5-nu
P02293664A0946 |105 115|base pairscts of neo
P02293664A0946 |145 155|base pairs08997A0472
P02293664A0946 |27 36|deletionsith alkal
P02293664A0946 |172 185|mRNA cap site is shown as 
P02294048A0881 |80 85|hsp701T000
P02294048A0881 |24 58|% amino acid sequence similaritiesn with alkaline phosphatases and 5
P02294048A0881 |110 129|Bacillus megateriumf neonatal hyperbil
P02295521A0922 |69 74|levelse P0
P02295521A0922 |10 19|relations0076 Comp
P02295521A0922 |215 226|risk factora of K-depl
P02295521A0922 |45 56|correlationhatases and
P02295521A0922 |231 242|developmentrats are no
P02295521A0922 |162 186|muscle activity patternsSF [HCO3-] is shown as a
P02295521A0922 |78 96|trapezius activity171T0000 Pharmacol
P02295521A0922 |101 111|complaintsaspects of
P02295521A0922 |263 273|complaintsn compared
P02295521A0922 |138 148|individuala. P000089
P02296509A0997 |21 38|household membersison with alkalin
P02296509A0997 |95 112|serum p24 antigenlogic aspects of 
P02296509A0997 |53 65|seronegativeand 5-nucleo
P02298741A0809 |0 8|AnalysisP0000160
P02298741A0809 |162 172|JKPE cellsSF [HCO3-]
P02298741A0809 |78 87|gamma PKC171T0000 
P02298741A0809 |265 279|alpha antibodycompared to co
P02298741A0809 |122 125|PKCype
P02298741A0809 |62 67|alphaleoti
P02298741A0809 |143 151|JK cells0008997A
P02298741A0809 |113 118|typeseonat
P02298741A0809 |232 239|proteinats are
P02298741A0809 |38 48|antibodiese phosphat
P02298741A0809 |203 206|kDaPCO
P02298741A0809 |69 73|betase P
P02299543A0317 |54 61|outlooknd 5-nu
P02300541A0000 |119 123|MDIsl hy
P02300541A0000 |167 177|surfactantCO3-] is s
P02300541A0000 |150 154|doseA047
P02300541A0000 |104 117|dose inhalersects of neona
P02300541A0000 |61 68|surfacecleotid
P02300541A0000 |76 82|agents08171T
P02300541A0000 |42 49|barrierosphata
P02300541A0000 |214 223|rat lungsta of K-d
P02300541A0000 |185 192|airwaysa funct
P02300541A0000 |86 92|series Pharm
P02300541A0000 |17 24|effectsmpariso
P02300577A0852 |118 128|beta chainal hyperbi
P02300577A0852 |148 155|complex97A0472
P02300577A0852 |73 98|endoglycosidase digestion00008171T0000 Pharmacolog
P02300577A0852 |48 67|glycosylation sitesases and 5-nucleoti
P02300577A0852 |4 14|beta chain01606T0076
P02300577A0852 |169 180|side chains3-] is show
P02300759A0000 |136 142|T1B-T2mia. P
P02300759A0000 |180 187|surgeryn as a 
P02300759A0000 |129 134|formsirubi
P02300759A0000 |76 87|epithelioma08171T0000 
P02300759A0000 |166 175|radiologyHCO3-] is
P02300759A0000 |16 25|protocoleomparison
P02300759A0000 |38 62|Gustave Roussy Institutee phosphatases and 5-nuc
P02300759A0000 |103 109|cervixpects 
P02303158T0000 |80 92|trk oncogene1T0000 Pharm
P02303158T0000 |36 40|geneine 
P02303158T0000 |57 64|protein5-nucle
P02303158T0000 |20 30|expressionrison with
P02303470A0242 |4 11|introns01606T0
P02303470A0242 |24 27|kbpn w
P02303874A1643 |68 72|dosease 
P02303874A1643 |143 160|micrograms/24 hrs0008997A0472 When
P02303874A1643 |89 94|dosesarmac
P02303874A1643 |134 138|meannemi
P02303874A1643 |115 132|micrograms/24 hrsnatal hyperbiliru
P02303874A1643 |38 48|adjustmente phosphat
P02303874A1643 |17 33|titration periodmparison with al
P02305014A0226 |23 34|experimentson with alk
P02305014A0226 |13 19|series6 Comp
P02305014A0226 |94 108|guide cannulasologic aspects
P02305014A0226 |56 60|rats 5-n
P02305014A0226 |130 139|ventriclerubinemia
P02306539T0000 |51 55|foods an
P02306539T0000 |60 73|Daphnia pulexucleotidase P
P02306539T0000 |37 47|Microfeastne phospha
P02306539T0000 |7 32|Selenastrum capricornutum06T0076 Comparison with a
P02306539T0000 |0 3|UseP00
P02307067A1348 |171 179|evidence] is sho
P02307067A1348 |126 127|%b
P02307067A1348 |183 194|adaptationss a functio
P02307067A1348 |47 64|families Tydeidaetases and 5-nucle
P02307067A1348 |4 15|persistence01606T0076 
P02307067A1348 |66 80|Nanorchestidaeidase P0000817
P02307067A1348 |128 152|concentration treatmentslirubinemia. P00008997A0
P02307067A1348 |19 26|membersarison 
P02307067A1348 |216 224|habitats of K-de
P02307067A1348 |85 97|Tarsonemidae0 Pharmacolo
P02307371A0263 |100 118|c-myc deregulation aspects of neonat
P02307371A0263 |216 238|lymphoma c-myc alleles of K-depleted rats ar
P02307371A0263 |251 256|cellsispla
P02307371A0263 |52 85|transcription elongation blockage and 5-nucleotidase P00008171T000
P02307371A0263 |261 275|Xenopus oocytehen compared t
P02307371A0263 |122 129|Burkittyperbil
P02307371A0263 |183 191|transfers a func
P02307371A0263 |44 48|lossphat
P02307371A0263 |285 293|vesicles but sti
P02307371A0263 |154 176|transcription patterns2 When CSF [HCO3-] is 
P02307371A0263 |132 140|lymphomabinemia.
P02307371A0263 |14 23|mechanism Comparis
P02307371A0263 |206 213|Burkitt2 the d
P02307613A0783 |0 40|Erythrocyte protoporphyrin concentrationP00001606T0076 Comparison with alkaline 
P02307613A0783 |66 67|Pi
P02307613A0783 |90 94|daysrmac
P02307613A0783 |175 179|dogs sho
P02307613A0783 |98 102|dogsic a
P02307613A0783 |233 238|studyts ar
P02307613A0783 |216 225|remainder of K-dep
P02307613A0783 |201 207|groupsF PCO2
P02307613A0783 |117 121|diettal 
P02307848A0347 |87 96|sequencesPharmacol
P02307848A0347 |62 65|DNAleo
P02307848A0347 |28 37|Crry geneth alkali
P02307848A0347 |11 20|sequences076 Compa
P02307848A0347 |133 148|Eco-R1 fragmentinemia. P000089
P02307848A0347 |56 58|kb 5
P02307848T0042 |50 54|Crryes a
P02307848T0042 |67 72|genesdase 
P02307848T0042 |32 42|complexitylkaline ph
P02307850A0000 |8 34|RNK-16 lambda-gt11 library6T0076 Comparison with alk
P02307850A0000 |75 100|cDNA rat NK cell protease008171T0000 Pharmacologic
P02307850A0000 |121 136|characteristicshyperbilirubine
P02307850A0000 |104 110|RNKP-1ects o
P02307850A0000 |147 163|serine proteases997A0472 When CS
P02307850A1197 |17 34|RNKP-1 expressionmparison with alk
P02307850A1197 |106 108|NKts
P02307850A1197 |88 97|increasesharmacolo
P02307850A1197 |134 162|killer lymphocyte activitiesnemia. P00008997A0472 When C
P02307850A1197 |42 45|Conosp
P02307850A1197 |57 69|spleen cells5-nucleotida
P02307850A1197 |4 13|induction01606T007
P02308496A0000 |137 144|sessionia. P00
P02308496A0000 |148 159|respiration97A0472 Whe
P02308496A0000 |209 215|GHM-10he dat
P02308496A0000 |108 117|C-peptide of neona
P02308496A0000 |75 78|STH008
P02308496A0000 |85 93|cortisol0 Pharma
P02308496A0000 |184 191|mixture a func
P02308496A0000 |54 65|blood levelnd 5-nucleo
P02308496A0000 |80 83|TSH1T0
P02308496A0000 |95 97|T3lo
P02308496A0000 |99 106|insulinc aspec
P02308496A0000 |199 207|% oxygenCSF PCO2
P02308496A0000 |40 46|changephosph
P02308496A0000 |32 36|datalkal
P02308496A0000 |4 9|paper01606
P02308496A0000 |69 73|ACTHse P
P02310261A0115 |86 97|pericardium Pharmacolo
P02310261A0115 |4 11|abscess01606T0
P02310261A0115 |66 71|layeridase
P02310261A0115 |33 39|septumkaline
P02310300A0298 |5 19|% lymphography1606T0076 Comp
P02310300A0298 |45 47|CTha
P02310350A0221 |87 94|contentPharmac
P02310350A0221 |31 37|effectalkali
P02310350A0221 |41 50|intensityhosphatas
P02310350A0221 |12 17|study76 Co
P02310350A0221 |62 70|polarityleotidas
P02310350A0221 |52 56|rate and
P02310350A0221 |124 132|subjectserbiliru
P02310350A0221 |98 102|ABRsic a
P02310496X0000 |68 72|bandase 
P02310496X0000 |147 170|nucleus basalis lesions997A0472 When CSF [HCO3
P02310496X0000 |265 267|NBco
P02310496X0000 |121 135|memory defectshyperbilirubin
P02310496X0000 |186 192|degree funct
P02310496X0000 |221 230|cell loss-depleted
P02310496X0000 |86 101|nucleus basalis Pharmacologic 
P02310496X0000 |320 327|MS-VDBBater sl
P02310496X0000 |248 263|nucleus basalisr displaced whe
P02310496X0000 |334 355|place navigation task21 +/- 0.23 vs. P0001
P02310496X0000 |366 382|reference memorylurazepam thus a
P02310496X0000 |8 26|memory impairments6T0076 Comparison 
P02310496X0000 |76 81|Broca08171
P02310496X0000 |111 115|rats neo
P02310496X0000 |236 244|functionare no l
P02310496X0000 |313 318|Brocatly g
P02310496X0000 |305 309|bandgnif
P02311544A0086 |0 7|StudiesP000016
P02311544A0086 |56 65|MSMR cyst 5-nucleo
P02311544A0086 |31 43|relationshipalkaline pho
P02311544A0086 |99 106|diseasec aspec
P02311544A0086 |78 83|signs171T0
P02311544A0086 |87 95|symptomsPharmaco
P02312470A0774 |68 70|Naas
P02312470A0774 |256 260|timeced 
P02312470A0774 |112 115|ELFneo
P02312470A0774 |266 272|lavageompare
P02312470A0774 |179 183|timewn a
P02312470A0774 |27 35|activityith alka
P02312470A0774 |89 93|ureaarma
P02312470A0774 |209 211|Nahe
P02312470A0774 |200 204|ureaSF P
P02312470A0774 |134 136|Nane
P02312470A0774 |152 153|s4
P02312470A0774 |4 17|BAL-to-plasma01606T0076 Co
P02312470A0774 |39 43|urea pho
P02312470A0774 |236 247|circulationare no long
P02312689A0360 |68 83|standard methodase P00008171T0
P02312689A0360 |25 34|agreement with alk
P02312689A0360 |47 59|Patho Dx Kittases and 5-
P02312689A0360 |4 21|kappa coefficient01606T0076 Compar
P02315151T0020 |38 45|illnesse phosp
P02315151T0020 |7 14|systems06T0076
P02315151T0020 |27 33|healthith al
P02315151T0020 |53 56|ageand
P02315472A0583 |100 109|unit time aspects 
P02315472A0583 |79 83|RASE71T0
P02315472A0583 |122 123|%y
P02315472A0583 |20 32|imaging timerison with a
P02315472A0583 |92 95|C/Aaco
P02315472A0583 |38 48|parameterse phosphat
P02317413A0364 |186 194|patients functio
P02317413A0364 |172 182|volunteers is shown 
P02317413A0364 |78 97|neutrophil elastase171T0000 Pharmacolo
P02317413A0364 |31 41|infarctionalkaline p
P02317413A0364 |155 159|acid Whe
P02317413A0364 |217 230|heart diseaseof K-depleted
P02317413A0364 |53 74|plasma concentrationsand 5-nucleotidase P0
P02317413A0364 |0 8|PatientsP0000160
P02317413A0364 |136 142|isomermia. P
P02317413A0364 |119 124|dienel hyp
P02317554T0000 |0 13|DeterminationP00001606T007
P02317554T0000 |65 82|microscope systemtidase P00008171T
P02317554T0000 |35 53|imaging propertiesline phosphatases 
P02318208A0817 |185 191|Ad2MLPa func
P02318208A0817 |164 181|promoter sequence [HCO3-] is shown
P02318208A0817 |134 147|core sequencenemia. P00008
P02318208A0817 |15 22|elementCompari
P02318208A0817 |38 49|CACGTGACCCGe phosphata
P02318208A0817 |65 67|bpti
P02318208A0817 |86 115|transcription initiation site Pharmacologic aspects of neo
P02319610A1527 |32 40|findingslkaline 
P02319610A1527 |13 22|relevance6 Compari
P02319610A1527 |151 156|route0472 
P02319610A1527 |64 75|observationotidase P00
P02319610A1527 |89 96|resultsarmacol
P02319610A1527 |116 121|P.HClatal 
P02320008A0651 |0 6|TMBr-1P00001
P02320008A0651 |135 146|amino acidsemia. P0000
P02320008A0651 |123 129|regionperbil
P02320008A0651 |62 73|amino acidsleotidase P
P02320008A0651 |32 56|muscle alpha-tropomyosinlkaline phosphatases and
P02320999A0606 |51 65|particle boards and 5-nucleo
P02320999A0606 |40 49|materialsphosphata
P02320999A0606 |215 224|compoundsa of K-de
P02320999A0606 |79 91|gypsum board71T0000 Phar
P02320999A0606 |192 202|mg m-2 h-1ion of CSF
P02320999A0606 |112 119|plywoodneonata
P02320999A0606 |97 106|wallpapergic aspec
P02320999A0606 |125 145|polyurethane lacquerrbilirubinemia. P000
P02320999A0606 |4 13|procedure01606T007
P02320999A0606 |174 190|emission factorss shown as a fun
P02320999A0606 |71 77|carpet P0000
P02322535A0658 |0 6|IntronP00001
P02322535A0658 |89 91|kbar
P02322535A0658 |16 18|kbom
P02322535A0658 |41 46|sizeshosph
P02322535A0658 |50 57|intronses and 
P02323517A0557 |137 171|prostaglandin generation techniqueia. P00008997A0472 When CSF [HCO3-
P02323517A0557 |8 9|h6
P02323517A0557 |11 18|lesions076 Com
P02323517A0557 |80 106|prostaglandin E2 synthesis1T0000 Pharmacologic aspec
P02323517A0557 |36 40|partine 
P02323517A0557 |48 55|stomachases an
P02324102A1157 |0 10|ComparisonP00001606T
P02324102A1157 |148 156|Cassiman97A0472 
P02324102A1157 |90 94|48K5rmac
P02324102A1157 |14 27|transmembrane Comparison w
P02324102A1157 |44 51|domainsphatase
P02324102A1157 |185 190|Davida fun
P02324102A1157 |158 160|J.en
P02324102A1157 |144 146|J.00
P02324102A1157 |177 179|H.ho
P02324102A1157 |124 131|Marynenerbilir
P02324102A1157 |106 122|lung fibroblaststs of neonatal h
P02324102A1157 |133 135|P.in
P02324102A1157 |192 194|C.io
P02324102A1157 |76 88|proteoglycan08171T0000 P
P02324102A1157 |162 175|Vanden BergheSF [HCO3-] is
P02324102A1157 |137 142|Zhangia. P
P02324104A0151 |102 111|fractionsspects of
P02324104A0151 |115 126|homogenatesnatal hyper
P02324104A0151 |46 73|phosphotransferase activityatases and 5-nucleotidase P
P02324104A0151 |169 179|C. elegans3-] is sho
P02324104A0151 |154 165|populations2 When CSF 
P02324104A0151 |16 17|%o
P02324104A0516 |5 11|levels1606T0
P02324104A0516 |88 99|developmentharmacologi
P02324104A0516 |15 25|C subunitsComparison
P02324104A0516 |78 84|stages171T00
P02324104A0929 |16 25|C subunitomparison
P02324104A0929 |27 38|CeCAT alphaith alkalin
P02324104A0929 |45 53|residueshatases 
P02324104A0929 |157 167|C pre-mRNAhen CSF [H
P02324104A0929 |97 103|regiongic as
P02324104A0929 |141 149|splicingP0000899
P02324104A1195 |16 20|exonompa
P02324104A1195 |217 228|nucleotidesof K-deplet
P02324104A1195 |172 180|residues is show
P02324104A1195 |42 59|carboxyl terminusosphatases and 5-
P02324104A1195 |70 93|translation stop signale P00008171T0000 Pharma
P02324104A1195 |138 146|sequencea. P0000
P02324104A1195 |184 195|CeCAT alpha a function
P02325208A0209 |0 6|FrenchP00001
P02325208A0209 |8 10|M.6T
P02325895T0000 |17 21|typempar
P02325895T0000 |75 80|force00817
P02325895T0000 |129 136|raccoonirubine
P02325895T0000 |24 49|mechanoreceptor dischargen with alkaline phosphata
P02325895T0000 |121 125|skinhype
P02325895T0000 |55 63|functiond 5-nucl
P02325895T0000 |96 108|displacementogic aspects
P02325895T0000 |141 161|squirrel monkey handP00008997A0472 When 
P02326716A0139 |186 190|tilt fun
P02326716A0139 |176 184|rotationshown as
P02326716A0139 |79 85|convex71T000
P02326716A0139 |195 207|displacement of CSF PCO2
P02326716A0139 |90 117|concave rib-vertebra anglesrmacologic aspects of neona
P02326716A0139 |60 66|T7-T12ucleot
P02326716A0139 |48 58|evaluationases and 5
P02326716A0139 |21 31|Cobb angleison with 
P02326716A0139 |158 163|RVADsen CS
P02326716A0139 |0 7|MethodsP000016
P02326716A0139 |139 156|angle differences. P00008997A0472 
P02326716A0139 |119 123|RVAsl hy
P02326946T0000 |51 59|activitys and 5-
P02326946T0000 |133 154|liver transplantationinemia. P00008997A047
P02326946T0000 |88 97|predictorharmacolo
P02326946T0000 |45 49|LCAThata
P02326946T0000 |101 120|allograft viabilityaspects of neonatal
P02326946T0000 |78 84|donors171T00
P02326946T0000 |0 43|Plasma lecithin/cholesterol acyltransferaseP00001606T0076 Comparison with alkaline pho
P02327159T0001 |0 4|LarsP000
P02327159T0001 |9 13|AIDST007
P02327159T0001 |32 36|lifelkal
P02327159T0001 |42 46|careosph
P02327159T0001 |50 54|homees a
P02328328A0419 |187 190|yrsfun
P02328328A0419 |15 21|statusCompar
P02328328A0419 |23 58|tumour progesterone receptor statuson with alkaline phosphatases and 5
P02328328A0419 |192 200|patientsion of C
P02328328A0419 |74 90|tumour detection0008171T0000 Pha
P02328328A0419 |156 159|yrsWhe
P02328328A0419 |64 70|seasonotidas
P02328328A0419 |116 124|survivalatal hyp
P02329840A0383 |103 104|op
P02329840A0383 |80 87|changes1T0000 
P02329840A0383 |25 40|microelectrodes with alkaline 
P02329840A0383 |48 59|measurementases and 5-
P02329840A0383 |4 15|application01606T0076 
P02329840A0383 |100 101|K 
P02330041A0335 |0 10|ExpressionP00001606T
P02330041A0335 |47 68|transcription studiestases and 5-nucleotid
P02330041A0335 |268 274|mannerpared 
P02330041A0335 |195 213|rRNA gene promoter of CSF PCO2 the d
P02330041A0335 |91 95|hUBFmaco
P02330041A0335 |245 252|bindingnger di
P02330041A0335 |226 239|transcriptioneted rats are
P02330041A0335 |183 187|cores a 
P02330041A0335 |21 33|localizationison with al
P02330041A0335 |163 178|control elementF [HCO3-] is sh
P02330041A0335 |116 122|factoratal h
P02330110A1085 |85 92|outcome0 Pharm
P02330110A1085 |48 53|valueases 
P02330110A1085 |19 37|laboratory studiesarison with alkali
P02330333A0325 |85 92|muscles0 Pharm
P02330333A0325 |43 48|timessphat
P02330333A0325 |75 80|brain00817
P02330333A0325 |23 34|202Tl labelon with alk
P02330333A0325 |110 116|plasmaf neon
P02330333A0325 |59 61|Ganu
P02330333A0325 |0 13|AccumulationsP00001606T007
P02330333A0325 |101 106|timesaspec
P02330333A0325 |17 21|Tl+1mpar
P02331361A0268 |20 28|increaserison wi
P02331361A0268 |88 105|autopsy specimensharmacologic aspe
P02331361A0268 |36 52|myocyte diameterine phosphatases
P02331361A0268 |77 83|biopsy8171T0
P02331361A0268 |66 69|ageida
P02332018A0538 |186 187|P 
P02332018A0538 |40 46|asthmaphosph
P02332018A0538 |12 19|absence76 Comp
P02332018A0538 |158 166|subjectsen CSF [
P02332018A0538 |127 145|mean GH incrementsilirubinemia. P000
P02332018A0538 |179 184|ng/mlwn as
P02332018A0538 |87 95|patientsPharmaco
P02332018A0538 |48 51|EIAase
P02332018A0538 |69 75|WH airse P00
P02332798A0725 |4 13|afferents01606T007
P02332798A0725 |62 77|EVS stimulationleotidase P0000
P02332798A0725 |15 20|phaseCompa
P02332798A0725 |24 32|responsen with a
P02333239T0000 |19 26|problemarison 
P02333239T0000 |11 14|age076
P02333545A0313 |87 99|distributionPharmacologi
P02333545A0313 |114 122|controlsonatal h
P02333545A0313 |26 43|fibrinogen levelswith alkaline pho
P02333545A0313 |4 16|distribution01606T0076 C
P02333749A0411 |69 79|occurrencese P000081
P02333749A0411 |107 120|P. orbiculares of neonatal
P02333749A0411 |167 173|eczemaCO3-] 
P02333749A0411 |46 49|SPTata
P02333749A0411 |149 154|value7A047
P02333749A0411 |83 103|serum IgE antibodies000 Pharmacologic as
P02333749A0411 |23 42|regression analysison with alkaline ph
P02333749A0411 |54 63|RAST datand 5-nucl
P02334972A0145 |64 70|drusenotidas
P02334972A0145 |180 186|visionn as a
P02334972A0145 |31 41|assessmentalkaline p
P02334972A0145 |164 168|loss [HC
P02334972A0145 |75 85|evaluation008171T000
P02334972A0145 |146 159|complications8997A0472 Whe
P02334972A0145 |109 118|incidenceof neonat
P02334972A0145 |122 134|risk factorsyperbilirubi
P02334972A0145 |4 15|examination01606T0076 
P02334972A0145 |93 104|developmentcologic asp
P02334972A0145 |55 60|typesd 5-n
P02335034A0584 |85 92|minutes0 Pharm
P02335034A0584 |96 100|LBNPogic
P02335034A0584 |67 72|suitsdase 
P02335034A0584 |39 50|heat stress phosphatas
P02335521T0000 |55 68|transcriptiond 5-nucleotid
P02335521T0000 |15 45|vitellogenin activator elementComparison with alkaline phosp
P02335521T0000 |97 133|Xenopus laevis vitellogenin promotergic aspects of neonatal hyperbilirub
P02335713A0905 |53 66|ALAD activityand 5-nucleot
P02335713A0905 |74 90|stearate workers0008171T0000 Pha
P02335713A0905 |45 48|PbBhat
P02335713A0905 |7 18|correlation06T0076 Com
P02335815A0530 |85 95|C assembly0 Pharmaco
P02335815A0530 |123 131|activityperbilir
P02335815A0530 |45 52|residuehatases
P02335815A0530 |7 24|carboxyl terminus06T0076 Compariso
P02335815A0530 |26 34|deletionwith alk
P02335815A0530 |81 84|TRFT00
P02336338A0931 |100 107|account aspect
P02336338A0931 |63 73|expressioneotidase P
P02336338A0931 |15 29|mean luminanceComparison wit
P02336338A0931 |4 11|effects01606T0
P02339005T0000 |0 6|EffectP00001
P02339005T0000 |10 23|hyperglycemia0076 Comparis
P02339005T0000 |62 66|ratsleot
P02339005T0000 |27 41|pain thresholdith alkaline p
P02339447A0162 |100 108|9,11-2H2 aspects
P02339447A0162 |182 183|Aa
P02339447A0162 |85 92|7,7-2H20 Pharm
P02339447A0162 |289 297|subjects still h
P02339447A0162 |118 120|E1al
P02339447A0162 |153 158|assay72 Wh
P02339447A0162 |21 28|7,7-2H2ison wi
P02339447A0162 |189 191|E1nc
P02339447A0162 |93 94|Ac
P02339447A0162 |162 180|serum level 19-OHASF [HCO3-] is show
P02339447A0162 |109 116|estroneof neon
P02339447A0162 |47 64|deuterium contenttases and 5-nucle
P02339447A0162 |309 318|pregnancyicantly g
P02339447A0162 |202 266|gas chromatography/mass spectrometry-mass fragmentography method PCO2 the data of K-depleted rats are no longer displaced when c
P02339447A0162 |33 36|OHAkal
P02340595A0124 |0 17|Sequence analysisP00001606T0076 Co
P02340595A0124 |109 119|tRNA genesof neonata
P02340595A0124 |125 143|plant mitochondriarbilirubinemia. P0
P02340595A0124 |27 32|genesith a
P02340595A0124 |55 64|sequencesd 5-nucle
P02341669A0000 |102 107|typesspect
P02341669A0000 |63 72|responseseotidase 
P02341669A0000 |74 79|BAERs00081
P02341669A0000 |164 167|MLS [H
P02341669A0000 |36 46|brain-stemine phosph
P02341669A0000 |111 136|pseudorandom pulse trains neonatal hyperbilirubine
P02341669A0000 |193 196|LGSon 
P02341669A0000 |138 162|maximum length sequencesa. P00008997A0472 When C
P02341669A0000 |173 191|Legendre sequencesis shown as a func
P02341669A0000 |0 11|ExperimentsP00001606T0
P02342477A1292 |232 251|sequence similarityats are no longer d
P02342477A1292 |113 124|endometriumeonatal hyp
P02342477A1292 |295 303|function have a 
P02342477A1292 |93 105|biosynthesiscologic aspe
P02342477A1292 |126 143|P4-responsivenessbilirubinemia. P0
P02342477A1292 |63 71|featureseotidase
P02342477A1292 |270 274|UTMPred 
P02342477A1292 |149 157|presence7A0472 W
P02342477A1292 |85 89|site0 Ph
P02342477A1292 |19 23|UTMParis
P02342477A1292 |257 261|UfAPed w
P02342477A1292 |165 172|mannose[HCO3-]
P02342477A1292 |195 213|recognition marker of CSF PCO2 the d
P02342477A1292 |10 14|UfAP0076
P02343033A0000 |101 110|placentaeaspects o
P02343033A0000 |8 13|light6T007
P02343033A0000 |83 90|infants000 Pha
P02343033A0000 |42 51|placentaeosphatase
P02343033A0000 |18 31|dates infantsparison with 
P02344529T0000 |46 60|erythropoietinatases and 5-n
P02344529T0000 |15 22|anaemiaCompari
P02347102A0000 |84 99|lymphadenopathy00 Pharmacologi
P02347102A0000 |77 82|fever8171T
P02347102A0000 |4 27|pseudolymphoma syndrome01606T0076 Comparison w
P02347102A0000 |53 62|conditionand 5-nuc
P02347102A0000 |116 120|rashatal
P02347407A0217 |36 43|animalsine pho
P02347407A0217 |58 67|SE-sector-nucleoti
P02347407A0217 |25 30|field with
P02347655A0193 |171 182|composition] is shown 
P02347655A0193 |117 139|blood inlet conditionstal hyperbilirubinemia
P02347655A0193 |18 22|lungpari
P02347655A0193 |190 201|gas mixturection of CS
P02347655A0193 |251 262|consumptionisplaced wh
P02347655A0193 |158 169|temperatureen CSF [HCO
P02347655A0193 |211 222|ventilation data of K-
P02347655A0193 |44 48|lungphat
P02347655A0193 |105 115|parameterscts of neo
P02347655A0193 |224 246|blood tissue perfusionpleted rats are no lon
P02347655A0193 |141 156|blood flow rateP00008997A0472 
P02347655A0193 |73 86|gas exchanges00008171T0000
P02347655A0193 |64 71|tissuesotidase
P02348225A0192 |0 4|MeanP000
P02348225A0192 |83 92|half-life000 Pharm
P02348225A0192 |240 248|jaundiceno longe
P02348225A0192 |268 276|controlspared to
P02348225A0192 |30 39|clearance alkaline
P02348225A0192 |120 125|hours hype
P02348225A0192 |132 138|volumebinemi
P02348225A0192 |226 234|patientseted rat
P02348225A0192 |14 26|measurements Comparison 
P02348225A0192 |184 188|L/m2 a f
P02348225A0192 |142 154|distribution00008997A047
P02348225A0192 |10 12|SE00
P02348225A0192 |71 80|mL/min/m2 P0000817
P02348408A0126 |0 9|AttitudesP00001606
P02348408A0126 |94 101|samplesologic 
P02348408A0126 |58 68|dimensions-nucleotid
P02348728A1153 |17 27|DNA ploidymparison w
P02348728A1153 |111 120|carcinoma neonatal
P02348728A1153 |60 66|factorucleot
P02348728A1153 |83 94|determinant000 Pharmac
P02349827A0193 |32 41|Videoplanlkaline p
P02349827A0193 |24 30|systemn with
P02349942A0287 |55 62|cohortsd 5-nuc
P02349942A0287 |14 21|factors Compar
P02349942A0287 |97 103|recallgic as
P02349998A0297 |0 21|Dopamine SERS spectraP00001606T0076 Compar
P02349998A0297 |33 43|electrodeskaline pho
P02349998A0297 |86 96|electrodes Pharmacol
P02351239A0693 |6 14|findings606T0076
P02351239A0693 |253 269|gastrin infusionplaced when comp
P02351239A0693 |92 98|mucosaacolog
P02351239A0693 |214 230|hypergastrinemiata of K-depleted
P02351239A0693 |29 45|hypergastrinemiah alkaline phosp
P02351239A0693 |123 130|effectsperbili
P02351239A0693 |166 189|histamine concentrationHCO3-] is shown as a fu
P02351239A0693 |286 295|treatmentbut still
P02351239A0693 |194 210|ECL cell densityn of CSF PCO2 th
P02351239A0693 |152 164|HDC activity472 When CSF
P02351239A0693 |311 328|antisecretagoguesantly greater slo
P02351239A0693 |106 109|ratts 
P02351239A0693 |66 73|removalidase P
P02351297A0000 |205 212|percentO2 the 
P02351297A0000 |23 40|toxicity researchon with alkaline 
P02351297A0000 |127 131|centilir
P02351297A0000 |76 113|atmosphere metal corrosion inhibitors08171T0000 Pharmacologic aspects of n
P02351297A0000 |237 241|centre n
P02351297A0000 |185 190|levela fun
P02351297A0000 |171 175|cent] is
P02353453A1249 |68 78|RUB genomease P00008
P02353453A1249 |193 202|evolutionon of CSF
P02353453A1249 |96 103|respectogic as
P02353453A1249 |212 219|virusesdata of
P02353453A1249 |111 128|alphavirus genome neonatal hyperbi
P02353453A1249 |40 60|nsP3 homology regionphosphatases and 5-n
P02353453A1249 |155 168|rearrangement When CSF [HC
P02353453A1249 |4 9|order01606
P02353453A1249 |17 31|helicase motifmparison with 
P02353875A0800 |119 124|casesl hyp
P02353875A0800 |135 146|eosinophilsemia. P0000
P02353875A0800 |83 97|hypersecretion000 Pharmacolo
P02353875A0800 |161 166|casesCSF [
P02353875A0800 |40 51|eosinophilsphosphatase
P02353875A0800 |56 67|neutrophils 5-nucleoti
P02353875A0800 |4 11|results01606T0
P02353875A0800 |20 30|followingsrison with
P02353875A0800 |101 108|type Ibaspects
P02354381A0207 |34 35|Ca
P02354381A0207 |82 86|cage0000
P02354381A0207 |25 32|control with a
P02354381A0207 |94 113|fiberglass rollawayologic aspects of n
P02354381A0207 |147 151|cage997A
P02354381A0207 |215 219|backa of
P02354381A0207 |182 185|H/Sas 
P02354381A0207 |88 89|Sh
P02354381A0207 |13 23|treatments6 Comparis
P02354381A0207 |254 255|Nl
P02354381A0207 |153 154|H7
P02354381A0207 |190 198|nest boxction of
P02354381A0207 |227 231|cageted 
P02354381A0207 |133 139|cornerinemia
P02354381A0207 |68 74|cornerase P0
P02355293A0749 |48 57|responsesases and 
P02355293A0749 |211 219|strength data of
P02355293A0749 |143 147|drip0008
P02355293A0749 |129 135|graftsirubin
P02355293A0749 |61 84|failure characteristicscleotidase P00008171T00
P02355293A0749 |224 231|moduluspleted 
P02355293A0749 |21 32|differencesison with a
P02355293A0749 |191 198|tissuestion of
P02355293A0749 |156 172|bath environmentWhen CSF [HCO3-]
P02355765A0220 |81 86|weeksT0000
P02355765A0220 |29 50|benzathine penicillinh alkaline phosphatas
P02355765A0220 |62 70|U weeklyleotidas
P02355765A0220 |4 11|patient01606T0
P02355920A0681 |2 24|consensus binding site0001606T0076 Compariso
P02355920A0681 |76 82|intron08171T
P02355920A0681 |104 143|proenkephalin germ cell cap site regionects of neonatal hyperbilirubinemia. P0
P02355920A0681 |33 57|transcription factor SP1kaline phosphatases and 
P02356823A0063 |35 44|principleline phos
P02356823A0063 |14 20|method Compa
P02356823A0063 |52 66|sets technique and 5-nucleot
P02356823A0063 |109 113|timeof n
P02356823A0063 |117 133|alarm propertiestal hyperbilirub
P02357537A0451 |84 89|mg/kg00 Ph
P02357537A0451 |43 48|paCO2sphat
P02357537A0451 |72 80|naloxoneP0000817
P02357537A0451 |134 141|animalsnemia. 
P02357537A0451 |52 55|pHa an
P02357537A0451 |22 31|latenciesson with 
P02357537A0451 |4 11|effects01606T0
P02358975A0709 |70 78|symptomse P00008
P02358975A0709 |108 121|gluten intake of neonatal 
P02358975A0709 |142 156|IgA deficiency00008997A0472 
P02360336A0574 |0 4|DrugP000
P02360336A0574 |74 89|multidose vials0008171T0000 Ph
P02360336A0574 |9 24|personnel costsT0076 Compariso
P02360336A0574 |150 155|vialsA0472
P02360336A0574 |43 62|batch manufacturingsphatases and 5-nuc
P02361008T0000 |0 7|ChangesP000016
P02361008T0000 |29 35|birthsh alka
P02361008T0000 |44 49|yearsphata
P02361008T0000 |11 20|prognosis076 Compa
P02361575T0000 |20 35|carcinogenicityrison with alka
P02361575T0000 |61 70|diepoxidecleotidas
P02361575T0000 |91 102|B6C3F1 micemacologic a
P02361575T0000 |74 86|Fischer rats0008171T0000
P02361575T0000 |7 15|toxicity06T0076 
P02361812A1110 |139 141|EX. 
P02361812A1110 |198 207|treatment CSF PCO2
P02361812A1110 |209 210|Ph
P02361812A1110 |62 70|EX groupleotidas
P02361812A1110 |150 154|centA047
P02361812A1110 |99 107|subjectsc aspect
P02361812A1110 |159 160|Dn
P02361812A1110 |163 165|DEF 
P02361812A1110 |131 137|valuesubinem
P02361812A1110 |38 53|baseline valuese phosphatases 
P02361812A1110 |4 14|kg FFM SMR01606T0076
P02361812A1110 |175 179|cent sho
P02362161T0000 |0 6|MK-927P00001
P02362161T0000 |55 74|anhydrase inhibitord 5-nucleotidase P0
P02362803A0608 |50 59|isolationes and 5-
P02362803A0608 |108 119|Arabidopsis of neonata
P02362803A0608 |12 21|fragments76 Compar
P02362803A0608 |97 104|librarygic asp
P02362803A0608 |67 81|U3 snRNA genesdase P00008171
P02362803A0608 |35 41|probesline p
P02368931A0587 |3 36|addition serum IgE concentrations001606T0076 Comparison with alkal
P02370571A0663 |221 222|s-
P02370571A0663 |183 188|womens a f
P02370571A0663 |120 126|cohort hyper
P02370571A0663 |75 80|cause00817
P02370571A0663 |36 53|iodine deficiencyine phosphatases 
P02370571A0663 |97 107|immigrantsgic aspect
P02370571A0663 |145 155|population08997A0472
P02370571A0663 |214 220|factorta of 
P02370571A0663 |175 178|men sh
P02370571A0663 |4 12|findings01606T00
P02370571A0663 |84 90|goiter00 Pha
P02371273A0144 |64 78|kilobase pairsotidase P00008
P02371273A0144 |20 24|unitriso
P02371273A0144 |45 51|regionhatase
P02371273A0144 |80 83|kbp1T0
P02371517A0747 |11 19|patients076 Comp
P02372496A0782 |186 204|5FU administration function of CSF P
P02372496A0782 |74 80|artery000817
P02372496A0782 |45 57|microsphereshatases and 
P02372496A0782 |92 105|drug exposureacologic aspe
P02372496A0782 |177 182|ratiohown 
P02372496A0782 |26 37|angiotensinwith alkali
P02372496A0782 |122 133|compartmentyperbilirub
P02372496A0782 |221 227|artery-deple
P02372496A0782 |21 24|5FUiso
P02372496A0782 |0 17|Co-administrationP00001606T0076 Co
P02372712A0002 |85 99|carbon dioxide0 Pharmacologi
P02372712A0002 |73 81|pressure00008171
P02372712A0002 |61 63|pHcl
P02372712A0002 |15 18|tapCom
P02372712A0002 |20 22|TWri
P02372712A0002 |159 167|broilersn CSF [H
P02372712A0002 |111 125|plasma lactate neonatal hype
P02372712A0002 |43 48|watersphat
P02372712A0002 |4 11|effects01606T0
P02372712A0002 |39 41|CW p
P02372712A0002 |101 105|PCO2aspe
P02373686T0000 |34 64|chicken progesterone receptorsaline phosphatases and 5-nucle
P02373686T0000 |10 20|expression0076 Compa
P02373686T0000 |133 137|mRNAinem
P02373686T0000 |145 154|mechanism08997A047
P02373686T0000 |108 118|initiation of neonat
P02373686T0000 |170 187|receptor isoforms-] is shown as a 
P02373810A1118 |102 103|ps
P02373810A1118 |95 100|weekslogic
P02373810A1118 |41 53|risk factorshosphatases 
P02373810A1118 |63 67|riskeoti
P02373810A1118 |83 84|%0
P02373810A1118 |22 23|%s
P02373810A1118 |3 11|contrast001606T0
P02374886A0305 |102 109|abilityspects 
P02374886A0305 |40 52|outcome dataphosphatases
P02374886A0305 |147 163|presence/absence997A0472 When CS
P02374886A0305 |167 181|symptomatologyCO3-] is shown
P02374886A0305 |88 100|productivityharmacologic
P02374886A0305 |219 228|admission K-deplet
P02374886A0305 |128 141|relationshipslirubinemia. 
P02374886A0305 |199 204|yearsCSF P
P02374886A0305 |78 84|degree171T00
P02374886A0305 |185 192|averagea funct
P02374886A0305 |4 30|Community Adjustment Scale01606T0076 Comparison with
P02374886A0305 |68 76|subjectsase P000
P02376023A0307 |51 57|levelss and 
P02376023A0307 |130 137|infantsrubinem
P02376023A0307 |61 65|IgG1cleo
P02376023A0307 |15 21|monthsCompar
P02376023A0307 |189 193|kU/lncti
P02376023A0307 |67 68|Pd
P02376023A0307 |25 28|age wi
P02376023A0307 |92 96|IgG4acol
P02376023A0307 |155 158|IgE Wh
P02376023A0307 |98 99|Pi
P02376023A0307 |222 227|leveldeple
P02378615A0807 |103 109|regionpects 
P02378615A0807 |163 175|carbohydrateF [HCO3-] is
P02378615A0807 |131 135|siteubin
P02378615A0807 |4 20|protein sequence01606T0076 Compa
P02378615A0807 |140 150|attachment P00008997
P02378615A0807 |55 74|glycosylation sitesd 5-nucleotidase P0
P02378945A0487 |35 41|stressline p
P02378945A0487 |5 15|adaptation1606T0076 
P02378945A0487 |111 121|vagal tone neonatal 
P02378945A0487 |70 76|effecte P000
P02383693A0301 |139 144|pumps. P00
P02383693A0301 |63 71|solutioneotidase
P02383693A0301 |121 135|M KOH solutionhyperbilirubin
P02383693A0301 |164 190|chemiluminescence detector [HCO3-] is shown as a fun
P02383693A0301 |83 92|lucigenin000 Pharm
P02383693A0301 |97 109|Triton X-100gic aspects 
P02383693A0301 |20 26|columnrison 
P02383771A0544 |185 194|cytoplasma functio
P02383771A0544 |160 166|nuclei CSF [
P02383771A0544 |135 147|distributionemia. P00008
P02383771A0544 |14 25|examination Comparison
P02383771A0544 |39 49|epithelium phosphata
P02383771A0544 |111 121|epithelium neonatal 
P02383771A0544 |64 72|membraneotidase 
P02384265A0947 |35 39|riskline
P02384265A0947 |67 81|polyp patientsdase P00008171
P02384265A0947 |128 139|polypectomylirubinemia
P02384265A0947 |105 124|prophylactic effectcts of neonatal hyp
P02384265A0947 |90 101|possibilityrmacologic 
P02384265A0947 |6 13|results606T007
P02384265A0947 |159 165|cancern CSF 
P02384265A0947 |54 60|cancernd 5-n
P02384389A0854 |118 128|fed cattleal hyperbi
P02384389A0854 |9 14|trendT0076
P02384389A0854 |40 47|heifersphospha
P02384389A0854 |106 114|seam fatts of ne
P02384389A0854 |52 54|YG a
P02384389A0854 |92 102|depositionacologic a
P02384389A0854 |33 35|YGka
P02386485A0554 |4 23|nucleotide sequence01606T0076 Comparis
P02386485A0554 |150 157|bp polyA0472 W
P02386485A0554 |104 106|bpec
P02386485A0554 |128 134|regionlirubi
P02386485A0554 |161 165|tailCSF 
P02386485A0554 |89 95|regionarmaco
P02386485A0554 |63 69|regioneotida
P02386485A0554 |158 159|Ae
P02386485A0554 |76 78|bp08
P02386485A0554 |39 41|bp p
P02386895A0496 |0 10|ToxicitiesP00001606T
P02386895A0496 |116 117|%a
P02386895A0496 |21 36|nausea/vomitingison with alkal
P02386895A0496 |82 93|tumor sites0000 Pharma
P02386895A0496 |56 57|% 
P02386895A0496 |124 136|hypertensionerbilirubine
P02386895A0496 |60 66|chillsucleot
P02386895A0496 |97 98|%g
P02386895A0496 |40 41|%p
P02386895A0496 |44 52|headachephatases
P02386895A0496 |74 78|pain0008
P02386895A0496 |101 112|hypotensionaspects of 
P02386895A0496 |140 141|% 
P02386895A0496 |70 71|%e
P02388685A0577 |4 11|results01606T0
P02388685A0577 |251 258|calciumisplace
P02388685A0577 |263 281|phosphorus contentn compared to cont
P02388685A0577 |214 216|CVta
P02388685A0577 |245 246|%n
P02388685A0577 |299 304|tibiae a s
P02388685A0577 |118 137|bone mineralizational hyperbilirubinem
P02388685A0577 |187 199|coefficientsfunction of 
P02388685A0577 |289 294|femur stil
P02388685A0577 |87 116|alkaline phosphatase activityPharmacologic aspects of neon
P02388685A0577 |203 212|variationPCO2 the 
P02388685A0577 |230 231|% 
P02388685A0577 |38 66|oyster shell supplementatione phosphatases and 5-nucleot
P02390538A0000 |38 43|weekse pho
P02390538A0000 |94 103|anomaliesologic as
P02390538A0000 |11 18|infants076 Com
P02390538A0000 |192 194|mmio
P02390538A0000 |47 56|gestationtases and
P02390538A0000 |111 118|airways neonat
P02390538A0000 |160 170|fiberscope CSF [HCO3
P02390538A0000 |172 186|Olympus PF18 S is shown as a
P02390633T0000 |6 18|encephalitis606T0076 Com
P02390633T0000 |63 70|diseaseeotidas
P02390633T0000 |24 31|patientn with 
P02390989A0745 |85 100|point mutations0 Pharmacologic
P02390989A0745 |45 49|exonhata
P02390989A0745 |161 174|reading frameCSF [HCO3-] i
P02390989A0745 |131 141|stop codonubinemia. 
P02390989A0745 |121 123|bphy
P02390989A0745 |105 114|insertioncts of ne
P02390989A0745 |16 27|counterpartomparison w
P02390989A0745 |59 67|GPE genenucleoti
P02390989A0745 |35 43|GPB geneline pho
P02391344T0000 |23 27|cDNAon w
P02391344T0000 |92 96|geneacol
P02391344T0000 |10 17|cloning0076 Co
P02391344T0000 |37 69|rat NADH-cytochrome b5 reductasene phosphatases and 5-nucleotida
P02392032A0657 |205 216|ambiguitiesO2 the data
P02392032A0657 |28 32|ideath a
P02392032A0657 |82 93|information0000 Pharma
P02392032A0657 |127 139|architectureilirubinemia
P02392032A0657 |42 51|structureosphatase
P02392032A0657 |147 157|pore space997A0472 W
P02392032A0657 |55 72|relaxation curvesd 5-nucleotidase 
P02392032A0657 |4 11|results01606T0
P02392032A0657 |101 115|distance scaleaspects of neo
P02392511T0000 |0 32|Serotonin 5-HT2 receptor bindingP00001606T0076 Comparison with a
P02392511T0000 |73 79|marker000081
P02392511T0000 |36 51|blood plateletsine phosphatase
P02392511T0000 |57 62|state5-nuc
P02392511T0000 |99 107|disorderc aspect
P02393001A0324 |169 176|results3-] is 
P02393001A0324 |47 48|rt
P02393001A0324 |129 141|densitometryirubinemia. 
P02393001A0324 |9 12|%BFT00
P02393001A0324 |41 45|BMIshosp
P02393001A0324 |122 125|%BFype
P02393001A0324 |97 104|obesitygic asp
P02393001A0324 |82 93|definitions0000 Pharma
P02393001A0324 |114 118|BMIsonat
P02393895A0918 |69 74|scalese P0
P02393895A0918 |243 257|regurgitationslonger displac
P02393895A0918 |284 288|oness bu
P02393895A0918 |112 113|rn
P02393895A0918 |97 110|insufficiencygic aspects o
P02393895A0918 |78 86|severity171T0000
P02393895A0918 |123 124|pp
P02393895A0918 |4 13|RF values01606T007
P02393895A0918 |200 215|differentiationSF PCO2 the dat
P02393895A0918 |169 176|authors3-] is 
P02394707A0789 |137 142|CCAATia. P
P02394707A0789 |91 106|initiation sitemacologic aspec
P02394707A0789 |144 149|ATTGG00899
P02394707A0789 |59 68|CCAAT boxnucleotid
P02394707A0789 |176 196|nucleotide stretchesshown as a function 
P02394707A0789 |122 133|complimentsyperbilirub
P02394707A0789 |48 52|GTTAases
P02394707A0789 |38 46|TATA boxe phosph
P02394707A0789 |0 17|Promoter elementsP00001606T0076 Co
P02394718A0130 |154 173|amino acid sequence2 When CSF [HCO3-] 
P02394718A0130 |11 16|genes076 C
P02394718A0130 |44 53|librariesphatases 
P02394718A0130 |92 119|deoxyoligonucleotide probesacologic aspects of neonata
P02394718A0130 |57 80|hybridization screening5-nucleotidase P0000817
P02394718A0130 |190 196|enzymection 
P02395868A0322 |50 57|ligandses and 
P02395868A0322 |147 154|ligands997A047
P02395868A0322 |26 36|zinc siteswith alkal
P02395868A0322 |121 134|hydrogen bondhyperbilirubi
P02395868A0322 |96 102|ligandogic a
P02395868A0322 |67 75|sequencedase P00
P02395868A0322 |4 11|pattern01606T0
P02396415T0001 |0 7|ResultsP000016
P02396415T0001 |41 50|treatmenthosphatas
P02396415T0001 |25 36|observation with alkal
P02396415T0001 |77 89|hypertension8171T0000 Ph
P02396415T0001 |54 62|patientsnd 5-nuc
P02398897A0000 |84 94|efficiency00 Pharmac
P02398897A0000 |11 32|transcription factors076 Comparison with a
P02398897A0000 |98 108|elongationic aspects
P02398897A0000 |147 157|RNA chains997A0472 W
P02398897A0000 |48 62|RNA polymeraseases and 5-nuc
P02399053A0153 |49 57|% oxygenses and 
P02399053A0153 |76 78|RA08
P02399053A0153 |29 30|nh
P02399053A0153 |122 124|RAyp
P02399053A0153 |107 111|lifes of
P02399053A0153 |66 74|room airidase P0
P02399053A0153 |23 27|ratson w
P02399053A0153 |99 103|daysc as
P02399053A1032 |49 64|recoil pressureses and 5-nucle
P02399053A1032 |25 36|alveoli/mm2 with alkal
P02399053A1032 |4 6|Lm01
P02400070T0000 |0 10|ComparisonP00001606T
P02400070T0000 |14 22|propofol Compari
P02400070T0000 |83 90|therapy000 Pha
P02400070T0000 |27 38|thiopentoneith alkalin
P02400070T0000 |54 60|agentsnd 5-n
P02400457A0469 |254 267|Experiment I.laced when co
P02400457A0469 |211 222|adjustments data of K-
P02400457A0469 |181 188|manners as a f
P02400457A0469 |59 68|% VO2 maxnucleotid
P02400457A0469 |77 84|minutes8171T00
P02400457A0469 |130 135|womenrubin
P02400457A0469 |41 55|supine cyclinghosphatases an
P02400457A0469 |3 13|Experiment001606T007
P02400457A0469 |99 114|LBNP conditionsc aspects of ne
P02400457A0469 |238 244|phasese no l
P02402678A0463 |236 252|mosquito controlare no longer di
P02402678A0463 |49 68|% lambdacyhalothrinses and 5-nucleotid
P02402678A0463 |115 137|aerosol space-sprayingnatal hyperbilirubinem
P02402678A0463 |23 35|formulationson with alka
P02402678A0463 |146 161|diesel/kerosene8997A0472 When 
P02402678A0463 |271 287|housefly controled to controls b
P02402678A0463 |197 214|application ratesf CSF PCO2 the da
P02402678A0463 |106 109|ULVts 
P02402678A0463 |224 231|g ai/hapleted 
P02402678A0463 |259 266|g ai/ha when c
P02402678A0463 |96 101|waterogic 
P02402678A0463 |42 43|%o
P02402678A0463 |174 181|foggings shown
P02403035A0621 |80 88|fumarase1T0000 P
P02403035A0621 |11 24|reading frame076 Compariso
P02403035A0621 |53 62|precursorand 5-nuc
P02403634A0788 |0 17|Sequence analysisP00001606T0076 Co
P02403634A0788 |302 332|muscle-CAAT consensus sequence significantly greater slope (
P02403634A0788 |51 54|ATAs a
P02403634A0788 |190 192|bpct
P02403634A0788 |292 294|bpil
P02403634A0788 |59 65|GC boxnucleo
P02403634A0788 |245 268|binding site homologiesnger displaced when com
P02403634A0788 |360 368|cap site0733 Flu
P02403634A0788 |88 95|domainsharmaco
P02403634A0788 |36 44|additionine phos
P02403634A0788 |129 139|regulationirubinemia
P02403634A0788 |72 78|regionP00008
P02403634A0788 |165 170|genes[HCO3
P02403634A0788 |236 242|factorare no
P02403634A0788 |174 182|CArG boxs shown 
P02403634A0788 |341 343|bp0.
P02403926A0000 |305 311|Gronergnific
P02403926A0000 |146 187|trk proto-oncogene receptor kinase domain8997A0472 When CSF [HCO3-] is shown as a 
P02403926A0000 |299 303|S.M.e a 
P02403926A0000 |94 110|DNA-transfectionologic aspects o
P02403926A0000 |245 250|Kozmanger 
P02403926A0000 |327 331|N.E.ope 
P02403926A0000 |252 256|S.C.spla
P02403926A0000 |291 297|Saurertill h
P02403926A0000 |116 128|NIH3T3 cellsatal hyperbi
P02403926A0000 |320 325|Hynesater 
P02403926A0000 |213 223|amino acidata of K-d
P02403926A0000 |267 273|S.M.S.mpared
P02403926A0000 |313 315|B.tl
P02403926A0000 |287 289|F.ut
P02403926A0000 |45 78|breast carcinoma cell line MDA-MBhatases and 5-nucleotidase P00008
P02403926A0000 |258 265|Redmondd when 
P02403926A0000 |4 19|trk-2h oncogene01606T0076 Comp
P02403926A0000 |235 243|sequence are no 
P02403926A0000 |275 285|Xiao-Chango controls
P02403926A0307 |0 10|AntibodiesP00001606T
P02403926A0307 |145 151|serine08997A
P02403926A0307 |109 126|kd phosphoproteinof neonatal hyper
P02403926A0307 |167 175|tyrosineCO3-] is
P02403926A0307 |210 222|NIH3T3 cellse data of K-
P02403926A0307 |49 92|beta gal-trk receptor kinase fusion proteinses and 5-nucleotidase P00008171T0000 Pharm
P02403926A0307 |179 187|extractswn as a 
P02403926A0307 |153 162|threonine72 When C
P02404451A1532 |186 201|Cys-118 residue function of CS
P02404451A1532 |91 99|activitymacologi
P02404451A1532 |105 112|Cys-118cts of 
P02404451A1532 |80 86|region1T0000
P02404451A1532 |261 269|activityhen comp
P02404451A1532 |226 239|glycosylationeted rats are
P02404451A1532 |122 129|Cys-118yperbil
P02404451A1532 |155 163|activity When CS
P02404451A1532 |18 44|scanning-deletion analysisparison with alkaline phos
P02404451A1532 |273 279|GM-CSF to co
P02405393T0000 |49 57|promoterses and 
P02405393T0000 |77 89|c-ets-2 gene8171T0000 Ph
P02405393T0000 |61 65|ETS2cleo
P02405393T0000 |25 41|characterization with alkaline p
P02405589A0000 |0 11|InformationP00001606T0
P02405589A0000 |90 108|drug-use decisionsrmacologic aspects
P02405589A0000 |30 47|drug interactions alkaline phospha
P02405589A0000 |61 72|pharmacistscleotidase 
P02405818A0550 |0 16|Branch occlusionP00001606T0076 C
P02405818A0550 |125 134|mechanismrbilirubi
P02405818A0550 |41 52|perforatorshosphatases
P02405818A0550 |30 36|artery alkal
P02405818A0550 |99 107|arteriesc aspect
P02405818A0550 |20 27|Heubnerrison w
P02405818A0550 |138 148|infarctiona. P000089
P02406570A0466 |17 22|sitesmpari
P02406570A0466 |38 44|origine phos
P02406570A0466 |60 63|UASucl
P02406570A0466 |98 111|test plasmidsic aspects of
P02406570A0898 |169 179|activation3-] is sho
P02406570A0898 |58 62|ARS1-nuc
P02406570A0898 |94 98|ABFIolog
P02406570A0898 |22 32|propertiesson with a
P02406570A0898 |145 149|ARS10899
P02406570A0898 |126 141|DNA replicationbilirubinemia. 
P02406570A0898 |77 88|possibility8171T0000 P
P02406570A0898 |36 45|sequencesine phosp
P02406570A0898 |112 122|initiationneonatal h
P02406570A0898 |3 14|examination001606T0076
P02406992A0192 |38 47|disorderse phospha
P02406992A0192 |123 133|evaluationperbilirub
P02406992A0192 |210 232|carotid artery studiese data of K-depleted r
P02406992A0192 |74 89|amaurosis fugax0008171T0000 Ph
P02406992A0192 |161 172|examinationCSF [HCO3-]
P02406992A0192 |109 118|algorithmof neonat
P02406992A0192 |174 192|laboratory studiess shown as a funct
P02408248A0414 |41 47|actionhospha
P02408248A0414 |62 79|enzyme inhibitorsleotidase P000081
P02409297A0984 |118 133|virus particlesal hyperbilirub
P02409297A0984 |11 20|antiserum076 Compa
P02409297A0984 |180 198|HBsAg determinantsn as a function of
P02409297A0984 |38 52|fusion proteine phosphatases
P02409297A0984 |140 152|polypeptides P00008997A0
P02409297A0984 |100 112|polypeptides aspects of 
P02411513A0667 |6 21|characteristics606T0076 Compar
P02411513A0667 |88 93|eventharma
P02411513A0667 |121 127|dipolehyperb
P02411513A0667 |179 189|positivitywn as a fu
P02411513A0667 |133 150|dorsal negativityinemia. P00008997
P02411513A0667 |25 32|N22/P22 with a
P02417023T0001 |51 60|processess and 5-n
P02417023T0001 |79 92|determination71T0000 Pharm
P02417023T0001 |107 116|materialss of neon
P02417023T0001 |65 71|methodtidase
P02417023T0001 |8 28|superoxide dismutase6T0076 Comparison wi
P02417023T0001 |0 4|RoleP000
P02417669A0218 |206 213|animals2 the d
P02417669A0218 |83 90|taurine000 Pha
P02417669A0218 |128 138|metabolitelirubinemi
P02417669A0218 |43 54|amino acidssphatases a
P02417669A0218 |74 78|acid0008
P02417669A0218 |3 27|maximum photosensitivity001606T0076 Comparison w
P02417669A0218 |157 177|amino acid aspartatehen CSF [HCO3-] is s
P02417669A0218 |116 126|asparagineatal hyper
P02418701A0000 |17 27|likelihoodmparison w
P02418701A0000 |121 137|antigen staininghyperbilirubinem
P02418701A0000 |91 100|intensitymacologic
P02418701A0000 |31 38|tissuesalkalin
P02418701A0000 |75 82|antigen008171T
P02418701A0000 |162 170|adenomasSF [HCO3
P02418701A0000 |214 222|adenomasta of K-
P02418701A0000 |228 242|diverticulitised rats are no
P02418701A0000 |195 203|adenomas of CSF 
P02418701A0000 |141 150|specimensP00008997
P02418701A0000 |178 186|polypoidown as a
P02418701A0000 |279 288|techniquentrols bu
P02419327A0998 |207 211|side the
P02419327A0998 |24 27|DNAn w
P02419327A0998 |227 231|siteted 
P02419327A0998 |193 196|DNAon 
P02419327A0998 |64 71|enzymesotidase
P02419327A0998 |4 20|priming activity01606T0076 Compa
P02419327A0998 |115 125|incubationnatal hype
P02419588A0284 |0 2|A.P0
P02420432A1060 |84 91|history00 Phar
P02420432A1060 |42 56|pregnancy testosphatases and
P02420432A1060 |124 142|serum PAPP-A levelerbilirubinemia. P
P02420432A1060 |14 25|conjunction Comparison
P02420432A1060 |65 72|patienttidase 
P02420432A1060 |158 167|diagnosisen CSF [H
P02420432A1060 |184 193|pregnancy a functi
P02423533A1314 |51 56|mRNAss and
P02423533A1314 |127 131|mRNAilir
P02423533A1314 |93 98|braincolog
P02423533A1314 |179 187|exposurewn as a 
P02423533A1314 |104 109|levelects 
P02423533A1314 |191 210|nerve growth factortion of CSF PCO2 th
P02423533A1314 |159 173|rat PC12 cellsn CSF [HCO3-] 
P02423533A1314 |4 10|levels01606T
P02423533A1790 |68 79|chicken DNAase P000081
P02423533A1790 |52 55|rat an
P02423533A1790 |124 134|sea urchinerbilirubi
P02423533A1790 |94 97|DNAolo
P02423533A1790 |4 9|cDNAs01606
P02423533A1790 |39 48|sequences phosphat
P02423533A1790 |103 107|frogpect
P02423773T0001 |51 56|bloods and
P02423773T0001 |13 19|method6 Comp
P02423773T0001 |35 43|glycerinline pho
P02423850A0292 |0 17|Deletion analysisP00001606T0076 Co
P02423850A0292 |107 113|regions of n
P02423850A0292 |121 136|yeast CYC1 genehyperbilirubine
P02423850A0292 |67 73|regiondase P
P02423850A0292 |43 47|partspha
P02423850A0292 |82 90|homology0000 Pha
P02424743A0280 |33 42|amplitudekaline ph
P02424743A0280 |77 84|periods8171T00
P02424743A0280 |11 13|P207
P02424743A0280 |4 6|N101
P02427024X0000 |0 9|ToleranceP00001606
P02427024X0000 |167 177|generalityCO3-] is s
P02427024X0000 |13 34|fenfluramine anorexia6 Comparison with alk
P02427024X0000 |44 51|fictionphatase
P02427024X0000 |60 68|findingsucleotid
P02427024X0000 |36 40|factine 
P02427024X0000 |197 207|phenomenonf CSF PCO2
P02427024X0000 |93 99|regardcologi
P02427024X0000 |77 87|laboratory8171T0000 
P02427024X0000 |116 137|fenfluramine anorexiaatal hyperbilirubinem
P02427024X0000 |156 163|respectWhen CS
P02427024X0000 |103 112|tolerancepects of 
P02427797A0199 |139 147|ischemia. P00008
P02427797A0199 |20 24|limbriso
P02427797A0199 |112 122|blood flowneonatal h
P02427797A0199 |189 199|time pointnction of 
P02427797A0199 |176 180|dogsshow
P02427797A0199 |26 30|tailwith
P02427797A0199 |242 249|lactate longer
P02427797A0199 |6 10|dogs606T
P02427797A0199 |233 240|Ringersts are 
P02427797A0199 |280 287|vesselstrols b
P02427797A0199 |86 92|cavity Pharm
P02427797A0199 |39 47|pancreas phospha
P02427797A0199 |99 108|cessationc aspects
P02427797A0199 |168 171|minO3-
P02427812A0865 |50 56|6-OHDAes and
P02427812A0865 |112 115|ratneo
P02427812A0865 |26 30|viewwith
P02427812A0865 |89 104|pressor actionsarmacologic asp
P02427812A0865 |151 157|action0472 W
P02427812A0865 |36 45|clonidineine phosp
P02427812A0865 |6 13|results606T007
P02427812A0865 |66 74|alpha-MDidase P0
P02427869A0939 |33 44|sensitivitykaline phos
P02427869A0939 |13 17|beta6 Co
P02427869A0939 |72 75|BHTP00
P02431314A0834 |17 23|Hanselmparis
P02431314A0834 |106 112|Wrightts of 
P02431314A0834 |74 88|eosinophiluria0008171T0000 P
P02431314A0834 |59 70|recognitionnucleotidas
P02436005A0707 |84 94|inhibition00 Pharmac
P02436005A0707 |142 144|Ca00
P02436005A0707 |126 138|mobilizationbilirubinemi
P02436005A0707 |60 70|nicorandilucleotidas
P02436005A0707 |98 107|Ca influxic aspect
P02436005A0707 |6 13|results606T007
P02436005A0707 |50 56|actiones and
P02437625A0197 |118 121|AMDal 
P02437625A0197 |104 116|degenerationects of neon
P02437625A0197 |74 78|POHS0008
P02437625A0197 |4 9|study01606
P02437625A0197 |23 27|eyeson w
P02437625A0197 |49 72|histoplasmosis syndromeses and 5-nucleotidase 
P02437792T0000 |0 10|ComparisonP00001606T
P02437792T0000 |88 97|diagnosisharmacolo
P02437792T0000 |14 24|elastase-1 Compariso
P02437792T0000 |30 37|amylase alkali
P02437792T0000 |39 45|lipase phosp
P02437792T0000 |107 119|pancreatitiss of neonata
P02437792T0000 |64 80|immunoreactivityotidase P0000817
P02437895A0000 |68 78|engagementase P00008
P02437895A0000 |241 252|dysarthricso longer di
P02437895A0000 |153 159|groups72 Whe
P02437895A0000 |324 332|subjects slope (
P02437895A0000 |117 130|language tasktal hyperbili
P02437895A0000 |184 194|hemisphere a functio
P02437895A0000 |260 270|hemispherewhen compa
P02437895A0000 |295 303|patients have a 
P02437895A0000 |208 216|aphasicsthe data
P02437895A0000 |96 107|hemispheresogic aspect
P02437895A0000 |233 239|strokets are
P02437895A0000 |196 198|LHof
P02437895A0000 |15 35|potentials procedureComparison with alka
P02437895A0000 |2 7|probe00016
P02437895A0000 |272 274|RHd 
P02437895A0000 |171 177|adults] is s
P02438637T0000 |0 18|Mucolipidosis typeP00001606T0076 Com
P02438637T0000 |53 60|historyand 5-n
P02438637T0000 |32 40|spectrumlkaline 
P02442837A0060 |17 23|groupsmparis
P02442837A0060 |62 85|calcium channel blockerleotidase P00008171T000
P02442837A0060 |91 100|verapamilmacologic
P02442837A0060 |212 228|bypass proceduredata of K-deplet
P02442837A0060 |42 51|dauricineosphatase
P02442837A0060 |128 151|calcium channel blockerlirubinemia. P00008997A
P02442837A0060 |245 252|minutesnger di
P02442837A0060 |175 182|minutes shown 
P02442837A0060 |232 238|periodats ar
P02442837A0060 |201 204|endF P
P02443028A0695 |3 9|reflow001606
P02443028A0695 |39 46|percent phosph
P02443028A0695 |83 94|reperfusion000 Pharmac
P02443028A0695 |54 77|muscle microvasculaturend 5-nucleotidase P0000
P02443924A0083 |81 87|cancerT0000 
P02443924A0083 |104 112|survivalects of 
P02443924A0083 |8 16|patients6T0076 C
P02444507A0240 |0 17|Lysozyme activityP00001606T0076 Co
P02444507A0240 |77 81|sera8171
P02444507A0240 |100 108|patients aspects
P02445751A0925 |85 103|cytochrome oxidase0 Pharmacologic as
P02445751A0925 |62 67|mRNAsleoti
P02445751A0925 |146 150|type8997
P02445751A0925 |160 171|hem2 mutant CSF [HCO3-
P02445751A0925 |72 79|subunitP000081
P02445751A0925 |46 58|state levelsatases and 5
P02445751A0925 |112 124|beta subunitneonatal hyp
P02445751A0925 |128 137|F1 ATPaselirubinem
P02445751A0925 |19 31|measurementsarison with 
P02446871A1021 |97 106|LSU rRNAsgic aspec
P02446871A1021 |12 21|structure76 Compar
P02446871A1021 |165 168|end[HC
P02446871A1021 |134 143|structurenemia. P0
P02446871A1021 |111 119|contrast neonata
P02446871A1021 |56 62|region 5-nuc
P02446871A1021 |178 187|moleculesown as a 
P02449431A1121 |0 22|ATP gamma S inhibitionP00001606T0076 Compari
P02449431A1121 |76 82|araATP08171T
P02449431A1121 |47 61|concentrationstases and 5-nu
P02449431A1121 |70 74|dATPe P0
P02449431A1121 |65 68|ATPtid
P02449431A1121 |87 92|ddATPPharm
P02451872A0391 |4 12|recovery01606T00
P02451872A0391 |25 40|methoxydextrane with alkaline 
P02451872A0391 |52 53|% 
P02452313A0114 |254 256|M.la
P02452313A0114 |245 246|Xn
P02452313A0114 |215 223|ASL-8123a of K-d
P02452313A0114 |89 111|guinea pig right atriaarmacologic aspects of
P02452313A0114 |157 165|activityhen CSF 
P02452313A0114 |231 232|Xr
P02452313A0114 |197 211|concentrationsf CSF PCO2 the
P02452313A0114 |59 76|blocking activitynucleotidase P000
P02452313A0114 |0 8|ASL-8123P0000160
P02452313A0114 |187 193|tissuefuncti
P02452313A0114 |119 122|pA2l h
P02454390T0000 |0 8|EnhancerP0000160
P02454390T0000 |89 113|alpha 1-fetoprotein genearmacologic aspects of n
P02454390T0000 |13 30|promoter elements6 Comparison with
P02454390T0000 |56 81|glucocorticoid repression 5-nucleotidase P00008171
P02454390T0000 |41 51|activationhosphatase
P02454390T0000 |117 128|hepatocytestal hyperbi
P02454976A0944 |262 267|gyrusen co
P02454976A0944 |195 200|gyrus of C
P02454976A0944 |224 229|areasplete
P02454976A0944 |15 22|resultsCompari
P02454976A0944 |271 279|primatesed to co
P02454976A0944 |149 158|divisions7A0472 Wh
P02454976A0944 |132 143|possibilitybinemia. P0
P02454976A0944 |47 54|systemstases a
P02454976A0944 |111 114|cat ne
P02454976A0944 |26 34|relationwith alk
P02454976A0944 |98 103|gyrusic as
P02455821A0099 |87 90|mapPha
P02455821A0099 |125 134|UL regionrbilirubi
P02455821A0099 |44 83|AccI-EcoRI restriction fragment mappingphatases and 5-nucleotidase P00008171T0
P02455821A0099 |142 154|EHV-1 genome00008997A047
P02455821A0099 |179 184|rightwn as
P02455821A0099 |4 8|gene0160
P02456827A0899 |102 105|TEAspe
P02456827A0899 |40 48|decreasephosphat
P02456827A0899 |109 112|Ba2of 
P02456827A0899 |15 17|mMCo
P02456827A0899 |64 72|activityotidase 
P02456827A0899 |4 8|4-AP0160
P02456827A0899 |19 25|effectarison
P02457922A0991 |0 13|HybridizationP00001606T007
P02457922A0991 |96 103|tissuesogic as
P02457922A0991 |197 201|sizef CS
P02457922A0991 |125 137|2.8-kilobaserbilirubinem
P02457922A0991 |61 66|blotscleot
P02457922A0991 |19 24|probeariso
P02457922A0991 |191 193|kbti
P02457922A0991 |173 178|bandsis sh
P02457922A0991 |143 150|message0008997
P02457922A0991 |139 141|kb. 
P02457922A0991 |70 74|RNAse P0
P02457922A0991 |35 41|regionline p
P02458080T0000 |0 9|PrognosisP00001606
P02458080T0000 |35 42|myelomaline ph
P02458234T0000 |34 42|analysisaline ph
P02458234T0000 |89 103|EEG recordingsarmacologic as
P02458234T0000 |46 60|sleep spindlesatases and 5-n
P02458234T0000 |6 12|method606T00
P02458699A0650 |0 8|SvenssonP0000160
P02459309T0000 |102 105|ratspe
P02459309T0000 |79 94|caudate-putamen71T0000 Pharmac
P02459309T0000 |11 18|release076 Com
P02459309T0000 |135 143|dialysisemia. P0
P02459309T0000 |31 40|serotoninalkaline 
P02459309T0000 |212 221|detectiondata of K
P02459309T0000 |179 193|chromatographywn as a functi
P02459309T0000 |67 71|aciddase
P02461368A0162 |118 128|sequencingal hyperbi
P02461368A0162 |41 45|timehosp
P02461368A0162 |106 113|cloningts of n
P02461368A0162 |149 152|DNA7A0
P02461368A0162 |132 136|cDNAbine
P02461368A0162 |67 76|structuredase P000
P02461368A0162 |8 14|report6T0076
P02461368A0162 |80 95|type X collagen1T0000 Pharmaco
P02462047A0208 |103 107|veinpect
P02462047A0208 |123 126|dayper
P02462047A0208 |7 17|flap areas06T0076 Co
P02462047A0208 |93 99|arterycologi
P02462047A0208 |77 84|vessels8171T00
P02462047A0208 |133 150|flap replantationinemia. P00008997
P02462047A0208 |54 70|pedicle ligationnd 5-nucleotidas
P02462047A0208 |159 165|islandn CSF 
P02462047A0208 |175 180|flaps show
P02462305A1071 |35 48|glycosylationline phosphat
P02462305A1071 |52 67|phosphorylation and 5-nucleoti
P02462305A1071 |111 119|sequence neonata
P02462305A1071 |141 152|polypeptideP00008997A0
P02462305A1071 |4 20|size discrepancy01606T0076 Compa
P02462305A1071 |71 75|Ag35 P00
P02462523A0394 |138 147|phenotypea. P00008
P02462523A0394 |74 76|Hw00
P02462523A0394 |43 54|DNA changessphatases a
P02462523A0394 |9 27|KpnI-SalI fragmentT0076 Comparison w
P02462523A0394 |78 87|mutations171T0000 
P02462523A0394 |124 126|suer
P02462523A0394 |173 197|germ-line transformationis shown as a function o
P02462523A0394 |127 129|Hwil
P02462523A0394 |71 73|su P
P02463050A0514 |101 115|corticosteroneaspects of neo
P02463050A0514 |147 152|males997A0
P02463050A0514 |121 126|levelhyper
P02463050A0514 |54 59|mg/kgnd 5-
P02463050A0514 |93 97|risecolo
P02463050A0514 |4 49|corticosterone synthesis inhibitor metyrapone01606T0076 Comparison with alkaline phosphata
P02464097T0000 |137 148|arrhythmiasia. P000089
P02464097T0000 |95 103|ischemialogic as
P02464097T0000 |15 19|L655Comp
P02464097T0000 |53 90|prostaglandin endoperoxide antagonistand 5-nucleotidase P00008171T0000 Pha
P02464097T0000 |37 48|thromboxanene phosphat
P02464097T0000 |4 11|effects01606T0
P02466414A0000 |139 144|steps. P00
P02466414A0000 |176 178|mlsh
P02466414A0000 |148 168|exchange transfusion97A0472 When CSF [HC
P02466414A0000 |182 188|plasmaas a f
P02466414A0000 |243 246|mollon
P02466414A0000 |30 46|plasma viscosity alkaline phosph
P02466414A0000 |87 102|blood viscosityPharmacologic a
P02466414A0000 |48 50|Epas
P02466414A0000 |261 269|% wt/volhen comp
P02466414A0000 |24 28|dogsn wi
P02466414A0000 |104 106|Eaec
P02466414A0000 |194 200|plasman of C
P02466414A0000 |227 241|weight dextranted rats are n
P02466665A0202 |22 29|proteinson wit
P02466665A0202 |60 65|fluiducleo
P02468795A1086 |102 103|rs
P02468795A1086 |70 81|correlatione P00008171
P02468795A1086 |146 155|parameter8997A0472
P02468795A1086 |16 39|acid phosphatase levelsomparison with alkaline
P02468795A1086 |87 100|cancer volumePharmacologic
P02468795A1086 |0 5|SerumP0000
P02469451A0239 |4 17|investigation01606T0076 Co
P02469451A0239 |91 98|mg dosemacolog
P02469451A0239 |143 151|subjects0008997A
P02469451A0239 |106 130|MAO-B inhibitor deprenylts of neonatal hyperbili
P02469451A0239 |54 61|fashionnd 5-nu
P02470955A0101 |55 70|CSF AP activityd 5-nucleotidas
P02470955A0101 |43 51|increasesphatase
P02470955A0101 |83 95|meningitides000 Pharmaco
P02470955A0101 |6 13|studies606T007
P02470955A0101 |114 126|meningitidesonatal hyper
P02473156A0000 |152 169|adhesion proteins472 When CSF [HCO
P02473156A0000 |28 60|lymphocyte cell surface moleculeth alkaline phosphatases and 5-n
P02473156A0000 |142 148|family000089
P02473156A0000 |110 116|memberf neon
P02473156A0000 |2 6|cDNA0001
P02473198A0613 |0 8|DopamineP0000160
P02473198A0613 |63 69|effluxeotida
P02473198A0613 |107 113|effects of n
P02473198A0613 |28 44|potassium effluxth alkaline phos
P02473198A0613 |128 134|glandslirubi
P02473198A0613 |57 61|86Rb5-nu
P02473198A0613 |83 89|glands000 Ph
P02473619A0202 |186 195|reactions function
P02473619A0202 |73 88|control animals00008171T0000 P
P02473619A0202 |44 53|chemicalsphatases 
P02473619A0202 |231 239|exposurerats are
P02473619A0202 |59 69|proportionnucleotida
P02473619A0202 |213 221|blockersata of K
P02473619A0202 |12 25|sensitization76 Comparison
P02473619A0202 |141 154|sensitizationP00008997A047
P02473619A0202 |158 166|patientsen CSF [
P02473619A0202 |253 267|IgE antibodiesplaced when co
P02473693A0174 |5 13|approach1606T007
P02473693A0174 |47 54|proteintases a
P02473693A0174 |56 62|HGB F. 5-nuc
P02473718A0000 |71 82|metabolites P00008171T
P02473718A0000 |100 113|catecholamine aspects of n
P02473718A0000 |369 374|yearsazepa
P02473718A0000 |42 54|relationshiposphatases a
P02473718A0000 |314 322|subjectsly great
P02473718A0000 |167 179|T-suppressorCO3-] is sho
P02473718A0000 |356 359|age943
P02473718A0000 |254 260|femalelaced 
P02473718A0000 |115 121|5-HIAAnatal 
P02473718A0000 |294 300|stressl have
P02473718A0000 |126 129|VMAbil
P02473718A0000 |242 250|subjects longer 
P02473718A0000 |181 185|OKT8 as 
P02473718A0000 |221 226|cells-depl
P02473718A0000 |327 335|subjectsope (1.2
P02473718A0000 |86 95|serotonin Pharmaco
P02473718A0000 |159 163|OKT4n CS
P02473718A0000 |264 268|male com
P02473718A0000 |270 273|agered
P02473718A0000 |149 157|T-helper7A0472 W
P02473718A0000 |283 288|yearsls bu
P02473718A0000 |350 354|maleP000
P02473718A0000 |132 139|T-cellsbinemia
P02473718A0000 |192 199|B-cellsion of 
P02473718A0000 |4 17|investigation01606T0076 Co
P02473718A0000 |339 345|female- 0.23
P02473718A0000 |141 145|OKT3P000
P02473907A1338 |204 208|siteCO2 
P02473907A1338 |183 195|Fc epsilon Rs a function
P02473907A1338 |8 13|C mAb6T007
P02473907A1338 |128 132|siteliru
P02473907A1338 |27 31|siteith 
P02473907A1338 |79 91|Fc epsilon R71T0000 Phar
P02473907A1338 |35 38|IgElin
P02473907A1338 |100 104|site asp
P02473907A1338 |136 139|IgEmia
P02473942A1207 |18 23|plotsparis
P02473942A1207 |76 84|segments08171T00
P02473942A1207 |115 137|transmembrane segmentsnatal hyperbilirubinem
P02474093T0000 |0 11|AngiotensinP00001606T0
P02474093T0000 |131 138|effectsubinemi
P02474093T0000 |23 40|enzyme inhibitorson with alkaline 
P02474093T0000 |82 91|diuretics0000 Phar
P02474093T0000 |70 78|efficacye P00008
P02474110A1039 |100 118|inhibitor ramipril aspects of neonat
P02474110A1039 |44 58|blood pressurephatases and 5
P02474110A1039 |31 40|reductionalkaline 
P02474110A1039 |241 257|echocardiographyo longer displac
P02474110A1039 |140 150|regression P00008997
P02474110A1039 |219 236|resonance imaging K-depleted rats 
P02474110A1039 |95 98|ACElog
P02474110A1039 |182 193|hypertrophyas a functi
P02474110A1039 |3 11|addition001606T0
P02474110A1039 |64 75|angiotensinotidase P00
P02474110A1039 |87 93|enzymePharma
P02474204A0105 |32 37|meanslkali
P02474204A0105 |41 50|Grimeliushosphatas
P02474204A0105 |72 86|immunostainingP00008171T0000
P02474204A0105 |135 140|cellsemia.
P02474204A0105 |91 103|chromograninmacologic as
P02474204A0105 |59 67|stainingnucleoti
P02474204A0105 |10 15|cells0076 
P02474204A0105 |115 121|markernatal 
P02474356A0559 |68 75|N ratioase P00
P02474356A0559 |165 176|circulation[HCO3-] is 
P02474356A0559 |30 36|tumour alkal
P02474356A0559 |145 151|portal08997A
P02474356A0559 |58 64|tissue-nucle
P02474356A0559 |123 135|microspheresperbilirubin
P02474356A0559 |13 26|radioactivity6 Comparison 
P02474356A0559 |4 9|ratio01606
P02474356A0559 |66 67|Ti
P02474356A0559 |185 191|animala func
P02475506A0878 |4 8|mRNA0160
P02475506A0878 |26 30|cDNAwith
P02475506A0878 |52 87|polymerase chain reaction technique and 5-nucleotidase P00008171T0000 
P02475717A0565 |0 15|Tissue necrosisP00001606T0076 
P02475717A0565 |36 65|triphenyltetrazolium stainingine phosphatases and 5-nucleo
P02475717A0565 |95 114|baseline predictorslogic aspects of ne
P02475717A0565 |169 184|collateral flow3-] is shown as
P02475717A0565 |141 155|risk zone sizeP00008997A0472
P02475717A0565 |118 130|infarct sizeal hyperbili
P02476030A0000 |84 109|laser scanning tomography00 Pharmacologic aspects 
P02476030A0000 |21 28|surfaceison wi
P02476030A0000 |42 45|eyeosp
P02476030A0000 |69 75|statesse P00
P02476664A0563 |69 71|D.se
P02476664A0563 |28 36|sequenceth alkal
P02476664A0563 |44 48|genephat
P02476664A0563 |64 67|K14oti
P02477373A0930 |68 97|transcription initiation sitease P00008171T0000 Pharmacolo
P02477373A0930 |12 20|TATA box76 Compa
P02477373A0930 |35 45|base pairsline phosp
P02479635A0659 |0 14|CotransfectionP00001606T0076
P02479635A0659 |58 61|PKI-nu
P02479635A0659 |40 48|plasmidsphosphat
P02479635A0659 |25 34|construct with alk
P02479635A0659 |111 118|phorbol neonat
P02479635A0659 |136 146|expressionmia. P0000
P02479823A0727 |0 17|Sequence analysisP00001606T0076 Co
P02479823A0727 |61 69|GC boxescleotida
P02479823A0727 |90 98|TATA boxrmacolog
P02479823A0727 |37 43|regionne pho
P02480419A0735 |84 95|hepatitis B00 Pharmaco
P02480419A0735 |104 113|infectionects of n
P02480419A0735 |15 24|cirrhosisCompariso
P02480419A0735 |76 77|%0
P02480419A0735 |132 133|%b
P02480419A0735 |50 51|%e
P02480959A0470 |35 46|consequenceline phosph
P02480959A0470 |132 136|daysbine
P02480959A0470 |180 193|gonadotropinsn as a functi
P02480959A0470 |61 66|surgecleot
P02480959A0470 |113 118|cellseonat
P02480959A0470 |267 271|cAMPmpar
P02480959A0470 |213 223|modulationata of K-d
P02480959A0470 |227 236|prolactinted rats 
P02480959A0470 |156 160|daysWhen
P02480959A0470 |5 18|P-450scc mRNA1606T0076 Com
P02480959A0470 |169 176|absence3-] is 
P02481230A1258 |69 77|placentase P0000
P02481230A1258 |29 51|bovine alpha transgeneh alkaline phosphatase
P02481230A1258 |92 96|miceacol
P02481429T0000 |8 26|staining technique6T0076 Comparison 
P02481429T0000 |31 51|Leishmania parasitesalkaline phosphatase
P02481429T0000 |72 78|smearsP00008
P02481779A0213 |0 7|NIK-244P000016
P02481779A0213 |291 301|mg/kg i.v.till have 
P02481779A0213 |219 229|mg/kg i.v. K-deplete
P02481779A0213 |125 136|arrhythmiasrbilirubine
P02481779A0213 |28 36|ligationth alkal
P02481779A0213 |331 335|mean(1.2
P02481779A0213 |60 71|arrhythmiasucleotidase
P02481779A0213 |303 315|microgram/mlsignificantl
P02481779A0213 |350 354|meanP000
P02481779A0213 |356 357|n9
P02481779A0213 |184 193|digitalis a functi
P02481779A0213 |252 262|mg/kg i.v.splaced wh
P02481779A0213 |340 342|SD 0
P02481779A0213 |99 120|plasma concentrationsc aspects of neonatal
P02481779A0213 |171 179|ligation] is sho
P02482293A1518 |119 122|EGFl h
P02482293A1518 |178 186|activityown as a
P02482293A1518 |127 140|phorbol esterilirubinemia.
P02482293A1518 |46 49|TNFata
P02482293A1518 |194 202|receptorn of CSF
P02482293A1518 |66 104|EGF-R tyrosine protein kinase activityidase P00008171T0000 Pharmacologic asp
P02482293A1518 |212 217|cellsdata 
P02482293A1518 |17 44|T24 bladder carcinoma cellsmparison with alkaline phos
P02482511A0860 |153 172|withdrawal syndrome72 When CSF [HCO3-]
P02482511A0860 |109 116|stimuliof neon
P02482511A0860 |121 132|weight losshyperbiliru
P02482511A0860 |75 83|syndrome008171T0
P02482511A0860 |6 34|phosphodiesterase inhibitors606T0076 Comparison with alk
P02482511A0860 |189 199|naltrexonenction of 
P02482511A0860 |222 226|ratsdepl
P02483210A0000 |69 76|trypsinse P000
P02483210A0000 |57 63|lipase5-nucl
P02483210A0000 |105 127|relapsing pancreatitiscts of neonatal hyperb
P02483210A0000 |15 20|valueCompa
P02483210A0000 |80 93|exacerbations1T0000 Pharma
P02483210A0000 |24 35|blood serumn with alka
P02483210A0000 |48 55|amylaseases an
P02483438A0498 |33 39|actionkaline
P02483438A0498 |7 12|basis06T00
P02483438A0498 |90 118|phosphodiesterase inhibitorsrmacologic aspects of neonat
P02483438A0498 |45 51|groupshatase
P02483438A0498 |140 146|agents P0000
P02483438A0498 |20 29|mechanismrison wit
P02483438A0498 |55 66|inodilatorsd 5-nucleot
P02484714T0000 |11 23|organization076 Comparis
P02484714T0000 |28 38|expressionth alkalin
P02484714T0000 |46 69|mouse estrogen receptoratases and 5-nucleotida
P02484994T0001 |12 27|gamma globulins76 Comparison w
P02485188A0415 |103 119|dermatan sulfatepects of neonata
P02485188A0415 |158 159|pe
P02485188A0415 |260 266|levelswhen c
P02485188A0415 |93 99|levelscologi
P02485188A0415 |56 65|reactions 5-nucleo
P02485188A0415 |270 290|chondroitin sulfatesred to controls but 
P02485188A0415 |151 156|group0472 
P02485188A0415 |303 311|diabetessignific
P02485188A0415 |228 236|diabetesed rats 
P02485188A0415 |132 140|diabetesbinemia.
P02485188A0415 |318 323|groupreate
P02485188A0415 |325 326|ps
P02485188A0415 |10 27|chondroitinase AC0076 Comparison w
P02485188A0415 |198 199|p 
P02485188A0415 |32 45|ABC digestionlkaline phosp
P02486634A0632 |152 174|collateral development472 When CSF [HCO3-] i
P02486634A0632 |127 137|morphologyilirubinem
P02486634A0632 |59 64|levelnucle
P02486634A0632 |11 20|perfusion076 Compa
P02486634A0632 |99 104|levelc asp
P02486634A0632 |142 148|degree000089
P02486634A0632 |71 89|contrast injection P00008171T0000 Ph
P02487898A0315 |87 91|waysPhar
P02487898A0315 |95 113|NGF administrationlogic aspects of n
P02487898A0315 |5 23|NGF administration1606T0076 Comparis
P02488148A1156 |50 57|programes and 
P02488148A1156 |79 88|diagnosis71T0000 P
P02488148A1156 |11 18|program076 Com
P02488148A1156 |107 108|%s
P02488148A1156 |116 120|timeatal
P02488148A1156 |21 24|useiso
P02488148A1156 |32 44|RSNA meetinglkaline phos
P02489032A0000 |220 229|VL regionK-deplete
P02489032A0000 |63 70|chickeneotidas
P02489032A0000 |149 162|gene segments7A0472 When C
P02489032A0000 |28 31|IgLth 
P02489032A0000 |74 87|recombination0008171T0000 
P02489032A0000 |33 42|diversitykaline ph
P02489032A0000 |21 26|chainison 
P02489032A0000 |145 147|JL08
P02489032A0000 |128 130|VLli
P02489032A0000 |0 14|ImmunoglobulinP00001606T0076
P02489032A0000 |118 126|variableal hyper
P02489032A0000 |186 201|diversification function of CS
P02489753A0581 |49 61|EMG activityses and 5-nu
P02489753A0581 |114 122|positiononatal h
P02489753A0581 |65 73|FB grouptidase P
P02489753A0581 |147 155|GF group997A0472
P02489753A0581 |180 188|positionn as a f
P02489753A0581 |4 11|results01606T0
P02489753A0581 |140 142|CG P
P02489753A0581 |168 176|positionO3-] is 
P02489895T0001 |0 13|Muscle actionP00001606T007
P02489895T0001 |105 111|adultscts of
P02489895T0001 |92 100|childrenacologic
P02489895T0001 |40 46|rhythmphosph
P02489895T0001 |81 88|musclesT0000 P
P02492111A0670 |34 50|bone lead valuesaline phosphatas
P02492111A0670 |63 67|LXRFeoti
P02492111A0670 |24 32|childrenn with a
P02492111A0670 |148 154|adults97A047
P02492111A0670 |5 6|%1
P02492111A0868 |170 176|safety-] is 
P02492111A0868 |160 166|margin CSF [
P02492111A0868 |193 199|safetyon of 
P02492111A0868 |105 112|resultscts of 
P02492111A0868 |53 61|childrenand 5-nu
P02492111A0868 |42 49|effectsosphata
P02492111A0868 |267 291|blood lead concentrationmpared to controls but s
P02492111A0868 |298 311|micrograms/dlve a signific
P02492111A0868 |223 238|U.S. guidelinesepleted rats ar
P02492111A0868 |81 89|exposureT0000 Ph
P02492111A0868 |70 76|levelse P000
P02493644A0588 |71 76|c-jun P000
P02493644A0588 |53 58|leveland 5
P02493644A0588 |22 27|jun-Dson w
P02493644A0588 |11 20|3T3 cells076 Compa
P02493644A0588 |81 86|jun-BT0000
P02493644A0588 |96 109|transcriptionogic aspects 
P02493644A0588 |141 161|serum growth factorsP00008997A0472 When 
P02495745T0000 |17 24|effectsmpariso
P02495745T0000 |70 76|AK-124e P000
P02495745T0000 |110 120|thrombosisf neonatal
P02495745T0000 |35 68|tissue-type plasminogen activatorline phosphatases and 5-nucleotid
P02496090A0252 |18 35|tracheostomy tubeparison with alka
P02496090A0252 |7 10|CO206T
P02496090A0252 |126 144|sampling techniquebilirubinemia. P00
P02496090A0252 |67 84|mass spectrometrydase P00008171T00
P02496100T0000 |48 60|aflatoxin B1ases and 5-n
P02496100T0000 |28 33|assayth al
P02496100T0000 |114 119|studyonata
P02496100T0000 |94 98|feedolog
P02496100T0000 |64 83|cottonseed productsotidase P00008171T0
P02496109A0754 |307 313|regionifican
P02496109A0754 |48 59|transcriptsases and 5-
P02496109A0754 |355 367|L17 interval0943A0733 Fl
P02496109A0754 |335 340|genes1 +/-
P02496109A0754 |26 36|S1 mappingwith alkal
P02496109A0754 |61 77|gene disruptionscleotidase P0000
P02496109A0754 |181 190|promoters as a fun
P02496109A0754 |348 351|IF1. P
P02496109A0754 |133 146|fusion vectorinemia. P0000
P02496109A0754 |85 97|alpha region0 Pharmacolo
P02496109A0754 |255 263|promoteraced whe
P02496109A0754 |232 238|growthats ar
P02496109A0754 |9 20|experimentsT0076 Compa
P02496109A0754 |272 284|alpha operond to control
P02497340A0989 |101 103|Vkas
P02497340A0989 |56 58|JH 5
P02497340A0989 |72 84|chain probesP00008171T00
P02497340A0989 |63 65|VHeo
P02497340A0989 |110 122|chain probesf neonatal h
P02497340A0989 |94 96|Jkol
P02497340A0989 |22 36|antibody genesson with alkal
P02498322A0226 |117 138|oligonucleotide probetal hyperbilirubinemi
P02498322A0226 |25 34|complexes with alk
P02498322A0226 |164 170|region [HCO3
P02498322A0226 |54 76|gel retardation assaysnd 5-nucleotidase P000
P02498322A0226 |83 92|HeLa cell000 Pharm
P02498322A0226 |101 109|extractsaspects 
P02498652A0460 |6 18|transfection606T0076 Com
P02498652A0460 |29 55|TSH beta promoter activityh alkaline phosphatases an
P02498652A0460 |135 148|cell culturesemia. P000089
P02498652A0460 |109 112|GH3of 
P02500432A1416 |100 103|DNA as
P02500432A1416 |140 147|segment P00008
P02500432A1416 |203 211|CAT genePCO2 the
P02500432A1416 |37 51|CAT expressionne phosphatase
P02500432A1416 |88 96|kilobaseharmacol
P02500432A1416 |190 195|frontction
P02500432A1416 |175 186|orientation shown as a
P02500432A1416 |116 119|endata
P02502096A0462 |67 86|excretion processesdase P00008171T0000
P02502096A0462 |22 32|blood flowson with a
P02502602A0323 |0 9|TonometryP00001606
P02502602A0323 |82 102|acid-base quantities0000 Pharmacologic a
P02502602A0323 |125 133|affinityrbilirub
P02502602A0323 |13 26|blood samples6 Comparison 
P02502602A0323 |32 40|patientslkaline 
P02502602A0323 |65 78|determinationtidase P00008
P02502602A0323 |139 142|p50. P
P02502960A0762 |11 13|p.07
P02504603T0000 |0 9|IsolationP00001606
P02504603T0000 |40 53|CDC group IIfphosphatases 
P02504603T0000 |13 29|Weeksella virosa6 Comparison wit
P02504603T0000 |70 76|samplee P000
P02505087A1037 |19 43|dimerization specificityarison with alkaline pho
P02505087A1037 |78 92|leucine zipper171T0000 Pharm
P02505087A1037 |47 50|Fostas
P02505087A1037 |108 112|GCN4 of 
P02506390T0001 |0 6|GrowthP00001
P02506390T0001 |42 49|animalsosphata
P02506390T0001 |19 30|anastomosesarison with
P02506740A0742 |34 39|hoursaline
P02506740A0742 |43 51|recoverysphatase
P02506740A0742 |98 105|hypoxiaic aspe
P02506740A0742 |80 86|effect1T0000
P02506740A0742 |118 128|blood flowal hyperbi
P02507523A0791 |34 44|competencealine phos
P02507523A0791 |52 56|ORF2 and
P02507523A0791 |131 142|amino acidsubinemia. P
P02507523A0791 |116 123|proteinatal hy
P02507523A0791 |4 16|ORF1 product01606T0076 C
P02507523A0791 |87 91|ORF1Phar
P02507815A0000 |85 89|cats0 Ph
P02507815A0000 |31 37|cortexalkali
P02507815A0000 |39 41|VC p
P02507815A0000 |73 81|amygdala00008171
P02507815A0000 |0 8|KindlingP0000160
P02508306A0528 |87 96|carcinomaPharmacol
P02508306A0528 |133 142|folliclesinemia. P
P02508306A0528 |9 21|infiltrationT0076 Compar
P02508306A0528 |41 53|plasma cellshosphatases 
P02508306A0528 |25 36|lymphocytes with alkal
P02508726A0498 |35 43|evidenceline pho
P02508726A0498 |113 121|behavioreonatal 
P02508726A0498 |299 305|agentse a si
P02508726A0498 |89 98|treatmentarmacolog
P02508726A0498 |270 281|conjunctionred to cont
P02508726A0498 |210 223|neurotoxicitye data of K-d
P02508726A0498 |232 242|populationats are no
P02508726A0498 |196 205|potentialof CSF PC
P02508726A0498 |49 54|LiCO3ses a
P02508726A0498 |154 166|brain injury2 When CSF [
P02508726A0498 |71 81|medication P00008171
P02508726A0498 |6 18|case reports606T0076 Com
P02508726A0498 |136 147|instabilitymia. P00008
P02509123A0371 |68 71|VEPase
P02509123A0371 |46 60|P100 componentatases and 5-n
P02509123A0371 |31 38|latencyalkalin
P02509123A0371 |22 25|IFNson
P02509123A0371 |7 15|sessions06T0076 
P02509123A0371 |101 120|baseline conditionsaspects of neonatal
P02510242A0313 |103 109|searchpects 
P02510242A0313 |208 213|teststhe d
P02510242A0313 |36 45|hepatitisine phosp
P02510242A0313 |232 239|virusesats are
P02510242A0313 |10 15|cases0076 
P02510242A0313 |160 167|viruses CSF [H
P02510242A0313 |114 120|HBs Agonatal
P02510242A0313 |65 82|hepatitis B virustidase P00008171T
P02510242A0313 |251 254|CMVisp
P02511069A0532 |17 26|mutationsmparison 
P02511069A0532 |104 106|3Lec
P02511069A0532 |160 185|polytene chromosome bands CSF [HCO3-] is shown as 
P02511069A0532 |130 140|DRE regionrubinemia.
P02511069A0532 |107 110|RR2s o
P02511069A0532 |88 97|lethalityharmacolo
P02511069A0532 |114 122|deletiononatal h
P02511069A0532 |52 59|failure and 5-
P02511069A0532 |101 103|Dfas
P02511150T0025 |8 14|status6T0076
P02511150T0025 |26 38|perspectiveswith alkalin
P02511207A0282 |0 2|K.P0
P02511430A0000 |171 178|factors] is sh
P02511430A0000 |21 27|regionison w
P02511430A0000 |67 95|immunoglobulin gene enhancerdase P00008171T0000 Pharmaco
P02511430A0000 |127 134|bindingilirubi
P02511430A0000 |35 45|mouse MOPCline phosp
P02511430A0000 |49 54|kappases a
P02511430A0000 |17 19|bpmp
P02511898A0000 |55 69|Chagas diseased 5-nucleotida
P02511898A0000 |24 31|reasonsn with 
P02511898A0000 |36 45|countriesine phosp
P02511898A0000 |111 119|research neonata
P02511898A0000 |5 10|paper1606T
P02512010A0801 |98 104|returnic asp
P02512010A0801 |41 52|compressionhosphatases
P02512010A0801 |120 131|circulation hyperbilir
P02512010A0801 |67 74|successdase P0
P02512010A0801 |78 92|defibrillation171T0000 Pharm
P02512010A0801 |4 22|PETCO2 measurement01606T0076 Compari
P02514498A0000 |187 208|Henderson-Hasselbalchfunction of CSF PCO2 
P02514498A0000 |8 16|CO2/HCO36T0076 C
P02514498A0000 |73 87|acid secretion00008171T0000 
P02514498A0000 |210 214|pCO2e da
P02514498A0000 |91 96|intramacol
P02514498A0000 |233 236|usets 
P02514498A0000 |142 149|persons0000899
P02514498A0000 |246 255|electrodeger displ
P02514498A0000 |59 69|inhibitionnucleotida
P02514498A0000 |175 183|equation shown a
P02514498A0000 |115 135|pCO2/pH measurementsnatal hyperbilirubin
P02514498A0000 |35 42|absenceline ph
P02515953A0459 |50 63|effectivenesses and 5-nucl
P02515953A0459 |25 26|% 
P02515953A0459 |10 15|study0076 
P02515953A0459 |36 44|patientsine phos
P02517008A0481 |33 38|trialkalin
P02517008A0481 |57 62|doses5-nuc
P02517008A0481 |10 18|patients0076 Com
P02517008A0481 |66 77|monotherapyidase P0000
P02518645T0001 |71 75|life P00
P02518645T0001 |9 23|Chagas diseaseT0076 Comparis
P02518645T0001 |63 67|yeareoti
P02518645T0001 |25 45|laboratory diagnosis with alkaline phosp
P02518691A0251 |220 230|regulationK-depleted
P02518691A0251 |180 196|kappa B enhancern as a function 
P02518691A0251 |14 44|IL2R alpha promoter constructs Comparison with alkaline phos
P02518691A0251 |75 93|DNA binding assays008171T0000 Pharma
P02518691A0251 |234 260|IL2R alpha gene expressions are no longer displaced 
P02518691A0251 |58 70|transfection-nucleotidas
P02518691A0251 |119 128|sequencesl hyperbi
P02519327T0001 |12 22|rheumatism76 Compari
P02519679T0000 |0 10|InefficacyP00001606T
P02519679T0000 |14 34|phosphine fumigation Comparison with alk
P02519679T0000 |43 48|tickssphat
P02520622A0200 |103 111|symptomspects of
P02520622A0200 |167 174|placeboCO3-] i
P02520622A0200 |225 237|group designleted rats a
P02520622A0200 |74 87|transit times0008171T0000 
P02520622A0200 |181 186|month as a
P02520622A0200 |6 14|patients606T0076
P02520622A0200 |131 150|cimetropium bromideubinemia. P00008997
P02520622A0200 |154 163|mg t.d.s.2 When CS
P02521217A1035 |51 59|ribosomes and 5-
P02521217A1035 |64 82|membrane fractionsotidase P00008171T
P02521217A1035 |27 34|proteinith alk
P02521217A1035 |86 98|mitochondria Pharmacolog
P02521674T0000 |0 7|MappingP000016
P02521674T0000 |112 116|nsP4neon
P02521674T0000 |57 62|virus5-nuc
P02521674T0000 |11 14|RNA076
P02521674T0000 |64 95|complementation group F mutantsotidase P00008171T0000 Pharmaco
P02521674T0000 |38 45|mutantse phosp
P02521674T0000 |101 108|lesionsaspects
P02522297A0000 |34 38|TXA2alin
P02522297A0000 |40 86|prostaglandin endoperoxide receptor antagonistphosphatases and 5-nucleotidase P00008171T0000
P02522297A0000 |167 171|dogsCO3-
P02522297A0000 |88 90|SQha
P02522297A0000 |18 32|thromboxane A2parison with a
P02522297A0000 |4 10|effect01606T
P02522297A0000 |116 124|ischemiaatal hyp
P02523800A1178 |174 187|BAR1 promoters shown as a 
P02523800A1178 |43 52|CHS1 genesphatases
P02523800A1178 |199 201|J.CS
P02523800A1178 |95 121|TGAAACA consensus sequencelogic aspects of neonatal 
P02523800A1178 |27 35|sequenceith alka
P02523800A1178 |82 89|repeats0000 Ph
P02523800A1178 |59 67|fragmentnucleoti
P02523800A1178 |189 197|Kronstadnction o
P02525044A1026 |71 79|patients P000081
P02525044A1026 |127 140|suxamethoniumilirubinemia.
P02525044A1026 |93 103|mivacuriumcologic as
P02525044A1026 |39 47|infusion phospha
P02525044A1026 |20 27|T25-T75rison w
P02525044A1026 |4 18|recovery index01606T0076 Com
P02526165X0000 |4 8|sign0160
P02526165X0000 |12 24|Leser-Trelat76 Compariso
P02526165X0000 |45 49|signhata
P02526165X0000 |129 139|malignancyirubinemia
P02526165X0000 |110 116|markerf neon
P02526165X0000 |53 65|Leser-Trelatand 5-nucleo
P02527365T0000 |0 15|Xenopus homologP00001606T0076 
P02527365T0000 |62 73|fibroblastsleotidase P
P02527365T0000 |86 96|maturation Pharmacol
P02527365T0000 |23 40|mos protooncogeneon with alkaline 
P02527365T0000 |100 115|Xenopus oocytes aspects of neo
P02527745A0865 |0 22|Southern blot analysesP00001606T0076 Compari
P02527745A0865 |79 83|gene71T0
P02527745A0865 |88 100|conservationharmacologic
P02527745A0865 |125 136|vertebratesrbilirubine
P02527745A0865 |109 115|domainof neo
P02527745A0865 |58 69|copy number-nucleotida
P02528329A0000 |168 175|subunitO3-] is
P02528329A0000 |179 183|genewn a
P02528329A0000 |162 166|uncBSF [
P02528329A0000 |26 33|subunitwith al
P02528329A0000 |60 71|F1F0-ATPaseucleotidase
P02528329A0000 |6 22|missense mutants606T0076 Compari
P02528329A0000 |110 135|hydroxylamine mutagenesisf neonatal hyperbilirubin
P02528329A0000 |141 148|plasmidP000089
P02528730A1073 |87 90|usePha
P02528730A1073 |26 31|sharewith 
P02528730A1073 |107 125|donor splice sitess of neonatal hype
P02528730A1073 |44 52|sequencephatases
P02528730A1073 |10 18|exons 2a0076 Com
P02528730A1073 |130 132|bpru
P02528730A1073 |146 150|gene8997
P02529378A0536 |0 20|S1 nuclease analysisP00001606T0076 Compa
P02529378A0536 |219 226|element K-depl
P02529378A0536 |24 27|RNAn w
P02529378A0536 |177 184|portionhown as
P02529378A0536 |150 158|enhancerA0472 Wh
P02529378A0536 |120 130|adenovirus hyperbili
P02529378A0536 |160 163|SP1 CS
P02529378A0536 |165 169|TATA[HCO
P02529378A0536 |85 95|HeLa cells0 Pharmaco
P02529378A0536 |294 301|HIV LTRl have 
P02529378A0536 |276 286|activation controls 
P02529378A0536 |43 55|transfectionsphatases an
P02529378A0536 |65 79|HIV constructstidase P000081
P02530413A0195 |3 18|supine position001606T0076 Com
P02530413A0195 |67 72|pg/mldase 
P02530413A0195 |90 95|levelrmaco
P02530413A0195 |113 118|pg/mleonat
P02530413A0195 |53 58|pg/mland 5
P02530413A0195 |20 37|plasma ANP levelsrison with alkali
P02530470A0604 |101 105|areaaspe
P02530470A0604 |12 22|prevalence76 Compari
P02530470A0604 |55 68|staff membersd 5-nucleotid
P02530470A0604 |26 37|HBV markerswith alkali
P02530470A0604 |81 93|blood donorsT0000 Pharma
P02531203A0241 |114 124|SSTS modelonatal hyp
P02531203A0241 |56 65|responses 5-nucleo
P02531203A0241 |13 24|predictions6 Compariso
P02531203A0241 |83 92|negatives000 Pharm
P02532032A0385 |0 21|Plasma concentrationsP00001606T0076 Compar
P02532032A0385 |37 48|aldosteronene phosphat
P02532032A0385 |59 64|reninnucle
P02532032A0385 |25 28|ANF wi
P02532032A0385 |30 34|pANF alk
P02532032A0385 |66 69|PRCida
P02532032A0385 |112 122|parametersneonatal h
P02532032A0385 |50 53|PACes 
P02532210A0000 |34 41|proteinaline p
P02532210A0000 |4 23|adenovirus E1A gene01606T0076 Comparis
P02532210A0000 |87 92|genesPharm
P02534067A0316 |0 14|AdministrationP00001606T0076
P02534067A0316 |18 31|dexamethasoneparison with 
P02534067A0316 |293 306|alpha OH DHEAll have a sig
P02534067A0316 |263 278|etiocholanolonen compared to c
P02534067A0316 |83 104|alpha OH progesterone000 Pharmacologic asp
P02534067A0316 |145 160|androstenedione08997A0472 When
P02534067A0316 |211 220|excretion data of 
P02534067A0316 |241 261|beta OH androsteroneo longer displaced w
P02534067A0316 |130 143|DHEA sulphaterubinemia. P0
P02534067A0316 |73 79|plasma000081
P02534067A0316 |165 177|testosterone[HCO3-] is s
P02534067A0316 |224 236|androsteronepleted rats 
P02534067A0316 |280 284|DHEAtrol
P02534067A0316 |109 128|beta-desoxycortisolof neonatal hyperbi
P02534067A0316 |64 69|risesotida
P02535460A1443 |0 15|RNA transcriptsP00001606T0076 
P02535460A1443 |57 61|gene5-nu
P02536096A0327 |258 296|chloramphenicol acetyltransferase gened when compared to controls but still 
P02536096A0327 |211 236|thymidine kinase promoter data of K-depleted rats 
P02536096A0327 |3 13|HeLa cells001606T007
P02536096A0327 |79 104|thymidine kinase promoter71T0000 Pharmacologic asp
P02536096A0327 |183 194|orientations a functio
P02536096A0327 |28 41|transcriptionth alkaline p
P02536096A0327 |51 76|herpes simplex virus types and 5-nucleotidase P000
P02536096A0327 |304 312|sequenceignifica
P02536096A0327 |119 157|chloramphenicol acetyltransferase genel hyperbilirubinemia. P00008997A0472 W
P02536160A0518 |170 178|sequence-] is sh
P02536160A0518 |105 119|CAT expressioncts of neonata
P02536160A0518 |144 151|pUTKAT1008997A
P02536160A0518 |129 140|TK promoterirubinemia.
P02536160A0518 |196 207|orientationof CSF PCO2
P02536160A0518 |26 35|conditionwith alka
P02536160A0518 |55 63|sequenced 5-nucl
P02536160A0518 |37 42|Ren1dne ph
P02536160A0518 |71 88|sense orientation P00008171T0000 P
P02537441A0231 |0 4|NoneP000
P02537441A0231 |78 86|globulin171T0000
P02537441A0231 |101 108|diseaseaspects
P02537441A0231 |54 70|varicella-zosternd 5-nucleotidas
P02537441A0231 |35 41|dutiesline p
P02537485A0841 |102 107|mg/kgspect
P02537485A0841 |159 163|dosen CS
P02537485A0841 |7 20|formalin test06T0076 Compa
P02537485A0841 |125 143|morphine analgesiarbilirubinemia. P0
P02537485A0841 |31 39|naloxonealkaline
P02537485A0841 |168 173|mg/kgO3-] 
P02537485A0841 |83 88|doses000 P
P02537485A0841 |51 69|morphine analgesias and 5-nucleotida
P02538450A0000 |34 43|rat brainaline pho
P02538450A0000 |95 119|Na,K-ATPase beta subunitlogic aspects of neonata
P02538450A0000 |80 87|isoform1T0000 
P02538450A0000 |54 59|livernd 5-
P02538450A0000 |17 28|cDNA clonesmparison wi
P02538656A0172 |69 78|R regionsse P00008
P02538656A0172 |92 98|mutantacolog
P02538656A0172 |147 168|transforming activity997A0472 When CSF [HC
P02538656A0172 |208 214|genomethe da
P02538656A0172 |63 64|Me
P02538656A0172 |172 188|mouse C127 cells is shown as a f
P02538656A0172 |126 132|regionbiliru
P02538656A0172 |32 42|E1 mutantslkaline ph
P02538720A0582 |0 4|UbiAP000
P02538720A0582 |83 90|introns000 Pha
P02538720A0582 |109 117|sequenceof neona
P02538720A0582 |32 51|polyubiquitin geneslkaline phosphatase
P02541251A1327 |48 53|sitesases 
P02541251A1327 |230 237|T1 gene rats a
P02541251A1327 |12 19|T2 gene76 Comp
P02541251A1327 |121 136|CCAAT sequenceshyperbilirubine
P02541251A1327 |164 167|end [H
P02541251A1327 |80 104|transcription factor SP11T0000 Pharmacologic asp
P02541251A1327 |113 117|TATAeona
P02541251A1327 |191 199|featurestion of 
P02541882A0251 |0 17|Radiation therapyP00001606T0076 Co
P02541882A0251 |59 69|metastasisnucleotida
P02541882A0251 |83 91|patients000 Phar
P02542194A1496 |96 108|astrocytomasogic aspects
P02542194A1496 |130 141|ependymomasrubinemia. 
P02542194A1496 |63 74|irradiationeotidase P0
P02542194A1496 |28 36|patientsth alkal
P02542194A1496 |6 13|results606T007
P02542194A1496 |160 168|survival CSF [HC
P02542194A1496 |83 88|grade000 P
P02542270A0000 |118 141|C4 photosynthesis genesal hyperbilirubinemia. 
P02542270A0000 |31 47|chloroplast DNAsalkaline phospha
P02542270A0000 |197 205|greeningf CSF PC
P02542270A0000 |167 182|mesophyll cellsCO3-] is shown 
P02542270A0000 |149 162|bundle sheath7A0472 When C
P02542270A0000 |104 114|expressionects of ne
P02542270A0000 |223 228|maizeeplet
P02542270A0000 |4 15|methylation01606T0076 
P02542270A0000 |69 77|relationse P0000
P02542612A0530 |0 20|S1 nuclease analysisP00001606T0076 Compa
P02542612A0530 |73 83|Vero cells00008171T0
P02542612A0530 |24 27|RNAn w
P02542612A0530 |146 163|Z transactivation8997A0472 When CS
P02542612A0530 |215 230|RNA transcriptsa of K-depleted
P02542612A0530 |132 133|Zb
P02542612A0530 |52 63|B95-8 cells and 5-nucl
P02542612A0530 |178 183|levelown a
P02542612A0530 |103 127|NotI repeat promoter-CATpects of neonatal hyperb
P02543226A1559 |102 126|adipose tissue componentspects of neonatal hyper
P02543226A1559 |223 231|samplingepleted 
P02543226A1559 |25 35|likelihood with alka
P02543226A1559 |145 160|breast biopsies08997A0472 When
P02543226A1559 |213 219|methodata of
P02543226A1559 |247 262|breast biopsieser displaced wh
P02543226A1559 |298 305|maximumve a si
P02543226A1559 |385 391|tissuears to
P02543226A1559 |330 340|parenchyma (1.21 +/-
P02543226A1559 |312 318|blocksntly g
P02543226A1559 |350 354|caseP000
P02543226A1559 |437 448|hyperplasiam dose for 
P02543226A1559 |49 58|carcinomases and 5
P02543226A1559 |415 424|carcinomac drug wi
P02543226A1559 |470 476|blockse bein
P02543226A1559 |71 82|hyperplasia P00008171T
P02543621A0788 |0 8|AnalysisP0000160
P02543621A0788 |59 64|Wilmsnucle
P02543621A0788 |28 33|casesth al
P02543621A0788 |91 98|changesmacolog
P02543621A0788 |120 144|translocation breakpoint hyperbilirubinemia. P00
P02543621A0788 |169 173|gene3-] 
P02543621A0788 |66 71|tumoridase
P02543621A0788 |16 19|DNAomp
P02543679A1291 |84 88|DnaJ00 P
P02543679A1291 |144 155|propagation008997A0472
P02543679A1291 |93 117|DnaK heat shock proteinscologic aspects of neona
P02543679A1291 |42 50|lambda Oosphatas
P02543679A1291 |132 136|rolebine
P02543679A1291 |55 67|P initiatorsd 5-nucleoti
P02543679A1291 |159 177|lambda replicationn CSF [HCO3-] is s
P02543679A1291 |16 24|evidenceompariso
P02543734A0414 |99 122|IE1/2 enhancer/promoterc aspects of neonatal h
P02543734A0414 |47 61|bp repeat unittases and 5-nu
P02543734A0414 |164 174|expression [HCO3-] i
P02543734A0414 |126 147|cotransfection assaysbilirubinemia. P00008
P02543734A0414 |10 26|oligonucleotides0076 Comparison 
P02543734A0414 |83 91|activity000 Phar
P02544059A0377 |0 7|EffectsP000016
P02544059A0377 |52 55|PHe an
P02544059A0377 |11 19|nitrogen076 Comp
P02544059A0377 |44 50|heliumphatas
P02544059A0377 |21 24|PN2iso
P02544059A0377 |67 70|MPadas
P02544059A0377 |35 38|MPalin
P02545357A0000 |4 34|mustard chloroplast gene rps1601606T0076 Comparison with alk
P02545357A0000 |75 81|intron008171
P02545357A0000 |54 62|bp groupnd 5-nuc
P02545903A0639 |85 89|NS3A0 Ph
P02545903A0639 |42 54|immunizationosphatases a
P02545903A0639 |77 80|NS3817
P02545903A0639 |58 62|mice-nuc
P02545903A0639 |109 118|BHK cellsof neonat
P02545903A0639 |35 38|NS3lin
P02545903A0639 |139 161|BTV-10 virus particles. P00008997A0472 When 
P02545903A0639 |0 10|AntibodiesP00001606T
P02546234A1382 |64 71|effortsotidase
P02546234A1382 |28 39|tachycaydiath alkaline
P02546234A1382 |114 121|outcomeonatal 
P02547079A0910 |34 54|hyperparathyroidemiaaline phosphatases a
P02547079A0910 |13 28|calcium balance6 Comparison wi
P02547079A0910 |104 106|Cdec
P02547079A0910 |156 163|calciumWhen CS
P02547079A0910 |143 152|excretion0008997A0
P02547079A0910 |86 100|administration Pharmacologic
P02547611A0318 |0 8|Clone 4cP0000160
P02547611A0318 |60 69|clone 22cucleotida
P02547611A0318 |15 17|bpCo
P02547611A0318 |97 103|introngic as
P02547611A0318 |111 113|bp n
P02547611A0318 |32 38|regionlkalin
P02547706A0928 |117 123|CMV-IPtal hy
P02547706A0928 |83 97|classification000 Pharmacolo
P02547706A0928 |128 131|IIPlir
P02547706A0928 |27 30|IHCith
P02547706A0928 |101 111|pneumoniasaspects of
P02547706A0928 |4 15|application01606T0076 
P02547706A0928 |19 22|ISHari
P02547706T0001 |0 8|ValidityP0000160
P02547706T0001 |167 194|bone marrow transplantationCO3-] is shown as a functio
P02547706T0001 |12 27|immunohistology76 Comparison w
P02547706T0001 |74 83|diagnosis0008171T0
P02547706T0001 |141 150|pneumoniaP00008997
P02547706T0001 |40 53|hybridizationphosphatases 
P02547706T0001 |87 112|cytomegalovirus pneumoniaPharmacologic aspects of 
P02547778A0786 |113 123|expressioneonatal hy
P02547778A0786 |62 78|control elementsleotidase P00008
P02547778A0786 |41 45|ANT1hosp
P02547778A0786 |11 17|nature076 Co
P02547778A0786 |22 33|arrangementson with al
P02548683T0001 |39 47|Shanghai phospha
P02548683T0001 |57 68|hepatitis A5-nucleotid
P02548683T0001 |28 35|seminarth alka
P02548683T0001 |8 15|account6T0076 
P02549036A0000 |222 232|propertiesdepleted r
P02549036A0000 |36 45|repressorine phosp
P02549036A0000 |180 185|ordern as 
P02549036A0000 |165 176|homogeneity[HCO3-] is 
P02549036A0000 |98 105|proteinic aspe
P02549036A0000 |4 31|Bacillus subtilis phage phi01606T0076 Comparison with 
P02549036A0000 |49 55|lambdases an
P02549343A1008 |137 142|cellsia. P
P02549343A1008 |285 292|rabbits but st
P02549343A1008 |319 324|viruseater
P02549343A1008 |115 118|gpInat
P02549343A1008 |20 23|gpIris
P02549343A1008 |218 224|weightf K-de
P02549343A1008 |396 406|complementn effectiv
P02549343A1008 |57 61|mO745-nu
P02549343A1008 |264 272|antibody compare
P02549343A1008 |336 357|neutralizing activity +/- 0.23 vs. P000109
P02549343A1008 |37 42|cellsne ph
P02549343A1008 |79 94|characteristics71T0000 Pharmac
P02549343A1008 |166 193|immunoprecipitation patternHCO3-] is shown as a functi
P02549343A1008 |368 376|reactionrazepam 
P02549343A1008 |233 244|polypeptidets are no l
P02549343A1008 |3 14|consequence001606T0076
P02549417A0000 |42 51|parasitesosphatase
P02549417A0000 |13 19|stages6 Comp
P02549417A0000 |60 82|acristate mitochondriaucleotidase P00008171T
P02549417A0000 |89 98|functionsarmacolog
P02550118A0610 |64 68|daysotid
P02550118A0610 |37 50|infiltrationsne phosphatas
P02550682A0411 |71 74|IIc P0
P02550682A0411 |28 46|type IIc carcinomath alkaline phosph
P02550682A0411 |13 22|incidence6 Compari
P02550682A0411 |55 56|%d
P02550682A0411 |94 95|%o
P02550682A0411 |81 85|typeT000
P02551886A0332 |0 16|Restriction mapsP00001606T0076 C
P02551886A0332 |31 39|plasmidsalkaline
P02551886A0332 |105 114|fragmentscts of ne
P02551886A0332 |72 79|insertsP000081
P02552143A0748 |0 3|VP5P00
P02552143A0748 |29 43|capsid proteinh alkaline pho
P02552143A0748 |63 101|chloramphenicol acetyltransferase geneeotidase P00008171T0000 Pharmacologic 
P02552316A0526 |82 87|woman0000 
P02552316A0526 |73 77|days0000
P02552316A0526 |30 40|caretakers alkaline 
P02552316A0526 |148 155|percent97A0472
P02552316A0526 |122 141|seroconversion rateyperbilirubinemia. 
P02552316A0526 |58 65|average-nucleo
P02554310A0419 |3 11|contrast001606T0
P02554310A0419 |57 63|region5-nucl
P02554310A0419 |88 94|effectharmac
P02554310A0419 |23 31|fragmenton with 
P02555177A0488 |16 20|LEU2ompa
P02555177A0488 |179 197|COX1 mRNA splicingwn as a function o
P02555177A0488 |9 14|pet54T0076
P02555177A0488 |147 167|COX3 gene expression997A0472 When CSF [H
P02555177A0488 |90 112|COX1 introns aI5 alpharmacologic aspects of 
P02555177A0488 |201 217|mRNA translationF PCO2 the data 
P02555177A0488 |67 73|genomedase P
P02555177A0488 |117 125|aI5 betatal hype
P02555418A0973 |0 7|Insert2P000016
P02555418A0973 |43 52|sequencessphatases
P02555418A0973 |76 84|sequence08171T00
P02555519A0798 |152 164|conservation472 When CSF
P02555519A0798 |130 138|H-chainsrubinemi
P02555519A0798 |74 108|complementarity determining region0008171T0000 Pharmacologic aspects
P02555519A0798 |33 39|lengthkaline
P02555519A0798 |172 190|D-region structure is shown as a fun
P02555519A0798 |52 60|sequence and 5-n
P02555519A0798 |110 118|peptidesf neonat
P02555519A0798 |237 251|hapten bindingre no longer d
P02555519A0798 |19 29|variationsarison wit
P02555519A0798 |68 72|CDR3ase 
P02555703T0000 |0 25|Tyrosine kinase oncogenesP00001606T0076 Comparison
P02555703T0000 |92 110|signaling pathwaysacologic aspects o
P02555703T0000 |199 204|v-ablCSF P
P02555703T0000 |78 83|cells171T0
P02555703T0000 |121 126|c-mychyper
P02555703T0000 |154 173|c-myc transcription2 When CSF [HCO3-] 
P02555703T0000 |140 150|regulation P00008997
P02555703T0000 |35 59|interleukin-3 dependenceline phosphatases and 5-
P02556264A0278 |137 142|cellsia. P
P02556264A0278 |198 214|cell specificity CSF PCO2 the da
P02556264A0278 |47 60|kappa B motiftases and 5-n
P02556264A0278 |70 90|kappa chain enhancere P00008171T0000 Pha
P02556264A0278 |5 19|TC-II enhanson1606T0076 Comp
P02556264A0278 |222 235|kappa B motifdepleted rats
P02556269A0187 |102 118|hypersensitivityspects of neonat
P02556269A0187 |282 293|topoisomersols but sti
P02556269A0187 |145 153|nuclease08997A04
P02556269A0187 |40 54|13mer sequencephosphatases a
P02556269A0187 |182 189|plasmidas a fu
P02556269A0187 |4 13|DNA helix01606T007
P02556269A0187 |218 221|DNAf K
P02556269A0187 |259 278|gel electrophoresis when compared to c
P02556603A0606 |119 135|bile duct cancerl hyperbilirubin
P02556603A0606 |23 34|improvementon with alk
P02556603A0606 |75 81|cancer008171
P02556603A0606 |83 101|gallbladder cancer000 Pharmacologic 
P02557217A0000 |0 14|Beta-endorphinP00001606T0076
P02557217A0000 |25 43|cortisol secretion with alkaline pho
P02557217A0000 |125 145|IU salmon calcitoninrbilirubinemia. P000
P02557217A0000 |100 120|spray administration aspects of neonatal
P02557217A0000 |82 87|males0000 
P02557217A0000 |16 20|ACTHompa
P02557217A0398 |4 8|data0160
P02557217A0398 |59 67|increasenucleoti
P02557217A0398 |92 123|corticotrophin-cortisol releaseacologic aspects of neonatal hy
P02557217A0398 |23 33|calcitoninon with al
P02557350A0632 |51 58|SRP54sps and 5
P02557350A0632 |93 101|SRP54mamcologic 
P02557350A0632 |78 79|%1
P02557350A0632 |26 34|proteinswith alk
P02557350A0632 |4 17|DNA sequences01606T0076 Co
P02557350A0632 |39 46|SRP54sc phosph
P02557350A0632 |70 71|%e
P02559630A0270 |17 23|valuesmparis
P02559630A0270 |57 77|thromboplastin times5-nucleotidase P0000
P02559630A0270 |147 185|fibrin/fibrinogen degradation products997A0472 When CSF [HCO3-] is shown as 
P02559630A0270 |79 96|prothrombin times71T0000 Pharmacol
P02559630A0270 |114 124|fibrinogenonatal hyp
P02559630A0270 |126 141|platelet countsbilirubinemia. 
P02559630A0270 |98 112|thrombin timesic aspects of 
P02560415T0012 |16 21|tumorompar
P02560415T0012 |41 46|mouthhosph
P02560415T0012 |27 37|metastasisith alkali
P02560415T0012 |56 68|face regions 5-nucleotid
P02560415T0012 |48 51|jawase
P02562787A0637 |23 30|proteinon with
P02562787A0637 |47 51|CNBPtase
P02562787A0637 |41 44|NBPhos
P02562825A0413 |0 14|ResponsivenessP00001606T0076
P02562825A0413 |64 70|agentsotidas
P02562825A0413 |72 73|pP
P02562825A0413 |18 40|beta-2 agonist therapyparison with alkaline 
P02565405T0000 |0 8|Drug useP0000160
P02565405T0000 |12 26|trauma victims76 Comparison 
P02565683A0841 |84 93|instances00 Pharma
P02565683A0841 |127 138|tachycardiailirubinemi
P02565683A0841 |11 21|heart rate076 Compar
P02565683A0841 |97 106|reentrantgic aspec
P02565683A0841 |163 174|tachycardiaF [HCO3-] i
P02565683A0841 |53 58|stateand 5
P02565807A1198 |17 35|neu proto-oncogenemparison with alka
P02565807A1198 |3 11|contrast001606T0
P02565807A1198 |81 91|propertiesT0000 Phar
P02565807A1198 |143 151|ABSTRACT0008997A
P02565807A1198 |128 141|NIH 3T3 cellslirubinemia. 
P02565807A1198 |169 174|WORDS3-] i
P02565807A1198 |49 64|kinase activityses and 5-nucle
P02565807A1198 |118 124|levelsal hyp
P02566613A0831 |68 71|CREase
P02566613A0831 |73 81|TGACGTCA00008171
P02566613A0831 |58 66|enhancer-nucleot
P02566613A0831 |10 18|sequence0076 Com
P02566613A0831 |83 94|nucleotides000 Pharmac
P02566613T0000 |0 28|Somatostatin gene expressionP00001606T0076 Comparison wi
P02566613T0000 |43 54|islet cellssphatases a
P02566613T0000 |121 129|proteinshyperbil
P02566613T0000 |84 104|DNA control elements00 Pharmacologic asp
P02566680A0820 |137 142|dosesia. P
P02566680A0820 |226 227|%e
P02566680A0820 |61 72|I-methadonecleotidase 
P02566680A0820 |206 220|response rates2 the data of 
P02566680A0820 |3 11|contrast001606T0
P02566680A0820 |77 88|levorphanol8171T0000 P
P02566680A0820 |160 165|times CSF 
P02566680A0820 |100 101|% 
P02566680A0820 |32 49|agonists fentanyllkaline phosphata
P02566680A0820 |51 59|morphines and 5-
P02567030A0482 |35 49|discriminationline phosphata
P02567030A0482 |55 63|controlsd 5-nucl
P02567030A0482 |82 92|difficulty0000 Pharm
P02567030A0482 |115 123|reversalnatal hy
P02568930T0000 |0 9|IsolationP00001606
P02568930T0000 |61 69|cytokinecleotida
P02568930T0000 |14 30|characterization Comparison with
P02568930T0000 |90 101|stimulationrmacologic 
P02568930T0000 |110 123|CD2 structuref neonatal hy
P02568930T0000 |133 146|T lymphocytesinemia. P0000
P02568930T0000 |36 40|cDNAine 
P02569411A0151 |21 31|medicationison with 
P02569411A0151 |6 17|termination606T0076 Co
P02569411A0151 |77 93|nucleus amygdala8171T0000 Pharma
P02569411A0151 |36 43|animalsine pho
P02571924A0000 |17 30|mating type Amparison with
P02571924A0000 |143 156|undecapeptide0008997A0472 
P02571924A0000 |96 112|mating pheromoneogic aspects of 
P02571924A0000 |8 13|cells6T007
P02571924A0000 |195 211|carboxy terminus of CSF PCO2 the
P02571924A0000 |114 129|rhodotorucine Aonatal hyperbil
P02571924A0000 |54 85|yeast Rhodosporidium toruloidesnd 5-nucleotidase P00008171T000
P02571924A0000 |168 187|S-farnesyl cysteineO3-] is shown as a 
P02572777T0000 |0 22|Tumour necrosis factorP00001606T0076 Compari
P02572777T0000 |45 62|distress syndromehatases and 5-nuc
P02572928T0000 |0 10|MonitoringP00001606T
P02572928T0000 |25 34|arthritis with alk
P02573303A0000 |34 36|LVal
P02573303A0000 |83 91|pressure000 Phar
P02573303A0000 |93 97|PEEPcolo
P02573303A0000 |130 132|LVru
P02573303A0000 |4 12|decrease01606T00
P02573303A0000 |157 174|contractile statehen CSF [HCO3-] i
P02573303A0000 |38 51|stroke volumee phosphatase
P02573336A0000 |139 144|event. P00
P02573336A0000 |194 203|magnituden of CSF 
P02573336A0000 |172 178|retest is sh
P02573336A0000 |37 40|ROFne 
P02573336A0000 |88 96|subjectsharmacol
P02573336A0000 |211 214|ROF da
P02573336A0000 |3 13|experiment001606T007
P02573336A0000 |64 69|snakeotida
P02573336A0000 |100 105|order aspe
P02573829T0000 |49 54|sitesses a
P02573829T0000 |105 123|transcription unitcts of neonatal hy
P02573829T0000 |142 159|segmentation gene00008997A0472 Whe
P02573829T0000 |13 25|conservation6 Comparison
P02573829T0000 |65 74|sequencestidase P0
P02573836A0244 |103 107|mdr1pect
P02573836A0244 |25 35|importance with alka
P02573836A0244 |123 147|amino acid substitutionsperbilirubinemia. P00008
P02573836A0244 |183 201|nucleotide bindings a function of CS
P02573836A0244 |45 48|NBShat
P02573836A0244 |64 89|drug resistance phenotypeotidase P00008171T0000 Ph
P02573836A0244 |203 209|GXGKSTPCO2 t
P02573836A0244 |155 178|core consensus sequence When CSF [HCO3-] is sh
P02574016A0428 |152 159|infants472 Whe
P02574016A0428 |164 172|children [HCO3-]
P02574016A0428 |124 130|adultserbili
P02574016A0428 |63 76|control valueeotidase P000
P02574016A0428 |107 120|micrograms/kgs of neonatal
P02574016A0428 |135 148|micrograms/kgemia. P000089
P02574016A0428 |58 59|%-
P02574016A0428 |78 89|neostigmine171T0000 Ph
P02574016A0428 |25 28|TOF wi
P02574052A0910 |53 69|Type A behaviourand 5-nucleotida
P02574052A0910 |74 100|beta-adrenoceptor blockade0008171T0000 Pharmacologic
P02574052A0910 |15 26|differencesComparison 
P02574052A0910 |41 49|relationhosphata
P02574193A0663 |0 9|SelectionP00001606
P02574193A0663 |20 25|itemsrison
P02574193A0663 |158 166|baselineen CSF [
P02574193A0663 |212 220|subjectsdata of 
P02574193A0663 |270 278|diazepamred to c
P02574193A0663 |91 97|CIWA-Bmacolo
P02574193A0663 |180 198|withdrawal periodsn as a function of
P02574193A0663 |233 241|symptomsts are n
P02574193A0663 |42 89|Institute Withdrawal Assessment-Benzodiazepinesosphatases and 5-nucleotidase P00008171T0000 Ph
P02574193A0663 |258 265|placebod when 
P02574193A0663 |291 299|subjectstill hav
P02574193A0663 |138 149|differencesa. P0000899
P02574193A0663 |339 358|regression analysis- 0.23 vs. P0001094
P02574193A0663 |307 325|contingency tablesificantly greater 
P02574551T0000 |0 14|AntihistaminesP00001606T0076
P02574551T0000 |18 24|asthmapariso
P02575174A0229 |169 187|airflow limitation3-] is shown as a 
P02575174A0229 |55 64|doxazosind 5-nucle
P02575174A0229 |96 101|alphaogic 
P02575174A0229 |104 111|blockerects of
P02575174A0229 |45 51|safetyhatase
P02575174A0229 |32 40|efficacylkaline 
P02575174A0229 |116 124|patientsatal hyp
P02575174A0229 |139 151|hypertension. P00008997A
P02575490A1021 |0 22|Northern blot analysisP00001606T0076 Compari
P02575490A1021 |111 122|transcripts neonatal h
P02575490A1021 |41 59|oIGF-I transcriptshosphatases and 5-
P02575490A1021 |89 100|nucleotidesarmacologic
P02575490A1021 |71 75|band P00
P02575490A1021 |143 149|weight000899
P02575490A1021 |153 158|liver72 Wh
P02575567T0001 |68 73|wiresase P
P02575567T0001 |0 25|Materials science studiesP00001606T0076 Comparison
P02575959A0643 |64 70|valuesotidas
P02575959A0643 |104 106|T2ec
P02575959A0643 |25 46|lactate concentration with alkaline phosph
P02575959A0643 |94 102|trainingologic a
P02575959A0643 |4 16|latency time01606T0076 C
P02576405A0223 |153 161|platinum72 When 
P02576405A0223 |40 49|therapiesphosphata
P02576405A0223 |198 206|patients CSF PCO
P02576405A0223 |193 194|%o
P02576405A0223 |132 144|EDAP regimenbinemia. P00
P02576405A0223 |97 124|cyclophosphamide-BCNU-VP-16gic aspects of neonatal hyp
P02576405A0223 |67 76|melphalandase P000
P02576405A0223 |25 28|VAD wi
P02576405A0223 |146 151|VP-168997A
P02576405A0223 |80 95|CBV combination1T0000 Pharmaco
P02576405A0223 |172 181|responses is shown
P02576405A0223 |3 11|patients001606T0
P02577458A0412 |139 158|calcium antagonists. P00008997A0472 Wh
P02577458A0412 |57 68|angiotensin5-nucleotid
P02577458A0412 |46 51|drugsatase
P02577458A0412 |4 14|discussion01606T0076
P02577458A0412 |80 97|enzyme inhibitors1T0000 Pharmacolo
P02577458A0412 |116 133|receptor blockersatal hyperbilirub
P02577867T0000 |34 47|oncogene jun.aline phospha
P02577867T0000 |19 26|homologarison 
P02580830A1131 |137 143|regionia. P0
P02580830A1131 |9 17|sequenceT0076 Co
P02580830A1131 |151 165|mouse AFP gene0472 When CSF 
P02580830A1131 |60 68|cap siteucleotid
P02580830A1131 |82 90|AFP gene0000 Pha
P02580830A1131 |37 43|regionne pho
P02580830A1131 |101 113|% similarityaspects of n
P02582240A1009 |119 129|initiationl hyperbil
P02582240A1009 |43 63|RNA primer synthesissphatases and 5-nucl
P02582240A1009 |95 109|ATP/GTP ratioslogic aspects 
P02582240A1009 |29 39|initiationh alkaline
P02582240A1009 |70 81|dCTTT sitese P00008171
P02582240A1009 |5 19|ATP/GTP ratios1606T0076 Comp
P02582240A1009 |136 146|dCCC sitesmia. P0000
P02582918A0000 |101 109|anti-HBsaspects 
P02582918A0000 |211 212|% 
P02582918A0000 |224 226|T0pl
P02582918A0000 |194 195|%n
P02582918A0000 |220 222|T2K-
P02582918A0000 |187 188|%f
P02582918A0000 |216 218|T1 o
P02582918A0000 |124 127|S/Nerb
P02582918A0000 |148 150|T097
P02582918A0000 |90 95|casesrmaco
P02582918A0000 |231 234|T12rat
P02582918A0000 |129 143|S/N Ratio Unitirubinemia. P0
P02582918A0000 |40 63|serum antibody responsephosphatases and 5-nucl
P02582918A0000 |79 83|type71T0
P02582918A0000 |174 178|rates sh
P02582918A0000 |6 38|hepatitis B vaccine immunization606T0076 Comparison with alkalin
P02582918A0000 |201 202|%F
P02584969A0119 |17 23|designmparis
P02584969A0119 |107 116|end points of neon
P02584969A0119 |120 121|% 
P02584969A0119 |127 142|protection timeilirubinemia. P
P02584969A0119 |77 87|treatments8171T0000 
P02584969A0119 |48 64|regression modelases and 5-nucle
P02585492A1005 |100 112|parB mutants aspects of 
P02585492A1005 |122 133|P1 proteinsyperbilirub
P02585492A1005 |14 35|complementation tests Comparison with alka
P02585492A1005 |52 63|P7 proteins and 5-nucl
P02585492A1005 |89 96|P1 parAarmacol
P02585492A1005 |157 169|P7 mutationshen CSF [HCO
P02586485A0511 |0 5|GN101P0000
P02586485A0511 |7 14|YC819-906T0076
P02586485A0511 |20 23|SB3ris
P02586513A0622 |0 8|AnalysisP0000160
P02586513A0622 |287 304|consensus Tyr Serut still have a s
P02586513A0622 |73 81|identity00008171
P02586513A0622 |195 209|amino terminus of CSF PCO2 t
P02586513A0622 |154 162|presence2 When C
P02586513A0622 |321 324|Serter
P02586513A0622 |268 277|heptamerspared to 
P02586513A0622 |39 52|ama-1 product phosphatases
P02586513A0622 |99 106|subunitc aspec
P02586513A0622 |110 114|RNAPf ne
P02586513A0622 |129 138|organismsirubinemi
P02586513A0622 |235 241|domain are n
P02586513A0622 |309 316|Thr Sericantly
P02586513A0622 |168 185|zinc finger motifO3-] is shown as 
P02590097A0093 |153 156|IgA72 
P02590097A0093 |158 168|Type Kappaen CSF [HC
P02590097A0093 |8 19|involvement6T0076 Comp
P02590097A0093 |41 53|infiltrationhosphatases 
P02590097A0093 |61 67|mucosacleoti
P02590097A0093 |86 99|lobe bronchus Pharmacologi
P02590097A0093 |141 151|gammopathyP00008997A
P02590097A0093 |32 36|lunglkal
P02590391A0442 |0 4|NoneP000
P02590391A0442 |159 172|sphingomyelinn CSF [HCO3-]
P02590391A0442 |59 65|lipidsnucleo
P02590391A0442 |208 226|phospholipid classthe data of K-depl
P02590391A0442 |88 107|phosphatidylcholineharmacologic aspect
P02590391A0442 |183 199|acid compositions a function of 
P02590391A0442 |73 86|phospholipids00008171T0000
P02590391A0442 |135 157|diphosphatidylglycerolemia. P00008997A0472 W
P02590391A0442 |21 31|parametersison with 
P02590391A0442 |260 267|gradingwhen co
P02590391A0442 |33 47|heart contentskaline phospha
P02590391A0442 |109 133|phosphatidylethanolamineof neonatal hyperbilirub
P02590391A0442 |275 282|lesionso contr
P02590540A0741 |85 89|U/ml0 Ph
P02590540A0741 |62 68|levelsleotid
P02590540A0741 |98 99|%i
P02590540A0741 |55 57|CAd 
P02590540A0741 |7 12|women06T00
P02590540A0741 |72 78|excessP00008
P02590540A0741 |32 41|diagnoseslkaline p
P02590540A0741 |48 49|%a
P02590540A0741 |117 121|U/mltal 
P02590615A0636 |55 59|meald 5-
P02590615A0636 |27 32|stateith a
P02590615A0636 |109 115|mannerof neo
P02590615A0636 |120 136|pharmacokinetics hyperbilirubine
P02590615A0636 |37 43|timingne pho
P02590615A0636 |176 183|tabletsshown a
P02590615A0636 |140 150|nifedipine P00008997
P02590869A0743 |118 123|serumal hy
P02590869A0743 |63 66|IgAeot
P02590869A0743 |48 58|lavage IgGases and 5
P02590869A0743 |156 164|bacteriaWhen CSF
P02590869A0743 |81 91|LNA titersT0000 Phar
P02590869A0743 |37 46|serum IgGne phosph
P02590869A0743 |100 113|lavage fluids aspects of n
P02590869A0743 |138 145|SC dosea. P000
P02590869A0743 |16 22|calvesompari
P02591078A0000 |237 241|timere n
P02591078A0000 |7 21|investigations06T0076 Compar
P02591078A0000 |215 224|epidermisa of K-de
P02591078A0000 |123 139|Langerhans cellsperbilirubinemia
P02591078A0000 |75 102|contact dermatitis reaction008171T0000 Pharmacologic a
P02591078A0000 |175 194|electron microscopy shown as a functio
P02591078A0000 |38 48|Grenz rayse phosphat
P02591078A0000 |155 170|OKT6 antibodies When CSF [HCO3
P02591969A0961 |115 121|regionnatal 
P02591969A0961 |29 55|glucocorticoid stimulationh alkaline phosphatases an
P02591969A0961 |59 81|ADH gene transcriptionnucleotidase P00008171
P02591969A0961 |4 12|elements01606T00
P02592543A0106 |118 125|patiental hype
P02592543A0106 |44 59|characteristicsphatases and 5-
P02592543A0106 |164 172|organism [HCO3-]
P02592543A0106 |12 19|studies76 Comp
P02592543A0106 |61 89|Kanagawa hemolysin reactionscleotidase P00008171T0000 Ph
P02592543A0106 |148 156|isolates97A0472 
P02592543A0106 |95 111|plasmid profileslogic aspects of
P02592640A0466 |69 76|cheesesse P000
P02592640A0466 |262 269|retinolen comp
P02592640A0466 |20 27|retinolrison w
P02592640A0466 |90 95|creamrmaco
P02592640A0466 |241 246|creamo lon
P02592640A0466 |280 293|beta-carotenetrols but sti
P02592640A0466 |164 169|cream [HCO
P02592640A0466 |152 153|g4
P02592640A0466 |186 192|cheese funct
P02592640A0466 |229 230|gd
P02592640A0466 |109 115|cheeseof neo
P02592640A0466 |5 11|values1606T0
P02592640A0466 |32 45|beta-carotenelkaline phosp
P02592961A0327 |0 6|COGLABP00001
P02592961A0327 |73 96|psychomotor performance00008171T0000 Pharmacol
P02592961A0327 |16 24|measuresompariso
P02595451A1136 |137 141|MIC1ia. 
P02595451A1136 |22 35|aniridia geneson with alka
P02595451A1136 |128 133|sideslirub
P02595451A1136 |58 84|T-cell leukemia breakpoint-nucleotidase P00008171T00
P02595451A1136 |6 10|data606T
P02595451A1136 |37 40|AN2ne 
P02595451A1136 |99 114|marker sequencec aspects of ne
P02595451A1136 |86 90|TCL2 Pha
P02595451T0000 |17 29|deletion mapmparison wit
P02595451T0000 |67 84|J1 series hybridsdase P00008171T00
P02595451T0000 |39 53|chromosome 11p phosphatases 
P02595451T0000 |55 63|analysisd 5-nucl
P02597484A0624 |154 163|materials2 When CS
P02597484A0624 |93 94|Kc
P02597484A0624 |41 50|plateletshosphatas
P02597484A0624 |26 37|diffusivitywith alkali
P02597484A0624 |5 12|respect1606T00
P02597484A0624 |52 54|De a
P02597484A0624 |114 125|differencesonatal hype
P02597484A0624 |64 82|surface reactivityotidase P00008171T
P02597549A0964 |99 106|aspirinc aspec
P02597549A0964 |135 150|recovery periodemia. P00008997
P02597549A0964 |212 232|thromboplastin timesdata of K-depleted r
P02597549A0964 |111 117|mg/day neona
P02597549A0964 |161 165|daysCSF 
P02597549A0964 |41 45|dayshosp
P02597549A0964 |83 93|mg X 3/day000 Pharma
P02597549A0964 |66 78|dipyridamoleidase P00008
P02597549A0964 |188 199|prothrombinunction of 
P02597549A0964 |20 28|patientsrison wi
P02598034A0000 |0 23|Middle-latency auditoryP00001606T0076 Comparis
P02598034A0000 |135 141|cortexemia. 
P02598034A0000 |31 41|potentialsalkaline p
P02598034A0000 |67 75|controlsdase P00
P02598034A0000 |43 48|MAEPssphat
P02598034A0000 |80 88|patients1T0000 P
P02598034A0000 |100 107|lesions aspect
P02598745A0251 |50 55|caseses an
P02598745A0251 |30 45|Sylvius fissure alkaline phosp
P02599995A1031 |170 171|%-
P02599995A1031 |132 145|staphylococcibinemia. P000
P02599995A1031 |14 30|activity studies Comparison with
P02599995A1031 |156 164|survivalWhen CSF
P02599995A1031 |54 63|times MBCnd 5-nucl
P02599995A1031 |101 109|activityaspects 
P02599995A1031 |70 80|penicilline P0000817
P02600306A0140 |68 92|envelope phase disparityase P00008171T0000 Pharm
P02600306A0140 |113 123|processingeonatal hy
P02600306A0140 |161 169|AM tonesCSF [HCO
P02600306A0140 |140 147|channel P00008
P02600306A0140 |55 64|detectiond 5-nucle
P02601707A0986 |119 125|factorl hype
P02601707A0986 |45 57|footprintinghatases and 
P02601707A0986 |162 176|BC3H1 myocytesSF [HCO3-] is 
P02601707A0986 |146 157|C2 myotubes8997A0472 W
P02601707A0986 |62 96|diethyl pyrocarbonate interferenceleotidase P00008171T0000 Pharmacol
P02601707A0986 |211 219|sequence data of
P02601707A0986 |200 201|AS
P02601707A0986 |37 42|DNasene ph
P02601707A0986 |253 259|regionplaced
P02601707A0986 |0 22|Gel retardation assaysP00001606T0076 Compari
P02602150A0993 |239 253|virus replicon no longer dis
P02602150A0993 |164 174|generation [HCO3-] i
P02602150A0993 |212 218|plantsdata o
P02602150A0993 |178 185|vectorsown as 
P02602150A0993 |73 90|sequence elements00008171T0000 Pha
P02602150A0993 |61 69|analysiscleotida
P02602150A0993 |190 208|gene amplificationction of CSF PCO2 
P02602150A0993 |142 154|construction00008997A047
P02602150A0993 |16 22|plantsompari
P02602150A0993 |102 127|replication origin regionspects of neonatal hyperb
P02603374A0383 |71 88|patient morbidity P00008171T0000 P
P02603374A0383 |44 60|dorsal rhinotomyphatases and 5-n
P02603374A0383 |8 17|rhinotomy6T0076 Co
P02603374A0383 |113 126|complicationseonatal hyper
P02603923A0220 |119 121|mll 
P02603923A0220 |107 111|dayss of
P02603923A0220 |135 148|growth factoremia. P000089
P02603923A0220 |181 197|lactate solution as a function o
P02603923A0220 |172 178|Ringer is sh
P02603923A0220 |52 56|back and
P02603923A0220 |228 235|fashioned rats
P02603923A0220 |166 168|mlHC
P02603923A0220 |20 34|skin incisionsrison with alk
P02603923A0220 |96 99|dayogi
P02603923A0220 |70 74|pigse P0
P02603923A0220 |154 159|ng/ml2 Whe
P02604420A0234 |18 26|rebiopsyparison 
P02604420A0234 |88 93|yearsharma
P02604420A0234 |135 145|year studyemia. P000
P02604420A0234 |120 123|end hy
P02604420A0234 |41 61|reticulin antibodieshosphatases and 5-nu
P02604420A0234 |106 108|.0ts
P02604420A0234 |95 100|rangelogic
P02604420A0234 |7 16|challenge06T0076 C
P02605160A0000 |153 157|rats72 W
P02605160A0000 |29 44|59Fe absorptionh alkaline phos
P02605160A0000 |122 131|pregnancyyperbilir
P02605160A0000 |14 25|iron intake Comparison
P02605160A0000 |93 102|Fe statuscologic a
P02605160A0000 |56 65|pregnancy 5-nucleo
P02605160A0000 |4 10|effect01606T
P02605160A0000 |115 118|endnat
P02605182A0936 |86 100|signal peptide Pharmacologic
P02605182A0936 |12 28|protein sequence76 Comparison wi
P02605182A0936 |145 156|polypeptide08997A0472 
P02605679A0306 |137 142|deltaia. P
P02605679A0306 |113 129|degradation rateeonatal hyperbil
P02605679A0306 |145 155|ester kdeg08997A0472
P02605679A0306 |177 192|hydrolysis ratehown as a funct
P02605679A0306 |208 217|ester k24the data 
P02605679A0306 |16 30|rate constantsomparison with
P02605679A0306 |200 205|deltaSF PC
P02605679A0306 |50 72|isomerization rate k12es and 5-nucleotidase 
P02605679A0306 |0 8|AnalysisP0000160
P02607766A0000 |410 415|saltspnoti
P02607766A0000 |49 65|characterizationses and 5-nucleo
P02607766A0000 |352 357|blood00109
P02607766A0000 |191 204|micrograms/dLtion of CSF P
P02607766A0000 |431 433|Pbop
P02607766A0000 |297 309|micrograms/Lave a signif
P02607766A0000 |419 421|Cdug
P02607766A0000 |123 136|concentrationperbilirubine
P02607766A0000 |423 425|Hgit
P02607766A0000 |240 243|QCMno 
P02607766A0000 |181 183|Pb a
P02607766A0000 |158 169|microgram/Len CSF [HCO
P02607766A0000 |149 151|Cd7A
P02607766A0000 |33 44|preparationkaline phos
P02607766A0000 |175 179|lead sho
P02607766A0000 |97 100|QCMgic
P02607766A0000 |316 318|Pb g
P02607766A0000 |378 395|spiking-solutionsus appears to be 
P02607766A0000 |255 257|Cdac
P02607766A0000 |287 289|Hgut
P02607766A0000 |325 338|micrograms/dLslope (1.21 +
P02607766A0000 |263 275|micrograms/Ln compared t
P02607766A0000 |218 223|bloodf K-d
P02607766A0000 |140 147|cadmium P00008
P02607766A0000 |278 285|mercuryontrols
P02607766A0000 |71 95|quality control material P00008171T0000 Pharmaco
P02607766A0000 |2 10|protocol0001606T
P02609112A0000 |0 14|Reagent stripsP00001606T0076
P02609112A0000 |42 50|practiceosphatas
P02609112A0000 |110 122|laboratoriesf neonatal h
P02609112A0000 |54 73|laboratory medicinend 5-nucleotidase P
P02614668A0971 |22 35|concentrationson with alka
P02614668A0971 |44 49|ng/mlphata
P02614668A0971 |57 62|serum5-nuc
P02615078A0283 |42 55|actinomycetesosphatases an
P02615078A0283 |60 64|M.f.ucle
P02615078A0283 |14 24|antibodies Compariso
P02617623A0740 |34 40|LON-71aline 
P02617623A0740 |11 19|isolates076 Comp
P02617623A0740 |121 128|villagehyperbi
P02617623A0740 |74 83|altitudes0008171T0
P02617623A0740 |96 97|mo
P02617623A0740 |22 28|LON-73son wi
P02617623A0740 |49 55|LON-10ses an
P02617623A0740 |0 6|LON-72P00001
P02620085A0656 |85 105|replacement implants0 Pharmacologic aspe
P02620085A0656 |129 137|materialirubinem
P02620085A0656 |57 63|screws5-nucl
P02620085A0656 |49 55|platesses an
P02620085A0656 |33 45|applicationskaline phosp
P02620085A0656 |154 161|results2 When 
P02620085A0656 |0 6|AnimalP00001
P02621983T0001 |0 12|SignificanceP00001606T00
P02621983T0001 |63 68|testseotid
P02621983T0001 |37 50|acid analysisne phosphatas
P02623038A0632 |3 10|changes001606T
P02623038A0632 |83 100|saline injections000 Pharmacologic
P02623038A0632 |39 50|performance phosphatas
P02623038A0632 |54 62|controlsnd 5-nuc
P02627159A0899 |50 55|indexes an
P02627159A0899 |21 34|IgG4 antibodyison with alk
P02627159A0899 |70 83|immunotherapye P00008171T0
P02629109A0000 |245 256|1880 levelsnger displa
P02629109A0000 |13 30|fertility decline6 Comparison with
P02629109A0000 |44 54|populationphatases a
P02629109A0000 |62 79|Mississippi Deltaleotidase P000081
P02629109A0000 |167 177|populationCO3-] is s
P02630543A0210 |19 36|staining affinityarison with alkal
P02630543A0210 |106 107|Tt
P02630543A0210 |74 86|tissue cells0008171T0000
P02630543A0210 |241 247|tissueo long
P02630543A0210 |172 188|cell populations is shown as a f
P02630543A0210 |110 111|Tf
P02630543A0210 |208 214|volumethe da
P02630543A0210 |123 124|Tp
P02630543A0210 |140 147|changes P00008
P02630543A0210 |114 115|To
P02630543A0210 |48 58|antibodiesases and 5
P02630543A0210 |155 162|numbers When C
P02631505A0382 |85 90|cases0 Pha
P02631505A0382 |12 15|AMP76 
P02631505A0382 |50 53|AMIes 
P02631505A0382 |63 72|treatmenteotidase 
P02631505A0382 |0 10|AmpicillinP00001606T
P02631505A0382 |34 48|aminoglycosidealine phosphat
P02631566A0151 |220 244|1-ethyloxymethylimidazolK-depleted rats are no l
P02631566A0151 |250 277|chloromethyl alkyl sulfidesdisplaced when compared to 
P02631566A0151 |180 189|chloridesn as a fu
P02631566A0151 |75 95|3,4-dimethylpyridine008171T0000 Pharmaco
P02631566A0151 |207 216|reactions the data
P02631566A0151 |101 126|chloromethyl alkyl ethersaspects of neonatal hyper
P02631566A0151 |0 14|Alkoxymetgyl-3P00001606T0076
P02631566A0151 |17 45|dimethylpyridinium chloridesmparison with alkaline phosp
P02631743A0275 |114 120|platesonatal
P02631743A0275 |44 60|color deficiencyphatases and 5-n
P02631743A0275 |67 74|Koreansdase P0
P02631743A0275 |89 94|H-R-Rarmac
P02631743A0275 |82 85|use000
P02631743A0275 |20 29|incidencerison wit
P02631887A0000 |54 63|lymphomasnd 5-nucl
P02631887A0000 |30 34|HGGM alk
P02631887A0000 |7 15|patients06T0076 
P02632904A0619 |68 79|correlationase P000081
P02632904A0619 |92 93|pa
P02632904A0619 |21 27|VE/VO2ison w
P02632904A0619 |4 12|relation01606T00
P02632904A0619 |81 82|rT
P02632904A0619 |32 37|Q/VO2lkali
P02634490A0186 |17 26|diagnosismparison 
P02634490A0186 |192 199|therapyion of 
P02634490A0186 |134 147|ATB treatmentnemia. P00008
P02634490A0186 |95 109|CT examinationlogic aspects 
P02634490A0186 |79 90|sialography71T0000 Pha
P02634490A0186 |71 77|course P0000
P02634490A0186 |35 45|affectionsline phosp
P02634872A0000 |0 10|RetrogradeP00001606T
P02634872A0000 |39 57|endodontics system phosphatases and 
P02634872A0000 |81 85|zoneT000
P02634872A0000 |101 109|approachaspects 
P02636920T0001 |32 79|Pharmacopoeia Heparin Sodium Reference Standardlkaline phosphatases and 5-nucleotidase P000081
P02636920T0001 |14 19|study Comp
P02637597A0362 |33 46|relapse stagekaline phosph
P02637597A0362 |91 94|IgAmac
P02637597A0362 |129 137|decreaseirubinem
P02637597A0362 |148 150|C497
P02637597A0362 |12 19|studies76 Comp
P02637597A0362 |121 124|IgGhyp
P02637597A0362 |99 108|IgM levelc aspects
P02637597A0362 |80 89|serum ANA1T0000 Ph
P02637597A0362 |55 62|diseased 5-nuc
P02637597A0362 |141 143|C3P0
P02638964A0372 |4 18|maximum stress01606T0076 Com
P02638964A0372 |61 70|compositecleotidas
P02638964A0372 |90 101|equilibriumrmacologic 
P02638964A0372 |131 140|compositeubinemia.
P02638964A0372 |109 114|waterof ne
P02638964A0372 |42 53|examinationosphatases 
P02638964A0372 |80 86|kg/mm21T0000
P02641762T0001 |116 120|bullatal
P02641762T0001 |123 134|eye displayperbilirubi
P02641762T0001 |106 111|SPECTts of
P02641762T0001 |92 102|comparisonacologic a
P02641762T0001 |9 22|heart diseaseT0076 Compari
P02641762T0001 |76 88|scintigraphy08171T0000 P
P02641762T0001 |36 64|exercise stress thallium-201ine phosphatases and 5-nucle
P02642466T0000 |0 17|Sequence analysisP00001606T0076 Co
P02642466T0000 |54 72|membrane immunogennd 5-nucleotidase 
P02642976A1474 |10 29|consensus sequences0076 Comparison wit
P02642976A1474 |60 68|elementsucleotid
P02644735A0427 |116 127|S1 analysisatal hyperb
P02644735A0427 |162 180|host cell sequenceSF [HCO3-] is show
P02644735A0427 |95 106|transcriptslogic aspec
P02644735A0427 |14 23|AcFP875-2 Comparis
P02644735A0427 |82 85|end000
P02644735A0427 |52 69|S. frugiperda DNA and 5-nucleotida
P02644735A0427 |39 48|insertion phosphat
P02644735A0427 |3 12|FP mutant001606T00
P02645276T0088 |0 12|ConstructionP00001606T00
P02645276T0088 |78 85|mutants171T000
P02645276T0088 |43 52|isolationsphatases
P02645276T0088 |18 38|RIP1 deletion strainparison with alkalin
P02645431A1562 |114 122|functiononatal h
P02645431A1562 |88 94|defectharmac
P02645431A1562 |24 38|hypocitraturian with alkalin
P02645431A1562 |63 71|acidosiseotidase
P02645431A1562 |42 46|typeosph
P02645431A1562 |6 10|data606T
P02646007T0000 |70 80|thrombosise P0000817
P02646007T0000 |56 64|leukemia 5-nucle
P02646007T0000 |86 106|protein C deficiency Pharmacologic aspec
P02646007T0000 |32 40|leukemialkaline 
P02647403A0000 |97 102|yearsgic a
P02647403A0000 |13 27|hallucinations6 Comparison w
P02647403A0000 |42 57|psychopathologyosphatases and 
P02647918A0423 |103 107|meanpect
P02647918A0423 |26 28|GHwi
P02647918A0423 |13 18|group6 Com
P02647918A0423 |90 95|errorrmaco
P02647918A0423 |33 53|somatomedin-C levelskaline phosphatases 
P02647918A0423 |142 147|ng/ml00008
P02647918A0423 |71 75|mean P00
P02647918A0423 |184 188|U/ml a f
P02647918A0588 |0 11|ApplicationP00001606T0
P02647918A0588 |59 67|patientsnucleoti
P02647918A0588 |332 343|GH response1.21 +/- 0.
P02647918A0588 |299 312|disappearancee a significa
P02647918A0588 |124 125|%e
P02647918A0588 |285 293|criteria but sti
P02647918A0588 |258 259|%d
P02647918A0588 |84 93|GH levels00 Pharma
P02647918A0588 |191 205|GH suppressiontion of CSF PC
P02647918A0588 |219 224|ng/ml K-de
P02647918A0588 |112 120|patientsneonatal
P02647918A0588 |246 254|patientsger disp
P02647918A0588 |25 33|criteria with al
P02647918A0588 |233 237|OGTTts a
P02647918A0588 |37 41|curene p
P02647918A0588 |163 171|patientsF [HCO3-
P02647918A0588 |347 360|TRH/GnRH tests. P00010943A
P02647918A0588 |138 158|somatomedin-C valuesa. P00008997A0472 Wh
P02647918A0588 |175 176|% 
P02647918A0588 |71 72|% 
P02647918A0588 |102 107|ng/mlspect
P02647937A0191 |35 43|planningline pho
P02647937A0191 |14 22|sequence Compari
P02647937A0191 |107 115|problemss of neo
P02647937A0191 |82 86|ways0000
P02648396A0565 |100 107|agarose aspect
P02648396A0565 |40 50|c-jun mRNAphosphatas
P02648396A0565 |132 136|micebine
P02648396A0565 |75 82|ability008171T
P02648396A0565 |20 30|expressionrison with
P02648396A0565 |112 123|form tumorsneonatal hy
P02648396A0565 |3 15|Rat-1a cells001606T0076 
P02648396A0565 |86 91|clone Phar
P02648396A1033 |68 79|combinationase P000081
P02648396A1033 |46 50|RECsatas
P02648396A1033 |13 22|formation6 Compari
P02648396A1033 |26 30|fociwith
P02648396A1033 |108 159|tumor promoter phorbol 12-tetradecanoate 13-acetate of neonatal hyperbilirubinemia. P00008997A0472 Whe
P02648646A0216 |0 26|Platelet activating factorP00001606T0076 Comparison 
P02648646A0216 |123 138|expiratory flowperbilirubinemi
P02648646A0216 |165 169|Vp30[HCO
P02648646A0216 |44 49|dosesphata
P02648646A0216 |105 111|changects of
P02648646A0216 |77 92|airway response8171T0000 Pharm
P02648646A0216 |56 72|minute intervals 5-nucleotidase 
P02648646A0216 |144 145|%0
P02648646A0216 |155 163|capacity When CS
P02648646A0932 |154 158|dose2 Wh
P02648646A0932 |128 138|microgramslirubinemi
P02648646A0932 |88 92|fallharm
P02648646A0932 |45 71|baseline PC40 methacholinehatases and 5-nucleotidase
P02648646A0932 |163 173|microgramsF [HCO3-] 
P02648646A0932 |25 36|correlation with alkal
P02648646A0932 |178 204|platelet activating factorown as a function of CSF P
P02648646A0932 |96 100|Vp30ogic
P02649445A0412 |81 87|mediumT0000 
P02649445A0412 |12 30|IRI concentrations76 Comparison with
P02649445A0412 |91 99|controlsmacologi
P02649445A0412 |42 46|OGTTosph
P02649445A0412 |126 129|menbil
P02649445A0412 |66 79|body buildersidase P000081
P02649445A0412 |5 7|BG16
P02649811T0000 |11 24|contraception076 Compariso
P02649811T0000 |28 49|family planning studyth alkaline phosphata
P02650663A0178 |168 174|degreeO3-] i
P02650663A0178 |42 50|subjectsosphatas
P02650663A0178 |210 218|dementiae data o
P02650663A0178 |74 84|impairment0008171T00
P02650663A0178 |188 197|diagnosisunction o
P02650663A0178 |6 12|rating606T00
P02650663A0178 |99 107|dementiac aspect
P02650663A0178 |115 129|Alzheimer typenatal hyperbil
P02651448A0000 |152 162|bioerosion472 When C
P02651448A0000 |66 77|dissolutionidase P0000
P02651448A0000 |25 29|drug wit
P02651448A0000 |40 49|diffusionphosphata
P02651448A0000 |120 136|depolymerization hyperbilirubine
P02651448A0000 |191 197|Type Btion o
P02651448A0000 |173 189|depolymerizationis shown as a fu
P02651448A0000 |138 144|Type Aa. P00
P02651448A0000 |103 111|materialpects of
P02651487A0000 |70 81|contractione P00008171
P02651487A0000 |123 132|knowledgeperbiliru
P02651487A0000 |243 259|glucagon releaselonger displaced
P02651487A0000 |150 181|excitation contraction couplingA0472 When CSF [HCO3-] is shown
P02651487A0000 |31 55|calcium channel blockersalkaline phosphatases an
P02651487A0000 |231 238|insulinrats ar
P02651487A0000 |199 205|glandsCSF PC
P02651487A0000 |140 146|effect P0000
P02651487A0000 |101 107|muscleaspect
P02655381A0000 |34 45|possibilityaline phosp
P02655381A0000 |191 201|occlusionstion of CS
P02655381A0000 |248 256|arteriesr displa
P02655381A0000 |125 150|laboratory investigationsrbilirubinemia. P00008997
P02655381A0000 |265 277|incompetencecompared to 
P02655381A0000 |86 95|impotence Pharmaco
P02655381A0000 |116 121|meansatal 
P02655381A0000 |291 303|neuropathiestill have a 
P02655381A0000 |157 169|hypogonadismhen CSF [HCO
P02655381A0000 |66 73|factorsidase P
P02655381A0000 |229 233|sited ra
P02655381A0000 |5 12|studies1606T00
P02655381A0000 |171 189|hyperprolactinemia] is shown as a fu
P02656257A0000 |18 42|DNA inversion system Cinparison with alkaline ph
P02656257A0000 |58 74|bacteriophage P1-nucleotidase P0
P02656257A0000 |89 100|recombinasearmacologic
P02656257A0000 |157 165|enhancerhen CSF 
P02656257A0000 |115 134|crossing-over sitesnatal hyperbilirubi
P02657388A1011 |32 43|terminationlkaline pho
P02657388A1011 |47 58|transcriptstases and 5
P02657388A1011 |72 88|RNA polymerase IP00008171T0000 P
P02657388A1011 |4 21|terminator region01606T0076 Compar
P02657883A0000 |0 10|US-DopplerP00001606T
P02657883A0000 |31 40|attentionalkaline 
P02657883A0000 |58 64|method-nucle
P02657883A0000 |122 125|FAVype
P02657883A0000 |112 120|fistulasneonatal
P02657883A0000 |84 94|evaluation00 Pharmac
P02657883T0001 |0 7|DopplerP000016
P02657883T0001 |41 49|fistulaehosphata
P02657883T0001 |54 62|dialysisnd 5-nuc
P02664229A0138 |184 198|Arap procedure a function of
P02664229A0138 |224 234|advantagespleted rat
P02664229A0138 |164 168|ease [HC
P02664229A0138 |90 96|repairrmacol
P02664229A0138 |108 117|treatment of neona
P02664229A0138 |245 254|operationnger disp
P02664229A0138 |147 154|fistula997A047
P02664229A0138 |285 304|hypospadias repairs but still have a s
P02664229A0138 |36 41|scopeine p
P02664229A0138 |9 17|cosmesisT0076 Co
P02664229A0138 |19 28|extensionarison wi
P02664229A0138 |49 57|problemsses and 
P02666034A1520 |32 38|courselkalin
P02666034A1520 |198 212|placebo course CSF PCO2 the 
P02666034A1520 |14 22|patients Compari
P02666034A1520 |42 49|therapyosphata
P02666034A1520 |126 138|vasodilationbilirubinemi
P02666034A1520 |67 97|vasodilator calcium antagonistdase P00008171T0000 Pharmacolo
P02666034A1520 |216 223|therapy of K-d
P02666404A0220 |136 153|HepG2-erythrocytemia. P00008997A04
P02666404A0220 |260 266|xylosewhen c
P02666404A0220 |92 110|sugar transportersacologic aspects o
P02666404A0220 |271 290|arabinose permeasesed to controls but 
P02666404A0220 |61 69|homologycleotida
P02666404A0220 |211 237|liver glucose transporters data of K-depleted rats a
P02666404A0220 |77 88|superfamily8171T0000 P
P02666404A0220 |314 321|glucosely grea
P02666404A0220 |164 191|muscle glucose transporters [HCO3-] is shown as a func
P02666404A0220 |323 330|maltoser slope
P02666404A0220 |37 45|sequencene phosp
P02666404A0220 |197 206|rat brainf CSF PCO
P02666404A0220 |336 358|galactose transporters +/- 0.23 vs. P0001094
P02666404A0220 |4 25|galactose transporter01606T0076 Comparison
P02666568A0000 |66 81|protocol TCL821idase P00008171
P02666568A0000 |28 36|patientsth alkal
P02666568A0000 |57 62|study5-nuc
P02667259A0331 |50 54|ADRses a
P02667259A0331 |78 84|nausea171T00
P02667259A0331 |120 124|flow hyp
P02667259A0331 |39 48|reactions phosphat
P02667259A0331 |25 29|cent wit
P02667259A0331 |65 69|casetida
P02667259A0331 |86 95|dizziness Pharmaco
P02668691A0570 |98 102|nagCic a
P02668691A0570 |91 96|genesmacol
P02668691A0570 |27 31|nagBith 
P02668691A0570 |107 111|nagDs of
P02668691A0570 |36 40|nagAine 
P02668691A0570 |5 9|mRNA1606
P02669199A0000 |51 65|shock syndromes and 5-nucleo
P02669199A0000 |94 103|endotoxinologic as
P02669199A0000 |105 108|LPScts
P02669199A0000 |23 26|TNFon 
P02669199A0000 |0 21|Tumor necrosis factorP00001606T0076 Compar
P02670457T0000 |4 23|calcium requirement01606T0076 Comparis
P02670457T0000 |63 70|explanteotidas
P02670457T0000 |40 47|storagephospha
P02674141A1202 |32 36|CTSElkal
P02674141A1202 |12 28|cysteine residue76 Comparison wi
P02674141A1202 |92 101|proenzymeacologic 
P02674141A1202 |59 84|activation peptide regionnucleotidase P00008171T00
P02674327A0493 |4 7|p34016
P02674327A0493 |28 44|codon usage biasth alkaline phos
P02674327A0493 |10 14|gene0076
P02674327A0493 |92 107|polyhedrin geneacologic aspect
P02674671A0601 |23 40|DNA transformantson with alkaline 
P02674671A0601 |44 45|%p
P02674671A0601 |60 71|replacementucleotidase
P02674671A0601 |88 101|met2 mutationharmacologic 
P02674671A0601 |129 135|alleleirubin
P02674674A1308 |33 39|notionkaline
P02674674A1308 |133 139|origininemia
P02674674A1308 |62 67|sitesleoti
P02674674A1308 |143 154|replication0008997A047
P02674674A1308 |76 88|OBF1 protein08171T0000 P
P02674674A1308 |114 126|ARS functiononatal hyper
P02674674A1308 |4 11|results01606T0
P02674679A1237 |51 67|RNA preparationss and 5-nucleoti
P02674679A1237 |120 125|genes hype
P02674679A1237 |7 12|basis06T00
P02674679A1237 |195 217|start site utilization of CSF PCO2 the data 
P02674679A1237 |180 191|specificityn as a func
P02674679A1237 |151 161|expression0472 When 
P02674679A1237 |141 147|levelsP00008
P02674679A1237 |81 94|mouse tissuesT0000 Pharmac
P02674679A1237 |101 105|dhfraspe
P02674679A1237 |16 47|S1 nuclease protection analysisomparison with alkaline phospha
P02675492A0806 |100 103|CRP as
P02675492A0806 |15 23|patientsComparis
P02675492A0806 |92 95|ESRaco
P02675492A0806 |40 51|improvementphosphatase
P02675492A0806 |65 78|Ritchie-Indextidase P00008
P02675492A0806 |80 90|pain score1T0000 Pha
P02677002A0205 |68 71|Aspase
P02677002A0205 |75 109|equilibrium N-carbamyl-L-aspartate008171T0000 Pharmacologic aspects 
P02677002A0205 |111 116|C-Asp neon
P02677002A0205 |131 149|carbamyl phosphateubinemia. P0000899
P02677002A0205 |44 47|ATPpha
P02677002A0205 |151 154|C-P047
P02677002A0205 |159 183|equilibrium Pi exchangesn CSF [HCO3-] is shown a
P02677002A0205 |127 130|32Pili
P02677002A0205 |64 67|14Coti
P02677002A0205 |35 42|enzymesline ph
P02677429A0366 |0 14|Survival ratesP00001606T0076
P02677429A0366 |120 135|treatment group hyperbilirubin
P02677429A0366 |151 152|%0
P02677429A0366 |287 288|%u
P02677429A0366 |166 172|monthsHCO3-]
P02677429A0366 |221 227|months-deple
P02677429A0366 |250 258|subjectsdisplace
P02677429A0366 |82 88|months0000 P
P02677429A0366 |264 268|AIDS com
P02677429A0366 |57 58|%5
P02677429A0366 |362 377|treatment group33 Flurazepam t
P02677429A0366 |311 319|subjectsantly gr
P02677429A0366 |277 278|%c
P02677429A0366 |67 68|%d
P02677429A0366 |196 197|%o
P02677429A0366 |141 142|%P
P02677429A0366 |338 345|complex/- 0.23
P02677429A0366 |206 207|%2
P02677429A0366 |32 47|treatment grouplkaline phospha
P02677666A0356 |0 7|MappingP000016
P02677666A0356 |114 122|mutationonatal h
P02677666A0356 |77 84|mutants8171T00
P02677666A0356 |35 56|complementation groupline phosphatases and
P02677666A0356 |103 111|ag alphapects of
P02679804A2000 |16 27|genes ura10omparison w
P02679804A2000 |4 12|products01606T00
P02679804A2000 |72 82|channelingP00008171T
P02679804A2000 |86 109|orotidine monophosphate Pharmacologic aspects 
P02679804A2000 |32 36|ura3lkal
P02680843A0724 |32 43|REM latencylkaline pho
P02680843A0724 |78 91|investigation171T0000 Phar
P02680843A0724 |10 21|application0076 Compar
P02680843A0724 |25 27|RS w
P02680843A0724 |65 71|groupstidase
P02684159A0870 |51 55|mRNAs an
P02684159A0870 |39 43|size pho
P02684159A0870 |69 78|kilobasesse P00008
P02684159A0870 |0 22|Hybridization analysisP00001606T0076 Compari
P02684585T0001 |0 25|Agranulocytosis treatmentP00001606T0076 Comparison
P02684585T0001 |31 39|rhGM-CSFalkaline
P02685331A0523 |4 29|R. meliloti nifH promoter01606T0076 Comparison wit
P02685331A0523 |228 237|promotersed rats a
P02685331A0523 |56 69|nifH promoter 5-nucleotida
P02685331A0523 |209 214|sigmahe da
P02685331A0523 |122 138|guanine residuesyperbilirubinemi
P02685331A0523 |179 190|nucleotideswn as a fun
P02685331A0523 |77 82|sigma8171T
P02685331A0523 |42 44|K.os
P02685331A0523 |96 118|methylation protectionogic aspects of neonat
P02685461A0380 |69 77|patientsse P0000
P02685461A0380 |15 23|symptomsComparis
P02685461A0380 |60 65|groupucleo
P02685461A0380 |31 38|diseasealkalin
P02685565A0165 |137 148|c-myb genesia. P000089
P02685565A0165 |57 61|mRNA5-nu
P02685565A0165 |92 97|cellsacolo
P02685565A0165 |35 39|formline
P02686588A0592 |17 25|analysismparison
P02686588A0592 |89 109|alkaline phosphatasearmacologic aspects 
P02686588A0592 |56 66|hemoglobin 5-nucleot
P02686588A0592 |41 51|hematocrithosphatase
P02686588A0592 |125 130|grouprbili
P02686588A0592 |81 84|BUNT00
P02686749A0000 |275 279|yearo co
P02686749A0000 |14 33|health significance Comparison with al
P02686749A0000 |120 128|exposure hyperbi
P02686749A0000 |75 83|exposure008171T0
P02686749A0000 |53 60|changesand 5-n
P02686749A0000 |178 187|excretionown as a 
P02686749A0000 |144 153|discovery008997A04
P02686749A0000 |215 238|retinol binding proteina of K-depleted rats ar
P02686749A0000 |191 211|beta 2-microglobulintion of CSF PCO2 the
P02686749A0000 |99 106|workersc aspec
P02686749A0000 |87 94|cadmiumPharmac
P02686749A0000 |289 294|years stil
P02686980A0000 |48 60|organizationases and 5-n
P02686980A0000 |162 167|yeastSF [H
P02686980A0000 |79 88|nucleolus71T0000 P
P02686980A0000 |144 154|components008997A047
P02686980A0000 |3 8|order00160
P02686985A0811 |100 106|stages aspec
P02686985A0811 |110 123|transcriptionf neonatal hy
P02686985A0811 |193 200|effectson of C
P02686985A0811 |243 250|complexlonger 
P02686985A0811 |219 228|component K-deplet
P02686985A0811 |159 176|complex formationn CSF [HCO3-] is 
P02686985A0811 |65 78|PCF1 mutationtidase P00008
P02686985A0811 |2 38|transcription factor exclusion assay0001606T0076 Comparison with alkalin
P02688772T0000 |0 10|PsychiatryP00001606T
P02688772T0000 |19 23|skinaris
P02689136A1851 |41 45|timehosp
P02689136A1851 |14 21|effects Compar
P02689439A0000 |48 50|ECas
P02689439A0000 |14 40|glutathione S-transferases Comparison with alkaline 
P02689439A0000 |120 131|conjugation hyperbilir
P02689439A0000 |90 100|isoenzymesrmacologic
P02689439A0000 |149 159|substrates7A0472 Whe
P02689439A0000 |165 176|glutathione[HCO3-] is 
P02689439A0000 |42 46|GSTsosph
P02689439A0000 |67 78|superfamilydase P00008
P02689439A0402 |68 74|degreease P0
P02689439A0402 |198 204|region CSF P
P02689439A0402 |44 50|pmGT10phatas
P02689439A0402 |212 224|rat Yb2 genedata of K-de
P02689439A0402 |111 123|rat Yb1 gene neonatal hy
P02689439A0402 |146 151|pmGT28997A
P02689439A0402 |78 86|homology171T0000
P02689439A0402 |33 40|regionskaline 
P02689439A0402 |97 103|regiongic as
P02689439A0402 |168 176|homologyO3-] is 
P02689439A0402 |136 142|regionmia. P
P02689544A0456 |0 5|ModelP0000
P02689544A0456 |45 52|incisorhatases
P02689544A0456 |18 27|abutmentsparison w
P02689544A0456 |87 96|abutmentsPharmacol
P02691557A0273 |4 13|incidence01606T007
P02691557A0273 |199 208|gestationCSF PCO2 
P02691557A0273 |56 57|h 
P02691557A0273 |122 136|concentrationsyperbilirubine
P02691557A0273 |189 195|periodnction
P02691557A0273 |97 100|agegic
P02691557A0273 |23 42|breathing movementson with alkaline ph
P02691557A0273 |140 150|plasma PGE P00008997
P02691811A0355 |69 74|spitese P0
P02691811A0355 |151 164|concentration0472 When CSF
P02691811A0355 |95 109|blood acidosislogic aspects 
P02691811A0355 |26 34|recoverywith alk
P02691811A0355 |36 52|plasma potassiumine phosphatases
P02691811A0355 |19 22|minari
P02691998A0672 |152 156|ET-1472 
P02691998A0672 |12 16|data76 C
P02691998A0672 |74 77|bed000
P02691998A0672 |128 148|bolus administrationlirubinemia. P000089
P02691998A0672 |102 105|bedspe
P02692881A0354 |35 40|womenline 
P02692881A0354 |362 378|sodium excretion33 Flurazepam th
P02692881A0354 |210 218|functione data o
P02692881A0354 |258 262|acidd wh
P02692881A0354 |322 339|calcium excretioner slope (1.21 +/
P02692881A0354 |353 358|level01094
P02692881A0354 |83 86|PIH000
P02692881A0354 |189 200|derangementnction of C
P02692881A0354 |267 276|reductionmpared to
P02692881A0354 |247 252|serumer di
P02692881A0354 |301 306|totala sig
P02692881A0354 |97 105|increasegic aspe
P02692881A0354 |280 296|sodium excretiontrols but still 
P02692881A0354 |109 119|heart rateof neonata
P02692881A0354 |72 77|womenP0000
P02692881A0354 |235 243|increase are no 
P02692881A0354 |65 70|womentidas
P02692881A0354 |168 172|toneO3-]
P02692881A0354 |3 13|comparison001606T007
P02693208A0166 |69 78|mutationsse P00008
P02693208A0166 |106 126|repeat recombinationts of neonatal hyper
P02693208A0166 |89 94|rad52armac
P02693208A0166 |21 25|roleison
P02693208A0166 |80 84|rad11T00
P02693208A0166 |33 46|recombinationkaline phosph
P02693208A0166 |168 177|sequencesO3-] is s
P02693593A0866 |48 59|amino acidsases and 5-
P02693593A0866 |12 19|protein76 Comp
P02693593A0866 |26 41|leader sequencewith alkaline p
P02694731A0241 |19 28|knowledgearison wi
P02694731A0241 |179 186|profilewn as a
P02694731A0241 |109 119|hypothesesof neonata
P02694731A0241 |132 142|hypothesesbinemia. P
P02694731A0241 |13 17|hand6 Co
P02694731A0241 |36 48|epidemiologyine phosphat
P02694731A0241 |52 61|Parkinson and 5-nu
P02694731A0241 |203 210|testingPCO2 th
P02694731A0241 |64 71|diseaseotidase
P02695914T0000 |4 21|stereoselectivity01606T0076 Compar
P02695914T0000 |25 36|drug action with alkal
P02700977A0444 |34 45|penetrationaline phosp
P02700977A0444 |82 95|XR bond/Silus0000 Pharmaco
P02700977A0444 |101 112|combinationaspects of 
P02700977A0444 |0 10|ScotchbondP00001606T
P02702566A0000 |17 26|cisplatinmparison 
P02702566A0000 |88 96|infusionharmacol
P02702566A0000 |31 45|5-fluorouracilalkaline phosp
P02702566A0000 |123 127|headperb
P02702566A0000 |132 143|neck cancerbinemia. P0
P02702566A0000 |67 71|daysdase
P02702566A0000 |2 13|combination0001606T007
P02702849A0418 |0 31|Metformin plasma concentrationsP00001606T0076 Comparison with 
P02702849A0418 |230 231|p 
P02702849A0418 |62 70|patientsleotidas
P02702849A0418 |114 116|mgon
P02702849A0418 |99 100|gc
P02702849A0418 |216 228|micrograms/l of K-deplet
P02702849A0418 |139 169|patients plasma concentrations. P00008997A0472 When CSF [HCO
P02703121T0000 |0 9|DiagnosisP00001606
P02703121T0000 |75 105|serum alanine aminotransferase008171T0000 Pharmacologic aspe
P02703121T0000 |21 43|sclerosing cholangitisison with alkaline pho
P02703121T0000 |49 60|blood donorses and 5-n
P02703925A0359 |207 222|sedimentability the data of K-
P02703925A0359 |779 786|surfacemide, s
P02703925A0359 |301 309|S valuesa signif
P02703925A0359 |727 747|proteoglycan contenthibitors (acetazolam
P02703925A0359 |39 51|subgroupings phosphatase
P02703925A0359 |445 452|findingor use 
P02703925A0359 |857 863|amountt depe
P02703925A0359 |314 327|proteoglycansly greater sl
P02703925A0359 |376 382|valuesthus a
P02703925A0359 |642 662|S value distributionceased. P00015731A00
P02703925A0359 |105 128|polydispersity profilescts of neonatal hyperbi
P02703925A0359 |424 429|areasth th
P02703925A0359 |670 689|cartilage thicknessvenous administrati
P02703925A0359 |252 256|signspla
P02703925A0359 |904 919|sedimentabilityecrease of pH i
P02703925A0359 |837 842|casesal p 
P02703925A0359 |530 548|matrix degradation P00013683A0210 Wh
P02703925A0359 |178 202|proteoglycan aggregationown as a function of CSF
P02703925A0359 |486 495|inversion night. P
P02703925A0359 |360 365|areas0733 
P02703925A0359 |966 973|samplesstudy o
P02703925A0359 |153 164|conclusions72 When CSF
P02703925A0359 |867 877|aggregatest on incre
P02703925A0359 |260 288|cartilage matrix degradationwhen compared to controls bu
P02703925A0359 |755 763|distancehazolami
P02703925A0359 |808 823|cartilage layerarly important 
P02703925A0359 |570 580|HW regionsremoval ap
P02703925A0359 |170 174|loss-] i
P02703925A0359 |504 511|pattern0045 Be
P02703925A0359 |74 100|sedimentation coefficients0008171T0000 Pharmacologic
P02703925A0359 |404 410|weightive hy
P02703925A0359 |947 951|zone0000
P02703925A0359 |463 480|cartilage samplespractice being 15
P02703925A0359 |619 624|areaslar v
P02703925A0359 |348 350|HW. 
P02703925A0359 |412 414|LWot
P02703925A0359 |340 346|weight 0.23 
P02704579A1078 |138 139|Pa
P02704579A1078 |90 113|gas exchange parametersrmacologic aspects of n
P02704579A1078 |79 85|CRS/BW71T000
P02704579A1078 |63 70|diseaseeotidas
P02704579A1078 |46 55|evolutionatases an
P02704579A1078 |14 26|relationship Comparison 
P02704579A1078 |161 173|gas exchangeCSF [HCO3-] 
P02704579A1078 |124 135|a/AO2 ratioerbilirubin
P02704579A1078 |196 210|lung mechanicsof CSF PCO2 th
P02704579A1078 |115 119|FIO2nata
P02705072A0464 |0 10|End pointsP00001606T
P02705072A0464 |59 69|infarctionnucleotida
P02705072A0464 |75 79|rate0081
P02705072A0464 |71 73|MI P
P02705072A0464 |84 89|death00 Ph
P02705296A0231 |85 88|kDa0 P
P02705296A0231 |72 83|kilodaltonsP00008171T0
P02705296A0231 |61 65|ORF1cleo
P02705296A0231 |24 30|weightn with
P02705296A0231 |38 49|polyproteine phosphata
P02705556A1049 |34 40|supplyaline 
P02705556A1049 |11 17|demand076 Co
P02705556A1049 |28 30|RCth
P02705556A1049 |5 7|RV16
P02705556A1049 |65 77|flow reservetidase P0000
P02707909A0209 |69 77|fractionse P0000
P02707909A0209 |25 28|UKM wi
P02707909A0209 |120 128|dialyses hyperbi
P02707909A0209 |3 21|alternative method001606T0076 Compar
P02707909A0209 |87 101|dialysate flowPharmacologic 
P02708288A0139 |51 56|LC/ADs and
P02708288A0139 |40 49|detectionphosphata
P02708288A0139 |177 188|soybean oilhown as a f
P02708288A0139 |89 93|acidarma
P02708288A0139 |164 172|soybeans [HCO3-]
P02708288A0139 |145 160|fluazifop-butyl08997A0472 When
P02708288A0139 |126 141|base hydrolysisbilirubinemia. 
P02708288A0139 |112 122|metabolismneonatal h
P02708288A0139 |0 21|Liquid chromatographyP00001606T0076 Compar
P02708288A0621 |292 306|oxidation modeill have a sig
P02708288A0621 |125 131|columnrbilir
P02708288A0621 |215 224|potentiala of K-de
P02708288A0621 |96 108|PRP-1 liquidogic aspects
P02708288A0621 |276 284|detector control
P02708288A0621 |67 75|aliquotsdase P00
P02708288A0621 |178 187|compoundsown as a 
P02708288A0621 |39 44|phase phos
P02708288A0621 |143 147|acid0008
P02708288A0621 |4 19|dichloromethane01606T0076 Comp
P02708288A0621 |235 236|V 
P02708353A1080 |102 106|genespec
P02708353A1080 |175 186|P-450e gene shown as a
P02708353A1080 |90 98|positionrmacolog
P02708353A1080 |48 77|transcription initiation siteases and 5-nucleotidase P0000
P02708353A1080 |0 28|Primer extension experimentsP00001606T0076 Comparison wi
P02708353A1452 |184 190|tissue a fun
P02708353A1452 |120 138|polysome fractions hyperbilirubinemi
P02708353A1452 |79 90|transcripts71T0000 Pha
P02708353A1452 |164 175|utilization [HCO3-] is
P02708353A1452 |71 75|gene P00
P02708353A1452 |19 44|polymerase chain reactionarison with alkaline phos
P02709081T0000 |0 10|ValidationP00001606T
P02709081T0000 |43 58|profile measuresphatases and 5
P02709081T0000 |28 39|work stylesth alkaline
P02709081T0000 |66 90|type A behaviour patternidase P00008171T0000 Pha
P02709081T0000 |18 24|surveypariso
P02709819A0495 |39 60|ciprofloxacin therapy phosphatases and 5-n
P02709819A0495 |9 12|ADRT00
P02711145T0000 |0 18|HIV infectiousnessP00001606T0076 Com
P02711145T0000 |27 31|AIDSith 
P02711167A0818 |18 25|turnoutparison
P02711167A0818 |132 138|damagebinemi
P02711167A0818 |31 40|PFB-groupalkaline 
P02711167A0818 |113 119|degreeeonata
P02711167A0818 |148 155|animals97A0472
P02711167A0818 |5 8|day160
P02711167A0818 |65 88|serum pepsinogen levelstidase P00008171T0000 P
P02711601A0601 |85 96|guinea pigs0 Pharmacol
P02711601A0601 |61 68|controlcleotid
P02711601A0601 |18 28|inhibitionparison wi
P02711601A0601 |106 107|%t
P02711601A0601 |32 57|acid phosphatase activitylkaline phosphatases and 
P02711601A0601 |117 118|%t
P02712246T0042 |33 48|characteristicskaline phosphat
P02712450A0989 |169 173|Type3-] 
P02712450A0989 |116 124|responseatal hyp
P02712450A0989 |250 256|groupsdispla
P02712450A0989 |24 29|mm Hgn wit
P02712450A0989 |176 184|responseshown as
P02712450A0989 |209 216|changeshe data
P02712450A0989 |13 18|PACO26 Com
P02712450A0989 |192 203|hypercapniaion of CSF 
P02712450A0989 |74 75|p0
P02712450A0989 |220 225|driveK-dep
P02712450A0989 |161 167|othersCSF [H
P02712450A0989 |109 113|Typeof n
P02712450A0989 |43 48|drivesphat
P02712450A0989 |99 107|subjectsc aspect
P02713310T0000 |0 14|Fundus changesP00001606T0076
P02713310T0000 |46 64|glomerulonephritisatases and 5-nucle
P02713310T0000 |104 110|reportects o
P02713310T0000 |76 82|drusen08171T
P02713310T0000 |19 23|typearis
P02713520T0000 |8 20|dose effects6T0076 Compa
P02713520T0000 |44 54|nuthatchesphatases a
P02713520T0000 |75 90|ptilochronology008171T0000 Pha
P02713520T0000 |56 70|cholinesterase 5-nucleotidas
P02713520T0000 |24 40|methyl parathionn with alkaline 
P02713994A0482 |49 59|antibodiesses and 5-
P02713994A0482 |67 74|mothersdase P0
P02713994A0482 |4 9|titer01606
P02713994A0482 |80 90|cord blood1T0000 Pha
P02713994A0482 |38 46|HSV typee phosph
P02713994A0482 |18 26|HSV typeparison 
P02714525A0529 |137 148|dose levelsia. P000089
P02714525A0529 |167 175|exposureCO3-] is
P02714525A0529 |89 99|dose levelarmacologi
P02714525A0529 |158 163|weeksen CS
P02714525A0529 |109 114|weeksof ne
P02714525A0529 |33 45|weight ratiokaline phosp
P02714525A0529 |0 13|Kidney weightP00001606T007
P02714852T0000 |55 64|evolutiond 5-nucle
P02714852T0000 |72 85|HLA-B allelesP00008171T000
P02714852T0000 |31 46|HLA-C sequencesalkaline phosph
P02714852T0000 |8 17|variation6T0076 Co
P02714852T0000 |21 26|HLA-Bison 
P02717133T0001 |2 8|method000160
P02717133T0001 |59 85|summary oxygen consumptionnucleotidase P00008171T000
P02717133T0001 |33 55|development conditionskaline phosphatases an
P02717349A0311 |0 3|MenP00
P02717349A0311 |44 51|fitnessphatase
P02717349A0311 |57 62|women5-nuc
P02718683A0142 |0 20|Handgrip dynamometryP00001606T0076 Compa
P02718683A0142 |56 64|patients 5-nucle
P02720966A0455 |119 127|patientsl hyperb
P02720966A0455 |105 115|meningitiscts of neo
P02720966A0455 |27 30|ADAith
P02720966A0455 |41 54|concentrationhosphatases a
P02720966A0455 |148 159|sensitivity97A0472 Whe
P02720966A0455 |166 177|specificityHCO3-] is s
P02720966A0455 |141 146|yearsP0000
P02720966A0455 |66 74|mu kat/Lidase P0
P02720966A0455 |187 197|efficiencyfunction o
P02720966A0455 |17 22|fluidmpari
P02721169A0171 |0 9|NERVTRACKP00001606
P02721169A0171 |114 127|relationshipsonatal hyperb
P02721169A0171 |70 76|mannere P000
P02721169A0171 |35 45|data itemsline phosp
P02723503T0000 |0 9|Swim-overP00001606
P02723503T0000 |14 32|alternative method Comparison with a
P02723503T0000 |55 66|spermatozoad 5-nucleot
P02724227T0000 |51 65|flap tolerances and 5-nucleo
P02724227T0000 |69 77|ischemiase P0000
P02724227T0000 |0 17|Perfusion washoutP00001606T0076 Co
P02725495A0929 |137 153|metazoan U2 RNAsia. P00008997A04
P02725495A0929 |15 23|sequenceComparis
P02725495A0929 |31 44|U2 RNA regionalkaline phos
P02725495A0929 |105 110|yeastcts o
P02725495A0929 |180 192|trypanosomesn as a funct
P02725495A0929 |69 101|pre-mRNA branchpoint recognitionse P00008171T0000 Pharmacologic 
P02725513A0617 |84 88|rule00 P
P02725513A0617 |120 129|promoters hyperbil
P02725513A0617 |94 117|metazoan RNA polymeraseologic aspects of neona
P02725513A0617 |31 50|CHO spacer promoteralkaline phosphatas
P02725513A0617 |141 150|G residueP00008997
P02725513A0617 |154 162|position2 When C
P02727909A0383 |186 189|HLP fu
P02727909A0383 |89 100|sensitivityarmacologic
P02727909A0383 |132 139|personsbinemia
P02727909A0383 |104 107|ADPect
P02727909A0383 |145 154|types IIa08997A047
P02727909A0383 |9 18|amplitudeT0076 Com
P02727909A0383 |41 47|plateshospha
P02727909A0383 |26 37|aggregationwith alkali
P02727909A0383 |54 62|decreasend 5-nuc
P02727909A0383 |159 166|IIb HLPn CSF [
P02727909A0383 |174 177|CHDs s
P02727909A0383 |70 79|thresholde P000081
P02729666A0267 |69 82|dentoskeletalse P00008171T
P02729666A0267 |12 34|intergroup differences76 Comparison with alk
P02729666A0267 |92 116|tissue profile variablesacologic aspects of neon
P02731611A0134 |170 195|Mental Research Institute-] is shown as a function
P02731611A0134 |22 31|rationaleson with 
P02731611A0134 |73 77|case0000
P02731611A0134 |53 57|viewand 
P02731611A0134 |142 152|principles00008997A0
P02731611A0134 |4 10|author01606T
P02731611A0134 |101 108|hiccupsaspects
P02731671A0000 |201 210|days/weekF PCO2 th
P02731671A0000 |191 197|hr/daytion o
P02731671A0000 |219 224|weeks K-de
P02731671A0000 |25 37|nickel oxide with alkali
P02731671A0000 |147 158|B6C3F1 mice997A0472 Wh
P02731671A0000 |90 107|nickel subsulfidermacologic aspect
P02731671A0000 |73 78|NiSO400008
P02731671A0000 |165 184|inhalation exposure[HCO3-] is shown as
P02731671A0000 |45 71|nickel sulfate hexahydratehatases and 5-nucleotidase
P02731671A0000 |80 83|H2O1T0
P02731671A0000 |109 114|Ni3S2of ne
P02731671A0000 |13 21|toxicity6 Compar
P02731671A0000 |131 142|F344/N ratsubinemia. P
P02731671A0000 |39 42|NiO ph
P02732341A0000 |100 105|woman aspe
P02732341A0000 |91 95|yearmaco
P02732341A0000 |74 82|neoplasm0008171T
P02732341A0000 |181 203|chloroacetate esterase as a function of CSF 
P02732341A0000 |52 59|studies and 5-
P02732341A0000 |228 237|diagnosised rats a
P02732341A0000 |140 148|lymphoma P000089
P02732341A0000 |168 176|stainingO3-] is 
P02733116T0000 |32 38|Healthlkalin
P02733116T0000 |9 28|National InstitutesT0076 Comparison wi
P02733690T0000 |86 95|reductase Pharmaco
P02733690T0000 |10 17|cloning0076 Co
P02733690T0000 |61 66|genescleot
P02733690T0000 |22 38|characterisationson with alkalin
P02733690T0000 |99 106|tobaccoc aspec
P02735364A1330 |70 71|pe
P02735364A1330 |13 18|model6 Com
P02735364A1330 |61 68|resultscleotid
P02735364A1330 |159 160|pn
P02735364A1330 |129 132|ageiru
P02735364A1330 |27 28|pi
P02735364A1330 |149 157|variable7A0472 W
P02735364A1330 |113 114|pe
P02735364A1330 |83 111|progesterone receptor status000 Pharmacologic aspects of
P02735364A1330 |20 25|graderison
P02735364A1330 |217 225|survivalof K-dep
P02736482A0550 |49 65|brain metastasesses and 5-nucleo
P02736482A0550 |30 47|radiation therapy alkaline phospha
P02736482A0550 |3 11|contrast001606T0
P02739739T0000 |0 25|COUP transcription factorP00001606T0076 Comparison
P02739739T0000 |45 73|steroid receptor superfamilyhatases and 5-nucleotidase P
P02739739T0000 |31 37|memberalkali
P02740196A0704 |102 107|rangespect
P02740196A0704 |31 45|classificationalkaline phosp
P02740196A0704 |88 94|centerharmac
P02740196A0704 |61 69|standardcleotida
P02740196A0704 |111 125|target numbers neonatal hype
P02740196A0704 |3 13|Experiment001606T007
P02740347A0644 |0 13|Cosmid clonesP00001606T007
P02740347A0644 |30 44|VNTR sequences alkaline phos
P02740347A0644 |66 85|restriction mappingidase P00008171T000
P02740347A0644 |117 119|kbta
P02740627A0137 |139 154|oxygen pressure. P00008997A047
P02740627A0137 |125 127|VArb
P02740627A0137 |73 75|fR00
P02740627A0137 |221 227|volume-deple
P02740627A0137 |256 261|spaceced w
P02740627A0137 |19 22|VO2ari
P02740627A0137 |48 52|VCO2ases
P02740627A0137 |156 160|PAO2When
P02740627A0137 |263 265|VDn 
P02740627A0137 |112 123|ventilationneonatal hy
P02740627A0137 |25 46|carbon dioxide output with alkaline phosph
P02740627A0137 |199 203|cowsCSF 
P02740627A0137 |78 96|minute ventilation171T0000 Pharmacol
P02740627A0137 |167 179|VE/VO2 ratioCO3-] is sho
P02740627A0137 |286 292|horsesbut st
P02740627A0137 |67 71|ratedase
P02740627A0137 |229 231|VTd 
P02740627A0137 |98 100|VEic
P02740627A0137 |4 17|oxygen uptake01606T0076 Co
P02740874A0957 |85 88|SO20 P
P02740874A0957 |11 17|damage076 Co
P02740874A0957 |42 50|controlsosphatas
P02740874A0957 |66 73|tissuesidase P
P02740955A0333 |102 112|deliveriesspects of 
P02740955A0333 |13 21|patients6 Compar
P02740955A0333 |78 86|patients171T0000
P02740955A0333 |35 49|mortality rateline phosphata
P02743842A0000 |204 208|PGE2CO2 
P02743842A0000 |420 423|ming w
P02743842A0000 |149 158|influence7A0472 Wh
P02743842A0000 |322 325|rater 
P02743842A0000 |55 66|cytoprotectd 5-nucleot
P02743842A0000 |80 86|mucosa1T0000
P02743842A0000 |114 131|stress ulcerationonatal hyperbilir
P02743842A0000 |397 402|shock effe
P02743842A0000 |334 340|mucosa21 +/-
P02743842A0000 |266 275|tissue pHompared t
P02743842A0000 |177 193|prostaglandin E2hown as a functi
P02743842A0000 |360 364|acid0733
P02743842A0000 |370 376|mM HClzepam 
P02743842A0000 |280 294|back-diffusiontrols but stil
P02743842A0000 |12 17|study76 Co
P02743842A0000 |407 412|ml/kg hypn
P02743842A0000 |308 318|blood flowficantly g
P02743842A0000 |277 278|Hc
P02743842A0000 |39 53|prostaglandins phosphatases 
P02743842A0000 |235 251|lesion formation are no longer d
P02743981A0347 |0 11|TranscriptsP00001606T0
P02743981A0347 |61 65|L11ecleo
P02743981A0347 |224 234|transcriptpleted rat
P02743981A0347 |141 149|NAB-L11eP0000899
P02743981A0347 |83 108|L1e-L10e-L12e transcripts000 Pharmacologic aspects
P02743981A0347 |168 183|NAB transcriptsO3-] is shown a
P02743981A0347 |206 209|ORF2 t
P02744123A0237 |51 58|speciess and 5
P02744123A0237 |162 166|timeSF [
P02744123A0237 |209 229|background luminancehe data of K-deplete
P02744123A0237 |65 78|rhesus monkeytidase P00008
P02744123A0237 |83 86|man000
P02744123A0237 |114 122|branchesonatal h
P02744123A0237 |19 26|resultsarison 
P02744490A0894 |0 8|EvidenceP0000160
P02744490A0894 |121 131|hypothesishyperbilir
P02744490A0894 |83 107|primer extension studies000 Pharmacologic aspect
P02744490A0894 |67 78|S1 nucleasedase P00008
P02744490A0894 |43 54|cDNA clonessphatases a
P02744490A0894 |242 249|domains longer
P02744490A0894 |141 151|PTHrP geneP00008997A
P02744490A0894 |174 205|mRNA transcription start pointss shown as a function of CSF PC
P02744490A0894 |18 27|structureparison w
P02744490A0894 |33 39|numberkaline
P02745280A0276 |17 21|PaO2mpar
P02745280A0276 |210 213|ATPe d
P02745280A0276 |150 164|concentrationsA0472 When CSF
P02745280A0276 |241 263|resonance spectroscopyo longer displaced whe
P02745280A0276 |126 133|changesbilirub
P02745280A0276 |228 231|31Ped 
P02745280A0276 |79 90|blood gases71T0000 Pha
P02745280A0276 |47 55|measurestases an
P02745280A0276 |178 187|phosphateown as a 
P02745280A0276 |8 13|level6T007
P02745280A0276 |189 204|phosphocreatinenction of CSF P
P02745280A0276 |99 120|lactate concentrationc aspects of neonatal
P02745444A0391 |4 33|transcription initiation site01606T0076 Comparison with al
P02745444A0391 |52 71|S1 nuclease mapping and 5-nucleotidase
P02745666A0000 |117 143|replacement therapy cyclestal hyperbilirubinemia. P0
P02745666A0000 |25 42|plasma oestradiol with alkaline ph
P02745666A0000 |12 20|biopsies76 Compa
P02745666A0000 |166 173|failureHCO3-] 
P02745666A0000 |44 46|E2ph
P02745666A0000 |66 68|P4id
P02745666A0000 |52 64|progesterone and 5-nucle
P02745666A0000 |83 91|patients000 Phar
P02745666A0000 |70 76|levelse P000
P02746099A0000 |4 12|mobility01606T00
P02746099A0000 |107 114|contacts of ne
P02746099A0000 |128 134|facetslirubi
P02746099A0000 |77 85|relation8171T000
P02746099A0000 |52 56|load and
P02746099A0000 |36 45|premolarsine phosp
P02747653A0910 |100 109|beginning aspects 
P02747653A0910 |59 67|stainingnucleoti
P02747653A0910 |130 135|stagerubin
P02747653A0910 |113 126|metamorphosiseonatal hyper
P02747653A0910 |22 29|proteinson wit
P02747653A0910 |80 88|tadpoles1T0000 P
P02747653A0910 |71 76|serum P000
P02748188A0091 |136 138|PSmi
P02748188A0091 |144 146|Ss00
P02748188A0091 |178 181|secown
P02748188A0091 |264 271|studies compar
P02748188A0091 |208 209|tt
P02748188A0091 |30 35|group alka
P02748188A0091 |129 134|groupirubi
P02748188A0091 |45 47|Ssha
P02748188A0091 |82 87|means0000 
P02748188A0091 |219 220|P 
P02748188A0091 |202 206|test PCO
P02748188A0091 |76 80|test0817
P02748188A0091 |37 39|PTne
P02748188A0091 |100 103|sec as
P02748595A0492 |70 77|lineagee P0000
P02748595A0492 |91 99|ADH-betamacologi
P02748595A0492 |41 44|ADHhos
P02748595A0492 |20 38|baboon liver classrison with alkalin
P02749215A0000 |35 44|hematurialine phos
P02749215A0000 |74 81|finding0008171
P02749215A0000 |9 20|proteinuriaT0076 Compa
P02749215A0000 |52 58|pyuria and 5
P02751080A0176 |16 20|shotompa
P02751080A0176 |43 50|minutessphatas
P02751080A0176 |24 31|bulletsn with 
P02751080A0176 |58 73|intensity level-nucleotidase P
P02751080A0176 |92 94|dBac
P02752303A0000 |0 14|Lithium delaysP00001606T0076
P02752303A0000 |75 96|plasma concentrations008171T0000 Pharmacol
P02752303A0000 |29 35|rhythmh alka
P02752303A0000 |134 145|weight lossnemia. P000
P02752303A0000 |63 71|hamsterseotidase
P02752303A0000 |108 110|mM o
P02752629A0163 |0 7|DynamicP000016
P02752629A0163 |52 75|methylene diphosphonate and 5-nucleotidase P00
P02752629A0163 |124 132|fractureerbiliru
P02752629A0163 |112 117|weeksneona
P02752629A0163 |19 30|scintigramsarison with
P02752651A0480 |34 43|Septemberaline pho
P02752651A0480 |180 191|disturbancen as a func
P02752651A0480 |162 164|ThSF
P02752651A0480 |106 116|impairmentts of neon
P02752651A0480 |89 100|paraparesisarmacologic
P02752651A0480 |132 142|modalitiesbinemia. P
P02752651A0480 |55 62|patientd 5-nuc
P02752651A0480 |20 30|departmentrison with
P02752651A0480 |3 12|admission001606T00
P02752651A0480 |153 158|level72 Wh
P02756731T0001 |0 14|ProstaglandinsP00001606T0076
P02756731T0001 |19 29|gallstonesarison wit
P02756878A0075 |51 62|occurrencess and 5-nuc
P02756878A0075 |99 107|patientsc aspect
P02756878A0075 |149 151|AF7A
P02756878A0075 |115 122|historynatal h
P02756878A0075 |4 10|nature01606T
P02756878A0075 |18 25|processparison
P02756878A0075 |71 81|arrhythmia P00008171
P02757033A0905 |171 184|transcription] is shown as
P02757033A0905 |194 199|genesn of 
P02757033A0905 |151 166|position effect0472 When CSF [
P02757033A0905 |24 30|effectn with
P02757033A0905 |78 81|arm171
P02757033A0905 |110 125|heterochromatinf neonatal hype
P02757033A0905 |50 55|geneses an
P02757862T0000 |66 79|defibrillatoridase P000081
P02757862T0000 |26 40|microprocessorwith alkaline 
P02757862T0000 |8 18|experience6T0076 Com
P02758382A0478 |0 7|ObesityP000016
P02758382A0478 |183 193|proportions a functi
P02758382A0478 |132 160|sex hormone binding globulinbinemia. P00008997A0472 When
P02758382A0478 |91 100|estradiolmacologic
P02758382A0478 |41 52|proportionshosphatases
P02758382A0478 |208 217|estradiolthe data 
P02758382A0478 |162 166|SHBGSF [
P02758382A0478 |168 174|levelsO3-] i
P02760922A0000 |48 63|core protein A1ases and 5-nucl
P02760922A0000 |75 84|component008171T00
P02760922A0000 |41 46|hnRNPhosph
P02760922A0000 |107 118|S particless of neonat
P02760922A0000 |22 39|ribonucleoproteinson with alkaline
P02760922A0000 |98 103|hnRNPic as
P02761008X0000 |0 29|Brain cholinesterase activityP00001606T0076 Comparison wit
P02761008X0000 |48 54|egretsases a
P02761008X0000 |115 135|brain cholinesterasenatal hyperbilirubin
P02761008X0000 |62 68|egretsleotid
P02761008X0000 |209 225|organophosphorushe data of K-dep
P02761008X0000 |198 203|death CSF 
P02761008X0000 |186 194|exposure functio
P02761008X0000 |87 99|night-heronsPharmacologi
P02761008X0000 |154 159|birds2 Whe
P02761008X0000 |142 150|activity00008997
P02761008X0000 |229 249|carbamate pesticidesd rats are no longer
P02761008X0000 |101 111|inhibitionaspects of
P02761008X0000 |137 140|ChEia.
P02761150A0000 |68 74|kidneyase P0
P02761150A0000 |122 129|controlyperbil
P02761150A0000 |149 153|rats7A04
P02761150A0000 |180 189|pregnancyn as a fu
P02761150A0000 |60 66|spleenucleot
P02761150A0000 |160 164|days CSF
P02761150A0000 |14 29|zinc deficiency Comparison wit
P02761150A0000 |53 58|liverand 5
P02761150A0000 |89 97|duodenumarmacolo
P02761150A0000 |172 176|days is 
P02761150A0000 |76 84|pancreas08171T00
P02761150A0000 |4 10|effect01606T
P02761150A0000 |33 45|trace metalskaline phosp
P02761492A0124 |50 57|genesises and 
P02761492A0124 |95 103|patientslogic as
P02761492A0124 |73 84|involvement00008171T00
P02761492A0124 |25 29|view wit
P02761492A0124 |4 12|findings01606T00
P02761537A0168 |0 13|Heating cellsP00001606T007
P02761537A0168 |20 29|degrees Crison wit
P02761537A0168 |260 271|readthroughwhen compar
P02761537A0168 |297 315|transcription unitave a significantl
P02761537A0168 |245 253|28S rRNAnger dis
P02761537A0168 |91 92|%m
P02761537A0168 |72 76|rRNAP000
P02761537A0168 |44 50|amountphatas
P02761537A0168 |187 193|regionfuncti
P02761537A0168 |156 181|transcription terminationWhen CSF [HCO3-] is shown
P02761537A0168 |100 113|control level aspects of n
P02761537A0168 |140 152|% inhibition P00008997A0
P02761537A0168 |238 241|ende n
P02761537A0168 |205 216|nucleotidesO2 the data
P02761540A0873 |34 40|NF-4FAaline 
P02761540A0873 |97 114|enhancer activitygic aspects of ne
P02761540A0873 |42 48|NF-4FBosphat
P02761540A0873 |54 68|AP-1 sequencesnd 5-nucleotid
P02761540A0873 |0 17|Deletion analysisP00001606T0076 Co
P02762006A0071 |0 4|CordP000
P02762006A0071 |64 71|lesionsotidase
P02762006A0071 |32 40|patientslkaline 
P02762198T0001 |17 24|reportsmpariso
P02762198T0001 |43 49|periodsphata
P02762198T0001 |30 35|cases alka
P02762198T0001 |7 15|syndrome06T0076 
P02762198T0001 |0 4|ReyeP000
P02763467A0903 |69 72|35Sse 
P02763467A0903 |297 304|N1L ORFave a s
P02763467A0903 |92 100|proteinsacologic
P02763467A0903 |160 167|viruses CSF [H
P02763467A0903 |56 64|patterns 5-nucle
P02763467A0903 |115 120|cellsnatal
P02763467A0903 |21 39|polyacrylamide gelison with alkaline
P02763467A0903 |262 267|pointen co
P02763467A0903 |185 189|spota fu
P02764797A0182 |0 5|PULSEP0000
P02764797A0182 |62 67|delayleoti
P02764797A0182 |150 168|imaging parametersA0472 When CSF [HC
P02764797A0182 |44 54|parametersphatases a
P02764797A0182 |125 139|sampling timesrbilirubinemia
P02764797A0182 |108 113|gates of n
P02764797A0182 |26 29|NMRwit
P02764797A0182 |72 80|durationP0000817
P02764797A0182 |191 209|gradient waveformstion of CSF PCO2 t
P02764797A0182 |172 186|rf pulse shape is shown as a
P02764797A0182 |115 123|rf phasenatal hy
P02764797A0182 |84 86|rf00
P02765001A0105 |168 176|criteriaO3-] is 
P02765001A0105 |228 242|family historyed rats are no
P02765001A0105 |122 126|rashyper
P02765001A0105 |178 188|dactylitisown as a f
P02765001A0105 |43 52|arthritissphatases
P02765001A0105 |9 13|JPsAT007
P02765001A0105 |131 140|arthritisubinemia.
P02765001A0105 |219 223|rash K-d
P02765001A0105 |246 255|psoriasisger displ
P02765001A0105 |190 194|nailctio
P02765001A0105 |18 26|patientsparison 
P02765214A0486 |71 80|arguments P0000817
P02765214A0486 |14 19|Kurti Comp
P02765214A0486 |22 28|demandson wi
P02765214A0486 |53 63|importanceand 5-nucl
P02766330A0779 |4 10|author01606T
P02766330A0779 |88 95|effectsharmaco
P02766330A0779 |104 123|calcium antagonistsects of neonatal hy
P02766330A0779 |144 155|application008997A0472
P02766330A0779 |20 27|accountrison w
P02766508A0421 |100 114|mean IQRST map aspects of ne
P02766508A0421 |72 83|map patternP00008171T0
P02766508A0421 |53 63|similarityand 5-nucl
P02766508A0421 |2 25|correlation coefficient0001606T0076 Comparison
P02766745T0000 |85 95|dairy cows0 Pharmaco
P02766745T0000 |60 68|placentaucleotid
P02766745T0000 |30 42|relationship alkaline ph
P02766745T0000 |73 81|mastitis00008171
P02766745T0000 |17 22|studympari
P02767166A0368 |204 210|myopiaCO2 th
P02767166A0368 |110 121|consequencef neonatal 
P02767166A0368 |133 139|damageinemia
P02767166A0368 |62 73|developmentleotidase P
P02767166A0368 |181 189|diabetes as a fu
P02767166A0368 |169 177|cataract3-] is s
P02767166A0368 |20 38|lipid peroxidationrison with alkalin
P02767166A0368 |84 92|cataract00 Pharm
P02767166A0368 |153 165|pathogenesis72 When CSF 
P02767733A0690 |17 24|gradingmpariso
P02767733A0690 |122 123|%y
P02767733A0690 |62 64|G2le
P02767733A0690 |45 50|caseshatas
P02767733A0690 |55 57|G1d 
P02767733A0690 |113 118|caseseonat
P02767733A0690 |87 93|spreadPharma
P02767733A0690 |69 71|G3se
P02772495A0641 |0 6|AsthmaP00001
P02772495A0641 |78 80|AT17
P02772495A0641 |73 74|%0
P02772495A0641 |52 61|ASA group and 5-nu
P02772495A0641 |95 96|%l
P02772495A0641 |65 66|%t
P02772495A0641 |100 110|INTR group aspects o
P02773507A0750 |103 108|valuepects
P02773507A0750 |92 94|CLac
P02773507A0750 |183 189|plasmas a fu
P02773507A0750 |61 77|sample estimatescleotidase P0000
P02773507A0750 |150 166|sample estimatesA0472 When CSF [
P02773507A0750 |198 202|drug CSF
P02773507A0750 |15 19|l/kgComp
P02773507A0750 |116 120|l/kgatal
P02773507A0750 |81 90|clearanceT0000 Pha
P02773507A0750 |2 7|value00016
P02773507A0750 |33 34|Vk
P02773507A0750 |204 209|CLunbCO2 t
P02773507A0750 |170 179|clearance-] is sho
P02773930T0000 |23 28|modelon wi
P02773930T0000 |13 19|kidney6 Comp
P02773930T0000 |40 55|hyperfiltrationphosphatases an
P02773930T0000 |59 65|humansnucleo
P02774271A0000 |102 106|acidspec
P02774271A0000 |150 158|pathwaysA0472 Wh
P02774271A0000 |179 187|fluoridewn as a 
P02774271A0000 |108 112|TFAA of 
P02774271A0000 |41 48|pathwayhosphat
P02774271A0000 |72 84|end productsP00008171T00
P02774271A0000 |189 190|Fn
P02774271A0000 |127 129|Bril
P02774271A0000 |118 125|bromideal hype
P02774271A0000 |0 9|HalothaneP00001606
P02774808A0194 |118 124|winteral hyp
P02774808A0194 |36 37|Pi
P02774808A0194 |61 67|summercleoti
P02774808A0194 |83 100|micrograms/100 ml000 Pharmacologic
P02774808A0194 |4 10|values01606T
P02775136A1151 |69 87|breathing patternsse P00008171T0000 
P02775136A1151 |135 146|developmentemia. P0000
P02775136A1151 |27 35|HAPE-S-Sith alka
P02775136A1151 |215 233|breathing patternsa of K-depleted ra
P02775136A1151 |240 245|causeno lo
P02775136A1151 |150 153|AMSA04
P02775136A1151 |96 104|altitudeogic asp
P02775136A1151 |6 13|results606T007
P02775136A1151 |262 265|AMSen 
P02775136A1151 |252 258|effectsplace
P02775333A1137 |0 10|BuflomedilP00001606T
P02775333A1137 |12 16|i.v.76 C
P02775333A1137 |194 198|dosen of
P02775333A1137 |83 88|mg/kg000 P
P02775333A1137 |43 51|increasesphatase
P02775333A1137 |124 129|mg/kgerbil
P02775333A1137 |63 69|outputeotida
P02775333A1137 |99 106|changesc aspec
P02775333A1137 |143 151|decrease0008997A
P02775333A1137 |174 182|increases shown 
P02775333A1137 |207 212|mg/kg the 
P02776471A0235 |32 39|animalslkaline
P02776471A0235 |58 68|responders-nucleotid
P02776471A0235 |112 120|responseneonatal
P02776471A0235 |86 93|pattern Pharma
P02776742A0000 |0 10|Heart rateP00001606T
P02776742A0000 |328 347|breathing apparatuspe (1.21 +/- 0.23 v
P02776742A0000 |150 157|firemenA0472 W
P02776742A0000 |181 183|yr a
P02776742A0000 |164 167|age [H
P02776742A0000 |84 100|humidity changes00 Pharmacologic
P02776742A0000 |252 254|SUsp
P02776742A0000 |185 192|VO2 maxa funct
P02776742A0000 |59 70|temperaturenucleotidas
P02776742A0000 |24 35|temperaturen with alka
P02776742A0000 |299 307|clothinge a sign
P02776742A0000 |242 250|uniforms longer 
P02776742A0000 |271 275|fireed t
P02776742A0000 |349 351|FE P
P02776742A0000 |108 116|clothing of neon
P02776742A0000 |227 239|fire fighterted rats are
P02776742A0000 |12 14|HR76
P02776742A0000 |313 317|selftly 
P02776742A0000 |43 57|blood pressuresphatases and 
P02776742A0000 |37 40|Trene 
P02776742A0000 |204 217|ml kg-1 min-1CO2 the data 
P02776823A0000 |205 214|i.v. doseO2 the da
P02776823A0000 |82 94|hydroxyethyl0000 Pharmac
P02776823A0000 |58 64|sodium-nucle
P02776823A0000 |27 43|pharmacokineticsith alkaline pho
P02776823A0000 |147 152|penem997A0
P02776823A0000 |13 22|tolerance6 Compari
P02776823A0000 |47 50|FCEtas
P02776823A0000 |220 227|mg.kg-1K-deple
P02776823A0000 |248 258|volunteersr displace
P02776823A0000 |66 68|5Rid
P02776823A0000 |78 80|1R17
P02776823A0000 |98 138|carbamoyloxymethyl-2-penem-3-carboxylateic aspects of neonatal hyperbilirubinemi
P02776823A0000 |70 72|6Se 
P02777797A0720 |0 22|DNA blot hybridizationP00001606T0076 Compari
P02777797A0720 |41 51|rat genomehosphatase
P02777797A0720 |78 82|gene171T
P02777797A0720 |92 115|PtdIns transfer proteinacologic aspects of neo
P02778237A0585 |68 75|problemase P00
P02778237A0585 |41 43|IAho
P02778237A0585 |11 15|term076 
P02778237A0585 |87 89|IAPh
P02778237A0585 |100 130|maintenance prednisone therapy aspects of neonatal hyperbili
P02778873A0761 |19 23|CRL3aris
P02778873A0761 |122 127|DR-A2yperb
P02778873A0761 |8 15|segment6T0076 
P02778873A0761 |56 73|enhancer function 5-nucleotidase P
P02778873A0761 |112 117|DR-A1neona
P02778873A0761 |101 110|sequencesaspects o
P02779752A0000 |3 13|1-Naphthyl001606T007
P02779752A0000 |26 30|1-NPwith
P02779752A0000 |167 182|agonist actionsCO3-] is shown 
P02779752A0000 |14 24|piperazine Compariso
P02779752A0000 |97 110|5-HT2 subtypegic aspects o
P02779752A0000 |58 89|serotonin antagonist properties-nucleotidase P00008171T0000 Ph
P02779752A0000 |114 122|receptoronatal h
P02779752A0000 |190 200|5-HT1 sitection of C
P02779752A0776 |3 17|m-Chlorophenyl001606T0076 Co
P02779752A0776 |94 99|TFMPPologi
P02779752A0776 |150 161|5-HT1 sitesA0472 When 
P02779752A0776 |240 244|1-NPno l
P02779752A0776 |30 34|mCPP alk
P02779752A0776 |18 28|piperazineparison wi
P02779752A0776 |257 267|ketanserined when co
P02779752A0776 |82 92|piperazine0000 Pharm
P02779752A0776 |58 81|m-trifluoromethylphenyl-nucleotidase P00008171
P02779752A0776 |44 49|mg/kgphata
P02779752A0776 |220 232|methysergideK-depleted r
P02779752A0776 |198 204|effect CSF P
P02779752A0776 |109 114|mg/kgof ne
P02780157A0576 |278 287|MP systemontrols b
P02780157A0576 |156 164|reactionWhen CSF
P02780157A0576 |248 256|standingr displa
P02780157A0576 |261 270|depletionhen compa
P02780157A0576 |330 335|HBsAg (1.2
P02780157A0576 |62 70|patientsleotidas
P02780157A0576 |180 189|spleen MPn as a fu
P02780157A0576 |30 35|liver alka
P02780157A0576 |40 58|spleen MP functionphosphatases and 5
P02780157A0576 |131 135|lackubin
P02780157A0576 |229 239|overstraind rats are
P02780157A0576 |19 26|featurearison 
P02780157A0576 |76 79|VHA081
P02780157A0576 |315 326|stimulationy greater s
P02780157A0576 |172 176|part is 
P02780157A0576 |96 113|HBsAg carriershipogic aspects of n
P02781495T0001 |0 7|ChangesP000016
P02781495T0001 |11 36|xanthine oxidase activity076 Comparison with alkal
P02781495T0001 |40 48|patientsphosphat
P02781495T0001 |66 73|failureidase P
P02781567A0544 |2 6|soap0001
P02781567A0544 |73 88|stratum corneum00008171T0000 P
P02781567A0544 |28 36|solutionth alkal
P02781567A0544 |11 16|water076 C
P02781567A0544 |23 26|v/von 
P02783181A0000 |51 69|antacid magaldrates and 5-nucleotida
P02783181A0000 |124 134|blood flowerbilirubi
P02783181A0000 |180 183|ratn a
P02783181A0000 |33 43|activitieskaline pho
P02783181A0000 |97 104|effectsgic asp
P02783181A0000 |71 80|ES Riopan P0000817
P02783181A0000 |139 155|mucus secretions. P00008997A0472
P02784507A0000 |138 143|cellsa. P0
P02784507A0000 |10 37|immunodeficiency virus type0076 Comparison with alkali
P02784507A0000 |41 46|HIV-1hosph
P02784507A0000 |157 164|periodshen CSF
P02784507A0000 |76 89|T lymphocytes08171T0000 Ph
P02784507A0000 |71 74|CD4 P0
P02784507A0000 |116 124|provirusatal hyp
P02787430A0124 |41 57|biopsy specimenshosphatases and 
P02787430A0124 |12 24|panniculitis76 Compariso
P02787430A0124 |63 79|cytophagocytosiseotidase P000081
P02789062A0000 |51 55|genes an
P02789062A0000 |27 30|4F2ith
P02789062A0000 |121 127|eventshyperb
P02789062A0000 |61 73|model systemcleotidase P
P02789062A0000 |44 49|4F2HCphata
P02789062A0000 |77 84|studies8171T00
P02789062A0000 |161 176|gene expressionCSF [HCO3-] is 
P02789062A0000 |197 214|T-cell activationf CSF PCO2 the da
P02789062A0000 |37 42|chainne ph
P02789062A1420 |2 6|cDNA0001
P02789062A1420 |129 144|oligonucleotideirubinemia. P00
P02789062A1420 |166 193|NF-4FB recognition sequenceHCO3-] is shown as a functi
P02789062A1420 |83 107|lambda gt11 cDNA library000 Pharmacologic aspect
P02789062A1420 |20 51|NF-4FB enhancer binding proteinrison with alkaline phosphatase
P02789180A0407 |84 95|hypertrophy00 Pharmaco
P02789180A0407 |39 50|hypertrophy phosphatas
P02789180A0407 |101 109|patientsaspects 
P02789217A1323 |54 69|polyadenylationnd 5-nucleotida
P02789217A1323 |94 102|distanceologic a
P02789217A1323 |73 78|sites00008
P02789217A1323 |8 24|IL6 mRNA species6T0076 Compariso
P02789217A1323 |110 119|kilobasesf neonata
P02790009A0375 |0 19|Sequencing analysisP00001606T0076 Comp
P02790009A0375 |124 130|regionerbili
P02790009A0375 |94 105|nucleotidesologic aspe
P02790009A0375 |145 153|fragment08997A04
P02790009A0375 |55 64|fragmentsd 5-nucle
P02790009A1052 |69 75|regionse P00
P02790009A1052 |104 130|serine protease inhibitorsects of neonatal hyperbili
P02790009A1052 |132 140|residuesbinemia.
P02790009A1052 |11 18|protein076 Com
P02792270A1220 |170 183|flexion phase-] is shown a
P02792270A1220 |91 100|responsesmacologic
P02792270A1220 |14 29|EPSP components Comparison wit
P02792270A1220 |104 122|flexor motoneuronsects of neonatal h
P02792270A1220 |149 158|amplitude7A0472 Wh
P02792430A0000 |0 11|ExperimentsP00001606T0
P02792430A0000 |148 159|development97A0472 Whe
P02792430A0000 |225 233|vagotomyleted ra
P02792430A0000 |113 137|prostaglandins synthesiseonatal hyperbilirubinem
P02792430A0000 |36 47|guinea pigsine phospha
P02792430A0000 |213 217|ratsata 
P02792430A0000 |24 28|ratsn wi
P02792430A0000 |99 109|inhibitionc aspects 
P02792430A0000 |173 179|oedemais sho
P02792430A0000 |237 248|guinea pigsre no longe
P02792430A0000 |204 209|serumCO2 t
P02793216A0876 |137 147|importanceia. P00008
P02793216A0876 |13 17|hand6 Co
P02793216A0876 |151 154|CgA047
P02793216A0876 |27 39|conservationith alkaline
P02793216A0876 |47 75|membrane attachment sequencetases and 5-nucleotidase P00
P02793216A0876 |19 23|lackaris
P02793216A0876 |102 106|acidspec
P02793620A0214 |92 106|Red Poll bullsacologic aspec
P02793620A0214 |124 132|pastureserbiliru
P02793620A0214 |63 74|parturitioneotidase P0
P02793620A0214 |78 87|Charolais171T0000 
P02793620A0214 |24 28|cowsn wi
P02793753A0354 |68 73|l/minase P
P02793753A0354 |145 155|dispersion08997A0472
P02793753A0354 |58 61|CFV-nu
P02793753A0354 |106 111|sitests of
P02793753A0354 |12 16|lobe76 C
P02793753A0354 |96 98|PAog
P02793753A0354 |22 35|PA dispersionson with alka
P02793753A0354 |80 84|flow1T00
P02793753A0354 |49 54|cmH2Oses a
P02794828A0214 |4 10|system01606T
P02794828A0214 |121 130|pacemakerhyperbili
P02794828A0214 |63 76|microcomputereotidase P000
P02794828A0214 |42 47|heartospha
P02795923A0000 |3 8|order00160
P02795923A0000 |44 58|CT appearancesphatases and 5
P02795923A0000 |75 84|pneumonia008171T00
P02795923A0000 |166 171|lungsHCO3-
P02795923A0000 |121 126|studyhyper
P02795923A0000 |177 184|autopsyhown as
P02795923A0000 |189 196|surgerynction 
P02796216A0063 |4 11|disease01606T0
P02796216A0063 |28 34|courseth alk
P02796216A0063 |73 86|enterorrhagia00008171T0000
P02796216A0063 |47 64|jaundice syndrometases and 5-nucle
P02796216A0063 |110 117|roseolaf neona
P02796216A0063 |96 106|appearanceogic aspec
P02796988A0735 |70 89|footprinting assayse P00008171T0000 Ph
P02796988A0735 |94 112|gel shift analysisologic aspects of 
P02796988A0735 |44 49|sitesphata
P02796988A0735 |127 130|Sp1ili
P02796988A0735 |4 28|transcription factor Sp101606T0076 Comparison wi
P02797877A0475 |85 93|regrowth0 Pharma
P02797877A0475 |122 133|antibioticsyperbilirub
P02797877A0475 |107 112|hourss of 
P02797877A0475 |23 33|microgramson with al
P02797877A0475 |42 52|microgramsosphatases
P02797877A0475 |36 39|PEFine
P02797877A0475 |4 19|combination PIP01606T0076 Comp
P02798953A0307 |17 24|mothersmpariso
P02798953A0307 |133 144|consistencyinemia. P00
P02798953A0307 |183 192|stabilitys a funct
P02798953A0307 |36 43|infantsine pho
P02798953A0307 |7 13|sample06T007
P02798953A0307 |162 177|days postpartumSF [HCO3-] is s
P02798953A0307 |92 97|WPL-Racolo
P02798953A0307 |114 120|levelsonatal
P02798953A0307 |80 90|instrument1T0000 Pha
P02798953A0307 |200 215|administrationsSF PCO2 the dat
P02798953A0307 |55 64|subscalesd 5-nucle
P02799892A0154 |102 113|transfusionspects of n
P02799892A0154 |131 134|PNHubi
P02799892A0154 |41 46|cellshosph
P02799892A0154 |86 95|hemolysis Pharmaco
P02799892A0154 |48 53|WRBCsases 
P02799892A0154 |117 125|patientstal hype
P02799892A0154 |16 19|useomp
P02800417A0332 |103 119|histamine valuespects of neonata
P02800417A0332 |132 133|pb
P02800417A0332 |121 122|rh
P02800417A0332 |53 64|correlationand 5-nucle
P02800417A0332 |7 12|group06T00
P02800417A0332 |83 98|PC20 PGF2 alpha000 Pharmacolog
P02800417A0332 |16 26|asthmaticsomparison 
P02800435A0000 |154 160|system2 When
P02800435A0000 |43 47|catsspha
P02800435A0000 |125 130|fieldrbili
P02800435A0000 |132 135|PMFbin
P02800435A0000 |104 105|Te
P02800435A0000 |52 57|mg/kg and 
P02800435A0000 |92 98|effectacolog
P02800435A0000 |6 17|experiments606T0076 Co
P02800435A0000 |168 171|legO3-
P02802280A0495 |50 52|TSes
P02802280A0495 |15 26|differencesComparison 
P02802280A0495 |61 64|PTScle
P02805945A0000 |305 313|degree Cgnifican
P02805945A0000 |127 135|culturesilirubin
P02805945A0000 |26 31|cystswith 
P02805945A0000 |180 185|yearsn as 
P02805945A0000 |363 371|seawater3 Fluraz
P02805945A0000 |329 345|microEin m-2 s-1e (1.21 +/- 0.23
P02805945A0000 |106 113|cosinorts of n
P02805945A0000 |192 213|laboratory conditionsion of CSF PCO2 the d
P02805945A0000 |316 324|lighting greater
P02805945A0000 |255 265|view pointaced when 
P02805945A0000 |36 48|growth ratesine phosphat
P02805945A0000 |283 294|temperaturels but stil
P02805945A0000 |4 15|percentages01606T0076 
P02805945A0000 |139 167|Scripsiella trochoidea Stein. P00008997A0472 When CSF [H
P02806916A0000 |234 241|oc cDNAs are n
P02806916A0000 |29 42|oryzacystatinh alkaline ph
P02806916A0000 |208 211|DNAthe
P02806916A0000 |121 147|lambda EMBL3 phage libraryhyperbilirubinemia. P00008
P02806916A0000 |180 187|digestsn as a 
P02806916A0000 |191 195|ricetion
P02806916A0000 |82 90|cystatin0000 Pha
P02806916A0000 |247 252|probeer di
P02806916A0000 |95 99|ricelogi
P02806916A0000 |165 171|Sau3AI[HCO3-
P02806916A0000 |51 80|cysteine proteinase inhibitors and 5-nucleotidase P0000817
P02806916A0000 |44 46|Ocph
P02806916A0000 |10 19|DNA clone0076 Comp
P02807780A0143 |153 162|diagnosis72 When C
P02807780A0143 |122 127|areasyperb
P02807780A0143 |97 105|staininggic aspe
P02807780A0143 |57 58|%5
P02807780A0143 |26 34|solutionwith alk
P02807780A0143 |132 135|CISbin
P02807780A0143 |80 83|min1T0
P02807780A0143 |66 72|M NaClidase 
P02807780A0143 |4 7|use016
P02807780A0143 |38 52|methylene bluee phosphatases
P02808232A0681 |20 33|micrograms/kgrison with al
P02808232A0681 |67 78|reliabilitydase P00008
P02808232A0681 |82 83|%0
P02808232A0681 |6 12|limits606T00
P02809116A0237 |85 93|husbands0 Pharma
P02809116A0237 |74 81|effects0008171
P02809116A0237 |29 36|effectsh alkal
P02809116A0237 |121 133|satisfactionhyperbilirub
P02809116A0237 |95 105|retirementlogic aspe
P02809116A0237 |146 151|wives8997A
P02809651A0492 |116 125|questionsatal hype
P02809651A0492 |46 59|meta-analysisatases and 5-
P02809651A0492 |38 42|rolee ph
P02809651A0492 |8 12|turn6T00
P02809651A0492 |71 81|clinicians P00008171
P02809651A0492 |86 99|policy makers Pharmacologi
P02809722A0926 |34 45|improvementaline phosp
P02809722A0926 |78 90|GH secretion171T0000 Pha
P02809722A0926 |19 26|patientarison 
P02809831A0799 |17 21|PPSFmpar
P02809831A0799 |46 53|amountsatases 
P02809831A0799 |24 32|DBP siden with a
P02809831A0799 |57 71|bone formation5-nucleotidase
P02809831A0799 |77 81|bone8171
P02809831A0799 |3 11|contrast001606T0
P02810911A0372 |18 26|presenceparison 
P02810911A0372 |30 37|absence alkali
P02810911A0372 |41 54|neuroblastomahosphatases a
P02810911A0372 |107 120|tumor markerss of neonatal
P02810911A0372 |77 94|131I-MIBG imaging8171T0000 Pharmac
P02810911A0372 |4 14|accuracies01606T0076
P02811378A0250 |116 121|ridgeatal 
P02811378A0250 |79 85|mucosa71T000
P02811378A0250 |15 20|formsCompa
P02811378A0250 |129 136|maxillairubine
P02811378A0250 |24 29|casesn wit
P02811378A0250 |144 152|mandible008997A0
P02811378A0250 |54 61|infantsnd 5-nu
P02811378A0379 |156 169|cell epulidesWhen CSF [HCO
P02811378A0379 |46 54|stainingatases a
P02811378A0379 |92 103|cell tumorsacologic as
P02811378A0379 |124 128|noneerbi
P02811378A0379 |59 71|S100 proteinnucleotidase
P02811378A0379 |20 27|studiesrison w
P02813369A0390 |113 119|haremseonata
P02813369A0390 |75 86|territories008171T0000
P02813369A0390 |28 33|malesth al
P02813369A0390 |151 160|neighbors0472 When
P02813369A0390 |57 62|years5-nuc
P02813369A0390 |127 132|yearsiliru
P02813404T0000 |79 85|stages71T000
P02813404T0000 |14 26|antigen gene Comparison 
P02813404T0000 |89 104|spermatogenesisarmacologic asp
P02814182A1211 |3 7|rats0016
P02814182A1211 |63 71|ABSTRACTeotidase
P02814182A1211 |89 94|WORDSarmac
P02814182A1211 |42 47|4-EPIospha
P02814820A0967 |200 207|minutesSF PCO2
P02814820A0967 |261 267|solidshen co
P02814820A0967 |144 148|t1/20089
P02814820A0967 |209 210|ph
P02814820A0967 |181 189|Billroth as a fu
P02814820A0967 |11 20|Roux limb076 Compa
P02814820A0967 |73 81|emptying00008171
P02814820A0967 |85 92|liquids0 Pharm
P02814820A0967 |156 160|RouxWhen
P02814820A0967 |43 53|pacemakerssphatases 
P02814820A0967 |111 115|rate neo
P02814820A0967 |129 142|Billroth dogsirubinemia. P
P02814820A0967 |172 179|minutes is sho
P02815229A0139 |119 122|14Cl h
P02815229A0139 |92 96|doseacol
P02815229A0139 |41 50|mg t.i.d.hosphatas
P02815229A0139 |123 132|diltiazemperbiliru
P02815229A0139 |61 65|dayscleo
P02815229A0139 |23 32|mg t.i.d.on with a
P02815229A0139 |67 76|treatmentdase P000
P02815229A0139 |114 117|MBqona
P02815229A0139 |4 14|treatments01606T0076
P02816251A0397 |152 159|surface472 Whe
P02816251A0397 |28 39|capillariesth alkaline
P02816251A0397 |113 120|networkeonatal
P02816251A0397 |168 178|ventriclesO3-] is sh
P02817724A0075 |68 74|planesase P0
P02817724A0075 |36 48|T2 sequencesine phosphat
P02817724A0075 |29 31|T1h 
P02817724A0075 |53 58|scansand 5
P02817724A0075 |4 15|examination01606T0076 
P02818122A0000 |16 27|informationomparison w
P02818122A0000 |196 202|nucleiof CSF
P02818122A0000 |179 185|cortexwn as 
P02818122A0000 |147 160|relationships997A0472 When
P02818122A0000 |130 142|distributionrubinemia. P
P02818122A0000 |66 75|claustrumidase P00
P02818122A0000 |8 12|deal6T00
P02818122A0000 |48 58|morphologyases and 5
P02818122A0000 |87 101|animal speciesPharmacologic 
P02818260T0000 |10 16|glioma0076 C
P02820128A1333 |3 8|terms00160
P02820128A1333 |72 93|hexanucleotide ATTGTTP00008171T0000 Pharma
P02820128A1333 |12 32|sequence repetitions76 Comparison with a
P02820128A1333 |160 167|ORF T3C CSF [H
P02820128A1333 |124 137|dyad symmetryerbilirubinem
P02820128A1333 |58 64|copies-nucle
P02820128A1333 |113 120|regionseonatal
P02820128A1670 |237 248|palindromesre no longe
P02820128A1670 |114 124|palindromeonatal hyp
P02820128A1670 |264 274|T2 protein compared 
P02820128A1670 |299 304|unitse a s
P02820128A1670 |182 190|homologyas a fun
P02820128A1670 |211 218|insulin data o
P02820128A1670 |77 88|coincidence8171T0000 P
P02820128A1670 |134 137|endnem
P02820128A1670 |156 172|protein sequenceWhen CSF [HCO3-]
P02820128A1670 |54 57|ORFnd 
P02820128A1670 |200 207|B chainSF PCO2
P02820128A1670 |96 99|endogi
P02820128A1670 |38 45|domainse phosp
P02820128A1670 |4 16|significance01606T0076 C
P02821340A0434 |19 27|exercisearison w
P02821340A0434 |181 186|speed as a
P02821340A0434 |134 154|mm Hg X ml-1 X min-1nemia. P00008997A047
P02821340A0434 |160 168|workload CSF [HC
P02821340A0434 |193 198|gradeon of
P02821340A0434 |29 32|DCRh a
P02821340A0434 |73 78|value00008
P02821340A0434 |176 179|kphsho
P02821340A0434 |40 47|UT dogsphospha
P02821340A0434 |96 116|mm Hg X ml-1 X min-1ogic aspects of neon
P02821340A0434 |190 191|%c
P02824334A0972 |6 10|data606T
P02824334A0972 |28 49|G-protein gene familyth alkaline phosphata
P02824334A0972 |93 104|chromosomescologic asp
P02825139A0661 |19 22|DNAari
P02825139A0661 |78 92|acid sequences171T0000 Pharm
P02825139A0661 |42 50|homologyosphatas
P02825750A0260 |16 24|patientsompariso
P02825750A0260 |29 42|response rateh alkaline ph
P02825750A0260 |49 50|%s
P02825750A0260 |70 78|responsee P00008
P02826127A0709 |220 230|cell linesK-depleted
P02826127A0709 |61 79|SV40 octamer motifcleotidase P000081
P02826127A0709 |37 48|interactionne phosphat
P02826127A0709 |111 125|protein oct-B2 neonatal hype
P02826127A0709 |189 197|extractsnction o
P02826127A0709 |156 165|componentWhen CSF 
P02826717A0179 |0 6|AnoxiaP00001
P02826717A0179 |92 102|water flowacologic a
P02826717A0179 |67 73|oxygendase P
P02826717A0179 |110 114|gillf ne
P02826717A0179 |39 43|gill pho
P02826717A0179 |49 54|waterses a
P02826729A0790 |68 78|B-6 intakease P00008
P02826729A0790 |88 92|ratsharm
P02826729A0790 |50 52|WBes
P02826729A0790 |8 12|4-PA6T00
P02826729A0790 |0 6|GrowthP00001
P02826729A0790 |17 34|14C turnover datamparison with alk
P02828926A1870 |24 31|factorsn with 
P02828926A1870 |135 143|programsemia. P0
P02828926A1870 |193 215|muscle differentiationon of CSF PCO2 the dat
P02828926A1870 |147 168|actin gene expression997A0472 When CSF [HC
P02829183A0117 |0 21|DNA sequence analysisP00001606T0076 Compar
P02829183A0117 |78 89|translocase171T0000 Ph
P02829183A0117 |42 48|clonesosphat
P02829183A0117 |69 74|formsse P0
P02830214A0000 |51 61|activitiess and 5-nu
P02830214A0000 |29 32|ACZh a
P02830214A0000 |47 49|Clta
P02830214A0000 |14 27|acetazolamide Comparison w
P02830214A0000 |4 10|effect01606T
P02830214A0000 |37 41|HCO3ne p
P02830214A0000 |115 137|microelectrode methodsnatal hyperbilirubinem
P02830214A0000 |71 80|ear fluid P0000817
P02830265A0341 |17 34|polypeptide chainmparison with alk
P02830265A0341 |46 53|daltonsatases 
P02830265A0341 |79 92|reading frame71T0000 Pharm
P02830265A0341 |0 6|RPA190P00001
P02830282A0155 |16 26|A1 proteinomparison 
P02830282A0155 |61 72|UP1 proteincleotidase 
P02830282A0155 |161 172|amino acidsCSF [HCO3-]
P02830282A0155 |47 55|fragmenttases an
P02830282A0155 |142 154|polypeptides00008997A047
P02830282A0155 |114 126|V-8 proteaseonatal hyper
P02831398A0346 |0 7|IrmiereP000016
P02831398A0346 |13 15|W.6 
P02831556A0173 |118 126|responseal hyper
P02831556A0173 |41 48|mothershosphat
P02831556A0173 |72 76|painP000
P02831556A0173 |6 15|offspring606T0076 
P02831556A0173 |130 138|morphinerubinemi
P02831556A0173 |23 32|alpha-MSHon with a
P02831556A0173 |84 90|adults00 Pha
P02831796A0000 |85 97|similarities0 Pharmacolo
P02831796A0000 |199 205|humansCSF PC
P02831796A0000 |41 51|lentivirushosphatase
P02831796A0000 |107 129|immunodeficiency viruss of neonatal hyperbil
P02831796A0000 |31 34|SIValk
P02831796A0000 |163 188|immunodeficiency syndromeF [HCO3-] is shown as a f
P02831796A0000 |145 150|agent08997
P02831796A0000 |7 29|immunodeficiency virus06T0076 Comparison wit
P02831796A0000 |190 194|AIDSctio
P02832149A1009 |254 264|activationlaced when
P02832149A1009 |12 18|change76 Com
P02832149A1009 |224 235|consequencepleted rats
P02832149A1009 |173 184|amino acidsis shown as
P02832149A1009 |145 154|insertion08997A047
P02832149A1009 |199 214|myb transcriptsCSF PCO2 the da
P02832149A1009 |26 31|ratiowith 
P02832149A1009 |4 8|lack0160
P02832149A1009 |114 117|mybona
P02832149A1009 |272 290|mouse myb oncogened to controls but 
P02832149A1009 |51 59|productss and 5-
P02832293T0000 |51 58|Cushings and 5
P02832293T0000 |61 69|syndromecleotida
P02832293T0000 |11 17|CRF-41076 Co
P02832293T0000 |74 81|obesity0008171
P02832293T0000 |4 7|use016
P02832293T0000 |38 47|diagnosise phospha
P02832744A0403 |76 83|chicken08171T0
P02832744A0403 |12 27|mos transcripts76 Comparison w
P02832744A0403 |88 101|quail ovariesharmacologic 
P02832744A0403 |31 39|Northernalkaline
P02832744A0403 |106 112|testests of 
P02832744A0403 |46 54|analysesatases a
P02832744A0403 |41 44|RNAhos
P02832744A0403 |58 61|RNA-nu
P02833012A0428 |137 148|amino acidsia. P000089
P02833012A0428 |30 41|nucleotides alkaline p
P02833012A0428 |14 20|L mRNA Compa
P02833012A0428 |75 88|reading frame008171T0000 P
P02833012A0428 |109 118|L proteinof neonat
P02833012A0428 |156 158|MWWh
P02833021A1185 |186 203|promoter function function of CSF 
P02833021A1185 |29 41|organizationh alkaline p
P02833021A1185 |75 81|repeat008171
P02833021A1185 |111 122|enhancement neonatal h
P02833021A1185 |56 61|units 5-nu
P02833021A1185 |4 11|results01606T0
P02833021A1185 |136 144|promotermia. P00
P02833049A0630 |0 10|VariationsP00001606T
P02833049A0630 |29 31|U3h 
P02833049A0630 |54 64|insertionsnd 5-nucle
P02833049A0630 |69 78|deletionsse P00008
P02833049A1041 |343 353|cell types23 vs. P00
P02833049A1041 |57 67|cell lines5-nucleoti
P02833049A1041 |198 209|RD-114 mRNA CSF PCO2 t
P02833049A1041 |26 42|state RNA levelswith alkaline ph
P02833049A1041 |268 272|locipare
P02833049A1041 |176 184|majorityshown as
P02833049A1041 |125 136|transcriptsrbilirubine
P02833049A1041 |3 11|analysis001606T0
P02833049A1041 |155 163|products When CS
P02833101T0000 |42 62|bone marrow necrosisosphatases and 5-nuc
P02833101T0000 |73 93|parvovirus infection00008171T0000 Pharma
P02833101T0000 |26 40|cell disorderswith alkaline 
P02833101T0000 |9 15|crisisT0076 
P02833517A0467 |51 59|cleavages and 5-
P02833517A0467 |73 80|element0000817
P02833517A0467 |29 38|sequencesh alkalin
P02834478A0000 |51 59|interests and 5-
P02834478A0000 |14 29|weight heparins Comparison wit
P02834478A0000 |113 122|Xa factoreonatal h
P02834478A0000 |103 109|actionpects 
P02834843A0000 |169 179|rifampicin3-] is sho
P02834843A0000 |149 152|CGP7A0
P02834843A0000 |241 245|testo lo
P02834843A0000 |181 184|RMP as
P02834843A0000 |60 69|rifabutinucleotida
P02834843A0000 |107 110|RPEs o
P02834843A0000 |17 25|activitymparison
P02834843A0000 |290 304|phase culturesstill have a s
P02834843A0000 |113 116|CGPeon
P02834843A0000 |261 269|activityhen comp
P02834843A0000 |214 223|log phaseta of K-d
P02834843A0000 |94 105|rifapentineologic aspe
P02834843A0000 |124 127|C29erb
P02834843A0000 |88 91|F22har
P02834843A0000 |37 58|rifamycin derivativesne phosphatases and 5
P02834843A0000 |77 80|FCE817
P02834843A0000 |160 163|C27 CS
P02834843A0000 |130 133|CGPrub
P02834843A0000 |140 143|C70 P0
P02834843A0000 |336 341|H37Rv +/- 
P02834843A0000 |308 334|Mycobacterium tuberculosisficantly greater slope (1.
P02834843A0000 |71 74|RBU P0
P02836623A1094 |0 2|MoP0
P02836623A1094 |26 33|animalswith al
P02836623A1094 |104 106|SVec
P02836623A1094 |61 83|months postinoculationcleotidase P00008171T0
P02836623A1094 |125 132|animalsrbiliru
P02836623A1094 |160 182|months postinoculation CSF [HCO3-] is shown 
P02836623A1094 |93 101|delta Mocologic 
P02836623A1094 |5 7|SV16
P02837575A0979 |0 14|Sodium dodecylP00001606T0076
P02837575A0979 |89 95|enzymearmaco
P02837575A0979 |55 68|topoisomerased 5-nucleotid
P02837575A0979 |130 133|endrub
P02837575A0979 |141 144|DNAP00
P02837575A0979 |32 40|cleavagelkaline 
P02837763A0259 |0 19|Amino acid sequenceP00001606T0076 Comp
P02837763A0259 |90 116|muscle phosphatase 2A cDNArmacologic aspects of neon
P02837763A0259 |46 51|HL-14atase
P02837763A0259 |74 80|rabbit000817
P02837763A0259 |125 146|% nucleotide identityrbilirubinemia. P0000
P02837763A0259 |33 44|liver clonekaline phos
P02838246A0225 |0 22|Herpes virus infectionP00001606T0076 Compari
P02838246A0225 |263 264|Pn
P02838246A0225 |219 235|rejection crises K-depleted rats
P02838246A0225 |61 72|T4/T8 ratiocleotidase 
P02838246A0225 |150 166|T8 subpopulationA0472 When CSF [
P02838246A0225 |193 201|findingson of CS
P02838246A0225 |44 53|inversionphatases 
P02838246A0225 |84 95|sensitivity00 Pharmaco
P02838246A0225 |115 116|%n
P02838246A0225 |98 99|%i
P02838246A0225 |129 142|proliferationirubinemia. P
P02838246A0225 |101 112|specificityaspects of 
P02838246A0225 |205 213|patientsO2 the d
P02838319A0527 |0 4|RVEFP000
P02838319A0527 |9 13|LVEFT007
P02838319A0527 |40 41|%p
P02838319A0527 |43 44|ps
P02838319A0527 |64 65|po
P02838710A0299 |101 110|treatmentaspects o
P02838710A0299 |14 20|NPY-ir Compa
P02838710A0299 |28 31|ratth 
P02838710A0299 |4 10|levels01606T
P02839488A1314 |33 41|activitykaline p
P02839488A1314 |13 19|assays6 Comp
P02839488A1314 |211 216|error data
P02839488A1314 |59 68|alpha s-1nucleotid
P02839488A1314 |161 169|productsCSF [HCO
P02839488A1314 |115 136|erythrocyte type-1 Gsnatal hyperbilirubine
P02839488A1314 |201 207|marginF PCO2
P02839716A0673 |103 132|HPV-11 enhancer-SV40 promoterpects of neonatal hyperbiliru
P02839716A0673 |9 14|cellsT0076
P02839716A0673 |57 63|effect5-nucl
P02839716A0673 |87 95|activityPharmaco
P02839716A0673 |16 27|E2 proteinsomparison w
P02839716A1907 |51 68|enhancer activitys and 5-nucleotid
P02839716A1907 |167 175|ABSTRACTCO3-] is
P02839716A1907 |107 109|E2s 
P02839716A1907 |90 101|competitionrmacologic 
P02839716A1907 |161 165|siteCSF 
P02839716A1907 |193 198|WORDSon of
P02839716A1907 |23 27|E2-Con w
P02839716A1907 |4 13|mechanism01606T007
P02840034A1266 |114 121|factorsonatal 
P02840034A1266 |27 36|treatmentith alkal
P02840034A1266 |61 81|lung cancer patientscleotidase P00008171
P02840034A1266 |9 19|evaluationT0076 Comp
P02840034A1266 |127 134|accountilirubi
P02840376A0461 |1 9|anti-IIa00001606
P02840376A0461 |15 21|HolmerCompar
P02843495A0544 |0 12|IntroductionP00001606T00
P02843495A0544 |29 34|CSF-1h alk
P02843495A0544 |105 119|tumorigenicitycts of neonata
P02843495A0544 |81 100|factor independenceT0000 Pharmacologic
P02843495A0544 |52 72|macrophage cell line and 5-nucleotidase 
P02843495A0544 |138 147|mechanisma. P00008
P02843495A0544 |16 21|v-fmsompar
P02843694T0001 |64 75|case reportotidase P00
P02843694T0001 |8 27|E-B virus infection6T0076 Comparison w
P02843694T0001 |52 60|lymphoma and 5-n
P02844767A0191 |173 179|Kallasis sho
P02844767A0191 |26 41|cotranscriptionwith alkaline p
P02844767A0191 |210 212|R.e 
P02844767A0191 |181 183|T. a
P02844767A0191 |105 111|plantscts of
P02844767A0191 |194 196|S.n 
P02844767A0191 |49 60|petCA genesses and 5-n
P02844767A0191 |117 130|apocytochrometal hyperbili
P02844767A0191 |185 192|Spillera funct
P02844767A0191 |133 141|proteinsinemia. 
P02844767A0191 |74 84|Rieske-FeS0008171T00
P02844767A0191 |12 21|structure76 Compar
P02844767A0191 |202 208|Malkin PCO2 
P02844767A0596 |84 95|photosystem00 Pharmaco
P02844767A0596 |165 182|chloroplast genes[HCO3-] is shown 
P02844767A0596 |53 62|psbB geneand 5-nuc
P02844767A0596 |131 138|intronsubinemi
P02844767A0596 |99 110|polypeptidec aspects o
P02844767A0596 |4 22|Nostoc petBD genes01606T0076 Compari
P02844767A1022 |0 23|RNA blot hybridizationsP00001606T0076 Comparis
P02844767A1022 |60 73|cytochrome b6ucleotidase P
P02844767A1022 |45 49|mRNAhata
P02844767A1022 |78 85|subunit171T000
P02844767A1022 |147 154|subunit997A047
P02844767A1022 |126 130|mRNAbili
P02844767A1022 |158 168|gene probeen CSF [HC
P02844797A1225 |221 234|acid sequence-depleted rat
P02844797A1225 |132 143|amino acidsbinemia. P0
P02844797A1225 |165 176|replacement[HCO3-] is 
P02844797A1225 |147 153|length997A04
P02844797A1225 |79 103|sequence Ala-Ile-Leu-Glu71T0000 Pharmacologic as
P02844797A1225 |193 204|amino acidson of CSF P
P02844797A1225 |12 26|muscle isoform76 Comparison 
P02844797A1225 |331 349|glycosylation site(1.21 +/- 0.23 vs.
P02844797A1225 |296 314|consensus sequencehave a significant
P02844797A1225 |43 54|amino acidssphatases a
P02844797A1225 |261 281|transmembrane domainhen compared to cont
P02844797A1225 |116 123|isoformatal hy
P02845654A0510 |0 12|SubstitutionP00001606T00
P02845654A0510 |217 219|P1of
P02845654A0510 |260 270|processingwhen compa
P02845654A0510 |146 162|tyrosine residue8997A0472 When C
P02845654A0510 |61 69|positioncleotida
P02845654A0510 |228 241|cleavage siteed rats are n
P02845654A0510 |193 212|amino acid positionon of CSF PCO2 the 
P02845654A0510 |74 76|P200
P02845654A0510 |18 35|threonine residueparison with alka
P02845654A0510 |86 99|cleavage site Pharmacologi
P02845654A0510 |110 118|cleavagef neonat
P02845654A0510 |128 140|substitutionlirubinemia.
P02845654A0510 |42 57|alanine residueosphatases and 
P02845654A0510 |168 189|phenylalanine residueO3-] is shown as a fu
P02846640A0643 |71 73|pI P
P02846640A0643 |44 63|indoxyl phosphatasephatases and 5-nucl
P02846640A0643 |28 36|bacteriath alkal
P02846852A1459 |49 66|E strand promoterses and 5-nucleot
P02846852A1459 |14 25|polymerases Comparison
P02846852A1459 |4 10|number01606T
P02846852A1459 |96 107|polymerasesogic aspect
P02846852A1459 |115 132|L strand promoternatal hyperbiliru
P02846852A1459 |86 92|number Pharm
P02848842A0643 |2 8|family000160
P02848842A0643 |74 79|probe00081
P02848842A0643 |90 94|genermac
P02848842A0643 |41 55|kilobase rangehosphatases an
P02848842A0643 |12 25|RNA molecules76 Comparison
P02848842A0643 |130 135|cellsrubin
P02848842A0643 |38 40|.2e 
P02849100A0441 |119 125|anchorl hype
P02849100A0441 |82 90|molecule0000 Pha
P02849100A0441 |133 148|plasma membraneinemia. P000089
P02849100A0441 |65 74|extremitytidase P0
P02849100A0441 |21 29|sequenceison wit
P02849759A0865 |4 17|SV40 enhancer01606T0076 Co
P02849759A0865 |28 39|replicationth alkaline
P02849759A0865 |47 51|foldtase
P02850472A0112 |18 29|origin coreparison wit
P02850472A0112 |52 67|DNA replication and 5-nucleoti
P02850967T0000 |85 101|characterization0 Pharmacologic 
P02850967T0000 |123 130|elementperbili
P02850967T0000 |13 45|proto-oncogene fos transcription6 Comparison with alkaline phosp
P02850967T0000 |58 83|adenylate cyclase pathway-nucleotidase P00008171T0
P02850967T0000 |0 9|InductionP00001606
P02850971A0180 |103 122|hybridization probepects of neonatal h
P02850971A0180 |9 29|oligodeoxynucleotideT0076 Comparison wit
P02850971A0180 |135 147|Vitreoscillaemia. P00008
P02850971A0180 |64 88|VtHb amino acid sequenceotidase P00008171T0000 P
P02850971A0180 |196 216|cosmid vector pVK102of CSF PCO2 the data
P02850971A0180 |156 163|libraryWhen CS
P02850971A0180 |50 56|regiones and
P02852805A0216 |66 75|influenceidase P00
P02852805A0216 |15 21|solidsCompar
P02852805A0216 |89 99|treatmentsarmacologi
P02852805A0216 |40 55|characteristicsphosphatases an
P02852894T0000 |0 6|CausesP00001
P02852894T0000 |44 49|studyphata
P02852894T0000 |60 68|chickensucleotid
P02852894T0000 |72 85|Thai villagesP00008171T000
P02852894T0000 |10 15|death0076 
P02853799T0001 |32 41|hepatitislkaline p
P02853799T0001 |104 113|carcinomaects of n
P02853799T0001 |4 15|progression01606T0076 
P02853799T0001 |53 61|diseasesand 5-nu
P02853799T0001 |71 85|transformation P00008171T000
P02853799T0001 |19 24|non-Aariso
P02853922A0596 |59 64|studynucle
P02853922A0596 |29 37|patientsh alkali
P02853922A0596 |9 12|IOPT00
P02853922A0596 |42 46|eyesosph
P02856622T0001 |0 3|UseP00
P02856622T0001 |76 86|carcinomas08171T0000
P02856622T0001 |94 101|thyroidologic 
P02856622T0001 |7 40|serum thyroglobulin determination06T0076 Comparison with alkaline 
P02856622T0001 |48 57|follow-upases and 
P02859434T0000 |0 13|Poor responseP00001606T007
P02859434T0000 |42 47|rangeospha
P02859434T0000 |52 65|serum lithium and 5-nucleo
P02859434T0000 |19 29|laboratoryarison wit
P02861067A0000 |16 21|studyompar
P02861067A0000 |66 77|ipratropiumidase P0000
P02861067A0000 |111 116|order neon
P02861067A0000 |181 198|beta agonist drug as a function of
P02861067A0000 |45 52|effectshatases
P02861067A0000 |81 89|patientsT0000 Ph
P02861067A0000 |4 7|aim016
P02861067A0000 |101 107|asthmaaspect
P02861067A0000 |154 175|bronchodilator effect2 When CSF [HCO3-] is
P02861144A0242 |55 60|genesd 5-n
P02861144A0242 |8 16|analysis6T0076 C
P02861144A0242 |73 90|encoding proteins00008171T0000 Pha
P02861144A0242 |25 37|DNA fragment with alkali
P02861144A0242 |114 118|kDalonat
P02861238T0000 |8 13|virus6T007
P02862656T0000 |0 7|ChangesP000016
P02862656T0000 |44 50|humansphatas
P02862656T0000 |63 77|alcohol intakeeotidase P0000
P02862656T0000 |11 40|dopamine receptor sensitivity076 Comparison with alkaline 
P02863492A0544 |140 149|IgG index P0000899
P02863492A0544 |15 26|differencesComparison 
P02863492A0544 |227 237|respondersted rats a
P02863492A0544 |107 111|means of
P02863492A0544 |43 59|treatment groupssphatases and 5-
P02863492A0544 |82 92|responders0000 Pharm
P02863747T0000 |0 11|ReplacementP00001606T0
P02863747T0000 |20 33|histone genesrison with al
P02863747T0000 |54 63|sequencesnd 5-nucl
P02865502T0000 |86 93|placebo Pharma
P02865502T0000 |45 78|tissue-type plasminogen activatorhatases and 5-nucleotidase P00008
P02865502T0000 |24 29|trialn wit
P02865502T0000 |114 124|infarctiononatal hyp
P02868446A0184 |207 212|alpha the 
P02868446A0184 |270 290|core enzyme subunitsred to controls but 
P02868446A0184 |226 232|enzymeeted r
P02868446A0184 |73 85|dnaG protein00008171T000
P02868446A0184 |60 71|DNA primaseucleotidase
P02868446A0184 |15 22|domainsCompari
P02868446A0184 |37 55|RPase beta subunitne phosphatases an
P02868446A0184 |24 28|CTDsn wi
P02868446A0184 |295 302|primase have a
P02868446A0184 |175 186|RPase alpha shown as a
P02868848A0167 |119 131|penicillin Gl hyperbilir
P02868848A0167 |9 19|vancomycinT0076 Comp
P02868848A0167 |164 168|mode [HC
P02868848A0167 |179 191|gas gangrenewn as a func
P02868848A0167 |24 34|fosfomycinn with alk
P02868848A0167 |84 92|activity00 Pharm
P02868848A0167 |136 144|imipenemmia. P00
P02869125A0120 |137 158|locomotor stimulationia. P00008997A0472 Wh
P02869125A0120 |183 193|tachypnoeas a functi
P02869125A0120 |210 217|arousale data 
P02869125A0120 |90 98|syndromermacolog
P02869125A0120 |33 49|receptor agonistkaline phosphata
P02869125A0120 |123 132|analgesiaperbiliru
P02869125A0120 |170 181|tachycardia-] is shown
P02869125A0120 |0 8|FentanylP0000160
P02870249T0000 |13 25|chemotherapy6 Comparison
P02870720A0188 |0 10|BisoprololP00001606T
P02870720A0188 |120 136|guinea pig atria hyperbilirubine
P02870720A0188 |104 116|isoprenalineects of neon
P02870720A0188 |74 84|pA2 values0008171T00
P02870720A0188 |40 68|beta-adrenoceptor antagonistphosphatases and 5-nucleotid
P02870720A0188 |141 156|tracheal muscleP00008997A0472 
P02870851A0349 |0 6|OutputP00001
P02870851A0349 |26 39|parotid glandwith alkaline
P02870851A0349 |73 97|parotid saliva flow rate00008171T0000 Pharmacolo
P02870851A0349 |10 18|99mTcO-40076 Com
P02870851A0349 |57 69|fluctuations5-nucleotida
P02872786A0147 |21 29|equationison wit
P02872786A0147 |120 129|sandflies hyperbil
P02872786A0147 |89 96|foregutarmacol
P02872786A0147 |72 81|parasitesP00008171
P02872786A0147 |133 143|blood flowinemia. P0
P02872786A0147 |52 59|effects and 5-
P02873593A0581 |171 177|reward] is s
P02873593A0581 |13 17|rats6 Co
P02873593A0581 |195 215|5-HT uptake blockers of CSF PCO2 the dat
P02873593A0581 |98 104|rewardic asp
P02873593A0581 |106 109|BZPts 
P02873593A0581 |235 242|effects are no
P02873593A0581 |138 147|frequencya. P00008
P02874078A0252 |76 84|patients08171T00
P02874078A0252 |15 38|luteal phase deficiencyComparison with alkalin
P02874078A0252 |61 62|%c
P02874635T0000 |119 123|ratsl hy
P02874635T0000 |74 84|ballooning0008171T00
P02874635T0000 |61 72|torticolliscleotidase 
P02874635T0000 |105 109|micects 
P02874635T0000 |9 17|exposureT0076 Co
P02874635T0000 |89 101|cleft palatearmacologic 
P02874635T0000 |25 42|fungicide dinocap with alkaline ph
P02874635T0000 |127 135|hamstersilirubin
P02875224A1059 |0 11|ReperfusionP00001606T0
P02875224A1059 |24 29|bloodn wit
P02875224A1059 |89 95|damagearmaco
P02875224A1059 |192 193|pi
P02875224A1059 |135 148|contractilityemia. P000089
P02875224A1059 |105 111|reflowcts of
P02875224A1059 |54 60|heartsnd 5-n
P02875224A1059 |37 44|beatingne phos
P02875224A1059 |156 164|instanceWhen CSF
P02875224A1059 |169 170|%3
P02875967A0377 |115 129|fertility ratenatal hyperbil
P02875967A0377 |39 49|adrenaline phosphata
P02875967A0377 |80 91|guinea pigs1T0000 Phar
P02875967A0377 |4 15|sensitivity01606T0076 
P02876820A0841 |81 83|mVT0
P02876820A0841 |13 21|acidosis6 Compar
P02876820A0841 |41 52|stimulationhosphatases
P02876899A0568 |87 119|bevantolol plasma concentrationsPharmacologic aspects of neonata
P02876899A0568 |126 142|absorption phasebilirubinemia. P
P02876899A0568 |41 49|subjectshosphata
P02876899A0568 |76 83|decline08171T0
P02876899A0568 |3 7|Days0016
P02877124A0000 |551 557|sacrumextrac
P02877124A0000 |534 539|femur01368
P02877124A0000 |291 297|agentstill h
P02877124A0000 |250 264|drinking waterdisplaced when
P02877124A0000 |429 431|Tce 
P02877124A0000 |541 546|ilium0210 
P02877124A0000 |178 193|trifluoperazineown as a functi
P02877124A0000 |485 488|endt n
P02877124A0000 |58 67|tap water-nucleoti
P02877124A0000 |301 321|bone mineral contenta significantly grea
P02877124A0000 |25 36|B6D2F1 mice with alkal
P02877124A0000 |91 104|phenothiazinemacologic asp
P02877124A0000 |444 453|indicatorfor use i
P02877124A0000 |163 173|H1 blockerF [HCO3-] 
P02877124A0000 |110 139|H1 receptor blocking activityf neonatal hyperbilirubinemia
P02877124A0000 |436 439|MDPum 
P02877124A0000 |496 503|studies0012653
P02877124A0000 |379 393|body retentions appears to b
P02877124A0000 |523 530|weightsagents.
P02877124A0000 |404 427|methylene diphosphonateive hypnotic drug with 
P02877124A0000 |15 20|B6AF1Compa
P02877124A0000 |397 399|Tc e
P02877124A0000 |457 472|bone metabolismneral practice 
P02877124A0000 |219 239|H1 blocking activity K-depleted rats are
P02877124A0000 |142 158|chlorpheniramine00008997A0472 Wh
P02877124A0000 |197 210|phenothiazinef CSF PCO2 th
P02877124A0000 |71 87|promethazine HCl P00008171T0000 
P02877124A0000 |274 281|effectsto cont
P02878100A0674 |70 82|transmissione P00008171T
P02878100A0674 |8 15|results6T0076 
P02878100A0674 |45 55|inhibitionhatases an
P02878100A0674 |203 215|transmissionPCO2 the dat
P02878100A0674 |158 166|activityen CSF [
P02878100A0674 |114 123|diltiazemonatal hy
P02878100A0674 |86 95|diltiazem Pharmaco
P02879906A0000 |0 7|StudiesP000016
P02879906A0000 |88 100|relationshipharmacologic
P02879906A0000 |61 72|rabbit facecleotidase 
P02879906A0000 |109 147|beta adrenoceptor subtype distributionof neonatal hyperbilirubinemia. P00008
P02879906A0000 |46 51|veinsatase
P02879906A0000 |189 206|nerve innervationnction of CSF PCO
P02879906A0000 |168 172|toneO3-]
P02879951T0000 |34 39|agentaline
P02879951T0000 |41 49|SGB-1534hosphata
P02879951T0000 |54 78|rat platelet aggregationnd 5-nucleotidase P00008
P02879951T0000 |0 7|EffectsP000016
P02880841A0313 |110 119|structuref neonata
P02880841A0313 |188 192|geneunct
P02880841A0313 |296 308|chloroplastshave a signi
P02880841A0313 |127 139|beta subunitilirubinemia
P02880841A0313 |267 269|F1mp
P02880841A0313 |89 92|TF1arm
P02880841A0313 |208 216|sequencethe data
P02880841A0313 |73 77|gene0000
P02880841A0313 |285 294|membranes but stil
P02880841A0313 |50 59|structurees and 5-
P02880841A0313 |253 263|categoriesplaced whe
P02880841A0313 |23 26|TF1on 
P02880841A0313 |161 180|nucleotide sequenceCSF [HCO3-] is show
P02880841A0313 |314 326|mitochondrialy greater s
P02880841A0313 |10 19|stability0076 Comp
P02880841A0313 |231 235|betarats
P02882893A0301 |0 16|Body temperatureP00001606T0076 C
P02882893A0301 |29 40|conductanceh alkaline 
P02882893A0301 |83 98|P. s. campbelli000 Pharmacolog
P02882893A0301 |118 120|spal
P02883327A0413 |69 75|regionse P00
P02883327A0413 |111 114|end ne
P02883327A0413 |131 137|regionubinem
P02883327A0413 |89 92|DNAarm
P02883327A0413 |66 67|Ei
P02883327A0413 |128 129|Ll
P02883327A0413 |4 25|polyadenylation sites01606T0076 Comparison
P02883327A0413 |48 51|endase
P02883871A1075 |2 6|drug0001
P02883871A1075 |12 15|ISA76 
P02883871A1075 |165 168|ISA[HC
P02883871A1075 |150 156|agentsA0472 
P02883871A1075 |64 68|drugotid
P02883871A1075 |113 134|drug hypersensitivityeonatal hyperbilirubi
P02883871A1075 |33 47|beta receptorskaline phospha
P02883871A1075 |138 146|contrasta. P0000
P02883963A0000 |4 12|patients01606T00
P02883963A0000 |89 92|HAMarm
P02883963A0000 |44 54|virus typephatases a
P02883963A0000 |58 64|HTLV-I-nucle
P02883963A0000 |24 30|T-celln with
P02883963A0000 |77 87|myelopathy8171T0000 
P02883963A0000 |129 136|methodsirubine
P02884860A0329 |34 42|prazosinaline ph
P02884860A0329 |122 129|therapyyperbil
P02884860A0329 |58 63|alpha-nucl
P02884860A0329 |24 30|analogn with
P02884860A0329 |66 79|adrenoceptorsidase P000081
P02884860A0329 |0 9|TerazosinP00001606
P02885517T0000 |38 47|hepatitise phospha
P02885517T0000 |8 20|blood donors6T0076 Compa
P02885517T0000 |25 30|non-A with
P02889352A0000 |136 152|enzyme inhibitormia. P00008997A0
P02889352A0000 |24 38|blood pressuren with alkalin
P02889352A0000 |40 42|BPph
P02889352A0000 |88 97|compoundsharmacolo
P02889352A0000 |111 123|beta blocker neonatal hy
P02889352A0000 |77 84|classes8171T00
P02889352A0000 |5 13|patients1606T007
P02889352A0000 |156 174|calcium antagonistWhen CSF [HCO3-] i
P02889495A0000 |138 142|dosea. P
P02889495A0000 |29 34|studyh alk
P02889495A0000 |150 153|endA04
P02889495A0000 |91 103|flupenthixolmacologic as
P02889495A0000 |45 67|episode schizophrenicshatases and 5-nucleoti
P02889495A0000 |79 87|pimozide71T0000 
P02889495A0000 |182 197|mg flupenthixolas a function o
P02889495A0000 |163 174|mg pimozideF [HCO3-] i
P02889495A0000 |116 121|weeksatal 
P02890200T0001 |70 87|neurofibromatosise P00008171T0000 
P02890200T0001 |44 49|tumorphata
P02890200T0001 |53 67|Recklinghausenand 5-nucleoti
P02892762A0296 |20 35|repeat elementsrison with alka
P02892762A0296 |75 77|nt00
P02892762A0296 |62 73|nucleotidesleotidase P
P02892762A0296 |89 102|promoter sitearmacologic a
P02894689A0000 |34 47|DNA fragmentsaline phospha
P02894689A0000 |135 144|lithium-3emia. P00
P02894689A0000 |105 125|extraction procedurects of neonatal hype
P02894689A0000 |89 93|helparma
P02894689A0000 |149 165|diiodosalicylate7A0472 When CSF 
P02894689A0000 |55 60|basesd 5-n
P02894689A0000 |64 79|chromatin loopsotidase P000081
P02894741A0000 |35 45|vecuroniumline phosp
P02894741A0000 |60 77|muscle relaxationucleotidase P0000
P02894741A0000 |26 31|doseswith 
P02894741A0000 |97 115|NLA II anaesthesiagic aspects of neo
P02894789A0954 |68 73|T1/T0ase P
P02894789A0954 |13 29|recovery indexes6 Comparison wit
P02894789A0954 |78 83|T4/T1171T0
P02894789A0954 |106 107|%t
P02894789A0954 |99 100|%c
P02894789A0954 |49 54|timesses a
P02895472A0178 |81 85|cDNAT000
P02895472A0178 |61 69|plasmidscleotida
P02895472A0178 |120 136|mRNA translation hyperbilirubine
P02895472A0178 |22 30|coloniesson with
P02895472A0178 |97 100|BiPgic
P02895566A0187 |152 175|pressure pain component472 When CSF [HCO3-] is
P02895566A0187 |65 89|pressure pain componentstidase P00008171T0000 Ph
P02895566A0187 |106 123|ischemia durationts of neonatal hy
P02895566A0187 |19 27|increasearison w
P02895566A0187 |138 144|effecta. P00
P02895566A0187 |35 44|intensityline phos
P02895566A0187 |0 3|DPAP00
P02895754A0000 |274 282|syndrometo contr
P02895754A0000 |39 47|presence phospha
P02895754A0000 |260 263|eyewhe
P02895754A0000 |188 195|chamberunction
P02895754A0000 |10 31|percent isoproterenol0076 Comparison with 
P02895754A0000 |265 271|Hornercompar
P02895754A0000 |55 95|phosphodiesterase inhibitor theophyllined 5-nucleotidase P00008171T0000 Pharmaco
P02895754A0000 |140 144|rate P00
P02895754A0000 |115 122|abilitynatal h
P02895754A0000 |156 166|humor flowWhen CSF [
P02897651A0000 |0 15|HyperthyroidismP00001606T0076 
P02897651A0000 |75 83|abortion008171T0
P02897651A0000 |39 45|causes phosp
P02897651A0000 |49 60|infertilityses and 5-n
P02898752A0683 |102 120|platelets recoveryspects of neonatal
P02898752A0683 |40 47|numbersphospha
P02898752A0683 |77 81|rate8171
P02898752A0683 |9 20|correlationT0076 Compa
P02898752A0683 |51 57|CFU-GMs and 
P02898752A0683 |85 97|granulocytes0 Pharmacolo
P02899177A0605 |186 193|regions functi
P02899177A0605 |146 151|drugs8997A
P02899177A0605 |104 111|effectsects of
P02899177A0605 |20 29|techniquerison wit
P02899177A0605 |159 171|excitabilityn CSF [HCO3-
P02899177A0605 |81 86|modelT0000
P02899177A0605 |33 55|low-frequency kindlingkaline phosphatases an
P02899792T0000 |0 9|OestrogenP00001606
P02899792T0000 |18 26|overdoseparison 
P02900760A0073 |158 178|transcription systemen CSF [HCO3-] is sh
P02900760A0073 |123 128|pol Iperbi
P02900760A0073 |243 252|3T6 cellslonger di
P02900760A0073 |105 121|RNA polymerase Icts of neonatal 
P02900760A0073 |76 101|transcription termination08171T0000 Pharmacologic 
P02900760A0073 |213 237|rDNA minigene constructsata of K-depleted rats a
P02900760A0073 |197 209|transfectionf CSF PCO2 t
P02900760A0073 |6 23|sequence elements606T0076 Comparis
P02901498A0354 |51 59|proteinss and 5-
P02901498A0354 |161 187|chicken embryo fibroblastsCSF [HCO3-] is shown as a 
P02901498A0354 |140 147|ability P00008
P02901498A0354 |99 111|erbB proteinc aspects of
P02901498A0354 |4 16|biosynthesis01606T0076 C
P02901498A0354 |21 30|stabilityison with
P02901763A0977 |119 124|genesl hyp
P02901763A0977 |147 158|codon usage997A0472 Wh
P02901763A0977 |72 78|codonsP00008
P02901763A0977 |285 302|protein synthesis but still have a
P02901763A0977 |15 42|C. reinhardtii mitochondriaComparison with alkaline ph
P02901763A0977 |190 210|C. reinhardtii mtDNAction of CSF PCO2 th
P02901763A0977 |247 252|tRNAser di
P02901763A0977 |237 243|numberre no 
P02901763A0977 |0 11|Codon usageP00001606T0
P02902615A0000 |50 63|polyarteritises and 5-nucl
P02902615A0000 |120 131|hepatitis B hyperbilir
P02902615A0000 |92 101|treatmentacologic 
P02902615A0000 |148 156|patients97A0472 
P02902615A0000 |25 34|treatment with alk
P02902615A0000 |76 84|advances08171T00
P02902656A0481 |137 142|casesia. P
P02902656A0481 |126 128|TEbi
P02902656A0481 |148 160|hyperintense97A0472 When
P02902656A0481 |60 63|fatucl
P02902656A0481 |90 105|repetition timermacologic aspe
P02902656A0481 |120 124|time hyp
P02902656A0481 |45 56|hypointensehatases and
P02902656A0481 |164 174|isointense [HCO3-] i
P02902656A0481 |221 226|cases-depl
P02902656A0481 |190 205|TR/TE sequencesction of CSF PC
P02902656A0481 |178 181|fatown
P02902656A0481 |13 19|testes6 Comp
P02902656A0481 |107 109|TRs 
P02902656A0481 |67 76|sequencesdase P000
P02902656A0481 |33 39|testeskaline
P02902844A1219 |36 40|geneine 
P02902844A1219 |120 131|atp operons hyperbilir
P02902844A1219 |72 79|proteinP000081
P02902844A1219 |14 18|gene Com
P02902844A1219 |162 175|cyanobacteriaSF [HCO3-] is
P02902844A1219 |144 157|bacterium PS3008997A0472 W
P02902927A0145 |22 31|isolationson with 
P02902927A0145 |46 67|rat GHF-1 cDNA clonesatases and 5-nucleoti
P02903500A0278 |169 183|immunoglobulin3-] is shown a
P02903500A0278 |26 36|propertieswith alkal
P02903500A0278 |63 66|neueot
P02903500A0278 |44 51|proteinphatase
P02903500A0278 |120 126|domain hyper
P02903500A0278 |81 92|fusion geneT0000 Pharm
P02903500A0278 |130 133|neurub
P02903500A0278 |190 195|chainction
P02903500A0278 |155 162|portion When C
P02904322A0002 |25 33|antelope with al
P02904322A0002 |88 95|studiesharmaco
P02904322A0002 |57 71|model ruminant5-nucleotidase
P02906027A0553 |153 170|CpG dinucleotides72 When CSF [HCO3
P02906027A0553 |27 33|blocksith al
P02906027A0553 |111 121|CpG island neonatal 
P02906027A0553 |77 83|region8171T0
P02906027A0553 |37 45|homologyne phosp
P02906027A0553 |3 22|sequence comparison001606T0076 Compari
P02906027A1156 |70 79|sequencese P000081
P02906027A1156 |14 22|features Compari
P02906027A1156 |101 107|intronaspect
P02906027A1156 |49 50|Gs
P02906249A1195 |118 124|Oxy-Hbal hyp
P02906249A1195 |40 45|mg/kgphosp
P02906249A1195 |13 18|group6 Com
P02906249A1195 |128 138|PGF2 alphalirubinemi
P02906249A1195 |24 34|% Prazosinn with alk
P02906249A1195 |86 91|hours Phar
P02906249A1195 |103 114|applicationpects of ne
P02906673T0000 |0 8|EfficacyP0000160
P02906673T0000 |89 110|floodwater mosquitoesarmacologic aspects o
P02906673T0000 |13 29|field evaluation6 Comparison wit
P02906673T0000 |67 80|B. sphaericusdase P0000817
P02906673T0000 |57 61|H-145-nu
P02906673T0000 |114 124|Californiaonatal hyp
P02906673T0000 |33 55|Bacillus thuringiensiskaline phosphatases an
P02907308T0001 |32 56|Richner-Hanhart syndromelkaline phosphatases and
P02907308T0001 |11 15|type076 
P02907308T0001 |2 7|cases00016
P02907308T0001 |19 30|tyrosinosisarison with
P02907533A0362 |54 71|correction factornd 5-nucleotidase
P02907533A0362 |29 47|drug concentrationh alkaline phospha
P02907533A0362 |112 134|diazepam concentrationneonatal hyperbilirubi
P02907533A0362 |5 9|loss1606
P02907533T0000 |51 67|diazepam bindings and 5-nucleoti
P02907533T0000 |31 47|blood substitutealkaline phospha
P02907533T0000 |77 84|albumin8171T00
P02907533T0000 |0 7|EffectsP000016
P02909528A1081 |49 55|regionses an
P02909528A1081 |94 105|start sitesologic aspe
P02909528A1081 |9 26|promoter activityT0076 Comparison 
P02910496A0583 |171 185|RNAase MRP RNA] is shown as 
P02910496A0583 |23 36|CGA-CCCCUCC-3on with alkal
P02910496A0583 |2 18|decamer sequence0001606T0076 Com
P02910496A0583 |138 151|RNA substratea. P00008997A
P02910496A0583 |103 116|cleavage sitepects of neon
P02910496A0583 |68 76|sequencease P000
P02910989T0000 |0 7|EffectsP000016
P02910989T0000 |11 16|aging076 C
P02910989T0000 |66 80|QT/QS2 changesidase P0000817
P02910989T0000 |21 45|beta-adrenergic-blockadeison with alkaline phosp
P02911540A0478 |136 140|caremia.
P02911540A0478 |59 64|handsnucle
P02911540A0478 |27 32|woundith a
P02911540A0478 |72 76|faceP000
P02911540A0478 |66 70|feetidas
P02911540A0478 |53 57|areaand 
P02911540A0478 |81 89|perineumT0000 Ph
P02911540A0478 |2 9|patient0001606
P02913368A1037 |0 20|Pharmacology studiesP00001606T0076 Compa
P02913368A1037 |94 112|calcium antagonistologic aspects of 
P02913368A1037 |26 44|potassium chloridewith alkaline phos
P02913368A1037 |129 135|influxirubin
P02913368A1037 |76 83|raveron08171T0
P02913368A1037 |49 62|acetylcholineses and 5-nuc
P02913368A1037 |153 160|calcium72 When
P02914422A0409 |0 17|Computer analysisP00001606T0076 Co
P02914422A0409 |89 104|frequency bandsarmacologic asp
P02914422A0409 |164 171|notches [HCO3-
P02914422A0409 |131 146|frequency rangeubinemia. P0000
P02914422A0409 |108 113|order of n
P02914422A0409 |176 181|slursshown
P02914422A0409 |35 44|averagingline phos
P02914492A0183 |236 242|mEq/dlare no
P02914492A0183 |20 23|ICUris
P02914492A0183 |189 196|percentnction 
P02914492A0183 |94 100|mEq/dlologic
P02914492A0183 |177 185|patientshown as 
P02914492A0183 |29 37|patientsh alkali
P02914492A0183 |160 166|mEq/dl CSF [
P02914492A0183 |106 114|patientsts of ne
P02914492A0183 |132 147|normomagnesemiabinemia. P00008
P02914492A0183 |119 126|percentl hyper
P02914492A0183 |55 69|hypomagnesemiad 5-nucleotida
P02914492A0183 |202 217|hypermagnesemia PCO2 the data 
P02914492A0183 |42 49|percentosphata
P02914492A0183 |71 79|serum Mg P000081
P02914492A0183 |3 12|admission001606T00
P02916764A0253 |35 38|sexlin
P02916764A0253 |40 52|hypertensionphosphatases
P02916764A0253 |124 134|life-styleerbilirubi
P02916764A0253 |73 93|hypercholesterolemia00008171T0000 Pharma
P02916764A0253 |54 71|diabetes mellitusnd 5-nucleotidase
P02916764A0253 |95 112|cigarette smokinglogic aspects of 
P02916764A0253 |140 154|family history P00008997A047
P02916764A0253 |4 16|risk factors01606T0076 C
P02918474A0817 |100 114|subendocardium aspects of ne
P02918474A0817 |63 73|blood floweotidase P
P02918474A0817 |149 162|subepicardium7A0472 When C
P02918474A0817 |41 51|collateralhosphatase
P02918474A0817 |133 141|ml/min/ginemia. 
P02918474A0817 |8 17|verapamil6T0076 Co
P02918474A0817 |22 32|nifedipineson with a
P02919483A0091 |26 31|girlswith 
P02919483A0091 |45 48|agehat
P02919483A0091 |14 18|boys Com
P02919483A0091 |63 73|half yearseotidase P
P02919530A0000 |171 182|wall motion] is shown 
P02919530A0000 |31 42|reperfusionalkaline ph
P02919530A0000 |94 110|artery occlusionologic aspects o
P02919530A0000 |210 221|alterationse data of K
P02919530A0000 |140 146|effect P0000
P02919530A0000 |55 65|myocardiumd 5-nucleo
P02919832A0144 |85 109|Doppler echocardiography0 Pharmacologic aspects 
P02919832A0144 |8 15|disease6T0076 
P02919832A0144 |38 44|M-modee phos
P02920591A0251 |86 99|micrograms/kg Pharmacologi
P02920591A0251 |75 82|digoxin008171T
P02920591A0251 |106 114|dopaminets of ne
P02920591A0251 |12 22|assessment76 Compari
P02920591A0251 |124 141|micrograms/kg/minerbilirubinemia. 
P02920591A0251 |57 71|administration5-nucleotidase
P02923687A0218 |86 94|patients Pharmac
P02923687A0218 |46 50|sideatas
P02923687A0218 |111 123|cleft palate neonatal hy
P02923687A0218 |72 82|cleft sideP00008171T
P02923687A0218 |54 63|sinusitisnd 5-nucl
P02923687A0218 |21 33|relationshipison with al
P02925013A1112 |103 115|accumulationpects of neo
P02925013A1112 |46 54|aluminumatases a
P02925013A1112 |30 36|levels alkal
P02925013A1112 |131 145|citrate ligandubinemia. P000
P02925013A1112 |81 87|tissueT0000 
P02925568A0460 |50 60|conditionses and 5-n
P02925568A0460 |180 195|psychopathologyn as a function
P02925568A0460 |151 167|family stressors0472 When CSF [H
P02925568A0460 |83 90|samples000 Pha
P02925568A0460 |10 17|effects0076 Co
P02925568A0460 |21 35|father absenceison with alka
P02925568A0460 |116 123|effectsatal hy
P02926499A0340 |35 47|analog modelline phospha
P02926499A0340 |261 265|heathen 
P02926499A0340 |126 129|CBFbil
P02926499A0340 |148 151|CBF97A
P02926499A0340 |243 244|cl
P02926499A0340 |210 213|rhoe d
P02926499A0340 |166 167|cH
P02926499A0340 |194 199|decayn of 
P02926499A0340 |51 60|heat flows and 5-n
P02926499A0340 |221 228|density-deplet
P02926499A0340 |154 156|Cb2 
P02926499A0340 |111 121|expression neonatal 
P02926499A0340 |72 77|brainP0000
P02926499A0340 |232 237|bloodats a
P02926499A0340 |175 178|tau sh
P02927391A0238 |159 166|tissuesn CSF [
P02927391A0238 |225 234|germ lineleted rat
P02927391A0238 |120 129|germ line hyperbil
P02927391A0238 |26 36|proviruseswith alkal
P02927391A0238 |193 204|integrationon of CSF P
P02927391A0238 |58 81|founder SWR/J-RF/J mice-nucleotidase P00008171
P02927391A0238 |266 274|lineagesompared 
P02928112T0000 |65 72|proteintidase 
P02928112T0000 |62 63|Al
P02928112T0000 |44 46|U2ph
P02928112T0000 |10 17|cloning0076 Co
P02928112T0000 |25 29|cDNA wit
P02928376A0312 |136 137|%m
P02928376A0312 |79 84|gases71T00
P02928376A0312 |29 34|waterh alk
P02928376A0312 |100 111|heat defect aspects of
P02928376A0312 |58 65|mixture-nucleo
P02928376A0312 |16 20|workompa
P02928376A0312 |69 71|H2se
P02929056T0000 |18 42|transureteroureterostomyparison with alkaline ph
P02929056T0000 |11 14|use076
P02929056T0000 |93 100|failurecologic
P02929056T0000 |54 74|ureterosigmoidostomynd 5-nucleotidase P0
P02930623A0404 |96 98|msog
P02930623A0404 |105 111|impactcts of
P02930623A0404 |29 35|torqueh alka
P02930623A0404 |74 83|direction0008171T0
P02930623A0404 |7 23|flexion whiplash06T0076 Comparis
P02930623A0404 |53 60|condyleand 5-n
P02934778A0702 |35 40|5-HT2line 
P02934778A0702 |97 104|speciesgic asp
P02934778A0702 |54 63|receptorsnd 5-nucl
P02934778A0702 |23 31|presenceon with 
P02934778A0702 |4 8|data0160
P02934778A0702 |81 87|arteryT0000 
P02934889A0558 |0 11|OxfendazoleP00001606T0
P02934889A0558 |95 98|Maylog
P02934889A0558 |123 137|cent reductionperbilirubinem
P02934889A0558 |62 66|daysleot
P02934889A0558 |47 51|timetase
P02934889A0558 |194 205|D viviparusn of CSF PC
P02934889A0558 |77 82|start8171T
P02934889A0558 |176 190|cent reductionshown as a fun
P02934889A0558 |141 159|Ostertagia speciesP00008997A0472 Whe
P02934889A0558 |86 93|grazing Pharma
P02934891A0845 |85 90|cells0 Pha
P02934891A0845 |208 211|endthe
P02934891A0845 |165 176|nucleotides[HCO3-] is 
P02934891A0845 |14 20|method Compa
P02934891A0845 |200 202|MuSF
P02934891A0845 |67 70|nerdas
P02934891A0845 |55 63|extractsd 5-nucl
P02934891A0845 |139 144|sites. P00
P02935638A0000 |76 116|sea urchin Strongylocentrotus purpuratus08171T0000 Pharmacologic aspects of neon
P02935638A0000 |41 50|structurehosphatas
P02935638A0000 |58 68|Spec1 gene-nucleotid
P02936163T0000 |0 17|Platelet functionP00001606T0076 Co
P02936163T0000 |60 71|interactionucleotidase
P02936163T0000 |75 83|patients008171T0
P02936163T0000 |99 129|platelet lipoxygenase activityc aspects of neonatal hyperbil
P02936284A0357 |85 88|man0 P
P02936284A0357 |41 47|plasmahospha
P02936284A0357 |12 23|degradation76 Comparis
P02936284A0357 |61 66|routecleot
P02936284A0357 |158 161|minen 
P02936284A0357 |27 37|atracuriumith alkali
P02936284A0357 |116 137|elimination half-lifeatal hyperbilirubinem
P02936284A0357 |70 81|eliminatione P00008171
P02938185A0223 |153 162|degrees C72 When C
P02938185A0223 |93 100|virusescologic
P02938185A0223 |56 73|E1b gene products 5-nucleotidase P
P02938185A0223 |41 44|E1ahos
P02938185A0223 |12 22|cell lines76 Compari
P02938185A0223 |210 222|architecturee data of K-
P02938185A0223 |173 182|degrees Cis shown 
P02938185A0223 |261 271|CREF cellshen compar
P02938185A0223 |140 146|growth P0000
P02938185A0223 |48 51|E1aase
P02939260A1553 |252 269|Edman degradationsplaced when comp
P02939260A1553 |95 105|methioninelogic aspe
P02939260A1553 |109 117|residuesof neona
P02939260A1553 |242 248|cycles longe
P02939260A1553 |72 86|42K T antigensP00008171T0000
P02939260A1553 |149 161|DNA sequence7A0472 When 
P02939260A1553 |64 67|43Koti
P02939260A1553 |174 184|methionines shown as
P02939260A1553 |19 47|amino acid sequence analysisarison with alkaline phospha
P02939260A1553 |207 220|39K T antigen the data of 
P02940334A0141 |0 7|Group AP000016
P02940334A0141 |109 118|schedulesof neonat
P02940334A0141 |67 75|globulindase P00
P02940334A0141 |77 81|HBIG8171
P02940334A0141 |39 44|doses phos
P02940334A0141 |48 59|hepatitis Bases and 5-
P02941237A0160 |204 219|pyrophosphataseCO2 the data of
P02941237A0160 |57 87|phosphorous ion concentrations5-nucleotidase P00008171T0000 
P02941237A0160 |298 303|rolesve a 
P02941237A0160 |89 98|tissue pHarmacolog
P02941237A0160 |14 22|instance Compari
P02941237A0160 |164 171|enzymes [HCO3-
P02941237A0160 |114 122|hormonesonatal h
P02941237A0160 |179 199|alkaline phosphatasewn as a function of 
P02941237A0160 |27 35|additionith alka
P02941237A0160 |39 52|serum calcium phosphatases
P02941237A0160 |130 139|vitamin Drubinemia
P02941237A0160 |141 150|vitamin AP00008997
P02941237A0160 |100 112|blood supply aspects of 
P02943562T0000 |0 24|Penicillinase productionP00001606T0076 Compariso
P02943562T0000 |70 80|importancee P0000817
P02943562T0000 |50 57|strainses and 
P02947866A1416 |19 27|analysisarison w
P02947866A1416 |31 50|thallium-201 uptakealkaline phosphatas
P02947866A1416 |140 151|angioplasty P00008997A
P02947866A1416 |82 90|evidence0000 Pha
P02947866A1416 |55 62|washoutd 5-nuc
P02947866A1416 |115 124|perfusionnatal hyp
P02949170A0184 |5 10|study1606T
P02949170A0184 |23 30|effectson with
P02949170A0184 |56 84|micrograms ethinyl estradiol 5-nucleotidase P00008171T00
P02949170A0184 |271 277|monthsed to 
P02949170A0184 |91 113|mg cyproterone acetatemacologic aspects of n
P02949170A0184 |132 141|prolactinbinemia. 
P02949170A0184 |194 209|androstenedionen of CSF PCO2 t
P02949170A0184 |187 191|SHBGfunc
P02949170A0184 |117 130|gonadotropinstal hyperbili
P02949170A0184 |157 185|sex hormone binding globulinhen CSF [HCO3-] is shown as 
P02949170A0184 |231 249|testosterone indexrats are no longer
P02949170A0184 |281 290|treatmentrols but 
P02949170A0184 |143 155|testosterone0008997A0472
P02949170A0184 |36 47|preparationine phospha
P02950216A0084 |81 94|output signalT0000 Pharmac
P02950216A0084 |11 15|flow076 
P02950216A0084 |135 140|termsemia.
P02950216A0084 |61 64|LDFcle
P02950216A0084 |36 59|laser Doppler flowmetryine phosphatases and 5-
P02950216A0084 |144 149|volts00899
P02950216A0084 |96 111|blood cell fluxogic aspects of
P02950216A0084 |113 116|BCFeon
P02957125A0601 |86 100|cent reduction Pharmacologic
P02957125A0601 |104 128|plasma ANP concentrationects of neonatal hyperbi
P02957125A0601 |44 57|haemodialysisphatases and 
P02957125A0601 |28 35|failureth alka
P02957125A0601 |8 16|patients6T0076 C
P02958204A0175 |70 87|HDL phospholipidse P00008171T0000 
P02958204A0175 |127 145|HDL-C subfractionsilirubinemia. P000
P02958204A0175 |147 153|HDL2-C997A04
P02958204A0175 |215 221|coursea of K
P02958204A0175 |63 68|HDL-Ceotid
P02958204A0175 |89 95|HDL-PLarmaco
P02958204A0175 |243 252|mg/kg/daylonger di
P02958204A0175 |30 42|isotretinoin alkaline ph
P02958204A0175 |258 267|treatmentd when co
P02958204A0175 |186 194|patients functio
P02958204A0175 |19 26|effectsarison 
P02958204A0175 |113 120|apo A-1eonatal
P02958204A0175 |158 164|HDL3-Cen CSF
P02958204A0175 |46 49|HDLata
P02958204A0175 |225 237|isotretinoinleted rats a
P02958204A0175 |278 291|acne vulgarisontrols but s
P02958204A0175 |98 111|apoprotein A1ic aspects of
P02958233A0123 |70 93|serum sickness reactione P00008171T0000 Pharma
P02958233A0123 |13 20|picture6 Compa
P02958233A0123 |25 46|laboratory parameters with alkaline phosph
P02958660A1094 |116 126|experimentatal hyper
P02958660A1094 |76 86|LDF signal08171T0000
P02958660A1094 |130 140|experimentrubinemia.
P02958660A1094 |54 71|conversion factornd 5-nucleotidase
P02958660A1094 |39 48|existence phosphat
P02958660A1094 |99 110|flow valuesc aspects o
P02958660A1094 |4 8|data0160
P02959089T0000 |48 58|vasospasmsases and 5
P02959089T0000 |11 17|effect076 Co
P02959089T0000 |21 29|ONO-3708ison wit
P02959089T0000 |33 43|thrombosiskaline pho
P02960012A0838 |17 29|PPNG strainsmparison wit
P02960012A0838 |4 13|frequency01606T007
P02960012A0838 |64 65|%o
P02960012A0838 |48 49|%a
P02962859A0276 |85 90|clone0 Pha
P02962859A0276 |41 74|beta-galactosidase fusion proteinhosphatases and 5-nucleotidase P0
P02962859A0276 |13 23|antibodies6 Comparis
P02962859A0276 |108 110|U1 o
P02962859A0276 |126 135|A antigenbilirubin
P02963517A0453 |117 125|increasetal hype
P02963517A0453 |13 21|analysis6 Compar
P02963517A0453 |91 101|dilatationmacologic 
P02963517A0453 |161 165|areaCSF 
P02963517A0453 |198 201|mm2 CS
P02963517A0453 |77 81|PTCA8171
P02963517A0453 |38 46|stenosise phosph
P02964329A0000 |136 145|incidencemia. P000
P02964329A0000 |28 42|Joint Mobilityth alkaline ph
P02964329A0000 |44 47|LJMpha
P02964329A0000 |52 60|diabetes and 5-n
P02964329A0000 |149 164|microangiopathy7A0472 When CSF
P02964329A0000 |4 16|pathogenesis01606T0076 C
P02964329A0000 |81 92|abnormalityT0000 Pharm
P02965149A0727 |21 27|Brandlison w
P02965149A0727 |14 19|study Comp
P02965149A0727 |29 31|C.h 
P02966671A0151 |205 210|weeksO2 th
P02966671A0151 |63 69|tumorseotida
P02966671A0151 |241 250|treatmento longer 
P02966671A0151 |113 121|survivaleonatal 
P02966671A0151 |37 41|timene p
P02966671A0151 |93 107|treatment sizecologic aspect
P02966671A0151 |125 135|stem cellsrbilirubin
P02966671A0151 |228 233|weeksed ra
P02966671A0151 |168 182|breathing rateO3-] is shown 
P02966671A0151 |81 86|timesT0000
P02966671A0151 |17 27|end pointsmparison w
P02966671A0151 |152 158|crypts472 Wh
P02966671A0551 |0 8|ScheduleP0000160
P02966671A0551 |25 36|mg/kg c-DDP with alkal
P02966671A0551 |147 163|radiation effect997A0472 When CS
P02966671A0551 |122 128|degreeyperbi
P02966671A0551 |221 232|enhancement-depleted r
P02966671A0551 |252 263|mg/kg c-DDPsplaced whe
P02966671A0551 |190 196|factorction 
P02966671A0551 |293 298|startll ha
P02966671A0551 |321 333|radiotherapyter slope (1
P02966671A0551 |73 78|X-ray00008
P02966671A0551 |132 143|enhancementbinemia. P0
P02966671A0551 |280 281|ht
P02966671A0551 |96 100|daysogic
P02967496A0182 |154 160|region2 When
P02967496A0182 |141 146|cpc-1P0000
P02967496A0182 |112 126|leader segmentneonatal hyper
P02967496A0182 |18 28|transcriptparison wi
P02967496A0182 |49 63|reading framesses and 5-nucl
P02967915A0000 |17 49|hormone 1,25-dihydroxyvitamin D3mparison with alkaline phosphata
P02967915A0000 |120 134|calbindin-D28K hyperbilirubi
P02967915A0000 |73 83|expression00008171T0
P02967915A0000 |151 165|target tissues0472 When CSF 
P02967915A0000 |89 112|calcium binding proteinarmacologic aspects of 
P02967915A0000 |140 147|variety P00008
P02967915A0968 |85 94|sequences0 Pharmac
P02967915A0968 |148 155|signals97A0472
P02967915A0968 |114 124|componentsonatal hyp
P02967915A0968 |58 65|variety-nucleo
P02967915A0968 |3 11|addition001606T0
P02967915A0968 |17 40|calbindin-D28K promotermparison with alkaline 
P02968055A0984 |34 42|increasealine ph
P02968055A0984 |46 49|ANFata
P02968055A0984 |4 7|HOI016
P02969316A0002 |255 261|pacingaced w
P02969316A0002 |109 112|ANPof 
P02969316A0002 |56 77|plasma concentrations 5-nucleotidase P0000
P02969316A0002 |29 34|atriah alk
P02969316A0002 |226 227|he
P02969316A0002 |14 21|ability Compar
P02969316A0002 |212 216|dogsdata
P02969316A0002 |128 135|changeslirubin
P02969316A0002 |100 107|peptide aspect
P02969316A0002 |139 164|plasma ANP concentrations. P00008997A0472 When CSF
P02969819A0814 |0 22|Ig D-JH recombinationsP00001606T0076 Compari
P02969819A0814 |73 85|T cell lines00008171T000
P02969819A0814 |124 139|Cmu transcriptserbilirubinemia
P02969819A0814 |35 57|TcR gene recombinationline phosphatases and 
P02970061A0271 |100 106|weight aspec
P02970061A0271 |59 70|amino acidsnucleotidas
P02970061A0271 |44 51|proteinphatase
P02970061A0271 |20 33|reading framerison with al
P02970061A0271 |4 14|RAD18 gene01606T0076
P02970640A0341 |187 191|zincfunc
P02970640A0341 |165 177|acid protein[HCO3-] is s
P02970640A0341 |110 122|acid proteinf neonatal h
P02970640A0341 |133 141|zinc ioninemia. 
P02970640A0341 |7 35|absorption spectrophotometry06T0076 Comparison with alka
P02970640A0341 |69 81|E1A proteinsse P00008171
P02971603A0883 |35 44|injectionline phos
P02971603A0883 |24 31|tabletsn with 
P02971603A0883 |53 56|dayand
P02971603A0883 |5 13|patients1606T007
P02971710A0734 |0 5|PlotsP0000
P02971710A0734 |93 103|hematocritcologic as
P02971710A0734 |24 33|2A weightn with al
P02971710A0734 |149 158|viscosity7A0472 Wh
P02971710A0734 |106 107|%t
P02971710A0734 |13 15|LV6 
P02971710A0734 |73 84|inflections00008171T00
P02971710A0734 |192 202|hematocrition of CSF
P02971710A0734 |18 19|Sp
P02971710A0734 |162 164|COSF
P02971710A0734 |131 135|roleubin
P02971710A0734 |9 11|RVT0
P02971710A0734 |42 52|hematocritosphatases
P02971957A0287 |100 110|techniques aspects o
P02971957A0287 |133 141|bleedinginemia. 
P02971957A0287 |73 78|cases00008
P02971957A0287 |27 31|meshith 
P02971957A0287 |48 59|improvementases and 5-
P02973304A0000 |87 91|veinPhar
P02973304A0000 |15 21|courseCompar
P02973304A0000 |166 181|cardiosclerosisHCO3-] is shown
P02973304A0000 |62 72|thrombosisleotidase 
P02973304A0000 |25 45|Budd-Chiari syndrome with alkaline phosp
P02973304A0000 |127 144|patient sufferingilirubinemia. P00
P02975680A0000 |239 244|group no l
P02975680A0000 |248 256|patientsr displa
P02975680A0000 |321 329|patientster slop
P02975680A0000 |92 98|nightsacolog
P02975680A0000 |31 51|sleep EEG recordingsalkaline phosphatase
P02975680A0000 |150 166|anxiety disorderA0472 When CSF [
P02975680A0000 |316 319|MDD gr
P02975680A0000 |116 126|inpatientsatal hyper
P02975680A0000 |190 200|depressionction of C
P02975680A0000 |262 265|GADen 
P02975680A0000 |218 221|agef K
P02975680A0000 |306 314|disordernificant
P02975680A0000 |10 29|accommodation night0076 Comparison wit
P02975680A0000 |272 277|groupd to 
P02975680A0000 |168 171|GADO3-
P02975753A1333 |0 27|Oligonucleotide mutagenesisP00001606T0076 Comparison w
P02975753A1333 |121 132|E3 promoterhyperbiliru
P02975753A1333 |69 79|importancese P000081
P02975753A1333 |37 52|binding domainsne phosphatases
P02975753A1333 |103 113|regulationpects of n
P02975753A1333 |136 147|yeast cellsmia. P00008
P02976332A1277 |21 25|PGI2ison
P02976332A1277 |54 61|surfacend 5-nu
P02976332A1277 |4 17|concentration01606T0076 Co
P02979426T0000 |0 21|Organ transplantationP00001606T0076 Compar
P02979426T0000 |25 32|Denmark with a
P02979834T0000 |119 134|ethyl carbamatel hyperbilirubi
P02979834T0000 |155 166|lung cancer When CSF [
P02979834T0000 |31 67|maltose tetrapalmitate immunotherapyalkaline phosphatases and 5-nucleoti
P02979834T0000 |103 115|radiotherapypects of neo
P02979834T0000 |69 98|cyclophosphamide chemotherapyse P00008171T0000 Pharmacolog
P02979834T0000 |170 178|A/J mice-] is sh
P02979834T0000 |0 7|EffectsP000016
P02981457A0368 |0 2|D.P0
P02981840A0907 |102 103|ds
P02981840A0907 |11 24|pair sequence076 Compariso
P02981840A0907 |104 106|ACec
P02981840A0907 |108 115|repeats of neo
P02981840A0907 |70 81|nucleotidese P00008171
P02982332T0001 |0 5|PhaseP0000
P02982332T0001 |43 49|tumorssphata
P02982332T0001 |9 14|studyT0076
P02982332T0001 |25 32|capsule with a
P02982332T0001 |18 23|VP-16paris
P02983316A0310 |275 283|sequenceo contro
P02983316A0310 |195 207|caiman genes of CSF PCO2
P02983316A0310 |329 348|nucleotide sequencee (1.21 +/- 0.23 vs
P02983316A0310 |366 372|periodluraze
P02983316A0310 |161 169|analysisCSF [HCO
P02983316A0310 |41 50|frameworkhosphatas
P02983316A0310 |122 137|probe sequencesyperbilirubinem
P02983316A0310 |389 393|timeto b
P02983316A0310 |55 90|complementarity-determining regionsd 5-nucleotidase P00008171T0000 Pha
P02983316A0310 |313 325|preservationtly greater 
P02983316A0310 |101 106|genesaspec
P02983316A0310 |16 24|segmentsompariso
P02983331T0000 |0 8|EvidenceP0000160
P02983331T0000 |15 19|roleComp
P02983331T0000 |58 64|factor-nucle
P02983331T0000 |74 79|ether00081
P02983331T0000 |111 117|stress neona
P02983331T0000 |81 95|immobilizationT0000 Pharmaco
P02985812A0984 |66 70|mRNAidas
P02985812A0984 |40 45|genesphosp
P02985812A0984 |11 18|feature076 Com
P02985812A0984 |125 129|mRNArbil
P02985812A0984 |97 110|reading framegic aspects o
P02985820A1287 |152 155|MH2472
P02985820A1287 |10 27|sequence elements0076 Comparison w
P02985820A1287 |124 141|retroviruses CMIIerbilirubinemia. 
P02985820A1287 |96 103|genesisogic as
P02985820A1287 |67 77|c-myc genedase P0000
P02985820A1287 |143 147|MC290008
P02985820A1287 |51 58|vectorss and 5
P02986279A0000 |34 40|donorsaline 
P02986279A0000 |128 131|CMVlir
P02986279A0000 |111 126|cytomegalovirus neonatal hyper
P02986279A0000 |43 47|daysspha
P02986279A0000 |53 59|monthsand 5-
P02986279A0000 |97 107|occurrencegic aspect
P02986279A0000 |66 74|deliveryidase P0
P02986279A0000 |3 15|milk samples001606T0076 
P02987220A0472 |51 53|kbs 
P02987220A0472 |159 165|regionn CSF 
P02987220A0472 |130 133|FBPrub
P02987220A0472 |135 139|geneemia
P02987220A0472 |14 27|DNA fragments Comparison w
P02987220A0472 |55 61|insertd 5-nu
P02987220A0472 |65 70|pAVO4tidas
P02987220A0472 |86 98|DNA fragment Pharmacolog
P02987220A0472 |0 10|SubcloningP00001606T
P02987777A0000 |35 49|cell carcinomaline phosphata
P02987777A0000 |57 63|rectum5-nucl
P02987777A0000 |6 11|cases606T0
P02988457A0650 |68 86|Bestatin treatmentase P00008171T0000
P02988457A0650 |52 64|potentiality and 5-nucle
P02988457A0650 |106 116|malignancyts of neon
P02988457A0650 |97 102|typesgic a
P02988457A0650 |4 8|data0160
P02989637A0671 |239 245|system no lo
P02989637A0671 |130 138|patientsrubinemi
P02989637A0671 |329 332|mene (
P02989637A0671 |6 10|data606T
P02989637A0671 |310 325|renin secretioncantly greater 
P02989637A0671 |37 47|regulationne phospha
P02989637A0671 |59 90|zona glomerulosa corticosteroidnucleotidase P00008171T0000 Pha
P02989637A0671 |264 290|metoclopramide stimulation compared to controls but 
P02989637A0671 |156 173|cord transectionsWhen CSF [HCO3-] 
P02989637A0671 |294 305|aldosteronel have a si
P02989637A0671 |101 116|renin secretionaspects of neon
P02989637A0671 |205 213|pathwaysO2 the d
P02989786A0328 |18 36|enhancer sequencesparison with alkal
P02989786A0328 |42 61|adenovirus E1A geneosphatases and 5-nu
P02989786A0328 |7 14|absence06T0076
P02989786A0328 |80 96|CATase synthesis1T0000 Pharmacol
P02991060A0465 |100 105|cases aspe
P02991060A0465 |28 34|babiesth alk
P02991060A0465 |121 127|monthshyperb
P02991060A0465 |60 68|deliveryucleotid
P02991060A0465 |146 152|babies8997A0
P02991060A0465 |131 135|agesubin
P02991060A0465 |162 168|monthsSF [HC
P02991060A0465 |6 20|IgG antibodies606T0076 Compa
P02993630A1190 |51 57|eventss and 
P02993630A1190 |65 74|digestiontidase P0
P02993630A1190 |5 13|analysis1606T007
P02993630A1190 |107 121|enzyme attackss of neonatal 
P02993630A1190 |165 172|message[HCO3-]
P02993630A1190 |151 154|G-A047
P02993630A1190 |21 37|nucleotide levelison with alkali
P02993630A1190 |80 91|nuclease S11T0000 Phar
P02993630A1190 |141 149|sequenceP0000899
P02993630A1190 |187 193|strandfuncti
P02994253A0482 |263 264|%n
P02994253A0482 |29 46|mean NTE activityh alkaline phosph
P02994253A0482 |284 291|animalss but s
P02994253A0482 |95 100|brainlogic
P02994253A0482 |57 61|cord5-nu
P02994253A0482 |215 232|days postexposurea of K-depleted r
P02994253A0482 |133 147|control valuesinemia. P00008
P02994253A0482 |89 90|%a
P02994253A0482 |197 211|cord pathologyf CSF PCO2 the
P02994253A0482 |128 129|%l
P02994253A0482 |6 13|dosages606T007
P02994253A0482 |158 173|hr postexposureen CSF [HCO3-] 
P02994336A0864 |0 2|FKP0
P02994336A0864 |97 110|bromocriptinegic aspects o
P02994336A0864 |56 67|plasma ACTH 5-nucleoti
P02994336A0864 |73 74|%0
P02994336A0864 |142 148|change000089
P02994336A0864 |112 118|CB-154neonat
P02994336A0864 |35 43|analogueline pho
P02994336A0864 |84 89|level00 Ph
P02995967T0000 |17 30|protooncogenemparison with
P02995967T0000 |147 167|gland adenocarcinoma997A0472 When CSF [H
P02995967T0000 |63 71|c-erbB-1eotidase
P02995967T0000 |82 109|growth factor-receptor gene0000 Pharmacologic aspects 
P02995967T0000 |32 40|c-erbB-2lkaline 
P02995999A0000 |4 21|sequence analysis01606T0076 Compar
P02995999A0000 |53 56|phiand
P02995999A0000 |145 155|attachment08997A0472
P02995999A0000 |240 259|recombination eventno longer displaced
P02995999A0000 |30 38|products alkalin
P02995999A0000 |314 334|recombination eventsly greater slope (1.
P02995999A0000 |226 234|positioneted rat
P02995999A0000 |74 94|recombination events0008171T0000 Pharmac
P02995999A0000 |114 127|recombinationonatal hyperb
P02995999A0000 |157 160|atthen
P02995999A0000 |162 166|siteSF [
P02995999A0000 |281 299|base-pair deletionrols but still hav
P02995999A0000 |368 391|base-pair substitutionsrazepam thus appears to
P02995999A0000 |201 207|jointsF PCO2
P02997622A0916 |83 103|SCLC tumour specimen000 Pharmacologic as
P02997622A0916 |11 19|sequence076 Comp
P02997622A0916 |126 133|patientbilirub
P02997622A0916 |52 71|SCLC cell line DNAs and 5-nucleotidase
P02997777A0609 |273 283|treatments to contro
P02997777A0609 |106 108|tsts
P02997777A0609 |183 189|blockss a fu
P02997777A0609 |202 209|killing PCO2 t
P02997777A0609 |67 82|delta top1 top2dase P00008171T
P02997777A0609 |332 350|delta top1 top2 ts1.21 +/- 0.23 vs. 
P02997777A0609 |314 324|cell deathly greater
P02997777A0609 |56 61|cells 5-nu
P02997777A0609 |251 262|temperatureisplaced wh
P02997777A0609 |217 224|top2 tsof K-de
P02997777A0609 |141 155|top2 ts strainP00008997A0472
P02997777A0609 |18 29|experimentsparison wit
P02998016A0527 |102 108|regionspects
P02998016A0527 |47 55|sequencetases an
P02998016A0527 |112 116|exonneon
P02998016A0527 |59 63|exonnucl
P02998016A0527 |198 211|reading frame CSF PCO2 the
P02998016A0527 |124 135|nucleotideserbilirubin
P02998016A0527 |227 232|c-milted r
P02998016A0527 |156 170|nonsense codonWhen CSF [HCO3
P02998016A0527 |4 12|homology01606T00
P02998016A0527 |237 242|v-milre no
P02998016A0527 |16 21|v-milompar
P02998043A1199 |137 141|acidia. 
P02998043A1199 |143 159|carboxy-proximal0008997A0472 Whe
P02998043A1199 |106 115|sequencests of neo
P02998043A1199 |73 81|presence00008171
P02998043A1199 |181 183|G2 a
P02998043A1199 |19 27|sequencearison w
P02998043A1199 |173 179|regionis sho
P02998043A1199 |35 60|Punta Toro M gene productline phosphatases and 5-n
P02998043A1199 |0 11|ExaminationP00001606T0
P02999267A0606 |96 105|intensityogic aspe
P02999267A0606 |79 86|uptakes71T0000
P02999267A0606 |132 139|sternumbinemia
P02999267A0606 |10 13|FAP007
P02999267A0606 |27 38|amyloidosisith alkalin
P02999267A0885 |186 196|appearance function 
P02999267A0885 |269 280|hypertrophyared to con
P02999267A0885 |52 60|patients and 5-n
P02999267A0885 |198 200|GS C
P02999267A0885 |149 155|echoes7A0472
P02999267A0885 |28 34|uptaketh alk
P02999267A0885 |285 287|GS b
P02999267A0885 |38 48|Tc-99m-PYPe phosphat
P02999267A0885 |4 13|intensity01606T007
P02999267A0885 |101 112|hypertrophyaspects of 
P02999267A0885 |236 244|patientsare no l
P03000457A1554 |118 122|betaal h
P03000457A1554 |93 96|kDacol
P03000457A1554 |8 21|kDa precursor6T0076 Compar
P03000457A1554 |43 44|ts
P03000457A1554 |125 132|speciesrbiliru
P03000457A1554 |113 116|kDaeon
P03000457A1554 |53 54|ha
P03000457A1554 |98 103|alphaic as
P03000457A1554 |71 81|processing P00008171
P03000489A0822 |171 181|activation] is shown
P03000489A0822 |159 167|criterian CSF [H
P03000489A0822 |57 65|patients5-nucleo
P03000489A0822 |95 96|%l
P03000489A0822 |120 124|mean hyp
P03000489A0822 |151 152|%0
P03000489A0822 |203 220|blood lymphopeniaPCO2 the data of 
P03000489A0822 |9 20|lymphocytesT0076 Compa
P03000489A0822 |77 81|mean8171
P03000489A0822 |108 109|% 
P03000489A0822 |115 118|CGLnat
P03000489A0822 |98 103|rangeic as
P03000489A0822 |141 146|rangeP0000
P03000489A0822 |138 139|%a
P03000489A0822 |71 75|AIDS P00
P03001054A0703 |79 84|sites71T00
P03001054A0703 |30 35|nicks alka
P03001084A0406 |84 86|bp00
P03001084A0406 |124 126|bper
P03001084A0406 |109 114|alphaof ne
P03001084A0406 |133 142|psi alphainemia. P
P03001084A0406 |44 48|pairphat
P03001084A0406 |54 61|segmentnd 5-nu
P03001084A0406 |97 105|cap sitegic aspe
P03001084A0406 |4 12|sequence01606T00
P03001084A0406 |50 52|bpes
P03001086A0587 |102 115|Xenopus hsp70spects of neo
P03001086A0587 |82 87|hsp700000 
P03001086A0587 |89 100|trout hsp70armacologic
P03001086A0587 |14 33|amino acid sequence Comparison with al
P03001086A0587 |139 147|homology. P00008
P03001086A0587 |117 128|yeast hsp70tal hyperbi
P03001086A0587 |50 58|homologyes and 5
P03001086A0587 |170 187|dnaK gene product-] is shown as a 
P03001110A0546 |34 52|peptide substratesaline phosphatases
P03001110A0546 |188 191|molunc
P03001110A0546 |83 112|receptor self-phosphorylation000 Pharmacologic aspects of 
P03001110A0546 |209 212|molhe 
P03001110A0546 |195 204|phosphate of CSF P
P03001110A0546 |114 138|tyrosine kinase activityonatal hyperbilirubinemi
P03001110A0546 |5 20|phosphorylation1606T0076 Compa
P03001110A0546 |216 224|receptor of K-de
P03001110A0546 |71 79|function P000081
P03001353A0146 |3 15|temperatures001606T0076 
P03001353A0146 |47 56|6m2 cellstases and
P03001353A0146 |104 106|kbec
P03001353A0146 |31 45|transformationalkaline phosp
P03001353A0146 |173 177|mRNAis s
P03001353A0146 |129 139|P85gag-mosirubinemia
P03001353A0146 |65 71|P58gagtidase
P03001353A0146 |114 124|RNA genomeonatal hyp
P03001645A0785 |4 9|pet5601606
P03001645A0785 |14 24|his3 genes Compariso
P03001645A0785 |106 108|bpts
P03001645A0785 |58 74|initiation sites-nucleotidase P0
P03001705T0000 |49 74|herpes simplex virus typeses and 5-nucleotidase P0
P03001705T0000 |107 119|gene products of neonata
P03001705T0000 |77 80|DNA817
P03001705T0000 |10 24|transformation0076 Compariso
P03001705T0000 |92 98|regionacolog
P03001705T0000 |36 45|fragmentsine phosp
P03001952A0958 |206 217|recurrences2 the data 
P03001952A0958 |131 142|recurrencesubinemia. P
P03001952A0958 |79 82|HSV71T
P03001952A0958 |164 173|acyclovir [HCO3-] 
P03001952A0958 |105 116|determinantcts of neon
P03001952A0958 |59 65|herpesnucleo
P03001952A0958 |24 32|patientsn with a
P03001952A0958 |71 75|type P00
P03001952A0958 |185 191|effecta func
P03002501A1327 |0 10|ComparisonP00001606T
P03002501A1327 |45 48|rathat
P03002501A1327 |109 117|homologyof neona
P03002501A1327 |14 23|sequences Comparis
P03002501A1327 |53 85|guinea-pig alpha s1-casein mRNAsand 5-nucleotidase P00008171T000
P03002501A1327 |157 164|regionshen CSF
P03002786A0143 |85 92|mg i.m.0 Pharm
P03002786A0143 |11 12|n0
P03002786A0143 |4 9|group01606
P03002786A0143 |40 49|midazolamphosphata
P03002786A0143 |55 62|mg kg-1d 5-nuc
P03002786A0143 |68 76|atropinease P000
P03003695A0395 |0 10|ComparisonP00001606T
P03003695A0395 |37 53|c-sis cDNA clonene phosphatases 
P03003695A0395 |121 135|kbp DNA regionhyperbilirubin
P03003695A0395 |55 62|Collinsd 5-nuc
P03003695A0395 |157 167|c-sis exonhen CSF [H
P03003695A0395 |71 77|Nature P0000
P03003695A0395 |185 187|bpa 
P03004364A0775 |117 123|MMCLIPtal hy
P03004364A0775 |56 60|5-FU 5-n
P03004364A0775 |106 112|ADRLIPts of 
P03004364A0775 |62 65|ADMleo
P03004364A0775 |42 52|activitiesosphatases
P03004364A0775 |77 83|FAMLIP8171T0
P03004364A0775 |99 104|FULIPc asp
P03004364A0775 |70 73|MMCe P
P03004739A0753 |16 17|Co
P03004739A0753 |129 138|promotersirubinemi
P03004739A0753 |176 195|CAT binding proteinshown as a function
P03004739A0753 |160 168|affinity CSF [HC
P03004739A0753 |21 35|G transversionison with alka
P03004739A0753 |112 120|activityneonatal
P03004739A0753 |64 83|CAT pentanucleotideotidase P00008171T0
P03004739A0753 |49 56|residueses and
P03004982A0199 |32 34|bplk
P03004982A0199 |120 124|fbcB hyp
P03004982A0199 |45 59|R. sphaeroideshatases and 5-
P03004982A0199 |108 118|genes fbcF of neonat
P03004982A0199 |72 75|DNAP00
P03004982A0199 |129 133|fbcCirub
P03004982A0199 |4 23|nucleotide sequence01606T0076 Comparis
P03004982A1094 |58 69|FeS protein-nucleotida
P03004982A1094 |15 23|sequenceComparis
P03004982A1094 |108 126|fbcF reading frame of neonatal hyper
P03004982A1094 |43 50|peptidesphatas
P03005231A0649 |219 228|sequences K-deplet
P03005231A0649 |27 36|sequencesith alkal
P03005231A0649 |60 69|sequencesucleotida
P03005231A0649 |125 138|transcriptionrbilirubinemi
P03005231A0649 |95 105|initiationlogic aspe
P03005231A0649 |110 121|terminationf neonatal 
P03005231A0649 |163 172|promotersF [HCO3-]
P03006066A0653 |100 108|proteins aspects
P03006066A0653 |41 60|translation producthosphatases and 5-n
P03006066A0653 |31 33|Mral
P03006066A0653 |7 22|P135gag-myb-ets06T0076 Compari
P03006066A0653 |110 118|P54c-etsf neonat
P03006066A0653 |64 69|c-mybotida
P03006066A0653 |71 79|P75c-myb P000081
P03007281A0905 |51 53|2Ls 
P03007281A0905 |97 101|locigic 
P03007281A0905 |127 129|kbil
P03007281A0905 |111 118|maximum neonat
P03007281A0905 |4 16|Dox-A2 locus01606T0076 C
P03007281A0905 |54 69|OD15 breakpointnd 5-nucleotida
P03007281A0905 |38 40|kbe 
P03007281A0905 |48 50|Dfas
P03008094A0697 |71 80|sequences P0000817
P03008094A0697 |15 18|endCom
P03008094A0697 |27 38|polypeptideith alkalin
P03008094A0697 |53 58|typesand 5
P03008405A0532 |50 61|deer calveses and 5-nu
P03008405A0532 |28 35|diseaseth alka
P03008405A0532 |72 77|HVC-1P0000
P03008405A0532 |8 17|outbreaks6T0076 Co
P03009366A0438 |102 108|targetspects
P03009366A0438 |112 121|radiationneonatal 
P03009366A0438 |77 88|pneumocytes8171T0000 P
P03009366A0438 |215 220|weeksa of 
P03009366A0438 |130 137|releaserubinem
P03009366A0438 |41 48|studieshosphat
P03009366A0438 |206 210|days2 th
P03009366A0438 |141 151|surfactantP00008997A
P03009366A0438 |184 192|exposure a funct
P03009366A0438 |69 73|Typese P
P03009826A0201 |46 66|base-pair dimer unitatases and 5-nucleot
P03009826A0201 |14 20|clones Compa
P03009826A0201 |74 80|repeat000817
P03010281A0220 |50 60|activationes and 5-n
P03010281A0220 |24 30|repeatn with
P03010281A0220 |4 10|copies01606T
P03010281A0220 |64 79|gene expressionotidase P000081
P03011793A0582 |85 104|amino acid residues0 Pharmacologic asp
P03011793A0582 |27 31|rbsDith 
P03011793A0582 |43 47|rbsCspha
P03011793A0582 |9 23|reading framesT0076 Comparis
P03011793A0582 |55 63|proteinsd 5-nucl
P03011793A0582 |33 37|rbsAkali
P03013477A0000 |342 349|group B.23 vs.
P03013477A0000 |240 248|patientsno longe
P03013477A0000 |90 100|metabolismrmacologic
P03013477A0000 |152 168|superoxide anion472 When CSF [HC
P03013477A0000 |250 255|groupdispl
P03013477A0000 |191 196|bloodtion 
P03013477A0000 |217 223|groupsof K-d
P03013477A0000 |22 31|influenceson with 
P03013477A0000 |178 181|PMNown
P03013477A0000 |332 337|ng/ml1.21 
P03013477A0000 |299 320|serum ferritin levelse a significantly gre
P03013477A0000 |124 136|hemodialysiserbilirubine
P03013477A0000 |362 373|individuals33 Flurazep
P03013477A0000 |282 293|individualsols but sti
P03013477A0000 |379 400|serum ferritin levelss appears to be an ef
P03013477A0000 |74 83|leucocyte0008171T0
P03013477A0000 |104 112|patientsects of 
P03013477A0000 |85 88|PMN0 P
P03013477A0000 |138 148|generationa. P000089
P03013477A0000 |412 417|ng/mlotic 
P03013477A0000 |3 8|order00160
P03013477A0000 |35 48|iron overloadline phosphat
P03013841A0207 |0 8|CattaneoP0000160
P03013841A0207 |14 16|J. C
P03014515T0000 |85 91|enzyme0 Phar
P03014515T0000 |29 48|nucleotide sequenceh alkaline phosphat
P03014515T0000 |6 27|alpha-galactosidase A606T0076 Comparison w
P03014515T0000 |54 64|cDNA clonend 5-nucle
P03014593A0681 |34 36|Roal
P03014593A0681 |91 96|mg/kgmacol
P03014593A0681 |12 17|mg/kg76 Co
P03014593A0681 |104 109|mg/kgects 
P03014593A0681 |78 87|Ro 5-4864171T0000 
P03014593A0681 |0 8|DiazepamP0000160
P03015611A0331 |4 23|amino acid sequence01606T0076 Comparis
P03015611A0331 |45 53|residueshatases 
P03015611A0331 |72 86|lysine residueP00008171T0000
P03015611A0331 |125 129|siterbil
P03015628A1078 |0 11|OsteocalcinP00001606T0
P03015628A1078 |109 119|mechanismsof neonata
P03015628A1078 |193 228|serum alkaline phosphatase activityon of CSF PCO2 the data of K-deplet
P03015628A1078 |141 154|bone turnoverP00008997A047
P03015628A1078 |25 39|hydroxyproline with alkaline
P03015628A1078 |71 91|hyperphosphatasaemia P00008171T0000 Phar
P03015628A1078 |238 246|subjectse no lon
P03015953T0000 |0 8|AnalysisP0000160
P03015953T0000 |12 26|glucocorticoid76 Comparison 
P03015953T0000 |62 91|mouse glucocorticoid receptorleotidase P00008171T0000 Phar
P03015953T0000 |106 115|DNA clonets of neo
P03015953T0000 |40 53|cell variantsphosphatases 
P03016301A0605 |70 78|terminuse P00008
P03016301A0605 |151 157|region0472 W
P03016301A0605 |93 103|c-myc exoncologic as
P03016301A0605 |10 22|v-myc codons0076 Compari
P03016301A0605 |113 119|codonseonata
P03016301A0605 |138 143|c-myca. P0
P03016506A0611 |117 129|B95-8 straintal hyperbil
P03016506A0611 |14 20|vector Compa
P03016506A0611 |22 26|p410son 
P03016506A0611 |282 298|G-418 resistanceols but still ha
P03016506A0611 |199 207|sequenceCSF PCO2
P03016506A0611 |167 181|antigen EBNA-1CO3-] is shown
P03016506A0611 |302 314|animal cells significant
P03016506A0611 |217 233|BamHI-C fragmentof K-depleted ra
P03016506A0611 |261 272|marker genehen compare
P03016506A0611 |81 92|nucleotidesT0000 Pharm
P03016506A0611 |71 79|fragment P000081
P03016883A0000 |3 6|men001
P03016883A0000 |79 88|infection71T0000 P
P03016883A0000 |72 77|HSV-2P0000
P03016883A0000 |149 156|urethra7A0472 
P03016883A0000 |14 21|history Compar
P03016883A0000 |43 68|herpes simplex virus typesphatases and 5-nucleotid
P03016883A0000 |161 176|virus isolationCSF [HCO3-] is 
P03016883A0000 |126 133|samplesbilirub
P03016883A0000 |115 120|weeksnatal
P03017225A0706 |34 48|leather bottlealine phosphat
P03017225A0706 |120 127|stomach hyperb
P03017225A0706 |173 182|carcinomais shown 
P03017225A0706 |11 20|carcinoma076 Compa
P03017225A0706 |148 154|glands97A047
P03017225A0706 |226 234|Nakamuraeted rat
P03017225A0706 |209 214|focushe da
P03017225A0706 |100 112|II c portion aspects of 
P03017225A0706 |80 87|stomach1T0000 
P03017225A0706 |237 243|theoryre no 
P03017225A0706 |50 71|linitis plastica typees and 5-nucleotidase
P03017996A0731 |171 173|X3] 
P03017996A0731 |62 76|signal peptideleotidase P000
P03017996A0731 |44 56|polypeptidesphatases and
P03017996A0731 |11 23|biosynthesis076 Comparis
P03017996A0731 |132 139|proteinbinemia
P03017996A0731 |178 191|cleavage siteown as a func
P03017996A0731 |156 166|mutants X2When CSF [
P03018491A0840 |102 110|sequencespects o
P03018491A0840 |179 182|endwn 
P03018491A0840 |61 73|GRE activitycleotidase P
P03018491A0840 |134 140|regionnemia.
P03018491A0840 |4 18|hexanucleotide01606T0076 Com
P03018491A0840 |22 30|TGTCCT-3son with
P03018491A0840 |190 194|genectio
P03018491A0840 |222 238|receptor bindingdepleted rats ar
P03019505A0390 |35 41|spreadline p
P03019505A0390 |67 72|tumordase 
P03019505A0390 |5 13|patients1606T007
P03020001A0781 |170 184|kilobase pairs-] is shown as
P03020001A0781 |214 224|insertionsta of K-de
P03020001A0781 |94 107|DNA fragmentsologic aspect
P03020001A0781 |243 257|kilobase pairslonger displac
P03020001A0781 |122 136|kilobase pairsyperbilirubine
P03020001A0781 |20 36|mini-Mu elementsrison with alkal
P03020001A0781 |83 90|cloning000 Pha
P03020001A0781 |201 207|clonesF PCO2
P03020001A0781 |49 63|kilobase pairsses and 5-nucl
P03020513T0000 |68 80|gyrA-proteinase P0000817
P03020513T0000 |15 22|subunitCompari
P03020513T0000 |26 46|T4 DNA topoisomerasewith alkaline phosph
P03020513T0000 |84 90|gyrase00 Pha
P03021050A0501 |55 64|sulbactamd 5-nucle
P03021050A0501 |26 31|peakswith 
P03021050A0501 |39 51|quantitation phosphatase
P03021088A0135 |171 175|days] is
P03021088A0135 |11 18|periods076 Com
P03021088A0135 |182 187|yearsas a 
P03021088A0135 |52 62|occurrence and 5-nuc
P03021088A0135 |212 217|yearsdata 
P03021088A0135 |197 204|averagef CSF P
P03021088A0135 |78 84|ulcers171T00
P03021088A0135 |130 134|typerubi
P03021088A0135 |35 44|exclusionline phos
P03021088A0135 |138 152|reconstructiona. P00008997A0
P03021088A0135 |102 113|gastrectomyspects of n
P03021088A0135 |119 127|Billrothl hyperb
P03022129A0842 |85 89|loss0 Ph
P03022129A0842 |93 99|detailcologi
P03022129A0842 |146 152|extent8997A0
P03022129A0842 |44 46|IIph
P03022129A0842 |194 212|transcription raten of CSF PCO2 the 
P03022129A0842 |16 22|arraysompari
P03022129A0842 |127 140|accessibilityilirubinemia.
P03022129A0842 |35 43|MPE X Feline pho
P03022129A0842 |221 225|gene-dep
P03023067A0779 |0 11|TranslationP00001606T0
P03023067A0779 |72 83|transcriptsP00008171T0
P03023067A0779 |33 38|geneskalin
P03023679A0624 |103 111|proteinspects of
P03023679A0624 |14 20|weight Compa
P03023679A0624 |149 161|modification7A0472 When 
P03023679A0624 |40 48|proteinsphosphat
P03023682A0271 |0 9|InsertionP00001606
P03023682A0271 |15 17|bpCo
P03023682A0271 |26 30|SV40with
P03023682A0271 |91 94|CATmac
P03023682A0271 |56 89|chloramphenicol acetyltransferase 5-nucleotidase P00008171T0000 Ph
P03023682A0271 |96 106|expressionogic aspec
P03023859A0000 |102 112|chromosomespects of 
P03023859A0000 |179 182|bcrwn 
P03023859A0000 |88 98|breakpointharmacolog
P03023859A0000 |121 135|Ph1 chromosomehyperbilirubin
P03023859A0000 |164 169|probe [HCO
P03023859A0000 |80 84|date1T00
P03023859A0000 |7 11|DNAs06T0
P03023859A0000 |184 209|breakpoint cluster region a function of CSF PCO2 t
P03023859A0000 |51 68|leukemia patientss and 5-nucleotid
P03023887A0470 |0 21|Nuclease footprintingP00001606T0076 Compar
P03023887A0470 |45 68|glucocorticoid receptorhatases and 5-nucleotid
P03023887A0470 |181 183|Sa a
P03023887A0470 |120 127|borders hyperb
P03023887A0470 |96 101|sitesogic 
P03023887A0470 |153 167|sequence motif72 When CSF [H
P03023970A0922 |118 128|generational hyperbi
P03023970A0922 |134 145|p53 productnemia. P000
P03023970A0922 |75 86|termination008171T0000
P03023970A0922 |148 159|amino acids97A0472 Whe
P03023970A0922 |29 47|termination signalh alkaline phospha
P03023970A0922 |94 101|proteinologic 
P03023970A0922 |10 16|insert0076 C
P03024343A0372 |4 10|tumors01606T
P03024343A0372 |57 63|origin5-nucl
P03024343A0372 |39 53|neuroendocrine phosphatases 
P03024703A1036 |137 151|hsp108 proteinia. P00008997A
P03024703A1036 |11 17|region076 Co
P03024703A1036 |112 118|weightneonat
P03024703A1036 |26 37|nucleotideswith alkali
P03024703A1036 |80 91|amino acids1T0000 Phar
P03024703A1036 |55 72|polypeptide chaind 5-nucleotidase 
P03025606T0000 |16 31|control signalsomparison with 
P03025606T0000 |133 141|terminusinemia. 
P03025606T0000 |149 153|mRNA7A04
P03025606T0000 |96 101|basesogic 
P03025606T0000 |37 62|herpes simplex virus typene phosphatases and 5-nuc
P03025606T0000 |80 88|gene lie1T0000 P
P03025606T0000 |71 76|gamma P000
P03025655T0000 |67 74|kinasesdase P0
P03025655T0000 |88 103|kinase functionharmacologic as
P03025655T0000 |15 21|domainCompar
P03025655T0000 |133 167|Fujinami sarcoma virus P130gag-fpsinemia. P00008997A0472 When CSF [H
P03025655T0000 |108 129|transforming activity of neonatal hyperbil
P03025661A0260 |0 7|GluzmanP000016
P03025661A0260 |9 16|EMBO J.T0076 C
P03025862A0860 |139 140|A.
P03025862A0860 |9 13|exonT007
P03025862A0860 |47 58|amino acidstases and 5
P03025862A0860 |134 138|polynemi
P03025862A0860 |66 75|ssd chainidase P00
P03025862A0860 |142 155|addition site00008997A0472
P03025862A0860 |114 118|mRNAonat
P03025862A0860 |100 106|region aspec
P03026915A1024 |35 40|partsline 
P03026915A1024 |76 87|yeast genes08171T0000 
P03026915A1024 |125 144|lacZ fusion vectorsrbilirubinemia. P00
P03026915A1024 |21 30|sequencesison with
P03026915A1024 |55 64|sequencesd 5-nucle
P03027661A0000 |4 14|activities01606T0076
P03027661A0000 |22 31|D proteinson with 
P03027661A0000 |39 52|miniF plasmid phosphatases
P03027779A0000 |0 17|SPECT examinationP00001606T0076 Co
P03027779A0000 |148 155|normals97A0472
P03027779A0000 |133 137|discinem
P03027779A0000 |66 74|patientsidase P0
P03027779A0000 |25 28|TMJ wi
P03027779A0000 |39 45|Tc-MDP phosp
P03027779A0000 |114 125|dislocationonatal hype
P03027905A0632 |0 21|Plasma renin activityP00001606T0076 Compar
P03027905A0632 |78 88|lisinopril171T0000 P
P03027905A0632 |35 59|plasma aldosterone levelline phosphatases and 5-
P03029111A0155 |18 32|representativeparison with a
P03029111A0155 |47 72|pet complementation grouptases and 5-nucleotidase 
P03029111A0155 |4 11|mutants01606T0
P03031602A1001 |82 87|genes0000 
P03031602A1001 |31 39|elementsalkaline
P03031602A1001 |11 16|group076 C
P03031602A1001 |67 73|regiondase P
P03032143A0218 |204 213|chromatinCO2 the d
P03032143A0218 |83 89|length000 Ph
P03032143A0218 |219 236|yeast kinetochore K-depleted rats 
P03032143A0218 |159 167|proteinsn CSF [H
P03032143A0218 |77 79|bp81
P03032143A0218 |44 50|regionphatas
P03032143A0218 |2 12|centromere0001606T00
P03032143A0218 |54 57|DNAnd 
P03032143A0218 |184 196|conformation a function 
P03032143A0218 |118 135|sequence elementsal hyperbilirubin
P03032964T0000 |69 78|sequencesse P00008
P03032964T0000 |13 21|function6 Compar
P03032964T0000 |93 101|activitycologic 
P03032964T0000 |48 56|promoterases and
P03033283A0837 |115 127|DNA sequencenatal hyperb
P03033283A0837 |132 170|competition filter binding experimentsbinemia. P00008997A0472 When CSF [HCO3
P03033283A0837 |77 81|HCMV8171
P03033283A0837 |106 110|casets o
P03033283A0837 |89 92|DNAarm
P03033283A0837 |271 277|regioned to 
P03033283A0837 |183 190|maximums a fun
P03033283A0837 |212 235|consensus binding sitesdata of K-depleted rats
P03033283A0837 |25 29|loci wit
P03033283A0837 |82 87|Towne0000 
P03033283A0837 |64 73|IE68 geneotidase P
P03033283A1415 |239 244|sites no l
P03033283A1415 |330 339|SCMV IE94 (1.21 +/
P03033283A1415 |316 326|expression greater s
P03033283A1415 |301 311|host rangea signific
P03033283A1415 |30 34|sets alk
P03033283A1415 |354 363|HCMV IE6810943A073
P03033283A1415 |177 188|arrangementhown as a f
P03033283A1415 |71 86|repeat elements P00008171T0000
P03033283A1415 |155 163|strength When CS
P03034570A0943 |222 229|vectorsdeplete
P03034570A0943 |113 117|geneeona
P03034570A0943 |129 139|resistanceirubinemia
P03034570A0943 |41 45|codehosp
P03034570A0943 |148 158|hygromycin97A0472 Wh
P03034570A0943 |12 17|genes76 Co
P03034570A0943 |21 34|gene segmentsison with alk
P03034570A0943 |188 207|papillomavirus typeunction of CSF PCO2
P03034570A0943 |64 97|chloramphenicol acetyltransferaseotidase P00008171T0000 Pharmacolo
P03034570A0943 |168 174|ORF E7O3-] i
P03034956A0666 |33 48|androgen levelskaline phosphat
P03034956A0666 |106 114|subjectsts of ne
P03034956A0666 |150 160|prednisoneA0472 When
P03034956A0666 |127 130|dayili
P03034956A0666 |162 163|PS
P03034956A0666 |142 145|day000
P03034956A0666 |3 11|contrast001606T0
P03035056T0000 |103 113|cell linespects of n
P03035056T0000 |55 62|Abelsond 5-nuc
P03035056T0000 |7 13|lambda06T007
P03035056T0000 |18 51|kappa antibody gene rearrangementparison with alkaline phosphatase
P03035056T0000 |70 78|leukemiae P00008
P03035218T0000 |0 14|IdentificationP00001606T0076
P03035218T0000 |45 54|sequenceshatases a
P03035218T0000 |72 98|T-cell leukemia virus typeP00008171T0000 Pharmacolog
P03035218T0000 |115 121|repeatnatal 
P03035658A0355 |170 173|VO2-] 
P03035658A0355 |56 65|ml/kg/min 5-nucleo
P03035658A0355 |208 211|VO2the
P03035658A0355 |181 190|ml/kg/min as a fun
P03035658A0355 |104 108|doseects
P03035658A0355 |119 125|mannerl hype
P03035658A0355 |87 98|epinephrinePharmacolog
P03035658A0355 |21 31|anesthesiaison with 
P03035658A0355 |219 228|ml/kg/min K-deplet
P03035658A0355 |163 168|ng/mlF [HC
P03035658A0355 |43 46|VO2sph
P03035658A0355 |129 150|plasma concentrationsirubinemia. P00008997
P03035658A0355 |201 206|ng/mlF PCO
P03036415T0000 |0 9|InfluenceP00001606
P03036415T0000 |13 39|cyclo-oxygenase inhibition6 Comparison with alkaline
P03036415T0000 |164 168|dogs [HC
P03036415T0000 |47 76|leukotriene receptor blockadetases and 5-nucleotidase P000
P03036415T0000 |99 135|pressure/cardiac index relationshipsc aspects of neonatal hyperbilirubin
P03036817A0213 |96 99|ATGogi
P03036817A0213 |107 115|yeast R.s of neo
P03036817A0213 |25 36|mutagenesis with alkal
P03036817A0213 |59 80|NdeI restriction sitenucleotidase P0000817
P03036933A0774 |0 12|ACTH releaseP00001606T00
P03036933A0774 |47 55|childrentases an
P03036933A0774 |72 86|ACTH treatmentP00008171T0000
P03037334A0932 |39 55|promoter element phosphatases an
P03037334A0932 |63 79|yeast RP39A geneeotidase P000081
P03037334A0932 |108 123|sequence motifs of neonatal hy
P03038643A1374 |139 143|gene. P0
P03038643A1374 |92 102|divergenceacologic a
P03038643A1374 |44 58|alpha-spectrinphatases and 5
P03038643A1374 |6 10|data606T
P03038643A1374 |70 81|duplicatione P00008171
P03038891A0935 |0 17|Northern analysesP00001606T0076 Co
P03038891A0935 |31 44|mouse tissuesalkaline phos
P03038891A0935 |75 90|p11 mRNA levels008171T0000 Pha
P03038891A0935 |21 25|RNAsison
P03038891A0935 |49 59|cell linesses and 5-
P03039177A0503 |17 28|cDNA clonesmparison wi
P03039177A0503 |123 152|restriction site polymorphismperbilirubinemia. P00008997A0
P03039177A0503 |93 111|IR2 repeat elementcologic aspects of
P03039177A0503 |161 172|enzyme SmaICSF [HCO3-]
P03039177A0503 |67 77|transcriptdase P0000
P03039177A0503 |4 9|group01606
P03039387A0920 |102 108|effectspects
P03039387A0920 |159 171|methotrexaten CSF [HCO3-
P03039387A0920 |144 155|combination008997A0472
P03039387A0920 |177 180|BCGhow
P03039387A0920 |73 84|enhancement00008171T00
P03039387A0920 |33 49|cyclophosphamidekaline phosphata
P03039387A0920 |55 58|BCGd 5
P03039387A0920 |185 201|cyclophosphamidea function of CS
P03039387A0920 |207 217|levamisole the data 
P03040023A0113 |0 8|MorphineP0000160
P03040023A0113 |59 70|tachycardianucleotidas
P03040023A0113 |35 46|bradycardialine phosph
P03040403A0155 |4 12|PSS gene01606T00
P03040403A0155 |74 86|YEp13 vector0008171T0000
P03040403A0155 |41 49|fragmenthosphata
P03040403A0155 |57 66|yeast DNA5-nucleot
P03041046A0127 |259 261|N. w
P03041046A0127 |58 70|Moloney MuLV-nucleotidas
P03041046A0127 |199 203|MuLVCSF 
P03041046A0127 |121 127|A-MuLVhyperb
P03041046A0127 |151 158|viruses0472 Wh
P03041046A0127 |37 44|virusesne phos
P03041046A0127 |8 14|A-MuLV6T0076
P03041046A0127 |172 178|BALB/c is sh
P03041046A0127 |248 257|potentialr displac
P03041802A0975 |186 190|role fun
P03041802A0975 |133 152|platelet activationinemia. P00008997A0
P03041802A0975 |28 47|platelet aggregatesth alkaline phospha
P03041802A0975 |91 107|cleavage productmacologic aspect
P03041802A0975 |61 67|levelscleoti
P03041802A0975 |164 174|deposition [HCO3-] i
P03041802A0975 |219 227|disorder K-deple
P03041802A0975 |198 210|pathogenesis CSF PCO2 th
P03041802A0975 |4 12|presence01606T00
P03041802A0975 |71 87|fibrinopeptide A P00008171T0000 
P03042778A0643 |4 8|gene0160
P03042778A0643 |26 31|yeastwith 
P03042778A0643 |43 49|growthsphata
P03045117A0936 |186 191|Asp27 func
P03045117A0936 |268 273|Leu47pared
P03045117A0936 |225 228|Thrlet
P03045117A0936 |43 50|methodssphatas
P03045117A0936 |78 85|species171T000
P03045117A0936 |160 165|Glu24 CSF 
P03045117A0936 |130 135|orderrubin
P03045117A0936 |242 247|Tyr29 long
P03045117A0936 |142 146|type0000
P03045117A0936 |59 68|agreementnucleotid
P03045117A0936 |99 112|growth factorc aspects of 
P03045117A0936 |16 22|valuesompari
P03045725A0872 |141 158|tumor sensitivityP00008997A0472 Wh
P03045725A0872 |88 110|breast cancer patientsharmacologic aspects o
P03045725A0872 |45 61|prolactin levelshatases and 5-nu
P03045725A0872 |162 174|chemotherapySF [HCO3-] i
P03045725A0872 |21 32|suppressionison with a
P03046655A0000 |71 74|eye P0
P03046655A0000 |91 99|patientsmacologi
P03046655A0000 |147 153|period997A04
P03046655A0000 |12 28|prevalence study76 Comparison wi
P03046655A0000 |114 123|keratitisonatal hy
P03046655A0000 |48 54|acuityases a
P03046931A0247 |17 23|eIF-4Amparis
P03046931A0247 |74 78|cDNA0008
P03046931A0247 |98 119|nucleotide differenceic aspects of neonata
P03046931A0247 |35 45|retroposonline phosp
P03048024A0418 |85 86|p0
P03048024A0418 |14 21|culture Compar
P03048024A0418 |75 83|NIB rats008171T0
P03048024A0418 |63 65|IBeo
P03048024A0418 |36 42|tissueine ph
P03049570A1242 |38 49|E2 proteinse phosphata
P03049570A1242 |6 18|similarities606T0076 Com
P03050147A0896 |83 90|viruses000 Pha
P03050147A0896 |106 113|amountsts of n
P03050147A0896 |58 75|E1a-E1b functions-nucleotidase P00
P03050147A0896 |130 148|mRNA transcriptionrubinemia. P000089
P03050147A0896 |6 15|infection606T0076 
P03050147A0896 |23 28|cellson wi
P03050147A1520 |102 111|ribosomesspects of
P03050147A1520 |44 58|scanning modelphatases and 5
P03050147A1520 |151 160|mRNA site0472 When
P03050147A1520 |176 195|initiator AUG codonshown as a function
P03050147A1520 |73 83|initiation00008171T0
P03050147A1520 |5 16|observation1606T0076 C
P03050147A1520 |204 213|C proteinCO2 the d
P03052327A1474 |102 108|choicespects
P03052327A1474 |129 137|patientsirubinem
P03052327A1474 |89 98|treatmentarmacolog
P03052327A1474 |39 70|pancreas-kidney transplantation phosphatases and 5-nucleotidas
P03052327A1474 |113 117|Typeeona
P03052327A1474 |3 7|view0016
P03052327A1474 |17 24|resultsmpariso
P03052641A0204 |17 26|compoundsmparison 
P03052641A0204 |41 49|vehicleshosphata
P03052641A0204 |70 75|gasese P00
P03053713A0752 |0 14|DNA sequencingP00001606T0076
P03053713A0752 |22 31|DPM1 geneson with 
P03053713A0752 |49 62|reading frameses and 5-nuc
P03053713A0752 |70 75|basese P00
P03057259A0514 |4 16|relationship01606T0076 C
P03057259A0514 |79 90|thyroiditis71T0000 Pha
P03057259A0514 |43 51|lymphomasphatase
P03057259A0514 |59 66|thyroidnucleot
P03059171A1232 |119 127|symptomsl hyperb
P03059171A1232 |18 32|anticoagulantsparison with a
P03059171A1232 |40 47|heparinphospha
P03059171A1232 |70 81|ticlopidinee P00008171
P03059171A1232 |49 65|prostaglandin E1ses and 5-nucleo
P03059171A1232 |154 167|deterioration2 When CSF [H
P03059171A1232 |0 14|AdministrationP00001606T0076
P03060846T0000 |27 42|L1 binding siteith alkaline ph
P03060846T0000 |46 54|23S rRNAatases a
P03060846T0000 |11 19|analysis076 Comp
P03060953A0481 |0 7|AnimalsP000016
P03060953A0481 |58 68|mechanisms-nucleotid
P03060953A0481 |93 102|outbreakscologic a
P03060953A0481 |33 44|vaccinationkaline phos
P03061301A0624 |137 153|radioimmunoassayia. P00008997A04
P03061301A0624 |128 133|meanslirub
P03061301A0624 |228 240|participantsed rats are 
P03061301A0624 |41 55|excretion ratehosphatases an
P03061301A0624 |211 217|period data 
P03061301A0624 |164 179|urine specimens [HCO3-] is sho
P03061301A0624 |253 258|smokeplace
P03061301A0624 |283 293|cigarettesls but sti
P03061301A0624 |70 110|metabolite 6-keto-prostaglandin F1 alphae P00008171T0000 Pharmacologic aspects o
P03061301A0624 |0 22|Prostacyclin formationP00001606T0076 Compari
P03061301A1409 |101 115|contraceptivesaspects of neo
P03061301A1409 |79 86|smokers71T0000
P03061301A1409 |149 159|creatinine7A0472 Whe
P03061301A1409 |9 18|excretionT0076 Com
P03061301A1409 |161 162|pC
P03061301A1409 |43 51|F1 alphasphatase
P03061301A1409 |140 145|ng/gm P000
P03061383A0000 |201 224|agar dilution techniqueF PCO2 the data of K-de
P03061383A0000 |25 35|mecillinam with alka
P03061383A0000 |111 126|beta-lactamases neonatal hyper
P03061383A0000 |63 67|acideoti
P03061383A0000 |13 21|activity6 Compar
P03061383A0000 |134 139|TEM-1nemia
P03061383A0000 |163 167|typeF [H
P03061383A0000 |93 100|strainscologic
P03061383A0000 |191 196|brothtion 
P03061383A0000 |141 146|Oxa-1P0000
P03062370A0000 |68 73|genesase P
P03062370A0000 |31 40|activatoralkaline 
P03062370A0000 |44 54|amino acidphatases a
P03062370A0000 |0 4|GCN4P000
P03062370A0384 |118 141|amino acid availabilityal hyperbilirubinemia. 
P03062370A0384 |75 85|activation008171T000
P03062370A0384 |29 41|GCN3 producth alkaline p
P03062370A0384 |61 71|repressioncleotidase
P03062370A0384 |89 104|GCN4 expressionarmacologic asp
P03062370A0384 |6 13|results606T007
P03064524A0160 |4 12|efficacy01606T00
P03064524A0160 |40 45|drugsphosp
P03064811A0485 |168 171|AspO3-
P03064811A0485 |31 48|S. aureus peptidealkaline phosphat
P03064811A0485 |62 78|phosphoryl groupleotidase P00008
P03064811A0485 |4 23|amino acid sequence01606T0076 Comparis
P03065140A0273 |55 73|DNA binding domaind 5-nucleotidase P
P03065140A0273 |37 49|GAL4 proteinne phosphata
P03065140A0273 |26 33|regionswith al
P03065140A0273 |6 15|mutations606T0076 
P03065140A0273 |83 114|transcription activation domain000 Pharmacologic aspects of ne
P03065141A0448 |119 128|citB genel hyperbi
P03065141A0448 |38 42|citAe ph
P03065141A0448 |4 11|results01606T0
P03065141A0448 |67 76|promotersdase P000
P03065141A0448 |47 51|citBtase
P03065141A0448 |31 36|genesalkal
P03065141A0448 |86 94|location Pharmac
P03065141A0448 |190 196|pMS185ction 
P03065141A0448 |136 162|Tn3411 nucleotide sequencemia. P00008997A0472 When C
P03065141A0448 |102 110|promoterspects o
P03065610A0375 |4 12|rci gene01606T00
P03065610A0375 |28 32|lacZth a
P03065610A0375 |72 93|Western blot analysisP00008171T0000 Pharma
P03065610A0375 |41 53|gene producthosphatases 
P03065621T0000 |0 9|StructureP00001606
P03065621T0000 |95 102|proteinlogic a
P03065621T0000 |14 24|regulation Compariso
P03065621T0000 |38 42|genee ph
P03065621T0000 |145 153|ribosome08997A04
P03065621T0000 |86 91|MRP13 Phar
P03065621T0000 |116 123|subunitatal hy
P03066131A0000 |119 126|lesionsl hyper
P03066131A0000 |284 298|aggressivenesss but still ha
P03066131A0000 |134 142|amygdalanemia. P
P03066131A0000 |83 102|behaviour disorders000 Pharmacologic a
P03066131A0000 |246 253|controlger dis
P03066131A0000 |231 241|operationsrats are n
P03066131A0000 |8 14|survey6T0076
P03066131A0000 |210 221|experiencese data of K
P03066131A0000 |185 191|authora func
P03066131A0000 |168 180|hypothalamusO3-] is show
P03066131A0000 |70 79|treatmente P000081
P03066131A0000 |51 56|basiss and
P03066208A0310 |55 59|cystd 5-
P03066208A0310 |13 24|examination6 Compariso
P03066208A0310 |82 96|cell carcinoma0000 Pharmacol
P03066625A0756 |102 114|risk factorsspects of ne
P03066625A0756 |29 36|studiesh alkal
P03066625A0756 |76 89|contributions08171T0000 Ph
P03066625A0756 |161 168|studiesCSF [HC
P03066625A0756 |143 155|risk factors0008997A0472
P03066625A0756 |207 216|questions the data
P03067505A0688 |69 80|ear vesselsse P0000817
P03067505A0688 |47 55|propertytases an
P03067505A0688 |6 18|prostacyclin606T0076 Com
P03069046A0126 |34 43|precisionaline pho
P03069046A0126 |57 68|sensitivity5-nucleotid
P03069046A0126 |4 10|method01606T
P03069980T0000 |0 7|FactorsP000016
P03069980T0000 |88 95|dentineharmaco
P03069980T0000 |24 37|bond strengthn with alkali
P03069980T0000 |46 65|glass polyalkenoateatases and 5-nucleo
P03069980T0000 |76 83|cements08171T0
P03069980T0000 |67 74|ionomerdase P0
P03072021A0696 |32 37|yeastlkali
P03072021A0696 |131 143|polypeptidesubinemia. P0
P03072021A0696 |66 85|targeting sequencesidase P00008171T000
P03072021A0696 |4 24|amino acid sequences01606T0076 Compariso
P03072580A0455 |0 12|Van der EndeP00001606T00
P03072580A0455 |14 16|R. C
P03073091A0338 |101 108|patientaspects
P03073091A0338 |79 84|order71T00
P03073091A0338 |29 48|% dextrose solutionh alkaline phosphat
P03073091A0338 |126 131|mg/dlbilir
P03073091A0338 |111 119|glycemia neonata
P03073091A0338 |7 23|insulin infusion06T0076 Comparis
P03073091A0338 |66 75|Biostatoridase P00
P03073091A0449 |0 7|AmountsP000016
P03073091A0449 |357 366|mg/kg/min43A0733 F
P03073091A0449 |327 328|Ko
P03073091A0449 |253 266|indomethacineplaced when c
P03073091A0449 |320 325|drugsater 
P03073091A0449 |295 304|mg/kg/min have a s
P03073091A0449 |189 203|spironolactonenction of CSF 
P03073091A0449 |214 220|mmol/lta of 
P03073091A0449 |268 269|Kp
P03073091A0449 |60 81|hour insulin infusionucleotidase P00008171
P03073091A0449 |151 157|mmol/l0472 W
P03073091A0449 |142 143|K0
P03073091A0449 |172 181|mg/kg/min is shown
P03073091A0449 |131 140|treatmentubinemia.
P03073091A0449 |11 18|glucose076 Com
P03073091A0449 |46 49|minata
P03073091A0449 |277 283|mmol/lcontro
P03073091A0449 |336 342|mmol/l +/- 0
P03073091A0449 |236 245|mg/kg/minare no lo
P03073091A0449 |205 206|KO
P03073192T0000 |0 53|Mycobacterium avium-intracellulare complex infectionsP00001606T0076 Comparison with alkaline phosphatases 
P03073192T0000 |70 95|immunodeficiency syndromee P00008171T0000 Pharmaco
P03075154T0000 |0 10|RecurrenceP00001606T
P03075154T0000 |14 32|oxalate deposition Comparison with a
P03075154T0000 |44 54|transplantphatases a
P03075154T0000 |62 83|ciclosporin A therapyleotidase P00008171T0
P03076124A0496 |70 74|acide P0
P03076124A0496 |254 275|hypercholesterolaemialaced when compared t
P03076124A0496 |359 360|%A
P03076124A0496 |322 327|totaler sl
P03076124A0496 |297 318|plasma concentrationsave a significantly g
P03076124A0496 |92 102|inhibitorsacologic a
P03076124A0496 |179 190|simvastatinwn as a fun
P03076124A0496 |332 347|LDL-cholesterol1.21 +/- 0.23 v
P03076124A0496 |215 220|drugsa of 
P03076124A0496 |28 42|cholestyramineth alkaline ph
P03076124A0496 |149 158|reductase7A0472 Wh
P03076124A0496 |76 87|fenofibrate08171T0000 
P03076124A0496 |106 138|hydroxymethylglutaryl coenzyme Ats of neonatal hyperbilirubinemi
P03076124A0496 |47 57|colestipoltases and 
P03076124A0496 |165 175|lovastatin[HCO3-] is
P03076124A0496 |225 228|uselet
P03076124A0496 |232 240|patientsats are 
P03076124A0496 |283 289|agentsls but
P03076124A0496 |140 147|HMG CoA P00008
P03076124A0496 |4 26|bile acid sequestrants01606T0076 Comparison 
P03078268A0529 |254 267|acidificationlaced when co
P03078268A0529 |218 222|rolef K-
P03078268A0529 |146 170|amphotericin B treatment8997A0472 When CSF [HCO3
P03078268A0529 |106 121|acidosis modelsts of neonatal 
P03078268A0529 |134 141|maleatenemia. 
P03078268A0529 |234 242|steroidss are no
P03078268A0529 |191 201|mechanismstion of CS
P03078268A0529 |32 39|aspectslkaline
P03078268A0529 |51 64|acidifications and 5-nucle
P03079276T0029 |85 94|flare-ups0 Pharmac
P03079276T0029 |14 20|groups Compa
P03079276T0029 |24 32|patientsn with a
P03079276T0029 |0 8|AnalysisP0000160
P03080793T0000 |51 61|preventions and 5-nu
P03080793T0000 |90 99|workplacermacologi
P03080793T0000 |32 42|guidelineslkaline ph
P03080793T0000 |65 82|AIDS transmissiontidase P00008171T
P03080793T0000 |0 9|StatementP00001606
P03080793T0000 |17 28|developmentmparison wi
P03083441T0000 |0 13|ModificationsP00001606T007
P03083441T0000 |61 67|peoplecleoti
P03083441T0000 |33 48|postcontractionkaline phosphat
P03088643A0000 |118 130|control ratsal hyperbili
P03088643A0000 |86 88|CS P
P03088643A0000 |77 84|stimuli8171T00
P03088643A0000 |32 42|preferencelkaline ph
P03088643A0000 |16 20|ratsompa
P03090237A0202 |168 180|response keyO3-] is show
P03090237A0202 |107 119|response keys of neonata
P03090237A0202 |121 129|work keyhyperbil
P03090237A0202 |193 196|keyon 
P03090237A0202 |12 21|schedules76 Compar
P03090237A0202 |94 99|timesologi
P03090237A0202 |36 48|response runine phosphat
P03090372A0607 |85 88|CyA0 P
P03090372A0607 |12 35|glucose tolerance tests76 Comparison with alka
P03090372A0607 |58 67|operation-nucleoti
P03090372A0607 |101 106|weeksaspec
P03091849A0000 |274 282|membraneto contr
P03091849A0000 |188 197|perfusionunction o
P03091849A0000 |218 223|mm Hgf K-d
P03091849A0000 |88 101|rat mesenteryharmacologic 
P03091849A0000 |122 127|kindsyperb
P03091849A0000 |131 141|experimentubinemia. 
P03091849A0000 |161 169|fixativeCSF [HCO
P03091849A0000 |15 29|glutaraldehydeComparison wit
P03091849A0000 |48 62|ultrastructureases and 5-nuc
P03091849A0000 |80 84|beds1T00
P03091849A0000 |203 211|pressurePCO2 the
P03091849A0000 |231 242|superfusionrats are no
P03091849A0000 |4 11|effects01606T0
P03091849A0000 |33 43|dimensionskaline pho
P03097509A0654 |18 31|RNA moleculesparison with 
P03097509A0654 |90 100|base pairsrmacologic
P03097509A0654 |10 14|rise0076
P03097509A0654 |53 60|regionsand 5-n
P03097643A1357 |68 84|octamer sequencease P00008171T00
P03097643A1357 |147 153|region997A04
P03097643A1357 |40 52|substitutionphosphatases
P03097643A1357 |10 21|BALB/c gene0076 Compar
P03097643A1357 |178 188|expressionown as a f
P03097643A1357 |112 123|nucleotidesneonatal hy
P03098018A0139 |35 37|cmli
P03098018A0139 |9 17|findingsT0076 Co
P03098018A0139 |79 84|limbs71T00
P03098018A0139 |63 69|lengtheotida
P03098018A0139 |105 115|micropeniscts of neo
P03098018A0139 |39 45|weight phosp
P03098018A0139 |24 30|heightn with
P03098018A0139 |86 100|P2-A2 pilosity Pharmacologic
P03098018A0139 |49 51|kgse
P03102289A0786 |118 127|folliclesal hyperb
P03102289A0786 |193 196|hCGon 
P03102289A0786 |149 159|ultrasound7A0472 Whe
P03102289A0786 |143 145|cm00
P03102289A0786 |202 217|serum E2 levels PCO2 the data 
P03102289A0786 |163 172|cycle dayF [HCO3-]
P03102289A0786 |58 76|hCG administration-nucleotidase P000
P03102289A0786 |108 114|number of ne
P03102289A0786 |80 88|midcycle1T0000 P
P03102289A0786 |248 256|follicler displa
P03102289A0786 |4 8|data0160
P03102289A0786 |237 243|pmol/lre no 
P03104245A0402 |170 175|range-] is
P03104245A0402 |210 215|rangee dat
P03104245A0402 |90 91|pr
P03104245A0402 |202 208|months PCO2 
P03104245A0402 |42 50|additionosphatas
P03104245A0402 |25 30|Ir192 with
P03104245A0402 |162 168|monthsSF [HC
P03104245A0402 |63 72|radiationeotidase 
P03104245A0402 |185 191|monthsa func
P03104245A0402 |6 14|patients606T0076
P03104245A0402 |223 229|monthseplete
P03104245A0402 |100 108|survival aspects
P03104248A0322 |21 29|patientsison wit
P03104248A0322 |123 131|patientsperbilir
P03104248A0322 |104 109|tumorects 
P03104248A0322 |61 63|G1cl
P03104248A0322 |7 15|Stage IA06T0076 
P03104248A0322 |111 113|G2 n
P03104248A0322 |159 161|G3n 
P03104248A0322 |54 59|tumornd 5-
P03104914T0000 |17 18|tm
P03104914T0000 |38 51|translocatione phosphatase
P03104914T0000 |113 121|partnerseonatal 
P03104914T0000 |64 72|analysisotidase 
P03104914T0000 |0 9|MechanismP00001606
P03104982A0690 |139 144|years. P00
P03104982A0690 |104 118|sex differenceects of neonat
P03104982A0690 |6 9|age606
P03104982A0690 |41 44|menhos
P03104982A0690 |148 151|age97A
P03104982A0690 |80 85|women1T000
P03104982A0690 |19 36|hemoglobin levelsarison with alkal
P03108171A0088 |0 10|RitanserinP00001606T
P03108171A0088 |52 69|blocking activity and 5-nucleotida
P03108171A0088 |73 85|S2 receptors00008171T000
P03108171A0088 |90 94|5-HTrmac
P03108171A0088 |20 29|substancerison wit
P03108171A0088 |118 124|systemal hyp
P03109147A0000 |0 15|Ethylene glycolP00001606T0076 
P03109147A0000 |127 134|dosagesilirubi
P03109147A0000 |149 151|mg7A
P03109147A0000 |91 97|groupsmacolo
P03109147A0000 |143 146|und000
P03109147A0000 |159 163|dosen CS
P03109147A0000 |112 121|NMRI miceneonatal 
P03109147A0000 |20 37|diethylene glycolrison with alkali
P03109147A0000 |168 173|mouseO3-] 
P03109147T0127 |0 8|ResearchP0000160
P03109147T0127 |12 27|ethylene glycol76 Comparison w
P03109147T0127 |67 74|effectsdase P0
P03109147T0127 |32 49|diethylene glycollkaline phosphata
P03109954A0945 |207 215|lowering the dat
P03109954A0945 |366 379|atherogenesislurazepam thu
P03109954A0945 |122 132|inhibitionyperbiliru
P03109954A0945 |284 291|balances but s
P03109954A0945 |327 339|relationshipope (1.21 +/
P03109954A0945 |48 57|influenceases and 
P03109954A0945 |219 255|plasma HDL cholesterol concentration K-depleted rats are no longer displ
P03109954A0945 |145 167|artery atherosclerosis08997A0472 When CSF [H
P03109954A0945 |78 85|ethinyl171T000
P03109954A0945 |348 361|plasma lipids. P00010943A0
P03109954A0945 |107 109|OCs 
P03109954A0945 |310 319|influencecantly gr
P03109954A0945 |4 11|results01606T0
P03110119A0267 |184 190|carina a fun
P03110119A0267 |107 117|side portss of neona
P03110119A0267 |165 176|cm cephalad[HCO3-] is 
P03110119A0267 |14 24|ventilator Compariso
P03110119A0267 |75 80|l/min00817
P03110119A0267 |144 147|tip008
P03110119A0267 |129 137|catheterirubinem
P03110119A0267 |63 64|%e
P03110119A0267 |7 9|BH06
P03110119A0267 |48 57|bias flowases and 
P03110678A0702 |220 235|treatment modesK-depleted rats
P03110678A0702 |181 191|convection as a func
P03110678A0702 |200 209|diffusionSF PCO2 t
P03110678A0702 |129 149|beta 2-microglobulinirubinemia. P0000899
P03110678A0702 |267 281|urea clearancempared to cont
P03110678A0702 |58 79|polysulphone membrane-nucleotidase P000081
P03110678A0702 |14 18|beta Com
P03110678A0702 |84 97|haemodialysis00 Pharmacolo
P03110678A0702 |35 42|removalline ph
P03110678A0702 |252 262|blood flowsplaced wh
P03110678A0702 |0 10|ComparisonP00001606T
P03110678A0702 |102 117|haemofiltrationspects of neona
P03110692A0156 |100 108|patients aspects
P03110692A0156 |424 427|dayth 
P03110692A0156 |187 195|dialysisfunction
P03110692A0156 |257 267|bone cystsed when co
P03110692A0156 |20 22|SDri
P03110692A0156 |114 124|bone cystsonatal hyp
P03110692A0156 |215 216|Pa
P03110692A0156 |331 339|dialysis(1.21 +/
P03110692A0156 |243 251|patientslonger d
P03110692A0156 |60 67|beta 2mucleoti
P03110692A0156 |380 392|urine volume appears to 
P03110692A0156 |41 42|Ph
P03110692A0156 |287 294|beta 2mut stil
P03110692A0156 |14 18|mg/l Com
P03110692A0156 |356 360|year943A
P03110692A0156 |308 316|patientsficantly
P03110692A0156 |140 144|mg/l P00
P03110692A0156 |278 284|monthsontrol
P03110692A0156 |175 183|duration shown a
P03110692A0156 |414 419|litreic dr
P03110746A0146 |32 36|acidlkal
P03110746A0146 |44 57|triglyceridesphatases and 
P03110746A0146 |9 19|percentageT0076 Comp
P03110746A0146 |78 92|adipose tissue171T0000 Pharm
P03110746A0146 |94 100|PLASATologic
P03110746A0146 |111 119|subjects neonata
P03110746A0146 |168 173|groupO3-] 
P03110794A0991 |3 12|overdoses001606T00
P03110794A0991 |52 59|effects and 5-
P03110794A0991 |21 34|g fluvoxamineison with alk
P03110801A0532 |59 69|microgramsnucleotida
P03110801A0532 |25 50|plasma prolactin response with alkaline phosphatas
P03111946A0309 |32 40|behaviorlkaline 
P03111946A0309 |3 9|effect001606
P03112028A0404 |51 52|ns
P03112028A0404 |18 26|patientsparison 
P03112028A0404 |69 70|ns
P03112028A0404 |84 94|parameters00 Pharmac
P03112412A0985 |118 139|thr operon expressional hyperbilirubinemia
P03112412A0985 |183 187|nones a 
P03112412A0985 |195 202|mutants of CSF
P03112412A0985 |25 31|strain with 
P03112412A0985 |162 173|temperatureSF [HCO3-] 
P03112412A0985 |214 220|changeta of 
P03112412A0985 |81 100|synthetase mutationT0000 Pharmacologic
P03112412A0985 |3 11|addition001606T0
P03114188A0907 |102 120|chest wall sarcomaspects of neonatal
P03114188A0907 |135 143|patientsemia. P0
P03114188A0907 |30 38|problems alkalin
P03114188A0907 |175 181|breast shown
P03114188A0907 |66 72|decadeidase 
P03114188A0907 |78 86|patients171T0000
P03114188A0907 |201 206|areasF PCO
P03114188A0907 |169 171|Gy3-
P03114829T0000 |38 50|panic statese phosphatas
P03114829T0000 |24 34|correlatesn with alk
P03114995T0000 |0 7|EffectsP000016
P03114995T0000 |45 60|gastrin releasehatases and 5-n
P03114995T0000 |64 68|dogsotid
P03114995T0000 |32 41|nutritionlkaline p
P03115087A0515 |64 72|standardotidase 
P03115087A0515 |9 15|weightT0076 
P03115087A0515 |46 47|%a
P03115087A0515 |20 37|height velocitiesrison with alkali
P03115087A0515 |55 56|%d
P03115787A0633 |238 244|monthse no l
P03115787A0633 |45 63|hexamethylmelaminehatases and 5-nucl
P03115787A0633 |146 154|response8997A047
P03115787A0633 |27 43|cyclophosphamideith alkaline pho
P03115787A0633 |167 176|responsesCO3-] is 
P03115787A0633 |192 198|monthsion of
P03115787A0633 |91 97|CHAP-5macolo
P03115787A0633 |65 75|adriamycintidase P00
P03115787A0633 |5 13|patients1606T007
P03115787A0633 |213 222|responsesata of K-
P03115787A0633 |80 89|cisplatin1T0000 Ph
P03115787A0633 |117 124|diseasetal hyp
P03117046T0000 |68 79|fibroblastsase P000081
P03117046T0000 |14 30|characterization Comparison with
P03117046T0000 |36 49|vinculin cDNAine phosphata
P03117046T0000 |0 9|IsolationP00001606
P03117147A1059 |68 84|oesophageal EMGdase P00008171T00
P03117147A1059 |164 177|investigation [HCO3-] is s
P03117147A1059 |146 150|tool8997
P03117147A1059 |56 63|surface 5-nucl
P03117147A1059 |107 119|surface EMGds of neonata
P03117147A1059 |38 47|agreemente phospha
P03117147A1059 |16 21|studyompar
P03118631A0140 |103 111|cochleaspects of
P03118631A0140 |3 14|differences001606T0076
P03118631A0140 |57 65|cochleas5-nucleo
P03118631A0140 |89 98|perfusionarmacolog
P03118631A0140 |18 34|fixation qualityparison with alk
P03118631A0140 |139 148|perfusion. P000089
P03119227A0079 |171 182|amino acids] is shown 
P03119227A0079 |195 201|region of CS
P03119227A0079 |91 119|c-abl proto-oncogene productmacologic aspects of neonata
P03119227A0079 |60 77|sequence homologyucleotidase P0000
P03119227A0079 |4 16|DNA sequence01606T0076 C
P03119227A0079 |43 54|amino acidssphatases a
P03119227A0079 |27 34|proteinith alk
P03119227A0079 |216 240|tyrosine kinase activity of K-depleted rats are 
P03119227A0079 |138 152|amino terminusa. P00008997A0
P03119485A0476 |186 191|shock func
P03119485A0476 |45 50|acidshatas
P03119485A0476 |173 182|prognosisis shown 
P03119485A0476 |142 149|respect0000899
P03119485A0476 |128 136|interestlirubine
P03119485A0476 |193 199|sepsison of 
P03119485A0476 |107 113|injurys of n
P03119485A0476 |4 15|requirement01606T0076 
P03119485A0476 |157 168|developmenthen CSF [HC
P03119485A0476 |54 62|patientsnd 5-nuc
P03119485A0476 |221 238|distress syndrome-depleted rats ar
P03119485A0476 |85 94|nutrition0 Pharmac
P03120334A0893 |5 6|%1
P03120334A0893 |95 101|systemlogic 
P03120334A0893 |79 83|vein71T0
P03120334A0893 |122 127|veinsyperb
P03120334A0893 |52 58|origin and 5
P03120334A0893 |23 27|veinon w
P03123310A0000 |80 87|pathway1T0000 
P03123310A0000 |62 72|activitiesleotidase 
P03123310A0000 |28 37|Gart geneth alkali
P03123310A0000 |107 116|synthesiss of neon
P03123310A0000 |92 98|purineacolog
P03123983T0000 |35 43|responseline pho
P03123983T0000 |47 52|drugstases
P03123983T0000 |12 27|neuroplasticity76 Comparison w
P03123983T0000 |4 8|role0160
P03125420A0421 |0 4|BiolP000
P03125422A0202 |69 88|activator sequencesse P00008171T0000 P
P03125422A0202 |111 120|induction neonatal
P03125422A0202 |124 133|galactoseerbilirub
P03125422A0202 |90 93|UASrma
P03125422A0202 |4 11|results01606T0
P03125422A0202 |21 32|experimentsison with a
P03126531T0000 |0 8|ReversalP0000160
P03126531T0000 |104 134|dopamine agonist pretreatmentsects of neonatal hyperbilirubi
P03126531T0000 |96 100|ratsogic
P03126531T0000 |77 86|REM sleep8171T0000
P03126531T0000 |63 73|aggressioneotidase P
P03126531T0000 |48 58|stereotypyases and 5
P03126531T0000 |16 24|increaseompariso
P03127034A0591 |68 78|resistancease P00008
P03127034A0591 |28 32|rateth a
P03127034A0591 |4 14|heart rate01606T0076
P03127463A1017 |201 209|culturesF PCO2 t
P03127463A1017 |6 11|rIL-3606T0
P03127463A1017 |93 110|bone marrow cellscologic aspects o
P03127463A1017 |25 35|COS7 cells with alka
P03127463A1017 |164 170|marrow [HCO3
P03127463A1017 |174 190|cord blood cellss shown as a fun
P03127463A1017 |157 162|My-10hen C
P03127463A1017 |140 153|proliferation P00008997A04
P03127463A1017 |55 67|CSF activityd 5-nucleoti
P03127463A1017 |81 89|culturesT0000 Ph
P03132498A0730 |187 192|hoursfunct
P03132498A0730 |6 14|patients606T0076
P03132498A0730 |59 63|torrnucl
P03132498A0730 |161 165|torrCSF 
P03132498A0730 |130 135|PaCO2rubin
P03132498A0730 |148 152|mean97A0
P03132498A0730 |99 111|asthma scorec aspects of
P03132498A0730 |80 84|torr1T00
P03132498A0730 |65 70|rangetidas
P03132498A0730 |21 26|PaCO2ison 
P03132498A0730 |175 179|mean sho
P03133250A0000 |222 229|programdeplete
P03133250A0000 |179 192|fertilizationwn as a funct
P03133250A0000 |214 220|IVF-ETta of 
P03133250A0000 |26 31|studywith 
P03133250A0000 |149 156|hormone7A0472 
P03133250A0000 |158 162|hFSHen C
P03133250A0000 |113 116|hMGeon
P03133250A0000 |197 212|embryo transferf CSF PCO2 the 
P03133250A0000 |65 76|stimulationtidase P000
P03133250A0000 |99 111|gonadotropinc aspects of
P03133360A1215 |84 94|inhibition00 Pharmac
P03133360A1215 |54 79|transcription attenuationnd 5-nucleotidase P000081
P03133360A1215 |113 122|trpE mRNAeonatal h
P03133360A1215 |30 41|mtr product alkaline p
P03133360A1215 |4 12|findings01606T00
P03133360A1215 |98 109|translationic aspects 
P03134872T0029 |0 7|AproposP000016
P03134872T0029 |13 17|case6 Co
P03137105A0146 |70 82|gonadotropine P00008171T
P03137105A0146 |128 133|phaselirub
P03137105A0146 |40 49|pregnancyphosphata
P03137105A0146 |177 182|cyclehown 
P03137105A0146 |242 255|oocyte donors longer displ
P03137105A0146 |191 208|oocyte collectiontion of CSF PCO2 
P03137105A0146 |260 277|embryo recipientswhen compared to 
P03137105A0146 |232 238|cyclesats ar
P03137105A0146 |98 101|endic 
P03137105A0146 |2 24|prostaglandin analogue0001606T0076 Compariso
P03137346A0319 |69 74|exonsse P0
P03137346A0319 |95 114|amino acid residueslogic aspects of ne
P03137346A0319 |122 129|proteinyperbil
P03137346A0319 |37 47|base-pairsne phospha
P03137346A0319 |4 18|nucleolin gene01606T0076 Com
P03137601A0212 |175 179|mice sho
P03137601A0212 |40 44|DOPSphos
P03137601A0212 |107 117|immobilitys of neona
P03137601A0212 |210 228|NE neurotoxin DSP4e data of K-deplet
P03137601A0212 |61 75|norepinephrinecleotidase P00
P03137601A0212 |134 138|DOPSnemi
P03137601A0212 |77 79|NE81
P03137601A0212 |9 38|L-threo-dihydroxyphenylserineT0076 Comparison with alkalin
P03137601A0212 |161 171|immobilityCSF [HCO3-
P03137601A0212 |128 132|miceliru
P03137601A0212 |81 90|precursorT0000 Pha
P03138190A0347 |33 43|ampicillinkaline pho
P03138190A0347 |12 19|amounts76 Comp
P03138190A0347 |73 86|Kupffer cells00008171T0000
P03138190A0347 |92 104|target cellsacologic asp
P03138190A0347 |143 154|inoculation0008997A047
P03138449A0759 |84 94|conditions00 Pharmac
P03138449A0759 |110 119|w6 supplyf neonata
P03138449A0759 |40 63|desaturation activitiesphosphatases and 5-nucl
P03138449A0759 |105 108|C18cts
P03138449A0759 |20 25|deltarison
P03138449A0759 |32 37|deltalkali
P03139750A0000 |68 74|rabbitase P0
P03139750A0000 |12 17|basis76 Co
P03139750A0000 |26 36|expressionwith alkal
P03139750A0000 |49 60|VH allotypeses and 5-n
P03142875A0366 |116 125|structureatal hype
P03142875A0366 |28 52|6-kilobase cDNA sequenceth alkaline phosphatases
P03142875A0366 |66 71|chainidase
P03142875A0366 |80 91|amino acids1T0000 Phar
P03143048A1091 |85 99|concentrations0 Pharmacologi
P03143048A1091 |43 61|apolipoprotein A-Isphatases and 5-nu
P03143048A1091 |19 20|%a
P03143048A1091 |65 66|%t
P03143048A1091 |22 23|Ps
P03143048A1091 |0 15|HDL-cholesterolP00001606T0076 
P03143048A1091 |68 69|Pa
P03143485A0366 |205 234|liverwort chloroplast genomesO2 the data of K-depleted rat
P03143485A0366 |72 86|protein operonP00008171T0000
P03143485A0366 |180 185|genesn as 
P03143485A0366 |22 42|protein gene clusterson with alkaline ph
P03143485A0366 |110 127|gene organizationf neonatal hyperb
P03143485A0366 |193 200|tobaccoon of C
P03143485A0366 |157 162|orderhen C
P03143485A0366 |4 11|Euglena01606T0
P03144705A0859 |49 59|resolutionses and 5-
P03144705A0859 |159 160|%n
P03144705A0859 |247 265|Alu family repeatser displaced when 
P03144705A0859 |24 29|sitesn wit
P03144705A0859 |4 16|distribution01606T0076 C
P03144705A0859 |113 132|sequence divergenceeonatal hyperbiliru
P03144705A0859 |219 220|X 
P03144705A0859 |101 109|gradientaspects 
P03144705A0859 |168 169|XO
P03146017A0983 |102 110|presencespects o
P03146017A0983 |192 195|molion
P03146017A0983 |166 188|amino acid polypeptideHCO3-] is shown as a f
P03146017A0983 |62 69|ORFtrpAleotida
P03146017A0983 |31 37|regionalkali
P03146017A0983 |142 149|ORFtrpB0000899
P03146017A0983 |52 54|M. a
P03146017A0983 |129 140|nucleotidesirubinemia.
P03146017A0983 |4 23|nucleotide sequence01606T0076 Comparis
P03146017A0983 |117 120|ORFtal
P03146150T0000 |0 12|PotentiationP00001606T00
P03146150T0000 |33 41|efficacykaline p
P03146150T0000 |58 67|urokinase-nucleoti
P03146150T0000 |87 94|heparinPharmac
P03146150T0000 |69 82|Pro-urokinasese P00008171T
P03146784A0158 |171 188|stretch receptors] is shown as a f
P03146784A0158 |243 257|chemoreceptorslonger displac
P03146784A0158 |31 36|phasealkal
P03146784A0158 |6 15|receptors606T0076 
P03146784A0158 |42 53|ventilationosphatases 
P03146784A0158 |108 125|stretch receptors of neonatal hype
P03146784A0158 |190 193|PSRcti
P03146784A0158 |259 262|IPC wh
P03147912A0422 |119 123|timel hy
P03147912A0422 |94 102|baselineologic a
P03147912A0422 |12 28|hyperventilators76 Comparison wi
P03147912A0422 |42 48|numberosphat
P03147912A0422 |146 152|PETCO28997A0
P03147912A0422 |78 90|fluctuations171T0000 Pha
P03147912A0422 |52 57|sighs and 
P03147912A0422 |136 140|timemia.
P03149774A0173 |207 229|bicuculline methiodide the data of K-deplete
P03149774A0173 |60 70|picrotoxinucleotidas
P03149774A0173 |177 186|retentionhown as a
P03149774A0173 |46 56|injectionsatases and
P03149774A0173 |149 150|h7
P03149774A0173 |302 309|barrier signif
P03149774A0173 |75 86|bicuculline008171T0000
P03149774A0173 |7 14|IA task06T0076
P03149774A0173 |127 136|retentionilirubine
P03149774A0173 |161 169|trainingCSF [HCO
P03149774A0173 |112 123|enhancementneonatal hy
P03149774A0173 |233 257|GABA receptor antagonistts are no longer displac
P03150015T0001 |51 60|hepatitiss and 5-n
P03150015T0001 |9 17|researchT0076 Co
P03150015T0001 |21 26|non-Aison 
P03150296A0594 |254 274|creatinine clearancelaced when compared 
P03150296A0594 |91 106|filtration ratemacologic aspec
P03150296A0594 |43 63|creatinine clearancesphatases and 5-nucl
P03150296A0594 |176 182|methodshown 
P03150296A0594 |108 111|GFR of
P03150296A0594 |122 129|cautionyperbil
P03150296A0594 |302 310|practice signifi
P03150296A0594 |157 168|limitationshen CSF [HC
P03150296A0594 |25 28|use wi
P03150296A0594 |213 229|serum creatinineata of K-deplete
P03150296A0594 |201 211|techniquesF PCO2 the
P03150296A0594 |138 149|recognitiona. P0000899
P03154072A0862 |4 20|protein mixtures01606T0076 Compa
P03154072A0862 |41 54|soybean flourhosphatases a
P03154072A0862 |24 36|sesame flourn with alkal
P03159903A0352 |7 10|end06T
P03159903A0352 |124 143|amino acid sequenceerbilirubinemia. P0
P03159903A0352 |79 98|amino acid sequence71T0000 Pharmacolog
P03159903A0352 |147 150|IHF997
P03159903A0352 |25 31|region with 
P03166458A1356 |2 19|protein footprint0001606T0076 Comp
P03166458A1356 |46 60|GC box elementatases and 5-n
P03166458A1356 |64 75|nucleotidesotidase P00
P03167060A0000 |70 75|mRNAse P00
P03167060A0000 |31 36|IGFIIalkal
P03167060A0000 |109 114|formsof ne
P03167060A0000 |149 153|gene7A04
P03167060A0000 |13 26|growth factor6 Comparison 
P03167060A0000 |124 134|derivationerbilirubi
P03167060A0000 |53 64|polypeptideand 5-nucle
P03168709A0000 |85 94|threshold0 Pharmac
P03168709A0000 |19 25|fieldsarison
P03168709A0000 |49 62|glaucoma eyesses and 5-nuc
P03168709A0000 |103 126|suprathreshold strategypects of neonatal hyper
P03171221A0531 |33 39|resultkaline
P03171221A0531 |67 72|exonsdase 
P03171221A0531 |90 109|elastin transcriptsrmacologic aspects 
P03171221A0531 |4 15|variability01606T0076 
P03171221A0531 |55 63|splicingd 5-nucl
P03171279A0158 |221 225|vein-dep
P03171279A0158 |167 173|graftsCO3-] 
P03171279A0158 |73 79|toe MP000081
P03171279A0158 |47 53|arterytases 
P03171279A0158 |16 26|conclusionomparison 
P03171279A0158 |86 92|grafts Pharm
P03171279A0158 |130 136|arteryrubine
P03171279A0158 |153 160|toe PIP72 When
P03171279A0158 |204 210|dorsalCO2 th
P03172863T0000 |0 6|EffectP00001
P03172863T0000 |59 65|stressnucleo
P03172863T0000 |90 94|ratsrmac
P03172863T0000 |36 50|susceptibilityine phosphatas
P03172863T0000 |18 32|undernutritionparison with a
P03175942A0706 |64 68|damsotid
P03175942A0706 |127 132|dosesiliru
P03175942A0706 |92 102|experimentacologic a
P03175942A0706 |40 45|dosesphosp
P03175942A0706 |5 11|effect1606T0
P03175942A0706 |20 24|factriso
P03178097A0000 |4 22|CHARGE association01606T0076 Compari
P03178097A0000 |42 53|multisystemosphatases 
P03178097A0000 |28 38|collectionth alkalin
P03178097A0000 |93 100|atresiacologic
P03178097A0000 |65 74|anomaliestidase P0
P03178161A0000 |170 174|risk-] i
P03178161A0000 |112 115|B12neo
P03178161A0000 |58 78|blood concentrations-nucleotidase P00008
P03178161A0000 |208 216|Transkeithe data
P03178161A0000 |29 38|screeningh alkalin
P03178161A0000 |123 127|acidperb
P03178161A0000 |160 166|adults CSF [
P03178161A0000 |132 142|methioninebinemia. P
P03178161A0000 |221 227|Ciskei-deple
P03178161A0000 |190 199|carcinomaction of 
P03178161A0000 |82 96|micronutrients0000 Pharmacol
P03178161A0000 |229 244|Southern Africad rats are no l
P03178161A0000 |11 16|brush076 C
P03178161A0000 |109 110|Eo
P03178161A0000 |201 203|ECF 
P03178161A0000 |98 107|vitamin Aic aspect
P03178626A0137 |0 8|AviatorsP0000160
P03178626A0137 |24 35|Attack Wingn with alka
P03178626A0137 |95 108|aircraft typelogic aspects
P03178626A0137 |37 44|Pacificne phos
P03178626A0137 |67 74|resultsdase P0
P03179496T0000 |0 10|EvaluationP00001606T
P03179496T0000 |31 59|modified-hemoglobin solutionalkaline phosphatases and 5-
P03179496T0000 |89 113|blood volume replacementarmacologic aspects of n
P03179496T0000 |79 84|fluid71T00
P03180595A1040 |51 68|ejection fractions and 5-nucleotid
P03180595A1040 |8 33|gallbladder visualization6T0076 Comparison with al
P03180595A1040 |122 129|diseaseyperbil
P03180595A1040 |38 47|reductione phospha
P03180595A1040 |100 110|indicators aspects o
P03181276A0422 |3 17|micrograms PAF001606T0076 Co
P03181276A0422 |57 63|cavity5-nucl
P03181276A0422 |91 109|allergen challengemacologic aspects 
P03181276A0422 |74 75|h0
P03181276A0422 |66 67|hi
P03181276A0422 |21 28|placeboison wi
P03182802A0278 |0 3|SciP00
P03182872A1122 |0 4|ChemP000
P03183103A0000 |97 105|h periodgic aspe
P03183103A0000 |121 131|volunteershyperbilir
P03183103A0000 |61 68|sinusescleotid
P03183103A0000 |11 26|MR examinations076 Comparison 
P03183103A0000 |40 46|cavityphosph
P03183127A0068 |0 10|ComparisonP00001606T
P03183127A0068 |95 114|CT ventriculographylogic aspects of ne
P03183127A0068 |78 80|CT17
P03183127A0068 |120 142|CT myelocisternography hyperbilirubinemia. P
P03183127A0068 |82 93|myelography0000 Pharma
P03183127A0068 |49 67|imaging modalitiesses and 5-nucleoti
P03184267A0000 |206 212|humans2 the 
P03184267A0000 |24 40|broiler chickensn with alkaline 
P03184267A0000 |4 8|feed0160
P03184267A0000 |99 107|serotypec aspect
P03184267A0000 |188 202|food poisoningunction of CSF
P03184267A0000 |141 151|infectionsP00008997A
P03184267A0000 |175 183|chickens shown a
P03185322A1305 |138 139|%a
P03185322A1305 |90 95|classrmaco
P03185322A1305 |82 88|result0000 P
P03185322A1305 |7 18|correlation06T0076 Com
P03185322A1305 |125 134|diagnosisrbilirubi
P03185322A1305 |143 157|class-2 smears0008997A0472 W
P03185322A1305 |191 200|dysplasiation of C
P03185540T0000 |0 7|FactorsP000016
P03185540T0000 |75 87|purification008171T0000 
P03185540T0000 |56 70|RNA polymerase 5-nucleotidas
P03185540T0000 |148 153|TFIID97A04
P03185540T0000 |29 42|transcriptionh alkaline ph
P03185540T0000 |97 108|specificitygic aspects
P03185540T0000 |114 144|TATA box-promoter interactionsonatal hyperbilirubinemia. P00
P03186091T0000 |0 6|ChangeP00001
P03186091T0000 |120 132|hypertension hyperbiliru
P03186091T0000 |10 38|plasma cystyl aminopeptidase0076 Comparison with alkalin
P03186091T0000 |89 98|predictorarmacolog
P03186091T0000 |74 83|gestation0008171T0
P03186091T0000 |40 51|oxytocinasephosphatase
P03186091T0000 |67 72|weeksdase 
P03186270T0001 |13 22|diagnosis6 Compari
P03190481A0292 |155 166|correlation When CSF [
P03190481A0292 |91 113|infiltration area unitmacologic aspects of n
P03190481A0292 |198 209|macrophages CSF PCO2 t
P03190481A0292 |130 137|abscessrubinem
P03190481A0292 |79 85|number71T000
P03190481A0292 |41 53|quantitationhosphatases 
P03190481A0292 |28 36|esteraseth alkal
P03190481A0292 |188 194|numberunctio
P03190481A0292 |231 238|capsulerats ar
P03190481A0292 |57 68|macrophages5-nucleotid
P03190481A0292 |218 223|widthf K-d
P03190481A0292 |4 8|test0160
P03190914A0149 |68 82|responsivenessase P00008171T
P03190914A0149 |14 37|migration differentials Comparison with alkali
P03190914A0149 |122 127|groupyperb
P03192537A0370 |139 144|HMG-I. P00
P03192537A0370 |179 190|amino acidswn as a fun
P03192537A0370 |41 49|sequencehosphata
P03192537A0370 |73 77|cDNA0000
P03192537A0370 |23 33|amino acidon with al
P03192537A0370 |110 129|amino acid sequencef neonatal hyperbil
P03192537A0370 |213 220|proteinata of 
P03192537A0370 |64 69|HMG-Iotida
P03192537A0370 |70 71|Ye
P03192724A0000 |71 75|Ryan P00
P03192724A0000 |107 128|FIRO-B interpretations of neonatal hyperbi
P03192724A0000 |14 31|style differences Comparison with 
P03192724A0000 |97 103|systemgic as
P03192724A0000 |38 50|drug abuserse phosphatas
P03192799T0000 |17 33|American Academymparison with al
P03192799T0000 |37 54|Implant Dentistryne phosphatases a
P03192799T0000 |0 9|StatementP00001606
P03192950A0566 |0 4|SeraP000
P03192950A0566 |91 96|rangemacol
P03192950A0566 |62 72|TSH levelsleotidase 
P03192950A0566 |48 53|womenases 
P03194410A0771 |3 14|UOxase mRNA001606T0076
P03194410A0771 |56 59|rat 5-
P03194410A0771 |72 90|tissue specificityP00008171T0000 Pha
P03194410A0771 |45 52|tissueshatases
P03194410A0771 |94 104|expressionologic asp
P03194410A0771 |113 124|UOxase geneeonatal hyp
P03195167A0104 |87 105|haemocompatibilityPharmacologic aspe
P03195167A0104 |36 42|layersine ph
P03195167A0104 |142 145|PUR000
P03195167A0104 |177 188|polystyrenehown as a f
P03195167A0104 |167 170|PVCCO3
P03195167A0104 |148 165|polyvinylchloride97A0472 When CSF 
P03195167A0104 |4 26|platelet adhesion rate01606T0076 Comparison 
P03195167A0104 |218 231|test chambersf K-depleted 
P03195167A0104 |113 140|basic-polymers polyurethaneeonatal hyperbilirubinemia.
P03195167A0104 |190 192|PSct
P03195167A0104 |70 79|valuatione P000081
P03198436T0000 |55 65|cystectomyd 5-nucleo
P03198436T0000 |13 22|treatment6 Compari
P03198436T0000 |26 43|bladder carcinomawith alkaline pho
P03198436T0000 |83 90|iridium000 Pha
P03198525A0164 |137 140|d-1ia.
P03198525A0164 |217 226|mg MGA/hdof K-depl
P03198525A0164 |62 68|mediumleotid
P03198525A0164 |121 124|MGAhyp
P03198525A0164 |30 37|heifers alkali
P03198525A0164 |163 171|DEPO-MGAF [HCO3-
P03198525A0164 |11 24|feedlot trial076 Compariso
P03198525A0164 |79 85|weight71T000
P03198525A0164 |155 158|MGA Wh
P03198525A0164 |55 60|lightd 5-n
P03198525A0164 |143 150|control0008997
P03198525A0164 |197 202|ml/hdf CSF
P03198525A0164 |129 136|mg.hd-1irubine
P03198525A0164 |175 176|d 
P03198525A0164 |101 111|treatmentsaspects of
P03199043A0248 |119 144|permeability coefficientsl hyperbilirubinemia. P00
P03199043A0248 |149 164|transport rates7A0472 When CSF
P03199043A0248 |28 37|solutionsth alkali
P03199043A0248 |14 24|uniqueness Compariso
P03199043A0248 |105 109|casects 
P03199043A0248 |57 80|boundary value problems5-nucleotidase P0000817
P03199043A0248 |227 236|constantsted rats 
P03199043A0248 |208 218|resistancethe data o
P03199043A0248 |175 197|diffusion coefficients shown as a function o
P03199043A0248 |0 9|ExistenceP00001606
P03199436A1060 |34 59|photosynthesis componentsaline phosphatases and 5-
P03199436A1060 |72 91|psbB-psbH-petB-petDP00008171T0000 Phar
P03199436A1060 |11 24|gene clusters076 Compariso
P03199436A1060 |100 118|psbE-psbF clusters aspects of neonat
P03200488A0439 |51 64|turnover rates and 5-nucle
P03200488A0439 |144 150|period008997
P03200488A0439 |154 158|mice2 Wh
P03200488A0439 |86 102|dopamine neurons Pharmacologic a
P03200488A0439 |4 11|results01606T0
P03200488A0439 |35 38|TIQlin
P03200488A0439 |118 132|administrational hyperbiliru
P03200844A1211 |171 177|family] is s
P03200844A1211 |12 20|sequence76 Compa
P03200844A1211 |74 84|similarity0008171T00
P03200844A1211 |189 207|pore glycoproteinsnction of CSF PCO2
P03200844A1211 |43 60|pore glycoproteinsphatases and 5-n
P03200844A1211 |108 116|proteins of neon
P03200844A1211 |143 151|features0008997A
P03200844A1211 |157 163|memberhen CS
P03207975A0709 |54 75|plasma concentrationsnd 5-nucleotidase P00
P03207975A0709 |24 38|administrationn with alkalin
P03207975A0709 |12 17|hours76 Co
P03207975A0709 |42 52|vitamin K1osphatases
P03207975A0709 |83 90|vitamin000 Pha
P03208493A0849 |50 67|lithium clearancees and 5-nucleoti
P03208493A0849 |15 30|filtration rateComparison with
P03208493A0849 |78 79|%1
P03209019A0662 |17 35|promotion bioassaymparison with alka
P03209019A0662 |37 43|groupsne pho
P03209019A0662 |198 211|test material CSF PCO2 the
P03209019A0662 |132 139|acetonebinemia
P03209019A0662 |122 127|mg/mlyperb
P03209019A0662 |91 101|microlitermacologic 
P03209019A0662 |233 238|weeksts ar
P03209019A0662 |188 192|weekunct
P03209019A0662 |112 116|DMBAneon
P03209019A0662 |55 64|CD-1 miced 5-nucle
P03209019A0662 |154 159|weeks2 Whe
P03212551T0001 |32 43|contracturelkaline pho
P03212551T0001 |20 29|Dupuytrenrison wit
P03212551T0001 |4 16|pathogenesis01606T0076 C
P03212929A0000 |85 114|Dirofilaria immitis infection0 Pharmacologic aspects of ne
P03212929A0000 |61 73|IgE responsecleotidase P
P03212929A0000 |77 81|dogs8171
P03212929A0000 |3 18|ELISA procedure001606T0076 Com
P03214709A0559 |50 78|plasma corticosterone levelses and 5-nucleotidase P00008
P03214709A0559 |90 96|stressrmacol
P03214709A0559 |163 168|groupF [HC
P03214709A0559 |29 35|stressh alka
P03214709A0559 |121 126|grouphyper
P03214709A0559 |6 9|min606
P03214709A0559 |16 23|releaseomparis
P03216131A0559 |20 40|Aeromonas hydrophilarison with alkaline 
P03216131A0559 |60 71|enterotoxinucleotidase
P03216131A0559 |9 16|isolateT0076 C
P03218714A0000 |84 93|tetralogy00 Pharma
P03218714A0000 |97 103|Fallotgic as
P03218714A0000 |63 66|DWMeot
P03218714A0000 |105 108|TOFcts
P03218714A0000 |36 61|Dandy-Walker malformationine phosphatases and 5-nu
P03218714A0000 |16 20|girlompa
P03219107A0212 |32 43|convulsionslkaline pho
P03219107A0212 |80 86|births1T0000
P03219107A0212 |4 13|incidence01606T007
P03219107A0212 |55 61|babiesd 5-nu
P03220077A0274 |71 76|years P000
P03220077A0274 |11 19|survival076 Comp
P03220077A0274 |59 63|timenucl
P03223123T0001 |71 79|maturity P000081
P03223123T0001 |9 19|evaluationT0076 Comp
P03223123T0001 |31 38|methodsalkalin
P03223123T0001 |92 97|fluidacolo
P03223123T0001 |54 61|markersnd 5-nu
P03227288A0542 |69 75|monthsse P00
P03227288A0542 |10 17|infants0076 Co
P03227288A0542 |36 40|lossine 
P03227288A0542 |86 89|age Ph
P03227568T0001 |0 7|VarietyP000016
P03227568T0001 |11 15|cows076 
P03227568T0001 |104 110|cattleects o
P03227568T0001 |39 44|types phos
P03227568T0001 |20 25|siresrison
P03227568T0001 |94 100|mirrorologic
P03227568T0001 |65 73|patternstidase P
P03227568T0001 |48 63|dermatoglyphicsases and 5-nucl
P03228518A0339 |123 133|dimensionsperbilirub
P03228518A0339 |44 51|samplesphatase
P03228518A0339 |73 96|Personal Responsibility00008171T0000 Pharmacol
P03228518A0339 |63 71|Academiceotidase
P03228785A1047 |220 227|controlK-deple
P03228785A1047 |98 102|weekic a
P03228785A1047 |191 194|cm2tio
P03228785A1047 |36 47|improvementine phospha
P03228785A1047 |230 238|ABSTRACT rats ar
P03228785A1047 |196 197|po
P03228785A1047 |139 143|area. P0
P03228785A1047 |71 81|parameters P00008171
P03228785A1047 |175 180|weeks show
P03228785A1047 |256 261|WORDSced w
P03228785A1047 |0 8|RecoveryP0000160
P03229917A0099 |65 82|remnant infectiontidase P00008171T
P03229917A0099 |30 39|resection alkaline
P03232410A1467 |49 60|lung cancerses and 5-n
P03232410A1467 |109 116|smokingof neon
P03232410A1467 |40 45|casesphosp
P03232410A1467 |83 87|year000 
P03233862T0000 |0 20|Neuromyelitis opticaP00001606T0076 Compa
P03233862T0000 |30 38|syndrome alkalin
P03233862T0000 |61 70|sclerosiscleotidas
P03234790T0001 |0 6|EffectP00001
P03234790T0001 |53 75|methyl isobutyl ketoneand 5-nucleotidase P00
P03234790T0001 |14 21|methods Compar
P03234790T0001 |83 91|toxicity000 Phar
P03234790T0001 |35 49|administrationline phosphata
P03235487A0404 |0 13|IncorporationP00001606T007
P03235487A0404 |125 134|diltiazemrbilirubi
P03235487A0404 |95 103|decreaselogic as
P03235487A0404 |28 57|M sodium dihydrogen phosphateth alkaline phosphatases and 
P03235487A0404 |111 121|shelf-life neonatal 
P03235487A0404 |65 80|sugar solutionstidase P0000817
P03237446A0377 |0 4|NoneP000
P03237446A0377 |74 85|lymphopenia0008171T000
P03237446A0377 |41 51|infectionshosphatase
P03237446A0377 |16 23|historyomparis
P03239106A0856 |87 96|magnesiumPharmacol
P03239106A0856 |75 82|calcium008171T
P03239106A0856 |15 33|phosphorus contentComparison with al
P03239106A0856 |41 45|diethosp
P03239106A0856 |59 71|reabsorptionnucleotidase
P03243027T0000 |21 31|regulationison with 
P03243027T0000 |45 68|protein gene expressionhatases and 5-nucleotid
P03243027T0000 |91 115|Dictyostelium discoideummacologic aspects of neo
P03243027T0000 |76 87|development08171T0000 
P03243920A0591 |100 108|modeling aspects
P03243920A0591 |120 130|regression hyperbili
P03243920A0591 |24 65|plasma concentration-effect relationshipsn with alkaline phosphatases and 5-nucleo
P03246999A0483 |34 40|b-wavealine 
P03246999A0483 |52 69|adaptation period and 5-nucleotida
P03246999A0483 |122 130|controlsyperbili
P03246999A0483 |105 113|subjectscts of n
P03246999A0483 |4 12|increase01606T00
P03246999A0483 |16 26|amplitudesomparison 
P03249792A0241 |170 179|psychoses-] is sho
P03249792A0241 |130 144|stress factorsrubinemia. P00
P03249792A0241 |72 88|group activitiesP00008171T0000 P
P03249792A0241 |105 119|group dynamicscts of neonata
P03249792A0241 |97 101|rolegic 
P03249792A0241 |25 36|development with alkal
P03249792A0241 |9 16|factorsT0076 C
P03249792A0241 |200 214|manifestationsSF PCO2 the da
P03249792A0241 |50 64|symptomatologyes and 5-nucle
P03249840A0411 |0 21|Baseline measurementsP00001606T0076 Compar
P03249840A0411 |55 56|sd
P03249840A0411 |58 62|FEV1-nuc
P03249840A0411 |94 98|SGawolog
P03249840A0411 |268 275|smokingpared t
P03249840A0411 |150 161|% reductionA0472 When 
P03249840A0411 |120 124|dose hyp
P03249840A0411 |128 137|carbachollirubinem
P03249840A0411 |74 92|airway conductance0008171T0000 Pharm
P03249840A0411 |165 169|SGaw[HCO
P03249840A0411 |186 197|% reduction function o
P03249840A0411 |250 257|subjectdisplac
P03249840A0411 |201 205|FEV1F PC
P03249840A0411 |233 238|entryts ar
P03249840A0411 |43 49|volumesphata
P03249840A0411 |207 211|PD20 the
P03249840A0411 |171 175|PD35] is
P03251210A0981 |19 22|BGCari
P03251210A0981 |133 144|dysfunctioninemia. P00
P03251210A0981 |61 75|calcificationscleotidase P00
P03251210A0981 |44 55|developmentphatases an
P03251210A0981 |113 118|formseonat
P03251210A0981 |5 13|children1606T007
P03253219T0000 |48 76|anthracycline cardiomyopathyases and 5-nucleotidase P000
P03253219T0000 |89 94|studyarmac
P03253219T0000 |7 14|voltage06T0076
P03253219T0000 |39 44|leads phos
P03256150A1866 |55 59|taskd 5-
P03256150A1866 |4 11|results01606T0
P03256150A1866 |38 50|requirementse phosphatas
P03257146A1037 |156 165|childhoodWhen CSF 
P03257146A1037 |94 102|maturityologic a
P03257146A1037 |47 64|neutrophil countstases and 5-nucle
P03257146A1037 |28 33|CSFHUth al
P03257146A1037 |6 13|results606T007
P03257146A1037 |110 138|marrow neutrophil precursorsf neonatal hyperbilirubinemi
P03257146A1037 |147 152|types997A0
P03257146A1037 |83 89|number000 Ph
P03257146A1037 |174 185|neutropenias shown as 
P03258069A0000 |254 260|effectlaced 
P03258069A0000 |243 250|changeslonger 
P03258069A0000 |65 74|intensitytidase P0
P03258069A0000 |266 270|timeompa
P03258069A0000 |213 218|wristata o
P03258069A0000 |147 165|acupuncture points997A0472 When CSF 
P03258069A0000 |182 196|pain thresholdas a function 
P03258069A0000 |21 26|studyison 
P03258069A0000 |4 12|purposes01606T00
P03258069A0000 |80 89|frequency1T0000 Ph
P03258069A0000 |116 133|nerve stimulationatal hyperbilirub
P03258069A0000 |50 56|effectes and
P03259437A0140 |16 50|neonates serum alpha-amylase valueomparison with alkaline phosphatas
P03259437A0140 |182 190|neonatesas a fun
P03259437A0140 |122 130|controlsyperbili
P03259437A0140 |165 169|IU/l[HCO
P03259437A0140 |104 105|%e
P03259437A0140 |269 273|IU/lared
P03259437A0140 |217 218|po
P03259437A0140 |246 251|valueger d
P03259437A0140 |78 91|starch method171T0000 Phar
P03259437A0140 |141 146|valueP0000
P03259437A0140 |291 299|neonatestill hav
P03261005A0216 |0 7|RecordsP000016
P03261005A0216 |14 22|children Compari
P03261005A0216 |93 102|care unitcologic a
P03261005A0216 |125 132|failurerbiliru
P03261005A0216 |28 32|AIDSth a
P03261005A0216 |155 161|period When 
P03261005A0216 |49 56|complexses and
P03261223A0644 |76 81|SPECT08171
P03261223A0644 |41 54|disease grouphosphatases a
P03261223A0644 |9 17|patientsT0076 Co
P03261223A0644 |92 95|TCTaco
P03261331A0563 |0 5|SPECTP0000
P03261331A0563 |91 104|understandingmacologic asp
P03261331A0563 |131 141|mechanismsubinemia. 
P03261331A0563 |46 67|AIDS dementia complexatases and 5-nucleoti
P03261331A0563 |150 158|disorderA0472 Wh
P03261331A0563 |22 25|aidson
P03261331A0563 |33 42|diagnosiskaline ph
P03263357A0112 |35 47|relationshipline phospha
P03263357A0112 |213 217|IL-1ata 
P03263357A0112 |145 149|iron0899
P03263357A0112 |106 116|variationsts of neon
P03263357A0112 |151 155|zinc0472
P03263357A0112 |120 141|plasma concentrations hyperbilirubinemia. 
P03263357A0112 |191 209|plasma interleukintion of CSF PCO2 t
P03263357A0112 |80 96|body temperature1T0000 Pharmacol
P03263357A0112 |219 227|activity K-deple
P03263357A0112 |70 76|rhythme P000
P03263357A0112 |169 185|leukocyte counts3-] is shown as 
P03263465T0000 |103 108|genespects
P03263465T0000 |30 35|H-2Dq alka
P03263465T0000 |40 45|H-2Lqphosp
P03263465T0000 |11 20|MHC class076 Compa
P03263465T0000 |88 93|H-2Ldharma
P03263465T0000 |23 28|geneson wi
P03263465T0000 |143 151|antigens0008997A
P03264073A0224 |169 180|albino rats3-] is show
P03264073A0224 |82 90|activity0000 Pha
P03264073A0224 |129 140|albino miceirubinemia.
P03264073A0224 |11 22|derivatives076 Compari
P03264073A0224 |157 165|activityhen CSF 
P03264073A0224 |38 44|seriese phos
P03264299A0679 |32 40|activitylkaline 
P03264299A0679 |95 99|dayslogi
P03264299A0679 |106 118|ip injectionts of neonat
P03264299A0679 |13 17|mice6 Co
P03264299A0679 |55 66|macrophagesd 5-nucleot
P03264299A0679 |86 89|day Ph
P03264886A0000 |143 148|croup00089
P03264886A0000 |91 96|areasmacol
P03264886A0000 |211 221|physicians data of K
P03264886A0000 |55 58|aged 5
P03264886A0000 |114 121|Germanyonatal 
P03264886A0000 |177 190|months periodhown as a fun
P03264886A0000 |29 37|childrenh alkali
P03264886A0000 |62 68|mediumleotid
P03264886A0000 |46 51|yearsatase
P03264886A0000 |75 80|towns00817
P03264886A0000 |134 139|casesnemia
P03264886A0000 |131 132|%u
P03264886A0000 |8 18|population6T0076 Com
P03267732A0788 |155 161|effect When 
P03267732A0788 |179 186|therapywn as a
P03267732A0788 |124 131|thrombierbilir
P03267732A0788 |55 61|methodd 5-nu
P03267732A0788 |18 37|Ga-fbg scintigraphyparison with alkali
P03268555T0000 |69 92|millipore filter methodse P00008171T0000 Pharm
P03268555T0000 |27 43|biocompatibilityith alkaline pho
P03268555T0000 |9 19|assessmentT0076 Comp
P03268555T0000 |54 63|materialsnd 5-nucl
P03270085A0382 |51 57|kidneys and 
P03270085A0382 |26 43|magnesium wastingwith alkaline pho
P03270085A0382 |0 14|HypomagnesemiaP00001606T0076
P03274204A0642 |68 77|dentitionase P0000
P03274204A0642 |111 130|cent alkaline fuxin neonatal hyperbili
P03274204A0642 |49 54|indexses a
P03274204A0642 |0 12|DentalplaqueP00001606T00
P03275867A0187 |51 59|elementss and 5-
P03275867A0187 |160 163|UAS CS
P03275867A0187 |150 158|sequenceA0472 Wh
P03275867A0187 |61 70|silencerscleotidas
P03275867A0187 |14 23|sequences Comparis
P03275867A0187 |113 118|HMR Eeonat
P03275867A0187 |178 191|transcriptionown as a func
P03275867A0187 |199 214|MAT alpha genesCSF PCO2 the da
P03275867A0187 |86 108|mating type loci HML E Pharmacologic aspects
P03275867A0187 |0 4|GRFIP000
P03275873A0379 |34 48|RNA polymerasealine phosphat
P03275873A0379 |109 114|genesof ne
P03275873A0379 |192 197|cellsion o
P03275873A0379 |91 98|abilitymacolog
P03275873A0379 |157 169|transfectionhen CSF [HCO
P03275873A0379 |140 150|resistance P00008997
P03275873A0379 |52 60|activity and 5-n
P03275873A0379 |4 11|effects01606T0
P03275873A0379 |21 30|mutationsison with
P03276246A0037 |50 57|colloides and 
P03276246A0037 |76 83|TAC-WBC08171T0
P03276246A0037 |111 123|appendicitis neonatal hy
P03276246A0037 |14 17|use Co
P03276246A0037 |97 107|evaluationgic aspect
P03276246A0037 |64 74|blood cellotidase P0
P03276924A0090 |69 78|insertionse P00008
P03276924A0090 |92 107|MoMuLV provirusacologic aspect
P03276924A0090 |36 49|rearrangementine phosphata
P03276924A0090 |16 22|tumorsompari
P03278829A0082 |4 15|indications01606T0076 
P03278829A0082 |76 85|candidate08171T000
P03278829A0082 |126 133|tensionbilirub
P03278829A0082 |24 27|usen w
P03278829A0082 |93 103|tip graftscologic as
P03278829A0082 |144 153|deformity008997A04
P03280021A1615 |152 156|NaBr472 
P03280021A1615 |78 84|M NaCl171T00
P03280021A1615 |106 112|M NaBrts of 
P03280021A1615 |13 15|dT6 
P03280021A1615 |117 150|measure alpha log Kobsd/alpha logtal hyperbilirubinemia. P00008997
P03280021A1615 |202 205|T/O PC
P03280021A1615 |52 59|buffers and 5-
P03280021A1615 |187 192|valuefunct
P03280021A1615 |17 25|affinitymparison
P03280807A0000 |186 208|UAG nonsense mutations function of CSF PCO2 
P03280807A0000 |154 157|CCX2 W
P03280807A0000 |159 165|codonsn CSF 
P03280807A0000 |178 181|UGAown
P03280807A0000 |127 134|glycineilirubi
P03280807A0000 |145 152|proline08997A0
P03280807A0000 |0 9|MutationsP00001606
P03280807A0000 |136 139|GGXmia
P03280807A0000 |103 123|frameshift mutationspects of neonatal hy
P03280807A0000 |17 28|suf12 locusmparison wi
P03280807A0000 |85 96|suppressors0 Pharmacol
P03280807A1447 |34 47|heterozygotesaline phospha
P03280807A1447 |246 251|SUF12ger d
P03280807A1447 |214 223|variationta of K-d
P03280807A1447 |193 201|proteinson of CS
P03280807A1447 |63 68|suf12eotid
P03280807A1447 |253 261|activityplaced w
P03280807A1447 |4 12|behavior01606T00
P03280807A1447 |114 119|suf12onata
P03280807A1447 |16 32|suf12-null/SUF12omparison with a
P03280807A1447 |136 147|suppressionmia. P00008
P03280912T0000 |0 23|Antituberculosis agentsP00001606T0076 Comparis
P03280946A0375 |170 174|gene-] i
P03280946A0375 |78 86|proteins171T0000
P03280946A0375 |13 29|immunity protein6 Comparison wit
P03280946A0375 |135 155|lac promoter controlemia. P00008997A0472
P03280946A0375 |194 212|expression vectorsn of CSF PCO2 the 
P03280946A0375 |223 230|controlepleted
P03280946A0375 |99 108|minicellsc aspects
P03280946A0375 |54 57|35Snd 
P03280946A0375 |236 261|bacteriophage T7 promoterare no longer displaced w
P03280946A0375 |118 121|cnial 
P03282232A0743 |0 10|AntibodiesP00001606T
P03282232A0743 |24 38|fusion proteinn with alkalin
P03282232A0743 |108 119|immunoblots of neonata
P03282232A0743 |92 96|DP-Iacol
P03282232A0743 |55 65|DP1A cloned 5-nucleo
P03282813A0794 |137 144|failureia. P00
P03282813A0794 |160 165|slope CSF 
P03282813A0794 |38 55|oxygen extractione phosphatases an
P03282813A0794 |191 196|slopetion 
P03282813A0794 |24 29|rangen wit
P03282813A0794 |146 147|r8
P03282813A0794 |177 178|rh
P03282813A0794 |206 207|p2
P03282813A0794 |71 79|patients P000081
P03282813A0794 |33 36|QO2kal
P03282813A0794 |85 89|ARDS0 Ph
P03282813A0794 |102 110|patientsspects o
P03283881A0216 |54 62|evidencend 5-nuc
P03283881A0216 |28 42|hypersecretionth alkaline ph
P03283881A0216 |72 84|inflammationP00008171T00
P03283881A0216 |7 15|patients06T0076 
P03285764A0675 |0 19|HyperprolactinaemiaP00001606T0076 Comp
P03285764A0675 |110 118|leakagesf neonat
P03285764A0675 |58 70|neuropathies-nucleotidas
P03285764A0675 |243 250|factorslonger 
P03285764A0675 |30 42|hypogonadism alkaline ph
P03285764A0675 |190 202|consequencesction of CSF
P03285764A0675 |81 89|stenosesT0000 Ph
P03285764A0675 |142 146|role0000
P03285764A0675 |291 299|failurestill hav
P03285764A0675 |169 177|cofactor3-] is s
P03286611A1198 |0 4|YangP000
P03286611A1198 |9 11|H.T0
P03287597T0000 |10 18|function0076 Com
P03287597T0000 |26 40|prostate glandwith alkaline 
P03292076A0820 |239 262|eicosanoid biosynthesis no longer displaced wh
P03292076A0820 |182 196|refractorinessas a function 
P03292076A0820 |105 113|tendencycts of n
P03292076A0820 |86 98|permeability Pharmacolog
P03292076A0820 |172 178|degree is sh
P03292076A0820 |8 19|endotoxemia6T0076 Comp
P03292076A0820 |222 234|hemodynamicsdepleted rat
P03292076A0820 |136 147|circulationmia. P00008
P03292082A0486 |101 107|systemaspect
P03292082A0486 |166 175|neurinomaHCO3-] is
P03292082A0486 |30 44|concentrations alkaline phos
P03292082A0486 |141 153|glioblastomaP00008997A04
P03292082A0486 |57 65|patients5-nucleo
P03292082A0486 |123 133|meningiomaperbilirub
P03292082A0486 |3 11|contrast001606T0
P03292082A0486 |71 77|tumors P0000
P03293844T0000 |0 4|DietP000
P03293844T0000 |16 22|eczemaompari
P03296019T0000 |34 47|bond strengthaline phospha
P03296019T0000 |65 75|Silicoatertidase P00
P03296019T0000 |0 18|Time delay effectsP00001606T0076 Com
P03296212A0603 |414 421|historyic drug
P03296212A0603 |186 191|order func
P03296212A0603 |460 469|potentialal practi
P03296212A0603 |323 338|tumor debulkingr slope (1.21 +
P03296212A0603 |430 438|diseases optimum
P03296212A0603 |176 181|termsshown
P03296212A0603 |486 492|agents night
P03296212A0603 |215 224|potentiala of K-de
P03296212A0603 |537 543|agents683A02
P03296212A0603 |270 275|agentred t
P03296212A0603 |28 38|interferonth alkalin
P03296212A0603 |72 79|EffortsP000081
P03296212A0603 |287 294|diseaseut stil
P03296212A0603 |379 388|communitys appears
P03296212A0603 |14 22|research Compari
P03296212A0603 |356 365|diagnosis943A0733 
P03296212A0603 |65 70|areastidas
P03296212A0603 |233 241|researchts are n
P03296212A0603 |228 231|IFNed 
P03296212A0603 |141 148|synergyP000089
P03296212A0603 |4 10|future01606T
P03296254A0556 |34 43|latamoxefaline pho
P03296254A0556 |129 139|depressionirubinemia
P03296254A0556 |143 149|factor000899
P03296254A0556 |83 99|prothrombin time000 Pharmacologi
P03296254A0556 |6 17|differences606T0076 Co
P03296254A0556 |157 167|factor VIIhen CSF [H
P03296254A0556 |70 79|elevatione P000081
P03297181A0127 |186 190|SR-F fun
P03297181A0127 |180 184|foodn as
P03297181A0127 |77 94|quinidine sulfate8171T0000 Pharmac
P03297181A0127 |167 174|productCO3-] i
P03297181A0127 |106 113|releasets of n
P03297181A0127 |73 75|RR00
P03297181A0127 |47 52|dosestases
P03297181A0127 |17 25|subjectsmparison
P03297181A0127 |115 117|SRna
P03297181A0127 |64 71|releaseotidase
P03297181A0127 |119 138|quinidine bisulfatel hyperbilirubinemi
P03297181A0127 |152 156|dose472 
P03298134A0000 |32 36|worklkal
P03298134A0000 |72 87|Schering-PloughP00008171T0000 
P03298134A0000 |62 70|Intron Aleotidas
P03298134A0000 |96 105|treatmentogic aspe
P03298134A0000 |42 60|interferon alfa-2bosphatases and 5-n
P03298134A0000 |130 133|HCLrub
P03298134A0000 |5 11|report1606T0
P03298134A0000 |115 128|cell leukemianatal hyperbi
P03300118A0392 |0 15|Oxygen deliveryP00001606T0076 
P03300118A0392 |20 31|base excessrison with 
P03300118A0392 |65 69|pigstida
P03304015T0000 |9 18|chemistryT0076 Com
P03304866T0001 |0 17|RevascularizationP00001606T0076 Co
P03304866T0001 |58 67|osteotomy-nucleoti
P03305875T0000 |38 49|microstomiae phosphata
P03305875T0000 |24 34|managementn with alk
P03305875T0000 |7 15|orthoses06T0076 
P03306340A0537 |171 186|pancreaticogram] is shown as a
P03306340A0537 |79 88|carcinoma71T0000 P
P03306340A0537 |106 110|bodyts o
P03306340A0537 |121 132|obstructionhyperbiliru
P03306340A0537 |90 98|hardnessrmacolog
P03306340A0537 |115 119|tailnata
P03306340A0537 |20 26|spreadrison 
P03306340A0537 |67 75|invasiondase P00
P03306340A0537 |34 43|carcinomaaline pho
P03306340A0537 |152 156|duct472 
P03308909A0485 |10 17|enzymes0076 Co
P03308909A0485 |31 40|cartilagealkaline 
P03309892A0637 |221 226|yeast-depl
P03309892A0637 |148 159|nucleotides97A0472 Whe
P03309892A0637 |44 46|S.ph
P03309892A0637 |53 58|genesand 5
P03309892A0637 |110 131|actin gene transcriptf neonatal hyperbilir
P03309892A0637 |176 197|initiation start siteshown as a function o
P03309892A0637 |86 91|yeast Phar
P03309892A0637 |16 27|observationomparison w
P03311954A0000 |136 146|ranitidinemia. P0000
P03311954A0000 |107 117|ranitidines of neona
P03311954A0000 |180 199|reflux oesophagitisn as a function of 
P03311954A0000 |14 19|study Comp
P03311954A0000 |151 159|mg nocte0472 Whe
P03311954A0000 |40 52|institutionsphosphatases
P03311954A0000 |167 176|treatmentCO3-] is 
P03311954A0000 |122 131|mg b.i.d.yperbilir
P03311954A0000 |97 103|safetygic as
P03311954A0000 |84 92|efficacy00 Pharm
P03312033A0501 |17 28|ceftazidimemparison wi
P03312033A0501 |109 118|cefazolinof neonat
P03312033A0501 |123 133|tobramycinperbilirub
P03312033A0501 |84 103|combination therapy00 Pharmacologic as
P03312033A0501 |0 11|MonotherapyP00001606T0
P03312514A0756 |170 177|animals-] is s
P03312514A0756 |246 261|control animalsger displaced w
P03312514A0756 |125 146|preischemia amplituderbilirubinemia. P0000
P03312514A0756 |193 194|%o
P03312514A0756 |84 92|recovery00 Pharm
P03312514A0756 |19 23|SSEParis
P03312514A0756 |116 117|%a
P03312514A0756 |217 222|groupof K-
P03312514A0756 |201 202|%F
P03312514A0756 |108 109|% 
P03312514A0756 |229 230|%d
P03312514A0756 |4 11|N3 wave01606T0
P03312514A0756 |237 238|%r
P03315359A0732 |0 11|ProctoscopyP00001606T0
P03315359A0732 |130 141|suppurationrubinemia. 
P03315359A0732 |61 65|partcleo
P03315359A0732 |143 149|masses000899
P03315359A0732 |159 167|fissuresn CSF [H
P03315359A0732 |95 103|patientslogic as
P03315359A0732 |33 40|studieskaline 
P03315359A0732 |69 79|evaluationse P000081
P03317796A0853 |38 45|picturee phosp
P03317796A0853 |56 70|osteoarthritis 5-nucleotidas
P03317796A0853 |7 20|control group06T0076 Compa
P03319621A0707 |84 93|myoblasts00 Pharma
P03319621A0707 |28 29|%t
P03319621A0707 |98 106|myotubesic aspec
P03319621A0707 |20 24|mRNAriso
P03319621A0707 |43 59|beta actin mRNAssphatases and 5-
P03319621A0707 |3 11|contrast001606T0
P03319621A0707 |33 38|alphakalin
P03319646T0000 |0 21|Plasma renin activityP00001606T0076 Compar
P03319646T0000 |60 68|efficacyucleotid
P03319646T0000 |72 86|chlorthalidoneP00008171T0000
P03319912A0000 |0 10|CephradineP00001606T
P03319912A0000 |217 226|frequencyof K-depl
P03319912A0000 |56 76|prophylactic measure 5-nucleotidase P000
P03319912A0000 |90 98|patientsrmacolog
P03319912A0000 |133 140|historyinemia.
P03319912A0000 |193 199|medianon of 
P03319912A0000 |15 17|mgCo
P03319912A0000 |116 121|yearsatal 
P03319912A0000 |21 26|nightison 
P03319912A0000 |205 213|episodesO2 the d
P03319912A0000 |234 241|dysurias are n
P03319912A0000 |161 167|monthsCSF [H
P03319912A0000 |102 110|mean agespects o
P03319912A0000 |34 40|monthsaline 
P03320875A2090 |51 57|records and 
P03320875A2090 |106 115|infectionts of neo
P03320875A2090 |29 37|Supramidh alkali
P03320875A2090 |92 102|resistanceacologic a
P03320875A2090 |67 87|tissue compatibilitydase P00008171T0000 
P03322829A0952 |237 238|%r
P03322829A0952 |213 222|deviationata of K-
P03322829A0952 |125 130|grouprbili
P03322829A0952 |194 198|dosen of
P03322829A0952 |16 21|groupompar
P03322829A0952 |115 119|sizenata
P03322829A0952 |250 262|prescriptiondisplaced wh
P03322829A0952 |82 96|digoxin marker0000 Pharmacol
P03322829A0952 |172 173|% 
P03322829A0952 |44 63|compliance categoryphatases and 5-nucl
P03322829A0952 |134 142|patientsnemia. P
P03322829A0952 |4 8|size0160
P03322829A0952 |71 74|use P0
P03325081A0524 |8 19|keratopathy6T0076 Comp
P03325081A0524 |95 106|keratopathylogic aspec
P03325081A0524 |133 138|causeinemi
P03325081A0524 |150 161|keratopathyA0472 When 
P03325081A0524 |108 111|PBK of
P03325081A0524 |43 49|originsphata
P03326381A0423 |102 109|effectsspects 
P03326381A0423 |20 28|findingsrison wi
P03326381A0423 |53 72|C-peptide excretionand 5-nucleotidase 
P03326381A0423 |196 204|pancreasof CSF P
P03326381A0423 |168 173|drugsO3-] 
P03326381A0423 |154 160|action2 When
P03329716A0187 |4 12|activity01606T00
P03329716A0187 |151 161|calf serum0472 When 
P03329716A0187 |111 122|stimulation neonatal h
P03329716A0187 |78 97|receptor RNA levels171T0000 Pharmacolo
P03329716A0187 |62 73|E1A proteinleotidase P
P03329716A0187 |128 141|phorbol esterlirubinemia. 
P03329716A0187 |20 41|EGF receptor promoterrison with alkaline p
P03330711T0000 |34 38|neemalin
P03330711T0000 |40 61|Azadirachta indica A.phosphatases and 5-nu
P03330711T0000 |22 30|activityson with
P03331525T0001 |98 108|isocyanateic aspects
P03331525T0001 |59 77|urethane moleculesnucleotidase P0000
P03331525T0001 |11 16|study076 C
P03331525T0001 |88 94|groupsharmac
P03331525T0001 |20 35|dentin adhesionrison with alka
P03331525T0001 |39 48|adhesives phosphat
P03331933T0048 |3 17|Felix Lagrange001606T0076 Co
P03332022A1094 |238 254|protein kinase Ce no longer disp
P03332022A1094 |11 37|cysteine clustering region076 Comparison with alkali
P03332022A1094 |104 123|nucleotide sequenceects of neonatal hy
P03332022A1094 |134 160|cysteine clustering regionnemia. P00008997A0472 When
P03332022A1094 |280 297|cysteine clusterstrols but still h
P03332022A1094 |228 234|regioned rat
P03332022A1094 |79 86|product71T0000
P03332022A1094 |55 61|regiond 5-nu
P03332022A1094 |69 74|c-rafse P0
P03332848A0000 |71 79|analysis P000081
P03332848A0000 |106 129|carotid artery stenosists of neonatal hyperbil
P03332848A0000 |27 41|Doppler probesith alkaline p
P03334950A0000 |207 216|radiation the data
P03334950A0000 |179 186|controlwn as a
P03334950A0000 |125 136|combinationrbilirubine
P03334950A0000 |63 80|Cooperative Ewingeotidase P0000817
P03334950A0000 |192 199|surgeryion of 
P03334950A0000 |140 152|chemotherapy P00008997A0
P03334950A0000 |83 96|Sarcoma Study000 Pharmacol
P03334950A0000 |22 40|Pediatric Oncologyson with alkaline 
P03334950A0000 |4 18|German Society01606T0076 Com
P03334950A0000 |98 102|CESSic a
P03335127A0176 |51 56|orders and
P03335127A0176 |42 47|BASICospha
P03335127A0176 |4 11|program01606T0
P03335127A0176 |69 78|procedurese P00008
P03335398A0568 |68 75|surfacease P00
P03335398A0568 |93 105|immunizationcologic aspe
P03335398A0568 |11 17|levels076 Co
P03335398A0568 |107 135|passive transfer experimentss of neonatal hyperbilirubin
P03335398A0568 |83 86|NVS000
P03335398A0568 |21 37|immunoglobulin Gison with alkali
P03335444A0000 |2 7|study00016
P03335444A0000 |77 79|Pu81
P03335444A0000 |56 63|mixture 5-nucl
P03335444A0000 |67 72|241Amdase 
P03335444A0000 |33 37|malekali
P03335651A0000 |119 126|conceptl hyper
P03335651A0000 |165 173|approach[HCO3-] 
P03335651A0000 |67 76|resonancedase P000
P03335651A0000 |78 80|MR17
P03335651A0000 |215 217|T1a 
P03335651A0000 |227 245|hydrogen weightingted rats are no lo
P03335651A0000 |12 18|method76 Com
P03335651A0000 |219 221|T2 K
P03335651A0000 |142 153|sensitivity00008997A04
P03335651A0000 |82 89|imaging0000 Ph
P03335651A0000 |203 210|indexesPCO2 th
P03335651A0000 |35 54|parameter weightingline phosphatases a
P03335923A0257 |205 211|ulcersO2 the
P03335923A0257 |247 255|patientser displ
P03335923A0257 |121 129|patientshyperbil
P03335923A0257 |181 189|patients as a fu
P03335923A0257 |228 232|bulbed r
P03335923A0257 |106 116|volunteersts of neon
P03335923A0257 |73 85|presentation00008171T000
P03335923A0257 |152 170|reflux gastropathy472 When CSF [HCO3
P03335923A0257 |261 269|Moynihanhen comp
P03335923A0257 |234 237|RUDs a
P03335923A0257 |172 175|DRG is
P03335923A0257 |11 19|patients076 Comp
P03335923A0257 |38 44|groupse phos
P03335923A0257 |272 279|diseased to co
P03337024A0000 |204 211|testingCO2 the
P03337024A0000 |73 85|procainamide00008171T000
P03337024A0000 |135 139|rateemia
P03337024A0000 |120 125|mg/kg hype
P03337024A0000 |109 113|doseof n
P03337024A0000 |167 175|practiceCO3-] is
P03337024A0000 |12 19|studies76 Comp
P03337024A0000 |40 57|pharmaco-dynamicsphosphatases and 
P03337024A0000 |146 152|mg/min8997A0
P03338154T0000 |5 19|concentrations1606T0076 Comp
P03338154T0000 |74 82|patients0008171T
P03338154T0000 |40 57|trypsin inhibitorphosphatases and 
P03340548A1018 |119 137|lipopolysaccharidel hyperbilirubinem
P03340548A1018 |7 20|chicken liver06T0076 Compa
P03340548A1018 |92 95|Cu2aco
P03340548A1018 |72 78|metalsP00008
P03340548A1018 |99 114|glucocorticoidsc aspects of ne
P03340548A1018 |80 83|Cd21T0
P03340548A1018 |22 28|levelsson wi
P03340548A1018 |86 89|Zn2 Ph
P03340548A1018 |32 47|chicken MT mRNAlkaline phospha
P03340726A1103 |19 24|Evansariso
P03340726A1103 |30 40|injections alkaline 
P03340726A1103 |5 14|histology1606T0076
P03340726A1103 |111 115|dose neo
P03340726A1103 |122 124|Gyyp
P03340726A1103 |54 73|barrier alterationsnd 5-nucleotidase P
P03340726A1103 |98 102|daysic a
P03340774A0328 |152 154|Gy47
P03340774A0328 |31 37|organsalkali
P03340774A0328 |125 133|estimaterbilirub
P03340774A0328 |11 20|estimates076 Compa
P03340774A0328 |88 90|Gyha
P03340774A0328 |142 145|rad000
P03340774A0328 |71 74|rad P0
P03343730A0486 |36 50|family historyine phosphatas
P03343730A0486 |105 127|calcium stone patientscts of neonatal hyperb
P03343730A0486 |14 25|association Comparison
P03343730A0486 |72 74|pHP0
P03344586T0000 |34 48|classificationaline phosphat
P03344586T0000 |52 62|malignancy and 5-nuc
P03344586T0000 |20 29|diagnosisrison wit
P03344586T0000 |0 16|New technologiesP00001606T0076 C
P03344812A0924 |341 351|individual0.23 vs. P
P03344812A0924 |212 214|BPda
P03344812A0924 |266 272|animalompare
P03344812A0924 |297 306|influenceave a sig
P03344812A0924 |361 370|HR levels733 Flura
P03344812A0924 |151 158|factors0472 Wh
P03344812A0924 |17 21|datampar
P03344812A0924 |326 333|rankinglope (1
P03344812A0924 |256 261|cycleced w
P03344812A0924 |354 356|BP10
P03344812A0924 |219 228|HR values K-deplet
P03344812A0924 |106 113|factorsts of n
P03344812A0924 |47 62|HR measurementstases and 5-nuc
P03344812A0924 |192 197|stateion o
P03344812A0924 |382 392|populationppears to 
P03344812A0924 |40 42|BPph
P03345706A0561 |34 39|PtcO2aline
P03345706A0561 |43 46|RDSsph
P03345706A0561 |24 29|PaCO2n wit
P03345706A0561 |4 15|correlation01606T0076 
P03345706A0561 |81 90|judgementT0000 Pha
P03346157A0000 |103 106|AHSpec
P03346157A0000 |177 183|x-rayshown a
P03346157A0000 |300 305|doses a si
P03346157A0000 |269 281|examinationsared to cont
P03346157A0000 |228 232|RERFed r
P03346157A0000 |258 265|numbersd when 
P03346157A0000 |18 23|timesparis
P03346157A0000 |156 165|exposuresWhen CSF 
P03346157A0000 |83 101|Adult Health Study000 Pharmacologic 
P03346157A0000 |65 77|examinationstidase P0000
P03346157A0000 |42 51|ABCC/RERFosphatase
P03346157A0000 |108 116|subjects of neon
P03346157A0000 |236 241|orderare n
P03346157A0000 |204 216|institutionsCO2 the data
P03346210A0000 |137 166|self-phosphorylation reactionia. P00008997A0472 When CSF [
P03346210A0000 |177 191|EGF activationhown as a func
P03346210A0000 |29 32|EGFh a
P03346210A0000 |14 27|growth factor Comparison w
P03346210A0000 |69 101|protein tyrosine kinase activityse P00008171T0000 Pharmacologic 
P03346210A0000 |34 42|receptoraline ph
P03348382A0785 |48 52|HCO3ases
P03348382A0785 |15 22|ouabainCompari
P03348382A0785 |54 63|secretionnd 5-nucl
P03351478A0371 |53 65|% G residuesand 5-nucleo
P03351478A0371 |44 47|% Cpha
P03351478A0371 |28 32|runsth a
P03351478A0371 |10 17|regions0076 Co
P03352254A0203 |18 27|structureparison w
P03352254A0203 |95 104|syllableslogic asp
P03352254A0203 |76 82|vowels08171T
P03352254A0203 |38 48|predictione phosphat
P03352439T0000 |6 35|cord abduction rehabilitation606T0076 Comparison with alka
P03352439T0000 |57 68|anastomosis5-nucleotid
P03352727T0000 |0 2|UKP0
P03352727T0000 |27 38|specialistsith alkalin
P03352727T0000 |5 18|biotechnology1606T0076 Com
P03352947T0001 |32 39|ARC/LASlkaline
P03352947T0001 |46 59|health workeratases and 5-
P03352947T0001 |23 30|complexon with
P03352947T0001 |2 6|case0001
P03354295A0157 |87 99|micrograms/lPharmacologi
P03354295A0157 |62 70|serum Tgleotidas
P03354295A0157 |31 39|patientsalkaline
P03354295A0157 |43 44|%s
P03354295A0157 |8 14|spread6T0076
P03354341A0177 |51 62|plasma flows and 5-nuc
P03354341A0177 |93 109|clearance methodcologic aspects 
P03354341A0177 |132 140|infusionbinemia.
P03354341A0177 |15 30|filtration rateComparison with
P03354341A0177 |144 150|inulin008997
P03354341A0177 |174 178|acids sh
P03355122A0238 |34 55|plasma glucose levelsaline phosphatases an
P03355122A0238 |127 128|hi
P03355122A0238 |10 14|meal0076
P03355122A0238 |26 32|potatowith a
P03355122A0238 |113 119|levelseonata
P03355122A0238 |86 89|min Ph
P03359860A0000 |85 95|aggression0 Pharmaco
P03359860A0000 |106 121|undercompliancets of neonatal 
P03359860A0000 |62 77|characteristicsleotidase P0000
P03359860A0000 |210 237|New York Longitudinal Studye data of K-depleted rats a
P03359860A0000 |134 138|moodnemi
P03359860A0000 |97 104|anxietygic asp
P03359860A0000 |144 154|adjustment008997A047
P03359860A0000 |177 180|usehow
P03359860A0000 |4 13|relations01606T007
P03359860A0000 |184 188|data a f
P03360667A0000 |206 214|subjects2 the da
P03360667A0000 |113 118|youtheonat
P03360667A0000 |144 150|status008997
P03360667A0000 |26 34|altitudewith alk
P03360667A0000 |270 271|nr
P03360667A0000 |240 248|subjectsno longe
P03360667A0000 |60 71|developmentucleotidase
P03360667A0000 |186 195|sea level function
P03360667A0000 |16 22|effectompari
P03360667A0000 |49 55|growthses an
P03360667A0000 |217 229|mid-altitudeof K-deplete
P03360667A0000 |260 268|altitudewhen com
P03360667A0000 |231 232|nr
P03360667A0000 |162 170|groupingSF [HCO3
P03360667A0000 |79 85|groups71T000
P03360667A0000 |197 198|nf
P03360667A0000 |279 287|subjectsntrols b
P03360948A0477 |119 122|CAPl h
P03360948A0477 |12 15|CAP76 
P03360948A0477 |25 34|variables with alk
P03360948A0477 |131 139|MHI Lossubinemia
P03360948A0477 |57 65|behavior5-nucleo
P03360948A0477 |143 177|Behavioral/Emotional Control scale0008997A0472 When CSF [HCO3-] is s
P03360948A0477 |81 93|relationshipT0000 Pharma
P03361653A0459 |21 27|systemison w
P03361653A0459 |40 60|contour digitizationphosphatases and 5-n
P03361653A0459 |131 138|objectsubinemi
P03361653A0459 |92 103|limitationsacologic as
P03366720A1335 |87 91|acidPhar
P03366720A1335 |132 142|glycolysisbinemia. P
P03366720A1335 |44 55|utilizationphatases an
P03366720A1335 |120 127|glucose hyperb
P03366720A1335 |106 116|metabolismts of neon
P03366720A1335 |7 13|change06T007
P03366864A0099 |70 78|cathetere P00008
P03366864A0099 |94 99|bloodologi
P03366864A0099 |54 62|segmentsnd 5-nuc
P03366864A0099 |4 13|skin site01606T007
P03368701A0113 |81 87|choiceT0000 
P03368701A0113 |72 77|placeP0000
P03368701A0113 |47 60|arteriographytases and 5-n
P03368701A0113 |106 124|imaging techniquests of neonatal hyp
P03368701A0113 |21 32|reliabilityison with a
P03370815T0000 |68 78|radioassayase P00008
P03370815T0000 |82 93|vitamin B120000 Pharma
P03370815T0000 |6 15|detection606T0076 
P03370815T0000 |50 60|test serumes and 5-n
P03371139A0829 |76 82|groups08171T
P03371139A0829 |44 52|materialphatases
P03371139A0829 |11 16|group076 C
P03371806A0000 |138 145|speciesa. P000
P03371806A0000 |28 31|EDPth 
P03371806A0000 |150 170|organ identificationA0472 When CSF [HCO3
P03371806A0000 |112 117|serumneona
P03371806A0000 |76 92|acid phosphatase08171T0000 Pharm
P03371806A0000 |11 26|data processing076 Comparison 
P03371806A0000 |188 194|stainsunctio
P03371806A0000 |33 50|latex immunoassaykaline phosphatas
P03371894A0355 |0 19|Vimentin positivityP00001606T0076 Comp
P03371894A0355 |71 81|components P00008171
P03372422A0558 |68 73|phasease P
P03372422A0558 |27 32|phaseith a
P03372422A0558 |182 187|lungsas a 
P03372422A0558 |47 49|N2ta
P03372422A0558 |111 119|position neonata
P03372422A0558 |78 84|slopes171T00
P03372422A0558 |40 42|Arph
P03372422A0558 |145 170|tracer gas concentrations08997A0472 When CSF [HCO3
P03372422A0558 |4 23|maximum deflections01606T0076 Comparis
P03373755T0001 |68 73|ulcerase P
P03373755T0001 |45 52|factorshatases
P03373755T0001 |97 105|problemsgic aspe
P03373755T0001 |7 19|developments06T0076 Comp
P03373755T0001 |107 134|gastrin receptor blockaderss of neonatal hyperbilirubi
P03373755T0001 |23 28|drugson wi
P03373755T0001 |84 92|efficacy00 Pharm
P03375184A0000 |32 38|memberlkalin
P03375184A0000 |151 163|n-1 CH2CH2OH0472 When CS
P03375184A0000 |90 108|polyethoxyethanolsrmacologic aspects
P03375184A0000 |65 88|alkylphenol-ethoxylatestidase P00008171T0000 P
P03375184A0000 |143 150|CH2CH2O0008997
P03375184A0000 |121 141|formula C9H19-C6H6-Ohyperbilirubinemia. 
P03375184A0000 |4 26|spermicide nonoxynol-901606T0076 Comparison 
P03375184A0000 |55 61|seriesd 5-nu
P03377864A0000 |34 43|diffusionaline pho
P03377864A0000 |93 106|Lorentz forcecologic aspec
P03377864A0000 |111 125|Maxwell stress neonatal hype
P03377864A0000 |58 67|particles-nucleoti
P03377864A0000 |71 80|solutions P0000817
P03377864A0000 |16 22|fieldsompari
P03377891A0652 |50 67|life stress groupes and 5-nucleoti
P03377891A0652 |245 255|depressionnger displ
P03377891A0652 |182 194|somatizationas a functio
P03377891A0652 |121 135|severity indexhyperbilirubin
P03377891A0652 |14 25|disturbance Comparison
P03377891A0652 |269 291|psychoticism subscalesared to controls but s
P03377891A0652 |143 163|Symptom Checklist-900008997A0472 When CS
P03377891A0652 |96 106|elevationsogic aspec
P03377891A0652 |232 243|sensitivityats are no 
P03377891A0652 |168 178|elevationsO3-] is sh
P03377891A0652 |257 264|anxietyed when
P03378994T0000 |54 70|extraction rationd 5-nucleotidas
P03378994T0000 |74 78|dogs0008
P03378994T0000 |26 40|sodium cyanatewith alkaline 
P03378994T0000 |8 22|administration6T0076 Compari
P03379058A0188 |0 21|Nucleotide sequencingP00001606T0076 Compar
P03379058A0188 |131 133|bpub
P03379058A0188 |109 122|reading frameof neonatal h
P03379058A0188 |89 95|lengtharmaco
P03379058A0188 |156 162|regionWhen C
P03379058A0188 |82 84|bp00
P03379058A0188 |42 61|E1 alpha cDNA cloneosphatases and 5-nu
P03379058A0188 |70 80|base pairse P0000817
P03379058A0188 |170 172|bp-]
P03380547A0169 |0 3|SPAP00
P03380547A0169 |9 18|PAG sitesT0076 Com
P03380547A0169 |39 47|aversion phospha
P03381039A0364 |68 73|rangease P
P03381039A0364 |47 59|distributiontases and 5-
P03381039A0364 |3 11|contrast001606T0
P03381039A0364 |114 121|maximumonatal 
P03381039A0364 |129 135|micronirubin
P03381039A0364 |101 107|micronaspect
P03381039A0364 |17 20|MANmpa
P03382310A0903 |83 98|polyarthralgias000 Pharmacolog
P03382310A0903 |122 133|arthropathyyperbilirub
P03382310A0903 |9 22|technetium TcT0076 Compari
P03382310A0903 |46 54|patientsatases a
P03382310A0903 |149 169|management decisions7A0472 When CSF [HCO
P03382310A0903 |197 205|outcomesf CSF PC
P03382310A0903 |37 42|scansne ph
P03382772A0319 |0 18|Practical interestP00001606T0076 Com
P03382772A0319 |27 34|studiesith alk
P03382772A0319 |72 82|parametersP00008171T
P03382772A0319 |134 140|trialsnemia.
P03382772A0319 |126 131|phasebilir
P03382772A0319 |115 118|mannat
P03382855A0368 |84 93|adhesions00 Pharma
P03382855A0368 |120 127|picture hyperb
P03382855A0368 |4 15|artery cuff01606T0076 
P03382855A0368 |49 53|wrapses 
P03383897A0189 |187 196|treatmentfunction 
P03383897A0189 |89 95|effectarmaco
P03383897A0189 |165 173|patients[HCO3-] 
P03383897A0189 |99 111|leukopoiesisc aspects of
P03383897A0189 |177 183|coursehown a
P03383897A0189 |147 157|conditions997A0472 W
P03383897A0189 |18 24|actionpariso
P03383897A0189 |32 49|radiation therapylkaline phosphata
P03384033A0155 |186 187|% 
P03384033A0155 |10 15|units0076 
P03384033A0155 |130 131|%r
P03384033A0155 |56 58|Hz 5
P03384033A0155 |41 47|motionhospha
P03384033A0155 |64 68|cm/sotid
P03384033A0155 |163 168|inputF [HC
P03384033A0155 |77 78|%8
P03384033A0155 |207 217|modalities the data 
P03384033A0155 |102 115|otolith inputspects of neo
P03384272A0145 |17 25|locationmparison
P03384272A0145 |42 46|massosph
P03384272A0145 |73 86|presentations00008171T0000
P03384272A0145 |30 34|size alk
P03384272A0145 |110 116|lesionf neon
P03384272A0145 |55 60|ranged 5-n
P03387665A0000 |4 15|development01606T0076 
P03387665A0000 |72 80|T bruceiP0000817
P03387665A0000 |88 92|skinharm
P03387665A0000 |60 67|T vivaxucleoti
P03387665A0000 |96 101|goatsogic 
P03387665A0000 |36 47|Trypanosomaine phospha
P03387665A0000 |125 132|animalsrbiliru
P03387665A0000 |20 32|distributionrison with a
P03387665A0000 |157 185|Glossina morsitans centralishen CSF [HCO3-] is shown as 
P03390074A0000 |0 19|ElectroglottographyP00001606T0076 Comp
P03390074A0000 |104 115|dysfunctionects of neo
P03390074A0000 |46 55|techniqueatases an
P03390074A0000 |79 89|assessment71T0000 Ph
P03395009A1750 |171 180|diameters] is show
P03395009A1750 |56 72|cord compression 5-nucleotidase 
P03395009A1750 |28 35|degreesth alka
P03395009A1750 |243 246|T12lon
P03395009A1750 |271 277|T11-12ed to 
P03395009A1750 |90 102|group-1 dogsrmacologic a
P03395009A1750 |225 234|locationsleted rat
P03395009A1750 |289 291|L2 s
P03395009A1750 |250 252|L1di
P03395009A1750 |266 269|T11omp
P03395009A1750 |297 303|regionave a 
P03395009A1750 |130 136|ratiosrubine
P03395009A1750 |12 20|analysis76 Compa
P03395009A1750 |316 328|intervention greater slo
P03395009A1750 |279 283|L1-2ntro
P03395009A1750 |206 219|cord sections2 the data of
P03395164A0000 |20 27|effectsrison w
P03395164A0000 |41 53|compound WEBhosphatases 
P03395164A0000 |59 61|FUnu
P03395249A1044 |69 73|typese P
P03395249A1044 |92 96|damsacol
P03395249A1044 |77 88|pneumocytes8171T0000 P
P03395249A1044 |131 136|cellsubine
P03395249A1044 |166 177|developmentHCO3-] is s
P03395249A1044 |181 189|neonates as a fu
P03395249A1044 |217 222|WORDSof K-
P03395249A1044 |191 199|ABSTRACTtion of 
P03395249A1044 |52 65|proliferation and 5-nucleo
P03395249A1044 |18 29|examinationparison wit
P03395249A1044 |101 114|proliferationaspects of ne
P03396437A0321 |43 50|strainssphatas
P03396437A0321 |10 18|problems0076 Com
P03396628A0207 |204 209|spotsCO2 t
P03396628A0207 |149 153|mice7A04
P03396628A0207 |61 66|spotscleot
P03396628A0207 |80 89|ventricle1T0000 Ph
P03396628A0207 |157 158|%h
P03396628A0207 |93 104|BALB/c micecologic asp
P03396628A0207 |247 251|miceer d
P03396628A0207 |177 186|incidencehown as a
P03396628A0207 |11 29|observation period076 Comparison wit
P03396628A0207 |134 139|weeksnemia
P03396628A0207 |255 256|%a
P03396628A0207 |40 45|weeksphosp
P03396628A0207 |231 236|weeksrats 
P03398433T0001 |17 22|livermpari
P03398433T0001 |61 70|infectioncleotidas
P03398433T0001 |4 9|state01606
P03398433T0001 |38 43|formse pho
P03398714A0594 |99 106|radicalc aspec
P03398714A0594 |27 28|%i
P03398714A0594 |41 50|solvationhosphatas
P03398714A0594 |15 17|RHCo
P03398714A0594 |125 153|propagation transition staterbilirubinemia. P00008997A04
P03398714A0594 |58 72|peroxy radical-nucleotidase 
P03398823A0459 |51 65|mg/kg p-xylenes and 5-nucleo
P03398823A0459 |109 115|effectof neo
P03398823A0459 |29 43|administrationh alkaline pho
P03398823A0459 |181 189|exposure as a fu
P03398823A0459 |164 171|removal [HCO3-
P03398823A0459 |157 160|minhen
P03398823A0459 |127 135|p-xyleneilirubin
P03398823A0459 |95 97|hrlo
P03398823A0459 |4 11|effects01606T0
P03398823A0459 |69 76|toluenese P000
P03400694A0245 |0 8|PATIENTSP0000160
P03400694A0245 |76 80|rest0817
P03400694A0245 |167 178|sarcoidosisCO3-] is sh
P03400694A0245 |46 58|scintigraphyatases and 5
P03400694A0245 |13 20|METHODS6 Compa
P03400694A0245 |114 126|dipyridamoleonatal hyper
P03400694A0245 |96 101|mg/kgogic 
P03400694A0245 |22 34|Thallium-201son with alk
P03400694A0245 |139 146|minutes. P0000
P03400694A0245 |153 161|patients72 When 
P03401060A0000 |5 14|melanomas1606T0076
P03402183A0171 |35 40|formsline 
P03402183A0171 |132 143|circulationbinemia. P0
P03402183A0171 |281 292|circulationrols but st
P03402183A0171 |199 201|HzCS
P03402183A0171 |215 234|voltage stimulationa of K-depleted rat
P03402183A0171 |123 126|MVCper
P03402183A0171 |63 75|contractionseotidase P00
P03402183A0171 |99 111|contractionsc aspects of
P03402183A0171 |113 116|MVCeon
P03402183A0171 |178 190|contractionsown as a fun
P03402183A0171 |263 275|contractionsn compared t
P03402183A0171 |4 13|TA muscle01606T007
P03403313A0298 |103 111|excisionpects of
P03403313A0298 |133 141|excisioninemia. 
P03403313A0298 |195 203|excision of CSF 
P03403313A0298 |121 122|%h
P03403313A0298 |60 76|treatment groupsucleotidase P000
P03403313A0298 |161 178|radiation therapyCSF [HCO3-] is sh
P03403313A0298 |40 45|yearsphosp
P03403313A0298 |182 183|%a
P03403313A0298 |213 214|%a
P03403313A0298 |20 33|control ratesrison with al
P03403412A0000 |68 78|efficiencyase P00008
P03403412A0000 |42 53|compositionosphatases 
P03403412A0000 |24 32|implantsn with a
P03403412A0000 |147 160|grain content997A0472 When
P03403412A0000 |4 11|effects01606T0
P03403412A0000 |36 40|rateine 
P03403412A0000 |82 88|growth0000 P
P03403412A0000 |115 124|fed dietsnatal hyp
P03403412A0000 |136 142|foragemia. P
P03403480A0299 |202 209|density PCO2 t
P03403480A0299 |10 20|suspension0076 Compa
P03403480A0299 |133 141|diameterinemia. 
P03403480A0299 |88 106|femur middiaphysisharmacologic aspec
P03403480A0299 |224 247|collagen concentrationspleted rats are no long
P03403480A0299 |211 218|mineral data o
P03403480A0299 |196 200|areaof C
P03403480A0299 |145 146|%0
P03403480A0299 |43 49|changesphata
P03403480A0299 |67 80|configurationdase P0000817
P03403480A0299 |172 183|alterations is shown a
P03403826T0000 |102 119|stenosis severityspects of neonata
P03403826T0000 |150 158|analysisA0472 Wh
P03403826T0000 |212 224|flow reservedata of K-de
P03403826T0000 |229 278|exercise/redistribution thallium-201 scintigraphyd rats are no longer displaced when compared to c
P03403826T0000 |123 133|comparisonperbilirub
P03403826T0000 |175 188|cineangiogram shown as a f
P03403826T0000 |86 98|measurements Pharmacolog
P03404334T0000 |0 13|Water contentP00001606T007
P03404334T0000 |58 67|cartilage-nucleoti
P03404334T0000 |18 45|equilibrium water partitionparison with alkaline phosp
P03404495A0172 |0 22|Thyroid function testsP00001606T0076 Compari
P03404495A0172 |45 55|admissionshatases an
P03406054A0351 |85 89|slit0 Ph
P03406054A0351 |77 79|mm81
P03406054A0351 |12 32|line spread function76 Comparison with a
P03406054A0351 |166 177|polystyreneHCO3-] is s
P03406054A0351 |62 67|imageleoti
P03406054A0351 |155 160|front When
P03406054A0351 |98 106|tungstenic aspec
P03406054A0351 |142 151|isocentre00008997A
P03406054A0351 |0 4|DataP000
P03406054A0351 |34 37|LSFali
P03407676A0585 |8 17|infection6T0076 Co
P03407843T0000 |0 6|PapersP00001
P03407843T0000 |14 21|Society Compar
P03407843T0000 |44 51|Surgeryphatase
P03413681A0659 |137 145|functionia. P000
P03413681A0659 |73 80|patient0000817
P03413681A0659 |44 49|yearsphata
P03413681A0659 |59 63|factnucl
P03413681A0659 |24 27|agen w
P03413681A0659 |9 22|heart diseaseT0076 Compari
P03413681A0659 |110 120|predictorsf neonatal
P03413681A0659 |87 92|womanPharm
P03413890T0001 |0 9|PrognosisP00001606
P03413890T0001 |13 18|Bowen6 Com
P03413890T0001 |58 64|region-nucle
P03413890T0001 |21 28|diseaseison wi
P03417104A0536 |20 27|resultsrison w
P03417104A0536 |91 107|stimulus effectsmacologic aspect
P03417104A0536 |41 57|chlorphenterminehosphatases and 
P03417104A0536 |111 118|animals neonat
P03417588T0000 |68 72|cornase 
P03417588T0000 |0 6|LiquidP00001
P03417588T0000 |23 29|methodon wit
P03417588T0000 |77 81|rice8171
P03417588T0000 |34 47|determinationaline phospha
P03417588T0000 |51 64|citreoviridins and 5-nucle
P03417668A1233 |87 99|beta subunitPharmacologi
P03417668A1233 |29 48|autophosphorylationh alkaline phosphat
P03417668A1233 |134 147|CaM-kinase IInemia. P00008
P03417668A1233 |120 130|transition hyperbili
P03417668A1233 |60 73|alpha subunitucleotidase P
P03417668A1233 |172 176|form is 
P03417668A1233 |52 58|Thr286 and 5
P03417668A1233 |79 85|Thr28771T000
P03417668A1233 |6 14|findings606T0076
P03417668A1233 |155 158|Ca2 Wh
P03418727A0992 |138 148|treatmentsa. P000089
P03418727A0992 |107 117|myelopathys of neona
P03418727A0992 |90 97|insightrmacolo
P03418727A0992 |25 36|penetration with alkal
P03418727A0992 |67 79|chemotherapydase P000081
P03420266A0000 |136 148|animal modelmia. P000089
P03420266A0000 |105 119|adenocarcinomacts of neonata
P03420266A0000 |33 45|hyperthermiakaline phosp
P03420266A0000 |4 15|interaction01606T0076 
P03420266A0000 |80 94|Dunning R3327G1T0000 Pharmac
P03420266A0000 |19 28|radiationarison wi
P03420266A0000 |169 175|cancer3-] is
P03420324A0178 |174 189|h/day beginnings shown as a fu
P03420324A0178 |86 90|days Pha
P03420324A0178 |261 264|dayhen
P03420324A0178 |249 252|day di
P03420324A0178 |212 213|%d
P03420324A0178 |58 59|%-
P03420324A0178 |145 146|%0
P03420324A0178 |193 196|dayon 
P03420324A0178 |104 107|dayect
P03420324A0178 |75 76|%0
P03420324A0178 |220 222|N2K-
P03420324A0178 |153 155|N272
P03420324A0178 |128 137|pregnancylirubinem
P03420324A0178 |162 163|%S
P03420324A0178 |41 50|followinghosphatas
P03420324A0178 |9 13|ratsT007
P03420324A0178 |66 68|N2id
P03420466A0000 |17 34|cryptosporidiosismparison with alk
P03420466A0000 |4 13|incidence01606T007
P03420466A0000 |44 52|childrenphatases
P03420466A0000 |90 99|specimensrmacologi
P03420466A0000 |71 79|staining P000081
P03420466A0000 |116 123|Kinyounatal hy
P03421425A0878 |20 27|percentrison w
P03421425A0878 |40 54|hypothyroidismphosphatases a
P03421425A0878 |6 14|patients606T0076
P03421425A0878 |83 97|determinations000 Pharmacolo
P03423732A0341 |0 8|AdditionP0000160
P03423732A0341 |108 109|% 
P03423732A0341 |26 32|De-Nolwith a
P03423732A0341 |12 22|sucralfate76 Compari
P03423732A0341 |45 55|incrementshatases an
P03423732A0341 |172 176|PGE2 is 
P03423732A0341 |67 81|HCO3 secretiondase P00008171
P03423732A0341 |178 184|dmPGE2own as
P03423732A0341 |140 153|HCO3 response P00008997A04
P03423732A0341 |100 101|% 
P03427474A0853 |102 121|saccharin solutionsspects of neonatal 
P03427474A0853 |39 46|animals phosph
P03427474A0853 |60 68|aversionucleotid
P03427474A0853 |84 98|concentrations00 Pharmacolog
P03427474A0853 |17 29|control ratsmparison wit
P03427613A0659 |35 41|systemline p
P03427613A0659 |128 133|brainlirub
P03427613A0659 |89 101|pineal organarmacologic 
P03427613A0659 |52 59|vessels and 5-
P03427613A0659 |112 120|portionsneonatal
P03428084A0430 |101 117|pattern onset C1aspects of neona
P03428084A0430 |6 21|degrees stimuli606T0076 Compar
P03428084A0430 |43 62|scalp distributionssphatases and 5-nuc
P03428084A0430 |134 141|striatenemia. 
P03428084A0430 |175 182|origins shown 
P03428084A0430 |71 92|pattern reversal P100 P00008171T0000 Pharm
P03428274A0000 |32 39|proteinlkaline
P03428274A0000 |45 55|HeLa cellshatases an
P03428274A0000 |8 14|factor6T0076
P03428274A0000 |214 220|factorta of 
P03428274A0000 |109 112|Ad2of 
P03428274A0000 |182 188|originas a f
P03428274A0000 |90 105|adenovirus typermacologic aspe
P03428274A0000 |114 129|DNA replicationonatal hyperbil
P03428274A0000 |20 25|NFIIIrison
P03428274A0000 |76 86|initiation08171T0000
P03428274A0000 |155 174|nucleotide sequence When CSF [HCO3-] i
P03428274A0000 |223 239|recognition siteepleted rats are
P03429306T0000 |49 55|cortexses an
P03429306T0000 |27 32|layerith a
P03429306T0000 |2 13|Golgi study0001606T007
P03429371A1051 |17 38|cephalothin clearancemparison with alkalin
P03429371A1051 |78 88|phagocytes171T0000 P
P03429371A1051 |59 63|sitenucl
P03429371A1051 |143 147|site0008
P03430221A1236 |51 61|propertiess and 5-nu
P03430221A1236 |78 87|detectors171T0000 
P03430221A1236 |4 12|findings01606T00
P03430221A1236 |34 41|contextaline p
P03434347A0358 |0 9|Mean rCBFP00001606
P03434347A0358 |41 46|weekshosph
P03434347A0358 |28 36|patientsth alkal
P03434347A0358 |53 60|surgeryand 5-n
P03434347A0358 |80 84|side1T00
P03436119A0000 |22 32|tomographyson with a
P03436119A0000 |90 101|sensitivityrmacologic 
P03436119A0000 |106 121|reproducibilityts of neonatal 
P03436119A0000 |57 77|bone mineral content5-nucleotidase P0000
P03436529A1066 |152 164|nt positions472 When CSF
P03436529A1066 |196 204|templateof CSF P
P03436529A1066 |61 65|paircleo
P03436529A1066 |21 29|enhancerison wit
P03436529A1066 |4 13|structure01606T007
P03436529A1066 |93 114|oligodeoxynucleotidescologic aspects of ne
P03436529A1066 |222 230|enhancerdepleted
P03436529A1066 |137 143|regionia. P0
P03436877A0950 |0 2|KfP0
P03436877A0950 |324 329|WORDS slop
P03436877A0950 |219 220|P 
P03436877A0950 |298 306|ABSTRACTve a sig
P03436877A0950 |148 149|P9
P03436877A0950 |88 108|lung mass % delta Kfharmacologic aspects
P03436877A0950 |122 128|% massyperbi
P03436877A0950 |209 210|rh
P03436877A0950 |276 296|blocker pretreatment controls but still 
P03436877A0950 |9 11|CTT0
P03436877A0950 |109 110|co
P03436877A0950 |193 199|% masson of 
P03436877A0950 |74 84|reductions0008171T00
P03436877A0950 |3 4|c0
P03436877A0950 |138 139|ra
P03436877A0950 |39 48|lung mass phosphat
P03436877A0950 |237 250|relationshipsre no longer 
P03436877A0950 |170 180|% delta CT-] is show
P03439248A0000 |205 219|artery diseaseO2 the data of
P03439248A0000 |52 73|exercise thallium-201 and 5-nucleotidase P
P03439248A0000 |35 47|dipyridamoleline phospha
P03439248A0000 |18 25|methodsparison
P03439248A0000 |172 180|patients is show
P03439248A0000 |136 151|artery stenosismia. P00008997A
P03439248A0000 |85 102|perfusion imaging0 Pharmacologic a
P03440780A0779 |118 142|calcium entry mechanismsal hyperbilirubinemia. P
P03440780A0779 |11 18|results076 Com
P03440780A0779 |208 213|EDLFsthe d
P03440780A0779 |181 204|vasoconstrictor effects as a function of CSF P
P03440780A0779 |162 173|differencesSF [HCO3-] 
P03440780A0779 |56 82|vasoconstrictor properties 5-nucleotidase P00008171T
P03440780A0779 |41 45|EDLFhosp
P03440780A0779 |219 226|respect K-depl
P03440780A0779 |249 253|beds dis
P03441587A0000 |0 8|ResearchP0000160
P03441587A0000 |58 63|serum-nucl
P03441587A0000 |43 50|factorssphatas
P03441587A0000 |199 205|methodCSF PC
P03441587A0000 |160 167|results CSF [H
P03441587A0000 |209 218|referencehe data o
P03441587A0000 |113 124|polystyreneeonatal hyp
P03441587A0000 |96 101|testsogic 
P03441587A0000 |83 88|means000 P
P03441587A0000 |71 79|patients P000081
P03441587A0000 |138 150|erythrocytesa. P00008997
P03443144A0409 |102 111|reactionsspects of
P03443144A0409 |6 31|aspirin esterase activity606T0076 Comparison with 
P03443144A0409 |54 60|factornd 5-n
P03443144A0409 |84 91|aspirin00 Phar
P03443566A0675 |35 39|gainline
P03443566A0675 |8 19|experiments6T0076 Comp
P03443566A0675 |44 62|gain-to-feed ratiophatases and 5-nuc
P03443566A0675 |80 82|TR1T
P03443566A0675 |87 89|CRPh
P03443573A0329 |142 143|g0
P03443573A0329 |147 153|tissue997A04
P03443573A0329 |88 91|fathar
P03443573A0329 |120 122|mg h
P03443573A0329 |8 21|least-squares6T0076 Compar
P03443573A0329 |52 70|longissimus muscle and 5-nucleotidas
P03443609A0000 |102 110|productsspects o
P03443609A0000 |65 74|techniquetidase P0
P03443609A0000 |160 178|column methodology CSF [HCO3-] is sh
P03443609A0000 |26 46|fluid chromatographywith alkaline phosph
P03443609A0000 |4 8|role0160
P03443609A0000 |48 51|SFCase
P03446332A0831 |0 13|NitrofurazoneP00001606T007
P03446332A0831 |62 66|LHRHleot
P03446332A0831 |40 44|risephos
P03446332A0831 |48 50|LHas
P03448035T0000 |18 27|pregnancyparison w
P03448035T0000 |8 14|tumors6T0076
P03449358T0001 |16 21|studyompar
P03449358T0001 |25 38|polyarteritis with alkalin
P03450438A0446 |34 38|needalin
P03450438A0446 |14 30|Yates correction Comparison with
P03450438A0446 |65 71|methodtidase
P03450438A0446 |0 7|X2 testP000016
P03451761A0215 |102 106|basespec
P03451761A0215 |130 133|RNVrub
P03451761A0215 |54 65|stimulationnd 5-nucleo
P03451761A0215 |8 22|baseline study6T0076 Compari
P03451761A0215 |24 36|WPW syndromen with alkal
P03451761A0215 |114 124|ventriclesonatal hyp
P03451761A0215 |85 90|sites0 Pha
P03452920T0001 |0 3|ManP00
P03452920T0001 |8 14|insect6T0076
P03452920T0001 |16 20|pastompa
P03457330A0271 |85 94|operation0 Pharmac
P03457330A0271 |4 12|patients01606T00
P03457330A0271 |28 33|assayth al
P03457330A0271 |21 23|CAis
P03457330A0271 |55 59|weekd 5-
P03459385T0000 |0 7|AllergyP000016
P03459385T0000 |12 20|Tourette76 Compa
P03459385T0000 |23 31|syndromeon with 
P03459736A0184 |69 76|varietyse P000
P03459736A0184 |80 85|pills1T000
P03459736A0184 |36 44|sessionsine phos
P03459736A0184 |90 98|capsulesrmacolog
P03459736A0184 |4 13|criterion01606T007
P03459736A0184 |49 63|generalizationses and 5-nucl
P03463537T0001 |55 64|anomaliesd 5-nucle
P03463537T0001 |9 15|methodT0076 
P03463537T0001 |75 79|bite0081
P03463537T0001 |24 33|treatmentn with al
P03463537T0001 |37 42|Classne ph
P03463543A1613 |68 71|UTIase
P03463543A1613 |43 52|treatmentsphatases
P03463543A1613 |0 8|EnoxacinP0000160
P03465957A1008 |0 21|Mean fluorosis scoresP00001606T0076 Compar
P03466730A0210 |48 54|pupilsases a
P03466730A0210 |10 22|dysfunctions0076 Compari
P03473253A0000 |184 198|U.S. companies a function of
P03473253A0000 |31 53|cohort mortality studyalkaline phosphatases 
P03473253A0000 |77 93|chemical workers8171T0000 Pharma
P03473253A0000 |142 172|chloromethyl ether manufacture00008997A0472 When CSF [HCO3-]
P03473379A0183 |17 28|amyloidosismparison wi
P03473379A0183 |67 79|gland biopsydase P000081
P03473379A0183 |4 13|diagnosis01606T007
P03476002A0148 |0 4|HairP000
P03476002A0148 |9 22|blood samplesT0076 Compari
P03476002A0148 |41 50|vitamin Chosphatas
P03476002A0148 |105 114|intervalscts of ne
P03476002A0148 |54 77|placebo supplementationnd 5-nucleotidase P0000
P03476002A0148 |136 142|monthsmia. P
P03478354A0436 |18 22|cowspari
P03478354A0436 |56 69|corpus luteum 5-nucleotida
P03478354A0436 |11 16|herds076 C
P03478354A0436 |79 101|prostaglandin F2 alpha71T0000 Pharmacologic 
P03478354A0436 |36 48|d postpartumine phosphat
P03479897A0961 |35 44|angle ANBline phos
P03479897A0961 |108 117|Class III of neona
P03479897A0961 |13 17|hand6 Co
P03479897A0961 |76 81|angle08171
P03479897A0961 |96 104|relationogic asp
P03484075T0001 |0 19|Emergency treatmentP00001606T0076 Comp
P03484075T0001 |55 63|injuriesd 5-nucl
P03484894A0782 |6 11|cases606T0
P03484894A0782 |109 117|biotypesof neona
P03484894A0782 |56 63|biotype 5-nucl
P03484894A0782 |13 21|isolates6 Compar
P03484894A0782 |78 85|biotype171T000
P03484894A0782 |125 127|V.rb
P03485064A0135 |51 59|patientss and 5-
P03485064A0135 |15 29|EVS treatmentsComparison wit
P03485064A0135 |2 7|total00016
P03486405A0341 |119 129|IL-1 alphal hyperbil
P03486405A0341 |111 115|form neo
P03486405A0341 |89 94|exonsarmac
P03486405A0341 |164 169|exons [HCO
P03486405A0341 |23 30|portionon with
P03486405A0341 |38 59|precursor polypeptidee phosphatases and 5-
P03487348A0000 |69 91|afterhyperpolarizationse P00008171T0000 Phar
P03487348A0000 |47 52|modeltases
P03487348A0000 |13 20|version6 Compa
P03487348A0000 |24 31|Kernelln with 
P03487348A0000 |93 96|AHPcol
P03488532A0235 |85 93|symptoms0 Pharma
P03488532A0235 |99 118|acyclovir treatmentc aspects of neonat
P03488532A0235 |22 28|reportson wi
P03488532A0235 |64 80|dermatomal signsotidase P0000817
P03488532A0235 |50 60|resolutiones and 5-n
P03491190A0233 |81 86|scansT0000
P03491190A0233 |60 61|%u
P03491190A0233 |25 32|defects with a
P03491190A0233 |43 53|LAD regionsphatases 
P03491190A0233 |90 104|stress studiesrmacologic asp
P03491190A0233 |36 39|RCAine
P03491190A0233 |4 17|detectability01606T0076 Co
P03493240T0000 |67 72|drugsdase 
P03493240T0000 |14 24|properties Compariso
P03493240T0000 |41 47|agentshospha
P03494649A0472 |87 93|changePharma
P03494649A0472 |97 101|MABPgic 
P03494649A0472 |72 79|absenceP000081
P03494649A0472 |61 64|CBFcle
P03494649A0472 |23 32|challengeon with a
P03494649A0472 |49 57|increaseses and 
P03499608A1054 |55 77|heterozygote detectiond 5-nucleotidase P0000
P03499608A1054 |91 100|diagnosismacologic
P03499608A1054 |42 50|reagentsosphatas
P03499608A1054 |161 166|causeCSF [
P03499608A1054 |107 134|beta-hydroxylase deficiencys of neonatal hyperbilirubi
P03499608A1054 |189 200|hyperplasianction of C
P03499608A1054 |6 10|data606T
P03499657A0000 |0 11|OsteocalcinP00001606T0
P03499657A0000 |243 257|hypercalcaemialonger displac
P03499657A0000 |211 215|PHPT dat
P03499657A0000 |13 35|serum bone-Gla protein6 Comparison with alka
P03499657A0000 |44 70|serum alkaline phosphatasephatases and 5-nucleotidas
P03499657A0000 |190 209|hyperparathyroidismction of CSF PCO2 t
P03499657A0000 |261 271|malignancyhen compar
P03499657A0000 |89 120|hydroxyproline/creatinine ratioarmacologic aspects of neonatal
P03499657A0000 |122 141|uOH-Prol/creatinineyperbilirubinemia. 
P03499657A0000 |37 41|sBGPne p
P03499657A0000 |229 237|patientsd rats a
P03499657A0000 |72 75|sAPP00
P03499657A0000 |168 176|patientsO3-] is 
P03499657A0000 |273 275|HM t
P03499822A0182 |137 145|employeeia. P000
P03499822A0182 |148 155|country97A0472
P03499822A0182 |105 115|prevalencects of neo
P03499822A0182 |159 164|birthn CSF
P03499822A0182 |22 41|regression analysisson with alkaline p
P03499822A0182 |57 71|seropositivity5-nucleotidase
P03499822A0182 |174 177|ages s
P03499822A0182 |119 130|hepatitis Bl hyperbili
P03504971A0000 |0 6|HexsynP00001
P03504971A0000 |166 171|bondsHCO3-
P03504971A0000 |14 27|Goodyear Tire Comparison w
P03504971A0000 |140 146|source P0000
P03504971A0000 |176 189|vulcanizationshown as a fu
P03504971A0000 |63 80|polyolefin rubbereotidase P0000817
P03504971A0000 |115 132|% methylhexadienenatal hyperbiliru
P03504971A0000 |32 56|Rubber Company tradenamelkaline phosphatases and
P03507689A0000 |220 243|beta-galactosidase geneK-depleted rats are no 
P03507689A0000 |123 129|originperbil
P03507689A0000 |183 208|bacteriophage T7 promoters a function of CSF PCO2 
P03507689A0000 |150 166|bacteriophage f1A0472 When CSF [
P03507689A0000 |111 114|DNA ne
P03507689A0000 |9 41|phage-plasmid expression vectorsT0076 Comparison with alkaline p
P03507689A0000 |133 144|replicationinemia. P00
P03507689A0000 |64 81|pUC18/19 plasmidsotidase P00008171
P03507689A0000 |116 121|ssDNAatal 
P03508698A0535 |3 8|order00160
P03508698A0535 |45 48|jawhat
P03508698A0535 |58 67|adductors-nucleoti
P03508698A0535 |29 43|finger flexorsh alkaline pho
P03508698A0535 |73 89|triceps reflexes00008171T0000 Ph
P03508698A0535 |128 134|groupslirubi
P03508698A0535 |23 27|rateon w
P03510185A0187 |0 5|Natl.P0000
P03513989A0580 |20 28|estrogenrison wi
P03513989A0580 |72 79|animalsP000081
P03513989A0580 |8 15|ethanol6T0076 
P03513989A0580 |53 68|UROD-deficiencyand 5-nucleotid
P03513989A1149 |200 207|effectsSF PCO2
P03513989A1149 |227 233|agentsted ra
P03513989A1149 |134 141|insightnemia. 
P03513989A1149 |67 78|disturbancedase P00008
P03513989A1149 |25 33|disorder with al
P03513989A1149 |111 120|countries neonatal
P03513989A1149 |82 102|porphyrin metabolism0000 Pharmacologic a
P03513989A1149 |159 171|pathogenesisn CSF [HCO3-
P03515840A0000 |207 212|death the 
P03515840A0000 |163 169|monthsF [HCO
P03515840A0000 |72 81|granulomaP00008171
P03515840A0000 |30 35|cases alka
P03515840A0000 |175 180|years show
P03515840A0000 |188 202|generalizationunction of CSF
P03515840A0000 |112 125|histiocytosisneonatal hype
P03515840A0000 |49 57|symptomsses and 
P03515840A0000 |139 146|sarcoma. P0000
P03516189A0406 |4 12|patients01606T00
P03516189A0406 |45 57|mg kg-1 i.v.hatases and 
P03516189A0406 |27 40|suxamethoniumith alkaline 
P03517388A0763 |71 74|U/L P0
P03517388A0763 |90 93|U/Lrma
P03517388A0763 |95 96|pl
P03517388A0763 |57 59|BC5-
P03517388A0763 |26 37|CK-MB levelwith alkali
P03517388A0763 |76 78|CC08
P03517388A0763 |53 55|BCan
P03520729A0381 |69 83|renin activityse P00008171T0
P03520729A0381 |52 65|plasma levels and 5-nucleo
P03520729A0381 |12 19|changes76 Comp
P03520729A0381 |88 113|aldosterone concentrationharmacologic aspects of n
P03520729A0381 |23 33|heart rateon with al
P03520729A0381 |35 46|body weightline phosph
P03522105A1011 |5 36|trough serum TOB concentrations1606T0076 Comparison with alkal
P03522105A1011 |89 97|recoveryarmacolo
P03522105A1011 |58 63|death-nucl
P03522105A1011 |77 83|levels8171T0
P03526279T0000 |26 38|nursing R.N.with alkalin
P03526279T0000 |15 22|schoolsCompari
P03528748A0414 |5 20|maxicell system1606T0076 Compa
P03528748A0414 |61 67|weightcleoti
P03528748A0414 |23 30|proteinon with
P03531317A0930 |103 108|modelpects
P03531317A0930 |112 118|Fisherneonat
P03531317A0930 |28 38|recessivesth alkalin
P03531317A0930 |20 24|lossriso
P03531317A0930 |69 83|hypergeometricse P00008171T0
P03534581A0976 |68 73|groupase P
P03534581A0976 |58 59|%-
P03534581A0976 |160 173|control group CSF [HCO3-] 
P03534581A0976 |120 136|cyclophosphamide hyperbilirubine
P03534581A0976 |87 101|5-fluorouracilPharmacologic 
P03534581A0976 |4 13|incidence01606T007
P03534581A0976 |178 179|%o
P03534581A0976 |103 114|doxorubicinpects of ne
P03534581A0976 |34 43|neoplasmsaline pho
P03536682A0572 |0 9|OvulationP00001606
P03536682A0572 |32 33|%l
P03536682A0572 |35 43|patientsline pho
P03536864A0000 |12 16|work76 C
P03537686A0099 |238 243|cellse no 
P03537686A0099 |178 187|mutationsown as a 
P03537686A0099 |335 345|background1 +/- 0.23
P03537686A0099 |10 14|size0076
P03537686A0099 |280 289|mutationstrols but
P03537686A0099 |120 126|vector hyper
P03537686A0099 |60 85|supF suppressor tRNA geneucleotidase P00008171T000
P03537686A0099 |36 54|mutagenesis markerine phosphatases a
P03537686A0099 |249 260|plasmid DNA displaced 
P03537686A0099 |212 224|transfectiondata of K-de
P03537686A0099 |19 28|placementarison wi
P03537686A0099 |153 162|frequency72 When C
P03537711A0181 |0 2|W.P0
P03537721A0491 |68 77|PEP4 genease P0000
P03537721A0491 |28 53|recombination experimentsth alkaline phosphatases 
P03537721A0491 |90 94|GAL4rmac
P03537721A0491 |7 15|analysis06T0076 
P03537721A0491 |98 112|chromosome XVIic aspects of 
P03537721A0876 |136 149|yeast vacuolemia. P0000899
P03537721A0876 |40 45|modelphosp
P03537721A0876 |63 82|precursor moleculeseotidase P00008171T
P03537721A0876 |13 25|observations6 Comparison
P03537721A0876 |191 201|hydrolasestion of CS
P03537721A0876 |101 124|PEP4 gene self-activateaspects of neonatal hyp
P03537727A0243 |4 8|poly0160
P03537727A0243 |12 19|segment76 Comp
P03537727A0243 |104 111|proteinects of
P03537727A0243 |91 98|proteinmacolog
P03537727A0243 |27 30|RNAith
P03537727A0243 |9 10|AT
P03540591A0330 |175 188|reading frame shown as a f
P03540591A0330 |9 20|translationT0076 Compa
P03540591A0330 |56 61|cDNAs 5-nu
P03540591A0330 |135 142|proteinemia. P
P03540591A0330 |24 27|RNAn w
P03540591A0330 |76 90|P0 transcripts08171T0000 Pha
P03540853A0652 |69 89|DNA binding proteinsse P00008171T0000 Ph
P03540853A0652 |15 34|amino acid sequenceComparison with alk
P03540853A0652 |46 63|sequence homologyatases and 5-nucl
P03540853A0652 |38 41|Mope p
P03541263A0368 |52 59|control and 5-
P03541263A0368 |12 22|techniques76 Compari
P03541263A0368 |63 71|diabeteseotidase
P03542945T0000 |0 13|CiprofloxacinP00001606T007
P03542945T0000 |38 49|experiencese phosphata
P03542945T0000 |18 26|overviewparison 
P03543485A0069 |71 91|space flight effects P00008171T0000 Phar
P03543485A0069 |59 67|responsenucleoti
P03543485A0069 |22 32|mechanismsson with a
P03543485A0069 |48 55|changesases an
P03543936A0000 |51 57|familys and 
P03543936A0000 |75 83|homology008171T0
P03543936A0000 |91 110|ras oncogene familymacologic aspects o
P03543936A0000 |4 13|rho genes01606T007
P03544858A0374 |85 90|sexes0 Pha
P03544858A0374 |106 116|metabolismts of neon
P03544858A0374 |121 136|HDL-cholesterolhyperbilirubine
P03544858A0374 |141 148|femalesP000089
P03544858A0374 |6 15|component606T0076 
P03544858A0374 |56 63|insulin 5-nucl
P03544858A0374 |153 158|males72 Wh
P03544858A0374 |68 75|VO2 maxase P00
P03545955A0751 |305 312|lactosegnifica
P03545955A0751 |291 295|milktill
P03545955A0751 |253 258|Studyplace
P03545955A0751 |262 269|glucoseen comp
P03545955A0751 |115 122|glucosenatal h
P03545955A0751 |156 166|mmol X h/lWhen CSF [
P03545955A0751 |125 133|fructoserbilirub
P03545955A0751 |177 184|glucosehown as
P03545955A0751 |209 215|appleshe dat
P03545955A0751 |61 66|Studycleot
P03545955A0751 |91 96|juicemacol
P03545955A0751 |241 251|mmol X h/lo longer d
P03545955A0751 |143 151|fructose0008997A
P03545955A0751 |276 285|ice cream controls
P03545955A0751 |198 203|juice CSF 
P03545955A0751 |317 327|mmol X h/lgreater sl
P03545955A0751 |225 236|apple juiceleted rats 
P03545955A0751 |49 54|foodsses a
P03545955A0751 |70 77|glucosee P0000
P03545955A0751 |168 173|StudyO3-] 
P03545955A0751 |4 17|glucose areas01606T0076 Co
P03545955A0751 |32 41|ingestionlkaline p
P03545955A0751 |102 109|sucrosespects 
P03545955A1378 |4 26|serum insulin response01606T0076 Comparison 
P03549045A0878 |0 3|SCLP00
P03549045A0878 |29 38|verapamilh alkalin
P03549045A0878 |104 109|groupects 
P03549045A0878 |44 56|sinus arrestphatases and
P03549045A0878 |112 119|animalsneonata
P03549045A0878 |80 85|group1T000
P03550444T0000 |17 29|yeast systemmparison wit
P03550444T0000 |33 38|assaykalin
P03550444T0000 |50 61|specificityes and 5-nu
P03550444T0000 |0 11|DevelopmentP00001606T0
P03552363A0568 |186 198|correlations function of
P03552363A0568 |120 123|men hy
P03552363A0568 |95 116|blood pressure levelslogic aspects of neon
P03552363A0568 |12 32|serum insulin levels76 Comparison with a
P03552363A0568 |165 173|subjects[HCO3-] 
P03552363A0568 |55 67|correlationsd 5-nucleoti
P03552363A0568 |238 258|blood pressure levele no longer displace
P03553149A0299 |33 44|mutagenesiskaline phos
P03553149A0299 |95 108|cleavage sitelogic aspects
P03553149A0299 |56 60|site 5-n
P03553149A0299 |112 116|LexAneon
P03553149A0299 |64 68|MucAotid
P03553439A0404 |51 63|tumor tissues and 5-nucl
P03553439A0404 |180 191|tumor cellsn as a func
P03553439A0404 |104 115|tumor cellsects of neo
P03553439A0404 |211 222|tumor cells data of K-
P03553439A0404 |4 10|latter01606T
P03553439A0404 |131 143|tumor tissueubinemia. P0
P03553439A0404 |193 197|Typeon o
P03553439A0404 |38 42|Typee ph
P03553439A0404 |117 121|Typetal 
P03555318T0000 |4 16|pharmacology01606T0076 C
P03555318T0000 |20 29|carnitinerison wit
P03556834T0000 |6 25|inhalation toxicity606T0076 Comparison
P03556834T0000 |29 42|T-2 mycotoxinh alkaline ph
P03556834T0000 |46 50|miceatas
P03559193A0000 |102 106|FTASspec
P03559193A0000 |95 100|scalelogic
P03559193A0000 |12 25|investigation76 Comparison
P03559193A0000 |166 176|correlatesHCO3-] is 
P03559193A0000 |77 92|Framingham Type8171T0000 Pharm
P03559193A0000 |59 69|dimensionsnucleotida
P03559232T0000 |32 41|arthritislkaline p
P03559232T0000 |14 19|study Comp
P03559287T0000 |0 10|LegionellaP00001606T
P03559287T0000 |22 29|ecologyson wit
P03559287T0000 |49 60|consumptionses and 5-n
P03561036T0000 |0 10|LymphaticsP00001606T
P03561036T0000 |27 31|ratsith 
P03561036T0000 |56 67|oil extract 5-nucleoti
P03561036T0000 |18 23|aortaparis
P03561036T0000 |69 79|lipofundinse P000081
P03561622A0659 |220 243|term vancomycin therapyK-depleted rats are no 
P03561622A0659 |194 208|blood culturesn of CSF PCO2 
P03561622A0659 |99 126|DiaTAP button graft complexc aspects of neonatal hyper
P03561622A0659 |10 16|resort0076 C
P03561622A0659 |62 70|dialysisleotidas
P03561622A0659 |51 58|patients and 5
P03561622A0659 |85 91|health0 Phar
P03563399A0534 |51 55|SoNos an
P03563399A0534 |120 130|difference hyperbili
P03563399A0534 |60 77|S pi No thresholducleotidase P0000
P03563399A0534 |4 20|signal durations01606T0076 Compa
P03563399A0534 |34 36|msal
P03563604A1075 |64 65|%o
P03563604A1075 |105 122|drug interventioncts of neonatal h
P03563604A1075 |92 93|%a
P03563604A1075 |29 38|villagersh alkalin
P03563604A1075 |74 87|parasite rate0008171T0000 
P03563604A1075 |42 44|RKos
P03563604A1075 |4 15|spleen rate01606T0076 
P03567017A0000 |118 127|half-lifeal hyperb
P03567017A0000 |9 15|dosingT0076 
P03567017A0000 |62 64|mgle
P03567017A0000 |47 57|indoprofentases and 
P03567017A0000 |180 188|subjectsn as a f
P03567017A0000 |39 43|days pho
P03567017A0000 |129 133|t1/2irub
P03567017A0000 |145 162|drug accumulation08997A0472 When C
P03567017A0000 |21 26|timesison 
P03567017A0000 |100 104|drug asp
P03568311A0273 |118 125|indexesal hype
P03568311A0273 |89 92|IPParm
P03568311A0273 |74 77|PWP000
P03568311A0273 |6 14|patients606T0076
P03568311A0273 |37 46|tamponadene phosph
P03568311A0273 |58 72|wedge pressure-nucleotidase 
P03568311A0273 |80 83|RAP1T0
P03568311A0273 |138 146|functiona. P0000
P03568311A1361 |103 114|correlationpects of ne
P03568311A1361 |147 148|r9
P03568311A1361 |13 22|tamponade6 Compari
P03568311A1361 |120 125|TMFP1 hype
P03568311A1361 |140 145|TMFP2 P000
P03568311A1361 |127 128|ri
P03568311A1361 |27 50|pericardiocentesis dataith alkaline phosphatas
P03568311A1361 |169 174|TMFP33-] i
P03568311A1361 |69 86|stroke work indexse P00008171T0000
P03570455A0433 |0 7|RabbitsP000016
P03570455A0433 |94 99|mg/dlologi
P03570455A0433 |123 129|TSST-1perbil
P03570455A0433 |46 52|levelsatases
P03570455A0433 |27 39|hypocalcemiaith alkaline
P03570455A0433 |110 119|influencef neonata
P03571135T0000 |37 45|languagene phosp
P03571135T0000 |90 98|childrenrmacolog
P03571135T0000 |25 33|features with al
P03571135T0000 |7 12|value06T00
P03572706A0329 |186 197|F-K indices function o
P03572706A0329 |180 181|Fn
P03572706A0329 |211 223|MMPI profile data of K-d
P03572706A0329 |99 109|therapistsc aspects 
P03572706A0329 |52 61|protocols and 5-nu
P03572706A0329 |163 172|elevationF [HCO3-]
P03572706A0329 |21 36|interpretationsison with alkal
P03572706A0329 |139 158|treatment condition. P00008997A0472 Wh
P03575656A0120 |155 159|time Whe
P03575656A0120 |30 43|chemical form alkaline pho
P03575656A0120 |145 151|period08997A
P03575656A0120 |88 92|boneharm
P03575656A0120 |45 49|90Srhata
P03575656A0120 |113 120|portioneonatal
P03575656A0120 |80 84|lung1T00
P03577670A0102 |68 88|matter hypodensitiesase P00008171T0000 P
P03577670A0102 |4 9|study01606
P03577670A0102 |32 39|atrophylkaline
P03577670A0236 |4 13|diagnosis01606T007
P03577670A0236 |47 50|MLDtas
P03577670A0236 |31 45|leukodystrophyalkaline phosp
P03577670A0236 |105 108|ASActs
P03577670A0236 |149 156|sisters7A0472 
P03577670A0236 |88 103|arylsulfatase Aharmacologic as
P03577670A0236 |73 80|finding0000817
P03577670A0236 |110 116|levelsf neon
P03577670A0236 |129 140|fibroblastsirubinemia.
P03578948A0448 |51 57|volumes and 
P03578948A0448 |97 106|c X min-1gic aspec
P03578948A0448 |11 22|ventilation076 Compari
P03578948A0448 |80 84|rate1T00
P03578948A0448 |64 73|ml X kg-1otidase P
P03581160A0583 |171 179|controls] is sho
P03581160A0583 |90 122|artery pulse amplitude responsesrmacologic aspects of neonatal h
P03581160A0583 |151 162|TH subjects0472 When C
P03581160A0583 |20 41|heart rate reactivityrison with alkaline p
P03582149T0001 |117 133|Jiangxi Provincetal hyperbilirub
P03582149T0001 |39 52|valve disease phosphatases
P03582149T0001 |67 72|feverdase 
P03582149T0001 |98 113|school studentsic aspects of n
P03582149T0001 |19 25|surveyarison
P03582184A0448 |0 5|DrugsP0000
P03582184A0448 |31 36|phasealkal
P03582184A0448 |73 90|dosage adjustment00008171T0000 Pha
P03582184A0448 |40 49|reactionsphosphata
P03582982A0000 |51 54|RNAs a
P03582982A0000 |2 7|study00016
P03582982A0000 |17 22|genesmpari
P03582982A0000 |34 36|U4al
P03583001A0111 |168 173|fluidO3-] 
P03583001A0111 |177 187|vitrectomyhown as a 
P03583001A0111 |63 69|bubbleeotida
P03583001A0111 |46 59|gas injectionatases and 5-
P03583001A0111 |145 153|drainage08997A04
P03583001A0111 |22 31|procedureson with 
P03584426A0706 |17 28|enterotoxinmparison wi
P03584426A0706 |172 173|% 
P03584426A0706 |59 73|stool isolatesnucleotidase P
P03584426A0706 |77 78|%8
P03584426A0706 |104 112|isolatesects of 
P03584426A0706 |30 32|LT a
P03584426A0706 |115 116|%n
P03584426A0706 |234 242|materials are no
P03584426A0706 |143 151|activity0008997A
P03584426A0706 |201 208|strainsF PCO2 
P03584426A0706 |155 168|suckling mice When CSF [HC
P03586925T0001 |51 70|descriptor languages and 5-nucleotidas
P03586925T0001 |76 111|Roentgenology and Medical Radiology08171T0000 Pharmacologic aspects of
P03586925T0001 |128 144|Medinform systemlirubinemia. P00
P03586925T0001 |117 120|usetal
P03586925T0001 |0 11|DevelopmentP00001606T0
P03590911T0001 |50 67|light sensitivityes and 5-nucleoti
P03590911T0001 |24 34|dermatosisn with alk
P03591464A0840 |70 78|efficacye P00008
P03591464A0840 |82 110|calcium antagonist treatment0000 Pharmacologic aspects o
P03591464A0840 |46 62|disease activityatases and 5-nuc
P03591464A0840 |46 62|disease activityatases and 5-nuc
P03591464A0840 |70 78|efficacye P00008
P03591464A0840 |18 22|testpari
P03591464A0840 |82 110|calcium antagonist treatment0000 Pharmacologic aspects o
P03591464A0840 |18 22|testpari
P03592297A0138 |0 17|Dorsal foot TcpO2P00001606T0076 Co
P03592297A0138 |265 277|vasodilationcompared to 
P03592297A0138 |183 197|vasomotor tones a function o
P03592297A0138 |243 252|degrees Clonger di
P03592297A0138 |211 215|skin dat
P03592297A0138 |129 135|theoryirubin
P03592297A0138 |160 168|activity CSF [HC
P03592297A0138 |227 236|electrodeted rats 
P03592297A0138 |55 65|electrodesd 5-nucleo
P03592297A0138 |115 124|degrees Cnatal hyp
P03592297A0138 |294 303|degrees Cl have a 
P03592297A0138 |98 107|degrees Cic aspect
P03592297A0138 |202 207|TcpO2 PCO2
P03592297A0138 |313 325|vasodilationtly greater 
P03592297A0138 |71 91|surface temperatures P00008171T0000 Phar
P03592297A0138 |137 144|changesia. P00
P03592297A0679 |102 107|TcpO2spect
P03592297A0679 |196 205|degrees Cof CSF PC
P03592297A0679 |128 146|vasodilation indexlirubinemia. P0000
P03592297A0679 |89 100|cord traumaarmacologic
P03592297A0679 |62 66|toneleot
P03592297A0679 |13 14|n6
P03592297A0679 |3 11|subjects001606T0
P03592297A0679 |114 123|degrees Conatal hy
P03592297A0679 |25 37|quadriplegia with alkali
P03592297A0679 |168 172|mmHgO3-]
P03592297A0679 |184 189|TcpO2 a fu
P03595418A0688 |49 78|ornithine decarboxylase mRNAsses and 5-nucleotidase P00008
P03595418A0688 |90 100|% homologyrmacologic
P03595418A0688 |129 136|regionsirubine
P03595418A0688 |4 24|nucleotide sequences01606T0076 Compariso
P03597218A0901 |200 206|shiftsSF PCO
P03597218A0901 |31 36|alphaalkal
P03597218A0901 |210 222|plasma watere data of K-
P03597218A0901 |85 97|antithrombin0 Pharmacolo
P03597218A0901 |117 125|exercisetal hype
P03597218A0901 |262 272|inhibitorsen compare
P03597218A0901 |297 298|Pa
P03597218A0901 |58 79|alpha 2-macroglobulin-nucleotidase P000081
P03597218A0901 |244 252|quantityonger di
P03597218A0901 |160 174|concentrations CSF [HCO3-] i
P03597218A0901 |13 27|concentrations6 Comparison w
P03597218A0901 |47 56|inhibitortases and
P03597218A0901 |131 132|Pu
P03597218A0901 |230 238|exercise rats ar
P03597269A0409 |50 58|constantes and 5
P03597269A0409 |10 15|model0076 
P03597269A0409 |81 82|bT
P03597269A0409 |83 86|exp000
P03597269A0409 |66 73|form Laidase P
P03597269A0409 |33 44|exponentialkaline phos
P03597269A0409 |87 91|cVO2Phar
P03600633A1069 |0 4|CellP000
P03600705T0000 |0 6|TimingP00001
P03600705T0000 |10 18|symptoms0076 Com
P03600705T0000 |23 39|oocyst excretionon with alkaline
P03600705T0000 |49 66|cryptosporidiosisses and 5-nucleot
P03601275A0601 |153 158|ratio72 Wh
P03601275A0601 |162 185|dopamine/norepinephrineSF [HCO3-] is shown as 
P03601275A0601 |27 32|womenith a
P03601275A0601 |79 87|controls71T0000 
P03601275A0601 |210 216|groupse data
P03601275A0601 |6 23|dopamine infusion606T0076 Comparis
P03601275A0601 |112 127|plasma dopamineneonatal hyperb
P03601275A0601 |129 143|norepinephrineirubinemia. P0
P03601275A0601 |96 108|state levelsogic aspects
P03601275A0601 |55 63|syndromed 5-nucl
P03601533T0001 |68 76|childrenase P000
P03601533T0001 |11 21|importance076 Compar
P03601533T0001 |41 64|complement constituentshosphatases and 5-nucle
P03601533T0001 |93 104|thyroiditiscologic asp
P03602261A0238 |306 320|norepinephrinenificantly gre
P03602261A0238 |157 158|rh
P03602261A0238 |294 295|rl
P03602261A0238 |249 261|correlations displaced w
P03602261A0238 |147 155|dopamine997A0472
P03602261A0238 |270 279|melatoninred to co
P03602261A0238 |211 212|r 
P03602261A0238 |72 84|correlationsP00008171T00
P03602261A0238 |284 292|dopamines but st
P03602261A0238 |184 185|r 
P03602261A0238 |86 87|p 
P03602261A0238 |322 323|re
P03602261A0238 |353 354|r0
P03602261A0238 |36 45|conditionine phosp
P03602261A0238 |128 142|blood pressurelirubinemia. P
P03602261A0238 |198 209|epinephrine CSF PCO2 t
P03602261A0238 |337 351|growth hormone+/- 0.23 vs. P
P03602261A0238 |168 182|norepinephrineO3-] is shown 
P03605895A0888 |117 127|populationtal hyperb
P03605895A0888 |83 108|carbon monoxide poisoning000 Pharmacologic aspects
P03605895A0888 |6 14|patients606T0076
P03605895A0888 |60 61|%u
P03605895A0888 |20 44|carboxyhemoglobin levelsrison with alkaline phos
P03605895A0888 |48 54|excessases a
P03607109A0370 |66 75|pregnancyidase P00
P03607109A0370 |57 62|month5-nuc
P03607109A0370 |10 19|processes0076 Comp
P03607109A0370 |95 102|picturelogic a
P03607109A0370 |110 118|controlsf neonat
P03607961T0001 |70 87|diabetes mellituse P00008171T0000 
P03607961T0001 |13 19|action6 Comp
P03607961T0001 |57 66|mechanism5-nucleot
P03607961T0001 |33 47|zhuang qi gongkaline phospha
P03608916A0790 |136 144|increasemia. P00
P03608916A0790 |44 46|OHph
P03608916A0790 |31 37|plasmaalkali
P03608916A0790 |14 25|degrees HPT Comparison
P03608916A0790 |89 90|Pa
P03608916A0790 |47 55|2D leveltases an
P03608916A0790 |121 128|patternhyperbi
P03608916A0790 |82 87|cases0000 
P03608916A0790 |3 8|cases00160
P03608989A0668 |137 147|rod regionia. P00008
P03608989A0668 |111 129|filament formation neonatal hyperbil
P03608989A0668 |61 73|interactionscleotidase P
P03608989A0668 |5 11|region1606T0
P03608989A0668 |18 29|amino acidsparison wit
P03610663A0201 |50 61|calculationes and 5-nu
P03610663A0201 |132 141|precisionbinemia. 
P03610663A0201 |122 128|effectyperbi
P03610663A0201 |37 42|errorne ph
P03610663A0201 |196 202|statesof CSF
P03610663A0201 |26 33|sourceswith al
P03610663A0201 |5 13|approach1606T007
P03610663A0201 |65 85|nutrient utilizationtidase P00008171T000
P03610674T0000 |51 69|fiber zinc contents and 5-nucleotida
P03610674T0000 |77 92|rat hippocampus8171T0000 Pharm
P03610674T0000 |22 37|zinc deficiencyson with alkali
P03610674T0000 |4 10|effect01606T
P03612316A0102 |139 143|days. P0
P03612316A0102 |88 94|salineharmac
P03612316A0102 |30 34|diet alk
P03612316A0102 |7 11|rats06T0
P03612316A0102 |126 130|g BWbili
P03612316A0102 |40 51|low-proteinphosphatase
P03612316A0102 |64 68|dietotid
P03612316A0102 |98 107|thyroxineic aspect
P03612648A0085 |119 130|cardiolipinl hyperbili
P03612648A0085 |107 115|antibodys of neo
P03612648A0085 |79 98|thromboplastin time71T0000 Pharmacolog
P03612648A0085 |27 46|lupus anticoagulantith alkaline phosph
P03615550A0000 |141 144|FCNP00
P03615550A0000 |30 38|agonists alkalin
P03615550A0000 |54 73|antagonist naloxonend 5-nucleotidase P
P03615550A0000 |146 154|schedule8997A047
P03615550A0000 |91 95|ratsmaco
P03615550A0000 |4 11|effects01606T0
P03615550A0000 |115 139|fixed-consecutive-numbernatal hyperbilirubinemia
P03615550A1094 |20 27|effectsrison w
P03615550A1094 |44 50|U50488phatas
P03615550A1094 |31 39|morphinealkaline
P03615550A1094 |94 104|mg/kg doseologic asp
P03615550A1094 |108 116|naloxone of neon
P03615763A0170 |0 4|DataP000
P03615763A0170 |119 127|relationl hyperb
P03615763A0170 |255 262|smokingaced wh
P03615763A0170 |222 234|hypertensiondepleted rat
P03615763A0170 |155 162|measure When C
P03615763A0170 |25 30|women with
P03615763A0170 |264 270|angina compa
P03615763A0170 |214 220|incometa of 
P03615763A0170 |300 313|heart disease a significan
P03615763A0170 |209 212|sexhe 
P03615763A0170 |315 338|Type A behavior patterny greater slope (1.21 +
P03615763A0170 |166 181|atherosclerosisHCO3-] is shown
P03615763A0170 |14 17|men Co
P03615763A0170 |74 85|opportunity0008171T000
P03615763A0170 |344 353|hostility3 vs. P00
P03615763A0170 |51 62|angiographys and 5-nuc
P03615763A0170 |272 280|diabetesd to con
P03615763A0170 |236 253|serum cholesterolare no longer dis
P03615763A0170 |282 296|family historyols but still 
P03615763A0170 |204 207|ageCO2
P03615763A0170 |103 115|associationspects of neo
P03616174A1069 |99 109|blood flowc aspects 
P03616174A1069 |14 20|change Compa
P03616174A1069 |214 225|circulationta of K-dep
P03616174A1069 |160 167|tissues CSF [H
P03616174A1069 |133 143|blood flowinemia. P0
P03616174A1069 |24 35|temperaturen with alka
P03616174A1069 |54 63|degrees Cnd 5-nucl
P03616237T0001 |48 57|cisplatinases and 
P03616237T0001 |11 29|status epilepticus076 Comparison wit
P03616237T0001 |36 44|infusionine phos
P03618039A0126 |33 43|antibodieskaline pho
P03618039A0126 |120 151|catecholamine biotransformation hyperbilirubinemia. P00008997A
P03618039A0126 |106 116|disruptionts of neon
P03618039A0126 |62 75|noradrenalineleotidase P00
P03618039A0126 |47 57|adrenalinetases and 
P03618039A0126 |4 12|presence01606T00
P03618039A0126 |21 29|patientsison wit
P03619249A0428 |275 280|serumo con
P03619249A0428 |185 191|HBc Aga func
P03619249A0428 |261 267|non-Bchen co
P03619249A0428 |52 56|skin and
P03619249A0428 |112 118|HBs Agneonat
P03619249A0428 |296 298|Agha
P03619249A0428 |177 180|HBshow
P03619249A0428 |123 129|HBe Agperbil
P03619249A0428 |240 248|antibodyno longe
P03619249A0428 |61 66|livercleot
P03619249A0428 |199 204|liverCSF P
P03619249A0428 |131 139|anti-HBsubinemia
P03619249A0428 |107 110|HBVs o
P03619249A0428 |14 21|markers Compar
P03619249A0428 |74 82|patients0008171T
P03619249A0428 |45 50|serumhatas
P03619249A0428 |233 235|Agts
P03619249A0428 |96 105|hepatitisogic aspe
P03619249A0428 |282 287|non-Aols b
P03619249A0428 |306 311|livernific
P03619249A0428 |170 175|serum-] is
P03622423A0000 |0 6|GroupsP00001
P03622423A0000 |61 80|Hartley guinea pigscleotidase P0000817
P03622423A0000 |161 168|controlCSF [HC
P03622423A0000 |44 55|B6C3F1 micephatases an
P03622423A0000 |105 107|hrct
P03622423A0000 |116 130|concentrationsatal hyperbili
P03622423A0000 |26 33|Fischerwith al
P03622423A0000 |177 194|methyl isocyanatehown as a functio
P03622423A0000 |201 206|vaporF PCO
P03622423A0000 |196 199|MICof 
P03622423A0000 |10 14|male0076
P03622423A0000 |38 42|ratse ph
P03622423A0000 |170 173|ppm-] 
P03622571A0208 |0 18|Radionuclide studyP00001606T0076 Com
P03622571A0208 |65 77|degenerationtidase P0000
P03622571A0208 |38 44|biopsye phos
P03622571A0208 |81 91|myocardiumT0000 Phar
P03625688A0372 |0 14|ImmobilizationP00001606T0076
P03625688A0372 |93 100|methodscologic
P03625688A0372 |47 57|cuff slingtases and 
P03625688A0372 |22 30|fractureson with
P03625688A0372 |36 42|collarine ph
P03625762A0308 |0 10|ComparisonP00001606T
P03625762A0308 |93 98|serumcolog
P03625762A0308 |196 206|sub-groupsof CSF PCO
P03625762A0308 |133 142|phenytoininemia. P
P03625762A0308 |14 22|patients Compari
P03625762A0308 |33 42|phenytoinkaline ph
P03625762A0308 |173 183|differenceis shown a
P03625762A0308 |212 219|respectdata of
P03625762A0308 |223 234|vitamin B12epleted rat
P03625762A0308 |238 262|behaviour problem ratinge no longer displaced wh
P03626129T0001 |0 7|EffectsP000016
P03626129T0001 |60 66|embryoucleot
P03626129T0001 |24 34|laser beamn with alk
P03626129T0001 |42 47|cellsospha
P03627720A0196 |56 64|sac cyst 5-nucle
P03627720A0196 |30 38|features alkalin
P03628532A0000 |4 8|role0160
P03628532A0000 |27 43|taste perceptionith alkaline pho
P03628532A0000 |12 18|saliva76 Com
P03628532A0000 |78 89|experiments171T0000 Ph
P03628532A0000 |66 72|seriesidase 
P03628596A0000 |137 142|fluidia. P
P03628596A0000 |74 79|value00081
P03628596A0000 |31 39|patientsalkaline
P03628596A0000 |83 108|acid alpha 1-glycoprotein000 Pharmacologic aspects
P03628596A0000 |0 7|SamplesP000016
P03628713A0961 |85 89|days0 Ph
P03628713A0961 |38 51|86RbCl uptakee phosphatase
P03628713A0961 |9 20|experimentsT0076 Compa
P03628713A0961 |195 203|trap AIB of CSF 
P03628713A0961 |180 191|tumor cellsn as a func
P03628713A0961 |30 33|AIB al
P03628713A0961 |168 176|capacityO3-] is 
P03628713A0961 |141 155|radiation doseP00008997A0472
P03628713A0961 |55 67|36B-10 cellsd 5-nucleoti
P03628713A0961 |207 209|Rb t
P03628713A0961 |103 117|Gy irradiationpects of neona
P03628794A0648 |119 125|choicel hype
P03628794A0648 |42 49|diseaseosphata
P03628794A0648 |73 96|I-131 MIBG scintigraphy00008171T0000 Pharmacol
P03628794A0648 |104 115|examinationects of neo
P03628794A0648 |4 12|patients01606T00
P03628794A0648 |55 59|datad 5-
P03629973A0240 |0 2|W.P0
P03629974A1468 |0 10|ComparisonP00001606T
P03629974A1468 |106 131|Rift Valley fever virusests of neonatal hyperbilir
P03629974A1468 |62 77|Uukuniemi virusleotidase P0000
P03629974A1468 |240 243|endno 
P03629974A1468 |91 101|Punta Toromacologic 
P03629974A1468 |45 58|M RNA producthatases and 5
P03629974A1468 |202 210|proteins PCO2 th
P03629974A1468 |160 168|homology CSF [HC
P03629974A1468 |147 152|cases997A0
P03629974A1468 |251 260|precursorisplaced 
P03629974A1468 |18 37|amino acid sequenceparison with alkali
P03632739T0000 |0 22|Cyclosporine treatmentP00001606T0076 Compari
P03632739T0000 |39 51|polymyositis phosphatase
P03635597A0377 |137 144|mothersia. P00
P03635597A0377 |52 59|mothers and 5-
P03635597A0377 |150 151|PA
P03635597A0377 |3 11|addition001606T0
P03635597A0377 |38 43|scalee pho
P03635597A0377 |20 26|Cohlerrison 
P03635597A0377 |101 108|passiveaspects
P03635597A0377 |85 92|infants0 Pharm
P03637037T0000 |46 54|patientsatases a
P03637037T0000 |15 31|teaching bookletComparison with 
P03645733T0001 |0 15|HyperthyroidismP00001606T0076 
P03649340A1119 |35 45|precursorsline phosp
P03649340A1119 |73 79|choice000081
P03649340A1119 |164 180|splicing process [HCO3-] is show
P03649340A1119 |109 123|exon sequencesof neonatal hy
P03649340A1119 |83 95|splice sites000 Pharmaco
P03651330T0000 |24 31|lesionsn with 
P03651840A0266 |87 93|effectPharma
P03651840A0266 |125 140|tranylcyprominerbilirubinemia.
P03651840A0266 |67 72|MAO-Bdase 
P03651840A0266 |144 153|pargyline008997A04
P03651840A0266 |8 27|MAO inhibition data6T0076 Comparison w
P03651840A0266 |54 63|inhibitornd 5-nucl
P03651840A0266 |38 44|DPGPEAe phos
P03652083A0720 |80 89|crosslink1T0000 Ph
P03652083A0720 |13 19|region6 Comp
P03652083A0720 |27 46|vessel pyridinolineith alkaline phosph
P03652083A0720 |93 101|collagencologic 
P03653226A0833 |103 107|fatepect
P03653226A0833 |111 122|perhexiline neonatal h
P03653226A0833 |25 50|tissue-distribution study with alkaline phosphatas
P03658866A0081 |9 28|lupus erythematosusT0076 Comparison wi
P03659603A0797 |84 92|increase00 Pharm
P03659603A0797 |37 46|responsesne phosph
P03659603A0797 |7 14|evening06T0076
P03659603A0797 |62 65|CO2leo
P03659603A0797 |96 111|CO2 sensitivityogic aspects of
P03659603A0797 |20 29|amplituderison wit
P03659805A0404 |119 124|modell hyp
P03659805A0404 |93 100|methodscologic
P03659805A0404 |128 131|Coxlir
P03659805A0404 |16 28|significanceomparison wi
P03659805A0404 |36 53|prognosis factorsine phosphatases 
P03659805A0404 |142 146|help0000
P03659805A0404 |69 72|unise 
P03659805A0404 |153 165|IMB computer72 When CSF 
P03659994A0150 |170 186|signal intensity-] is shown as a
P03659994A0150 |202 208|images PCO2 
P03659994A0150 |128 130|T1li
P03659994A0150 |58 69|abnormality-nucleotida
P03659994A0150 |108 124|signal intensity of neonatal hyp
P03659994A0150 |29 38|injectionh alkalin
P03659994A0150 |140 146|images P0000
P03659994A0150 |96 104|increaseogic asp
P03659994A0150 |6 13|changes606T007
P03659994A0150 |21 25|siteison
P03659994A0150 |190 192|T2ct
P03663789A0568 |49 57|activityses and 
P03663789A0568 |61 65|RHALcleo
P03663789A0568 |6 13|results606T007
P03663789A0568 |146 149|HAL899
P03663789A0568 |124 134|conversionerbilirubi
P03663789A0568 |86 90|test Pha
P03663789A0568 |138 142|RHALa. P
P03664038A0000 |64 68|formotid
P03664038A0000 |109 112|GSSof 
P03664038A0000 |148 161|reliabilities97A0472 When 
P03664038A0000 |20 25|studyrison
P03664038A0000 |76 107|Gudjonsson Suggestibility Scale08171T0000 Pharmacologic aspect
P03664038A0000 |179 193|suggestibilitywn as a functi
P03664038A0000 |114 118|Formonat
P03664038A0000 |4 11|purpose01606T0
P03666957A0219 |34 45|conjunctivaaline phosp
P03666957A0219 |109 118|infectionof neonat
P03666957A0219 |167 171|catsCO3-
P03666957A0219 |149 158|infection7A0472 Wh
P03666957A0219 |58 63|weeks-nucl
P03666957A0219 |0 9|OrganismsP00001606
P03668003T0000 |48 60|skin lesionsases and 5-n
P03668003T0000 |24 34|microscopyn with alk
P03668396A0171 |86 103|convex polyhedron Pharmacologic as
P03668396A0171 |61 69|verticescleotida
P03668396A0171 |6 27|equilibrium solutions606T0076 Comparison w
P03668736A0177 |59 67|elementsnucleoti
P03668736A0177 |30 42|X-ray counts alkaline ph
P03668736A0177 |146 153|element8997A04
P03668736A0177 |124 129|counterbil
P03668736A0177 |12 22|deviations76 Compari
P03668736A0177 |77 83|series8171T0
P03668736A0177 |162 167|blockSF [H
P03672532A1111 |48 53|dosesases 
P03672532A1111 |26 33|effectswith al
P03673640A0533 |4 16|MAO subjects01606T0076 C
P03673640A0533 |94 97|KSPolo
P03673640A0533 |242 260|suicide attempters longer displaced 
P03673640A0533 |183 203|personality profiless a function of CSF 
P03673640A0533 |151 168|KSP Socialization0472 When CSF [HC
P03673640A0533 |225 236|psychopathsleted rats 
P03673640A0533 |44 50|scoresphatas
P03673640A0533 |118 130|Irritabilityal hyperbili
P03673640A0533 |54 71|KSP Impulsivenessnd 5-nucleotidase
P03673640A0533 |213 223|alcoholicsata of K-d
P03673640A0533 |26 33|patternwith al
P03673640A0533 |287 308|platelet MAO activityut still have a signi
P03673640A0533 |106 113|Anxietyts of n
P03673640A0533 |73 88|EPQ Neuroticism00008171T0000 P
P03673640A0533 |173 177|lineis s
P03673640A0533 |141 147|scoresP00008
P03673881A0000 |257 270|valve diseaseed when compa
P03673881A0000 |25 33|accuracy with al
P03673881A0000 |196 203|devicesof CSF 
P03673881A0000 |145 163|pressure gradients08997A0472 When CS
P03673881A0000 |95 99|HPRFlogi
P03673881A0000 |165 185|Doppler examinations[HCO3-] is shown as 
P03673881A0000 |48 52|waveases
P03673881A0000 |54 56|CWnd
P03673881A0000 |67 93|pulse repetition frequencydase P00008171T0000 Pharma
P03673881A0000 |101 108|Doppleraspects
P03673881A0000 |236 244|patientsare no l
P03676054A0865 |17 24|delta Vmpariso
P03676054A0865 |159 175|injector cannulan CSF [HCO3-] is
P03676054A0865 |41 43|VTho
P03676054A0865 |26 30|PaO2with
P03676054A0865 |12 15|Paw76 
P03676054A0865 |3 8|group00160
P03676054A0865 |99 100|Ec
P03676054A0865 |143 151|diameter0008997A
P03676054A0865 |86 94|pressure Pharmac
P03676054A0865 |32 36|Vinjlkal
P03676174A0730 |119 122|dayl h
P03676174A0730 |60 67|g DM/kgucleoti
P03676174A0730 |36 41|dietsine p
P03676174A0730 |128 134|calveslirubi
P03676174A0730 |106 107|%t
P03676174A0730 |3 9|calves001606
P03676174A0730 |69 81|milk intakesse P00008171
P03678269A0633 |0 5|TodayP0000
P03678269A0633 |165 170|years[HCO3
P03678269A0633 |38 63|plasma cholesterol levelse phosphatases and 5-nucl
P03678269A0633 |99 111|modificationc aspects of
P03678269A0633 |126 135|childhoodbilirubin
P03678269A0633 |18 23|doubtparis
P03678269A0633 |154 157|age2 W
P03678372A0170 |68 79|pellets/dayase P000081
P03678372A0170 |122 129|pelletsyperbil
P03678372A0170 |151 158|pellets0472 Wh
P03678372A0170 |54 59|weeksnd 5-
P03678372A0170 |20 27|pelletsrison w
P03678372A0170 |166 171|weeksHCO3-
P03678372A0170 |4 10|number01606T
P03678372A0170 |136 141|weeksmia. 
P03679407A0556 |186 200|bladder cancer function of C
P03679407A0556 |177 181|riskhown
P03679407A0556 |118 129|associational hyperbil
P03679407A0556 |6 13|results606T007
P03679407A0556 |27 46|N-nitroso compoundsith alkaline phosph
P03679407A0556 |85 92|bladder0 Pharm
P03679407A0556 |152 162|infections472 When C
P03679756A0830 |98 104|plexusic asp
P03679756A0830 |11 30|nerve fiber defects076 Comparison with
P03679756A0830 |61 73|architecturecleotidase P
P03679756A0830 |40 47|absencephospha
P03679756A0830 |126 135|terminalsbilirubin
P03680791A0230 |115 120|heartnatal
P03680791A0230 |61 67|heartscleoti
P03680791A0230 |15 20|gradeCompa
P03680791A0230 |43 47|sitespha
P03680791A0230 |97 102|sitesgic a
P03682805A0375 |119 123|daysl hy
P03682805A0375 |92 101|postshockacologic 
P03682805A0375 |125 142|skin lymph levelsrbilirubinemia. P
P03682805A0375 |160 163|Day CS
P03682805A0375 |39 67|coagulation protein activity phosphatases and 5-nucleoti
P03682805A0375 |82 90|preshock0000 Pha
P03682805A0375 |25 33|globulin with al
P03682805A0375 |16 23|albuminomparis
P03682805A0375 |0 12|Serum levelsP00001606T00
P03684378A0653 |85 86|r0
P03684378A0653 |43 54|correlationsphatases a
P03684378A0653 |214 218|milkta o
P03684378A0653 |147 151|role997A
P03684378A0653 |72 83|cholesterolP00008171T0
P03684378A0653 |14 18|milk Com
P03684378A0653 |188 198|vitamin K1unction of
P03684378A0653 |112 117|lipidneona
P03684378A0653 |58 68|vitamin K1-nucleotid
P03684378A0653 |156 167|cholesterolWhen CSF [H
P03684378A0653 |175 184|secretion shown as
P03684517A0462 |34 42|increasealine ph
P03684517A0462 |94 100|fibersologic
P03684517A0462 |46 55|stiffnessatases an
P03684517A0462 |74 82|decrease0008171T
P03684517A0462 |10 18|training0076 Com
P03684517A0462 |86 90|type Pha
P03685073A0200 |18 22|dosepari
P03685073A0200 |121 135|atropine doseshyperbilirubin
P03685073A0200 |91 102|combinationmacologic a
P03685073A0200 |44 74|acetylcholinesterase inhibitorphatases and 5-nucleotidase P0
P03685073A0200 |26 39|physostigminewith alkaline
P03685073A0200 |112 117|rangeneona
P03687078T0001 |0 10|ReferencesP00001606T
P03687078T0001 |94 99|lungsologi
P03687078T0001 |56 64|diseases 5-nucle
P03687078T0001 |28 35|fitnessth alka
P03687078T0001 |39 50|adolescents phosphatas
P03687078T0001 |84 89|tract00 Ph
P03687148T0187 |0 8|SalzburgP0000160
P03687148T0187 |15 24|SeptemberCompariso
P03687313A0000 |32 37|BAY mlkali
P03687313A0000 |75 85|volunteers008171T000
P03687313A0000 |122 132|conditionsyperbiliru
P03687313A0000 |47 52|BAY otases
P03687313A0000 |90 94|typermac
P03687313A0000 |8 30|glucosidase inhibitors6T0076 Comparison with
P03687313A0000 |98 107|diabeticsic aspect
P03688202A0377 |4 10|models01606T
P03688202A0377 |74 76|CN00
P03688202A0377 |43 53|boundariessphatases 
P03688202A0377 |66 69|PBBida
P03688301A0129 |17 22|casesmpari
P03688301A0129 |135 141|type Bemia. 
P03688301A0129 |61 69|invasioncleotida
P03688301A0129 |164 174|carcinomas [HCO3-] i
P03688301A0129 |99 104|casesc asp
P03688301A0129 |124 133|extensionerbilirub
P03688301A0129 |182 189|bladderas a fu
P03688301A0129 |38 44|spreade phos
P03688301A0129 |71 77|type A P0000
P03688676A0487 |65 71|resulttidase
P03688676A0487 |9 20|conversionsT0076 Compa
P03688676A0487 |27 29|mmit
P03688676A0487 |92 101|infectionacologic 
P03688676A0487 |82 88|spread0000 P
P03690262A0428 |70 75|trunke P00
P03690262A0428 |173 184|stimulationis shown as
P03690262A0428 |212 216|ramidata
P03690262A0428 |196 198|T4of
P03690262A0428 |192 194|T3io
P03690262A0428 |107 112|ramuss of 
P03690262A0428 |4 21|maximum amplitude01606T0076 Compar
P03690262A0428 |203 205|T5PC
P03690262A0428 |188 190|T1un
P03690262A0428 |98 100|T2ic
P03690262A0428 |32 41|responseslkaline p
P03691316A0560 |21 36|contact allergyison with alkal
P03691316A0560 |40 44|K-CGphos
P03692331A0000 |34 44|antagonistaline phos
P03692331A0000 |74 80|muscle000817
P03692331A0000 |98 103|womenic as
P03692331A0000 |4 10|effect01606T
P03692331A0000 |46 54|pindololatases a
P03692331A0000 |154 159|women2 Whe
P03692331A0000 |84 88|term00 P
P03693543A0405 |258 265|speciesd when 
P03693543A0405 |82 90|patterns0000 Pha
P03693543A0405 |230 236|number rats 
P03693543A0405 |198 213|N. brasiliensis CSF PCO2 the d
P03693543A0405 |271 281|separationed to cont
P03693543A0405 |240 245|peaksno lo
P03693543A0405 |121 134|elution timeshyperbilirubi
P03693543A0405 |39 58|Rhodococcus species phosphatases and 5
P03693543A0405 |294 300|general have
P03693543A0405 |173 192|N. otitidiscaviarumis shown as a funct
P03693543A0405 |140 148|patterns P000089
P03693543A0405 |152 171|Nocardia asteroides472 When CSF [HCO3-
P03694102A0000 |86 107|ECG computer programs Pharmacologic aspect
P03694102A0000 |72 81|referenceP00008171
P03694102A0000 |151 156|leads0472 
P03694102A0000 |4 15|development01606T0076 
P03694102A0000 |21 30|data baseison with
P03696899T0001 |0 32|Blood serum erythropoietin levelP00001606T0076 Comparison with a
P03696899T0001 |106 113|infantsts of n
P03696899T0001 |57 64|indices5-nucle
P03696899T0001 |76 86|adaptation08171T0000
P03697587T0000 |4 28|XXXXY chromosome anomaly01606T0076 Comparison wi
P03697587T0000 |41 48|varianthosphat
P03697587T0000 |52 63|Klinefelter and 5-nucl
P03697587T0000 |66 74|syndromeidase P0
P03697798T0001 |0 11|ContractionP00001606T0
P03697798T0001 |43 51|activitysphatase
P03697798T0001 |28 34|muscleth alk
P03697798T0001 |80 87|trachea1T0000 
P03697798T0001 |55 72|stretch receptorsd 5-nucleotidase 
P03697971A0311 |69 74|liverse P0
P03697971A0311 |62 67|bloodleoti
P03697971A0311 |23 54|glutathione peroxidase activityon with alkaline phosphatases a
P03697971A0311 |142 152|diet group00008997A0
P03697971A0311 |178 188|diet groupown as a f
P03697971A0311 |80 94|stomach mucosa1T0000 Pharmac
P03697971A0311 |4 18|selenium level01606T0076 Com
P03698251T0000 |0 15|Oxygen deliveryP00001606T0076 
P03698251T0000 |43 51|patientssphatase
P03698251T0000 |74 84|infarction0008171T00
P03698251T0000 |36 39|P50ine
P03698251T0000 |20 31|consumptionrison with 
P03700952A0273 |0 7|InfantsP000016
P03700952A0273 |109 127|laboratory settingof neonatal hyperb
P03700952A0273 |88 96|McDonaldharmacol
P03700952A0273 |47 55|acuitiestases an
P03700952A0273 |37 39|PLne
P03700952A0273 |16 22|sampleompari
P03701640A1178 |32 38|effectlkalin
P03701640A1178 |96 106|FR30 FI600ogic aspec
P03701640A1178 |6 13|results606T007
P03701640A1178 |46 53|isomersatases 
P03701640A1178 |174 182|ABSTRACTs shown 
P03701640A1178 |200 205|WORDSSF PC
P03703493A0654 |68 73|areasase P
P03703493A0654 |26 34|depositswith alk
P03703493A0654 |4 10|number01606T
P03703493A0654 |81 109|RPE-choriocapillaris complexT0000 Pharmacologic aspects 
P03704087A0394 |98 105|anxietyic aspe
P03704087A0394 |88 93|angerharma
P03704087A0394 |121 154|State-Trait Personality Inventoryhyperbilirubinemia. P00008997A047
P03704087A0394 |74 84|components0008171T00
P03704087A0394 |160 182|Anger Expression Scale CSF [HCO3-] is shown 
P03704087A0394 |192 218|State Anger Reaction Scaleion of CSF PCO2 the data o
P03704087A0394 |107 118|Spielbergers of neonat
P03704087A0394 |40 51|instrumentsphosphatase
P03704087A0394 |7 15|subjects06T0076 
P03709191A0125 |51 54|rats a
P03709191A0125 |74 80|volume000817
P03709191A0125 |37 43|cortexne pho
P03709191A0125 |95 104|asymmetrylogic asp
P03709191A0125 |148 155|neurons97A0472
P03709191A0125 |114 130|side differencesonatal hyperbili
P03709191A0125 |138 144|numbera. P00
P03709627A0247 |171 181|production] is shown
P03709627A0247 |4 12|subjects01606T00
P03709627A0247 |144 145|h0
P03709627A0247 |131 136|urineubine
P03709627A0247 |46 64|acetaminophen i.v.atases and 5-nucle
P03709627A0247 |149 154|order7A047
P03709627A0247 |87 93|plasmaPharma
P03709627A0247 |185 196|metabolitesa function 
P03709627A0247 |116 123|minutesatal hy
P03709627A0247 |35 42|mg doseline ph
P03709627A0247 |69 83|concentrationsse P00008171T0
P03710973A0817 |0 4|MeanP000
P03710973A0817 |14 30|skin temperature Comparison with
P03710973A0817 |105 116|acclimationcts of neon
P03710973A0817 |48 49|Pa
P03710973A0817 |157 176|Tre-to-Tsk gradienthen CSF [HCO3-] is 
P03710973A0817 |76 87|acclimation08171T0000 
P03710973A0817 |32 35|Tsklka
P03710973A0817 |139 140|P.
P03712050T0000 |0 28|Indium-111 leukocyte imagingP00001606T0076 Comparison wi
P03712050T0000 |57 66|arthritis5-nucleot
P03712050T0000 |32 40|patientslkaline 
P03712106A0000 |50 61|utilizationes and 5-nu
P03712106A0000 |14 42|L-methionine supplementation Comparison with alkaline ph
P03712106A0000 |67 86|soy protein isolatedase P00008171T0000
P03712106A0000 |88 91|SPIhar
P03712106A0000 |121 145|nitrogen balance studieshyperbilirubinemia. P000
P03712106A0000 |4 10|effect01606T
P03712106A0000 |155 160|women When
P03712153T0000 |17 54|Haemophilus influenzae type b diseasemparison with alkaline phosphatases a
P03712153T0000 |75 85|assessment008171T000
P03712153T0000 |89 101|risk factorsarmacologic 
P03713187A0691 |254 261|lesionslaced w
P03713187A0691 |9 16|lesionsT0076 C
P03713187A0691 |265 275|comparisoncompared t
P03713187A0691 |198 203|sites CSF 
P03713187A0691 |79 88|frequency71T0000 P
P03713187A0691 |166 176|carcinomasHCO3-] is 
P03713187A0691 |149 155|muscle7A0472
P03713187A0691 |39 53|lamina propria phosphatases 
P03713187A0691 |296 303|lesionshave a 
P03713187A0691 |92 102|occurrenceacologic a
P03713187A0691 |115 122|lesionsnatal h
P03713187A0691 |221 230|frequency-depleted
P03714348A0833 |85 92|portion0 Pharm
P03714348A0833 |125 134|NIH scorerbilirubi
P03714348A0833 |56 59|CIC 5-
P03714348A0833 |209 218|serum IgGhe data o
P03714348A0833 |32 43|correlationlkaline pho
P03714348A0833 |163 188|peak expiratory flow rateF [HCO3-] is shown as a f
P03714348A0833 |146 157|patient age8997A0472 W
P03714348A0833 |100 114|CIC population aspects of ne
P03714348A0833 |0 7|FactorsP000016
P03714473A0496 |0 9|InductionP00001606
P03714473A0496 |28 39|transcriptsth alkaline
P03714473A0496 |48 58|heat shockases and 5
P03717475A0208 |0 3|NewP00
P03717475A0208 |43 60|immunodiagnosticssphatases and 5-n
P03717475A0208 |130 141|infertilityrubinemia. 
P03717475A0208 |62 75|immunotherapyleotidase P00
P03717475A0208 |81 98|immunoprophylaxisT0000 Pharmacolog
P03717475A0208 |19 24|stepsariso
P03717936A0252 |0 8|AmikacinP0000160
P03717936A0252 |90 100|conditionsrmacologic
P03717936A0252 |65 79|aminoglycosidetidase P000081
P03717936A0252 |33 43|tobramycinkaline pho
P03720615A0434 |35 40|trendline 
P03720615A0434 |94 101|infantsologic 
P03720615A0434 |73 82|gestation00008171T
P03720615A0434 |57 68|birthweight5-nucleotid
P03720615A0434 |20 24|partriso
P03720966A1043 |18 35|acid N absorptionparison with alka
P03720966A1043 |47 55|N intaketases an
P03720966A1043 |42 43|%o
P03721594A0000 |0 8|AdhesionP0000160
P03721594A0000 |84 93|reduction00 Pharma
P03721594A0000 |145 161|fibrinogen level08997A0472 When 
P03721594A0000 |363 370|animals3 Flura
P03721594A0000 |312 333|Shwartzman phenomenonntly greater slope (1
P03721594A0000 |10 22|phagocytosis0076 Compari
P03721594A0000 |108 127|exudate neutrophils of neonatal hyperb
P03721594A0000 |47 56|migrationtases and
P03721594A0000 |132 143|macrophagesbinemia. P0
P03721594A0000 |258 269|New Zealandd when comp
P03721594A0000 |201 232|dilution protamine sulfate testF PCO2 the data of K-depleted r
P03721594A0000 |276 283|rabbits contro
P03721594A0000 |163 171|gelationF [HCO3-
P03721594A0000 |341 346|colon0.23 
P03721594A0000 |68 79|tetrazoliumase P000081
P03721666A0000 |0 6|NickelP00001
P03721666A0000 |44 62|contact dermatitisphatases and 5-nuc
P03721666A0000 |66 75|Singaporeidase P00
P03721666A0000 |112 123|patch testsneonatal hy
P03721666A0000 |26 31|causewith 
P03721666A0000 |99 108|reactionsc aspects
P03721666A0000 |140 141|% 
P03722016A0797 |34 35|Pa
P03722016A0797 |56 69|meal interval 5-nucleotida
P03722016A0797 |4 14|FFA levels01606T0076
P03728230A0104 |48 52|cystases
P03728230A0104 |15 23|hospitalComparis
P03732252A0556 |239 245|change no lo
P03732252A0556 |112 118|VO2maxneonat
P03732252A0556 |247 252|deltaer di
P03732252A0556 |63 66|VO2eot
P03732252A0556 |268 278|m run timepared to c
P03732252A0556 |120 121|r 
P03732252A0556 |350 360|m run timeP00010943A
P03732252A0556 |199 205|extentCSF PC
P03732252A0556 |229 235|amountd rats
P03732252A0556 |17 25|analysesmparison
P03732252A0556 |321 330|delta VO2ter slope
P03732252A0556 |82 83|P0
P03732252A0556 |71 72|r 
P03732252A0556 |168 186|m race performanceO3-] is shown as a
P03732252A0556 |338 343|delta/- 0.
P03732252A0556 |33 37|datakali
P03732252A0556 |306 317|combinationnificantly 
P03733563A0716 |65 78|serum dextrantidase P00008
P03733563A0716 |14 39|herd X period interaction Comparison with alkaline
P03733563A0716 |92 118|cholesterol concentrationsacologic aspects of neonat
P03733563A0716 |52 60|liver TG and 5-n
P03733563A0820 |0 8|Liver TGP0000160
P03733563A0820 |13 38|serum NEFA concentrations6 Comparison with alkalin
P03734641A0203 |70 75|forcee P00
P03734641A0203 |96 103|failureogic as
P03734641A0203 |22 27|nerveson w
P03734641A0203 |121 133|biomechanicshyperbilirub
P03734641A0203 |4 11|results01606T0
P03734641A0203 |32 37|rootslkali
P03736081A0465 |373 383|differenceam thus ap
P03736081A0465 |217 218|po
P03736081A0465 |430 431|p 
P03736081A0465 |416 428|% saturation drug with t
P03736081A0465 |94 99|indexologi
P03736081A0465 |245 249|risenger
P03736081A0465 |270 278|pressurered to c
P03736081A0465 |209 215|ml/minhe dat
P03736081A0465 |389 390|%t
P03736081A0465 |130 138|L/min/m2rubinemi
P03736081A0465 |407 408|% 
P03736081A0465 |44 48|torrphat
P03736081A0465 |74 82|decrease0008171T
P03736081A0465 |18 32|sinus pressureparison with a
P03736081A0465 |398 399|%e
P03736081A0465 |338 346|increase/- 0.23 
P03736081A0465 |140 141|p 
P03736081A0465 |312 313|pn
P03736081A0465 |237 241|ratere n
P03736081A0465 |169 179|blood flow3-] is sho
P03738919A0000 |0 14|CalcificationsP00001606T0076
P03738919A0000 |31 36|aortaalkal
P03738919A0000 |113 118|womeneonat
P03738919A0000 |147 157|tomography997A0472 W
P03738919A0000 |44 49|levelphata
P03738919A0000 |101 104|menasp
P03738919A0000 |84 93|vertebrae00 Pharma
P03743683A0000 |119 122|agel h
P03743683A0000 |31 40|autopsiesalkaline 
P03743683A0000 |110 115|yearsf neo
P03743683A0000 |59 66|plaquesnucleot
P03743683A0000 |89 100|individualsarmacologic
P03743683A0000 |5 11|series1606T0
P03743683A0000 |68 70|PPas
P03743702A0158 |68 73|intraase P
P03743702A0158 |157 163|nerveshen CS
P03743702A0158 |260 266|micronwhen c
P03743702A0158 |176 181|rangeshown
P03743702A0158 |245 247|SDng
P03743702A0158 |330 336|micron (1.21
P03743702A0158 |230 234|area rat
P03743702A0158 |44 51|neuronsphatase
P03743702A0158 |119 127|alveolarl hyperb
P03743702A0158 |16 17|%o
P03743702A0158 |87 97|structuresPharmacolo
P03743702A0158 |21 32|cell bodiesison with a
P03743702A0158 |202 208|micron PCO2 
P03743702A0158 |129 136|lingualirubine
P03743702A0158 |282 288|micronols bu
P03743702A0158 |236 240|meanare 
P03743702A0158 |304 310|micronignifi
P03744168T0001 |16 22|actionompari
P03744168T0001 |26 36|eptazocinewith alkal
P03744168T0001 |90 115|methano-1H-4-benz azoninermacologic aspects of neo
P03744168T0001 |76 87|hexahydro-108171T0000 
P03744168T0001 |38 41|l-1e p
P03745833A0258 |170 182|arborization-] is shown 
P03745833A0258 |31 38|voltagealkalin
P03745833A0258 |91 92|%m
P03745833A0258 |130 135|areasrubin
P03745833A0258 |80 88|pressure1T0000 P
P03745833A0258 |113 117|floweona
P03745833A0258 |124 125|%e
P03745833A0258 |63 67|falleoti
P03745833A0258 |243 253|cerebellumlonger dis
P03745833A0258 |200 209|formationSF PCO2 t
P03745833A0258 |143 148|brain00089
P03745833A0258 |230 238|cerebrum rats ar
P03745833A0258 |101 109|increaseaspects 
P03745833A0258 |3 13|transition001606T007
P03746053A0670 |0 8|FindingsP0000160
P03746053A0670 |44 46|N1ph
P03746053A0670 |120 126|column hyper
P03746053A0670 |65 69|areatida
P03746053A0670 |146 159|dorsal column8997A0472 Whe
P03746053A0670 |131 133|N2ub
P03746053A0670 |21 31|potentialsison with 
P03746053A0670 |86 92|matter Pharm
P03746107A0192 |50 57|tumourses and 
P03746107A0192 |29 33|centh al
P03746508A0390 |0 8|FailuresP0000160
P03746508A0390 |61 71|conditionscleotidase
P03746508A0390 |25 35|additivity with alka
P03746601A0299 |116 124|exposureatal hyp
P03746601A0299 |31 44|extravasationalkaline phos
P03746601A0299 |58 64|sepsis-nucle
P03746601A0299 |108 112|days of 
P03746601A0299 |72 80|hematomaP0000817
P03746601A0299 |93 98|totalcolog
P03746601A0299 |21 29|problemsison wit
P03746896A0890 |169 184|Type A behavior3-] is shown as
P03746896A0890 |27 34|resultsith alk
P03746896A0890 |88 93|meansharma
P03746896A0890 |61 72|possibilitycleotidase 
P03746896A0890 |127 141|susceptibilityilirubinemia. 
P03746896A0890 |158 165|effectsen CSF 
P03746906A0000 |34 45|reliabilityaline phosp
P03746906A0000 |25 30|types with
P03746906A0000 |4 11|studies01606T0
P03746906A0000 |53 84|student Jenkins Activity Surveyand 5-nucleotidase P00008171T00
P03746906A0000 |93 114|questionnaire measurecologic aspects of ne
P03746906A0000 |86 89|JAS Ph
P03746906A0000 |118 133|Type A behavioral hyperbilirub
P03747493A0000 |81 91|infectionsT0000 Phar
P03747493A0000 |15 23|patientsComparis
P03749226A0506 |51 64|response rates and 5-nucle
P03749226A0506 |120 125|doses hype
P03749226A0506 |5 18|phencyclidine1606T0076 Com
P03749226A0506 |87 93|errorsPharma
P03750700T0001 |0 13|PossibilitiesP00001606T007
P03750700T0001 |30 35|wrist alka
P03750700T0001 |42 56|endoprosthesisosphatases and
P03750700T0001 |18 25|outlookparison
P03751308T0001 |0 5|StudyP0000
P03751308T0001 |13 30|energy metabolism6 Comparison with
P03751308T0001 |60 71|hippocampusucleotidase
P03751308T0001 |38 55|sensomotor cortexe phosphatases an
P03751308T0001 |80 83|14C1T0
P03751308T0001 |144 150|states008997
P03751308T0001 |117 128|developmenttal hyperbi
P03751308T0001 |84 105|2-deoxyglucose method00 Pharmacologic aspe
P03753022A0000 |68 76|behaviorase P000
P03753022A0000 |44 49|termsphata
P03753022A0000 |10 18|lymphoma0076 Com
P03755623A1233 |84 94|properties00 Pharmac
P03755623A1233 |8 22|investigations6T0076 Compari
P03755623A1233 |98 102|DLISic a
P03755673A0054 |15 20|casesCompa
P03757294A0414 |69 74|casesse P0
P03757294A0414 |25 26|% 
P03757294A0414 |60 61|%u
P03757294A0414 |18 21|PLDpar
P03757294A0414 |80 84|APCD1T00
P03757294A0414 |7 12|cases06T00
P03757294A0414 |48 53|cystsases 
P03757294A0414 |100 111|liver cysts aspects of
P03758250A0000 |154 161|muscles2 When 
P03758250A0000 |125 137|EMG activityrbilirubinem
P03758250A0000 |29 38|movementsh alkalin
P03758250A0000 |58 67|extremity-nucleoti
P03758250A0000 |115 121|burstsnatal 
P03759330A0713 |85 87|G10 
P03759330A0713 |73 83|population00008171T0
P03759330A0713 |61 64|CHDcle
P03759330A0713 |4 15|combination01606T0076 
P03759330A0713 |124 139|trunk adiposityerbilirubinemia
P03759330A0713 |26 28|F2wi
P03759330A0713 |48 57|predictorases and 
P03759330A0713 |19 21|F1ar
P03759731A0992 |51 53|m2s 
P03759731A0992 |91 93|m2ma
P03759731A0992 |6 15|clearance606T0076 
P03759731A0992 |95 100|grouplogic
P03759731A0992 |79 87|ml/min/171T0000 
P03759731A0992 |39 47|ml/min/1 phospha
P03759731A0992 |55 60|groupd 5-n
P03761122T0000 |101 109|childrenaspects 
P03761122T0000 |59 67|behaviornucleoti
P03761122T0000 |95 97|IQlo
P03761122T0000 |78 89|achievement171T0000 Ph
P03761122T0000 |22 37|type A behaviorson with alkali
P03761122T0000 |4 13|relations01606T007
P03761523A0000 |51 57|sepsiss and 
P03761523A0000 |40 47|effectsphospha
P03761523A0000 |27 32|studyith a
P03761523A0000 |94 102|emulsionologic a
P03761523A0000 |65 76|utilizationtidase P000
P03761523A0000 |4 8|rats0160
P03763241A0446 |20 28|weaknessrison wi
P03763241A0446 |42 53|extremitiesosphatases 
P03763836T0001 |51 56|sitess and
P03763836T0001 |31 37|tumorsalkali
P03763836T0001 |11 27|electron therapy076 Comparison w
P03763836T0001 |0 7|ResultsP000016
P03765552A0582 |102 108|systemspects
P03765552A0582 |110 113|RESf n
P03765552A0582 |44 50|detailphatas
P03765552A0582 |115 135|Fc receptor blockadenatal hyperbilirubin
P03765552A0582 |4 13|mechanism01606T007
P03765552A0582 |140 151|suppression P00008997A
P03765552A0582 |168 186|antibody synthesisO3-] is shown as a
P03765552A0582 |17 23|actionmparis
P03765731A0918 |0 10|IncidencesP00001606T
P03765731A0918 |42 52|infarctionosphatases
P03765731A0918 |91 102|hypertrophymacologic a
P03765731A0918 |23 29|strokeon wit
P03765731A0918 |54 73|angina pectoris undnd 5-nucleotidase P
P03766370A0546 |76 78|LV08
P03766370A0546 |12 20|r values76 Compa
P03766370A0546 |41 51|deviationshosphatase
P03766370A0546 |111 118|regions neonat
P03768208A0879 |68 88|bone formation ratesase P00008171T0000 P
P03768208A0879 |6 13|results606T007
P03768208A0879 |131 135|massubin
P03768208A0879 |109 118|increasesof neonat
P03768208A0879 |55 64|increasesd 5-nucle
P03768208A0879 |35 44|pregnancyline phos
P03769224A0000 |69 72|SLEse 
P03769224A0000 |12 16|data76 C
P03769224A0000 |88 96|biopsiesharmacol
P03769224A0000 |25 33|patients with al
P03769224A0000 |48 67|Lupus Erythematosusases and 5-nucleoti
P03770143A1209 |32 40|disorderlkaline 
P03770143A1209 |78 93|fibre structure171T0000 Pharma
P03770143A1209 |60 66|defectucleot
P03770143A1209 |4 15|possibility01606T0076 
P03770143A1209 |141 148|lesionsP000089
P03771670T0058 |0 10|PreventionP00001606T
P03771670T0058 |41 52|combinationhosphatases
P03771670T0058 |16 36|heparin-antithrombinomparison with alkal
P03771703A0000 |100 108|analysis aspects
P03771703A0000 |14 38|trimethylsilylcarbamates Comparison with alkalin
P03771703A0000 |67 75|reagentsdase P00
P03771703A0000 |80 83|gas1T0
P03771749A0465 |0 4|MICsP000
P03771749A0465 |112 120|isolatesneonatal
P03771749A0465 |179 184|mediawn as
P03771749A0465 |24 30|agentsn with
P03771749A0465 |132 147|Candida speciesbinemia. P00008
P03771749A0465 |62 74|ketoconazoleleotidase P0
P03771749A0465 |206 239|microtiter broth dilution systems2 the data of K-depleted rats are
P03771749A0465 |80 94|amphotericin B1T0000 Pharmac
P03771749A0465 |188 201|agar dilutionunction of CS
P03771749A0465 |32 48|5-fluorocytosinelkaline phosphat
P03771749A0465 |50 60|miconazolees and 5-n
P03772471A1054 |170 174|case-] i
P03772471A1054 |28 36|Group IIth alkal
P03772471A1054 |14 22|patients Compari
P03772471A1054 |57 69|tumor biopsy5-nucleotida
P03772471A1054 |40 46|tumorsphosph
P03772471A1054 |133 137|timeinem
P03772471A1054 |141 148|surgeryP000089
P03772471A1054 |116 125|diagnosisatal hype
P03774111T0000 |0 8|EvidenceP0000160
P03774111T0000 |37 41|partne p
P03774111T0000 |52 60|response and 5-n
P03774111T0000 |21 30|addictionison with
P03776080A0400 |118 121|E/Sal 
P03776080A0400 |105 112|animalscts of 
P03776080A0400 |60 67|animalsucleoti
P03776080A0400 |126 138|CWE antigensbilirubinemi
P03776080A0400 |16 39|post-mortem examinationomparison with alkaline
P03776438A0000 |0 14|GlucocorticoidP00001606T0076
P03776438A0000 |149 151|Na7A
P03776438A0000 |88 96|contrastharmacol
P03776438A0000 |23 35|hypertensionon with alka
P03776438A0000 |126 138|hypertensionbilirubinemi
P03776438A0000 |72 78|sodiumP00008
P03776438A0000 |80 82|Na1T
P03776438A0000 |100 117|mineralocorticoid aspects of neona
P03776779A0238 |50 58|steroidses and 5
P03776779A0238 |26 35|treatmentwith alka
P03777398A0156 |0 8|ExamplesP0000160
P03777398A0156 |37 49|therapy unitne phosphata
P03777398A0156 |16 19|useomp
P03779182A0370 |71 76|cases P000
P03779182A0370 |12 24|drug problem76 Compariso
P03779182A0370 |61 67|numbercleoti
P03779182A0370 |112 118|deathsneonat
P03779182A0370 |80 91|hepatitis B1T0000 Phar
P03779205A0459 |170 175|years-] is
P03779205A0459 |11 19|patients076 Comp
P03779205A0459 |98 110|presentationic aspects o
P03779205A0459 |80 85|years1T000
P03779205A0459 |143 154|secondaries0008997A047
P03779205A0459 |117 125|patientstal hype
P03779205A0459 |50 57|diseasees and 
P03780248A0274 |137 140|IMVia.
P03780248A0274 |142 150|settings00008997
P03780248A0274 |43 50|infantssphatas
P03780248A0274 |9 20|differencesT0076 Compa
P03780248A0274 |124 135|ventilationerbilirubin
P03780248A0274 |183 190|infantss a fun
P03780248A0274 |241 243|pHo 
P03780248A0274 |216 224|hospital of K-de
P03780248A0274 |248 259|PCO2 valuesr displaced
P03780248A0274 |158 167|transporten CSF [H
P03780248A0274 |71 76|group P000
P03780248A0274 |86 93|changes Pharma
P03780371A0792 |51 58|intronss and 5
P03780371A0792 |11 20|sequences076 Compa
P03780371A0792 |104 109|exonsects 
P03780371A0792 |129 135|regionirubin
P03780371A0792 |66 91|cytochrome P-450PBc2 geneidase P00008171T0000 Phar
P03780704A0573 |118 126|increaseal hyper
P03780704A0573 |94 102|quotientologic a
P03780704A0573 |73 81|exercise00008171
P03780704A0573 |165 167|CW[H
P03780704A0573 |134 145|utilizationnemia. P000
P03780704A0573 |178 180|CCow
P03780704A0573 |8 16|increase6T0076 C
P03780704A0573 |147 149|WW99
P03780704A0573 |53 63|conditionsand 5-nucl
P03780704A0573 |20 33|serum ketonesrison with al
P03781000A0101 |141 148|diseaseP000089
P03781000A0101 |13 24|correlation6 Compariso
P03781000A0101 |97 105|implantsgic aspe
P03781000A0101 |67 75|activitydase P00
P03781000A0101 |127 133|stagesilirub
P03781000A0101 |5 9|lack1606
P03781000A0101 |39 49|variations phosphata
P03781948T0000 |34 41|hypoxiaaline p
P03781948T0000 |12 22|adaptation76 Compari
P03781948T0000 |53 57|ratsand 
P03783160A0285 |0 8|CompoundP0000160
P03783160A0285 |67 79|21-O-tigloyldase P000081
P03783160A0285 |95 108|R1-barrigenollogic aspects
P03783160A0285 |21 34|21-O-angeloylison with alk
P03783160A0285 |49 62|R1-barrigenolses and 5-nuc
P03785212A0091 |18 47|hamster S14 protein sequencesparison with alkaline phospha
P03785212A0091 |65 70|cDNAstidas
P03785212A1128 |0 13|RPS14 intronsP00001606T007
P03785212A1128 |35 48|Alu sequencesline phosphat
P03788231A0802 |221 231|ventricles-depleted 
P03788231A0802 |243 248|chestlonge
P03788231A0802 |61 69|survivalcleotida
P03788231A0802 |25 32|aspects with a
P03788231A0802 |111 123|implantation neonatal hy
P03788231A0802 |146 151|heart8997A
P03788231A0802 |76 82|animal08171T
P03788231A0802 |197 206|placementf CSF PCO
P03789052A0527 |205 212|effectsO2 the 
P03789052A0527 |15 30|tissue responseComparison with
P03789052A0527 |114 122|reactiononatal h
P03789052A0527 |94 102|chemicalologic a
P03789052A0527 |47 65|cyanoacrylate sitetases and 5-nucleo
P03789052A0527 |140 155|tissue adhesive P00008997A0472
P03789052A0527 |174 182|evidences shown 
P03791645A1124 |68 80|pathogenesisase P0000817
P03791645A1124 |43 55|relationshipsphatases an
P03791645A1124 |89 99|narcolepsyarmacologi
P03791645A1124 |105 108|OSActs
P03791645A1124 |6 14|findings606T0076
P03791645A1124 |84 87|MAL00 
P03795488A0487 |21 28|lesionsison wi
P03795488A0487 |120 121|% 
P03795488A0487 |88 90|PRha
P03795488A0487 |99 112|response ratec aspects of 
P03799323A0501 |119 131|sickle cellsl hyperbilir
P03799323A0501 |148 153|cells97A04
P03799323A0501 |30 45|flow conditions alkaline phosp
P03799323A0501 |15 25|hematocritComparison
P03799323A0501 |59 85|oxygen saturation decreasenucleotidase P00008171T000
P03799323A0501 |51 55|rates an
P03799790A0146 |102 107|lightspect
P03799790A0146 |159 166|marginsn CSF [
P03799790A0146 |128 138|light pipelirubinemi
P03799790A0146 |10 18|examiner0076 Com
P03799790A0146 |86 98|point source Pharmacolog
P03799790A0146 |48 51|eyease
P03799790A0146 |66 80|ophthalmoscopyidase P0000817
P03799790A0146 |185 191|plaquea func
P03799790A0146 |32 40|interiorlkaline 
P03802195A0481 |117 129|ToxR proteintal hyperbil
P03802195A0481 |172 179|portion is sho
P03802195A0481 |90 109|DNA binding domainsrmacologic aspects 
P03802195A0481 |75 85|activation008171T000
P03802195A0481 |6 21|fusion proteins606T0076 Compar
P03802195A0481 |39 51|localization phosphatase
P03805090A0645 |34 42|patientsaline ph
P03805090A0645 |181 186|years as a
P03805090A0645 |132 139|diseasebinemia
P03805090A0645 |16 24|analysesompariso
P03805090A0645 |156 160|centWhen
P03805090A0645 |263 280|Maffucci syndromen compared to con
P03805090A0645 |245 253|patientsnger dis
P03805090A0645 |89 103|chondrosarcomaarmacologic as
P03805090A0645 |66 75|incidenceidase P00
P03805090A0645 |232 241|certaintyats are n
P03805090A0645 |107 115|patientss of neo
P03805090A0645 |168 171|ageO3-
P03805090A0645 |207 219|degeneration the data of
P03806696A0000 |34 39|HgCl2aline
P03806696A0000 |265 270|trialcompa
P03806696A0000 |11 19|toxicity076 Comp
P03806696A0000 |123 140|Coturnix japonicaperbilirubinemia.
P03806696A0000 |63 79|mercury chlorideeotidase P000081
P03806696A0000 |107 121|Japanese quails of neonatal 
P03806696A0000 |165 170|hatch[HCO3
P03806696A0000 |233 243|injectionsts are no 
P03806696A0000 |97 105|Coturnixgic aspe
P03806696A0000 |179 188|adulthoodwn as a f
P03806696A0000 |54 61|CH3HgClnd 5-nu
P03806696A0000 |155 159|ages Whe
P03810361A0576 |187 194|Cushingfunctio
P03810361A0576 |109 135|plasma cortisol estimationof neonatal hyperbilirubin
P03810361A0576 |159 166|adjunctn CSF [
P03810361A0576 |197 205|syndromef CSF PC
P03810361A0576 |92 96|meanacol
P03810361A0576 |174 183|diagnosiss shown a
P03810361A0576 |33 59|plasma cortisol estimationkaline phosphatases and 5-
P03810867A0305 |64 65|%o
P03810867A0305 |104 121|Lederman-Gadebergects of neonatal 
P03810867A0305 |92 102|TNM systemacologic a
P03810867A0305 |123 135|Sisson-Jesseperbilirubin
P03810867A0305 |12 20|patients76 Compa
P03810867A0305 |42 49|lesionsosphata
P03810867A0305 |54 58|T3-4nd 5
P03811852A0109 |222 230|maturitydepleted
P03811852A0109 |111 128|magnesium sulfate neonatal hyperbi
P03811852A0109 |63 70|factorseotidas
P03811852A0109 |166 169|useHCO
P03811852A0109 |149 156|agonist7A0472 
P03811852A0109 |4 8|risk0160
P03811852A0109 |173 195|adrenocortico-steroidsis shown as a function
P03811852A0109 |96 107|combinationogic aspect
P03811852A0109 |81 90|gestationT0000 Pha
P03811852A0109 |19 32|complicationsarison with a
P03814493T0000 |17 27|interferonmparison w
P03814493T0000 |56 64|lymphoma 5-nucle
P03814493T0000 |36 41|gradeine p
P03814493T0000 |0 12|ChlorambucilP00001606T00
P03818467A0180 |0 8|SeleniumP0000160
P03818467A0180 |146 175|plasma glutathione peroxidase8997A0472 When CSF [HCO3-] is
P03818467A0180 |177 183|GSH-Pxhown a
P03818467A0180 |106 123|Se concentrationsts of neonatal hy
P03818467A0180 |28 33|IU/kgth al
P03818467A0180 |13 16|ppm6 C
P03818467A0180 |185 193|activitya functi
P03818467A0180 |22 23|Es
P03818467A0180 |58 62|diet-nuc
P03818467A0180 |35 50|supplementationline phosphatas
P03818467A0180 |84 101|plasma tocopherol00 Pharmacologic 
P03818866A0116 |68 82|blood pressurease P00008171T
P03818866A0116 |18 26|behaviorparison 
P03818866A0116 |94 95|po
P03818866A0116 |122 127|womenyperb
P03818866A0116 |84 85|r0
P03818866A0116 |0 15|Framingham TypeP00001606T0076 
P03820222A0203 |142 147|group00008
P03820222A0203 |27 34|potencyith alk
P03824908A0116 |68 78|nucleotidease P00008
P03824908A0116 |47 55|sequencetases an
P03824908A0116 |121 153|arginine amino acid substitutionhyperbilirubinemia. P00008997A04
P03824908A0116 |163 179|carboxy-terminusF [HCO3-] is sho
P03824908A0116 |111 117|lysine neona
P03824908A0116 |214 229|paramyxovirusesta of K-deplete
P03824908A0116 |200 210|M proteinsSF PCO2 th
P03824908A0116 |4 19|M reading frame01606T0076 Comp
P03826871A0000 |3 6|ion001
P03826871A0000 |52 58|Br ion and 5
P03826871A0000 |75 85|Greyhounds008171T000
P03826871A0000 |23 29|methodon wit
P03826871A0000 |66 71|urineidase
P03827071T0040 |0 2|IIP0
P03828209T0000 |46 56|intubationatases and
P03828209T0000 |15 22|changesCompari
P03828209T0000 |60 66|adultsucleot
P03828500T0001 |0 15|IntensificationP00001606T0076 
P03828500T0001 |72 83|blood serumP00008171T0
P03828500T0001 |36 56|contractile activityine phosphatases and
P03829848T0001 |0 19|AutotransplantationP00001606T0076 Comp
P03829848T0001 |74 78|vein0008
P03829848T0001 |43 48|valvesphat
P03829848T0001 |56 65|treatment 5-nucleo
P03829848T0001 |88 101|insufficiencyharmacologic 
P03829848T0001 |25 37|vein segment with alkali
P03829848T0001 |115 124|extremitynatal hyp
P03830147A0000 |408 412|OBLAhypn
P03830147A0000 |431 444|blood lactateoptimum dose 
P03830147A0000 |355 360|value0943A
P03830147A0000 |543 554|performance10 When ext
P03830147A0000 |298 301|VO2ve 
P03830147A0000 |366 368|mMlu
P03830147A0000 |418 421|VO2rug
P03830147A0000 |62 79|lactate thresholdleotidase P000081
P03830147A0000 |516 522|VO2maxocking
P03830147A0000 |103 130|blood lactate concentrationpects of neonatal hyperbili
P03830147A0000 |578 586|studentsapproxim
P03830147A0000 |168 173|levelO3-] 
P03830147A0000 |234 247|blood lactates are no long
P03830147A0000 |506 514|capacity45 Beta 
P03830147A0000 |311 338|blood lactate concentrationantly greater slope (1.21 +
P03830147A0000 |371 376|onsetepam 
P03830147A0000 |380 406|blood lactate accumulation appears to be an effectiv
P03830147A0000 |44 60|lactate increasephatases and 5-n
P03830147A0000 |289 292|LT2 st
P03830147A0000 |531 534|minP00
P03830147A0000 |81 83|LTT0
P03830147A0000 |260 262|mMwh
P03830147A0000 |212 215|LT1dat
P03830147A0000 |455 468|concentrationgeneral pract
P03830147A0000 |29 40|descriptorsh alkaline 
P03830147A0000 |90 93|VO2rma
P03830147A0000 |196 209|exercise testof CSF PCO2 t
P03830147A0000 |281 286|levelrols 
P03830147A0000 |221 224|VO2-de
P03830147A0000 |4 17|relationships01606T0076 Co
P03830147A0000 |474 476|mMin
P03830255A0074 |64 76|distributionotidase P000
P03835413A0616 |38 50|irradiationse phosphatas
P03835413A0616 |60 73|space flightsucleotidase P
P03835413A0616 |24 31|effectsn with 
P03835413A0616 |131 136|risksubine
P03835413A0616 |149 171|duration space flights7A0472 When CSF [HCO3-
P03835413A0616 |83 95|difficulties000 Pharmaco
P03835413A0616 |4 15|observation01606T0076 
P03836777T0001 |119 134|hepatitis stagel hyperbilirubi
P03836777T0001 |18 32|interpretationparison with a
P03836777T0001 |42 61|hepatitis B markersosphatases and 5-nu
P03836777T0001 |74 80|biopsy000817
P03836777T0001 |84 99|HBs Ag carriers00 Pharmacologi
P03836777T0001 |0 13|Practical useP00001606T007
P03836853A0204 |50 51|%e
P03836853A0204 |63 64|%e
P03836853A0204 |45 46|%h
P03836853A0204 |55 56|%d
P03836853A0204 |18 37|year survival ratesparison with alkali
P03836854T0000 |0 10|InhibitionP00001606T
P03836854T0000 |62 64|RPle
P03836854T0000 |106 111|agentts of
P03836854T0000 |42 51|secretionosphatase
P03837609T0000 |48 59|blood cellsases and 5-
P03837609T0000 |74 87|mononucleosis0008171T0000 
P03837609T0000 |22 27|studyson w
P03838797A0903 |0 17|Northern blottingP00001606T0076 Co
P03838797A0903 |72 79|absenceP000081
P03838797A0903 |150 154|riseA047
P03838797A0903 |110 114|mRNAf ne
P03838797A0903 |130 142|cDNA libraryrubinemia. P
P03838797A0903 |94 102|sequenceologic a
P03838797A0903 |39 54|oligonucleotide phosphatases a
P03838797A0903 |169 173|cDNA3-] 
P03840480T0000 |16 24|familiesompariso
P03840480T0000 |52 69|peptide sequences and 5-nucleotida
P03841627T0001 |0 12|ChemotherapyP00001606T00
P03841627T0001 |30 43|breast cancer alkaline pho
P03843496A0919 |155 169|extrapolations When CSF [HCO
P03843496A0919 |75 82|variety008171T
P03843496A0919 |10 15|years0076 
P03843496A0919 |132 139|abilitybinemia
P03843496A0919 |180 195|risk assessmentn as a function
P03843496A0919 |111 120|chemicals neonatal
P03843496A0919 |42 48|modelsosphat
P03843676A0381 |119 124|dosesl hyp
P03843676A0381 |107 111|risks of
P03843676A0381 |7 20|extrapolation06T0076 Compa
P03843676A0381 |52 56|data and
P03848527T0020 |85 90|years0 Pha
P03848527T0020 |60 68|industryucleotid
P03848527T0020 |46 56|counselloratases and
P03848527T0020 |0 13|Hisako MinowaP00001606T007
P03857577A0413 |137 147|HeLa cellsia. P00008
P03857577A0413 |52 65|DNA sequences and 5-nucleo
P03857577A0413 |177 190|transcriptionhown as a fun
P03857577A0413 |114 133|level transcriptiononatal hyperbilirub
P03857577A0413 |0 24|Deletion mapping studiesP00001606T0076 Compariso
P03860162A0000 |0 13|IncorporationP00001606T007
P03860162A0000 |56 59|AMB 5-
P03860162A0000 |148 155|potency97A0472
P03860162A0000 |107 120|drug toxicitys of neonatal
P03860162A0000 |129 133|lossirub
P03860162A0000 |40 54|amphotericin Bphosphatases a
P03860162A0000 |94 103|reductionologic as
P03860162A0000 |21 28|polyeneison wi
P03860162A0000 |64 73|liposomesotidase P
P03861687A0000 |100 109|treatment aspects 
P03861687A0000 |73 77|care0000
P03861687A0000 |150 158|responseA0472 Wh
P03861687A0000 |135 146|alterationsemia. P0000
P03861687A0000 |192 210|system stimulationion of CSF PCO2 th
P03861687A0000 |29 34|malesh alk
P03862898A0563 |0 9|Serum IgMP00001606
P03862898A0563 |130 149|risk classificationrubinemia. P0000899
P03862898A0563 |72 88|tumor E2R statusP00008171T0000 P
P03862898A0563 |14 32|IgE concentrations Comparison with a
P03862898A0563 |52 62|IgE scores and 5-nuc
P03862898A0563 |202 212|components PCO2 the 
P03863231A0530 |4 15|M-3 subtype01606T0076 
P03863231A0530 |42 48|factorosphat
P03863561A0405 |102 110|cricetusspects o
P03863561A0405 |62 72|differenceleotidase 
P03863561A0405 |135 142|respectemia. P
P03863561A0405 |151 161|clump size0472 When 
P03863561A0405 |112 113|pn
P03863561A0405 |11 16|Strep076 C
P03863561A0405 |88 100|mutans/Strepharmacologic
P03863561A0405 |81 86|StrepT0000
P03863561A0405 |18 30|mutans groupparison with
P03865743A0859 |34 40|LDL-C.aline 
P03865743A0859 |59 64|apo Bnucle
P03865743A0859 |42 48|HDL-C.osphat
P03865743A0859 |147 160|heart disease997A0472 When
P03865743A0859 |28 32|T.C.th a
P03865743A0859 |86 102|apo A-II/B ratio Pharmacologic a
P03865743A0859 |66 81|apo A-I/B ratioidase P00008171
P03865743A0859 |6 13|results606T007
P03865743A0859 |50 57|HDL2-C.es and 
P03865743A0859 |118 130|risk factorsal hyperbili
P03866085A0795 |32 55|suppository formulationlkaline phosphatases an
P03866085A0795 |109 117|childrenof neona
P03866085A0795 |194 199|drugsn of 
P03866085A0795 |164 172|children [HCO3-]
P03866085A0795 |59 64|CZX-Snucle
P03866085A0795 |95 105|infectionslogic aspe
P03866085A0795 |147 156|disorders997A0472 
P03866085A0795 |82 91|treatment0000 Phar
P03866085A0795 |218 226|vomitingf K-depl
P03869442A0223 |50 58|disorderes and 5
P03869442A0223 |96 108|hypertensionogic aspects
P03869442A0223 |67 80|abnormalitiesdase P0000817
P03869442A0223 |147 166|vasopressin therapy997A0472 When CSF [
P03869442A0223 |20 32|hypertensionrison with a
P03869442A0223 |3 11|addition001606T0
P03871298A0217 |152 164|localization472 When CSF
P03871298A0217 |7 22|photon emission06T0076 Compari
P03871298A0217 |131 138|promiseubinemi
P03871298A0217 |116 122|Tl-201atal h
P03871298A0217 |48 53|SPECTases 
P03871298A0217 |36 46|tomographyine phosph
P03871298A0217 |168 171|CADO3-
P03871298A0217 |87 101|representationPharmacologic 
P03871445T0000 |0 8|ComputerP0000160
P03871445T0000 |63 90|positron emission tomogramseotidase P00008171T0000 Pha
P03871445T0000 |42 50|analysisosphatas
P03871445T0000 |18 25|mappingparison
P03873141A0304 |102 110|patientsspects o
P03873141A0304 |134 135|%n
P03873141A0304 |6 23|patients vagotomy606T0076 Comparis
P03873141A0304 |77 84|therapy8171T00
P03873141A0304 |44 52|bleedingphatases
P03873141A0304 |86 92|Visick Pharm
P03873141A0304 |117 131|mortality ratetal hyperbilir
P03874921A0862 |205 213|drawbackO2 the d
P03874921A0862 |43 56|fertilizationsphatases and
P03874921A0862 |130 132|EPru
P03874921A0862 |62 70|deliveryleotidas
P03874921A0862 |143 154|anovulation0008997A047
P03874921A0862 |76 85|term baby08171T000
P03874921A0862 |111 122|feasibility neonatal h
P03874921A0862 |0 13|DocumentationP00001606T007
P03874921A0862 |171 180|procedure] is show
P03875231A0627 |239 252|abnormalities no longer di
P03875231A0627 |66 67|%i
P03875231A0627 |189 199|hemorrhagenction of 
P03875231A0627 |213 217|cystata 
P03875231A0627 |43 56|abnormalitiessphatases and
P03875231A0627 |121 136|differentiationhyperbilirubine
P03875231A0627 |175 183|hematoma shown a
P03875231A0627 |96 100|lossogic
P03875231A0627 |83 90|kidneys000 Pha
P03875231A0627 |0 3|MRIP00
P03875231A0627 |152 157|fluid472 W
P03877298A0718 |70 91|Cremophor formulatione P00008171T0000 Phar
P03877298A0718 |172 192|emulsion formulation is shown as a funct
P03877298A0718 |124 133|inductionerbilirub
P03877298A0718 |109 120|variabilityof neonatal
P03877298A0718 |4 11|results01606T0
P03877298A0718 |138 152|recovery timesa. P00008997A0
P03878585A0507 |100 101|r 
P03878585A0507 |114 136|oxygen flow rate indexonatal hyperbilirubine
P03878585A0507 |299 326|machine/min CPB time/m2 bsae a significantly greater s
P03878585A0507 |328 329|rp
P03878585A0507 |210 231|blood flow rate indexe data of K-depleted 
P03878585A0507 |43 46|CPBsph
P03878585A0507 |166 190|bubble oxygenator/m2 bsaHCO3-] is shown as a fun
P03878585A0507 |192 193|ri
P03878585A0507 |86 98|CPB duration Pharmacolog
P03878585A0507 |253 259|volumeplaced
P03878585A0507 |263 268|bloodn com
P03878585A0507 |36 39|endine
P03878585A0507 |66 77|correlationidase P0000
P03878585A0507 |233 237|BFRIts a
P03878585A0507 |4 28|percentage RFR reduction01606T0076 Comparison wi
P03878585A0507 |138 142|OFRIa. P
P03880838T0000 |51 75|captopril administrations and 5-nucleotidase P00
P03880838T0000 |30 44|artery lesions alkaline phos
P03880838T0000 |0 9|DiagnosisP00001606
P03881260A0000 |34 44|gene CP A1aline phos
P03881260A0000 |79 126|arginine pathway carbamoyl-phosphate synthetase71T0000 Pharmacologic aspects of neonatal hyper
P03881260A0000 |64 71|subunitotidase
P03881260A0000 |2 20|yeast DNA fragment0001606T0076 Compa
P03882029A0000 |16 21|studyompar
P03882029A0000 |72 89|granuloma complexP00008171T0000 Ph
P03882029A0000 |120 124|cats hyp
P03882029A0000 |45 49|catshata
P03882029A0000 |141 151|antibodiesP00008997A
P03882029A0000 |176 190|cat epitheliumshown as a fun
P03882029A0000 |106 107|%t
P03882029A0000 |155 165|components When CSF 
P03882029A0000 |32 36|seralkal
P03883052T0001 |3 9|memory001606
P03883052T0001 |13 32|Magdelaine Comtesse6 Comparison with a
P03883541A0200 |32 47|sucralfate costlkaline phospha
P03883541A0200 |4 27|H2 receptor antagonists01606T0076 Comparison w
P03883541A0200 |81 88|effectsT0000 P
P03885983A0254 |71 79|activity P000081
P03885983A0254 |46 55|Class IIIatases an
P03885983A0254 |27 36|indoraminith alkal
P03885983A0254 |6 13|results606T007
P03887085A0000 |103 111|mexaminepects of
P03887085A0000 |180 181|%n
P03887085A0000 |133 143|conditionsinemia. P0
P03887085A0000 |48 53|dosesases 
P03887085A0000 |116 121|mg/kgatal 
P03887085A0000 |212 219|F1 micedata of
P03887085A0000 |92 97|mg/kgacolo
P03887085A0000 |61 76|pharmaceuticalscleotidase P000
P03887085A0000 |200 211|CBA X C57BlSF PCO2 the
P03887085A0000 |7 15|efficacy06T0076 
P03887085A0000 |78 87|cystamine171T0000 
P03887085A0000 |168 175|hypoxiaO3-] is
P03887085A0000 |32 35|uselka
P03887769A0093 |4 8|Mean0160
P03887769A0093 |60 77|micrograms J/g Crucleotidase P0000
P03887769A0093 |27 44|micrograms J/g Crith alkaline phos
P03887769A0584 |49 59|populationses and 5-
P03887769A0584 |133 134|%i
P03887769A0584 |63 80|iodine deficiencyeotidase P0000817
P03887769A0584 |107 124|iodine deficiencys of neonatal hyp
P03887769A0584 |7 13|region06T007
P03887769A0584 |98 99|%i
P03888621A0185 |86 88|Da P
P03888621A0185 |75 79|mass0081
P03888621A0185 |15 19|geneComp
P03888621A0185 |46 61|protein productatases and 5-nu
P03888621A0185 |24 35|hydrogenasen with alka
P03890486A0000 |119 129|propensityl hyperbil
P03890486A0000 |150 160|malignancyA0472 When
P03890486A0000 |76 82|source08171T
P03890486A0000 |58 63|cause-nucl
P03890486A0000 |183 194|obstructions a functio
P03890486A0000 |20 42|lymph node enlargementrison with alkaline ph
P03890486A0000 |86 103|imaging confusion Pharmacologic as
P03891766A1473 |0 12|InterferenceP00001606T00
P03891766A1473 |29 35|factorh alka
P03891766A1473 |61 66|ELISAcleot
P03891766A1473 |110 126|latex adsorbentsf neonatal hyper
P03891766A1473 |80 84|sera1T00
P03894482A0549 |87 101|binding valuesPharmacologic 
P03894482A0549 |151 164|control serum0472 When CSF
P03894482A0549 |36 56|serum IgE antibodiesine phosphatases and
P03894482A0549 |126 131|timesbilir
P03894482A0549 |26 32|levelswith a
P03894482A0549 |4 12|patients01606T00
P03894482A0549 |70 85|soybean extracte P00008171T000
P03896991T0000 |0 14|New techniquesP00001606T0076
P03896991T0000 |52 60|products and 5-n
P03896991T0000 |23 40|mass spectrometryon with alkaline 
P03898382A0000 |18 37|subtraction imagingparison with alkali
P03898382A0000 |75 80|99mTc00817
P03898382A0000 |45 51|spleenhatase
P03898382A0000 |231 236|imagerats 
P03898382A0000 |162 181|radiogallium surveySF [HCO3-] is shown
P03898382A0000 |58 70|67Ga citrate-nucleotidas
P03898382A0000 |203 217|sulfur colloidPCO2 the data 
P03898382A0000 |114 121|lesionsonatal 
P03904004A1577 |238 242|124Ie no
P03904004A1577 |73 79|window000081
P03904004A1577 |31 37|energyalkali
P03904004A1577 |146 166|breakthrough signals8997A0472 When CSF [
P03904004A1577 |41 66|medium energy collimationhosphatases and 5-nucleot
P03904004A1577 |208 222|energy photonsthe data of K-
P03904004A1577 |100 118|keV 123I photopeak aspects of neonat
P03904004A1577 |184 199|Compton scatter a function of 
P03904952T0000 |0 17|Nursing educationP00001606T0076 Co
P03904952T0000 |23 42|computer obligationon with alkaline ph
P03908196T0000 |0 19|Shear bond strengthP00001606T0076 Comp
P03908196T0000 |54 67|glass ionomernd 5-nucleoti
P03908196T0000 |35 40|resinline 
P03908493A0246 |65 91|immunoperoxidase techniquetidase P00008171T0000 Phar
P03908493A0246 |14 23|advantage Comparis
P03908493A0246 |112 120|sectionsneonatal
P03908493A0246 |36 41|resinine p
P03910310A0666 |33 46|understandingkaline phosph
P03910310A0666 |7 14|concept06T0076
P03910310A0666 |54 63|pathologynd 5-nucl
P03911052A0909 |17 23|DIL-CPmparis
P03911052A0909 |97 99|CPgi
P03911052A0909 |126 138|CABG surgerybilirubinemi
P03911052A0909 |107 115|patientss of neo
P03911052A0909 |54 66|CABG surgerynd 5-nucleot
P03911052A0909 |48 50|CPas
P03911702A0530 |204 214|anesthesiaCO2 the da
P03911702A0530 |164 170|trauma [HCO3
P03911702A0530 |174 178|pigss sh
P03911702A0530 |40 45|modelphosp
P03911702A0530 |89 111|microembolism syndromearmacologic aspects of
P03911702A0530 |234 244|conditionss are no l
P03911702A0530 |49 54|meansses a
P03911965A0513 |143 161|Galphimia dilution0008997A0472 When 
P03911965A0513 |211 218|placebo data o
P03911965A0513 |120 132|Galphimia D6 hyperbiliru
P03911965A0513 |105 116|superioritycts of neon
P03911965A0513 |91 96|trendmacol
P03911965A0513 |24 36|significancen with alkal
P03912247A0282 |51 57|ml/mins and 
P03912247A0282 |183 192|flap agess a funct
P03912247A0282 |165 175|blood flow[HCO3-] is
P03912247A0282 |14 19|blood Comp
P03912247A0282 |59 81|collateral circulationnucleotidase P00008171
P03912247A0282 |27 31|flapith 
P03912247A0282 |89 93|flaparma
P03912247A0282 |4 10|volume01606T
P03912247A0282 |141 147|changeP00008
P03913522A0000 |17 24|aspectsmpariso
P03913522A0000 |5 10|aging1606T
P03913522A0000 |35 50|function changeline phosphatas
P03914875T0001 |5 16|candidiasis1606T0076 C
P03915540A0863 |119 123|gcn3l hy
P03915540A0863 |109 113|gcn2of n
P03915540A0863 |3 11|addition001606T0
P03915540A0863 |82 96|GCN4-lacZ mRNA0000 Pharmacol
P03915540A0863 |125 130|cellsrbili
P03915540A0863 |17 34|gcd1-101 mutationmparison with alk
P03915540A0863 |68 78|efficiencyase P00008
P03920700A0491 |99 104|alphac asp
P03920700A0491 |107 120|adrenoceptorss of neonatal
P03920700A0491 |53 67|responsivenessand 5-nucleoti
P03921727A0523 |34 42|apo A-IIaline ph
P03921727A0523 |22 29|apo A-Ison wit
P03921727A0523 |124 132|controlserbiliru
P03921727A0523 |46 56|abstainersatases and
P03921727A0523 |113 120|changeseonatal
P03921727A0523 |4 18|concentrations01606T0076 Com
P03922116A0197 |4 16|distribution01606T0076 C
P03922116A0197 |62 75|gamma-therapyleotidase P00
P03922116A0197 |88 93|groupharma
P03922116A0197 |150 155|casesA0472
P03922116A0197 |241 262|luc type installationo longer displaced wh
P03922116A0197 |105 118|gamma-therapycts of neonat
P03922116A0197 |293 298|casesll ha
P03922116A0197 |20 28|patientsrison wi
P03922116A0197 |80 85|cases1T000
P03922116A0197 |178 197|radiation treatmentown as a function o
P03922116A0197 |267 288|iliac lymphadenectomympared to controls bu
P03922116A0197 |130 145|lymphadenectomyrubinemia. P000
P03922116A0197 |227 231|beamted 
P03922116A0197 |45 50|grouphatas
P03922116A0197 |161 166|groupCSF [
P03922116A0197 |203 211|megavoltPCO2 the
P03923828A1031 |141 149|patientsP0000899
P03923828A1031 |110 118|reversalf neonat
P03923828A1031 |40 45|DDAVPphosp
P03923828A1031 |82 91|treatment0000 Phar
P03923828A1031 |178 188|proceduresown as a f
P03923828A1031 |129 137|bleedingirubinem
P03923828A1031 |20 35|cryoprecipitaterison with alka
P03923828A1031 |4 16|availability01606T0076 C
P03923976T0001 |0 16|ThrombophlebitisP00001606T0076 C
P03923976T0001 |31 39|embolismalkaline
P03923976T0001 |54 75|factor XII deficiencynd 5-nucleotidase P00
P03925712A0229 |51 66|enzyme activitys and 5-nucleot
P03925712A0229 |86 106|transport mechanisms Pharmacologic aspec
P03925712A0229 |24 30|mucosan with
P03925712A0229 |70 82|deficienciese P00008171T
P03925712A0229 |0 8|BiopsiesP0000160
P03928357A0340 |0 20|Laboratory pyrolysesP00001606T0076 Compa
P03928357A0340 |44 48|PCBsphat
P03928357A0340 |112 117|PCDFsneona
P03928357A0340 |76 81|PCDFs08171
P03928357A0340 |122 127|PCDDsyperb
P03928357A0340 |66 72|yieldsidase 
P03928357A0340 |87 101|chlorobenzenesPharmacologic 
P03928442A0463 |96 105|phage SPRogic aspe
P03928442A0463 |60 65|genesucleo
P03928442A0463 |148 172|modification specificity97A0472 When CSF [HCO3-]
P03928442A0463 |74 84|Mtase gene0008171T00
P03928442A0463 |14 20|degree Compa
P03928442A0463 |24 32|homologyn with a
P03928442A0463 |126 132|enzymebiliru
P03928678T0000 |38 49|contractione phosphata
P03928678T0000 |74 80|muscle000817
P03928678T0000 |53 61|urethraland 5-nu
P03929486A0309 |32 40|patientslkaline 
P03929486A0309 |191 198|placebotion of
P03929486A0309 |22 27|trialson w
P03929486A0309 |52 63|NYHA II-III and 5-nucl
P03929486A0309 |125 130|LV-EFrbili
P03929486A0309 |215 223|releasesa of K-d
P03929486A0309 |147 148|%9
P03929486A0309 |281 286|dosesrols 
P03929486A0309 |46 50|COCMatas
P03929486A0309 |106 123|ejection fractionts of neonatal hy
P03929486A0309 |226 228|SRet
P03929486A0309 |252 257|drugssplac
P03929486A0309 |184 188|mg/d a f
P03929486A0309 |234 241|mg/d SRs are n
P03929486A0309 |200 204|PLACSF P
P03929486A0309 |172 173|D 
P03929486A0309 |207 208|P 
P03929486A0309 |70 82|sinus rhythme P00008171T
P03929610A0268 |41 49|patientshosphata
P03929610A0268 |13 23|discomfort6 Comparis
P03930549A0209 |38 52|centrifugatione phosphatases
P03930549A0209 |74 85|supernatant0008171T000
P03930549A0209 |110 114|formf ne
P03930549A0209 |125 134|injectionrbilirubi
P03930549A0209 |62 66|acidleot
P03930549A0209 |144 161|gas chromatograph008997A0472 When 
P03930549A0209 |4 10|sample01606T
P03930894T0000 |0 7|ChangesP000016
P03930894T0000 |129 134|drugsirubi
P03930894T0000 |111 125|administration neonatal hype
P03930894T0000 |77 82|aging8171T
P03930894T0000 |60 64|lungucle
P03930894T0000 |140 148|vagotomy P000089
P03930894T0000 |66 73|effectsidase P
P03930894T0000 |22 45|acetylcholine receptorsson with alkaline phosp
P03930894T0000 |101 109|allergenaspects 
P03930894T0000 |84 94|inhalation00 Pharmac
P03931293A0437 |101 106|virusaspec
P03931293A0437 |77 93|thermoresistance8171T0000 Pharma
P03931293A0437 |24 35|stabilizersn with alka
P03931293A0437 |47 54|sucrosetases a
P03931293A0437 |7 14|absence06T0076
P03931293A0437 |113 122|% albumineonatal h
P03931797A0134 |49 52|menses
P03931797A0134 |12 22|prevalence76 Compari
P03931797A0134 |61 62|%c
P03931797A0134 |44 45|%p
P03931797A0134 |26 35|psoriasiswith alka
P03931797A0134 |66 71|womenidase
P03933232T0000 |65 82|animal morphologytidase P00008171T
P03933232T0000 |27 36|structureith alkal
P03933232T0000 |6 16|classicism606T0076 C
P03933232T0000 |53 61|pathwaysand 5-nu
P03933784A0420 |32 45|CSF prolactinlkaline phosp
P03933784A0420 |13 19|origin6 Comp
P03933784A0420 |24 28|rolen wi
P03934667A0124 |34 39|crsA1aline
P03934667A0124 |221 226|sigma-depl
P03934667A0124 |18 32|crsA mutationsparison with a
P03934667A0124 |113 139|B. subtilis plasmid pRPD11eonatal hyperbilirubinemia
P03934667A0124 |52 58|crsA47 and 5
P03934667A0124 |180 184|rpoDn as
P03934667A0124 |240 266|B. subtilis RNA polymeraseno longer displaced when c
P03934667A0124 |41 46|crsA4hosph
P03934667A0124 |192 200|sequenceion of C
P03934667A0124 |85 100|gene conversion0 Pharmacologic
P03934667A0124 |272 278|pUB110d to c
P03934667A0124 |230 236|factor rats 
P03934667A0124 |102 109|processspects 
P03935117T0000 |77 85|rat lung8171T000
P03935117T0000 |10 16|effect0076 C
P03935117T0000 |30 36|oedema alkal
P03935117T0000 |40 73|prostaglandin E2 pharmacokineticsphosphatases and 5-nucleotidase P
P03935375A0414 |85 97|biochemistry0 Pharmacolo
P03935375A0414 |229 241|degenerationd rats are n
P03935375A0414 |160 163|RPN CS
P03935375A0414 |193 200|changeson of C
P03935375A0414 |47 51|datatase
P03935375A0414 |134 143|pathologynemia. P0
P03935375A0414 |5 12|article1606T00
P03935375A0414 |212 216|risedata
P03935375A0414 |59 69|morphologynucleotida
P03935375A0414 |256 265|carcinomaced when 
P03935375A0414 |71 79|function P000081
P03935375A0414 |118 125|medullaal hype
P03935797A0183 |256 260|betaced 
P03935797A0183 |109 116|embryosof neon
P03935797A0183 |149 154|sites7A047
P03935797A0183 |216 223|regions of K-d
P03935797A0183 |4 8|data0160
P03935797A0183 |249 254|order disp
P03935797A0183 |272 277|deltad to 
P03935797A0183 |262 267|alphaen co
P03935797A0183 |70 88|sry messenger RNAse P00008171T0000 P
P03936828T0000 |25 36|risk factor with alkal
P03936828T0000 |40 55|B-cell lymphomaphosphatases an
P03936828T0000 |63 76|thyroid glandeotidase P000
P03936828T0000 |8 19|thyroiditis6T0076 Comp
P03937294A0404 |0 22|Plasma secretin levelsP00001606T0076 Compari
P03937294A0404 |111 115|hour neo
P03937294A0404 |92 97|delayacolo
P03937294A0404 |135 149|acid secretionemia. P0000899
P03937294A0404 |66 83|ethanol solutionsidase P00008171T0
P03937294A0404 |126 131|onsetbilir
P03937294A0404 |48 62|administrationases and 5-nuc
P03937481T0001 |85 97|preparations0 Pharmacolo
P03937481T0001 |62 66|acidleot
P03937481T0001 |19 32|microanalysisarison with a
P03939317A0352 |35 42|regionsline ph
P03939317A0352 |134 140|regionnemia.
P03939317A0352 |72 83|HS promoterP00008171T0
P03939317A0352 |91 115|soybean HS-protein genesmacologic aspects of neo
P03939317A0352 |2 12|comparison0001606T00
P03940426A0618 |0 7|ResultsP000016
P03940426A0618 |253 265|agar cultureplaced when 
P03940426A0618 |188 191|firunc
P03940426A0618 |126 131|testsbilir
P03940426A0618 |94 103|anaerobesologic as
P03940426A0618 |61 66|acidscleot
P03940426A0618 |211 231|genus identification data of K-depleted 
P03940426A0618 |166 176|morphologyHCO3-] is 
P03940426A0618 |16 21|studyompar
P03940426A0618 |49 54|chainses a
P03940426A0618 |36 39|GLCine
P03940426A0618 |79 90|agar medium71T0000 Pha
P03940426A0618 |140 144|Gram P00
P03940733A0755 |49 54|dosesses a
P03940733A0755 |11 17|method076 Co
P03940733A0755 |31 41|absorptionalkaline p
P03940733A0755 |120 130|assessment hyperbili
P03940733A0755 |58 67|vitamin A-nucleoti
P03940733A0755 |108 116|approach of neon
P03940733A0755 |138 151|malabsorptiona. P00008997A
P03940818T0000 |33 44|HBV carrierkaline phos
P03940818T0000 |10 21|hepatitis A0076 Compar
P03944212A0166 |17 21|rCBFmpar
P03944212A0166 |125 138|MCA territoryrbilirubinemi
P03944212A0166 |27 40|water contentith alkaline 
P03944212A0166 |65 71|mattertidase
P03944212A0166 |111 117|margin neona
P03944212A0166 |146 147|h8
P03944212A0166 |154 158|MCAO2 Wh
P03944212A0166 |87 91|corePhar
P03944212A0166 |0 15|Tissue pressureP00001606T0076 
P03944239A0780 |175 177|T3 s
P03944239A0780 |105 123|amiodarone therapycts of neonatal hy
P03944239A0780 |58 88|plasma thyroid hormone changes-nucleotidase P00008171T0000 P
P03944239A0780 |12 16|time76 C
P03944239A0780 |149 151|T47A
P03944239A0780 |140 142|T4 P
P03944239A0780 |22 30|patientsson with
P03944239A0780 |157 160|rT3hen
P03946125T0000 |0 4|DrugP000
P03946125T0000 |9 30|nutrient interactionsT0076 Comparison with
P03952387A0336 |114 118|HbO2onat
P03952387A0336 |41 48|tissueshosphat
P03952387A0336 |63 71|reactioneotidase
P03952387A0336 |8 19|compartment6T0076 Comp
P03952387A0336 |78 83|place171T0
P03952387A0336 |99 112|oxyhemoglobinc aspects of 
P03953361A0000 |274 278|dogsto c
P03953361A0000 |27 38|propranololith alkalin
P03953361A0000 |177 179|CKho
P03953361A0000 |151 158|calcium0472 Wh
P03953361A0000 |164 172|contents [HCO3-]
P03953361A0000 |16 23|effectsomparis
P03953361A0000 |184 195|lactic acid a function
P03953361A0000 |53 63|metabolismand 5-nucl
P03953361A0000 |92 111|serial measurementsacologic aspects of
P03953361A0000 |126 141|creatine kinasebilirubinemia. 
P03953361A0000 |228 239|sinus blooded rats are
P03953361A0000 |79 90|reperfusion71T0000 Pha
P03953361A0000 |160 162|Ca C
P03953361A0000 |143 145|CK00
P03953361A0000 |197 199|LAf 
P03953361A0000 |201 215|concentrationsF PCO2 the dat
P03956647A1063 |254 263|densitieslaced whe
P03956647A1063 |161 168|erosionCSF [HC
P03956647A1063 |95 111|charge densitieslogic aspects of
P03956647A1063 |270 285|microC/cm2 X phred to controls
P03956647A1063 |182 205|iridium microelectrodesas a function of CSF PC
P03956647A1063 |63 91|scanning electron microscopyeotidase P00008171T0000 Phar
P03956647A1063 |145 150|A/cm208997
P03956647A1063 |126 141|microC/cm2 X phbilirubinemia. 
P03956647A1063 |24 46|%Ir microelectrode tipn with alkaline phosph
P03956647A1063 |290 295|A/cm2still
P03956647A1063 |235 241|charge are n
P03956647A1063 |0 11|DissolutionP00001606T0
P03956695A0617 |0 18|Cortisol excretionP00001606T0076 Com
P03956695A0617 |123 129|stressperbil
P03956695A0617 |60 66|seasonucleot
P03956695A0617 |82 89|factors0000 Ph
P03959045A0000 |19 31|relationshiparison with 
P03959045A0000 |131 135|MCATubin
P03959045A0000 |60 75|coaching courseucleotidase P00
P03959045A0000 |99 129|Medical College Admission Testc aspects of neonatal hyperbil
P03959045A0000 |80 91|performance1T0000 Phar
P03959045A0000 |4 11|studies01606T0
P03963860A0137 |2 7|total00016
P03963860A0137 |14 22|patients Compari
P03963860A0137 |60 64|MY-1ucle
P03963860A0137 |89 94|grouparmac
P03964489A1195 |22 26|PaO2son 
P03964489A1195 |28 32|NADHth a
P03964489A1195 |8 18|% decrease6T0076 Com
P03964855A0254 |0 11|AngiographyP00001606T0
P03964855A0254 |40 50|rCBF studyphosphatas
P03964855A0254 |99 109|angiogramsc aspects 
P03964855A0254 |59 65|degreenucleo
P03964855A0254 |69 78|vasospasmse P00008
P03965012A0163 |118 132|heart diseasesal hyperbiliru
P03965012A0163 |174 190|reference cohorts shown as a fun
P03965012A0163 |194 212|paper mill workersn of CSF PCO2 the 
P03965012A0163 |134 145|ICD A83-A84nemia. P000
P03965012A0163 |32 37|yearslkali
P03965012A0163 |4 11|results01606T0
P03965012A0163 |84 93|mortality00 Pharma
P03966687A0000 |119 126|Allergyl hyper
P03966687A0000 |14 20|impact Compa
P03966687A0000 |130 135|yearsrubin
P03966687A0000 |109 115|Annalsof neo
P03966687A0000 |79 85|Taylor71T000
P03966687A0000 |101 105|dataaspe
P03966687A0000 |24 40|childhood asthman with alkaline 
P03966687A0000 |69 74|Vancese P0
P03967144T0001 |0 13|HypersplenismP00001606T007
P03970191A0275 |103 105|DCpe
P03970191A0275 |11 19|activity076 Comp
P03970191A0275 |60 78|electrocorticogramucleotidase P00008
P03970191A0275 |113 122|potentialeonatal h
P03970191A0275 |128 133|siteslirub
P03970191A0275 |80 84|ECoG1T00
P03972038A0000 |19 31|trajectoriesarison with 
P03972038A0000 |135 144|techniqueemia. P00
P03972038A0000 |91 94|STRmac
P03972038A0000 |39 57|commissural fibers phosphatases and 
P03972038A0000 |83 89|region000 Ph
P03972038A0000 |4 14|topography01606T0076
P03972185A0137 |171 176|times] is 
P03972185A0137 |45 63|insulin deficiencyhatases and 5-nucl
P03972185A0137 |111 124|hyperglycemia neonatal hyp
P03972185A0137 |92 100|controlsacologic
P03972185A0137 |13 18|state6 Com
P03972185A0137 |65 78|plasma levelstidase P00008
P03972185A0137 |142 163|plasma glucose levels00008997A0472 When CS
P03972185A0137 |87 88|%P
P03974790A0053 |49 62|brain infarctses and 5-nuc
P03974790A0053 |12 23|CT findings76 Comparis
P03974790A0053 |77 83|tumour8171T0
P03976323A0821 |34 55|blood pressure changealine phosphatases an
P03976323A0821 |60 70|SCR-changeucleotidas
P03976323A0821 |14 25|correlation Comparison
P03977577T0000 |0 24|Shoulder forearm supportP00001606T0076 Compariso
P03977577T0000 |42 50|shoulderosphatas
P03977603A0326 |0 9|PiroxicamP00001606
P03977603A0326 |27 36|incidenceith alkal
P03977603A0326 |48 54|ulcersases a
P03977603A0326 |80 92|indomethacin1T0000 Pharm
P03977603A0326 |71 76|doses P000
P03978045A0857 |174 182|syndromes shown 
P03978045A0857 |121 136|hyperreactivityhyperbilirubine
P03978045A0857 |220 226|originK-depl
P03978045A0857 |81 87|stagesT0000 
P03978045A0857 |263 274|alterationsn compared 
P03978045A0857 |54 56|0Tnd
P03978045A0857 |58 60|0N-n
P03978045A0857 |91 94|VWFmac
P03978045A0857 |46 52|stagesatases
P03978045A0857 |164 171|Raynaud [HCO3-
P03978045A0857 |152 159|vessels472 Whe
P03978045A0857 |96 102|stagesogic a
P03978045A0857 |196 205|disordersof CSF PC
P03978045A0857 |6 14|findings606T0076
P03978132A0108 |119 138|distribution curvesl hyperbilirubinemi
P03978132A0108 |62 87|photoacceptor sensitivityleotidase P00008171T0000 
P03978132A0108 |42 60|surface reflectionosphatases and 5-n
P03978132A0108 |25 40|source emission with alkaline 
P03978132A0108 |3 17|MCCP functions001606T0076 Co
P03979084A1019 |68 77|functionsase P0000
P03979084A1019 |108 112|IBPK of 
P03979084A1019 |33 35|hrka
P03979084A1019 |9 16|kidneysT0076 C
P03979084A1019 |100 104|IMPK asp
P03980386A0000 |186 191|lambs func
P03980386A0000 |61 69|infusioncleotida
P03980386A0000 |14 21|effects Compar
P03980386A0000 |46 57|angiotensinatases and 
P03980386A0000 |107 111|lungs of
P03980386A0000 |73 85|distribution00008171T000
P03980386A0000 |125 139|perfusion lungrbilirubinemia
P03980386A0000 |89 99|blood flowarmacologi
P03980386A0000 |34 41|hypoxiaaline p
P03981421A0246 |2 11|flow rate0001606T0
P03981421A0246 |94 101|resultsologic 
P03981421A0246 |26 30|mL/hwith
P03981421A0246 |65 71|volumetidase
P03981421A0246 |77 79|mL81
P03981421A0246 |55 63|receptord 5-nucl
P03981640A0168 |58 63|mRNAs-nucl
P03981640A0168 |27 31|endsith 
P03981952T0000 |71 81|estimation P00008171
P03981952T0000 |91 102|salt intakemacologic a
P03981952T0000 |45 63|chloride titratorshatases and 5-nucl
P03981952T0000 |4 12|efficacy01606T00
P03982288T0000 |0 15|Doctor BerglundP00001606T0076 
P03982288T0000 |22 29|membersson wit
P03982288T0000 |33 47|union pitfallskaline phospha
P03984683A0000 |35 45|hemiplegialine phosp
P03984683A0000 |95 110|stroke patientslogic aspects o
P03984683A0000 |66 76|spasticityidase P000
P03984683A0000 |6 16|appearance606T0076 C
P03984683A0000 |20 31|hemiparesisrison with 
P03985849A0221 |50 56|groupses and
P03985849A0221 |181 187|nature as a 
P03985849A0221 |134 142|patientsnemia. P
P03985849A0221 |60 68|patientsucleotid
P03985849A0221 |196 205|conditionof CSF PC
P03985849A0221 |78 89|development171T0000 Ph
P03985849A0221 |148 152|CVID97A0
P03985849A0221 |101 115|rhinosinusitisaspects of neo
P03985849A0221 |230 244|IgA deficiency rats are no l
P03985849A0221 |16 30|rhinosinusitisomparison with
P03987818A0440 |6 10|data606T
P03987818A0440 |24 28|AP-An wi
P03987818A0440 |62 72|managementleotidase 
P03987818A0440 |76 89|heart failure08171T0000 Ph
P03987857A0733 |34 46|floor regionaline phosph
P03987857A0733 |12 19|muscles76 Comp
P03987857A0733 |143 154|stimulation0008997A047
P03987857A0733 |130 139|intensityrubinemia
P03987857A0733 |103 112|mass unitpects of 
P03988001A0227 |26 53|rat blood chloroform levelswith alkaline phosphatases 
P03988001A0227 |104 108|ClO2ects
P03988001A0227 |89 98|treatmentarmacolog
P03989827T0000 |17 35|lactase phenotypesmparison with alka
P03989827T0000 |39 54|Aymara children phosphatases a
P03989827T0000 |4 13|frequency01606T007
P03992022A0330 |0 10|ActivitiesP00001606T
P03992022A0330 |95 112|TMO N-demethylaselogic aspects of 
P03992022A0330 |78 89|aminopyrine171T0000 Ph
P03992022A0330 |62 69|enzymesleotida
P03992022A0330 |180 184|ratsn as
P03992022A0330 |164 176|pretreatment [HCO3-] is 
P03992022A0330 |190 200|cimetidinection of C
P03992022A0330 |217 221|ratsof K
P03992022A0330 |22 32|cytochromeson with a
P03992022A0330 |256 273|enzyme activitiesced when compared
P03992022A0330 |117 145|aniline hydroxylase activitytal hyperbilirubinemia. P000
P03992022A0330 |238 248|ranitidinee no longe
P03995513T0000 |0 11|DoxorubicinP00001606T0
P03995513T0000 |106 120|leiomyosarcomats of neonatal
P03995513T0000 |13 24|dacarbazine6 Compariso
P03995513T0000 |43 59|cyclophosphamidesphatases and 5-
P03995513T0000 |26 37|vincristinewith alkali
P03995513T0000 |67 76|treatmentdase P000
P03997467A0000 |4 10|effect01606T
P03997467A0000 |76 84|patients08171T00
P03997467A0000 |25 44|antagonist naloxone with alkaline phos
P03997467A0000 |99 107|ischemiac aspect
P03998071T0000 |51 57|levelss and 
P03998071T0000 |61 71|vitamin K1cleotidase
P03998071T0000 |75 87|osteoporosis008171T0000 
P03998071T0000 |0 25|Electrochemical detectionP00001606T0076 Comparison
P03998813A0406 |113 121|ontogenyeonatal 
P03998813A0406 |15 26|experimentsComparison 
P03998813A0406 |149 154|mouse7A047
P03998813A0406 |47 51|roletase
P03998813A0406 |75 82|pattern008171T
P03998813A0406 |93 101|activitycologic 
P03998813A0406 |125 141|frequency tuningrbilirubinemia. 
P03998813A0406 |172 178|system is sh
P03999219A0463 |0 14|UltrastructureP00001606T0076
P03999219A0463 |149 158|chromatin7A0472 Wh
P03999219A0463 |211 226|alum irrigation data of K-depl
P03999219A0463 |22 27|tumorson w
P03999219A0463 |89 94|weeksarmac
P03999219A0463 |63 72|resectioneotidase 
P03999219A0463 |33 40|patientkaline 
P03999219A0463 |191 198|changestion of
P03999219A0463 |101 116|alum irrigationaspects of neon
P04000347A0442 |168 171|BENO3-
P04000347A0442 |181 192|individuals as a funct
P04000347A0442 |22 30|criteriason with
P04000347A0442 |94 100|groupsologic
P04000347A0442 |133 136|BENine
P04000347A0442 |65 72|personstidase 
P04000347A0442 |218 225|diseasef K-dep
P04000347A0442 |201 206|signsF PCO
P04001413A0093 |142 147|scans00008
P04001413A0093 |90 97|patientrmacolo
P04001413A0093 |109 123|breath-holdingof neonatal hy
P04001413A0093 |47 53|devicetases 
P04001413A0093 |9 16|purposeT0076 C
P04001490T0001 |50 64|Endocrinopathyes and 5-nucle
P04001490T0001 |77 86|component8171T0000
P04001490T0001 |88 92|Skinharm
P04001490T0001 |20 34|Polyneuropathyrison with alk
P04001490T0001 |36 48|Organomegalyine phosphat
P04001490T0001 |4 18|POEMS syndrome01606T0076 Com
P04002131A0506 |119 120|Pl
P04002131A0506 |40 48|increasephosphat
P04002131A0506 |90 106|hyperheparinuriarmacologic aspec
P04002131A0506 |52 65|GAG secretion and 5-nucleo
P04002131A0506 |9 26|disease remissionT0076 Comparison 
P04002131A0506 |71 76|urine P000
P04002667A0181 |19 27|patientsarison w
P04002667A0181 |89 91|cmar
P04002667A0181 |112 124|localizationneonatal hyp
P04002667A0181 |178 193|lung parenchymaown as a functi
P04002667A0181 |128 139|lung tissuelirubinemia
P04002667A0181 |38 45|resultse phosp
P04002667A0181 |65 80|tumor diameterstidase P0000817
P04002667A0181 |156 165|cm tumorsWhen CSF 
P04004168A0000 |119 127|syndromel hyperb
P04004168A0000 |28 34|anemiath alk
P04004168A0000 |45 81|triosephosphate isomerase deficiencyhatases and 5-nucleotidase P00008171
P04004168A0000 |176 187|tract signsshown as a 
P04004168A0000 |147 156|movements997A0472 
P04004168A0000 |193 201|evidenceon of CS
P04004168A0000 |158 164|tremoren CSF
P04004168A0000 |212 236|motor neuron involvementdata of K-depleted rats 
P04004168A0000 |4 12|siblings01606T00
P04005190A1288 |4 11|extract01606T0
P04005190A1288 |28 39|PCA contentth alkaline
P04011338A0620 |136 137|rm
P04011338A0620 |242 246|loss lon
P04011338A0620 |209 216|placebohe data
P04011338A0620 |48 59|steatorrheaases and 5-
P04011338A0620 |250 257|taurinedisplac
P04011338A0620 |80 84|loss1T00
P04011338A0620 |112 124|relationshipneonatal hyp
P04011338A0620 |146 147|p8
P04011338A0620 |176 182|extentshown 
P04011338A0620 |196 205|acid lossof CSF PC
P04011338A0620 |10 18|patients0076 Com
P04011338A0620 |225 233|decreaseleted ra
P04011338A0620 |64 72|decreaseotidase 
P04011338A0620 |98 99|%i
P04011338A0620 |38 44|degreee phos
P04011466T0000 |71 75|data P00
P04011466T0000 |20 27|infantsrison w
P04011466T0000 |7 16|diameters06T0076 C
P04011466T0000 |38 46|childrene phosph
P04013576A0981 |184 193|exception a functi
P04013576A0981 |133 145|distributioninemia. P000
P04013576A0981 |12 25|investigation76 Comparison
P04013576A0981 |149 159|Leptospira7A0472 Whe
P04013576A0981 |88 112|Leptospira phospholipidsharmacologic aspects of 
P04013576A0981 |228 240|carbon atomsed rats are 
P04013576A0981 |215 219|acida of
P04013576A0981 |79 84|acids71T00
P04013576A0981 |48 60|distributionases and 5-n
P04013576A0981 |262 275|phospholipidsen compared t
P04013576A0981 |168 174|lipidsO3-] i
P04013604A0412 |108 131|slow-release tablet use of neonatal hyperbilir
P04013604A0412 |15 24|frequencyCompariso
P04013604A0412 |73 78|cases00008
P04013604A0412 |91 104|patient-yearsmacologic asp
P04013604A0412 |46 56|ulcerationatases and
P04014833A0400 |0 14|HydrocortisoneP00001606T0076
P04014833A0400 |146 154|mitogens8997A047
P04014833A0400 |131 143|concanavalinubinemia. P0
P04014833A0400 |108 126|phytohemagglutinin of neonatal hyper
P04014833A0400 |64 72|responseotidase 
P04014833A0400 |22 33|lymphopeniason with al
P04014833A0400 |87 104|blood lymphocytesPharmacologic asp
P04014861A0000 |153 161|catalase72 When 
P04014861A0000 |123 143|superoxide dismutaseperbilirubinemia. P0
P04014861A0000 |12 23|feasibility76 Comparis
P04014861A0000 |91 97|effectmacolo
P04014861A0000 |80 85|lungs1T000
P04014861A0000 |66 72|agentsidase 
P04014861A0000 |145 148|SOD089
P04014861A0000 |33 42|liposomeskaline ph
P04014861A0000 |175 190|oxygen toxicity shown as a fun
P04014861A0000 |206 210|rats2 th
P04015988T0000 |0 20|Marrow cell necrosisP00001606T0076 Compa
P04015988T0000 |57 67|starvation5-nucleoti
P04015988T0000 |24 40|anorexia nervosan with alkaline 
P04017295A0139 |55 63|dialysesd 5-nucl
P04017295A0139 |76 84|patients08171T00
P04017295A0139 |28 35|heparinth alka
P04017295A0139 |4 14|comparison01606T0076
P04018444A0000 |17 21|acidmpar
P04018444A0000 |97 100|mangic
P04018444A0000 |56 60|urso 5-n
P04018444A0000 |71 93|cholesterol gallstones P00008171T0000 Pharma
P04018444A0000 |23 28|chenoon wi
P04018444A0000 |50 54|acides a
P04019066A0000 |204 208|ratsCO2 
P04019066A0000 |90 93|MRFrma
P04019066A0000 |15 31|field potentialsComparison with 
P04019066A0000 |177 186|halothanehown as a
P04019066A0000 |79 88|formation71T0000 P
P04019066A0000 |132 138|cortexbinemi
P04019066A0000 |140 143|SCX P0
P04019066A0000 |110 112|CGf 
P04019066A0000 |168 173|dosesO3-] 
P04021281T0001 |0 14|UltrastructureP00001606T0076
P04021281T0001 |89 97|trainingarmacolo
P04021281T0001 |62 69|infarctleotida
P04021281T0001 |22 34|heart muscleson with alk
P04021305A0530 |16 32|desympathizationomparison with a
P04021305A0530 |122 130|dopamineyperbili
P04021305A0530 |104 117|noradrenalineects of neona
P04021305A0530 |61 77|hyper-reactivitycleotidase P0000
P04021305A0530 |90 100|pacemakersrmacologic
P04021305A0530 |208 213|cellsthe d
P04021305A0530 |148 155|changes97A0472
P04021305A0530 |46 57|developmentatases and 
P04021305A0530 |217 231|catecholaminesof K-depleted 
P04021305A0530 |163 173|regulationF [HCO3-] 
P04021305A0530 |190 198|activityction of
P04021431A0000 |0 4|OODGP000
P04021431A0000 |242 252|dilatation longer di
P04021431A0000 |150 156|systemA0472 
P04021431A0000 |104 119|blood pressuresects of neonata
P04021431A0000 |60 72|pulse curvesucleotidase 
P04021431A0000 |39 49|assessment phosphata
P04021431A0000 |260 266|pupilswhen c
P04021431A0000 |228 232|eyesed r
P04021431A0000 |87 100|determinationPharmacologic
P04021431A0000 |21 27|methodison w
P04021431A0000 |187 202|blood pressuresfunction of CSF
P04021437A0000 |70 76|numbere P000
P04021437A0000 |6 16|infections606T0076 C
P04021437A0000 |58 64|agents-nucle
P04021437A0000 |86 102|ear dysfunctions Pharmacologic a
P04024685A0650 |304 307|RBVign
P04024685A0650 |164 166|cm [
P04024685A0650 |86 91|mVolt Phar
P04024685A0650 |223 225|mlep
P04024685A0650 |262 264|mlen
P04024685A0650 |55 63|increased 5-nucl
P04024685A0650 |114 115|po
P04024685A0650 |23 33|parameterson with al
P04024685A0650 |188 190|HVun
P04024685A0650 |246 249|EDVger
P04024685A0650 |280 282|mltr
P04024685A0650 |227 228|pt
P04024685A0650 |133 136|EDDine
P04024685A0650 |107 112|mVolts of 
P04024685A0650 |319 321|mlea
P04024685A0650 |284 285|ps
P04024685A0650 |65 73|RS indextidase P
P04024685A0650 |336 338|ml +
P04024685A0650 |9 10|%T
P04024685A0650 |340 341|p 
P04024685A0650 |168 169|pO
P04024685A0650 |204 206|mlCO
P04025178A0126 |138 143|ml/m2a. P0
P04025178A0126 |60 68|decreaseucleotid
P04025178A0126 |94 96|LVol
P04025178A0126 |31 36|deathalkal
P04025178A0126 |14 22|analyses Compari
P04025178A0126 |126 130|EDVIbili
P04025178A0126 |147 148|%9
P04025178A0126 |112 124|volume indexneonatal hyp
P04025179A0955 |32 41|variableslkaline p
P04025179A0955 |11 17|adults076 Co
P04025179A0955 |3 8|group00160
P04026903A0512 |186 192|barium funct
P04026903A0512 |96 106|rat uterusogic aspec
P04026903A0512 |37 46|stimulantne phosph
P04026903A0512 |76 92|guinea pig ileum08171T0000 Pharm
P04026903A0512 |160 173|acetylcholine CSF [HCO3-] 
P04026903A0512 |194 213|5-hydroxytryptaminen of CSF PCO2 the d
P04026903A0512 |175 184|histamine shown as
P04026903A0512 |248 254|mannerr disp
P04026903A0512 |218 227|carbacholf K-deple
P04026903A0512 |136 148|contractionsmia. P000089
P04026903A0512 |50 65|relaxant effectes and 5-nucleo
P04026903A0512 |0 11|PolysorbateP00001606T0
P04026972T0000 |11 36|alcohol reaction profiles076 Comparison with alkal
P04027182T0000 |0 8|VitiligoP0000160
P04027182T0000 |12 29|diabetes mellitus76 Comparison wit
P04028871A0133 |71 84|blister fluid P00008171T00
P04028871A0133 |45 50|serumhatas
P04028871A0133 |125 139|mg lymecyclinerbilirubinemia
P04028871A0133 |147 161|mg doxycycline997A0472 When 
P04028871A0133 |29 41|tetracyclineh alkaline p
P04028871A0133 |173 176|dayis 
P04028871A0133 |112 117|dosesneona
P04028871A0133 |4 20|pharmacokinetics01606T0076 Compa
P04031488A1091 |17 28|correlationmparison wi
P04031488A1091 |7 13|degree06T007
P04031488A1091 |57 67|conception5-nucleoti
P04031488A1091 |36 41|senseine p
P04031488A1091 |112 121|syndromesneonatal 
P04031488A1091 |71 89|brain localization P00008171T0000 Ph
P04032268A0358 |32 34|nmlk
P04032268A0358 |150 154|drugA047
P04032268A0358 |9 20|UV detectorT0076 Compa
P04032268A0358 |108 124|Ag/AgCl/3 M NaCl of neonatal hyp
P04032268A0358 |62 70|detectorleotidas
P04032268A0358 |80 89|potential1T0000 Ph
P04032268A0358 |58 60|EC-n
P04032268A0358 |98 99|Vi
P04032349A0000 |32 42|occlusionslkaline ph
P04032349A0000 |192 207|Lys Plasminogenion of CSF PCO2
P04032349A0000 |52 68|graft thromboses and 5-nucleotid
P04032349A0000 |108 116|ischemia of neon
P04032349A0000 |147 154|therapy997A047
P04032349A0000 |156 165|UrokinaseWhen CSF 
P04032349A0000 |173 186|units/kg/houris shown as a
P04032349A0000 |3 11|patients001606T0
P04032716A0299 |259 266|oviduct when c
P04032716A0299 |132 146|transfer ratiobinemia. P0000
P04032716A0299 |107 112|bloods of 
P04032716A0299 |54 61|tissuesnd 5-nu
P04032716A0299 |229 239|myometriumd rats are
P04032716A0299 |214 220|cervixta of 
P04032716A0299 |32 36|druglkal
P04032716A0299 |4 24|mean transfer ratios01606T0076 Compariso
P04032716A0299 |69 82|concentrationse P00008171T
P04033402A1112 |143 171|triglyceride lipase activity0008997A0472 When CSF [HCO3-
P04033402A1112 |28 36|hormonesth alkal
P04033402A1112 |44 74|HDL-cholesterol concentrationsphatases and 5-nucleotidase P0
P04033402A1112 |83 111|HDL2-cholesterol subfraction000 Pharmacologic aspects of
P04034220A0205 |169 178|treatment3-] is sh
P04034220A0205 |62 72|ampicillinleotidase 
P04034220A0205 |194 210|tract infectionsn of CSF PCO2 th
P04034220A0205 |214 222|childrenta of K-
P04034220A0205 |94 107|H. influenzaeologic aspect
P04034220A0205 |132 150|tolerance Cefaclorbinemia. P00008997
P04034220A0205 |20 28|spectrumrison wi
P04034220A0205 |83 90|strains000 Pha
P04034220A0205 |32 40|activitylkaline 
P04034666T0000 |6 30|extremity weight bearing606T0076 Comparison with
P04034666T0000 |107 118|hemiparesiss of neonat
P04034666T0000 |45 64|standing conditionshatases and 5-nucle
P04034666T0000 |93 101|patientscologic 
P04036838A0918 |170 171|r-
P04036838A0918 |46 50|dataatas
P04036838A0918 |181 182|p 
P04036838A0918 |6 12|factor606T00
P04036838A0918 |97 98|pg
P04036838A0918 |148 168|pressure differences97A0472 When CSF [HC
P04036838A0918 |70 85|pressure ratiose P00008171T000
P04036838A0918 |55 60|RV/LVd 5-n
P04036838A0918 |87 88|rP
P04037809A0964 |46 53|KW-2083atases 
P04037809A0964 |28 42|dose schedulesth alkaline ph
P04038454A0984 |118 133|micrograms dl-1al hyperbilirub
P04038454A0984 |25 45|plasma retinol level with alkaline phosp
P04038454A0984 |244 259|micrograms dl-1onger displaced
P04038454A0984 |265 272|mg dl-1compare
P04038454A0984 |49 60|conjunctionses and 5-n
P04038454A0984 |66 69|RBPida
P04038454A0984 |231 237|cancerrats a
P04038454A0984 |169 186|cancer recurrence3-] is shown as a
P04038454A0984 |139 146|mg dl-1. P0000
P04038454A0984 |103 111|patientspects of
P04038702A0768 |4 11|results01606T0
P04038702A0768 |223 234|disruptionsepleted rat
P04038702A0768 |54 63|tetheringnd 5-nucl
P04038702A0768 |114 124|experienceonatal hyp
P04038702A0768 |320 343|cortisol concentrationsater slope (1.21 +/- 0.
P04038702A0768 |93 100|penningcologic
P04038702A0768 |210 216|estruse data
P04038702A0768 |152 158|rhythm472 Wh
P04038702A0768 |258 262|typed wh
P04038702A0768 |288 294|stallst stil
P04038702A0768 |162 170|cortisolSF [HCO3
P04038702A0768 |347 352|giltss. P0
P04038702A0768 |42 50|responseosphatas
P04039109A0139 |86 93|vessels Pharma
P04039109A0139 |132 139|secondsbinemia
P04039109A0139 |31 36|poweralkal
P04039109A0139 |145 158|power density08997A0472 Wh
P04039109A0139 |108 110|mm o
P04039109A0139 |167 172|W/cm2CO3-]
P04039109A0139 |5 10|laser1606T
P04039109A0139 |52 64|fluid medium and 5-nucle
P04039109A0139 |114 122|diameteronatal h
P04039307A0613 |35 36|Pl
P04039307A0613 |10 22|progesterone0076 Compari
P04039307A0613 |3 4|d0
P04039307A0613 |93 109|treatment groupscologic aspects 
P04039307A0613 |71 78|heifers P00008
P04039439A0000 |68 70|Mnas
P04039439A0000 |120 124|diet hyp
P04039439A0000 |145 149|days0899
P04039439A0000 |104 109|Mn3O4ects 
P04039439A0000 |14 19|quail Comp
P04039439A0000 |87 102|manganese oxidePharmacologic a
P04039439A0000 |53 66|ppm manganeseand 5-nucleot
P04039439A0000 |153 156|age72 
P04039439A0842 |99 106|rodentsc aspec
P04039439A0842 |5 10|study1606T
P04039439A0842 |79 93|Mn3O4 exposure71T0000 Pharma
P04039439A0842 |39 44|quail phos
P04039525A0475 |0 6|PlasmaP00001
P04039525A0475 |79 82|DDP71T
P04039525A0475 |11 41|bladder platinum concentration076 Comparison with alkaline p
P04039525A0475 |195 200|order of C
P04039525A0475 |111 122|examination neonatal h
P04039525A0475 |161 176|blood chemistryCSF [HCO3-] is 
P04039525A0475 |124 134|urinalysiserbilirubi
P04039525A0475 |213 221|toxicityata of K
P04039525A0475 |145 156|blood count08997A0472 
P04039525A0475 |238 241|DDPe n
P04039667T0000 |102 111|monocytesspects of
P04039667T0000 |14 27|visualisation Comparison w
P04039667T0000 |78 83|means171T0
P04039667T0000 |31 51|Walker carcinoma-256alkaline phosphatase
P04039667T0000 |55 74|Sprague-Dawley ratsd 5-nucleotidase P0
P04039744A0141 |152 158|period472 Wh
P04039744A0141 |120 139|i.u. vitamin D3/day hyperbilirubinemia
P04039744A0141 |105 115|supplementcts of neo
P04039744A0141 |162 171|lactationSF [HCO3-
P04039744A0141 |176 180|daysshow
P04039744A0141 |89 96|mothersarmacol
P04039744A0141 |6 13|results606T007
P04039744A0141 |52 61|D mothers and 5-nu
P04039744A0141 |66 70|pupsidas
P04040083A0000 |0 11|Rabbit eyesP00001606T0
P04040083A0000 |59 67|chambersnucleoti
P04040083A0000 |87 93|salinePharma
P04040307A0145 |55 61|nervesd 5-nu
P04040307A0145 |94 103|NE levelsologic as
P04040307A0145 |7 12|birth06T00
P04040339T0001 |0 18|Monitoring changesP00001606T0076 Com
P04040339T0001 |106 117|partusistents of neona
P04040339T0001 |122 129|Pre-paryperbil
P04040339T0001 |67 76|tocolysisdase P000
P04040339T0001 |26 36|heart ratewith alkal
P04040339T0001 |54 59|fetusnd 5-
P04040858A0000 |53 61|patientsand 5-nu
P04040858A0000 |24 28|Junen wi
P04040858A0000 |75 81|cancer008171
P04040858A0000 |6 15|September606T0076 
P04041307A0614 |49 58|diltiazemses and 5
P04041307A0614 |29 47|calcium antagonisth alkaline phospha
P04041307A0614 |75 82|effects008171T
P04041307A0614 |4 11|results01606T0
P04041307A0614 |111 119|function neonata
P04041307A0614 |86 96|isoflurane Pharmacol
P04041346T0000 |17 28|arrhythmiasmparison wi
P04041346T0000 |30 37|digoxin alkali
P04041346T0000 |42 51|quinidineosphatase
P04043489A0648 |0 7|VisidexP000016
P04043489A0648 |28 35|storageth alka
P04043489A0648 |40 50|re-readingphosphatas
P04048245A0331 |0 9|TreatmentP00001606
P04048245A0331 |37 51|hydrocortisonene phosphatase
P04048245A0331 |15 32|oxyphenylbutazoneComparison with a
P04048245A0331 |81 97|serum CPN levelsT0000 Pharmacolo
P04050771A0474 |118 126|survivalal hyper
P04050771A0474 |96 103|factorsogic as
P04050771A0474 |62 67|orderleoti
P04050771A0474 |4 7|Cox016
P04050771A0474 |54 58|datand 5
P04050771A0474 |21 34|hazards modelison with alk
P04050821A0531 |154 162|hospital2 When C
P04050821A0531 |123 131|episodesperbilir
P04050821A0531 |54 62|increasend 5-nuc
P04050821A0531 |77 90|oxygen demand8171T0000 Pha
P04050821A0531 |19 29|mechanismsarison wit
P04051521T0001 |0 8|DurationP0000160
P04051521T0001 |12 21|remission76 Compar
P04051521T0001 |91 94|MTXmac
P04051521T0001 |83 87|dose000 
P04051521T0001 |42 57|cancer patientsosphatases and 
P04051521T0001 |99 103|5-FUc as
P04052919A0205 |373 382|indicatoram thus a
P04052919A0205 |296 307|measurementhave a sign
P04052919A0205 |386 395|ovulationrs to be 
P04052919A0205 |24 46|progesterone secretionn with alkaline phosph
P04052919A0205 |264 274|thresholds compared 
P04052919A0205 |483 490|results at nig
P04052919A0205 |181 189|subjects as a fu
P04052919A0205 |280 283|usetro
P04052919A0205 |194 213|progesterone levelsn of CSF PCO2 the d
P04052919A0205 |425 431|nmol/lh the 
P04052919A0205 |399 408|thresholdffective 
P04052919A0205 |81 93|luteal phaseT0000 Pharma
P04052919A0205 |458 464|numbereral p
P04052919A0205 |6 10|data606T
P04052919A0205 |311 323|progesteroneantly greate
P04052919A0205 |108 117|frequency of neona
P04052919A0205 |170 175|phase-] is
P04052919A0205 |342 347|phase.23 v
P04052919A0205 |136 141|phasemia. 
P04055593A0523 |155 170|gas composition When CSF [HCO3
P04055593A0523 |133 140|effectsinemia.
P04055593A0523 |45 47|N2ha
P04055593A0523 |144 151|changes008997A
P04055593A0523 |95 107|compensationlogic aspect
P04055593A0523 |27 37|processingith alkali
P04055593A0523 |113 124|correctionseonatal hyp
P04055593A0523 |52 64|flow signals and 5-nucle
P04055593A0523 |175 186|temperature shown as a
P04056218A0463 |85 87|dB0 
P04056218A0463 |61 63|L1cl
P04056218A0463 |5 10|slope1606T
P04056218A0463 |66 68|L2id
P04056218A0463 |50 55|dB/dBes an
P04056256A0416 |0 20|Histamine reactivityP00001606T0076 Compa
P04056256A0416 |91 95|meanmaco
P04056256A0416 |134 140|% fallnemia.
P04056256A0416 |197 202|mg/mlf CSF
P04056256A0416 |108 121|concentration of neonatal 
P04056256A0416 |57 75|nifedipine aerosol5-nucleotidase P00
P04056256A0416 |206 215|histamine2 the dat
P04056256A0416 |217 218|po
P04056256A0416 |153 171|airway conductance72 When CSF [HCO3-
P04058985A0000 |23 33|vitamin B6on with al
P04058985A0000 |14 19|doses Comp
P04058985A0000 |60 65|womenucleo
P04058985A0000 |97 113|plasma prolactingic aspects of n
P04061342A0512 |154 155|p2
P04061342A0512 |120 121|p 
P04061342A0512 |57 63|uptake5-nucl
P04061342A0512 |147 152|state997A0
P04061342A0512 |74 90|min postexercise0008171T0000 Pha
P04061342A0512 |98 99|%i
P04061342A0512 |36 45|elevationine phosp
P04061342A0512 |49 53|meanses 
P04062128T0028 |0 19|National InstitutesP00001606T0076 Comp
P04062128T0028 |23 72|Health Consensus Development Conference Statementon with alkaline phosphatases and 5-nucleotidase 
P04063732A0509 |3 11|controls001606T0
P04063732A0509 |72 80|activityP0000817
P04063732A0509 |91 92|%m
P04063732A0509 |25 31|output with 
P04063732A0509 |41 48|conduithosphat
P04063732A0509 |65 69|typetida
P04066194A0163 |0 19|Greater attenuationP00001606T0076 Comp
P04066194A0163 |37 58|baseline-P2 amplitudene phosphatases and 5
P04066194A0163 |27 32|N1-P2ith a
P04066194A0163 |140 143|ear P0
P04066194A0163 |66 75|probe EPsidase P00
P04066194A0163 |159 167|materialn CSF [H
P04066194A0163 |98 112|probe stimulusic aspects of 
P04066194A0163 |217 240|stimulation arrangementof K-depleted rats are 
P04066194A0163 |190 193|earcti
P04066274A0265 |119 120|%l
P04066274A0265 |12 20|patients76 Compa
P04066274A0265 |104 110|T.C.P.ects o
P04066274A0265 |40 49|neoplasmsphosphata
P04066274A0265 |26 27|%w
P04066274A0265 |89 102|parotidectomyarmacologic a
P04066274A0265 |146 148|En89
P04066274A0265 |125 129|S.P.rbil
P04066274A0265 |140 141|% 
P04067540A0413 |326 333|victimslope (1
P04067540A0413 |113 120|victimseonatal
P04067540A0413 |349 355|spouse P0001
P04067540A0413 |226 238|suicide noteeted rats ar
P04067540A0413 |166 174|ex-loverHCO3-] i
P04067540A0413 |4 15|comparisons01606T0076 
P04067540A0413 |157 162|loverhen C
P04067540A0413 |54 66|perpetratorsnd 5-nucleot
P04067540A0413 |139 144|homes. P00
P04067540A0413 |250 257|weekenddisplac
P04067540A0413 |187 192|crimefunct
P04068663A0452 |171 178|rabbits] is sh
P04068663A0452 |47 53|valuestases 
P04068663A0452 |24 39|mouse CRF-floran with alkaline
P04068663A0452 |10 17|rabbits0076 Co
P04068663A0452 |123 136|unsuitabilityperbilirubine
P04068663A0452 |140 155|mouse CRF flora P00008997A0472
P04068663A0452 |83 90|animals000 Pha
P04068663A0452 |100 110|parameters aspects o
P04068774A1292 |118 122|boneal h
P04068774A1292 |31 32|Fa
P04068774A1292 |106 114|elementsts of ne
P04068774A1292 |88 96|contentsharmacol
P04068774A1292 |74 80|effect000817
P04068774A1292 |43 45|Mgsp
P04068774A1292 |9 22|relationshipsT0076 Compari
P04068774A1292 |37 39|Znne
P04068969A0300 |0 5|L3-L4P0000
P04068969A0300 |46 51|modelatase
P04068969A0300 |74 79|trunk00081
P04068969A0300 |96 102|systemogic a
P04068969A0300 |59 66|anatomynucleot
P04068969A0300 |18 22|loadpari
P04069756T0025 |34 53|leukoencephalopathyaline phosphatases 
P04069756T0025 |0 9|DiagnosisP00001606
P04070725A0442 |0 14|Component P100P00001606T0076
P04070725A0442 |45 55|negativityhatases an
P04070725A0442 |122 131|generatoryperbilir
P04070725A0442 |88 98|hypothesisharmacolog
P04070725A0442 |67 74|latencydase P0
P04071063A0863 |136 142|levelsmia. P
P04071063A0863 |12 23|differences76 Comparis
P04071063A0863 |197 202|groupf CSF
P04071063A0863 |42 50|decreaseosphatas
P04071063A0863 |94 111|fibrinogen levelsologic aspects of
P04071063A0863 |86 92|groups Pharm
P04071063A0863 |54 69|platelet countsnd 5-nucleotida
P04071063A0863 |116 121|alphaatal 
P04073848T0000 |0 7|FailureP000016
P04073848T0000 |41 50|diagnosishosphatas
P04073848T0000 |11 33|stapedius reflexometry076 Comparison with al
P04073848T0000 |54 71|myasthenia gravisnd 5-nucleotidase
P04074214A0000 |51 56|boarss and
P04074214A0000 |81 92|environmentT0000 Pharm
P04074214A0000 |20 41|semen characteristicsrison with alkaline p
P04074214A0000 |0 7|FactorsP000016
P04075021T0000 |50 64|administrationes and 5-nucle
P04075021T0000 |31 43|distributionalkaline pho
P04075021T0000 |6 25|beta-phenethylamine606T0076 Comparison
P04075021T0000 |76 82|routes08171T
P04075021T0000 |111 139|monoamine oxidase inhibitors neonatal hyperbilirubinemia
P04075021T0000 |100 107|effects aspect
P04075021T0000 |86 90|cats Pha
P04075021T0000 |1 4|14C000
P04075061A0355 |33 34|Lk
P04075061A0355 |20 25|totalrison
P04075061A0355 |38 43|watere pho
P04075061A0355 |4 11|runners01606T0
P04075061A0355 |55 59|raced 5-
P04079738A0677 |137 146|degrees Cia. P0000
P04079738A0677 |31 35|meanalka
P04079738A0677 |158 168|degrees C.en CSF [HC
P04079738A0677 |40 42|SDph
P04079738A0677 |74 84|kJ X min-10008171T00
P04079738A0677 |86 87|P 
P04079738A0677 |4 9|rates01606
P04079738A0677 |19 29|energy usearison wit
P04081425T0016 |21 28|therapyison wi
P04081425T0016 |9 16|aspectsT0076 C
P04082267A0720 |16 20|daysompa
P04082267A0720 |61 70|degrees Ccleotidas
P04082267A0720 |44 53|degrees Cphatases 
P04082267A0720 |120 125|virus hype
P04082267A0720 |76 82|vexans08171T
P04082267A0720 |72 74|AeP0
P04082267A0720 |22 32|incubationson with a
P04082592T0000 |0 17|Blood eosinophilsP00001606T0076 Co
P04082592T0000 |21 29|patientsison wit
P04082592T0000 |35 41|Taenialine p
P04084607A0663 |4 16|imino proton01606T0076 C
P04084607A0663 |30 35|O6meG alka
P04084607A0663 |49 51|G3se
P04084607A0663 |20 22|T3ri
P04084607A0663 |157 162|fieldhen C
P04084607A0663 |59 64|O6meGnucle
P04084607A0663 |247 250|ppmer 
P04084607A0663 |209 232|Watson-Crick base pairshe data of K-depleted r
P04084607A0663 |111 128|modification site neonatal hyperbi
P04084607A0663 |192 205|imino protonsion of CSF PC
P04084607A0663 |74 79|helix00081
P04084607A0663 |65 66|Nt
P04084607A0663 |36 37|Ti
P04084607A0663 |175 178|ppm sh
P04084896A0569 |116 139|intervention strategiesatal hyperbilirubinemia
P04084896A0569 |4 18|recommendation01606T0076 Com
P04084896A0569 |41 51|sub-groupshosphatase
P04084896A0569 |55 65|attemptersd 5-nucleo
P04085589A0264 |34 49|secretor statusaline phosphata
P04085589A0264 |134 139|ratesnemia
P04085589A0264 |34 49|secretor statusaline phosphata
P04085589A0264 |155 173|tract colonization When CSF [HCO3-] 
P04085589A0264 |71 94|spirometry measurements P00008171T0000 Pharmac
P04085589A0264 |109 130|serum lysozyme levelsof neonatal hyperbili
P04085589A0264 |63 69|statuseotida
P04085589A0264 |14 25|correlation Comparison
P04085589A0264 |63 69|statuseotida
P04085589A0264 |14 25|correlation Comparison
P04085589A0264 |134 139|ratesnemia
P04085589A0264 |71 94|spirometry measurements P00008171T0000 Pharmac
P04085589A0264 |109 130|serum lysozyme levelsof neonatal hyperbili
P04085589A0264 |155 173|tract colonization When CSF [HCO3-] 
P04086403A1016 |0 5|GainsP0000
P04086403A1016 |43 58|feed conversionsphatases and 5
P04086403A1016 |131 135|gainubin
P04086403A1016 |108 116|% AS-VFA of neon
P04086403A1016 |74 75|P0
P04086403A1016 |140 155|feed conversion P00008997A0472
P04086403A1016 |22 23|Ps
P04086403A1016 |163 170|controlF [HCO3
P04086403A1016 |101 104|fedasp
P04086403A1016 |71 72|% 
P04086403A1016 |19 20|%a
P04086657T0000 |51 57|cortexs and 
P04086657T0000 |65 68|rattid
P04086657T0000 |21 32|developmentison with a
P04086993T0000 |68 77|compoundsase P0000
P04086993T0000 |99 107|hamstersc aspect
P04086993T0000 |53 59|pinealand 5-
P04086993T0000 |128 138|conditionslirubinemi
P04086993T0000 |19 30|rhythmicityarison with
P04086993T0000 |38 49|methylatione phosphata
P04086993T0000 |0 5|DailyP0000
P04088233A0309 |4 16|transit time01606T0076 C
P04088396A0145 |35 36|%l
P04088396A0145 |105 113|patientscts of n
P04088396A0145 |10 31|patients grades 1-2-30076 Comparison with 
P04088396A0145 |133 134|%i
P04088396A0145 |82 93|abnormality0000 Pharma
P04088733T0001 |0 8|ActivityP0000160
P04088733T0001 |12 27|acid hydrolases76 Comparison w
P04088733T0001 |42 58|blood leukocytesosphatases and 5
P04088733T0001 |95 103|childrenlogic as
P04088733T0001 |82 91|pneumonia0000 Phar
P04088936T0001 |102 118|thrombophlebitisspects of neonat
P04088936T0001 |88 96|patientsharmacol
P04088936T0001 |44 49|levelphata
P04088936T0001 |27 39|antithrombinith alkaline
P04088936T0001 |12 19|studies76 Comp
P04088936T0001 |54 84|plasminogen activator activitynd 5-nucleotidase P00008171T00
P04093211A0560 |37 44|abilityne phos
P04093211A0560 |75 87|orientations008171T0000 
P04093211A0560 |61 70|attitudescleotidas
P04101003T0001 |0 9|RelationsP00001606
P04101003T0001 |82 85|man000
P04101003T0001 |91 94|dogmac
P04101003T0001 |70 78|activitye P00008
P04101003T0001 |38 46|activitye phosph
P04101003T0001 |103 109|rabbitpects 
P04102280T0000 |0 9|TreatmentP00001606
P04102280T0000 |13 18|Paget6 Com
P04102280T0000 |21 28|diseaseison wi
P04103248T0000 |0 11|ImprovementP00001606T0
P04103248T0000 |37 45|averagerne phosp
P04103248T0000 |19 30|CRT displayarison with
P04113011T0000 |4 19|desensitization01606T0076 Comp
P04113011T0000 |25 42|ragweed hay fever with alkaline ph
P04114211T0000 |19 33|sulphadimidinearison with al
P04114211T0000 |56 64|subjects 5-nucle
P04114211T0000 |6 15|excretion606T0076 
P04115870T0000 |0 11|ExperiencesP00001606T0
P04115870T0000 |47 50|usetas
P04115870T0000 |54 73|Urat-I lithotriptornd 5-nucleotidase P
P04123217T0000 |0 9|FormationP00001606
P04123217T0000 |24 38|chlamydosporesn with alkalin
P04123217T0000 |13 19|hyphae6 Comp
P04123217T0000 |42 64|Cryptococcus laurentiiosphatases and 5-nucle
P04123662T0000 |0 10|EvaluationP00001606T
P04123662T0000 |14 30|thyroid function Comparison with
P04138224T0095 |16 31|tissue emulsionomparison with 
P04138224T0095 |4 10|effect01606T
P04138224T0095 |59 73|gamma-globulinnucleotidase P
P04138224T0095 |33 42|vitamin Akaline ph
P04138224T0095 |81 96|blood clearanceT0000 Pharmacol
P04138224T0095 |100 107|rabbits aspect
P04139081T0001 |34 42|patientsaline ph
P04139081T0001 |5 15|antibodies1606T0076 
P04139943T0001 |0 13|DemonstrationP00001606T007
P04139943T0001 |59 64|Cortinucle
P04139943T0001 |92 107|silver stainingacologic aspect
P04139943T0001 |39 55|guinea pig organ phosphatases an
P04139943T0001 |22 31|structureson with 
P04139943T0001 |71 79|electron P000081
P04140567T0001 |0 20|Histamine metabolismP00001606T0076 Compa
P04140567T0001 |48 53|shockases 
P04143528A0394 |31 43|nomenclaturealkaline pho
P04145244T0000 |0 10|RelaxationP00001606T
P04145244T0000 |14 19|catch Comp
P04145244T0000 |42 48|muscleosphat
P04152725T0001 |0 7|StudiesP000016
P04152725T0001 |21 33|liver injuryison with al
P04160980T0000 |33 44|circulationkaline phos
P04160980T0000 |13 20|control6 Compa
P04160980T0000 |52 55|dog an
P04164595T0020 |0 8|EvidenceP0000160
P04164595T0020 |74 79|types00081
P04164595T0020 |83 92|infection000 Pharm
P04164669T0000 |51 55|skins an
P04164669T0000 |26 41|kinin formationwith alkaline p
P04172166T0000 |0 13|PoliomyelitisP00001606T007
P04172166T0000 |21 28|vaccineison wi
P04175007T0001 |66 72|tumorsidase 
P04175007T0001 |41 47|growthhospha
P04175007T0001 |123 134|antibioticsperbilirubi
P04175007T0001 |7 14|problem06T0076
P04175007T0001 |76 83|animals08171T0
P04175007T0001 |22 33|stimulationson with al
P04176249T0001 |0 10|AssessmentP00001606T
P04176249T0001 |36 45|diagnosisine phosp
P04176249T0001 |23 28|mediaon wi
P04176249T0001 |49 58|diptheriases and 5
P04176268T0000 |0 15|Aluminium resinP00001606T0076 
P04176268T0000 |41 53|hyperkalamiahosphatases 
P04176268T0000 |63 70|failureeotidas
P04176268T0000 |24 33|treatmentn with al
P04176625T0000 |0 5|ValueP0000
P04176625T0000 |13 16|EMG6 C
P04176625T0000 |39 53|cardiomyopathy phosphatases 
P04176625T0000 |24 33|diagnosisn with al
P04176625T0000 |81 89|myopathyT0000 Ph
P04179445T0036 |0 2|D.P0
P04189158T0000 |0 10|PreventionP00001606T
P04189158T0000 |56 64|globulin 5-nucle
P04189158T0000 |23 39|Rh sensitizationon with alkaline
P04194466T0000 |0 16|Serotonin levelsP00001606T0076 C
P04194466T0000 |20 41|infant hypothyroidismrison with alkaline p
P04196986T0000 |35 42|studiesline ph
P04196986T0000 |88 94|systemharmac
P04196986T0000 |14 31|fluid transferrin Comparison with 
P04196986T0000 |55 64|disordersd 5-nucle
P04213917T0001 |16 31|D-penicillamineomparison with 
P04213917T0001 |45 53|fibroseshatases 
P04213917T0001 |5 12|dosages1606T00
P04214345T0000 |86 108|Zambian African adults Pharmacologic aspects
P04214345T0000 |8 16|relation6T0076 C
P04214345T0000 |53 60|glucoseand 5-n
P04214345T0000 |25 48|serum IgG concentration with alkaline phosphat
P04214345T0000 |65 82|xylose absorptiontidase P00008171T
P04226360T0001 |0 9|DisordersP00001606
P04226360T0001 |13 30|platelet function6 Comparison with
P04226360T0001 |50 59|leukemiases and 5-
P04239041T0045 |68 74|sodiumase P0
P04239041T0045 |14 29|anticonvulsants Comparison wit
P04239041T0045 |60 66|ATPaseucleot
P04239041T0045 |80 88|potassim1T0000 P
P04239041T0045 |92 98|cortexacolog
P04239041T0045 |4 10|effect01606T
P04246054T0028 |17 28|lymphocytesmparison wi
P04246054T0028 |88 99|macrophagesharmacologi
P04246054T0028 |121 143|incubation temperaturehyperbilirubinemia. P0
P04246054T0028 |69 74|RAMLGse P0
P04246054T0028 |36 67|rabbit-anti-lymphocyte globulinine phosphatases and 5-nucleoti
P04246054T0028 |0 6|EffectP00001
P04247472T0001 |22 26|ratsson 
P04247472T0001 |47 56|mountainstases and
P04247472T0001 |60 69|Kirghiziaucleotida
P04247472T0001 |7 12|cycle06T00
P04247966T0000 |0 9|LactationP00001606
P04247966T0000 |31 55|protein maintenance dietalkaline phosphatases an
P04247966T0000 |13 20|baboons6 Compa
P04262268T0001 |0 7|StudiesP000016
P04262268T0001 |23 29|matrixon wit
P04262268T0001 |39 51|ear ossicles phosphatase
P04263748T0042 |23 29|reviewon wit
P04281856T0001 |51 77|Ornithodoros tatarovski Ols and 5-nucleotidase P0000
P04281856T0001 |37 47|populationne phospha
P04281856T0001 |8 21|sex structure6T0076 Compar
P04281856T0001 |0 3|AgeP00
P04282315T0001 |17 32|hyperlactatemiamparison with a
P04282315T0001 |44 54|phenforminphatases a
P04282315T0001 |70 78|ablatione P00008
P04282315T0001 |86 94|pancreas Pharmac
P04282315T0001 |0 13|SensitizationP00001606T007
P04284435T0000 |0 10|Vitamin D3P00001606T
P04284435T0000 |15 33|calcium absorptionComparison with al
P04284435T0000 |41 46|chickhosph
P04289156T0000 |34 42|chickensaline ph
P04289156T0000 |4 13|incidence01606T007
P04289156T0000 |17 24|tumoursmpariso
P04291759T0048 |0 18|Laboratory aspectsP00001606T0076 Com
P04291759T0048 |48 60|chemotherapyases and 5-n
P04291759T0048 |65 72|controltidase 
P04291759T0048 |35 44|referenceline phos
P04295031T0062 |20 30|guinea pigrison with
P04295031T0062 |6 12|effect606T00
P04305850T0000 |0 9|AndrogensP00001606
P04305850T0000 |14 20|growth Compa
P04308979T0000 |0 6|EffectP00001
P04308979T0000 |46 55|treatmentatases an
P04308979T0000 |122 127|lungsyperb
P04308979T0000 |61 64|BCGcle
P04308979T0000 |24 37|time intervaln with alkali
P04308979T0000 |146 157|lymph nodes8997A0472 W
P04308979T0000 |10 20|variations0076 Compa
P04308979T0000 |69 80|quartz dustse P0000817
P04308979T0000 |101 112|quartz dustaspects of 
P04308979T0000 |84 97|translocation00 Pharmacolo
P04311951T0001 |87 94|otologyPharmac
P04311951T0001 |49 60|associationses and 5-n
P04311951T0001 |12 18|action76 Com
P04311951T0001 |70 83|instillationse P00008171T0
P04315233T0128 |22 32|experimentson with a
P04316696T0001 |0 6|EnzymeP00001
P04316696T0001 |65 70|horsetidas
P04316696T0001 |53 57|bodyand 
P04316696T0001 |21 29|findingsison wit
P04321861T0001 |87 98|erythrocytePharmacolog
P04321861T0001 |9 41|glutathione reductase deficiencyT0076 Comparison with alkaline p
P04321861T0001 |46 54|disorderatases a
P04321861T0001 |58 79|glutathione synthesis-nucleotidase P000081
P04323641T0000 |0 7|StudiesP000016
P04323641T0000 |11 30|swine enteroviruses076 Comparison with
P04325736T0001 |17 27|ectromeliamparison w
P04325736T0001 |31 46|laboratory micealkaline phosph
P04325736T0001 |0 13|SerodiagnosisP00001606T007
P04328746T0073 |0 17|Ultrasound effectP00001606T0076 Co
P04328746T0073 |25 52|cytochrome oxidase activity with alkaline phosphatases
P04335965T0000 |0 10|MetastasisP00001606T
P04335965T0000 |14 29|colon carcinoma Comparison wit
P04335965T0000 |37 40|lipne 
P04350410T0000 |0 7|GenesisP000016
P04350410T0000 |11 21|foam cells076 Compar
P04350410T0000 |61 69|Cloforexcleotida
P04350410T0000 |23 28|studyon wi
P04350410T0000 |43 57|administrationsphatases and 
P04350410T0000 |32 36|ratslkal
P04364369T0000 |0 22|Pre-beta-1 lipoproteinP00001606T0076 Compari
P04364369T0000 |72 85|heart diseaseP00008171T000
P04364369T0000 |46 58|risk factorsatases and 5
P04364369T0000 |33 42|detectionkaline ph
P04369884T0000 |68 71|CSFase
P04369884T0000 |23 33|inhibitorson with al
P04369884T0000 |60 66|factorucleot
P04369884T0000 |0 10|ConditionsP00001606T
P04371279T0000 |0 7|AbsenceP000016
P04371279T0000 |11 28|action potentials076 Comparison wi
P04371279T0000 |32 36|froglkal
P04371279T0000 |42 55|muscle fibresosphatases an
P04371279T0000 |69 84|botulinum toxinse P00008171T00
P04377003A0000 |235 243|patients are no 
P04377003A0000 |211 214|CNS da
P04377003A0000 |252 258|tumorssplace
P04377003A0000 |216 222|tumors of K-
P04377003A0000 |80 90|spermidine1T0000 Pha
P04377003A0000 |57 78|polyamines putrescine5-nucleotidase P00008
P04377003A0000 |95 103|sperminelogic as
P04377003A0000 |121 126|fluidhyper
P04377003A0000 |41 49|analysishosphata
P04377003A0000 |13 19|method6 Comp
P04377003A0000 |153 164|CSF samples72 When CSF
P04377003A0000 |203 209|systemPCO2 t
P04377003A0000 |128 131|CSFlir
P04377003A0000 |173 181|patientsis shown
P04377328T0027 |0 2|I.P0
P04385060T0000 |0 10|DisulfiramP00001606T
P04385060T0000 |43 51|motilitysphatase
P04385060T0000 |32 39|effectslkaline
P04387103T0000 |0 9|ParticlesP00001606
P04387103T0000 |67 73|glandsdase P
P04387103T0000 |77 81|dogs8171
P04387103T0000 |21 32|microbodiesison with a
P04392584T0000 |20 28|malariasrison wi
P04392584T0000 |40 58|hemisphere monkeysphosphatases and 5
P04394290T0000 |2 7|study00016
P04394290T0000 |30 39|receptors alkaline
P04394290T0000 |78 87|sphincter171T0000 
P04394290T0000 |47 53|rectumtases 
P04394290T0000 |95 98|catlog
P04407649T0000 |42 47|fossaospha
P04407649T0000 |13 27|arachnoid cyst6 Comparison w
P04407649T0000 |73 96|99mTc brainscintigraphy00008171T0000 Pharmacol
P04418687T0000 |0 7|EffectsP000016
P04418687T0000 |74 79|fetus00081
P04418687T0000 |24 39|glucocorticoidsn with alkaline
P04418687T0000 |11 19|estrogen076 Comp
P04418687T0000 |55 66|developmentd 5-nucleot
P04423347T0001 |0 6|CopperP00001
P04423347T0001 |45 50|womenhatas
P04423347T0001 |11 32|ceruloplasmin content076 Comparison with a
P04423347T0001 |91 99|diseasesmacologi
P04423347T0001 |58 63|women-nucl
P04428800T0001 |51 63|GPT activitys and 5-nucl
P04428800T0001 |43 46|LAPsph
P04428800T0001 |10 15|noise0076 
P04428800T0001 |30 39|increases alkaline
P04428800T0001 |71 77|plasma P0000
P04428800T0001 |81 85|ratsT000
P04428800T0001 |0 6|EffectP00001
P04428981T0000 |0 8|KineticsP0000160
P04428981T0000 |12 30|calcium metabolism76 Comparison with
P04429269T0000 |20 25|mucusrison
P04429269T0000 |7 16|transport06T0076 C
P04429269T0000 |44 53|simulantsphatases 
P04429269T0000 |66 73|systemsidase P
P04437406T0000 |119 127|exchangel hyperb
P04437406T0000 |15 26|descriptionComparison 
P04437406T0000 |42 64|reflection coefficientosphatases and 5-nucle
P04437406T0000 |89 100|pore theoryarmacologic
P04437406T0000 |70 81|applicatione P00008171
P04445874T0001 |0 9|PathologyP00001606
P04445874T0001 |44 49|horsephata
P04445874T0001 |13 21|neuritis6 Compar
P04446923T0001 |9 24|characteristicsT0076 Compariso
P04446923T0001 |47 68|Platynothrus peltifertases and 5-nucleotid
P04446923T0001 |29 43|verticillationh alkaline pho
P04460692T0000 |19 45|laboratory animal medicinearison with alkaline phosp
P04460692T0000 |9 15|topicsT0076 
P04468264T0053 |34 48|anesthesiologyaline phosphat
P04468264T0053 |19 29|pediatricsarison wit
P04468264T0053 |0 8|ProblemsP0000160
P04482661T0001 |50 65|decubitus ulceres and 5-nucleo
P04482661T0001 |9 15|courseT0076 
P04482661T0001 |95 110|buckwheat chafflogic aspects o
P04482661T0001 |74 81|pillows0008171
P04482661T0001 |36 44|patientsine phos
P04482661T0001 |67 70|usedas
P04482661T0001 |20 32|nursing carerison with a
P04487835T0001 |3 10|parents001606T
P04487920T0001 |9 39|Icelandic Red Cross activitiesT0076 Comparison with alkaline
P04488232T0001 |0 7|EffectsP000016
P04488232T0001 |29 35|familyh alka
P04488232T0001 |11 21|alcoholism076 Compar
P04488271T0001 |0 9|TreatmentP00001606
P04488271T0001 |28 45|diabetes mellitusth alkaline phosp
P04488271T0001 |14 18|care Com
P04488271T0001 |54 58|comand 5
P04495034T0000 |42 51|treatmentosphatase
P04495034T0000 |28 35|tolueneth alka
P04495034T0000 |13 26|methylbenzene6 Comparison 
P04495034T0000 |56 76|Ancylostomum caninum 5-nucleotidase P000
P04506738T0000 |0 9|JunctionsP00001606
P04506738T0000 |37 49|enamel organne phosphata
P04506738T0000 |18 23|cellsparis
P04510102T0000 |0 18|ElectrocardiogramsP00001606T0076 Com
P04510102T0000 |26 31|monthwith 
P04511139T0001 |0 10|CompositesP00001606T
P04511139T0001 |14 35|restoration materials Comparison with alka
P04512496T0000 |0 7|HodgkinP000016
P04512496T0000 |10 17|disease0076 Co
P04515631T0000 |0 5|ValueP0000
P04515631T0000 |45 55|assessmenthatases an
P04515631T0000 |59 73|liver functionnucleotidase P
P04515631T0000 |9 18|NormotestT0076 Com
P04515631T0000 |23 35|antithrombinon with alka
P04518624T0000 |0 22|Glutathione peroxidaseP00001606T0076 Compari
P04518624T0000 |56 63|disease 5-nucl
P04518624T0000 |45 51|healthhatase
P04518624T0000 |36 41|cellsine p
P04524081T0000 |16 24|responseompariso
P04524081T0000 |61 88|aluminum chloride solutionscleotidase P00008171T0000 P
P04524081T0000 |37 44|tissuesne phos
P04524081T0000 |92 121|tissue displacement materialsacologic aspects of neonatal 
P04524081T0000 |48 56|hemodentases and
P04533208T0083 |0 7|ChangesP000016
P04533208T0083 |30 37|surgery alkali
P04536964T0000 |33 63|H ion permeability coefficientkaline phosphatases and 5-nucl
P04536964T0000 |67 86|bullfrog toe muscledase P00008171T0000
P04536964T0000 |14 16|pH C
P04536964T0000 |18 28|H ion fluxparison wi
P04539552T0001 |25 31|SF-837 with 
P04539552T0001 |14 21|studies Compar
P04543036T0001 |0 10|DirectivesP00001606T
P04543036T0001 |30 34|care alk
P04544430T0001 |0 11|ProceedingsP00001606T0
P04544430T0001 |55 62|surgeryd 5-nuc
P04544430T0001 |77 90|heart defects8171T0000 Pha
P04544430T0001 |33 44|heart blockkaline phos
P04544704T0001 |0 6|MethodP00001
P04544704T0001 |38 44|factore phos
P04544704T0001 |10 19|synthesis0076 Comp
P04544704T0001 |70 77|studiese P0000
P04546974T0000 |51 68|bundle recordingss and 5-nucleotid
P04546974T0000 |18 24|timingpariso
P04546974T0000 |28 39|deflectionsth alkaline
P04546974T0000 |0 10|VariationsP00001606T
P04547933T0000 |94 97|eyeolo
P04547933T0000 |14 30|fibril formation Comparison with
P04547933T0000 |45 50|cellshatas
P04547933T0000 |72 80|junctionP0000817
P04548483T0001 |17 36|coagulation factorsmparison with alkal
P04548483T0001 |95 109|rhesus monkeyslogic aspects 
P04548483T0001 |86 91|shock Phar
P04548483T0001 |53 66|organ changesand 5-nucleot
P04548483T0001 |0 15|Blood plateletsP00001606T0076 
P04551650T0001 |0 14|Cell viabilityP00001606T0076
P04551650T0001 |29 36|enzymesh alkal
P04552263T0000 |35 39|R.N.line
P04552263T0000 |15 22|schoolsCompari
P04552263T0000 |26 33|nursingwith al
P04562038T0001 |8 21|investigation6T0076 Compar
P04562038T0001 |72 83|lymphocytesP00008171T0
P04562038T0001 |61 68|hormonecleotid
P04562038T0001 |41 50|influencehosphatas
P04563045T0000 |0 7|1,3-bisP000016
P04563045T0000 |25 36|nitrosourea with alkal
P04563045T0000 |8 21|2-chloroethyl6T0076 Compar
P04563045T0000 |90 96|reviewrmacol
P04563045T0000 |38 42|bcnue ph
P04563045T0000 |54 66|nitrosoureasnd 5-nucleot
P04563045T0000 |70 86|cancer treatmente P00008171T0000
P04578686T0000 |0 12|PneumothoraxP00001606T00
P04578686T0000 |23 35|lung abscesson with alka
P04578686T0000 |49 67|transplant patientses and 5-nucleoti
P04579436T0000 |109 116|pigmentof neon
P04579436T0000 |44 65|Brevibacterium linensphatases and 5-nucleo
P04579436T0000 |26 40|colour changeswith alkaline 
P04580044T0047 |9 22|relationshipsT0076 Compari
P04580044T0047 |31 48|development phasealkaline phosphat
P04583791T0000 |34 39|Lagosaline
P04583791T0000 |8 15|history6T0076 
P04583791T0000 |41 48|Nigeriahosphat
P04583791T0000 |19 30|dermatologyarison with
P04598670T0000 |55 72|immunosuppressiond 5-nucleotidase 
P04598670T0000 |30 37|adjunct alkali
P04598670T0000 |6 23|graft irradiation606T0076 Comparis
P04600603T0001 |0 6|LetterP00001
P04600603T0001 |19 28|detectionarison wi
P04613073T0001 |0 4|RoleP000
P04613073T0001 |43 61|Shigella virulencesphatases and 5-nu
P04613073T0001 |26 39|manifestationwith alkaline
P04613073T0001 |8 18|biocenosis6T0076 Com
P04615525T0001 |85 93|immunity0 Pharma
P04615525T0001 |37 46|formationne phosph
P04615525T0001 |29 33|serah al
P04615525T0001 |4 10|effect01606T
P04615525T0001 |97 101|micegic 
P04615525T0001 |50 65|transplantationes and 5-nucleo
P04615828T0001 |17 43|colonel prof. e.cerny m.d.mparison with alkaline pho
P04615828T0001 |5 13|birthday1606T007
P04621188T0000 |0 10|MorphologyP00001606T
P04621188T0000 |14 28|bacteriophages Comparison wi
P04621188T0000 |32 50|Klebsiella bacillilkaline phosphatas
P04622430T0000 |51 64|Rhesus monkeys and 5-nucle
P04622430T0000 |9 18|afferentsT0076 Com
P04622430T0000 |37 43|cortexne pho
P04624863T0001 |0 9|MechanismP00001606
P04624863T0001 |13 26|immunogenesis6 Comparison 
P04624863T0001 |30 41|vaccination alkaline p
P04624863T0001 |81 92|salmonellaeT0000 Pharm
P04624863T0001 |97 106|shigellaegic aspec
P04624863T0001 |70 77|mutantse P0000
P04627477T0001 |0 18|Resistance patternP00001606T0076 Com
P04627477T0001 |22 48|Mycobacterium tuberculosisson with alkaline phosphat
P04627477T0001 |55 57|Rvd 
P04627477T0001 |80 91|lividomycin1T0000 Phar
P04627477T0001 |50 51|He
P04632967T0000 |49 61|patas monkeyses and 5-nu
P04632967T0000 |78 92|administration171T0000 Pharm
P04632967T0000 |19 27|pressurearison w
P04632967T0000 |96 113|aminorex fumarateogic aspects of n
P04632967T0000 |32 41|structurelkaline p
P04638365T0001 |0 6|EffectP00001
P04638365T0001 |10 19|triftazin0076 Comp
P04638365T0001 |60 68|activityucleotid
P04638365T0001 |24 32|aminazinn with a
P04640155T0045 |0 9|Sex ratioP00001606
P04640155T0045 |13 18|birth6 Com
P04645078T0001 |13 22|processes6 Compari
P04645078T0001 |30 42|cervix uteri alkaline ph
P04646045T0001 |32 41|esophaguslkaline p
P04646045T0001 |18 24|tumorspariso
P04653144T0000 |0 16|General formulaeP00001606T0076 C
P04653144T0000 |32 44|heritabilitylkaline phos
P04653144T0000 |74 81|parents0008171
P04653144T0000 |50 60|populationes and 5-n
P04654249T0000 |0 11|MeasurementP00001606T0
P04654249T0000 |74 78|bulb0008
P04654249T0000 |82 85|cat000
P04654249T0000 |25 34|responses with alk
P04654249T0000 |49 60|stimulationses and 5-n
P04656185T0000 |0 26|Glucose disappearance rateP00001606T0076 Comparison 
P04656185T0000 |31 38|changesalkalin
P04656185T0000 |143 151|newborns0008997A
P04656185T0000 |42 58|plasma nutrientsosphatases and 5
P04656185T0000 |87 94|glucosePharmac
P04661961T0001 |33 38|bloodkalin
P04661961T0001 |43 54|bone marrowsphatases a
P04661961T0001 |78 85|hamster171T000
P04661961T0001 |7 13|values06T007
P04676734T0000 |4 16|relationship01606T0076 C
P04676734T0000 |73 88|corticosteroids00008171T0000 P
P04676734T0000 |104 107|ageect
P04676734T0000 |56 69|plasma levels 5-nucleotida
P04679438T0001 |34 39|hevizaline
P04679438T0001 |11 17|effect076 Co
P04679438T0001 |25 28|mud wi
P04679807T0000 |9 27|acid concentrationT0076 Comparison w
P04679807T0000 |45 65|breathalyzer ampuleshatases and 5-nucleo
P04704137T0001 |0 4|RoleP000
P04704137T0001 |37 48|prophylaxisne phosphat
P04704137T0001 |22 29|studiesson wit
P04704137T0001 |64 73|abortionsotidase P
P04704186T0000 |0 14|Range behaviorP00001606T0076
P04704186T0000 |28 36|Herefordth alkal
P04704186T0000 |75 82|heifers008171T
P04704186T0000 |39 47|Holstein phospha
P04704186T0000 |52 60|Holstein and 5-n
P04704186T0000 |18 26|Herefordparison 
P04712626T0000 |0 21|Chemical constituentsP00001606T0076 Compar
P04712626T0000 |74 99|Swertia chirata Buch.-Ham0008171T0000 Pharmacologi
P04712626T0000 |61 70|xanthonescleotidas
P04712626T0000 |29 43|gentianaceae Vh alkaline pho
P04718233T0000 |0 27|Methyl mercury intoxicationP00001606T0076 Comparison w
P04718233T0000 |31 42|rat kidneysalkaline ph
P04727344T0000 |0 18|MicrodeterminationP00001606T0076 Com
P04727344T0000 |56 70|isotope method 5-nucleotidas
P04727344T0000 |37 45|steroidsne phosp
P04729063T0000 |71 78|Koreans P00008
P04729063T0000 |31 41|investmentalkaline p
P04729063T0000 |13 20|justice6 Compa
P04730467T0000 |0 7|EffectsP000016
P04730467T0000 |59 76|enzyme activitiesnucleotidase P000
P04730467T0000 |11 20|cortisone076 Compa
P04730467T0000 |106 110|ratsts o
P04730467T0000 |80 100|epiphyseal cartilage1T0000 Pharmacologic
P04730467T0000 |22 32|starvationson with a
P04730467T0000 |38 45|ricketse phosp
P04733391T0000 |0 28|Metal coordination compoundsP00001606T0076 Comparison wi
P04733391T0000 |32 45|thiabendazolelkaline phosp
P04746559T0053 |0 10|EstimationP00001606T
P04746559T0053 |14 34|renin secretion rate Comparison with alk
P04746559T0053 |45 56|plasma flowhatases and
P04746559T0053 |83 100|vein renin levels000 Pharmacologic
P04752455T0000 |34 42|securityaline ph
P04752455T0000 |0 20|Disability insuranceP00001606T0076 Compa
P04753073T0000 |0 6|ChoiceP00001
P04753073T0000 |10 16|vessel0076 C
P04753286T0000 |34 37|ratali
P04753286T0000 |41 49|tung oilhosphata
P04753286T0000 |15 26|food intakeComparison 
P04753286T0000 |0 11|SuppressionP00001606T0
P04757217T0000 |0 7|StudiesP000016
P04757217T0000 |11 24|lipoprotein-X076 Compariso
P04757217T0000 |59 74|LCAT deficiencynucleotidase P0
P04757217T0000 |26 30|LP-Xwith
P04757217T0000 |36 46|bile acidsine phosph
P04758799T0000 |0 12|PneumothoraxP00001606T00
P04758799T0000 |36 53|steroid treatmentine phosphatases 
P04759722T0000 |0 17|Polycythemia-1973P00001606T0076 Co
P04760826T0000 |20 37|Vietnam returneesrison with alkali
P04760826T0000 |9 16|anxietyT0076 C
P04760826T0000 |42 56|undergraduatesosphatases and
P04764049T0001 |18 34|nephronophthisisparison with alk
P04766888T0000 |48 63|meningococcemiaases and 5-nucl
P04766888T0000 |28 36|childrenth alkal
P04766888T0000 |6 21|heparin therapy606T0076 Compar
P04778129T0000 |0 18|9,11-Seco steroidsP00001606T0076 Com
P04778129T0000 |32 56|estradiol 3-methyl etherlkaline phosphatases and
P04782788T0001 |52 72|kidney insufficiency and 5-nucleotidase 
P04782788T0001 |30 38|patients alkalin
P04782788T0001 |14 26|examinations Comparison 
P04784432T0001 |68 75|animalsase P00
P04784432T0001 |54 64|substancesnd 5-nucle
P04784432T0001 |28 42|administrationth alkaline ph
P04784432T0001 |0 13|PossibilitiesP00001606T007
P04787472T0001 |0 6|ChangeP00001
P04787472T0001 |28 33|bloodth al
P04787472T0001 |14 20|makeup Compa
P04787472T0001 |94 99|fieldologi
P04787472T0001 |63 69|actioneotida
P04787472T0001 |113 117|bodyeona
P04787716T0000 |0 12|ObservationsP00001606T00
P04787716T0000 |41 63|Chrysops caecutiens L.hosphatases and 5-nucl
P04787716T0000 |20 37|flight activitiesrison with alkali
P04788701T0001 |0 11|CombinationP00001606T0
P04788701T0001 |81 87|uterusT0000 
P04788701T0001 |55 61|tumorsd 5-nu
P04788701T0001 |69 76|breastsse P000
P04789916T0001 |0 8|AnalysisP0000160
P04789916T0001 |12 27|clearance curve76 Comparison w
P04789916T0001 |36 48|bengal-I-131ine phosphat
P04791420T0000 |0 11|ProceedingsP00001606T0
P04791420T0000 |73 79|possum000081
P04791420T0000 |13 20|Barrels6 Compa
P04791420T0000 |25 35|somatotopy with alka
P04791420T0000 |43 52|neocortexsphatases
P04791420T0000 |39 40|S 
P04794218T0001 |12 20|K agents76 Compa
P04796997T0000 |102 108|organsspects
P04796997T0000 |7 19|reproduction06T0076 Comp
P04796997T0000 |41 50|injectionhosphatas
P04796997T0000 |21 28|effectsison wi
P04796997T0000 |54 81|medroxyprogesterone acetatend 5-nucleotidase P00008171
P04796997T0000 |116 121|bitchatal 
P04801663T0049 |30 40|properties alkaline 
P04803629T0001 |38 45|allergye phosp
P04803629T0001 |14 20|system Compa
P04810131T0000 |0 6|LetterP00001
P04810131T0000 |41 48|smokinghosphat
P04810131T0000 |8 36|Aryl hydrocarbon hydroxylase6T0076 Comparison with alkal
P04813394T0000 |0 10|EvaluationP00001606T
P04813394T0000 |58 77|acid determinations-nucleotidase P0000
P04813394T0000 |14 33|1,10-phenanthroline Comparison with al
P04813394T0000 |39 46|reagent phosph
P04820791T0001 |21 25|acidison
P04820791T0001 |63 71|diseaseseotidase
P04820791T0001 |75 83|children008171T0
P04820791T0001 |43 53|conditionssphatases 
P04824747T0000 |51 60|compoundss and 5-n
P04824747T0000 |38 46|potatoese phosph
P04824747T0000 |21 25|ratsison
P04824747T0000 |0 17|NonteratogenicityP00001606T0076 Co
P04826272T0074 |0 3|VIIP00
P04828587T0000 |0 9|IsolationP00001606
P04828587T0000 |43 48|virussphat
P04828587T0000 |13 16|tha6 C
P04828587T0000 |50 58|strain Tes and 5
P04837183T0000 |0 12|ObservationsP00001606T00
P04837183T0000 |54 66|hypergravitynd 5-nucleot
P04837183T0000 |28 32|ratsth a
P04837183T0000 |16 24|sacculesompariso
P04839176T0001 |0 6|EffectP00001
P04839176T0001 |44 68|blood coagulation systemphatases and 5-nucleotid
P04839176T0001 |27 36|SHF fieldith alkal
P04843031T0000 |48 52|seraases
P04843031T0000 |78 86|patients171T0000
P04843031T0000 |14 44|galactosyltransferase activity Comparison with alkaline phos
P04843031T0000 |99 107|fibrosisc aspect
P04843031T0000 |65 73|childrentidase P
P04843031T0000 |4 10|levels01606T
P04852635T0000 |0 4|LackP000
P04852635T0000 |22 50|appetite stimulant pizotifenson with alkaline phosphatas
P04852635T0000 |8 14|effect6T0076
P04852635T0000 |67 77|absorptiondase P0000
P04852635T0000 |52 54|BC a
P04852635T0000 |81 102|isonicotinylhydrazineT0000 Pharmacologic a
P04863895T0000 |0 12|RelationshipP00001606T00
P04863895T0000 |106 113|poultryts of n
P04863895T0000 |89 96|diseasearmacol
P04863895T0000 |27 34|lesionsith alk
P04863895T0000 |56 65|serotypes 5-nucleo
P04863895T0000 |98 101|CRDic 
P04871589T0001 |32 41|ankylosislkaline p
P04871589T0001 |8 16|solution6T0076 C
P04871589T0001 |74 78|flap0008
P04871589T0001 |20 25|elbowrison
P04878680T0000 |0 7|EffectsP000016
P04878680T0000 |20 29|radiationrison wit
P04878680T0000 |59 69|oropharynxnucleotida
P04878680T0000 |71 78|results P00008
P04878680T0000 |48 54|cavityases a
P04878680T0000 |84 90|survey00 Pha
P04884060T0000 |33 59|Pomeranian Medical Academykaline phosphatases and 5-
P04884060T0000 |4 25|Twentieth Anniversary01606T0076 Comparison
P04890336T0001 |32 49|Wassermann reaginlkaline phosphata
P04890336T0001 |72 87|appearance timeP00008171T0000 
P04890336T0001 |105 119|FTA antibodiescts of neonata
P04890336T0001 |54 64|comparisonnd 5-nucle
P04890336T0001 |96 100|RPCFogic
P04890336T0001 |21 28|patternison wi
P04909355T0000 |17 32|Actinomycetalesmparison with a
P04911925T0001 |0 34|Electrocardiographic QRS complexesP00001606T0076 Comparison with alk
P04911925T0001 |59 67|QRS loopnucleoti
P04919613T0001 |0 5|StudyP0000
P04919613T0001 |21 35|autoantibodiesison with alka
P04919613T0001 |39 65|immunofluorescence technic phosphatases and 5-nucleo
P04919613T0001 |69 86|collagen diseasesse P00008171T0000
P04921762T0000 |8 20|preservation6T0076 Compa
P04925617T0000 |7 10|bar06T
P04941419T0000 |0 28|Yusuf Dawood Docrat L.R.C.P.P00001606T0076 Comparison wi
P04941951T0000 |0 3|Dr.P00
P04942414T0000 |35 49|5-fluorouracilline phosphata
P04942414T0000 |4 14|metabolism01606T0076
P04942414T0000 |19 31|pharmacologyarison with 
P04947347T0000 |17 21|ratsmpar
P04947347T0000 |50 69|homograft rejectiones and 5-nucleotida
P04947347T0000 |29 42|tumour growthh alkaline ph
P04947347T0000 |0 13|Spleen weightP00001606T007
P04948325T0000 |0 9|IsolationP00001606
P04948325T0000 |72 78|effectP00008
P04948325T0000 |13 20|Proteus6 Compa
P04948325T0000 |30 35|MC-63 alka
P04948325T0000 |41 50|carcinomahosphatas
P04948325T0000 |106 123|Ehrlich carcinomats of neonatal hy
P04948325T0000 |82 97|Crocker sarcoma0000 Pharmacolo
P04959816T0000 |22 31|detectionson with 
P04959816T0000 |15 20|fluidCompa
P04959816T0000 |41 50|componenthosphatas
P04967824T0000 |0 7|EffectsP000016
P04967824T0000 |45 62|melanin synthesishatases and 5-nuc
P04967824T0000 |36 41|cycleine p
P04967824T0000 |11 22|temperature076 Compari
P04967824T0000 |70 74|newte P0
P04970131T0001 |50 55|studyes an
P04970131T0001 |72 81|embolismsP00008171
P04970131T0001 |5 23|reflexions apropos1606T0076 Comparis
P04970918T0069 |0 10|LA-3848-MSP00001606T
P04973523T0000 |37 45|antigensne phosp
P04973523T0000 |15 22|studiesCompari
P04975676T0000 |66 85|allotransplantationidase P00008171T000
P04975676T0000 |29 40|alterationsh alkaline 
P04975676T0000 |53 59|baboonand 5-
P04976988T0000 |0 13|HeterogeneityP00001606T007
P04976988T0000 |23 36|serum albuminon with alkal
P04989251T0000 |0 8|AnalysisP0000160
P04989251T0000 |12 27|corticosteroids76 Comparison w
P04990556T0000 |0 12|ReactivitiesP00001606T00
P04990556T0000 |38 46|globuline phosph
P04990556T0000 |16 21|horseompar
P04992478T0000 |0 18|Plasma histaminaseP00001606T0076 Com
P04992478T0000 |44 50|asthmaphatas
P04992478T0000 |22 30|patientsson with
P04992478T0000 |59 65|effectnucleo
P04992478T0000 |82 96|administration0000 Pharmacol
P04999086T0001 |103 110|monkeyspects o
P04999086T0001 |56 64|analyzer 5-nucle
P04999086T0001 |14 19|study Comp
P04999086T0001 |36 39|endine
P04999086T0001 |82 93|ontogenesis0000 Pharma
P04999086T0001 |115 118|mannat
P05000171T0000 |34 46|distributionaline phosph
P05000171T0000 |22 26|flowson 
P05000171T0000 |108 131|toad bladder epithelium of neonatal hyperbilir
P05000171T0000 |98 104|spacesic asp
P05000171T0000 |4 10|effect01606T
P05000171T0000 |50 72|horseradish peroxidasees and 5-nucleotidase 
P05005311T0000 |0 14|ImmunogenicityP00001606T0076
P05005311T0000 |61 67|levelscleoti
P05005311T0000 |26 38|mycobacteriawith alkalin
P05005311T0000 |106 113|speciests of n
P05005311T0000 |71 87|cross-protection P00008171T0000 
P05012220T0000 |35 50|proctocolectomyline phosphatas
P05012220T0000 |60 69|ileostomyucleotida
P05012220T0000 |9 19|experienceT0076 Comp
P05015678T0000 |48 56|chlorinsases and
P05015678T0000 |18 29|tautomerismparison wit
P05015678T0000 |33 43|porphyrinskaline pho
P05020660T0000 |0 7|FactorsP000016
P05020660T0000 |52 66|chlorpromazine and 5-nucleot
P05020660T0000 |22 32|inhibitionson with a
P05020660T0000 |36 48|phagocytosisine phosphat
P05021912T0000 |18 29|sensitivityparison wit
P05021912T0000 |74 84|pigeon eye0008171T00
P05025918T0000 |0 11|AngiographyP00001606T0
P05025918T0000 |26 35|bone cystwith alka
P05027295T0034 |0 14|CholinesteraseP00001606T0076
P05027799T0000 |0 18|Sodium restrictionP00001606T0076 Com
P05027799T0000 |30 37|failure alkali
P05028628T0001 |84 92|arteries00 Pharm
P05028628T0001 |26 38|examinationswith alkalin
P05028628T0001 |42 59|occlusion diseaseosphatases and 5-
P05031074T0001 |0 19|Serum lipid changesP00001606T0076 Comp
P05031074T0001 |27 36|pregnancyith alkal
P05031074T0001 |49 71|calcium administrationses and 5-nucleotidase
P05031659T0000 |24 35|candidiasisn with alka
P05031659T0000 |11 20|treatment076 Compa
P05031659T0000 |41 56|transfer factorhosphatases and
P05034373T0000 |68 79|requirementase P000081
P05034373T0000 |30 60|function oxidase enzyme system alkaline phosphatases and 5-n
P05034373T0000 |100 103|rat as
P05034373T0000 |11 15|role076 
P05034373T0000 |84 92|selenium00 Pharm
P05045351T0000 |23 28|apneaon wi
P05045351T0000 |40 47|infantsphospha
P05045351T0000 |9 18|breathingT0076 Com
P05049711T0000 |8 22|session report6T0076 Compari
P05049711T0000 |41 50|screeninghosphatas
P05060388T0000 |18 25|studiesparison
P05060388T0000 |40 46|tumorsphosph
P05060388T0000 |54 59|ovarynd 5-
P05065548T0075 |23 43|Dryopteris polylepison with alkaline pho
P05065548T0075 |7 19|constituents06T0076 Comp
P05066316T0001 |51 62|compositions and 5-nuc
P05066316T0001 |37 46|materialsne phosph
P05066316T0001 |24 29|ration wit
P05066316T0001 |95 111|aluminosilicateslogic aspects of
P05066316T0001 |66 74|productsidase P0
P05066316T0001 |82 91|synthesis0000 Phar
P05066316T0001 |0 8|RelationP0000160
P05068271T0000 |0 9|InfluenceP00001606
P05068271T0000 |13 17|diet6 Co
P05068271T0000 |29 42|VMA excretionh alkaline ph
P05075857T0000 |51 61|transientss and 5-nu
P05075857T0000 |70 82|sweep speedse P00008171T
P05075857T0000 |0 31|Oscilloscope triggering circuitP00001606T0076 Comparison with 
P05081814T0000 |0 11|DerivativesP00001606T0
P05081814T0000 |25 30|acids with
P05083872T0000 |70 79|audiologye P000081
P05083872T0000 |14 23|education Comparis
P05083872T0000 |4 10|status01606T
P05083872T0000 |28 45|training programsth alkaline phosp
P05083872T0000 |49 65|speech pathologyses and 5-nucleo
P05087496T0000 |9 17|arteriesT0076 Co
P05091970T0000 |10 16|agents0076 C
P05093030T0001 |68 75|methodsase P00
P05093030T0001 |79 106|medium-tension intophoresis71T0000 Pharmacologic aspec
P05093030T0001 |46 51|urineatase
P05093030T0001 |33 42|compoundskaline ph
P05093030T0001 |111 135|partition chromatography neonatal hyperbilirubin
P05093030T0001 |0 10|SeparationP00001606T
P05095988T0001 |42 57|system injuriesosphatases and 
P05095988T0001 |13 22|treatment6 Compari
P05101762T0000 |0 14|Spasmus nutansP00001606T0076
P05101762T0000 |18 26|syndromeparison 
P05110049T0001 |34 41|therapyaline p
P05110049T0001 |45 56|sclerodermahatases and
P05110049T0001 |4 8|data0160
P05114515T0000 |17 31|enzyme releasemparison with 
P05114515T0000 |57 62|drugs5-nuc
P05114515T0000 |40 53|normalizationphosphatases 
P05114515T0000 |83 96|polyarthritis000 Pharmacol
P05119546T0001 |0 9|TreatmentP00001606
P05119546T0001 |21 30|neoplasmsison with
P05120197T0000 |29 33|pigsh al
P05120197T0000 |13 25|pancreatitis6 Comparison
P05123884T0000 |24 46|4-chlorophenoxyacetaten with alkaline phosph
P05123884T0000 |10 20|metabolism0076 Compa
P05124707T0001 |0 8|DynamicsP0000160
P05124707T0001 |12 25|hospital stay76 Comparison
P05124707T0001 |36 50|ulcer patientsine phosphatas
P05124972T0042 |0 2|I.P0
P05128149T0001 |0 18|Surgical treatmentP00001606T0076 Com
P05128149T0001 |53 60|infarctand 5-n
P05128149T0001 |33 38|scarskalin
P05132558T0000 |19 27|caffeinearison w
P05132558T0000 |29 41|theophyllineh alkaline p
P05132558T0000 |63 91|monoamine oxidase inhibitorseotidase P00008171T0000 Phar
P05132558T0000 |46 57|theobromineatases and 
P05132558T0000 |4 15|interaction01606T0076 
P05133723T0000 |0 6|EffectP00001
P05133723T0000 |24 39|gluconeogenesisn with alkaline
P05133723T0000 |10 20|phenformin0076 Compa
P05133723T0000 |52 61|rat liver and 5-nu
P05135168T0000 |0 13|New alkaloidsP00001606T007
P05135168T0000 |27 49|Erythrophleum ivorenseith alkaline phosphata
P05135168T0000 |19 23|barkaris
P05138738T0001 |2 6|case0001
P05138738T0001 |10 26|M hemoglobinosis0076 Comparison 
P05145925T0000 |81 93|spleen cellsT0000 Pharma
P05145925T0000 |15 21|natureCompar
P05145925T0000 |59 68|potentialnucleotid
P05152314T0001 |11 23|oscillations076 Comparis
P05152314T0001 |29 51|gas dilution indicatorh alkaline phosphatase
P05154132T0000 |34 42|nitrogenaline ph
P05154132T0000 |73 77|calf0000
P05154132T0000 |23 30|sourceson with
P05154132T0000 |46 51|dietsatase
P05154132T0000 |4 9|value01606
P05162342T0001 |20 29|childhoodrison wit
P05162342T0001 |10 16|tumors0076 C
P05170106T0034 |119 126|trypsinl hyper
P05170106T0034 |148 150|NF97
P05170106T0034 |71 90|enzyme preparations P00008171T0000 Pha
P05170106T0034 |24 34|inspectionn with alk
P05170106T0034 |130 135|meansrubin
P05170106T0034 |0 7|ResultsP000016
P05170106T0034 |154 161|methods2 When 
P05170106T0034 |102 114|chymotrypsinspects of ne
P05172320T0001 |0 7|StudiesP000016
P05172320T0001 |62 71|referenceleotidase
P05172320T0001 |75 87|interdigital008171T0000 
P05172320T0001 |41 47|printshospha
P05172320T0001 |26 32|naturewith a
P05172320T0001 |92 100|triradiiacologic
P05172970T0001 |4 11|problem01606T0
P05172970T0001 |44 56|tuberculosisphatases and
P05172970T0001 |15 26|disablementComparison 
P05172970T0001 |93 100|historycologic
P05172970T0001 |77 85|analysis8171T000
P05172970T0001 |108 113|cases of n
P05172970T0001 |143 148|years00089
P05172970T0001 |129 135|Gdanskirubin
P05172970T0001 |65 70|basistidas
P05174753T0001 |14 24|dysostosis Compariso
P05177935T0001 |0 9|ProposalsP00001606
P05177935T0001 |13 26|authorization6 Comparison 
P05177935T0001 |66 75|hospitalsidase P00
P05177935T0001 |42 48|nursesosphat
P05177935T0001 |33 38|groupkalin
P05203499T0001 |103 109|spleenpects 
P05203499T0001 |58 69|description-nucleotida
P05203499T0001 |111 121|comparison neonatal 
P05203499T0001 |92 98|kidneyacolog
P05203499T0001 |77 90|thyroid gland8171T0000 Pha
P05203499T0001 |53 56|BSPand
P05203499T0001 |127 135|131-I-RBilirubin
P05203499T0001 |21 34|scintillationison with alk
P05210791T0001 |0 9|PneumoniaP00001606
P05210791T0001 |13 21|children6 Compar
P05253274T0001 |0 12|OsteosarcomaP00001606T00
P05253274T0001 |23 38|3,4-benzopyreneon with alkalin
P05274128T0001 |48 54|tartarases a
P05274128T0001 |31 44|galactosaminealkaline phos
P05274128T0001 |15 26|glucosamineComparison 
P05274128T0001 |4 11|content01606T0
P05274526T0000 |0 7|RelapseP000016
P05274526T0000 |11 19|leukemia076 Comp
P05274526T0000 |36 45|remissionine phosp
P05276380T0000 |0 9|InfluenceP00001606
P05276380T0000 |13 30|cigarette smoking6 Comparison with
P05276380T0000 |39 62|blood coagulation tests phosphatases and 5-nuc
P05284310T0000 |16 24|fluorideompariso
P05284310T0000 |86 89|rat Ph
P05284310T0000 |43 57|plasma calciumsphatases and 
P05284310T0000 |32 39|controllkaline
P05285978T0076 |7 13|report06T007
P05285978T0076 |31 45|Cancer Societyalkaline phosp
P05299993T0000 |0 12|ModificationP00001606T00
P05299993T0000 |30 41|Tetrahymena alkaline p
P05299993T0000 |83 92|mechanism000 Pharm
P05299993T0000 |45 54|compoundshatases a
P05299993T0000 |20 26|growthrison 
P05303700T0066 |0 12|SAM-TR-68-54P00001606T00
P05305671T0000 |22 40|color deficienciesson with alkaline 
P05305671T0000 |8 18|discussion6T0076 Com
P05308271T0000 |0 3|BIMP00
P05309471T0000 |0 8|ProblemsP0000160
P05309471T0000 |58 76|influenza vaccines-nucleotidase P000
P05309471T0000 |47 54|contenttases a
P05309471T0000 |16 29|determinationomparison wit
P05316745T0000 |51 65|Singapore Citys and 5-nucleo
P05316745T0000 |15 17|L.Co
P05316745T0000 |23 39|Aedes albopictuson with alkaline
P05316745T0000 |41 46|Skusehosph
P05316745T0000 |0 13|Aedes aegyptiP00001606T007
P05322558T0000 |0 18|Homograft responseP00001606T0076 Com
P05322558T0000 |93 97|micecolo
P05322558T0000 |23 47|hemagglutinin productionon with alkaline phospha
P05322747T0034 |32 40|overloadlkaline 
P05322747T0034 |47 58|tolbutamidetases and 5
P05322747T0034 |63 73|tolazamideeotidase P
P05322747T0034 |12 17|study76 Co
P05322747T0034 |97 105|subjectsgic aspe
P05340801T0000 |0 10|MycotoxinsP00001606T
P05340801T0000 |24 29|foodsn wit
P05344097T0000 |68 83|Vibrio choleraease P00008171T0
P05344097T0000 |29 64|skin permeability factor productionh alkaline phosphatases and 5-nucle
P05344097T0000 |0 7|FactorsP000016
P05353667T0000 |34 45|micturitionaline phosp
P05353667T0000 |7 26|cord representation06T0076 Comparison 
P05356107T0001 |70 74|dogse P0
P05356107T0001 |11 17|action076 Co
P05356107T0001 |53 66|tritium oxideand 5-nucleot
P05356107T0001 |22 30|kineticsson with
P05356107T0001 |38 49|eliminatione phosphata
P05357390T0001 |0 4|AutoP000
P05357390T0001 |10 17|isotopy0076 Co
P05357390T0001 |25 36|conjunctiva with alkal
P05359464T0000 |0 8|PitfallsP0000160
P05359464T0000 |16 19|useomp
P05359464T0000 |23 53|chromosome aberration analysison with alkaline phosphatases 
P05359464T0000 |69 88|radiation dosimetryse P00008171T0000 P
P05362866T0000 |0 15|Renin secretionP00001606T0076 
P05362866T0000 |45 57|hypertensionhatases and 
P05363816T0001 |4 8|need0160
P05363816T0001 |57 61|list5-nu
P05363816T0001 |40 49|expertisephosphata
P05363816T0001 |95 102|actionslogic a
P05364951T0001 |0 14|HistopathologyP00001606T0076
P05364951T0001 |19 31|pathogenesisarison with 
P05364951T0001 |49 56|virosesses and
P05368978T0000 |0 11|CNS effectsP00001606T0
P05368978T0000 |21 32|anestheticsison with a
P05368978T0000 |70 86|amine mechanismse P00008171T0000
P05372511T0105 |0 18|Diethylene benzeneP00001606T0076 Com
P05379901T0000 |17 31|flood channelsmparison with 
P05379901T0000 |0 13|Midge controlP00001606T007
P05388567T0000 |69 75|musclese P00
P05388567T0000 |30 43|aminophylline alkaline pho
P05388567T0000 |15 25|taloximineComparison
P05388567T0000 |4 11|effects01606T0
P05389125T0000 |51 55|mices an
P05389125T0000 |16 25|behaviouromparison
P05394352T0000 |0 12|GenitographyP00001606T00
P05394352T0000 |28 34|statesth alk
P05394461T0001 |0 14|Tolerance testP00001606T0076
P05394461T0001 |28 46|animal experimentsth alkaline phosph
P05394461T0001 |18 20|HBpa
P05410590T0000 |33 43|preventionkaline pho
P05410590T0000 |4 8|role0160
P05410590T0000 |47 70|bladder tumor formationtases and 5-nucleotidas
P05410590T0000 |21 25|acidison
P05410641T0000 |17 29|Venturi maskmparison wit
P05410641T0000 |45 59|airway diseasehatases and 5-
P05410641T0000 |8 15|percent6T0076 
P05412122T0000 |3 9|Methyl001606
P05412122T0000 |63 65|,7eo
P05412122T0000 |25 45|8-phenyl derivatives with alkaline phosp
P05412122T0000 |11 19|8-methyl076 Comp
P05412122T0000 |66 79|benzomorphansidase P000081
P05412687T0000 |81 95|tract neuronesT0000 Pharmaco
P05412687T0000 |11 19|invasion076 Comp
P05412687T0000 |46 67|collateral inhibitionatases and 5-nucleoti
P05412687T0000 |23 31|impulseson with 
P05413428T0000 |4 16|distribution01606T0076 C
P05413428T0000 |74 91|combat casualties0008171T0000 Phar
P05413428T0000 |42 52|hemorrhageosphatases
P05413428T0000 |57 70|resuscitation5-nucleotidas
P05413428T0000 |20 31|body fluidsrison with 
P05414186T0001 |37 48|Netherlandsne phosphat
P05414186T0001 |10 29|Hong Kong influenza0076 Comparison wit
P05417431T0001 |35 39|centline
P05417431T0001 |6 16|disagnosis606T0076 C
P05417431T0001 |47 55|patientstases an
P05417431T0001 |20 26|cancerrison 
P05421537T0001 |0 12|DifficultiesP00001606T00
P05421537T0001 |35 51|sputum viscosityline phosphatase
P05424220T0001 |0 19|Lipid concentrationP00001606T0076 Comp
P05424220T0001 |24 39|lipase activityn with alkaline
P05424220T0001 |47 56|epiphysistases and
P05424220T0001 |92 96|foodacol
P05424220T0001 |77 81|rats8171
P05424220T0001 |112 126|sodium contentneonatal hyper
P05425195T0001 |0 8|BehaviorP0000160
P05425195T0001 |12 38|aspartate aminotransferase76 Comparison with alkalin
P05425195T0001 |134 152|radiation syndromenemia. P00008997A0
P05425195T0001 |82 84|EC00
P05425195T0001 |40 42|ECph
P05425195T0001 |56 80|alanine aminotransferase 5-nucleotidase P0000817
P05425195T0001 |169 187|body X-irradiation3-] is shown as a 
P05425195T0001 |97 106|rat serumgic aspec
P05425195T0001 |118 124|courseal hyp
P05437405T0000 |85 99|salt retention0 Pharmacologi
P05437405T0000 |11 18|forearm076 Com
P05437405T0000 |30 46|dilator capacity alkaline phosph
P05437405T0000 |103 106|manpec
P05441564T0001 |0 7|StudiesP000016
P05441564T0001 |46 51|virusatase
P05441564T0001 |60 67|mutantsucleoti
P05441564T0001 |15 28|pathogenicityComparison wi
P05441564T0001 |40 44|HILLphos
P05441564T0001 |72 85|suckling miceP00008171T000
P05441564T0001 |32 36|ECHOlkal
P05445187T0000 |69 74|waterse P0
P05445187T0000 |79 91|heat balance71T0000 Phar
P05445187T0000 |49 57|passagesses and 
P05445187T0000 |59 65|effectnucleo
P05445187T0000 |16 29|heat exchangeomparison wit
P05451324T0000 |0 11|CalibrationP00001606T0
P05451324T0000 |41 48|contenthosphat
P05451324T0000 |61 64|Po2cle
P05451324T0000 |32 37|bloodlkali
P05451324T0000 |18 28|correctionparison wi
P05451324T0000 |69 82|CO saturationse P00008171T
P05456002T0000 |17 32|doctor shortagemparison with a
P05456002T0000 |0 8|Mae WestP0000160
P05460466T0001 |0 11|EliminationP00001606T0
P05460466T0001 |62 79|drug preparationsleotidase P000081
P05460466T0001 |15 32|gamma-irradiationComparison with a
P05460466T0001 |41 50|oxidationhosphatas
P05463837T0023 |50 54|acides a
P05463837T0023 |30 33|C-2 al
P05463837T0023 |13 26|configuration6 Comparison 
P05466177T0001 |23 36|actinomycin Don with alkal
P05466177T0001 |12 19|effects76 Comp
P05466177T0001 |40 44|ratsphos
P05471866T0000 |4 39|plasma growth hormone concentration01606T0076 Comparison with alkaline
P05471866T0000 |54 58|lambnd 5
P05472485T0000 |36 43|rodentsine pho
P05472485T0000 |8 32|cochlear response curves6T0076 Comparison with a
P05474466T0001 |65 71|factortidase
P05474466T0001 |45 50|assayhatas
P05474466T0001 |6 27|hemagglutination test606T0076 Comparison w
P05488121T0000 |0 16|CO2 assimilationP00001606T0076 C
P05488121T0000 |20 32|chloroplastsrison with a
P05488121T0000 |48 60|filter paperases and 5-n
P05492285T0000 |4 11|biology01606T0
P05492285T0000 |15 35|Hyostrongylus ruidusComparison with alka
P05496619T0000 |20 52|air pollution control activitiesrison with alkaline phosphatases
P05496619T0000 |8 16|profiles6T0076 C
P05497793T0000 |0 7|EffectsP000016
P05497793T0000 |60 68|activityucleotid
P05497793T0000 |130 142|environmentsrubinemia. P
P05497793T0000 |104 108|ratsects
P05497793T0000 |19 40|metaraminol treatmentarison with alkaline 
P05500957T0001 |19 28|clopamidearison wi
P05500957T0001 |106 115|pregnancyts of neo
P05500957T0001 |62 71|treatmentleotidase
P05500957T0001 |44 53|Brinedinephatases 
P05500957T0001 |4 15|association01606T0076 
P05500957T0001 |93 102|syndromescologic a
P05500957T0001 |33 42|hyderginekaline ph
P05501347T0001 |69 79|rat kidneyse P000081
P05501347T0001 |53 61|functionand 5-nu
P05501347T0001 |91 99|ischemiamacologi
P05501347T0001 |38 48|metabolisme phosphat
P05501347T0001 |4 10|effect01606T
P05501347T0001 |18 34|dosage radiationparison with alk
P05502054T0000 |0 8|LeukemiaP0000160
P05502054T0000 |12 17|twins76 Co
P05502054T0000 |30 36|review alkal
P05502054T0000 |49 54|casesses a
P05525652T0064 |12 18|report76 Com
P05529283T0000 |0 12|QuantitationP00001606T00
P05529283T0000 |47 53|healthtases 
P05529283T0000 |25 28|IgA wi
P05529283T0000 |58 65|disease-nucleo
P05529283T0000 |38 43|serume pho
P05532854T0001 |17 31|manifestationsmparison with 
P05532854T0001 |44 53|sclerosisphatases 
P05533214T0001 |0 17|Iodine metabolismP00001606T0076 Co
P05533214T0001 |29 40|thyroiditish alkaline 
P05536803T0001 |84 94|furosemide00 Pharmac
P05536803T0001 |74 80|effect000817
P05536803T0001 |6 16|body water606T0076 C
P05536803T0001 |52 57|space and 
P05536803T0001 |18 33|rhodanide spaceparison with al
P05544291T0031 |0 2|V.P0
P05552149T0000 |0 3|18FP00
P05552149T0000 |32 37|studylkali
P05552149T0000 |8 24|85Sr scintimetry6T0076 Compariso
P05552149T0000 |49 62|arthropathiesses and 5-nuc
P05552642T0000 |0 11|PropagationP00001606T0
P05552642T0000 |80 84|rats1T00
P05552642T0000 |65 76|trophoblasttidase P000
P05552642T0000 |16 34|hormone productionomparison with alk
P05553261T0000 |0 6|HealthP00001
P05553261T0000 |23 32|reticulumon with a
P05555149T0001 |54 64|S-S-groupsnd 5-nucle
P05555149T0001 |46 48|SHat
P05555149T0001 |23 29|methodon wit
P05556977T0001 |0 13|MorphogenesisP00001606T007
P05556977T0001 |52 64|regeneration and 5-nucle
P05556977T0001 |72 100|phasmid Carausius morosus BrP00008171T0000 Pharmacologic
P05556977T0001 |21 31|trochanterison with 
P05560428T0001 |52 57|sleep and 
P05560428T0001 |62 73|wakefulnessleotidase P
P05560428T0001 |30 40|expression alkaline 
P05560428T0001 |77 85|reptiles8171T000
P05567721T0000 |17 32|thromboplastinsmparison with a
P05567721T0000 |36 57|factor VII deficiencyine phosphatases and 
P05567721T0000 |0 13|SensitivitiesP00001606T007
P05572662T0000 |0 7|CentralP000016
P05572662T0000 |15 23|catheterComparis
P05572662T0000 |56 73|electrocardiogram 5-nucleotidase P
P05574818T0000 |34 37|useali
P05574818T0000 |121 127|musclehyperb
P05574818T0000 |45 50|studyhatas
P05574818T0000 |4 7|Lab016
P05574818T0000 |10 29|computer programmes0076 Comparison wit
P05574818T0000 |81 108|contractile characteristicsT0000 Pharmacologic aspects
P05593469T0001 |16 24|injuriesompariso
P05594277T0051 |103 109|mediumpects 
P05594277T0051 |40 54|Jensen sarcomaphosphatases a
P05594277T0051 |20 30|P32 uptakerison with
P05594277T0051 |77 85|peroxide8171T000
P05594277T0051 |4 16|modification01606T0076 C
P05595036T0001 |0 8|StudentsP0000160
P05595036T0001 |40 49|disordersphosphata
P05595036T0001 |10 17|parents0076 Co
P05595036T0001 |19 27|teachersarison w
P05621339T0001 |33 50|Cs137 irradiationkaline phosphatas
P05621339T0001 |24 29|dosesn wit
P05627251T0000 |54 59|sleepnd 5-
P05627251T0000 |9 15|shiftsT0076 
P05627251T0000 |25 40|skin potentials with alkaline 
P05642051T0000 |19 40|department managementarison with alkaline 
P05671267T0000 |51 57|pyridos and 
P05671267T0000 |64 71|azepineotidase
P05671267T0000 |30 46|dihydro-5H-benzo alkaline phosph
P05671267T0000 |3 22|Dimethylaminopropyl001606T0076 Compari
P05672903T0001 |0 23|Osteogenesis imperfectaP00001606T0076 Comparis
P05683363T0001 |0 13|InvestigationP00001606T007
P05683363T0001 |79 94|analysis method71T0000 Pharmac
P05683363T0001 |21 29|exchangeison wit
P05683363T0001 |59 63|ratsnucl
P05683363T0001 |33 37|Ca45kali
P05683809T0000 |0 6|EffectP00001
P05683809T0000 |94 107|blood vesselsologic aspect
P05683809T0000 |40 45|drugsphosp
P05683809T0000 |130 137|studiesrubinem
P05683809T0000 |53 83|surface charge characteristicsand 5-nucleotidase P00008171T0
P05684081T0001 |0 12|MeasurementsP00001606T00
P05684081T0001 |16 24|activityompariso
P05684081T0001 |74 89|osimeter VA-J180008171T0000 Ph
P05684081T0001 |50 66|chamber VA-K-254es and 5-nucleot
P05689427T0052 |3 37|N-Alkyl-N-2-chloroethylaminomethyl001606T0076 Comparison with alkali
P05689427T0052 |61 62|bc
P05689427T0052 |72 86|hydrochloridesP00008171T0000
P05692759T0001 |0 11|NephrectomyP00001606T0
P05692759T0001 |23 29|cattleon wit
P05693602T0001 |0 10|EvaluationP00001606T
P05693602T0001 |24 43|blood cell countersn with alkaline pho
P05693605T0001 |17 30|transaminasesmparison with
P05693605T0001 |39 51|autoanalyzer phosphatase
P05693605T0001 |0 13|DeterminationP00001606T007
P05715613T0000 |0 7|SterolsP000016
P05715613T0000 |11 17|pollen076 Co
P05718386T0001 |23 32|skin flapon with a
P05718386T0001 |40 52|complicationphosphatases
P05718386T0001 |59 68|treatmentnucleotid
P05718386T0001 |8 12|cyst6T00
P05718386T0001 |82 88|hernia0000 P
P05718500T0001 |33 40|deciduakaline 
P05718500T0001 |63 72|pregnancyeotidase 
P05718500T0001 |13 25|observations6 Comparison
P05718500T0001 |55 59|halfd 5-
P05718994T0000 |54 65|coarctationnd 5-nucleo
P05718994T0000 |79 84|aorta71T00
P05718994T0000 |12 27|fibro-elastosis76 Comparison w
P05718994T0000 |36 48|incompetenceine phosphat
P05719031T0000 |0 7|StudiesP000016
P05719031T0000 |25 39|size reduction with alkaline
P05719031T0000 |15 21|methodCompar
P05719031T0000 |53 62|compoundsand 5-nuc
P05719746T0001 |0 8|ChildrenP0000160
P05719746T0001 |24 30|visionn with
P05722341T0000 |0 14|IdentificationP00001606T0076
P05722341T0000 |53 66|disaccharidesand 5-nucleot
P05722341T0000 |90 104|chromatographyrmacologic asp
P05722341T0000 |19 29|estimationarison wit
P05722341T0000 |33 48|monosaccharideskaline phosphat
P05722341T0000 |70 75|urinee P00
P05725509T0000 |0 8|SteroidsP0000160
P05725509T0000 |12 20|germfree76 Compa
P05725509T0000 |38 42|ratse ph
P05727222T0000 |4 11|effects01606T0
P05727222T0000 |52 70|oxygen consumption and 5-nucleotidas
P05727222T0000 |74 90|Callionymus lyra0008171T0000 Pha
P05727222T0000 |39 44|pumps phos
P05732641T0001 |34 49|mosquito larvaealine phosphata
P05732641T0001 |10 25|sevine activity0076 Comparison
P05732641T0001 |0 6|TrialsP00001
P05733952T0001 |87 94|culturePharmac
P05733952T0001 |31 40|integrityalkaline 
P05733952T0001 |4 16|significance01606T0076 C
P05733952T0001 |53 59|tissueand 5-
P05733952T0001 |64 83|antibody productionotidase P00008171T0
P05733953T0001 |34 39|fieldaline
P05733953T0001 |4 10|effect01606T
P05733953T0001 |58 66|activity-nucleot
P05733953T0001 |70 79|Parameciae P000081
P05734847T0000 |0 7|StudiesP000016
P05734847T0000 |29 54|Glossina morsitans colonyh alkaline phosphatases a
P05734847T0000 |58 64|Lisbon-nucle
P05740389T0001 |0 9|RelationsP00001606
P05740389T0001 |29 39|mechanismsh alkaline
P05740389T0001 |54 61|effectsnd 5-nu
P05742879T0000 |0 15|TransformationsP00001606T0076 
P05742879T0000 |23 38|morphine serieson with alkalin
P05749438T0001 |76 82|CI-58108171T
P05749438T0001 |28 42|o-chlorophenylth alkaline ph
P05749438T0001 |13 24|anesthetics6 Compariso
P05749438T0001 |46 74|methyl-amino cyclohexane HCLatases and 5-nucleotidase P0
P05750950T0001 |0 6|EstrusP00001
P05750950T0001 |22 31|abilitiesson with 
P05750950T0001 |55 59|ratsd 5-
P05751819T0000 |85 93|calvings0 Pharma
P05751819T0000 |15 21|seasonCompar
P05751819T0000 |97 109|Hariana cowsgic aspects 
P05751819T0000 |26 34|sequencewith alk
P05751819T0000 |62 66|maleleot
P05751819T0000 |38 45|calvinge phosp
P05751819T0000 |4 11|bearing01606T0
P05751819T0000 |49 58|frequencyses and 5
P05758469T0001 |0 20|Hemodynamics changesP00001606T0076 Compa
P05758469T0001 |24 27|mann w
P05758469T0001 |35 41|flightline p
P05760665T0000 |0 17|Caries preventionP00001606T0076 Co
P05760665T0000 |32 38|officelkalin
P05763287T0063 |0 2|I.P0
P05763347T0000 |70 81|propranolole P00008171
P05763347T0000 |25 35|inhibition with alka
P05763347T0000 |9 21|applicationsT0076 Compar
P05763347T0000 |55 64|receptorsd 5-nucle
P05769307T0000 |0 18|Automatic view boxP00001606T0076 Com
P05774062T0000 |0 11|MeasurementP00001606T0
P05774062T0000 |41 53|conductivityhosphatases 
P05774062T0000 |23 37|acid secretionon with alkali
P05779953T0000 |51 54|FSHs a
P05779953T0000 |10 20|castration0076 Compa
P05779953T0000 |38 46|serum LHe phosph
P05779953T0000 |82 86|rats0000
P05779953T0000 |0 6|EffectP00001
P05781385T0000 |102 118|Nocardia speciesspects of neonat
P05781385T0000 |24 55|phenolphthalein sulphatase testn with alkaline phosphatases an
P05781385T0000 |64 79|differentiationotidase P000081
P05781385T0000 |4 16|significance01606T0076 C
P05781385T0000 |84 98|identification00 Pharmacolog
P05782943T0001 |0 12|RelationshipP00001606T00
P05782943T0001 |59 63|skinnucl
P05782943T0001 |30 51|sarcoidosis granuloma alkaline phosphatase
P05782943T0001 |16 26|mast cellsomparison 
P05787318T0000 |33 42|Atromid-Skaline ph
P05787318T0000 |47 59|serum lipidstases and 5-
P05787318T0000 |10 17|effects0076 Co
P05787318T0000 |63 66|maneot
P05787318T0000 |21 31|clofibrateison with 
P05789870T0001 |51 69|hyperbilirubinemias and 5-nucleotida
P05789870T0001 |0 42|Phosphate glucose dehydrogenase deficiencyP00001606T0076 Comparison with alkaline ph
P05792868T0000 |0 37|Evidence forthe electroosmosis theoryP00001606T0076 Comparison with alkali
P05792868T0000 |41 50|transporthosphatas
P05792868T0000 |58 64|phloem-nucle
P05792911T0000 |0 7|EffectsP000016
P05792911T0000 |107 115|subjectss of neo
P05792911T0000 |48 66|airway conductanceases and 5-nucleot
P05792911T0000 |27 44|receptor blockadeith alkaline phos
P05792911T0000 |71 82|lung volume P00008171T
P05794247T0000 |0 6|EffectP00001
P05794247T0000 |41 65|serum lipoprotein lipasehosphatases and 5-nucleo
P05794247T0000 |73 78|liver00008
P05794247T0000 |25 37|inactivation with alkali
P05794247T0000 |10 17|heparin0076 Co
P05794247T0000 |97 101|dogsgic 
P05796272T0000 |13 37|chlorpromazine cataracts6 Comparison with alkali
P05797287T0069 |0 2|I.P0
P05798063T0000 |0 10|SpecialistP00001606T
P05798063T0000 |31 40|prototypealkaline 
P05798063T0000 |14 29|family practice Comparison wit
P05798063T0000 |46 52|doctoratases
P05799686T0001 |119 132|incorporationl hyperbiliru
P05799686T0001 |94 97|aidolo
P05799686T0001 |29 41|chemotherapyh alkaline p
P05799686T0001 |75 84|carcinoma008171T00
P05799686T0001 |4 15|possibility01606T0076 
P05799686T0001 |143 154|idoxuridine0008997A047
P05799686T0001 |101 114|cytodiagnosisaspects of ne
P05805644T0001 |34 46|distributionaline phosph
P05805644T0001 |60 65|224Raucleo
P05805644T0001 |125 139|colloidal ThO2rbilirubinemia
P05805644T0001 |108 121|incorporation of neonatal 
P05805644T0001 |73 76|RES000
P05805644T0001 |50 55|228Raes an
P05805644T0001 |93 101|skeletoncologic 
P05805644T0001 |0 9|VariationP00001606
P05806615T0001 |99 104|valuec asp
P05806615T0001 |10 21|degradation0076 Compar
P05806615T0001 |73 79|stages000081
P05806615T0001 |47 52|studytases
P05806615T0001 |129 135|soluteirubin
P05806615T0001 |25 45|adrenaline solutions with alkaline phosp
P05806615T0001 |113 120|controleonatal
P05806936T0000 |0 10|AbsorptionP00001606T
P05806936T0000 |14 26|electrolytes Comparison 
P05806936T0000 |45 50|caseshatas
P05806936T0000 |36 41|colonine p
P05806936T0000 |88 96|subjectsharmacol
P05806936T0000 |65 72|colitistidase 
P05807222T0052 |0 13|Ion injectionP00001606T007
P05810259T0001 |0 17|Polyvinyl alcoholP00001606T0076 Co
P05810259T0001 |23 40|solution mediatoron with alkaline 
P05819249T0000 |0 6|MiningP00001
P05819249T0000 |22 30|iron oreson with
P05822499T0034 |17 29|digiprogeninmparison wit
P05822499T0034 |4 13|structure01606T007
P05823624T0031 |4 8|need0160
P05823624T0031 |22 30|hospitalson with
P05826818T0098 |0 2|I.P0
P05833022T0001 |85 93|epilepsy0 Pharma
P05833022T0001 |58 70|brain tissue-nucleotidas
P05833022T0001 |20 27|changesrison w
P05833022T0001 |7 16|character06T0076 C
P05833022T0001 |35 50|enzyme activityline phosphatas
P05836483T0000 |17 25|teratomamparison
P05836483T0000 |29 34|liverh alk
P05836483T0000 |38 47|childhoode phospha
P05837169T0001 |0 14|MethoxyfluraneP00001606T0076
P05837169T0001 |25 33|function with al
P05839844T0000 |0 14|HistochemistryP00001606T0076
P05839844T0000 |73 85|Aflatoxin B100008171T000
P05839844T0000 |48 61|liver lesionsases and 5-nu
P05839844T0000 |89 98|ducklingsarmacolog
P05839844T0000 |19 38|electron microscopyarison with alkalin
P05847772T0001 |57 64|surgery5-nucle
P05847772T0001 |28 34|ureterth alk
P05847772T0001 |11 20|disorders076 Compa
P05850652T0001 |0 5|StudyP0000
P05850652T0001 |108 111|rat of
P05850652T0001 |63 77|I-131-trioleineotidase P0000
P05850652T0001 |13 24|alterations6 Compariso
P05850652T0001 |39 49|absorption phosphata
P05850652T0001 |92 96|bodyacol
P05850652T0001 |54 59|meansnd 5-
P05857301T0000 |0 8|ChemicalP0000160
P05857301T0000 |76 82|routes08171T
P05857301T0000 |57 62|CC1-45-nuc
P05857301T0000 |86 100|administration Pharmacologic
P05857301T0000 |36 45|responsesine phosp
P05857301T0000 |49 53|ratsses 
P05858571T0000 |21 28|1,3-bisison wi
P05858571T0000 |29 42|2-chloroethylh alkaline ph
P05858571T0000 |9 15|trialsT0076 
P05858571T0000 |46 57|nitrosoureaatases and 
P05858571T0000 |59 69|NSC-409962nucleotida
P05859016T0000 |0 26|Hydroxypropyl methacrylateP00001606T0076 Comparison 
P05859016T0000 |49 65|embedding mediumses and 5-nucleo
P05859016T0000 |70 89|electron microscopye P00008171T0000 Ph
P05879595T0094 |0 10|StatisticsP00001606T
P05879595T0094 |25 30|years with
P05881833T0001 |64 76|Lower Saxonyotidase P000
P05881833T0001 |27 35|leucosisith alka
P05881833T0001 |44 51|controlphatase
P05881833T0001 |7 16|diagnosis06T0076 C
P05884183T0001 |0 10|ExperienceP00001606T
P05884183T0001 |93 101|culturescologic 
P05884183T0001 |111 114|use ne
P05884183T0001 |130 136|methodrubine
P05884183T0001 |35 59|agglutination propertiesline phosphatases and 5-
P05884183T0001 |20 31|restorationrison with 
P05884183T0001 |118 127|Rzhaninoval hyperb
P05890093T0000 |0 5|StudyP0000
P05890093T0000 |63 70|hypoxiaeotidas
P05890093T0000 |28 39|mouse fetusth alkaline
P05890093T0000 |121 135|mother animalshyperbilirubin
P05890093T0000 |97 115|hypervitaminosis-Agic aspects of neo
P05890093T0000 |9 20|micromeliasT0076 Compa
P05890093T0000 |72 78|trypanP00008
P05890093T0000 |50 61|x-radiationes and 5-nu
P05890093T0000 |143 152|pregnancy0008997A0
P05890093T0000 |84 93|injection00 Pharma
P05890351T0001 |35 41|wealthline p
P05890351T0001 |6 23|antitetanus serum606T0076 Comparis
P05893495T0001 |0 7|StudiesP000016
P05893495T0001 |30 39|infection alkaline
P05893495T0001 |43 50|rabbitssphatas
P05896996T0001 |17 29|aminoketonesmparison wit
P05896996T0001 |45 48|agehat
P05896996T0001 |3 13|catabolism001606T007
P05901778T0000 |38 48|depositione phosphat
P05901778T0000 |52 56|mice and
P05901778T0000 |22 30|patternsson with
P05901778T0000 |4 10|effect01606T
P05902458T0001 |0 11|NaphthaleneP00001606T0
P05902458T0001 |48 58|toxicologyases and 5
P05902458T0001 |16 35|paradichlorobenzeneomparison with alka
P05909034T0000 |0 7|StudiesP000016
P05909034T0000 |20 32|preparationsrison with a
P05917315T0026 |2 13|case report0001606T007
P05917315T0026 |42 47|studyospha
P05919308T0001 |51 79|monoamine oxidase inhibitorss and 5-nucleotidase P000081
P05919308T0001 |0 12|InteractionsP00001606T00
P05919308T0001 |21 32|adrenergicsison with a
P05919308T0001 |34 46|adrenolyticsaline phosph
P05930797T0000 |33 53|isoprecipitin systemkaline phosphatases 
P05930797T0000 |8 15|studies6T0076 
P05930797T0000 |55 72|Australia antigend 5-nucleotidase 
P05933228T0000 |36 50|neurosecretionine phosphatas
P05933228T0000 |11 18|rhythms076 Com
P05933228T0000 |22 32|indicatorsson with a
P05938720T0000 |0 5|StoryP0000
P05938720T0000 |11 19|hospital076 Comp
P05938720T0000 |36 64|employee orientation programine phosphatases and 5-nucle
P05939748T0000 |18 27|Pap smearparison w
P05942953T0049 |0 2|I.P0
P05947377T0001 |70 87|growth deficiencye P00008171T0000 
P05947377T0001 |31 37|uptakealkali
P05947377T0001 |45 52|thyroidhatases
P05947377T0001 |56 64|children 5-nucle
P05947377T0001 |11 22|test iodine076 Compari
P05947377T0001 |24 29|I-132n wit
P05949971T0000 |0 11|PersistenceP00001606T0
P05949971T0000 |15 24|toxapheneCompariso
P05949971T0000 |36 41|lakesine p
P05959588T0000 |0 7|StudiesP000016
P05959588T0000 |30 46|virus infections alkaline phosph
P05959588T0000 |11 27|Coxsackie B Type076 Comparison w
P05960999T0001 |0 5|ValueP0000
P05960999T0001 |181 186|serum as a
P05960999T0001 |134 145|capillariesnemia. P000
P05960999T0001 |94 101|proteinologic 
P05960999T0001 |13 19|method6 Comp
P05960999T0001 |150 166|slide latex testA0472 When CSF [
P05960999T0001 |53 69|polysaccharide Cand 5-nucleotida
P05960999T0001 |23 47|passive hemagglutinationon with alkaline phospha
P05960999T0001 |117 130|precipitationtal hyperbili
P05967610T0000 |51 71|noradrenaline uptakes and 5-nucleotidase
P05967610T0000 |91 99|membranemacologi
P05967610T0000 |75 78|cat008
P05967610T0000 |11 25|nerve function076 Comparison
P05967610T0000 |106 125|reserpine treatmentts of neonatal hype
P05967610T0000 |27 46|noradrenaline levelith alkaline phosph
P05969185T0001 |0 10|ConcussionP00001606T
P05969185T0001 |25 29|cord wit
P05982700T0000 |0 5|StudyP0000
P05982700T0000 |13 24|evagination6 Compariso
P05982700T0000 |28 50|Cysticercus pisiformisth alkaline phosphatas
P05985275T0000 |41 54|acorn extracthosphatases a
P05985275T0000 |14 23|substance Comparis
P05992157T0001 |21 43|Achromobacter puntatumison with alkaline pho
P05992157T0001 |53 60|bloodedand 5-n
P05992157T0001 |78 85|animals171T000
P05992157T0001 |4 17|pathogenicity01606T0076 Co
P05994421T0045 |0 13|ConsanguinityP00001606T007
P05994421T0045 |52 58|region and 5
P05994421T0045 |62 67|Nunoaleoti
P05994421T0045 |35 44|marriagesline phos
P05994421T0045 |18 27|migrationparison w
P05994421T0045 |69 77|Santiagose P0000
P05995140T0001 |48 61|glucose levelases and 5-nu
P05995140T0001 |65 71|tumorstidase
P05995140T0001 |7 13|amount06T007
P05995140T0001 |18 30|significanceparison with
P05999607T0001 |0 7|StudiesP000016
P05999607T0001 |11 22|lipogenesis076 Compari
P05999607T0001 |62 65|ratleo
P05999607T0001 |35 45|precursorsline phosp
P06012827T0000 |16 23|studiesomparis
P06012827T0000 |46 52|systematases
P06012827T0000 |83 87|rats000 
P06027841T0000 |16 21|249Bkompar
P06027841T0000 |58 75|emission spectrum-nucleotidase P00
P06027841T0000 |31 50|hyperfine structurealkaline phosphatas
P06027841T0000 |8 12|spin6T00
P06035001T0000 |38 49|guinea pigse phosphata
P06035001T0000 |60 70|injectionsucleotidas
P06035001T0000 |24 34|resorptionn with alk
P06035001T0000 |74 85|trypan blue0008171T000
P06035001T0000 |8 20|observations6T0076 Compa
P06048505T0000 |0 11|DerivativesP00001606T0
P06048505T0000 |15 23|fluoreneComparis
P06051644T0000 |39 52|determination phosphatases
P06051644T0000 |56 66|creatinine 5-nucleot
P06051644T0000 |15 21|methodCompar
P06051644T0000 |8 12|Slot6T00
P06054411T0000 |34 52|gas chromatographyaline phosphatases
P06054411T0000 |60 66|seriesucleot
P06054411T0000 |70 89|combination columnse P00008171T0000 Ph
P06054411T0000 |22 30|steroidsson with
P06054411T0000 |0 18|Retention behaviorP00001606T0076 Com
P06065507T0000 |19 30|hypertrophyarison with
P06065507T0000 |45 49|ratshata
P06070204T0025 |0 3|XXIP00
P06072512T0000 |37 43|actionne pho
P06072512T0000 |47 51|ureatase
P06072512T0000 |9 19|evaluationT0076 Comp
P06073427T0001 |68 73|bloodase P
P06073427T0001 |78 83|urine171T0
P06073427T0001 |16 32|characteriaztionomparison with a
P06073427T0001 |87 94|rabbitsPharmac
P06073427T0001 |50 60|interferones and 5-n
P06074093T0001 |0 4|IronP000
P06074093T0001 |30 39|pregnancy alkaline
P06074093T0001 |9 26|folate deficiencyT0076 Comparison 
P06074640T0001 |0 9|SymposiumP00001606
P06074640T0001 |30 46|encephalopathies alkaline phosph
P06084279A0218 |21 29|patientsison wit
P06084279A0218 |36 40|riseine 
P06084279A0218 |78 82|ERCP171T
P06084279A0218 |54 67|serum amylasend 5-nucleoti
P06084810A0169 |69 73|cDNAse P
P06084810A0169 |120 127|library hyperb
P06084810A0169 |20 24|mRNAriso
P06084810A0169 |96 98|D.og
P06084810A0169 |32 48|polysome complexlkaline phosphat
P06084864T0001 |18 36|alpha fetoproteinsparison with alkal
P06084864T0001 |60 69|prognosisucleotida
P06084864T0001 |41 52|oligoamnioshosphatases
P06085839A0721 |22 33|possibilityson with al
P06085839A0721 |74 82|etiology0008171T
P06088722A0171 |0 7|CoursesP000016
P06088722A0171 |47 63|myelosuppressiontases and 5-nucl
P06088722A0171 |35 43|recoveryline pho
P06089575A0464 |68 78|cGMP levelase P00008
P06089575A0464 |120 123|min hy
P06089575A0464 |93 103|fmol/glandcologic as
P06089575A0464 |162 165|minSF 
P06089575A0464 |151 156|level0472 
P06089575A0464 |0 11|StimulationP00001606T0
P06089575A0464 |55 64|elevationd 5-nucle
P06089575A0464 |17 20|MChmpa
P06090369A0000 |69 76|studiesse P000
P06090369A0000 |24 32|patientsn with a
P06090369A0000 |47 54|WR-2721tases a
P06090369A0000 |58 63|Phase-nucl
P06090458A0407 |101 108|TK geneaspects
P06090458A0407 |128 139|orientationlirubinemia
P06090458A0407 |4 27|PEPCK promoter fragment01606T0076 Comparison w
P06090458A0407 |80 93|transcription1T0000 Pharma
P06090458A0407 |64 75|orientationotidase P00
P06091914A0000 |119 125|genomel hype
P06091914A0000 |74 82|provirus0008171T
P06091914A0000 |31 36|mousealkal
P06091914A0000 |45 56|tumor virushatases and
P06091914A0000 |58 62|MMTV-nuc
P06091914A0000 |95 101|regionlogic 
P06091914A0000 |13 19|tumors6 Comp
P06091914A0000 |188 193|int-1uncti
P06091914A0000 |172 180|oncogene is show
P06091914A0000 |138 148|expressiona. P000089
P06092048A1111 |16 24|asbestosompariso
P06092048A1111 |63 71|fibrosiseotidase
P06092048A1111 |44 50|burdenphatas
P06092048A1111 |9 14|casesT0076
P06092588T0000 |0 17|Hepatitis B virusP00001606T0076 Co
P06092588T0000 |22 30|hepatomason with
P06093354A0000 |50 64|leukemia viruses and 5-nucle
P06093354A0000 |66 70|MuLVidas
P06093354A0000 |151 167|Balb/c mouse DNA0472 When CSF [H
P06093354A0000 |140 147|library P00008
P06093354A0000 |80 93|DNA sequences1T0000 Pharma
P06093354A0000 |18 28|DNA clonesparison wi
P06093363A0612 |0 3|USAP00
P06093363A0612 |43 55|% identitiessphatases an
P06093363A0612 |27 35|proteinsith alka
P06093363A0612 |65 84|amino acid sequencetidase P00008171T00
P06093363A0612 |92 101|alignmentacologic 
P06093363A0612 |116 120|gapsatal
P06094591A0000 |204 220|carboxy terminusCO2 the data of 
P06094591A0000 |56 60|gp85 5-n
P06094591A0000 |132 138|domainbinemi
P06094591A0000 |91 99|membranemacologi
P06094591A0000 |224 228|gp37plet
P06094591A0000 |30 48|Rous sarcoma virus alkaline phosphat
P06094591A0000 |114 118|acidonat
P06094591A0000 |65 69|gp37tida
P06094591A0000 |172 176|acid is 
P06094591A0000 |190 196|domainction 
P06094591A0000 |4 26|envelope glycoproteins01606T0076 Comparison 
P06094591A0000 |50 53|RSVes 
P06095372A0435 |35 39|doseline
P06095372A0435 |47 51|g/m2tase
P06095372A0435 |57 58|h5
P06095372A0435 |73 92|radiation treatment00008171T0000 Pharm
P06095372A0435 |4 8|drug0160
P06095774T0001 |36 44|nephromaine phos
P06095774T0001 |13 20|aspects6 Compa
P06096246T0000 |0 6|EffectP00001
P06096246T0000 |40 46|stressphosph
P06096246T0000 |104 108|ratsects
P06096246T0000 |87 95|hormonesPharmaco
P06096380A0662 |140 144|mRNA P00
P06096380A0662 |165 171|enzyme[HCO3-
P06096380A0662 |179 182|ratwn 
P06096380A0662 |95 101|lengthlogic 
P06096380A0662 |26 59|phosphoenolpyruvate carboxykinasewith alkaline phosphatases and 5-
P06096380A0662 |67 74|chickendase P0
P06096380A0662 |7 11|mRNA06T0
P06096380A0662 |82 91|kilobases0000 Phar
P06096863T0000 |33 42|CYC1 genekaline ph
P06096863T0000 |135 143|TATA boxemia. P0
P06096863T0000 |9 25|activation sitesT0076 Comparison
P06097027A0000 |17 25|provirusmparison
P06097027A0000 |121 141|myeloblastosis virushyperbilirubinemia. 
P06097027A0000 |164 177|tumor viruses [HCO3-] is s
P06097027A0000 |39 65|erythroblastosis virus E26 phosphatases and 5-nucleo
P06097027A0000 |143 146|AMV000
P06097027A0000 |98 109|comparisonsic aspects 
P06097285A1077 |21 32|haloperidolison with a
P06097285A1077 |111 126|motor behaviour neonatal hyper
P06097285A1077 |57 63|animal5-nucl
P06097285A1077 |66 74|capacityidase P0
P06098719A0369 |33 52|laboratory findingskaline phosphatases
P06098719A0369 |13 19|effect6 Comp
P06098719A0369 |65 69|drugtida
P06098828A0352 |68 77|sequencesase P0000
P06098828A0352 |106 120|RNA polymerasets of neonatal
P06098828A0352 |30 36|report alkal
P06098828A0352 |54 58|SV40nd 5
P06098828A0352 |148 156|elements97A0472 
P06098828A0352 |4 11|results01606T0
P06099656T0000 |102 118|cotransformationspects of neonat
P06099656T0000 |63 98|adenovirus DNA binding protein geneeotidase P00008171T0000 Pharmacolog
P06099656T0000 |22 32|cell linesson with a
P06099656T0000 |128 141|HSV-1 tk genelirubinemia. 
P06099656T0000 |0 12|ConstructionP00001606T00
P06101359T0000 |0 9|DiagnosisP00001606
P06101359T0000 |45 52|tumourshatases
P06101359T0000 |14 23|treatment Comparis
P06108610A0518 |0 8|TheoriesP0000160
P06108610A0518 |38 59|modality shift effecte phosphatases and 5-
P06109017A0000 |279 289|blood flowntrols but
P06109017A0000 |31 37|beta-1alkali
P06109017A0000 |61 77|4-hydroxyphenoxycleotidase P0000
P06109017A0000 |49 56|agonistses and
P06109017A0000 |223 228|dP/dteplet
P06109017A0000 |263 271|pressuren compar
P06109017A0000 |294 304|heart ratel have a s
P06109017A0000 |113 124|prenalteroleonatal hyp
P06109017A0000 |321 325|dogster 
P06109017A0000 |213 221|diameterata of K
P06109017A0000 |199 201|LVCS
P06109017A0000 |79 104|isopropylamino-2-propanol71T0000 Pharmacologic asp
P06109017A0000 |165 177|measurements[HCO3-] is s
P06109017A0000 |203 211|pressurePCO2 the
P06109017A0000 |230 238|velocity rats ar
P06109017A0000 |4 11|effects01606T0
P06110026T0000 |0 10|EndorphinsP00001606T
P06110026T0000 |30 35|death alka
P06110026T0000 |18 26|approachparison 
P06111283T0032 |0 15|Trial treatmentP00001606T0076 
P06111283T0032 |38 61|des-Tyr-gamma-endorphine phosphatases and 5-nu
P06111283T0032 |19 32|schizophreniaarison with a
P06113084T0000 |39 63|calcium binding activity phosphatases and 5-nucl
P06113084T0000 |88 102|cardiomyopathyharmacologic a
P06113084T0000 |8 22|taurine levels6T0076 Compari
P06113443T0000 |0 10|SeparationP00001606T
P06113443T0000 |31 43|erythrocytesalkaline pho
P06113443T0000 |62 65|useleo
P06113443T0000 |104 124|separation techniqueects of neonatal hyp
P06113443T0000 |55 60|bloodd 5-n
P06119262T0000 |4 18|roll-over test01606T0076 Com
P06119262T0000 |30 37|toxemia alkali
P06119262T0000 |41 50|pregnancyhosphatas
P06120429T0000 |4 23|thyroglobulin assay01606T0076 Comparis
P06120429T0000 |61 69|patientscleotida
P06120429T0000 |90 104|thyroid cancerrmacologic asp
P06120429T0000 |40 51|radioiodinephosphatase
P06121577A0280 |184 193|decreases a functi
P06121577A0280 |108 109|% 
P06121577A0280 |124 125|%e
P06121577A0280 |88 93|dosesharma
P06121577A0280 |135 137|mgem
P06121577A0280 |14 24|reductions Compariso
P06121577A0280 |143 144|%0
P06121577A0280 |212 233|plasma renin activitydata of K-depleted ra
P06121577A0280 |197 207|heart ratef CSF PCO2
P06121577A0280 |101 103|mgas
P06121577A0280 |48 62|blood pressureases and 5-nuc
P06121577A0280 |116 118|mgat
P06130348T0000 |0 9|IsolationP00001606
P06130348T0000 |13 22|Aeromonas6 Compari
P06130348T0000 |28 34|faecesth alk
P06131038A0000 |0 6|PlasmaP00001
P06131038A0000 |106 113|rabbitsts of n
P06131038A0000 |140 149|incidence P0000899
P06131038A0000 |40 67|lipoprotein lipase activityphosphatases and 5-nucleoti
P06131038A0000 |11 35|erthrocyte lipid profile076 Comparison with alka
P06131038A0000 |71 89|postheparin plasma P00008171T0000 Ph
P06131038A0000 |191 195|bedstion
P06131038A0000 |153 168|atherosclerosis72 When CSF [HC
P06131378A0818 |153 162|DHFR cDNA72 When C
P06131378A0818 |109 132|polyadenylation signalsof neonatal hyperbiliru
P06131378A0818 |72 75|endP00
P06131378A0818 |52 61|sequences and 5-nu
P06131378A0818 |10 14|mRNA0076
P06131378A0818 |83 92|DHFR cDNA000 Pharm
P06136374A0151 |67 84|swimming velocitydase P00008171T00
P06136374A0151 |28 31|VO2th 
P06136374A0151 |8 26|water temperatures6T0076 Comparison 
P06137028A0624 |0 11|PropranololP00001606T0
P06137028A0624 |53 59|tremorand 5-
P06138015T0114 |6 12|report606T00
P06138313A0948 |115 121|volumenatal 
P06138313A0948 |41 58|elimination phasehosphatases and 5
P06138313A0948 |89 99|mean valuearmacologi
P06138313A0948 |104 107|minect
P06138313A0948 |125 137|distributionrbilirubinem
P06138313A0948 |78 87|half-life171T0000 
P06138313A0948 |4 22|distribution phase01606T0076 Compari
P06141764A0339 |137 148|informationia. P000089
P06141764A0339 |105 111|clonescts of
P06141764A0339 |80 91|plasmid DNA1T0000 Phar
P06141764A0339 |56 59|RNA 5-
P06141764A0339 |0 28|Hybrid-selection experimentsP00001606T0076 Comparison wi
P06142279T0000 |0 4|RiskP000
P06142279T0000 |8 22|HTLV infection6T0076 Compari
P06142279T0000 |26 34|patientswith alk
P06142279T0000 |38 51|haemodialysise phosphatase
P06143734T0000 |23 35|progesteroneon with alka
P06143734T0000 |61 67|testiscleoti
P06143734T0000 |9 19|metabolismT0076 Comp
P06147504A0086 |4 12|patients01606T00
P06147504A0086 |27 34|therapyith alk
P06147504A0086 |90 94|massrmac
P06147504A0086 |53 60|reasonsand 5-n
P06150069A0422 |49 54|weeksses a
P06150069A0422 |60 77|dose modificationucleotidase P0000
P06150069A0422 |30 35|mg/m2 alka
P06150069A0422 |82 95|neurotoxicity0000 Pharmaco
P06150069A0422 |22 25|VCRson
P06150069A0422 |4 12|patients01606T00
P06151518A0000 |19 23|dosearis
P06151518A0000 |149 159|injections7A0472 Whe
P06151518A0000 |73 84|sodium salt00008171T00
P06151518A0000 |9 13|acidT007
P06151518A0000 |40 44|LD50phos
P06151518A0000 |124 128|dayserbi
P06151518A0000 |113 117|ratseona
P06151518A0000 |163 171|dexazoneF [HCO3-
P06151518A0000 |65 69|formtida
P06151942A0235 |0 5|SerumP0000
P06151942A0235 |149 160|cholesterol7A0472 When
P06151942A0235 |104 116|risk factorsects of neon
P06151942A0235 |15 19|acidComp
P06151942A0235 |162 174|triglycerideSF [HCO3-] i
P06151942A0235 |176 185|gamma-GTPshown as 
P06151942A0235 |79 93|blood pressure71T0000 Pharma
P06151942A0235 |53 64|associationand 5-nucle
P06151942A0235 |127 141|blood pressureilirubinemia. 
P06151942A0235 |190 197|obesityction o
P06152670T0000 |17 29|pancreozyminmparison wit
P06152670T0000 |53 60|hormoneand 5-n
P06152670T0000 |78 94|failure patients171T0000 Pharmac
P06152670T0000 |0 15|Plasma secretinP00001606T0076 
P06152844T0000 |0 6|EffectP00001
P06152844T0000 |73 81|subjects00008171
P06152844T0000 |24 38|growth hormonen with alkalin
P06152844T0000 |10 20|bromazepam0076 Compa
P06152844T0000 |43 62|prolactin secretionsphatases and 5-nuc
P06153936A0784 |50 68|gland examinationses and 5-nucleotid
P06153936A0784 |29 32|SjSh a
P06153936A0784 |91 104|year intervalmacologic asp
P06153936A0784 |177 184|changeshown as
P06153936A0784 |11 16|cases076 C
P06153936A0784 |127 136|occasionsilirubine
P06155967A1132 |50 68|reporting terminales and 5-nucleotid
P06155967A1132 |27 34|machineith alk
P06155967A1132 |151 157|effort0472 W
P06155967A1132 |4 16|radiologists01606T0076 C
P06155967A1132 |176 180|timeshow
P06155967A1132 |117 130|abnormalitiestal hyperbili
P06158844A0000 |0 11|ThalamotomyP00001606T0
P06158844A0000 |63 80|gamma irradiationeotidase P0000817
P06158844A0000 |151 161|malignancy0472 When 
P06158844A0000 |105 111|seriescts of
P06158844A0000 |139 143|pain. P0
P06158844A0000 |26 39|CM-Pf complexwith alkaline
P06158844A0000 |118 126|patientsal hyper
P06161823A0129 |102 105|menspe
P06161823A0129 |11 19|capsules076 Comp
P06161823A0129 |128 139|hypertrophylirubinemia
P06161823A0129 |43 45|mgsp
P06161823A0129 |49 66|ethinyl estradiolses and 5-nucleot
P06162419A0118 |98 109|developmentic aspects 
P06162419A0118 |45 52|maximumhatases
P06162419A0118 |63 68|doseseotid
P06162419A0118 |150 154|centA047
P06162419A0118 |113 132|lymphadenosis NK/Lieonatal hyperbiliru
P06163433T0000 |0 6|EffectP00001
P06163433T0000 |28 44|cyclopropylamineth alkaline phos
P06163433T0000 |13 27|p-chlorophenyl6 Comparison w
P06163433T0000 |112 121|rat brainneonatal 
P06163433T0000 |82 108|monoamine oxidase activity0000 Pharmacologic aspects
P06163433T0000 |64 77|concentrationotidase P0000
P06165068A0547 |49 57|duodenumses and 
P06165068A0547 |22 27|juiceson w
P06165132A0000 |102 113|spray lentospects of n
P06165132A0000 |128 136|vaccineslirubine
P06165132A0000 |79 84|farms71T00
P06165132A0000 |210 222|pseudoplaguee data of K-
P06165132A0000 |241 246|viruso lon
P06165132A0000 |172 182|pseodopest is shown 
P06165132A0000 |52 60|broilers and 5-n
P06165132A0000 |42 47|fowlsospha
P06165132A0000 |3 13|experiment001606T007
P06165132A0000 |191 195|RIHAtion
P06165132A0000 |155 163|immunity When CS
P06165551A0793 |205 211|windowO2 the
P06165551A0793 |72 78|spikesP00008
P06165551A0793 |191 197|lengthtion o
P06165551A0793 |217 220|secof 
P06165551A0793 |59 68|isolationnucleotid
P06165551A0793 |144 152|duration008997A0
P06165551A0793 |126 130|viewbili
P06165551A0793 |89 94|wavesarmac
P06165551A0793 |277 299|segmentation algorithmcontrols but still hav
P06165551A0793 |8 25|inappropriateness6T0076 Comparison
P06165551A0793 |161 171|transientsCSF [HCO3-
P06165551A0793 |175 183|relation shown a
P06165551A0793 |235 250|autocorrelation are no longer 
P06165551A0793 |38 50|segmentatione phosphatas
P06167806A0000 |220 224|daysK-de
P06167806A0000 |247 257|infarctioner displac
P06167806A0000 |77 86|induction8171T0000
P06167806A0000 |31 50|dimethylpropranololalkaline phosphatas
P06167806A0000 |159 162|dogn C
P06167806A0000 |112 128|tachyarrhythmiasneonatal hyperbi
P06167806A0000 |52 61|treatment and 5-nu
P06167806A0000 |4 11|ability01606T0
P06167806A0000 |23 29|UM-272on wit
P06167806A0000 |205 216|stimulationO2 the data
P06173032T0000 |70 78|pressuree P00008
P06173032T0000 |44 52|responsephatases
P06173032T0000 |14 27|echothiophate Comparison w
P06173032T0000 |82 92|dipivefrin0000 Pharm
P06173032T0000 |56 62|rabbit 5-nuc
P06173032T0000 |4 10|effect01606T
P06173860A0000 |152 170|segment elevations472 When CSF [HCO3
P06173860A0000 |8 13|cases6T007
P06173860A0000 |64 83|segment depressionsotidase P00008171T0
P06173860A0000 |96 115|contralateral leadsogic aspects of neo
P06173860A0000 |34 44|infarctionaline phos
P06175691T0000 |0 31|Bacillus cereus cross-infectionP00001606T0076 Comparison with 
P06175691T0000 |37 51|maternity-unitne phosphatase
P06181216A0070 |38 46|patientse phosph
P06181216A0070 |60 84|serum IgA concentrationsucleotidase P00008171T00
P06181216A0070 |93 98|yearscolog
P06182979A0807 |34 42|emphasisaline ph
P06182979A0807 |122 153|cisplatinum diammine dichlorideyperbilirubinemia. P00008997A04
P06182979A0807 |14 22|category Compari
P06182979A0807 |93 104|doxorubicincologic asp
P06182979A0807 |109 118|analoguesof neonat
P06182979A0807 |66 89|anthracycline analoguesidase P00008171T0000 Ph
P06184276T0001 |18 31|plasmocytosisparison with 
P06184276T0001 |8 14|course6T0076
P06184487A1485 |102 111|synthesisspects of
P06184487A1485 |199 202|RNACSF
P06184487A1485 |79 88|AcNPV map71T0000 P
P06184487A1485 |123 135|30K proteinsperbilirubin
P06184487A1485 |47 71|HindIII-P/EcoRI-B regiontases and 5-nucleotidase
P06184487A1485 |219 248|HindIII-A/EcoRI-C/SstI-G cDNA K-depleted rats are no longe
P06184487A1485 |162 165|31KSF 
P06184487A1485 |24 28|cDNAn wi
P06184487A1485 |115 118|31Knat
P06184487A1485 |5 9|mRNA1606
P06184487A1485 |170 182|30K proteins-] is shown 
P06185014A0642 |21 42|complement factor C3cison with alkaline ph
P06185014A0642 |58 59|%-
P06185014A0642 |67 86|alpha 1-antitrypsindase P00008171T0000
P06185014A0642 |127 128|%i
P06185014A0642 |113 121|increaseeonatal 
P06185493A0468 |50 75|yeast amino acid sequencees and 5-nucleotidase P00
P06185493A0468 |26 34|residueswith alk
P06185493A0468 |120 136|ADP binding site hyperbilirubine
P06185493A0468 |96 112|peptide sequenceogic aspects of 
P06185493A0468 |147 169|muscle pyruvate kinase997A0472 When CSF [HCO
P06185493A0468 |2 19|polypeptide chain0001606T0076 Comp
P06189698A0246 |153 155|N272
P06189698A0246 |72 82|componentsP00008171T
P06189698A0246 |105 114|amplitudects of ne
P06189698A0246 |160 173|P3 amplitudes CSF [HCO3-] 
P06189698A0246 |130 142|task demandsrubinemia. P
P06189698A0246 |4 18|P165 component01606T0076 Com
P06191243T0000 |53 65|brain damageand 5-nucleo
P06191243T0000 |13 25|drawing size6 Comparison
P06193351A1010 |68 77|incidencease P0000
P06193351A1010 |128 144|artery occlusionlirubinemia. P00
P06193351A1010 |41 46|drugshosph
P06193351A1010 |81 83|VFT0
P06193351A1010 |99 106|releasec aspec
P06193351A1010 |18 32|administrationparison with a
P06198241A0209 |6 13|fusions606T007
P06198241A0209 |165 170|yeast[HCO3
P06198241A0209 |74 93|replication origins0008171T0000 Pharma
P06198241A0209 |31 39|plasmidsalkaline
P06198241A0209 |56 61|yeast 5-nu
P06198241A0209 |182 187|cellsas a 
P06198241A0209 |109 116|markersof neon
P06198532A0982 |118 121|RHDal 
P06198532A0982 |74 82|patients0008171T
P06198532A0982 |44 52|tendencyphatases
P06198532A0982 |149 155|causes7A0472
P06198532A0982 |88 90|MSha
P06198532A0982 |195 210|thromboembolism of CSF PCO2 th
P06198532A0982 |214 224|comparisonta of K-de
P06198532A0982 |182 191|incidenceas a func
P06198532A0982 |234 237|RHDs a
P06199132A0179 |0 8|ToxicityP0000160
P06199132A0179 |117 125|patientstal hype
P06199132A0179 |37 42|casesne ph
P06199132A0179 |69 72|WBCse 
P06199132A0179 |50 58|patientses and 5
P06199132A0179 |136 142|sepsismia. P
P06200300A0409 |66 82|scalp electrodesidase P00008171T
P06200300A0409 |9 19|electrodesT0076 Comp
P06200300A0409 |57 62|skull5-nuc
P06200300A0409 |37 51|VEP amplitudesne phosphatase
P06203843A0757 |0 8|ProductsP0000160
P06203843A0757 |53 64|lymphokinesand 5-nucle
P06203843A0757 |108 113|group of n
P06203843A0757 |19 24|cellsariso
P06203843A0757 |33 48|transfer factorkaline phosphat
P06203843A0757 |136 142|agentsmia. P
P06204120T0001 |0 3|UseP00
P06204120T0001 |11 36|immunofluorescence method076 Comparison with alkal
P06204120T0001 |59 72|enterovirusesnucleotidase 
P06204120T0001 |41 55|identificationhosphatases an
P06204120T0001 |76 89|cell cultures08171T0000 Ph
P06208024A0168 |103 113|hydrolysispects of n
P06208024A0168 |30 40|digestions alkaline 
P06208024A0168 |56 64|RNase T1 5-nucle
P06208024A0168 |44 49|DNasephata
P06208024A0168 |5 13|fraction1606T007
P06208477A0000 |4 16|construction01606T0076 C
P06208477A0000 |28 35|libraryth alka
P06208477A0000 |90 97|Pietrasrmacolo
P06208477A0000 |39 44|mouse phos
P06208477A0000 |56 59|DNA 5-
P06208477A0000 |114 123|Acids Resonatal hy
P06209403A0562 |10 17|repeats0076 Co
P06209403A0562 |28 38|pseudogeneth alkalin
P06209403A0562 |46 56|U2/4 locusatases and
P06209499A0682 |68 71|MAPase
P06209499A0682 |11 18|effects076 Com
P06209499A0682 |91 105|pressor effectmacologic aspe
P06209499A0682 |60 64|fallucle
P06209499A0682 |22 41|transmitter releaseson with alkaline p
P06209499A0682 |124 135|bradycardiaerbilirubin
P06209499A0682 |155 166|tachycardia When CSF [
P06212776A0000 |118 124|peopleal hyp
P06212776A0000 |176 184|diseasesshown as
P06212776A0000 |198 208|prevention CSF PCO2 
P06212776A0000 |11 19|Oristano076 Comp
P06212776A0000 |66 78|thalassaemiaidase P00008
P06212776A0000 |53 62|incidenceand 5-nuc
P06212776A0000 |24 28|townn wi
P06212776A0000 |3 9|Cabras001606
P06212776A0000 |83 98|G6PD deficiency000 Pharmacolog
P06212776A0000 |155 164|knowledge When CSF
P06214605A0123 |101 112|experimentsaspects of 
P06214605A0123 |4 10|number01606T
P06214605A0123 |14 22|elements Compari
P06214605A0123 |33 38|sizeskalin
P06214605A0123 |55 68|configurationd 5-nucleotid
P06214605A0123 |86 92|series Pharm
P06216125A0470 |3 11|addition001606T0
P06216125A0470 |122 124|mmyp
P06216125A0470 |61 63|ETcl
P06216125A0470 |110 118|folliclef neonat
P06216125A0470 |25 31|chance with 
P06216125A0470 |160 165|cycle CSF 
P06216125A0470 |81 86|cycleT0000
P06216125A0470 |39 46|patient phosph
P06216125A0470 |190 198|folliclection of
P06217859T0000 |0 10|ExperienceP00001606T
P06217859T0000 |46 50|flapatas
P06217859T0000 |20 26|tensorrison 
P06218005A0948 |36 44|L-L sizeine phos
P06218005A0948 |12 20|patients76 Compa
P06218005A0948 |58 70|A-P diameter-nucleotidas
P06223586A0000 |0 18|ImmunochemotherapyP00001606T0076 Com
P06223586A0000 |24 37|schizophyllann with alkali
P06223586A0000 |75 81|agents008171
P06223586A0000 |113 122|tumor-C3Heonatal h
P06223586A0000 |126 139|mouse systemsbilirubinemia
P06223586A0000 |39 42|SPG ph
P06223586A0460 |169 173|mice3-] 
P06223586A0460 |88 102|administrationharmacologic a
P06223586A0460 |28 39|mitomycin Cth alkaline
P06223586A0460 |106 109|SPGts 
P06223586A0460 |63 71|intervaleotidase
P06223586A0460 |138 147|life-spana. P00008
P06224974A0833 |68 71|CPAase
P06224974A0833 |112 117|agentneona
P06224974A0833 |54 64|metabolitend 5-nucle
P06224974A0833 |39 51|beta-hydroxy phosphatase
P06224974A0833 |0 4|DataP000
P06225279A0498 |68 73|layerase P
P06225279A0498 |14 21|surface Compar
P06225279A0498 |99 105|tissuec aspe
P06227570A0523 |35 38|ENLlin
P06227570A0523 |3 11|contrast001606T0
P06227570A0523 |56 75|suppressor response 5-nucleotidase P00
P06227570A0523 |16 27|LL patientsomparison w
P06229542T0045 |33 41|fractionkaline p
P06229542T0045 |11 27|characterization076 Comparison w
P06229542T0045 |60 68|activityucleotid
P06229542T0045 |81 102|template rescue assayT0000 Pharmacologic a
P06230499A0128 |343 350|results23 vs. 
P06230499A0128 |213 224|irradiationata of K-de
P06230499A0128 |61 65|formcleo
P06230499A0128 |303 309|periodsignif
P06230499A0128 |130 133|dayrub
P06230499A0128 |73 86|fractionation00008171T0000
P06230499A0128 |105 109|dosects 
P06230499A0128 |256 267|performanceced when co
P06230499A0128 |115 117|Gyna
P06230499A0128 |190 197|surgeryction o
P06230499A0128 |158 160|Gyen
P06230499A0128 |202 206|days PCO
P06230499A0128 |42 53|irradiationosphatases 
P06230499A0128 |383 401|dose fractionationpears to be an eff
P06230499A0128 |139 151|summary dose. P00008997A
P06230499A0128 |173 177|daysis s
P06230499A0128 |275 281|courseo cont
P06233924T0000 |0 11|Fibrin gelsP00001606T0
P06233924T0000 |31 42|implicationalkaline ph
P06233924T0000 |82 89|disease0000 Ph
P06233924T0000 |47 67|surface hemorheologytases and 5-nucleoti
P06233924T0000 |71 77|health P0000
P06234369T0000 |12 23|vaccination76 Comparis
P06234786A0606 |0 20|Radiogallium imagingP00001606T0076 Compa
P06234786A0606 |47 57|evaluationtases and 
P06234786A0606 |77 88|cell tumors8171T0000 P
P06234786A0606 |40 43|usepho
P06234786A0606 |92 96|boneacol
P06237518A0117 |155 158|KCN Wh
P06237518A0117 |134 140|systemnemia.
P06237518A0117 |121 125|flowhype
P06237518A0117 |91 95|acidmaco
P06237518A0117 |14 30|coupling reagent Comparison with
P06237518A0117 |163 173|chloramineF [HCO3-] 
P06237518A0117 |42 46|acidosph
P06237518A0117 |97 101|CNClgic 
P06238540A0798 |70 73|LVHe P
P06238540A0798 |197 202|slopef CSF
P06238540A0798 |176 179|LVHsho
P06238540A0798 |12 28|volume stiffness76 Comparison wi
P06238540A0798 |113 134|wall muscle stiffnesseonatal hyperbilirubi
P06238540A0798 |37 66|mean wall stress relationshipne phosphatases and 5-nucleot
P06238540A0798 |143 172|mean wall stress relationship0008997A0472 When CSF [HCO3-]
P06238704T0001 |0 9|SynthesisP00001606
P06238704T0001 |26 43|acid diethylamidewith alkaline pho
P06239545A0649 |0 11|Weight lossP00001606T0
P06239545A0649 |133 141|activityinemia. 
P06239545A0649 |29 37|pressureh alkali
P06239545A0649 |88 94|outputharmac
P06239545A0649 |113 117|falleona
P06239545A0649 |43 51|decreasesphatase
P06239545A0649 |69 75|volumese P00
P06240448A0652 |275 293|pretreatment levelo controls but sti
P06240448A0652 |179 189|resistancewn as a fu
P06240448A0652 |90 99|reductionrmacologi
P06240448A0652 |241 249|increaseo longer
P06240448A0652 |226 233|LV masseted ra
P06240448A0652 |14 23|treatment Comparis
P06240448A0652 |318 326|decreasereater s
P06240448A0652 |152 158|change472 Wh
P06240448A0652 |117 126|reductiontal hyper
P06240448A0652 |261 267|outputhen co
P06240448A0652 |58 64|phases-nucle
P06240448A0652 |4 10|effect01606T
P06240448A0652 |77 82|phase8171T
P06240448A0652 |347 357|resistances. P000109
P06240448A0652 |204 209|phaseCO2 t
P06240448A0652 |138 144|outputa. P00
P06240448A0652 |103 110|LV masspects o
P06241900A0000 |51 62|hypothermias and 5-nuc
P06241900A0000 |181 187|period as a 
P06241900A0000 |40 47|effectsphospha
P06241900A0000 |198 207|ischaemia CSF PCO2
P06241900A0000 |107 115|recoverys of neo
P06241900A0000 |67 88|chemical cardioplegiadase P00008171T0000 P
P06241900A0000 |145 155|rat hearts08997A0472
P06241900A0000 |5 10|study1606T
P06241980A0855 |0 15|Oxygen profilesP00001606T0076 
P06241980A0855 |135 144|diffusionemia. P00
P06241980A0855 |114 120|modelsonatal
P06241980A0855 |62 71|diffusionleotidase
P06241980A0855 |35 46|Krogh modelline phosph
P06242113T0001 |0 20|Cultivation technicsP00001606T0076 Compa
P06242113T0001 |25 44|Codonopsis pilosula with alkaline phos
P06244732T0000 |0 16|RadioimmunoassayP00001606T0076 C
P06244732T0000 |91 101|infarctionmacologic 
P06244732T0000 |61 70|diagnosiscleotidas
P06244732T0000 |20 53|serum creatine kinase B isoenzymerison with alkaline phosphatases 
P06245672T0000 |59 68|reductionnucleotid
P06245672T0000 |72 82|metastasisP00008171T
P06245672T0000 |10 31|macrophage inhibition0076 Comparison with 
P06246254A0676 |0 18|Restriction enzymeP00001606T0076 Com
P06246254A0676 |120 126|center hyper
P06246254A0676 |60 69|sequencesucleotida
P06246254A0676 |23 44|heteroduplex analyseson with alkaline phos
P06246254A0676 |172 186|kilobase pairs is shown as a
P06246254A0676 |134 145|FeSV genomenemia. P000
P06246254A0676 |190 196|lengthction 
P06246254A0676 |80 84|FeSV1T00
P06246254A0676 |86 99|src sequences Pharmacologi
P06251469A0830 |20 36|library isolatesrison with alkal
P06251469A0830 |147 157|occurrence997A0472 W
P06251469A0830 |61 70|IAP unitscleotidas
P06251469A0830 |77 94|restriction sites8171T0000 Pharmac
P06251469A0830 |125 131|othersrbilir
P06251469A0830 |162 170|positionSF [HCO3
P06252520T0000 |0 14|CatecholaminesP00001606T0076
P06252520T0000 |28 36|learningth alkal
P06252520T0000 |40 46|reviewphosph
P06252883A0100 |48 52|O149ases
P06252883A0100 |104 107|PWDect
P06252883A0100 |91 98|pigletsmacolog
P06252883A0100 |146 152|number8997A0
P06252883A0100 |57 60|H105-n
P06252883A0100 |29 35|strainh alka
P06252883A0100 |114 123|rotavirusonatal hy
P06252883A0100 |53 56|K88and
P06252883A0100 |156 165|occasionsWhen CSF 
P06254403A0000 |100 114|blocking assay aspects of ne
P06254403A0000 |4 18|antibody titer01606T0076 Com
P06254403A0000 |26 34|chickenswith alk
P06254403A0000 |38 53|SA-11 rotaviruse phosphatases 
P06254973A1757 |343 345|dT23
P06254973A1757 |188 190|dTun
P06254973A1757 |260 272|binding sitewhen compare
P06254973A1757 |330 338|residues (1.21 +
P06254973A1757 |209 211|dThe
P06254973A1757 |130 133|HDPrub
P06254973A1757 |346 348|n.vs
P06254973A1757 |75 90|polynucleotides008171T0000 Pha
P06254973A1757 |288 291|HDPt s
P06254973A1757 |293 305|accumulationll have a si
P06254973A1757 |191 192|nt
P06254973A1757 |23 38|calf thymus DNAon with alkalin
P06254973A1757 |174 183|moleculess shown a
P06254973A1757 |111 123|accumulation neonatal hy
P06254973A1757 |199 201|dTCS
P06254973A1757 |137 139|dTia
P06254973A1757 |5 7|dT16
P06254973A1757 |0 4|PolyP000
P06258699T0000 |38 49|Polybactrine phosphata
P06258699T0000 |58 79|GU bladder irrigation-nucleotidase P000081
P06258699T0000 |15 20|trialCompa
P06258699T0000 |83 93|cystoscopy000 Pharma
P06258806A0963 |69 77|terminusse P0000
P06258806A0963 |96 100|geneogic
P06258806A0963 |126 136|expressionbilirubine
P06258806A0963 |49 56|elementses and
P06258806A0963 |21 30|insertionison with
P06258806A0963 |169 175|enzyme3-] is
P06259220A0000 |254 268|shock exposurelaced when com
P06259220A0000 |95 103|reactionlogic as
P06259220A0000 |210 220|reexposuree data of 
P06259220A0000 |224 229|shockplete
P06259220A0000 |151 156|shock0472 
P06259220A0000 |30 39|influence alkaline
P06259220A0000 |5 16|experiments1606T0076 C
P06259220A0000 |233 235|hrts
P06259220A0000 |127 135|exposureilirubin
P06259220A0000 |117 120|mintal
P06259220A0000 |185 193|reactiona functi
P06259220A0000 |50 61|antagonistses and 5-nu
P06259220A0464 |0 10|ExperimentP00001606T
P06259220A0464 |135 140|shockemia.
P06259220A0464 |121 131|reexposurehyperbilir
P06259220A0464 |101 111|naltrexoneaspects of
P06259220A0464 |83 97|administration000 Pharmacolo
P06259220A0464 |49 57|reactionses and 
P06259389A0000 |65 69|foottida
P06259389A0000 |30 36|August alkal
P06259389A0000 |89 93|HFMDarma
P06259389A0000 |107 122|Gifu prefectures of neonatal h
P06259389A0000 |74 87|mouth disease0008171T0000 
P06259389A0000 |59 63|handnucl
P06259389A0000 |11 17|period076 Co
P06259389A0000 |23 26|Mayon 
P06270347A0740 |2 17|22K polypeptide0001606T0076 Co
P06270347A0740 |36 55|translation productine phosphatases an
P06270347A0740 |92 104|DNA fragmentacologic asp
P06270347A0740 |64 67|RNAoti
P06272844A0000 |35 46|chromosomesline phosph
P06272844A0000 |147 155|nuclease997A0472
P06272844A0000 |29 33|SV40h al
P06272844A0000 |164 173|digestion [HCO3-] 
P06272844A0000 |157 162|MNasehen C
P06272844A0000 |92 103|chromosomesacologic as
P06272844A0000 |125 131|extentrbilir
P06272844A0000 |236 250|SV40 chromatinare no longer 
P06272844A0000 |116 120|rateatal
P06272844A0000 |19 24|virusariso
P06277159T0033 |2 12|hypothesis0001606T00
P06278424A0145 |116 124|gamma 2batal hyp
P06278424A0145 |135 148|mouse myelomaemia. P000089
P06278424A0145 |45 59|CH gene switchhatases and 5-
P06278424A0145 |94 108|gamma 2b genesologic aspects
P06278424A0145 |150 156|MPC-11A0472 
P06278424A0145 |25 37|requirements with alkali
P06278544T0027 |0 10|PhysiologyP00001606T
P06278544T0027 |15 30|PhysiopathologyComparison with
P06279309A0000 |119 129|activitiesl hyperbil
P06279309A0000 |105 111|v-erbBcts of
P06279309A0000 |178 183|virusown a
P06279309A0000 |94 100|v-erbAologic
P06279309A0000 |88 92|lociharm
P06279309A0000 |20 42|erythroblastosis virusrison with alkaline ph
P06279309A0000 |159 170|oncogenesisn CSF [HCO3
P06279309A0000 |4 10|genome01606T
P06281759A1086 |48 62|sib regulationases and 5-nuc
P06281759A1086 |132 146|int mRNA decaybinemia. P0000
P06281759A1086 |105 121|endoribonucleasects of neonatal 
P06281759A1086 |93 96|sibcol
P06281759A1086 |8 13|RNase6T007
P06281759A1086 |160 173|int synthesis CSF [HCO3-] 
P06281759A1086 |64 74|processingotidase P0
P06281759A1086 |82 89|PL mRNA0000 Ph
P06281759A1086 |18 30|host mutantsparison with
P06281786A1222 |48 56|additionases and
P06281786A1222 |13 18|clone6 Com
P06281786A1222 |145 156|nucleotides08997A0472 
P06281786A1222 |160 166|length CSF [
P06281786A1222 |123 126|RNAper
P06281786A1222 |64 77|histone genesotidase P0000
P06281786A1222 |20 30|lambda HHGrison with
P06281786A1222 |81 87|regionT0000 
P06281891A0399 |115 132|pain transmissionnatal hyperbiliru
P06281891A0399 |25 33|pathways with al
P06281891A0399 |80 85|roles1T000
P06281891A0399 |93 111|complex modulationcologic aspects of
P06281891A0399 |64 74|substancesotidase P0
P06286191T0000 |0 11|RestorationP00001606T0
P06286191T0000 |31 40|functionsalkaline 
P06286191T0000 |50 57|animalses and 
P06286443A0498 |14 31|serum ACTH levels Comparison with 
P06286549A0000 |0 7|WR-2721P000016
P06286549A0000 |185 190|lungsa fun
P06286549A0000 |55 59|acidd 5-
P06286549A0000 |115 119|lungnata
P06286549A0000 |158 161|FSaen 
P06286549A0000 |144 156|fibrosarcoma008997A0472 
P06286549A0000 |125 131|testisrbilir
P06286549A0000 |91 98|abilitymacolog
P06286549A0000 |9 12|S-2T00
P06286549A0000 |194 198|micen of
P06286549A0000 |16 32|aminopropylaminoomparison with a
P06286549A0000 |110 113|gutf n
P06286549A0000 |163 176|tumor nodulesF [HCO3-] is 
P06286549A0000 |204 226|gamma-radiation injuryCO2 the data of K-depl
P06287212A1352 |119 122|VP1l h
P06287212A1352 |65 76|translationtidase P000
P06287212A1352 |127 128|Ti
P06287212A1352 |9 17|familiesT0076 Co
P06287212A1352 |146 152|result8997A0
P06287212A1352 |243 247|AUGslong
P06287212A1352 |98 107|sequencesic aspect
P06287212A1352 |21 33|polypeptidesison with al
P06287212A1352 |80 90|AUG codons1T0000 Pha
P06287212A1352 |3 7|fact0016
P06287212A1352 |156 187|transcription initiation eventsWhen CSF [HCO3-] is shown as a 
P06287212A1352 |51 61|initiations and 5-nu
P06287231A0914 |68 72|sizease 
P06287231A0914 |13 31|TRP1 RI Circle DNA6 Comparison with 
P06287231A0914 |120 140|bulk yeast chromatin hyperbilirubinemia.
P06287231A0914 |3 11|addition001606T0
P06287231A0914 |77 84|spacing8171T00
P06287231A0914 |50 61|nucleosomeses and 5-nu
P06287737A0477 |102 111|type NANBspects of
P06287737A0477 |89 98|carcinomaarmacolog
P06287737A0477 |183 208|posttransfusion hepatitiss a function of CSF PCO2 
P06287737A0477 |60 69|cirrhosisucleotida
P06287737A0477 |164 173|incidence [HCO3-] 
P06287737A0477 |395 409|type B diseasean effective h
P06287737A0477 |326 338|transfusionslope (1.21 +
P06287737A0477 |49 58|hepatitisses and 5
P06287737A0477 |290 298|jaundicestill ha
P06287737A0477 |257 271|liver diseasesed when compar
P06287737A0477 |26 37|transfusionwith alkali
P06287737A0477 |279 286|historyntrols 
P06287737A0477 |229 230|%d
P06287737A0477 |135 136|%e
P06287737A0477 |306 315|hepatitisnificantl
P06287737A0477 |4 13|frequency01606T007
P06287737A0477 |375 384|type NANB thus app
P06290859A0426 |116 126|antibodiesatal hyper
P06290859A0426 |91 92|%m
P06290859A0426 |7 27|hepatitis B patients06T0076 Comparison w
P06290859A0426 |62 87|hepatitis Bs antigenaemialeotidase P00008171T0000 
P06290859A0426 |135 136|%e
P06290859A0426 |156 170|liver functionWhen CSF [HCO3
P06290859A0426 |39 45|months phosp
P06290859A0426 |48 49|%a
P06290899T0000 |0 6|SurveyP00001
P06290899T0000 |62 76|chicken flocksleotidase P000
P06290899T0000 |27 55|egg drop syndrome-1976 virusith alkaline phosphatases an
P06290899T0000 |10 18|antibody0076 Com
P06290899T0000 |80 85|Japan1T000
P06291369A0000 |70 85|catheterizatione P00008171T000
P06291369A0000 |271 279|pressureed to co
P06291369A0000 |197 214|ejection fractionf CSF PCO2 the da
P06291369A0000 |147 155|portions997A0472
P06291369A0000 |29 57|equilibrium ventriculographyh alkaline phosphatases and 
P06291369A0000 |6 14|patients606T0076
P06291369A0000 |112 124|day intervalneonatal hyp
P06291369A0000 |216 220|RVEF of 
P06295429A0412 |169 179|protection3-] is sho
P06295429A0412 |122 135|sensitizationyperbilirubin
P06295429A0412 |28 35|WR-2721th alka
P06295429A0412 |200 205|dosesSF PC
P06295429A0412 |57 65|response5-nucleo
P06295429A0412 |148 153|doses97A04
P06295429A0412 |19 23|MISOaris
P06295429A0412 |4 15|combination01606T0076 
P06295429A0412 |87 91|drugPhar
P06296833A0000 |33 64|cuticle protein gene expressionkaline phosphatases and 5-nucle
P06296833A0000 |108 114|strain of ne
P06296833A0000 |4 13|mutations01606T007
P06298014A0647 |55 63|activityd 5-nucl
P06298014A0647 |46 51|formsatase
P06298014A0647 |108 113|units of n
P06298014A0647 |124 131|columnserbilir
P06298014A0647 |4 13|ensembles01606T007
P06298720A0893 |49 64|repeat sequenceses and 5-nucle
P06298720A0893 |11 23|conservation076 Comparis
P06298720A0893 |112 125|VL30 elementsneonatal hype
P06298720A0893 |130 145|MuLV provirusesrubinemia. P000
P06298720A0893 |86 107|integration mechanism Pharmacologic aspect
P06300662T0000 |35 45|expressionline phosp
P06300662T0000 |2 21|cDNA cloning vector0001606T0076 Compar
P06300662T0000 |75 80|cells00817
P06300662T0000 |49 61|cDNA insertsses and 5-nu
P06300836A0285 |119 127|presencel hyperb
P06300836A0285 |90 101|genome RNAsrmacologic 
P06300836A0285 |234 250|rotavirus genomes are no longer 
P06300836A0285 |54 66|RR1 coloniesnd 5-nucleot
P06300836A0285 |131 156|DNA clones representativeubinemia. P00008997A0472 
P06300836A0285 |206 226|constituent segments2 the data of K-depl
P06300836A0285 |175 188|reovirus RNAs shown as a f
P06300836A0285 |0 13|HybridizationP00001606T007
P06304771A1284 |68 82|polyomavirusesase P00008171T
P06304771A1284 |198 210|JCV sequence CSF PCO2 th
P06304771A1284 |132 136|rolebine
P06304771A1284 |54 59|timesnd 5-
P06304771A1284 |163 176|transcriptionF [HCO3-] is 
P06304771A1284 |8 16|sequence6T0076 C
P06304771A1284 |18 26|GGGXGGAGparison 
P06304771A1284 |140 155|DNA replication P00008997A0472
P06304771A1284 |87 99|adenovirusesPharmacologi
P06306342A1156 |139 149|disruption. P0000899
P06306342A1156 |43 47|LiClspha
P06306342A1156 |195 211|Heidenhain pouch of CSF PCO2 the
P06306342A1156 |91 105|acid secretionmacologic aspe
P06306342A1156 |21 28|studiesison wi
P06306342A1156 |173 180|barrieris show
P06306342A1156 |3 13|conclusion001606T007
P06307099A1005 |0 12|Lung densityP00001606T00
P06307099A1005 |74 81|animals0008171
P06308536T0001 |32 40|anti-HAVlkaline 
P06308536T0001 |61 75|liver diseasescleotidase P00
P06308536T0001 |4 30|hepatitis A virus antibody01606T0076 Comparison with
P06308607A0375 |102 113|nucleotidesspects of n
P06308607A0375 |41 50|sequenceshosphatas
P06308607A0375 |167 186|polymerase sequenceCO3-] is shown as a
P06308607A0375 |123 135|p30 sequenceperbilirubin
P06308607A0375 |4 13|junctions01606T007
P06308607A0375 |146 157|nucleotides8997A0472 W
P06308607A0375 |70 91|DNA sequence analysise P00008171T0000 Phar
P06309020A0473 |0 8|NaloxoneP0000160
P06309020A0473 |75 80|doses00817
P06309020A0473 |88 106|lipopolysaccharideharmacologic aspec
P06309020A0473 |28 43|mg X kg-1 X h-1th alkaline pho
P06309020A0473 |12 23|mg/kg bolus76 Comparis
P06309855T0000 |0 21|Gel route preparationP00001606T0076 Compar
P06309855T0000 |29 35|fusingh alka
P06309855T0000 |43 57|porcelain fritsphatases and 
P06309969T0055 |0 2|I.P0
P06310159A0000 |80 94|retrovirus MH21T0000 Pharmac
P06310159A0000 |6 9|RNA606
P06310159A0000 |63 70|proteineotidas
P06310159A0000 |39 42|DNA ph
P06310457A0000 |53 59|tectumand 5-
P06310457A0000 |14 24|recordings Compariso
P06310457A0000 |67 71|carpdase
P06310553T0000 |37 43|originne pho
P06310553T0000 |61 78|muscle actin genecleotidase P00008
P06310553T0000 |10 19|structure0076 Comp
P06310608A0749 |152 159|Moloney472 Whe
P06310608A0749 |125 137|Ableson MuLVrbilirubinem
P06310608A0749 |182 187|M-MSVas a 
P06310608A0749 |167 180|sarcoma virusCO3-] is show
P06310608A0749 |29 41|substitutionh alkaline p
P06310608A0749 |4 11|mutants01606T0
P06310608A0749 |82 85|DNA000
P06310608A0749 |59 64|clonenucle
P06310608A0749 |139 146|Ab-MuLV. P0000
P06310608A0749 |116 123|virusesatal hy
P06310608A0749 |68 78|M-MuLV DNAase P00008
P06314276T0000 |17 24|cloningmpariso
P06314276T0000 |98 102|SV40ic a
P06314276T0000 |83 90|control000 Pha
P06314276T0000 |29 39|expressionh alkaline
P06314276T0000 |117 130|gene promotertal hyperbili
P06314276T0000 |71 76|cDNAs P000
P06314276T0000 |0 8|PlasmidsP0000160
P06314312A0359 |274 280|levelsto con
P06314312A0359 |211 212|% 
P06314312A0359 |50 54|dietes a
P06314312A0359 |154 162|purities2 When C
P06314312A0359 |86 89|ppm Ph
P06314312A0359 |188 194|chicksunctio
P06314312A0359 |245 252|averagenger di
P06314312A0359 |122 129|sourcesyperbil
P06314312A0359 |60 66|levelsucleot
P06314312A0359 |226 241|feed efficiencyeted rats are n
P06314312A0359 |258 259|%d
P06314312A0359 |16 31|soybean proteinomparison with 
P06314312A0359 |198 205|average CSF PC
P06314312A0359 |286 287|Pb
P06314312A0359 |173 184|weight gainis shown as
P06316347A0852 |85 112|beta-galactosidase activity0 Pharmacologic aspects of 
P06316347A0852 |22 30|rnh-lacZson with
P06316347A0852 |4 13|dnaQ-lacZ01606T007
P06316347A0852 |37 42|genesne ph
P06316347A0852 |71 79|proteins P000081
P06316623A0188 |100 105|goats aspe
P06316623A0188 |44 48|centphat
P06316623A0188 |75 80|sheep00817
P06316623A0188 |8 19|prevalences6T0076 Comp
P06316623A0188 |92 96|centacol
P06316623A0188 |124 144|immunodiffusion testerbilirubinemia. P00
P06316623A0188 |67 71|centdase
P06316623A0188 |52 58|cattle and 5
P06316623A0188 |23 31|antibodyon with 
P06318078T0000 |0 10|ExpressionP00001606T
P06318078T0000 |44 55|gamma genesphatases an
P06318078T0000 |14 39|herpes simplex virus beta Comparison with alkaline
P06318078T0000 |96 105|inductionogic aspe
P06318078T0000 |112 130|alpha gene productneonatal hyperbili
P06318078T0000 |80 85|cells1T000
P06318091A0395 |4 24|splice acceptor site01606T0076 Compariso
P06318322A0350 |68 81|recombinationase P00008171
P06318322A0350 |224 237|messenger RNApleted rats a
P06318322A0350 |134 139|virusnemia
P06318322A0350 |144 153|proto-sis008997A04
P06318322A0350 |26 31|modelwith 
P06318322A0350 |47 50|SSVtas
P06318322A0350 |99 102|DNAc a
P06318322A0350 |163 170|intronsF [HCO3
P06318322A0350 |115 122|sarcomanatal h
P06319040A1627 |220 228|increaseK-deplet
P06319040A1627 |41 56|system activityhosphatases and
P06319040A1627 |241 249|pressureo longer
P06319040A1627 |128 136|reflexlylirubine
P06319040A1627 |146 155|reduction8997A0472
P06319040A1627 |94 104|activationologic asp
P06319040A1627 |168 178|blood flowO3-] is sh
P06319040A1627 |65 86|carotid chemoreceptortidase P00008171T0000
P06319040A1627 |204 207|dogCO2
P06319071A0173 |250 260|creatininedisplaced 
P06319071A0173 |63 84|calcium stone-formerseotidase P00008171T00
P06319071A0173 |209 212|AMPhe 
P06319071A0173 |113 123|AMP levelseonatal hy
P06319071A0173 |7 15|subjects06T0076 
P06319071A0173 |163 173|differenceF [HCO3-] 
P06319071A0173 |39 47|subjects phospha
P06319071A0173 |233 246|units mumol/gts are no lon
P06319071A0173 |140 152|counterparts P00008997A0
P06319072A0711 |174 180|groupss show
P06319072A0711 |107 127|cell receptor numbers of neonatal hyperb
P06319072A0711 |57 65|patients5-nucleo
P06319072A0711 |193 219|beta-adrenoceptor functionon of CSF PCO2 the data of
P06319072A0711 |148 155|results97A0472
P06319072A0711 |22 33|morning dipson with al
P06319072A0711 |131 139|affinityubinemia
P06319072A0711 |96 103|changesogic as
P06319421A0937 |137 143|uptakeia. P0
P06319421A0937 |14 25|desipramine Comparison
P06319421A0937 |106 124|mianserin blockadets of neonatal hyp
P06319421A0937 |46 56|inhibitionatases and
P06319421A0937 |88 101|amitriptylineharmacologic 
P06319421A0937 |4 10|effect01606T
P06319421A0937 |162 185|alpha 2-adrenoreceptorsSF [HCO3-] is shown as 
P06319421A0937 |69 75|uptakese P00
P06319740A1331 |171 187|Rauscher disease] is shown as a 
P06319740A1331 |162 167|phaseSF [H
P06319740A1331 |58 68|initiation-nucleotid
P06319740A1331 |72 85|amplificationP00008171T000
P06319740A1331 |21 25|gp54ison
P06319740A1331 |37 41|genene p
P06319740A1331 |101 125|erythroblast hyperplasiaaspects of neonatal hype
P06320380T0001 |0 18|Surgical treatmentP00001606T0076 Com
P06320380T0001 |32 42|metastaseslkaline ph
P06321505A0401 |118 131|transcriptional hyperbilir
P06321505A0401 |209 222|transcriptionhe data of K-
P06321505A0401 |104 114|initiationects of ne
P06321505A0401 |151 170|S1 nuclease mapping0472 When CSF [HCO3
P06321505A0401 |95 100|pointlogic
P06321505A0401 |41 49|TATA boxhosphata
P06321505A0401 |226 238|rat PTH mRNAeted rats ar
P06321505A0401 |21 37|Goldberg-Hognessison with alkali
P06321505A0401 |66 76|base pairsidase P000
P06321505A0401 |2 19|promoter sequence0001606T0076 Comp
P06321634A0123 |118 123|basesal hy
P06321634A0123 |160 177|TRs/IRs sequences CSF [HCO3-] is s
P06321634A0123 |90 96|intronrmacol
P06321634A0123 |48 63|leader sequenceases and 5-nucl
P06321634A0123 |22 27|mRNAsson w
P06321634A0123 |71 76|bases P000
P06321770A1353 |118 123|virusal hy
P06321770A1353 |74 75|h0
P06321770A1353 |146 152|nature8997A0
P06321770A1353 |95 100|cellslogic
P06321770A1353 |160 169|promoters CSF [HCO
P06321770A1353 |4 14|expression01606T0076
P06321770A1353 |82 91|infection0000 Phar
P06321770A1353 |18 51|chloramphenicol acetyltransferaseparison with alkaline phosphatase
P06322183A1070 |51 71|kanamycin resistances and 5-nucleotidase
P06322183A1070 |30 47|agar plate assays alkaline phospha
P06322183A1070 |143 151|presence0008997A
P06322183A1070 |79 98|immunoprecipitation71T0000 Pharmacolog
P06322183A1070 |106 120|NPT II proteints of neonatal
P06322183A1070 |187 194|absencefunctio
P06322183A1070 |155 163|cysteine When CS
P06322183A1070 |0 16|NPT II synthesisP00001606T0076 C
P06323556A0126 |116 124|catheteratal hyp
P06323556A0126 |43 58|EOE-13 infusionsphatases and 5
P06323556A0126 |11 22|tomographic076 Compari
P06323556A0126 |81 98|perfusion patternT0000 Pharmacolog
P06324089A0453 |115 120|genesnatal
P06324089A0453 |62 70|featuresleotidas
P06324089A0453 |29 33|GAL7h al
P06324089A0453 |12 21|structure76 Compar
P06324089A0453 |46 52|regionatases
P06324121A0256 |80 85|codon1T000
P06324121A0256 |15 18|12KCom
P06324121A0256 |46 54|IEmRNA-5atases a
P06324121A0256 |121 125|basehype
P06324121A0256 |91 104|reading framemacologic asp
P06324121A0256 |144 150|region008997
P06324121A0256 |11 13|MW07
P06324121A0256 |23 34|polypeptideon with alk
P06325415A0757 |170 181|amino acids-] is shown
P06325415A0757 |44 52|Ad5 DBPsphatases
P06325415A0757 |60 67|absenceucleoti
P06325415A0757 |76 87|Ad7 protein08171T0000 
P06325415A0757 |95 106|amino acidslogic aspec
P06325415A0757 |13 23|difference6 Comparis
P06325415A0757 |36 39|Ad7ine
P06325415A0757 |142 149|domains0000899
P06325415A0757 |157 168|Ad5 proteinhen CSF [HC
P06327039A0743 |71 88|body surface area P00008171T0000 P
P06327039A0743 |90 93|agerma
P06327039A0743 |45 48|LVMhat
P06327039A0743 |156 166|resistanceWhen CSF [
P06327039A0743 |251 265|catecholaminesisplaced when 
P06327039A0743 |218 222|CD25f K-
P06327039A0743 |52 66|wall thickness and 5-nucleot
P06327039A0743 |297 298|ra
P06327039A0743 |95 109|blood pressurelogic aspects 
P06327039A0743 |131 137|outputubinem
P06327039A0743 |287 295|patientsut still
P06327039A0743 |15 26|correlationComparison 
P06327039A0743 |197 208|wall stressf CSF PCO2 
P06327039A0743 |111 121|heart rate neonatal 
P06327039A0743 |308 309|pf
P06327292A0846 |16 40|Shine-Dalgarno sequencesomparison with alkaline 
P06327292A0846 |92 104|start codonsacologic asp
P06327638A0155 |4 15|gene cat-8601606T0076 
P06327638A0155 |127 130|DNAili
P06327638A0155 |107 119|1.1-kilobases of neonata
P06327638A0155 |54 87|chloramphenicol acetyltransferasend 5-nucleotidase P00008171T0000 
P06328002A0000 |70 91|Moloney sarcoma viruse P00008171T0000 Phar
P06328002A0000 |59 66|passagenucleot
P06328002A0000 |111 115|mice neo
P06328002A0000 |23 36|sarcoma viruson with alkal
P06328002A0000 |93 100|Mo-MuSVcologic
P06328002A0000 |38 42|MPSVe ph
P06328012A0549 |84 91|BamHI-K00 Phar
P06328012A0549 |126 141|I1f subfragmentbilirubinemia. 
P06328012A0549 |147 150|kbp997
P06328012A0549 |15 27|EBNA proteinComparison w
P06328012A0549 |66 78|transfectionidase P00008
P06328012A0549 |97 111|kilobase pairsgic aspects of
P06328012A0549 |113 116|kbpeon
P06328485A0277 |290 312|chicken proto-myc genestill have a significa
P06328485A0277 |77 86|delta gag8171T0000
P06328485A0277 |227 230|mhtted
P06328485A0277 |192 197|virusion o
P06328485A0277 |132 139|MH2 DNAbinemia
P06328485A0277 |28 47|nucleotide sequenceth alkaline phospha
P06328485A0277 |55 57|kbd 
P06328485A0277 |97 100|endgic
P06328485A0277 |144 149|order00899
P06328485A0277 |262 269|virusesen comp
P06328485A0277 |175 184|structure shown as
P06328485A0277 |70 73|ende P
P06328504A0161 |0 3|USAP00
P06328504A0161 |79 86|portion71T0000
P06328504A0161 |47 65|clone lambda PGK-1tases and 5-nucleo
P06328504A0161 |138 141|PGKa. 
P06328504A0161 |113 136|phosphoglycerate kinaseeonatal hyperbilirubine
P06328504A0161 |103 108|locuspects
P06330082A0329 |0 2|A.P0
P06330478A0304 |71 73|mg P
P06330478A0304 |22 32|cimetidineson with a
P06330478A0304 |4 12|patients01606T00
P06330478A0304 |37 46|mg q.i.d.ne phosph
P06330478A0304 |98 103|dosesic as
P06331684A0607 |84 88|risk00 P
P06331684A0607 |26 33|stomachwith al
P06331684A0607 |15 19|testComp
P06331684A0607 |93 107|stomach cancercologic aspect
P06331684A0607 |57 66|screening5-nucleot
P06331684A0607 |38 52|tumor antigense phosphatases
P06333433A0000 |203 206|LPSPCO
P06333433A0000 |166 173|profileHCO3-] 
P06333433A0000 |73 81|outbreak00008171
P06333433A0000 |31 48|influenzae type balkaline phosphat
P06333433A0000 |94 122|H. influenzae type b diseaseologic aspects of neonatal h
P06333433A0000 |183 201|lipopolysaccharides a function of CS
P06333433A0000 |7 15|isolates06T0076 
P06333878T0000 |12 25|acid overdose76 Comparison
P06336045A0261 |153 156|TRP72 
P06336045A0261 |169 174|phase3-] i
P06336045A0261 |100 117|indentation phase aspects of neona
P06336045A0261 |81 87|spikesT0000 
P06336045A0261 |38 40|Fte 
P06336045A0261 |188 193|spikeuncti
P06336045A0261 |66 71|unitsidase
P06336045A0261 |127 151|threshold response phaseilirubinemia. P00008997A
P06336045A0261 |24 33|frog typen with al
P06336045A0261 |62 64|SAle
P06336045A0261 |14 18|Ft I Com
P06336045A0261 |66 71|unitsidase
P06336045A0261 |127 151|threshold response phaseilirubinemia. P00008997A
P06336045A0261 |24 33|frog typen with al
P06336045A0261 |62 64|SAle
P06336045A0261 |14 18|Ft I Com
P06336045A0261 |153 156|TRP72 
P06336045A0261 |1 10|Frog type00001606T
P06336045A0261 |81 87|spikesT0000 
P06336045A0261 |38 40|Fte 
P06336045A0261 |188 193|spikeuncti
P06336045A0261 |169 174|phase3-] i
P06336045A0261 |100 117|indentation phase aspects of neona
P06336045A0261 |1 10|Frog type00001606T
P06340643A0598 |0 4|DMCMP000
P06340643A0598 |18 27|extensionparison w
P06340643A0598 |80 92|donor organs1T0000 Pharm
P06340643A0598 |35 48|possibilitiesline phosphat
P06340703A0324 |0 9|GrimeliusP00001606
P06340703A0324 |30 44|Masson Fontana alkaline phos
P06341139A0213 |0 13|Blood glucoseP00001606T007
P06341139A0213 |95 98|minlog
P06341139A0213 |121 130|g glucosehyperbili
P06341139A0213 |220 228|g applesK-deplet
P06341139A0213 |18 32|plasma insulinparison with a
P06341139A0213 |55 59|timed 5-
P06341139A0213 |190 191|gc
P06341139A0213 |159 166|g honeyn CSF [
P06341139A0213 |144 151|lactose008997A
P06341139A0213 |179 184|breadwn as
P06341139A0213 |198 202|rice CSF
P06341139A0213 |132 140|fructosebinemia.
P06341139A0213 |105 114|ingestioncts of ne
P06341139A0213 |236 245|g carrotsare no lo
P06341139A0213 |206 214|potatoes2 the da
P06341139A0213 |171 172|g]
P06341661T0001 |55 70|Blalock-Taussigd 5-nucleotidas
P06341661T0001 |40 51|acid suturephosphatase
P06341661T0001 |73 82|operation00008171T
P06341661T0001 |9 12|useT00
P06342141A0226 |479 483|type5 mg
P06342141A0226 |41 54|understandinghosphatases a
P06342141A0226 |164 172|efficacy [HCO3-]
P06342141A0226 |105 116|specificitycts of neon
P06342141A0226 |291 296|needstill 
P06342141A0226 |253 257|typeplac
P06342141A0226 |188 198|modalitiesunction of
P06342141A0226 |58 80|family pathophysiology-nucleotidase P0000817
P06342141A0226 |487 491|carenigh
P06342141A0226 |604 609|studyn (VC
P06342141A0226 |422 434|consequenceswith the opt
P06342141A0226 |538 545|attempt83A0210
P06342141A0226 |89 100|sensitivityarmacologic
P06342141A0226 |330 337|members (1.21 
P06342141A0226 |389 399|importanceto be an e
P06342141A0226 |304 310|familyignifi
P06342141A0226 |443 470|health care delivery system for use in general practic
P06342141A0226 |506 523|literature review45 Beta blocking 
P06342141A0226 |582 591|questionsoximated 
P06342141A0226 |562 569|querieseal CO2
P06342141A0226 |261 265|carehen 
P06342141A0226 |212 230|family health caredata of K-depleted
P06342141A0226 |346 362|value judgementsvs. P00010943A07
P06342141A0226 |153 159|safety72 Whe
P06342141A0226 |131 141|techniquesubinemia. 
P06345840A0348 |103 111|velocitypects of
P06345840A0348 |42 44|CIos
P06345840A0348 |46 56|heart rateatases and
P06345840A0348 |15 22|group ACompari
P06345840A0348 |140 143|TPR P0
P06345840A0348 |65 69|meantida
P06345840A0348 |113 117|mVCFeona
P06345840A0348 |33 35|CIka
P06345840A0348 |3 11|patients001606T0
P06345840A0348 |86 91|fiber Phar
P06346427A0000 |80 84|rats1T00
P06346427A0000 |109 119|test-mealsof neonata
P06346427A0000 |25 39|insulin levels with alkaline
P06349364A1051 |81 95|serum globulinT0000 Pharmaco
P06349364A1051 |198 207|infection CSF PCO2
P06349364A1051 |56 63|passive 5-nucl
P06349364A1051 |120 149|group B Streptococcus antigen hyperbilirubinemia. P0000899
P06349364A1051 |97 107|antibodiesgic aspect
P06349364A1051 |111 115|type neo
P06349364A1051 |6 13|results606T007
P06350092A0916 |48 52|CCHDases
P06350092A0916 |166 173|diseaseHCO3-] 
P06350092A0916 |120 127|degrees hyperb
P06350092A0916 |58 68|occurrence-nucleotid
P06350092A0916 |29 32|AMIh a
P06350092A0916 |226 231|deatheted 
P06350092A0916 |83 87|VPBs000 
P06350092A0916 |189 200|possibilitynction of C
P06350092A0916 |20 25|phaserison
P06354594A0114 |48 52|limeases
P06354594A0114 |15 23|mandarinComparis
P06354594A0114 |76 86|processing08171T0000
P06354594A0114 |25 35|grapefruit with alka
P06354594A0114 |6 13|oranges606T007
P06355483A0134 |116 121|locusatal 
P06355483A0134 |67 76|sequencesdase P000
P06355483A0134 |130 140|base-pairsrubinemia.
P06355483A0134 |98 108|base-pairsic aspects
P06355483A0134 |4 9|genes01606
P06355483A0134 |18 23|locusparis
P06360426A0501 |86 99|colour change Pharmacologi
P06360426A0501 |107 119|pH indicators of neonata
P06360426A0501 |26 30|ureawith
P06360426A0501 |12 22|hydrolysis76 Compari
P06360426A0501 |40 47|ammoniaphospha
P06361318A0440 |152 153|%4
P06361318A0440 |125 142|committee membersrbilirubinemia. P
P06361318A0440 |94 99|casesologi
P06361318A0440 |182 183|%a
P06361318A0440 |13 27|efficacy rates6 Comparison w
P06361318A0440 |45 50|caseshatas
P06361318A0440 |52 63|KS-R1 group and 5-nucl
P06361318A0440 |197 202|groupf CSF
P06361318A0440 |162 173|KS-R1 groupSF [HCO3-] 
P06361318A0440 |113 121|criteriaeonatal 
P06361318A0440 |82 87|group0000 
P06361318A0440 |70 75|casese P00
P06361318A1127 |0 11|Side effectP00001606T0
P06361318A1127 |191 202|KS-R1 grouption of CSF
P06361318A1127 |112 117|casesneona
P06361318A1127 |94 105|KS-R1 groupologic aspe
P06361318A1127 |124 129|grouperbil
P06361318A1127 |181 182|% 
P06361318A1127 |211 212|% 
P06361318A1127 |152 166|incidence rate472 When CSF [
P06361318A1127 |254 264|differencelaced when
P06361318A1127 |87 92|casesPharm
P06361318A1127 |47 55|symptomstases an
P06361318A1127 |226 231|groupeted 
P06361318A1127 |136 141|casesmia. 
P06362143A0565 |68 89|isoprenaline infusionase P00008171T0000 Ph
P06362143A0565 |60 64|tiltucle
P06362143A0565 |97 105|patientsgic aspe
P06362143A0565 |40 48|responsephosphat
P06362143A0565 |0 21|Plasma renin activityP00001606T0076 Compar
P06362239T0001 |0 13|Martin LutherP00001606T007
P06362239T0001 |22 32|physiciansson with a
P06362602T0001 |0 11|EnhancementP00001606T0
P06362602T0001 |109 114|swineof ne
P06362602T0001 |26 34|responsewith alk
P06362602T0001 |123 128|swineperbi
P06362602T0001 |93 105|immunizationcologic aspe
P06362602T0001 |58 75|vaccine additives-nucleotidase P00
P06362602T0001 |48 54|actionases a
P06364265T0062 |8 30|gamma-ray spectroscopy6T0076 Comparison with
P06367414A0000 |68 73|hoursase P
P06367414A0000 |12 30|calcium antagonist76 Comparison with
P06367414A0000 |132 147|crossover trialbinemia. P00008
P06367414A0000 |38 47|half-lifee phospha
P06367414A0000 |93 100|placebocologic
P06367414A0000 |0 8|BepridilP0000160
P06369355A0834 |0 8|AnalysisP0000160
P06369355A0834 |149 168|replication protein7A0472 When CSF [HC
P06369355A0834 |77 88|trfA region8171T0000 P
P06369355A0834 |108 118|A2 protein of neonat
P06369355A0834 |12 20|proteins76 Compa
P06369355A0834 |36 44|plasmidsine phos
P06369355A0834 |172 183|plasmid RK2 is shown a
P06369355A0834 |64 69|formsotida
P06369954T0000 |0 7|EffectsP000016
P06369954T0000 |28 36|pressureth alkal
P06369954T0000 |57 69|hemodynamics5-nucleotida
P06370553A0444 |102 104|wksp
P06370553A0444 |186 191|ng/ml func
P06370553A0444 |87 94|therapyPharmac
P06370553A0444 |55 61|levelsd 5-nu
P06370553A0444 |52 53|E 
P06370553A0444 |147 156|plasma NE997A0472 
P06370553A0444 |123 133|guanfacineperbilirub
P06370553A0444 |31 33|NEal
P06370553A0444 |8 29|plasma norepinephrine6T0076 Comparison wit
P06370553A0444 |111 121|withdrawal neonatal 
P06370553A0444 |193 201|plasma Eon of CS
P06370553A0444 |39 50|epinephrine phosphatas
P06370553A0444 |231 236|ng/mlrats 
P06370553A0444 |138 145|controla. P000
P06372563T0000 |103 115|hyponatremiapects of neo
P06372563T0000 |75 86|natriuresis008171T0000
P06372563T0000 |6 14|response606T0076
P06372563T0000 |91 99|reversalmacologi
P06372563T0000 |61 71|furosemidecleotidase
P06372563T0000 |38 51|heart failuree phosphatase
P06372563T0000 |53 57|roleand 
P06372563T0000 |18 27|captoprilparison w
P06373409A1163 |0 9|LaucielloP00001606
P06373409A1163 |40 49|placementphosphata
P06373409A1163 |132 137|teethbinem
P06373409A1163 |93 105|restorationscologic aspe
P06373409A1163 |76 83|amalgam08171T0
P06373409A1163 |22 31|techniqueson with 
P06373855A0000 |136 141|acutamia. 
P06373855A0000 |63 70|lesionseotidas
P06373855A0000 |46 51|duskyatase
P06373855A0000 |30 37|papules alkali
P06373855A0000 |7 23|biopsy specimens06T0076 Comparis
P06373855A0000 |144 149|PLEVA00899
P06373855A0000 |198 223|immunoperoxidase technics CSF PCO2 the data of K-d
P06373855A0000 |96 118|pityriasis lichenoidesogic aspects of neonat
P06373855A0000 |82 90|patients0000 Pha
P06373855A0000 |175 193|immunofluorescence shown as a functi
P06374369A1112 |118 122|dietal h
P06374369A1112 |57 68|food intake5-nucleotid
P06374369A1112 |149 155|events7A0472
P06374369A1112 |44 53|reductionphatases 
P06374369A1112 |32 36|partlkal
P06374369A1112 |6 10|data606T
P06374369A1112 |84 88|rats00 P
P06374418A0877 |32 36|cystlkal
P06374418A0877 |95 102|hormonelogic a
P06374418A0877 |73 79|amount000081
P06374418A0877 |4 12|aspirate01606T00
P06376227A0217 |0 3|EGVP00
P06376227A0217 |71 81|conditions P00008171
P06376227A0217 |22 28|effectson wi
P06376227A0217 |32 44|PP secretionlkaline phos
P06379363A0415 |92 99|therapyacologi
P06379363A0415 |151 159|practice0472 Whe
P06379363A0415 |13 18|tests6 Com
P06379363A0415 |121 138|diabetes mellitushyperbilirubinemi
P06379363A0415 |40 46|HDL-2Mphosph
P06381438A1280 |0 28|Lung prostacyclin productionP00001606T0076 Comparison wi
P06382374A0206 |17 20|minmpa
P06382374A0206 |125 133|patientsrbilirub
P06382374A0206 |31 53|insulin administrationalkaline phosphatases 
P06382374A0206 |211 219|disorder data of
P06382374A0206 |67 73|changedase P
P06382374A0206 |59 63|ratenucl
P06382374A0206 |77 91|glucose levels8171T0000 Phar
P06382374A0206 |156 164|disorderWhen CSF
P06382374A0206 |234 250|control subjectss are no longer 
P06382374A0206 |187 195|patientsfunction
P06384983T0000 |0 10|ManagementP00001606T
P06384983T0000 |14 26|hypertension Comparison 
P06385474T0001 |48 55|allergyases an
P06385474T0001 |9 18|treatmentT0076 Com
P06385474T0001 |22 30|childrenson with
P06388189T0001 |0 15|TransplantationP00001606T0076 
P06388189T0001 |55 65|recipientsd 5-nucleo
P06388189T0001 |39 45|donors phosp
P06388189T0001 |19 26|kidneysarison 
P06388818A0000 |64 73|lymphomasotidase P
P06388818A0000 |211 217|rescue data 
P06388818A0000 |194 197|HDCn o
P06388818A0000 |128 149|chemotherapy regimenslirubinemia. P0000899
P06388818A0000 |245 265|bone marrow infusionnger displaced when 
P06388818A0000 |180 192|chemotherapyn as a funct
P06388818A0000 |36 43|Hodgkinine pho
P06388818A0000 |267 271|ABMTmpar
P06388818A0000 |4 12|patients01606T00
P06391496T0000 |34 46|polypeptidesaline phosph
P06391496T0000 |93 101|antacidscologic 
P06391496T0000 |74 82|almagate0008171T
P06391496T0000 |54 70|antacid activitynd 5-nucleotidas
P06391496T0000 |22 29|enzymesson wit
P06391496T0000 |0 6|EffectP00001
P06394228T0073 |0 7|ResultsP000016
P06394228T0073 |24 29|studyn wit
P06394347A1024 |34 42|increasealine ph
P06394347A1024 |46 67|plasma renin activityatases and 5-nucleoti
P06394347A1024 |80 89|excretion1T0000 Ph
P06394347A1024 |93 106|noradrenalinecologic aspec
P06394347A1024 |0 12|HydrallazineP00001606T00
P06395804A0382 |0 15|Urease activityP00001606T0076 
P06395804A0382 |21 22|%i
P06395804A0382 |67 70|mindas
P06395804A0382 |32 41|organismslkaline p
P06397009A0204 |68 85|conductor Bozziniase P00008171T000
P06397009A0204 |135 144|physicianemia. P00
P06397009A0204 |31 35|lifealka
P06397009A0204 |172 180|medicine is show
P06397009A0204 |43 54|explanationsphatases a
P06397009A0204 |88 93|meritharma
P06397009A0204 |203 216|possibilitiesPCO2 the data
P06397009A0204 |6 17|description606T0076 Co
P06397009A0204 |116 125|inventionatal hype
P06401749T0000 |4 10|effect01606T
P06401749T0000 |47 77|arginine vasopressin secretiontases and 5-nucleotidase P0000
P06401749T0000 |14 21|lithium Compar
P06401749T0000 |29 43|osmoregulationh alkaline pho
P06402480A0373 |253 262|treatmentplaced wh
P06402480A0373 |148 160|surveillance97A0472 When
P06402480A0373 |62 73|antibioticsleotidase P
P06402480A0373 |90 105|plasmid patternrmacologic aspe
P06402480A0373 |219 234|recommendations K-depleted rat
P06402480A0373 |125 134|necessityrbilirubi
P06402480A0373 |26 38|PPNG strainswith alkalin
P06402480A0373 |175 185|infections shown as 
P06402480A0373 |4 18|susceptibility01606T0076 Com
P06402480A0373 |201 211|evaluationF PCO2 the
P06402859A0000 |0 16|Antithrombin IIIP00001606T0076 C
P06402859A0000 |74 83|inhibitor0008171T0
P06402859A0000 |31 45|plasma proteinalkaline phosp
P06402859A0000 |138 149|coagulationa. P0000899
P06402859A0000 |111 120|modulator neonatal
P06402859A0000 |87 95|thrombinPharmaco
P06404842A0127 |152 160|duration472 When
P06404842A0127 |9 17|patientsT0076 Co
P06404842A0127 |131 136|weeksubine
P06404842A0127 |79 97|depot testosterone71T0000 Pharmacolo
P06404842A0127 |168 173|yearsO3-] 
P06404842A0127 |64 73|treatmentotidase P
P06404842A0127 |102 104|mgsp
P06406060A0000 |49 51|ipse
P06406060A0000 |75 79|mice0081
P06406060A0000 |15 24|cisplatinCompariso
P06406060A0000 |63 67|miceeoti
P06406060A0000 |88 95|Sarcomaharmaco
P06406060A0000 |42 44|ivos
P06407348A0516 |0 3|NewP00
P06407348A0516 |135 143|blockadeemia. P0
P06407348A0516 |159 168|receptorsn CSF [HC
P06407348A0516 |92 102|situationsacologic a
P06407348A0516 |198 214|muscle receptors CSF PCO2 the da
P06407348A0516 |18 23|drugsparis
P06407348A0516 |216 221|beta2 of K
P06407348A0516 |170 175|beta1-] is
P06411659A0264 |69 73|ratese P
P06411659A0264 |3 13|facilities001606T007
P06411659A0264 |37 48|consumptionne phosphat
P06411659A0264 |18 30|measurementsparison with
P06411659A0793 |112 121|mg/kg/dayneonatal 
P06411659A0793 |62 80|energy expenditureleotidase P0000817
P06411659A0793 |24 37|energy intaken with alkali
P06411659A0793 |89 97|N intakearmacolo
P06411659A0793 |52 57|times and 
P06412385A0356 |343 352|pneumonia23 vs. P0
P06412385A0356 |299 309|dependencee a signif
P06412385A0356 |265 270|PaCO2compa
P06412385A0356 |241 263|carbon dioxide tensiono longer displaced whe
P06412385A0356 |134 147|lung capacitynemia. P00008
P06412385A0356 |326 337|atelectasislope (1.21 
P06412385A0356 |118 126|capacityal hyper
P06412385A0356 |153 160|maximum72 When
P06412385A0356 |221 227|volume-deple
P06412385A0356 |52 67|muscle weakness and 5-nucleoti
P06412385A0356 |27 39|lung diseaseith alkaline
P06412385A0356 |10 18|patients0076 Com
P06412385A0356 |199 208|increasesCSF PCO2 
P06412385A0356 |285 295|likelihood but still
P06412385A0356 |99 108|decreasesc aspects
P06412385A0356 |313 324|ventilatorstly greater
P06412385A0356 |171 182|ventilation] is shown 
P06413492A0990 |0 6|CommunP00001
P06414990A0057 |50 56|samplees and
P06414990A0057 |28 32|datath a
P06414990A0057 |180 184|arean as
P06414990A0057 |36 44|TRH testine phos
P06414990A0057 |144 164|thyrotropin response008997A0472 When CSF
P06414990A0057 |123 129|limitsperbil
P06414990A0057 |71 81|volunteers P00008171
P06414990A0057 |99 109|evaluationc aspects 
P06414990A0057 |16 24|analysisompariso
P06415299A0233 |17 22|dosesmpari
P06415299A0233 |26 37|doxorubicinwith alkali
P06415299A0233 |61 63|mgcl
P06415299A0233 |65 67|m.ti
P06419251T0000 |0 20|Movement programmingP00001606T0076 Compa
P06419251T0000 |60 72|requirementsucleotidase 
P06419251T0000 |32 45|understandinglkaline phosp
P06426493A0331 |98 108|heart rateic aspects
P06426493A0331 |150 155|groupA0472
P06426493A0331 |159 167|patientsn CSF [H
P06426493A0331 |127 130|CVPili
P06426493A0331 |58 70|measurements-nucleotidas
P06426493A0331 |27 44|state anaesthesiaith alkaline phos
P06426493A0331 |215 226|pancuroniuma of K-depl
P06426493A0331 |177 187|atracuriumhown as a 
P06426493A0331 |88 96|pressureharmacol
P06426493A0331 |13 16|min6 C
P06426493A0331 |74 77|IOP000
P06426493A0331 |116 121|FE'COatal 
P06426493A0331 |110 114|FIO2f ne
P06426493A0331 |193 200|mg kg-1on of C
P06426493A0331 |231 238|mg kg-1rats ar
P06428116T0000 |37 51|hypothyroidismne phosphatase
P06428116T0000 |78 89|thyroiditis171T0000 Ph
P06428116T0000 |59 65|coursenucleo
P06429992T0000 |0 19|Gonadotropin levelsP00001606T0076 Comp
P06429992T0000 |23 30|motherson with
P06429992T0000 |56 64|DZ twins 5-nucle
P06429992T0000 |48 52|setsases
P06433442T0000 |0 8|FreezingP0000160
P06433442T0000 |45 51|factorhatase
P06433442T0000 |57 59|C.5-
P06433442T0000 |12 18|plasma76 Com
P06433442T0000 |36 41|yieldine p
P06434572A0157 |171 172|n]
P06434572A0157 |151 169|growth retardation0472 When CSF [HCO
P06434572A0157 |49 59|categoriesses and 5-
P06434572A0157 |325 330|testsslope
P06434572A0157 |248 249|nr
P06434572A0157 |334 344|GH reserve21 +/- 0.2
P06434572A0157 |127 128|ni
P06434572A0157 |210 216|growthe data
P06434572A0157 |90 91|nr
P06434572A0157 |6 14|children606T0076
P06434572A0157 |110 125|hypopituitarismf neonatal hype
P06434572A0157 |75 88|GH deficiency008171T0000 P
P06434572A0157 |201 206|delayF PCO
P06434572A0157 |278 286|criteriaontrols 
P06434572A0157 |239 246|stature no lon
P06434587A0551 |69 78|secretionse P00008
P06434587A0551 |5 12|patient1606T00
P06434587A0551 |93 95|LHco
P06434587A0551 |28 30|LHth
P06434587A0551 |117 120|LRHtal
P06434587A0551 |100 113|FSH responses aspects of n
P06434587A0551 |35 45|FSH levelsline phosp
P06435565A0648 |35 43|decreaseline pho
P06435565A0648 |214 222|dynes/cmta of K-
P06435565A0648 |122 123|py
P06435565A0648 |47 56|afterloadtases and
P06435565A0648 |23 29|resulton wit
P06435565A0648 |6 13|changes606T007
P06435565A0648 |162 172|resistanceSF [HCO3-]
P06435565A0648 |116 120|mmHgatal
P06435565A0648 |234 235|ps
P06435565A0648 |70 78|pressuree P00008
P06437579A0727 |0 10|CimetidineP00001606T
P06437579A0727 |27 32|nightith a
P06437579A0727 |56 58|mg 5
P06437579A0727 |15 17|mgCo
P06437579A0727 |146 155|treatment8997A0472
P06437579A0727 |108 126|patient compliance of neonatal hyper
P06437579A0727 |83 95|dose regimen000 Pharmaco
P06439114A0677 |0 11|CeftazidimeP00001606T0
P06439114A0677 |18 25|promiseparison
P06439114A0677 |42 49|therapyosphata
P06439114A0677 |86 96|infections Pharmacol
P06439135A0250 |0 12|Regional CBFP00001606T00
P06439135A0250 |105 115|procedurescts of neo
P06439135A0250 |60 68|patientsucleotid
P06439135A0250 |44 49|xenonphata
P06439135A0250 |31 40|clearancealkaline 
P06439135A0250 |89 95|bypassarmaco
P06441624A0263 |50 61|measurementes and 5-nu
P06441624A0263 |65 80|bone metabolismtidase P0000817
P06441624A0263 |26 35|serum BGPwith alka
P06441624A0263 |4 11|results01606T0
P06443550T0000 |32 39|patientlkaline
P06443550T0000 |4 14|management01606T0076
P06443639T0001 |0 5|StudyP0000
P06443639T0001 |40 48|movementphosphat
P06443639T0001 |19 27|motilityarison w
P06443639T0001 |64 82|circuit televisionotidase P00008171T
P06443639T0001 |32 36|ratelkal
P06443714T0001 |11 33|Rhodnius prolixus Stal076 Comparison with al
P06443714T0001 |44 62|babassu palm treesphatases and 5-nuc
P06444119A0340 |205 212|factorsO2 the 
P06444119A0340 |47 57|preferencetases and 
P06444119A0340 |91 99|salinitymacologi
P06444119A0340 |15 23|organismComparis
P06444119A0340 |78 89|temperature171T0000 Ph
P06444119A0340 |130 144|growth factorsrubinemia. P00
P06444119A0340 |62 73|requirementleotidase P
P06444119A0340 |101 103|pHas
P06444119A0340 |115 124|nutrientsnatal hyp
P06444119A0340 |154 169|toxin formation2 When CSF [HCO
P06446048A0356 |119 126|probleml hyper
P06446048A0356 |57 65|solution5-nucleo
P06446048A0356 |37 44|by-passne phos
P06451557A0777 |0 11|DeformitiesP00001606T0
P06451557A0777 |30 39|olecranon alkaline
P06451557A0777 |130 137|Weselohrubinem
P06451557A0777 |88 96|De Palmaharmacol
P06451557A0777 |60 67|processucleoti
P06451557A0777 |19 22|tipari
P06451557A0777 |116 123|Ahlbergatal hy
P06451557A0777 |103 109|Jordanpects 
P06452461A0930 |69 85|post AVR studiesse P00008171T000
P06452461A0930 |57 64|pre-AVR5-nucle
P06452461A0930 |37 43|LVM/M2ne pho
P06452461A0930 |22 33|correlationson with al
P06452461A0930 |48 52|PWVnases
P06452827T0001 |18 27|recordingparison w
P06452827T0001 |31 49|Huntington choreasalkaline phosphata
P06453290A0000 |115 123|materialnatal hy
P06453290A0000 |73 78|ducts00008
P06453290A0000 |36 48|organizationine phosphat
P06453290A0000 |132 137|weeksbinem
P06453290A0000 |4 15|development01606T0076 
P06454625A0000 |187 212|magnification angiographyfunction of CSF PCO2 the 
P06454625A0000 |105 115|hemostasiscts of neo
P06454625A0000 |72 83|vasculatureP00008171T0
P06454625A0000 |88 98|parenchymaharmacolog
P06454625A0000 |47 58|alterationstases and 5
P06454625A0000 |24 41|animal experimentn with alkaline p
P06454625A0000 |214 234|magnification factorta of K-depleted rat
P06454625A0000 |129 157|Infrared-Contact-Coagulationirubinemia. P00008997A0472 W
P06459831T0001 |0 14|CardiovascularP00001606T0076
P06459831T0001 |47 56|reactionstases and
P06459831T0001 |66 83|tobacco poisoningidase P00008171T0
P06460889A0111 |154 164|blood flow2 When CSF
P06460889A0111 |26 31|SG-75with 
P06460889A0111 |12 22|injections76 Compari
P06460889A0111 |166 169|PBFHCO
P06460889A0111 |82 85|SBP000
P06460889A0111 |40 45|mg/kgphosp
P06460889A0111 |66 80|blood pressureidase P0000817
P06460889A0512 |68 82|pulse pressurease P00008171T
P06460889A0512 |132 140|pressurebinemia.
P06460889A0512 |151 162|LVdP/dt max0472 When C
P06460889A0512 |18 31|.3 mg/kg i.v.parison with 
P06460889A0512 |3 8|doses00160
P06460889A0512 |142 145|LVP000
P06460889A0512 |84 94|heart rate00 Pharmac
P06460889A0512 |33 38|SG-75kalin
P06460889A0512 |103 113|blood flowpects of n
P06463429A0414 |38 39|%e
P06463429A0414 |25 30|phase with
P06463429A0414 |8 10|VE6T
P06463429A0414 |76 81|phase08171
P06466804A0686 |68 82|tape recordingase P00008171T
P06466804A0686 |199 204|shearCSF P
P06466804A0686 |12 23|endothelium76 Comparis
P06466804A0686 |132 141|flowmeterbinemia. 
P06466804A0686 |219 227|dyne/cm2 K-deple
P06466804A0686 |37 51|shear stressesne phosphatase
P06466804A0686 |163 169|injuryF [HCO
P06466804A0686 |100 114|flow waveforms aspects of ne
P06466804A0686 |173 183|denudationis shown a
P06466804A0686 |0 8|ExposureP0000160
P06467241A0000 |0 21|Modern cancer therapyP00001606T0076 Compar
P06467241A0000 |91 104|immunotherapymacologic asp
P06467241A0000 |44 56|radiotherapyphatases and
P06467241A0000 |58 70|chemotherapy-nucleotidas
P06467241A0000 |109 121|hyperthermiaof neonatal 
P06467241A0000 |35 42|surgeryline ph
P06467797A0233 |101 106|ratioaspec
P06467797A0233 |157 158|Ph
P06467797A0233 |58 60|NT-n
P06467797A0233 |145 147|rs08
P06467797A0233 |179 185|Swedeswn as 
P06467797A0233 |89 90|Da
P06467797A0233 |120 125|urine hype
P06467797A0233 |108 116|D/4-OH-D of neon
P06467797A0233 |134 143|Ghanaiansnemia. P0
P06467797A0233 |187 189|rsfu
P06467797A0233 |18 29|correlationparison wit
P06467797A0233 |64 80|10-hydroxylationotidase P0000817
P06467797A0233 |199 200|PC
P06467797A0233 |38 54|plasma clearancee phosphatases a
P06468565A0000 |186 210|frequency gain constants function of CSF PCO2 th
P06468565A0000 |95 105|parameterslogic aspe
P06468565A0000 |27 30|catith
P06468565A0000 |134 137|taunem
P06468565A0000 |212 214|Gmda
P06468565A0000 |144 168|frequency gain constants008997A0472 When CSF [HC
P06468565A0000 |59 60|Nn
P06468565A0000 |42 57|canal afferentsosphatases and 
P06468565A0000 |118 132|time constantsal hyperbiliru
P06468565A0000 |4 23|response properties01606T0076 Comparis
P06468565A0000 |170 172|G1-]
P06468632A0135 |0 11|EndotheliumP00001606T0
P06468632A0135 |27 37|ear arteryith alkali
P06468632A0135 |130 136|vesselrubine
P06468632A0135 |108 111|ear of
P06468632A0135 |57 63|rabbit5-nucl
P06468632A0135 |86 100|artery forceps Pharmacologic
P06468673A0358 |127 128|Pi
P06468673A0358 |62 74|mucus scoresleotidase P0
P06468673A0358 |120 125|group hype
P06468673A0358 |25 42|E2 concentrations with alkaline ph
P06468694A0441 |0 11|StimulationP00001606T0
P06468694A0441 |147 160|deterioration997A0472 When
P06468694A0441 |130 139|phenaminerubinemia
P06468694A0441 |73 78|means00008
P06468694A0441 |194 204|componentsn of CSF P
P06468694A0441 |55 61|systemd 5-nu
P06468694A0441 |114 124|microgramsonatal hyp
P06468694A0441 |65 69|dogstida
P06468694A0441 |82 96|administration0000 Pharmacol
P06468694A0441 |19 34|caudate nucleusarison with alk
P06468694A0441 |216 225|behaviour of K-dep
P06468694A0441 |100 109|dophamine aspects 
P06473219T0000 |0 5|ValueP0000
P06473219T0000 |9 28|urine glucose testsT0076 Comparison wi
P06473219T0000 |36 46|managementine phosph
P06473219T0000 |58 75|diabetes mellitus-nucleotidase P00
P06473219T0000 |50 54|typees a
P06473252A1073 |50 53|sexes 
P06473252A1073 |131 136|WORDSubine
P06473252A1073 |105 113|ABSTRACTcts of n
P06473252A1073 |5 15|experiment1606T0076 
P06473252A1073 |97 103|factorgic as
P06473252A1073 |64 78|egg productionotidase P00008
P06479362A0680 |0 14|HydrocortisoneP00001606T0076
P06479362A0680 |79 94|muscle membrane71T0000 Pharmac
P06479362A0680 |148 155|changes97A0472
P06479362A0680 |121 128|hormonehyperbi
P06479362A0680 |163 178|muscle membraneF [HCO3-] is sh
P06479362A0680 |108 113|doses of n
P06479362A0680 |48 71|postdenervation changesases and 5-nucleotidase
P06479976A0386 |119 128|diagnosisl hyperbi
P06479976A0386 |132 139|illnessbinemia
P06479976A0386 |45 53|patientshatases 
P06479976A0386 |21 32|differencesison with a
P06479976A0386 |212 220|patientsdata of 
P06479976A0386 |95 108|survival timelogic aspects
P06479976A0386 |79 82|AMB71T
P06479976A0386 |185 196|nerve signsa function 
P06479976A0386 |141 142|PP
P06479976A0386 |222 223|Pd
P06480542A0000 |18 23|studyparis
P06480542A0000 |27 37|apalcillinith alkali
P06480542A0000 |88 92|unitharm
P06480542A0000 |58 66|patients-nucleot
P06482179A0497 |0 15|Catch-up growthP00001606T0076 
P06482179A0497 |61 69|childrencleotida
P06482179A0497 |96 101|yearsogic 
P06482179A0497 |77 85|bone age8171T000
P06482179A0497 |49 55|periodses an
P06482318A0117 |0 20|Thrombocyte functionP00001606T0076 Compa
P06482318A0117 |41 49|patientshosphata
P06482318A0117 |81 102|platelet shape changeT0000 Pharmacologic a
P06482665A0735 |4 12|findings01606T00
P06482665A0735 |120 124|peak hyp
P06482665A0735 |30 49|AMPH administration alkaline phosphata
P06482665A0735 |132 147|caudate nucleusbinemia. P00008
P06482665A0735 |88 94|heightharmac
P06482665A0735 |210 219|increasese data of
P06482665A0735 |151 166|pigtail monkeys0472 When CSF [
P06482665A0735 |282 287|stateols b
P06482665A0735 |72 80|increaseP0000817
P06482665A0735 |295 301|animal have 
P06483863A0000 |169 173|days3-] 
P06483863A0000 |149 152|oil7A0
P06483863A0000 |293 303|Experimentll have a 
P06483863A0000 |260 271|Experimentswhen compar
P06483863A0000 |212 216|daysdata
P06483863A0000 |247 258|concretionser displace
P06483863A0000 |94 104|injectionsologic asp
P06483863A0000 |124 138|beta-estradiolerbilirubinemi
P06483863A0000 |177 181|lifehown
P06483863A0000 |110 120|microgramsf neonatal
P06483863A0000 |285 291|silica but s
P06483863A0000 |220 223|ageK-d
P06483863A0000 |50 69|BALB/cfC3HCrgl micees and 5-nucleotida
P06483863A0000 |36 46|BALB/cCrgline phosph
P06483863A0000 |7 18|experiments06T0076 Com
P06483863A0000 |234 238|times ar
P06486932A0000 |51 57|peoples and 
P06486932A0000 |164 169|death [HCO
P06486932A0000 |15 21|deathsCompar
P06486932A0000 |25 26|% 
P06486932A0000 |78 93|Malumfashi area171T0000 Pharma
P06486932A0000 |106 113|Nigeriats of n
P06486932A0000 |28 37|occurringth alkali
P06486932A0000 |115 119|datanata
P06486932A0000 |67 70|agedas
P06486932A0000 |138 146|symptomsa. P0000
P06487290A0000 |259 264|cycle when
P06487290A0000 |209 217|controlshe data 
P06487290A0000 |28 38|E2-17 betath alkalin
P06487290A0000 |44 56|progesteronephatases and
P06487290A0000 |22 26|betason 
P06487290A0000 |129 136|femalesirubine
P06487290A0000 |58 59|P-
P06487290A0000 |9 18|estradiolT0076 Com
P06487290A0000 |168 178|trimestersO3-] is sh
P06487290A0000 |86 113|radioimmunoassay techniques Pharmacologic aspects of n
P06487290A0000 |236 241|phaseare n
P06492188A0615 |55 61|numberd 5-nu
P06492188A0615 |41 47|effecthospha
P06492188A0615 |11 12|d0
P06492188A0615 |65 73|implantstidase P
P06493655A0415 |87 88|%P
P06493655A0415 |9 26|FHR decelerationsT0076 Comparison 
P06493655A0415 |30 42|bradycardias alkaline ph
P06493655A0415 |113 121|patientseonatal 
P06493655A0415 |66 81|nonstress testsidase P00008171
P06493655A0415 |101 102|%a
P06494215A0248 |55 72|food presentationd 5-nucleotidase 
P06494215A0248 |93 101|schedulecologic 
P06494215A0248 |27 36|componentith alkal
P06494215A0248 |4 18|response chain01606T0076 Com
P06494297A0939 |137 148|stimulationia. P000089
P06494297A0939 |76 87|acquisition08171T0000 
P06494297A0939 |123 129|effectperbil
P06494297A0939 |91 97|HPC SSmacolo
P06494297A0939 |66 72|effectidase 
P06494297A0939 |23 31|kindlingon with 
P06494297A0939 |4 11|results01606T0
P06494766A0241 |21 31|dispersionison with 
P06494766A0241 |90 96|septumrmacol
P06494766A0241 |45 66|Hiss bundle fragmentshatases and 5-nucleot
P06494766A0241 |123 134|explanationperbilirubi
P06495195A0536 |68 88|alkaline phosphatasease P00008171T0000 P
P06495195A0536 |164 176|liver damage [HCO3-] is 
P06495195A0536 |60 63|U/lucl
P06495195A0536 |41 49|activityhosphata
P06495195A0536 |29 34|testsh alk
P06495195A0536 |117 125|patientstal hype
P06497671T0001 |51 60|responsess and 5-n
P06497671T0001 |11 32|plasma cortisol level076 Comparison with a
P06497671T0001 |0 7|ChangesP000016
P06501086A0165 |137 160|vas deferens granulomasia. P00008997A0472 When
P06501086A0165 |12 23|alterations76 Comparis
P06501086A0165 |44 48|ratsphat
P06501086A0165 |216 222|levels of K-
P06501086A0165 |54 63|sham ratsnd 5-nucl
P06501086A0165 |113 122|formationeonatal h
P06501086A0165 |178 191|serum proteinown as a func
P06501086A0165 |272 304|sperm agglutinin antibody titersd to controls but still have a s
P06501086A0165 |235 256|serum electrophoresis are no longer displa
P06501086A0165 |100 111|hypertrophy aspects of
P06503132A0784 |34 36|Hnal
P06503132A0784 |38 39|se
P06503132A0784 |0 3|SFPP00
P06503329A0588 |85 98|control group0 Pharmacolog
P06503329A0588 |58 60|SD-n
P06503329A0588 |125 126|Pr
P06503329A0588 |12 22|birth mass76 Compari
P06503329A0588 |122 123|gy
P06503329A0588 |113 115|SDeo
P06503329A0588 |67 68|gd
P06503329A0588 |32 40|newbornslkaline 
P06503885A0342 |136 151|x-ray tube heatmia. P00008997A
P06503885A0342 |183 197|overestimations a function o
P06503885A0342 |74 85|temperature0008171T000
P06503885A0342 |60 65|waterucleo
P06503885A0342 |52 56|rise and
P06503885A0342 |231 235|rCBFrats
P06503885A0342 |315 334|interscan intervalsy greater slope (1.
P06503885A0342 |243 265|xenon/CT rCBF protocollonger displaced when 
P06503885A0342 |5 18|machine drift1606T0076 Com
P06503885A0342 |219 229|blood flow K-deplete
P06503885A0342 |291 296|scanstill 
P06505014A1192 |49 54|Vincases a
P06505014A1192 |40 44|Y-12phos
P06505014A1192 |27 36|dosimetryith alkal
P06505014A1192 |6 19|uncertainties606T0076 Comp
P06506074A0456 |0 13|E2 treatmentsP00001606T007
P06506074A0456 |23 36|hen plasma TGon with alkal
P06506074A0456 |56 57|C 
P06506074A0456 |88 89|Xh
P06506074A0456 |61 62|Xc
P06506074A0456 |91 93|PLma
P06506074A0456 |109 111|X.of
P06506074A0456 |104 105|Ce
P06506074A0456 |75 84|plasma TG008171T00
P06506074A0456 |49 50|Xs
P06506074A0456 |43 45|PLsp
P06506074A0456 |40 41|Xp
P06506074A0456 |97 98|Xg
P06507629A0717 |3 11|contrast001606T0
P06507629A0717 |133 152|mumol X min-1 X g-1inemia. P00008997A0
P06507629A0717 |13 20|kidneys6 Compa
P06507629A0717 |91 94|NH3mac
P06507629A0717 |111 117|groups neona
P06507629A0717 |26 30|ratswith
P06507629A0717 |54 62|acidosisnd 5-nuc
P06508393T0000 |17 32|trypanosomiasismparison with a
P06508393T0000 |90 102|Testryp CATTrmacologic a
P06508393T0000 |46 52|camelsatases
P06508393T0000 |61 88|card agglutination test setcleotidase P00008171T0000 P
P06508393T0000 |0 13|SerodiagnosisP00001606T007
P06513456T0001 |68 73|ulcerase P
P06513456T0001 |45 53|patientshatases 
P06513456T0001 |35 41|mucosaline p
P06513456T0001 |91 100|treatmentmacologic
P06513456T0001 |0 23|Adenyl cyclase activityP00001606T0076 Comparis
P06516369T0001 |0 11|ProteinuriaP00001606T0
P06516369T0001 |54 62|problemsnd 5-nuc
P06516847A0393 |37 48|pneumococcine phosphat
P06516847A0393 |62 71|mortalityleotidase
P06516847A0393 |77 88|pneumococci8171T0000 P
P06516977T0000 |0 8|ReactionP0000160
P06516977T0000 |30 38|exercise alkalin
P06516977T0000 |18 26|organismparison 
P06517816A0388 |102 103|ps
P06517816A0388 |120 123|Msw hy
P06517816A0388 |75 84|b X min-1008171T00
P06517816A0388 |53 62|degrees Cand 5-nuc
P06517816A0388 |128 141|g X m-2 X h-1lirubinemia. 
P06517816A0388 |26 27|pw
P06517816A0388 |44 47|Trepha
P06517816A0388 |0 2|HAP0
P06517816A0388 |154 172|saline experiments2 When CSF [HCO3-]
P06517816A0388 |68 70|HRas
P06520418A0325 |103 111|patientspects of
P06520418A0325 |133 159|LVIT flow velocity patterninemia. P00008997A0472 Whe
P06520418A0325 |168 176|patientsO3-] is 
P06520418A0325 |190 191|pc
P06520418A0325 |4 11|results01606T0
P06520418A0325 |182 186|typeas a
P06520418A0325 |117 121|typetal 
P06520418A0325 |49 67|valve orifice areases and 5-nucleoti
P06520418A0325 |69 72|MVAse 
P06521802A0251 |0 22|Scientific cooperationP00001606T0076 Compari
P06521802A0251 |90 101|sponsorshiprmacologic 
P06521802A0251 |191 200|frameworktion of C
P06521802A0251 |109 134|Cancer Research Instituteof neonatal hyperbilirubi
P06521802A0251 |26 47|CMEA member countrieswith alkaline phospha
P06521802A0251 |164 178|Czechoslovakia [HCO3-] is sh
P06521802A0251 |136 150|Slovak Academymia. P00008997
P06521802A0251 |154 162|Sciences2 When C
P06521802A0251 |204 208|CMEACO2 
P06521999A0677 |54 63|melanomasnd 5-nucl
P06521999A0677 |75 86|enucleation008171T0000
P06521999A0677 |27 34|resultsith alk
P06524202A0167 |100 106|method aspec
P06524202A0167 |120 128|training hyperbi
P06524202A0167 |159 169|spasticityn CSF [HCO
P06524202A0167 |37 49|multichannelne phosphata
P06524202A0167 |179 190|antagonistswn as a fun
P06524202A0167 |214 232|motor coordinationta of K-depleted r
P06524202A0167 |21 35|EMG-BFB methodison with alka
P06524202A0167 |6 13|variant606T007
P06524202A0167 |138 145|musclesa. P000
P06524727A0601 |0 11|LymphocytesP00001606T0
P06524727A0601 |146 160|blood dilution8997A0472 When
P06524727A0601 |72 80|prelabelP0000817
P06524727A0601 |47 56|responsestases and
P06524727A0601 |135 136|Ce
P06524727A0601 |23 30|specieson with
P06524727A0601 |111 128|incubation period neonatal hyperbi
P06524727A0601 |96 100|hourogic
P06524761A0596 |171 180|challenge] is show
P06524761A0596 |21 31|differenceison with 
P06524761A0596 |323 332|RH strainr slope (
P06524761A0596 |248 256|hamstersr displa
P06524761A0596 |267 290|live-toxoplasma vaccinempared to controls but 
P06524761A0596 |300 309|challenge a signif
P06524761A0596 |60 65|feverucleo
P06524761A0596 |129 154|killed-toxoplasma vaccineirubinemia. P00008997A047
P06524761A0596 |194 204|T-1 strainn of CSF P
P06524761A0596 |220 227|changesK-deple
P06524761A0596 |50 58|immunityes and 5
P06524761A0596 |100 108|hamsters aspects
P06524761A0596 |39 46|quality phosph
P06524761A0596 |70 86|body weight losse P00008171T0000
P06527379T0044 |85 97|DNA sequence0 Pharmacolo
P06527379T0044 |12 36|proline/alanine sequence76 Comparison with alkal
P06527379T0044 |40 55|beta B1 subunitphosphatases an
P06527872T0000 |171 176|means] is 
P06527872T0000 |183 199|acid phosphatases a function of 
P06527872T0000 |132 136|cordbine
P06527872T0000 |96 117|substantia gelatinosaogic aspects of neona
P06527872T0000 |82 88|nerves0000 P
P06527872T0000 |162 167|studySF [H
P06527872T0000 |27 38|projectionsith alkalin
P06527872T0000 |201 204|ACPF P
P06527872T0000 |140 144|rats P00
P06527872T0000 |206 212|method2 the 
P06531286A0382 |0 7|RemovalP000016
P06531286A0382 |11 26|lipid fractions076 Comparison 
P06531286A0382 |30 47|plant extractions alkaline phospha
P06531286A0382 |98 109|HPLC columnic aspects 
P06531286A0382 |53 59|hexaneand 5-
P06531286A0382 |84 90|damage00 Pha
P06535384A1115 |171 179|ABSTRACT] is sho
P06535384A1115 |62 72|difficultyleotidase 
P06535384A1115 |145 152|success08997A0
P06535384A1115 |161 169|subjectsCSF [HCO
P06535384A1115 |130 141|possibilityrubinemia. 
P06535384A1115 |106 111|itemsts of
P06535384A1115 |37 42|itemsne ph
P06535384A1115 |197 202|WORDSf CSF
P06535384A1115 |18 25|subtestparison
P06539738T0000 |32 50|chlorofluorocarbonlkaline phosphatas
P06539738T0000 |55 58|CFCd 5
P06539738T0000 |18 28|evaluationparison wi
P06541019A0555 |51 59|responses and 5-
P06541019A0555 |4 12|patients01606T00
P06541019A0555 |32 40|toxicitylkaline 
P06541932A0000 |0 7|MethodsP000016
P06541932A0000 |37 48|algesimetryne phosphat
P06541932A0000 |95 102|effectslogic a
P06541932A0000 |140 150|analgesics P00008997
P06542372A0159 |117 122|termstal h
P06542372A0159 |127 137|additivityilirubinem
P06542372A0159 |42 55|discrepanciesosphatases an
P06542372A0159 |12 17|paper76 Co
P06542372A0159 |141 153|potentiationP00008997A04
P06542372A0159 |81 92|terminologyT0000 Pharm
P06542372A0159 |168 178|similarityO3-] is sh
P06542918A1131 |81 91|evaluationT0000 Phar
P06542918A1131 |135 147|P3 latenciesemia. P00008
P06542918A1131 |30 44|discrimination alkaline phos
P06542918A1131 |64 68|timeotid
P06545651A0346 |51 61|treatmentss and 5-nu
P06545651A0346 |65 72|findingtidase 
P06545651A0346 |111 139|protein nitrogen degradation neonatal hyperbilirubinemia
P06545651A0346 |165 168|NH3[HC
P06545651A0346 |155 163|nitrogen When CS
P06545651A0346 |101 107|effectaspect
P06545651A0346 |0 21|Ammonia concentrationP00001606T0076 Compar
P06546392A0542 |84 114|erythrocyte sedimentation rate00 Pharmacologic aspects of ne
P06546392A0542 |27 49|protein concentrationsith alkaline phosphata
P06546392A0542 |72 82|cell countP00008171T
P06546392A0542 |120 131|temperature hyperbilir
P06546392A0542 |158 171|antiproteasesen CSF [HCO3-
P06546392A0542 |8 17|respect C6T0076 Co
P06546392A0542 |140 154|concentrations P00008997A047
P06548953T0001 |34 50|thyroid diseasesaline phosphatas
P06548953T0001 |26 29|HTSwit
P06548953T0001 |6 24|thyroid stimulator606T0076 Compariso
P06555107A1227 |17 31|administrationmparison with 
P06555107A1227 |88 93|valueharma
P06555107A1227 |122 135|beta-mimeticsyperbilirubin
P06555107A1227 |107 116|treatments of neon
P06555107A1227 |39 67|calcium antagonist Verapamil phosphatases and 5-nucleoti
P06568939A0000 |0 9|BrainstemP00001606
P06568939A0000 |99 110|informationc aspects o
P06568939A0000 |37 42|BAERsne ph
P06568939A0000 |131 139|pathwaysubinemia
P06568939A0000 |26 35|responseswith alka
P06568939A0000 |70 90|eye movement studiese P00008171T0000 Pha
P06568939A0000 |155 164|brainstem When CSF
P06568939A0000 |118 127|integrityal hyperb
P06571587T0000 |0 7|EffectsP000016
P06571587T0000 |53 76|body tissue oxygenationand 5-nucleotidase P000
P06571587T0000 |11 19|ketamine076 Comp
P06571587T0000 |80 84|dogs1T00
P06571587T0000 |39 48|functions phosphat
P06571587T0000 |114 124|conditionsonatal hyp
P06579147A0060 |35 43|problemsline pho
P06579147A0060 |73 83|approaches00008171T0
P06579147A0060 |47 57|managementtases and 
P06579147A0060 |91 105|reconstructionmacologic aspe
P06579147A0060 |141 148|diseaseP000089
P06579147A0060 |21 29|featuresison wit
P06579147A0060 |116 127|deformitiesatal hyperb
P06579152A1061 |103 106|waypec
P06579152A1061 |76 99|velopharyngeal activity08171T0000 Pharmacologi
P06579152A1061 |62 72|activationleotidase 
P06579152A1061 |53 57|tooland 
P06579152A1061 |36 39|NPFine
P06579152A1061 |117 134|feed-back controltal hyperbilirubi
P06582285A0222 |119 124|weeksl hyp
P06582285A0222 |126 135|gestationbilirubin
P06582285A0222 |46 49|D&Eata
P06582285A0222 |28 34|safetyth alk
P06582285A0222 |38 41|U-Pe p
P06582285A0222 |83 96|D&E abortions000 Pharmacol
P06582285A0222 |69 72|U-Pse 
P06584416A0157 |50 54|dataes a
P06584416A0157 |125 128|PGFrbi
P06584416A0157 |40 48|patientsphosphat
P06584416A0157 |27 36|knowledgeith alkal
P06584416A0157 |104 116|examinationsects of neon
P06584416A0157 |6 18|radiologists606T0076 Com
P06584416A0157 |59 68|treatmentnucleotid
P06584416A0157 |81 91|angiogramsT0000 Phar
P06585277A0000 |187 196|existencefunction 
P06585277A0000 |107 112|serums of 
P06585277A0000 |121 129|presencehyperbil
P06585277A0000 |5 8|man160
P06585277A0000 |43 54|associationsphatases a
P06585277A0000 |78 103|acid phosphatase activity171T0000 Pharmacologic as
P06585277A0000 |29 37|leukemiah alkali
P06585277A0000 |141 153|bone lesionsP00008997A04
P06585277A0000 |157 172|roentgenographyhen CSF [HCO3-]
P06585277A0000 |223 232|carcinomaepleted r
P06588306A0076 |49 56|therapyses and
P06588306A0076 |21 43|prophylactic treatmentison with alkaline pho
P06588306A0076 |81 84|AILT00
P06588306A0076 |64 76|meningopathyotidase P000
P06588306A0076 |86 101|AIEOP protocols Pharmacologic 
P06588501T0059 |26 31|studywith 
P06591992A0569 |50 58|solutiones and 5
P06591992A0569 |3 15|anisotropism001606T0076 
P06593862T0001 |0 19|Hepatitis B vaccineP00001606T0076 Comp
P06594105A0560 |98 102|pulpic a
P06594105A0560 |222 231|lambda tpdepleted 
P06594105A0560 |249 260|temperature displaced 
P06594105A0560 |25 34|lambda tb with alk
P06594105A0560 |178 185|gingivaown as 
P06594105A0560 |62 78|cent haematocritleotidase P00008
P06594105A0560 |286 296|degrees C.but still 
P06594105A0560 |15 21|valuesCompar
P06594105A0560 |118 124|tongueal hyp
P06594105A0560 |154 159|gland2 Whe
P06594105A0560 |198 207|lambda cp CSF PCO2
P06594105A0560 |193 196|dogon 
P06594105A0560 |41 50|degrees Chosphatas
P06597709A0596 |207 212|cases the 
P06597709A0596 |71 83|lung volumes P00008171T0
P06597709A0596 |42 52|asbestosisosphatases
P06597709A0596 |92 97|ratioacolo
P06597709A0596 |151 158|results0472 Wh
P06597709A0596 |168 180|measurementsO3-] is show
P06597709A0596 |101 116|transfer factoraspects of neon
P06597709A0596 |139 145|volume. P000
P06599282T0001 |33 47|cell carcinomakaline phospha
P06599282T0001 |13 20|pattern6 Compa
P06599282T0001 |66 73|gingivaidase P
P06600533T0000 |68 80|lobe bronchiase P0000817
P06600533T0000 |35 39|wallline
P06600533T0000 |91 101|CT variantmacologic 
P06600533T0000 |0 11|Azygos veinP00001606T0
P06602580A0664 |169 176|normals3-] is 
P06602580A0664 |123 153|alpha 1-antitrypsin deficiencyperbilirubinemia. P00008997A04
P06602580A0664 |106 117|individualsts of neona
P06602580A0664 |13 20|history6 Compa
P06602580A0664 |37 50|complicationsne phosphatas
P06602580A0664 |56 68|otitis media 5-nucleotid
P06602580A0664 |87 96|frequencyPharmacol
P06602600A0582 |4 13|Sarns 51F01606T007
P06602600A0582 |25 32|cannula with a
P06602600A0582 |57 63|system5-nucl
P06602600A0582 |99 107|cannulasc aspect
P06606043A0598 |84 96|phenyl group00 Pharmacol
P06606043A0598 |37 48|6-positionsne phosphat
P06606043A0598 |128 136|decreaselirubine
P06606043A0598 |10 17|changes0076 Co
P06606043A0598 |140 148|activity P000089
P06606043A0598 |65 76|replacementtidase P000
P06606043A0598 |100 108|position aspects
P06607427A0000 |70 77|lesionse P0000
P06607427A0000 |243 252|behaviourlonger di
P06607427A0000 |132 143|projectionsbinemia. P0
P06607427A0000 |6 17|experiments606T0076 Co
P06607427A0000 |179 185|cortexwn as 
P06607427A0000 |162 174|hypothalamusSF [HCO3-] i
P06607427A0000 |111 117|dorsal neona
P06607427A0000 |33 40|effectskaline 
P06607427A0000 |260 263|ratwhe
P06607427A0000 |206 225|body weight changes2 the data of K-dep
P06607714T0000 |0 15|Limb allograftsP00001606T0076 
P06607714T0000 |46 60|cyclosporin A.atases and 5-n
P06607714T0000 |19 23|ratsaris
P06609166A0209 |103 114|microliterspects of ne
P06609166A0209 |63 75|acetonitrileeotidase P00
P06609166A0209 |88 97|injectionharmacolo
P06609166A0209 |151 176|C18 reversed-phase column0472 When CSF [HCO3-] is 
P06609166A0209 |4 10|method01606T
P06609166A0209 |52 59|volumes and 5-
P06609166A0209 |35 42|samplesline ph
P06610347A0581 |101 108|AV nodeaspects
P06610347A0581 |11 18|periods076 Com
P06610347A0581 |78 88|conduction171T0000 P
P06610347A0581 |26 37|AV junctionwith alkali
P06610347A0581 |67 74|fashiondase P0
P06612373A0000 |103 106|usepec
P06612373A0000 |123 128|drugsperbi
P06612373A0000 |60 67|sourcesucleoti
P06612373A0000 |157 162|1970shen C
P06612373A0000 |5 10|paper1606T
P06612373A0000 |76 82|extent08171T
P06612373A0000 |27 31|dataith 
P06612373A0000 |86 98|prescription Pharmacolog
P06612373A0000 |141 146|1960sP0000
P06612373A0000 |49 56|varietyses and
P06615053A0202 |49 62|resuscitationses and 5-nuc
P06615053A0202 |40 45|hoursphosp
P06615053A0202 |106 114|ejectionts of ne
P06615053A0202 |164 170|RVEDVI [HCO3
P06615053A0202 |156 162|volumeWhen C
P06615053A0202 |8 16|patients6T0076 C
P06615053A0202 |116 120|RVEFatal
P06615403A0718 |50 56|serieses and
P06615403A0718 |60 61|nu
P06615403A0718 |114 121|minutesonatal 
P06615403A0718 |179 186|minuteswn as a
P06615403A0718 |128 136|ligationlirubine
P06615403A0718 |41 48|minuteshosphat
P06615403A0718 |70 81|microns TMse P00008171
P06615403A0718 |141 152|microns TMsP00008997A0
P06615403A0718 |16 29|LAD occlusionomparison wit
P06625058A0666 |71 75|cost P00
P06625058A0666 |80 86|capita1T0000
P06625058A0666 |4 14|population01606T0076
P06627123A0000 |85 93|calories0 Pharma
P06627123A0000 |7 18|Wistar rats06T0076 Com
P06627123A0000 |43 51|Sustacalsphatase
P06627123A0000 |109 116|sucroseof neon
P06627123A0000 |80 81|%1
P06627123A0000 |37 41|dietne p
P06627123A0000 |69 76|ethanolse P000
P06627569T0001 |0 2|HLP0
P06627569T0001 |6 32|type oculomotor stimulator606T0076 Comparison with a
P06629370A0252 |35 64|basement membrane nephropathyline phosphatases and 5-nucle
P06629370A0252 |15 20|groupCompa
P06629370A0252 |124 141|basement membraneerbilirubinemia. 
P06629370A0252 |183 191|syndromes a func
P06629370A0252 |28 32|typeth a
P06629370A0252 |105 116|lamellationcts of neon
P06629370A0252 |5 13|patients1606T007
P06629370A0252 |147 154|pattern997A047
P06629370A0252 |174 180|Alports show
P06630319A0244 |0 8|Brain pHP0000160
P06630319A0244 |125 136|barbituraterbilirubine
P06630319A0244 |41 49|ischemiahosphata
P06630319A0244 |72 77|valueP0000
P06630319A0244 |141 161|halothane anesthesiaP00008997A0472 When 
P06630319A0244 |21 22|hi
P06630319A0244 |103 110|animalspects o
P06634712A0557 |4 11|results01606T0
P06634712A0557 |42 51|phosphateosphatase
P06634712A0557 |56 63|calcium 5-nucl
P06634712A0557 |28 38|importanceth alkalin
P06634712A0557 |104 106|CTec
P06634712A0557 |83 92|secretion000 Pharm
P06634712A0557 |110 116|uremiaf neon
P06634712A0557 |96 99|PTHogi
P06643612A0000 |69 76|studiesse P000
P06643612A0000 |105 110|urinects o
P06643612A0000 |27 34|methodsith alk
P06643612A0000 |94 100|plasmaologic
P06643612A0000 |80 90|imipramine1T0000 Pha
P06648156T0034 |13 20|remarks6 Compa
P06652293A0353 |84 85|%0
P06652293A0353 |121 122|%h
P06652293A0353 |104 115|specificityects of neo
P06652293A0353 |67 78|sensitivitydase P00008
P06652293A0353 |43 52|responsessphatases
P06652293A0353 |23 28|pointon wi
P06653755A0192 |34 56|autoregulation bordersaline phosphatases and
P06653755A0192 |6 29|clofelin administration606T0076 Comparison wit
P06653755A0192 |78 83|i. e.171T0
P06653755A0192 |99 108|AP levelsc aspects
P06654047A0694 |69 79|cell deathse P000081
P06654047A0694 |161 165|caseCSF 
P06654047A0694 |106 115|apoptosists of neo
P06654047A0694 |37 44|variantne phos
P06654047A0694 |179 195|rhabdomyosarcomawn as a function
P06654047A0694 |5 15|phenomenon1606T0076 
P06654686T0001 |85 89|girl0 Ph
P06654686T0001 |0 11|CombinationP00001606T0
P06654686T0001 |50 79|granulocyte function disorderes and 5-nucleotidase P000081
P06654686T0001 |17 35|Shwachman syndromemparison with alka
P06655634A0195 |100 104|rate asp
P06655634A0195 |131 132|%u
P06655634A0195 |11 17|series076 Co
P06655634A0195 |44 47|TOLpha
P06655634A0195 |75 94|cesarean deliveries008171T0000 Pharmac
P06655634A0195 |21 29|patientsison wit
P06655634A0195 |161 170|morbidityCSF [HCO3
P06655634A0195 |116 124|deliveryatal hyp
P06656249T0000 |0 23|Nursing home dischargesP00001606T0076 Comparis
P06656249T0000 |36 44|practiceine phos
P06657559A0489 |0 5|TrialP0000
P06657559A0489 |78 83|weeks171T0
P06657559A0489 |228 238|heart rateed rats ar
P06657559A0489 |44 56|control feedphatases and
P06657559A0489 |186 190|feed fun
P06657559A0489 |87 90|agePha
P06657559A0489 |298 300|hrve
P06657559A0489 |243 257|blood pressurelonger displac
P06657559A0489 |141 143|hrP0
P06657559A0489 |278 287|half hourontrols b
P06657559A0489 |8 24|broiler chickens6T0076 Compariso
P06657559A0489 |128 132|feedliru
P06657559A0489 |100 104|time asp
P06657559A0489 |206 222|ppm ochratoxin A2 the data of K-
P06657559A0489 |170 182|control feed-] is shown 
P06658029A0086 |71 78|battery P00008
P06658029A0086 |110 127|hazard evaluationf neonatal hyperb
P06658029A0086 |54 63|componentnd 5-nucl
P06658029A0086 |96 101|testsogic 
P06658029A0086 |4 23|carcinogen bioassay01606T0076 Comparis
P06658445A0140 |19 26|animalsarison 
P06658445A0140 |90 96|intakermacol
P06658445A0140 |79 86|amounts71T0000
P06658445A0140 |31 34|manalk
P06658445A0140 |8 15|effects6T0076 
P06658586T0001 |0 23|AngionephroscintigraphyP00001606T0076 Comparis
P06658586T0001 |31 40|diagnosisalkaline 
P06658586T0001 |60 66|kidneyucleot
P06658586T0001 |44 52|diseasesphatases
P06659982A0231 |4 12|analysis01606T00
P06659982A0231 |363 367|life3 Fl
P06659982A0231 |303 309|monthssignif
P06659982A0231 |184 193|increases a functi
P06659982A0231 |116 121|stageatal 
P06659982A0231 |253 259|changeplaced
P06659982A0231 |20 29|structurerison wit
P06659982A0231 |217 222|phaseof K-
P06659982A0231 |333 337|ones.21 
P06659982A0231 |123 125|DSpe
P06659982A0231 |172 182|parameters is shown 
P06659982A0231 |351 355|year0001
P06659982A0231 |226 231|sleepeted 
P06659982A0231 |134 136|QSne
P06659982A0231 |37 49|sleep periodne phosphata
P06659982A0231 |97 100|agegic
P06659982A0231 |233 235|PSts
P06662623A0124 |50 57|Br-MISOes and 
P06662623A0124 |39 46|samples phosph
P06662623A0124 |6 10|MISO606T
P06662623A0124 |124 134|n cm-2 s-1erbilirubi
P06662623A0124 |63 79|SLOWPOKE reactoreotidase P000081
P06662623A0124 |101 113|neutron fluxaspects of n
P06662623A0124 |86 87|h 
P06662623A0124 |1 5|82Br0000
P06667015A0832 |155 172|serum CK-MB level When CSF [HCO3-]
P06667015A0832 |79 88|ischaemia71T0000 P
P06667015A0832 |123 131|recoveryperbilir
P06667015A0832 |12 20|findings76 Compa
P06667015A0832 |96 103|surgeryogic as
P06667015A0832 |37 48|sensitivityne phosphat
P06667015A0832 |71 75|wall P00
P06667868T0001 |137 149|BR-1 benzeneia. P0000899
P06667868T0001 |125 133|exposurerbilirub
P06667868T0001 |63 67|ratseoti
P06667868T0001 |91 99|variantsmacologi
P06667868T0001 |38 46|elementse phosph
P06667868T0001 |54 59|bloodnd 5-
P06667868T0001 |17 23|statusmparis
P06668316A0178 |239 249|phenacetin no longer
P06668316A0178 |88 93|phaseharma
P06668316A0178 |134 145|metabolitesnemia. P000
P06668316A0178 |273 276|min to
P06668316A0178 |21 42|reversed-phase columnison with alkaline ph
P06668316A0178 |229 237|standardd rats a
P06668316A0178 |95 114|baseline separationlogic aspects of ne
P06668316A0178 |118 128|antipyrineal hyperbi
P06668316A0178 |50 66|phosphate bufferes and 5-nucleot
P06668316A0178 |68 80|acetonitrilease P0000817
P06669864T0001 |4 9|liver01606
P06670732A0000 |136 144|Fentanylmia. P00
P06670732A0000 |29 37|patientsh alkali
P06670732A0000 |121 132|combinationhyperbiliru
P06670732A0000 |150 152|mgA0
P06670732A0000 |256 266|parametersced when c
P06670732A0000 |87 94|effectsPharmac
P06670732A0000 |217 227|mg/kg b.w.of K-deple
P06670732A0000 |158 168|Droperidolen CSF [HC
P06670732A0000 |112 114|mgne
P06670732A0000 |57 66|induction5-nucleot
P06670732A0000 |177 184|Innovarhown as
P06670732A0000 |202 210|Atropine PCO2 th
P06670732A0000 |172 174|mg i
P06670732A0000 |186 196|Thalamonal function 
P06670732A0000 |16 21|studyompar
P06670732A0000 |98 106|Fentanylic aspec
P06670732A0000 |39 42|ASA ph
P06670732A0000 |70 81|anaesthesiae P00008171
P06671047A1124 |275 280|tonuso con
P06671047A1124 |264 266|DA c
P06671047A1124 |390 396|stateso be a
P06671047A1124 |61 65|testcleo
P06671047A1124 |46 49|NOMata
P06671047A1124 |73 82|diagnosis00008171T
P06671047A1124 |192 201|existenceion of CS
P06671047A1124 |220 233|ProlactinomasK-depleted ra
P06671047A1124 |156 161|CD/LDWhen 
P06671047A1124 |114 120|statesonatal
P06671047A1124 |296 307|possibilityhave a sign
P06671047A1124 |340 347|factors 0.23 v
P06671047A1124 |6 13|results606T007
P06671047A1124 |143 152|responses0008997A0
P06671047A1124 |163 165|LDF 
P06671047A1124 |170 173|DOM-] 
P06671047A1124 |207 216|sub-group the data
P06671047A1124 |34 42|validityaline ph
P06671065A0000 |17 29|lipoproteinsmparison wit
P06671065A0000 |63 71|childreneotidase
P06671065A0000 |122 128|statusyperbi
P06671065A0000 |136 144|patientsmia. P00
P06671065A0000 |36 43|insulinine pho
P06671065A0000 |0 12|Serum lipidsP00001606T00
P06671385A0856 |137 156|body sodium contentia. P00008997A0472 
P06671385A0856 |45 66|plasma renin activityhatases and 5-nucleot
P06671385A0856 |76 78|PA08
P06671385A0856 |11 12|A0
P06671385A0856 |4 6|NA01
P06671925T0000 |0 23|Amikacin concentrationsP00001606T0076 Comparis
P06671925T0000 |27 32|serumith a
P06671925T0000 |62 72|volunteersleotidase 
P06671925T0000 |80 88|patients1T0000 P
P06671925T0000 |37 50|blister fluidne phosphatas
P06671925T0000 |100 110|impairment aspects o
P06672094A0390 |201 208|mammalsF PCO2 
P06672094A0390 |77 81|face8171
P06672094A0390 |161 171|fasciculusCSF [HCO3-
P06672094A0390 |89 107|oculomotor nucleusarmacologic aspect
P06672094A0390 |36 42|rectusine ph
P06672094A0390 |126 133|neuronsbilirub
P06672094A0390 |4 12|subgroup01606T00
P06674374T0000 |0 32|Hepatitis B vaccination strategyP00001606T0076 Comparison with a
P06674374T0000 |37 56|health-care workersne phosphatases and
P06674374T0000 |62 69|countryleotida
P06674374T0000 |86 108|hepatitis B endemicity Pharmacologic aspects
P06674516A0350 |139 144|field. P00
P06674516A0350 |15 28|drip infusionComparison wi
P06674516A0350 |48 54|dosageases a
P06674516A0350 |106 114|diseasests of ne
P06674516A0350 |32 35|AMKlka
P06674977A1181 |67 68|%d
P06674977A1181 |26 27|%w
P06674977A1181 |13 21|families6 Compar
P06674977A1181 |104 112|table VIects of 
P06674977A1181 |93 102|diagnosiscologic a
P06674977A1181 |41 50|pregnancyhosphatas
P06674977A1181 |52 57|table and 
P06675047A0000 |84 93|Berthelot00 Pharma
P06675047A0000 |106 115|Berthelotts of neo
P06675047A0000 |28 40|interferenceth alkaline 
P06675047A0000 |74 81|methods0008171
P06675047A0000 |134 147|determinationnemia. P00008
P06675047A0000 |4 11|authors01606T0
P06675047A0000 |161 165|ureaCSF 
P06675047A0000 |48 58|hemoglobinases and 5
P06683807A0160 |48 58|prevalenceases and 5
P06683807A0160 |13 21|patients6 Compar
P06683807A0160 |62 73|alcohol useleotidase P
P06683876A0244 |103 117|daughter cellspects of neona
P06683876A0244 |79 87|clusters71T0000 
P06683876A0244 |62 69|fissionleotida
P06683876A0244 |6 11|cells606T0
P06683876A0244 |24 31|micronsn with 
P06683876A0244 |35 43|diameterline pho
P06684624A0298 |71 75|rats P00
P06684624A0298 |95 103|diet 41Blogic as
P06684624A0298 |20 31|mortalitiesrison with 
P06684624A0736 |96 102|groupsogic a
P06684624A0736 |45 58|mg creatininehatases and 5
P06684624A0736 |8 40|N-acetylglucosaminidase activity6T0076 Comparison with alkaline 
P06685004A0000 |155 160|women When
P06685004A0000 |45 62|globulin capacityhatases and 5-nuc
P06685004A0000 |112 119|fitnessneonata
P06685004A0000 |144 147|men008
P06685004A0000 |93 96|BMIcol
P06685004A0000 |76 91|body mass index08171T0000 Phar
P06685004A0000 |64 68|SHBGotid
P06685004A0000 |4 16|associations01606T0076 C
P06685004A0000 |71 74|age P0
P06685177T0000 |0 12|DipetalonemaP00001606T00
P06685177T0000 |26 45|hydrochoerus subgenwith alkaline phosp
P06685177T0000 |14 24|Alafilaria Compariso
P06685177T0000 |54 56|n.nd
P06685536A0502 |51 55|ewess an
P06685536A0502 |10 15|years0076 
P06685536A0502 |90 101|enucleationrmacologic 
P06685536A0502 |38 45|controle phosp
P06685643A0179 |119 125|stagesl hype
P06685643A0179 |22 24|C4so
P06685643A0179 |29 35|C1-INHh alka
P06685643A0179 |61 66|stagecleot
P06685643A0179 |70 77|diseasee P0000
P06685643A0179 |4 18|concentrations01606T0076 Com
P06685643A0179 |100 111|mean values aspects of
P06686454A0585 |19 27|activityarison w
P06686454A0585 |63 70|bacillieotidas
P06686454A0585 |91 114|Klebsiella-Enterobactermacologic aspects of ne
P06686454A0585 |116 124|Shigellaatal hyp
P06686454A0585 |144 163|Serratia marcescens008997A0472 When CS
P06686454A0585 |168 175|ProteusO3-] is
P06687953T0000 |49 66|leukocyte enzymesses and 5-nucleot
P06687953T0000 |12 28|defence capacity76 Comparison wi
P06689413A0174 |152 155|KeV472
P06689413A0174 |56 59|mCi 5-
P06689413A0174 |29 35|Am-241h alka
P06689413A0174 |45 51|sourcehatase
P06689413A0174 |93 95|mmco
P06689413A0174 |111 118|K alpha neonat
P06689413A0174 |131 137|x-raysubinem
P06689413A0174 |177 183|iodinehown a
P06689413A0174 |70 81|Ge detectore P00008171
P06689413A0174 |4 13|apparatus01606T007
P06689413A0174 |85 90|mm2 X0 Pha
P06689513T0001 |16 23|studiesomparis
P06689513T0001 |27 38|retinopathyith alkalin
P06689513T0001 |52 59|infants and 5-
P06691304A0284 |153 163|age groups72 When CS
P06691304A0284 |121 126|maleshyper
P06691304A0284 |76 86|deviations08171T0000
P06691304A0284 |131 138|femalesubinemi
P06691304A0284 |40 46|valuesphosph
P06691304A0284 |13 33|serum concentrations6 Comparison with al
P06691304A0284 |4 9|range01606
P06691304A0284 |96 103|analyteogic as
P06691304A0284 |55 61|valuesd 5-nu
P06692517T0000 |70 77|thrombie P0000
P06692517T0000 |95 122|indium-111 platelet imaginglogic aspects of neonatal h
P06692517T0000 |79 89|assessment71T0000 Ph
P06692517T0000 |30 35|drugs alka
P06692517T0000 |39 47|patients phospha
P06692517T0000 |143 159|echocardiography0008997A0472 Whe
P06692517T0000 |4 11|effects01606T0
P06692631A0129 |49 73|microstress distributionses and 5-nucleotidase P
P06692631A0129 |9 18|interfaceT0076 Com
P06692631A0129 |38 44|stresse phos
P06692631A0129 |111 115|bone neo
P06692631A0129 |81 85|boneT000
P06694380A1483 |137 142|WORDSia. P
P06694380A1483 |39 44|group phos
P06694380A1483 |111 119|ABSTRACT neonata
P06694380A1483 |90 91|Pr
P06694380A1483 |50 58|mg/literes and 5
P06694380A1483 |70 72|SDe 
P06694380A1483 |0 9|Plasma NEP00001606
P06694778A0000 |118 124|courseal hyp
P06694778A0000 |13 34|hemodialysis patients6 Comparison with alk
P06694778A0000 |128 140|hemodialysislirubinemia.
P06694778A0000 |92 99|imagingacologi
P06694778A0000 |53 80|redistribution thallium-201and 5-nucleotidase P0000817
P06698047A0445 |119 124|casesl hyp
P06698047A0445 |75 78|TRH008
P06698047A0445 |4 20|Prolactin levels01606T0076 Compa
P06698047A0445 |62 71|responsesleotidase
P06698047A0445 |51 56|normss and
P06700231A0259 |115 121|monthsnatal 
P06700231A0259 |14 29|tumor resection Comparison wit
P06700231A0259 |130 134|yearrubi
P06700231A0259 |56 69|tumor nodules 5-nucleotida
P06700231A0259 |81 86|sizesT0000
P06700469T0000 |8 30|hospital accreditation6T0076 Comparison with
P06702257T0001 |0 16|Antithrombin IIIP00001606T0076 C
P06702257T0001 |20 31|hip surgeryrison with 
P06702643A0000 |184 186|SA a
P06702643A0000 |44 61|arch interruptionphatases and 5-nu
P06702643A0000 |134 141|Celorianemia. 
P06702643A0000 |146 152|Patton8997A0
P06702643A0000 |124 130|type Berbili
P06702643A0000 |29 30|%h
P06702643A0000 |12 25|infant hearts76 Comparison
P06702643A0000 |114 122|arteriesonatal h
P06702643A0000 |176 182|arteryshown 
P06702643A0000 |86 93|carotid Pharma
P06704467A0539 |16 27|sensitivityomparison w
P06704467A0539 |31 42|photoperiodalkaline ph
P06704467A0539 |79 86|mammals71T0000
P06704467A0539 |107 119|pineal glands of neonata
P06704467A0539 |53 57|batsand 
P06705456A0346 |34 38|timealin
P06705456A0346 |53 56|minand
P06705456A0346 |42 46|peakosph
P06705456A0346 |0 10|AbsorptionP00001606T
P06707357A0180 |186 191|types func
P06707357A0180 |135 146|differencesemia. P0000
P06707357A0180 |104 121|valve replacementects of neonatal 
P06707357A0180 |14 26|observations Comparison 
P06707357A0180 |67 80|regurgitationdase P0000817
P06707357A0180 |195 210|volume overload of CSF PCO2 th
P06707357A0180 |32 40|patientslkaline 
P06709310A0000 |2 6|case0001
P06709310A0000 |26 35|nystagmuswith alka
P06709310A0000 |44 49|onsetphata
P06709310A0000 |67 71|girldase
P06709700A0230 |51 61|depressions and 5-nu
P06709700A0230 |26 35|dimensionwith alka
P06709700A0230 |11 22|compartment076 Compari
P06709700A0230 |80 105|Hamilton Depression Scale1T0000 Pharmacologic aspe
P06709700A0230 |39 47|severity phospha
P06709700A0230 |232 241|treatmentats are n
P06709700A0230 |198 213|outcome measure CSF PCO2 the d
P06709700A0230 |64 72|subscaleotidase 
P06709700A0230 |114 131|Melancholia Scaleonatal hyperbilir
P06709700A0230 |175 185|perfection shown as 
P06711642A0093 |254 262|oligurialaced wh
P06711642A0093 |12 30|immunoglobulinuria76 Comparison with
P06711642A0093 |217 219|gmof
P06711642A0093 |54 65|developmentnd 5-nucleo
P06711642A0093 |232 248|urine collectionats are no longe
P06711642A0093 |178 186|dipstickown as a
P06711642A0093 |103 123|creatinine clearancepects of neonatal hy
P06711642A0093 |69 77|azotemiase P0000
P06711642A0093 |137 148|proteinuriaia. P000089
P06712314A0148 |23 28|caseson wi
P06712314A0148 |61 73|institutionscleotidase P
P06712314A0148 |8 14|number6T0076
P06713200A0630 |0 21|Epileptiform activityP00001606T0076 Compar
P06713200A0630 |108 119|projections of neonata
P06713200A0630 |90 95|layerrmaco
P06713200A0630 |66 71|layeridase
P06713200A0630 |163 172|phenytoinF [HCO3-]
P06713200A0630 |48 55|laminaeases an
P06713204A0867 |64 69|stateotida
P06713204A0867 |77 80|rat817
P06713204A0867 |94 106|V1 componentologic aspec
P06713204A0867 |4 17|AD components01606T0076 Co
P06714298X0000 |279 280|%n
P06714298X0000 |52 59|preload and 5-
P06714298X0000 |265 275|resistancecompared t
P06714298X0000 |182 192|nifedipineas a funct
P06714298X0000 |331 337|output(1.21 
P06714298X0000 |240 241|%n
P06714298X0000 |134 157|calcium channel blockernemia. P00008997A0472 W
P06714298X0000 |87 98|nisoldipinePharmacolog
P06714298X0000 |291 301|maxLVdP/dttill have 
P06714298X0000 |81 85|pigsT000
P06714298X0000 |317 318|%g
P06714298X0000 |104 129|micrograms X kg-1 X min-1ects of neonatal hyperbil
P06714298X0000 |228 236|pressureed rats 
P06714354A0194 |0 7|MonkeysP000016
P06714354A0194 |72 79|removalP000081
P06714354A0194 |101 107|cortexaspect
P06715792A0295 |0 17|HBB concentrationP00001606T0076 Co
P06715792A0295 |58 70|accumulation-nucleotidas
P06715792A0295 |25 32|fetuses with a
P06716977A0136 |68 74|lossesase P0
P06716977A0136 |24 31|declinen with 
P06716977A0136 |4 11|samples01606T0
P06716977A0136 |112 121|mg% rangeneonatal 
P06716977A0136 |35 56|ethanol concentrationline phosphatases and
P06718064T0001 |0 18|Plasma lactoferrinP00001606T0076 Com
P06718064T0001 |27 38|blood countith alkalin
P06718064T0001 |54 65|neutrophilsnd 5-nucleo
P06719057A0181 |85 94|hematuria0 Pharmac
P06719057A0181 |59 69|evaluationnucleotida
P06719057A0181 |131 138|urogramubinemi
P06719057A0181 |4 14|importance01606T0076
P06719057A0181 |99 113|filing defectsc aspects of n
P06719057A0181 |34 51|vein phlebographyaline phosphatase
P06720371T0000 |0 11|Pilot studyP00001606T0
P06720371T0000 |15 32|blood coagulationComparison with a
P06720371T0000 |36 49|gout patientsine phosphata
P06721188A0200 |16 24|analysisompariso
P06721188A0200 |59 67|Snedecornucleoti
P06721188A0200 |40 46|F testphosph
P06721188A0200 |71 84|contrast test P00008171T00
P06723849A0197 |101 112|transectionaspects of 
P06723849A0197 |59 62|MRFnuc
P06723849A0197 |14 19|tract Comp
P06723849A0197 |48 57|Formationases and 
P06726257A1179 |70 73|LSDe P
P06726257A1179 |159 165|cortexn CSF 
P06726257A1179 |246 258|methiothepinger displace
P06726257A1179 |179 187|striatumwn as a 
P06726257A1179 |26 45|5-hydroxytryptophanwith alkaline phosp
P06726257A1179 |210 242|autoreceptor antagonist activitye data of K-depleted rats are no
P06726257A1179 |269 277|ABSTRACTared to 
P06726257A1179 |90 101|differencesrmacologic 
P06726257A1179 |105 115|inhibitioncts of neo
P06726257A1179 |119 131|methiothepinl hyperbilir
P06726257A1179 |54 66|accumulationnd 5-nucleot
P06726257A1179 |295 300|WORDS have
P06726257A1179 |13 22|reduction6 Compari
P06726257A1179 |47 52|5-HTPtases
P06726257A1179 |133 145|hypothalamusinemia. P000
P06726257T0000 |0 7|EffectsP000016
P06726257T0000 |58 75|serotonin release-nucleotidase P00
P06726257T0000 |11 23|methiothepin076 Comparis
P06726257T0000 |89 108|serotonin synthesisarmacologic aspects
P06726257T0000 |37 54|acid diethylamidene phosphatases a
P06726257T0000 |127 135|relationilirubin
P06726257T0000 |139 170|serotonin autoreceptor function. P00008997A0472 When CSF [HCO3
P06728580A0291 |32 39|El Pasolkaline
P06728580A0291 |107 113|results of n
P06728580A0291 |88 96|criteriaharmacol
P06728580A0291 |121 129|studentshyperbil
P06728580A0291 |42 44|TXos
P06728580A0291 |12 19|measles76 Comp
P06728580A0291 |54 61|recordsnd 5-nu
P06731302A0930 |16 31|bradyarrhythmiaomparison with 
P06731302A0930 |75 80|block00817
P06731302A0930 |41 44|SCDhos
P06731302A0930 |91 103|branch blockmacologic as
P06731302A0930 |3 10|patient001606T
P06732946A0281 |171 180|Videoplan] is show
P06732946A0281 |182 187|scaleas a 
P06732946A0281 |91 96|timesmacol
P06732946A0281 |23 28|areason wi
P06732946A0281 |128 141|magnificationlirubinemia. 
P06732946A0281 |43 49|tissuesphata
P06732946A0281 |146 147|X8
P06732946A0281 |4 15|measurement01606T0076 
P06732946A0281 |54 66|fibrinolysisnd 5-nucleot
P06732946A0281 |155 169|image analyser When CSF [HCO
P06734713T0000 |0 10|DiclofenacP00001606T
P06734713T0000 |32 41|poisoninglkaline p
P06735247A0803 |139 140|r.
P06735247A0803 |149 150|p7
P06735247A0803 |13 48|plasma enteroglucagon concentration6 Comparison with alkaline phosphat
P06735247A0803 |58 65|minutes-nucleo
P06735247A0803 |79 87|patients71T0000 
P06735247A0803 |128 137|excretionlirubinem
P06738410T0000 |0 14|Blood pressureP00001606T0076
P06738410T0000 |18 26|childrenparison 
P06740373A0891 |33 40|captivekaline 
P06740373A0891 |46 56|cynomolgusatases and
P06740373A0891 |8 13|study6T007
P06740373A0891 |123 141|drug testing modelperbilirubinemia. 
P06740373A0891 |97 103|rhesusgic as
P06740697A0318 |55 73|guinea pig strainsd 5-nucleotidase P
P06740697A0318 |28 39|sensitivityth alkaline
P06740697A0318 |4 11|results01606T0
P06740919A0162 |69 79|heartwaterse P000081
P06740919A0162 |95 98|Boslog
P06740919A0162 |107 111|calfs of
P06740919A0162 |52 56|goat and
P06740919A0162 |37 43|nymphsne pho
P06740919A0162 |6 23|Amblyomma lepidum606T0076 Comparis
P06743061A0239 |100 108|tinnitus aspects
P06743061A0239 |11 18|percent076 Com
P06743061A0239 |28 36|patientsth alkal
P06743061A0239 |52 59|disease and 5-
P06744024A0000 |0 8|MorphineP0000160
P06744024A0000 |93 106|formalin testcologic aspec
P06744024A0000 |76 85|analgesia08171T000
P06744024A0000 |52 55|rat an
P06744024A0000 |144 148|pain0089
P06744024A0000 |35 44|ventricleline phos
P06748227A0423 |69 74|rightse P0
P06748227A0423 |12 16|Case76 C
P06748227A0423 |132 138|thoraxbinemi
P06748227A0423 |4 8|maps0160
P06748227A0423 |110 114|sidef ne
P06748227A0423 |33 40|maximumkaline 
P06749072A0116 |70 75|uratee P00
P06749072A0116 |149 153|hour7A04
P06749072A0116 |31 40|clearancealkaline 
P06749072A0116 |164 179|water immersion [HCO3-] is sho
P06749072A0116 |111 126|water immersion neonatal hyper
P06749072A0116 |57 66|excretion5-nucleot
P06749072A0116 |8 23|urate excretion6T0076 Comparis
P06750608A1442 |0 9|MutationsP00001606
P06750608A1442 |56 59|mak 5-
P06750608A1442 |61 70|phenotypecleotidas
P06750608A1442 |25 34|lts genes with alk
P06751455A0117 |65 74|remaindertidase P0
P06751455A0117 |30 40|gallstones alkaline 
P06751455A0117 |97 105|glucagongic aspe
P06751455A0117 |79 87|patients71T0000 
P06751455A0117 |113 120|placeboeonatal
P06753902A0437 |153 158|death72 Wh
P06753902A0437 |7 15|patients06T0076 
P06753902A0437 |41 50|captoprilhosphatas
P06753902A0437 |121 130|class IIMhyperbili
P06753902A0437 |83 89|months000 Ph
P06753902A0437 |142 145|IIS000
P06753902A0437 |32 37|monthlkali
P06754662T0001 |39 51|eosinophilia phosphatase
P06754662T0001 |8 33|angiolymphoid hyperplasia6T0076 Comparison with al
P06755468A0180 |68 74|intronase P0
P06755468A0180 |110 129|amino acid homologyf neonatal hyperbil
P06755468A0180 |94 99|yeastologi
P06755468A0180 |31 45|reading framesalkaline phosp
P06755468A0180 |49 53|cobAses 
P06755468A0180 |82 90|cob gene0000 Pha
P06755468A0180 |0 7|RegionsP000016
P06755986A0382 |55 72|toxico-infectionsd 5-nucleotidase 
P06755986A0382 |120 127|strains hyperb
P06755986A0382 |15 22|strainsCompari
P06755986A0382 |37 43|humansne pho
P06755986A0382 |94 98|miceolog
P06755986A0382 |140 159|hospital infections P00008997A0472 Whe
P06760394T0001 |34 37|aidali
P06760394T0001 |45 48|ITIhat
P06760394T0001 |7 24|tooth replacement06T0076 Compariso
P06760394T0001 |88 94|type Fharmac
P06760394T0001 |50 86|International Team fur Implantologiees and 5-nucleotidase P00008171T0000
P06762025A0171 |50 60|PGF2 alphaes and 5-n
P06762025A0171 |109 115|effectof neo
P06762025A0171 |41 45|PGE2hosp
P06762025A0171 |4 37|13,14-dihydro-15-keto-metabolites01606T0076 Comparison with alkali
P06762321T0000 |0 19|Nucleotide sequenceP00001606T0076 Comp
P06762321T0000 |63 90|maltosaccharide utilizationeotidase P00008171T0000 Pha
P06762321T0000 |23 49|DNA controlling expressionon with alkaline phosphata
P06762321T0000 |94 107|Streptococcusologic aspect
P06762321T0000 |53 58|genesand 5
P06763897A0216 |87 93|analogPharma
P06763897A0216 |82 85|AII000
P06763897A0216 |95 99|Sar1logi
P06763897A0216 |107 110|ALLs o
P06763897A0216 |31 34|PRAalk
P06763897A0216 |4 16|hypertension01606T0076 C
P06763897A0216 |66 77|angiotensinidase P0000
P06763897A0216 |101 105|Ile8aspe
P06764669T0001 |38 42|irone ph
P06764669T0001 |89 96|reagentarmacol
P06764669T0001 |13 26|determination6 Comparison 
P06764669T0001 |58 72|deferoxamine B-nucleotidase 
P06767648A0734 |0 12|MeasurementsP00001606T00
P06767648A0734 |59 65|valuesnucleo
P06767648A0734 |79 86|therapy71T0000
P06767648A0734 |16 25|perfusionomparison
P06772370A0342 |0 6|VolumeP00001
P06772370A0342 |184 188|ages a f
P06772370A0342 |159 164|womenn CSF
P06772370A0342 |58 62|l/kg-nuc
P06772370A0342 |122 127|rangeyperb
P06772370A0342 |90 100|correctionrmacologic
P06772370A0342 |173 176|menis 
P06772370A0342 |10 22|distribution0076 Compari
P06772370A0342 |79 83|DMDZ71T0
P06772370A0342 |105 120|protein bindingcts of neonatal
P06772370A0342 |139 143|l/kg. P0
P06772370A0342 |38 43|rangee pho
P06772370A0342 |32 36|DMDZlkal
P06772612A0000 |51 62|haloperidols and 5-nuc
P06772612A0000 |11 19|dopamine076 Comp
P06772612A0000 |115 122|hypoxianatal h
P06772612A0000 |127 138|hypercapniailirubinemi
P06772612A0000 |42 49|blockerosphata
P06772612A0000 |176 180|catsshow
P06772612A0000 |84 111|carotid body chemoreceptors00 Pharmacologic aspects of
P06772612A0000 |71 80|responses P0000817
P06772612A0000 |0 7|EffectsP000016
P06775834A0000 |0 5|HLA-AP0000
P06775834A0000 |104 110|regardects o
P06775834A0000 |134 141|relapsenemia. 
P06775834A0000 |30 38|patients alkalin
P06775834A0000 |126 130|formbili
P06775834A0000 |10 22|B phenotypes0076 Compari
P06775834A0000 |64 73|melanomasotidase P
P06776918T0000 |0 17|Trypanosoma cruziP00001606T0076 Co
P06777229A0243 |86 93|disease Pharma
P06777229A0243 |41 49|subjectshosphata
P06777229A0243 |20 25|studyrison
P06777229A0243 |57 65|patients5-nucleo
P06777229A0243 |4 12|subjects01606T00
P06781339A0501 |85 94|treatment0 Pharmac
P06781339A0501 |77 81|mode8171
P06781339A0501 |121 136|hypoventilationhyperbilirubine
P06781339A0501 |5 10|study1606T
P06781339A0501 |52 61|follow-up and 5-nu
P06781339A0501 |98 106|patientsic aspec
P06781728A0690 |19 34|differentiationarison with alk
P06781728A0690 |90 104|mineralizationrmacologic asp
P06781728A0690 |178 199|fluorochrome labelingown as a function of 
P06781728A0690 |228 232|ratsed r
P06781728A0690 |147 161|bone formation997A0472 When 
P06781728A0690 |79 86|failure71T0000
P06781728A0690 |38 59|osteoprogenitor cellse phosphatases and 5-
P06781728A0690 |4 15|alterations01606T0076 
P06781728A0690 |138 143|ratesa. P0
P06782612A0142 |103 120|lithium clearancepects of neonatal
P06782612A0142 |122 125|CLiype
P06782612A0142 |13 20|measure6 Compa
P06782612A0142 |75 87|urine volume008171T0000 
P06782612A0142 |89 90|Va
P06782612A0142 |29 39|impairmenth alkaline
P06782612A0142 |66 71|ratioidase
P06782869A0263 |171 197|serum alkaline phosphatase] is shown as a function o
P06782869A0263 |150 154|SGPTA047
P06782869A0263 |45 58|complicationshatases and 5
P06782869A0263 |93 109|serum creatininecologic aspects 
P06782869A0263 |111 131|creatinine clearance neonatal hyperbilir
P06782869A0263 |133 142|serum CO2inemia. P
P06782869A0263 |88 91|BUNhar
P06782869A0263 |156 165|serum LDHWhen CSF 
P06782869A0263 |144 148|SGOT0089
P06782869A0263 |0 16|Nitrogen balanceP00001606T0076 C
P06784123A0286 |102 107|locusspect
P06784123A0286 |59 72|recombinationnucleotidase 
P06784123A0286 |14 23|C mu RNAs Comparis
P06784123A0286 |90 96|regionrmacol
P06784123A0286 |32 40|mu mRNAslkaline 
P06784123A0286 |98 100|JHic
P06784123A0286 |0 10|ProductionP00001606T
P06784123A0771 |137 144|mu chinia. P00
P06784123A0771 |72 80|mu chainP0000817
P06784123A0771 |36 59|sequence characteristicine phosphatases and 5-
P06784123A0771 |11 19|C mu RNA076 Comp
P06784123A0771 |101 108|speciesaspects
P06784123T0000 |0 11|TranscriptsP00001606T0
P06784123T0000 |91 102|developmentmacologic a
P06784123T0000 |66 74|splicingidase P0
P06784123T0000 |52 61|structure and 5-nu
P06784123T0000 |19 43|immunoglobulin C mu genearison with alkaline pho
P06785113A0337 |87 92|mucusPharm
P06785113A0337 |44 52|activityphatases
P06785113A0337 |104 112|patientsects of 
P06786756T0000 |68 78|expressionase P00008
P06786756T0000 |12 29|DNA rearrangement76 Comparison wit
P06786756T0000 |82 108|immunoglobulin delta genes0000 Pharmacologic aspects
P06786756T0000 |46 60|RNA processingatases and 5-n
P06786756T0000 |4 8|role0160
P06788388A0000 |138 145|studiesa. P000
P06788388A0000 |26 32|actionwith a
P06788388A0000 |13 22|mechanism6 Compari
P06788388A0000 |157 166|compoundshen CSF [
P06788388A0000 |36 44|ICRF-159ine phos
P06788388A0000 |174 182|interests shown 
P06790572A0330 |34 44|lincomycinaline phos
P06790572A0330 |56 64|nystatin 5-nucle
P06790572A0330 |46 54|colistinatases a
P06790572A0330 |121 131|anisomycinhyperbilir
P06790572A0330 |104 115|polymyxin Bects of neo
P06790572A0330 |82 102|trimethoprim lactate0000 Pharmacologic a
P06790572A0330 |7 15|isolates06T0076 
P06790572A0330 |66 80|amphotericin Bidase P0000817
P06791500A0622 |69 80|cornerstonese P0000817
P06791500A0622 |93 103|managementcologic as
P06791500A0622 |27 44|fluid delta OD450ith alkaline phos
P06791500A0622 |4 14|evaluation01606T0076
P06793764T0001 |0 11|Host lipidsP00001606T0
P06793764T0001 |27 36|infectionith alkal
P06794480A0785 |70 76|otherse P000
P06794480A0785 |78 79|p1
P06794480A0785 |29 39|differenceh alkaline
P06794480A0785 |48 57|age groupases and 
P06794666A0208 |119 148|neurotransmitter biosynthesisl hyperbilirubinemia. P000089
P06794666A0208 |87 94|measurePharmac
P06794666A0208 |63 67|ATCIeoti
P06794666A0208 |47 57|myocardiumtases and 
P06794666A0208 |165 194|cardiomyocyte adrenoreceptors[HCO3-] is shown as a functio
P06794666A0208 |153 161|function72 When 
P06794666A0208 |16 39|neuroeffector influenceomparison with alkaline
P06794666A0208 |102 111|intensityspects of
P06795119T0000 |51 60|cataractss and 5-n
P06795119T0000 |0 21|Lens aldose reductaseP00001606T0076 Compar
P06795654A0434 |17 22|dosesmpari
P06795654A0434 |125 144|minimum requirementrbilirubinemia. P00
P06795654A0434 |47 61|mg/kg/infusiontases and 5-nu
P06795654A0434 |80 108|self-administration behavior1T0000 Pharmacologic aspects
P06795654A0434 |146 148|FR89
P06795654A0434 |0 12|FenfluramineP00001606T00
P06795832A0148 |17 28|Hepatitis Amparison wi
P06795832A0148 |89 103|HBe-antibodiesarmacologic as
P06795832A0148 |73 76|IgG000
P06795832A0148 |61 64|HBccle
P06795832A0148 |65 68|IgMtid
P06795832A0148 |7 13|course06T007
P06795832A0148 |38 49|HBe-antigene phosphata
P06795900A0000 |115 119|ratenata
P06795900A0000 |24 67|acid cyclo-oxygenase inhibitor indomethacinn with alkaline phosphatases and 5-nucleoti
P06795900A0000 |124 130|oxygenerbili
P06795900A0000 |192 196|ratsion 
P06795900A0000 |132 137|CMRO2binem
P06795900A0000 |80 90|blood flow1T0000 Pha
P06795900A0000 |92 95|CBFaco
P06795900A0000 |4 10|effect01606T
P06795971A0000 |32 44|model systemlkaline phos
P06795971A0000 |63 74|amelgenesiseotidase P0
P06795971A0000 |4 15|rat incisor01606T0076 
P06796300A0759 |86 111|oestradiol administration Pharmacologic aspects of
P06796300A0759 |41 54|nursing womenhosphatases a
P06796300A0759 |21 37|prolactin levelsison with alkali
P06797063A0000 |0 6|FactorP00001
P06797063A0000 |12 33|procoagulant activity76 Comparison with al
P06797063A0000 |132 137|timesbinem
P06797063A0000 |88 107|ristocetin cofactorharmacologic aspect
P06797063A0000 |61 84|von Willebrand activitycleotidase P00008171T00
P06797063A0000 |158 161|DICen 
P06797063A0000 |144 152|patients008997A0
P06797063A0000 |35 56|antigen concentrationline phosphatases and
P06798609A0000 |169 176|periods3-] is 
P06798609A0000 |126 134|mg/kg IPbilirubi
P06798609A0000 |104 107|GVGect
P06798609A0000 |31 35|ratsalka
P06798609A0000 |142 146|days0000
P06798609A0000 |59 67|protocolnucleoti
P06798609A0000 |86 102|gamma-vinyl GABA Pharmacologic a
P06801778T0001 |0 12|SignificanceP00001606T00
P06801778T0001 |30 51|gas exchange reaction alkaline phosphatase
P06801778T0001 |114 128|commissurotomyonatal hyperbi
P06801778T0001 |90 103|effectivenessrmacologic as
P06801778T0001 |64 71|loadingotidase
P06802500T0001 |0 18|Thyreoliberin VUFBP00001606T0076 Com
P06802500T0001 |22 41|thyroid gammagraphyson with alkaline p
P06803634A0810 |85 92|respect0 Pharm
P06803634A0810 |226 230|sonseted
P06803634A0810 |61 65|sonscleo
P06803634A0810 |105 129|blood gas determinationscts of neonatal hyperbil
P06803634A0810 |176 184|patientsshown as
P06803634A0810 |146 155|responses8997A0472
P06803634A0810 |26 39|relationshipswith alkaline
P06803634A0810 |167 172|Paco2CO3-]
P06803634A0810 |3 12|silicosis001606T00
P06803634A0810 |213 222|responsesata of K-
P06803634A0810 |48 56|patientsases and
P06805504A0629 |84 90|weight00 Pha
P06805504A0629 |23 31|N valueson with 
P06805504A0629 |76 78|kg08
P06805504A0629 |161 169|mg/kg W0CSF [HCO
P06805504A0629 |114 125|N excretiononatal hype
P06805504A0629 |143 144|N0
P06805504A0629 |49 57|mg/kg W0ses and 
P06805537T0001 |51 57|factors and 
P06805537T0001 |63 74|concentrateeotidase P0
P06805537T0001 |12 32|hemophilia treatment76 Comparison with a
P06805537T0001 |0 8|AdvancesP0000160
P06807149A0222 |50 57|abilityes and 
P06807149A0222 |77 82|forms8171T
P06807149A0222 |99 102|EIBc a
P06807149A0222 |5 10|study1606T
P06807149A0222 |86 89|DSG Ph
P06807149T0000 |0 10|ComparisonP00001606T
P06807149T0000 |75 85|prevention008171T000
P06807149T0000 |30 42|preparations alkaline ph
P06807149T0000 |46 67|disodium cromoglycateatases and 5-nucleoti
P06807149T0000 |135 140|studyemia.
P06807149T0000 |106 118|bronchospasmts of neonat
P06807192A0312 |0 4|LCBFP000
P06807192A0312 |91 95|LCGUmaco
P06807192A0312 |134 144|conditionsnemia. P00
P06807192A0312 |146 151|Duffy8997A
P06807192A0312 |27 34|puppiesith alk
P06807192A0312 |70 89|glucose utilizatione P00008171T0000 Ph
P06807659T0001 |0 12|PhagocytosisP00001606T00
P06807659T0001 |25 32|bacilli with a
P06807659T0001 |36 47|macrophagesine phospha
P06808287T0001 |0 9|DetectionP00001606
P06808287T0001 |13 34|hemophilia A carriers6 Comparison with alk
P06808529A0167 |17 36|isoniazid solutionsmparison with alkal
P06808529A0167 |72 75|NTAP00
P06808529A0167 |79 97|EDTA concentration71T0000 Pharmacolo
P06808529A0167 |106 112|mmol/lts of 
P06808529A0167 |4 13|stability01606T007
P06809474A1156 |0 14|Bile bilirubinP00001606T0076
P06809474A1156 |62 69|findingleotida
P06809474A1156 |93 106|investigationcologic aspec
P06809474A1156 |46 59|haem infusionatases and 5-
P06809474A1156 |38 39|he
P06809586T0000 |0 28|Autoimmune manipulation aidsP00001606T0076 Comparison wi
P06809586T0000 |38 57|diabetes managemente phosphatases and 
P06810070A0502 |20 22|Hgri
P06810070A0502 |63 77|control sporeseotidase P0000
P06810070A0502 |28 37|Cd-sporesth alkali
P06810070A0502 |6 16|properties606T0076 C
P06810694A0328 |16 31|HDL-cholesterolomparison with 
P06810694A0328 |127 134|apo A-Iilirubi
P06810694A0328 |115 123|decreasenatal hy
P06810694A0328 |4 12|decrease01606T00
P06810694A0328 |48 66|VLDL-triglyceridesases and 5-nucleot
P06810694A1000 |0 13|Apo A-I levelP00001606T007
P06810694A1000 |94 103|adiposityologic as
P06810694A1000 |31 34|agealk
P06810694A1000 |55 74|ethanol consumptiond 5-nucleotidase P0
P06812389A0658 |0 5|TEMTUP0000
P06812389A0658 |10 14|DPTU0076
P06812389A0658 |36 46|teratogensine phosph
P06815368A0203 |21 29|mannitolison wit
P06815368A0203 |53 61|patientsand 5-nu
P06816053A0849 |34 48|drug reactionsaline phosphat
P06816053A0849 |62 66|centleot
P06816053A0849 |100 114|mast cell test aspects of ne
P06816053A0849 |7 15|patients06T0076 
P06816053A0849 |84 92|response00 Pharm
P06816123A0526 |0 8|SeleniumP0000160
P06816123A0526 |62 66|roleleot
P06816123A0526 |135 140|rolesemia.
P06816123A0526 |30 52|glutathione peroxidase alkaline phosphatases
P06816123A0526 |15 26|constituentComparison 
P06816123A0526 |145 153|selenium08997A04
P06816123A0526 |109 113|bodyof n
P06816123A0526 |86 101|defense systems Pharmacologic 
P06816442T0001 |39 44|cases phos
P06816442T0001 |11 16|value076 C
P06816442T0001 |62 69|diseaseleotida
P06816442T0001 |20 35|serum myoglobinrison with alka
P06816609A0639 |51 54|kPas a
P06816609A0639 |58 66|decrease-nucleot
P06816609A0639 |104 112|CBF fallects of 
P06816609A0639 |33 37|PCO2kali
P06816609A0639 |5 31|% blood pressure reduction1606T0076 Comparison with 
P06816609A0639 |118 119|%a
P06817410A0982 |49 55|changeses an
P06817410A0982 |150 159|incidenceA0472 Whe
P06817410A0982 |134 142|increasenemia. P
P06817410A0982 |83 94|hepatitis A000 Pharmac
P06817410A0982 |59 71|epidemiologynucleotidase
P06817410A0982 |176 185|hepatitisshown as 
P06817410A0982 |192 204|drug addictsion of CSF P
P06817410A0982 |168 172|typeO3-]
P06817410A0982 |18 24|monthspariso
P06817410A0982 |32 37|studylkali
P06818113A0384 |34 43|responsesaline pho
P06818113A0384 |161 170|responsesCSF [HCO3
P06818113A0384 |10 18|patients0076 Com
P06818113A0384 |174 195|plasminogen activators shown as a function
P06818113A0384 |66 76|adrenalineidase P000
P06818113A0384 |82 90|controls0000 Pha
P06818113A0384 |52 62|parameters and 5-nuc
P06818113A0384 |235 243|infusion are no 
P06818113A0384 |200 215|clotting factorSF PCO2 the dat
P06818113A0384 |117 141|corticosteroid treatmenttal hyperbilirubinemia. 
P06821147A0468 |0 19|Sulphur amino acidsP00001606T0076 Comp
P06821147A0468 |71 77|flours P0000
P06821147A0468 |26 29|g Nwit
P06821147A0468 |50 58|isolateses and 5
P06822645T0039 |0 4|TimeP000
P06822645T0039 |12 43|increase growth hormone release76 Comparison with alkaline pho
P06823837A0562 |38 48|wavefrontse phosphat
P06823837A0562 |121 134|outflow tracthyperbilirubi
P06823837A0562 |110 116|groovef neon
P06825641A0076 |85 94|knowledge0 Pharmac
P06825641A0076 |147 152|waste997A0
P06825641A0076 |14 33|landfill operations Comparison with al
P06825641A0076 |128 139|containmentlirubinemia
P06826813A0264 |0 8|VesiclesP0000160
P06826813A0264 |45 54|exposureshatases a
P06826813A0264 |58 61|UVA-nu
P06828396A0095 |34 39|woundaline
P06828396A0095 |73 98|biopsy fixation technique00008171T0000 Pharmacolog
P06828396A0095 |13 26|contamination6 Comparison 
P06828396A0095 |4 9|level01606
P06829082A0187 |139 162|incubation temperatures. P00008997A0472 When C
P06829082A0187 |225 229|ratslete
P06829082A0187 |40 49|degrees Cphosphata
P06829082A0187 |182 191|degrees Cas a func
P06829082A0187 |89 123|brain tissues glutaminase activityarmacologic aspects of neonatal hy
P06829082A0187 |73 81|increase00008171
P06829082A0187 |216 220|rats of 
P06829082A0187 |24 35|hypothermian with alka
P06829082A0187 |236 247|hypothermiaare no long
P06830033A0661 |66 71|cmH2Oidase
P06830033A0661 |79 82|min71T
P06830033A0661 |47 59|pneumothoraxtases and 5-
P06830033A0661 |8 20|observations6T0076 Compa
P06830351A0397 |102 103|%s
P06830351A0397 |73 80|Type Ib0000817
P06830351A0397 |13 20|Sugiura6 Compa
P06830351A0397 |57 64|Type Ia5-nucle
P06830351A0397 |109 113|Typeof n
P06830351A0397 |123 124|%p
P06830351A0397 |89 93|Typearma
P06830351A0397 |86 87|% 
P06830351A0397 |23 37|classificationon with alkali
P06830351A0397 |70 71|%e
P06833047A0000 |137 141|HFOVia. 
P06833047A0000 |124 135|ventilationerbilirubin
P06833047A0000 |5 10|study1606T
P06833047A0000 |40 49|mechanismphosphata
P06833047A0000 |70 80|inhibitione P0000817
P06833422T0000 |0 13|DeterminationP00001606T007
P06833422T0000 |44 58|alpha-pregna-4phatases and 5
P06833422T0000 |75 81|plasma008171
P06833422T0000 |94 108|ion monitoringologic aspects
P06833422T0000 |61 71|dien-3-onecleotidase
P06833422T0000 |20 40|alpha-hydroxy-9 betarison with alkaline 
P06835516A0000 |2 6|case0001
P06835516A0000 |53 60|cisternand 5-n
P06835516A0000 |18 33|epidermoid cystparison with al
P06835914A0192 |68 81|copper intakease P00008171
P06835914A0192 |126 137|feed intakebilirubinem
P06835914A0192 |58 64|levels-nucle
P06835914A0192 |105 116|differencescts of neon
P06835914A0192 |187 195|industryfunction
P06835914A0192 |153 161|practice72 When 
P06835914A0192 |0 17|Copper treatmentsP00001606T0076 Co
P06837312A0000 |102 104|IUsp
P06837312A0000 |72 77|aortaP0000
P06837312A0000 |14 21|intimal Compar
P06837312A0000 |218 225|lesionsf K-dep
P06837312A0000 |179 200|vitamin D3 withdrawalwn as a function of C
P06837312A0000 |125 129|dietrbil
P06837312A0000 |108 121|vitamin D3/kg of neonatal 
P06837312A0000 |169 175|months3-] is
P06837312A0000 |140 155|months duration P00008997A0472
P06837312A0000 |85 90|swine0 Pha
P06838388A0896 |205 208|dayO2 
P06838388A0896 |79 84|place71T00
P06838388A0896 |185 193|functiona functi
P06838388A0896 |142 155|normalization00008997A0472
P06838388A0896 |112 128|parenchyma areasneonatal hyperbi
P06838388A0896 |163 168|organF [HC
P06838388A0896 |49 61|tissue scarsses and 5-nu
P06838388A0896 |19 30|developmentarison with
P06838388A0896 |171 180|structure] is show
P06840803A0397 |35 43|reactionline pho
P06840803A0397 |120 124|days hyp
P06840803A0397 |79 93|i.v. challenge71T0000 Pharma
P06840803A0397 |13 18|signs6 Com
P06840803A0397 |70 72|hre 
P06842629A0446 |46 51|shockatase
P06842629A0446 |60 76|treatment groupsucleotidase P000
P06842629A0446 |12 27|GMBF reductions76 Comparison w
P06848729A0000 |21 34|neuroblastomaison with alk
P06848729A0000 |46 49|St.ata
P06848729A0000 |7 15|children06T0076 
P06849842T0000 |51 65|granulopoiesiss and 5-nucleo
P06849842T0000 |0 33|Penicillin-G degradation productsP00001606T0076 Comparison with al
P06851280A0144 |0 17|Plasma fibrinogenP00001606T0076 Co
P06851280A0144 |52 58|method and 5
P06851280A0144 |62 67|timolleoti
P06851280A0144 |82 87|units0000 
P06851327A0000 |19 23|typearis
P06851327A0000 |44 53|infectionphatases 
P06851327A0000 |123 129|periodperbil
P06851327A0000 |73 90|Neisseria species00008171T0000 Pha
P06851327A0000 |5 13|patients1606T007
P06853042A0282 |68 92|bicarbonate reabsorptionase P00008171T0000 Pharm
P06853042A0282 |15 28|acidificationComparison wi
P06853042A0282 |37 46|thresholdne phosph
P06853042A0282 |133 141|capacityinemia. 
P06853042A0282 |113 118|urineeonat
P06854957T0066 |0 9|DetectionP00001606
P06854957T0066 |30 38|asynergy alkalin
P06854957T0066 |49 65|echocardiographyses and 5-nucleo
P06856306T0000 |68 80|significancease P0000817
P06856306T0000 |41 50|Henneberthosphatas
P06856306T0000 |53 57|signand 
P06856306T0000 |23 35|fistula teston with alka
P06856306T0000 |4 21|Tullio phenomenon01606T0076 Compar
P06856669A1004 |50 60|metabolismes and 5-n
P06856669A1004 |6 13|results606T007
P06856669A1004 |110 116|outputf neon
P06856669A1004 |91 97|5-HIAAmacolo
P06856669A1004 |64 68|5-HTotid
P06856669A1004 |143 154|circulation0008997A047
P06856669A1004 |81 87|effluxT0000 
P06858449A0335 |0 12|DisturbancesP00001606T00
P06858449A0335 |26 36|maturationwith alkal
P06858640A0262 |34 42|findingsaline ph
P06858640A0262 |104 115|fibroblastsects of neo
P06858640A0262 |7 12|basis06T00
P06858640A0262 |58 65|amyloid-nucleo
P06858640A0262 |48 54|originases a
P06858805A0314 |69 77|Candidinse P0000
P06858805A0314 |47 63|hypersensitivitytases and 5-nucl
P06858805A0314 |30 35|tests alka
P06858805A0314 |95 105|Tuberculinlogic aspe
P06858805A0314 |79 90|Trycophytin71T0000 Pha
P06858805A0314 |5 11|groups1606T0
P06858967A0167 |0 27|Serum lactate dehydrogenaseP00001606T0076 Comparison w
P06858967A0167 |74 83|bilirubin0008171T0
P06858967A0167 |32 50|haptoglobin levelslkaline phosphatas
P06863087A0664 |20 22|mgri
P06863087A0664 |28 30|DBth
P06863087A0664 |91 98|controlmacolog
P06863087A0664 |9 10|DT
P06863087A0664 |40 42|mgph
P06863087A0664 |76 85|parameter08171T000
P06864837T0000 |0 8|EfficacyP0000160
P06864837T0000 |21 49|spine immobilization methodsison with alkaline phosphata
P06864955T0000 |15 19|MMWRComp
P06868345A0000 |16 27|visna-maediomparison w
P06868345A0000 |63 67|timeeoti
P06868345A0000 |31 36|Italyalkal
P06868345A0000 |4 12|presence01606T00
P06869215A0347 |5 11|levels1606T0
P06869215A0347 |15 17|ICCo
P06869215A0347 |42 60|hypocomplementemiaosphatases and 5-n
P06869986A0000 |117 126|ruminantstal hyper
P06869986A0000 |93 100|lesionscologic
P06869986A0000 |12 21|platelets76 Compar
P06869986A0000 |65 73|collagentidase P
P06872800T0000 |32 40|patientslkaline 
P06872800T0000 |6 10|type606T
P06872800T0000 |13 22|hepatitis6 Compari
P06872800T0000 |54 67|HBV infectionnd 5-nucleoti
P06873504T0000 |49 57|acidosisses and 
P06873504T0000 |62 91|sodium metabolism alterationsleotidase P00008171T0000 Phar
P06873504T0000 |13 26|relationships6 Comparison 
P06873504T0000 |95 110|liver cirrhosislogic aspects o
P06875478A0542 |2 22|microU/l thyrotropin0001606T0076 Compari
P06875478A0542 |53 54|%a
P06875478A0542 |26 27|%w
P06875478A0542 |38 39|%e
P06876006A0930 |0 15|EchosismographyP00001606T0076 
P06876006A0930 |105 110|casescts o
P06876006A0930 |39 48|diagnosis phosphat
P06876006A0930 |78 88|sonography171T0000 P
P06876006A0930 |100 101|% 
P06876317T0033 |0 13|RelationshipsP00001606T007
P06876317T0033 |39 58|deficiency syndrome phosphatases and 5
P06880563A0516 |49 53|typeses 
P06880563A0516 |56 64|diabetes 5-nucle
P06880563A0516 |183 197|administrations a function o
P06880563A0516 |38 42|typee ph
P06880563A0516 |4 14|prevalence01606T0076
P06880563A0516 |145 160|administrations08997A0472 When
P06880563A0516 |95 98|menlog
P06880563A0516 |201 215|chlorpropamideF PCO2 the dat
P06880563A0516 |81 86|womenT0000
P06880563A0516 |18 22|CPAFpari
P06880604A0167 |153 160|January72 When
P06880604A0167 |22 37|prevalence datason with alkali
P06880604A0167 |109 117|provinceof neona
P06880604A0167 |132 146|prevalence daybinemia. P0000
P06880604A0167 |121 126|Vaasahyper
P06880604A0167 |2 14|reassessment0001606T0076
P06880604A0167 |82 89|Uusimaa0000 Ph
P06880604A0167 |70 78|provincee P00008
P06880650A0316 |4 11|results01606T0
P06880650A0316 |40 44|workphos
P06880650A0316 |54 65|researchersnd 5-nucleo
P06882578A0464 |152 160|training472 When
P06882578A0464 |72 81|beginningP00008171
P06882578A0464 |209 214|ng/mlhe da
P06882578A0464 |240 254|hours trainingno longer disp
P06882578A0464 |121 126|ng/mlhyper
P06882578A0464 |7 27|ultramarathon runner06T0076 Comparison w
P06882578A0464 |197 202|hoursf CSF
P06882578A0464 |227 230|endted
P06882578A0464 |89 105|training sessionarmacologic aspe
P06882578A0464 |32 51|testosterone levelslkaline phosphatase
P06882578A0464 |261 266|ng/mlhen c
P06882578A0464 |136 141|ng/mlmia. 
P06883385A0509 |3 11|patients001606T0
P06883385A0509 |104 110|valuesects o
P06883385A0509 |54 59|tumornd 5-
P06883385A0509 |37 46|remissionne phosph
P06883385A0509 |65 85|neopterine excretiontidase P00008171T000
P06884450A0234 |70 73|TBNe P
P06884450A0234 |28 35|resultsth alka
P06884450A0234 |61 62|%c
P06884450A0234 |92 93|%a
P06884450A0234 |11 18|tumours076 Com
P06884450A0234 |55 57|FBd 
P06886031A0898 |119 128|test dosel hyperbi
P06886031A0898 |29 34|fluidh alk
P06886031A0898 |132 140|tolmetinbinemia.
P06886031A0898 |75 88|patient group008171T0000 P
P06886031A0898 |6 16|PGE levels606T0076 C
P06886031A0898 |144 147|day008
P06886031A0898 |96 101|hoursogic 
P06886948A0750 |16 27|weight gainomparison w
P06886948A0750 |7 12|rates06T00
P06886948A0750 |82 83|%0
P06886948A0750 |52 66|energy intakes and 5-nucleot
P06886948A0750 |87 99|requirementsPharmacologi
P06890622A0067 |152 163|coagulation472 When CS
P06890622A0067 |61 68|effectscleotid
P06890622A0067 |181 194|pre-eclampsia as a functio
P06890622A0067 |125 137|hypertensionrbilirubinem
P06890622A0067 |40 48|plateletphosphat
P06890622A0067 |115 123|ischemianatal hy
P06890935T0001 |0 6|BehcetP00001
P06890935T0001 |9 17|syndromeT0076 Co
P06891051A0587 |85 95|correction0 Pharmaco
P06891051A0587 |43 52|plateletssphatases
P06891051A0587 |70 78|patientse P00008
P06891051A0587 |99 113|platelet countc aspects of n
P06891051A0587 |0 8|SurvivalP0000160
P06891270A0000 |118 128|rat atriumal hyperbi
P06891270A0000 |77 90|contractility8171T0000 Pha
P06891270A0000 |40 43|EPSpho
P06891270A0000 |4 10|effect01606T
P06891270A0000 |59 72|extensibilitynucleotidase 
P06891270A0000 |32 38|stresslkalin
P06895559A0000 |119 130|combinationl hyperbili
P06895559A0000 |162 165|daySF 
P06895559A0000 |135 149|rabbit fetusesemia. P0000899
P06895559A0000 |61 88|phosphodiesterase inhibitorcleotidase P00008171T0000 P
P06895559A0000 |45 57|aminophyllinhatases and 
P06895559A0000 |169 178|gestation3-] is sh
P06895559A0000 |32 39|agonistlkaline
P06895559A0000 |0 11|TerbutalineP00001606T0
P06895663A0810 |68 71|RLFase
P06895663A0810 |40 51|associationphosphatase
P06895663A0810 |60 63|RBTucl
P06895663A0810 |114 115|Po
P06895663A0810 |8 15|therapy6T0076 
P06895663A0810 |100 112|significance aspects of 
P06897114A0240 |87 90|CAPPha
P06897114A0240 |15 20|motifCompa
P06897114A0240 |59 83|DNA sequence recognitionnucleotidase P00008171T0
P06902722T0000 |50 60|infarctiones and 5-n
P06902722T0000 |15 20|phaseCompa
P06911559T0000 |0 10|StatisticsP00001606T
P06911559T0000 |15 29|nurse managersComparison wit
P06916588A0304 |115 116|pn
P06916588A0304 |104 113|cathetersects of n
P06916588A0304 |45 53|patientshatases 
P06916588A0304 |59 76|Hickman cathetersnucleotidase P000
P06916588A0304 |28 33|timesth al
P06916588A0304 |4 18|infection rate01606T0076 Com
P06919347T0001 |16 24|planningompariso
P06919347T0001 |65 74|Stockholmtidase P0
P06919347T0001 |8 12|year6T00
P06919347T0001 |94 115|laboratory assistantsologic aspects of neo
P06919347T0001 |55 61|Schoold 5-nu
P06919347T0001 |80 89|education1T0000 Ph
P06919347T0001 |32 53|Laboratory Assistantslkaline phosphatases 
P06928974T0000 |4 21|electrocardiogram01606T0076 Compar
P06931124A0109 |50 59|NH4Mg PO4es and 5-
P06931124A0109 |14 19|place Comp
P06931124A0109 |90 95|waterrmaco
P06931124A0109 |75 84|reactants008171T00
P06931124A0109 |28 45|complex formationth alkaline phosp
P06931124A0109 |61 64|H2Ocle
P06931124A0109 |65 66|nt
P06935514A0000 |155 166|alterations When CSF [
P06935514A0000 |42 50|researchosphatas
P06935514A0000 |214 223|componentta of K-d
P06935514A0000 |133 138|orderinemi
P06935514A0000 |63 74|preparationeotidase P0
P06935514A0000 |4 11|Authors01606T0
P06935514A0000 |174 188|dentinogenesiss shown as a f
P06935514A0000 |116 128|desametazoneatal hyperbi
P06938948T0001 |18 39|serum immunoglobulinsparison with alkaline
P06938948T0001 |107 116|leukemiass of neon
P06938948T0001 |91 97|mucosamacolo
P06938948T0001 |43 50|indicessphatas
P06938948T0001 |10 13|IgA007
P06938948T0001 |64 72|immunityotidase 
P06946314T0000 |0 16|Serum IgE levelsP00001606T0076 C
P06946314T0000 |20 37|Tauranga childrenrison with alkali
P06946693T0000 |0 3|UseP00
P06946693T0000 |46 52|cattleatases
P06946693T0000 |31 41|PGF2 alphaalkaline p
P06946693T0000 |7 29|prostaglandin F2 alpha06T0076 Comparison wit
P06948398A0523 |39 44|blood phos
P06948398A0523 |25 35|management with alka
P06948398A0523 |76 86|importance08171T0000
P06948493T0026 |0 5|RangeP0000
P06948493T0026 |7 17|variations06T0076 Co
P06948493T0026 |33 42|potentialkaline ph
P06948868A0082 |55 74|faculty evaluationsd 5-nucleotidase P0
P06948868A0082 |40 51|reliabilityphosphatase
P06948868A0082 |28 32|partth a
P06948868A0082 |4 10|scores01606T
P06950004T0047 |0 5|StudyP0000
P06950004T0047 |25 30|metal with
P06950004T0047 |9 21|distributionT0076 Compar
P06950004T0047 |55 68|iontophoresisd 5-nucleotid
P06950004T0047 |38 43|teethe pho
P06950004T0047 |86 95|specimens Pharmaco
P06953957A0503 |153 163|peak value72 When CS
P06953957A0503 |193 204|correlationon of CSF P
P06953957A0503 |107 115|episodess of neo
P06953957A0503 |76 85|myoglobin08171T000
P06953957A0503 |8 32|creatine kinase activity6T0076 Comparison with a
P06953957A0503 |70 74|peake P0
P06957125T0000 |35 41|effectline p
P06957125T0000 |65 82|stimulating drugstidase P00008171T
P06957125T0000 |45 49|betahata
P06957125T0000 |16 26|blood flowomparison 
P06957633T0001 |85 92|patient0 Pharm
P06957633T0001 |130 135|yearsrubin
P06957633T0001 |26 34|leukemiawith alk
P06957633T0001 |63 79|erythroblastosiseotidase P000081
P06957633T0001 |120 126|anemia hyper
P06957633T0001 |100 107|history aspect
P06957633T0001 |40 47|trisomyphospha
P06957633T0001 |0 11|DevelopmentP00001606T0
P06959130A0996 |50 60|conversiones and 5-n
P06959130A0996 |127 140|Arg145-Ala146ilirubinemia.
P06959130A0996 |145 158|Arg180-Val18108997A0472 Wh
P06959130A0996 |90 93|IXarma
P06959130A0996 |4 25|arginyl peptide bonds01606T0076 Comparison
P06959130A0996 |97 107|factor XIagic aspect
P06959130A0996 |70 76|factore P000
P06962492A0612 |113 123|bone baseseonatal hy
P06962492A0612 |9 15|growthT0076 
P06962492A0612 |89 99|hypotrophyarmacologi
P06962492A0612 |42 50|eruptionosphatas
P06962634A0190 |136 145|clearancemia. P000
P06962634A0190 |13 20|methods6 Compa
P06962634A0190 |112 131|porphyrin transportneonatal hyperbilir
P06962634A0190 |56 79|porphyrin binding sites 5-nucleotidase P000081
P06962634A0190 |38 49|informatione phosphata
P06963337T0000 |61 73|hypertensioncleotidase P
P06963337T0000 |44 55|hyperplasiaphatases an
P06966678A0523 |137 141|acidia. 
P06966678A0523 |245 255|injectionsnger displ
P06966678A0523 |270 276|atriumred to
P06966678A0523 |28 37|clearanceth alkali
P06966678A0523 |209 216|changeshe data
P06966678A0523 |303 309|atriumsignif
P06966678A0523 |344 345|r3
P06966678A0523 |288 289|nt
P06966678A0523 |117 127|metabolismtal hyperb
P06966678A0523 |20 24|rateriso
P06966678A0523 |354 355|n1
P06966678A0523 |321 322|nt
P06966678A0523 |334 342|ear vein21 +/- 0
P06966678A0523 |311 312|ra
P06966678A0523 |233 238|indexts ar
P06966678A0523 |67 74|portiondase P0
P06966678A0523 |41 47|tracerhospha
P06966678A0523 |168 174|lipidsO3-] i
P06966678A0523 |278 279|ro
P06966678A0523 |100 105|curve aspe
P06969638A0180 |170 179|prognosis-] is sho
P06969638A0180 |129 141|determinantsirubinemia. 
P06969638A0180 |46 63|CNS abnormalitiesatases and 5-nucl
P06969638A0180 |149 156|therapy7A0472 
P06969638A0180 |90 110|meningeal infectionsrmacologic aspects o
P06969638A0180 |5 17|examinations1606T0076 Co
P06969638A0180 |188 201|complicationsunction of CS
P06969638A0180 |32 42|indicatorslkaline ph
P06972179A0556 |84 89|range00 Ph
P06972179A0556 |9 19|IgE levelsT0076 Comp
P06972443A0375 |17 27|evaluationmparison w
P06972443A0375 |43 50|carriersphatas
P06972443A0375 |70 83|abnormalitiese P00008171T0
P06972501A0615 |0 11|CorrelationP00001606T0
P06972501A0615 |57 64|outcome5-nucle
P06972501A0615 |32 43|involvementlkaline pho
P06973664A0000 |19 36|cleavage syndromearison with alkal
P06973664A0000 |61 68|patientcleotid
P06973664A0000 |2 6|case0001
P06975206A0279 |52 57|weeks and 
P06975206A0279 |79 89|absorption71T0000 Ph
P06975206A0279 |28 41|betamethasoneth alkaline p
P06975206A0279 |105 114|phosphatects of ne
P06975206A0279 |10 24|administration0076 Compariso
P06975206A0279 |130 141|growth raterubinemia. 
P06975206A0279 |93 100|calciumcologic
P06977605T0000 |0 10|EndorphinsP00001606T
P06977605T0000 |21 27|issuesison w
P06978566A0197 |139 144|units. P00
P06978566A0197 |96 108|maximum doseogic aspects
P06978566A0197 |148 159|M. pulmonis97A0472 Whe
P06978566A0197 |61 73|lung lesionscleotidase P
P06978566A0197 |15 19|daysComp
P06978566A0197 |3 11|necropsy001606T0
P06978566A0197 |38 47|F344 ratse phospha
P06978566A0197 |116 117|Xa
P06981991A0756 |0 14|AneurysmectomyP00001606T0076
P06981991A0756 |231 245|artery diseaserats are no lo
P06981991A0756 |193 204|ECG changeson of CSF P
P06981991A0756 |168 173|groupO3-] 
P06981991A0756 |38 42|CABGe ph
P06981991A0756 |96 107|ECG changesogic aspect
P06981991A0756 |23 34|performanceon with alk
P06981991A0756 |118 131|bypass graftsal hyperbilir
P06981991A0756 |273 278|group to c
P06981991A0756 |136 143|patientmia. P0
P06984225A0367 |0 5|REV IP0000
P06984225A0367 |11 18|vessels076 Com
P06984225A0367 |45 57|patent grafthatases and 
P06984225A0367 |27 28|%i
P06986168A0304 |9 18|sequencesT0076 Com
P06986168A0304 |62 70|peptidesleotidas
P06986168A0304 |104 112|peptidesects of 
P06986168A0304 |122 133|V8 proteaseyperbilirub
P06992600A0405 |64 77|contaminationotidase P0000
P06992600A0405 |88 95|outflowharmaco
P06992600A0405 |4 27|extraction measurements01606T0076 Comparison w
P06993660A0000 |66 67|Ki
P06993660A0000 |55 64|potassiumd 5-nucle
P06993660A0000 |114 124|papaverineonatal hyp
P06993660A0000 |248 252|daysr di
P06993660A0000 |25 39|norepinephrine with alkaline
P06993660A0000 |181 187|strips as a 
P06993660A0000 |12 21|responses76 Compar
P06993660A0000 |74 92|relaxant responses0008171T0000 Pharm
P06993660A0000 |326 334|controlslope (1.
P06993660A0000 |222 226|ratsdepl
P06993660A0000 |41 50|serotoninhosphatas
P06993660A0000 |228 231|AHRed 
P06993660A0000 |96 109|isoproterenologic aspects 
P06994035T0001 |49 65|radioimmunoassayses and 5-nucleo
P06994035T0001 |23 45|steroid concentrationson with alkaline phosp
P06994035T0001 |3 19|line calculation001606T0076 Comp
P06994049T0001 |0 9|DetectionP00001606
P06994049T0001 |57 64|infants5-nucle
P06994049T0001 |24 38|hypothyroidismn with alkalin
P06997203A0325 |51 53|HIs 
P06997203A0325 |62 66|testleot
P06997203A0325 |180 181|%n
P06997203A0325 |151 170|antibody conversion0472 When CSF [HCO3
P06997203A0325 |189 197|patientsnction o
P06997203A0325 |133 141|PHA testinemia. 
P06997203A0325 |106 107|%t
P06997203A0325 |88 93|risesharma
P06997203A0325 |116 124|patientsatal hyp
P06997203A0325 |3 19|rubella patients001606T0076 Comp
P06997203A0325 |35 47|confirmationline phospha
P07004236A0741 |103 120|formate oxidationpects of neonatal
P07004236A0741 |26 42|folate compoundswith alkaline ph
P07004236A0741 |182 191|treatmentas a func
P07004236A0741 |167 174|folatesCO3-] i
P07004236A0741 |159 162|usen C
P07004236A0741 |52 72|formate accumulation and 5-nucleotidase 
P07004236A0741 |124 135|utilizationerbilirubin
P07004236A0741 |79 87|methanol71T0000 
P07004236A0741 |218 236|methanol poisoningf K-depleted rats 
P07004236A0741 |203 208|casesPCO2 
P07004236A0741 |4 11|results01606T0
P07007181T0000 |38 42|diete ph
P07007181T0000 |53 63|microfloraand 5-nucl
P07007181T0000 |14 30|sodium saccharin Comparison with
P07007181T0000 |4 10|effect01606T
P07007591A0324 |4 21|residue functions01606T0076 Compar
P07007591A0324 |33 41|C-11 CPZkaline p
P07007591A0324 |236 237|ta
P07007591A0324 |234 235|Es
P07007591A0324 |162 163|ES
P07007591A0324 |46 65|In-113m transferrinatases and 5-nucleo
P07007591A0324 |225 232|formulaleted r
P07007591A0324 |164 165|t 
P07007591A0324 |105 110|areascts o
P07007591A0324 |253 254|tp
P07007591A0324 |250 252|RRdi
P07007591A0324 |114 122|interestonatal h
P07007591A0324 |245 246|tn
P07007591A0324 |242 244|RT l
P07007591A0324 |23 24|Ro
P07007591A0324 |25 26|t 
P07007591A0324 |335 346|transferrin1 +/- 0.23 
P07007591A0324 |265 266|tc
P07007591A0324 |150 160|extractionA0472 When
P07007591A0324 |210 214|msece da
P07007591A0324 |305 322|residue functionsgnificantly great
P07007591A0324 |194 199|areasn of 
P07007591A0324 |327 330|CPZope
P07007591A0324 |87 91|timePhar
P07007591A0324 |262 264|RRen
P07007591A0324 |283 285|RRls
P07007591A0324 |132 135|CPZbin
P07007591A0324 |276 278|RT c
P07015018A0395 |43 63|migration inhibitionsphatases and 5-nucl
P07015018A0395 |12 20|extracts76 Compa
P07015018A0395 |78 84|assays171T00
P07015262A0396 |4 8|days0160
P07015262A0396 |133 145|microgram/mlinemia. P000
P07015262A0396 |12 30|cefadroxil therapy76 Comparison with
P07015262A0396 |74 89|tract infection0008171T0000 Ph
P07015262A0396 |160 165|group CSF 
P07015262A0396 |94 104|CRP valuesologic asp
P07015262A0396 |52 60|children and 5-n
P07016141A0238 |85 94|clearance0 Pharmac
P07016141A0238 |13 23|blood flow6 Comparis
P07016141A0238 |75 80|Xenon00817
P07016141A0238 |42 52|blood flowosphatases
P07016141A0238 |25 28|RBF wi
P07016141A0238 |54 57|NBFnd 
P07018810A0002 |0 26|Plasma renin concentrationP00001606T0076 Comparison 
P07018810A0002 |202 209|medulla PCO2 t
P07018810A0002 |179 183|halfwn a
P07018810A0002 |77 84|outflow8171T00
P07018810A0002 |147 154|outflow997A047
P07018810A0002 |217 227|cat kidneyof K-deple
P07018810A0002 |191 197|cortextion o
P07018810A0002 |115 121|cortexnatal 
P07021505A0510 |6 17|acclimation606T0076 Co
P07021505A0510 |90 94|mmHgrmac
P07021505A0510 |46 49|DPBata
P07021505A0510 |61 62|Pc
P07021505A0510 |27 33|supineith al
P07026328A0369 |137 138|%i
P07026328A0369 |81 87|mmol/1T0000 
P07026328A0369 |114 122|glucagononatal h
P07026328A0369 |23 32|infusionson with a
P07026328A0369 |188 189|pu
P07026328A0369 |94 98|fallolog
P07026328A0369 |43 47|risespha
P07026328A0369 |51 61|plasma Ca2s and 5-nu
P07026328A0369 |18 21|Ca2par
P07026328A0369 |185 186|%a
P07026328A0369 |7 16|diabetics06T0076 C
P07026328A0369 |163 170|glucoseF [HCO3
P07026328A0369 |140 141|p 
P07034479A1050 |34 47|placebo groupaline phospha
P07034479A1050 |92 93|pa
P07034479A1050 |12 15|RMI76 
P07034479A1050 |82 90|AC group0000 Pha
P07037479T0000 |20 28|syndromerison wi
P07037479T0000 |5 18|cracked-tooth1606T0076 Com
P07038189A2301 |32 35|CXDlka
P07038189A2301 |14 21|results Compar
P07038189A2301 |45 53|efficacyhatases 
P07038189A2301 |128 133|fieldlirub
P07038189A2301 |58 64|safety-nucle
P07038189A2301 |97 101|druggic 
P07038684A1050 |233 236|p62ts 
P07038684A1050 |121 124|p60hyp
P07038684A1050 |58 71|sequence data-nucleotidase
P07038684A1050 |9 33|peptide map similaritiesT0076 Comparison with al
P07038684A1050 |193 217|p60 initiator methionineon of CSF PCO2 the data 
P07038684A1050 |148 168|amino acid sequences97A0472 When CSF [HC
P07038684A1050 |129 132|p62iru
P07038684A1050 |92 98|originacolog
P07038684A1050 |219 226|residue K-depl
P07040659A0212 |118 123|groupal hy
P07040659A0212 |76 80|PEFR0817
P07040659A0212 |94 102|patientsologic a
P07040659A0212 |134 145|improvementnemia. P000
P07040659A0212 |4 12|patients01606T00
P07040659A0212 |20 33|control grouprison with al
P07040659A0212 |55 66|improvementd 5-nucleot
P07044389T0000 |0 5|FactsP0000
P07044389T0000 |67 79|pathologistsdase P000081
P07044389T0000 |13 38|Economic Recovery Tax Act6 Comparison with alkalin
P07044389T0000 |84 96|audiologists00 Pharmacol
P07044562T0000 |5 8|Pap160
P07044562T0000 |12 16|ApUp76 C
P07044842A2062 |34 47|complicationsaline phospha
P07044842A2062 |91 98|Barttermacolog
P07044842A2062 |4 16|relationship01606T0076 C
P07044842A2062 |72 87|pathophysiologyP00008171T0000 
P07044842A2062 |101 109|syndromeaspects 
P07045156A0204 |153 161|antibody72 When 
P07045156A0204 |57 66|rat model5-nucleot
P07045156A0204 |36 41|assayine p
P07045156A0204 |111 125|immunoglobulin neonatal hype
P07045156A0204 |70 80|GBS sepsise P0000817
P07049690T0000 |11 18|lesions076 Com
P07049690T0000 |28 38|allograftsth alkalin
P07053251A0666 |33 40|effectskaline 
P07053251A0666 |72 77|tractP0000
P07053251A0666 |112 117|studyneona
P07053251A0666 |42 53|bone marrowosphatases 
P07053251A0666 |83 88|heart000 P
P07061263A0293 |100 102|Px a
P07061263A0293 |74 87|air inflation0008171T0000 
P07061263A0293 |14 22|pressure Compari
P07061263A0293 |24 28|Pvasn wi
P07061263A0293 |95 98|minlog
P07061263A0293 |65 70|cmH2Otidas
P07061350A0042 |137 142|f2-f1ia. P
P07061350A0042 |8 15|Science6T0076 
P07061350A0042 |79 83|COCB71T0
P07061350A0042 |167 175|pressureCO3-] is
P07061350A0042 |100 109|magnitude aspects 
P07061350A0042 |71 77|bundle P0000
P07061350A0042 |117 135|distortion producttal hyperbilirubin
P07062036A0072 |0 4|RatsP000
P07062036A0072 |29 34|% JIBh alk
P07062036A0072 |40 54|sham operationphosphatases a
P07062269A0798 |139 146|effects. P0000
P07062269A0798 |104 115|l-methadoneects of neo
P07062269A0798 |74 83|tolerance0008171T0
P07062269A0798 |162 171|mechanismSF [HCO3-
P07062269A0798 |62 70|naloxoneleotidas
P07062269A0798 |39 47|receptor phospha
P07063606T0000 |0 9|MicrowaveP00001606
P07063606T0000 |43 62|barrier alterationssphatases and 5-nuc
P07064662A0222 |48 58|occurrenceases and 5
P07064662A0222 |26 33|lesionswith al
P07064662A0222 |62 75|target fibresleotidase P00
P07064662A0222 |145 157|dorsal roots08997A0472 W
P07064662A0222 |95 102|muscleslogic a
P07064662A0222 |127 137|neurolysisilirubinem
P07064923T0000 |51 66|phenylketonurias and 5-nucleot
P07064923T0000 |13 49|phenylalanine hydroxylase deficiency6 Comparison with alkaline phosphata
P07064923T0000 |0 9|DiagnosisP00001606
P07065206A0398 |118 121|minal 
P07065206A0398 |25 50|plasma TXB2 concentration with alkaline phosphatas
P07065206A0398 |125 131|bypassrbilir
P07065206A0398 |71 86|ng/ml prebypass P00008171T0000
P07065206A0398 |6 19|control sheep606T0076 Comp
P07065206A0398 |100 105|ng/ml aspe
P07068493A0414 |34 45|breaths/minaline phosp
P07068493A0414 |95 106|inspirationlogic aspec
P07068493A0414 |156 160|TorrWhen
P07068493A0414 |80 85|cycle1T000
P07068493A0414 |59 60|%n
P07068493A0414 |176 179|SIPsho
P07068493A0414 |16 20|rateompa
P07068493A0414 |168 172|runsO3-]
P07068493A0414 |118 130|CO2 pressureal hyperbili
P07068493A0636 |33 51|oxygen consumptionkaline phosphatase
P07068493A0636 |63 71|subjectseotidase
P07068493A0636 |21 29|increaseison wit
P07068493A0636 |114 117|SIPona
P07068493A0636 |98 107|pressuresic aspect
P07068496A0000 |69 80|water spacese P0000817
P07068496A0000 |98 116|sucrose indicatorsic aspects of neon
P07068496A0000 |146 158|rabbit lungs8997A0472 Wh
P07068496A0000 |87 93|sodiumPharma
P07068496A0000 |175 185|techniques shown as 
P07068496A0000 |16 22|volumeompari
P07068887A0000 |17 28|reliabilitymparison wi
P07068887A0000 |30 38|validity alkalin
P07068887A0000 |179 187|lifetimewn as a 
P07068887A0000 |126 160|Michigan Alcoholism Screening Testbilirubinemia. P00008997A0472 When
P07068887A0000 |43 57|dimensionalitysphatases and 
P07068887A0000 |61 67|scorescleoti
P07068887A0000 |200 214|symptomatologySF PCO2 the da
P07068887A0000 |110 111|Nf
P07068887A0000 |98 108|inpatientsic aspects
P07072635A0000 |38 42|irone ph
P07072635A0000 |75 90|desferrioxamine008171T0000 Pha
P07072635A0000 |9 15|methodT0076 
P07072635A0000 |57 71|administration5-nucleotidase
P07072635A0000 |92 94|DFac
P07073520A0153 |101 109|decreaseaspects 
P07073520A0153 |127 139|fluid volumeilirubinemia
P07073520A0153 |92 97|mEq/Lacolo
P07073520A0153 |176 188|fluid volumeshown as a f
P07073520A0153 |41 59|substitution fluidhosphatases and 5-
P07073520A0153 |20 34|hemofiltrationrison with alk
P07073520A0153 |67 69|Nada
P07073520A0153 |71 84|concentration P00008171T00
P07075024A0540 |35 40|feverline 
P07075024A0540 |18 23|casesparis
P07075024A0540 |106 111|casests of
P07075024A0540 |70 74|CMIRe P0
P07075438T0000 |12 34|serial xeroradiography76 Comparison with alk
P07076222A0543 |0 15|RecommendationsP00001606T0076 
P07076222A0543 |47 53|issuestases 
P07078263T0000 |0 3|UseP00
P07078263T0000 |20 32|deferoxaminerison with a
P07078263T0000 |110 116|anemiaf neon
P07078263T0000 |49 64|hemochromatosisses and 5-nucle
P07078263T0000 |38 43|childe pho
P07078263T0000 |118 125|type I.al hype
P07079595A0848 |70 71|re
P07079595A0848 |24 35|correlationn with alka
P07079595A0848 |161 169|sectionsCSF [HCO
P07079595A0848 |123 144|diameter measurementsperbilirubinemia. P00
P07079595A0848 |195 211|sperm production of CSF PCO2 the
P07079595A0848 |65 68|spgtid
P07079595A0848 |52 60|diameter and 5-n
P07079595A0848 |80 81|P1
P07080496A0097 |34 46|lipoproteinsaline phosph
P07080496A0097 |104 113|fractionsects of n
P07080496A0097 |181 193|lipoproteins as a functi
P07080496A0097 |248 255|attacksr displ
P07080496A0097 |158 165|respecten CSF 
P07080496A0097 |212 220|infarctsdata of 
P07080496A0097 |195 198|LDL of
P07080496A0097 |86 97|lipoprotein Pharmacolo
P07080496A0097 |99 102|HDLc a
P07080496A0097 |17 30|investigationmparison with
P07081327A0546 |138 145|samplesa. P000
P07081327A0546 |90 101|differencesrmacologic 
P07081327A0546 |45 59|concentrationshatases and 5-
P07081327A0546 |78 82|zinc171T
P07081327A0546 |63 73|phosphoruseotidase P
P07081327A0546 |23 28|fluidon wi
P07084198T0000 |0 15|Selenium statusP00001606T0076 
P07084198T0000 |40 54|United Kingdomphosphatases a
P07084198T0000 |19 32|thoroughbredsarison with a
P07084617A0204 |98 100|wkic
P07084617A0204 |107 116|treatments of neon
P07084617A0204 |15 24|follow-upCompariso
P07084617A0204 |76 80|drug0817
P07084617A0204 |26 35|parasiteswith alka
P07084617A0204 |53 61|patientsand 5-nu
P07084814T0000 |0 11|PreparationP00001606T0
P07084814T0000 |24 44|phospholipid reagentn with alkaline phos
P07084814T0000 |49 67|coagulation assaysses and 5-nucleoti
P07088195T0019 |2 6|note0001
P07088195T0019 |31 40|UV visionalkaline 
P07088195T0019 |15 27|consequencesComparison w
P07088195T0019 |44 49|birdsphata
P07090151A0165 |18 26|morantelparison 
P07090151A0165 |7 14|turnout06T0076
P07090151A0165 |107 115|categorys of neo
P07090151A0165 |52 56|MSRB and
P07090151A0165 |37 50|release bolusne phosphatas
P07090151A0165 |83 89|animal000 Ph
P07094856A0115 |68 77|intervalsase P0000
P07094856A0115 |95 104|gestationlogic asp
P07094856A0115 |18 23|studyparis
P07094856A0115 |37 44|fetusesne phos
P07094856A0115 |86 91|weeks Phar
P07094905A0644 |33 43|injectionskaline pho
P07094905A0644 |132 143|hippocampusbinemia. P0
P07094905A0644 |47 49|KAta
P07094905A0644 |96 101|cellsogic 
P07094905A0644 |78 82|loss171T
P07094905A0644 |115 124|CA3 fieldnatal hyp
P07096587A0267 |185 193|materiala functi
P07096587A0267 |105 110|monthcts o
P07096587A0267 |147 155|strategy997A0472
P07096587A0267 |63 79|training programeotidase P000081
P07096587A0267 |20 28|patientsrison wi
P07097182A0480 |156 160|earsWhen
P07097182A0480 |199 203|earsCSF 
P07097182A0480 |109 119|overgrowthof neonata
P07097182A0480 |47 56|potentialtases and
P07097182A0480 |4 12|duration01606T00
P07097182A0480 |99 103|earsc as
P07097182A0480 |21 30|amplitudeison with
P07105635A0412 |0 7|SamplesP000016
P07105635A0412 |29 39|volunteersh alkaline
P07105635A0412 |121 127|effecthyperb
P07105635A0412 |75 83|patients008171T0
P07105635A0412 |59 67|majoritynucleoti
P07105635A0412 |106 112|asthmats of 
P07105635A0412 |139 146|beating. P0000
P07106323A0560 |49 54|fetusses a
P07106323A0560 |93 100|E3-16-Gcologic
P07106323A0560 |79 89|production71T0000 Ph
P07106323A0560 |28 39|possibilityth alkaline
P07106323A0560 |67 71|roledase
P07106323A0560 |110 119|pregnancyf neonata
P07106323A0560 |6 13|results606T007
P07106534A0160 |136 140|massmia.
P07106534A0160 |123 128|curveperbi
P07106534A0160 |91 97|lengthmacolo
P07106534A0160 |8 11|way6T0
P07106534A0160 |111 114|man ne
P07106534A0160 |43 58|growth functionsphatases and 5
P07106534A0160 |78 83|curve171T0
P07106534A0160 |99 107|increasec aspect
P07106534A0160 |142 150|increase00008997
P07106534A0160 |154 157|rat2 W
P07107287A1083 |33 40|driverskaline 
P07107287A1083 |12 17|doses76 Co
P07107287A1083 |74 89|99Mo generators0008171T0000 Ph
P07107287A1083 |63 70|numberseotidas
P07107462A0202 |33 51|dissociation curvekaline phosphatase
P07107462A0202 |108 112|Hill of 
P07107462A0202 |79 94|training period71T0000 Pharmac
P07107462A0202 |4 13|steepness01606T007
P07107462A0202 |96 104|increaseogic asp
P07107462A0202 |115 116|nn
P07107773A0000 |138 146|subjectsa. P0000
P07107773A0000 |50 51|me
P07107773A0000 |257 275|gas chromatographyed when compared t
P07107773A0000 |325 339|ion monitoringslope (1.21 +/
P07107773A0000 |188 197|ingestionunction o
P07107773A0000 |112 118|plasmaneonat
P07107773A0000 |179 183|mealwn a
P07107773A0000 |349 396|trifluoroethyl-pentafluoropropionyl derivatives P00010943A0733 Flurazepam thus appears to be a
P07107773A0000 |41 45|acidhosp
P07107773A0000 |79 83|acid71T0
P07107773A0000 |220 236|amine precursorsK-depleted rats 
P07107773A0000 |162 173|consumptionSF [HCO3-] 
P07107773A0000 |282 310|resolution mass spectrometryols but still have a signifi
P07107773A0000 |201 210|deuteriumF PCO2 th
P07109788A0333 |17 25|patientsmparison
P07109788A0333 |54 62|vagotomynd 5-nuc
P07109788A0333 |67 79|pyloroplastydase P000081
P07109788A0333 |3 10|concept001606T
P07110999A0160 |55 67|incontinenced 5-nucleoti
P07110999A0160 |72 92|oculomotor paralysisP00008171T0000 Pharm
P07110999A0160 |30 39|disorders alkaline
P07110999A0160 |41 53|tetraparesishosphatases 
P07112320A0086 |34 37|ADAali
P07112320A0086 |64 68|timeotid
P07112320A0086 |0 32|CSF adenosine deaminase activityP00001606T0076 Comparison with a
P07112471A0639 |119 125|workerl hype
P07112471A0639 |56 63|workers 5-nucl
P07112471A0639 |92 101|factoriesacologic 
P07112471A0639 |160 167|factory CSF [H
P07112471A0639 |0 20|Histamine reactivityP00001606T0076 Compa
P07112654A0388 |70 80|prevalencee P0000817
P07112654A0388 |90 98|carriagermacolog
P07112654A0388 |124 138|hospital stafferbilirubinemi
P07112654A0388 |47 57|differencetases and 
P07112654A0388 |147 155|patients997A0472
P07113365A0737 |0 5|FicatP0000
P07113365A0737 |10 15|Bizou0076 
P07113365A0737 |79 89|Brattstrom71T0000 Ph
P07113365A0737 |62 75|surface angleleotidase P00
P07113365A0737 |129 136|methodsirubine
P07113365A0737 |27 38|depth indexith alkalin
P07113365A0737 |140 151|measurement P00008997A
P07113897A0285 |175 176|% 
P07113897A0285 |121 123|NShy
P07113897A0285 |211 222|correlation data of K-
P07113897A0285 |60 67|studiesucleoti
P07113897A0285 |114 115|%o
P07113897A0285 |157 158|%h
P07113897A0285 |249 255|groups displ
P07113897A0285 |178 179|po
P07113897A0285 |267 273|rest rmpared
P07113897A0285 |26 37|differenceswith alkali
P07113897A0285 |182 184|NSas
P07113897A0285 |301 302|pa
P07113897A0285 |41 43|EFho
P07113897A0285 |134 142|exercisenemia. P
P07113897A0285 |259 265|values when 
P07113897A0285 |117 118|pt
P07113897A0285 |282 292|exercise rols but st
P07113897A0285 |77 81|rest8171
P07113897A0285 |96 97|%o
P07114083A0153 |100 124|glucocerebrosidase level aspects of neonatal hyp
P07114083A0153 |29 38|remissionh alkalin
P07114083A0153 |129 142|disappearanceirubinemia. P
P07114083A0153 |42 49|Hodgkinosphata
P07114083A0153 |146 153|Gaucher8997A04
P07114083A0153 |79 92|normalization71T0000 Pharm
P07114083A0153 |6 18|MOPP therapy606T0076 Com
P07114083A0153 |52 59|disease and 5-
P07114083A0153 |156 161|cellsWhen 
P07116298A1079 |207 210|BCG th
P07116298A1079 |266 269|BCGomp
P07116298A1079 |247 255|patientser displ
P07116298A1079 |329 337|patientse (1.21 
P07116298A1079 |316 320|DTIC gre
P07116298A1079 |134 156|Corynebacterium parvumnemia. P00008997A0472 
P07116298A1079 |84 92|survival00 Pharm
P07116298A1079 |21 25|typeison
P07116298A1079 |115 123|patientsnatal hy
P07116298A1079 |293 299|monthsll hav
P07116298A1079 |188 196|patientsunction 
P07116298A1079 |218 224|monthsf K-de
P07116298A1079 |98 107|stage IVAic aspect
P07116298A1079 |173 179|monthsis sho
P07116298A1079 |232 238|monthsats ar
P07116298A1079 |351 357|months000109
P07116298A1079 |71 79|interval P000081
P07116298A1079 |38 45|therapye phosp
P07116298A1079 |272 276|DTICd to
P07116962A0299 |4 21|COP-PAWP gradient01606T0076 Compar
P07116962A0299 |97 102|edemagic a
P07116962A0299 |73 81|patients00008171
P07116962A0299 |53 58|shockand 5
P07119890T0000 |0 2|ReP0
P07119890T0000 |54 65|blood cellsnd 5-nucleo
P07119890T0000 |15 21|methodCompar
P07119890T0000 |38 46|labelinge phosph
P07119890T0000 |4 5|A0
P07119890T0000 |71 77|Tc-99m P0000
P07124743A1223 |70 81|measuremente P00008171
P07124743A1223 |418 428|absorptionrug with t
P07124743A1223 |391 396|hands be a
P07124743A1223 |40 54|As2O3 exposurephosphatases a
P07124743A1223 |438 443|lungs dose
P07124743A1223 |291 313|microgram/g creatininetill have a significan
P07124743A1223 |155 165|evaluation When CSF 
P07124743A1223 |21 38|glassware factoryison with alkalin
P07124743A1223 |113 126|determinationeonatal hyper
P07124743A1223 |178 197|mouth contaminationown as a function o
P07124743A1223 |366 372|intakeluraze
P07124743A1223 |201 208|arsenicF PCO2 
P07124743A1223 |279 285|levelsntrols
P07124743A1223 |230 239|workshift rats are
P07124743A1223 |10 15|study0076 
P07124743A1223 |169 173|hand3-] 
P07124743A1223 |138 145|arsenica. P000
P07124743A1223 |100 107|arsenic aspect
P07125064T0000 |101 120|Schistosoma mansoniaspects of neonatal
P07125064T0000 |54 61|monkeysnd 5-nu
P07125064T0000 |76 97|Schistosoma japonicum08171T0000 Pharmacolo
P07125064T0000 |33 41|findingskaline p
P07125238T0000 |33 38|entrykalin
P07125238T0000 |42 55|blood vesselsosphatases an
P07125238T0000 |21 25|siteison
P07125238T0000 |4 13|pia mater01606T007
P07125238T0000 |81 87|systemT0000 
P07126067T0000 |49 54|feverses a
P07126067T0000 |13 25|reproduction6 Comparison
P07126067T0000 |58 69|Bali cattle-nucleotida
P07126413A0000 |68 73|drugsase P
P07126413A0000 |12 27|delivery system76 Comparison w
P07126413A0000 |150 155|resinA0472
P07126413A0000 |120 127|coating hyperb
P07126413A0000 |157 167|Eudragit Shen CSF [H
P07126413A0000 |112 116|siteneon
P07126413A0000 |81 86|colonT0000
P07130335A1081 |186 191|ng/dl func
P07130335A1081 |75 78|day008
P07130335A1081 |67 72|timesdase 
P07130335A1081 |22 52|dopamine agonist bromocriptineson with alkaline phosphatases
P07130335A1081 |58 60|mg-n
P07130335A1081 |131 151|plasma 18-OHB levelsubinemia. P00008997A
P07130335A1081 |0 14|AdministrationP00001606T0076
P07130335A1081 |103 104|Pp
P07130335A1081 |85 89|days0 Ph
P07132408A0387 |36 58|magnesium cardioplegiaine phosphatases and 5
P07132408A0387 |11 15|time076 
P07134924A0640 |16 21|typesompar
P07134924A0640 |25 38|malformations with alkalin
P07134924A0640 |44 55|eye defectsphatases an
P07134924A0640 |65 72|coelomstidase 
P07135112T0000 |0 6|RepairP00001
P07135112T0000 |21 27|defectison w
P07135112T0000 |41 44|leghos
P07135112T0000 |70 74|flape P0
P07136524A0180 |17 27|literaturemparison w
P07136524A0180 |57 64|tumours5-nucle
P07136524A0180 |73 81|contrast00008171
P07136524A0180 |113 125|osteosarcomaeonatal hype
P07136524A0180 |97 104|tumoursgic asp
P07136524A0180 |140 164|retinoblastoma survivors P00008997A0472 When CSF
P07136569A0000 |87 96|scoliosisPharmacol
P07136569A0000 |25 40|school children with alkaline 
P07136569A0000 |10 16|Sweden0076 C
P07136569A0000 |121 125|ageshype
P07136569A0000 |104 108|yearects
P07136569A0000 |3 8|Malmo00160
P07136569A0000 |53 58|yearsand 5
P07136569A0000 |138 143|yearsa. P0
P07137927A0000 |7 11|past06T0
P07137927A0000 |13 23|immunology6 Comparis
P07137927A0000 |60 68|serologyucleotid
P07137927A0000 |27 36|Singaporeith alkal
P07137927A0000 |109 117|diseasesof neona
P07137927A0000 |77 86|diagnosis8171T0000
P07140060T0000 |35 42|patellaline ph
P07140060T0000 |16 27|dislocationomparison w
P07140493A1045 |119 133|acid secretionl hyperbilirub
P07140493A1045 |24 33|secretionn with al
P07140493A1045 |108 109|% 
P07140493A1045 |62 69|stomachleotida
P07140493A1045 |83 87|rate000 
P07140493A1045 |37 48|bicarbonatene phosphat
P07140493A1045 |5 10|study1606T
P07141130A0615 |239 244|cells no l
P07141130A0615 |165 182|cells/100 microns[HCO3-] is shown 
P07141130A0615 |269 275|groupsared t
P07141130A0615 |194 200|mucosan of C
P07141130A0615 |144 150|number008997
P07141130A0615 |209 220|mean heighthe data of 
P07141130A0615 |107 112|cellss of 
P07141130A0615 |13 23|evaluation6 Comparis
P07141130A0615 |114 115|po
P07141130A0615 |53 61|increaseand 5-nu
P07141130A0615 |69 75|numberse P00
P07143347T0000 |0 6|CrampsP00001
P07143347T0000 |25 34|disorders with alk
P07147622T0000 |35 41|cattleline p
P07147622T0000 |16 31|storage diseaseomparison with 
P07149047A0260 |69 77|Torr/cm2se P0000
P07149047A0260 |12 23|dog vessels76 Comparis
P07149047A0260 |61 62|Xc
P07149047A0260 |33 37|Q/Dkkali
P07149303T0000 |16 22|actionompari
P07149303T0000 |79 83|cats71T0
P07149303T0000 |26 35|lidocainewith alka
P07149303T0000 |39 42|CNS ph
P07149303T0000 |67 75|behaviordase P00
P07149303T0000 |54 62|activitynd 5-nuc
P07154928T0001 |0 12|ModificationP00001606T00
P07154928T0001 |24 34|resorptionn with alk
P07154928T0001 |49 56|therapyses and
P07155579T0001 |33 42|fertilitykaline ph
P07155579T0001 |13 28|bacteriospermia6 Comparison wi
P07158726T0001 |0 7|TriumphP000016
P07158726T0001 |29 35|policyh alka
P07160491A0547 |78 86|increase171T0000
P07160491A0547 |90 97|LD50/30rmacolo
P07160491A0547 |15 21|effectCompar
P07160491A0547 |107 128|dose reduction factors of neonatal hyperbi
P07162146A0000 |19 34|ultrafiltrationarison with alk
P07162146A0000 |4 15|application01606T0076 
P07162146A0000 |96 111|ethylene glycologic aspects of
P07162146A0000 |125 143|gas chromatographyrbilirubinemia. P0
P07162146A0000 |78 92|quantification171T0000 Pharm
P07162146A0000 |64 73|detectionotidase P
P07162146A0000 |38 56|sample preparatione phosphatases and
P07162146A0000 |115 121|plasmanatal 
P07165767T0000 |0 12|MastocytosisP00001606T00
P07168531T0001 |49 55|cattleses an
P07168531T0001 |28 36|parasiteth alkal
P07168531T0001 |60 67|Senegalucleoti
P07168531T0001 |6 24|Onchocerca species606T0076 Compariso
P07169630A0983 |68 78|conditionsase P00008
P07169630A0983 |104 114|complexityects of ne
P07169630A0983 |134 138|typenemi
P07169630A0983 |26 33|absencewith al
P07169630A0983 |122 126|taskyper
P07169630A0983 |48 59|differencesases and 5-
P07172690A0547 |274 287|% restrictionto controls b
P07172690A0547 |53 69|energy transportand 5-nucleotida
P07172690A0547 |126 138|calcium pumpbilirubinemi
P07172690A0547 |145 151|ATPase08997A
P07172690A0547 |214 222|decreaseta of K-
P07172690A0547 |300 310|blood flow a signifi
P07172690A0547 |183 186|SPRs a
P07172690A0547 |91 113|creatine phosphokinasemacologic aspects of n
P07172690A0547 |240 250|propertiesno longer 
P07172690A0547 |43 49|systemsphata
P07172690A0547 |11 17|factor076 Co
P07172690A0547 |258 268|myocardiumd when com
P07172690A0547 |23 35|disturbanceson with alka
P07172690A0547 |140 142|Ca P
P07172690A0547 |172 181|reticulum is shown
P07172690A0547 |71 89|creatine phosphate P00008171T0000 Ph
P07173729A0000 |139 144|mucus. P00
P07173729A0000 |9 26|penetration testsT0076 Comparison 
P07173729A0000 |56 61|mucus 5-nu
P07173729A0000 |120 125|sperm hype
P07173729A0000 |81 86|orderT0000
P07173729A0000 |36 41|spermine p
P07173729A0000 |100 111|interaction aspects of
P07174046T0000 |0 16|Vibrio fluvialisP00001606T0076 C
P07174046T0000 |37 48|Maharashtrane phosphat
P07174046T0000 |18 32|group F vibrioparison with a
P07174122A0000 |0 21|Serum creatine kinaseP00001606T0076 Compar
P07174122A0000 |23 26|SCKon 
P07174122A0000 |111 128|bicycle ergometry neonatal hyperbi
P07174122A0000 |135 147|lifting taskemia. P00008
P07174122A0000 |64 74|laboratoryotidase P0
P07174122A0000 |96 107|performanceogic aspect
P07174122A0000 |48 56|subjectsases and
P07174437A0181 |0 9|OrganismsP00001606
P07174437A0181 |37 44|bobcatsne phos
P07174437A0181 |64 72|countiesotidase 
P07175474A0102 |116 121|deathatal 
P07175474A0102 |148 156|official97A0472 
P07175474A0102 |106 112|mannerts of 
P07175474A0102 |13 18|death6 Com
P07175474A0102 |83 91|findings000 Phar
P07175474A0102 |162 172|difficultySF [HCO3-]
P07175474A0102 |4 9|cause01606
P07179412A1131 |51 53|USs 
P07179412A1131 |28 32|headth a
P07179412A1131 |36 46|populationine phosph
P07179412A1131 |56 57|X 
P07179412A1131 |19 23|costaris
P07180901A0539 |152 160|necrosis472 When
P07180901A0539 |30 40|blood flow alkaline 
P07180901A0539 |121 130|ibuprofenhyperbili
P07180901A0539 |74 98|prostaglandin synthetase0008171T0000 Pharmacolog
P07180901A0539 |110 117|effectsf neona
P07181985A0107 |51 59|mg/40 mls and 5-
P07181985A0107 |10 28|mg mitomycin/20 ml0076 Comparison wi
P07181985A0107 |122 130|catheteryperbili
P07181985A0107 |107 114|bladders of ne
P07181985A0107 |39 44|water phos
P07181985A0107 |179 182|minwn 
P07181985A0107 |70 75|watere P00
P07182523A0462 |71 88|SOA concentration P00008171T0000 P
P07182523A0462 |37 40|SOAne 
P07182523A0462 |62 67|timesleoti
P07182523A0462 |5 11|groups1606T0
P07183576A0157 |169 181|micrograms/g3-] is shown
P07183576A0157 |118 123|fluidal hy
P07183576A0157 |19 32|concentrationarison with a
P07183576A0157 |155 163|synovium When CS
P07183576A0157 |82 95|micrograms/ml0000 Pharmaco
P07183576A0157 |219 231|micrograms/g K-depleted 
P07183576A0157 |63 72|operationeotidase 
P07183576A0157 |183 185|SDs 
P07183576A0157 |143 145|SD00
P07183576A0157 |97 99|SDgi
P07183576A0157 |129 141|micrograms/girubinemia. 
P07183576A0157 |254 258|bonelace
P07183576A0157 |233 235|SDts
P07183576A0157 |36 50|flucloxacillinine phosphatas
P07183576A0157 |206 210|bone2 th
P07184375T0001 |68 70|VMas
P07184375T0001 |23 34|vincristineon with alk
P07184375T0001 |132 140|lymphomabinemia.
P07184375T0001 |74 98|combination chemotherapy0008171T0000 Pharmacolog
P07184375T0001 |14 19|study Comp
P07184375T0001 |54 66|prednisolonend 5-nucleot
P07184375T0001 |36 48|methotrexateine phosphat
P07184375T0001 |71 72|P 
P07184598T0001 |22 37|hyperthyroidismson with alkali
P07184598T0001 |9 18|secretionT0076 Com
P07184774T0000 |0 14|Re-examinationP00001606T0076
P07184774T0000 |22 32|ED01 studyson with a
P07184795A0517 |86 91|liter Phar
P07184795A0517 |13 27|determinations6 Comparison w
P07184795A0517 |81 85|I.U.T000
P07184795A0517 |46 64|serum CPK activityatases and 5-nucle
P07184795A0517 |33 40|controlkaline 
P07190627T0000 |19 48|plasminogen activator releasearison with alkaline phosphat
P07190627T0000 |10 15|study0076 
P07190627T0000 |63 69|agentseotida
P07190627T0000 |95 102|dog leglogic a
P07190869A0316 |0 4|CDDPP000
P07190869A0316 |27 32|agentith a
P07190869A0316 |50 58|lymphomaes and 5
P07191183A0505 |0 9|TreatmentP00001606
P07191183A0505 |107 113|lipidss of n
P07191183A0505 |13 24|meat muscle6 Compariso
P07191183A0505 |91 103|autoxidationmacologic as
P07191183A0505 |83 87|rate000 
P07191183A0505 |29 30|Vh
P07191183A0505 |38 39|se
P07191804A0000 |119 120|hl
P07191804A0000 |13 21|response6 Compar
P07191804A0000 |135 143|activityemia. P0
P07191804A0000 |105 111|coursects of
P07191804A0000 |161 168|h sleepCSF [HC
P07191804A0000 |40 61|bicycle exercise testphosphatases and 5-nu
P07191804A0000 |85 91|cadets0 Phar
P07191972A0391 |103 108|phasepects
P07191972A0391 |14 25|temperature Comparison
P07191972A0391 |67 74|coolingdase P0
P07191972A0391 |47 56|responsestases and
P07191972A0391 |32 41|degrees Clkaline p
P07192369T0000 |2 8|method000160
P07192369T0000 |75 89|administration008171T0000 Ph
P07192369T0000 |126 130|ratsbili
P07192369T0000 |47 55|toxicitytases an
P07192369T0000 |93 115|l-alpha-acetylmethadolcologic aspects of neo
P07192722A0682 |171 173|CL] 
P07192722A0682 |26 43|parathyroidectomywith alkaline pho
P07192722A0682 |106 111|groupts of
P07192722A0682 |72 89|serum iPTH levelsP00008171T0000 Ph
P07192722A0682 |60 68|decreaseucleotid
P07192722A0682 |200 201|pS
P07192722A0682 |114 118|PMNsonat
P07192722A0682 |127 134|abilityilirubi
P07192722A0682 |146 150|sera8997
P07192722A0682 |100 102|CL a
P07192722A0682 |138 143|groupa. P0
P07192722A0682 |184 188|PMNs a f
P07194905A0332 |0 3|TCZP00
P07194905A0332 |45 55|indicationhatases an
P07194905A0332 |108 118|hemorrhage of neonat
P07194905A0332 |132 148|brain maturationbinemia. P000089
P07194905A0332 |59 74|tissue necrosisnucleotidase P0
P07195615A0087 |118 130|accumulational hyperbili
P07195615A0087 |44 52|increasephatases
P07195615A0087 |134 136|Cdne
P07195615A0087 |60 68|durationucleotid
P07195615A0087 |93 104|associationcologic asp
P07195615A0087 |24 28|ratsn wi
P07195615A0087 |177 183|regionhown a
P07195615A0087 |72 89|Cd administrationP00008171T0000 Ph
P07195615A0087 |4 10|number01606T
P07195615A0087 |191 196|braintion 
P07195615A0087 |154 158|bulb2 Wh
P07195880A0621 |5 9|test1606
P07195880A0621 |43 48|meanssphat
P07195880A0621 |58 65|leprosy-nucleo
P07202224A0452 |32 41|vis-a-vislkaline p
P07202224A0452 |66 76|injectionsidase P000
P07202224A0452 |52 57|males and 
P07202224A0452 |129 136|femalesirubine
P07202224A0452 |107 121|attractivenesss of neonatal 
P07202224A0452 |80 82|TP1T
P07202224A0452 |96 105|castratesogic aspe
P07202224A0452 |4 15|preferences01606T0076 
P07202525A0200 |137 145|stimulusia. P000
P07202525A0200 |24 29|lightn wit
P07202525A0200 |109 116|secondsof neon
P07202525A0200 |94 99|shockologi
P07202525A0200 |73 80|stimuli0000817
P07202525A0200 |50 57|secondses and 
P07202525A0200 |5 10|trial1606T
P07202525A0200 |34 40|buzzeraline 
P07202919A0142 |0 5|UlcerP0000
P07202919A0142 |78 88|ulcer scar171T0000 P
P07202919A0142 |57 61|week5-nu
P07202919A0142 |37 44|stomachne phos
P07202919A0142 |22 29|angulusson wit
P07202919A0142 |96 105|42nd weekogic aspe
P07203410T0000 |0 13|Family visitsP00001606T007
P07203410T0000 |60 74|state hospitalucleotidase P0
P07203410T0000 |18 29|involvementparison wit
P07203410T0000 |46 54|patientsatases a
P07203410T0000 |33 42|treatmentkaline ph
P07205120T0000 |49 63|ECG wave formsses and 5-nucl
P07205120T0000 |14 21|overlay Compar
P07205120T0000 |36 45|amplitudeine phosp
P07205967T0000 |54 62|responsend 5-nuc
P07205967T0000 |107 114|partners of ne
P07205967T0000 |8 16|reaction6T0076 C
P07205967T0000 |43 50|partnersphatas
P07205967T0000 |66 77|improvementidase P0000
P07208984A0000 |85 103|tomography studies0 Pharmacologic as
P07208984A0000 |56 65|MAA brain 5-nucleo
P07208984A0000 |47 54|albumintases a
P07208984A0000 |105 107|CTct
P07208984A0000 |157 165|diseaseshen CSF 
P07208984A0000 |130 138|patientsrubinemi
P07208984A0000 |0 5|BrainP0000
P07214230T0000 |0 10|InhibitionP00001606T
P07214230T0000 |79 91|pitch canker71T0000 Phar
P07214230T0000 |14 38|Fusarium moniliforme var Comparison with alkalin
P07214230T0000 |65 70|agenttidas
P07214230T0000 |40 52|subglutinansphosphatases
P07214230T0000 |100 130|soil bacterium Arthrobacter sp aspects of neonatal hyperbili
P07214665A0000 |168 173|womenO3-] 
P07214665A0000 |73 81|triazeno00008171
P07214665A0000 |14 25|combination Comparison
P07214665A0000 |83 94|vincristine000 Pharmac
P07214665A0000 |129 139|prednisoneirubinemia
P07214665A0000 |148 149|P9
P07214665A0000 |29 63|fluorouracil imidazole carboxamideh alkaline phosphatases and 5-nucl
P07214665A0000 |141 145|FIVBP000
P07214665A0000 |96 123|bis-chloroethyl nitrosoureaogic aspects of neonatal hy
P07214665A0000 |190 203|breast cancerction of CSF 
P07217329A0000 |205 214|biofluidsO2 the da
P07217329A0000 |107 118|metabolitess of neonat
P07217329A0000 |85 89|LAAM0 Ph
P07217329A0000 |187 200|dinormethadolfunction of C
P07217329A0000 |291 302|UV detectortill have a
P07217329A0000 |63 83|alpha-acetylmethadoleotidase P00008171T0
P07217329A0000 |242 256|chromatography longer displa
P07217329A0000 |120 137|noracetylmethadol hyperbilirubinem
P07217329A0000 |278 284|columnontrol
P07217329A0000 |310 312|nmca
P07217329A0000 |43 56|determinationsphatases and
P07217329A0000 |160 168|methadol CSF [HC
P07217329A0000 |2 8|method000160
P07217329A0000 |139 158|dinoracetylmethadol. P00008997A0472 Wh
P07217329A0000 |170 181|normethadol-] is shown
P07217523A0364 |0 7|ResultsP000016
P07217523A0364 |122 133|recognitionyperbilirub
P07217523A0364 |74 81|voicing0008171
P07217523A0364 |15 31|recognition taskComparison with 
P07217523A0364 |83 91|position000 Phar
P07217523A0364 |53 60|effectsand 5-n
P07217523A0364 |96 109|vowel contextogic aspects 
P07218008T0000 |66 71|areasidase
P07218008T0000 |195 200|areas of C
P07218008T0000 |91 108|Aotus trivirgatusmacologic aspects
P07218008T0000 |30 37|neurons alkali
P07218008T0000 |126 136|comparisonbilirubine
P07218008T0000 |79 89|owl monkey71T0000 Ph
P07218008T0000 |7 26|response properties06T0076 Comparison 
P07219297T0000 |10 18|approach0076 Com
P07219297T0000 |45 54|allergenshatases a
P07219297T0000 |26 41|standardizationwith alkaline p
P07219821T0028 |24 38|considerationsn with alkalin
P07221179A0156 |17 21|fallmpar
P07221179A0156 |162 169|minutesSF [HCO
P07221179A0156 |95 109|administrationlogic aspects 
P07221179A0156 |123 128|nadirperbi
P07221179A0156 |135 138|minemi
P07221179A0156 |52 65|GABA decrease and 5-nucleo
P07221179A0156 |25 37|GABA content with alkali
P07221179A0156 |81 84|minT00
P07221354T0000 |0 6|TheoryP00001
P07221354T0000 |11 23|applications076 Comparis
P07221354T0000 |43 50|summarysphatas
P07221354T0000 |27 39|pulse dosingith alkaline
P07221354T0000 |58 67|symposium-nucleoti
P07225300A0968 |116 127|sensitivityatal hyperb
P07225300A0968 |92 99|effectsacologi
P07225300A0968 |107 111|drugs of
P07225300A0968 |62 69|respectleotida
P07225300A0968 |28 35|neonateth alka
P07225300A0968 |6 13|results606T007
P07225300A0968 |82 88|nature0000 P
P07225300A0968 |53 58|adultand 5
P07225540A0193 |16 19|gasomp
P07225540A0193 |92 106|plasma samplesacologic aspec
P07225540A0193 |134 144|techniquesnemia. P00
P07225540A0193 |36 69|electron capture detection methodine phosphatases and 5-nucleotida
P07226440T0000 |50 57|failurees and 
P07226440T0000 |65 68|rattid
P07226440T0000 |4 16|hemodynamics01606T0076 C
P07228955A0000 |55 76|theophylline analysisd 5-nucleotidase P000
P07228955A0000 |8 15|authors6T0076 
P07228955A0000 |130 140|metaboliterubinemia.
P07228955A0000 |94 114|1,7-dimethylxanthineologic aspects of ne
P07228955A0000 |39 51|interference phosphatase
P07228955A0000 |144 152|caffeine008997A0
P07228955A0000 |80 92|paraxanthine1T0000 Pharm
P07234308A0121 |33 37|CHOPkali
P07234308A0121 |25 31|C-MOPP with 
P07234308A0121 |125 132|diseaserbiliru
P07234308A0121 |88 93|casesharma
P07234308A0121 |60 75|remission ratesucleotidase P00
P07234308A0121 |6 19|drug regimens606T0076 Comp
P07234308A0121 |42 47|BACOPospha
P07234308A0121 |113 117|cureeona
P07234755A0838 |34 42|Hematrakaline ph
P07234755A0838 |4 13|monocytes01606T007
P07234755A0838 |55 56|%d
P07234974T0000 |26 39|Jat dentitionwith alkaline
P07234974T0000 |14 22|features Compari
P07235317T0000 |9 17|accuracyT0076 Co
P07235317T0000 |44 62|Phadebas RAST testphatases and 5-nuc
P07235317T0000 |29 36|versionh alkal
P07235355A0462 |68 73|testsase P
P07235355A0462 |56 64|sequence 5-nucle
P07235355A0462 |13 21|subjects6 Compar
P07235355A0462 |134 152|density dependencenemia. P00008997A0
P07235355A0462 |120 130|flow rates hyperbili
P07235355A0462 |27 31|COPDith 
P07235355A0462 |94 95|%o
P07235355A0462 |110 116|changef neon
P07236351A0812 |19 27|recoveryarison w
P07236351A0812 |90 99|areas CA3rmacologi
P07236351A0812 |40 43|EEGpho
P07236351A0812 |104 107|CA4ect
P07236351A0812 |82 86|loss0000
P07237123T0000 |103 107|bulbpect
P07237123T0000 |56 69|nerve volleys 5-nucleotida
P07237123T0000 |28 42|unit responsesth alkaline ph
P07237123T0000 |86 92|turtle Pharm
P07237560A1038 |100 105|genes aspe
P07237560A1038 |74 84|inactivity0008171T00
P07237560A1038 |31 39|sequencealkaline
P07237560A1038 |10 19|deletions0076 Comp
P07237560A1038 |107 119|substitutions of neonata
P07237560A1038 |62 66|tRNAleot
P07237560A1038 |135 142|portionemia. P
P07237560A1038 |185 195|gene unitsa function
P07237560A1038 |159 175|Hind III linkersn CSF [HCO3-] is
P07237560A1038 |206 219|transcription2 the data of
P07237817T0000 |0 16|Cross reactivityP00001606T0076 C
P07237817T0000 |20 40|theophylline RIA kitrison with alkaline 
P07240343A0000 |51 54|days a
P07240343A0000 |24 28|i.v.n wi
P07240343A0000 |75 79|p.c.0081
P07240343A0000 |58 73|post conception-nucleotidase P
P07240343A0000 |43 47|ratsspha
P07240343A0000 |0 12|Strontium-90P00001606T00
P07242929T0001 |34 42|activityaline ph
P07242929T0001 |116 123|methodsatal hy
P07242929T0001 |56 67|extremities 5-nucleoti
P07242929T0001 |0 9|RecordingP00001606
P07243380A0327 |115 119|torrnata
P07243380A0327 |73 76|P50000
P07243380A0327 |61 69|decreasecleotida
P07243380A0327 |43 44|Ps
P07243380A0327 |12 20|acidosis76 Compa
P07243380A0327 |6 8|hr60
P07247059A0775 |0 16|Catheter transitP00001606T0076 C
P07247059A0775 |27 35|responseith alka
P07247059A0775 |41 54|step increasehosphatases a
P07247059A0775 |210 211|se
P07247059A0775 |86 87|s 
P07247059A0775 |113 117|centeona
P07247059A0775 |58 71|concentration-nucleotidase
P07247059A0775 |161 169|catheterCSF [HCO
P07247059A0775 |222 224|N2de
P07247059A0775 |101 108|cent-90aspects
P07247059A0775 |136 148|transit timemia. P000089
P07249497A0688 |85 90|women0 Pha
P07249497A0688 |172 180|patients is show
P07249497A0688 |197 204|coursesf CSF P
P07249497A0688 |133 136|PPIine
P07249497A0688 |44 56|estrogen PPIphatases and
P07249497A0688 |98 103|risksic as
P07249497A0688 |6 11|women606T0
P07249497A0688 |117 129|estrogen usetal hyperbil
P07249544A0343 |34 62|serum creatine kinase levelsaline phosphatases and 5-nuc
P07249544A0343 |9 20|temperatureT0076 Compa
P07249544A0343 |82 90|patients0000 Pha
P07249660T0000 |0 13|DeterminationP00001606T007
P07249660T0000 |24 38|distensibilityn with alkalin
P07249660T0000 |47 57|variationstases and 
P07249660T0000 |70 82|hypertensione P00008171T
P07249895A0177 |205 214|inhibitorO2 the da
P07249895A0177 |293 301|recoveryll have 
P07249895A0177 |23 37|prostaglandinson with alkali
P07249895A0177 |218 241|prostaglandin synthesisf K-depleted rats are n
P07249895A0177 |148 160|indomethacin97A0472 When
P07249895A0177 |271 282|esophagitised to contr
P07249895A0177 |85 100|LES hypotension0 Pharmacologic
P07249895A0177 |117 126|treatmenttal hyper
P07249895A0177 |257 267|productioned when co
P07249895A0177 |54 65|esophagitisnd 5-nucleo
P07249895A0177 |135 142|animalsemia. P
P07249895A0177 |15 19|roleComp
P07249895A0177 |166 179|micrograms/kgHCO3-] is sho
P07251564A0569 |69 78|diagnosisse P00008
P07251564A0569 |22 28|sampleson wi
P07251564A0569 |13 14|%6
P07251564A0569 |99 112|ASDC nosologyc aspects of 
P07252346A0223 |41 48|problemhosphat
P07252346A0223 |11 20|technique076 Compa
P07253335T0000 |68 74|strokease P0
P07253335T0000 |43 48|onsetsphat
P07253335T0000 |78 90|stroke-prone171T0000 Pha
P07253335T0000 |11 35|prostaglandin inhibitors076 Comparison with alka
P07253335T0000 |118 122|ratsal h
P07253335T0000 |52 63|proteinuria and 5-nucl
P07253335T0000 |0 7|EffectsP000016
P07256543A0814 |68 76|presencease P000
P07256543A0814 |265 271|injurycompar
P07256543A0814 |150 156|sputumA0472 
P07256543A0814 |104 109|burnsects 
P07256543A0814 |218 231|airway injuryf K-depleted 
P07256543A0814 |36 44|criteriaine phos
P07256543A0814 |8 13|study6T007
P07256543A0814 |111 135|carboxyhemoglobin levels neonatal hyperbilirubin
P07256543A0814 |49 66|inhalation injuryses and 5-nucleot
P07256543A0814 |168 180|space injuryO3-] is show
P07256543A0814 |204 212|patientsCO2 the 
P07259325A0394 |0 8|SurvivalP0000160
P07259325A0394 |73 82|diagnosis00008171T
P07259325A0394 |65 69|datetida
P07259325A0394 |46 51|onsetatase
P07259325A0394 |38 42|datee ph
P07260389A0221 |34 41|blockeraline p
P07260389A0221 |80 91|development1T0000 Phar
P07260389A0221 |125 134|serotoninrbilirubi
P07260389A0221 |45 64|serotonin receptorshatases and 5-nucle
P07260389A0221 |18 23|mg/kgparis
P07260389A0221 |115 121|effectnatal 
P07260389A0221 |0 12|MethisergideP00001606T00
P07260987A0336 |138 145|rabbitsa. P000
P07260987A0336 |129 134|hoursirubi
P07260987A0336 |78 82|hour171T
P07260987A0336 |29 56|disposition phase t1/2 betah alkaline phosphatases and
P07260987A0336 |164 174|impairment [HCO3-] i
P07260987A0336 |4 20|plasma half-life01606T0076 Compa
P07260987A0336 |112 120|functionneonatal
P07260987A0336 |86 93|rabbits Pharma
P07262239T0000 |0 7|EffectsP000016
P07262239T0000 |27 38|deprivationith alkalin
P07262239T0000 |42 53|developmentosphatases 
P07262239T0000 |95 98|catlog
P07262239T0000 |76 87|projections08171T0000 
P07262625A0000 |0 22|Corticosteroid therapyP00001606T0076 Compari
P07262625A0000 |223 236|Giardia murisepleted rats 
P07262625A0000 |253 260|effectsplaced 
P07262625A0000 |113 139|host parasite relationshipeonatal hyperbilirubinemia
P07262625A0000 |297 306|parasitesave a sig
P07262625A0000 |264 279|corticosteroids compared to co
P07262625A0000 |331 337|course(1.21 
P07262625A0000 |90 99|mechanismrmacologi
P07262625A0000 |314 323|intestinely greate
P07262625A0000 |287 293|numberut sti
P07262625A0000 |51 59|patientss and 5-
P07262625A0000 |154 162|steroids2 When C
P07262625A0000 |203 221|protozoal parasitePCO2 the data of K
P07262625A0000 |351 360|infection00010943A
P07262625A0000 |65 81|occult infectiontidase P00008171
P07263374T0000 |38 51|pneumonectomye phosphatase
P07263374T0000 |24 31|puppiesn with 
P07263374T0000 |7 20|lung function06T0076 Compa
P07263421A0351 |5 9|Sair1606
P07263421A0351 |30 38|capacity alkalin
P07263421A0351 |63 70|controleotidas
P07263421A0351 |14 17|So2 Co
P07263421A0351 |56 57|% 
P07263745T0000 |10 31|Charnley arthroplasty0076 Comparison with 
P07263745T0000 |44 53|procedurephatases 
P07264787A0351 |114 115|%o
P07264787A0351 |72 83|thyroiditisP00008171T0
P07264787A0351 |121 136|hyperthyroidismhyperbilirubine
P07264787A0351 |147 148|%9
P07264787A0351 |11 19|patients076 Comp
P07264787A0351 |52 60|evidence and 5-n
P07266969A0246 |50 59|Tamoxifenes and 5-
P07266969A0246 |4 16|relationship01606T0076 C
P07266969A0246 |36 46|propertiesine phosph
P07266969A0246 |64 88|breast cancer managementotidase P00008171T0000 P
P07267675A0000 |84 90|number00 Pha
P07267675A0000 |28 41|cephalosporinth alkaline p
P07267675A0000 |43 46|CGPsph
P07267675A0000 |107 115|patientss of neo
P07267675A0000 |129 139|infectionsirubinemia
P07268828A0000 |153 174|solid-phase particles72 When CSF [HCO3-] i
P07268828A0000 |28 41|determinationth alkaline p
P07268828A0000 |45 50|serumhatas
P07268828A0000 |71 82|propranolol P00008171T
P07268828A0000 |54 67|plasma levelsnd 5-nucleoti
P07268828A0000 |214 220|tracerta of 
P07268828A0000 |199 210|propranololCSF PCO2 th
P07268828A0000 |117 128|propranololtal hyperbi
P07268828A0000 |2 19|fluoroimmunoassay0001606T0076 Comp
P07268828A0000 |103 113|antibodiespects of n
P07270163A0684 |222 230|controlsdepleted
P07270163A0684 |130 135|layerrubin
P07270163A0684 |188 195|vesselsunction
P07270163A0684 |143 148|villi00089
P07270163A0684 |214 217|CNFta 
P07270163A0684 |27 38|projectionsith alkalin
P07270163A0684 |99 108|structurec aspects
P07270163A0684 |80 83|CNF1T0
P07270163A0684 |157 163|lininghen CS
P07270991A0149 |32 45|grass specieslkaline phosp
P07270991A0149 |5 20|pollen allergen1606T0076 Compa
P07270991A0149 |109 115|valuesof neo
P07270991A0149 |71 78|results P00008
P07274042A0249 |85 93|patients0 Pharma
P07274042A0249 |0 3|DMIP00
P07274042A0249 |61 66|groupcleot
P07274042A0249 |17 31|concentrationsmparison with 
P07274428A0000 |137 153|cholecystographyia. P00008997A04
P07274428A0000 |158 169|Bengal pinken CSF [HCO
P07274428A0000 |179 187|affinitywn as a 
P07274428A0000 |297 308|liver cellsave a signi
P07274428A0000 |245 259|indigo-carminenger displaced
P07274428A0000 |211 224|RCA triombrin data of K-de
P07274428A0000 |119 128|bilignostl hyperbi
P07274428A0000 |290 292|PMst
P07274428A0000 |21 32|experimentsison with a
P07274428A0000 |114 117|RCAona
P07274428A0000 |279 288|membranesntrols bu
P07274428A0000 |73 79|anions000081
P07274428A0000 |98 112|contrast agentic aspects of 
P07274482A0000 |68 79|selectivityase P000081
P07274482A0000 |13 20|neurons6 Compa
P07274482A0000 |120 125|sound hype
P07274482A0000 |108 116|movement of neon
P07274482A0000 |147 155|movement997A0472
P07274482A0000 |89 104|afterdischargesarmacologic asp
P07274482A0000 |28 31|catth 
P07274482A0000 |179 184|deg/swn as
P07274482A0000 |131 139|velocityubinemia
P07274482A0000 |50 54|bodyes a
P07274505A0660 |3 11|controls001606T0
P07274505A0660 |25 36|differences with alkal
P07276210T0000 |0 5|AssayP0000
P07276210T0000 |47 58|blood spotstases and 5
P07276210T0000 |30 37|trypsin alkali
P07276210T0000 |9 14|serumT0076
P07276210T0000 |73 82|detection00008171T
P07276210T0000 |93 101|fibrosiscologic 
P07277222A1391 |186 198|interactions function of
P07277222A1391 |77 87|oscillator8171T0000 
P07277222A1391 |47 57|motor unittases and 
P07277222A1391 |8 13|waves6T007
P07277222A1391 |111 121|occurrence neonatal 
P07277222A1391 |159 168|existencen CSF [HC
P07278104T0001 |0 25|Leukocyte enzyme activityP00001606T0076 Comparison
P07278104T0001 |30 67|blood lymphocyte blast transformation alkaline phosphatases and 5-nucleoti
P07278104T0001 |79 89|bronchitis71T0000 Ph
P07278578T0001 |35 42|Hodgkinline ph
P07278578T0001 |8 14|status6T0076
P07278578T0001 |45 52|diseasehatases
P07278578T0001 |18 30|chemotherapyparison with
P07280654A0000 |19 22|HBEari
P07280654A0000 |64 80|averaging methodotidase P0000817
P07280654A0000 |45 56|applicationhatases and
P07280654A0000 |3 13|literature001606T007
P07282444A0075 |59 65|tumournucleo
P07282444A0075 |11 16|cases076 C
P07282444A0075 |43 51|approachsphatase
P07282444A0075 |108 113|shunt of n
P07282444A0075 |77 82|cases8171T
P07282552A0990 |103 109|tissuepects 
P07282552A0990 |129 142|subepicardiumirubinemia. P
P07282552A0990 |25 31|tissue with 
P07282552A0990 |111 116|ratio neon
P07282552A0990 |86 90|zone Pha
P07282552A0990 |3 10|Group V001606T
P07282552A0990 |155 169|subendocardium When CSF [HCO
P07282943A0097 |205 212|tensionO2 the 
P07282943A0097 |165 172|changes[HCO3-]
P07282943A0097 |90 97|controlrmacolo
P07282943A0097 |30 39|decreases alkaline
P07282943A0097 |80 83|PO21T0
P07282943A0097 |129 133|mmHgirub
P07282943A0097 |43 61|superfusate oxygensphatases and 5-nu
P07282943A0097 |106 114|aerationts of ne
P07282943A0097 |116 119|PO2ata
P07282943A0097 |101 102|%a
P07282943A0097 |70 78|pressuree P00008
P07283110A0000 |49 55|valuesses an
P07283110A0000 |10 12|B100
P07283110A0000 |15 25|deficiencyComparison
P07283110A0000 |67 75|exercisedase P00
P07286057A0159 |171 173|mg] 
P07286057A0159 |183 197|administrations a function o
P07286057A0159 |9 30|AUC infinity analysesT0076 Comparison with
P07286057A0159 |146 155|injection8997A0472
P07286057A0159 |56 66|buflomedil 5-nucleot
P07286057A0159 |133 135|mgin
P07286057A0159 |140 142|i. P
P07286057A0159 |36 52|pharmacokineticsine phosphatases
P07286057A0159 |102 106|dosespec
P07293100T0001 |0 17|Gastrin secretionP00001606T0076 Co
P07293100T0001 |25 41|food stimulation with alkaline p
P07293100T0001 |55 70|system diseasesd 5-nucleotidas
P07293327T0001 |0 24|Fibrinogen determinationP00001606T0076 Compariso
P07293327T0001 |35 46|KZM-1 meterline phosph
P07295033A0513 |86 87|% 
P07295033A0513 |95 100|urinelogic
P07295033A0513 |27 28|%i
P07295033A0513 |72 78|faecesP00008
P07295033A0513 |36 40|doseine 
P07295033A0513 |7 13|period06T007
P07295033A0513 |20 24|daysriso
P07295417A0092 |34 41|regionsaline p
P07295417A0092 |54 63|ventriclend 5-nucl
P07295417A0092 |106 115|techniquets of neo
P07295417A0092 |117 130|phase imagingtal hyperbili
P07296303A0418 |0 9|ResponsesP00001606
P07296303A0418 |26 32|nucleiwith a
P07296303A0418 |13 22|brainstem6 Compari
P07296303A0418 |52 71|lateralis posterior and 5-nucleotidase
P07296303A0418 |42 50|dorsalisosphatas
P07296303A0418 |100 107|latency aspect
P07296997A0125 |55 58|OCGd 5
P07296997A0125 |76 104|Tc-99m-PyG cholescintigraphy08171T0000 Pharmacologic asp
P07296997A0125 |9 17|patientsT0076 Co
P07296997A0125 |38 49|gallbladdere phosphata
P07297576A0454 |22 47|drinking water ad libitumson with alkaline phospha
P07297576A0454 |74 81|Aludrox0008171
P07297576A0454 |91 105|drinking watermacologic aspe
P07297978A0570 |35 47|case historyline phospha
P07297978A0570 |11 15|data076 
P07297978A0570 |99 101|C.c 
P07297978A0570 |93 94|Ac
P07297978A0570 |49 63|smoking habitsses and 5-nucl
P07298209A0291 |153 170|bicycle ergometer72 When CSF [HCO3
P07298209A0291 |92 99|VO2 maxacologi
P07298209A0291 |73 74|%0
P07298209A0291 |30 50|performance capacity alkaline phosphatas
P07298209A0291 |64 68|W170otid
P07298209A0291 |4 17|determination01606T0076 Co
P07298209A0291 |138 147|work loada. P00008
P07298259T0000 |17 21|leadmpar
P07298259T0000 |25 30|blood with
P07298259T0000 |0 13|DeterminationP00001606T007
P07298523T0000 |68 73|swinease P
P07298523T0000 |10 22|indomethacin0076 Compari
P07298523T0000 |53 64|parturitionand 5-nucle
P07298523T0000 |27 49|prostaglandin F2 alphaith alkaline phosphata
P07298523T0000 |0 6|EffectP00001
P07299857A0294 |0 11|LD50 valuesP00001606T0
P07299857A0294 |144 148|male0089
P07299857A0294 |24 26|KPn 
P07299857A0294 |332 334|KP1.
P07299857A0294 |177 183|KP-T10hown a
P07299857A0294 |62 67|mg/kgleoti
P07299857A0294 |88 94|KP-CMCharmac
P07299857A0294 |303 308|mg/kgsigni
P07299857A0294 |165 171|female[HCO3-
P07299857A0294 |15 20|termsCompa
P07299857A0294 |290 295|malesstill
P07299857A0294 |49 53|ratsses 
P07299857A0294 |156 161|mg/kgWhen 
P07299857A0294 |323 328|termsr slo
P07299857A0294 |263 274|LD50 valuesn compared 
P07299857A0294 |249 255|KP-CMC displ
P07299857A0294 |312 319|femalesntly gr
P07299857A0294 |281 286|mg/kgrols 
P07299857A0294 |78 82|rats171T
P07299857A0294 |135 140|mg/kgemia.
P07299857A0294 |201 215|intrarectally.F PCO2 the dat
P07299857A0294 |231 245|administrationrats are no lo
P07299857A0294 |35 40|mg/kgline 
P07304905A0336 |0 15|AutotransfusionP00001606T0076 
P07304905A0336 |42 55|Heparin-ACD-Bosphatases an
P07304905A0336 |57 68|Heparin-DPD5-nucleotid
P07304905A0336 |70 88|Heparin-ACD-B etc.e P00008171T0000 P
P07306839T0001 |0 8|ElectronP0000160
P07306839T0001 |45 51|cortexhatase
P07306839T0001 |21 28|pictureison wi
P07306839T0001 |73 82|degrees C00008171T
P07306839T0001 |55 59|ratsd 5-
P07308849A0817 |48 70|sham operation animalsases and 5-nucleotidas
P07308849A0817 |14 25|differences Comparison
P07308849A0817 |125 131|weightrbilir
P07308849A0817 |40 43|gutpho
P07308849A0817 |92 96|dataacol
P07309562T0000 |66 70|acididas
P07309562T0000 |90 95|acidsrmaco
P07309562T0000 |40 53|determinationphosphatases 
P07310206A0154 |119 139|resin casting methodl hyperbilirubinemia
P07310206A0154 |79 107|scanning electron microscopy71T0000 Pharmacologic aspect
P07310206A0154 |4 16|architecture01606T0076 C
P07310206A0154 |20 36|microvasculaturerison with alkal
P07310206A0154 |50 57|regionses and 
P07311881T0000 |0 12|MSMS CouncilP00001606T00
P07311881T0000 |30 45|health director alkaline phosp
P07312707T0000 |0 8|ChordomaP0000160
P07312707T0000 |23 27|cordon w
P07312707T0000 |33 41|F344 ratkaline p
P07320153T0000 |119 137|injection analysisl hyperbilirubinem
P07320153T0000 |99 107|detectorc aspect
P07320153T0000 |23 29|liquidon wit
P07320153T0000 |159 170|body fluidsn CSF [HCO3
P07320153T0000 |46 52|systematases
P07320153T0000 |141 155|catecholaminesP00008997A0472
P07320153T0000 |64 73|precolumnotidase P
P07320153T0000 |0 5|MicroP0000
P07323063A0000 |216 222|degree of K-
P07323063A0000 |105 109|SHRscts 
P07323063A0000 |227 238|time courseted rats ar
P07323063A0000 |63 67|ratseoti
P07323063A0000 |286 294|recoverybut stil
P07323063A0000 |165 169|dose[HCO
P07323063A0000 |99 103|ratsc as
P07323063A0000 |176 198|mg/kg dl-isoproterenolshown as a function of
P07323063A0000 |263 270|failuren compa
P07323573A0644 |9 13|zoneT007
P07323573A0644 |31 43|dissociationalkaline pho
P07326596A0061 |4 18|IgA deficiency01606T0076 Com
P07326596A0061 |40 43|IgEpho
P07327097A0647 |118 119|%a
P07327097A0647 |121 122|ph
P07327097A0647 |3 10|PB mice001606T
P07327097A0647 |162 175|granule cellsSF [HCO3-] is
P07327097A0647 |147 154|deficit997A047
P07327097A0647 |106 114|controlsts of ne
P07327097A0647 |35 42|deficitline ph
P07327097A0647 |86 93|neurons Pharma
P07327097A0647 |50 56|numberes and
P07328000T0000 |0 21|Nutritional cataractsP00001606T0076 Compar
P07328000T0000 |25 38|timber wolves with alkalin
P07330073T0000 |68 79|blood cellsase P000081
P07330073T0000 |14 35|transfusion reactions Comparison with alka
P07330073T0000 |50 56|salinees and
P07330073T0000 |43 46|usesph
P07330073T0000 |0 10|PreventionP00001606T
P07337609A0531 |184 196|immunization a function 
P07337609A0531 |123 131|chickensperbilir
P07337609A0531 |226 235|challengeeted rats
P07337609A0531 |47 62|antibody titerstases and 5-nuc
P07337609A0531 |14 18|mean Com
P07337609A0531 |64 67|GMToti
P07337609A0531 |208 220|immunizationthe data of 
P07337609A0531 |156 165|intervalsWhen CSF 
P07340196T0001 |34 39|HBSAGaline
P07340196T0001 |74 88|infectiousness0008171T0000 P
P07340196T0001 |52 55|aid an
P07340196T0001 |92 118|hepatitis B virus carriersacologic aspects of neonat
P07340196T0001 |17 30|determinationmparison with
P07341346A0174 |19 32|shunt vesselsarison with a
P07341346A0174 |73 81|arteries00008171
P07341346A0174 |111 117|system neona
P07345217A0000 |86 96|malignancy Pharmacol
P07345217A0000 |11 24|complications076 Compariso
P07345217A0000 |59 68|treatmentnucleotid
P07347728T0000 |0 14|Arachnoid cystP00001606T0076
P07349416A0337 |21 32|summer coatison with a
P07354367A0162 |0 11|HypotensionP00001606T0
P07354367A0162 |28 32|headth a
P07354367A0162 |36 40|tiltine 
P07355527A0467 |68 74|adultsase P0
P07355527A0467 |14 23|procedure Comparis
P07355527A0467 |27 39|Lich-Gregoirith alkaline
P07356273T0022 |55 62|tissuesd 5-nuc
P07356273T0022 |27 42|cell carcinomasith alkaline ph
P07365183A0000 |239 243|SECT no 
P07365183A0000 |182 189|therapyas a fu
P07365183A0000 |133 141|responseinemia. 
P07365183A0000 |104 110|safetyects o
P07365183A0000 |7 15|patients06T0076 
P07365183A0000 |42 51|diagnosisosphatase
P07365183A0000 |230 237|therapy rats a
P07365183A0000 |95 100|termslogic
P07365183A0000 |191 196|MMECTtion 
P07365183A0000 |66 76|depressionidase P000
P07365183A0000 |115 123|efficacynatal hy
P07369183T0000 |8 17|artifacts6T0076 Co
P07369183T0000 |31 50|coagulation testingalkaline phosphatas
P07369458A0606 |138 154|amputation levela. P00008997A047
P07369458A0606 |72 90|muscle temperatureP00008171T0000 Pha
P07369458A0606 |44 53|techniquephatases 
P07369458A0606 |114 121|adjunctonatal 
P07372433A0000 |119 124|yearsl hyp
P07372433A0000 |43 60|guinea pig uretersphatases and 5-n
P07372433A0000 |26 39|relationshipswith alkaline
P07372433A0000 |105 111|monthscts of
P07372433A0000 |96 101|weeksogic 
P07372433A0000 |128 131|agelir
P07372433A0000 |86 93|animals Pharma
P07372928A0105 |0 5|TestsP0000
P07372928A0105 |172 178|source is sh
P07372928A0105 |37 53|Mossbauer sourcene phosphatases 
P07372928A0105 |13 19|method6 Comp
P07372928A0105 |151 158|cochlea0472 Wh
P07372928A0105 |83 91|membrane000 Phar
P07372928A0105 |202 210|membrane PCO2 th
P07372928A0105 |113 143|signal-transmission propertieseonatal hyperbilirubinemia. P0
P07375836T0000 |52 62|metastasis and 5-nuc
P07375836T0000 |26 33|patientwith al
P07375836T0000 |13 20|work-up6 Compa
P07375836T0000 |76 85|carcinoma08171T000
P07375864A0431 |205 217|platelet MAOO2 the data 
P07375864A0431 |166 171|proofHCO3-
P07375864A0431 |75 84|correlate008171T00
P07375864A0431 |189 197|findingsnction o
P07375864A0431 |127 140|schizophreniailirubinemia.
P07375864A0431 |26 40|nonspecificitywith alkaline 
P07375864A0431 |106 114|disorderts of ne
P07375864A0431 |156 162|burdenWhen C
P07375864A0431 |4 11|authors01606T0
P07375864A0431 |48 60|platelet MAOases and 5-n
P07376165T0001 |17 24|diseasempariso
P07376165T0001 |0 7|EcthymaP000016
P07377378A0143 |0 20|Estrogen replacementP00001606T0076 Compa
P07377378A0143 |144 149|rates00899
P07377378A0143 |177 186|heat losshown as a
P07377378A0143 |224 232|controlspleted r
P07377378A0143 |105 113|capsulescts of n
P07377378A0143 |35 49|beta-estradiolline phosphata
P07377378A0143 |53 78|beta-estradiol-3-benzoateand 5-nucleotidase P00008
P07377378A0143 |153 168|heat production72 When CSF [HC
P07377954A0117 |137 155|oxygen consumptionia. P00008997A0472
P07377954A0117 |183 200|health volunteerss a function of C
P07377954A0117 |362 370|subjects33 Flura
P07377954A0117 |121 131|pulse ratehyperbilir
P07377954A0117 |74 80|system000817
P07377954A0117 |45 51|effecthatase
P07377954A0117 |84 89|terms00 Ph
P07377954A0117 |157 160|VO2hen
P07377954A0117 |320 355|postexercise ankle pressure changesater slope (1.21 +/- 0.23 vs. P0001
P07377954A0117 |248 269|gastrocnemius musclesr displaced when comp
P07377954A0117 |419 427|diseasesug with 
P07377954A0117 |300 310|volunteers a signifi
P07377954A0117 |277 285|exercisecontrols
P07377954A0117 |111 119|pressure neonata
P07377954A0117 |226 234|tibialiseted rat
P07377954A0117 |14 21|aspects Compar
P07377954A0117 |169 177|exercise3-] is s
P07377954A0117 |206 218|emg activity2 the data o
P07377954A0117 |441 452|extremitiesse for use 
P07379334A0503 |0 7|ChangesP000016
P07379334A0503 |56 71|transfer factor 5-nucleotidase
P07379334A0503 |132 139|placebobinemia
P07379334A0503 |23 33|reactivityon with al
P07379334A0503 |37 45|subjectsne phosp
P07379334A0503 |113 121|subjectseonatal 
P07380615A0478 |39 50|possibility phosphatas
P07380615A0478 |60 66|natureucleot
P07380615A0478 |110 114|lossf ne
P07380615A0478 |282 286|jobsols 
P07380615A0478 |192 207|work efficiencyion of CSF PCO2
P07380615A0478 |75 86|collar jobs008171T0000
P07380615A0478 |296 310|collar workershave a signifi
P07380615A0478 |129 135|tissueirubin
P07380615A0478 |249 259|efficiency displaced
P07385543T0001 |0 10|ImportanceP00001606T
P07385543T0001 |30 53|blood sulfhydryl groups alkaline phosphatases 
P07385543T0001 |108 117|infection of neona
P07385543T0001 |57 66|fractures5-nucleot
P07385543T0001 |87 92|bonesPharm
P07385920A0189 |4 11|results01606T0
P07385920A0189 |74 91|blood haemoglobin0008171T0000 Phar
P07385920A0189 |31 47|blood lead levelalkaline phospha
P07385920A0189 |127 138|delta aminoilirubinemi
P07385920A0189 |149 153|acid7A04
P07385920A0189 |114 123|excretiononatal hy
P07385933A0085 |118 123|14CO2al hy
P07385933A0085 |148 157|intervals97A0472 W
P07385933A0085 |46 60|kg body weightatases and 5-n
P07385933A0085 |107 116|galactoses of neon
P07385933A0085 |30 41|g galactose alkaline p
P07385933A0085 |78 83|mu Ci171T0
P07385933A0085 |10 22|iv injection0076 Compari
P07385933A0085 |169 173|hour3-] 
P07386500A0174 |51 61|deficiencys and 5-nu
P07386500A0174 |9 31|clotting factor assaysT0076 Comparison with 
P07386500A0174 |65 73|factor Xtidase P
P07386500A0174 |113 127|determinationseonatal hyperb
P07386500A0174 |99 103|centc as
P07386864T0000 |21 29|dialysisison wit
P07387242A0236 |34 43|intervalsaline pho
P07387242A0236 |158 176|clotting functionsen CSF [HCO3-] is 
P07387242A0236 |144 152|elements008997A0
P07387242A0236 |125 135|hemoglobinrbilirubin
P07387242A0236 |103 118|plasma proteinspects of neonat
P07387242A0236 |70 79|operatione P000081
P07387242A0236 |0 15|Blood variablesP00001606T0076 
P07392519T0001 |8 15|changes6T0076 
P07392519T0001 |30 41|retinopathy alkaline p
P07392519T0001 |45 53|childrenhatases 
P07393856A0314 |98 109|Experimentsic aspects 
P07393856A0314 |76 94|reference standard08171T0000 Pharmac
P07393856A0314 |13 23|beta-apo-86 Comparis
P07393856A0314 |5 11|result1606T0
P07393856A0314 |36 52|acid ethyl esterine phosphatases
P07393856A0314 |54 60|apo-EEnd 5-n
P07393976A0000 |51 66|sodium barbitals and 5-nucleot
P07393976A0000 |242 247|water long
P07393976A0000 |91 105|taste aversionmacologic aspe
P07393976A0000 |211 238|% sodium saccharin solution data of K-depleted rats ar
P07393976A0000 |15 35|sodium phenobarbitalComparison with alka
P07393976A0000 |112 120|hr fluidneonatal
P07393976A0000 |178 204|bottle taste aversion taskown as a function of CSF P
P07393976A0000 |40 45|mg/kgphosp
P07393976A0000 |130 134|ratsrubi
P07393976A0000 |156 170|discriminationWhen CSF [HCO3
P07393976A0000 |4 11|ability01606T0
P07393976A0000 |71 76|mg/kg P000
P07394364A0738 |254 257|VO2lac
P07394364A0738 |146 152|levels8997A0
P07394364A0738 |109 117|organismof neona
P07394364A0738 |72 79|mammalsP000081
P07394364A0738 |30 53|gas exchange parenchyma alkaline phosphatases 
P07394364A0738 |221 231|adaptation-depleted 
P07394364A0738 |190 195|ratesction
P07394364A0738 |239 243|lung no 
P07395750A0294 |0 16|UnderestimationsP00001606T0076 C
P07395750A0294 |81 94|methodologiesT0000 Pharmac
P07395750A0294 |56 64|problems 5-nucle
P07395750A0294 |33 34|%k
P07396545A0217 |51 57|courses and 
P07396545A0217 |65 73|disordertidase P
P07396545A0217 |0 12|ChemotherapyP00001606T00
P07397066T0000 |0 15|Drug inhibitionP00001606T0076 
P07397066T0000 |25 47|blood aspirin esterase with alkaline phospha
P07401318A0823 |87 96|staircasePharmacol
P07401318A0823 |112 114|Hzne
P07401318A0823 |43 52|staircasesphatases
P07401318A0823 |18 29|temperatureparison wit
P07405701T0000 |23 32|responseson with a
P07405701T0000 |37 63|platelet monoamine oxidasene phosphatases and 5-nucl
P07405701T0000 |91 101|alcoholismmacologic 
P07405701T0000 |67 75|patientsdase P00
P07406527A0212 |69 86|porphyrin contentse P00008171T0000
P07406527A0212 |90 96|lijverrmacol
P07406527A0212 |159 160|%n
P07406527A0212 |7 10|end06T
P07406527A0212 |177 189|HCB controlshown as a fu
P07406527A0212 |41 60|porphyrin excretionhosphatases and 5-n
P07406527A0212 |18 28|experimentparison wi
P07406527A0212 |140 147|animals P00008
P07406527A0212 |101 105|skinaspe
P07408970A0706 |51 53|Gfs 
P07408970A0706 |41 47|uterushospha
P07408970A0706 |120 130|difference hyperbili
P07408970A0706 |4 9|hours01606
P07408970A0706 |25 39|administration with alkaline
P07408970A0706 |162 163|pS
P07408970A0706 |58 65|Cv mice-nucleo
P07408970A0706 |71 77|weight P0000
P07408970A0706 |98 101|mg%ic 
P07408970A0706 |84 87|mg%00 
P07410037A0752 |254 264|propensitylaced when
P07410037A0752 |214 220|factorta of 
P07410037A0752 |124 137|control grouperbilirubinem
P07410037A0752 |172 181|magnesium is shown
P07410037A0752 |159 168|excretionn CSF [HC
P07410037A0752 |197 204|calciumf CSF P
P07410037A0752 |9 22|stone-formersT0076 Compari
P07410037A0752 |65 85|magnesium metabolismtidase P00008171T000
P07410037A0752 |53 61|featuresand 5-nu
P07410037A0752 |185 193|relationa functi
P07413144T0018 |0 8|AnalysisP0000160
P07413144T0018 |23 33|populationon with al
P07413242A0000 |32 43|paraplegicslkaline pho
P07413242A0000 |20 25|studyrison
P07413242A0000 |58 65|lesions-nucleo
P07413242A0000 |71 76|T1-L3 P000
P07413441T0070 |17 29|localisationmparison wit
P07413441T0070 |46 58|distributionatases and 5
P07413441T0070 |66 72|kidneyidase 
P07413781A0169 |119 130|stimulationl hyperbili
P07413781A0169 |167 178|preexposureCO3-] is sh
P07413781A0169 |148 160|conditioning97A0472 When
P07413781A0169 |12 23|stimulation76 Comparis
P07413781A0169 |48 68|stimulus preexposureases and 5-nucleotid
P07413781A0169 |78 89|attenuation171T0000 Ph
P07413781A0169 |100 110|inhibition aspects o
P07413806T0000 |51 55|ratss an
P07413806T0000 |38 47|pathologye phospha
P07413806T0000 |17 25|amygdalamparison
P07414817T0001 |0 19|Cataract extractionP00001606T0076 Comp
P07414817T0001 |31 39|glaucomaalkaline
P07415340A0280 |0 6|NumberP00001
P07415340A0280 |11 15|size076 
P07415340A0280 |30 40|structures alkaline 
P07415340A0280 |48 63|pneumocytes typases and 5-nucl
P07416204A0437 |238 240|t0e 
P07416204A0437 |118 130|extrasystoleal hyperbili
P07416204A0437 |184 196|potentiation a function 
P07416204A0437 |256 268|potentiationced when com
P07416204A0437 |92 94|t0ac
P07416204A0437 |213 215|t1at
P07416204A0437 |166 168|t1HC
P07416204A0437 |14 20|animal Compa
P07416204A0437 |104 110|timingects o
P07416204A0437 |75 90|pacing interval008171T0000 Pha
P07416204A0437 |40 52|potentiationphosphatases
P07416204A0437 |132 134|t1bi
P07416204A0437 |141 143|t0P0
P07418498A0217 |137 151|amphotericin Bia. P00008997A
P07418498A0217 |181 193|lung abscess as a functi
P07418498A0217 |27 40|complicationsith alkaline 
P07418498A0217 |122 131|treatmentyperbilir
P07418498A0217 |165 173|excision[HCO3-] 
P07418498A0217 |44 59|corticosteroidsphatases and 5-
P07418498A0217 |3 8|spite00160
P07418498A0217 |77 85|recovery8171T000
P07418498A0217 |102 111|infectionspects of
P07418829A0191 |0 12|ImplicationsP00001606T00
P07418829A0191 |37 47|pediatricsne phospha
P07418829A0191 |21 32|observationison with a
P07419485A0158 |49 54|wavesses a
P07419485A0158 |67 72|wavesdase 
P07419485A0158 |8 13|study6T007
P07419485A0158 |88 96|solutionharmacol
P07419485A0158 |157 161|costhen 
P07419485A0158 |173 187|simplificationis shown as a 
P07419485A0158 |21 31|transitionison with 
P07423803T0001 |0 9|TreatmentP00001606
P07423803T0001 |25 36|peritonitis with alkal
P07425838A0182 |20 36|pheochromocytomarison with alkal
P07425838A0182 |79 88|pregnancy71T0000 P
P07425838A0182 |12 16|case76 C
P07425838A0182 |66 75|trimesteridase P00
P07426101A0124 |118 137|alcohol consumptional hyperbilirubinem
P07426101A0124 |162 173|mileage runSF [HCO3-] 
P07426101A0124 |195 212|bicycle ergometer of CSF PCO2 the 
P07426101A0124 |53 95|adipose tissue lipoprotein lipase activityand 5-nucleotidase P00008171T0000 Pharmaco
P07426101A0124 |97 116|anthropometric datagic aspects of neon
P07426101A0124 |178 189|performanceown as a fu
P07426101A0124 |8 14|plasma6T0076
P07426101A0124 |19 51|lipoprotein lipid concentrationsarison with alkaline phosphatase
P07426101A0124 |248 263|training periodr displaced whe
P07426101A0124 |139 153|smoking habits. P00008997A04
P07426604A0397 |4 9|C18:101606
P07426604A0397 |134 139|acidsnemia
P07426604A0397 |37 44|measurene phos
P07426604A0397 |11 20|C10 value076 Compa
P07426604A0397 |54 61|changesnd 5-nu
P07426745A0177 |86 90|rats Pha
P07426745A0177 |107 123|gamma-irradiatons of neonatal hy
P07426745A0177 |14 20|growth Compa
P07426745A0177 |24 57|blood erythrocyte membrane injuryn with alkaline phosphatases and 
P07426745A0177 |148 150|Gy97
P07426745A0177 |129 133|doseirub
P07428037A0989 |85 105|bp hairpin structure0 Pharmacologic aspe
P07428037A0989 |192 199|subunition of 
P07428037A0989 |165 168|RNA[HC
P07428037A0989 |241 258|mRNA binding siteo longer displace
P07428037A0989 |260 266|ACCUCCwhen c
P07428037A0989 |112 120|sequenceneonatal
P07428037A0989 |43 60|mouse mt 12S rRNAsphatases and 5-n
P07428037A0989 |26 37|nucleotideswith alkali
P07428037A0989 |207 214|systems the da
P07428037A0989 |139 150|nucleotides. P00008997
P07428037A0989 |289 311|corn chloroplast rRNAs still have a signific
P07429009T0121 |24 48|cell population dynamicsn with alkaline phosphat
P07429009T0121 |12 19|anatomy76 Comp
P07431059A0000 |69 74|orderse P0
P07431059A0000 |296 300|veinhave
P07431059A0000 |246 251|Galenger d
P07431059A0000 |267 276|Rosenthalmpared to
P07431059A0000 |150 162|relationshipA0472 When C
P07431059A0000 |42 43|Xo
P07431059A0000 |403 409|nervestive h
P07431059A0000 |327 331|veinope 
P07431059A0000 |118 131|pineal regional hyperbilir
P07431059A0000 |259 263|vein whe
P07431059A0000 |359 364|notchA0733
P07431059A0000 |52 65|magnification and 5-nucleo
P07431059A0000 |219 236|cerebellar artery K-depleted rats 
P07431059A0000 |337 341|size+/- 
P07431059A0000 |311 316|sinusantly
P07431059A0000 |7 21|cadaver brains06T0076 Compar
P07431059A0000 |202 208|artery PCO2 
P07431059A0000 |170 181|pineal body-] is shown
P07431059A0000 |238 242|veine no
P07431059A0000 |103 110|anatomypects o
P07432288A0218 |0 20|Serum antibody titreP00001606T0076 Compa
P07432288A0218 |98 107|infectionic aspect
P07432288A0218 |63 78|recurrence rateeotidase P00008
P07432288A0218 |86 94|duration Pharmac
P07434431A0203 |16 25|refeedingomparison
P07434431A0203 |60 70|activationucleotidas
P07434431A0203 |46 55|mechanismatases an
P07434431A0203 |88 98|infectionsharmacolog
P07434431A0203 |124 130|famineerbili
P07434456A0286 |187 192|fluidfunct
P07434456A0286 |116 134|% glycerol contentatal hyperbilirubi
P07434456A0286 |217 226|osmometryof K-depl
P07434456A0286 |140 152|measurements P00008997A0
P07434456A0286 |47 58|blood cellstases and 5
P07434456A0286 |70 78|glycerole P00008
P07434456A0286 |19 24|unitsariso
P07434456A0286 |207 212|index the 
P07435185A0074 |81 90|diagnosisT0000 Pha
P07435185A0074 |63 71|lymphomaeotidase
P07435185A0074 |114 126|drill biopsyonatal hyper
P07435185A0074 |27 35|findingsith alka
P07435185A0074 |4 12|symptoms01606T00
P07436187A0147 |171 181|disability] is shown
P07436187A0147 |127 132|rangeiliru
P07436187A0147 |160 167|factors CSF [H
P07436187A0147 |104 108|timeects
P07436187A0147 |4 9|study01606
P07436187A0147 |80 86|entity1T0000
P07436187A0147 |32 39|studieslkaline
P07436459A0245 |174 195|tryptophan metabolisms shown as a function
P07436459A0245 |108 129|vitamin B6 deficiency of neonatal hyperbil
P07436459A0245 |162 170|responseSF [HCO3
P07436459A0245 |199 205|stressCSF PC
P07436459A0245 |67 77|acid ratiodase P0000
P07436702A0156 |33 41|reactionkaline p
P07436702A0156 |45 49|DNFBhata
P07436702A0156 |4 19|control persons01606T0076 Comp
P07436794A0148 |49 52|CCAses
P07436794A0148 |31 47|carotid arteriesalkaline phospha
P07436794A0148 |5 18|control group1606T0076 Com
P07438346A0381 |3 5|pH00
P07438346A0381 |125 126|%r
P07438346A0381 |94 100|actionologic
P07438346A0381 |132 136|Vmaxbine
P07438346A0381 |90 91|%r
P07438346A0381 |143 144|%0
P07438346A0381 |111 120|amplitude neonatal
P07438346A0381 |20 44|lidocaine concentrationsrison with alkaline phos
P07438482A0145 |119 129|oestradioll hyperbil
P07438482A0145 |111 113|E1 n
P07438482A0145 |131 133|E2ub
P07438482A0145 |13 18|right6 Com
P07438482A0145 |84 97|determination00 Pharmacolo
P07438482A0145 |101 109|oestroneaspects 
P07438482A0145 |51 64|blood sampless and 5-nucle
P07440085T0061 |0 18|Arm function testsP00001606T0076 Com
P07440430A1074 |68 71|endase
P07440430A1074 |15 25|B breedingComparison
P07440430A1074 |51 60|Hb levelss and 5-n
P07440430A1074 |184 191|B lambs a func
P07440430A1074 |115 126|S x B lambsnatal hyper
P07440430A1074 |148 157|Hb levels97A0472 W
P07440430A1074 |209 210|Ph
P07440430A1074 |99 107|NB lambsc aspect
P07440430A1074 |79 89|experiment71T0000 Ph
P07440430A1074 |109 110|bo
P07440430A1074 |167 178|D x B lambsCO3-] is sh
P07440430A1074 |235 260|hemoglobin concentrations are no longer displaced 
P07440430A1074 |4 9|lambs01606
P07440430A1074 |139 140|P.
P07445971A0241 |71 85|nerve ligation P00008171T000
P07445971A0241 |9 17|responseT0076 Co
P07445971A0241 |91 95|weekmaco
P07445971A0241 |33 43|acrylamidekaline pho
P07449221A0086 |85 91|repair0 Phar
P07449221A0086 |57 61|slip5-nu
P07449221A0086 |29 37|excisionh alkali
P07449221A0086 |99 105|tendonc aspe
P07449221A0086 |43 45|mmsp
P07449221A0086 |4 13|operation01606T007
P07449253A0411 |17 22|groupmpari
P07449253A0411 |111 119|diuresis neonata
P07449253A0411 |161 162|%C
P07449253A0411 |132 140|decreasebinemia.
P07449253A0411 |75 76|h0
P07449253A0411 |54 58|mmHgnd 5
P07449253A0411 |144 156|blood volume008997A0472 
P07449253A0411 |32 40|pressurelkaline 
P07450031A0691 |99 106|dioxidec aspec
P07450031A0691 |161 177|benzothiazepin-6CSF [HCO3-] is s
P07450031A0691 |108 112|NF19 of 
P07450031A0691 |180 187|dioxiden as a 
P07450031A0691 |189 193|NF20ncti
P07450031A0691 |7 24|sedative activity06T0076 Compariso
P07450031A0691 |80 96|benzothiazepin-61T0000 Pharmacol
P07450388A0406 |17 23|effectmparis
P07450388A0406 |78 87|bile duct171T0000 
P07450388A0406 |27 33|CCK-PZith al
P07450388A0406 |41 49|movementhosphata
P07450388A0406 |132 149|duodenofiberscopebinemia. P0000899
P07450388A0406 |66 70|partidas
P07450388A0406 |108 123|pressure sensor of neonatal hy
P07450388A0406 |3 11|patients001606T0
P07453919A0000 |136 144|alkalinemia. P00
P07453919A0000 |270 287|blood neutrophilsred to controls b
P07453919A0000 |149 165|acid phosphatase7A0472 When CSF 
P07453919A0000 |180 188|esterasen as a f
P07453919A0000 |120 134|determinations hyperbilirubi
P07453919A0000 |356 360|head943A
P07453919A0000 |87 103|blood cell countPharmacologic as
P07453919A0000 |20 26|Hortonrison 
P07453919A0000 |52 66|investigations and 5-nucleot
P07453919A0000 |219 222|IgM K-
P07453919A0000 |212 217|testsdata 
P07453919A0000 |332 336|area1.21
P07453919A0000 |29 37|headacheh alkali
P07453919A0000 |382 386|sideppea
P07453919A0000 |314 318|painly g
P07453919A0000 |227 238|IgG bindingted rats ar
P07453919A0000 |344 348|skin3 vs
P07453919A0000 |6 14|patients606T0076
P07453919A0000 |401 407|fingerective
P07453919A0000 |306 310|areanifi
P07455042A0457 |221 227|atrium-deple
P07455042A0457 |61 69|machinescleotida
P07455042A0457 |249 253|vein dis
P07455042A0457 |82 111|Dynamic Spatial Reconstructor0000 Pharmacologic aspects of
P07455042A0457 |178 187|injectionown as a 
P07455042A0457 |26 33|imagingwith al
P07455042A0457 |141 159|density resolutionP00008997A0472 Whe
P07455042A0457 |191 205|contrast agenttion of CSF PC
P07455042A0457 |290 302|measurementsstill have a
P07455521A0414 |38 48|NEXT studye phosphat
P07455521A0414 |24 30|resultn with
P07455521A0414 |4 8|ESEG0160
P07456774A0448 |29 34|drugsh alk
P07457931A0655 |18 22|micepari
P07457931A0655 |56 63|5-OH-DA 5-nucl
P07457931A0655 |8 14|series6T0076
P07457931A0655 |43 52|injectionsphatases
P07457931A0655 |110 115|studyf neo
P07458171A0086 |34 48|Platyhelminthaaline phosphat
P07458171A0086 |54 62|Nematodand 5-nuc
P07458171A0086 |72 81|CrustaceaP00008171
P07458171A0086 |19 26|speciesarison 
P07461226A0958 |3 11|symptoms001606T0
P07461226A0958 |74 92|plasma epinephrine0008171T0000 Pharm
P07461226A0958 |57 68|correlation5-nucleotid
P07461226A0958 |27 32|flushith a
P07461226A0958 |96 117|norepinephrine levelsogic aspects of neona
P07461848A0230 |138 151|micrograms/m3a. P00008997A
P07461848A0230 |23 37|concentrationson with alkali
P07461848A0230 |82 84|CO00
P07461848A0230 |178 191|micrograms/m3own as a func
P07461848A0230 |63 76|tobacco smokeeotidase P000
P07461848A0230 |123 131|nicotineperbilir
P07461848A0230 |91 94|ppmmac
P07461848A0230 |104 107|ppbect
P07461848A0230 |165 171|matter[HCO3-
P07461848A0230 |45 55|componentshatases an
P07461848A0230 |118 121|ppbal 
P07461848A0230 |96 98|NOog
P07461848A0230 |109 112|NO2of 
P07461848A0230 |4 15|mean values01606T0076 
P07462481A0422 |171 180|occlusion] is show
P07462481A0422 |104 113|occlusionects of n
P07462481A0422 |44 48|timephat
P07462481A0422 |127 134|regionsilirubi
P07462481A0422 |59 66|regionsnucleot
P07462481A0422 |92 97|weeksacolo
P07462481A0422 |12 35|backscatter coefficient76 Comparison with alka
P07462481A0422 |138 145|infarcta. P000
P07462481A0422 |159 164|weeksn CSF
P07462481A0422 |70 77|infarcte P0000
P07463294A1216 |51 56|groups and
P07463294A1216 |150 151|pA
P07463294A1216 |104 109|groupects 
P07463294A1216 |83 88|group000 P
P07463294A1216 |59 69|respondersnucleotida
P07463294A1216 |130 135|grouprubin
P07463294A1216 |167 172|groupCO3-]
P07463294A1216 |138 148|respondersa. P000089
P07463294A1216 |5 7|wk16
P07463294A1216 |17 30|tumor relapsemparison with
P07463465A0297 |84 90|infant00 Pha
P07463465A0297 |6 15|infection606T0076 
P07463465A0297 |42 55|control womenosphatases an
P07463465A0297 |65 70|birthtidas
P07466831A0714 |34 39|onsetaline
P07466831A0714 |146 157|disturbance8997A0472 W
P07466831A0714 |165 182|porphyrin pattern[HCO3-] is shown 
P07466831A0714 |104 123|porphyrin excretionects of neonatal hy
P07466831A0714 |67 72|wordsdase 
P07466831A0714 |43 56|HCB porphyriasphatases and
P07466831A0714 |0 17|PentachlorophenolP00001606T0076 Co
P07467975A0316 |0 15|Family planningP00001606T0076 
P07467975A0316 |146 153|periods8997A04
P07467975A0316 |303 311|approachsignific
P07467975A0316 |109 123|contraceptivesof neonatal hy
P07467975A0316 |377 383|Europehus ap
P07467975A0316 |184 194|primiparae a functio
P07467975A0316 |157 161|timehen 
P07467975A0316 |260 274|multigraviditywhen compared 
P07467975A0316 |355 373|behaviour patterns0943A0733 Flurazep
P07467975A0316 |219 225|births K-dep
P07467975A0316 |246 256|percentageger displa
P07467975A0316 |42 46|roleosph
P07467975A0316 |315 327|reproductiony greater sl
P07467975A0316 |78 86|patients171T0000
P07467975A0316 |199 211|secundiparaeCSF PCO2 the
P07467975A0316 |279 289|parametersntrols but
P07467975A0316 |66 70|centidas
P07467975A0316 |169 180|percentages3-] is show
P07469692A0000 |154 162|families2 When C
P07469692A0000 |56 68|bone disease 5-nucleotid
P07469692A0000 |83 94|inheritance000 Pharmac
P07469692A0000 |128 135|memberslirubin
P07469692A0000 |4 26|term osteomesopycnosis01606T0076 Comparison 
P07471210A0384 |4 15|87K protein01606T0076 
P07471210A0384 |62 69|daltonsleotida
P07471210A0384 |31 39|proteinsalkaline
P07471210A0384 |189 198|positionsnction of
P07471210A0384 |123 137|messenger RNAsperbilirubinem
P07471210A0384 |174 180|genomes show
P07472582A0993 |50 67|99mTc-tetrofosmines and 5-nucleoti
P07472582A0993 |29 39|myocardiumh alkaline
P07472582A0993 |115 121|degreenatal 
P07472582A0993 |4 18|identification01606T0076 Com
P07472582A0993 |129 137|severityirubinem
P07472582A0993 |72 77|201TlP0000
P07472582A0993 |154 162|activity2 When C
P07472582A0993 |141 150|reductionP00008997
P07472582A0993 |184 191|defects a func
P07472736A0278 |70 78|eminencee P00008
P07472736A0278 |13 22|component6 Compari
P07472736A0278 |43 48|fossasphat
P07473169A0133 |0 5|EUK-8P0000
P07473169A0133 |66 73|complexidase P
P07473169A0133 |93 113|superoxide dismutasecologic aspects of n
P07473169A0133 |118 137|catalase activitiesal hyperbilirubinem
P07473742A0187 |4 17|protein ELT-101606T0076 Co
P07473742A0187 |164 171|element [HCO3-
P07473742A0187 |67 78|GATA familydase P00008
P07473742A0187 |44 48|genephat
P07473742A0187 |82 114|vertebrate transcription factors0000 Pharmacologic aspects of ne
P07474078A0838 |170 171|%-
P07474078A0838 |110 125|CA dinucleotidef neonatal hype
P07474078A0838 |12 20|contrast76 Compa
P07474078A0838 |75 85|alteration008171T000
P07474078A0838 |140 146|mutant P0000
P07474078A0838 |54 73|integration studiesnd 5-nucleotidase P
P07474078A0838 |185 205|integration activitya function of CSF PC
P07474085A0932 |103 108|codonpects
P07474085A0932 |14 23|R protein Comparis
P07474085A0932 |40 46|codonsphosph
P07474085A0932 |88 97|V proteinharmacolo
P07474085A0932 |65 80|frameshift sitetidase P0000817
P07474124A1360 |171 183|requirements] is shown a
P07474124A1360 |149 156|respect7A0472 
P07474124A1360 |132 143|differencesbinemia. P0
P07474124A1360 |6 13|results606T007
P07474124A1360 |112 119|virusesneonata
P07474124A1360 |40 43|PI2pho
P07474124A1360 |79 104|parainfluenza virus genus71T0000 Pharmacologic asp
P07474124A1360 |48 59|PI3 virusesases and 5-
P07474124A1360 |216 230|F glycoprotein of K-depleted
P07474124A1360 |204 208|tailCO2 
P07474140A1036 |17 28|mutagenesismparison wi
P07474140A1036 |131 145|ICP27 homologsubinemia. P000
P07474140A1036 |198 203|C-483 CSF 
P07474140A1036 |177 182|E-358hown 
P07474140A1036 |209 214|C-488he da
P07474140A1036 |250 258|activitydisplace
P07474140A1036 |191 196|C-400tion 
P07474140A1036 |76 95|amino acid residues08171T0000 Pharmaco
P07474140A1036 |59 64|ICP27nucle
P07474140A1036 |184 189|H-479 a fu
P07474140A1036 |155 168|herpesviruses When CSF [HC
P07474140A1036 |170 175|D-357-] is
P07474451A0000 |81 90|pathologyT0000 Pha
P07474451A0000 |28 31|MRIth 
P07474451A0000 |109 125|signal intensityof neonatal hype
P07474451A0000 |94 105|differencesologic aspe
P07474451A0000 |9 26|resonance imagingT0076 Comparison 
P07474617A1035 |0 8|PatientsP0000160
P07474617A1035 |61 71|PRL levelscleotidase
P07474617A1035 |27 32|drugsith a
P07474772A0274 |156 164|functionWhen CSF
P07474772A0274 |57 68|examination5-nucleotid
P07474772A0274 |96 106|comparisonogic aspec
P07474772A0274 |127 137|appearanceilirubinem
P07474772A0274 |4 33|Laser Scanning Ophthalmoscope01606T0076 Comparison with al
P07475733T0000 |0 7|MalariaP000016
P07475733T0000 |22 40|HIV-1 transmissionson with alkaline 
P07475733T0000 |9 16|anaemiaT0076 C
P07475733T0000 |52 58|Africa and 5
P07475793T0000 |0 3|BSEP00
P07475793T0000 |8 19|farmworkers6T0076 Comp
P07476164A1602 |170 182|CspB protein-] is shown 
P07476164A1602 |75 79|K13Q0081
P07476164A1602 |143 152|structure0008997A0
P07476164A1602 |113 120|mutantseonatal
P07476164A1602 |46 63|resonance studiesatases and 5-nucl
P07476164A1602 |90 94|F27Yrmac
P07476164A1602 |3 11|addition001606T0
P07476164A1602 |81 85|F15YT000
P07476164A1602 |69 73|F17Ase P
P07476701A0654 |102 116|correspondencespects of neon
P07476701A0654 |76 83|pollens08171T0
P07476701A0654 |28 42|IgE antibodiesth alkaline ph
P07476701A0654 |18 24|levelspariso
P07476963A0000 |34 43|receptorsaline pho
P07476963A0000 |78 82|RXRs171T
P07476963A0000 |56 76|retinoid X receptors 5-nucleotidase P000
P07476963A0000 |167 171|acidCO3-
P07476963A0000 |45 50|PPARshatas
P07476963A0000 |96 113|hormone receptorsogic aspects of n
P07476963A0000 |142 147|acids00008
P07476963A0000 |0 10|PeroxisomeP00001606T
P07476971A0381 |66 92|transcription factor Pit-1idase P00008171T0000 Pharm
P07476971A0381 |40 56|SKUT-1B-20 cellsphosphatases and
P07476975A0492 |101 109|controlsaspects 
P07476975A0492 |41 52|thyrotropeshosphatases
P07476975A0492 |14 25|lactotropes Comparison
P07476975A0492 |58 70|gonadotropes-nucleotidas
P07476975A0492 |214 224|cell typesta of K-de
P07476975A0492 |27 39|somatotropesith alkaline
P07476975A0492 |198 210|distribution CSF PCO2 th
P07476975A0492 |4 10|number01606T
P07476975A0492 |140 149|pituitary P0000899
P07476975A0492 |156 164|productsWhen CSF
P07477245A0625 |170 175|mg/kg-] is
P07477245A0625 |89 93|onesarma
P07477245A0625 |5 12|strains1606T00
P07477245A0625 |143 153|aflatoxins0008997A04
P07477245A0625 |111 113|G1 n
P07477245A0625 |125 139|concentrationsrbilirubinemia
P07477245A0625 |16 30|A. parasiticusomparison with
P07477245A0625 |49 71|aflatoxins B1 B2 G1 G2ses and 5-nucleotidase
P07477245A0625 |103 108|AF B1pects
P07478514A0237 |49 54|cloneses a
P07478514A0237 |31 34|ratalk
P07478523A0551 |3 11|addition001606T0
P07478523A0551 |40 56|amino acid formsphosphatases and
P07478523A0551 |151 170|RET protein isoform0472 When CSF [HCO3
P07478523A0551 |111 122|amino acids neonatal h
P07478525A1177 |50 56|dimerses and
P07478525A1177 |5 12|classes1606T00
P07478525A1177 |96 108|dimerizationogic aspects
P07478525A1177 |16 30|MHBst proteinsomparison with
P07479004A0421 |85 87|P20 
P07479004A0421 |135 139|HeLaemia
P07479004A0421 |121 129|extractshyperbil
P07479004A0421 |81 83|P1T0
P07479004A0421 |92 94|P3ac
P07479004A0421 |147 152|cells997A0
P07479004A0421 |46 50|PEREatas
P07479004A0421 |19 40|mobility shift assaysarison with alkaline 
P07479004A0421 |101 109|proteinsaspects 
P07479004A0421 |70 79|complexese P000081
P07482069A0606 |69 88|vasculitis symptomsse P00008171T0000 P
P07482069A0606 |47 53|monthstases 
P07482069A0606 |31 38|mg/weekalkalin
P07482069A0606 |23 26|MTXon 
P07483276A0139 |239 261|varicella-zoster virus no longer displaced w
P07483276A0139 |220 233|herpesvirus-1K-depleted ra
P07483276A0139 |16 24|sequenceompariso
P07483276A0139 |187 205|pseudorabies virusfunction of CSF PC
P07483276A0139 |155 177|herpes simplex virus-1 When CSF [HCO3-] is s
P07483276A0139 |179 184|HSV-1wn as
P07483276A0139 |94 97|UL2olo
P07483276A0139 |89 92|UL1arm
P07483276A0139 |62 66|ORFsleot
P07483276A0139 |143 151|proteins0008997A
P07483276A0139 |129 137|homologyirubinem
P07483276A0139 |108 111|UL3 of
P07483276A0139 |46 60|reading framesatases and 5-n
P07483276A0139 |207 210|PRV th
P07483276A0139 |99 102|UL3c a
P07483276A0139 |0 8|AnalysisP0000160
P07483285A0322 |152 161|induction472 When 
P07483285A0322 |6 23|HPV16 E6/E7 cDNAs606T0076 Comparis
P07483285A0322 |77 85|MMTV LTR8171T000
P07483285A0322 |133 147|transformationinemia. P00008
P07483285A0322 |46 68|SV40 enhancer/promoteratases and 5-nucleotid
P07483285A0322 |217 232|E7 gene productof K-depleted r
P07483285A0322 |174 187|DNA synthesiss shown as a 
P07483285A0322 |101 111|activitiesaspects of
P07483857A0350 |102 109|proteinspects 
P07483857A0350 |37 54|reference methodsne phosphatases a
P07483857A0350 |59 62|NITnuc
P07483857A0350 |179 204|connective-tissue-proteinwn as a function of CSF P
P07483857A0350 |84 89|water00 Ph
P07483857A0350 |114 157|connective-tissue-protein frei meat proteinonatal hyperbilirubinemia. P00008997A0472 W
P07483857A0350 |0 24|Correlation coefficientsP00001606T0076 Compariso
P07487067A0592 |33 39|cloneskaline
P07487067A0592 |124 131|lengthserbilir
P07487067A0592 |65 69|APS1tida
P07487067A0592 |158 167|sequencesen CSF [H
P07487067A0592 |143 148|amino00089
P07487067A0592 |179 195|transit peptideswn as a function
P07487067A0592 |200 220|plastid localizationSF PCO2 the data of 
P07487067A0592 |80 90|% identity1T0000 Pha
P07487067A0592 |4 24|translation products01606T0076 Compariso
P07487363A0447 |4 16|serum levels01606T0076 C
P07487363A0447 |29 34|asIgEh alk
P07487363A0447 |20 23|IgEris
P07487363A0447 |63 77|food allergenseotidase P0000
P07487363A0447 |39 44|IgG-4 phos
P07487811A0000 |34 41|effectsaline p
P07487811A0000 |150 155|PSE-1A0472
P07487811A0000 |172 183|spaceflight is shown a
P07487811A0000 |82 95|bone turnover0000 Pharmaco
P07487811A0000 |128 148|Systems Experiment-1lirubinemia. P000089
P07487811A0000 |56 67|spaceflight 5-nucleoti
P07487811A0000 |203 209|flightPCO2 t
P07487811A0000 |189 194|PSE-2nctio
P07487811A0000 |4 15|experiments01606T0076 
P07487908A0230 |137 143|originia. P0
P07487908A0230 |145 151|AR-42J08997A
P07487908A0230 |109 113|geneof n
P07487908A0230 |104 107|CATect
P07487908A0230 |164 169|cells [HCO
P07487908A0230 |5 13|sequence1606T007
P07487908A0230 |188 194|originunctio
P07487908A0230 |36 49|transcriptionine phosphata
P07487908A0230 |196 199|Ratof 
P07487908A0230 |70 102|chloramphenicol acetyltranferasee P00008171T0000 Pharmacologic a
P07487908A0230 |206 209|IEC2 t
P07487908A0230 |117 122|cellstal h
P07488247T0000 |138 144|systema. P00
P07488247T0000 |88 113|aryl hydrocarbon receptorharmacologic aspects of n
P07488247T0000 |121 126|yeasthyper
P07488247T0000 |57 82|translocator interactions5-nucleotidase P00008171T
P07488247T0000 |11 19|analysis076 Comp
P07488247T0000 |23 48|aryl hydrocarbon receptoron with alkaline phosphat
P07488291A0934 |152 175|triamcinolone acetonide472 When CSF [HCO3-] is
P07488291A0934 |63 86|triamcinolone acetonideeotidase P00008171T0000
P07488291A0934 |46 58|somatostatinatases and 5
P07488291A0934 |112 117|signsneona
P07488291A0934 |131 141|structuresubinemia. 
P07488291A0934 |16 28|observationsomparison wi
P07488959T0000 |33 38|modelkalin
P07488959T0000 |42 59|lymphocytopoiesisosphatases and 5-
P07488959T0000 |3 11|approach001606T0
P07489502A0000 |153 158|mRNAs72 Wh
P07489502A0000 |135 139|polyemia
P07489502A0000 |99 109|inhibitionc aspects 
P07489502A0000 |163 173|inhibitionF [HCO3-] 
P07489502A0000 |125 131|exportrbilir
P07489502A0000 |177 194|pre-mRNA splicinghown as a functio
P07489502A0000 |64 73|regulatorotidase P
P07489502A0000 |4 31|influenza virus NS1 protein01606T0076 Comparison with 
P07489502A0000 |87 97|activitiesPharmacolo
P07490079A0825 |68 76|evidencease P000
P07490079A0825 |107 114|homologs of ne
P07490079A0825 |14 21|regions Compar
P07490079A0825 |92 96|STEPacol
P07490079A0825 |41 48|syntenyhosphat
P07490079A0825 |129 138|STEP geneirubinemi
P07490079T0000 |102 109|mappingspects 
P07490079T0000 |31 38|homologalkalin
P07490079T0000 |134 138|locinemi
P07490079T0000 |75 79|STEP0081
P07490079T0000 |10 17|cloning0076 Co
P07490079T0000 |62 73|phosphataseleotidase P
P07490079T0000 |81 85|geneT000
P07490083A0000 |68 73|liverase P
P07490083A0000 |9 20|anhydrase VT0076 Compa
P07490083A0000 |92 99|tissuesacologi
P07490083A0000 |58 64|matrix-nucle
P07490083A0000 |22 26|CA Vson 
P07490156A0647 |119 130|correlationl hyperbili
P07490156A0647 |91 98|modulusmacolog
P07490156A0647 |74 78|mass0008
P07490156A0647 |16 34|nicotine treatmentomparison with alk
P07490156A0647 |53 62|increasesand 5-nuc
P07490156A0647 |0 10|Vitamin D3P00001606T
P07490278A0799 |54 59|Num1pnd 5-
P07490278A0799 |11 17|domain076 Co
P07490278A0799 |67 85|mother cell cortexdase P00008171T000
P07490742A0636 |117 127|subdomainstal hyperb
P07490742A0636 |36 42|notionine ph
P07490742A0636 |52 73|dsRNA binding domains and 5-nucleotidase P
P07490742A0636 |5 12|finding1606T00
P07490766T0000 |71 74|Max P0
P07490766T0000 |142 154|interactions00008997A047
P07490766T0000 |27 35|parallelith alka
P07490766T0000 |79 100|c-Myc leucine zippers71T0000 Pharmacologic
P07490766T0000 |104 115|descriptionects of neo
P07490766T0000 |190 208|heterodimerizationction of CSF PCO2 
P07490766T0000 |175 186|specificity shown as a
P07490766T0000 |48 57|formationases and 
P07490770A0267 |0 10|ComparisonP00001606T
P07490770A0267 |20 30|coxI genesrison with
P07490770A0267 |57 63|intron5-nucl
P07490770A0267 |107 112|yeasts of 
P07490770A0267 |181 197|DNA endonuclease as a function o
P07490770A0267 |49 54|groupses a
P07490770A0267 |81 89|homologyT0000 Ph
P07490770A0267 |118 128|intron aI4al hyperbi
P07491111A0221 |21 33|DMS-79 cellsison with al
P07491111A0221 |15 17|GRCo
P07491111A0221 |76 92|cell lung cancer08171T0000 Pharm
P07491305A0102 |220 227|reportsK-deple
P07491305A0102 |5 10|study1606T
P07491305A0102 |117 128|QRS complextal hyperbi
P07491305A0102 |32 44|localizationlkaline phos
P07491305A0102 |101 109|polarityaspects 
P07491305A0102 |156 167|surface ECGWhen CSF [H
P07491305A0102 |136 148|sinus rhythmmia. P000089
P07491305A0102 |184 203|delta wave polarity a function of CSF 
P07491305A0102 |51 68|accessory pathways and 5-nucleotid
P07491791A0263 |50 62|E1A productses and 5-nuc
P07491791A0263 |83 105|helper adenovirus type000 Pharmacologic aspe
P07491791A0263 |109 112|Ad5of 
P07491791A0263 |4 21|promoter mutation01606T0076 Compar
P07493327A0507 |49 58|integrityses and 5
P07493327A0507 |62 64|U2le
P07493327A0507 |74 83|U6 snRNAs0008171T0
P07493327A0507 |66 68|U4id
P07493627A0882 |0 9|TreatmentP00001606
P07493627A0882 |13 17|PCC46 Co
P07493627A0882 |52 59|agonist and 5-
P07493627A0882 |93 102|EC-1 mRNAcologic a
P07493627A0882 |109 118|treatmentof neonat
P07493627A0882 |79 89|expression71T0000 Ph
P07493627A0882 |141 148|agonistP000089
P07493627A0882 |157 172|EC-1 expressionhen CSF [HCO3-]
P07493627A0882 |18 29|aza1R cellsparison wit
P07494244A0335 |71 76|c-fos P000
P07494244A0335 |7 14|absence06T0076
P07494244A0335 |108 125|ATF/CREB proteins of neonatal hype
P07494244A0335 |26 29|YY1wit
P07494244A0335 |54 67|transcriptionnd 5-nucleoti
P07494244A0335 |143 146|CRE000
P07494244A0335 |18 24|E1A243pariso
P07494274A1015 |136 147|disfunctionmia. P00008
P07494274A1015 |11 22|experiments076 Compari
P07494274A1015 |63 72|reductioneotidase 
P07494274A1015 |194 211|virion maturationn of CSF PCO2 the
P07494274A1015 |151 160|alpha TIF0472 When
P07494274A1015 |76 87|virus yield08171T0000 
P07494274A1015 |109 120|temperatureof neonatal
P07494274A1015 |169 178|infection3-] is sh
P07494293A0585 |156 166|activationWhen CSF [
P07494293A0585 |31 34|tipalk
P07494293A0585 |120 123|Lck hy
P07494293A0585 |6 13|results606T007
P07494293A0585 |52 57|stage and 
P07494293A0585 |65 99|T-cell signal transduction cascadetidase P00008171T0000 Pharmacologi
P07494303A0000 |36 39|Vprine
P07494303A0000 |75 82|protein008171T
P07494303A0000 |135 156|monocytes/macrophagesemia. P00008997A0472 
P07494303A0000 |120 131|replication hyperbilir
P07494303A0000 |6 33|immunodeficiency virus type606T0076 Comparison with al
P07494306A0240 |152 160|fraction472 When
P07494306A0240 |95 100|cellslogic
P07494306A0240 |243 255|protein VP22longer displ
P07494306A0240 |181 192|polypeptide as a funct
P07494306A0240 |115 119|VP16nata
P07494306A0240 |20 29|potentialrison wit
P07494306A0240 |55 67|interactionsd 5-nucleoti
P07494306A0240 |34 38|VP16alin
P07494314A1287 |34 42|splicingaline ph
P07494314A1287 |106 120|LMP2A homologsts of neonatal
P07494314A1287 |74 98|tyrosine phosphorylation0008171T0000 Pharmacolog
P07494314A1287 |44 68|kinase interaction sitesphatases and 5-nucleotid
P07494314A1287 |22 32|regulationson with a
P07494314A1287 |161 184|sequences heterogeneityCSF [HCO3-] is shown as
P07494314A1287 |204 218|repeat regionsCO2 the data o
P07494314A1287 |255 259|EBVsaced
P07495059T0078 |0 7|ResultsP000016
P07495059T0078 |15 47|ECAT Angina Pectoris Study GroupComparison with alkaline phospha
P07495120A0260 |152 162|recurrence472 When C
P07495120A0260 |82 90|efficacy0000 Pha
P07495120A0260 |25 30|Phase with
P07495120A0260 |94 105|cryosurgeryologic aspe
P07495120A0260 |116 133|radiation therapyatal hyperbilirub
P07495120A0260 |71 77|safety P0000
P07495120A0260 |34 39|trialaline
P07495120A0260 |137 140|menia.
P07495726A1189 |116 136|Bcl-2 proto-oncogeneatal hyperbilirubine
P07495726A1189 |6 12|motifs606T00
P07495726A1189 |162 173|breakpointsSF [HCO3-] 
P07495726A1189 |177 188|T-ALL lineshown as a f
P07495726A1189 |80 108|recombination hotspot region1T0000 Pharmacologic aspects
P07495726A1189 |23 32|Chi motifon with a
P07495726A1189 |141 146|closeP0000
P07495726A1189 |48 55|elementases an
P07496184T0001 |19 28|prospectsarison wi
P07496184T0001 |41 51|gynecologyhosphatase
P07496184T0001 |75 99|Vienna University Clinic008171T0000 Pharmacologi
P07496184T0001 |59 66|Charitenucleot
P07496184T0001 |7 14|history06T0076
P07496400A0525 |220 229|seedlingsK-deplete
P07496400A0525 |122 127|plantyperb
P07496400A0525 |107 114|tissuess of ne
P07496400A0525 |241 255|inflorescenceso longer displ
P07496400A0525 |231 236|rootsrats 
P07496400A0525 |129 140|HMGR1L mRNAirubinemia.
P07496400A0525 |93 99|levelscologi
P07496400A0525 |41 51|HMGR1 mRNAhosphatase
P07496400A0525 |3 11|contrast001606T0
P07496400A0525 |53 64|HMGR1S mRNAand 5-nucle
P07496400A0525 |185 195|expressiona function
P07496400A0525 |170 176|levels-] is 
P07498727A0724 |185 201|T.A transversiona function of CS
P07498727A0724 |41 51|productionhosphatase
P07498727A0724 |28 32|rev3th a
P07498727A0724 |13 24|requirement6 Compariso
P07498727A0724 |61 78|T.A transversionscleotidase P00008
P07498727A0724 |179 182|G.Cwn 
P07498727A0724 |126 139|substitutionsbilirubinemia
P07498727A0724 |55 58|G.Cd 5
P07498727A0724 |86 99|rad18 mutator Pharmacologi
P07498791A0680 |85 89|gene0 Ph
P07498791A0680 |164 189|osmolarity stress pathway [HCO3-] is shown as a fu
P07498791A0680 |122 136|protein kinaseyperbilirubine
P07498791A0680 |91 95|PBS2maco
P07498791A0680 |11 19|mutation076 Comp
P07498791A0680 |67 73|alleledase P
P07499242A0898 |58 74|RAFTK expression-nucleotidase P0
P07499242A0898 |9 16|tissuesT0076 C
P07499252A0150 |171 182|PI 3-kinase] is shown 
P07499252A0150 |46 64|consensus sequenceatases and 5-nucle
P07499252A0150 |21 25|hGMRison
P07499252A0150 |157 167|activationhen CSF [H
P07499252A0150 |80 91|PI 3-kinase1T0000 Phar
P07499252A0150 |93 97|hGMRcolo
P07499252A0150 |69 76|bindingse P000
P07499252A0150 |3 19|hGM-CSF receptor001606T0076 Comp
P07499252A0150 |118 127|mechanismal hyperb
P07499252A0150 |136 147|associationmia. P00008
P07499394A0187 |0 2|J.P0
P07499401A0444 |85 86|F0
P07499401A0444 |63 64|%e
P07499401A0444 |59 60|Fn
P07499401A0444 |42 43|%o
P07499401A0444 |78 79|H1
P07499401A0444 |89 90|%a
P07499401A0444 |4 12|identity01606T00
P07499401A0444 |53 54|Ha
P07499401A0444 |21 29|hnRNPs Hison wit
P07499401A0444 |34 35|Ha
P07499409A0367 |0 4|TPBFP000
P07499409A0367 |75 81|region008171
P07499409A0367 |52 58|region and 5
P07499409A0367 |126 144|targeting sequencebilirubinemia. P00
P07499409A0367 |100 110|N terminus aspects o
P07499409A0367 |35 42|regionsline ph
P07499421A0237 |70 94|rat hepatocytes plasmidse P00008171T0000 Pharmac
P07499421A0237 |15 20|studyCompa
P07499421A0237 |109 115|CYP3A1of neo
P07499421A0237 |149 199|chloramphenicol acetyltransferase reporter plasmid7A0472 When CSF [HCO3-] is shown as a function of 
P07499421A0237 |58 66|cultures-nucleot
P07499421A0237 |128 137|sequenceslirubinem
P07499848A0409 |114 133|epsilon transcriptsonatal hyperbilirub
P07499848A0409 |151 160|cytokines0472 When
P07499848A0409 |74 83|Sf9 cells0008171T0
P07499848A0409 |44 51|B cellsphatase
P07499848A0409 |13 24|stimulation6 Compariso
P07499848A0409 |92 107|germ-line gammaacologic aspect
P07500386A0870 |83 90|domains000 Pha
P07500386A0870 |15 38|GapIII protein activityComparison with alkalin
P07500386A0870 |125 130|yeastrbili
P07500386A0870 |40 50|constructsphosphatas
P07500386A0870 |178 182|IRA1own 
P07500386A0870 |159 166|abilityn CSF [
P07500597A0212 |35 38|agelin
P07500597A0212 |57 61|days5-nu
P07500597A0212 |29 33|BPVsh al
P07500597A0212 |90 92|SDrm
P07500597A0212 |7 11|time06T0
P07500597A0212 |77 81|mean8171
P07500597A0212 |97 102|yearsgic a
P07500597A0212 |70 75|yearse P00
P07500950A0000 |118 141|Nicotiana tabacum L. cval hyperbilirubinemia. 
P07500950A0000 |21 26|trolCison 
P07500950A0000 |52 87|Agrobacterium rhizogenes Ri-plasmid and 5-nucleotidase P00008171T0000 
P07500950A0000 |2 19|tobacco homologue0001606T0076 Comp
P07500950A0000 |35 44|rolC geneline phos
P07500953A0305 |80 88|proteins1T0000 P
P07500953A0305 |120 129|ADR1 gene hyperbil
P07500953A0305 |36 49|transcriptionine phosphata
P07500953A0305 |108 112|copy of 
P07500953A0305 |53 58|genesand 5
P07500953A0305 |5 21|ADR1 gene dosage1606T0076 Compar
P07501016T0000 |40 59|galaxy TXFS2226-184phosphatases and 5-
P07501016T0000 |15 25|giga-maserComparison
P07501458A0578 |19 42|C/EBP family inhibitorsarison with alkaline ph
P07501458A0578 |44 50|Ig/EBPphatas
P07501458A0578 |60 67|CHOP-10ucleoti
P07501458A0578 |74 80|Ig/EBP000817
P07501458A0578 |52 55|LIP an
P07501700A0000 |81 84|MLAT00
P07501700A0000 |31 51|pretreatment regimenalkaline phosphatase
P07501700A0000 |164 174|occlusions [HCO3-] i
P07501700A0000 |57 79|monophosphoryl lipid A5-nucleotidase P000081
P07501700A0000 |89 107|micrograms/kg i.v.armacologic aspect
P07501700A0000 |213 217|dogsata 
P07501700A0000 |4 11|effects01606T0
P07501992A0125 |171 180|strontium] is show
P07501992A0125 |162 167|linesSF [H
P07501992A0125 |78 99|spectroscopy analysis171T0000 Pharmacologi
P07501992A0125 |31 48|scanning electronalkaline phosphat
P07501992A0125 |120 130|microscopy hyperbili
P07501992A0125 |188 199|rat incisorunction of 
P07501992A0125 |6 14|incisors606T0076
P07501992A0125 |101 108|SEM-EDSaspects
P07501992A0125 |207 213|dentin the d
P07504171A0715 |51 65|phosphopeptides and 5-nucleo
P07504171A0715 |43 49|PDGF-Rsphata
P07504171A0715 |183 186|Srcs a
P07504171A0715 |159 178|PDGF-R binding siten CSF [HCO3-] is sh
P07504171A0715 |77 84|Tyr-8578171T00
P07504171A0715 |19 41|growth factor receptorarison with alkaline p
P07504171A0715 |118 132|Src SH2 domainal hyperbiliru
P07504171A1214 |101 106|lightaspec
P07504171A1214 |90 97|resultsrmacolo
P07504171A1214 |46 64|binding propertiesatases and 5-nucle
P07504171A1214 |121 147|crystal structure solutionhyperbilirubinemia. P00008
P07504171A1214 |20 35|Src SH2 mutantsrison with alka
P07504171A1214 |156 170|Src SH2 domainWhen CSF [HCO3
P07504712A0843 |6 18|observations606T0076 Com
P07504712A0843 |24 45|actin plaque assemblyn with alkaline phosp
P07504712A0843 |59 82|cell substrate adhesionnucleotidase P00008171T
P07505349A0702 |38 46|resectioe phosph
P07505349A0702 |10 19|lethality0076 Comp
P07505349A0702 |91 97|monthsmacolo
P07505349A0702 |76 84|survival08171T00
P07505349A0702 |52 53|% 
P07505798A0000 |119 124|classl hyp
P07505798A0000 |194 207|T lymphocytesn of CSF PCO2
P07505798A0000 |133 159|histocompatibility complexinemia. P00008997A0472 Whe
P07505798A0000 |89 91|HAar
P07505798A0000 |209 213|CTLshe d
P07505798A0000 |74 87|hemagglutinin0008171T0000 
P07505798A0000 |161 164|MHCCSF
P07505798A0000 |26 31|siteswith 
P07505798A0000 |39 66|type A influenza A/Japan/57 phosphatases and 5-nucleot
P07505798A0000 |68 72|H2N2ase 
P07506253A0742 |50 59|promoterses and 5-
P07506253A0742 |41 43|TKho
P07506253A0742 |63 73|HeLa cellseotidase P
P07506253A0742 |5 13|enhancer1606T007
P07506253A0742 |33 36|K19kal
P07507187T0000 |102 112|adenovirusspects of 
P07507187T0000 |13 24|enhancement6 Compariso
P07507187T0000 |57 74|cointernalization5-nucleotidase P0
P07507187T0000 |28 42|DNA expressionth alkaline ph
P07507187T0000 |128 139|plasmid DNAlirubinemia
P07507187T0000 |0 9|MechanismP00001606
P07507207A0991 |19 35|IRF binding sitearison with alka
P07507207A0991 |57 71|IRF-2 promoter5-nucleotidase
P07507207A0991 |148 164|IRF-1 expression97A0472 When CSF
P07507207A0991 |95 105|IRF-2 genelogic aspe
P07507207A0991 |77 87|expression8171T0000 
P07507458A0250 |153 165|RIBA methods72 When CSF 
P07507458A0250 |43 51|patientssphatase
P07507458A0250 |122 132|antibodiesyperbiliru
P07507458A0250 |61 64|aimcle
P07507458A0250 |98 115|hepatitis C virusic aspects of neo
P07507458A0250 |143 148|ELISA00089
P07507458A0250 |117 120|HCVtal
P07507458A0250 |84 94|prevalence00 Pharmac
P07508082A0821 |34 42|activityaline ph
P07508082A0821 |104 112|chlorineects of 
P07508082A0821 |12 20|decrease76 Compa
P07508082A0821 |71 80|bleaching P0000817
P07508140A0448 |0 27|Hepatitis B surface antigenP00001606T0076 Comparison w
P07508140A0448 |46 54|patientsatases a
P07508140A0448 |70 96|hepatitis C virus antibodye P00008171T0000 Pharmacol
P07508250A0537 |275 288|investigationo controls bu
P07508250A0537 |122 123|py
P07508250A0537 |62 77|selenium intakeleotidase P0000
P07508250A0537 |112 113|rn
P07508250A0537 |82 110|liver selenium concentration0000 Pharmacologic aspects o
P07508250A0537 |146 155|treatment8997A0472
P07508250A0537 |166 185|time liver seleniumHCO3-] is shown as 
P07508250A0537 |140 142|mo P
P07508250A0537 |36 47|correlationine phospha
P07508250A0537 |206 210|time2 th
P07508250A0537 |220 231|correlationK-depleted 
P07508441A0487 |0 10|AntibodiesP00001606T
P07508441A0487 |367 373|memberurazep
P07508441A0487 |241 260|amino acid sequenceo longer displaced 
P07508441A0487 |313 321|56K cDNAtly grea
P07508441A0487 |281 291|annexin XIrols but s
P07508441A0487 |193 199|degreeon of 
P07508441A0487 |73 80|protein0000817
P07508441A0487 |220 230|nucleotideK-depleted
P07508441A0487 |117 134|HeLa cell extracttal hyperbilirubi
P07508441A0487 |353 363|annexin XI010943A073
P07508441A0487 |266 267|%o
P07508441A0487 |234 235|%s
P07508441A0487 |96 111|56K autoantigenogic aspects of
P07508441A0487 |203 211|homologyPCO2 the
P07508441A0487 |381 383|Caap
P07508441A0487 |170 185|56K cDNA shares-] is shown as 
P07508441A0487 |340 349|homologue 0.23 vs.
P07508441A0487 |136 151|cDNA sequencingmia. P00008997A
P07508441A0487 |411 433|binding protein familynotic drug with the op
P07508954A0000 |100 107|results aspect
P07508954A0000 |149 162|Ziehl-Neelsen7A0472 When C
P07508954A0000 |164 166|ZN [
P07508954A0000 |45 51|methodhatase
P07508954A0000 |18 36|complex peroxidaseparison with alkal
P07508954A0000 |38 43|ABC-Pe pho
P07508954A0000 |71 90|Mycobacterium bovis P00008171T0000 Pha
P07508954A0000 |168 177|techniqueO3-] is s
P07509053A0139 |18 27|processesparison w
P07509053A0139 |46 54|functionatases a
P07509053A0139 |58 63|c-Myb-nucl
P07509053A0139 |94 107|establishmentologic aspect
P07509053A0139 |129 136|lineageirubine
P07509053A0139 |4 8|role0160
P07509449A0000 |17 21|genempar
P07509449A0000 |150 159|sequencesA0472 Whe
P07509449A0000 |64 78|fusion proteinotidase P00008
P07509449A0000 |80 90|p47gag-crk1T0000 Pha
P07509449A0000 |214 217|SH2ta 
P07509449A0000 |94 99|v-Crkologi
P07509449A0000 |222 235|SH3 sequencesdepleted rats
P07509449A0000 |184 204|Src homology regions a function of CSF P
P07509449A0000 |35 53|sarcoma virus CT10line phosphatases 
P07509449A0000 |118 131|Gag sequencesal hyperbilir
P07509450A0705 |184 204|HSV tk gene activity a function of CSF P
P07509450A0705 |41 53|inactivationhosphatases 
P07509450A0705 |61 72|HSV tk genecleotidase 
P07509450A0705 |14 33|methylation pattern Comparison with al
P07509450A0705 |80 91|methylation1T0000 Phar
P07509450A0705 |128 147|nucleotide sequencelirubinemia. P00008
P07509450A0705 |99 116|cytosine residuesc aspects of neon
P07509450A0705 |174 180|effects show
P07509472A1320 |17 32|study documentsmparison with a
P07509472A1320 |38 48|regressione phosphat
P07509472A1320 |62 80|neovascularizationleotidase P0000817
P07509472A1320 |100 126|alpha interferon treatment aspects of neonatal hyper
P07509472A1320 |0 10|CONCLUSIONP00001606T
P07509624T0000 |51 73|chromosome aberrationss and 5-nucleotidase P
P07509624T0000 |106 125|gel electrophoresists of neonatal hype
P07509624T0000 |150 160|chromosomeA0472 When
P07509624T0000 |11 18|mapping076 Com
P07509624T0000 |133 138|yeastinemi
P07509624T0000 |26 38|11q23 regionwith alkalin
P07509624T0000 |83 89|tumors000 Ph
P07509811A1357 |0 4|GTREP000
P07509811A1357 |212 215|TREdat
P07509811A1357 |480 501|transcription factors mg at night. P000126
P07509811A1357 |121 136|protein bindinghyperbilirubine
P07509811A1357 |269 272|TREare
P07509811A1357 |468 476|familiesice bein
P07509811A1357 |435 456|transcription factorsmum dose for use in g
P07509811A1357 |15 35|CRE oligonucleotidesComparison with alka
P07509811A1357 |357 364|members43A0733
P07509811A1357 |221 241|CRE oligonucleotides-depleted rats are n
P07509811A1357 |458 466|CREB/ATFeral pra
P07509811A1357 |263 267|GTREn co
P07509811A1357 |334 342|proteins21 +/- 0
P07509811A1357 |206 210|GTRE2 th
P07509811A1357 |278 298|CRE oligonucleotidesontrols but still ha
P07509811A1357 |506 522|chromaffin cells45 Beta blocking
P07509811A1357 |6 9|TRE606
P07509811A1357 |69 84|protein bindingse P00008171T00
P07509811A1357 |168 184|oligonucleotidesO3-] is shown as
P07509811A1357 |372 379|Jun/Fospam thu
P07509811A1357 |102 111|congenersspects of
P07510461A0731 |4 11|patient01606T0
P07510461A0731 |25 43|test abnormalities with alkaline pho
P07510635A0479 |100 113|transcription aspects of n
P07510635A0479 |229 232|Pold r
P07510635A0479 |61 68|epitopecleotid
P07510635A0479 |14 20|mAb1C2 Compa
P07510635A0479 |219 222|Pol K-
P07510635A0479 |159 168|promotersn CSF [HC
P07510635A0479 |4 12|antibody01606T00
P07510635A0479 |38 45|peptidee phosp
P07510724A1208 |32 40|patientslkaline 
P07510724A1208 |142 153|association00008997A04
P07510724A1208 |162 173|sarcoidosisSF [HCO3-] 
P07510724A1208 |57 66|arthritis5-nucleot
P07510724A1208 |99 110|granulomatac aspects o
P07510724A1208 |189 198|arthritisnction of
P07510724A1208 |4 15|lymph nodes01606T0076 
P07510724A1208 |86 93|sarcoid Pharma
P07511444A0728 |0 13|HCV infectionP00001606T007
P07511444A0728 |147 152|years997A0
P07511444A0728 |107 118|hepatitis Cs of neonat
P07511444A0728 |159 162|BMTn C
P07511444A0728 |126 133|patientbilirub
P07511444A0728 |66 77|hepatitis Cidase P0000
P07511444A0728 |39 42|BMT ph
P07511444T0000 |0 27|Hepatitis C virus infectionP00001606T0076 Comparison w
P07511444T0000 |83 90|disease000 Pha
P07511444T0000 |97 124|bone marrow transplantationgic aspects of neonatal hyp
P07511444T0000 |33 44|risk factorkaline phos
P07511444T0000 |49 62|liver failureses and 5-nuc
P07511496A1511 |38 48|E-selectine phosphat
P07511496A1511 |109 114|deathof ne
P07511496A1511 |93 104|dysfunctioncologic asp
P07511496A1511 |5 26|plasma concentrations1606T0076 Comparison 
P07511818A0485 |170 175|cells-] is
P07511818A0485 |183 188|cellss a f
P07511818A0485 |132 136|ratebine
P07511818A0485 |210 224|control vectore data of K-de
P07511818A0485 |104 107|IFNect
P07511818A0485 |33 49|cell populationskaline phosphata
P07511818A0485 |242 259|IFN-beta sequence longer displaced
P07511818A0485 |290 297|proteinstill h
P07511818A0485 |84 94|production00 Pharmac
P07512159A0992 |0 11|ImprovementP00001606T0
P07512159A0992 |59 78|splicing efficiencynucleotidase P00008
P07512159A0992 |89 95|degreearmaco
P07512159A0992 |138 158|branchpoint mutationa. P00008997A0472 Wh
P07512159A0992 |19 39|polypyrimidine tractarison with alkaline
P07512258A0441 |0 21|Liver transplantationP00001606T0076 Compar
P07512258A0441 |132 143|neutropeniabinemia. P0
P07512258A0441 |90 99|PMN countrmacologi
P07512258A0441 |56 69|complications 5-nucleotida
P07512258A0441 |29 36|patienth alkal
P07512258A0441 |161 166|G-CSFCSF [
P07512258A0441 |118 124|statusal hyp
P07512552A0270 |0 4|JoysP000
P07512552A0270 |9 11|F.T0
P07513703T0000 |102 110|peptidesspects o
P07513703T0000 |124 152|insulin receptor substrate-1erbilirubinemia. P00008997A0
P07513703T0000 |63 70|SH-PTP2eotidas
P07513703T0000 |33 61|protein tyrosine phosphatasekaline phosphatases and 5-nu
P07513703T0000 |0 10|ActivationP00001606T
P07514295A0000 |0 24|Tyrosine phosphorylationP00001606T0076 Compariso
P07514295A0000 |91 114|T-cell antigen receptormacologic aspects of ne
P07514295A0000 |75 80|event00817
P07514295A0000 |176 195|signaling machineryshown as a function
P07514295A0000 |121 132|stimulationhyperbiliru
P07514295A0000 |37 45|proteinsne phosp
P07514295A0000 |116 119|TCRata
P07514301A0000 |136 145|infectionmia. P000
P07514301A0000 |37 51|protein kinasene phosphatase
P07514301A0000 |93 97|rolecolo
P07514301A0000 |247 257|propertieser displac
P07514301A0000 |114 121|defenseonatal 
P07514301A0000 |53 56|PKRand
P07514301A0000 |191 212|tumor suppressor genetion of CSF PCO2 the 
P07514301A0000 |154 162|addition2 When C
P07516337A1119 |127 139|Jurkat cellsilirubinemia
P07516337A1119 |89 96|bindingarmacol
P07516337A1119 |72 85|stoichiometryP00008171T000
P07516337A1119 |56 62|p95Vav 5-nuc
P07516337A1119 |10 13|Lck007
P07516466A1054 |119 127|activityl hyperb
P07516466A1054 |192 213|phosphorylation stateion of CSF PCO2 the d
P07516466A1054 |28 35|plasmidth alka
P07516466A1054 |13 22|injection6 Compari
P07516466A1054 |67 76|t antigendase P000
P07516466A1054 |52 57|virus and 
P07516466A1054 |178 184|effectown as
P07516466A1054 |144 169|phosphoprotein substrates008997A0472 When CSF [HCO
P07516466A1054 |217 221|CREBof K
P07516466A1054 |99 103|PP2Ac as
P07516466A1054 |3 11|contrast001606T0
P07516466A1054 |252 265|NIH 3T3 cellssplaced when 
P07516469A1025 |8 11|Src6T0
P07516469A1025 |72 77|cellsP0000
P07516469A1025 |24 32|proteinsn with a
P07516597A1017 |139 157|antigen processing. P00008997A0472 W
P07516597A1017 |79 98|polyprotein segment71T0000 Pharmacolog
P07516597A1017 |182 185|MVEas 
P07516597A1017 |121 135|proteinase NS3hyperbilirubin
P07516597A1017 |61 64|MVEcle
P07516597A1017 |162 174|presentationSF [HCO3-] i
P07516597A1017 |43 53|processingsphatases 
P07516597A1017 |203 221|T cell determinantPCO2 the data of K
P07516597A1017 |21 27|effectison w
P07516866A0000 |48 51|DNAase
P07516866A0000 |91 116|pigeon crop sac librariesmacologic aspects of neon
P07516866A0000 |14 26|PRL receptor Comparison 
P07516866A0000 |132 145|transcriptionbinemia. P000
P07516866A0000 |28 32|PRLRth a
P07516866A0000 |57 64|pigeons5-nucle
P07516866A0000 |159 184|polymerase chain reactionn CSF [HCO3-] is shown as
P07517544A0515 |223 227|timeeple
P07517544A0515 |104 116|pancreatitisects of neon
P07517544A0515 |134 142|recoverynemia. P
P07517544A0515 |281 290|mg/kg/dayrols but 
P07517544A0515 |176 184|pancreasshown as
P07517544A0515 |160 168|function CSF [HC
P07517544A0515 |28 38|regressionth alkalin
P07517544A0515 |213 219|periodata of
P07517544A0515 |58 69|alterations-nucleotida
P07517544A0515 |8 12|days6T00
P07517544A0515 |233 238|L-364ts ar
P07517869A0411 |17 34|dephosphorylationmparison with alk
P07517869A0411 |213 233|sodium orthovanadateata of K-depleted ra
P07517869A0411 |126 135|increasesbilirubin
P07517869A0411 |164 186|phosphatase inhibitors [HCO3-] is shown as a
P07517869A0411 |80 91|C/EBP-delta1T0000 Phar
P07517869A0411 |143 151|presence0008997A
P07517869A0411 |69 76|abilityse P000
P07517869A0411 |204 208|acidCO2 
P07518257A0351 |33 52|S1 nuclease mappingkaline phosphatases
P07518257A0351 |78 80|bp17
P07518257A0351 |120 122|P2 h
P07518257A0351 |144 146|bp00
P07518257A0351 |110 114|genef ne
P07518257A0351 |54 56|P1nd
P07518257A0351 |4 13|promoters01606T007
P07518426A0000 |85 101|C-X-C chemokines0 Pharmacologic 
P07518426A0000 |75 81|family008171
P07518426A0000 |15 19|IL-8Comp
P07518426A0000 |46 54|mediatoratases a
P07518426A0000 |0 13|Interleukin-8P00001606T007
P07518460A0771 |19 24|cellsariso
P07518460A0771 |13 17|hand6 Co
P07518460A0771 |140 151|phosphatase P00008997A
P07518460A0771 |67 71|sitedase
P07518460A0771 |38 43|PTP1Ce pho
P07518460A0771 |101 112|mutagenesisaspects of 
P07518561A0496 |92 107|TCR/CD3 complexacologic aspect
P07518561A0496 |164 183|receptor triggering [HCO3-] is shown a
P07518561A0496 |123 131|tyrosineperbilir
P07518561A0496 |192 199|T cellsion of 
P07518561A0496 |208 214|p56lckthe da
P07518561A0496 |27 57|p72syk protein tyrosine kinaseith alkaline phosphatases and 
P07518578A0000 |17 24|proteinmpariso
P07518578A0000 |28 46|Rous sarcoma virusth alkaline phosph
P07518578A0000 |219 228|pp60v-src K-deplet
P07518578A0000 |202 217|binding ability PCO2 the data 
P07518578A0000 |172 184|localization is shown as
P07518578A0000 |92 101|pp60c-srcacologic 
P07518578A0000 |320 329|pp60c-srcater slop
P07518578A0000 |83 90|homolog000 Pha
P07518578A0000 |48 57|pp60v-srcases and 
P07518578A0000 |304 310|matrixignifi
P07519447T0000 |0 12|OrganizationP00001606T00
P07519447T0000 |27 31|geneith 
P07519447T0000 |64 78|oxide synthaseotidase P00008
P07519463A0000 |84 95|consumption00 Pharmaco
P07519463A0000 |42 57|work efficiencyosphatases and 
P07519463A0000 |59 80|segment work/regionalnucleotidase P0000817
P07519463A0000 |139 145|inflow. P000
P07519481A1275 |101 106|stageaspec
P07519481A1275 |112 118|resultneonat
P07519481A1275 |176 180|roleshow
P07519481A1275 |26 30|micewith
P07519481A1275 |147 161|follicle cells997A0472 When 
P07519481A1275 |194 207|oocyte growthn of CSF PCO2
P07519481A1275 |18 20|Slpa
P07519481A1275 |185 190|c-kita fun
P07519481A1275 |21 24|paniso
P07519481A1275 |130 143|KL expressionrubinemia. P0
P07519481A1275 |13 16|pan6 C
P07519481A1275 |40 60|follicle developmentphosphatases and 5-n
P07519481A1275 |10 12|Sl00
P07519606A1269 |0 13|Anti-NPROSP-CP00001606T007
P07519606A1269 |96 111|lamellar bodiesogic aspects of
P07519606A1269 |79 92|proSP-C forms71T0000 Pharm
P07519606A1269 |55 66|appearancesd 5-nucleot
P07519606A1269 |116 127|homogenatesatal hyperb
P07520098A0211 |119 124|classl hyp
P07520098A0211 |75 77|Db00
P07520098A0211 |67 72|classdase 
P07520098A0211 |41 45|bm13hosp
P07520098A0211 |47 53|straintases 
P07520098A0211 |28 39|B6.CH-2bm13th alkaline
P07520098A0211 |55 59|partd 5-
P07520098A0211 |97 103|groovegic as
P07520098A0211 |18 20|Dbpa
P07520098A0211 |138 146|sequencea. P0000
P07521009A0377 |6 13|mutants606T007
P07521009A0377 |58 66|MW104-1B-nucleot
P07521009A0377 |177 183|Kramerhown a
P07521009A0377 |148 151|G/T97A
P07521009A0377 |30 34|pms3 alk
P07521009A0377 |15 19|pms1Comp
P07521009A0377 |153 156|A/C72 
P07521009A0377 |21 25|pms2ison
P07521009A0377 |158 161|G/Gen 
P07521009A0377 |132 146|DNA mismatchesbinemia. P0000
P07521009A0377 |192 197|1989aion o
P07521009A0377 |163 167|etc.F [H
P07521009A0377 |110 118|plasmidsf neonat
P07521285A1109 |205 222|F wave parametersO2 the data of K-
P07521285A1109 |357 371|F wave studies43A0733 Fluraz
P07521285A1109 |292 300|additionill have
P07521285A1109 |83 87|CIDP000 
P07521285A1109 |52 65|nerve lesions and 5-nucleo
P07521285A1109 |261 268|latencyhen com
P07521285A1109 |182 192|assessmentas a funct
P07521285A1109 |30 39|frequency alkaline
P07521285A1109 |348 353|yield. P00
P07521285A1109 |133 163|motor conduction abnormalitiesinemia. P00008997A0472 When CS
P07521285A1109 |316 331|minimum latency greater slope 
P07521285A1109 |75 78|GBS008
P07521285A1109 |4 12|findings01606T00
P07521285A1109 |278 287|amplitudeontrols b
P07521285A1109 |304 311|absenceignific
P07521285A1109 |238 254|chronodispersione no longer disp
P07521601A0000 |123 138|cancer patientsperbilirubinemi
P07521601A0000 |74 86|myelopoiesis0008171T0000
P07521601A0000 |14 28|growth factors Comparison wi
P07521601A0000 |62 70|recoveryleotidas
P07521601A0000 |107 119|chemotherapys of neonata
P07521916T0000 |0 7|EffectsP000016
P07521916T0000 |41 55|site sequenceshosphatases an
P07521916T0000 |11 22|alterations076 Compari
P07521916T0000 |95 106|replicationlogic aspec
P07521916T0000 |65 92|immunodeficiency virus typetidase P00008171T0000 Pharm
P07522163T0000 |0 12|PresentationP00001606T00
P07522163T0000 |122 129|C57BL/6yperbil
P07522163T0000 |104 107|MHCect
P07522163T0000 |76 102|histocompatibility complex08171T0000 Pharmacologic a
P07522163T0000 |57 67|H-2b class5-nucleoti
P07522163T0000 |109 118|moleculesof neonat
P07522163T0000 |193 211|MHC anchor residueon of CSF PCO2 the
P07522163T0000 |157 170|T lymphocyteshen CSF [HCO3
P07522163T0000 |172 180|presence is show
P07522163T0000 |250 265|CTL recognitiondisplaced when 
P07522163T0000 |18 44|horse cytochrome c peptideparison with alkaline phos
P07523363A0440 |35 50|fragment islandline phosphatas
P07523363A0440 |106 138|USF2 translation initiation sitets of neonatal hyperbilirubinemi
P07523363A0440 |24 29|HpaIIn wit
P07523363A0440 |80 90|base pairs1T0000 Pha
P07523710T0000 |0 9|DiagnosisP00001606
P07523710T0000 |123 138|ultrasonographyperbilirubinemi
P07523710T0000 |47 61|serum prostatetases and 5-nu
P07523710T0000 |23 32|carcinomaon with a
P07523710T0000 |95 106|examinationlogic aspec
P07523710T0000 |38 43|yielde pho
P07523710T0000 |71 78|antigen P00008
P07524265T0000 |49 54|G-CSFses a
P07524265T0000 |29 47|stimulating factorh alkaline phospha
P07524265T0000 |90 103|complicationsrmacologic as
P07524265T0000 |56 62|levels 5-nuc
P07524265T0000 |66 74|neonatesidase P0
P07525548A1380 |136 139|CS1mia
P07525548A1380 |93 101|rsVCAM-1cologic 
P07525548A1380 |149 169|fibronectin variants7A0472 When CSF [HCO
P07525548A1380 |104 124|fibronectin variantsects of neonatal hyp
P07525548A1380 |36 53|ligand affinitiesine phosphatases 
P07525548A1380 |23 32|hierarchyon with a
P07525548A1380 |83 91|activity000 Phar
P07525548A1380 |4 11|results01606T0
P07525596A0584 |71 75|Fpr3 P00
P07525596A0584 |107 113|domains of n
P07525596A0584 |141 156|PPIase activityP00008997A0472 
P07525843A0859 |305 312|removalgnifica
P07525843A0859 |149 154|lysis7A047
P07525843A0859 |209 213|H-2dhe d
P07525843A0859 |119 131|target cellsl hyperbilir
P07525843A0859 |186 196|affinities function 
P07525843A0859 |220 256|histocompatibility complex moleculesK-depleted rats are no longer displa
P07525843A0859 |357 364|removal43A0733
P07525843A0859 |21 37|H-2d NP peptidesison with alkali
P07525843A0859 |267 275|peptidesmpared t
P07525843A0859 |57 61|logs5-nu
P07525843A0859 |330 339|H-2b mice (1.21 +/
P07525843A0859 |283 290|accountls but 
P07525843A0859 |401 403|NPec
P07525843A0859 |316 322|NP CTL great
P07525843A0859 |13 17|H-2b6 Co
P07525843A0859 |200 204|H-2bSF P
P07525843A0859 |67 82|H-2b NP peptidedase P00008171T
P07525843A0859 |368 377|H-2d micerazepam t
P07525843A0859 |0 9|DilutionsP00001606
P07526609A0736 |70 92|PKR activator sequencee P00008171T0000 Pharm
P07526609A0736 |42 48|UTR/S1osphat
P07526609A0736 |9 19|expressionT0076 Comp
P07526609A0736 |122 124|S4yp
P07526609A0736 |164 166|S4 [
P07526609A0736 |36 38|S4in
P07526609A0736 |23 28|sigmaon wi
P07526609A0736 |98 100|S1ic
P07526609A0736 |115 118|UTRnat
P07527168A0524 |0 12|MicrovesselsP00001606T00
P07527168A0524 |61 65|areacleo
P07527168A0524 |31 41|x200 fieldalkaline p
P07527168A0524 |77 89|angiogenesis8171T0000 Ph
P07527168A0524 |49 52|mm2ses
P07528028A1192 |100 107|studies aspect
P07528028A1192 |123 136|transfectantsperbilirubine
P07528028A1192 |165 170|FGF-1[HCO3
P07528028A1192 |45 73|FGF-1 cell surface receptorshatases and 5-nucleotidase P
P07528028A1192 |249 254|WORDS disp
P07528028A1192 |26 36|cell lineswith alkal
P07528028A1192 |191 204|transfectantstion of CSF P
P07528028A1192 |223 231|ABSTRACTepleted 
P07528325A0165 |252 267|gene expressionsplaced when co
P07528325A0165 |133 141|tyrosineinemia. 
P07528325A0165 |226 239|DNA sequenceseted rats are
P07528325A0165 |181 188|nucleus as a f
P07528325A0165 |7 14|studies06T0076
P07528325A0165 |78 83|Stat1171T0
P07528325A0165 |52 63|GH receptor and 5-nucl
P07528325A0165 |99 119|transcription factorc aspects of neonata
P07528531A0904 |66 68|rsid
P07528531A0904 |59 64|cellsnucle
P07528531A0904 |178 180|rsow
P07528531A0904 |94 111|blood cell countsologic aspects of
P07528531A0904 |124 125|Pe
P07528531A0904 |148 150|rs97
P07528531A0904 |21 26|G-CSFison 
P07528531A0904 |113 115|rseo
P07528531A0904 |189 190|Pn
P07528531A0904 |159 160|Pn
P07528531A0904 |77 78|P8
P07528531A0904 |135 146|neutrophilsemia. P0000
P07528531A0904 |9 19|infectionsT0076 Comp
P07528531A0904 |173 176|CRPis 
P07528667A0834 |6 22|initiation sites606T0076 Compari
P07528667A0834 |37 46|positionsne phosph
P07528746A1049 |0 26|Phosphoamino acid analysisP00001606T0076 Comparison 
P07528746A1049 |156 173|phosphoamino acidWhen CSF [HCO3-] 
P07528746A1049 |112 113|%n
P07528746A1049 |212 220|presencedata of 
P07528746A1049 |247 248|%e
P07528746A1049 |123 124|Pp
P07528746A1049 |182 193|polypeptideas a functi
P07528746A1049 |224 227|Tyrple
P07528746A1049 |119 122|Thrl h
P07528746A1049 |153 154|%7
P07528746A1049 |253 257|RHL1plac
P07528746A1049 |228 229|Pe
P07528746A1049 |73 74|P0
P07528746A1049 |43 57|ASGPR subunitssphatases and 
P07528746A1049 |69 72|Serse 
P07528772A0616 |304 310|regionignifi
P07528772A0616 |258 266|peptidesd when c
P07528772A0616 |50 68|ZAP-70 interactiones and 5-nucleotid
P07528772A0616 |187 190|NH2fun
P07528772A0616 |334 346|TCR zeta cyt21 +/- 0.23 
P07528772A0616 |213 224|SH2 domainsata of K-de
P07528772A0616 |362 370|TCR zeta33 Flura
P07528772A0616 |78 81|TCR171
P07528772A0616 |130 171|glutathione S-transferase fusion proteinsrubinemia. P00008997A0472 When CSF [HCO3-
P07528772A0616 |228 234|ZAP-70ed rat
P07528772A0616 |318 332|TCR zeta chainreater slope (
P07528772A0616 |98 111|binding assayic aspects of
P07528772A0616 |276 284|sequence control
P07528772A0616 |33 45|requirementskaline phosp
P07528772A0616 |375 397|CD3 epsilon TAM motifs thus appears to be an
P07528772A1539 |16 24|tyrosineompariso
P07528772A1539 |109 120|SH2 domainsof neonatal
P07528772A1539 |124 130|ZAP-70erbili
P07528772A1539 |40 52|TAM peptidesphosphatases
P07529124A0119 |205 225|amino acid sequencesO2 the data of K-dep
P07529124A0119 |128 136|subunitslirubine
P07529124A0119 |79 90|heterodimer71T0000 Pha
P07529124A0119 |227 235|residuested rats
P07529124A0119 |148 155|weights97A0472
P07529124A0119 |159 162|kDan C
P07529124A0119 |22 31|structureson with 
P07529124A0119 |35 37|RTli
P07529124A0119 |170 173|kDa-] 
P07529504A0000 |168 175|studiesO3-] is
P07529504A0000 |79 109|X-ray contrast agent iopromide71T0000 Pharmacologic aspects 
P07529504A0000 |122 125|CASype
P07529504A0000 |111 120|Ultravist neonatal
P07529504A0000 |36 51|characteristicsine phosphatase
P07529516A0474 |70 74|EDXRe P0
P07529516A0474 |15 23|patientsComparis
P07529516A0474 |62 66|doseleot
P07529516A0474 |79 88|mg/m2/day71T0000 P
P07530128A0578 |59 64|ng/mlnucle
P07530128A0578 |41 50|serum PSAhosphatas
P07530502A0974 |0 8|AdditionP0000160
P07530502A0974 |45 62|SI4-h220 cultureshatases and 5-nuc
P07530502A0974 |123 142|protein degradationperbilirubinemia. P
P07530502A0974 |72 81|reductionP00008171
P07530502A0974 |38 41|SLFe p
P07530502A0974 |98 114|c-kit expressionic aspects of ne
P07530502T0000 |103 108|c-kitpects
P07530502T0000 |15 27|Steel factorComparison w
P07530502T0000 |122 129|proteinyperbil
P07530502T0000 |90 99|life spanrmacologi
P07530502T0000 |147 151|form997A
P07530502T0000 |52 78|tyrosine kinase activation and 5-nucleotidase P00008
P07530549A0956 |239 244|genes no l
P07530549A0956 |121 127|cloneshyperb
P07530549A0956 |45 59|GRAIL programshatases and 5-
P07530549A0956 |173 179|clonesis sho
P07530549A0956 |143 152|sequences0008997A0
P07530549A0956 |202 211|sequences PCO2 the
P07530549A0956 |92 100|evidenceacologic
P07530549A0956 |16 25|sequencesomparison
P07530549A0956 |223 231|portionsepleted 
P07530549A0956 |35 40|BLASTline 
P07530549A0956 |0 8|AnalysisP0000160
P07531321A0369 |0 8|PatientsP0000160
P07531321A0369 |28 40|PVC/24 hoursth alkaline 
P07531321A0369 |75 78|PVC008
P07531321A0369 |59 71|distributionnucleotidase
P07531321A0369 |83 96|CI evaluation000 Pharmacol
P07532278A0833 |0 7|HorvathP000016
P07532278A0833 |9 11|I.T0
P07533527A0128 |152 163|marker loss472 When CS
P07533527A0128 |72 85|hybridizationP00008171T000
P07533527A0128 |28 34|tumorsth alk
P07533527A0128 |126 136|chromosomebilirubine
P07533527A0128 |94 100|statusologic
P07533527A0128 |144 147|PCR008
P07533527A0128 |0 10|Cell linesP00001606T
P07533758A1038 |51 64|RfbB homologss and 5-nucle
P07533758A1038 |90 91|%r
P07533758A1038 |125 126|%r
P07533758A1038 |72 82|identitiesP00008171T
P07533758A1038 |132 133|%b
P07533758A1038 |105 115|similaritycts of neo
P07533758A1038 |97 98|%g
P07533758A1038 |42 46|RfbAosph
P07533758A1038 |140 150|similarity P00008997
P07533758A1038 |4 24|amino acid sequences01606T0076 Compariso
P07533858A1503 |102 117|oligomerizationspects of neona
P07533858A1503 |135 143|GP64 EFPemia. P0
P07533858A1503 |122 131|transportyperbilir
P07533858A1503 |73 86|substitutions00008171T0000
P07533858A1503 |43 50|prolinesphatas
P07533858A1503 |18 39|alanine substitutionsparison with alkaline
P07533880T0000 |55 58|RNAd 5
P07533880T0000 |40 44|FinPphos
P07533880T0000 |75 84|traJ mRNA008171T00
P07533880T0000 |20 33|IncF plasmidsrison with al
P07533880T0000 |67 73|targetdase P
P07533880T0000 |99 115|duplex formationc aspects of neo
P07533880T0000 |4 16|FinO protein01606T0076 C
P07534285A0155 |138 147|BaF3/mMpla. P00008
P07534285A0155 |29 43|ligand bindingh alkaline pho
P07534285A0155 |8 13|paper6T007
P07534285A0155 |124 136|Mpl receptorerbilirubine
P07534285A0155 |52 76|tyrosine phosphorylation and 5-nucleotidase P000
P07534285A0155 |80 90|BaF3 cells1T0000 Pha
P07534286A0842 |69 76|proteinse P000
P07534286A0842 |93 94|%c
P07534286A0842 |114 123|paxil-linonatal hy
P07534286A0842 |2 23|chicken paxillin cDNA0001606T0076 Comparis
P07534297A0141 |158 161|CATen 
P07534297A0141 |89 109|AP endonuclease genearmacologic aspects 
P07534297A0141 |60 66|regionucleot
P07534297A0141 |111 114|APE ne
P07534297A0141 |123 156|chloramphenicol acetyltransferaseperbilirubinemia. P00008997A0472 
P07534297A0141 |25 50|pair HindIII DNA fragment with alkaline phosphatas
P07534297A0141 |163 167|geneF [H
P07534306A0444 |153 160|studies72 When
P07534306A0444 |30 46|GrsA derivatives alkaline phosph
P07534306A0444 |208 236|carboxyl thioester formationthe data of K-depleted rats 
P07534306A0444 |89 99|propertiesarmacologi
P07534306A0444 |316 324|D-isomer greater
P07534306A0444 |107 123|deletion mutantss of neonatal hy
P07534306A0444 |246 253|abilityger dis
P07534306A0444 |287 300|phenylalanineut still have
P07534306A0444 |185 206|amino acid activationa function of CSF PCO
P07534306A0444 |306 307|Ln
P07535593A0714 |0 3|CD7P00
P07535593A0714 |36 52|V delta 2D deltaine phosphatases
P07535593A0714 |10 27|T-cell precursors0076 Comparison w
P07535593A0714 |5 8|CD3160
P07535593A0714 |55 69|rearrangementsd 5-nucleotida
P07535768A1076 |0 9|HVH2 mRNAP00001606
P07535768A1076 |95 99|PAC1logi
P07535768A1076 |79 89|mouse MKP171T0000 Ph
P07535768A1076 |53 58|CL100and 5
P07535768A1076 |127 150|MAP kinase phosphatasesilirubinemia. P00008997
P07535768A1076 |66 75|homologueidase P00
P07535768A1076 |20 38|expression patternrison with alkalin
P07537267A2094 |70 80|breakpointe P0000817
P07537267A2094 |88 103|HPFH-3 deletionharmacologic as
P07537267A2094 |30 39|sequences alkaline
P07537267A2094 |6 10|data606T
P07537267A2094 |296 300|lifehave
P07537267A2094 |198 209|specificity CSF PCO2 t
P07537267A2094 |122 131|structureyperbilir
P07537267A2094 |155 163|enhancer When CS
P07537267A2094 |140 148|function P000089
P07537267A2094 |223 241|gamma-globin genesepleted rats are n
P07537267A2094 |272 282|expressiond to contr
P07537362A1112 |83 104|coimmunoprecipitation000 Pharmacologic asp
P07537362A1112 |28 57|Shb-SH3 domain proteins v-Srcth alkaline phosphatases and 
P07537362A1112 |62 66|Eps8leot
P07537362A1112 |8 19|association6T0076 Comp
P07537736A0453 |118 124|regional hyp
P07537736A0453 |181 188|members as a f
P07537736A0453 |196 225|cytokine receptor superfamilyof CSF PCO2 the data of K-dep
P07537736A0453 |26 37|interactionwith alkali
P07537736A0453 |46 50|Jak2atas
P07537736A0453 |132 140|receptorbinemia.
P07537736A0453 |55 59|PRLRd 5-
P07537736A0453 |4 11|results01606T0
P07537736A0453 |100 108|membrane aspects
P07537736A0453 |84 92|sequence00 Pharm
P07537851A0000 |0 13|TranscriptionP00001606T007
P07537851A0000 |177 204|tumor necrosis factor alphahown as a function of CSF P
P07537851A0000 |56 62|VCAM-1 5-nuc
P07537851A0000 |104 122|lipopolysaccharideects of neonatal h
P07537851A0000 |30 52|cell adhesion molecule alkaline phosphatases
P07537851A0000 |64 68|geneotid
P07537851A0000 |144 172|cytokines interleukin-1 beta008997A0472 When CSF [HCO3-]
P07537851A0000 |206 215|TNF-alpha2 the dat
P07537851A0000 |84 89|cells00 Ph
P07537851A0891 |0 11|ExperimentsP00001606T0
P07537851A0891 |247 248|Ie
P07537851A0891 |125 132|bindingrbiliru
P07537851A0891 |214 217|p50ta 
P07537851A0891 |29 37|proteinsh alkali
P07537851A0891 |149 158|VCAM1 IRF7A0472 Wh
P07537851A0891 |181 186|IRF-1 as a
P07537851A0891 |252 259|proteinsplaced
P07537851A0891 |87 94|proteinPharmac
P07537851A0891 |249 250|Y 
P07537851A0891 |82 83|I0
P07537851A0891 |50 57|p50/p65es and 
P07537851A0891 |84 85|Y0
P07537851A0891 |167 171|siteCO3-
P07537851A0891 |136 141|IRF-1mia. 
P07538068A1094 |84 92|boundary00 Pharm
P07538068A1094 |15 22|resultsCompari
P07538068A1094 |52 54|AX a
P07538068A1094 |129 144|Hoxa-7 enhancerirubinemia. P00
P07538068A1094 |96 110|Hox expressionogic aspects o
P07538068A1094 |35 50|control elementline phosphatas
P07538122A0800 |8 14|report6T0076
P07538122A0800 |31 40|isolationalkaline 
P07538122A0800 |60 66|Fab A8ucleot
P07538122A0800 |123 125|nMpe
P07538122A0800 |46 58|Fab fragmentatases and 5
P07538122A0800 |109 117|receptorof neona
P07538122A0800 |92 100|affinityacologic
P07538173A0307 |137 145|strengthia. P000
P07538173A0307 |95 98|Mg2log
P07538173A0307 |60 74|ATP hydrolysisucleotidase P0
P07538173A0307 |83 91|presence000 Phar
P07538173A0307 |25 50|DNA-RNA helicase activity with alkaline phosphatas
P07538173A0307 |100 104|ions asp
P07538173A0307 |0 9|MBP-Rep68P00001606
P07538818A0197 |255 259|IL-3aced
P07538818A0197 |271 276|Ba/F3ed to
P07538818A0197 |240 253|interleukin-3no longer dis
P07538818A0197 |105 129|amino acid substitutionscts of neonatal hyperbil
P07538818A0197 |281 296|FDCP cell linesrols but still 
P07538818A0197 |78 87|deletions171T0000 
P07538818A0197 |177 184|hG-CSFRhown as
P07538818A0197 |167 173|domainCO3-] 
P07538818A0197 |21 28|regionsison wi
P07538818A0197 |39 65|growth signal transduction phosphatases and 5-nucleo
P07538818A0197 |201 206|cDNAsF PCO
P07538818A0197 |69 76|hG-CSFRse P000
P07539119A0291 |100 114|G128R mutation aspects of ne
P07539119A0291 |42 51|mutationsosphatase
P07539119A0291 |123 137|transformationperbilirubinem
P07539119A0291 |180 192|G128R mutantn as a funct
P07539119A0291 |82 94|NH2-terminus0000 Pharmac
P07539119A0291 |59 78|c-abl kinase domainnucleotidase P00008
P07539119A0291 |217 222|cellsof K-
P07539119A0291 |235 242|reasons are no
P07539119A0985 |51 65|Abl SH3 domains and 5-nucleo
P07539119A0985 |36 43|bindingine pho
P07539119A0985 |82 97|target proteins0000 Pharmacolo
P07539119A0985 |5 14|mutations1606T0076
P07539119A0985 |118 123|assayal hy
P07539314T0000 |102 114|nifurpirinolspects of ne
P07539314T0000 |23 28|gillson wi
P07539314T0000 |126 132|P-7138biliru
P07539314T0000 |90 98|exposurermacolog
P07539314T0000 |116 124|Furanaceatal hyp
P07539314T0000 |66 77|fingerlingsidase P0000
P07539314T0000 |49 55|chanosses an
P07539314T0000 |0 7|ChangesP000016
P07540607A0709 |0 11|RetreatmentP00001606T0
P07540607A0709 |82 96|immunoglobulin0000 Pharmacol
P07540607A0709 |23 27|dogson w
P07540607A0709 |64 72|responseotidase 
P07540773A0576 |68 71|PVBase
P07540773A0576 |22 25|MBPson
P07540773A0576 |14 17|NSE Co
P07540773A0576 |4 10|levels01606T
P07540773A0576 |33 37|IJVBkali
P07540866A1069 |17 31|insulin effectmparison with 
P07540866A1069 |104 117|A/K1018 cellsects of neona
P07540866A1069 |44 61|ras GTP formationphatases and 5-nu
P07540866A1069 |149 159|Y/F2 cells7A0472 Whe
P07540866A1069 |66 85|MAP kinase activityidase P00008171T000
P07541589A0652 |116 137|lymph node metastasisatal hyperbilirubinem
P07541589A0652 |31 44|cancer volumealkaline phos
P07541589A0652 |12 21|variables76 Compar
P07541589A0652 |73 84|penetration00008171T00
P07541589A0652 |94 110|vesicle invasionologic aspects o
P07541589A0652 |57 62|grade5-nuc
P07541912A0485 |0 17|Sequence analysisP00001606T0076 Co
P07541912A0485 |121 123|P2hy
P07541912A0485 |44 52|CAAT boxphatases
P07541912A0485 |82 101|G-C content regions0000 Pharmacologic 
P07541912A0485 |27 34|regionsith alk
P07541912A0485 |65 72|exon 1atidase 
P07541912A0485 |114 116|P1on
P07542577A0438 |35 40|ELISAline 
P07542577A0438 |94 99|orderologi
P07542577A0438 |63 68|paneleotid
P07542577A0438 |45 55|reactivityhatases an
P07542577A0438 |114 120|natureonatal
P07542577A0438 |128 136|epitopeslirubine
P07542577A0438 |4 19|fusion proteins01606T0076 Comp
P07542577A0438 |86 90|sera Pha
P07542616A0313 |0 5|GCD10P0000
P07542616A0313 |58 67|repressor-nucleoti
P07542616A0313 |71 75|GCN4 P00
P07542616A0486 |119 144|yeast initiation factor-3l hyperbilirubinemia. P00
P07542616A0486 |12 15|RNA76 
P07542616A0486 |178 185|complexown as 
P07542616A0486 |59 67|evidencenucleoti
P07542616A0486 |146 151|eIF-38997A
P07542616A0486 |108 115|subunit of neo
P07542616A0486 |154 159|eIF-32 Whe
P07542616A0486 |202 224|translation initiation PCO2 the data of K-de
P07542616A0486 |255 260|stepsaced 
P07542616A0486 |0 5|GCD10P0000
P07542698A0137 |0 7|SourcesP000016
P07542698A0137 |26 33|signalswith al
P07542698A0137 |11 16|noise076 C
P07542698A0137 |52 64|preparations and 5-nucle
P07542698A0137 |97 109|probe RH-414gic aspects 
P07543592A0624 |54 64|E5 proteinnd 5-nucle
P07543592A0624 |27 33|mutantith al
P07543592A0624 |135 150|down-regulationemia. P00008997
P07543592A0624 |76 84|receptor08171T00
P07543592A0624 |97 130|receptor tyrosine phosphorylationgic aspects of neonatal hyperbili
P07543684A1027 |17 21|cAMPmpar
P07543684A1027 |78 98|CFTR gene expression171T0000 Pharmacolog
P07543684A1027 |150 160|cell typesA0472 When
P07543684A1027 |59 68|regulatornucleotid
P07543684A1027 |131 135|CFTRubin
P07543684A1027 |38 41|PKAe p
P07543684A1027 |118 127|inductional hyperb
P07543868A0414 |155 156|A 
P07543868A0414 |150 154|polyA047
P07543868A0414 |72 85|cDNA fragmentP00008171T000
P07543868A0414 |12 29|restriction sites76 Comparison wit
P07543868A0414 |123 131|sequenceperbilir
P07543868A0414 |158 162|tailen C
P07544357A0808 |171 183|CD44 variant] is shown a
P07544357A0808 |151 162|correlation0472 When C
P07544357A0808 |90 101|LNCap cellsrmacologic 
P07544357A0808 |15 28|ALVA-31 cellsComparison wi
P07544357A0808 |37 50|tumorigenesisne phosphatas
P07544357A0808 |127 136|phenotypeilirubine
P07544357A0808 |76 80|mice0817
P07544357A0808 |192 202|expressionion of CSF
P07544357A0808 |5 10|PPC-11606T
P07544357A0808 |218 241|prostate tumor behaviorf K-depleted rats are n
P07544357A0808 |55 67|invasivenessd 5-nucleoti
P07544357A0808 |185 190|CD44va fun
P07545510A0735 |69 77|SDS-PAGEse P0000
P07545510A0735 |58 65|Cot40-2-nucleo
P07545510A0735 |161 172|cotS regionCSF [HCO3-]
P07545510A0735 |20 24|cotSriso
P07545510A0735 |82 96|immunoblotting0000 Pharmacol
P07545510A0735 |4 16|gene product01606T0076 C
P07545510A0735 |138 145|plasmida. P000
P07545920A1336 |93 96|DNAcol
P07545920A1336 |27 37|hsiggll150ith alkali
P07545920A1336 |9 14|genesT0076
P07545920A1336 |42 52|hsiggll295osphatases
P07546256A0000 |32 37|studylkali
P07546256A0000 |132 142|Casablancabinemia. P
P07546256A0000 |111 115|unit neo
P07546256A0000 |124 128|careerbi
P07546256A0000 |82 90|children0000 Pha
P07546256A0000 |66 74|injuriesidase P0
P07546293A0968 |85 95|expression0 Pharmaco
P07546293A0968 |57 66|sequences5-nucleot
P07546293A0968 |25 40|protein binding with alkaline 
P07546293A0968 |4 11|results01606T0
P07546294A0000 |137 148|sporulationia. P000089
P07546294A0000 |4 18|RAD6/UBC2 gene01606T0076 Com
P07546294A0000 |120 131|mutagenesis hyperbilir
P07546294A0000 |81 87|enzymeT0000 
P07546294A0000 |100 110|DNA repair aspects o
P07546794A0100 |0 16|EchocardiographyP00001606T0076 C
P07546794A0100 |54 62|collapsend 5-nuc
P07546794A0100 |104 113|tamponadeects of n
P07546794A0100 |64 68|RVDCotid
P07546794A0100 |87 92|signsPharm
P07547220A0229 |70 76|slidese P000
P07547220A0229 |127 132|slideiliru
P07547220A0229 |12 32|screening programmes76 Comparison with a
P07547220A0229 |83 87|test000 
P07547220A0229 |38 53|Haemoccult teste phosphatases 
P07547500A0066 |152 158|growth472 Wh
P07547500A0066 |166 171|yeastHCO3-
P07547500A0066 |28 42|fusion proteinth alkaline ph
P07547500A0066 |91 95|GAL4maco
P07547500A0066 |44 52|GAL4-p40phatases
P07547500A0066 |81 87|domainT0000 
P07547500A0066 |113 136|chicken l kappa B-alphaeonatal hyperbilirubine
P07547500A0066 |138 141|p40a. 
P07547500A0066 |100 109|sequences aspects 
P07547510A0261 |289 315|HNF-3 beta gene expression still have a significantl
P07547510A0261 |244 254|LF-H3 betaonger disp
P07547510A0261 |124 131|factorserbilir
P07547510A0261 |319 330|hepatocyteseater slope
P07547510A0261 |181 185|site as 
P07547510A0261 |203 215|binding sitePCO2 the dat
P07547510A0261 |67 86|HNF-3 beta promoterdase P00008171T0000
P07547510A0261 |236 242|factorare no
P07547510A0261 |49 54|sitesses a
P07548425A0000 |221 230|lesioning-depleted
P07548425A0000 |108 111|Sur of
P07548425A0000 |160 183|tail muscle motoneurons CSF [HCO3-] is shown a
P07548425A0000 |26 33|effectswith al
P07548425A0000 |46 52|inputsatases
P07548425A0000 |234 244|S2-3 levels are no l
P07548425A0000 |77 83|nerves8171T0
P07548425A0000 |101 106|nerveaspec
P07548425A0000 |16 20|catsompa
P07548858A0000 |51 57|dermiss and 
P07548858A0000 |76 84|function08171T00
P07548858A0000 |96 104|pressureogic asp
P07548858A0000 |36 42|salineine ph
P07548858A0000 |4 13|flow rate01606T007
P07548858A0000 |17 26|phosphatemparison 
P07549005A0530 |64 77|Epon sectionsotidase P0000
P07549005A0530 |9 30|parallax measurementsT0076 Comparison with
P07549005A0530 |92 97|placeacolo
P07549005A0530 |52 60|collapse and 5-n
P07550216A0195 |23 29|limitson wit
P07550216A0195 |31 38|latencyalkalin
P07551787A0917 |68 81|investigationase P00008171
P07551787A0917 |151 173|radiotherapy technique0472 When CSF [HCO3-] 
P07551787A0917 |4 11|outcome01606T0
P07551787A0917 |96 103|resultsogic as
P07551787A0917 |19 31|optimizationarison with 
P07551787A0917 |51 55|plans an
P07552974A0217 |69 77|argininese P0000
P07552974A0217 |41 52|amino acidshosphatases
P07552974A0217 |9 21|requirementsT0076 Compar
P07552974A0217 |54 63|glutaminend 5-nucl
P07553942A0810 |49 54|rrn26ses a
P07553942A0810 |96 102|genomeogic a
P07553942A0810 |59 63|cox3nucl
P07553942A0810 |145 151|intron08997A
P07553942A0810 |4 20|pea rps10 intron01606T0076 Compa
P07553942A0810 |114 135|Marchantia rps10 geneonatal hyperbilirubin
P07553942A0810 |38 45|intronse phosp
P07553942A0810 |71 81|Marchantia P00008171
P07554541A0587 |81 105|electrolyte disturbancesT0000 Pharmacologic aspe
P07554541A0587 |61 71|managementcleotidase
P07554541A0587 |45 56|recognitionhatases and
P07554541A0587 |12 16|care76 C
P07554541A0587 |20 31|CHF patientrison with 
P07555373A0000 |0 15|Serum magnesiumP00001606T0076 
P07555373A0000 |89 97|controlsarmacolo
P07555373A0000 |46 55|neoplasmsatases an
P07555373A0000 |22 30|patientsson with
P07555373A0000 |69 78|cisplatinse P00008
P07557091A0314 |0 7|METHODSP000016
P07557091A0314 |9 13|rHb1T007
P07557091A0314 |25 38|serum albumin with alkalin
P07557091A0314 |86 96|volunteers Pharmacol
P07557276A0526 |0 24|Alanine aminotransferaseP00001606T0076 Compariso
P07557276A0526 |91 102|hepatitis Bmacologic a
P07557276A0526 |31 37|levelsalkali
P07557276A0526 |109 118|infectionof neonat
P07557276A0526 |26 29|ALTwit
P07557276A0526 |78 86|patients171T0000
P07557276A0526 |64 70|monthsotidas
P07557387A0241 |87 94|programPharmac
P07557387A0241 |47 57|C/EBP betatases and 
P07557387A0241 |142 161|NIH-3T3 fibroblasts00008997A0472 When 
P07557387A0241 |8 13|study6T007
P07557387A0241 |113 123|C/EBP betaeonatal hy
P07557387A0241 |39 43|role pho
P07557424A0124 |0 4|XYL1P000
P07557424A0124 |61 65|lacZcleo
P07557424A0124 |40 52|fusion clonephosphatases
P07557424A0124 |80 94|fusion library1T0000 Pharmac
P07557446T0000 |69 77|splicingse P0000
P07557446T0000 |43 53|VCSA1 genesphatases 
P07557446T0000 |108 111|rat of
P07557446T0000 |90 100|processingrmacologic
P07557446T0000 |8 19|transcripts6T0076 Comp
P07557446T0000 |126 131|glandbilir
P07557446T0000 |82 86|poly0000
P07557446T0000 |87 88|AP
P07557717A0184 |103 112|morbiditypects of 
P07557717A0184 |9 17|divisionT0076 Co
P07557717A0184 |94 98|painolog
P07557717A0184 |58 67|diathermy-nucleoti
P07557717A0184 |25 43|chest wall muscles with alkaline pho
P07558263T0000 |0 7|ClosureP000016
P07558263T0000 |87 93|devicePharma
P07558263T0000 |35 62|guillotine amputation woundline phosphatases and 5-nuc
P07558583A0562 |102 120|peptide substratesspects of neonatal
P07558583A0562 |31 40|synthesisalkaline 
P07558583A0562 |164 188|tyrosine kinase activity [HCO3-] is shown as a f
P07558583A0562 |81 86|orderT0000
P07558583A0562 |4 9|study01606
P07558583A0562 |214 224|inhibitorsta of K-de
P07558583A0562 |243 248|classlonge
P07558583A0562 |49 60|derivativesses and 5-n
P07558583A0562 |138 147|detectiona. P00008
P07558583A0562 |252 259|enzymessplaced
P07558583A0562 |69 77|sequencese P0000
P07559233A0534 |0 25|Citrate synthase activityP00001606T0076 Comparison
P07559233A0534 |62 63|%l
P07559233A0534 |104 105|Pe
P07559233A0534 |181 185|head as 
P07559233A0534 |93 97|headcolo
P07559233A0534 |148 154|R rats97A047
P07559233A0534 |192 193|Pi
P07559233A0534 |122 144|triceps brachii muscleyperbilirubinemia. P00
P07559233A0534 |54 58|headnd 5
P07559233A0534 |189 190|%n
P07559233A0534 |65 66|Pt
P07559233A0534 |101 102|%a
P07559347A0000 |86 90|bglP Pha
P07559347A0000 |31 43|operon bglPHalkaline pho
P07559347A0000 |92 96|lacZacol
P07559347A0000 |47 64|Bacillus subtilistases and 5-nucle
P07559347A0000 |113 120|fusionseonatal
P07559347A0000 |4 14|expression01606T0076
P07559355A0066 |171 191|Proteus gene cluster] is shown as a func
P07559355A0066 |26 31|geneswith 
P07559355A0066 |46 61|urease activityatases and 5-nu
P07559355A0066 |114 126|organizationonatal hyper
P07559355A0066 |131 141|regulationubinemia. 
P07559355A0066 |154 159|genes2 Whe
P07559355A0066 |221 227|detail-deple
P07559356T0000 |115 126|mutagenesisnatal hyper
P07559356T0000 |25 62|Rhizobium leguminosarum biovar viciae with alkaline phosphatases and 5-nuc
P07559356T0000 |134 143|fnrN genenemia. P0
P07559356T0000 |93 101|promotercologic 
P07559356T0000 |4 19|hypBFCDE operon01606T0076 Comp
P07559402A0622 |69 85|protein kinase Cse P00008171T000
P07559402A0622 |26 33|peptidewith al
P07559402A0622 |22 24|VTso
P07559402A0622 |131 134|PKAubi
P07559402A0622 |113 129|protein kinase Aeonatal hyperbil
P07559402A0622 |87 90|PKCPha
P07559430A0909 |0 2|R.P0
P07559478A0389 |24 26|T.n 
P07559478A0389 |15 22|O'NeillCompari
P07559488A0440 |186 193|type ER functi
P07559488A0440 |89 106|estradiol-17 betaarmacologic aspec
P07559488A0440 |63 84|affinity binding siteeotidase P00008171T00
P07559488A0440 |37 51|fusion proteinne phosphatase
P07559488A0440 |160 165|yeast CSF 
P07559488A0440 |143 156|reporter gene0008997A0472 
P07559488A0440 |0 19|Control experimentsP00001606T0076 Comp
P07559510A0000 |168 170|L.O3
P07559510A0000 |160 166|Gordon CSF [
P07559510A0000 |122 136|endonuclease Vyperbilirubine
P07559510A0000 |9 43|Micrococcus luteus UV endonucleaseT0076 Comparison with alkaline pho
P07559510A0000 |78 84|enzyme171T00
P07559510A0000 |142 158|bacteriophage T400008997A0472 Wh
P07559510A0000 |99 107|homologyc aspect
P07559524A0000 |32 46|growth factorslkaline phosph
P07559524A0000 |55 75|G1 phase progressiond 5-nucleotidase P00
P07559524A0000 |18 27|oncogenesparison w
P07559524A0741 |0 27|Cyclin D1 promoter activityP00001606T0076 Comparison w
P07559524A0741 |46 60|overexpressionatases and 5-n
P07559524A0741 |82 96|protein kinase0000 Pharmacol
P07559524A0741 |110 117|c-Ets-2f neona
P07559524A0741 |142 152|base pairs00008997A0
P07559524A0741 |98 105|p41MAPKic aspe
P07559555A0557 |16 21|c-Junompar
P07559555A0557 |95 102|complexlogic a
P07559555A0557 |8 11|ERM6T0
P07559555A0557 |52 59|EBS-CRE and 5-
P07559563A0282 |42 45|Ca2osp
P07559563A0282 |61 69|activitycleotida
P07559563A0282 |10 18|residues0076 Com
P07559639A0996 |17 39|R206S HSF substitutionmparison with alkaline
P07559639A0996 |111 115|HSE2 neo
P07559639A0996 |78 88|activation171T0000 P
P07559639A0996 |96 109|consensus HSEogic aspects 
P07559639A0996 |3 11|addition001606T0
P07559640A1230 |137 142|basesia. P
P07559640A1230 |42 45|endosp
P07559640A1230 |8 13|bases6T007
P07559640A1230 |53 60|elementand 5-n
P07559640A1230 |110 121|UAS elementf neonatal 
P07559640A1230 |96 104|functionogic asp
P07559640A1230 |170 180|core motif-] is show
P07559650A0558 |69 72|E2Fse 
P07559650A0558 |6 13|results606T007
P07559650A0558 |54 65|target genend 5-nucleo
P07559650A0558 |32 41|PCNA genelkaline p
P07560137T0000 |32 56|MMPI-2 depression scaleslkaline phosphatases and
P07560137T0000 |61 70|subscalescleotidas
P07560137T0000 |13 24|sensitivity6 Compariso
P07560662A0496 |6 14|recovery606T0076
P07560662A0496 |29 45|saline challengeh alkaline phosp
P07562775A0596 |34 35|%a
P07562775A0596 |88 93|nadirharma
P07562775A0596 |13 24|eosinophils6 Compariso
P07562775A0596 |96 97|%o
P07562775A0596 |43 49|numbersphata
P07562775A0596 |4 9|range01606
P07562775A0596 |70 81|blood cellse P00008171
P07563072A0773 |0 11|ComparisonsP00001606T0
P07563072A0773 |88 92|rpoDharm
P07563072A0773 |15 38|rrnB P1-lacZ expressionComparison with alkalin
P07563072A0773 |93 98|P504Lcolog
P07563072A0773 |147 152|ppGpp997A0
P07563072A0773 |127 143|hypersensitivityilirubinemia. P0
P07563072A0773 |52 64|ppGpp levels and 5-nucle
P07563076A0766 |272 289|splicing proteinsd to controls but
P07563076A0766 |61 69|elementscleotida
P07563076A0766 |211 214|bi4 da
P07563076A0766 |194 199|coresn of 
P07563076A0766 |6 21|intron chimeras606T0076 Compar
P07563076A0766 |43 52|sequencessphatases
P07563076A0766 |160 168|portions CSF [HC
P07563076A0766 |130 138|activityrubinemi
P07563076A0766 |86 98|splice sites Pharmacolog
P07563076A0766 |203 206|ai4PCO
P07563076A0766 |236 241|coresare n
P07563076A0766 |257 264|targetsed when
P07563090A0124 |239 247|sequence no long
P07563090A0124 |132 140|boundarybinemia.
P07563090A0124 |165 171|repeat[HCO3-
P07563090A0124 |173 177|PPT1is s
P07563090A0124 |249 253|PPT2 dis
P07563090A0124 |108 113|sites of n
P07563090A0124 |192 198|middleion of
P07563090A0124 |49 62|DNA synthesisses and 5-nuc
P07563090A0124 |206 214|pol gene2 the da
P07563090A0124 |70 87|yeast Ty1 elemente P00008171T0000 
P07563090A0124 |222 231|integrasedepleted 
P07563090A0624 |51 64|DNA fragmentss and 5-nucle
P07563090A0624 |27 31|endsith 
P07563090A0624 |177 185|majorityhown as 
P07563090A0624 |124 128|PPT2erbi
P07563090A0624 |310 315|modelcantl
P07563090A0624 |282 291|agreementols but s
P07563090A0624 |213 226|DNA fragmentsata of K-depl
P07563090A0624 |95 103|fragmentlogic as
P07563090A0624 |338 363|RNA reverse transcription/- 0.23 vs. P00010943A073
P07563090A0624 |234 238|copys ar
P07563090A0624 |259 278|primer binding site when compared to c
P07563090A0624 |0 16|CharacterizationP00001606T0076 C
P07563994A0488 |205 206|pO
P07563994A0488 |126 127|pb
P07563994A0488 |145 155|blood loss08997A0472
P07563994A0488 |176 178|mlsh
P07563994A0488 |182 185|OLBas 
P07563994A0488 |121 124|minhyp
P07563994A0488 |72 76|VTLBP000
P07563994A0488 |157 161|VTLBhen 
P07563994A0488 |93 96|mincol
P07563994A0488 |24 28|VTLBn wi
P07563994A0488 |201 203|mlF 
P07563994A0488 |65 70|timestidas
P07563994A0488 |4 12|patients01606T00
P07563994A0488 |101 104|OLBasp
P07564004A0292 |21 37|Cr2O3 inhalationison with alkali
P07564004A0292 |7 14|minutes06T0076
P07564004A0292 |39 45|FEV1.0 phosp
P07564004A0292 |65 66|%t
P07564210A0557 |102 103|hs
P07564210A0557 |72 81|analgesiaP00008171
P07564210A0557 |129 134|signsirubi
P07564210A0557 |56 67|anaesthesia 5-nucleoti
P07564210A0557 |38 45|regimene phosp
P07564210A0557 |85 89|pigs0 Ph
P07565031A0454 |278 290|milk dessertontrols but 
P07565031A0454 |186 191|pasta func
P07565031A0454 |357 366|tuna fish43A0733 F
P07565031A0454 |250 265|spinach raviolidisplaced when 
P07565031A0454 |113 125|cream cheeseeonatal hype
P07565031A0454 |127 144|apricot marmeladeilirubinemia. P00
P07565031A0454 |302 307|cocoa sign
P07565031A0454 |60 65|Ogawaucleo
P07565031A0454 |241 245|meato lo
P07565031A0454 |95 102|strainslogic a
P07565031A0454 |391 395|milk be 
P07565031A0454 |309 323|milk confitureicantly greate
P07565031A0454 |368 375|ricottarazepam
P07565031A0454 |227 239|meat sausageted rats are
P07565031A0454 |166 176|mayonnaiseHCO3-] is 
P07565031A0454 |104 111|yoghurtects of
P07565031A0454 |44 58|V. cholerae O1phatases and 5
P07565031A0454 |155 164|marmelade When CSF
P07565031A0454 |325 331|starchslope 
P07565031A0454 |267 276|margarinempared to
P07565031A0454 |146 149|hip899
P07565031A0454 |197 206|empanadasf CSF PCO
P07565031A0454 |348 355|lettuce. P0001
P07565031A0454 |336 345|additives +/- 0.23
P07565031A0454 |7 20|food products06T0076 Compa
P07565049A1032 |137 140|ageia.
P07565049A1032 |45 52|outlinehatases
P07565049A1032 |210 212|g.e 
P07565049A1032 |104 106|NBec
P07565049A1032 |183 189|weights a fu
P07565049A1032 |144 148|term0089
P07565104A0084 |34 38|tcpAalin
P07565104A0084 |58 62|ToxR-nuc
P07565104A0084 |72 76|ToxTP000
P07565104A0084 |22 32|pilin geneson with a
P07565104A0084 |4 14|expression01606T0076
P07565113A0000 |170 178|excision-] is sh
P07565113A0000 |194 202|plasmidsn of CSF
P07565113A0000 |122 145|Clostridium perfringensyperbilirubinemia. P000
P07565113A0000 |31 48|transposon Tn4451alkaline phosphat
P07565113A0000 |79 87|deletion71T0000 
P07565113A0000 |97 118|parent plasmid plP401gic aspects of neonat
P07565669T0000 |0 10|Ras p21ValP00001606T
P07565669T0000 |52 63|DNA binding and 5-nucl
P07565669T0000 |133 140|factorsinemia.
P07565669T0000 |83 93|activities000 Pharma
P07565669T0000 |20 30|myogenesisrison with
P07565672A0798 |50 55|arg-2es an
P07565672A0798 |95 100|cox-5logic
P07565672A0798 |60 65|cpc-1ucleo
P07565672A0798 |36 46|expressionine phosph
P07565672A0798 |145 155|components08997A0472
P07565672A0798 |81 91|expressionT0000 Phar
P07565672A0798 |3 8|cells00160
P07565685A0420 |38 44|factore phos
P07565685A0420 |72 81|GABP betaP00008171
P07565685A0420 |57 67|GABP alpha5-nucleoti
P07565685A0420 |89 92|Etsarm
P07565685A0420 |97 109|Notch motifsgic aspects 
P07565685A0420 |4 21|peptide sequences01606T0076 Compar
P07565688A0797 |171 180|cytoplasm] is show
P07565688A0797 |86 93|protein Pharma
P07565688A0797 |202 207|cells PCO2
P07565688A0797 |139 146|protein. P0000
P07565688A0797 |185 192|nucleusa funct
P07565688A0797 |0 29|Immunofluorescence microscopyP00001606T0076 Comparison wit
P07565688A0797 |34 61|cell fractionation analysesaline phosphatases and 5-nu
P07565688T0000 |0 10|ExpressionP00001606T
P07565688T0000 |74 93|adenosine deaminase0008171T0000 Pharma
P07565688T0000 |105 110|cellscts o
P07565688T0000 |15 25|regulationComparison
P07565688T0000 |129 134|formsirubi
P07565688T0000 |29 39|interferonh alkaline
P07565688T0000 |112 120|evidenceneonatal
P07565688T0000 |142 151|deaminase00008997A
P07565709A0000 |0 17|T-cell hybridomasP00001606T0076 Co
P07565709A0000 |79 89|cell death71T0000 Ph
P07565709A0000 |116 131|T-cell receptoratal hyperbilir
P07565709A0000 |93 103|activationcologic as
P07565709A0000 |19 29|thymocytesarison wit
P07565709A0000 |35 42|T cellsline ph
P07565712A0286 |0 9|DeletionsP00001606
P07565712A0286 |93 100|insertscologic
P07565712A0286 |167 183|quasipalindromesCO3-] is shown a
P07565712A0286 |31 40|LYS2 genealkaline 
P07565712A0286 |71 78|inserts P00008
P07565712A0286 |142 151|structure00008997A
P07565712A0286 |50 53|setes 
P07565712A0286 |118 127|potentialal hyperb
P07565713A0634 |0 14|OverexpressionP00001606T0076
P07565713A0634 |126 140|Hsp60 activitybilirubinemia.
P07565713A0634 |47 64|HSP60-null alleletases and 5-nucle
P07565713A0634 |82 93|suppression0000 Pharma
P07565713A0634 |18 22|SCS1pari
P07565720A0256 |103 124|Schistosoma japonicumpects of neonatal hyp
P07565720A0256 |26 30|NirAwith
P07565720A0256 |74 99|glutathione S-transferase0008171T0000 Pharmacologi
P07565720A0256 |4 22|DNA binding domain01606T0076 Compari
P07565720A0256 |50 64|fusion proteines and 5-nucle
P07565723A0200 |85 91|growth0 Phar
P07565723A0200 |66 69|CTDida
P07565723A0200 |43 58|phosphorylationsphatases and 5
P07565723A0200 |96 111|differentiationogic aspects of
P07565723A0200 |4 10|kinase01606T
P07565731A1629 |33 49|mRNA degradationkaline phosphata
P07565731A1629 |10 15|model0076 
P07565731A1629 |72 76|roleP000
P07565731A1629 |146 154|proteins8997A047
P07565731A1629 |111 129|ribonucleoproteins neonatal hyperbil
P07565736A2134 |106 111|cellsts of
P07565736A2134 |61 91|GM-CSF receptor alpha promotercleotidase P00008171T0000 Phar
P07565736A2134 |29 40|C/EBP alphah alkaline 
P07565740T0000 |0 11|EndocytosisP00001606T0
P07565740T0000 |44 50|plasmaphatas
P07565740T0000 |25 36|degradation with alkal
P07565740T0000 |106 117|transporterts of neona
P07565740T0000 |70 74|Pdr5e P0
P07565740T0000 |87 95|cassettePharmaco
P07565775A1265 |137 150|EpG formationia. P00008997
P07565775A1265 |24 30|motifsn with
P07565775A1265 |126 135|catalysisbilirubin
P07565775A1265 |89 95|enzymearmaco
P07565775A1265 |62 69|effectsleotida
P07565775A1265 |181 187|enzyme as a 
P07565775A1265 |109 113|rateof n
P07565775A1265 |160 168|transfer CSF [HC
P07565775A1265 |44 45|Vp
P07565775A1265 |191 194|RNAtio
P07565775A1265 |77 85|affinity8171T000
P07565775A1265 |11 20|mutations076 Compa
P07565775A1265 |172 175|GMP is
P07565775A1265 |100 103|GTP as
P07565775T0000 |139 142|RNA. P
P07565775T0000 |78 89|GTP binding171T0000 Ph
P07565775T0000 |11 19|analysis076 Comp
P07565775T0000 |123 135|GMP transferperbilirubin
P07565775T0000 |23 27|mRNAon w
P07565775T0000 |108 117|formation of neona
P07565775T0000 |36 42|enzymeine ph
P07565775T0000 |54 65|amino acidsnd 5-nucleo
P07565776A0612 |0 10|DisruptionP00001606T
P07565776A0612 |167 175|increaseCO3-] is
P07565776A0612 |74 92|HSP12 inducibility0008171T0000 Pharm
P07565776A0612 |211 216|shift data
P07565776A0612 |27 37|PBS2 genesith alkali
P07565776A0612 |124 138|overproductionerbilirubinemi
P07565776A0612 |109 114|cellsof ne
P07565776A0612 |227 245|salt concentrationted rats are no lo
P07565776A0612 |197 203|levelsf CSF 
P07565776A0612 |58 66|decrease-nucleot
P07565776A0612 |142 146|Hog10000
P07565776A0612 |18 22|HOG1pari
P07565797A0116 |0 8|DeletionP0000160
P07565797A0116 |12 24|inactivation76 Compariso
P07565797A0116 |28 32|CRY1th a
P07565797A0116 |76 85|CRY2 mRNA08171T000
P07565797A0116 |66 72|levelsidase 
P07567079A0014 |169 176|numbers3-] is 
P07567079A0014 |82 89|percoll0000 Ph
P07567079A0014 |215 228|contaminationa of K-deplet
P07567079A0014 |31 50|Cryptosporidium sppalkaline phosphatas
P07567079A0014 |180 187|oocystsn as a 
P07567079A0014 |104 120|density gradientects of neonatal
P07567079A0014 |17 27|separationmparison w
P07567079A0014 |191 200|C. parvumtion of C
P07567079A0014 |52 59|oocysts and 5-
P07567079A0014 |142 148|choice000089
P07567079A0014 |132 138|methodbinemi
P07567079A0014 |7 13|method06T007
P07567079A0014 |65 70|fecestidas
P07567300T0000 |48 55|illnessases an
P07567300T0000 |15 26|enterotoxinComparison 
P07567300T0000 |29 40|involvementh alkaline 
P07567300T0000 |79 86|patient71T0000
P07567830A0072 |137 144|femalesia. P00
P07567830A0072 |92 100|patientsacologic
P07567830A0072 |146 149|age899
P07567830A0072 |164 169|years [HCO
P07567830A0072 |116 122|tremoratal h
P07567830A0072 |127 132|malesiliru
P07567830A0072 |0 7|METHODSP000016
P07567830A0072 |68 74|curvesase P0
P07567979A1266 |84 91|ligands00 Phar
P07567979A1266 |44 55|developmentphatases an
P07567979A1266 |30 35|basis alka
P07567979A1266 |59 65|assaysnucleo
P07567979A1266 |95 110|testis receptorlogic aspects o
P07567979A1266 |4 12|findings01606T00
P07567979A1266 |117 122|hERR1tal h
P07567980T0000 |85 88|DNA0 P
P07567980T0000 |63 71|elementseotidase
P07567980T0000 |5 8|p53160
P07567980T0000 |21 36|domain peptidesison with alkal
P07568026A0622 |51 58|proteins and 5
P07568026A0622 |66 77|amino acidsidase P0000
P07568026A0622 |22 26|sizeson 
P07568026A0622 |4 15|Stat5b mRNA01606T0076 
P07568026A0622 |34 36|kbal
P07568116A0902 |101 115|signal peptideaspects of neo
P07568116A0902 |61 67|regioncleoti
P07568116A0902 |76 83|absence08171T0
P07568116A0902 |4 19|hydropathy plot01606T0076 Comp
P07568118A1267 |51 70|Shc phosphorylations and 5-nucleotidas
P07568118A1267 |27 33|G betaith al
P07568118A1267 |122 139|p21ras activationyperbilirubinemia
P07568118A1267 |91 95|stepmaco
P07568118A1267 |6 13|results606T007
P07568118A1267 |178 217|growth factor tyrosine kinase receptorsown as a function of CSF PCO2 the data 
P07568118A1267 |156 165|mechanismWhen CSF 
P07568118A1267 |103 110|pathwaypects o
P07568576A0074 |48 63|Type A behaviorases and 5-nucl
P07568576A0074 |27 39|relationshipith alkaline
P07568576A0074 |5 11|report1606T0
P07568576A0074 |80 98|emotion dimensions1T0000 Pharmacolog
P07568865A0305 |206 212|CFU/ml2 the 
P07568865A0305 |180 189|thresholdn as a fu
P07568865A0305 |144 145|%0
P07568865A0305 |214 220|Figureta of 
P07568865A0305 |26 39|contaminationwith alkaline
P07568865A0305 |166 174|bacteriaHCO3-] i
P07568865A0305 |4 13|carcasses01606T007
P07568865A0305 |80 85|range1T000
P07568865A0305 |64 72|bacteriaotidase 
P07568865A0305 |116 122|CFU/mlatal h
P07569075A0585 |102 110|responsespects o
P07569075A0585 |10 15|stage0076 
P07569075A0585 |180 189|histologyn as a fu
P07569075A0585 |164 172|cytology [HCO3-]
P07569075A0585 |21 41|lung cancer patientsison with alkaline p
P07569075A0585 |159 162|FBSn C
P07569075A0585 |43 45|CRsp
P07569075A0585 |95 96|%l
P07569075A0585 |155 157|CT W
P07569075A0585 |71 72|% 
P07569075A0585 |136 153|chest radiographymia. P00008997A04
P07569075A0585 |85 87|PR0 
P07569532T0001 |0 9|PediatricP00001606
P07569532T0001 |44 52|hospitalphatases
P07569532T0001 |66 72|localeidase 
P07569532T0001 |18 29|emergenciesparison wit
P07569640A0539 |0 23|Protein electrophoresisP00001606T0076 Comparis
P07569640A0539 |93 95|G2co
P07569640A0539 |41 55|albumin levelshosphatases an
P07569640A0539 |83 89|values000 Ph
P07569640A0539 |64 70|groupsotidas
P07569770A0298 |0 7|METHODSP000016
P07569770A0298 |22 36|non-respondersson with alkal
P07569770A0298 |72 79|vaccineP000081
P07569770A0298 |166 171|yearsHCO3-
P07569770A0298 |122 134|booster doseyperbilirubi
P07569770A0298 |55 59|dosed 5-
P07569770A0298 |82 88|months0000 P
P07569770A0298 |156 163|vaccineWhen CS
P07569770A0298 |103 115|immunizationpects of neo
P07571766A0122 |19 29|percentagearison wit
P07571766A0122 |72 73|%P
P07571766A0122 |46 54|patientsatases a
P07571766A0122 |129 133|painirub
P07571766A0122 |94 109|catheterizationologic aspects 
P07571766A0122 |158 180|ST-segment depressionsen CSF [HCO3-] is show
P07571766A0122 |218 226|arteriesf K-depl
P07571953T0000 |65 71|smearstidase
P07571953T0000 |30 42|mycobacteria alkaline ph
P07572582A0000 |0 10|MibefradilP00001606T
P07572582A0000 |12 14|Ro76
P07572582A0000 |132 147|calcium channelbinemia. P00008
P07572582A0000 |65 79|chemical classtidase P000081
P07572582A0000 |35 53|calcium antagonistline phosphatases 
P07574064A1416 |152 159|l.min-1472 Whe
P07574064A1416 |198 219|response relationship CSF PCO2 the data of
P07574064A1416 |28 52|concentration anesthesiath alkaline phosphatases
P07574064A1416 |114 118|mmHgonat
P07574064A1416 |95 97|VElo
P07574064A1416 |185 190|shifta fun
P07574064A1416 |103 107|PCO2pect
P07574682T0000 |0 4|cDNAP000
P07574682T0000 |57 77|alkaline phosphatase5-nucleotidase P0000
P07575416A0000 |239 249|properties no longer
P07575416A0000 |45 51|enzymehatase
P07575416A0000 |18 21|PKCpar
P07575416A0000 |128 134|familylirubi
P07575416A0000 |214 226|localizationta of K-depl
P07575416A0000 |181 200|tissue distribution as a function of C
P07575416A0000 |154 164|isoenzymes2 When CSF
P07575416A0000 |70 80|regulatione P0000817
P07575416A0000 |103 112|processespects of 
P07575416A0000 |0 16|Protein kinase CP00001606T0076 C
P07575416A1970 |115 128|PKC zeta mRNAnatal hyperbi
P07575416A1970 |74 89|oligonucleotide0008171T0000 Ph
P07575416A1970 |42 52|importanceosphatases
P07575416A1970 |94 105|cDNA probesologic aspe
P07575416A1970 |5 9|work1606
P07575416A1970 |64 70|choiceotidas
P07575438A1409 |5 11|action1606T0
P07575438A1409 |45 52|factorshatases
P07575438A1409 |66 76|E1 elementidase P000
P07575947T0000 |16 25|electivesomparison
P07575947T0000 |4 10|debate01606T
P07576178A0000 |102 111|receptorsspects of
P07576178A0000 |31 40|cytokinesalkaline 
P07576178A0000 |67 76|functionsdase P000
P07576178A0000 |0 26|Polypeptide growth factorsP00001606T0076 Comparison 
P07576179A0781 |43 60|CpG dinucleotidessphatases and 5-n
P07576179A0781 |30 39|frequency alkaline
P07576307A0144 |137 147|regulationia. P00008
P07576307A0144 |78 80|bp17
P07576307A0144 |89 103|rat enkephalinarmacologic as
P07576307A0144 |105 109|rENKcts 
P07576307A0144 |111 115|gene neo
P07576307A0144 |58 66|cassette-nucleot
P07576307A0144 |23 27|roleon w
P07576307A0144 |155 175|enkephalin phenotype When CSF [HCO3-] is
P07576307A1654 |86 95|complexes Pharmaco
P07576307A1654 |31 37|motifsalkali
P07576307A1654 |180 183|ENKn a
P07576307A1654 |150 154|HeLaA047
P07576307A1654 |133 148|tumor cell lineinemia. P000089
P07576307A1654 |109 117|extractsof neona
P07577904A0141 |187 198|dislocationfunction of
P07577904A0141 |135 146|buphthalmosemia. P0000
P07577904A0141 |31 42|persistencealkaline ph
P07577904A0141 |159 162|eyen C
P07577904A0141 |167 181|microphthalmosCO3-] is shown
P07577904A0141 |107 120|camera aquosas of neonatal
P07577904A0141 |88 99|dislocationharmacologi
P07577904A0141 |234 238|bodys ar
P07577904A0141 |66 70|bodyidas
P07577904A0141 |252 255|eyespl
P07577904A0141 |16 21|yearsompar
P07579023A0214 |70 80|medicatione P0000817
P07579023A0214 |29 37|patientsh alkali
P07579023A0214 |11 23|dose-finding076 Comparis
P07579023A0214 |89 96|patientarmacol
P07579023A0214 |130 136|levelsrubine
P07579023A0214 |140 153|liver enzymes P00008997A04
P07579164A0409 |34 43|sequencesaline pho
P07579164A0409 |49 67|RNA editing eventsses and 5-nucleoti
P07579164A0409 |3 13|comparison001606T007
P07579164A0409 |87 97|atp9 genesPharmacolo
P07579164A0409 |17 21|cDNAmpar
P07579328A0653 |0 5|MZF-1P0000
P07579328A0653 |92 110|cell lines NIH 3T3acologic aspects o
P07579328A0653 |49 67|GAL4 binding sitesses and 5-nucleoti
P07579328A0653 |16 44|CAT reporter gene expressionomparison with alkaline phos
P07579328A1345 |159 169|cell linesn CSF [HCO
P07579328A1345 |45 50|MZF-1hatas
P07579328A1345 |106 116|cell linests of neon
P07579328A1345 |61 85|reporter gene expressioncleotidase P00008171T000
P07579328A1345 |131 141|expressionubinemia. 
P07579328A1345 |25 43|DNA binding domain with alkaline pho
P07579683A0660 |0 8|AnalysesP0000160
P07579683A0660 |180 188|activityn as a f
P07579683A0660 |63 70|regionseotidas
P07579683A0660 |12 37|hGMR beta subunit mutants76 Comparison with alkali
P07579683A0660 |83 93|activation000 Pharma
P07579683A0660 |101 115|c-myc promoteraspects of neo
P07579695A0336 |87 96|mutationsPharmacol
P07579695A0336 |112 147|yeast centromere protein genes-CEP1neonatal hyperbilirubinemia. P00008
P07579695A0336 |52 61|mutations and 5-nu
P07579695A0336 |148 157|CBF1/CPF197A0472 W
P07579695A0336 |65 69|MIF2tida
P07579695A0336 |159 169|NDC10/CBF2n CSF [HCO
P07579695A0336 |175 185|CEP3/CBF3B shown as 
P07579695A0336 |33 43|phenotypeskaline pho
P07579695A0693 |152 157|order472 W
P07579695A0693 |72 77|Cep1pP0000
P07579695A0693 |44 56|Mif2 proteinphatases and
P07579695A0693 |22 26|datason 
P07579695A0693 |109 125|yeast centromereof neonatal hype
P07579695A0693 |170 177|complex-] is s
P07579695A0693 |85 95|centromere0 Pharmaco
P07579704A0085 |141 152|cell growthP00008997A0
P07579704A0085 |105 115|componentscts of neo
P07579704A0085 |131 136|sitesubine
P07579704A0085 |74 84|cell cycle0008171T00
P07579704A0085 |37 44|patchesne phos
P07579704A0085 |20 32|actin cablesrison with a
P07580058A0000 |102 133|plasminogen activator inhibitorspects of neonatal hyperbilirub
P07580058A0000 |135 138|PAIemi
P07580058A0000 |181 194|heart disease as a functio
P07580058A0000 |15 34|Codonopsis pilosulaComparison with alk
P07580058A0000 |57 90|tissue-type plasminogen activator5-nucleotidase P00008171T0000 Pha
P07580058A0000 |40 46|liquorphosph
P07580058A0000 |160 168|patients CSF [HC
P07580058A0000 |147 153|plasma997A04
P07580058A0000 |200 212|blood stasisSF PCO2 the 
P07580058A0000 |92 96|t-PAacol
P07580058A0000 |4 11|effects01606T0
P07580058A0000 |48 52|CPOLases
P07580330A0331 |35 41|personline p
P07580330A0331 |112 121|microgramneonatal 
P07580330A0331 |25 29|EDIs wit
P07580330A0331 |126 134|dieldrinbilirubi
P07580330A0331 |176 185|microgramshown as 
P07580330A0331 |16 23|intakesomparis
P07580330A0331 |190 193|HCBcti
P07580330A0331 |52 61|microgram and 5-nu
P07580330A0331 |82 91|microgram0000 Phar
P07580330A0331 |162 165|DDTSF 
P07580330A0331 |72 75|HCHP00
P07580330A0331 |96 105|gamma-HCHogic aspe
P07580330A0331 |141 151|microgramsP00008997A
P07580782T0000 |0 16|Imaging featuresP00001606T0076 C
P07580782T0000 |60 71|correlationucleotidase
P07580782T0000 |28 43|epidermoid cystth alkaline pho
P07581364A0500 |50 53|SMAes 
P07581364A0500 |26 30|typewith
P07581364A0500 |105 109|C212cts 
P07581364A0500 |15 20|casesCompa
P07581364A0500 |94 100|Ag1-CAologic
P07581364A0500 |41 45|typehosp
P07581364A0500 |64 73|deletionsotidase P
P07581364A0500 |86 90|copy Pha
P07582316A0696 |32 40|isolateslkaline 
P07582316A0696 |135 146|MTB strainsemia. P0000
P07582316A0696 |79 102|IS6110 banding patterns71T0000 Pharmacologic a
P07582316A0696 |62 66|caseleot
P07582316A0696 |42 46|caseosph
P07582316A0696 |23 28|pairson wi
P07582592A0545 |68 74|damagease P0
P07582592A0545 |176 201|botulinum toxin injectionshown as a function of CS
P07582592A0545 |95 105|dilatationlogic aspe
P07582592A0545 |209 218|treatmenthe data o
P07582592A0545 |143 157|administration0008997A0472 W
P07582592A0545 |128 131|LESlir
P07582592A0545 |222 231|achalasiadepleted 
P07582592A0545 |0 4|HRESP000
P07583190A0306 |187 214|phrase structure violationsfunction of CSF PCO2 the da
P07583190A0306 |151 155|area0472
P07583190A0306 |77 82|parts8171T
P07583190A0306 |95 105|hemispherelogic aspe
P07583190A0306 |124 140|brain potentialserbilirubinemia.
P07583190A0306 |319 329|assignmenteater slop
P07583190A0306 |266 275|area leadompared t
P07583190A0306 |282 292|impairmentols but st
P07583190A0306 |23 32|processeson with a
P07583190A0306 |250 257|lesionsdisplac
P07583562A1826 |3 6|men001
P07583562A1826 |26 28|ORwi
P07583562A1826 |12 15|BMI76 
P07583562A1826 |112 118|modelsneonat
P07583562A1826 |59 60|Pn
P07583562A1826 |145 150|LDL-C08997
P07583562A1826 |95 97|RPlo
P07583562A1826 |55 57|TGd 
P07583562A1826 |99 100|Pc
P07583562A1826 |141 143|TGP0
P07583562A1826 |156 168|hypertensionWhen CSF [HC
P07585246T0000 |0 18|SL1 trans-splicingP00001606T0076 Com
P07585246T0000 |73 76|end000
P07585246T0000 |80 111|Caenorhabditis elegans pre-mRNA1T0000 Pharmacologic aspects of
P07585246T0000 |50 53|RNAes 
P07585559A0000 |119 122|SCHl h
P07585559A0000 |193 229|muscle alpha-actin promoter activityon of CSF PCO2 the data of K-deplete
P07585559A0000 |72 77|aminoP0000
P07585559A0000 |31 42|6-methoxy-4alkaline ph
P07585559A0000 |66 71|ethylidase
P07585559A0000 |249 254|cells disp
P07585559A0000 |159 166|abilityn CSF [
P07585559A0000 |108 117|quinoline of neona
P07585559A0000 |81 100|methyl-1M-pyrazo loT0000 Pharmacologic
P07585559A0000 |21 29|compoundison wit
P07585559A0000 |48 64|2-hydroxyethoxylases and 5-nucle
P07585559A0000 |102 107|3,4-bspect
P07586403A0765 |35 62|risk factor-selection scaleline phosphatases and 5-nuc
P07586403A0765 |7 12|basis06T00
P07586403A0765 |126 133|weightsbilirub
P07586403A0765 |143 154|risk factor0008997A047
P07586403A0765 |22 31|relationsson with 
P07586403A0765 |64 68|RFSSotid
P07586403A0765 |71 76|range P000
P07588240A0000 |119 137|interleukin-1 betal hyperbilirubinem
P07588240A0000 |161 167|enzymeCSF [H
P07588240A0000 |4 52|Caenorhabditis elegans death susceptibility gene01606T0076 Comparison with alkaline phosphatases
P07588240A0000 |54 59|ced-3nd 5-
P07588240A0000 |67 73|numberdase P
P07588240A0000 |77 85|homologs8171T000
P07588240A0000 |100 107|species aspect
P07588240A0000 |190 195|CPP32ction
P07588240A0000 |139 148|IL-1 beta. P000089
P07588240A0000 |169 172|ICE3-]
P07588245T0000 |0 10|RepressionP00001606T
P07588245T0000 |14 28|glucocorticoid Comparison wi
P07588245T0000 |88 112|thyroid hormone receptorharmacologic aspects of 
P07588245T0000 |121 123|TRhy
P07588245T0000 |63 73|activationeotidase P
P07588245T0000 |114 116|TRon
P07588603A1054 |34 45|flexibilityaline phosp
P07588603A1054 |83 88|sites000 P
P07588603A1054 |53 60|spacingand 5-n
P07588603A1054 |4 11|results01606T0
P07588603A1054 |69 71|DHse
P07588608A1687 |0 11|ObstructionP00001606T0
P07588608A1687 |94 99|genesologi
P07588608A1687 |65 72|memberstidase 
P07588608A1687 |143 150|control0008997
P07588608A1687 |172 190|cell proliferation is shown as a fun
P07588608A1687 |231 238|effectsrats ar
P07588608A1687 |101 116|i.e.gag-myb-etsaspects of neon
P07588608A1687 |80 90|ets family1T0000 Pha
P07588608A1687 |19 41|ERF repressor functionarison with alkaline p
P07588608A1687 |154 159|genes2 Whe
P07588628A0318 |0 14|OverexpressionP00001606T0076
P07588628A0318 |45 54|apoptosishatases a
P07588628A0318 |61 64|LCLcle
P07588628A0318 |28 31|p53th 
P07588633A0362 |97 104|proteingic asp
P07588633A0362 |194 207|NIH 3T3 cellsn of CSF PCO2
P07588633A0362 |13 18|c-Fos6 Com
P07588633A0362 |180 190|efficiencyn as a fun
P07588633A0362 |24 51|c-fos protooncogene productn with alkaline phosphatase
P07588633A0362 |212 215|Mosdat
P07588750T0061 |0 7|CloningP000016
P07588750T0061 |9 19|sequencingT0076 Comp
P07588750T0061 |61 72|kinase genecleotidase 
P07588750T0061 |76 93|Pyrococcus woesei08171T0000 Pharma
P07588750T0061 |24 34|expressionn with alk
P07588750T0061 |142 149|protein0000899
P07588750T0061 |118 134|characterizational hyperbilirubi
P07588777A1524 |118 137|p44mapk MAP kinasesal hyperbilirubinem
P07588777A1524 |106 113|p42mapkts of n
P07588777A1524 |31 39|proposalalkaline
P07588777A1524 |6 18|observations606T0076 Com
P07588777A1524 |57 60|CTD5-n
P07588777A1524 |81 87|targetT0000 
P07588777A1524 |49 53|RNAPses 
P07589069A1245 |187 194|CD6-PB1functio
P07589069A1245 |43 48|formssphat
P07589069A1245 |75 84|sequences008171T00
P07589069A1245 |112 119|regionsneonata
P07589069A1245 |58 66|CD6 cDNA-nucleot
P07589069A1245 |139 145|domain. P000
P07589069A1245 |170 183|reading frame-] is shown a
P07590264A0373 |101 105|DHFRaspe
P07590264A0373 |190 201|differencesction of CS
P07590264A0373 |262 263|Ae
P07590264A0373 |298 313|gene expressionve a significan
P07590264A0373 |265 270|sitescompa
P07590264A0373 |208 226|end RNA processingthe data of K-depl
P07590264A0373 |91 97|levelsmacolo
P07590264A0373 |110 115|mRNAsf neo
P07590264A0373 |51 66|polyadenylations and 5-nucleot
P07590264A0373 |289 294|level stil
P07590264A0373 |257 261|polyed w
P07590264A0373 |36 47|differencesine phospha
P07590264A0373 |232 236|geneats 
P07590264A0373 |168 173|senseO3-] 
P07590264A0373 |138 144|allelea. P00
P07590268A0350 |48 52|cDNAases
P07590268A0350 |132 141|MAPKAPK-2binemia. 
P07590268A0350 |44 46|Dmph
P07590268A0350 |95 114|sequence similaritylogic aspects of ne
P07590268A0350 |64 75|polypeptideotidase P00
P07590268A0740 |51 62|developments and 5-nuc
P07590268A0740 |9 26|MAPKAPK-2 messageT0076 Comparison 
P07590268A0740 |109 111|kbof
P07590268A0740 |82 93|transcripts0000 Pharma
P07590268A0740 |155 163|germline When CS
P07590283A0820 |35 51|Pol beta proteinline phosphatase
P07590283A0820 |293 301|Pol betall have 
P07590283A0820 |249 256|finding displa
P07590283A0820 |93 112|polymerase activitycologic aspects of 
P07590283A0820 |127 129|aail
P07590283A0820 |30 33|TdT al
P07590283A0820 |283 289|domainls but
P07590283A0820 |350 352|J.P0
P07590283A0820 |195 218|polymerization reaction of CSF PCO2 the data o
P07590283A0820 |326 334|activitylope (1.
P07590283A0820 |336 341|Kumar +/- 
P07590283A0820 |163 183|template utilizationF [HCO3-] is shown a
P07590283A0820 |4 11|finding01606T0
P07590283A0820 |138 146|Pol betaa. P0000
P07590525A0811 |36 48|revertants/gine phosphat
P07590525A0811 |12 18|values76 Com
P07590525A0811 |57 67|hamburgers5-nucleoti
P07590525A0811 |76 80|dogs0817
P07590657A0624 |0 15|CholangiographyP00001606T0076 
P07590657A0624 |37 42|casesne ph
P07590657A0624 |115 123|patientsnatal hy
P07590657A0624 |71 77|system P0000
P07590744A0829 |21 34|cDNA sequenceison with alk
P07590744A0829 |52 60|analysis and 5-n
P07590744A0829 |92 98|clonesacolog
P07590744A0829 |113 122|GAR1 geneeonatal h
P07590744A0829 |4 13|integrity01606T007
P07592072A0217 |136 145|injectionmia. P000
P07592072A0217 |39 45|farrow phosp
P07592072A0217 |57 58|d5
P07592072A0217 |149 171|prostaglandin F2 alpha7A0472 When CSF [HCO3-
P07592072A0217 |104 110|farrowects o
P07592072A0217 |175 176|d 
P07592072A0217 |64 66|NFot
P07592072A0217 |3 8|Trial00160
P07592072A0217 |184 193|gestation a functi
P07592220A0846 |98 104|PETCO2ic asp
P07592220A0846 |73 79|VE/VO2000081
P07592220A0846 |31 49|minute ventilationalkaline phosphata
P07592220A0846 |120 123|Hyp hy
P07592220A0846 |125 126|Pr
P07592220A0846 |10 13|PO2007
P07592220A0846 |22 27|ratioson w
P07592220A0846 |53 71|oxygen consumptionand 5-nucleotidase
P07592337A0891 |6 13|results606T007
P07592337A0891 |29 33|NfxBh al
P07592337A0891 |63 73|expressioneotidase P
P07592337A0891 |77 81|nfxB8171
P07592439A0000 |0 4|A511P000
P07592439A0000 |37 45|myovirusne phosp
P07592439A0000 |50 72|Listeria monocytogeneses and 5-nucleotidase 
P07592467A0000 |17 41|peroxisome proliferationmparison with alkaline p
P07592467A0000 |4 13|mechanism01606T007
P07592485A0734 |17 32|gene expressionmparison with a
P07592485A0734 |135 139|geneemia
P07592485A0734 |60 67|pathwayucleoti
P07592485A0734 |142 152|expression00008997A0
P07592485A0734 |178 197|ure2 delta mutationown as a function o
P07592485A0734 |99 103|casec as
P07592485A0734 |114 129|NCR sensitivityonatal hyperbil
P07592647A0797 |69 78|complexesse P00008
P07592647A0797 |20 53|DNA Pur alpha recognition elementrison with alkaline phosphatases 
P07592647T0000 |0 11|AssociationP00001606T0
P07592647T0000 |40 62|retinoblastoma proteinphosphatases and 5-nuc
P07592647T0000 |109 142|DNA Pur alpha recognition elementof neonatal hyperbilirubinemia. P
P07592647T0000 |21 30|Pur alphaison with
P07592647T0000 |64 66|Rbot
P07592658A0309 |32 39|complexlkaline
P07592658A0309 |62 81|p50/p65 heterodimerleotidase P00008171
P07592676A0466 |96 106|NIP regionogic aspec
P07592676A0466 |14 24|conditions Compariso
P07592676A0466 |41 50|complexeshosphatas
P07592676A0466 |142 160|repressor activity00008997A0472 When
P07592706A1465 |0 8|ExchangeP0000160
P07592706A1465 |24 31|HL lidsn with 
P07592706A1465 |125 129|rolerbil
P07592706A1465 |46 54|reversalatases a
P07592706A1465 |168 179|specificityO3-] is sho
P07592706A1465 |138 144|regiona. P00
P07592706A1465 |16 19|LPLomp
P07592706A1465 |84 96|lipase ratio00 Pharmacol
P07592710T0000 |25 43|protein kinase PKR with alkaline pho
P07592710T0000 |74 84|activation0008171T00
P07592710T0000 |88 113|immunoglobulin kappa geneharmacologic aspects of n
P07592711T0000 |69 103|G protein alpha subunit deficiencyse P00008171T0000 Pharmacologic as
P07592711T0000 |27 40|yeast proteinith alkaline 
P07592711T0000 |10 15|forms0076 
P07592711T0000 |128 140|beta subunitlirubinemia.
P07592711T0000 |54 63|lethalitynd 5-nucl
P07592721A0827 |33 44|amino acidskaline phos
P07592721A0827 |15 23|mutationComparis
P07592721A0827 |79 87|contacts71T0000 
P07592721A0827 |93 96|DNAcol
P07592723A0814 |85 94|sequences0 Pharmac
P07592723A0814 |45 61|CSK 35H proteinshatases and 5-nu
P07592723A0814 |156 170|PKC substratesWhen CSF [HCO3
P07592723A0814 |26 41|phosphorylationwith alkaline p
P07592723A0814 |117 137|PKC binding activitytal hyperbilirubinem
P07592723A0814 |0 14|Phorbol estersP00001606T0076
P07592730A0204 |0 6|LevelsP00001
P07592730A0204 |182 196|phase proteinsas a function 
P07592730A0204 |210 226|TSG-14 synthesise data of K-depl
P07592730A0204 |269 274|liverared 
P07592730A0204 |151 159|contrast0472 Whe
P07592730A0204 |241 249|organismo longer
P07592730A0204 |77 81|mice8171
P07592730A0204 |10 24|TSG-14 protein0076 Compariso
P07592730A0204 |86 92|humans Pharm
P07592730A0204 |124 142|lipopolysaccharideerbilirubinemia. P
P07592730A0204 |99 108|injectionc aspects
P07592730A0204 |202 206|bulk PCO
P07592730A0204 |38 43|PTX-3e pho
P07592730A0204 |68 73|serumase P
P07592771A0258 |139 144|alpha. P00
P07592771A0258 |123 131|positionperbilir
P07592771A0258 |28 32|geneth a
P07592771A0258 |91 101|homologuesmacologic 
P07592771A0258 |66 71|exonsidase
P07592771A0258 |40 49|kilobasesphosphata
P07592771A0258 |158 162|geneen C
P07592771A0258 |4 14|mouse beta01606T0076
P07592790A1457 |34 38|PEDFalin
P07592790A1457 |147 155|activity997A0472
P07592790A1457 |15 19|dataComp
P07592790A1457 |112 118|regionneonat
P07592790A1457 |163 170|proteinF [HCO3
P07592790A1457 |54 62|subgroupnd 5-nuc
P07592790A1457 |80 87|serpins1T0000 
P07592946A0261 |19 26|cloningarison 
P07592946A0261 |108 121|determination of neonatal 
P07592946A0261 |41 55|p44 MAP kinasehosphatases an
P07592946A0261 |88 94|kinaseharmac
P07592946A0261 |129 151|intron/exon boundariesirubinemia. P00008997A
P07592946A0261 |161 177|characterizationCSF [HCO3-] is s
P07592946A0261 |98 102|geneic a
P07592946A0261 |185 193|promotera functi
P07592946A0997 |205 208|Sp1O2 
P07592946A0997 |27 37|TATA boxesith alkali
P07592946A0997 |360 368|factor-50733 Flu
P07592946A0997 |63 81|start sites regioneotidase P00008171
P07592946A0997 |225 239|binding factorleted rats are
P07592946A0997 |187 200|binding sitesfunction of C
P07592946A0997 |324 329|Zeste slop
P07592946A0997 |87 95|AP-1 boxPharmaco
P07592946A0997 |115 123|Malt boxnatal hy
P07592946A0997 |263 266|Mybn c
P07592946A0997 |248 255|CTF-NF1r displ
P07592946A0997 |298 304|NF-IL6ve a s
P07592946A0997 |129 137|GAGA boxirubinem
P07592946A0997 |312 316|MyoDntly
P07592946A0997 |285 290|Ets-1 but 
P07592946A0997 |165 172|element[HCO3-]
P07592946A0997 |101 109|AP-2 boxaspects 
P07592946A0997 |143 147|half0008
P07592946A0997 |341 351|hepatocyte0.23 vs. P
P07592946A0997 |274 277|p53to 
P07593266A1174 |86 105|pair stem structure Pharmacologic aspe
P07593266A1174 |54 60|regionnd 5-n
P07593896A1053 |78 94|P0.1 measurement171T0000 Pharmac
P07593896A1053 |122 131|equipmentyperbilir
P07593896A1053 |149 159|lung model7A0472 Whe
P07593896A1053 |26 47|measurement techniquewith alkaline phospha
P07594047T0000 |137 148|QT syndromeia. P000089
P07594047T0000 |106 117|epinephrinets of neona
P07594047T0000 |46 66|afterdepolarizationsatases and 5-nucleot
P07594047T0000 |25 36|propranolol with alkal
P07594047T0000 |11 20|verapamil076 Compa
P07594047T0000 |83 94|arrhythmias000 Pharmac
P07594047T0000 |0 7|EffectsP000016
P07594592A0755 |0 8|DeletionP0000160
P07594592A0755 |78 89|interaction171T0000 Ph
P07594592A0755 |108 116|proteins of neon
P07594592A0755 |16 49|NF-IL6 beta leucine zipper domainomparison with alkaline phosphata
P07595221A0733 |113 122|MHC classeonatal h
P07595221A0733 |72 77|genesP0000
P07595221A0733 |210 215|cellse dat
P07595221A0733 |150 162|transfectionA0472 When C
P07595221A0733 |126 135|promotersbilirubin
P07595221A0733 |41 46|CIITAhosph
P07595221A0733 |59 68|MHC classnucleotid
P07595221A0733 |6 11|cells606T0
P07595374A1215 |186 194|residues functio
P07595374A1215 |130 139|promotersrubinemia
P07595374A1215 |44 55|amino acidsphatases an
P07595374A1215 |241 254|LMP1 promotero longer disp
P07595374A1215 |15 20|EBNA2Compa
P07595374A1215 |111 121|activation neonatal 
P07595374A1215 |161 168|domainsCSF [HC
P07595374A1215 |4 11|domains01606T0
P07595374A1215 |32 40|deletionlkaline 
P07595857A0521 |4 19|peak velocities01606T0076 Comp
P07595857A0521 |89 104|flow velocitiesarmacologic asp
P07595857A0521 |182 186|flowas a
P07595857A0521 |150 154|waveA047
P07595857A0521 |322 326|dayser s
P07595857A0521 |156 160|PVS1When
P07595857A0521 |457 471|cardiomyopathyneral practice
P07595857A0521 |188 197|durationsunction o
P07595857A0521 |112 115|PVAneo
P07595857A0521 |385 388|dayars
P07595857A0521 |333 346|cardioversion.21 +/- 0.23 
P07595857A0521 |56 67|transmitral 5-nucleoti
P07595857A0521 |265 271|motioncompar
P07595857A0521 |106 107|At
P07595857A0521 |286 293|systolebut sti
P07595857A0521 |222 227|wavesdeple
P07595857A0521 |392 405|cardioversionbe an effecti
P07595857A0521 |43 48|wavessphat
P07595857A0521 |435 443|patientsmum dose
P07595857A0521 |413 421|patientstic drug
P07595857A0521 |233 242|amplitudets are no
P07596283A0396 |84 94|tributyrin00 Pharmac
P07596283A0396 |31 39|activityalkaline
P07596283A0396 |18 24|enzymepariso
P07596283A0396 |76 79|oil081
P07596283A0396 |48 61|triglyceridesases and 5-nu
P07596283A0396 |116 125|emulsionsatal hype
P07596287A0183 |68 82|reading framesase P00008171T
P07596287A0183 |268 274|uptakepared 
P07596287A0183 |45 49|fimAhata
P07596287A0183 |113 129|protein productseonatal hyperbil
P07596287A0183 |93 97|ORF1colo
P07596287A0183 |161 172|superfamilyCSF [HCO3-]
P07596287A0183 |148 155|members97A0472
P07596287A0183 |4 23|nucleotide sequence01606T0076 Comparis
P07596287A0183 |188 224|cassette membrane transport proteinsunction of CSF PCO2 the data of K-de
P07596287A0183 |279 293|export systemsntrols but sti
P07596287A0183 |84 88|ORF500 P
P07596287A1724 |115 131|mutagenesis datanatal hyperbilir
P07596287A1724 |40 53|bp transcriptphosphatases 
P07596287A1724 |74 78|size0008
P07596287A1724 |82 86|ORF30000
P07596287A1724 |4 14|ORF3 probe01606T0076
P07596558A0824 |117 127|hemorrhagetal hyperb
P07596558A0824 |89 98|treatmentarmacolog
P07596558A0824 |31 45|concentrationsalkaline phosp
P07596558A0824 |6 13|results606T007
P07596558A0824 |49 58|IL-1 betases and 5
P07596697A0971 |117 125|childrental hype
P07596697A0971 |44 61|motilin responsesphatases and 5-nu
P07596697A0971 |133 146|control groupinemia. P0000
P07596697A0971 |28 39|polypeptideth alkaline
P07596697A0971 |67 71|mealdase
P07596697A0971 |100 108|children aspects
P07597030A0260 |87 94|subunitPharmac
P07597030A0260 |28 38|expressionth alkalin
P07597030A0260 |105 106|hc
P07597030A0260 |56 72|characterization 5-nucleotidase 
P07597030A0260 |122 130|hTAFII32yperbili
P07597030A0260 |108 113|TFIID of n
P07597030A0260 |19 26|cloningarison 
P07597488T0000 |50 61|kernicteruses and 5-nu
P07597488T0000 |26 41|G6PD deficiencywith alkaline p
P07597488T0000 |10 18|jaundice0076 Com
P07597804A1007 |85 107|glycoprotein gene EUS40 Pharmacologic aspect
P07597804A1007 |23 25|kbon
P07597804A1007 |4 15|transcripts01606T0076 
P07597804A1007 |34 36|kbal
P07598106A0709 |0 19|Mean growth changesP00001606T0076 Comp
P07598106A0709 |120 133|malocclusions hyperbilirub
P07598106A0709 |37 43|samplene pho
P07598106A0709 |230 236|groups rats 
P07598106A0709 |148 158|age period97A0472 Wh
P07598106A0709 |28 33|Classth al
P07598106A0709 |173 183|similarityis shown a
P07598106A0709 |112 117|Classneona
P07598106A0709 |200 211|developmentSF PCO2 the
P07598106A0709 |98 106|subjectsic aspec
P07598303A1728 |119 135|survival benefitl hyperbilirubin
P07598303A1728 |52 63|prophylaxis and 5-nucl
P07598303A1728 |67 94|bone marrow transplantationdase P00008171T0000 Pharmac
P07598303A1728 |17 24|studiesmpariso
P07599449A0445 |70 79|menopausee P000081
P07599449A0445 |89 103|control groupsarmacologic as
P07599449A0445 |58 63|years-nucl
P07599449A0445 |4 19|fracture groups01606T0076 Comp
P07599653A0898 |171 177|organs] is s
P07599653A0898 |60 67|factorsucleoti
P07599653A0898 |131 141|activitiesubinemia. 
P07599653A0898 |41 48|bindinghosphat
P07599653A0898 |149 157|promoter7A0472 W
P07599653A0898 |73 79|shoots000081
P07599653A0898 |22 33|differencesson with al
P07599653A0898 |92 97|rootsacolo
P07599653A0898 |3 11|addition001606T0
P07599653A0898 |102 111|agreementspects of
P07600111A0000 |238 244|cohorte no l
P07600111A0000 |248 263|police officersr displaced whe
P07600111A0000 |112 123|virus typesneonatal hy
P07600111A0000 |267 280|Guinea-Bissaumpared to con
P07600111A0000 |180 191|associationn as a func
P07600111A0000 |161 171|infectionsCSF [HCO3-
P07600111A0000 |134 143|HTLV-I/IInemia. P0
P07600111A0000 |19 28|incidencearison wi
P07600111A0000 |83 88|HIV-2000 P
P07600111A0000 |38 66|immunodeficiency virus typese phosphatases and 5-nucleot
P07600111A0000 |76 81|HIV-108171
P07600111A0000 |4 14|prevalence01606T0076
P07600111A0000 |206 216|infections2 the data
P07600986A0605 |116 121|sitesatal 
P07600986A0605 |73 80|classes0000817
P07600986A0605 |89 97|affinityarmacolo
P07600986A0605 |12 32|immunoprecipitations76 Comparison with a
P07600986A0605 |163 182|transcription unitsF [HCO3-] is shown 
P07600986A0605 |37 53|gel shift assaysne phosphatases 
P07601078A1003 |0 8|SubjectsP0000160
P07601078A1003 |153 155|OR72
P07601078A1003 |185 193|hypoergya functi
P07601078A1003 |22 39|postexposure timeson with alkaline
P07601078A1003 |211 215|% CI dat
P07601078A1003 |198 200|OR C
P07601078A1003 |46 59|dioxin burdenatases and 5-
P07601078A1003 |107 115|hypoergys of neo
P07601078A1003 |166 170|% CIHCO3
P07601078A1003 |66 71|pg/m3idase
P07601078A1003 |131 139|subjectsubinemia
P07601078A1003 |99 103|riskc as
P07601078A1003 |141 151|hypoergy IP00008997A
P07601121A0153 |85 91|region0 Phar
P07601121A0153 |177 186|sequenceshown as a
P07601121A0153 |117 122|starttal h
P07601121A0153 |126 139|transcriptionbilirubinemia
P07601121A0153 |0 8|AnalysisP0000160
P07601121A0153 |17 25|sequencemparison
P07601445A0207 |68 75|rat p47ase P00
P07601445A0207 |183 190|memberss a fun
P07601445A0207 |203 217|protein familyPCO2 the data 
P07601445A0207 |53 60|homologand 5-n
P07601445A0207 |97 124|WM6 Drosophila gene productgic aspects of neonatal hyp
P07601445A0207 |144 151|Ce08102008997A
P07601445A0207 |235 248|RNA helicases are no longe
P07601445A0207 |21 45|BAT1 translation productison with alkaline phosp
P07601445A0207 |155 177|Caenorhabditis elegans When CSF [HCO3-] is s
P07601445A0207 |84 91|protein00 Phar
P07601827A0778 |139 145|region. P000
P07601827A0778 |97 107|repressiongic aspect
P07601827A0778 |9 21|lacZ fusionsT0076 Compar
P07601827A0778 |55 68|DNA sequencesd 5-nucleotid
P07601827A0778 |115 118|pflnat
P07601828A0095 |32 48|characterizationlkaline phosphat
P07601828A0095 |62 67|classleoti
P07601828A0095 |104 119|orfX-fliP locusects of neonata
P07601828A0095 |8 14|report6T0076
P07601828A0095 |71 86|flagellar genes P00008171T0000
P07603726T0000 |36 44|recoveryine phos
P07603726T0000 |73 90|neuroma resection00008171T0000 Pha
P07603726T0000 |11 31|adaptation exercises076 Comparison with 
P07603726T0000 |52 57|stage and 
P07603956A0115 |152 160|chickens472 When
P07603956A0115 |144 145|%0
P07603956A0115 |125 128|RSBrbi
P07603956A0115 |108 121|incorporation of neonatal 
P07603956A0115 |98 104|levelsic asp
P07603956A0115 |53 64|arrangementand 5-nucle
P07603956A0115 |17 23|designmparis
P07603956A0115 |68 78|treatmentsase P00008
P07604047A0704 |290 294|GA19stil
P07604047A0704 |281 285|GA44rols
P07604047A0704 |199 209|capabilityCSF PCO2 t
P07604047A0704 |107 131|transcription-PCR methods of neonatal hyperbilir
P07604047A0704 |157 167|cDNA clonehen CSF [H
P07604047A0704 |65 73|sequencetidase P
P07604047A0704 |43 45|GAsp
P07604047A0704 |298 302|GA20ve a
P07604047A0704 |141 149|identityP0000899
P07604047A0704 |217 231|fusion proteinof K-depleted 
P07604047A0704 |2 12|cDNA clone0001606T00
P07604047A0704 |273 277|GA53 to 
P07604783A0952 |101 122|bile acid compositionaspects of neonatal h
P07604783A0952 |126 130|bilebili
P07604783A0952 |26 33|changeswith al
P07604783A0952 |82 90|lecithin0000 Pha
P07604783A0952 |54 70|acid compositionnd 5-nucleotidas
P07604794A0958 |84 90|mg/day00 Pha
P07604794A0958 |128 134|mg/daylirubi
P07604794A0958 |75 76|%0
P07604794A0958 |53 54|%a
P07604794A0958 |6 17|cholesterol606T0076 Co
P07604794A0958 |144 145|%0
P07604794A0958 |59 65|mg/daynucleo
P07604794A0958 |38 42|weeke ph
P07604794A0958 |157 163|mg/dayhen CS
P07604794A0958 |115 116|%n
P07604794A0958 |100 104|week asp
P07605990A1110 |17 24|studiesmpariso
P07605990A1110 |224 230|levelspleted
P07605990A1110 |172 177|ratio is s
P07605990A1110 |145 155|importance08997A0472
P07605990A1110 |63 67|roleeoti
P07605990A1110 |122 130|findingsyperbili
P07605990A1110 |71 76|PEBP2 P000
P07605990A1110 |191 205|PEBP2 isoformstion of CSF PC
P07605990A1110 |84 108|GM-CSF promoter activity00 Pharmacologic aspects
P07605990A1110 |238 255|promoter activitye no longer displ
P07606548T0000 |0 8|BenefitsP0000160
P07606548T0000 |45 60|pharmacotherapyhatases and 5-n
P07606548T0000 |22 41|board certificationson with alkaline p
P07606587A0266 |0 23|Piperacillin-tazobactamP00001606T0076 Comparis
P07606587A0266 |44 53|treatmentphatases 
P07606587A0266 |57 67|infections5-nucleoti
P07606587A0266 |131 139|bacteriaubinemia
P07607197A1048 |99 107|controlsc aspect
P07607197A1048 |29 32|PRAh a
P07607197A1048 |73 74|P0
P07607197A1048 |63 71|trainingeotidase
P07607197A1048 |6 27|plasma renin activity606T0076 Comparison w
P07607213A0140 |175 185|expression shown as 
P07607213A0140 |75 81|issues008171
P07607213A0140 |26 57|structure/activity relationshipwith alkaline phosphatases and 
P07607213A0140 |104 113|evolutionects of n
P07607213A0140 |128 136|peptideslirubine
P07607213A0140 |145 155|mechanisms08997A0472
P07607233A0186 |51 63|epilancin K7s and 5-nucl
P07607233A0186 |15 19|geneComp
P07607233A0186 |96 98|K7og
P07607233A0186 |118 137|nucleotide sequenceal hyperbilirubinem
P07607342A0703 |201 209|patientsF PCO2 t
P07607342A0703 |72 78|trialsP00008
P07607342A0703 |122 130|patientsyperbili
P07607342A0703 |180 191|drug trialsn as a func
P07607342A0703 |159 166|resultsn CSF [
P07607342A0703 |82 109|aldose reductase inhibitors0000 Pharmacologic aspects 
P07607342A0703 |5 10|paper1606T
P07607342A0703 |39 47|evidence phospha
P07607537A0954 |16 26|phenotypesomparison 
P07607537A0954 |43 52|mutationssphatases
P07607537A0954 |4 12|spectrum01606T00
P07607537A0954 |83 92|mutations000 Pharm
P07607537A0954 |116 138|VP16 activation domainatal hyperbilirubinemi
P07607537A0954 |100 107|adaptor aspect
P07607607T0000 |0 8|IncreaseP0000160
P07607607T0000 |46 63|fructose infusionatases and 5-nucl
P07607607T0000 |20 27|calciumrison w
P07607607T0000 |32 39|oxalatelkaline
P07607669A1112 |32 34|GClk
P07607669A1112 |91 104|binding sitesmacologic asp
P07607669A1112 |15 21|regionCompar
P07607669A1112 |109 112|Sp1of 
P07607669A1112 |55 67|CpG doubletsd 5-nucleoti
P07608268A0194 |207 208|n 
P07608268A0194 |25 34|disorders with alk
P07608268A0194 |162 164|DPSF
P07608268A0194 |166 167|nH
P07608268A0194 |151 152|n0
P07608268A0194 |82 110|melatonin secretion profiles0000 Pharmacologic aspects o
P07608268A0194 |197 205|controlsf CSF PC
P07608268A0194 |140 149|males IGD P0000899
P07608268A0194 |38 53|GnRH deficiencye phosphatases 
P07608649A1429 |32 45|CyA treatmentlkaline phosp
P07608649A1429 |10 24|blood pressure0076 Compariso
P07608649A1429 |77 88|ET-1 levels8171T0000 P
P07608968A0836 |0 8|AnalysisP0000160
P07608968A0836 |78 90|core domains171T0000 Pha
P07608968A0836 |99 113|transactivatorc aspects of n
P07608968A0836 |20 31|Tat mutantsrison with 
P07608968A0836 |174 177|TBPs s
P07608968A0836 |155 168|transcription When CSF [HC
P07609037A0775 |288 297|sequencest still h
P07609037A0775 |26 31|Oct-1with 
P07609037A0775 |13 22|depletion6 Compari
P07609037A0775 |3 11|addition001606T0
P07609037A0775 |81 90|antiserumT0000 Pha
P07609037A0775 |114 132|DNA affinity resinonatal hyperbiliru
P07609037A0775 |244 252|promoteronger di
P07609037A0775 |49 56|extractses and
P07609037A0775 |185 198|MMTV promotera function of
P07609037A0775 |204 209|levelCO2 t
P07609037A0775 |152 165|transcription472 When CSF 
P07609079A0387 |220 230|activationK-depleted
P07609079A0387 |284 293|sequencess but sti
P07609079A0387 |58 74|receptor mutants-nucleotidase P0
P07609079A0387 |176 202|transcription factor TFIIBshown as a function of CSF
P07609079A0387 |301 304|LTRa s
P07609079A0387 |132 141|T3R alphabinemia. 
P07609079A0387 |36 45|T3R alphaine phosp
P07609079A0387 |23 32|HIV-1 LTRon with a
P07609079A0387 |118 128|A/B regional hyperbi
P07609079A0387 |0 15|TransactivationP00001606T0076 
P07609372A0261 |102 107|casesspect
P07609372A0261 |112 123|HR patientsneonatal hy
P07609372A0261 |128 139|LR patientslirubinemia
P07609372A0261 |24 31|minutesn with 
P07609372A0261 |88 95|minutesharmaco
P07609372A0261 |64 75|LR patientsotidase P00
P07609372A0261 |38 43|casese pho
P07609372A0261 |48 59|HR patientsases and 5-
P07609372A0261 |0 6|M.M.C.P00001
P07610052A1064 |139 155|EMSA experiments. P00008997A0472
P07610052A1064 |88 98|rat cortexharmacolog
P07610052A1064 |47 50|C25tas
P07610052A1064 |60 73|C35 complexesucleotidase P
P07610052A1064 |198 210|observations CSF PCO2 th
P07610052A1064 |124 135|SAA elementerbilirubin
P07610052A1064 |226 237|functioningeted rats a
P07610052A1064 |107 115|extractss of neo
P07610052A1064 |22 31|complexesson with 
P07610052A1064 |245 261|rat APP promoternger displaced w
P07610052A1064 |52 55|C30 an
P07610052A1064 |172 181|relevance is shown
P07610324A0319 |202 209|centers PCO2 t
P07610324A0319 |40 47|aspectsphospha
P07610324A0319 |108 113|years of n
P07610324A0319 |142 156|reconstruction00008997A0472 
P07610716A0117 |68 80|MS-frequencyase P0000817
P07610716A0117 |20 37|prevalence valuesrison with alkali
P07610716A0117 |4 12|analysis01606T00
P07610716A0117 |141 149|latitudeP0000899
P07610735A1471 |0 9|DiltiazemP00001606
P07610735A1471 |88 100|sinus rhythmharmacologic
P07610735A1471 |74 84|conversion0008171T00
P07610735A1471 |29 37|decreaseh alkali
P07610735A1471 |57 65|response5-nucleo
P07612174A1064 |101 107|humansaspect
P07612174A1064 |91 95|PCBsmaco
P07612174A1064 |9 17|primatesT0076 Co
P07612174A1064 |80 87|effects1T0000 
P07612557A0635 |102 110|childrenspects o
P07612557A0635 |15 23|childrenComparis
P07612557A0635 |71 76|pairs P000
P07612557A0635 |49 58|pathologyses and 5
P07614762A0224 |17 29|antigen testmparison wit
P07614762A0224 |55 74|latex agglutinationd 5-nucleotidase P0
P07615541T0000 |23 30|DNase-Ion with
P07615541T0000 |46 51|sitesatase
P07615541T0000 |11 19|analysis076 Comp
P07615541T0000 |59 101|mouse porphobilinogen deaminase gene locusnucleotidase P00008171T0000 Pharmacologic 
P07615634A0535 |118 120|kDal
P07615634A0535 |6 17|transcripts606T0076 Co
P07615634A0535 |47 53|regiontases 
P07615634A0535 |71 79|sequence P000081
P07615634A0535 |103 110|proteinpects o
P07616056A0278 |50 69|feedback inhibitiones and 5-nucleotida
P07616056A0278 |79 103|chain gene rearrangement71T0000 Pharmacologic as
P07616056A0278 |12 20|gamma 2b76 Compa
P07616056A0278 |27 38|chain genesith alkalin
P07616056A0278 |5 7|mu16
P07616563A0532 |115 124|stretchesnatal hyp
P07616563A0532 |107 109|bps 
P07616563A0532 |9 13|CarPT007
P07616563A0532 |78 83|DNase171T0
P07616563A0532 |36 56|carAB control regionine phosphatases and
P07616563A0532 |173 186|GATC sequenceis shown as a
P07616569A0168 |239 242|srn no
P07616569A0168 |82 97|apocytochrome b0000 Pharmacolo
P07616569A0168 |127 153|NADH dehydrogenase complexilirubinemia. P00008997A04
P07616569A0168 |178 193|ATPase subunitsown as a functi
P07616569A0168 |297 302|rps11ave a
P07616569A0168 |247 250|lrner 
P07616569A0168 |314 319|rpl16ly gr
P07616569A0168 |227 231|RNAsted 
P07616569A0168 |13 18|genes6 Com
P07616569A0168 |166 171|nad4LHCO3-
P07616569A0168 |195 199|atp6 of 
P07616569A0168 |50 68|cytochrome oxidasees and 5-nucleotid
P07616569A0168 |256 261|tRNAsced w
P07616569A0168 |291 295|rps3till
P07616569A0168 |155 159|nad1 Whe
P07616569A0168 |99 102|cobc a
P07616569A0168 |233 237|rrn5ts a
P07616569A0168 |111 119|subunits neonata
P07616569A0168 |281 289|proteinsrols but
P07616569A0168 |204 208|atp9CO2 
P07616569A0168 |70 74|cox1e P0
P07616569A0168 |304 309|rps12ignif
P07616569A0168 |34 42|subunitsaline ph
P07616802A0315 |118 119|pa
P07616802A0315 |134 140|returnnemia.
P07616802A0315 |39 53|platelet count phosphatases 
P07616802A0315 |5 8|day160
P07616802A0315 |27 35|increaseith alka
P07616802A0315 |109 116|heparinof neon
P07616802A0315 |156 161|valueWhen 
P07616802A0315 |200 210|respondersSF PCO2 th
P07616802A0315 |168 185|heparin cessationO3-] is shown as 
P07616802A0315 |87 95|patientsPharmaco
P07618280A0550 |26 36|structureswith alkal
P07618280A0550 |62 93|density gradient centrifugationleotidase P00008171T0000 Pharma
P07618548T0000 |4 27|Babcock Surgical Clinic01606T0076 Comparison w
P07620491T0000 |0 9|ResourcesP00001606
P07620491T0000 |22 30|patientsson with
P07620491T0000 |39 46|smoking phosph
P07622058A0411 |51 53|aas 
P07622058A0411 |111 133|segmentation gene runt neonatal hyperbilirub
P07622058A0411 |4 24|PEBP2 alpha proteins01606T0076 Compariso
P07622058A0411 |55 61|regiond 5-nu
P07622060A0967 |49 60|ME activityses and 5-n
P07622060A0967 |105 121|thyroid hormonescts of neonatal 
P07622060A0967 |23 28|cellson wi
P07622521A0418 |33 60|G beta gamma binding regionkaline phosphatases and 5-n
P07622521A0418 |249 261|G beta gamma displaced w
P07622521A0418 |266 278|PIP2 bindingompared to c
P07622521A0418 |88 96|residuesharmacol
P07622521A0418 |151 158|mutants0472 Wh
P07622521A0418 |228 236|residuesed rats 
P07622521A0418 |166 183|carboxyl terminusHCO3-] is shown a
P07622521A0418 |187 195|beta ARKfunction
P07622521A0418 |18 25|mappingparison
P07622521A0418 |108 117|PH domain of neona
P07622521A0418 |199 204|orderCSF P
P07622521A0418 |141 147|seriesP00008
P07622521A0418 |64 72|beta ARKotidase 
P07622932T0000 |18 26|featuresparison 
P07622932T0000 |39 46|leprosy phosph
P07623807A0162 |17 27|mechanismsmparison w
P07623807A0162 |93 99|systemcologi
P07623807A0162 |165 170|cells[HCO3
P07623807A0162 |184 193|membranes a functi
P07623807A0162 |114 130|plasma membranesonatal hyperbili
P07623807A0162 |50 64|Raf-1 proteinses and 5-nucle
P07623807A0162 |136 141|v-Rasmia. 
P07623814A1040 |50 68|estrogen receptorses and 5-nucleotid
P07623814A1040 |37 45|retinoidne phosp
P07623814A1040 |109 117|activityof neona
P07623814A1040 |183 202|breast cancer cellss a function of CSF
P07623814A1040 |15 29|cotransfectionComparison wit
P07623814A1040 |141 151|inhibitionP00008997A
P07623814A1040 |83 93|inhibition000 Pharma
P07623814A1040 |3 13|CV-1 cells001606T007
P07623814A1040 |155 166|ER activity When CSF [
P07623821A0649 |22 27|HRF-1son w
P07623821A0649 |13 20|factors6 Compa
P07623821A0649 |92 97|motifacolo
P07623821A0649 |42 53|cis elementosphatases 
P07623821T0000 |51 62|combinations and 5-nuc
P07623821T0000 |14 45|Gax homeobox gene transcription Comparison with alkaline phosp
P07623821T0000 |75 82|factors008171T
P07623821T0000 |110 125|enhancer factorf neonatal hype
P07623821T0000 |0 10|RegulationP00001606T
P07623825T0000 |48 65|heat shock factorases and 5-nucleo
P07623825T0000 |22 44|transactivation domainson with alkaline phos
P07623825T0000 |96 102|stressogic a
P07623838A1112 |0 2|D.P0
P07623840A0352 |138 142|tRNAa. P
P07623840A0352 |44 53|sequencesphatases 
P07623840A0352 |57 61|GCN25-nu
P07623840A0352 |167 188|amino acid limitationCO3-] is shown as a f
P07623840A0352 |92 98|kinaseacolog
P07623840A0352 |76 84|activity08171T00
P07623844A0639 |103 116|growth arrestpects of neon
P07623844A0639 |30 46|E1B 19K proteins alkaline phosph
P07623844A0639 |163 181|cell proliferationF [HCO3-] is shown
P07623844A0639 |145 158|DNA synthesis08997A0472 Wh
P07623844A0639 |124 134|expressionerbilirubi
P07623844A0639 |226 229|p53ete
P07623844A0639 |71 80|apoptosis P0000817
P07623844A0639 |189 197|presencenction o
P07623844A0639 |206 212|levels2 the 
P07623844A0639 |16 21|Bcl-2ompar
P07624119A0528 |33 66|PAX3-FKHR transactivation domainskaline phosphatases and 5-nucleot
P07624119A0528 |123 127|GAL4perb
P07624119A0528 |88 102|test fragmentsharmacologic a
P07624119A0528 |15 19|PAX3Comp
P07624119A0528 |158 168|activationen CSF [HC
P07624119A0528 |213 223|cell typesata of K-d
P07624119A0528 |140 146|domain P0000
P07624119A0528 |174 187|reporter genes shown as a 
P07624581A0312 |304 307|T45ign
P07624581A0312 |48 76|blood pressure determinationases and 5-nucleotidase P000
P07624581A0312 |156 178|glutamine transaminaseWhen CSF [HCO3-] is sh
P07624581A0312 |125 132|glucoserbiliru
P07624581A0312 |146 154|nitrogen8997A047
P07624581A0312 |270 273|T30red
P07624581A0312 |240 242|T0no
P07624581A0312 |31 34|ECGalk
P07624581A0312 |180 191|cholesteroln as a func
P07624581A0312 |120 123|PRL hy
P07624581A0312 |196 223|triglycerides plasma levelsof CSF PCO2 the data of K-d
P07624581A0312 |134 144|creatininenemia. P00
P07624581A0312 |254 268|treatment dayslaced when com
P07624581A0312 |290 302|days washoutstill have a
P07624581A0312 |98 101|TSHic 
P07624581A0312 |231 238|therapyrats ar
P07624581A0312 |4 12|subjects01606T00
P07624581A0312 |103 118|thyroid hormonepects of neonat
P07624615A0267 |68 72|mmHgase 
P07624615A0267 |177 182|ratiohown 
P07624615A0267 |284 293|phosphates but sti
P07624615A0267 |254 264|phosphoruslaced when
P07624615A0267 |18 34|body temperatureparison with alk
P07624615A0267 |48 53|PaCO2ases 
P07624615A0267 |218 221|SIDf K
P07624615A0267 |295 297|Pi h
P07624615A0267 |266 268|PTom
P07624615A0267 |93 98|mEq/Lcolog
P07624615A0267 |126 129|pHabil
P07624615A0267 |108 113|mEq/L of n
P07624615A0267 |79 83|HCO371T0
P07624615A0267 |227 231|Atotted 
P07624615A0267 |167 169|OHCO
P07624615A0267 |36 38|TBin
P07624615A0267 |173 174|Hi
P07624615A0267 |6 14|decrease606T0076
P07624615A0267 |207 213|effect the d
P07626378T0000 |0 19|Hepatitis B vaccineP00001606T0076 Comp
P07626378T0000 |35 43|problemsline pho
P07626469A1341 |138 147|CHO cellsa. P00008
P07626469A1341 |52 61|M1 domain and 5-nu
P07626469A1341 |106 110|MLTCts o
P07626469A1341 |6 23|promoter activity606T0076 Comparis
P07626469A1341 |80 104|mouse Leydig tumor cells1T0000 Pharmacologic asp
P07626806A1098 |4 13|RAT3 gene01606T007
P07626806A1098 |57 67|similarity5-nucleoti
P07626806A1098 |36 48|acid proteinine phosphat
P07626806A1098 |83 91|proteins000 Phar
P07627317A1502 |4 6|Al01
P07627317A1502 |46 51|shiftatase
P07627317A1502 |29 34|mg/m3h alk
P07627317A1502 |12 20|exposure76 Compa
P07627317A1502 |78 91|concentration171T0000 Phar
P07627317A1502 |123 145|microgram/g creatinineperbilirubinemia. P000
P07627317A1502 |110 115|shiftf neo
P07627317A1502 |99 102|endc a
P07628389A0145 |0 27|Tumor necrosis factor-alphaP00001606T0076 Comparison w
P07628389A0145 |29 38|TNF alphah alkalin
P07628389A0145 |121 139|mouse Leydig cellshyperbilirubinemia
P07628389A0145 |94 117|testosterone productionologic aspects of neona
P07628389A0145 |59 67|cytokinenucleoti
P07628438T0000 |96 113|receptor isoformsogic aspects of n
P07628438T0000 |72 83|developmentP00008171T0
P07628438T0000 |15 39|insulin receptor homologComparison with alkaline
P07628438T0000 |43 47|genespha
P07628438T0000 |129 148|signaling potentialirubinemia. P000089
P07628451A0114 |18 20|RApa
P07628451A0114 |78 89|kDa protein171T0000 Ph
P07628451A0114 |91 95|p300maco
P07628451A0114 |25 28|E1A wi
P07628451A0114 |108 123|differentiation of neonatal hy
P07628451A0114 |127 135|F9 cellsilirubin
P07628451A0114 |36 51|phosphorylationine phosphatase
P07628456A0000 |238 241|PKRe n
P07628456A0000 |196 201|RNaseof CS
P07628456A0000 |40 45|dsRBDphosp
P07628456A0000 |106 113|varietyts of n
P07628456A0000 |166 169|RNAHCO
P07628456A0000 |20 38|RNA binding domainrison with alkalin
P07628456A0000 |230 236|kinase rats 
P07628456A0000 |70 86|amino acid motife P00008171T0000
P07628456A0000 |117 125|proteinstal hype
P07629103T0000 |118 123|sitesal hy
P07629103T0000 |131 156|beta-casein gene promoterubinemia. P00008997A0472 
P07629103T0000 |91 96|cellsmacol
P07629103T0000 |23 44|protein isoforms betaon with alkaline phos
P07629103T0000 |49 54|deltases a
P07629113A0726 |0 3|SCAP00
P07629113A0726 |57 73|metalloproteases5-nucleotidase P
P07629113A0726 |99 115|N-ethylmaleimidec aspects of neo
P07629113A0726 |43 51|aspartylsphatase
P07629113A0726 |21 31|inhibitorsison with 
P07629113A0726 |35 41|serineline p
P07629122A0323 |100 115|protein kinases aspects of neo
P07629122A0323 |75 79|NIMA0081
P07629122A0323 |133 137|NIMAinem
P07629122A0323 |44 65|phosphorylation sitesphatases and 5-nucleo
P07629122A0323 |11 19|analysis076 Comp
P07629122A0323 |81 86|NIM-1T0000
P07629123A0885 |153 163|activation72 When CS
P07629123A0885 |64 72|positionotidase 
P07629123A0885 |52 60|arginine and 5-n
P07629123A0885 |121 132|DNA bindinghyperbiliru
P07629123A0885 |101 119|heterodimerizationaspects of neonata
P07629123A0885 |33 48|leucine residuekaline phosphat
P07629123A0885 |19 27|mutationarison w
P07629123A0885 |87 97|alterationPharmacolo
P07629150A0155 |0 10|ExpressionP00001606T
P07629150A0155 |47 55|hormonestases an
P07629150A0155 |18 30|CYP11A1 geneparison with
P07629150A0155 |65 84|adrenocorticotropintidase P00008171T00
P07629150A0155 |172 180|promoter is show
P07629150A0155 |126 132|numberbiliru
P07629150A0155 |136 150|growth factorsmia. P00008997
P07629150A0155 |101 108|hormoneaspects
P07629150A0155 |204 212|elementsCO2 the 
P07629150A0155 |238 266|signal transduction pathwayse no longer displaced when c
P07629163A0770 |0 3|NH2P00
P07629163A0770 |180 194|transformationn as a functio
P07629163A0770 |23 40|deletion analysison with alkaline 
P07629163A0770 |145 159|zinc butterfly08997A0472 Whe
P07629163A0770 |80 122|guanine nucleotide exchange factor domains1T0000 Pharmacologic aspects of neonatal h
P07629163A0770 |64 66|PHot
P07629196A0274 |152 155|Jun472
P07629196A0274 |134 144|activationnemia. P00
P07629196A0274 |75 88|alpha 12Q229L008171T0000 P
P07629196A0274 |23 33|expressionon with al
P07629196A0274 |93 98|alphacolog
P07629196A0274 |196 204|JNK/SAPKof CSF P
P07629196A0274 |180 194|protein kinasen as a functio
P07629196A0274 |65 70|alphatidas
P07629196A0274 |54 61|mutantsnd 5-nu
P07629196A0274 |206 213|pathway2 the d
P07629196A0274 |103 116|alpha 13Q226Lpects of neon
P07630687A0010 |238 260|protein S deficienciese no longer displaced 
P07630687A0010 |224 233|protein Cpleted ra
P07630687A0010 |290 298|childrenstill ha
P07630687A0010 |154 165|development2 When CSF 
P07630687A0010 |325 330|eventslope
P07630687A0010 |21 26|studyison 
P07630687A0010 |52 55|sex an
P07630687A0010 |266 286|lupus anticoagulantsompared to controls 
P07630687A0010 |179 190|involvementwn as a fun
P07630687A0010 |94 98|siteolog
P07630687A0010 |142 152|evaluation00008997A0
P07630687A0010 |78 92|family history171T0000 Pharm
P07630687A0010 |47 50|agetas
P07630687A0010 |192 202|prevalenceion of CSF
P07630687A0010 |4 13|objective01606T007
P07630687A0010 |66 76|conditionsidase P000
P07630687A0010 |206 218|antithrombin2 the data o
P07630687A0010 |100 120|catheter association aspects of neonatal
P07630934A0343 |0 5|HarelP0000
P07630934A0343 |7 11|E.M.06T0
P07631267T0001 |0 12|RadiotherapyP00001606T00
P07631267T0001 |57 66|carcinoma5-nucleot
P07631267T0001 |23 34|orchiectomyon with alk
P07631267T0001 |38 46|stage D1e phosph
P07633444T0000 |68 95|mouse WD-repeat gene DMR-N9ase P00008171T0000 Pharmaco
P07633444T0000 |133 148|dystrophy locusinemia. P000089
P07633444T0000 |11 23|organization076 Comparis
P07633444T0000 |42 60|expression patternosphatases and 5-n
P07633756A0690 |305 325|artefact propagationgnificantly greater 
P07633756A0690 |186 193|version functi
P07633756A0690 |53 56|sumand
P07633756A0690 |83 106|background EEG activity000 Pharmacologic aspec
P07633756A0690 |267 272|sweepmpare
P07633756A0690 |66 73|signalsidase P
P07633756A0690 |199 215|reference signalCSF PCO2 the dat
P07633756A0690 |280 286|signaltrols 
P07633756A0690 |164 169|noise [HCO
P07633756A0690 |4 25|ARX2 procedure models01606T0076 Comparison
P07633756A0690 |39 45|signal phosp
P07633756A0690 |138 145|processa. P000
P07633756A0690 |237 248|informationre no longe
P07635140A0172 |119 122|usel h
P07635140A0172 |40 46|enzymephosph
P07635140A0172 |147 157|mechanisms997A0472 W
P07635140A0172 |72 76|partP000
P07635140A0172 |97 106|promotersgic aspec
P07635140A0172 |22 26|geneson 
P07635140A0172 |4 14|expression01606T0076
P07635140A0172 |48 53|CYP19ases 
P07635312A0692 |114 128|act1 mutationsonatal hyperbi
P07635312A0692 |42 51|mutationsosphatase
P07635312A0692 |132 140|interestbinemia.
P07635312A0692 |6 17|mutagenesis606T0076 Co
P07635312A0692 |80 86|domain1T0000
P07635572A1153 |137 143|effectia. P0
P07635572A1153 |127 129|RBil
P07635572A1153 |110 123|re-expressionf neonatal hy
P07635572A1153 |147 174|CIITA mRNA induction levels997A0472 When CSF [HCO3-] i
P07635572A1153 |104 108|lineects
P07635572A1153 |86 91|lines Phar
P07635572A1153 |36 45|IFN-gammaine phosp
P07635572A1153 |49 54|classses a
P07635572A1153 |0 10|CIITA mRNAP00001606T
P07636179A0000 |136 143|kinasesmia. P0
P07636179A0000 |46 55|moleculesatases an
P07636179A0000 |86 97|protein pRb Pharmacolo
P07636179A0000 |11 21|cell cycle076 Compar
P07636179A0000 |155 165|inhibitors When CSF 
P07636179A0000 |103 113|G1 cyclinspects of n
P07636187A0585 |20 43|protein expression datarison with alkaline pho
P07636187A0585 |107 112|liness of 
P07636187A0585 |45 51|V betahatase
P07636187A0585 |132 140|promoterbinemia.
P07636187A0585 |56 72|gene transcripts 5-nucleotidase 
P07636337A0687 |85 106|serum estradiol level0 Pharmacologic aspec
P07636337A0687 |59 67|hormonesnucleoti
P07636337A0687 |127 132|womeniliru
P07636337A0687 |110 113|HRTf n
P07636337A0687 |6 13|results606T007
P07636337A0687 |50 55|doseses an
P07636408T0000 |0 10|ComparisonP00001606T
P07636408T0000 |107 117|evaluations of neona
P07636408T0000 |63 80|resonance imagingeotidase P0000817
P07636408T0000 |132 155|intervertebral foraminabinemia. P00008997A0472
P07636408T0000 |18 23|Teslaparis
P07636408T0000 |33 53|Tesla field strengthkaline phosphatases 
P07636648A1229 |51 57|groupss and 
P07636648A1229 |147 161|concentrations997A0472 When 
P07636648A1229 |89 118|serum antibody concentrationsarmacologic aspects of neonat
P07636648A1229 |240 241|pn
P07636648A1229 |180 198|pertussis antigensn as a function of
P07636648A1229 |230 238|children rats ar
P07636648A1229 |126 134|antigensbilirubi
P07636648A1229 |20 44|DTaP booster vaccinationrison with alkaline phos
P07636648A1229 |4 9|month01606
P07636962A1288 |136 144|activitymia. P00
P07636962A1288 |76 89|HSV-alpha TIF08171T0000 Ph
P07636962A1288 |35 46|determinantline phosph
P07636962A1883 |170 178|activity-] is sh
P07636962A1883 |130 135|aminorubin
P07636962A1883 |72 80|activityP0000817
P07636962A1883 |61 65|GAL4cleo
P07636962A1883 |39 57|DNA binding domain phosphatases and 
P07636962A1883 |22 29|fusionsson wit
P07636962A1883 |140 156|carboxyl termini P00008997A0472 
P07636962A1883 |101 114|BHV-alpha TIFaspects of ne
P07636984A1349 |37 40|SP1ne 
P07636984A1349 |90 95|cellsrmaco
P07636984A1349 |62 70|extractsleotidas
P07636984A1349 |29 33|roleh al
P07637718A0218 |101 114|epimastigotesaspects of ne
P07637718A0218 |135 150|trypomastigotesemia. P00008997
P07637718A0218 |74 81|repeats0008171
P07637718A0218 |42 58|trans-sialidasesosphatases and 5
P07637718A0218 |18 32|messenger RNAsparison with a
P07638517A0000 |101 125|individuals AIDS victimsaspects of neonatal hype
P07638517A0000 |89 97|cadaversarmacolo
P07638517A0000 |31 41|necropsiesalkaline p
P07638517A0000 |142 148|deaths000089
P07638517A0000 |162 183|police investigationsSF [HCO3-] is shown a
P07638517A0000 |5 8|May160
P07638517A0000 |64 85|Sao Paulo City Morgueotidase P00008171T000
P07639106A0678 |87 93|heightPharma
P07639106A0678 |75 81|weight008171
P07639106A0678 |113 116|fiteon
P07639106A0678 |127 137|body TBBMCilirubinem
P07639106A0678 |47 50|fittas
P07639106A0678 |13 16|age6 C
P07639106A0678 |55 60|TBBMDd 5-n
P07639106A0678 |21 27|weightison w
P07639106A0678 |2 7|model00016
P07639106A0678 |70 73|agee P
P07639703A1703 |168 194|islet cell differentiationO3-] is shown as a functio
P07639703A1703 |12 16|acid76 C
P07639703A1703 |125 132|elementrbiliru
P07639703A1703 |89 98|processesarmacolog
P07639703A1703 |157 164|processhen CSF
P07639703A1703 |21 36|thyroid hormoneison with alkal
P07640309A0000 |153 170|splice mechanisms72 When CSF [HCO3
P07640309A0000 |199 201|X.CS
P07640309A0000 |15 32|peptide sequencesComparison with a
P07640309A0000 |71 85|mobility group P00008171T000
P07640309A0000 |92 122|box transcription factor TCF-1acologic aspects of neonatal h
P07640309A0000 |185 190|exonsa fun
P07640309A0000 |87 90|HMGPha
P07640422A0649 |0 14|Thromboxane B2P00001606T0076
P07640422A0649 |135 147|hemodialysisemia. P00008
P07640422A0649 |172 180|Wilcoxon is show
P07640422A0649 |97 104|heparingic asp
P07640422A0649 |110 122|hemodialysisf neonatal h
P07640422A0649 |162 163|pS
P07640422A0649 |54 59|pg/mlnd 5-
P07640422A0649 |189 194|pairsnctio
P07640422A0649 |207 211|test the
P07640422A0649 |153 160|heparin72 When
P07642490A0318 |55 63|analysisd 5-nucl
P07642490A0318 |14 21|pHBK280 Compar
P07642490A0318 |6 12|vector606T00
P07642538A0138 |69 73|RSK3se P
P07642538A0138 |59 67|RSK cDNAnucleoti
P07642538A0138 |386 391|N-Serrs to
P07642538A0138 |244 251|N/C-Lysonger d
P07642538A0138 |148 152|K91A97A0
P07642538A0138 |28 42|RSK activationth alkaline ph
P07642538A0138 |379 384|S218As app
P07642538A0138 |135 146|RSK mutantsemia. P0000
P07642538A0138 |195 200|K444A of C
P07642538A0138 |15 24|mechanismCompariso
P07642538A0138 |356 360|VIII943A
P07642538A0138 |186 192|mutant funct
P07642538A0138 |393 399|mutante an e
P07642538A0138 |154 159|N-Lys2 Whe
P07642538A0138 |294 300|mutantl have
P07642538A0138 |434 441|residueimum do
P07642538A0138 |280 285|T570Atrols
P07642538A0138 |317 342|MAPK phosphorylation sitegreater slope (1.21 +/- 0
P07642538A0138 |287 292|C-Thrut st
P07642538A0138 |368 376|C-domainrazepam 
P07642538A0138 |202 207|C-Lys PCO2
P07642538A0138 |235 241|mutant are n
P07642538A0138 |272 278|mutantd to c
P07642538A0744 |48 54|levelsases a
P07642538A0744 |28 33|C-Thrth al
P07642538A0744 |58 73|kinase activity-nucleotidase P
P07642538A0744 |108 119|stimulation of neonata
P07642538A0744 |3 11|contrast001606T0
P07642538A0744 |18 23|C-Lysparis
P07642544A0868 |48 59|phosphataseases and 5-
P07642544A0868 |120 124|loss hyp
P07642544A0868 |92 110|phenylarsine oxideacologic aspects o
P07642544A0868 |12 21|treatment76 Compar
P07642544A0868 |145 164|NF-kappa B activity08997A0472 When CSF
P07642544A0868 |81 86|cellsT0000
P07642633T0000 |171 176|TEF-1] is 
P07642633T0000 |92 96|cellacol
P07642633T0000 |12 20|promoter76 Compa
P07642633T0000 |61 82|transcription factorscleotidase P00008171T
P07642633T0000 |129 133|geneirub
P07642633T0000 |111 121|regulation neonatal 
P07642633T0000 |138 169|transcription enhancer factor-1a. P00008997A0472 When CSF [HCO
P07642633T0000 |32 45|binding siteslkaline phosp
P07644127A0000 |32 40|neuroneslkaline 
P07644127A0000 |93 99|fibrescologi
P07644127A0000 |212 214|SIda
P07644127A0000 |247 256|carbacholer displa
P07644127A0000 |63 74|cell bodieseotidase P0
P07644127A0000 |319 328|glutamateeater slo
P07644127A0000 |17 28|stimulationmparison wi
P07644127A0000 |185 210|rat substantia innominataa function of CSF PCO2 th
P07644127A0000 |262 269|effectsen comp
P07644127A0000 |106 111|studyts of
P07644127A0000 |166 177|stimulationHCO3-] is s
P07644127A0000 |229 243|microinjectiond rats are no 
P07644127A0000 |278 299|acetylcholine agonistontrols but still hav
P07644466A0578 |186 197|translation function o
P07644466A0578 |45 63|NS3-4A polyproteinhatases and 5-nucl
P07644466A0578 |145 158|NS4A cofactor08997A0472 Wh
P07644466A0578 |131 134|NS3ubi
P07644466A0578 |29 34|assayh alk
P07644466A0578 |74 98|serine proteinase domain0008171T0000 Pharmacolog
P07644466A0578 |246 256|substratesger displa
P07644466A0578 |213 229|trans-processingata of K-deplete
P07644466A0578 |65 68|NS3tid
P07644466A0578 |119 127|residuesl hyperb
P07644503A0729 |137 149|target genesia. P0000899
P07644503A0729 |13 28|over-expression6 Comparison wi
P07644503A0729 |105 114|RAR gammacts of ne
P07644503A0729 |123 133|activationperbilirub
P07644503A0729 |62 77|differentiationleotidase P0000
P07644503A0729 |3 11|contrast001606T0
P07644503A0729 |32 40|RAR betalkaline 
P07646439A0535 |17 25|proteinsmparison
P07646439A0535 |104 135|mAb F11 affinity chromatographyects of neonatal hyperbilirubin
P07646439A0535 |77 91|chromatography8171T0000 Phar
P07646439A0535 |37 55|platelet membranesne phosphatases an
P07647303T0000 |85 93|seedling0 Pharma
P07647303T0000 |67 77|shoot apexdase P0000
P07647303T0000 |26 46|Arabidopsis thalianawith alkaline phosph
P07647303T0000 |143 149|plants000899
P07647303T0000 |113 126|inflorescenceeonatal hyper
P07647303T0000 |4 22|homeobox gene ATK101606T0076 Compari
P07647303T0000 |101 108|flowersaspects
P07647570A0713 |16 27|explanationomparison w
P07647570A0713 |105 111|cortexcts of
P07647570A0713 |45 49|goldhata
P07647570A0713 |122 127|cellsyperb
P07647570A0713 |150 160|deiodinaseA0472 When
P07647570A0713 |143 147|Type0008
P07647570A0713 |81 94|Kupffer cellsT0000 Pharmac
P07648338A0815 |119 131|TNF responsel hyperbilir
P07648338A0815 |148 167|SMA occlusion model97A0472 When CSF [H
P07648338A0815 |192 202|laparotomyion of CSF
P07648338A0815 |37 43|modelsne pho
P07648338A0815 |58 66|ischemia-nucleot
P07648338A0815 |82 99|cytokine profiles0000 Pharmacologi
P07648338A0815 |6 13|results606T007
P07649098A0676 |279 281|ntnt
P07649098A0676 |117 119|ntta
P07649098A0676 |358 372|cotransfection3A0733 Fluraze
P07649098A0676 |190 209|reporter expressionction of CSF PCO2 t
P07649098A0676 |429 436|plasmide optim
P07649098A0676 |665 672|subunitIntrave
P07649098A0676 |530 533|PKA P0
P07649098A0676 |296 300|exonhave
P07649098A0676 |723 742|reporter expressione inhibitors (aceta
P07649098A0676 |124 132|promotererbiliru
P07649098A0676 |481 488|subunitmg at n
P07649098A0676 |61 83|transfection constructcleotidase P00008171T0
P07649098A0676 |606 620|cotransfection(VCO2), alveol
P07649098A0676 |628 635|plasmidlation 
P07649098A0676 |267 275|presencempared t
P07649098A0676 |450 463|alpha-isoforme in general 
P07649098A0676 |234 253|reporter expressions are no longer dis
P07649098A0676 |514 528|protein kinaseblocking agent
P07649098A0676 |582 596|PGE2 treatmentoximated CO2 p
P07649098A0676 |42 54|observationsosphatases a
P07649098A0676 |376 421|IGF-I promoter-luciferase-reporter constructsthus appears to be an effective hypnotic drug
P07649098A0676 |104 115|nucleotidesects of neo
P07649098A0676 |676 679|PKA ad
P07649098A0676 |326 333|contextlope (1
P07649098A0676 |156 159|UTRWhe
P07649098A0676 |697 701|cAMPg/kg
P07649098A0676 |337 351|IGF-I promoter+/- 0.23 vs. P
P07649098A0676 |544 551|results0 When 
P07649098A0676 |143 145|nt00
P07649098A0676 |4 12|evidence01606T00
P07650958A0123 |138 148|indicatorsa. P000089
P07650958A0123 |53 69|electromyographyand 5-nucleotida
P07650958A0123 |88 105|motor improvementharmacologic aspe
P07650958A0123 |4 11|changes01606T0
P07650958A0123 |18 27|treatmentparison w
P07651131A1407 |139 146|targets. P0000
P07651131A1407 |73 94|kDa repressor isoform00008171T0000 Pharmac
P07651131A1407 |151 158|binding0472 Wh
P07651131A1407 |30 54|footprinting experiments alkaline phosphatases a
P07651131A1407 |11 17|assays076 Co
P07651131A1407 |167 174|proteinCO3-] i
P07651131A1407 |110 114|CIRsf ne
P07651131A1407 |22 27|DNaseson w
P07651141A0265 |53 64|nucleotidesand 5-nucle
P07651141A0265 |77 83|p-gvpF8171T0
P07651141A0265 |91 97|p-gvpEmacolo
P07651141A0265 |7 15|terminus06T0076 
P07651141A0265 |23 36|p-gvpF-M mRNAon with alkal
P07651340A0286 |0 16|RetransformationP00001606T0076 C
P07651340A0286 |129 131|UVir
P07651340A0286 |109 120|restorationof neonatal
P07651340A0286 |164 170|levels [HCO3
P07651340A0286 |83 96|transformants000 Pharmacol
P07651340A0286 |52 59|cosmids and 5-
P07651340A0286 |20 34|uvsH77 mutantsrison with alk
P07651340A0286 |136 150|MMS resistancemia. P00008997
P07651386A0925 |34 47|p53 inductionaline phospha
P07651386A0925 |79 89|adenovirus71T0000 Ph
P07651386A0925 |18 25|elementparison
P07651386A0925 |101 109|promoteraspects 
P07651398A0257 |68 78|Drosophilaase P00008
P07651398A0257 |121 124|DERhyp
P07651398A0257 |14 26|dShc protein Comparison 
P07651398A0257 |161 169|tyrosineCSF [HCO
P07651398A0257 |89 119|growth factor receptor homologarmacologic aspects of neonata
P07651398A0257 |173 176|DERis 
P07651398A0257 |3 8|flies00160
P07651398A0803 |33 48|dShc PTB domainkaline phosphat
P07651398A0803 |75 78|DER008
P07651398A0803 |12 24|binding site76 Compariso
P07651398A0803 |63 71|Tyr-1228eotidase
P07651398T0000 |17 29|gene productmparison wit
P07651398T0000 |47 56|signalingtases and
P07651398T0000 |64 92|DER receptor tyrosine kinaseotidase P00008171T0000 Pharm
P07651400A0335 |71 82|splice site P00008171T
P07651400A0335 |134 152|consensus sequencenemia. P00008997A0
P07651400A0335 |5 15|inhibition1606T0076 
P07651400A0335 |55 59|exond 5-
P07651424A0487 |32 37|Ssm1plkali
P07651424A0487 |107 114|subunits of ne
P07651424A0487 |73 77|part0000
P07651424A0487 |142 146|pool0000
P07651424A0487 |12 20|analysis76 Compa
P07651424A0487 |54 61|proteinnd 5-nu
P07651424A0487 |155 163|proteins When CS
P07651424A0743 |71 88|SSM1a transcripts P00008171T0000 P
P07651424A0743 |135 143|majorityemia. P0
P07651424A0743 |151 161|Ssm1p pool0472 When 
P07651424A0743 |62 67|levelleoti
P07651424A0743 |13 18|cells6 Com
P07651424A0743 |106 111|SSM1bts of
P07651424A0743 |20 37|SSM1b transcriptsrison with alkali
P07651734A0961 |0 22|Northern blot analysisP00001606T0076 Compari
P07651734A0961 |111 122|LIMK-2 mRNA neonatal h
P07651734A0961 |149 152|rat7A0
P07651734A0961 |134 141|tissuesnemia. 
P07651734A0961 |36 46|expressionine phosph
P07651734A0961 |97 107|expressiongic aspect
P07651734A0961 |83 88|brain000 P
P07651734A0961 |50 61|LIMK-1 mRNAes and 5-nu
P07651835A0652 |22 38|binding affinityson with alkalin
P07651835A0652 |47 53|motifstases 
P07652066A0677 |259 264|scars when
P07652066A0677 |57 66|procedure5-nucleot
P07652066A0677 |226 230|risketed
P07652066A0677 |30 37|concept alkali
P07652066A0677 |140 146|fascia P0000
P07652066A0677 |202 211|incisions PCO2 the
P07652066A0677 |7 12|basis06T00
P07652066A0677 |246 255|migrationger displ
P07652066A0677 |115 123|arm flapnatal hy
P07652066A0677 |98 107|anchoringic aspect
P07652066A0677 |279 287|contoursntrols b
P07652066A0677 |185 198|system repaira function of
P07652575A0435 |49 54|formsses a
P07652575A0435 |13 27|microinjection6 Comparison w
P07652575A0435 |58 61|Rac-nu
P07652575A0435 |133 146|DNA synthesisinemia. P0000
P07652575A0435 |82 110|Rho inhibitor C3 transferase0000 Pharmacologic aspects o
P07652575A0435 |66 71|Cdc42idase
P07652582A0000 |0 17|INF-alpha therapyP00001606T0076 Co
P07652582A0000 |67 70|CMLdas
P07652582A0000 |54 63|treatmentnd 5-nucl
P07652582A0000 |35 46|developmentline phosph
P07653094A0169 |102 112|processingspects of 
P07653094A0169 |27 43|deletion mutantsith alkaline pho
P07653094A0169 |60 63|d31ucl
P07653094A0169 |283 293|HeLa cellsls but sti
P07653094A0169 |79 82|d7371T
P07653094A0169 |12 17|amino76 Co
P07653094A0169 |45 48|d10hat
P07653094A0169 |50 53|d20es 
P07653094A0169 |252 269|pcDL-SR alpha-296splaced when comp
P07653094A0169 |222 227|genesdeple
P07653094A0169 |55 58|d27d 5
P07653094A0169 |114 137|cell surface expressiononatal hyperbilirubinem
P07653094A0169 |201 211|expressionF PCO2 the
P07653094A0169 |175 185|attributes shown as 
P07653094A0169 |65 68|d40tid
P07653094A0169 |143 154|maintenance0008997A047
P07653094A0169 |70 73|d44e P
P07653094A0169 |236 250|plasmid vectorare no longer 
P07653094A0169 |2 8|series000160
P07653094A0169 |274 278|CV-1to c
P07653812T0000 |101 110|clonidineaspects o
P07653812T0000 |12 44|acetyl cholinesterase inhibitors76 Comparison with alkaline phos
P07653812T0000 |88 96|morphineharmacol
P07653812T0000 |53 62|analgesiaand 5-nuc
P07653812T0000 |114 118|ratsonat
P07653892A0306 |139 140|n.
P07653892A0306 |36 46|triplicateine phosph
P07653892A0306 |77 84|agonist8171T00
P07653892A0306 |130 137|U50488Hrubinem
P07653892A0306 |121 128|agonisthyperbi
P07653892A0306 |18 32|isoflurane MACparison with a
P07653892A0306 |96 97|no
P07653892A0306 |48 53|birdsases 
P07653892A0306 |86 94|morphine Pharmac
P07654239A0698 |51 56|levels and
P07654239A0698 |64 86|cell cycle progressionotidase P00008171T0000
P07654239A0698 |0 3|MaxP00
P07654712A0774 |170 172|pH-]
P07654712A0774 |4 16|yeast enzyme01606T0076 C
P07654712A0774 |54 61|enzymesnd 5-nu
P07654712A0774 |141 149|analysisP0000899
P07654712A0774 |156 165|degrees CWhen CSF 
P07654740A0563 |17 34|selection processmparison with alk
P07654740A0563 |224 242|disease etiologiespleted rats are no
P07654740A0563 |151 169|inclusion criteria0472 When CSF [HCO
P07654740A0563 |82 97|transplantation0000 Pharmacolo
P07654740A0563 |283 300|contraindicationsls but still have
P07654740A0563 |247 261|co-morbiditieser displaced w
P07654740A0563 |122 140|transplant work-upyperbilirubinemia.
P07654740A0563 |203 210|factorsPCO2 th
P07654740A0563 |66 78|alternativesidase P00008
P07654740A0563 |103 114|compositionpects of ne
P07654740A0563 |0 9|Key areasP00001606
P07655184A0852 |51 72|transmembrane proteins and 5-nucleotidase 
P07655184A0852 |91 109|ER leader sequencemacologic aspects 
P07655184A0852 |151 158|protein0472 Wh
P07655184A0852 |174 185|ER sequences shown as 
P07655184A0852 |4 13|transport01606T007
P07655505A0527 |187 194|patternfunctio
P07655505A0527 |128 139|developmentlirubinemia
P07655505A0527 |198 227|phytochrome A gene expression CSF PCO2 the data of K-deple
P07655505A0527 |109 115|stagesof neo
P07655505A0527 |26 38|GT-2 proteinwith alkalin
P07655505A0527 |159 163|rolen CS
P07655505A0527 |8 14|shoots6T0076
P07655505A0527 |71 77|tissue P0000
P07655505A0527 |19 24|rootsariso
P07655509T0000 |119 132|Pisum sativuml hyperbiliru
P07655509T0000 |24 37|motif signalsn with alkali
P07655509T0000 |46 55|targetingatases an
P07655509T0000 |114 117|peaona
P07655509T0000 |81 89|proteinsT0000 Ph
P07656588A0101 |234 241|D19S412s are n
P07656588A0101 |188 192|FUT1unct
P07656588A0101 |124 128|FUT1erbi
P07656588A0101 |265 267|cMco
P07656588A0101 |243 252|lod scorelonger di
P07656588A0101 |150 157|clusterA0472 W
P07656588A0101 |289 298|lod score still ha
P07656588A0101 |221 223|cM-d
P07656588A0101 |86 88|kb P
P07656588A0101 |114 120|regiononatal
P07656588A0101 |12 33|DNA sequence analysis76 Comparison with al
P07656588A0101 |45 76|Genethon microsatellite D19S596hatases and 5-nucleotidase P000
P07656588A0101 |280 287|D19S571trols b
P07656588A0101 |197 207|FUT2 genesf CSF PCO2
P07657162A1412 |85 92|process0 Pharm
P07657162A1412 |45 50|LEF-1hatas
P07657162A1412 |147 155|addition997A0472
P07657162A1412 |120 143|trans-activation domain hyperbilirubinemia. P0
P07657162A1412 |163 173|HMG domainF [HCO3-] 
P07657162A1412 |17 41|transcription activationmparison with alkaline p
P07657668A0642 |0 14|TH-SH3 bindingP00001606T0076
P07657668A0642 |57 81|amino acid substitutions5-nucleotidase P00008171
P07657668A0642 |93 106|Btk TH domaincologic aspec
P07657668A0642 |114 128|Fyn SH3 domainonatal hyperbi
P07657705A1181 |6 13|results606T007
P07657705A1181 |90 101|developmentrmacologic 
P07657705A1181 |28 38|K-glypicanth alkalin
P07657705A1181 |63 67|HSPGeoti
P07658262A0944 |137 147|correctionia. P00008
P07658262A0944 |95 104|infusionslogic asp
P07658262A0944 |121 127|plasmahyperb
P07658262A0944 |60 69|admissionucleotida
P07658262A0944 |188 195|factorsunction
P07658262A0944 |52 56|time and
P07658262A0944 |157 169|procoagulanthen CSF [HCO
P07658262A0944 |0 16|Protein S levelsP00001606T0076 C
P07658471A0000 |4 23|plant hormone auxin01606T0076 Comparis
P07658471A0000 |58 63|genes-nucl
P07658777A0400 |35 43|patientsline pho
P07658777A0400 |4 8|test0160
P07658777A0400 |55 72|contraindicationsd 5-nucleotidase 
P07659085A1520 |137 152|kidney extractsia. P00008997A0
P07659085A1520 |15 57|transcription factor Oct-1 forms complexesComparison with alkaline phosphatases and 
P07659085A1520 |95 99|FPIVlogi
P07659085A1520 |210 229|androgen regulatione data of K-deplete
P07659085A1520 |195 206|partnership of CSF PCO
P07659085A1520 |181 190|candidate as a fun
P07659085A1520 |127 132|liveriliru
P07659085A1520 |161 166|Oct-1CSF [
P07659085A1520 |66 79|octamer motifidase P000081
P07659085A1520 |103 121|gel shift analysispects of neonatal 
P07659515T0000 |84 92|elements00 Pharm
P07659515T0000 |14 29|retrotransposon Comparison wit
P07659515T0000 |96 133|Crithidia fasciculata miniexon arraysogic aspects of neonatal hyperbilirub
P07659515T0000 |39 47|evidence phospha
P07659529A0135 |55 79|reporter gene constructsd 5-nucleotidase P000081
P07659529A0135 |30 49|transfection assays alkaline phosphata
P07659529A0135 |95 125|transcription control elementslogic aspects of neonatal hype
P07659529A0135 |165 174|EpoR gene[HCO3-] i
P07659529A0135 |145 151|region08997A
P07659529A0135 |8 25|deletion analysis6T0076 Comparison
P07659746A1464 |102 108|ovulesspects
P07659746A1464 |122 137|d post-anthesisyperbilirubinem
P07659746A1464 |4 34|CVA16.4 proteolipid transcript01606T0076 Comparison with alk
P07659746A1464 |68 88|proteolipid messagesase P00008171T0000 P
P07659757A0191 |0 10|IncubationP00001606T
P07659757A0191 |78 83|assay171T0
P07659757A0191 |27 42|fusion proteinsith alkaline ph
P07659757A0191 |59 62|ATPnuc
P07659757A0191 |126 145|autophosphorylationbilirubinemia. P000
P07659757A0191 |101 109|proteinsaspects 
P07659757A0191 |49 58|gamma-32Pses and 5
P07660712A0118 |33 41|responsekaline p
P07660712A0118 |121 128|respecthyperbi
P07660712A0118 |105 115|risk groupcts of neo
P07660712A0118 |78 84|adults171T00
P07660712A0118 |132 135|VHBbin
P07660712A0118 |59 67|childrennucleoti
P07660712A0118 |4 13|character01606T007
P07663138A0835 |69 72|PBFse 
P07663138A0835 |61 64|PBVcle
P07663138A0835 |15 25|heart rateComparison
P07663138A0835 |46 47|%a
P07663138A0835 |6 13|nadolol606T007
P07663160A0287 |118 127|avoidanceal hyperb
P07663160A0287 |14 26|DNA sequence Comparison 
P07663160A0287 |173 184|codon usageis shown as
P07663160A0287 |113 116|RNAeon
P07663160A0287 |244 255|preferencesonger displ
P07663160A0287 |150 159|structureA0472 Whe
P07663160A0287 |200 218|protein expressionSF PCO2 the data o
P07663160A0287 |99 102|16Sc a
P07663160A0287 |64 76|base pairingotidase P000
P07663160A0287 |222 228|accorddeplet
P07663963A1588 |207 222|control animals the data of K-
P07663963A1588 |11 28|system activation076 Comparison wi
P07663963A1588 |134 139|monthnemia
P07663963A1588 |105 110|malescts o
P07663963A1588 |90 94|timermac
P07663963A1588 |178 184|levelsown as
P07663963A1588 |43 73|metanephrine/epinephrine ratiosphatases and 5-nucleotidase P
P07663963A1588 |143 155|cohabitation0008997A0472
P07663963A1588 |157 165|turnoverhen CSF 
P07663998T0000 |25 29|type wit
P07663998T0000 |15 21|repairCompar
P07663998T0000 |58 67|aneurysms-nucleoti
P07664278A0135 |0 2|A.P0
P07665172A0000 |0 21|Transcription factorsP00001606T0076 Compar
P07665172A0000 |125 131|numberrbilir
P07665172A0000 |114 119|genesonata
P07665172A0000 |65 70|motiftidas
P07665172A0000 |156 163|systemsWhen CS
P07665172A0000 |84 94|expression00 Pharmac
P07665187A0208 |0 16|Primer extensionP00001606T0076 C
P07665187A0208 |82 93|Nramp1 mRNA0000 Pharma
P07665187A0208 |21 33|cDNA cloningison with al
P07665187A0208 |71 74|end P0
P07665187A0824 |0 16|Primer extensionP00001606T0076 C
P07665187A0824 |134 142|presencenemia. P
P07665187A0824 |110 116|Nramp1f neon
P07665187A0824 |77 106|transcription initiation site8171T0000 Pharmacologic aspec
P07665187A0824 |174 190|initiation sitess shown as a fun
P07665187A0824 |21 52|S1 nuclease mapping experimentsison with alkaline phosphatases
P07665477A0901 |0 4|EsaRP000
P07665477A0901 |25 35|expression with alka
P07665477A0901 |66 76|expressionidase P000
P07665477A0901 |80 84|esaI1T00
P07665567A0495 |0 17|Sequence analysisP00001606T0076 Co
P07665567A0495 |253 263|NF-kappa Bplaced whe
P07665567A0495 |114 124|base pairsonatal hyp
P07665567A0495 |332 336|gene1.21
P07665567A0495 |147 176|transcription initiation site997A0472 When CSF [HCO3-] is 
P07665567A0495 |265 270|Egr-1compa
P07665567A0495 |230 251|transcription factors rats are no longer d
P07665567A0495 |198 215|binding sequences CSF PCO2 the dat
P07665567A0495 |74 82|presence0008171T
P07665567A0495 |51 60|CD69 genes and 5-n
P07665567A0495 |37 43|regionne pho
P07665567A0495 |313 323|expressiontly greate
P07665567A0495 |98 110|TATA elementic aspects o
P07665567A0495 |272 276|AP-1d to
P07665605A1127 |20 21|Dr
P07665605A1127 |91 100|DD dimersmacologic
P07665605A1127 |46 53|productatases 
P07665633A0284 |51 65|disk diffusions and 5-nucleo
P07665633A0284 |146 166|Laboratory Standards8997A0472 When CSF [
P07665633A0284 |13 21|isolates6 Compar
P07665633A0284 |114 132|National Committeeonatal hyperbiliru
P07665633A0284 |70 94|agar dilution procedurese P00008171T0000 Pharmac
P07665948A0591 |51 62|individualss and 5-nuc
P07665948A0591 |67 77|IgE levelsdase P0000
P07665948A0591 |93 108|children groupscologic aspects
P07665948A0591 |25 31|values with 
P07665948A0591 |155 164|infection When CSF
P07665948A0591 |142 151|intensity00008997A
P07665948A0591 |117 123|adultstal hy
P07665948A0591 |0 10|IgE levelsP00001606T
P07666414A0614 |34 44|tmy-1 genealine phos
P07666414A0614 |63 77|microinjectioneotidase P0000
P07666414A0614 |83 108|promoter/lacZ fusion gene000 Pharmacologic aspects
P07666414A0614 |182 199|anti-tropomyosinsas a function of 
P07666414A0614 |16 26|expressionomparison 
P07666414A0614 |118 138|immunohistochemistryal hyperbilirubinemi
P07666415A0000 |48 51|DNAase
P07666415A0000 |31 42|chloroplastalkaline ph
P07666415A0000 |57 62|maize5-nuc
P07666415A0000 |44 46|cpph
P07666415A0000 |4 23|nucleotide sequence01606T0076 Comparis
P07666415A0000 |64 72|Zea maysotidase 
P07666523T0000 |0 13|InvestigationP00001606T007
P07666523T0000 |21 28|controlison wi
P07666523T0000 |111 126|RNA transcripts neonatal hyper
P07666523T0000 |55 73|mRNA transcriptiond 5-nucleotidase P
P07666523T0000 |32 43|coronaviruslkaline pho
P07666538A0000 |0 10|InitiationP00001606T
P07666538A0000 |130 136|regionrubine
P07666538A0000 |63 73|RNA genomeeotidase P
P07666538A0000 |166 172|mannerHCO3-]
P07666538A0000 |14 25|translation Comparison
P07666538A0000 |93 107|ribosome entrycologic aspect
P07666538A0000 |58 61|HCV-nu
P07666538A0000 |39 56|hepatitis C virus phosphatases and
P07666538A0000 |140 143|NCR P0
P07666966A0207 |0 4|MeanP000
P07666966A0207 |44 50|lesionphatas
P07666966A0207 |18 27|extensionparison w
P07666966A0207 |69 77|segmentsse P0000
P07667097A0267 |68 75|findingase P00
P07667097A0267 |163 180|splicing productsF [HCO3-] is show
P07667097A0267 |110 118|splicingf neonat
P07667097A0267 |123 140|immunoprecipitateperbilirubinemia.
P07667097A0267 |29 47|splicing complexesh alkaline phospha
P07667097A0267 |81 88|mAb CC3T0000 P
P07667097A0267 |4 15|association01606T0076 
P07667097A0267 |155 158|RNA Wh
P07667097A0267 |19 23|p255aris
P07667195A0146 |0 5|L-735P0000
P07667195A0146 |75 83|solution008171T0
P07667195A0146 |15 19|baseComp
P07667195A0146 |126 137|Beagle dogsbilirubinem
P07667195A0146 |63 73|suspensioneotidase P
P07667195A0146 |23 35|sulfate salton with alka
P07667195A0146 |96 108|dosage formsogic aspects
P07667621T0001 |0 26|Doppler ultrasound studiesP00001606T0076 Comparison 
P07667621T0001 |40 49|follow-upphosphata
P07667621T0001 |53 61|childrenand 5-nu
P07667621T0001 |84 92|syndrome00 Pharm
P07668009A0172 |28 48|hepatitis A diseasesth alkaline phosphat
P07668009A0172 |14 24|cumlations Compariso
P07669351A1278 |4 14|properties01606T0076
P07669351A1278 |29 46|SSB-ssDNA complexh alkaline phosph
P07669351A1278 |22 25|phison
P07670504A0834 |138 151|binding assaya. P00008997A
P07670504A0834 |47 62|banding patterntases and 5-nuc
P07670504A0834 |110 115|G-boxf neo
P07670504A0834 |179 182|GBFwn 
P07670504A0834 |66 71|plantidase
P07670504A0834 |80 88|proteins1T0000 P
P07670943A0308 |34 42|patientsaline ph
P07670943A0308 |15 19|maleComp
P07670943A0308 |160 163|CAD CS
P07670943A0308 |105 113|familiescts of n
P07670943A0308 |142 149|sibling0000899
P07670943A0308 |54 57|CADnd 
P07672821A0763 |157 165|proteinshen CSF 
P07672821A0763 |41 55|factor H geneshosphatases an
P07672821A0763 |28 32|FHR2th a
P07672821A0763 |13 20|linkage6 Compa
P07672821A0763 |97 108|relatednessgic aspects
P07672821A0763 |76 84|evidence08171T00
P07672821A0763 |112 131|complement factor Hneonatal hyperbilir
P07672821A0763 |140 146|factor P0000
P07672822T0000 |34 42|locationaline ph
P07672822T0000 |8 17|structure6T0076 Co
P07672822T0000 |67 86|receptor alpha genedase P00008171T0000
P07672822T0000 |50 55|mousees an
P07673128A0989 |36 57|cAMP response elementine phosphatases and 
P07673128A0989 |10 16|domain0076 C
P07673128A0989 |25 30|motif with
P07673128A0989 |59 62|CREnuc
P07673154A0688 |117 126|3Y1 cellstal hyper
P07673154A0688 |28 33|stateth al
P07673154A0688 |37 45|CAK betane phosp
P07673154A0688 |132 143|fibronectinbinemia. P0
P07673154A0688 |97 105|responsegic aspe
P07673154A0688 |65 79|trypsinizationtidase P000081
P07673178A0982 |154 172|MCK-L type E-boxes2 When CSF [HCO3-]
P07673178A0982 |120 143|MDF/bH-L-H heterodimers hyperbilirubinemia. P0
P07673178A0982 |108 116|spectrum of neon
P07673178A0982 |211 218|factors data o
P07673178A0982 |36 55|muscle gene E-boxesine phosphatases an
P07673178A0982 |4 11|results01606T0
P07674649A0508 |82 105|treatment effectiveness0000 Pharmacologic aspe
P07674649A0508 |41 56|baseline designhosphatases and
P07674649A0508 |27 31|ABABith 
P07675445A0463 |85 113|sequence length polymorphism0 Pharmacologic aspects of n
P07675445A0463 |62 64|CAle
P07675445A0463 |60 61|pu
P07675445A0463 |6 12|clones606T00
P07675445A0463 |42 48|domainosphat
P07675445A0463 |65 74|n repeatstidase P0
P07675445A0463 |115 119|SSLPnata
P07675449A0848 |85 90|PDGFR0 Pha
P07675449A0848 |7 29|glioblastoma cell line06T0076 Comparison wit
P07675449A0848 |48 52|p190ases
P07676492A1000 |35 42|reportsline ph
P07676492A1000 |133 136|IHDine
P07676492A1000 |54 61|regionsnd 5-nu
P07676492A1000 |82 103|transplant recipients0000 Pharmacologic as
P07676492A1000 |21 31|comparisonison with 
P07676492A1000 |116 120|riskatal
P07676587T0000 |11 24|certification076 Compariso
P07676587T0000 |29 45|livestock exporth alkaline phosp
P07676655A0214 |4 23|serum concentration01606T0076 Comparis
P07676655A0214 |27 29|iPit
P07676655A0214 |47 49|HDta
P07676655A0214 |93 94|Dc
P07676655A0214 |126 130|mmolbili
P07676655A0214 |37 45|dialysisne phosp
P07676655A0214 |82 88|mmol/l0000 P
P07677573A0000 |136 142|mucosamia. P
P07677573A0000 |57 67|parameters5-nucleoti
P07677573A0000 |79 88|secretion71T0000 P
P07677573A0000 |14 25|correlation Comparison
P07677573A0000 |90 99|incretionrmacologi
P07677573A0000 |36 42|numberine ph
P07677573A0000 |178 187|gastritisown as a 
P07677573A0000 |156 164|patientsWhen CSF
P07677573A0000 |117 124|changestal hyp
P07677715A1076 |4 14|TAF factor01606T0076
P07677715A1076 |57 60|OCD5-n
P07677836A1356 |152 159|absence472 Whe
P07677836A1356 |14 27|matter injury Comparison w
P07677836A1356 |92 100|deficitsacologic
P07677836A1356 |106 125|leukoencephalopathyts of neonatal hype
P07677836A1356 |163 175|chemotherapyF [HCO3-] is
P07677836A1356 |49 58|radiationses and 5
P07678006A0472 |0 25|RNase protection analysesP00001606T0076 Comparison
P07678006A0472 |122 138|CaM PDE isoformsyperbilirubinemi
P07678006A0472 |91 102|transcriptsmacologic a
P07678006A0472 |54 66|CaM PDE mRNAnd 5-nucleot
P07678006A0472 |174 180|manners show
P07678006A0901 |51 57|cortexs and 
P07678006A0901 |128 131|RNAlir
P07678006A0901 |109 121|T-lymphocyteof neonatal 
P07678006A0901 |13 23|protection6 Comparis
P07678006A0901 |67 74|medulladase P0
P07678006A0901 |76 81|liver08171
P07678006A0901 |83 96|kidney cortex000 Pharmacol
P07678006A0901 |98 104|spleenic asp
P07678051A1303 |102 112|productionspects of 
P07678051A1303 |4 17|PDGFR mutants01606T0076 Co
P07678051A1303 |48 57|PLC gammaases and 
P07678051A1303 |116 135|inositol phosphatesatal hyperbilirubin
P07678242A0473 |18 29|correlationparison wit
P07678242A0473 |91 95|ratemaco
P07678242A0473 |108 114|growth of ne
P07678242A0473 |73 82|acc genes00008171T
P07678242A0473 |42 48|levelsosphat
P07678242A0473 |52 65|transcription and 5-nucleo
P07678593A0708 |51 54|DNAs a
P07678593A0708 |25 38|V. vulnificus with alkalin
P07678593A0708 |70 92|V. cholerae fur mutante P00008171T0000 Pharm
P07678593A0708 |16 21|cloneompar
P07678602A0153 |154 161|parents2 When 
P07678602A0153 |130 137|diseaserubinem
P07678602A0153 |75 83|patients008171T0
P07678602A0153 |25 49|B lymphoblast cell lines with alkaline phosphata
P07678602A0153 |55 63|controlsd 5-nucl
P07678695A0604 |71 79|promoter P000081
P07678695A0604 |149 157|promoter7A0472 W
P07678695A0604 |26 31|Oct-3with 
P07678695A0604 |12 22|expression76 Compari
P07678695A0604 |37 49|hybrid cellsne phosphata
P07678695A0604 |114 124|activationonatal hyp
P07679390A0721 |102 116|DDT1 aFGF mRNAspects of neon
P07679390A0721 |78 82|exon171T
P07679390A0721 |180 182|bpn 
P07679390A0721 |134 158|transcription start sitenemia. P00008997A0472 Wh
P07679390A0721 |21 44|primer extension assaysison with alkaline phos
P07679390A0721 |213 228|splice junctionata of K-deplet
P07679390A0721 |237 241|exonre n
P07679390A0721 |0 16|RNase protectionP00001606T0076 C
P07679836A0387 |64 69|agentotida
P07679836A0387 |73 95|kidney transplantation00008171T0000 Pharmaco
P07679836A0387 |27 29|FKit
P07679836A0387 |6 13|results606T007
P07680035A0221 |4 9|roles01606
P07680035A0221 |60 73|GnRH responseucleotidase P
P07680035A0221 |13 27|phorbol esters6 Comparison w
P07680035A0221 |39 42|AMP ph
P07680120A1008 |0 6|RT-PCRP00001
P07680120A1008 |90 96|D mRNArmacol
P07680120A1008 |26 33|primerswith al
P07680120A1008 |148 154|source97A047
P07680120A1008 |46 52|kidneyatases
P07680120A1008 |120 125|brain hype
P07680120A1008 |159 171|aFGF proteinn CSF [HCO3-
P07680120A1008 |109 115|kidneyof neo
P07680120A1008 |54 59|brainnd 5-
P07680120A1008 |64 72|prostateotidase 
P07680629T0000 |119 130|cell fusionl hyperbili
P07680629T0000 |61 66|gp138cleot
P07680629T0000 |134 158|Dictyostelium discoideumnemia. P00008997A0472 Wh
P07680629T0000 |10 17|cloning0076 Co
P07680629T0000 |46 51|genesatase
P07680629T0000 |22 38|characterizationson with alkalin
P07680629T0000 |70 95|cell surface glycoproteine P00008171T0000 Pharmaco
P07681147A1420 |136 143|abilitymia. P0
P07681147A1420 |107 112|cellss of 
P07681147A1420 |73 79|Ser-12000081
P07681147A1420 |31 39|analysesalkaline
P07681147A1420 |54 69|phosphorylationnd 5-nucleotida
P07681147A1420 |161 170|pp60c-srcCSF [HCO3
P07681147A1420 |201 211|signallingF PCO2 the
P07681147A1420 |84 90|Ser-4800 Pha
P07681513A0000 |0 10|PiroximoneP00001606T
P07681513A0000 |42 51|inhibitorosphatase
P07681513A0000 |20 37|phosphodiesteraserison with alkali
P07681513A0000 |80 102|vasodilator properties1T0000 Pharmacologic a
P07681539A0000 |117 120|mSvtal
P07681539A0000 |12 19|studies76 Comp
P07681539A0000 |38 49|lymphocytese phosphata
P07681539A0000 |96 105|radiationogic aspe
P07681539A0000 |55 71|hospital workersd 5-nucleotidase
P07681539A0000 |87 92|dosesPharm
P07682842A0294 |168 179|copy numberO3-] is sho
P07682842A0294 |88 102|receptor genesharmacologic a
P07682842A0294 |13 19|origin6 Comp
P07682842A0294 |126 148|fMLF-R gene expressionbilirubinemia. P000089
P07682842A0294 |244 252|sequenceonger di
P07682842A0294 |214 226|organizationta of K-depl
P07682842A0294 |193 201|locationon of CS
P07682842A0294 |112 122|regulationneonatal h
P07682842A0294 |266 277|fMLF-R geneompared to 
P07682842A0294 |65 72|linkagetidase 
P07682842A0294 |33 51|fMLF-R transcriptskaline phosphatase
P07682842A0771 |68 72|exonase 
P07682842A0771 |26 28|bpwi
P07682842A0771 |52 60|sequence and 5-n
P07682842A0771 |10 14|exon0076
P07682842A0771 |114 123|sequencesonatal hy
P07682842A0771 |87 93|codingPharma
P07683131A0885 |141 147|familyP00008
P07683131A0885 |30 37|members alkali
P07683131A0885 |12 21|structure76 Compar
P07683131A0885 |45 55|SRC-familyhatases an
P07683131A0885 |126 132|domainbiliru
P07683131A0885 |82 104|exon/intron boundaries0000 Pharmacologic asp
P07683375A0000 |34 48|growth factorsaline phosphat
P07683375A0000 |80 82|E21T
P07683375A0000 |23 30|effectson with
P07683375A0000 |53 57|cAMPand 
P07683375A0000 |144 161|estrogen receptor008997A0472 When 
P07683375A0000 |298 300|ERve
P07683375A0000 |120 125|genes hype
P07683375A0000 |282 290|activityols but 
P07683375A0000 |187 194|studiesfunctio
P07683375A0000 |87 97|regulationPharmacolo
P07683375A0000 |223 233|activatorsepleted ra
P07683375A0000 |101 111|expressionaspects of
P07683375A0000 |163 165|ERF 
P07683375A0000 |237 252|protein kinasesre no longer di
P07683375A0000 |69 78|estradiolse P00008
P07685263A0503 |54 67|DNA fragmentsnd 5-nucleoti
P07685263A0503 |75 85|base pairs008171T000
P07685263A0503 |10 35|polymerase chain reaction0076 Comparison with alka
P07685263A0503 |109 126|Whipple bacteriumof neonatal hyper
P07685263A0503 |95 101|genomelogic 
P07685263A0503 |128 148|Tropheryma whippeliilirubinemia. P000089
P07685823A1234 |0 14|RNA polymeraseP00001606T0076
P07685823A1234 |90 95|DNasermaco
P07685823A1234 |124 134|start siteerbilirubi
P07685823A1234 |31 41|A promoteralkaline p
P07685823A1234 |66 84|base-pair sequenceidase P00008171T00
P07685823A1234 |98 107|digestionic aspect
P07685874A0258 |17 24|calciummpariso
P07685874A0258 |9 15|sodiumT0076 
P07685874A0258 |88 100|SLE patientsharmacologic
P07685874A0258 |164 186|protein concentrations [HCO3-] is shown as a
P07685874A0258 |30 54|magnesium concentrations alkaline phosphatases a
P07685874A0258 |246 254|controlsger disp
P07685874A0258 |144 153|potassium008997A04
P07685874A0258 |191 207|amylase activitytion of CSF PCO2
P07685874A0258 |115 134|lupus erythematosusnatal hyperbilirubi
P07686619A0704 |0 4|ChemP000
P07687320A0526 |103 106|ge6pec
P07687320A0526 |60 67|abilityucleoti
P07687320A0526 |12 26|plasmid pFV10076 Comparison 
P07687320A0526 |71 99|complement B-band expression P00008171T0000 Pharmacologi
P07687541A0200 |205 215|degrees C.O2 the dat
P07687541A0200 |142 157|mtr1/prp20/srm100008997A0472 W
P07687541A0200 |82 90|mutation0000 Pha
P07687541A0200 |107 111|genes of
P07687541A0200 |195 198|RNA of
P07687541A0200 |191 192|At
P07687541A0200 |159 166|mutantsn CSF [
P07687541A0200 |49 62|fission yeastses and 5-nuc
P07687541A0200 |186 190|poly fun
P07687541A0992 |137 141|CNR1ia. 
P07687541A0992 |6 11|RCC1p606T0
P07687541A0992 |146 150|CNR28997
P07687541A0992 |29 32|Ranh a
P07687541A0992 |104 112|homologsects of 
P07687541A0992 |64 79|ras superfamilyotidase P000081
P07687541A0992 |20 24|GNRPriso
P07687541A0992 |116 119|Ranata
P07687541A0992 |50 56|GTPasees and
P07687745T0000 |37 54|amino acid importne phosphatases a
P07687745T0000 |22 27|FK506son w
P07688112A0274 |0 8|ProstateP0000160
P07688112A0274 |47 52|casestases
P07688112A0274 |61 71|correctioncleotidase
P07688112A0274 |97 113|acid phosphatasegic aspects of n
P07688112A0274 |18 25|antigenparison
P07689154A0168 |0 23|Protein phosphorylationP00001606T0076 Comparis
P07689154A0168 |59 78|uPA gene expressionnucleotidase P00008
P07689154A0168 |95 109|protein kinaselogic aspects 
P07689154A0168 |299 314|uPA mRNA levelse a significant
P07689154A0168 |123 137|phorbol estersperbilirubinem
P07689154A0168 |88 93|cellsharma
P07689154A0168 |221 225|cAMP-dep
P07689154A0168 |216 219|AMP of
P07689154A0168 |191 199|uPA mRNAtion of 
P07689154A0168 |263 269|agentsn comp
P07689154A0168 |51 55|roles an
P07689154A0168 |153 162|pp60v-src72 When C
P07689154A0168 |285 289|cAMP but
P07689154A0168 |237 244|proteinre no l
P07689501A0420 |9 17|carriersT0076 Co
P07691837A1359 |185 208|NFkB consensus sequencea function of CSF PCO2 
P07691837A1359 |108 116|promoter of neon
P07691837A1359 |228 234|GC boxed rat
P07691837A1359 |165 171|motifs[HCO3-
P07691837A1359 |9 11|bpT0
P07691837A1359 |131 139|clustersubinemia
P07691837A1359 |24 32|sequencen with a
P07691837A1359 |36 51|K3 keratin geneine phosphatase
P07691885T0000 |0 14|IdentificationP00001606T0076
P07691885T0000 |160 173|c-kit product CSF [HCO3-] 
P07691885T0000 |90 118|mast cell leukemia cell linermacologic aspects of neonat
P07691885T0000 |58 78|proto-oncogene c-kit-nucleotidase P00008
P07691885T0000 |146 156|activation8997A0472 
P07691885T0000 |42 50|sequenceosphatas
P07691885T0000 |18 27|mutationsparison w
P07692366A0000 |0 10|BACKGROUNDP00001606T
P07692366A0000 |12 23|Delineation76 Comparis
P07692366A0000 |88 92|ARMDharm
P07692366A0000 |74 86|degeneration0008171T0000
P07692366A0000 |43 50|aspectssphatas
P07692366A0000 |108 119|correlation of neonata
P07692366A0000 |138 146|featuresa. P0000
P07692366A0000 |187 199|pathogenesisfunction of 
P07692668A0326 |249 260|arrangement displaced 
P07692668A0326 |47 50|RNAtas
P07692668A0326 |211 233|transcription strategy data of K-depleted ra
P07692668A0326 |264 268|ORFs com
P07692668A0326 |95 99|RNAslogi
P07692668A0326 |126 128|kbbi
P07692668A0326 |162 180|blot hybridizationSF [HCO3-] is show
P07692754T0000 |0 12|Risk factorsP00001606T00
P07692754T0000 |94 106|blood donorsologic aspec
P07692754T0000 |36 50|seroprevalenceine phosphatas
P07692754T0000 |54 81|hepatitis C virus infectionnd 5-nucleotidase P00008171
P07693132A0100 |58 67|Zm-ERabp4-nucleoti
P07693132A0100 |47 56|Zm-ERabp1tases and
P07693132A0100 |31 39|analysisalkaline
P07693132A0100 |73 88|Zm-ERabp5 genes00008171T0000 P
P07693132A0100 |9 16|cloningT0076 C
P07693372A0115 |70 79|mechanisme P000081
P07693372A0115 |109 121|cyclosporineof neonatal 
P07693372A0115 |30 36|fungus alkal
P07693372A0115 |83 89|action000 Ph
P07693372A0115 |5 10|agent1606T
P07693672A0259 |0 5|DNaseP0000
P07693672A0259 |8 20|footprinting6T0076 Compa
P07693672A0259 |60 67|regionsucleoti
P07693672A0259 |37 45|promoterne phosp
P07693672A0259 |71 81|protection P00008171
P07693699A0831 |119 123|ureal hy
P07693699A0831 |104 115|sensitivityects of neo
P07693699A0831 |30 57|nucleotide binding function alkaline phosphatases and 
P07693699A0831 |13 22|stability6 Compari
P07693699A0831 |69 77|proteinsse P0000
P07693708A0000 |35 44|protein-2line phos
P07693708A0000 |73 82|rat liver00008171T
P07693708A0000 |13 19|growth6 Comp
P07693708A0000 |56 69|transcription 5-nucleotida
P07693708A0000 |46 54|IGF-BP-2atases a
P07693708A0000 |109 112|ageof 
P07693708A0000 |117 124|fastingtal hyp
P07693967A0905 |4 12|presence01606T00
P07693967A0905 |76 87|translation08171T0000 
P07693967A0905 |28 39|SL sequenceth alkaline
P07693967A0905 |66 72|effectidase 
P07693967A0905 |20 22|RVri
P07693975A1418 |17 25|proteinsmparison
P07693975A1418 |111 113|PR n
P07693975A1418 |43 53|methioninesphatases 
P07693975A1418 |65 72|residuetidase 
P07693975A1418 |97 107|N terminusgic aspect
P07693975A1418 |3 11|contrast001606T0
P07693975A1418 |138 149|proteolysisa. P0000899
P07693975T0000 |55 93|leukosis virus Gag-Pol fusion proteinsd 5-nucleotidase P00008171T0000 Pharma
P07693975T0000 |26 45|protease activitieswith alkaline phosp
P07693975T0000 |8 21|transcriptase6T0076 Compar
P07693975T0000 |114 119|cellsonata
P07695629A0489 |16 30|mck1 mds1 mrk1omparison with
P07695629A0489 |38 48|disruptante phosphat
P07695629A0489 |3 11|addition001606T0
P07696183A0567 |102 105|Rakspe
P07696183A0567 |330 351|membrane localization (1.21 +/- 0.23 vs. P
P07696183A0567 |361 364|Rak733
P07696183A0567 |88 98|expressionharmacolog
P07696183A0567 |210 220|cell linese data of 
P07696183A0567 |495 501|p54rak000126
P07696183A0567 |290 297|glycinestill h
P07696183A0567 |253 256|Rakpla
P07696183A0567 |459 480|fractionation studiesral practice being 15
P07696183A0567 |531 538|nucleusP000136
P07696183A0567 |431 441|SH2 domainoptimum do
P07696183A0567 |188 193|liveruncti
P07696183A0567 |25 35|properties with alka
P07696183A0567 |146 156|cell lines8997A0472 
P07696183A0567 |198 204|kidney CSF P
P07696183A0567 |404 423|localization signalive hypnotic drug w
P07696183A0567 |75 82|kinases008171T
P07696183A0567 |224 230|breastpleted
P07696183A0567 |312 325|myristylationntly greater 
P07696183A0567 |161 168|tissuesCSF [HC
P07696183A0567 |39 42|Rak ph
P07696183A0567 |235 247|colon origin are no long
P07696450A0271 |0 8|PATIENTSP0000160
P07696450A0271 |253 258|weeksplace
P07696450A0271 |189 203|Nestle-Clintecnction of CSF 
P07696450A0271 |212 223|Switzerlanddata of K-d
P07696450A0271 |58 66|children-nucleot
P07696450A0271 |183 187|Diets a 
P07696450A0271 |36 46|experienceine phosph
P07696450A0271 |13 20|METHODS6 Compa
P07696450A0271 |85 96|bowel Crohn0 Pharmacol
P07696450A0271 |152 160|TGF-beta472 When
P07696450A0271 |237 246|nutritionre no lon
P07696450A0271 |99 106|diseasec aspec
P07696450A0271 |139 143|feed. P0
P07696450A0271 |205 210|VeveyO2 th
P07696878A0222 |4 19|leader sequence01606T0076 Comp
P07696878A0222 |75 89|reading frames008171T0000 Ph
P07696878A0222 |172 191|homeodomain protein is shown as a func
P07696878A0222 |106 122|initiation codonts of neonatal h
P07696878A0222 |36 46|cDNA cloneine phosph
P07696878A0222 |143 156|reading frame0008997A0472 
P07697294A0329 |18 30|HSP81-1 mRNAparison with
P07697294A0329 |8 14|amount6T0076
P07697294A0329 |52 57|roots and 
P07698219A0551 |0 13|Cell adhesionP00001606T007
P07698219A0551 |148 156|PE cells97A0472 
P07698219A0551 |60 64|betaucle
P07698219A0551 |80 96|laminin receptor1T0000 Pharmacol
P07698219A0551 |52 57|alpha and 
P07698219A0551 |18 34|migration assaysparison with alk
P07698219A0551 |117 125|F9 cellstal hype
P07698727A0386 |33 42|infectionkaline ph
P07698727A0386 |9 20|destructionT0076 Compa
P07698727A0386 |24 29|tumorn wit
P07698727A0386 |76 89|HIV infection08171T0000 Ph
P07699632A0522 |16 28|race personsomparison wi
P07699632A0522 |89 98|arthritisarmacolog
P07699632A0522 |33 47|Chukcha-Eskimokaline phospha
P07699632A0522 |100 103|PsA as
P07699632A0715 |136 147|populationsmia. P00008
P07699632A0715 |108 111|SPA of
P07699632A0715 |26 33|studieswith al
P07699632A0715 |4 19|data complement01606T0076 Comp
P07699632A0715 |93 104|prevalencescologic asp
P07699632A0715 |116 123|HLA-B27atal hy
P07699632A0715 |49 60|populationsses and 5-n
P07699845A0537 |103 114|pharyngitispects of ne
P07699845A0537 |149 168|lacunar tonsillitis7A0472 When CSF [HC
P07699845A0537 |362 375|lymphadenitis33 Flurazepam
P07699845A0537 |240 245|feverno lo
P07699845A0537 |254 273|impetigo contagiosalaced when compared
P07699845A0537 |424 429|dosesth th
P07699845A0537 |80 88|diseases1T0000 P
P07699845A0537 |188 198|bronchitisunction of
P07699845A0537 |321 336|balanoposthitister slope (1.21
P07699845A0537 |387 395|vulvitiss to be 
P07699845A0537 |296 312|tract infectionshave a significa
P07699845A0537 |214 223|pertussista of K-d
P07699845A0537 |452 458|t.i.d.in gen
P07699845A0537 |469 473|daysce b
P07699845A0537 |406 413|colitise hypno
P07699845A0537 |377 385|S.S.S.S.hus appe
P07699845A0537 |47 55|patientstases an
P07699845A0537 |129 140|tonsillitisirubinemia.
P07699845A0537 |9 23|studies SY5555T0076 Comparis
P07699845A0537 |200 209|pneumoniaSF PCO2 t
P07699845A0537 |445 450|mg/kgor us
P07700361A0125 |64 69|typesotida
P07700361A0125 |73 82|molecules00008171T
P07700361A0125 |131 135|typeubin
P07700361A0125 |23 35|interactionson with alka
P07701266A0808 |0 7|RESULTSP000016
P07701266A0808 |9 21|Closure timeT0076 Compar
P07701266A0808 |56 59|TPN 5-
P07701266A0808 |62 74|somatostatinleotidase P0
P07701266A0808 |37 45|patientsne phosp
P07701266A0808 |25 33|fistulas with al
P07701266A0808 |138 142|daysa. P
P07701266A0808 |168 171|TPNO3-
P07702327T0000 |51 79|tissue plasminogen activators and 5-nucleotidase P000081
P07702327T0000 |13 33|adhesion prophylaxis6 Comparison with al
P07702378A0668 |48 58|dermatitisases and 5
P07702378A0668 |88 91|VO2har
P07702378A0668 |27 35|childrenith alka
P07702378A0668 |18 23|sleepparis
P07702752A0545 |326 342|mouse cell lineslope (1.21 +/- 0
P07702752A0545 |106 124|gene transcriptionts of neonatal hyp
P07702752A0545 |180 190|base pairsn as a fun
P07702752A0545 |378 396|Leydig MA-10 cellsus appears to be a
P07702752A0545 |36 56|rat P450c17 promoterine phosphatases and
P07702752A0545 |276 300|reporter gene luciferase controls but still have
P07702752A0545 |219 235|rat P450c17 gene K-depleted rats
P07702752A0545 |126 145|deletion constructsbilirubinemia. P000
P07702752A0545 |206 209|DNA2 t
P07702752A0545 |352 361|Y-1 cells0010943A0
P07702752A0545 |19 28|sequencesarison wi
P07702752A0545 |252 260|plasmidssplaced 
P07702808A0427 |51 69|corn oil treatments and 5-nucleotida
P07702808A0427 |120 125|mm Hg hype
P07702808A0427 |15 29|BP differencesComparison wit
P07702808A0427 |38 46|fish oile phosph
P07702808A0427 |140 143|ABP P0
P07702808A0427 |87 94|DinamapPharmac
P07702808A0427 |169 174|mm Hg3-] i
P07704040A0000 |68 71|NADase
P07704040A0000 |114 117|NADona
P07704040A0000 |157 174|quinone reductasehen CSF [HCO3-] i
P07704040A0000 |123 139|quinone acceptorperbilirubinemia
P07704040A0000 |210 212|ECe 
P07704040A0000 |120 121|H 
P07704040A0000 |74 75|H0
P07704040A0000 |195 208|DT diaphorase of CSF PCO2 
P07704040A0000 |118 119|Pa
P07704040A0000 |184 193|reductase a functi
P07704040A0000 |76 100|menadione oxidoreductase08171T0000 Pharmacologic
P07704040A0000 |72 73|PP
P07704040A0000 |141 155|oxidoreductaseP00008997A0472
P07704040A0000 |33 48|mouse NMO1 cDNAkaline phosphat
P07704273A0000 |171 191|Citrobacter freundii] is shown as a func
P07704273A0000 |63 74|strain HfrHeotidase P0
P07704273A0000 |30 59|ampD ampE deletion derivative alkaline phosphatases and 5-
P07704273A0000 |113 123|expressioneonatal hy
P07704273A0000 |148 167|beta-lactamase gene97A0472 When CSF [H
P07704273A0000 |204 218|plasmid pNU305CO2 the data o
P07704273A0000 |17 23|JRG582mparis
P07704456A1014 |7 16|mechanism06T0076 C
P07704456A1014 |62 72|conditionsleotidase 
P07704456A1014 |27 39|accelerationith alkaline
P07704456A1014 |148 160|HMS subjects97A0472 When
P07704456A1014 |108 118|prevalence of neonat
P07704456A1014 |127 137|conditionsilirubinem
P07704689T0000 |9 23|thyroid noduleT0076 Comparis
P07704730T0000 |34 40|futurealine 
P07704730T0000 |5 18|contraception1606T0076 Com
P07704730T0000 |20 25|ideasrison
P07705476A0292 |102 114|urine volumespects of ne
P07705476A0292 |70 83|protein levele P00008171T0
P07705476A0292 |12 23|food intake76 Comparis
P07705476A0292 |153 160|protein72 When
P07705476A0292 |85 97|water intake0 Pharmacolo
P07705627A1107 |51 61|componentss and 5-nu
P07705627A1107 |24 29|Medean wit
P07705627A1107 |74 86|dpp pathways0008171T0000
P07705627A1107 |98 109|developmentic aspects 
P07705627A1107 |16 19|Madomp
P07706273T0000 |16 26|regulationomparison 
P07706273T0000 |90 101|THP-1 cellsrmacologic 
P07706273T0000 |43 44|Hs
P07706273T0000 |48 70|ATPase B2 subunit geneases and 5-nucleotidas
P07706287A0698 |103 108|phasepects
P07706287A0698 |61 70|cytoplasmcleotidas
P07706287A0698 |46 53|nucleusatases 
P07706287A0698 |13 22|inability6 Compari
P07706287A0698 |33 36|RNAkal
P07706287A0698 |116 135|cell division cycleatal hyperbilirubin
P07706291T0000 |3 16|E box element001606T0076 C
P07706291T0000 |148 159|development97A0472 Whe
P07706291T0000 |92 103|ftz-f1 geneacologic as
P07706291T0000 |79 88|homologue71T0000 P
P07706291T0000 |37 47|expressionne phospha
P07706291T0000 |55 65|ad4bp gened 5-nucleo
P07706299A0563 |171 179|features] is sho
P07706299A0563 |144 150|detail008997
P07706299A0563 |192 223|oligosaccharide-protein bindingion of CSF PCO2 the data of K-d
P07706299A0563 |100 109|compounds aspects 
P07706299A0563 |0 17|Inhibition assaysP00001606T0076 Co
P07706307A0914 |101 103|S.as
P07706307A0914 |132 134|C.bi
P07706307A0914 |31 38|proteinalkalin
P07706307A0914 |60 78|specificity pocketucleotidase P00008
P07706307A0914 |125 126|Br
P07706307A0914 |46 52|regionatases
P07706307A0914 |112 121|proteasesneonatal 
P07706307A0914 |4 23|amino acid sequence01606T0076 Comparis
P07706396T0000 |17 27|VPS45 genemparison w
P07706396T0000 |94 106|accumulationologic aspec
P07706396T0000 |31 45|SEC1 homologuealkaline phosp
P07706396T0000 |82 89|defects0000 Ph
P07706396T0000 |110 127|membrane vesiclesf neonatal hyperb
P07706396T0000 |66 73|proteinidase P
P07706396T0000 |0 9|MutationsP00001606
P07707523A0704 |32 52|NF-kappa B inhibitorlkaline phosphatases
P07707523A0704 |14 24|expression Compariso
P07707523A0704 |95 103|activitylogic as
P07707523A0704 |107 110|LMPs o
P07707523A0704 |7 12|cells06T00
P07707523A0704 |54 69|I kappa B-alphand 5-nucleotida
P07707531A0550 |51 57|effects and 
P07707531A0550 |125 130|alpharbili
P07707531A0550 |133 151|gene transcriptioninemia. P00008997A
P07707531A0550 |91 103|binding sitemacologic as
P07707531A0550 |61 73|displacementcleotidase P
P07707531A0550 |81 86|alphaT0000
P07707531A0550 |111 121|repression neonatal 
P07707531A0550 |18 24|designpariso
P07707531A0550 |155 159|ICP4 Whe
P07707544T0000 |69 85|characterizationse P00008171T000
P07707544T0000 |109 120|transcriptsof neonatal
P07707544T0000 |39 67|channel catfish virus genome phosphatases and 5-nucleoti
P07707544T0000 |16 29|transcriptionomparison wit
P07708058A0178 |100 104|AP-1 asp
P07708058A0178 |11 21|nucleotide076 Compar
P07708058A0178 |106 111|motifts of
P07708058A0178 |47 51|cGREtase
P07708058A0178 |120 135|c-jun homodimer hyperbilirubin
P07708058A0178 |42 45|GREosp
P07708058A0178 |79 98|activator protein-171T0000 Pharmacolog
P07708058A0178 |140 163|c-jun/c-fos heterodimer P00008997A0472 When CS
P07708058A0178 |4 7|GRE016
P07708488A0151 |3 11|contrast001606T0
P07708488A0151 |88 91|refhar
P07708488A0151 |66 82|sequence variantidase P00008171T
P07708488A0151 |20 27|resultsrison w
P07708497A0000 |85 96|T3 receptor0 Pharmacol
P07708497A0000 |60 72|interactionsucleotidase 
P07708497A0000 |30 45|thyroid hormone alkaline phosp
P07708497A0000 |106 126|T3 response elementsts of neonatal hyper
P07708497A0000 |47 49|T3ta
P07708497A0000 |150 156|copiesA0472 
P07708497A0000 |181 187|AGGTCA as a 
P07708497A0000 |128 132|TREsliru
P07708497A0000 |160 169|sequences CSF [HCO
P07708497A0000 |98 100|TRic
P07708497A0000 |16 26|activationomparison 
P07711667A0766 |239 260|consolidation therapy no longer displaced 
P07711667A0766 |124 137|marrow blastserbilirubinem
P07711667A0766 |330 339|isolation (1.21 +/
P07711667A0766 |301 325|GVHD prophylaxis regimena significantly greater 
P07711667A0766 |61 64|agecle
P07711667A0766 |44 51|relapsephatase
P07711667A0766 |344 359|decontamination3 vs. P00010943
P07711667A0766 |15 23|analysisComparis
P07711667A0766 |84 95|blast count00 Pharmaco
P07711667A0766 |262 278|marrow cell doseen compared to c
P07711667A0766 |156 162|numberWhen C
P07711667A0766 |218 237|maintenance therapyf K-depleted rats a
P07711667A0766 |296 299|sexhav
P07711667A0766 |27 39|risk factorsith alkaline
P07711667A0766 |66 69|WBCida
P07711667A0766 |110 120|percentagef neonatal
P07711667A0766 |73 82|diagnosis00008171T
P07711667A0766 |166 193|remission induction coursesHCO3-] is shown as a functi
P07711667A0766 |99 108|diagnosisc aspects
P07711667A0766 |371 384|airflow roomsepam thus app
P07711667A0766 |139 150|FAB subtype. P00008997
P07711667A0766 |207 216|remission the data
P07711730A0000 |0 30|Carnitine palmitoyltransferaseP00001606T0076 Comparison with
P07711730A0000 |40 50|deficiencyphosphatas
P07711730A0000 |128 134|musclelirubi
P07711730A0000 |92 108|lipid metabolismacologic aspects
P07711730A0000 |80 88|disorder1T0000 P
P07711730A0000 |32 35|CPTlka
P07713421A1435 |102 126|sex determination signalspects of neonatal hyper
P07713421A1435 |133 138|SxlM4inemi
P07713421A1435 |102 126|sex determination signalspects of neonatal hyper
P07713421A1435 |80 87|ability1T0000 
P07713421A1435 |163 168|SxlM1F [HC
P07713421A1435 |26 50|gain-of-function mutantswith alkaline phosphatas
P07713421A1435 |26 50|gain-of-function mutantswith alkaline phosphatas
P07713421A1435 |133 138|SxlM4inemi
P07713421A1435 |163 168|SxlM1F [HC
P07713421A1435 |80 87|ability1T0000 
P07713936A0393 |152 160|presence472 When
P07713936A0393 |11 16|meAda076 C
P07713936A0393 |72 86|response genesP00008171T0000
P07713936A0393 |164 169|meAda [HCO
P07713936A0393 |110 123|transcriptionf neonatal hy
P07713936A0393 |42 55|transcriptionosphatases an
P07713936A0393 |127 131|aidBilir
P07713936A0393 |0 7|BindingP000016
P07714608A1252 |51 57|groupss and 
P07714608A1252 |130 144|glucose levelsrubinemia. P00
P07714608A1252 |62 64|pHle
P07714608A1252 |15 26|differencesComparison 
P07714608A1252 |66 71|PaCO2idase
P07714608A1252 |108 125|brain temperature of neonatal hype
P07714608A1252 |96 106|heart rateogic aspec
P07714608A1252 |86 94|pressure Pharmac
P07714758A1193 |0 14|Blood pressureP00001606T0076
P07714758A1193 |37 46|lidocainene phosph
P07714758A1193 |50 57|mg kg-1es and 
P07715200A0000 |0 17|AnesthesiologistsP00001606T0076 Co
P07715200A0000 |108 122|blood pressure of neonatal h
P07715200A0000 |73 88|target response00008171T0000 P
P07715200A0000 |42 46|drugosph
P07715200A0000 |52 59|patient and 5-
P07715602A1088 |70 93|cytochrome c haem lyasee P00008171T0000 Pharma
P07715602A1088 |45 50|partshatas
P07715602A1088 |21 39|gene cluster codesison with alkaline
P07715922A0188 |51 56|shapes and
P07715922A0188 |146 149|PRK899
P07715922A0188 |40 46|numberphosph
P07715922A0188 |133 139|monthsinemia
P07715922A0188 |60 67|cornealucleoti
P07715922A0188 |8 13|paper6T007
P07715922A0188 |111 119|patients neonata
P07715922A0188 |80 85|cells1T000
P07715922A0188 |17 27|comparisonmparison w
P07717823A0328 |68 73|childase P
P07717823A0328 |121 128|supporthyperbi
P07717823A0328 |148 157|functions97A0472 W
P07717823A0328 |88 94|heightharmac
P07717823A0328 |110 116|kcal/df neon
P07717823A0328 |0 26|Standard reference sourcesP00001606T0076 Comparison 
P07719527T0000 |34 45|hirudin CGPaline phosp
P07719527T0000 |53 59|REVASCand 5-
P07719527T0000 |5 18|allergenicity1606T0076 Com
P07719527T0000 |80 90|volunteers1T0000 Pha
P07720572A0701 |19 32|myoD promoterarison with a
P07720572A0701 |99 103|micec as
P07720572A0701 |67 79|conservationdase P000081
P07720572A0701 |88 94|humansharmac
P07720572A0701 |38 51|myoD enhancere phosphatase
P07720572A0701 |140 148|position P000089
P07720572A0701 |3 11|contrast001606T0
P07720572A0701 |116 124|sequenceatal hyp
P07720572A1584 |17 27|differencemparison w
P07720572A1584 |43 52|myoblastssphatases
P07720572A1584 |57 69|10T1/2 cells5-nucleotida
P07720572A1584 |245 257|10T1/2 cellsnger displac
P07720572A1584 |150 168|myoD core enhancerA0472 When CSF [HC
P07720572A1584 |111 130|chromatin structure neonatal hyperbili
P07720572A1584 |92 102|cell typesacologic a
P07720572A1584 |231 241|mechanismsrats are n
P07720572A1584 |190 203|myoD enhancerction of CSF 
P07720709A0755 |138 156|cell proliferationa. P00008997A0472 
P07720709A0755 |227 246|AP1 transrepressionted rats are no lon
P07720709A0755 |72 74|RAP0
P07720709A0755 |25 34|3T3 cells with alk
P07720709A0755 |40 52|model systemphosphatases
P07720709A0755 |191 208|growth inhibitiontion of CSF PCO2 
P07720709A0755 |98 107|retinoidsic aspect
P07720710A0861 |4 7|Oct016
P07720710A0861 |12 25|HMG2 proteins76 Comparison
P07721074A0766 |136 148|multiplicitymia. P000089
P07721074A0766 |196 203|itchingof CSF 
P07721074A0766 |162 177|trigger factorsSF [HCO3-] is s
P07721074A0766 |91 116|patient treatment programmacologic aspects of neon
P07721074A0766 |7 17|dermatitis06T0076 Co
P07721074A0766 |25 29|itch wit
P07721074A0766 |36 42|rashesine ph
P07721074A0766 |53 57|rashand 
P07721422A0241 |0 28|Primer extension experimentsP00001606T0076 Comparison wi
P07721422A0241 |89 91|bpar
P07721422A0241 |105 115|mouse typects of neo
P07721422A0241 |55 85|transcription initiation sitesd 5-nucleotidase P00008171T000
P07721422A0241 |118 131|receptor geneal hyperbilir
P07721878A1163 |50 73|tyrosine phosphoproteines and 5-nucleotidase P
P07721878A1163 |24 37|Fc epsilon R1n with alkali
P07721878A1163 |133 139|reportinemia
P07721878A1163 |151 175|Fc epsilon R1 beta chain0472 When CSF [HCO3-] is
P07721878A1163 |4 16|beta subunit01606T0076 C
P07721878A1163 |83 86|p33000
P07721878A1163 |100 107|protein aspect
P07721878A1163 |184 192|identity a funct
P07723247A0187 |35 44|magnitudeline phos
P07723247A0187 |195 213|pressure recording of CSF PCO2 the d
P07723247A0187 |106 115|dialysatets of neo
P07723247A0187 |132 144|computerizedbinemia. P00
P07723247A0187 |88 96|productsharmacol
P07723247A0187 |13 23|mechanisms6 Comparis
P07723247A0187 |251 257|inflowisplac
P07723247A0187 |52 74|transmembrane transfer and 5-nucleotidase P0
P07723247A0187 |262 275|outflow portsen compared t
P07723247A0187 |154 168|dialysis model2 When CSF [HC
P07723247A1161 |48 54|IL-1Raases a
P07723247A1161 |95 111|radioimmunoassaylogic aspects of
P07723247A1161 |9 24|hour incubationT0076 Compariso
P07723247A1161 |59 68|IL-1 betanucleotid
P07724452A0344 |38 41|pene p
P07724452A0344 |13 22|treatment6 Compari
P07724452A0344 |61 67|chickscleoti
P07724452A0344 |72 75|penP00
P07724452A0344 |83 85|d.00
P07728201A0660 |3 11|contrast001606T0
P07728201A0660 |57 84|sickle-hemoglobin C disease5-nucleotidase P00008171T00
P07728201A0660 |177 199|penicillin prophylaxishown as a function of 
P07728201A0660 |134 139|yearsnemia
P07728201A0660 |111 119|asplenia neonata
P07728201A0660 |43 51|childrensphatase
P07728201A0660 |143 146|age000
P07728201A0660 |20 28|evidencerison wi
P07729427A0942 |171 179|hTAFII30] is sho
P07729427A0942 |67 74|domainsdase P0
P07729427A0942 |78 86|hTAFII28171T0000
P07729427A0942 |41 49|hTAFII18hosphata
P07729427A0942 |88 96|hTAFII18harmacol
P07729427A0942 |33 36|TBPkal
P07729427A0942 |158 166|hTAFII28en CSF [
P07729427A0942 |117 120|TBPtal
P07729427A0942 |0 17|Deletion analysisP00001606T0076 Co
P07730273A1309 |32 56|amino acid substitutionslkaline phosphatases and
P07730273A1309 |13 26|NarQ proteins6 Comparison 
P07730273A1309 |135 149|NarL-phosphateemia. P0000899
P07730273A1309 |80 98|histidine position1T0000 Pharmacolog
P07730273A1309 |4 8|NarX0160
P07730328A0000 |103 111|spectrumpects of
P07730328A0000 |142 147|genes00008
P07730328A0000 |44 51|changesphatase
P07730328A0000 |21 26|cellsison 
P07730328A0000 |66 76|activationidase P000
P07730328A0000 |115 119|cellnata
P07730328A0000 |87 97|expressionPharmacolo
P07730336A0606 |68 71|CREase
P07730336A0606 |44 66|cAMP response elementsphatases and 5-nucleot
P07730336A0606 |90 98|sequencermacolog
P07730336A0606 |8 13|ATF-16T007
P07730336A0606 |123 126|CREper
P07730336A0606 |113 121|kappa E3eonatal 
P07730336A0606 |18 22|CREMpari
P07730337A1439 |85 96|development0 Pharmacol
P07730337A1439 |46 64|expression patternatases and 5-nucle
P07730337A1439 |15 30|PKC-gamma genesComparison with
P07730337A1439 |72 77|brainP0000
P07730337A1439 |4 10|Ng/RC301606T
P07730337T0000 |0 9|StructureP00001606
P07730337T0000 |14 24|regulation Compariso
P07730337T0000 |93 104|neurogranincologic asp
P07730337T0000 |106 117|RC3 proteints of neona
P07730337T0000 |66 82|protein kinase Cidase P00008171T
P07730337T0000 |32 36|genelkal
P07730795A0104 |4 24|amino acid sequences01606T0076 Compariso
P07730795A0104 |79 86|species71T0000
P07730795A0104 |46 54|subunitsatases a
P07730795A0104 |58 63|DdRPs-nucl
P07730795A0104 |112 119|regionsneonata
P07731686A0000 |86 101|T-cell leukemia Pharmacologic 
P07731686A0000 |62 76|translocationsleotidase P000
P07731686A0000 |105 110|T-ALLcts o
P07731686A0000 |42 46|siteosph
P07731686A0000 |4 14|TTG-2 gene01606T0076
P07731898A0823 |252 271|catalase activitiessplaced when compar
P07731898A0823 |60 76|bicarbonate ionsucleotidase P000
P07731898A0823 |172 176|ions is 
P07731898A0823 |22 33|blood cellsson with al
P07731898A0823 |230 247|erythrocyte SOD-1 rats are no long
P07731898A0823 |9 16|studiesT0076 C
P07731898A0823 |130 142|hemodialysisrubinemia. P
P07731898A0823 |80 94|concentrations1T0000 Pharmac
P07731898A0823 |276 315|erythrocyte membrane lipid peroxidation controls but still have a significantl
P07731898A0823 |200 228|superoxide anions generationSF PCO2 the data of K-deplet
P07731898A0823 |49 56|acetateses and
P07733075A1200 |68 72|i.d.ase 
P07733075A1200 |86 90|mg/q Pha
P07733075A1200 |262 266|mg/den c
P07733075A1200 |248 258|omeprazoler displace
P07733075A1200 |176 185|H. pylorishown as 
P07733075A1200 |63 67|mg/beoti
P07733075A1200 |122 133|combinationyperbilirub
P07733075A1200 |91 95|i.d.maco
P07733075A1200 |78 81|CBS171
P07733075A1200 |44 58|clarithromycinphatases and 5
P07733075A1200 |284 286|wks 
P07733075A1200 |19 29|omeprazolearison wit
P07733075A1200 |154 172|% eradication rate2 When CSF [HCO3-]
P07733075A1200 |6 13|therapy606T007
P07733075A1200 |199 218|ulcer healing ratesCSF PCO2 the data o
P07733075A1200 |38 42|i.d.e ph
P07733075A1200 |33 37|mg/bkali
P07735590A0990 |171 198|micrograms Fel d milligrams] is shown as a function of
P07735590A0990 |226 229|catete
P07735590A0990 |74 86|p milligrams0008171T0000
P07735590A0990 |161 164|catCSF
P07735590A0990 |94 104|house dustologic asp
P07735590A0990 |26 34|allergenwith alk
P07735590A0990 |148 153|homes97A04
P07735590A0990 |123 135|cat allergenperbilirubin
P07735590A0990 |212 217|homesdata 
P07735590A0990 |59 69|microgramsnucleotida
P07735590A0990 |4 17|concentration01606T0076 Co
P07735590A0990 |235 262|micrograms Fel d milligrams are no longer displaced wh
P07735833A1078 |0 11|CONCLUSIONSP00001606T0
P07735833A1078 |104 115|synthetasesects of neo
P07735833A1078 |15 25|comparisonComparison
P07735833A1078 |65 75|structurestidase P00
P07735833A1078 |79 84|seryl71T00
P07735833A1078 |33 55|LysU crystal structurekaline phosphatases an
P07735833A1078 |136 140|coremia.
P07737024A1003 |83 88|drugs000 P
P07737024A1003 |72 79|passageP000081
P07737024A1003 |47 56|techniquetases and
P07737024A1003 |108 115|pylorus of neo
P07737024A1003 |6 22|bowel irrigation606T0076 Compari
P07737118A0317 |68 80|LexA proteinase P0000817
P07737118A0317 |14 27|reading frame Comparison w
P07737118A0317 |4 8|MPS10160
P07737118A0317 |88 99|GST proteinharmacologi
P07737118A0317 |141 146|yeastP0000
P07737118A0317 |118 128|constructsal hyperbi
P07737508A0649 |102 106|genespec
P07737508A0649 |10 12|U600
P07737508A0649 |30 34|gene alk
P07737508A0649 |67 74|tRNAIledase P0
P07737508A0649 |43 53|tRNA genessphatases 
P07737508A0649 |6 8|Tb60
P07737508A0649 |55 62|tRNAGlnd 5-nuc
P07737944A0000 |68 88|transfusion practicease P00008171T0000 P
P07737944A0000 |240 254|erythropoietinno longer disp
P07737944A0000 |180 186|statesn as a
P07737944A0000 |14 28|growth factors Comparison wi
P07737944A0000 |120 124|need hyp
P07737944A0000 |228 236|decreaseed rats 
P07737944A0000 |133 156|blood cell transfusionsinemia. P00008997A0472 
P07737944A0000 |58 64|impact-nucle
P07737944A0000 |162 169|varietySF [HCO
P07738026A0216 |67 72|formsdase 
P07738026A0216 |13 18|mouse6 Com
P07738026A0216 |76 79|ADH081
P07738839A0173 |69 81|CO2 pressurese P00008171
P07738839A0173 |83 86|PET000
P07738839A0173 |53 57|restand 
P07738839A0173 |7 17|IC breaths06T0076 Co
P07738839A0173 |32 34|EClk
P07738839A0173 |39 49|VC breaths phosphata
P07738839A0173 |87 90|CO2Pha
P07738839A0173 |117 121|mmHgtal 
P07739382A0457 |197 205|proteinsf CSF PC
P07739382A0457 |13 21|analyses6 Compar
P07739382A0457 |165 173|ancestor[HCO3-] 
P07739382A0457 |62 75|protein typesleotidase P00
P07739382A0457 |28 48|amino acid sequencesth alkaline phosphat
P07739382A0457 |107 115|proteinss of neo
P07739382A0457 |127 135|gelsolinilirubin
P07739520A1250 |3 11|homologs001606T0
P07739520A1250 |97 99|D.gi
P07739520A1250 |120 130|rpL7a gene hyperbili
P07739520A1250 |113 119|Surf-3eonata
P07739520A1250 |36 56|Surfeit gene clusterine phosphatases and
P07739520A1250 |80 89|proximity1T0000 Ph
P07739520A1250 |21 28|membersison wi
P07739542A1419 |119 150|retinoblastoma protein functionl hyperbilirubinemia. P00008997
P07739542A1419 |105 110|cellscts o
P07739542A1419 |37 45|contrastne phosp
P07739542A1419 |24 32|cyclin En with a
P07739542A1419 |81 96|G1/S transitionT0000 Pharmacol
P07739542A1419 |49 58|cyclin D1ses and 5
P07739544A0364 |70 76|regione P000
P07739544A0364 |135 141|domainemia. 
P07739544A0364 |14 33|amino acid sequence Comparison with al
P07739544A0364 |41 58|SGC1 gene producthosphatases and 5
P07739544A0364 |149 159|Myc family7A0472 Whe
P07739544A0364 |94 104|similarityologic asp
P07739544A0364 |175 183|proteins shown a
P07739566A1076 |129 135|domainirubin
P07739566A1076 |194 205|specificityn of CSF PC
P07739566A1076 |12 38|Pax-6-BSAP fusion proteins76 Comparison with alkalin
P07739566A1076 |73 91|amino acid stretch00008171T0000 Phar
P07739566A1076 |167 178|differencesCO3-] is sh
P07739566A1076 |110 114|partf ne
P07740487A0167 |98 103|casesic as
P07740487A0167 |179 195|SSC Subcommitteewn as a function
P07740487A0167 |242 252|Thrombosis longer di
P07740487A0167 |90 94|datarmac
P07740487A0167 |114 124|affectionsonatal hyp
P07740487A0167 |217 238|International Societyof K-depleted rats ar
P07740487A0167 |53 70|dysfibrinogenemiaand 5-nucleotidas
P07740487A0167 |24 35|associationn with alka
P07740487A0167 |145 150|study08997
P07740487A0167 |75 88|thrombophilia008171T0000 P
P07740487A0167 |257 268|Haemostasised when com
P07740487A0167 |199 209|FibrinogenCSF PCO2 t
P07740487A0167 |162 171|frameworkSF [HCO3-
P07740490T0000 |38 42|timee ph
P07740490T0000 |46 53|uraemiaatases 
P07740490T0000 |74 83|serotonin0008171T0
P07740490T0000 |11 20|estrogens076 Compa
P07740490T0000 |66 70|roleidas
P07741255A0194 |58 68|population-nucleotid
P07741255A0194 |28 32|areath a
P07741255A0194 |10 19|districts0076 Comp
P07741255A0194 |43 46|km2sph
P07742024A0121 |168 173|typesO3-] 
P07742024A0121 |30 46|imaging features alkaline phosph
P07742024A0121 |213 219|extentata of
P07742024A0121 |124 129|tumorerbil
P07742024A0121 |106 116|directionsts of neon
P07742024A0121 |183 189|clivals a fu
P07742024A0121 |13 21|symptoms6 Compar
P07742024A0121 |81 87|placesT0000 
P07742024A0121 |23 28|signson wi
P07742024A0121 |175 181|sellar shown
P07742024A0121 |48 66|operation findingsases and 5-nucleot
P07742363A0135 |54 57|HCRnd 
P07742363A0135 |241 246|eIF-2o lon
P07742363A0135 |108 111|dsI of
P07742363A0135 |198 209|nucleotides CSF PCO2 t
P07742363A0135 |227 236|recyclingted rats 
P07742363A0135 |180 188|exchangen as a f
P07742363A0135 |14 21|enzymes Compar
P07742363A0135 |128 134|Ser-51lirubi
P07742363A0135 |43 52|repressorsphatases
P07742363A0135 |97 106|inhibitorgic aspec
P07742363A0135 |142 155|alpha subunit00008997A0472
P07742363A0941 |34 51|yeast eIF-2 alphaaline phosphatase
P07742363A0941 |15 18|AlaCom
P07742363A0941 |131 155|casein kinase activitiesubinemia. P00008997A0472
P07742363A0941 |26 30|formwith
P07742363A0941 |9 12|SerT00
P07742363A0941 |110 115|yeastf neo
P07742550A0407 |239 241|FL n
P07742550A0407 |270 273|MCLred
P07742550A0407 |300 314|cell lymphomas a significant
P07742550A0407 |60 63|DALucl
P07742550A0407 |49 58|lymphomasses and 5
P07742550A0407 |154 163|lymphomas2 When CS
P07742550A0407 |188 197|lymphomasunction o
P07742550A0407 |82 92|mixed-cell0000 Pharm
P07742550A0407 |247 268|mantle cell lymphomaser displaced when com
P07742550A0407 |228 237|lymphomased rats a
P07742550A0407 |316 320|SNCL gre
P07742550A0407 |199 202|TFLCSF
P07742550A0407 |4 9|cases01606
P07742917T0001 |0 7|IcterusP000016
P07742917T0001 |12 28|beta-thalassemia76 Comparison wi
P07742917T0001 |42 50|childrenosphatas
P07742917T0001 |54 65|Brazzavillend 5-nucleo
P07743472A0181 |119 127|New Yorkl hyperb
P07743472A0181 |7 15|patients06T0076 
P07743472A0181 |163 188|cigarette smoking historyF [HCO3-] is shown as a f
P07743472A0181 |110 117|Buffalof neona
P07743472A0181 |196 200|timeof C
P07743472A0181 |210 219|diagnosise data of
P07743472A0181 |21 34|breast cancerison with alk
P07743472A0181 |142 153|information00008997A04
P07743472A0181 |101 105|RPCIaspe
P07743472A0181 |70 99|Roswell Park Cancer Institutee P00008171T0000 Pharmacologi
P07743515A0223 |103 108|cellspects
P07743515A0223 |110 126|cytotrophoblastsf neonatal hyper
P07743515A0223 |44 48|AAMPphat
P07743515A0223 |21 40|tissue distributionison with alkaline 
P07743515A0223 |5 13|analysis1606T007
P07743515A0223 |190 200|lymphaticsction of C
P07743515A0223 |154 180|colon adenocarcinoma cells2 When CSF [HCO3-] is show
P07743697A0703 |152 159|disease472 Whe
P07743697A0703 |284 316|hydralazine/isosorbide dinitrates but still have a significantly
P07743697A0703 |120 134|treatment arms hyperbilirubi
P07743697A0703 |77 98|plasma norepinephrine8171T0000 Pharmacolog
P07743697A0703 |245 254|enalaprilnger disp
P07743697A0703 |227 243|enzyme inhibitorted rats are no 
P07743697A0703 |44 53|follow-upphatases 
P07743697A0703 |14 20|V-HeFT Compa
P07743697A0703 |69 73|risese P
P07743697A0703 |179 188|treatmentwn as a f
P07743697A0703 |259 278|vasodilator therapy when compared to c
P07743697A0703 |0 4|DataP000
P07744763A0514 |0 16|Binding activityP00001606T0076 C
P07744763A0514 |230 235|HNF-4 rats
P07744763A0514 |198 205|element CSF PC
P07744763A0514 |94 132|electromobility supershift experimentsologic aspects of neonatal hyperbiliru
P07744763A0514 |209 216|CYP2C11he data
P07744763A0514 |62 78|orphan receptorsleotidase P00008
P07744763A0514 |20 29|rat liverrison wit
P07744763A0514 |142 149|results0000899
P07744763A0514 |174 183|receptorss shown a
P07744763A0514 |38 46|extractse phosph
P07744776A0617 |0 19|Transcript analysisP00001606T0076 Comp
P07744776A0617 |40 61|B block substitutionsphosphatases and 5-nu
P07744776A0617 |69 85|U6 RNA synthesisse P00008171T000
P07744846A1006 |0 8|AnalysisP0000160
P07744846A1006 |18 40|Bcl-2 homodimerizationparison with alkaline 
P07744846A1006 |353 364|combination010943A0733
P07744846A1006 |217 226|sequencesof K-depl
P07744846A1006 |251 259|A domainisplaced
P07744846A1006 |176 198|Bcl-2 homodimerizationshown as a function of
P07744846A1006 |89 94|yeastarmac
P07744846A1006 |122 130|evidenceyperbili
P07744846A1006 |61 75|binding assayscleotidase P00
P07744846A1006 |160 165|model CSF 
P07744846A1006 |12 17|Bcl-276 Co
P07744846A1006 |106 112|methodts of 
P07744846A1006 |134 141|supportnemia. 
P07744846A1006 |325 335|carboxyl Bslope (1.2
P07744846A1006 |340 349|C domains 0.23 vs.
P07744846A1006 |276 285|structure controls
P07744846A1006 |170 175|Bcl-2-] is
P07744846A1006 |304 312|presenceignifica
P07744954A0418 |119 126|epitopel hyper
P07744954A0418 |145 153|antibody08997A04
P07744954A0418 |89 92|NH2arm
P07744954A0418 |73 80|domains0000817
P07744954A0418 |191 196|stalktion 
P07744954A0418 |97 109|COOH terminigic aspects 
P07744954A0418 |4 11|protein01606T0
P07744954A0418 |51 58|portions and 5
P07745008A0892 |0 19|Radioligand bindingP00001606T0076 Comp
P07745008A0892 |73 83|constructs00008171T0
P07745311A0264 |0 9|DiagnosisP00001606
P07745311A0264 |13 17|FHCS6 Co
P07745311A0264 |53 61|findingsand 5-nu
P07745684T0000 |35 50|gene expressionline phosphatas
P07745684T0000 |109 123|RNA processingof neonatal hy
P07745684T0000 |72 86|protein kinaseP00008171T0000
P07745684T0000 |6 25|papillomavirus type606T0076 Comparison
P07745684T0000 |98 105|changesic aspe
P07745685A1442 |138 157|CAT fusion partnersa. P00008997A0472 W
P07745685A1442 |15 22|virionsCompari
P07745685A1442 |46 54|proteinsatases a
P07745685A1442 |73 83|antibodies00008171T0
P07745685A1442 |131 133|SNub
P07745685A1442 |101 119|accessory proteinsaspects of neonata
P07745693A0914 |152 161|component472 When 
P07745693A0914 |162 163|sS
P07745693A0914 |95 106|translationlogic aspec
P07745693A0914 |123 134|proteolysisperbilirubi
P07745693A0914 |0 7|StudiesP000016
P07745693A0914 |39 52|Lb proteinase phosphatases
P07745693A0914 |17 26|inhibitormparison 
P07745693A0914 |68 79|stimulationase P000081
P07745696A0932 |0 28|Restriction mapping analysisP00001606T0076 Comparison wi
P07745696A0932 |165 171|SalI L[HCO3-
P07745696A0932 |44 48|cDNAphat
P07745696A0932 |147 153|genome997A04
P07745696A0932 |109 112|endof 
P07745696A0932 |56 62|HHV-6A 5-nuc
P07745696A0932 |63 68|U1102eotid
P07745696A0932 |132 139|segmentbinemia
P07745696A0932 |176 192|SalI O fragmentsshown as a funct
P07745696A0932 |78 94|BamHI G fragment171T0000 Pharmac
P07745696A0932 |235 249|repeat regions are no longer
P07745696A0932 |204 208|leftCO2 
P07745726A0960 |49 51|E2se
P07745726A0960 |92 110|expression vectorsacologic aspects o
P07745726A0960 |133 143|half sitesinemia. P0
P07745726A0960 |166 170|roleHCO3
P07745726A0960 |112 120|distanceneonatal
P07745726A0960 |42 44|E1os
P07745726A0960 |188 201|relationshipsunction of CS
P07745726A0960 |4 35|replication reporter constructs01606T0076 Comparison with alka
P07745726A1496 |50 60|palindromees and 5-n
P07745726A1496 |157 177|E1 recognition motifhen CSF [HCO3-] is s
P07745726A1496 |199 208|half siteCSF PCO2 
P07745726A1496 |81 112|nucleotide sequence informationT0000 Pharmacologic aspects of 
P07745726A1496 |117 127|E1 bindingtal hyperb
P07746397A0233 |239 244|value no l
P07746397A0233 |95 103|patientslogic as
P07746397A0233 |215 219|aPTTa of
P07746397A0233 |63 67|Julyeoti
P07746397A0233 |121 130|embolismshyperbili
P07746397A0233 |77 85|December8171T000
P07746397A0233 |225 230|timesleted
P07746397A0233 |194 213|thromboplastin timen of CSF PCO2 the d
P07746397A0233 |20 28|patientsrison wi
P07746397A0233 |158 163|hoursen CS
P07746397A0233 |39 54|anticoagulation phosphatases a
P07746397A0233 |140 147|heparin P00008
P07746397A0233 |169 174|onset3-] i
P07746397A0233 |0 7|METHODSP000016
P07746794A0000 |153 158|agent72 Wh
P07746794A0000 |72 81|SandimmunP00008171
P07746794A0000 |42 53|formulationosphatases 
P07746794A0000 |57 70|Cyclosporin A5-nucleotidas
P07746794A0000 |113 125|Cremophor ELeonatal hype
P07746794A0000 |101 111|castor oilaspects of
P07746937A0100 |0 19|Lung function testsP00001606T0076 Comp
P07746937A0100 |65 71|periodtidase
P07746937A0100 |88 94|monthsharmac
P07746937A0100 |21 24|EFRiso
P07746937A0100 |50 58|patientses and 5
P07747462A0332 |119 142|metal coordination sitel hyperbilirubinemia. P
P07747462A0332 |36 50|RCR initiatorsine phosphatas
P07747462A0332 |172 186|tyrosine motif is shown as a
P07747462A0332 |234 253|replicator proteinss are no longer dis
P07747462A0332 |66 69|setida
P07747462A0332 |86 92|motifs Pharm
P07747462A0332 |0 20|Sequence comparisonsP00001606T0076 Compa
P07748451A0343 |18 29|discrepancyparison wit
P07748451A0343 |104 109|stoneects 
P07748451A0343 |151 172|medium-viscosity poly0472 When CSF [HCO3-]
P07748451A0343 |75 87|restorations008171T0000 
P07748451A0343 |45 57|restorationshatases and 
P07748451A0343 |125 129|polyrbil
P07748451A0343 |130 144|vinyl siloxanerubinemia. P00
P07748451A0343 |173 187|vinyl siloxaneis shown as a 
P07748451A0343 |4 8|mean0160
P07748493A1045 |186 191|gland func
P07748493A1045 |125 128|ELHrbi
P07748493A1045 |79 83|role71T0
P07748493A1045 |166 171|cellsHCO3-
P07748493A1045 |91 101|processingmacologic 
P07748493A1045 |18 33|Aplysia Afurin2parison with al
P07748493A1045 |39 51|candidate PC phosphatase
P07748493A1045 |116 123|hormoneatal hy
P07748493A1045 |138 148|precursorsa. P000089
P07748502A0794 |0 4|RatsP000
P07748502A0794 |81 95|discriminationT0000 Pharmaco
P07748502A0794 |55 62|abilityd 5-nuc
P07748502A0794 |18 27|8-OH-DPATparison w
P07748502A0794 |101 111|water mazeaspects of
P07748848A0263 |4 8|term0160
P07748848A0263 |22 43|papillary haemangiomason with alkaline pho
P07748952A0462 |136 159|translation start sitesmia. P00008997A0472 Whe
P07748952A0462 |47 52|P1hfqtases
P07748952A0462 |95 106|nucleotideslogic aspec
P07748952A0462 |26 35|promoterswith alka
P07748952A0462 |37 42|PmiaAne ph
P07748952A0462 |3 11|addition001606T0
P07748952A1329 |152 157|genes472 W
P07748952A1329 |90 100|mechanismsrmacologic
P07748952A1329 |208 224|RNase E activitythe data of K-de
P07748952A1329 |182 199|promoter strengthas a function of 
P07748952A1329 |122 137|cotranscriptionyperbilirubinem
P07748952A1329 |28 32|mutLth a
P07748952A1329 |44 58|hfq expressionphatases and 5
P07748952A1329 |159 169|modulationn CSF [HCO
P07748952A1329 |112 118|degreeneonat
P07748952A1329 |6 13|results606T007
P07748952A1329 |34 38|miaAalin
P07749088A0119 |16 18|T2om
P07749088A0119 |28 34|imagesth alk
P07749088A0119 |9 11|T1T0
P07749461A0632 |86 92|region Pharm
P07749461A0632 |132 145|sGTH alpha-G1binemia. P000
P07749461A0632 |60 78|sGTH alpha subunitucleotidase P00008
P07749461A0632 |24 30|regionn with
P07749461A0632 |125 130|clonerbili
P07749461A0632 |43 45|kbsp
P07749461A0632 |6 8|kb60
P07749461A1022 |201 211|expressionF PCO2 the
P07749461A1022 |72 84|transfectionP00008171T00
P07749461A1022 |134 147|rainbow troutnemia. P00008
P07749461A1022 |120 128|plasmids hyperbi
P07749461A1022 |27 54|sGTH alpha subunit promoterith alkaline phosphatases a
P07749461A1022 |11 19|analysis076 Comp
P07749461A1022 |96 110|sGTH alpha/CATogic aspects o
P07749461A1022 |158 163|cellsen CS
P07750217T0000 |0 26|Indium-111 OncoScint CR/OVP00001606T0076 Comparison 
P07750217T0000 |31 39|F-18 FDGalkaline
P07750217T0000 |66 87|carcinoma recurrencesidase P00008171T0000 
P07751848A0222 |50 60|activitieses and 5-n
P07751848A0222 |125 130|valuerbili
P07751848A0222 |166 185|nmol/min/mg proteinHCO3-] is shown as 
P07751848A0222 |36 39|CPTine
P07751848A0222 |212 220|subjectsdata of 
P07751848A0222 |80 99|nmol/min/mg protein1T0000 Pharmacologi
P07751848A0222 |4 34|carnitine palmitoyltransferase01606T0076 Comparison with alk
P07752223A0960 |4 10|Myc LZ01606T
P07752223A0960 |44 56|interactionsphatases and
P07752223A0960 |74 87|Myc inability0008171T0000 
P07752454A0341 |87 92|DMPPCPharm
P07752454A0341 |74 85|methicillin0008171T000
P07752454A0341 |26 29|CNSwit
P07752454A0341 |54 70|resistance ratesnd 5-nucleotidas
P07752644A1031 |83 100|plasma drug level000 Pharmacologic
P07752644A1031 |126 136|conductionbilirubine
P07752644A1031 |22 36|defibrillationson with alkal
P07752644A1031 |6 8|VF60
P07752886A0595 |49 68|amino acid residuesses and 5-nucleotid
P07752886A0595 |92 100|residuesacologic
P07752886A0595 |20 35|FecR derivativerison with alka
P07752886A0595 |114 118|FecRonat
P07753027A0240 |71 78|strands P00008
P07753027A0240 |29 38|psbH-psbNh alkalin
P07753027A0240 |4 24|gene pairs psbB-psbT01606T0076 Compariso
P07753030A0173 |0 21|Hybridization signalsP00001606T0076 Compar
P07753030A0173 |88 96|phaseoliharmacol
P07753030A0173 |60 86|Rhizobium leguminosarum bvucleotidase P00008171T0000
P07753030A0173 |52 56|DNAs and
P07753030A0173 |160 185|Xanthomonas campestris pv CSF [HCO3-] is shown as 
P07753030A0173 |98 120|Rhodobacter capsulatusic aspects of neonatal
P07753030A0173 |187 197|campestrisfunction o
P07753796A0625 |68 77|sequencesase P0000
P07753796A0625 |43 50|regionssphatas
P07753796A0625 |14 33|amino acid sequence Comparison with al
P07753796A0625 |110 136|liver eIF-2B alpha subunitf neonatal hyperbilirubine
P07753796A0625 |81 89|peptidesT0000 Ph
P07753796A0743 |0 10|ExpressionP00001606T
P07753796A0743 |96 119|SDS/polyacrylamide gelsogic aspects of neonata
P07753796A0743 |42 49|peptideosphata
P07753796A0743 |80 92|eIF-2B alpha1T0000 Pharm
P07753796A0743 |19 23|cDNAaris
P07753837A0724 |68 83|plakoglobin RNAase P00008171T0
P07753837A0724 |125 137|accumulationrbilirubinem
P07753837A0724 |106 112|effectts of 
P07753837A0724 |37 47|desmogleinne phospha
P07753837A0724 |22 33|tail domainson with al
P07753837A0724 |5 8|RNA160
P07753837A0724 |141 152|plakoglobinP00008997A0
P07754713A0227 |19 24|PRP21ariso
P07754713A0227 |110 114|genef ne
P07754713A0227 |46 50|CDC6atas
P07754713A0227 |62 66|geneleot
P07754713A0227 |13 17|NUC16 Co
P07754713A0227 |90 101|protein S24rmacologic 
P07754713A0227 |38 43|SPP91e pho
P07754713A0227 |52 56|CRY2 and
P07754713A0227 |141 148|proteinP000089
P07754713A0227 |156 167|amino acidsWhen CSF [H
P07755884A0000 |117 122|motortal h
P07755884A0000 |194 209|dopamine systemn of CSF PCO2 t
P07755884A0000 |165 172|lesions[HCO3-]
P07755884A0000 |14 20|grafts Compa
P07755884A0000 |43 50|tissuessphatas
P07755884A0000 |127 148|sensorimotor deficitsilirubinemia. P000089
P07755914A0000 |137 141|AIDSia. 
P07755914A0000 |28 34|impactth alk
P07755914A0000 |42 54|introductionosphatases a
P07755914A0000 |111 119|survival neonata
P07755914A0000 |77 89|azithromycin8171T0000 Ph
P07755914A0000 |58 72|clarithromycin-nucleotidase 
P07755914A0000 |123 131|patientsperbilir
P07755914A0000 |159 186|Mycobacterium avium complexn CSF [HCO3-] is shown as a
P07755914A0000 |97 106|treatmentgic aspec
P07755914A0000 |188 192|DMACunct
P07755914A0000 |0 9|OBJECTIVEP00001606
P07757315A1227 |51 58|% values and 5
P07757315A1227 |124 142|observation perioderbilirubinemia. P
P07757315A1227 |107 112|levels of 
P07757315A1227 |61 62|hc
P07757315A1227 |16 27|aggregationomparison w
P07757315A1227 |144 152|ABSTRACT008997A0
P07757315A1227 |69 85|drug applicationse P00008171T000
P07757315A1227 |170 175|WORDS-] is
P07758167A1488 |102 103|%s
P07758167A1488 |46 55|clone CA9atases an
P07758167A1488 |29 42|proliferationh alkaline ph
P07758167A1488 |77 84|% serum8171T00
P07758167A1488 |63 71|presenceeotidase
P07758167A1488 |118 128|clone ME10al hyperbi
P07758167A1488 |0 13|Growth curvesP00001606T007
P07758246A0469 |19 25|regionarison
P07758246A0469 |76 81|exons08171
P07758246A0469 |60 66|intronucleot
P07758246A0469 |4 11|protein01606T0
P07758246A0469 |33 36|bpskal
P07758459A1277 |204 235|ABF1 consensus binding sequenceCO2 the data of K-depleted rats
P07758459A1277 |15 24|AAC2 geneCompariso
P07758459A1277 |56 62|motifs 5-nuc
P07758459A1277 |149 176|core HAP2/3/4 binding motif7A0472 When CSF [HCO3-] is 
P07758459A1277 |95 105|activatorslogic aspe
P07758459A1277 |4 7|UAS016
P07758837A1118 |115 121|probesnatal 
P07758837A1118 |280 284|exontrol
P07758837A1118 |13 23|complexity6 Comparis
P07758837A1118 |225 234|sequencesleted rat
P07758837A1118 |135 142|exon 1Bemia. P
P07758837A1118 |45 51|regionhatase
P07758837A1118 |264 275|P1 promoter compared t
P07758837A1118 |161 176|intron boundaryCSF [HCO3-] is 
P07758837A1118 |59 75|GH receptor genenucleotidase P00
P07758837A1118 |98 109|observationic aspects 
P07759094A0634 |34 42|n repeataline ph
P07759094A0634 |14 26|dinucleotide Comparison 
P07759094A0634 |60 71|NHE5 cosmiducleotidase
P07759094A0634 |28 33|GT/CAth al
P07759094A0634 |108 133|microsatellite PCR marker of neonatal hyperbilirub
P07759525A0417 |102 103|%s
P07759525A0417 |123 136|casein kinaseperbilirubine
P07759525A0417 |29 30|%h
P07759525A0417 |66 87|protein kinase domainidase P00008171T0000 
P07759525A0417 |160 166|region CSF [
P07759525A0417 |4 12|proteins01606T00
P07759525A0417 |139 147|isoforms. P00008
P07759529A0288 |64 73|repressorotidase P
P07759529A0288 |44 51|CDP/cutphatase
P07759529A0288 |12 22|approaches76 Compari
P07759529A0288 |77 102|gp91-phox gene expression8171T0000 Pharmacologic a
P07760790A0327 |102 128|MEF2 site binding activityspects of neonatal hyperbi
P07760790A0327 |21 39|MEF2 reporter geneison with alkaline
P07760790A0327 |62 66|lineleot
P07760790A0327 |70 83|NIH 3T3 cellse P00008171T0
P07760790A0327 |0 15|Serum inductionP00001606T0076 
P07760819A0731 |152 167|differentiation472 When CSF [H
P07760819A0731 |120 126|effect hyper
P07760819A0731 |56 65|molecules 5-nucleo
P07760819A0731 |12 22|activation76 Compari
P07760819A0731 |130 148|cell proliferationrubinemia. P000089
P07760819A0731 |67 96|PDGF beta receptor activationdase P00008171T0000 Pharmacol
P07760841A0221 |0 4|UAS1P000
P07760841A0221 |12 24|binding site76 Compariso
P07760841A0221 |49 64|regulator Adr1pses and 5-nucle
P07760841A0647 |207 218|helix phase the data o
P07760841A0647 |47 53|regiontases 
P07760841A0647 |22 26|ADH2son 
P07760841A0647 |7 14|context06T0076
P07760841A0647 |144 159|gene activation008997A0472 Whe
P07760841A0647 |110 127|promoter elementsf neonatal hyperb
P07760841A0647 |177 188|orientationhown as a f
P07760841A0647 |65 69|UAS1tida
P07760841A0647 |82 89|concert0000 Ph
P07760841A0647 |99 103|ADH2c as
P07760841A0647 |190 201|copy numberction of CS
P07760844A0413 |0 9|InductionP00001606
P07760844A0413 |13 29|AP-1 DNA binding6 Comparison wit
P07760844A0413 |60 79|GH trans-activationucleotidase P000081
P07760844A0413 |93 104|c-fos genescologic asp
P07760844A0413 |83 88|c-jun000 P
P07761091A0294 |0 12|InactivationP00001606T00
P07761091A0294 |63 68|MKP-1eotid
P07761091A0294 |16 27|MAP kinasesomparison w
P07761091A0294 |50 61|phosphatasees and 5-nu
P07761216T0000 |64 72|patientsotidase 
P07761216T0000 |13 35|amphotericin B therapy6 Comparison with alka
P07761216T0000 |40 50|candidemiaphosphatas
P07761420A0909 |68 71|Ca2ase
P07761420A0909 |47 52|CCaMKtases
P07761420A0909 |26 32|assayswith a
P07761434A1084 |68 76|findingsase P000
P07761434A1084 |135 147|antioxidantsemia. P00008
P07761434A1084 |6 10|AP-1606T
P07761434A1084 |27 35|mediatorith alka
P07761434A1084 |39 60|tumor promoter action phosphatases and 5-n
P07761434A1084 |114 122|activityonatal h
P07761467A0666 |50 68|protein componentses and 5-nucleotid
P07761467A0666 |90 97|proteinrmacolo
P07761467A0666 |11 18|complex076 Com
P07762431A0356 |102 104|mgsp
P07762431A0356 |109 114|litreof ne
P07762431A0356 |4 11|protein01606T0
P07762431A0356 |83 89|yields000 Ph
P07762431A0356 |38 42|cDNAe ph
P07762431A0356 |64 78|culture mediumotidase P00008
P07762504A0648 |101 106|dosesaspec
P07762504A0648 |52 62|amiodarone and 5-nuc
P07762504A0648 |130 131|gr
P07762504A0648 |29 43|administrationh alkaline pho
P07762504A0648 |83 87|days000 
P07762504A0648 |67 76|mg/kg/daydase P000
P07762504A0648 |113 117|doseeona
P07762504A0648 |4 9|study01606
P07763727A1035 |17 23|pAMS13mparis
P07763727A1035 |28 34|pAMS14th alk
P07763727A1035 |163 181|wine yeast strainsF [HCO3-] is shown
P07763727A1035 |59 76|laboratory strainnucleotidase P000
P07763727A1035 |114 120|pAMS15onatal
P07763727A1035 |0 15|Plasmids pAMS12P00001606T0076 
P07765118A0967 |69 70|hs
P07765118A0967 |77 85|excision8171T000
P07765118A0967 |97 120|maximum enzyme activitygic aspects of neonatal
P07765118A0967 |25 48|ACC-oxidase transcripts with alkaline phosphat
P07765118A0967 |140 142|h. P
P07765118A0967 |4 21|maximum induction01606T0076 Compar
P07766885A0405 |187 202|junction regionfunction of CSF
P07766885A0405 |88 98|plant CDPKharmacolog
P07766885A0405 |13 30|polypeptide chain6 Comparison with
P07766885A0405 |100 106|kinase aspec
P07766885A0405 |65 73|featurestidase P
P07766885A0405 |117 126|sequencestal hyper
P07766885A0405 |170 176|domain-] is 
P07767011A0689 |0 6|RepairP00001
P07767011A0689 |122 130|mutationyperbili
P07767011A0689 |15 24|insertionCompariso
P07767011A0689 |66 74|activityidase P0
P07767011A0689 |82 92|hprt locus0000 Pharm
P07767011A0689 |39 52|recombination phosphatases
P07767011A0689 |114 118|siteonat
P07768824A0167 |156 164|proteinsWhen CSF
P07768824A0167 |41 51|cell cyclehosphatase
P07768824A0167 |14 33|fla gene expression Comparison with al
P07768824A0167 |90 104|RNA polymerasermacologic asp
P07768824A0167 |113 123|appearanceeonatal hy
P07768824A0167 |131 141|activationubinemia. 
P07768824A0167 |4 10|timing01606T
P07768824A0167 |81 86|formsT0000
P07768836A1126 |0 28|Primer extension experimentsP00001606T0076 Comparison wi
P07768836A1126 |47 76|transcription initiation sitetases and 5-nucleotidase P000
P07768836A1126 |114 124|start siteonatal hyp
P07768836A1126 |81 83|bpT0
P07768848A1880 |0 12|PolypeptidesP00001606T00
P07768848A1880 |95 100|basislogic
P07768848A1880 |264 268|coat com
P07768848A1880 |56 62|spores 5-nuc
P07768848A1880 |198 204|layers CSF P
P07768848A1880 |135 146|cotJ operonemia. P0000
P07768848A1880 |119 127|productsl hyperb
P07768848A1880 |212 216|coatdata
P07768848A1880 |246 256|componentsger displa
P07768848A1880 |175 184|formation shown as
P07768848A1880 |78 84|mutant171T00
P07768848A1880 |68 72|cotEase 
P07768848A1880 |34 39|sizesaline
P07768898A0492 |68 73|termsase P
P07768898A0492 |197 204|proteinf CSF P
P07768898A0492 |160 167|apobec1 CSF [H
P07768898A0492 |122 135|suhstitutionsyperbilirubin
P07768898A0492 |47 64|apobec1 sequencestases and 5-nucle
P07768898A0492 |140 144|site P00
P07768898A0492 |23 29|valueson wit
P07768898A0492 |81 88|numbersT0000 P
P07768898A0492 |33 43|divergencekaline pho
P07768953T0039 |0 4|EEA1P000
P07768953T0039 |73 81|cysteine00008171
P07768953T0039 |45 61|membrane proteinhatases and 5-nu
P07768953T0039 |126 134|IQ motifbilirubi
P07768953T0039 |83 90|fingers000 Pha
P07770033A0978 |0 20|Nucleotide sequencesP00001606T0076 Compa
P07770033A0978 |192 232|Neurospora crassa copper metallothioneinion of CSF PCO2 the data of K-depleted r
P07770033A0978 |28 34|clonesth alk
P07770033A0978 |180 188|homologyn as a f
P07770033A0978 |135 139|acidemia
P07770033A0978 |60 64|cap3ucle
P07770033A0978 |99 102|ORFc a
P07770033A0978 |53 58|cloneand 5
P07770033A0978 |155 162|peptide When C
P07770033A0978 |84 97|reading frame00 Pharmacolo
P07771671T0000 |50 67|carbon electrodeses and 5-nucleoti
P07771745A0442 |17 24|tissuesmpariso
P07771745A0442 |77 85|forehead8171T000
P07771745A0442 |113 123|cheekboneseonatal hy
P07771745A0442 |96 102|regionogic a
P07771745A0442 |32 36|facelkal
P07771745A0442 |0 9|ElevationP00001606
P07772036A1000 |119 126|CTF/NF1l hyper
P07772036A1000 |5 11|region1606T0
P07772036A1000 |41 48|factorshosphat
P07772036A1000 |80 115|transcription factor/nuclear factor1T0000 Pharmacologic aspects of neo
P07772036A1000 |50 58|USF/MLTFes and 5
P07774137A0000 |85 94|treatment0 Pharmac
P07774137A0000 |55 66|Strep A OIAd 5-nucleot
P07774137A0000 |143 154|pharyngitis0008997A047
P07774137A0000 |198 204|clinic CSF P
P07774137A0000 |14 20|impact Compa
P07774137A0000 |71 80|detection P0000817
P07774137A0000 |98 105|group Aic aspe
P07774137A0000 |49 53|testses 
P07774137A0000 |136 141|GABHSmia. 
P07774807A0405 |152 166|family members472 When CSF [
P07774807A0405 |53 63|activatorsand 5-nucl
P07774807A0405 |9 17|proteinsT0076 Co
P07774807A0405 |83 88|genes000 P
P07774807A0405 |100 112|heterodimers aspects of 
P07774925A0084 |171 175|head] is
P07774925A0084 |36 48|BRCA1 regionine phosphat
P07774925A0084 |8 22|cosmid contigs6T0076 Compari
P07774925A0084 |95 100|cDNAslogic
P07774925A0084 |130 140|HeLa cellsrubinemia.
P07774925A0084 |120 128|placenta hyperbi
P07774925A0084 |69 80|cDNA clonesse P0000817
P07774925A0084 |86 91|pools Phar
P07774925A0084 |0 3|YACP00
P07774925A0084 |152 159|T cells472 Whe
P07775428A0172 |33 34|sk
P07775428A0172 |14 20|clones Compa
P07775428A0172 |40 60|nucleotide sequencesphosphatases and 5-n
P07775428A0172 |109 115|regionof neo
P07775428A0172 |76 86|Ash-l cDNA08171T0000
P07775428A0172 |22 27|Ash-mson w
P07776685A0000 |170 179|resection-] is sho
P07776685A0000 |61 74|immunotherapycleotidase P0
P07776685A0000 |127 140|interleukin-2ilirubinemia.
P07776685A0000 |24 35|feasibilityn with alka
P07776685A0000 |40 48|toxicityphosphat
P07776685A0000 |147 155|patients997A0472
P07776685A0000 |209 220|lung cancerhe data of 
P07776685A0000 |80 85|tumor1T000
P07776685A0000 |5 10|study1606T
P07776685A0000 |99 110|lymphocytesc aspects o
P07776685A0000 |184 189|stage a fu
P07776711A0295 |68 73|yearsase P
P07776711A0295 |32 35|menlka
P07776711A0295 |77 80|age817
P07776711A0295 |43 48|womensphat
P07776711A0295 |13 20|METHODS6 Compa
P07776711A0295 |169 183|polyneuropathy3-] is shown a
P07776711A0295 |100 105|motor aspe
P07776711A0295 |118 133|neuropathy typeal hyperbilirub
P07776711A0295 |0 8|MATERIALP0000160
P07776882A0000 |32 52|cell volume dynamicslkaline phosphatases
P07776882A0000 |63 73|rat heartseotidase P
P07776882A0000 |12 17|study76 Co
P07776882A0000 |82 90|ischemia0000 Pha
P07776882A0000 |101 112|reperfusionaspects of 
P07776979A0702 |34 40|effectaline 
P07776979A0702 |13 20|COUP-TF6 Compa
P07776979A0702 |62 84|reporter gene activityleotidase P00008171T00
P07776979A0702 |3 11|contrast001606T0
P07777518A0483 |0 14|DNA sequencingP00001606T0076
P07777518A0483 |63 74|cDNA cloneseotidase P0
P07777518A0483 |106 111|genests of
P07777518A0483 |19 41|Southern blot analysesarison with alkaline p
P07779558T0000 |0 22|Muscle GSH-Px activityP00001606T0076 Compari
P07779558T0000 |63 87|selenium supplementationeotidase P00008171T0000 
P07779558T0000 |39 47|exercise phospha
P07779558T0000 |49 57|trainingses and 
P07779811A0901 |0 8|MutationP0000160
P07779811A0901 |94 111|reporter activityologic aspects of
P07779811A0901 |45 56|Sp1 bindinghatases and
P07779811A0901 |81 90|reductionT0000 Pha
P07779811A0901 |16 27|Sp1 elementomparison w
P07779812A0000 |136 146|cell typesmia. P0000
P07779812A0000 |93 97|rolecolo
P07779812A0000 |126 132|numberbiliru
P07779812A0000 |114 120|growthonatal
P07779812A0000 |37 44|varietyne phos
P07779812A0000 |4 14|c-myc gene01606T0076
P07779812A0000 |48 59|tumor typesases and 5-
P07780148A1153 |102 107|levelspect
P07780148A1153 |63 71|M phaseseotidase
P07780148A1153 |14 17|PML Co
P07780148A1153 |111 119|G1 phase neonata
P07780148A1153 |43 48|levelsphat
P07780148A1153 |52 53|S 
P07780148A1153 |55 57|G2d 
P07780525A0495 |0 9|SchoolingP00001606
P07780525A0495 |75 86|differences008171T0000
P07780525A0495 |41 47|healthhospha
P07780525A0495 |101 114|health inputsaspects of ne
P07780719A0477 |29 36|drivingh alkal
P07780738A0091 |103 110|antigenpects o
P07780738A0091 |46 56|cell cycleatases and
P07780738A0091 |90 94|cellrmac
P07780738A0091 |30 38|S phases alkalin
P07780738A0091 |128 143|DNA replicationlirubinemia. P0
P07780738A0091 |11 15|Cdks076 
P07780738A0091 |112 116|PCNAneon
P07780738A0091 |23 25|G1on
P07782087A0559 |170 186|primer extension-] is shown as a
P07782087A0559 |72 81|positionsP00008171
P07782087A0559 |195 208|RACE analyses of CSF PCO2 
P07782087A0559 |24 54|transcription initiation sitesn with alkaline phosphatases a
P07782087A0559 |130 141|combinationrubinemia. 
P07782087A0559 |145 168|ribonuclease protection08997A0472 When CSF [HC
P07782087A0559 |97 105|positiongic aspe
P07782113A0726 |85 97|blood levels0 Pharmacolo
P07782113A0726 |4 23|roxithromycin doses01606T0076 Comparis
P07782113A0726 |51 58|studiess and 5
P07782302A0479 |118 138|affinity interactional hyperbilirubinemi
P07782302A0479 |90 96|domainrmacol
P07782302A0479 |30 45|DEDDDL sequence alkaline phosp
P07782302A0479 |167 179|HTF9A/RanBP1CO3-] is sho
P07782302A0479 |72 75|RanP00
P07782302A0479 |57 60|GDP5-n
P07782302A0479 |158 165|proteinen CSF 
P07782775A0889 |102 119|BBTV coat proteinspects of neonata
P07782775A0889 |60 68|proteinsucleotid
P07782775A0889 |13 17|ORFs6 Co
P07782775A0889 |90 94|sizermac
P07782775A0889 |21 31|componentsison with 
P07782775A0889 |81 84|kDaT00
P07783064A0452 |16 29|strength dataomparison wit
P07783064A0452 |72 89|creatinine kinaseP00008171T0000 Ph
P07783064A0452 |91 93|CKma
P07783064A0452 |95 101|levelslogic 
P07783064A0452 |36 44|patientsine phos
P07783641A0591 |0 4|CodYP000
P07783641A0591 |41 51|data-baseshosphatase
P07783641A0591 |23 33|homologueson with al
P07783822A0000 |0 9|OBJECTIVEP00001606
P07783822A0000 |44 56|presentationphatases and
P07783822A0000 |30 39|incidence alkaline
P07783822A0000 |92 100|beriberiacologic
P07783822A0000 |114 131|district hospitalonatal hyperbilir
P07784061A0894 |69 72|TTFse 
P07784061A0894 |109 114|cellsof ne
P07784061A0894 |124 137|kb transcripterbilirubinem
P07784061A0894 |24 34|G proteinsn with alk
P07784078A1064 |118 133|APL cell growthal hyperbilirub
P07784078A1064 |76 82|levels08171T
P07784078A1064 |41 56|gene expressionhosphatases and
P07784078A1064 |3 14|explanation001606T0076
P07784078A1064 |99 102|PMLc a
P07784078A1064 |33 37|lackkali
P07784078A1064 |86 95|RAR alpha Pharmaco
P07784079A1018 |137 154|expression vectoria. P00008997A047
P07784079A1018 |213 216|FGFata
P07784079A1018 |28 45|expression vectorth alkaline phosp
P07784079A1018 |195 203|presence of CSF 
P07784079A1018 |104 112|activityects of 
P07784079A1018 |75 86|acquisition008171T0000
P07784079A1018 |174 182|activitys shown 
P07784079A1018 |129 133|formirub
P07784079A1018 |0 12|TransfectionP00001606T00
P07784079A1018 |51 63|NIH3T3 cellss and 5-nucl
P07784197A0827 |206 234|BALB/c 3T3 mouse fibroblasts2 the data of K-depleted rat
P07784197A0827 |110 117|HeLa S3f neona
P07784197A0827 |59 70|monkey Cos7nucleotidas
P07784197A0827 |10 18|extracts0076 Com
P07784197A0827 |26 33|varietywith al
P07784197A0827 |47 57|cell linestases and 
P07784197A0827 |188 200|cell extractunction of C
P07784197A0827 |173 184|band shiftsis shown as
P07784197A0827 |80 99|mouse fibrosarcomas1T0000 Pharmacologi
P07784197A0827 |140 148|TGF-beta P000089
P07784199A0000 |205 211|factorO2 the
P07784199A0000 |124 129|siteserbil
P07784199A0000 |14 21|protein Compar
P07784199A0000 |181 185|site as 
P07784199A0000 |145 165|gene regulator Rap1p08997A0472 When CSF 
P07784199A0000 |27 41|gene promotersith alkaline p
P07784199A0000 |213 218|Abf1pata o
P07784199A0000 |23 25|rpon
P07784870A0119 |16 23|reportsomparis
P07784870A0119 |179 193|histochemistrywn as a functi
P07784870A0119 |58 66|findings-nucleot
P07784870A0119 |228 248|immunohistochemistryed rats are no longe
P07784870A0119 |167 177|microscopyCO3-] is s
P07784870A0119 |106 117|informationts of neona
P07784870A0119 |86 93|reports Pharma
P07784870A0119 |144 158|investigations008997A0472 Wh
P07784870A0119 |207 226|electron microscopy the data of K-depl
P07784870A0119 |256 268|microbiologyced when com
P07784942T0001 |36 45|knowledgeine phosp
P07784942T0001 |12 26|thrombomodulin76 Comparison 
P07784942T0001 |57 66|prospects5-nucleot
P07786820A0284 |0 6|CPT-11P00001
P07786820A0284 |58 62|dose-nuc
P07786820A0284 |91 93|mlma
P07786820A0284 |101 107|salineaspect
P07786820A0284 |39 52|i.v. infusion phosphatases
P07786820A0284 |116 121|weeksatal 
P07786820A0284 |70 75|mg/m2e P00
P07786821A2292 |51 90|consecutive-days-every-3 weeks schedules and 5-nucleotidase P00008171T0000 Pha
P07786821A2292 |125 134|mg/m2/dayrbilirubi
P07786821A2292 |99 117|patient populationc aspects of neona
P07786821A2292 |24 30|CPT-11n with
P07786821A2292 |16 19|MTDomp
P07786821A2292 |0 10|CONCLUSIONP00001606T
P07787179A0312 |119 142|ethylene responsivenessl hyperbilirubinemia. P
P07787179A0312 |150 163|reporter geneA0472 When CS
P07787179A0312 |5 16|bp fragment1606T0076 C
P07787179A0312 |36 51|PRB-1b promoterine phosphatase
P07787179A0312 |18 27|X1 regionparison w
P07787179A0312 |69 78|positionsse P00008
P07789275A0325 |100 126|loss-of-function mutations aspects of neonatal hyper
P07789275A0325 |14 22|function Compari
P07789275A0325 |40 53|metamorphosisphosphatases 
P07789275A0325 |29 32|E74h a
P07789275A0325 |144 162|transcription unit008997A0472 When C
P07789275A0325 |23 24|so
P07789342A1352 |70 86|affinity bindinge P00008171T0000
P07789342A1352 |41 46|TSH-Rhosph
P07789342A1352 |90 93|TSHrma
P07789342A1352 |143 163|transmembrane domain0008997A0472 When CS
P07789342A1352 |27 33|domainith al
P07789342A1352 |175 186|TSH binding shown as a
P07789342A1352 |116 128|hyt mutationatal hyperbi
P07789396A0504 |0 8|LipiodolP0000160
P07789396A0504 |40 44|EDTBphos
P07789809A1246 |50 55|typeses an
P07789809A1246 |78 80|Vc17
P07789809A1246 |10 23|Western blots0076 Comparis
P07789809A1246 |121 140|household functionshyperbilirubinemia.
P07789809A1246 |104 107|Yptect
P07789809A1246 |157 174|vesicle transporthen CSF [HCO3-] i
P07789809A1246 |59 62|Yptnuc
P07789809A1246 |200 215|differentiationSF PCO2 the dat
P07789809A1246 |71 73|Cr P
P07789971A0758 |32 45|hybridizationlkaline phosp
P07789971A0758 |89 98|sequencesarmacolog
P07789971A0758 |209 214|geneshe da
P07789971A0758 |164 170|genome [HCO3
P07789971A0758 |126 137|pseudogenesbilirubinem
P07789971A0758 |244 249|GSTT2onger
P07789971A0758 |4 11|absence01606T0
P07789971A0758 |21 28|regionsison wi
P07790271A1185 |78 88|techniques171T0000 P
P07790271A1185 |13 22|lens dose6 Compari
P07790271A1185 |28 43|Gy/25 fractionsth alkaline pho
P07790377A0561 |0 10|AntibodiesP00001606T
P07790377A0561 |45 52|proteinhatases
P07790377A0561 |24 29|PTS1Rn wit
P07790377A0561 |63 69|monkeyeotida
P07790377A0561 |80 93|hamster cells1T0000 Pharma
P07790377A0561 |71 74|rat P0
P07790719A0098 |69 84|family violencese P00008171T00
P07790719A0098 |20 26|effortrison 
P07790719A0098 |54 62|patientsnd 5-nuc
P07791760A0424 |102 115|MAPK activityspects of neo
P07791760A0424 |60 77|tyrosine residuesucleotidase P0000
P07791760A0424 |144 164|complex kinase assay008997A0472 When CSF
P07791760A0424 |41 56|phosphorylationhosphatases and
P07791760A0424 |81 85|MAPKT000
P07791760A0424 |0 14|GnRH treatmentP00001606T0076
P07791763T0000 |68 72|cDNAase 
P07791763T0000 |10 17|cloning0076 Co
P07791763T0000 |92 121|phosphatidylinositol 3-kinaseacologic aspects of neonatal 
P07791763T0000 |77 88|involvement8171T0000 P
P07791763T0000 |141 166|Xenopus oocyte maturationP00008997A0472 When CSF [
P07791763T0000 |34 60|insulin receptor substratealine phosphatases and 5-n
P07791764A0357 |32 46|Jurkat T cellslkaline phosph
P07791764A0357 |75 83|antibody008171T0
P07791764A0357 |96 116|adapter protein Grb2ogic aspects of neon
P07791764A0357 |48 51|Cblase
P07791768A0930 |102 106|swi6spec
P07791768A0930 |147 156|mutations997A0472 
P07791768A0930 |74 94|hmr delta A mutation0008171T0000 Pharmac
P07791768A0930 |20 41|cell cycle regulatorsrison with alkaline p
P07791768A0930 |197 210|establishmentf CSF PCO2 th
P07791768A0930 |214 223|silencingta of K-d
P07791768A0930 |108 112|swi4 of 
P07791768A0930 |160 164|SIR1 CSF
P07791768A0930 |174 178|genes sh
P07791768A0930 |65 70|rap1stidas
P07791768A0930 |4 10|effect01606T
P07791768A0930 |118 132|clb5 mutationsal hyperbiliru
P07791769A0826 |152 160|TATA box472 When
P07791769A0826 |162 164|C.SF
P07791769A0826 |128 145|ICP4 binding sitelirubinemia. P000
P07791769A0826 |89 96|proteinarmacol
P07791769A0826 |72 76|TATAP000
P07791769A0826 |39 48|complexes phosphat
P07791769A0826 |110 113|DNAf n
P07791769A0826 |101 106|TFIIBaspec
P07791769A0826 |0 4|ICP4P000
P07791771A0183 |0 4|OtteP000
P07791771A0183 |6 9|Mol606
P07791776T0000 |0 16|CharacterizationP00001606T0076 C
P07791776T0000 |104 115|conjugationects of neo
P07791776T0000 |20 24|fus1riso
P07791776T0000 |84 92|function00 Pharm
P07791783A0000 |69 72|boxse 
P07791783A0000 |28 35|proteinth alka
P07791783A0000 |150 183|rainbow trout testis cDNA libraryA0472 When CSF [HCO3-] is shown a
P07791783A0000 |12 16|cDNA76 C
P07791783A0000 |122 128|SOX-LZyperbi
P07791783A0000 |79 99|leucine zipper motif71T0000 Pharmacologi
P07791783A0000 |64 67|HMGoti
P07793783A0189 |0 11|Scalp flapsP00001606T0
P07793783A0189 |133 140|closureinemia.
P07793783A0189 |40 45|pointphosp
P07793783A0189 |148 158|donor site97A0472 Wh
P07793783A0189 |99 123|scalp flap transpositionc aspects of neonatal hy
P07793783A0189 |81 86|weeksT0000
P07794556A0000 |119 126|servicel hyper
P07794556A0000 |202 219|mutation analysis PCO2 the data of
P07794556A0000 |7 13|Center06T007
P07794556A0000 |24 32|Geneticsn with a
P07794556A0000 |161 172|DNA-linkageCSF [HCO3-]
P07794556A0000 |133 141|Novemberinemia. 
P07794556A0000 |55 66|DNA-testingd 5-nucleot
P07794556A0000 |36 42|Leuvenine ph
P07794556A0000 |71 81|Huntington P00008171
P07794556A0000 |84 91|disease00 Phar
P07795104T0000 |0 5|RisksP0000
P07795104T0000 |9 19|chronicityT0076 Comp
P07795104T0000 |67 73|reviewdase P
P07795104T0000 |36 63|hepatitis B virus infectionine phosphatases and 5-nucl
P07795576A0126 |0 11|ExaminationP00001606T0
P07795576A0126 |28 35|factorsth alka
P07795576A0126 |105 126|plasma renin activitycts of neonatal hyper
P07795576A0126 |79 85|system71T000
P07795576A0126 |93 101|increasecologic 
P07796935A0284 |64 72|hTR betaotidase 
P07796935A0284 |147 157|peroxisome997A0472 W
P07796935A0284 |240 244|TREsno l
P07796935A0284 |181 189|receptor as a fu
P07796935A0284 |256 258|DRce
P07796935A0284 |191 196|hPPARtion 
P07796935A0284 |247 254|TRE-PALer disp
P07796935A0284 |267 274|TRE-LAPmpared 
P07796935A0284 |27 33|effectith al
P07796935A0284 |109 116|mutantsof neon
P07796935A0284 |118 130|c-erbA alphaal hyperbili
P07796935A0284 |230 238|elements rats ar
P07796935A0284 |97 106|hTR alphagic aspec
P07797077A0842 |71 79|homology P000081
P07797077A0842 |208 219|ISGF3 gammathe data of
P07797077A0842 |183 188|IRF-1s a f
P07797077A0842 |31 37|domainalkali
P07797077A0842 |61 67|degreecleoti
P07797077A0842 |160 166|family CSF [
P07797077A0842 |155 158|IRF Wh
P07797077A0842 |190 195|IRF-2ction
P07797077A0842 |125 135|interferonrbilirubin
P07797077A0842 |147 153|factor997A04
P07797077A0842 |197 202|ICSBPf CSF
P07797077A0842 |41 44|Piphos
P07797077A0842 |110 117|membersf neona
P07797077A0842 |99 106|domainsc aspec
P07797346T0000 |51 60|Amsterdams and 5-n
P07797346T0000 |15 26|hepatitis AComparison 
P07797346T0000 |44 47|menpha
P07797346T0000 |3 11|outbreak001606T0
P07797476A1001 |84 90|region00 Pha
P07797476A1001 |106 117|stimulationts of neona
P07797476A1001 |59 67|activitynucleoti
P07797476A1001 |147 155|residues997A0472
P07797476A1001 |4 17|RAP74 subunit01606T0076 Co
P07797476A1001 |21 26|TFIIFison 
P07797583A0222 |273 279|factor to co
P07797583A0222 |58 67|deletions-nucleoti
P07797583A0222 |125 132|respectrbiliru
P07797583A0222 |244 251|bindingonger d
P07797583A0222 |26 44|base substitutionswith alkaline phos
P07797583A0222 |303 311|activitysignific
P07797583A0222 |324 343|Drosophila Kc cells slope (1.21 +/- 0.
P07797583A0222 |87 107|nucleotide positionsPharmacologic aspect
P07797583A0222 |82 85|DRE000
P07797583A0222 |178 187|PCNA geneown as a 
P07797583A0222 |365 370|fliesFlura
P07797583A0222 |285 294|PCNA gene but stil
P07797583A0222 |255 259|DREFaced
P07797583A0222 |229 236|effectsd rats 
P07797583A0222 |140 169|transcription initiation site P00008997A0472 When CSF [HCO
P07798134T0000 |4 21|hsp70 gene family01606T0076 Compar
P07798134T0000 |44 51|cloningphatase
P07798134T0000 |134 140|membernemia.
P07798134T0000 |25 42|Neurospora crassa with alkaline ph
P07798134T0000 |72 82|expressionP00008171T
P07798134T0000 |53 70|sequence analysisand 5-nucleotidas
P07798134T0000 |96 103|mappingogic as
P07798207A0759 |170 194|Paracoccus denitrificans-] is shown as a functio
P07798207A0759 |145 148|ETF089
P07798207A0759 |161 164|ratCSF
P07798207A0759 |95 105|% identitylogic aspe
P07798207A0759 |12 32|amino acid sequences76 Comparison with a
P07798207A0759 |232 233|%a
P07798207A0759 |129 137|subunitsirubinem
P07798207A0759 |48 65|W3A1 ETF subunitsases and 5-nucleo
P07798207A0759 |207 212|group the 
P07798217T0000 |83 90|control000 Pha
P07798217T0000 |12 27|phosphorylation76 Comparison w
P07798217T0000 |31 38|CREB341alkalin
P07798217T0000 |94 109|gene expressionologic aspects 
P07798217T0000 |42 48|Ser129osphat
P07798217T0095 |2 6|role0001
P07798217T0095 |45 52|controlhatases
P07798217T0095 |11 37|glycogen synthase kinase-3076 Comparison with alkali
P07798217T0095 |56 71|gene expression 5-nucleotidase
P07798271A0330 |92 100|extractsacologic
P07798271A0330 |30 35|sites alka
P07798271A0330 |10 16|region0076 C
P07798271A0330 |133 146|Ets-1 proteininemia. P0000
P07798271A0330 |78 83|liver171T0
P07798271A0330 |58 66|proteins-nucleot
P07799437A0656 |6 12|assays606T00
P07799437A0656 |62 72|pNeo.Myc-2leotidase 
P07799437A0656 |47 58|replicationtases and 5
P07799437A0656 |107 123|control plasmidss of neonatal hy
P07799437A0656 |95 103|labelinglogic as
P07799925A0526 |51 75|src family kinase p59fyns and 5-nucleotidase P00
P07799925A0526 |166 169|p62HCO
P07799925A0526 |18 27|complexesparison w
P07799925A0526 |39 42|p62 ph
P07799925A0526 |199 202|SH3CSF
P07799925A0526 |108 125|complex formation of neonatal hype
P07799925A0526 |79 89|HeLa cells71T0000 Ph
P07799925A0526 |207 218|SH2 domains the data o
P07799925A0526 |138 162|tyrosine phosphorylationa. P00008997A0472 When C
P07799925A0526 |222 228|p59fyndeplet
P07799925A0526 |0 14|ReconstitutionP00001606T0076
P07799931A0287 |136 140|fatemia.
P07799931A0287 |60 67|controlucleoti
P07799931A0287 |145 157|organization08997A0472 W
P07799931A0287 |75 91|L7 gene insights008171T0000 Phar
P07799931A0287 |173 179|systemis sho
P07799931A0287 |101 111|mechanismsaspects of
P07799931A1232 |3 11|contrast001606T0
P07799931A1232 |61 74|c-Maf actionscleotidase P0
P07799931A1232 |27 34|proteinith alk
P07799931A1232 |36 39|Nrline
P07799939A0628 |117 124|nucleustal hyp
P07799939A0628 |12 19|element76 Comp
P07799939A0628 |52 83|serine/threonine phosphoprotein and 5-nucleotidase P00008171T0
P07799939A0628 |141 150|3T3 cellsP00008997
P07799948A0777 |138 143|Raf-1a. P0
P07799948A0777 |78 90|Raf-1 kinase171T0000 Pha
P07799948A0777 |94 97|Srcolo
P07799948A0777 |13 21|deletion6 Compar
P07799948A0777 |121 124|Rashyp
P07799948A0777 |164 174|mechanisms [HCO3-] i
P07799948A0777 |113 116|Srceon
P07799948A0777 |42 46|siteosph
P07799948A0777 |64 74|activationotidase P0
P07799948A0777 |3 11|contrast001606T0
P07799950A0282 |3 10|studies001606T
P07799950A0282 |107 116|prototypes of neon
P07799950A0282 |75 101|somatostatin gene promoter008171T0000 Pharmacologic 
P07799950A0282 |145 152|element08997A0
P07799950A0282 |166 170|CREBHCO3
P07799950A0282 |53 58|cellsand 5
P07799950A0282 |64 67|CREoti
P07800479A0201 |136 144|proteinsmia. P00
P07800479A0201 |123 132|transportperbiliru
P07800479A0201 |46 50|geneatas
P07800479A0201 |62 69|proteinleotida
P07800479A0201 |92 106|RNA maturationacologic aspec
P07800479A0201 |10 14|gene0076
P07800479A0201 |154 161|nucleus2 When 
P07800479A0201 |16 20|NSR1ompa
P07800505T0000 |0 16|CharacterizationP00001606T0076 C
P07800505T0000 |24 32|promotern with a
P07800505T0000 |64 85|phospholipase A2 geneotidase P00008171T000
P07800505T0000 |50 53|kDaes 
P07801180A0197 |64 80|study approachesotidase P0000817
P07801180A0197 |40 51|limitationsphosphatase
P07801180A0197 |25 35|advantages with alka
P07801180A0197 |5 10|paper1606T
P07802355T0000 |83 92|analyzers000 Pharm
P07802355T0000 |44 60|blood cell countphatases and 5-n
P07802355T0000 |94 106|Coulter STKSologic aspec
P07802355T0000 |12 17|study76 Co
P07802355T0000 |108 117|Sysmex NE of neona
P07802355T0000 |127 140|Technicon H-1ilirubinemia.
P07802655T0000 |0 16|CharacterizationP00001606T0076 C
P07802655T0000 |113 116|L14eon
P07802655T0000 |127 140|protein genesilirubinemia.
P07802655T0000 |106 108|L1ts
P07802655T0000 |98 102|exonic a
P07802655T0000 |20 28|FIII/YY1rison wi
P07802655T0000 |32 46|Xenopus laevislkaline phosph
P07802655T0000 |69 84|protein bindingse P00008171T00
P07803809A1852 |186 194|ABSTRACT functio
P07803809A1852 |147 182|protein kinase C inhibitor Compound997A0472 When CSF [HCO3-] is shown 
P07803809A1852 |60 76|beta-globin mRNAucleotidase P000
P07803809A1852 |212 217|WORDSdata 
P07803809A1852 |8 15|studies6T0076 
P07803809A1852 |48 56|increaseases and
P07803809A1852 |103 138|tyrosine kinase inhibitor genisteinpects of neonatal hyperbilirubinemi
P07806492A1162 |84 93|precursor00 Pharma
P07806492A1162 |5 14|structure1606T0076
P07806492A1162 |18 27|cucumisinparison w
P07806507A0121 |39 54|CD3-TCR complex phosphatases a
P07806507A0121 |10 20|dissection0076 Compa
P07806507A0121 |107 115|CD3 zetas of neo
P07806507A0121 |120 131|CD3 epsilon hyperbilir
P07806507A0121 |230 248|activation cascade rats are no longe
P07806507A0121 |199 205|eventsCSF PC
P07806507A0121 |93 105|polypeptidescologic aspe
P07806507A0121 |163 180|recognition eventF [HCO3-] is show
P07806532A0659 |0 13|Protein cHMGIP00001606T007
P07806532A0659 |46 49|DNAata
P07806532A0659 |57 78|half-saturation value5-nucleotidase P00008
P07806532A0659 |86 88|nM P
P07806651A0097 |119 128|MF scalesl hyperbi
P07806651A0097 |112 113|Kn
P07806651A0097 |109 110|Lo
P07806651A0097 |28 34|degreeth alk
P07806651A0097 |90 101|performancermacologic 
P07806651A0097 |71 88|Mexican-Americans P00008171T0000 P
P07806651A0097 |5 10|study1606T
P07806651A0097 |136 142|MMPI-2mia. P
P07806651A0097 |51 59|identitys and 5-
P07806820A0091 |84 90|artery00 Pha
P07806820A0091 |120 131|fascia flap hyperbilir
P07806820A0091 |42 49|pedicleosphata
P07807002A0500 |113 137|luciferase reporter geneeonatal hyperbilirubinem
P07807002A0500 |12 20|segments76 Compa
P07807002A0500 |74 94|germline epsilon RNA0008171T0000 Pharmac
P07807002A0500 |224 227|IgEple
P07807002A0500 |24 27|DNAn w
P07807002A0500 |40 45|flankphosp
P07807002A0500 |163 181|mouse B cell linesF [HCO3-] is shown
P07807002A0500 |53 69|initiation sitesand 5-nucleotida
P07808210A1510 |35 36|%l
P07808210A1510 |24 29|valuen wit
P07808210A1510 |43 44|%s
P07808210A1510 |53 60|NCEP I.and 5-n
P07809128T0000 |10 18|capacity0076 Com
P07809128T0000 |26 35|E2F1 genewith alka
P07809410A0606 |223 230|therapyepleted
P07809410A0606 |41 57|serum TSH levelshosphatases and 
P07809410A0606 |91 103|131I proteinmacologic as
P07809410A0606 |120 128|131I-PBI hyperbi
P07809410A0606 |15 20|casesCompa
P07809410A0606 |112 118|iodineneonat
P07809410A0606 |59 85|serum thyroglobulin valuesnucleotidase P00008171T000
P07809410A0606 |175 186|differences shown as a
P07809410A0606 |33 39|lesionkaline
P07811639A0222 |0 18|Endo16 transcriptsP00001606T0076 Com
P07811639A0222 |94 108|gastrula stageologic aspects
P07811639A0222 |182 188|midgutas a f
P07811639A0222 |58 63|plate-nucl
P07811639A0222 |147 158|archenteron997A0472 Wh
P07811639A0222 |76 89|stage embryos08171T0000 Ph
P07811639A0222 |114 118|geneonat
P07811964A1252 |119 123|rolel hy
P07811964A1252 |76 82|domain08171T
P07811964A1252 |25 39|repeat element with alkaline
P07811964A1252 |142 154|dimerization00008997A047
P07811964A1252 |86 92|EmBP-1 Pharm
P07812450A0849 |70 79|nspC genee P000081
P07812450A0849 |13 16|ORF6 C
P07812450A0849 |43 49|strandsphata
P07813466A0074 |34 37|ratali
P07813466A0074 |158 170|protein geneen CSF [HCO3
P07813466A0074 |172 177|hsc70 is s
P07813466A0074 |67 72|troutdase 
P07813466A0074 |92 99|intronsacologi
P07813466A0074 |4 13|U14 genes01606T007
P07813466A0074 |39 46|hamster phosph
P07813466A0074 |55 62|Xenopusd 5-nuc
P07813466A0074 |17 22|mousempari
P07813786A0641 |72 89|XMyoDa TATA motifP00008171T0000 Ph
P07813786A0641 |44 52|proteinsphatases
P07813786A0641 |12 17|cDNAs76 Co
P07814321A0850 |17 21|prfAmpar
P07814321A0850 |26 30|ponAwith
P07814321A0850 |71 80|reduction P0000817
P07814321A0850 |58 64|growth-nucle
P07814321A0850 |84 106|sporulation efficiency00 Pharmacologic aspec
P07814321A0850 |0 8|DeletionP0000160
P07814323A0313 |51 55|FliQs an
P07814323A0313 |28 36|proteinsth alkal
P07814323A0313 |60 64|FliRucle
P07814323A0313 |18 24|familypariso
P07814323A0313 |115 133|flagellum assemblynatal hyperbilirub
P07814323A0313 |87 101|export pathwayPharmacologic 
P07814323A0313 |0 9|InclusionP00001606
P07814388A0662 |119 153|pertussis toxin substrate activityl hyperbilirubinemia. P00008997A04
P07814388A0662 |10 26|L-cell membranes0076 Comparison 
P07814388A0662 |58 65|M6P/IGF-nucleo
P07814388A0662 |43 47|typespha
P07814388A0662 |83 89|nM IGF000 Ph
P07814388A0662 |69 78|receptorsse P00008
P07814403A0433 |0 4|ChemP000
P07814405A1170 |184 192|proteins a funct
P07814405A1170 |31 39|deletionalkaline
P07814405A1170 |14 18|time Com
P07814405A1170 |97 123|guanylyl cyclase receptorsgic aspects of neonatal hy
P07814405A1170 |44 59|point mutationsphatases and 5-
P07814405A1170 |143 152|formation0008997A0
P07814405A1170 |71 93|plasma membrane family P00008171T0000 Pharma
P07814717A0669 |0 8|IncreaseP0000160
P07814717A0669 |95 109|concentrationslogic aspects 
P07814717A0669 |57 75|AA supplementation5-nucleotidase P00
P07814717A0669 |12 22|blood NEFA76 Compari
P07814717A0669 |120 123|Met hy
P07814717A0669 |113 116|Lyseon
P07814717A0669 |127 132|bloodiliru
P07814717A0669 |48 51|fatase
P07814717A0669 |84 91|changes00 Phar
P07815546A0411 |0 5|VirolP0000
P07815811A1487 |119 133|concentrationsl hyperbilirub
P07815811A1487 |10 26|vasoconstriction0076 Comparison 
P07815811A1487 |37 49|endothelin-1ne phosphata
P07815811A1487 |93 107|norepinephrinecologic aspect
P07815811A1487 |65 85|ischemia-reperfusiontidase P00008171T000
P07815811A1487 |184 190|bypass a fun
P07816025A0196 |0 10|ComparisonP00001606T
P07816025A0196 |125 129|Coixrbil
P07816025A0196 |95 110|gamma-prolaminslogic aspects o
P07816025A0196 |26 45|amino acid sequencewith alkaline phosp
P07816025A0196 |114 119|maizeonata
P07816025A0196 |82 91|sequences0000 Phar
P07816025A0196 |156 163|domainsWhen CS
P07816025A0196 |49 62|gamma-kafirinses and 5-nuc
P07816049A0686 |0 6|Atcys1P00001
P07816049A0686 |90 98|polarityrmacolog
P07816049A0686 |251 264|transcriptionisplaced when
P07816049A0686 |8 14|Athyp16T0076
P07816049A0686 |192 200|elementsion of C
P07816049A0686 |122 129|regionsyperbil
P07816049A0686 |31 34|ORFalk
P07816049A0686 |169 171|kb3-
P07816049A0686 |236 247|terminationare no long
P07816049A0686 |16 22|AKin10ompari
P07816049A0686 |221 231|initiation-depleted 
P07816049A1157 |68 72|copyase 
P07816049A1157 |126 148|Northern blot analysisbilirubinemia. P000089
P07816049A1157 |95 101|AKin10logic 
P07816049A1157 |215 220|rootsa of 
P07816049A1157 |177 182|geneshown 
P07816049A1157 |106 120|haploid genomets of neonatal
P07816049A1157 |52 60|presence and 5-n
P07816049A1157 |76 82|Atcys108171T
P07816049A1157 |84 90|Athyp100 Pha
P07816049A1157 |0 39|Southern blot hybridization experimentsP00001606T0076 Comparison with alkaline
P07816617A0763 |6 13|results606T007
P07816617A0763 |63 68|geneseotid
P07816617A0763 |27 31|HAC1ith 
P07816619A0000 |86 95|phenotype Pharmaco
P07816619A0000 |164 186|cAMP phosphodiesterase [HCO3-] is shown as a
P07816619A0000 |129 140|pde1 mutantirubinemia.
P07816619A0000 |23 55|Arabidopsis thaliana cDNA cloneson with alkaline phosphatases an
P07816619A0872 |17 31|identificationmparison with 
P07816619A0872 |109 116|proteinof neon
P07816619A0872 |46 53|proteinatases 
P07816619A0872 |183 207|transcription initiations a function of CSF PCO2
P07816619A0872 |134 140|generanemia.
P07816619A0872 |161 170|mechanismCSF [HCO3
P07816619A0872 |57 67|A.thaliana5-nucleoti
P07816619A0872 |92 100|ubiquityacologic
P07816619A0872 |222 225|Dr1dep
P07816630A1333 |34 42|sequencealine ph
P07816630A1333 |150 156|regionA0472 
P07816630A1333 |61 87|translation terminator TGAcleotidase P00008171T0000 
P07816630A1333 |164 173|H4-I gene [HCO3-] 
P07816630A1333 |95 107|beta-tubulinlogic aspect
P07816630A1333 |28 30|bpth
P07816630A1333 |111 115|BTU2 neo
P07816630A1333 |117 121|genetal 
P07816808A1102 |153 163|Arthropoda72 When CS
P07816808A1102 |6 10|data606T
P07816808A1102 |72 80|nematodeP0000817
P07816808A1102 |46 51|genesatase
P07816808A1102 |168 176|ChordataO3-] is 
P07816808A1102 |141 145|riseP000
P07816808A1102 |32 42|STR familylkaline ph
P07816808A1102 |87 95|ancestorPharmaco
P07818416A0895 |102 105|g/Lspe
P07818416A0895 |149 152|g/L7A0
P07818416A0895 |135 138|THRemi
P07818416A0895 |177 189|revision THRhown as a fu
P07818416A0895 |72 77|groupP0000
P07818416A0895 |27 53|haemoglobin concentrationsith alkaline phosphatases 
P07818416A0895 |161 170|instancesCSF [HCO3
P07819225A1094 |119 126|Lys-220l hyper
P07819225A1094 |75 86|suppression008171T0000
P07819225A1094 |30 37|residue alkali
P07819225A1094 |197 220|tetracycline resistancef CSF PCO2 the data of 
P07819225A1094 |131 138|Gln-220ubinemi
P07819225A1094 |94 110|Asn-285 mutationologic aspects o
P07819225A1094 |166 180|Asn-285 mutantHCO3-] is show
P07819225A1094 |151 158|mutants0472 Wh
P07819225A1094 |248 253|WORDSr dis
P07819225A1094 |52 56|site and
P07819225A1094 |4 16|introduction01606T0076 C
P07819225A1094 |222 230|ABSTRACTdepleted
P07820057A0000 |0 27|Tumor necrosis factor alphaP00001606T0076 Comparison w
P07820057A0000 |77 91|growth control8171T0000 Phar
P07820057A0000 |142 152|properties00008997A0
P07820057A0000 |126 130|bonebili
P07820057A0000 |33 41|cytokinekaline p
P07820057A0000 |101 114|cell leukemiaaspects of ne
P07821790A1084 |136 150|transactivatormia. P00008997
P07821790A1084 |74 83|repressor0008171T0
P07821790A1084 |14 19|UCRBP Comp
P07821790A1084 |175 187|UCR elements shown as a 
P07821790A1084 |156 164|reporterWhen CSF
P07821790A1084 |201 223|co-transfection assaysF PCO2 the data of K-d
P07821790A1084 |103 108|UCRBPpects
P07822161A1172 |16 28|monkey opsinomparison wi
P07822161A1172 |73 83|nucleotide00008171T0
P07822161A1172 |164 172|residues [HCO3-]
P07822161A1172 |92 109|amino acid levelsacologic aspects 
P07822161A1172 |57 65|sequence5-nucleo
P07822161A1172 |4 12|sequence01606T00
P07822161A1172 |141 152|differencesP00008997A0
P07822329A0773 |152 156|mass472 
P07822329A0773 |62 67|cellsleoti
P07822329A0773 |4 11|complex01606T0
P07822329A0773 |177 180|kDahow
P07822329A0773 |87 94|bindingPharmac
P07822329A0773 |118 124|factoral hyp
P07822333A0376 |0 4|ChemP000
P07823919A1422 |34 42|promoteraline ph
P07823919A1422 |26 31|Oct-3with 
P07823919A1422 |46 49|RARata
P07823919A1422 |12 22|activation76 Compari
P07823919A1422 |101 109|COUP-TFIaspects 
P07823919A1422 |95 100|EAR-3logic
P07823919A1422 |117 122|ARP-1tal h
P07823919A1422 |50 66|RXR heterodimerses and 5-nucleot
P07823951A1100 |84 101|globin expression00 Pharmacologic 
P07823951A1100 |172 177|CACCC is s
P07823951A1100 |159 168|regulatorn CSF [HC
P07823951A1100 |128 132|idealiru
P07823951A1100 |195 208|transcription of CSF PCO2 
P07823951A1100 |31 35|EKLFalka
P07823951A1100 |55 79|transactivation functiond 5-nucleotidase P000081
P07823951A1100 |6 13|results606T007
P07823951A1100 |138 142|EKLFa. P
P07823951A1100 |222 227|cellsdeple
P07823953A0777 |137 143|regionia. P0
P07823953A0777 |19 42|I kappa B alpha mutantsarison with alkaline ph
P07823953A0777 |320 330|inhibitionater slope
P07823953A0777 |334 345|DNA binding21 +/- 0.23
P07823953A0777 |484 492|subunitsat night
P07823953A0777 |297 303|regionave a 
P07823953A0777 |264 269|dimer comp
P07823953A0777 |147 162|I kappa B alpha997A0472 When C
P07823953A0777 |63 68|dimereotid
P07823953A0777 |361 371|inhibition733 Fluraz
P07823953A0777 |199 206|bindingCSF PCO
P07823953A0777 |436 442|regionum dos
P07823953A0777 |463 469|regionpracti
P07823953A0777 |220 224|maskK-de
P07823953A0777 |84 108|I kappa B alpha molecule00 Pharmacologic aspects
P07823953A0777 |402 413|interactionctive hypno
P07823953A0777 |8 15|battery6T0076 
P07823953A0777 |500 505|dimer653T0
P07823953A0777 |237 256|localization signalre no longer displa
P07823964A0922 |51 57|domains and 
P07823964A0922 |120 125|trans hype
P07823964A0922 |90 97|segmentrmacolo
P07823964A0922 |24 32|activityn with a
P07823964A0922 |101 107|Pho81paspect
P07824325A0714 |35 45|proceduresline phosp
P07824325A0714 |127 135|patientsilirubin
P07824325A0714 |246 257|microgram/gger displac
P07824325A0714 |210 213|MICe d
P07824325A0714 |151 176|vancomycin concentrations0472 When CSF [HCO3-] is 
P07824325A0714 |47 61|thorax openingtases and 5-nu
P07824325A0714 |192 199|tissuesion of 
P07824325A0714 |75 81|period008171
P07824325A0714 |118 119|%a
P07824325A0714 |293 305|micrograms/gll have a si
P07824325A0714 |66 73|closureidase P
P07824325A0714 |13 18|times6 Com
P07824325A0714 |101 107|bypassaspect
P07824325A0714 |139 144|group. P00
P07824464A0169 |237 247|mechanismsre no long
P07824464A0169 |30 42|tissue flaps alkaline ph
P07824464A0169 |143 155|fissurations0008997A0472
P07824464A0169 |96 119|artery wall dissectionsogic aspects of neonata
P07824464A0169 |172 184|haemorrhages is shown as
P07824464A0169 |59 64|lumennucle
P07824464A0169 |121 136|plaque ruptureshyperbilirubine
P07824464A0169 |20 26|imagesrison 
P07824464A0169 |260 275|artery stenosiswhen compared t
P07824464A0169 |206 212|colour2 the 
P07824464A0169 |87 94|thrombiPharmac
P07824657A1456 |64 71|sulfiteotidase
P07824657A1456 |13 31|cysteine formation6 Comparison with 
P07824657A1456 |93 103|leaf discscologic as
P07824657A1456 |37 49|pCSK4F plantne phosphata
P07824726A0454 |69 73|bodyse P
P07824726A0454 |90 98|pancreasrmacolog
P07824726A0454 |163 180|fatty replacementF [HCO3-] is show
P07824726A0454 |78 82|tail171T
P07824726A0454 |182 188|type bas a f
P07824726A0454 |133 137|typeinem
P07824726A0454 |31 40|subgroupsalkaline 
P07824726A0454 |5 9|type1606
P07824726A0454 |212 229|fatty replacementdata of K-deplete
P07824726A0454 |114 131|fatty replacementonatal hyperbilir
P07824726A0454 |48 53|basisases 
P07825888A0715 |70 81|differencese P00008171
P07825888A0715 |91 106|cortisol levelsmacologic aspec
P07825888A0715 |12 21|subgroups76 Compar
P07825888A0715 |25 43|dementia disorders with alkaline pho
P07826412T0112 |68 82|gamma-subunitsase P00008171T
P07826412T0112 |6 16|hypothesis606T0076 C
P07826412T0112 |56 64|subunits 5-nucle
P07826412T0112 |87 97|activationPharmacolo
P07826412T0112 |20 30|mechanismsrison with
P07826412T0112 |117 127|transducintal hyperb
P07826412T0112 |103 113|holoenzymepects of n
P07826625X0000 |98 116|activation domainsic aspects of neon
P07826625X0000 |81 88|proteinT0000 P
P07826625X0000 |250 266|proline residuesdisplaced when c
P07826625X0000 |24 47|transcription apparatusn with alkaline phospha
P07826625X0000 |299 317|activation domainse a significantly 
P07826625X0000 |147 153|domain997A04
P07826625X0000 |420 443|polyglutamine stretchesg with the optimum dose
P07826625X0000 |211 218|Regions data o
P07826625X0000 |348 353|parts. P00
P07826625X0000 |193 208|enhancer domainon of CSF PCO2 
P07826625X0000 |227 233|serineted ra
P07826625X0000 |49 63|RNA polymeraseses and 5-nucl
P07826625X0000 |155 158|CTD Wh
P07826625X0000 |163 177|RNA polymeraseF [HCO3-] is s
P07826625X0000 |380 388|proteins appears
P07826625X0000 |6 16|components606T0076 C
P07826625X0000 |235 244|threonine are no l
P07828584A0681 |0 11|MutagenesisP00001606T0
P07828584A0681 |43 48|c-Fossphat
P07828584A0681 |15 18|IM1Com
P07828584A0681 |64 84|AP1 bearing promoterotidase P00008171T00
P07828584A0681 |32 39|abilitylkaline
P07828600A0095 |0 7|BindingP000016
P07828600A0095 |22 44|stage selector elementson with alkaline phos
P07828600A0095 |198 202|K562 CSF
P07828600A0095 |11 14|SSP076
P07828600A0095 |46 49|SSEata
P07828600A0095 |120 129|silencing hyperbil
P07828600A0095 |142 155|beta-promoter00008997A0472
P07828600A0095 |67 88|gamma-globin promoterdase P00008171T0000 P
P07828600A0095 |175 196|stage erythroleukemia shown as a function 
P07828600A0095 |204 209|cellsCO2 t
P07828811A0556 |34 45|G1/S arrestaline phosp
P07828811A0556 |74 91|thermosensitivity0008171T0000 Phar
P07828811A0556 |110 117|abilityf neona
P07828811A0556 |5 12|failure1606T00
P07828824A0307 |0 9|MutationsP00001606
P07828824A0307 |110 119|deletionsf neonata
P07828824A0307 |54 65|developmentnd 5-nucleo
P07828824A0307 |21 49|photoreceptor cell structureison with alkaline phosphata
P07828852A0153 |67 76|functionsdase P000
P07828852A0153 |45 51|nucleihatase
P07828852A0153 |24 33|telomeresn with al
P07829057A1097 |4 17|marker orders01606T0076 Co
P07829057A1097 |39 46|RH maps phosph
P07829057T0000 |0 27|Integrated mapping analysisP00001606T0076 Comparison w
P07829057T0000 |61 71|chromosomecleotidase
P07829057T0000 |35 57|Werner syndrome regionline phosphatases and 
P07829097A0000 |19 24|DXS52ariso
P07829097A0000 |92 95|G+Caco
P07829097A0000 |124 129|geneserbil
P07829097A0000 |41 45|genehosp
P07829097A0000 |29 35|Factorh alka
P07829097A0000 |76 80|band0817
P07829097A0000 |59 63|Xq28nucl
P07829097A0000 |4 10|region01606T
P07829097A0000 |101 109|isochoreaspects 
P07829102T0000 |119 128|parasitesl hyperbi
P07829102T0000 |90 99|infectionrmacologi
P07829102T0000 |72 86|susceptibilityP00008171T0000
P07829102T0000 |47 63|mouse Nramp genetases and 5-nucl
P07829102T0000 |22 39|sequence analysisson with alkaline
P07829102T0000 |0 17|Haplotype mappingP00001606T0076 Co
P07829519A1251 |169 186|immunoglobulin mu3-] is shown as a
P07829519A1251 |193 198|chainon of
P07829519A1251 |73 83|exon usage00008171T0
P07829519A1251 |105 114|mechanismcts of ne
P07829519A1251 |5 16|utilization1606T0076 C
P07829519A1251 |230 235|locus rats
P07829519A1251 |156 161|formsWhen 
P07829519A1251 |32 52|polyadenylation sitelkaline phosphatases
P07829554A0257 |272 280|antibodyd to con
P07829554A0257 |148 161|wear products97A0472 When 
P07829554A0257 |242 247|ELISA long
P07829554A0257 |303 309|metalssignif
P07829554A0257 |185 192|devicesa funct
P07829554A0257 |114 132|protein conjugatesonatal hyperbiliru
P07829554A0257 |260 267|testingwhen co
P07829554A0257 |249 255|method displ
P07829554A0257 |59 74|system responsenucleotidase P0
P07829554A0257 |134 143|corrosionnemia. P0
P07829554A0257 |290 298|immunitystill ha
P07829554A0257 |15 24|knowledgeCompariso
P07829554A0257 |235 240|assay are 
P07830112A0532 |274 275|pt
P07830112A0532 |180 184|TPFRn as
P07830112A0532 |74 77|EDV000
P07830112A0532 |288 296|patientst still 
P07830112A0532 |325 332|normalsslope (
P07830112A0532 |156 157|pW
P07830112A0532 |251 261|mass indexisplaced w
P07830112A0532 |83 96|stroke volume000 Pharmacol
P07830112A0532 |26 30|ratewith
P07830112A0532 |123 128|ratioperbi
P07830112A0532 |302 312|acromegaly significa
P07830112A0532 |175 178|PFR sh
P07830112A0532 |66 72|volumeidase 
P07830112A0532 |167 171|timeCO3-
P07830112A0532 |13 17|peak6 Co
P07830112A0532 |132 142|PFR-to-PERbinemia. P
P07830112A0532 |201 202|pF
P07830112A0532 |98 100|SVic
P07830112A0532 |3 11|contrast001606T0
P07830112A0532 |32 35|PFRlka
P07831310A0000 |81 91|polymeraseT0000 Phar
P07831310A0000 |130 141|protoplastsrubinemia. 
P07831310A0000 |56 74|tobacco etch virus 5-nucleotidase P0
P07831310A0000 |120 126|plants hyper
P07831310A0000 |10 32|complementation system0076 Comparison with a
P07831310A0000 |177 188|TEV mutantshown as a f
P07831310A0000 |76 79|TEV081
P07831310A0000 |93 96|NIbcol
P07831799T0000 |0 19|Nucleotide sequenceP00001606T0076 Comp
P07831799T0000 |79 85|Bombyx71T000
P07831799T0000 |56 75|DNA polymerase gene 5-nucleotidase P00
P07831799T0000 |40 48|analysisphosphat
P07831799T0000 |99 117|polyhedrosis virusc aspects of neona
P07831829A1324 |0 10|ComparisonP00001606T
P07831829A1324 |63 74|furoviruseseotidase P0
P07831829A1324 |46 51|SBWMVatase
P07831829A1324 |29 33|PMTVh al
P07831829A1324 |113 132|genome organizationeonatal hyperbiliru
P07831829A1324 |96 109|heterogeneityogic aspects 
P07831829A1324 |18 25|genomesparison
P07831829A1324 |35 40|BNYVVline 
P07832086A1023 |137 147|fosfomycinia. P00008
P07832086A1023 |54 55|%n
P07832086A1023 |95 99|MINOlogi
P07832086A1023 |149 152|FOM7A0
P07832086A1023 |28 29|%t
P07832086A1023 |60 68|imipenamucleotid
P07832086A1023 |120 123|AMK hy
P07832086A1023 |131 132|%u
P07832086A1023 |78 79|%1
P07832086A1023 |46 49|VCMata
P07832086A1023 |104 105|%e
P07832086A1023 |84 93|minomycin00 Pharma
P07832086A1023 |4 20|drug sensitivity01606T0076 Compa
P07832086A1023 |110 118|amikacinf neonat
P07832086A1023 |70 73|IMPe P
P07832086A1023 |34 44|vancomycinaline phos
P07832779A0719 |0 15|DeglycosylationP00001606T0076 
P07832779A0719 |62 71|receptorsleotidase
P07832779A0719 |96 118|oligosaccharide chainsogic aspects of neonat
P07832779A0719 |21 38|endoglycosidase Hison with alkalin
P07834582A0115 |100 108|property aspects
P07834582A0115 |124 130|humanserbili
P07834582A0115 |45 53|n-3 EFAshatases 
P07834582A0115 |24 32|fish oiln with a
P07834582A0115 |161 173|hypertensionCSF [HCO3-] 
P07834582A0115 |8 18|supplement6T0076 Com
P07834582A0115 |112 119|animalsneonata
P07835088A0238 |155 179|chromosome 1p13.1 region When CSF [HCO3-] is sho
P07835088A0238 |15 27|HSD3B2 genesComparison w
P07835088A0238 |41 46|typeshosph
P07835088A0238 |134 147|hybridizationnemia. P00008
P07835088A0238 |58 77|beta-HSD isoenzymes-nucleotidase P0000
P07835088A0238 |4 10|HSD3B101606T
P07835214A0603 |35 43|diabetesline pho
P07835214A0603 |61 62|%c
P07835214A0603 |14 25|prevalences Comparison
P07835214A0603 |48 51|GDMase
P07835214A0603 |71 72|% 
P07835273A0000 |70 86|insulin receptore P00008171T0000
P07835273A0000 |40 50|adipocytesphosphatas
P07835273A0000 |19 36|glucose transportarison with alkal
P07835273A0411 |34 44|adipocytesaline phos
P07835273A0411 |178 195|3T3-L1 adipocytesown as a function
P07835273A0411 |59 74|EGFR expressionnucleotidase P0
P07835273A0411 |199 208|5000/cellCSF PCO2 
P07835273A0411 |133 137|cellinem
P07835273A0411 |20 30|conversionrison with
P07835273A0411 |6 15|selection606T0076 
P07835273A0411 |101 111|adipocytesaspects of
P07835273A0411 |50 55|leveles an
P07835710T0000 |29 46|porcine I kappa Bh alkaline phosph
P07835710T0000 |62 66|geneleot
P07835710T0000 |12 21|structure76 Compar
P07835826A0195 |0 8|FractionP0000160
P07835826A0195 |57 59|OH5-
P07835826A0195 |28 40|2-vitamin D3th alkaline 
P07835826A0195 |61 71|vitamin D3cleotidase
P07835826A0195 |42 52|vitamin D3osphatases
P07835826A0195 |25 27|OH w
P07835826A0195 |87 99|3-vitamin D3Pharmacologi
P07835826A0195 |84 86|OH00
P07835886A0894 |69 89|chromosome 14q31-q32se P00008171T0000 Ph
P07835886A0894 |128 152|alpha 1-antichymotrypsinlirubinemia. P00008997A0
P07835886A0894 |106 118|serpin genests of neonat
P07835886A0894 |46 59|hybridizationatases and 5-
P07835886A0894 |175 194|alpha 1-antitrypsin shown as a functio
P07835886A0894 |4 20|kallistatin gene01606T0076 Compa
P07835886A0894 |223 231|globulinepleted 
P07835886A0894 |154 173|protein C inhibitor2 When CSF [HCO3-] 
P07835888A0402 |103 121|haplotype analysispects of neonatal 
P07835888A0402 |43 45|Xdsp
P07835888A0402 |72 76|partP000
P07835888A0402 |143 157|backcross mice0008997A0472 W
P07835888A0402 |23 30|XD geneon with
P07835888A0402 |80 96|mouse chromosome1T0000 Pharmacol
P07835888A0402 |4 9|locus01606
P07836218A0128 |16 24|exerciseompariso
P07836218A0128 |41 63|beta-endorphin releasehosphatases and 5-nucl
P07836218A0128 |167 181|beta-endorphinCO3-] is shown
P07836218A0128 |106 114|evidencets of ne
P07836218A0128 |129 137|acidosisirubinem
P07836218A0128 |79 94|exertion levels71T0000 Pharmac
P07836218A0128 |5 12|studies1606T00
P07836218A0128 |156 163|releaseWhen CS
P07836228A1052 |98 102|dropic a
P07836228A1052 |120 128|pressure hyperbi
P07836228A1052 |15 28|communicationComparison wi
P07836228A1052 |57 68|LV function5-nucleotid
P07836228A1052 |43 53|impairmentsphatases 
P07836364A0000 |0 4|SelfP000
P07836364A0000 |105 108|MHCcts
P07836364A0000 |42 50|peptidesosphatas
P07836364A0000 |25 33|proteins with al
P07836364A0000 |77 103|histocompatibility complex8171T0000 Pharmacologic as
P07836364A0000 |146 170|antigen presenting cells8997A0472 When CSF [HCO3
P07836364A0000 |135 142|surfaceemia. P
P07836364A0000 |172 175|APC is
P07836364A0000 |110 115|classf neo
P07836364A0000 |55 67|presentationd 5-nucleoti
P07836364A0000 |118 127|moleculesal hyperb
P07836390A1152 |119 132|IncP plasmidsl hyperbiliru
P07836390A1152 |145 155|initiation08997A0472
P07836390A1152 |104 115|relaxosomesects of neo
P07836390A1152 |4 19|characteristics01606T0076 Comp
P07836390A1152 |159 183|transfer DNA replicationn CSF [HCO3-] is shown a
P07836390A1152 |201 212|conjugationF PCO2 the 
P07836390A1152 |48 65|cleavage reactionases and 5-nucleo
P07836406A0884 |187 201|chromatographyfunction of CS
P07836406A0884 |56 61|MHC-B 5-nu
P07836406A0884 |113 127|phosphopeptideeonatal hyperb
P07836406A0884 |82 93|cdc2 kinase0000 Pharma
P07836406A0884 |168 179|performanceO3-] is sho
P07836406A0884 |32 40|peptideslkaline 
P07836471A0375 |35 36|%l
P07836471A0375 |12 28|protein sequence76 Comparison wi
P07836471A0375 |59 63|hNUCnucl
P07836471A0375 |87 105|osteosarcoma cellsPharmacologic aspe
P07838156A0789 |186 195|repressor function
P07838156A0789 |46 49|RVRata
P07838156A0789 |132 145|reporter genebinemia. P000
P07838156A0789 |9 31|cotransfection studiesT0076 Comparison with 
P07838156A0789 |199 217|ROR alpha functionCSF PCO2 the data 
P07838156A0789 |92 116|hormone response elementacologic aspects of neon
P07838156A0789 |68 81|transcriptionase P00008171
P07840643A1006 |118 126|identityal hyper
P07840643A1006 |193 198|formson of
P07840643A1006 |133 134|%i
P07840643A1006 |73 93|glycosylasparaginase00008171T0000 Pharma
P07840643A1006 |105 106|%c
P07840643A1006 |20 55|Flavobacterium glycosylasparaginaserison with alkaline phosphatases an
P07840643A1006 |143 153|similarity0008997A04
P07840643A1006 |206 212|enzyme2 the 
P07840643A1006 |2 12|comparison0001606T00
P07841230T0000 |17 29|complexationmparison wit
P07841230T0000 |53 67|antimicrobialsand 5-nucleoti
P07841230T0000 |0 12|DissociationP00001606T00
P07841663A0685 |0 20|Superoxide dismutaseP00001606T0076 Compa
P07841663A0685 |177 183|mediumhown a
P07841663A0685 |109 119|comparisonof neonata
P07841663A0685 |63 68|spermeotid
P07841663A0685 |127 134|controlilirubi
P07841663A0685 |27 35|activityith alka
P07841663A0685 |22 25|SODson
P07841663A0685 |142 148|sample000089
P07841663A0845 |139 143|part. P0
P07841663A0845 |90 104|oxygen speciesrmacologic asp
P07841663A0845 |60 71|stimulationucleotidase
P07841663A0845 |174 186|sperm motions shown as a
P07841663A0845 |6 13|studies606T007
P07841663A0845 |191 200|viabilitytion of C
P07841663A0845 |116 128|SOD activityatal hyperbi
P07844142A0640 |119 127|SR alphal hyperb
P07844142A0640 |22 32|sequencingson with a
P07844142A0640 |144 150|member008997
P07844142A0640 |10 17|cloning0076 Co
P07844142A0640 |132 137|SRP54binem
P07844142A0640 |74 81|SR beta0008171
P07844142A0640 |158 176|GTPase superfamilyen CSF [HCO3-] is 
P07844142A0640 |52 59|SR beta and 5-
P07844142A0640 |38 42|cDNAe ph
P07844142A0640 |101 108|proteinaspects
P07844155A0327 |186 195|processes function
P07844155A0327 |78 89|development171T0000 Ph
P07844155A0327 |46 67|tyrosine phosphatasesatases and 5-nucleoti
P07844155A0327 |166 172|systemHCO3-]
P07844155A0327 |18 26|functionparison 
P07844155A0327 |113 125|LAR isoformseonatal hype
P07844155A0327 |223 231|splicingepleted 
P07844155A0327 |207 210|LAR th
P07844201T0000 |0 13|Sex selectionP00001606T007
P07844201T0000 |47 54|resultstases a
P07844201T0000 |38 43|yearse pho
P07844201T0000 |18 33|albumin columnsparison with al
P07844425A0289 |19 24|countariso
P07844425A0289 |53 58|urineand 5
P07844425A0289 |41 51|eggs/10 mlhosphatase
P07844425A0289 |83 92|eggs/10ml000 Pharm
P07844425A0289 |4 12|students01606T00
P07844555A0406 |136 141|birthmia. 
P07844555A0406 |24 34|E mu pim-1n with alk
P07844555A0406 |46 50|miceatas
P07844555A0406 |126 132|M-MuLVbiliru
P07844555A0406 |76 96|lymphoma development08171T0000 Pharmacol
P07845672A0368 |152 162|% identity472 When C
P07845672A0368 |31 44|blk sequencesalkaline phos
P07845672A0368 |142 148|domain000089
P07845672A0368 |73 94|% amino acid identity00008171T0000 Pharmac
P07845672A0368 |115 121|regionnatal 
P07845672A0368 |0 10|ComparisonP00001606T
P07846153A0403 |0 10|ChrispeelsP00001606T
P07846153A0403 |18 24|EMBO Jpariso
P07846163A0422 |17 26|GRF genesmparison 
P07846163A0422 |46 51|exonsatase
P07846163A0422 |72 79|intronsP000081
P07846163A0422 |4 9|mRNAs01606
P07846199A0000 |4 10|effect01606T
P07846199A0000 |14 21|ethanol Compar
P07846199A0000 |31 54|sensorimotor reactivityalkaline phosphatases a
P07846199A0000 |94 110|startle responseologic aspects o
P07846942A0717 |0 20|Digitalis glycosidesP00001606T0076 Compa
P07846942A0717 |73 80|therapy0000817
P07846942A0717 |104 116|fibrillationects of neon
P07846942A0717 |148 153|drugs97A04
P07846942A0717 |89 93|formarma
P07846942A0717 |125 130|classrbili
P07846942A0717 |24 49|beta-receptor antagonistsn with alkaline phosphata
P07846942T0001 |7 19|fibrillation06T0076 Comp
P07846942T0001 |46 52|systematases
P07847036A0353 |18 23|timesparis
P07847036A0353 |74 83|inhibitor0008171T0
P07847036A0353 |8 13|doses6T007
P07847036A0353 |52 65|haemophiliacs and 5-nucleo
P07848358A0254 |19 54|aspartate aminotransferase activityarison with alkaline phosphatases a
P07848358A0254 |88 97|d onwardsharmacolo
P07848358A0254 |77 87|mg/kg b.w.8171T0000 
P07848358A0254 |2 11|reduction0001606T0
P07851643A1365 |101 115|germline cellsaspects of neo
P07851643A1365 |12 19|studies76 Comp
P07851643A1365 |132 154|oocyte differentiationbinemia. P00008997A047
P07851643A1365 |46 53|isoformatases 
P07851643A1365 |77 90|proliferation8171T0000 Pha
P07851758A0330 |54 58|TPK2nd 5
P07851758A0330 |31 45|chromosome XVIalkaline phosp
P07851758A0330 |63 68|spt14eotid
P07851758A0330 |9 27|analysis maps SAL6T0076 Comparison w
P07852037A0548 |18 35|DCT method yieldsparison with alka
P07852037A0548 |45 49|datahata
P07852037A0548 |63 66|TBFeot
P07852361A0868 |0 7|RemovalP000016
P07852361A0868 |11 15|PDMP076 
P07852361A0868 |90 95|cellsrmaco
P07852361A0868 |112 119|S phaseneonata
P07852361A0868 |25 36|cell medium with alkal
P07852361A0868 |65 83|cell cycle changestidase P00008171T0
P07852361A0868 |49 57|reversalses and 
P07852400A0519 |0 30|Rho GDP/GTP exchange inhibitorP00001606T0076 Comparison with
P07852400A0519 |66 70|RhoAidas
P07852400A0519 |57 61|Rac25-nu
P07852400A0519 |80 84|Rac11T00
P07852400A0519 |32 39|Rho GDIlkaline
P07853448A0601 |68 74|naturease P0
P07853448A0601 |92 97|modelacolo
P07853448A0601 |105 120|sport performercts of neonatal
P07853448A0601 |8 12|task6T00
P07853448A0601 |17 34|sports scientistsmparison with alk
P07853476A0159 |0 7|SchnellP000016
P07853476A0159 |9 11|J.T0
P07853488T0000 |17 37|poliovirus repliconsmparison with alkali
P07853488T0000 |66 93|immunodeficiency virus typeidase P00008171T0000 Pharma
P07853488T0000 |179 184|transwn as
P07853488T0000 |158 175|P1 capsid proteinen CSF [HCO3-] is
P07853488T0000 |96 104|gag geneogic asp
P07853488T0000 |116 138|complementation systematal hyperbilirubinemi
P07853488T0000 |0 13|EncapsidationP00001606T007
P07853524A1944 |0 7|RemovalP000016
P07853524A1944 |42 50|thrombinosphatas
P07853524A1944 |31 38|GST-Taxalkalin
P07853524A1944 |60 63|Taxucl
P07853524A1944 |15 25|GST domainComparison
P07853524A1944 |66 73|abilityidase P
P07853524A1944 |127 135|ABSTRACTilirubin
P07853524A1944 |96 125|Tax-CREB-21-bp-repeat complexogic aspects of neonatal hype
P07853524A1944 |153 158|WORDS72 Wh
P07854130A1387 |19 23|PilEaris
P07854130A1387 |120 125|pilus hype
P07854130A1387 |131 149|twitching-motilityubinemia. P0000899
P07854130A1387 |27 43|pilus biogenesisith alkaline pho
P07854130A1387 |92 114|pilE insertion mutantsacologic aspects of ne
P07854130A1387 |4 15|requirement01606T0076 
P07854130T0000 |138 142|typea. P
P07854130T0000 |62 78|pilus biogenesisleotidase P00008
P07854130T0000 |145 162|prepilin proteins08997A0472 When C
P07854130T0000 |125 134|N-terminirbilirubi
P07854130T0000 |80 115|shares amino acid sequence identity1T0000 Pharmacologic aspects of neo
P07854130T0000 |4 21|pilE gene product01606T0076 Compar
P07854324A0281 |163 172|mutationsF [HCO3-]
P07854324A0281 |91 106|vertebrate wee1macologic aspec
P07854324A0281 |75 85|expression008171T000
P07854324A0281 |176 181|yeastshown
P07854324A0281 |26 38|conservationwith alkalin
P07854324A0281 |42 69|cell cycle control elementsosphatases and 5-nucleotida
P07854324A0281 |110 122|mik1 homologf neonatal h
P07854324A0742 |117 134|growth conditionstal hyperbilirubi
P07854324A0742 |23 28|cloneon wi
P07854324A0742 |61 67|causescleoti
P07854324A0742 |4 14|expression01606T0076
P07854324A0742 |81 95|cell phenotypeT0000 Pharmaco
P07856102A1616 |102 116|virus assemblyspects of neon
P07856102A1616 |44 53|M proteinphatases 
P07856102A1616 |75 80|sites00817
P07856102A1616 |25 40|phosphorylation with alkaline 
P07856102A1616 |6 10|data606T
P07857086A0949 |103 110|H Whitepects o
P07857086A0949 |67 88|Non Insulin Dependentdase P00008171T0000 P
P07857086A0949 |24 31|Insulinn with 
P07857086A0949 |60 61|%u
P07857086A0949 |113 118|Classeonat
P07857086A0949 |97 98|Dg
P07857086A0949 |18 19|%p
P07857086A0949 |100 101|F 
P07857163A0551 |16 34|6-fluoroquinolonesomparison with alk
P07857163A0551 |60 71|derivativesucleotidase
P07857163A0551 |4 12|activity01606T00
P07857344A0591 |85 91|change0 Phar
P07857344A0591 |95 128|pidotimod administration schedulelogic aspects of neonatal hyperbi
P07857344A0591 |61 65|datacleo
P07857344A0591 |7 16|half-life06T0076 C
P07857344A0591 |24 32|compoundn with a
P07857344A0591 |142 143|h0
P07857344A0591 |54 55|hn
P07857762A0611 |50 60|eukaryoteses and 5-n
P07857762A0611 |95 104|responseslogic asp
P07857762A0611 |4 22|MAP kinase cascade01606T0076 Compari
P07858986A0310 |171 177|valves] is s
P07858986A0310 |79 85|valves71T000
P07858986A0310 |195 219|glutaraldehyde treatment of CSF PCO2 the data of
P07858986A0310 |121 131|BioImplanthyperbilir
P07858986A0310 |14 19|study Comp
P07858986A0310 |93 115|Carpentier-Edwards SAVcologic aspects of neo
P07858986A0310 |57 64|porcine5-nucle
P07858986A0310 |140 146|Valcor P0000
P07858986A0310 |35 49|interferometryline phosphata
P07859238A1150 |11 23|side effects076 Comparis
P07859301A0325 |137 164|transcription factor familyia. P00008997A0472 When CSF
P07859301A0325 |40 46|domainphosph
P07859301A0325 |79 100|leucine-zipper motifs71T0000 Pharmacologic
P07859301A0325 |5 11|region1606T0
P07859301A0325 |102 110|featuresspects o
P07859371A1246 |69 84|mouse fragmentsse P00008171T00
P07859371A1246 |62 65|ratleo
P07859371A1246 |107 115|extractss of neo
P07859371A1246 |9 16|bindingT0076 C
P07859665A0498 |4 15|mean jitter01606T0076 
P07859665A0498 |72 75|dayP00
P07859665A0498 |24 37|fiber densityn with alkali
P07859665A0498 |123 126|dayper
P07859665A0498 |92 104|microsecondsacologic asp
P07859665A0498 |144 156|microseconds008997A0472 
P07859739T0000 |0 4|LackP000
P07859739T0000 |46 51|cellsatase
P07859739T0000 |73 79|levels000081
P07859739T0000 |8 30|cyclin D-Cdk complexes6T0076 Comparison with
P07859739T0000 |83 126|p16INK4/MTS1 tumour suppressor gene product000 Pharmacologic aspects of neonatal hyper
P07859777A0000 |33 37|rHSAkali
P07859777A0000 |177 191|technetium-99mhown as a func
P07859777A0000 |106 119|microcapsulests of neonata
P07859777A0000 |226 234|chlorideeted rat
P07859777A0000 |134 141|micronsnemia. 
P07859777A0000 |60 72|fermentationucleotidase 
P07859777A0000 |202 211|reduction PCO2 the
P07859777A0000 |145 153|diameter08997A04
P07859777A0000 |98 102|formic a
P07859777A0000 |18 31|serum albuminparison with 
P07860208A0000 |32 50|interleukin-1 betalkaline phosphatas
P07860208A0000 |127 136|monocytesilirubine
P07860208A0000 |92 95|TNFaco
P07860208A0000 |298 306|controlsve a sig
P07860208A0000 |62 90|tumour necrosis factor-alphaleotidase P00008171T0000 Pha
P07860208A0000 |258 276|glomerulonephritisd when compared to
P07860208A0000 |153 171|lipopolysaccharide72 When CSF [HCO3-
P07860208A0000 |21 28|releaseison wi
P07860208A0000 |113 122|monocyteseonatal h
P07860208A0000 |52 56|IL-1 and
P07860208A0000 |173 176|LPSis 
P07860208A0000 |220 228|patientsK-deplet
P07860208A0000 |278 281|AGNont
P07860208A0000 |207 212|blood the 
P07860646A1363 |8 20|intervention6T0076 Compa
P07860646A1363 |56 65|treatment 5-nucleo
P07860646A1363 |44 47|usepha
P07860646A1363 |92 100|diseasesacologic
P07860646A1363 |111 116|FGF-2 neon
P07862092A0302 |175 190|haploid strains shown as a fun
P07862092A0302 |246 255|librariesger displ
P07862092A0302 |125 141|mutation pol3-11rbilirubinemia. 
P07862092A0302 |208 222|pol3-11 sdp5-1the data of K-
P07862092A0302 |259 269|singlecopy when comp
P07862092A0302 |21 26|cloneison 
P07862092A0302 |114 120|sdp5-1onatal
P07862092A0302 |52 63|suppressors and 5-nucl
P07862092A0302 |93 109|mutation pol3-14cologic aspects 
P07862092A0302 |72 82|ts mutantsP00008171T
P07862092A0302 |84 88|sdp100 P
P07862092A0302 |199 203|sdp1CSF 
P07862092A0302 |283 290|vectorsls but 
P07862108A0987 |0 28|UV cross-linking experimentsP00001606T0076 Comparison wi
P07862108A0987 |94 97|kDaolo
P07862108A0987 |39 42|TEP ph
P07862108A0987 |69 73|massse P
P07862129A1391 |157 165|TTR genehen CSF 
P07862129A1391 |122 132|expressionyperbiliru
P07862129A1391 |15 21|liversCompar
P07862129A1391 |106 114|decreasets of ne
P07862129A1391 |46 55|reductionatases an
P07862129A1391 |59 81|HNF-3 alpha expressionnucleotidase P00008171
P07862129A1391 |140 151|target gene P00008997A
P07862141A0317 |32 39|alleleslkaline
P07862141A0317 |107 122|differentiations of neonatal h
P07862141A0317 |62 71|cAPK leadleotidase
P07862141A0317 |79 88|inability71T0000 P
P07862141A0317 |43 48|genessphat
P07862141A1412 |19 25|familyarison
P07862141A1412 |27 31|RFX1ith 
P07862141A1412 |65 72|varietytidase 
P07862141A1412 |95 100|geneslogic
P07862141A1412 |4 10|member01606T
P07862141A1412 |38 58|transcription factore phosphatases and 5
P07862150A0429 |85 94|mink lung0 Pharmac
P07862150A0429 |226 234|TGF-betaeted rat
P07862150A0429 |135 160|TGF-beta binding activityemia. P00008997A0472 When
P07862150A0429 |75 81|series008171
P07862150A0429 |213 222|responsesata of K-
P07862150A0429 |106 117|cell clonests of neona
P07862150A0429 |66 72|vectoridase 
P07862150A0429 |5 11|mutant1606T0
P07862154A0340 |0 7|CloningP000016
P07862154A0340 |63 71|analysiseotidase
P07862154A0340 |11 26|complementation076 Comparison 
P07862154A0340 |97 101|RAF1gic 
P07862162A0408 |32 39|cholinelkaline
P07862162A0408 |123 137|UASINO elementperbilirubinem
P07862162A0408 |73 82|OPI1 gene00008171T
P07862162A0408 |93 106|transcriptioncologic aspec
P07862162A0408 |58 65|product-nucleo
P07862162A0408 |7 15|presence06T0076 
P07862162A0408 |19 27|inositolarison w
P07862165A0184 |34 50|oligonucleotidesaline phosphatas
P07862165A0184 |195 210|helix formation of CSF PCO2 th
P07862165A0184 |61 69|psoralencleotida
P07862165A0184 |164 169|cells [HCO
P07862165A0184 |120 125|virus hype
P07862165A0184 |130 134|SV40rubi
P07862165A0184 |12 28|monkey COS cells76 Comparison wi
P07862165A0184 |98 107|mutationsic aspect
P07862165A0184 |136 142|vectormia. P
P07862168A0000 |18 38|receptor alpha-chainparison with alkalin
P07862168A0000 |40 51|IL-2R alphaphosphatase
P07862168A0000 |104 112|responseects of 
P07862168A0000 |93 100|T cellscologic
P07862168A0000 |126 133|stimulibilirub
P07862168A0000 |53 57|geneand 
P07862168A0000 |4 15|interleukin01606T0076 
P07862533A0000 |205 210|EGR-1O2 th
P07862533A0000 |38 41|WT1e p
P07862533A0000 |4 9|Wilms01606
P07862533A0000 |212 219|proteindata of
P07862533A0000 |11 36|tumour suppressor protein076 Comparison with alkal
P07862533A0000 |84 91|protein00 Phar
P07862533A0000 |155 172|sequence homology When CSF [HCO3-]
P07862533A0000 |102 114|zinc fingersspects of ne
P07862533A0000 |186 203|growth response-1 function of CSF 
P07863047A0229 |171 182|correlation] is shown 
P07863047A0229 |191 194|ACEtio
P07863047A0229 |244 253|parameteronger dis
P07863047A0229 |132 136|CAOTbine
P07863047A0229 |28 46|serum ACE activityth alkaline phosph
P07863047A0229 |116 130|oxygen therapyatal hyperbili
P07863047A0229 |64 68|COPDotid
P07863047A0229 |50 58|patientses and 5
P07863047A0229 |0 10|OBJECTIVESP00001606T
P07863619A0098 |170 177|objects-] is s
P07863619A0098 |124 130|objecterbili
P07863619A0098 |89 98|fragmentsarmacolog
P07863619A0098 |29 36|contourh alkal
P07863619A0098 |55 61|systemd 5-nu
P07863619A0098 |145 154|fragments08997A047
P07863619A0098 |3 8|order00160
P07863619A0098 |18 23|shapeparis
P07863992A0908 |85 93|evidence0 Pharma
P07863992A0908 |41 47|resulthospha
P07863992A0908 |123 137|mean follow-upperbilirubinem
P07863992A0908 |172 180|episodes is show
P07863992A0908 |142 147|years00008
P07863992A0908 |8 13|group6T007
P07863992A0908 |213 223|medicationata of K-d
P07863992A0908 |108 121|heart disease of neonatal 
P07863992A0908 |70 77|testinge P0000
P07863992A0908 |260 268|exercisewhen com
P07863992A0908 |184 191|syncope a func
P07863992A0908 |16 24|patientsompariso
P07864652A0753 |0 10|ConstructsP00001606T
P07864652A0753 |160 179|amino acid sequence CSF [HCO3-] is sho
P07864652A0753 |51 55|E2L1s an
P07864652A0753 |87 89|L2Ph
P07864652A0753 |188 196|portionsunction 
P07864652A0753 |82 86|E2H10000
P07864652A0753 |56 58|H1 5
P07864652A0753 |39 43|E2L1 pho
P07864652A0753 |67 71|E2L2dase
P07864652A0753 |111 113|L2 n
P07864652A0753 |128 135|numberslirubin
P07864652A0753 |108 110|H1 o
P07864652A0753 |237 246|constructre no lon
P07864652A0753 |139 150|parentheses. P00008997
P07864652A0753 |103 107|E2L1pect
P07864652A0753 |204 216|E2 componentCO2 the data
P07864652A1901 |102 106|E2L1spec
P07864652A1901 |111 115|E2L2 neo
P07864652A1901 |30 47|domain constructs alkaline phospha
P07864652A1901 |93 98|rolescolog
P07864652A1901 |157 166|processeshen CSF [
P07864709A0324 |0 7|METHODSP000016
P07864709A0324 |144 162|enzyme immunoassay008997A0472 When C
P07864709A0324 |26 30|H3N2with
P07864709A0324 |88 98|resistanceharmacolog
P07864709A0324 |60 69|outbreaksucleotida
P07864709A0324 |202 206|acid PCO
P07864709A0324 |13 24|influenza A6 Compariso
P07864709A0324 |132 137|meansbinem
P07864709A0324 |252 262|M2 proteinsplaced wh
P07864709A0324 |117 128|rimantadinetal hyperbi
P07864709A0324 |238 244|domaine no l
P07864709A0324 |32 39|viruseslkaline
P07864709A0324 |170 180|sequencing-] is show
P07864709A0324 |102 112|amantadinespects of 
P07865129A0293 |19 26|ATF/CREarison 
P07865129A0293 |31 55|TBP/TATA sequence motifsalkaline phosphatases an
P07865129A0293 |72 78|regionP00008
P07865786A0457 |0 15|Gene expressionP00001606T0076 
P07865786A0457 |92 98|plantsacolog
P07865786A0457 |60 65|lightucleo
P07865786A0457 |38 44|rhythme phos
P07865786A0457 |69 75|leavesse P00
P07865787A1086 |86 87|s 
P07865787A1086 |47 61|octamer motifstases and 5-nu
P07865787A1086 |31 38|hexameralkalin
P07865787A1086 |181 202|wheat histone H3 gene as a function of CSF
P07865787A1086 |163 173|expressionF [HCO3-] 
P07865787A1086 |92 102|regulationacologic a
P07865787A1086 |4 11|results01606T0
P07865787A1086 |81 85|roleT000
P07865876A1292 |152 161|phenotype472 When 
P07865876A1292 |20 30|expressionrison with
P07865876A1292 |121 130|DRTF1/E2Fhyperbili
P07865876A1292 |169 173|cell3-] 
P07865876A1292 |70 81|combinatione P00008171
P07865876A1292 |34 51|DP family membersaline phosphatase
P07865876A1292 |85 104|DP/E2F heterodimers0 Pharmacologic asp
P07865888A1309 |82 90|membrane0000 Pha
P07865888A1309 |123 135|mitochondriaperbilirubin
P07865888A1309 |24 35|cells PBP74n with alka
P07865888A1309 |56 67|pre-protein 5-nucleoti
P07865888A1309 |111 117|import neona
P07865888A1309 |144 154|maturation008997A047
P07865895A0896 |136 145|rationalemia. P000
P07865895A0896 |12 22|experiment76 Compari
P07865895A0896 |226 231|eventeted 
P07865895A0896 |150 162|LGL/NK cellsA0472 When C
P07865895A0896 |104 116|LGL/NK cellsects of neon
P07865895A0896 |75 78|mAb008
P07865895A0896 |212 219|absencedata of
P07865895A0896 |41 61|lung clearance assayhosphatases and 5-nu
P07865895A0896 |96 100|ratsogic
P07865895A0896 |191 196|eventtion 
P07865917A0191 |137 144|resultsia. P00
P07865917A0191 |23 27|FSGSon w
P07865917A0191 |111 125|ACE inhibitors neonatal hype
P07865917A0191 |91 105|plasmapheresismacologic aspe
P07865917A0191 |0 9|TreatmentP00001606
P07865917A0191 |71 83|cyclosporine P00008171T0
P07865917A0191 |51 59|steroidss and 5-
P07865917A0191 |85 88|CSA0 P
P07867604A1777 |255 259|cAMPaced
P07867604A1777 |267 281|phorbol estersmpared to cont
P07867604A1777 |228 237|promotersed rats a
P07867604A1777 |133 142|promotersinemia. P
P07867604A1777 |107 123|initiation sitess of neonatal hy
P07867604A1777 |194 202|elementsn of CSF
P07867604A1777 |38 58|inhibin/activin betae phosphatases and 5
P07867604A1777 |4 11|results01606T0
P07867604A1777 |292 302|conditionsill have a
P07867604A1777 |69 74|mRNAsse P0
P07867622X0000 |186 193|protein functi
P07867622X0000 |198 204|p21rac CSF P
P07867622X0000 |109 116|proteinof neon
P07867622X0000 |242 248|events longe
P07867622X0000 |208 215|proteinthe dat
P07867622X0000 |121 127|p21rachyperb
P07867622X0000 |39 43|unit pho
P07867622X0000 |129 146|alpha 1-chimaerinirubinemia. P0000
P07867622X0000 |54 71|alpha 1-chimaerinnd 5-nucleotidase
P07867622X0000 |0 15|Promoter regionP00001606T0076 
P07867944A0365 |0 8|UpstreamP0000160
P07867944A0365 |151 160|promoters0472 When
P07867944A0365 |45 48|tsphat
P07867944A0365 |53 72|nucleotide sequenceand 5-nucleotidase 
P07867944A0365 |131 136|sigmaubine
P07867944A0365 |98 122|consensus sequence motific aspects of neonatal h
P07867944A0365 |18 43|transcription start pointparison with alkaline pho
P07869721A0000 |34 42|dynamicsaline ph
P07869721A0000 |108 130|heart valve prosthesis of neonatal hyperbili
P07869721A0000 |18 26|analysisparison 
P07869721A0000 |8 13|paper6T007
P07869721A0000 |71 79|occluder P000081
P07869721A0000 |50 63|closing phasees and 5-nucl
P07869913A1076 |100 114|control values aspects of ne
P07869913A1076 |133 141|subjectsinemia. 
P07869913A1076 |7 22|ISO+AT infusion06T0076 Compari
P07869913A1076 |38 48|blood flowe phosphat
P07869937A1142 |102 105|RMRspe
P07869937A1142 |144 145|%0
P07869937A1142 |162 169|P groupSF [HCO
P07869937A1142 |126 134|decreasebilirubi
P07869937A1142 |94 95|%o
P07869937A1142 |46 49|GITata
P07869937A1142 |19 39|kilogram body weightarison with alkaline
P07869937A1142 |67 75|dF groupdase P00
P07869937A1142 |153 154|%7
P07869937A1142 |85 86|%0
P07870305A1015 |222 243|haloperidol influencedepleted rats are no 
P07870305A1015 |112 136|nucleus entopeduncularisneonatal hyperbilirubine
P07870305A1015 |198 200|ms C
P07870305A1015 |30 81|thalami-nucleus ventralis lateralis thalami neurons alkaline phosphatases and 5-nucleotidase P00008171
P07870305A1015 |3 20|nucleus ventralis001606T0076 Compa
P07870305A1015 |202 203|P 
P07870305A1015 |101 106|inputaspec
P07870305A1015 |154 164|inhibition2 When CSF
P07871718A1132 |87 105|factors GABP alphaPharmacologic aspe
P07871718A1132 |61 74|ICP4 promotercleotidase P0
P07871718A1132 |9 18|inclusionT0076 Com
P07871718A1132 |148 158|activation97A0472 Wh
P07871718A1132 |110 114|betaf ne
P07871718A1132 |38 51|CGGAAR motifse phosphatase
P07871721A0000 |136 139|kDamia
P07871721A0000 |121 128|proteinhyperbi
P07871721A0000 |15 28|reading frameComparison wi
P07871721A0000 |72 78|genomeP00008
P07871721A0000 |46 63|scorch carlavirusatases and 5-nucl
P07871721A0000 |65 70|BBScVtidas
P07871721A0000 |141 145|p223P000
P07871721A0392 |55 62|virusesd 5-nuc
P07871721A0392 |134 151|proteinase domainnemia. P00008997A
P07871721A0392 |105 109|p223cts 
P07871721A0392 |74 85|tymoviruses0008171T000
P07871721A0392 |194 207|histidine1075n of CSF PCO2
P07871721A0392 |178 189|cysteine994own as a fu
P07871721A0392 |5 24|sequence alignments1606T0076 Compariso
P07871754A0857 |5 12|finding1606T00
P07871754A0857 |72 91|HPV gene expressionP00008171T0000 Phar
P07871754A0857 |128 133|modellirub
P07871754A0857 |167 180|cooperativityCO3-] is show
P07871754A0857 |142 147|study00008
P07871754A0857 |53 62|mechanismand 5-nuc
P07871755A0521 |19 23|VLPsaris
P07871755A0521 |75 91|characterization008171T0000 Phar
P07871755A0521 |11 17|method076 Co
P07871755A0521 |41 51|quantitieshosphatase
P07871757A0846 |85 102|promotor sequence0 Pharmacologic a
P07871757A0846 |71 79|presence P000081
P07871757A0846 |42 58|initiation codonosphatases and 5
P07871757A0846 |16 24|sequenceompariso
P07871757A0846 |0 8|AnalysisP0000160
P07871891A0227 |0 5|SUP46P0000
P07871891A0227 |23 43|translation fidelityon with alkaline pho
P07871891A0227 |70 81|protein S13e P00008171
P07872673A0332 |156 177|SV40 promoter complexWhen CSF [HCO3-] is s
P07872673A0332 |47 52|c-fostases
P07872673A0332 |74 92|expression plasmid0008171T0000 Pharm
P07872673A0332 |124 134|c-fos geneerbilirubi
P07872673A0332 |26 38|relationshipwith alkalin
P07872673A0332 |57 59|Rb5-
P07872673A0332 |141 148|controlP000089
P07872788A1717 |186 197|duplication function o
P07872788A1717 |132 137|genesbinem
P07872788A1717 |202 212|divergence PCO2 the 
P07872788A1717 |67 68|Cd
P07872788A1717 |9 15|degreeT0076 
P07872788A1717 |40 41|%p
P07872788A1717 |106 112|regionts of 
P07872788A1717 |235 239|gene are
P07872788A1717 |157 174|carboxylesteraseshen CSF [HCO3-] i
P07872788A1717 |19 36|sequence identityarison with alkal
P07872788A1717 |51 62|hydrolase Bs and 5-nuc
P07873631A0114 |19 33|tooth fracturearison with al
P07873631A0114 |4 11|regions01606T0
P07873831T0000 |21 32|involvementison with a
P07873831T0000 |88 92|massharm
P07873831T0000 |36 53|mycosis fungoidesine phosphatases 
P07873876A1035 |184 190|region a fun
P07873876A1035 |57 63|probes5-nucl
P07873876A1035 |72 78|regionP00008
P07873876A1035 |29 33|toolh al
P07873876A1035 |121 127|probeshyperb
P07873876A1035 |42 49|mappingosphata
P07873876A1035 |145 153|deletion08997A04
P07873876A1035 |4 14|NR2 hybrid01606T0076
P07873876A1035 |169 176|cloning3-] is 
P07874060A0810 |0 5|TDEYAP0000
P07874060A0810 |29 34|mg/kgh alk
P07874060A0810 |132 146|administrationbinemia. P0000
P07874060A0810 |60 76|xanthine oxidaseucleotidase P000
P07874060A0810 |9 14|dosesT0076
P07874060A0810 |78 80|XO17
P07874060A0810 |82 90|activity0000 Pha
P07874060A0810 |98 112|stomach tissueic aspects of 
P07875595A0910 |17 33|PITSLRE PK genesmparison with al
P07875595A0910 |37 45|chickensne phosp
P07875595A0910 |160 183|chicken microchromosome CSF [HCO3-] is shown a
P07875595A0910 |120 132|localization hyperbiliru
P07875595A0910 |5 11|humans1606T0
P07875595A0910 |142 147|genes00008
P07875595A0910 |99 112|hybridizationc aspects of 
P07875595A0910 |114 118|FISHonat
P07876134A0348 |138 151|reading framea. P00008997A
P07876134A0348 |75 83|AFAP-110008171T0
P07876134A0348 |67 71|formdase
P07876134A0348 |126 128|bpbi
P07876134A0348 |20 36|characterizationrison with alkal
P07876134A0348 |115 124|base pairnatal hyp
P07876191A0808 |0 10|ExpressionP00001606T
P07876191A0808 |23 31|ADH mRNAon with 
P07876191A0808 |14 19|class Comp
P07876191A0808 |54 61|stomachnd 5-nu
P07876191A0808 |70 75|livere P00
P07876192A0443 |3 12|ICE gamma001606T00
P07876192A0443 |124 142|ICE autoprocessingerbilirubinemia. P
P07876192A0443 |26 36|propeptidewith alkal
P07876192A0443 |111 119|catalyst neonata
P07876192A0443 |38 49|amino acidse phosphata
P07876194T0000 |0 11|EndocytosisP00001606T0
P07876194T0000 |127 149|tyrosine kinase domainilirubinemia. P0000899
P07876194T0000 |26 35|targetingwith alka
P07876194T0000 |98 107|sequencesic aspect
P07876194T0000 |49 72|growth factor receptorsses and 5-nucleotidase 
P07876210A0275 |170 188|Barbie box element-] is shown as a f
P07876210A0275 |149 157|proteins7A0472 W
P07876210A0275 |93 100|regionscologic
P07876210A0275 |69 74|genesse P0
P07876210A0751 |0 8|MutationP0000160
P07876210A0751 |269 275|levelsared t
P07876210A0751 |83 91|P450BM-3000 Phar
P07876210A0751 |202 209|protein PCO2 t
P07876210A0751 |214 222|responseta of K-
P07876210A0751 |146 159|P450BM-3 gene8997A0472 Whe
P07876210A0751 |240 249|inductionno longer
P07876210A0751 |64 74|expressionotidase P0
P07876210A0751 |96 101|Bm3P1ogic 
P07876210A0751 |117 121|genetal 
P07876210A0751 |16 35|P450BM-3 Barbie boxomparison with alka
P07876300A0994 |17 23|nucleimparis
P07876300A0994 |63 77|protein importeotidase P0000
P07876562A1646 |100 107|T cells aspect
P07876562A1646 |121 132|stimulationhyperbiliru
P07876562A1646 |149 164|HIV-1 infection7A0472 When CSF
P07876562A1646 |73 87|responsiveness00008171T0000 
P07876562A1646 |12 19|outcome76 Comp
P07876562A1646 |41 48|effectshosphat
P07877308A1175 |50 51|%e
P07877308A1175 |9 17|protocolT0076 Co
P07877308A1175 |38 46|patientse phosph
P07877308A1175 |64 70|cohortotidas
P07877619A1284 |119 148|base pair nucleotide sequencel hyperbilirubinemia. P000089
P07877619A1284 |41 52|suppressionhosphatases
P07877619A1284 |3 11|addition001606T0
P07877619A1284 |190 196|regionction 
P07877619A1284 |70 92|zif268 gene expressione P00008171T0000 Pharm
P07877619A1284 |204 215|zif268 geneCO2 the dat
P07878029A0721 |64 83|CBF-A-CBF-C complexotidase P00008171T0
P07878029A0721 |122 127|CBF-Ayperb
P07878029A0721 |13 18|CBF-A6 Com
P07878029A0721 |131 136|CBF-Cubine
P07878029A0721 |182 201|CBF-A-CBF-C complexas a function of CS
P07878029A0721 |93 98|CBF-Bcolog
P07878029A0721 |23 28|CBF-Con wi
P07878040A0505 |102 106|lossspec
P07878040A0505 |25 34|sequences with alk
P07878040A0505 |146 150|mice8997
P07878040A0505 |110 118|activityf neonat
P07878040A0505 |55 69|mouse enhancerd 5-nucleotida
P07879204T0000 |0 16|OKT3 prophylaxisP00001606T0076 C
P07879204T0000 |94 106|cyclosporineologic aspec
P07879204T0000 |70 78|patientse P00008
P07879204T0000 |42 56|graft survivalosphatases and
P07879204T0000 |117 124|resultstal hyp
P07879204T0000 |170 180|US studies-] is show
P07880442A0236 |67 83|primer extensiondase P00008171T0
P07880442A0236 |88 110|S1 nuclease protectionharmacologic aspects o
P07880442A0236 |10 48|PKC beta transcription initiation site0076 Comparison with alkaline phosphat
P07880449A0091 |184 194|cGy X-rays a functio
P07880449A0091 |111 122|suppression neonatal h
P07880449A0091 |72 75|ICRP00
P07880449A0091 |88 92|miceharm
P07880449A0091 |135 143|behavioremia. P0
P07880449A0091 |156 172|body irradiationWhen CSF [HCO3-]
P07880449A0091 |7 13|course06T007
P07880449A0091 |19 24|studyariso
P07880449A0091 |32 51|dose X-rays effectslkaline phosphatase
P07880650A0493 |84 97|electron dose00 Pharmacolo
P07880650A0493 |56 64|function 5-nucle
P07880650A0493 |31 52|diffraction intensityalkaline phosphatases
P07880650A0493 |15 23|analysisComparis
P07880650A0493 |111 122|possibility neonatal h
P07880650A0493 |146 166|diffraction patterns8997A0472 When CSF [
P07880650A0493 |178 188|resolutionown as a f
P07880650A0493 |203 227|crotoxin complex crystalPCO2 the data of K-deple
P07881077A0195 |0 33|Supplementary Phase Contraste RSEP00001606T0076 Comparison with al
P07881077A0195 |53 63|Excitationand 5-nucl
P07881077A0195 |66 75|sequencesidase P00
P07881077A0195 |99 107|patientsc aspect
P07883167A0157 |3 8|yeast00160
P07883167A0157 |30 34|UPF1 alk
P07883167A0157 |199 204|decayCSF P
P07883167A0157 |228 233|mRNAsed ra
P07883167A0157 |72 85|decay pathwayP00008171T000
P07883167A0157 |122 136|identificationyperbilirubine
P07883167A0157 |14 22|products Compari
P07883167A0157 |39 49|UPF3 genes phosphata
P07883167A0157 |172 179|factors is sho
P07883167A0157 |99 105|reportc aspe
P07883167A0157 |141 157|characterizationP00008997A0472 W
P07883168A0090 |0 9|MutationsP00001606
P07883168A0090 |13 22|UPF1 lead6 Compari
P07883168A0090 |121 132|decay rateshyperbiliru
P07883168A0090 |40 53|stabilizationphosphatases 
P07883168A0090 |147 152|mRNAs997A0
P07883168A0090 |57 62|mRNAs5-nuc
P07883168A0090 |80 98|nonsense mutations1T0000 Pharmacolog
P07883193A0000 |207 232|glutathione S-transferase the data of K-depleted r
P07883193A0000 |110 119|regulatorf neonata
P07883193A0000 |40 46|domainphosph
P07883193A0000 |193 197|geneon o
P07883193A0000 |140 154|pGEX-KT vector P00008997A047
P07883193A0000 |172 177|frame is s
P07883193A0000 |48 59|amino acidsases and 5-
P07883193A0000 |2 14|DNA fragment0001606T0076
P07883754A0993 |34 39|HepG2aline
P07883754A0993 |77 85|presence8171T000
P07883754A0993 |6 28|gel retardation assays606T0076 Comparison wi
P07883754A0993 |127 139|NRE fragmentilirubinemia
P07883754A0993 |48 55|extractases an
P07883754A0993 |100 107|protein aspect
P07885999A0000 |16 23|factorsomparis
P07885999A0000 |72 78|regionP00008
P07885999A0000 |43 52|sequencessphatases
P07885999A0000 |130 140|band shiftrubinemia.
P07885999A0000 |145 176|methylation interference assays08997A0472 When CSF [HCO3-] is 
P07885999A0000 |86 107|mouse tyrosinase gene Pharmacologic aspect
P07886610A0000 |103 113|prevalencepects of n
P07886610A0000 |56 64|patients 5-nucle
P07886610A0000 |7 17|population06T0076 Co
P07886610A0000 |127 137|populationilirubinem
P07886610A0000 |86 91|India Phar
P07886610A0000 |70 82|hemophilia Ae P00008171T
P07887226A0858 |69 101|serum transferrin receptor assayse P00008171T0000 Pharmacologic 
P07887226A0858 |262 268|anemiaen com
P07887226A0858 |38 63|hemoglobin determinationse phosphatases and 5-nucl
P07887226A0858 |249 252|IDA di
P07887226A0858 |142 149|surveys0000899
P07887226A0858 |280 287|diseasetrols b
P07887226A0858 |185 192|measurea funct
P07887226A0858 |116 124|additionatal hyp
P07887226A0858 |19 33|serum ferritinarison with al
P07887226A0858 |207 222|iron deficiency the data of K-
P07887859A0315 |23 31|patientson with 
P07887859A0315 |120 123|TBI hy
P07887859A0315 |125 132|indicesrbiliru
P07887859A0315 |47 53|ulcerstases 
P07887859A0315 |58 63|tcPO2-nucl
P07887859A0315 |97 100|ABIgic
P07887859A0998 |0 17|TcPO2 measurementP00001606T0076 Co
P07887859A0998 |43 52|techniquesphatases
P07887859A0998 |82 98|ulcer management0000 Pharmacolog
P07888156A0169 |139 145|access. P000
P07888156A0169 |15 34|University HospitalComparison with alk
P07888156A0169 |114 129|section serviceonatal hyperbil
P07888156A0169 |218 228|discussionf K-deplet
P07888156A0169 |249 255|issues displ
P07888156A0169 |197 205|findingsf CSF PC
P07888156A0169 |149 166|video conferences7A0472 When CSF [
P07888156A0169 |64 73|hospitalsotidase P
P07888156A0169 |38 44|Tromsoe phos
P07888156A0169 |175 181|review shown
P07888156A0169 |86 92|Norway Pharm
P07888156T0000 |18 31|telepathologyparison with 
P07888156T0000 |8 14|status6T0076
P07888306A1659 |0 10|ExpressionP00001606T
P07888306A1659 |223 237|concentrationsepleted rats a
P07888306A1659 |251 259|ABSTRACTisplaced
P07888306A1659 |22 33|COS-1 cellsson with al
P07888306A1659 |112 116|cGMPneon
P07888306A1659 |146 154|activity8997A047
P07888306A1659 |241 249|rolipramo longer
P07888306A1659 |181 184|Ca2 as
P07888306A1659 |128 137|substratelirubinem
P07888306A1659 |193 197|cGMPon o
P07888306A1659 |14 18|h6.1 Com
P07888306A1659 |45 55|productionhatases an
P07888306A1659 |186 189|CaM fu
P07888306A1659 |277 282|WORDScontr
P07888306A1659 |77 89|PDE activity8171T0000 Ph
P07888306A1659 |98 102|cAMPic a
P07888306A1659 |69 73|typese P
P07888623A0721 |0 14|PMEK1 displaysP00001606T0076
P07888623A0721 |57 69|tobacco NTF35-nucleotida
P07888623A0721 |74 100|Arabidopsis ATMPK1 kinases0008171T0000 Pharmacologic
P07888623A0721 |145 168|plant MAP kinase MsERK108997A0472 When CSF [HC
P07888623A0721 |24 34|% identityn with alk
P07888623A0721 |113 114|%e
P07888623A0721 |174 181|alfalfas shown
P07888629A0344 |0 11|TranslationP00001606T0
P07888629A0344 |147 162|signal sequence997A0472 When C
P07888629A0344 |56 62|MsPRP2 5-nuc
P07888629A0344 |26 33|segmentwith al
P07888629A0344 |273 296|lipid transfer proteins to controls but still 
P07888629A0344 |190 198|sequencection of
P07888629A0344 |103 123|Da cell wall proteinpects of neonatal hy
P07888629A0344 |238 246|sequencee no lon
P07888788A1010 |205 218|aspergillomasO2 the data o
P07888788A1010 |4 12|presence01606T00
P07888788A1010 |173 181|responseis shown
P07888788A1010 |23 39|hypersensitivityon with alkaline
P07888788A1010 |57 70|aspergillomas5-nucleotidas
P07888788A1010 |45 53|subgrouphatases 
P07888788A1010 |116 123|diseaseatal hy
P07888788A1010 |98 107|componentic aspect
P07888788A1010 |185 196|Aspergillusa function 
P07888788A1010 |16 20|typeompa
P07888828A0765 |33 47|identificationkaline phospha
P07888828A0765 |78 86|primates171T0000
P07888828A0765 |59 64|genesnucle
P07888828A0765 |5 12|concept1606T00
P07890485A0827 |171 176|g.min] is 
P07890485A0827 |41 54|photoreceptorhosphatases a
P07890485A0827 |12 24|illumination76 Compariso
P07890485A0827 |122 125|QO2ype
P07890485A0827 |181 185|cats as 
P07890485A0827 |160 162|ml C
P07890485A0827 |56 59|QO2 5-
P07890485A0827 |96 101|g.minogic 
P07890485A0827 |85 87|ml0 
P07890599A0132 |168 180|acid proteinO3-] is show
P07890599A0132 |226 232|n-Sec1eted r
P07890599A0132 |241 269|Caenorhabditis elegans unc18o longer displaced when comp
P07890599A0132 |202 212|% identity PCO2 the 
P07890599A0132 |142 146|cDNA0000
P07890599A0132 |112 119|isoformneonata
P07890599A0132 |300 305|Sec1p a si
P07890599A0132 |46 60|MIN6 cell lineatases and 5-n
P07890599A0132 |233 239|rbSec1ts are
P07890599A0132 |218 225|munc-18f K-dep
P07890599A0132 |21 39|mouse cDNA libraryison with alkaline
P07890599A0132 |86 96|beta cells Pharmacol
P07890674A0916 |155 163|catenins When CS
P07890674A0916 |144 151|absence008997A
P07890674A0916 |29 39|E-cadherinh alkaline
P07890674A0916 |132 140|presencebinemia.
P07890674A0916 |74 84|E-cadherin0008171T00
P07890674A0916 |66 69|APCida
P07890674A0916 |53 60|fashionand 5-n
P07890674A0916 |4 12|catenins01606T00
P07890674A0916 |21 24|APCiso
P07890680A1193 |152 167|primer terminus472 When CSF [H
P07890680A1193 |9 17|additionT0076 Co
P07890680A1193 |130 135|gammarubin
P07890680A1193 |62 69|complexleotida
P07890680A1193 |21 40|core DNA polymeraseison with alkaline 
P07890680A1193 |92 102|holoenzymeacologic a
P07890680A1193 |115 126|replacementnatal hyper
P07890680A1193 |139 144|alpha. P00
P07890740A0997 |4 13|PSD2 gene01606T007
P07890740A0997 |46 55|infectionatases an
P07890740A0997 |130 138|increaserubinemi
P07890740A0997 |94 105|baculovirusologic aspe
P07890740A0997 |59 76|Sf-9 insect cellsnucleotidase P000
P07890740A0997 |142 154|PSD activity00008997A047
P07891638T0000 |35 44|asymmetryline phos
P07891638T0000 |13 22|detection6 Compari
P07891638T0000 |56 73|chest radiographs 5-nucleotidase P
P07891685A1051 |68 75|bindingase P00
P07891685A1051 |79 84|Cat8p71T00
P07891685A1051 |41 46|geneshosph
P07891685A1051 |135 140|Mig1pemia.
P07891685A1051 |151 164|CAT8 promoter0472 When CSF
P07891685A1051 |128 133|Cat4plirub
P07891685A1051 |92 101|synthesisacologic 
P07891685A1051 |6 13|results606T007
P07891685A1051 |117 124|releasetal hyp
P07891708A0690 |51 62|Hep3B cellss and 5-nuc
P07891708A0690 |74 84|HeLa cells0008171T00
P07891708A0690 |40 45|liverphosp
P07891708A0690 |10 15|HNF-40076 
P07891708A0690 |5 8|Epo160
P07891708A0690 |32 38|kidneylkalin
P07891708A1192 |99 110|Hep3B cellsc aspects o
P07891708A1192 |30 40|expression alkaline 
P07891708A1192 |135 149|HNF-4 delta C.emia. P0000899
P07891708A1192 |59 67|Epo genenucleoti
P07891709A1542 |86 96|transcript Pharmacol
P07891709A1542 |123 136|deadenylationperbilirubine
P07891709A1542 |52 62|mechanisms and 5-nuc
P07891709A1542 |6 18|observations606T0076 Com
P07891713T0000 |70 80|repressorse P0000817
P07891713T0000 |88 114|NF-E2 transcription factorharmacologic aspects of ne
P07891713T0000 |6 18|Maf proteins606T0076 Com
P07891713T0000 |39 42|Fos ph
P07891720A0818 |33 36|C1Fkal
P07891720A0818 |22 29|bindingson wit
P07891720A0818 |66 79|concentrationidase P000081
P07891720A0818 |83 95|calcium ions000 Pharmaco
P07892076A0578 |0 8|SurvivalP0000160
P07892076A0578 |42 51|infectionosphatase
P07892076A0578 |15 26|developmentComparison 
P07892076A0578 |76 93|transmission mode08171T0000 Pharma
P07892076A0578 |53 56|P-2and
P07892353A0667 |86 92|cortex Pharm
P07892353A0667 |163 171|patternsF [HCO3-
P07892353A0667 |111 117|cortex neona
P07892353A0667 |56 60|rCBF 5-n
P07892353A0667 |133 139|factorinemia
P07892353A0667 |5 12|factors1606T00
P07892353A0667 |203 216|brain regionsPCO2 the data
P07892353A0667 |38 50|correlationse phosphatas
P07892353A0667 |175 187|correlations shown as a 
P07894021A1130 |85 88|DNA0 P
P07894021A1130 |44 47|DS2pha
P07894021A1130 |94 105|desiccationologic aspe
P07894021A1130 |28 36|functionth alkal
P07894021A1130 |59 69|protectionnucleotida
P07894021A1130 |6 10|data606T
P07894359T0000 |51 53|RUs 
P07894359T0000 |62 68|sepsisleotid
P07894359T0000 |31 39|abortionalkaline
P07894359T0000 |72 76|ratsP000
P07894359T0000 |11 23|hemodynamics076 Comparis
P07894761A0000 |100 110|hemorrhage aspects o
P07894761A0000 |198 205|surgery CSF PC
P07894761A0000 |147 153|vision997A04
P07894761A0000 |30 35|study alka
P07894761A0000 |112 115|ECHneo
P07894761A0000 |128 135|successlirubin
P07894761A0000 |4 7|aim016
P07894761A0000 |71 76|cases P000
P07896088A0720 |118 130|rap1 allelesal hyperbili
P07896088A0720 |212 219|effectsdata of
P07896088A0720 |88 92|RAP1harm
P07896088A0720 |31 35|tailalka
P07896088A0720 |164 168|tail [HC
P07896088A0720 |105 116|factor RIF1cts of neon
P07896088A0720 |39 59|telomere maintenance phosphatases and 5-
P07896088A0720 |173 197|RIF1 interaction domainsis shown as a function o
P07896088A0720 |4 12|function01606T00
P07896088A0720 |223 238|telomere lengthepleted rats ar
P07896291A0693 |115 120|genesnatal
P07896291A0693 |149 162|WAGR syndrome7A0472 When C
P07896291A0693 |60 63|mapucl
P07896291A0693 |78 86|resource171T0000
P07896291A0693 |95 111|characterizationlogic aspects of
P07896615A0554 |118 127|skin flowal hyperb
P07896615A0554 |37 44|changesne phos
P07896615A0554 |131 149|laser flow Dopplerubinemia. P0000899
P07896615A0554 |56 69|nm absorption 5-nucleotida
P07896615A0554 |180 195|water immersionn as a function
P07896615A0554 |4 16|contribution01606T0076 C
P07896615A0554 |20 29|skin flowrison wit
P07896615A0554 |154 168|NIR recordings2 When CSF [HC
P07896615A0554 |103 114|measurementpects of ne
P07896817A0204 |0 8|ProteinsP0000160
P07896817A0204 |208 219|Immobilon-Pthe data of
P07896817A0204 |73 77|BAEC0000
P07896817A0204 |150 188|SDS-polyacrylamide gel electrophoresisA0472 When CSF [HCO3-] is shown as a f
P07896817A0204 |44 51|controlphatase
P07896817A0204 |83 91|antisera000 Phar
P07896817A0204 |95 116|phospholipase C-gammalogic aspects of neon
P07896817A0204 |33 40|lysateskaline 
P07896817A0204 |118 127|PLC-gammaal hyperb
P07896846T0000 |139 149|chain gene. P0000899
P07896846T0000 |121 132|beta-myosinhyperbiliru
P07896846T0000 |90 107|suppressor regionrmacologic aspect
P07896846T0000 |24 32|isoformsn with a
P07896846T0000 |66 73|proteinidase P
P07896852T0000 |0 11|InvolvementP00001606T0
P07896852T0000 |53 89|apolipoprotein AI gene transcriptionand 5-nucleotidase P00008171T0000 Ph
P07896852T0000 |21 49|growth response factor Egr-1ison with alkaline phosphata
P07897359A0354 |118 126|vacciniaal hyper
P07897359A0354 |78 91|HeLa T4 cells171T0000 Phar
P07897359A0354 |26 31|formswith 
P07897359A0354 |67 73|BHK-21dase P
P07897359A0354 |95 98|uselog
P07897359A0354 |142 162|T7 polymerase system00008997A0472 When C
P07897359A0354 |39 48|F protein phosphat
P07897696A0000 |0 11|ErythrocyteP00001606T0
P07897696A0000 |51 55|ALADs an
P07897696A0000 |294 307|micrograms/dll have a sign
P07897696A0000 |145 147|UC08
P07897696A0000 |57 65|activity5-nucleo
P07897696A0000 |265 277|blood levelscompared to 
P07897696A0000 |149 162|concentration7A0472 When C
P07897696A0000 |129 143|coproporphyrinirubinemia. P0
P07897696A0000 |196 206|indicatorsof CSF PCO
P07897696A0000 |281 287|excessrols b
P07897696A0000 |318 326|subjectsreater s
P07897696A0000 |105 115|heme ratiocts of neo
P07897696A0000 |233 246|lead exposurets are no lon
P07897696A0000 |67 98|erythrocyte zinc protoporphyrindase P00008171T0000 Pharmacolog
P07897696A0000 |33 49|acid dehydratasekaline phosphata
P07897696A0000 |100 103|ZPP as
P07898178A0849 |137 160|cyclosporin maintenanceia. P00008997A0472 When
P07898178A0849 |52 64|azathioprine and 5-nucle
P07898178A0849 |110 122|azathioprinef neonatal h
P07898178A0849 |199 203|riskCSF 
P07898178A0849 |79 89|graft loss71T0000 Ph
P07898178A0849 |13 17|risk6 Co
P07898178A0849 |21 31|graft lossison with 
P07898178A0849 |96 106|conversionogic aspec
P07898178A0849 |38 48|conversione phosphat
P07898178A0849 |207 220|patient death the data of 
P07898275A0254 |171 182|test object] is shown 
P07898275A0254 |86 106|31P MRS measurements Pharmacologic aspec
P07898275A0254 |295 302|systems have a
P07898275A0254 |267 278|performancempared to c
P07898275A0254 |309 313|ISISican
P07898275A0254 |6 13|classes606T007
P07898275A0254 |349 357|31P MRS. P000109
P07898275A0254 |317 345|volume localization sequencegreater slope (1.21 +/- 0.23
P07898275A0254 |17 29|test objectsmparison wit
P07898275A0254 |138 147|sequencesa. P00008
P07898275A0254 |236 248|test objectsare no longe
P07898275A0254 |70 81|test objecte P00008171
P07898275A0254 |204 210|1H MRSCO2 th
P07898589T0000 |5 18|tobacco issue1606T0076 Com
P07898840X0000 |0 19|Pregnancy screeningP00001606T0076 Comp
P07898840X0000 |185 194|gestationa functio
P07898840X0000 |219 224|power K-de
P07898840X0000 |127 142|Doppler studiesilirubinemia. P
P07898840X0000 |212 216|testdata
P07898840X0000 |419 428|waveformsug with t
P07898840X0000 |301 304|FGRa s
P07898840X0000 |31 57|artery Doppler velocimetryalkaline phosphatases and 
P07898840X0000 |90 99|OBJECTIVErmacologi
P07898840X0000 |281 299|growth restrictionrols but still hav
P07898840X0000 |165 176|circulation[HCO3-] is 
P07898840X0000 |319 327|analysiseater sl
P07898840X0000 |258 270|hypertensiond when compa
P07898840X0000 |460 468|analysisal pract
P07898840X0000 |447 454|results use in
P07898840X0000 |383 394|assessmentspears to be
P07898840X0000 |65 74|criteriontidase P0
P07898840X0000 |339 350|combination- 0.23 vs. 
P07899581A0000 |222 226|ratsdepl
P07899581A0000 |211 212|n 
P07899581A0000 |114 126|nitrendipineonatal hyper
P07899581A0000 |99 110|combinationc aspects o
P07899581A0000 |65 85|superoxide dismutasetidase P00008171T000
P07899581A0000 |203 209|groupsPCO2 t
P07899581A0000 |131 151|superoxide dismutaseubinemia. P00008997A
P07899581A0000 |4 10|effect01606T
P07899581A0000 |174 182|functions shown 
P07899581A0000 |18 47|Ca entry blocker nitrendipineparison with alkaline phospha
P07899581A0000 |87 90|SODPha
P07899634A0000 |0 7|PURPOSEP000016
P07899634A0000 |56 65|anchorage 5-nucleo
P07899634A0000 |13 16|aim6 C
P07899634A0000 |158 160|muen
P07899634A0000 |25 30|study with
P07899634A0000 |98 112|surface effectic aspects of 
P07899634A0000 |118 132|alloy Ti Al Vaal hyperbiliru
P07900915A0000 |33 38|waterkalin
P07900915A0000 |221 232|restitution-depleted r
P07900915A0000 |21 25|foodison
P07900915A0000 |296 306|hematocrithave a sig
P07900915A0000 |92 104|blood volumeacologic asp
P07900915A0000 |265 270|Evanscompa
P07900915A0000 |63 68|tracteotid
P07900915A0000 |199 215|min-1 hemorrhageCSF PCO2 the dat
P07900915A0000 |109 123|plasma proteinof neonatal hy
P07900915A0000 |130 140|hemorrhagerubinemia.
P07900915A0000 |284 292|dilutions but st
P07900915A0000 |187 196|ml.kg-1 xfunction 
P07900915A0000 |142 145|fed000
P07900915A0000 |77 88|restitution8171T0000 P
P07900915A0000 |236 248|blood volumeare no longe
P07900915A0000 |168 172|ratsO3-]
P07901121T0000 |0 24|Cooperative dimerizationP00001606T0076 Compariso
P07901121T0000 |58 61|DNA-nu
P07901121T0000 |35 54|class homeo domainsline phosphatases a
P07901125A0416 |69 75|DAHPSsse P00
P07901125A0416 |89 96|speciesarmacol
P07901125A0416 |30 36|degree alkal
P07901125A0416 |108 123|ARO3 homologues of neonatal hy
P07901125A0416 |40 60|aa sequence homologyphosphatases and 5-n
P07901125A0416 |8 17|advantage6T0076 Co
P07901125A0416 |144 166|yeast Candida albicans008997A0472 When CSF [
P07902532A0312 |35 42|BOX DNAline ph
P07902532A0312 |8 13|study6T007
P07902532A0312 |75 91|thymidine kinase008171T0000 Phar
P07902532A0312 |52 65|transcription and 5-nucleo
P07902532A0312 |93 95|TKco
P07902532A0312 |97 105|promotergic aspe
P07902532A0312 |117 125|EC cellstal hype
P07902532A1655 |0 17|Deletion analysesP00001606T0076 Co
P07902532A1655 |97 104|BOX DNAgic asp
P07902532A1655 |25 34|construct with alk
P07902532A1655 |53 66|transcriptionand 5-nucleot
P07902532A1655 |172 177|cells is s
P07902532A1655 |141 149|EC cellsP0000899
P07902532A1655 |70 80|BOXF1 genee P0000817
P07902583A0545 |0 8|AnalysisP0000160
P07902583A0545 |88 97|half-lifeharmacolo
P07902583A0545 |151 156|Grf100472 
P07902583A0545 |52 74|Grf10-Swi5-DNA complex and 5-nucleotidase P0
P07902583A0545 |12 32|disassociation rates76 Comparison with a
P07902583A0545 |143 147|Swi50008
P07902583A0545 |115 124|complexesnatal hyp
P07903099A0918 |49 59|IVS2C betases and 5-
P07903099A0918 |72 80|terminusP0000817
P07903099A0918 |95 103|cleavagelogic as
P07903099A0918 |27 37|transcriptith alkali
P07903099A0918 |111 126|splice acceptor neonatal hyper
P07903099A0918 |4 12|presence01606T00
P07903670A1202 |25 45|alpha 1-tubulin gene with alkaline phosp
P07903670A1202 |61 67|tua1-1cleoti
P07903670A1202 |11 17|allele076 Co
P07905413A0585 |238 245|placeboe no lo
P07905413A0585 |31 52|plasma concentrationsalkaline phosphatases
P07905413A0585 |180 188|workloadn as a f
P07905413A0585 |90 91|hr
P07905413A0585 |15 24|treatmentCompariso
P07905413A0585 |222 223|%d
P07905413A0585 |113 114|he
P07905413A0585 |266 272|pointsompare
P07905413A0585 |247 248|Pe
P07905413A0585 |77 84|ng.ml-18171T00
P07905413A0585 |131 149|segment depressionubinemia. P0000899
P07905413A0585 |276 280|time con
P07905413A0585 |99 106|ng.ml-1c aspec
P07905453A0281 |0 7|ResultsP000016
P07905453A0281 |61 81|maxicell experimentscleotidase P00008171
P07905453A0281 |108 111|ORF of
P07905453A0281 |22 56|transcription-translation analysisson with alkaline phosphatases and
P07906265A0897 |69 81|fasD mutantsse P00008171
P07906265A0897 |89 97|productsarmacolo
P07906265A0897 |12 23|experiments76 Comparis
P07906265A0897 |129 135|exportirubin
P07906265A0897 |140 148|assembly P000089
P07906616A0191 |140 151|anaesthesia P00008997A
P07906616A0191 |25 33|response with al
P07906616A0191 |106 111|goatsts of
P07906616A0191 |59 70|stimulationnucleotidas
P07906616A0191 |76 78|Hz08
P07907846A0623 |0 5|GroupP0000
P07907846A0623 |158 169|combinationen CSF [HCO
P07907846A0623 |96 99|minogi
P07907846A0623 |66 92|cholinesterase degradationidase P00008171T0000 Pharm
P07907846A0623 |37 47|mg/kg i.v.ne phospha
P07907846A0623 |107 133|bupivacaine administrations of neonatal hyperbilirub
P07907846A0623 |18 31|physostigmineparison with 
P07907846A0623 |173 199|physostigmine pretreatmentis shown as a function of 
P07907846A0623 |139 144|Group. P00
P07907846A0623 |221 232|stimulation-depleted r
P07908012A0678 |70 76|groupse P000
P07908012A0678 |178 195|medication levelsown as a function
P07908012A0678 |126 134|analysesbilirubi
P07908012A0678 |15 26|possibilityComparison 
P07908012A0678 |157 169|relationshiphen CSF [HCO
P07908012A0678 |114 124|medicationonatal hyp
P07908012A0678 |200 211|LNNB scoresSF PCO2 the
P07908012A0678 |32 48|LNNB performancelkaline phosphat
P07908187T0000 |0 4|ISISP000
P07908187T0000 |7 20|possibilities06T0076 Compa
P07908827A1200 |254 257|RARlac
P07908827A1200 |43 57|identificationsphatases and 
P07908827A1200 |177 186|COS cellshown as a
P07908827A1200 |106 115|complexests of neo
P07908827A1200 |135 144|sequencesemia. P00
P07908827A1200 |269 276|elementared to
P07908827A1200 |157 161|RARshen 
P07908827A1200 |20 30|antibodiesrison with
P07908827A1200 |4 7|use016
P07908827A1200 |70 78|RAR betae P00008
P07909936A0672 |186 189|use fu
P07909936A0672 |193 202|cytokineson of CSF
P07909936A0672 |46 55|disordersatases an
P07909936A0672 |12 30|treatment strategy76 Comparison with
P07909936A0672 |93 99|effectcologi
P07909936A0672 |230 237|factors rats a
P07909936A0672 |113 130|radiochemotherapyeonatal hyperbili
P07909936A0672 |143 168|stem-cell transplantation0008997A0472 When CSF [HC
P07910716A0359 |373 382|IU/m2/dayam thus a
P07910716A0359 |245 250|weeksnger 
P07910716A0359 |56 64|SC rIL-2 5-nucle
P07910716A0359 |94 103|IU/m2/dayologic as
P07910716A0359 |150 158|patientsA0472 Wh
P07910716A0359 |283 299|SC rIFN-alpha 2bls but still hav
P07910716A0359 |129 134|totalirubi
P07910716A0359 |315 330|U/m2/day thricey greater slope
P07910716A0359 |469 474|weeksce be
P07910716A0359 |109 113|daysof n
P07910716A0359 |437 441|daysm do
P07910716A0359 |424 433|IU/m2/dayth the op
P07910716A0359 |259 267|patients when co
P07910716A0359 |118 122|weekal h
P07910716A0359 |386 390|daysrs t
P07910716A0359 |4 17|study cohorts01606T0076 Co
P07910716A0359 |140 145|weeks P000
P07910716A0359 |234 239|totals are
P07910716A0359 |446 450|weekr us
P07910716A0359 |172 185|rIFN-alpha 2b is shown as 
P07910716A0359 |68 73|dosesase P
P07910716A0359 |205 220|U/m2/day thriceO2 the data of 
P07910716A0359 |34 42|patientsaline ph
P07910716A0359 |343 351|SC rIL-223 vs. P
P07910946A0323 |0 8|AnalysisP0000160
P07910946A0323 |112 122|luciferaseneonatal h
P07910946A0323 |97 110|reporter genegic aspects o
P07910946A0323 |124 132|activityerbiliru
P07910946A0323 |195 212|promoter activity of CSF PCO2 the 
P07910946A0323 |14 17|set Co
P07910946A0323 |54 73|transfection assaysnd 5-nucleotidase P
P07910946A0323 |232 240|L2 cellsats are 
P07910946A0323 |174 180|regions show
P07910946A0323 |21 40|deletion constructsison with alkaline 
P07911736A1715 |70 86|myelosuppressione P00008171T0000
P07911736A1715 |44 52|toxicityphatases
P07911736A1715 |14 23|mg/m2/day Comparis
P07911736A1715 |61 66|agentcleot
P07911736A1715 |7 10|MTD06T
P07912123A0711 |16 40|lymphocyte proliferationomparison with alkaline 
P07913080A0564 |2 34|decanucleotide promoter sequence0001606T0076 Comparison with alk
P07913080A0564 |129 139|horse geneirubinemia
P07913080A0564 |75 79|mice0081
P07913080A0564 |64 70|humansotidas
P07913080A0564 |115 121|regionnatal 
P07913891A0174 |152 161|Hox genes472 When 
P07913891A0174 |14 21|targets Compar
P07913891A0174 |105 117|relationshipcts of neona
P07913891A0174 |80 92|interactions1T0000 Pharm
P07913891A0174 |172 193|transcription factors is shown as a functi
P07913891A0174 |48 57|moleculesases and 
P07913891A0174 |237 255|tissue specificityre no longer displ
P07913926A0878 |137 144|absenceia. P00
P07913926A0878 |78 89|ntcA mutant171T0000 Ph
P07913926A0878 |62 70|culturesleotidas
P07913926A0878 |105 112|amountscts of 
P07913926A0878 |21 32|RNA samplesison with a
P07913926A0878 |157 167|transcripthen CSF [H
P07913926A0878 |116 128|glnA messageatal hyperbi
P07913926A0878 |0 17|Northern analysisP00001606T0076 Co
P07914192A0211 |0 25|HER2 overexpressing cellsP00001606T0076 Comparison
P07914192A0211 |192 200|CAAT boxion of C
P07914192A0211 |165 182|bases down-stream[HCO3-] is shown 
P07914192A0211 |224 232|TATA boxpleted r
P07914192A0211 |75 79|site0081
P07914192A0211 |145 151|GAGGAA08997A
P07914192A0211 |123 143|ets response elementperbilirubinemia. P0
P07914192A0211 |246 259|HER2 promoterger displaced
P07914192A0211 |52 57|DNase and 
P07914192A0844 |0 16|Gel-shift assaysP00001606T0076 C
P07914192A0844 |245 268|GAGGAA response elementnger displaced when com
P07914192A0844 |195 199|HER2 of 
P07914192A0844 |91 106|promoter regionmacologic aspec
P07914192A0844 |30 38|extracts alkalin
P07914192A0844 |174 179|cellss sho
P07914192A0844 |43 68|oligonucleotide sequencessphatases and 5-nucleotid
P07914192A0844 |138 145|complexa. P000
P07914192A0844 |221 228|binding-deplet
P07914507A1029 |102 106|polyspec
P07914507A1029 |107 108|As
P07914507A1029 |14 28|cDNA sequences Comparison wi
P07914507A1029 |75 81|result008171
P07914507A1029 |110 124|addition sitesf neonatal hyp
P07914507A1029 |95 98|uselog
P07914507A1029 |0 10|ComparisonP00001606T
P07914507A1029 |51 63|mRNA speciess and 5-nucl
P07914700A0000 |4 8|gene0160
P07914700A0000 |59 62|PKRnuc
P07914700A0000 |31 57|eIF-2 alpha protein kinasealkaline phosphatases and 
P07914700A0000 |82 87|mouse0000 
P07914700A0000 |96 99|DNAogi
P07915144A0000 |119 124|hoursl hyp
P07915144A0000 |45 56|hippocampushatases and
P07915144A0000 |26 37|stimulationwith alkali
P07915144A0000 |90 98|efficacyrmacolog
P07915144A0000 |69 77|increasese P0000
P07915144A0000 |0 14|High-frequencyP00001606T0076
P07916003A0688 |185 189|genea fu
P07916003A0688 |134 147|octamer motifnemia. P00008
P07916003A0688 |15 25|mouse geneComparison
P07916003A0688 |78 86|TATA box171T0000
P07916003A0688 |104 120|mouse CD79 alphaects of neonatal
P07916003A0688 |43 49|regionsphata
P07916003A0688 |59 69|CD79 alphanucleotida
P07916326A0000 |70 77|regionse P0000
P07916326A0000 |39 45|coding phosp
P07916326A0000 |121 126|Msx-1hyper
P07916326A0000 |115 119|genenata
P07916326A0000 |19 31|organizationarison with 
P07916327A0250 |19 26|cloningarison 
P07916327A0250 |56 59|GSC 5-
P07916327A0250 |92 100|sequenceacologic
P07916327A0250 |40 54|goosecoid genephosphatases a
P07916327A0250 |76 83|library08171T0
P07916327A0250 |116 123|proteinatal hy
P07916577A0190 |184 189|cDNAs a fu
P07916577A0190 |95 110|gene expressionlogic aspects o
P07916577A0190 |29 44|candidate genesh alkaline phos
P07916577A0190 |59 68|disordersnucleotid
P07916577A0190 |161 165|zincCSF 
P07916577A0190 |140 149|sequences P0000899
P07916577A0190 |3 8|order00160
P07916588A0471 |51 80|passion fruit woodiness viruss and 5-nucleotidase P0000817
P07916588A0471 |195 199|part of 
P07916588A0471 |164 171|strains [HCO3-
P07916588A0471 |249 252|PWV di
P07916588A0471 |82 85|PWV000
P07916588A0471 |214 222|subgroupta of K-
P07916588A0471 |41 47|strainhospha
P07916588A0471 |226 237|potyviruseseted rats a
P07916588A0471 |141 144|CPsP00
P07916588A0471 |5 10|virus1606T
P07916588A0471 |175 178|PWV sh
P07916588A0471 |100 111|CP sequence aspects of
P07916685A0455 |17 25|activitymparison
P07916685A0455 |164 174|activities [HCO3-] i
P07916685A0455 |4 9|ratio01606
P07916685A0455 |29 52|arogenate dehydrogenaseh alkaline phosphatases
P07916685A0455 |64 88|prephenate dehydrogenaseotidase P00008171T0000 P
P07916685A0455 |138 150|purificationa. P00008997
P07916689A0312 |106 112|oleatets of 
P07916689A0312 |45 59|kb RNA specieshatases and 5-
P07916689A0312 |121 134|carbon sourcehyperbilirubi
P07916689A0312 |13 24|POT1 clones6 Compariso
P07916689A1407 |102 105|kbpspe
P07916689A1407 |109 112|DNAof 
P07916689A1407 |26 35|POT1 genewith alka
P07916689A1407 |67 69|bpda
P07916689A1407 |127 150|Y. lipolytica LEU2 geneilirubinemia. P00008997
P07916689A1407 |4 17|Y. lipolytica01606T0076 Co
P07916689A1407 |84 92|sequence00 Pharm
P07916729T0000 |2 23|leucine zipper domain0001606T0076 Comparis
P07916729T0000 |88 94|effectharmac
P07916729T0000 |31 41|suppressoralkaline p
P07916729T0000 |56 63|protein 5-nucl
P07916729T0000 |98 115|enhancer functionic aspects of neo
P07916983A0623 |70 88|N1-N3 neck diseasee P00008171T0000 P
P07916983A0623 |56 64|patients 5-nucle
P07916983A0623 |129 141|prescriptionirubinemia. 
P07916983A0623 |21 23|CTis
P07917016A0581 |27 62|zinc finger domain protein sequenceith alkaline phosphatases and 5-nuc
P07917016A0581 |14 25|DNA-binding Comparison
P07917540A0000 |119 124|timesl hyp
P07917540A0000 |89 108|interferon-alpha 2barmacologic aspects
P07917540A0000 |72 82|mg/m2/weekP00008171T
P07917540A0000 |112 116|U/m2neon
P07917540A0000 |129 133|weekirub
P07917540A0000 |59 68|vindesinenucleotid
P07917540A0000 |43 48|studysphat
P07917540A0000 |160 170|interferon CSF [HCO3
P07917540A0000 |3 11|patients001606T0
P07917540A0000 |219 227|melanoma K-deple
P07917540A0000 |138 147|vindesinea. P00008
P07917540A0000 |185 194|treatmenta functio
P07918097T0000 |65 86|growth factor-repeatstidase P00008171T0000
P07918097T0000 |121 136|neuroepitheliumhyperbilirubine
P07918097T0000 |10 37|Notch homologue mouse Notch0076 Comparison with alkali
P07918128A0000 |68 85|hydroxytryptaminease P00008171T000
P07918128A0000 |56 58|EF 5
P07918128A0000 |123 131|patientsperbilir
P07918128A0000 |89 94|5-HT3armac
P07918128A0000 |46 49|MDLata
P07918128A0000 |96 115|receptor antagonistogic aspects of neo
P07918128A0000 |27 32|phaseith a
P07918128A0000 |153 165|chemotherapy72 When CSF 
P07918128A0000 |0 10|BACKGROUNDP00001606T
P07918494A1163 |119 126|mutantsl hyper
P07918494A1163 |40 46|systemphosph
P07918494A1163 |177 181|molehown
P07918494A1163 |167 172|dCTPsCO3-]
P07918494A1163 |88 93|NADPHharma
P07918494A1163 |61 82|thioredoxin reductasecleotidase P00008171T
P07918494A1163 |141 150|formationP00008997
P07918494A1163 |7 15|presence06T0076 
P07918494A1163 |48 59|thioredoxinases and 5-
P07918494A1163 |185 191|enzymea func
P07919540A0240 |117 126|AUG codontal hyper
P07919540A0240 |14 25|alterations Comparison
P07919540A0240 |130 134|exonrubi
P07919540A0240 |63 76|c-myc proteineotidase P000
P07919540A0240 |40 49|synthesisphosphata
P07919540A0240 |78 81|p64171
P07919540A1119 |51 56|formss and
P07919540A1119 |22 26|exonson 
P07919540A1119 |127 145|reporter constructilirubinemia. P000
P07919540A1119 |89 102|transcriptionarmacologic a
P07919540A1119 |64 77|c-Myc proteinotidase P0000
P07919540A1119 |159 164|leveln CSF
P07919540A1119 |3 11|addition001606T0
P07919540A1119 |34 38|exonalin
P07922709T0000 |39 53|growth factors phosphatases 
P07922709T0000 |11 21|activities076 Compar
P07922709T0000 |83 94|application000 Pharmac
P07925022A0285 |0 10|ExpressionP00001606T
P07925022A0285 |63 69|stageseotida
P07925022A0285 |41 44|CNShos
P07925097A1205 |87 96|8-Br-cAMPPharmacol
P07925097A1205 |15 25|AR contentComparison
P07925097A1205 |75 83|exposure008171T0
P07925097A1205 |41 52|COS-1 cellshosphatases
P07925282A0705 |34 39|genesaline
P07925282A0705 |160 171|ER membrane CSF [HCO3-
P07925282A0705 |99 110|cell growthc aspects o
P07925282A0705 |127 148|protein translocationilirubinemia. P000089
P07925282A0705 |70 82|SRP proteinse P00008171T
P07925282A0705 |0 10|DisruptionP00001606T
P07926729A0000 |99 105|eventsc aspe
P07926729A0000 |148 156|programs97A0472 
P07926729A0000 |134 144|activationnemia. P00
P07926729A0000 |8 19|alterations6T0076 Comp
P07926729A0000 |160 178|gene transcription CSF [HCO3-] is sh
P07926729A0000 |42 72|signal transduction mechanismsosphatases and 5-nucleotidase 
P07926729A0000 |23 31|elementson with 
P07926739A0766 |169 189|trichome development3-] is shown as a fu
P07926739A0766 |26 29|GL2wit
P07926739A0766 |122 138|progenitor cellsyperbilirubinemi
P07926739A0766 |58 71|hybridization-nucleotidase
P07926739A0766 |146 152|stages8997A0
P07926739A0766 |92 96|geneacol
P07926739A0766 |4 22|expression pattern01606T0076 Compari
P07926748A0383 |0 4|NOT4P000
P07926748A0383 |89 93|NOT4arma
P07926748A0383 |63 77|overexpressioneotidase P0000
P07926748A0383 |29 33|NOT3h al
P07926748A0383 |105 109|not1cts 
P07926748A0383 |20 24|NOT1riso
P07926748A0383 |52 57|assay and 
P07926748A0383 |114 128|not2 mutationsonatal hyperbi
P07926748A0383 |81 85|NOT3T000
P07926749A0471 |137 162|hormone response elementsia. P00008997A0472 When C
P07926749A0471 |241 245|ROREo lo
P07926749A0471 |76 85|ROR alpha08171T000
P07926749A0471 |8 22|site selection6T0076 Compari
P07926749A0471 |92 101|ROR alphaacologic 
P07926749A0471 |125 133|monomersrbilirub
P07926749A0471 |104 112|isoformsects of 
P07926749A0471 |50 58|proteinses and 5
P07926749A0471 |190 198|sequencection of
P07926749A0471 |118 121|DNAal 
P07926749A0471 |221 239|core motif PuGGTCA-depleted rats are
P07926774A0652 |64 67|MCBoti
P07926774A0652 |76 79|SCB081
P07926774A0652 |83 92|E2F sites000 Pharm
P07926774A0652 |4 28|p73pct1/p85cdc10 complex01606T0076 Comparison wi
P07926775A0895 |205 207|hhO2
P07926775A0895 |162 166|timeSF [
P07926775A0895 |77 89|slp activity8171T0000 Ph
P07926775A0895 |121 132|maintenancehyperbiliru
P07926775A0895 |105 116|requirementcts of neon
P07926775A0895 |60 67|embryosucleoti
P07926775A0895 |20 27|stripesrison w
P07926775A0895 |172 188|wg transcription is shown as a f
P07926775A0895 |49 52|slpses
P07926775A0895 |136 149|wg expressionmia. P0000899
P07926789A0960 |100 108|products aspects
P07926789A0960 |4 16|DNA sequence01606T0076 C
P07926789A0960 |160 167|fusions CSF [H
P07926789A0960 |81 93|fusion genesT0000 Pharma
P07926789A0960 |33 42|lacZ genekaline ph
P07927130A0625 |0 33|CMV hyperimmunoglobulin treatmentP00001606T0076 Comparison with al
P07927130A0625 |45 52|Biotesthatases
P07927130A0625 |81 84|dayT00
P07927130A0625 |202 212|myocardium PCO2 the 
P07927130A0625 |172 182|infiltrate is shown 
P07927130A0625 |144 155|eradication008997A0472
P07927130A0625 |109 113|daysof n
P07927130A0625 |35 43|Cytotectline pho
P07927130A0625 |100 105|ml/kg aspe
P07927130A0625 |69 77|ml/kg bwse P0000
P07927130A0625 |187 194|CMV-DNAfunctio
P07927267T0000 |17 25|drainagemparison
P07927267T0000 |43 51|drainagesphatase
P07927267T0000 |75 87|regeneration008171T0000 
P07927267T0000 |127 138|hepatectomyilirubinemi
P07927267T0000 |103 112|rat liverpects of 
P07927711A0698 |0 3|ORFP00
P07927711A0698 |40 47|proteinphospha
P07927711A0698 |58 60|Da-n
P07927711A0698 |98 105|regionsic aspe
P07927838A0000 |186 195|stiffness function
P07927838A0000 |150 156|fingerA0472 
P07927838A0000 |9 15|groupsT0076 
P07927838A0000 |95 100|yearslogic
P07927838A0000 |177 181|painhown
P07927838A0000 |167 175|numbnessCO3-] is
P07927838A0000 |106 122|prevalence ratests of neonatal h
P07927838A0000 |66 71|toolsidase
P07927838A0000 |219 230|extremities K-depleted
P07927838A0000 |158 161|VWFen 
P07927838A0000 |19 27|subjectsarison w
P07928954A0545 |51 53|bps 
P07928954A0545 |193 233|consensus prolipoprotein processing siteon of CSF PCO2 the data of K-depleted ra
P07928954A0545 |88 95|proteinharmaco
P07928954A0545 |113 119|weighteonata
P07928954A0545 |162 188|lipoprotein signal peptideSF [HCO3-] is shown as a f
P07928954A0545 |38 42|genee ph
P07928954A0545 |0 21|DNA sequence analysisP00001606T0076 Compar
P07929165T0000 |34 46|actVI regionaline phosph
P07929165T0000 |120 122|A3 h
P07929165T0000 |80 92|gene cluster1T0000 Pharm
P07929165T0000 |54 66|actinorhodinnd 5-nucleot
P07929165T0000 |0 12|DNA sequenceP00001606T00
P07929165T0000 |17 26|functionsmparison 
P07929238A0734 |7 15|Genomics06T0076 
P07929411A0087 |239 254|enzyme activity no longer disp
P07929411A0087 |121 126|yeasthyper
P07929411A0087 |194 201|regionsn of CS
P07929411A0087 |30 50|polypeptide sequence alkaline phosphatas
P07929411A0087 |111 116|mouse neon
P07929411A0087 |58 76|Drosophila protein-nucleotidase P000
P07929411A0087 |97 105|subunitsgic aspe
P07929411A0087 |2 12|comparison0001606T00
P07929431A0949 |0 8|PlasmidsP0000160
P07929431A0949 |172 183|INS-1 cells is shown a
P07929431A0949 |120 123|CAT hy
P07929431A0949 |71 118|reporter gene chloramphenicol acetyltransferase P00008171T0000 Pharmacologic aspects of neonat
P07929431A0949 |35 56|mouse promoter regionline phosphatases and
P07929559A0000 |201 211|organellesF PCO2 the
P07929559A0000 |12 18|dynein76 Com
P07929559A0000 |148 157|movements97A0472 W
P07929559A0000 |123 130|varietyperbili
P07929559A0000 |76 82|enzyme08171T
P07929559A0000 |188 197|transportunction o
P07929560T0000 |0 14|IdentificationP00001606T0076
P07929560T0000 |79 94|plaque assembly71T0000 Pharmac
P07929560T0000 |52 62|desmoglein and 5-nuc
P07929560T0000 |42 48|domainosphat
P07929560T0000 |112 130|filament anchorageneonatal hyperbili
P07929560T0000 |71 75|role P00
P07931490A0237 |0 8|PATIENTSP0000160
P07931490A0237 |161 178|granisetron dosesCSF [HCO3-] is sh
P07931490A0237 |94 103|cisplatinologic as
P07931490A0237 |13 20|METHODS6 Compa
P07931490A0237 |232 244|chemotherapyats are no l
P07931490A0237 |197 210|micrograms/kgf CSF PCO2 th
P07931490A0237 |65 73|patientstidase P
P07931490A0237 |115 120|mg/m2natal
P07932095A0000 |137 146|root barkia. P0000
P07932095A0000 |29 38|compoundsh alkalin
P07932095A0000 |47 48|Vt
P07932095A0000 |150 171|Oroxylum indicum VentA0472 When CSF [HCO3-
P07932095A0000 |104 106|VIec
P07932095A0000 |9 20|naphthaleneT0076 Compa
P07932095A0000 |108 112|XIII of 
P07932095A0000 |50 57|VII-XIIes and 
P07932095A0000 |84 93|compounds00 Pharma
P07932943A0113 |117 144|Five-Step Approach strategytal hyperbilirubinemia. P00
P07932943A0113 |61 79|awareness strategycleotidase P000081
P07932943A0113 |101 109|strategyaspects 
P07932943A0113 |40 49|influencephosphata
P07932943A0113 |155 172|control condition When CSF [HCO3-]
P07932943A0113 |19 24|studyariso
P07933066T0000 |19 30|interactionarison with
P07933066T0000 |72 99|retinoblastoma gene productP00008171T0000 Pharmacologi
P07933066T0000 |135 139|DP-1emia
P07933066T0000 |125 130|E2F-1rbili
P07933066T0000 |56 63|protein 5-nucl
P07933066T0000 |114 121|domainsonatal 
P07933066T0000 |38 53|adenovirus E4-6e phosphatases 
P07933076A0211 |21 26|EBNA2ison 
P07933076A0211 |46 55|promotersatases an
P07933076A0211 |76 93|membrane proteins08171T0000 Pharma
P07933095A0000 |138 143|sitesa. P0
P07933095A0000 |161 185|transcription factor Sp1CSF [HCO3-] is shown as 
P07933095A0000 |109 118|promotersof neonat
P07933095A0000 |26 31|v-Relwith 
P07933095A0000 |62 78|retrovirus Rev-Tleotidase P00008
P07933095A0000 |37 48|oncoproteinne phosphat
P07933095A0000 |93 103|expressioncologic as
P07933095A0000 |189 215|chicken embryo fibroblastsnction of CSF PCO2 the dat
P07933095A0000 |217 219|S.of
P07933101A0131 |9 16|studiesT0076 C
P07933101A0131 |44 56|TATA elementphatases and
P07933101A0131 |95 116|HIV-1 gene expressionlogic aspects of neon
P07933107A0991 |102 105|E75spe
P07933107A0991 |131 142|virus Ba71Vubinemia. P
P07933107A0991 |94 97|E70olo
P07933107A0991 |47 55|p54 genetases an
P07933107A0991 |80 92|ASFV strains1T0000 Pharm
P07933107A0991 |20 39|nucleotide sequencerison with alkaline
P07933107A0991 |2 12|comparison0001606T00
P07933107A0991 |153 165|% similarity72 When CSF 
P07933116A0412 |103 107|U937pect
P07933116A0412 |92 101|cell lineacologic 
P07933116A0412 |56 68|T-cell lines 5-nucleotid
P07933116A0412 |4 12|p55 mRNA01606T00
P07933116A0412 |49 50|Bs
P07934331T0037 |42 53|improvementosphatases 
P07934331T0037 |28 37|incentiveth alkali
P07934331T0037 |9 21|registrationT0076 Compar
P07934666A0158 |100 102|T2 a
P07934666A0158 |89 92|T2farm
P07934666A0158 |15 28|magnetizationComparison wi
P07934666A0158 |66 76|componentsidase P000
P07934666A0158 |109 112|T2sof 
P07934666A0158 |80 82|T21T
P07934666A0158 |114 123|componentonatal hy
P07935094A0516 |0 7|RESULTSP000016
P07935094A0516 |147 156|FDG study997A0472 
P07935094A0516 |115 131|liver backgroundnatal hyperbilir
P07935094A0516 |24 31|qualityn with 
P07935094A0516 |35 45|FDG imagesline phosp
P07935094A0516 |84 103|Tl-201 counterparts00 Pharmacologic as
P07935370A0000 |16 26|expressionomparison 
P07935370A0000 |30 33|CD4 al
P07935370A0000 |96 112|maturation stateogic aspects of 
P07935370A0000 |120 126|T cell hyper
P07935370A0000 |38 41|CD8e p
P07935370A0000 |49 67|T-cell developmentses and 5-nucleoti
P07935375A1197 |34 42|ras genealine ph
P07935375A1197 |79 84|v-src71T00
P07935375A1197 |55 75|TIS10/PGS2 inductiond 5-nucleotidase P00
P07935375A1197 |0 10|ExpressionP00001606T
P07935379A0347 |69 76|changesse P000
P07935379A0347 |26 31|cellswith 
P07935379A0347 |95 100|cellslogic
P07935379A0347 |112 121|apoptosisneonatal 
P07935383A0108 |69 76|subunitse P000
P07935383A0108 |9 14|RNaseT0076
P07935383A0108 |214 237|adenovirus L3 pre-mRNAsta of K-depleted rats a
P07935383A0108 |26 43|mapping techniquewith alkaline pho
P07935383A0108 |134 141|regionsnemia. 
P07935383A0108 |80 84|CstF1T00
P07935383A0108 |196 201|virusof CS
P07935383A0108 |114 123|pre-mRNAsonatal hy
P07935383A0108 |168 181|cleavage siteO3-] is shown
P07935395A0094 |137 145|moleculeia. P000
P07935395A0094 |104 112|clustersects of 
P07935395A0094 |125 129|endsrbil
P07935395A0094 |27 30|kDaith
P07935395A0094 |4 11|protein01606T0
P07935395A0094 |50 68|zinc finger motifses and 5-nucleotid
P07935415T0000 |51 60|inhibitors and 5-n
P07935415T0000 |89 96|cloningarmacol
P07935415T0000 |113 125|localizationeonatal hype
P07935415T0000 |133 137|geneinem
P07935415T0000 |98 107|structureic aspect
P07935415T0000 |16 26|expressionomparison 
P07935418A0447 |87 92|RLD-1Pharm
P07935418A0447 |78 85|protein171T000
P07935418A0447 |8 20|v-erbA probe6T0076 Compa
P07935418A0447 |146 155|receptors8997A0472
P07935418A0447 |127 134|domainsilirubi
P07935418A0447 |36 40|cDNAine 
P07935426A0714 |16 24|isoformsompariso
P07935426A0714 |104 124|TdT promoter bindingects of neonatal hyp
P07935426A0714 |48 66|zinc finger domainases and 5-nucleot
P07935447A0972 |237 247|expressionre no long
P07935447A0972 |262 274|alpha-myosinen compared 
P07935447A0972 |251 257|MLC-2visplac
P07935447A0972 |27 35|evidenceith alka
P07935447A0972 |123 128|HF-1aperbi
P07935447A0972 |134 145|PRE B sitesnemia. P000
P07935447A0972 |85 106|leucine zipper family0 Pharmacologic aspec
P07935447A0972 |117 121|MLE1tal 
P07935447A0972 |48 54|memberases a
P07935447A0972 |185 202|protein complexesa function of CSF
P07935447A0972 |41 44|USFhos
P07935447A0972 |287 292|genesut st
P07935447A0972 |172 181|component is shown
P07935447A0972 |5 10|study1606T
P07935451T0000 |152 161|induction472 When 
P07935451T0000 |6 32|T-cell leukemia virus type606T0076 Comparison with a
P07935451T0000 |112 127|I kappa B alphaneonatal hyperb
P07935451T0000 |97 108|degradationgic aspects
P07935451T0000 |77 92|phosphorylation8171T0000 Pharm
P07935451T0000 |132 136|RelAbine
P07935451T0000 |138 141|p65a. 
P07935451T0000 |53 67|NF-kappa B/Reland 5-nucleoti
P07935451T0000 |169 179|c-rel gene3-] is sho
P07935451T0000 |35 49|Tax activationline phosphata
P07935468T0000 |68 90|growth factor receptorase P00008171T0000 Pha
P07935468T0000 |14 35|c-fos gene expression Comparison with alka
P07935468T0000 |0 10|ActivationP00001606T
P07935471A0613 |186 197|maintenance function o
P07935471A0613 |215 220|statea of 
P07935471A0613 |124 130|systemerbili
P07935471A0613 |94 105|Xenopus HSFologic aspe
P07935471A0613 |135 150|mapping regionsemia. P00008997
P07935471A0613 |19 22|HSFari
P07935471A0613 |66 74|antibodyidase P0
P07935471A0613 |154 159|hHSF12 Whe
P07935471A0613 |35 43|activityline pho
P07935472A0276 |0 9|EnhancersP00001606
P07935472A0276 |124 126|E1er
P07935472A0276 |147 158|LVb element997A0472 Wh
P07935472A0276 |31 36|Ets-1alkal
P07935472A0276 |181 198|enhancer activity as a function of
P07935472A0276 |108 123|T-cell line EL4 of neonatal hy
P07935472A0276 |229 232|LVbd r
P07935472A0276 |280 297|enhancer activitytrols but still h
P07935472A0276 |45 50|siteshatas
P07935472A0276 |258 265|phorbold when 
P07935472A0276 |76 93|expression assays08171T0000 Pharma
P07935472A0276 |128 139|alterationslirubinemia
P07935472A0276 |236 247|LVc elementare no long
P07935472A0276 |206 214|mutation2 the da
P07935472A0790 |16 32|binding activityomparison with a
P07935472A0790 |41 46|Ets-1hosph
P07935472A0790 |115 136|mobility shift assaysnatal hyperbilirubine
P07935472A0790 |86 95|complexes Pharmaco
P07935491A0495 |116 131|gene expressionatal hyperbilir
P07935491A0495 |46 52|familyatases
P07935491A0495 |29 36|membersh alkal
P07935491A0495 |6 18|RZR subtypes606T0076 Com
P07935491A0495 |71 80|receptors P0000817
P07935491A1182 |68 76|affinityase P000
P07935491A1182 |90 136|acid receptor-retinoid-X receptor heterodimersrmacologic aspects of neonatal hyperbilirubine
P07935491A1182 |21 38|response elementsison with alkalin
P07935577A0305 |34 45|flucytosinealine phosp
P07935577A0305 |72 80|symptomsP0000817
P07935577A0305 |107 122|micro-organismss of neonatal h
P07935577A0305 |15 29|amphotericin BComparison wit
P07935577A0305 |53 64|improvementand 5-nucle
P07935577A0305 |146 151|fluid8997A
P07935577A0305 |153 156|CSF72 
P07935577A0305 |0 9|TreatmentP00001606
P07935626A1249 |65 77|mitochondriatidase P0000
P07935626A1249 |15 23|presenceComparis
P07935626A1249 |46 61|gene transcriptatases and 5-nu
P07935626A1249 |31 35|tRNAalka
P07935626A1249 |41 44|CCAhos
P07935626A1249 |36 39|trpine
P07935997A0000 |152 168|cervix carcinoma472 When CSF [HC
P07935997A0000 |38 46|immunitye phosph
P07935997A0000 |4 14|parameters01606T0076
P07935997A0000 |203 207|yearPCO2
P07935997A0000 |130 138|patientsrubinemi
P07935997A0000 |121 126|grouphyper
P07935997A0000 |48 69|serum immunoglobulinsases and 5-nucleotida
P07935997A0000 |81 90|complexesT0000 Pha
P07935997A0000 |185 189|IIIBa fu
P07935997A0000 |170 180|Stages IIB-] is show
P07936635A1134 |0 8|MutationP0000160
P07936635A1134 |12 16|KRKR76 C
P07936635A1134 |91 98|proteinmacolog
P07936635A1134 |57 68|compartment5-nucleotid
P07936635A1134 |130 137|nucleusrubinem
P07936635A1134 |20 24|NGERriso
P07936635A1134 |33 37|MO15kali
P07936640A0900 |259 265|levels when 
P07936640A0900 |15 22|bindingCompari
P07936640A0900 |43 48|sitessphat
P07936640A0900 |26 33|proteinwith al
P07936640A0900 |123 130|portionperbili
P07936640A0900 |243 247|genelong
P07936640A0900 |183 192|rat livers a funct
P07936640A0900 |52 57|cells and 
P07936640A0900 |93 114|footprinting analysiscologic aspects of ne
P07936640A0900 |138 156|TGF alpha promotera. P00008997A0472 
P07936640A0900 |204 214|cell linesCO2 the da
P07936650A0656 |102 112|p58c-ets-2spects of 
P07936650A0656 |132 135|BECbin
P07936650A0656 |140 150|Ets-1-beta P00008997
P07936650A0656 |167 175|sequenceCO3-] is
P07936650A0656 |81 98|activating regionT0000 Pharmacolog
P07936650A0656 |17 26|subdomainmparison 
P07936650A1752 |39 44|ets-1 phos
P07936650A1752 |89 93|timearma
P07936650A1752 |45 55|ets-2 genehatases an
P07936650A1752 |128 137|evidenceslirubinem
P07936650A1752 |58 67|evolution-nucleoti
P07936650A1752 |25 30|model with
P07936650A1752 |5 9|work1606
P07937106A0100 |102 126|amino acid substitutionsspects of neonatal hyper
P07937106A0100 |144 154|isoleucine008997A047
P07937106A0100 |264 267|end co
P07937106A0100 |269 279|mutation Cared to co
P07937106A0100 |128 135|alaninelirubin
P07937106A0100 |162 169|c-ets-1SF [HCO
P07937106A0100 |73 94|progenitor p68c-ets-100008171T0000 Pharmac
P07937106A0100 |223 224|Be
P07937106A0100 |190 196|valinection 
P07937106A0100 |4 18|v-ets oncogene01606T0076 Com
P07937106A0100 |200 205|v-etsSF PC
P07937106A0100 |207 216|mutations the data
P07937106A0100 |32 46|retrovirus E26lkaline phosph
P07937108A0325 |24 29|mRNAsn wit
P07937108A0325 |60 77|RNA polymerase I.ucleotidase P0000
P07937112A0220 |86 98|denaturation Pharmacolog
P07937112A0220 |72 77|cellsP0000
P07937112A0220 |15 23|subunitsComparis
P07937112A0220 |27 29|Kuit
P07937112A0220 |146 148|Ku89
P07937127A0645 |174 185|herpesviruss shown as 
P07937127A0645 |107 114|regionss of ne
P07937127A0645 |63 81|activation domainseotidase P00008171
P07937127A0645 |122 135|herpesvirusesyperbilirubin
P07937127A0645 |11 17|method076 Co
P07937127A0645 |144 162|pseudorabies virus008997A0472 When C
P07937132A0819 |102 110|28S rRNAspects o
P07937132A0819 |90 98|sequencermacolog
P07937132A0819 |12 15|U2176 
P07937132A0819 |44 46|ntph
P07937132A0819 |52 67|complementarity and 5-nucleoti
P07937132A0819 |32 39|stretchlkaline
P07937147A0205 |152 162|Filutowicz472 When C
P07937147A0205 |96 98|DRog
P07937147A0205 |43 61|pi protein mutantssphatases and 5-nu
P07937147A0205 |10 16|system0076 C
P07937147A0205 |89 91|IRar
P07937147A0205 |164 166|J. [
P07937147A0205 |143 147|York0008
P07937147A0205 |113 117|Geneeona
P07937147A0205 |100 104|York asp
P07937147A0205 |119 123|Amstl hy
P07937656A0182 |0 10|UnivariateP00001606T
P07937656A0182 |228 254|serum alkaline phosphataseed rats are no longer disp
P07937656A0182 |356 357|p9
P07937656A0182 |216 217|p 
P07937656A0182 |323 337|activity indexr slope (1.21 
P07937656A0182 |293 306|serum albuminll have a sig
P07937656A0182 |23 31|analysison with 
P07937656A0182 |146 159|disease stage8997A0472 Whe
P07937656A0182 |269 272|U/lare
P07937656A0182 |173 188|NSE serum levelis shown as a f
P07937656A0182 |202 214|micrograms/l PCO2 the da
P07937656A0182 |129 136|factorsirubine
P07937656A0182 |161 162|pC
P07937656A0182 |41 63|Kaplan-Meier-estimateshosphatases and 5-nucl
P07937656A0182 |341 348|minimum0.23 vs
P07937656A0182 |308 309|pf
P07937656A0182 |274 275|pt
P07937656A0182 |68 81|Log-Rank-Testase P00008171
P07937841A0790 |99 107|pathwaysc aspect
P07937841A0790 |127 146|myb oncogene familyilirubinemia. P0000
P07937841A0790 |77 87|cell cycle8171T0000 
P07937841A0790 |6 13|results606T007
P07937841A0790 |22 30|evidenceson with
P07937841A0790 |36 42|bypassine ph
P07937841A0790 |113 119|membereonata
P07937954A0612 |0 3|HBxP00
P07937954A0612 |42 45|Rasosp
P07937954A0612 |123 133|MAP kinaseperbilirub
P07937954A0612 |76 79|Raf081
P07937954A0612 |22 28|levelsson wi
P07937965T0000 |0 4|RoleP000
P07937965T0000 |61 74|DNA synthesiscleotidase P0
P07937965T0000 |24 29|virusn wit
P07937965T0000 |88 112|3T3-L1 mouse fibroblastsharmacologic aspects of 
P07937965T0000 |8 13|c-myc6T007
P07937965T0000 |39 44|tumor phos
P07938137A0384 |119 124|signsl hyp
P07938137A0384 |45 53|naloxonehatases 
P07938137A0384 |59 64|mg/kgnucle
P07938137A0384 |135 145|withdrawalemia. P000
P07938137A0384 |4 10|groups01606T
P07938137A0384 |85 96|environment0 Pharmacol
P07941174T0001 |0 13|Laser therapyP00001606T007
P07941174T0001 |24 33|carcinoman with al
P07941739A0000 |82 96|chromosome XIV0000 Pharmacol
P07941739A0000 |26 38|yeast genomewith alkalin
P07941739A0000 |72 78|regionP00008
P07941739A0000 |108 115|mapping of neo
P07941739A0000 |7 18|kb fragment06T0076 Com
P07941750A0344 |102 106|halfspec
P07941750A0344 |41 47|lengthhospha
P07941750A0344 |29 33|halfh al
P07941750A0344 |110 126|hydatoinase HyuBf neonatal hyper
P07941750A0344 |67 84|hydantoinase HyuAdase P00008171T00
P07942076A0497 |18 42|estradiol concentrationsparison with alkaline ph
P07942076A0497 |134 141|patientnemia. 
P07942076A0497 |58 76|estradiol valerate-nucleotidase P000
P07942076A0497 |181 185|type as 
P07942076A0497 |92 111|estradiol ingestionacologic aspects of
P07942076A0497 |144 147|age008
P07942448A1227 |85 90|WORDS0 Pha
P07942448A1227 |25 35|NYHA class with alka
P07942448A1227 |13 21|patients6 Compar
P07942448A1227 |59 67|ABSTRACTnucleoti
P07942448A1227 |49 54|classses a
P07942722T0000 |0 12|ConstipationP00001606T00
P07942722T0000 |97 103|agentsgic as
P07942722T0000 |22 33|risk factorson with al
P07942722T0000 |66 71|studyidase
P07942722T0000 |38 49|hemorrhoidse phosphata
P07943556A0694 |68 79|Og4C3 assayase P000081
P07943556A0694 |7 14|persons06T0076
P07943556A0694 |34 35|%a
P07944461A0321 |0 6|TG-dayP00001
P07944461A0321 |11 19|TG-night076 Comp
P07944461A0321 |60 63|mm3ucl
P07944461A0321 |37 38|%n
P07944461A0321 |52 53|% 
P07944542T0000 |0 20|Vibrio cholerae O139P00001606T0076 Compa
P07944542T0000 |24 32|Calcuttan with a
P07945134A0079 |136 142|soundsmia. P
P07945134A0079 |47 48|mt
P07945134A0079 |164 179|head microphone [HCO3-] is sho
P07945134A0079 |37 39|ftne
P07945134A0079 |88 90|ftha
P07945134A0079 |4 14|volunteers01606T0076
P07945134A0079 |116 117|ma
P07945330A0103 |35 39|acidline
P07945330A0103 |41 43|RAho
P07945330A0103 |46 59|transcriptionatases and 5-
P07945330A0103 |67 77|Rex-1 genedase P0000
P07945330A0103 |5 20|differentiation1606T0076 Compa
P07945937A0358 |0 17|Sequence analysisP00001606T0076 Co
P07945937A0358 |145 154|exception08997A047
P07945937A0358 |95 100|mouselogic
P07945937A0358 |215 221|regiona of K
P07945937A0358 |79 87|homology71T0000 
P07945937A0358 |47 53|regiontases 
P07945937A0358 |259 271|Egr1 protein when compar
P07945937A0358 |117 127|Egr1 genestal hyperb
P07945937A0358 |25 39|zebrafish egr1 with alkaline
P07945937A0358 |237 251|amino terminusre no longer d
P07945937A0358 |173 207|triplet nucleotide repeat sequenceis shown as a function of CSF PCO2
P07945937A0358 |70 75|levele P00
P07945937A0358 |102 105|ratspe
P07947930A0499 |51 59|membranes and 5-
P07947930A0499 |83 84|%0
P07947930A0499 |92 93|%a
P07947930A0499 |88 89|%h
P07947930A0499 |75 77|Cm00
P07947930A0499 |32 46|sodium heparinlkaline phosph
P07947930A0499 |4 14|fibrinogen01606T0076
P07947930A0499 |100 101|% 
P07947930A0499 |16 30|serum proteinsomparison with
P07948129A0297 |254 257|NEOlac
P07948129A0297 |88 122|chloramphenicol acetyl transferaseharmacologic aspects of neonatal h
P07948129A0297 |44 50|repeatphatas
P07948129A0297 |52 57|chLTR and 
P07948129A0297 |129 142|reporter geneirubinemia. P
P07948129A0297 |9 16|vectorsT0076 C
P07948129A0297 |124 127|CATerb
P07948129A0297 |192 207|region promoterion of CSF PCO2
P07948129A0297 |70 80|expressione P0000817
P07948129A0297 |175 185|SV40 virus shown as 
P07948129A0297 |222 249|neomycin phosphotransferasedepleted rats are no longer
P07948129A0297 |259 263|gene whe
P07948921A0051 |0 6|OptimaP00001
P07948921A0051 |61 83|stilbene synthase cDNAcleotidase P00008171T0
P07948921A0051 |89 94|probearmac
P07948921A0051 |16 23|libraryomparis
P07949137A0000 |152 159|January472 Whe
P07949137A0000 |36 44|patientsine phos
P07949137A0000 |67 78|bone marrowdase P00008
P07949137A0000 |126 132|periodbiliru
P07949137A0000 |94 105|mafosfamideologic aspe
P07949137A0000 |107 113|ASTA Zs of n
P07949137A0000 |21 29|leukemiaison wit
P07949137A0000 |80 82|BM1T
P07949137A0000 |2 7|total00016
P07949137A0000 |136 143|Januarymia. P0
P07949137A0532 |18 25|regimenparison
P07949137A0532 |61 66|mg/kgcleot
P07949137A0532 |78 94|body irradiation171T0000 Pharmac
P07949137A0532 |39 55|cyclophosphamide phosphatases an
P07949164A0799 |51 55|IL-6s an
P07949164A0799 |56 67|CAT plasmid 5-nucleoti
P07949164A0799 |107 129|IL-6 promoter activitys of neonatal hyperbil
P07949164A0799 |18 26|mutationparison 
P07949164A0799 |93 103|abrogationcologic as
P07949164A0799 |139 144|cells. P00
P07949164A0799 |34 47|kappa B motifaline phospha
P07949205A0286 |103 119|breast carcinomapects of neonata
P07949205A0286 |11 25|testololactone076 Comparison
P07949205A0286 |64 81|aminoglutethimideotidase P00008171
P07949551A0000 |0 3|UseP00
P07949551A0000 |47 51|veintase
P07949551A0000 |11 20|vena cava076 Compa
P07949551A0000 |56 79|cadaver transplantation 5-nucleotidase P000081
P07949770T0000 |98 102|pigsic a
P07949770T0000 |73 94|liver transplantation00008171T0000 Pharmac
P07949770T0000 |46 62|prostaglandin E1atases and 5-nuc
P07949770T0000 |24 34|blood flown with alk
P07951235A0277 |84 90|muscle00 Pha
P07951235A0277 |4 8|gene0160
P07951410A0647 |100 109|formation aspects 
P07951410A0647 |81 83|RBT0
P07951410A0647 |54 59|E2F-1nd 5-
P07951410A0647 |25 35|A549 cells with alka
P07951410A0647 |183 188|E2F-1s a f
P07951410A0647 |61 65|DP-1cleo
P07951410A0647 |67 75|cyclin Adase P00
P07951410A0647 |160 167|factors CSF [H
P07951410A0647 |192 196|DP-1ion 
P07951410A0647 |15 19|U937Comp
P07951410A0647 |118 127|complexesal hyperb
P07951410A0647 |143 156|participation0008997A0472 
P07951410A0647 |37 50|participationne phosphatas
P07951410A0647 |200 206|othersSF PCO
P07951410A0647 |4 8|HeLa0160
P07951410A1332 |0 18|E1A autoactivationP00001606T0076 Com
P07951410A1332 |124 136|E1A promotererbilirubine
P07951410A1332 |37 42|sitesne ph
P07951410A1332 |86 96|activation Pharmacol
P07951874A0320 |119 125|systeml hype
P07951874A0320 |31 44|host organismalkaline phos
P07951874A0320 |87 96|radiationPharmacol
P07951874A0320 |104 111|hamsterects of
P07951874A0320 |0 16|Cestode invasionP00001606T0076 C
P07951874A0320 |68 74|effectase P0
P07953785A0648 |64 77|% restrictionotidase P0000
P07953785A0648 |106 110|foodts o
P07953785A0648 |121 131|H/L ratioshyperbilir
P07953785A0648 |7 20|heat exposure06T0076 Compa
P07953785A0648 |145 155|resistance08997A0472
P07953785A0648 |22 28|chicksson wi
P07953785A0648 |159 190|marble spleen disease infectionn CSF [HCO3-] is shown as a fun
P07954475A0714 |0 8|AnalysesP0000160
P07954475A0714 |246 267|tumor suppressor geneger displaced when co
P07954475A0714 |121 137|C3H/HeJ x A/J F1hyperbilirubinem
P07954475A0714 |210 216|allelee data
P07954475A0714 |41 45|micehosp
P07954475A0714 |75 91|A/J x C3H/HeJ F1008171T0000 Phar
P07954475A0714 |156 161|C3AF1When 
P07954475A0714 |190 202|inactivationction of CSF
P07954475A0714 |23 29|tumorson wit
P07954475A0714 |233 243|chromosomets are no 
P07954475A0714 |110 115|AC3F1f neo
P07954475A0714 |173 181|evidenceis shown
P07954475A0714 |66 73|crossesidase P
P07954891T0000 |0 4|ERV1P000
P07954891T0000 |52 63|maintenance and 5-nucl
P07954891T0000 |38 43|cyclee pho
P07954891T0000 |81 88|genomesT0000 P
P07956578A0851 |0 16|Lesion diametersP00001606T0076 C
P07956578A0851 |36 38|mmin
P07956578A0851 |131 138|removalubinemi
P07956578A0851 |66 80|configurationsidase P0000817
P07956578A0851 |86 93|factors Pharma
P07956869A0000 |168 173|yearsO3-] 
P07956869A0000 |193 207|flow cytometryon of CSF PCO2
P07956869A0000 |89 97|archivesarmacolo
P07956869A0000 |149 156|storage7A0472 
P07956869A0000 |105 125|Pathology laboratorycts of neonatal hype
P07956869A0000 |42 62|breast cancer tissueosphatases and 5-nuc
P07956869A0000 |227 243|S-phase fractionted rats are no 
P07956869A0000 |129 132|Dariru
P07956869A0000 |212 222|DNA ploidydata of K-
P07957085A0207 |0 4|Cbf3P000
P07957085A0207 |47 52|Cbf3ctases
P07957085A0207 |30 35|Cbf3a alka
P07957085A0207 |37 42|Cbf3bne ph
P07957085A0207 |20 28|proteinsrison wi
P07957106A0471 |8 19|interaction6T0076 Comp
P07957106A0471 |46 68|GST-POU fusion proteinatases and 5-nucleotid
P07957106A0471 |78 103|glutathione-agarose beads171T0000 Pharmacologic as
P07957106A0875 |6 15|mutations606T0076 
P07957106A0875 |120 133|VP16 contacts hyperbilirub
P07957106A0875 |42 48|regionosphat
P07957106A0875 |59 82|HSV transactivator VP16nucleotidase P00008171T
P07957158A1532 |186 193|control functi
P07957158A1532 |201 216|Starling forcesF PCO2 the data
P07957158A1532 |44 49|areasphata
P07957158A1532 |101 110|parameteraspects o
P07957158A1532 |16 31|filtration rateomparison with 
P07957243A1316 |49 56|domainsses and
P07957243A1316 |15 23|residuesComparis
P07957559A1557 |9 18|rapamycinT0076 Com
P07957559A1557 |104 126|p70 S6 kinase activityects of neonatal hyper
P07957559A1557 |90 100|inhibitionrmacologic
P07957559A1557 |29 42|proliferationh alkaline ph
P07957559A1557 |135 140|cellsemia.
P07957559A1557 |46 58|Ba/F3-EpoRgpatases and 5
P07957559A1557 |72 81|MEL cellsP00008171
P07957632A0000 |102 109|agonistspects 
P07957632A0000 |252 260|pmol/ratsplaced 
P07957632A0000 |127 146|glutamate receptorsilirubinemia. P0000
P07957632A0000 |31 33|2Sal
P07957632A0000 |151 155|rats0472
P07957632A0000 |44 45|Rp
P07957632A0000 |75 82|glycine008171T
P07957632A0000 |17 26|injectionmparison 
P07957632A0000 |186 194|recovery functio
P07957632A0000 |84 90|DCG-IV00 Pha
P07957632A0000 |40 41|Rp
P07957632A0000 |226 236|dose rangeeted rats 
P07957632A0000 |36 37|Ri
P07957632A0000 |200 220|halothane anesthesiaSF PCO2 the data of 
P07958446A0000 |187 210|helix DNA binding motiffunction of CSF PCO2 th
P07958446A0000 |23 31|factor-3on with 
P07958446A0000 |40 48|forkheadphosphat
P07958446A0000 |160 168|homology CSF [HC
P07958446A0000 |132 147|gene regulatorsbinemia. P00008
P07958446A0000 |88 94|familyharmac
P07958446A0000 |55 63|proteinsd 5-nucl
P07958446A0000 |4 14|hepatocyte01606T0076
P07958446A0000 |33 38|HNF-3kalin
P07958446A0000 |50 53|fkhes 
P07958865A1152 |16 23|embryosomparis
P07958865A1152 |95 105|conclusionlogic aspe
P07958865A1152 |56 73|heart development 5-nucleotidase P
P07958865A1152 |39 52|abnormalities phosphatases
P07958865A1152 |111 114|Tek ne
P07958865A1152 |175 186|development shown as a
P07958865A1152 |155 167|interactions When CSF [H
P07958898A1050 |103 124|transcription factorspects of neonatal hyp
P07958898A1050 |15 25|dTFIIA-L/SComparison
P07958898A1050 |150 155|NTF-1A0472
P07958898A1050 |135 138|Sp1emi
P07958898A1050 |80 90|activation1T0000 Pha
P07958898A1050 |140 144|VP16 P00
P07958911A0500 |155 162|complex When C
P07958911A0500 |61 69|locationcleotida
P07958911A0500 |120 124|gene hyp
P07958911A0500 |9 31|trithorax binding siteT0076 Comparison with 
P07958911A0500 |77 91|fork head gene8171T0000 Phar
P07958915A1507 |188 191|Ca2unc
P07958915A1507 |214 229|protein kinasesta of K-deplete
P07958915A1507 |108 112|cAMP of 
P07958915A1507 |40 43|Ca2pho
P07958915A1507 |15 22|changesCompari
P07958915A1507 |179 184|formswn as
P07958915A1507 |126 139|transcriptionbilirubinemia
P07958915A1507 |97 104|abilitygic asp
P07958915A1507 |158 166|presenceen CSF [
P07958920A1157 |0 10|AntibodiesP00001606T
P07958920A1157 |94 102|extractsologic a
P07958920A1157 |167 178|RNase P RNACO3-] is sh
P07958920A1157 |64 77|RNase MRP RNAotidase P0000
P07958920A1157 |32 44|SNM1 proteinlkaline phos
P07959011A0379 |1 12|C/EBP alpha00001606T00
P07959011A0379 |115 119|Archnata
P07959011A0379 |92 98|manneracolog
P07959011A0379 |92 98|manneracolog
P07959011A0379 |1 12|C/EBP alpha00001606T00
P07959011A0379 |100 106|Potter aspec
P07959011A0379 |32 40|promoterlkaline 
P07959011A0379 |48 68|rat class-I ADH geneases and 5-nucleotid
P07959011A0379 |48 68|rat class-I ADH geneases and 5-nucleotid
P07959011A0379 |115 119|Archnata
P07959011A0379 |32 40|promoterlkaline 
P07959011A0379 |100 106|Potter aspec
P07959015A0478 |51 62|amino acidss and 5-nuc
P07959015A0478 |121 131|identitieshyperbilir
P07959015A0478 |110 115|rAMPKf neo
P07959015A0478 |76 79|kDa081
P07959015A0478 |162 171|nt levelsSF [HCO3-
P07959015A0478 |146 147|%8
P07959015A0478 |26 29|ORFwit
P07959015A0478 |64 66|aaot
P07959015A0478 |4 11|results01606T0
P07959015A0478 |33 38|hAMPKkalin
P07959015A0478 |155 157|aa W
P07959734A0194 |69 87|peptide sequencingse P00008171T0000 
P07959734A0194 |117 135|glycoprotein Gp135tal hyperbilirubin
P07959734A0194 |9 14|brainT0076
P07959734A0194 |16 25|contactinomparison
P07959734A0194 |50 55|aminoes an
P07959760A0763 |103 107|STSspect
P07959760A0763 |16 26|YAC contigomparison 
P07959760A0763 |255 257|kbac
P07959760A0763 |398 408|Fli-1 geneeffective 
P07959760A0763 |189 194|Fli-1nctio
P07959760A0763 |332 346|microsatellite1.21 +/- 0.23 
P07959760A0763 |177 182|c-etshown 
P07959760A0763 |215 225|ets familya of K-dep
P07959760A0763 |360 361|n0
P07959760A0763 |61 65|YACscleo
P07959760A0763 |151 175|Ewing sarcoma breakpoint0472 When CSF [HCO3-] is
P07959760A0763 |348 355|D11S912. P0001
P07959760A0763 |134 136|Mbne
P07959760A0763 |119 126|minimuml hyper
P07959760A0763 |357 359|CA43
P07959760A0763 |289 295|contig still
P07959760A0763 |200 207|membersSF PCO2
P07959760A0763 |96 101|sitesogic 
P07959760A0763 |70 76|orderse P000
P07959760A0763 |273 276|DNA to
P07959952A1446 |153 158|mouse72 Wh
P07959952A1446 |30 40|pseudogene alkaline 
P07959952A1446 |182 196|mast cell lineas a function 
P07959952A1446 |106 145|polymerase chain reaction amplificationts of neonatal hyperbilirubinemia. P000
P07959952A1446 |65 89|mouse mast cell chymasestidase P00008171T0000 Ph
P07959952A1446 |2 6|cDNA0001
P07959953A0423 |0 5|IFI16P0000
P07959953A0423 |89 91|kbar
P07959953A0423 |22 27|exonsson w
P07959953A0423 |78 87|kilobases171T0000 
P07959953A0423 |96 99|DNAogi
P07959953A0423 |49 56|intronsses and
P07960608A0228 |0 7|CoursesP000016
P07960608A0228 |33 38|weekskalin
P07960796A0154 |0 11|Peter ElferP00001606T0
P07960796A0154 |45 51|rulinghatase
P07960796A0154 |25 37|implications with alkali
P07961545A1314 |68 75|placeboase P00
P07961545A1314 |26 36|incidenceswith alkal
P07961545A1314 |106 114|sweatingts of ne
P07961545A1314 |14 20|events Compa
P07961545A1314 |142 153|ejaculation00008997A04
P07961545A1314 |92 104|constipationacologic asp
P07961545A1314 |81 90|dizzinessT0000 Pha
P07961545A1314 |116 127|nervousnessatal hyperb
P07961755A0474 |0 8|HomologyP0000160
P07961755A0474 |130 146|leader sequencesrubinemia. P0000
P07961755A0474 |76 95|cysteine synthase C08171T0000 Pharmaco
P07961755A0474 |48 72|transit peptide sequenceases and 5-nucleotidase 
P07961957A1565 |17 21|datampar
P07961957A1565 |82 88|factor0000 P
P07961957A1565 |41 49|additionhosphata
P07961957A1565 |53 58|TEF-1and 5
P07961957A1565 |114 139|alpha-MHC gene EM elementonatal hyperbilirubinemia
P07961958T0000 |0 27|Rat kidney carboxylesteraseP00001606T0076 Comparison w
P07963540A0795 |71 86|factor-kappa B1 P00008171T0000
P07963540A0795 |88 92|RelAharm
P07963540A0795 |164 177|cross-linking [HCO3-] is s
P07963540A0795 |134 136|UVne
P07963540A0795 |120 127|studies hyperb
P07963540A0795 |213 236|kappa B oligonucleotideata of K-depleted rats 
P07963540A0795 |12 27|I-kappa B alpha76 Comparison w
P07963540A0795 |38 59|kappa B motif bindinge phosphatases and 5-
P07963540A0795 |98 103|c-Relic as
P07963782A0000 |152 156|pain472 
P07963782A0000 |26 35|stabilitywith alka
P07963782A0000 |56 61|drugs 5-nu
P07963782A0000 |41 52|combinationhosphatases
P07963782A0000 |131 140|treatmentubinemia.
P07963782A0000 |117 122|spacetal h
P07964162A0941 |118 131|specificational hyperbilir
P07964162A0941 |144 153|responses008997A04
P07964162A0941 |11 21|mechanisms076 Compar
P07964162A0941 |53 71|MAP kinase cascadeand 5-nucleotidase
P07964162A0941 |35 45|activationline phosp
P07964458A0179 |87 92|NrampPharm
P07964458A0179 |211 218|animals data o
P07964458A0179 |67 85|macrophage proteindase P00008171T000
P07964458A0179 |161 177|membrane proteinCSF [HCO3-] is s
P07964458A0179 |21 24|Bcgiso
P07964458A0179 |2 16|candidate gene0001606T0076 C
P07964459A0845 |5 10|motif1606T
P07964459A0845 |47 57|LIM domaintases and 
P07964459A0845 |128 135|regionslirubin
P07964459A0845 |66 84|RING finger familyidase P00008171T00
P07964624A0491 |137 145|P131 ORFia. P000
P07964624A0491 |176 177|rs
P07964624A0491 |108 129|UGA termination codon of neonatal hyperbil
P07964624A0491 |89 100|readthrougharmacologic
P07964624A0491 |46 49|ORFata
P07964624A0491 |174 175|Ms
P07964624A0491 |159 170|polypeptiden CSF [HCO3
P07964624A0491 |4 12|P131 ORF01606T00
P07964624A0491 |187 191|P191func
P07964770A0172 |18 26|patientsparison 
P07964770A0172 |46 50|yearatas
P07964770A0172 |57 69|arthroplasty5-nucleotida
P07964814T0000 |49 57|epilepsyses and 
P07964814T0000 |36 44|migraineine phos
P07964814T0000 |18 32|hallucinationsparison with a
P07964918A0000 |33 40|factorskaline 
P07964918A0000 |78 88|evaluation171T0000 P
P07964918A0000 |105 110|signscts o
P07964918A0000 |59 70|variabilitynucleotidas
P07964918A0000 |4 13|influence01606T007
P07965152A0764 |0 8|SegmentsP0000160
P07965152A0764 |130 137|reserverubinem
P07965152A0764 |45 56|MIBI uptakehatases and
P07965152A0764 |58 69|mismatching-nucleotida
P07965152A0764 |27 39|BMIPP uptakeith alkaline
P07965152A0764 |92 103|wall motionacologic as
P07965152A0764 |145 167|dobutamine stimulation08997A0472 When CSF [H
P07966565A0901 |119 136|replication cyclel hyperbilirubine
P07966565A0901 |26 30|mRNAwith
P07966565A0901 |12 18|length76 Com
P07966565A0901 |90 93|RNArma
P07966565A0901 |58 67|agreement-nucleoti
P07966565A0901 |160 166|stages CSF [
P07966565A0901 |38 49|nucleotidese phosphata
P07966565A0901 |170 179|infection-] is sho
P07966583A1268 |187 191|massfunc
P07966583A1268 |145 159|fusion protein08997A0472 Whe
P07966583A1268 |10 23|transfections0076 Comparis
P07966583A1268 |198 201|kDa CS
P07966583A1268 |29 38|constructh alkalin
P07966583A1268 |134 142|Env/Mlvinemia. P
P07966583A1268 |54 68|RNA transcriptnd 5-nucleotid
P07966583A1268 |96 105|D17 cellsogic aspe
P07966583A1268 |80 88|clone B11T0000 P
P07966583A1268 |117 127|expressiontal hyperb
P07966602A0130 |0 7|RoizmanP000016
P07966602A0130 |9 11|J.T0
P07966873A0693 |0 8|ArticlesP0000160
P07966873A0693 |90 100|infarctionrmacologic
P07966873A0693 |29 42|heart diseaseh alkaline ph
P07966873A0693 |104 110|Chagasects o
P07966873A0693 |46 59|heart failureatases and 5-
P07966873A0693 |112 119|diseaseneonata
P07967360A1048 |50 66|TGBM nephropathyes and 5-nucleot
P07967360A1048 |134 152|glomerulonephritisnemia. P00008997A0
P07967360A1048 |90 105|IgA nephropathyrmacologic aspe
P07967360A1048 |12 16|data76 C
P07967360A1048 |36 44|patientsine phos
P07967725A0262 |65 72|domainstidase 
P07967725A0262 |151 168|carboxyl terminus0472 When CSF [HC
P07967725A0262 |12 21|receptors76 Compar
P07967725A0262 |122 143|ligand binding domainyperbilirubinemia. P0
P07967725A0262 |108 114|domain of ne
P07967725A0262 |176 184|receptorshown as
P07968409A0123 |116 124|Diseasesatal hyp
P07968409A0123 |79 97|Outpatient Service71T0000 Pharmacolo
P07968409A0123 |164 180|General Hospital [HCO3-] is show
P07968409A0123 |134 141|Bolognanemia. 
P07968409A0123 |145 162|Ospedale Maggiore08997A0472 When C
P07968409A0123 |198 202|days CSF
P07968409A0123 |213 217|Julyata 
P07968409A0123 |4 10|sample01606T
P07969115A0000 |221 232|DNA origins-depleted r
P07969115A0000 |160 169|intervals CSF [HCO
P07969115A0000 |132 139|bindingbinemia
P07969115A0000 |241 257|promoter regionso longer displac
P07969115A0000 |111 116|level neon
P07969115A0000 |9 37|organello footprint analysisT0076 Comparison with alkali
P07969115A0000 |82 94|mitochondria0000 Pharmac
P07969115A0000 |190 196|regionction 
P07969116A0196 |155 162|stimuli When C
P07969116A0196 |120 125|genes hype
P07969116A0196 |129 137|responseirubinem
P07969116A0196 |95 105|expressionlogic aspe
P07969116A0196 |4 17|Nur77 protein01606T0076 Co
P07969116A0196 |38 61|transcription activatore phosphatases and 5-nu
P07969132A0268 |117 126|histidinetal hyper
P07969132A0268 |213 221|gcn2-507ata of K
P07969132A0268 |94 99|cellsologi
P07969132A0268 |72 83|suppressionP00008171T0
P07969132A0268 |13 21|plasmids6 Compar
P07969132A0268 |134 142|plasmidsnemia. P
P07969132A0268 |4 9|class01606
P07969132A0268 |42 47|genesospha
P07969132A0268 |156 169|gcn2 deletionWhen CSF [HCO
P07969132A0268 |32 36|tRNAlkal
P07969135A0913 |10 18|presence0076 Com
P07969135A0913 |88 95|proteinharmaco
P07969135A0913 |26 42|Cln2 PEST domainwith alkaline ph
P07969136A0273 |16 37|mobility shift assaysomparison with alkali
P07969136A0273 |57 66|sequences5-nucleot
P07969136A0273 |132 147|NF-kappa B sitebinemia. P00008
P07969136A0273 |80 89|complexes1T0000 Ph
P07969136A0273 |95 105|mobilitieslogic aspe
P07969136A0273 |157 162|kappahen C
P07969136A0273 |175 179|gene sho
P07969152A0721 |305 317|hsp70 familygnificantly 
P07969152A0721 |123 131|responseperbilir
P07969152A0721 |29 32|HSFh a
P07969152A0721 |101 119|CUP1 transcriptionaspects of neonata
P07969152A0721 |140 157|heat shock stress P00008997A0472 W
P07969152A0721 |276 283|members contro
P07969152A0721 |261 266|geneshen c
P07969152A0721 |162 180|glucose starvationSF [HCO3-] is show
P07969152A0721 |49 66|activation domainses and 5-nucleot
P07969152A0721 |223 244|heat shock activationepleted rats are no l
P07969152A0721 |87 97|activationPharmacolo
P07969152A0721 |187 193|regionfuncti
P07969181A0313 |152 163|p53 protein472 When CS
P07969181A0313 |41 49|CKB mRNAhosphata
P07969181A0313 |31 37|levelsalkali
P07969181A0313 |53 63|HeLa cellsand 5-nucl
P07969181A0313 |77 82|study8171T
P07969181A0313 |141 148|amountsP000089
P07969181A0313 |175 185|HeLa cells shown as 
P07969954T0000 |51 60|serum IgMs and 5-n
P07969954T0000 |104 117|immunotherapyects of neona
P07969954T0000 |163 179|cyclophosphamideF [HCO3-] is sho
P07969954T0000 |131 146|plasma exchangeubinemia. P0000
P07969954T0000 |13 34|motor neuron syndrome6 Comparison with alk
P07969954T0000 |82 93|improvement0000 Pharma
P07969954T0000 |70 80|antibodiese P0000817
P07971282A0000 |0 10|RegulatorsP00001606T
P07971282A0000 |106 115|metazoansts of neo
P07971282A0000 |70 102|pre-mRNA splicing characteristice P00008171T0000 Pharmacologic a
P07971709A0907 |18 26|responseparison 
P07971709A0907 |104 109|stateects 
P07971709A0907 |82 90|activity0000 Pha
P07971709A0907 |66 73|rhG-CSFidase P
P07972012A0956 |169 181|ANP-receptor3-] is shown
P07972012A0956 |91 98|proteinmacolog
P07972012A0956 |14 24|cDNA clone Compariso
P07972012A0956 |194 200|domainn of C
P07972012A0956 |144 150|domain008997
P07972012A0956 |267 285|phosphatase domainmpared to controls
P07972012A0956 |41 57|rat lung libraryhosphatases and 
P07972012A0956 |223 240|carboxyl terminusepleted rats are 
P07972012A0956 |117 131|amino terminustal hyperbilir
P07972237A0665 |18 33|restriction mapparison with al
P07972237A0665 |106 121|subcloning YACsts of neonatal 
P07972237A0665 |63 66|DNAeot
P07972237A0665 |46 48|kbat
P07972237A0665 |78 83|N-myc171T0
P07972237A0665 |127 134|cosmidsilirubi
P07972831A0563 |0 12|PAI-1 levelsP00001606T00
P07972831A0563 |62 69|iohexolleotida
P07972831A0563 |40 48|patientsphosphat
P07972831A0563 |100 109|ioxaglate aspects 
P07973364A0325 |84 107|carcinogenicity studies00 Pharmacologic aspect
P07973364A0325 |198 201|OF1 CS
P07973364A0325 |28 34|causesth alk
P07973364A0325 |180 187|studiesn as a 
P07973364A0325 |15 22|articleCompari
P07973364A0325 |129 132|OFAiru
P07973364A0325 |162 173|Wistar ratsSF [HCO3-] 
P07973364A0325 |111 118|studies neonat
P07973364A0325 |38 43|deathe pho
P07973364A0325 |206 215|NMRI mice2 the dat
P07973397T0001 |51 55|salts an
P07973397T0001 |0 13|DeterminationP00001606T007
P07973397T0001 |17 33|potassium iodidemparison with al
P07973825A0445 |4 18|recovery value01606T0076 Com
P07973825A0445 |31 39|pressurealkaline
P07973825A0445 |79 93|pulse pressure71T0000 Pharma
P07973825A0445 |66 74|pressureidase P0
P07975763A0000 |18 35|hepatitis C virusparison with alka
P07975763A0000 |57 62|cause5-nuc
P07975763A0000 |74 87|liver disease0008171T0000 
P07975763A0000 |114 126|introductiononatal hyper
P07975763A0000 |37 40|HCVne 
P07975763A0000 |42 51|infectionosphatase
P07975763A0000 |140 157|detection methods P00008997A0472 W
P07975763A0000 |4 14|importance01606T0076
P07975882T0000 |38 44|fiberse phos
P07975882T0000 |6 21|adenovirus type606T0076 Compar
P07977239A1283 |0 19|Outflow obstructionP00001606T0076 Comp
P07977239A1283 |57 65|stenosis5-nucleo
P07977239A1283 |125 133|patientsrbilirub
P07977239A1283 |176 184|patientsshown as
P07977239A1283 |147 154|papilla997A047
P07977239A1283 |198 205|papilla CSF PC
P07977239A1283 |286 291|juicebut s
P07977239A1283 |322 333|dorsal ducter slope (1
P07977239A1283 |190 194|typectio
P07977239A1283 |263 271|drainagen compar
P07977239A1283 |306 314|pressurenificant
P07977239A1283 |230 242|pancreatitis rats are no
P07977239A1283 |79 86|papilla71T0000
P07977239A1283 |139 143|type. P0
P07977239A1283 |34 39|juicealine
P07977648A0880 |0 10|SequencingP00001606T
P07977648A0880 |40 45|exonsphosp
P07977648A0880 |79 88|mutations71T0000 P
P07977648A0880 |106 112|allelets of 
P07977648A0880 |129 135|tumorsirubin
P07977648A0880 |18 34|TP53 transcriptsparison with alk
P07978229T0000 |41 48|patienthosphat
P07978229T0000 |11 23|complication076 Comparis
P07978406A0998 |85 88|g-10 P
P07978406A0998 |92 100|responseacologic
P07978406A0998 |146 154|ABSTRACT8997A047
P07978406A0998 |72 80|mL.min-1P0000817
P07978406A0998 |104 115|hypercapniaects of neo
P07978406A0998 |30 33|CBF al
P07978406A0998 |21 28|pre-DEXison wi
P07978406A0998 |172 177|WORDS is s
P07978406A0998 |7 16|ISO group06T0076 C
P07978406A0998 |117 121|PCO2tal 
P07978406A0998 |139 143|mmHg. P0
P07979810A0340 |32 39|densitylkaline
P07979810A0340 |144 153|pregnancy008997A04
P07979810A0340 |41 49|motilityhosphata
P07979810A0340 |60 64|testucle
P07979810A0340 |66 82|penetration testidase P00008171T
P07979810A0340 |20 30|parametersrison with
P07979827A0722 |0 7|KRN2391P000016
P07979827A0722 |12 22|cromakalim76 Compari
P07979827A0722 |81 91|blood flowT0000 Phar
P07979827A0722 |49 57|increaseses and 
P07980440A0138 |136 150|phorbol estersmia. P00008997
P07980440A0138 |76 80|cAMP0817
P07980440A0138 |124 131|insulinerbilir
P07980440A0138 |29 44|glucocorticoidsh alkaline phos
P07980440A0138 |3 27|H4IIE rat hepatoma cells001606T0076 Comparison w
P07980440A0138 |55 59|acidd 5-
P07980440A0138 |82 115|increase PEPCK gene transcription0000 Pharmacologic aspects of neo
P07980440A0138 |71 74|AMP P0
P07980440A0138 |169 175|effect3-] is
P07980468A0298 |0 4|ActaP000
P07980669A0373 |81 98|plasma NPY levelsT0000 Pharmacolog
P07980669A0373 |125 132|samplesrbiliru
P07980669A0373 |28 39|AVP releaseth alkaline
P07980669A0373 |6 23|plasma AVP levels606T0076 Comparis
P07980669A0373 |55 61|changed 5-nu
P07981143A0633 |16 27|nucleotidesomparison w
P07981143A0633 |2 9|stretch0001606
P07981143A0633 |71 88|IL-4 inducibility P00008171T0000 P
P07981143A0633 |142 149|factors0000899
P07981143A0633 |49 55|IL-4REses an
P07981143A0633 |100 123|nucleoprotein complexes aspects of neonatal hy
P07981246A0112 |51 54|IAPs a
P07981246A0112 |180 195|c-fos inductionn as a function
P07981246A0112 |150 163|hormones/IBMXA0472 When CS
P07981246A0112 |120 127|process hyperb
P07981246A0112 |90 99|G-proteinrmacologi
P07981246A0112 |131 146|differentiationubinemia. P0000
P07981246A0112 |78 85|protein171T000
P07981246A0112 |13 18|study6 Com
P07981246A0112 |86 87|s 
P07981246A0112 |34 49|pertussis toxinaline phosphata
P07982964A1017 |0 3|ATXP00
P07982964A1017 |10 14|PC-10076
P07982964A1017 |105 118|monophosphatects of neonat
P07982964A1017 |43 47|typespha
P07982964A1017 |50 103|phosphodiesterase substrate p-nitrophenyl thymidine-5es and 5-nucleotidase P00008171T0000 Pharmacologic as
P07982995A0000 |68 81|growth factorase P00008171
P07982995A0000 |179 184|glandwn as
P07982995A0000 |124 126|Naer
P07982995A0000 |89 102|beta-receptorarmacologic a
P07982995A0000 |28 37|mutationsth alkali
P07982995A0000 |131 140|exchangerubinemia.
P07982995A0000 |106 116|activationts of neon
P07982995A0000 |45 50|mousehatas
P07982995A0000 |216 229|hamster ovary of K-deplete
P07982995A0000 |83 87|PDGF000 
P07982995A0000 |231 234|CHOrat
P07982995A0000 |197 202|NMuMGf CSF
P07982995A0000 |128 129|Hl
P07982995A0000 |4 10|effect01606T
P07982995A0000 |236 241|cellsare n
P07983011A0617 |0 17|Sequence analysisP00001606T0076 Co
P07983011A0617 |354 361|segment10943A0
P07983011A0617 |396 402|domainn effe
P07983011A0617 |455 462|domainsgeneral
P07983011A0617 |124 131|memberserbilir
P07983011A0617 |210 250|fibroblast growth factor receptor familye data of K-depleted rats are no longer 
P07983011A0617 |328 332|acidpe (
P07983011A0617 |109 115|hybridof neo
P07983011A0617 |498 520|domain binding regions12653T0045 Beta blocki
P07983011A0617 |493 496|SH3 P0
P07983011A0617 |50 56|domaines and
P07983011A0617 |80 104|serine/threonine kinases1T0000 Pharmacologic asp
P07983011A0617 |33 39|kinasekaline
P07983011A0617 |172 201|protein kinase kinase kinases is shown as a function of CS
P07983011A0617 |282 303|leucine zipper motifsols but still have a 
P07983011A0617 |477 489|src homology 15 mg at ni
P07983011A0617 |139 145|family. P000
P07983704A0330 |0 4|TypeP000
P07983704A0330 |76 85|structure08171T000
P07983704A0330 |177 181|typehown
P07983704A0330 |31 39|sequencealkaline
P07983704A0330 |155 168|HERV-K family When CSF [HC
P07983704A0330 |7 14|genomes06T0076
P07983704A0330 |127 147|retrovirus ancestorsilirubinemia. P00008
P07983704A0330 |206 214|sequence2 the da
P07983704A0330 |184 191|genomes a func
P07983712A0914 |85 96|replication0 Pharmacol
P07983712A0914 |14 20|domain Compa
P07983712A0914 |75 81|levels008171
P07983712A0914 |61 68|plasmidcleotid
P07983712A0914 |27 33|domainith al
P07983715A0996 |0 15|Point mutationsP00001606T0076 
P07983715A0996 |89 92|armarm
P07983715A0996 |166 183|complex formationHCO3-] is shown a
P07983715A0996 |105 113|activitycts of n
P07983715A0996 |45 52|bindinghatases
P07983715A0996 |229 246|expression assaysd rats are no lon
P07983715A0996 |130 141|P4 promoterrubinemia. 
P07983715A0996 |56 60|NF-Y 5-n
P07983715A0996 |189 192|USFnct
P07983715A0996 |257 281|luciferase reporter geneed when compared to cont
P07983716A1082 |171 180|Y88L RNAs] is show
P07983716A1082 |106 111|COS-7ts of
P07983716A1082 |29 42|blot analysish alkaline ph
P07983716A1082 |209 215|levelshe dat
P07983716A1082 |14 22|Northern Compari
P07983716A1082 |90 102|transfectionrmacologic a
P07983716A1082 |143 147|RNAs0008
P07983716A1082 |162 166|Y88SSF [
P07983716A1082 |24 27|RNAn w
P07983716A1082 |55 73|transcriptase-PCRsd 5-nucleotidase P
P07983716A1082 |115 125|HeLa cellsnatal hype
P07983744A0920 |186 191|IE175 func
P07983744A0920 |144 149|IE11000899
P07983744A0920 |78 83|IE175171T0
P07983744A0920 |177 182|formshown 
P07983744A0920 |31 36|IE110alkal
P07983744A0920 |70 74|forme P0
P07983744A0920 |97 116|punctate structuresgic aspects of neon
P07983744A0920 |22 27|formsson w
P07983744A0920 |207 226|punctate structures the data of K-depl
P07983744A0920 |136 140|formmia.
P07984088A0592 |0 13|TranscriptionP00001606T007
P07984088A0592 |47 57|expressiontases and 
P07984088A0592 |30 42|ivanolysin O alkaline ph
P07984088A0592 |80 102|virulence gene cluster1T0000 Pharmacologic a
P07984088A0592 |67 72|genesdase 
P07984088A0592 |106 117|L. ivanoviits of neona
P07984088A0592 |21 25|geneison
P07984088A0592 |136 140|PrfAmia.
P07984105A1509 |102 117|mouse virulencespects of neona
P07984105A1509 |76 97|yersiniabactin uptake08171T0000 Pharmacolo
P07984105A1509 |13 28|complementation6 Comparison wi
P07984105A1509 |36 50|WA fyuA mutantine phosphatas
P07984105A1509 |65 74|fyuA genetidase P0
P07984261A0536 |51 60|reductions and 5-n
P07984261A0536 |26 32|cortexwith a
P07984261A0536 |106 113|tissuests of n
P07984261A0536 |80 86|centre1T0000
P07984261A0536 |4 8|ICBF0160
P07985305T0001 |17 31|hydronephrosismparison with 
P07985305T0001 |4 13|treatment01606T007
P07985305T0001 |35 43|childrenline pho
P07987924A0670 |68 94|USCI Tuohy-Borst Y adaptorase P00008171T0000 Pharmac
P07987924A0670 |132 146|probe hypotubebinemia. P0000
P07987924A0670 |25 30|probe with
P07987924A0670 |4 17|inflation hub01606T0076 Co
P07988559A0836 |24 35|RBP-J kappan with alka
P07988559A0836 |45 53|affinityhatases 
P07988559A0836 |10 17|element0076 Co
P07988730A0220 |168 180|transfectionO3-] is show
P07988730A0220 |31 41|constructsalkaline p
P07988730A0220 |91 94|LTRmac
P07988730A0220 |151 157|assays0472 W
P07988730A0220 |220 228|presenceK-deplet
P07988730A0220 |184 194|HeLa cells a functio
P07988730A0220 |249 275|transactivator tax protein displaced when compared t
P07988730A0220 |57 66|deletions5-nucleot
P07988730A0220 |146 149|CAT899
P07988730A0220 |10 27|promoter strength0076 Comparison w
P07988730A0220 |198 212|Jurkat T-cells CSF PCO2 the 
P07988730A0220 |74 83|U5 region0008171T0
P07988730A0220 |111 144|chloramphenicol acetyltransferase neonatal hyperbilirubinemia. P00
P07988730A0220 |232 239|absenceats are
P07988731A0002 |206 211|G-box2 the
P07988731A0002 |15 21|numberCompar
P07988731A0002 |213 221|CCACGTGGata of K
P07988731A0002 |78 87|promoters171T0000 
P07988731A0002 |167 184|promoter activityCO3-] is shown as
P07988731A0002 |114 122|presenceonatal h
P07988731A0002 |141 149|elementsP0000899
P07988731A1301 |82 101|GBF protein complex0000 Pharmacologic 
P07988731A1301 |31 35|GF14alka
P07988731A1301 |12 19|protein76 Comp
P07988945T0000 |0 3|NewP00
P07988945T0000 |15 25|strategiesComparison
P07988945T0000 |30 50|lupus anticoagulants alkaline phosphatas
P07988945T0000 |72 82|antibodiesP00008171T
P07990136A1124 |97 125|tRNA gene transcription unitgic aspects of neonatal hype
P07990136A1124 |228 237|complexesed rats a
P07990136A1124 |182 192|propertiesas a funct
P07990136A1124 |14 21|ability Compar
P07990136A1124 |25 54|selectivity arrest elongation with alkaline phosphatases a
P07990136A1124 |213 219|polIIIata of
P07990136A1124 |58 64|polIII-nucle
P07990136A1124 |76 85|positions08171T000
P07990136A1124 |144 158|identification008997A0472 Wh
P07991437A1032 |0 11|PropafenoneP00001606T0
P07991437A1032 |37 45|majorityne phosp
P07991437A1032 |55 63|patientsd 5-nucl
P07991582A1023 |80 86|motifs1T0000
P07991582A1023 |12 20|analysis76 Compa
P07991582A1023 |24 34|yeast CEG1n with alk
P07991582A1023 |113 128|enzyme functioneonatal hyperbi
P07992027A0485 |2 10|patients0001606T
P07992027A0485 |79 94|transplantation71T0000 Pharmac
P07992027A0485 |14 15|% 
P07992027A0485 |55 59|daysd 5-
P07992027A0485 |33 42|morbiditykaline ph
P07993559A0233 |51 58|Pendryss and 5
P07993559A0233 |91 97|reviewmacolo
P07993559A0233 |9 14|indexT0076
P07993559A0233 |16 36|Fluorosis Risk Indexomparison with alkal
P07994021A1223 |139 150|association. P00008997
P07994021A1223 |74 90|PECAM-1 isoforms0008171T0000 Pha
P07994021A1223 |40 44|tailphos
P07994021A1223 |109 124|phosphorylationof neonatal hyp
P07994021A1223 |12 20|splicing76 Compa
P07994021A1223 |156 175|affinity modulationWhen CSF [HCO3-] is
P07994021A1223 |190 197|proteinction o
P07995173A0585 |0 8|TransferP0000160
P07995173A0585 |58 59|r-
P07995173A0585 |48 56|juice pHases and
P07995173A0585 |70 71|Pe
P07995910A0119 |139 149|laparotomy. P0000899
P07995910A0119 |93 96|waycol
P07995910A0119 |21 32|sensitivityison with a
P07995910A0119 |39 50|specificity phosphatas
P07995910A0119 |5 14|technique1606T0076
P07995910A0119 |64 65|%o
P07995910A0119 |115 126|involvementnatal hyper
P07997174A0936 |51 58|His-304s and 5
P07997174A0936 |97 106|functionsgic aspec
P07997174A0936 |110 128|A. vinelandii NifLf neonatal hyperbi
P07997174A0936 |4 8|data0160
P07997174A0936 |32 47|phosphorylationlkaline phospha
P07999066A0238 |171 179|tat gene] is sho
P07999066A0238 |92 115|IL-2 gene transcriptionacologic aspects of neo
P07999066A0238 |183 196|phorbol esters a function 
P07999066A0238 |229 241|Jurkat cellsd rats are n
P07999066A0238 |12 19|HIV tat76 Comp
P07999066A0238 |153 163|expression72 When CS
P07999066A0238 |259 263|IL-2 whe
P07999066A0238 |289 326|acetyltransferase reporter constructs still have a significantly greater s
P07999066A0238 |39 55|enhancing factor phosphatases an
P07999066A0238 |66 69|LTRida
P07999066A0238 |78 88|regulation171T0000 P
P07999066A0238 |201 208|calciumF PCO2 
P07999066A0238 |4 8|role0160
P07999363A0000 |70 74|FGFRe P0
P07999363A0000 |42 68|transmembrane FGF receptorosphatases and 5-nucleotid
P07999363A0000 |182 195|kinase domainas a function
P07999363A0000 |21 26|genesison 
P07999363A0000 |112 122|ectodomainneonatal h
P07999363A0000 |7 17|variations06T0076 Co
P07999363A0000 |86 94|isoforms Pharmac
P07999363A0000 |138 158|juxtamembrane domaina. P00008997A0472 Wh
P07999604A0139 |80 87|lesions1T0000 
P07999604A0139 |25 33|patients with al
P07999982A0086 |205 211|searchO2 the
P07999982A0086 |72 77|D9S15P0000
P07999982A0086 |63 67|FRDAeoti
P07999982A0086 |46 50|D9S5atas
P07999982A0086 |37 41|FRDAne p
P07999982A0086 |163 183|recombination eventsF [HCO3-] is shown a
P07999982A0086 |10 28|maximum lod scores0076 Comparison wi
P07999982A0086 |219 223|gene K-d
P07999982A0086 |118 140|recombination fractional hyperbilirubinemia.
P07999995A0000 |16 30|protein kinaseomparison with
P07999995A0000 |61 65|ricecleo
P07999995A0000 |67 79|Oryza sativadase P000081
P07999995A0000 |32 38|OsPK10lkalin
P08000074A0162 |84 95|translation00 Pharmaco
P08000074A0162 |59 67|sequencenucleoti
P08000074A0162 |159 167|fragmentn CSF [H
P08000074A0162 |112 126|reading framesneonatal hyper
P08000074A0162 |144 150|kb DNA008997
P08000074A0162 |2 10|sequence0001606T
P08000074A0162 |32 33|%l
P08000112T0000 |0 11|GoodpastureP00001606T0
P08000112T0000 |57 84|membrane oxygenator support5-nucleotidase P00008171T00
P08000112T0000 |19 27|syndromearison w
P08000112T0000 |32 38|effectlkalin
P08000427A0000 |2 17|cDNA clone pCZ10001606T0076 Co
P08000427A0000 |142 153|kDa protein00008997A04
P08000427A0000 |74 99|tobacco cell cDNA library0008171T0000 Pharmacologi
P08000427A0000 |30 39|kb insert alkaline
P08000427A0000 |159 170|amino acidsn CSF [HCO3
P08000427A0000 |190 192|pIct
P08000497A0179 |0 7|METHODSP000016
P08000497A0179 |121 127|volumehyperb
P08000497A0179 |44 73|methacholine provocation testphatases and 5-nucleotidase P
P08000497A0179 |86 90|test Pha
P08000497A0179 |144 147|VTG008
P08000497A0179 |28 38|spirometryth alkalin
P08000497A0179 |101 108|airwaysaspects
P08000497A0179 |139 142|gas. P
P08001136T0000 |0 12|RelationshipP00001606T00
P08001136T0000 |60 82|CTD kinase TFIIH/TFIIKucleotidase P00008171T
P08001136T0000 |31 37|kinasealkali
P08001136T0000 |42 56|RNA polymeraseosphatases and
P08001792A0284 |16 20|git5ompa
P08001792A0284 |107 143|adenylate cyclase activation pathways of neonatal hyperbilirubinemia. P0
P08001792A0284 |28 32|git8th a
P08001792A0284 |37 48|git10 genesne phosphat
P08001792A0284 |22 26|git7son 
P08001792A0284 |10 14|git30076
P08001792A0284 |65 82|adenylate cyclasetidase P00008171T
P08001792A0284 |4 8|git10160
P08001966A0563 |84 90|skin-100 Pha
P08001966A0563 |11 18|regions076 Com
P08001966A0563 |37 45|homologyne phosp
P08001966A0563 |76 79|CNC081
P08001966A0563 |125 136|developmentrbilirubine
P08001966A0563 |66 74|proteinsidase P0
P08001966A0563 |168 190|Caenorhabditis elegansO3-] is shown as a fun
P08002564A0249 |137 145|positionia. P000
P08002564A0249 |46 54|mutationatases a
P08002564A0249 |166 175|rpoAL290HHCO3-] is
P08002564A0249 |155 164|histidine When CSF
P08002564A0249 |92 105|alpha subunitacologic aspe
P08002564A0249 |78 84|region171T00
P08002564A0249 |118 133|leucine residueal hyperbilirub
P08002564A0249 |0 21|DNA sequence analysisP00001606T0076 Compar
P08002857A1070 |0 11|CONCLUSIONSP00001606T0
P08002857A1070 |199 205|attackCSF PC
P08002857A1070 |209 213|bilehe d
P08002857A1070 |105 111|degreects of
P08002857A1070 |48 55|barrierases an
P08002857A1070 |115 125|protectionnatal hype
P08002857A1070 |59 81|oesophageal surfactantnucleotidase P00008171
P08002857A1070 |19 27|findingsarison w
P08002857A1070 |153 159|reflux72 Whe
P08003700T0000 |102 112|sugar-beetspects of 
P08003700T0000 |40 54|cDNA librariesphosphatases a
P08003700T0000 |13 22|screening6 Compari
P08003700T0000 |121 142|genome rearrangementshyperbilirubinemia. P
P08003700T0000 |146 150|atp68997
P08003700T0000 |155 164|atpA loci When CSF
P08004442A0265 |152 156|axis472 
P08004442A0265 |93 100|animalscologic
P08004442A0265 |147 150|HPA997
P08004442A0265 |195 219|corticosterone secretion of CSF PCO2 the data of
P08004442A0265 |52 70|locomotor activity and 5-nucleotidas
P08004442A0265 |22 31|isolationson with 
P08004442A0265 |163 170|animalsF [HCO3
P08004442A0265 |4 11|effects01606T0
P08004442A0265 |235 248|adrenalectomy are no longe
P08005230A0222 |71 81|activation P00008171
P08005230A0222 |89 103|c-fos promoterarmacologic as
P08005230A0222 |150 159|elevationA0472 Whe
P08005230A0222 |11 31|reporter gene system076 Comparison with 
P08005230A0222 |172 191|luciferase activity is shown as a func
P08005412A0608 |139 147|PS sites. P00008
P08005412A0608 |166 178|interactionsHCO3-] is sh
P08005412A0608 |25 40|gene expression with alkaline 
P08005412A0608 |72 81|formationP00008171
P08005412A0608 |46 47|Pa
P08005412A0608 |201 204|DNAF P
P08005412A0608 |87 102|protein complexPharmacologic a
P08005438A1185 |0 5|SPP41P0000
P08005438A1185 |146 155|regulator8997A0472
P08005438A1185 |104 119|suppressor srn1ects of neonata
P08005438A1185 |58 63|spp43-nucl
P08005438A1185 |159 174|gene expressionn CSF [HCO3-] i
P08006101A1142 |0 39|Standard curve correlation coefficientsP00001606T0076 Comparison with alkaline
P08006101A1142 |120 133|study samples hyperbilirub
P08006101A1142 |108 116|analysis of neon
P08006101A1142 |81 103|validation experimentsT0000 Pharmacologic as
P08006772A0000 |43 48|fetussphat
P08006772A0000 |120 126|labour hyper
P08006772A0000 |90 95|womenrmaco
P08006772A0000 |12 26|pulse oximeter76 Comparison 
P08006772A0000 |56 62|labour 5-nuc
P08006773A0836 |170 182|preeclampsia-] is shown 
P08006773A0836 |58 64|figure-nucle
P08006773A0836 |27 48|plasma concentrationsith alkaline phosphat
P08006773A0836 |242 243|p 
P08006773A0836 |122 134|preeclampsiayperbilirubi
P08006773A0836 |80 88|patients1T0000 P
P08006773A0836 |260 264|TxA2when
P08006773A0836 |188 208|plasma concentrationunction of CSF PCO2 
P08006773A0836 |52 56|PGI2 and
P08006773A0836 |212 216|PGI2data
P08006773A0836 |287 288|pu
P08006773A0836 |72 76|TxA2P000
P08006773A0836 |13 23|difference6 Comparis
P08006773A0836 |101 115|blood pressureaspects of neo
P08006773A0836 |139 150|hypotension. P00008997
P08007835A0538 |152 157|event472 W
P08007835A0538 |125 135|importancerbilirubin
P08007835A0538 |57 66|formation5-nucleot
P08007835A0538 |31 40|variablesalkaline 
P08007835A0538 |181 189|response as a fu
P08007835A0538 |197 201|newsf CS
P08007835A0538 |162 167|levelSF [H
P08007835A0538 |9 17|analysisT0076 Co
P08007835A0538 |116 121|levelatal 
P08007835A0538 |70 81|FB memoriese P00008171
P08007954A0374 |0 16|Deletion studiesP00001606T0076 C
P08007954A0374 |108 118|properties of neonat
P08007954A0374 |151 159|enhancer0472 Whe
P08007954A0374 |37 53|response elementne phosphatases 
P08007954A0374 |82 99|cytokine response0000 Pharmacologi
P08007975A0000 |4 13|IPL1 gene01606T007
P08007975A0000 |30 66|high-fidelity chromosome segregation alkaline phosphatases and 5-nucleot
P08007975A0000 |82 87|yeast0000 
P08011017A0169 |3 7|drop0016
P08011017A0169 |30 34|SaO2 alk
P08011017A0169 |11 28|oxygen saturation076 Comparison wi
P08011017A0169 |123 145|repeat polysomnographyperbilirubinemia. P000
P08011017A0169 |46 54|evidenceatases a
P08011017A0169 |93 96|EEGcol
P08011017A0169 |98 106|arousalsic aspec
P08011166A0207 |118 134|characterizational hyperbilirubi
P08011166A0207 |61 68|resultscleotid
P08011166A0207 |94 100|clonesologic
P08011166A0207 |182 190|segmentsas a fun
P08011166A0207 |13 30|gene organization6 Comparison with
P08011166A0207 |76 84|sequence08171T00
P08011166A0207 |138 154|polymerase chaina. P00008997A047
P08012448T0000 |0 4|INO2P000
P08012448T0000 |92 113|bud pattern formationacologic aspects of n
P08012448T0000 |27 32|yeastith a
P08012448T0000 |46 58|biosynthesisatases and 5
P08012448T0000 |76 87|segregation08171T0000 
P08012448T0000 |19 23|genearis
P08012566A0254 |103 108|limitpects
P08012566A0254 |131 136|ng/mlubine
P08012566A0254 |148 161|plasma sample97A0472 When 
P08012566A0254 |80 83|m/z1T0
P08012566A0254 |36 52|clonidine yieldsine phosphatases
P08012566A0254 |112 121|detectionneonatal 
P08012566A0254 |4 32|pentafluorobenzyl derivative01606T0076 Comparison with a
P08012566A0254 |64 76|ion fragmentotidase P000
P08013348A0143 |19 24|SHBGsariso
P08013348A0143 |72 90|binding propertiesP00008171T0000 Pha
P08013348A0143 |104 111|speciesects of
P08013348A0143 |30 42|sex steroids alkaline ph
P08013348A0143 |10 14|ABPs0076
P08013348A0143 |53 61|affinityand 5-nu
P08013457A0342 |51 63|interactionss and 5-nucl
P08013457A0342 |81 125|tyrosine kinase receptor signal transductionT0000 Pharmacologic aspects of neonatal hype
P08013457A0342 |14 16|SH C
P08013457A0342 |18 24|domainpariso
P08013457A0342 |0 12|Src homologyP00001606T00
P08014228A0278 |34 39|orderaline
P08014228A0278 |116 128|racemizationatal hyperbi
P08014228A0278 |76 102|labetalol diastereoisomers08171T0000 Pharmacologic a
P08014228A0278 |62 72|extractionleotidase 
P08014228A0278 |136 146|extractionmia. P0000
P08014228A0278 |0 16|Sample treatmentP00001606T0076 C
P08014377A1277 |152 163|interaction472 When CS
P08014377A1277 |75 83|outflows008171T0
P08014377A1277 |128 136|subjectslirubine
P08014377A1277 |26 41|activity levelswith alkaline p
P08014377A1277 |14 24|conditions Compariso
P08014377A1277 |202 211|divisions PCO2 the
P08014377A1277 |53 58|vagaland 5
P08014919A0530 |175 178|DGR sh
P08014919A0530 |41 46|unitshosph
P08014919A0530 |165 171|length[HCO3-
P08014919A0530 |127 134|rostralilirubi
P08014919A0530 |145 154|direction08997A047
P08014919A0530 |56 67|progression 5-nucleoti
P08014919A0530 |81 87|fieldsT0000 
P08014919A0530 |115 119|bodynata
P08015672A1282 |3 19|control patients001606T0076 Comp
P08015672A1282 |150 154|TypeA047
P08015672A1282 |61 65|Typecleo
P08015672A1282 |83 87|Type000 
P08015672A1282 |111 115|Type neo
P08015672A1282 |47 51|Typetase
P08015672A1282 |158 166|baselineen CSF [
P08015672A1282 |21 36|baseline imagesison with alkal
P08015850A1076 |16 24|analysisompariso
P08015850A1076 |60 77|Ga administrationucleotidase P0000
P08015850A1076 |79 88|preinjury71T0000 P
P08015850A1076 |193 201|efficacyon of CS
P08015850A1076 |28 41|dose responseth alkaline p
P08015850A1076 |210 218|compounde data o
P08015850A1076 |151 158|barrier0472 Wh
P08015850A1076 |43 47|timespha
P08015850A1076 |125 127|Garb
P08015850A1076 |109 121|availabilityof neonatal 
P08015850A1076 |92 102|postinjuryacologic a
P08015850A1076 |52 56|mode and
P08016102A1238 |101 105|AP-2aspe
P08016102A1238 |113 123|activationeonatal hy
P08016102A1238 |27 36|sequencesith alkal
P08016102A1238 |56 77|transcription factors 5-nucleotidase P0000
P08016102A1238 |241 245|HO-1o lo
P08016102A1238 |45 52|bindinghatases
P08016102A1238 |258 276|defense mechanismsd when compared to
P08016102A1238 |184 190|injury a fun
P08016102A1238 |86 96|NF-kappa B Pharmacol
P08016102A1238 |157 165|responsehen CSF 
P08016102A1238 |202 212|indication PCO2 the 
P08016102A1238 |230 234|role rat
P08016102A1238 |285 298|tissue injury but still ha
P08016102A1238 |173 177|cellis s
P08016102A1238 |4 12|presence01606T00
P08016189A0741 |0 11|GranisetronP00001606T0
P08016189A0741 |113 120|regimeneonatal
P08016189A0741 |52 58|nausea and 5
P08016189A0741 |73 85|intervention00008171T000
P08016189A0741 |39 47|vomiting phospha
P08016189A0741 |21 27|salineison w
P08017290A1347 |48 55|lactateases an
P08017290A1347 |90 111|potassium differencesrmacologic aspects of
P08017290A1347 |77 79|pH81
P08017290A1347 |125 130|grouprbili
P08017290A1347 |28 44|sinus differenceth alkaline phos
P08017290A1347 |140 146|pacing P0000
P08017290A1347 |81 85|PCO2T000
P08018361A0636 |35 50|neutron fluencyline phosphatas
P08018361A0636 |64 69|n/cm2otida
P08020702A0000 |0 11|EndotoxemiaP00001606T0
P08020702A0000 |142 146|wall0000
P08020702A0000 |37 45|bacteriane phosp
P08020702A0000 |148 156|lipid A.97A0472 
P08020702A0000 |65 70|shocktidas
P08020702A0000 |115 124|componentnatal hyp
P08020702A0137 |171 196|antibodies administration] is shown as a function 
P08020702A0137 |128 143|dog experimentslirubinemia. P0
P08020702A0137 |40 47|lipid Aphospha
P08020702A0137 |29 36|abilityh alkal
P08020702A0137 |113 124|endotoxemiaeonatal hyp
P08020702A0137 |93 105|disturbancescologic aspe
P08020702A0137 |59 69|antibodiesnucleotida
P08020702A0137 |4 9|study01606
P08020702A0137 |155 163|efficacy When CS
P08020806A0187 |81 88|diseaseT0000 P
P08020806A0187 |73 78|Crohn00008
P08020806A0187 |126 134|outcomesbilirubi
P08020806A0187 |199 211|feeding tubeCSF PCO2 the
P08020806A0187 |161 165|dietCSF 
P08020806A0187 |228 235|peptideed rats
P08020806A0187 |242 246|diet lon
P08020806A0187 |178 183|% fatown a
P08020806A0187 |144 154|amino acid008997A047
P08020806A0187 |25 30|trial with
P08020806A0187 |52 60|patients and 5-n
P08020806A0187 |260 265|% fatwhen 
P08020962A1226 |100 103|Alu as
P08020962A1226 |121 124|MERhyp
P08020962A1226 |15 21|regionCompar
P08020962A1226 |111 113|L1 n
P08020962A1226 |29 41|V beta locush alkaline p
P08020962A1226 |62 68|numberleotid
P08020962A1226 |83 95|DNA elements000 Pharmaco
P08020962A1226 |155 163|elements When CS
P08020965A0465 |84 94|transcript00 Pharmac
P08020965A0465 |22 28|regionson wi
P08020965A0465 |126 130|endsbili
P08020965A0465 |100 102|kb a
P08020965A0465 |139 149|transcript. P0000899
P08021175A0486 |170 175|sites-] is
P08021175A0486 |113 133|AMP receptor proteineonatal hyperbilirub
P08021175A0486 |92 101|consensusacologic 
P08021175A0486 |64 73|sequencesotidase P
P08021175A0486 |4 8|pexB0160
P08021175A0486 |39 50|nucleotides phosphatas
P08021175A0486 |18 24|regionpariso
P08021175A0486 |138 161|integration host factora. P00008997A0472 When 
P08021177A0000 |69 85|transport systemse P00008171T000
P08021177A0000 |131 140|promotersubinemia.
P08021177A0000 |172 193|Fur repressor protein is shown as a functi
P08021177A0000 |42 64|enterobactin synthesisosphatases and 5-nucle
P08021177A0000 |213 223|conditionsata of K-d
P08021177A0000 |4 13|fepA-entD01606T007
P08021177A0000 |18 34|fes-entF operonsparison with alk
P08021225A0000 |0 17|Sequence analysisP00001606T0076 Co
P08021225A0000 |161 170|DNA probeCSF [HCO3
P08021225A0000 |57 78|Alcaligenes eutrophus5-nucleotidase P00008
P08021225A0000 |121 137|dihydrolipoamidehyperbilirubinem
P08021225A0000 |172 174|A. i
P08021225A0000 |39 53|EcoRI-fragment phosphatases 
P08022212A0071 |278 300|phase angle alpha pi/2ontrols but still have
P08022212A0071 |122 142|low-frequency regionyperbilirubinemia. P
P08022212A0071 |302 313|conductance significan
P08022212A0071 |151 153|Hz04
P08022212A0071 |266 276|parametersompared to
P08022212A0071 |213 217|lineata 
P08022212A0071 |335 347|frequency G01 +/- 0.23 v
P08022212A0071 |360 383|ion relaxation time tau0733 Flurazepam thus ap
P08022212A0071 |29 42|two-frequencyh alkaline ph
P08022212A0071 |44 57|AC excitationphatases and 
P08022212A0071 |75 81|method008171
P08022212A0071 |87 108|admittance locus plotPharmacologic aspects
P08022212A0071 |350 354|1/R0P000
P08022212A0071 |110 113|ALPf n
P08023662T0000 |48 67|thromboplastin timeases and 5-nucleoti
P08023662T0000 |15 26|measurementComparison 
P08023662T0000 |72 88|prothrombin timeP00008171T0000 P
P08023662T0000 |108 115|monitor of neo
P08024139A0393 |35 45|hypothesisline phosp
P08024139A0393 |115 126|differencesnatal hyper
P08024139A0393 |212 222|impairmentdata of K-
P08024139A0393 |63 70|volumeseotidas
P08024139A0393 |3 11|addition001606T0
P08024139A0393 |184 193|solutions a functi
P08025074A0000 |140 144|shot P00
P08025074A0000 |15 20|studyCompa
P08025074A0000 |108 120|suture lysis of neonatal
P08025074A0000 |27 32|nylonith a
P08025074A0000 |177 184|prolenehown as
P08025074A0000 |162 168|DacronSF [HC
P08025074A0000 |76 96|laser energy density08171T0000 Pharmacol
P08025669A0724 |35 39|rpoNline
P08025669A0724 |73 78|sigma00008
P08025669A0724 |82 90|activity0000 Pha
P08025669A0724 |4 12|proteins01606T00
P08028671A0687 |50 59|antiserumes and 5-
P08028671A0687 |110 114|cAMPf ne
P08028671A0687 |126 134|promoterbilirubi
P08028671A0687 |89 102|transcriptionarmacologic a
P08028671A0687 |20 34|microinjectionrison with alk
P08028671A0687 |65 76|fibroblaststidase P000
P08029001A1020 |204 227|transcription machineryCO2 the data of K-deple
P08029001A1020 |182 188|targetas a f
P08029001A1020 |55 73|activator proteinsd 5-nucleotidase P
P08029001A1020 |6 13|results606T007
P08029001A1020 |78 92|RNA polymerase171T0000 Pharm
P08029001A1020 |33 38|classkalin
P08029001A1020 |139 148|component. P000089
P08029334T0000 |0 7|CloningP000016
P08029334T0000 |38 54|acid desaturasese phosphatases a
P08029334T0000 |18 31|plant omega-3parison with 
P08030239A0833 |34 38|formalin
P08030239A0833 |195 212|EHV-1 tk promoter of CSF PCO2 the 
P08030239A0833 |230 237|ability rats a
P08030239A0833 |148 165|activation domain97A0472 When CSF 
P08030239A0833 |72 91|amino acid residuesP00008171T0000 Phar
P08030239A0833 |49 60|polypeptideses and 5-n
P08030239A0833 |259 276|EHV-1 IE promoter when compared to
P08030243A1011 |137 141|NS35ia. 
P08030243A1011 |29 46|RNA capture assayh alkaline phosph
P08030243A1011 |52 61|multimers and 5-nu
P08030243A1011 |100 108|activity aspects
P08030704A1503 |0 10|CONCLUSIONP00001606T
P08030704A1503 |26 31|birthwith 
P08030704A1503 |123 128|womenperbi
P08030704A1503 |134 147|preterm labornemia. P00008
P08030704A1503 |161 165|termCSF 
P08030704A1503 |71 108|progesterone/17 beta-estradiol ratios P00008171T0000 Pharmacologic aspects
P08031424T0000 |0 8|KetamineP0000160
P08031424T0000 |60 71|ventilationucleotidase
P08031424T0000 |29 41|bronchospasmh alkaline p
P08031424T0000 |16 25|treatmentomparison
P08033490A0875 |102 109|diseasespects 
P08033490A0875 |3 13|conclusion001606T007
P08033490A0875 |156 164|patientsWhen CSF
P08033490A0875 |121 138|dosage adjustmenthyperbilirubinemi
P08033490A0875 |50 72|O-desmethylvenlafaxinees and 5-nucleotidase 
P08033490A0875 |207 213|ml/min the d
P08033490A0875 |19 30|dispositionarison with
P08033490A0875 |170 197|creatinine clearance values-] is shown as a function o
P08033490A0875 |34 45|venlafaxinealine phosp
P08034318A0724 |170 191|transcription factors-] is shown as a func
P08034318A0724 |109 119|similarityof neonata
P08034318A0724 |123 129|motifsperbil
P08034318A0724 |90 98|UBE sitermacolog
P08034318A0724 |140 147|members P00008
P08034318A0724 |20 28|sequencerison wi
P08034318A0724 |43 50|speciessphatas
P08034318A0724 |4 16|availability01606T0076 C
P08034318A0724 |155 166|NF-1 family When CSF [
P08034486A0579 |17 22|HSV-2mpari
P08034486A0579 |151 156|areas0472 
P08034486A0579 |4 13|incidence01606T007
P08034486A0579 |42 47|HSV-2ospha
P08034486A0579 |109 119|populationof neonata
P08034486A0579 |48 68|HSV-1 antibody ratioases and 5-nucleotid
P08034486A0579 |32 40|subjectslkaline 
P08034680A0180 |156 159|kDaWhe
P08034680A0180 |104 120|I kappa B kinaseects of neonatal
P08034680A0180 |134 138|massnemi
P08034680A0180 |198 208|I kappa B. CSF PCO2 
P08034680A0180 |79 89|activation71T0000 Ph
P08034680A0180 |41 51|NF-kappa Bhosphatase
P08034680A0180 |22 30|zeta PKCson with
P08034680A0180 |4 13|mechanism01606T007
P08034682T0000 |81 96|3T3 fibroblastsT0000 Pharmacol
P08034682T0000 |31 77|inositol 1,4,5-trisphosphate receptor subunitsalkaline phosphatases and 5-nucleotidase P0000
P08034682T0000 |7 17|expression06T0076 Co
P08034708A0000 |38 49|progenitorse phosphata
P08034708A0000 |120 125|genes hype
P08034708A0000 |161 176|differentiationCSF [HCO3-] is 
P08034708A0000 |57 75|eosinophil lineage5-nucleotidase P00
P08034708A0000 |14 19|basis Comp
P08034708A0000 |24 34|commitmentn with alk
P08034708A0000 |80 90|mechanisms1T0000 Pha
P08034741A0000 |33 49|characterizationkaline phosphata
P08034741A0000 |60 66|myosinucleot
P08034741A0000 |144 160|border myosin I.008997A0472 When
P08034741A0000 |72 75|ratP00
P08034741A0000 |14 28|identification Comparison wi
P08034741A0000 |53 56|myrand
P08034741A0000 |98 106|myosin Iic aspec
P08034742A0307 |0 2|M.P0
P08034742A0307 |8 10|D.6T
P08035498A0833 |70 84|A stem elemente P00008171T00
P08035498A0833 |13 30|computer analysis6 Comparison with
P08035498A0833 |45 54|sequenceshatases a
P08035498A0833 |114 134|AAV promoter regionsonatal hyperbilirubi
P08035498A0833 |3 11|addition001606T0
P08035499A0941 |35 44|stabilityline phos
P08035499A0941 |167 176|complexesCO3-] is 
P08035499A0941 |104 121|dissociation rateects of neonatal 
P08035499A0941 |90 94|factrmac
P08035499A0941 |65 74|complexestidase P0
P08035499A0941 |129 145|A stem substrateirubinemia. P000
P08035499A0941 |56 61|kinds 5-nu
P08035499A0941 |21 31|differenceison with 
P08035499A0941 |237 239|TRre
P08035505A0586 |0 10|ProcessingP00001606T
P08035505A0586 |24 37|B polyproteinn with alkali
P08035505A0586 |18 21|NS3par
P08035517A0753 |36 41|IEP86ine p
P08035517A0753 |90 95|IEP72rmaco
P08035517A0753 |14 22|promoter Compari
P08035517A0753 |78 86|addition171T0000
P08035796A0890 |119 134|phosphorylationl hyperbilirubi
P08035796A0890 |265 282|growth conditionscompared to contr
P08035796A0890 |228 235|strainsed rats
P08035796A0890 |79 92|casein kinase71T0000 Pharm
P08035796A0890 |192 203|eIF-2 alphaion of CSF 
P08035796A0890 |183 188|formss a f
P08035796A0890 |138 149|eIF-2 alphaa. P0000899
P08035796A0890 |38 46|analysise phosph
P08035796A0890 |96 103|mutantsogic as
P08035796A0890 |50 61|eIF-2 alphaes and 5-nu
P08035796A0890 |0 13|32Pi labelingP00001606T007
P08035833A1556 |101 117|import machineryaspects of neona
P08035833A1556 |38 42|RMIPe ph
P08035833A1556 |6 10|YMIP606T
P08035833A1556 |27 34|homologith alk
P08035833A1556 |64 73|componentotidase P
P08035833A1556 |81 86|yeastT0000
P08036004A0292 |119 135|binding activityl hyperbilirubin
P08036004A0292 |227 237|expressionted rats a
P08036004A0292 |89 94|cellsarmac
P08036004A0292 |61 68|elementcleotid
P08036004A0292 |4 13|R2 region01606T007
P08036004A0292 |219 224|class K-de
P08036004A0292 |25 30|class with
P08036004A0292 |33 41|enhancerkaline p
P08036004A0292 |187 192|cellsfunct
P08037338A0000 |85 97|pathogenesis0 Pharmacolo
P08037338A0000 |150 157|infantsA0472 W
P08037338A0000 |37 51|erythropoietinne phosphatase
P08037338A0000 |25 33|kinetics with al
P08037338A0000 |111 122|prematurity neonatal h
P08037338A0000 |58 68|production-nucleotid
P08037338A0000 |183 187|lifes a 
P08037338A0000 |101 107|anemiaaspect
P08037338A0000 |175 179|year sho
P08037338A0000 |53 56|EPOand
P08037338A0000 |136 146|EPO levelsmia. P0000
P08037338A0000 |0 7|PURPOSEP000016
P08039422A0000 |35 39|NGFBline
P08039422A0000 |73 78|group00008
P08039422A0000 |105 121|mouse Chromosomects of neonatal 
P08039422A0000 |88 98|chromosomeharmacolog
P08039422A0000 |4 33|nerve growth factor beta gene01606T0076 Comparison with al
P08040336A0435 |34 50|collagen elementaline phosphatas
P08040336A0435 |25 32|element with a
P08040336A0435 |128 144|albumin promoterlirubinemia. P00
P08040336A0435 |79 87|homology71T0000 
P08040336A0435 |97 120|LAP binding cis-elementgic aspects of neonatal
P08040336A0435 |154 156|bp2 
P08040391T0000 |51 59|clusterss and 5-
P08040391T0000 |11 15|size076 
P08040391T0000 |112 120|featuresneonatal
P08040391T0000 |82 93|correlation0000 Pharma
P08040391T0000 |125 141|tumour behaviourrbilirubinemia. 
P08040391T0000 |71 80|seminomas P0000817
P08040391T0000 |0 6|NumberP00001
P08040468A0303 |18 41|mast cell degranulationparison with alkaline p
P08040468A0303 |172 181|reactions is shown
P08040468A0303 |105 131|fibroblast enzyme activitycts of neonatal hyperbilir
P08040468A0303 |65 77|pathogenesistidase P0000
P08040468A0303 |81 92|necrobiosisT0000 Pharm
P08041362T0000 |138 147|auxotropha. P00008
P08041362T0000 |61 69|vulgariscleotida
P08041362T0000 |10 17|cloning0076 Co
P08041362T0000 |94 109|complementationologic aspects 
P08041362T0000 |133 136|Cysine
P08041362T0000 |23 45|cysteine synthase cDNAon with alkaline phosp
P08041362T0000 |71 81|watermelon P00008171
P08041793A0242 |140 145|genes P000
P08041793A0242 |147 152|COX5b997A0
P08041793A0242 |11 18|studies076 Com
P08041793A0242 |90 100|activationrmacologic
P08041793A0242 |52 60|elements and 5-n
P08041793A0242 |113 123|repressioneonatal hy
P08043523A0000 |34 44|antibodiesaline phos
P08043523A0000 |62 84|acetylcholine receptorleotidase P00008171T00
P08043523A0000 |135 143|patientsemia. P0
P08043523A0000 |18 30|serum levelsparison with
P08043523A0000 |174 184|antibodiess shown as
P08043523A0000 |157 167|dyskinesiahen CSF [H
P08043523A0000 |86 91|nAChR Phar
P08043523A0000 |238 246|patientse no lon
P08044794A0000 |4 20|tumor suppressor01606T0076 Compa
P08044794A0000 |72 79|proteinP000081
P08044794A0000 |41 51|factor p53hosphatase
P08044800A0550 |64 72|entiretyotidase 
P08044800A0550 |123 128|sitesperbi
P08044800A0550 |5 37|DNA containing promoter activity1606T0076 Comparison with alkali
P08044802A0462 |154 157|p532 W
P08044802A0462 |109 123|rearrangementsof neonatal hy
P08044802A0462 |88 99|copy numberharmacologi
P08044802A0462 |9 22|Southern blotT0076 Compari
P08044802A0462 |131 139|p53 geneubinemia
P08044802A0462 |27 45|karyotype analysesith alkaline phosp
P08044802A0462 |77 84|changes8171T00
P08044802A0462 |159 169|cell linesn CSF [HCO
P08045431A0894 |0 4|HupIP000
P08045431A0894 |62 70|proteinsleotidas
P08045431A0894 |31 41|rubredoxinalkaline p
P08045431A0894 |19 27|identityarison w
P08045431A0894 |87 95|bacteriaPharmaco
P08045834A0783 |84 97|ATP synthesis00 Pharmacolo
P08045834A0783 |26 27|Pw
P08045834A0783 |62 66|rateleot
P08045834A0783 |99 100|Pc
P08045834A0783 |4 24|PCr resynthesis rate01606T0076 Compariso
P08046923A0000 |35 43|patientsline pho
P08046923A0000 |104 113|resectionects of n
P08046923A0000 |73 85|osteomalacia00008171T000
P08046923A0000 |3 14|examination001606T0076
P08048582A0821 |205 208|g-1O2 
P08048582A0821 |125 128|g-1rbi
P08048582A0821 |183 200|ml O2.min-1 timess a function of C
P08048582A0821 |138 148|LAD regiona. P000089
P08048582A0821 |18 22|MVO2pari
P08048582A0821 |65 68|CFXtid
P08048582A0821 |103 120|ml O2.min-1 timespects of neonatal
P08048582A0821 |51 57|extents and 
P08048916A0000 |0 5|IGF IP0000
P08048916A0000 |10 27|insulin receptors0076 Comparison w
P08048916A0000 |43 51|proteinssphatase
P08048916A0000 |92 100|pathwaysacologic
P08049401A0428 |51 74|glucocorticoid activitys and 5-nucleotidase P0
P08049401A0428 |115 122|changesnatal h
P08049401A0428 |39 47|increase phospha
P08049401A0428 |126 142|thyroid hormonesbilirubinemia. P
P08049401A0428 |86 92|cortex Pharm
P08049401A0428 |0 16|ImmunodepressionP00001606T0076 C
P08049444A0351 |117 124|proteintal hyp
P08049444A0351 |162 167|SATB1SF [H
P08049444A0351 |242 245|DNA lo
P08049444A0351 |75 82|protein008171T
P08049444A0351 |231 238|regionsrats ar
P08049444A0351 |8 16|cleavage6T0076 C
P08049444A0351 |247 256|MARs/SARser displa
P08049444A0351 |143 158|binding protein0008997A0472 Wh
P08049444A0351 |21 46|peptide sequence analysisison with alkaline phosph
P08049521T0000 |86 92|action Pharm
P08049521T0000 |9 32|protein phosphorylationT0076 Comparison with a
P08049521T0000 |123 128|yeastperbi
P08049521T0000 |36 44|tyrosineine phos
P08049521T0000 |96 105|pp60v-srcogic aspe
P08049885T0000 |6 18|pancreatitis606T0076 Com
P08049885T0000 |22 41|multisystem diseaseson with alkaline p
P08051019A0365 |9 21|biosynthesisT0076 Compar
P08051019A0365 |60 69|mechanismucleotida
P08051059A1000 |117 131|RhlR regulatortal hyperbilir
P08051059A1000 |95 108|binding siteslogic aspects
P08051059A1000 |29 42|rhlA promoterh alkaline ph
P08051059A1000 |65 72|repeatstidase 
P08051059A1000 |4 12|sequence01606T00
P08051074A0000 |169 178|digestion3-] is sh
P08051074A0000 |107 111|types of
P08051074A0000 |44 50|regionphatas
P08051074A0000 |161 166|DNaseCSF [
P08051074A0000 |29 41|footprintingh alkaline p
P08051074A0000 |122 130|promoteryperbili
P08051074A0000 |83 105|immunodeficiency virus000 Pharmacologic aspe
P08051074A0000 |115 120|HIV-1natal
P08051102A0532 |0 7|HeparinP000016
P08051102A0532 |104 109|formsects 
P08051102A0532 |45 71|chain phosphatase activityhatases and 5-nucleotidase
P08051102A0532 |15 21|effectCompar
P08051102A0532 |25 38|rAC-st myosin with alkalin
P08051102A0532 |83 84|B0
P08051151A0347 |153 163|cell lines72 When CS
P08051151A0347 |109 123|chain reactionof neonatal hy
P08051151A0347 |13 22|abundance6 Compari
P08051151A0347 |53 57|mRNAand 
P08051151A0347 |141 148|tissuesP000089
P08053697A0000 |0 10|BACKGROUNDP00001606T
P08053697A0000 |149 157|diameter7A0472 W
P08053697A0000 |74 91|hyperpigmentation0008171T0000 Phar
P08053697A0000 |105 109|dotscts 
P08053697A0000 |15 21|DESIGNCompar
P08053697A0000 |66 70|fociidas
P08053697A0000 |214 224|correlatesta of K-de
P08053697A0000 |46 50|neviatas
P08053697A0000 |143 145|mm00
P08053697A0000 |237 241|dotsre n
P08054281A0731 |71 80|potential P0000817
P08054281A0731 |183 195|201Tl uptakes a function
P08054281A0731 |107 117|predictions of neona
P08054281A0731 |47 56|indicatortases and
P08054281A0731 |121 130|prognosishyperbili
P08054281A0731 |23 34|201Tl SPECTon with alk
P08054281A0731 |162 174|relationshipSF [HCO3-] i
P08054281A0731 |145 152|insight08997A0
P08054281A0731 |200 210|malignancySF PCO2 th
P08054281A0731 |4 19|retention index01606T0076 Comp
P08055939A0159 |55 62|regionsd 5-nuc
P08055939A0159 |74 86|H1 molecules0008171T0000
P08055939A0159 |142 159|hexapeptide motif00008997A0472 Whe
P08055939A0159 |199 211|H1 moleculesCSF PCO2 the
P08055939A0159 |161 169|variantsCSF [HCO
P08055939A0159 |114 120|domainonatal
P08055939A0159 |21 27|domainison w
P08055939A0707 |205 209|exonO2 t
P08055939A0707 |163 167|exonF [H
P08055939A0707 |144 150|region008997
P08055939A0707 |76 82|tomato08171T
P08055939A0707 |43 49|intronsphata
P08055939A0707 |29 35|lengthh alka
P08055939A0707 |115 121|intronnatal 
P08055939A0707 |4 12|location01606T00
P08055939A0707 |197 203|domainf CSF 
P08055939A0707 |138 142|nosea. P
P08055939A0707 |87 104|Arabidopsis genesPharmacologic asp
P08055941A1264 |17 22|chainmpari
P08055941A1264 |79 85|capsid71T000
P08055941A1264 |120 124|beta hyp
P08055941A1264 |112 117|alphaneona
P08055941A1264 |59 75|artifactual betanucleotidase P00
P08055941A1264 |128 134|enzymelirubi
P08055941A1264 |4 12|topology01606T00
P08055941A1264 |38 51|beta subunitse phosphatase
P08056474A0438 |33 34|%k
P08056474A0438 |45 46|%h
P08056474A0438 |106 107|%t
P08056474A0438 |74 75|%0
P08056474A0438 |60 61|%u
P08056474A0438 |9 13|NMSCT007
P08056474A0438 |96 97|%o
P08057356A0531 |84 102|response regulator00 Pharmacologic a
P08057356A0531 |41 53|substitutionhosphatases 
P08057356A0531 |104 110|regionects o
P08057356A0531 |22 26|formson 
P08057356A0531 |55 59|V88Ad 5-
P08057356A1824 |0 11|ComparisonsP00001606T0
P08057356A1824 |131 138|spacingubinemi
P08057356A1824 |73 87|NarL heptamers00008171T0000 
P08057356A1824 |24 46|operon control regionsn with alkaline phosph
P08057356A1824 |114 126|orientationsonatal hyper
P08057421A1583 |171 184|CD23 promoter] is shown as
P08057421A1583 |230 237|Cp site rats a
P08057421A1583 |193 217|EBV LMP-1 promoter siteson of CSF PCO2 the data 
P08057421A1583 |136 140|CBF1mia.
P08057421A1583 |19 37|competition assaysarison with alkali
P08057421A1583 |7 14|binding06T0076
P08057421A1583 |51 73|oligonucleotide probess and 5-nucleotidase P
P08057421A1583 |102 120|CBF1 binding sitesspects of neonatal
P08057762A0878 |152 153|%4
P08057762A0878 |133 135|T1in
P08057762A0878 |72 73|%P
P08057762A0878 |29 44|reproducibilityh alkaline phos
P08057762A0878 |62 63|%l
P08057762A0878 |55 57|T1d 
P08057762A0878 |65 67|T2ti
P08057762A0878 |144 146|T200
P08057762A0878 |141 142|%P
P08057762A0878 |86 101|reproducibility Pharmacologic 
P08057833A0573 |141 154|reading frameP00008997A047
P08057833A0573 |107 119|start codonss of neonata
P08057833A0573 |45 51|resulthatase
P08057833A0573 |8 21|ParA proteins6T0076 Compar
P08057833A0573 |67 89|translation initiationdase P00008171T0000 Ph
P08058326A0463 |67 83|tal-1 expressiondase P00008171T0
P08058326A0463 |167 179|counterpartsCO3-] is sho
P08058326A0463 |105 114|sequencescts of ne
P08058326A0463 |15 23|insightsComparis
P08058326A0463 |43 53|mechanismssphatases 
P08058326A0463 |129 133|geneirub
P08058948A0810 |51 55|roles an
P08058948A0810 |107 110|CRFs o
P08058948A0810 |93 101|patientscologic 
P08058948A0810 |24 35|angiographyn with alka
P08058948A0810 |63 72|detectioneotidase 
P08058948A0810 |82 89|nodules0000 Ph
P08058948A0810 |0 10|CONCLUSIONP00001606T
P08062824A0626 |34 41|FKBP-33aline p
P08062824A0626 |86 104|isomerase activity Pharmacologic asp
P08062824A0626 |15 21|domainCompar
P08062824A0626 |138 148|activitiesa. P000089
P08062824A0626 |154 161|FKBP-122 When 
P08062833A0000 |69 86|mouse desmin genese P00008171T0000
P08062833A0000 |13 15|nt6 
P08062833A0000 |121 133|binding sitehyperbilirub
P08062833A0000 |105 110|E boxcts o
P08062833A0000 |230 240|expression rats are 
P08062833A0000 |208 213|levelthe d
P08062833A0000 |167 177|regulatorsCO3-] is s
P08062833A0000 |112 114|E1ne
P08062833A0000 |32 61|transcription initiation sitelkaline phosphatases and 5-nu
P08063108A0109 |84 91|protein00 Phar
P08063108A0109 |30 32|nt a
P08063108A0109 |80 82|aa1T
P08063108A0109 |4 13|acfD gene01606T007
P08063766A0595 |84 88|rate00 P
P08063766A0595 |13 17|beta6 Co
P08063766A0595 |165 170|rates[HCO3
P08063766A0595 |74 79|times00081
P08063766A0595 |21 24|PKCiso
P08063766A0595 |92 101|alpha PKCacologic 
P08063766A0595 |146 153|lamin B8997A04
P08063766A0595 |48 64|envelope lamin Bases and 5-nucle
P08063766A0595 |116 123|kinasesatal hy
P08063775T0000 |51 56|PTHrPs and
P08063775T0000 |58 73|gene expression-nucleotidase P
P08063775T0000 |42 49|proteinosphata
P08063775T0000 |0 10|RegulationP00001606T
P08063791A1370 |137 149|Ras proteinsia. P0000899
P08063791A1370 |6 13|results606T007
P08063791A1370 |41 44|sethos
P08063791A1370 |104 117|modificationsects of neona
P08063791A1370 |66 81|sequence motifsidase P00008171
P08063791A1370 |153 158|yeast72 Wh
P08063836A0904 |17 22|c-Ablmpari
P08063836A0904 |72 83|requirementP00008171T0
P08063836A0904 |88 99|DNA bindingharmacologi
P08063836A0904 |33 52|c-myc transcriptionkaline phosphatases
P08063836A0904 |103 108|c-Ablpects
P08064351A1020 |0 12|Long-latencyP00001606T00
P08064351A1020 |40 46|shocksphosph
P08064351A1020 |89 91|msar
P08064351A1020 |75 82|latency008171T
P08064351A1020 |59 65|jitternucleo
P08064351A1020 |21 26|unitsison 
P08065310A1144 |158 167|inhibitoren CSF [H
P08065310A1144 |56 74|heterodimerization 5-nucleotidase P0
P08065310A1144 |195 215|receptor gene family of CSF PCO2 the dat
P08065310A1144 |181 187|member as a 
P08065310A1144 |27 33|heptadith al
P08065310A1144 |125 136|interactionrbilirubine
P08065324A0458 |51 56|maizes and
P08065324A0458 |88 91|USEhar
P08065324A0458 |22 32|expressionson with a
P08065324A0458 |77 82|plant8171T
P08065324A0458 |149 162|transcription7A0472 When C
P08065324A0458 |36 47|snRNA genesine phospha
P08065324A0458 |96 109|TATA elementsogic aspects 
P08065327A0000 |95 117|germ line micronucleuslogic aspects of neona
P08065327A0000 |46 57|developmentatases and 
P08065327A0000 |73 85|macronucleus00008171T000
P08065327A0000 |130 140|protozoansrubinemia.
P08065327A0000 |10 27|DNA rearrangement0076 Comparison w
P08065331A0279 |171 172|t]
P08065331A0279 |188 197|leukemiasunction o
P08065331A0279 |67 80|DNA sequencesdase P0000817
P08065331A0279 |132 148|E2A-HLF proteinsbinemia. P000089
P08065331A0279 |20 44|site selection procedurerison with alkaline phos
P08065331A0279 |115 118|HLFnat
P08065338T0000 |4 9|Oct-201606
P08065338T0000 |94 104|duplicatesologic asp
P08065338T0000 |131 144|transcriptionubinemia. P00
P08065338T0000 |42 60|activation domainsosphatases and 5-n
P08065365A0000 |0 7|BindingP000016
P08065365A0000 |61 69|pre-mRNAcleotida
P08065365A0000 |11 13|U207
P08065365A0000 |47 52|snRNPtases
P08065365A0000 |28 45|ribonucleoproteinth alkaline phosp
P08065365A0000 |96 100|stepogic
P08065365A0000 |116 124|assemblyatal hyp
P08065366A0918 |71 93|chromosome segregation P00008171T0000 Pharma
P08065366A0918 |63 67|roleeoti
P08065366A0918 |20 24|datariso
P08065366A0918 |38 43|Dbf8pe pho
P08065368A0839 |0 5|ArigaP0000
P08065368A0839 |7 14|Biochem06T0076
P08065901A0997 |102 115|transcriptionspects of neo
P08065901A0997 |182 195|KRAB-A domainas a function
P08065901A0997 |243 252|apparatuslonger di
P08065901A0997 |30 41|KRAB domain alkaline p
P08065901A0997 |200 210|componentsSF PCO2 th
P08065901A0997 |157 169|interactionshen CSF [HCO
P08065901A0997 |83 92|ZFP genes000 Pharm
P08065901A0997 |4 11|results01606T0
P08065901A0997 |68 74|regionase P0
P08066094T0000 |0 11|Marine oilsP00001606T0
P08066094T0000 |31 41|reactivityalkaline p
P08067013T0001 |119 127|diseasesl hyperb
P08067013T0001 |15 27|significanceComparison w
P08067013T0001 |31 64|creatine phosphokinase antibodiesalkaline phosphatases and 5-nucle
P08067013T0001 |80 86|muscle1T0000
P08067123A0248 |279 294|anti-HCV-C100-3ntrols but stil
P08067123A0248 |53 56|useand
P08067123A0248 |267 273|donorsmpared
P08067123A0248 |28 34|assaysth alk
P08067123A0248 |302 307|blood sign
P08067123A0248 |180 186|Moscown as a
P08067123A0248 |60 85|assay systems ORTHO ELISAucleotidase P00008171T000
P08067123A0248 |90 104|ABBOTT HCV EIArmacologic asp
P08067123A0248 |134 149|anti-HCV-C100-3nemia. P0000899
P08067123A0248 |164 176|blood donors [HCO3-] is 
P08067123A0248 |17 24|resultsmpariso
P08067123A0248 |254 255|%l
P08067123A0248 |116 130|detection rateatal hyperbili
P08067123A0248 |106 109|USAts 
P08067123A0248 |316 317|p 
P08067123A0248 |195 196|% 
P08067123A0248 |312 313|%n
P08067123A0248 |235 249|HBsAg carriers are no longer
P08067546A0000 |254 278|vasoconstrictor activitylaced when compared to c
P08067546A0000 |45 64|vasomotor responseshatases and 5-nucle
P08067546A0000 |199 201|NOCS
P08067546A0000 |124 127|STPerb
P08067546A0000 |79 82|ETO71T
P08067546A0000 |192 197|oxideion o
P08067546A0000 |105 122|sodium thiopentalcts of neonatal h
P08067546A0000 |293 296|dogll 
P08067546A0000 |213 229|vasodilator toneata of K-deplete
P08067546A0000 |162 169|effectsSF [HCO
P08067546A0000 |16 26|hypothesisomparison 
P08067546A0000 |85 93|propofol0 Pharma
P08067607A0568 |115 119|dogsnata
P08067607A0568 |43 66|serum CRP concentrationsphatases and 5-nucleot
P08067607A0568 |27 38|CBC resultsith alkalin
P08067607A0568 |12 23|alterations76 Comparis
P08067607A0568 |127 140|control groupilirubinemia.
P08067607A0568 |82 97|baseline values0000 Pharmacolo
P08069298A0492 |51 54|RNAs a
P08069298A0492 |104 125|leptomeningeal tissueects of neonatal hype
P08069298A0492 |175 178|LMC sh
P08069298A0492 |145 149|line0899
P08069298A0492 |77 84|sources8171T00
P08069298A0492 |18 33|splice variantsparison with al
P08069298A0492 |153 173|leptomeningeal cells72 When CSF [HCO3-] 
P08069427T0000 |0 27|Roux-en-Y gastroenterostomyP00001606T0076 Comparison w
P08069427T0000 |62 73|gallbladderleotidase P
P08069427T0000 |46 54|emptyingatases a
P08069481A0736 |50 62|calf muscleses and 5-nuc
P08069481A0736 |13 24|experiments6 Compariso
P08069481A0736 |28 36|phantomsth alkal
P08070004A0782 |19 28|variationarison wi
P08070004A0782 |150 158|patientsA0472 Wh
P08070004A0782 |90 106|plasma half-lifermacologic aspec
P08070004A0782 |143 146|min000
P08070004A0782 |37 54|PCZ plasma levelsne phosphatases a
P08070004A0782 |108 118|t1/2 alpha of neonat
P08070004A0782 |173 182|mg/m2 PCZis shown 
P08070004A0782 |64 69|ng/mlotida
P08070393A0631 |35 44|ng/ml EGFline phos
P08070393A0631 |73 75|h.00
P08070393A0631 |12 18|effect76 Com
P08070393A0631 |53 61|time lagand 5-nu
P08070654A0000 |68 71|SPBase
P08070654A0000 |26 35|componentwith alka
P08070654A0000 |108 123|SPB duplication of neonatal hy
P08070654A0000 |57 66|pole body5-nucleot
P08070654A0000 |94 103|karyogamyologic as
P08070654A0000 |43 48|yeastsphat
P08070654A0000 |0 4|KAR1P000
P08070654A0574 |68 75|proteinase P00
P08070654A0574 |130 137|proteinrubinem
P08070654A0574 |22 37|SPB duplicationson with alkali
P08070654A0574 |178 182|bodyown 
P08070654A0574 |108 126|caltractin/centrin of neonatal hyper
P08070654A0574 |158 171|Chlamydomonasen CSF [HCO3-
P08070654A0574 |0 5|CDC31P0000
P08071356A0232 |85 105|transcription bubble0 Pharmacologic aspe
P08071356A0232 |7 28|transcript elongation06T0076 Comparison wi
P08071356A0232 |126 149|transcription complexesbilirubinemia. P0000899
P08071356A0232 |47 60|DNA footprinttases and 5-n
P08071356A0232 |170 188|template positions-] is shown as a f
P08071356A0232 |34 39|sizesaline
P08071982T0000 |36 44|syndromeine phos
P08072352A0567 |35 36|%l
P08072352A0567 |56 57|% 
P08072352A0567 |63 82|aspirin sensitivityeotidase P00008171T
P08072352A0567 |120 121|% 
P08072352A0567 |90 91|%r
P08072352A0567 |97 109|eosinophiliagic aspects 
P08072352A0567 |42 48|asthmaosphat
P08072352A0567 |8 16|patients6T0076 C
P08072352A0567 |143 153|IgE levels0008997A04
P08072352A0567 |21 27|polypsison w
P08072547A0690 |68 73|c-Junase P
P08072547A0690 |96 105|positionsogic aspe
P08072547A0690 |77 92|serine residues8171T0000 Pharm
P08072547A0690 |150 158|activityA0472 Wh
P08072547A0690 |33 48|protein kinaseskaline phosphat
P08072547A0690 |0 3|RasP00
P08072547A1009 |102 106|partspec
P08072547A1009 |149 154|c-Fos7A047
P08072547A1009 |67 72|c-Jundase 
P08072547A1009 |8 16|sequence6T0076 C
P08072547A1009 |89 94|c-Fosarmac
P08072547A1009 |39 63|JNK phosphorylation site phosphatases and 5-nucl
P08072547A1009 |114 131|activation domainonatal hyperbilir
P08072547T0000 |0 5|c-FosP0000
P08072547T0000 |61 75|protein kinasecleotidase P00
P08072547T0000 |90 93|JNKrma
P08072547T0000 |22 30|activityson with
P08072547T0000 |98 101|ERKic 
P08073505T0000 |68 75|examplease P00
P08073505T0000 |6 16|generation606T0076 C
P08073505T0000 |52 62|biologists and 5-nuc
P08073505T0000 |83 100|ExPASy WWW server000 Pharmacologic
P08073505T0000 |20 47|information retrieval toolsrison with alkaline phospha
P08075070A1632 |84 98|operator sites00 Pharmacolog
P08075070A1632 |182 188|motifsas a f
P08075070A1632 |63 68|helixeotid
P08075070A1632 |73 80|contact0000817
P08075070A1632 |210 218|proteinse data o
P08075070A1632 |104 121|repressor domainsects of neonatal 
P08075070A1632 |10 18|features0076 Com
P08075070A1632 |177 180|HTHhow
P08075070A1632 |130 149|sequence homologiesrubinemia. P0000899
P08075070A1632 |27 32|modelith a
P08075070A1632 |52 55|DNA an
P08075421A0621 |50 60|C terminuses and 5-n
P08075421A0621 |50 60|C terminuses and 5-n
P08075421A0621 |64 69|HrpJ2otida
P08075421A0621 |13 16|ORF6 C
P08075421A0621 |13 16|ORF6 C
P08075421A0621 |64 69|HrpJ2otida
P08076631A0000 |255 261|SaOs-2aced w
P08076631A0000 |15 40|transcription factor AP-1Comparison with alkaline 
P08076631A0000 |142 146|VDRE0000
P08076631A0000 |161 177|osteocalcin geneCSF [HCO3-] is s
P08076631A0000 |135 139|AP-1emia
P08076631A0000 |269 292|osteosarcoma cell linesared to controls but st
P08076631A0000 |45 63|vitamin D receptorhatases and 5-nucl
P08076631A0000 |87 91|AP-1Phar
P08076631A0000 |4 11|binding01606T0
P08076631A0000 |65 68|VDRtid
P08076631A0000 |222 227|MG-63deple
P08076631A0000 |118 133|promoter regional hyperbilirub
P08076937A0851 |102 117|mismatch primerspects of neona
P08076937A0851 |95 98|DNAlog
P08076937A0851 |6 15|detection606T0076 
P08076937A0851 |24 32|mutationn with a
P08076937A0851 |161 183|Tru9I restriction siteCSF [HCO3-] is shown a
P08076937A0851 |48 69|restriction digestionases and 5-nucleotida
P08076937A0851 |136 150|point mutationmia. P00008997
P08077236A0243 |85 95|COS7 cells0 Pharmaco
P08077236A0243 |66 72|levelsidase 
P08077236A0243 |76 80|COS10817
P08077236A0243 |21 30|Epo cDNAsison with
P08077236A0243 |0 9|Wild typeP00001606
P08078167A0000 |0 9|OBJECTIVEP00001606
P08078167A0000 |25 29|risk wit
P08078167A0000 |62 71|travelersleotidase
P08078167A0000 |33 44|hepatitis Akaline phos
P08078167A0000 |100 108|measures aspects
P08078416A0581 |119 133|concentrationsl hyperbilirub
P08078416A0581 |141 154|disinfectantsP00008997A047
P08078416A0581 |27 40|disinfectantsith alkaline 
P08078416A0581 |49 62|biofilm cellsses and 5-nuc
P08078416A0581 |17 23|effectmparis
P08078473A1107 |0 10|ExpressionP00001606T
P08078473A1107 |14 24|ME31B cDNA Compariso
P08078473A1107 |28 30|S.th
P08078473A1107 |52 66|ste13 mutation and 5-nucleot
P08079268T0028 |0 3|UseP00
P08079268T0028 |7 30|Medi-Jector EZ dermojet06T0076 Comparison with
P08079268T0028 |55 62|surgeryd 5-nuc
P08079268T0028 |35 45|anesthesialine phosp
P08082215A0230 |64 72|patientsotidase 
P08082215A0230 |41 56|cytomegalovirushosphatases and
P08082215A0230 |11 19|response076 Comp
P08082215A0230 |76 80|RTID0817
P08082215A0230 |23 37|past-infectionon with alkali
P08082286A0748 |0 18|Acupuncture effectP00001606T0076 Com
P08082286A0748 |27 36|receptorsith alkal
P08082286A0748 |60 65|pointucleo
P08082286A0748 |108 114|effect of ne
P08082286A0748 |87 91|areaPhar
P08082292T0000 |103 115|tuberculosispects of neo
P08082292T0000 |8 19|NK activity6T0076 Comp
P08082292T0000 |43 50|diseasesphatas
P08082292T0000 |59 67|patientsnucleoti
P08082292T0000 |54 57|HIVnd 
P08082360A0411 |0 15|Smoking historyP00001606T0076 
P08082360A0411 |45 49|SaO2hata
P08082360A0411 |26 43|oxygen saturationwith alkaline pho
P08082440A0339 |2 6|LH P0001
P08082440A0339 |15 23|LH/FSH PComparis
P08083011A0584 |136 152|R-L brain weightmia. P00008997A0
P08083011A0584 |126 130|catsbili
P08083011A0584 |28 35|weightsth alka
P08083011A0584 |13 14|R6
P08083011A0584 |195 203|estrogen of CSF 
P08083011A0584 |116 118|RHat
P08083011A0584 |188 193|malesuncti
P08083011A0584 |172 184|testosterone is shown as
P08083011A0584 |87 103|R-L brain weightPharmacologic as
P08083011A0584 |207 214|females the da
P08083220A0988 |21 38|complex formationison with alkalin
P08083220A0988 |228 235|complexed rats
P08083220A0988 |195 209|serum response of CSF PCO2 t
P08083220A0988 |120 129|formation hyperbil
P08083220A0988 |45 53|contrasthatases 
P08083220A0988 |179 187|assemblywn as a 
P08083220A0988 |145 152|complex08997A0
P08083220A0988 |77 85|promoter8171T000
P08083220A0988 |93 112|c-fos protooncogenecologic aspects of 
P08083220A0988 |5 9|mode1606
P08083963A0795 |35 41|a1/EBPline p
P08083963A0795 |62 77|extract proteinleotidase P0000
P08083963A0795 |47 53|B-celltases 
P08083963A0795 |30 33|VBP al
P08083963A0795 |143 174|methylation interference assays0008997A0472 When CSF [HCO3-] i
P08083963A0795 |125 137|footprintingrbilirubinem
P08083963A0795 |106 115|gel shiftts of neo
P08083963A0795 |117 122|DNasetal h
P08083963A0795 |16 26|activitiesomparison 
P08083998A1723 |50 75|coronavirus transcriptiones and 5-nucleotidase P00
P08083998A1723 |100 119|RNA-RNA interaction aspects of neonata
P08083998A1723 |142 151|sequences00008997A
P08083998A1723 |7 14|results06T0076
P08083998A1723 |28 46|leader-mRNA fusionth alkaline phosph
P08083998A1723 |7 14|results06T0076
P08083998A1723 |28 46|leader-mRNA fusionth alkaline phosph
P08083998A1723 |50 75|coronavirus transcriptiones and 5-nucleotidase P00
P08083998A1723 |142 151|sequences00008997A
P08083998A1723 |100 119|RNA-RNA interaction aspects of neonata
P08083999A0501 |186 199|transcription function of 
P08083999A0501 |47 53|HPV-16tases 
P08083999A0501 |121 131|affinitieshyperbilir
P08083999A0501 |159 160|Mn
P08083999A0501 |58 75|BPV-1 E2 proteins-nucleotidase P00
P08083999A0501 |133 135|Kdin
P08083999A0501 |84 101|consensus E2 site00 Pharmacologic 
P08083999A0501 |0 8|VacciniaP0000160
P08084339A0907 |220 242|amino acid polypeptideK-depleted rats are no
P08084339A0907 |124 135|nucleotideserbilirubin
P08084339A0907 |56 69|reading frame 5-nucleotida
P08084339A0907 |98 105|J alphaic aspe
P08084339A0907 |111 117|region neona
P08084339A0907 |27 37|transcriptith alkali
P08084339A0907 |154 163|beginning2 When CS
P08084339A0907 |171 189|TCR C alpha region] is shown as a fu
P08084592A0145 |3 7|HeLa0016
P08084592A0145 |10 33|fibroblast cell hybrids0076 Comparison with al
P08084592A0145 |65 79|tumorigenicitytidase P000081
P08084592A0145 |38 48|expressione phosphat
P08085228A0000 |117 126|infectiontal hyper
P08085228A0000 |60 67|clientsucleoti
P08085228A0000 |197 215|testing facilitiesf CSF PCO2 the dat
P08085228A0000 |162 165|HIVSF 
P08085228A0000 |228 232|Tex.ed r
P08085228A0000 |182 192|counselingas a funct
P08085228A0000 |12 27|characteristics76 Comparison w
P08085228A0000 |101 113|distributionaspects of n
P08085228A0000 |175 178|use sh
P08085228A0000 |219 226|Houston K-depl
P08085228A0000 |138 160|immunodeficiency virusa. P00008997A0472 When
P08085228A0000 |32 48|risk factor datalkaline phosphat
P08085609A0384 |137 158|crown fissure terminiia. P00008997A0472 Wh
P08085609A0384 |22 28|KNM-LUson wi
P08085609A0384 |88 97|distancesharmacolo
P08085609A0384 |61 75|chimpanzee M1scleotidase P00
P08085609A0384 |117 127|dimensionstal hyperb
P08085609A0384 |0 7|ResultsP000016
P08085782A0164 |36 41|tumorine p
P08085782A0164 |15 20|casesCompa
P08085782A0164 |46 48|cmat
P08086450A0467 |0 10|ComparisonP00001606T
P08086450A0467 |60 66|regionucleot
P08086450A0467 |27 31|geneith 
P08086450A0467 |208 211|Sp1the
P08086450A0467 |122 124|GCyp
P08086450A0467 |104 120|guanine-cytosineects of neonatal
P08086450A0467 |74 84|hATP1 gene0008171T00
P08086450A0467 |157 171|binding motifshen CSF [HCO3-
P08086450A0467 |213 217|AP-2ata 
P08086450A0467 |131 137|regionubinem
P08086450A0467 |191 198|factorstion of
P08086450A0467 |223 226|GCFepl
P08086453T0000 |0 9|StructureP00001606
P08086453T0000 |45 55|assignmenthatases an
P08086453T0000 |11 28|promoter analysis076 Comparison wi
P08086453T0000 |69 78|APEX genese P00008
P08087887A1067 |4 22|polyubiquitin gene01606T0076 Compari
P08087887A1067 |144 158|post-inversion008997A0472 Wh
P08087887A1067 |77 82|peaks8171T
P08087887A1067 |130 138|cleavagerubinemi
P08087887A1067 |97 108|mRNA levelsgic aspects
P08087887A1067 |54 71|Volvox life cyclend 5-nucleotidase
P08088022A1417 |171 179|ischemia] is sho
P08088022A1417 |66 79|heart diseaseidase P000081
P08088022A1417 |125 130|heartrbili
P08088022A1417 |35 42|diseaseline ph
P08088022A1417 |103 108|linkspects
P08088513A0419 |103 121|DEAH protein Prp16pects of neonatal 
P08088513A0419 |25 33|evidence with al
P08088513A0419 |131 133|U6ub
P08088513A0419 |79 90|interaction71T0000 Pha
P08088513A0419 |138 140|U2a.
P08088513A0419 |154 160|snRNAs2 When
P08088777A0754 |136 140|Pbx3mia.
P08088777A0754 |158 162|Acraen C
P08088777A0754 |93 99|Col5a1cologi
P08088777A0754 |147 149|.299
P08088777A0754 |122 126|Fpgsyper
P08088777A0754 |150 152|HcA0
P08088777A0754 |61 68|crossescleotid
P08088777A0754 |106 116|Spna2-Ab lts of neon
P08088777A0754 |153 156|Gsn72 
P08088777A0754 |84 90|Notch100 Pha
P08088777A0754 |118 121|Ak1al 
P08088777A0754 |80 83|Dbh1T0
P08088777A0754 |130 135|Grp78rubin
P08088777A0754 |46 50|dataatas
P08088777A0754 |72 78|D2Mit1P00008
P08088777A0754 |4 24|consensus gene order01606T0076 Compariso
P08088777A0754 |100 104|Rxra asp
P08088818A1053 |141 147|strainP00008
P08088818A1053 |106 110|hostts o
P08088818A1053 |44 53|deletionsphatases 
P08088818A1053 |164 174|RAD52 gene [HCO3-] i
P08088818A1053 |9 14|levelT0076
P08088818A1053 |67 71|YACsdase
P08089184A0825 |17 32|megabase regionmparison with a
P08089184A0825 |3 11|addition001606T0
P08089184A0825 |49 59|dagA locusses and 5-
P08089834A0561 |18 27|deletionsparison w
P08089834A0561 |58 66|residues-nucleot
P08089834A0561 |77 95|amino acid residue8171T0000 Pharmaco
P08089834A0561 |6 13|mutants606T007
P08089887A0742 |10 25|OUTCOME MEASURE0076 Comparison
P08089887A0742 |60 70|evaluationucleotidas
P08090571T0001 |0 11|EliminationP00001606T0
P08090571T0001 |23 33|antibodieson with al
P08090571T0001 |48 58|xenograftsases and 5
P08090746A1288 |154 183|tomato fruit-ripening E4 gene2 When CSF [HCO3-] is shown a
P08090746A1288 |75 83|homology008171T0
P08090746A1288 |8 16|sequence6T0076 C
P08090746A1288 |89 107|promoter sequencesarmacologic aspect
P08090746A1288 |121 144|ethylene responsivenesshyperbilirubinemia. P00
P08090746A1288 |18 26|ATTTCAAAparison 
P08090746A1288 |49 62|region sharesses and 5-nuc
P08090767A0000 |201 223|DNA methylation damageF PCO2 the data of K-d
P08090767A0000 |107 116|viabilitys of neon
P08090767A0000 |11 19|evidence076 Comp
P08090767A0000 |167 187|base excision repairCO3-] is shown as a 
P08090767A0000 |133 144|replicationinemia. P00
P08090767A0000 |78 84|enzyme171T00
P08090767A0000 |25 45|DNA polymerase delta with alkaline phosp
P08091655A0000 |68 84|EcoRI-B fragmentase P00008171T00
P08091655A0000 |31 44|Disease Virusalkaline phos
P08091655A0000 |23 28|Marekon wi
P08091655A0000 |46 49|MDVata
P08091655A0000 |88 94|MDV-GAharmac
P08091655A0000 |103 106|DNApec
P08091655A0000 |51 56|geness and
P08091665T0000 |0 12|Cowpox virusP00001606T00
P08091665T0000 |26 32|copieswith a
P08091665T0000 |90 94|typermac
P08091665T0000 |45 49|genehata
P08091665T0000 |78 82|form171T
P08091665T0000 |98 110|TNF receptoric aspects o
P08091669A0828 |84 87|p3500 
P08091669A0828 |44 56|39k promoterphatases and
P08091669A0828 |75 78|IE1008
P08091669A0828 |143 155|ie1 promoter0008997A0472
P08091669A0828 |93 106|reading framecologic aspec
P08091669A0828 |128 135|controllirubin
P08091669A0828 |21 24|P35iso
P08091669A0828 |64 71|absenceotidase
P08093450A0688 |0 11|MutagenesisP00001606T0
P08093450A0688 |209 213|losshe d
P08093450A0688 |164 176|NRF-1 motifs [HCO3-] is 
P08093450A0688 |90 134|chloramphenicol acetyltransferase expressionrmacologic aspects of neonatal hyperbilirubi
P08093450A0688 |39 52|ALAS promoter phosphatases
P08093450A0688 |20 31|NRF-1 motifrison with 
P08093450A0688 |144 155|mutagenesis008997A0472
P08093450A0688 |80 86|levels1T0000
P08093450A0688 |217 227|expressionof K-deple
P08093616A1214 |0 5|DNaseP0000
P08093616A1214 |87 112|DNA polymerase alpha genePharmacologic aspects of 
P08093616A1214 |8 29|footprinting analysis6T0076 Comparison wit
P08093616A1214 |45 49|DREFhata
P08093616A1214 |139 148|sequences. P000089
P08093616A1214 |69 79|DRE regionse P000081
P08093616T0000 |85 99|binding factor0 Pharmacologi
P08093616T0000 |6 26|8-base pair sequence606T0076 Comparison 
P08093616T0000 |63 70|elementeotidas
P08093616T0000 |151 171|DNA polymerase alpha0472 When CSF [HCO3-
P08093616T0000 |141 146|genesP0000
P08093616T0000 |39 42|DNA ph
P08093616T0000 |203 210|antigenPCO2 th
P08093616T0000 |190 194|cellctio
P08093616T0000 |116 126|expressionatal hyper
P08093642A0600 |186 198|lambda clone function of
P08093642A0600 |15 49|microsatellite repeat polymorphismComparison with alkaline phosphata
P08093642A0600 |77 78|%8
P08093642A0600 |57 71|heterozygosity5-nucleotidase
P08093642A0600 |208 220|D10S94 locusthe data of 
P08093642A0600 |150 164|heterozygosityA0472 When CSF
P08093642A0600 |269 284|linkage mappingared to control
P08093642A0600 |86 95|RET locus Pharmaco
P08093642A0600 |3 11|addition001606T0
P08093642A0600 |311 318|testingantly g
P08093642A0600 |170 171|%-
P08093642A0600 |102 142|restriction fragment length polymorphismspects of neonatal hyperbilirubinemia. P
P08094464A0869 |115 119|aroFnata
P08094464A0869 |60 68|promoterucleotid
P08094464A0869 |104 111|portionects of
P08094464A0869 |9 13|tyrAT007
P08094464A2014 |19 36|attenuator regionarison with alkal
P08094464A2014 |11 15|span076 
P08094464A2014 |123 146|base-residue divergenceperbilirubinemia. P0000
P08094464A2014 |66 76|structuresidase P000
P08094464A2014 |176 183|regionsshown a
P08094464A2014 |95 108|configurationlogic aspects
P08094464A2014 |80 84|mRNA1T00
P08094464A2014 |114 119|spotsonata
P08094498A0614 |77 86|prognosis8171T0000
P08094498A0614 |30 36|spouse alkal
P08094498A0614 |46 51|truthatase
P08094498A0614 |63 72|diagnosiseotidase 
P08094927A0311 |117 124|virionstal hyp
P08094927A0311 |29 38|mutationsh alkalin
P08094927A0311 |73 80|release0000817
P08094927A0311 |46 56|6K proteinatases and
P08094927A0311 |9 16|studiesT0076 C
P08095698T0000 |0 10|MetabolismP00001606T
P08095698T0000 |104 112|patientsects of 
P08095698T0000 |14 21|calcium Compar
P08095698T0000 |40 48|patientsphosphat
P08095698T0000 |79 88|nephritis71T0000 P
P08095698T0000 |26 36|vitamin D3with alkal
P08095698T0000 |92 97|studyacolo
P08095698T0000 |118 140|nephropathia epidemicaal hyperbilirubinemia.
P08095872A1672 |50 58|inotropyes and 5
P08095872A1672 |135 150|LONG/CIRC ratioemia. P00008997
P08095872A1672 |18 23|studyparis
P08095872A1672 |64 71|timololotidase
P08095872A1672 |93 104|contractioncologic asp
P08095872A1672 |154 164|transition2 When CSF
P08095872A1672 |184 204|contraction efficacy a function of CSF P
P08095875T0000 |0 7|EffectsP000016
P08095875T0000 |72 76|ratsP000
P08095875T0000 |63 68|He-O2eotid
P08095875T0000 |20 31|hypercapniarison with 
P08095875T0000 |35 46|hypothermialine phosph
P08096066A0623 |4 17|RFLP patterns01606T0076 Co
P08096066A0623 |160 175|drug resistance CSF [HCO3-] is
P08096066A0623 |127 131|bandilir
P08096066A0623 |25 33|isolates with al
P08096066A0623 |145 156|development08997A0472 
P08096066A0623 |52 60|patients and 5-n
P08096066A0623 |97 104|strainsgic asp
P08096944A0951 |71 81|indication P00008171
P08096944A0951 |131 136|womenubine
P08096944A0951 |95 105|assessmentlogic aspe
P08096944A0951 |26 37|stimulationwith alkali
P08096944A0951 |113 120|ovarieseonatal
P08096944A0951 |158 169|stimulationen CSF [HCO
P08097666A1135 |0 6|A23187P00001
P08097666A1135 |26 39|modificationswith alkaline
P08097666A1135 |107 116|frequencys of neon
P08097666A1135 |61 70|potentialcleotidas
P08097666A1135 |76 84|ampullar08171T00
P08097666A1135 |140 146|spikes P0000
P08097732A0000 |0 10|ActivationP00001606T
P08097732A0000 |124 130|regionerbili
P08097732A0000 |73 91|sea urchin embryos00008171T0000 Phar
P08097732A0000 |178 181|RSRown
P08097732A0000 |43 54|Spec2a genesphatases a
P08097732A0000 |160 176|sequence element CSF [HCO3-] is 
P08097732A0000 |203 220|Spec1/Spec2 genesPCO2 the data of 
P08097732A0000 |139 143|part. P0
P08098228A0625 |2 12|transcript0001606T00
P08098228A0625 |24 26|kbn 
P08098228A0625 |48 51|PPOase
P08098842A0660 |68 92|transcription start sitease P00008171T0000 Pharm
P08098842A0660 |15 21|regionCompar
P08098842A0660 |145 149|exon0899
P08098842A0660 |229 237|increased rats a
P08098842A0660 |109 117|homologyof neona
P08098842A0660 |123 131|sequenceperbilir
P08098842A0660 |195 202|element of CSF
P08098842A0660 |39 41|bp p
P08098842A0660 |282 292|regulationols but st
P08098842A0660 |247 262|gene expressioner displaced wh
P08098842A0660 |153 158|c-fos72 Wh
P08098842A0660 |0 9|MutationsP00001606
P08098882T0001 |13 28|desensitization6 Comparison wi
P08098914A0400 |168 169|PO
P08098914A0400 |74 79|slope00081
P08098914A0400 |61 65|leftcleo
P08098914A0400 |105 108|Eescts
P08098914A0400 |159 166|mmHg/mln CSF [
P08098914A0400 |7 15|exercise06T0076 
P08098914A0400 |94 103|elastanceologic as
P08098914A0400 |21 37|Pes-Ves relationison with alkali
P08098914A0400 |155 157|SD W
P08099443A0359 |141 157|GCN4 translationP00008997A0472 W
P08099443A0359 |161 166|yeastCSF [
P08099443A0359 |13 16|HRI6 C
P08099443A0359 |44 61|yeast eIF-2 alphaphatases and 5-nu
P08099443A0359 |21 29|dsRNA-PKison wit
P08099443A0359 |115 127|GCN2 proteinnatal hyperb
P08100057A0577 |51 62|populationss and 5-nuc
P08100057A0577 |111 122|dendrocytes neonatal h
P08100057A0577 |80 91|macrophages1T0000 Phar
P08100765A0361 |139 151|compartments. P00008997A
P08100765A0361 |88 93|linesharma
P08100765A0361 |29 58|transgene expression patternsh alkaline phosphatases and 5
P08100765A0361 |70 80|cerebellume P0000817
P08100843A0134 |0 17|Southern analysisP00001606T0076 Co
P08100843A0134 |197 199|kbf 
P08100843A0134 |59 69|cell linesnucleotida
P08100843A0134 |29 32|DNAh a
P08100843A0134 |47 54|tissuestases a
P08100843A0134 |156 161|mCD22When 
P08100843A0134 |174 183|copy genes shown a
P08100843A0134 |83 96|mouse strains000 Pharmacol
P08100843A0134 |103 113|mCD22 cDNApects of n
P08100843A0134 |136 146|Cd22 locusmia. P0000
P08101134A0376 |70 71|%e
P08101134A0376 |22 33|plasma ACTHson with al
P08101134A0376 |78 92|MPTP treatment171T0000 Pharm
P08101134A0376 |62 63|%l
P08101134A0376 |4 18|concentrations01606T0076 Com
P08101134A0376 |38 46|cortisole phosph
P08101171A0924 |100 110|boundaries aspects o
P08101171A0924 |13 20|results6 Compa
P08101171A0924 |76 82|memory08171T
P08101171A0924 |162 172|regulatorsSF [HCO3-]
P08101171A0924 |43 60|Pc group productssphatases and 5-n
P08101171A0924 |144 147|gap008
P08101171A0924 |33 37|ideakali
P08101839A0000 |19 29|regulationarison wit
P08101839A0000 |105 112|signalscts of 
P08101839A0000 |57 66|mdr1 gene5-nucleot
P08101839A0000 |72 80|responseP0000817
P08101839A0000 |88 101|mdr1 promoterharmacologic 
P08101839A0000 |125 143|cell proliferationrbilirubinemia. P0
P08101839A0000 |33 43|expressionkaline pho
P08101843A0151 |102 104|bpsp
P08101843A0151 |31 33|THal
P08101843A0151 |63 76|consensus CREeotidase P000
P08101843A0151 |122 151|transcription initiation siteyperbilirubinemia. P00008997A
P08101843A0151 |91 100|base pairmacologic
P08101843A0151 |53 57|copyand 
P08101843A0151 |4 29|tyrosine hydroxylase gene01606T0076 Comparison wit
P08102364A0000 |0 7|TobaccoP000016
P08102364A0000 |30 37|tobacco alkali
P08102364A0000 |39 60|Nicotiana tabacum var phosphatases and 5-n
P08103379A0577 |54 65|MADS domainnd 5-nucleo
P08103379A0577 |10 17|stretch0076 Co
P08103379A0577 |75 83|proteins008171T0
P08103379A0577 |24 35|amino acidsn with alka
P08103379A0577 |126 150|amino acid substitutionsbilirubinemia. P00008997
P08103935T0000 |34 56|SRF accessory proteinsaline phosphatases and
P08103935T0000 |14 30|characterization Comparison with
P08103935T0000 |0 9|IsolationP00001606
P08104189A1168 |84 92|reaction00 Pharm
P08104189A1168 |172 178|ATPase is sh
P08104189A1168 |112 114|pHne
P08104189A1168 |29 45|proSRIF cleavageh alkaline phosp
P08104189A1168 |6 10|data606T
P08104189A1168 |66 69|TGNida
P08105727A0099 |0 10|FenoldopamP00001606T
P08105727A0099 |60 78|animal experimentsucleotidase P00008
P08105727A0099 |14 39|dopamine receptor agonist Comparison with alkaline
P08105727A0099 |97 106|perfusiongic aspec
P08105994T0000 |38 70|serum gamma-glutamyl transferasee phosphatases and 5-nucleotidas
P08105994T0000 |26 34|increasewith alk
P08105994T0000 |9 16|aspectsT0076 C
P08105994T0000 |83 93|infarction000 Pharma
P08106087A0139 |87 95|sequencePharmaco
P08106087A0139 |36 49|kDa zein geneine phosphata
P08106087A0139 |129 137|sequenceirubinem
P08106087A0139 |161 182|polyadenylation sitesCSF [HCO3-] is shown 
P08106087A0139 |71 80|sequences P0000817
P08106087A0139 |19 25|regionarison
P08106245A0325 |272 278|Bq m-3d to c
P08106245A0325 |214 220|Bq m-3ta of 
P08106245A0325 |242 248|period longe
P08106245A0325 |328 340|measurementspe (1.21 +/-
P08106245A0325 |181 193|measurements as a functi
P08106245A0325 |104 110|winterects o
P08106245A0325 |152 158|Bq m-3472 Wh
P08106245A0325 |320 324|yearater
P08106245A0325 |83 89|Bq m-3000 Ph
P08106245A0325 |52 58|period and 5
P08106245A0325 |11 30|radon concentration076 Comparison with
P08106245A0325 |228 234|summered rat
P08106245A0325 |286 292|winterbut st
P08106245A0325 |173 177|yearis s
P08106245A0325 |38 44|summere phos
P08106313A1492 |168 178|expressionO3-] is sh
P08106313A1492 |26 31|hrpRSwith 
P08106313A1492 |120 124|hrpL hyp
P08106313A1492 |106 116|expressionts of neon
P08106313A1492 |45 49|parthata
P08106313A1492 |83 87|HrpR000 
P08106313A1492 |92 96|HrpSacol
P08106313A1492 |146 158|sigma factor8997A0472 Wh
P08106313A1492 |66 73|cascadeidase P
P08106313A1492 |129 133|HrpLirub
P08106313A1492 |198 203|genes CSF 
P08106313A1492 |36 40|hrpLine 
P08106313A1492 |4 11|results01606T0
P08106325A0000 |0 4|DtxRP000
P08106325A0000 |161 182|diphtheria toxin geneCSF [HCO3-] is shown 
P08106325A0000 |56 63|protein 5-nucl
P08106325A0000 |82 94|tox operator0000 Pharmac
P08106325A0000 |115 134|nucleotide sequencenatal hyperbilirubi
P08106369A0000 |205 207|V2O2
P08106369A0000 |196 199|V1bof 
P08106369A0000 |125 143|membrane receptorsrbilirubinemia. P0
P08106369A0000 |57 68|nonapeptide5-nucleotid
P08106369A0000 |13 16|AVP6 C
P08106369A0000 |181 189|subtypes as a fu
P08106369A0000 |98 99|Gi
P08106369A0000 |191 194|V1atio
P08106369A0000 |36 43|hormoneine pho
P08106369A0000 |235 245|messengers are no lo
P08106369A0000 |0 11|VasopressinP00001606T0
P08106398A1003 |80 96|nisin maturation1T0000 Pharmacol
P08106398A1003 |72 76|stepP000
P08106398A1003 |29 37|cleavageh alkali
P08106398A1003 |45 59|leader peptidehatases and 5-
P08106398A1003 |148 155|peptide97A0472
P08106398A1003 |6 13|results606T007
P08106512A0522 |139 155|interferon-alpha. P00008997A0472
P08106512A0522 |89 104|promoter regionarmacologic asp
P08106512A0522 |194 200|factorn of C
P08106512A0522 |9 24|promoter regionT0076 Compariso
P08106512A0522 |161 166|gammaCSF [
P08106512A0522 |56 69|reporter gene 5-nucleotida
P08106512A0522 |126 137|interferonsbilirubinem
P08106512A0522 |172 182|interferon is shown 
P08107167A0222 |119 122|IFAl h
P08107167A0222 |43 49|anti-Bsphata
P08107167A0222 |160 161|% 
P08107167A0222 |208 215|IFA-ABSthe dat
P08107167A0222 |29 38|turicataeh alkalin
P08107167A0222 |169 182|serum samples3-] is shown 
P08107167A0222 |235 236|% 
P08107167A0222 |112 117|assayneona
P08107167A0222 |0 6|Anti-BP00001
P08107167A0222 |51 69|parkeri antibodiess and 5-nucleotida
P08107208A0673 |102 105|EBVspe
P08107208A0673 |126 128|B.bi
P08107208A0673 |47 55|strategytases an
P08107208A0673 |120 124|DNAs hyp
P08107208A0673 |67 79|recombinantsdase P000081
P08107208A0673 |4 12|approach01606T00
P08108099T0000 |0 10|EvaluationP00001606T
P08108099T0000 |78 87|disorders171T0000 
P08108099T0000 |14 26|desmopressin Comparison 
P08108099T0000 |53 61|patientsand 5-nu
P08108099T0000 |38 49|extractionse phosphata
P08108343A0000 |207 212|signs the 
P08108343A0000 |112 120|patientsneonatal
P08108343A0000 |296 317|gonadotropin reserveshave a significantly 
P08108343A0000 |12 20|analysis76 Compa
P08108343A0000 |224 237|insufficiencypleted rats a
P08108343A0000 |184 192|patients a funct
P08108343A0000 |250 259|diagnosisdisplaced
P08108343A0000 |263 268|ordern com
P08108343A0000 |99 107|subjectsc aspect
P08108343A0000 |42 50|niftolidosphatas
P08108343A0000 |161 173|hypogonadismCSF [HCO3-] 
P08108343A0000 |65 69|GnRHtida
P08108343A0000 |141 145|onesP000
P08108413A0964 |137 142|brainia. P
P08108413A0964 |58 68|cell lines-nucleotid
P08108413A0964 |106 121|PANG expressionts of neonatal 
P08108413A0964 |80 87|tissues1T0000 
P08108413A0964 |175 186|transcripts shown as a
P08111035A0098 |174 188|tobacco plantss shown as a f
P08111035A0098 |149 159|expression7A0472 Whe
P08111035A0098 |73 94|B. napus oleosin gene00008171T0000 Pharmac
P08111035A0098 |47 67|bp promoter fragmenttases and 5-nucleoti
P08111035A0098 |240 246|fusionno lon
P08111035A0098 |144 147|GUS008
P08111035A0098 |124 142|beta-glucuronidaseerbilirubinemia. P
P08111035A0098 |26 36|propertieswith alkal
P08111035A0098 |112 120|analysisneonatal
P08111035A0098 |203 223|oleosin promoter-GUSPCO2 the data of K-d
P08111974A1034 |156 167|involvementWhen CSF [H
P08111974A1034 |74 86|tubulin mRNA0008171T0000
P08111974A1034 |43 45|CXsp
P08111974A1034 |24 33|mechanismn with al
P08111974A1034 |182 194|trans-factoras a functio
P08111974A1034 |59 70|degradationnucleotidas
P08111974A1034 |127 138|translationilirubinemi
P08112341A1128 |0 2|L.P0
P08112341A1128 |24 26|G.n 
P08112341A1128 |11 13|J.07
P08112341A1128 |4 9|Greer01606
P08112341A1128 |16 22|Carterompari
P08112526A0443 |118 125|controlal hype
P08112526A0443 |29 50|calcium concentrationh alkaline phosphatas
P08112526A0443 |60 82|detrusor contractilityucleotidase P00008171T
P08112526A0443 |141 149|bladdersP0000899
P08112526A0443 |103 109|mannerpects 
P08112601T0000 |85 94|synthesis0 Pharmac
P08112601T0000 |11 23|organization076 Comparis
P08112601T0000 |31 35|genealka
P08112601T0000 |114 121|proteinonatal 
P08112601T0000 |55 64|lipocalind 5-nucle
P08112611A0404 |32 45|reading framelkaline phosp
P08112611A0404 |72 83|amino acidsP00008171T0
P08112611A0404 |57 64|protein5-nucle
P08112611A0404 |4 12|sequence01606T00
P08112870A0484 |0 16|Western blottingP00001606T0076 C
P08112870A0484 |166 169|kDaHCO
P08112870A0484 |112 120|proteinsneonatal
P08112870A0484 |42 51|antiserumosphatase
P08112870A0484 |146 152|masses8997A0
P08112870A0484 |65 68|SODtid
P08112870A0484 |18 32|immunoblottingparison with a
P08113736A0309 |221 224|ORF-de
P08113736A0309 |120 126|mosaic hyper
P08113736A0309 |128 133|SCNMVlirub
P08113736A0309 |79 85|mosaic71T000
P08113736A0309 |63 69|clovereotida
P08113736A0309 |135 149|dianthovirusesemia. P0000899
P08113736A0309 |104 110|cloverects o
P08113736A0309 |174 184|CRSV RNA-1s shown as
P08113736A0309 |159 168|exceptionn CSF [HC
P08113736A0309 |25 35|CRSV RNA-1 with alka
P08113736A0309 |4 21|gene organization01606T0076 Compar
P08113736A0309 |87 92|RCNMVPharm
P08114702A0000 |0 7|MembersP000016
P08114702A0000 |183 188|geness a f
P08114702A0000 |75 96|transcription factors008171T0000 Pharmacol
P08114702A0000 |65 71|familytidase
P08114702A0000 |59 63|MEF2nucl
P08114702A0000 |123 131|sequenceperbilir
P08114702A0000 |49 55|factorses an
P08114702A0000 |139 154|control regions. P00008997A047
P08114710A0137 |84 91|binding00 Phar
P08114710A0137 |46 65|HIV-1 transcriptionatases and 5-nucleo
P08114710A0137 |30 35|LBP-1 alka
P08114710A0137 |95 100|TFIIDlogic
P08114710A0137 |108 116|TATA box of neon
P08114745A0953 |187 210|transcription complexesfunction of CSF PCO2 th
P08114745A0953 |214 217|polta 
P08114745A0953 |131 136|classubine
P08114745A0953 |89 96|abilityarmacol
P08114745A0953 |47 49|Lata
P08114745A0953 |180 183|usen a
P08114745A0953 |53 67|RNA productionand 5-nucleoti
P08114745A0953 |6 13|results606T007
P08114745A0953 |110 127|termination sitesf neonatal hyperb
P08114745A0953 |38 42|rolee ph
P08114745A0953 |141 150|templatesP00008997
P08115744A0462 |102 109|micronsspects 
P08115744A0462 |4 9|films01606
P08115744A0462 |53 71|laser densitometerand 5-nucleotidase
P08115744A0462 |32 40|scanninglkaline 
P08115744A0462 |85 93|aperture0 Pharma
P08115744A0846 |71 79|analysis P000081
P08115744A0846 |15 21|methodCompar
P08115744A0846 |120 145|quality assurance program hyperbilirubinemia. P000
P08115744A0846 |61 67|methodcleoti
P08116245A0174 |71 80|specimens P0000817
P08116245A0174 |14 17|RNA Co
P08116245A0174 |28 37|reactionsth alkali
P08116245A0174 |93 104|infant ratscologic asp
P08118044A0318 |0 11|GATA-1 mRNAP00001606T0
P08118044A0318 |63 73|cell lineseotidase P
P08118044A0318 |88 93|levelharma
P08118044A0318 |97 109|FDC-P1 cellsgic aspects 
P08118044A0318 |38 44|levelse phos
P08119149A0000 |119 126|effectsl hyper
P08119149A0000 |130 134|bonerubi
P08119149A0000 |29 38|TNF alphah alkalin
P08119149A0000 |78 85|factors171T000
P08119149A0000 |0 27|Tumor necrosis factor-alphaP00001606T0076 Comparison w
P08119907A0000 |102 107|IGF-Ispect
P08119907A0000 |25 29|role wit
P08119907A0000 |109 127|signaling pathwaysof neonatal hyperb
P08119907A0000 |60 67|insulinucleoti
P08119907A0000 |42 56|p21ras proteinosphatases and
P08119907A0000 |85 100|growth factor-I0 Pharmacologic
P08119958A0273 |50 54|PKCses a
P08119958A0273 |210 218|subgroupe data o
P08119958A0273 |231 235|PKCsrats
P08119958A0273 |178 184|PKC muown as
P08119958A0273 |196 202|memberof CSF
P08119958A0273 |123 137|signal peptideperbilirubinem
P08119958A0273 |63 71|presenceeotidase
P08119958A0273 |4 8|lack0160
P08119958A0273 |158 164|domainen CSF
P08119958A0273 |97 105|sequencegic aspe
P08119958A0273 |33 35|Caka
P08119958A0273 |16 25|C2 domainomparison
P08119995A0814 |101 111|half-sitesaspects of
P08119995A0814 |135 146|orientationemia. P0000
P08119995A0814 |31 39|functionalkaline
P08119995A0814 |194 199|partsn of 
P08119995A0814 |67 84|response elementsdase P00008171T00
P08119995A0814 |43 63|T3R-RXR heterodimerssphatases and 5-nucl
P08119995A0814 |244 253|half-siteonger dis
P08119995A0814 |159 170|nucleotidesn CSF [HCO3
P08119995A0814 |219 227|sequence K-deple
P08120019A1500 |137 147|mechanismsia. P00008
P08120019A1500 |15 26|Hm1 mutantsComparison 
P08120019A1500 |73 84|PI turnover00008171T00
P08120019A1500 |102 115|sequestrationspects of neo
P08120029A0864 |22 45|decay reaction mixturesson with alkaline phosp
P08120029A0864 |74 94|sense RNA transcript0008171T0000 Pharmac
P08120029A0864 |107 120|stabilizations of neonatal
P08120029A0864 |124 134|R2 messageerbilirubi
P08122364A0954 |0 17|Deletion analysesP00001606T0076 Co
P08122364A0954 |165 174|synthesis[HCO3-] i
P08122364A0954 |45 48|usehat
P08122364A0954 |25 36|pCD41 ORF-A with alkal
P08122364A0954 |199 206|proteinCSF PCO
P08122364A0954 |130 144|pCD41 sequencerubinemia. P00
P08122364A0954 |110 118|promoterf neonat
P08122364A0954 |52 71|promoter constructs and 5-nucleotidase
P08122370A0331 |68 73|HSV-1ase P
P08122370A0331 |133 138|EHV-1inemi
P08122370A0331 |45 64|herpes simplex typehatases and 5-nucle
P08122370A0331 |113 129|herpesvirus typeeonatal hyperbil
P08122370A0331 |96 99|PRVogi
P08122370A0331 |76 94|pseudorabies virus08171T0000 Pharmac
P08122370A0331 |39 41|US p
P08122370A0331 |19 31|counterpartsarison with 
P08123787A0554 |222 230|analysisdepleted
P08123787A0554 |13 32|amino acid sequence6 Comparison with a
P08123787A0554 |159 166|enzymesn CSF [
P08123787A0554 |110 136|metal cofactor requirementf neonatal hyperbilirubine
P08123787A0554 |92 102|differenceacologic a
P08123787A0554 |191 205|overexpressiontion of CSF PC
P08123787A0554 |55 67|HemB proteind 5-nucleoti
P08124785A0445 |0 7|METHODSP000016
P08124785A0445 |251 252|Pi
P08124785A0445 |140 146|artery P0000
P08124785A0445 |52 56|dogs and
P08124785A0445 |27 37|open-chestith alkali
P08124785A0445 |12 19|RESULTS76 Comp
P08124785A0445 |117 125|decreasetal hype
P08124785A0445 |70 96|circumflex artery stenosise P00008171T0000 Pharmacol
P08124785A0445 |223 249|mean transit time Tmicro-1epleted rats are no longer
P08124785A0445 |169 173|flow3-] 
P08124785A0445 |184 196|flow reserve a function 
P08124912A0456 |85 88|LDH0 P
P08124912A0456 |90 110|beta 2-microglobulinrmacologic aspects o
P08124912A0456 |57 61|IL-85-nu
P08124912A0456 |11 22|correlation076 Compari
P08124912A0456 |44 53|SF levelsphatases 
P08124912A0456 |76 83|lactate08171T0
P08124912A0456 |115 122|glucosenatal h
P08124956T0000 |98 102|pigsic a
P08124956T0000 |46 58|pancreatitisatases and 5
P08124956T0000 |83 94|oxygenation000 Pharmac
P08125258A0142 |21 26|cellsison 
P08125258A0142 |91 98|varietymacolog
P08125258A0142 |40 50|conditionsphosphatas
P08125258A0142 |56 65|CHOP gene 5-nucleo
P08125258A0142 |166 179|perturbationsHCO3-] is sho
P08125258A0142 |111 119|stresses neonata
P08125258A0142 |140 151|deprivation P00008997A
P08125319A1085 |118 132|data librariesal hyperbiliru
P08125319A1085 |97 106|sequencesgic aspec
P08125319A1085 |52 60|proteins and 5-n
P08125319A1085 |83 91|homology000 Phar
P08125319A1085 |4 14|ipiO genes01606T0076
P08125337A0940 |0 15|Sterol analysisP00001606T0076 
P08125337A0940 |57 69|accumulation5-nucleotida
P08125337A0940 |106 121|Erg24p activityts of neonatal 
P08125337A0940 |73 83|ignosterol00008171T0
P08125337A0940 |98 102|lossic a
P08125337A0940 |33 39|mutantkaline
P08125949A1162 |34 45|translationaline phosp
P08125949A1162 |287 297|eubacteriaut still h
P08125949A1162 |135 146|Arabidopsisemia. P0000
P08125949A1162 |120 131|rpl12 genes hyperbilir
P08125949A1162 |86 96|AUG codons Pharmacol
P08125949A1162 |203 209|copiesPCO2 t
P08125949A1162 |213 237|L12/chloroplast ribosomeata of K-depleted rats a
P08125949A1162 |168 178|mechanismsO3-] is sh
P08125949A1162 |49 65|spinach L12 mRNAses and 5-nucleo
P08126096A0478 |258 263|formsd whe
P08126096A0478 |9 20|experimentsT0076 Compa
P08126096A0478 |147 156|sequences997A0472 
P08126096A0478 |133 136|ratine
P08126096A0478 |90 96|domainrmacol
P08126096A0478 |173 180|studiesis show
P08126096A0478 |53 62|functionsand 5-nuc
P08126096A0478 |110 120|homologiesf neonatal
P08126096A0478 |70 75|alphae P00
P08126096A0478 |207 223|domain antiserum the data of K-d
P08126096A1071 |119 120|Al
P08126096A1071 |125 136|B form RNAsrbilirubine
P08126096A1071 |4 21|alpha 7A form RNA01606T0076 Compar
P08126096A1071 |158 172|reading framesen CSF [HCO3-]
P08126096A1071 |77 83|B form8171T0
P08126096A1071 |98 111|coding regionic aspects of
P08126096A1071 |49 60|nucleotidesses and 5-n
P08127950A0000 |3 8|order00160
P08127950A0000 |290 298|TSH-IRMAstill ha
P08127950A0000 |184 200|triiodothyronine a function of C
P08127950A0000 |249 254|means disp
P08127950A0000 |25 33|function with al
P08127950A0000 |212 239|thyroid stimulating hormonedata of K-depleted rats are
P08127950A0000 |95 105|depressionlogic aspe
P08127950A0000 |241 244|TSHo l
P08127950A0000 |162 171|thyroxineSF [HCO3-
P08127950A0000 |78 82|axis171T
P08127950A0000 |314 322|controlsly great
P08127950A0000 |73 76|HPT000
P08127950A0000 |134 153|0800h plasma levelsnemia. P00008997A04
P08127950A0000 |381 389|subjectsappears 
P08127950A0000 |282 288|assaysols bu
P08127950A0000 |111 118|authors neonat
P08127950A0000 |202 205|FT3 PC
P08127950A0000 |173 176|FT4is 
P08128629A1164 |0 12|CRS functionP00001606T00
P08128629A1164 |128 135|LTR RNAlirubin
P08128629A1164 |74 81|ability0008171
P08128629A1164 |90 96|p60CRSrmacol
P08128629A1164 |101 107|p40CRSaspect
P08128629A1164 |32 53|gene expression assaylkaline phosphatases 
P08129955A0572 |85 86|h0
P08129955A0572 |48 53|CK-MBases 
P08129955A0572 |36 44|activityine phos
P08129955A0572 |7 13|levels06T007
P08129955A0572 |100 110|unclamping aspects o
P08129955A0572 |17 27|troponin Tmparison w
P08130942A0051 |0 15|RegionalizationP00001606T0076 
P08130942A0051 |48 54|methodases a
P08130942A0051 |19 32|drug deliveryarison with a
P08130942A0051 |69 76|problemse P000
P08131545A0158 |103 109|livingpects 
P08131545A0158 |27 32|groupith a
P08131545A0158 |265 282|Coxiella burnetiicompared to contr
P08131545A0158 |61 64|mencle
P08131545A0158 |253 263|adenovirusplaced whe
P08131545A0158 |83 86|age000
P08131545A0158 |189 199|Mycoplasmanction of 
P08131545A0158 |212 234|Legionella pneumophiladata of K-depleted rat
P08131545A0158 |179 184|testswn as
P08131545A0158 |39 56|community members phosphatases and
P08131545A0158 |96 101|yearsogic 
P08131545A0158 |288 297|Chlamydiat still h
P08131545A0158 |236 251|cytomegalovirusare no longer d
P08131545A0158 |71 76|women P000
P08131746A0140 |0 3|MEKP00
P08131746A0140 |63 80|activator kinaseseotidase P0000817
P08131746A0140 |107 117|MEK kinases of neona
P08131746A0140 |28 50|serine phosphorylationth alkaline phosphatas
P08131746A0140 |92 97|c-rafacolo
P08131746A0140 |99 102|mosc a
P08132541A0000 |8 18|DNA clones6T0076 Com
P08132541A0000 |56 64|MAL gene 5-nucle
P08132574A0831 |0 7|MembersP000016
P08132574A0831 |75 84|kilobases008171T00
P08132574A0831 |108 111|HLA of
P08132574A0831 |11 14|SVA076
P08132574A0831 |123 145|cytochrome CYP1A1 geneperbilirubinemia. P000
P08132574A0831 |97 100|RP1gic
P08132574A0831 |39 57|complement C2 gene phosphatases and 
P08132667T0000 |85 94|promoters0 Pharmac
P08132667T0000 |26 60|proprotein processing enzyme furinwith alkaline phosphatases and 5-n
P08132667T0000 |0 10|ExpressionP00001606T
P08133502T0105 |0 29|European Community HuntingtonP00001606T0076 Comparison wit
P08133502T0105 |32 65|Disease Collaborative Study Grouplkaline phosphatases and 5-nucleo
P08134108A0277 |4 9|c-myc01606
P08134108A0277 |133 141|elementsinemia. 
P08134108A0277 |58 75|YY1 binding sites-nucleotidase P00
P08134108A0277 |23 49|alpha-actin gene promoterson with alkaline phosphata
P08134115A1161 |152 155|H-P472
P08134115A1161 |165 174|consensus[HCO3-] i
P08134115A1161 |216 218|TT o
P08134115A1161 |114 117|mycona
P08134115A1161 |52 55|GST an
P08134115A1161 |130 137|ACT-ATTrubinem
P08134115A1161 |148 151|myc97A
P08134115A1161 |32 46|fusion proteinlkaline phosph
P08134115A1161 |206 215|A/TCTA/TA2 the dat
P08134115A1161 |101 107|TCTTATaspect
P08134115A1161 |118 121|H-Pal 
P08134115A1161 |0 6|MSSP-1P00001
P08136383A0359 |22 35|MR tomographyson with alka
P08136383A0359 |10 15|hours0076 
P08136383A0359 |40 48|patientsphosphat
P08138180A0593 |142 151|functions00008997A
P08138180A0593 |26 33|alleleswith al
P08138180A0593 |106 119|SPT10 proteints of neonata
P08138180A0593 |73 84|growth rate00008171T00
P08138180A0593 |43 54|suppressorssphatases a
P08138180A0593 |8 13|spt106T007
P08138364T0000 |0 9|VarietiesP00001606
P08138364T0000 |21 31|experienceison with 
P08139001A1235 |64 84|NS1 protein moleculeotidase P00008171T00
P08139001A1235 |31 36|aminoalkal
P08139001A1235 |145 161|tubule formation08997A0472 When 
P08139001A1235 |41 56|carboxy terminihosphatases and
P08139001A1235 |106 114|residuests of ne
P08139001A1235 |93 102|cysteinescologic a
P08139001A1235 |4 11|results01606T0
P08139004A0278 |80 93|UGC sequences1T0000 Pharma
P08139004A0278 |30 38|hairpins alkalin
P08139004A0278 |76 79|A/U081
P08139004A0278 |7 10|UTR06T
P08139017A1465 |187 192|cellsfunct
P08139017A1465 |79 95|primer extension71T0000 Pharmaco
P08139017A1465 |133 149|Ets-1 cDNA cloneinemia. P0000899
P08139017A1465 |122 125|endype
P08139017A1465 |44 54|initiationphatases a
P08139017A1465 |231 242|Tpl-1 locusrats are no
P08139017A1465 |197 203|tumorsf CSF 
P08139017A1465 |215 223|provirusa of K-d
P08139017A1465 |20 24|siteriso
P08139017A1465 |100 102|bp a
P08139031A1168 |356 373|ORF4 inducibility943A0733 Flurazep
P08139031A1168 |56 67|mutagenesis 5-nucleoti
P08139031A1168 |286 298|interactionsbut still ha
P08139031A1168 |224 241|cysteine residuespleted rats are n
P08139031A1168 |120 136|ORF4 polypeptide hyperbilirubine
P08139031A1168 |143 148|C-42100089
P08139031A1168 |95 112|cysteine residueslogic aspects of 
P08139031A1168 |177 200|transactivator functionhown as a function of C
P08139031A1168 |153 158|C-42672 Wh
P08139031A1168 |327 344|acid interactionsope (1.21 +/- 0.2
P08139539A0446 |17 32|m1R stimulationmparison with a
P08139539A0446 |125 129|cAMPrbil
P08139539A0446 |94 101|calciumologic 
P08139539A0446 |72 76|riseP000
P08139539A0446 |120 123|AMP hy
P08139539A0446 |36 56|phospholipase C betaine phosphatases and
P08139539A0446 |159 169|activationn CSF [HCO
P08139539A0446 |131 140|synthesisubinemia.
P08139539A0446 |173 190|protein kinase A.is shown as a fun
P08139539A0446 |3 15|Rat 1a cells001606T0076 
P08139542A1229 |33 43|repressionkaline pho
P08139542A1229 |47 51|CPA1tase
P08139542A1229 |4 13|mutations01606T007
P08139542A1229 |55 63|arginined 5-nucl
P08139542T0000 |85 93|arginine0 Pharma
P08139542T0000 |31 45|leader peptidealkaline phosp
P08139542T0000 |53 62|CPA1 geneand 5-nuc
P08139542T0000 |112 133|yeast gene transcriptneonatal hyperbilirub
P08139542T0000 |13 17|mRNA6 Co
P08139542T0000 |71 81|repression P00008171
P08139542T0000 |2 9|segment0001606
P08139543A0427 |81 99|suppression screenT0000 Pharmacologi
P08139543A0427 |14 19|genes Comp
P08139543A0427 |43 60|SLK1-SLT2 pathwaysphatases and 5-n
P08139543A1520 |86 90|SLT2 Pha
P08139543A1520 |47 52|NHP6Atases
P08139543A1520 |57 71|NHP6B function5-nucleotidase
P08139543A1520 |23 31|analysison with 
P08139562A0404 |85 89|GCN40 Ph
P08139562A0404 |165 180|GCN4 start site[HCO3-] is show
P08139562A0404 |31 36|linesalkal
P08139562A0404 |58 67|ribosomes-nucleoti
P08139562A0404 |40 48|evidencephosphat
P08139562A0404 |132 140|scanningbinemia.
P08139562A0404 |8 14|report6T0076
P08139562A0404 |117 122|uORF1tal h
P08139577T0000 |139 144|genes. P00
P08139577T0000 |88 101|transcriptionharmacologic 
P08139577T0000 |105 109|TATActs 
P08139577T0000 |10 20|components0076 Compa
P08139577T0000 |24 55|yeast transcription factor IIIBn with alkaline phosphatases an
P08139914A0554 |101 106|cellsaspec
P08139914A0554 |63 78|differentiationeotidase P00008
P08139914A0554 |82 88|muscle0000 P
P08139914A0554 |36 53|dnHLH protein Id1ine phosphatases 
P08139928T0000 |0 4|RNP1P000
P08139928T0000 |12 34|ribonucleoprotein gene76 Comparison with alk
P08139928T0000 |42 47|yeastospha
P08140847X0001 |0 5|CrohnP0000
P08140847X0001 |152 157|study472 W
P08140847X0001 |253 258|orderplace
P08140847X0001 |188 193|Crohnuncti
P08140847X0001 |29 38|remissionh alkalin
P08140847X0001 |120 123|aim hy
P08140847X0001 |196 212|disease patientsof CSF PCO2 the 
P08140847X0001 |226 235|remissioneted rats
P08140847X0001 |135 139|yearemia
P08140847X0001 |75 81|intake008171
P08140847X0001 |105 113|subjectscts of n
P08140847X0001 |277 288|body weightcontrols bu
P08140847X0001 |351 357|intake000109
P08140847X0001 |8 15|disease6T0076 
P08140847X0001 |237 241|CDAIre n
P08140847X0001 |408 416|controlshypnotic
P08142875A0877 |136 141|casesmia. 
P08142875A0877 |111 123|intervention neonatal hy
P08142875A0877 |20 30|dissectionrison with
P08142875A0877 |80 84|lens1T00
P08143198T0001 |0 11|RestorationP00001606T0
P08143198T0001 |62 95|composites dorsal pedal skin flapleotidase P00008171T0000 Pharmaco
P08143198T0001 |15 23|opponensComparis
P08143198T0001 |107 134|m. extensor hallucis breviss of neonatal hyperbilirubi
P08143198T0001 |38 53|transplantatione phosphatases 
P08143236A1055 |85 98|day-1 regimen0 Pharmacolog
P08143236A1055 |8 23|ethanol regimen6T0076 Comparis
P08143236A1055 |131 137|trialsubinem
P08143236A1055 |45 56|alternationhatases and
P08143236A1055 |113 120|percenteonatal
P08143236A1055 |68 82|g ethanol.kg-1ase P00008171T
P08143667A0222 |34 42|pressurealine ph
P08143667A0222 |89 93|MUCParma
P08143667A0222 |165 170|ratio[HCO3
P08143667A0222 |44 47|IVPpha
P08143667A0222 |14 16|sd C
P08143667A0222 |4 8|mean0160
P08143667A0222 |188 191|IVPunc
P08143667A0222 |179 183|MUCPwn a
P08143667A0222 |70 87|closure pressurese P00008171T0000 
P08143667A0222 |136 141|cmH2Omia. 
P08144035A0387 |84 94|C terminus00 Pharmac
P08144035A0387 |61 71|N terminuscleotidase
P08144035A0387 |25 32|regions with a
P08144037A0000 |0 11|ThioredoxinP00001606T0
P08144037A0000 |57 63|enzyme5-nucl
P08144037A0000 |13 15|TR6 
P08144037A0000 |97 103|plantsgic as
P08144037A0000 |84 92|bacteria00 Pharm
P08144470A0711 |117 129|substitutiontal hyperbil
P08144470A0711 |24 38|asgB480 allelen with alkalin
P08144470A0711 |147 162|protein product997A0472 When C
P08144470A0711 |67 77|transitiondase P0000
P08144470A0711 |4 12|mutation01606T00
P08144497T0000 |50 54|zinces a
P08144497T0000 |72 81|liposomesP00008171
P08144497T0000 |28 40|raf-1 kinaseth alkaline 
P08144497T0000 |104 111|segmentects of
P08144497T0000 |123 130|GTP-rasperbili
P08144497T0000 |18 24|regionpariso
P08144504T0064 |21 32|requirementison with a
P08144504T0064 |8 16|coupling6T0076 C
P08144504T0064 |37 51|ATP hydrolysisne phosphatase
P08144572A0786 |0 3|ATPP00
P08144572A0786 |151 154|BiP047
P08144572A0786 |27 46|polypeptide bindingith alkaline phosph
P08144572A0786 |63 68|leveleotid
P08144572A0786 |121 139|Ssa Hsp70 proteinshyperbilirubinemia
P08144572A0786 |159 163|DnaKn CS
P08144572A0786 |50 57|Ssb1/2pes and 
P08144615A0533 |0 9|DigestionP00001606
P08144615A0533 |25 43|endoprotease Asp-N with alkaline pho
P08144615A0533 |125 131|domainrbilir
P08144615A0533 |79 82|TCD71T
P08144615A0533 |13 19|NF-IL66 Comp
P08144615A0533 |105 109|NFBDcts 
P08144615A0533 |55 61|domaind 5-nu
P08144615A0533 |157 164|absencehen CSF
P08144615A0533 |172 180|presence is show
P08144615A0533 |184 187|DNA a 
P08144615A0533 |84 103|NF-IL6 bZIP domains00 Pharmacologic as
P08144631A0000 |102 109|domainsspects 
P08144631A0000 |123 147|tyrosine phosphorylationperbilirubinemia. P00008
P08144631A0000 |46 58|associationsatases and 5
P08144631A0000 |13 29|tyrosine kinases6 Comparison wit
P08144631A0000 |114 119|sitesonata
P08144631A0000 |97 100|SH2gic
P08144631A0000 |67 75|proteinsdase P00
P08144631A0000 |81 93|Src homologyT0000 Pharma
P08144631A0000 |0 9|SignalingP00001606
P08144668A0802 |139 143|GPHe. P0
P08144668A0802 |62 66|exonleot
P08144668A0802 |195 213|membrane anchoring of CSF PCO2 the d
P08144668A0802 |90 95|shiftrmaco
P08144668A0802 |182 190|sequenceas a fun
P08144668A0802 |29 35|exon Vh alka
P08144668A0802 |73 80|exon VI0000817
P08144668A0802 |108 121|reading frame of neonatal 
P08144668A0802 |144 146|P200
P08144852A0000 |4 13|responses01606T007
P08144852A0000 |158 163|malesen CS
P08144852A0000 |22 37|stress hormonesson with alkali
P08144852A0000 |240 249|inhibitorno longer
P08144852A0000 |120 126|factor hyper
P08144852A0000 |73 84|vasopressin00008171T00
P08144852A0000 |49 65|11-deoxycortisolses and 5-nucleo
P08144852A0000 |86 89|AVP Ph
P08144852A0000 |185 204|cortisol deficiencya function of CSF P
P08144852A0000 |251 261|metyraponeisplaced w
P08144852A0000 |67 71|ACTHdase
P08144852A0000 |128 131|CRFlir
P08144852A0000 |167 175|responseCO3-] is
P08144852A0000 |96 109|corticotropinogic aspects 
P08144852A0000 |39 47|cortisol phospha
P08145646T0000 |0 9|StructureP00001606
P08145646T0000 |105 114|relevancects of ne
P08145646T0000 |135 157|nifU2-rpoN superoperonemia. P00008997A0472 W
P08145646T0000 |44 56|sigma factorphatases and
P08145646T0000 |14 24|expression Compariso
P08145646T0000 |58 62|RpoN-nuc
P08145646T0000 |67 89|Rhodobacter capsulatusdase P00008171T0000 Ph
P08145770A1078 |70 87|retinoid pathwayse P00008171T0000 
P08145770A1078 |9 21|observationsT0076 Compar
P08145770A1078 |62 65|PKCleo
P08145770A1078 |45 49|linkhata
P08145770A1078 |141 151|activitiesP00008997A
P08145770A1078 |155 180|differentiation processes When CSF [HCO3-] is show
P08148463A0000 |32 36|CSFslkal
P08148463A0000 |23 30|factorson with
P08148463A0000 |110 125|granulocyte CSFf neonatal hype
P08148463A0000 |150 153|CSFA04
P08148463A0000 |80 91|neutrophils1T0000 Phar
P08148463A0000 |96 105|monocytesogic aspe
P08148463A0000 |66 76|productionidase P000
P08148463A0000 |175 186|interleukin shown as a
P08148463A0000 |155 169|macrophage CSF When CSF [HCO
P08148756A0358 |4 10|degree01606T
P08148756A0358 |95 113|hemoglobin contentlogic aspects of n
P08148756A0358 |121 126|fluidhyper
P08148756A0358 |14 30|lung destruction Comparison with
P08148756A0358 |58 68|hemorrhage-nucleotid
P08148756A0358 |142 147|lungs00008
P08149484A0151 |0 19|Expression plasmidsP00001606T0076 Comp
P08149484A0151 |76 85|PKC delta08171T000
P08149484A0151 |62 71|PKC alphaleotidase
P08149484A0151 |45 58|kinase domainhatases and 5
P08149484A0151 |87 98|PKC alpha KPharmacolog
P08149484A0151 |103 114|PKC delta Kpects of ne
P08149484A1551 |33 42|PKC alphakaline ph
P08149484A1551 |183 192|sequencess a funct
P08149484A1551 |165 169|AP-1[HCO
P08149484A1551 |44 51|calciumphatase
P08149484A1551 |67 76|PKC deltadase P000
P08149484A1551 |146 151|genes8997A
P08149484A1551 |78 85|calcium171T000
P08149484A1551 |6 13|results606T007
P08149484A1551 |115 128|transcriptionnatal hyperbi
P08150970A0434 |48 53|pg/mlases 
P08150970A0434 |110 116|TSST-1f neon
P08150970A0434 |58 65|samples-nucleo
P08150970A0434 |24 30|TSST-1n with
P08150970A0434 |7 19|cutoff level06T0076 Comp
P08150970A0434 |83 91|patients000 Phar
P08151787A0355 |0 9|InsertionP00001606
P08151787A0355 |125 130|IE110rbili
P08151787A0355 |94 99|IE175ologi
P08151787A0355 |242 248|motifs longe
P08151787A0355 |302 314|localization significant
P08151787A0355 |104 119|500-VRPRKRR-506ects of neonata
P08151787A0355 |156 161|formsWhen 
P08151787A0355 |55 88|amino acid motifs 726-GRKRKSP-732d 5-nucleotidase P00008171T0000 P
P08151787A0355 |173 181|proteinsis shown
P08151787A0355 |19 35|oligonucleotidesarison with alka
P08151787A0355 |207 216|phenotype the data
P08151787T0000 |0 7|MappingP000016
P08151787T0000 |25 45|localization domains with alkaline phosp
P08151787T0000 |63 90|colocalization interactionseotidase P00008171T0000 Pha
P08151787T0000 |154 174|herpes simplex virus2 When CSF [HCO3-] i
P08151787T0000 |113 118|IE175eonat
P08151787T0000 |127 150|transactivator proteinsilirubinemia. P00008997
P08151787T0000 |50 58|evidencees and 5
P08151787T0000 |103 108|IE110pects
P08151790A0354 |103 106|LTRpec
P08151790A0354 |89 96|contextarmacol
P08151790A0354 |192 203|infectivityion of CSF 
P08151790A0354 |165 171|effect[HCO3-
P08151790A0354 |134 142|deletionnemia. P
P08151790A0354 |120 132|Sp1 mutation hyperbiliru
P08151790A0354 |53 68|HIV replicationand 5-nucleotid
P08151790A0354 |146 150|site8997
P08151790A0354 |41 49|kineticshosphata
P08151790A0354 |217 220|HIVof 
P08151790A0354 |4 24|revertant TATA boxes01606T0076 Compariso
P08151980T0001 |11 20|emphysema076 Compa
P08152800A0357 |220 223|ERMK-d
P08152800A0357 |132 136|PEA3bine
P08152800A0357 |65 71|regiontidase
P08152800A0357 |179 185|memberwn as 
P08152800A0357 |199 217|Molecule PEA3-likeCSF PCO2 the data 
P08152800A0357 |10 20|ETS domain0076 Compa
P08152800A0357 |109 110|%o
P08152800A0357 |101 102|%a
P08152800A0357 |48 55|carboxyases an
P08152800A0357 |141 145|ER81P000
P08152800A0357 |87 94|proteinPharmac
P08152800A0357 |187 190|Etsfun
P08152800A0709 |186 198|Ets proteins function of
P08152800A0709 |97 112|oligonucleotidegic aspects of 
P08152800A0709 |128 167|consensus nucleotide core sequence GGAAlirubinemia. P00008997A0472 When CSF [H
P08152800A0709 |50 61|ERM proteines and 5-nu
P08152800A0709 |0 18|Gel shift analysisP00001606T0076 Com
P08153130T0000 |102 106|ratsspec
P08153130T0000 |24 35|worm burdenn with alka
P08153130T0000 |11 20|estradiol076 Compa
P08153130T0000 |0 7|EffectsP000016
P08153130T0000 |51 61|leukocytess and 5-nu
P08153146A0327 |0 10|DotarizineP00001606T
P08153146A0327 |29 37|dilationh alkali
P08153146A0327 |135 146|artery flowemia. P0000
P08153146A0327 |200 209|pressuresSF PCO2 t
P08153146A0327 |174 185|artery means shown as 
P08153146A0327 |233 242|pressurests are no
P08153146A0327 |69 80|circulationse P0000817
P08153146A0327 |103 113|resistancepects of n
P08154171A0649 |139 148|treatment. P000089
P08154171A0649 |109 120|conjunctionof neonatal
P08154171A0649 |41 49|patientshosphata
P08154171A0649 |182 190|embolismas a fun
P08154171A0649 |89 99|infarctionarmacologi
P08154171A0649 |158 166|patientsen CSF [
P08154171A0649 |6 12|issues606T00
P08154171A0649 |25 28|use wi
P08154171A0649 |64 74|thrombosisotidase P0
P08154171A0649 |32 37|LMWHslkali
P08154182A0955 |4 14|usefulness01606T0076
P08154182A0955 |108 140|Neurospora crassa cDNA libraries of neonatal hyperbilirubinemia.
P08154182A0955 |42 68|lambda AD5 cloning vectorsosphatases and 5-nucleotid
P08154182A0955 |22 33|lambda PG15son with al
P08156332T0000 |85 94|ischaemia0 Pharmac
P08156332T0000 |25 38|sympathectomy with alkalin
P08156332T0000 |51 60|treatments and 5-n
P08157009A0264 |0 20|Sequence comparisonsP00001606T0076 Compa
P08157009A0264 |37 42|Aps1pne ph
P08157009A0264 |131 136|Aps2pubine
P08157009A0264 |167 201|plasma membrane AP-2 sigma subunitCO3-] is shown as a function of CS
P08157009A0264 |66 79|sigma subunitidase P000081
P08157009A0264 |113 125|AP-1 complexeonatal hype
P08157009T0000 |118 126|evidenceal hyper
P08157009T0000 |95 116|clathrin AP-1 complexlogic aspects of neon
P08157009T0000 |29 38|APS1 geneh alkalin
P08157009T0000 |175 188|Golgi complex shown as a f
P08157009T0000 |159 167|clathrinn CSF [H
P08157009T0000 |142 153|interaction00008997A04
P08157009T0000 |49 56|homologses and
P08157009T0000 |70 77|subunite P0000
P08157663A0882 |168 174|memberO3-] i
P08157663A0882 |145 153|envelope08997A04
P08157663A0882 |58 70|organization-nucleotidas
P08157663A0882 |180 186|familyn as a
P08157663A0882 |113 129|membrane proteineonatal hyperbil
P08157663A0882 |6 13|results606T007
P08157663A0882 |76 91|vertebrate gene08171T0000 Phar
P08157663A0882 |190 202|polypeptidesction of CSF
P08157663A0882 |216 225|evolution of K-dep
P08157674T0000 |51 58|proteins and 5
P08157674T0000 |62 95|protein tyrosine kinase substrateleotidase P00008171T0000 Pharmaco
P08157674T0000 |12 28|characterization76 Comparison wi
P08157674T0000 |113 118|cellseonat
P08159174A0581 |50 67|Southern analysises and 5-nucleoti
P08159174A0581 |28 32|geneth a
P08159174A0581 |4 12|presence01606T00
P08160054A0224 |18 32|deterioriationparison with a
P08160054A0224 |78 91|liver enzymes171T0000 Phar
P08160054A0224 |107 133|alanine aminotransaminasess of neonatal hyperbilirub
P08160054A0224 |93 102|aspartatecologic a
P08160054A0224 |43 49|statussphata
P08160054A0224 |146 158|coagulopathy8997A0472 Wh
P08160054A0224 |66 74|increaseidase P0
P08160054A0224 |4 12|patients01606T00
P08160387T0000 |21 32|developmentison with a
P08160387T0000 |74 78|role0008
P08160387T0000 |40 43|ratpho
P08160387T0000 |106 113|rearingts of n
P08160387T0000 |89 99|experiencearmacologi
P08160387T0000 |128 139|deprivationlirubinemia
P08160387T0000 |59 65|cortexnucleo
P08160905A0217 |69 74|HBsAgse P0
P08160905A0217 |40 67|hepatitis B surface antigenphosphatases and 5-nucleoti
P08160905A0217 |7 15|patients06T0076 
P08163183T0000 |117 129|XylA enzymestal hyperbil
P08163183T0000 |45 78|Clostridium thermosaccharolyticumhatases and 5-nucleotidase P00008
P08163183T0000 |30 34|gene alk
P08163183T0000 |36 40|xylAine 
P08163183T0000 |89 99|sequencingarmacologi
P08163183T0000 |104 113|phylogenyects of n
P08163183T0000 |80 87|cloning1T0000 
P08163183T0000 |4 10|xylose01606T
P08163498A0789 |69 83|SGASGLLTSEHHSRse P00008171T0
P08163498A0789 |162 169|peptideSF [HCO
P08163498A0789 |43 57|SGASGLLTSEHHSRsphatases and 
P08163498A0789 |62 63|Sl
P08163498A0789 |120 135|phosphorylation hyperbilirubin
P08163498A0789 |140 154|trypsinization P00008997A047
P08163498A0789 |65 68|32Ptid
P08163498A0789 |39 42|32P ph
P08163498A0789 |4 19|phosphopeptides01606T0076 Comp
P08163498A0789 |35 37|RSli
P08163528T0000 |14 43|Mas70p signal anchor sequence Comparison with alkaline pho
P08163546A1230 |184 196|intersection a function 
P08163546A1230 |56 62|Ypt53p 5-nuc
P08163546A1230 |107 114|pathways of ne
P08163546A1230 |44 50|Ypt52pphatas
P08163546A1230 |151 161|hydrolases0472 When 
P08163546A1230 |36 42|Ypt51pine ph
P08163546A1230 |232 247|sorting pathwayats are no long
P08163546A1230 |131 138|sortingubinemi
P08163546A1230 |80 89|transport1T0000 Ph
P08163546A1230 |18 22|datapari
P08164302A0547 |119 131|energy levell hyperbilir
P08164302A0547 |157 164|glucosehen CSF
P08164302A0547 |105 115|differencects of neo
P08164302A0547 |17 30|TPN solutionsmparison with
P08164302A0547 |68 88|nutrient compositionase P00008171T0000 P
P08164661A0414 |34 42|homologyaline ph
P08164661A0414 |14 26|TFIIIC alpha Comparison 
P08164661A0414 |120 126|degree hyper
P08164661A0414 |143 153|divergence0008997A04
P08164661A0414 |57 62|yeast5-nuc
P08164661A0414 |177 184|factorshown as
P08164661A0414 |158 172|RNA polymeraseen CSF [HCO3-]
P08164661A0414 |70 78|subunitse P00008
P08164679A0809 |0 22|Transactivation domainP00001606T0076 Compari
P08164679A0809 |108 119|Runt domain of neonata
P08164679A0809 |67 87|runt homology regiondase P00008171T0000 
P08164680A1086 |21 38|protease activityison with alkalin
P08164680A1086 |77 84|B cells8171T00
P08164680A1086 |99 104|cellsc asp
P08164684A1266 |35 39|acidline
P08164684A1266 |104 111|complexects of
P08164684A1266 |15 18|RXRCom
P08164684A1266 |58 64|effect-nucle
P08164684A1266 |4 10|ligand01606T
P08166402A0631 |0 19|Cerebral125 albuminP00001606T0076 Comp
P08166402A0631 |45 56|proportionshatases and
P08166402A0631 |66 72|groupsidase 
P08166402A0631 |86 101|hyperosmolality Pharmacologic 
P08167396A0154 |22 29|neuronsson wit
P08167396A0154 |73 103|substantia nigra pars compacta00008171T0000 Pharmacologic as
P08167555A0972 |0 8|ResponseP0000160
P08167555A0972 |12 21|treatment76 Compar
P08167555A0972 |122 126|onesyper
P08167555A0972 |55 67|pretreatmentd 5-nucleoti
P08167555A0972 |83 93|treatments000 Pharma
P08167555A0972 |36 44|patientsine phos
P08167555A0972 |206 207|p2
P08167555A0972 |154 162|relation2 When C
P08169201A0291 |55 67|carA productd 5-nucleoti
P08169201A0291 |134 143|organismsnemia. P0
P08169201A0291 |30 38|sequence alkalin
P08169201A0291 |180 191|amino acidsn as a func
P08169201A0291 |106 125|nucleotide sequencets of neonatal hype
P08169709T0000 |34 42|analysisaline ph
P08169709T0000 |28 32|jawsth a
P08169709T0000 |11 20|bone cyst076 Compa
P08169709T0000 |49 54|casesses a
P08170400T0000 |0 8|LocationP0000160
P08170400T0000 |73 93|transcription factor00008171T0000 Pharma
P08170400T0000 |13 24|orientation6 Compariso
P08170400T0000 |95 98|FNRlog
P08170400T0000 |42 48|regionosphat
P08172416A0860 |17 22|timesmpari
P08172416A0860 |130 146|folliculogenesisrubinemia. P0000
P08172416A0860 |148 157|ovulation97A0472 W
P08172416A0860 |192 203|developmention of CSF 
P08172416A0860 |183 188|phases a f
P08172416A0860 |98 109|performanceic aspects 
P08172416A0860 |81 84|cowT00
P08172416A0860 |39 43|dose pho
P08172416A0860 |70 77|effectse P0000
P08172416A0860 |0 10|MoxidectinP00001606T
P08172598A0237 |49 63|N. patriciarumses and 5-nucl
P08172598A0237 |26 30|mRNAwith
P08172598A0237 |14 22|analysis Compari
P08172598A0237 |76 80|xynB0817
P08172598A0237 |101 116|kb mRNA speciesaspects of neon
P08172653A1589 |117 126|sequencestal hyper
P08172653A1589 |13 20|regions6 Compa
P08172653A1589 |135 139|riseemia
P08172653A1589 |44 56|TnT isoformsphatases and
P08172653A1589 |143 150|members0008997
P08172653A1589 |172 178|family is sh
P08172653A1589 |93 105|modificationcologic aspe
P08172653A1589 |158 161|TnTen 
P08172653A1589 |80 88|addition1T0000 P
P08172905A0000 |68 84|RNA miniduplexesase P00008171T00
P08172905A0000 |30 53|alanine tRNA synthetase alkaline phosphatases 
P08172905A0000 |158 171|U70 base pairen CSF [HCO3-
P08172905A0000 |108 120|acceptor end of neonatal
P08172905A0000 |124 136|alanine tRNAerbilirubine
P08172905A0000 |4 9|class01606
P08172905A0000 |155 157|G3 W
P08173532A0000 |102 104|S1sp
P08173532A0000 |7 20|reaction time06T0076 Compa
P08173532A0000 |144 146|ms00
P08173532A0000 |57 59|S25-
P08173532A0000 |124 135|S2 locationerbilirubin
P08173532A0000 |174 186|facilitations shown as a
P08173532A0000 |97 100|cuegic
P08173532A0000 |22 24|RTso
P08173532A0000 |49 55|targetses an
P08173532A0000 |154 166|target onset2 When CSF [
P08173693A0390 |71 79|patients P000081
P08173693A0390 |9 20|study groupT0076 Compa
P08173693A0390 |92 113|angina pectoris classacologic aspects of n
P08173693A0390 |42 53|innervationosphatases 
P08173814A0132 |6 13|viruses606T007
P08173814A0132 |149 164|host physiology7A0472 When CSF
P08173814A0132 |73 85|interference00008171T000
P08173814A0132 |28 47|host cell machineryth alkaline phospha
P08173814A0132 |58 67|existence-nucleoti
P08173814A0132 |97 106|processesgic aspec
P08175031A0566 |0 9|TreatmentP00001606
P08175188A0685 |2 15|concentration0001606T0076 
P08175188A0685 |122 123|%y
P08175188A0685 |91 92|%m
P08175188A0685 |24 31|ppm SO2n with 
P08175188A0685 |56 71|baseline values 5-nucleotidase
P08175188A0685 |132 135|CBFbin
P08175188A0685 |42 50|decreaseosphatas
P08175188A0685 |101 104|MCAasp
P08176742A0190 |70 91|transposition pathwaye P00008171T0000 Phar
P08176742A0190 |28 44|assay conditionsth alkaline phos
P08176742A0190 |55 62|studiesd 5-nuc
P08177143T0000 |6 20|cell carcinoma606T0076 Compa
P08177143T0000 |57 67|experience5-nucleoti
P08177143T0000 |24 32|childrenn with a
P08177143T0000 |43 54|institutionsphatases a
P08178446A1160 |103 107|rolepect
P08178446A1160 |22 27|ICP10son w
P08178446A1160 |134 152|signaling pathwaysnemia. P00008997A0
P08178446A1160 |75 85|TM segment008171T000
P08178446A1160 |53 65|ras activityand 5-nucleo
P08178446A1160 |4 8|data0160
P08178490A0879 |53 68|anchor functionand 5-nucleotid
P08178490A0879 |28 43|signal functionth alkaline pho
P08178490A0879 |79 90|K SA domain71T0000 Pha
P08178572A1118 |115 121|regionnatal 
P08178572A1118 |60 70|base pairsucleotidas
P08178572A1118 |97 104|proteingic asp
P08178572A1118 |5 36|concensus poly A addition sites1606T0076 Comparison with alkal
P08179827T0000 |85 90|Korea0 Pha
P08179827T0000 |54 81|hepatitis B virus infectionnd 5-nucleotidase P00008171
P08179827T0000 |38 50|transmissione phosphatas
P08179827T0000 |0 7|FactorsP000016
P08180129A1256 |0 8|ExposureP0000160
P08180129A1256 |52 59|content and 5-
P08180129A1256 |19 37|TPA concentrationsarison with alkali
P08180129A1256 |69 80|transcriptsse P0000817
P08181755A0989 |0 17|Northern analysisP00001606T0076 Co
P08181755A0989 |72 82|transcriptP00008171T
P08181755A0989 |115 119|mRNAnata
P08181755A0989 |35 51|pcbAB transcriptline phosphatase
P08182041A1067 |85 95|inhibition0 Pharmaco
P08182041A1067 |4 11|results01606T0
P08182041A1067 |99 106|insulinc aspec
P08182041A1067 |77 80|PKA817
P08182041A1067 |123 145|CREB activation domainperbilirubinemia. P000
P08182041A1067 |201 215|hepatoma cellsF PCO2 the dat
P08182041A1067 |55 64|inductiond 5-nucle
P08182041A1067 |38 50|requirementse phosphatas
P08182041A1067 |154 173|PEPCK TATA sequence2 When CSF [HCO3-] 
P08182041A1067 |68 73|PEPCKase P
P08182056A0695 |100 109|NQO2 gene aspects 
P08182056A0695 |131 137|memberubinem
P08182056A0695 |40 44|NQO2phos
P08182056A0695 |76 84|sequence08171T00
P08182056A0695 |145 160|NQO gene family08997A0472 When
P08182056A0695 |9 15|degreeT0076 
P08182056A0695 |19 31|conservationarison with 
P08182056A0695 |49 71|NQO1 gene organizationses and 5-nucleotidase
P08182171A0000 |18 49|Propionibacterium acnes productparison with alkaline phosphata
P08182171A0000 |67 84|coliform mastitisdase P00008171T00
P08182171A0000 |122 130|infusionyperbili
P08182171A0000 |54 63|treatmentnd 5-nucl
P08182171A0000 |4 12|efficacy01606T00
P08183552T0000 |33 58|tyrosine kinase substratekaline phosphatases and 5
P08183552T0000 |90 94|mapsrmac
P08183552T0000 |10 20|eps15 gene0076 Compa
P08183552T0000 |76 85|evolution08171T000
P08183915A0000 |220 224|p105K-de
P08183915A0000 |124 145|p70 I kappa B proteinerbilirubinemia. P000
P08183915A0000 |62 73|p50 subunitleotidase P
P08183915A0000 |45 54|precursorhatases a
P08183915A0000 |30 37|protein alkali
P08183915A0000 |39 43|p105 pho
P08183915A0000 |77 108|transcription factor NF-kappa B8171T0000 Pharmacologic aspects
P08183915A0000 |147 162|I kappa B gamma997A0472 When C
P08183915A0000 |4 8|gene0160
P08183915A0000 |205 216|amino acidsO2 the data
P08183915T0000 |144 154|activities008997A047
P08183915T0000 |12 20|splicing76 Compa
P08183915T0000 |62 82|p105 NF-kappa B geneleotidase P00008171T
P08183915T0000 |24 39|RNA transcriptsn with alkaline
P08183915T0000 |93 117|I kappa B gamma isoformscologic aspects of neona
P08184923A0829 |69 70|%s
P08184923A0829 |75 79|CeBF0081
P08184923A0829 |41 49|increasehosphata
P08184923A0829 |106 114|exposurets of ne
P08184923A0829 |91 92|%m
P08184923A0829 |8 13|L-NNA6T007
P08184923A0829 |53 57|CoBFand 
P08185288A0106 |4 14|experiment01606T0076
P08185288A0106 |95 115|respiration chamberslogic aspects of neo
P08185288A0106 |147 156|afternoon997A0472 
P08185288A0106 |26 30|malewith
P08185288A0106 |135 142|morningemia. P
P08185288A0106 |202 207|kg m. PCO2
P08185288A0106 |52 60|subjects and 5-n
P08185288A0106 |161 172|min cyclingCSF [HCO3-]
P08185288A0106 |83 87|stay000 
P08185288A0106 |188 192|workunct
P08187085A0086 |35 44|formationline phos
P08187085A0086 |75 97|tyrosine kinase domain008171T0000 Pharmacolo
P08187085A0086 |57 62|genes5-nuc
P08187085A0086 |123 136|end sequencesperbilirubine
P08187085A0086 |150 155|genesA0472
P08187085A0086 |6 20|rearrangements606T0076 Compa
P08187085A0086 |101 104|retasp
P08187088A0530 |136 138|8pmi
P08187088A0530 |185 188|13qa f
P08187088A0530 |250 251|%d
P08187088A0530 |112 114|5qne
P08187088A0530 |124 126|6per
P08187088A0530 |241 244|19qo l
P08187088A0530 |120 121|% 
P08187088A0530 |181 182|% 
P08187088A0530 |148 150|9p97
P08187088A0530 |88 102|chromosomes 3pharmacologic a
P08187088A0530 |211 214|17q da
P08187088A0530 |33 36|LOHkal
P08187088A0530 |168 169|%O
P08187088A0530 |233 234|%t
P08187088A0530 |172 175|11p is
P08187088A0530 |108 109|% 
P08187088A0530 |160 162|9q C
P08187088A0530 |224 227|18qple
P08187088A0530 |45 46|%h
P08187088A0530 |194 195|%n
P08187088A0530 |17 31|heterozygositymparison with 
P08187088A0530 |220 221|%K
P08187088A0530 |156 157|%W
P08187088A0530 |144 145|%0
P08187088A0530 |9 13|lossT007
P08187088A0530 |198 201|17p CS
P08187088A0530 |132 133|%b
P08187088A0530 |66 71|casesidase
P08187088A0530 |207 208|% 
P08187177A0405 |34 37|CPYali
P08187177A0405 |47 61|sorting signaltases and 5-nu
P08187177A0405 |9 26|amino acid changeT0076 Comparison 
P08187177A0405 |76 87|interaction08171T0000 
P08188258A0000 |98 109|synthetasesic aspects 
P08188258A0000 |29 51|prolyl-tRNA synthetaseh alkaline phosphatase
P08188258A0000 |14 24|synthetase Compariso
P08188258A0000 |72 79|classesP000081
P08188258A0000 |174 182|pathwayss shown 
P08188290A0544 |119 124|assayl hyp
P08188290A0544 |48 66|TCRAC/TCRDC regionases and 5-nucleot
P08188290A0544 |141 151|expressionP00008997A
P08188290A0544 |10 23|sequence data0076 Comparis
P08188290A0544 |87 103|polymerase chainPharmacologic as
P08188290A0544 |170 189|TCRAJ gene segments-] is shown as a fu
P08188603A0230 |70 78|homologye P00008
P08188603A0230 |113 122|CPA2 geneeonatal h
P08188603A0230 |142 149|subunit0000899
P08188603A0230 |60 66|degreeucleot
P08188603A0230 |39 43|arg4 pho
P08188603A0230 |5 13|analysis1606T007
P08188603A0230 |173 183|synthetaseis shown a
P08188603A0230 |33 37|genekali
P08188603A0230 |185 190|CPS-Aa fun
P08188606A1034 |186 204|cadmium resistance function of CSF P
P08188606A1034 |73 79|Tn5422000081
P08188606A1034 |61 69|presencecleotida
P08188606A1034 |143 150|strains0008997
P08188606A1034 |212 222|chromosomedata of K-
P08188606A1034 |25 47|Southern hybridization with alkaline phospha
P08188606A1034 |169 176|strains3-] is 
P08188606A1034 |0 20|Restriction analysisP00001606T0076 Compa
P08188978A0822 |33 43|ECG R-wavekaline pho
P08188978A0822 |123 128|sleepperbi
P08188978A0822 |62 77|MSNA burst peakleotidase P0000
P08188978A0822 |15 22|latencyCompari
P08188978A0822 |146 165|pulse-synchronicity8997A0472 When CSF 
P08188978A0822 |114 115|so
P08189174A0148 |0 6|DESIGNP00001
P08189174A0148 |135 139|cityemia
P08189174A0148 |121 127|livinghyperb
P08189174A0148 |65 70|yearstidas
P08189174A0148 |143 150|Utrecht0008997
P08189174A0148 |93 116|breast cancer screeningcologic aspects of neon
P08189174A0148 |21 26|studyison 
P08189174A0148 |48 53|womenases 
P08189498T0000 |85 98|repeat region0 Pharmacolog
P08189498T0000 |49 54|Marekses a
P08189498T0000 |37 41|genene p
P08189498T0000 |57 70|disease virus5-nucleotidas
P08189498T0000 |136 147|polypeptidemia. P00008
P08189498T0000 |0 14|IdentificationP00001606T0076
P08189503A0000 |103 106|RNApec
P08189503A0000 |27 37|cDNA cloneith alkali
P08189503A0000 |121 141|cassette mutagenesishyperbilirubinemia. 
P08189503A0000 |191 205|mRNA synthesistion of CSF PC
P08189503A0000 |43 75|mouse hepatitis virus strain A59sphatases and 5-nucleotidase P00
P08189503A0000 |108 115|pMIDI-C of neo
P08189503A0000 |155 164|mechanism When CSF
P08189503A0000 |168 179|coronavirusO3-] is sho
P08189533A0203 |85 89|NS530 Ph
P08189533A0203 |46 53|productatases 
P08189533A0203 |194 200|vTF7-3n of C
P08189533A0203 |202 219|expression system PCO2 the data of
P08189533A0203 |127 156|baculovirus expression systemilirubinemia. P00008997A0472 
P08189533A0203 |76 81|forms08171
P08189533A0203 |39 43|gene pho
P08189533A0203 |175 192|vaccinia virus/T7 shown as a funct
P08189533A0919 |0 19|Gel electrophoresisP00001606T0076 Comp
P08189533A0919 |178 189|associationown as a fu
P08189533A0919 |163 170|cytosolF [HCO3
P08189533A0919 |127 134|amountsilirubi
P08189533A0919 |138 142|NS53a. P
P08189533A0919 |101 106|cellsaspec
P08189533A0919 |212 218|matrixdata o
P08189533A0919 |32 51|immunoblot analyseslkaline phosphatase
P08189533A0919 |69 78|fractionsse P00008
P08190633A0000 |84 93|HLA locus00 Pharma
P08190633A0000 |62 72|chromosomeleotidase 
P08190633A0000 |46 50|geneatas
P08190633A0000 |4 29|transcription factor AP-201606T0076 Comparison wit
P08190633A0273 |64 70|regionotidas
P08190633A0273 |11 20|AP-2 mRNA076 Compa
P08190633A0273 |88 91|DNAhar
P08190633A0273 |77 79|kb81
P08190633A0273 |39 44|exons phos
P08191910A0228 |119 129|strategistl hyperbil
P08191910A0228 |106 115|abilitiests of neo
P08191910A0228 |67 73|lodgesdase P
P08191910A0228 |144 149|ruler00899
P08191910A0228 |27 33|traitsith al
P08191910A0228 |49 53|workses 
P08191910A0228 |0 10|San MartinP00001606T
P08192140A0209 |119 132|San Franciscol hyperbiliru
P08192140A0209 |134 135|nn
P08192140A0209 |105 106|nc
P08192140A0209 |90 103|New York Cityrmacologic as
P08192140A0209 |81 82|nT
P08192140A0209 |4 16|participants01606T0076 C
P08192140A0209 |40 66|hepatitis B vaccine trialsphosphatases and 5-nucleot
P08192140A0209 |33 36|menkal
P08192140A0209 |70 79|Amsterdame P000081
P08192451A0885 |34 42|decreasealine ph
P08192451A0885 |95 105|NAO uptakelogic aspe
P08192451A0885 |10 19|treatment0076 Comp
P08192451A0885 |60 66|uptakeucleot
P08192451A0885 |83 91|increase000 Phar
P08192451A0885 |70 75|Rh123e P00
P08192795T0000 |48 67|lupus erythematosusases and 5-nucleoti
P08192795T0000 |28 35|purpurath alka
P08193147A0831 |0 10|ComparisonP00001606T
P08193147A0831 |125 133|topologyrbilirub
P08193147A0831 |198 200|Pf C
P08193147A0831 |41 60|Desulfovibrio gigashosphatases and 5-n
P08193147A0831 |62 64|Dgle
P08193147A0831 |173 181|elementsis shown
P08193147A0831 |66 68|Fdid
P08193147A0831 |213 218|Dg Fdata o
P08193147A0831 |20 37|crystal structurerison with alkali
P08193147A0831 |70 79|Kissingere P000081
P08194139A0498 |0 11|CONCLUSIONSP00001606T0
P08194139A0498 |13 43|Serum prolactin concentrations6 Comparison with alkaline pho
P08194139A0498 |61 71|variationscleotidase
P08194139A0498 |94 97|menolo
P08194139A0498 |49 52|ageses
P08194549A0000 |102 104|CPsp
P08194549A0000 |151 155|OBLA0472
P08194549A0000 |95 100|powerlogic
P08194549A0000 |26 34|kayakerswith alk
P08194549A0000 |123 149|blood lactate accumulationperbilirubinemia. P0000899
P08194549A0000 |65 77|relationshiptidase P0000
P08194549A0000 |114 119|onsetonata
P08194753A0157 |138 144|regiona. P00
P08194753A0157 |92 95|DNAaco
P08194753A0157 |114 121|elementonatal 
P08194753A0157 |37 42|rhp51ne ph
P08194753A0157 |25 33|sequence with al
P08194753A0157 |55 59|MluId 5-
P08194753A0157 |71 76|boxes P000
P08194970A0000 |0 5|WomenP0000
P08194970A0000 |94 99|carerologi
P08194970A0000 |31 35|workalka
P08194970A0000 |126 137|Trudy Wynnebilirubinem
P08194970A0000 |111 117|family neona
P08194970A0000 |78 82|role171T
P08194970A0000 |8 21|opportunities6T0076 Compar
P08194970A0000 |48 52|homeases
P08195186A0000 |304 306|K.ig
P08195186A0000 |73 77|gene0000
P08195186A0000 |194 203|ecoR/CAT1n of CSF 
P08195186A0000 |290 294|C.L.stil
P08195186A0000 |256 269|T lymphocytesced when comp
P08195186A0000 |296 302|Finleyhave a
P08195186A0000 |94 101|proteinologic 
P08195186A0000 |210 219|RNA blotse data of
P08195186A0000 |43 55|T lymphocytesphatases an
P08195186A0000 |10 23|cDNA sequence0076 Comparis
P08195186A0000 |281 288|MacLeodrols bu
P08195186A0000 |79 82|Tea71T
P08195186A0000 |316 318|D. g
P08195186A0000 |274 279|liverto co
P08195186A0000 |141 151|retrovirusP00008997A
P08195186A0000 |308 314|Kakudaficant
P08195186A0000 |238 252|Tea expressione no longer di
P08195186A0000 |170 192|amino acid transporter-] is shown as a funct
P08195216A1022 |186 202|GCN4p activation function of CSF
P08195216A1022 |33 37|HIS3kali
P08195216A1022 |59 65|subsetnucleo
P08195216A1022 |24 28|casen wi
P08195216A1022 |79 88|sequences71T0000 P
P08195216A1022 |136 141|GCN4pmia. 
P08195216A1022 |206 210|TRP32 th
P08195216A1022 |168 177|sequencesO3-] is s
P08195216A1022 |102 115|transcriptionspects of neo
P08195216A1022 |119 130|conjunctionl hyperbili
P08195217A0799 |55 94|reticulocyte lysate translation productd 5-nucleotidase P00008171T0000 Pharmac
P08195217A0799 |132 139|proteinbinemia
P08195217A0799 |181 185|gels as 
P08195217A0799 |22 29|proteinson wit
P08195217A0799 |143 157|sodium dodecyl0008997A0472 W
P08195233A0147 |168 174|stagesO3-] i
P08195233A0147 |91 96|genesmacol
P08195233A0147 |178 191|tumorigenesisown as a func
P08195233A0147 |124 134|chromosomeerbilirubi
P08195233A0147 |106 114|positionts of ne
P08195233A0147 |3 11|addition001606T0
P08195233A0147 |18 24|kinasepariso
P08196607A0280 |0 17|Deletion analysisP00001606T0076 Co
P08196607A0280 |109 116|UASICL1of neon
P08196607A0280 |121 131|CATTCATCCGhyperbilir
P08196607A0280 |91 107|sequence elementmacologic aspect
P08196607A0280 |25 38|ICL1 promoter with alkalin
P08196607A0280 |230 243|reporter gene rats are no 
P08196607A0280 |177 183|carbonhown a
P08196607A0280 |201 211|regulationF PCO2 the
P08196607A0280 |50 64|identificationes and 5-nucle
P08196616A1112 |34 40|ZAP-70aline 
P08196616A1112 |129 146|tyrosine residuesirubinemia. P0000
P08196616A1112 |77 85|presence8171T000
P08196616A1112 |177 183|ZAP-70hown a
P08196616A1112 |94 112|ZAP-70 SH2 domainsologic aspects of 
P08196616A1112 |241 248|bindingo longe
P08196616A1112 |19 30|interactionarison with
P08196616A1112 |260 271|SH2 domainswhen compar
P08196616A1112 |203 227|phosphotyrosine residuesPCO2 the data of K-deple
P08196616A1112 |154 159|motif2 Whe
P08196616A1112 |50 55|motifes an
P08196618A0473 |0 5|PRL-1P0000
P08196618A0473 |93 109|cysteine residuecologic aspects 
P08196618A0473 |125 133|activityrbilirub
P08196618A0473 |65 73|mutationtidase P
P08196618A0473 |33 59|phosphotyrosine substrateskaline phosphatases and 5-
P08196624A0593 |186 195|receptors function
P08196624A0593 |129 140|associationirubinemia.
P08196624A0593 |25 30|cells with
P08196624A0593 |166 173|ligandsHCO3-] 
P08196624A0593 |44 61|T beta R-I signalphatases and 5-nu
P08196624A0593 |71 74|set P0
P08196624A0593 |3 13|Mv1Lu lung001606T007
P08196624A0593 |178 182|typeown 
P08196624A0593 |116 125|responsesatal hype
P08196624A0593 |32 39|ActR-IBlkaline
P08198524A1134 |19 22|kDaari
P08198524A1134 |3 6|kDa001
P08199204A0746 |85 109|tyrosine phosphorylation0 Pharmacologic aspects 
P08199204A0746 |52 66|PKC activation and 5-nucleot
P08199204A0746 |125 138|P2 productionrbilirubinemi
P08199204A0746 |75 81|effect008171
P08199204A0746 |114 120|PtdInsonatal
P08199204A0746 |0 3|H-7P00
P08199878T0000 |85 99|brain ischemia0 Pharmacologi
P08199878T0000 |24 45|glucose concentrationn with alkaline phosp
P08199878T0000 |4 11|effects01606T0
P08199878T0000 |49 65|brain metabolismses and 5-nucleo
P08200528A0970 |119 122|PALl h
P08200528A0970 |181 185|REP2 as 
P08200528A0970 |164 171|control [HCO3-
P08200528A0970 |5 13|strategy1606T007
P08200528A0970 |41 55|Tn903 neo genehosphatases an
P08200528A0970 |133 137|geneinem
P08200528A0970 |64 117|Rhodosporidium toruloides phenylalanine ammonia lyaseotidase P00008171T0000 Pharmacologic aspects of neona
P08200528A0970 |175 179|pPGK sho
P08201352A0239 |116 129|skin necrosisatal hyperbil
P08201352A0239 |108 112|risk of 
P08201352A0239 |26 46|protein C deficiencywith alkaline phosph
P08201352A0239 |7 11|case06T0
P08201352A0239 |48 69|vitamin K antagonistsases and 5-nucleotida
P08201758A0125 |53 64|obstructionand 5-nucle
P08201758A0125 |75 85|laparotomy008171T000
P08201758A0125 |14 21|patient Compar
P08201758A0125 |92 97|timesacolo
P08201932A0355 |76 82|joints08171T
P08201932A0355 |12 23|examination76 Comparis
P08201932A0355 |43 56|polyarthritissphatases and
P08202546A1206 |33 58|hUBF-promoter interactionkaline phosphatases and 5
P08202546A1206 |124 131|adductserbilir
P08202546A1206 |99 106|effectsc aspec
P08202546A1206 |3 11|addition001606T0
P08203260A1204 |21 25|SIMVison
P08203260A1204 |47 55|neonatestases an
P08203260A1204 |65 75|ventilatortidase P00
P08204348T0000 |0 5|VP-16P0000
P08204348T0000 |7 17|ifosfamide06T0076 Co
P08204348T0000 |58 74|cell lung cancer-nucleotidase P0
P08204348T0000 |22 31|cisplatinson with 
P08204348T0000 |33 36|VIPkal
P08204403A0000 |16 21|malesompar
P08204403A0000 |149 154|I-1317A047
P08204403A0000 |28 35|femalesth alka
P08204403A0000 |120 143|radioimmunoscintigraphy hyperbilirubinemia. P0
P08204403A0000 |105 116|sensitivitycts of neon
P08204403A0000 |191 201|antibodiestion of CS
P08204403A0000 |82 87|study0000 
P08204403A0000 |37 45|patientsne phosp
P08204403A0000 |168 174|CEA/CAO3-] i
P08204403A0000 |2 7|total00016
P08204426T0001 |119 130|indicationsl hyperbili
P08204426T0001 |77 86|childhood8171T0000
P08204426T0001 |57 73|diaphragm pacing5-nucleotidase P
P08204426T0001 |92 114|implantation techniqueacologic aspects of ne
P08204426T0001 |38 49|ventilatione phosphata
P08204824A0000 |144 163|Catharanthus roseus008997A0472 When CS
P08204824A0000 |120 128|cultures hyperbi
P08204824A0000 |75 82|S phase008171T
P08204824A0000 |94 104|cell cycleologic asp
P08204824A0000 |132 142|periwinklebinemia. P
P08204824A0000 |165 170|cells[HCO3
P08204824A0000 |10 15|clone0076 
P08204824A0000 |24 34|cyc07 genen with alk
P08205827A0940 |152 165|translocation472 When CSF 
P08205827A0940 |78 83|tract171T0
P08205827A0940 |123 141|animal experimentsperbilirubinemia. 
P08205827A0940 |13 26|Translocation6 Comparison 
P08205827A0940 |30 38|bacteria alkalin
P08205827A0940 |190 198|patientsction of
P08205827A0940 |93 104|bloodstreamcologic asp
P08205827A0940 |42 51|endotoxinosphatase
P08205827A0940 |216 221|shock of K
P08205827A0940 |0 11|CONCLUSIONSP00001606T0
P08206848A0296 |32 44|polypeptideslkaline phos
P08206848A0296 |95 98|kDalog
P08206848A0296 |13 23|pyrP genes6 Comparis
P08206848A0296 |4 8|pyrR0160
P08206848A0296 |71 77|masses P0000
P08206867A0874 |0 26|Southern blotting analysisP00001606T0076 Comparison 
P08206867A0874 |62 73|COXVb genesleotidase P
P08206867A0874 |39 49|occurrence phosphata
P08206867A0874 |81 91|rat genomeT0000 Phar
P08206991A0466 |171 176|Cys-6] is 
P08206991A0466 |162 167|Cys-3SF [H
P08206991A0466 |131 144|palmitylationubinemia. P00
P08206991A0466 |192 198|serineion of
P08206991A0466 |55 60|Gly-2d 5-n
P08206991A0466 |99 114|N-myristylationc aspects of ne
P08206991A0466 |76 83|alanine08171T0
P08206991A0466 |19 35|palmitate analogarison with alka
P08206991A0466 |0 9|AcylationP00001606
P08207022T0000 |0 19|Subunit compositionP00001606T0076 Comp
P08207022T0000 |90 107|Bacillus subtilisrmacologic aspect
P08207022T0000 |24 40|domain structuren with alkaline 
P08207022T0000 |48 86|Spo0A sporulation transcription factorases and 5-nucleotidase P00008171T0000
P08207232A0503 |16 39|mobility shift analysisomparison with alkaline
P08207232A0503 |158 171|IL-8 promoteren CSF [HCO3-
P08207232A0503 |89 96|membersarmacol
P08207232A0503 |105 111|familycts of
P08207232A0503 |55 62|NF-IL-6d 5-nuc
P08207232A0503 |138 150|NF-IL-6 sitea. P00008997
P08207405A0372 |220 231|HSP70 genesK-depleted 
P08207405A0372 |121 146|kb amplification productshyperbilirubinemia. P0000
P08207405A0372 |59 63|BYSVnucl
P08207405A0372 |46 57|stunt virusatases and 
P08207405A0372 |192 201|fragmentsion of CS
P08207405A0372 |88 109|fleck virus templatesharmacologic aspects 
P08207405A0372 |28 31|CTVth 
P08207405A0372 |69 78|carnationse P00008
P08207405A0372 |168 178|sequencingO3-] is sh
P08207405A0372 |5 26|citrus tristeza virus1606T0076 Comparison 
P08207405A0372 |0 3|BYVP00
P08207405A0372 |34 38|beetalin
P08207795A0409 |99 121|mutagenesis proceduresc aspects of neonatal 
P08207795A0409 |75 82|protein008171T
P08207795A0409 |40 60|phosphorylation sitephosphatases and 5-n
P08207795A0409 |24 32|locationn with a
P08207805A0000 |137 146|repressoria. P0000
P08207805A0000 |123 132|activatorperbiliru
P08207805A0000 |4 37|p53 tumor suppressor gene product01606T0076 Comparison with alkali
P08207805A0000 |71 78|protein P00008
P08208247T0030 |51 57|regions and 
P08208247T0030 |11 19|analysis076 Comp
P08208247T0030 |82 105|acid decarboxylase gene0000 Pharmacologic aspe
P08208247T0030 |35 47|segment 64ABline phospha
P08208540A0000 |0 14|RearrangementsP00001606T0076
P08208540A0000 |95 107|significancelogic aspect
P08208540A0000 |62 74|malignanciesleotidase P0
P08208540A0000 |22 32|NFKB2 geneson with a
P08208540A0000 |117 128|alterationstal hyperbi
P08208540A0417 |152 158|p84/85472 Wh
P08208540A0417 |44 49|cDNAsphata
P08208540A0417 |82 90|splicing0000 Pha
P08208540A0417 |126 134|proteinsbilirubi
P08208540A0417 |148 150|kD97
P08208540A0417 |12 22|sequencing76 Compari
P08208540A0417 |107 117|gene codess of neona
P08208540A0417 |295 309|ankyrin repeat have a signif
P08208540A0417 |219 234|ankyrin repeats K-depleted rat
P08208540A0417 |189 199|rel domainnction of 
P08208540A0417 |256 272|carboxy-terminusced when compare
P08208540A0417 |0 7|CloningP000016
P08208540A1114 |119 128|NFKB2 p85l hyperbi
P08208540A1114 |72 77|kappaP0000
P08208540A1114 |196 205|NFKB2 p52of CSF PC
P08208540A1114 |43 67|NFKB2 expression vectorssphatases and 5-nucleoti
P08208540A1114 |10 32|co-transfection assays0076 Comparison with a
P08208540A1114 |158 177|repressor functionsen CSF [HCO3-] is s
P08208540A1114 |87 104|reporter plasmidsPharmacologic asp
P08208618A1334 |68 79|Sp1 bindingase P000081
P08208618A1334 |24 31|HR21Xapn with 
P08208618A1334 |6 12|HR21ap606T00
P08208618A1334 |54 64|inhibitionnd 5-nucle
P08209051T0000 |69 73|homese P
P08209051T0000 |41 49|fibrosishosphata
P08209051T0000 |23 30|therapyon with
P08209051T0000 |54 62|hospitalnd 5-nuc
P08209423T0000 |85 93|evidence0 Pharma
P08209423T0000 |30 49|nucleotide sequence alkaline phosphata
P08209423T0000 |57 83|MDV-1 BamHI-D DNA fragment5-nucleotidase P00008171T0
P08209423T0000 |132 149|glycoprotein genebinemia. P0000899
P08209423T0000 |13 19|frames6 Comp
P08209423T0000 |110 114|mRNAf ne
P08209423T0000 |98 106|splicingic aspec
P08209772A0167 |86 88|ns P
P08209772A0167 |90 97|proteinrmacolo
P08209772A0167 |46 49|ORFata
P08209772A0167 |31 44|reading framealkaline phos
P08209772A0167 |105 116|amino acidscts of neon
P08209772A0167 |144 148|mass0089
P08209772A0167 |4 12|ns2 gene01606T00
P08212571A0597 |0 15|Co-transfectionP00001606T0076 
P08212571A0597 |78 95|tat ORF mutations171T0000 Pharmaco
P08212571A0597 |193 196|taton 
P08212571A0597 |165 172|effects[HCO3-]
P08212571A0597 |181 188|mutants as a f
P08212571A0597 |21 24|tatiso
P08212571A0597 |36 43|plasmidine pho
P08212571A0597 |125 141|virus productionrbilirubinemia. 
P08212571A0597 |55 62|virusesd 5-nuc
P08212571A0597 |115 121|levelsnatal 
P08212571A0971 |0 8|AnalysisP0000160
P08212571A0971 |24 36|rev proteinsn with alkal
P08212571A0971 |56 61|cells 5-nu
P08212571A0971 |240 261|tat expression vectorno longer displaced w
P08212571A0971 |86 94|proteins Pharmac
P08212571A0971 |196 205|mutationsof CSF PC
P08212571A0971 |145 156|tat mutants08997A0472 
P08212571A0971 |16 19|gagomp
P08212571A0971 |118 123|cellsal hy
P08212897A0404 |34 51|methyltransferasealine phosphatase
P08212897A0404 |4 26|hydrophobicity profile01606T0076 Comparison 
P08212897A0404 |64 72|presenceotidase 
P08212897A0404 |100 121|transmembrane domains aspects of neonatal 
P08213235A1024 |0 11|MeasurementP00001606T0
P08213235A1024 |63 67|careeoti
P08213235A1024 |104 111|infantsects of
P08213235A1024 |15 19|SaO2Comp
P08213235A1024 |92 100|newbornsacologic
P08213235A1024 |32 40|altitudelkaline 
P08213747A0000 |576 587|Los Angelesl approxima
P08213747A0000 |90 99|infectionrmacologi
P08213747A0000 |303 310|authorssignifi
P08213747A0000 |255 263|diseasesaced whe
P08213747A0000 |495 502|centers0001265
P08213747A0000 |223 230|historyepleted
P08213747A0000 |563 570|Chicagoal CO2 
P08213747A0000 |83 88|HIV-1000 P
P08213747A0000 |158 161|menen 
P08213747A0000 |52 79|immunodeficiency virus type and 5-nucleotidase P000081
P08213747A0000 |385 403|HIV-1 risk factorsars to be an effec
P08213747A0000 |214 221|factorsta of K
P08213747A0000 |481 484|menmg 
P08213747A0000 |182 193|differencesas a functi
P08213747A0000 |339 347|analysis- 0.23 v
P08213747A0000 |547 549|DChe
P08213747A0000 |351 380|baseline HIV-1 seroprevalence00010943A0733 Flurazepam thus
P08213747A0000 |525 545|Baltimore/Washingtonents. P00013683A0210
P08213747A0000 |288 297|behaviorst still h
P08213747A0000 |136 139|menmia
P08213747A0000 |510 523|United Stateseta blocking 
P08213747A0000 |32 42|prevalencelkaline ph
P08213747A0000 |103 105|USpe
P08213747A0000 |551 561|Pittsburghextracorpo
P08216115A0158 |170 176|labour-] is 
P08216115A0158 |108 118|percentile of neonat
P08216115A0158 |130 138|activityrubinemi
P08216115A0158 |20 25|grouprison
P08216115A0158 |66 74|oxytocinidase P0
P08216115A0158 |43 52|catheterssphatases
P08216115A0158 |4 12|patients01606T00
P08216115A0158 |190 196|parityction 
P08217862A1336 |255 261|statesaced w
P08217862A1336 |94 101|abilityologic 
P08217862A1336 |29 54|rat conditioning paradigmh alkaline phosphatases a
P08217862A1336 |10 21|development0076 Compar
P08217862A1336 |215 222|strainsa of K-
P08217862A1336 |124 138|nerve activityerbilirubinemi
P08217862A1336 |179 185|numberwn as 
P08217862A1336 |156 164|subjectsWhen CSF
P08218056A0000 |4 18|ultrastructure01606T0076 Com
P08218056A0000 |79 87|patients71T0000 
P08218056A0000 |60 64|eyesucle
P08218056A0000 |30 37|vessels alkali
P08218056A0000 |96 100|eyesogic
P08218056A0000 |114 122|subjectsonatal h
P08218230A1505 |153 162|positions72 When C
P08218230A1505 |91 111|transcription factormacologic aspects of
P08218230A1505 |15 21|regionCompar
P08218230A1505 |142 147|HNF-100008
P08218230A1505 |57 69|binding site5-nucleotida
P08218230A1505 |132 138|factorbinemi
P08218230A1505 |113 123|hepatocyteeonatal hy
P08218230A1505 |33 41|sequencekaline p
P08218230A1920 |252 264|liver tissuesplaced when
P08218230A1920 |192 230|Xenopus fibrinogen B beta subunit geneion of CSF PCO2 the data of K-depleted
P08218230A1920 |62 89|glucocorticoid inducibilityleotidase P00008171T0000 Ph
P08218230A1920 |121 129|promoterhyperbil
P08218230A1920 |145 157|determinants08997A0472 W
P08218230A1920 |27 30|GREith
P08218230A1920 |177 184|controlhown as
P08218230A1920 |97 107|HNF-1 sitegic aspect
P08218230A1920 |234 239|cellss are
P08219072A0287 |0 4|AcadP000
P08219081A0000 |4 15|PRB-1b gene01606T0076 
P08219081A0000 |41 50|componenthosphatas
P08219081A0000 |79 98|PR-1 protein family71T0000 Pharmacolog
P08219227A0830 |0 11|ReplacementP00001606T0
P08219227A0830 |144 152|sequence008997A0
P08219227A0830 |177 186|AP-1 sitehown as a
P08219227A0830 |208 216|activitythe data
P08219227A0830 |72 77|levelP0000
P08219227A0830 |194 197|CREn o
P08219227A0830 |158 169|replacementen CSF [HCO
P08219227A0830 |97 105|activitygic aspe
P08219227A0830 |37 41|copyne p
P08219227A0830 |19 22|CREari
P08219227A0830 |49 58|AP-1 siteses and 5
P08220494A0231 |152 169|promotor activity472 When CSF [HCO
P08220494A0231 |42 48|originosphat
P08220494A0231 |179 183|stemwn a
P08220494A0231 |10 18|promoter0076 Com
P08220494A0231 |62 68|plantaleotid
P08220494A0231 |188 198|root cellsunction of
P08220494A0231 |173 177|leafis s
P08220494A0231 |202 216|tobacco plants PCO2 the data
P08220494A0231 |80 96|bp cyt-1 element1T0000 Pharmacol
P08220494A0231 |117 123|regiontal hy
P08220621T0000 |10 21|manuscripts0076 Compar
P08220621T0000 |47 53|systemtases 
P08221251A0239 |69 73|arease P
P08221251A0239 |41 50|diagnosishosphatas
P08221251A0239 |54 60|tumorsnd 5-n
P08221251A0239 |16 18|CTom
P08222384A0455 |0 5|SIN-1P0000
P08222384A0455 |46 56|parametersatases and
P08222384A0455 |13 22|influence6 Compari
P08222384A0455 |91 94|ECGmac
P08222384A0455 |64 89|surface electrocardiogramotidase P00008171T0000 Ph
P08222384A0455 |117 120|ECGtal
P08222556T0000 |0 6|EffectP00001
P08222556T0000 |10 15|aging0076 
P08222556T0000 |40 47|musclesphospha
P08222618A0000 |34 54|logit transformationaline phosphatases a
P08222618A0000 |63 71|analysiseotidase
P08222618A0000 |10 27|computer programs0076 Comparison w
P08222618A0000 |84 90|curves00 Pha
P08223425T0000 |4 19|yeast SSS1 gene01606T0076 Comp
P08223425T0000 |120 129|reticulum hyperbil
P08223425T0000 |47 68|protein translocationtases and 5-nucleotid
P08223425T0000 |93 100|proteincologic
P08223554A0574 |4 11|lengths01606T0
P08223554A0574 |111 119|residues neonata
P08223554A0574 |28 45|polypeptide chainth alkaline phosp
P08223554A0574 |65 71|enzymetidase
P08223554A0574 |80 95|transit peptide1T0000 Pharmaco
P08223576A1261 |68 78|conditionsase P00008
P08223576A1261 |4 11|absence01606T0
P08223576A1261 |97 106|H4PteGlungic aspec
P08223576A1261 |15 24|H4PteGlunCompariso
P08223576A1261 |38 47|T proteine phospha
P08223576A1261 |139 148|T protein. P000089
P08223592A0424 |0 4|TATAP000
P08223592A0424 |208 229|polyadenylation sitesthe data of K-deplete
P08223592A0424 |126 132|leaderbiliru
P08223592A0424 |9 20|CCAAT boxesT0076 Compa
P08223592A0424 |176 180|geneshow
P08223592A0424 |80 104|transcription start site1T0000 Pharmacologic asp
P08223592A0424 |139 150|nucleotides. P00008997
P08223613A0105 |102 130|synthase/phosphatase complexspects of neonatal hyperbili
P08223613A0105 |25 29|TPS1 wit
P08223613A0105 |162 166|byp1SF [
P08223613A0105 |177 191|cif1 mutationshown as a func
P08223613A0105 |168 172|glc6O3-]
P08223613A0105 |156 160|fdp1When
P08223613A0105 |65 72|subunittidase 
P08223613A0105 |0 4|GGS1P000
P08223613A0105 |17 21|genempar
P08223613A0519 |220 228|functionK-deplet
P08223613A0519 |57 65|products5-nucleo
P08223613A0519 |133 141|subunitsinemia. 
P08223613A0519 |149 175|trehalose synthase complex7A0472 When CSF [HCO3-] is
P08223613A0519 |87 97|genes TPS2Pharmacolo
P08223613A0519 |21 29|sequenceison wit
P08223613A0519 |203 207|TPS3PCO2
P08223613A0519 |187 201|TSL1 homologuefunction of CS
P08223613A0519 |102 106|TSL1spec
P08223823T0000 |0 19|Stroop interferenceP00001606T0076 Comp
P08223823T0000 |53 75|Stroop Color-Word Testand 5-nucleotidase P00
P08223823T0000 |21 34|aging effectsison with alk
P08223875A0711 |0 11|StimulationP00001606T0
P08223875A0711 |148 156|activity97A0472 
P08223875A0711 |62 63|%l
P08223875A0711 |19 32|PA productionarison with a
P08223875A0711 |87 91|CD45Phar
P08223875A0711 |113 118|cellseonat
P08223875A0711 |93 98|cellscolog
P08223875A0711 |176 181|cellsshown
P08223875A0711 |160 166|p59fyn CSF [
P08223875A0711 |107 111|CD45s of
P08223875A0711 |16 18|3Hom
P08223875A0711 |38 55|CD3 cross-linkinge phosphatases an
P08223875A0711 |170 174|CD45-] i
P08224260A1248 |0 10|CONCLUSIONP00001606T
P08224260A1248 |146 152|masses8997A0
P08224260A1248 |177 178|%h
P08224260A1248 |160 171|specificity CSF [HCO3-
P08224260A1248 |53 68|ultrasonographyand 5-nucleotid
P08224260A1248 |76 86|efficiency08171T0000
P08224260A1248 |92 93|%a
P08224260A1248 |113 126|endometriomaseonatal hyper
P08224260A1248 |16 21|studyompar
P08224907A0000 |34 42|rat EFIAaline ph
P08224907A0000 |123 146|cDNA subfragment probesperbilirubinemia. P0000
P08224907A0000 |44 73|gene encoding enhancer factorphatases and 5-nucleotidase P
P08224907A0000 |105 117|band patterncts of neona
P08224907A0000 |8 30|Southern blot analysis6T0076 Comparison with
P08224907A0000 |76 85|subunit A08171T000
P08225657A0000 |4 10|effect01606T
P08225657A0000 |14 23|ibopamine Comparis
P08225657A0000 |60 72|NYHA Class Iucleotidase 
P08225657A0000 |77 93|II heart failure8171T0000 Pharma
P08225657A0000 |46 54|patientsatases a
P08225657A0000 |28 38|furosemideth alkalin
P08225657A0000 |179 184|trialwn as
P08225657A0000 |112 120|parallelneonatal
P08226616A0000 |34 58|fungus Neurospora crassaaline phosphatases and 5
P08226616A0000 |123 127|stepperb
P08226616A0000 |90 96|enzymermacol
P08226616A0000 |75 84|reductase008171T00
P08226616A0000 |4 14|nit-3 gene01606T0076
P08226616A0000 |139 151|assimilation. P00008997A
P08226776A0990 |67 72|deltadase 
P08226776A0990 |90 99|delta Hvarmacologi
P08226776A0990 |58 63|ratio-nucl
P08226776A0990 |42 49|processosphata
P08226777A0936 |2 28|Dictyostelium transformant0001606T0076 Comparison wi
P08226777A0936 |44 50|DdPTPaphatas
P08226780A0160 |65 69|casetida
P08226780A0160 |73 80|ankyrin0000817
P08226780A0160 |121 129|proteinshyperbil
P08226780A0160 |37 57|protein interactionsne phosphatases and 
P08226780A0160 |5 10|motif1606T
P08226794A0501 |1 6|Ala8500001
P08226794A0501 |41 49|activityhosphata
P08226794A0501 |7 9|Dk06
P08226798A1124 |171 181|inhibition] is shown
P08226798A1124 |208 217|functionsthe data 
P08226798A1124 |165 169|part[HCO
P08226798A1124 |18 29|CaM bindingparison wit
P08226798A1124 |110 119|mechanismf neonata
P08226798A1124 |93 100|effectscologic
P08226798A1124 |33 54|HIV envelope proteinskaline phosphatases a
P08226798A1124 |136 148|cytotoxicitymia. P000089
P08226956A1397 |32 50|growth temperaturelkaline phosphatas
P08226956A1397 |99 110|type plantsc aspects o
P08226956A1397 |22 28|effectson wi
P08226956A1397 |81 90|fad7 mRNAT0000 Pha
P08226956A1397 |71 77|levels P0000
P08227129T0000 |100 123|immunoglobulin C2 motif aspects of neonatal hy
P08227129T0000 |44 57|muscle MyBP-Cphatases and 
P08227129T0000 |25 31|domain with 
P08227129T0000 |59 68|C proteinnucleotid
P08228805A0540 |139 162|protein tyrosine kinase. P00008997A0472 When C
P08228805A0540 |31 54|TCR signal transductionalkaline phosphatases a
P08228805A0540 |173 182|mechanismis shown 
P08228805A0540 |130 133|TCRrub
P08228805A0540 |62 96|guanine nucleotide binding proteinleotidase P00008171T0000 Pharmacol
P08228805A0540 |98 104|p21rasic asp
P08228805A0540 |19 27|moleculearison w
P08228997A0866 |38 56|lipid accumulatione phosphatases and
P08228997A0866 |80 91|oxygenation1T0000 Phar
P08228997A0866 |4 11|results01606T0
P08229102A0768 |49 58|potentialses and 5
P08229102A0768 |105 113|patientscts of n
P08229102A0768 |90 92|QLrm
P08229102A0768 |65 75|instrumenttidase P00
P08229102A0768 |21 39|QLMI questionnaireison with alkaline
P08229330A0000 |34 41|smokingaline p
P08229330A0000 |5 12|smokers1606T00
P08229826A1145 |103 111|activitypects of
P08229826A1145 |27 31|tapsith 
P08229826A1145 |15 23|responseComparis
P08229826A1145 |131 138|musclesubinemi
P08229826A1145 |175 182|objects shown 
P08230418A0812 |71 77|effect P0000
P08230418A0812 |293 304|amino acidsll have a s
P08230418A0812 |246 256|frameshiftger displa
P08230418A0812 |212 220|activitydata of 
P08230418A0812 |125 156|urokinase plasminogen activatorrbilirubinemia. P00008997A0472 
P08230418A0812 |60 63|nefucl
P08230418A0812 |161 165|typeCSF 
P08230418A0812 |46 56|expressionatases and
P08230418A0812 |14 17|nef Co
P08230418A0812 |85 93|activity0 Pharma
P08230418A0812 |118 123|c-fmsal hy
P08230418A0812 |38 41|LTRe p
P08230418A0812 |312 319|proteinntly gr
P08230418A0812 |108 113|virus of n
P08230418A0812 |4 10|action01606T
P08230418A0812 |168 193|acid phosphatase promoterO3-] is shown as a functi
P08230445A0000 |51 78|immunodeficiency virus types and 5-nucleotidase P00008
P08230445A0000 |160 170|quantities CSF [HCO3
P08230445A0000 |193 196|Gagon 
P08230445A0000 |28 41|reading frameth alkaline p
P08230445A0000 |4 11|product01606T0
P08230445A0000 |143 150|virions0008997
P08230445A0000 |82 87|HIV-10000 
P08230445A0000 |116 123|proteinatal hy
P08230445A0000 |19 22|vprari
P08230452A0551 |440 455|capsid proteinsose for use in 
P08230452A0551 |332 348|vaccinia viruses1.21 +/- 0.23 vs
P08230452A0551 |94 112|processing defectsologic aspects of 
P08230452A0551 |240 256|assembly defectsno longer displa
P08230452A0551 |389 406|poliovirus genometo be an effectiv
P08230452A0551 |16 24|vacciniaompariso
P08230452A0551 |357 373|capsid precursor43A0733 Flurazep
P08230452A0551 |48 63|P1 polyproteinsases and 5-nucl
P08230452A0551 |116 121|cellsatal 
P08230452A0551 |457 459|D.ne
P08230452A0551 |193 216|poliovirus 3CD proteaseon of CSF PCO2 the data
P08230452A0551 |225 235|processingleted rats
P08230452A0551 |152 166|vaccinia virus472 When CSF [
P08230452A0551 |168 172|VVP3O3-]
P08230452A0551 |274 296|complementation systemto controls but still 
P08230452A1489 |116 125|VP1-G001Vatal hype
P08230452A1489 |208 215|virionsthe dat
P08230452A1489 |46 58|P1 precursoratases and 5
P08230452A1489 |13 28|capsid proteins6 Comparison wi
P08230452A1489 |66 85|valine substitutionidase P00008171T000
P08230452A1489 |93 107|amino terminuscologic aspect
P08230452A1489 |111 114|VP1 ne
P08230452A1489 |143 159|capsid particles0008997A0472 Whe
P08230452A1489 |3 11|contrast001606T0
P08231398A0802 |0 7|RESULTSP000016
P08231398A0802 |112 120|episodesneonatal
P08231398A0802 |213 235|immunodeficiency virusata of K-depleted rats
P08231398A0802 |124 134|bacteremiaerbilirubi
P08231398A0802 |97 107|isolationsgic aspect
P08231398A0802 |43 48|totalsphat
P08231398A0802 |286 289|CD4but
P08231398A0802 |259 276|immunosuppression when compared to
P08231398A0802 |18 29|moth periodparison wit
P08231398A0802 |65 79|blood culturestidase P000081
P08231398A0802 |278 282|meanontr
P08231398A0802 |173 188|prison patientsis shown as a f
P08231398A0802 |138 153|M. tuberculosisa. P00008997A04
P08231398A0802 |306 307|ln
P08231577A1027 |0 4|AcidP000
P08231577A1027 |105 110|apneacts o
P08231577A1027 |41 48|rabbitshosphat
P08231577A1027 |22 28|larynxson wi
P08231816A1473 |156 173|promoter fragmentWhen CSF [HCO3-] 
P08231816A1473 |57 88|penicillin producing conditions5-nucleotidase P00008171T0000 P
P08231816A1473 |120 128|activity hyperbi
P08231816A1473 |23 31|extractson with 
P08231816A1473 |217 225|IPNS tspof K-dep
P08232304A1166 |2 8|series000160
P08232304A1166 |43 51|fragmentsphatase
P08232304A1166 |72 75|TSSP00
P08232304A1166 |15 24|deletionsCompariso
P08232304A1166 |92 109|promoter activityacologic aspects 
P08232304A1166 |158 201|chloramphenicol acetyltransferase constructen CSF [HCO3-] is shown as a function of CS
P08232412A1342 |34 59|expression vector pALTNEOaline phosphatases and 5-
P08232412A1342 |134 139|cellsnemia
P08232412A1342 |158 169|vinblastineen CSF [HCO
P08232412A1342 |183 189|levelss a fu
P08232412A1342 |91 103|L. enriettiimacologic as
P08232412A1342 |218 223|cellsf K-d
P08232412A1342 |4 15|lemdr1 gene01606T0076 
P08234166A0425 |136 149|RT conditionsmia. P0000899
P08234166A0425 |37 45|capsulesne phosp
P08234166A0425 |107 113|humanss of n
P08234166A0425 |4 19|bioavailability01606T0076 Comp
P08234166A0425 |66 76|conditionsidase P000
P08234166A0425 |23 31|etodolacon with 
P08234166A0425 |98 102|dogsic a
P08234166A0425 |117 125|capsulestal hype
P08234276A0556 |102 126|NF-kappa B binding sitesspects of neonatal hyper
P08234276A0556 |91 97|NF-IL6macolo
P08234276A0556 |20 30|activationrison with
P08234276A0556 |51 64|IL-8 promoters and 5-nucle
P08234308T0000 |0 6|NoticeP00001
P08234308T0000 |10 20|retraction0076 Compa
P08237112A0553 |34 45|36K proteinaline phosp
P08237112A0553 |56 66|structures 5-nucleot
P08237112A0553 |3 11|homology001606T0
P08237112A0553 |70 78|proteinse P00008
P08237171A0000 |17 21|casempar
P08237171A0000 |99 112|hydrocephalusc aspects of 
P08237171A0000 |59 65|recessnucleo
P08237171A0000 |71 78|patient P00008
P08237171A0000 |32 43|enlargementlkaline pho
P08237578A0253 |152 170|Norplant-2 rod use472 When CSF [HCO3
P08237578A0253 |143 148|years00089
P08237578A0253 |83 98|LDL-cholesterol000 Pharmacolog
P08237578A0253 |179 185|monthswn as 
P08237578A0253 |131 134|endubi
P08237578A0253 |11 27|lipid metabolism076 Comparison w
P08237578A0253 |33 44|mean valueskaline phos
P08237578A0253 |55 68|triglyceridesd 5-nucleotid
P08237578A0253 |218 235|preinsertion meanf K-depleted rats
P08237578A0253 |70 81|cholesterole P00008171
P08237578A0253 |103 118|HDL-cholesterolpects of neonat
P08238626A0248 |17 21|mmHgmpar
P08238626A0248 |90 100|blood flowrmacologic
P08238626A0248 |23 41|baseline brain pHion with alkaline p
P08238626A0248 |129 134|min-1irubi
P08238626A0248 |125 128|g-1rbi
P08238626A0248 |5 10|PaCO21606T
P08238626A0248 |118 120|mlal
P08239164A0551 |186 194|patients functio
P08239164A0551 |77 84|dyspnea8171T00
P08239164A0551 |94 102|patientsologic a
P08239164A0551 |13 20|isotime6 Compa
P08239164A0551 |210 222|lung diseasee data of K-
P08239164A0551 |120 132|lung disease hyperbiliru
P08239164A0551 |49 55|minuteses an
P08239164A0551 |144 150|values008997
P08239164A0551 |59 67|exercisenucleoti
P08239164A0551 |69 72|VO2se 
P08239164A0551 |0 4|CPAPP000
P08239586T0000 |0 7|EffectsP000016
P08239586T0000 |61 68|rabbitscleotid
P08239586T0000 |11 20|diltiazem076 Compa
P08239586T0000 |43 57|nephrotoxicitysphatases and 
P08240170A0000 |80 83|sea1T0
P08240170A0000 |47 55|feedlotstases an
P08240170A0000 |14 27|salmonellosis Comparison w
P08240170A0000 |67 76|transportdase P000
P08240170A0000 |5 10|forms1606T
P08241139A0378 |85 89|none0 Ph
P08241139A0378 |61 69|presencecleotida
P08241139A0378 |123 134|nucleotidesperbilirubi
P08241139A0378 |29 40|DNA bindingh alkaline 
P08241139A0378 |73 79|MgdTDP000081
P08241139A0378 |8 9|%6
P08241139A0378 |112 119|absenceneonata
P08241656A0189 |35 39|caseline
P08241656A0189 |113 121|syndromeeonatal 
P08241656A0189 |7 16|knowledge06T0076 C
P08241656A0189 |60 71|associationucleotidase
P08241656A0189 |80 94|cholelithiasis1T0000 Pharmac
P08241656A0189 |99 110|Wildervanckc aspects o
P08242861A0368 |49 55|p.p.b.ses an
P08242861A0368 |5 16|4,8-DiMeIQx1606T0076 C
P08242861A0368 |21 30|A alpha Cison with
P08243476A1177 |102 112|reductasesspects of 
P08243476A1177 |131 148|Paracoccus enzymeubinemia. P000089
P08243476A1177 |24 43|tryptophan residuesn with alkaline pho
P08243476A1177 |6 14|cysteine606T0076
P08244034T0000 |68 97|baculovirus expression systemase P00008171T0000 Pharmacolo
P08244034T0000 |12 48|Leishmania surface glycoprotein GP6376 Comparison with alkaline phosphat
P08244034T0000 |110 127|metalloproteinasef neonatal hyperb
P08245013A0000 |71 75|mRNA P00
P08245013A0000 |214 223|receptorsta of K-d
P08245013A0000 |26 31|basiswith 
P08245013A0000 |227 234|agonistted rat
P08245013A0000 |96 105|receptorsogic aspe
P08245013A0000 |52 67|destabilization and 5-nucleoti
P08245013A0000 |126 150|receptor down-regulationbilirubinemia. P00008997
P08245013A0000 |173 186|understandingis shown as a
P08245013A0000 |200 210|regulationSF PCO2 th
P08245125A0822 |34 48|F-actin nucleialine phosphat
P08245125A0822 |114 124|degrees C.onatal hyp
P08245125A0822 |53 63|phalloidinand 5-nucl
P08245125A0822 |73 84|L266D actin00008171T00
P08245125A0822 |87 94|abilityPharmac
P08245125A0822 |0 8|AdditionP0000160
P08245456A0501 |85 102|O2-dibutyryl cAMP0 Pharmacologic a
P08245456A0501 |134 137|PMAnem
P08245456A0501 |197 201|mRNAf CS
P08245456A0501 |26 31|levelwith 
P08245456A0501 |210 224|protein levelse data of K-de
P08245456A0501 |104 111|Bt2cAMPects of
P08245456A0501 |61 64|PMAcle
P08245456A0501 |81 83|N6T0
P08245456A0501 |174 189|IL-5 productions shown as a fu
P08245456A0501 |6 11|cells606T0
P08245456A0501 |117 128|combinationtal hyperbi
P08245456A0501 |35 39|IL-5line
P08245461A0700 |0 24|Hu-Met-1 mRNA expressionP00001606T0076 Compariso
P08245461A0700 |131 142|developmentubinemia. P
P08245461A0700 |109 118|phenotypeof neonat
P08245461A0700 |122 127|stageyperb
P08245461A0700 |52 70|T cell tumor lines and 5-nucleotidas
P08245461A0700 |36 42|numberine ph
P08245933A0617 |38 48|treatmentse phosphat
P08245933A0617 |8 19|engorgement6T0076 Comp
P08246984A0512 |0 8|NorthernP0000160
P08246984A0512 |15 23|analysisComparis
P08246984A0512 |57 68|PI 3-kinase5-nucleotid
P08246984A0512 |10 13|RNA007
P08246984A0512 |88 98|cell linesharmacolog
P08246984A0512 |76 83|tissues08171T0
P08246984A0512 |37 47|expressionne phospha
P08246984A0923 |87 93|familyPharma
P08246984A0923 |121 132|PI 3-kinasehyperbiliru
P08246984A0923 |30 39|existence alkaline
P08246984A0923 |6 13|results606T007
P08246984A0923 |97 102|genesgic a
P08246984A0923 |176 179|p85sho
P08246984A0923 |53 73|PI 3-kinase isoformsand 5-nucleotidase P
P08246984A0923 |143 151|subunits0008997A
P08246987A0260 |68 80|Src homologyase P0000817
P08246987A0260 |142 148|region000089
P08246987A0260 |90 93|SH2rma
P08246987A0260 |3 11|addition001606T0
P08246987A0260 |98 101|SH3ic 
P08246987A0260 |36 49|kinase domainine phosphata
P08246987A0260 |103 110|domainspects o
P08246987A0260 |51 57|p56lcks and 
P08247005A0584 |0 7|StrainsP000016
P08247005A0584 |125 133|subunitsrbilirub
P08247005A0584 |46 59|20S precursoratases and 5-
P08247005A0584 |74 82|18S rRNA0008171T
P08247005A0584 |111 114|40S ne
P08247005A0584 |20 41|drs2 mutation processrison with alkaline p
P08247043T0000 |0 11|Hepatitis BP00001606T0
P08247043T0000 |16 37|liver transplantationomparison with alkali
P08248246A0838 |51 58|complexs and 5
P08248246A0838 |83 90|binding000 Pha
P08248246A0838 |112 116|roleneon
P08248246A0838 |145 163|R1 gene expression08997A0472 When CS
P08248246A0838 |4 11|complex01606T0
P08248246A0838 |34 37|Sp1ali
P08248253A1785 |70 88|chicken L-CAM genee P00008171T0000 P
P08248253A1785 |15 27|observationsComparison w
P08248253A1785 |37 45|promoterne phosp
P08248253A1785 |53 61|enhancerand 5-nu
P08248688A0726 |51 58|nitrates and 5
P08248688A0726 |20 31|stimulationrison with 
P08248688A0726 |135 143|moleculeemia. P0
P08248688A0726 |104 117|NO productionects of neona
P08248688A0726 |4 8|rate0160
P08248688A0726 |87 91|ratePhar
P08249319A0578 |70 74|peake P0
P08249319A0578 |31 46|mislocalizationalkaline phosph
P08249319A0578 |104 109|fieldects 
P08249319A0578 |54 62|positionnd 5-nuc
P08249390A0111 |16 33|diabetes mellitusomparison with al
P08249390A0111 |75 80|years00817
P08249390A0111 |43 51|patientssphatase
P08249390A0111 |63 69|monthseotida
P08249390A0111 |132 142|infarctionbinemia. P
P08249390A0111 |93 101|patientscologic 
P08249390A0111 |4 12|duration01606T00
P08251506A0503 |171 190|DRE oligonucleotide] is shown as a fun
P08251506A0503 |12 19|complex76 Comp
P08251506A0503 |262 273|cross-linksen compared
P08251506A0503 |64 73|complexesotidase P
P08251506A0503 |126 134|proteinsbilirubi
P08251506A0503 |223 232|complexesepleted r
P08251506A0503 |103 106|kDapec
P08251622A0000 |170 180|expression-] is show
P08251622A0000 |26 32|regionwith a
P08251622A0000 |120 129|sequences hyperbil
P08251622A0000 |40 83|Brassica napus 2S storage protein napA genephosphatases and 5-nucleotidase P00008171T0
P08251622A0000 |4 12|promoter01606T00
P08252067A0917 |51 54|NH2s a
P08252067A0917 |132 144|conservationbinemia. P00
P08252067A0917 |36 43|domainsine pho
P08252067A0917 |59 71|COOH termininucleotidase
P08252067A0917 |89 95|degreearmaco
P08252067A0917 |99 109|similarityc aspects 
P08252067A0917 |17 28|comparisonsmparison wi
P08252976A0467 |0 5|RinitP0000
P08252976A0467 |122 128|systemyperbi
P08252976A0467 |45 50|Rdiffhatas
P08252976A0467 |29 40|resistancesh alkaline 
P08252976A0467 |93 114|pressure dissipationscologic aspects of ne
P08253386A0800 |152 170|splicing complexes472 When CSF [HCO3
P08253386A0800 |231 252|branch site sequencesrats are no longer di
P08253386A0800 |198 209|interaction CSF PCO2 t
P08253386A0800 |134 142|assemblynemia. P
P08253386A0800 |21 30|mechanismison with
P08253386A0800 |217 225|U2 snRNPof K-dep
P08253386A0800 |97 107|SE elementgic aspect
P08253386A0800 |48 77|fibronectin splicing enhancerases and 5-nucleotidase P0000
P08253386A0800 |34 40|actionaline 
P08253387A0801 |102 107|TCF-2spect
P08253387A0801 |14 30|enhancer mutants Comparison with
P08253387A0801 |194 198|siten of
P08253387A0801 |45 61|trans-activationhatases and 5-nu
P08253387A0801 |206 214|enhancer2 the da
P08253387A0801 |65 74|hLEF/GAL4tidase P0
P08253387A0801 |158 167|sequencesen CSF [H
P08253387A0801 |136 143|proteinmia. P0
P08253387A0801 |0 10|InspectionP00001606T
P08253387A1291 |17 26|sequencesmparison 
P08253387A1291 |167 171|hLEFCO3-
P08253387A1291 |63 67|celleoti
P08253387A1291 |90 100|activationrmacologic
P08253387A1291 |146 158|interactions8997A0472 Wh
P08253387A1291 |108 126|TCR alpha enhancer of neonatal hyper
P08253387A1291 |198 205|factors CSF PC
P08253387A1291 |42 54|hLEF HMG boxosphatases a
P08253387A1291 |223 231|enhancerepleted 
P08253777A0301 |153 159|manner72 Whe
P08253777A0301 |123 126|Kv1per
P08253777A0301 |90 94|cAMPrmac
P08253777A0301 |30 46|consensus signal alkaline phosph
P08253777A0301 |129 133|geneirub
P08253777A0301 |25 28|CRE wi
P08253777A0301 |109 119|expressionof neonata
P08253777A0301 |82 88|region0000 P
P08253777A0301 |2 23|cAMP response element0001606T0076 Comparis
P08253958A0000 |85 107|serum immunoglobulin G0 Pharmacologic aspect
P08253958A0000 |109 112|IgGof 
P08253958A0000 |56 68|Helicobacter 5-nucleotid
P08253958A0000 |44 52|presencephatases
P08253958A0000 |24 29|testsn wit
P08253958A0000 |2 8|number000160
P08254738A0428 |156 161|TS677When 
P08254738A0428 |123 133|activitiesperbilirub
P08254738A0428 |106 112|origints of 
P08254738A0428 |225 234|T antigenleted rat
P08254738A0428 |61 74|baculovirusescleotidase P0
P08254738A0428 |25 35|T antigens with alka
P08254738A0428 |8 14|series6T0076
P08254738A0428 |78 87|Sf9 cells171T0000 
P08254738A0428 |142 147|TS67700008
P08254738A0428 |191 207|T-antigen kinasetion of CSF PCO2
P08255022A0827 |70 71|%e
P08255022A0827 |73 76|V25000
P08255022A0827 |14 27|hypoperfusion Comparison w
P08255022A0827 |90 98|increasermacolog
P08255022A0827 |4 10|degree01606T
P08255022A0827 |114 126|blood volumeonatal hyper
P08255022A0827 |146 163|blood cell counts8997A0472 When CS
P08255022A0827 |64 68|FEV1otid
P08255022A0827 |81 85|PaO2T000
P08255341A0554 |101 111|diloxanideaspects of
P08255341A0554 |123 133|amoebicideperbilirub
P08255341A0554 |46 57|combinationatases and 
P08255341A0554 |61 74|metronidazolecleotidase P0
P08255341A0554 |78 95|tissue amoebicide171T0000 Pharmaco
P08255341A0554 |4 12|patients01606T00
P08255758A0000 |155 168|homeoproteins When CSF [HC
P08255758A0000 |42 48|regionosphat
P08255758A0000 |73 88|retrotransposon00008171T0000 P
P08255758A0000 |105 108|LTRcts
P08255758A0000 |112 120|sequenceneonatal
P08255758A0000 |141 151|regulationP00008997A
P08257666A0662 |86 89|IHA Ph
P08257666A0662 |73 82|afferents00008171T
P08257666A0662 |120 126|effect hyper
P08257666A0662 |15 20|studyCompa
P08257666A0662 |145 165|learning performance08997A0472 When CSF 
P08257666A0662 |94 96|HDol
P08257666A0662 |63 69|sourceeotida
P08257666A0662 |22 29|lesionsson wit
P08257666A0662 |37 48|OPT complexne phosphat
P08257754A0711 |35 42|resultsline ph
P08257754A0711 |11 15|dose076 
P08257754A0711 |148 161|HB antibodies97A0472 When 
P08257754A0711 |135 136|%e
P08257754A0711 |104 109|IU/mlects 
P08257754A0711 |54 65|individualsnd 5-nucleo
P08257754A0711 |126 130|onesbili
P08257754A0711 |176 181|IU/mlshown
P08257754A0711 |48 49|%a
P08257754A0711 |71 84|HB antibodies P00008171T00
P08258025A1131 |0 11|CONCLUSIONSP00001606T0
P08258025A1131 |82 85|age000
P08258025A1131 |126 133|diseasebilirub
P08258025A1131 |44 49|rangephata
P08258025A1131 |157 164|factorshen CSF
P08258025A1131 |20 28|patientsrison wi
P08258025A1131 |53 72|treatment variablesand 5-nucleotidase 
P08258025A1131 |87 102|Karnofsky indexPharmacologic a
P08258025A1131 |184 193|mortality a functi
P08259650A0640 |0 28|Nucleotide sequence analysisP00001606T0076 Comparison wi
P08259650A0640 |57 64|mutants5-nucle
P08259650A0640 |79 81|HA71
P08259650A0640 |36 43|HA geneine pho
P08259650A0640 |83 92|phenotype000 Pharm
P08260635A0926 |33 41|positionkaline p
P08260635A0926 |121 132|GAPDH geneshyperbiliru
P08260635A0926 |134 138|GapAnemi
P08260635A0926 |83 105|transit peptide region000 Pharmacologic aspe
P08260635A0926 |159 165|plantsn CSF 
P08260635A0926 |67 73|introndase P
P08260635A0926 |143 147|GapB0008
P08260635A0926 |5 11|intron1606T0
P08261398A0392 |84 105|alpha mRNA transcript00 Pharmacologic aspe
P08261398A0392 |45 55|P388/ADR/7hatases an
P08261398A0392 |76 80|topo0817
P08261398A0392 |109 117|additionof neona
P08261398A0392 |132 142|transcriptbinemia. P
P08261398A0392 |173 189|P388/4 cell lineis shown as a fu
P08261398A0392 |19 40|cell lines P388/ADR/3arison with alkaline 
P08261398A0838 |34 38|cDNAalin
P08261398A0838 |133 144|transcriptsinemia. P00
P08261398A0838 |44 52|strategyphatases
P08261398A0838 |69 74|cDNAsse P0
P08261398A0838 |155 165|P388/ADR/3 When CSF 
P08261398A0838 |95 102|terminilogic a
P08261398A0838 |170 186|P388/ADR/7 cells-] is shown as a
P08261398A0838 |17 30|amplificationmparison with
P08262041A0727 |32 46|phosphoproteinlkaline phosph
P08262041A0727 |52 58|extent and 5
P08262041A0727 |106 116|cell cyclets of neon
P08262041A0727 |66 81|phosphorylationidase P00008171
P08262041A0727 |4 18|phi AP3 factor01606T0076 Com
P08262054A0565 |137 141|copyia. 
P08262054A0565 |176 181|motifshown
P08262054A0565 |149 160|Tyr-X-X-Leu7A0472 When
P08262054A0565 |107 112|viruss of 
P08262054A0565 |210 214|rolee da
P08262054A0565 |80 85|LMP2A1T000
P08262054A0565 |218 239|B cell transformationf K-depleted rats are
P08262054A0565 |59 78|membrane protein 2Anucleotidase P00008
P08262054A0565 |114 117|EBVona
P08262054A0565 |38 44|domaine phos
P08262067A1608 |114 118|linkonat
P08262067A1608 |160 173|establishment CSF [HCO3-] 
P08262067A1608 |88 101|cell polarityharmacologic 
P08262067A1608 |195 217|cell wall biosynthesis of CSF PCO2 the data 
P08262067A1608 |15 23|homologyComparis
P08262067A1608 |77 84|control8171T00
P08262067A1608 |27 31|Cwg2ith 
P08262067A1608 |177 190|cell polarityhown as a fun
P08262067A1608 |145 151|events08997A
P08262067A1608 |37 42|Cdc43ne ph
P08263933T0000 |51 82|cyanobacterium Synechocystis sps and 5-nucleotidase P00008171T
P08263933T0000 |30 41|ATPase gene alkaline p
P08263933T0000 |10 17|cloning0076 Co
P08264579A1209 |4 11|cloning01606T0
P08264579A1209 |74 90|characterization0008171T0000 Pha
P08264579A1209 |15 19|PTR2Comp
P08264579A1209 |107 129|peptide transport genes of neonatal hyperbil
P08264579A1209 |41 48|examplehosphat
P08264582A0750 |169 188|amino acid residues3-] is shown as a f
P08264582A0750 |124 139|point mutationserbilirubinemia
P08264582A0750 |192 196|LIFRion 
P08264582A0750 |90 99|deletionsrmacologi
P08264582A0750 |37 43|domainne pho
P08264582A0750 |212 218|regiondata o
P08264582A0750 |110 119|deletionsf neonata
P08264582A0750 |233 242|signalingts are no
P08264582A0750 |48 55|mutantsases an
P08264583A0520 |117 127|cell linestal hyperb
P08264583A0520 |61 69|extractscleotida
P08264583A0520 |27 32|basisith a
P08264583A0520 |149 156|ability7A0472 
P08264583A0520 |165 188|test plasmid substrates[HCO3-] is shown as a f
P08264583A0520 |40 43|endpho
P08264583A0520 |96 103|varietyogic as
P08264591A1190 |70 75|TFIIBe P00
P08264591A1190 |241 249|proteinso longer
P08264591A1190 |211 222|interaction data of K-
P08264591A1190 |90 102|determinantsrmacologic a
P08264591A1190 |37 44|subunitne phos
P08264591A1190 |106 140|transcription start site selectionts of neonatal hyperbilirubinemia.
P08264591A1190 |180 188|functionn as a f
P08264591A1190 |6 10|data606T
P08264591A1190 |48 62|RNA polymeraseases and 5-nuc
P08264617A0000 |119 125|eventsl hype
P08264617A0000 |61 80|NIH 3T3 fibroblastscleotidase P0000817
P08264617A0000 |142 168|ErbB-3 signal transduction00008997A0472 When CSF [HC
P08264617A0000 |37 46|EGFR/ErbBne phosph
P08264617A0000 |12 22|expression76 Compari
P08264617A0000 |174 191|ligand activations shown as a func
P08264617A0000 |49 57|receptorses and 
P08264628A0418 |0 27|Oligonucleotide competitorsP00001606T0076 Comparison w
P08264628A0418 |96 102|TIF-IBogic a
P08264628A0418 |88 92|siteharm
P08264628A0418 |104 109|TFIIDects 
P08264628A0418 |54 67|accessibilitynd 5-nucleoti
P08264628A0418 |115 121|TFIIIBnatal 
P08264631A0746 |117 140|ADH2 promoter sequencestal hyperbilirubinemia.
P08264631A0746 |65 68|TADtid
P08264631A0746 |30 43|ADR1 activity alkaline pho
P08264631A0746 |15 21|regionCompar
P08264631A0746 |80 84|ADR11T00
P08264631A0746 |86 102|ADR1 DNA binding Pharmacologic a
P08264650A0925 |0 8|AnalysisP0000160
P08264650A0925 |155 162|meiosis When C
P08264650A0925 |33 51|mds1 null mutationkaline phosphatase
P08264650A0925 |12 19|strains76 Comp
P08264650A0925 |70 74|MDS1e P0
P08264650A0925 |117 123|growthtal hy
P08264664A0128 |51 69|AP-1 binding sitess and 5-nucleotida
P08264664A0128 |95 104|promoterslogic asp
P08264664A0128 |11 21|expression076 Compar
P08264664A0128 |113 117|geneeona
P08264664A0128 |0 8|TGF betaP0000160
P08265602T0000 |0 3|ValP00
P08265602T0000 |6 19|Ala mutations606T0076 Comp
P08265602T0000 |90 112|phage M13 coat proteinrmacologic aspects of 
P08265602T0000 |65 86|transmembrane segmenttidase P00008171T0000
P08265602T0000 |50 57|packinges and 
P08265955T0000 |24 27|NHSn w
P08265955T0000 |10 16|change0076 C
P08267658A0391 |83 88|MgSO4000 P
P08267658A0391 |56 57|K 
P08267658A0391 |133 145|preservationinemia. P000
P08267658A0391 |149 164|rat hepatocytes7A0472 When CSF
P08267658A0391 |61 73|lactobionatecleotidase P
P08267658A0391 |75 81|KH2PO4008171
P08267658A0391 |22 30|solutionson with
P08267658A0391 |93 102|raffinosecologic a
P08267658A0391 |179 201|drug transport studieswn as a function of CS
P08267658A0391 |172 174|hr i
P08267658A0391 |36 38|UWin
P08267667A0748 |35 40|mg/kgline 
P08267667A0748 |296 297|Fh
P08267667A0748 |365 383|h memory retentionFlurazepam thus ap
P08267667A0748 |385 386|Fa
P08267667A0748 |27 31|GRg2ith 
P08267667A0748 |182 183|da
P08267667A0748 |208 209|Ft
P08267667A0748 |480 481|F 
P08267667A0748 |186 206|learning acquisition function of CSF PCO
P08267667A0748 |495 496|p0
P08267667A0748 |460 478|h memory retrievalal practice being 
P08267667A0748 |223 224|pe
P08267667A0748 |399 400|pf
P08267667A0748 |140 144|rate P00
P08267667A0748 |311 312|pa
P08267667A0748 |9 23|administrationT0076 Comparis
P08267667A0748 |99 107|deficitsc aspect
P08267667A0748 |274 294|h memory acquisitionto controls but stil
P08268718A0676 |53 62|complexesand 5-nuc
P08268718A0676 |43 46|p50sph
P08268718A0676 |6 18|bcl3 protein606T0076 Com
P08268833T0000 |16 22|actionompari
P08268833T0000 |41 50|Sandimmunhosphatas
P08268833T0000 |26 39|cyclosporin Awith alkaline
P08268833T0000 |57 68|application5-nucleotid
P08268833T0000 |83 92|arthritis000 Pharm
P08268912A0657 |84 91|protein00 Phar
P08268912A0657 |62 65|RNAleo
P08268912A0657 |99 107|mobilityc aspect
P08268912A0657 |9 32|translation experimentsT0076 Comparison with a
P08268912A0657 |123 146|SDS polyacrylamide gelsperbilirubinemia. P0000
P08268912A0657 |49 53|cDNAses 
P08268912A0657 |117 119|kDta
P08269424A0339 |17 31|administrationmparison with 
P08269424A0339 |98 108|tumor sideic aspects
P08269424A0339 |53 64|ACTH levelsand 5-nucle
P08269424A0339 |40 43|CRFpho
P08269424A0339 |48 51|TRHase
P08269424A0339 |116 124|patientsatal hyp
P08269439X0000 |34 39|nichealine
P08269439X0000 |134 138|painnemi
P08269439X0000 |12 21|analgesia76 Compar
P08269439X0000 |107 117|managements of neona
P08269439X0000 |44 53|Talwin Nxphatases 
P08269439X0000 |93 98|agentcolog
P08269439X0000 |55 66|Pentazocined 5-nucleot
P08270257A0551 |119 129|boundariesl hyperbil
P08270257A0551 |167 174|speciesCO3-] i
P08270257A0551 |59 71|homolog genenucleotidase
P08270257A0551 |43 50|nm23-H1sphatas
P08270257A0551 |79 82|rat71T
P08270257A0551 |2 28|sequence homology analysis0001606T0076 Comparison wi
P08270257A0551 |84 94|NDP-K beta00 Pharmac
P08270580A0155 |76 89|cotrimoxazole08171T0000 Ph
P08270580A0155 |13 21|response6 Compar
P08270580A0155 |57 71|amphotericin B5-nucleotidase
P08270580A0155 |42 53|combinationosphatases 
P08270985A0590 |0 18|Response durationsP00001606T0076 Com
P08273122A0708 |205 227|component transfusionsO2 the data of K-deple
P08273122A0708 |33 46|QA/QI processkaline phosph
P08273122A0708 |109 117|varianceof neona
P08273122A0708 |62 92|blood administration practicesleotidase P00008171T0000 Pharm
P08273122A0708 |195 200|blood of C
P08273122A0708 |16 25|beginningomparison
P08273122A0708 |184 191|percent a func
P08273122A0708 |48 58|monitoringases and 5
P08273122A0708 |0 7|RESULTSP000016
P08273122A0708 |137 164|blood administration policyia. P00008997A0472 When CSF
P08274774A0958 |136 148|mosaic virusmia. P000089
P08274774A0958 |63 68|rangeeotid
P08274774A0958 |13 25|REP21 plants6 Comparison
P08274774A0958 |180 192|mosaic virusn as a funct
P08274774A0958 |150 156|TMV-U5A0472 
P08274774A0958 |164 170|tomato [HCO3
P08274774A0958 |96 115|tomato mosaic virusogic aspects of neo
P08274774A0958 |198 219|ribgrass mosaic virus CSF PCO2 the data of
P08274774A0958 |72 85|tobamovirusesP00008171T000
P08274774A0958 |3 11|addition001606T0
P08274774A0958 |117 124|tobaccotal hyp
P08275618A0457 |0 11|Drug effectP00001606T0
P08275618A0457 |267 275|patientsmpared t
P08275618A0457 |124 129|ratioerbil
P08275618A0457 |281 290|cirrhosisrols but 
P08275618A0457 |133 144|effect areainemia. P00
P08275618A0457 |193 198|curveon of
P08275618A0457 |164 182|concentration area [HCO3-] is shown 
P08275618A0457 |155 160|curve When
P08275618A0457 |213 224|sensitivityata of K-de
P08275618A0457 |64 72|patientsotidase 
P08275618A0457 |202 209|measure PCO2 t
P08275618A0457 |78 87|cirrhosis171T0000 
P08275618A0457 |100 108|subjects aspects
P08275618A0457 |307 315|subjectsificantl
P08276234A0119 |152 165|DNA structure472 When CSF 
P08276234A0119 |90 98|activityrmacolog
P08276234A0119 |25 28|YY1 wi
P08276234A0119 |11 19|evidence076 Comp
P08276234A0119 |106 120|c-fos promoterts of neonatal
P08276234A0119 |67 74|proteindase P0
P08276234A0119 |142 148|effect000089
P08276336A0371 |69 77|patientsse P0000
P08276336A0371 |99 111|relationshipc aspects of
P08276336A0371 |149 155|polyps7A0472
P08276336A0371 |48 61|colonoscopiesases and 5-nu
P08276336A0371 |19 27|analysisarison w
P08276732A0799 |100 114|susceptibility aspects of ne
P08276732A0799 |12 21|decrement76 Compar
P08276732A0799 |25 40|DPOAE amplitude with alkaline 
P08276732A0799 |131 137|traumaubinem
P08276732A0799 |89 96|measurearmacol
P08276732A0799 |59 70|time periodnucleotidas
P08276732A0799 |4 8|rate0160
P08276762T0000 |17 35|base substitutionsmparison with alka
P08276762T0000 |39 56|glycine-870 codon phosphatases and
P08276762T0000 |94 112|proline activationologic aspects of 
P08276762T0000 |60 83|gramicidin S synthetaseucleotidase P00008171T0
P08276762T0000 |86 90|gene Pha
P08276762T0000 |0 6|EffectP00001
P08276851A0347 |137 145|proteinsia. P000
P08276851A0347 |92 105|relationshipsacologic aspe
P08276851A0347 |63 70|domainseotidas
P08276851A0347 |14 28|Pay4p sequence Comparison wi
P08276851A0347 |169 178|processes3-] is sh
P08276851A0347 |292 302|regulationill have a
P08276851A0347 |233 250|protein transportts are no longer 
P08276851A0347 |252 270|cell cycle controlsplaced when compa
P08276851A0347 |204 214|biogenesisCO2 the da
P08276854A1894 |101 122|proteoglycan promoteraspects of neonatal h
P08276854A1894 |26 35|structurewith alka
P08276854A1894 |166 181|pur/pyr segmentHCO3-] is shown
P08276854A1894 |4 11|results01606T0
P08276854A1894 |202 212|regulation PCO2 the 
P08276854A1894 |43 64|decorin gene promotersphatases and 5-nucle
P08276854A1894 |190 194|rolectio
P08276854A1894 |216 234|gene transcription of K-depleted rat
P08276865A1188 |84 90|growth00 Pha
P08276865A1188 |132 142|MAP kinasebinemia. P
P08276865A1188 |107 117|activations of neona
P08276865A1188 |121 127|p21rashyperb
P08276865A1188 |203 215|LPA receptorPCO2 the dat
P08276865A1188 |219 236|p21ras activation K-depleted rats 
P08276865A1188 |176 190|protein kinaseshown as a fun
P08276865A1188 |4 34|kinase inhibitor staurosporine01606T0076 Comparison with alk
P08276865A1188 |38 44|microMe phos
P08276871A1001 |38 46|identitye phosph
P08276871A1001 |59 60|%n
P08276871A1001 |92 102|% identityacologic a
P08276871A1001 |127 140|transmembraneilirubinemia.
P08276871A1001 |157 164|domainshen CSF
P08276900A0543 |0 2|S.P0
P08276900A0543 |4 6|K.01
P08277632A0997 |4 17|survival rate01606T0076 Co
P08277632A0997 |40 48|patientsphosphat
P08277632A0997 |27 33|monthsith al
P08277632A0997 |79 92|R2b operation71T0000 Pharm
P08277632A0997 |54 64|N2 diseasend 5-nucle
P08277632A0997 |99 100|%c
P08278423A0147 |0 7|MothersP000016
P08278423A0147 |92 100|childrenacologic
P08278423A0147 |125 150|disaccharide intolerancesrbilirubinemia. P00008997
P08278423A0147 |31 44|abnormalitiesalkaline phos
P08278423A0147 |54 57|HIVnd 
P08278423A0147 |80 82|TB1T
P08278480T0002 |0 2|G.P0
P08278548A0597 |16 20|psaHompa
P08278548A0597 |179 187|isoformswn as a 
P08278548A0597 |10 14|psaF0076
P08278548A0597 |26 39|psaL productswith alkaline
P08278548A0597 |157 169|psaE producthen CSF [HCO
P08278548A0597 |99 109|mobilitiesc aspects 
P08278548A0597 |113 147|polyacrylamide gel electrophoresiseonatal hyperbilirubinemia. P00008
P08278548A0597 |4 8|psaD0160
P08278548A0597 |49 57|isoformsses and 
P08278929A0866 |205 213|controlsO2 the d
P08278929A0866 |59 61|mlnu
P08278929A0866 |92 98|ml CRSacolog
P08278929A0866 |77 80|CRS817
P08278929A0866 |215 216|Pa
P08278929A0866 |12 30|SPF type V embryos76 Comparison with
P08278929A0866 |165 166|%[
P08278929A0866 |64 73|% ethanolotidase P
P08278929A0866 |144 157|VSD incidence008997A0472 W
P08278929A0866 |127 134|embryosilirubi
P08278929A0866 |100 108|controls aspects
P08278929A0866 |186 197|% incidence function o
P08279098T0001 |46 61|myopia patientsatases and 5-nu
P08279098T0001 |31 42|dystrophiesalkaline ph
P08280476A0602 |152 156|site472 
P08280476A0602 |43 68|HIV-1 Z2Z6 core enhancerssphatases and 5-nucleotid
P08280476A0602 |106 120|point mutationts of neonatal
P08280476A0602 |28 38|HIV-1 HXB2th alkalin
P08280476A0602 |7 14|studies06T0076
P08280476A0602 |81 92|Z2Z6 strainT0000 Pharm
P08280925A0261 |139 145|groups. P000
P08280925A0261 |182 185|IgMas 
P08280925A0261 |63 75|C57Bl/6 miceeotidase P00
P08280925A0261 |45 54|responseshatases a
P08280925A0261 |147 158|differences997A0472 Wh
P08280925A0261 |124 128|miceerbi
P08280925A0261 |94 98|miceolog
P08280925A0261 |203 213|antibodiesPCO2 the d
P08280925A0261 |190 193|IgGcti
P08281153A0543 |98 105|speciesic aspe
P08281153A0543 |29 35|degreeh alka
P08281153A0543 |39 51|conservation phosphatase
P08281153A0543 |55 71|intron sequencesd 5-nucleotidase
P08281536A0626 |0 13|Interleukin-6P00001606T007
P08281536A0626 |60 66|myxomaucleot
P08281536A0626 |38 48|metastasise phosphat
P08281634A1801 |20 35|iron metabolismrison with alka
P08281634A1801 |47 55|ferritintases an
P08281634A1801 |93 97|riskcolo
P08281634A1801 |6 16|parameters606T0076 C
P08281740A0000 |17 45|Plowright Rinderpest vaccinemparison with alkaline phosp
P08281740A0000 |177 188|ELISA assayhown as a f
P08281740A0000 |124 138|IgG antibodieserbilirubinemi
P08281740A0000 |72 78|cattleP00008
P08281740A0000 |52 58|calves and 5
P08281740A0000 |110 120|productionf neonatal
P08281740A0000 |161 166|weeksCSF [
P08281740A0000 |82 88|Uganda0000 P
P08281740A0000 |0 9|ResponsesP00001606
P08282501A0358 |186 193|grade-2 functi
P08282501A0358 |198 205|grade-3 CSF PC
P08282501A0358 |130 141|differencesrubinemia. 
P08282501A0358 |93 104|conclusionscologic asp
P08282501A0358 |214 220|eventsta of 
P08282501A0358 |40 62|angiography proceduresphosphatases and 5-nuc
P08282501A0358 |21 27|numberison w
P08282501A0358 |169 175|agents3-] is
P08282576A0297 |0 7|TumoursP000016
P08282576A0297 |30 40|oropharynx alkaline 
P08282576A0297 |15 25|cavum orisComparison
P08282576A0297 |44 52|T1-stagephatases
P08282576A0297 |81 86|casesT0000
P08282749A1474 |152 158|arrest472 Wh
P08282749A1474 |94 104|myocardiumologic asp
P08282749A1474 |132 140|durationbinemia.
P08282749A1474 |70 76|demande P000
P08282749A1474 |8 25|Hospital solution6T0076 Comparison
P08282749A1474 |40 45|% CO2phosp
P08282749A1474 |0 6|ThomasP00001
P08282749A1474 |34 35|%a
P08283292A0779 |220 233|control groupK-depleted ra
P08283292A0779 |154 159|diets2 Whe
P08283292A0779 |143 149|groups000899
P08283292A0779 |83 90|control000 Pha
P08283292A0779 |8 11|LDL6T0
P08283292A0779 |187 192|fiberfunct
P08283292A0779 |118 125|controlal hype
P08283292A0779 |16 48|liver cholesterol concentrationsomparison with alkaline phosphat
P08283292A0779 |0 6|PlasmaP00001
P08283292A0779 |171 177|pectin] is s
P08283531A0700 |117 129|localizationtal hyperbil
P08283531A0700 |182 188|gantryas a f
P08283531A0700 |149 156|calculi7A0472 
P08283531A0700 |47 71|Dornier HM3 lithotriptortases and 5-nucleotidase
P08283531A0700 |92 105|visualizationacologic aspe
P08283531A0700 |4 30|Stryker frame modification01606T0076 Comparison with
P08284227A0336 |204 212|culturesCO2 the 
P08284227A0336 |88 96|contrastharmacol
P08284227A0336 |53 71|kb mRNA transcriptand 5-nucleotidase
P08284227A0336 |76 79|Id1081
P08284227A0336 |106 125|cell types Id1 mRNAts of neonatal hype
P08284227A0336 |157 170|cycling cellshen CSF [HCO3
P08284227A0336 |21 26|cellsison 
P08284337A0825 |34 46|IHD patientsaline phosph
P08284337A0825 |177 185|patientshown as 
P08284337A0825 |94 107|cardiologistsologic aspect
P08284337A0825 |112 122|internistsneonatal h
P08284337A0825 |76 81|means08171
P08284337A0825 |146 152|levels8997A0
P08284337A0825 |21 30|screeningison with
P08284337A0825 |156 164|distressWhen CSF
P08285710A0634 |136 140|sitemia.
P08285710A0634 |144 154|initiation008997A047
P08285710A0634 |93 97|mapscolo
P08285710A0634 |58 61|RNA-nu
P08285710A0634 |63 76|blot analysiseotidase P000
P08285710A0634 |48 56|Northernases and
P08285710A0634 |115 117|bpna
P08285710A0634 |158 175|protein synthesisen CSF [HCO3-] is
P08285710A0634 |16 31|transcript mRNAomparison with 
P08285710A0634 |103 111|positionpects of
P08286035A0587 |99 102|RNAc a
P08286035A0587 |41 46|c11/1hosph
P08286035A0587 |192 195|PCRion
P08286035A0587 |165 190|polymerase chain reaction[HCO3-] is shown as a fun
P08286035A0587 |150 161|combinationA0472 When 
P08286035A0587 |91 95|polymaco
P08286035A0587 |15 35|sequence informationComparison with alka
P08286035A0587 |67 71|cDNAdase
P08286035A0587 |197 204|methodsf CSF P
P08286035A0587 |130 143|transcriptionrubinemia. P0
P08286035A0587 |96 97|Ao
P08286035A0587 |113 118|PMNLseonat
P08288240A0304 |4 23|sequence similarity01606T0076 Comparis
P08288240A0304 |125 130|genesrbili
P08288240A0304 |43 48|SCG10sphat
P08288240A0304 |53 61|stathminand 5-nu
P08288240A1343 |103 115|modificationpects of neo
P08288240A1343 |65 75|SCG10 genetidase P00
P08288240A1343 |6 10|data606T
P08288240A1343 |146 165|stathmin/Lap18 gene8997A0472 When CSF 
P08288240A1343 |87 98|duplicationPharmacolog
P08288240A1343 |35 39|idealine
P08288554A0295 |136 157|mouse BALBc/3T3 cellsmia. P00008997A0472 W
P08288554A0295 |79 82|p3271T
P08288554A0295 |12 31|amino acid sequence76 Comparison with 
P08288554A0295 |125 132|proteinrbiliru
P08288554A0295 |39 54|mouse HO-1 gene phosphatases a
P08288596A0663 |70 77|rGH-TREe P0000
P08288596A0663 |25 26|M 
P08288596A0663 |176 181|frontshown
P08288596A0663 |300 308|sequence a signi
P08288596A0663 |14 16|T3 C
P08288596A0663 |51 64|transcriptions and 5-nucle
P08288596A0663 |157 161|TREshen 
P08288596A0663 |83 89|TREpal000 Ph
P08288596A0663 |112 118|F2-TREneonat
P08288596A0663 |189 192|rGHnct
P08288596A0663 |283 298|binding proteinls but still ha
P08288596A0663 |230 254|TATA box binding protein rats are no longer disp
P08288596A0663 |132 141|templatesbinemia. 
P08288596A0663 |201 209|promoterF PCO2 t
P08288596A0663 |100 106|ME-TRE aspec
P08288606A0240 |221 225|gene-dep
P08288606A0240 |8 24|polymerase chain6T0076 Compariso
P08288606A0240 |40 48|approachphosphat
P08288606A0240 |94 104|sialymotifologic asp
P08288606A0240 |165 170|clone[HCO3
P08288606A0240 |71 84|pair fragment P00008171T00
P08288606A0240 |156 161|probeWhen 
P08288606A0240 |233 245|cDNA libraryts are no lo
P08288606A0240 |116 129|placenta mRNAatal hyperbil
P08288606A0240 |184 199|coding sequence a function of 
P08288622A0725 |51 64|heterogeneitys and 5-nucle
P08288622A0725 |165 187|splicing acceptor site[HCO3-] is shown as a 
P08288622A0725 |15 23|analysisComparis
P08288622A0725 |97 106|insertiongic aspec
P08288622A0725 |72 80|HDC mRNAP0000817
P08288622A0725 |122 137|intron sequenceyperbilirubinem
P08288622A0725 |200 204|exonSF P
P08288622A0725 |154 157|use2 W
P08288633A0144 |221 235|protein region-depleted rats
P08288633A0144 |278 286|proteinsontrols 
P08288633A0144 |294 307|Rho subfamilyl have a sign
P08288633A0144 |96 115|amino acid residuesogic aspects of neo
P08288633A0144 |76 87|polypeptide08171T0000 
P08288633A0144 |240 243|Bcrno 
P08288633A0144 |194 201|segmentn of CS
P08288633A0144 |117 122|CeGAPtal h
P08288633A0144 |141 147|domainP00008
P08288633A0144 |38 60|Caenorhabditis eleganse phosphatases and 5-n
P08288633A0144 |16 19|DNAomp
P08288633A0144 |153 172|sequence similarity72 When CSF [HCO3-]
P08289339A0527 |119 121|E1l 
P08289339A0527 |11 22|exonuclease076 Compari
P08289339A0527 |62 73|core regionleotidase P
P08289339A0527 |150 159|sequencesA0472 Whe
P08289339A0527 |27 37|protectionith alkali
P08289339A0527 |96 101|sidesogic 
P08289341A1202 |85 91|copies0 Phar
P08289341A1202 |95 100|E2-RSlogic
P08289341A1202 |61 65|E2-Ccleo
P08289341A1202 |43 45|E2sp
P08289341A1202 |0 10|RepressionP00001606T
P08289342A0931 |69 84|DNA replicationse P00008171T00
P08289342A0931 |101 106|assayaspec
P08289342A0931 |46 49|trsata
P08289342A0931 |29 44|resolution siteh alkaline phos
P08289342A0931 |2 8|mutant000160
P08289342A0931 |16 19|AAVomp
P08289357A0724 |84 92|elements00 Pharm
P08289357A0724 |52 60|function and 5-n
P08289357A0724 |26 29|repwit
P08289357A0724 |4 11|results01606T0
P08289357A0724 |100 103|LTR as
P08289593A1404 |137 144|vehicleia. P00
P08289593A1404 |208 214|MK-801the da
P08289593A1404 |91 103|cocaine dosemacologic as
P08289593A1404 |184 185|n 
P08289593A1404 |55 61|MK-801d 5-nu
P08289593A1404 |156 160|ratsWhen
P08289593A1404 |125 126|nr
P08289593A1404 |177 182|mg/kghown 
P08289593A1404 |265 273|toxicitycompared
P08289593A1404 |310 314|ratscant
P08289593A1404 |288 296|urethanet still 
P08289593A1404 |118 123|mg/kgal hy
P08289593A1404 |277 284|cocainecontrol
P08289593A1404 |33 37|ratskali
P08289783A0000 |4 9|Oct-301606
P08289783A0000 |12 24|gene product76 Compariso
P08289783A0000 |47 57|POU familytases and 
P08289783A0000 |61 82|transcription factorscleotidase P00008171T
P08289783A0000 |94 103|candidateologic as
P08289783A0000 |127 152|differentiation decisionsilirubinemia. P00008997A0
P08289783A1476 |186 196|repression function 
P08289783A1476 |93 103|activationcologic as
P08289783A1476 |107 112|Oct-3s of 
P08289783A1476 |20 31|mutagenesisrison with 
P08289783A1476 |218 226|EC cellsf K-depl
P08289783A1476 |127 136|P19 cellsilirubine
P08289783A1476 |115 123|promoternatal hy
P08289783A1476 |50 57|RAREoctes and 
P08289784A0381 |19 21|M.ar
P08289793A1226 |141 149|enhancerP0000899
P08289793A1226 |42 48|effectosphat
P08289793A1226 |122 126|stemyper
P08289793A1226 |107 111|Oct4s of
P08289793A1226 |93 99|effectcologi
P08289793A1226 |52 60|COUP-TFs and 5-n
P08289831A0290 |0 8|AnalysisP0000160
P08289831A0290 |12 19|mig/CAT76 Comp
P08289831A0290 |73 76|RAW000
P08289831A0290 |83 88|mouse000 P
P08289831A0290 |148 155|element97A0472
P08289831A0290 |29 39|constructsh alkaline
P08289831A0290 |99 108|cell linec aspects
P08289831A0290 |157 167|gamma RE-1hen CSF [H
P08289834A0341 |70 77|activine P0000
P08289834A0341 |82 86|bone0000
P08289834A0341 |24 34|test cellsn with alk
P08289834A0341 |60 68|TGF-betaucleotid
P08289834A0341 |36 41|Atr-Iine p
P08289834A0341 |101 108|proteinaspects
P08290278A0374 |20 23|Madris
P08290278A0374 |62 94|candidate tumor suppressor genesleotidase P00008171T0000 Pharmac
P08290278A0374 |11 15|Mxi1076 
P08290278A0374 |41 53|Myc functionhosphatases 
P08290421A0165 |102 108|Alportspects
P08290421A0165 |132 139|patientbinemia
P08290421A0165 |7 16|knowledge06T0076 C
P08290421A0165 |111 119|syndrome neonata
P08290421A0165 |40 48|acidosisphosphat
P08290421A0165 |18 22|typepari
P08290421A0165 |85 96|association0 Pharmacol
P08291233A0000 |100 105|probe aspe
P08291233A0000 |140 162|Rous sarcoma virus LTR P00008997A0472 When C
P08291233A0000 |123 132|U3 regionperbiliru
P08291233A0000 |33 60|chicken embryo cDNA librarykaline phosphatases and 5-n
P08291233A0000 |2 12|cDNA clone0001606T00
P08291620A0372 |22 40|locomotor behaviorson with alkaline 
P08291620A0372 |10 18|patterns0076 Com
P08291620A0372 |95 106|anthropoidslogic aspec
P08291620A0372 |59 75|torso morphologynucleotidase P00
P08291761A0416 |0 10|Animal ageP00001606T
P08291761A0416 |38 45|effectse phosp
P08291761A0416 |109 112|ageof 
P08291761A0416 |15 18|sexCom
P08291761A0416 |49 64|CSF compositionses and 5-nucle
P08291761A0416 |70 93|serum IgG concentratione P00008171T0000 Pharma
P08291886T0024 |16 25|expansionomparison
P08293412T0000 |59 71|tolerabilitynucleotidase
P08293412T0000 |181 191|prevention as a func
P08293412T0000 |75 86|tropisetron008171T0000
P08293412T0000 |26 31|studywith 
P08293412T0000 |46 54|efficacyatases a
P08293412T0000 |165 173|cocktail[HCO3-] 
P08293412T0000 |94 119|5-HT3 receptor antagonistologic aspects of neonata
P08293412T0000 |213 219|emesisata of
P08293992A0432 |5 11|repeat1606T0
P08293992A0432 |27 29|ntit
P08293992A0432 |57 65|sequence5-nucleo
P08293992A0432 |67 73|K/NPAGdase P
P08293993A0948 |0 3|ENVP00
P08293993A0948 |122 147|invertase signal sequenceyperbilirubinemia. P00008
P08293993A0948 |63 99|alpha-factor prepro secretion leadereotidase P00008171T0000 Pharmacologi
P08293993A0948 |27 38|P. pastorisith alkalin
P08294386A0000 |0 10|BACKGROUNDP00001606T
P08294386A0000 |82 89|authors0000 Ph
P08294386A0000 |176 184|hospitalshown as
P08294386A0000 |29 39|predictorsh alkaline
P08294386A0000 |134 144|depressionnemia. P00
P08294386A0000 |114 122|patientsonatal h
P08294386A0000 |66 76|depressionidase P000
P08294386A0000 |202 213|desipramine PCO2 the d
P08294386A0000 |103 110|outcomepects o
P08294386A0000 |238 249|blood levele no longer
P08294429A0153 |186 207|hGH promoter activity function of CSF PCO2
P08294429A0153 |59 61|FRnu
P08294429A0153 |78 86|hGh cDNA171T0000
P08294429A0153 |160 164|cAMP CSF
P08294429A0153 |90 123|chloramphenicol acetyltransferasermacologic aspects of neonatal hy
P08294429A0153 |35 38|hGHlin
P08294429A0153 |23 31|hGH geneon with 
P08294429A0153 |127 143|luciferase genesilirubinemia. P0
P08294429A0153 |0 8|AnalysisP0000160
P08294429A0153 |51 54|DNAs a
P08294459A0446 |71 76|SAP-1 P000
P08294459A0446 |14 33|amino acid sequence Comparison with al
P08294459A0446 |95 106|amino acidslogic aspec
P08294459A0446 |41 51|SAP-1 cDNAhosphatase
P08294459A0446 |132 135|PTPbin
P08294459A0446 |176 182|domainshown 
P08294459A0446 |202 208|region PCO2 
P08294511A0639 |48 55|proteinases an
P08294511A0639 |135 155|snRNP core particlesemia. P00008997A0472
P08294511A0639 |14 22|evidence Compari
P08294511A0639 |96 103|proteinogic as
P08294511A0639 |175 186|interaction shown as a
P08294865A0236 |51 59|mutations and 5-
P08294865A0236 |28 33|cellsth al
P08294865A0236 |90 99|formationrmacologi
P08294865A0236 |8 16|features6T0076 C
P08294865A0236 |103 123|peptide/DR complexespects of neonatal hy
P08294906A1315 |137 146|substrateia. P0000
P08294906A1315 |72 81|aspartateP00008171
P08294906A1315 |151 160|transport0472 When
P08294906A1315 |120 131|amino acids hyperbilir
P08294906A1315 |40 67|neurotransmitters glutamatephosphatases and 5-nucleoti
P08294906A1315 |5 17|distribution1606T0076 Co
P08296434A1141 |87 96|treatmentPharmacol
P08296434A1141 |122 131|conditionyperbilir
P08296434A1141 |73 82|diagnosis00008171T
P08296434A1141 |58 65|adjunct-nucleo
P08296434A1141 |4 21|Harleco apparatus01606T0076 Compar
P08297376A0236 |0 15|Co-transfectionP00001606T0076 
P08297376A0236 |195 201|region of CS
P08297376A0236 |91 101|C/EBP betamacologic 
P08297376A0236 |74 79|C/EBP00081
P08297376A0236 |42 72|CCAAT/enhancer binding proteinosphatases and 5-nucleotidase 
P08297376A0236 |166 175|sequencesHCO3-] is
P08297376A0236 |122 158|rat uncoupling protein gene promoteryperbilirubinemia. P00008997A0472 Wh
P08297376A0236 |81 86|alphaT0000
P08297376A0236 |19 37|expression vectorsarison with alkali
P08298129A0274 |103 116|gene promoterpects of neon
P08298129A0274 |59 69|expressionnucleotida
P08298129A0274 |78 82|gene171T
P08298129A0274 |96 100|betaogic
P08298129A0274 |33 38|basiskalin
P08298129T0000 |0 9|IsolationP00001606
P08298129T0000 |46 54|promoteratases a
P08298129T0000 |14 30|characterization Comparison with
P08298129T0000 |76 89|integrin gene08171T0000 Ph
P08298129T0000 |69 73|betase P
P08299181A1148 |86 89|eye Ph
P08299181A1148 |45 48|eyehat
P08299181A1148 |95 99|eyeslogi
P08299181A1148 |11 16|fluid076 C
P08299181A1148 |105 106|%c
P08299181A1148 |65 66|%t
P08299181A1148 |55 59|eyesd 5-
P08299568A1401 |85 96|stimulation0 Pharmacol
P08299568A1401 |25 35|activation with alka
P08299568A1401 |45 52|enzymeshatases
P08299568A1401 |6 10|data606T
P08299568A1401 |100 117|glucose transport aspects of neona
P08299725A0724 |119 130|readthroughl hyperbili
P08299725A0724 |132 136|formbine
P08299725A0724 |13 19|region6 Comp
P08299725A0724 |61 67|musclecleoti
P08299725A0724 |41 47|intronhospha
P08299725A0724 |148 156|residues97A0472 
P08299725A0724 |89 105|tumor cell linesarmacologic aspe
P08299725A0724 |177 180|endhow
P08299725A0724 |51 56|brains and
P08299896A0626 |0 11|ConcordanceP00001606T0
P08299896A0626 |15 26|IBDQ scoresComparison 
P08299896A0626 |52 60|subjects and 5-n
P08299896A0880 |0 22|Regression line slopesP00001606T0076 Compari
P08299896A0880 |129 130|bi
P08299896A0880 |26 37|IBDQ scoreswith alkali
P08299896A0880 |140 141|P 
P08299896A0880 |70 78|patientse P00008
P08300463A0581 |17 28|Albendazolemparison wi
P08300463A0581 |146 151|cases8997A
P08300463A0581 |57 66|treatment5-nucleot
P08300463A0581 |70 88|neurocysticercosise P00008171T0000 P
P08300463A0581 |201 206|casesF PCO
P08300463A0581 |157 162|drugshen C
P08300463A0581 |118 125|effectsal hype
P08300463A0581 |0 12|PraziquantelP00001606T00
P08300527T0000 |0 10|InhibitionP00001606T
P08300527T0000 |40 50|disruptionphosphatas
P08300527T0000 |14 36|erythromycin synthesis Comparison with alkal
P08300527T0000 |54 96|malonyl-coenzyme A decarboxylase gene eryMnd 5-nucleotidase P00008171T0000 Pharmacol
P08300527T0000 |100 127|Saccharopolyspora erythraea aspects of neonatal hyperb
P08300601A0745 |85 106|E12/MyoD heterodimers0 Pharmacologic aspec
P08300601A0745 |42 53|DNA bindingosphatases 
P08300601A0745 |57 61|MyoD5-nu
P08300601A0745 |28 38|activationth alkalin
P08300601A0745 |66 80|E12 homodimersidase P0000817
P08300601A0745 |5 11|region1606T0
P08300605A0432 |118 128|silk glandal hyperbi
P08300605A0432 |40 56|deletion mutantsphosphatases and
P08300605A0432 |148 161|instar larvae97A0472 When 
P08300605A0432 |211 219|elements data of
P08300605A0432 |30 36|series alkal
P08300605A0432 |175 183|presence shown a
P08300605A0432 |64 68|geneotid
P08300605A0432 |264 279|initiation site compared to co
P08300605A0432 |16 24|analysisompariso
P08300605A0432 |84 92|extracts00 Pharm
P08300605A0671 |47 54|elementtases a
P08300605A0671 |91 101|regulationmacologic 
P08300605A0671 |13 21|elements6 Compar
P08300611A0341 |49 53|geneses 
P08300611A0341 |14 25|mutagenesis Comparison
P08300611A0341 |181 200|amino acid residues as a function of C
P08300611A0341 |157 167|importancehen CSF [H
P08300611A0341 |58 69|application-nucleotida
P08300611A0341 |89 102|TraI proteinsarmacologic a
P08300611A0341 |33 37|traIkali
P08300611A0341 |116 122|assaysatal h
P08300611T0000 |103 107|TraIpect
P08300611T0000 |124 135|plasmid RP4erbilirubin
P08300611T0000 |71 79|reaction P000081
P08300611T0000 |93 101|relaxasecologic 
P08300611T0000 |10 16|action0076 C
P08300611T0000 |35 42|domainsline ph
P08300611T0000 |50 53|DNAes 
P08300625A1352 |71 87|peptide sequence P00008171T0000 
P08300625A1352 |129 142|slyD functionirubinemia. P
P08300625A1352 |31 35|slyDalka
P08300625A1352 |157 162|lysishen C
P08300625A1352 |21 27|codonsison w
P08301702A1083 |100 110|microsomes aspects o
P08301702A1083 |180 185|heronn as 
P08301702A1083 |133 142|cormorantinemia. P
P08301702A1083 |13 23|antibodies6 Comparis
P08301702A1083 |210 224|immunoblottinge data of K-de
P08301702A1083 |77 84|protein8171T00
P08301702A1083 |39 63|rat cytochrome P-450 1A1 phosphatases and 5-nucl
P08301841A0000 |18 33|enzyme activityparison with al
P08301841A0000 |66 76|infarctionidase P000
P08301841A0000 |37 42|serumne ph
P08301841A0000 |78 81|AMI171
P08301841A0000 |96 111|angina pectorisogic aspects of
P08301841A0000 |113 116|UAPeon
P08302589A1132 |16 29|cell motilityomparison wit
P08302589A1132 |115 128|phorbol esternatal hyperbi
P08302589A1132 |146 155|ionophore8997A0472
P08302589A1132 |141 144|Ca2P00
P08302589A1132 |87 101|protein kinasePharmacologic 
P08303233A0313 |3 11|addition001606T0
P08303233A0313 |89 93|textarma
P08303233A0313 |59 67|identitynucleoti
P08303233A0313 |21 28|primingison wi
P08304301A0331 |0 7|METHODSP000016
P08304301A0331 |53 60|nodulesand 5-n
P08304301A0331 |78 89|examination171T0000 Ph
P08304301A0331 |122 126|HCCsyper
P08304301A0331 |20 25|casesrison
P08304301A0331 |64 67|HCCoti
P08304342A0605 |153 159|probes72 Whe
P08304342A0605 |26 50|hemochromatosis familieswith alkaline phosphatas
P08304342A0605 |226 236|HLA-F locieted rats 
P08304342A0605 |107 118|chromosomess of neonat
P08304342A0605 |15 21|reportCompar
P08304342A0605 |201 208|markersF PCO2 
P08304342A0605 |64 91|hemochromatosis chromosomesotidase P00008171T0000 Phar
P08304342A0605 |142 149|battery0000899
P08304342A0605 |257 259|kbed
P08304342A0605 |273 278|HLA-A to c
P08305058T0000 |0 12|PneumothoraxP00001606T00
P08305058T0000 |65 71|hiatustidase
P08305058T0000 |33 43|dissectionkaline pho
P08306356A0000 |50 54|ratses a
P08306356A0000 |75 81|X-rays008171
P08306356A0000 |67 71|dosedase
P08306356A0000 |111 115|days neo
P08306356A0000 |123 132|gestationperbiliru
P08306356A0000 |19 32|malformationsarison with a
P08306356A0000 |87 90|cGyPha
P08306834A0866 |0 10|T2 cancersP00001606T
P08306834A0866 |43 50|benefitsphatas
P08306834A0866 |67 78|irradiationdase P00008
P08306959A0278 |0 9|IFN alphaP00001606
P08306959A0278 |14 36|IFN gamma inducibility Comparison with alkal
P08306959A0278 |106 113|versionts of n
P08306959A0278 |121 146|IFN gamma activation sitehyperbilirubinemia. P0000
P08306959A0278 |61 68|elementcleotid
P08306959A0278 |148 151|GAS97A
P08306959A0278 |77 85|affinity8171T000
P08307338A0227 |0 9|MutationsP00001606
P08307338A0227 |63 69|resulteotida
P08307338A0227 |73 84|degradation00008171T00
P08307338A0227 |126 129|cobbil
P08307338A0227 |146 151|cells8997A
P08307338A0227 |131 134|RNAubi
P08307338A0227 |25 34|gene CBP1 with alk
P08307338A0227 |112 124|cytochrome bneonatal hyp
P08307564A0233 |65 71|contigtidase
P08307564A0233 |29 34|sitesh alk
P08307564A0233 |75 82|density008171T
P08307564A0233 |110 112|kbf 
P08307564A0233 |36 40|STSsine 
P08308008A0201 |35 42|bindingline ph
P08308008A0201 |61 68|proteincleotid
P08308008A0201 |120 124|unit hyp
P08308008A0201 |157 167|activationhen CSF [H
P08308008A0201 |8 13|paper6T007
P08308008A0201 |79 98|ets sequence motifs71T0000 Pharmacolog
P08308008A0201 |175 189|COXIV promoter shown as a fu
P08308008A0201 |70 74|GABPe P0
P08309726A0000 |275 283|patientso contro
P08309726A0000 |398 402|ARDSeffe
P08309726A0000 |293 297|ARDSll h
P08309726A0000 |126 139|relationshipsbilirubinemia
P08309726A0000 |214 217|PMNta 
P08309726A0000 |245 253|severitynger dis
P08309726A0000 |150 167|activation statusA0472 When CSF [H
P08309726A0000 |90 94|ARDSrmac
P08309726A0000 |313 322|pneumoniatly great
P08309726A0000 |407 416|pneumonia hypnotic
P08309726A0000 |376 384|patientsthus app
P08309726A0000 |220 235|cytokine levelsK-depleted rats
P08309726A0000 |16 23|insightomparis
P08309726A0000 |257 268|lung injuryed when com
P08309726A0000 |71 88|distress syndrome P00008171T0000 P
P08309726A0000 |101 108|authorsaspects
P08309726A0000 |201 212|neutrophilsF PCO2 the 
P08309726A0000 |33 45|pathogenesiskaline phosp
P08309726A0000 |340 344|ARDS 0.2
P08309912A0306 |0 10|AmiodaroneP00001606T
P08309912A0306 |82 86|drug0000
P08309912A0306 |38 47|treatmente phospha
P08309953A0776 |139 154|characteristics. P00008997A047
P08309953A0776 |31 60|dopamine receptor stimulationalkaline phosphatases and 5-n
P08309953A0776 |162 184|reaction time responseSF [HCO3-] is shown as
P08309953A0776 |124 131|effectserbilir
P08309953A0776 |74 91|dopamine agonists0008171T0000 Phar
P08309953A0776 |6 13|results606T007
P08309953A0776 |113 120|patterneonatal
P08309957A0000 |4 15|experiments01606T0076 
P08309957A0000 |133 148|agent reserpineinemia. P000089
P08309957A0000 |91 105|administrationmacologic aspe
P08309957A0000 |77 81|rats8171
P08309957A0000 |52 65|jaw movements and 5-nucleo
P08309975A0662 |0 9|DepletionP00001606
P08309975A0662 |161 169|increaseCSF [HCO
P08309975A0662 |29 46|nucleus accumbensh alkaline phosph
P08309975A0662 |13 21|dopamine6 Compar
P08309975A0662 |74 82|behavior0008171T
P08309975A0662 |188 196|lab chowunction 
P08309975A0662 |173 184|consumptionis shown as
P08309975A0662 |128 133|leverlirub
P08309975A0662 |65 70|shifttidas
P08309975A0662 |116 124|decreaseatal hyp
P08312243A0177 |102 104|Cusp
P08312243A0177 |25 34|influence with alk
P08312243A0177 |126 130|ratsbili
P08312243A0177 |109 122|Ca metabolismof neonatal h
P08312243A0177 |193 198|dietson of
P08312243A0177 |44 48|EDTAphat
P08312243A0177 |98 100|Znic
P08312243A0177 |38 43|NaFe3e pho
P08312243A0177 |76 82|levels08171T
P08312243A0177 |86 93|Na2EDTA Pharma
P08312243A0177 |138 151|Zn-sufficienta. P00008997A
P08314163T0000 |0 8|RecoveryP0000160
P08314163T0000 |130 144|administrationrubinemia. P00
P08314163T0000 |120 128|rhGM-CSF hyperbi
P08314163T0000 |93 118|colony stimulating factorcologic aspects of neonat
P08314163T0000 |32 47|agranulocytosislkaline phospha
P08314922A0941 |84 97|brain surface00 Pharmacolo
P08314922A0941 |10 16|system0076 C
P08314922A0941 |57 74|perfusion changes5-nucleotidase P0
P08314922A0941 |111 124|tissue damage neonatal hyp
P08316100A0586 |50 55|rangees an
P08316100A0586 |15 23|RichardsComparis
P08316100A0586 |59 66|factorsnucleot
P08316100A0586 |146 155|influence8997A0472
P08316100A0586 |26 32|theorywith a
P08316100A0586 |188 194|theoryunctio
P08316100A0586 |4 11|neglect01606T0
P08316209A0000 |169 186|sulfur catabolism3-] is shown as a
P08316209A0000 |94 104|expressionologic asp
P08316209A0000 |63 80|Neurospora crassaeotidase P0000817
P08316209A0000 |45 52|proteinhatases
P08316209A0000 |158 165|enzymesen CSF 
P08316209A0000 |110 116|familyf neon
P08316209A0000 |27 33|sulfurith al
P08316209A0000 |54 58|CYS3nd 5
P08316209A0000 |140 145|genes P000
P08316240A1068 |239 244|yeast no l
P08316240A1068 |83 98|hexamer element000 Pharmacolog
P08316240A1068 |67 75|presencedase P00
P08316240A1068 |111 132|MluI restriction site neonatal hyperbiliru
P08316240A1068 |208 227|DNA synthesis genesthe data of K-deple
P08316240A1068 |164 174|expression [HCO3-] i
P08316240A1068 |48 53|CHL15ases 
P08316240A1068 |190 200|regulationction of C
P08316240A1068 |38 44|regione phos
P08316240A1068 |100 106|ACGCGT aspec
P08316240A1068 |0 8|AnalysisP0000160
P08317092A0304 |69 83|helicase motifse P00008171T0
P08317092A0304 |240 246|tobamono lon
P08317092A0304 |104 110|regionects o
P08317092A0304 |15 21|regionCompar
P08317092A0304 |115 135|RNA polymerase motifnatal hyperbilirubin
P08317092A0304 |37 44|proteinne phos
P08317092A0304 |196 219|RNA replication complexof CSF PCO2 the data of
P08317092A0304 |175 183|proteins shown a
P08317092A0304 |252 264|tobravirusessplaced when
P08317094A0778 |119 127|promoterl hyperb
P08317094A0778 |24 35|transcriptsn with alka
P08317094A0778 |135 137|ntem
P08317094A0778 |90 92|ntrm
P08317094A0778 |15 18|F3RCom
P08317094A0778 |55 56|Ad
P08317094A0778 |80 85|TAAAG1T000
P08317094A0778 |7 11|ends06T0
P08317094A0778 |156 172|initiation codonWhen CSF [HCO3-]
P08317094A0778 |68 76|sequencease P000
P08319396A0448 |273 281|peduncle to cont
P08319396A0448 |149 164|intensity areas7A0472 When CSF
P08319396A0448 |121 130|tegmentumhyperbili
P08319396A0448 |210 214|limbe da
P08319396A0448 |108 115|capsule of neo
P08319396A0448 |15 21|imagesCompar
P08319396A0448 |50 58|thalamuses and 5
P08319396A0448 |87 91|limbPhar
P08319396A0448 |252 256|partspla
P08319396A0448 |27 42|intensity areasith alkaline ph
P08319396A0448 |64 72|striatumotidase 
P08319396A0448 |175 194|cerebellar peduncle shown as a functio
P08319396A0448 |231 238|capsulerats ar
P08319396A0448 |3 5|T200
P08319396A0448 |306 312|matternifica
P08319907A0754 |186 195|structure function
P08319907A0754 |177 181|sizehown
P08319907A0754 |46 51|cellsatase
P08319907A0754 |162 169|changesSF [HCO
P08319907A0754 |214 219|tractta of
P08319907A0754 |10 23|rap1t alleles0076 Comparis
P08319907A0754 |112 137|telomere position effectsneonatal hyperbilirubinem
P08319907A0754 |70 92|telomere tract lengthse P00008171T0000 Pharm
P08320120A0361 |84 95|capillaries00 Pharmaco
P08320120A0361 |11 26|microangiopathy076 Comparison 
P08320120A0361 |54 60|fieldsnd 5-n
P08320120A0361 |202 209|nodules PCO2 t
P08320120A0361 |125 134|diffusionrbilirubi
P08320120A0361 |190 194|areactio
P08320120A0361 |138 156|sodium fluoresceina. P00008997A0472 
P08321199T0000 |70 77|factorse P0000
P08321199T0000 |105 114|silencingcts of ne
P08321199T0000 |11 20|switching076 Compa
P08321199T0000 |122 131|HMR locusyperbilir
P08321199T0000 |88 101|establishmentharmacologic 
P08321199T0000 |40 46|statesphosph
P08321199T0000 |48 51|cisase
P08321203A0840 |0 14|NF-kappa B p65P00001606T0076
P08321203A0840 |86 97|C/EBP delta Pharmacolo
P08321203A0840 |25 28|Rel wi
P08321203A0840 |57 68|C/EBP alpha5-nucleotid
P08321203A0840 |70 80|C/EBP betae P0000817
P08321203A0840 |16 19|p50omp
P08321227A0854 |40 54|culture mediumphosphatases a
P08321227A0854 |75 84|COS cells008171T00
P08321741A0396 |291 292|%t
P08321741A0396 |131 139|Myelosisubinemia
P08321741A0396 |10 15|group0076 
P08321741A0396 |268 280|increase-CMLpared to con
P08321741A0396 |210 211|%e
P08321741A0396 |30 33|BMB al
P08321741A0396 |219 227|patients K-deple
P08321741A0396 |67 80|myelofibrosisdase P0000817
P08321741A0396 |244 247|CMLong
P08321741A0396 |188 205|Metaplasia-AMM-inunction of CSF PC
P08321741A0396 |55 63|progressd 5-nucl
P08322117A1019 |34 42|patientsaline ph
P08322117A1019 |135 150|Sussett formulaemia. P00008997
P08322117A1019 |120 125|cmH2O hype
P08322117A1019 |96 101|cmH2Oogic 
P08322117A1019 |8 15|methods6T0076 
P08322117A1019 |179 186|centilewn as a
P08322117A1019 |188 194|cutoffunctio
P08322117A1019 |65 74|pressurestidase P0
P08322823A0839 |19 30|correlationarison with
P08322823A0839 |43 46|MFAsph
P08322823A0839 |55 63|severityd 5-nucl
P08322823A0839 |71 84|UTS phenotype P00008171T00
P08323294T0000 |0 57|Chicken sterol carrier protein 2/sterol carrier protein xP00001606T0076 Comparison with alkaline phosphatases and 
P08323294T0000 |109 118|structureof neonat
P08323294T0000 |133 143|expressioninemia. P0
P08323294T0000 |59 71|cDNA cloningnucleotidase
P08323294T0000 |93 105|conservationcologic aspe
P08324107A0000 |85 99|plasma protein0 Pharmacologi
P08324107A0000 |45 49|g/dlhata
P08324107A0000 |14 35|albumin concentration Comparison with alka
P08324107A0000 |70 71|%e
P08324280A0098 |83 93|ulceration000 Pharma
P08324280A0098 |6 13|lesions606T007
P08324792T0000 |21 27|periodison w
P08324792T0000 |44 50|pacingphatas
P08324792T0000 |94 106|rabbit heartologic aspec
P08324792T0000 |66 78|infarct sizeidase P00008
P08325504A0226 |17 36|RD21 mRNA synthesismparison with alkal
P08325504A0226 |8 12|RD196T00
P08325504A0226 |66 77|heat stressidase P0000
P08325639A0129 |236 245|ubiquitinare no lo
P08325639A0129 |9 16|studiesT0076 C
P08325639A0129 |78 81|26S171
P08325639A0129 |94 101|complexologic 
P08325639A0129 |203 212|breakdownPCO2 the 
P08325639A0129 |66 70|coreidas
P08325639A0129 |36 50|20S proteasomeine phosphatas
P08325639A0129 |141 160|proteinase activityP00008997A0472 When
P08325639A0129 |216 224|proteins of K-de
P08325720A0840 |205 206|%O
P08325720A0840 |66 74|exerciseidase P0
P08325720A0840 |219 241|muscle buffer capacity K-depleted rats are n
P08325720A0840 |7 14|deficit06T0076
P08325720A0840 |76 98|muscle enzyme activity08171T0000 Pharmacolog
P08325720A0840 |209 215|fibreshe dat
P08325720A0840 |151 172|lactate dehydrogenase0472 When CSF [HCO3-]
P08325720A0840 |100 116|citrate synthase aspects of neon
P08325720A0840 |185 203|muscle capillariesa function of CSF 
P08325720A0840 |175 181|number shown
P08325720A0840 |118 149|3-hydroxyacyl-CoA-dehydrogenaseal hyperbilirubinemia. P0000899
P08325720A0840 |34 47|blood lactatealine phospha
P08325883A0368 |68 89|RNA recognition motifase P00008171T0000 Ph
P08325883A0368 |192 205|alpha-helixesion of CSF PC
P08325883A0368 |135 141|regionemia. 
P08325883A0368 |161 167|regionCSF [H
P08325883A0368 |95 114|glutamine stretcheslogic aspects of ne
P08325883A0368 |29 41|RBP1 proteinh alkaline p
P08325883A0368 |4 12|sequence01606T00
P08325883A0368 |55 61|copiesd 5-nu
P08327488A0839 |232 235|p70ats
P08327488A0839 |14 17|RNA Co
P08327488A0839 |130 143|helper genomerubinemia. P0
P08327488A0839 |47 50|p70tas
P08327488A0839 |31 39|deletionalkaline
P08327488A0839 |58 64|region-nucle
P08327488A0839 |202 205|RNA PC
P08331064A0440 |68 78|resolutionase P00008
P08331064A0440 |98 108|structuresic aspects
P08331064A0440 |26 34|pressurewith alk
P08331064A0440 |50 53|wayes 
P08331064A0440 |0 7|ReleaseP000016
P08331067T0000 |99 105|endo-Nc aspe
P08331067T0000 |135 142|homologemia. P
P08331067T0000 |9 28|nucleotide sequenceT0076 Comparison wi
P08331067T0000 |146 164|bacteriophage PK1E8997A0472 When CSF
P08331067T0000 |73 97|endo-N-acylneuraminidase00008171T0000 Pharmacolo
P08331067T0000 |111 121|comparison neonatal 
P08331067T0000 |36 63|bacteriophage K1F tail geneine phosphatases and 5-nucl
P08331728A0686 |0 7|BindingP000016
P08331728A0686 |28 45|ribonucleoproteinth alkaline phosp
P08331728A0686 |11 13|U207
P08332033T0000 |102 112|assessmentspects of 
P08332033T0000 |96 100|miceogic
P08332033T0000 |78 92|micro-infarcts171T0000 Pharm
P08332033T0000 |15 29|quantificationComparison wit
P08332033T0000 |33 44|brain edemakaline phos
P08332033T0000 |116 134|neurotropin effectatal hyperbilirubi
P08332492A0145 |103 109|targetpects 
P08332492A0145 |29 35|familyh alka
P08332492A0145 |151 156|HIV-10472 
P08332492A0145 |120 147|immunodeficiency virus type hyperbilirubinemia. P00008
P08332492A0145 |172 183|replication is shown a
P08332492A0145 |37 43|GATA-3ne pho
P08332492A0145 |77 90|T lymphocytes8171T0000 Pha
P08332492A0145 |158 167|infectionen CSF [H
P08332492A0145 |4 10|member01606T
P08332495A0408 |85 91|A549-10 Phar
P08332495A0408 |131 138|complexubinemi
P08332495A0408 |198 207|liposomes CSF PCO2
P08332495A0408 |29 41|CAT activityh alkaline p
P08332495A0408 |181 188|DC-chol as a f
P08332495A0408 |142 159|T7 RNA polymerase00008997A0472 Whe
P08332495A0408 |93 98|cellscolog
P08332495A0408 |161 176|pT7-EMC-CAT DNACSF [HCO3-] is 
P08332495A0408 |20 25|levelrison
P08332495A0408 |64 83|lung adenocarcinomaotidase P00008171T0
P08333643A0000 |0 13|PneumoscrotumP00001606T007
P08333643A0000 |24 33|conditionn with al
P08333643A0000 |78 83|texts171T0
P08333643A0000 |55 65|discussiond 5-nucleo
P08333643A0000 |87 94|urologyPharmac
P08334158A0660 |49 65|cystein residuesses and 5-nucleo
P08334158A0660 |10 20|gene codes0076 Compa
P08334158A0660 |72 83|arrangementP00008171T0
P08334158A0660 |27 34|proteinith alk
P08334158A0660 |96 109|Fe/S proteinsogic aspects 
P08334304A0473 |17 22|cellsmpari
P08334304A0473 |45 55|activationhatases an
P08334304A0473 |79 101|peptide growth factors71T0000 Pharmacologic 
P08334304A0473 |63 70|pathwayeotidas
P08334304A0473 |132 144|p21 rasVal12binemia. P00
P08334304A0473 |109 117|additionof neona
P08334304A0473 |32 40|capacitylkaline 
P08334989A0070 |119 127|sequencel hyperb
P08334989A0070 |24 33|mechanismn with al
P08334989A0070 |95 106|mouse B-myblogic aspec
P08334989A0070 |46 56|expressionatases and
P08334989A0070 |65 69|genetida
P08334989A0070 |219 243|luciferase reporter gene K-depleted rats are no 
P08334989A0070 |266 284|NIH3T3 fibroblastsompared to control
P08334989A0070 |200 213|transcriptionSF PCO2 the d
P08334989A0070 |155 162|library When C
P08335710A0338 |4 13|influence01606T007
P08335710A0338 |30 38|strength alkalin
P08335710A0338 |46 56|resolutionatases and
P08336012A0632 |68 82|BAL fluid cellase P00008171T
P08336012A0632 |30 34|lung alk
P08336012A0632 |123 125|FNpe
P08336012A0632 |14 22|bacteria Compari
P08336012A0632 |105 119|administrationcts of neonata
P08336012A0632 |53 63|blood celland 5-nucl
P08336012A0632 |4 10|number01606T
P08336543A0243 |68 69|Va
P08336543A0243 |110 118|sequencef neonat
P08336543A0243 |59 60|Fn
P08336543A0243 |135 143|terminusemia. P0
P08336543A0243 |21 29|familiesison wit
P08336543A0243 |54 55|An
P08336543A0243 |97 102|basisgic a
P08336543A0243 |3 7|mice0016
P08336543A0243 |33 44|L1 elementskaline phos
P08336698T0000 |0 4|TFECP000
P08336698T0000 |46 58|heterodimersatases and 5
P08336698T0000 |31 38|proteinalkalin
P08336698T0000 |97 121|transcription activationgic aspects of neonatal 
P08336698T0000 |64 68|TFE3otid
P08336738A1273 |4 14|equivalent01606T0076
P08336738A1273 |28 34|ligandth alk
P08336738A1273 |45 49|T-47hata
P08336738A1273 |57 79|PSTAIRE sequence motif5-nucleotidase P000081
P08336738A1273 |36 40|H-87ine 
P08337828A0895 |8 15|results6T0076 
P08337828A0895 |29 42|Western blotsh alkaline ph
P08337828A0895 |75 81|AcMNPV008171
P08337828A0895 |46 73|Autographa californica MNPVatases and 5-nucleotidase P
P08337828A0895 |92 119|Spodoptera frugiperda cellsacologic aspects of neonata
P08337841A0612 |136 154|consensus sequencemia. P00008997A047
P08337841A0612 |183 189|G genes a fu
P08337841A0612 |259 270|nucleotides when compa
P08337841A0612 |289 318|GNS protein termination codon still have a significantly g
P08337841A0612 |156 161|AACAGWhen 
P08337841A0612 |22 27|cellsson w
P08337841A0612 |213 235|polyadenylation signalata of K-depleted rats
P08337841A0612 |242 243|A 
P08337841A0612 |33 38|ARV Gkalin
P08337841A0612 |98 102|mRNAic a
P08337841A0612 |43 52|GNS genessphatases
P08337841A0612 |237 241|CATGre n
P08337841A0612 |170 175|start-] is
P08340400T0000 |98 105|proteinic aspe
P08340400T0000 |59 66|pigmentnucleot
P08340400T0000 |10 17|cloning0076 Co
P08340400T0000 |22 32|expressionson with a
P08340400T0000 |36 41|RPE65ine p
P08342703A0966 |19 23|mu Waris
P08342703A0966 |147 155|pressure997A0472
P08342703A0966 |90 106|outflow pressurermacologic aspec
P08342703A0966 |58 67|flow rate-nucleoti
P08342703A0966 |9 14|powerT0076
P08342703A0966 |177 183|vesselhown a
P08342703A0966 |129 138|flow rateirubinemi
P08342703A0966 |114 121|productonatal 
P08343041A0000 |68 89|hospital laboratoriesase P00008171T0000 Ph
P08343041A0000 |112 122|antibodiesneonatal h
P08343041A0000 |19 29|antibodiesarison wit
P08343041A0000 |50 61|infertilityes and 5-nu
P08343216A0883 |13 35|IgG subclass responses6 Comparison with alka
P08343216A0883 |61 75|IgG subclassescleotidase P00
P08343961A0000 |0 21|Anterior body patternP00001606T0076 Compar
P08343961A0000 |133 138|genesinemi
P08343961A0000 |63 75|distributioneotidase P00
P08343961A0000 |90 97|proteinrmacolo
P08343961A0000 |160 167|domains CSF [H
P08343961A0000 |99 102|bcdc a
P08344248A0910 |0 5|GAP-NP0000
P08344248A0910 |62 68|growthleotid
P08344248A0910 |87 92|cellsPharm
P08345191A1140 |68 78|similarityase P00008
P08345191A1140 |45 56|amino acidshatases and
P08345191A1140 |4 20|peptide sequence01606T0076 Compa
P08345191A1140 |82 87|bcl-20000 
P08345191A1140 |132 136|genebine
P08345191A1140 |138 142|MCL1a. P
P08345191A1140 |32 38|regionlkalin
P08347677A0308 |289 295|microM still
P08347677A0308 |82 99|arginine residues0000 Pharmacologi
P08347677A0308 |197 218|4-Ala-Ala-Ser-Val-Alaf CSF PCO2 the data o
P08347677A0308 |281 283|Kmro
P08347677A0308 |264 272|peptides compare
P08347677A0308 |193 196|Argon 
P08347677A0308 |61 67|numbercleoti
P08347677A0308 |138 145|residuea. P000
P08347677A0308 |4 30|phosphorylation efficiency01606T0076 Comparison with
P08347677A0308 |234 243|substrates are no 
P08347677A0308 |168 174|serineO3-] i
P08347677A0308 |118 133|arginyl clusteral hyperbilirub
P08348919T0000 |0 15|Botulinum toxinP00001606T0076 
P08348919T0000 |27 36|treatmentith alkal
P08348919T0000 |52 57|spasm and 
P08349104A0000 |68 76|responsease P000
P08349104A0000 |160 168|proteins CSF [HC
P08349104A0000 |29 33|GAL1h al
P08349104A0000 |211 215|UASG dat
P08349104A0000 |38 49|GAL10 genese phosphata
P08349104A0000 |114 121|glucoseonatal 
P08349104A0000 |202 207|sites PCO2
P08349104A0000 |100 109|galactose aspects 
P08349104A0000 |84 96|availability00 Pharmacol
P08349104A0450 |101 108|factorsaspects
P08349104A0450 |222 229|varietydeplete
P08349104A0450 |18 25|resultsparison
P08349104A0450 |145 155|expression08997A0472
P08349104A0450 |300 306|mating a sig
P08349104A0450 |276 283|defects contro
P08349104A0450 |110 114|tsf1f ne
P08349104A0450 |312 323|sporulationntly greate
P08349104A0450 |161 166|yeastCSF [
P08349104A0450 |287 298|cell growthut still ha
P08349104A0450 |118 132|tsf6 mutationsal hyperbiliru
P08349104A0450 |233 251|operator sequencests are no longer d
P08349104A0450 |37 48|experimentsne phosphat
P08349104A0450 |202 206|lacZ PCO
P08349104A0450 |66 75|TSF genesidase P00
P08349104A0450 |175 191|hybrid promoters shown as a func
P08349499A1169 |0 3|SexP00
P08349499A1169 |77 81|head8171
P08349499A1169 |57 62|width5-nuc
P08349499A1169 |13 20|variate6 Compa
P08349499A1169 |7 11|calf06T0
P08349499A1169 |66 72|muzzleidase 
P08349632A0679 |0 19|Sequence comparisonP00001606T0076 Comp
P08349632A0679 |67 76|PSG12 psidase P000
P08349632A0679 |128 142|PSG12 psi genelirubinemia. P
P08349632A0679 |57 62|PSG125-nuc
P08349632A0679 |44 45|Lp
P08349632A0679 |154 164|stop codon2 When CSF
P08349632A0679 |83 84|%0
P08349632A0679 |112 120|L/N exonneonatal
P08349632A0679 |35 40|exonsline 
P08349632A0679 |50 53|L/Nes 
P08350061A0209 |64 72|CD8 geneotidase 
P08350061A0209 |105 131|T cell development programcts of neonatal hyperbilir
P08350061A0209 |45 56|suppressionhatases and
P08350061A0209 |31 41|activationalkaline p
P08350061A0209 |4 14|mechanisms01606T0076
P08350398A1616 |170 175|class-] is
P08350398A1616 |159 166|domainsn CSF [
P08350398A1616 |178 183|heavyown a
P08350398A1616 |40 46|domainphosph
P08350398A1616 |192 198|chainsion of
P08350398A1616 |151 156|alpha0472 
P08350398A1616 |185 190|alphaa fun
P08350398A1616 |80 89|structure1T0000 Ph
P08350398A1616 |20 22|ERri
P08350398A1616 |139 144|alpha. P00
P08350398A1616 |50 55|gp19Kes an
P08352066A0000 |102 116|bone formationspects of neon
P08352066A0000 |26 40|beta-estradiolwith alkaline 
P08352066A0000 |150 154|ratsA047
P08352066A0000 |135 139|boneemia
P08352066A0000 |42 44|E2os
P08352066A0000 |66 81|bone resorptionidase P00008171
P08352268A0000 |34 41|epoetinaline p
P08352268A0000 |94 98|i.v.olog
P08352268A0000 |121 126|routehyper
P08352268A0000 |18 32|erythropoietinparison with a
P08352268A0000 |117 119|SCta
P08355062A0000 |32 42|tomographylkaline ph
P08355062A0000 |165 173|patients[HCO3-] 
P08355062A0000 |44 49|SPECTphata
P08355062A0000 |14 22|emission Compari
P08355062A0000 |94 99|HMPAOologi
P08355062A0000 |56 92|99mTc-hexamethylpropyleneamine oxime 5-nucleotidase P00008171T0000 Pharm
P08355062A0000 |195 205|impairment of CSF PC
P08355062A0000 |125 132|changesrbiliru
P08355062A0000 |145 155|blood flow08997A0472
P08355063A0456 |4 14|rCBF ratio01606T0076
P08355063A0456 |45 50|lobeshatas
P08355063A0456 |54 55|%n
P08355539A0133 |0 7|METHODSP000016
P08355539A0133 |297 305|etiologyave a si
P08355539A0133 |61 69|etiologycleotida
P08355539A0133 |220 228|etiologyK-deplet
P08355539A0133 |118 127|diagnosisal hyperb
P08355539A0133 |259 264|study when
P08355539A0133 |184 187|EAA a 
P08355539A0133 |20 28|patientsrison wi
P08355539A0133 |83 88|study000 P
P08355539A0133 |232 235|EATats
P08355539A0133 |104 114|antibodiesects of ne
P08355539A0133 |135 142|diseaseemia. P
P08355539A0133 |172 180|etiology is show
P08355539A0133 |309 312|EAIica
P08355680A0824 |0 4|2-APP000
P08355680A0824 |106 122|HIV-1 constructsts of neonatal h
P08355680A0824 |28 33|risesth al
P08355680A0824 |159 163|genen CS
P08355680A0824 |37 54|mRNA accumulationne phosphatases a
P08355680A0824 |130 139|increasesrubinemia
P08355680A0824 |173 184|gamma-actinis shown as
P08355680A0824 |188 221|glucose 6-phosphate dehydrogenaseunction of CSF PCO2 the data of K
P08355696A0236 |4 16|UV induction01606T0076 C
P08355696A0236 |90 99|sequencesrmacologi
P08355696A0236 |45 65|UV response elementshatases and 5-nucleo
P08355696A0236 |122 128|regionyperbi
P08355696A0236 |20 25|c-junrison
P08355697A0000 |119 134|cell activationl hyperbilirubi
P08355697A0000 |31 35|PTPsalka
P08355697A0000 |105 115|regulationcts of neo
P08355697A0000 |52 76|protein tyrosine kinases and 5-nucleotidase P000
P08355697A0000 |78 82|PTKs171T
P08355697A0000 |148 163|differentiation97A0472 When CS
P08355697A0000 |136 142|growthmia. P
P08355697A0000 |0 29|Protein tyrosine phosphatasesP00001606T0076 Comparison wit
P08355857A1293 |3 12|elevation001606T00
P08355857A1293 |66 73|patientidase P
P08355857A1293 |25 33|patients with al
P08355857A1293 |45 55|subgroup Ahatases an
P08355857A1293 |39 40|% 
P08355857A1293 |81 92|subgroup B.T0000 Pharm
P08356792A1275 |81 87|levelsT0000 
P08356792A1275 |192 202|provirusesion of CSF
P08356792A1275 |15 27|p21X proteinComparison w
P08356792A1275 |93 97|datacolo
P08356792A1275 |40 50|N-terminusphosphatas
P08356792A1275 |147 151|mRNA997A
P08356792A1275 |112 116|p21Xneon
P08356792A1275 |54 58|Rex1nd 5
P08356792T0000 |0 22|HTLV-1 gene expressionP00001606T0076 Compari
P08356792T0000 |62 73|T-cell lineleotidase P
P08356792T0000 |36 46|provirusesine phosph
P08356944A0589 |137 161|cyanmethemoglobin methodia. P00008997A0472 When 
P08356944A0589 |197 203|wastesf CSF 
P08356944A0589 |177 187|generationhown as a 
P08356944A0589 |75 99|hemoglobin concentration008171T0000 Pharmacologi
P08356944A0589 |32 60|sodium lauryl sulfate methodlkaline phosphatases and 5-n
P08356944A0589 |118 129|alternativeal hyperbil
P08357834A0285 |305 317|counterpartsgnificantly 
P08357834A0285 |218 239|sequence conservationf K-depleted rats are
P08357834A0285 |266 284|PKC family membersompared to control
P08357834A0285 |94 97|ratolo
P08357834A0285 |208 214|degreethe da
P08357834A0285 |149 168|sequence divergence7A0472 When CSF [HC
P08357834A0285 |30 50|amino acid sequences alkaline phosphatas
P08357834A0285 |139 145|degree. P000
P08357834A0285 |2 12|comparison0001606T00
P08357834A0285 |175 185|% homology shown as 
P08357834A0285 |68 84|PKC-delta clonesase P00008171T00
P08357834A0285 |102 118|mouse homologuesspects of neonat
P08360112T0036 |0 3|XIIP00
P08360180A1041 |118 128|similarityal hyperbi
P08360180A1041 |210 220|progenitore data of 
P08360180A1041 |60 74|PSI-K sequenceucleotidase P0
P08360180A1041 |234 248|cyanobacterials are no longe
P08360180A1041 |36 41|PSI-Gine p
P08360180A1041 |108 114|degree of ne
P08360180A1041 |168 172|geneO3-]
P08360180A1041 |19 31|barley PSI-Karison with 
P08361754A0733 |23 33|structureson with al
P08361754A0733 |13 17|hand6 Co
P08361754A0733 |47 53|domaintases 
P08361754A0733 |97 105|proteinsgic aspe
P08361755A0734 |138 149|Tax bindinga. P0000899
P08361755A0734 |56 70|NF-kappa B p50 5-nucleotidas
P08361755A0734 |12 22|conditions76 Compari
P08361755A0734 |121 122|sh
P08361755A0734 |181 189|CArG box as a fu
P08361755A0734 |75 96|serum response factor008171T0000 Pharmacol
P08361755A0734 |114 120|factoronatal
P08361755A0734 |43 48|cDNAssphat
P08361755A0734 |24 37|transfectionsn with alkali
P08361755A0734 |157 172|NF-kappa B sitehen CSF [HCO3-]
P08361755A0734 |98 101|SRFic 
P08361761A0174 |102 119|Sp1 binding sitesspects of neonata
P08361761A0174 |257 267|expressioned when co
P08361761A0174 |457 474|Sp1 binding sitesneral practice be
P08361761A0174 |145 171|chicken embryo fibroblasts08997A0472 When CSF [HCO3-
P08361761A0174 |389 410|kappa B binding sitesto be an effective hy
P08361761A0174 |363 369|repeat3 Flur
P08361761A0174 |173 177|CEFsis s
P08361761A0174 |311 338|immunodeficiency virus typeantly greater slope (1.21 +
P08361761A0174 |229 234|sitesd rat
P08361761A0174 |47 57|expressiontases and 
P08361761A0174 |192 197|v-Relion o
P08361761A0174 |18 23|v-Relparis
P08361761A0174 |236 241|v-Relare n
P08361761A0174 |65 81|reporter plasmidtidase P00008171
P08361761A0174 |371 374|LTRepa
P08361761A0174 |342 347|HIV-1.23 v
P08361761A0174 |275 291|reporter plasmido controls but s
P08363332A0365 |17 26|recordingmparison 
P08363332A0365 |133 139|atriuminemia
P08363332A0365 |243 262|activation sequencelonger displaced wh
P08363332A0365 |150 155|sinusA0472
P08363332A0365 |104 108|apexects
P08363332A0365 |41 49|activityhosphata
P08363332A0365 |270 275|heartred t
P08363332A0365 |182 198|mapping catheteras a function of
P08363332A0365 |59 84|surface electrocardiogramnucleotidase P00008171T00
P08363332A0365 |114 120|bundleonatal
P08365944A1537 |171 183|radiotherapy] is shown a
P08365944A1537 |210 215|booste dat
P08365944A1537 |61 69|efficacycleotida
P08365944A1537 |31 39|analysisalkaline
P08365944A1537 |116 130|5-fluorouracilatal hyperbili
P08365944A1537 |144 155|association008997A0472
P08365944A1537 |77 83|course8171T0
P08365944A1537 |100 111|Mitomycin-C aspects of
P08365944A1537 |0 10|CONCLUSIONP00001606T
P08366034A0637 |80 89|formation1T0000 Ph
P08366034A0637 |12 21|existence76 Compar
P08366034A0637 |47 65|carboxymethylationtases and 5-nucleo
P08366034A0637 |28 45|cysteine residuesth alkaline phosp
P08366034A0637 |109 124|disulfide bondsof neonatal hyp
P08366034A0637 |158 163|cellsen CS
P08367388T0035 |51 59|syndromes and 5-
P08367388T0035 |28 36|syndrometh alkal
P08367487A1014 |255 263|extractsaced whe
P08367487A1014 |195 205|antibodies of CSF PC
P08367487A1014 |135 144|U2 snRNPsemia. P00
P08367487A1014 |22 30|additionson with
P08367487A1014 |43 56|17S U2 snRNPssphatases and
P08367487A1014 |225 247|mRNA-splicing activityleted rats are no long
P08367487A1014 |87 109|HeLa splicing extractsPharmacologic aspects 
P08367487A1014 |69 82|12S U2 snRNPsse P00008171T
P08369887A0781 |68 71|EADase
P08369887A0781 |27 46|viscosity variablesith alkaline phosph
P08369887A0781 |75 86|RA patients008171T0000
P08369887A0781 |15 23|profilesComparis
P08369887A0781 |55 64|subgroupsd 5-nucle
P08369887A0781 |0 11|DifferencesP00001606T0
P08370119A0642 |86 95|sequences Pharmaco
P08370119A0642 |126 139|reading framebilirubinemia
P08370119A0642 |183 214|muscle cell AT1a receptor cDNAss a function of CSF PCO2 the da
P08370119A0642 |31 35|exonalka
P08370119A0642 |53 55|bpan
P08370119A0642 |99 107|additionc aspect
P08370119A1521 |0 8|DeletionP0000160
P08370119A1521 |26 41|promoter regionwith alkaline p
P08370119A1521 |151 159|elements0472 Whe
P08370119A1521 |97 105|TATA boxgic aspe
P08370119A1521 |131 138|abilityubinemi
P08370119A1521 |57 81|transcription start site5-nucleotidase P00008171
P08370119A1521 |190 205|luciferase cDNAction of CSF PC
P08370119A1521 |169 182|transcription3-] is shown 
P08370275A0290 |4 14|chimpanzee01606T0076
P08370275A0290 |88 92|pairharm
P08370275A0290 |61 68|testingcleotid
P08370275A0290 |44 51|numeralphatase
P08370275A0290 |106 112|chimpsts of 
P08370275A0290 |123 133|preferenceperbilirub
P08371650T0000 |0 11|DissipationP00001606T0
P08371650T0000 |15 32|claudication painComparison with a
P08371650T0000 |75 83|training008171T0
P08371650T0000 |48 60|implicationsases and 5-n
P08371713T0000 |48 67|endothelin receptorases and 5-nucleoti
P08371713T0000 |73 82|rat brain00008171T
P08371713T0000 |12 22|transcript76 Compari
P08371936T0000 |51 56|studys and
P08371936T0000 |15 35|Independence MeasureComparison with alka
P08371936T0000 |60 69|clinicianucleotida
P08371936T0000 |74 86|self ratings0008171T0000
P08373274A0546 |0 11|Polymyxin BP00001606T0
P08373274A0546 |42 55|week postburnosphatases an
P08373274A0546 |59 64|dosesnucle
P08373274A0546 |100 111|endotoxemia aspects of
P08373972A0335 |0 4|SvO2P000
P08374753A0335 |49 70|diffusion coefficientses and 5-nucleotidas
P08374753A0335 |15 30|relaxation timeComparison with
P08374753A0335 |74 79|water00081
P08374753A0335 |32 34|T2lk
P08375651T0000 |42 59|clathrin functionosphatases and 5-
P08375651T0000 |30 40|chain gene alkaline 
P08375651T0000 |92 100|organismacologic
P08376397A0788 |70 73|E2Fe P
P08376397A0788 |99 108|E2F sitesc aspects
P08376397A0788 |112 123|competitorsneonatal hy
P08376397A0788 |82 88|number0000 P
P08376397A0788 |4 23|binding specificity01606T0076 Comparis
P08376397A0788 |32 39|proteinlkaline
P08376796A0172 |70 79|attentione P000081
P08376796A0172 |146 150|IgG18997
P08376796A0172 |176 183|B cellsshown a
P08376796A0172 |265 272|patientcompare
P08376796A0172 |361 363|Ag73
P08376796A0172 |210 217|patiente data 
P08376796A0172 |241 258|diabetes mellituso longer displace
P08376796A0172 |135 138|IgGemi
P08376796A0172 |165 168|mAb[HC
P08376796A0172 |344 348|self3 vs
P08376796A0172 |15 25|VH regionsComparison
P08376796A0172 |324 330|number slope
P08376796A0172 |159 163|IgG3n CS
P08376796A0172 |42 52|antibodiesosphatases
P08376796A0172 |199 206|subjectCSF PCO
P08376796A0172 |109 115|statusof neo
P08376796A0172 |278 281|SLEont
P08376796A0172 |309 321|efficienciesicantly grea
P08377199A1432 |52 64|conformation and 5-nucle
P08377199A1432 |104 115|recognitionects of neo
P08377199A1432 |72 76|siteP000
P08377199A1432 |24 29|patchn wit
P08378082A1031 |70 76|p21rase P000
P08378082A1031 |36 46|cross-talkine phosph
P08378082A1031 |6 14|findings606T0076
P08378082A1031 |97 111|cell phenotypegic aspects of
P08378082A1031 |143 149|states000899
P08378082A1031 |55 65|RB proteind 5-nucleo
P08380736A0895 |69 76|proteinse P000
P08380736A0895 |9 13|mRNAT007
P08380736A0895 |93 107|amino terminuscologic aspect
P08380736A0895 |37 45|splicingne phosp
P08380896A0938 |0 8|KineticsP0000160
P08380896A0938 |111 130|preinitiation stage neonatal hyperbili
P08380896A0938 |47 64|polymerase domaintases and 5-nucle
P08380896A0938 |83 94|replication000 Pharmac
P08380896A0938 |16 26|inhibitionomparison 
P08381121A0773 |10 31|transmembrane regions0076 Comparison with 
P08381121A0773 |61 67|domaincleoti
P08382296A0766 |0 10|McCann IIIP00001606T
P08382296A0766 |12 14|F.76
P08382300A0341 |35 42|abilityline ph
P08382300A0341 |148 155|mutants97A0472
P08382300A0341 |97 107|VP5 mutantgic aspect
P08382300A0341 |58 69|replication-nucleotida
P08382300A0341 |130 133|VP5rub
P08382300A0341 |6 16|cell lines606T0076 C
P08382300A0341 |138 142|VP23a. P
P08382303A0507 |4 6|E101
P08382303A0507 |120 126|region hyper
P08382303A0507 |75 91|papillomaviruses008171T0000 Phar
P08382303A0507 |15 30|transport motifComparison with
P08382303A0507 |58 64|animal-nucle
P08382303A0507 |142 150|E1 genes00008997
P08382303T0000 |4 26|E1 replication protein01606T0076 Comparison 
P08382303T0000 |88 107|localization signalharmacologic aspect
P08382303T0000 |124 152|p34cdc2 phosphorylation siteerbilirubinemia. P00008997A0
P08382303T0000 |37 56|papillomavirus typene phosphatases and
P08382359A0469 |205 214|T antigenO2 the da
P08382359A0469 |99 104|virusc asp
P08382359A0469 |248 259|experimentsr displaced
P08382359A0469 |76 91|tumor induction08171T0000 Phar
P08382359A0469 |282 289|effectsols but
P08382359A0469 |44 55|interactionphatases an
P08382359A0469 |318 328|activitiesreater slo
P08382359A0469 |139 154|point mutations. P00008997A047
P08382359A0469 |32 38|extentlkalin
P08382359A0469 |3 8|order00160
P08382359A0469 |341 356|tumor induction0.23 vs. P00010
P08382359A0469 |187 195|sequencefunction
P08382769A0924 |155 168|SRP54 protein When CSF [HC
P08382769A0924 |37 48|nucleotidesne phosphat
P08382769A0924 |127 146|recognition elementilirubinemia. P0000
P08382769A0924 |78 89|consequence171T0000 Ph
P08382769A0924 |99 103|rolec as
P08382769A0924 |21 33|conservationison with al
P08382778A0891 |137 158|transcription factorsia. P00008997A0472 Wh
P08382778A0891 |125 130|TFIIErbili
P08382778A0891 |75 81|region008171
P08382778A0891 |49 57|homologyses and 
P08382778A0891 |2 8|region000160
P08382778A0891 |24 38|protein sharesn with alkalin
P08382778A0891 |100 107|feature aspect
P08382778A0891 |85 96|Raf kinases0 Pharmacol
P08383129A0776 |18 42|mass polypeptide complexparison with alkaline ph
P08383129A0776 |193 206|T-lymphocyteson of CSF PCO
P08383129A0776 |72 92|antigen presentationP00008171T0000 Pharm
P08383129A0776 |105 113|peptidescts of n
P08383129A0776 |214 226|cell surfaceta of K-depl
P08383129A0776 |129 145|protein antigensirubinemia. P000
P08383214A0389 |70 74|forme P0
P08383214A0389 |10 18|cleavage0076 Com
P08383214A0389 |47 50|Poltas
P08383214A0389 |28 43|Trp-595-Tyr-596th alkaline pho
P08383214A0389 |22 24|RTso
P08383214A0389 |98 112|RNase H domainic aspects of 
P08383217A0357 |32 43|amino acidslkaline pho
P08383217A0357 |47 52|Bel-1tases
P08383217A0357 |151 168|activation domain0472 When CSF [HC
P08383217A0357 |172 176|VP16 is 
P08383217A0357 |83 97|Bel-1 activity000 Pharmacolo
P08383287A0611 |20 27|elementrison w
P08383287A0611 |121 145|hormone response elementhyperbilirubinemia. P000
P08383287A0611 |56 86|thyroid hormone responsiveness 5-nucleotidase P00008171T0000
P08383287A0611 |43 51|estrogensphatase
P08383323A0000 |52 59|signals and 5-
P08383323A0000 |8 18|activation6T0076 Com
P08383323A0000 |22 29|T cellsson wit
P08383492A1205 |206 224|c-type cytochromes2 the data of K-de
P08383492A1205 |148 156|affinity97A0472 
P08383492A1205 |83 89|region000 Ph
P08383492A1205 |97 108|differencesgic aspects
P08383492A1205 |126 131|termsbilir
P08383492A1205 |64 74|aa stretchotidase P0
P08383492A1205 |175 194|cytochrome oxidases shown as a functio
P08383526A0591 |16 21|genesompar
P08383526A0591 |94 98|exonolog
P08383526A0591 |57 73|receptor protein5-nucleotidase P
P08383526A0591 |37 46|structurene phosph
P08383622T0000 |119 139|ETS domain activatorl hyperbilirubinemia
P08383622T0000 |107 111|roles of
P08383622T0000 |44 53|activatorphatases 
P08383622T0000 |57 86|cytochrome oxidase expression5-nucleotidase P00008171T0000
P08383622T0000 |12 16|GABP76 C
P08383622T0000 |149 158|promoters7A0472 Wh
P08383622T0000 |22 27|NRF-2son w
P08383622T0000 |0 8|IdentityP0000160
P08383850A0206 |70 73|NTIe P
P08383850A0206 |192 196|ratsion 
P08383850A0206 |15 20|studyCompa
P08383850A0206 |76 93|nonequilibrium mu08171T0000 Pharma
P08383850A0206 |43 51|beta-FNAsphatase
P08383850A0206 |57 68|naltrindole5-nucleotid
P08383850A0206 |22 41|beta-funaltrexamineson with alkaline p
P08383850A0206 |156 166|withdrawalWhen CSF [
P08384309A0000 |103 109|dioxinpects 
P08384309A0000 |111 146|2,3,7,8-tetrachlorodibenzo-p-dioxin neonatal hyperbilirubinemia. P0000
P08384309A0000 |24 47|region/helix-loop-helixn with alkaline phospha
P08384309A0000 |55 70|dioxin receptord 5-nucleotidas
P08384309A0000 |80 99|signal transduction1T0000 Pharmacologi
P08384309A0000 |230 242|target genes rats are no
P08384309A0000 |257 281|dioxin response elementsed when compared to cont
P08384309A0000 |184 203|DNA binding protein a function of CSF 
P08385131A0000 |34 44|alpha 2AARaline phos
P08385131A0000 |62 69|varietyleotida
P08385131A0000 |24 32|receptorn with a
P08385131A0000 |125 133|proteinsrbilirub
P08385131A0000 |73 82|effectors00008171T
P08385131A0000 |4 9|alpha01606
P08385131A0000 |87 96|pertussisPharmacol
P08385337A0282 |34 64|CCAAT/enhancer binding proteinaline phosphatases and 5-nucle
P08385337A0282 |148 153|bZIP197A04
P08385337A0282 |123 138|leucine zippersperbilirubinemi
P08385337A0282 |73 92|consensus sequences00008171T0000 Pharm
P08385337A0282 |158 163|bZIP2en CS
P08385337A0282 |66 71|C/EBPidase
P08385337A0282 |178 184|regionown as
P08385337A0282 |2 21|sequence comparison0001606T0076 Compar
P08385337A0282 |100 118|DNA binding region aspects of neonat
P08385581A0126 |152 159|mitosis472 Whe
P08385581A0126 |13 18|genes6 Com
P08385581A0126 |140 148|function P000089
P08385581A0126 |20 26|REC114rison 
P08385581A0126 |73 79|REC114000081
P08385581A0126 |55 59|datad 5-
P08385581A0126 |102 120|recombination genespects of neonatal
P08386279A1621 |118 133|HIV-1 infectional hyperbilirub
P08386279A1621 |79 88|cell line71T0000 P
P08386279A1621 |63 67|HeLaeoti
P08386279A1621 |143 148|cells00089
P08386279A1621 |163 188|HIV-1 promoter activationF [HCO3-] is shown as a f
P08386279A1621 |110 113|EBVf n
P08386279A1621 |4 28|transactivation function01606T0076 Comparison wi
P08386279A1621 |32 37|EBNA2lkali
P08386280T0000 |0 8|MutationP0000160
P08386280T0000 |76 82|repeat08171T
P08386280T0000 |43 61|Rous sarcoma virussphatases and 5-nu
P08386280T0000 |87 100|gag enhancersPharmacologic
P08386280T0000 |16 35|C/EBP binding sitesomparison with alka
P08386317T0000 |48 62|protein kinaseases and 5-nuc
P08386317T0000 |8 30|protein phosphatase 2A6T0076 Comparison with
P08386317T0000 |120 131|stimulation hyperbilir
P08386317T0000 |80 84|CREB1T00
P08386317T0000 |99 103|CREBc as
P08386318A1102 |137 139|Caia
P08386318A1102 |183 188|Raf-1s a f
P08386318A1102 |28 35|JRE-IL6th alka
P08386318A1102 |13 17|IL-66 Co
P08386318A1102 |90 106|protein kinase Crmacologic aspec
P08386318A1102 |60 67|pathwayucleoti
P08386318A1102 |178 181|Rasown
P08386318A1102 |129 135|kinaseirubin
P08386318A1102 |193 199|NF-IL6on of 
P08386318A1102 |201 211|C/EBP betaF PCO2 the
P08386318A1102 |169 176|kinases3-] is 
P08386319A1229 |0 8|MutationP0000160
P08386319A1229 |56 74|threonine residues 5-nucleotidase P0
P08386319A1229 |159 173|Mpk1p functionn CSF [HCO3-] 
P08386319A1229 |43 51|tyrosinesphatase
P08386319A1229 |78 83|Mpk1p171T0
P08386319A1229 |100 113|phenylalanine aspects of n
P08386319A1229 |118 125|alanineal hype
P08386592A0089 |220 222|kdK-
P08386592A0089 |232 244|Elk-1 kinaseats are no l
P08386592A0089 |109 116|complexof neon
P08386592A0089 |183 189|regions a fu
P08386592A0089 |166 171|Elk-1HCO3-
P08386592A0089 |201 211|activationF PCO2 the
P08386592A0089 |55 61|changed 5-nu
P08386592A0089 |143 158|phosphorylation0008997A0472 Wh
P08386592A0089 |0 25|Growth factor stimulationP00001606T0076 Comparison
P08386592A0089 |85 93|mobility0 Pharma
P08386637A1220 |153 162|receptors72 When C
P08386637A1220 |59 67|exposurenucleoti
P08386637A1220 |42 47|cellsospha
P08386637A1220 |75 82|agonist008171T
P08386637A1220 |3 11|contrast001606T0
P08386637A1220 |114 124|regulationonatal hyp
P08386637A1220 |144 145|%0
P08386637A1220 |19 28|situationarison wi
P08386637A1220 |87 88|hP
P08387155A1248 |17 23|effectmparis
P08387155A1248 |125 129|toporbil
P08387155A1248 |78 82|topo171T
P08387155A1248 |149 154|assay7A047
P08387155A1248 |98 103|c-Fosic as
P08387155A1248 |50 55|c-Junes an
P08387507A1015 |258 282|myoblast differentiationd when compared to contr
P08387507A1015 |123 128|serumperbi
P08387507A1015 |62 69|pathwayleotida
P08387507A1015 |28 41|MyoD functionth alkaline p
P08387507A1015 |225 232|factorsleted r
P08387507A1015 |141 163|peptide growth factorsP00008997A0472 When CS
P08387507A1015 |4 14|regulation01606T0076
P08387507A1015 |189 196|nucleusnction 
P08387507A1015 |18 23|Myf-5paris
P08387507A1015 |102 109|signalsspects 
P08387519A0000 |50 67|desmin expressiones and 5-nucleoti
P08387519A0000 |90 94|pairrmac
P08387519A0000 |111 119|enhancer neonata
P08387519A0000 |183 198|gene expressions a function of
P08387519A0000 |151 159|myotubes0472 Whe
P08387519A0000 |202 211|myoblasts PCO2 the
P08387519A0000 |38 43|levele pho
P08387662A0302 |114 121|codeineonatal 
P08387662A0302 |147 149|mg99
P08387662A0302 |133 142|ibuprofeninemia. P
P08387662A0302 |105 112|placebocts of 
P08387662A0302 |15 28|patients selfComparison wi
P08387662A0302 |162 166|painSF [
P08387662A0302 |77 88|medications8171T0000 P
P08387662A0302 |125 127|mgrb
P08387662A0302 |196 205|intensityof CSF PC
P08387662A0302 |6 13|surgery606T007
P08387743A0624 |0 11|ReplacementP00001606T0
P08387743A0624 |155 178|Mn-superoxide dismutase When CSF [HCO3-] is sh
P08387743A0624 |43 49|regionsphata
P08387743A0624 |134 144|expressionnemia. P00
P08387743A0624 |100 107|element aspect
P08387743A0624 |69 76|mutantsse P000
P08387994A0980 |4 22|orf61 gene product01606T0076 Compari
P08387994A0980 |90 101|integrationrmacologic 
P08387994A0980 |121 130|attB sitehyperbili
P08387994A0980 |57 65|promoter5-nucleo
P08388496A1117 |0 10|ExpressionP00001606T
P08388496A1117 |58 79|virus producer status-nucleotidase P000081
P08388496A1117 |125 132|passagerbiliru
P08388496A1117 |26 30|LCLswith
P08388496A1117 |287 296|BamHI-C/Wut still 
P08388496A1117 |91 102|consequencemacologic a
P08388496A1117 |230 233|day ra
P08388496A1117 |213 220|B cellsata of 
P08388496A1117 |162 181|BamHI-A transcriptsSF [HCO3-] is shown
P08388496A1117 |351 356|mRNAs00010
P08388496A1117 |256 265|infectionced when 
P08388510A0891 |0 8|AnalysisP0000160
P08388510A0891 |60 69|UL28 geneucleotida
P08388510A0891 |12 43|cell surface immunofluorescence76 Comparison with alkaline pho
P08388510A0891 |151 156|cells0472 
P08388510A0891 |90 100|expressionrmacologic
P08388510A0891 |131 138|surfaceubinemi
P08388510A0891 |110 123|glycoproteinsf neonatal hy
P08388543A1263 |32 43|Y977F/Y989Flkaline pho
P08388543A1263 |92 95|Rasaco
P08388543A1263 |147 167|calcium mobilization997A0472 When CSF [H
P08388543A1263 |182 188|effectas a f
P08388543A1263 |63 68|siteseotid
P08388543A1263 |225 234|cell lineleted rat
P08388543A1263 |45 48|PLChat
P08388543A1263 |213 216|Rasata
P08388543A1263 |196 209|GDP/GTP stateof CSF PCO2 t
P08388543A1263 |126 142|protein kinase Cbilirubinemia. P
P08388543A1263 |22 30|receptorson with
P08388543A1263 |112 122|activationneonatal h
P08388600A0000 |0 18|Estrogen treatmentP00001606T0076 Com
P08388600A0000 |27 32|dosesith a
P08388600A0000 |97 102|girlsgic a
P08388600A0000 |64 71|statureotidase
P08389074A1227 |0 9|MutationsP00001606
P08389074A1227 |151 160|structure0472 When
P08389074A1227 |25 35|C-terminus with alka
P08389074A1227 |78 105|activation domain functions171T0000 Pharmacologic aspe
P08389074A1227 |62 73|RNA bindingleotidase P
P08389074A1227 |39 47|EIAV Tat phospha
P08389074A1227 |118 125|effectsal hype
P08389365A1344 |51 64|repair systems and 5-nucle
P08389365A1344 |5 16|observation1606T0076 C
P08389365A1344 |95 103|sequencelogic as
P08389365A1344 |89 93|GATCarma
P08389365A1344 |114 124|correctiononatal hyp
P08389365A1344 |87 88|dP
P08389453A0193 |119 129|duplex DNAl hyperbil
P08389453A0193 |107 113|uracils of n
P08389453A0193 |45 49|stephata
P08389453A0193 |57 71|repair pathway5-nucleotidase
P08389453A0193 |0 22|Uracil DNA glycosylaseP00001606T0076 Compari
P08390120A0785 |17 23|trialsmparis
P08390120A0785 |79 86|options71T0000
P08390120A0785 |106 110|lifets o
P08390120A0785 |95 102|qualitylogic a
P08390120A0785 |42 50|questionosphatas
P08390665A0000 |0 22|Lithium phthalocyanineP00001606T0076 Compari
P08390665A0000 |56 66|generation 5-nucleot
P08390665A0000 |112 124|crystallitesneonatal hyp
P08390665A0000 |196 214|resonance oximetryof CSF PCO2 the da
P08390665A0000 |24 28|LiPcn wi
P08390665A0000 |174 182|electrons shown 
P08390665A0000 |35 44|prototypeline phos
P08390747A0586 |32 40|geneticslkaline 
P08390747A0586 |105 114|syncytialcts of ne
P08390747A0586 |8 14|report6T0076
P08390747A0586 |147 150|syn997
P08390747A0586 |130 140|phenotypesrubinemia.
P08390747A0586 |65 80|hep syn gB genetidase P0000817
P08390747A0586 |48 54|regionases a
P08390831A0143 |0 10|RecipientsP00001606T
P08390831A0143 |125 129|riskrbil
P08390831A0143 |41 50|remissionhosphatas
P08390831A0143 |70 79|leukaemiae P000081
P08390831A0143 |97 102|phasegic a
P08390831A0143 |22 31|leukaemiason with 
P08390831A0143 |154 160|stages2 When
P08390831A0143 |170 183|risk patients-] is shown a
P08391534A0828 |0 7|ElledgeP000016
P08391534A0828 |9 11|P.T0
P08391748A0452 |0 5|DrugsP0000
P08391748A0452 |26 27|%w
P08391748A0452 |63 75|contractionseotidase P00
P08391748A0452 |119 135|QRS prolongationl hyperbilirubin
P08391748A0452 |184 185|% 
P08391748A0452 |217 233|QRS prolongationof K-depleted ra
P08391748A0452 |83 91|patients000 Phar
P08391748A0452 |189 197|patientsnction o
P08391748A0452 |246 247|%g
P08391748A0452 |336 352|QRS prolongation +/- 0.23 vs. P0
P08391748A0452 |162 177|QT prolongationSF [HCO3-] is s
P08391748A0452 |379 394|QT prolongations appears to be
P08391748A0452 |307 308|%i
P08391748A0452 |275 290|QT prolongationo controls but 
P08392221A0449 |0 6|LossesP00001
P08392221A0449 |244 265|O-desmethylangolensinonger displaced when 
P08392221A0449 |193 205|matairesinolon of CSF PC
P08392221A0449 |73 92|estrogen conjugates00008171T0000 Pharm
P08392221A0449 |156 165|standardsWhen CSF 
P08392221A0449 |219 232|enterolactone K-depleted r
P08392221A0449 |267 272|equolmpare
P08392221A0449 |27 36|procedureith alkal
P08392221A0449 |278 287|genisteinontrols b
P08392221A0449 |173 182|compoundsis shown 
P08392221A0449 |110 115|stepsf neo
P08392221A0449 |234 242|daidzeins are no
P08392221A0449 |207 217|enterodiol the data 
P08392623A1374 |0 20|IE2-IE2 interactionsP00001606T0076 Compa
P08392623A1374 |107 117|C terminuss of neona
P08392623A1374 |121 124|IE2hyp
P08392623A1374 |134 145|amino acidsnemia. P000
P08392623A1374 |38 44|domaine phos
P08392623A1374 |84 89|motif00 Ph
P08393143A1281 |4 14|Sp1 region01606T0076
P08393143A1281 |63 66|TREeot
P08393143A1281 |80 90|tat factor1T0000 Pha
P08394019A0695 |51 58|Fyn SH2s and 5
P08394019A0695 |150 153|FynA04
P08394019A0695 |60 63|SH3ucl
P08394019A0695 |69 84|SH2/SH3 domainsse P00008171T00
P08394019A0695 |99 110|PI 3-kinasec aspects o
P08394019A0695 |20 39|GST fusion proteinsrison with alkaline
P08394019A0695 |136 146|SH3 domainmia. P0000
P08394019A0695 |0 13|PrecipitationP00001606T007
P08394255A0000 |100 125|polymerase chain reaction aspects of neonatal hype
P08394255A0000 |127 130|PCRili
P08394255A0000 |47 60|pcDNA1 vectortases and 5-n
P08394255A0000 |194 215|hormone receptor cDNAn of CSF PCO2 the dat
P08394255A0000 |81 86|probeT0000
P08394255A0000 |159 170|kb fragmentn CSF [HCO3
P08394255A0000 |178 181|ratown
P08394255A0000 |2 7|sheep00016
P08394255A0000 |19 31|cDNA libraryarison with 
P08394464A1080 |50 56|masseses and
P08394464A1080 |13 25|Rev proteins6 Comparison
P08394464A1080 |141 148|speciesP000089
P08394464A1080 |113 116|p20eon
P08394464A1080 |92 96|p2/2acol
P08394464A1080 |101 105|p176aspe
P08394464A1080 |70 73|kDae P
P08394862A0565 |48 53|groupases 
P08394862A0565 |56 63|patient 5-nucl
P08394862A0565 |74 87|CMV hepatitis0008171T0000 
P08394862A0565 |14 22|patients Compari
P08394862A0565 |6 11|group606T0
P08394862A0565 |33 44|CMV diseasekaline phos
P08395004A0141 |171 187|HIS4 mRNA levels] is shown as a 
P08395004A0141 |149 157|increase7A0472 W
P08395004A0141 |62 74|interferenceleotidase P0
P08395004A0141 |15 29|spt2 mutationsComparison wit
P08395004A0141 |89 129|delta promoter insertion his-4-912 deltaarmacologic aspects of neonatal hyperbil
P08395004A0141 |4 11|ability01606T0
P08395004A0558 |137 149|protein HMG1ia. P0000899
P08395004A0558 |74 91|SPT2/SIN1 protein0008171T0000 Phar
P08395004A0558 |8 20|localization6T0076 Compa
P08395004A0558 |25 54|protein sequence similarities with alkaline phosphatases a
P08395010T0000 |102 111|responsesspects of
P08395010T0000 |125 136|heterodimerrbilirubine
P08395010T0000 |41 56|thyroid hormonehosphatases and
P08395010T0000 |31 37|heptadalkali
P08395010T0000 |145 164|homodimer formation08997A0472 When CSF
P08395010T0000 |70 84|acid receptorse P00008171T00
P08395014A1364 |8 20|interactions6T0076 Compa
P08395014A1364 |105 119|pathway branchcts of neonata
P08395014A1364 |29 33|BCK2h al
P08395014A1364 |44 62|pathway componentsphatases and 5-nuc
P08395014A1364 |134 138|PPZ2nemi
P08395014A1364 |78 92|BCK2 functions171T0000 Pharm
P08395014A1364 |125 129|PPZ1rbil
P08395654T0000 |84 102|rat aromatase gene00 Pharmacologic a
P08395654T0000 |42 50|receptorosphatas
P08395654T0000 |14 20|factor Compa
P08395654T0000 |66 76|expressionidase P000
P08395654T0000 |114 121|tissuesonatal 
P08395681A0388 |203 218|binding abilityPCO2 the data o
P08395681A0388 |242 264|retinoblastoma protein longer displaced when
P08395681A0388 |116 118|E7at
P08395681A0388 |54 58|HPV5nd 5
P08395681A0388 |266 268|RBom
P08395681A0388 |24 35|differencesn with alka
P08395681A0388 |124 138|reading frameserbilirubinemi
P08395681A0388 |63 71|HPV8 E7seotidase
P08395681A0388 |84 92|HPV16 E700 Pharm
P08395681A0388 |187 197|activitiesfunction o
P08395681A0388 |324 345|adenovirus E1A mutant slope (1.21 +/- 0.23
P08395681A0388 |280 304|complementation activitytrols but still have a s
P08395681A0388 |228 236|productsed rats 
P08396120A0690 |68 73|startase P
P08396120A0690 |77 88|translation8171T0000 P
P08396120A0690 |4 33|rhaB transcription start site01606T0076 Comparison with al
P08396261A0388 |171 177|strain] is s
P08396261A0388 |17 25|evidencemparison
P08396261A0388 |221 232|growth rate-depleted r
P08396261A0388 |48 65|growth inhibitionases and 5-nucleo
P08396261A0388 |114 123|phenotypeonatal hy
P08396261A0388 |491 494|DE3t. 
P08396261A0388 |457 466|phenotypeneral pra
P08396261A0388 |82 94|PKA subunits0000 Pharmac
P08396261A0388 |486 490|BL21 nig
P08396261A0388 |242 255|transformants longer displ
P08396261A0388 |388 398|RI protein to be an 
P08396261A0388 |337 344|RI cDNA+/- 0.2
P08396261A0388 |8 13|lines6T007
P08396261A0388 |281 285|cAMProls
P08396261A0388 |527 542|C alpha proteints. P00013683A0
P08396261A0388 |496 501|cells00126
P08396261A0388 |195 211|cyclase activity of CSF PCO2 the
P08396261A0388 |140 144|cAMP P00
P08396261A0388 |308 314|growthficant
P08396261A0388 |412 424|cAMP bindingotic drug wi
P08396261A0388 |99 103|cAMPc as
P08396261A0388 |369 376|RI cDNAazepam 
P08396657A0452 |0 3|LiuP00
P08396657A0452 |5 7|B.16
P08396667T0000 |0 7|BCR-ABLP000016
P08396667T0000 |63 71|lymphomaeotidase
P08396667T0000 |44 52|patternsphatases
P08396667T0000 |92 110|lymphocyte subsetsacologic aspects o
P08396667T0000 |18 27|oncogenesparison w
P08396713A0305 |103 108|cellspects
P08396713A0305 |226 244|heat shock proteineted rats are no l
P08396713A0305 |122 157|2,3,7,8-tetrachlorodibenzo-p-dioxinyperbilirubinemia. P00008997A0472 W
P08396713A0305 |91 99|extractsmacologi
P08396713A0305 |60 68|receptorucleotid
P08396713A0305 |202 206|ARNT PCO
P08396713A0305 |159 163|TCDDn CS
P08396713A0305 |178 197|Ah receptor proteinown as a function o
P08396713A0305 |6 17|experiments606T0076 Co
P08396713A0305 |48 52|formases
P08396749A1112 |1 16|LDL cholesterol00001606T0076 C
P08396749A1112 |157 162|mg/dlhen C
P08396749A1112 |78 83|weeks171T0
P08396749A1112 |63 69|mmol/leotida
P08396749A1112 |164 165|P 
P08396749A1112 |63 69|mmol/leotida
P08396749A1112 |164 165|P 
P08396749A1112 |1 16|LDL cholesterol00001606T0076 C
P08396749A1112 |100 101|P 
P08396749A1112 |87 98|simvastatinPharmacolog
P08396749A1112 |116 121|apo Batal 
P08396749A1112 |116 121|apo Batal 
P08396749A1112 |157 162|mg/dlhen C
P08396749A1112 |78 83|weeks171T0
P08396749A1112 |87 98|simvastatinPharmacolog
P08396749A1112 |100 101|P 
P08396913A1379 |68 72|cellase 
P08396913A1379 |14 21|element Compar
P08396913A1379 |105 113|DGK genects of n
P08396913A1379 |39 43|part pho
P08396913A1379 |87 97|expressionPharmacolo
P08397123T0000 |68 104|corticotropin-releasing hormone genease P00008171T0000 Pharmacologic asp
P08397123T0000 |130 138|featuresrubinemi
P08397123T0000 |47 54|elementtases a
P08397123T0000 |160 171|transcripts CSF [HCO3-
P08397123T0000 |10 18|activity0076 Com
P08399970T0000 |48 58|inoculantsases and 5
P08399970T0000 |6 33|bioencapsulation technology606T0076 Comparison with al
P08400240A0166 |102 110|A gamma*spects o
P08400240A0166 |10 31|hypersensitivity site0076 Comparison with 
P08400240A0166 |192 209|gamma-globin mRNAion of CSF PCO2 t
P08400240A0166 |71 74|LCR P0
P08400240A0166 |83 100|gamma-globin gene000 Pharmacologic
P08400240A0166 |145 155|transcript08997A0472
P08400240A0166 |49 69|locus control regionses and 5-nucleotida
P08400240A0166 |35 38|HS2lin
P08400928A0318 |152 163|combination472 When CS
P08400928A0318 |176 189|bromocriptineshown as a fu
P08400928A0318 |165 168|arm[HC
P08400928A0318 |105 148|levodopa/decarboxylase inhibitor/selegilinects of neonatal hyperbilirubinemia. P000089
P08400928A0318 |15 23|PatientsComparis
P08400928A0318 |97 100|armgic
P08400928A0318 |52 89|levodopa/dopa decarboxylase inhibitor and 5-nucleotidase P00008171T0000 Ph
P08400928A0318 |37 46|treatmentne phosph
P08400928A0318 |191 194|armtio
P08400928A0318 |0 13|INTERVENTIONSP00001606T007
P08401570A0828 |173 194|transcription factorsis shown as a functio
P08401570A0828 |95 104|sequenceslogic asp
P08401570A0828 |27 40|binding sitesith alkaline 
P08401570A0828 |45 69|transcription factor Sp1hatases and 5-nucleotida
P08401570A0828 |163 168|sitesF [HC
P08401570A0828 |142 151|enhancers00008997A
P08401614A0187 |54 57|PALnd 
P08401614A0187 |91 95|PAL3maco
P08401614A0187 |151 161|mRNA level0472 When 
P08401614A0187 |75 80|genes00817
P08401614A0187 |7 11|bean06T0
P08401614A0187 |29 35|familyh alka
P08401614A0187 |165 177|bean tissues[HCO3-] is s
P08401614A0187 |82 86|PAL20000
P08401614A0187 |39 44|genes phos
P08403245A1234 |0 28|Plasma thromboxane B2 levelsP00001606T0076 Comparison wi
P08403245A1234 |42 47|groupospha
P08403245A1234 |83 90|piglets000 Pha
P08403804A0754 |154 170|serum creatinine2 When CSF [HCO3
P08403804A0754 |209 220|cyclosporinhe data of 
P08403804A0754 |183 193|transplants a functi
P08403804A0754 |28 47|regression analysisth alkaline phospha
P08403804A0754 |172 176|time is 
P08403804A0754 |131 142|cholesterolubinemia. P
P08403804A0754 |57 66|magnesium5-nucleot
P08403804A0754 |96 120|cyclosporin trough levelogic aspects of neonatal
P08403804A0754 |201 205|doseF PC
P08405433A0000 |68 77|promotersase P0000
P08405433A0000 |79 81|P171
P08405433A0000 |41 47|IGF-IIhospha
P08405433A0000 |83 85|P200
P08405433A0000 |23 36|growth factoron with alkal
P08405433A0000 |94 96|P4ol
P08405433A0000 |49 53|geneses 
P08405433A0000 |87 89|P3Ph
P08406004A0691 |100 114|JB cis-element aspects of ne
P08406004A0691 |44 48|PU.1phat
P08406004A0691 |181 189|sequence as a fu
P08406004A0691 |23 42|transfection assayson with alkaline ph
P08406004A0691 |212 219|portiondata of
P08406004A0691 |124 134|activationerbilirubi
P08406004A0691 |65 84|reporter constructstidase P00008171T00
P08406004A0691 |223 227|PU.1eple
P08406352A0172 |137 145|veteransia. P000
P08406352A0172 |244 251|receiptonger d
P08406352A0172 |27 40|fever vaccineith alkaline 
P08406352A0172 |89 97|controlsarmacolo
P08406352A0172 |166 175|carcinomaHCO3-] is
P08406352A0172 |268 275|vaccinepared t
P08406352A0172 |121 126|studyhyper
P08406352A0172 |219 227|controls K-deple
P08406352A0172 |59 76|hepatitis B virusnucleotidase P000
P08406352A0172 |179 205|Veterans Affairs hospitalswn as a function of CSF PC
P08406352A0172 |233 240|respectts are 
P08406352A0172 |0 13|Army veteransP00001606T007
P08406419A0155 |139 147|Westwood. P00008
P08406419A0155 |149 151|MA7A
P08406419A0155 |53 70|hepatitis C virusand 5-nucleotidas
P08406419A0155 |92 99|testingacologi
P08406419A0155 |109 137|Ortho Diagnostic Systems Incof neonatal hyperbilirubinem
P08406419A0155 |39 49|antibodies phosphata
P08406419A0155 |101 105|RIBAaspe
P08406497A0000 |0 7|DefectsP000016
P08406497A0000 |11 20|fibrillin076 Compa
P08406497A0000 |31 53|glycoprotein componentalkaline phosphatases 
P08406497A0000 |75 86|microfibril008171T0000
P08406497A0000 |94 109|Marfan syndromeologic aspects 
P08406497A0000 |22 26|FBN1son 
P08407784A0850 |21 25|recJison
P08407784A0850 |27 34|strainsith alk
P08407784A0850 |36 50|srjA mutationsine phosphatas
P08407784A0850 |96 106|phenotypesogic aspec
P08408194T0000 |119 120|Kl
P08408194T0000 |28 49|membrane-cytoskeletonth alkaline phosphata
P08408194T0000 |15 20|rolesCompa
P08408194T0000 |158 167|epitheliaen CSF [H
P08408194T0000 |82 90|adhesion0000 Pha
P08408194T0000 |124 144|ATPase distributionserbilirubinemia. P00
P08408194T0000 |54 62|cadherinnd 5-nuc
P08408194T0000 |115 117|Nana
P08408825A0000 |82 84|Ro00
P08408825A0000 |89 100|La antigensarmacologic
P08408825A0000 |9 28|lupus erythematosusT0076 Comparison wi
P08408825A0000 |59 73|autoantibodiesnucleotidase P
P08408841A0281 |103 112|mutationspects of 
P08408841A0281 |73 86|abnormalities00008171T0000
P08408841A0281 |41 52|mutagenesishosphatases
P08408841A0281 |8 21|abnormalities6T0076 Compar
P08408963A0048 |10 12|L.00
P08409284A0262 |68 79|amino acidsase P000081
P08409284A0262 |131 142|PHE carrierubinemia. P
P08409284A0262 |10 20|absorption0076 Compa
P08409284A0262 |109 120|amino acidsof neonatal
P08409284A0262 |89 95|systemarmaco
P08409284A0262 |224 231|cholerapleted 
P08409284A0262 |191 196|stagetion 
P08409284A0262 |43 54|NBB carriersphatases a
P08409284A0262 |24 35|amino acidsn with alka
P08409284A0262 |86 87|Y 
P08409284A0262 |207 216|diarrhoea the data
P08409593A0357 |69 78|H. pylorise P00008
P08409593A0357 |130 138|activityrubinemi
P08409593A0357 |150 154|timeA047
P08409593A0357 |96 100|AMPCogic
P08409593A0357 |52 60|activity and 5-n
P08409593A0357 |9 13|AMPCT007
P08409593A0357 |3 7|CFDN0016
P08409593A0357 |18 21|MNZpar
P08410042T0000 |18 25|diseaseparison
P08410042T0000 |75 80|cases00817
P08410042T0000 |61 67|reportcleoti
P08410042T0000 |42 59|dura mater graftsosphatases and 5-
P08410097A0356 |152 153|p4
P08410097A0356 |94 95|po
P08410097A0356 |243 253|covariateslonger dis
P08410097A0356 |192 209|plasma fibrinogenion of CSF PCO2 t
P08410097A0356 |25 30|CLTPA with
P08410097A0356 |58 85|regression coefficient beta-nucleotidase P00008171T000
P08410097A0356 |124 137|oxygen uptakeerbilirubinem
P08410097A0356 |7 21|mean intensity06T0076 Compar
P08410097A0356 |139 143|beta. P0
P08411024T0000 |58 82|fibrosis carrier testing-nucleotidase P00008171T
P08411024T0000 |11 17|people076 Co
P08411024T0000 |40 46|optionphosph
P08411276A0302 |102 124|Trauma Score variablesspects of neonatal hyp
P08411276A0302 |20 31|PIC patientrison with 
P08411276A0302 |54 63|mechanismnd 5-nucl
P08411276A0302 |320 321|Ca
P08411276A0302 |189 193|ratencti
P08411276A0302 |126 150|Glascow Coma Scale scorebilirubinemia. P00008997
P08411276A0302 |211 214|age da
P08411276A0302 |356 364|injuries943A0733
P08411276A0302 |327 343|ASCOT componentsope (1.21 +/- 0.
P08411276A0302 |84 90|coding00 Pha
P08411276A0302 |221 246|Severity Characterization-depleted rats are no lon
P08411276A0302 |259 264|ASCOT when
P08411276A0302 |250 256|Traumadispla
P08411276A0302 |67 73|injurydase P
P08411276A0302 |313 314|Bt
P08411276A0302 |161 175|blood pressureCSF [HCO3-] is
P08411276A0302 |310 311|Ac
P08411276A0302 |2 9|patient0001606
P08412120A0839 |0 4|SkinP000
P08412120A0839 |9 19|bowel TPO2T0076 Comp
P08412120A0839 |52 53|P 
P08412120A0839 |32 35|DO2lka
P08412620A0688 |2 8|region000160
P08412620A0688 |27 29|bpit
P08412620A0688 |144 152|promoter008997A0
P08412620A0688 |77 81|virB8171
P08412620A0688 |125 135|activationrbilirubin
P08412620A0688 |156 160|VirFWhen
P08412620A0688 |48 73|transcription start pointases and 5-nucleotidase P
P08412662A0333 |137 154|kb EcoRI fragmentia. P00008997A047
P08412662A0333 |73 93|transposon insertion00008171T0000 Pharma
P08412662A0333 |97 103|257DH4gic as
P08412662A0333 |37 40|DNAne 
P08412662A0333 |123 126|Tn5per
P08412662A0333 |65 69|sitetida
P08412662A0333 |19 25|cosmidarison
P08412665A0000 |19 25|pUR400arison
P08412665A0000 |56 67|scr regulon 5-nucleoti
P08412665A0000 |157 161|ScrRhen 
P08412665A0000 |93 100|KAY2026cologic
P08412665A0000 |146 155|repressor8997A0472
P08412665A0000 |4 15|scr regulon01606T0076 
P08412665A0000 |71 81|Klebsiella P00008171
P08413186A0077 |51 61|regulations and 5-nu
P08413186A0077 |195 210|reductase genes of CSF PCO2 th
P08413186A0077 |251 258|pathwayisplace
P08413186A0077 |157 167|expressionhen CSF [H
P08413186A0077 |23 33|mechanismson with al
P08413186A0077 |138 145|factorsa. P000
P08413186A0077 |236 243|enzymesare no 
P08413186A1199 |4 13|Ntl1 gene01606T007
P08413186A1199 |57 83|N. plumbaginifolia species5-nucleotidase P00008171T0
P08413186A1199 |37 41|copyne p
P08413205A0733 |154 160|copies2 When
P08413205A0733 |130 138|promoterrubinemi
P08413205A0733 |109 122|transcriptionof neonatal h
P08413205A0733 |180 200|recognition sequencen as a function of C
P08413205A0733 |49 63|Pax-8 isoformsses and 5-nucl
P08413205A0733 |81 82|cT
P08413205A0733 |10 34|transfection experiments0076 Comparison with alk
P08413205A0733 |70 71|be
P08413205A0733 |87 88|dP
P08413209A0159 |32 39|proteinlkaline
P08413209A0159 |107 115|proteinss of neo
P08413209A0159 |71 91|motif characteristic P00008171T0000 Phar
P08413209A0159 |19 24|thirdariso
P08413215A0327 |85 98|transcription0 Pharmacolog
P08413215A0327 |109 122|IL-8 promoterof neonatal h
P08413215A0327 |40 59|NF-kappa B subunitsphosphatases and 5-
P08413215A0327 |21 28|abilityison wi
P08413223A0847 |116 123|elementatal hy
P08413223A0847 |14 20|copies Compa
P08413223A0847 |144 157|phorbol ester008997A0472 W
P08413223A0847 |92 97|virusacolo
P08413223A0847 |28 53|IL-1 beta NF-kappa B siteth alkaline phosphatases 
P08413223A0847 |191 206|gene expressiontion of CSF PCO
P08413223A0847 |101 109|promoteraspects 
P08413239A0490 |34 45|sequence CAaline phosp
P08413239A0490 |97 110|U snRNA genesgic aspects o
P08413239A0490 |229 237|mutationd rats a
P08413239A0490 |47 48|Nt
P08413239A0490 |75 84|plant Pol008171T00
P08413239A0490 |49 60|3-10AGTNNAAses and 5-n
P08413239A0490 |188 198|vertebrateunction of
P08413239A0490 |202 205|box PC
P08413239A0490 |136 149|end formationmia. P0000899
P08413239A0490 |153 167|U2 transcripts72 When CSF [H
P08413260A1437 |84 88|cell00 P
P08413260A1437 |74 75|s0
P08413260A1437 |123 131|G2 phaseperbilir
P08413260A1437 |106 115|machineryts of neo
P08413260A1437 |28 38|Rb proteinth alkalin
P08413260A1437 |6 13|results606T007
P08413260A1437 |64 73|componentotidase P
P08413274A0452 |0 4|MDBPP000
P08413274A0452 |141 151|MDBP sitesP00008997A
P08413274A0452 |64 86|X-box oligonucleotidesotidase P00008171T0000
P08413274A0452 |10 14|HeLa0076
P08413274A0452 |19 29|Raji cellsarison wit
P08413274A0452 |49 58|complexesses and 5
P08413291A1473 |68 76|reporterase P000
P08413291A1473 |30 53|rat TnI-CAT fusion gene alkaline phosphatases 
P08413291A1473 |106 112|musclets of 
P08413291A1473 |11 15|mice076 
P08414410A0270 |239 244|nerve no l
P08414410A0270 |196 204|measuresof CSF P
P08414410A0270 |57 61|eyes5-nu
P08414410A0270 |27 31|eyesith 
P08414410A0270 |133 146|field defectsinemia. P0000
P08414410A0270 |249 266|nerve fiber layer displaced when c
P08414410A0270 |219 225|damage K-dep
P08414410A0270 |110 114|eyesf ne
P08414410A0270 |81 87|fieldsT0000 
P08414410A0270 |0 7|METHODSP000016
P08414502A0244 |102 105|DNAspe
P08414502A0244 |145 154|promoters08997A047
P08414502A0244 |63 72|regulatoreotidase 
P08414502A0244 |120 133|transcription hyperbilirub
P08414502A0244 |20 30|hypothesisrison with
P08414502A0244 |84 95|p53 protein00 Pharmaco
P08415637A0000 |137 147|G proteinsia. P00008
P08415637A0000 |29 32|ARFh a
P08415637A0000 |75 90|RAS superfamily008171T0000 Pha
P08415637A0000 |127 135|proteinsilirubin
P08415637A0000 |108 114|weight of ne
P08415637A0000 |56 67|subfamilies 5-nucleoti
P08415637A0000 |4 27|ADP-ribosylation factor01606T0076 Comparison w
P08415637A0000 |34 40|familyaline 
P08415643A0555 |103 110|mitosispects o
P08415643A0555 |63 67|RCC1eoti
P08415643A0555 |54 58|genend 5
P08415643A0555 |40 46|intronphosph
P08415643A0555 |94 99|onsetologi
P08415643A0555 |4 11|E1 gene01606T0
P08415643A0555 |71 78|protein P00008
P08415712A1153 |204 228|Huntington disease locusCO2 the data of K-deplet
P08415712A1153 |123 134|chromosomesperbilirubi
P08415712A1153 |106 111|genests of
P08415712A1153 |232 242|chromosomeats are no
P08415712A1153 |8 30|Southern blot analysis6T0076 Comparison with
P08415712A1153 |182 186|GPRKas a
P08415712A1153 |66 71|GPRK6idase
P08415712A1153 |35 53|chromosome mappingline phosphatases 
P08416952A0956 |85 103|protein substrates0 Pharmacologic as
P08416952A0956 |163 175|substitutionF [HCO3-] is
P08416952A0956 |10 26|labeling studies0076 Comparison 
P08416952A0956 |107 112|Nmt1ps of 
P08416952A0956 |151 156|Leu990472 
P08416952A0956 |65 71|nmt72ptidase
P08416952A0956 |232 250|protein substratesats are no longer 
P08416952A0956 |202 211|acylation PCO2 the
P08416952A0956 |48 61|co-expressionases and 5-nu
P08416952A0956 |185 194|reductiona functio
P08416977A0892 |85 92|Mono Q.0 Pharm
P08416977A0892 |40 45|CTDK2phosp
P08416977A0892 |30 35|CTDK1 alka
P08416977A0892 |67 81|chromatographydase P00008171
P08416977A0892 |6 17|CTD kinases606T0076 Co
P08417117A0592 |9 13|mRNAT007
P08417117A0592 |29 31|kbh 
P08417117A0592 |56 65|abundance 5-nucleo
P08417330A0149 |34 51|promoter fragmentaline phosphatase
P08417330A0149 |125 148|CYC1-lacZ reporter generbilirubinemia. P000089
P08417330A0149 |167 169|N.CO
P08417330A0149 |53 63|oligo31/32and 5-nucl
P08417330A0149 |81 104|heat shock inducibilityT0000 Pharmacologic asp
P08417331A0745 |68 75|repeatsase P00
P08417331A0745 |20 29|HIR1 generison wit
P08417331A0745 |179 183|Tup1wn a
P08417331A0745 |126 136|transducinbilirubine
P08417331A0745 |146 151|yeast8997A
P08417331A0745 |168 177|repressorO3-] is s
P08417331A0745 |81 86|motifT0000
P08417331A0745 |4 12|sequence01606T00
P08417331A0745 |49 56|proteinses and
P08417331A0745 |100 114|G beta subunit aspects of ne
P08417349A1633 |139 156|mutation fixation. P00008997A0472 
P08417349A1633 |13 17|data6 Co
P08417349A1633 |31 42|replicationalkaline ph
P08417349A1633 |57 66|templates5-nucleot
P08417349A1633 |116 127|replicationatal hyperb
P08418183A0000 |305 306|Hg
P08418183A0000 |159 180|Miyazaki Cohort Studyn CSF [HCO3-] is show
P08418183A0000 |189 197|Novembernction o
P08418183A0000 |295 296|H 
P08418183A0000 |298 299|Wv
P08418183A0000 |264 265|H 
P08418183A0000 |268 272|wifepare
P08418183A0000 |135 142|couplesemia. P
P08418183A0000 |75 110|T cell leukemia/lymphoma virus type008171T0000 Pharmacologic aspects o
P08418183A0000 |323 324|Wr
P08418183A0000 |114 120|HTLV-Ionatal
P08418183A0000 |320 321|Ha
P08418183A0000 |53 65|transmissionand 5-nucleo
P08418183A0000 |308 309|Wf
P08418183A0000 |12 19|factors76 Comp
P08418183A0000 |287 288|Wu
P08418183A0000 |235 242|husband are no
P08418183A0000 |207 212|April the 
P08419318A1695 |0 4|BiolP000
P08419333A0126 |101 106|cloneaspec
P08419333A0126 |20 30|expressionrison with
P08419333A0126 |39 56|DNA repair enzyme phosphatases and
P08419338A0273 |0 2|L.P0
P08419338A0273 |63 65|A.eo
P08419338A0273 |91 93|H.ma
P08419338A0273 |31 36|Biberalkal
P08419338A0273 |12 14|G.76
P08419338A0273 |84 89|Murer00 Ph
P08419338A0273 |16 25|Markovichomparison
P08419338A0273 |50 52|X.es
P08419338A0273 |54 61|Zorzanond 5-nu
P08419338A0273 |27 29|D.it
P08419338A0273 |67 74|Palacindase P0
P08419338A0273 |42 48|Testarosphat
P08419338A0273 |76 78|M.08
P08419338A0273 |38 40|J.e 
P08419338A0273 |4 10|Stange01606T
P08419376A0357 |84 87|kDa00 
P08419376A0357 |125 132|domainsrbiliru
P08419376A0357 |47 58|polypeptidetases and 5
P08419376A0357 |31 35|genealka
P08419376A0357 |66 77|amino acidsidase P0000
P08419376A0357 |4 23|nucleotide sequence01606T0076 Comparis
P08420230A0544 |0 5|SAECGP0000
P08420230A0544 |77 82|month8171T
P08420230A0544 |28 48|thallium-201 imagingth alkaline phosphat
P08420230A0544 |7 23|echocardiography06T0076 Comparis
P08420230A0544 |99 110|angioplastyc aspects o
P08420571A1880 |17 22|PACE4mpari
P08420571A1880 |27 30|PC4ith
P08421295A0365 |98 122|4ACAG consensus sequenceic aspects of neonatal h
P08421295A0365 |42 51|complexesosphatase
P08421295A0365 |130 144|LexA repressorrubinemia. P00
P08421295A0365 |90 94|CTGTrmac
P08421295A0365 |5 20|fusion proteins1606T0076 Compa
P08421295A0365 |65 75|DNA duplextidase P00
P08421687A0397 |4 27|selenocysteine residues01606T0076 Comparison w
P08421823A1041 |68 76|patientsase P000
P08421823A1041 |127 136|conditionilirubine
P08421823A1041 |90 97|absencermacolo
P08421823A1041 |18 38|protein S deficiencyparison with alkalin
P08421823A1041 |0 11|CONCLUSIONSP00001606T0
P08421897A0000 |34 39|typesaline
P08421897A0000 |106 112|genomets of 
P08421897A0000 |65 74|sequencestidase P0
P08421897A0000 |163 173|DNA probesF [HCO3-] 
P08421897A0000 |128 152|stringency hybridizationlirubinemia. P00008997A0
P08421897A0000 |200 223|animal retrovirus genesSF PCO2 the data of K-d
P08421897A0000 |16 22|decadeompari
P08421910A0599 |69 72|p46se 
P08421910A0599 |27 36|complexesith alkal
P08421910A0599 |149 171|uv cross-linking assay7A0472 When CSF [HCO3-
P08421910A0599 |74 77|p50000
P08421910A0599 |120 127|TAR RNA hyperb
P08421910A0599 |52 57|TRBPs and 
P08421910A0599 |7 17|components06T0076 Co
P08421910A0599 |59 62|p30nuc
P08421910A0599 |83 86|p56000
P08421910A0599 |64 67|p37oti
P08422975A1205 |48 74|kinetoplastid mitochondriaases and 5-nucleotidase P0
P08422975A1205 |37 44|editingne phos
P08422975A1205 |108 113|mRNAs of n
P08422975A1205 |82 91|formation0000 Phar
P08422975A1205 |23 32|necessityon with a
P08423831A0523 |16 21|modelompar
P08423831A0523 |95 103|diseaseslogic as
P08423831A0523 |147 157|parameters997A0472 W
P08423831A0523 |73 79|issues000081
P08423831A0523 |4 7|use016
P08423831A0523 |139 143|sets. P0
P08425050A0898 |140 148|sequence P000089
P08425050A0898 |46 50|rpeAatas
P08425050A0898 |121 125|datehype
P08425050A0898 |61 68|repeatscleotid
P08425050A0898 |22 28|repeatson wi
P08425050A0898 |97 107|PE operonsgic aspect
P08425221A0000 |153 158|cells72 Wh
P08425221A0000 |128 137|B lineagelirubinem
P08425221A0000 |56 59|BPK 5-
P08425221A0000 |61 85|B cell progenitor kinasecleotidase P00008171T000
P08425221A0000 |114 120|stagesonatal
P08425221A0000 |32 47|tyrosine kinaselkaline phospha
P08427501A0221 |173 179|polypsis sho
P08427501A0221 |30 36|groups alkal
P08427501A0221 |210 216|polypse data
P08427501A0221 |74 89|enzyme activity0008171T0000 Ph
P08427501A0221 |194 199|typesn of 
P08427501A0221 |107 122|enzyme activitys of neonatal h
P08427501A0221 |6 17|differences606T0076 Co
P08428722A1123 |34 43|variablesaline pho
P08428722A1123 |89 114|blood urea nitrogen levelarmacologic aspects of ne
P08428722A1123 |226 231|scoreeted 
P08428722A1123 |210 213|agee d
P08428722A1123 |20 28|analysisrison wi
P08428722A1123 |197 208|peritonitisf CSF PCO2 
P08428722A1123 |79 87|survival71T0000 
P08428722A1123 |116 154|serum aspartate aminotransferase levelatal hyperbilirubinemia. P00008997A047
P08428722A1123 |236 241|ileusare n
P08428750T0000 |0 12|LocalizationP00001606T00
P08428750T0000 |31 35|genealka
P08428750T0000 |63 74|protein CLPeotidase P0
P08428750T0000 |84 104|chromosome 10p13-ter00 Pharmacologic asp
P08428907A0653 |108 111|RNA of
P08428907A0653 |31 45|OBP transcriptalkaline phosp
P08428907A0653 |13 25|stage larvae6 Comparison
P08428940A1763 |49 56|hexamerses and
P08428940A1763 |193 202|merR mRNAon of CSF
P08428940A1763 |104 108|MerRects
P08428940A1763 |60 62|PRuc
P08428940A1763 |113 127|RNA polymeraseeonatal hyperb
P08428940A1763 |179 189|initiationwn as a fu
P08428940A1763 |9 15|mutantT0076 
P08428940A1763 |141 147|resultP00008
P08428940A1763 |86 95|occupancy Pharmaco
P08428952A0399 |119 129|expressionl hyperbil
P08428952A0399 |177 184|tissueshown as
P08428952A0399 |42 47|typesospha
P08428952A0399 |92 98|originacolog
P08428952A0399 |9 18|L-plastinT0076 Com
P08428952A0399 |67 72|cellsdase 
P08428952A0399 |154 167|tumorigenesis2 When CSF [H
P08428952A1957 |34 41|fimbrinaline p
P08428952A1957 |20 28|evidencerison wi
P08428952A1957 |62 77|plastin isoformleotidase P0000
P08428952A1957 |138 147|intestinea. P00008
P08428952A1957 |118 124|levelsal hyp
P08428953A1718 |98 107|frequencyic aspect
P08428953A1718 |123 131|coloniesperbilir
P08428953A1718 |62 89|reporter beta-galactosidaseleotidase P00008171T0000 Ph
P08428953A1718 |210 218|promotere data o
P08428953A1718 |363 371|colonies3 Fluraz
P08428953A1718 |401 412|fibroblastsective hypn
P08428953A1718 |166 175|L-plastinHCO3-] is
P08428953A1718 |44 54|expressionphatases a
P08428953A1718 |195 203|contrast of CSF 
P08428953A1718 |257 265|coloniesed when 
P08428953A1718 |147 152|cells997A0
P08428953A1718 |337 347|activation+/- 0.23 v
P08428953A1718 |276 287|fibroblasts controls b
P08428953A1718 |435 455|L-plastin expressionmum dose for use in 
P08428953A1718 |311 320|frequencyantly gre
P08428953A1718 |5 13|promoter1606T007
P08428965A1868 |35 58|CBP/tk binding activityline phosphatases and 5
P08428965A1868 |91 93|h.ma
P08428965A1868 |120 125|WORDS hype
P08428965A1868 |94 102|ABSTRACTologic a
P08428965A1868 |4 13|half-life01606T007
P08429019A0735 |4 9|DNase01606
P08429019A0735 |41 56|silencer regionhosphatases and
P08429019A0735 |12 21|footprint76 Compar
P08429019A0735 |107 112|motifs of 
P08429019A0735 |135 137|bpem
P08429019A0735 |80 86|repeat1T0000
P08429019A0735 |159 164|basesn CSF
P08429019A0735 |145 151|shares08997A
P08429019A0735 |114 121|epsilononatal 
P08429019A0735 |174 199|GATA-1 consensus sequences shown as a function of 
P08429019A2022 |102 112|competitorspects of 
P08429019A2022 |75 92|protein B binding008171T0000 Pharm
P08429019A2022 |39 61|YY1 consensus sequence phosphatases and 5-nu
P08429019A2022 |13 23|competitor6 Comparis
P08429019A2022 |134 164|yeast ABF-1 consensus sequencenemia. P00008997A0472 When CSF
P08429019A2022 |174 182|ABSTRACTs shown 
P08429019A2022 |200 205|WORDSSF PC
P08429020A0495 |70 73|DNAe P
P08429020A0495 |95 108|reading framelogic aspects
P08429020A0495 |57 66|kilobases5-nucleot
P08429020A0495 |158 162|exonen C
P08429020A0495 |113 125|glycoproteineonatal hype
P08429020A0495 |24 29|exonsn wit
P08429020A0495 |4 8|gene0160
P08429020A0495 |38 45|intronse phosp
P08429568A0000 |0 18|Rhizobium melilotiP00001606T0076 Com
P08429568A0000 |149 156|ability7A0472 
P08429568A0000 |25 41|plasmid pRmeGR4b with alkaline p
P08429568A0000 |111 132|nodulation efficiency neonatal hyperbiliru
P08429568A0000 |160 170|strain GR4 CSF [HCO3
P08429568A0000 |54 90|nodulation competitiveness locus nfend 5-nucleotidase P00008171T0000 Pha
P08429568A0000 |174 187|alfalfa rootss shown as a 
P08430087A0467 |48 60|gamma chainsases and 5-n
P08430087A0467 |106 125|beta gamma activityts of neonatal hype
P08430087A0467 |13 20|ability6 Compa
P08430087A0467 |96 102|assaysogic a
P08430087A0467 |36 40|betaine 
P08430087A0467 |177 186|fractionshown as a
P08430087A0467 |143 160|membrane extracts0008997A0472 When
P08430087A0467 |201 210|Sf9 cellsF PCO2 th
P08430095A0161 |5 11|report1606T0
P08430095A0161 |46 50|geneatas
P08430095A0161 |62 70|functionleotidas
P08430095A0161 |104 109|PRP38ects 
P08430095A0161 |72 76|SMD1P000
P08430095A0161 |26 40|identificationwith alkaline 
P08430095A0913 |102 118|snRNA maturationspects of neonat
P08430095A0913 |123 132|stabilityperbiliru
P08430095A0913 |67 85|splicing apparatusdase P00008171T000
P08430095A0913 |92 98|factoracolog
P08430095A0913 |41 50|componenthosphatas
P08430095A0913 |6 10|data606T
P08430095A0913 |21 26|Smd1pison 
P08431100A0108 |186 200|children group function of C
P08431100A0108 |213 216|ageata
P08431100A0108 |128 132|lossliru
P08431100A0108 |166 171|hoursHCO3-
P08431100A0108 |91 99|childrenmacologi
P08431100A0108 |39 56|motor performance phosphatases and
P08431100A0108 |5 10|study1606T
P08431100A0108 |112 117|yearsneona
P08431100A0108 |136 149|consciousnessmia. P0000899
P08431100A0108 |221 224|sex-de
P08432137A0000 |35 54|adenosine deaminaseline phosphatases a
P08432137A0000 |80 88|patients1T0000 P
P08432137A0000 |249 252|IFN di
P08432137A0000 |145 153|lysozyme08997A04
P08432137A0000 |95 115|PADA/serum ADA ratiologic aspects of neo
P08432137A0000 |56 60|PADA 5-n
P08432137A0000 |177 197|PLYS/serum LYS ratiohown as a function o
P08432137A0000 |211 216|cases data
P08432137A0000 |165 170|cases[HCO3
P08432137A0000 |326 335|effusionslope (1.2
P08432137A0000 |258 263|casesd whe
P08432137A0000 |16 26|parametersomparison 
P08432137A0000 |117 123|P/SADAtal hy
P08432137A0000 |155 159|PLYS Whe
P08432137A0000 |129 134|casesirubi
P08432137A0000 |281 288|abilityrols bu
P08432137A0000 |199 205|P/SLYSCSF PC
P08432137A0000 |231 247|interferon gammarats are no long
P08432137A0000 |341 347|others0.23 v
P08432526A0580 |117 140|fibroblast cDNA librarytal hyperbilirubinemia.
P08432526A0580 |72 111|polymerase chain reaction amplificationP00008171T0000 Pharmacologic aspects of
P08432526A0580 |43 59|sequencing cDNAssphatases and 5-
P08432526A0580 |6 11|exons606T0
P08432696A1117 |68 79|proteinasesase P000081
P08432696A1117 |143 154|cell growth0008997A047
P08432696A1117 |97 113|aminopeptidase Ngic aspects of n
P08432696A1117 |133 139|effectinemia
P08432696A1117 |50 58|deletiones and 5
P08432696A1117 |16 25|apeA geneomparison
P08432696A1117 |81 89|proteaseT0000 Ph
P08432696A1117 |170 175|media-] is
P08432696A1117 |0 8|DeletionP0000160
P08435755A0938 |85 86|h0
P08435755A0938 |133 136|ratine
P08435755A0938 |54 59|mg/kgnd 5-
P08435755A0938 |110 121|stimulationf neonatal 
P08435755A0938 |148 163|stage-3 seizure97A0472 When CS
P08435755A0938 |3 13|Experiment001606T007
P08435755A0938 |16 40|scopolamine hydrobromideomparison with alkaline 
P08435755A1078 |51 64|kindling rates and 5-nucle
P08435755A1078 |179 185|valueswn as 
P08435755A1078 |130 137|stage-3rubinem
P08435755A1078 |41 49|kindlinghosphata
P08435755A1078 |88 96|seizuresharmacol
P08435755A1078 |73 80|stage-30000817
P08435755A1078 |13 16|BSS6 C
P08435755A1078 |98 116|seizure parametersic aspects of neon
P08435755A1078 |5 8|ADD160
P08435755A1078 |213 218|groupata o
P08435755A1078 |32 37|stagelkali
P08435755A1078 |0 3|PNTP00
P08435794A0658 |0 11|CONCLUSIONSP00001606T0
P08435885A0787 |21 32|correlationison with a
P08435885A0787 |41 72|pyridinium cross-link excretionhosphatases and 5-nucleotidase 
P08435885A0787 |77 107|thyroid hormone concentrations8171T0000 Pharmacologic aspect
P08437521A0000 |0 9|MutationsP00001606
P08437521A0000 |230 242|areA product rats are no
P08437521A0000 |215 222|abilitya of K-
P08437521A0000 |106 115|areA genets of neo
P08437521A0000 |286 298|areA controlbut still ha
P08437521A0000 |47 55|residuestases an
P08437521A0000 |81 90|activatorT0000 Pha
P08437521A0000 |173 181|nidulansis shown
P08437521A0000 |127 157|nitrogen metabolite repressionilirubinemia. P00008997A0472 W
P08437521A0000 |255 265|expressionaced when 
P08437521A0000 |274 279|genesto co
P08437737A0100 |0 15|Naval personnelP00001606T0076 
P08437737A0100 |74 78|duty0008
P08437737A0100 |41 44|%BFhos
P08437737A0100 |27 36|standardsith alkal
P08438584A0524 |100 108|promoter aspects
P08438584A0524 |60 62|C1uc
P08438584A0524 |67 74|C2 ORFsdase P0
P08438584A0524 |76 86|C1-C2 gene08171T0000
P08438584A0524 |44 52|promoterphatases
P08438584A0524 |5 22|promoter activity1606T0076 Compari
P08438584A0524 |116 122|V1 ORFatal h
P08438584T0000 |101 120|C1-C2 gene productsaspects of neonatal
P08438584T0000 |61 73|mosaic viruscleotidase P
P08438584T0000 |20 41|coat protein promoterrison with alkaline p
P08438584T0000 |4 12|activity01606T00
P08439564A0883 |170 171|%-
P08439564A0883 |133 152|porcine haptocorrininemia. P00008997A0
P08439564A0883 |62 82|Cbl binding proteinsleotidase P00008171T
P08439564A0883 |180 188|homologyn as a f
P08439564A0883 |4 33|amino acid sequence alignment01606T0076 Comparison with al
P08439564A0883 |112 128|transcobalamin Ineonatal hyperbi
P08439564A0883 |37 39|TCne
P08439564A0883 |98 104|factoric asp
P08439564A0883 |84 87|rat00 
P08439597A0000 |86 90|FEIA Pha
P08439597A0000 |150 163|determinationA0472 When CS
P08439597A0000 |124 141|fluoroimmunoassayerbilirubinemia. 
P08439597A0000 |11 24|communication076 Compariso
P08439597A0000 |167 178|thyrotropinCO3-] is sh
P08439597A0000 |66 84|enzyme immunoassayidase P00008171T00
P08439597A0000 |188 199|blood spotsunction of 
P08439597A0176 |102 119|screening centresspects of neonata
P08439597A0176 |77 90|blood samples8171T0000 Pha
P08439597A0176 |4 14|evaluation01606T0076
P08439597A0176 |51 63|study designs and 5-nucl
P08440238T0000 |16 26|C-terminusomparison 
P08440238T0000 |147 157|modulation997A0472 W
P08440238T0000 |73 84|association00008171T00
P08440238T0000 |194 207|tumorigenesisn of CSF PCO2
P08440238T0000 |45 56|E1a proteinhatases and
P08440238T0000 |30 40|adenovirus alkaline 
P08440238T0000 |212 222|metastasisdata of K-
P08440238T0000 |178 192|transformationown as a funct
P08440238T0000 |161 168|T24-rasCSF [HC
P08440238T0000 |101 115|phosphoproteinaspects of neo
P08440238T0000 |2 8|region000160
P08440688A1509 |103 109|growthpects 
P08440688A1509 |132 147|hormone signalsbinemia. P00008
P08440688A1509 |6 13|studies606T007
P08440688A1509 |111 126|differentiation neonatal hyper
P08440688A1509 |46 51|genesatase
P08440688A1509 |36 43|G alphaine pho
P08440688A1509 |81 94|LLC-PK1 cellsT0000 Pharmac
P08440720A1404 |0 10|ConstructsP00001606T
P08440720A1404 |99 104|levelc asp
P08440720A1404 |38 48|PfCPK cDNAe phosphat
P08440720A1404 |138 145|proteina. P000
P08441379A0912 |51 57|regions and 
P08441379A0912 |126 131|virusbilir
P08441379A0912 |135 152|enhancer elementsemia. P00008997A0
P08441379A0912 |251 271|IL-1 beta expressionisplaced when compar
P08441379A0912 |20 36|proIL-1 beta caprison with alkal
P08441379A0912 |202 212|HeLa cells PCO2 the 
P08441379A0912 |98 110|proIL-1 betaic aspects o
P08441379A0912 |184 193|monocytes a functi
P08441394A1297 |38 65|signal transduction pathwaye phosphatases and 5-nucleo
P08441394A1297 |11 17|PC-PLC076 Co
P08441394A1297 |132 137|c-mycbinem
P08441394A1297 |104 108|junBects
P08441394A1297 |77 90|transcription8171T0000 Pha
P08441394A1297 |160 169|PKC-delta CSF [HCO
P08441394A1297 |94 99|c-fosologi
P08441394A1297 |23 32|componenton with a
P08441394A1297 |174 188|Ras activations shown as a f
P08441411A1260 |35 51|Gfi-1 expressionline phosphatase
P08441411A1260 |300 307|S phase a sign
P08441411A1260 |241 249|receptoro longer
P08441411A1260 |185 191|eventsa func
P08441411A1260 |81 92|stimulationT0000 Pharm
P08441411A1260 |115 121|levelsnatal 
P08441411A1260 |22 33|splenocytesson with al
P08441411A1260 |212 223|interactiondata of K-d
P08441411A1260 |270 280|transitionred to con
P08441411A1260 |227 231|IL-2ted 
P08441411A1260 |73 74|h0
P08441411A1260 |290 292|G1st
P08441411A1260 |131 132|hu
P08441411A1260 |315 325|cell cycley greater 
P08441423A0145 |48 58|GCD7 genesases and 5
P08441423A0145 |113 129|GCN4 translationeonatal hyperbil
P08441423A0145 |150 160|conditionsA0472 When
P08441423A0145 |39 43|GCD6 pho
P08441423A0145 |80 88|products1T0000 P
P08441869A0334 |55 63|relationd 5-nucl
P08441869A0334 |4 21|plateau MO2 value01606T0076 Compar
P08442384A0430 |152 170|amino acid peptide472 When CSF [HCO3
P08442384A0430 |115 121|leadernatal 
P08442384A0430 |80 93|reading frame1T0000 Pharma
P08442384A0430 |95 99|uORFlogi
P08442384A0430 |35 42|proteinline ph
P08442384A0430 |50 61|amino acidses and 5-nu
P08442384T0000 |48 54|leaderases a
P08442384T0000 |73 86|reading frame00008171T0000
P08442384T0000 |4 28|SCH9 protein kinase mRNA01606T0076 Comparison wi
P08443122A0657 |87 90|PMAPha
P08443122A0657 |27 60|fibroblasts PILOT gene expressionith alkaline phosphatases and 5-n
P08443122A0657 |79 85|signal71T000
P08443122A0657 |15 22|T cellsCompari
P08443122A0657 |115 118|CyAnat
P08443122A0657 |3 11|contrast001606T0
P08443339A1374 |119 125|cortexl hype
P08443339A1374 |43 60|promoter functionsphatases and 5-n
P08443339A1374 |14 26|localization Comparison 
P08443339A1374 |30 33|GUS al
P08443339A1374 |155 159|root Whe
P08443339A1374 |64 78|leaf epidermisotidase P00008
P08443339A1374 |80 89|mesophyll1T0000 Ph
P08443339A1374 |139 147|cylinder. P00008
P08443339A1374 |103 110|bundlespects o
P08443340A0522 |34 53|expression patternsaline phosphatases 
P08443340A0522 |196 206|expressionof CSF PCO
P08443340A0522 |122 136|glucanase geneyperbilirubine
P08443340A0522 |241 255|tobacco plantso longer displ
P08443340A0522 |164 167|GUS [H
P08443340A0522 |216 226|constructs of K-depl
P08443340A0522 |80 96|promoter regions1T0000 Pharmacol
P08443340A0522 |144 162|beta-glucuronidase008997A0472 When C
P08443340A0522 |3 8|order00160
P08443340A0522 |169 182|reporter gene3-] is shown 
P08443341A0384 |119 138|MA type myrosinasesl hyperbilirubinemi
P08443341A0384 |92 106|MB cDNA clonesacologic aspec
P08443341A0384 |29 35|probesh alka
P08443341A0384 |183 202|MB type myrosinasess a function of CSF
P08443341A0384 |240 248|B. napusno longe
P08443341A0384 |48 56|portionsases and
P08443341A0384 |231 236|genesrats 
P08443341A0384 |76 87|B. napus MA08171T0000 
P08443341A0384 |170 175|genes-] is
P08443341A0384 |0 22|Southern blot analysisP00001606T0076 Compari
P08444184A0245 |0 9|SudomoinaP00001606
P08444184A0245 |11 13|A.07
P08444344A0000 |0 12|Zinc fingersP00001606T00
P08444344A0000 |14 16|Zf C
P08444344A0000 |42 47|motifospha
P08444344A0000 |83 91|proteins000 Phar
P08444345A0403 |87 88|%P
P08444345A0403 |160 164|DbpB CSF
P08444345A0403 |56 57|% 
P08444345A0403 |26 36|amino acidwith alkal
P08444345A0403 |123 136|family memberperbilirubine
P08444345A0403 |149 158|protein B7A0472 Wh
P08444345A0403 |38 40|aae 
P08444345A0403 |42 50|sequenceosphatas
P08444345A0403 |108 120|EFIA/DbpB/YB of neonatal
P08444345A0403 |71 79|rat EFIA P000081
P08444345A0403 |19 23|EFIAaris
P08445299T0000 |0 6|EffectP00001
P08445299T0000 |57 71|ozone toxicity5-nucleotidase
P08445299T0000 |75 79|rats0081
P08445299T0000 |19 31|insufflationarison with 
P08445299T0000 |35 47|deferoxamineline phospha
P08445655A1009 |0 12|LocalizationP00001606T00
P08445655A1009 |43 55|yeast genomesphatases an
P08445655A1009 |60 83|complementation studiesucleotidase P00008171T0
P08445655A1009 |144 153|mutations008997A04
P08445655A1009 |20 35|insertion locusrison with alka
P08445729A0657 |51 55|ARMss an
P08445729A0657 |71 78|stretch P00008
P08445729A0657 |82 90|sequence0000 Pha
P08445729A0657 |104 115|RNA bindingects of neo
P08445729A0657 |19 34|spacer sequencearison with alk
P08445729A0657 |0 11|ReplacementP00001606T0
P08445792A0469 |0 4|TypeP000
P08445792A0469 |123 129|stagesperbil
P08445792A0469 |142 149|species0000899
P08445792A0469 |42 47|formsospha
P08445792A0469 |57 60|IIB5-n
P08445792A0469 |98 105|speciesic aspe
P08445792A0469 |49 52|IIAses
P08446579A0784 |139 156|activating domain. P00008997A0472 
P08446579A0784 |89 93|cellarma
P08446579A0784 |12 39|transcription factor Gal-ER76 Comparison with alkaline
P08446579A0784 |164 188|herpesvirus protein VP16 [HCO3-] is shown as a f
P08446579A0784 |198 208|C terminus CSF PCO2 
P08446579A0784 |108 117|variation of neona
P08446579A1210 |54 60|levelsnd 5-n
P08446579A1210 |14 22|fos gene Compari
P08446579A1210 |72 74|hrP0
P08446579A1210 |78 95|estrogen addition171T0000 Pharmaco
P08447005T0001 |0 11|EliminationP00001606T0
P08447005T0001 |62 74|introductionleotidase P0
P08447005T0001 |27 55|influenzae type b meningitisith alkaline phosphatases an
P08447005T0001 |78 89|vaccination171T0000 Ph
P08449133A0578 |0 14|EndosonographyP00001606T0076
P08449133A0578 |58 67|T2 tumors-nucleoti
P08449133A0578 |72 81|T3 tumorsP00008171
P08449133A0578 |93 102|T4 tumorscologic a
P08449133A0578 |35 50|tumor extensionline phosphatas
P08449943A0225 |69 78|8-Cl-cAMPse P00008
P08449943A0225 |151 165|leukemia cells0472 When CSF 
P08449943A0225 |15 20|studyCompa
P08449943A0225 |125 130|HL-60rbili
P08449943A0225 |106 121|kinase isozymests of neonatal 
P08449943A0225 |46 55|mechanismatases an
P08449943A0225 |59 65|actionnucleo
P08449943A0225 |86 96|regulation Pharmacol
P08449978A0000 |0 8|AnalysisP0000160
P08449978A0000 |12 33|cell cycle regulation76 Comparison with al
P08449978A0000 |149 156|changes7A0472 
P08449978A0000 |132 137|Cdc28binem
P08449978A0000 |268 273|timespared
P08449978A0000 |181 191|cell cycle as a func
P08449978A0000 |116 130|protein kinaseatal hyperbili
P08449978A0000 |231 238|cyclinsrats ar
P08449978A0000 |160 168|activity CSF [HC
P08449978A0000 |49 54|yeastses a
P08449978A0000 |221 227|groups-deple
P08449986A0455 |54 63|MMI alphand 5-nucl
P08449986A0455 |44 49|cDNAsphata
P08449986A0455 |12 18|clones76 Com
P08449986A0455 |83 94|mouse brain000 Pharmac
P08450015A0175 |69 77|standardse P0000
P08450015A0175 |148 178|n-propyl carbamate derivatives97A0472 When CSF [HCO3-] is sh
P08450015A0175 |45 55|oxiracetamhatases an
P08450015A0175 |83 89|plasma000 Ph
P08450015A0175 |129 138|formationirubinemi
P08450015A0175 |93 115|solid-phase extractioncologic aspects of neo
P08450015A0175 |4 10|method01606T
P08450015A0175 |32 41|isolationlkaline p
P08451187A0267 |28 39|differencesth alkaline
P08451187A0267 |60 73|ars sequencesucleotidase P
P08451331T0000 |0 8|PathwaysP0000160
P08451331T0000 |126 130|micebili
P08451331T0000 |31 36|bulbsalkal
P08451331T0000 |112 122|aggressionneonatal h
P08451331T0000 |71 83|hypothalamus P00008171T0
P08453101A0128 |0 16|Pokeweed mitogenP00001606T0076 C
P08453101A0128 |80 84|mRNA1T00
P08453101A0128 |96 103|T cellsogic as
P08453101A0128 |59 78|c-jun messenger RNAnucleotidase P00008
P08453101A0128 |18 21|PWMpar
P08453101A0128 |86 92|levels Pharm
P08453950A0498 |51 56|mm Hgs and
P08453950A0498 |29 33|MABPh al
P08453950A0498 |61 70|brain pHicleotidas
P08453950A0498 |143 144|P0
P08453950A0498 |128 133|levellirub
P08453950A0498 |10 27|seizure induction0076 Comparison w
P08453950A0498 |140 141|h 
P08453950A0498 |103 106|minpec
P08454077A0956 |3 11|contrast001606T0
P08454077A0956 |124 128|GMBFerbi
P08454077A0956 |301 304|GMVa s
P08454077A0956 |159 162|minn C
P08454077A0956 |213 216|minata
P08454077A0956 |385 392|normalsars to 
P08454077A0956 |28 35|U74500Ath alka
P08454077A0956 |328 335|musclespe (1.2
P08454077A0956 |236 237|pa
P08454077A0956 |39 58|mg/kg i.v. infusion phosphatases and 5
P08454077A0956 |308 309|%f
P08454077A0956 |377 379|NShu
P08454077A0956 |439 444|WORDSdose 
P08454077A0956 |186 189|min fu
P08454077A0956 |249 257|controls displac
P08454077A0956 |13 17|rats6 Co
P08454077A0956 |285 299|muscle salvage but still hav
P08454077A0956 |153 155|PI72
P08454077A0956 |86 103|revascularisation Pharmacologic as
P08454077A0956 |262 269|normalsen comp
P08454077A0956 |399 410|h ischaemiaffective hy
P08454077A0956 |413 421|ABSTRACTtic drug
P08454077A0956 |350 358|controlsP0001094
P08454077A0956 |73 76|min000
P08454077A0956 |337 338|p+
P08454077A0956 |140 151|reperfusion P00008997A
P08454591A0692 |0 10|SequencingP00001606T
P08454591A0692 |130 154|transcription start siterubinemia. P00008997A047
P08454591A0692 |106 120|CAAT sequencests of neonatal
P08454591A0692 |29 37|fragmenth alkali
P08454591A0692 |57 63|region5-nucl
P08454591A0692 |71 80|TSG6 gene P0000817
P08454591A1322 |137 144|NF-IL-6ia. P00
P08454591A1322 |24 36|inducibilityn with alkal
P08454591A1322 |95 108|binding siteslogic aspects
P08454591A1322 |40 44|IL-1phos
P08454591A1322 |113 118|IRF-1eonat
P08454591A1322 |53 62|positionsand 5-nuc
P08454591A1322 |127 131|AP-1ilir
P08454591A1322 |4 10|region01606T
P08454591A1322 |48 51|TNFase
P08454858A0285 |102 111|associatespects of
P08454858A0285 |13 20|Ig-beta6 Compa
P08454858A0285 |185 204|signal transductiona function of CSF P
P08454858A0285 |71 82|amino acids P00008171T
P08454858A0285 |129 138|effectorsirubinemi
P08454858A0285 |50 59|structurees and 5-
P08454858A0285 |0 8|Ig-alphaP0000160
P08455598A0000 |156 170|mating abilityWhen CSF [HCO3
P08455598A0000 |63 76|alpha * cellseotidase P000
P08455598A0000 |209 219|repressionhe data of
P08455598A0000 |88 111|a/alpha aar1-6 genotypeharmacologic aspects of
P08455598A0000 |176 182|resultshown 
P08455598A0000 |198 206|a1-alpha CSF PCO
P08455598A0000 |124 144|alpha mating abilityerbilirubinemia. P00
P08455598A0000 |8 15|mutants6T0076 
P08455598A0000 |188 194|defectunctio
P08455611A0000 |170 181|globin gene-] is shown
P08455611A0000 |126 131|HS-40bilir
P08455611A0000 |26 37|interactionwith alkali
P08455611A0000 |62 66|zetaleot
P08455611A0000 |163 167|zetaF [H
P08455611A0000 |144 146|kb00
P08455611A0000 |93 105|alpha globincologic aspe
P08455611A0000 |117 124|elementtal hyp
P08455611A0000 |69 84|globin promoterse P00008171T00
P08455611A0154 |137 147|K562 cellsia. P00008
P08455611A0154 |109 133|globin promoter activityof neonatal hyperbilirub
P08455611A0154 |26 42|expression assaywith alkaline ph
P08455611A0154 |162 171|cell lineSF [HCO3-
P08455611A0154 |78 86|enhancer171T0000
P08455611A0154 |198 204|origin CSF P
P08455611A0154 |48 53|HS-40ases 
P08455611A0154 |102 106|zetaspec
P08455623A0630 |153 157|GAR172 W
P08455623A0630 |135 148|proteins NOP1emia. P000089
P08455623A0630 |181 187|strain as a 
P08455623A0630 |168 173|snr10O3-] 
P08455623A0630 |67 74|speciesdase P0
P08455623A0630 |8 15|results6T0076 
P08455623A0630 |87 96|depletionPharmacol
P08455623A0630 |35 47|23S pre-rRNAline phospha
P08455629A0335 |0 9|BreitbartP00001606
P08455629A0335 |11 13|L.07
P08456378A0134 |117 122|modeltal h
P08456378A0134 |95 104|techniquelogic asp
P08456378A0134 |60 76|lymphangiographyucleotidase P000
P08456378A0134 |25 36|feasibility with alkal
P08456378A0134 |5 10|study1606T
P08456879A0000 |0 9|OBJECTIVEP00001606
P08456879A0000 |75 89|serum cotinine008171T0000 Ph
P08456879A0000 |15 22|purposeCompari
P08456879A0000 |57 71|concentrations5-nucleotidase
P08456879A0000 |117 122|bloodtal h
P08457205A0240 |169 174|cDNAs3-] i
P08457205A0240 |61 68|proteincleotid
P08457205A0240 |144 151|G alpha008997A
P08457205A0240 |9 28|amino acid sequenceT0076 Comparison wi
P08457205A0240 |88 107|% sequence identityharmacologic aspect
P08457205A0240 |159 166|G alphan CSF [
P08457205A0240 |113 122|sequenceseonatal h
P08457291A0170 |51 66|proto-oncogeness and 5-nucleot
P08457291A0170 |140 154|c-fos oncogene P00008997A047
P08457291A0170 |29 39|expressionh alkaline
P08457291A0170 |116 123|regionsatal hy
P08457291A0170 |0 9|EstradiolP00001606
P08458660A0855 |0 8|Air leadP0000160
P08458660A0855 |43 51|variablesphatase
P08458849A0364 |17 27|regulationmparison w
P08458849A0364 |97 109|ftr elementsgic aspects 
P08458849A0364 |179 183|+120wn a
P08458849A0364 |31 49|flaN transcriptionalkaline phosphata
P08458849A0364 |185 189|ftr3a fu
P08458849A0364 |71 76|sigma P000
P08458849A0364 |80 88|promoter1T0000 P
P08458849A0364 |169 173|ftr23-] 
P08458849A0364 |136 160|transcription start sitemia. P00008997A0472 When
P08458906A0827 |2 14|micrograms/l0001606T0076
P08458906A0827 |31 36|urinealkal
P08458906A0827 |74 81|persons0008171
P08459012T0000 |21 31|deficiencyison with 
P08459012T0000 |8 15|dimelia6T0076 
P08459012T0000 |39 44|tibia phos
P08459465A0257 |254 278|energy expenditure timeslaced when compared to c
P08459465A0257 |283 298|activity factorls but still ha
P08459465A0257 |95 106|calorimetrylogic aspec
P08459465A0257 |134 152|energy expenditurenemia. P00008997A0
P08459465A0257 |45 64|energy expenditureshatases and 5-nucle
P08459465A0257 |306 319|stress factornificantly gr
P08459465A0257 |71 79|patients P000081
P08459465A0257 |216 234|energy expenditure of K-depleted rat
P08459465A0257 |17 22|studympari
P08459465A0257 |186 194|equation functio
P08460270A0205 |24 34|infectionsn with alk
P08460270A0205 |47 53|larvaetases 
P08460346A0350 |71 76|study P000
P08460918A0252 |0 5|GroupP0000
P08460918A0252 |247 257|IU liter-1er displac
P08460918A0252 |146 155|bilirubin8997A0472
P08460918A0252 |123 133|impairmentperbilirub
P08460918A0252 |160 173|mumol liter-1 CSF [HCO3-] 
P08460918A0252 |319 327|patientseater sl
P08460918A0252 |50 55|groupes an
P08460918A0252 |358 376|hyperbilirubinemia3A0733 Flurazepam 
P08460918A0252 |260 265|groupwhen 
P08460918A0252 |213 241|gamma-glutamyltranspeptidaseata of K-depleted rats are n
P08460918A0252 |96 104|patientsogic asp
P08460918A0252 |383 396|mumol liter-1pears to be a
P08460918A0252 |40 48|patientsphosphat
P08460918A0252 |201 211|IU liter-1F PCO2 the
P08460918A0252 |175 195|alkaline phosphatase shown as a function
P08461946A0386 |87 101|split functionPharmacologic 
P08461946A0386 |60 68|findingsucleotid
P08461946A0386 |20 26|changerison 
P08461946A0386 |109 117|patientsof neona
P08461946A0386 |121 122|%h
P08461946A0386 |33 44|improvementkaline phos
P08461946A0386 |70 79|t1/2 timee P000081
P08461981A0882 |48 54|monthsases a
P08461981A0882 |63 68|studyeotid
P08461981A0882 |121 125|ratshype
P08461981A0882 |15 19|needComp
P08461981A0882 |27 34|animalsith alk
P08461981A0882 |80 102|regeneration phenomena1T0000 Pharmacologic a
P08463284A1531 |16 19|PKComp
P08463284A1531 |8 12|beta6T00
P08463284A1531 |26 40|p34cdc2 kinasewith alkaline 
P08463284A1531 |75 81|lamina008171
P08463284A1531 |93 102|stabilitycologic a
P08463284A1531 |110 120|cell cyclef neonatal
P08463320A1219 |204 217|SSB tetramersCO2 the data 
P08463320A1219 |57 89|gel shift assembly intermediates5-nucleotidase P00008171T0000 Ph
P08463320A1219 |123 129|G4oricperbil
P08463320A1219 |8 42|copper-phenanthroline footprinting6T0076 Comparison with alkaline ph
P08463320A1219 |145 158|SSB tetramers08997A0472 Wh
P08463320A1219 |229 238|formationd rats ar
P08463320A1219 |251 260|structureisplaced 
P08463320A1219 |187 195|additionfunction
P08463485T0000 |0 7|EffectsP000016
P08463485T0000 |62 78|oxytocin releaseleotidase P00008
P08463485T0000 |24 42|endotoxin infusionn with alkaline ph
P08464056A0000 |0 6|FingerP00001
P08464056A0000 |89 103|C2H2 type ZFPsarmacologic as
P08464056A0000 |107 121|Xenopus laeviss of neonatal 
P08464056A0000 |44 52|FAX-ZFPsphatases
P08464056A0000 |27 42|finger proteinsith alkaline ph
P08464056A0000 |67 76|subfamilydase P000
P08464056A0510 |220 233|hybridizationK-depleted ra
P08464056A0510 |244 255|chromosomesonger displ
P08464056A0510 |132 153|restriction fragmentsbinemia. P00008997A04
P08464056A0510 |178 203|field gel electrophoresisown as a function of CSF 
P08464056A0510 |8 16|evidence6T0076 C
P08464056A0510 |92 114|Southern blot analysisacologic aspects of ne
P08464056A0510 |33 45|organizationkaline phosp
P08464056A0510 |49 76|FAX-ZFP transcription unitsses and 5-nucleotidase P000
P08464924A0243 |2 10|rat cDNA0001606T
P08464924A0243 |24 29|eIF-5n wit
P08464924A0243 |114 127|eIF-5 proteinonatal hyperb
P08466864A0878 |169 181|binding site3-] is shown
P08466864A0878 |270 287|promoter activityred to controls b
P08466864A0878 |11 19|analyses076 Comp
P08466864A0878 |186 194|TGF-beta functio
P08466864A0878 |81 91|bp segmentT0000 Phar
P08466864A0878 |56 65|sequences 5-nucleo
P08466864A0878 |123 126|AMPper
P08466864A0878 |242 259|Sp1 binding sites longer displaced
P08466864A0878 |233 237|PU-1ts a
P08466864A0878 |42 52|importanceosphatases
P08466864A0878 |163 167|CREBF [H
P08466864A0878 |201 219|PMA responsivenessF PCO2 the data of
P08466864A0878 |138 161|element binding proteina. P00008997A0472 When 
P08468320A0941 |7 9|J.06
P08468475A1280 |220 243|F42A-IL-2R beta complexK-depleted rats are no 
P08468475A1280 |300 308|affinity a signi
P08468475A1280 |63 73|YT-1 cellseotidase P
P08468475A1280 |316 337|F42A binding reaction greater slope (1.21 
P08468475A1280 |143 161|IL-2R beta subunit0008997A0472 When 
P08468475A1280 |178 189|IL-2R alphaown as a fu
P08468475A1280 |79 96|IL-2R alpha chain71T0000 Pharmacol
P08468475A1280 |260 273|alpha-subunitwhen compared
P08468475A1280 |19 41|internalization assaysarison with alkaline p
P08469831T0001 |33 49|prostaglandin E1kaline phosphata
P08469831T0001 |106 111|hyperts of
P08469831T0001 |89 98|reactionsarmacolog
P08469831T0001 |129 134|stateirubi
P08469831T0001 |145 150|shock08997
P08469831T0001 |57 68|nicardipine5-nucleotid
P08469831T0001 |21 29|dynamicsison wit
P08469831T0001 |156 165|rat modelWhen CSF 
P08470021A0195 |137 151|Ignacio Chavezia. P00008997A
P08470021A0195 |124 135|Cardiologiaerbilirubin
P08470021A0195 |30 44|IgG antibodies alkaline phos
P08470021A0195 |156 167|Mexico CityWhen CSF [H
P08470021A0195 |53 70|Trypanosoma cruziand 5-nucleotidas
P08470021A0195 |82 94|blood donors0000 Pharmac
P08470021A0195 |16 26|prevalenceomparison 
P08470021A0195 |102 120|Instituto Nacionalspects of neonatal
P08470895A1617 |0 11|ExaminationP00001606T0
P08470895A1617 |29 37|sequenceh alkali
P08470895A1617 |75 83|TATA box008171T0
P08470895A1617 |48 63|mRNA start siteases and 5-nucl
P08470895A1617 |103 121|enhancer sequencespects of neonatal 
P08471241T0000 |57 61|milk5-nu
P08471241T0000 |15 24|synthesisCompariso
P08471241T0000 |75 80|women00817
P08471241T0000 |46 53|removalatases 
P08471629A0816 |152 159|peptide472 Whe
P08471629A0816 |109 122|nPKC activityof neonatal h
P08471629A0816 |41 51|C-terminushosphatase
P08471629A0816 |170 179|substrate-] is sho
P08471629A0816 |136 148|Histone IIISmia. P000089
P08471629A0816 |92 100|beta-PKCacologic
P08471629A0816 |0 15|PseudosubstrateP00001606T0076 
P08471629A0816 |68 80|PKC isotypesase P0000817
P08471796A1654 |85 99|A. caulinodans0 Pharmacologi
P08471796A1654 |30 35|model alka
P08471796A1654 |15 22|resultsCompari
P08471796A1654 |44 54|regulationphatases a
P08471796A1654 |66 81|gene expressionidase P00008171
P08472750A0999 |70 93|porcine endotoxin shocke P00008171T0000 Pharma
P08472750A0999 |132 134|pHbi
P08472750A0999 |7 23|oxide inhalation06T0076 Comparis
P08472750A0999 |176 186|activationshown as a
P08472750A0999 |149 160|attenuation7A0472 When
P08472750A0999 |54 66|hypertensionnd 5-nucleot
P08472750A0999 |116 127|oxygenationatal hyperb
P08473731A0149 |0 1|BP
P08473731A0149 |90 97|complexrmacolo
P08473731A0149 |25 34|B29 genes with alk
P08473731A0149 |108 112|sIgM of 
P08473731A0149 |46 67|alpha/beta componentsatases and 5-nucleoti
P08473731A0149 |114 121|B cellsonatal 
P08473731A0149 |16 20|mb-1ompa
P08473967T0000 |0 10|BipolarityP00001606T
P08473967T0000 |14 33|Jungian type theory Comparison with al
P08473967T0000 |42 69|Myers-Briggs Type Indicatorosphatases and 5-nucleotida
P08474438A0000 |2 9|variety0001606
P08474438A0000 |88 102|RNA polymeraseharmacologic a
P08474438A0000 |269 283|mRNA transportared to contro
P08474438A0000 |231 239|splicingrats are
P08474438A0000 |106 117|transcriptsts of neona
P08474438A0000 |166 190|RNA processing reactionsHCO3-] is shown as a fun
P08474438A0000 |202 226|pre-mRNA polyadenylation PCO2 the data of K-depl
P08474438A0000 |21 39|ribonucleoproteinsison with alkaline
P08474439A0877 |0 9|MutationsP00001606
P08474439A0877 |158 167|mutationsen CSF [H
P08474439A0877 |261 270|mutationshen compa
P08474439A0877 |249 255|muscle displ
P08474439A0877 |144 156|muscle types008997A0472 
P08474439A0877 |89 102|site mutationarmacologic a
P08474439A0877 |120 126|effect hyper
P08474439A0877 |315 325|expressiony greater 
P08474439A0877 |226 236|expressioneted rats 
P08474439A0877 |194 198|siten of
P08474439A0877 |187 192|E-boxfunct
P08474439A0877 |19 24|sitesariso
P08474439A0877 |48 54|muscleases a
P08474439A0877 |278 287|CArG siteontrols b
P08474439A0877 |337 343|muscle+/- 0.
P08474439A0877 |37 44|effectsne phos
P08474439A0877 |175 179|MEF1 sho
P08474439A0877 |70 75|cellse P00
P08474456A1041 |80 86|region1T0000
P08474456A1041 |10 31|transfection analysis0076 Comparison with 
P08474456A1041 |130 149|LyF-1 binding sitesrubinemia. P0000899
P08474456A1041 |166 177|D' activityHCO3-] is s
P08474456A1041 |43 52|mutationssphatases
P08474456A1041 |113 116|Etseon
P08474464A0348 |69 85|TR binding sitesse P00008171T000
P08474464A0348 |45 52|Rev-Erbhatases
P08474464A0348 |41 43|TRho
P08474464A0348 |21 33|relationshipison with al
P08475104A0341 |168 173|cellsO3-] 
P08475104A0341 |198 206|cyclin A CSF PCO
P08475104A0341 |133 136|htkine
P08475104A0341 |28 44|promoter elementth alkaline phos
P08475104A0341 |115 131|thymidine kinasenatal hyperbilir
P08475104A0341 |188 194|targetunctio
P08475104A0341 |215 232|p33cdk2 complexesa of K-depleted r
P08475104A0341 |86 101|G1-S activation Pharmacologic 
P08475104A0341 |138 146|promotera. P0000
P08476087A0814 |17 27|influencesmparison w
P08476087A0814 |74 83|pressures0008171T0
P08476087A0814 |107 111|mmHgs of
P08476087A0814 |57 62|range5-nuc
P08476854A0097 |0 5|DNaseP0000
P08476854A0097 |88 95|domainsharmaco
P08476854A0097 |150 160|base pairsA0472 When
P08476854A0097 |44 52|extractsphatases
P08476854A0097 |8 20|footprinting6T0076 Compa
P08476854A0097 |126 148|base pair DNA fragmentbilirubinemia. P000089
P08476854A0097 |26 35|rat liverwith alka
P08476854A0097 |114 116|P7on
P08476854A0097 |103 105|P1pe
P08479742A0985 |80 98|cell proliferation1T0000 Pharmacolog
P08479742A0985 |44 51|abilityphatase
P08479742A0985 |30 34|part alk
P08479742A0985 |132 141|processesbinemia. 
P08479742A0985 |65 68|p53tid
P08481004A0321 |34 46|endonucleasealine phosph
P08481004A0321 |8 13|clone6T007
P08482539A0913 |0 22|Northern blot analysisP00001606T0076 Compari
P08482539A0913 |41 44|RNAhos
P08482539A0913 |60 64|xylPucle
P08482539A0913 |82 92|transcript0000 Pharm
P08482539A0913 |113 118|xylaneonat
P08483412A0000 |100 109|promoters aspects 
P08483412A0000 |147 159|NifA protein997A0472 Whe
P08483412A0000 |13 27|nifH promoters6 Comparison w
P08483412A0000 |31 41|Klebsiellaalkaline p
P08483412A0000 |4 8|nifJ0160
P08483412A0000 |81 86|sigmaT0000
P08483479A1056 |102 106|micespec
P08483479A1056 |21 24|PTHiso
P08483479A1056 |29 33|cAMPh al
P08483479A1056 |76 85|calvariae08171T000
P08483479A1056 |128 133|alphalirub
P08483479A1056 |280 284|bonetrol
P08483479A1056 |46 72|collagen promoter activityatases and 5-nucleotidase 
P08483479A1056 |225 228|PTHlet
P08483479A1056 |252 276|collagen gene expressionsplaced when compared to
P08483479A1056 |173 193|elements down-streamis shown as a functi
P08483479A1056 |233 248|cAMP repressionts are no longe
P08483479A1056 |202 211|kilobases PCO2 the
P08483479A1056 |6 10|data606T
P08483479A1056 |139 156|collagen promoter. P00008997A0472 
P08484514A1536 |51 73|baseline vein diameters and 5-nucleotidase P
P08484514A1536 |28 38|isofluraneth alkalin
P08484514A1536 |81 92|stimulationT0000 Pharm
P08484689T0000 |0 10|PrevalenceP00001606T
P08484689T0000 |25 34|arthritis with alk
P08484689T0000 |90 97|declinermacolo
P08484689T0000 |60 65|womenucleo
P08484689T0000 |67 75|evidencedase P00
P08484689T0000 |50 56|factores and
P08484891A0000 |102 109|changesspects 
P08484891A0000 |224 232|memoriespleted r
P08484891A0000 |140 148|evidence P000089
P08484891A0000 |127 131|bulbilir
P08484891A0000 |31 43|conditioningalkaline pho
P08484891A0000 |55 59|ratsd 5-
P08484891A0000 |175 183|circuits shown a
P08485317A0000 |4 22|fission yeast dsk101606T0076 Compari
P08485317A0000 |108 122|protein kinase of neonatal h
P08485317A0000 |72 84|dis1 mutantsP00008171T00
P08485317A0000 |24 28|genen wi
P08485317A0000 |42 52|suppressorosphatases
P08486035T0000 |0 7|ClosureP000016
P08486035T0000 |15 39|patent ductus arteriosusComparison with alkaline
P08486035T0000 |47 55|Ligacliptases an
P08486035T0000 |66 81|minithoracotomyidase P00008171
P08486276A0419 |0 19|Sequence comparisonP00001606T0076 Comp
P08486276A0419 |149 151|TM7A
P08486276A0419 |134 147|transmembranenemia. P00008
P08486276A0419 |153 161|proteins72 When 
P08486276A0419 |53 69|protein databaseand 5-nucleotida
P08486276A0419 |188 203|chloramphenicolunction of CSF 
P08486276A0419 |266 281|symport proteinompared to cont
P08486276A0419 |213 225|tetracyclineata of K-dep
P08486276A0419 |231 241|resistancerats are n
P08486276A0419 |43 46|ORFsph
P08486276A0419 |227 229|Tcte
P08486276A0419 |98 120|% aa sequence homologyic aspects of neonatal
P08486276A0419 |205 207|CmO2
P08486705A0181 |136 149|eIF-5 proteinmia. P0000899
P08486705A0181 |28 33|eIF-5th al
P08486705A0181 |46 50|TIF5atas
P08486705A0181 |4 14|yeast gene01606T0076
P08488700A0283 |101 113|immunizationaspects of n
P08488700A0283 |24 35|hepatitis Bn with alka
P08488700A0283 |40 51|hepatitis Dphosphatase
P08488700A0283 |228 239|hepatitis Bed rats are
P08488700A0283 |166 183|blood derivativesHCO3-] is shown a
P08488700A0283 |135 143|exposureemia. P0
P08488700A0283 |188 197|educationunction o
P08488700A0283 |266 273|diseaseompared
P08488700A0283 |213 222|awarenessata of K-
P08488700A0283 |157 162|bloodhen C
P08488700A0283 |4 14|strategies01606T0076
P08490002A0620 |0 6|XyloseP00001
P08490002A0620 |91 97|breadsmacolo
P08490002A0620 |72 81|celluloseP00008171
P08490002A0620 |33 41|polymerskaline p
P08491124A0517 |34 50|mouth protectorsaline phosphatas
P08491124A0517 |164 180|mouth protectors [HCO3-] is show
P08491124A0517 |77 81|need8171
P08491124A0517 |124 133|materialserbilirub
P08491124A0517 |14 26|construction Comparison 
P08491124A0517 |110 115|costsf neo
P08491124A0517 |86 101|instrumentation Pharmacologic 
P08491383A0154 |4 17|alpha-subunit01606T0076 Co
P08491383A0154 |47 50|DNAtas
P08491383A1291 |21 34|alpha-subunitison with alk
P08491383A1291 |147 166|interaction domains997A0472 When CSF [
P08491383A1291 |78 99|transcription factors171T0000 Pharmacologi
P08491383A1291 |59 66|proteinnucleot
P08491683A0651 |117 125|prostatetal hype
P08491683A0651 |28 36|patientsth alkal
P08491683A0651 |60 68|patientsucleotid
P08491683A0651 |95 109|adenocarcinomalogic aspects 
P08491683A0651 |6 14|patients606T0076
P08492164T0000 |49 55|cortexses an
P08492164T0000 |90 96|effectrmacol
P08492164T0000 |12 24|burst firing76 Compariso
P08492164T0000 |107 127|interaction measuress of neonatal hyperb
P08492164T0000 |28 31|catth 
P08492164T0000 |57 60|age5-n
P08492164T0000 |65 81|depth dependencetidase P00008171
P08492290A0306 |50 56|mediumes and
P08492290A0306 |89 108|stability constantsarmacologic aspects
P08492290A0306 |132 140|log betabinemia.
P08492290A0306 |31 37|methodalkali
P08492290A0306 |110 118|log betaf neonat
P08492290A0306 |66 77|strength muidase P0000
P08495786A0085 |0 23|Cryopreservation strawsP00001606T0076 Comparis
P08495786A0085 |104 109|donorects 
P08495786A0085 |78 85|surface171T000
P08495786A0085 |36 41|mediaine p
P08496157A0000 |4 14|bcl-2 gene01606T0076
P08496157A0000 |88 102|carboxyl tailsharmacologic a
P08496157A0000 |129 147|splicing mechanismirubinemia. P00008
P08496157A0000 |53 61|proteinsand 5-nu
P08496184A0772 |16 29|reading frameomparison wit
P08496184A0772 |123 139|type counterpartperbilirubinemia
P08496184A0772 |73 83|chromosome00008171T0
P08496184A0772 |104 112|sequenceects of 
P08496184A0772 |37 42|clonene ph
P08496184A0772 |54 57|minnd 
P08496185A0484 |68 89|adenylate kinase genease P00008171T0000 Ph
P08496185A0484 |91 95|adk1maco
P08496185A0484 |129 140|nucleotidesirubinemia.
P08496185A0484 |59 61|S.nu
P08496185A0484 |11 18|cloning076 Com
P08496185A0484 |23 51|nucleotide sequence analysison with alkaline phosphatase
P08496185A0484 |115 121|regionnatal 
P08496475T0000 |68 80|Bacterionemaase P0000817
P08496475T0000 |82 93|matruchotii0000 Pharma
P08496475T0000 |30 43|Streptococcus alkaline pho
P08496475T0000 |0 13|CalcificationP00001606T007
P08496475T0000 |51 66|Corynebacteriums and 5-nucleot
P08496599A0310 |5 11|result1606T0
P08496599A0310 |41 49|BGP genehosphata
P08496599A0310 |94 106|mRNA speciesologic aspec
P08496599A0310 |27 35|splicingith alka
P08496601A1153 |34 46|muMIP-1 betaaline phosph
P08496601A1153 |113 131|expression studieseonatal hyperbilir
P08496601A1153 |145 156|macrophages08997A0472 
P08496601A1153 |215 228|muMIP-1 alphaa of K-deplet
P08496601A1153 |195 207|muMIP-1 beta of CSF PCO2
P08496601A1153 |51 64|muMIP-1 alphas and 5-nucle
P08496601A1153 |85 97|CK-1 element0 Pharmacolo
P08496601A1153 |258 308|growth hormone reporter gene link LPS-inducibilityd when compared to controls but still have a signi
P08496601A1153 |20 29|promotersrison wit
P08496601A1153 |320 337|promoter segmentsater slope (1.21 
P08496601A1153 |2 12|comparison0001606T00
P08496601A1153 |232 240|promoterats are 
P08496601A1153 |135 138|RAWemi
P08496601A1153 |375 398|consensus CK-1 sequence thus appears to be an 
P08496601A1153 |171 180|fragments] is show
P08496848A0692 |19 39|contrast differencesarison with alkaline
P08496848A0692 |61 74|FSE sequencescleotidase P0
P08496848A0692 |109 123|SE counterpartof neonatal hy
P08497190T0079 |0 17|Sequence analysisP00001606T0076 Co
P08497190T0079 |44 47|hyppha
P08497190T0079 |59 66|mutantsnucleot
P08497190T0079 |22 36|identificationson with alkal
P08497248A0000 |35 45|macrophageline phosp
P08497248A0000 |183 195|trophoblastss a function
P08497248A0000 |75 80|CSF-100817
P08497248A0000 |4 8|gene0160
P08497248A0000 |65 71|factortidase
P08497248A0000 |22 30|receptorson with
P08497248A0000 |168 178|phagocytesO3-] is sh
P08497248A0000 |87 106|c-fms protooncogenePharmacologic aspec
P08497259A0452 |17 38|SUP4A53T61 transcriptmparison with alkalin
P08497259A0452 |67 80|tap1-1 mutantdase P0000817
P08497259A0452 |4 9|level01606
P08497259A0452 |98 102|typeic a
P08497269A0999 |187 194|processfunctio
P08497269A0999 |198 220|translation elongation CSF PCO2 the data of 
P08497269A0999 |73 82|ribosomes00008171T
P08497269A0999 |135 139|GCN2emia
P08497269A0999 |164 175|tRNA levels [HCO3-] is
P08497269A0999 |105 114|functionscts of ne
P08497269A0999 |5 24|sequence similarity1606T0076 Compariso
P08497269A0999 |53 57|GCN1and 
P08497269A0999 |36 47|possibilityine phospha
P08497269A0999 |86 100|tRNA molecules Pharmacologic
P08497269A0999 |118 129|conjunctional hyperbil
P08497273T0000 |0 5|NF-HBP0000
P08497273T0000 |72 86|alpha enhancerP00008171T0000
P08497273T0000 |7 11|BSAP06T0
P08497273T0000 |42 56|immunoglobulinosphatases and
P08497273T0000 |106 128|B-cell differentiationts of neonatal hyperbi
P08497273T0000 |96 102|stagesogic a
P08497273T0000 |18 27|repressorparison w
P08497280A0266 |98 101|cisic 
P08497280A0266 |10 20|regulation0076 Compa
P08497280A0266 |134 152|SWI4 transcriptionnemia. P00008997A0
P08497280A0266 |120 130|regulators hyperbili
P08497280A0266 |24 28|SWI4n wi
P08497280A0266 |52 74|cell cycle progression and 5-nucleotidase P0
P08497280A1397 |103 107|SWI6pect
P08497280A1397 |92 99|absenceacologi
P08497280A1397 |66 84|SWI4 transcriptionidase P00008171T00
P08497280A1397 |39 46|pathway phosph
P08497280T0000 |35 43|elementsline pho
P08497280T0000 |52 70|SWI4 transcription and 5-nucleotidas
P08497280T0000 |83 93|cell cycle000 Pharma
P08498570A1118 |3 13|conclusion001606T007
P08498570A1118 |120 122|Ra h
P08498570A1118 |15 22|changesCompari
P08498570A1118 |77 85|hindlimb8171T000
P08498570A1118 |94 101|changesologic 
P08498570A1118 |26 51|carotid sinus stimulationwith alkaline phosphatase
P08498570A1118 |59 69|blood flownucleotida
P08498570A1118 |110 115|Pcritf neo
P08499376A0000 |49 63|predictabilityses and 5-nucl
P08499376A0000 |10 13|PRK007
P08499376A0000 |81 92|correctionsT0000 Pharm
P08499903A0883 |54 62|deletionnd 5-nuc
P08499903A0883 |44 50|originphatas
P08499903A0883 |6 14|patients606T0076
P08499903A0883 |20 29|deletionsrison wit
P08499916A0000 |4 15|COL7A1 gene01606T0076 
P08499916A0000 |151 172|epidermolysis bullosa0472 When CSF [HCO3-]
P08499916A0000 |75 89|candidate gene008171T0000 Ph
P08499916A0000 |31 48|type VII collagenalkaline phosphat
P08499916A0000 |131 136|formsubine
P08500524A0424 |33 43|gamma genekaline pho
P08500524A0424 |9 14|studyT0076
P08500524A0424 |104 120|splicing signalsects of neonatal
P08500524A0424 |77 81|exon8171
P08500524A0424 |143 162|intron organization0008997A0472 When C
P08500938A0408 |17 22|gradempari
P08500938A0408 |130 140|metaphysisrubinemia.
P08500938A0408 |73 81|excision00008171
P08500938A0408 |105 113|surfacescts of n
P08500938A0408 |27 31|BGCTith 
P08500938A0408 |118 122|partal h
P08501030A0456 |85 89|narL0 Ph
P08501030A0456 |95 102|strainslogic a
P08501030A0456 |104 108|M.H.ects
P08501030A0456 |16 25|inductionomparison
P08501030A0456 |35 55|.5 operon expressionline phosphatases an
P08501678A0498 |70 97|immunoprophylactic strategye P00008171T0000 Pharmacolo
P08501678A0498 |9 18|knowledgeT0076 Com
P08501678A0498 |42 53|developmentosphatases 
P08501678A0498 |114 125|Hib diseaseonatal hype
P08503348A0226 |4 32|HMG CoA reductase inhibitors01606T0076 Comparison with a
P08503348A0226 |77 83|agents8171T0
P08504707A0376 |4 12|etiology01606T00
P08504707A0376 |14 23|pathology Comparis
P08504707A0376 |25 33|brain CT with al
P08504707A0376 |77 86|treatment8171T0000
P08504707A0376 |58 72|manifestations-nucleotidase 
P08504707A0376 |96 105|accidentsogic aspe
P08504707A0376 |39 47|features phospha
P08504928T0000 |18 31|TFIID subunitparison with 
P08504928T0000 |132 136|TATAbine
P08504928T0000 |160 165|TFIID CSF 
P08504928T0000 |46 53|homologatases 
P08504928T0000 |149 156|subunit7A0472 
P08504928T0000 |67 90|cell cycle gene productdase P00008171T0000 Pha
P08504928T0000 |113 124|DNA bindingeonatal hyp
P08504932A0123 |169 174|cells3-] i
P08504932A0123 |122 138|site specificityyperbilirubinemi
P08504932A0123 |14 20|aspect Compa
P08504932A0123 |63 76|GATA proteinseotidase P000
P08504932A0123 |24 46|GATA factor expressionn with alkaline phosph
P08504933A0000 |0 5|Pit-1P0000
P08504933A0000 |126 131|glandbilir
P08504933A0000 |27 44|POU domain factorith alkaline phos
P08504933A0000 |64 74|appearanceotidase P0
P08504933A0000 |84 99|cell phenotypes00 Pharmacologi
P08505075A0236 |0 14|Maximum numberP00001606T0076
P08505075A0236 |31 32|%a
P08505075A0236 |52 72|S. bareilly serotype and 5-nucleotidase 
P08505075A0236 |106 107|%t
P08505075A0236 |122 130|S. typhiyperbili
P08505075A0236 |18 25|strainsparison
P08505075A0236 |136 137|%m
P08505312A0285 |0 4|BiolP000
P08505340T0000 |0 16|CharacterizationP00001606T0076 C
P08505340T0000 |114 129|granulosa cellsonatal hyperbil
P08505340T0000 |106 110|genets o
P08505340T0000 |30 40|regulation alkaline 
P08505340T0000 |64 103|rat prostaglandin endoperoxide synthaseotidase P00008171T0000 Pharmacologic as
P08505340T0000 |48 56|promoterases and
P08505495A0253 |17 25|75SeHCATmparison
P08505495A0253 |4 13|retention01606T007
P08505605A0461 |137 141|timeia. 
P08505605A0461 |75 96|wound characteristics008171T0000 Pharmacol
P08505605A0461 |45 51|woundshatase
P08505605A0461 |115 121|extentnatal 
P08505605A0461 |125 132|healingrbiliru
P08505605A0461 |63 70|patienteotidas
P08505605A0461 |155 162|healing When C
P08505605A0461 |0 23|Patient characteristicsP00001606T0076 Comparis
P08506317A0000 |0 7|MembersP000016
P08506317A0000 |151 166|enhancer motifs0472 When CSF [
P08506317A0000 |15 27|C/EBP familyComparison w
P08506317A0000 |53 57|bZipand 
P08506317A0000 |59 80|transcription factorsnucleotidase P0000817
P08506317A0000 |31 51|basic-leucine zipperalkaline phosphatase
P08506317A0000 |115 123|CAAT boxnatal hy
P08506317A0000 |86 98|heterodimers Pharmacolog
P08506384A0146 |116 121|eIF-2atal 
P08506384A0146 |13 18|cells6 Com
P08506384A0146 |20 35|phosphorylationrison with alka
P08506384A0146 |76 82|eIF-2B08171T
P08506384A0146 |88 111|GDP-GTP exchange factorharmacologic aspects of
P08506384A0146 |39 50|eIF-2 alpha phosphatas
P08506384A0146 |64 72|activityotidase 
P08507921A1021 |205 209|riskO2 t
P08507921A1021 |52 66|stratification and 5-nucleot
P08507921A1021 |76 87|MI patients08171T0000 
P08507921A1021 |133 139|methodinemia
P08507921A1021 |91 107|plasma ANF levelmacologic aspect
P08507921A1021 |155 164|prognosis When CSF
P08507921A1021 |3 13|conclusion001606T007
P08507921A1021 |21 33|observationsison with al
P08507921A1021 |185 196|individualsa function 
P08507921A1021 |221 226|death-depl
P08508774A0242 |0 8|AnalysisP0000160
P08508774A0242 |63 76|DNA fragmentseotidase P000
P08508774A0242 |121 124|DNAhyp
P08508774A0242 |36 39|setine
P08508774A0242 |27 30|Lrpith
P08508774A0242 |109 112|Lrpof 
P08508774A0242 |87 93|regionPharma
P08508774A0242 |16 23|bindingomparis
P08508778A0112 |152 162|processing472 When C
P08508778A0112 |94 105|temperatureologic aspe
P08508778A0112 |74 85|fibrillarin0008171T000
P08508778A0112 |120 126|growth hyper
P08508778A0112 |35 44|NOP1 geneline phos
P08508778A0112 |0 13|Yeast mutantsP00001606T007
P08508861A0294 |86 92|change Pharm
P08508861A0294 |31 40|ischaemiaalkaline 
P08508861A0294 |59 65|groupsnucleo
P08508861A0294 |128 145|balloon inflationlirubinemia. P000
P08508861A0294 |73 78|basis00008
P08508861A0294 |96 120|lactate extraction ratioogic aspects of neonatal
P08508861A0294 |4 12|patients01606T00
P08509051A0316 |16 24|patientsompariso
P08509051A0316 |60 61|%u
P08509051A0316 |40 54|mortality ratephosphatases a
P08509333A0843 |154 170|membrane protein2 When CSF [HCO3
P08509333A0843 |9 16|proteinT0076 C
P08509333A0843 |143 147|FtsN0008
P08509333A0843 |77 86|minicells8171T0000
P08509333A0843 |43 60|membrane fractionsphatases and 5-n
P08509333A0843 |98 106|plasmidsic aspec
P08509333A0843 |116 125|ftsN geneatal hype
P08509335T0000 |0 4|SSG1P000
P08509335T0000 |45 63|1,3-beta-glucanasehatases and 5-nucl
P08509335T0000 |8 12|gene6T00
P08509419A0785 |0 10|ExpressionP00001606T
P08509419A0785 |128 142|TyrRS activitylirubinemia. P
P08509419A0785 |56 64|tyrosine 5-nucle
P08509419A0785 |89 100|suppressionarmacologic
P08509419A0785 |110 115|yeastf neo
P08509419A0785 |19 26|proteinarison 
P08509430A0372 |68 81|Chlamydomonasase P00008171
P08509430A0372 |212 218|mediumdata o
P08509430A0372 |144 153|psaB gene008997A04
P08509430A0372 |92 102|ac-u-g-2.3acologic a
P08509430A0372 |58 64|mutant-nucle
P08509430A0372 |19 34|complementationarison with alk
P08509430A0372 |83 90|CC-2341000 Pha
P08509430A0372 |159 168|selectionn CSF [HC
P08509430A0372 |117 136|frameshift mutationtal hyperbilirubine
P08509430A0372 |187 200|transformantsfunction of C
P08510320A0000 |137 141|MICsia. 
P08510320A0000 |12 19|strains76 Comp
P08510320A0000 |121 135|concentrationshyperbilirubin
P08510320A0000 |174 180|agentss show
P08510320A0000 |202 205|ABK PC
P08510320A0000 |148 153|total97A04
P08510320A0000 |191 200|arbekacintion of C
P08510320A0000 |68 72|MRSAase 
P08510320A1249 |184 196|beta-lactams a function 
P08510320A1249 |64 69|Japanotida
P08510320A1249 |165 175|resistance[HCO3-] is
P08510320A1249 |45 50|MRSAshatas
P08510320A1249 |98 108|resistanceic aspects
P08510320A1249 |117 122|drugstal h
P08510647A1347 |0 4|Beg2P000
P08510647A1347 |59 68|variationnucleotid
P08510647A1347 |9 13|Beg1T007
P08510647A1347 |72 79|storageP000081
P08510647A1347 |83 105|utilization properties000 Pharmacologic aspe
P08510647A1347 |116 132|barley globulinsatal hyperbiliru
P08510924A0490 |69 83|HSP70 promoterse P00008171T0
P08510924A0490 |40 55|transactivationphosphatases an
P08510924A0490 |87 99|Myb proteinsPharmacologi
P08511994A0000 |85 99|concentrations0 Pharmacologi
P08511994A0000 |36 41|carpsine p
P08511994A0000 |115 129|micrograms/dm3natal hyperbil
P08511994A0000 |69 81|ichthiomycinse P00008171
P08512728A0991 |0 7|RESULTSP000016
P08512728A0991 |159 169|conductionn CSF [HCO
P08512728A0991 |213 217|msecata 
P08512728A0991 |199 201|RRCS
P08512728A0991 |177 194|accessory pathwayhown as a functio
P08512728A0991 |109 117|patientsof neona
P08512728A0991 |237 238|pr
P08512728A0991 |141 153|fibrillationP00008997A04
P08512728A0991 |99 105|numberc aspe
P08512728A0991 |35 46|differencesline phosph
P08512728A0991 |69 74|groupse P0
P08513025A0000 |51 62|correlations and 5-nuc
P08513025A0000 |134 142|readingsnemia. P
P08513025A0000 |15 21|effectCompar
P08513025A0000 |71 76|serum P000
P08513025A0000 |83 98|bilirubin level000 Pharmacolog
P08513025A0000 |129 132|TcBiru
P08513025A0000 |118 127|bilirubinal hyperb
P08513025A0000 |34 43|thicknessaline pho
P08514757A1100 |101 107|ligandaspect
P08514757A1100 |47 64|receptor assemblytases and 5-nucle
P08514757A1100 |145 161|protein function08997A0472 When 
P08514757A1100 |131 141|modulatorsubinemia. 
P08514757A1100 |89 97|categoryarmacolo
P08514757A1100 |5 18|immunophilins1606T0076 Com
P08514757A1100 |38 43|rolese pho
P08514766A0732 |98 105|proteinic aspe
P08514766A0732 |23 30|CDC42Ceon with
P08514766A0732 |122 130|p21 rac1yperbili
P08514766A0732 |65 76|n-chimaerintidase P000
P08514766A0732 |4 19|GTPase activity01606T0076 Comp
P08515619A0184 |0 19|Tl-201 uptake ratioP00001606T0076 Comp
P08515619A0184 |148 154|Tl-20197A047
P08515619A0184 |200 209|emphysemaSF PCO2 t
P08515619A0184 |229 251|Burrows classificationd rats are no longer d
P08515619A0184 |80 86|counts1T0000
P08515619A0184 |113 119|countseonata
P08515619A0184 |260 268|controlswhen com
P08515619A0184 |214 225|B type COPDta of K-dep
P08515619A0184 |33 42|ventriclekaline ph
P08515619A0184 |65 70|ratiotidas
P08515619A0184 |140 144|dose P00
P08515619A0184 |100 109|ventricle aspects 
P08515619A0184 |170 174|COPD-] i
P08515776A0971 |21 27|domainison w
P08515776A0971 |57 64|regions5-nucle
P08515776A0971 |99 105|regionc aspe
P08516301A0080 |19 21|kbar
P08516301A0080 |61 68|intronscleotid
P08516301A0080 |46 51|exonsatase
P08516301A0080 |5 9|gene1606
P08516308A0669 |19 24|cellsariso
P08516308A0669 |44 57|microcoloniesphatases and 
P08516308A0669 |14 17|RAD Co
P08516308A0669 |109 114|cellsof ne
P08516308A0669 |64 69|cellsotida
P08516324A0000 |258 267|FLI1 gened when co
P08516324A0000 |59 72|Ewing sarcomanucleotidase 
P08516324A0000 |131 139|moleculeubinemia
P08516324A0000 |190 198|EWS genection of
P08516324A0000 |175 182|portion shown 
P08516324A0000 |22 35|translocationson with alka
P08516324A0000 |236 242|domainare no
P08516324A0000 |103 108|tumorpects
P08517737A0889 |141 149|bacteriaP0000899
P08517737A0889 |58 68|conditions-nucleotid
P08517737A0889 |91 104|water systemsmacologic asp
P08517737A0889 |30 35|range alka
P08517737A0889 |126 137|populationsbilirubinem
P08517737A0889 |6 14|findings606T0076
P08518797T0000 |9 27|liver glycogenosisT0076 Comparison w
P08518797T0000 |61 75|candidate genecleotidase P00
P08518797T0000 |29 41|localizationh alkaline p
P08518797T0000 |46 55|isolationatases an
P08519621A0150 |100 106|stages aspec
P08519621A0150 |227 232|tractted r
P08519621A0150 |182 190|bacteriaas a fun
P08519621A0150 |149 160|association7A0472 When
P08519621A0150 |5 15|conclusion1606T0076 
P08519621A0150 |110 117|illnessf neona
P08519621A0150 |198 205|pharynx CSF PC
P08519621A0150 |64 71|changesotidase
P08519621A0150 |32 44|observationslkaline phos
P08519862T0001 |0 11|MeasurementP00001606T0
P08519862T0001 |60 63|kitucl
P08519862T0001 |24 38|IgM antibodiesn with alkalin
P08520646A0000 |0 23|Embryo coculture systemP00001606T0076 Comparis
P08520646A0000 |95 104|fertilitylogic asp
P08520646A0000 |57 67|mechanisms5-nucleoti
P08520646A0000 |110 115|agingf neo
P08520646A0000 |83 91|decrease000 Phar
P08521414A1384 |239 253|p16INK4A locus no longer dis
P08521414A1384 |27 38|methylationith alkalin
P08521414A1384 |215 225|cell linesa of K-dep
P08521414A1384 |79 83|exon71T0
P08521414A1384 |182 186|exonas a
P08521414A1384 |46 56|CpG islandatases and
P08521414A1384 |188 195|E1 betaunction
P08521414A1384 |6 16|cell lines606T0076 C
P08521414A1384 |145 149|mRNA0899
P08521414A1384 |87 95|p16INK4APharmaco
P08521414A1384 |119 125|levelsl hype
P08521717A0126 |171 179|activity] is sho
P08521717A0126 |199 210|endotheliumCSF PCO2 th
P08521717A0126 |228 237|insertioned rats a
P08521717A0126 |91 99|antibodymacologi
P08521717A0126 |241 251|LNG-IUD-20o longer d
P08521717A0126 |30 40|PAP method alkaline 
P08521717A0126 |64 70|Factorotidas
P08521717A0126 |20 28|reactionrison wi
P08521717A0126 |159 165|Factorn CSF 
P08521717A0126 |136 144|biopsiesmia. P00
P08521717A0126 |51 60|antiserums and 5-n
P08521780A0485 |0 10|UmweltchemP00001606T
P08522175A0306 |137 140|NACia.
P08522175A0306 |63 75|beta subuniteotidase P00
P08522175A0306 |29 34|BTF3bh alk
P08522175A0306 |240 246|Natureno lon
P08522175A0306 |188 203|protein sortingunction of CSF 
P08522175A0306 |128 135|complexlirubin
P08522175A0306 |208 221|translocationthe data of K
P08522175A0306 |223 231|Wiedmannepleted 
P08522175A0306 |0 5|Egd1pP0000
P08522511A1250 |9 12|PLBT00
P08522511A1250 |28 42|lyase activityth alkaline ph
P08522511A1250 |46 48|pHat
P08522511A1578 |16 23|regionsomparis
P08522511A1578 |41 45|pelBhosp
P08522511A1578 |151 180|beta-glucuronidase activities0472 When CSF [HCO3-] is show
P08522511A1578 |134 139|f. spnemia
P08522511A1578 |80 103|beta-glucuronidase gene1T0000 Pharmacologic as
P08522511A1578 |188 201|transformantsunction of CS
P08522511A1578 |124 126|F.er
P08522511A1578 |141 145|pisiP000
P08522511A1578 |32 36|pelAlkal
P08522530A1342 |185 187|bpa 
P08522530A1342 |129 138|anaeroboxirubinemi
P08522530A1342 |162 172|transcriptSF [HCO3-]
P08522530A1342 |24 30|pointsn with
P08522530A1342 |46 62|primer extensionatases and 5-nuc
P08522530A1342 |211 214|box da
P08522530A1342 |202 207|sigma PCO2
P08522530A1342 |112 114|bpne
P08522530A1342 |97 98|sg
P08522530A1342 |5 14|nifA mRNA1606T0076
P08522530A1342 |86 96|transcript Pharmacol
P08523031A0737 |85 93|seizures0 Pharma
P08523031A0737 |126 136|recurrencebilirubine
P08523031A0737 |24 28|datan wi
P08523031A0737 |60 64|timeucle
P08523031A0737 |115 121|strokenatal 
P08523031A0737 |68 73|onsetase P
P08523545T0000 |103 118|transactivationpects of neonat
P08523545T0000 |166 169|ATFHCO
P08523545T0000 |122 137|adenovirus typeyperbilirubinem
P08523545T0000 |74 77|E1A000
P08523545T0000 |146 151|genes8997A
P08523545T0000 |10 29|papillomavirus type0076 Comparison wit
P08523545T0000 |56 71|adenovirus type 5-nucleotidase
P08523545T0000 |174 200|Oct-1 DNA binding activitys shown as a function of C
P08523545T0000 |33 43|E7 proteinkaline pho
P08523566A1106 |110 116|naturef neon
P08523566A1106 |62 73|interactionleotidase P
P08523566A1106 |13 22|detergent6 Compari
P08523566A1106 |124 135|interactionerbilirubin
P08523566A1106 |27 41|% Nonidet P-40ith alkaline p
P08524036A0747 |169 174|sites3-] i
P08524036A0747 |52 57|level and 
P08524036A0747 |78 84|stripe171T00
P08524036A0747 |193 198|levelon of
P08524036A0747 |12 24|expectations76 Compariso
P08524036A0747 |61 70|variationcleotidas
P08524036A0747 |235 242|regions are no
P08524036A0747 |114 133|point substitutionsonatal hyperbilirub
P08524036A0747 |202 211|variation PCO2 the
P08524036A0747 |138 157|insertion/deletionsa. P00008997A0472 W
P08524036A0747 |87 102|enhancer regionPharmacologic a
P08524229T0000 |85 89|SRS40 Ph
P08524229T0000 |40 83|bisphosphate carboxylase small-subunit mRNAphosphatases and 5-nucleotidase P00008171T0
P08524229T0000 |122 130|cleavageyperbili
P08524229T0000 |19 37|soybean ribulose-1arison with alkali
P08524229T0000 |0 11|DegradationP00001606T0
P08524235A0695 |137 143|regionia. P0
P08524235A0695 |161 167|resultCSF [H
P08524235A0695 |108 112|loop of 
P08524235A0695 |12 22|sequencing76 Compari
P08524235A0695 |183 191|splicings a func
P08524235A0695 |195 202|max RNA of CSF
P08524235A0695 |53 61|deletionand 5-nu
P08524235A0695 |37 41|dMaxne p
P08524235A0695 |92 97|helixacolo
P08524235A0695 |81 87|regionT0000 
P08524235A0695 |0 7|CloningP000016
P08524241A0212 |32 37|HSP82lkali
P08524241A0212 |72 81|IME1-IME2P00008171
P08524241A0212 |98 105|cascadeic aspe
P08524241A0212 |19 28|inductionarison wi
P08524260A0835 |258 264|motifsd when
P08524260A0835 |179 197|consensus sequencewn as a function o
P08524260A0835 |298 304|LTBP-1ve a s
P08524260A0835 |130 136|growthrubine
P08524260A0835 |149 156|repeats7A0472 
P08524260A0835 |31 37|LTBP-2alkali
P08524260A0835 |75 81|LTBP-2008171
P08524260A0835 |202 217|calcium binding PCO2 the data 
P08524260A0835 |97 105|examplesgic aspe
P08524260A0835 |283 293|fibrillinsls but sti
P08524260A0835 |4 20|domain structure01606T0076 Compa
P08524260A0835 |235 243|examples are no 
P08524267A1022 |11 21|expression076 Compar
P08524267A1022 |211 222|myc mutants data of K-
P08524267A1022 |165 168|myc[HC
P08524267A1022 |91 99|reportermacologi
P08524267A1022 |61 83|prothymosin alpha genecleotidase P00008171T0
P08524267A1022 |122 132|repertoireyperbiliru
P08524267A1022 |148 153|genes97A04
P08524272T0000 |64 80|Jak/Stat pathwayotidase P0000817
P08524272T0000 |13 23|regulation6 Comparis
P08524272T0000 |31 41|alpha/betaalkaline p
P08524272T0000 |88 91|SH2har
P08524272T0000 |110 137|tyrosine phosphatase SHPTP1f neonatal hyperbilirubinem
P08524284A0309 |32 42|expressionlkaline ph
P08524284A0309 |61 70|PTF gammacleotidas
P08524284A0309 |181 194|HeLa extracts as a functio
P08524284A0309 |75 84|PTF delta008171T00
P08524284A0309 |108 115|studies of neo
P08524284A0309 |46 51|cDNAsatase
P08524284A0309 |166 177|PTF complexHCO3-] is s
P08524284A0309 |129 139|antibodiesirubinemia
P08524284A0309 |18 27|isolationparison w
P08524292A1022 |17 32|mechanism studymparison with a
P08524292A1022 |146 149|YY1899
P08524292A1022 |133 140|proteininemia.
P08524292A1022 |75 90|transactivation008171T0000 Pha
P08524292A1022 |52 55|YY1 an
P08524292A1022 |110 113|AP1f n
P08524292A1022 |162 170|activitySF [HCO3
P08524292A1022 |174 185|DNA bindings shown as 
P08524292A1022 |0 7|ResultsP000016
P08524294A0652 |4 8|skp10160
P08524294A0652 |10 14|gene0076
P08524314A0216 |84 94|N terminus00 Pharmac
P08524314A0216 |167 173|familyCO3-] 
P08524314A0216 |123 141|dimerization motifperbilirubinemia. 
P08524314A0216 |106 118|zinc clusterts of neonat
P08524314A0216 |74 77|kDa000
P08524314A0216 |189 197|proteinsnction o
P08524314A0216 |58 65|protein-nucleo
P08524314A0216 |10 31|Ty enhancer activator0076 Comparison with 
P08524314A0216 |4 8|TEA10160
P08524314A0216 |33 46|gene sequencekaline phosph
P08525186A0288 |0 8|RefugeesP0000160
P08525186A0288 |122 134|counterpartsyperbilirubi
P08525186A0288 |144 154|odds ratio008997A047
P08525186A0288 |92 102|proportionacologic a
P08525186A0288 |43 48|Chilesphat
P08525186A0288 |66 72|healthidase 
P08525186A0288 |19 23|Lundaris
P08526620A1344 |103 113|evaluationpects of n
P08526620A1344 |89 95|markerarmaco
P08526620A1344 |5 10|study1606T
P08526620A1344 |162 168|bypassSF [HC
P08526620A1344 |26 36|importancewith alkal
P08526620A1344 |49 74|SC5b-9 complement complexses and 5-nucleotidase P0
P08526620A1344 |117 138|complement activationtal hyperbilirubinemi
P08528479A0000 |0 18|VideonystagmoscopyP00001606T0076 Com
P08528479A0000 |140 148|deficits P000089
P08528479A0000 |89 95|systemarmaco
P08528479A0000 |61 70|responsescleotidas
P08528479A0000 |115 123|patientsnatal hy
P08528479A0000 |101 111|populationaspects of
P08528796A1470 |4 7|MCA016
P08528796A1470 |45 54|deviationhatases a
P08528796A1470 |12 24|UA PI values76 Compariso
P08528796A1470 |77 86|parameter8171T0000
P08529098A0549 |102 106|SMF2spec
P08529098A0549 |63 68|yeasteotid
P08529098A0549 |182 195|transmembraneas a function
P08529098A0549 |155 159|exon Whe
P08529098A0549 |83 91|proteins000 Phar
P08529098A0549 |261 265|exonhen 
P08529098A0549 |93 97|SMF1colo
P08529098A0549 |213 217|siteata 
P08529098A0549 |146 153|domains8997A04
P08529098A0549 |9 30|sequence similaritiesT0076 Comparison with
P08529098A0549 |41 42|%h
P08529098A0549 |290 305|transport motifstill have a si
P08529098A0549 |232 255|susceptibility mutationats are no longer displ
P08529098A0549 |205 211|domainO2 the
P08529630A0840 |71 76|roots P000
P08529630A0840 |30 44|P protein mRNA alkaline phos
P08529630A0840 |62 67|levelleoti
P08529654A0589 |138 143|Cyp-1a. P0
P08529654A0589 |88 107|cyclophilin isoformharmacologic aspect
P08529654A0589 |58 68|% identity-nucleotid
P08529654A0589 |4 55|B. germanica cyclophilin amino acid sequence shares01606T0076 Comparison with alkaline phosphatases an
P08529662A0507 |50 61|ERp57/GRP58es and 5-nu
P08529662A0507 |42 46|formosph
P08529662A0507 |65 81|Western blottingtidase P00008171
P08529662A0507 |99 107|labelingc aspect
P08530105A0308 |136 139|mapmia
P08530105A0308 |108 116|patients of neon
P08530105A0308 |193 202|endpointson of CSF
P08530105A0308 |12 18|region76 Com
P08530105A0308 |143 151|analysis0008997A
P08530105A0308 |172 181|deletions is shown
P08530105A0308 |93 101|analysiscologic 
P08530105A0308 |157 165|patientshen CSF 
P08530105A0308 |33 66|Langer-Giedion syndrome deletionskaline phosphatases and 5-nucleot
P08530107A1003 |144 151|factors008997A
P08530107A1003 |56 65|histidase 5-nucleo
P08530107A1003 |72 79|findingP000081
P08530107A1003 |94 117|histidase transcriptionologic aspects of neona
P08530107A1003 |42 52|expressionosphatases
P08530149A0689 |0 10|ComparisonP00001606T
P08530149A0689 |95 98|Inrlog
P08530149A0689 |109 112|TCAof 
P08530149A0689 |14 23|promoters Comparis
P08530149A0689 |116 121|YYYNYatal 
P08530149A0689 |37 42|c-mycne ph
P08530149A0689 |58 76|consensus sequence-nucleotidase P000
P08530149A0689 |100 107|element aspect
P08530149A0689 |84 93|initiator00 Pharma
P08530342T0000 |10 23|gp39 promoter0076 Comparis
P08530345A0880 |205 212|HD PPREO2 the 
P08530345A0880 |82 92|truncation0000 Pharm
P08530345A0880 |131 134|DR1ubi
P08530345A0880 |193 201|responseon of CS
P08530345A0880 |107 114|HD PPREs of ne
P08530345A0880 |216 240|peroxisome proliferators of K-depleted rats are 
P08530345A0880 |65 78|TGACCT motifstidase P00008
P08530345A0880 |36 44|mutationine phos
P08530345A0880 |139 150|DR2 element. P00008997
P08530345A0880 |0 21|Transfection analysesP00001606T0076 Compar
P08530369A0099 |35 41|Tyr397line p
P08530369A0099 |111 138|Src family tyrosine kinases neonatal hyperbilirubinemi
P08530369A0099 |12 31|autophosphorylation76 Comparison with 
P08530369A0099 |67 101|consensus autophosphorylation sitedase P00008171T0000 Pharmacologic 
P08530369A0099 |4 8|site0160
P08530384A0559 |206 210|Oct22 th
P08530384A0559 |183 186|BOBs a
P08530384A0559 |198 202|Oct1 CSF
P08530384A0559 |192 194|.1io
P08530384A0559 |21 32|interactionison with a
P08530384A0559 |247 250|DNAer 
P08530384A0559 |94 97|DNAolo
P08530384A0559 |147 158|interaction997A0472 Wh
P08530384A0559 |230 241|interaction rats are n
P08530384A0559 |78 90|Oct proteins171T0000 Pha
P08530384A0559 |108 131|resolution footprinting of neonatal hyperbilir
P08530384A0559 |172 179|binding is sho
P08530384A0559 |67 74|bindingdase P0
P08530418A1182 |100 110|activation aspects o
P08530418A1182 |122 126|HREsyper
P08530418A1182 |14 18|data Com
P08530418A1182 |142 149|CRBPIIp0000899
P08530418A1182 |128 137|RARE betalirubinem
P08530418A1182 |176 208|acid signal transduction pathwayshown as a function of CSF PCO2 
P08530418A1182 |36 55|TR2 orphan receptorine phosphatases an
P08530418A1182 |65 81|master regulatortidase P00008171
P08530432A0093 |81 91|activationT0000 Phar
P08530432A0093 |95 105|repressionlogic aspe
P08530432A0093 |57 64|domains5-nucle
P08530432A0093 |8 14|series6T0076
P08530432A0093 |25 33|proteins with al
P08530503A1004 |16 36|ARP immunoreactivityomparison with alkal
P08530503A1004 |7 10|ARF06T
P08530503A1004 |105 117|3T3-L1 cellscts of neona
P08530503A1004 |53 69|plasma membranesand 5-nucleotida
P08530503A1004 |81 88|cytosolT0000 P
P08531373A0470 |103 123|SS-A/SS-B antibodiespects of neonatal hy
P08531373A0470 |44 52|erythemaphatases
P08531373A0470 |89 92|SjSarm
P08531373A0470 |67 85|skin manifestationdase P00008171T000
P08531669A0950 |0 11|CompetitionP00001606T0
P08531669A0950 |91 95|kindmaco
P08531669A0950 |49 64|Central Americases and 5-nucle
P08531669A0950 |99 104|studyc asp
P08531669A0950 |132 139|controlbinemia
P08531669A0950 |69 85|Caribean islandsse P00008171T000
P08531669A0950 |153 160|species72 When
P08532516A0000 |67 80|fission yeastdase P0000817
P08532516A0000 |44 59|cdc10-C4 mutantphatases and 5-
P08532516A0000 |26 36|propertieswith alkal
P08532516A0000 |8 13|paper6T007
P08532536A0925 |119 128|inductionl hyperbi
P08532536A0925 |65 69|bonetida
P08532536A0925 |189 213|growth factors/cytokinesnction of CSF PCO2 the d
P08532536A0925 |142 155|growth factor00008997A0472
P08532536A0925 |52 60|TGF-beta and 5-n
P08532536A0925 |95 100|BMP-2logic
P08532536A0925 |84 93|protein-200 Pharma
P08532536A0925 |19 29|hFOB cellsarison wit
P08532536A0925 |157 160|EGFhen
P08532536A0925 |170 179|induction-] is sho
P08532536A0925 |0 15|TIEG expressionP00001606T0076 
P08532967A0364 |72 79|therapyP000081
P08532967A0364 |14 20|origin Compa
P08533472A0777 |34 44|ORFs N2417aline phos
P08533472A0777 |127 175|Candida maltosa cycloheximide-resistance proteinilirubinemia. P00008997A0472 When CSF [HCO3-] is
P08533472A0777 |94 102|proteinsologic a
P08533472A0777 |63 75|similaritieseotidase P00
P08533472A0777 |14 30|protein products Comparison with
P08533472A0777 |224 229|ILF-2plete
P08533472A0777 |216 222|factor of K-
P08533472A0777 |81 88|domainsT0000 P
P08533472A0777 |112 121|organismsneonatal 
P08533472A0777 |49 54|N2403ses a
P08533472A0777 |187 198|interleukinfunction of
P08533473A0375 |69 77|databasese P0000
P08533473A0375 |97 110|EST sequencesgic aspects o
P08533473A0375 |36 45|ADH1 geneine phosp
P08533757A0204 |17 41|Ashkenazi Jewish descentmparison with alkaline p
P08533757A0204 |164 169|BRCA1 [HCO
P08533757A0204 |158 160|kben
P08533757A0204 |92 101|haplotypeacologic 
P08533757A0204 |123 130|markersperbili
P08533757A0204 |5 13|families1606T007
P08533757A0204 |54 71|185delAG mutationnd 5-nucleotidase
P08534217A0402 |48 63|pollution levelases and 5-nucl
P08534217A0402 |82 93|FEV1 values0000 Pharma
P08534217A0402 |26 33|regionswith al
P08534217A0402 |74 77|FVC000
P08534217A0402 |114 128|Viskovo regiononatal hyperbi
P08534217A0402 |4 12|subjects01606T00
P08534367A0984 |0 6|PTP-S3P00001
P08534367A0984 |20 26|PTP-S4rison 
P08534367A0984 |83 90|exon E1000 Pha
P08534367A0984 |39 47|deletion phospha
P08534367A0984 |54 65|amino acidsnd 5-nucleo
P08534848A0188 |40 42|cvph
P08534848A0188 |11 22|NR isoforms076 Compari
P08534848A0188 |40 42|cvph
P08534848A0188 |11 22|NR isoforms076 Compari
P08534855A0000 |4 25|Arabidopsis FAD7 gene01606T0076 Comparison
P08534855A0000 |97 109|desaturationgic aspects 
P08534855A0000 |62 77|acid desaturaseleotidase P0000
P08534855A0000 |36 55|chloroplast omega-3ine phosphatases an
P08534855A0000 |140 145|acids P000
P08535138A0857 |32 42|leaf cellslkaline ph
P08535138A0857 |167 180|DNA synthesisCO3-] is show
P08535138A0857 |158 163|onseten CS
P08535138A0857 |83 92|treatment000 Pharm
P08535138A0857 |66 79|cell divisionidase P000081
P08535138A0857 |114 134|cycMs4 transcriptiononatal hyperbilirubi
P08535138A0857 |98 112|plant hormonesic aspects of 
P08535537A0000 |2 8|survey000160
P08535537A0000 |107 119|hypertensions of neonata
P08535537A0000 |41 52|backgroundshosphatases
P08535537A0000 |79 93|drug treatment71T0000 Pharma
P08536694A0000 |0 15|Protein kinasesP00001606T0076 
P08536694A0000 |29 34|rolesh alk
P08536694A0000 |42 49|controlosphata
P08536694A0000 |67 76|processesdase P000
P08537388A0825 |116 124|activityatal hyp
P08537388A0825 |148 158|base pairs97A0472 Wh
P08537388A0825 |192 209|promoter activityion of CSF PCO2 t
P08537388A0825 |31 40|deletionsalkaline 
P08537388A0825 |162 168|WNT-5ASF [HC
P08537388A0825 |65 73|promotertidase P
P08537403A0336 |141 144|VIBP00
P08537403A0336 |164 170|insert [HCO3
P08537403A0336 |30 35|LIMK1 alka
P08537403A0336 |40 45|LIMK2phosp
P08537403A0336 |198 202|VIII CSF
P08537403A0336 |89 127|sequence motif Asp-Leu-Asn-Ser-His-Asnarmacologic aspects of neonatal hyperb
P08537403A0336 |179 193|subdomains VIIwn as a functi
P08537403A0336 |4 26|protein kinase domains01606T0076 Comparison 
P08538052A0000 |411 421|c-myc genenotic drug
P08538052A0000 |384 391|elementears to
P08538052A0000 |212 239|oligodeoxynucleotide probesdata of K-depleted rats are
P08538052A0000 |297 305|peptidesave a si
P08538052A0000 |335 342|protein1 +/- 0
P08538052A0000 |95 102|THZif-1logic a
P08538052A0000 |177 196|leukemia HL60 cellshown as a function 
P08538052A0000 |265 285|amino acid sequencescompared to controls
P08538052A0000 |48 68|amino acids residuesases and 5-nucleotid
P08538052A0000 |86 93|protein Pharma
P08538052A0000 |20 30|cDNA clonerison with
P08538052A0000 |393 396|NHEe a
P08538052A0000 |130 142|cDNA libraryrubinemia. P
P08538382A1012 |0 14|Erythrocyte AAP00001606T0076
P08538382A1012 |18 24|FO+EPOpariso
P08538382A1012 |81 88|placeboT0000 P
P08538382A1012 |38 45|infantse phosp
P08538382A1012 |101 107|levelsaspect
P08538382A1012 |69 75|breastse P00
P08538483A0207 |68 73|totalase P
P08538483A0207 |208 219|leiomyomatathe data of
P08538483A0207 |46 53|changesatases 
P08538483A0207 |12 32|consideration weight76 Comparison with a
P08538483A0207 |180 186|monthsn as a
P08538483A0207 |75 80|TBBMC00817
P08538483A0207 |95 120|body bone mineral contentlogic aspects of neonatal
P08538483A0207 |57 66|bone mass5-nucleot
P08538483A0207 |160 173|GnRH agonists CSF [HCO3-] 
P08538483A0207 |191 204|endometriosistion of CSF P
P08538483A0207 |141 146|womenP0000
P08538702A0214 |85 93|gp15/4000 Pharma
P08538702A0214 |95 101|ladderlogic 
P08538702A0214 |72 79|AscarisP000081
P08538702A0214 |12 23|polypeptide76 Comparis
P08538702A0214 |183 190|antigens a fun
P08538702A0214 |194 213|Dirofilaria immitisn of CSF PCO2 the d
P08538702A0214 |114 127|Brugia malayionatal hyperb
P08538702A0214 |54 68|ABA-1 allergennd 5-nucleotid
P08538702A0214 |129 143|Brugia pahangiirubinemia. P0
P08538702A0214 |38 46|sequencee phosph
P08538702A0214 |103 110|proteinpects o
P08541499A0306 |8 27|transcript patterns6T0076 Comparison w
P08541499A0306 |31 48|Epifagus plastidsalkaline phosphat
P08541499A0306 |92 107|tobacco operonsacologic aspect
P08541793A0796 |38 41|mine p
P08541793A0796 |47 50|hrstas
P08541793A0796 |12 20|recovery76 Compa
P08542026A0792 |0 3|DAFP00
P08542026A0792 |120 130|regulation hyperbili
P08542026A0792 |12 27|kD glycoprotein76 Comparison w
P08542026A0792 |134 155|complement activationnemia. P00008997A0472
P08542026A0792 |86 90|SCRs Pha
P08542026A0792 |157 160|RCAhen
P08542026A0792 |178 188|chromosomeown as a f
P08542026A0792 |213 217|sizeata 
P08542026A0792 |67 84|consensus repeatsdase P00008171T00
P08542026A0792 |97 101|genegic 
P08542026A0792 |162 174|gene clusterSF [HCO3-] i
P08542026A0792 |39 49|complement phosphata
P08542026A0792 |207 209|kb t
P08542027A1471 |49 59|expressionses and 5-
P08542027A1471 |106 110|CD44ts o
P08542027A1471 |63 71|LU geneseotidase
P08542027A1471 |92 102|expressionacologic a
P08542027A1471 |4 12|XS2 gene01606T00
P08542746T0000 |34 44|facilitiesaline phos
P08542746T0000 |88 97|standardsharmacolo
P08542746T0000 |0 13|Diabetes careP00001606T007
P08542746T0000 |17 26|guidelinemparison 
P08543173A0314 |85 110|primer extension analysis0 Pharmacologic aspects o
P08543173A0314 |62 65|tspleo
P08543173A0314 |12 20|TATA box76 Compa
P08543173A0314 |48 60|start pointsases and 5-n
P08543275A0130 |119 127|presencel hyperb
P08543275A0130 |79 83|area71T0
P08543275A0130 |167 180|Arctic regionCO3-] is show
P08543275A0130 |211 220|Japan Sea data of 
P08543275A0130 |246 255|host fishger displ
P08543275A0130 |43 48|burstsphat
P08543275A0130 |131 140|sea lionsubinemia.
P08543275A0130 |52 70|pseudoterranovosis and 5-nucleotidas
P08543275A0130 |17 30|investigationmparison with
P08543595A1093 |68 80|radiotherapyase P0000817
P08543595A1093 |39 50|carboplatin phosphatas
P08543595A1093 |3 10|summary001606T
P08543595A1093 |16 26|efficaciesomparison 
P08543810A0000 |100 106|clones aspec
P08543810A0000 |166 169|setHCO
P08543810A0000 |57 69|coelomocytes5-nucleotida
P08543810A0000 |198 202|ESTs CSF
P08543810A0000 |183 196|sequence tagss a function 
P08543810A0000 |24 29|genesn wit
P08543810A0000 |140 152|cDNA library P00008997A0
P08544820T0000 |0 16|CharacterizationP00001606T0076 C
P08544820T0000 |111 121|Lsp-2 gene neonatal 
P08544820T0000 |23 54|EcR/USP heterodimer target siteon with alkaline phosphatases a
P08544820T0000 |69 92|ecdysone responsivenessse P00008171T0000 Pharm
P08545502A0914 |48 63|activation taskases and 5-nucl
P08545502A0914 |6 11|SPECT606T0
P08545502A0914 |36 39|PETine
P08546707T0000 |102 115|NF-kappa Bp50spects of neo
P08546707T0000 |16 26|activationomparison 
P08546707T0000 |59 72|NF-kappa Bp65nucleotidase 
P08546707T0000 |74 78|RelA0008
P08546707T0000 |84 89|c-Rel00 Ph
P08546707T0000 |34 55|chicken lysozyme genealine phosphatases an
P08547205A1060 |103 111|efficacypects of
P08547205A1060 |120 123|SVT hy
P08547205A1060 |42 58|agents alinidineosphatases and 5
P08547205A1060 |63 74|zatebradineeotidase P0
P08547205A1060 |183 187|dogss a 
P08547205A1060 |159 169|infarctionn CSF [HCO
P08547205A1060 |4 11|results01606T0
P08548291A1059 |50 59|formationes and 5-
P08548291A1059 |94 99|Elk-1ologi
P08548291A1059 |75 82|complex008171T
P08548291A1059 |101 122|serum response factoraspects of neonatal h
P08548291A1059 |33 38|SAPKskalin
P08548291A1059 |131 153|serum response elementubinemia. P00008997A04
P08548291A1059 |19 29|activationarison wit
P08548291A1059 |184 197|transcription a function o
P08549706T0000 |61 71|drug userscleotidase
P08549706T0000 |15 42|hepatitis B virus infectionComparison with alkaline ph
P08549706T0000 |75 82|Iceland008171T
P08549859A1604 |34 38|oddsalin
P08549859A1604 |52 65|chromosome 3p and 5-nucleo
P08549859A1604 |4 8|gene0160
P08549859A1604 |69 117|Centre d'Etude du Polymorphisme Humain pedigreesse P00008171T0000 Pharmacologic aspects of neona
P08550425A1401 |117 127|% identitytal hyperb
P08550425A1401 |91 113|Halobacterium halobiummacologic aspects of n
P08550425A1401 |15 23|subunitsComparis
P08550425A1401 |59 62|PORnuc
P08550425A1401 |81 89|archaeonT0000 Ph
P08550460A0374 |98 115|protein precursoric aspects of neo
P08550460A0374 |27 31|geneith 
P08550460A0374 |44 48|pilPphat
P08550460A0374 |57 59|bp5-
P08550460A0374 |140 176|membrane lipoprotein leader sequence P00008997A0472 When CSF [HCO3-] is 
P08550461A0284 |0 6|CheungP00001
P08550461A0284 |11 13|S.07
P08550462A0815 |0 8|UpstreamP0000160
P08550462A0815 |54 65|amino acidsnd 5-nucleo
P08550462A0815 |33 46|reading framekaline phosph
P08550462A0815 |16 24|dra geneompariso
P08550467A0863 |171 181|start site] is shown
P08550467A0863 |89 97|sequencearmacolo
P08550467A0863 |150 154|scrBA047
P08550467A0863 |31 35|scrBalka
P08550467A0863 |55 63|deletiond 5-nucl
P08550467A0863 |99 101|OBc 
P08550467A0863 |112 121|positionsneonatal 
P08550467A0863 |69 71|bpse
P08550467A0863 |17 27|regulationmparison w
P08550470A1021 |55 64|receptorsd 5-nucle
P08550470A1021 |12 16|CheW76 C
P08550470A1021 |72 83|kinase CheAP00008171T0
P08550470A1021 |39 47|coupling phospha
P08550476A0610 |32 36|epiFlkal
P08550476A0610 |26 30|genewith
P08550476A0610 |106 114|sequencets of ne
P08550476A0610 |4 12|promoter01606T00
P08550476A0610 |197 201|EpiQf CS
P08550476A0610 |130 147|EpiQ binding siterubinemia. P00008
P08550476A0610 |55 77|activator protein EpiQd 5-nucleotidase P0000
P08550476A0610 |155 168|epiA promoter When CSF [HC
P08550564T0000 |152 177|interleukin-8 receptor B.472 When CSF [HCO3-] is s
P08550564T0000 |135 142|domainsemia. P
P08550564T0000 |30 34|sets alk
P08550564T0000 |38 62|selectivity determinantse phosphatases and 5-nuc
P08550564T0000 |0 14|CXC chemokinesP00001606T0076
P08551572A0155 |0 21|OligodeoxynucleotidesP00001606T0076 Compar
P08551572A0155 |160 164|CU91 CSF
P08551572A0155 |130 140|MSB1 cellsrubinemia.
P08551572A0155 |166 187|reticuloendotheliosisHCO3-] is shown as a 
P08551572A0155 |149 158|MDCC-CU917A0472 Wh
P08551572A0155 |113 126|proliferationeonatal hyper
P08551572A0155 |83 87|ICP4000 
P08551572A0155 |92 102|pp38 mRNAsacologic a
P08551572A0155 |206 211|cells2 the
P08551572A0155 |49 79|translation initiation regionsses and 5-nucleotidase P000081
P08551577A0000 |184 192|src mRNA a funct
P08551577A0000 |11 22|replication076 Compari
P08551577A0000 |62 73|transcriptsleotidase P
P08551577A0000 |39 46|portion phosph
P08551577A0000 |162 180|Rous sarcoma virusSF [HCO3-] is show
P08551577A0000 |125 129|mRNArbil
P08551577A0000 |98 101|DNAic 
P08551577A0000 |138 154|envelope proteina. P00008997A047
P08552042A1497 |85 92|borders0 Pharm
P08552042A1497 |213 220|meiosisata of 
P08552042A1497 |27 47|promoter methylationith alkaline phospha
P08552042A1497 |148 152|poly97A0
P08552042A1497 |183 188|states a f
P08552042A1497 |122 131|reductionyperbilir
P08552042A1497 |225 237|reactivationleted rats a
P08552042A1497 |253 264|generationsplaced when
P08552042A1497 |157 168|mRNA levelshen CSF [HC
P08552042A1497 |8 12|case6T00
P08552042A1497 |153 154|A7
P08552042A1497 |17 23|degreemparis
P08552045A0973 |119 136|binding sequencesl hyperbilirubine
P08552045A0973 |172 185|transcription is shown as 
P08552045A0973 |145 158|Cpflp protein08997A0472 Wh
P08552045A0973 |10 29|consensus sequences0076 Comparison wit
P08552045A0973 |193 198|geneson of
P08552045A0973 |64 75|GCACGTGGG-3otidase P00
P08552045A0973 |234 253|centromere functions are no longer dis
P08552045A0973 |202 225|methionine biosynthesis PCO2 the data of K-dep
P08552045A0973 |84 95|GCACGTTTT-300 Pharmaco
P08552045A0973 |34 56|phosphatase regulationaline phosphatases and
P08552082A0480 |119 124|yeastl hyp
P08552082A0480 |72 83|SH3 domainsP00008171T0
P08552082A0480 |47 50|CAPtas
P08552082A0480 |37 43|regionne pho
P08552082A0480 |95 103|proteinslogic as
P08552082A0480 |142 155|protein Abp1p00008997A0472
P08552086A0150 |80 88|promoter1T0000 P
P08552086A0150 |67 71|VDREdase
P08552086A0150 |92 97|c-fosacolo
P08552086A0150 |39 65|vitamin D response element phosphatases and 5-nucleo
P08552092A1678 |171 185|protein factor] is shown as 
P08552092A1678 |109 121|footprintingof neonatal 
P08552092A1678 |72 82|regulationP00008171T
P08552092A1678 |15 30|protein bindingComparison with
P08552092A1678 |223 229|introneplete
P08552092A1678 |86 99|transcription Pharmacologi
P08552092A1678 |3 11|addition001606T0
P08552092A1678 |136 151|promoter regionmia. P00008997A
P08552092A1678 |237 246|rep3 genere no lon
P08552092A1678 |34 43|sequencesaline pho
P08552093A0657 |0 15|DifferentiationP00001606T0076 
P08552093A0657 |120 131|selectivity hyperbilir
P08552093A0657 |140 149|Gq family P0000899
P08552093A0657 |79 84|forms71T00
P08552093A0657 |88 96|alpha i2harmacol
P08552093A0657 |100 105|alpha aspe
P08552093A0657 |48 58|expressionases and 5
P08552093A0657 |153 163|G proteins72 When CS
P08552095A0686 |50 55|Paf1pes an
P08552095A0686 |76 83|nucleus08171T0
P08552095A0686 |27 31|roleith 
P08552095A0686 |35 48|transcriptionline phosphat
P08552095A0758 |17 27|abundancesmparison w
P08552095A0758 |92 99|strainsacologi
P08552095A0758 |132 142|expressionbinemia. P
P08552095A0758 |120 125|genes hype
P08552095A0758 |158 162|PAF1en C
P08552095A0758 |36 53|yeast transcriptsine phosphatases 
P08552095A0758 |80 84|paf11T00
P08552095A1115 |0 5|Paf1pP0000
P08552095A1115 |63 73|regulationeotidase P
P08552095A1115 |88 99|yeast genesharmacologi
P08552095A1115 |77 84|subsets8171T00
P08552096A0151 |18 38|suppression strategyparison with alkalin
P08552096A0151 |73 77|UBS10000
P08552096A0151 |61 71|yeast genecleotidase
P08552096A0151 |167 182|cdc34 mutationsCO3-] is shown 
P08552096A0151 |132 150|cell cycle defectsbinemia. P00008997
P08552096A0151 |94 104|expressionologic asp
P08552387A0000 |119 143|chromosome translocationl hyperbilirubinemia. P0
P08552387A0000 |57 62|parts5-nuc
P08552387A0000 |40 48|melanomaphosphat
P08552387A0000 |10 26|characterization0076 Comparison 
P08552387A0000 |190 207|factor gene ATF-1ction of CSF PCO2
P08552387A0000 |163 166|EWSF [
P08552387A0000 |110 111|tf
P08552387A0000 |84 96|cell sarcoma00 Pharmacol
P08552387A0000 |71 77|tissue P0000
P08552387A0000 |153 159|fusion72 Whe
P08552643A0261 |0 6|ClonesP00001
P08552643A0261 |122 138|stomatitis virusyperbilirubinemi
P08552643A0261 |95 103|activitylogic as
P08552643A0261 |160 173|IFN treatment CSF [HCO3-] 
P08552643A0261 |56 65|phenotype 5-nucleo
P08552643A0261 |22 25|DBDson
P08552643A0261 |145 154|infection08997A047
P08552643A0261 |140 143|VSV P0
P08552670A0665 |0 4|Abp1P000
P08552670A0665 |67 83|DNA polymer polydase P00008171T0
P08552670A0665 |47 50|ARStas
P08552670A0665 |86 89|A.T Ph
P08552670A0665 |38 43|sitese pho
P08552670A0665 |84 85|d0
P08552670T0000 |0 14|IdentificationP00001606T0076
P08552670T0000 |44 51|cloningphatase
P08552670T0000 |112 125|fission yeastneonatal hype
P08552670T0000 |97 104|proteingic asp
P08552670T0000 |16 28|purificationomparison wi
P08553580A0102 |46 54|functionatases a
P08553580A0102 |13 26|reading frame6 Comparison 
P08553580A0102 |74 86|FIV isolates0008171T0000
P08553580A0102 |28 32|ORF2th a
P08554069A0743 |152 156|exon472 
P08554069A0743 |46 54|mutationatases a
P08554069A0743 |80 81|G1
P08554069A0743 |178 190|RNA splicingown as a fun
P08554069A0743 |110 130|acceptor splice sitef neonatal hyperbili
P08554069A0743 |139 145|intron. P000
P08554069A0743 |4 11|patient01606T0
P08554069A0743 |84 98|T transversion00 Pharmacolog
P08554540A1480 |6 13|regions606T007
P08554540A1480 |31 61|HIT protein similarity regionsalkaline phosphatases and 5-nu
P08554723A0187 |171 172|M]
P08554723A0187 |83 86|PBN000
P08554723A0187 |63 75|acid lesionseotidase P00
P08554723A0187 |149 152|CTA7A0
P08554723A0187 |88 92|PBNxharm
P08554723A0187 |13 17|rats6 Co
P08554723A0187 |156 165|l-alanineWhen CSF 
P08554723A0187 |217 237|furosemide treatmentof K-depleted rats a
P08554723A0187 |191 206|sodium appetitetion of CSF PCO
P08554723A0187 |279 283|chowntro
P08554723A0187 |262 268|sodiumen com
P08554723A0187 |252 258|accesssplace
P08555076A0333 |68 75|mycosisase P00
P08555076A0333 |90 99|infectionrmacologi
P08555076A0333 |129 136|Candidairubine
P08555076A0333 |10 24|Amphotericin-B0076 Compariso
P08555076A0333 |105 116|Aspergilluscts of neon
P08555076A0333 |138 139|na
P08555076A0333 |39 47|patients phospha
P08555076A0333 |118 119|na
P08555168A0390 |34 39|sitesaline
P08555168A0390 |70 78|affinitye P00008
P08555168A0390 |9 12|Mn2T00
P08555168A0390 |0 3|Mg2P00
P08555289A0207 |83 91|purposes000 Phar
P08555289A0207 |9 25|storm indicatorsT0076 Comparison
P08555289A0207 |56 66|geophysics 5-nucleot
P08555289A0207 |43 51|medicinesphatase
P08555446A0000 |138 144|levelsa. P00
P08555446A0000 |27 32|ppa-1ith a
P08555446A0000 |11 25|tobacco plants076 Comparison
P08555446A0000 |104 121|35S CaMV promoterects of neonatal 
P08555446A0000 |172 178|leaves is sh
P08555446A0000 |77 92|pyrophosphatase8171T0000 Pharm
P08555446A0000 |156 162|sugarsWhen C
P08555498A0427 |87 98|gene familyPharmacolog
P08555498A0427 |132 152|vertebrate evolutionbinemia. P00008997A0
P08555498A0427 |45 50|mousehatas
P08555498A0427 |36 41|genesine p
P08555498A0427 |6 11|LAF-4606T0
P08555498A0427 |55 62|chickend 5-nuc
P08555597A0808 |0 9|Hb levelsP00001606
P08555597A0808 |29 31|Hbh 
P08555597A0808 |75 81|months008171
P08555597A0808 |49 53|g/dlses 
P08555753A0591 |152 157|lobes472 W
P08555753A0591 |40 54|Wisconsin Cardphosphatases a
P08555753A0591 |124 136|neuroimagingerbilirubine
P08555753A0591 |63 67|Testeoti
P08555753A0591 |20 30|comparisonrison with
P08555753A0591 |93 108|activation taskcologic aspects
P08555753A0591 |0 3|CBTP00
P08556707A1390 |102 107|yeastspect
P08556707A1390 |56 80|transactivation activity 5-nucleotidase P0000817
P08556707A1390 |208 214|allelethe da
P08556707A1390 |167 179|p53 functionCO3-] is sho
P08556707A1390 |218 230|SNU-C5 cellsf K-depleted
P08556707A1390 |6 10|data606T
P08556707A1390 |125 137|temperaturesrbilirubinem
P08556707A1390 |187 195|presencefunction
P08556707A1390 |86 98|p53 promoter Pharmacolog
P08556707A1390 |34 40|218leualine 
P08558187A0403 |0 6|CyclesP00001
P08558187A0403 |29 34|weeksh alk
P08561607A1443 |8 13|class6T007
P08561607A1443 |45 60|transplantationhatases and 5-n
P08561607A1443 |24 34|infectionsn with alk
P08561893A0100 |68 86|gene transcriptionase P00008171T0000
P08561893A0100 |91 120|E-box DNA consensus sequencesmacologic aspects of neonatal
P08561893A0100 |164 174|eukaryotes [HCO3-] i
P08561893A0100 |138 153|factor functiona. P00008997A04
P08561893A0100 |228 242|family membersed rats are no
P08561893A0100 |122 129|studiesyperbil
P08561893A0100 |17 21|dealmpar
P08561893A0100 |207 215|presence the dat
P08561893A0100 |51 58|factorss and 5
P08561897A0604 |0 8|MobilityP0000160
P08561897A0604 |123 146|competition experimentsperbilirubinemia. P0000
P08561897A0604 |192 207|CRE/TRE elemention of CSF PCO2
P08561897A0604 |13 30|supershift assays6 Comparison with
P08561897A0604 |110 118|elementsf neonat
P08561897A0604 |162 170|CREB/ATFSF [HCO3
P08561897A0604 |78 81|USF171
P08561897A0604 |70 76|factore P000
P08561897A0604 |175 179|AP-1 sho
P08561897A0604 |87 90|Sp1Pha
P08562688A0968 |0 8|UpstreamP0000160
P08562688A0968 |89 97|sequencearmacolo
P08562688A0968 |37 46|sequencesne phosph
P08562688A0968 |78 84|length171T00
P08562688A0968 |54 62|isolatesnd 5-nuc
P08563483A0094 |69 75|levelsse P00
P08563483A0094 |9 14|casesT0076
P08563483A0094 |135 143|activityemia. P0
P08563483A0094 |91 101|TSH levelsmacologic 
P08563483A0094 |115 118|hCGnat
P08563483A0094 |64 67|hCGoti
P08563483A0094 |50 62|gonadotropines and 5-nuc
P08564488A1359 |39 43|risk pho
P08564488A1359 |62 72|thrombosisleotidase 
P08564488A1359 |5 22|fibrinogen levels1606T0076 Compari
P08564588A1318 |0 21|Strontium chloride SrP00001606T0076 Compar
P08564588A1318 |90 113|management expendituresrmacologic aspects of n
P08564588A1318 |123 131|ABSTRACTperbilir
P08564588A1318 |149 154|WORDS7A047
P08564588A1318 |52 60|analysis and 5-n
P08565330A1783 |55 62|controld 5-nuc
P08565330A1783 |27 35|featuresith alka
P08565330A1783 |74 81|control0008171
P08565330A1783 |93 103|expressioncologic as
P08565548A0196 |154 161|DA rats2 When 
P08565548A0196 |111 114|BII ne
P08565548A0196 |40 49|potentialphosphata
P08565548A0196 |132 144|silicone gelbinemia. P00
P08565548A0196 |5 10|study1606T
P08565548A0196 |53 65|silicone geland 5-nucleo
P08565548A0196 |98 106|collagenic aspec
P08566747A0756 |17 25|promotermparison
P08566747A0756 |95 111|Cln/Cdc28 kinaselogic aspects of
P08566747A0756 |75 77|G100
P08566747A0756 |39 49|activation phosphata
P08566747A0756 |53 66|transcriptionand 5-nucleot
P08566747A0756 |126 133|abilitybilirub
P08566747A0756 |170 183|transcription-] is shown a
P08566747A0756 |154 157|SBF2 W
P08566747A0756 |0 3|SBFP00
P08566751A0455 |171 180|Hox genes] is show
P08566751A0455 |28 36|questionth alkal
P08566751A0455 |45 65|vertebrate Hox geneshatases and 5-nucleo
P08566751A0455 |86 93|control Pharma
P08566751A0455 |148 156|function97A0472 
P08566751A0455 |119 128|sequencesl hyperbi
P08566751A0788 |87 90|labPha
P08566751A0788 |21 28|gHoxb-1ison wi
P08566751A0788 |5 13|approach1606T007
P08566751A0788 |70 77|contexte P0000
P08566754A0783 |115 133|ribonucleoproteinsnatal hyperbilirub
P08566754A0783 |8 28|splice site sequence6T0076 Comparison wi
P08566754A0783 |135 141|snRNPsemia. 
P08566754A0783 |194 201|ASF/SF2n of CS
P08566754A0783 |55 70|polyadenylationd 5-nucleotidas
P08566754A0783 |159 190|splicing factor/splicing factorn CSF [HCO3-] is shown as a fun
P08566754A0783 |98 100|U1ic
P08566756A0752 |100 108|pre-mRNA aspects
P08566756A0752 |62 80|SF3a/SF3b subunitsleotidase P0000817
P08566756A0752 |28 31|SAPth 
P08566756A0752 |151 154|BPS047
P08566756A0752 |82 96|UV cross-links0000 Pharmacol
P08566756A0752 |128 134|regionlirubi
P08566756A0752 |5 13|analysis1606T007
P08566773A1023 |16 20|CTS1ompa
P08566773A1023 |40 47|membersphospha
P08566773A1023 |82 92|chitinases0000 Pharm
P08566773A1023 |25 29|CTS2 wit
P08566773A1023 |146 152|fungus8997A0
P08566773A1023 |64 71|classesotidase
P08566773A1023 |97 108|observationgic aspects
P08566773A1023 |33 35|Cika
P08567556A0000 |102 114|seal musclesspects of ne
P08567556A0000 |148 154|diving97A047
P08567556A0000 |122 144|laboratory simulationsyperbilirubinemia. P00
P08567556A0000 |13 24|consumption6 Compariso
P08567556A0000 |192 204|field divingion of CSF P
P08567556A0000 |48 52|MbO2ases
P08567556A0000 |54 60|storesnd 5-n
P08567556A0000 |214 226|measurementsta of K-depl
P08567556A0000 |245 263|lactate productionnger displaced whe
P08567556A0000 |174 181|features shown
P08567556A0000 |276 287|differences controls b
P08567556A0000 |230 240|heart rate rats are 
P08567556A0000 |306 321|diving responsenificantly grea
P08567556A0000 |64 76|seal musclesotidase P000
P08567556A0000 |340 349|immersion 0.23 vs.
P08567683A0401 |42 48|lengthosphat
P08567683A0401 |74 89|acid polypeptic0008171T0000 Ph
P08567683A0401 |28 38|base pairsth alkalin
P08567683A0401 |91 93|Mrma
P08567683A0401 |10 19|purH cDNA0076 Comp
P08567717T0000 |72 76|partP000
P08567717T0000 |90 100|checkpointrmacologic
P08567717T0000 |29 68|spindle pole body duplication gene MPS1h alkaline phosphatases and 5-nucleotid
P08567847A1005 |51 63|shortcomingss and 5-nucl
P08567847A1005 |125 136|examinationrbilirubine
P08567847A1005 |110 120|instrumentf neonatal
P08567847A1005 |176 184|featuresshown as
P08567847A1005 |146 159|semen samples8997A0472 Whe
P08567847A1005 |20 33|SM-CMA systemrison with al
P08567847A1005 |7 14|opinion06T0076
P08567847A1005 |71 85|user-interface P00008171T000
P08569443A0123 |119 130|consequencel hyperbili
P08569443A0123 |88 90|T2ha
P08569443A0123 |164 170|volume [HCO3
P08569443A0123 |134 145|differencesnemia. P000
P08569443A0123 |99 105|tumorsc aspe
P08569443A0123 |66 77|differencesidase P0000
P08569443A0123 |192 203|compartmention of CSF 
P08569443A0123 |81 83|T1T0
P08569443A0123 |4 11|purpose01606T0
P08569443A0123 |19 24|studyariso
P08569680A0636 |110 116|domainf neon
P08569680A0636 |91 95|GATAmaco
P08569680A0636 |9 21|areA productT0076 Compar
P08569680A0636 |133 141|functioninemia. 
P08569680A0636 |59 66|residuenucleot
P08569684A0000 |34 39|basisaline
P08569684A0000 |133 149|protein kinase Cinemia. P0000899
P08569684A0000 |62 90|amino acid sequence segmentsleotidase P00008171T0000 Pha
P08569684A0000 |284 309|fungus Trichoderma reeseis but still have a signif
P08569684A0000 |151 154|PKC047
P08569684A0000 |191 217|polymerase chain reactionstion of CSF PCO2 the data 
P08569684A0000 |112 118|domainneonat
P08569684A0000 |179 186|primerswn as a
P08569684A0000 |250 262|DNA fragmentdisplaced wh
P08569684A0000 |156 164|proteinsWhen CSF
P08569684A0000 |0 16|OligonucleotidesP00001606T0076 C
P08570615T0000 |0 10|DisruptionP00001606T
P08570615T0000 |79 92|S-phase entry71T0000 Pharm
P08570615T0000 |14 20|RB/E2F Compa
P08570615T0000 |45 60|point mutationshatases and 5-n
P08570615T0000 |23 34|interactionon with alk
P08570615T0000 |97 106|apoptosisgic aspec
P08570615T0000 |64 69|E2F-1otida
P08572616A0000 |17 40|differentiation markersmparison with alkaline 
P08572616A0000 |74 83|neoplasms0008171T0
P08572616A0000 |9 13|lossT007
P08573083A0645 |5 11|region1606T0
P08573083A0645 |60 72|binding siteucleotidase 
P08573083A0645 |42 50|identityosphatas
P08573083A0645 |92 112|transcription factoracologic aspects of 
P08573083A0645 |134 140|factornemia.
P08573083A0645 |23 28|motifon wi
P08573083A0645 |142 145|USF000
P08573083A0645 |173 189|insulin promoteris shown as a fu
P08573637A0434 |50 63|determinationes and 5-nucl
P08573637A0434 |125 131|fluidsrbilir
P08573637A0434 |97 109|formulationsgic aspects 
P08573637A0434 |67 78|paracetamoldase P00008
P08573637A0434 |4 10|method01606T
P08574414A1037 |99 108|pathovarsc aspects
P08574414A1037 |75 94|Xanthomonas species008171T0000 Pharmac
P08574414A1037 |24 35|PCR productn with alka
P08574414A1037 |56 62|length 5-nuc
P08574414A1037 |6 13|primers606T007
P08574583A0658 |153 164|sim mutants72 When CSF
P08574583A0658 |76 82|arrest08171T
P08574583A0658 |108 114|strain of ne
P08574583A0658 |124 132|activityerbiliru
P08574583A0658 |86 91|cells Phar
P08574583A0658 |4 15|Clb5 kinase01606T0076 
P08574583A0658 |32 39|S phaselkaline
P08575609A0526 |69 75|valuesse P00
P08575609A0526 |126 134|patientsbilirubi
P08575609A0526 |107 111|eyess of
P08575609A0526 |44 49|casesphata
P08575609A0526 |4 13|C/D ratio01606T007
P08575609A0526 |54 58|eyesnd 5
P08575609A0526 |117 118|%t
P08575614A0264 |0 12|Rad6 mutantsP00001606T00
P08575614A0264 |46 55|phenotypeatases an
P08575614A0264 |73 80|protein0000817
P08575614A0264 |116 138|postreplication repairatal hyperbilirubinemi
P08575614A0264 |140 150|repression P00008997
P08575614A0264 |178 189|sporulationown as a fu
P08575614A0264 |84 87|DNA00 
P08575614A0264 |154 172|retrotransposition2 When CSF [HCO3-]
P08575614A0264 |103 114|mutagenesispects of ne
P08575618A1138 |0 23|RNase protection assaysP00001606T0076 Comparis
P08575618A1138 |109 145|pigmentation/phaeomelanin phenotypesof neonatal hyperbilirubinemia. P000
P08575618A1138 |88 103|skin expressionharmacologic as
P08575618A1138 |35 46|correlationline phosph
P08575618A1138 |59 65|levelsnucleo
P08575618A1138 |69 75|dorsalse P00
P08575754T0000 |19 37|expression patternarison with alkali
P08575754T0000 |10 17|cloning0076 Co
P08575754T0000 |94 103|inhibitorologic as
P08575754T0000 |107 113|cyclins of n
P08575754T0000 |126 133|kinasesbilirub
P08575754T0000 |77 89|CDKN2D/INK4d8171T0000 Ph
P08575754T0000 |55 67|localizationd 5-nucleoti
P08576042A0765 |0 14|OverproductionP00001606T0076
P08576042A0765 |214 227|transcriptionta of K-deple
P08576042A0765 |148 168|heat shock induction97A0472 When CSF [HC
P08576042A0765 |271 278|amountsed to c
P08576042A0765 |185 197|groE operonsa function o
P08576042A0765 |53 57|hrcAand 
P08576042A0765 |82 87|phrcA0000 
P08576042A0765 |296 307|temperaturehave a sign
P08576042A0765 |93 104|B. subtiliscologic asp
P08576042A0765 |176 180|dnaKshow
P08576042A0765 |45 49|copyhata
P08576042A0765 |119 137|delta hrcA strainsl hyperbilirubinem
P08576042A0765 |18 30|HrcA proteinparison with
P08576042A0765 |282 286|mRNAols 
P08576042A0765 |73 80|plasmid0000817
P08576042A0765 |205 210|levelO2 th
P08576131A0151 |117 122|USF2atal h
P08576131A0151 |150 155|USF2bA0472
P08576131A0151 |108 115|subunit of neo
P08576131A0151 |183 191|splicings a func
P08576131A0151 |47 63|characterizationtases and 5-nucl
P08576131A0151 |67 80|USF2 isoformsdase P0000817
P08576131A0151 |24 31|cloningn with 
P08576131A0151 |141 148|subunitP000089
P08576131A0685 |17 35|heterodimerizationmparison with alka
P08576131A0685 |123 131|subunitsperbilir
P08576131A0685 |95 106|associationlogic aspec
P08576131A0685 |148 160|USF proteins97A0472 When
P08576131A0685 |39 51|USF subunits phosphatase
P08576179A0126 |69 98|translation initiation factorse P00008171T0000 Pharmacolog
P08576179A0126 |10 13|PKR007
P08576179A0126 |29 34|dimerh alk
P08576179A0126 |101 114|alpha subunitaspects of ne
P08576179A0126 |140 168|polypeptide chain initiation P00008997A0472 When CSF [HC
P08576179A0126 |116 127|cIF-2 alphaatal hyperb
P08576245A0000 |0 5|GRP78P0000
P08576245A0000 |198 222|glycoprotein trafficking CSF PCO2 the data of K-
P08576245A0000 |113 129|stress responseseonatal hyperbil
P08576245A0000 |93 100|proteincologic
P08576245A0000 |58 67|reticulum-nucleoti
P08576245A0000 |19 28|chaperonearison wi
P08576245A0000 |143 150|glucose0008997
P08576245A0000 |169 176|calcium3-] is 
P08576262A0160 |117 119|Gita
P08576262A0160 |124 127|G16erb
P08576262A0160 |96 106|G proteinsogic aspec
P08576262A0160 |23 60|seven-transmembrane spanning receptoron with alkaline phosphatases and 5-n
P08576262A0160 |4 17|IL-8 receptor01606T0076 Co
P08576546A0975 |51 61|PDC/HDC Acs and 5-nu
P08576546A0975 |104 118|dose regimentsects of neonat
P08576546A0975 |22 33|experimentsson with al
P08576546A0975 |12 18|series76 Com
P08576546A0975 |39 47|efficacy phospha
P08580083A0259 |103 124|Fyn-expression vectorpects of neonatal hyp
P08580083A0259 |28 40|significanceth alkaline 
P08580083A0259 |44 47|Fynpha
P08580083A0259 |75 84|promoters008171T00
P08580083A0259 |55 65|expressiond 5-nucleo
P08580083A0259 |173 211|chloramphenicol acetyltransferase geneis shown as a function of CSF PCO2 the
P08580083A0259 |243 254|T cell linelonger disp
P08580083A0259 |222 229|HIV LTRdeplete
P08580083A0259 |141 157|reporter plasmidP00008997A0472 W
P08580083A0259 |256 262|Jurkatced wh
P08580671A0137 |152 164|hypertension472 When CSF
P08580671A0137 |198 211|liver disease CSF PCO2 the
P08580671A0137 |242 250|bleeding longer 
P08580671A0137 |83 95|beta-blocker000 Pharmaco
P08580671A0137 |59 69|metoprololnucleotida
P08580671A0137 |131 139|bleedingubinemia
P08580671A0137 |184 192|patients a funct
P08580671A0137 |100 110|prevention aspects o
P08580671A0137 |50 55|triales an
P08581174A0472 |50 62|qutA mutantses and 5-nuc
P08581174A0472 |24 32|analysisn with a
P08581174A0472 |147 159|QUTA protein997A0472 Whe
P08581174A0472 |82 91|mutations0000 Phar
P08581174A0472 |127 131|halfilir
P08581174A0472 |101 104|mapasp
P08582143A0614 |169 194|beta-lactamase production3-] is shown as a functio
P08582143A0614 |89 113|cephalosporin substratesarmacologic aspects of n
P08582143A0614 |44 48|testphat
P08582143A0614 |211 218|species data o
P08582143A0614 |6 13|studies606T007
P08582143A0614 |123 133|nitrocefinperbilirub
P08582143A0614 |138 140|S1a.
P08582633T0000 |0 11|SuppressorsP00001606T0
P08582633T0000 |45 52|effectshatases
P08582633T0000 |25 34|silencing with alk
P08582633T0000 |72 82|repressionP00008171T
P08582633T0000 |90 99|HMR locusrmacologi
P08582633T0000 |101 112|cell growthaspects of 
P08582633T0000 |38 43|yeaste pho
P08582633T0000 |117 135|telomere structuretal hyperbilirubin
P08583783A0870 |65 75|filtrationtidase P00
P08583783A0870 |40 50|filtrationphosphatas
P08583783A0870 |59 63|calfnucl
P08583783A0870 |9 12|ANPT00
P08583783A0870 |93 96|ANPcol
P08583846A0121 |87 93|markerPharma
P08583846A0121 |37 55|beta-2 transferrinne phosphatases an
P08583846A0121 |7 17|literature06T0076 Co
P08583846A0121 |98 107|perilymphic aspect
P08583846A0807 |86 92|marker Pharm
P08583846A0807 |124 131|settingerbilir
P08583846A0807 |13 43|methodology beta-2 transferrin6 Comparison with alkaline pho
P08583846A0807 |97 106|perilymphgic aspec
P08584026A0115 |35 37|P1li
P08584026A0115 |42 44|P2os
P08584026A0115 |24 33|promotersn with al
P08584026A0115 |4 15|hIGF-I gene01606T0076 
P08584035A0740 |102 120|binding propertiesspects of neonatal
P08584035A0740 |211 213|R1 d
P08584035A0740 |200 209|complexesSF PCO2 t
P08584035A0740 |133 140|abilityinemia.
P08584035A0740 |63 71|proteinseotidase
P08584035A0740 |155 171|beta I-A element When CSF [HCO3-
P08584035A0740 |217 219|R4of
P08584035A0740 |0 25|Gel mobility shift assaysP00001606T0076 Comparison
P08584074A0000 |153 159|period72 Whe
P08584074A0000 |166 172|monthsHCO3-]
P08584074A0000 |44 50|monthsphatas
P08584074A0000 |124 127|TLEerb
P08584074A0000 |109 122|lobe epilepsyof neonatal h
P08584074A0000 |11 19|patients076 Comp
P08584074A0000 |58 63|years-nucl
P08584074A0000 |176 198|Bethel Epilepsy Centershown as a function of
P08584074A0000 |36 41|yearsine p
P08584530A0545 |68 74|valuesase P0
P08584530A0545 |164 176|test results [HCO3-] is 
P08584530A0545 |78 81|Raw171
P08584530A0545 |41 45|FEV1hosp
P08584530A0545 |12 24|correlations76 Compariso
P08584530A0545 |144 155|differences008997A0472
P08584530A0545 |93 98|MEF25colog
P08584530A0545 |83 88|MEF50000 P
P08585324A0467 |34 43|SSC1 genealine pho
P08585324A0467 |45 50|Smithhatas
P08585324A0823 |84 95|tau element00 Pharmaco
P08585324A0823 |28 32|geneth a
P08585324A0823 |55 64|precursord 5-nucle
P08585324A0823 |5 11|region1606T0
P08585324A0823 |71 78|remnant P00008
P08585639T0000 |53 75|immunodeficiency virusand 5-nucleotidase P00
P08585639T0000 |13 21|exposure6 Compar
P08585639T0000 |91 104|risk analysismacologic asp
P08585639T0000 |25 42|hepatitis B virus with alkaline ph
P08585883A0381 |0 6|HybridP00001
P08585883A0381 |129 145|copulation plugsirubinemia. P000
P08585883A0381 |14 18|mice Com
P08585883A0381 |164 167|day [H
P08585883A0381 |105 108|daycts
P08585883A0381 |75 86|LNG pellets008171T0000
P08585883A0381 |20 31|C57BL x CBArison with 
P08585883A0381 |173 176|dayis 
P08585883A0381 |197 203|periodf CSF 
P08585883A0381 |116 119|dayata
P08585883A0381 |65 69|CD-1tida
P08585883A0381 |50 63|breeder maleses and 5-nucl
P08585957A0101 |138 145|domainsa. P000
P08585957A0101 |232 255|mobility group proteinsats are no longer displ
P08585957A0101 |197 204|AT-hookf CSF P
P08585957A0101 |92 100|proteinsacologic
P08585957A0101 |29 49|transcription factorh alkaline phosphata
P08585957A0101 |5 9|gene1606
P08585957A0101 |218 223|motiff K-d
P08585957A0101 |66 74|homologyidase P0
P08585957A0101 |55 62|regionsd 5-nuc
P08585957A0101 |174 186|gene products shown as a
P08585957A0101 |115 127|zinc fingersnatal hyperb
P08585994A0567 |258 264|embryod when
P08585994A0567 |120 138|band interval 89A1 hyperbilirubinemi
P08585994A0567 |6 22|reference probes606T0076 Compari
P08585994A0567 |213 250|segmentation gene expression patternsata of K-depleted rats are no longer 
P08585994A0567 |63 85|ost transcription uniteotidase P00008171T000
P08585994A0567 |35 44|standardsline phos
P08585994A0567 |154 157|arm2 W
P08585994A0567 |171 181|chromosome] is shown
P08586643A0951 |51 70|phosphoryl transfers and 5-nucleotidas
P08586643A0951 |91 94|CMPmac
P08586643A0951 |76 79|ATP081
P08586643A0951 |25 31|enzyme with 
P08586643A0951 |83 86|UMP000
P08586874T0000 |0 7|StudiesP000016
P08586874T0000 |29 47|Haplorchis pumilioh alkaline phospha
P08586874T0000 |62 67|Loossleoti
P08586874T0000 |15 25|life cycleComparison
P08586874T0000 |127 133|stagesilirub
P08586874T0000 |93 106|redescriptioncologic aspec
P08586874T0000 |49 54|Loossses a
P08587075T0000 |66 86|polyarteritis nodosaidase P00008171T0000
P08587075T0000 |11 25|microaneurysms076 Comparison
P08587075T0000 |31 36|casesalkal
P08587075T0000 |40 57|hepatitis B virusphosphatases and 
P08588852A0236 |68 73|fetusase P
P08588852A0236 |181 187|tibiae as a 
P08588852A0236 |120 132|micrognathia hyperbiliru
P08588852A0236 |94 103|gestationologic as
P08588852A0236 |149 155|thumbs7A0472
P08588852A0236 |165 169|toes[HCO
P08588852A0236 |48 55|studiesases an
P08588852A0236 |21 30|pregnancyison with
P08588852A0236 |86 90|week Pha
P08589315A1029 |220 228|syndromeK-deplet
P08589315A1029 |246 247|%g
P08589315A1029 |199 200|%C
P08589315A1029 |41 49|survivalhosphata
P08589315A1029 |122 142|tumor lysis syndromeyperbilirubinemia. P
P08589315A1029 |181 189|patients as a fu
P08589315A1029 |38 39|%e
P08589315A1029 |234 242|patientss are no
P08589315A1029 |114 120|groupsonatal
P08589315A1029 |19 32|survival ratearison with a
P08589315A1029 |156 175|lupus erythematosusWhen CSF [HCO3-] is
P08589315A1029 |87 88|%P
P08589358A0235 |100 104|week asp
P08589358A0235 |58 63|rhEPO-nucl
P08589358A0235 |12 20|units/kg76 Compa
P08589358A0235 |111 116|weeks neon
P08589358A0235 |92 97|timesacolo
P08589358A0235 |42 56|erythropoietinosphatases and
P08589358A0841 |152 162|milligrams472 When C
P08589358A0841 |9 16|regimenT0076 C
P08589358A0841 |56 61|donor 5-nu
P08589358A0841 |91 108|blood transfusionmacologic aspects
P08589358A0841 |20 34|erythropoietinrison with alk
P08589358A0841 |127 136|Hb levelsilirubine
P08589358A0841 |64 68|needotid
P08589735A0577 |119 123|Adh1l hy
P08589735A0577 |126 141|maize ubiquitinbilirubinemia. 
P08589735A0577 |9 19|constructsT0076 Comp
P08589735A0577 |150 160|rice actinA0472 When
P08589735A0577 |143 147|Ubi10008
P08589735A0577 |172 186|CaMV 35S genes is shown as a
P08589735A0577 |162 166|Act1SF [
P08589735A0577 |50 66|promoter regionses and 5-nucleot
P08589735A0577 |21 35|GUS expressionison with alka
P08589735A0577 |84 117|Arabidopsis alcohol dehydrogenase00 Pharmacologic aspects of neona
P08590465A0773 |119 136|URA2 gene productl hyperbilirubine
P08590465A0773 |59 76|URA1 gene productnucleotidase P000
P08590465A0773 |21 31|regulationison with 
P08590465A0773 |4 16|organization01606T0076 C
P08590465A0773 |50 52|S.es
P08591700A0972 |71 76|kg/m2 P000
P08591700A0972 |26 29|BMIwit
P08591700A0972 |90 93|menrma
P08591700A0972 |4 24|mean body mass index01606T0076 Compariso
P08591700A0972 |80 85|women1T000
P08591700A0972 |48 53|kg/m2ases 
P08592590A0822 |68 79|hepatitis Case P000081
P08592590A0822 |96 116|interferon treatmentogic aspects of neon
P08592590A0822 |6 14|findings606T0076
P08592590A0822 |183 191|patientss a func
P08592590A0822 |32 54|haemodialysis patientslkaline phosphatases a
P08592590A0822 |138 146|responsea. P0000
P08592590A0822 |169 179|proportion3-] is sho
P08592713T0001 |25 30|drugs with
P08592713T0001 |10 21|enantiomers0076 Compar
P08593813A0967 |140 150|transcript P00008997
P08593813A0967 |47 51|germtase
P08593813A0967 |112 122|efficiencyneonatal h
P08593813A0967 |9 17|analysisT0076 Co
P08593813A0967 |66 75|Sp1 mRNAsidase P00
P08595012A0817 |85 89|rest0 Ph
P08595012A0817 |20 28|responserison wi
P08595012A0817 |75 81|values008171
P08595012A0817 |32 37|tcPO2lkali
P08595012A0817 |3 15|nondiabetics001606T0076 
P08595012A0817 |49 52|LDFses
P08595184A0407 |86 98|correlations Pharmacolog
P08595184A0407 |63 70|effectseotidas
P08595184A0407 |132 136|LFPsbine
P08595184A0407 |5 10|study1606T
P08595184A0407 |23 32|estimatoron with a
P08595184A0407 |114 130|field potentialsonatal hyperbili
P08595414A0000 |258 269|orientationd when comp
P08595414A0000 |57 61|maps5-nu
P08595414A0000 |225 231|clonesleted 
P08595414A0000 |104 111|contigsects of
P08595414A0000 |190 196|extentction 
P08595414A0000 |4 12|assembly01606T00
P08595414A0000 |66 78|constructionidase P00008
P08595414A0000 |16 24|sequenceompariso
P08595414A0000 |169 182|determination3-] is shown 
P08595414A0000 |137 150|model genomesia. P00008997
P08595627A1513 |51 58|channels and 5
P08595627A1513 |209 211|VFhe
P08595627A1513 |107 116|occlusions of neon
P08595627A1513 |172 174|VF i
P08595627A1513 |82 94|consequences0000 Pharmac
P08595627A1513 |128 140|KATP openinglirubinemia.
P08595627A1513 |33 43|inhibitionkaline pho
P08595627A1513 |5 12|opening1606T00
P08595627A1513 |16 20|KATPompa
P08595658A0961 |64 100|plant mitochondrial-processing sitesotidase P00008171T0000 Pharmacologic
P08595658A0961 |128 132|endsliru
P08595658A0961 |164 178|RNA processing [HCO3-] is sh
P08595658A0961 |36 43|terminiine pho
P08595658A0961 |52 60|homology and 5-n
P08595658A0961 |4 17|DNA sequences01606T0076 Co
P08595836T0000 |84 93|materials00 Pharma
P08595836T0000 |7 16|shrinkage06T0076 C
P08595836T0000 |58 71|glass ionomer-nucleotidase
P08595836T0000 |32 39|changeslkaline
P08595878A0201 |100 124|receptor tyrosine kinase aspects of neonatal hyp
P08595878A0201 |78 82|Ras1171T
P08595878A0201 |126 129|RTKbil
P08595878A0201 |24 32|evidencen with a
P08595878A0201 |131 158|signal transduction pathwayubinemia. P00008997A0472 Wh
P08595878A0201 |174 200|R7 photoreceptor cell fates shown as a function of C
P08595878A0201 |219 233|Drosophila eye K-depleted ra
P08595878A0201 |49 63|PP2A functionsses and 5-nucl
P08597108A0642 |0 5|QBMDsP0000
P08597108A0642 |25 33|response with al
P08597108A0642 |13 21|% change6 Compar
P08597108A0642 |65 72|averagetidase 
P08597108A0642 |97 102|NOAELgic a
P08597108A0642 |35 41|QBMD05line p
P08597177T0000 |0 7|EffectsP000016
P08597177T0000 |20 29|exposuresrison wit
P08597177T0000 |33 50|hydrogen sulphidekaline phosphatas
P08597177T0000 |54 57|ratnd 
P08597177T0000 |70 73|EEGe P
P08597596A0135 |32 40|cassettelkaline 
P08597596A0135 |42 57|ABC transporterosphatases and 
P08597596A0135 |4 8|gene0160
P08597636A0000 |32 38|familylkalin
P08597636A0000 |42 47|genesospha
P08597636A0000 |78 97|expression patterns171T0000 Pharmacolo
P08597636A0000 |10 15|motif0076 
P08597636A0000 |65 73|featurestidase P
P08597636A0000 |112 123|involvementneonatal hy
P08597636A0000 |141 156|gene regulationP00008997A0472 
P08598051T0000 |76 98|RNP consensus-sequence08171T0000 Pharmacolog
P08598051T0000 |30 49|schizosaccharomyces alkaline phosphata
P08598051T0000 |10 18|analysis0076 Com
P08598051T0000 |56 60|gene 5-n
P08598051T0000 |111 118|domains neonat
P08598359X0000 |102 117|cell carcinomasspects of neona
P08598359X0000 |264 269|T1-T2 comp
P08598359X0000 |27 37|field sizeith alkali
P08598359X0000 |176 183|patientshown a
P08598359X0000 |43 69|treatment energy influencesphatases and 5-nucleotida
P08598359X0000 |162 171|treatmentSF [HCO3-
P08598359X0000 |11 25|treatment time076 Comparison
P08598359X0000 |133 139|larynxinemia
P08598359X0000 |87 92|T1-T2Pharm
P08598359X0000 |251 260|treatmentisplaced 
P08598359X0000 |141 148|PURPOSEP000089
P08598359X0000 |203 210|factorsPCO2 th
P08598359X0000 |76 83|control08171T0
P08598359X0000 |309 315|larynxicantl
P08598359X0000 |279 293|cell carcinomantrols but sti
P08598359X0000 |236 243|controlare no 
P08598449A0784 |307 321|concentrationsificantly grea
P08598449A0784 |302 305|CA2 si
P08598449A0784 |192 195|fynion
P08598449A0784 |19 28|signalingarison wi
P08598449A0784 |82 95|CD38 ligation0000 Pharmaco
P08598449A0784 |212 215|vavdat
P08598449A0784 |243 250|proteinlonger 
P08598449A0784 |121 145|tyrosine phosphorylationhyperbilirubinemia. P000
P08598449A0784 |42 63|surface Ig engagementosphatases and 5-nucl
P08598449A0784 |162 190|protein tyrosine kinases lynSF [HCO3-] is shown as a fun
P08598449A0784 |281 288|changesrols bu
P08598449A0784 |201 204|btkF P
P08598449A0784 |67 80|B lymphocytesdase P0000817
P08598449A0784 |3 11|contrast001606T0
P08599945T0000 |17 31|alpha-amanitinmparison with 
P08599945T0000 |42 48|domainosphat
P08599945T0000 |149 160|transitions7A0472 When
P08599945T0000 |75 95|yeast RNA polymerase008171T0000 Pharmaco
P08599945T0000 |116 128|RNA cleavageatal hyperbi
P08599945T0000 |64 71|subunitotidase
P08599945T0000 |0 9|MutationsP00001606
P08599946A0999 |171 181|structures] is shown
P08599946A0999 |63 88|ribonucleoprotein complexeotidase P00008171T0000 P
P08599946A0999 |46 57|p40 complexatases and 
P08599946A0999 |4 12|evidence01606T00
P08599946A0999 |199 219|example coiled-coilsCSF PCO2 the data of
P08599946A0999 |109 110|so
P08599946A0999 |238 245|complexe no lo
P08599946A0999 |100 108|L1Hs RNA aspects
P08599946A0999 |137 149|interactionsia. P0000899
P08600028A1129 |139 150|Myc protein. P00008997
P08600028A1129 |90 100|reflectionrmacologic
P08600028A1129 |60 75|intron enhancerucleotidase P00
P08600028A1129 |22 38|trans-activationson with alkalin
P08600028A1129 |121 131|propertieshyperbilir
P08600028A1129 |4 8|data0160
P08600048T0000 |17 31|conjunctivitismparison with 
P08600048T0000 |42 69|bone marrow transplantationosphatases and 5-nucleotida
P08600048T0000 |123 127|caseperb
P08600048T0000 |110 115|studyf neo
P08601283A0875 |239 253|SECIS function no longer dis
P08601283A0875 |89 103|selenoproteinsarmacologic as
P08601283A0875 |183 196|SECIS elements a function 
P08601283A0875 |135 139|typeemia
P08601283A0875 |120 127|effects hyperb
P08601283A0875 |15 23|presenceComparis
P08601283A0875 |54 68|reading framesnd 5-nucleotid
P08601283A0875 |142 152|deiodinase00008997A0
P08601283A0875 |27 41|SECIS elementsith alkaline p
P08601283A0875 |70 74|ORFse P0
P08601283A0875 |3 7|view0016
P08601283A0875 |170 173|ORF-] 
P08601284A0000 |103 111|sequencepects of
P08601284A0000 |120 122|bp h
P08601284A0000 |41 47|regionhospha
P08601284A0000 |28 34|spacerth alk
P08601284A0000 |134 149|complementaritynemia. P0000899
P08601284A0000 |157 166|U3 snoRNAhen CSF [
P08601284A0000 |36 39|ETSine
P08601284A0000 |55 63|pre-rRNAd 5-nucl
P08601490A0659 |6 13|animals606T007
P08601616A0726 |101 114|G1/S boundaryaspects of ne
P08601616A0726 |133 149|spindle assemblyinemia. P0000899
P08601616A0726 |73 77|step0000
P08601616A0726 |23 35|pds1 mutantson with alka
P08601616A0726 |125 129|timerbil
P08601616A0726 |5 19|spindle defect1606T0076 Comp
P08601806A0875 |64 69|stepsotida
P08601806A0875 |24 29|RPF-1n wit
P08601806A0875 |109 123|ganglion cellsof neonatal hy
P08601806A0875 |6 10|data606T
P08601806A0875 |77 92|differentiation8171T0000 Pharm
P08601806A0875 |96 104|amacrineogic asp
P08602169A0484 |85 89|type0 Ph
P08602169A0484 |110 114|CPDsf ne
P08602169A0484 |122 131|MAT alphayperbilir
P08602169A0484 |39 45|repair phosp
P08602169A0484 |66 70|siteidas
P08602169A0484 |7 19|point mutant06T0076 Comp
P08602169A0484 |49 61|endonucleaseses and 5-nu
P08602169A0484 |99 106|removalc aspec
P08602169A0484 |136 150|HML alpha locimia. P00008997
P08602608A1056 |38 50|performancese phosphatas
P08602608A1056 |73 77|STKS0000
P08602608A1056 |58 64|CD3500-nucle
P08602608A1056 |27 32|casesith a
P08602608A1056 |145 164|reference procedure08997A0472 When CSF
P08603921A1346 |85 91|growth0 Phar
P08603921A1346 |125 129|cellrbil
P08603921A1346 |49 72|calmodulin binding siteses and 5-nucleotidase 
P08603921A1346 |145 151|manner08997A
P08603921A1346 |17 36|Spc110p truncationsmparison with alkal
P08604338A0198 |19 33|FLI-1 proteinsarison with al
P08604338A0198 |46 67|transcription factorsatases and 5-nucleoti
P08604338A0198 |135 152|promoter elementsemia. P00008997A0
P08604338A0198 |113 122|ets boxeseonatal h
P08604338A0198 |94 107|ets sequencesologic aspect
P08604338A0198 |5 14|EWS-FLI-11606T0076
P08604338A0885 |155 166|interaction When CSF [
P08604338A0885 |58 61|SRE-nu
P08604338A0885 |94 97|SRFolo
P08604338A0885 |209 226|complex formationhe data of K-depl
P08604338A0885 |183 187|steps a 
P08604338A0885 |121 126|FLI-1hyper
P08604338A0885 |172 175|DNA is
P08604338A0885 |110 117|bindingf neona
P08604338A0885 |230 235|FLI-1 rats
P08604338A0885 |3 31|electromobility shift assays001606T0076 Comparison with 
P08604338A0885 |83 90|absence000 Pha
P08604338A0885 |33 50|EWS-FLI-1 bindingkaline phosphatas
P08604708A1086 |156 159|BTGWhe
P08604708A1086 |11 18|studies076 Com
P08604708A1086 |105 121|blood flow ratescts of neonatal 
P08604708A1086 |146 152|change8997A0
P08604708A1086 |56 75|cellulose dialyzers 5-nucleotidase P00
P08604708A1086 |128 135|minuteslirubin
P08605302A1770 |0 15|DNA methylationP00001606T0076 
P08605302A1770 |160 174|rice CatA gene CSF [HCO3-] i
P08605302A1770 |212 234|CatA promoter activitydata of K-depleted rat
P08605302A1770 |146 152|intron8997A0
P08605302A1770 |57 72|deoxyadenosines5-nucleotidase 
P08605302A1770 |263 268|assayn com
P08605302A1770 |114 118|exononat
P08605302A1770 |84 95|GATC motifs00 Pharmaco
P08605324A0434 |10 13|LTR007
P08605324A0434 |30 38|promoter alkalin
P08605326A0772 |12 23|cDNA clones76 Comparis
P08605705A0676 |48 51|CICase
P08605705A0676 |15 28|IgM class CICComparison wi
P08605705A0676 |93 109|disease activitycologic aspects 
P08605705A0676 |61 72|hepatitis Acleotidase 
P08605705A0676 |3 13|conclusion001606T007
P08605931A0777 |0 15|Epitope mappingP00001606T0076 
P08605931A0777 |123 132|RNP motifperbiliru
P08605931A0777 |82 96|epitope domain0000 Pharmacol
P08605931A0777 |42 48|clonesosphat
P08605931A0777 |140 151|U1A protein P00008997A
P08606267A0740 |0 9|VariablesP00001606
P08606267A0740 |166 176|evaluationHCO3-] is 
P08606267A0740 |180 216|Tc-99m 2-methoxy isobutyl isonitrilen as a function of CSF PCO2 the data
P08606267A0740 |135 147|registrationemia. P00008
P08606267A0740 |224 229|scansplete
P08606267A0740 |58 62|data-nuc
P08606267A0740 |244 253|variablesonger dis
P08606267A0740 |79 95|exercise testing71T0000 Pharmaco
P08606267A0740 |218 222|MIBIf K-
P08606267A0740 |25 31|number with 
P08606267A0740 |50 56|eventses and
P08608126A0811 |86 90|acid Pha
P08608126A0811 |179 190|short-chainwn as a fun
P08608126A0811 |111 112|K 
P08608126A0811 |27 31|acidith 
P08608126A0811 |132 134|nMbi
P08608126A0811 |47 63|binding affinitytases and 5-nucl
P08608126A0811 |7 13|length06T007
P08608126A0811 |212 218|lipidsdata o
P08608126A0811 |163 167|acidF [H
P08608126A0811 |140 152|medium-chain P00008997A0
P08608126A0811 |113 114|de
P08608126A0811 |201 205|acidF PC
P08608222T0000 |32 38|regionlkalin
P08608222T0000 |79 94|factor receptor71T0000 Pharmac
P08608222T0000 |111 116|STAT3 neon
P08608222T0000 |125 150|STAT1 homodimer formationrbilirubinemia. P00008997
P08608222T0000 |48 59|granulocyteases and 5-
P08608447A0806 |33 50|codon recognitionkaline phosphatas
P08608447A0806 |58 73|TPI transcripts-nucleotidase P
P08608447A0806 |104 112|splicingects of 
P08608447A0806 |80 85|place1T000
P08608448A0353 |237 242|loopsre no
P08608448A0353 |167 172|S RNACO3-]
P08608448A0353 |14 22|residues Compari
P08608448A0353 |188 198|reactivityunction of
P08608448A0353 |82 89|regions0000 Ph
P08608448A0353 |145 160|structure model08997A0472 When
P08608448A0353 |49 65|dimethylsulphateses and 5-nucleo
P08608448A0353 |216 224|residues of K-de
P08608448A0353 |70 78|kethoxale P00008
P08610272A0265 |239 246|outcome no lon
P08610272A0265 |199 213|growth factorsCSF PCO2 the d
P08610272A0265 |176 194|response modifiersshown as a functio
P08610272A0265 |270 277|diseasered to 
P08610272A0265 |104 112|durationects of 
P08610272A0265 |251 259|patientsisplaced
P08610272A0265 |83 90|control000 Pha
P08610272A0265 |159 163|rolen CS
P08610272A0265 |116 140|maintenance chemotherapyatal hyperbilirubinemia.
P08610272A0265 |64 72|approachotidase 
P08610272A0265 |19 33|investigationsarison with al
P08610328A0228 |34 42|criteriaaline ph
P08610328A0228 |93 104|experiencescologic asp
P08610328A0228 |58 65|studies-nucleo
P08610328A0228 |11 17|REVIEW076 Co
P08610328A0228 |115 122|studiesnatal h
P08610328A0228 |144 149|world00899
P08610328A0228 |0 7|SUMMARYP000016
P08610582A0150 |33 40|lesionskaline 
P08610582A0150 |11 19|patients076 Comp
P08610582A0150 |112 114|T.ne
P08610582A0150 |94 104|MR imagingologic asp
P08610582A0150 |55 63|CT scansd 5-nucl
P08611280A0820 |238 244|cm3/m2e no l
P08611280A0820 |190 191|pc
P08611280A0820 |246 247|pg
P08611280A0820 |145 152|systole08997A0
P08611280A0820 |89 95|cm3/m2armaco
P08611280A0820 |182 188|cm3/m2as a f
P08611280A0820 |60 68|subjectsucleotid
P08611280A0820 |12 19|volumes76 Comp
P08611280A0820 |220 226|cm3/m2K-depl
P08611280A0820 |116 117|pa
P08611280A0820 |163 169|cm3/m2F [HCO
P08611280A0820 |108 114|cm3/m2 of ne
P08611280A0820 |129 134|onsetirubi
P08612852A0553 |119 127|controlsl hyperb
P08612852A0553 |46 61|body mass indexatases and 5-nu
P08612852A0553 |15 34|plasma IGF-I levelsComparison with alk
P08612852A0553 |94 102|patientsologic a
P08612852A0553 |63 66|BMIeot
P08612852A0553 |0 7|RESULTSP000016
P08614403A0557 |21 27|levelsison w
P08614403A0557 |164 172|myotubes [HCO3-]
P08614403A0557 |63 78|C2C12 myoblastseotidase P00008
P08614403A0557 |31 50|Rev-erbA alpha mRNAalkaline phosphatas
P08614403A0557 |111 116|cells neon
P08614403A0989 |168 176|presenceO3-] is 
P08614403A0989 |29 57|GAL4-REV-erbA alpha chimerash alkaline phosphatases and 
P08614403A0989 |180 189|8-Br-cAMPn as a fu
P08614403A0989 |121 134|transcriptionhyperbilirubi
P08614403A0989 |104 110|regionects o
P08614403A0989 |224 227|LBDple
P08614403A0989 |80 86|region1T0000
P08614403A0989 |76 78|AB08
P08614403A0989 |264 272|silencer compare
P08614403A0989 |101 102|Ea
P08614403A0989 |216 222|domain of K-
P08614403A0989 |138 160|GAL4 response elementsa. P00008997A0472 When
P08614410A0000 |138 148|regulationa. P000089
P08614410A0000 |88 99|oncogenesisharmacologi
P08614410A0000 |44 65|gonadotroph cell linephatases and 5-nucleo
P08614410A0000 |194 201|activinn of CS
P08614410A0000 |4 24|alpha T3-1 cell line01606T0076 Compariso
P08614410A0000 |114 118|miceonat
P08614410A0000 |156 190|glycoprotein hormone alpha-subunitWhen CSF [HCO3-] is shown as a fun
P08615012A0627 |0 14|CotransfectionP00001606T0076
P08615012A0627 |72 78|amountP00008
P08615012A0627 |90 97|enzymesrmacolo
P08615012A0627 |24 32|ie1 genen with a
P08615012A0627 |56 64|increase 5-nucle
P08615012A0627 |127 132|cellsiliru
P08615025A1214 |410 415|cellspnoti
P08615025A1214 |145 148|Env089
P08615025A1214 |297 310|cell membraneave a signifi
P08615025A1214 |176 192|immunoreactivityshown as a funct
P08615025A1214 |384 399|membrane fusionears to be an e
P08615025A1214 |94 117|glycosylation phenotypeologic aspects of neona
P08615025A1214 |30 33|Env al
P08615025A1214 |405 408|CD4ve 
P08615025A1214 |325 330|gp120slope
P08615025A1214 |48 55|mutantsases an
P08615025A1214 |253 258|gp120place
P08615025A1214 |263 267|gp41n co
P08615025A1214 |218 223|gp160f K-d
P08615025A1214 |196 198|V3of
P08615025A1214 |131 141|quantitiesubinemia. 
P08615025A1214 |13 26|glycosylation6 Comparison 
P08615025A1214 |337 340|CD4+/-
P08615025A1214 |351 364|membrane gp4100010943A0733
P08615025A1214 |274 277|Envto 
P08615183T0000 |0 7|EffectsP000016
P08615183T0000 |41 50|Parkinsonhosphatas
P08615183T0000 |26 37|pallidotomywith alkali
P08615183T0000 |53 60|diseaseand 5-n
P08616743T0000 |16 19|Dr.omp
P08616743T0000 |7 12|trail06T00
P08617216A0584 |64 71|proteinotidase
P08617216A0584 |73 77|GrpE0000
P08617216A0584 |47 51|DnaKtase
P08617216A0584 |82 91|refolding0000 Phar
P08617216A0584 |110 120|luciferasef neonatal
P08617216A0584 |23 27|DnaJon w
P08617237A0489 |34 39|STAT5aline
P08617237A0489 |92 102|reactivityacologic a
P08617237A0489 |108 132|tyrosine phosphopeptides of neonatal hyperbiliru
P08617237A0489 |64 87|DNA binding specificityotidase P00008171T0000 
P08617237A0489 |163 175|localizationF [HCO3-] is
P08617237A0489 |18 30|phosphoformsparison with
P08617238A0334 |85 100|phosphorylation0 Pharmacologic
P08617238A0334 |145 178|substrate protein MAPKAP kinase-208997A0472 When CSF [HCO3-] is sh
P08617238A0334 |226 244|heat shock proteineted rats are no l
P08617238A0334 |104 118|p38 MAP kinaseects of neonat
P08617238A0334 |36 58|p38 MAP kinase pathwayine phosphatases and 5
P08617238A0334 |249 254|hsp27 disp
P08617238A0334 |127 137|activationilirubinem
P08617238A0334 |0 13|TNF TreatmentP00001606T007
P08617238A0334 |203 218|phosphorylationPCO2 the data o
P08617238A0334 |17 21|cellmpar
P08617243A0336 |116 122|regionatal h
P08617243A0336 |25 32|protein with a
P08617243A0336 |57 65|extracts5-nucleo
P08617243A0336 |96 100|siteogic
P08617311A0979 |51 65|membrane exonss and 5-nucleo
P08617311A0979 |148 160|Xenopus mIgY97A0472 When
P08617311A0979 |132 142|similaritybinemia. P
P08617311A0979 |75 79|mIgY0081
P08617311A0979 |19 38|sequence similarityarison with alkalin
P08617311A0979 |94 98|mIgGolog
P08617311A0979 |103 106|IgEpec
P08617800A0150 |0 7|ControlP000016
P08617800A0150 |60 71|determinantucleotidase
P08617800A0150 |11 24|transcription076 Compariso
P08617800A0150 |75 94|receptor expression008171T0000 Pharmac
P08617800A0150 |32 43|erbB-2 genelkaline pho
P08617800A0675 |0 5|DNaseP0000
P08617800A0675 |94 103|half-siteologic as
P08617800A0675 |41 62|mobility shift assayshosphatases and 5-nuc
P08617800A0675 |132 164|core recognition sequence TGGGAGbinemia. P00008997A0472 When CSF
P08617800A0675 |8 20|footprinting6T0076 Compa
P08617800A0675 |77 80|PBP817
P08617800A0675 |112 122|palindromeneonatal h
P08617802A0993 |70 78|p120 GAPe P00008
P08617802A0993 |111 119|activity neonata
P08617802A0993 |31 40|sequencesalkaline 
P08617802A0993 |6 13|results606T007
P08617802A0993 |127 130|Rasili
P08617802A0993 |48 66|SH2/SH3/SH2 regionases and 5-nucleot
P08618433A0000 |85 89|FLT30 Ph
P08618433A0000 |151 156|STK-10472 
P08618433A0000 |141 146|FLK-2P0000
P08618433A0000 |24 49|growth factor FLT3 ligandn with alkaline phosphata
P08618433A0000 |91 115|tyrosine kinase receptormacologic aspects of neo
P08618433A0000 |117 118|Rt
P08618433A0000 |70 76|ligande P000
P08618433A0000 |51 53|FLs 
P08618433A1720 |3 11|contrast001606T0
P08618433A1720 |47 55|receptortases an
P08618433A1720 |124 143|leukemia cell lineserbilirubinemia. P0
P08618433A1720 |167 180|cell lineagesCO3-] is show
P08618433A1720 |29 39|expressionh alkaline
P08618433A1720 |93 94|%c
P08618433A1720 |57 70|FL expression5-nucleotidas
P08618433A1720 |110 120|cell typesf neonatal
P08618864A0754 |69 73|corese P
P08618864A0754 |8 16|analysis6T0076 C
P08618864A0754 |44 55|mutagenesisphatases an
P08618864A0754 |129 137|activityirubinem
P08618864A0754 |25 31|domain with 
P08618864A0754 |100 108|residues aspects
P08618882A0343 |0 8|AnalysisP0000160
P08618882A0343 |12 29|RAR alpha mutants76 Comparison wit
P08618882A0343 |122 136|BZLF1 activityyperbilirubine
P08618882A0343 |33 53|transfection studieskaline phosphatases 
P08618882A0343 |108 118|inhibition of neonat
P08618882A0343 |71 89|DNA binding domain P00008171T0000 Ph
P08619866A0000 |83 93|infarction000 Pharma
P08619866A0000 |122 136|heart diseasesyperbilirubine
P08619866A0000 |44 47|HGFpha
P08619866A0000 |95 110|angina pectorislogic aspects o
P08619866A0000 |12 42|serum hepatocyte growth factor76 Comparison with alkaline ph
P08619866A0000 |52 60|patients and 5-n
P08619910A0000 |69 75|tremorse P00
P08619910A0000 |300 308|findings a signi
P08619910A0000 |331 350|nigra zona compacta(1.21 +/- 0.23 vs. 
P08619910A0000 |255 262|diseaseaced wh
P08619910A0000 |352 355|SNc001
P08619910A0000 |80 88|akinesia1T0000 P
P08619910A0000 |59 67|rigiditynucleoti
P08619910A0000 |266 274|relationompared 
P08619910A0000 |179 191|observationswn as a func
P08619910A0000 |199 205|effectCSF PC
P08619910A0000 |11 20|mechanism076 Compa
P08619910A0000 |104 110|resultects o
P08619910A0000 |37 51|motor symptomsne phosphatase
P08619910A0000 |128 147|dopamine deficiencylirubinemia. P00008
P08619910A0000 |238 247|treatmente no long
P08620003T0000 |34 56|N-O acyl rearrangementaline phosphatases and
P08620003T0000 |72 76|stepP000
P08620003T0000 |84 100|splicing process00 Pharmacologic
P08620003T0000 |18 26|evidenceparison 
P08620003T0000 |0 16|Protein splicingP00001606T0076 C
P08620856A1172 |207 220|reading frame the data of 
P08620856A1172 |24 28|datan wi
P08620856A1172 |126 145|mouse c-kit proteinbilirubinemia. P000
P08620856A1172 |247 257|c-kit cDNAer displac
P08620856A1172 |180 184|sizen as
P08620856A1172 |30 54|western blot experiments alkaline phosphatases a
P08620856A1172 |329 340|spermatozoae (1.21 +/-
P08620856A1172 |160 171|polypeptide CSF [HCO3-
P08620856A1172 |285 291|stages but s
P08620856A1172 |295 310|spermatogenesis have a signifi
P08620856A1172 |64 72|antibodyotidase 
P08620856A1172 |111 118|portion neonat
P08620856A1172 |3 12|agreement001606T00
P08620889A0771 |32 39|elementlkaline
P08620889A0771 |75 88|transcription008171T0000 P
P08620889A0771 |127 132|cellsiliru
P08620889A0771 |47 66|aldolase C promotertases and 5-nucleot
P08620889A0771 |22 25|G+Cson
P08621017A1186 |0 8|LY290181P0000160
P08621017A1186 |28 51|uPA promoter activationth alkaline phosphatase
P08621017A1186 |181 188|element as a f
P08621017A1186 |108 116|proteins of neon
P08621017A1186 |124 135|uPA PEA3/12erbilirubin
P08621017A1186 |89 96|bindingarmacol
P08621017A1186 |190 193|TREcti
P08621017A1186 |64 71|phorbolotidase
P08621017A1186 |138 169|tetradecanoylphorbol 13-acetatea. P00008997A0472 When CSF [HCO
P08621384A0935 |0 9|TreatmentP00001606
P08621384A0935 |134 137|minnem
P08621384A0935 |146 179|PKCdelta tyrosine phosphorylation8997A0472 When CSF [HCO3-] is sho
P08621384A0935 |57 79|growth factor receptor5-nucleotidase P000081
P08621384A0935 |13 26|keratinocytes6 Comparison 
P08621384A0935 |114 127|growth factoronatal hyperb
P08621384A0935 |92 100|TGFalphaacologic
P08621384A0935 |81 85|EGFRT000
P08621420A1166 |69 79|antibodiesse P000081
P08621420A1166 |56 59|p50 5-
P08621420A1166 |122 128|effectyperbi
P08621420A1166 |44 52|antibodyphatases
P08621420A1166 |96 114|NF-kappaB proteinsogic aspects of ne
P08621420A1166 |83 86|p65000
P08621420A1166 |18 23|bandsparis
P08621448A0862 |33 37|cDNAkali
P08621448A0862 |112 119|proteinneonata
P08621448A0862 |28 31|DNAth 
P08621448A0862 |96 98|C1og
P08621448A0862 |53 78|RL95-2 expression libraryand 5-nucleotidase P00008
P08621448A0862 |39 44|clone phos
P08621451A0552 |0 4|BiolP000
P08621453A0815 |34 44|antibodiesaline phos
P08621453A0815 |75 87|cell lysates008171T0000 
P08621453A0815 |64 69|80K-Hotida
P08621453A0815 |127 138|fibroblastsilirubinemi
P08621453A0815 |3 11|addition001606T0
P08621542A0535 |117 126|TNF-alphatal hyper
P08621542A0535 |46 53|kinasesatases 
P08621542A0535 |78 93|protein kinases171T0000 Pharma
P08621542A0535 |27 32|c-Junith a
P08621542A0535 |10 25|protein kinases0076 Comparison
P08621542A0535 |55 59|JNKsd 5-
P08621542A0535 |128 132|IL-1liru
P08621542A0535 |138 156|CD28 costimulationa. P00008997A0472 
P08621628A1233 |6 13|hGRbeta606T007
P08621628A1233 |72 89|hGRalpha activityP00008171T0000 Ph
P08621628A1233 |59 68|inhibitornucleotid
P08621659A0189 |119 126|domainsl hyper
P08621659A0189 |116 117|Ga
P08621659A0189 |30 40|Gla domain alkaline 
P08621659A0189 |0 4|Gas6P000
P08621659A0189 |87 94|repeatsPharmac
P08621659A0189 |68 74|growthase P0
P08621661A1035 |5 22|P5CDh cDNA clones1606T0076 Compari
P08621661A1035 |192 202|transcription of CSF
P08621661A1035 |122 126|cDNAyper
P08621661A1035 |60 74|Northern blotsucleotidase P0
P08621661A1035 |93 100|tissuescologic
P08621661A1035 |46 56|transcriptatases and
P08621661A1035 |158 164|intronen CSF
P08621664A1430 |68 83|phosphorylationase P00008171T0
P08621664A1430 |114 117|PKNona
P08621664A1430 |87 110|neurofilament L proteinPharmacologic aspects o
P08621664A1430 |18 41|neurofilament L proteinparison with alkaline p
P08621664A1430 |0 14|PolymerizationP00001606T0076
P08621714A0361 |64 75|thiol groupotidase P00
P08621714A0361 |37 52|disulfide bondsne phosphatases
P08621714A0361 |79 84|Cys2571T00
P08621714A0361 |4 11|protein01606T0
P08621719A0000 |7 13|others06T007
P08621719A0000 |134 161|T cell receptor stimulationnemia. P00008997A0472 When 
P08621719A0000 |41 69|c-cbl proto-oncogene producthosphatases and 5-nucleotida
P08621719A0000 |104 128|tyrosine phosphorylationects of neonatal hyperbi
P08621719A0000 |93 100|targetscologic
P08621719A0568 |65 69|Grb2tida
P08621719A0568 |14 22|fraction Compari
P08621719A0568 |26 29|Cblwit
P08621719A0568 |107 123|Grb2 SH3 domainss of neonatal hy
P08621719A0568 |79 90|interaction71T0000 Pha
P08621730T0000 |86 92|COL1A2 Pharm
P08621730T0000 |73 74|I0
P08621730T0000 |42 52|regulationosphatases
P08621730T0000 |128 146|growth factor-betalirubinemia. P0000
P08621730T0000 |94 111|promoter activityologic aspects of
P08621730T0000 |66 72|alpha2idase 
P08621730T0000 |76 84|collagen08171T00
P08621730T0000 |3 24|AP-1 binding sequence001606T0076 Compariso
P08622030A0667 |51 61|age groupss and 5-nu
P08622030A0667 |15 26|differencesComparison 
P08622030A0667 |179 184|levelwn as
P08622030A0667 |145 172|serum lactate dehydrogenase08997A0472 When CSF [HCO3-]
P08622030A0667 |121 139|performance statushyperbilirubinemia
P08622030A0667 |174 177|LDHs s
P08622030A0667 |65 89|baseline characteristicstidase P00008171T0000 Ph
P08622030A0667 |101 119|treatment protocolaspects of neonata
P08622070A0889 |71 82|progression P00008171T
P08622070A0889 |9 17|patientsT0076 Co
P08622070A0889 |31 33|CAal
P08622070A0889 |54 58|timend 5
P08622070A0889 |22 23|%s
P08622070A0889 |38 46|responsee phosph
P08622596A0189 |35 39|dietline
P08622596A0189 |43 47|homespha
P08622596A0189 |89 92|fatarm
P08622596A0189 |4 7|men016
P08622596A0189 |99 103|weekc as
P08622596A0189 |70 73|fate P
P08622645A1026 |17 20|VDRmpa
P08622645A1026 |39 49|vitamin D3 phosphata
P08622645A1026 |67 79|RA inductiondase P000081
P08622645A1026 |103 110|elementpects o
P08622668A1155 |170 186|binding affinity-] is shown as a
P08622668A1155 |74 84|modulation0008171T00
P08622668A1155 |90 129|phosphorylation-dephosphorylation cyclermacologic aspects of neonatal hyperbil
P08622668A1155 |133 149|C1 hnRNP proteininemia. P0000899
P08622668A1155 |62 68|U6 RNAleotid
P08622668A1155 |195 202|protein of CSF
P08622668A1155 |207 215|pre-mRNA the dat
P08622668A1155 |6 13|results606T007
P08622668A1155 |50 58|functiones and 5
P08622675A0587 |0 9|InclusionP00001606
P08622675A0587 |26 36|N terminuswith alkal
P08622675A0587 |97 107|similaritygic aspect
P08622675A0587 |124 136|factor Lef-1erbilirubine
P08622675A0587 |66 73|proteinidase P
P08622698T0000 |69 78|mechanismse P00008
P08622698T0000 |111 122|virus EBNA2 neonatal h
P08622698T0000 |58 63|genes-nucl
P08622698T0000 |20 26|Notch1rison 
P08622887A1026 |16 37|mobility shift assaysomparison with alkali
P08622887A1026 |268 271|DBDpar
P08622887A1026 |61 103|glucocorticoid receptor DNA binding domaincleotidase P00008171T0000 Pharmacologic as
P08622887A1026 |105 108|DBDcts
P08622887A1026 |146 152|motifs8997A0
P08622887A1026 |167 170|DBDCO3
P08622887A1026 |133 138|GRE-2inemi
P08622887A1026 |175 214|oligonucleotide competition experiments shown as a function of CSF PCO2 the da
P08622887A1026 |39 44|EMSAs phos
P08622887A1026 |253 263|affinitiesplaced whe
P08622893A0000 |50 54|RTKses a
P08622893A0000 |160 171|development CSF [HCO3-
P08622893A0000 |193 212|signalling pathwayson of CSF PCO2 the 
P08622893A0000 |122 135|communicationyperbilirubin
P08622893A0000 |230 236|family rats 
P08622893A0000 |77 86|prototype8171T0000
P08622893A0000 |10 19|subfamily0076 Comp
P08622893A0000 |66 69|EPHida
P08622893A0000 |23 48|receptor tyrosine kinaseson with alkaline phosphat
P08622893A0000 |99 104|rolesc asp
P08623554A1058 |48 57|infectionases and 
P08623554A1058 |61 67|plantscleoti
P08623554A1058 |11 18|protein076 Com
P08624445A0257 |152 157|wx-m9472 W
P08624445A0257 |176 178|Acsh
P08624445A0257 |62 91|cytosine methylation patternsleotidase P00008171T0000 Phar
P08624445A0257 |200 210|tenth exonSF PCO2 th
P08624445A0257 |99 124|transposase binding sitesc aspects of neonatal hyp
P08624445A0257 |159 168|Ac allelen CSF [HC
P08624445A0257 |35 54|sequencing analysisline phosphatases a
P08624445A0257 |223 227|geneeple
P08624445A0257 |137 139|Acia
P08625806A0263 |0 7|Krox-20P000016
P08625806A0263 |63 73|expressioneotidase P
P08625806A0263 |126 137|maintenancebilirubinem
P08625806A0263 |77 79|r381
P08625806A0263 |11 27|zinc finger gene076 Comparison w
P08625806A0263 |141 154|mouse embryosP00008997A047
P08625806A0263 |52 59|pattern and 5-
P08625806A0263 |84 86|r500
P08625900T0000 |39 50|polypeptide phosphatas
P08625900T0000 |10 19|adenylate0076 Comp
P08625900T0000 |121 128|pathwayhyperbi
P08625900T0000 |61 88|prolactin promoter activitycleotidase P00008171T0000 P
P08625900T0000 |214 221|hormoneta of K
P08625900T0000 |95 109|protein kinaselogic aspects 
P08625900T0000 |172 179|pathway is sho
P08625924A0411 |0 10|Clones 33FP00001606T
P08625924A0411 |167 172|mRNAsCO3-]
P08625924A0411 |63 74|amino acidseotidase P0
P08625924A0411 |15 18|34BCom
P08625924A0411 |37 55|aromatase proteinsne phosphatases an
P08625924A0411 |92 96|sizeacol
P08625924A0411 |116 144|polyadenylation signal usageatal hyperbilirubinemia. P00
P08625987A1086 |213 220|B cellsata of 
P08625987A1086 |47 58|VpreB genestases and 5
P08625987A1086 |134 146|state levelsnemia. P0000
P08625987A1086 |75 87|pro-B/pre-BI008171T0000 
P08625987A1086 |123 126|RNAper
P08625987A1086 |106 111|cellsts of
P08625987A1086 |10 38|bone marrow cells expression0076 Comparison with alkalin
P08626065A0000 |39 56|Bacillus subtilis phosphatases and
P08626065A0000 |95 99|nrdAlogi
P08626065A0000 |62 74|DNA fragmentleotidase P0
P08626065A0000 |104 114|citB genesects of ne
P08626065A0000 |128 135|degreeslirubin
P08626065A0000 |58 60|Bs-n
P08626065A0000 |143 153|chromosome0008997A04
P08626290T0000 |51 59|homologss and 5-
P08626290T0000 |79 95|membrane protein71T0000 Pharmaco
P08626290T0000 |36 41|genesine p
P08626290T0000 |97 101|OmpAgic 
P08626290T0000 |0 21|Aeromonas salmonicidaP00001606T0076 Compar
P08626313A1037 |0 10|ExpressionP00001606T
P08626313A1037 |14 17|Msp Co
P08626313A1037 |55 63|msp gened 5-nucl
P08626325A0543 |70 74|UmuDe P0
P08626325A0543 |130 134|UmuDrubi
P08626325A0543 |124 128|UmuDerbi
P08626325A0543 |61 65|UmuDcleo
P08626325A0543 |143 154|heterodimer0008997A047
P08626325A0543 |36 40|dataine 
P08626325A0543 |110 119|UmuD-UmuDf neonata
P08626325A0543 |156 165|UmuD-UmuDWhen CSF 
P08626325A0543 |98 108|homodimersic aspects
P08626325A0543 |3 12|agreement001606T00
P08626437A0332 |0 10|Lyn kinaseP00001606T
P08626437A0332 |181 189|tyrosine as a fu
P08626437A0332 |86 111|glutathione S-transferase Pharmacologic aspects of
P08626437A0332 |113 116|GSTeon
P08626437A0332 |57 60|BCP5-n
P08626437A0332 |118 128|Lyn fusional hyperbi
P08626437A0332 |35 42|lysatesline ph
P08626437A0332 |170 177|p34cdc2-] is s
P08626493A1468 |0 9|MutationsP00001606
P08626493A1468 |27 33|regionith al
P08626493A1468 |227 235|type E1Ated rats
P08626493A1468 |88 115|retinoblastoma gene productharmacologic aspects of neo
P08626493A1468 |181 195|PEPCK promoter as a function
P08626493A1468 |45 48|E1Ahat
P08626493A1468 |66 73|bindingidase P
P08626493A1468 |37 40|CR2ne 
P08626493A1468 |77 80|E1A817
P08626493A1468 |158 171|transcriptionen CSF [HCO3-
P08626493A1468 |143 154|stimulation0008997A047
P08626493A1468 |117 120|pRbtal
P08626529A0000 |154 158|face2 Wh
P08626529A0000 |28 35|Sjogrenth alka
P08626529A0000 |194 196|B.n 
P08626529A0000 |189 192|Tohnct
P08626529A0000 |179 183|Kooywn a
P08626529A0000 |107 123|membrane proteins of neonatal hy
P08626529A0000 |38 54|syndrome patiente phosphatases a
P08626529A0000 |6 20|autoantibodies606T0076 Compa
P08626529A0000 |185 187|J.a 
P08626529A0799 |69 73|p230se P
P08626529A0799 |124 138|characteristicerbilirubinemi
P08626529A0799 |242 253|amino acids longer dis
P08626529A0799 |28 35|regionsth alka
P08626529A0799 |198 202|p230 CSF
P08626529A0799 |285 298|granin family but still ha
P08626529A0799 |186 196|structures function 
P08626529A0799 |221 240|sequence ESLALEELEL-depleted rats are 
P08626529A0799 |266 271|motifompar
P08626529A0799 |95 104|frequencylogic asp
P08626529A0799 |142 155|alpha-helices00008997A0472
P08626529A0799 |351 371|neuroendocrine cells00010943A0733 Fluraz
P08626529A0799 |108 122|heptad repeats of neonatal h
P08626529A0799 |309 317|proteinsicantly 
P08626529A0799 |37 48|amino acidsne phosphat
P08626529A0799 |339 347|granules- 0.23 v
P08626539T0000 |0 19|Binding specificityP00001606T0076 Comp
P08626539T0000 |24 34|modulationn with alk
P08626539T0000 |104 113|receptorsects of n
P08626539T0000 |80 92|heterodimers1T0000 Pharm
P08626539T0000 |42 66|ApoA-I promoter activityosphatases and 5-nucleot
P08626539T0000 |70 74|homoe P0
P08626540A1007 |98 106|ceramideic aspec
P08626540A1007 |61 69|turnovercleotida
P08626540A1007 |108 124|glucosylceramide of neonatal hyp
P08626540A1007 |130 146|lactosylceramiderubinemia. P0000
P08626540A1007 |42 56|concentrationsosphatases and
P08626596A0000 |85 89|role0 Ph
P08626596A0000 |104 109|cellsects 
P08626596A0000 |55 69|protein kinased 5-nucleotida
P08626596A0000 |193 201|pathwayson of CS
P08626596A0000 |135 148|ATP depletionemia. P000089
P08626596A0000 |71 75|AMPK P00
P08626596A0000 |115 123|stressesnatal hy
P08626596A0000 |17 25|evidencemparison
P08626610A0931 |170 175|forms-] is
P08626610A0931 |181 187|result as a 
P08626610A0931 |134 147|COOH terminusnemia. P00008
P08626610A0931 |43 50|SREBP-1sphatas
P08626610A0931 |106 112|regionts of 
P08626610A0931 |31 39|cleavagealkaline
P08626610A0931 |114 121|residueonatal 
P08626610A0931 |203 211|splicingPCO2 the
P08626610A0931 |16 27|suppressionomparison w
P08626612A1040 |0 2|AmP0
P08626667A1372 |0 28|EMSA competition experimentsP00001606T0076 Comparison wi
P08626667A1372 |41 50|mutationshosphatas
P08626667A1372 |122 130|proteinsyperbili
P08626667A1372 |99 106|bindingc aspec
P08626667A1372 |147 167|type oligonucleotide997A0472 When CSF [H
P08626667A1372 |69 76|repeatsse P000
P08626667A1517 |171 190|GPT gene expression] is shown as a fun
P08626667A1517 |62 69|repeatsleotida
P08626667A1517 |135 151|motifs functionsemia. P00008997A
P08626667A1517 |113 123|conclusioneonatal hy
P08626667A1517 |23 31|promoteron with 
P08626667A1517 |0 13|TranscriptionP00001606T007
P08626698A0989 |171 191|complex kinase assay] is shown as a func
P08626698A0989 |55 76|PKC beta transfectantd 5-nucleotidase P000
P08626698A0989 |21 29|increaseison wit
P08626698A0989 |90 109|immunoprecipitationrmacologic aspects 
P08626698A0989 |33 46|ERK3 activitykaline phosph
P08626698A0989 |201 217|gel kinase assayF PCO2 the data 
P08626698A0989 |136 144|antibodymia. P00
P08626777A0537 |171 185|cartilage gene] is shown as 
P08626777A0537 |144 161|link protein gene008997A0472 When 
P08626777A0537 |93 99|motifscologi
P08626777A0537 |130 136|regionrubine
P08626777A0537 |33 48|Col2a1 enhancerkaline phosphat
P08626777A0537 |66 81|sequence motifsidase P00008171
P08626777A0537 |0 17|Sequence analysisP00001606T0076 Co
P08626785A0674 |305 312|mTGRRE1gnifica
P08626785A0674 |328 353|hexanucleotide half-sitespe (1.21 +/- 0.23 vs. P00
P08626785A0674 |397 410|DR7/DR5 motif effective hy
P08626785A0674 |295 302|mTGRRE1 have a
P08626785A0674 |430 446|RXR heterodimers optimum dose fo
P08626785A0674 |126 135|sequencesbilirubin
P08626785A0674 |179 218|mouse tissue transglutaminase promoterswn as a function of CSF PCO2 the data o
P08626785A0674 |451 465|RXR homodimers in general pr
P08626785A0674 |19 29|activationarison wit
P08626785A0674 |426 429|RAR th
P08626785A0674 |263 293|pair retinoid response elementn compared to controls but sti
P08626785A0674 |232 238|regionats ar
P08626785A0674 |108 114|region of ne
P08626785A0674 |37 69|tissue transglutaminase promoterne phosphatases and 5-nucleotida
P08626809A0729 |84 102|eIF-2alpha peptide00 Pharmacologic a
P08626809A0729 |15 19|pPKRComp
P08626809A0729 |63 68|Ser51eotid
P08626809A0729 |132 156|eIF-2alpha kinase familybinemia. P00008997A0472 
P08626809A0729 |110 124|characteristicf neonatal hyp
P08627354A0000 |34 40|familyaline 
P08627354A0000 |11 20|synapsins076 Compa
P08627354A0000 |86 96|regulation Pharmacol
P08627354A0000 |53 61|proteinsand 5-nu
P08627354A0000 |100 124|neurotransmitter release aspects of neonatal hyp
P08627649A0734 |239 242|Sp3 no
P08627649A0734 |219 229|Sp1 family K-deplete
P08627649A0734 |89 96|bindingarmacol
P08627649A0734 |133 154|transcription factorsinemia. P00008997A047
P08627649A0734 |119 129|Ets familyl hyperbil
P08627649A0734 |16 37|mobility shift assaysomparison with alkali
P08627649A0734 |50 58|extractses and 5
P08627649A0734 |185 196|interactiona function 
P08627649A0734 |262 268|GC boxen com
P08627649A0734 |231 234|Sp1rat
P08627649A0734 |162 168|P4 EBSSF [HC
P08627649A0734 |109 110|so
P08627649A0734 |204 211|membersCO2 the
P08627649A0734 |64 75|FREJ4 cellsotidase P00
P08627649A0734 |102 108|memberspects
P08627667A0132 |0 5|ZEBRAP0000
P08627667A0132 |115 128|specificitiesnatal hyperbi
P08627667A0132 |49 54|c-Fosses a
P08627667A0132 |19 39|AP-1 bZip activatorsarison with alkaline
P08627667A0132 |84 91|domains00 Phar
P08627688A1520 |34 38|I299alin
P08627688A1520 |66 74|activityidase P0
P08627688A1520 |5 11|result1606T0
P08627719A0784 |0 28|UV cross-linking experimentsP00001606T0076 Comparison wi
P08627719A0784 |88 103|protein factorsharmacologic as
P08627719A0784 |183 184|As
P08627719A0784 |47 60|HSV infectiontases and 5-n
P08627719A0784 |186 195|site RNAs function
P08627719A0784 |291 295|IE63till
P08627719A0784 |260 267|bindingwhen co
P08627719A0784 |178 182|polyown 
P08627719A0784 |126 135|componentbilirubin
P08627719A0784 |277 287|expressioncontrols b
P08627719A0784 |77 84|binding8171T00
P08627719A0784 |229 236|classesd rats 
P08627719A0784 |168 172|CstFO3-]
P08627719A0784 |201 212|virus genesF PCO2 the 
P08627719A0784 |139 166|cleavage stimulation factor. P00008997A0472 When CSF [
P08628251A1455 |0 7|CM-ACO3P000016
P08628251A1455 |24 31|flowersn with 
P08628251A1455 |65 72|stimulitidase 
P08628254A0665 |71 80|AP1 sites P0000817
P08628254A0665 |133 137|fociinem
P08628254A0665 |52 67|transactivators and 5-nucleoti
P08628254A0665 |24 40|Jun/eb1 chimerasn with alkaline 
P08628254A0665 |114 122|c-Ha-Rasonatal h
P08628255A0932 |16 26|HeLa cellsomparison 
P08628255A0932 |28 38|expressionth alkalin
P08628255A0932 |160 164|site CSF
P08628255A0932 |94 107|DNA synthesisologic aspect
P08628255A0932 |133 141|presenceinemia. 
P08628255A0932 |172 186|H2A.1 promoter is shown as a
P08628255A0932 |42 61|luciferase activityosphatases and 5-nu
P08628255A0932 |81 90|beginningT0000 Pha
P08628260A0895 |20 40|transfection studiesrison with alkaline 
P08628260A0895 |104 122|promoter sequencesects of neonatal h
P08628260A0895 |44 55|HepG2 cellsphatases an
P08628260A0895 |133 143|nucleotideinemia. P0
P08628260A0895 |183 191|increases a func
P08628260A0895 |195 212|promoter activity of CSF PCO2 the 
P08628260A0895 |92 98|factoracolog
P08628260A0895 |148 155|results97A0472
P08628260A0895 |76 84|deletion08171T00
P08628284A0181 |17 38|yeast reporter strainmparison with alkalin
P08628284A0181 |135 140|TRE-1emia.
P08628284A0181 |74 81|control0008171
P08628284A0181 |125 131|copiesrbilir
P08628284A0181 |89 102|CYC1 promoterarmacologic a
P08628284A0181 |54 63|lacZ genend 5-nucl
P08628302A0683 |16 36|transcription factoromparison with alkal
P08628302A0683 |43 55|interactionssphatases an
P08628302A0683 |65 79|RNA polymerasetidase P000081
P08628302A0683 |83 106|transcription apparatus000 Pharmacologic aspec
P08628302A0683 |3 10|hnRNP K001606T
P08628681A0364 |32 39|kb mRNAlkaline
P08628681A0364 |57 71|Northern blots5-nucleotidase
P08628681A0364 |75 85|oocyte RNA008171T000
P08628681A0364 |96 109|X.laevis cDNAogic aspects 
P08628681A0821 |0 21|Sequence conservationP00001606T0076 Compar
P08628681A0821 |94 105|pol domainsologic aspe
P08628681A0821 |120 134|DNA polymerase hyperbilirubi
P08628681A0821 |71 78|centers P00008
P08628681A0821 |38 46|residuese phosph
P08628681A0821 |86 89|exo Ph
P08629348A0237 |184 189|cysts a fu
P08629348A0237 |93 100|changescologic
P08629348A0237 |245 258|hydrocephalusnger displace
P08629348A0237 |31 38|historyalkalin
P08629348A0237 |235 243|epilepsy are no 
P08629348A0237 |159 168|processesn CSF [HC
P08629348A0237 |48 50|BIas
P08630542A1421 |84 92|increase00 Pharm
P08630542A1421 |44 45|Vp
P08630542A1421 |96 97|Qo
P08630542A1421 |6 14|findings606T0076
P08630542A1421 |131 140|procedureubinemia.
P08630542A1421 |115 123|responsenatal hy
P08630542A1421 |65 76|consequencetidase P000
P08630542A1421 |32 40|increaselkaline 
P08630548A0000 |85 92|potency0 Pharm
P08630548A0000 |151 160|TNF-alpha0472 When
P08630548A0000 |52 62|regulation and 5-nuc
P08630548A0000 |8 17|cytokines6T0076 Co
P08630548A0000 |122 149|tumor necrosis factor-alphayperbilirubinemia. P0000899
P08630548A0000 |33 39|degreekaline
P08630548A0000 |115 119|IL-1nata
P08630548A0000 |100 113|interleukin-1 aspects of n
P08630583A1056 |69 70|Qs
P08630583A1056 |10 12|Hb00
P08630583A1056 |59 65|effectnucleo
P08630583A1056 |42 53|CO2 contentosphatases 
P08630583A1056 |3 5|pH00
P08630599A0534 |205 214|policemenO2 the da
P08630599A0534 |188 201|micrograms/mlunction of CS
P08630599A0534 |158 166|patientsen CSF [
P08630599A0534 |113 117|meaneona
P08630599A0534 |82 90|patients0000 Pha
P08630599A0534 |122 124|SDyp
P08630599A0534 |250 261|coal minersdisplaced w
P08630599A0534 |141 154|micrograms/mlP00008997A047
P08630599A0534 |233 246|micrograms/mlts are no lon
P08630599A0534 |103 111|subjectspects of
P08630599A0534 |3 13|difference001606T007
P08630599A0534 |17 46|elastin peptide concentrationmparison with alkaline phosph
P08631667A0851 |0 14|IdentificationP00001606T0076
P08631667A0851 |198 213|kinase activity CSF PCO2 the d
P08631667A0851 |270 278|plasmidsred to c
P08631667A0851 |166 178|enzyme assayHCO3-] is sh
P08631667A0851 |45 53|tmk genehatases 
P08631667A0851 |23 29|regionon wit
P08631667A0851 |82 97|complementation0000 Pharmacolo
P08631667A0851 |245 248|usenge
P08631667A0851 |217 230|cell extractsof K-depleted
P08631667A0851 |143 149|mutant000899
P08631667A0851 |103 120|yeast dTMP kinasepects of neonatal
P08631685A0000 |100 118|amine oxidase gene aspects of neonat
P08631685A0000 |79 83|maoA71T0
P08631685A0000 |60 77|monoamine oxidaseucleotidase P0000
P08631685A0000 |15 19|geneComp
P08631685A0000 |145 148|min089
P08631685A0000 |24 30|coppern with
P08631685A0000 |173 183|chromosomeis shown a
P08631760A0609 |50 53|Crkes 
P08631760A0609 |82 96|phosphopeptide0000 Pharmacol
P08631760A0609 |36 46|SH2 domainine phosph
P08631760A0609 |112 133|Crk-SH2 binding motifneonatal hyperbilirub
P08631760A0609 |5 16|interaction1606T0076 C
P08631797A0982 |16 22|ErbB-2ompari
P08631797A0982 |180 191|EGF bindingn as a func
P08631797A0982 |120 127|ligands hyperb
P08631797A0982 |60 84|tyrosine phosphorylationucleotidase P00008171T00
P08631797A0982 |173 176|NDFis 
P08631797A0982 |163 169|effectF [HCO
P08631797A0982 |38 54|receptor subunite phosphatases a
P08631817T0000 |0 14|IdentificationP00001606T0076
P08631817T0000 |47 74|kinase phosphorylation sitetases and 5-nucleotidase P0
P08631817T0000 |97 101|formgic 
P08631817T0000 |111 156|deoxyuridine triphosphate nucleotidohydrolase neonatal hyperbilirubinemia. P00008997A0472 
P08631817T0000 |20 29|consensusrison wit
P08631820A0755 |4 8|cDNA0160
P08631820A0755 |149 157|Lacroute7A0472 W
P08631820A0755 |135 143|Delourmeemia. P0
P08631820A0755 |121 133|FPS activityhyperbilirub
P08631820A0755 |30 39|FPS1 gene alkaline
P08631820A0755 |145 147|D.08
P08631820A0755 |95 107|yeast strainlogic aspect
P08631820A0755 |167 172|KarstCO3-]
P08631820A0755 |159 161|F.n 
P08631820A0755 |67 82|complementationdase P00008171T
P08631820A0755 |174 176|F.s 
P08631822A0677 |34 38|VEGFalin
P08631822A0677 |13 30|plasmin fragments6 Comparison with
P08631822A0677 |111 125|VEGF receptors neonatal hype
P08631822A0677 |58 65|respect-nucleo
P08631822A0677 |131 138|abilityubinemi
P08631822A0677 |86 97|interaction Pharmacolo
P08631822A0677 |162 178|cell mitogenesisSF [HCO3-] is sh
P08631822A0677 |69 84|heparin bindingse P00008171T00
P08631908A0224 |0 7|VDR/RXRP000016
P08631908A0224 |47 50|DR5tas
P08631908A0224 |77 97|mobility shift assay8171T0000 Pharmacolo
P08631908A0224 |26 31|VDREswith 
P08631908A0224 |39 42|DR4 ph
P08631934A0000 |171 174|G/A] i
P08631934A0000 |159 160|Cn
P08631934A0000 |131 135|siteubin
P08631934A0000 |161 166|A/C/GCSF [
P08631934A0000 |167 170|GTTCO3
P08631934A0000 |152 154|YG47
P08631934A0000 |19 29|Myb familyarison wit
P08631934A0000 |155 158|A/G Wh
P08631934A0000 |4 11|members01606T0
P08631934A0000 |98 104|domainic asp
P08631934A0000 |142 150|sequence00008997
P08631934A0000 |70 78|homologye P00008
P08631934A0000 |33 54|transcription factorskaline phosphatases a
P08631934A0000 |137 140|MBSia.
P08631944A0663 |223 232|secretionepleted r
P08631944A0663 |209 219|regulationhe data of
P08631944A0663 |45 62|C epsilon4 domainhatases and 5-nuc
P08631944A0663 |22 29|isoformson wit
P08631944A0663 |127 142|J558L cell lineilirubinemia. P
P08631944A0663 |95 105|IgE grandelogic aspe
P08631944A0663 |3 11|contrast001606T0
P08631944A0663 |189 193|cellncti
P08631944A0663 |86 93|M2 exon Pharma
P08631958T0000 |38 57|protein IE2 tetherse phosphatases and 
P08631958T0000 |97 100|p53gic
P08631958T0000 |76 93|repression domain08171T0000 Pharma
P08631958T0000 |6 21|cytomegalovirus606T0076 Compar
P08632009A1067 |19 25|actionarison
P08632009A1067 |29 49|C/EBP family membersh alkaline phosphata
P08632009A1067 |74 89|characteristics0008171T0000 Ph
P08632009A1067 |120 139|expression profiles hyperbilirubinemia
P08632009A1067 |145 167|DNA binding affinities08997A0472 When CSF [H
P08632009A1067 |214 239|DNA binding specificitiesta of K-depleted rats are
P08632009A1067 |198 206|addition CSF PCO
P08632009A1067 |4 15|specificity01606T0076 
P08632009A1067 |173 182|cofactorsis shown 
P08632009A1067 |98 104|factoric asp
P08632015A0879 |4 14|antibodies01606T0076
P08632015A0879 |42 55|transcriptionosphatases an
P08632015A0879 |59 88|DNA polymerase alpha promoternucleotidase P00008171T0000 P
P08632015A1226 |19 27|analysisarison w
P08632015A1226 |210 220|expressione data of 
P08632015A1226 |165 169|DREF[HCO
P08632015A1226 |224 227|DNAple
P08632015A1226 |45 53|presencehatases 
P08632015A1226 |57 73|DREF polypeptide5-nucleotidase P
P08632015A1226 |109 123|division cycleof neonatal hy
P08632015A1226 |149 161|accumulation7A0472 When 
P08632015A1226 |248 253|genesr dis
P08632015A1226 |77 83|nuclei8171T0
P08632015A1226 |263 276|DRE sequencesn compared to
P08632018A0587 |85 96|UGT1A1 gene0 Pharmacol
P08632018A0587 |30 41|nucleotides alkaline p
P08632018A0587 |71 77|region P0000
P08632018A0587 |112 124|MC inductionneonatal hyp
P08632018A0587 |2 14|DNA fragment0001606T0076
P08632463A1508 |100 108|progress aspects
P08632463A1508 |76 80|role0817
P08632463A1508 |25 33|argument with al
P08632463A1508 |43 47|betaspha
P08632463A1508 |5 11|result1606T0
P08632463A1508 |112 136|transcription elongationneonatal hyperbilirubine
P08632463A1508 |49 56|subunitses and
P08632779A0351 |204 214|HeLa cellsCO2 the da
P08632779A0351 |193 200|nucleuson of C
P08632779A0351 |89 94|NLS-Carmac
P08632779A0351 |183 184|%s
P08632779A0351 |47 49|AAta
P08632779A0351 |30 33|NLS al
P08632779A0351 |4 15|XPG regions01606T0076 
P08632779A0351 |157 165|beta-galhen CSF 
P08632779A0351 |96 98|AAog
P08632779A0351 |71 73|AA P
P08632779A0351 |64 69|NLS-Botida
P08632779A0351 |35 45|amino acidline phosp
P08633855A1064 |4 13|lacS gene01606T007
P08633855A1064 |124 139|S. thermophiluserbilirubinemia
P08633855A1064 |31 67|E. coli-Streptococcus shuttle vectoralkaline phosphatases and 5-nucleoti
P08633855A1064 |179 185|NZ6091wn as 
P08633855A1064 |161 167|strainCSF [H
P08633855A1064 |96 120|lacS deletion derivativeogic aspects of neonatal
P08634290A0000 |18 30|retrovirusesparison with
P08634290A0000 |97 100|endgic
P08634290A0000 |57 61|RNAs5-nu
P08634290A0000 |4 10|genome01606T
P08634357A0527 |4 23|extraction recovery01606T0076 Comparis
P08634357A0527 |88 89|%h
P08634357A0527 |113 118|rangeeonat
P08634357A0527 |27 41|Amphotericin Bith alkaline p
P08634357A0527 |65 70|fluidtidas
P08634420A1784 |85 90|clone0 Pha
P08634420A1784 |42 58|UT-7 cell growthosphatases and 5
P08634420A1784 |147 170|UT-7 cell proliferation997A0472 When CSF [HCO3
P08634420A1784 |115 122|muEpo-Rnatal h
P08634420A1784 |76 81|cells08171
P08634420A1784 |0 10|HuEpo-R AbP00001606T
P08634423A0498 |17 29|integrationsmparison wit
P08634423A0498 |130 131|%r
P08634423A0498 |63 72|lacZ geneeotidase 
P08634423A0498 |105 117|integrationscts of neona
P08634423A0498 |173 182|32D cellsis shown 
P08634423A0498 |96 97|%o
P08634423A0498 |42 55|transcriptionosphatases an
P08634423A0498 |4 13|frequency01606T007
P08634423A0498 |191 202|neutrophilstion of CSF
P08634423A0498 |154 169|differentiation2 When CSF [HCO
P08634697A1155 |175 182|domains shown 
P08634697A1155 |105 110|mousects o
P08634697A1155 |78 88|expression171T0000 P
P08634697A1155 |26 31|cDNAswith 
P08634697A1155 |132 142|importancebinemia. P
P08634697A1155 |52 60|reagents and 5-n
P08634697A1155 |92 97|Brca1acolo
P08634697A1155 |4 12|sequence01606T00
P08635771A0000 |2 7|study00016
P08635771A0000 |133 157|methaqualone metabolitesinemia. P00008997A0472 W
P08635771A0000 |121 129|analysishyperbil
P08635771A0000 |74 112|gas chromatographic/mass spectrometric0008171T0000 Pharmacologic aspects of 
P08635771A0000 |173 180|samplesis show
P08635771A0000 |37 43|ONLINEne pho
P08635771A0000 |161 166|urineCSF [
P08635771A0000 |48 68|EMIT II immunoassaysases and 5-nucleotid
P08635771A0000 |114 119|GC/MSonata
P08635771A0000 |206 211|study2 the
P08636031A1413 |119 138|Fur titration assayl hyperbilirubinemi
P08636031A1413 |73 86|pvdS promoter00008171T0000
P08636031A1413 |47 55|fragmenttases an
P08636031A1413 |165 192|gel retardation experiments[HCO3-] is shown as a funct
P08636031A1413 |19 32|Fur repressorarison with a
P08636031A1413 |219 234|Fur preparation K-depleted rat
P08636031A1413 |0 11|InteractionP00001606T0
P08636124A0410 |5 12|protein1606T00
P08636124A0410 |29 33|cDNAh al
P08636124A0410 |181 190|evolution as a fun
P08636124A0410 |146 153|nucleus8997A04
P08636124A0410 |56 63|p150TSP 5-nucl
P08636124A0410 |97 111|phosphoproteingic aspects of
P08636149A0220 |137 145|responseia. P000
P08636149A0220 |149 156|insulin7A0472 
P08636149A0220 |44 56|cell surfacephatases and
P08636149A0220 |67 74|insulindase P0
P08636149A0220 |12 21|receptors76 Compar
P08636149A0220 |114 133|autophosphorylationonatal hyperbilirub
P08636211A0983 |0 7|EMBO J.P000016
P08636428A1363 |171 179|mitogens] is sho
P08636428A1363 |20 27|resultsrison w
P08636428A1363 |135 145|expressionemia. P000
P08636428A1363 |71 98|smooth muscle proliferation P00008171T0000 Pharmacolog
P08637006A0000 |0 13|TranscriptionP00001606T007
P08637006A0000 |181 192|orientation as a funct
P08637006A0000 |134 142|TBP sitenemia. P
P08637006A0000 |148 157|E2F sites97A0472 W
P08637006A0000 |74 79|array00081
P08637006A0000 |224 232|ATF sitepleted r
P08637006A0000 |99 107|elementsc aspect
P08637006A0000 |39 47|promoter phospha
P08637006A0000 |19 29|adenovirusarison wit
P08637711A1121 |207 224|binding complexes the data of K-de
P08637711A1121 |147 151|site997A
P08637711A1121 |106 112|IR/IRFts of 
P08637711A1121 |90 104|IRF-1 promoterrmacologic asp
P08637711A1121 |66 82|response elementidase P00008171T
P08637711A1121 |37 53|interferon gammane phosphatases 
P08637711A1121 |177 181|sitehown
P08637711A1121 |236 247|JRE-IL6-BCsare no long
P08637711A1121 |55 64|IFN gammad 5-nucle
P08637711A1121 |32 36|IL-6lkal
P08637717A0817 |136 149|cyclin E/Cdk2mia. P0000899
P08637717A0817 |77 84|peptide8171T00
P08637717A0817 |9 16|peptideT0076 C
P08637717A0817 |104 111|abilityects of
P08637717A0817 |115 118|p21nat
P08637717A0817 |54 66|p21-activitynd 5-nucleot
P08637717A0817 |18 29|amino acidsparison wit
P08637717A1231 |2 13|p21 peptide0001606T007
P08637717A1231 |132 152|p21-PCNA interactionbinemia. P00008997A0
P08637717A1231 |61 65|PCNAcleo
P08637717A1231 |71 91|filter binding assay P00008171T0000 Phar
P08637717A1231 |23 34|amino acidson with alk
P08637717A1231 |101 108|peptideaspects
P08638435A0522 |0 7|ResultsP000016
P08638435A0522 |30 51|agar diffusion method alkaline phosphatase
P08638435A0522 |56 73|Y. enterocolitica 5-nucleotidase P
P08638435A0522 |121 134|A. hydrophilahyperbilirubi
P08638435A0522 |83 102|inhibition activity000 Pharmacologic a
P08639310A0548 |0 3|ONDP00
P08639310A0548 |29 44|mg tid prn daysh alkaline phos
P08639310A0548 |149 152|MCP7A0
P08639310A0548 |73 84|mg qds days00008171T00
P08639310A0548 |142 144|CT00
P08639310A0548 |178 179|ho
P08639310A0548 |127 134|mg i.v.ilirubi
P08639310A0548 |96 99|MCPogi
P08639310A0548 |6 17|mg tid days606T0076 Co
P08639310A0548 |156 163|mg p.r.When CS
P08639521A1032 |112 118|modelsneonat
P08639521A1032 |132 138|motionbinemi
P08639521A1032 |31 47|protein fragmentalkaline phospha
P08639521A1032 |12 22|properties76 Compari
P08639561T0000 |0 9|AdductionP00001606
P08639561T0000 |253 273|deoxyadenosyl adductplaced when compared
P08639561T0000 |190 192|7Sct
P08639561T0000 |23 34|N-ras codonon with alk
P08639561T0000 |57 59|7S5-
P08639561T0000 |124 130|pyreneerbili
P08639561T0000 |240 247|pyrenylno long
P08639561T0000 |61 62|Rc
P08639561T0000 |90 97|epoxy-7rmacolo
P08639561T0000 |143 153|refinement0008997A04
P08639561T0000 |197 198|Sf
P08639561T0000 |194 195|Rn
P08639561T0000 |75 86|dihydroxy-9008171T0000
P08639561T0000 |105 120|tetrahydrobenzocts of neonatal
P08639561T0000 |222 237|tetrahydrobenzodepleted rats a
P08639561T0000 |38 46|sequencee phosph
P08639561T0000 |64 65|Ro
P08639561T0000 |174 178|SRSRs sh
P08639561T0000 |279 285|1H NMRntrols
P08639561T0000 |201 202|RF
P08639561T0000 |68 69|Sa
P08639742T0000 |68 75|petuniaase P00
P08639742T0000 |54 64|similaritynd 5-nucle
P08639742T0000 |22 32|cDNA cloneson with a
P08639742T0000 |13 16|PCR6 C
P08639742T0000 |38 48|pea petalse phosphat
P08639742T0000 |80 106|wheat zinc finger proteins1T0000 Pharmacologic aspec
P08639742T0000 |0 9|IsolationP00001606
P08639837A0268 |98 108|Ets familyic aspects
P08639837A0268 |44 51|factorsphatase
P08639837A0268 |83 90|members000 Pha
P08639837A0268 |72 78|GATA-1P00008
P08639837A0268 |5 13|fragment1606T007
P08640866A0473 |0 8|ExposureP0000160
P08640866A0473 |164 172|activity [HCO3-]
P08640866A0473 |60 63|PHAucl
P08640866A0473 |23 36|blood T cellson with alkal
P08640866A0473 |128 137|increaseslirubinem
P08640866A0473 |150 153|MEKA04
P08640866A0473 |48 56|subjectsases and
P08640866A0473 |141 145|MAPKP000
P08640866A0473 |100 110|antibodies aspects o
P08641705A0986 |16 28|observationsomparison wi
P08641705A0986 |109 117|deletionof neona
P08641705A0986 |226 237|inheritanceeted rats a
P08641705A0986 |166 194|beta-globin gene duplicationHCO3-] is shown as a functio
P08641705A0986 |61 62|Ac
P08641705A0986 |241 254|Hb Costa Ricao longer disp
P08641705A0986 |140 150|Hbs Lepore P00008997
P08641705A0986 |39 53|heterozygosity phosphatases 
P08641705A0986 |67 77|G mutationdase P0000
P08641705A0986 |81 91|codon betaT0000 Phar
P08641705A0986 |200 205|pointSF PC
P08641705A0986 |154 159|Kenya2 Whe
P08642282A1009 |85 95|expression0 Pharmaco
P08642282A1009 |38 47|knowledgee phospha
P08642282A1009 |63 71|elementseotidase
P08642282A1009 |134 142|moleculenemia. P
P08642282A1009 |101 105|geneaspe
P08642282A1009 |18 29|descriptionparison wit
P08642282A1009 |117 119|B7ta
P08642285A1548 |0 18|DNA-STAT complexesP00001606T0076 Com
P08642285A1548 |60 70|cell linesucleotidas
P08642285A1548 |130 135|STAT5rubin
P08642285A1548 |120 125|STAT1 hype
P08642285A1548 |101 111|antibodiesaspects of
P08642313A0770 |138 145|fashiona. P000
P08642313A0770 |182 189|proteinas a fu
P08642313A0770 |83 98|transactivation000 Pharmacolog
P08642313A0770 |112 132|reporter gene assaysneonatal hyperbiliru
P08642313A0770 |37 46|cell linene phosph
P08642313A0770 |191 196|Bcl-3tion 
P08642313A0770 |65 70|kappatidas
P08642313A0770 |48 54|TAN-1Cases a
P08642313T0000 |0 6|T cellP00001
P08642313T0000 |173 180|T cellsis show
P08642313T0000 |146 169|factor-kappa B proteins8997A0472 When CSF [HCO
P08642313T0000 |64 79|Notch homologueotidase P000081
P08642313T0000 |99 107|activityc aspect
P08642313T0000 |84 91|I kappa00 Phar
P08642693T0000 |0 22|Polyprotein processingP00001606T0076 Compari
P08642693T0000 |45 59|identificationhatases and 5-
P08642693T0000 |26 43|Southampton viruswith alkaline pho
P08642693T0000 |107 118|mutagenesiss of neonat
P08642693T0000 |71 94|protease cleavage sites P00008171T0000 Pharmac
P08643111A0855 |288 304|oligosaccharidest still have a s
P08643111A0855 |314 318|mLL2ly g
P08643111A0855 |147 150|LL2997
P08643111A0855 |243 254|counterpartlonger disp
P08643111A0855 |210 220|propertiese data of 
P08643111A0855 |14 17|LL2 Co
P08643111A0855 |19 23|hLL2aris
P08643111A0855 |55 75|region glycosylationd 5-nucleotidase P00
P08643111A0855 |40 45|chainphosp
P08643111A0855 |341 356|antigen binding0.23 vs. P00010
P08643111A0855 |87 105|immunoreactivitiesPharmacologic aspe
P08643111A0855 |152 156|cLL2472 
P08643382A0752 |69 73|polyse P
P08643382A0752 |77 81|tail8171
P08643382A0752 |95 105|cDNA clonelogic aspe
P08643382A0752 |74 75|A0
P08643382A0752 |23 38|transit peptideon with alkalin
P08643382A0752 |126 145|chloroplast proteinbilirubinemia. P000
P08643382A0752 |53 59|regionand 5-
P08643513A0361 |205 232|osteocalcin gene expressionO2 the data of K-depleted r
P08643513A0361 |196 201|levelof CS
P08643513A0361 |166 168|ntHC
P08643513A0361 |21 24|rOCiso
P08643513A0361 |114 122|sequenceonatal h
P08643513A0361 |143 151|promoter0008997A
P08643513A0361 |187 188|%f
P08643513A0361 |50 78|acetyltransferase constructses and 5-nucleotidase P00008
P08643513A0361 |0 17|Deletion analysisP00001606T0076 Co
P08643557A0259 |17 25|questionmparison
P08643557A0259 |65 69|setstida
P08643557A0259 |73 85|target genes00008171T000
P08643557A0259 |33 45|HOX proteinskaline phosp
P08643578A0000 |0 9|RAS2val19P00001606
P08643578A0000 |142 153|reporter FG00008997A04
P08643578A0000 |110 120|expressionf neonatal
P08643578A0000 |160 164|lacZ CSF
P08643578A0000 |65 69|Ras2tida
P08643578A0000 |219 223|lacZ K-d
P08643578A0000 |189 217|mating pathway reporter FUS1nction of CSF PCO2 the data 
P08643578A0000 |32 36|formlkal
P08643578A0000 |99 105|growthc aspe
P08643578A0000 |154 157|TyA2 W
P08643578A0532 |119 125|growthl hype
P08643578A0532 |94 103|regulatorologic as
P08643578A0532 |133 136|TyAine
P08643578A0532 |14 38|Rho family protein Cdc42 Comparison with alkalin
P08643578A0532 |66 75|G proteinidase P00
P08643578A0532 |130 132|FGru
P08643578A0532 |139 154|lacZ expression. P00008997A047
P08643633A1187 |35 42|complexline ph
P08643633A1187 |62 66|CBF1leot
P08643633A1187 |5 22|immunoprecipitate1606T0076 Compari
P08643633A1187 |46 48|N1at
P08643633A1187 |49 56|deltaECses and
P08643646A0479 |84 96|biosynthesis00 Pharmacol
P08643646A0479 |40 44|genephos
P08643646A0479 |5 11|region1606T0
P08643646A0479 |232 242|conditionsats are no
P08643646A0479 |131 142|transcriptsubinemia. P
P08643646A0479 |175 177|kb s
P08643646A0479 |21 25|verAison
P08643646A0479 |154 158|size2 Wh
P08643682A0268 |173 187|fusion proteinis shown as a 
P08643682A0268 |12 25|localizations76 Comparison
P08643682A0268 |107 125|immunofluorescences of neonatal hype
P08643682A0268 |59 87|CBFbeta-SMMHC fusion proteinnucleotidase P00008171T0000 
P08643682A0268 |43 50|CBFbetasphatas
P08643682A0268 |129 142|NIH 3T3 cellsirubinemia. P
P08643759A0338 |51 72|personality variabless and 5-nucleotidase 
P08643759A0338 |83 88|group000 P
P08643759A0338 |16 21|phaseompar
P08644734A0404 |86 107|segment-polarity gene Pharmacologic aspect
P08644734A0404 |14 23|isolation Comparis
P08644734A0404 |33 38|cDNAskalin
P08645214A1052 |17 21|BL21mpar
P08645214A1052 |135 143|proteinsemia. P0
P08645214A1052 |164 172|SDS/PAGE [HCO3-]
P08645214A1052 |59 66|plasmidnucleot
P08645214A1052 |125 131|amountrbilir
P08645214A1052 |27 32|plysSith a
P08645214A1052 |189 195|enzymenction
P08645214A1052 |82 106|catalase-peroxidase gene0000 Pharmacologic aspec
P08645214A1052 |23 26|DE3on 
P08645219A1377 |0 3|Ca2P00
P08645219A1377 |31 40|S100 betaalkaline 
P08645219A1377 |15 18|Zn2Com
P08645219A1377 |109 121|binding siteof neonatal 
P08645219A1377 |167 170|Ca2CO3
P08645219A1377 |104 107|Zn2ect
P08645219A1377 |172 187|binding domains is shown as a 
P08645219A1377 |77 82|MRP148171T
P08645219A1377 |20 27|bindingrison w
P08647086A0622 |0 4|Cdk2P000
P08647086A0622 |14 21|complex Compar
P08647086A0622 |45 51|systemhatase
P08647086A0622 |27 36|cyclin D1ith alkal
P08647086A0720 |4 26|Cdk2-cyclin-D1 complex01606T0076 Comparison 
P08647086A0720 |124 129|E2F-1erbil
P08647086A0720 |60 70|substratesucleotidas
P08647086A0720 |187 195|contrastfunction
P08647086A0720 |250 258|proteinsdisplace
P08647086A0720 |80 90|H1 histone1T0000 Pha
P08647086A0720 |158 166|proteinsen CSF [
P08647086A0720 |92 95|pRBaco
P08647086A0720 |215 228|Cdk2-cyclin-Aa of K-deplet
P08647086A0720 |108 117|T antigen of neona
P08647086A0720 |135 146|preparationemia. P0000
P08647086A0720 |119 122|p53l h
P08647086A0720 |172 182|HeLa cells is shown 
P08647086A0720 |197 210|Cdk2-cyclin-Ef CSF PCO2 th
P08647086A0720 |97 101|SV40gic 
P08647086T0000 |51 58|complexs and 5
P08647086T0000 |64 73|cyclin D1otidase P
P08647086T0000 |80 84|Cdk21T00
P08647086T0000 |27 31|Cdk2ith 
P08647086T0000 |136 149|Cdk7-cyclin-Hmia. P0000899
P08647086T0000 |101 110|cyclin D1aspects o
P08647086T0000 |17 25|kinase-2mparison
P08647091A0592 |171 180|ADH genes] is show
P08647091A0592 |121 128|intronshyperbi
P08647091A0592 |91 97|regionmacolo
P08647091A0592 |74 79|exons00081
P08647091A0592 |108 117|placement of neona
P08647091A0592 |46 56|Adh-2 geneatases and
P08647091A0592 |16 22|clonesompari
P08647264T0000 |186 194|cleavage functio
P08647264T0000 |12 16|CD4076 C
P08647264T0000 |135 145|activationemia. P000
P08647264T0000 |61 78|calcium ionophorecleotidase P00008
P08647264T0000 |39 55|lymphoma B cells phosphatases an
P08647264T0000 |202 216|substrate PARP PCO2 the data
P08647264T0000 |111 120|apoptosis neonatal
P08647264T0000 |153 181|cysteine protease CPP32/Yama72 When CSF [HCO3-] is shown
P08647264T0000 |84 91|antigen00 Phar
P08647264T0000 |0 8|LigationP0000160
P08647434A1124 |143 153|conditions0008997A04
P08647434A1124 |73 76|TBP000
P08647434A1124 |44 54|antibodiesphatases a
P08647434A1124 |94 98|hTAFolog
P08647434A1124 |89 92|TBParm
P08647434A1124 |107 111|hTAFs of
P08647434A1124 |160 170|holo-TFIID CSF [HCO3
P08647434A1124 |124 128|hTAFerbi
P08647434A1124 |6 15|T antigen606T0076 
P08647451A0663 |0 27|Northern blot hybridizationP00001606T0076 Comparison w
P08647451A0663 |109 116|tissuesof neon
P08647451A0663 |46 53|HEP-COPatases 
P08647451A0663 |78 83|range171T0
P08647802A0000 |20 37|signaling proteinrison with alkali
P08647802A0000 |89 100|arrangementarmacologic
P08647802A0000 |104 123|SH3-SH2-SH3 domainsects of neonatal hy
P08647802A0000 |127 131|Grb2ilir
P08647822T0000 |18 24|sterolpariso
P08647822T0000 |63 73|activationeotidase P
P08647822T0000 |104 112|coenzymeects of 
P08647822T0000 |36 59|element binding proteinine phosphatases and 5-
P08647822T0000 |9 13|roleT007
P08647822T0000 |115 129|reductase genenatal hyperbil
P08647884A0547 |34 43|reticulumaline pho
P08647884A0547 |74 83|molecules0008171T0
P08647884A0547 |110 119|transportf neonata
P08647884A0547 |62 71|MHC classleotidase
P08647884A0547 |127 139|cell surfaceilirubinemia
P08648408A0792 |17 27|CSA groupsmparison w
P08648408A0792 |9 12|PHTT00
P08648408A0792 |95 100|grouplogic
P08648408A0792 |121 126|grouphyper
P08648408A0792 |113 119|CSA-GOeonata
P08648408A0792 |43 53|Hyp levelssphatases 
P08648408A0792 |87 93|PHT-GOPharma
P08648665A0956 |48 73|transformation efficiencyases and 5-nucleotidase P
P08648665A0956 |142 145|LE6000
P08648665A0956 |10 23|LE6 deletions0076 Comparis
P08648665A0956 |99 104|cellsc asp
P08648665A1320 |0 15|ORF E8 colinearP00001606T0076 
P08648665A1320 |147 161|pZipNeo vector997A0472 When 
P08648665A1320 |120 125|cells hype
P08648665A1320 |66 73|proteinidase P
P08648665A1320 |93 100|segmentcologic
P08648665A1320 |21 27|ORF E6ison w
P08648726A0713 |0 7|CloningP000016
P08648726A0713 |91 94|ZICmac
P08648726A0713 |55 63|promoterd 5-nucl
P08648726A0713 |22 32|ZI domainsson with a
P08648726A0713 |125 135|ZIB domainrbilirubin
P08648726A0713 |86 89|ZIA Ph
P08648726A0713 |141 144|TPAP00
P08648726A0713 |100 111|ZID domains aspects of
P08649372A0501 |68 74|factorase P0
P08649372A0501 |42 52|repressionosphatases
P08649372A0501 |91 99|activitymacologi
P08649372A0501 |103 105|G2pe
P08649372A0501 |110 117|M phasef neona
P08649372A0501 |0 17|Clb2/Cdc28 kinaseP00001606T0076 Co
P08649372A0755 |119 130|interactionl hyperbili
P08649372A0755 |47 58|interactiontases and 5
P08649372A0755 |4 20|carboxy terminus01606T0076 Compa
P08649372A0755 |24 28|Mbp1n wi
P08649372A0755 |78 94|carboxy terminus171T0000 Pharmac
P08649372A0755 |98 102|Swi6ic a
P08649372A0755 |64 68|Swi6otid
P08649372A0755 |136 140|Mbp1mia.
P08649373T0000 |68 77|chromatinase P0000
P08649373T0000 |91 101|c-myc genemacologic 
P08649373T0000 |25 37|cis elements with alkali
P08649386A1032 |86 100|consensus Abf1 Pharmacologic
P08649386A1032 |59 67|analysisnucleoti
P08649386A1032 |109 113|siteof n
P08649386A1032 |6 29|UASH consensus sequence606T0076 Comparison wit
P08649389A0000 |184 194|% identity a functio
P08649389A0000 |163 170|proteinF [HCO3
P08649389A0000 |36 52|CTCF cDNA clonesine phosphatases
P08649389A0000 |219 239|amino acid sequences K-depleted rats are
P08649389A0000 |114 125|factor CTCFonatal hype
P08649389A0692 |141 150|repressorP00008997
P08649389A0692 |61 97|transient-cotransfection experimentscleotidase P00008171T0000 Pharmacolo
P08649389A0692 |164 174|c-myc gene [HCO3-] i
P08649389A0692 |39 56|CTCF binding site phosphatases and
P08649389A0692 |11 19|analysis076 Comp
P08649389A0692 |115 119|CTCFnata
P08649393A0000 |117 120|CENtal
P08649393A0000 |105 115|centromerects of neo
P08649393A0000 |36 39|ctfine
P08649393A0000 |41 47|mutanthospha
P08649393A0000 |182 203|kinetochore integrityas a function of CSF 
P08649393A0000 |2 34|chromosome transmission fidelity0001606T0076 Comparison with alk
P08649393A0000 |138 159|readthrough phenotypea. P00008997A0472 Whe
P08649393A0000 |49 53|s138ses 
P08649403A0963 |4 17|growth defect01606T0076 Co
P08649403A0963 |40 46|mutantphosph
P08649403A0963 |23 32|reg1 reg2on with a
P08649403A0963 |112 126|protein kinaseneonatal hyper
P08649403A0963 |83 91|mutation000 Phar
P08649405T0000 |0 3|Sp1P00
P08649405T0000 |74 79|cells00081
P08649405T0000 |14 19|sites Comp
P08649405T0000 |116 129|transcriptionatal hyperbil
P08649405T0000 |27 41|CD11c promoterith alkaline p
P08649405T0000 |100 103|AP1 as
P08649424A0000 |0 10|ExpressionP00001606T
P08649424A0000 |122 137|glucocorticoidsyperbilirubinem
P08649424A0000 |74 81|rodents0008171
P08649424A0000 |160 165|liver CSF 
P08649424A0000 |63 70|kidneyseotidas
P08649424A0000 |149 152|AMP7A0
P08649424A0000 |98 103|birthic as
P08649424A0000 |52 58|livers and 5
P08649424A0000 |18 48|phenylalanine hydroxylase geneparison with alkaline phosphat
P08649425A0373 |68 73|DNasease P
P08649425A0373 |28 36|enhancerth alkal
P08649425A0373 |18 20|bppa
P08649425A0373 |55 59|cored 5-
P08649425A0373 |100 118|B-cell development aspects of neonat
P08649425T0000 |85 93|enhancer0 Pharma
P08649425T0000 |28 47|chromatin structureth alkaline phospha
P08649425T0000 |55 81|mouse immunoglobulin kappad 5-nucleotidase P00008171
P08649427A0689 |119 136|GTPase regulatorsl hyperbilirubine
P08649427A0689 |109 115|familyof neo
P08649427A0689 |63 69|membereotida
P08649427A0689 |104 107|GAPect
P08649427A0689 |39 43|cDNA pho
P08649427A0689 |95 102|proteinlogic a
P08649427A0689 |19 33|identificationarison with al
P08649428A1227 |143 147|Cdc20008
P08649428A1227 |78 100|c-mos oncogene product171T0000 Pharmacologic
P08649428A1227 |61 70|synthesiscleotidas
P08649428A1227 |8 13|study6T007
P08649428A1227 |43 53|regulationsphatases 
P08649428A1227 |129 139|activationirubinemia
P08649440T0000 |34 38|VIIIalin
P08649440T0000 |28 32|IgG2th a
P08649440T0000 |4 17|heterogeneity01606T0076 Co
P08649773A1374 |138 151|cell lymphomaa. P00008997A
P08649773A1374 |107 120|B lymphocytess of neonatal
P08649773A1374 |15 20|BCL-6Compa
P08649773A1374 |4 11|ability01606T0
P08649773A1374 |54 63|repressornd 5-nucl
P08649773A1374 |86 93|ability Pharma
P08649841A0956 |119 136|CAT reporter genel hyperbilirubine
P08649841A0956 |215 223|CAT mRNAa of K-d
P08649841A0956 |94 102|promoterologic a
P08649841A0956 |54 69|Kozak sequencesnd 5-nucleotida
P08649841A0956 |203 211|decreasePCO2 the
P08649841A0956 |108 112|SV40 of 
P08649841A0956 |170 192|CAT protein production-] is shown as a funct
P08649841A0956 |156 166|inhibitionWhen CSF [
P08649841A0956 |17 21|uORFmpar
P08650818A0000 |86 90|MRSA Pha
P08650818A0000 |12 18|spread76 Com
P08650818A0000 |165 174|isolation[HCO3-] i
P08650818A0000 |105 113|patientscts of n
P08650818A0000 |229 236|arrivald rats 
P08650818A0000 |78 84|strain171T00
P08650818A0000 |148 152|ward97A0
P08650818A0000 |260 278|Mediterranean areawhen compared to c
P08650818A0000 |244 252|hospitalonger di
P08650818A0000 |156 161|spiteWhen 
P08651853A0607 |221 229|patients-deplete
P08651853A0607 |129 137|patientsirubinem
P08651853A0607 |179 187|patientswn as a 
P08651853A0607 |161 174|dentate gyrusCSF [HCO3-] i
P08651853A0607 |108 124|CA1/prosubiculum of neonatal hyp
P08651853A0607 |63 67|losseoti
P08651853A0607 |233 234|%t
P08651853A0607 |83 90|gliosis000 Pha
P08651853A0607 |142 143|%0
P08651853A0607 |206 216|CA4 region2 the data
P08651853A0607 |191 192|%t
P08651853A0607 |16 25|sclerosisomparison
P08651853T0000 |16 25|sclerosisomparison
P08652081A1953 |136 145|skin rashmia. P000
P08652081A1953 |210 214|IL-4e da
P08652081A1953 |74 84|toxicities0008171T00
P08652081A1953 |151 155|IL-30472
P08652081A1953 |124 132|headacheerbiliru
P08652081A1953 |94 105|hypotensionologic aspe
P08652081A1953 |167 177|congestionCO3-] is s
P08652081A1953 |197 204|lesionsf CSF P
P08652081A1953 |111 115|IL-1 neo
P08652081A1953 |22 28|eventsson wi
P08654200A0274 |204 209|mg/kgCO2 t
P08654200A0274 |244 249|mg/kgonger
P08654200A0274 |147 163|model substrates997A0472 When CS
P08654200A0274 |165 174|lorazepam[HCO3-] i
P08654200A0274 |181 186|mg/kg as a
P08654200A0274 |60 72|liver volumeucleotidase 
P08654200A0274 |20 37|resonance imagingrison with alkali
P08654200A0274 |189 199|antipyrinenction of 
P08654200A0274 |128 137|clearancelirubinem
P08654200A0274 |235 238|ICG ar
P08654200A0274 |216 227|indocyanine of K-deple
P08654200A0274 |101 109|patientsaspects 
P08654375A0544 |184 189|Oct-2 a fu
P08654375A0544 |149 171|DNA binding POU domain7A0472 When CSF [HCO3-
P08654375A0544 |13 21|analysis6 Compar
P08654375A0544 |37 43|regionne pho
P08654375A0544 |92 102|N-terminusacologic a
P08654375A0544 |106 110|Bob1ts o
P08654375A0544 |66 77|amino acidsidase P0000
P08654375A0544 |53 64|amino acidsand 5-nucle
P08654375A0544 |175 180|Oct-1 show
P08654390A0000 |85 95|biliverdin0 Pharmaco
P08654390A0000 |43 58|heme catabolismsphatases and 5
P08654390A0000 |72 76|hemeP000
P08654390A0000 |107 122|carbon monoxides of neonatal h
P08654390A0000 |33 39|enzymekaline
P08654390A0000 |97 101|irongic 
P08654390A0000 |0 14|Heme oxygenaseP00001606T0076
P08654435A0540 |34 38|WM12alin
P08654435A0540 |124 132|activityerbiliru
P08654435A0540 |12 18|analog76 Com
P08654435A0540 |110 116|effectf neon
P08654435A0540 |92 102|wortmanninacologic a
P08654435A0540 |177 183|assayshown a
P08654435A0540 |71 86|Erk2 activation P00008171T0000
P08654435A0540 |22 32|wortmanninson with a
P08654435A0540 |136 140|Erk2mia.
P08654946A0475 |17 27|% identitymparison w
P08654946A0475 |47 53|regiontases 
P08654946A0475 |8 14|shares6T0076
P08654946A0475 |57 76|Xenopus laevis FGF35-nucleotidase P000
P08654946A0475 |147 151|gene997A
P08654946A0475 |4 6|aa01
P08654946A0475 |83 93|% identity000 Pharma
P08654946A0475 |103 110|productpects o
P08654946A0986 |119 125|regionl hype
P08654946A0986 |73 90|mouse promoter P300008171T0000 Pha
P08654946A0986 |129 137|sequenceirubinem
P08654946A0986 |46 54|promoteratases a
P08654946A0986 |4 29|transcription start point01606T0076 Comparison wit
P08654972A0000 |0 7|DefectsP000016
P08654972A0000 |46 50|cellatas
P08654972A0000 |87 109|cell cycle progressionPharmacologic aspects 
P08654972A0000 |42 44|Spos
P08654972A0000 |69 74|genesse P0
P08654983A0000 |51 63|SRP receptors and 5-nucl
P08654983A0000 |80 97|Bacillus subtilis1T0000 Pharmacolo
P08654983A0000 |65 68|Srbtid
P08654983A0000 |202 207|Oguro PCO2
P08654983A0000 |147 156|homologue997A0472 
P08654983A0000 |46 49|SRPata
P08654983A0000 |216 223|DNA Res of K-d
P08654983A0000 |174 200|SRP receptor alpha-subunits shown as a function of C
P08654983A0000 |99 101|Bsc 
P08654983A0000 |118 129|Bs srb geneal hyperbil
P08654983A0000 |70 76|systeme P000
P08654983A0000 |17 44|signal recognition particlemparison with alkaline phos
P08655497A0000 |50 53|mines 
P08655497A0000 |24 27|cmrn w
P08655497A0000 |78 89|K-12 genome171T0000 Ph
P08655497A0000 |181 187|vector as a 
P08655497A0000 |8 12|gene6T00
P08655497A0000 |126 141|chloramphenicolbilirubinemia. 
P08655497A0000 |112 122|resistanceneonatal h
P08655555A0772 |16 25|deletionsomparison
P08655555A0772 |65 90|transcription start pointtidase P00008171T0000 Pha
P08655555A0772 |160 167|hexamer CSF [H
P08655555A0772 |46 48|bpat
P08655555A0772 |190 207|promoter activityction of CSF PCO2
P08655555A0772 |115 134|% promoter activitynatal hyperbilirubi
P08655555A0772 |3 11|addition001606T0
P08655555A1368 |4 16|DNA sequence01606T0076 C
P08655555A1368 |74 83|TGn motif0008171T0
P08655555A1368 |52 59|hexamer and 5-
P08655555A1368 |135 144|promotersemia. P00
P08655555A1368 |113 119|regioneonata
P08656672A0678 |152 183|cervix carcinoma cell line HeLa472 When CSF [HCO3-] is shown a
P08656672A0678 |73 92|leukemia cell lines00008171T0000 Pharm
P08656672A0678 |135 144|subclonesemia. P00
P08656672A0678 |12 35|ufo mRNA overexpression76 Comparison with alka
P08657135A1444 |138 149|muscle genea. P0000899
P08657135A1444 |76 86|myogenesis08171T0000
P08657135A1444 |161 169|elementsCSF [HCO
P08657135A1444 |63 72|regulatoreotidase 
P08657135A1444 |36 40|CKIIine 
P08657135A1444 |23 30|studieson with
P08657135A1444 |101 121|E protein homodimersaspects of neonatal 
P08657150A1049 |21 31|regulatorsison with 
P08657150A1049 |40 44|NCE3phos
P08657150A1049 |147 157|activators997A0472 W
P08657150A1049 |112 132|promoter specificityneonatal hyperbiliru
P08657150A1049 |82 91|SIN5 gene0000 Phar
P08657150A1049 |4 8|role0160
P08657157A0000 |170 181|recognition-] is shown
P08657157A0000 |41 51|POU domainhosphatase
P08657157A0000 |193 218|octamer sequence elementson of CSF PCO2 the data o
P08657157A0000 |135 145|POU domainemia. P000
P08657157A0000 |64 69|motifotida
P08657157A0000 |108 117|complexes of neona
P08657157A0000 |16 26|regulatorsomparison 
P08657183A0145 |68 73|genesase P
P08657183A0145 |95 99|genelogi
P08657183A0145 |26 32|repairwith a
P08657183A0145 |75 79|DHFR0081
P08657183A0145 |112 116|DHFRneon
P08657183A0145 |9 15|strandT0076 
P08657183A0145 |36 49|DNA fragmentsine phosphata
P08657918A0360 |0 9|MATERIALSP00001606
P08657918A0360 |228 238|dissectioned rats ar
P08657918A0360 |14 21|METHODS Compar
P08657918A0360 |120 128|patients hyperbi
P08657918A0360 |212 215|SLLdat
P08657918A0360 |110 113|SLLf n
P08657918A0360 |161 164|SLLCSF
P08657918A0360 |87 102|dorsal portionsPharmacologic a
P08657918A0360 |23 45|Coronal 3D GRE imagingon with alkaline phosp
P08657918A0360 |187 193|wristsfuncti
P08659545A0000 |171 180|fragments] is show
P08659545A0000 |58 68|chromosome-nucleotid
P08659545A0000 |198 203|genes CSF 
P08659545A0000 |120 127|trisomy hyperb
P08659545A0000 |80 93|understanding1T0000 Pharma
P08659545A0000 |6 12|effort606T00
P08659545A0000 |145 158|exon trapping08997A0472 Wh
P08659545A0000 |184 194|chromosome a functio
P08659545A0000 |101 116|pathophysiologyaspects of neon
P08659545A0000 |34 48|transcript mapaline phosphat
P08660733X0000 |32 37|aphidlkali
P08660733X0000 |12 23|populations76 Comparis
P08660733X0000 |61 72|Puerto Ricocleotidase 
P08660733X0000 |76 81|April08171
P08660748X0000 |48 56|dynamicsases and
P08660748X0000 |79 90|predictions71T0000 Pha
P08660748X0000 |23 30|essenceon with
P08660748X0000 |94 113|population patternsologic aspects of n
P08660748X0000 |4 9|model01606
P08660866A0504 |239 244|cells no l
P08660866A0504 |210 215|shafte dat
P08660866A0504 |50 64|loss phenotypees and 5-nucle
P08660866A0504 |221 229|tormogen-deplete
P08660866A0504 |115 119|SOPsnata
P08660866A0504 |178 183|cellsown a
P08660866A0504 |89 96|progenyarmacol
P08660866A0504 |148 155|neurons97A0472
P08660866A0504 |199 208|trichogenCSF PCO2 
P08660866A0504 |160 168|thecogen CSF [HC
P08660866A0504 |13 22|positions6 Compari
P08660866A0504 |38 41|Brde p
P08660866A0504 |231 237|socketrats a
P08660866A0504 |170 176|sheath-] is 
P08660892A1044 |152 159|factors472 Whe
P08660892A1044 |41 57|co-transfectionshosphatases and 
P08660892A1044 |123 133|expressionperbilirub
P08660892A1044 |73 94|SRF expression vector00008171T0000 Pharmac
P08660892A1044 |169 173|MyoD3-] 
P08660892A1044 |178 184|Mef-2Cown as
P08660892A1044 |16 24|blockadeompariso
P08660998A0851 |171 177|mMIWC1] is s
P08660998A0851 |192 207|initiation siteion of CSF PCO2
P08660998A0851 |150 152|bpA0
P08660998A0851 |61 65|GATAcleo
P08660998A0851 |55 59|CAATd 5-
P08660998A0851 |4 19|mMIWC1 promoter01606T0076 Comp
P08660998A0851 |112 142|mMIWC transcription initiationneonatal hyperbilirubinemia. P
P08660998A0851 |86 102|primer extension Pharmacologic a
P08660998A0851 |71 84|AP-2 elements P00008171T00
P08660998A0851 |49 53|TATAses 
P08661007T0000 |68 77|structurease P0000
P08661007T0000 |27 33|memberith al
P08661007T0000 |90 118|protein domain relationshipsrmacologic aspects of neonat
P08661007T0000 |6 17|MN/CA9 gene606T0076 Co
P08661007T0000 |82 86|exon0000
P08661007T0000 |50 66|anhydrase familyes and 5-nucleot
P08661100A0285 |153 162|structure72 When C
P08661100A0285 |96 103|regionsogic as
P08661100A0285 |127 134|domainsilirubi
P08661100A0285 |176 181|partsshown
P08661100A0285 |32 37|Cdebplkali
P08661100A0285 |80 88|App gene1T0000 P
P08661100A0285 |16 28|distributionomparison wi
P08661101A0396 |0 21|DNA sequence analysisP00001606T0076 Compar
P08661101A0396 |39 43|gene pho
P08661101A0396 |83 91|rat CRP1000 Phar
P08661101A0396 |54 61|proteinnd 5-nu
P08661104A0687 |50 54|mRNAes a
P08661104A0687 |132 137|colonbinem
P08661104A0687 |121 126|liverhyper
P08661104A0687 |105 113|prostatects of n
P08661104A0687 |81 94|cells/tissuesT0000 Pharmac
P08661104A0687 |4 8|gene0160
P08661104A0687 |115 119|lungnata
P08661114A0564 |65 68|SIMtid
P08661114A0564 |88 96|proteinsharmacol
P08661114A0564 |14 21|domains Compar
P08661114A0564 |36 53|sequence homologyine phosphatases 
P08661116A0963 |0 17|Promoter activityP00001606T0076 Co
P08661116A0963 |107 129|Northern blot analysess of neonatal hyperbil
P08661116A0963 |61 67|levelscleoti
P08661116A0963 |30 40|cell lines alkaline 
P08661116A0963 |201 203|bpF 
P08661116A0963 |82 89|D3 mRNA0000 Ph
P08661116A0963 |170 178|promoter-] is sh
P08661119A0085 |95 104|EP4R cDNAlogic asp
P08661119A0085 |133 150|blood lymphocytesinemia. P00008997
P08661119A0085 |73 82|structure00008171T
P08661119A0085 |27 53|EP4 receptor gene sequenceith alkaline phosphatases 
P08661613A0691 |86 94|response Pharmac
P08661613A0691 |5 10|users1606T
P08661613A0691 |166 188|enforcement activitiesHCO3-] is shown as a f
P08661613A0691 |135 140|groupemia.
P08661613A0691 |38 57|management measurese phosphatases and 
P08661613A0691 |65 70|userstidas
P08661613A0691 |98 107|educationic aspect
P08662193A0404 |142 146|NIT40000
P08662193A0404 |15 36|activation subdomainsComparison with alkal
P08662193A0404 |88 93|yeastharma
P08662193A0404 |62 68|regionleotid
P08662193A0404 |132 138|regionbinemi
P08662499A0484 |4 9|front01606
P08662499A0484 |14 25|interaction Comparison
P08662499A0484 |11 12|F0
P08662499A0484 |61 64|RNAcle
P08662499A0484 |54 57|endnd 
P08662617A2051 |169 179|cell lines3-] is sho
P08662617A2051 |79 86|protein71T0000
P08662617A2051 |104 111|surfaceects of
P08662617A2051 |20 24|datariso
P08662617A2051 |128 145|uterine epithelialirubinemia. P000
P08662617A2051 |39 42|HIP ph
P08662789A0673 |68 86|sequence alignmentase P00008171T0000
P08662789A0673 |98 104|RPS30Aic asp
P08662789A0673 |45 64|GenBankTM data basehatases and 5-nucle
P08662789A0673 |18 22|genepari
P08662852A1297 |34 60|GRK5 phosphoacceptor sitesaline phosphatases and 5-n
P08662852A1297 |25 29|GRK2 wit
P08662852A1297 |167 176|rhodopsinCO3-] is 
P08662852A1297 |148 163|phosphorylation97A0472 When CS
P08662852A1297 |4 12|location01606T00
P08662852A1297 |76 93|carboxyl terminus08171T0000 Pharma
P08662852A1297 |101 108|beta2ARaspects
P08662928A1153 |5 15|regulation1606T0076 
P08662928A1153 |62 72|expressionleotidase 
P08662928A1153 |76 89|STAT proteins08171T0000 Ph
P08662928T0000 |0 9|ReceptorsP00001606
P08662928T0000 |27 29|ILit
P08662928T0000 |104 117|transcriptionects of neona
P08662928T0000 |14 25|interleukin Comparison
P08662928T0000 |48 57|cytokinesases and 
P08662928T0000 |126 148|IL-6 response elementsbilirubinemia. P000089
P08662928T0000 |70 90|signaling mechanismse P00008171T0000 Pha
P08662936A0428 |154 157|TEA2 W
P08662936A0428 |105 119|chicken TEF-1Acts of neonata
P08662936A0428 |176 182|factorshown 
P08662936A0428 |26 51|FR-19 amino acid sequencewith alkaline phosphatase
P08662936A0428 |121 132|mouse TEF-1hyperbiliru
P08662936A0428 |83 84|%0
P08662936A0428 |93 101|identitycologic 
P08662936A0428 |138 143|mousea. P0
P08662980A0762 |220 226|effectK-depl
P08662980A0762 |5 15|phenomenon1606T0076 
P08662980A0762 |178 186|receptorown as a
P08662980A0762 |32 43|DNA bindinglkaline pho
P08662980A0762 |65 73|receptortidase P
P08662980A0762 |154 158|form2 Wh
P08663000A0000 |17 27|hyaluronanmparison w
P08663000A0000 |47 52|RHAMMtases
P08663000A0000 |37 45|motilityne phosp
P08663000A0000 |94 107|fibrosarcomasologic aspect
P08663000A0000 |132 151|growth factor-beta1binemia. P00008997A
P08663000A0000 |4 12|receptor01606T00
P08663000A0000 |54 69|gene expressionnd 5-nucleotida
P08663000A0000 |153 162|TGF-beta172 When C
P08663120T0000 |64 71|proteinotidase
P08663120T0000 |26 39|p70 S6 kinasewith alkaline
P08663120T0000 |91 98|pathwaymacolog
P08663120T0000 |10 15|Raf-10076 
P08663127A0697 |154 173|glycosylation sites2 When CSF [HCO3-] 
P08663127A0697 |209 216|regionshe data
P08663127A0697 |61 65|NKCCcleo
P08663127A0697 |125 129|looprbil
P08663127A0697 |94 101|domainsologic 
P08663127A0697 |11 19|analysis076 Comp
P08663127A0697 |191 192|Nt
P08663127A0697 |23 27|KCC1on w
P08663127A0697 |49 57|homologyses and 
P08663141T0000 |141 161|angiotensinogen geneP00008997A0472 When 
P08663141T0000 |122 131|sequencesyperbilir
P08663141T0000 |13 24|DNA element6 Compariso
P08663141T0000 |54 83|transcription initiation sitend 5-nucleotidase P00008171T0
P08663141T0000 |41 49|TATA boxhosphata
P08663141T0000 |99 107|responsec aspect
P08663172A0311 |32 46|amino terminuslkaline phosph
P08663172A0311 |72 79|proteinP000081
P08663172A0311 |5 12|protein1606T00
P08663219A0246 |119 139|hormone inducibilityl hyperbilirubinemia
P08663219A0246 |192 204|E-box regionion of CSF P
P08663219A0246 |151 168|CAT reporter gene0472 When CSF [HC
P08663219A0246 |145 150|PGS-208997
P08663219A0246 |92 100|CAAT boxacologic
P08663219A0246 |46 50|CAATatas
P08663219A0246 |4 12|promoter01606T00
P08663219A0246 |20 34|rat PGS-2 generison with alk
P08663219A0246 |68 90|protein consensus sitease P00008171T0000 Pha
P08663310A0157 |84 98|response genes00 Pharmacolog
P08663310A0157 |192 203|cell growthion of CSF 
P08663310A0157 |122 127|genesyperb
P08663310A0157 |9 12|SRFT00
P08663310A0157 |40 49|regulatorphosphata
P08663310A0157 |208 223|differentiationthe data of K-d
P08663310A0157 |53 60|membersand 5-n
P08663310A0157 |129 133|IEGsirub
P08663310A0157 |66 71|classidase
P08663326A0000 |102 109|enzymesspects 
P08663326A0000 |129 135|methylirubin
P08663326A0000 |28 42|DmpR activatorth alkaline ph
P08663326A0000 |74 84|dmp operon0008171T00
P08663326A0000 |114 124|catabolismonatal hyp
P08663326A0000 |53 66|transcriptionand 5-nucleot
P08663326A0000 |136 143|phenolsmia. P0
P08663392A0215 |101 111|expressionaspects of
P08663392A0215 |8 13|study6T007
P08663392A0215 |40 49|DSG3 genephosphata
P08663392A0215 |83 93|regulation000 Pharma
P08664229T0000 |49 62|autorefractorses and 5-nuc
P08664229T0000 |9 19|evaluationT0076 Comp
P08664229T0000 |27 44|Allergan Humphreyith alkaline phos
P08664229T0000 |71 98|Nidek AR-1000 autorefractor P00008171T0000 Pharmacolog
P08664347A0923 |17 48|proprotein processing proteasesmparison with alkaline phosphat
P08664347A0923 |150 160|maturationA0472 When
P08664347A0923 |169 175|enzyme3-] is
P08664347A0923 |87 94|pro-LPHPharmac
P08664347A0923 |0 4|NoneP000
P08664462A1404 |222 233|hypothermiadepleted ra
P08664462A1404 |25 31|result with 
P08664462A1404 |198 214|plasma clearance CSF PCO2 the da
P08664462A1404 |47 51|handtase
P08664462A1404 |6 13|changes606T007
P08664462A1404 |178 184|resultown as
P08664462A1404 |129 149|muscle contractilityirubinemia. P0000899
P08664462A1404 |99 111|transmissionc aspects of
P08664462A1404 |66 77|sensitivityidase P0000
P08664462A1404 |168 172|handO3-]
P08664667A0093 |22 27|Indiason w
P08664667A0093 |9 14|DelhiT0076
P08665853A0228 |33 38|cellskalin
P08665853A0228 |74 87|ErbB proteins0008171T0000 
P08665853A0228 |244 252|activityonger di
P08665853A0228 |125 131|ErbB-3rbilir
P08665853A0228 |160 168|activity CSF [HC
P08665853A0228 |97 109|combinationsgic aspects 
P08665853A0228 |178 184|ErbB-1own as
P08665853A0228 |189 195|ErbB-2nction
P08666102A0820 |0 4|ZIOSP000
P08666102A0820 |71 74|Ptc P0
P08666102A0820 |58 65|methods-nucleo
P08666102A0820 |116 120|FEV1atal
P08666238T0000 |36 44|ribosomeine phos
P08666238T0000 |10 32|translation initiation0076 Comparison with a
P08666238T0000 |93 98|cellscolog
P08666241A0930 |85 103|Dex responsiveness0 Pharmacologic as
P08666241A0930 |40 46|regionphosph
P08666241A0930 |54 67|24p3 promoternd 5-nucleoti
P08666383A1252 |136 146|definitionmia. P0000
P08666383A1252 |75 88|hybridization008171T0000 P
P08666383A1252 |181 187|genome as a 
P08666383A1252 |164 167|map [H
P08666383A1252 |120 128|approach hyperbi
P08666383A1252 |54 66|fluorescencend 5-nucleot
P08666383A1252 |6 14|findings606T0076
P08666383A1252 |35 47|cDNA mappingline phospha
P08666398T0000 |68 81|16p12.1-p11.2ase P00008171
P08666398T0000 |8 22|cosmid contigs6T0076 Compari
P08666398T0000 |58 64|region-nucle
P08666398T0000 |36 50|Batten diseaseine phosphatas
P08666398T0000 |52 56|CLN3 and
P08666398T0000 |0 3|YACP00
P08666404A0311 |0 9|IsolationP00001606
P08666404A0311 |181 186|PPP5C as a
P08666404A0311 |188 191|PP5unc
P08666404A0311 |130 153|tetratricopeptide motifrubinemia. P00008997A04
P08666404A0311 |56 74|brain cDNA library 5-nucleotidase P0
P08666404A0311 |86 122|protein serine-threonine phosphatase Pharmacologic aspects of neonatal h
P08666404A0311 |218 225|rat PPTf K-dep
P08666404A0311 |32 36|cDNAlkal
P08666913A0000 |85 95|chromosome0 Pharmaco
P08666913A0000 |62 74|gene clusterleotidase P0
P08666913A0000 |26 48|transmembrane proteinswith alkaline phosphat
P08666913A0000 |11 22|family type076 Compari
P08666913A0000 |0 5|Ly-49P0000
P08668124A0744 |4 14|Dox-A2 ORF01606T0076
P08668124A0744 |60 69|phenotypeucleotida
P08668124A0744 |29 42|TDH3 promoterh alkaline ph
P08668124A0744 |75 81|strain008171
P08668124A0744 |94 98|sun2olog
P08668142A1048 |33 38|cellskalin
P08668142A1048 |104 115|Sec7p poolsects of neo
P08668142A1048 |54 61|balancend 5-nu
P08668142A1048 |20 25|hARF4rison
P08668142A1048 |4 16|introduction01606T0076 C
P08668158A0765 |35 40|Rpm1rline 
P08668158A0765 |255 259|geneaced
P08668158A0765 |92 99|tRNAProacologi
P08668158A0765 |176 183|portionshown a
P08668158A0765 |214 222|promoterta of K-
P08668158A0765 |244 248|tRNAonge
P08668158A0765 |264 268|RPM1 com
P08668158A0765 |77 81|tRNA8171
P08668158A0765 |108 116|promoter of neon
P08668158A0765 |152 156|gene472 
P08668158A0765 |141 145|tRNAP000
P08668158A0765 |65 75|substratestidase P00
P08668158A0765 |4 8|data0160
P08668158A1252 |138 156|biogenesis defectsa. P00008997A0472 
P08668158A1252 |13 20|strains6 Compa
P08668158A1252 |60 75|precursor Rpm1rucleotidase P00
P08668158A1252 |113 117|geneeona
P08668158A1252 |93 102|mutationscologic a
P08668158A1252 |33 43|RPM1 geneskaline pho
P08668190A1364 |170 178|membrane-] is sh
P08668190A1364 |9 26|membrane vesiclesT0076 Comparison 
P08668190A1364 |132 135|Ca2bin
P08668190A1364 |62 79|antiport activityleotidase P000081
P08668190A1364 |120 128|exchange hyperbi
P08668190A1364 |141 142|HP
P08668190A1364 |54 57|Ca2nd 
P08668190A1364 |59 60|Hn
P08668190A1364 |32 44|hum1 mutantslkaline phos
P08668190A1364 |155 160|yeast When
P08668190A1364 |100 105|Hum1p aspe
P08668201A1059 |200 208|intervalSF PCO2 
P08668201A1059 |28 35|elementth alka
P08668201A1059 |123 135|MATalpha1 IEperbilirubin
P08668201A1059 |166 171|codonHCO3-
P08668201A1059 |107 115|activitys of neo
P08668201A1059 |9 20|mutagenesisT0076 Compa
P08668201A1059 |57 74|sequence boundary5-nucleotidase P0
P08668201A1059 |179 186|elementwn as a
P08668203A1230 |0 3|FTFP00
P08668203A1230 |63 88|differentiation functionseotidase P00008171T0000 P
P08668203A1230 |149 156|tissues7A0472 
P08668203A1230 |127 131|SF-1ilir
P08668203A1230 |40 48|pancreasphosphat
P08668203A1230 |103 114|sublineagespects of ne
P08668209A0406 |0 6|MerlieP00001
P08668209A0406 |8 31|Cold Spring Harbor Symp6T0076 Comparison with 
P08668210A0000 |100 122|protein kinase pathway aspects of neonatal h
P08668210A0000 |12 20|evidence76 Compa
P08668210A0000 |149 163|transformation7A0472 When CS
P08668210A0000 |41 45|rolehosp
P08668210A0000 |72 77|Raf-1P0000
P08668210A0000 |54 64|activationnd 5-nucle
P08669274T0000 |54 62|approachnd 5-nuc
P08669274T0000 |31 37|choicealkali
P08669274T0000 |11 29|chain ossification076 Comparison wit
P08669676A1644 |69 70|ns
P08669676A1644 |59 67|propofolnucleoti
P08669676A1644 |94 95|Po
P08669676A1644 |123 131|propofolperbilir
P08669676A1644 |133 134|ni
P08669676A1644 |152 153|n4
P08669676A1644 |87 88|nP
P08669676A1644 |48 57|Q wave MIases and 
P08669676A1644 |112 121|Q wave MIneonatal 
P08669676A1644 |25 30|death with
P08669676A1644 |40 45|groupphosp
P08669676A1644 |160 161|P 
P08669676A1644 |193 209|treatment groupson of CSF PCO2 t
P08669676A1644 |141 150|midazolamP00008997
P08669676A1644 |76 85|midazolam08171T000
P08669676A1644 |4 13|incidence01606T007
P08670556A0425 |17 18|pm
P08670556A0425 |107 117|0-infinitys of neona
P08670556A0425 |44 75|plasma concentration-time curvephatases and 5-nucleotidase P00
P08670556A0425 |92 104|infinity AUCacologic asp
P08670556A0425 |29 33|areah al
P08670556A0425 |5 15|micromol/11606T0076 
P08670853A0000 |0 17|Cluster formationP00001606T0076 Co
P08670853A0000 |104 112|adhesionects of 
P08670853A0000 |39 51|cell surface phosphatase
P08670853A0000 |79 89|importance71T0000 Ph
P08670853A0000 |21 31|E-cadherinison with 
P08670910A0156 |0 16|DNA polymerase EP00001606T0076 C
P08670910A0156 |62 84|endonuclease co-purifyleotidase P00008171T00
P08670910A0156 |99 118|polypeptide complexc aspects of neonat
P08670910A0156 |39 42|DNA ph
P08670910A0156 |18 28|DNA ligaseparison wi
P08672242A0517 |9 33|reporter gene constructsT0076 Comparison with al
P08672242A0517 |61 70|sequencescleotidas
P08672242A0517 |106 113|regionsts of n
P08672242A0517 |132 142|expressionbinemia. P
P08672242A0517 |78 89|P1 promoter171T0000 Ph
P08673026T0000 |38 44|traitse phos
P08673026T0000 |54 71|replication studynd 5-nucleotidase
P08673026T0000 |25 36|schizotypal with alkal
P08673026T0000 |4 20|factor structure01606T0076 Compa
P08675026A0420 |93 101|functioncologic 
P08675026A0420 |107 129|Caenorhabditis eleganss of neonatal hyperbil
P08675026A0420 |62 75|sequence tagsleotidase P00
P08675026A0420 |131 143|Oryza sativaubinemia. P0
P08675026A0420 |148 152|Homo97A0
P08675026A0420 |77 80|EST817
P08675395A0751 |0 7|RESULTSP000016
P08675395A0751 |22 27|modelson w
P08675395A0751 |60 63|fitucl
P08675395A0751 |71 90|acuity outcome data P00008171T0000 Pha
P08675608T0000 |0 7|OutcomeP000016
P08675608T0000 |29 43|hypothyroidismh alkaline pho
P08675763A0788 |17 35|milk protein yieldmparison with alka
P08675763A0788 |61 64|Lyscle
P08675763A0788 |75 83|increase008171T0
P08675763A0788 |92 107|protein contentacologic aspect
P08675763A0788 |43 46|g/dsph
P08675763A0788 |124 128|milkerbi
P08675763A0788 |116 120|g/kgatal
P08675763A0788 |52 55|Met an
P08675763A0788 |0 13|Mean increaseP00001606T007
P08675769A0158 |255 266|performanceaced when c
P08675769A0158 |228 237|fertilityed rats a
P08675769A0158 |243 247|bulllong
P08675769A0158 |91 101|efficiencymacologic 
P08675769A0158 |111 126|conception rate neonatal hyper
P08675769A0158 |131 143|calving rateubinemia. P0
P08675769A0158 |10 15|rates0076 
P08675769A0158 |200 204|rateSF P
P08675769A0158 |65 73|measurestidase P
P08675769A0158 |273 286|AI technician to controls 
P08675821A0657 |54 58|areand 5
P08675821A0657 |30 41|glans penis alkaline p
P08675821A0657 |12 16|EMPD76 C
P08675821A0657 |62 68|searchleotid
P08675821A0657 |82 92|malignancy0000 Pharm
P08676266A0838 |70 81|test groupse P00008171
P08676266A0838 |94 107|control groupologic aspect
P08676266A0838 |4 15|mean values01606T0076 
P08676266A0838 |111 119|baseline neonata
P08676266A0838 |19 36|protease activityarison with alkal
P08676383A0518 |33 51|disulfide linkageskaline phosphatase
P08676383A0518 |61 73|cis peptidescleotidase P
P08676383A0518 |5 18|half molecule1606T0076 Com
P08676454A0731 |48 53|ICP35ases 
P08676454A0731 |74 83|B capsids0008171T0
P08676454A0731 |131 138|virionsubinemi
P08676454A0731 |41 46|ICP35hosph
P08676454A0731 |26 28|N0wi
P08676454A0731 |21 24|Praiso
P08676454A0731 |110 120|precursorsf neonatal
P08676454A0731 |33 35|Nbka
P08676456A0879 |83 102|AP-1 responsiveness000 Pharmacologic a
P08676456A0879 |45 62|leucine mutationshatases and 5-nuc
P08676456A0879 |106 116|comparisonts of neon
P08676456A0879 |134 156|VP16 activation domainnemia. P00008997A0472 
P08676456A0879 |11 29|VP16-Tat construct076 Comparison wit
P08676495A0129 |205 210|wartsO2 th
P08676495A0129 |134 144|C127 cellsnemia. P00
P08676495A0129 |52 54|nt a
P08676495A0129 |78 88|processing171T0000 P
P08676495A0129 |40 50|nucleotidephosphatas
P08676495A0129 |174 179|timess sho
P08676495A0129 |97 112|BPV-1 pre-mRNAsgic aspects of 
P08676495A0129 |16 27|splice siteomparison w
P08676858A0309 |221 227|RNases-deple
P08676858A0309 |42 55|S-RNase genesosphatases an
P08676858A0309 |131 145|Pyrus serotinaubinemia. P000
P08676858A0309 |125 129|pearrbil
P08676858A0309 |10 17|cloning0076 Co
P08676858A0309 |22 38|characterizationson with alkalin
P08676858A0309 |93 110|Malus x domesticacologic aspects o
P08676858A0309 |76 84|Rosaceae08171T00
P08676858A0309 |86 91|apple Phar
P08676858A0309 |65 72|speciestidase 
P08676858A0309 |170 179|sequences-] is sho
P08676858A1084 |64 70|plantsotidas
P08676858A1084 |23 30|memberson with
P08676858A1084 |15 19|treeComp
P08676858A1084 |38 60|T2/S-RNase superfamilye phosphatases and 5-n
P08677443A0238 |273 274|% 
P08677443A0238 |268 269|%p
P08677443A0238 |181 187|months as a 
P08677443A0238 |285 286|% 
P08677443A0238 |223 229|monthseplete
P08677443A0238 |250 264|survival ratesdisplaced when
P08677443A0238 |158 169|progressionen CSF [HCO
P08677443A0238 |88 91|VIPhar
P08677443A0238 |150 154|timeA047
P08677443A0238 |280 281|%t
P08677443A0238 |133 139|regardinemia
P08677443A0238 |73 86|SCLC patients00008171T0000
P08677443A0238 |39 44|study phos
P08677443A0238 |197 211|survival timesf CSF PCO2 the
P08677443A0238 |5 27|Hoosier Oncology Group1606T0076 Comparison w
P08677678A0258 |136 154|avoidance behaviormia. P00008997A047
P08677678A0258 |111 120|retention neonatal
P08677678A0258 |124 131|feedingerbilir
P08677678A0258 |203 212|phenomenaPCO2 the 
P08677678A0258 |36 63|immunomodulator neurotropinine phosphatases and 5-nucl
P08677678A0258 |93 106|consolidationcologic aspec
P08677678A0258 |18 32|administrationparison with a
P08677678A0258 |65 68|NSPtid
P08677678A0258 |184 194|mechanisms a functio
P08678959A0640 |0 22|Sestamibi scintigraphyP00001606T0076 Compari
P08678959A0640 |40 48|patientsphosphat
P08678959A0640 |74 89|ultrasonography0008171T0000 Ph
P08678959A0640 |93 94|%c
P08679131T0000 |7 14|allergy06T0076
P08679131T0000 |25 43|hypersensitivities with alkaline pho
P08680702A0548 |237 238|pr
P08680702A0548 |212 215|Daydat
P08680702A0548 |416 417|p 
P08680702A0548 |335 343|Vo2INDIR1 +/- 0.
P08680702A0548 |247 250|Dayer 
P08680702A0548 |391 394|Day be
P08680702A0548 |148 159|differences97A0472 Whe
P08680702A0548 |121 128|animalshyperbi
P08680702A0548 |345 354|ml/kg/min vs. P000
P08680702A0548 |356 359|Day943
P08680702A0548 |85 89|Days0 Ph
P08680702A0548 |49 60|dysfunctionses and 5-n
P08680702A0548 |20 29|lethalityrison wit
P08680702A0548 |178 182|cartown 
P08680702A0548 |76 81|group08171
P08680702A0548 |314 322|catheterly great
P08680702A0548 |193 199|Vo2DIRon of 
P08680702A0548 |201 210|ml/kg/minF PCO2 th
P08680702A0548 |381 382|pa
P08680702A0548 |272 273|pd
P08680706A0889 |152 157|mm Hg472 W
P08680706A0889 |215 221|valuesa of K
P08680706A0889 |26 40|PO2/FlO2 ratiowith alkaline 
P08680706A0889 |13 24|reperfusion6 Compariso
P08680706A0889 |225 243|Donor Aerosol dogsleted rats are no 
P08680706A0889 |120 139|Recipient Instilled hyperbilirubinemia
P08680706A0889 |189 194|mm Hgnctio
P08680706A0889 |163 177|Control groupsF [HCO3-] is s
P08680706A0889 |8 9|h6
P08680706A0889 |101 106|mm Hgaspec
P08680706A0889 |81 88|TherapyT0000 P
P08680706A0889 |256 261|mm Hgced w
P08682155A0902 |136 147|differencesmia. P00008
P08682155A0902 |78 89|non-smokers171T0000 Ph
P08682155A0902 |4 30|euglobulin clot lysis time01606T0076 Comparison with
P08682155A0902 |58 65|smokers-nucleo
P08682155A0902 |116 126|situationsatal hyper
P08682317A0900 |119 124|cellsl hyp
P08682317A0900 |52 77|HS transcription factor-1 and 5-nucleotidase P0000
P08682317A0900 |78 83|HSF-1171T0
P08682317A0900 |29 32|HSEh a
P08682317A0900 |136 138|HSmi
P08682317A0900 |96 104|extractsogic asp
P08682317A0900 |0 15|HS inducibilityP00001606T0076 
P08682868A0738 |84 90|domain00 Pha
P08682868A0738 |13 28|DSK2-1 mutation6 Comparison wi
P08682868A0738 |120 125|Dsk2p hype
P08682868A0738 |105 116|differencescts of neon
P08682868A0738 |129 145|Cdc31p stabilityirubinemia. P000
P08682868A0738 |63 68|Dsk2peotid
P08682868A0738 |48 55|residueases an
P08683106A0374 |137 148|STAT1 alphaia. P000089
P08683106A0374 |90 95|STAT5rmaco
P08683106A0374 |54 59|STAT5nd 5-
P08683106A0374 |9 13|IL-2T007
P08683106A0374 |61 65|IL-2cleo
P08683106A0374 |18 27|IFN-alphaparison w
P08683106A0374 |38 49|STAT1 alphae phosphata
P08683106A0374 |103 112|IFN-alphapects of 
P08683108A0965 |69 98|transcription factor proteinsse P00008171T0000 Pharmacolog
P08683108A0965 |109 113|junBof n
P08683108A0965 |123 127|siteperb
P08683108A0965 |21 35|interpretationison with alka
P08683108A0965 |173 177|siteis s
P08683108A0965 |49 53|CREBses 
P08683108A1501 |20 27|resultsrison w
P08683108A1501 |41 51|componentshosphatase
P08683108A1501 |111 114|mIg ne
P08683108A1501 |125 143|junB transcriptionrbilirubinemia. P0
P08683108A1501 |59 93|protein kinase A signaling pathwaynucleotidase P00008171T0000 Pharma
P08683983A0785 |4 11|complex01606T0
P08683983A0785 |28 37|D proteinth alkali
P08683983A0785 |108 122|leukemia cells of neonatal h
P08683983A1163 |102 107|mousespect
P08683983A1163 |41 47|intronhospha
P08683983A1163 |165 175|mechanisms[HCO3-] is
P08683983A1163 |241 260|cell growth controlo longer displaced 
P08683983A1163 |212 227|differentiationdata of K-deple
P08683983A1163 |179 189|activationwn as a fu
P08683983A1163 |24 37|participationn with alkali
P08683983A1163 |87 97|c-myb genePharmacolo
P08683983A1163 |4 11|results01606T0
P08683983A1163 |69 79|regulationse P000081
P08684522A0415 |102 110|collagenspects o
P08684522A0415 |115 122|lamininnatal h
P08684522A0415 |82 90|matrices0000 Pha
P08684522A0415 |94 98|typeolog
P08684522A0415 |139 143|wall. P0
P08684522A0415 |49 59|depositionses and 5-
P08684522A0415 |0 29|Immunofluorescence microscopyP00001606T0076 Comparison wit
P08684742A0000 |0 9|OBJECTIVEP00001606
P08684742A0000 |123 136|amniocentesisperbilirubine
P08684742A0000 |22 45|pregnancy complicationsson with alkaline phosp
P08684742A0000 |93 98|weekscolog
P08684742A0000 |146 151|weeks8997A
P08684742A0000 |70 83|amniocentesise P00008171T0
P08684742A0000 |49 54|womenses a
P08684742A0000 |153 162|gestation72 When C
P08686381A0527 |205 211|regionO2 the
P08686381A0527 |242 254|protein Swi3 longer disp
P08686381A0527 |12 23|9765orfR00276 Comparis
P08686381A0527 |183 190|proteins a fun
P08686381A0527 |25 36|9765orfR011 with alkal
P08686381A0527 |198 201|BCR CS
P08686381A0527 |41 52|9765orfR013hosphatases
P08686381A0527 |113 142|polyadenylate binding proteineonatal hyperbilirubinemia. P
P08686381A0527 |6 10|ORFs606T
P08686381A0527 |217 230|transcriptionof K-depleted
P08688190A0000 |154 159|parts2 Whe
P08688190A0000 |8 26|flavone glucosides6T0076 Comparison 
P08688190A0000 |28 59|nevadensin 5-O-beta-D-glucosideth alkaline phosphatases and 5-
P08688190A0000 |64 94|nevadensin 5-O-beta-D-glucosylotidase P00008171T0000 Pharmac
P08688190A0000 |163 185|Lysionotus pauciflorusF [HCO3-] is shown as 
P08688190A0000 |101 117|beta-D-glucosideaspects of neona
P08688556A0242 |152 157|yeast472 W
P08688556A0242 |14 24|laboratory Compariso
P08688556A0242 |75 86|suppressors008171T0000
P08688556A0242 |176 185|viabilityshown as 
P08688556A0242 |165 171|scd1-i[HCO3-
P08688556A0242 |121 129|clathrinhyperbil
P08688556A0242 |37 43|screenne pho
P08688556A0242 |110 117|strainsf neona
P08688556A0242 |159 162|Chcn C
P08689520T0000 |0 19|Reproductive periodP00001606T0076 Comp
P08689520T0000 |28 40|water intaketh alkaline 
P08689520T0000 |69 74|goatsse P0
P08690118A0845 |119 129|predictorsl hyperbil
P08690118A0845 |89 93|IVOSarma
P08690118A0845 |73 83|morphology00008171T0
P08690118A0845 |13 32|regression analysis6 Comparison with a
P08690118A0845 |40 53|manual methodphosphatases 
P08690118A0845 |133 146|fertilizationinemia. P0000
P08690118A0845 |55 65|percentaged 5-nucleo
P08690198A0346 |0 7|METHODSP000016
P08690198A0346 |110 136|Lactobacillus reuteri R2LCf neonatal hyperbilirubine
P08690198A0346 |9 13|RatsT007
P08690198A0346 |193 205|fermentationon of CSF PC
P08690198A0346 |47 55|infusiontases an
P08690198A0346 |233 238|studyts ar
P08690198A0346 |142 169|Lactobacillus plantarum DSM00008997A0472 When CSF [HCO
P08690198A0346 |82 97|supplementation0000 Pharmacolo
P08690198A0346 |101 108|oatbaseaspects
P08690198A0346 |216 225|beginning of K-dep
P08690198A0346 |69 73|dietse P
P08691106A0733 |101 105|cellaspe
P08691106A0733 |61 71|lactotrophcleotidase
P08691106A0733 |36 55|nuclease protectionine phosphatases an
P08691106A0733 |9 19|D8 bindingT0076 Comp
P08691106A0733 |114 121|proteinonatal 
P08691962T0000 |50 57|diseasees and 
P08691962T0000 |27 36|diagnosisith alkal
P08691962T0000 |74 79|blood00081
P08691962T0000 |92 97|cellsacolo
P08691962T0000 |40 47|Whipplephospha
P08691962T0000 |8 12|role6T00
P08692885A0663 |4 11|ability01606T0
P08692885A0663 |28 48|NF-kappaB activationth alkaline phosphat
P08692885A0663 |15 18|A20Com
P08692885A0663 |78 96|zinc finger domain171T0000 Pharmacol
P08692892A0330 |19 24|P258Lariso
P08692892A0330 |14 17|Leu Co
P08692892A0330 |105 106|%c
P08692892A0330 |172 184|alpha-factor is shown as
P08692892A0330 |26 34|mutationwith alk
P08692892A0330 |150 155|cellsA0472
P08692892A0330 |4 11|Pro-25801606T0
P08692892A0330 |114 127|maximum levelonatal hyperb
P08692892A0330 |55 73|receptor signalingd 5-nucleotidase P
P08692924A0328 |103 108|BCL-6pects
P08692924A0328 |41 48|abilityhosphat
P08692924A0328 |11 23|DNA sequence076 Comparis
P08692924A0328 |135 144|complexesemia. P00
P08692924A0328 |156 164|extractsWhen CSF
P08692924A0328 |178 190|B-cell linesown as a fun
P08692924A0328 |69 74|BCL-6se P0
P08697728A1199 |35 39|flagline
P08697728A1199 |15 20|valueCompa
P08697728A1199 |48 49|%a
P08698756A1240 |17 25|findingsmparison
P08698756A1240 |122 132|proceduresyperbiliru
P08698756A1240 |194 200|degreen of C
P08698756A1240 |93 97|rolecolo
P08698756A1240 |58 70|coenzyme Q10-nucleotidas
P08698756A1240 |160 165|cross CSF 
P08698756A1240 |217 223|damageof K-d
P08698756A1240 |39 52|pre-treatment phosphatases
P08698756A1240 |0 11|CONCLUSIONSP00001606T0
P08700531A1420 |168 180|localizationO3-] is show
P08700531A1420 |188 197|cph locusunction o
P08700531A1420 |246 258|cph oncogeneger displace
P08700531A1420 |58 69|alterations-nucleotida
P08700531A1420 |267 271|rolempar
P08700531A1420 |91 104|hamster cellsmacologic asp
P08700531A1420 |120 140|chemical carcinogens hyperbilirubinemia.
P08700531A1420 |326 345|hamster fibroblastslope (1.21 +/- 0.23
P08700531A1420 |289 299|conversion still hav
P08700531A1420 |155 162|viruses When C
P08700531A1420 |8 20|chromosome X6T0076 Compa
P08700531A1420 |230 236|notion rats 
P08700531A1420 |206 216|chromosome2 the data
P08702517A0000 |16 21|genesompar
P08702517A0000 |71 78|B6SUtA1 P00008
P08702517A0000 |5 11|screen1606T0
P08702517A0000 |87 107|progenitor cell linePharmacologic aspect
P08702543A0000 |0 4|Gap1P000
P08702543A0000 |22 28|memberson wi
P08702543A0000 |164 166|P. [
P08702543A0000 |134 137|IP4nem
P08702543A0000 |98 132|inositol 1,3,4,5-tetrakisphosphateic aspects of neonatal hyperbiliru
P08702543A0000 |54 62|proteinsnd 5-nuc
P08702543A0000 |5 10|IP4BP1606T
P08702543A0000 |32 35|Raslka
P08702543A0000 |156 162|CullenWhen C
P08702543A0000 |139 154|binding protein. P00008997A047
P08702556A0000 |136 140|Imaimia.
P08702556A0000 |85 88|PAP0 P
P08702556A0000 |157 159|K.he
P08702556A0000 |125 130|Kanohrbili
P08702556A0000 |28 40|purificationth alkaline 
P08702556A0000 |149 155|Yamada7A0472
P08702556A0000 |181 183|J. a
P08702556A0000 |172 174|F. i
P08702556A0000 |132 134|H.bi
P08702556A0000 |164 170|Sakane [HCO3
P08702556A0000 |67 83|acid phosphatasedase P00008171T0
P08702556A0000 |142 147|S.-i.00008
P08702556A0000 |99 123|porcine thymus membranesc aspects of neonatal hy
P08702633A0164 |51 60|increasess and 5-n
P08702633A0164 |121 143|Grb2 complex formationhyperbilirubinemia. P0
P08702633A0164 |164 211|Ras guanine nucleotide exchange factor activity [HCO3-] is shown as a function of CSF PCO2 the
P08702633A0164 |96 115|Shc adapter proteinogic aspects of neo
P08702633A0164 |23 33|Gbetagammaon with al
P08702633A0164 |149 160|recruitment7A0472 When
P08702633A0164 |64 88|tyrosine phosphorylationotidase P00008171T0000 P
P08702633A0164 |4 13|mechanism01606T007
P08702633A0164 |117 120|Shctal
P08702644A0499 |2 6|cDNA0001
P08702644A0499 |177 223|glycosylphosphatidylinositol anchor attachmenthown as a function of CSF PCO2 the data of K-d
P08702644A0499 |133 139|factorinemia
P08702644A0499 |166 172|signalHCO3-]
P08702644A0499 |99 110|amino acidsc aspects o
P08702644A0499 |37 38|%n
P08702644A0499 |42 46|apoBosph
P08702644A0499 |48 54|apoB17ases a
P08702644A0499 |141 144|DAFP00
P08702644A0499 |71 75|cDNA P00
P08702728A1325 |69 79|HIRc cellsse P000081
P08702728A1325 |47 52|Y317Ftases
P08702728A1325 |60 63|Shcucl
P08702728A1325 |40 43|Shcpho
P08702756A0000 |52 61|functions and 5-nu
P08702756A0000 |148 166|muscle contraction97A0472 When CSF [
P08702756A0000 |122 135|cell motilityyperbilirubin
P08702756A0000 |10 20|GTPase Rho0076 Compa
P08702756A0000 |109 120|cytokinesisof neonatal
P08702756A0000 |78 100|actin-myosin filaments171T0000 Pharmacologic
P08702807A0964 |157 185|cyclin D1 protein expressionhen CSF [HCO3-] is shown as 
P08702807A0964 |90 94|MKK1rmac
P08702807A0964 |12 22|activation76 Compari
P08702807A0964 |192 198|growthion of
P08702807A0964 |31 48|signaling pathwayalkaline phosphat
P08702807A0964 |52 62|expression and 5-nuc
P08702807A0964 |125 152|cyclin D1 promoter activityrbilirubinemia. P00008997A0
P08702807A0964 |218 224|mannerf K-de
P08702826A0870 |119 129|MCF7 cellsl hyperbil
P08702826A0870 |107 115|promoters of neo
P08702826A0870 |39 61|GSTP1 silencer element phosphatases and 5-nu
P08702826A0870 |22 31|insertionson with 
P08702826A0870 |80 88|activity1T0000 P
P08702845A0000 |100 120|dopamine transporter aspects of neonatal
P08702845A0000 |144 168|dopamine uptake kinetics008997A0472 When CSF [HC
P08702845A0000 |177 204|CFT binding characteristicshown as a function of CSF P
P08702845A0000 |208 219|COS-7 cellsthe data of
P08702845A0000 |122 125|DAType
P08702845A0000 |61 69|affinitycleotida
P08702845A0000 |268 281|COOH terminuspared to cont
P08702845A0000 |174 176|3Hs 
P08702845A0000 |74 85|recognition0008171T000
P08702845A0000 |250 254|DATsdisp
P08702845A0000 |33 39|motifskaline
P08702845A0000 |141 143|3HP0
P08702845A0000 |3 8|order00160
P08702936A0168 |71 76|cDNAs P000
P08702936A0168 |188 196|CD4 cDNAunction 
P08702936A0168 |123 128|bloodperbi
P08702936A0168 |164 170|signal [HCO3
P08702936A0168 |216 236|virus shuttle vector of K-depleted rats 
P08702936A0168 |141 146|cellsP0000
P08702936A0168 |3 21|expression library001606T0076 Compar
P08702936A0984 |99 108|monocytesc aspects
P08702936A0984 |25 29|TARC wit
P08702936A0984 |112 124|granulocytesneonatal hyp
P08702936A0984 |52 64|T cell lines and 5-nucle
P08702936A0984 |80 87|T cells1T0000 
P08703005A0645 |71 76|sites P000
P08703005A0645 |130 135|CCAATrubin
P08703005A0645 |148 155|protein97A0472
P08703005A0645 |15 23|elementsComparis
P08703005A0645 |37 54|promoter activityne phosphatases a
P08703005A0645 |111 119|alphaCbf neonata
P08703005A0645 |81 106|transcription factors Sp1T0000 Pharmacologic aspec
P08703010A0905 |239 243|site no 
P08703010A0905 |173 184|GAP-43 geneis shown as
P08703010A0905 |43 50|elementsphatas
P08703010A0905 |56 64|E1 E-box 5-nucle
P08703010A0905 |81 103|GAP-43 promoter regionT0000 Pharmacologic as
P08703010A0905 |218 226|proteinsf K-depl
P08703010A0905 |155 165|expression When CSF 
P08703908A1814 |18 26|findingsparison 
P08703908A1814 |44 48|SF-1phat
P08703908A1814 |111 121|expression neonatal 
P08703908A1814 |61 65|rolecleo
P08703908A1814 |129 138|StAR geneirubinemi
P08703959A0659 |102 113|lesion sitespects of n
P08703959A0659 |75 82|segment008171T
P08703959A0659 |202 210|spectrum PCO2 th
P08703959A0659 |163 176|sugar protonsF [HCO3-] is 
P08703959A0659 |144 154|assignment008997A047
P08703959A0659 |184 194|C7 residue a functio
P08703959A0659 |218 231|adduct duplexf K-depleted 
P08703959A0659 |34 51|proton resonancesaline phosphatase
P08704124A0420 |69 77|VrCDPK-1se P0000
P08704124A0420 |60 67|bp cDNAucleoti
P08704124A0420 |86 119|Vigna radiata lambda gt11 library Pharmacologic aspects of neonata
P08704124A0420 |21 30|fragmentsison with
P08704124A0420 |32 38|CPK3-8lkalin
P08704240A1111 |32 38|GM-CSFlkalin
P08704240A1111 |46 56|starvationatases and
P08704240A1111 |12 22|TF-1 cells76 Compari
P08704240A1111 |95 102|minuteslogic a
P08704240A1111 |109 128|PIXY321 stimulationof neonatal hyperbi
P08704240A1111 |58 78|CREB phosphorylation-nucleotidase P00008
P08705056T0000 |0 18|Workplace violenceP00001606T0076 Com
P08705056T0000 |30 34|risk alk
P08705056T0000 |20 26|nursesrison 
P08706368A1024 |102 103|ps
P08706368A1024 |148 158|brightness97A0472 Wh
P08706368A1024 |88 100|correlationsharmacologic
P08706368A1024 |13 34|LV maximum brightness6 Comparison with alk
P08706368A1024 |202 203|p 
P08706368A1024 |189 200|correlationnction of C
P08706368A1024 |124 128|FIO2erbi
P08706368A1024 |54 59|curvend 5-
P08706368A1024 |39 43|area pho
P08706368A1024 |0 7|RESULTSP000016
P08706662A1125 |32 39|absencelkaline
P08706662A1125 |43 62|perforin expressionsphatases and 5-nuc
P08706662A1125 |123 132|inductionperbiliru
P08706662A1125 |104 115|suppressionects of neo
P08706662A1125 |174 186|factor NF-P2s shown as a
P08706662A1125 |80 85|cells1T000
P08706662A1125 |4 11|results01606T0
P08706731A1303 |71 90|expression patterns P00008171T0000 Pha
P08706731A1303 |41 53|similaritieshosphatases 
P08706731A1303 |270 284|PR-10 proteinsred to control
P08706731A1303 |167 186|sequence similarityCO3-] is shown as a
P08706731A1303 |194 214|ginseng ribonucleasen of CSF PCO2 the da
P08706731A1303 |299 309|predictione a signif
P08706731A1303 |228 238|hypothesised rats ar
P08706731A1303 |94 105|Ypr10 genesologic aspe
P08706731A1303 |244 265|ribonuclease functiononger displaced when 
P08706731A1303 |333 338|roles.21 +
P08706731A1303 |110 128|ribonuclease genesf neonatal hyperbi
P08707424A0709 |118 124|stagesal hyp
P08707424A0709 |4 14|expression01606T0076
P08707424A0709 |86 96|expression Pharmacol
P08707424A0709 |18 31|ERV3 env mRNAparison with 
P08707424A0709 |138 149|developmenta. P0000899
P08707516A0194 |39 45|people phosp
P08707516A0194 |60 67|receiptucleoti
P08707516A0194 |92 109|handicap servicesacologic aspects 
P08707516A0194 |77 81|need8171
P08707516A0194 |8 17|estimates6T0076 Co
P08707825A0063 |253 260|proteinplaced 
P08707825A0063 |211 223|antibody R4A data of K-d
P08707825A0063 |95 103|analysislogic as
P08707825A0063 |130 140|smoothelinrubinemia.
P08707825A0063 |241 245|cDNAo lo
P08707825A0063 |53 70|Northern blottingand 5-nucleotidas
P08707825A0063 |37 49|muscle cellsne phosphata
P08707825A0063 |158 177|muscle cDNA libraryen CSF [HCO3-] is s
P08707840A0753 |17 36|electron microscopymparison with alkal
P08707840A0753 |130 133|p62rub
P08707840A0753 |90 95|sidesrmaco
P08707840A0753 |52 59|p58/p45 and 5-
P08707840A0753 |111 123|pore complex neonatal hy
P08707840A0753 |64 67|p54oti
P08707846A2308 |257 268|endocytosised when com
P08707846A2308 |128 151|receptor ubiquitinationlirubinemia. P00008997A
P08707846A2308 |208 225|a-factor receptorthe data of K-dep
P08707846A2308 |62 70|receptorleotidas
P08707846A2308 |96 110|ubiquitinationogic aspects o
P08707846A2308 |189 200|endocytosisnction of C
P08707846A2308 |33 39|uptakekaline
P08707922A0334 |0 30|Transcription initiation sitesP00001606T0076 Comparison with
P08707922A0334 |146 174|translation initiation codon8997A0472 When CSF [HCO3-] i
P08707922A0334 |198 223|primer extension analysis CSF PCO2 the data of K-d
P08707922A0334 |123 125|bppe
P08707922A0334 |45 49|betahata
P08707922A0334 |52 60|III beta and 5-n
P08707922A0334 |111 121|base pairs neonatal 
P08707922A0334 |176 179|ATGsho
P08707922A0334 |38 41|rate p
P08707922A0334 |66 85|O beta-globin genesidase P00008171T000
P08707922A0334 |190 194|genectio
P08708984T0000 |63 69|lesioneotida
P08708984T0000 |73 76|rat000
P08708984T0000 |31 43|indomethacinalkaline pho
P08708984T0000 |12 19|process76 Comp
P08709224T0000 |38 43|EBNA2e pho
P08709224T0000 |56 65|component 5-nucleo
P08709224T0000 |13 18|virus6 Com
P08709224T0000 |27 34|proteinith alk
P08709224T0000 |79 94|SNF-SWI complex71T0000 Pharmac
P08709224T0000 |96 106|hSNF5/Ini1ogic aspec
P08709245A1521 |102 107|rolesspect
P08709245A1521 |51 66|phosphorylations and 5-nucleot
P08709245A1521 |155 159|HDAg Whe
P08709245A1521 |115 141|trans-suppression activitynatal hyperbilirubinemia. 
P08709245A1521 |244 249|HDAgsonger
P08709245A1521 |89 96|Ser-210armacol
P08709245A1521 |30 41|possibility alkaline p
P08709245A1521 |197 210|HDAg particlef CSF PCO2 th
P08709245A1521 |231 240|transportrats are 
P08709245A1521 |77 84|Ser-1238171T00
P08709245A1521 |168 176|assemblyO3-] is 
P08709245A1521 |4 11|studies01606T0
P08709245A1521 |70 75|Ser-2e P00
P08709251A0000 |68 86|polyhedrosis virusase P00008171T0000
P08709251A0000 |160 177|DNA helicase gene CSF [HCO3-] is s
P08709251A0000 |11 24|recombination076 Compariso
P08709251A0000 |88 93|AcNPVharma
P08709251A0000 |121 133|DNA fragmenthyperbilirub
P08709251A0000 |181 187|Bombyx as a 
P08709251A0000 |230 239|eh2-AcNPV rats are
P08709251A0000 |264 276|AcNPV mutant compared to
P08709251A0000 |95 101|genomelogic 
P08709251A0000 |278 280|S.on
P08709251A0000 |37 59|Autographa californicane phosphatases and 5-
P08709251A0000 |201 219|polyhedrosis virusF PCO2 the data of
P08709637A1471 |35 53|IL-7R alpha chainsline phosphatases 
P08709637A1471 |151 160|signaling0472 When
P08709637A1471 |129 133|roleirub
P08709637A1471 |106 111|STATsts of
P08709637A1471 |164 181|precursor B cells [HCO3-] is shown
P08709637A1471 |83 93|activation000 Pharma
P08709637A1471 |97 101|JAKsgic 
P08709637A1471 |4 8|data0160
P08709831A0599 |17 24|potencympariso
P08709831A0599 |47 56|treatmenttases and
P08709831A0599 |28 39|Dacarbacineth alkaline
P08709831A0599 |70 76|tumorse P000
P08710151A0782 |137 144|patientia. P00
P08710151A0782 |148 155|class A97A0472
P08710151A0782 |74 81|class A0008171
P08710151A0782 |44 48|costphat
P08710151A0782 |31 36|valuealkal
P08710151A0782 |112 119|class Bneonata
P08710151A0782 |128 132|costliru
P08710151A0782 |182 190|class B.as a fun
P08710151A0782 |64 70|pnx s.otidas
P08710151A0782 |53 60|episodeand 5-n
P08710151A0782 |98 99|%i
P08710371A0000 |139 146|biology. P0000
P08710371A0000 |61 76|polyomavirus BKcleotidase P000
P08710371A0000 |109 120|protein p53of neonatal
P08710371A0000 |26 37|interactionwith alkali
P08710371A0000 |210 229|p53 transactivatione data of K-deplete
P08710371A0000 |196 206|mechanismsof CSF PCO
P08710371A0000 |78 81|BKV171
P08710371A0000 |155 160|virus When
P08710371A0499 |0 9|Site S-IIP00001606
P08710371A0499 |60 83|consensus binding sitesucleotidase P00008171T0
P08710371A0499 |26 37|bp sequencewith alkali
P08710371A0499 |134 152|base pair deletionnemia. P00008997A0
P08710371A0499 |95 115|base pair mismatcheslogic aspects of neo
P08710377A0577 |0 3|CblP00
P08710377A0577 |149 164|BCR stimulation7A0472 When CSF
P08710377A0577 |66 76|preferenceidase P000
P08710377A0577 |53 57|Grb2and 
P08710377A0577 |123 126|wayper
P08710377A0577 |38 49|SH3 domainse phosphata
P08710377A0577 |140 143|Shc P0
P08710377A0577 |100 106|domain aspec
P08710504A0995 |0 10|ActivationP00001606T
P08710504A0995 |59 70|cat1 mutantnucleotidas
P08710504A0995 |23 28|Cat8pon wi
P08711631A0989 |0 9|TreatmentP00001606
P08711631A0989 |44 60|cyclophosphamidephatases and 5-n
P08711631A0989 |29 39|prednisoneh alkaline
P08712799A0123 |25 32|smoking with a
P08712799A0123 |8 16|attempts6T0076 C
P08713933A0606 |0 21|Laboratory evaluationP00001606T0076 Compar
P08713933A0606 |38 50|neuroimaginge phosphatas
P08713933A0606 |104 112|drainageects of 
P08713933A0606 |69 80|obstructionse P0000817
P08716757T0001 |0 24|Microcomputer managementP00001606T0076 Compariso
P08716757T0001 |67 75|patientsdase P00
P08716757T0001 |36 53|hepatitis B virusine phosphatases 
P08717391A0466 |84 90|fusion00 Pha
P08717391A0466 |211 225|immunogenicity data of K-dep
P08717391A0466 |194 206|antigenicityn of CSF PCO
P08717391A0466 |151 168|particle assembly0472 When CSF [HC
P08717391A0466 |120 130|C-terminus hyperbili
P08717391A0466 |59 66|surfacenucleot
P08717391A0466 |42 48|linkerosphat
P08717391A0466 |229 234|HBcAgd rat
P08717391A0466 |20 30|N-terminusrison with
P08717391A0466 |6 12|fusion606T00
P08717391A0466 |98 108|N-terminusic aspects
P08717559A0223 |98 108|microgramsic aspects
P08717559A0223 |13 19|dosage6 Comp
P08717559A0223 |75 82|ampoule008171T
P08717559A0223 |65 69|agestida
P08719155A0105 |304 306|CSig
P08719155A0105 |105 113|sequencects of n
P08719155A0105 |246 250|TRAPger 
P08719155A0105 |29 36|cloningh alkal
P08719155A0105 |182 192|Plasmodiumas a funct
P08719155A0105 |60 68|moleculeucleotid
P08719155A0105 |269 275|extentared t
P08719155A0105 |160 176|surface molecule CSF [HCO3-] is 
P08719155A0105 |286 302|circumsporozoitebut still have a
P08719155A0105 |74 87|P. falciparum0008171T0000 
P08719155A0105 |308 315|proteinficantl
P08719155A0105 |129 141|similaritiesirubinemia. 
P08719155A0105 |237 244|proteinre no l
P08719156A0953 |68 81|reading framease P00008171
P08719156A0953 |13 20|introns6 Compa
P08719156A0953 |104 111|proteinects of
P08719156A0953 |32 36|genelkal
P08719697A0221 |34 37|eyeali
P08719697A0221 |9 12|DSFT00
P08719697A0221 |76 79|eye081
P08719697A0221 |59 61|CFnu
P08719697A0221 |126 129|KCSbil
P08719697A0221 |112 120|patientsneonatal
P08719697A0221 |93 101|subjectscologic 
P08719697A0221 |0 7|METHODSP000016
P08719832A0397 |68 75|surgeryase P00
P08719832A0397 |79 89|acromegaly71T0000 Ph
P08719832A0397 |30 48|rhinotomy approach alkaline phosphat
P08719832A0397 |4 14|experience01606T0076
P08720407A1386 |0 10|CONCLUSIONP00001606T
P08720407A1386 |111 130|interleukin-1 alpha neonatal hyperbili
P08720407A1386 |161 188|prostaglandin E2 productionCSF [HCO3-] is shown as a f
P08720407A1386 |63 78|disc herniationeotidase P00008
P08720407A1386 |48 52|siteases
P08720407A1386 |93 102|cytokinescologic a
P08720407A1386 |16 23|resultsomparis
P08721526A0000 |59 67|childrennucleoti
P08721526A0000 |28 37|allergensth alkali
P08721526A0000 |79 90|pet animals71T0000 Pha
P08721989A1012 |50 57|domainses and 
P08721989A1012 |194 211|signal transducern of CSF PCO2 the
P08721989A1012 |149 155|beta c7A0472
P08721989A1012 |135 143|evidenceemia. P0
P08721989A1012 |104 122|signaling pathwaysects of neonatal h
P08721989A1012 |67 85|cytokine receptorsdase P00008171T000
P08721989A1012 |160 179|IL-2R beta function CSF [HCO3-] is sho
P08721989A1012 |4 11|results01606T0
P08721999A0432 |33 41|featureskaline p
P08721999A0432 |79 89|snoRNA U1471T0000 Ph
P08721999A0432 |3 11|addition001606T0
P08721999A0727 |0 3|U24P00
P08721999A0727 |72 77|tractP0000
P08721999A0727 |81 89|28S rRNAT0000 Ph
P08721999A0727 |24 26|ntn 
P08721999A0727 |32 49|complementaritieslkaline phosphata
P08722011A0103 |87 99|binding sitePharmacologi
P08722011A0103 |30 43|GTPase domain alkaline pho
P08722011A0103 |57 69|subunit rRNA5-nucleotida
P08722011A0103 |107 114|proteins of ne
P08722011A0103 |135 146|counterpartemia. P0000
P08722011A0103 |173 184|protein L15is shown as
P08722011A0103 |199 210|protein L12CSF PCO2 th
P08722011A0103 |5 12|complex1606T00
P08722568A1001 |119 147|replacement H3 histone genesl hyperbilirubinemia. P00008
P08722568A1001 |30 47|replacement genes alkaline phospha
P08722568A1001 |151 157|plants0472 W
P08722568A1001 |105 115|expressioncts of neo
P08722568A1001 |0 20|Chromatin repressionP00001606T0076 Compa
P08723352A0084 |81 85|cdksT000
P08723352A0084 |109 116|productof neon
P08723352A0084 |72 79|kinasesP000081
P08723352A0084 |163 166|pRbF [
P08723352A0084 |124 161|retinoblastoma tumour suppressor geneerbilirubinemia. P00008997A0472 When 
P08723352A0084 |5 15|transition1606T0076 
P08723365T0000 |77 92|nephrosclerosis8171T0000 Pharm
P08723365T0000 |62 73|hypertrophyleotidase P
P08723365T0000 |30 46|hyperinsulinemia alkaline phosph
P08723365T0000 |9 21|relationshipT0076 Compar
P08723883A0823 |0 21|Blood GSH-Px activityP00001606T0076 Compar
P08723883A0823 |42 59|spectrophotometerosphatases and 5-
P08723883A0823 |108 113|assay of n
P08723883A0823 |69 81|modificationse P00008171
P08723883A1684 |187 195|vitaminsfunction
P08723883A1684 |109 115|levelsof neo
P08723883A1684 |132 143|alfalfa haybinemia. P0
P08723883A1684 |47 56|vitamin Etases and
P08723883A1684 |120 126|llamas hyper
P08723883A1684 |22 42|vitamin A precursorsson with alkaline ph
P08723883A1684 |212 219|speciesdata of
P08723883A1684 |177 183|sourcehown a
P08723883A1684 |4 18|concentrations01606T0076 Com
P08723883A1684 |202 203|E 
P08723883A1684 |64 67|hayoti
P08726024A0244 |6 10|cats606T
P08726024A0244 |25 34|H. pylori with alk
P08726024A0244 |52 57|study and 
P08726024A0532 |35 42|primersline ph
P08726024A0532 |131 144|fluid samplesubinemia. P00
P08726024A0532 |108 118|weeks p.t. of neonat
P08726024A0532 |198 202|cats CSF
P08726024A0532 |26 29|PCRwit
P08726024A0532 |208 218|weeks p.t.the data o
P08726024A0532 |67 74|productdase P0
P08726024A0532 |230 236|plaque rats 
P08726024A0532 |92 96|catsacol
P08726024A0532 |80 88|majority1T0000 P
P08726024A0532 |260 269|H. pyloriwhen comp
P08726024A0532 |169 178|H. pylori3-] is sh
P08726247A0175 |50 62|measurementses and 5-nuc
P08726247A0175 |97 108|path lengthgic aspects
P08726247A0175 |72 83|attenuationP00008171T0
P08726247A0175 |23 44|concentration changeson with alkaline phos
P08727192A0000 |0 12|STUDY DESIGNP00001606T00
P08727992A0570 |39 46|heifers phosph
P08727992A0570 |74 79|signs00081
P08727992A0570 |14 23|injection Comparis
P08727992A0570 |111 114|min ne
P08727992A0570 |27 37|PGF2 alphaith alkali
P08727992A0570 |83 89|estrus000 Ph
P08728040T0000 |85 111|Janus kinase-Stat pathways0 Pharmacologic aspects of
P08728040T0000 |13 23|activation6 Comparis
P08728040T0000 |188 201|sarcoma cellsunction of CS
P08728040T0000 |179 185|Kaposiwn as 
P08728040T0000 |62 68|kinaseleotid
P08728040T0000 |138 162|fibroblast growth factora. P00008997A0472 When C
P08728040T0000 |115 127|oncostatin Mnatal hyperb
P08728040T0000 |70 80|Jun kinasee P0000817
P08730470A0000 |17 26|agreementmparison 
P08730470A0000 |178 195|household contactown as a function
P08730470A0000 |144 150|babies008997
P08730470A0000 |133 140|mothersinemia.
P08730470A0000 |115 127|transmissionnatal hyperb
P08730470A0000 |36 53|hepatitis C virusine phosphatases 
P08730470A0000 |101 105|dataaspe
P08731155A0499 |16 30|reconstructionomparison with
P08731155A0499 |81 87|nervesT0000 
P08731155A0499 |4 9|weeks01606
P08731155A0499 |49 55|nervesses an
P08731222A0000 |169 173|area3-] 
P08731222A0000 |122 125|SRDype
P08731222A0000 |302 310|C7 level signifi
P08731222A0000 |165 167|Cu[H
P08731222A0000 |225 259|Phaseolus vulgaris leucoagglutininleted rats are no longer displaced
P08731222A0000 |21 33|organizationison with al
P08731222A0000 |261 266|PHA-Lhen c
P08731222A0000 |89 120|subnucleus reticularis dorsalisarmacologic aspects of neonatal
P08731222A0000 |148 163|Cuneate nucleus97A0472 When CS
P08731222A0000 |283 290|laminaels but 
P08731222A0000 |193 196|raton 
P08731222A0000 |74 85|enlargement0008171T000
P08731222A0000 |4 16|distribution01606T0076 C
P08731222A0000 |37 48|projectionsne phosphat
P08731222A0000 |206 221|microinjections2 the data of K
P08731511A0625 |86 90|HCII Pha
P08731511A0625 |14 24|fibrinogen Compariso
P08731511A0625 |143 150|animals0008997
P08731511A0625 |36 48|antithrombinine phosphat
P08731511A0625 |92 102|activitiesacologic a
P08731511A0625 |65 81|heparin cofactortidase P00008171
P08731511A0625 |54 59|ATIIInd 5-
P08731511A0625 |4 10|levels01606T
P08732665A0000 |0 13|AmplificationP00001606T007
P08732665A0000 |329 336|culturee (1.21
P08732665A0000 |18 32|overexpressionparison with a
P08732665A0000 |81 103|breast carcinoma cellsT0000 Pharmacologic as
P08732665A0000 |293 306|growth factorll have a sig
P08732665A0000 |261 264|IGFhen
P08732665A0000 |246 259|growth factorger displaced
P08732665A0000 |57 63|21MT-25-nucl
P08732665A0000 |313 325|independencetly greater 
P08732665A0000 |40 53|c-erbB-2 genephosphatases 
P08732665A0000 |187 197|p185erbB-2function o
P08732665A0000 |138 144|levelsa. P00
P08732665A0000 |308 311|EGFfic
P08732665A0000 |68 74|21MT-1ase P0
P08733123A0000 |136 143|musclesmia. P0
P08733123A0000 |151 155|face0472
P08733123A0000 |40 44|FSHDphos
P08733123A0000 |124 132|weaknesserbiliru
P08733123A0000 |29 38|dystrophyh alkalin
P08733123A0000 |157 165|shoulderhen CSF 
P08733123A0000 |176 179|armsho
P08733123A0000 |86 94|disorder Pharmac
P08733123A0951 |48 50|bpas
P08733123A0951 |109 116|proteinof neon
P08733123A0951 |79 84|exons71T00
P08733123A0951 |11 21|chromosome076 Compar
P08733123A0951 |24 39|FRG1 transcriptn with alkaline
P08733123A0951 |124 143|amino acid residueserbilirubinemia. P0
P08733123A0951 |54 60|lengthnd 5-n
P08733874A0000 |152 156|131I472 
P08733874A0000 |46 63|thyroid carcinomaatases and 5-nucl
P08733874A0000 |28 41|thyroidectomyth alkaline p
P08733874A0000 |181 192|measurement as a funct
P08733874A0000 |163 176|body scanningF [HCO3-] is 
P08733874A0000 |196 204|serum TGof CSF P
P08733874A0000 |92 99|periodsacologi
P08733874A0000 |136 147|preparationmia. P00008
P08733874A0000 |118 132|hypothyroidismal hyperbiliru
P08733874A0000 |0 8|PatientsP0000160
P08733881A0343 |69 76|samplesse P000
P08733881A0343 |135 145|TSH levelsemia. P000
P08733881A0343 |112 120|subjectsneonatal
P08733881A0343 |89 99|TSH valuesarmacologi
P08733881A0343 |5 29|thyroid function testing1606T0076 Comparison wit
P08734538A0613 |55 63|texturesd 5-nucl
P08734538A0613 |121 129|textureshyperbil
P08734538A0613 |142 144|AM00
P08734538A0613 |11 21|experiment076 Compar
P08734538A0613 |23 32|crossoveron with a
P08738510A0254 |76 87|meningiomas08171T0000 
P08738510A0254 |61 67|cortexcleoti
P08738510A0254 |31 38|Q-MRGlualkalin
P08738510A0254 |13 29|tumor FDG-uptake6 Comparison wit
P08739209A0700 |0 11|ZatebradineP00001606T0
P08739209A0700 |194 198|dogsn of
P08739209A0700 |160 161|h 
P08739209A0700 |148 156|ligation97A0472 
P08739209A0700 |106 117|arrhythmiasts of neona
P08739209A0700 |53 57|rateand 
P08739209A0700 |172 180|ligation is show
P08739209A0700 |81 86|ratioT0000
P08739260T0000 |0 5|CathaP0000
P08739260T0000 |31 50|amphetamine effectsalkaline phosphatas
P08739260T0000 |16 21|plantompar
P08740416A0239 |102 108|regionspects
P08740416A0239 |14 21|protein Compar
P08740416A0239 |45 56|amino acidshatases and
P08740416A0239 |23 28|Seb1pon wi
P08740416A0239 |145 160|signal sequence08997A0472 When
P08740416A0239 |116 126|C-terminusatal hyper
P08740416A0919 |34 38|SEB2alin
P08740416A0919 |60 61|%u
P08740416A0919 |4 18|SEB1 homologue01606T0076 Com
P08740416A0919 |75 80|Seb1p00817
P08740416A0919 |50 57|proteines and 
P08741206A1551 |123 134|hypotensionperbilirubi
P08741206A1551 |60 68|settingsucleotid
P08741206A1551 |30 39|afferents alkaline
P08741206A1551 |106 118|vasodilationts of neonat
P08741280A0374 |113 117|lobeeona
P08741280A0374 |94 100|lengthologic
P08741280A0374 |44 48|lobephat
P08741280A0374 |59 63|onesnucl
P08741280A0374 |27 31|sizeith 
P08741280A0374 |6 10|ones606T
P08742135A0000 |0 9|FragmentsP00001606
P08742135A0000 |29 41|hormone ACTHh alkaline p
P08742135A0000 |14 21|analogs Compar
P08742135A0000 |162 164|CSSF
P08742135A0000 |146 160|corticosterone8997A0472 When
P08742135A0000 |108 119|head injury of neonata
P08742135A0000 |83 89|effect000 Ph
P08742135A0000 |97 104|outcomegic asp
P08742135A0000 |136 142|levelsmia. P
P08742385A0211 |139 140|%.
P08742385A0211 |113 114|%e
P08742385A0211 |72 80|drainageP0000817
P08742385A0211 |120 131|head injury hyperbilir
P08742385A0211 |86 87|% 
P08742385A0211 |18 24|causespariso
P08742385A0211 |32 42|meningitislkaline ph
P08745669A0000 |204 214|bleomocyinCO2 the da
P08745669A0000 |10 18|patients0076 Com
P08745669A0000 |192 202|methyl GAGion of CSF
P08745669A0000 |120 127|disease hyperb
P08745669A0000 |110 117|Hodgkinf neona
P08745669A0000 |179 190|cisplatinumwn as a fun
P08745669A0000 |92 100|lymphomaacologic
P08745669A0000 |216 234|methyl prednisolon of K-depleted rat
P08745669A0000 |65 73|lymphomatidase P
P08745669A0000 |170 177|regimen-] is s
P08746605A0377 |20 23|useris
P08746605A0377 |47 56|incidencetases and
P08746605A0377 |27 41|ACE inhibitorsith alkaline p
P08746605A0377 |73 80|effects0000817
P08746605A0377 |108 120|pancreatitis of neonatal
P08746981A0154 |20 24|dietriso
P08746981A0154 |62 82|mg probiotic/kg foodleotidase P00008171T
P08746981A0154 |5 15|treatments1606T0076 
P08747078T0000 |9 16|aspirinT0076 C
P08747078T0000 |31 42|miscarriagealkaline ph
P08747343A0790 |0 13|Protein filmsP00001606T007
P08747343A0790 |93 102|materialscologic a
P08747343A0790 |73 78|films00008
P08747343A0790 |53 61|profilesand 5-nu
P08748033A0874 |68 92|LamB-LacZ hybrid proteinase P00008171T0000 Pharm
P08748033A0874 |126 135|cytoplasmbilirubin
P08748033A0874 |111 118|effects neonat
P08748033A0874 |13 17|cpxA6 Co
P08748033A0874 |19 28|mutationsarison wi
P08748033A0874 |42 50|toxicityosphatas
P08748033A0874 |154 158|DegP2 Wh
P08749393A0783 |4 17|PI3K_68D cDNA01606T0076 Co
P08749393A0783 |28 35|proteinth alka
P08749393A0783 |60 69|sequencesucleotida
P08749393A0783 |43 46|kDasph
P08749393A0783 |245 254|C2 domainnger disp
P08749393A0783 |209 220|SH3 domainshe data of 
P08749393A0783 |179 187|sequencewn as a 
P08749393A0783 |92 109|p110 PI 3-kinasesacologic aspects 
P08749393A0783 |113 133|p85 adaptor proteinseonatal hyperbilirub
P08749394A0874 |170 186|Drosophila Notch-] is shown as a
P08749394A0874 |9 28|interaction studiesT0076 Comparison wi
P08749394A0874 |109 111|Suof
P08749394A0874 |36 44|proteinsine phos
P08749394A0874 |112 113|Hn
P08749394A0874 |93 104|RBP-J kappacologic asp
P08749394A0874 |136 149|RAM23 regionsmia. P0000899
P08749394A0874 |54 79|glutathione-S-transferasend 5-nucleotidase P000081
P08749394A0874 |153 165|mouse Notch172 When CSF 
P08750173A0000 |34 49|system functionaline phosphata
P08750173A0000 |150 165|D-galactosamineA0472 When CSF 
P08750173A0000 |66 75|clearanceidase P00
P08750173A0000 |93 101|bacteriacologic 
P08750173A0000 |126 138|liver injurybilirubinemi
P08750173A0000 |169 173|rats3-] 
P08750173A0000 |206 229|% liver resection model2 the data of K-deplete
P08750173A0000 |0 12|AIMS/METHODSP00001606T00
P08750190A0000 |49 57|splicingses and 
P08750190A0000 |181 189|isoforms as a fu
P08750190A0000 |105 109|sitects 
P08750190A0000 |174 179|CD44vs sho
P08750190A0000 |146 156|generation8997A0472 
P08750190A0000 |160 172|CD44 variant CSF [HCO3-]
P08750190A0000 |71 76|exons P000
P08750190A0000 |4 14|laboratory01606T0076
P08750190A0000 |19 25|othersarison
P08750702A0183 |0 12|Study groupsP00001606T00
P08750702A0183 |82 97|blockers WB41010000 Pharmacolo
P08750702A0183 |144 154|mg/kg i.v.008997A047
P08750702A0183 |103 113|mg/kg i.v.pects of n
P08750702A0183 |18 25|controlparison
P08750702A0183 |118 138|chloroethylclonidineal hyperbilirubinemi
P08751635A0135 |48 52|lossases
P08751635A0135 |28 34|damageth alk
P08751635A0135 |92 97|hilusacolo
P08751635A0135 |56 81|hippocampus subfields CA1 5-nucleotidase P00008171
P08751635A0135 |83 86|CA3000
P08752714A0000 |152 157|years472 W
P08752714A0000 |27 37|malignancyith alkali
P08752714A0000 |122 132|departmentyperbiliru
P08752714A0000 |83 95|malignancies000 Pharmaco
P08752714A0000 |57 65|patients5-nucleo
P08752714A0000 |4 14|occurrence01606T0076
P08754777A1214 |86 88|T3 P
P08754777A1214 |45 65|T3R-RXR heterodimershatases and 5-nucleo
P08754777A1214 |157 162|upTREhen C
P08754777A1214 |114 133|heterodimer bindingonatal hyperbilirub
P08754777A1214 |75 80|dnTRE00817
P08754777A1214 |21 35|T3R homodimersison with alka
P08754777A1214 |4 9|upTRE01606
P08754777A1214 |141 143|dnP0
P08754802T0000 |16 23|controlomparis
P08754802T0000 |109 113|miceof n
P08754802T0000 |132 141|receptorsbinemia. 
P08754802T0000 |73 94|acid oxidation enzyme00008171T0000 Pharmac
P08754802T0000 |37 41|genene p
P08754802T0000 |163 181|adipose expressionF [HCO3-] is shown
P08754802T0000 |115 119|rolenata
P08754827A0231 |0 6|HoebenP00001
P08754827A0231 |8 12|F.J.6T00
P08754834A1097 |83 101|transcription unit000 Pharmacologic 
P08754834A1097 |15 24|fragmentsCompariso
P08754834A1097 |161 167|detailCSF [H
P08754834A1097 |131 138|NN-84AGubinemi
P08754834A1097 |42 59|response elementsosphatases and 5-
P08754840A0793 |98 114|deltabem4 mutantic aspects of ne
P08754840A0793 |10 34|glucan synthase activity0076 Comparison with alk
P08754840A0793 |58 63|Rho1p-nucl
P08754852A0960 |84 91|protein00 Phar
P08754852A0960 |30 33|RCS al
P08754852A0960 |162 170|sequenceSF [HCO3
P08754852A0960 |182 188|18-meras a f
P08754852A0960 |132 144|chondrocytesbinemia. P00
P08754852A0960 |3 25|gel retardation assays001606T0076 Comparison
P08754852A0960 |110 119|RCS cellsf neonata
P08754852A0960 |48 55|proteinases an
P08755898A0339 |137 143|avrBs2ia. P0
P08755898A0339 |45 64|Bs2 host resistancehatases and 5-nucle
P08755898A0339 |27 36|pathogensith alkal
P08755898A0339 |88 95|fitnessharmaco
P08755898A0339 |4 11|classes01606T0
P08756332A0000 |0 7|MembersP000016
P08756332A0000 |15 28|Ras subfamilyComparison wi
P08756332A0000 |232 239|Ral-GEFats are
P08756332A0000 |196 230|guanine nucleotide exchange factorof CSF PCO2 the data of K-depleted
P08756332A0000 |123 141|effector moleculesperbilirubinemia. 
P08756332A0000 |50 58|proteinses and 5
P08756332A0000 |154 174|protein kinase c-Raf2 When CSF [HCO3-] i
P08756332A0000 |103 110|varietypects o
P08756433A0282 |34 49|promoter regionaline phosphata
P08756433A0282 |10 26|characterization0076 Comparison 
P08756433A0282 |157 167|MAP1B genehen CSF [H
P08756433A0282 |83 91|elements000 Phar
P08756433A0282 |139 149|expression. P0000899
P08756556A0406 |4 8|cDNA0160
P08756556A0406 |26 33|proteinwith al
P08756556A0406 |75 95|acid signal sequence008171T0000 Pharmaco
P08756556A0406 |41 52|amino acidshosphatases
P08756597A0854 |0 7|MutantsP000016
P08756597A0854 |47 58|% reductiontases and 5
P08756597A0854 |75 84|psaB mRNA008171T00
P08756597A0854 |66 71|levelidase
P08756609A0498 |136 144|protozoamia. P00
P08756609A0498 |12 31|amino acid sequence76 Comparison with 
P08756609A0498 |90 101|vertebratesrmacologic 
P08756609A0498 |125 131|plantsrbilir
P08756609A0498 |78 88|eukaryotes171T0000 P
P08756609A0498 |160 164|gene CSF
P08756609A0498 |103 116|invertebratespects of neon
P08756609A0498 |69 74|rangese P0
P08756609A0498 |118 123|fungial hy
P08756617A1204 |0 4|BiolP000
P08756636T0000 |83 96|Srs2 helicase000 Pharmacol
P08756636T0000 |60 73|relationshipsucleotidase P
P08756636T0000 |30 49|yeast Rad51 protein alkaline phosphata
P08756636T0000 |13 22|mutations6 Compari
P08756642A0230 |0 11|AlterationsP00001606T0
P08756642A0230 |28 36|intervalth alkal
P08756642A0230 |91 99|leukemiamacologi
P08756642A0230 |64 78|myelodysplasiaotidase P00008
P08756712A0227 |64 71|subunitotidase
P08756712A0227 |75 78|RPA008
P08756712A0227 |45 55|amino acidhatases an
P08756712A0227 |9 16|studiesT0076 C
P08756712A0227 |134 141|domainsnemia. 
P08756712A0227 |80 83|RPA1T0
P08757265A0466 |0 7|NeuronsP000016
P08757265A0466 |56 63|effects 5-nucl
P08757265A0466 |25 27|mV w
P08757943A0876 |5 9|site1606
P08757943A0876 |29 36|elementh alkal
P08757943A0876 |61 86|thymidine kinase promotercleotidase P00008171T0000
P08757943A0876 |108 120|inducibility of neonatal
P08759870A1128 |68 89|footprinting analysisase P00008171T0000 Ph
P08759870A1128 |109 116|bindingof neon
P08759870A1128 |45 47|bpha
P08759870A1128 |4 10|extent01606T
P08759870A1128 |124 144|Fur repressor dimerserbilirubinemia. P00
P08759870A1128 |18 40|fbpA operator sequenceparison with alkaline 
P08760286A0696 |34 37|Vavali
P08760286A0696 |268 272|MAPKpare
P08760286A0696 |106 114|proteinsts of ne
P08760286A0696 |15 25|similarityComparison
P08760286A0696 |48 83|guanine nucleotide exchange factorsases and 5-nucleotidase P00008171T0
P08760286A0696 |191 198|memberstion of
P08760286A0696 |295 305|components have a si
P08760286A0696 |214 224|Rho familyta of K-de
P08760286A0696 |276 279|JNK co
P08760286A0696 |313 335|Vav signaling pathwaystly greater slope (1.2
P08760286A0696 |228 235|GTPasesed rats
P08760286A0696 |206 209|Ras2 t
P08760286A0696 |141 155|identificationP00008997A0472
P08760286A0696 |171 177|routes] is s
P08760776A1559 |0 10|CONCLUSIONP00001606T
P08760776A1559 |91 101|microgramsmacologic 
P08760776A1559 |160 169|treatment CSF [HCO
P08760776A1559 |73 83|micrograms00008171T0
P08760776A1559 |47 69|fluticasone propionatetases and 5-nucleotida
P08760776A1559 |140 152|theophylline P00008997A0
P08760776A1559 |24 33|treatmentn with al
P08760776A1559 |190 196|asthmaction 
P08760872A0696 |154 166|CHR elements2 When CSF [
P08760872A0696 |93 99|stagescologi
P08760872A0696 |107 117|cell cycles of neona
P08760872A0696 |61 71|repressioncleotidase
P08760872A0696 |39 42|E2F ph
P08760872A0696 |22 27|modelson w
P08760872A0696 |4 11|results01606T0
P08760889A0170 |4 14|cDNA clone01606T0076
P08760889A0170 |77 82|clone8171T
P08760889A0170 |40 45|probephosp
P08760889A0170 |92 96|H2A1acol
P08760889A0531 |0 10|ComparisonP00001606T
P08760889A0531 |256 266|divergenceced when c
P08760889A0531 |52 69|protein sequences and 5-nucleotida
P08760889A0531 |178 182|H2A1own 
P08760889A0531 |26 46|amino acid sequenceswith alkaline phosph
P08760889A0531 |208 212|H2A2the 
P08760889A0531 |149 154|total7A047
P08760889A0531 |192 203|amino acidsion of CSF 
P08760889A0531 |118 129|differencesal hyperbil
P08760889A0531 |87 91|H2AsPhar
P08760889A0531 |162 173|amino acidsSF [HCO3-] 
P08760889A0531 |280 287|speciestrols b
P08760889A0531 |233 238|genests ar
P08761169T0000 |34 39|childaline
P08761169T0000 |54 60|damagend 5-n
P08761169T0000 |17 28|dysfunctionmparison wi
P08761480A0331 |0 11|InteractionP00001606T0
P08761480A0331 |223 226|RD1epl
P08761480A0331 |397 411|fusion protein effective hyp
P08761480A0331 |159 169|N-terminusn CSF [HCO
P08761480A0331 |246 249|PDEger
P08761480A0331 |56 69|splice region 5-nucleotida
P08761480A0331 |88 100|PDE4A spliceharmacologic
P08761480A0331 |109 116|RPDE-39of neon
P08761480A0331 |73 79|RPDE-6000081
P08761480A0331 |439 452|splice regiondose for use 
P08761480A0331 |344 355|association3 vs. P0001
P08761480A0331 |359 365|RPDE-6A0733 
P08761480A0331 |325 334|v-Src-SH3slope (1.
P08761480A0331 |370 379|v-Src-SH3zepam thu
P08761480A0331 |196 205|v-Src-SH3of CSF PC
P08761480A0331 |230 233|rat ra
P08761480A0331 |207 215|met26RD1 the dat
P08761480A0331 |277 290|splice regioncontrols but 
P08761480A0331 |137 143|RPDE-6ia. P0
P08762021A0156 |53 64|performanceand 5-nucle
P08762021A0156 |135 142|rabbitsemia. P
P08762021A0156 |29 37|measuresh alkali
P08762172A0178 |204 209|boxesCO2 t
P08762172A0178 |74 84|proportion0008171T00
P08762172A0178 |44 53|variablesphatases 
P08762172A0178 |6 24|strain differences606T0076 Compariso
P08762172A0178 |163 174|transitionsF [HCO3-] i
P08762172A0178 |109 113|timeof n
P08762172A0178 |98 103|malesic as
P08762172A0178 |140 143|box P0
P08762172A0178 |153 159|number72 Whe
P08762472A0000 |117 124|studiestal hyp
P08762472A0000 |14 40|ligustrazine hydrochloride Comparison with alkaline 
P08762472A0000 |4 10|effect01606T
P08762472A0000 |42 45|LTHosp
P08762472A0000 |71 90|artery hypertension P00008171T0000 Pha
P08763207A0402 |102 105|DPVspe
P08763207A0402 |60 65|mediaucleo
P08763207A0402 |127 139|accumulationilirubinemia
P08763207A0402 |10 24|oxidation peak0076 Compariso
P08763207A0402 |74 75|V0
P08763207A0402 |143 154|clenbuterol0008997A047
P08763207A0402 |178 181|CPEown
P08763207A0402 |33 40|productkaline 
P08763311A0189 |0 13|PhenylephrineP00001606T007
P08763311A0189 |120 132|hypertension hyperbiliru
P08763311A0189 |88 104|vasoconstrictionharmacologic asp
P08763311A0189 |165 176|bradycardia[HCO3-] is 
P08763311A0189 |24 54|alpha-1 adrenoreceptor agonistn with alkaline phosphatases a
P08763925A0588 |32 37|geneslkali
P08763925A0588 |142 150|antisera00008997
P08763925A0588 |127 135|analysesilirubin
P08763925A0588 |60 66|c-gvpDucleot
P08763925A0588 |4 14|expression01606T0076
P08763925A0588 |54 58|unitnd 5
P08763925A0588 |172 180|proteins is show
P08763925A0588 |71 77|c-gvpE P0000
P08763925A0588 |115 125|immunoblotnatal hype
P08763925A0588 |101 113|Western blotaspects of n
P08763953A0805 |17 21|traAmpar
P08763953A0805 |4 8|unit0160
P08763953A0805 |80 84|traG1T00
P08763953A0805 |23 27|traFon w
P08763953A0805 |33 37|traBkali
P08763953A0805 |64 68|traCotid
P08763953A0805 |70 74|traDe P0
P08764015A0284 |0 2|A.P0
P08764136A0000 |275 281|76R-30o cont
P08764136A0000 |178 191|hybridizationown as a func
P08764136A0000 |24 29|genesn wit
P08764136A0000 |146 150|MECs8997
P08764136A0000 |139 144|cells. P00
P08764136A0000 |96 110|transformationogic aspects o
P08764136A0000 |6 12|effort606T00
P08764136A0000 |50 60|expressiones and 5-n
P08764136A0000 |207 221|MEC strain 76N the data of K
P08764136A0000 |68 78|mRNA levelase P00008
P08766049A0000 |220 230|VancomycinK-depleted
P08766049A0000 |183 185|mls 
P08766049A0000 |166 175|injectionHCO3-] is
P08766049A0000 |107 114|patients of ne
P08766049A0000 |210 212|mle 
P08766049A0000 |75 83|reaction008171T0
P08766049A0000 |189 191|mgnc
P08766049A0000 |41 60|corneal perforationhosphatases and 5-n
P08766049A0000 |193 201|Amikacinon of CS
P08766049A0000 |216 218|mg o
P08766049A0000 |96 103|chamberogic as
P08766049A0000 |0 11|CASE REPORTP00001606T0
P08766781A0322 |68 69|%a
P08766781A0322 |89 91|Hbar
P08766781A0322 |12 18|period76 Com
P08766781A0322 |75 76|%0
P08766781A0322 |37 45|increasene phosp
P08766781A0322 |110 114|g/dlf ne
P08766781A0322 |49 59|hematocritses and 5-
P08768374A0765 |4 8|P-wr0160
P08768374A0765 |13 32|P-rr cDNA sequences6 Comparison with a
P08768374A0765 |62 69|regionsleotida
P08768377A1387 |143 150|cloning0008997
P08768377A1387 |41 49|distancehosphata
P08768377A1387 |12 24|hcf109 locus76 Compariso
P08768377A1387 |78 96|phytochrome C gene171T0000 Pharmacol
P08768377A1387 |56 68|centimorgans 5-nucleotid
P08768377A1387 |112 128|characterizationneonatal hyperbi
P08769132A0000 |34 40|memberaline 
P08769132A0000 |429 435|cancere opti
P08769132A0000 |189 193|MutSncti
P08769132A0000 |486 501|chromosome 2p16 night. P000126
P08769132A0000 |360 370|base pairs0733 Flura
P08769132A0000 |63 69|familyeotida
P08769132A0000 |121 136|mismatch repairhyperbilirubine
P08769132A0000 |328 337|deletionspe (1.21 
P08769132A0000 |232 246|MSH-2 proteinsats are no lon
P08769132A0000 |10 28|MSH-2 gene product0076 Comparison wi
P08769132A0000 |437 442|HNPCCm dos
P08769132A0000 |73 81|proteins00008171
P08769132A0000 |288 293|sitest sti
P08769132A0000 |222 227|MSH-1deple
P08769132A0000 |444 466|tumor suppressor genesfor use in general pra
P08769132A0000 |308 323|base mismatchesficantly greate
P08769132A0000 |277 280|DNAcon
P08769132A0000 |341 351|insertions0.23 vs. P
P08769132A0000 |138 144|hMSH-2a. P00
P08769132A0000 |372 378|hMSH-2pam th
P08769409A0114 |85 98|mouse embryos0 Pharmacolog
P08769409A0114 |228 232|A.M.ed r
P08769409A0114 |208 214|regionthe da
P08769409A0114 |133 138|levelinemi
P08769409A0114 |224 226|A.pl
P08769409A0114 |178 183|uORFsown a
P08769409A0114 |162 176|reading framesSF [HCO3-] is 
P08769409A0114 |77 81|gene8171
P08769409A0114 |216 222|Zimmer of K-
P08769409A0114 |66 74|RAR betaidase P0
P08769409A0114 |48 58|expressionases and 5
P08769566A0000 |187 190|ZD2fun
P08769566A0000 |125 132|proteinrbiliru
P08769566A0000 |41 61|transcription factorhosphatases and 5-nu
P08769566A0000 |30 34|cDNA alk
P08769566A0000 |212 215|DNAdat
P08769566A0000 |179 182|ZD1wn 
P08769566A0000 |77 82|Zfhep8171T
P08769566A0000 |223 234|homeodomainepleted rat
P08769566A0000 |158 177|zinc finger domainsen CSF [HCO3-] is s
P08769566A0000 |84 107|zinc finger homeodomain00 Pharmacologic aspect
P08769568A0949 |4 13|structure01606T007
P08769568A0949 |72 82|PLA2 genesP00008171T
P08769568A0949 |47 55|ancestortases an
P08769568A0949 |23 28|geneson wi
P08770021T0000 |32 56|tyrosine kinase oncogenelkaline phosphatases and
P08770021T0000 |79 100|Ras signaling pathway71T0000 Pharmacologic
P08770021T0000 |58 65|Tpr-Met-nucleo
P08770021T0000 |10 26|PTHRP production0076 Comparison 
P08770021T0000 |67 71|roledase
P08770896A1121 |136 143|speciesmia. P0
P08770896A1121 |149 154|appMr7A047
P08770896A1121 |45 49|xz97hata
P08770896A1121 |159 162|17Kn C
P08770896A1121 |95 101|mediumlogic 
P08770896A1121 |167 170|14KCO3
P08770896A1121 |54 63|G11 cellsnd 5-nucl
P08770896A1121 |20 29|secretionrison wit
P08770896A1121 |35 41|IGF-IIline p
P08770920A1220 |137 142|IDX-1ia. P
P08770920A1220 |183 194|enhancements a functio
P08770920A1220 |88 93|IDX-1harma
P08770920A1220 |15 27|coexpressionComparison w
P08770920A1220 |101 109|proteinsaspects 
P08770920A1220 |198 213|transactivation CSF PCO2 the d
P08770920A1220 |237 260|TAAT-1 element reporterre no longer displaced 
P08770981A0328 |49 52|vWFses
P08770981A0328 |144 164|weight vWF multimers008997A0472 When CSF
P08770981A0328 |109 115|weightof neo
P08770981A0328 |26 47|von Willebrand factorwith alkaline phospha
P08770981A0328 |54 67|fragmentationnd 5-nucleoti
P08770981A0328 |172 183|circulation is shown a
P08770981A0328 |4 12|patients01606T00
P08771781A0103 |256 273|leaf cDNA libraryced when compared
P08771781A0103 |97 110|reading framegic aspects o
P08771781A0103 |52 58|region and 5
P08771781A0103 |196 201|ORFIIof CS
P08771781A0103 |122 136|Brassica napusyperbilirubine
P08771781A0103 |203 214|cDNA clonesPCO2 the da
P08771781A0103 |6 13|attempt606T007
P08771781A0103 |112 117|ORFIIneona
P08771781A0103 |71 78|oleosin P00008
P08771781A0103 |157 165|promoterhen CSF 
P08771781A0103 |138 140|L.a.
P08771781A1103 |4 22|ORFII gene product01606T0076 Compari
P08771781A1103 |89 93|dataarma
P08771781A1103 |121 134|PMSR activityhyperbilirubi
P08771781A1103 |42 53|chloroplastosphatases 
P08771781A1103 |109 117|presenceof neona
P08771781A1103 |142 153|chloroplast00008997A04
P08771787T0000 |0 16|CharacterizationP00001606T0076 C
P08771787T0000 |53 60|proteinand 5-n
P08771787T0000 |40 46|repeatphosph
P08771787T0000 |105 117|pathogenesiscts of neona
P08771787T0000 |20 23|LRPris
P08771787T0000 |66 79|tomato plantsidase P000081
P08771787T0000 |48 51|LRRase
P08774732A0271 |16 19|Sp1omp
P08774732A0271 |56 61|motif 5-nu
P08774732A0271 |63 85|gel retardation assayseotidase P00008171T000
P08774732A0271 |24 34|zif268/egrn with alk
P08775674A0000 |0 10|OBJECTIVESP00001606T
P08775674A0000 |61 76|characteristicscleotidase P000
P08775674A0000 |27 32|studyith a
P08775674A0000 |107 115|patientss of neo
P08775674A0000 |121 138|hydatidiform molehyperbilirubinemi
P08775674A0000 |92 99|outcomeacologi
P08775674A0000 |78 87|treatment171T0000 
P08775674A0000 |16 19|aimomp
P08776735A0000 |205 214|rLHR-t628O2 the da
P08776735A0000 |122 127|tailsyperb
P08776735A0000 |87 91|rLHRPhar
P08776735A0000 |190 199|rLHR-t631ction of 
P08776735A0000 |295 309|responsiveness have a signif
P08776735A0000 |25 31|kidney with 
P08776735A0000 |179 188|rLHR-t653wn as a f
P08776735A0000 |62 85|type rat LH/CG receptorleotidase P00008171T000
P08776735A0000 |36 41|cellsine p
P08776735A0000 |96 105|receptorsogic aspe
P08776735A0000 |258 264|regiond when
P08776735A0000 |272 282|regulationd to contr
P08776735A0000 |141 149|residuesP0000899
P08776735A0000 |239 249|importance no longer
P08776748T0000 |37 50|schizophreniane phosphatas
P08776748T0000 |26 32|markerwith a
P08776748T0000 |8 23|P300 amplitudes6T0076 Comparis
P08776792A0626 |0 5|SleepP0000
P08776792A0626 |47 51|daystase
P08776792A0626 |58 63|hours-nucl
P08776793A0811 |35 40|malesline 
P08776793A0811 |4 12|patients01606T00
P08776901A0000 |0 19|Chloroplast mutatorP00001606T0076 Comp
P08776901A0000 |21 24|chmiso
P08776901A0000 |159 166|fashionn CSF [
P08776901A0000 |29 40|Arabidopsish alkaline 
P08776901A0000 |101 112|variegationaspects of 
P08776901A0000 |64 72|mutationotidase 
P08776901A0000 |116 122|leavesatal h
P08777374A1471 |101 110|exposuresaspects o
P08777374A1471 |7 21|concentrations06T0076 Compar
P08777374A1471 |63 77|concentrationseotidase P0000
P08777374A1471 |157 171|concentrationshen CSF [HCO3-
P08778265A0422 |85 89|test0 Ph
P08778265A0422 |91 113|Street completion testmacologic aspects of n
P08778265A0422 |115 126|Stroop testnatal hyper
P08778265A0422 |21 33|test batteryison with al
P08778265A0422 |62 76|Wisconsin cardleotidase P000
P08778265A0422 |175 191|recognition test shown as a func
P08778265A0422 |156 160|testWhen
P08778265A0422 |139 145|memory. P000
P08778700A0476 |16 20|caseompa
P08778700A0476 |63 74|involvementeotidase P0
P08778700A0476 |91 95|ARVDmaco
P08778700A0476 |36 42|rarityine ph
P08780339A0142 |35 53|Latin-square studyline phosphatases 
P08780339A0142 |31 32|xa
P08780339A0142 |221 224|RS2-de
P08780339A0142 |154 161|glucose2 When 
P08780339A0142 |114 121|femalesonatal 
P08780339A0142 |59 70|correctionsnucleotidas
P08780339A0142 |271 274|RS3ed 
P08780339A0142 |183 185|RSs 
P08780339A0142 |209 219|cornstarchhe data of
P08780339A0142 |79 96|carryover effects71T0000 Pharmacol
P08780339A0142 |259 269|cornstarch when comp
P08780339A0142 |16 28|single-blindomparison wi
P08780339A0142 |175 181|starch shown
P08780339A0142 |131 142|supplementsubinemia. P
P08780339A0142 |101 106|malesaspec
P08781119A0723 |16 22|regionompari
P08781119A0723 |131 149|rat Met-ase-1 geneubinemia. P0000899
P08781119A0723 |30 50|mouse Met-ase-1 gene alkaline phosphatas
P08781119A0723 |87 95|identityPharmaco
P08781119A0723 |76 83|regions08171T0
P08781119A0723 |117 123|regiontal hy
P08781144A1520 |54 59|indexnd 5-
P08781144A1520 |74 88|tumour hypoxia0008171T0000 P
P08781144A1520 |92 95|NPCaco
P08781144A1520 |9 19|FMISO TMRRT0076 Comp
P08781144A1520 |5 8|18F160
P08783180A0000 |9 16|methodsT0076 C
P08783180A0000 |106 128|Carollia perspicillatats of neonatal hyperbi
P08783180A0000 |166 173|settingHCO3-] 
P08783180A0000 |95 104|fruit batlogic asp
P08783666A0957 |17 21|timempar
P08783666A0957 |25 36|engraftment with alkal
P08783666A0957 |3 11|addition001606T0
P08783666A0957 |93 100|cohortscologic
P08783666A0957 |70 84|amifostine arme P00008171T00
P08784787A0383 |33 37|PAR2kali
P08784787A0383 |14 31|thrombin receptor Comparison with 
P08784787A0383 |135 152|receptor cleavageemia. P00008997A0
P08784787A0383 |104 119|ligand sequenceects of neonata
P08784787A0383 |62 73|hexapeptideleotidase P
P08787110A0981 |34 47|investigationaline phospha
P08787110A0981 |55 65|managementd 5-nucleo
P08787110A0981 |99 106|diseasec aspec
P08787110A0981 |179 198|function laboratorywn as a function of
P08787110A0981 |69 77|patientsse P0000
P08787110A0981 |141 155|investigationsP00008997A0472
P08787110A0981 |17 21|CPETmpar
P08789441A0339 |171 172|t]
P08789441A0339 |245 251|regionnger d
P08789441A0339 |180 193|translocationn as a functi
P08789441A0339 |120 132|sex reversal hyperbiliru
P08789441A0339 |213 227|cosmid markersata of K-deple
P08789441A0339 |111 115|CMPD neo
P08789441A0339 |27 40|hybridizationith alkaline 
P08789441A0339 |86 93|patient Pharma
P08789441A0339 |6 18|fluorescence606T0076 Com
P08789441A0339 |70 80|breakpointe P0000817
P08790288A0068 |51 58|spinachs and 5
P08790288A0068 |91 109|Hordeum vulgare cvmacologic aspects 
P08790288A0068 |60 77|Spinacia oleraceaucleotidase P0000
P08790288A0068 |40 45|cDNAsphosp
P08790288A0068 |27 36|isolationith alkal
P08790288A0068 |83 89|barley000 Ph
P08790291A1022 |4 8|data0160
P08790291A1022 |75 95|DNA damage tolerance008171T0000 Pharmaco
P08790291A1022 |27 31|workith 
P08790291A1022 |46 50|thi1atas
P08790291A1022 |99 110|plant cellsc aspects o
P08790387A0299 |7 21|rat rnu allele06T0076 Compar
P08790387A0299 |61 65|exoncleo
P08790387A0299 |75 83|whn gene008171T0
P08790387A0299 |40 57|nonsense mutationphosphatases and 
P08792217A1407 |137 147|germ cellsia. P00008
P08792217A1407 |198 206|increase CSF PCO
P08792217A1407 |88 94|resultharmac
P08792217A1407 |240 257|TIMP-2 mRNA levelno longer displac
P08792217A1407 |48 65|TIMP-2 mRNA levelases and 5-nucleo
P08792217A1407 |172 177|cells is s
P08792217A1407 |8 16|increase6T0076 C
P08792217A1407 |222 226|celldepl
P08792217A1407 |101 114|up-regulationaspects of ne
P08792217A1407 |118 128|germ cellsal hyperbi
P08793029A0246 |0 7|ControlP000016
P08793029A0246 |15 19|ratsComp
P08793029A0246 |62 68|groupsleotid
P08793693A0237 |0 6|DESIGNP00001
P08793693A0237 |26 31|studywith 
P08794254A2957 |83 93|graft loss000 Pharma
P08794254A2957 |15 27|PTA categoryComparison w
P08794254A2957 |41 48|therapyhosphat
P08794254A2957 |75 79|risk0081
P08794254A2957 |7 10|SPK06T
P08794326A0405 |85 88|end0 P
P08794326A0405 |123 131|pol geneperbilir
P08794326A0405 |63 66|TREeot
P08794326A0405 |135 140|SFV-1emia.
P08794326A0405 |96 104|gag geneogic asp
P08794326A0405 |43 50|elementsphatas
P08794326A0405 |68 70|GPas
P08794339A1162 |64 68|CREBotid
P08794339A1162 |189 193|CREBncti
P08794339A1162 |24 27|IE2n w
P08794339A1162 |126 130|p300bili
P08794339A1162 |176 180|turnshow
P08794339A1162 |94 97|IE2olo
P08794339A1162 |211 227|adaptor proteins data of K-deple
P08794339A1162 |72 81|deltaCREBP00008171
P08794339A1162 |13 20|binding6 Compa
P08794339A1162 |152 159|protein472 Whe
P08794339A1162 |111 120|complexes neonatal
P08794339A1162 |161 164|CBPCSF
P08794339A1162 |232 245|CREB functionats are no lo
P08794348A1067 |76 81|trans08171
P08794348A1067 |60 63|NIaucl
P08794348A1067 |13 34|complementation assay6 Comparison with alk
P08794348A1067 |150 162|NIa proteinsA0472 When C
P08794348A1067 |125 132|genomesrbiliru
P08794363A0259 |84 103|jun-fos gene family00 Pharmacologic as
P08794363A0259 |7 12|basis06T00
P08794363A0259 |124 130|originerbili
P08794363A0259 |46 49|meqata
P08794363A0259 |20 24|bZIPriso
P08794363A0259 |36 44|homologyine phos
P08794363A0259 |70 76|membere P000
P08794547A0648 |4 8|rCBF0160
P08794547A0648 |13 23|vasomotion6 Comparis
P08794547A0648 |41 64|laser-doppler fluxmetryhosphatases and 5-nucle
P08794547A1403 |85 88|SAH0 P
P08794547A1403 |15 22|vesselsCompari
P08794547A1403 |56 63|vessels 5-nucl
P08794601A0000 |116 117|%a
P08794601A0000 |11 22|combination076 Compari
P08794601A0000 |58 76|bismuth subcitrate-nucleotidase P000
P08794601A0000 |125 151|H. pylori eradication raterbilirubinemia. P00008997A
P08794601A0000 |26 36|nizatidinewith alkal
P08794601A0000 |157 158|%h
P08794601A0000 |92 110|ulcer healing rateacologic aspects o
P08794601A0000 |38 52|clarithromycine phosphatases
P08794869A0274 |17 25|evidencemparison
P08794869A0274 |8 13|lines6T007
P08794869A0274 |79 84|alpha71T00
P08794869A0274 |71 75|role P00
P08794869A0274 |54 62|PKC-zetand 5-nuc
P08794869A0274 |87 111|integrin gene expressionPharmacologic aspects of
P08795304T0000 |0 21|Plasma thrombomodulinP00001606T0076 Compar
P08795304T0000 |67 84|diabetes mellitusdase P00008171T00
P08795304T0000 |25 31|marker with 
P08795304T0000 |50 63|complicationses and 5-nucl
P08797362T0037 |0 6|UpdateP00001
P08797362T0037 |74 78|USSR0008
P08797362T0037 |53 59|statesand 5-
P08797362T0037 |8 18|diphtheria6T0076 Com
P08797362T0037 |80 87|January1T0000 
P08798420A0207 |171 179|CAAT box] is sho
P08798420A0207 |144 163|PRDII/kappaB domain008997A0472 When CS
P08798420A0207 |214 218|pp60ta o
P08798420A0207 |28 43|promoter regionth alkaline pho
P08798420A0207 |4 20|characterization01606T0076 Compa
P08798420A0207 |200 210|activationSF PCO2 th
P08798420A0207 |114 131|AP-1 binding siteonatal hyperbilir
P08798420A0207 |136 139|TREmia
P08798420A0207 |222 225|srcdep
P08798420A0207 |85 93|elements0 Pharma
P08798443A0660 |0 6|SerineP00001
P08798443A0660 |80 86|serine1T0000
P08798443A0660 |218 224|mim-1Af K-de
P08798443A0660 |179 187|promoterwn as a 
P08798443A0660 |146 149|Myb899
P08798443A0660 |94 101|alanineologic 
P08798443A0660 |240 247|elementno long
P08798443A0660 |135 142|abilityemia. P
P08798443A0660 |48 58|cell linesases and 5
P08798443A0660 |262 280|herpes tk promoteren compared to con
P08798443A0660 |204 210|copiesCO2 th
P08798443A0660 |64 76|substitutionotidase P000
P08798443A0660 |103 108|S528Apects
P08798443A1218 |50 55|c-Mybes an
P08798443A1218 |123 138|phosphorylationperbilirubinemi
P08798443A1218 |183 221|transcription transactivating activitys a function of CSF PCO2 the data of K
P08798443A1218 |225 230|c-Mybleted
P08798443A1218 |269 277|proteinsared to 
P08798443A1218 |20 46|multimerization activitiesrison with alkaline phosph
P08798443A1218 |142 148|serine000089
P08798443A1218 |245 257|interactionsnger displac
P08798443A1218 |87 105|S528A substitutionPharmacologic aspe
P08798443A1218 |4 15|DNA binding01606T0076 
P08798443A1218 |169 175|effect3-] is
P08798512A1197 |4 10|amount01606T
P08798512A1197 |66 76|u-PAR geneidase P000
P08798512A1197 |43 52|GEO cellssphatases
P08798512A1197 |20 27|factorsrison w
P08798610A0843 |0 4|PIP2P000
P08798610A0843 |88 95|guanineharmaco
P08798610A0843 |269 284|Dbl oncoproteinared to control
P08798610A0843 |160 164|form CSF
P08798610A0843 |124 131|Cdc42Hserbilir
P08798610A0843 |29 65|phosphatidylcholine carrier vesiclesh alkaline phosphatases and 5-nucleo
P08798610A0843 |223 230|Cdc42Hsepleted
P08798610A0843 |116 120|formatal
P08798610A0843 |184 191|protein a func
P08798635A0870 |102 108|effectspects
P08798635A0870 |125 139|myristoylationrbilirubinemia
P08798635A0870 |46 49|GTPata
P08798635A0870 |93 97|ARF6colo
P08798635A0870 |77 81|ARF38171
P08798635A0870 |9 19|spleen GAPT0076 Comp
P08798635A0870 |71 75|ARF1 P00
P08798635A0870 |83 87|ARF5000 
P08798635A0870 |32 42|hydrolysislkaline ph
P08798641A0400 |0 4|BiolP000
P08798643T0000 |32 38|domainlkalin
P08798643T0000 |134 141|T cellsnemia. 
P08798643T0000 |57 76|transforming region5-nucleotidase P000
P08798643T0000 |124 130|ZAP-70erbili
P08798643T0000 |80 83|Cbl1T0
P08798648A1816 |0 7|Cys-757P000016
P08798648A1816 |76 91|enzyme activity08171T0000 Phar
P08798648A1816 |44 50|domainphatas
P08798648A1816 |20 25|Fe4S4rison
P08798700A0134 |204 223|activation sequenceCO2 the data of K-d
P08798700A0134 |161 165|partCSF 
P08798700A0134 |148 153|Rox1p97A04
P08798700A0134 |73 79|oxygen000081
P08798700A0134 |225 228|UASlet
P08798700A0134 |61 69|responsecleotida
P08798700A0134 |4 17|transcription01606T0076 Co
P08798700A0134 |83 98|heme deficiency000 Pharmacolog
P08798700A0134 |126 136|repressionbilirubine
P08798700A0134 |169 179|activation3-] is sho
P08798700A0134 |116 122|reliefatal h
P08798700A0134 |103 107|partpect
P08798762A1279 |16 23|resultsomparis
P08798762A1279 |99 102|PKCc a
P08798762A1279 |58 66|activity-nucleot
P08798762A1279 |70 82|Cut proteinse P00008171T
P08798782A0976 |0 3|LckP00
P08798782A0976 |56 67|SH3 domains 5-nucleoti
P08798782A0976 |48 51|SH2ase
P08798893A0611 |48 59|lactalbuminases and 5-
P08798893A0611 |150 157|respectA0472 W
P08798893A0611 |29 37|presenceh alkali
P08798893A0611 |107 116|viabilitys of neon
P08798893A0611 |13 21|freezing6 Compar
P08798893A0611 |79 90|maintenance71T0000 Pha
P08798893A0611 |167 172|cellsCO3-]
P08798893A0611 |128 146|CCCD heterogeneitylirubinemia. P0000
P08801403T0001 |32 49|presentation formlkaline phosphata
P08801403T0001 |62 69|myelomaleotida
P08801403T0001 |20 28|effusionrison wi
P08803710A0701 |35 36|%l
P08803710A0701 |56 57|% 
P08803710A0701 |90 93|IVArma
P08803710A0701 |65 66|%t
P08803710A0701 |42 43|%o
P08803710A0701 |10 19|survivals0076 Comp
P08803710A0701 |71 77|stages P0000
P08803710A0701 |98 101|IVBic 
P08803710A0701 |49 50|%s
P08803845A0665 |201 209|excisionF PCO2 t
P08803845A0665 |135 144|insertionemia. P00
P08803845A0665 |79 84|cells71T00
P08803845A0665 |56 64|clusters 5-nucle
P08803845A0665 |148 154|lesion97A047
P08803845A0665 |173 180|attemptis show
P08803845A0665 |127 131|lineilir
P08803845A0665 |4 12|presence01606T00
P08804012A0662 |84 92|pastimes00 Pharm
P08804012A0662 |30 33|SIP al
P08804012A0662 |94 109|home managementologic aspects 
P08804012A0662 |63 67|workeoti
P08804012A0662 |12 22|categories76 Compari
P08804012A0662 |115 120|sleepnatal
P08804012A0662 |125 129|restrbil
P08804012A0662 |69 79|recreationse P000081
P08804389A0893 |0 22|Northern blot analysisP00001606T0076 Compari
P08804389A0893 |210 218|decreasee data o
P08804389A0893 |150 159|Ltp4 mRNAA0472 Whe
P08804389A0893 |120 128|increase hyperbi
P08804389A0893 |188 190|pvun
P08804389A0893 |97 108|translucensgic aspects
P08804389A0893 |192 200|japonicaion of C
P08804389A0893 |48 53|probeases 
P08804389A0893 |140 146|levels P0000
P08804389A0893 |70 95|Xanthomonas campestris pve P00008171T0000 Pharmaco
P08805338A1061 |137 141|Ogg1ia. 
P08805338A1061 |27 36|OGG1 geneith alkal
P08805338A1061 |9 19|disruptionT0076 Comp
P08805338A1061 |176 178|OGsh
P08805338A1061 |40 45|yeastphosp
P08805338A1061 |112 116|Ogg2neon
P08805338A1061 |179 181|G.wn
P08805338A1061 |64 92|OG glycosylase/lyase proteinotidase P00008171T0000 Pharm
P08805824A1155 |17 20|usempa
P08805824A1155 |183 193|scatterings a functi
P08805824A1155 |47 58|combinationtases and 5
P08805824A1155 |219 235|lens aberrations K-depleted rats
P08805824A1155 |24 33|zero-lossn with al
P08805824A1155 |198 208|microscope CSF PCO2 
P08805824A1155 |64 93|exit wavefront reconstructionotidase P00008171T0000 Pharma
P08805824A1155 |248 257|techniquer displac
P08805824A1155 |141 148|effectsP000089
P08806491A0542 |0 11|TranscriptsP00001606T0
P08806491A0542 |66 77|TAAG motifsidase P0000
P08806491A0542 |127 134|hr p.i.ilirubi
P08806491A0542 |21 28|ODV-E18ison wi
P08806491A0542 |83 94|transcripts000 Pharmac
P08806491A0542 |33 41|ODV-EC27kaline p
P08806693A0584 |169 197|luciferase expression vector3-] is shown as a function o
P08806693A0584 |227 244|mouse fibroblaststed rats are no l
P08806693A0584 |123 132|deletionsperbiliru
P08806693A0584 |106 113|proteints of n
P08806693A0584 |28 37|sequencesth alkali
P08806693A0584 |45 60|GATA-1 promoterhatases and 5-n
P08806693A0584 |77 87|activation8171T0000 
P08806693A0584 |95 99|ME26logi
P08806693A0584 |215 223|activitya of K-d
P08806693A0584 |140 148|promoter P000089
P08806693A0584 |267 273|GATA-1mpared
P08806693A0584 |3 8|order00160
P08806817A0244 |0 17|Sequence analysisP00001606T0076 Co
P08806817A0244 |42 47|cloneospha
P08806817A0244 |66 84|DNA binding domainidase P00008171T00
P08806817A0244 |93 108|orphan receptorcologic aspects
P08806817A0244 |141 153|TR2 receptorP00008997A04
P08806817A0716 |64 68|geneotid
P08806817A0716 |8 25|DNA hybridization6T0076 Comparison
P08806817A0716 |40 46|SpSHR2phosph
P08806817A0716 |76 96|S. purpuratus genome08171T0000 Pharmacol
P08807245A0843 |64 74|undercallsotidase P0
P08807245A0843 |7 27|retrospective review06T0076 Comparison w
P08807245A0843 |55 56|%d
P08807288T0000 |0 9|IsolationP00001606
P08807288T0000 |64 79|ADH2 expressionotidase P000081
P08807288T0000 |14 28|identification Comparison wi
P08807288T0000 |32 37|geneslkali
P08807408A0524 |0 7|METHODSP000016
P08807408A0524 |75 86|tachycardia008171T0000
P08807408A0524 |125 140|AV modificationrbilirubinemia.
P08807408A0524 |56 58|AV 5
P08807408A0524 |12 19|RESULTS76 Comp
P08807408A0524 |155 181|radiofrequency application When CSF [HCO3-] is shown
P08807408A0524 |116 123|pathwayatal hy
P08807408A0524 |35 40|womanline 
P08808120A0774 |0 8|PatientsP0000160
P08808120A0774 |266 277|probabilityompared to 
P08808120A0774 |245 253|patientsnger dis
P08808120A0774 |148 154|values97A047
P08808120A0774 |361 373|micrograms/L733 Flurazep
P08808120A0774 |109 121|micrograms/Lof neonatal 
P08808120A0774 |288 305|aluminum overloadt still have a si
P08808120A0774 |18 29|probabilityparison wit
P08808120A0774 |158 168|serum ironen CSF [HC
P08808120A0774 |82 94|micrograms/L0000 Pharmac
P08808120A0774 |334 346|micrograms/L21 +/- 0.23 
P08808120A0774 |59 76|serum iron levelsnucleotidase P000
P08808120A0774 |203 224|serum ferritin levelsPCO2 the data of K-de
P08808120A0774 |351 354|DAI000
P08808120A0774 |40 57|aluminum overloadphosphatases and 
P08808120A0774 |307 328|serum aluminum levelsificantly greater slo
P08808120A0774 |99 102|DAIc a
P08808120A0774 |170 197|iron transferrin saturation-] is shown as a function o
P08808275A1193 |140 157|yeast counterpart P00008997A0472 W
P08808275A1193 |121 130|phenotypehyperbili
P08808275A1193 |57 66|evolution5-nucleot
P08808275A1193 |13 30|RAD23 equivalents6 Comparison with
P08808275A1193 |82 87|genes0000 
P08808707A0631 |0 9|Ha-RasV12P00001606
P08808707A0631 |124 128|SAPKerbi
P08808707A0631 |148 154|kinase97A047
P08808707A0631 |133 136|Junine
P08808707A0631 |209 224|gene expressionhe data of K-de
P08808707A0631 |161 169|cascadesCSF [HCO
P08808707A0631 |108 122|protein kinase of neonatal h
P08808707A0631 |78 81|ERK171
P08808707A0631 |156 159|JNKWhe
P08808707A0631 |24 32|proteinsn with a
P08808707A0631 |70 76|kinasee P000
P08808756A0587 |0 17|Sequence analysisP00001606T0076 Co
P08808756A0587 |78 81|RNA171
P08808756A0587 |224 236|accumulationpleted rats 
P08808756A0587 |162 170|productsSF [HCO3
P08808756A0587 |131 139|presenceubinemia
P08808756A0587 |108 113|cells of n
P08808756A0587 |203 208|basesPCO2 
P08808756A0587 |52 56|cDNA and
P08808756A0587 |250 254|mRNAdisp
P08808924A0326 |205 214|proximityO2 the da
P08808924A0326 |52 57|spans and 
P08808924A0326 |76 90|amino terminus08171T0000 Pha
P08808924A0326 |182 186|L-61as a
P08808924A0326 |249 256|segment displa
P08808924A0326 |142 150|presence00008997
P08808924A0326 |112 120|residuesneonatal
P08808924A0326 |4 22|hydropathy profile01606T0076 Compari
P08808924A0326 |260 264|ProWwhen
P08808924A0326 |190 194|F-97ctio
P08808927A0417 |25 33|fragment with al
P08808927A0417 |62 75|M. bovis PG45leotidase P00
P08808927A0417 |47 56|vspA genetases and
P08808927A0417 |9 16|HindIIIT0076 C
P08808939A0000 |0 28|Carbon catabolite repressionP00001606T0076 Comparison wi
P08808939A0000 |163 188|phosphotransferase systemF [HCO3-] is shown as a f
P08808939A0000 |126 129|HPrbil
P08808939A0000 |133 155|phosphocarrier proteininemia. P00008997A0472
P08808939A0000 |87 118|catabolite control protein CcpAPharmacologic aspects of neonat
P08808939A0000 |36 46|gnt operonine phosph
P08808939A0000 |50 67|Bacillus subtilises and 5-nucleoti
P08809680T0000 |0 9|MelatoninP00001606
P08809680T0000 |14 25|seasonality Comparison
P08809680T0000 |39 42|gap ph
P08810040A0955 |102 113|replacementspects of n
P08810040A0955 |28 32|lossth a
P08810040A0955 |13 19|screen6 Comp
P08810040A0955 |124 133|frequencyerbilirub
P08810040A0955 |62 81|target locus markerleotidase P00008171
P08810040A0955 |138 139|%a
P08810278A0682 |136 144|tyrosinemia. P00
P08810278A0682 |60 67|BCR/ABLucleoti
P08810278A0682 |255 267|ALL patientsaced when co
P08810278A0682 |115 118|CASnat
P08810278A0682 |293 301|controlsll have 
P08810278A0682 |80 95|CRKL-SH2 domain1T0000 Pharmaco
P08810278A0682 |188 217|BCR/ABL expressing cell linesunction of CSF PCO2 the data 
P08810278A0682 |247 250|CMLer 
P08810278A0682 |180 184|CRKLn as
P08810278A0682 |280 287|samplestrols b
P08810278A0682 |104 107|CASect
P08810278A0682 |225 232|samplesleted r
P08810278A0682 |42 49|proteinosphata
P08810278A0682 |110 114|p130f ne
P08810278A0682 |99 103|p130c as
P08810323A0735 |69 76|regionsse P000
P08810323A0735 |15 35|polyglutamine motifsComparison with alka
P08812012T0000 |4 11|effects01606T0
P08812012T0000 |26 36|variationswith alkal
P08812012T0000 |52 66|Stroop effects and 5-nucleot
P08812020A0597 |71 77|boards P0000
P08812020A0597 |11 21|experiment076 Compar
P08812020A0597 |167 173|piecesCO3-] 
P08812020A0597 |61 67|numbercleoti
P08812020A0597 |25 36|Chessmaster with alkal
P08812020A0597 |124 132|accuracyerbiliru
P08812020A0597 |114 115|%o
P08812106T0000 |0 9|PCNA mRNAP00001606
P08812106T0000 |42 54|crescent RNAosphatases a
P08812106T0000 |18 21|UTRpar
P08812106T0000 |93 100|embryoscologic
P08812106T0000 |84 88|eggs00 P
P08812490A0000 |113 132|kidney cDNA libraryeonatal hyperbiliru
P08812490A0000 |60 68|homologyucleotid
P08812490A0000 |30 34|hKID alk
P08812490A0000 |76 86|aquaporins08171T0000
P08812490A0000 |9 19|cDNA cloneT0076 Comp
P08812490A0000 |36 53|gene symbol AQP2Line phosphatases 
P08812490A0542 |0 26|PCR/Southern blot analysisP00001606T0076 Comparison 
P08812490A0542 |133 137|mRNAinem
P08812490A0542 |192 196|exonion 
P08812490A0542 |105 115|expressioncts of neo
P08812490A0542 |75 79|hKID0081
P08812490A0542 |36 47|kidney cDNAine phospha
P08812490A0542 |199 208|deletionsCSF PCO2 
P08812490A0542 |148 159|transcripts97A0472 Whe
P08812490A0542 |54 61|primersnd 5-nu
P08812490A0542 |173 177|exonis s
P08812490A0542 |87 95|sequencePharmaco
P08812490A1509 |81 85|lociT000
P08812490A1509 |120 143|MIP family gene cluster hyperbilirubinemia. P0
P08812490A1509 |89 93|hKIDarma
P08812490A1509 |104 109|AQP-2ects 
P08812490A1509 |44 53|structurephatases 
P08812490A1509 |95 98|MIPlog
P08812490A1509 |147 169|chromosome locus 12q13997A0472 When CSF [HCO
P08812490A1509 |9 26|sequence homologyT0076 Comparison 
P08813766A0605 |200 211|yeast Mig1pSF PCO2 the
P08813766A0605 |186 194|homology functio
P08813766A0605 |118 136|consensus sequenceal hyperbilirubine
P08813766A0605 |216 221|Cre-A of K
P08813766A0605 |26 36|transcriptwith alkal
P08813766A0605 |61 68|proteincleotid
P08813766A0605 |240 250|Emericellano longer 
P08813766A0605 |227 238|Aspergillusted rats ar
P08813766A0605 |44 46|kbph
P08813766A0605 |105 110|matchcts o
P08813766A0605 |76 84|residues08171T00
P08813766A0605 |10 13|ORF007
P08813766A0605 |142 165|C2H2 zinc finger domain00008997A0472 When CSF 
P08813900A1088 |153 165|P deficiency72 When CSF 
P08813900A1088 |7 14|phytase06T0076
P08813900A1088 |213 219|tibiasata of
P08813900A1088 |196 205|structureof CSF PC
P08813900A1088 |111 121|bone cells neonatal 
P08813900A1088 |63 77|mineralizationeotidase P0000
P08813900A1088 |142 149|effects0000899
P08813900A1088 |97 106|cartilagegic aspec
P08813900A1088 |82 93|arrangement0000 Pharma
P08813900A1088 |35 46|orderlinessline phosph
P08813900A1088 |19 21|nPar
P08813900A1088 |50 61|developmentes and 5-nu
P08814651A0000 |138 144|tremora. P00
P08814651A0000 |124 136|rating scaleerbilirubine
P08814651A0000 |167 176|paradigmsCO3-] is 
P08814651A0000 |67 91|ethanol withdrawal signsdase P00008171T0000 Phar
P08814651A0000 |42 50|presenceosphatas
P08814651A0000 |27 34|factorsith alk
P08814651A0000 |4 14|importance01606T0076
P08814651A0000 |99 102|ratc a
P08814651A0000 |55 63|severityd 5-nucl
P08816052A0238 |171 177|K-SNAP] is s
P08816052A0238 |80 88|validity1T0000 P
P08816052A0238 |19 26|brevityarison 
P08816052A0238 |116 169|Kaufman Short Neuropsychological Assessment Procedureatal hyperbilirubinemia. P00008997A0472 When CSF [HCO
P08816052A0238 |101 107|K-FASTaspect
P08816052A0238 |0 4|DataP000
P08816052A0238 |49 53|formses 
P08816052A0238 |34 42|WISC-IIIaline ph
P08816438A0316 |153 168|DNA replication72 When CSF [HC
P08816438A0316 |13 21|analysis6 Compar
P08816438A0316 |132 138|defectbinemi
P08816438A0316 |73 81|plasmids00008171
P08816438A0316 |47 63|cdc28-1N strainstases and 5-nucl
P08816438A0316 |96 115|replication originsogic aspects of neo
P08816438A0316 |25 43|plasmid loss rates with alkaline pho
P08816438A0316 |190 212|plasmid loss phenotypection of CSF PCO2 the 
P08816443A1674 |186 199|kinase domain function of 
P08816443A1674 |24 33|ROK alphan with al
P08816443A1674 |243 256|stress fiberslonger displa
P08816443A1674 |105 106|Nc
P08816443A1674 |60 74|reorganizationucleotidase P0
P08816443A1674 |267 285|adhesion complexesmpared to controls
P08816443A1674 |230 239|formation rats are
P08816443A1674 |111 120|C termini neonatal
P08816443A1674 |206 214|activity2 the da
P08816443A1674 |82 94|cytoskeleton0000 Pharmac
P08816443A1674 |153 163|regulators72 When CS
P08816452A0936 |117 127|regulationtal hyperb
P08816452A0936 |90 97|proteinrmacolo
P08816452A0936 |6 14|findings606T0076
P08816452A0936 |189 195|mannernction
P08816452A0936 |59 62|p54nuc
P08816452A0936 |143 151|splicing0008997A
P08816452A0936 |36 55|tissue distributionine phosphatases an
P08816452A0936 |157 163|tissuehen CS
P08816453A0000 |35 41|levelsline p
P08816453A0000 |72 80|activityP0000817
P08816453A0000 |29 33|cAMPh al
P08816453A0000 |88 100|Raf-1 kinaseharmacologic
P08816453A0000 |4 13|elevation01606T007
P08816453A0000 |24 27|AMPn w
P08816453A0000 |49 53|cellses 
P08816459A0090 |117 141|thyroid hormone receptortal hyperbilirubinemia. 
P08816459A0090 |31 48|repression domainalkaline phosphat
P08816459A0090 |90 95|N-CoRrmaco
P08816459A0090 |143 145|TR00
P08816459A0090 |160 173|acid receptor CSF [HCO3-] 
P08816459A0090 |56 78|orphan receptor RevErb 5-nucleotidase P00008
P08816459A0090 |3 21|interaction screen001606T0076 Compar
P08816459A0090 |175 178|RAR sh
P08816459A0090 |101 112|corepressoraspects of 
P08816460A1769 |143 148|Erk-200089
P08816460A1769 |121 129|presencehyperbil
P08816460A1769 |90 108|Ras transformationrmacologic aspects
P08816460A1769 |42 63|Jun kinase activationosphatases and 5-nucl
P08816460A1769 |28 38|inhibitionth alkalin
P08816460A1769 |6 13|results606T007
P08816461A0892 |4 12|analysis01606T00
P08816461A0892 |122 142|nonsense suppressionyperbilirubinemia. P
P08816461A0892 |104 117|mRNA turnoverects of neona
P08816461A0892 |77 87|activities8171T0000 
P08816461A0892 |27 32|Upf1pith a
P08816461A0892 |54 61|proteinnd 5-nu
P08816472T0000 |51 55|Byr2s an
P08816472T0000 |38 47|regulatore phospha
P08816472T0000 |70 86|response pathwaye P00008171T0000
P08816472T0000 |18 22|Ste4pari
P08816472T0000 |0 14|IdentificationP00001606T0076
P08816482A0234 |50 56|Stat5bes and
P08816482A0234 |82 87|genes0000 
P08816482A0234 |39 45|Stat5a phosp
P08816482A0234 |20 28|variantsrison wi
P08816482A0234 |32 37|Stat5lkali
P08816483A0869 |0 9|MutationsP00001606
P08816483A0869 |31 35|SWI5alka
P08816483A0869 |25 29|SIC1 wit
P08816483A0869 |41 45|RIC3hosp
P08816483A0869 |19 23|lociaris
P08816498A0000 |68 95|signal transduction cascadease P00008171T0000 Pharmaco
P08816498A0000 |58 62|Rats-nuc
P08816498A0000 |122 129|stimuliyperbil
P08816498A0000 |4 33|serine/threonine kinase Raf-101606T0076 Comparison with al
P08816498A0000 |162 169|nucleusSF [HCO
P08816498A0000 |139 154|plasma membrane. P00008997A047
P08816504T0000 |17 23|growthmparis
P08816504T0000 |143 151|proteins0008997A
P08816504T0000 |41 51|activationhosphatase
P08816504T0000 |101 117|receptor bindingaspects of neona
P08816504T0000 |55 84|phosphatidylinositol 3-kinased 5-nucleotidase P00008171T00
P08816504T0000 |168 180|Ras activityO3-] is show
P08816507A1125 |50 58|activityes and 5
P08816507A1125 |13 32|cotransfections E1A6 Comparison with a
P08816507A1125 |150 158|activityA0472 Wh
P08816507A1125 |164 167|YY1 [H
P08816507A1125 |134 141|13S E1Anemia. 
P08816507A1125 |66 78|p53 promoteridase P00008
P08816507A1125 |232 241|inductionats are n
P08816507A1125 |89 94|levelarmac
P08816507A1125 |191 198|elementtion of
P08816507A1125 |96 103|12S E1Aogic as
P08816507A1125 |222 223|%d
P08816759A0000 |139 148|subfamily. P000089
P08816759A0000 |104 107|RARect
P08816759A0000 |44 59|orphan receptorphatases and 5-
P08816759A0000 |30 38|RZR beta alkalin
P08816759A0000 |109 133|thyroid hormone receptorof neonatal hyperbilirub
P08816759A0000 |89 102|acid receptorarmacologic a
P08816759A0000 |135 137|TRem
P08816759A0000 |66 72|memberidase 
P08816759A0000 |160 169|receptors CSF [HCO
P08816759A0000 |4 28|retinoid Z receptor beta01606T0076 Comparison wi
P08816792A0000 |101 108|subunitaspects
P08816792A0000 |75 77|Ku00
P08816792A0000 |30 36|DNA-PK alkal
P08816792A0000 |110 118|DNA-PKcsf neonat
P08816792A0000 |14 28|protein kinase Comparison wi
P08816792A0000 |66 73|proteinidase P
P08817323A0714 |102 115|sequence tagsspects of neo
P08817323A0714 |179 183|EST.wn a
P08817323A0714 |70 83|DXS6673E genee P00008171T0
P08817323A0714 |142 145|end000
P08817323A0714 |59 62|endnuc
P08817323A0714 |16 33|sequence identityomparison with al
P08817323A0714 |117 121|ESTstal 
P08817323A0714 |153 166|DXS6673E gene72 When CSF [
P08817324A1070 |0 10|SequencingP00001606T
P08817324A1070 |27 55|Xq28 duplication breakpointsith alkaline phosphatases an
P08817324A1070 |73 81|presence00008171
P08817324A1070 |18 21|16ppar
P08817324A1070 |156 175|paralogy boundariesWhen CSF [HCO3-] is
P08817324A1070 |116 140|CAGGG pentamer sequencesatal hyperbilirubinemia.
P08818436A0557 |119 125|genderl hype
P08818436A0557 |76 83|history08171T0
P08818436A0557 |27 35|analysisith alka
P08818436A0557 |164 169|death [HCO
P08818436A0557 |48 51|agease
P08818436A0557 |53 59|genderand 5-
P08818436A0557 |102 110|diseasesspects o
P08818718A1229 |184 190|organs a fun
P08818718A1229 |151 159|GC cDNAs0472 Whe
P08818718A1229 |130 138|deliveryrubinemi
P08818718A1229 |124 128|miceerbi
P08818718A1229 |41 50|injectionhosphatas
P08818718A1229 |99 108|liposomesc aspects
P08818718A1229 |142 146|MDR10000
P08818718A1229 |70 76|vectore P000
P08820324A1699 |32 35|DBSlka
P08820324A1699 |40 53|TOF responsesphosphatases 
P08820324A1699 |14 23|agreement Comparis
P08820324A1699 |4 10|limits01606T
P08820642A0173 |206 214|bacteria2 the da
P08820642A0173 |47 53|operontases 
P08820642A0173 |285 292|tobacco but st
P08820642A0173 |135 142|clusteremia. P
P08820642A0173 |146 155|hrp genes8997A0472
P08820642A0173 |167 180|cosmid pHIR11CO3-] is show
P08820642A0173 |72 104|Hrp secretion pathway componentsP00008171T0000 Pharmacologic asp
P08820642A0173 |20 29|hrpZ generison wit
P08820642A0173 |112 116|partneon
P08820642A0173 |279 281|HRnt
P08820648A0123 |118 124|growthal hyp
P08820648A0123 |12 20|presence76 Compa
P08820648A0123 |132 136|cellbine
P08820648A0123 |219 225|oxygen K-dep
P08820648A0123 |161 168|mutantsCSF [HC
P08820648A0123 |177 184|specieshown as
P08820648A0123 |39 63|ribonucleotide reductase phosphatases and 5-nucl
P08820648A0123 |83 89|enzyme000 Ph
P08820648A0123 |207 215|presence the dat
P08822208A1364 |16 23|resultsomparis
P08822208A1364 |120 130|regulation hyperbili
P08822208A1364 |99 110|differencesc aspects o
P08822208A1364 |73 82|responses00008171T
P08822208A1364 |49 57|isoformsses and 
P08822399A0518 |33 42|attitudeskaline ph
P08822399A0518 |13 20|factors6 Compa
P08822399A0518 |97 104|factorsgic asp
P08822399A0518 |72 81|pregnancyP00008171
P08822399A0518 |54 68|susceptibilitynd 5-nucleotid
P08823163T0000 |153 157|role72 W
P08823163T0000 |75 81|cobalt008171
P08823163T0000 |174 188|co-corepressors shown as a f
P08823163T0000 |161 170|phosphateCSF [HCO3
P08823163T0000 |122 128|domainyperbi
P08823163T0000 |86 95|manganese Pharmaco
P08823163T0000 |33 59|diphtheria toxin repressorkaline phosphatases and 5-
P08823163T0000 |16 25|structureomparison
P08823187A1020 |0 9|TitrationP00001606
P08823187A1020 |27 43|porcine proteinsith alkaline pho
P08823187A1020 |151 166|disulfide bonds0472 When CSF [
P08823187A1020 |92 112|membrane dipeptidaseacologic aspects of 
P08823260A1161 |0 4|FEV1P000
P08823260A1161 |104 112|patientsects of 
P08823260A1161 |35 43|patientsline pho
P08823260A1161 |146 155|infection8997A0472
P08823260A1161 |69 73|GVHDse P
P08823646A1012 |0 14|AdministrationP00001606T0076
P08823646A1012 |90 102|measurementsrmacologic a
P08823646A1012 |71 75|SaO2 P00
P08823646A1012 |18 28|adrenalineparison wi
P08823646A1012 |49 63|overestimationses and 5-nucl
P08823709A0220 |0 7|TherapyP000016
P08823709A0220 |92 100|symptomsacologic
P08823709A0220 |78 88|resolution171T0000 P
P08823709A0220 |105 112|parotidcts of 
P08823709A0220 |21 33|modificationison with al
P08823709A0220 |129 136|patientirubine
P08823709A0220 |38 65|triglyceride lowering drugse phosphatases and 5-nucleo
P08824201A0270 |0 8|ChernoffP0000160
P08824201A0270 |24 35|publicationn with alka
P08824585A0260 |137 142|cellsia. P
P08824585A0260 |60 77|progenitor kinaseucleotidase P0000
P08824585A0260 |23 37|protein kinaseon with alkali
P08824585A0260 |160 176|progenitor cells CSF [HCO3-] is 
P08824585A0260 |81 85|HPK1T000
P08824798A0761 |32 43|LIM domainslkaline pho
P08824798A0761 |91 99|residuesmacologi
P08824798A0761 |134 137|CRPnem
P08824798A0761 |6 23|ESP1/CRP2 protein606T0076 Comparis
P08824798A0761 |125 132|proteinrbiliru
P08824798A0761 |79 80|%7
P08824798A0761 |54 60|sharesnd 5-n
P08824798A0761 |143 151|rat CRIP0008997A
P08824798A0761 |65 66|%t
P08824800A0808 |50 77|agarose gel electrophoresises and 5-nucleotidase P0000
P08824800A0808 |4 13|fragments01606T007
P08824805A0832 |49 59|boundariesses and 5-
P08824805A0832 |74 81|domains0008171
P08824805A0832 |15 30|exon boundariesComparison with
P08824805A0832 |89 100|p55 proteinarmacologic
P08824881A0133 |0 15|Linkage studiesP00001606T0076 
P08824881A0133 |75 90|chromosome 9q34008171T0000 Pha
P08824881A0133 |56 64|TSC gene 5-nucle
P08824881A0133 |107 114|16p13.3s of ne
P08824881A0133 |27 46|locus heterogeneityith alkaline phosph
P08824884A0000 |34 40|folatealine 
P08824884A0000 |142 154|X chromosome00008997A047
P08824884A0000 |59 63|sitenucl
P08824884A0000 |124 128|Xq28erbi
P08824884A0000 |86 95|expansion Pharmaco
P08824884A0000 |200 208|handicapSF PCO2 
P08824884A0000 |65 70|FRAXEtidas
P08824884A0000 |185 189|forma fu
P08824884A0000 |101 111|GCC repeataspects of
P08824884A0000 |16 26|expressionomparison 
P08825087A0213 |0 21|DNA sequence analysisP00001606T0076 Compar
P08825087A0213 |127 138|orientationilirubinemi
P08825087A0213 |80 94|reading frames1T0000 Pharmac
P08825087A0213 |96 100|ORFsogic
P08825087A0213 |32 54|bp BamHI-ClaI fragmentlkaline phosphatases a
P08825178A0071 |66 68|TBid
P08825178A0071 |91 101|acceptancemacologic 
P08825178A0071 |134 141|TB carenemia. 
P08825178A0071 |109 122|participationof neonatal h
P08825178A0071 |12 32|inpatient experience76 Comparison with a
P08825178A0071 |37 48|individualsne phosphat
P08825554A0000 |17 20|TTPmpa
P08825554A0000 |29 38|prototypeh alkalin
P08825554A0000 |44 49|groupphata
P08825554A0000 |118 135|CCCH zinc fingersal hyperbilirubin
P08825554A0000 |63 84|transcription factorseotidase P00008171T00
P08825554A0000 |0 15|TristetraprolinP00001606T0076 
P08825556A0522 |86 89|CRE Ph
P08825556A0522 |91 97|CREpalmacolo
P08825556A0522 |30 38|TGACCTCA alkalin
P08825556A0522 |143 152|homodimer0008997A0
P08825556A0522 |56 66|nucleotide 5-nucleot
P08825556A0522 |133 137|CREBinem
P08825556A0522 |99 107|TGACGTCAc aspect
P08825556A0522 |5 12|element1606T00
P08825556A0522 |21 28|CREsp-aison wi
P08825633A0304 |0 8|AnalysisP0000160
P08825633A0304 |73 81|homology00008171
P08825633A0304 |91 98|G alphamacolog
P08825633A0304 |52 60|sequence and 5-n
P08825633A0304 |26 29|DNAwit
P08825633A0304 |101 105|cDNAaspe
P08825636T0000 |85 89|p1050 Ph
P08825636T0000 |181 189|NF-kappa as a fu
P08825636T0000 |164 176|implications [HCO3-] is 
P08825636T0000 |25 34|structure with alk
P08825636T0000 |147 162|I kappa B-gamma997A0472 When C
P08825636T0000 |94 106|p50 proteinsologic aspec
P08825636T0000 |55 65|gene NFKB1d 5-nucleo
P08825636T0000 |110 142|transcription factors NF-kappa Bf neonatal hyperbilirubinemia. P
P08825636T0000 |201 220|signal transductionF PCO2 the data of 
P08825639A0827 |127 135|cap siteilirubin
P08825639A0827 |58 65|repeats-nucleo
P08825639A0827 |12 30|Alu repeat element76 Comparison with
P08825639A0827 |93 99|regioncologi
P08827783A0499 |71 73|h. P
P08827783A0499 |40 50|monitoringphosphatas
P08827783A0499 |26 34|normoxiawith alk
P08827783A0499 |4 8|ewes0160
P08828142A0000 |98 109|cat speciesic aspects 
P08828142A0000 |151 163|environments0472 When CS
P08828142A0000 |7 23|leukemia viruses06T0076 Comparis
P08828142A0000 |25 30|FeLVs with
P08828142A0000 |65 81|oncoretrovirusestidase P00008171
P08828152A1238 |0 10|ComparisonP00001606T
P08828152A1238 |73 77|LCDV0000
P08828152A1238 |180 201|amino acid similarityn as a function of CS
P08828152A1238 |165 176|differences[HCO3-] is 
P08828152A1238 |67 71|IIV6dase
P08828152A1238 |147 155|proteins997A0472
P08828152A1238 |46 63|RPO1 polypeptidesatases and 5-nucl
P08828152A1238 |83 88|MCV-1000 P
P08828152A1238 |219 232|relationships K-depleted r
P08828152A1238 |18 38|amino acid sequencesparison with alkalin
P08828152A1825 |35 45|similarityline phosp
P08828152A1825 |61 65|IIV6cleo
P08828152A1825 |53 57|RPO1and 
P08828152A1825 |12 16|LCDV76 C
P08828152A1825 |88 98|similarityharmacolog
P08828152A1825 |4 8|RPO10160
P08828152A1825 |173 180|subunitis show
P08828152A1825 |117 128|polymerasestal hyperbi
P08828857A2423 |186 195|pregnancy function
P08828857A2423 |132 139|factorsbinemia
P08828857A2423 |107 116|paracrines of neon
P08828857A2423 |96 105|endocrineogic aspe
P08828857A2423 |83 88|study000 P
P08828857A2423 |163 178|gene expressionF [HCO3-] is sh
P08828857A2423 |64 70|systemotidas
P08828857A2423 |4 7|use016
P08828857A2423 |19 27|GE cellsarison w
P08829393A0083 |34 40|spikesaline 
P08829393A0083 |13 30|dipole estimation6 Comparison with
P08829393A0083 |45 59|SEP componentshatases and 5-
P08829393A0083 |73 81|patients00008171
P08831364A1252 |154 158|dose2 Wh
P08831364A1252 |129 138|verapamilirubinemi
P08831364A1252 |162 171|adenosineSF [HCO3-
P08831364A1252 |89 91|AVar
P08831364A1252 |192 194|AVio
P08831364A1252 |65 74|adenosinetidase P0
P08831364A1252 |5 14|verapamil1606T0076
P08831364A1252 |52 59|effects and 5-
P08831364A1252 |201 206|blockF PCO
P08831364A1252 |98 113|conduction timeic aspects of n
P08831364A1252 |19 30|propranololarison with
P08832146A0959 |102 105|PTHspe
P08832146A0959 |43 68|bone alkaline phosphatasesphatases and 5-nucleotid
P08832146A0959 |9 12|CBDT00
P08832146A0959 |107 108|rs
P08832146A0959 |70 71|re
P08832146A0959 |81 82|pT
P08832146A0959 |118 119|pa
P08833153A0628 |102 109|portionspects 
P08833153A0628 |317 328|chromosomesgreater slo
P08833153A0628 |166 173|domainsHCO3-] 
P08833153A0628 |15 25|comparisonComparison
P08833153A0628 |119 124|genesl hyp
P08833153A0628 |248 252|partr di
P08833153A0628 |215 223|proteinsa of K-d
P08833153A0628 |33 53|hCHLR gene sequenceskaline phosphatases 
P08833153A0628 |199 205|regionCSF PC
P08833153A0628 |281 296|repeat sequencerols but still 
P08833153A0628 |136 141|exonsmia. 
P08833153A0628 |3 11|addition001606T0
P08833153A0628 |69 78|databasesse P00008
P08833653A0304 |70 89|rat amylin promotere P00008171T0000 Ph
P08833653A0304 |113 129|islet cell lineseonatal hyperbil
P08833653A0304 |22 55|LIM domain homeobox protein isl-1son with alkaline phosphatases an
P08833653A0304 |98 108|fibroblastic aspects
P08833653A0783 |116 127|differencesatal hyperb
P08833653A0783 |91 100|sequencesmacologic
P08833653A0783 |45 74|amylin gene promoter elementshatases and 5-nucleotidase P0
P08833653A0783 |162 172|propertiesSF [HCO3-]
P08833653A0783 |9 14|isl-1T0076
P08833653A0783 |243 247|InR1long
P08833653A0783 |249 263|G9 islet cells displaced whe
P08833653A0783 |213 221|promoterata of K
P08833653A0783 |33 40|insulinkaline 
P08835393A2829 |85 105|calcium mobilization0 Pharmacologic aspe
P08835393A2829 |24 32|pathwaysn with a
P08835393A2829 |145 148|SRE089
P08835393A2829 |111 137|promoter response elements neonatal hyperbilirubinem
P08835393A2829 |51 77|signal transduction eventss and 5-nucleotidase P0000
P08835895A1292 |86 90|risk Pha
P08835895A1292 |108 117|infection of neona
P08835895A1292 |23 32|remissionon with a
P08835895A1292 |59 75|immunodeficiencynucleotidase P00
P08835895A1292 |4 13|CD4 count01606T007
P08835969A0000 |103 112|pregnancypects of 
P08835969A0000 |154 164|sonography2 When CSF
P08835969A0000 |250 262|gonadotropindisplaced wh
P08835969A0000 |20 31|laparoscopyrison with 
P08835969A0000 |114 116|EPon
P08835969A0000 |218 230|beta subunitf K-depleted
P08835969A0000 |82 91|diagnosis0000 Phar
P08835969A0000 |264 272|beta-hCG compare
P08835969A0000 |315 318|EPsy g
P08835969A0000 |198 210|serum assays CSF PCO2 th
P08835969A0000 |119 122|usel h
P08835969A0000 |65 74|referencetidase P0
P08835969A0000 |282 291|detectionols but s
P08835969A0000 |169 180|conjunction3-] is show
P08836032T0000 |0 15|BifunctionalityP00001606T0076 
P08836032T0000 |58 61|hr1-nu
P08836032T0000 |41 56|region sequencehosphatases and
P08836032T0000 |106 127|sequence requirementsts of neonatal hyperb
P08836032T0000 |23 29|AcMNPVon wit
P08836032T0000 |77 90|ori functions8171T0000 Pha
P08836032T0000 |64 72|enhancerotidase 
P08836172A1382 |0 3|RVRP00
P08836172A1382 |47 62|over-expressiontases and 5-nuc
P08836172A1382 |13 21|function6 Compar
P08836172A1382 |120 126|levels hyper
P08836172A1382 |23 30|studieson with
P08836172A1382 |147 161|myogenin mRNAs997A0472 When 
P08836172A1382 |130 142|p21Cip1/Waf1rubinemia. P
P08836172A1382 |86 97|RVR delta E Pharmacolo
P08836172A1382 |5 9|loss1606
P08836172A1382 |168 184|serum withdrawalO3-] is shown as
P08836740A1025 |17 21|CES4mpar
P08836740A1025 |39 50|cell growth phosphatas
P08836740A1025 |8 12|CES16T00
P08836740A1025 |65 80|deletion mutanttidase P0000817
P08837503A0392 |205 220|dicot extensinsO2 the data of 
P08837503A0392 |195 201|groups of CS
P08837503A0392 |165 178|repeat motifs[HCO3-] is sh
P08837503A0392 |145 153|proteins08997A04
P08837503A0392 |111 118|SbHRGP3 neonat
P08837503A0392 |10 23|repeat motifs0076 Comparis
P08837503A0392 |83 89|domain000 Ph
P08837503A0392 |67 74|patterndase P0
P08837503A0392 |136 141|groupmia. 
P08837746A0951 |81 103|postglutamate cleavageT0000 Pharmacologic as
P08837746A0951 |31 45|BrAAP activityalkaline phosp
P08837746A0951 |63 74|postprolineeotidase P0
P08837746A0951 |132 143|specificitybinemia. P0
P08837746A0951 |6 9|use606
P08838144A0107 |119 142|S1 or/and S2 subdomainsl hyperbilirubinemia. P
P08838144A0107 |26 38|significancewith alkalin
P08838144A0107 |62 73|PRL bindingleotidase P
P08838144A0107 |99 115|deletion mutantsc aspects of neo
P08838144A0107 |78 97|signal transduction171T0000 Pharmacolo
P08838144A0107 |48 58|subdomainsases and 5
P08838148A1218 |85 97|transfection0 Pharmacolo
P08838148A1218 |47 65|mouse TRH receptortases and 5-nucleo
P08838148A1218 |118 123|cellsal hy
P08838148A1218 |22 31|cell lineson with 
P08838148A1218 |136 154|L channel activitymia. P00008997A047
P08838314A0129 |168 175|mappingO3-] is
P08838314A0129 |41 51|regulationhosphatase
P08838314A0129 |26 36|expressionwith alkal
P08838314A0129 |110 127|tissue expressionf neonatal hyperb
P08838314A0129 |93 108|characteristicscologic aspects
P08838314A0129 |59 63|V1aRnucl
P08838314A0129 |200 206|AVPR1ASF PCO
P08838314A0129 |189 198|V1aR genenction of
P08838314A0129 |141 153|localizationP00008997A04
P08838585A0968 |86 93|ras-p21 Pharma
P08838585A0968 |45 63|backbone deviationhatases and 5-nucl
P08838585A0968 |20 29|structurerison wit
P08838805T0000 |34 51|beta-catenin genealine phosphatase
P08838805T0000 |8 20|organization6T0076 Compa
P08838805T0000 |53 59|CTNNB1and 5-
P08839498A0507 |137 143|stagesia. P0
P08839498A0507 |158 170|distributionen CSF [HCO3
P08839498A0507 |56 67|tissue mass 5-nucleoti
P08839498A0507 |75 80|trunk00817
P08839498A0507 |35 47|distributionline phospha
P08839498A0507 |174 177|fats s
P08839498A0507 |85 89|legs0 Ph
P08839832A0729 |20 33|CD30v proteinrison with al
P08839832A0729 |120 127|domains hyperb
P08839832A0729 |66 72|regionidase 
P08839832A1220 |36 49|CD30v proteinine phosphata
P08839832A1220 |79 87|labeling71T0000 
P08839832A1220 |13 28|phosphorylation6 Comparison wi
P08839832A1220 |94 97|32Polo
P08839911A0716 |4 5|%0
P08839911A0716 |9 15|cyclesT0076 
P08840501A0345 |19 28|discoveryarison wi
P08840501A0345 |52 56|gene and
P08840501A0345 |95 99|ACT4logi
P08840501A0345 |65 73|organismtidase P
P08840506A0544 |50 54|oneses a
P08840506A0544 |11 15|ORFs076 
P08840506A0544 |92 97|G2850acolo
P08840997A0765 |0 10|MVR typingP00001606T
P08840997A0765 |26 33|alleleswith al
P08840997A0765 |157 164|alleleshen CSF
P08840997A0765 |124 135|resemblanceerbilirubin
P08840997A0765 |84 93|sequences00 Pharma
P08842143A0000 |102 108|viciaespects
P08842143A0000 |122 129|clusteryperbil
P08842143A0000 |64 67|hupoti
P08842143A0000 |53 62|H2 uptakeand 5-nuc
P08842143A0000 |36 48|determinantsine phosphat
P08842143A0000 |136 141|genesmia. 
P08842143A0000 |98 100|bvic
P08842143A0000 |0 14|Plasmid pAL618P00001606T0076
P08843411A0801 |85 95|activation0 Pharmaco
P08843411A0801 |24 33|receptorsn with al
P08843411A0801 |4 11|classes01606T0
P08843411A0801 |173 183|activationis shown a
P08843411A0801 |100 112|dimerization aspects of 
P08843412A0543 |117 146|promoter transcription factortal hyperbilirubinemia. P0000
P08843412A0543 |210 221|interactione data of K
P08843412A0543 |180 188|identityn as a f
P08843412A0543 |90 107|chicken ovalbuminrmacologic aspect
P08843412A0543 |77 80|RAR817
P08843412A0543 |244 255|DNA bindingonger displ
P08843412A0543 |72 75|RXRP00
P08843412A0543 |64 68|LBDsotid
P08843412A0543 |82 84|TR00
P08843412A0543 |32 52|40-amino acid regionlkaline phosphatases
P08843419A1290 |0 3|OKAP00
P08843419A1290 |8 19|calyculin A6T0076 Comp
P08843419A1290 |36 41|OCFREine p
P08843419A1290 |110 122|interactionsf neonatal h
P08843419A1290 |54 66|interactionsnd 5-nucleot
P08844448A0000 |238 248|absorptione no longe
P08844448A0000 |196 212|lipase inhibitorof CSF PCO2 the 
P08844448A0000 |167 175|orlistatCO3-] is
P08844448A0000 |324 332|vitamins slope (
P08844448A0000 |55 70|crossover studyd 5-nucleotidas
P08844448A0000 |157 163|effecthen CS
P08844448A0000 |294 301|obesityl have 
P08844448A0000 |276 290|weight control controls but 
P08844448A0000 |310 320|absorptioncantly gre
P08844448A0000 |129 134|yearsirubi
P08844448A0000 |339 341|E.- 
P08844448A0000 |99 109|volunteersc aspects 
P08844448A0000 |138 141|agea. 
P08844577A0000 |85 93|medicine0 Pharma
P08844577A0000 |67 70|usedas
P08844577A0000 |22 31|macrolideson with 
P08844577A0000 |0 10|TilmicosinP00001606T
P08844712A0000 |0 6|EffectP00001
P08844712A0000 |120 124|rats hyp
P08844712A0000 |25 28|N2O wi
P08844712A0000 |62 72|C-reflexesleotidase 
P08844712A0000 |164 172|urethane [HCO3-]
P08844712A0000 |55 56|Ad
P08844712A0000 |143 159|alpha-chloralose0008997A0472 Whe
P08844712A0000 |18 23|oxideparis
P08845378A0368 |0 26|Restriction enzyme mappingP00001606T0076 Comparison 
P08845378A0368 |110 114|genef ne
P08845378A0368 |31 48|Southern analysisalkaline phosphat
P08845378A0368 |82 92|MZF-1 gene0000 Pharm
P08846775A0110 |139 143|CLN2. P0
P08846775A0110 |105 114|G1 cyclincts of ne
P08846775A0110 |131 135|CLN1ubin
P08846775A0110 |27 46|Swi6 cell viabilityith alkaline phosph
P08846775A0110 |124 129|geneserbil
P08846775A0110 |18 22|Swi4pari
P08846775A0110 |7 14|absence06T0076
P08846775A0110 |87 97|expressionPharmacolo
P08847138A0609 |85 90|years0 Pha
P08847138A0609 |94 97|ageolo
P08847138A0609 |30 34|ages alk
P08847138A0609 |4 19|detection ratio01606T0076 Comp
P08847403T0000 |32 40|patientslkaline 
P08847403T0000 |9 16|embryosT0076 C
P08847403T0000 |52 55|IVF an
P08847723A2351 |0 12|IMPLICATIONSP00001606T00
P08847723A2351 |74 81|results0008171
P08847723A2351 |194 202|findingsn of CSF
P08847723A2351 |30 34|size alk
P08847723A2351 |43 48|studysphat
P08847723A2351 |108 115|studies of neo
P08847723A2351 |57 70|inconsistency5-nucleotidas
P08847723A2351 |172 184|replications is shown as
P08847723A2351 |127 133|cancerilirub
P08847723A2351 |158 170|associationsen CSF [HCO3
P08848013A1469 |17 25|TATA boxmparison
P08848013A1469 |63 67|roleeoti
P08848013A1469 |29 39|promoter Bh alkaline
P08848013A1469 |98 106|TATA boxic aspec
P08848013A1469 |110 121|promoter A.f neonatal 
P08848013A1469 |71 88|promoter activity P00008171T0000 P
P08848052A0733 |119 127|functionl hyperb
P08848052A0733 |131 135|Gle1ubin
P08848052A0733 |91 101|RNA exportmacologic 
P08848052A0733 |31 35|Gle1alka
P08848052A0733 |6 16|properties606T0076 C
P08848052A0733 |42 59|RNA-export factorosphatases and 5-
P08848052A0733 |69 72|Revse 
P08849208A1022 |51 58|statures and 5
P08849208A1022 |40 47|measurephospha
P08849208A1022 |0 8|DemispanP0000160
P08849569A0615 |116 124|cortisolatal hyp
P08849569A0615 |105 112|patterncts of 
P08849569A0615 |24 42|assay coefficientsn with alkaline ph
P08849569A0615 |46 55|variationatases an
P08849569A0615 |4 14|techniques01606T0076
P08849778A0226 |84 90|duplex00 Pha
P08849778A0226 |110 113|RNAf n
P08849778A0226 |42 51|repA mRNAosphatase
P08849778A0226 |115 119|CopAnata
P08849778A0226 |55 65|plasmid R1d 5-nucleo
P08849778A0226 |18 38|toeprinting analysesparison with alkalin
P08849778A0598 |51 61|expressions and 5-nu
P08849778A0598 |92 103|translationacologic as
P08849778A0598 |9 13|workT007
P08849778A0598 |26 30|repAwith
P08849778A0598 |71 74|tap P0
P08849778A0598 |76 90|leader peptide08171T0000 Pha
P08849778A0598 |32 49|initiator proteinlkaline phosphata
P08849834A0000 |35 51|volume flow rateline phosphatase
P08849834A0000 |104 137|colour Doppler ultrasound imagingects of neonatal hyperbilirubinem
P08849834A0000 |55 60|bloodd 5-n
P08849834A0000 |66 72|vesselidase 
P08849834A0000 |2 8|system000160
P08850585A0602 |86 92|caries Pharm
P08850585A0602 |60 75|pathophysiologyucleotidase P00
P08850585A0602 |122 139|virulence factorsyperbilirubinemia
P08850585A0602 |44 52|elementsphatases
P08850585A0602 |4 21|enzyme activities01606T0076 Compar
P08851337A1092 |0 13|TonsillectomyP00001606T007
P08851337A1092 |30 35|means alka
P08851337A1092 |95 110|angina patientslogic aspects o
P08851337A1092 |73 82|infection00008171T
P08851337A1092 |39 50|prophylaxis phosphatas
P08851434A0383 |85 89|mice0 Ph
P08851434A0383 |65 69|halftida
P08851434A0383 |8 12|mice6T00
P08851434A0383 |18 43|fat/water intensity ratioparison with alkaline pho
P08853303A0431 |139 143|Tmax. P0
P08853303A0431 |63 73|literatureeotidase P
P08853303A0431 |271 274|mined 
P08853303A0431 |150 153|minA04
P08853303A0431 |181 193|MMC infusion as a functi
P08853303A0431 |254 263|T1/2 betalaced whe
P08853303A0431 |16 26|parametersomparison 
P08853303A0431 |221 227|ml/min-deple
P08853303A0431 |117 137|bolus MMC injectionstal hyperbilirubinem
P08853303A0431 |113 115|IAeo
P08853303A0431 |249 252|min di
P08853303A0431 |212 214|C1da
P08853303A0431 |43 49|valuessphata
P08853303A0431 |228 230|kged
P08853303A0431 |195 198|Vss of
P08853303A0431 |206 210|1/kg2 th
P08853303A0431 |232 242|T1/2 alphaats are no
P08853303A0431 |168 177|beginningO3-] is s
P08853893A0158 |8 13|study6T007
P08853893A0158 |109 120|fibroblastsof neonatal
P08853893A0158 |43 56|E2F complexessphatases and
P08854459A0000 |68 79|earthquakesase P000081
P08854459A0000 |150 158|FebruaryA0472 Wh
P08854459A0000 |5 10|paper1606T
P08854459A0000 |129 138|Septemberirubinemi
P08854459A0000 |43 50|patternsphatas
P08854459A0000 |54 64|casualtiesnd 5-nucle
P08854459A0000 |20 28|overviewrison wi
P08854459A0000 |115 121|periodnatal 
P08854844A0637 |102 111|diagnosisspects of
P08854844A0637 |134 142|accuracynemia. P
P08854844A0637 |60 76|h post injectionucleotidase P000
P08854844A0637 |115 117|ACna
P08854844A0637 |52 54|GB a
P08854844A0637 |27 44|non-visualizationith alkaline phos
P08854844A0637 |16 23|findingomparis
P08854844A0637 |156 157|%W
P08854844A0637 |84 93|criterion00 Pharma
P08855804A1528 |138 144|monthsa. P00
P08855804A1528 |78 81|men171
P08855804A1528 |120 125|times hype
P08855804A1528 |105 108|SLTcts
P08855804A1528 |6 13|results606T007
P08855804A1528 |111 113|mg n
P08855804A1528 |48 53|studyases 
P08856077T0000 |94 99|cellsologi
P08856077T0000 |30 63|tryptophanyl-tRNA synthetase mRNA alkaline phosphatases and 5-nucl
P08856077T0000 |12 22|processing76 Compari
P08856132T0000 |0 8|EvidenceP0000160
P08856132T0000 |120 128|abortion hyperbi
P08856132T0000 |27 31|roleith 
P08856132T0000 |74 85|development0008171T000
P08856132T0000 |53 66|kinin releaseand 5-nucleot
P08858211A0694 |34 58|3T3-L1 adipocyte lysatesaline phosphatases and 5
P08858211A0694 |120 123|GTP hy
P08858211A0694 |148 157|alpha-32P97A0472 W
P08858211A0694 |133 141|GST-Rab4inemia. 
P08858211A0694 |91 101|hydrolysismacologic 
P08858211A0694 |158 161|GDPen 
P08858211A0694 |110 119|alpha-32Pf neonata
P08858211A0694 |5 17|GAP activity1606T0076 Co
P08858268A1307 |0 10|CONCLUSIONP00001606T
P08858268A1307 |149 157|patients7A0472 W
P08858268A1307 |134 145|improvementnemia. P000
P08858268A1307 |163 166|CHFF [
P08858268A1307 |27 36|treatmentith alkal
P08858268A1307 |72 82|cilazaprilP00008171T
P08858268A1307 |55 63|responsed 5-nucl
P08858268A1307 |218 225|effectsf K-dep
P08858268A1307 |170 173|CLZ-] 
P08858463A0853 |220 234|nephrotoxicityK-depleted rat
P08858463A0853 |40 54|cryptococcosisphosphatases a
P08858463A0853 |56 65|tolerance 5-nucleo
P08858463A0853 |107 113|dosages of n
P08858463A0853 |157 162|mg/kghen C
P08858463A0853 |212 216|ratedata
P08858463A0853 |131 136|mg/kgubine
P08858463A0853 |169 175|dosage3-] is
P08858463A0853 |21 34|AIDS patientsison with alk
P08858463A0853 |69 76|ILd-AmBse P000
P08861955A0927 |152 164|Rab proteins472 When CSF
P08861955A0927 |52 66|amino-terminus and 5-nucleot
P08861955A0927 |129 136|membersirubine
P08861955A0927 |225 231|R-Ras2leted 
P08861955A0927 |31 36|motifalkal
P08861955A0927 |218 221|Ranf K
P08861955A0927 |232 236|TC21ats 
P08861955A0927 |189 209|GTP binding proteinsnction of CSF PCO2 t
P08861955A0927 |70 74|p619e P0
P08861955A0927 |86 113|guanine nucleotide exchange Pharmacologic aspects of n
P08861955A0927 |117 121|ARF1tal 
P08861963A0375 |153 170|rrnBP1 UP element72 When CSF [HCO3
P08861963A0375 |96 104|responseogic asp
P08861963A0375 |108 132|transcription activation of neonatal hyperbiliru
P08861963A0375 |50 71|mutant alpha subunitses and 5-nucleotidase
P08861963A0375 |19 34|RNA polymerasesarison with alk
P08861963A0375 |136 144|cAMP-CRPmia. P00
P08861963T0000 |0 40|Transcription factor recognition surfaceP00001606T0076 Comparison with alkaline 
P08861963T0000 |92 99|contactacologi
P08861963T0000 |109 129|DNA enhancer elementof neonatal hyperbil
P08861963T0000 |48 76|RNA polymerase alpha subunitases and 5-nucleotidase P000
P08862522A0690 |21 31|similarityison with 
P08862522A0690 |105 116|temperaturects of neon
P08862522A0690 |75 85|precursors008171T000
P08862522A0690 |37 45|cdc28-P8ne phosp
P08862743A0603 |34 37|ageali
P08862743A0603 |14 28|erythrocyte Mn Comparison wi
P08862743A0603 |71 72|p 
P08862743A0603 |52 58|nmol/L and 5
P08862743A0603 |2 10|decrease0001606T
P08863824A0509 |0 7|CloningP000016
P08863824A0509 |134 138|loopnemi
P08863824A0509 |82 88|region0000 P
P08863824A0509 |182 190|5-HT2C-Ras a fun
P08863824A0509 |12 29|sequence analyses76 Comparison wit
P08863824A0509 |48 52|cDNAases
P08863824A0509 |66 74|deletionidase P0
P08863824A0509 |154 174|transmembrane domain2 When CSF [HCO3-] i
P08864061A0000 |0 10|ExpressionP00001606T
P08864061A0000 |14 35|thymidine kinase gene Comparison with alka
P08864061A0000 |60 65|cellsucleo
P08864061A0000 |74 84|cell cycle0008171T00
P08864219A0178 |48 60|ketoconazoleases and 5-n
P08864219A0178 |74 86|itraconazole0008171T0000
P08864219A0178 |105 119|amphotericin Bcts of neonata
P08864219A0178 |23 37|concentrationson with alkali
P08864219A0178 |88 99|fluconazoleharmacologi
P08864219A0178 |62 72|miconazoleleotidase 
P08864219A0178 |157 170|inoculum sizehen CSF [HCO3
P08864219A0178 |39 43|MICs pho
P08864219A0178 |190 200|techniquesction of C
P08866485A0125 |168 173|cellsO3-] 
P08866485A0125 |151 160|functions0472 When
P08866485A0125 |27 42|export proteinsith alkaline ph
P08866485A0125 |124 129|ordererbil
P08866485A0125 |63 75|interactionseotidase P00
P08866485A0125 |111 120|molecules neonatal
P08866485A0125 |95 99|celllogi
P08866485A0125 |6 14|bacteria606T0076
P08867519A0557 |86 100|administration Pharmacologic
P08867519A0557 |123 130|periodsperbili
P08867519A0557 |4 14|elevations01606T0076
P08867519A0557 |27 31|LDEEith 
P08867519A0557 |38 42|s.c.e ph
P08868473A1287 |154 164|cell cycle2 When CSF
P08868473A1287 |75 84|cleavages008171T00
P08868473A1287 |15 18|p28Com
P08868473A1287 |43 47|rolespha
P08868473A1287 |146 150|type8997
P08868473A1287 |111 122|development neonatal h
P08868660A0087 |137 145|researchia. P000
P08868660A0087 |90 100|Infermierermacologic
P08868660A0087 |49 54|arenases a
P08868660A0087 |20 32|contributionrison with a
P08868660A0087 |249 260|instruments displaced 
P08868660A0087 |59 69|discussionnucleotida
P08868660A0087 |267 277|discussionmpared to 
P08868660A0087 |213 235|hypothesis formulationata of K-depleted rats
P08868660A0087 |183 190|noveltys a fun
P08868660A0087 |77 89|Rivista dell8171T0000 Ph
P08868660A0087 |281 288|resultsrols bu
P08868660A0087 |195 205|weaknesses of CSF PC
P08868660A0087 |237 244|methodsre no l
P08868660A0087 |9 12|aimT00
P08868660A0087 |169 178|strengths3-] is sh
P08868954A0648 |32 39|effectslkaline
P08868954A0648 |198 210|hemodynamics CSF PCO2 th
P08868954A0648 |165 182|enzyme inhibitors[HCO3-] is shown 
P08868954A0648 |60 65|drugsucleo
P08868954A0648 |114 133|calcium antagonistsonatal hyperbilirub
P08868954A0648 |142 153|angiotensin00008997A04
P08868954A0648 |101 107|agentsaspect
P08869358A0121 |101 106|cellsaspec
P08869358A0121 |73 82|apoptosis00008171T
P08869358A0121 |127 134|T cellsilirubi
P08869358A0121 |11 18|viruses076 Com
P08869358A0121 |48 58|strategiesases and 5
P08869763A0378 |68 76|morphinease P000
P08869763A0378 |56 64|response 5-nucle
P08869763A0378 |97 108|differencesgic aspects
P08869763A0378 |127 138|sensitivityilirubinemi
P08869763A0378 |43 52|phenomenasphatases
P08869763A0378 |175 183|migraine shown a
P08869763A0378 |112 122|expressionneonatal h
P08869763A0378 |154 171|receptor subtypes2 When CSF [HCO3-
P08869825A0000 |113 119|mannereonata
P08869825A0000 |57 71|monooxygenases5-nucleotidase
P08869825A0000 |73 76|FMO000
P08869825A0000 |9 16|studiesT0076 C
P08870266A0651 |175 195|secretion efficiency shown as a function
P08870266A0651 |126 132|regionbiliru
P08870266A0651 |150 156|domainA0472 
P08870266A0651 |67 78|amino acidsdase P00008
P08870266A0651 |22 34|observationsson with alk
P08870266A0651 |98 112|NodO secretionic aspects of 
P08871542A1352 |50 60|mechanismses and 5-n
P08871542A1352 |76 84|evidence08171T00
P08871542A1352 |104 107|Mtxect
P08871542A1352 |116 124|promoteratal hyp
P08871542A1352 |18 27|potentialparison w
P08871542A1352 |155 176|Thbs3 gene expression When CSF [HCO3-] is 
P08871567A0000 |0 13|MSSP proteinsP00001606T007
P08871567A0000 |78 83|c-myc171T0
P08871567A0000 |44 51|bindingphatase
P08871567A0000 |67 74|elementdase P0
P08871567A0629 |0 4|GeneP000
P08871635A0000 |0 23|B cell antigen receptorP00001606T0076 Comparis
P08871635A0000 |25 28|BCR wi
P08871635A0000 |38 47|apoptosise phospha
P08871635A0000 |114 118|CD40onat
P08871635A0000 |55 84|WEHI-231 B lymphoma cell lined 5-nucleotidase P00008171T00
P08872162A0884 |5 12|alleles1606T00
P08872162A0884 |77 91|T cell subsets8171T0000 Phar
P08872162A0884 |72 75|CD8P00
P08872162A0884 |67 70|CD4das
P08872671A0573 |4 9|model01606
P08872671A0573 |90 96|oxygenrmacol
P08872671A0573 |29 54|blood flow shunt fractionh alkaline phosphatases a
P08872671A0573 |192 197|bloodion o
P08872671A0573 |107 130|amplitude perturbationss of neonatal hyperbili
P08872671A0573 |158 161|airen 
P08872671A0573 |56 61|Qs/QT 5-nu
P08872671A0573 |217 226|equationsof K-depl
P08873063A0493 |35 41|LvUSF2line p
P08873063A0493 |65 71|LvUSF1tidase
P08873063A0493 |12 31|amino acid sequence76 Comparison with 
P08873063A0493 |86 95|amino end Pharmaco
P08873063A0875 |0 14|ECM disruptionP00001606T0076
P08873063A0875 |63 90|USF RNA accumulation levelseotidase P00008171T0000 Pha
P08873063A0875 |55 59|dropd 5-
P08873063A0875 |189 190|%n
P08873063A0875 |110 111|%f
P08873063A0875 |18 36|Lytechinus embryosparison with alkal
P08873063A0875 |115 130|control embryosnatal hyperbili
P08873063A0875 |138 166|LpS1 RNA accumulation levelsa. P00008997A0472 When CSF [
P08873159A0791 |32 37|grouplkali
P08873159A0791 |62 74|chemotherapyleotidase P0
P08873159A0791 |20 28|patientsrison wi
P08874399A0277 |153 155|B.72
P08874399A0277 |126 128|Cabi
P08874399A0277 |105 108|Ca2cts
P08874399A0277 |6 10|days606T
P08874399A0277 |129 130|oi
P08874399A0277 |110 123|concentrationf neonatal hy
P08874399A0277 |140 146|groups P0000
P08874399A0277 |54 62|tensionsnd 5-nuc
P08874399A0277 |21 33|interventionison with al
P08874631A1133 |0 14|DiscriminationP00001606T0076
P08874631A1133 |46 54|evidenceatases a
P08874631A1133 |75 80|HIV-100817
P08874631A1133 |23 28|HIV-1on wi
P08874631A1133 |63 71|presenceeotidase
P08874631A1133 |33 38|HIV-2kalin
P08876167A0322 |34 41|subunitaline p
P08876167A0322 |46 52|HiNF-Datases
P08876167A0717 |168 176|promoterO3-] is 
P08876167A0717 |104 107|pRBect
P08876167A0717 |116 120|p107atal
P08876167A0717 |21 28|complexison wi
P08876167A0717 |178 187|gp91-phoxown as a 
P08876167A0717 |92 99|CDP/cutacologi
P08876167A0717 |214 229|p107 antibodiesta of K-deplete
P08876167A0717 |142 149|complex0000899
P08876167A0717 |12 19|CDP/cut76 Comp
P08876167A0717 |73 83|antibodies00008171T0
P08876167A0717 |4 10|HiNF-D01606T
P08876167A0717 |38 49|H4 promotere phosphata
P08876167A0717 |206 209|CDP2 t
P08876701A0177 |44 48|DinBphat
P08876701A0177 |30 42|UmuC-homolog alkaline ph
P08877103A0081 |139 146|J7.V2-1. P0000
P08877103A0081 |27 42|mdr2 expressionith alkaline ph
P08877103A0081 |13 23|regulation6 Comparis
P08877103A0081 |64 73|mdr2 geneotidase P
P08877103A0081 |128 137|cell linelirubinem
P08877103A0081 |48 56|promoterases and
P08877818A0184 |69 92|TRH progenitor sequencese P00008171T0000 Pharm
P08877818A0184 |94 109|Lys/Arg-Arg-Glnologic aspects 
P08877818A0184 |41 48|primershosphat
P08877818A0184 |110 125|His-Pro-Gly-Lysf neonatal hype
P08877818A0184 |126 133|Arg-Argbilirub
P08877818A0184 |4 17|amplification01606T0076 Co
P08878019A0357 |155 159|case Whe
P08878019A0357 |46 55|sinusoidsatases an
P08878019A0357 |27 32|cellsith a
P08878019A0357 |63 74|lymph nodeseotidase P0
P08878019A0357 |141 146|tumorP0000
P08878037A0000 |4 13|gene ccpA01606T007
P08878037A0000 |27 58|catabolite control protein CcpAith alkaline phosphatases and 5
P08878044A1390 |138 144|Caco-2a. P00
P08878044A1390 |149 159|J774 cells7A0472 Whe
P08878044A1390 |128 134|mutantlirubi
P08878044A1390 |78 89|mouse model171T0000 Ph
P08878044A1390 |109 120|replicationof neonatal
P08878044A1390 |38 47|virulencee phospha
P08878044A1390 |212 218|straindata o
P08878044A1390 |3 23|InlC deletion mutant001606T0076 Comparis
P08878045A0606 |118 123|groupal hy
P08878045A0606 |177 190|transcriptionhown as a fun
P08878045A0606 |94 108|RNA polymeraseologic aspects
P08878045A0606 |163 173|initiationF [HCO3-] 
P08878045A0606 |77 90|alpha subunit8171T0000 Pha
P08878045A0606 |10 23|N-Nus complex0076 Comparis
P08878045A0606 |48 56|contactsases and
P08878045A0606 |66 69|CTDida
P08878045A0606 |138 146|proteinsa. P0000
P08878573A1370 |102 114|prolongationspects of ne
P08878573A1370 |176 180|RIFAshow
P08878573A1370 |150 154|miceA047
P08878573A1370 |60 63|ATOucl
P08878573A1370 |30 39|mg/kg/day alkaline
P08878573A1370 |71 80|mg/kg/day P0000817
P08878573A1370 |18 22|RIFApari
P08878573A1370 |43 54|combinationsphatases a
P08878573A1370 |118 126|survivalal hyper
P08878573A1370 |169 172|ATO3-]
P08878573A1370 |0 14|AdministrationP00001606T0076
P08879080A0265 |85 98|path analysis0 Pharmacolog
P08879080A0265 |77 81|data8171
P08879080A0265 |11 16|ACOAs076 C
P08879080A0265 |104 114|LISREL VIIects of ne
P08879080A0265 |64 69|modelotida
P08879080A0265 |53 56|fitand
P08879080A0265 |32 37|orderlkali
P08879237A0744 |136 137|Rm
P08879237A0744 |146 147|G8
P08879237A0744 |13 29|initiation sites6 Comparison wit
P08879237A0744 |75 99|consensus promoter motif008171T0000 Pharmacologi
P08879237A0744 |48 56|sequenceases and
P08879237A0744 |156 174|rice mitochondrionWhen CSF [HCO3-] i
P08879237A0744 |118 128|CRTA motifal hyperbi
P08880405A1170 |0 9|SelectionP00001606
P08880405A1170 |80 83|age1T0
P08880405A1170 |58 67|selection-nucleoti
P08880405A1170 |87 94|pubertyPharmac
P08880405A1170 |98 107|daughtersic aspect
P08880405A1170 |16 22|SC EPDompari
P08881036A0351 |22 32|VL elementson with a
P08881036A0351 |15 18|PCRCom
P08881036A0351 |47 50|CL2tas
P08881542T0000 |0 38|Sodium polystyrene sulfonate treatmentP00001606T0076 Comparison with alkalin
P08881542T0000 |72 102|serum potassium concentrationsP00008171T0000 Pharmacologic a
P08881542T0000 |61 68|effectscleotid
P08881542T0000 |43 59|lithium toxicitysphatases and 5-
P08882492A0000 |218 227|organismsf K-deple
P08882492A0000 |14 34|homeodomain proteins Comparison with alk
P08882492A0000 |199 203|axisCSF 
P08882492A0000 |46 55|Hox genesatases an
P08882492A0000 |74 78|role0008
P08882492A0000 |128 134|queueslirubi
P08882492A0000 |92 103|developmentacologic as
P08882492A0000 |162 172|identitiesSF [HCO3-]
P08882710A0000 |137 141|betaia. 
P08882710A0000 |58 78|transcription factor-nucleotidase P00008
P08882710A0000 |150 154|IFNsA047
P08882710A0000 |105 110|cellscts o
P08882710A0000 |37 42|ISGF3ne ph
P08882710A0000 |22 33|gene factorson with al
P08882710A0000 |92 101|treatmentacologic 
P08882710A0000 |116 132|interferon-alphaatal hyperbiliru
P08882710A0000 |143 147|type0008
P08882710A0000 |0 10|InterferonP00001606T
P08884273A1413 |100 107|studies aspect
P08884273A1413 |149 154|means7A047
P08884273A1413 |180 195|map integrationn as a function
P08884273A1413 |134 142|functionnemia. P
P08884273A1413 |80 88|resource1T0000 P
P08884273A1413 |111 129|telomere structure neonatal hyperbil
P08884273A1413 |43 56|polymorphismssphatases and
P08884273A1413 |4 20|TYAC/P1 resource01606T0076 Compa
P08884273A1413 |200 207|closureSF PCO2
P08884273A1413 |33 37|STSskali
P08884757A0653 |275 278|BGPo c
P08884757A0653 |178 182|helpown 
P08884757A0653 |63 73|Impressioneotidase P
P08884757A0653 |148 153|scale97A04
P08884757A0653 |91 96|scoremacol
P08884757A0653 |120 140|Assessment Geriatric hyperbilirubinemia.
P08884757A0653 |104 110|Sandozects o
P08884757A0653 |75 78|CGI008
P08884757A0653 |359 362|SKTA07
P08884757A0653 |323 339|Performance Testr slope (1.21 +/
P08884757A0653 |191 196|nursetion 
P08884757A0653 |294 299|scorel hav
P08884757A0653 |219 227|patients K-deple
P08884757A0653 |229 273|Beurteilungsskala fur geriatrische Patientend rats are no longer displaced when compared
P08884757A0653 |199 205|ratingCSF PC
P08884757A0653 |13 23|statistics6 Comparis
P08884757A0653 |33 37|itemkali
P08884757A0653 |142 146|SCAG0000
P08884757A0653 |341 357|Syndrom-Kurztest0.23 vs. P000109
P08885270A0428 |49 55|strainses an
P08885270A0428 |57 61|PAO15-nu
P08885270A0428 |6 13|mutants606T007
P08886845A1274 |220 229|myoblastsK-deplete
P08886845A1274 |52 60|presence and 5-n
P08886845A1274 |144 152|myotubes008997A0
P08886845A1274 |121 140|expression activityhyperbilirubinemia.
P08886845A1274 |33 50|myogenin promoterkaline phosphatas
P08886845A1274 |80 86|copies1T0000
P08886845A1274 |100 107|vectors aspect
P08887643A1167 |69 73|TC21se P
P08887643A1167 |47 57|activationtases and 
P08887643A1167 |61 64|Rascle
P08887643A1167 |33 40|signalskaline 
P08887643A1167 |89 114|TC21 controls cell growtharmacologic aspects of ne
P08887643A1167 |155 173|signaling pathways When CSF [HCO3-] 
P08887647T0000 |0 18|Fission yeast mal2P00001606T0076 Com
P08887647T0000 |36 58|chromosome segregationine phosphatases and 5
P08887652A0341 |137 144|segmentia. P00
P08887652A0341 |212 243|hygromycin B phosphotransferasedata of K-depleted rats are no 
P08887652A0341 |106 112|regionts of 
P08887652A0341 |269 272|hphare
P08887652A0341 |164 177|reading frame [HCO3-] is s
P08887652A0341 |187 192|framefunct
P08887652A0341 |23 33|expressionon with al
P08887652A0341 |261 266|con10hen c
P08887652A0341 |0 9|SelectionP00001606
P08887652A0341 |255 259|geneaced
P08887652A0341 |51 63|DNA fragments and 5-nucl
P08887659A0753 |51 60|threonines and 5-n
P08887659A0753 |29 34|sitesh alk
P08887659A0753 |36 42|serineine ph
P08887659A0753 |82 88|effect0000 P
P08887659A0753 |0 9|MutationsP00001606
P08887661A0138 |0 5|IRF-1P0000
P08887661A0138 |32 41|activatorlkaline p
P08887661A0138 |65 74|repressortidase P0
P08887661A0138 |49 54|IRF-2ses a
P08887661A1061 |3 11|contrast001606T0
P08887661A1061 |164 170|manner [HCO3
P08887661A1061 |41 46|IRF-1hosph
P08887661A1061 |13 27|cotransfection6 Comparison w
P08887661A1061 |31 36|TFIIBalkal
P08887661A1061 |95 105|repressionlogic aspe
P08887661A1061 |109 128|promoter activationof neonatal hyperbi
P08887661A1061 |52 65|NIH 3T3 cells and 5-nucleo
P08887667A0992 |19 43|Tyr-19 dephosphorylationarison with alkaline pho
P08887667A0992 |208 222|SPB separationthe data of K-
P08887667A0992 |88 98|conditionsharmacolog
P08887667A0992 |173 184|involvementis shown as
P08887667A0992 |144 151|mitosis008997A
P08887667A0992 |108 125|spindle formation of neonatal hype
P08887667A0992 |4 15|requirement01606T0076 
P08887667A0992 |188 204|Cdc28/Clb kinaseunction of CSF P
P08887667A0992 |48 64|spindle assemblyases and 5-nucle
P08887674A0630 |117 125|elementstal hype
P08887674A0630 |18 44|DMP1 recognition sequencesparison with alkaline phos
P08887674A0630 |58 80|GGA trinucleotide core-nucleotidase P0000817
P08887674A0630 |2 8|subset000160
P08887674A0920 |65 72|kinasestidase 
P08887674A0920 |46 52|cyclinatases
P08887674A0920 |110 118|activityf neonat
P08887674A0920 |8 16|settings6T0076 C
P08887674A0920 |158 168|mechanismsen CSF [HC
P08887678A0000 |0 10|ExpressionP00001606T
P08887678A0000 |31 42|protein Baxalkaline ph
P08887678A0000 |66 80|GAL10 promoteridase P0000817
P08887678A0000 |53 60|controland 5-n
P08887678A0000 |141 151|cell deathP00008997A
P08890537A0355 |34 42|patientsaline ph
P08890537A0355 |61 70|bone cystcleotidas
P08890537A0355 |5 14|technique1606T0076
P08891131A0000 |0 28|Enterococcus faecium strainsP00001606T0076 Comparison wi
P08891131A0000 |48 71|glycopeptide resistanceases and 5-nucleotidase
P08891131A0000 |156 163|speciesWhen CS
P08891131A0000 |190 191|%c
P08891131A0000 |214 215|%t
P08891131A0000 |89 107|enrichment culturearmacologic aspect
P08891131A0000 |183 187|dogss a 
P08891131A0000 |231 235|pigsrats
P08891131A0000 |132 137|fecesbinem
P08891131A0000 |117 127|intestinestal hyperb
P08891131A0000 |203 211|chickensPCO2 the
P08891131A0000 |172 178|horses is sh
P08891131A0000 |238 239|%e
P08891337A0614 |187 202|binding proteinfunction of CSF
P08891337A0614 |135 139|p300emia
P08891337A0614 |182 185|CREas 
P08891337A0614 |29 32|E1Ah a
P08891337A0614 |62 77|weight proteinsleotidase P0000
P08891337A0614 |159 180|cAMP response elementn CSF [HCO3-] is show
P08891337A0614 |111 131|coactivator function neonatal hyperbilir
P08891337A0614 |19 25|regionarison
P08891341A0724 |169 171|bp3-
P08891341A0724 |132 140|sequencebinemia.
P08891341A0724 |104 113|sequencesects of n
P08891341A0724 |194 204|expressionn of CSF P
P08891341A0724 |244 254|cell linesonger disp
P08891341A0724 |10 29|transfection assays0076 Comparison wit
P08891341A0724 |149 160|between-2477A0472 When
P08891341A0724 |36 60|reporter gene constructsine phosphatases and 5-n
P08891341A0724 |212 225|reporter genedata of K-dep
P08891341A0724 |80 87|lengths1T0000 
P08891345A0684 |87 98|translationPharmacolog
P08891345A0684 |130 141|transcriptsrubinemia. 
P08891345A0684 |229 234|uORFsd rat
P08891345A0684 |176 192|beta-globin mRNAshown as a funct
P08891345A0684 |57 67|c-mos mRNA5-nucleoti
P08891345A0684 |115 126|translationnatal hyper
P08891345A0684 |159 162|UTRn C
P08891345A0684 |19 37|UTR characteristicarison with alkali
P08891346A1217 |168 173|FGF8eO3-] 
P08891346A1217 |45 63|isoform expressionhatases and 5-nucl
P08891346A1217 |142 146|cDNA0000
P08891346A1217 |26 32|effectwith a
P08891346A1217 |151 156|FGF8a0472 
P08891346A1217 |158 163|FGF8ben CS
P08891346A1217 |113 130|expression vectoreonatal hyperbili
P08891346A1217 |65 77|NIH3T3 cellstidase P0000
P08891474A0667 |169 178|threshold3-] is sh
P08891474A0667 |82 106|depolarization threshold0000 Pharmacologic aspec
P08891474A0667 |58 68|motoneuron-nucleotid
P08891474A0667 |182 196|depolarizationas a function 
P08891474A0667 |6 14|findings606T0076
P08891474A0667 |142 154|nerve fibers00008997A047
P08891474A0667 |32 38|F-wavelkalin
P08892755A0186 |119 126|domainsl hyper
P08892755A0186 |106 112|kinasets of 
P08892755A0186 |13 22|carp JAK16 Compari
P08892755A0186 |97 100|JH2gic
P08892755A0186 |67 71|JAK1dase
P08892755A0186 |144 154|% identity008997A047
P08892755A0186 |114 117|JH1ona
P08892755A0186 |36 53|sequence homologyine phosphatases 
P08892755A0186 |3 11|addition001606T0
P08892755A0981 |85 88|CAT0 P
P08892755A0981 |165 174|synthesis[HCO3-] i
P08892755A0981 |90 103|reporter genermacologic as
P08892755A0981 |127 144|carp CF cell lineilirubinemia. P00
P08892755A0981 |10 22|DNA fragment0076 Compari
P08892755A0981 |192 197|timesion o
P08892755A0981 |237 247|pCAT-Basicre no long
P08892755A0981 |178 188|CAT enzymeown as a f
P08892755A0981 |50 83|chloramphenicol acetyltransferasees and 5-nucleotidase P00008171T0
P08892757T0000 |34 40|memberaline 
P08892757T0000 |76 95|mouse embryogenesis08171T0000 Pharmaco
P08892757T0000 |10 17|cloning0076 Co
P08892757T0000 |132 151|repression activitybinemia. P00008997A
P08892757T0000 |48 58|Ets familyases and 5
P08892757T0000 |21 26|Elk-3ison 
P08892757T0000 |100 108|analysis aspects
P08892859A0563 |169 181|c-myb allele3-] is shown
P08892859A0563 |60 69|cell lineucleotida
P08892859A0563 |132 138|resultbinemi
P08892859A0563 |13 20|example6 Compa
P08892859A0563 |91 97|levelsmacolo
P08892859A0563 |113 126|C-MYB proteineonatal hyper
P08892859A0563 |142 157|RAV integration00008997A0472 W
P08892859A0563 |71 73|T9 P
P08893779A0229 |103 110|failurepects o
P08893779A0229 |123 129|energyperbil
P08893779A0229 |151 152|p0
P08893779A0229 |185 186|pa
P08893779A0229 |294 303|interfacel have a 
P08893779A0229 |23 59|digitorum longus muscle tendon unitson with alkaline phosphatases and 5-
P08893779A0229 |112 113|pn
P08893779A0229 |95 99|loadlogi
P08893779A0229 |176 183|failureshown a
P08893779A0229 |244 252|locationonger di
P08893779A0229 |254 255|pl
P08893779A0229 |84 90|values00 Pha
P08893779A0229 |358 366|junction3A0733 F
P08893779A0229 |166 172|strainHCO3-]
P08893779A0229 |379 384|unitss app
P08893779A0229 |142 149|failure0000899
P08893822A0560 |0 17|Northern analysisP00001606T0076 Co
P08893822A0560 |124 131|tissueserbilir
P08893822A0560 |72 82|transcriptP00008171T
P08893822A0560 |32 42|PWP2H cDNAlkaline ph
P08894144A0330 |103 119|CsA vehicle p.o.pects of neonata
P08894144A0330 |125 138|FB vehicle scrbilirubinemi
P08894144A0330 |245 250|mg/kgnger 
P08894144A0330 |270 275|mg/kgred t
P08894144A0330 |210 212|FBe 
P08894144A0330 |252 256|p.o.spla
P08894144A0330 |262 264|FBen
P08894144A0330 |188 204|CsA vehicle p.o.unction of CSF P
P08894144A0330 |218 223|mg/kgf K-d
P08894144A0330 |159 163|p.o.n CS
P08894144A0330 |93 97|dayscolo
P08894144A0330 |144 147|CsA008
P08894144A0330 |47 51|ratstase
P08894144A0330 |225 227|scle
P08894144A0330 |152 157|mg/kg472 W
P08894144A0330 |237 240|CsAre 
P08894144A0330 |277 279|scco
P08894144A0330 |169 182|FB vehicle sc3-] is shown 
P08894144A1173 |0 3|CsAP00
P08894144A1173 |31 44|bone turnoveralkaline phos
P08894826A0228 |0 11|IndividualsP00001606T0
P08894826A0228 |251 256|studyispla
P08894826A0228 |188 197|infectionunction o
P08894826A0228 |159 165|herpesn CSF 
P08894826A0228 |144 149|warts00899
P08894826A0228 |26 40|GUM Departmentwith alkaline 
P08894826A0228 |121 134|HIV infectionhyperbilirubi
P08894826A0228 |199 203|NSGICSF 
P08894826A0228 |221 229|syphilis-deplete
P08894826A0228 |48 63|Royal Infirmaryases and 5-nucl
P08894826A0228 |67 76|Edinburghdase P000
P08894826A0228 |108 117|diagnosis of neona
P08894826A0228 |206 216|gonorrhoea2 the data
P08895522T0000 |86 92|fusion Pharm
P08895522T0000 |28 50|tyrosine kinase domainth alkaline phosphatas
P08895522T0000 |64 82|trk proto-oncogeneotidase P00008171T
P08895522T0000 |10 20|activation0076 Compa
P08895522T0000 |98 120|cell adhesion moleculeic aspects of neonatal
P08895579A0583 |0 17|Northern blottingP00001606T0076 Co
P08895579A0583 |41 45|MDM2hosp
P08895579A0583 |30 34|MDMX alk
P08895579A0583 |67 74|tissuesdase P0
P08895579A0583 |110 114|MDMXf ne
P08895579A0583 |100 105|mRNAs aspe
P08895997A0336 |0 7|PhysiolP000016
P08896272A0000 |34 36|bpal
P08896272A0000 |4 23|nucleotide sequence01606T0076 Comparis
P08896272A0000 |56 66|chromosome 5-nucleot
P08896272A0000 |49 52|armses
P08896280A0860 |51 55|IME1s an
P08896280A0860 |90 96|resultrmacol
P08896280A0860 |60 69|IME2 mRNAucleotida
P08896280A0860 |140 155|acid metabolism P00008997A0472
P08896280A0860 |41 47|levelshospha
P08896280A0860 |170 185|yvh1 disruption-] is shown as 
P08896402A0587 |118 130|glycoproteinal hyperbili
P08896402A0587 |147 158|kD subunits997A0472 Wh
P08896402A0587 |52 61|cell line and 5-nu
P08896402A0587 |8 18|FL protein6T0076 Com
P08896402A0587 |179 181|kDwn
P08896402A0587 |201 207|sugarsF PCO2
P08896402A0587 |83 85|kD00
P08896402A0587 |185 186|Na
P08896473A0282 |119 122|VGSl h
P08896473A0282 |47 56|influencetases and
P08896473A0282 |104 115|developmentects of neo
P08896473A0282 |60 64|HHCAucle
P08896473A0282 |4 13|objective01606T007
P08896473A0282 |22 27|studyson w
P08896473A0282 |87 94|factorsPharmac
P08896590T0000 |17 27|adenovirusmparison w
P08896590T0000 |8 13|exons6T007
P08896590T0000 |54 59|snRNPnd 5-
P08896590T0000 |82 88|domain0000 P
P08896590T0000 |33 37|RNAskali
P08896795A0166 |34 40|mediumaline 
P08896795A0166 |104 108|lensects
P08896795A0166 |14 19|resin Comp
P08896795A0166 |151 162|air bubbles0472 When C
P08896795A0166 |172 180|specimen is show
P08896795A0166 |128 138|coverslipslirubinemi
P08896795A0166 |121 124|usehyp
P08896795A0166 |65 74|specimenstidase P0
P08896795A0166 |6 11|Spurr606T0
P08896795A0166 |80 93|oil immersion1T0000 Pharma
P08896804A0000 |239 242|CGS no
P08896804A0000 |146 151|mg/kg8997A
P08896804A0000 |367 372|% v/vuraze
P08896804A0000 |299 300|Pe
P08896804A0000 |94 97|BDZolo
P08896804A0000 |124 133|RO19-4603erbilirub
P08896804A0000 |391 400|saccharin be an ef
P08896804A0000 |302 306|rats sig
P08896804A0000 |31 46|dose dependencealkaline phosph
P08896804A0000 |329 340|choice teste (1.21 +/-
P08896804A0000 |167 178|combinationCO3-] is sh
P08896804A0000 |225 227|ZKle
P08896804A0000 |51 70|time course effectss and 5-nucleotidas
P08896804A0000 |358 362|EtOH3A07
P08896804A0000 |252 257|mg/kgsplac
P08896804A0000 |115 122|agonistnatal h
P08896804A0000 |188 223|BDZ receptor antagonists flumazenilunction of CSF PCO2 the data of K-d
P08896804A0000 |349 356|ethanol P00010
P08896804A0000 |78 92|benzodiazepine171T0000 Pharm
P08896804A0000 |12 17|study76 Co
P08896804A0000 |279 297|alcohol-preferringntrols but still h
P08896804A0000 |415 423|solutionc drug w
P08896804A0000 |408 413|% g/vhypno
P08897663T0000 |20 25|Babelrison
P08897663T0000 |46 57|suicidologyatases and 
P08897663T0000 |29 41|nomenclatureh alkaline p
P08897663T0000 |11 16|Tower076 C
P08897721A0000 |0 9|InfectionP00001606
P08897721A0000 |106 111|groupts of
P08897721A0000 |15 24|NeisseriaCompariso
P08897721A0000 |38 45|group Be phosp
P08897721A0000 |114 128|polysaccharideonatal hyperbi
P08897721A0000 |139 148|immunogen. P000089
P08898336A0268 |0 25|RNase protection analysisP00001606T0076 Comparison
P08898336A0268 |111 121|transcript neonatal 
P08898336A0268 |133 142|sequencesinemia. P
P08898336A0268 |180 184|RNAsn as
P08898336A0268 |54 59|genesnd 5-
P08898336A0268 |82 90|evidence0000 Pha
P08898336A0268 |33 47|rRNA fragmentskaline phospha
P08898365A0274 |0 5|Rss1pP0000
P08898365A0274 |109 115|domainof neo
P08898365A0274 |47 58|amino acidstases and 5
P08898365A0274 |180 189|cytoplasmn as a fu
P08898365A0274 |163 167|NPCsF [H
P08898365A0274 |147 161|pore complexes997A0472 When 
P08898365A0274 |32 39|proteinlkaline
P08898866A0458 |119 126|annexinl hyper
P08898866A0458 |161 168|mutantsCSF [HC
P08898866A0458 |150 157|annexinA0472 W
P08898866A0458 |140 146|series P0000
P08898866A0458 |23 50|serine phosphorylation siteon with alkaline phosphatas
P08898866A0458 |214 229|serine residuesta of K-deplete
P08898866A0458 |87 104|expression systemPharmacologic asp
P08898866A0458 |185 198|substitutionsa function of
P08898866A0458 |256 262|domainced wh
P08898893A0202 |186 190|acid fun
P08898893A0202 |243 248|cellslonge
P08898893A0202 |225 230|U-937leted
P08898893A0202 |200 220|HT-1080 fibrosarcomaSF PCO2 the data of 
P08898893A0202 |142 145|PMA000
P08898893A0202 |95 140|phorbol ester phorbol 12-myristate 13-acetatelogic aspects of neonatal hyperbilirubinemia.
P08898893A0202 |155 176|phosphatase inhibitor When CSF [HCO3-] is 
P08898893A0202 |4 14|PAI-2 gene01606T0076
P08898893A0202 |49 54|genesses a
P08899719A0318 |139 148|certainty. P000089
P08899719A0318 |46 60|reading framesatases and 5-n
P08899719A0318 |62 66|ORFsleot
P08899719A0318 |28 33|totalth al
P08899719A0318 |98 102|ORFsic a
P08899719A0318 |10 17|contigs0076 Co
P08899719A0318 |86 93|operons Pharma
P08900164A0188 |0 2|T.P0
P08900164A0188 |11 13|S.07
P08900164A0188 |4 9|Patel01606
P08900190A0430 |0 14|Growth factorsP00001606T0076
P08900190A0430 |26 36|expressionwith alkal
P08900190A0430 |60 98|gene products MAP kinase phosphatase-1ucleotidase P00008171T0000 Pharmacolog
P08900190A0430 |100 105|MKP-1 aspe
P08900190A0430 |108 113|c-Fos of n
P08900190A0430 |118 123|c-Junal hy
P08900296A0000 |70 81|endotheliume P00008171
P08900296A0000 |142 150|response00008997
P08900296A0000 |112 121|mediationneonatal 
P08900296A0000 |44 62|adhesion moleculesphatases and 5-nuc
P08900296A0000 |4 17|up-regulation01606T0076 Co
P08900296A0000 |99 104|eventc asp
P08900296A0000 |21 31|E-selectinison with 
P08901135A1132 |85 93|fraction0 Pharma
P08901135A1132 |97 102|cellsgic a
P08901135A1132 |141 160|nitrogen repressionP00008997A0472 When
P08901135A1132 |4 16|NIT2 protein01606T0076 C
P08901135A1132 |200 204|NIT2SF P
P08901135A1132 |33 39|nucleikaline
P08901135A1132 |190 196|importction 
P08901135A1132 |116 137|nitrogen derepressionatal hyperbilirubinem
P08901635A0000 |17 23|effortmparis
P08901635A0000 |28 31|oneth 
P08901635A0000 |121 130|cellulosehyperbili
P08901635A0000 |163 169|plantsF [HCO
P08901635A0000 |108 117|synthesis of neona
P08901635A0000 |89 90|sa
P08901635A0000 |142 159|cell wall polymer00008997A0472 Whe
P08901635A0000 |82 88|enzyme0000 P
P08901635A0000 |3 8|spite00160
P08901658A0498 |143 146|GTN000
P08901658A0498 |122 141|glyceryl trinitrateyperbilirubinemia. 
P08901658A0498 |47 60|flow increasetases and 5-n
P08901658A0498 |31 40|hyperemiaalkaline 
P08901658A0498 |9 18|responsesT0076 Com
P08901658A0498 |94 102|dilationologic a
P08901658A0498 |172 180|dilation is show
P08902214A1486 |117 129|Stat factorstal hyperbil
P08902214A1486 |89 99|activationarmacologi
P08902214A1486 |12 18|period76 Com
P08902214A1486 |20 34|administrationrison with alk
P08902214A1486 |59 62|PRLnuc
P08902214A1486 |101 108|bindingaspects
P08902548A0144 |34 55|L-5-hydroxytryptophanaline phosphatases an
P08902548A0144 |57 64|L-5-HTP5-nucle
P08902548A0144 |130 134|micerubi
P08902548A0144 |88 93|mg/kgharma
P08902548A0144 |16 30|administrationomparison with
P08902548A0144 |116 126|defecationatal hyper
P08902548A0144 |69 74|dosesse P0
P08902641A0930 |115 122|outflownatal h
P08902641A0930 |56 64|conduits 5-nucle
P08902641A0930 |148 149|n9
P08902641A0930 |74 81|LV apex0008171
P08902641A0930 |24 34|connectionn with alk
P08902641A0930 |125 126|nr
P08902641A0930 |108 113|aorta of n
P08902641A0930 |83 89|inflow000 Ph
P08902641A0930 |7 18|VA-SMV mode06T0076 Com
P08902641A0930 |143 146|DAo000
P08902847A1946 |237 246|degrees Cre no lon
P08902847A1946 |178 187|hCG alphaown as a 
P08902847A1946 |214 219|min-1ta of
P08902847A1946 |299 304|rehCGe a s
P08902847A1946 |269 278|magnitudeared to c
P08902847A1946 |224 226|pHpl
P08902847A1946 |16 23|supportomparis
P08902847A1946 |324 329|min-1 slop
P08902847A1946 |155 174|order rate constant When CSF [HCO3-] i
P08902847A1946 |190 194|betactio
P08902847A1946 |260 265|orderwhen 
P08902847A1946 |53 57|factand 
P08902847A1946 |196 198|kmof
P08902847A1946 |79 90|interaction71T0000 Pha
P08902847A1946 |107 115|subunitss of neo
P08902847A1946 |4 12|evidence01606T00
P08902847A1946 |67 75|affinitydase P00
P08902847A1946 |306 308|kwni
P08902988A0258 |0 15|Factor V LeidenP00001606T0076 
P08902988A0258 |67 71|riskdase
P08902988A0258 |29 37|disorderh alkali
P08902988A0258 |82 92|thrombosis0000 Pharm
P08903339A0264 |18 31|determinationparison with 
P08903339A0264 |91 102|spliceosomemacologic a
P08903339A0264 |74 77|RNA000
P08903339A0264 |58 67|structure-nucleoti
P08905819A0531 |64 70|cancerotidas
P08905819A0531 |31 34|0-Ialk
P08905819A0531 |60 62|smuc
P08905819A0531 |4 12|majority01606T00
P08905819A0531 |20 25|casesrison
P08905819A0531 |38 54|0-III componentse phosphatases a
P08906056A1290 |81 87|statusT0000 
P08906056A1290 |121 127|degreehyperb
P08906056A1290 |131 154|health care utilizationubinemia. P00008997A047
P08906056A1290 |56 64|function 5-nucle
P08906056A1290 |6 14|patients606T0076
P08906139A2935 |102 113|adjustmentsspects of n
P08906139A2935 |61 88|alkaline phosphatase valuescleotidase P00008171T0000 P
P08906139A2935 |49 56|calciumses and
P08906139A2935 |5 16|observation1606T0076 C
P08906139A2935 |172 179|periods is sho
P08906139A2935 |139 149|fortifiers. P0000899
P08906139A2935 |117 133|vitamin D intaketal hyperbilirub
P08906139A2935 |35 45|monitoringline phosp
P08909546A0810 |19 23|PEA2aris
P08909546A0810 |101 108|proteinaspects
P08909546A0810 |65 72|patterntidase 
P08909546A0810 |138 144|domaina. P00
P08910292T0000 |68 73|c-Junase P
P08910292T0000 |109 131|protein kinase pathwayof neonatal hyperbilir
P08910292T0000 |55 60|Cdc42d 5-n
P08910292T0000 |37 50|proteins Rac1ne phosphatas
P08910292T0000 |0 9|SignalingP00001606
P08910373A0315 |0 18|Percent identitiesP00001606T0076 Com
P08910373A0315 |72 84|Y2 receptorsP00008171T00
P08910373A0315 |39 47|mouse Y1 phospha
P08910373A0315 |26 35|mouse PP2with alka
P08910373A0315 |49 61|mouse Y4/PP1ses and 5-nu
P08910550A0501 |100 104|EDTA asp
P08910550A0501 |121 137|cation chelatorshyperbilirubinem
P08910550A0501 |91 95|EGTAmaco
P08910550A0501 |30 41|observation alkaline p
P08910550A0501 |66 75|78C1 siteidase P00
P08910550A0501 |47 58|CBF bindingtases and 5
P08910550A0501 |175 188|transcription shown as a f
P08910567A2269 |102 110|enhancerspects o
P08910567A2269 |10 23|gene fragment0076 Comparis
P08910567A2269 |47 77|rat liver glucokinase promotertases and 5-nucleotidase P0000
P08910567A2269 |118 148|hepatocyte transfection systemal hyperbilirubinemia. P000089
P08912232A0260 |20 22|MLri
P08912232A0260 |88 93|girlsharma
P08912232A0260 |45 49|axishata
P08912232A0260 |63 71|childreneotidase
P08912232A0260 |12 16|role76 C
P08912232A0260 |76 80|boys0817
P08912807A0411 |101 107|domainaspect
P08912807A0411 |164 184|beta-casein promoter [HCO3-] is shown as
P08912807A0411 |146 156|activation8997A0472 
P08912807A0411 |63 79|tyrosine residueeotidase P000081
P08912807A0411 |23 36|deer receptoron with alkal
P08913186A0431 |119 130|developmentl hyperbili
P08913186A0431 |29 37|evidenceh alkali
P08913186A0431 |5 11|report1606T0
P08913186A0431 |59 66|controlnucleot
P08913186A0431 |46 51|riMLFatase
P08913186A0431 |138 170|convergence retraction nystagmusa. P00008997A0472 When CSF [HCO3
P08913186A0431 |86 96|synkinesis Pharmacol
P08913186A0431 |70 78|downgazee P00008
P08913387A1010 |0 9|RifabutinP00001606
P08913387A1010 |60 66|agentsucleot
P08913387A1010 |26 34|efficacywith alk
P08913974A0533 |152 163|salpingitis472 When CS
P08913974A0533 |12 19|percent76 Comp
P08913974A0533 |134 135|%n
P08913974A0533 |90 97|changesrmacolo
P08913974A0533 |27 30|EPsith
P08913974A0533 |177 183|othershown a
P08913974A0533 |167 168|%C
P08913974A0533 |49 50|%s
P08913974A0533 |58 63|tubes-nucl
P08913974A0533 |117 128|salpingitistal hyperbi
P08914388A1645 |34 40|mediumaline 
P08914388A1645 |182 194|levofloxacinas a functio
P08914388A1645 |150 158|AM-1155*A0472 Wh
P08914388A1645 |226 234|sequenceeted rat
P08914388A1645 |105 112|CS-940*cts of 
P08914388A1645 |117 129|sparfloxacintal hyperbil
P08914388A1645 |86 96|activities Pharmacol
P08914388A1645 |55 61|authord 5-nu
P08914388A1645 |23 24|Ho
P08914388A1645 |215 221|NM-394a of K
P08914388A1645 |196 200|LVFXof C
P08914388A1645 |131 135|SPFXubin
P08914388A1645 |160 173|ciprofloxacin CSF [HCO3-] 
P08914388A1645 |175 179|CPFX sho
P08914388A1645 |203 213|OPC-17116*PCO2 the d
P08914388A1645 |4 14|assessment01606T0076
P08914522A0118 |190 205|G beta mutationction of CSF PC
P08914522A0118 |128 134|screenlirubi
P08914522A0118 |27 41|protein kinaseith alkaline p
P08914522A0118 |55 84|pheromone signal transductiond 5-nucleotidase P00008171T00
P08914522A0118 |4 14|STE20 gene01606T0076
P08914522A0118 |156 167|suppressorsWhen CSF [H
P08914532A0598 |5 11|enzyme1606T0
P08914532A0598 |45 72|endohydrolase isoenzyme X-Ihatases and 5-nucleotidase 
P08915051T0000 |43 52|arthritissphatases
P08915051T0000 |9 26|resonance imagingT0076 Comparison 
P08915508A0000 |0 7|MoloneyP000016
P08915508A0000 |416 419|RNA dr
P08915508A0000 |126 141|trans-activatorbilirubinemia. 
P08915508A0000 |145 158|transcription08997A0472 Wh
P08915508A0000 |244 253|sequencesonger dis
P08915508A0000 |265 278|group antigencompared to c
P08915508A0000 |330 333|tat (1
P08915508A0000 |31 35|MMLValka
P08915508A0000 |121 124|Tathyp
P08915508A0000 |280 283|Gagtro
P08915508A0000 |286 294|proteasebut stil
P08915508A0000 |378 407|immunodeficiency virus type-1us appears to be an effective
P08915508A0000 |15 29|leukemia virusComparison wit
P08915508A0000 |325 327|RTsl
P08915508A0000 |354 368|coding regions10943A0733 Flu
P08915508A0000 |189 209|hammerhead ribozymesnction of CSF PCO2 t
P08915508A0000 |339 347|envelope- 0.23 v
P08915508A0000 |310 323|transcriptasecantly greate
P08915508A0000 |349 352|Env P0
P08915508A0000 |409 414|HIV-1ypnot
P08915508A0000 |71 78|vectors P00008
P08915508A0000 |170 180|expression-] is show
P08915559A0366 |0 21|REM sleep deprivationP00001606T0076 Compar
P08915559A0366 |46 64|platform techniqueatases and 5-nucle
P08916928A0950 |51 57|effects and 
P08916928A0950 |9 16|ligandsT0076 C
P08916928A0950 |135 154|PDGF beta-receptorsemia. P00008997A047
P08916928A0950 |83 106|thymidine incorporation000 Pharmacologic aspec
P08916928A0950 |110 119|PAE cellsf neonata
P08916928A0950 |80 82|3H1T
P08916960A0350 |19 35|biopsy specimensarison with alka
P08916960A0350 |47 55|patientstases an
P08916960A0350 |61 63|FLcl
P08916960A0350 |108 118|bcl-2 gene of neonat
P08916960A0350 |78 89|alterations171T0000 Ph
P08916960A0350 |166 173|regionsHCO3-] 
P08916960A0350 |161 164|ORFCSF
P08916960A0350 |146 159|reading frame8997A0472 Whe
P08916960A0350 |126 136|breakpointbilirubine
P08916960A1331 |35 44|DLL cellsline phos
P08916960A1331 |130 142|conservationrubinemia. P
P08916960A1331 |183 196|translocations a function 
P08916960A1331 |28 30|FLth
P08916960A1331 |13 18|cases6 Com
P08916960A1331 |150 160|bcl-2 geneA0472 When
P08916960A1331 |52 63|alterations and 5-nucl
P08916960A1331 |213 227|transformationata of K-deple
P08916960A1331 |95 112|breakpoint regionlogic aspects of 
P08916960A1331 |173 174|ti
P08916960A1331 |67 87|bcl-2 gene sequencesdase P00008171T0000 
P08916960A1331 |235 243|FL cells are no 
P08917270A0229 |0 10|BACKGROUNDP00001606T
P08917270A0229 |130 139|substraterubinemia
P08917270A0229 |106 113|diseasets of n
P08917270A0229 |37 40|QTcne 
P08917270A0229 |42 50|intervalosphatas
P08917270A0229 |58 66|exercise-nucleot
P08917270A0229 |86 92|marker Pharm
P08917270A0229 |33 35|QTka
P08917270A0229 |153 164|QT syndrome72 When CSF
P08917435A0481 |153 180|c-fos oligodeoxynucleotides72 When CSF [HCO3-] is show
P08917435A0481 |31 36|c-Fosalkal
P08917435A0481 |120 127|finding hyperb
P08917435A0481 |143 148|c-jun00089
P08917435A0481 |228 243|PAI-1 synthesised rats are no 
P08917435A0481 |13 17|role6 Co
P08917435A0481 |21 26|c-Junison 
P08917435A0481 |65 78|transcriptiontidase P00008
P08917435A0481 |86 96|PAI-1 gene Pharmacol
P08917449A0000 |153 164|populations72 When CSF
P08917449A0000 |96 104|survivalogic asp
P08917449A0000 |72 87|differentiationP00008171T0000 
P08917449A0000 |28 31|LIFth 
P08917449A0000 |20 26|factorrison 
P08917449A0000 |113 123|cell typeseonatal hy
P08917449A0000 |38 50|neuropoietine phosphatas
P08917696A0485 |343 358|luciferase gene23 vs. P0001094
P08917696A0485 |256 259|CREced
P08917696A0485 |250 254|cAMPdisp
P08917696A0485 |397 405|promoter effecti
P08917696A0485 |113 130|expression assayseonatal hyperbili
P08917696A0485 |244 247|SREong
P08917696A0485 |384 388|SV40ears
P08917696A0485 |28 46|fos/jun activationth alkaline phosph
P08917696A0485 |312 321|jun genesntly grea
P08917696A0485 |192 229|12-O-tetradecanoyl-phorbol-13-acetateion of CSF PCO2 the data of K-deplete
P08917696A0485 |15 24|mechanismCompariso
P08917696A0485 |134 158|reporter gene constructsnemia. P00008997A0472 Wh
P08917696A0485 |289 293|AhRE sti
P08917696A0485 |50 54|TCDDes a
P08917696A0485 |84 98|mobility shift00 Pharmacolog
P08917696A0485 |237 242|serumre no
P08917696A0485 |369 376|controlazepam 
P08917696A0485 |231 234|TRErat
P08917696A0485 |304 307|fosign
P08917696A0485 |170 187|response elements-] is shown as a 
P08917696A0485 |275 287|hydrocarbonso controls b
P08918456A0455 |141 151|position YP00008997A
P08918456A0455 |130 137|leucinerubinem
P08918456A0455 |56 60|AP-2 5-n
P08918456A0455 |12 20|sequence76 Compa
P08918456A0455 |42 44|muos
P08918456A0455 |25 36|interaction with alkal
P08918456A0455 |111 121|position Y neonatal 
P08918456A0455 |80 86|anchor1T0000
P08918456A0455 |65 73|tyrosinetidase P
P08918456A0455 |99 107|argininec aspect
P08918464A0225 |137 140|MELia.
P08918464A0225 |107 135|mouse erythroleukaemia cellss of neonatal hyperbilirubin
P08918464A0225 |31 36|cellsalkal
P08918464A0225 |71 77|growth P0000
P08918464A0225 |38 45|BaF/STKe phosp
P08918464A0225 |142 145|STK000
P08918464A0225 |87 90|STKPha
P08918464A0225 |19 24|Ba/F3ariso
P08918464A0225 |169 178|apoptosis3-] is sh
P08918810A0967 |17 29|footprintingmparison wit
P08918810A0967 |42 52|OxyR-C199Sosphatases
P08918810A0967 |9 14|DNaseT0076
P08918810A0967 |63 67|Pmomeoti
P08918810A0967 |173 177|OxyRis s
P08918810A0967 |96 102|strandogic a
P08918810A0967 |118 151|protection pattern characteristical hyperbilirubinemia. P00008997A
P08918885A0811 |0 4|Kss1P000
P08918885A0811 |29 44|GST-Dig1 fusionh alkaline phos
P08918885A0811 |73 86|yeast protein00008171T0000
P08918885A0811 |52 59|absence and 5-
P08918885A1087 |152 156|role472 
P08918885A1087 |195 209|growth pathway of CSF PCO2 t
P08918885A1087 |74 89|dig1 dig2 ste120008171T0000 Ph
P08918885A1087 |97 103|mutantgic as
P08918885A1087 |130 134|Dig1rubi
P08918885A1087 |13 28|dig1 dig2 cells6 Comparison wi
P08918885A1087 |139 143|Dig2. P0
P08918885A1087 |3 11|contrast001606T0
P08918885A1087 |51 62|agar mediums and 5-nuc
P08918918T0000 |102 118|trans-activationspects of neonat
P08918918T0000 |60 71|Tat proteinucleotidase
P08918918T0000 |10 20|activation0076 Compa
P08918918T0000 |28 46|HIV-1 LTR promoterth alkaline phosph
P08918918T0000 |128 132|cellliru
P08918934A0424 |152 156|core472 
P08918934A0424 |88 92|NTF2harm
P08918934A0424 |210 217|linkerse data 
P08918934A0424 |67 72|Nsplpdase 
P08918934A0424 |59 62|p62nuc
P08918934A0424 |166 173|repeatsHCO3-] 
P08918934A0424 |35 55|xFxFG repeat regionsline phosphatases an
P08918934A0424 |18 27|sequencesparison w
P08918934A0424 |0 10|ComparisonP00001606T
P08919289A0402 |18 24|reportpariso
P08919289A0402 |135 144|vena cavaemia. P00
P08919289A0402 |58 61|MFH-nu
P08919289A0402 |43 52|resectionsphatases
P08919289A0402 |96 102|tissueogic a
P08919907A0763 |71 81|activation P00008171
P08919907A0763 |10 20|expression0076 Compa
P08919907A0763 |56 60|vs-1 5-n
P08919907A0763 |24 29|VSF-1n wit
P08919907A0763 |108 116|promoter of neon
P08919907A0763 |33 44|protoplastskaline phos
P08919986A1262 |137 144|resultsia. P00
P08919986A1262 |90 94|drugrmac
P08919986A1262 |45 52|dosageshatases
P08919986A1262 |37 40|agene 
P08919986A1262 |11 15|mind076 
P08919986A1262 |28 33|rangeth al
P08919986A1262 |54 64|advantagesnd 5-nucle
P08919986A1262 |173 183|literatureis shown a
P08919986A1262 |69 82|disadvantagesse P00008171T
P08920499A0164 |0 25|Blood sampling proceduresP00001606T0076 Comparison
P08921387A1182 |0 8|AnalysisP0000160
P08921387A1182 |41 55|splicing eventhosphatases an
P08921387A1182 |197 203|domainf CSF 
P08921387A1182 |93 102|gene GPR2cologic a
P08921387A1182 |128 137|mechanismlirubinem
P08921387A1182 |156 168|EZH1 proteinWhen CSF [HC
P08921387A1182 |66 70|EZH1idas
P08921387A1182 |16 20|cDNAompa
P08921667A0294 |17 31|input functionmparison with 
P08921667A0294 |44 49|valuephata
P08921667A0294 |176 186|volunteersshown as a
P08921667A0294 |91 107|rCBF measurementmacologic aspect
P08921667A0294 |74 76|Vd00
P08921667A0294 |156 161|studyWhen 
P08921667A0294 |53 72|distribution volumeand 5-nucleotidase 
P08921667A0294 |116 122|methodatal h
P08921865A1293 |206 211|T4DNA2 the
P08921865A1293 |161 174|ssDNA regionsCSF [HCO3-] i
P08921865A1293 |108 115|T4 gp17 of neo
P08921865A1293 |39 41|ss p
P08921865A1293 |43 60|DNA binding motifsphatases and 5-n
P08921865A1293 |86 104|terminase proteins Pharmacologic asp
P08922344A1539 |116 130|blood pressureatal hyperbili
P08922344A1539 |41 49|subjectshosphata
P08922344A1539 |194 199|causen of 
P08922344A1539 |213 225|hypertensionata of K-dep
P08922344A1539 |160 167|factors CSF [H
P08922344A1539 |56 60|acid 5-n
P08922344A1539 |65 81|xanthine oxidasetidase P00008171
P08922344A1539 |203 209|effectPCO2 t
P08922344A1539 |99 110|associationc aspects o
P08922384A0466 |0 14|ImmunoblottingP00001606T0076
P08922384A0466 |40 48|proteinsphosphat
P08922384A0466 |135 142|proteinemia. P
P08922384A0466 |115 127|carboxyl endnatal hyperb
P08922384A0466 |96 107|08L epitopeogic aspect
P08922384A0466 |69 81|08L antibodyse P00008171
P08922385A0622 |175 183|lysosome shown a
P08922385A0622 |126 140|fusion subunitbilirubinemia.
P08922385A0622 |72 83|proteolysisP00008171T0
P08922385A0622 |91 118|beta-galactosidase tetramermacologic aspects of neonat
P08922385A0622 |159 167|tetramern CSF [H
P08922385A0622 |145 151|detour08997A
P08922385A0622 |36 46|inhibitionine phosph
P08922390A0361 |71 79|paxillin P000081
P08922390A0361 |12 17|study76 Co
P08922390A0361 |60 67|domainsucleoti
P08922390A0361 |30 38|vinculin alkalin
P08922390A0361 |124 132|adhesionerbiliru
P08922390A0361 |109 117|paxillinof neona
P08922390A0361 |143 148|motif00089
P08922390A0793 |100 105|sites aspe
P08922390A0793 |151 158|stretch0472 Wh
P08922390A0793 |110 113|FAKf n
P08922390A0793 |27 35|presenceith alka
P08922390A0793 |166 177|amino acidsHCO3-] is s
P08922390A0793 |65 73|vinculintidase P
P08922390A0793 |6 10|data606T
P08922390A0793 |48 60|binding siteases and 5-n
P08922390A2076 |156 169|demonstrationWhen CSF [HCO
P08922390A2076 |245 257|localizationnger displac
P08922390A2076 |56 65|adhesions 5-nucleo
P08922390A2076 |28 36|paxillinth alkal
P08922390A2076 |225 232|proteinleted r
P08922390A2076 |210 221|determinante data of K
P08922390A2076 |173 184|LIM domainsis shown as
P08922390A2076 |6 10|data606T
P08922390A2076 |267 276|adhesionsmpared to
P08922390A2076 |81 93|interactionsT0000 Pharma
P08922390A2076 |99 107|vinculinc aspect
P08922390A2076 |115 118|FAKnat
P08922391A0304 |69 80|PDZ repeatsse P0000817
P08922391A0304 |28 37|structureth alkali
P08922391A0304 |90 96|PDZ1-2rmacol
P08922391A0304 |111 118|protein neonat
P08922391A0304 |131 135|siteubin
P08922391A0304 |52 60|entirety and 5-n
P08922488A0187 |35 44|treatmentline phos
P08922488A0187 |74 81|effects0008171
P08922488A0187 |8 14|agents6T0076
P08923258A0353 |0 7|JerseysP000016
P08923258A0353 |67 68|dd
P08923258A0353 |27 44|Cu concentrationsith alkaline phos
P08923258A0353 |54 63|Holsteinsnd 5-nucl
P08923460A0565 |137 144|cloningia. P00
P08923460A0565 |88 96|splicingharmacol
P08923460A0565 |45 57|RUSH-1 alphahatases and 
P08923460A0565 |0 11|RUSH-1 betaP00001606T0
P08923460A0565 |108 112|exon of 
P08923460A0565 |34 41|versionaline p
P08923469A1391 |55 63|polarityd 5-nucl
P08923469A1391 |163 175|half-elementF [HCO3-] is
P08923469A1391 |104 129|hormone response elementsects of neonatal hyperbil
P08923469A1391 |6 13|results606T007
P08923469A1391 |67 90|RXR heterodimer bindingdase P00008171T0000 Pha
P08923469A1391 |140 143|VDR P0
P08923470A0458 |0 22|PPAR gamma mRNA levelsP00001606T0076 Compari
P08923470A0458 |80 82|h.1T
P08923470A0458 |41 42|%h
P08923470A0458 |50 72|nM TNF alpha treatmentes and 5-nucleotidase 
P08924211A0941 |0 5|ExonsP0000
P08924211A0941 |109 114|typesof ne
P08924211A0941 |73 79|region000081
P08924211A0941 |42 48|regionosphat
P08924211A0941 |125 134|AST cDNAsrbilirubi
P08924211A0941 |118 121|PSTal 
P08924381T0000 |0 13|Growth factorP00001606T007
P08924381T0000 |46 53|regimenatases 
P08924381T0000 |66 88|breast cancer patientsidase P00008171T0000 P
P08925545T0001 |76 83|myeloma08171T0
P08925545T0001 |44 53|treatmentphatases 
P08925545T0001 |12 26|erythropoietin76 Comparison 
P08925545T0001 |28 35|r-HuEPOth alka
P08925545T0001 |57 63|anemia5-nucl
P08927169A0178 |119 143|Community Health Servicel hyperbilirubinemia. P0
P08927169A0178 |147 154|Utrecht997A047
P08927169A0178 |36 45|body liceine phosp
P08927169A0178 |76 84|patients08171T00
P08927169A0178 |92 98|clinicacolog
P08927169A0178 |64 69|timesotida
P08927169A0178 |21 30|infectionison with
P08927169A0178 |103 111|homelesspects of
P08927612T0000 |11 24|p53 mutations076 Compariso
P08927612T0000 |46 60|adenocarcinomaatases and 5-n
P08927841A0053 |16 20|dataompa
P08927841A0053 |88 96|activityharmacol
P08927841A0053 |120 130|occurrence hyperbili
P08927841A0053 |56 61|death 5-nu
P08929089A0231 |42 47|indexospha
P08929089A0231 |13 23|ratio M/Pc6 Comparis
P08929089A0231 |94 100|demandologic
P08929563T0000 |0 18|Rat liver catalaseP00001606T0076 Com
P08929563T0000 |106 123|Ser-Lys-Leu motifts of neonatal hy
P08929563T0000 |62 84|tripeptide Ala-Asn-Leuleotidase P00008171T00
P08929563T0000 |32 43|peroxisomeslkaline pho
P08931388A0806 |51 59|fragments and 5-
P08931388A0806 |131 135|bandubin
P08931388A0806 |167 173|sampleCO3-] 
P08931388A0806 |73 80|extract0000817
P08931388A0806 |35 37|bpli
P08931388A0806 |4 24|mobility shift assay01606T0076 Compariso
P08931388A0806 |103 109|samplepects 
P08931991A1026 |102 112|regulationspects of 
P08931991A1026 |26 34|evidencewith alk
P08931991A1026 |62 82|transcription factorleotidase P00008171T
P08931991A1026 |126 143|myosin expressionbilirubinemia. P0
P08931991A1026 |40 43|E2Fpho
P08931991A1026 |6 10|data606T
P08932363A0807 |51 73|squelshing experimentss and 5-nucleotidase P
P08932363A0807 |37 47|competitorne phospha
P08932363A0807 |9 23|E1A N-terminusT0076 Comparis
P08932363A0807 |134 144|E1A mutantnemia. P00
P08932363A0807 |99 109|activationc aspects 
P08932363A0807 |113 121|E2F1/DP1eonatal 
P08932363A0807 |153 172|CBP binding ability72 When CSF [HCO3-]
P08932385T0000 |6 18|Maf proteins606T0076 Com
P08932385T0000 |43 80|transcription factor TCF11/Nrf1/LCR-Fsphatases and 5-nucleotidase P0000817
P08933487A0325 |29 30|Wh
P08933487A0325 |60 63|runucl
P08933487A0325 |13 27|occasion water6 Comparison w
P08933640A0000 |119 126|rabbitsl hyper
P08933640A0000 |96 99|KBLogi
P08933640A0000 |23 32|ingestionon with a
P08933640A0000 |48 75|energy sweetener erythritolases and 5-nucleotidase P00
P08933640A0000 |4 10|effect01606T
P08933640A0000 |100 109|JW strain aspects 
P08934533A0784 |69 72|DNAse 
P08934533A0784 |52 56|junB and
P08934533A0784 |80 89|chromatin1T0000 Ph
P08934533A0784 |39 48|structure phosphat
P08934533A0784 |19 28|mutationsarison wi
P08934540A0673 |4 11|nm23-H101606T0
P08934540A0673 |41 55|activity ratiohosphatases an
P08934540A0673 |12 24|nm23-H2 gene76 Compariso
P08934540A0673 |80 89|cell line1T0000 Ph
P08935931A0787 |0 10|CONCLUSIONP00001606T
P08935931A0787 |195 198|EGD of
P08935931A0787 |90 94|SpO2rmac
P08935931A0787 |82 86|fall0000
P08935931A0787 |24 47|diazepam administrationn with alkaline phospha
P08935931A0787 |106 115|procedurets of neo
P08935931A0787 |168 172|SpO2O3-]
P08935931A0787 |55 58|EGDd 5
P08935931A0787 |154 164|monitoring2 When CSF
P08935991A0844 |168 173|sizesO3-] 
P08935991A0844 |72 82|% identityP00008171T
P08935991A0844 |181 188|introns as a f
P08935991A0844 |42 47|mouseospha
P08935991A0844 |58 60|CA-n
P08935991A0844 |131 141|boundariesubinemia. 
P08935991A0844 |4 33|nucleotide sequence alignment01606T0076 Comparison with al
P08935991A0844 |97 103|regiongic as
P08935991A0844 |64 69|showsotida
P08936128A0611 |0 11|DiscordanceP00001606T0
P08936128A0611 |61 65|G Hbcleo
P08936128A0611 |115 127|disagreementnatal hyperb
P08936128A0611 |94 101|controlologic 
P08936128A0611 |19 33|cost dimensionarison with al
P08936640A0105 |0 12|DATA SOURCESP00001606T00
P08936640A0105 |125 136|lung cancerrbilirubine
P08936640A0105 |109 121|epidemiologyof neonatal 
P08936640A0105 |28 35|studiesth alka
P08936640A0105 |37 53|research studiesne phosphatases 
P08936640A0105 |76 94|government reports08171T0000 Pharmac
P08936640A0105 |55 70|review articlesd 5-nucleotidas
P08937112A0561 |68 73|yearsase P
P08937112A0561 |13 29|age distribution6 Comparison wit
P08937112A0561 |54 58|meannd 5
P08937112A0561 |43 48|yearssphat
P08937112A0561 |0 7|RESULTSP000016
P08937631A1223 |137 146|relevanceia. P0000
P08937631A1223 |13 20|changes6 Compa
P08937631A1223 |180 191|vasculaturen as a func
P08937631A1223 |61 71|hemorrhagecleotidase
P08937631A1223 |154 164|remodeling2 When CSF
P08937631A1223 |41 56|cell involutionhosphatases and
P08937631A1223 |102 108|periodspects
P08937981A0840 |152 159|nucleus472 Whe
P08937981A0840 |105 108|p46cts
P08937981A0840 |123 126|p46per
P08937981A0840 |89 101|distributionarmacologic 
P08937981A0840 |13 26|co-expression6 Comparison 
P08937981A0840 |178 181|p54own
P08937981A0840 |43 55|p54 subunitssphatases an
P08937981A0840 |35 38|p46lin
P08937989A1365 |119 126|regionsl hyper
P08937989A1365 |134 141|proteinnemia. 
P08937989A1365 |73 78|talin00008
P08937989A1365 |62 69|regionsleotida
P08937989A1365 |44 45|Np
P08937989A1365 |4 11|results01606T0
P08937989A1365 |95 105|propertieslogic aspe
P08937989A1365 |84 89|actin00 Ph
P08938418A0099 |0 4|MerrP000
P08938418A0099 |7 21|embryo library06T0076 Compar
P08938420A0862 |85 91|sugars0 Phar
P08938420A0862 |4 16|accumulation01606T0076 C
P08938420A0862 |188 205|3-O-methylglucoseunction of CSF PC
P08938420A0862 |25 29|LHA4 wit
P08938420A0862 |63 71|additioneotidase
P08938420A0862 |138 150|sugar uptakea. P00008997
P08938420A0862 |101 110|inductionaspects o
P08938420A0862 |175 183|mannitol shown a
P08938420A0862 |223 240|mRNA accumulationepleted rats are 
P08938420A0862 |155 165|metabolism When CSF 
P08938420A0862 |34 44|LHA2 mRNAsaline phos
P08939891A0285 |50 53|NREes 
P08939891A0285 |10 15|yeast0076 
P08939891A0285 |122 125|Nrlype
P08939891A0285 |74 78|bait0008
P08939891A0285 |67 70|DNAdas
P08939891A0285 |27 33|screenith al
P08939891A0285 |96 101|cloneogic 
P08939966A0816 |102 114|mRNA declinespects of ne
P08939966A0816 |7 11|rate06T0
P08939966A0816 |15 32|protein synthesisComparison with a
P08939966A0816 |55 68|embryogenesisd 5-nucleotid
P08939966A0816 |80 85|SEC-11T000
P08939966A0816 |70 76|levelse P000
P08940132A1120 |239 244|CPP32 no l
P08940132A1120 |6 14|findings606T0076
P08940132A1120 |126 137|sensitivitybilirubinem
P08940132A1120 |28 46|fodrin proteolysisth alkaline phosph
P08940132A1120 |210 218|proteasee data o
P08940132A1120 |71 79|activity P000081
P08940132A1120 |141 149|DEVD-CHOP0000899
P08940132A1120 |248 267|DEVD-CHO inhibitionr displaced when co
P08940132A1120 |187 192|CPP32funct
P08940132A1120 |169 181|contribution3-] is shown
P08940132A1120 |102 111|proteasesspects of
P08940134A0705 |170 179|reticulum-] is sho
P08940134A0705 |11 14|3Y1076
P08940134A0705 |88 89|%h
P08940134A0705 |104 107|Casect
P08940134A0705 |99 103|p130c as
P08940134A0705 |126 135|membranesbilirubin
P08940134A0705 |109 120|co-sedimentof neonatal
P08940134A0705 |33 44|fibroblastskaline phos
P08940134A0705 |3 6|3Y1001
P08940134A0705 |70 75|PTP1Be P00
P08940298A0962 |137 145|receptoria. P000
P08940298A0962 |79 98|vitamin D3 receptor71T0000 Pharmacolog
P08940298A0962 |106 123|estrogen receptorts of neonatal hy
P08940298A0962 |30 38|delta419 alkalin
P08940298A0962 |58 69|AF-2 domain-nucleotida
P08940298A0962 |10 18|residues0076 Com
P08940298A0962 |184 192|activity a funct
P08942999T0000 |51 56|SREBPs and
P08942999T0000 |10 29|G-to-A substitution0076 Comparison wit
P08942999T0000 |134 158|hamster ovary cell linesnemia. P00008997A0472 Wh
P08942999T0000 |42 47|codonospha
P08942999T0000 |77 84|protein8171T00
P08942999T0000 |99 109|resistancec aspects 
P08943032A0000 |205 214|selectionO2 the da
P08943032A0000 |42 57|operator systemosphatases and 
P08943032A0000 |160 172|interactions CSF [HCO3-]
P08943032A0000 |36 40|TetRine 
P08943032A0000 |97 102|yeastgic a
P08943032A0000 |129 140|disruptionsirubinemia.
P08943032A0000 |114 119|assayonata
P08943032A0000 |80 89|variation1T0000 Ph
P08943032A0000 |21 34|tet-repressorison with alk
P08943354A0295 |35 40|SHP-1line 
P08943354A0295 |125 136|associationrbilirubine
P08943354A0295 |209 224|motheaten cellshe data of K-de
P08943354A0295 |166 186|hyperphosphorylationHCO3-] is shown as a
P08943354A0295 |7 14|studies06T0076
P08943354A0295 |246 251|SHP-1ger d
P08943354A0295 |146 157|Tyk2 kinase8997A0472 W
P08943354A0295 |55 63|functiond 5-nucl
P08943354A0295 |67 94|Jak family tyrosine kinasesdase P00008171T0000 Pharmac
P08943354A0295 |190 201|Jak kinasesction of CS
P08943928A1137 |0 14|AdministrationP00001606T0076
P08943928A1137 |54 62|outbreaknd 5-nuc
P08943928A1137 |27 31|doseith 
P08943928A1137 |35 42|vaccineline ph
P08943934A0604 |54 62|exposurend 5-nuc
P08943934A0604 |8 17|Theriault6T0076 Co
P08943934A0604 |28 40|improvementsth alkaline 
P08943934A0604 |113 121|findingseonatal 
P08944755A0211 |0 4|BiolP000
P08945479T0000 |68 92|tyrosine phosphorylationase P00008171T0000 Pharm
P08945479T0000 |41 62|lymphocyte kinase Lckhosphatases and 5-nuc
P08945479T0000 |11 16|basis076 C
P08945479T0000 |21 31|activationison with 
P08945810T0001 |38 42|bulbe ph
P08945810T0001 |72 79|mammalsP000081
P08945810T0001 |46 49|manata
P08945810T0001 |10 20|morphology0076 Compa
P08946166A0568 |54 63|FRDS genend 5-nucl
P08946166A0568 |11 18|results076 Com
P08946166A0568 |43 46|ORFsph
P08946668A0077 |0 5|FK506P0000
P08946668A0077 |93 101|toxicitycologic 
P08946668A0077 |42 55|cyclosporin Aosphatases an
P08946668A0077 |70 85|organ rejectione P00008171T000
P08947028A0992 |98 103|Pkc1pic as
P08947028A0992 |88 93|Bni1pharma
P08947028A0992 |27 32|Rho1pith a
P08947028A0992 |56 70|reorganization 5-nucleotidas
P08947028A0992 |6 13|results606T007
P08948440A0628 |50 53|An3es 
P08948440A0628 |78 95|animal hemisphere171T0000 Pharmaco
P08948440A0628 |99 106|oocytesc aspec
P08948440A0628 |142 148|embryo000089
P08948440A0628 |4 26|ERH expression profile01606T0076 Comparison 
P08950144A0172 |17 20|CNVmpa
P08950144A0172 |44 56|CNV paradigmphatases and
P08950144A0172 |138 141|seca. 
P08950144A0172 |128 131|ISIlir
P08950144A0172 |10 12|P300
P08950144A0172 |118 126|intervalal hyper
P08950144A0172 |69 87|reaction time taskse P00008171T0000 
P08950144A0172 |0 8|Waves N1P0000160
P08950352A0525 |174 186|significances shown as a
P08950352A0525 |45 52|sampleshatases
P08950352A0525 |106 111|ratests of
P08950352A0525 |149 153|area7A04
P08950352A0525 |211 215|test dat
P08950352A0525 |76 81|areas08171
P08950352A0525 |130 134|onesrubi
P08950352A0525 |188 189|pu
P08951815A0465 |0 10|RegulationP00001606T
P08951815A0465 |14 18|ASN1 Com
P08951815A0465 |110 115|timesf neo
P08951815A0465 |57 69|lacZ fusions5-nucleotida
P08951815A0465 |79 84|genes71T00
P08951815A0465 |138 145|absencea. P000
P08951815A0465 |23 38|ASN2 expressionon with alkalin
P08951815A0465 |153 182|transcription activator Gcn4p72 When CSF [HCO3-] is shown 
P08952483A0207 |19 27|featuresarison w
P08952483A0207 |133 141|assemblyinemia. 
P08952483A0207 |150 156|enzymeA0472 
P08952483A0207 |66 95|hamster lysyl-tRNA synthetaseidase P00008171T0000 Pharmaco
P08952483A0207 |36 56|polypeptide fragmentine phosphatases and
P08952483A0207 |168 191|multisynthetase complexO3-] is shown as a func
P08952796A0743 |17 22|yearsmpari
P08952796A0743 |29 36|relapseh alkal
P08952965A1182 |0 10|ComparisonP00001606T
P08952965A1182 |211 213|pN d
P08952965A1182 |230 249|MHC contact regions rats are no longer
P08952965A1182 |47 49|pNta
P08952965A1182 |18 28|proportionparison wi
P08952965A1182 |156 165|reductionWhen CSF 
P08952965A1182 |251 255|CDR1ispl
P08952965A1182 |260 264|CDR2when
P08952965A1182 |179 196|framework regionswn as a function 
P08952965A1182 |67 69|pSda
P08952965A1182 |111 118|tamarin neonat
P08952965A1182 |128 140|region geneslirubinemia.
P08952965A1182 |71 84|substitutions P00008171T00
P08952965A1182 |99 103|sitec as
P08952965A1182 |169 171|pN3-
P08953340A0000 |100 111|performance aspects of
P08953340A0000 |193 219|weight-training volunteerson of CSF PCO2 the data of
P08953340A0000 |63 76|anthropometryeotidase P000
P08953340A0000 |37 42|VOSO4ne ph
P08953340A0000 |78 94|body composition171T0000 Pharmac
P08953340A0000 |177 182|trialhown 
P08953340A0000 |4 11|effects01606T0
P08953340A0000 |20 35|vanadyl sulfaterison with alka
P08953340A0000 |49 58|mg/kg/dayses and 5
P08954725A1175 |139 145|source. P000
P08954725A1175 |9 20|developmentT0076 Compa
P08954725A1175 |125 131|streakrbilir
P08954725A1175 |149 157|mesoderm7A0472 W
P08954725A1175 |22 37|Tbx6 expressionson with alkali
P08954725A1175 |76 84|mesoderm08171T00
P08954725A1175 |96 104|tail budogic asp
P08955071T0000 |0 10|DisruptionP00001606T
P08955071T0000 |14 36|re-replication control Comparison with alkal
P08955071T0000 |40 54|overexpressionphosphatases a
P08955071T0000 |72 85|fission yeastP00008171T000
P08955071T0000 |64 68|ORC1otid
P08955111A0989 |154 180|activin betaA subunit gene2 When CSF [HCO3-] is show
P08955111A0989 |46 62|enhancer regionsatases and 5-nuc
P08955111A0989 |4 11|results01606T0
P08955111A0989 |123 140|promoter activityperbilirubinemia.
P08955111A0989 |33 41|promoterkaline p
P08955136A0606 |35 46|PIP5KIalphaline phosph
P08955136A0606 |57 71|PIP5K activity5-nucleotidase
P08955136A0606 |110 127|PIP5KI antibodiesf neonatal hyperb
P08955159A0000 |6 21|acid ceramidase606T0076 Compar
P08955159A0000 |62 64|ECle
P08955159A0000 |28 60|N-acylsphingosine amidohydrolaseth alkaline phosphatases and 5-n
P08955159A0000 |24 26|ACn 
P08955189A1198 |137 164|EGR-1 transcription factorsia. P00008997A0472 When CSF
P08955189A1198 |12 31|NheI/BglII promoter76 Comparison with 
P08955189A1198 |107 114|elements of ne
P08955189A1198 |129 132|Sp1iru
P08955189A1198 |42 58|PMA inducibilityosphatases and 5
P08955189A1198 |70 75|cellse P00
P08955306A0224 |0 8|NorthernP0000160
P08955306A0224 |10 13|RNA007
P08955306A0224 |165 171|growth[HCO3-
P08955306A0224 |15 28|blot analysesComparison wi
P08955306A0224 |97 110|reading framegic aspects o
P08955306A0224 |76 84|subunits08171T00
P08955306A0224 |131 139|functionubinemia
P08955306A0224 |175 182|acetate shown 
P08955306A0224 |112 116|ORF1neon
P08955306A0224 |48 57|cdh genesases and 
P08955402A0288 |84 88|HOL100 P
P08955402A0288 |74 80|region000817
P08955402A0288 |105 112|abilitycts of 
P08955402A0288 |15 24|mutationsCompariso
P08955402A0288 |188 205|HOL1-1 backgroundunction of CSF PC
P08955402A0288 |124 134|histidinolerbilirubi
P08955402A0288 |240 252|Hol1 proteinno longer di
P08955402A0288 |156 165|mutationsWhen CSF 
P08955402A0288 |4 11|classes01606T0
P08955402A0288 |222 232|expressiondepleted r
P08955928A0390 |0 6|DamageP00001
P08955928A0390 |14 17|BBB Co
P08955928A0390 |123 128|onsetperbi
P08955928A0390 |132 136|MCAobine
P08955928A0390 |61 63|EBcl
P08955928A0390 |32 45|extravasationlkaline phosp
P08955928A0390 |115 116|hn
P08955928A0390 |49 59|Evans Blueses and 5-
P08958137A0534 |0 26|Lipid hydroperoxide levelsP00001606T0076 Comparison 
P08958137A0534 |41 44|LDLhos
P08958137A0534 |30 36|plasma alkal
P08958137A0534 |79 84|study71T00
P08958720A1204 |19 27|exercisearison w
P08958720A1204 |41 45|mPAPhosp
P08958720A1204 |106 109|VO2ts 
P08958720A1204 |62 65|SVIleo
P08958720A1204 |77 79|HR81
P08958720A1204 |9 15|degreeT0076 
P08958720A1204 |99 101|COc 
P08959062A0372 |100 113|immunodeficit aspects of n
P08959062A0372 |12 16|case76 C
P08959062A0372 |122 125|EBVype
P08959062A0372 |75 84|discovery008171T00
P08959062A0372 |20 30|vasculitisrison with
P08959062A0372 |148 156|syndrome97A0472 
P08959062A0372 |138 145|Purtiloa. P000
P08959117A0708 |102 109|diseasespects 
P08959117A0708 |125 135|influencesrbilirubin
P08959117A0708 |41 48|changeshosphat
P08959117A0708 |249 252|REF di
P08959117A0708 |232 247|reference groupats are no long
P08959117A0708 |172 184|measurements is shown as
P08959117A0708 |69 79|hypoxaemiase P000081
P08959117A0708 |155 166|ICU setting When CSF [
P08959117A0708 |289 299|hypoxaemia still hav
P08959778A0292 |98 101|EGFic 
P08959778A0292 |107 110|DGFs o
P08959778A0292 |41 55|graft survivalhosphatases an
P08959778A0292 |26 37|differenceswith alkali
P08959778A0292 |148 166|retransplantations97A0472 When CSF [
P08959778A0292 |82 96|graft function0000 Pharmacol
P08959778A0292 |128 144|transplantationslirubinemia. P00
P08959778A0292 |64 70|groupsotidas
P08960827A1169 |119 130|associationl hyperbili
P08960827A1169 |6 13|results606T007
P08960827A1169 |76 89|transcription08171T0000 Ph
P08960827A1169 |181 187|factor as a 
P08960827A1169 |33 42|GG motifskaline ph
P08960827A1169 |140 147|binding P00008
P08960827A1169 |103 115|insulin genepects of neo
P08961873T0000 |17 38|coproporphyrin levelsmparison with alkalin
P08961873T0000 |42 50|patientsosphatas
P08961873T0000 |63 80|hepatitis C viruseotidase P0000817
P08961873T0000 |103 125|immunodeficiency viruspects of neonatal hype
P08962614A0000 |186 197|individuals function o
P08962614A0000 |94 110|skin-prick testsologic aspects o
P08962614A0000 |73 89|laboratory tests00008171T0000 Ph
P08962614A0000 |44 54|antibodiesphatases a
P08962614A0000 |39 42|IgE ph
P08962614A0000 |233 241|childrents are n
P08962614A0000 |129 149|challenge proceduresirubinemia. P0000899
P08962614A0000 |21 37|immunoglobulin Eison with alkali
P08962614A0000 |4 17|determination01606T0076 Co
P08962614A0000 |204 222|outcome predictorsCO2 the data of K-
P08964067A0188 |0 10|ThrombosisP00001606T
P08964067A0188 |63 70|failureeotidas
P08964067A0188 |24 28|veinn wi
P08964172A0221 |0 6|FilterP00001
P08964172A0221 |11 38|cytocentrifuge preparations076 Comparison with alkalin
P08964172A0221 |46 51|urineatase
P08964172A0221 |73 78|cases00008
P08964172A0221 |108 118|aggregates of neonat
P08964172A0221 |160 170|background CSF [HCO3
P08964172A0221 |129 140|tumor cellsirubinemia.
P08967870A0000 |54 72|Moscow hospitals Nnd 5-nucleotidase 
P08967870A0000 |12 21|protocols76 Compar
P08967870A0000 |25 48|postmortem examinations with alkaline phosphat
P08967963A1735 |4 20|promoter segment01606T0076 Compa
P08967963A1735 |150 172|beta cell line RIN-5AHA0472 When CSF [HCO3-]
P08967963A1735 |135 138|ratemi
P08967963A1735 |90 93|ratrma
P08967963A1735 |59 84|rat glioma cell line C6B4nucleotidase P00008171T00
P08967963A1735 |108 125|cell line RSMT-A5 of neonatal hype
P08967963A1735 |217 232|alpha2c-AR geneof K-depleted r
P08969495A0256 |222 227|locusdeple
P08969495A0256 |209 213|rolehe d
P08969495A0256 |122 131|mutationsyperbilir
P08969495A0256 |75 87|nrdE cistron008171T0000 
P08969495A0256 |176 180|nrdFshow
P08969495A0256 |41 56|mutation ts-A13hosphatases and
P08969495A0256 |167 171|nrdECO3-
P08969495A0256 |157 163|regionhen CS
P08969495A0256 |97 106|lethalitygic aspec
P08969495A0256 |4 14|sequencing01606T0076
P08969777A0771 |68 76|patientsase P000
P08969777A0771 |159 165|degreen CSF 
P08969777A0771 |108 134|serum 25-OHD concentration of neonatal hyperbilirubi
P08969777A0771 |53 64|differencesand 5-nucle
P08969777A0771 |23 29|scoreson wit
P08969777A0771 |169 178|paralysis3-] is sh
P08970352A0880 |51 55|risks an
P08970352A0880 |59 70|progressionnucleotidas
P08970352A0880 |74 78|MSOF0008
P08970352A0880 |30 33|use al
P08970352A0880 |82 88|sepsis0000 P
P08970352A0880 |37 40|LDDne 
P08970352A0880 |6 10|data606T
P08970951A0823 |117 129|Pol proteinstal hyperbil
P08970951A0823 |108 112|core of 
P08970951A0823 |29 35|levelsh alka
P08970951A0823 |62 69|antigenleotida
P08970951A0823 |98 104|levelsic asp
P08970951A0823 |146 167|HBV DNA intermediates8997A0472 When CSF [H
P08970951A0823 |48 59|hepatitis Bases and 5-
P08970979A1246 |137 145|promoteria. P000
P08970979A1246 |76 89|transcription08171T0000 Ph
P08970979A1246 |108 116|template of neon
P08970979A1246 |13 21|extracts6 Compar
P08970979A1246 |36 43|virionsine pho
P08970979A1246 |67 72|leveldase 
P08970979A1246 |3 11|contrast001606T0
P08970984A0765 |85 88|SRF0 P
P08970984A0765 |90 102|Rel/NFkappaBrmacologic a
P08970984A0765 |4 18|SCMV SNE sites01606T0076 Com
P08970984A0765 |113 144|YY1 class transcription factorseonatal hyperbilirubinemia. P00
P08970984A0765 |104 107|ETSect
P08970984A0765 |49 80|core recognition binding motifsses and 5-nucleotidase P0000817
P08970984A0765 |175 180|serum show
P08970984A0765 |184 211|tumor necrosis factor alpha a function of CSF PCO2 the
P08970991A0747 |99 100|%c
P08970991A0747 |40 51|temperaturephosphatase
P08970991A0747 |66 75|apoptosisidase P00
P08970991A0747 |108 113|cells of n
P08970991A0747 |5 21|serum withdrawal1606T0076 Compar
P08971009A0860 |19 26|problemarison 
P08971009A0860 |46 54|strategyatases a
P08971009A0860 |165 169|loci[HCO
P08971009A0860 |114 122|sequenceonatal h
P08971009A0860 |97 102|sitesgic a
P08971009A0860 |185 196|DNA genomesa function 
P08971721A1314 |70 74|HspAe P0
P08971721A1314 |60 66|domainucleot
P08971721A1314 |110 116|domainf neon
P08971721A1314 |28 35|studiesth alka
P08971721A1314 |7 12|basis06T00
P08971835A1057 |3 8|Group00160
P08971835A1057 |31 40|alpha-MSHalkaline 
P08971835A1057 |109 110|%o
P08971835A1057 |12 16|dogs76 C
P08971835A1057 |149 167|reperfusion period7A0472 When CSF [H
P08971835A1057 |53 64|reperfusionand 5-nucle
P08971835A1057 |124 132|Group IIerbiliru
P08971835A1057 |66 71|BAEPsidase
P08972182A0000 |101 106|hoursaspec
P08972182A0000 |110 132|receptor cross-linkingf neonatal hyperbiliru
P08972182A0000 |28 46|signalling cascadeth alkaline phosph
P08972182A0000 |4 16|Fas receptor01606T0076 C
P08972182A0000 |83 92|apoptosis000 Pharm
P08972182A0000 |71 81|cell death P00008171
P08972182A0527 |186 221|tetrapeptide ICE inhibitor YVAD-CMK function of CSF PCO2 the data of K
P08972182A0527 |231 269|tripeptide pan-ICE inhibitor Z-VAD-FMKrats are no longer displaced when comp
P08972182A0527 |73 89|family proteases00008171T0000 Ph
P08972182A0527 |30 33|ICE al
P08972182A0527 |100 109|apoptosis aspects 
P08972182A0527 |115 122|studiesnatal h
P08972182A0527 |65 71|enzymetidase
P08972182A0527 |0 3|FasP00
P08972182A0527 |35 48|interleukin-1line phosphat
P08972182A0527 |137 170|cowpox ICE inhibitor protein CrmAia. P00008997A0472 When CSF [HCO3
P08972211A0059 |137 145|sequenceia. P000
P08972211A0059 |72 76|miceP000
P08972211A0059 |149 151|kb7A
P08972211A0059 |14 24|expression Compariso
P08972211A0059 |43 47|genespha
P08972211A0059 |94 103|transgeneologic as
P08972211A0059 |167 175|sequenceCO3-] is
P08972211A0059 |218 227|enhancersf K-deple
P08972211A0059 |266 270|geneompa
P08972211A0059 |119 121|kbl 
P08972232A0365 |99 104|yGCN5c asp
P08972232A0365 |74 95|substrate specificity0008171T0000 Pharmaco
P08972232A0365 |36 41|hGCN5ine p
P08972232A0365 |8 14|report6T0076
P08972232A0365 |53 56|HATand
P08973185T0061 |50 65|phosphorylationes and 5-nucleo
P08973185T0061 |18 36|arginine mutationsparison with alkal
P08973185T0061 |4 10|effect01606T
P08973185T0061 |70 84|AAC expressione P00008171T00
P08973527A0000 |136 140|HoMVmia.
P08973527A0000 |36 48|coat proteinine phosphat
P08973527A0000 |104 108|AgMVects
P08973527A0000 |14 18|DNAs Com
P08973527A0000 |114 134|Hordeum mosaic virusonatal hyperbilirubi
P08973527A0000 |80 102|Agropyron mosaic virus1T0000 Pharmacologic a
P08973527A0000 |69 76|regionsse P000
P08973630A0923 |117 131|Rac activationtal hyperbilir
P08973630A0923 |91 107|Cdc42 activationmacologic aspect
P08973630A0923 |30 44|Rac activation alkaline phos
P08973630A0923 |8 13|cases6T007
P08973630A0923 |56 70|Rho activation 5-nucleotidas
P08973630A0923 |173 180|changesis show
P08973917A0632 |8 13|cDNAs6T007
P08973917A0632 |41 50|PWP2 genehosphatas
P08973917T0000 |0 9|IsolationP00001606
P08973917T0000 |73 91|tryptophan protein00008171T0000 Phar
P08973917T0000 |58 63|yeast-nucl
P08973917T0000 |43 50|homologsphatas
P08973917T0000 |95 99|PWP2logi
P08973917T0000 |101 113|gene mappingaspects of n
P08973917T0000 |22 31|structureson with 
P08973917T0000 |117 124|21q22.3tal hyp
P08974103A0451 |119 124|all-2l hyp
P08974103A0451 |56 74|laboratory results 5-nucleotidase P0
P08974103A0451 |107 110|PEMs o
P08974103A0451 |134 141|patternnemia. 
P08974103A0451 |20 32|combinationsrison with a
P08974103A0451 |93 103|likelihoodcologic as
P08974103A0451 |0 8|PatternsP0000160
P08974135A0052 |137 145|patientsia. P000
P08974135A0052 |29 39|vitamin B1h alkaline
P08974135A0052 |90 100|stomatitisrmacologic
P08974135A0052 |191 198|memberstion of
P08974135A0052 |113 130|vitamin B1 levelseonatal hyperbili
P08974135A0052 |41 51|deficiencyhosphatase
P08974135A0052 |170 180|stomatitis-] is show
P08974135A0052 |19 27|thiaminearison w
P08974135A0052 |204 217|control groupCO2 the data 
P08975532T0001 |0 14|Liver injuriesP00001606T0076
P08975713A0454 |35 40|probeline 
P08975713A0454 |208 222|p53p2 promoterthe data of K-
P08975713A0454 |135 139|cDNAemia
P08975713A0454 |15 27|cDNA libraryComparison w
P08975713A0454 |158 162|mRNAen C
P08975713A0454 |82 98|p53p2 start site0000 Pharmacolog
P08975713A0454 |54 63|sequencesnd 5-nucl
P08976253A0637 |68 85|plasma PSA levelsase P00008171T000
P08976253A0637 |30 41|correlation alkaline p
P08976253A0637 |50 55|serumes an
P08977013A0788 |70 81|differencese P00008171
P08977013A0788 |108 114|foveal of ne
P08977013A0788 |130 136|visionrubine
P08977013A0788 |89 104|specializationsarmacologic asp
P08977013A0788 |4 16|implications01606T0076 C
P08977013A0788 |43 56|magnificationsphatases and
P08977013A0788 |21 30|estimatesison with
P08977235A0134 |0 5|G-CSFP0000
P08977235A0134 |60 64|JAK1ucle
P08977235A0134 |35 44|moleculesline phos
P08977235A0134 |90 116|STAT transcription factorsrmacologic aspects of neon
P08977235A0134 |69 81|JAK2 kinasesse P00008171
P08977235A0588 |0 7|MutantsP000016
P08977235A0588 |79 86|ability71T0000
P08977235A0588 |166 182|STAT1 activationHCO3-] is shown 
P08977235A0588 |135 140|STAT3emia.
P08977235A0588 |20 37|tyrosine residuesrison with alkali
P08977235A0588 |57 63|domain5-nucl
P08977235A0588 |109 114|STAT1of ne
P08977235A0588 |200 233|receptor tyrosine phosphorylationSF PCO2 the data of K-depleted ra
P08977235A0588 |99 104|STAT5c asp
P08977235A0588 |156 161|STAT5When 
P08977401A0227 |341 353|leader exons0.23 vs. P00
P08977401A0227 |361 365|rise733 
P08977401A0227 |62 69|lengthsleotida
P08977401A0227 |389 403|messenger RNAsto be an effec
P08977401A0227 |45 50|exonshatas
P08977401A0227 |84 91|introns00 Phar
P08977401A0227 |117 123|lengthtal hy
P08977401A0227 |154 161|cloning2 When 
P08977401A0227 |217 223|regionof K-d
P08977401A0227 |263 271|RI alphan compar
P08977401A0227 |177 196|RI alpha pseudogenehown as a function 
P08977401A0227 |286 289|RNAbut
P08977401A0227 |104 108|geneects
P08977401A0227 |405 410|mRNAsve hy
P08977401A0227 |4 17|RI alpha gene01606T0076 Co
P08977401A0227 |309 322|RI alpha geneicantly great
P08977401A0227 |139 141|kb. 
P08978690A0262 |17 26|Rad3/Mec1mparison 
P08978690A0262 |49 56|proteinses and
P08978690A0262 |121 140|yeast model systemshyperbilirubinemia.
P08978690A0262 |87 112|DNA structure checkpointsPharmacologic aspects of 
P08978817A0620 |69 95|endocytosis mutants end4-1se P00008171T0000 Pharmaco
P08978817A0620 |126 140|growth defectsbilirubinemia.
P08978817A0620 |40 50|dim1-deltaphosphatas
P08978817A0620 |54 60|dim2-1nd 5-n
P08978817A0620 |20 27|mutantsrison w
P08978817A0620 |162 179|DIM gene productsSF [HCO3-] is sho
P08978817A0620 |3 11|addition001606T0
P08978817A0620 |99 105|act1-1c aspe
P08978817A0620 |223 230|pathwayepleted
P08978996A0000 |204 213|infectionCO2 the d
P08978996A0000 |57 62|cause5-nuc
P08978996A0000 |26 43|hepatitis C viruswith alkaline pho
P08978996A0000 |183 189|impacts a fu
P08978996A0000 |88 105|dialysis patientsharmacologic aspe
P08978996A0000 |66 79|liver diseaseidase P000081
P08978996A0000 |162 174|epidemiologySF [HCO3-] i
P08978996A0000 |145 154|attention08997A047
P08978996A0000 |4 18|identification01606T0076 Com
P08978996A0000 |113 132|transplant patientseonatal hyperbiliru
P08978996A0000 |223 237|patient groupsepleted rats a
P08979089A1197 |205 223|Ig kappa enhancersO2 the data of K-d
P08979089A1197 |124 132|Sp1 siteerbiliru
P08979089A1197 |72 95|core promoter mutationsP00008171T0000 Pharmaco
P08979089A1197 |172 182|activation is shown 
P08979089A1197 |7 19|transfection06T0076 Comp
P08979089A1197 |27 44|BL cell line Rajiith alkaline phos
P08979089A1197 |50 60|constructses and 5-n
P08979089A1197 |141 149|TATA boxP0000899
P08979089A1197 |186 197|promoter P1 function o
P08979828A1561 |18 30|interactionsparison with
P08979828A1561 |54 62|behaviornd 5-nuc
P08980413A0500 |19 25|ppSEPsarison
P08980413A0500 |12 15|N2276 
P08980413A0500 |74 76|N200
P08980413A0500 |30 57|phase reversal relationship alkaline phosphatases and 
P08980413A0500 |67 69|P2da
P08980413A0500 |95 98|PESlog
P08980413A0500 |4 7|P13016
P08980522A0280 |4 8|cDNA0160
P08980522A0280 |43 50|proteinsphatas
P08980522A0280 |12 16|cpm776 C
P08980522A0280 |59 62|kDanuc
P08980533A1160 |34 39|ENBP1aline
P08980533A1160 |67 74|proteindase P0
P08980533A1160 |24 30|regionn with
P08980533A1160 |80 83|rat1T0
P08980533A1160 |53 61|homologyand 5-nu
P08980533A1160 |118 131|testis tissueal hyperbilir
P08980536A1196 |4 16|conservation01606T0076 C
P08980536A1196 |89 99|importancearmacologi
P08980536A1196 |29 34|G-boxh alk
P08980536A1196 |39 44|H-box phos
P08980536A1196 |58 71|CHS promoters-nucleotidase
P08980536A1196 |114 120|motifsonatal
P08980819A0193 |0 9|MortalityP00001606
P08980819A0193 |123 128|birdsperbi
P08980819A0193 |134 139|birdsnemia
P08980819A0193 |163 168|eventF [HC
P08980819A0193 |77 83|groups8171T0
P08980819A0193 |109 113|tomsof n
P08980819A0193 |188 200|inseminationunction of C
P08980819A0193 |22 27|ranchson w
P08980819A0193 |87 94|turkeysPharmac
P08981371A2049 |78 93|CSF-1 treatment171T0000 Pharma
P08981371A2049 |40 51|kDa proteinphosphatase
P08981371A2049 |14 26|PIP2 content Comparison 
P08981371A2049 |14 26|PIP2 content Comparison 
P08981371A2049 |78 93|CSF-1 treatment171T0000 Pharma
P08981371A2049 |40 51|kDa proteinphosphatase
P08985109A1285 |49 53|apexses 
P08985109A1285 |67 72|crestdase 
P08985109A1285 |38 44|margine phos
P08985109A1285 |97 103|aspectgic as
P08985109A1285 |115 119|conenata
P08985115A1571 |274 284|metastasisto control
P08985115A1571 |145 149|gene0899
P08985115A1571 |92 96|stepacol
P08985115A1571 |108 117|isolation of neona
P08985115A1571 |10 24|identification0076 Compariso
P08985115A1571 |72 77|studyP0000
P08985115A1571 |39 53|37LRP/p40 gene phosphatases 
P08985115A1571 |158 171|understandingen CSF [HCO3-
P08985115A1571 |189 199|mechanismsnction of 
P08985115A1571 |237 247|expressionre no long
P08985115A1571 |216 229|up-regulation of K-deplete
P08985115A1571 |255 269|tumor invasionaced when comp
P08985122A0501 |238 248|CpG islande no longe
P08985122A0501 |51 56|groups and
P08985122A0501 |324 329|genes slop
P08985122A0501 |21 23|P1is
P08985122A0501 |113 123|CAAT boxeseonatal hy
P08985122A0501 |215 216|Ga
P08985122A0501 |60 90|transcription initiation sitesucleotidase P00008171T0000 Pha
P08985122A0501 |163 187|transcription factor SP1F [HCO3-] is shown as a 
P08985122A0501 |226 232|domaineted r
P08985122A0501 |104 108|TATAects
P08985122A0501 |4 19|promoter region01606T0076 Comp
P08985122A0501 |141 154|binding sitesP00008997A047
P08985122A0501 |273 282|promoters to contr
P08985415A1096 |51 60|mechanisms and 5-n
P08985415A1096 |108 117|monocytes of neona
P08985415A1096 |95 104|IFN-gammalogic asp
P08985415A1096 |65 75|activationtidase P00
P08985415A1096 |83 91|CAEV LTR000 Phar
P08985415A1096 |4 28|STAT-1 signaling pathway01606T0076 Comparison wi
P08986190A0927 |0 11|ReperfusionP00001606T0
P08986190A0927 |31 40|reductionalkaline 
P08986190A0927 |93 104|LDH releasecologic asp
P08986190A0927 |44 62|lactate productionphatases and 5-nuc
P08986190A0927 |81 89|increaseT0000 Ph
P08986214A0000 |102 110|patientsspects o
P08986214A0000 |133 142|hepatitisinemia. P
P08986214A0000 |88 92|seraharm
P08986214A0000 |73 86|liver disease00008171T0000
P08986214A0000 |150 159|cirrhosisA0472 Whe
P08986214A0000 |37 45|responsene phosp
P08986214A0000 |178 202|hepatocyte growth factorown as a function of CSF
P08986214A0000 |213 230|alpha-fetoproteinata of K-depleted
P08986214A0000 |49 57|patientsses and 
P08986214A0000 |232 235|AFPats
P08986214A0000 |204 207|HGFCO2
P08986228A0000 |0 8|ChildrenP0000160
P08986228A0000 |79 86|effects71T0000
P08986228A0000 |122 135|malformationsyperbilirubin
P08986228A0000 |37 44|mothersne phos
P08986692A0306 |0 12|INTERVENTIONP00001606T00
P08986692A0306 |74 82|patients0008171T
P08986692A0306 |28 49|hemostasis parametersth alkaline phosphata
P08986692A0306 |13 14|S6
P08986692A0306 |94 100|IVF-ETologic
P08986770A0268 |152 166|splice variant472 When CSF [
P08986770A0268 |129 134|I-POUirubi
P08986770A0268 |92 97|phaseacolo
P08986770A0268 |20 30|expressionrison with
P08986770A0268 |112 123|developmentneonatal hy
P08986770A0268 |38 58|I-POU/tI-POU messagee phosphatases and 5
P08986812A1214 |17 20|p53mpa
P08986812A1214 |91 101|cell linesmacologic 
P08986812A1214 |45 49|cDNAhata
P08986812A1214 |26 37|delta proAEwith alkali
P08986812A1214 |133 140|effectsinemia.
P08986812A1214 |77 82|tumor8171T
P08987009A0400 |100 113|psychoanalyst aspects of n
P08987009A0400 |14 18|role Com
P08987009A0400 |65 72|freedomtidase 
P08987009A0400 |37 50|prerequisitesne phosphatas
P08987009A0400 |4 11|patient01606T0
P08987225A0675 |16 27|risk factoromparison w
P08987225A0675 |165 172|history[HCO3-]
P08987225A0675 |135 145|proportionemia. P000
P08987225A0675 |91 98|historymacolog
P08987225A0675 |67 84|hepatitis C casesdase P00008171T00
P08987225A0675 |198 201|ACT CS
P08987225A0675 |149 154|cases7A047
P08987225A0675 |190 192|NTct
P08987225A0675 |112 120|drug useneonatal
P08987225A0675 |206 216|Queensland2 the data
P08988257A1256 |119 124|yeastl hyp
P08988257A1256 |58 60|kb-n
P08988257A1256 |43 51|telomeresphatase
P08988257A1256 |29 37|creationh alkali
P08988257A1256 |135 150|repeat sequenceemia. P00008997
P08988257A1256 |113 115|bpeo
P08988257A1256 |96 105|insertionogic aspe
P08988257A1256 |159 163|siten CS
P08988257A1256 |184 194|truncation a functio
P08988257A1256 |70 88|reporter constructe P00008171T0000 P
P08988257A1256 |0 9|SilencingP00001606
P08988913A0821 |35 41|modelsline p
P08988913A0821 |43 53|provisionssphatases 
P08988913A0821 |95 111|folate excretionlogic aspects of
P08988913A0821 |75 83|turnover008171T0
P08988913A0821 |3 11|contrast001606T0
P08988913A0821 |144 153|excretion008997A04
P08988913A0821 |168 177|processesO3-] is s
P08989025A0359 |152 161|responses472 When 
P08989025A0359 |27 35|channelsith alka
P08989025A0359 |22 25|Ca2son
P08989025A0359 |111 117|microM neona
P08989025A0359 |58 68|nifedipine-nucleotid
P08989025A0359 |70 79|midazolame P000081
P08989025A0359 |37 40|VOCne 
P08989025A0359 |84 98|concentrations00 Pharmacolog
P08989763A0605 |69 78|diaphragmse P00008
P08989763A0605 |8 17|artifacts6T0076 Co
P08989763A0605 |48 61|visualizationases and 5-nu
P08990168A0688 |70 75|STAT1e P00
P08990168A0688 |44 49|STAT1phata
P08990168A0688 |93 97|GATEcolo
P08990168A0688 |9 27|p48 gene inductionT0076 Comparison w
P08990168A0688 |54 58|JAK1nd 5
P08990194A0000 |16 26|resistanceomparison 
P08990194A0000 |75 80|serum00817
P08990194A0000 |30 45|thyroid hormone alkaline phosp
P08990194A0000 |104 111|failureects of
P08990194A0000 |181 195|refractoriness as a function
P08990194A0000 |134 155|thyrotropin secretionnemia. P00008997A0472
P08990194A0000 |4 12|syndrome01606T00
P08990194A0000 |199 213|hormone actionCSF PCO2 the d
P08990194A0000 |86 102|thyroid hormones Pharmacologic a
P08990397A1437 |85 88|H130 P
P08990397A1437 |132 146|RNA processingbinemia. P0000
P08990397A1437 |27 34|mutantsith alk
P08990397A1437 |63 74|photosystemeotidase P0
P08990397A1437 |103 111|evidencepects of
P08992115A0199 |223 226|airepl
P08992115A0199 |147 156|serotonin997A0472 
P08992115A0199 |132 137|bloodbinem
P08992115A0199 |88 108|acute-phase proteinsharmacologic aspects
P08992115A0199 |110 124|KKS activationf neonatal hyp
P08992115A0199 |25 35|bronchitis with alka
P08992115A0199 |161 180|lactic acid contentCSF [HCO3-] is show
P08992115A0199 |4 15|progression01606T0076 
P08992115A0199 |188 193|humoruncti
P08992115A0199 |64 84|blood concentrationsotidase P00008171T00
P08993393A0498 |65 75|physiologytidase P00
P08993393A0498 |47 55|findingstases an
P08993393A0498 |91 104|hPACAP-R genemacologic asp
P08993393A0498 |25 37|implications with alkali
P08993393T0000 |157 165|hPACAP-Rhen CSF 
P08993393T0000 |13 22|signaling6 Compari
P08993393T0000 |135 155|polypeptide receptoremia. P00008997A0472
P08993393T0000 |43 58|gene activationsphatases and 5
P08993393T0000 |106 115|adenylatets of neo
P08993393T0000 |67 82|splice variantsdase P00008171T
P08993831A0000 |16 34|muscle developmentomparison with alk
P08993831A0000 |46 51|typesatase
P08993831A0000 |140 153|gene products P00008997A04
P08993831A0000 |108 120|combinations of neonatal
P08993831A0000 |55 68|muscle fibersd 5-nucleotid
P08993836A0699 |17 24|resultsmpariso
P08993836A0699 |61 70|inductioncleotidas
P08993836A0699 |30 37|respect alkali
P08993836A0699 |128 141|embryogenesislirubinemia. 
P08993836A0699 |78 94|HNF-3 alpha gene171T0000 Pharmac
P08993836A0699 |110 120|epitheliumf neonatal
P08994825A0000 |0 10|BACKGROUNDP00001606T
P08994825A0000 |12 19|Mitosis76 Comp
P08994825A0000 |62 68|factorleotid
P08994825A0000 |90 116|Cdc2/28-cyclin B complexesrmacologic aspects of neon
P08994825A0000 |82 86|form0000
P08994825A0000 |41 51|maturationhosphatase
P08994825A0000 |36 39|MPFine
P08994832A0782 |67 76|apoptosisdase P000
P08994832A0782 |31 37|HEK293alkali
P08994832A0782 |8 18|expression6T0076 Com
P08994832A0782 |41 51|HeLa cellshosphatase
P08994832A0782 |22 27|Apo-3son w
P08994968A0926 |96 103|subunitogic as
P08994968A0926 |14 17|arm Co
P08994968A0926 |134 138|NADPnemi
P08994968A0926 |28 35|subunitth alka
P08994968A0926 |74 80|domain000817
P08994968A0926 |126 130|ringbili
P08995054A0618 |0 10|SimilarityP00001606T
P08995054A0618 |123 136|retroelementsperbilirubine
P08995054A0618 |83 92|gag genes000 Pharm
P08995054A0618 |58 64|region-nucle
P08995054A0618 |35 54|zinc knuckle regionline phosphatases a
P08995054A1368 |0 2|D.P0
P08995054A1368 |99 105|codonsc aspe
P08995054A1368 |58 64|region-nucle
P08995054A1368 |29 38|sequencesh alkalin
P08995054A1368 |70 90|insertions/deletionse P00008171T0000 Pha
P08995054A1368 |115 133|nucleotide changesnatal hyperbilirub
P08995054A1368 |16 21|HeT-Aompar
P08995410A0000 |32 36|eIF3lkal
P08995410A0000 |179 186|subunitwn as a
P08995410A0000 |213 229|ribosome subunitata of K-deplete
P08995410A0000 |247 253|factorer dis
P08995410A0000 |125 128|Metrbi
P08995410A0000 |62 69|complexleotida
P08995410A0000 |120 124|tRNA hyp
P08995410A0000 |107 117|eIF2 x GTPs of neona
P08995410A0000 |188 192|eIF3unct
P08995410A0000 |144 156|mRNA binding008997A0472 
P08995410A0000 |11 28|initiation factor076 Comparison wi
P08995410A0000 |167 168|SC
P08995410A0000 |98 105|complexic aspe
P08995410A1109 |168 171|p40O3-
P08995410A1109 |148 151|p6697A
P08995410A1109 |122 126|p170yper
P08995410A1109 |45 55|co-workershatases an
P08995410A1109 |134 139|hPrt1nemia
P08995410A1109 |153 156|p4872 
P08995410A1109 |80 84|eIF31T00
P08995410A1109 |158 161|p47en 
P08995410A1109 |112 120|subunitsneonatal
P08995410A1109 |182 185|p35as 
P08995410A1109 |142 146|p1100000
P08995410A1109 |163 166|p44F [
P08995410A1109 |128 132|p116liru
P08995410A1109 |4 8|data0160
P08995410A1109 |173 176|p36is 
P08995410A1109 |33 40|Hersheykaline 
P08995614T0000 |0 14|IdentificationP00001606T0076
P08995614T0000 |31 38|elementalkalin
P08995614T0000 |60 100|histocompatibility complex gene promoterucleotidase P00008171T0000 Pharmacologic
P08995614T0000 |140 149|sequences P0000899
P08995614T0000 |46 51|classatase
P08995614T0000 |115 125|activationnatal hype
P08995652A0812 |479 490|amino acids5 mg at nig
P08995652A0812 |455 463|sequencegeneral 
P08995652A0812 |268 279|amino acidspared to co
P08995652A0812 |689 695|UL26.5on (25
P08995652A0812 |651 675|maturation cleavage site00015731A0090 Intravenou
P08995652A0812 |310 317|capsidscantly 
P08995652A0812 |43 50|capsidssphatas
P08995652A0812 |498 512|UL80.5 protein12653T0045 Bet
P08995652A0812 |590 607|scaffold proteins CO2 production (
P08995652A0812 |378 381|VP5us 
P08995652A0812 |358 372|UL80.5 protein3A0733 Fluraze
P08995652A0812 |530 543|RRIFVA ALNKLE P00013683A02
P08995652A0812 |421 428|capsids with t
P08995652A0812 |129 140|amino acidsirubinemia.
P08995652A0812 |287 301|UL26.5 proteinut still have 
P08995652A0812 |623 634|sequences Nventilation
P08995652A0812 |741 760|scaffold structuresazolamide, methazol
P08995652A0812 |566 582|self-interactionCO2 removal appr
P08995652A0812 |700 715|UL80.5 proteinsg) of carbonic 
P08995652A0812 |216 230|UL80.5 protein of K-depleted
P08995652A0812 |142 156|UL80.5 protein00008997A0472 
P08995652A0812 |402 410|assemblyctive hy
P08995652A0812 |197 208|amino acidsf CSF PCO2 
P08995652A0812 |4 11|results01606T0
P08995652A0812 |547 559|RRIFVAAMMKLEhen extracor
P08995652A0812 |339 350|interaction- 0.23 vs. 
P08995659A0563 |152 159|primers472 Whe
P08995659A0563 |46 50|MSRsatas
P08995659A0563 |15 38|region splice junctionsComparison with alkalin
P08995659A0563 |178 191|splice regionown as a func
P08995659A0563 |109 136|sequencing RNA-PCR productsof neonatal hyperbilirubine
P08995659A0563 |80 89|infection1T0000 Ph
P08995681A0518 |49 54|formsses a
P08995681A0518 |66 73|proteinidase P
P08995681A0518 |58 62|ICP4-nuc
P08995681A0518 |5 10|ICP271606T
P08996730A1146 |186 197|measurement function o
P08996730A1146 |54 74|employment durationsnd 5-nucleotidase P0
P08996730A1146 |27 49|vibration measurementsith alkaline phosphata
P08996730A1146 |105 115|variationscts of neo
P08996730A1146 |136 150|grinder wheelsmia. P00008997
P08996730A1146 |19 23|dataaris
P08996730A1146 |86 97|uncertainty Pharmacolo
P08996730A1146 |0 4|LackP000
P08996730A1146 |170 182|difficulties-] is shown 
P08996730A1146 |119 134|tool conditionsl hyperbilirubi
P08997490A1127 |0 12|C/EBP beta VP00001606T00
P08997490A1127 |44 50|subsetphatas
P08997490A1127 |80 89|DBP sites1T0000 Ph
P08997490A1127 |54 65|C/EBP sitesnd 5-nucleo
P08997490A1127 |167 200|cholesterol hydroxylase promotersCO3-] is shown as a function of C
P08997490A1127 |155 162|albumin When C
P08997490A1127 |99 115|oligonucleotidesc aspects of neo
P08997490A1127 |139 147|contexts. P00008
P08997532A0116 |100 108|antigens aspects
P08997532A0116 |37 56|IgE immunoglobulinsne phosphatases and
P08997532A0116 |110 113|TESf n
P08997532A0116 |9 12|IgGT00
P08997532A0116 |65 73|Toxocaratidase P
P08997532A0116 |23 26|IgEon 
P08997532A0116 |138 153|ELISA techniquea. P00008997A04
P08998115A0114 |0 23|SUMMARY BACKGROUND DATAP00001606T0076 Comparis
P08998115A0114 |25 38|Melanoma care with alkalin
P08998115A0114 |123 145|lymph node dissectionsperbilirubinemia. P000
P08998115A0114 |154 161|disease2 When 
P08998115A0114 |99 110|controversyc aspects o
P08998115A0114 |84 89|years00 Ph
P08999414A0819 |4 15|differences01606T0076 
P08999414A0819 |22 31|subgenerason with 
P08999414A0819 |39 56|genus Dermacentor phosphatases and
P08999857A0801 |154 176|collagen gene promoter2 When CSF [HCO3-] is 
P08999857A0801 |151 152|I0
P08999857A0801 |128 136|activitylirubine
P08999857A0801 |26 33|contextwith al
P08999857A0801 |13 18|E-box6 Com
P08999857A0801 |97 108|enhancementgic aspects
P08999857A0801 |144 150|alpha1008997
P08999857A0801 |53 59|regionand 5-
P08999882T0000 |0 10|ExpressionP00001606T
P08999882T0000 |44 54|beta cellsphatases a
P08999882T0000 |23 29|traitson wit
P09000049A1341 |69 72|Mycse 
P09000049A1341 |73 87|Max activities00008171T0000 
P09000049A1341 |104 122|cell proliferationects of neonatal h
P09000049A1341 |20 23|Maxris
P09000049A1341 |29 38|complexesh alkalin
P09000049A1341 |16 19|Mntomp
P09000108A0330 |102 125|polyadenylation signalsspects of neonatal hype
P09000108A0330 |162 191|translation termination codonSF [HCO3-] is shown as a func
P09000108A0330 |4 25|transcription product01606T0076 Comparison
P09000108A0330 |65 69|sitetida
P09000108A0330 |196 200|CG30of C
P09000108A0330 |141 143|bpP0
P09000108A0330 |81 90|consensusT0000 Pha
P09000108A0330 |33 40|kb mRNAkaline 
P09000146T0000 |84 104|sequence alterations00 Pharmacologic asp
P09000146T0000 |52 63|c-src genes and 5-nucl
P09000146T0000 |11 18|changes076 Com
P09000146T0000 |35 39|typeline
P09000589A0000 |33 40|malariakaline 
P09000589A0000 |58 68|evaluation-nucleotid
P09000589A0000 |89 95|agentsarmaco
P09000589A0000 |4 14|resurgence01606T0076
P09000632A2341 |119 126|complexl hyper
P09000632A2341 |24 41|Cys181 side-chainn with alkaline p
P09000632A2341 |67 76|directiondase P000
P09000632A2341 |7 18|p51 subunit06T0076 Com
P09000632A2341 |84 101|Tyr181 side-chain00 Pharmacologic 
P09001213A1111 |187 203|expression sitesfunction of CSF 
P09001213A1111 |82 97|chromosome ends0000 Pharmacolo
P09001213A1111 |208 217|var genesthe data 
P09001213A1111 |101 114|P. falciparumaspects of ne
P09001213A1111 |20 39|level transcriptionrison with alkaline
P09001213A1111 |50 54|genees a
P09001245A0187 |0 6|NUP145P00001
P09001245A0187 |69 75|screense P00
P09001313A0000 |85 90|women0 Pha
P09001313A0000 |42 45|SDBosp
P09001313A0000 |31 40|breathingalkaline 
P09001313A0000 |0 10|PrevalenceP00001606T
P09001667A0312 |17 28|antigenemiamparison wi
P09001667A0312 |63 83|day post-vaccinationeotidase P00008171T0
P09001667A0312 |7 12|cases06T00
P09001828A0222 |171 176|study] is 
P09001828A0222 |74 78|time0008
P09001828A0222 |2 7|total00016
P09001828A0222 |140 149|treatment P0000899
P09001828A0222 |82 92|physicians0000 Pharm
P09001828A0222 |103 106|BPHpec
P09001828A0222 |16 19|menomp
P09001828A0222 |34 39|yearsaline
P09002648A0202 |0 5|BCL-2P0000
P09002648A0202 |10 19|inhibitor0076 Comp
P09002648A0202 |120 130|cell death hyperbili
P09002648A0202 |23 32|apoptosison with a
P09002648A0202 |43 50|varietysphatas
P09002648A0202 |54 64|cell typesnd 5-nucle
P09002672A0439 |171 177|arrays] is s
P09002672A0439 |89 102|repeat arraysarmacologic a
P09002672A0439 |28 38|mTRF1 cDNAth alkalin
P09002672A0439 |104 109|mTRF1ects 
P09002672A0439 |224 230|TTAGGCpleted
P09002672A0439 |181 195|TTAGGG repeats as a function
P09002672A0439 |129 149|sequence specificityirubinemia. P0000899
P09002672A0439 |9 20|translationT0076 Compa
P09002672A0439 |56 67|kDa protein 5-nucleoti
P09002672A0439 |235 249|TTGGGG repeats are no longer
P09002672A0439 |201 218|binding substrateF PCO2 the data o
P09002672A0439 |153 158|hTRF172 Wh
P09003001A1593 |87 94|factorsPharmac
P09003001A1593 |27 30|E12ith
P09003001A1593 |36 43|proteinine pho
P09003001A1909 |71 77|CATCTG P0000
P09003001A1909 |97 107|gel shiftsgic aspect
P09003001A1909 |26 38|SE2 fragmentwith alkalin
P09003001A1909 |46 66|transferrin promoteratases and 5-nucleot
P09003001A1909 |115 139|consensus E-box elementsnatal hyperbilirubinemia
P09003001A1909 |4 18|E-box sequence01606T0076 Com
P09003001A1909 |141 147|CANNTGP00008
P09003311A0478 |102 109|regionsspects 
P09003311A0478 |78 83|porCa171T0
P09003311A0478 |60 70|porin geneucleotidas
P09003311A0478 |9 21|DNA fragmentT0076 Compar
P09003312A0740 |204 211|mutantsCO2 the
P09003312A0740 |12 19|AT-PHH176 Comp
P09003312A0740 |30 37|AT-PHH1 alkali
P09003312A0740 |177 182|yeasthown 
P09003312A0740 |242 247|light long
P09003312A0740 |133 138|cDNAsinemi
P09003312A0740 |97 101|sizegic 
P09003312A0740 |42 61|AT-PHH1 delta C-513osphatases and 5-nu
P09003312A0740 |115 131|photolyase genesnatal hyperbilir
P09003410A0000 |84 89|virus00 Ph
P09003410A0000 |52 63|coactivator and 5-nucl
P09003410A0000 |10 22|p100 protein0076 Compari
P09003410A0000 |98 105|antigenic aspe
P09003462A0792 |34 37|S61ali
P09003462A0792 |44 47|S29pha
P09003462A0792 |90 101|nrdB intronrmacologic 
P09003462A0792 |114 127|self-splicingonatal hyperb
P09003462A0792 |65 70|SL126tidas
P09003462A0792 |39 42|SL1 ph
P09003462A0792 |18 32|mutation sitesparison with a
P09003462A0792 |55 60|SL196d 5-n
P09003462A0792 |49 53|SL11ses 
P09003463A0198 |87 89|kbPh
P09003463A0198 |25 34|isolation with alk
P09003463A0198 |95 99|exonlogi
P09003463A0198 |75 81|region008171
P09003463A0198 |39 55|characterization phosphatases an
P09003463A0198 |5 11|report1606T0
P09003463A0198 |115 129|RII alpha genenatal hyperbil
P09003617A0000 |50 56|monthses and
P09003617A0000 |63 68|yearseotid
P09003617A0000 |20 28|childrenrison wi
P09003617A0000 |72 75|ageP00
P09003617A0000 |2 8|cohort000160
P09004304A0000 |152 161|51Cr-EDTA472 When 
P09004304A0000 |106 133|chromium-51 ethylenediaminets of neonatal hyperbilirub
P09004304A0000 |61 67|numbercleoti
P09004304A0000 |82 99|clearance methods0000 Pharmacologi
P09004304A0000 |146 150|acid8997
P09004304A0000 |40 55|reproducibilityphosphatases an
P09004304A0000 |4 7|aim016
P09004304A0000 |202 224|blood sample technique PCO2 the data of K-de
P09004304A0000 |16 21|studyompar
P09004504A0000 |32 47|bp DNA fragmentlkaline phospha
P09004504A0000 |149 179|Yersinia pestis plasmid pYP3587A0472 When CSF [HCO3-] is sho
P09004504A0000 |120 131|replication hyperbilir
P09004504A0000 |60 68|pla geneucleotid
P09004504A0000 |79 100|plasminogen activator71T0000 Pharmacologic
P09004504A0000 |12 21|structure76 Compar
P09004504A0000 |110 116|originf neon
P09004987T0001 |0 23|Serotonin concentrationP00001606T0076 Comparis
P09004987T0001 |31 36|bloodalkal
P09004987T0001 |66 71|feveridase
P09004987T0001 |40 48|patientsphosphat
P09004987T0001 |83 91|syndrome000 Phar
P09005273A0322 |0 21|MAIN OUTCOME MEASURESP00001606T0076 Compar
P09005273A0322 |63 72|syndromeseotidase 
P09005273A0322 |95 116|chemical interactionslogic aspects of neon
P09005273A0322 |78 90|risk factors171T0000 Pha
P09005273A0322 |130 151|butyrylcholinesteraserubinemia. P00008997A
P09005273A0322 |39 45|factor phosp
P09005273A0322 |23 35|Associationson with alka
P09005273A0322 |156 182|neuropathy target esteraseWhen CSF [HCO3-] is shown 
P09005273A1558 |17 34|Gulf War veteransmparison with alk
P09005273A1558 |107 119|combinationss of neonata
P09005273A1558 |95 103|exposurelogic as
P09005273A1558 |123 132|chemicalsperbiliru
P09005273A1558 |72 81|syndromesP00008171
P09005273A1558 |172 198|neuropathy target esterase is shown as a function of
P09005273A1558 |146 167|butyrylcholinesterase8997A0472 When CSF [H
P09005273A1558 |0 10|CONCLUSIONP00001606T
P09005609A0299 |0 19|Control examinationP00001606T0076 Comp
P09005609A0299 |41 44|endhos
P09005609A0299 |53 59|periodand 5-
P09005836A0977 |3 14|correlation001606T0076
P09005836A0977 |53 67|antibody leveland 5-nucleoti
P09005836A0977 |27 30|ageith
P09005836A0977 |38 44|horsese phos
P09005979A0841 |4 12|GHR mRNA01606T00
P09005979A0841 |13 28|GHBP mRNA ratio6 Comparison wi
P09005979A0841 |76 91|differentiation08171T0000 Phar
P09006007A0997 |238 251|compatibilitye no longer d
P09006007A0997 |183 194|specificitys a functio
P09006007A0997 |61 70|UGA codoncleotidas
P09006007A0997 |131 143|SelB proteinubinemia. P0
P09006007A0997 |287 295|ribosomeut still
P09006007A0997 |270 277|complexred to 
P09006007A0997 |99 109|conditionsc aspects 
P09006007A0997 |212 223|interactiondata of K-d
P09006007A0997 |4 11|results01606T0
P09006010A0527 |206 222|secretion signal2 the data of K-
P09006010A0527 |86 104|S-layer biogenesis Pharmacologic asp
P09006010A0527 |53 63|amino acidand 5-nucl
P09006010A0527 |189 193|RsaAncti
P09006010A0527 |147 156|secretion997A0472 
P09006010A0527 |243 253|amino acidlonger dis
P09006010A0527 |121 131|amino acidhyperbilir
P09006010A0527 |76 82|effect08171T
P09006010A0527 |229 230|Cd
P09006010A0527 |164 171|protein [HCO3-
P09006010A0527 |36 51|RsaA C terminusine phosphatase
P09006010A0527 |277 287|amino acidcontrols b
P09006010A0527 |4 28|linker-peptide insertion01606T0076 Comparison wi
P09006022A0252 |87 94|controlPharmac
P09006022A0252 |39 48|cvaA gene phosphat
P09006022A0252 |20 33|gene productsrison with al
P09006022A0252 |98 124|T7 RNA polymerase promoteric aspects of neonatal hyp
P09006051A1162 |0 4|PrpBP000
P09006051A1162 |209 226|citrate synthaseshe data of K-depl
P09006051A1162 |240 248|homologyno longe
P09006051A1162 |322 330|homologyer slope
P09006051A1162 |262 288|Bacillus subtilis proteinsen compared to controls bu
P09006051A1162 |158 162|PrpCen C
P09006051A1162 |334 363|acetyl coenzyme A synthetases21 +/- 0.23 vs. P00010943A073
P09006051A1162 |24 68|carboxyphosphonoenolpyruvate phosphonomutasen with alkaline phosphatases and 5-nucleotid
P09006051A1162 |125 156|carnation Dianthus caryophyllusrbilirubinemia. P00008997A0472 
P09006051A1162 |300 308|function a signi
P09006051A1162 |12 20|homology76 Compa
P09006051A1162 |186 194|archaeal functio
P09006051A1162 |252 257|yeastsplac
P09006051A1162 |110 117|homologf neona
P09006051A1162 |228 232|PrpDed r
P09006051A1162 |310 314|PrpEcant
P09006555A0738 |0 21|MAIN OUTCOME MEASURESP00001606T0076 Compar
P09006555A0738 |149 173|neutrophil oxidant burst7A0472 When CSF [HCO3-] 
P09006555A0738 |240 247|studiesno long
P09006555A0738 |110 124|lavage proteinf neonatal hyp
P09006555A0738 |46 58|hemodynamicsatases and 5
P09006555A0738 |209 226|scanning electronhe data of K-depl
P09006555A0738 |175 203|lung myeloperoxidase content shown as a function of CSF 
P09006555A0738 |129 147|neutrophil contentirubinemia. P00008
P09006555A0738 |69 92|blood gas determinationse P00008171T0000 Pharm
P09006902A0370 |19 23|cDNAaris
P09006902A0370 |39 44|MEKK3 phos
P09006910A0000 |152 169|RXRgamma2 isoform472 When CSF [HCO
P09006910A0000 |132 138|regionbinemi
P09006910A0000 |73 92|retinoid X receptor00008171T0000 Pharm
P09006910A0000 |62 69|controlleotida
P09006910A0000 |99 114|gene expressionc aspects of ne
P09006910A0000 |94 97|RXRolo
P09006910A0000 |19 29|mechanismsarison wit
P09006914A0812 |0 3|JNKP00
P09006914A0812 |109 112|JNKof 
P09006914A0812 |79 84|ATF-271T00
P09006914A0812 |46 53|nucleusatases 
P09006914A0812 |117 120|p38tal
P09006914A0812 |8 11|p386T0
P09006914A0812 |69 74|c-JUNse P0
P09006914A1127 |153 179|E-selectin gene expression72 When CSF [HCO3-] is sho
P09006914A1127 |112 119|kinasesneonata
P09006914A1127 |92 102|activationacologic a
P09006914A1127 |4 11|effects01606T0
P09006914A1127 |36 41|formsine p
P09006914A1127 |49 74|JNK/p38 signaling pathwayses and 5-nucleotidase P0
P09006935A0590 |0 3|Sp1P00
P09006935A0590 |43 45|KDsp
P09006935A0590 |14 24|CTC repeat Compariso
P09006935A0590 |81 97|consensus GC boxT0000 Pharmacolo
P09006935A0590 |53 55|nMan
P09006935A0590 |33 41|affinitykaline p
P09006936T0000 |0 14|IdentificationP00001606T0076
P09006936T0000 |46 53|proteinatases 
P09006936T0000 |22 28|regionson wi
P09006936T0000 |94 114|glycoprotein IBalphaologic aspects of ne
P09006936T0000 |84 90|domain00 Pha
P09008301A0193 |116 123|proteinatal hy
P09008301A0193 |59 78|autoprocessing sitenucleotidase P00008
P09008301A0193 |147 154|studies997A047
P09008301A0193 |7 19|enzyme forms06T0076 Comp
P09009208A0337 |81 89|Tf1 mRNAT0000 Ph
P09009208A0337 |58 63|bases-nucl
P09009208A0337 |29 37|cleavageh alkali
P09009208A0337 |4 10|primer01606T
P09010223A0667 |85 98|PU.1 proteins0 Pharmacolog
P09010223A0667 |142 151|Egr1 SREI00008997A
P09010223A0667 |76 80|PEA30817
P09010223A0667 |131 134|SRFubi
P09010223A0667 |41 46|SAP1ahosph
P09010223A0667 |48 52|FLI1ases
P09010223A0667 |64 68|ETS1otid
P09010223A0667 |54 62|EWS-FLI1nd 5-nuc
P09010223A0667 |70 74|ETS2e P0
P09010223A0667 |116 125|complexesatal hype
P09010223A0667 |35 39|ELK1line
P09010223A1850 |48 51|SRFase
P09010223A1850 |108 116|EWS-FLI1 of neon
P09010223A1850 |195 205|regulation of CSF PC
P09010223A1850 |31 42|interactionalkaline ph
P09010223A1850 |143 151|function0008997A
P09010223A1850 |213 222|Egr1 geneata of K-
P09010223A1850 |162 187|ETS transcription factorsSF [HCO3-] is shown as a 
P09010223A1850 |65 74|mechanismtidase P0
P09010223A1850 |5 13|R-domain1606T007
P09010223A1850 |99 103|FLI1c as
P09011591A0309 |64 71|smokersotidase
P09011591A0309 |10 16|number0076 C
P09011591A0309 |46 56|nonsmokersatases and
P09011591A0309 |20 29|specimensrison wit
P09011744A0790 |101 108|epsilonaspects
P09011744A0790 |92 98|Grin2aacolog
P09011744A0790 |179 187|subunitswn as a 
P09011744A0790 |299 310|F1xC57BL/6Je a signifi
P09011744A0790 |265 272|crossescompare
P09011744A0790 |121 128|epsilonhyperbi
P09011744A0790 |45 75|NMDA receptor channel subunitshatases and 5-nucleotidase P00
P09011744A0790 |164 168|zeta [HC
P09011744A0790 |152 158|Grin2d472 Wh
P09011744A0790 |290 297|spretusstill h
P09011744A0790 |81 88|epsilonT0000 P
P09011744A0790 |23 32|locationson with a
P09011744A0790 |112 118|Grin2bneonat
P09011744A0790 |312 316|micently
P09011744A0790 |228 251|backcross mapping paneled rats are no longer d
P09011744A0790 |132 138|Grin2cbinemi
P09011744A0790 |278 288|C57BL/6JxMontrols bu
P09011744A0790 |172 177|Grinl is s
P09011744A0790 |141 148|epsilonP000089
P09011745T0000 |119 128|structurel hyperbi
P09011745T0000 |164 173|processes [HCO3-] 
P09011745T0000 |5 12|cloning1606T00
P09011745T0000 |189 198|receptorsnction of
P09011745T0000 |130 138|functionrubinemi
P09011745T0000 |16 27|chick brainomparison w
P09011745T0000 |80 94|acid receptors1T0000 Pharmac
P09011745T0000 |103 115|conservationpects of neo
P09012405A0785 |17 22|TTD-Ampari
P09012405A0785 |122 130|functionyperbili
P09012405A0785 |134 144|DNA repairnemia. P00
P09012405A0785 |60 68|subunitsucleotid
P09012405A0785 |27 39|XP-D defectsith alkaline
P09012405A0785 |72 77|TFIIHP0000
P09012405A0785 |87 107|transcription factorPharmacologic aspect
P09012636A0723 |0 10|AdjustmentP00001606T
P09012636A0723 |166 181|atherosclerosisHCO3-] is shown
P09012636A0723 |151 161|fibrinogen0472 When 
P09012636A0723 |15 18|ageCom
P09012636A0723 |79 86|smoking71T0000
P09012636A0723 |56 69|triglycerides 5-nucleotida
P09012636A0723 |26 37|cholesterolwith alkali
P09012636A0723 |39 54|HDL cholesterol phosphatases a
P09012636A0723 |131 142|associationubinemia. P
P09012636A0723 |101 109|pressureaspects 
P09013499A0198 |258 266|controlsd when c
P09013499A0198 |183 195|conditionings a function
P09013499A0198 |151 154|min047
P09013499A0198 |75 122|N-methyl-D-aspartate receptor antagonist MK-801008171T0000 Pharmacologic aspects of neonatal h
P09013499A0198 |233 237|odorts a
P09013499A0198 |128 133|mg/kglirub
P09013499A0198 |43 52|injectionsphatases
P09013499A0198 |207 211|time the
P09013499A0198 |3 13|Experiment001606T007
P09013499A0198 |17 21|pupsmpar
P09013760A0000 |0 11|CholesterolP00001606T0
P09013760A0000 |23 47|cleavage cytochrome P450on with alkaline phospha
P09013760A0000 |128 133|ovarylirub
P09013760A0000 |57 64|P450scc5-nucle
P09013760A0000 |150 154|cAMPA047
P09013760A0000 |141 145|ACTHP000
P09013760A0000 |98 111|gonadotropinsic aspects of
P09013760A0000 |66 81|gene expressionidase P00008171
P09013760A0000 |116 120|cAMPatal
P09013760A0000 |175 180|cells show
P09013760A0000 |49 55|CYP11Ases an
P09015543A0210 |39 46|forearm phosph
P09015543A0210 |13 21|solution6 Compar
P09015543A0210 |52 56|flap and
P09015757T0000 |118 121|BSPal 
P09015757T0000 |123 127|geneperb
P09015757T0000 |44 50|tissuephatas
P09015757T0000 |75 85|expression008171T000
P09015757T0000 |24 40|characterizationn with alkaline 
P09015757T0000 |11 19|analysis076 Comp
P09015757T0000 |99 116|bone sialoproteinc aspects of neon
P09015799T0000 |0 19|Serotonin receptorsP00001606T0076 Comp
P09015799T0000 |23 38|suicide victimson with alkalin
P09015799T0000 |50 60|depressiones and 5-n
P09016566A0655 |54 60|numbernd 5-n
P09016566A0655 |74 83|BiP mRNAs0008171T0
P09016566A0655 |22 27|motifson w
P09017443A0734 |102 108|effectspects
P09017443A0734 |157 158|ph
P09017443A0734 |112 119|regimenneonata
P09017443A0734 |79 87|syndrome71T0000 
P09017443A0734 |141 155|stratificationP00008997A0472
P09017443A0734 |55 65|occurrenced 5-nucleo
P09017443A0734 |17 30|marker screenmparison with
P09018122A1389 |17 32|ORF-1 sequencesmparison with a
P09018122A1389 |79 91|prerequisite71T0000 Phar
P09018122A1389 |121 138|tumor developmenthyperbilirubinemi
P09018122A1389 |60 65|proofucleo
P09018122A1389 |113 117|roleeona
P09018122A1389 |42 48|tumorsosphat
P09018122A1389 |4 13|detection01606T007
P09018133A0244 |136 155|alpha-Herpesvirinaemia. P00008997A0472
P09018133A0244 |61 73|relationshipcleotidase P
P09018133A0244 |27 35|evidenceith alka
P09018133A0244 |166 177|herpesvirusHCO3-] is s
P09018133A0244 |13 21|analysis6 Compar
P09018133A0244 |93 100|memberscologic
P09018133A0244 |108 128|Varicellovirus genus of neonatal hyperbi
P09018133A0244 |82 88|PhHV-10000 P
P09019302A0600 |16 19|PLPomp
P09019302A0600 |76 90|derivatization08171T0000 Pha
P09019302A0600 |8 14|method6T0076
P09019302A0600 |58 69|sensitivity-nucleotida
P09019302A0600 |23 29|plasmaon wit
P09019302A0600 |127 132|phaseiliru
P09019302A0600 |96 112|sodium bisulfiteogic aspects of 
P09020138A0833 |32 39|complexlkaline
P09020138A0833 |14 17|Cas Co
P09020138A0833 |106 114|tyrosinets of ne
P09020138A0833 |89 94|RAFTKarmac
P09020138A0833 |72 87|tyrosine kinaseP00008171T0000 
P09020138A0833 |5 9|HEF11606
P09020138A0833 |57 65|adhesion5-nucleo
P09020138A0833 |140 161|adapter molecule CrkL P00008997A0472 When 
P09020169A0552 |68 71|AHRase
P09020169A0552 |9 13|SIM2T007
P09020169A0552 |26 36|homodimerswith alkal
P09020169A0552 |0 4|SIM1P000
P09020172A0964 |0 9|ComplexesP00001606
P09020172A0964 |88 93|formsharma
P09020172A0964 |13 19|qTBP426 Comp
P09020172A0964 |44 50|strandphatas
P09020172A0964 |134 159|nM dissociation constantsnemia. P00008997A0472 Whe
P09020172A0964 |244 253|Kd valuesonger dis
P09020172A0964 |214 217|DNAta 
P09020172A0964 |161 163|KdCS
P09020172A0964 |114 120|strandonatal
P09020172A0964 |173 182|complexesis shown 
P09020172A0964 |64 67|DNAoti
P09020856A0560 |70 82|MCK promotere P00008171T
P09020856A0560 |14 20|effect Compa
P09020856A0560 |32 36|TIS1lkal
P09021684A1418 |204 228|transactivation activityCO2 the data of K-deplet
P09021684A1418 |90 97|nucleusrmacolo
P09021684A1418 |45 53|proteinshatases 
P09021684A1418 |167 181|NF-kappa B2p52CO3-] is shown
P09021684A1418 |13 17|data6 Co
P09021684A1418 |129 148|repressor functionsirubinemia. P000089
P09022040A0263 |239 247|function no long
P09022040A0263 |146 161|gene expression8997A0472 When 
P09022040A0263 |182 187|cellsas a 
P09022040A0263 |81 88|rodentsT0000 P
P09022040A0263 |8 28|L-plastin expression6T0076 Comparison wi
P09022040A0263 |297 321|L-plastin gene promotersave a significantly grea
P09022040A0263 |70 76|humanse P000
P09022040A0263 |116 126|mechanismsatal hyper
P09022040A0263 |252 272|nucleotide sequencessplaced when compare
P09022632T0000 |42 49|surgeryosphata
P09023197T0000 |19 36|Bacillus subtilisarison with alkal
P09023197T0000 |4 15|dnaK operon01606T0076 
P09023378A0959 |169 177|versions3-] is s
P09023378A0959 |135 153|activator sequenceemia. P00008997A04
P09023378A0959 |60 73|transcriptionucleotidase P
P09023378A0959 |24 28|CBF1n wi
P09023378A0959 |10 20|expression0076 Compa
P09023378A0959 |107 119|C-repeat/DREs of neonata
P09023378A0959 |185 196|DNA elementa function 
P09023378A0959 |77 91|reporter genes8171T0000 Phar
P09023378A0959 |32 37|yeastlkali
P09024039A0247 |140 143|CCA P0
P09024039A0247 |94 104|proceduresologic asp
P09024039A0247 |149 159|desflurane7A0472 Whe
P09024039A0247 |44 52|patientsphatases
P09024039A0247 |163 173|isofluraneF [HCO3-] 
P09024039A0247 |179 190|ventilationwn as a fun
P09024039A0247 |10 13|ASA007
P09024039A0247 |66 73|varietyidase P
P09024039A0247 |23 29|statuson wit
P09024039A0247 |83 84|h0
P09024097A0000 |137 145|ligationia. P000
P09024097A0000 |64 69|womenotida
P09024097A0000 |120 130|postpartum hyperbili
P09024097A0000 |15 19|goalComp
P09024097A0000 |84 88|rate00 P
P09024097A0000 |100 113|complications aspects of n
P09024097A0000 |0 9|OBJECTIVEP00001606
P09024793A1325 |184 192|presence a funct
P09024793A1325 |196 201|BMP-2of CS
P09024793A1325 |58 66|extracts-nucleot
P09024793A1325 |90 94|MyoDrmac
P09024793A1325 |7 43|electrophoresis mobility shift assay06T0076 Comparison with alkaline pho
P09024793A1325 |163 171|MCK geneF [HCO3-
P09024793A1325 |127 132|E-boxiliru
P09024793A1325 |99 107|myogeninc aspect
P09024793A1325 |83 88|cells000 P
P09024793A1325 |140 155|enhancer region P00008997A0472
P09024805A0905 |187 207|beta-globin TATA boxfunction of CSF PCO2
P09024805A0905 |219 245|phorbol ester inducibility K-depleted rats are no lo
P09024805A0905 |52 59|repeats and 5-
P09024805A0905 |125 128|ZIIrbi
P09024805A0905 |130 134|CREBrubi
P09024805A0905 |65 83|consensus Sp1 sitetidase P00008171T0
P09024805A0905 |158 172|BZLF1 promoteren CSF [HCO3-]
P09024805A0905 |113 117|copyeona
P09024805A0905 |16 34|promoter constructomparison with alk
P09024805A0905 |141 148|elementP000089
P09024805A0905 |136 139|AP1mia
P09025122A0374 |86 95|COWA task Pharmaco
P09025122A0374 |11 22|experiments076 Compari
P09025122A0374 |141 152|performanceP00008997A0
P09025122A0374 |43 48|taskssphat
P09025122A0374 |71 78|aspects P00008
P09025549A0000 |51 61|competences and 5-nu
P09025549A0000 |42 47|levelospha
P09025549A0000 |95 108|practitionerslogic aspects
P09025549A0000 |11 16|nurse076 C
P09025549A0000 |270 279|continentred to co
P09025549A0000 |123 160|Vancouver sex therapist Bianca Ruckerperbilirubinemia. P00008997A0472 When
P09025549A0000 |216 223|mentors of K-d
P09025549A0000 |201 211|colleaguesF PCO2 the
P09025549A0000 |190 197|networkction o
P09025549A0000 |250 254|homedisp
P09025549A0000 |235 241|fields are n
P09025549A0000 |116 121|fieldatal 
P09027346A1957 |159 163|exonn CS
P09027346A1957 |165 169|pE x[HCO
P09027346A1957 |46 68|hCG-ectodomain complexatases and 5-nucleotid
P09027346A1957 |29 38|site IIIah alkalin
P09027346A1957 |180 183|LHRn a
P09027346A1957 |9 25|antibody bindingT0076 Comparison
P09027346A1957 |106 109|mAbts 
P09027346A1957 |129 136|peptideirubine
P09027506T0000 |51 63|localizations and 5-nucl
P09027506T0000 |107 110|isos o
P09027506T0000 |14 33|expression analysis Comparison with al
P09027506T0000 |96 105|wheat eIFogic aspe
P09027506T0000 |128 134|eIF-4Glirubi
P09027506T0000 |111 113|4F n
P09027506T0000 |84 92|homology00 Pharm
P09027506T0000 |69 73|genese P
P09027506T0000 |0 12|cDNA cloningP00001606T00
P09028089A0183 |38 50|hypertensione phosphatas
P09028089A0183 |109 132|transplantation surgeryof neonatal hyperbiliru
P09028089A0183 |78 88|blood flow171T0000 P
P09028308A0590 |34 37|AZQali
P09028308A0590 |227 232|cycleted r
P09028308A0590 |193 196|dayon 
P09028308A0590 |12 20|patients76 Compa
P09028308A0590 |164 177|micrograms/kg [HCO3-] is s
P09028308A0590 |129 136|cohortsirubine
P09028308A0590 |42 55|mitroxantroneosphatases an
P09028308A0590 |78 101|bone marrow suppression171T0000 Pharmacologic 
P09028308A0590 |155 160|G-CSF When
P09028308A0590 |203 213|completionPCO2 the d
P09028308A0590 |236 248|chemotherapyare no longe
P09028942A0000 |84 89|genes00 Ph
P09028942A0000 |149 154|egr-17A047
P09028942A0000 |105 108|juncts
P09028942A0000 |77 80|set817
P09028942A0000 |125 145|growth response generbilirubinemia. P000
P09028942A0000 |56 63|hGM-CSF 5-nucl
P09028942A0000 |98 103|c-fosic as
P09028942A0000 |110 113|mycf n
P09028942A0000 |48 54|factorases a
P09028998A0143 |35 42|controlline ph
P09028998A0143 |73 80|outcome0000817
P09028998A0143 |134 137|BCTnem
P09028998A0143 |3 8|order00160
P09028998A0143 |96 109|breast tissueogic aspects 
P09028998A0143 |86 92|amount Pharm
P09029091A0881 |138 152|A2/HCP chimeraa. P00008997A0
P09029091A0881 |36 60|tyrosine phosphorylationine phosphatases and 5-n
P09029091A0881 |110 122|Jurkat cellsf neonatal h
P09029091A0881 |64 85|phospholipase C gammaotidase P00008171T000
P09029104A0226 |69 75|mannerse P00
P09029104A0226 |39 46|lineage phosph
P09029104A0226 |9 14|IGLL1T0076
P09029104A0226 |16 20|geneompa
P09029159A0000 |50 55|dsRNAes an
P09029159A0000 |91 94|PKRmac
P09029159A0000 |45 48|RNAhat
P09029159A0000 |67 89|Ser/Thr protein kinasedase P00008171T0000 Ph
P09029159A0000 |148 155|effects97A0472
P09029159A0000 |104 108|roleects
P09029159A0000 |4 14|interferon01606T0076
P09029159A0000 |159 162|IFNn C
P09029159A0000 |16 19|IFNomp
P09029713A1120 |100 117|repressor COUP-TF aspects of neona
P09029713A1120 |47 54|controltases a
P09029713A1120 |14 18|data Com
P09029713A1120 |149 162|transcription7A0472 When C
P09029713A1120 |62 69|amountsleotida
P09029713A1120 |77 91|activator SF-18171T0000 Phar
P09029956T0000 |49 68|structure formationses and 5-nucleotid
P09029956T0000 |25 35|management with alka
P09029956T0000 |7 16|relations06T0076 C
P09030581A0990 |103 111|JNK/SAPKpects of
P09030581A0990 |79 94|selectivity ERK71T0000 Pharmac
P09030581A0990 |44 54|activationphatases a
P09030581A0990 |31 36|MKP-4alkal
P09030581A0990 |97 100|p38gic
P09030581A0990 |58 69|MAP kinases-nucleotida
P09030581A0990 |18 29|COS-7 cellsparison wit
P09030688A0435 |86 104|Rap1p localization Pharmacologic asp
P09030688A0435 |27 36|chromatinith alkal
P09030688A0435 |61 70|silencingcleotidas
P09030688A0435 |3 15|rlf2 mutants001606T0076 
P09030781A0734 |5 12|kinases1606T00
P09030781A0734 |48 59|roscovitineases and 5-
P09030781A0734 |190 196|microMction 
P09030781A0734 |213 227|cdk4/cyclin D1ata of K-deple
P09030781A0734 |300 306|microM a sig
P09030781A0734 |61 74|cdc2/cyclin Bcleotidase P0
P09030781A0734 |91 104|cdk2/cyclin Emacologic asp
P09030781A0734 |109 117|cdk5/p35of neona
P09030781A0734 |152 163|IC50 values472 When CS
P09030781A0734 |289 293|IC50 sti
P09030781A0734 |276 287|roscovitine controls b
P09030781A0734 |76 89|cdk2/cyclin A08171T0000 Ph
P09030781A0734 |232 246|cdk6/cyclin D2ats are no lon
P09031639A0474 |50 53|ORFes 
P09031639A0474 |10 17|kb cDNA0076 Co
P09031639A0474 |148 156|position97A0472 
P09031639A0474 |62 64|bple
P09031639A0474 |176 188|U1-C proteinshown as a f
P09031639A0474 |108 110|aa o
P09031639A0474 |95 106|amino acidslogic aspec
P09031639A0474 |138 146|positiona. P0000
P09031639A0474 |76 87|polypeptide08171T0000 
P09031639A0474 |35 48|reading frameline phosphat
P09032233T0000 |0 11|InteractionP00001606T0
P09032233T0000 |15 20|Ets-1Compa
P09032233T0000 |59 64|Pit-1nucle
P09032233T0000 |29 58|POU-homeodomain protein GHF-1h alkaline phosphatases and 5
P09032233T0000 |98 113|gene expressionic aspects of n
P09032248A0239 |98 103|Startic as
P09032248A0239 |122 142|Cln1,2-Cdc28 kinasesyperbilirubinemia. P
P09032248A0239 |47 76|Pcl1,2-Pho85 kinase complexestases and 5-nucleotidase P000
P09032248A0239 |111 118|absence neonat
P09032248A0239 |9 14|Pho85T0076
P09032248A0239 |36 45|viabilityine phosp
P09032250A0257 |116 142|CCAAT binding protein NF-Yatal hyperbilirubinemia. P
P09032250A0257 |150 167|HeLa cDNA libraryA0472 When CSF [H
P09032250A0257 |77 81|Tax18171
P09032250A0257 |27 33|systemith al
P09032250A0257 |10 15|yeast0076 
P09032250A0257 |99 108|B subunitc aspects
P09032250A0257 |37 43|screenne pho
P09032250A0257 |48 56|proteinsases and
P09032254A0724 |0 17|Enhancer activityP00001606T0076 Co
P09032254A0724 |36 45|AP-1 siteine phosp
P09032254A0724 |65 74|sequencestidase P0
P09032258A0395 |0 7|StudiesP000016
P09032258A0395 |14 31|HLA-DR-B7-1-LFA-3 Comparison with 
P09032258A0395 |39 52|transfectants phosphatases
P09032258A0395 |83 109|NF-AT DNA binding activity000 Pharmacologic aspects 
P09032258A0395 |138 156|B7-1 costimulationa. P00008997A0472 
P09032259A0150 |103 112|functionspects of 
P09032259A0150 |27 31|Rac1ith 
P09032259A0150 |13 23|activation6 Comparis
P09032259A0150 |60 74|transformationucleotidase P0
P09032259A0150 |36 40|RhoAine 
P09032259A0150 |78 91|NIH 3T3 cells171T0000 Phar
P09032259A0150 |138 156|Ras transformationa. P00008997A0472 
P09032259A0972 |32 35|JNKlka
P09032259A0972 |13 28|Rac1 activation6 Comparison wi
P09032259A0972 |60 72|lamellipodiaucleotidase 
P09032259A0972 |39 42|SRF ph
P09032259A0972 |47 56|inductiontases and
P09032259A0972 |115 141|Rac1 transforming activitynatal hyperbilirubinemia. 
P09032267A0850 |0 14|OverexpressionP00001606T0076
P09032267A0850 |108 110|TR o
P09032267A0850 |89 99|cross talkarmacologi
P09032267A0850 |115 123|p45/NF-Enatal hy
P09032267A0850 |22 45|bZip interaction domainson with alkaline phosp
P09032267A0850 |49 52|CBPses
P09032275A1133 |16 22|domainompari
P09032275A1133 |67 87|AHC deletion mutantsdase P00008171T0000 
P09032275A1133 |101 105|dateaspe
P09032304T0000 |68 88|herpes simplex virusase P00008171T0000 P
P09032304T0000 |100 112|protein ICP4 aspects of 
P09032304T0000 |38 60|transactivation domaine phosphatases and 5-n
P09032304T0000 |0 14|IdentificationP00001606T0076
P09032328A0650 |0 14|DNA sequencingP00001606T0076
P09032328A0650 |126 134|presencebilirubi
P09032328A0650 |26 33|segmentwith al
P09032328A0650 |149 153|ORFs7A04
P09032328A0650 |107 112|ORF17s of 
P09032328A0650 |83 87|DL-B000 
P09032328A0650 |97 102|ORF11gic a
P09032328A0650 |76 81|locus08171
P09032328A0650 |49 65|gammaherpesvirusses and 5-nucleo
P09032328A0650 |203 211|proteinsPCO2 the
P09032328A0650 |169 182|gene products3-] is shown 
P09034337A0251 |85 100|phosphorylation0 Pharmacologic
P09034337A0251 |121 129|responsehyperbil
P09034337A0251 |104 111|p34cdc2ects of
P09034337A0251 |67 75|tyrosinedase P00
P09034337A0251 |43 52|inductionsphatases
P09034337A0251 |133 143|DNA damageinemia. P0
P09034337A0251 |21 26|cellsison 
P09034337A0251 |80 83|Y151T0
P09034337A0251 |0 7|StudiesP000016
P09035307A0000 |87 94|adenomaPharmac
P09035307A0000 |43 46|mansph
P09035307A0000 |157 167|99mTc-MIBIhen CSF [H
P09035307A0000 |111 155|99mTc-methoxyisobutylisonitrile scintigraphy neonatal hyperbilirubinemia. P00008997A0472
P09035307A0000 |21 25|caseison
P09035612T0000 |118 129|reperfusional hyperbil
P09035612T0000 |56 66|blood flow 5-nucleot
P09035612T0000 |31 43|infarct sizealkaline pho
P09035612T0000 |84 92|function00 Pharm
P09035612T0000 |8 26|endothelin release6T0076 Comparison 
P09035612T0000 |103 113|infarctionpects of n
P09036529A0343 |170 184|Apis mellifera-] is shown as
P09036529A0343 |211 216|venom data
P09036529A0343 |90 99|serum IgErmacologi
P09036529A0343 |105 113|RAST-CAPcts of n
P09036529A0343 |115 124|Pharmacianatal hyp
P09036529A0343 |190 194|waspctio
P09036529A0343 |20 30|skin testsrison with
P09036529A0343 |54 63|Pharmaciand 5-nucl
P09036529A0343 |218 229|Aquagen ALKf K-deplete
P09036529A0343 |147 161|concentrations997A0472 When 
P09036529A0343 |40 52|microgram/mlphosphatases
P09036529A0343 |131 135|CASTubin
P09036529A0343 |165 168|bee[HC
P09036529A0343 |66 77|measurementidase P0000
P09036529A0343 |196 208|Vespula specof CSF PCO2 
P09036529A0343 |4 10|workup01606T
P09037032T0000 |101 130|ribonucleoprotein associationaspects of neonatal hyperbili
P09037032T0000 |45 50|P2P-Rhatas
P09037032T0000 |163 173|expressionF [HCO3-] 
P09037032T0000 |62 69|domainsleotida
P09037032T0000 |135 146|Rb1 bindingemia. P0000
P09037032T0000 |4 17|proliferation01606T0076 Co
P09037032T0000 |52 56|gene and
P09037032T0000 |190 205|differentiationction of CSF PC
P09037064A0183 |34 53|canarypox ALVAC/HIValine phosphatases 
P09037064A0183 |89 94|HIV-1armac
P09037064A0183 |132 145|CTL responsesbinemia. P000
P09037064A0183 |163 169|numberF [HCO
P09037064A0183 |108 118|volunteers of neonat
P09037064A0183 |56 63|vectors 5-nucl
P09037064A0183 |67 85|vaccine immunogensdase P00008171T000
P09037064A0183 |7 18|application06T0076 Com
P09037064A0183 |173 182|vaccineesis shown 
P09037163A1652 |69 89|gpc4 gene expressionse P00008171T0000 Ph
P09037163A1652 |23 31|elementson with 
P09037163A1652 |56 65|induction 5-nucleo
P09037163A1652 |4 13|relevance01606T007
P09038166A0818 |68 74|intronase P0
P09038166A0818 |14 17|A1b Co
P09038166A0818 |0 9|Exons A1aP00001606
P09038192A0846 |37 43|Dudleyne pho
P09038192A0846 |45 47|D.ha
P09038192A0846 |15 24|inhibitorCompariso
P09038192A0846 |26 34|PD098059with alk
P09038202A1951 |170 179|promoters-] is sho
P09038202A1951 |6 10|data606T
P09038202A1951 |142 150|proteins00008997
P09038202A1951 |37 56|repression activityne phosphatases and
P09038202A1951 |60 69|NRSF/RESTucleotida
P09038202A1951 |98 106|promoteric aspec
P09038202A1951 |23 27|ideaon w
P09038202A1951 |87 94|speciesPharmac
P09039744T0000 |69 82|sinc functionse P00008171T
P09039744T0000 |21 29|analysisison wit
P09039744T0000 |33 55|electro-encephalogramskaline phosphatases an
P09040011A1316 |69 80|thymoblastsse P0000817
P09040011A1316 |41 56|G1/S transitionhosphatases and
P09040011A1316 |12 15|p5676 
P09040011A1316 |194 214|Ras/Raf/MAPK pathwayn of CSF PCO2 the da
P09040011A1316 |114 126|transductiononatal hyper
P09040011A1316 |143 161|activation signals0008997A0472 When 
P09040011A1316 |176 186|componentsshown as a
P09040011A1316 |95 109|cell viabilitylogic aspects 
P09040011A1316 |3 10|summary001606T
P09040011A1316 |21 29|activityison wit
P09040011A1316 |16 19|lckomp
P09041123A0195 |70 77|factorse P0000
P09041123A0195 |13 19|action6 Comp
P09041123A0195 |162 169|complexSF [HCO
P09041123A0195 |131 140|responsesubinemia.
P09041123A0195 |36 42|ligandine ph
P09042078A0202 |64 74|dimensionsotidase P0
P09042078A0202 |28 36|incisorsth alkal
P09042078A0202 |45 54|directionhatases a
P09042078A0202 |109 117|subjectsof neona
P09042078A0202 |89 101|jaw openingsarmacologic 
P09042078A0202 |21 24|MBFiso
P09042269A1007 |54 66|chemotherapynd 5-nucleot
P09042269A1007 |108 114|cancer of ne
P09042269A1007 |6 14|findings606T0076
P09042683A0492 |4 21|FBF questionnaire01606T0076 Compar
P09042683A0492 |63 79|symptoms profileeotidase P000081
P09042683A0492 |159 172|schizophrenian CSF [HCO3-]
P09042683A0492 |146 154|disorder8997A047
P09042683A0492 |99 107|disorderc aspect
P09042755T0000 |16 35|sigma factor sigmaBomparison with alka
P09042755T0000 |107 119|growth phases of neonata
P09042755T0000 |62 72|regulationleotidase 
P09042755T0000 |95 103|responselogic as
P09042755T0000 |124 134|heat shockerbilirubi
P09042755T0000 |80 91|sigB operon1T0000 Phar
P09042911A0626 |187 195|sequencefunction
P09042911A0626 |40 54|glucocorticoidphosphatases a
P09042911A0626 |74 84|regulation0008171T00
P09042911A0626 |99 104|liverc asp
P09042911A0626 |8 25|promoter elements6T0076 Comparison
P09042911A0626 |141 151|expressionP00008997A
P09043534A1600 |70 77|minutese P0000
P09043534A1600 |22 31|decreasesson with 
P09043534A1600 |39 53|alkalinization phosphatases 
P09043768A0139 |35 38|BLMlin
P09043768A0139 |20 31|biokineticsrison with 
P09043768A0139 |52 62|indium-111 and 5-nuc
P09043768A0139 |64 70|In-111otidas
P09045636A0789 |0 17|CD3 cross-linkingP00001606T0076 Co
P09045636A0789 |26 50|tyrosine phosphorylationwith alkaline phosphatas
P09045636A0789 |74 81|T cells0008171
P09045636A0789 |54 59|Sam68nd 5-
P09045805A0945 |84 96|acoK mutants00 Pharmacol
P09045805A0945 |158 182|transactivating functionen CSF [HCO3-] is shown 
P09045805A0945 |36 50|acoABCD operonine phosphatas
P09045805A0945 |112 119|plasmidneonata
P09045805A0945 |18 28|expressionparison wi
P09045805A0945 |190 202|gene productction of CSF
P09045805A0945 |139 143|acoK. P0
P09045842T0000 |17 22|alphampari
P09045842T0000 |36 44|subunitsine phos
P09045842T0000 |88 98|mer operonharmacolog
P09045842T0000 |70 80|expressione P0000817
P09045842T0000 |48 62|RNA polymeraseases and 5-nuc
P09045842T0000 |0 9|MutationsP00001606
P09045919A1250 |71 74|NFE P0
P09045919A1250 |260 284|B lymphocyte developmentwhen compared to control
P09045919A1250 |27 35|evidenceith alka
P09045919A1250 |146 176|transcription factor machinery8997A0472 When CSF [HCO3-] is 
P09045919A1250 |242 251|IgH locus longer d
P09045919A1250 |60 69|activatorucleotida
P09045919A1250 |195 212|enhancer activity of CSF PCO2 the 
P09045919A1250 |134 138|partnemi
P09045919A1250 |85 96|combination0 Pharmacol
P09045919A1250 |114 128|c-Rel proteinsonatal hyperbi
P09045919A1250 |227 234|controlted rat
P09045919A1250 |44 53|existencephatases 
P09045919A1250 |106 109|p50ts 
P09046013A0000 |170 173|min-] 
P09046013A0000 |192 200|ischemiaion of C
P09046013A0000 |149 153|rats7A04
P09046013A0000 |311 317|arteryantly 
P09046013A0000 |96 103|SNX-111ogic as
P09046013A0000 |214 222|ligationta of K-
P09046013A0000 |243 257|carotid arterylonger displac
P09046013A0000 |71 94|calcium channel blocker P00008171T0000 Pharmac
P09046013A0000 |20 28|efficacyrison wi
P09046013A0000 |272 281|occlusiond to cont
P09046090T0000 |86 105|glucose transporter Pharmacologic aspe
P09046090T0000 |23 52|transcription factor yTAFII60on with alkaline phosphatases
P09046090T0000 |58 70|G4p1 protein-nucleotidas
P09046090T0000 |130 145|kb DNA fragmentrubinemia. P000
P09046090T0000 |4 9|genes01606
P09046090T0000 |158 161|armen 
P09046090T0000 |190 204|chromosome VIIction of CSF P
P09046186A0189 |70 80|trochantere P0000817
P09046186A0189 |54 62|fracturend 5-nuc
P09046186A0189 |36 49|fall distanceine phosphata
P09046186A0189 |4 13|protector01606T007
P09046384A0403 |0 23|Marinol/marijuana usageP00001606T0076 Comparis
P09046384A0403 |105 117|DDI subgroupcts of neona
P09046384A0403 |59 65|countsnucleo
P09046384A0403 |79 93|amylase levels71T0000 Pharma
P09046384A0403 |54 57|CD4nd 
P09047252A0209 |0 7|METHODSP000016
P09047252A0209 |125 130|ng/mlrbili
P09047252A0209 |63 72|resectioneotidase 
P09047252A0209 |104 114|AFP levelsects of ne
P09047252A0209 |21 29|patientsison wit
P09047252A0209 |77 80|HCC817
P09047252A0209 |155 160|study When
P09047344A0000 |50 61|amino acidses and 5-nu
P09047344A0000 |75 88|muscle myosin008171T0000 P
P09047344A0000 |95 107|chain kinaselogic aspect
P09047344A0000 |109 113|MLCKof n
P09047344A0000 |28 31|CBPth 
P09047344A0000 |151 159|affinity0472 Whe
P09047344A0000 |36 43|peptideine pho
P09047344A0000 |125 135|calmodulinrbilirubin
P09047344A0000 |19 26|peptidearison 
P09048617A0648 |22 26|typeson 
P09048617A0648 |105 116|cAMP effectcts of neon
P09048617A0648 |30 54|tyrosine kinase receptor alkaline phosphatases a
P09048617A0648 |91 97|naturemacolo
P09049198A0289 |34 45|involvementaline phosp
P09049198A0289 |94 104|regulationologic asp
P09049198A0289 |79 89|expression71T0000 Ph
P09049198A0289 |56 73|liver cell growth 5-nucleotidase P
P09049198A0289 |197 211|liver diseasesf CSF PCO2 the
P09049198A0289 |178 187|specimensown as a 
P09049198A0289 |8 15|insight6T0076 
P09049198A0289 |145 151|models08997A
P09049198A0289 |155 173|liver regeneration When CSF [HCO3-] 
P09049198A0289 |112 120|p21 geneneonatal
P09049198A0289 |49 52|p21ses
P09049270A0488 |0 22|Northern blot analysisP00001606T0076 Compari
P09049270A0488 |114 120|leavesonatal
P09049270A0488 |213 217|typeata 
P09049270A0488 |58 69|transcripts-nucleotida
P09049270A0488 |126 131|rootsbilir
P09049270A0488 |26 30|LeMTwith
P09049270A0488 |31 32|Aa
P09049270A0488 |181 191|metal ions as a func
P09049270A0488 |135 148|tomato plantsemia. P000089
P09049270A0488 |195 209|characteristic of CSF PCO2 t
P09049270A0488 |221 224|MTs-de
P09049270A0488 |86 91|genes Phar
P09049270A0488 |163 171|additionF [HCO3-
P09049270A0488 |43 44|Bs
P09049270A0488 |38 42|LeMTe ph
P09049304A1193 |186 210|VPF/VEGF gene expression function of CSF PCO2 th
P09049304A1193 |126 138|AP-2 proteinbilirubinemi
P09049304A1193 |47 70|Egr-1 expression vectortases and 5-nucleotidas
P09049304A1193 |31 35|AP-2alka
P09049304A1193 |3 26|co-transfection studies001606T0076 Comparison 
P09049304A1193 |81 103|VPF/VEGF transcriptionT0000 Pharmacologic as
P09049304A1193 |168 171|TGFO3-
P09049306A0830 |34 39|exonsaline
P09049306A0830 |77 87|chromosome8171T0000 
P09049306A0830 |4 12|HBP gene01606T00
P09049306A0830 |54 56|kbnd
P09049306A0830 |70 73|arme P
P09049313A0116 |50 60|expressiones and 5-n
P09049313A0116 |120 143|initiation factor eIF4G hyperbilirubinemia. P0
P09049313A0116 |8 17|instances6T0076 Co
P09049313A0116 |108 116|cleavage of neon
P09049313A0116 |80 89|proteases1T0000 Ph
P09050689A0685 |119 123|J/cml hy
P09050689A0685 |76 90|administration08171T0000 Pha
P09050689A0685 |44 49|SnET2phata
P09050689A0685 |21 29|ablationison wit
P09050689A0685 |127 132|hoursiliru
P09050689A0685 |102 111|treatmentspects of
P09050847A0180 |34 51|TBP-TAF complexesaline phosphatase
P09050847A0180 |7 12|class06T00
P09050847A0180 |88 93|classharma
P09050847A0180 |105 147|transcription initiation factor TIF-IB/SL1cts of neonatal hyperbilirubinemia. P00008
P09050847A0180 |71 77|murine P0000
P09050847A0180 |201 209|promoterF PCO2 t
P09050847A0180 |170 181|selectivity-] is shown
P09050849A0000 |0 11|Cytohesin-1P00001606T0
P09050849A0000 |95 102|homologlogic a
P09050849A0000 |135 152|Sec7 gene productemia. P00008997A0
P09050849A0000 |15 22|proteinCompari
P09050849A0000 |55 61|systemd 5-nu
P09050849A0000 |174 191|protein transports shown as a func
P09050849A0000 |35 40|cellsline 
P09050849A1459 |66 73|ARF-GEPidase P
P09050849A1459 |95 101|domainlogic 
P09050849A1459 |8 14|regard6T0076
P09050861A0903 |38 41|DEKe p
P09050861A0903 |57 68|pets factor5-nucleotid
P09050861A0903 |20 34|identificationrison with alk
P09050867A0542 |87 100|octamer motifPharmacologic
P09050867A0542 |26 38|binding sitewith alkalin
P09050867A0542 |150 168|TN control elementA0472 When CSF [HC
P09050867A0542 |74 80|factor000817
P09050867A0542 |112 136|POU-homeodomain proteinsneonatal hyperbilirubine
P09050867A0542 |43 56|Krox proteinssphatases and
P09050867A0542 |6 14|elements606T0076
P09051656A0390 |0 14|Tissue samplesP00001606T0076
P09051656A0390 |132 136|shambine
P09051656A0390 |107 128|day morphine infusions of neonatal hyperbi
P09051656A0390 |78 88|withdrawal171T0000 P
P09051656A0390 |41 45|ratshosp
P09051656A0390 |153 161|subjects72 When 
P09053309A1103 |51 62|oep mutantss and 5-nuc
P09053309A1103 |99 122|floor plate inducer shhc aspects of neonatal h
P09053309A1103 |24 47|floor plate developmentn with alkaline phospha
P09053309A1103 |84 91|absence00 Phar
P09053494A0612 |0 7|RESULTSP000016
P09053494A0612 |60 68|patientsucleotid
P09053494A0612 |44 55|cell yieldsphatases an
P09053494A0612 |119 124|G-CSFl hyp
P09053494A0612 |253 258|G-CSFplace
P09053494A0612 |260 261|Pw
P09053494A0612 |82 92|paclitaxel0000 Pharm
P09053494A0612 |245 247|CYng
P09053494A0612 |215 230|reference groupa of K-depleted
P09053494A0612 |98 100|CYic
P09053494A0612 |110 113|CEPf n
P09053494A0612 |160 162|kg C
P09053494A0612 |13 20|medians6 Compa
P09053494A0612 |205 207|kgO2
P09053494A0612 |38 42|CD34e ph
P09053494A0612 |102 104|CEsp
P09053835A0865 |34 36|OPal
P09053835A0865 |10 22|p53 activity0076 Compari
P09053835A0865 |60 68|p53 mRNAucleotid
P09053835A0865 |76 90|protein levels08171T0000 Pha
P09053973A1252 |0 10|CONCLUSIONP00001606T
P09053973A1252 |123 130|ascitesperbili
P09053973A1252 |89 95|effectarmaco
P09053973A1252 |20 34|administrationrison with alk
P09053973A1252 |109 117|patientsof neona
P09053973A1252 |38 49|misoprostole phosphata
P09055221A0288 |100 115|signal contrast aspects of neo
P09055221A0288 |76 80|MSEs0817
P09055221A0288 |42 51|magnitudeosphatase
P09055221A0288 |124 131|effectserbilir
P09055221A0288 |21 26|SSTEsison 
P09055221A0288 |4 13|intensity01606T007
P09055221A0288 |33 38|orderkalin
P09056761A0000 |205 212|nucleusO2 the 
P09056761A0000 |46 57|translationatases and 
P09056761A0000 |104 109|causeects 
P09056761A0000 |31 42|terminationalkaline ph
P09056761A0000 |14 19|cells Comp
P09056761A0000 |115 122|varietynatal h
P09056761A0000 |188 197|cytoplasmunction o
P09056761A0000 |249 253|exon dis
P09056761A0000 |146 152|events8997A0
P09056761A0000 |222 243|splice site selectiondepleted rats are no 
P09056761A0000 |70 76|codonse P000
P09056761A0000 |170 180|mRNA decay-] is show
P09057325A0177 |102 125|complementation studiesspects of neonatal hype
P09057325A0177 |40 65|pathogenicity locus pat-1phosphatases and 5-nucleo
P09057325A0177 |14 26|plasmid pCM2 Comparison 
P09057325A0177 |4 10|region01606T
P09057325A0177 |80 97|deletion analysis1T0000 Pharmacolo
P09057325A0177 |138 161|Bg/II/SmaI DNA fragmenta. P00008997A0472 When 
P09057648A0422 |171 204|chloramphenicol acetyltransferase] is shown as a function of CSF P
P09057648A0422 |59 64|tat/Snucle
P09057648A0422 |416 426|U937 cells drug with
P09057648A0422 |299 300|%e
P09057648A0422 |148 153|front97A04
P09057648A0422 |28 36|tat cDNAth alkal
P09057648A0422 |122 125|FC3ype
P09057648A0422 |329 361|micrograms/mL phytohemagglutinine (1.21 +/- 0.23 vs. P00010943A0
P09057648A0422 |211 215|gene dat
P09057648A0422 |106 120|c-fos promoterts of neonatal
P09057648A0422 |407 410|PMA hy
P09057648A0422 |319 322|FCSeat
P09057648A0422 |285 293|addition but sti
P09057648A0422 |255 267|Jurkat cellsaced when co
P09057648A0422 |458 467|mol/L PMAeral prac
P09057648A0422 |83 90|plasmid000 Pha
P09057648A0422 |374 405|mol/L phorbol myristate acetatem thus appears to be an effecti
P09057648A0422 |206 209|CAT2 t
P09057648A0422 |10 24|cotransfection0076 Compariso
P09057648A0422 |40 57|sense orientationphosphatases and 
P09057648A0422 |442 447|% FCSe for
P09057648A0422 |307 317|calf serumificantly 
P09057648A0422 |239 251|CAT activity no longer d
P09057703A1389 |0 15|Snail mortalityP00001606T0076 
P09057703A1389 |49 69|treatment conditionsses and 5-nucleotida
P09057840A0946 |16 23|proteinomparis
P09057840A0946 |56 59|NH4 5-
P09057840A0946 |60 78|2SO4-precipitationucleotidase P00008
P09057840A0946 |83 106|affinity chromatography000 Pharmacologic aspec
P09057840A0946 |40 51|homogeneityphosphatase
P09057840A0946 |113 126|AMP-Sepharoseeonatal hyper
P09057841T0000 |0 12|DerepressionP00001606T00
P09057841T0000 |74 95|isocitrate lyase gene0008171T0000 Pharmaco
P09057841T0000 |60 66|regionucleot
P09057841T0000 |99 117|Candida tropicalisc aspects of neona
P09057841T0000 |159 167|pathwaysn CSF [H
P09057841T0000 |16 31|gene expressionomparison with 
P09058002T0000 |49 60|lobe damageses and 5-n
P09058002T0000 |18 22|taskpari
P09058250A0128 |65 68|NO2tid
P09058250A0128 |46 54|analysisatases a
P09058250A0128 |9 22|complicationsT0076 Compari
P09058250A0128 |94 101|therapyologic 
P09058250A0128 |58 60|NO-n
P09058323A1287 |153 165|CNS patterns72 When CSF 
P09058323A1287 |130 134|partrubi
P09058323A1287 |29 41|cis elementsh alkaline p
P09058323A1287 |91 98|regionsmacolog
P09058323A1287 |65 70|alphatidas
P09058323A1287 |77 81|beta8171
P09058323A1287 |198 216|gene transcription CSF PCO2 the data
P09058323A1287 |177 182|alphahown 
P09058323A1287 |190 195|alphaction
P09058323A1287 |4 11|results01606T0
P09058323A1287 |169 173|beta3-] 
P09058373A0670 |0 28|RNase protection experimentsP00001606T0076 Comparison wi
P09058373A0670 |79 89|IM-9 cells71T0000 Ph
P09058373A0670 |59 75|GHR1-279 variantnucleotidase P00
P09058373A0670 |43 51|presencesphatase
P09058373A0670 |100 105|liver aspe
P09058373A1620 |186 194|receptor functio
P09058373A1620 |108 112|form of 
P09058373A1620 |11 16|tests076 C
P09058373A1620 |158 166|functionen CSF [
P09058373A1620 |25 38|reporter gene with alkalin
P09058373A1620 |65 73|elementstidase P
P09058378A1134 |101 116|transrepressionaspects of neon
P09058378A1134 |90 93|p53rma
P09058378A1134 |62 86|transactivation functionleotidase P00008171T0000
P09058378A1134 |120 123|p53 hy
P09058378A1134 |22 46|glucocorticoid receptorsson with alkaline phosph
P09059039A0850 |0 11|99mTc-HMPAOP00001606T0
P09059039A0850 |284 294|papaverines but stil
P09059039A0850 |154 164|C4 segment2 When CSF
P09059039A0850 |54 57|ACAnd 
P09059039A0850 |320 326|ml/minater s
P09059039A0850 |215 218|ACAa o
P09059039A0850 |62 65|MCAleo
P09059039A0850 |122 130|infusionyperbili
P09059039A0850 |77 85|patients8171T000
P09059039A0850 |198 207|territory CSF PCO2
P09059039A0850 |227 235|patientsted rats
P09059039A0850 |134 144|papaverinenemia. P00
P09059039A0850 |35 46|territoriesline phosph
P09059039A0850 |272 280|infusiond to con
P09059039A0850 |304 314|C1 segmentignificant
P09060045A0576 |101 118|endotoxin releaseaspects of neonat
P09060045A0576 |67 75|settingsdase P00
P09060045A0576 |11 26|review analyses076 Comparison 
P09060045A0576 |33 45|interactionskaline phosp
P09060444A0557 |34 44|expressionaline phos
P09060444A0557 |214 218|geneta o
P09060444A0557 |161 179|EGF-responsivenessCSF [HCO3-] is sho
P09060444A0557 |131 139|reporterubinemia
P09060444A0557 |5 21|promoter segment1606T0076 Compar
P09060444A0557 |113 123|initiationeonatal hy
P09060444A0557 |50 74|luciferase reporter genees and 5-nucleotidase P0
P09060622A1679 |84 85|A0
P09060622A1679 |79 83|poly71T0
P09060622A1679 |151 157|genome0472 W
P09060622A1679 |105 114|infectioncts of ne
P09060622A1679 |18 24|reportpariso
P09060622A1679 |54 68|alphavirus RNAnd 5-nucleotid
P09060622A1679 |87 91|tailPhar
P09060623A0961 |53 62|SIV entryand 5-nuc
P09060623A0961 |10 20|coreceptor0076 Compa
P09060676A1634 |17 37|virus entry featuresmparison with alkali
P09060676A1634 |52 65|coronaviruses and 5-nucleo
P09060676A1634 |88 98|propertiesharmacolog
P09060676A1634 |6 13|changes606T007
P09060971A0982 |0 7|RESULTSP000016
P09060971A0982 |49 52|BMDses
P09060971A0982 |191 192|pt
P09060971A0982 |264 265|p 
P09060971A0982 |182 189|g/cm2/yas a fu
P09060971A0982 |243 246|hiplon
P09060971A0982 |79 84|sites71T00
P09060971A0982 |225 235|trochanterleted rats
P09060971A0982 |15 20|womenCompa
P09060971A0982 |255 262|g/cm2/yaced wh
P09060971A0982 |38 45|declinee phosp
P09060971A0982 |141 148|declineP000089
P09060971A0982 |169 173|neck3-] 
P09061697A0629 |239 243|days no 
P09061697A0629 |261 264|MBqhen
P09061697A0629 |112 115|MBqneo
P09061697A0629 |178 186|patientsown as a
P09061697A0629 |146 158|day protocol8997A0472 Wh
P09061697A0629 |269 272|mCiare
P09061697A0629 |60 77|99Tcm-tetrofosminucleotidase P0000
P09061697A0629 |120 123|mCi hy
P09061697A0629 |14 15|% 
P09061697A0629 |17 25|patientsmparison
P09061697A0629 |324 336|day protocol slope (1.21
P09061697A0629 |48 51|MBqase
P09061697A0629 |55 58|mCid 5
P09061697A0629 |81 85|restT000
P09061697A0629 |191 195|resttion
P09061697A0629 |200 222|stress imaging studiesSF PCO2 the data of K-
P09061697A0629 |97 98|hg
P09061697A0629 |282 299|99Tcm-tetrofosminols but still hav
P09061697A0629 |132 138|stressbinemi
P09061697A0629 |175 176|% 
P09061697A0629 |308 316|occasionficantly
P09061697A0629 |274 278|doseto c
P09061697T0000 |69 79|comparisonse P000081
P09061697T0000 |11 23|SPET imaging076 Comparis
P09061697T0000 |29 46|99Tcm-tetrofosminh alkaline phosph
P09061697T0000 |99 119|day imaging protocolc aspects of neonata
P09061697T0000 |59 67|practicenucleoti
P09061697T0000 |87 90|dayPha
P09061698A0177 |0 13|99Tcm-DMP-HSAP00001606T007
P09061698A0177 |41 50|behaviourhosphatas
P09061698A0177 |89 93|RBCsarma
P09061698A0177 |76 87|blood cells08171T0000 
P09061698A0177 |131 149|reference standardubinemia. P0000899
P09061698A0177 |154 171|blood pool agents2 When CSF [HCO3-
P09062130A0116 |0 6|ReliefP00001
P09062130A0116 |12 26|autoinhibition76 Comparison 
P09062130A0116 |166 174|deletionHCO3-] i
P09062130A0116 |55 63|increased 5-nucl
P09062130A0116 |217 230|PTPase domainof K-depleted
P09062130A0116 |67 68|Vd
P09062130A0116 |182 193|SH2 domainsas a functi
P09062130A0116 |69 72|maxse 
P09062130A0116 |98 121|N-SH2 domain engagementic aspects of neonatal 
P09062130A0116 |136 157|phosphotyrosyl ligandmia. P00008997A0472 W
P09064659A1055 |102 115|nonsense mRNAspects of neo
P09064659A1055 |44 51|homologphatase
P09064659A1055 |92 98|levelsacolog
P09064659A1055 |146 153|protein8997A04
P09064659A1055 |177 184|homologhown as
P09064659A1055 |160 165|HUPF1 CSF 
P09064659A1055 |55 65|yeast UPF1d 5-nucleo
P09064659A1055 |188 192|UPF1unct
P09064659A1055 |69 76|proteinse P000
P09064868T0001 |2 14|miracle cure0001606T0076
P09064868T0001 |23 31|solutionon with 
P09065170A0853 |50 58|transferes and 5
P09065170A0853 |4 12|addition01606T00
P09065170A0853 |16 26|zidovudineomparison 
P09065463A1012 |0 19|DNA strand exchangeP00001606T0076 Comp
P09065463A1012 |77 80|RPA817
P09065463A1012 |33 46|Rad51 proteinkaline phosph
P09065690A0463 |102 110|sequencespects o
P09065690A0463 |76 91|CAR1 expression08171T0000 Phar
P09065690A0463 |59 64|genesnucle
P09065690A0463 |128 136|functionlirubine
P09065690A0463 |31 41|expressionalkaline p
P09065690A0463 |118 121|URSal 
P09065690A0463 |140 161|nitrogen availability P00008997A0472 When 
P09065690A0463 |0 5|Ume6pP0000
P09065768A0862 |115 127|lactase mRNAnatal hyperb
P09065768A0862 |11 16|class076 C
P09065768A0862 |44 57|kb transcriptphatases and 
P09065768A0862 |20 24|cDNAriso
P09067577A0307 |3 13|cell lines001606T007
P09067577A0307 |47 55|tyrosinetases an
P09067577A0307 |78 81|CRK171
P09067577A0307 |29 36|BCR/ABLh alkal
P09067577A0307 |38 42|CRKLe ph
P09067577A0721 |85 88|C3G0 P
P09067577A0721 |36 44|proteinsine phos
P09067577A0721 |90 93|SOSrma
P09067577A0721 |98 103|c-ABLic as
P09067577A0721 |65 69|CRKLtida
P09067577A0721 |17 22|cellsmpari
P09068989T0000 |0 6|EffectP00001
P09068989T0000 |79 85|system71T000
P09068989T0000 |44 56|leaf extractphatases and
P09068989T0000 |10 28|Azadirachta indica0076 Comparison wi
P09071308A0376 |17 26|opacitiesmparison 
P09071308A0376 |151 155|NTMB0472
P09071308A0376 |52 64|distribution and 5-nucle
P09071308A0376 |129 137|patientsirubinem
P09071308A0376 |110 111|%f
P09071308A0376 |123 124|%p
P09071308A0376 |87 94|findingPharmac
P09071308A0376 |143 146|MTB000
P09071308A0376 |0 7|RESULTSP000016
P09071407T0000 |64 76|cohabitationotidase P000
P09071407T0000 |29 40|guinea pigsh alkaline 
P09071407T0000 |12 20|oxytocin76 Compa
P09071407T0000 |94 103|conditionologic as
P09072361A0357 |34 39|SHRSPaline
P09072361A0357 |122 137|magnesium ratioyperbilirubinem
P09072361A0357 |61 70|magnesiumcleotidas
P09072361A0357 |24 32|fractionn with a
P09072361A0357 |94 103|elevationologic as
P09072361A0357 |79 86|tissues71T0000
P09072361A0357 |167 170|WKYCO3
P09072361A0357 |175 180|SHRSR show
P09072361A0357 |111 118|calcium neonat
P09072361A0357 |49 57|decreaseses and 
P09073074T0000 |36 53|FGFR-3 psuedogeneine phosphatases 
P09073074T0000 |10 23|transcription0076 Comparis
P09073074T0000 |67 79|developementdase P000081
P09073582A0444 |69 81|SSO activityse P00008171
P09073582A0444 |89 96|Kataokaarmacol
P09073582A0444 |105 108|Molcts
P09073582A0444 |42 61|BglII-SmaI fragmentosphatases and 5-nu
P09073582A0444 |11 17|report076 Co
P09073582A0444 |83 87|ori2000 
P09074508A0397 |34 39|exonsaline
P09074508A0397 |65 67|kbti
P09074508A0397 |10 19|CD38 gene0076 Comp
P09074508A0397 |81 87|genomeT0000 
P09075739A0827 |0 4|TypeP000
P09075739A0827 |78 83|ovary171T0
P09075739A0827 |47 48|St
P09075739A0827 |67 73|kidneydase P
P09075739A0827 |8 22|splice pattern6T0076 Compari
P09075739A0827 |35 42|exon U3line ph
P09076336A0281 |205 217|GH secretionO2 the data 
P09076336A0281 |56 65|diagnosis 5-nucleo
P09076336A0281 |180 194|GH sufficiencyn as a functio
P09076336A0281 |90 103|constellationrmacologic as
P09076336A0281 |155 163|spectrum When CS
P09076336A0281 |129 137|findingsirubinem
P09076336A0281 |0 13|GH deficiencyP00001606T007
P09077076A0219 |9 17|CRP testT0076 Co
P09077108A0458 |85 94|TNF-alpha0 Pharmac
P09077108A0458 |126 131|fluidbilir
P09077108A0458 |27 38|pleocytosisith alkalin
P09077108A0458 |79 83|IL-671T0
P09077108A0458 |74 77|IgG000
P09077108A0458 |19 25|periodarison
P09077108A0458 |64 70|levelsotidas
P09077108A0458 |100 104|PGE2 asp
P09077437T0000 |0 22|Recognition mechanismsP00001606T0076 Compari
P09077437T0000 |82 96|RNA polymerase0000 Pharmacol
P09077437T0000 |43 49|originsphata
P09077437T0000 |53 61|phage f1and 5-nu
P09077438A0076 |4 11|minimum01606T0
P09077438A0076 |26 34|subunitswith alk
P09077438A0076 |39 52|RNA synthesis phosphatases
P09079625A0935 |51 62|interactions and 5-nuc
P09079625A0935 |113 118|siteseonat
P09079625A0935 |22 40|adhesion componentson with alkaline 
P09079625A0935 |130 139|adhesionsrubinemia
P09079625A0935 |101 109|activityaspects 
P09079625A0935 |81 84|PKCT00
P09079625A0935 |0 10|Syndecan-4P00001606T
P09079638A0883 |51 58|Ser-346s and 5
P09079638A0883 |95 103|mutationlogic as
P09079638A0883 |78 85|alanine171T000
P09079638A0883 |28 33|CXCR2th al
P09079638A0883 |241 257|ligand challengeo longer displac
P09079638A0883 |4 16|3ASubE cells01606T0076 C
P09079638A0883 |39 47|mutation phospha
P09079638A0883 |172 180|response is show
P09079638A0883 |131 137|domainubinem
P09079638A0883 |184 190|ligand a fun
P09079638A0883 |116 122|serineatal h
P09079638A0883 |204 205|%C
P09079650A0136 |119 126|kinasesl hyper
P09079650A0136 |128 132|JNKsliru
P09079650A0136 |79 85|p42/4471T000
P09079650A0136 |15 26|MAPK familyComparison 
P09079650A0136 |71 75|ERKs P00
P09079650A0136 |98 103|c-Junic as
P09079650A0136 |143 150|p38/Hog0008997
P09079650A0136 |53 69|response kinasesand 5-nucleotida
P09079650A0136 |153 168|protein kinases72 When CSF [HC
P09079650A0136 |86 90|MAPK Pha
P09079650A0136 |0 7|MembersP000016
P09079689A0472 |34 44|PAS domainaline phos
P09079689A0472 |145 158|reading frame08997A0472 Wh
P09079689A0472 |60 70|C terminusucleotidas
P09079689A0472 |117 123|domaintal hy
P09079689A0472 |96 100|cDNAogic
P09079689A0472 |0 4|MOP5P000
P09079817A0928 |35 40|cellsline 
P09079817A0928 |75 79|mRNA0081
P09079817A0928 |93 106|NO synthetasecologic aspec
P09079817A0928 |12 25|NO production76 Comparison
P09079817A0928 |65 71|levelstidase
P09079878A0000 |19 51|Lactobacillus sake plasmid pCIM1arison with alkaline phosphatase
P09079878A0000 |106 120|reading framests of neonatal
P09079878A0000 |122 126|ORFsyper
P09079878A0000 |9 11|kbT0
P09079878A0000 |177 179|S.ho
P09079878A0000 |144 148|lasA0089
P09079902A0713 |100 107|complex aspect
P09079902A0713 |73 75|Pk00
P09079902A0713 |134 136|Pkne
P09079902A0713 |85 88|Pra0 P
P09079902A0713 |179 187|affinitywn as a 
P09079902A0713 |56 71|pyruvate kinase 5-nucleotidase
P09079902A0713 |211 218|complex data o
P09079902A0713 |163 165|PkF 
P09079902A0713 |9 12|PraT00
P09079902A0713 |78 80|Pk17
P09079902A0713 |193 196|Praon 
P09079902A0713 |142 145|Pra000
P09079902A0713 |129 132|Ndkiru
P09079902A0713 |235 238|Ndk ar
P09079904A0995 |152 162|Bvg system472 When C
P09079904A0995 |11 26|iron regulation076 Comparison 
P09079904A0995 |28 43|sodA expressionth alkaline pho
P09079904A0995 |60 67|changesucleoti
P09079904A0995 |131 140|virulenceubinemia.
P09079904A0995 |95 108|coumermycin Alogic aspects
P09079904A0995 |71 83|DNA topology P00008171T0
P09079915T0000 |99 125|consensus sigma70 promoterc aspects of neonatal hype
P09079915T0000 |10 26|characterization0076 Comparison 
P09079915T0000 |59 74|motility operonnucleotidase P0
P09079928A0525 |0 14|M. leprae OxyRP00001606T0076
P09079928A0525 |90 96|regionrmacol
P09079928A0525 |100 109|M. leprae aspects 
P09079928A0525 |54 61|bindingnd 5-nu
P09079928A0525 |69 78|oxyR-ahpCse P00008
P09079928A1319 |21 25|OxyRison
P09079928A1319 |79 84|loops71T00
P09079928A1319 |37 43|P1oxyRne pho
P09079928A1319 |127 135|bacteriailirubin
P09079928A1319 |162 178|LysR superfamilySF [HCO3-] is sh
P09079928A1319 |111 115|oxyR neo
P09079928A1319 |140 154|characteristic P00008997A047
P09079928A1319 |97 107|expressiongic aspect
P09079928A1319 |4 16|binding site01606T0076 C
P09080250A0212 |155 159|P815 Whe
P09080250A0212 |108 133|polymerase chain reaction of neonatal hyperbilirub
P09080250A0212 |135 138|PCRemi
P09080250A0212 |61 85|p15E cDNA gene fragmentscleotidase P00008171T000
P09080250A0212 |15 20|studyCompa
P09080250A0212 |189 201|tumour cellsnction of CS
P09080250A0212 |178 187|P815/DTICown as a 
P09080250A0212 |99 104|meansc asp
P09080517A0215 |12 20|patients76 Compa
P09081389A1088 |0 5|GradeP0000
P09081389A1088 |10 19|mucositis0076 Comp
P09081389A1088 |46 52|cyclesatases
P09081389A1088 |37 38|%n
P09081392A0174 |36 52|salvage regimensine phosphatases
P09082335A0730 |0 4|NoneP000
P09082335A0730 |22 36|manifestationsson with alkal
P09082335A0730 |69 74|meansse P0
P09083291A1378 |102 106|cdksspec
P09083291A1378 |51 61|expressions and 5-nu
P09083291A1378 |118 121|MCsal 
P09083291A1378 |263 270|S phasen compa
P09083291A1378 |249 259|transition displaced
P09083291A1378 |213 225|inactivationata of K-dep
P09083291A1378 |150 158|activityA0472 Wh
P09083291A1378 |229 232|pRbd r
P09083291A1378 |79 97|G1 phase cyclin D171T0000 Pharmacolo
P09083291A1378 |193 208|phosphorylationon of CSF PCO2 
P09083291A1378 |135 147|cyclin E-cdkemia. P00008
P09083291A1378 |6 15|TGF-beta1606T0076 
P09083291A1378 |66 75|abundanceidase P00
P09083291A1378 |236 244|G1 phaseare no l
P09083345A0851 |204 212|durationCO2 the 
P09083345A0851 |116 121|SYPLRatal 
P09083345A0851 |216 224|symptoms of K-de
P09083345A0851 |22 28|valuesson wi
P09083345A0851 |59 63|neednucl
P09083345A0851 |127 134|respectilirubi
P09083345A0851 |106 112|valuests of 
P09083345A0851 |13 18|range6 Com
P09083345A0851 |187 202|characteristicsfunction of CSF
P09083345A0851 |252 270|treatment efficacysplaced when compa
P09083345A0851 |142 161|inter-relationships00008997A0472 When 
P09083345A0851 |79 88|districts71T0000 P
P09083345A0851 |235 247|presentation are no long
P09083563A0971 |255 264|B. cereusaced when
P09083563A0971 |242 247|fluid long
P09083563A0971 |208 214|toxinsthe da
P09083563A0971 |106 123|arachnoid vesselsts of neonatal hy
P09083563A0971 |14 21|lesions Compar
P09083563A0971 |168 173|fluidO3-] 
P09083563A0971 |52 65|surface layer and 5-nucleo
P09083563A0971 |70 91|leptomeningeal tissuee P00008171T0000 Phar
P09084174A0667 |119 160|aspartate-beta-semialdehyde dehydrogenasel hyperbilirubinemia. P00008997A0472 When
P09084174A0667 |199 209|similarityCSF PCO2 t
P09084174A0667 |57 61|leuB5-nu
P09084174A0667 |105 108|asdcts
P09084174A0667 |90 103|dehydrogenasermacologic as
P09084174A0667 |5 13|fragment1606T007
P09084174A0667 |172 176|orfA is 
P09084174A0667 |42 53|nucleotidesosphatases 
P09084174A0667 |162 165|AsdSF 
P09084174A0667 |235 245|Vibrio spp are no lo
P09084174A0667 |217 229|Asd proteinsof K-deplete
P09084174A0667 |184 191|product a func
P09084176A0601 |16 24|activityompariso
P09084176A0601 |107 126|M. smegmatis cloness of neonatal hyper
P09084176A0601 |83 86|RNA000
P09084176A0601 |41 64|slot-blot hybridizationhosphatases and 5-nucle
P09084176A0601 |101 105|lacZaspe
P09084227A0833 |0 11|Hovenitin IP00001606T0
P09084227A0833 |20 30|ampelopsinrison with
P09084227A0833 |158 166|activityen CSF [
P09084227A0833 |61 72|ingredientscleotidase 
P09084227A0833 |211 215|rats dat
P09084227A0833 |190 207|muscle relaxationction of CSF PCO2
P09084227A0833 |115 123|medicinenatal hy
P09084227A0833 |87 96|fractionsPharmacol
P09084621A0374 |171 189|movement variables] is shown as a fu
P09084621A0374 |162 166|taskSF [
P09084621A0374 |130 158|brain activity proportionaterubinemia. P00008997A0472 Wh
P09084621A0374 |28 43|characteristicsth alkaline pho
P09084621A0374 |121 126|areashyper
P09084621A0374 |98 108|blood flowic aspects
P09084621A0374 |76 85|magnitude08171T000
P09084621A0374 |0 13|Movement timeP00001606T007
P09084621A2567 |0 5|AreasP0000
P09084621A2567 |66 78|motor cortexidase P00008
P09084621A2567 |33 37|rCBFkali
P09084621A2567 |99 105|sulcusc aspe
P09084621A2567 |116 123|caudateatal hy
P09085842A0181 |169 176|SF2/ASF3-] is 
P09085842A0181 |150 164|U1-70K proteinA0472 When CSF
P09085842A0181 |135 142|domainsemia. P
P09085842A0181 |74 85|splice site0008171T000
P09085842A0181 |42 50|U1 snRNPosphatas
P09085842A0181 |89 117|protein/protein interactionsarmacologic aspects of neona
P09085842A0181 |7 14|studies06T0076
P09085842A1559 |146 167|phosphorylation state8997A0472 When CSF [H
P09085842A1559 |29 40|27K proteinh alkaline 
P09085842A1559 |183 200|pre-mRNA splicings a function of C
P09085842A1559 |94 122|protein/protein interactionsologic aspects of neonatal h
P09086268A0611 |84 86|P200
P09086268A0611 |108 110|P7 o
P09086268A0611 |88 102|RNA polymeraseharmacologic a
P09086268A0611 |61 70|particlescleotidas
P09086268A0611 |36 45|particlesine phosp
P09086268A0611 |9 11|P7T0
P09086268A0611 |54 56|P7nd
P09087430A1046 |50 53|BSAes 
P09087430A1046 |75 78|PAP008
P09087430A1046 |18 29|U1A peptideparison wit
P09088371T0000 |17 26|protein Cmparison 
P09088371T0000 |28 37|protein Sth alkali
P09088371T0000 |90 101|haemorrhagermacologic 
P09088371T0000 |43 55|antithrombinsphatases an
P09088371T0000 |63 71|patientseotidase
P09088371T0000 |0 13|Plasma levelsP00001606T007
P09088416A0000 |85 93|syndrome0 Pharma
P09088416A0000 |193 209|artery occlusionon of CSF PCO2 t
P09088416A0000 |150 162|hearing lossA0472 When C
P09088416A0000 |31 37|branchalkali
P09088416A0000 |66 73|IBRBRAOidase P
P09088416A0000 |178 184|branchown as
P09088416A0000 |111 129|migraine headaches neonatal hyperbil
P09088416A0000 |131 139|tinnitusubinemia
P09088416A0000 |141 148|vertigoP000089
P09088416A0000 |55 64|occlusiond 5-nucle
P09088416A0000 |221 229|etiology-deplete
P09088737T0000 |66 76|microscopyidase P000
P09088737T0000 |95 99|CMTFlogi
P09088737T0000 |23 45|thickness measurementson with alkaline phosp
P09089093A0373 |0 9|SequencesP00001606
P09089093A0373 |79 96|enhancer elements71T0000 Pharmacol
P09089093A0373 |38 46|CA genese phosph
P09089653A0615 |187 202|control plasmidfunction of CSF
P09089653A0615 |60 64|exonucle
P09089653A0615 |124 143|luciferase activityerbilirubinemia. P0
P09089653A0615 |12 20|plasmids76 Compa
P09089653A0615 |47 49|ntta
P09089653A0615 |104 112|sequenceects of 
P09089653A0615 |53 56|UTRand
P09089653A0615 |78 88|nt segment171T0000 P
P09089653A0615 |154 159|times2 Whe
P09089653A1112 |0 8|AnalysisP0000160
P09089653A1112 |126 128|ntbi
P09089653A1112 |90 96|regionrmacol
P09089653A1112 |100 110|protection aspects o
P09089653A1112 |25 37|interactions with alkali
P09089653A1112 |50 70|DNase-I footprintinges and 5-nucleotidas
P09090050A0419 |58 63|mouse-nucl
P09090050A0419 |31 45|sugar carriersalkaline phosp
P09090054A0186 |220 227|clusterK-deple
P09090054A0186 |73 82|regulator00008171T
P09090054A0186 |62 67|genesleoti
P09090054A0186 |97 114|alpha-glucosidasegic aspects of ne
P09090054A0186 |25 29|loci wit
P09090054A0186 |130 134|generubi
P09090054A0186 |193 197|MAL1on o
P09090054A0186 |237 242|genesre no
P09090054A0186 |156 178|alpha-glucosidase geneWhen CSF [HCO3-] is sh
P09090054A0186 |84 92|permease00 Pharm
P09090592A0175 |102 107|errorspect
P09090592A0175 |30 37|control alkali
P09090592A0175 |9 16|methodsT0076 C
P09090592A0175 |180 191|orientationn as a func
P09090592A0175 |42 63|activation fMR imagesosphatases and 5-nucl
P09091010A1003 |85 92|disease0 Pharm
P09091010A1003 |6 11|women606T0
P09091010A1003 |53 61|cytologyand 5-nu
P09091125A0161 |54 62|activitynd 5-nuc
P09091125A0161 |105 120|NBT-test valuescts of neonatal
P09091125A0161 |66 74|alkalineidase P0
P09091125A0161 |79 96|acid phosphatases71T0000 Pharmacol
P09091125A0161 |20 25|cellsrison
P09091403T0001 |68 73|mousease P
P09091403T0001 |113 131|microsatellite DNAeonatal hyperbilir
P09091403T0001 |23 36|DNA sequenceson with alkal
P09091403T0001 |104 108|siteects
P09091403T0001 |84 94|mts1 genes00 Pharmac
P09091403T0001 |54 60|intronnd 5-n
P09091403T0001 |0 8|AnalysisP0000160
P09092493A0861 |171 180|signaling] is show
P09092493A0861 |143 147|cell0008
P09092493A0861 |23 31|VIP CyREon with 
P09092493A0861 |52 75|AP-1 signaling pathways and 5-nucleotidase P00
P09092493A0861 |129 138|mechanismirubinemi
P09092493A0861 |4 15|integration01606T0076 
P09092493A0861 |39 47|Jak-Stat phospha
P09092493A0861 |100 108|proteins aspects
P09092580A1354 |140 145|sites P000
P09092580A1354 |109 123|transmigrationof neonatal hy
P09092580A1354 |72 82|activationP00008171T
P09092580A1354 |46 64|MAP kinase pathwayatases and 5-nucle
P09092580A1354 |6 13|studies606T007
P09092580A1354 |27 38|involvementith alkalin
P09092580A1354 |96 101|cellsogic 
P09092636A0802 |118 142|DYZ3 satellite sequencesal hyperbilirubinemia. P
P09092636A0802 |78 91|recombination171T0000 Phar
P09092636A0802 |180 184|DYZ5n as
P09092636A0802 |48 62|rad54-3 alleleases and 5-nuc
P09092636A0802 |4 11|results01606T0
P09092636A0802 |206 215|YAC clone2 the dat
P09092675A0283 |50 51|Ae
P09092675A0283 |41 48|P22 R17hosphat
P09092675A0283 |89 98|infectionarmacolog
P09092675A0283 |29 39|OcRNA siteh alkaline
P09092675A0283 |108 115|strains of neo
P09092675A0283 |56 57|U 
P09092675A0283 |2 20|P22 R17 derivative0001606T0076 Compa
P09093867T0000 |32 41|formationlkaline p
P09093867T0000 |57 61|fate5-nu
P09093867T0000 |13 30|Ac/Ds transposons6 Comparison with
P09093867T0000 |43 52|structuresphatases
P09094093A0578 |5 9|site1606
P09094093A0578 |31 39|TATA boxalkaline
P09094093A0578 |56 61|cells 5-nu
P09094315A0541 |68 79|cyclin-Cdksase P000081
P09094315A0541 |8 13|study6T007
P09094315A0541 |56 64|activity 5-nucle
P09094315A0541 |36 46|regulationine phosph
P09094671A1192 |34 38|Mts1alin
P09094671A1192 |60 68|p15INK4bucleotid
P09094671A1192 |111 133|Southern blot analysis neonatal hyperbilirub
P09094671A1192 |40 48|p16INK4aphosphat
P09094671A1192 |183 187|genes a 
P09094671A1192 |149 158|deletions7A0472 Wh
P09094671A1192 |54 58|Mts2nd 5
P09094671A1192 |96 102|regionogic a
P09094671A1192 |0 32|Candidate tumor suppressor genesP00001606T0076 Comparison with a
P09096229T0000 |0 15|Excision repairP00001606T0076 
P09096229T0000 |240 257|control sequencesno longer displac
P09096229T0000 |90 97|mappingrmacolo
P09096229T0000 |36 46|nucleotideine phosph
P09096229T0000 |23 28|levelon wi
P09096229T0000 |142 148|strand000089
P09096229T0000 |79 88|MFA2 gene71T0000 P
P09096229T0000 |116 122|repairatal h
P09096229T0000 |201 206|rad16F PCO
P09096229T0000 |168 182|identificationO3-] is shown 
P09096234T0000 |64 88|DNA sequence specificityotidase P00008171T0000 P
P09096234T0000 |90 118|operator site discriminationrmacologic aspects of neonat
P09096234T0000 |41 49|subunitshosphata
P09096234T0000 |122 147|phage lambda cI repressoryperbilirubinemia. P00008
P09096234T0000 |21 32|interactionison with a
P09096958A0000 |239 248|adhesions no longe
P09096958A0000 |78 92|platelet talin171T0000 Pharm
P09096958A0000 |46 56|antibodiesatases and
P09096958A0000 |209 228|actin stress fibershe data of K-deplet
P09096958A0000 |121 134|precipitationhyperbilirubi
P09096958A0000 |140 158|immunofluorescence P00008997A0472 Wh
P09096958A0000 |96 112|Western blottingogic aspects of 
P09096958A0000 |196 200|TD77of C
P09096958A0000 |24 29|paneln wit
P09096958A0000 |262 275|cell motilityen compared t
P09096958A0000 |175 191|antibodies TA205 shown as a func
P09096958A0000 |306 317|fibroblastsnificantly 
P09098066A0119 |205 214|phenotypeO2 the da
P09098066A0119 |161 169|proteinsCSF [HCO
P09098066A0119 |147 151|loss997A
P09098066A0119 |47 52|genestases
P09098066A0119 |104 108|HMW3ects
P09098066A0119 |86 99|proteins HMW1 Pharmacologi
P09098066A0119 |5 10|locus1606T
P09098066A0119 |266 271|locusompar
P09098066A0119 |230 241|designation rats are n
P09098066A0119 |118 128|insertionsal hyperbi
P09098066A0119 |273 276|crl to
P09098066A0119 |34 37|kbpali
P09098899A0000 |186 203|zinc-finger motif function of CSF 
P09098899A0000 |14 15|B 
P09098899A0000 |60 70|Ogr familyucleotidas
P09098899A0000 |30 42|acid protein alkaline ph
P09098899A0000 |84 105|transcription factors00 Pharmacologic aspe
P09098899A0000 |125 130|phagerbili
P09098899A0000 |0 9|ColiphageP00001606
P09098899A0435 |4 26|UV absorption spectrum01606T0076 Comparison 
P09098899A0435 |218 227|mM-1 cm-1f K-deple
P09098899A0435 |260 265|Cys-Swhen 
P09098899A0435 |58 72|characteristic-nucleotidase 
P09098899A0435 |243 251|presencelonger d
P09098899A0435 |268 274|centerpared 
P09098899A0435 |181 194|acidification as a functio
P09098899A0435 |196 209|delta epsilonof CSF PCO2 t
P09098899A0435 |104 131|charge-transfer transitionsects of neonatal hyperbilir
P09098899A0435 |257 259|Cded
P09098899A0435 |54 56|nmnd
P09098899A0435 |141 174|difference absorption coefficientP00008997A0472 When CSF [HCO3-] i
P09098899A0435 |76 83|CysS-Cd08171T0
P09098899A0435 |38 46|shouldere phosph
P09099683A0000 |0 21|Diacylglycerol kinaseP00001606T0076 Compar
P09099683A0000 |146 150|acid8997
P09099683A0000 |56 80|messenger diacylglycerol 5-nucleotidase P0000817
P09099683A0000 |122 131|messengeryperbilir
P09099683A0000 |39 45|levels phosp
P09099683A0000 |23 26|DGKon 
P09099683A0000 |84 89|cells00 Ph
P09099702A0000 |116 120|GCNFatal
P09099702A0000 |74 99|orphan receptor germ cell0008171T0000 Pharmacologi
P09099702A0000 |31 38|cloningalkalin
P09099702A0000 |46 50|germatas
P09099702A0000 |122 125|RTRype
P09099702A0000 |108 114|factor of ne
P09099702A0692 |187 192|stagefunct
P09099702A0692 |13 21|sequence6 Compar
P09099702A0692 |60 64|RTREucle
P09099702A0692 |215 218|RTRa o
P09099702A0692 |130 145|mouse protaminerubinemia. P000
P09099702A0692 |148 152|gene97A0
P09099702A0692 |29 36|conRTREh alkal
P09099702A0692 |81 86|P2-RET0000
P09099702A0692 |196 211|spermatogenesisof CSF PCO2 the
P09099702A0692 |116 122|regionatal h
P09099743A0585 |204 211|doubletCO2 the
P09099743A0585 |47 51|formtase
P09099743A0585 |194 197|kDan o
P09099743A0585 |168 180|polypeptidesO3-] is show
P09099743A0585 |80 88|particle1T0000 P
P09099743A0585 |131 143|polypeptidesubinemia. P0
P09099743A0585 |245 254|nucleolinnger disp
P09099743A0585 |19 31|purificationarison with 
P09099743A0585 |223 226|kDaepl
P09099743A0585 |103 110|mRNP3+4pects o
P09099745A1446 |139 143|Cdk2. P0
P09099745A1446 |352 356|Cdk20010
P09099745A1446 |112 115|p21neo
P09099745A1446 |159 168|threoninen CSF [HC
P09099745A1446 |333 348|phosphorylation.21 +/- 0.23 vs
P09099745A1446 |208 217|mechanismthe data 
P09099745A1446 |120 123|p27 hy
P09099745A1446 |7 16|complexes06T0076 C
P09099745A1446 |67 76|complexesdase P000
P09099745A1446 |46 52|weightatases
P09099745A1446 |221 231|activation-depleted 
P09099745A1446 |235 248|cyclin E-Cdk2 are no longe
P09099745A1446 |173 188|phosphorylationis shown as a f
P09099745A1446 |272 297|CDK inhibitor associationd to controls but still h
P09100202A0000 |19 38|Class II recessionsarison with alkalin
P09100202A0000 |108 130|tissue graft procedure of neonatal hyperbili
P09100202A0000 |45 53|patientshatases 
P09100202A0000 |7 12|Class06T00
P09101085A0686 |34 44|cell linesaline phos
P09101085A0686 |80 95|p27Kip1 protein1T0000 Pharmaco
P09101085A0686 |62 72|expressionleotidase 
P09101085A0686 |4 15|derivatives01606T0076 
P09101085A0686 |114 125|cell growthonatal hype
P09101085A0686 |100 110|inhibition aspects o
P09101910A0394 |51 52|%s
P09101910A0394 |58 67|mortality-nucleoti
P09101910A0394 |94 99|yearsologi
P09101910A0394 |107 108|%s
P09101910A0394 |71 79|patients P000081
P09101910A0394 |18 27|mortalityparison w
P09101910A0394 |35 43|patientsline pho
P09102113A0739 |157 158|%h
P09102113A0739 |106 113|diseasets of n
P09102113A0739 |14 30|failure patients Comparison with
P09102113A0739 |67 73|causesdase P
P09102113A0739 |130 135|deathrubin
P09102113A0739 |83 92|frequency000 Pharm
P09103382T0000 |55 63|critiqued 5-nucl
P09103382T0000 |8 23|FIGO definition6T0076 Comparis
P09103382T0000 |36 51|cancer stage IAine phosphatase
P09104816A0610 |119 121|VVl 
P09104816A0610 |29 39|biogenesish alkaline
P09104816A0610 |61 67|detailcleoti
P09104816A0610 |14 17|Vpu Co
P09104816A0610 |21 26|classison 
P09104816A0610 |4 10|effect01606T
P09104816A0610 |103 117|vaccinia viruspects of neona
P09105042A1497 |119 128|mutationsl hyperbi
P09105042A1497 |182 188|myosinas a f
P09105042A1497 |73 85|HCM patients00008171T000
P09105042A1497 |195 208|chain protein of CSF PCO2 
P09105042A1497 |30 39|phenotype alkaline
P09105042A1497 |279 285|effectntrols
P09105042A1497 |5 10|study1606T
P09105042A1497 |43 64|myofibrillar disarraysphatases and 5-nucle
P09105042A1497 |160 167|failure CSF [H
P09105042A1497 |237 247|sarcomeresre no long
P09105042A1497 |322 328|stresser slo
P09105042A1497 |342 359|beta MHC function.23 vs. P00010943
P09105363A0636 |34 55|emission spectroscopyaline phosphatases an
P09105363A0636 |83 110|tissue silicon measurements000 Pharmacologic aspects o
P09105363A0636 |20 26|plasmarison 
P09105530A0000 |16 24|lysozymeompariso
P09105530A0000 |74 92|cheese preparation0008171T0000 Pharm
P09105530A0000 |3 14|egg protein001606T0076
P09106057A0000 |238 242|HPLCe no
P09106057A0000 |222 236|chromatographydepleted rats 
P09106057A0000 |156 162|plasmaWhen C
P09106057A0000 |249 266|chemiluminescence displaced when c
P09106057A0000 |268 270|CLpa
P09106057A0000 |30 43|determination alkaline pho
P09106057A0000 |60 69|N-ethyl-8ucleotida
P09106057A0000 |167 172|urineCO3-]
P09106057A0000 |73 92|anhydroerythromycin00008171T0000 Pharm
P09106057A0000 |135 146|metabolitesemia. P0000
P09106057A0000 |50 58|N-methyles and 5
P09106057A0000 |272 281|detectiond to cont
P09106057A0000 |111 116|EM523 neon
P09106057A0000 |2 8|method000160
P09108029A0399 |102 114|redox factorspects of ne
P09108029A0399 |83 100|DNA repair enzyme000 Pharmacologic
P09108029A0399 |27 35|activityith alka
P09108029A0399 |150 167|DNA repair enzymeA0472 When CSF [H
P09108029A0399 |60 64|AP-1ucle
P09108029A0399 |169 184|AP endonuclease3-] is shown as
P09108029A0399 |39 56|activator protein phosphatases and
P09108029A0399 |118 123|Ref-1al hy
P09108038A1128 |100 106|family aspec
P09108038A1128 |10 20|LRR domain0076 Compa
P09108038A1128 |123 139|binding proteinsperbilirubinemia
P09108038A1128 |64 84|C. elegans homologueotidase P00008171T00
P09108038A1128 |40 46|domainphosph
P09108038A1128 |48 55|Acan125ases an
P09108207A0306 |49 73|oropharyngeal irritationses and 5-nucleotidase P
P09108207A0306 |13 26|participation6 Comparison 
P09108279A0431 |186 194|8-OxoG/C functio
P09108279A0431 |61 69|extractscleotida
P09108279A0431 |23 29|8-OxoGon wit
P09108279A0431 |176 184|cytosineshown as
P09108279A0431 |108 126|34mer DNA fragment of neonatal hyper
P09108279A0431 |147 161|8-OxoG residue997A0472 When 
P09108279A0431 |201 210|substrateF PCO2 th
P09108279A0431 |4 12|capacity01606T00
P09108279A0431 |87 99|ogg1 strainsPharmacologi
P09108451A0160 |0 7|ResultsP000016
P09108451A0160 |60 66|UCN-01ucleot
P09108451A0160 |27 39|laboratoriesith alkaline
P09108451A0160 |88 109|G1-phase accumulationharmacologic aspects 
P09108451A0160 |127 143|tumor cell linesilirubinemia. P0
P09110176A0890 |0 8|NorthernP0000160
P09110176A0890 |266 276|expressionompared to
P09110176A0890 |287 292|locusut st
P09110176A0890 |13 28|RT-PCR analysis6 Comparison wi
P09110176A0890 |235 243|evidence are no 
P09110176A0890 |203 210|animalsPCO2 th
P09110176A0890 |172 182|expression is shown 
P09110176A0890 |52 65|mouse tissues and 5-nucleo
P09110176A0890 |116 122|disomyatal h
P09110176A0890 |71 78|animals P00008
P09110176A0890 |32 48|Ube3a expressionlkaline phosphat
P09111004A0732 |68 101|phosphorylation motif Thr-Xaa-Tyrase P00008171T0000 Pharmacologic 
P09111004A0732 |181 187|length as a 
P09111004A0732 |127 166|L12 influence p38 substrate specificityilirubinemia. P00008997A0472 When CSF [
P09111004A0732 |229 248|autophosphorylationd rats are no longe
P09111004A0732 |209 213|rolehe d
P09111004A0732 |44 55|Xaa residuephatases an
P09111004A0732 |117 123|lengthtal hy
P09111004A0732 |191 194|L12tio
P09111004A0732 |16 23|effectsomparis
P09111048X0000 |207 220|cells/tissues the data of 
P09111048X0000 |25 40|mRNA transcript with alkaline 
P09111048X0000 |133 138|themeinemi
P09111048X0000 |180 195|gene expressionn as a function
P09111048X0000 |151 172|nitric-oxide synthase0472 When CSF [HCO3-]
P09111048X0000 |99 113|mRNA diversityc aspects of n
P09111048X0000 |76 97|nitric-oxide synthase08171T0000 Pharmacolo
P09111048X0000 |174 178|nNOSs sh
P09111059A0327 |102 105|DNAspe
P09111059A0327 |87 98|specificityPharmacolog
P09111059A0327 |23 29|domainon wit
P09111059A0327 |35 46|homeodomainline phosph
P09111309A0674 |0 14|CotransfectionP00001606T0076
P09111309A0674 |28 31|p44th 
P09111309A0674 |164 166|ER [
P09111309A0674 |141 149|responseP0000899
P09111309A0674 |64 89|kinase expression vectorsotidase P00008171T0000 Ph
P09111309A0674 |59 62|MAPnuc
P09111309A0674 |111 137|HB-EGF promoter activation neonatal hyperbilirubinem
P09111309A0674 |50 57|proteines and 
P09111309A0674 |18 23|Ets-2paris
P09111309A0674 |153 163|deltaRaf-172 When CS
P09111314A0970 |0 9|Cyclin D1P00001606
P09111314A0970 |60 81|184A1L5R cell lysatesucleotidase P00008171
P09111314A0970 |38 42|cdk4e ph
P09111314A1243 |274 291|kinase activationto controls but s
P09111314A1243 |62 70|TGF-betaleotidas
P09111314A1243 |180 196|p15INK4B proteinn as a function 
P09111314A1243 |36 46|regulationine phosph
P09111314A1243 |92 103|observationacologic as
P09111314A1243 |244 269|cyclin D1-cdk associationonger displaced when comp
P09111314A1243 |131 139|184A1L5Rubinemia
P09111314A1243 |154 168|p15 transcript2 When CSF [HC
P09111314A1243 |4 14|importance01606T0076
P09111314A1243 |50 58|p15INK4Bes and 5
P09111331A0119 |34 49|MADS box familyaline phosphata
P09111331A0119 |53 74|transcription factorsand 5-nucleotidase P0
P09111331A0119 |112 119|pathwayneonata
P09111331A0119 |76 85|functions08171T000
P09111331A0119 |4 16|Rlm1 protein01606T0076 C
P09111331A0119 |20 26|memberrison 
P09111331A0119 |100 104|Mpk1 asp
P09111340A0240 |259 292|chloramphenicol acetyltransferase when compared to controls but st
P09111340A0240 |59 73|downregulationnucleotidase P
P09111340A0240 |161 166|genesCSF [
P09111340A0240 |299 303|genee a 
P09111340A0240 |44 54|c-myc mRNAphatases a
P09111340A0240 |115 126|C2C12 cellsnatal hyper
P09111340A0240 |81 91|myogenesisT0000 Phar
P09111340A0240 |294 297|CATl h
P09111340A0240 |23 31|elementson with 
P09111340A0240 |184 197|myc sequences a function o
P09111340A0240 |139 148|myc genes. P000089
P09111340A0240 |222 238|beta-globin genedepleted rats ar
P09111367A1098 |409 422|tal-1 effectsypnotic drug 
P09111367A1098 |577 582|cells appr
P09111367A1098 |375 386|experiments thus appea
P09111367A1098 |308 317|host cellficantly 
P09111367A1098 |506 518|N-terminally45 Beta bloc
P09111367A1098 |167 173|effectCO3-] 
P09111367A1098 |594 601|effects produc
P09111367A1098 |529 542|tal-1 variant. P00013683A0
P09111367A1098 |124 135|temperatureerbilirubin
P09111367A1098 |56 65|p53 cells 5-nucleo
P09111367A1098 |362 367|tal-133 Fl
P09111367A1098 |561 566|T-ALLreal 
P09111367A1098 |261 270|integrityhen compa
P09111367A1098 |219 224|tal-1 K-de
P09111367A1098 |335 340|c-myc1 +/-
P09111367A1098 |89 105|tal-1 expressionarmacologic aspe
P09111367A1098 |30 33|32D al
P09111367A1098 |239 245|effect no lo
P09111367A1098 |619 626|proteinlar ven
P09111367A1098 |468 494|heterodimerization domainsice being 15 mg at night. 
P09111367A1098 |198 207|apoptosis CSF PCO2
P09111367A1098 |13 24|experiments6 Compariso
P09111367A1098 |544 546|M30 
P09111367A1098 |351 360|oncogenes00010943A
P09111367A1098 |278 300|cell cycle checkpointsontrols but still have
P09111863A0743 |4 14|likelihood01606T0076
P09111863A0743 |29 35|regionh alka
P09111863A0743 |192 204|introductionion of CSF P
P09111863A0743 |172 186|tumorigenicity is shown as a
P09111863A0743 |126 132|regionbiliru
P09111863A0743 |208 219|tumor cellsthe data of
P09111863A0743 |106 117|coincidencets of neona
P09111863A0743 |65 81|tumor suppressortidase P00008171
P09111863A0743 |39 48|deletions phosphat
P09111863A0743 |140 159|chromosome fragment P00008997A0472 Whe
P09112400A1155 |58 67|forskolin-nucleoti
P09112400A1155 |12 20|activity76 Compa
P09112400A1155 |88 93|cellsharma
P09112400A1155 |46 54|additionatases a
P09112589A0078 |32 39|patternlkaline
P09114972A1366 |18 21|SOSpar
P09114972A1366 |23 32|viabilityon with a
P09114972A1366 |5 14|induction1606T0076
P09115242A0934 |205 218|collagenase-1O2 the data o
P09115242A0934 |79 83|role71T0
P09115242A0934 |111 123|protein-beta neonatal hy
P09115242A0934 |24 34|supershiftn with alk
P09115242A0934 |125 135|C/EBP-betarbilirubin
P09115242A0934 |40 66|promoter deletion analysesphosphatases and 5-nucleot
P09115242A0934 |188 201|transcriptionunction of CS
P09115242A0934 |232 237|cellsats a
P09115242A0934 |137 149|binding siteia. P0000899
P09115247A2069 |0 25|11-Aminoundecanoyl-SK-NH2P00001606T0076 Comparison
P09115247A2069 |123 131|distanceperbilir
P09115247A2069 |286 305|epsilon-amino groupbut still have a si
P09115247A2069 |194 200|enzymen of C
P09115247A2069 |30 55|11-aminoundecanoyl-SH-NH2 alkaline phosphatases an
P09115247A2069 |219 223|site K-d
P09115247A2069 |312 321|imidazolently grea
P09115247A2069 |264 277|beta-hydroxyl compared to 
P09115247A2069 |146 154|elements8997A047
P09115247A2069 |80 94|alkyl backbone1T0000 Pharmac
P09115247A2069 |249 260|amino group displaced 
P09115247A2069 |168 179|recognitionO3-] is sho
P09115265A1160 |101 128|transcription factor GATA-1aspects of neonatal hyperbi
P09115265A1160 |77 83|domain8171T0
P09115265A1160 |22 33|CCCC moduleson with al
P09115279A0345 |102 109|partnerspects 
P09115279A0345 |66 70|Cdc2idas
P09115279A0345 |43 55|cell lysatessphatases an
P09115279A0345 |26 30|Pch1with
P09115279A0345 |0 20|Cdc2 co-precipitatesP00001606T0076 Compa
P09115279A0345 |115 126|Pch1 kinasenatal hyper
P09115279A0345 |34 36|S.al
P09115357A0073 |262 269|processen comp
P09115357A0073 |74 80|assays000817
P09115357A0073 |45 57|availabilityhatases and 
P09115357A0073 |162 177|culture systemsSF [HCO3-] is s
P09115357A0073 |147 158|development997A0472 Wh
P09115357A0073 |26 35|mechanismwith alka
P09115357A0073 |182 203|hypermutating B cellsas a function of CSF 
P09115357A0073 |96 124|immunoglobulin hypermutationogic aspects of neonatal hyp
P09115357A0073 |219 228|screening K-deplet
P09115357A0073 |233 244|individualsts are no l
P09115365A0000 |0 10|ExpressionP00001606T
P09115365A0000 |46 50|geneatas
P09115365A0000 |104 113|oncogenesects of n
P09115365A0000 |90 96|stressrmacol
P09115365A0000 |52 57|hsp70 and 
P09115365A0000 |24 42|heat shock proteinn with alkaline ph
P09115365A0000 |81 86|kindsT0000
P09115395A0478 |341 345|Cdc50.23
P09115395A0478 |519 524|Vent2ing a
P09115395A0478 |168 172|BRG1O3-]
P09115395A0478 |513 517|Sox3 blo
P09115395A0478 |506 511|HoxD145 Be
P09115395A0478 |500 504|Cdc5653T
P09115395A0478 |187 199|protein L18Afunction of 
P09115395A0478 |534 542|isoforms013683A0
P09115395A0478 |250 255|rolesdispl
P09115395A0478 |428 449|transcription factorshe optimum dose for u
P09115395A0478 |491 493|S.t.
P09115395A0478 |484 489|Oct91at ni
P09115395A0478 |122 133|protein-115yperbilirub
P09115395A0478 |302 313|protein-115 significan
P09115395A0478 |259 266|mitosis when c
P09115395A0478 |222 230|proteinsdepleted
P09115395A0478 |385 401|RNA helicase WM6ars to be an eff
P09115395A0478 |451 455|BRG1 in 
P09115395A0478 |88 110|epithelial-microtubuleharmacologic aspects o
P09115395A0478 |268 290|epithelial-microtubulepared to controls but 
P09115395A0478 |372 376|BRG1pam 
P09115395A0478 |79 86|mitosis71T0000
P09115395A0478 |347 370|innercentrosome proteins. P00010943A0733 Flura
P09115395A0478 |466 482|co-factor 2alphactice being 15 m
P09115395A0478 |135 140|Oct91emia.
P09115395A0478 |142 166|Elongation factor 1gamma00008997A0472 When CSF [
P09115395A0478 |9 17|proteinsT0076 Co
P09115395A0478 |546 551|Xbr1bWhen 
P09115989A0993 |35 55|psoralen cross-linksline phosphatases an
P09115989A0993 |88 106|initiation processharmacologic aspec
P09115989A0993 |75 80|steps00817
P09115989A0993 |25 33|location with al
P09117345A0945 |34 40|TS2/16aline 
P09117345A0945 |22 26|betason 
P09117345A0945 |132 147|phosphorylationbinemia. P00008
P09117345A0945 |121 128|patternhyperbi
P09117345A0945 |14 19|alpha Comp
P09117345A0945 |83 97|cell migration000 Pharmacolo
P09117345A0945 |67 78|protrusionsdase P00008
P09117345A0945 |0 10|ActivationP00001606T
P09118196A0281 |0 11|PerformanceP00001606T0
P09118196A0281 |120 161|Wechsler Adult Intelligence Scale-Revised hyperbilirubinemia. P00008997A0472 When 
P09118196A0281 |212 221|educationdata of K
P09118196A0281 |163 169|WAIS-RF [HCO
P09118196A0281 |76 82|NART-R08171T
P09118196A0281 |92 110|Vocabulary subtestacologic aspects o
P09118196A0281 |39 53|National Adult phosphatases 
P09118196A0281 |203 208|levelPCO2 
P09118196A0281 |185 197|correlationsa function o
P09118664A1734 |0 12|L-canavanineP00001606T00
P09118664A1734 |104 120|filling pressureects of neonatal
P09118664A1734 |60 74|oxide synthaseucleotidase P0
P09118664A1734 |26 35|inhibitorwith alka
P09118664A1734 |167 177|conditionsCO3-] is s
P09118664A1734 |147 153|return997A04
P09118704A0771 |0 7|RESULTSP000016
P09118704A0771 |88 109|% confidence intervalharmacologic aspects 
P09118704A0771 |52 64|chemotherapy and 5-nucle
P09118704A0771 |128 129|%l
P09118704A0771 |111 113|CI n
P09118704A0771 |176 194|bleomycin toxicityshown as a functio
P09118704A0771 |19 27|patientsarison w
P09118704A0771 |83 84|%0
P09118704A0771 |69 74|G-CSFse P0
P09119031A1036 |236 248|sigma factorare no longe
P09119031A1036 |125 140|alpha2beta betarbilirubinemia.
P09119031A1036 |208 214|enzymethe da
P09119031A1036 |104 123|core RNA polymeraseects of neonatal hy
P09119031A1036 |14 40|holoenzyme RNA polymerases Comparison with alkaline 
P09119031A1036 |178 186|activityown as a
P09119031A1036 |77 84|mutants8171T00
P09119031A1036 |190 200|comparisonction of C
P09119112A1350 |48 54|GATA-5ases a
P09119112A1350 |109 117|functionof neona
P09119112A1350 |135 140|heartemia.
P09119112A1350 |6 10|data606T
P09119112A1350 |145 149|lung0899
P09119112A1350 |33 38|modelkalin
P09119391A0870 |109 125|protein sequenceof neonatal hype
P09119391A0870 |30 37|protein alkali
P09119391A0870 |135 140|GPT-1emia.
P09119391A0870 |45 56|amino acidshatases and
P09119391A0870 |11 19|sequence076 Comp
P09121424A0296 |103 110|complexpects o
P09121424A0296 |123 130|homologperbili
P09121424A0296 |132 136|Sthlbine
P09121424A0296 |38 50|Swi3 homologe phosphatas
P09121424A0296 |52 56|Swh3 and
P09121424A0296 |70 78|evidencee P00008
P09121430A0132 |0 3|ShcP00
P09121430A0132 |127 128|Yi
P09121430A0132 |77 84|complex8171T00
P09121430A0132 |130 137|residuerubinem
P09121430A0132 |90 94|Grb2rmac
P09121430A0132 |53 57|MAPKand 
P09121430A0132 |37 51|protein kinasene phosphatase
P09121430A0132 |117 125|tyrosinetal hype
P09121430A1075 |71 84|c-myc message P00008171T00
P09121430A1075 |36 45|Y317F Shcine phosp
P09121430A1075 |13 26|Y239/240F Shc6 Comparison 
P09121430A1075 |3 11|contrast001606T0
P09121432A0000 |68 74|switchase P0
P09121432A0000 |120 127|kinases hyperb
P09121432A0000 |4 15|Ras guanine01606T0076 
P09121432A0000 |78 88|signalling171T0000 P
P09121432A0000 |35 42|proteinline ph
P09121433A0463 |138 142|SMP1a. P
P09121433A0463 |185 192|ACTACTAa funct
P09121433A0463 |22 26|Smp1son 
P09121433A0463 |112 116|MEF2neon
P09121433A0463 |126 130|4TAGbili
P09121433A0463 |57 70|specificities5-nucleotidas
P09121433A0463 |122 125|T/Aype
P09121433A0463 |193 196|T/Aon 
P09121433A0463 |13 17|Rlm16 Co
P09121433A0463 |165 183|consensus sequence[HCO3-] is shown a
P09121433A0463 |118 121|CTAal 
P09121433A0463 |197 201|4TAGf CS
P09121433A0463 |72 76|Rlm1P000
P09121433A0463 |97 108|specificitygic aspects
P09121435A1183 |0 7|DomainsP000016
P09121435A1183 |92 112|protein footprintingacologic aspects of 
P09121435A1183 |39 47|assembly phospha
P09121435A1183 |20 21|Br
P09121435A1183 |55 73|TFIIIB-DNA complexd 5-nucleotidase P
P09121452A0538 |102 119|activation domainspects of neonata
P09121452A0538 |231 239|promoterrats are
P09121452A0538 |163 175|2D5 promoterF [HCO3-] is
P09121452A0538 |264 274|C/EBP site compared 
P09121452A0538 |123 134|C/EBP alphaperbilirubi
P09121452A0538 |38 57|C/EBP beta proteinse phosphatases and 
P09121452A0538 |80 94|leucine zipper1T0000 Pharmac
P09121452A0538 |0 25|Domain switch experimentsP00001606T0076 Comparison
P09121454A1328 |171 194|transcription machinery] is shown as a functio
P09121454A1328 |12 22|phenotypes76 Compari
P09121454A1328 |47 56|mutationstases and
P09121454A1328 |80 85|Mot1p1T000
P09121454A1328 |147 155|activity997A0472
P09121454A1328 |41 45|mot1hosp
P09121454A1328 |26 30|bur6with
P09121454A1328 |35 39|bur3line
P09121454A1328 |70 75|Bur6pe P00
P09121454A1328 |119 128|functionsl hyperbi
P09121476T0000 |0 5|PRH75P0000
P09121476T0000 |31 37|memberalkali
P09121476T0000 |45 68|DEAD-box protein familyhatases and 5-nucleotid
P09121476T0000 |81 87|plantsT0000 
P09121774A0611 |38 49|stimulatione phosphata
P09121774A0611 |90 97|membersrmacolo
P09121774A0611 |6 16|activities606T0076 C
P09121774A0611 |105 122|MAP kinase familycts of neonatal h
P09121774A0611 |53 64|cell growthand 5-nucle
P09121774T0000 |35 47|polyomavirusline phospha
P09121774T0000 |122 141|cell transformationyperbilirubinemia. 
P09121774T0000 |74 84|activation0008171T00
P09121774T0000 |21 31|GTPase Racison with 
P09121774T0000 |92 114|serum response elementacologic aspects of ne
P09121774T0000 |2 6|role0001
P09121998A0663 |38 44|regione phos
P09121998A0663 |153 165|transit time72 When CSF 
P09121998A0663 |48 56|interestases and
P09121998A0663 |247 250|F90er 
P09121998A0663 |242 245|min lo
P09121998A0663 |183 191|fractions a func
P09121998A0663 |167 170|MTTCO3
P09121998A0663 |14 20|curves Compa
P09121998A0663 |74 84|subjection0008171T00
P09121998A0663 |225 232|stomachleted r
P09121998A0663 |111 121|procedures neonatal 
P09121998A0663 |199 208|test mealCSF PCO2 
P09121998A0663 |140 144|mean P00
P09122168A1427 |48 52|roleases
P09122168A1427 |209 220|interactionhe data of 
P09122168A1427 |122 126|GRK2yper
P09122168A1427 |105 118|translocationcts of neonat
P09122168A1427 |131 135|GRK3ubin
P09122168A1427 |57 68|G betagamma5-nucleotid
P09122168A1427 |182 201|isoform specificityas a function of CS
P09122168A1427 |29 42|demonstrationh alkaline ph
P09122168A1427 |158 164|systemen CSF
P09122168A1427 |230 240|components rats are 
P09122168A1427 |5 10|study1606T
P09122176A0970 |38 48|repressione phosphat
P09122176A0970 |124 143|RA response elementerbilirubinemia. P0
P09122176A0970 |56 65|hMGP gene 5-nucleo
P09122176A0970 |96 103|RAR/RXRogic as
P09122176A0970 |76 83|binding08171T0
P09122176A0970 |4 11|results01606T0
P09122198A0478 |0 15|Point mutationsP00001606T0076 
P09122198A0478 |28 45|tyrosine residuesth alkaline phosp
P09122198A0478 |126 137|conclusionsbilirubinem
P09122198A0478 |79 87|receptor71T0000 
P09122198A0478 |65 71|domaintidase
P09122215A0335 |116 124|interestatal hyp
P09122215A0335 |108 112|gene of 
P09122215A0335 |91 100|mutationsmacologic
P09122215A0335 |20 26|methodrison 
P09123055T0000 |51 57|liverss and 
P09123055T0000 |15 21|injuryCompar
P09123055T0000 |63 65|UWeo
P09123055T0000 |29 41|preservationh alkaline p
P09123055T0000 |70 82|HTK solutione P00008171T
P09123787A0486 |35 44|responsesline phos
P09123787A0486 |130 134|siderubi
P09123787A0486 |211 213|Rc d
P09123787A0486 |190 192|R2ct
P09123787A0486 |260 284|orbicularis oculi musclewhen compared to control
P09123787A0486 |67 78|R1 responsedase P00008
P09123787A0486 |228 239|R3 responseed rats are
P09123787A0486 |138 149|stimulationa. P0000899
P09123787A0486 |86 122|orbicularis oculi muscle ipsilateral Pharmacologic aspects of neonatal h
P09123787A0486 |168 176|responseO3-] is 
P09124054A1164 |4 13|prognosis01606T007
P09124054A1164 |45 50|ABSCThatas
P09124054A1164 |127 134|therapyilirubi
P09124054A1164 |92 100|patientsacologic
P09124054A1164 |23 31|patientson with 
P09126487A1399 |7 10|Hum06T
P09126622A0466 |119 123|typel hy
P09126622A0466 |40 48|coloniesphosphat
P09126622A0466 |4 21|pigment intensity01606T0076 Compar
P09126622A0466 |53 64|appressoriaand 5-nucle
P09126622A0466 |68 85|CAL transformantsase P00008171T000
P09128730A0000 |236 247|delta mu Naare no long
P09128730A0000 |59 68|formationnucleotid
P09128730A0000 |178 192|biotin proteinown as a funct
P09128730A0000 |146 154|malonate8997A047
P09128730A0000 |28 45|Malonomonas rubrath alkaline phosp
P09128730A0000 |120 140|acyl-carrier protein hyperbilirubinemia.
P09128730A0000 |72 81|malonyl-SP00008171
P09128730A0000 |156 172|carboxyltransferWhen CSF [HCO3-]
P09128730A0000 |83 103|acyl-carrier protein000 Pharmacologic as
P09128730A0000 |249 259|generation displaced
P09128730A0000 |110 118|acetyl-Sf neonat
P09128730A0000 |9 24|decarboxylationT0076 Compariso
P09128730A0000 |201 216|decarboxylationF PCO2 the data
P09129147A0644 |34 48|leucine-zipperaline phosphat
P09129147A0644 |94 101|Fos/Junologic 
P09129147A0644 |106 123|ATF/CREB proteinsts of neonatal hy
P09129147A0644 |63 68|motifeotid
P09129147A0644 |82 90|homology0000 Pha
P09129147A0644 |145 166|phosphorylation sites08997A0472 When CSF [
P09129147A0644 |4 24|Jem peptide sequence01606T0076 Compariso
P09130595A0478 |34 41|proteinaline p
P09130595A0478 |56 69|enhancer site 5-nucleotida
P09130595A0478 |19 26|cloningarison 
P09130700A0676 |51 57|Spc98ps and 
P09130700A0676 |62 68|Spc97pleotid
P09130700A0676 |44 49|Tub4pphata
P09130700A0676 |8 15|support6T0076 
P09130700A0676 |176 181|SPC98shown
P09130700A0676 |147 164|co-overexpression997A0472 When CSF
P09130700A0676 |29 40|interactionh alkaline 
P09130700A0676 |84 92|toxicity00 Pharm
P09130700A0676 |168 172|TUB4O3-]
P09130700A0676 |103 123|SPC97 overexpressionpects of neonatal hy
P09130718A0497 |0 9|SequencesP00001606
P09130718A0497 |109 111|kbof
P09130718A0497 |79 88|bp region71T0000 P
P09130718A0497 |36 46|expressionine phosph
P09130718A0497 |128 131|ATGlir
P09130718A0497 |50 54|sid1es a
P09130720A0417 |139 157|intron recognition. P00008997A0472 W
P09130720A0417 |28 35|mutantsth alka
P09130720A0417 |104 120|TACTAAC sequenceects of neonatal
P09130720A0417 |43 61|branch site regionsphatases and 5-nu
P09130720A0417 |10 16|screen0076 C
P09130720A0417 |77 86|positions8171T0000
P09131139T0000 |0 11|ImplicationP00001606T0
P09131139T0000 |72 79|diseaseP000081
P09131139T0000 |15 18|PAFCom
P09131139T0000 |23 38|acetylhydrolaseon with alkalin
P09131139T0000 |40 46|PAF-AHphosph
P09131139T0000 |48 56|activityases and
P09132011A0298 |0 10|ComparisonP00001606T
P09132011A0298 |111 118|protein neonat
P09132011A0298 |125 135|% homologyrbilirubin
P09132011A0298 |47 55|proteinstases an
P09132011A0298 |180 183|cdcn a
P09132011A0298 |141 178|Drosophila cell cycle control proteinP00008997A0472 When CSF [HCO3-] is sh
P09132011A0298 |67 77|% homologydase P0000
P09132011A0298 |18 30|p50 sequenceparison with
P09132057A0559 |275 281|tomatoo cont
P09132057A0559 |322 330|pathogener slope
P09132057A0559 |114 138|receptor protein kinasesonatal hyperbilirubinemi
P09132057A0559 |296 306|resistancehave a sig
P09132057A0559 |59 78|sequence similaritynucleotidase P00008
P09132057A0559 |144 150|plants008997
P09132057A0559 |215 226|self-pollena of K-depl
P09132057A0559 |29 32|NTSh a
P09132057A0559 |230 246|Brassica species rats are no lon
P09132057A0559 |41 54|reading framehosphatases a
P09132057A0559 |165 183|S-receptor kinases[HCO3-] is shown a
P09132057A0559 |255 271|Pto gene productaced when compar
P09132057A0559 |96 102|domainogic a
P09132057A0559 |202 211|rejection PCO2 the
P09132057A0559 |2 13|polypeptide0001606T007
P09132061A0828 |153 157|ESTs72 W
P09132061A0828 |29 43|cDNA sequencesh alkaline pho
P09132061A0828 |91 105|isoperoxidasesmacologic aspe
P09132061A0828 |14 17|atp Co
P09132061A0828 |20 25|typesrison
P09132061A0828 |133 143|peroxidaseinemia. P0
P09132061A0828 |4 7|atp016
P09133122A0656 |51 60|sequencess and 5-n
P09133122A0656 |11 22|information076 Compari
P09133122A0656 |148 155|program97A0472
P09133122A0656 |76 91|video sequences08171T0000 Phar
P09133122A0656 |109 119|angiogramsof neonata
P09133122A0656 |93 107|x-ray analysiscologic aspect
P09135066A0653 |98 101|Rasic 
P09135066A0653 |77 84|absence8171T00
P09135066A0653 |62 69|p96h2bkleotida
P09135066A0653 |42 46|Mek1osph
P09135149A0000 |34 42|activityaline ph
P09135149A0000 |95 101|kinaselogic 
P09135149A0000 |177 203|Pyp3 tyrosine phosphataseshown as a function of CSF 
P09135149A0000 |167 172|Cdc25CO3-]
P09135149A0000 |67 77|Cdc2/Cdc13dase P0000
P09135149A0000 |127 148|Mik1 tyrosine kinasesilirubinemia. P000089
P09135149A0000 |118 122|Wee1al h
P09135772T0000 |9 17|responseT0076 Co
P09135772T0000 |72 77|foodsP0000
P09135772T0000 |88 96|subjectsharmacol
P09135772T0000 |40 46|rollerphosph
P09135928A0912 |137 150|glibenclamideia. P00008997
P09135928A0912 |14 20|mmol/l Compa
P09135928A0912 |93 104|angiotensincologic asp
P09135928A0912 |46 58|BP responsesatases and 5
P09135928A0912 |183 184|Ps
P09135928A0912 |74 88|norepinephrine0008171T0000 P
P09135928A0912 |159 168|metforminn CSF [HC
P09135928A0912 |22 23|Ps
P09135928A0912 |170 171|P-
P09136015A0529 |4 14|sequencing01606T0076
P09136015A0529 |104 119|diversificationects of neonata
P09136015A0529 |93 100|patterncologic
P09136015A0529 |27 33|copiesith al
P09136015A0529 |66 73|clusteridase P
P09136080A1469 |186 190|gene fun
P09136080A1469 |43 62|chromatin structuresphatases and 5-nuc
P09136080A1469 |26 41|DNA methylationwith alkaline p
P09136080A1469 |135 145|expressionemia. P000
P09136080A1469 |90 98|Sp1 sitermacolog
P09136080A1469 |169 176|lineage3-] is 
P09136080A1469 |4 11|results01606T0
P09136080A1469 |68 83|transactivationase P00008171T0
P09138076A1099 |152 157|E-box472 W
P09138076A1099 |57 65|extracts5-nucleo
P09138076A1099 |94 104|osteoblastologic asp
P09138076A1099 |164 169|E-box [HCO
P09138076A1099 |30 37|factors alkali
P09138076A1099 |114 136|oligonucleotide probesonatal hyperbilirubine
P09138076A1099 |172 180|elements is show
P09138076A1099 |3 28|gel mobility shift assays001606T0076 Comparison wi
P09138492A0806 |17 20|IDRmpa
P09138492A0806 |58 75|chest radiography-nucleotidase P00
P09138492A0806 |131 136|tumorubine
P09138492A0806 |28 38|tuberculinth alkalin
P09138492A0806 |98 112|calcificationsic aspects of 
P09138492A0806 |191 195|examtion
P09138492A0806 |114 122|ORL examonatal h
P09138492A0806 |144 148|foot0089
P09138492A0806 |221 241|epidermoid carcinoma-depleted rats are n
P09138492A0806 |156 166|epiglottisWhen CSF [
P09138492A0806 |0 15|Laboratory examP00001606T0076 
P09139665A0784 |22 36|PhLP complexesson with alkal
P09139665A0784 |63 73|Gbetagammaeotidase P
P09139694A0789 |205 215|palindromeO2 the dat
P09139694A0789 |181 188|binding as a f
P09139694A0789 |146 159|DNA fragments8997A0472 Whe
P09139694A0789 |133 143|palindromeinemia. P0
P09139694A0789 |192 201|CTF1alphaion of CS
P09139694A0789 |73 83|palindrome00008171T0
P09139694A0789 |86 98|DNA fragment Pharmacolog
P09139694A0789 |110 120|palindromef neonatal
P09139694A0789 |0 9|CTF1alphaP00001606
P09139721A0183 |102 113|lymphocytesspects of n
P09139721A0183 |160 169|apoptosis CSF [HCO
P09139721A0183 |147 155|deletion997A0472
P09139721A0183 |44 50|systemphatas
P09139721A0183 |69 87|tolerance subjectsse P00008171T0000 
P09139721A0183 |126 135|selectionbilirubin
P09139721A0183 |0 9|Cyclin G2P00001606
P09139737A0000 |274 285|cholesterolto controls
P09139737A0000 |250 256|uptakedispla
P09139737A0000 |112 120|proteinsneonatal
P09139737A0000 |261 270|synthesishen compa
P09139737A0000 |296 301|acidshave 
P09139737A0000 |122 128|SREBPsyperbi
P09139737A0000 |211 224|transcription data of K-de
P09139737A0000 |228 233|genesed ra
P09139737A0000 |135 149|cell membranesemia. P0000899
P09139737A0000 |186 193|nucleus functi
P09139737A0000 |19 27|proteasearison w
P09139737A0000 |66 74|segmentsidase P0
P09139737A0000 |78 84|sterol171T00
P09139737A0000 |38 45|releasee phosp
P09139892A1150 |119 130|orientationl hyperbili
P09139892A1150 |78 89|orientation171T0000 Ph
P09139892A1150 |147 160|crp promoters997A0472 When
P09139892A1150 |33 46|vfr promoterskaline phosph
P09139892A1150 |24 28|orfXn wi
P09139892A1150 |138 142|dorfa. P
P09139910A0350 |220 225|pOST4K-dep
P09139910A0350 |28 40|PCR productsth alkaline 
P09139910A0350 |240 245|pOST2no lo
P09139910A0350 |91 104|DNA fragmentsmacologic asp
P09139910A0350 |235 238|kbp ar
P09139910A0350 |55 63|presenced 5-nucl
P09139910A0350 |162 168|probesSF [HC
P09139910A0350 |215 218|kbpa o
P09139910A0350 |187 207|clone XbaI fragmentsfunction of CSF PCO2
P09139910A0350 |138 142|nifVa. P
P09139910A0350 |0 17|Sequence analysisP00001606T0076 Co
P09139910A1572 |17 32|Anabaena strainmparison with a
P09139910A1572 |88 93|R229Iharma
P09139910A1572 |3 11|contrast001606T0
P09139910A1572 |38 47|leuA genee phospha
P09139910A1572 |71 84|nifV mutation P00008171T00
P09140079A2528 |53 56|TREand
P09140079A2528 |40 43|TRspho
P09140079A2528 |9 15|effectT0076 
P09140474T0000 |51 56|Spains and
P09140474T0000 |76 80|case0817
P09140474T0000 |42 49|Minorcaosphata
P09140474T0000 |106 113|Minorcats of n
P09140474T0000 |3 16|leishmaniasis001606T0076 C
P09140474T0000 |97 102|yearsgic a
P09140474T0000 |32 38|islandlkalin
P09142146A0887 |186 191|hours func
P09142146A0887 |193 194|po
P09142146A0887 |46 55|mortalityatases an
P09142146A0887 |62 68|traumaleotid
P09142146A0887 |23 35|PAF blockadeon with alka
P09142146A0887 |126 127|pb
P09142146A0887 |78 94|WEB-2086 animals171T0000 Pharmac
P09142146A0887 |109 124|vehicle animalsof neonatal hyp
P09142146A0887 |0 7|RESULTSP000016
P09142146A0887 |158 163|indexen CS
P09142146A0887 |171 179|delivery] is sho
P09143328A1002 |69 88|dinucleotide primerse P00008171T0000 P
P09143328A1002 |26 33|examplewith al
P09143328A1002 |37 48|utilizationne phosphat
P09143328A1002 |95 109|RNA polymeraselogic aspects 
P09143328A1002 |5 12|finding1606T00
P09143465A0838 |70 72|IQe 
P09143465A0838 |90 95|scalermaco
P09143465A0838 |5 7|T116
P09143465A0838 |12 26|dual-T1 images76 Comparison 
P09143465A0838 |55 68|image qualityd 5-nucleotid
P09144165A0614 |102 109|featurespects 
P09144165A0614 |154 158|size2 Wh
P09144165A0614 |26 33|complexwith al
P09144165A0614 |94 97|RIRolo
P09144165A0614 |63 67|AP-1eoti
P09144165A0614 |183 190|memberss a fun
P09144165A0614 |166 174|sequenceHCO3-] i
P09144165A0614 |75 92|Rel insert region008171T0000 Pharm
P09144165A0614 |134 150|hypervariabilitynemia. P00008997
P09144165A0614 |50 54|NFATes a
P09144165A0614 |39 46|segment phosph
P09144165A0614 |198 229|Rel transcription factor family CSF PCO2 the data of K-deplete
P09144165A0614 |5 10|model1606T
P09144165A1275 |99 106|bindingc aspec
P09144165A1275 |26 34|NFAT RIRwith alk
P09144165A1275 |110 143|AP-1 family transcription factorsf neonatal hyperbilirubinemia. P0
P09144165A1275 |59 63|rolenucl
P09144165A1275 |67 82|DNA recognitiondase P00008171T
P09144195A1051 |115 122|PS1 CTFnatal h
P09144195A1051 |74 107|phosphorylation/dephosphorylation0008171T0000 Pharmacologic aspect
P09144195A1051 |25 38|PS1 fragments with alkalin
P09144195A1051 |10 21|association0076 Compar
P09144195A1051 |64 70|cyclesotidas
P09144770A0906 |33 42|beta-turnkaline ph
P09144770A0906 |91 113|FKBP12 binding surfacemacologic aspects of n
P09144770A0906 |26 30|Typewith
P09144770A0906 |73 81|contacts00008171
P09144770A0906 |5 14|conformer1606T0076
P09144958A0047 |85 113|chlorophyll a/b protein gene0 Pharmacologic aspects of n
P09144958A0047 |56 67|Arabidopsis 5-nucleoti
P09144958A0047 |41 49|promoterhosphata
P09144958A0047 |165 176|phytochrome[HCO3-] is 
P09144958A0047 |151 161|regulation0472 When 
P09144958A0047 |5 12|protein1606T00
P09144958A0047 |27 33|regionith al
P09144958A0047 |115 120|Lhcb1natal
P09146027A0809 |87 92|trunkPharm
P09146027A0809 |97 101|neckgic 
P09146027A0809 |13 20|Group B6 Compa
P09146027A0809 |32 43|athetoid CPlkaline pho
P09146027A0809 |2 9|patient0001606
P09146027A0809 |49 59|spasticityses and 5-
P09146071T0001 |64 82|pontine hemorrhageotidase P00008171T
P09146071T0001 |9 17|movementT0076 Co
P09146071T0001 |46 50|caseatas
P09146071T0001 |36 40|limbine 
P09147420A0623 |34 46|HCMV IE1/IE2aline phosph
P09147420A0623 |79 88|HIV-1 LTR71T0000 P
P09147420T0000 |0 3|TARP00
P09147420T0000 |94 102|presenceologic a
P09147420T0000 |61 67|repeatcleoti
P09147420T0000 |75 86|Tat protein008171T0000
P09147420T0000 |43 46|HIVsph
P09147420T0000 |24 39|transactivationn with alkaline
P09147420T0000 |112 135|cytomegalovirus IE1/IE2neonatal hyperbilirubin
P09147788A0458 |12 33|chain enzyme activity76 Comparison with al
P09147832A0174 |102 112|predictorsspects of 
P09147832A0174 |61 62|nc
P09147832A0174 |79 84|years71T00
P09147832A0174 |11 22|temperament076 Compari
P09147832A0174 |182 190|measuresas a fun
P09147832A0174 |123 133|conscienceperbilirub
P09147832A0174 |53 57|Timeand 
P09147832A0174 |36 49|socializationine phosphata
P09147832A0174 |0 8|ChildrenP0000160
P09148770A0977 |98 112|Csk SH2 domainic aspects of 
P09148770A0977 |41 56|phosphoproteinshosphatases and
P09148770A0977 |9 12|CskT00
P09148903A1715 |219 230|degradation K-depleted
P09148903A1715 |57 75|HIV-1 LTR activity5-nucleotidase P00
P09148903A1715 |10 17|studies0076 Co
P09148903A1715 |284 291|pathways but s
P09148903A1715 |105 118|translocationcts of neonat
P09148903A1715 |126 156|NF-kappaB transcription factorbilirubinemia. P00008997A0472 
P09148903A1715 |43 53|activationsphatases 
P09148903A1715 |179 214|IkappaBalpha serine phosphorylationwn as a function of CSF PCO2 the da
P09148929A0372 |4 6|P101
P09148929A0372 |15 20|cloneCompa
P09148929A0372 |40 57|plasmid subclonesphosphatases and 
P09148929A0372 |105 117|organizationcts of neona
P09148929A0372 |125 135|Ctpct generbilirubin
P09148935A0805 |186 189|FAK fu
P09148935A0805 |131 141|expressionubinemia. 
P09148935A0805 |149 182|c-Src binding site Phe-397 mutant7A0472 When CSF [HCO3-] is shown 
P09148935A0805 |14 32|c-Src PTK activity Comparison with a
P09148935A0805 |97 107|activationgic aspect
P09148935A0805 |111 115|ERK2 neo
P09148935A0805 |54 73|type FAK expressionnd 5-nucleotidase P
P09149825A0151 |16 22|cementompari
P09149825A0151 |46 51|resinatase
P09149825A0151 |83 93|properties000 Pharma
P09149825A0151 |24 38|4-META/MMA-TBBn with alkalin
P09149825A0151 |99 110|bone cementc aspects o
P09149929A0750 |25 36|predictions with alkal
P09149929A0750 |56 64|children 5-nucle
P09149929A0750 |148 155|control97A0472
P09149929A0750 |109 119|separationof neonata
P09149929A0750 |79 86|control71T0000
P09149929A0750 |92 104|homesicknessacologic asp
P09150334A0559 |5 11|sample1606T0
P09150334A0559 |88 96|samplingharmacol
P09150334A0559 |78 81|min171
P09150566A0316 |19 23|rolearis
P09150566A0316 |41 50|formationhosphatas
P09150566A0316 |54 71|complex moleculesnd 5-nucleotidase
P09150566A0316 |27 33|grainsith al
P09150566A0316 |98 104|cloudsic asp
P09150595A0225 |51 53|HRs 
P09150595A0225 |41 49|reactionhosphata
P09150595A0225 |240 246|domainno lon
P09150595A0225 |113 121|HarpinEaeonatal 
P09150595A0225 |67 82|E. chrysanthemidase P00008171T
P09150595A0225 |178 193|signal sequenceown as a functi
P09150595A0225 |9 18|elicitorsT0076 Com
P09150595A0225 |99 111|E. amylovorac aspects of
P09150595A0225 |143 150|protein0008997
P09150595A0225 |84 93|HarpinEch00 Pharma
P09150595T0000 |49 80|Erwinia carotovora hrpNEcc geneses and 5-nucleotidase P0000817
P09150595T0000 |31 41|expressionalkaline p
P09150595T0000 |10 26|characterization0076 Comparison 
P09150595T0000 |130 138|reactionrubinemi
P09150595T0000 |99 107|elicitorc aspect
P09150728A0596 |103 109|musclepects 
P09150728A0596 |4 8|mRNA0160
P09150728A0596 |32 36|HES1lkal
P09150728A0596 |19 23|genearis
P09150728A0596 |84 89|heart00 Ph
P09150774A0616 |0 10|AnesthesiaP00001606T
P09150774A0616 |31 41|isofluranealkaline p
P09150774A0616 |43 46|ISOsph
P09150774A0616 |56 66|inhalation 5-nucleot
P09150774A0616 |48 51|N2Oase
P09151152A0174 |152 162|factor VII472 When C
P09151152A0174 |241 258|serum lipoproteino longer displace
P09151152A0174 |120 132|hemodialysis hyperbiliru
P09151152A0174 |202 216|heparinization PCO2 the data
P09151152A0174 |231 237|amountrats a
P09151152A0174 |24 42|protein C activityn with alkaline ph
P09151152A0174 |63 64|pe
P09151152A0174 |139 147|factor X. P00008
P09151152A0174 |174 175|ps
P09151152A0174 |184 185|p 
P09151376A0000 |21 25|typeison
P09151376A0000 |73 82|diagnosis00008171T
P09151376A0000 |13 17|case6 Co
P09151376A0000 |194 198|goutn of
P09151376A0000 |59 66|patientnucleot
P09151376A0000 |29 53|hyperbetalipoproteinemiah alkaline phosphatases 
P09151376A0000 |174 183|arthritiss shown a
P09151806A1125 |68 81|mLAT pre-mRNAase P00008171
P09151806A1125 |6 10|data606T
P09151806A1125 |44 47|LATpha
P09151806A1125 |54 60|intronnd 5-n
P09151806A1125 |96 108|branch pointogic aspects
P09151806A1125 |19 27|evidencearison w
P09151828A0919 |136 144|residuesmia. P00
P09151828A0919 |12 31|amino acid residues76 Comparison with 
P09151828A0919 |52 70|9ORF1 polypeptides and 5-nucleotidas
P09151828A0919 |126 132|regionbiliru
P09151828A0919 |214 222|residuesta of K-
P09151828A0919 |167 175|residuesCO3-] is
P09151828A0919 |156 162|regionWhen C
P09151828A0919 |202 208|region PCO2 
P09151828A0919 |103 110|regionspects o
P09151837A0723 |152 166|fusion protein472 When CSF [
P09151837A0723 |59 92|coimmunoprecipitation experimentsnucleotidase P00008171T0000 Pharm
P09151837A0723 |8 27|protein interaction6T0076 Comparison w
P09151837A0723 |211 216|Rep78 data
P09151837A0723 |251 283|transcription-translation systemisplaced when compared to contro
P09151837A0723 |188 191|35Sunc
P09151837A0723 |170 181|combination-] is shown
P09151925A0479 |68 71|TAEase
P09151925A0479 |124 149|ethanol injection therapyerbilirubinemia. P0000899
P09151925A0479 |73 78|C-LIP00008
P09151925A0479 |91 105|gelatin spongemacologic aspe
P09151925A0479 |151 155|PEIT0472
P09151925A0479 |4 9|C-LIP01606
P09151925A0479 |54 66|embolizationnd 5-nucleot
P09151925A0479 |33 44|transcatherkaline phos
P09152656A0149 |70 83|heart failuree P00008171T0
P09152656A0149 |128 133|studylirub
P09152656A0149 |9 17|patientsT0076 Co
P09152656A0149 |23 55|New York Heart Association classon with alkaline phosphatases an
P09153010A0499 |100 110|collection aspects o
P09153010A0499 |240 244|MUPsno l
P09153010A0499 |154 165|possibility2 When CSF 
P09153010A0499 |257 272|reproducibilityed when compare
P09153010A0499 |190 204|threshold MUPsction of CSF P
P09153010A0499 |144 148|site0089
P09153010A0499 |57 68|acquisition5-nucleotid
P09153010A0499 |215 219|biasa of
P09153010A0499 |122 126|MUPsyper
P09153010A0499 |77 81|MUPs8171
P09153010A0499 |349 361|laboratories P00010943A0
P09153010A0499 |280 287|resultstrols b
P09153010A0499 |227 236|selectionted rats 
P09153010A0499 |308 324|reference valuesficantly greater
P09153010A0499 |9 19|advantagesT0076 Comp
P09153010A0499 |33 41|analysiskaline p
P09153319A0844 |85 92|ethanol0 Pharm
P09153319A0844 |112 117|waterneona
P09153319A0844 |35 44|triplexesline phos
P09153319A1332 |0 24|Transfection experimentsP00001606T0076 Compariso
P09153319A1332 |41 50|triplexeshosphatas
P09153319A1332 |150 163|transcriptionA0472 When CS
P09153319A1332 |90 116|collagen promoter sequencermacologic aspects of neon
P09153319A1332 |185 213|control phosphorothioate ODNa function of CSF PCO2 the d
P09153319A1332 |58 74|reporter plasmid-nucleotidase P0
P09153319A1332 |136 146|inhibitionmia. P0000
P09153348A0647 |70 105|mineralocorticoid steroid secretione P00008171T0000 Pharmacologic aspe
P09153348A0647 |192 200|patientsion of C
P09153348A0647 |150 157|markersA0472 W
P09153348A0647 |181 188|disease as a f
P09153348A0647 |114 132|cortisol secretiononatal hyperbiliru
P09153348A0647 |162 173|progressionSF [HCO3-] 
P09153348A0647 |9 17|increaseT0076 Co
P09153348A0647 |57 65|androgen5-nucleo
P09153348A0647 |38 43|shifte pho
P09153348A0647 |21 31|plasma TBGison with 
P09153348A0647 |206 219|HIV-infection2 the data of
P09153795A0298 |50 61|reliabilityes and 5-nu
P09153795A0298 |11 18|studies076 Com
P09153795A0298 |66 74|validityidase P0
P09153795A0298 |23 27|RDFSon w
P09153795A0298 |38 46|evidencee phosph
P09154283A0307 |0 11|LatanoprostP00001606T0
P09154283A0307 |60 68|pressureucleotid
P09154283A0307 |127 140|acetazolamideilirubinemia.
P09154283A0307 |145 155|dipivefrin08997A0472
P09154283A0307 |88 99|combinationharmacologi
P09154283A0307 |105 112|timololcts of 
P09154283A0307 |70 73|IOPe P
P09154283A0307 |114 125|pilocarpineonatal hype
P09154283A0307 |35 44|reductionline phos
P09154621A1475 |35 58|safflower phospholipidsline phosphatases and 5
P09154621A1475 |77 87|ingredient8171T0000 
P09154621A1475 |135 152|serum cholesterolemia. P00008997A0
P09154621A1475 |91 97|layersmacolo
P09154621A1475 |6 13|results606T007
P09154621A1475 |111 130|liver triglycerides neonatal hyperbili
P09154621A1475 |173 180|effectsis show
P09154795A0628 |119 127|beta-poll hyperb
P09154795A0628 |14 24|techniques Compariso
P09154795A0628 |129 142|gene promoterirubinemia. P
P09154795A0628 |58 66|analysis-nucleot
P09154795A0628 |98 117|DNA polymerase betaic aspects of neona
P09154797A0777 |34 38|stk2alin
P09154797A0777 |10 30|spermidine transport0076 Comparison with
P09154797A0777 |89 97|affinityarmacolo
P09154797A0777 |142 148|strain000089
P09154797A0777 |40 52|lacZ mutantsphosphatases
P09154797A0777 |116 120|Vmaxatal
P09154819A0501 |86 91|FR3T3 Phar
P09154819A0501 |28 33|c-Junth al
P09154819A0501 |75 78|REF008
P09154819A0501 |108 128|fibroblast cell line of neonatal hyperbi
P09154819A0501 |10 24|overexpression0076 Compariso
P09154819A0501 |42 63|tenascin-C expressionosphatases and 5-nucl
P09154822T0000 |0 10|InhibitionP00001606T
P09154822T0000 |61 70|apoptosiscleotidas
P09154822T0000 |92 97|cellsacolo
P09154822T0000 |41 53|AMP agonistshosphatases 
P09154822T0000 |18 30|Raf-1 kinaseparison with
P09154827A0158 |171 177|subset] is s
P09154827A0158 |191 198|arreststion of
P09154827A0158 |218 228|degrees C.f K-deplet
P09154827A0158 |93 96|TAFcol
P09154827A0158 |58 62|ts13-nuc
P09154827A0158 |122 126|geneyper
P09154827A0158 |181 186|genes as a
P09154827A0158 |39 56|hamster cell line phosphatases and
P09154827A0158 |110 113|TAFf n
P09154827A0158 |9 16|studiesT0076 C
P09154827A0158 |155 165|expression When CSF 
P09154827A0158 |207 209|G1 t
P09154827A0158 |71 85|point mutation P00008171T000
P09154827A0158 |100 108|250/CCG1 aspects
P09155015A0140 |115 118|ANFnat
P09155015A0140 |107 113|factors of n
P09155015A0140 |180 191|hypertrophyn as a func
P09155015A0140 |120 128|promoter hyperbi
P09155015A0140 |54 78|reporter gene expressionnd 5-nucleotidase P00008
P09155015A0140 |22 42|protein kinase MEKK1son with alkaline ph
P09155015A0140 |140 146|marker P0000
P09155024A0955 |68 74|growthase P0
P09155024A0955 |99 111|pseudohyphaec aspects of
P09155024A0955 |82 86|form0000
P09155024A0955 |26 37|C. albicanswith alkali
P09155024A0955 |135 140|mediaemia.
P09155024A0955 |18 22|EFG1pari
P09155024A0955 |115 121|liquidnatal 
P09155024A0955 |0 14|OverexpressionP00001606T0076
P09156883A0294 |153 162|procedure72 When C
P09156883A0294 |47 61|blood pressuretases and 5-nu
P09156883A0294 |21 31|heart rateison with 
P09156883A0294 |96 100|SaO2ogic
P09156883A0294 |9 19|parametersT0076 Comp
P09156883A0294 |63 66|ABPeot
P09156883A0294 |33 35|HRka
P09156883A0294 |115 127|pulsoximetrynatal hyperb
P09156883A0294 |84 94|saturation00 Pharmac
P09157100A0583 |16 23|signingomparis
P09157100A0583 |62 65|SIBleo
P09157100A0583 |93 103|extinctioncologic as
P09157337A0545 |34 41|couplesaline p
P09157337A0545 |127 132|yearsiliru
P09157337A0545 |58 67|hepatitis-nucleoti
P09157337A0545 |4 11|husband01606T0
P09157337A0545 |99 121|Infectology Departmentc aspects of neonatal 
P09157337A0545 |84 92|etiology00 Pharm
P09157760A0000 |102 109|nucleusspects 
P09157760A0000 |92 99|Meynartacologi
P09157760A0000 |133 137|partinem
P09157760A0000 |164 172|thalamus [HCO3-]
P09157760A0000 |75 88|peculiarities008171T0000 P
P09157760A0000 |153 160|nucleus72 When
P09157760A0000 |206 217|individuals2 the data 
P09157760A0000 |34 42|analysisaline ph
P09159111A0437 |65 67|CDti
P09159111A0437 |126 134|proteinsbilirubi
P09159111A0437 |73 88|NMR experiments00008171T0000 P
P09159111A0437 |20 28|proposalrison wi
P09159111A0437 |96 106|Skn domainogic aspec
P09159111A0437 |54 63|dichroismnd 5-nucl
P09159160A0000 |76 81|genes08171
P09159160A0000 |107 115|diseasess of neo
P09159160A0000 |44 53|sequencesphatases 
P09159160A0000 |11 18|cloning076 Com
P09159183A0119 |171 177|plants] is s
P09159183A0119 |79 106|basic-region leucine zipper71T0000 Pharmacologic aspec
P09159183A0119 |39 43|OBFs pho
P09159183A0119 |161 167|numberCSF [H
P09159183A0119 |108 112|bZIP of 
P09159183A0119 |10 37|ocs element binding factors0076 Comparison with alkali
P09159183A0119 |70 75|classe P00
P09159183A0119 |114 135|transcription factorsonatal hyperbilirubin
P09159183A0119 |0 5|GenesP0000
P09160361A0858 |54 59|groupnd 5-
P09160361A0858 |133 134|pi
P09160361A0858 |28 37|CPB groupth alkali
P09160361A0858 |76 77|%0
P09160361A0858 |11 20|mortality076 Compa
P09160361A0858 |67 68|%d
P09160881A0491 |70 76|screene P000
P09160881A0491 |23 47|co-precipitation studieson with alkaline phospha
P09160881A0491 |109 121|interactionsof neonatal 
P09160881A0491 |53 58|yeastand 5
P09162084A0956 |100 127|GST-Src-SH2 affinity matrix aspects of neonatal hyperb
P09162084A0956 |67 74|PECAM-1dase P0
P09162084A0956 |43 57|Src-SH2 domainsphatases and 
P09162084A0956 |5 16|association1606T0076 C
P09162092A0675 |0 24|MKK3 autophosphorylationP00001606T0076 Compariso
P09162092A0675 |121 126|MEKK2hyper
P09162092A0675 |91 95|MKK3maco
P09162092A0675 |75 87|coexpression008171T0000 
P09162092A0675 |43 46|p38sph
P09162092A0675 |29 39|activationh alkaline
P09162092A0675 |101 106|MEKK3aspec
P09162097A0776 |68 72|exonase 
P09162097A0776 |140 146|LPAM-1 P0000
P09162097A0776 |25 41|MAdCAM-1 variant with alkaline p
P09162097A0776 |88 100|mucin domainharmacologic
P09162097A0776 |181 189|receptor as a fu
P09162097A0776 |155 163|adhesion When CS
P09162097A0776 |191 201|L-selectintion of CS
P09162097A0776 |118 136|leukocyte adhesional hyperbilirubine
P09162097A1258 |152 167|dissimilarities472 When CSF [H
P09162097A1258 |66 79|MAdCAM-1 cDNAidase P000081
P09162097A1258 |109 118|homologueof neonat
P09162097A1258 |122 136|mouse MAdCAM-1yperbilirubine
P09162097A1258 |195 205|structures of CSF PC
P09162097A1258 |3 10|summary001606T
P09162097A1258 |175 183|MAdCAM-1 shown a
P09162097A1258 |16 20|dataompa
P09163332A0275 |118 125|sequonsal hype
P09163332A0275 |77 84|hydroxy8171T00
P09163332A0275 |95 114|amino acid residueslogic aspects of ne
P09163332A0275 |29 49|mutagenesis approachh alkaline phosphata
P09163332A0275 |155 165|efficiency When CSF 
P09163332A0275 |86 93|Ser/Thr Pharma
P09163332A0275 |69 72|Xaase 
P09164543A0219 |0 8|MATERIALP0000160
P09164543A0219 |46 53|personsatases 
P09164543A0219 |13 20|METHODS6 Compa
P09164543A0219 |105 111|monthscts of
P09164543A0219 |93 98|yearscolog
P09164543A0219 |76 83|surgery08171T0
P09164543A0219 |26 33|authorswith al
P09164543A0219 |148 156|vagotomy97A0472 
P09164543A0219 |218 226|drainagef K-depl
P09164543A0219 |189 197|vagotomynction o
P09164543A0219 |118 122|meanal h
P09164856A0980 |138 146|promotera. P0000
P09164856A0980 |45 57|TATA elementhatases and 
P09164856A0980 |96 112|glutaminase geneogic aspects of 
P09164856A0980 |75 88|transcription008171T0000 P
P09164856A0980 |5 11|region1606T0
P09165004A1700 |0 12|SRE activityP00001606T00
P09165004A1700 |78 92|complex factor171T0000 Pharm
P09165004A1700 |121 136|complex factorshyperbilirubine
P09165004A1700 |49 64|phosphorylationses and 5-nucle
P09165004A1700 |140 145|Elk-1 P000
P09165004A1700 |35 45|activationline phosp
P09165035A0842 |0 35|Serum alkaline phosphatase activityP00001606T0076 Comparison with alka
P09165035A0842 |37 59|bone mass measurementsne phosphatases and 5-
P09165035A0842 |94 102|analysisologic a
P09165035A0842 |106 121|mineral densityts of neonatal 
P09165035A0842 |243 244|Dl
P09165035A0842 |156 165|vertebraeWhen CSF 
P09165035A0842 |191 198|animalstion of
P09165035A0842 |66 78|energy x-rayidase P00008
P09165035A0842 |249 256|animals displa
P09165035A0842 |185 186|Da
P09165035A0842 |138 152|testing valuesa. P00008997A0
P09165035A0842 |170 176|femora-] is 
P09165039A0728 |35 36|%l
P09165039A0728 |88 97|LHR cDNAsharmacolo
P09165039A0728 |45 62|sequence homologyhatases and 5-nuc
P09165039A0728 |4 19|monkey LHR cDNA01606T0076 Comp
P09165039A1372 |3 13|conclusion001606T007
P09165039A1372 |122 129|speciesyperbil
P09165039A1372 |15 34|marmoset monkey LHRComparison with alk
P09165039A1372 |94 102|LHR geneologic a
P09165039A1372 |79 83|exon71T0
P09165039A1372 |53 61|sequenceand 5-nu
P09165118A0311 |18 34|VA motor neuronsparison with alk
P09165118A0311 |107 119|sister cellss of neonata
P09165118A0311 |211 226|movement defect data of K-depl
P09165118A0311 |9 16|mutantsT0076 C
P09165118A0311 |125 141|VB motor neuronsrbilirubinemia. 
P09165118A0311 |147 151|loss997A
P09165118A0311 |46 53|patternatases 
P09165118A0311 |66 71|inputidase
P09165118A0311 |162 167|inputSF [H
P09165118A0311 |175 178|VAs sh
P09167421A0234 |49 67|microSelectron HDRses and 5-nucleoti
P09167421A0234 |105 107|Gyct
P09167421A0234 |127 136|fractionsilirubine
P09167421A0234 |14 25|irradiation Comparison
P09167421A0234 |81 87|deviceT0000 
P09168083A0987 |32 35|HATlka
P09168083A0987 |14 19|group Comp
P09168083A0987 |54 59|groupnd 5-
P09168083A0987 |37 38|Pn
P09168083A0987 |3 10|patient001606T
P09168134A0858 |0 19|Sequence comparisonP00001606T0076 Comp
P09168134A0858 |179 195|snRNP componentswn as a function
P09168134A0858 |160 165|genes CSF 
P09168134A0858 |79 88|Sm-E gene71T0000 P
P09168134A0858 |62 71|promotersleotidase
P09168134A0858 |32 52|kb promoter sequencelkaline phosphatases
P09168134A0858 |93 107|U1 snRNA genescologic aspect
P09168134A0858 |136 142|motifsmia. P
P09168218A0216 |68 86|pain syndrome typease P00008171T0000
P09168218A0216 |133 138|grillinemi
P09168218A0216 |13 22|responses6 Compari
P09168218A0216 |180 194|ganglion blockn as a functio
P09168218A0216 |40 45|womanphosp
P09168218A0216 |109 118|dystrophyof neonat
P09168218A0216 |0 7|METHODSP000016
P09168511A0640 |119 132|dexamethasonel hyperbiliru
P09168511A0640 |26 32|numberwith a
P09168511A0640 |72 75|useP00
P09168511A0640 |91 109|steroid budesonidemacologic aspects 
P09168511A0640 |36 48|developmentsine phosphat
P09168511A0640 |172 180|steroids is show
P09168511A0640 |153 161|argument72 When 
P09168623A0614 |2 6|xylE0001
P09168623A0614 |160 170|expression CSF [HCO3
P09168623A0614 |46 59|mxbD promoteratases and 5-
P09168623A0614 |132 141|compoundsbinemia. 
P09168623A0614 |23 29|fusionon wit
P09168623A0614 |189 198|succinatenction of
P09168623A0614 |128 130|C1li
P09168623A0614 |77 87|expression8171T0000 
P09168623A0614 |101 106|cellsaspec
P09168623A0614 |174 179|cellss sho
P09168623A0614 |116 126|one-carbonatal hyper
P09168879A0219 |136 146|TAAG sitesmia. P0000
P09168879A0219 |19 28|Sf9 cellsarison wi
P09168879A0219 |95 105|TAAG siteslogic aspe
P09168879A0219 |35 59|transcription initiationline phosphatases and 5-
P09168892A1016 |0 8|MutationP0000160
P09168892A1016 |12 23|nucleotides76 Comparis
P09168892A1016 |74 80|effect000817
P09168892A1016 |58 66|elements-nucleot
P09168892A1016 |40 44|AP-1phos
P09168892A1016 |84 100|trans-activation00 Pharmacologic
P09169127A0371 |288 296|sequencet still 
P09169127A0371 |10 19|proximity0076 Comp
P09169127A0371 |227 235|sequenceted rats
P09169127A0371 |31 60|neuropeptide Y receptor genesalkaline phosphatases and 5-n
P09169127A0371 |185 192|y1 genea funct
P09169127A0371 |138 144|introna. P00
P09169127A0371 |354 361|y1 gene10943A0
P09169127A0371 |247 254|y5 geneer disp
P09169127A0371 |169 177|sequence3-] is s
P09169127A0371 |100 122|gene duplication event aspects of neonatal h
P09169127A0371 |341 345|exon0.23
P09169420A0000 |171 174|PIK] i
P09169420A0000 |167 170|p55CO3
P09169420A0000 |14 40|phosphoinositide 3-kinases Comparison with alkaline 
P09169420A0000 |60 64|betaucle
P09169420A0000 |138 146|adaptorsa. P0000
P09169420A0000 |115 118|SH2nat
P09169420A0000 |99 111|Src homologyc aspects of
P09169420A0000 |42 47|PI3Ksospha
P09169420A0000 |49 58|p110alphases and 5
P09169420A0000 |155 163|p85alpha When CS
P09169420A0000 |70 93|delta form heterodimerse P00008171T0000 Pharma
P09169475A0272 |98 128|transcription initiation sitesic aspects of neonatal hyperbi
P09169475A0272 |7 14|studies06T0076
P09169475A0272 |46 52|regionatases
P09169475A0272 |66 76|gp130 geneidase P000
P09169475A0772 |0 12|LocalizationP00001606T00
P09169475A0772 |122 134|binding siteyperbilirubi
P09169475A0772 |88 99|mutagenesisharmacologi
P09169475A0772 |52 69|deletion analysis and 5-nucleotida
P09169475A0772 |149 163|STAT complexes7A0472 When CS
P09169475A0772 |20 45|cytokine response elementrison with alkaline phosp
P09169593T0000 |152 156|role472 
P09169593T0000 |164 174|regulation [HCO3-] i
P09169593T0000 |127 139|cell nucleusilirubinemia
P09169593T0000 |40 61|protein kinase kinasephosphatases and 5-nu
P09169593T0000 |106 119|casein kinasets of neonata
P09169593T0000 |63 66|MEKeot
P09169593T0000 |87 101|protein kinasePharmacologic 
P09169593T0000 |178 193|gene expressionown as a functi
P09169593T0000 |0 18|Insulin regulationP00001606T0076 Com
P09169852A0235 |220 228|tyrosineK-deplet
P09169852A0235 |165 176|zinc finger[HCO3-] is 
P09169852A0235 |0 10|SequencingP00001606T
P09169852A0235 |114 126|zinc fingersonatal hyper
P09169852A0235 |24 37|pag-3 allelesn with alkali
P09169852A0235 |133 150|missense mutationinemia. P00008997
P09169852A0235 |85 102|nonsense mutation0 Pharmacologic a
P09169852A0235 |68 75|allelesase P00
P09169852A0235 |205 214|histidineO2 the da
P09169853A0000 |0 5|Pax-3P0000
P09169853A0000 |23 36|homeobox geneon with alkal
P09169853A0000 |75 81|dorsal008171
P09169853A0000 |103 107|tubepect
P09170159A0348 |34 39|cellsaline
P09170159A0348 |123 130|proteinperbili
P09170159A0348 |89 99|tyrosinasearmacologi
P09170159A0348 |65 80|marker proteinstidase P0000817
P09170159A0721 |116 123|HLH-Zipatal hy
P09170159A0721 |127 140|Zip structureilirubinemia.
P09170159A0721 |28 34|codonsth alk
P09170159A0721 |99 107|proteinsc aspect
P09170159A0721 |6 15|mutations606T0076 
P09170159A0721 |38 42|exone ph
P09171038A0219 |16 23|Sjogrenomparis
P09171038A0219 |26 34|syndromewith alk
P09171038A0219 |121 130|treatmenthyperbili
P09171038A0219 |134 141|Sjogrennemia. 
P09171038A0219 |8 12|case6T00
P09171038A0219 |95 105|complaintslogic aspe
P09171038A0219 |144 152|patients008997A0
P09171081T0000 |34 38|cDNAalin
P09171081T0000 |12 28|characterization76 Comparison wi
P09171081T0000 |69 83|RNA polymerasese P00008171T0
P09171081T0000 |100 123|plant Chenopodium album aspects of neonatal hy
P09171081T0000 |0 7|CloningP000016
P09171235A0851 |146 152|TRbeta8997A0
P09171235A0851 |11 25|overexpression076 Comparison
P09171235A0851 |75 91|COUP-TFI delta35008171T0000 Phar
P09171235A0851 |40 53|concentrationphosphatases 
P09171235A0851 |109 127|silencing activityof neonatal hyperb
P09171235A0851 |57 65|COUP-TFI5-nucleo
P09171239A1118 |49 54|helixses a
P09171239A1118 |94 111|hormone receptorsologic aspects of
P09171239A1118 |26 30|partwith
P09171239A1118 |165 189|transactivation function[HCO3-] is shown as a fu
P09171239A1118 |129 140|core domainirubinemia.
P09171239A1118 |10 21|amino acids0076 Compar
P09171239A1118 |191 195|AF-2tion
P09171239A2146 |66 73|bindingidase P
P09171239A2146 |31 37|ligandalkali
P09171239A2146 |90 103|RXR componentrmacologic as
P09171239A2146 |77 82|SRC-18171T
P09171239A2146 |121 132|heterodimerhyperbiliru
P09171239A2146 |53 57|acidand 
P09171363A0149 |18 28|mechanismsparison wi
P09171363A0149 |3 11|ciliates001606T0
P09171389A0549 |305 324|pyr gene expressiongnificantly greater
P09171389A0549 |282 293|attenuationols but sti
P09171389A0549 |208 220|Bacillus sp.the data of 
P09171389A0549 |13 23|occurrence6 Comparis
P09171389A0549 |328 335|Thermuspe (1.2
P09171389A0549 |175 200|PyrR attenuation proteins shown as a function of C
P09171389A0549 |64 91|Thermus pyr promoter regionotidase P00008171T0000 Phar
P09171389A0549 |143 144|%0
P09171389A0549 |246 255|mechanismger displ
P09171389A0549 |35 56|transcription signalsline phosphatases and
P09171389A0549 |154 166|Thermus PyrR2 When CSF [
P09171389A0549 |103 133|amino acid sequence identitiespects of neonatal hyperbilirub
P09171468T0000 |0 5|DiverP0000
P09171468T0000 |56 75|breathing apparatus 5-nucleotidase P00
P09171468T0000 |18 27|responsesparison w
P09171969A1165 |0 11|MeasurementP00001606T0
P09171969A1165 |44 56|oxygen pulsephatases and
P09171969A1165 |36 39|VO2ine
P09171969A1165 |172 176|COPD is 
P09171969A1165 |73 91|work rate exercise00008171T0000 Phar
P09171969A1165 |121 131|evaluationhyperbilir
P09171969A1165 |19 23|timearis
P09171969A1165 |158 166|patientsen CSF [
P09171969A1165 |139 154|training effect. P00008997A047
P09172312T0000 |0 16|CharacterizationP00001606T0076 C
P09172312T0000 |20 30|CR1 repeatrison with
P09172312T0000 |66 80|chicken genomeidase P0000817
P09172312T0000 |38 49|PCR markerse phosphata
P09172414A0000 |137 142|serumia. P
P09172414A0000 |147 162|liver esterases997A0472 When C
P09172414A0000 |79 92|determination71T0000 Pharm
P09172414A0000 |96 115|cocaine metabolitesogic aspects of neo
P09172414A0000 |58 62|HPLC-nuc
P09172414A0000 |64 70|methodotidas
P09172641A0181 |85 94|subdomain0 Pharmac
P09172641A0181 |27 35|evidenceith alka
P09172641A0181 |11 18|studies076 Com
P09172641A0181 |44 47|endpha
P09172641A0181 |113 121|contactseonatal 
P09172641A0181 |131 142|nucleotidesubinemia. P
P09172641A0181 |70 81|side chainse P00008171
P09172812A0660 |21 32|fludarabineison with a
P09172812A0660 |61 64|CLLcle
P09172812A0660 |52 57|agent and 
P09173733A0404 |279 288|densitiesntrols bu
P09173733A0404 |59 64|studynucle
P09173733A0404 |267 269|EAmp
P09173733A0404 |244 259|factor analysisonger displaced
P09173733A0404 |180 189|expansionn as a fu
P09173733A0404 |30 41|EA analysis alkaline p
P09173733A0404 |120 124|band hyp
P09173733A0404 |106 108|EAts
P09173733A0404 |74 96|Fourier transformation0008171T0000 Pharmacol
P09173733A0404 |16 26|techniquesomparison 
P09173733A0404 |157 163|methodhen CS
P09173733A0404 |234 239|shapes are
P09173733A0404 |197 207|EEG curvesf CSF PCO2
P09173733A0404 |98 101|FFTic 
P09174049A1788 |171 181|cell death] is shown
P09174049A1788 |15 49|p34CDC2 histone H1 kinase activityComparison with alkaline phosphata
P09174049A1788 |97 107|cell linesgic aspect
P09174049A1788 |128 132|roleliru
P09174049A1788 |142 149|protein0000899
P09175708A1526 |187 194|nucleusfunctio
P09175708A1526 |78 86|receptor171T0000
P09175708A1526 |56 63|regions 5-nucl
P09175708A1526 |6 11|PRL-R606T0
P09175708A1526 |125 133|fragmentrbilirub
P09175708A1526 |100 111|possibility aspects of
P09175858A1449 |289 294|GAPDH stil
P09175858A1449 |219 226|account K-depl
P09175858A1449 |10 20|B-S mutant0076 Compa
P09175858A1449 |109 116|effectsof neon
P09175858A1449 |269 275|mutantared t
P09175858A1449 |185 195|structuresa function
P09175858A1449 |66 72|GAPDHsidase 
P09175858A1449 |153 163|inspection72 When CS
P09176340A1194 |0 13|TranscriptionP00001606T007
P09176340A1194 |23 28|geneson wi
P09176340A1194 |58 62|lung-nuc
P09176340A1194 |132 137|liverbinem
P09176340A1194 |105 112|tissuescts of 
P09176340A1194 |50 53|gutes 
P09176340A1194 |70 78|freezinge P00008
P09176340A1194 |84 95|mRNA levels00 Pharmaco
P09176837A0211 |137 153|P administrationia. P00008997A04
P09176837A0211 |37 41|CSAOne p
P09176837A0211 |76 88|P solubility08171T0000 P
P09176837A0211 |130 132|Caru
P09176837A0211 |103 107|datapect
P09176837A0211 |70 75|PN Cae P00
P09176837A0211 |0 17|Computer softwareP00001606T0076 Co
P09177169A0935 |102 110|bacteriaspects o
P09177169A0935 |10 17|chimera0076 Co
P09177169A0935 |45 51|halveshatase
P09177169A0935 |59 67|moleculenucleoti
P09177857A0000 |155 159|type Whe
P09177857A0000 |172 178|plasma is sh
P09177857A0000 |142 147|steel00008
P09177857A0000 |93 99|oxygencologi
P09177857A0000 |29 45|titanium dioxideh alkaline phosp
P09177857A0000 |4 14|conditions01606T0076
P09177857A0000 |188 221|chemical vapour deposition methodunction of CSF PCO2 the data of K
P09177857A0000 |55 88|substrates titanium tetrachlorided 5-nucleotidase P00008171T0000 P
P09178269A0107 |8 13|genes6T007
P09178491A0262 |16 23|regionsomparis
P09178491A0262 |124 141|initiator elementerbilirubinemia. 
P09178491A0262 |70 85|HBV adw subtypee P00008171T000
P09178491A0262 |36 62|preS2/S gene transcriptionine phosphatases and 5-nuc
P09178491A0262 |100 108|TATA box aspects
P09178494A1123 |218 221|RNAf K
P09178494A1123 |192 204|preservationion of CSF P
P09178494A1123 |88 92|stemharm
P09178494A1123 |284 291|controls but s
P09178494A1123 |296 307|replicationhave a sign
P09178494A1123 |178 187|selectionown as a 
P09178494A1123 |76 84|patterns08171T00
P09178494A1123 |59 66|regionsnucleot
P09178494A1123 |142 154|flaviviruses00008997A047
P09178494A1123 |97 112|loop structuresgic aspects of 
P09178494A1123 |232 242|structuresats are no
P09178752A0574 |68 72|cAMPase 
P09178752A0574 |22 27|meansson w
P09178752A0574 |31 58|transactivation domain AF-1alkaline phosphatases and 5
P09178752A0574 |117 119|ERta
P09178752A0574 |82 109|transactivation domain AF-20000 Pharmacologic aspects 
P09178752A0574 |0 3|EGFP00
P09180687A0096 |171 199|alanine substitution mutants] is shown as a function of 
P09180687A0096 |150 154|SulAA047
P09180687A0096 |101 107|seriesaspect
P09180687A0096 |55 65|inhibitiond 5-nucleo
P09180687A0096 |161 167|seriesCSF [H
P09180687A0096 |29 33|SulAh al
P09180687A0096 |69 82|cell divisionse P00008171T
P09180687A0096 |19 25|regionarison
P09180687A0096 |137 146|deletionsia. P0000
P09181130A1067 |116 124|deletionatal hyp
P09181130A1067 |128 130|r3li
P09181130A1067 |94 102|mutationologic a
P09181130A1067 |135 137|r5em
P09181130A1067 |59 67|ES cellsnucleoti
P09181130A1067 |42 55|recombinationosphatases an
P09181130A1067 |20 27|Krox-20rison w
P09181130A1587 |69 80|populationsse P0000817
P09181130A1587 |134 138|rolenemi
P09181130A1587 |97 105|mutationgic aspe
P09181130A1587 |215 227|inactivationa of K-deple
P09181130A1587 |195 207|consequences of CSF PCO2
P09181130A1587 |121 126|lighthyper
P09181130A1587 |39 47|analysis phospha
P09181130A1587 |142 149|Krox-200000899
P09181130A1587 |157 169|segmentationhen CSF [HCO
P09182281A0197 |37 50|Cyclosporin Ane phosphatas
P09182281A0197 |91 95|drugmaco
P09182527A0443 |48 54|mE6-APases a
P09182527A0443 |89 96|cytosolarmacol
P09182527A0443 |28 46|p53 ubiquitinationth alkaline phosph
P09182527A0443 |104 110|Nedd-4ects o
P09182527A0443 |77 84|nucleus8171T00
P09182527A0443 |133 140|cytosolinemia.
P09182527A0443 |20 24|roleriso
P09182707A0254 |102 117|tyrosine kinasespects of neona
P09182707A0254 |142 151|adhesions00008997A
P09182707A0254 |78 82|p125171T
P09182707A0254 |27 51|tyrosine phosphorylationith alkaline phosphatase
P09182707A0254 |61 76|adhesion kinasecleotidase P000
P09182707A0254 |188 204|protein paxillinunction of CSF P
P09182707A0254 |83 86|FAK000
P09182707A0254 |0 3|SPPP00
P09182990A0245 |186 192|factor funct
P09182990A0245 |233 238|yeastts ar
P09182990A0245 |66 77|combinationidase P0000
P09182990A0245 |165 171|Sup45p[HCO3-
P09182990A0245 |44 49|SUP45phata
P09182990A0245 |153 163|SUP45 gene72 When CS
P09182990A0245 |206 229|translation termination2 the data of K-deplete
P09182990A0245 |138 145|producta. P000
P09182990A0245 |175 179|eRF1 sho
P09182990A0245 |51 58|sup45-2s and 5
P09182990A0245 |34 40|allelealine 
P09182990A0245 |102 112|approachesspects of 
P09183145T0001 |0 10|EvaluationP00001606T
P09183145T0001 |123 134|angioplastyperbilirubi
P09183145T0001 |25 34|perfusion with alk
P09183145T0001 |56 61|SPECT 5-nu
P09183145T0001 |156 166|infarctionWhen CSF [
P09183406A0637 |55 59|Bakad 5-
P09183406A0637 |47 53|HPA-3atases 
P09183406A0637 |61 76|incompatibilitycleotidase P000
P09183406A0637 |22 38|thrombocytopeniason with alkalin
P09185183A0089 |35 40|yearsline 
P09185183A0089 |83 98|motor abilities000 Pharmacolog
P09185183A0089 |44 47|agepha
P09185183A0089 |70 79|worseninge P000081
P09185183T0000 |0 7|MerosinP000016
P09185183T0000 |37 46|dystrophyne phosph
P09185183T0000 |59 69|deficiencynucleotida
P09185183T0000 |84 95|MRI changes00 Pharmaco
P09185183T0000 |71 79|epilepsy P000081
P09185183T0000 |118 124|matteral hyp
P09185586A0000 |16 21|mRNAsompar
P09185586A0000 |62 71|mechanismleotidase
P09185586A0000 |43 60|scanning ribosomesphatases and 5-n
P09185645T0000 |0 10|ComparisonP00001606T
P09185645T0000 |107 116|detections of neon
P09185645T0000 |14 48|Tc-99m sestamibi perfusion imaging Comparison with alkaline phosphat
P09185645T0000 |129 143|artery diseaseirubinemia. P0
P09185645T0000 |79 98|arbutamine infusion71T0000 Pharmacolog
P09185645T0000 |53 69|echocardiographyand 5-nucleotida
P09186056A0514 |50 61|C2C12 cellses and 5-nu
P09186056A0514 |93 105|CAT-reportercologic aspe
P09186056A0514 |122 130|E12/MyoDyperbili
P09186056A0514 |74 87|transcription0008171T0000 
P09186056A0514 |138 146|enhancera. P0000
P09186056A0514 |39 46|protein phosph
P09186056A0514 |16 30|overexpressionomparison with
P09186430A0341 |44 52|albinismphatases
P09186507A0882 |222 239|CpG dinucleotidesdepleted rats are
P09186507A0882 |151 155|TATA0472
P09186507A0882 |160 170|CAAT boxes CSF [HCO3
P09186507A0882 |133 143|CpG islandinemia. P0
P09186507A0882 |331 335|gene(1.2
P09186507A0882 |192 203|G+C contention of CSF 
P09186507A0882 |96 109|cDNA sequenceogic aspects 
P09186507A0882 |53 61|sequenceand 5-nu
P09186507A0882 |279 283|sitentro
P09187136A0000 |0 6|SSeCKSP00001
P09187136A0000 |42 68|protein kinase C substrateosphatases and 5-nucleotid
P09187136A0000 |147 158|fibroblasts997A0472 Wh
P09187136A0000 |193 204|fibroblastson of CSF P
P09187136A0000 |74 84|expression0008171T00
P09187136A0000 |206 208|X.2 
P09187136A0000 |115 118|srcnat
P09187136A0000 |19 24|essexariso
P09187277A0118 |152 159|neurons472 Whe
P09187277A0118 |62 65|V Ileo
P09187277A0118 |97 103|numbergic as
P09187277A0118 |67 74|neuronsdase P0
P09187277A0118 |7 32|position-vestibular-pause06T0076 Comparison with a
P09187277A0118 |124 128|typeerbi
P09187277A0118 |0 4|TypeP000
P09187277A0118 |113 117|typeeona
P09187277A0118 |34 39|PVP Ialine
P09187371A0450 |103 108|heartpects
P09187371A0450 |78 85|species171T000
P09187371A0450 |56 61|heart 5-nu
P09187371A0450 |148 154|muscle97A047
P09187371A0450 |121 126|brainhyper
P09187371A0450 |158 163|liveren CS
P09187371A0450 |110 116|kidneyf neon
P09187371A0450 |20 32|mRNA speciesrison with a
P09187637A1199 |68 71|OP4ase
P09187637A1199 |47 56|amplitudetases and
P09187637A1199 |60 63|OP1ucl
P09187637A1199 |0 18|Taurine deficiencyP00001606T0076 Com
P09188094A0934 |70 78|responsee P00008
P09188094A0934 |25 30|cells with
P09188094A0934 |62 66|Spc1leot
P09188094A0934 |90 95|formsrmaco
P09188094A0934 |48 58|activationases and 5
P09188094A0934 |99 105|stressc aspe
P09188094A0934 |19 23|mcs4aris
P09188699A1388 |117 130|SDS-PAGE gelstal hyperbili
P09188699A1388 |91 103|SP-A speciesmacologic as
P09188699A1388 |13 30|rat SP-A isoforms6 Comparison with
P09188863A0954 |24 30|CDC25Bn with
P09188863A0954 |12 20|splicing76 Compa
P09188863A0954 |74 92|cell proliferation0008171T0000 Pharm
P09188863A0954 |63 70|controleotidas
P09189783A0000 |103 115|carbohydratepects of neo
P09189783A0000 |164 177|blood glucose [HCO3-] is s
P09189783A0000 |5 18|investigation1606T0076 Com
P09189783A0000 |144 149|bolus00899
P09189783A0000 |79 87|feedings71T0000 
P09189783A0000 |182 199|insulin responsesas a function of 
P09189783A0000 |117 120|CHOtal
P09189783A0000 |216 224|exercise of K-de
P09189783A0000 |207 211|rest the
P09189896A0611 |50 66|memory processeses and 5-nucleot
P09189896A0611 |113 125|instructionseonatal hype
P09189896A0611 |26 37|ERP effectswith alkali
P09189896A0611 |4 12|findings01606T00
P09190202A0166 |102 124|Sec13p protein complexspects of neonatal hyp
P09190202A0166 |30 35|Sar1p alka
P09190202A0166 |172 176|p150 is 
P09190202A0166 |163 170|proteinF [HCO3
P09190202A0166 |41 63|Sec23p protein complexhosphatases and 5-nucl
P09190202A0166 |75 81|Sec23p008171
P09190202A0166 |86 92|Sec24p Pharm
P09190202A0166 |5 17|coat protein1606T0076 Co
P09190202A0166 |136 142|Sec13pmia. P
P09190821A0707 |81 86|P243LT0000
P09190821A0707 |57 63|change5-nucl
P09190821A0707 |67 75|positiondase P00
P09190940A0127 |0 9|InductionP00001606
P09190940A0127 |31 51|germline transcriptsalkaline phosphatase
P09190940A0127 |77 90|switch region8171T0000 Pha
P09190940A0127 |95 108|recombinationlogic aspects
P09190940A0127 |113 122|switchingeonatal h
P09191052A0850 |68 80|Hox proteinsase P0000817
P09191052A0850 |10 13|PCE007
P09191052A0850 |60 65|Classucleo
P09191052A0850 |22 39|Pbx dimer partnerson with alkaline
P09192732A1384 |126 130|partbili
P09192732A1384 |45 54|homologuehatases a
P09192732A1384 |30 37|portion alkali
P09192732A1384 |91 99|membranemacologi
P09192769T0000 |69 87|chemokine receptorse P00008171T0000 
P09192769T0000 |22 38|characterizationson with alkalin
P09192769T0000 |95 103|homologylogic as
P09192769T0000 |10 17|cloning0076 Co
P09192769T0000 |44 48|cDNAphat
P09192769T0000 |117 139|C-C chemokine receptortal hyperbilirubinemia
P09192769T0000 |141 146|CCR-4P0000
P09192769T0000 |50 56|CHEMR1es and
P09192786T0000 |0 12|OrganizationP00001606T00
P09192786T0000 |26 33|LU genewith al
P09192786T0000 |73 97|blood group polymorphism00008171T0000 Pharmacolo
P09192786T0000 |61 63|Lucl
P09192786T0000 |48 53|basisases 
P09192786T0000 |67 69|Luda
P09192786T0000 |70 71|be
P09192842A0988 |255 269|carcinogenesisaced when comp
P09192842A0988 |26 33|hybridswith al
P09192842A0988 |89 107|chromosome 19q13.2armacologic aspect
P09192842A0988 |149 158|deletions7A0472 Wh
P09192842A0988 |225 235|ETS factorleted rats
P09192842A0988 |162 171|leukemiasSF [HCO3-
P09192842A0988 |111 117|region neona
P09192842A0988 |57 66|PE-2 gene5-nucleot
P09192842A0988 |130 144|translocationsrubinemia. P00
P09192842A0988 |38 51|FISH analysise phosphatase
P09192842A0988 |247 251|roleer d
P09192842A0988 |190 196|tumorsction 
P09192998A0356 |207 217|CJ signals the data 
P09192998A0356 |199 202|PTHCSF
P09192998A0356 |72 78|T7 DNAP00008
P09192998A0356 |159 166|rrnB T1n CSF [
P09192998A0356 |82 85|phi000
P09192998A0356 |92 99|rrnB T2acologi
P09192998A0356 |58 68|terminator-nucleotid
P09192998A0356 |138 155|termination sitesa. P00008997A0472
P09192998A0356 |80 81|T1
P09192998A0356 |19 26|enzymesarison 
P09193072A0199 |34 44|transgenesaline phos
P09193072A0199 |62 71|nucleolusleotidase
P09193072A0199 |12 16|data76 C
P09193077A0000 |152 172|Petroselinum crispum472 When CSF [HCO3-]
P09193077A0000 |25 29|LRU1 wit
P09193077A0000 |108 125|chalcone synthase of neonatal hype
P09193077A0000 |90 100|activationrmacologic
P09193077A0000 |140 148|promoter P000089
P09193077A0000 |127 130|CHSili
P09193077A0000 |17 21|unitmpar
P09193080A0904 |0 19|Sequence divergenceP00001606T0076 Comp
P09193080A0904 |48 55|regionsases an
P09193080A0904 |73 83|definition00008171T0
P09193080A0904 |101 107|probesaspect
P09193671A0347 |34 44|hydrolysisaline phos
P09193671A0347 |78 85|ARF-GDP171T000
P09193671A0347 |11 16|state076 C
P09193671A0347 |54 57|GTPnd 
P09194250A0708 |70 86|mortality targete P00008171T0000
P09194250A0708 |31 43|World Summitalkaline pho
P09194250A0708 |151 163|inequalities0472 When CS
P09194250A0708 |120 127|targets hyperb
P09194250A0708 |178 187|mortalityown as a 
P09194250A0708 |95 99|yearlogi
P09194250A0708 |48 56|Childrenases and
P09195923A0125 |205 217|immunophilinO2 the data 
P09195923A0125 |126 129|TPRbil
P09195923A0125 |131 137|domainubinem
P09195923A0125 |243 249|regionlonger
P09195923A0125 |86 91|hsp90 Phar
P09195923A0125 |48 75|cyclosporin A-binding classases and 5-nucleotidase P00
P09195923A0125 |38 43|FK506e pho
P09195923A0125 |4 16|immunophilin01606T0076 C
P09195923A0125 |100 124|tetratricopeptide repeat aspects of neonatal hyp
P09195923A0125 |253 258|hsp90place
P09195923A0125 |153 177|receptor heterocomplexes72 When CSF [HCO3-] is s
P09197241A0770 |119 122|lynl h
P09197241A0770 |25 32|absence with a
P09197241A0770 |77 92|hyperactivation8171T0000 Pharm
P09197241A0770 |12 23|macrophages76 Comparis
P09197241A0770 |96 102|p56/59ogic a
P09197241A0770 |36 40|CD45ine 
P09197241A0770 |112 118|p53/56neonat
P09197241A0770 |52 72|hyperphosphorylation and 5-nucleotidase 
P09197241A0770 |103 106|hckpec
P09197241A0770 |140 145|c-fgr P000
P09197241A0770 |136 139|p58mia
P09197342T0000 |0 9|SecretionP00001606
P09197342T0000 |95 102|rabbitslogic a
P09197342T0000 |13 17|milk6 Co
P09197342T0000 |61 65|oilscleo
P09197342T0000 |67 78|Lipiodol UFdase P00008
P09197342T0000 |37 45|transferne phosp
P09197342T0000 |83 90|Oriodol000 Pha
P09197408A0126 |0 10|SequencingP00001606T
P09197408A0126 |18 27|facB geneparison w
P09197408A0126 |55 62|proteind 5-nuc
P09197408A0126 |250 257|regionsdisplac
P09197408A0126 |148 159|DNA binding97A0472 Whe
P09197408A0126 |181 201|heptad repeat motifs as a function of CS
P09197408A0126 |161 168|leucineCSF [HC
P09197408A0126 |107 112|2Cys6s of 
P09197408A0126 |319 328|activatoreater slo
P09197408A0126 |117 124|C6 zinctal hyp
P09197408A0126 |101 103|Znas
P09197408A0126 |277 285|functioncontrols
P09197408A0126 |136 143|clustermia. P0
P09199167A0942 |0 14|OverexpressionP00001606T0076
P09199167A0942 |46 53|absenceatases 
P09199167A0942 |18 23|Sed5pparis
P09199167A0942 |57 62|Vti1p5-nuc
P09199167A0942 |32 38|growthlkalin
P09199286A0086 |55 59|exond 5-
P09199286A0086 |11 17|region076 Co
P09199286A0086 |88 95|proteinharmaco
P09199286A0086 |21 25|mkh1ison
P09199292A0536 |84 97|cyclin A-cdk200 Pharmacolo
P09199292A0536 |42 46|p107osph
P09199292A0536 |27 38|associationith alkalin
P09199292A0536 |130 137|kinasesrubinem
P09199292A0536 |67 80|cyclin E-cdk2dase P0000817
P09199292A0536 |110 120|activitiesf neonatal
P09199292A0536 |50 54|p130es a
P09199318A1147 |72 92|muscle alpha-actininP00008171T0000 Pharm
P09199318A1147 |13 17|p1506 Co
P09199318A1147 |29 43|actin gelationh alkaline pho
P09199322T0000 |0 12|DenaturationP00001606T00
P09199322T0000 |46 57|replicationatases and 
P09199322T0000 |76 98|replication protein A.08171T0000 Pharmacolog
P09199322T0000 |27 32|virusith a
P09199322T0000 |36 42|originine ph
P09199327A1250 |69 78|constructse P00008
P09199327A1250 |211 218|binding data o
P09199327A1250 |161 170|TEF-1-MaxCSF [HCO3
P09199327A1250 |226 233|complexeted ra
P09199327A1250 |183 190|complexs a fun
P09199327A1250 |241 249|EM motifo longer
P09199327A1250 |5 11|effect1606T0
P09199327A1250 |129 153|transactivation functionirubinemia. P00008997A04
P09199327A1250 |35 43|EM motifline pho
P09199328T0000 |68 73|Oct-1ase P
P09199328T0000 |75 78|HCF008
P09199328T0000 |15 23|residuesComparis
P09199328T0000 |49 53|VP16ses 
P09199328T0000 |39 45|region phosp
P09199328T0000 |84 87|DNA00 
P09199348A0156 |7 11|view06T0
P09199348A0156 |43 59|U14 interactionssphatases and 5-
P09199348A0156 |130 138|U14 RNAsrubinemi
P09199348A0156 |73 79|domain000081
P09199348A0156 |144 152|Y domain008997A0
P09199348A0156 |93 101|activitycologic 
P09199348A0156 |197 205|analysisf CSF PC
P09199353A1924 |205 212|originsO2 the 
P09199353A1924 |79 98|chromatin structure71T0000 Pharmacolog
P09199353A1924 |15 22|resultsCompari
P09199353A1924 |190 198|templatection of
P09199353A1924 |66 75|regulatoridase P00
P09199353A1924 |159 167|proteinsn CSF [H
P09199353A1924 |176 182|accessshown 
P09199353A1924 |35 40|Cdc68line 
P09199353A1924 |216 227|replication of K-deple
P09199353A1924 |118 134|polymerase alphaal hyperbilirubi
P09199413A0518 |65 74|CFU/mousetidase P0
P09199413A0518 |14 27|inoculum size Comparison w
P09199413A0518 |79 80|%7
P09199413A0518 |104 111|animalsects of
P09199413A0518 |126 130|daysbili
P09199626A0613 |16 17|%o
P09199626A0613 |6 11|cases606T0
P09199626A0613 |22 28|changeson wi
P09199626A0613 |32 37|stagelkali
P09199932A1357 |0 31|Promoter recognition algorithmsP00001606T0076 Comparison with 
P09199932A1357 |125 139|E14/NPAT genesrbilirubinemia
P09199932A1357 |263 267|exonn co
P09199932A1357 |53 70|promoter elementsand 5-nucleotidas
P09199932A1357 |82 92|CpG island0000 Pharm
P09199932A1357 |212 218|introndata o
P09199932A1357 |184 196|ATM promoter a function 
P09199932A1357 |117 120|ATMtal
P09199932A1357 |153 161|evidence72 When 
P09199970A1101 |20 24|pMCPriso
P09199970A1101 |109 121|C3b cleavageof neonatal 
P09199970A1101 |79 85|factor71T000
P09199970A1101 |88 105|cofactor activityharmacologic aspe
P09199970A1101 |37 50|transmembranene phosphatas
P09199970A1101 |197 200|MCPf C
P09199970A1101 |67 74|domainsdase P0
P09200029A0211 |76 85|diagnosis08171T000
P09200029A0211 |28 33|signsth al
P09200029A0211 |126 149|bone marrow examinationbilirubinemia. P0000899
P09200029A0211 |109 117|featuresof neona
P09200029A0211 |59 66|settingnucleot
P09200498T0000 |18 37|muscle coactivationparison with alkali
P09200498T0000 |8 13|zones6T007
P09200498T0000 |46 53|controlatases 
P09200498T0000 |66 75|stabilityidase P00
P09200530A0411 |0 6|LiquidP00001
P09200530A0411 |89 105|gradient elutionarmacologic aspe
P09200530A0411 |52 64|Zorbax RX C8 and 5-nucle
P09200530A0411 |76 82|column08171T
P09200530A0411 |23 33|separationon with al
P09200811T0000 |95 123|pGKL1-plasmid DNA polymeraselogic aspects of neonatal hy
P09200811T0000 |62 69|proteinleotida
P09200811T0000 |11 24|plasmid pDHL1076 Compariso
P09201946A0000 |204 210|lengthCO2 th
P09201946A0000 |72 108|transcription termination factor rhoP00008171T0000 Pharmacologic aspects
P09201946A0000 |28 47|helicase activitiesth alkaline phospha
P09201946A0000 |181 200|nucleotide residues as a function of C
P09201946A0000 |232 237|trp tats a
P09201946A0000 |146 159|RNA molecules8997A0472 Whe
P09201946A0000 |253 273|termination sequenceplaced when compared
P09201980A0910 |86 93|species Pharma
P09201980A0910 |4 18|p20-CGGBP gene01606T0076 Com
P09201980A0910 |59 67|homologynucleoti
P09201980A0910 |38 45|mammalse phosp
P09202147A0866 |118 129|degradational hyperbil
P09202147A0866 |30 35|yeast alka
P09202147A0866 |142 150|proteins00008997
P09202147A0866 |57 66|subfamily5-nucleot
P09202147A0866 |40 46|plantsphosph
P09202147A0866 |164 170|stress [HCO3
P09202147A0866 |70 73|UBCe P
P09202147A0866 |4 8|data0160
P09202147A0866 |154 160|result2 When
P09202669A0614 |153 172|neomycin resistance72 When CSF [HCO3-]
P09202669A0614 |28 31|AAVth 
P09202669A0614 |174 178|neoRs sh
P09202669A0614 |144 148|gene0089
P09202669A0614 |78 89|replication171T0000 Ph
P09202669A0614 |62 73|integrationleotidase P
P09202669A0614 |98 127|herpes virus thymidine kinaseic aspects of neonatal hyperb
P09202669A0614 |4 10|pWP-1901606T
P09202669A0614 |50 57|repeatses and 
P09202669A1530 |34 54|gene transfer systemaline phosphatases a
P09202669A1530 |63 80|rat preproinsulineotidase P0000817
P09202669A1530 |84 88|gene00 P
P09202859A0091 |55 58|HCGd 5
P09202859A0091 |41 53|gonadotropinhosphatases 
P09202859A0091 |74 94|alkaline phosphatase0008171T0000 Pharmac
P09202859A0091 |20 30|beta-humanrison with
P09202859A0091 |96 100|PLAPogic
P09202859A0091 |4 16|serum levels01606T0076 C
P09203585A0660 |100 124|neo replacement cassette aspects of neonatal hyp
P09203585A0660 |11 18|feature076 Com
P09203585A0660 |38 48|H19 allelee phosphat
P09203585A0660 |56 66|occurrence 5-nucleot
P09203585A0660 |81 88|imprintT0000 P
P09203586A1197 |101 105|stepaspe
P09203586A1197 |41 50|T antigenhosphatas
P09203586A1197 |75 78|SL1008
P09203586A1197 |113 131|activation processeonatal hyperbilir
P09203586A1197 |58 71|rRNA promoter-nucleotidase
P09203586A1197 |20 31|recruitmentrison with 
P09203731A0497 |77 102|Poliomyelitis Eradication8171T0000 Pharmacologic a
P09203731A0497 |194 206|transmissionn of CSF PCO
P09203731A0497 |134 166|Pan American Health Organizationnemia. P00008997A0472 When CSF [
P09203731A0497 |45 58|Certificationhatases and 5
P09203731A0497 |62 73|Eradicationleotidase P
P09203731A0497 |104 109|ICCPEects 
P09203731A0497 |12 36|International Commission76 Comparison with alkal
P09204566T0000 |78 113|Rhizobium leguminosarum strain VF39171T0000 Pharmacologic aspects of n
P09204566T0000 |46 52|copiesatases
P09204566T0000 |60 74|fixNOQP operonucleotidase P0
P09204566T0000 |26 34|analysiswith alk
P09204570A0110 |5 10|study1606T
P09204570A0110 |72 74|J.P0
P09204570A0110 |42 47|nmhC5ospha
P09204570A0110 |27 40|MADS box geneith alkaline 
P09204570A0110 |66 70|nmh7idas
P09205113A0587 |5 8|E14160
P09205113A0587 |164 179|mouse germ line [HCO3-] is sho
P09205113A0587 |145 154|frequency08997A047
P09205113A0587 |10 15|TG3B10076 
P09205113A0587 |122 134|transmissionyperbilirubi
P09205113A0587 |28 40|ES cell lineth alkaline 
P09205113A0587 |82 91|HPRT gene0000 Phar
P09205113A0587 |59 71|mouse genomenucleotidase
P09205113A0587 |97 113|selection markergic aspects of n
P09205677A0577 |0 4|LungP000
P09205677A0577 |40 50|indicatorsphosphatas
P09205677A0577 |22 28|damageson wi
P09205677A0577 |59 66|outcomenucleot
P09205677A0577 |87 94|diseasePharmac
P09205965A1249 |119 126|pathwayl hyper
P09205965A1249 |41 52|micturitionhosphatases
P09205965A1249 |133 145|transmissioninemia. P000
P09205965A1249 |90 96|L-doparmacol
P09205965A1249 |168 196|spinal alpha 1-adrenoceptorsO3-] is shown as a function 
P09205965A1249 |4 11|results01606T0
P09205965A1249 |70 85|bladder fillinge P00008171T000
P09206230A0000 |0 9|OBJECTIVEP00001606
P09206230A0000 |57 62|cause5-nuc
P09206230A0000 |16 21|studyompar
P09206230A0000 |66 76|asthenopiaidase P000
P09206230A0000 |84 95|astigmatism00 Pharmaco
P09206968A0000 |0 11|DisturbanceP00001606T0
P09206968A0000 |15 27|regenerationComparison w
P09206968A0000 |110 114|lossf ne
P09206968A0000 |161 172|homeostasisCSF [HCO3-]
P09206968A0000 |122 130|functionyperbili
P09206968A0000 |91 105|tunica propriamacologic aspe
P09206968A0000 |81 87|damageT0000 
P09206968A0000 |54 63|conditionnd 5-nucl
P09206968A0000 |139 146|support. P0000
P09208214A0572 |0 19|SternocleidomastoidP00001606T0076 Comp
P09208214A0572 |36 43|musclesine pho
P09208214A0572 |77 82|cases8171T
P09208214A0572 |21 25|neckison
P09208930T0000 |0 14|IdentificationP00001606T0076
P09208930T0000 |27 32|genesith a
P09208930T0000 |129 138|proteasesirubinemi
P09208930T0000 |57 74|interleukin-1beta5-nucleotidase P0
P09208930T0000 |86 97|enzyme gene Pharmacolo
P09209031A0350 |22 28|regionson wi
P09209031A0350 |58 82|serine carboxypeptidases-nucleotidase P00008171T
P09209312A0968 |103 110|complexpects o
P09209312A0968 |164 166|nt [
P09209312A0968 |120 123|RNA hy
P09209312A0968 |147 158|nucleotides997A0472 Wh
P09209312A0968 |41 52|nucleotideshosphatases
P09209312A0968 |63 65|nteo
P09209312A0968 |73 75|nt00
P09209312A0968 |174 176|nts 
P09209312A0968 |54 56|ntnd
P09209312A0968 |4 17|RNA construct01606T0076 Co
P09209372A0345 |186 194|affinity functio
P09209372A0345 |144 149|AML1b00899
P09209372A0345 |25 30|AML1a with
P09209372A0345 |160 165|AML1a CSF 
P09209372A0345 |130 140|activationrubinemia.
P09209372A0345 |81 90|regulatorT0000 Pha
P09209372A0345 |52 59|effects and 5-
P09209372A0345 |216 221|AML1b of K
P09209406A1021 |55 90|guanine nucleotide exchange factorsd 5-nucleotidase P00008171T0000 Pha
P09209406A1021 |42 49|regionsosphata
P09209406A1021 |128 138|c-cbl genelirubinemi
P09209406A1021 |112 120|proteinsneonatal
P09209438A0994 |154 163|GATA site2 When CS
P09209438A0994 |31 38|extractalkalin
P09209438A0994 |15 22|ATL-16TCompari
P09209438A0994 |133 140|complexinemia.
P09209438A0994 |61 67|GATA-4cleoti
P09209438A0994 |93 100|proteincologic
P09210012A0000 |21 28|supportison wi
P09210012A0000 |36 49|relationshipsine phosphata
P09210012A0000 |62 69|couplesleotida
P09210012A0000 |4 10|impact01606T
P09210478A0000 |55 60|HIF-1d 5-n
P09210478A0000 |45 53|factor-1hatases 
P09210478A0000 |126 131|genesbilir
P09210478A0000 |77 87|expression8171T0000 
P09210478A0000 |99 105|numberc aspe
P09211354A0000 |0 13|Stromelysin-1P00001606T007
P09211354A0000 |123 136|organ tissuesperbilirubine
P09211354A0000 |15 41|matrix metalloproteinase-3Comparison with alkaline p
P09211354A0000 |67 80|endopeptidasedase P0000817
P09211354A0000 |43 48|MMP-3sphat
P09211354A0000 |114 119|cellsonata
P09211605A0478 |0 6|TendonP00001
P09211605A0478 |30 43|extensibility alkaline pho
P09211605A0478 |20 26|degreerison 
P09211675A0392 |0 12|SurveillanceP00001606T00
P09211675A0392 |209 215|visitshe dat
P09211675A0392 |84 95|assignments00 Pharmaco
P09211675A0392 |325 332|recordsslope (
P09211675A0392 |116 128|measurementsatal hyperbi
P09211675A0392 |292 300|deliveryill have
P09211675A0392 |217 226|protocolsof K-depl
P09211675A0392 |248 260|measurementsr displaced 
P09211675A0392 |159 176|protein excretionn CSF [HCO3-] is 
P09211675A0392 |348 365|outpatient visits. P00010943A0733 
P09211675A0392 |47 56|personneltases and
P09211675A0392 |132 146|blood pressurebinemia. P0000
P09211675A0392 |17 29|preeclampsiamparison wit
P09211675A0392 |272 287|hospitalizationd to controls b
P09211675A0392 |306 313|reviewsnifican
P09211675A0392 |374 390|hospitalizationsm thus appears t
P09211913A0000 |0 25|Aryl hydrocarbon receptorP00001606T0076 Comparison
P09211913A0000 |189 201|target genesnction of CS
P09211913A0000 |59 68|componentnucleotid
P09211913A0000 |126 129|AhRbil
P09211913A0000 |300 313|concentration a significan
P09211913A0000 |211 217|CYP1A1 data 
P09211913A0000 |241 249|responseo longer
P09211913A0000 |76 97|transcription factors08171T0000 Pharmacolo
P09211913A0000 |153 159|factor72 Whe
P09211913A0000 |222 236|erythropoietindepleted rats 
P09211913A0000 |48 52|ARNTases
P09211913A0000 |273 285|hydrocarbons to controls
P09211913A0000 |99 124|aryl hydrocarbon receptorc aspects of neonatal hyp
P09211913A0000 |34 46|translocatoraline phosph
P09211934A0722 |0 5|DNaseP0000
P09211934A0722 |8 26|footprint analysis6T0076 Comparison 
P09211934A0722 |50 56|regiones and
P09211981A0526 |16 24|evidenceompariso
P09211981A0526 |131 139|extractsubinemia
P09211981A0526 |211 215|cdc2 dat
P09211981A0526 |30 34|gar2 alk
P09211981A0526 |216 222|kinase of K-
P09211981A0526 |175 183|activity shown a
P09211981A0526 |67 70|p13das
P09211981A0526 |93 99|kinasecologi
P09211981A0526 |154 158|cell2 Wh
P09211981A0526 |71 75|suc1 P00
P09211981A0526 |207 210|p34 th
P09212059A1356 |138 143|DhLBDa. P0
P09212059A1356 |61 77|self-associationcleotidase P0000
P09212059A1356 |24 59|metal affinity chromatography assayn with alkaline phosphatases and 5-
P09212059A1356 |147 162|hLBD constructs997A0472 When C
P09212059A1356 |81 85|PR-AT000
P09212059A1856 |289 291|PR s
P09212059A1856 |28 33|paperth al
P09212059A1856 |269 285|homodimerizationared to controls
P09212059A1856 |214 223|sequencesta of K-d
P09212059A1856 |12 19|results76 Comp
P09212059A1856 |166 173|regionsHCO3-] 
P09212059A1856 |132 147|PR dimerizationbinemia. P00008
P09212059A1856 |189 194|hingenctio
P09212059A1856 |58 68|conclusion-nucleotid
P09212059A1856 |96 99|LBDogi
P09212063A0425 |32 39|A-phagelkaline
P09212063A0425 |44 57|cosmid clonesphatases and 
P09212063A0425 |95 98|DNAlog
P09212063A0425 |124 132|VDR geneerbiliru
P09212063A0425 |83 85|kb00
P09214274T0001 |34 42|approachaline ph
P09214274T0001 |11 20|carcinoma076 Compa
P09214274T0001 |46 54|patientsatases a
P09214274T0001 |76 96|metastasis resection08171T0000 Pharmacol
P09215525A0581 |34 44|cell cyclealine phos
P09215525A0581 |110 124|C2C12 myocytesf neonatal hyp
P09215525A0581 |61 77|E2F/DP complexescleotidase P0000
P09215525A0581 |23 30|effectson with
P09215525A0581 |82 90|activity0000 Pha
P09215525A0581 |50 57|changeses and 
P09215891A0000 |51 55|CIN2s an
P09215891A0000 |60 70|CIN4 genesucleotidas
P09215891A0000 |45 49|CIN1hata
P09215891A0000 |4 12|products01606T00
P09215891A0000 |129 149|microtubule functionirubinemia. P0000899
P09215891A0000 |101 108|pathwayaspects
P09216017A0621 |0 10|VitrectomyP00001606T
P09216017A0621 |60 65|holesucleo
P09216017A0621 |35 46|risk factorline phosph
P09216936T0000 |51 59|exercises and 5-
P09216936T0000 |63 76|leptin levelseotidase P000
P09216936T0000 |8 17|editorial6T0076 Co
P09216936T0000 |40 47|effectsphospha
P09216936T0000 |80 86|humans1T0000
P09218436A0443 |71 80|promoters P0000817
P09218436A0443 |22 30|TATA boxson with
P09218436A0443 |56 67|MED-1 class 5-nucleoti
P09218436A0443 |123 128|sitesperbi
P09218436A0443 |36 40|Pintine 
P09218436A0443 |97 110|transcriptiongic aspects o
P09218436A0443 |5 14|promoters1606T0076
P09218459A0000 |0 21|Serum response factorP00001606T0076 Compar
P09218459A0000 |124 144|transcription factorerbilirubinemia. P00
P09218459A0000 |193 198|geneson of
P09218459A0000 |74 82|proteins0008171T
P09218459A0000 |31 37|memberalkali
P09218459A0000 |23 26|SRFon 
P09218459A0000 |52 58|family and 5
P09218459A0000 |168 174|growthO3-] i
P09218520A0075 |101 107|domainaspect
P09218520A0075 |120 125|IL-1R hype
P09218520A0075 |38 66|candidate signal transducerse phosphatases and 5-nucleot
P09218520A0075 |109 111|cdof
P09218520A0075 |18 25|studiesparison
P09218599A0184 |100 104|IL-4 asp
P09218599A0184 |8 13|study6T007
P09218599A0184 |89 96|effectsarmacol
P09218599A0184 |37 47|mechanismsne phospha
P09218775A0000 |23 30|strainson with
P09218775A0000 |41 49|patientshosphata
P09218775A0000 |72 74|CFP0
P09218775A0000 |62 70|fibrosisleotidas
P09218775A0000 |93 102|phenotypecologic a
P09218775A0000 |128 136|alginatelirubine
P09218775A0000 |110 124|overproductionf neonatal hyp
P09218775A1229 |0 8|ActivityP0000160
P09218775A1229 |41 44|CHAhos
P09218775A1229 |123 139|algD-xylE fusionperbilirubinemia
P09218775A1229 |12 17|palgD76 Co
P09218775A1229 |67 77|strain PAOdase P0000
P09218775A1229 |25 36|cysB mutant with alkal
P09218775A1229 |98 101|useic 
P09219526A0383 |216 222|region of K-
P09219526A0383 |40 54|cDNA constructphosphatases a
P09219526A0383 |75 86|observation008171T0000
P09219526A0383 |96 113|peptide sequencesogic aspects of n
P09219526A0383 |178 186|fragmentown as a
P09219526A0383 |21 32|specificityison with a
P09220158A0537 |220 229|Sf9 cellsK-deplete
P09220158A0537 |146 175|baculovirus expression vector8997A0472 When CSF [HCO3-] is
P09220158A0537 |109 120|amino acidsof neonatal
P09220158A0537 |62 72|processingleotidase 
P09220158A0537 |135 140|ORF-2emia.
P09220158A0537 |204 209|virusCO2 t
P09220158A0537 |97 105|sequencegic aspe
P09220158A0537 |17 24|proteinmpariso
P09220177A0564 |118 123|shockal hy
P09220177A0564 |60 63|CPKucl
P09220177A0564 |77 78|%8
P09220177A0564 |106 107|ht
P09220177A0564 |166 179|cardioversionHCO3-] is sho
P09220177A0564 |31 50|percentage increasealkaline phosphatas
P09220177A0564 |4 20|CPK-MB isoenzyme01606T0076 Compa
P09220177A0564 |144 150|number008997
P09220177A0564 |154 162|attempts2 When C
P09222057A0176 |0 5|SerumP0000
P09222057A0176 |82 88|course0000 P
P09222057A0176 |37 40|PDFne 
P09222057A0176 |61 66|assaycleot
P09222057A0176 |96 101|studyogic 
P09222057A0176 |112 116|daysneon
P09222057A0176 |21 35|dialysis fluidison with alka
P09222115A0545 |0 7|ResultsP000016
P09222115A0545 |215 224|isolationa of K-de
P09222115A0545 |234 246|surroundingss are no lon
P09222115A0545 |157 180|response characteristichen CSF [HCO3-] is show
P09222115A0545 |20 30|hypothesisrison with
P09222115A0545 |110 122|binding sitef neonatal h
P09222115A0545 |206 211|phase2 the
P09222115A0545 |71 77|factor P0000
P09222115A0545 |184 188|pups a f
P09223042A0000 |0 5|LiverP0000
P09223042A0000 |15 27|blood volumeComparison w
P09223042A0000 |57 71|disease states5-nucleotidase
P09223042A0000 |29 33|LRBVh al
P09223042A0000 |84 89|drugs00 Ph
P09223122A0774 |55 61|groupsd 5-nu
P09223122A0774 |9 28|matter NAA/mI ratioT0076 Comparison wi
P09223229A0565 |69 78|mb-1 genese P00008
P09223229A0565 |29 39|mb-1 genesh alkaline
P09223229A0565 |88 96|TATA boxharmacol
P09223229A0565 |48 54|regionases a
P09223475A0898 |0 40|Chloramphenicol acetyltransferase assaysP00001606T0076 Comparison with alkaline 
P09223475A0898 |66 70|IE86idas
P09223475A0898 |82 90|activity0000 Pha
P09223475A0898 |183 187|RNAss a 
P09223475A0898 |150 158|promoterA0472 Wh
P09223475A0898 |55 62|abilityd 5-nuc
P09223475A0898 |174 179|classs sho
P09223475A0898 |114 122|promoteronatal h
P09223475A0898 |233 245|IE86 proteints are no lo
P09223475A0898 |100 104|HCMV asp
P09223475A0898 |216 225|integrity of K-dep
P09223475A0898 |139 143|HCMV. P0
P09223479A1193 |0 6|ORF M1P00001
P09223479A1193 |56 63|ORF M11 5-nucl
P09223479A1193 |133 151|gammaherpesvirusesinemia. P00008997A
P09223479A1193 |106 115|moleculests of neo
P09223479A1193 |164 167|HVS [H
P09223479A1193 |185 195|BHRF1 genea function
P09223479A1193 |20 28|homologyrison wi
P09223479A1193 |172 176|KSHV is 
P09223479A1193 |199 202|EBVCSF
P09223479A1193 |84 91|homolog00 Phar
P09223479A1193 |32 48|poxvirus serpinslkaline phosphat
P09223479A1193 |153 157|gene72 W
P09223506T0000 |0 34|Transcription factor binding sitesP00001606T0076 Comparison with alk
P09223506T0000 |89 113|transcription start sitearmacologic aspects of n
P09223506T0000 |132 149|virus infectivitybinemia. P0000899
P09223506T0000 |59 86|immunodeficiency virus typenucleotidase P00008171T0000
P09223647T0000 |0 17|Crystal structureP00001606T0076 Co
P09223647T0000 |24 32|oligomern with a
P09223647T0000 |125 137|implicationsrbilirubinem
P09223647T0000 |148 158|activation97A0472 Wh
P09223647T0000 |113 120|complexeonatal
P09223647T0000 |82 90|analysis0000 Pha
P09223647T0000 |48 56|zymogensases and
P09223667A0139 |34 57|NIH3T3 fibroblast cellsaline phosphatases and 
P09223667A0139 |163 165|bpF 
P09223667A0139 |213 227|CTCCC sequenceata of K-deple
P09223667A0139 |62 87|gel mobility shift assaysleotidase P00008171T0000 
P09223667A0139 |104 116|binding siteects of neon
P09223667A0139 |175 199|transcription start site shown as a function of 
P09223667A0139 |142 148|region000089
P09223667A0139 |18 30|transfectionparison with
P09223880A1147 |21 36|injection speedison with alkal
P09223880A1147 |43 52|.2 ml.s-1sphatases
P09223880A1147 |77 87|anesthesia8171T0000 
P09224655T0000 |137 143|ClC-6cia. P0
P09224655T0000 |24 29|ClC-6n wit
P09224655T0000 |12 20|splicing76 Compa
P09224655T0000 |47 74|CIC chloride-channel familytases and 5-nucleotidase P0
P09224655T0000 |114 122|isoformsonatal h
P09224655T0000 |76 87|transcripts08171T0000 
P09224655T0000 |33 39|memberkaline
P09224811A0000 |171 177|animal] is s
P09224811A0000 |230 238|pathways rats ar
P09224811A0000 |108 113|P450R of n
P09224811A0000 |12 17|study76 Co
P09224811A0000 |157 163|statushen CS
P09224811A0000 |140 147|thyroid P00008
P09224811A0000 |76 106|cytochrome P450 oxidoreductase08171T0000 Pharmacologic aspec
P09224811A0000 |282 298|P450R mRNA levelols but still ha
P09224811A0000 |49 62|transcriptionses and 5-nuc
P09224811A0000 |115 119|genenata
P09224811A0000 |70 75|NADPHe P00
P09225151T0000 |35 58|polytetrafluoroethyleneline phosphatases and 5
P09225151T0000 |95 111|scarring processlogic aspects of
P09225151T0000 |26 31|typeswith 
P09225151T0000 |60 64|PTFEucle
P09225151T0000 |66 76|prosthesesidase P000
P09225151T0000 |125 137|wall defectsrbilirubinem
P09225151T0000 |4 12|behavior01606T00
P09225506A0462 |48 54|levelsases a
P09225506A0462 |58 77|coagulation factors-nucleotidase P0000
P09225506A0462 |88 92|VIIIharm
P09225506A0462 |82 83|V0
P09225506A0462 |110 121|index groupf neonatal 
P09225506A0462 |4 17|control group01606T0076 Co
P09225682A0579 |103 111|isolatespects of
P09225682A0579 |73 90|syndrome patients00008171T0000 Pha
P09225682A0579 |210 218|isolatese data o
P09225682A0579 |4 13|frequency01606T007
P09225682A0579 |203 206|PENPCO
P09225682A0579 |96 99|PENogi
P09225682A0579 |177 194|syndrome patientshown as a functio
P09225682A0579 |168 174|FisherO3-] i
P09225682A0579 |155 163|syndrome When CS
P09225682A0579 |35 50|antibody titersline phosphatas
P09225686A0683 |67 84|seizure remissiondase P00008171T00
P09225686A0683 |13 37|radiofrequency lesioning6 Comparison with alkali
P09225686A0683 |45 54|hamartomahatases a
P09225686A0683 |93 106|complicationscologic aspec
P09225686A0683 |123 130|surgeryperbili
P09225686A0683 |110 116|monthsf neon
P09225998A0000 |0 36|NF-kappa B/Rel transcription factorsP00001606T0076 Comparison with alkal
P09225998A0000 |79 84|genes71T00
P09225998A0000 |56 66|activation 5-nucleot
P09225998A0000 |149 171|cell surface receptors7A0472 When CSF [HCO3-
P09225998A0000 |104 127|regulation/inflammationects of neonatal hyperb
P09225998A0000 |203 217|phase proteinsPCO2 the data 
P09225998A0000 |173 191|adhesion moleculesis shown as a func
P09225998A0000 |138 147|cytokinesa. P00008
P09226113A0857 |54 62|boreholend 5-nuc
P09226113A0857 |90 98|boreholermacolog
P09226113A0857 |29 48|source water sampleh alkaline phosphat
P09226345A0436 |35 42|% groupline ph
P09226345A0436 |75 76|p0
P09226345A0436 |129 138|SEP groupirubinemi
P09226345A0436 |110 111|pf
P09226345A0436 |179 180|%w
P09226345A0436 |14 25|food intake Comparison
P09226345A0436 |190 201|requirementction of CS
P09226345A0436 |64 73|ACT groupotidase P
P09226345A0436 |155 162|amounts When C
P09227099A0106 |118 126|securityal hyper
P09227099A0106 |105 116|conveniencects of neon
P09227099A0106 |227 235|accuracyted rats
P09227099A0106 |210 218|implantse data o
P09227099A0106 |91 101|advantagesmacologic 
P09227099A0106 |14 23|technique Comparis
P09227099A0106 |36 48|modificationine phosphat
P09227099A0106 |196 206|angulationof CSF PCO
P09227099A0106 |54 72|bar superstructurend 5-nucleotidase 
P09227332A1798 |85 94|cytokines0 Pharmac
P09227332A1798 |12 15|DDC76 
P09227332A1798 |55 64|cytokinesd 5-nucle
P09227332A1798 |112 114|DCne
P09227332A1798 |24 33|receptorsn with al
P09227332A1798 |46 51|panelatase
P09227332A1798 |71 80|receptors P0000817
P09227332A1798 |3 10|summary001606T
P09227332A1798 |101 108|effectsaspects
P09227799A0254 |205 220|precipitin testO2 the data of 
P09227799A0254 |181 184|SEA as
P09227799A0254 |30 34|tool alk
P09227799A0254 |55 67|surveillanced 5-nucleoti
P09227799A0254 |130 147|stool examinationrubinemia. P00008
P09227799A0254 |123 128|testsperbi
P09227799A0254 |149 154|ELISA7A047
P09227799A0254 |222 226|COPTdepl
P09227799A0254 |168 179|egg antigenO3-] is sho
P09227799A0254 |84 94|comparison00 Pharmac
P09228042A0109 |258 263|stepsd whe
P09228042A0109 |229 232|Zn2d r
P09228042A0109 |79 87|biglycan71T0000 
P09228042A0109 |182 194|ion-exchangeas a functio
P09228042A0109 |20 49|dermatan sulfate proteoglycanrison with alkaline phosphata
P09228042A0109 |67 74|decorindase P0
P09228042A0109 |110 120|extractionf neonatal
P09228042A0109 |196 210|gel permeationof CSF PCO2 th
P09228042A0109 |51 60|epiphycans and 5-n
P09228042A0109 |234 241|chelates are n
P09228042A0109 |137 157|epiphyseal cartilageia. P00008997A0472 W
P09228092A1779 |136 139|usemia
P09228092A1779 |77 81|gene8171
P09228092A1779 |104 115|transcriptsects of neo
P09228092A1779 |36 52|dUTPase isoformsine phosphatases
P09228092A1779 |6 14|analyses606T0076
P09228092A1779 |158 163|exonsen CS
P09228202A0581 |68 75|KAE-393ase P00
P09228202A0581 |53 58|YM060and 5
P09228202A0581 |127 137|benzamidesilirubinem
P09228202A0581 |214 222|SC-53116ta of K-
P09228202A0581 |94 105|ondansetronologic aspe
P09228202A0581 |61 66|YM114cleot
P09228202A0581 |78 89|granisetron171T0000 Ph
P09228202A0581 |14 51|5-HT3 receptor antagonists ramosetron Comparison with alkaline phosphatase
P09228202A0581 |257 265|emptyinged when 
P09228202A0581 |190 209|cisapride mosapridection of CSF PCO2 t
P09228202A0581 |168 188|receptor antagonistsO3-] is shown as a f
P09228202A0581 |276 280|rats con
P09228202A0581 |139 166|5-HT4 receptor agonist/5-HT. P00008997A0472 When CSF [
P09229420A0158 |0 13|Re-evaluationP00001606T007
P09229420A0158 |89 98|operationarmacolog
P09229420A0158 |21 36|biopsy specimenison with alkal
P09229420A0158 |52 55|hip an
P09229420A0158 |145 155|background08997A0472
P09229420A0158 |106 111|areasts of
P09229420A0158 |168 182|chondromatosisO3-] is shown 
P09229420A0158 |115 129|chondrosarcomanatal hyperbil
P09229420A0158 |69 73|timese P
P09229595A0618 |4 19|corneal buttons01606T0076 Comp
P09229595A0618 |59 67|electronnucleoti
P09229595A0618 |80 87|studies1T0000 
P09230129A0039 |239 247|antibody no long
P09230129A0039 |260 266|enzymewhen c
P09230129A0039 |22 33|homogeneityson with al
P09230129A0039 |127 138|preparationilirubinemi
P09230129A0039 |88 101|DNA-celluloseharmacologic 
P09230129A0039 |210 220|productione data of 
P09230129A0039 |107 113|puritys of n
P09230129A0039 |165 169|lack[HCO
P09230129A0039 |155 163|SDS/PAGE When CS
P09230129A0039 |54 77|affinity chromatographynd 5-nucleotidase P0000
P09230129A0039 |43 50|% yieldsphatas
P09230129A0039 |196 205|nucleasesof CSF PC
P09230129A0039 |173 186|contaminationis shown as a
P09230216T0000 |87 101|heterozygosityPharmacologic 
P09230216T0000 |113 119|cancereonata
P09230216T0000 |79 83|loss71T0
P09230216T0000 |64 70|regionotidas
P09230216T0000 |38 58|chromosome 12q22-q24e phosphatases and 5
P09230216T0000 |18 34|glycosylase mapsparison with alk
P09230307A0329 |0 3|FOGP00
P09230307A0329 |96 101|cellsogic 
P09230307A0329 |24 30|GATA-1n with
P09230307A0329 |48 59|developmentases and 5-
P09230384A0725 |35 47|mycobacterialine phospha
P09230384A0725 |83 85|TB00
P09230384A0725 |53 59|BACTECand 5-
P09230384A0725 |9 14|timesT0076
P09230384A0725 |72 78|BACTECP00008
P09230384A0725 |114 118|daysonat
P09230384A0725 |65 67|MBti
P09230384A0725 |18 27|detectionparison w
P09230384A1056 |64 73|specimensotidase P
P09230384A1056 |11 17|BACTEC076 Co
P09230384A1056 |133 141|recoveryinemia. 
P09230384A1056 |210 215|sitese dat
P09230384A1056 |172 181|specimens is shown
P09230384A1056 |145 157|mycobacteria08997A0472 W
P09230384A1056 |23 32|MB systemon with a
P09230894A0422 |22 29|KmMig1pson wit
P09230945A0089 |18 27|deformityparison w
P09230945A0089 |66 70|slipidas
P09230986A0000 |0 22|Autoimmune neutropeniaP00001606T0076 Compari
P09230986A0000 |60 71|neutropeniaucleotidase
P09230986A0000 |24 27|AINn w
P09230986A0000 |95 103|childrenlogic as
P09230986A0000 |43 48|causesphat
P09232593A0946 |34 52|expression patternaline phosphatases
P09232593A0946 |120 125|roles hype
P09232593A0946 |5 11|regard1606T0
P09232593A0946 |56 66|DJ protein 5-nucleot
P09232593A0946 |87 99|repeat unitsPharmacologi
P09233487A1386 |117 130|ear selectiontal hyperbili
P09233487A1386 |106 113|benefitts of n
P09233487A1386 |29 45|outcome measuresh alkaline phosp
P09233487A1386 |141 150|Prom-EABRP00008997
P09233487A1386 |7 15|analysis06T0076 
P09233487A1386 |49 60|performanceses and 5-n
P09233772A0136 |509 537|E3 ubiquitin-protein ligasesBeta blocking agents. P00013
P09233772A0136 |384 394|G proteinsears to be
P09233772A0136 |63 69|weighteotida
P09233772A0136 |231 265|guanine nucleotide exchange factorrats are no longer displaced when 
P09233772A0136 |292 303|protein Ranill have a 
P09233772A0136 |323 330|domainsr slope
P09233772A0136 |353 365|beta subunit010943A0733 
P09233772A0136 |25 29|p532 wit
P09233772A0136 |146 153|regions8997A04
P09233772A0136 |124 131|domainserbilir
P09233772A0136 |71 77|EMBO J P0000
P09233772A0136 |5 12|protein1606T00
P09233772A0136 |172 179|repeats is sho
P09233772A0136 |202 227|cell cycle regulator RCC1 PCO2 the data of K-deple
P09233772A0136 |441 455|leucine-zipperse for use in 
P09233772A0136 |411 428|SH3 binding sitesnotic drug with t
P09233772A0136 |479 505|HECT domain characteristic5 mg at night. P00012653T0
P09233801A1180 |68 91|TGF-beta responsivenessase P00008171T0000 Phar
P09233801A1180 |106 114|receptorts of ne
P09233801A1180 |31 48|kinase subdomainsalkaline phosphat
P09233801A1180 |10 22|L45 sequence0076 Compari
P09233801A1180 |56 57|V 
P09233801A1180 |99 103|typec as
P09233809A0381 |171 182|Hnf3g locus] is shown 
P09233809A0381 |195 203|elements of CSF 
P09233809A0381 |8 19|mouse lines6T0076 Comp
P09233809A0381 |161 163|kbCS
P09233809A0381 |46 60|Hnf3g-lacZ YACatases and 5-n
P09233809A0381 |132 142|expressionbinemia. P
P09233809A0381 |221 231|regulation-depleted 
P09233809A0381 |235 240|Hnf3g are 
P09233809A0381 |85 89|copy0 Ph
P09233809A0815 |220 225|liverK-dep
P09233809A0815 |149 153|gene7A04
P09233809A0815 |135 141|regionemia. 
P09233809A0815 |24 34|transgenesn with alk
P09233809A0815 |227 235|pancreasted rats
P09233809A0815 |72 88|Hnf3g gene locusP00008171T0000 P
P09233809A0815 |192 216|reporter gene expressionion of CSF PCO2 the data
P09233809A0815 |237 244|stomachre no l
P09233809A0815 |39 53|gene targeting phosphatases 
P09233809A0815 |255 264|intestineaced when
P09233811A0072 |116 131|protein Mat1-Mcatal hyperbilir
P09233811A0072 |62 88|Ste11 transcription factorleotidase P00008171T0000 P
P09233811A0072 |97 98|Mg
P09233811A0072 |29 45|HMG-box proteinsh alkaline phosp
P09233811A0072 |5 15|regulation1606T0076 
P09234677A0770 |136 147|respirationmia. P00008
P09234677A0770 |24 34|hypothesisn with alk
P09234677A0770 |101 112|transcriptsaspects of 
P09234677A0770 |66 74|proteinsidase P0
P09234677A0770 |50 61|transcriptses and 5-nu
P09234690A0242 |0 8|UpstreamP0000160
P09234690A0242 |20 29|sequencesrison wit
P09234690A0242 |158 161|PREen 
P09234690A0242 |73 78|genes00008
P09234690A0242 |31 35|UASsalka
P09234690A0242 |175 187|binding site shown as a 
P09234690A0242 |141 145|PREsP000
P09234690A0242 |201 208|proteinF PCO2 
P09234696A0238 |85 88|MAP0 P
P09234696A0238 |10 33|protein kinase cascades0076 Comparison with al
P09234696A0238 |90 97|kinasesrmacolo
P09234696A0238 |76 83|protein08171T0
P09234703A0192 |68 73|Cdc42ase P
P09234703A0192 |49 63|G proteins Racses and 5-nucl
P09234703A0192 |0 3|JNKP00
P09234713A0754 |201 208|Jdelta1F PCO2 
P09234713A0754 |183 190|Ddelta3s a fun
P09234713A0754 |120 124|gene hyp
P09234713A0754 |30 36|notion alkal
P09234713A0754 |82 91|formation0000 Phar
P09234713A0754 |163 167|DSBsF [H
P09234713A0754 |8 13|study6T007
P09234713A0754 |126 129|RAGbil
P09234713A0754 |64 67|PCRoti
P09234713A0754 |172 176|RSSs is 
P09234713A0754 |141 161|double-strand breaksP00008997A0472 When 
P09234717A0000 |204 207|SH2CO2
P09234717A0000 |252 256|rolespla
P09234717A0000 |55 70|protein productd 5-nucleotidas
P09234717A0000 |260 279|signal transductionwhen compared to co
P09234717A0000 |112 121|substrateneonatal 
P09234717A0000 |127 133|numberilirub
P09234717A0000 |196 199|SH3of 
P09234717A0000 |78 98|c-cbl proto-oncogene171T0000 Pharmacolog
P09234717A0000 |226 234|proteinseted rat
P09234717A0000 |154 170|tyrosine kinases2 When CSF [HCO3
P09234717A0000 |175 190|forms complexes shown as a fun
P09234717A0000 |7 14|studies06T0076
P09234717A0000 |38 41|Cble p
P09234720A1015 |168 171|MEKO3-
P09234720A1015 |59 64|v-Srcnucle
P09234720A1015 |42 45|MEKosp
P09234720A1015 |176 181|v-Srcshown
P09234720A1015 |47 53|MEK-2Etases 
P09234720A1015 |114 125|H19-7 cellsonatal hype
P09234720A1015 |127 139|coexpressionilirubinemia
P09234720A1015 |190 207|neurite outgrowthction of CSF PCO2
P09234723A0846 |71 74|PTB P0
P09234723A0846 |5 14|mechanism1606T0076
P09234723A0846 |111 122|splice site neonatal h
P09234723A0846 |89 96|proteinarmacol
P09234723A0846 |21 29|contrastison wit
P09234723A0846 |39 44|cases phos
P09234723A0846 |48 67|splicing regulationases and 5-nucleoti
P09234725A1892 |37 52|transactivationne phosphatases
P09234725A1892 |126 139|AP-1 activitybilirubinemia
P09234725A1892 |107 122|transrepressions of neonatal h
P09234725A1892 |59 78|interaction surfacenucleotidase P00008
P09234727A0770 |34 47|transcriptionaline phospha
P09234727A0770 |79 87|promoter71T0000 
P09234727A0770 |53 66|reporter geneand 5-nucleot
P09234727A0770 |9 23|fusion proteinT0076 Comparis
P09234727A0770 |115 127|DNA elementsnatal hyperb
P09234736A0999 |239 251|goblet cells no longer d
P09234736A0999 |40 50|rat tissuephosphatas
P09234736A0999 |192 197|cellsion o
P09234736A0999 |216 220|type of 
P09234736A0999 |64 75|correlationotidase P00
P09234736A0999 |113 121|drm mRNAeonatal 
P09234736A0999 |8 30|hybridization analysis6T0076 Comparison with
P09234736A0999 |223 233|lung cellsepleted ra
P09234736A0999 |86 93|pattern Pharma
P09234736A0999 |207 214|neurons the da
P09234743A0475 |17 25|proteinsmparison
P09234743A0475 |82 85|UTR000
P09234743A0475 |67 79|alpha-globindase P000081
P09234743A0475 |167 180|alpha-complexCO3-] is show
P09234743A0475 |140 141|C 
P09234743A0475 |143 159|binding proteins0008997A0472 Whe
P09234743A0475 |48 52|pairases
P09235073A0000 |34 41|patientaline p
P09235073A0000 |52 61|diagnosis and 5-nu
P09235073A0000 |4 9|years01606
P09235073A0000 |65 80|Weaver syndrometidase P0000817
P09235073A0000 |16 22|monthsompari
P09235424A1200 |53 57|ABPMand 
P09235424A1200 |28 34|nursesth alk
P09235424A1200 |89 95|effectarmaco
P09235424A1200 |62 67|womenleoti
P09235424A1200 |11 19|measures076 Comp
P09235618A0000 |237 244|factorsre no l
P09235618A0000 |256 268|thrombocytesced when com
P09235618A0000 |292 304|erythrocytesill have a s
P09235618A0000 |59 82|Guillain Barre syndromenucleotidase P00008171T
P09235618A0000 |246 252|memberger di
P09235618A0000 |125 133|epilepsyrbilirub
P09235618A0000 |270 288|sedimentation ratered to controls bu
P09235618A0000 |29 43|neuroinfectionh alkaline pho
P09235618A0000 |15 23|patientsComparis
P09235618A0000 |45 57|Lyme diseasehatases and 
P09235618A0000 |84 99|demyelinization00 Pharmacologi
P09235618A0000 |187 190|IgGfun
P09235618A0000 |173 183|antibodiesis shown a
P09235618A0000 |195 207|IgM subtypes of CSF PCO2
P09235618A0000 |5 11|series1606T0
P09235995A0339 |1 6|1996a00001
P09235995A0339 |8 20|Biochemistry6T0076 Compa
P09235998A0788 |35 40|alphaline 
P09235998A0788 |75 86|cholesterol008171T0000
P09235998A0788 |45 58|beta subunitshatases and 5
P09235998A0788 |12 31|membrane expression76 Comparison with 
P09235998A0788 |91 109|17-ketocholesterolmacologic aspects 
P09235998A0788 |133 150|HMG-CoA reductaseinemia. P00008997
P09236118A1455 |118 128|DNA targetal hyperbi
P09236118A1455 |25 28|Lrp wi
P09236118A1455 |57 61|site5-nu
P09236118A1455 |150 156|dimersA0472 
P09236118A1455 |104 110|grooveects o
P09236118A1455 |4 11|results01606T0
P09236118A1455 |174 179|sitess sho
P09236118A1455 |190 222|nucleoprotein activation complexction of CSF PCO2 the data of K-
P09236224A0939 |101 104|NGFasp
P09236224A0939 |89 97|activityarmacolo
P09236224A0939 |74 81|feature0008171
P09236224A0939 |151 166|differentiation0472 When CSF [
P09236224A0939 |125 143|PC12 growth arrestrbilirubinemia. P0
P09236224A0939 |10 20|activation0076 Compa
P09236224A0939 |24 38|p21 expressionn with alkalin
P09236441A0639 |17 25|patientsmparison
P09236441A0639 |36 46|recordingsine phosph
P09236441A0639 |77 94|oxygen saturation8171T0000 Pharmac
P09236441A0639 |107 118|respirations of neonat
P09236441A0639 |158 167|breathingen CSF [H
P09236441A0639 |96 100|SaO2ogic
P09236441A0639 |50 53|ECGes 
P09236656A0124 |49 57|baselineses and 
P09236656A0124 |77 79|SD81
P09236656A0124 |104 106|SDec
P09236656A0124 |74 75|L0
P09236656A0124 |115 118|daynat
P09236656A0124 |21 31|cell countison with 
P09236656A0124 |101 102|La
P09237695A0000 |66 76|indicatorsidase P000
P09237695A0000 |28 33|studyth al
P09237695A0000 |93 108|virus infectioncologic aspects
P09237862A0782 |99 105|nervesc aspe
P09237862A0782 |45 54|reductionhatases a
P09237862A0782 |113 117|iriseona
P09237862A0782 |77 84|absence8171T00
P09237862A0782 |20 24|eyesriso
P09238467A0763 |32 43|propranolollkaline pho
P09238467A0763 |47 59|phentolaminetases and 5-
P09238467A0763 |6 13|lesions606T007
P09238850A0785 |87 100|feedback loopPharmacologic
P09238850A0785 |13 17|ICER6 Co
P09238850A0785 |59 67|promoternucleoti
P09238850A2042 |102 105|SCNspe
P09238850A2042 |93 100|nucleuscologic
P09238850A2042 |15 26|oscillationComparison 
P09238850A2042 |55 60|clockd 5-n
P09238860A0175 |21 28|nucleusison wi
P09238860A0175 |160 168|CREM tau CSF [HC
P09238860A0175 |194 211|protein kinase A.n of CSF PCO2 the
P09238860A0175 |113 155|AMP response element binding proteins CREBeonatal hyperbilirubinemia. P00008997A0472
P09238860A0175 |36 41|cellsine p
P09238860A0175 |174 180|manners show
P09238860A1974 |101 123|cytokine Interleukin-2aspects of neonatal hy
P09238860A1974 |165 173|increase[HCO3-] 
P09238860A1974 |134 142|responsenemia. P
P09238860A1974 |58 62|CREB-nuc
P09238860A1974 |146 152|agents8997A0
P09238860A1974 |125 129|IL-2rbil
P09238860A1974 |209 226|protein kinase C.he data of K-depl
P09238860A1974 |188 191|Ca2unc
P09238860A1974 |6 11|cells606T0
P09238860A1974 |33 40|signalskaline 
P09239635A0477 |49 54|mg/mlses a
P09239635A0477 |124 129|mg/mlerbil
P09239635A0477 |14 18|dogs Com
P09239635A0477 |99 108|serum IgAc aspects
P09239635A0477 |27 36|serum IgGith alkal
P09239635A0477 |71 81|littermate P00008171
P09241092A1108 |85 95|trans-diol0 Pharmaco
P09241092A1108 |46 61|glucuronidationatases and 5-nu
P09241092A1108 |13 22|Valproate6 Compari
P09241092A1108 |178 199|trans-diol derivativeown as a function of 
P09241092A1108 |162 169|epoxideSF [HCO
P09241092A1108 |128 138|conversionlirubinemi
P09241092A1108 |242 250|reaction longer 
P09241092A1108 |65 81|carbamazepine-10tidase P00008171
P09241092A1108 |142 158|carbamazepine-1000008997A0472 Wh
P09241092A1108 |0 11|CONCLUSIONSP00001606T0
P09241232A0653 |68 75|AP sitease P00
P09241232A0653 |107 111|AP/Cs of
P09241232A0653 |39 49|DNA duplex phosphata
P09241232A0653 |97 105|cytosinegic aspe
P09241232A0653 |4 16|Ogg1 protein01606T0076 C
P09241232A1154 |102 106|Ogg1spec
P09241232A1154 |94 98|K241olog
P09241232A1154 |74 86|endonuclease0008171T0000
P09241232A1154 |2 20|consensus sequence0001606T0076 Compa
P09241232A1154 |66 70|K120idas
P09241232A1154 |50 64|lysine residuees and 5-nucle
P09242375A1313 |238 243|MEN2Ae no 
P09242375A1313 |61 66|V804Lcleot
P09242375A1313 |15 23|findingsComparis
P09242375A1313 |248 263|MEN2B mutationsr displaced whe
P09242375A1313 |41 56|mutations E768Dhosphatases and
P09242375A1313 |192 201|mutationsion of CS
P09242375A1313 |122 133|RET isoformyperbilirub
P09242375A1313 |138 146|capacitya. P0000
P09242375A1313 |71 97|gain-of-function mutations P00008171T0000 Pharmacolo
P09242375A1313 |169 175|effect3-] is
P09242499A0505 |102 112|sunscreensspects of 
P09242499A0505 |148 153|sites97A04
P09242499A0505 |123 134|base lotionperbilirubi
P09242499A0505 |75 76|d0
P09242499A0505 |60 62|UVuc
P09242499A0505 |83 94|application000 Pharmac
P09242499A0505 |36 41|backsine p
P09242499A0505 |0 10|VolunteersP00001606T
P09242506A1033 |0 3|E2FP00
P09242506A1033 |74 85|DP proteins0008171T000
P09242506A1033 |45 63|E2F family membershatases and 5-nucl
P09242506A1033 |23 30|complexon with
P09242551A0653 |0 10|EBER1 mRNAP00001606T
P09242551A0653 |41 48|latencyhosphat
P09242551A0653 |142 158|EBER1 expression00008997A0472 Wh
P09242551A0653 |178 184|subsetown as
P09242551A0653 |25 31|marker with 
P09242551A0653 |126 134|controlsbilirubi
P09242551A0653 |99 105|levelsc aspe
P09242551A0653 |188 202|lymphoma cellsunction of CSF
P09242551A0653 |70 79|PEL casese P000081
P09243267A0401 |68 82|cell carcinomaase P00008171T
P09243267A0401 |95 101|cavitylogic 
P09243267A0401 |46 55|diagnosisatases an
P09243267A0401 |166 170|RPCIHCO3
P09243267A0401 |28 36|patientsth alkal
P09243267A0401 |138 164|Roswell Park Cancer Centera. P00008997A0472 When CSF
P09243267A0401 |125 134|treatmentrbilirubi
P09243267A0401 |0 7|METHODSP000016
P09243385A1314 |18 31|presaturationparison with 
P09243385A1314 |88 104|PC velocity dataharmacologic asp
P09243385A1314 |62 76|motion studiesleotidase P000
P09243385A1314 |11 14|use076
P09243505A1194 |305 316|specificitygnificantly
P09243505A1194 |73 85|MADS domains00008171T000
P09243505A1194 |268 273|casespared
P09243505A1194 |150 161|specificityA0472 When 
P09243505A1194 |91 96|dimermacol
P09243505A1194 |3 11|addition001606T0
P09243505A1194 |229 235|regiond rats
P09243505A1194 |29 40|experimentsh alkaline 
P09243505A1194 |243 254|MADS domainlonger disp
P09243505A1194 |324 332|proteins slope (
P09243505A1194 |169 176|complex3-] is 
P09243505A1194 |186 195|sequences function
P09243587A0000 |186 223|abortion increases breast cancer risk function of CSF PCO2 the data of K-d
P09243587A0000 |114 127|breast canceronatal hyperb
P09243587A0000 |80 89|pregnancy1T0000 Ph
P09243587A0000 |160 169|pregnancy CSF [HCO
P09243587A0000 |91 95|FFTPmaco
P09243587A0000 |35 43|questionline pho
P09243587A0000 |140 152|interruption P00008997A0
P09243587A0000 |0 18|PURPOSE/OBJECTIVESP00001606T0076 Com
P09243840A0663 |99 102|DNAc a
P09243840A0663 |132 157|DNA Laboratory structuresbinemia. P00008997A0472 W
P09243840A0663 |73 81|HLA-DQA100008171
P09243840A0663 |106 118|autopsy roomts of neonat
P09243840A0663 |12 19|studies76 Comp
P09243840A0663 |42 53|week periodosphatases 
P09244100A0194 |39 45|groups phosp
P09244100A0194 |11 15|rats076 
P09244282A1371 |0 11|MutagenesisP00001606T0
P09244282A1371 |71 76|sites P000
P09244282A1371 |55 63|presenced 5-nucl
P09244282A1371 |112 127|pec-1 phenotypeneonatal hyperb
P09244282A1371 |19 23|pecTaris
P09244282A1371 |86 96|insertions Pharmacol
P09244282A1371 |35 41|regionline p
P09244350A0000 |0 5|BRCA1P0000
P09244350A0000 |113 130|tumor suppressorseonatal hyperbili
P09244350A0000 |37 63|cancer susceptibility genene phosphatases and 5-nucl
P09244350A0000 |140 159|breast cancer cells P00008997A0472 Whe
P09244350A0000 |80 95|phosphoproteins1T0000 Pharmaco
P09244350A0000 |18 24|breastpariso
P09244430A0693 |119 124|exonsl hyp
P09244430A0693 |63 69|beta-3eotida
P09244430A0693 |46 61|adducin isoformatases and 5-nu
P09244430A0693 |87 92|donorPharm
P09244430A0693 |97 111|acceptor sitesgic aspects of
P09244430A0693 |16 28|splice sitesomparison wi
P09246343T0000 |0 11|ProteinuriaP00001606T0
P09246343T0000 |23 26|manon 
P09246585T0000 |7 15|blockade06T0076 
P09246585T0000 |31 42|cancer painalkaline ph
P09247645A0000 |103 109|fusionpects 
P09247645A0000 |30 37|alleles alkali
P09247645A0000 |41 45|SEC3hosp
P09247645A0000 |300 306|sec4-8 a sig
P09247645A0000 |150 165|plasma membraneA0472 When CSF 
P09247645A0000 |134 142|vesiclesnemia. P
P09247645A0000 |67 76|SEC genesdase P000
P09247645A0000 |214 220|screenta of 
P09247645A0000 |257 264|mutantsed when
P09248639A0152 |34 45|fibroblastsaline phosp
P09248639A0152 |91 104|blister fluidmacologic asp
P09248639A0152 |75 82|samples008171T
P09248639A0152 |113 119|effecteonata
P09248639A0152 |196 213|collagen latticesof CSF PCO2 the d
P09248639A0152 |146 157|contraction8997A0472 W
P09248639A0152 |215 219|FPCLa of
P09248639A0152 |175 185|fibroblast shown as 
P09248639A0152 |5 17|cell strains1606T0076 Co
P09248639A0152 |138 142|ratea. P
P09249039A0124 |87 93|growthPharma
P09249039A0124 |135 146|vertebratesemia. P0000
P09249039A0124 |121 131|metabolismhyperbilir
P09249039A0124 |95 110|differentiationlogic aspects o
P09249039A0124 |26 33|enzymeswith al
P09249039A0124 |76 83|control08171T0
P09249070A0989 |0 4|CellP000
P09249710A0331 |69 108|plaque reduction neutralization testingse P00008171T0000 Pharmacologic aspects
P09249710A0331 |26 30|serawith
P09250554A0402 |68 79|combinationase P000081
P09250554A0402 |25 37|diltiazem CD with alkali
P09250554A0402 |106 113|therapyts of n
P09250554A0402 |48 64|placebo once/dayases and 5-nucle
P09250554A0402 |42 44|mgos
P09250554A0402 |0 8|PatientsP0000160
P09251843A0189 |207 212|cases the 
P09251843A0189 |180 188|lymphoman as a f
P09251843A0189 |105 114|Castlemancts of ne
P09251843A0189 |90 101|hyperplasiarmacologic 
P09251843A0189 |144 155|hyperplasia008997A0472
P09251843A0189 |228 236|lymphomaed rats 
P09251843A0189 |270 275|casesred t
P09251843A0189 |46 51|casesatase
P09251843A0189 |18 29|hyperplasiaparison wit
P09251843A0189 |55 60|casesd 5-n
P09251843A0189 |117 124|diseasetal hyp
P09252397A0081 |255 263|promoteraced whe
P09252397A0081 |133 144|fibroblastsinemia. P00
P09252397A0081 |180 189|sequencesn as a fu
P09252397A0081 |76 97|nucleotide resolution08171T0000 Pharmacolo
P09252397A0081 |43 72|cyclobutane pyrimidine dimerssphatases and 5-nucleotidase 
P09252397A0081 |199 228|transcription initiation siteCSF PCO2 the data of K-deplet
P09252397A0081 |27 39|repair ratesith alkaline
P09252397A0081 |170 176|repair-] is 
P09252397A0081 |114 122|JUN geneonatal h
P09252397A0081 |238 244|repaire no l
P09252406A0511 |0 8|TyrosineP0000160
P09252406A0511 |132 138|kinasebinemi
P09252406A0511 |181 185|SHP2 as 
P09252406A0511 |37 49|binding sitene phosphata
P09252406A0511 |93 104|p85 subunitcologic asp
P09252406A0511 |58 62|Grb2-nuc
P09252406A0511 |108 128|phosphatidylinositol of neonatal hyperbi
P09252406A0511 |140 160|phospholipase Cgamma P00008997A0472 When
P09252406A0511 |67 87|Shc adaptor proteinsdase P00008171T0000 
P09252406A0511 |168 179|phosphataseO3-] is sho
P09252879A0470 |85 102|methacholine PC200 Pharmacologic a
P09252879A0470 |71 80|functions P0000817
P09252879A0470 |104 109|PC20Mects 
P09252879A0470 |19 32|HRCT findingsarison with a
P09252879A0470 |138 150|significancea. P00008997
P09252879A0470 |51 59|featuress and 5-
P09254678A0106 |0 8|Gtx mRNAP0000160
P09254678A0106 |298 312|point mutationve a significa
P09254678A0106 |150 153|PLPA04
P09254678A0106 |227 230|MBPted
P09254678A0106 |119 122|MBPl h
P09254678A0106 |252 258|brainssplace
P09254678A0106 |191 199|Gtx mRNAtion of 
P09254678A0106 |320 328|PLP geneater slo
P09254678A0106 |24 32|paralleln with a
P09254678A0106 |213 221|parallelata of K
P09254678A0106 |42 46|RNAsosph
P09254678A0106 |110 117|proteinf neona
P09254678A0106 |129 148|proteolipid proteinirubinemia. P000089
P09254678A0106 |77 85|proteins8171T000
P09254678A0106 |235 244|PLP mRNAs are no l
P09254678A0106 |172 189|brain development is shown as a fu
P09254678A0106 |279 283|ratsntro
P09254709T0000 |17 45|Bacillus subtilis catabolitemparison with alkaline phosp
P09254709T0000 |57 69|protein CcpA5-nucleotida
P09254709T0000 |74 90|amyO target site0008171T0000 Pha
P09254709T0000 |0 8|ContactsP0000160
P09255349A0836 |71 75|IRA2 P00
P09255349A0836 |24 30|GTPasen with
P09255349A0836 |62 66|IRA1leot
P09255349A0836 |42 50|proteinsosphatas
P09256973A0455 |84 92|capsules00 Pharm
P09256973A0455 |44 45|Gp
P09256973A0455 |37 42|groupne ph
P09256973A0455 |57 59|G25-
P09256973A0455 |13 16|cat6 C
P09256973A0455 |61 63|mgcl
P09256973A0455 |112 117|weeksneona
P09256973A0455 |67 82|itraconazole/kgdase P00008171T
P09256973A0455 |4 6|E201
P09256973A0673 |17 55|itraconazole plasma drug concentrationmparison with alkaline phosphatases an
P09256973A0673 |13 15|E16 
P09256973A0673 |167 172|hoursCO3-]
P09256973A0673 |148 151|MRT97A
P09256973A0673 |72 76|timeP000
P09256973A0673 |132 146|residence timebinemia. P0000
P09256973A0673 |86 90|dose Pha
P09256973A0673 |108 121|micrograms/ml of neonatal 
P09256973A0673 |0 7|RESULTSP000016
P09257651T0000 |38 51|90kD proteinse phosphatase
P09257651T0000 |125 130|Prp3prbili
P09257651T0000 |10 21|U4/U6 snRNP0076 Compar
P09257651T0000 |92 120|yeast splicing factors Prp4pacologic aspects of neonatal
P09257887A0457 |0 5|G-CSFP0000
P09257887A0457 |126 142|neutrophil countbilirubinemia. P
P09257887A0457 |79 82|day71T
P09257887A0457 |44 57|microg/kg/dayphatases and 
P09257887A0457 |21 24|dayiso
P09257887A0457 |99 108|apheresisc aspects
P09257887A0457 |35 40|cycleline 
P09258439A1001 |119 123|genel hy
P09258439A1001 |9 26|expression systemT0076 Comparison 
P09258439A1001 |67 73|SsEF-2dase P
P09258439A1001 |58 63|forms-nucl
P09258439A1001 |86 97|mutagenesis Pharmacolo
P09258606A0822 |0 9|CrosstalkP00001606
P09258606A0822 |88 99|developmentharmacologi
P09258606A0822 |105 115|malignancycts of neo
P09258606A0822 |20 28|pathwaysrison wi
P09258606A0822 |59 65|stressnucleo
P09258606A0822 |50 55|formses an
P09259052A0568 |0 17|Supershift assaysP00001606T0076 Co
P09259052A0568 |208 212|JunDthe 
P09259052A0568 |132 140|extractsbinemia.
P09259052A0568 |224 228|cJunplet
P09259052A0568 |60 70|antibodiesucleotidas
P09259052A0568 |188 206|Jun family membersunction of CSF PCO
P09259052A0568 |112 123|AtT-20 cellneonatal hy
P09259052A0568 |25 28|Jun wi
P09259052A0568 |214 218|JunBta o
P09259052A0568 |154 169|c-jun AP-1 site2 When CSF [HCO
P09259052A0568 |33 43|Fos familykaline pho
P09259052A0568 |84 101|protein complexes00 Pharmacologic 
P09259313A0950 |16 34|PI kinase activityomparison with alk
P09259313A0950 |4 12|majority01606T00
P09259313A0950 |71 86|PRL stimulation P00008171T0000
P09259315A0809 |171 204|CSEn enhancer/silencer activities] is shown as a function of CSF P
P09259315A0809 |208 212|BeWothe 
P09259315A0809 |12 16|Enh476 C
P09259315A0809 |81 89|enhancerT0000 Ph
P09259315A0809 |217 225|GC cellsof K-dep
P09259315A0809 |59 66|contextnucleot
P09259315A0809 |43 51|enhansonsphatase
P09259315A0809 |0 8|MutationP0000160
P09259315A0809 |101 118|silencer activityaspects of neonat
P09259315A0809 |137 153|GT-IIC enhansonsia. P00008997A04
P09259320A0830 |101 105|DSBPaspe
P09259320A0830 |73 88|O-glycosylation00008171T0000 P
P09259320A0830 |62 69|patternleotida
P09259320A0830 |22 36|chromatographyson with alkal
P09259320A0830 |92 96|SSBPacol
P09259320A0830 |38 49|discordancee phosphata
P09259328A0440 |0 28|Deletion mapping experimentsP00001606T0076 Comparison wi
P09259328A0440 |49 58|sequencesses and 5
P09259328A0440 |256 258|bpce
P09259328A0440 |126 128|bpbi
P09259328A0440 |247 249|bper
P09259328A0440 |267 269|bpmp
P09259328A0440 |89 100|MSC-1 cellsarmacologic
P09259328A0440 |236 238|bpar
P09259328A0440 |77 85|activity8171T000
P09259328A0440 |280 282|bptr
P09259328A0440 |290 297|regionsstill h
P09259328A0440 |170 177|regions-] is s
P09259328A0440 |206 225|luciferase activity2 the data of K-dep
P09259328A0440 |136 146|start sitemia. P0000
P09261155A0833 |17 19|PHmp
P09261155A0833 |24 35|PTB domainsn with alka
P09261155A0833 |160 165|IRS-3 CSF 
P09261155A0833 |149 154|IRS-27A047
P09261155A0833 |101 128|insulin receptor substratesaspects of neonatal hyperbi
P09261155A0833 |142 147|IRS-100008
P09261155A0833 |70 71|%e
P09261178T0000 |50 54|genees a
P09261178T0000 |41 47|kinasehospha
P09261178T0000 |4 9|mouse01606
P09261184A0170 |51 73|supershift experimentss and 5-nucleotidase P
P09261184A0170 |140 144|NF-Y P00
P09261184A0170 |75 80|FIRE100817
P09261184A0170 |19 46|gel mobility shift analysisarison with alkaline phosph
P09261200T0001 |0 10|MR imagingP00001606T
P09261200T0001 |44 59|FLAIR techniquephatases and 5-
P09261200T0001 |24 37|head injuriesn with alkali
P09261397A0509 |0 27|Gag protein sequence motifsP00001606T0076 Comparison w
P09261397A0509 |62 69|virusesleotida
P09261397A0509 |138 142|FeFVa. P
P09261397A0509 |96 116|genome encapsidationogic aspects of neon
P09261397A0509 |35 44|NC domainline phos
P09263010T0000 |0 9|InductionP00001606
P09263010T0000 |95 100|c-myclogic
P09263010T0000 |13 29|B cell apoptosis6 Comparison wit
P09263010T0000 |121 126|bcl-2hyper
P09263010T0000 |81 91|regulationT0000 Phar
P09263010T0000 |59 62|sIgnuc
P09263010T0000 |50 54|CD23es a
P09263094A0799 |0 12|MEASUREMENTSP00001606T00
P09263094A0799 |92 104|measurementsacologic asp
P09263094A0799 |331 340|intervals(1.21 +/-
P09263094A0799 |31 45|Lung elastancealkaline phosp
P09263094A0799 |150 161|airway flowA0472 When 
P09263094A0799 |17 29|MAIN RESULTSmparison wit
P09263094A0799 |393 395|mLe 
P09263094A0799 |359 366|volumesA0733 F
P09263094A0799 |325 327|Hzsl
P09263094A0799 |291 312|breathing frequenciestill have a significa
P09263094A0799 |55 65|resistanced 5-nucleo
P09263094A0799 |266 271|cmH2Oompar
P09263094A0799 |282 287|rangeols b
P09263094A0799 |108 123|airway pressure of neonatal hy
P09263094A0799 |47 49|ELta
P09263094A0799 |194 198|dogsn of
P09263094A0799 |136 144|pressuremia. P00
P09263094A0799 |67 69|RLda
P09263094A0799 |239 259|mean airway pressure no longer displaced
P09263856A0563 |51 64|EGF-1 moduless and 5-nucle
P09263856A0563 |133 143|structuresinemia. P0
P09263856A0563 |28 34|modelsth alk
P09263856A0563 |74 76|PS00
P09263856A0563 |43 46|Glasph
P09263856A0563 |95 106|prothrombinlogic aspec
P09263856A0563 |111 119|factor X neonata
P09264466A0947 |35 41|targetline p
P09264466A0947 |122 137|phosphorylationyperbilirubinem
P09264466A0947 |105 117|interactionscts of neona
P09264466A0947 |57 60|APC5-n
P09264466A0947 |72 80|functionP0000817
P09264466A0947 |4 16|Cut9 subunit01606T0076 C
P09265534A0455 |16 39|Gy/20 fractions/5 weeksomparison with alkaline
P09265534A0455 |4 8|dose0160
P09265642A0668 |87 102|internalizationPharmacologic a
P09265642A0668 |40 47|vacuolephospha
P09265642A0668 |166 177|sop mutantsHCO3-] is s
P09265642A0668 |132 141|marker FMbinemia. 
P09265642A0668 |25 32|pathway with a
P09265642A0668 |78 85|pathway171T000
P09265642A0668 |113 121|membraneeonatal 
P09265932A0575 |83 98|L2-3 interspace000 Pharmacolog
P09265932A0575 |28 30|mgth
P09265932A0575 |37 48|bupivacainene phosphat
P09265932A0575 |8 13|women6T007
P09265932A0575 |66 75|injectionidase P00
P09267306A0381 |187 199|laboratoriesfunction of 
P09267306A0381 |58 63|apo B-nucl
P09267306A0381 |43 54|measurementsphatases a
P09267306A0381 |24 28|casen wi
P09267306A0381 |89 97|standardarmacolo
P09267306A0381 |162 174|introductionSF [HCO3-] i
P09267306A0381 |126 137|reliabilitybilirubinem
P09267306A0381 |101 121|laboratory precisionaspects of neonatal 
P09267431A0000 |35 40|SPK-4line 
P09267431A0000 |25 30|SPK-3 with
P09267431A0000 |60 75|protein kinasesucleotidase P00
P09267431A0000 |4 23|soybean cDNA clones01606T0076 Comparis
P09267439A0000 |137 146|organismsia. P0000
P09267439A0000 |126 133|varietybilirub
P09267439A0000 |83 91|proteins000 Phar
P09267439A0000 |23 38|ras superfamilyon with alkalin
P09267439A0000 |0 5|GenesP0000
P09267542A0126 |0 10|NaltrexoneP00001606T
P09267542A0126 |45 49|Foodhata
P09267542A0126 |82 91|treatment0000 Phar
P09267542A0126 |95 113|alcohol dependencelogic aspects of n
P09267542A0126 |54 73|Drug Administrationnd 5-nucleotidase P
P09268298T0000 |0 20|Ent-kaurene synthaseP00001606T0076 Compa
P09268298T0000 |30 53|fungus Phaeosphaeria sp alkaline phosphatases 
P09268387A0293 |117 131|RNA polymerasetal hyperbilir
P09268387A0293 |61 64|ELLcle
P09268387A0293 |151 169|elongation complex0472 When CSF [HCO
P09268387A0293 |76 83|domains08171T0
P09268387A0293 |8 14|report6T0076
P09268387A0293 |100 111|interaction aspects of
P09268578A0225 |95 98|mudlog
P09268578A0225 |14 28|cDNA sequences Comparison wi
P09268578A0225 |60 67|messageucleoti
P09268578A0225 |88 93|deathharma
P09268631A0316 |69 74|genesse P0
P09268631A0316 |14 39|transcription orientation Comparison with alkaline
P09268631A0316 |4 12|position01606T00
P09268631A0316 |96 101|Igf2rogic 
P09268631A0316 |55 61|statusd 5-nu
P09268638A0332 |71 77|D8S260 P0000
P09268638A0332 |30 56|chromosome walking studies alkaline phosphatases and
P09268638A0332 |89 95|D8S285armaco
P09268652A0116 |101 106|dsRNAaspec
P09268652A0116 |77 95|expression library8171T0000 Pharmaco
P09268652A0116 |41 50|dsRBP-ZFahosphatas
P09268652A0116 |20 39|zinc finger proteinrison with alkaline
P09268661A1405 |51 64|transcriptases and 5-nucle
P09268661A1405 |30 42|retroplasmid alkaline ph
P09268661A1405 |97 111|cDNA synthesisgic aspects of
P09268661A1405 |132 144|CCA sequencebinemia. P00
P09268661A1405 |4 11|results01606T0
P09269879A0266 |34 49|bioavailabilityaline phosphata
P09269879A0266 |56 57|% 
P09269879A0266 |6 16|absorption606T0076 C
P09269879A0266 |67 69|ivda
P09269879A0266 |80 100|elimination profiles1T0000 Pharmacologic
P09269900A1035 |84 94|activation00 Pharmac
P09269900A1035 |130 136|factorrubine
P09269900A1035 |179 187|responsewn as a 
P09269900A1035 |161 170|repressorCSF [HCO3
P09269900A1035 |146 150|JunD8997
P09269900A1035 |57 70|transcription5-nucleotidas
P09269900A1035 |98 108|ATF3/c-Junic aspects
P09269900A1035 |37 48|EGF/Ras/Rafne phosphat
P09269900A1035 |16 23|resultsomparis
P09271393A1333 |69 84|HTLV-1 promoterse P00008171T00
P09271393A1333 |31 36|modelalkal
P09271393A1333 |159 169|activitiesn CSF [HCO
P09271393A1333 |199 210|recruitmentCSF PCO2 th
P09271393A1333 |46 61|Tax anchors CBPatases and 5-nu
P09271393A1333 |226 249|transcription machineryeted rats are no longer
P09271393A1333 |184 194|remodeling a functio
P09271393A1333 |114 124|activationonatal hyp
P09271393A1333 |16 20|dataompa
P09271394A0558 |152 155|TIR472
P09271394A0558 |39 51|footprinting phosphatase
P09271394A0558 |159 162|Mu1n C
P09271394A0558 |92 96|MURAacol
P09271394A0558 |138 144|regiona. P00
P09271394A0558 |55 77|MURA-Mu1 TIR complexesd 5-nucleotidase P0000
P09271394A0558 |0 5|DNaseP0000
P09271397A1596 |138 146|Sp1 sitea. P0000
P09271397A1596 |208 215|fashionthe dat
P09271397A1596 |74 80|copies000817
P09271397A1596 |95 118|LDL receptor SREBP sitelogic aspects of neonat
P09271397A1596 |40 49|constructphosphata
P09271397A1596 |21 26|modelison 
P09271400A0475 |100 115|E2F2 expression aspects of neo
P09271400A0475 |27 44|promoter activityith alkaline phos
P09271400A0475 |89 96|controlarmacol
P09271400A0475 |8 14|assays6T0076
P09271400A0475 |125 143|growth stimulationrbilirubinemia. P0
P09271400A0475 |53 61|sequenceand 5-nu
P09271417A0585 |141 146|acidsP0000
P09271417A0585 |58 64|kidney-nucle
P09271417A0585 |95 102|tissueslogic a
P09271417A0585 |13 18|mouse6 Com
P09271417A0585 |83 93|adipocytes000 Pharma
P09271417A0585 |66 71|heartidase
P09271417A0585 |20 29|ERR alpharison wit
P09271417A1011 |17 42|receptor response elementmparison with alkaline ph
P09271417A1011 |46 52|NRRE-1atases
P09271417A1011 |4 8|MCAD0160
P09271417A1011 |78 87|ERR alpha171T0000 
P09271417A1011 |101 112|COS-7 cellsaspects of 
P09271496T0000 |0 16|Mapping featuresP00001606T0076 C
P09271496T0000 |20 35|HIV-1 integraserison with alka
P09271496T0000 |125 144|photo-cross-linkingrbilirubinemia. P00
P09271496T0000 |50 55|siteses an
P09271496T0000 |114 121|complexonatal 
P09271496T0000 |69 89|target DNA moleculesse P00008171T0000 Ph
P09272108A1295 |1 9|Analysis00001606
P09272108A1295 |96 110|CAAT sequencesogic aspects o
P09272108A1295 |66 74|presenceidase P0
P09272108A1295 |43 47|genespha
P09272108A1295 |29 35|regionh alka
P09272108A1295 |43 47|genespha
P09272108A1295 |29 35|regionh alka
P09272108A1295 |1 9|Analysis00001606
P09272108A1295 |87 91|TATAPhar
P09272108A1295 |96 110|CAAT sequencesogic aspects o
P09272108A1295 |66 74|presenceidase P0
P09272108A1295 |87 91|TATAPhar
P09272138A1153 |138 143|weeksa. P0
P09272138A1153 |115 123|survivalnatal hy
P09272138A1153 |23 25|CRon
P09272138A1153 |27 31|rateith 
P09272138A1153 |57 70|rhG-CSF group5-nucleotidas
P09272138A1153 |176 177|Ps
P09272138A1153 |77 78|%8
P09272138A1153 |13 21|response6 Compar
P09272138A1153 |47 51|CODEtase
P09272138A1153 |86 90|CODE Pha
P09272138A1153 |38 39|%e
P09272138A1153 |97 102|groupgic a
P09272138A1153 |168 174|groupsO3-] i
P09275159T0000 |81 87|regionT0000 
P09275159T0000 |91 116|mouse hepatitis virus RNAmacologic aspects of neon
P09275159T0000 |22 42|ribonucleoprotein A1son with alkaline ph
P09275164A0000 |118 136|RNA triphosphataseal hyperbilirubine
P09275164A0000 |183 200|methyltransferases a function of C
P09275164A0000 |93 99|actioncologi
P09275164A0000 |40 44|mRNAphos
P09275164A0000 |109 116|enzymesof neon
P09275164A0000 |167 170|RNACO3
P09275164A0000 |4 25|m7GpppN cap structure01606T0076 Comparison
P09275164A0000 |172 181|guanine-7 is shown
P09275164A0000 |138 161|RNA guanylyltransferasea. P00008997A0472 When 
P09275990A0938 |103 113|activationpects of n
P09275990A0938 |73 84|TA98 strain00008171T00
P09275990A0938 |13 17|part6 Co
P09275990A0938 |44 56|mutagenicityphatases and
P09275990A0938 |142 165|mutagenicity prevalence00008997A0472 When CSF 
P09275990A0938 |25 30|study with
P09275990A0938 |169 175|diesel3-] is
P09276882A0479 |205 219|% carbohydrateO2 the data of
P09276882A0479 |143 167|% carbohydrate treatment0008997A0472 When CSF [H
P09276882A0479 |125 128|Dayrbi
P09276882A0479 |41 55|SW by-productshosphatases an
P09276882A0479 |31 33|CCal
P09276882A0479 |190 192|pHct
P09276882A0479 |38 40|CCe 
P09276882A0479 |4 12|addition01606T00
P09276882A0479 |114 121|cultureonatal 
P09276882A0479 |68 77|pH valuesase P0000
P09276882A0479 |16 23|cultureomparis
P09276882A0479 |85 86|P0
P09277472A1070 |98 107|DC shocksic aspect
P09277472A1070 |24 29|edeman wit
P09277472A1070 |57 66|mechanism5-nucleot
P09277472A1070 |80 91|dysfunction1T0000 Phar
P09277629A0268 |17 18|Nm
P09277629A0268 |107 118|memory tasks of neonat
P09277629A0268 |62 68|natureleotid
P09277629A0268 |146 157|memory task8997A0472 W
P09277629A0268 |72 88|ERP negativitiesP00008171T0000 P
P09277629A0268 |4 15|experiments01606T0076 
P09278441A0163 |0 4|BiolP000
P09278441A1160 |205 209|geneO2 t
P09278441A1160 |158 165|homologen CSF 
P09278441A1160 |142 145|Csx000
P09278441A1160 |26 46|CARP mRNA expressionwith alkaline phosph
P09278441A1160 |135 139|Nkx2emia
P09278441A1160 |101 105|daysaspe
P09278441A1160 |86 92|tongue Pharm
P09278441A1160 |4 11|pattern01606T0
P09278441A1160 |234 245|developments are no lo
P09278441A1160 |16 22|timingompari
P09278441A1160 |169 175|tinman3-] is
P09278441A1160 |68 78|expressionase P00008
P09278441A1777 |0 14|OverexpressionP00001606T0076
P09278441A1777 |60 70|troponin Cucleotidas
P09278441A1777 |94 114|factor transcriptionologic aspects of ne
P09278441A1777 |26 40|cardiomyocyteswith alkaline 
P09278441A1777 |18 22|CARPpari
P09278445T0000 |0 21|Substrate specificityP00001606T0076 Compar
P09278445T0000 |47 67|yeast RNA polymerasetases and 5-nucleoti
P09278445T0000 |29 43|RNase activityh alkaline pho
P09278450A1338 |16 37|mobility shift assaysomparison with alkali
P09278450A1338 |78 84|site A171T00
P09278450A1338 |105 116|NF1 proteincts of neon
P09278450A1338 |42 65|competition experimentsosphatases and 5-nucleo
P09278454A1261 |0 11|ExaminationP00001606T0
P09278454A1261 |147 183|DMS protection footprinting analysis997A0472 When CSF [HCO3-] is shown a
P09278454A1261 |61 75|Y-box sequencecleotidase P00
P09278454A1261 |19 37|MMP-2 RE1 sequencearison with alkali
P09278454A1261 |77 89|CTGCTGGGCAAG8171T0000 Ph
P09278454A1261 |139 143|YB-1. P0
P09278475A0465 |87 100|Ino-phenotypePharmacologic
P09278475A0465 |43 55|ts phenotypesphatases an
P09278475A0465 |104 112|rpo26-31ects of 
P09278475A0465 |7 12|scs3206T00
P09278494A0762 |18 21|Sp1par
P09278494A0762 |72 89|promoter activityP00008171T0000 Ph
P09278494A0762 |97 113|Surf-1 directiongic aspects of n
P09278494A0762 |26 38|ETS proteinswith alkalin
P09278494A0762 |3 11|contrast001606T0
P09278758A1636 |0 10|CONCLUSIONP00001606T
P09278758A1636 |12 24|Patients wit76 Compariso
P09278758A1636 |166 177|lymph nodesHCO3-] is s
P09278758A1636 |45 57|neck diseasehatases and 
P09278758A1636 |131 137|spreadubinem
P09278758A1636 |108 115|disease of neo
P09278758A1636 |79 87|evidence71T0000 
P09278758A1636 |193 197|riskon o
P09278758A1636 |212 219|failuredata of
P09278758A1636 |59 63|N1-3nucl
P09278758A1636 |231 236|sitesrats 
P09279379A0310 |53 56|DNAand
P09279379A0310 |144 160|H2B histone gene008997A0472 When
P09279379A0310 |58 67|sequences-nucleoti
P09279379A0310 |130 136|spacerrubine
P09279379A0310 |47 51|acidtase
P09279379A0310 |112 118|spacerneonat
P09279379A0310 |97 103|regiongic as
P09279379A0310 |23 29|pBR322on wit
P09279889A1124 |0 4|AreaP000
P09279889A1124 |47 57|AUC0-24 hrtases and 
P09279889A1124 |15 19|drugComp
P09279889A1124 |39 45|curves phosp
P09279889A1124 |124 139|% Azone systemserbilirubinemia
P09279889A1124 |106 113|% Azonets of n
P09279889A1124 |63 66|MTXeot
P09279889A1124 |100 104|PG-2 asp
P09279889A1124 |86 88|ng P
P09279889A1124 |118 122|PG-7al h
P09280747A0195 |84 92|survival00 Pharm
P09280747A0195 |105 115|comparisoncts of neo
P09280747A0195 |173 179|effectis sho
P09280747A0195 |142 150|evidence00008997
P09280747A0195 |197 211|ACE inhibitorsf CSF PCO2 the
P09280747A0195 |124 132|regimenserbiliru
P09280747A0195 |19 44|hydralazine hydrochloridearison with alkaline phos
P09280747A0195 |4 15|combination01606T0076 
P09280747A0195 |49 69|isosorbide dinitrateses and 5-nucleotida
P09282329A0527 |34 46|interactionsaline phosph
P09282329A0527 |11 21|mechanisms076 Compar
P09282329A0527 |192 213|G1/S phase transitionion of CSF PCO2 the d
P09282329A0527 |87 113|cell cycle control elementPharmacologic aspects of n
P09282329A0527 |217 223|FDC-P1of K-d
P09282329A0527 |174 184|regulations shown as
P09282329A0527 |142 154|determinants00008997A047
P09282329A0527 |69 76|factorsse P000
P09282329A0527 |50 54|Sitees a
P09282329A0527 |238 254|progenitor cellse no longer disp
P09282911A0277 |17 22|studympari
P09282911A0277 |131 133|T3ub
P09282911A0277 |167 177|regulationCO3-] is s
P09282911A0277 |75 90|RC3/neurogranin008171T0000 Pha
P09282911A0277 |48 61|cell culturesases and 5-nu
P09282911A0277 |4 8|goal0160
P09282911A0277 |154 163|mechanism2 When CS
P09282985A0961 |64 79|characteristicsotidase P000081
P09282985A0961 |11 22|differences076 Compari
P09282985A0961 |31 36|malesalkal
P09282985A0961 |38 39|pe
P09283828A0484 |16 25|responsesomparison
P09283828A0484 |56 60|cues 5-n
P09285715A1257 |136 139|CTEmia
P09285715A1257 |105 109|RNAscts 
P09285715A1257 |127 130|RNAili
P09285715A1257 |43 46|Revsph
P09285715A1257 |228 239|mRNA exported rats are
P09285715A1257 |61 75|export pathwaycleotidase P00
P09285715A1257 |114 116|5Son
P09285715A1257 |188 195|factorsunction
P09285715A1257 |18 22|datapari
P09285789A0712 |21 55|guanine nucleotide exchange factorison with alkaline phosphatases an
P09285789A0712 |57 60|GEF5-n
P09285789A0712 |132 138|domainbinemi
P09285789A0712 |107 126|pleckstrin homologys of neonatal hyper
P09285789A0712 |62 68|domainleotid
P09285789A0712 |6 9|Duo606
P09285789A0712 |128 130|PHli
P09285789A0712 |157 169|repeat unitshen CSF [HCO
P09286115T0000 |34 40|factoraline 
P09286115T0000 |70 77|elemente P0000
P09286115T0000 |111 121|RPL21 gene neonatal 
P09286115T0000 |0 3|S2FP00
P09286981A0147 |0 4|ArgRP000
P09286981A0147 |74 78|mass0008
P09286981A0147 |42 50|subunitsosphatas
P09286981A0147 |89 91|Daar
P09286981A0147 |23 28|dimeron wi
P09287036A0457 |0 28|Plasma leptin concentrationsP00001606T0076 Comparison wi
P09287036A0457 |44 49|womenphata
P09287036A0457 |134 139|womennemia
P09287036A0457 |90 101|differencesrmacologic 
P09287036A0457 |75 85|adjustment008171T000
P09287036A0457 |124 129|ng/mlerbil
P09287036A0457 |109 113|massof n
P09287036A0457 |55 58|mend 5
P09287352A0930 |169 174|SHP-13-] i
P09287352A0930 |295 305|% increase have a si
P09287352A0930 |52 68|SHP-1 expression and 5-nucleotid
P09287352A0930 |27 42|STAT activationith alkaline ph
P09287352A0930 |95 105|activationlogic aspe
P09287352A0930 |176 179|Cyssho
P09287352A0930 |245 255|expressionnger displ
P09287352A0930 |211 214|MEK da
P09287352A0930 |259 264|SHP-1 when
P09287352A0930 |16 23|effectsomparis
P09287352A0930 |184 187|Ser a 
P09287352A0930 |155 165|expression When CSF 
P09287352A0930 |131 153|protein kinase pathwayubinemia. P00008997A04
P09287352A0930 |199 207|activityCSF PCO2
P09287352A0930 |234 235|%s
P09287362A0589 |48 51|cskase
P09287362A0589 |72 78|regionP00008
P09287362A0589 |121 127|regionhyperb
P09287362A0589 |44 47|p50pha
P09287362A0589 |30 40|SH3 region alkaline 
P09287362A0589 |5 16|interaction1606T0076 C
P09287362A0589 |131 139|PTP-PESTubinemia
P09287362A0589 |80 97|PPPLPERTPESFVLADM1T0000 Pharmacolo
P09288848A0780 |18 30|HbO2 changesparison with
P09288848A0780 |14 16|Gy C
P09288916T0000 |152 164|kidney cells472 When CSF
P09288916T0000 |10 20|expression0076 Compa
P09288916T0000 |133 144|Madin-Darbyinemia. P00
P09288916T0000 |106 111|alphats of
P09288916T0000 |98 104|meprinic asp
P09288916T0000 |76 90|acid hydrolase08171T0000 Pha
P09288916T0000 |116 129|beta subunitsatal hyperbil
P09290207A0731 |52 68|mating type loci and 5-nucleotid
P09290207A0731 |25 37|derepression with alkali
P09290571A0420 |87 90|EPSPha
P09290571A0420 |9 17|patientsT0076 Co
P09290571A0420 |107 115|patientss of neo
P09290571A0420 |96 99|VTsogi
P09290571A0420 |43 46|VTssph
P09290571A0420 |80 85|study1T000
P09290571A0799 |32 33|nl
P09290571A0799 |28 30|VTth
P09290571A0799 |39 42|VTs ph
P09290571A0799 |59 63|msecnucl
P09290571A0799 |4 16|cycle length01606T0076 C
P09291077T0000 |10 25|hyperammonaemia0076 Comparison
P09291077T0000 |45 57|shepherd doghatases and 
P09291098A0452 |114 124|transcriptonatal hyp
P09291098A0452 |89 97|splicingarmacolo
P09291098A0452 |28 39|kb mRNA V-1th alkaline
P09291098A0452 |163 175|rat GGT geneF [HCO3-] is
P09291098A0452 |147 155|promoter997A0472
P09291098A0452 |52 67|kb GGT mRNA V-2 and 5-nucleoti
P09291098T0000 |102 105|ratspe
P09291098T0000 |18 26|promoterparison 
P09291098T0000 |36 81|gamma-glutamyl transpeptidase gene expressionine phosphatases and 5-nucleotidase P00008171
P09291098T0000 |118 129|liver cellsal hyperbil
P09292499A0887 |103 106|PTBpec
P09292499A0887 |124 132|extractserbiliru
P09292499A0887 |26 36|pyrimidinewith alkal
P09292499A0887 |150 184|UV crosslinking/competition assaysA0472 When CSF [HCO3-] is shown as
P09292499A0887 |6 21|repressor sites606T0076 Compar
P09292499A0887 |111 115|HeLa neo
P09292499A0887 |65 101|polypyrimidine tract binding proteintidase P00008171T0000 Pharmacologic 
P09293006A1412 |85 99|aphII promoter0 Pharmacologi
P09293006A1412 |11 21|expression076 Compar
P09293006A1412 |33 44|S. lividanskaline phos
P09293006A1412 |25 29|lipA wit
P09293006A1412 |50 54|genees a
P09294139A0729 |137 143|motifsia. P0
P09294139A0729 |333 339|motifs.21 +/
P09294139A0729 |109 116|homologof neon
P09294139A0729 |211 219|enhancer data of
P09294139A0729 |83 84|%0
P09294139A0729 |249 270|sequence conservation displaced when compa
P09294139A0729 |232 240|segmentsats are 
P09294139A0729 |283 294|possibilityls but stil
P09294139A0729 |48 62|HS12 enhancersases and 5-nuc
P09294139A0729 |188 196|functionunction 
P09294139A0729 |16 36|core homology regionomparison with alkal
P09294161A0650 |3 11|contrast001606T0
P09294161A0650 |75 92|activation domain008171T0000 Pharm
P09294161A0650 |52 61|p45 NF-E2 and 5-nu
P09294161A0650 |110 119|cell linef neonata
P09294161A0650 |29 36|proteinh alkal
P09294161A0650 |183 189|assayss a fu
P09294161A0650 |38 48|expressione phosphat
P09294161A0650 |99 104|NF-E2c asp
P09294161A0650 |156 169|transcriptionWhen CSF [HCO
P09294161A1103 |136 145|promotersmia. P000
P09294161A1103 |106 117|globin locits of neona
P09294161A1103 |91 98|regionsmacolog
P09294161A1103 |37 46|mechanismne phosph
P09294161A1103 |58 69|recruitment-nucleotida
P09294161A1103 |6 14|findings606T0076
P09294262A0885 |115 121|stressnatal 
P09294262A0885 |165 174|promoters[HCO3-] i
P09294262A0885 |75 85|CreA boxes008171T000
P09294262A0885 |30 48|consensus TATA box alkaline phosphat
P09294262A0885 |65 70|CCAATtidas
P09294262A0885 |144 154|regulation008997A047
P09294262A0885 |4 19|promoter region01606T0076 Comp
P09294422A1223 |171 179|activity] is sho
P09294422A1223 |8 25|cysteine residues6T0076 Comparison
P09294422A1223 |135 153|activation processemia. P00008997A04
P09294422A1223 |83 92|formation000 Pharm
P09294422A1223 |53 59|regionand 5-
P09294422A1223 |98 114|disulfide bridgeic aspects of ne
P09294422A1376 |153 165|tac promoter72 When CSF 
P09294422A1376 |198 201|POR CS
P09294422A1376 |47 51|timetase
P09294422A1376 |216 220|form of 
P09294422A1376 |4 12|por gene01606T00
P09294422A1376 |184 194|production a functio
P09294452A2107 |20 28|operatorrison wi
P09294452A2107 |63 72|reductioneotidase 
P09294452A2107 |76 98|reporter enzyme levels08171T0000 Pharmacolog
P09294453A0949 |85 89|role0 Ph
P09294453A0949 |93 114|T beta L biosynthesiscologic aspects of ne
P09294453A0949 |43 51|tabtoxinsphatase
P09294453A0949 |33 39|levelskaline
P09294453A0949 |4 15|ORF3 mutant01606T0076 
P09294453A0949 |69 73|ORF3se P
P09294471A1198 |138 141|fita. 
P09294471A1198 |120 125|model hype
P09294471A1198 |40 50|150/microLphosphatas
P09294471A1198 |27 36|CD4 countith alkal
P09294471A1198 |89 91|I0ar
P09294471A1198 |63 73|200/microLeotidase P
P09294471A1198 |96 98|I1og
P09294471A1198 |8 18|Cox models6T0076 Com
P09294471A1198 |158 162|dataen C
P09296251A0163 |50 56|numberes and
P09296251A0163 |23 30|reportson with
P09296251A0163 |60 68|patientsucleotid
P09296251A0163 |81 85|dataT000
P09297698A0933 |154 166|enolase gene2 When CSF [
P09297698A0933 |77 83|UbCRBP8171T0
P09297698A0933 |133 141|distanceinemia. 
P09297698A0933 |107 113|regions of n
P09297698A0933 |33 37|endskali
P09297698A0933 |6 17|transcripts606T0076 Co
P09297698A0933 |48 60|UbCRBP mRNAsases and 5-n
P09299696A1074 |185 189|kidsa fu
P09299696A1074 |56 62|number 5-nuc
P09299696A1074 |148 164|characterization97A0472 When CSF
P09299696A1074 |195 200|model of C
P09299696A1074 |91 97|villusmacolo
P09299696A1074 |66 80|cryptosporidiaidase P0000817
P09299696A1074 |172 181|infection is shown
P09299696A1074 |42 51|intestineosphatase
P09299696A1074 |111 114|DPI ne
P09299696A1074 |20 34|cryptosporidiarison with alk
P09299696A1074 |218 235|cryptosporidiosisf K-depleted rats
P09299696A1074 |4 16|distribution01606T0076 C
P09300323A1182 |64 72|ENDO/EPIotidase 
P09300323A1182 |46 62|blood flow ratioatases and 5-nuc
P09300323A1182 |150 153|ITFA04
P09300323A1182 |181 185|i.v. as 
P09300323A1182 |110 126|control stenosisf neonatal hyper
P09300323A1182 |214 217|NTGta 
P09300323A1182 |5 11|result1606T0
P09300697A0000 |0 11|ProteasomesP00001606T0
P09300697A0000 |106 115|moleculests of neo
P09300697A0000 |72 80|peptidesP0000817
P09300697A0000 |58 68|generation-nucleotid
P09300697A0000 |94 103|MHC classologic as
P09300697A0000 |33 41|proteasekaline p
P09300698A1219 |19 33|interpretationarison with al
P09300698A1219 |54 58|MQ9bnd 5
P09300698A1219 |125 133|peptidesrbilirub
P09300698A1219 |3 10|support001606T
P09301114A0573 |0 9|TakahashiP00001606
P09301114A0573 |11 13|H.07
P09301350A0946 |236 244|capacityare no l
P09301350A0946 |88 93|pg/mlharma
P09301350A0946 |328 330|pppe
P09301350A0946 |210 211|%e
P09301350A0946 |120 122|CI h
P09301350A0946 |181 196|expiratory flow as a function 
P09301350A0946 |289 306|percentage points still have a sig
P09301350A0946 |259 262|sex wh
P09301350A0946 |154 161|placebo2 When 
P09301350A0946 |53 80|treatment median differenceand 5-nucleotidase P0000817
P09301350A0946 |144 150|favour008997
P09301350A0946 |267 273|heightmpared
P09301350A0946 |332 357|mean treatment difference1.21 +/- 0.23 vs. P000109
P09301350A0946 |361 367|favour733 Fl
P09301350A0946 |97 118|% confidence intervalgic aspects of neonat
P09301350A0946 |202 203|% 
P09301350A0946 |315 319|% CIy gr
P09301350A0946 |134 139|pg/mlnemia
P09301350A0946 |308 310|ppfi
P09301350A0946 |371 378|placeboepam th
P09301350A0946 |4 24|sputum interleukin-801606T0076 Compariso
P09303437A0875 |255 274|CAT gene expressionaced when compared 
P09303437A0875 |123 131|functionperbilir
P09303437A0875 |240 251|stimulationno longer d
P09303437A0875 |30 33|Fp1 al
P09303437A0875 |197 205|promoterf CSF PC
P09303437A0875 |161 170|insertionCSF [HCO3
P09303437A0875 |41 52|hCRBP1 genehosphatases
P09303437A0875 |148 155|element97A0472
P09303437A0875 |71 83|CAT activity P00008171T0
P09303437A0875 |18 26|deletionparison 
P09303437A0875 |187 190|p12fun
P09303635A0000 |68 72|lackase 
P09303635A0000 |10 17|disease0076 Co
P09303635A0000 |100 106|enzyme aspec
P09303635A0000 |38 46|disordere phosph
P09303635A0000 |0 7|GaucherP000016
P09304123A0079 |70 85|tooth structuree P00008171T000
P09304123A0079 |161 165|bulkCSF 
P09304123A0079 |133 138|orderinemi
P09304123A0079 |123 129|mannerperbil
P09304123A0079 |190 198|materialction of
P09304123A0079 |6 19|discoloration606T0076 Comp
P09304123A0079 |48 52|waysases
P09305592A0000 |21 49|translocation characteristicison with alkaline phosphata
P09305592A0000 |105 119|fusion proteincts of neonata
P09305592A0000 |76 88|bcr/abl gene08171T0000 P
P09305592A0000 |121 132|p210bcr/ablhyperbiliru
P09305592A0000 |53 56|CMLand
P09305631A0770 |0 14|OverexpressionP00001606T0076
P09305631A0770 |47 57|cell linestases and 
P09305631A0770 |82 92|cell death0000 Pharm
P09305631A0770 |63 67|heateoti
P09305631A0770 |18 23|BAG-1paris
P09305755A0540 |137 142|C/EBPia. P
P09305755A0540 |164 171|factors [HCO3-
P09305755A0540 |16 22|regionompari
P09305755A0540 |187 191|HNF5func
P09305755A0540 |82 85|Sp1000
P09305755A0540 |145 155|hepatocyte08997A0472
P09305755A0540 |95 101|factorlogic 
P09305755A0540 |181 185|HNF1 as 
P09305755A0540 |111 135|CAAT-box binding protein neonatal hyperbilirubin
P09305755A0540 |73 80|protein0000817
P09305755A0540 |225 228|AP1let
P09305755A0540 |105 108|NF1cts
P09305755A0540 |197 215|activator proteinsf CSF PCO2 the dat
P09305755A0540 |230 233|AP2 ra
P09305755A0540 |42 55|binding sitesosphatases an
P09305870A0894 |103 107|hDlgpect
P09305870A0894 |88 99|PDZ domainsharmacologi
P09305870A0894 |115 135|lymphocyte homologuenatal hyperbilirubin
P09305870A0894 |4 27|recognition specificity01606T0076 Comparison w
P09305870A0894 |212 218|domaindata o
P09305870A0894 |166 182|tumor suppressorHCO3-] is shown 
P09305870A0894 |222 236|glycophorin C.depleted rats 
P09305870A0894 |154 159|discs2 Whe
P09305870A0894 |35 49|p55 PDZ domainline phosphata
P09305944A0621 |171 185|yeast proteins] is shown as 
P09305944A0621 |231 245|GTP hydrolysisrats are no lo
P09305944A0621 |129 137|sequenceirubinem
P09305944A0621 |72 96|rna1p mutant derivativesP00008171T0000 Pharmacol
P09305944A0621 |156 162|domainWhen C
P09305944A0621 |38 44|seriese phos
P09305944A0621 |17 32|RanGAP activitymparison with a
P09307065A0553 |258 264|microMd when
P09307065A0553 |88 102|enterotoxin C2harmacologic a
P09307065A0553 |150 151|MA
P09307065A0553 |211 214|sec da
P09307065A0553 |156 159|secWhe
P09307065A0553 |7 14|absence06T0076
P09307065A0553 |111 127|association rate neonatal hyperb
P09307065A0553 |229 250|dissociation constantd rats are no longer 
P09307065A0553 |49 56|D10 TCRses and
P09307065A0553 |18 27|MHC classparison w
P09307065A0553 |170 187|dissociation rate-] is shown as a 
P09307312A0172 |275 279|datao co
P09307312A0172 |208 239|membrane vibration measurementsthe data of K-depleted rats are
P09307312A0172 |74 86|nerve fibers0008171T0000
P09307312A0172 |164 169|cells [HCO
P09307312A0172 |23 29|shiftson wit
P09307312A0172 |97 109|microphonicsgic aspects 
P09307312A0172 |52 61|responses and 5-nu
P09307312A0172 |177 184|cochleahown as
P09307312A0172 |0 8|EvidenceP0000160
P09307312A0172 |138 148|hair cellsa. P000089
P09307312A0172 |119 128|responsesl hyperbi
P09308234A0225 |0 3|MntP00
P09308234A0225 |83 91|promoter000 Phar
P09308234A0225 |58 68|activation-nucleotid
P09308234A0225 |4 17|Max complexes01606T0076 Co
P09308738A1216 |153 193|factor VIII/von Willebrand factor levels72 When CSF [HCO3-] is shown as a functi
P09308738A1216 |29 32|HESh a
P09308738A1216 |7 20|United States06T0076 Compa
P09308738A1216 |123 125|MWpe
P09308738A1216 |141 149|decreaseP0000899
P09309457A0680 |0 6|AssaysP00001
P09309457A0680 |187 193|monthsfuncti
P09309457A0680 |48 52|HDL2ases
P09309457A0680 |54 57|LDLnd 
P09309457A0680 |59 72|triglyceridesnucleotidase 
P09309457A0680 |145 153|baseline08997A04
P09309457A0680 |88 99|lipoproteinharmacologi
P09309457A0680 |74 86|endothelin-10008171T0000
P09309457A0680 |105 114|estradiolcts of ne
P09309457A0680 |119 122|FSHl h
P09309457A0680 |16 27|cholesterolomparison w
P09309457A0680 |197 200|ERTf C
P09309457A0680 |43 46|HDLsph
P09309457A0680 |171 174|ERT] i
P09310836A1019 |50 63|SV40 promoteres and 5-nucl
P09310836A1019 |11 18|repeats076 Com
P09310836A1019 |130 138|elementsrubinemi
P09310836A1019 |26 35|P elementwith alka
P09310836A1019 |77 108|phorbol 12-myristate 13-acetate8171T0000 Pharmacologic aspects
P09311164A0245 |81 91|motor unitT0000 Phar
P09311164A0245 |24 33|density Jn with al
P09311164A0245 |59 65|volumenucleo
P09311568A0595 |50 51|Qe
P09311568A0595 |59 60|Gn
P09311568A0595 |57 58|A5
P09311568A0595 |27 45|C1YVV NIa proteaseith alkaline phosp
P09311568A0595 |4 23|cleavage dipeptides01606T0076 Comparis
P09311568A0595 |52 53|E 
P09311568A0595 |55 56|Sd
P09311796A0218 |16 23|studiesomparis
P09311796A0218 |106 130|TATA-box binding proteints of neonatal hyperbili
P09311796A0218 |132 135|TBPbin
P09311796A0218 |145 165|transcription factor08997A0472 When CSF 
P09311796A0218 |41 51|activationhosphatase
P09311796A0218 |80 93|IEP86 binding1T0000 Pharma
P09311808A0341 |38 49|p4 moleculee phosphata
P09311810A0814 |159 164|virusn CSF
P09311810A0814 |182 187|virusas a 
P09311810A0814 |46 56|Vero cellsatases and
P09311810A0814 |209 225|alpha0 sequenceshe data of K-dep
P09311810A0814 |74 96|alpha0 deletion mutant0008171T0000 Pharmacol
P09311810A0814 |25 42|cyclin D3 protein with alkaline ph
P09311810A0814 |9 21|accumulationT0076 Compar
P09311810A0814 |129 134|cellsirubi
P09311835A0147 |153 161|residues72 When 
P09311835A0147 |90 102|SV40 mutantsrmacologic a
P09311835A0147 |62 72|T antigensleotidase 
P09311835A0147 |181 199|ATP binding pocket as a function of 
P09311835A0147 |38 54|characterizatione phosphatases a
P09312025A0373 |152 160|LY294002472 When
P09312025A0373 |195 203|p85alpha of CSF 
P09312025A0373 |66 74|PKC zetaidase P0
P09312025A0373 |6 13|effects606T007
P09312025A0373 |93 136|phosphatidylinositol 3-kinase p85alpha-p110cologic aspects of neonatal hyperbilirubine
P09312025A0373 |79 89|inhibition71T0000 Ph
P09312025A0373 |185 191|mutanta func
P09312025A0373 |140 150|wortmannin P00008997
P09312025A0373 |32 45|co-expressionlkaline phosp
P09312025T0000 |0 22|Protein phosphatase 2AP00001606T0076 Compari
P09312025T0000 |94 98|SV40olog
P09312025T0000 |134 154|NF-kappaB activationnemia. P00008997A047
P09312025T0000 |105 106|tc
P09312025T0000 |50 81|protein kinase C zeta signalinges and 5-nucleotidase P00008171
P09312025T0000 |37 46|regulatorne phosph
P09312025T0000 |118 129|cell growthal hyperbil
P09312028A0975 |19 32|RXRalphaF318Aarison with a
P09312028A0975 |72 84|heterodimersP00008171T00
P09312028A0975 |46 54|activityatases a
P09312028A0975 |150 166|RAR AF-2 domainsA0472 When CSF [
P09312028A0975 |104 110|BMS614ects o
P09312028A0975 |92 100|presenceacologic
P09312028A0975 |124 133|integrityerbilirub
P09312028A0975 |142 145|RXR000
P09312032A0165 |34 46|snoRNA genesaline phosph
P09312032A0165 |130 144|intron lariatsrubinemia. P00
P09312032A0165 |107 113|snoRNAs of n
P09312032A0165 |92 99|releaseacologi
P09312032A0165 |57 67|processing5-nucleoti
P09312032A0165 |6 13|introns606T007
P09312087A0000 |35 49|Src homology-2line phosphata
P09312087A0000 |395 402|Tyr-686an effe
P09312087A0000 |51 54|SH2s a
P09312087A0000 |153 160|PECAM-172 When
P09312087A0000 |262 266|parten c
P09312087A0000 |335 341|domain1 +/- 
P09312087A0000 |366 391|tyrosine residues Tyr-663lurazepam thus appears to
P09312087A0000 |91 102|phosphatasemacologic a
P09312087A0000 |230 237|process rats a
P09312087A0000 |286 301|phosphopeptidesbut still have 
P09312087A0000 |104 109|SHP-2ects 
P09312087A0000 |345 352|PECAM-1 vs. P0
P09312087A0000 |143 149|domain000899
P09312087A0000 |7 14|studies06T0076
P09312087A0000 |206 226|platelet aggregation2 the data of K-depl
P09313755A0816 |35 49|risk variablesline phosphata
P09313755A0816 |15 25|clusteringComparison
P09313755A0816 |61 68|factorscleotid
P09314306A0571 |0 15|SupplementationP00001606T0076 
P09314306A0571 |52 56|g/dL and
P09314306A0571 |33 39|pl-ALBkaline
P09314487T0000 |0 9|DetectionP00001606
P09314487T0000 |52 66|air filtration and 5-nucleot
P09314487T0000 |22 48|Mycobacterium tuberculosisson with alkaline phosphat
P09314487T0000 |71 96|polymerase chain reaction P00008171T0000 Pharmacol
P09314537A1600 |6 14|findings606T0076
P09314537A1600 |61 82|ezrin binding proteincleotidase P00008171T
P09314537A1600 |25 30|EBP50 with
P09314554A0149 |234 272|influenza A PR/8/34 nucleoprotein genes are no longer displaced when compare
P09314554A0149 |208 222|reading framesthe data of K-
P09314554A0149 |182 190|epitopesas a fun
P09314554A0149 |75 78|AUG008
P09314554A0149 |97 110|reading framegic aspects o
P09314554A0149 |41 52|translationhosphatases
P09314554A0149 |158 170|presentationen CSF [HCO3
P09314570A0153 |119 129|repressionl hyperbil
P09314570A0153 |149 159|activities7A0472 Whe
P09314570A0153 |105 115|activationcts of neo
P09314570A0153 |15 23|proteinsComparis
P09314570A0153 |5 11|family1606T0
P09314570A0153 |67 81|gene promotersdase P00008171
P09314570A0153 |38 44|motifse phos
P09315631A1064 |0 8|DeletionP0000160
P09315631A1064 |67 73|yeastsdase P
P09315631A1064 |110 120|POR2 genesf neonatal
P09315631A1064 |79 88|deletions71T0000 P
P09315631A1064 |16 25|POR2 geneomparison
P09315631A1064 |168 177|degrees CO3-] is s
P09315631A1064 |101 105|POR1aspe
P09315631A1064 |203 213|delta por1PCO2 the d
P09315631A1064 |153 161|glycerol72 When 
P09315631A1064 |50 59|phenotypees and 5-
P09315631A1064 |221 228|mutants-deplet
P09315632A1137 |221 230|neoplasia-depleted
P09315632A1137 |23 34|observationon with alk
P09315632A1137 |40 50|expressionphosphatas
P09315632A1137 |130 141|fibroblastsrubinemia. 
P09315632A1137 |73 92|FGFR3 kinase domain00008171T0000 Pharm
P09315632A1137 |156 169|dysregulationWhen CSF [HCO
P09315632A1137 |173 178|FGFR3is sh
P09315632A1137 |207 211|role the
P09315633A0333 |98 105|factorsic aspe
P09315633A0333 |107 111|IRFss of
P09315633A0333 |60 68|homologyucleotid
P09315633A0333 |76 86|interferon08171T0000
P09315633A0333 |12 31|amino acid sequence76 Comparison with 
P09315633A0333 |39 43|gene pho
P09315651T0000 |0 11|InvolvementP00001606T0
P09315651T0000 |15 19|AP-2Comp
P09315651T0000 |23 33|regulationon with al
P09315651T0000 |41 52|R-FABP genehosphatases
P09315651T0000 |71 83|chick retina P00008171T0
P09315678A0278 |87 100|protein NAP57Pharmacologic
P09315678A0278 |73 76|rat000
P09315678A0278 |134 141|Nopp140nemia. 
P09315678A0278 |217 219|U.of
P09315678A0278 |9 14|Cbf5pT0076
P09315678A0278 |206 215|shuttling2 the dat
P09316937A0133 |21 29|organismison wit
P09316937A0133 |89 94|Vitekarmac
P09316937A0133 |63 76|discrepancieseotidase P000
P09316937A0133 |99 129|API 20E identification systemsc aspects of neonatal hyperbil
P09317131A0000 |0 2|IgP0
P09317131A0000 |46 55|cytokinesatases an
P09317131A0000 |97 105|CH genesgic aspe
P09317131A0000 |9 30|chain class switchingT0076 Comparison with
P09317131A0000 |65 78|transcriptiontidase P00008
P09317131A1332 |155 172|IgE germline gene When CSF [HCO3-]
P09317131A1332 |14 18|data Com
P09317131A1332 |36 69|NF kappa B2 nucleoprotein complexine phosphatases and 5-nucleotida
P09317131A1332 |131 141|activationubinemia. 
P09317131A1332 |99 104|STAT6c asp
P09317757T0000 |0 8|EXERCISEP0000160
P09317757T0000 |28 73|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALISth alkaline phosphatases and 5-nucleotidase P
P09317757T0000 |90 100|LOCOMOTIONrmacologic
P09317757T0000 |76 86|ENERGETICS08171T0000
P09317830T0000 |33 40|CICADASkaline 
P09317830T0000 |15 29|SONG FREQUENCYComparison wit
P09321406T0000 |101 110|chromatinaspects o
P09321406T0000 |58 78|Ty5 retrotransposons-nucleotidase P00008
P09321406T0000 |41 54|transcriptionhosphatases a
P09321406T0000 |4 30|pheromone response pathway01606T0076 Comparison with
P09321657A0439 |220 226|effectK-depl
P09321657A0439 |82 96|cox3 promoters0000 Pharmacol
P09321657A0439 |8 13|study6T007
P09321657A0439 |121 133|core elementhyperbilirub
P09321657A0439 |151 173|cox3 promoter activity0472 When CSF [HCO3-] 
P09321657A0439 |33 42|mutationskaline ph
P09321657A0439 |66 74|elementsidase P0
P09321657A0439 |184 201|element mutations a function of CS
P09321930A0567 |205 215|expressionO2 the dat
P09321930A0567 |63 66|APCeot
P09321930A0567 |149 159|mechanisms7A0472 Whe
P09321930A0567 |223 231|mutationepleted 
P09321930A0567 |262 277|binding proteinen compared to 
P09321930A0567 |217 220|LOEof 
P09321930A0567 |191 194|LOHtio
P09321930A0567 |23 45|tumor suppressor geneson with alkaline phosp
P09321930A0567 |53 56|p53and
P09321930A0567 |58 61|DCC-nu
P09321930A0567 |125 136|frequenciesrbilirubine
P09321930A0567 |197 201|lossf CS
P09321930A0567 |167 171|lossCO3-
P09321930A0567 |73 78|BRCA100008
P09321930A0567 |84 93|WAF1/CIP100 Pharma
P09321930A0567 |237 249|inactivationre no longer
P09321930A0567 |175 189|heterozygosity shown as a fu
P09321930A0567 |68 71|MCCase
P09322738A0510 |84 94|chromosome00 Pharmac
P09322738A0510 |21 25|geneison
P09322738A0510 |27 34|rpoCHISith alk
P09322738A0510 |116 127|S. lividansatal hyperb
P09322738A0510 |98 111|S. coelicoloric aspects of
P09322738A0510 |70 76|allelee P000
P09322872A0745 |34 41|TK genealine p
P09322872A0745 |12 20|deletion76 Compa
P09322872A0745 |105 118|recombinationcts of neonat
P09322872A0745 |43 52|selectionsphatases
P09322872A0745 |78 83|cells171T0
P09322872A0745 |58 69|gancyclovir-nucleotida
P09323366A0000 |4 24|malate synthase gene01606T0076 Compariso
P09323366A0000 |26 30|MLS1with
P09323366A0000 |129 142|growth mediumirubinemia. P
P09323366A0000 |108 121|carbon source of neonatal 
P09323366A0000 |39 44|yeast phos
P09323366A0299 |136 140|genemia.
P09323366A0299 |67 72|sitesdase 
P09323366A0299 |28 47|MLS1 control regionth alkaline phospha
P09323366A0299 |74 78|UAS10008
P09323366A0299 |3 20|deletion analysis001606T0076 Compa
P09323366A0299 |83 87|UAS2000 
P09323366A0299 |116 128|derepressionatal hyperbi
P09323612A0374 |85 88|use0 P
P09323612A0374 |226 232|speecheted r
P09323612A0374 |107 115|childrens of neo
P09323612A0374 |135 144|dysphasiaemia. P00
P09323612A0374 |31 38|studiesalkalin
P09323612A0374 |191 199|childrention of 
P09323612A0374 |42 69|sleep electroencephalogramsosphatases and 5-nucleotida
P09323612A0374 |92 102|medicationacologic a
P09323612A0374 |167 187|treatment strategiesCO3-] is shown as a 
P09323612A0374 |237 255|language disordersre no longer displ
P09323612A0374 |71 74|EEG P0
P09323612A0374 |0 4|LackP000
P09324720A0317 |54 60|Alzoonnd 5-n
P09324720A0317 |22 27|timesson w
P09324720A0317 |9 14|mealsT0076
P09324720A0317 |39 50|tablespoons phosphatas
P09324878A0952 |33 37|wallkali
P09324878A0952 |135 152|type B dissectionemia. P00008997A0
P09324878A0952 |44 66|ultrasound examinationphatases and 5-nucleot
P09324878A0952 |97 106|diagnosisgic aspec
P09324922T0065 |0 20|Fermentation processP00001606T0076 Compa
P09324922T0065 |96 100|acidogic
P09324922T0065 |27 42|supplementationith alkaline ph
P09324922T0065 |71 84|acid bacteria P00008171T00
P09324988X0000 |51 57|laminss and 
P09324988X0000 |83 91|proteins000 Phar
P09324988X0000 |23 26|p21on 
P09324988X0000 |28 31|rasth 
P09324988X0000 |33 41|proteinskaline p
P09324988X0000 |65 71|seriestidase
P09324988X0000 |0 10|SubstratesP00001606T
P09325022A0192 |51 60|CD-1 mices and 5-n
P09325022A0192 |14 21|animals Compar
P09325022A0192 |131 137|micromubinem
P09325022A0192 |40 47|studiesphospha
P09325022A0192 |26 31|groupwith 
P09325022A0192 |89 101|C57BL/6 micearmacologic 
P09325022A0192 |81 84|C3HT00
P09325022A0192 |67 72|studydase 
P09325022A0192 |0 7|OvariesP000016
P09325135A0737 |87 94|proteinPharmac
P09325135A0737 |11 25|fusion protein076 Comparison
P09325135A0737 |59 60|%n
P09325273A1240 |343 368|ubiquitin fusion proteins23 vs. P00010943A0733 Flu
P09325273A1240 |55 59|roled 5-
P09325273A1240 |80 89|ubiquitin1T0000 Ph
P09325273A1240 |260 269|ubiquitinwhen comp
P09325273A1240 |93 103|hydrolysiscologic as
P09325273A1240 |27 32|UBP41ith a
P09325273A1240 |329 337|proteinse (1.21 
P09325273A1240 |241 251|productiono longer d
P09325273A1240 |67 76|recyclingdase P000
P09325273A1240 |282 303|poly-ubiquitin chainsols but still have a 
P09325273A1240 |116 137|poly-ubiquitin chainsatal hyperbilirubinem
P09325273A1240 |155 161|action When 
P09325273A1240 |6 13|results606T007
P09325273A1240 |203 221|protein substratesPCO2 the data of K
P09325273A1240 |168 180|S proteasomeO3-] is show
P09325278A0458 |204 211|regionsCO2 the
P09325278A0458 |124 127|raterb
P09325278A0458 |56 79|ER1 amino acid sequence 5-nucleotidase P000081
P09325278A0458 |106 116|similarityts of neon
P09325278A0458 |284 288|mta1s bu
P09325278A0458 |190 194|mta1ctio
P09325278A0458 |233 264|Caenorhabditis elegans sequencets are no longer displaced when
P09325278A0458 |95 102|regionslogic a
P09325278A0458 |215 225|similaritya of K-dep
P09325278A0458 |2 27|data base homology search0001606T0076 Comparison w
P09325278A0458 |138 146|proteinsa. P0000
P09325278A0458 |184 188|gene a f
P09325284A0469 |55 56|%d
P09325284A0469 |40 52|acid proteinphosphatases
P09325284A0469 |14 18|cDNA Com
P09325284A0469 |76 92|progelatinase B.08171T0000 Pharm
P09325322A1293 |84 89|shift00 Ph
P09325322A1293 |93 97|EC50colo
P09325322A1293 |28 31|Ca2th 
P09325322A1293 |61 74|cooperativitycleotidase P0
P09325322A1293 |4 14|inhibition01606T0076
P09325322A1293 |112 132|InsP3 concentrationsneonatal hyperbiliru
P09325322A1293 |49 57|decreaseses and 
P09326163A0942 |0 7|RESULTSP000016
P09326163A0942 |26 41|mortality ratiowith alkaline p
P09326163A0942 |66 75|neoplasmsidase P00
P09326163A0942 |43 46|SMRsph
P09326163A0942 |86 90|% CI Pha
P09326246A0567 |119 125|levelsl hype
P09326246A0567 |129 148|luciferase activityirubinemia. P000089
P09326246A0567 |161 180|bp reporter plasmidCSF [HCO3-] is show
P09326246A0567 |26 32|regionwith a
P09326246A0567 |0 17|Sequence analysisP00001606T0076 Co
P09326246A0567 |82 90|deletion0000 Pha
P09326246A0567 |68 76|elementsase P000
P09326263A0410 |98 103|brainic as
P09326263A0410 |83 92|sequences000 Pharm
P09326263A0410 |52 65|methodologies and 5-nucleo
P09326263A0410 |25 42|transcription-PCR with alkaline ph
P09326263A0410 |181 186|exons as a
P09326263A0410 |269 271|1Bar
P09326263A0410 |132 140|materialbinemia.
P09326263A0410 |44 50|RT-PCRphatas
P09326263A0410 |225 229|exonlete
P09326263A0410 |263 267|exonn co
P09326263A0410 |231 233|1Ara
P09326263A0410 |108 116|placenta of neon
P09326263A0410 |8 12|RACE6T00
P09326317A0372 |84 88|EXT100 P
P09326317A0372 |93 103|EXT2 genescologic as
P09326317A0372 |33 51|mutation screeningkaline phosphatase
P09326317A0372 |18 23|studyparis
P09326317A0372 |117 133|linkage analysistal hyperbilirub
P09326727T0000 |4 17|regurgitation01606T0076 Co
P09326727T0000 |36 46|injectionsine phosph
P09327881T0000 |102 110|primatesspects o
P09327881T0000 |72 79|studiesP000081
P09327881T0000 |46 67|dopamine transportersatases and 5-nucleoti
P09327881T0000 |0 41|Positron emission tomography radioligandsP00001606T0076 Comparison with alkaline p
P09328341A1449 |0 11|AttenuationP00001606T0
P09328341A1449 |74 85|DNA binding0008171T000
P09328341A1449 |159 174|transactivationn CSF [HCO3-] i
P09328341A1449 |93 120|TR alpha DNA binding mutantcologic aspects of neonatal
P09328341A1449 |21 41|vit A2 consensus EREison with alkaline p
P09328343A0181 |0 10|ExpressionP00001606T
P09328343A0181 |128 136|proteinslirubine
P09328343A0181 |177 183|familyhown a
P09328343A0181 |107 110|E2As o
P09328343A0181 |157 164|membershen CSF
P09328343A0181 |59 74|protein complexnucleotidase P0
P09328343A0181 |21 28|elementison wi
P09328349A1679 |86 96|expression Pharmacol
P09328349A1679 |45 60|characteristicshatases and 5-n
P09328349A1679 |10 19|CCAAT box0076 Comp
P09328349A1679 |104 122|alpha-subunit geneects of neonatal h
P09328349A1679 |126 138|trophoblastsbilirubinemi
P09328476A0068 |51 68|ribonucleoproteins and 5-nucleotid
P09328476A0068 |88 90|U1ha
P09328476A0068 |96 98|U5og
P09328476A0068 |92 94|U2ac
P09328476A0068 |77 86|particles8171T0000
P09328476A0068 |125 136|spliceosomerbilirubine
P09328476A0068 |103 108|U4/U6pects
P09328476A0068 |70 75|snRNPe P00
P09328476A0068 |0 11|U4/U6 snRNPP00001606T0
P09328476A0374 |0 6|Hprp3pP00001
P09328476A0374 |15 26|kDa proteinComparison 
P09328476A0374 |80 101|splicing factor Prp3p1T0000 Pharmacologic 
P09328824A0000 |137 142|alphaia. P
P09328824A0000 |192 202|repressionion of CSF
P09328824A0000 |224 229|rolesplete
P09328824A0000 |99 131|chicken thyroid hormone receptorc aspects of neonatal hyperbilir
P09328824A0000 |233 235|TRts
P09328824A0000 |249 263|acid receptors displaced whe
P09328824A0000 |133 135|TRin
P09328824A0000 |50 65|v-erbA oncogenees and 5-nucleo
P09328824A0000 |21 31|propertiesison with 
P09328824A0000 |84 91|version00 Phar
P09328833A0588 |51 69|MCF-7 cDNA librarys and 5-nucleotida
P09328833A0588 |39 42|HET ph
P09328833A0588 |31 33|kbal
P09328833A0588 |21 25|cDNAison
P09331119A0659 |50 66|thrombocytopeniaes and 5-nucleot
P09331119A0659 |24 32|toxicityn with a
P09331119A0659 |106 112|cyclests of 
P09331119A0659 |72 84|parasthesiasP00008171T00
P09331119A0659 |101 102|%a
P09331119A0659 |37 48|neutropeniane phosphat
P09331119A0659 |16 21|gradeompar
P09331864A0230 |0 20|Serum concentrationsP00001606T0076 Compa
P09331864A0230 |31 35|TBOHalka
P09331864A0230 |120 127|heifers hyperb
P09331864A0230 |241 246|mg E2o lon
P09331864A0230 |252 261|Revalor-Hsplaced w
P09331864A0230 |155 165|treatments When CSF 
P09331864A0230 |190 192|mgct
P09331864A0230 |53 54|da
P09331864A0230 |24 26|E2n 
P09331864A0230 |264 267|MGA co
P09331864A0230 |214 223|Revalor-Hta of K-d
P09331864A0230 |182 185|MGAas 
P09331864A0230 |197 203|heiferf CSF 
P09331864A0230 |229 235|mg TBAd rats
P09331864A0230 |317 320|MGAgre
P09331864A0230 |288 294|mg TBAt stil
P09331864A0230 |170 177|control-] is s
P09331864A0230 |272 282|Finaplix-Hd to contr
P09331864A0230 |304 314|Finaplix-Hignificant
P09331864A0848 |0 23|Serum E2 concentrationsP00001606T0076 Comparis
P09331864A0848 |97 100|MGAgic
P09331864A0848 |133 136|MGAine
P09331864A0848 |69 70|ds
P09331864A0848 |116 124|controlsatal hyp
P09331864A0848 |84 92|controls00 Pharm
P09333018A0000 |0 10|InterferonP00001606T
P09333018A0000 |30 33|IRF al
P09333018A0000 |22 28|Factorson wi
P09333018A0000 |76 82|growth08171T
P09333018A0000 |115 135|transcription factornatal hyperbilirubin
P09333026A0397 |169 179|divergence3-] is sho
P09333026A0397 |12 21|structure76 Compar
P09333026A0397 |104 122|PTK family membersects of neonatal h
P09333026A0397 |43 48|exonssphat
P09333026A0397 |56 66|boundaries 5-nucleot
P09333026A0397 |25 28|brk wi
P09333026A0851 |170 176|growth-] is 
P09333026A0851 |148 157|anchorage97A0472 W
P09333026A0851 |133 138|cellsinemi
P09333026A0851 |64 72|brk cDNAotidase 
P09333026A0851 |76 81|mouse08171
P09333026A0851 |92 103|fibroblastsacologic as
P09333026A0851 |244 257|growth factoronger displac
P09333026A0851 |49 55|tumourses an
P09333026A0851 |33 43|expressionkaline pho
P09333026A0851 |222 230|responsedepleted
P09333168A0310 |0 22|Anti-hepatitis A virusP00001606T0076 Compari
P09333168A0310 |105 108|mencts
P09333168A0310 |41 52|vaccinationhosphatases
P09333168A0310 |29 34|titerh alk
P09333168A0310 |24 27|HAVn w
P09333231T0018 |21 28|speciesison wi
P09333231T0018 |4 9|skull01606
P09334264A0540 |117 120|kDatal
P09334264A0540 |14 30|calf thymus CstF Comparison with
P09334264A0540 |106 110|massts o
P09334264A0540 |62 66|formleot
P09334264A0540 |81 88|subunitT0000 P
P09334330A0252 |33 42|mutationskaline ph
P09334330A0252 |18 23|daf-3paris
P09334330A0252 |253 264|developmentplaced when
P09334330A0252 |113 146|Smad signal transduction proteinseonatal hyperbilirubinemia. P0000
P09334330A0252 |219 223|DPC4 K-d
P09334330A0252 |148 153|daf-397A04
P09334330A0252 |314 331|dauer developmently greater slope 
P09334330A0252 |46 51|genesatase
P09334330A0252 |164 176|Smad protein [HCO3-] is 
P09334330A0252 |87 96|receptorsPharmacol
P09334330A0252 |66 81|TGF-beta signalidase P00008171
P09334330A0252 |280 287|tissuestrols b
P09334330A0252 |5 14|mutations1606T0076
P09334331A0910 |118 126|receptoral hyper
P09334331A0910 |93 102|EMA cellscologic a
P09334331A0910 |131 135|Veinubin
P09334331A0910 |54 75|EGF receptor DER/Egfrnd 5-nucleotidase P00
P09334331A0910 |22 33|possibilityson with al
P09334331A0910 |4 11|results01606T0
P09334475A0327 |0 8|PATIENTSP0000160
P09334475A0327 |211 214|min da
P09334475A0327 |164 181|segment elevation [HCO3-] is shown
P09334475A0327 |223 230|CK riseepleted
P09334475A0327 |320 332|thrombolysisater slope (
P09334475A0327 |189 190|%n
P09334475A0327 |266 273|infarctompared
P09334475A0327 |246 262|T wave inversionger displaced wh
P09334475A0327 |146 156|chest pain8997A0472 
P09334475A0327 |240 241|hn
P09334475A0327 |41 49|patientshosphata
P09334475A0327 |13 20|METHODS6 Compa
P09334475A0327 |132 142|resolutionbinemia. P
P09334475A0327 |105 115|Infarctioncts of neo
P09334475A0327 |312 313|hn
P09334475A0327 |282 285|EKGols
P09334475A0327 |67 84|National Registrydase P00008171T00
P09335267A0142 |186 195|mutations function
P09335267A0142 |15 31|operon structureComparison with 
P09335267A0142 |213 219|genomeata of
P09335267A0142 |40 48|organismphosphat
P09335267A0142 |62 69|methodsleotida
P09335267A0142 |90 101|mutagenesisrmacologic 
P09335267A0142 |158 163|genesen CS
P09335267A0142 |110 114|riskf ne
P09335267A0142 |136 143|effectsmia. P0
P09335298A0529 |54 81|plasmid partitioning systemnd 5-nucleotidase P00008171
P09335298A0529 |30 43|parCBA operon alkaline pho
P09335298A0529 |83 85|M.00
P09335298A1227 |34 48|ColE1 cer sitealine phosphat
P09335298A1227 |121 128|plasmidhyperbi
P09335298A1227 |90 96|regionrmacol
P09335298A1227 |172 200|multimer resolution activity is shown as a function of C
P09335298A1227 |212 218|parCBAdata o
P09335298A1227 |297 303|operonave a 
P09335298A1227 |58 69|RK2 plasmid-nucleotida
P09335298A1227 |136 150|MC1061K strainmia. P00008997
P09335298A1227 |256 278|stabilization activityced when compared to c
P09335298A1227 |17 26|insertionmparison 
P09335298A2129 |103 110|strainspects o
P09335298A2129 |213 231|ParE toxin proteinata of K-depleted 
P09335298A2129 |198 205|strains CSF PC
P09335298A2129 |177 190|sensitivitieshown as a fun
P09335298A2129 |15 20|basisCompa
P09335298A2129 |38 49|differencese phosphata
P09335298A2129 |112 133|transformation assaysneonatal hyperbilirub
P09335298A2129 |71 78|killing P00008
P09335608T0000 |69 77|splicingse P0000
P09335608T0000 |109 130|chain gene transcriptof neonatal hyperbili
P09335608T0000 |38 47|sequencese phospha
P09335608T0000 |96 102|myosinogic a
P09335608T0000 |16 24|elementsompariso
P09335619A0583 |0 28|Nucleotide sequence analysisP00001606T0076 Comparison wi
P09335619A0583 |107 118|maize racess of neonat
P09335619A0583 |254 262|sequencelaced wh
P09335619A0583 |295 306|orf221 gene have a sig
P09335619A0583 |145 155|M1 plasmid08997A0472
P09335619A0583 |179 182|Zeawn 
P09335619A0583 |124 136|RU cytoplasmerbilirubine
P09335619A0583 |210 214|atp9e da
P09335619A0583 |67 77|R1 plasmiddase P0000
P09335619A0583 |229 233|gened ra
P09335619A0583 |193 201|teosinteon of CS
P09335619A0583 |47 59|similaritiestases and 5-
P09335619A0583 |169 175|source3-] is
P09335619A0583 |278 284|regionontrol
P09335619A0583 |32 33|Rl
P09336455A0000 |152 161|radiation472 When 
P09336455A0000 |91 101|RNR3 genesmacologic 
P09336455A0000 |120 131|yeast cells hyperbilir
P09336455A0000 |37 45|recoveryne phosp
P09336455A0000 |108 116|exposure of neon
P09336455A0000 |148 150|UV97
P09336455A0000 |135 146|ultravioletemia. P0000
P09336455A0000 |81 86|GAL10T0000
P09336455A0000 |21 29|kineticsison wit
P09336455A0000 |49 63|mRNA synthesisses and 5-nucl
P09337861T0000 |0 7|CloningP000016
P09337861T0000 |52 61|C2 domain and 5-nu
P09337861T0000 |84 95|sensitivity00 Pharmaco
P09337861T0000 |19 44|phosphoinositide 3-kinasearison with alkaline phos
P09337861T0000 |103 123|inhibitor wortmanninpects of neonatal hy
P09338414A0430 |0 8|Ea valueP0000160
P09338414A0430 |77 85|pressure8171T000
P09338414A0430 |31 36|ratioalkal
P09338414A0430 |96 109|stroke volumeogic aspects 
P09338414A0430 |111 125|thermodilution neonatal hype
P09338414A0430 |87 91|ESAPPhar
P09339900A0939 |70 79|cyclin D2e P000081
P09339900A0939 |157 162|c-Mychen C
P09339900A0939 |23 40|promoter activityon with alkaline 
P09339900A0939 |146 149|AP2899
P09339900A0939 |209 217|activityhe data 
P09339900A0939 |60 66|regionucleot
P09339900A0939 |151 155|NF-Y0472
P09339900A0939 |140 144|PEA3 P00
P09339900A0939 |11 19|analysis076 Comp
P09339900A0939 |133 138|C/EBPinemi
P09339900A0939 |222 232|expressiondepleted r
P09339900A0939 |168 171|Sp1O3-
P09339900A0939 |99 105|regionc aspe
P09339900A0939 |236 245|cyclin D2are no lo
P09340641T0001 |0 6|EffectP00001
P09340641T0001 |10 17|alcohol0076 Co
P09340641T0001 |39 53|nCPAP pressure phosphatases 
P09341139A0690 |137 141|GRK2ia. 
P09341139A0690 |57 71|beta2AR mutant5-nucleotidase
P09341139A0690 |73 78|Y326A00008
P09341139A0690 |13 28|resensitization6 Comparison wi
P09341139A0690 |112 126|overexpressionneonatal hyper
P09341139A0690 |145 158|beta-arrestin08997A0472 Wh
P09341139A0690 |3 11|contrast001606T0
P09341158A0167 |119 124|beta1l hyp
P09341158A0167 |177 188|recognitionhown as a f
P09341158A0167 |79 84|types71T00
P09341158A0167 |46 49|mu2ata
P09341158A0167 |88 99|interactionharmacologi
P09341158A0167 |4 17|medium chains01606T0076 Co
P09341158A0167 |163 172|complexesF [HCO3-]
P09341158A0167 |129 141|beta2 chainsirubinemia. 
P09341158A0167 |27 36|complexesith alkal
P09341158A0167 |101 109|assemblyaspects 
P09341158A0167 |38 41|mu1e p
P09341158A0167 |207 222|sorting signals the data of K-
P09341182A0605 |69 83|BTB/POZ domainse P00008171T0
P09341182A0605 |89 93|PLZFarma
P09341182A0605 |95 107|PLZF-BTB/POZlogic aspect
P09341192T0000 |48 64|3T3L1 adipocytesases and 5-nucle
P09341192T0000 |25 44|GLUT4 translocation with alkaline phos
P09341192T0000 |8 13|shock6T007
P09341192T0000 |76 99|tyrosine kinase pathway08171T0000 Pharmacologi
P09341193A0362 |102 106|TRE1spec
P09341193A0362 |24 27|Sp3n w
P09341193A0362 |121 139|Tax responsivenesshyperbilirubinemia
P09341193A0362 |19 22|Sp1ari
P09341193A0362 |33 43|NGFI-A/Egrkaline pho
P09341193A0362 |69 90|transcription factorsse P00008171T0000 Pha
P09343208A1405 |139 151|organization. P00008997A
P09343208A1405 |60 71|copy numberucleotidase
P09343208A1405 |15 22|segmentCompari
P09343208A1405 |197 206|functionsf CSF PCO
P09343208A1405 |92 101|segment Wacologic 
P09343208A1405 |215 220|virusa of 
P09343208A1405 |75 80|genes00817
P09343208A1405 |276 281|wasps cont
P09343208A1405 |249 260|association displaced 
P09343208A1405 |155 159|PDVs Whe
P09343210A1112 |51 66|VCAM-1 promoters and 5-nucleot
P09343210A1112 |13 21|deletion6 Compar
P09343210A1112 |318 328|expressionreater slo
P09343210A1112 |194 209|NF-kappaB sitesn of CSF PCO2 t
P09343210A1112 |337 354|adhesion molecule+/- 0.23 vs. P000
P09343210A1112 |82 126|chloramphenicol acetyltransferase constructs0000 Pharmacologic aspects of neonatal hyper
P09343210A1112 |26 43|mutation analyseswith alkaline pho
P09343210A1112 |243 263|VCAM-1 gene promoterlonger displaced whe
P09343210A1112 |170 185|VCAM-1 promoter-] is shown as 
P09343210A1112 |141 144|TaxP00
P09343210A1112 |221 223|bp-d
P09343222A0415 |68 69|%a
P09343222A0415 |12 41|NIH/Swiss mouse CCR5 proteins76 Comparison with alkaline p
P09343222A0415 |93 100|proteincologic
P09343222A0415 |58 59|%-
P09343222A0415 |4 7|AGM016
P09343398A1193 |0 12|ProcessivityP00001606T00
P09343398A1193 |44 54|holoenzymephatases a
P09343398A1193 |97 99|dAgi
P09343398A1193 |179 188|structurewn as a f
P09343398A1193 |92 96|polyacol
P09343398A1193 |109 111|dTof
P09343398A1193 |155 163|template When CS
P09343398A1193 |66 73|pcna-79idase P
P09343398A1193 |16 29|DNA synthesisomparison wit
P09343426A0456 |0 30|Alanine substitution mutationsP00001606T0076 Comparison with
P09343426A0456 |91 94|Ztamac
P09343426A0456 |80 87|ability1T0000 
P09343426A0456 |112 123|D-A complexneonatal hy
P09343426A0456 |38 59|Zta activation domaine phosphatases and 5-
P09343432A0209 |32 47|homology domainlkaline phospha
P09343432A0209 |158 167|C terminien CSF [H
P09343432A0209 |110 120|SPM domainf neonatal
P09343432A0209 |12 23|ph proteins76 Comparis
P09343432A0209 |73 79|length000081
P09343432A0209 |55 65|% identityd 5-nucleo
P09343432A0209 |4 7|Scm016
P09343432A0209 |86 97|amino acids Pharmacolo
P09343433A0000 |34 39|genesaline
P09343433A0000 |74 78|RNAP0008
P09343433A0000 |144 159|yeast telomeres008997A0472 Whe
P09343433A0000 |107 125|effect variegations of neonatal hype
P09343433A0000 |55 69|RNA polymerased 5-nucleotida
P09343433A0360 |98 102|ADE2ic a
P09343433A0360 |29 38|silencingh alkalin
P09343433A0360 |10 20|rad6-delta0076 Compa
P09343433A0360 |63 67|RNAPeoti
P09343433A0360 |83 93|genes URA3000 Pharma
P09343982A0890 |17 38|detrusor contractionsmparison with alkalin
P09343982A0890 |56 61|hours 5-nu
P09343982A0890 |4 13|amplitude01606T007
P09343982A0890 |112 120|controlsneonatal
P09343982A0890 |84 94|difference00 Pharmac
P09344650A0967 |17 37|transmembrane domainmparison with alkali
P09344650A0967 |52 60|Casr-rs3 and 5-n
P09344650A0967 |82 90|Casr-rs10000 Pha
P09344650A0967 |67 68|%d
P09344650A0967 |39 47|Casr-rs2 phospha
P09345037A0886 |57 76|trans-factor GATA-15-nucleotidase P000
P09345037A0886 |91 120|progenitor cell proliferationmacologic aspects of neonatal
P09345037A0886 |10 15|roles0076 
P09345495A0000 |0 22|PET activation studiesP00001606T0076 Compari
P09345495A0000 |59 73|brain functionnucleotidase P
P09346238T0000 |19 28|receptorsarison wi
P09346238T0000 |57 67|substrates5-nucleoti
P09346238T0000 |75 103|SCF ubiquitin-ligase complex008171T0000 Pharmacologic as
P09346238T0000 |6 14|proteins606T0076
P09346621A1181 |103 111|patientspects of
P09346621A1181 |7 14|context06T0076
P09346621A1181 |125 132|failurerbiliru
P09346621A1181 |148 151|OSF97A
P09346621A1181 |72 75|ELTP00
P09346621A1181 |18 42|liver allograft shortageparison with alkaline ph
P09346621A1181 |159 168|APACHE IIn CSF [HC
P09346621A1181 |48 55|resultsases an
P09346925A0660 |19 23|Grb2aris
P09346925A0660 |159 163|HPK1n CS
P09346925A0660 |179 189|Cos1 cellswn as a fu
P09346925A0660 |78 87|HPK1 tail171T0000 
P09346925A0660 |151 155|Grb20472
P09346925A0660 |4 15|SH3 domains01606T0076 
P09346925A0660 |140 147|binding P00008
P09346925A0660 |64 70|motifsotidas
P09346935A0459 |236 240|formare 
P09346935A0459 |79 84|ZNF7471T00
P09346935A0459 |28 57|coimmunoprecipitation studiesth alkaline phosphatases and 
P09346935A0459 |104 122|zinc finger domainects of neonatal h
P09346935A0459 |15 23|analysisComparis
P09346935A0459 |172 186|RNA polymerase is shown as a
P09346935A0459 |161 168|subunitCSF [HC
P09346935A0459 |191 198|pol IIotion of
P09346935A0927 |239 254|mRNA processing no longer disp
P09346935A0927 |178 182|formown 
P09346935A0927 |266 270|roleompa
P09346935A0927 |92 112|RNA binding activityacologic aspects of 
P09346935A0927 |146 157|interaction8997A0472 W
P09346935A0927 |329 343|RNA processinge (1.21 +/- 0.
P09346935A0927 |167 174|pol IIoCO3-] i
P09346935A0927 |190 204|RNA polymerasection of CSF P
P09346935A0927 |294 325|KRAB multifinger protein familyl have a significantly greater 
P09346935A0927 |59 86|pre-mRNA maturating factorsnucleotidase P00008171T0000
P09346935A0927 |6 27|ZNF74 sublocalization606T0076 Comparison w
P09346935A0927 |280 286|membertrols 
P09346935A0927 |39 46|domains phosph
P09346938A1680 |0 33|Ki-ras4BVal-12 transfectant cellsP00001606T0076 Comparison with al
P09346938A1680 |146 173|cathepsin B mRNA expression8997A0472 When CSF [HCO3-] 
P09346938A1680 |60 74|protein levelsucleotidase P0
P09346938A1680 |92 121|cysteine protease cathepsin Bacologic aspects of neonatal 
P09346953A0000 |35 63|heparan sulfate proteoglycanline phosphatases and 5-nucl
P09346953A0000 |149 157|activity7A0472 W
P09346953A0000 |13 17|rate6 Co
P09346953A0000 |74 84|generation0008171T00
P09346953A0000 |65 72|HSPGacttidase 
P09346953A0000 |159 184|HSact conversion activityn CSF [HCO3-] is shown as
P09346953A0000 |298 305|Shworakve a si
P09346953A0000 |106 111|levelts of
P09346953A0000 |290 295|3-OSTstill
P09346953A0000 |237 288|heparan sulfate D-glucosaminyl 3-O-sulfotransferasere no longer displaced when compared to controls bu
P09346953A0000 |307 309|N.if
P09348226A0852 |48 72|tyrosine phosphorylationases and 5-nucleotidase 
P09348226A0852 |90 101|associationrmacologic 
P09348226A0852 |15 18|EGFCom
P09348226A0852 |107 113|Crk-IIs of n
P09348226A0852 |28 35|insulinth alka
P09348226A0852 |76 81|c-cbl08171
P09348931T0000 |3 6|end001
P09348931T0000 |14 21|lottery Compar
P09349501A0196 |117 126|MLL-LTG19tal hyper
P09349501A0196 |41 48|portionhosphat
P09349501A0196 |209 213|rolehe d
P09349501A0196 |104 112|MLL-LTG9ects of 
P09349501A0196 |76 88|MLL products08171T0000 P
P09349501A0196 |145 151|nuclei08997A
P09349501A0196 |217 231|leukemogenesisof K-depleted 
P09349967A0653 |4 11|results01606T0
P09349967A0653 |29 36|patternh alkal
P09349967A0653 |40 52|blood supplyphosphatases
P09349967A0653 |106 119|lamellar bonets of neonata
P09349967A0653 |83 95|organisation000 Pharmaco
P09351242A0719 |171 184|cycloheximide] is shown as
P09351242A0719 |13 38|AtP5CS1 mRNA accumulation6 Comparison with alkalin
P09351242A0719 |55 64|seedlingsd 5-nucle
P09351242A0719 |131 145|ABA signallingubinemia. P000
P09351242A0719 |245 268|aba1 Arabidopsis mutantnger displaced when com
P09351242A0719 |109 117|responseof neona
P09351242A0719 |221 237|ABA biosynthesis-depleted rats a
P09351242A0719 |207 217|deficiency the data 
P09351242A0719 |0 9|InductionP00001606
P09351823A0414 |85 89|eggs0 Ph
P09351823A0414 |127 138|developmentilirubinemi
P09351823A0414 |47 57|maturationtases and 
P09351823A0414 |21 35|MAPK functionsison with alka
P09352016A1110 |34 36|mlal
P09352016A1110 |30 32|pg a
P09352016A1110 |8 22|AF G-CSF level6T0076 Compari
P09352016A1110 |58 67|predictor-nucleoti
P09352016A1110 |71 74|CAM P0
P09352127A0953 |51 72|CA III concentrationss and 5-nucleotidase 
P09352127A0953 |11 22|correlation076 Compari
P09352127A0953 |74 76|rs00
P09352127A0953 |31 46|serum myoglobinalkaline phosph
P09352127A0953 |86 87|P 
P09352127A0953 |126 134|patientsbilirubi
P09352127A0953 |154 161|failure2 When 
P09353247A0922 |68 76|p65cdc18ase P000
P09353247A0922 |111 130|cyclin/CDK activity neonatal hyperbili
P09353247A0922 |153 169|over-replication72 When CSF [HCO
P09353247A0922 |140 149|inhibitor P0000899
P09353247A0922 |17 43|over-replication phenotypemparison with alkaline pho
P09353255A0159 |119 132|pore proteinsl hyperbiliru
P09353255A0159 |94 115|FG-nucleoporin familyologic aspects of neo
P09353255A0159 |46 60|pore complexesatases and 5-n
P09353255A0159 |0 5|Rip1pP0000
P09353296A0510 |34 50|amino acid levelaline phosphatas
P09353296A0510 |131 143|moaC productubinemia. P0
P09353296A0510 |193 201|cistronson of CS
P09353296A0510 |75 92|moaA gene product008171T0000 Pharm
P09353296A0510 |4 15|CNXA domain01606T0076 
P09353296A0510 |163 171|productsF [HCO3-
P09353296A0510 |100 104|CNXC asp
P09353304A0732 |68 73|Tiam1ase P
P09353304A0732 |27 34|regionsith alk
P09353304A0732 |43 64|membrane localizationsphatases and 5-nucle
P09353304A0732 |78 95|membrane ruffling171T0000 Pharmaco
P09353304A0732 |0 9|DeletionsP00001606
P09353328A0736 |38 44|domaine phos
P09353328A0736 |75 82|zippers008171T
P09353328A0736 |129 137|proteinsirubinem
P09353328A0736 |109 117|homologyof neona
P09353328A0736 |21 27|kinaseison w
P09353343A0919 |0 14|RNA polymeraseP00001606T0076
P09353343A0919 |135 151|hnRNP A1 bindingemia. P00008997A
P09353343A0919 |59 72|AUBP activitynucleotidase 
P09353343A0919 |111 119|hnRNP A1 neonata
P09353343A0919 |43 50|bindingsphatas
P09353343A0919 |78 82|poly171T
P09353343A0919 |18 28|inhibitionparison wi
P09353343A0919 |83 84|U0
P09353343A0919 |86 95|Sepharose Pharmaco
P09353343T0000 |0 10|ModulationP00001606T
P09353343T0000 |70 90|ribonucleoprotein A1e P00008171T0000 Pha
P09353343T0000 |14 44|AUUUA response element binding Comparison with alkaline phos
P09353343T0000 |100 113|T lymphocytes aspects of n
P09354349A0338 |118 124|Giemsaal hyp
P09354349A0338 |13 19|slides6 Comp
P09354349A0338 |135 149|Warthin-Starryemia. P0000899
P09354349A0338 |151 153|WS04
P09354349A0338 |126 128|MGbi
P09354349A0338 |27 33|biopsyith al
P09354349A0338 |243 252|DAKO B471longer di
P09354349A0338 |183 189|methods a fu
P09354349A0338 |191 194|IMMtio
P09354349A0338 |42 49|patientosphata
P09354349A0338 |222 241|H. pylori antiserumdepleted rats are n
P09354644A0124 |103 108|IGnT6pects
P09354644A0124 |74 101|beta1,6-GlcNAc transferases0008171T0000 Pharmacologic 
P09354644A0124 |120 123|Gal hy
P09354644A0124 |6 18|biosynthesis606T0076 Com
P09354644A0124 |110 116|GlcNAcf neon
P09354644A0124 |39 49|precursors phosphata
P09354676A1714 |49 52|q32ses
P09354676A1714 |160 166|target CSF [
P09354676A1714 |227 229|MMte
P09354676A1714 |210 223|tumorigenesise data of K-d
P09354676A1714 |113 115|MMeo
P09354676A1714 |96 109|translocationogic aspects 
P09354676A1714 |6 14|findings606T0076
P09354676A1714 |42 47|p16.3ospha
P09354676A1714 |33 34|tk
P09354676A1714 |175 186|abnormality shown as a
P09354676A1714 |138 148|FGFR3 genea. P000089
P09354684A1158 |3 11|addition001606T0
P09354684A1158 |29 37|Sp1 siteh alkali
P09354684A1158 |13 21|mutation6 Compar
P09354684A1158 |65 82|promoter activitytidase P00008171T
P09354757A1444 |0 19|Amino acid residuesP00001606T0076 Comp
P09354757A1444 |60 64|loopucle
P09354757A1444 |76 82|His53908171T
P09354757A1444 |42 49|alpha Bosphata
P09354757A1444 |123 136|primer strandperbilirubine
P09354757A1444 |90 104|RNase H domainrmacologic asp
P09354757A1444 |23 27|betaon w
P09354757A1444 |144 149|dsDNA00899
P09354757A1444 |32 39|alpha Alkaline
P09356645A0672 |68 77|procedurease P0000
P09356645A0672 |32 39|sarcomalkaline
P09356645A0672 |90 107|nerve enlargementrmacologic aspect
P09356645A0672 |17 24|patientmpariso
P09358045A0000 |85 93|receptor0 Pharma
P09358045A0000 |9 29|length cDNA sequenceT0076 Comparison wit
P09358045A0000 |75 83|TGF-beta008171T0
P09358045A0000 |55 73|growth factor-betad 5-nucleotidase P
P09358045A0000 |140 163|nematode Brugia pahangi P00008997A0472 When CS
P09358045A0000 |35 39|Typeline
P09358055A0590 |101 104|LTRasp
P09358055A0590 |108 113|mouse of n
P09358055A0590 |130 141|A-particlesrubinemia. 
P09358055A0590 |62 78|promoter elementleotidase P00008
P09358055A0590 |5 13|sequence1606T007
P09358055A0590 |24 32|homologyn with a
P09358055A0590 |80 84|Enh21T00
P09358069T0000 |34 44|expressionaline phos
P09358069T0000 |88 93|cellsharma
P09358069T0000 |70 73|EPOe P
P09358069T0000 |54 68|erythropoietinnd 5-nucleotid
P09358069T0000 |0 18|Codon optimizationP00001606T0076 Com
P09358837T0000 |49 58|treatmentses and 5
P09358837T0000 |12 16|rise76 C
P09358837T0000 |28 42|albumin levelsth alkaline ph
P09358837T0000 |72 84|hypertensionP00008171T00
P09359844A0674 |51 61|adipocytess and 5-nu
P09359844A0674 |13 28|HSL transcripts6 Comparison wi
P09359844A0674 |2 3|%0
P09359887A1168 |103 109|regionpects 
P09359887A1168 |75 78|NPC008
P09359887A1168 |20 24|datariso
P09359887A1168 |123 132|sequencesperbiliru
P09359887A1168 |38 51|Rat7p/Nup159pe phosphatase
P09360422A0135 |275 285|volunteerso controls
P09360422A0135 |44 58|arteriopathiesphatases and 5
P09360422A0135 |17 25|patientsmparison
P09360422A0135 |115 117|TMna
P09360422A0135 |82 95|plasma levels0000 Pharmaco
P09360422A0135 |243 249|valueslonger
P09360422A0135 |120 139|betathromboglobulin hyperbilirubinemia
P09360422A0135 |151 158|D-dimer0472 Wh
P09360422A0135 |5 10|group1606T
P09360422A0135 |99 113|thrombomodulinc aspects of n
P09360422A0135 |160 162|DD C
P09360422A0135 |72 77|limbsP0000
P09360422A0135 |141 148|beta-TGP000089
P09360422A0135 |201 206|pAI-1F PCO
P09360422A0135 |168 199|plasminogen activator-inhibitorO3-] is shown as a function of 
P09360953A1057 |16 22|Ile244ompari
P09360953A1057 |106 113|portionts of n
P09360953A1057 |44 47|endpha
P09360953A1057 |6 14|residues606T0076
P09360953A1057 |163 166|IleF [
P09360953A1057 |131 135|loopubin
P09360953A1057 |78 84|Tyr318171T00
P09360953A1057 |174 188|PTH-1 receptors shown as a f
P09360953A1057 |65 70|helixtidas
P09360953A1057 |155 158|Leu Wh
P09360956A0840 |118 125|bindingal hype
P09360956A0840 |129 134|c-Rafirubi
P09360956A0840 |57 61|zeta5-nu
P09360956A0840 |31 46|phosphorylationalkaline phosph
P09360956A0840 |69 82|CKIalpha sitese P00008171T
P09360956A0840 |173 192|signal transductionis shown as a funct
P09360956A0840 |84 91|Thr-23300 Phar
P09360993T0000 |0 24|Mouse mast cell proteaseP00001606T0076 Compariso
P09360993T0000 |132 142|mast cellsbinemia. P
P09360993T0000 |74 90|serine proteases0008171T0000 Pha
P09360993T0000 |64 70|familyotidas
P09360993T0000 |36 42|memberine ph
P09360993T0000 |50 60|chromosomees and 5-n
P09361007A0922 |2 7|DNase00016
P09361007A0922 |25 29|site wit
P09361007A0922 |67 87|pair enhancer regiondase P00008171T0000 
P09362105X0422 |32 35|PVRlka
P09362105X0422 |144 147|HPV008
P09362105X0422 |126 142|vasoconstrictionbilirubinemia. P
P09362105X0422 |46 54|% O2-PVRatases a
P09362105X0422 |20 30|resistancerison with
P09362105X0422 |82 83|%0
P09362105X0422 |64 72|% O2/PVRotidase 
P09362473A1540 |274 288|twist activityto controls bu
P09362473A1540 |14 21|results Compar
P09362473A1540 |318 341|twist expression domainreater slope (1.21 +/- 
P09362473A1540 |151 157|inputs0472 W
P09362473A1540 |202 225|repressor binding sites PCO2 the data of K-dep
P09362473A1540 |59 64|arraynucle
P09362473A1540 |77 94|enhancer elements8171T0000 Pharmac
P09362473A1540 |301 306|areasa sig
P09362473A1540 |188 197|activatorunction o
P09362473A1540 |249 257|enhancer displac
P09362473A1540 |32 38|tinmanlkalin
P09362480A0452 |101 105|coreaspe
P09362480A0452 |45 54|sequenceshatases a
P09362480A0452 |58 68|TB domains-nucleotid
P09362480A0452 |11 27|cysteine triplet076 Comparison w
P09362480A0452 |114 124|C-terminusonatal hyp
P09362499A0000 |137 145|enhanceria. P000
P09362499A0000 |79 93|DNA invertases71T0000 Pharma
P09362499A0000 |4 15|Fis protein01606T0076 
P09362499A0000 |40 53|DNA inversionphosphatases 
P09362499A0000 |69 75|familyse P00
P09363759A0000 |0 20|Protein phosphatasesP00001606T0076 Compa
P09363759A0000 |78 88|cell cycle171T0000 P
P09363759A0000 |37 41|rolene p
P09363759A0000 |93 112|signal transductioncologic aspects of 
P09363759A0000 |49 59|regulationses and 5-
P09364211A0319 |81 88|bindingT0000 P
P09364211A0319 |25 49|transcription factor E2F with alkaline phosphata
P09364211A0319 |72 75|DNAP00
P09364211A0319 |4 8|cell0160
P09364440A2206 |35 44|structureline phos
P09364440A2206 |52 69|FSH receptor gene and 5-nucleotida
P09364440A2206 |121 130|effectorshyperbili
P09364440A2206 |99 107|couplingc aspect
P09364440A2206 |80 86|motifs1T0000
P09364440A2206 |4 9|study01606
P09364750T0000 |16 26|regulationomparison 
P09364750T0000 |30 35|SUP35 alka
P09364750T0000 |40 45|SUP45phosp
P09365201A2018 |84 93|mechanism00 Pharma
P09365201A2018 |127 140|breast cancerilirubinemia.
P09365201A2018 |145 149|ASCs0899
P09365201A2018 |27 32|basisith a
P09365201A2018 |6 13|studies606T007
P09365201A2018 |97 117|aromatase expressiongic aspects of neona
P09365201A2018 |49 65|characterizationses and 5-nucleo
P09365272T0000 |0 7|XenopusP000016
P09365272T0000 |41 53|interactionshosphatases 
P09365272T0000 |89 109|Xenopus egg extractsarmacologic aspects 
P09365272T0000 |77 85|assembly8171T000
P09365272T0000 |58 65|effects-nucleo
P09365272T0000 |20 27|proteinrison w
P09365431A0314 |35 50|benzodiazepinesline phosphatas
P09365431A0314 |59 103|acetylcholinesterase inhibitor physostigminenucleotidase P00008171T0000 Pharmacologic as
P09365431A0314 |20 31|combinationrison with 
P09366456A0234 |0 7|METHODSP000016
P09366456A0234 |105 120|body mass indexcts of neonatal
P09366456A0234 |58 68|anesthesia-nucleotid
P09366456A0234 |89 96|personsarmacol
P09366456A0234 |148 153|group97A04
P09366456A0234 |182 196|body mas indexas a function 
P09366456A0234 |131 133|kgub
P09366456A0234 |166 173|personsHCO3-] 
P09366456A0234 |74 79|group00081
P09366456A0234 |15 31|muscle paralysisComparison with 
P09366456A0234 |98 99|ni
P09366456A0234 |175 176|n 
P09366456A0234 |207 209|kg t
P09366517A0835 |0 3|PKAP00
P09366517A0835 |38 45|Ser-393e phosp
P09366517A0835 |97 112|phosphorylationgic aspects of 
P09366517A0835 |26 33|Ser-365with al
P09366517A0835 |151 154|WT1047
P09366517A0835 |19 22|WT1ari
P09366517A0835 |81 86|sitesT0000
P09366517A0835 |139 147|activity. P00008
P09366517A1828 |49 57|functionses and 
P09366517A1828 |31 39|evidencealkaline
P09366517A1828 |89 104|phosphorylationarmacologic asp
P09366517A1828 |61 64|WT1cle
P09366517A1828 |4 12|findings01606T00
P09366628T0000 |0 2|ReP0
P09366628T0000 |19 28|directionarison wi
P09366628T0000 |61 68|studiescleotid
P09366628T0000 |32 41|causalitylkaline p
P09367288A0115 |171 182|adaptations] is shown 
P09367288A0115 |200 206|tendonSF PCO
P09367288A0115 |42 50|decreaseosphatas
P09367288A0115 |9 12|aimT00
P09367288A0115 |107 121|immobilisations of neonatal 
P09367288A0115 |68 84|unit rest lengthase P00008171T00
P09367288A0115 |190 196|musclection 
P09367288A0115 |137 145|positionia. P000
P09367392A0567 |137 149|accumulationia. P0000899
P09367392A0567 |74 77|end000
P09367392A0567 |30 38|sequence alkalin
P09367392A0567 |4 12|presence01606T00
P09367392A0567 |42 53|nucleotidesosphatases 
P09367392A0567 |179 185|levelswn as 
P09367392A0567 |95 115|template recognitionlogic aspects of neo
P09367392A0567 |153 157|RNA372 W
P09367392A0567 |81 85|RNA3T000
P09367392A0567 |119 123|RdRpl hy
P09367426A1354 |34 36|hhal
P09367426A1354 |52 60|polarity and 5-n
P09367426A1354 |26 30|rolewith
P09367426A1354 |159 171|polarizationn CSF [HCO3-
P09367426A1354 |82 99|compartment cells0000 Pharmacologi
P09367426A1354 |117 131|interpretationtal hyperbilir
P09367676A0275 |0 26|Restriction enzyme mappingP00001606T0076 Comparison 
P09367676A0275 |44 67|DNA sequencing analysisphatases and 5-nucleoti
P09367676A0275 |199 202|DNACSF
P09367676A0275 |124 129|exonserbil
P09367676A0275 |28 38|subcloningth alkalin
P09367676A0275 |150 163|mouse TS mRNAA0472 When CS
P09367676A0275 |188 190|kbun
P09367676A0275 |83 95|phage lambda000 Pharmaco
P09367676A0275 |100 109|P1 clones aspects 
P09367676A1115 |0 21|Transfection analysesP00001606T0076 Compar
P09367676A1115 |41 51|expressionhosphatase
P09367676A1115 |115 123|sequencenatal hy
P09367676A1115 |55 61|Tbxas1d 5-nu
P09367676A1115 |156 164|elementsWhen CSF
P09368006A1332 |103 113|cell cyclepects of n
P09368006A1332 |82 93|interaction0000 Pharma
P09368006A1332 |125 132|proteinrbiliru
P09368006A1332 |134 139|E2F-1nemia
P09368006A1332 |39 57|NF-kappaB activity phosphatases and 
P09368006A1332 |20 25|studyrison
P09368006A1332 |4 11|results01606T0
P09368014A0740 |4 21|lysozyme FEF site01606T0076 Compar
P09368014A0740 |45 47|PUha
P09368026A0000 |0 11|OsteocalcinP00001606T0
P09368026A0000 |106 120|mineralizationts of neonatal
P09368026A0000 |13 15|OC6 
P09368026A0000 |45 52|proteinhatases
P09368026A0000 |82 94|odontoblasts0000 Pharmac
P09368026A0000 |22 28|matrixson wi
P09368026A0000 |66 77|osteoblastsidase P0000
P09368026A0435 |84 103|luciferase reporter00 Pharmacologic as
P09368026A0435 |135 155|MC3T3-E1 osteoblastsemia. P00008997A0472
P09368026A0435 |121 131|calcitriolhyperbilir
P09368026A0435 |60 82|OC promoter activationucleotidase P00008171T
P09368026A0435 |30 37|effects alkali
P09368026A0435 |108 116|FGF2/FSK of neon
P09368026A0435 |41 56|Msx2 expressionhosphatases and
P09368026A0435 |8 13|study6T007
P09368057A1083 |19 27|proteinsarison w
P09368057A1083 |178 189|SRF bindingown as a fu
P09368057A1083 |164 174|inhibition [HCO3-] i
P09368057A1083 |113 120|elementeonatal
P09368057A1083 |66 84|repressor activityidase P00008171T00
P09368057A1083 |48 60|SRF activityases and 5-n
P09368058A0969 |85 99|phosphopeptide0 Pharmacologi
P09368058A0969 |168 171|CAKO3-
P09368058A0969 |210 214|sitee da
P09368058A0969 |32 57|phosphopeptide comigrateslkaline phosphatases and 
P09368097T0000 |4 7|pen016
P09368100A1354 |51 56|exonss and
P09368100A1354 |28 32|geneth a
P09368100A1354 |4 16|mHIF-1 alpha01606T0076 C
P09368190A1053 |68 72|EMSAase 
P09368190A1053 |76 95|DNA binding pattern08171T0000 Pharmaco
P09368190A1053 |42 50|sequenceosphatas
P09368190A1053 |130 138|exposurerubinemi
P09368190A1053 |209 218|IFN-alphahe data o
P09368190A1053 |223 232|IFN-gammaepleted r
P09368190A1053 |142 151|IFN-gamma00008997A
P09368190A1053 |187 198|stimulationfunction of
P09368419A0000 |118 138|protein biosynthesisal hyperbilirubinemi
P09368419A0000 |157 172|gene expressionhen CSF [HCO3-]
P09368419A0000 |20 29|inductionrison wit
P09368419A0000 |58 62|gene-nuc
P09368419A0000 |94 98|acidolog
P09368419A0000 |3 14|Arabidopsis001606T0076
P09368419A0000 |64 68|rd22otid
P09368419A0000 |100 103|ABA as
P09368419A0628 |2 6|cDNA0001
P09368419A0628 |124 129|probeerbil
P09368419A0628 |30 49|DNA binding protein alkaline phosphata
P09368419A0628 |112 118|regionneonat
P09368419A0628 |146 153|rd22BP18997A04
P09368419A0628 |66 94|DNA-ligand binding screeningidase P00008171T0000 Pharmac
P09368760A0665 |100 110|regulation aspects o
P09368760A0665 |149 164|spermatogenesis7A0472 When CSF
P09368760A0665 |135 144|oogenesisemia. P00
P09368760A0665 |114 133|sex differentiationonatal hyperbilirub
P09368760A0665 |6 10|PDK1606T
P09368760A0665 |32 65|Drosophila protein kinase DSTPK61lkaline phosphatases and 5-nucleo
P09369450A1358 |205 217|interactionsO2 the data 
P09369450A1358 |230 251|transcription factors rats are no longer d
P09369450A1358 |135 145|HNF-1 siteemia. P000
P09369450A1358 |82 99|promoter activity0000 Pharmacologi
P09369450A1358 |22 29|effectsson wit
P09369450A1358 |283 306|transcription machineryls but still have a sig
P09369450A1358 |312 340|steroid receptor coactivatorntly greater slope (1.21 +/-
P09369450A1358 |154 157|GRE2 W
P09369450A1358 |33 42|HNF-1betakaline ph
P09369450A1358 |51 53|GRs 
P09369451A0693 |184 190|region a fun
P09369451A0693 |123 126|MEFper
P09369451A0693 |135 143|sequenceemia. P0
P09369451A0693 |98 121|myocyte enhancer factoric aspects of neonatal 
P09369451A0693 |39 43|AP-1 pho
P09369451A0693 |213 224|OP-1 effectata of K-de
P09369451A0693 |11 19|analysis076 Comp
P09369451A0693 |49 57|sequenceses and 
P09369451A0693 |156 169|TTAAAAATAAAAAWhen CSF [HCO
P09369451A0693 |70 80|TGAATCATCAe P0000817
P09369453A0273 |33 45|Bcl-2 familykaline phosp
P09369453A0273 |47 50|BADtas
P09369453A0273 |212 220|envelopedata of 
P09369453A0273 |129 149|transmembrane domainirubinemia. P0000899
P09369453A0273 |76 90|death promoter08171T0000 Pha
P09369453A0273 |95 109|death enhancerlogic aspects 
P09369453A0273 |191 199|membranetion of 
P09369453A0273 |52 62|Bcl-xL/Bcl and 5-nuc
P09369453A0273 |18 25|membersparison
P09369482A0690 |85 89|HNF40 Ph
P09369482A0690 |112 116|siteneon
P09369482A0690 |26 47|cotransfection assayswith alkaline phospha
P09369482A0690 |136 158|G6Pase gene expressionmia. P00008997A0472 Wh
P09369482A0690 |66 75|HNF1alphaidase P00
P09369482A0690 |0 21|Electromobility shiftP00001606T0076 Compar
P09370276A0781 |48 66|amino acid proteinases and 5-nucleot
P09370276A0781 |30 32|bp a
P09370276A0781 |8 21|reading frame6T0076 Compar
P09370307A0093 |119 137|barley gibberellinl hyperbilirubinem
P09370307A0093 |149 156|element7A0472 
P09370307A0093 |180 200|DNA binding proteinsn as a function of C
P09370307A0093 |61 70|regulatorcleotidas
P09370307A0093 |101 111|similarityaspects of
P09370307A0093 |83 90|tissues000 Pha
P09370307A0093 |17 27|AACA motifmparison w
P09371431A1172 |102 122|thiCOGE gene clusterspects of neonatal h
P09371431A1172 |79 94|promoter region71T0000 Pharmac
P09371431A1172 |55 71|Tn5mob insertiond 5-nucleotidase
P09371431A1172 |20 34|R. etli mutantrison with alk
P09371431A1172 |0 13|Strain CFN037P00001606T007
P09371431T0000 |0 10|ExpressionP00001606T
P09371431T0000 |79 100|terminal oxidase cbb371T0000 Pharmacologic
P09371431T0000 |104 118|Rhizobium etliects of neonat
P09371431T0000 |55 65|productiond 5-nucleo
P09371431T0000 |42 49|thiCOGEosphata
P09371431T0000 |35 40|genesline 
P09371455A0000 |49 62|lipase operonses and 5-nuc
P09371455A0000 |106 121|metalloproteasets of neonatal 
P09371455A0000 |31 37|regionalkali
P09371455A0000 |125 143|Vibrio cholerae O1rbilirubinemia. P0
P09371564A0713 |17 23|amountmparis
P09371564A0713 |145 150|virus08997
P09371564A0713 |27 31|tRNAith 
P09371564A0713 |80 87|viruses1T0000 
P09371564A0713 |65 68|RNAtid
P09371564A0713 |32 36|3Lyslkal
P09371566A1384 |154 161|protein2 When 
P09371566A1384 |91 111|protein preparationsmacologic aspects of
P09371566A1384 |45 53|extractshatases 
P09371566A1384 |5 12|protein1606T00
P09371566A1384 |58 71|S100 extracts-nucleotidase
P09371566A1384 |32 36|HeLalkal
P09371596T0000 |71 88|hepatitis B virus P00008171T0000 P
P09371596T0000 |13 23|regulation6 Comparis
P09371596T0000 |31 36|pre-Calkal
P09371596T0000 |52 61|promoters and 5-nu
P09371596T0000 |92 99|membersacologi
P09371596T0000 |115 135|receptor superfamilynatal hyperbilirubin
P09371612A1964 |0 4|AcadP000
P09371622A0779 |102 124|lac operator sequencesspects of neonatal hyp
P09371622A0779 |56 69|transcription 5-nucleotida
P09371622A0779 |20 32|IE1 peptidesrison with a
P09371622A0779 |83 91|promoter000 Phar
P09371622A0779 |0 8|ChimerasP0000160
P09371626A1345 |71 79|deletion P000081
P09371626A1345 |240 249|synthesisno longer
P09371626A1345 |150 161|replicationA0472 When 
P09371626A1345 |134 138|rolenemi
P09371626A1345 |15 31|replicase assaysComparison with 
P09371626A1345 |143 146|VP2000
P09371626A1345 |189 196|abilitynction 
P09371626A1345 |179 186|proteinwn as a
P09371626A1345 |209 222|mRNA templatehe data of K-
P09371626A1345 |99 105|domainc aspe
P09371626A1345 |54 57|VP2nd 
P09371626A1345 |4 11|results01606T0
P09371657A0165 |71 75|K79A P00
P09371657A0165 |127 151|triphosphatase componentilirubinemia. P00008997A
P09371657A0165 |62 63|Al
P09371657A0165 |28 53|alanine cluster mutationsth alkaline phosphatases 
P09371657A0165 |80 91|E192A-E194A1T0000 Phar
P09371657A0165 |65 69|R77Atida
P09371657A0165 |55 58|R77d 5
P09371698A1254 |0 12|TransfectionP00001606T00
P09371698A1254 |45 55|constructshatases an
P09371698A1254 |142 162|bp promoter fragment00008997A0472 When C
P09371698A1254 |178 193|pseudo-TATA boxown as a functi
P09371698A1254 |26 39|SK-N-MC cellswith alkaline
P09371698A1254 |90 99|fragmentsrmacologi
P09371698A1254 |223 228|siteseplet
P09371698A1254 |114 124|definitiononatal hyp
P09371698A1254 |16 21|HepG2ompar
P09371731A0627 |35 45|homologuesline phosp
P09371731A0627 |5 12|inserts1606T00
P09371731A0627 |49 67|eIF-2alpha kinasesses and 5-nucleoti
P09372287A0296 |136 140|MVSTmia.
P09372287A0296 |178 185|pathwayown as 
P09372287A0296 |129 134|tractirubi
P09372287A0296 |89 94|tractarmac
P09372287A0296 |149 159|C1 segment7A0472 Whe
P09372287A0296 |96 100|LVSTogic
P09372287A0296 |189 194|axonsnctio
P09372287A0296 |16 26|electrodesomparison 
P09372451T0000 |0 8|EpitopesP0000160
P09372451T0000 |105 118|integrin betacts of neonat
P09372451T0000 |121 128|subunithyperbi
P09372451T0000 |91 97|domainmacolo
P09372451T0000 |43 53|antibodiessphatases 
P09372908A1068 |119 134|gene repressionl hyperbilirubi
P09372908A1068 |196 200|PREsof C
P09372908A1068 |161 177|Polycomb proteinCSF [HCO3-] is s
P09372908A1068 |27 36|Sex Combsith alkal
P09372908A1068 |148 157|inclusion97A0472 W
P09372908A1068 |185 192|complexa funct
P09372908A1068 |217 226|silencingof K-depl
P09372908A1068 |87 96|mechanismPharmacol
P09372924A0758 |184 195|interaction a function
P09372924A0758 |95 103|proteinslogic as
P09372924A0758 |160 179|DNA repair reaction CSF [HCO3-] is sho
P09372924A0758 |56 66|NER system 5-nucleot
P09372924A0758 |123 134|involvementperbilirubi
P09372924A0758 |18 33|rhHR23 proteinsparison with al
P09372924A0758 |201 204|XPCF P
P09372924A0758 |138 152|hHR23 proteinsa. P00008997A0
P09372937T0000 |17 52|information regulator Sir4p anchorsmparison with alkaline phosphatases
P09372937T0000 |57 76|partitions plasmids5-nucleotidase P000
P09372937T0000 |4 9|yeast01606
P09372950A1283 |139 149|processing. P0000899
P09372950A1283 |77 86|sequences8171T0000
P09372950A1283 |95 100|sideslogic
P09372950A1283 |57 66|structure5-nucleot
P09372950A1283 |6 13|results606T007
P09372950A1283 |159 165|U2 RNAn CSF 
P09372950A1283 |115 128|cleavage sitenatal hyperbi
P09372960A0456 |0 17|Polysome analysesP00001606T0076 Co
P09372960A0456 |112 118|numberneonat
P09372960A0456 |122 125|40Sype
P09372960A0456 |45 58|fal1-1 mutanthatases and 5
P09372960A0456 |80 86|strain1T0000
P09372960A0456 |96 104|decreaseogic asp
P09372960A0456 |136 144|subunitsmia. P00
P09372968A0532 |0 17|Sequence analysisP00001606T0076 Co
P09372968A0532 |131 137|dyneinubinem
P09372968A0532 |106 113|homologts of n
P09372968A0532 |150 157|proteinA0472 W
P09372968A0532 |58 63|Dlc-1-nucl
P09372968A0532 |43 54|cDNA clonessphatases a
P09372968A0532 |67 75|sequencedase P00
P09372968A0996 |16 20|HeLaompa
P09372968A0996 |129 134|Dlc-1irubi
P09372968A0996 |29 34|cellsh alk
P09372968A0996 |65 77|kappaB alphatidase P0000
P09373140A0000 |32 40|enhancerlkaline 
P09373140A0000 |4 20|mouse M-lysozyme01606T0076 Compa
P09373140A0000 |96 111|gene regulationogic aspects of
P09373140A0000 |86 92|levels Pharm
P09373155T0000 |0 14|IdentificationP00001606T0076
P09373155T0000 |31 42|chain genesalkaline ph
P09373155T0000 |120 131|dynein gene hyperbilir
P09373155T0000 |66 78|mouse testisidase P00008
P09373155T0000 |92 104|localizationacologic asp
P09373155T0000 |18 24|dyneinpariso
P09373651A0255 |102 118|hydrogen cyanidespects of neonat
P09373651A0255 |47 57|processingtases and 
P09373651A0255 |7 14|cassava06T0076
P09373651A0255 |78 97|acetone cyanohydrin171T0000 Pharmacolo
P09373651A0255 |35 45|glycosidesline phosp
P09374082A0504 |275 287|inflammationo controls b
P09374082A0504 |333 339|asthma.21 +/
P09374082A0504 |26 39|effect stateswith alkaline
P09374082A0504 |94 112|hydrolysis productologic aspects of 
P09374082A0504 |208 220|thromboxanesthe data of 
P09374082A0504 |13 22|mechanism6 Compari
P09374082A0504 |75 79|MEHP0081
P09374082A0504 |258 262|riskd wh
P09374082A0504 |50 62|2-ethylhexyles and 5-nuc
P09374082A0504 |116 120|DEHPatal
P09374082A0504 |158 160|PGen
P09374082A0504 |295 302|airways have a
P09374082A0504 |179 187|betaPGF2wn as a 
P09374082A0504 |162 165|PGDSF 
P09374082A0504 |315 329|characteristicy greater slop
P09374082A0504 |228 233|lungsed ra
P09374082A0504 |193 202|PGF2alphaon of CSF
P09374082A0504 |64 73|phthalateotidase P
P09374082A0504 |142 156|prostaglandins00008997A0472 
P09374082A0504 |170 176|9alpha-] is 
P09374541A0277 |12 33|protein binding sites76 Comparison with al
P09374541T0000 |99 121|cell cycle progressionc aspects of neonatal 
P09374541T0000 |27 52|E2F recognition sequencesith alkaline phosphatases
P09374541T0000 |13 23|protection6 Comparis
P09374541T0000 |66 91|thymidine kinase promoteridase P00008171T0000 Phar
P09376325A0167 |0 10|ComparisonP00001606T
P09376325A0167 |22 30|sequenceson with
P09376325A0167 |46 54|ph locusatases a
P09376325A0167 |117 136|transcription unitstal hyperbilirubine
P09376626A0737 |34 36|T4al
P09376626A0737 |72 79|group AP000081
P09376626A0737 |46 47|ha
P09376626A0737 |60 67|group Cucleoti
P09376626A0737 |92 99|group Bacologi
P09376626A0737 |24 30|levelsn with
P09376626A0737 |41 43|T3ho
P09376626A0737 |106 120|h postexposurets of neonatal
P09376626A0737 |86 87|h 
P09376626A0737 |55 56|hd
P09376626A0737 |0 9|RadiationP00001606
P09376782A0328 |69 86|hepatitis C virusse P00008171T0000
P09376782A0328 |43 46|MMTsph
P09376782A0328 |88 91|HCVhar
P09376782A0328 |21 31|experienceison with 
P09376782A0328 |93 102|infectioncologic a
P09376782A0328 |55 63|practiced 5-nucl
P09377355A0362 |34 38|dataalin
P09377355A0362 |173 178|toolsis sh
P09377355A0362 |97 106|disordersgic aspec
P09377355A0362 |124 135|impairementerbilirubin
P09377355A0362 |148 151|use97A
P09377355A0362 |48 53|studyases 
P09377355A0362 |4 10|author01606T
P09377355A0362 |70 78|featurese P00008
P09377374A0000 |119 129|narcomanial hyperbil
P09377374A0000 |105 115|backgroundcts of neo
P09377374A0000 |15 31|characterizationComparison with 
P09377374A0000 |81 92|VH B courseT0000 Pharm
P09377374A0000 |8 13|paper6T007
P09377374A0000 |69 77|featuresse P0000
P09379301A2036 |85 95|proglottis0 Pharmaco
P09379301A2036 |41 48|micronshosphat
P09379301A2036 |74 80|testes000817
P09379301A2036 |4 11|microns01606T0
P09379301A2036 |53 61|A. wedliand 5-nu
P09379301A2036 |16 32|A. microcephalumomparison with a
P09380504A1255 |168 176|additionO3-] is 
P09380504A1255 |96 98|kbog
P09380504A1255 |160 161|h 
P09380504A1255 |180 194|actinomycin D.n as a functio
P09380504A1255 |121 144|cycloheximide treatmenthyperbilirubinemia. P00
P09380504A1255 |38 49|transcriptse phosphata
P09380504A1255 |4 14|ZnF20 cDNA01606T0076
P09380504A1255 |55 79|thyroid cancer cell lined 5-nucleotidase P000081
P09380507A0514 |0 25|Glutathione S-transferaseP00001606T0076 Comparison
P09380507A0514 |40 62|GST-DP fusion proteinsphosphatases and 5-nuc
P09380507A0514 |27 30|GSTith
P09380507A0514 |128 162|DNA polymerase alpha gene promoterlirubinemia. P00008997A0472 When C
P09380507A0514 |111 120|E2F sites neonatal
P09380507A0514 |32 35|E2Flka
P09380697T0000 |35 44|sequencesline phos
P09380697T0000 |4 10|sterol01606T
P09380697T0000 |53 66|up-regulationand 5-nucleot
P09380697T0000 |142 153|cholesterol00008997A04
P09380697T0000 |70 97|caveolin gene transcriptione P00008171T0000 Pharmacolo
P09380697T0000 |101 109|responseaspects 
P09380697T0000 |117 136|density lipoproteintal hyperbilirubine
P09380707A0714 |23 32|LAZ3/BCL6on with a
P09380707A0714 |79 87|proteins71T0000 
P09380707A0714 |121 125|dotshype
P09380707A0714 |42 46|SMRTosph
P09381261A0970 |0 11|CONCLUSIONSP00001606T0
P09381261A0970 |47 54|motherstases a
P09381261A0970 |120 124|ones hyp
P09381261A0970 |76 80|area0817
P09381261A0970 |59 67|newbornsnucleoti
P09381261A0970 |32 42|EPO levelslkaline ph
P09381950A0209 |0 9|IschaemiaP00001606
P09381950A0209 |31 40|flow ratealkaline 
P09381950A0209 |48 56|mL min-1ases and
P09381950A0209 |64 67|minoti
P09381950A0209 |101 112|reperfusionaspects of 
P09382498A0618 |84 88|area00 P
P09382498A0618 |11 15|MCTs076 
P09382498A0618 |148 152|size97A0
P09382498A0618 |29 38|electrodeh alkalin
P09382498A0618 |210 215|tumore dat
P09382498A0618 |142 144|cm00
P09382498A0618 |129 138|electrodeirubinemi
P09382498A0618 |42 44|cmos
P09382498A0618 |198 202|area CSF
P09382498A0618 |113 117|MCTseona
P09382498A0618 |96 101|tumorogic 
P09382498A0618 |48 52|sizeases
P09382850A0000 |51 62|progressions and 5-nuc
P09382850A0000 |12 31|Checkpoint pathways76 Comparison with 
P09382850A0000 |70 75|evente P00
P09382850A0000 |79 90|DNA lesions71T0000 Pha
P09382850A0000 |0 10|BACKGROUNDP00001606T
P09382886A1061 |137 140|SBMia.
P09382886A1061 |145 148|p53089
P09382886A1061 |121 128|matingshyperbi
P09382886A1061 |61 64|PKDcle
P09382886A1061 |90 93|p53rma
P09382886A1061 |48 57|apoptosisases and 
P09382886A1061 |7 12|proof06T00
P09382886A1061 |154 158|mice2 Wh
P09382924A0131 |142 148|PSMB10000089
P09382924A0131 |252 257|PSMB6splac
P09382924A0131 |59 75|interferon-gammanucleotidase P00
P09382924A0131 |126 130|LMP2bili
P09382924A0131 |176 190|20S proteasomeshown as a fun
P09382924A0131 |270 275|PSMB7red t
P09382924A0131 |12 20|evidence76 Compa
P09382924A0131 |132 136|LMP7bine
P09382924A0131 |105 113|subunitscts of n
P09382924A0131 |259 264|PSMB5 when
P09382924A0131 |42 53|stimulationosphatases 
P09382924A0131 |77 86|IFN-gamma8171T0000
P09382924A0131 |232 240|subunitsats are 
P09383156A0691 |10 34|RNase E cleavage product0076 Comparison with alk
P09383156A0691 |105 111|PNPasects of
P09383156A0691 |75 103|polynucleotide phosphorylase008171T0000 Pharmacologic as
P09383156A0691 |44 50|pSok-6phatas
P09383188A0654 |55 72|ARG box consensusd 5-nucleotidase 
P09383188A0654 |42 47|matchospha
P09383188A0654 |88 92|siteharm
P09383188A0654 |5 15|difference1606T0076 
P09383188A0654 |82 86|rocD0000
P09383188A0654 |80 81|O1
P09385169T0000 |4 8|AONE0160
P09385169T0000 |29 52|productivity indicatorsh alkaline phosphatases
P09385169T0000 |11 18|experts076 Com
P09386074A0694 |34 48|LV dysfunctionaline phosphat
P09386074A0694 |61 81|LV ejection fractioncleotidase P00008171
P09386074A0694 |90 91|%r
P09386074A0694 |4 8|pigs0160
P09387333T0001 |4 12|progress01606T00
P09387333T0001 |30 38|research alkalin
P09387333T0001 |59 66|nucleusnucleot
P09387999A1053 |69 85|hair cell lossesse P00008171T000
P09387999A1053 |124 128|earserbi
P09387999A1053 |4 14|amplitudes01606T0076
P09387999A1053 |52 58|extent and 5
P09387999A1053 |18 23|DPOAEparis
P09388198A1396 |85 88|ERK0 P
P09388198A1396 |214 218|rhoBta o
P09388198A1396 |131 140|inductionubinemia.
P09388198A1396 |94 108|p38 MAP kinaseologic aspects
P09388198A1396 |37 64|signal transduction pathwayne phosphatases and 5-nucle
P09388198A1396 |144 148|rhoB0089
P09388198A1396 |196 210|autoregulationof CSF PCO2 th
P09388198A1396 |162 168|stressSF [HC
P09388198A1396 |4 8|data0160
P09388198A1396 |80 83|JNK1T0
P09388198A1396 |17 25|evidencemparison
P09388199A0948 |85 99|ligand binding0 Pharmacologi
P09388199A0948 |25 32|domains with a
P09388199A0948 |179 186|regionswn as a
P09388199A0948 |160 164|LexA CSF
P09388199A0948 |36 40|FadRine 
P09388199A0948 |6 12|effort606T00
P09388199A0948 |67 79|dimerizationdase P000081
P09388199A0948 |110 125|protein fusionsf neonatal hype
P09388199A0948 |190 194|FadRctio
P09388199A0948 |54 65|DNA bindingnd 5-nucleo
P09388199A0948 |138 156|DNA binding domaina. P00008997A0472 
P09388200A0639 |137 146|promotersia. P0000
P09388200A0639 |55 76|transcription factorsd 5-nucleotidase P000
P09388200A0639 |114 119|c-fosonata
P09388200A0639 |165 178|transcription[HCO3-] is sh
P09388200A0639 |34 43|titrationaline pho
P09388200A0639 |0 10|InhibitionP00001606T
P09388200A0639 |85 104|MDM2 overexpression0 Pharmacologic asp
P09388201A1027 |34 38|TATAalin
P09388201A1027 |42 53|CAAT motifsosphatases 
P09388201A1027 |10 12|PD00
P09388201A1027 |3 5|PU00
P09388246A0903 |175 188|intermediates shown as a f
P09388246A0903 |121 131|cytomatrixhyperbilir
P09388246A0903 |106 111|nervets of
P09388246A0903 |72 83|amphiphysinP00008171T0
P09388246A0903 |27 66|electron microscopy immunocytochemistryith alkaline phosphatases and 5-nucleot
P09388271A1243 |115 122|proteinnatal h
P09388271A1243 |76 86|inhibitors08171T0000
P09388271A1243 |61 70|treatmentcleotidas
P09388271A1243 |90 93|PKCrma
P09388271A1243 |36 44|proteinsine phos
P09388271A1243 |159 172|kinase kinasen CSF [HCO3-]
P09388271A1243 |4 18|mobility shift01606T0076 Com
P09389137A0763 |21 29|apoplexyison wit
P09389137A0763 |45 49|T1-9hata
P09389137A0763 |54 58|L2-4nd 5
P09389137A0763 |39 43|C1-7 pho
P09389137A0763 |4 16|prescription01606T0076 C
P09389198A0363 |93 106|A delta unitscologic aspec
P09389198A0363 |11 20|aftermath076 Compa
P09389198A0363 |133 138|stateinemi
P09389198A0363 |165 174|threshold[HCO3-] i
P09389198A0363 |75 86|arithmetics008171T0000
P09389198A0363 |42 46|skinosph
P09389198A0363 |24 34|excitationn with alk
P09389198A0363 |59 64|nervenucle
P09389492A0520 |69 77|responsese P0000
P09389492A0520 |40 45|cellsphosp
P09389492A0520 |106 112|effectts of 
P09389492A0520 |47 52|serumtases
P09389492A0520 |13 20|fashion6 Compa
P09389492A0520 |141 149|activityP0000899
P09389492A0520 |81 94|dexamethasoneT0000 Pharmac
P09389492A0520 |116 123|phorbolatal hy
P09389666A0538 |6 20|Hex expression606T0076 Compa
P09389666A0538 |147 151|axis997A
P09389666A0538 |62 87|anteroposterior asymmetryleotidase P00008171T0000 
P09389666A0538 |210 219|asymmetrye data of
P09389666A0538 |180 190|conversionn as a fun
P09389666A0538 |159 165|embryon CSF 
P09389666A0538 |95 107|mouse embryologic aspect
P09389666A0538 |249 265|endoderm lineage displaced when 
P09389669A1009 |6 9|dpp606
P09389669A1009 |31 51|dorsal leg cell fatealkaline phosphatase
P09389669A1009 |14 17|omb Co
P09389669A1009 |92 106|leg disc cellsacologic aspec
P09389982A1383 |0 11|CONCLUSIONSP00001606T0
P09389982A1383 |121 137|prothrombin timehyperbilirubinem
P09389982A1383 |90 107|log reference INRrmacologic aspect
P09389982A1383 |67 74|methodsdase P0
P09389982A1383 |148 167|regression analysis97A0472 When CSF [H
P09389982A1383 |19 33|INR correctionarison with al
P09390125A0379 |0 7|RESULTSP000016
P09390125A0379 |95 103|quarterslogic as
P09390125A0379 |78 79|%1
P09390125A0379 |56 57|% 
P09390125A0379 |63 64|%e
P09390125A0379 |21 24|FNFiso
P09390125A0379 |42 43|%o
P09390125A0379 |69 70|%s
P09390183A1027 |0 21|Western blot analysisP00001606T0076 Compar
P09390183A1027 |40 47|tissuesphospha
P09390183A1027 |124 128|banderbi
P09390183A1027 |183 190|tissuess a fun
P09390183A1027 |172 175|kDa is
P09390183A1027 |59 79|NMT peptide antibodynucleotidase P000081
P09390183A1027 |156 160|massWhen
P09391173A0811 |0 25|Transcription start sitesP00001606T0076 Comparison
P09391173A0811 |142 151|cDNA ends00008997A
P09391173A0811 |125 138|amplificationrbilirubinemi
P09391173A0811 |33 53|plastid ACCase geneskaline phosphatases 
P09391173A0811 |113 117|RACEeona
P09391173A0811 |86 97|cDNA clones Pharmacolo
P09392979T0000 |59 69|Californianucleotida
P09392979T0000 |44 57|San Franciscophatases and 
P09392979T0000 |26 40|histoplasmosiswith alkaline 
P09393706A1171 |68 76|promoterase P000
P09393706A1171 |47 56|activatortases and
P09393706A1171 |6 9|Fis606
P09393717A1517 |171 175|mutA] is
P09393717A1517 |60 70|expressionucleotidas
P09393717A1517 |99 116|mutator phenotypec aspects of neon
P09393717A1517 |6 18|observations606T0076 Com
P09393717A1517 |149 158|phenotype7A0472 Wh
P09393717A1517 |180 190|mutC cellsn as a fun
P09393717A1517 |50 54|ideaes a
P09393717A1517 |81 85|tRNAT000
P09393717A1517 |34 41|supportaline p
P09393771A1659 |0 18|TNF-alpha exposureP00001606T0076 Com
P09393771A1659 |128 135|proteinlirubin
P09393771A1659 |38 46|activitye phosph
P09393771A1659 |99 101|Mrc 
P09393771A1659 |70 78|proteinse P00008
P09393875A0873 |85 91|copies0 Phar
P09393875A0873 |28 42|papillomavirusth alkaline ph
P09393875A0873 |195 202|factors of CSF
P09393875A0873 |156 167|c-fos mRNAsWhen CSF [H
P09393875A0873 |99 111|virus genomec aspects of
P09393875A0873 |266 280|papillomavirusompared to con
P09393875A0873 |132 137|cellsbinem
P09393875A0873 |290 295|cellsstill
P09393875A0873 |48 53|mRNAsases 
P09393875A0873 |238 256|Fos protein levelse no longer displa
P09393966A0190 |33 45|region geneskaline phosp
P09393966A0190 |20 23|IgHris
P09393966A0190 |47 50|CHAtas
P09393966A0190 |55 58|CHBd 5
P09394650A0121 |16 21|studyompar
P09394650A0121 |79 90|lymph nodes71T0000 Pha
P09394650A0121 |122 124|USyp
P09394650A0121 |4 7|aim016
P09395456A0424 |187 201|signal peptidefunction of CS
P09395456A0424 |106 124|proenteropeptidasets of neonatal hyp
P09395456A0424 |13 17|role6 Co
P09395456A0424 |75 83|variants008171T0
P09395456A0424 |43 64|substrate recognitionsphatases and 5-nucle
P09395456A0424 |27 39|chain motifsith alkaline
P09395456A0424 |159 179|transmembrane domainn CSF [HCO3-] is sho
P09395470A0294 |0 12|CKbeta4GT-IIP00001606T00
P09395470A0294 |46 72|transmembrane glycoproteinatases and 5-nucleotidase 
P09395470A0294 |112 131|glycosylation sitesneonatal hyperbilir
P09395470A0294 |79 82|kDa71T
P09395470A0294 |38 42|typee ph
P09395525A0395 |186 200|IGF-I promoter function of C
P09395525A0395 |47 54|proteintases a
P09395525A0395 |160 170|C/EBPdelta CSF [HCO3
P09395525A0395 |56 61|C/EBP 5-nu
P09395525A0395 |123 130|complexperbili
P09395525A0395 |63 68|deltaeotid
P09395525A0395 |141 145|HS3DP000
P09395525A0395 |80 89|component1T0000 Ph
P09395525A0395 |216 220|site of 
P09396402A0264 |85 87|HD0 
P09396402A0264 |193 205|radiotherapyon of CSF PC
P09396402A0264 |72 78|stagesP00008
P09396402A0264 |13 20|METHODS6 Compa
P09396402A0264 |172 179|effects is sho
P09396402A0264 |22 36|Semen analysesson with alkal
P09396402A0264 |58 66|patients-nucleot
P09396402A0264 |227 239|chemotherapyted rats are
P09396402A0264 |141 152|sperm countP00008997A0
P09396402A0264 |114 126|chemotherapyonatal hyper
P09396402A0264 |0 8|PATIENTSP0000160
P09396427A1488 |117 125|dilationtal hype
P09396427A1488 |195 203|geometry of CSF 
P09396427A1488 |30 52|infarct-zone viability alkaline phosphatases
P09396427A1488 |67 75|patientsdase P00
P09396427A1488 |10 17|absence0076 Co
P09396427A1488 |143 146|AMI000
P09396437A0878 |115 123|subjectsnatal hy
P09396437A0878 |78 86|subjects171T0000
P09396437A0878 |57 58|%5
P09396437A0878 |7 17|BMI cutoff06T0076 Co
P09396437A0878 |125 126|Pr
P09396437A0878 |38 50|NE spillovere phosphatas
P09396722A0185 |118 122|geneal h
P09396722A0185 |45 76|ascorbate peroxidase isoenzymeshatases and 5-nucleotidase P000
P09396722A0185 |4 8|gene0160
P09396722A0185 |10 15|ApxII0076 
P09396722A0185 |98 110|organizationic aspects o
P09396796A1173 |137 142|CDF-1ia. P
P09396796A1173 |52 69|E2F family member and 5-nucleotida
P09396796A1173 |93 104|differencescologic asp
P09396796A1173 |147 150|E2F997
P09396796A1173 |74 80|points000817
P09396796A1173 |36 41|CDF-1ine p
P09396796A1173 |112 133|cell cycle regulationneonatal hyperbilirub
P09396796A1173 |20 30|conclusionrison with
P09396823T0000 |17 23|domainmparis
P09396823T0000 |82 105|RNA exonuclease domains0000 Pharmacologic aspe
P09396823T0000 |44 58|DNA polymerasephatases and 5
P09396823T0000 |71 74|DNA P0
P09397261A0940 |0 20|Interleukin-1 levelsP00001606T0076 Compa
P09397261A0940 |49 55|courseses an
P09397723T0001 |0 22|Responsibility mattersP00001606T0076 Compari
P09397723T0001 |45 52|councilhatases
P09398267A0440 |119 123|MEK2l hy
P09398267A0440 |56 59|DNA 5-
P09398267A0440 |73 97|chick embryo fibroblasts00008171T0000 Pharmacolo
P09398267A0440 |165 172|species[HCO3-]
P09398267A0440 |141 145|geneP000
P09398267A0440 |99 102|CEFc a
P09398267A0440 |0 22|Southern blot analysisP00001606T0076 Compari
P09398332A0732 |0 9|SequencesP00001606
P09398332A0732 |106 114|sequencets of ne
P09398332A0732 |46 52|CTLA-4atases
P09398332A0732 |195 202|165YVKM of CSF
P09398332A0732 |38 41|mu2e p
P09398332A0732 |23 34|interactionon with alk
P09398332A0732 |93 99|CTLA-4cologi
P09398332A0732 |176 193|SH2 binding motifshown as a functi
P09398332A0732 |216 232|CTLA-4 signaling of K-depleted r
P09398332A0732 |81 89|161TTGVYT0000 Ph
P09398332A0732 |71 79|residues P000081
P09398598A0256 |205 214|multimersO2 the da
P09398598A0256 |58 61|CHO-nu
P09398598A0256 |43 56|hamster ovarysphatases and
P09398598A0256 |63 72|cell lineeotidase 
P09398598A0256 |142 149|domains0000899
P09398598A0256 |93 105|CD4 fragmentcologic aspe
P09398598A0256 |174 183|moleculess shown a
P09398855A0438 |0 6|SCID VP00001
P09398855A0438 |87 93|agentsPharma
P09398855A0438 |117 126|bieomycintal hyper
P09398855A0438 |154 162|p53 gene2 When C
P09398855A0438 |293 296|p53ll 
P09398855A0438 |95 112|gamma-irradiationlogic aspects of 
P09398855A0438 |265 274|apoptosiscompared 
P09398855A0438 |240 250|DNA damageno longer 
P09398855A0438 |282 289|absenceols but
P09398855A0438 |9 24|J recombinationT0076 Compariso
P09398855A0438 |228 236|responseed rats 
P09398855A0438 |50 63|T-lymphocyteses and 5-nucl
P09398855A0438 |138 146|mutationa. P0000
P09398855A0438 |7 8|D0
P09398855A0438 |205 224|DNA repair activityO2 the data of K-de
P09400613A0594 |0 12|CoexpressionP00001606T00
P09400613A0594 |219 228|mouse PKR K-deplet
P09400613A0594 |57 70|domain fusion5-nucleotidas
P09400613A0594 |124 136|K296R mutanterbilirubine
P09400613A0594 |300 310|activation a signifi
P09400613A0594 |180 190|K64E/K296Rn as a fun
P09400613A0594 |16 25|mouse PKRomparison
P09400613A0594 |327 341|lacZ reportersope (1.21 +/- 
P09400613A0594 |253 287|PKR-Gal4 activation domain fusionsplaced when compared to controls b
P09400613A0594 |113 116|PKReon
P09400613A0594 |40 44|Gal4phos
P09400613A0594 |318 322|HIS3reat
P09400613A0594 |170 173|PKR-] 
P09400613A1209 |53 64|interactionand 5-nucle
P09400613A1209 |93 105|PKR homologscologic aspe
P09400613A1209 |77 82|mouse8171T
P09400613A1209 |6 35|GST-PKR fusion chromatography606T0076 Comparison with alka
P09400738A1046 |87 91|ufCBPhar
P09400738A1046 |29 37|responseh alkali
P09400738A1046 |107 122|CB instillations of neonatal h
P09400738A1046 |71 83|instillation P00008171T0
P09402029A1632 |54 67|hybridizationnd 5-nucleoti
P09402029A1632 |242 254|strain H37Rv longer disp
P09402029A1632 |193 205|copy numberson of CSF PC
P09402029A1632 |29 41|strain H37Rah alkaline p
P09402029A1632 |83 89|probes000 Ph
P09402029A1632 |160 166|strain CSF [
P09402029A1632 |113 118|geneseonat
P09402088A2250 |17 22|doubtmpari
P09402088A2250 |46 59|configurationatases and 5-
P09402088A2250 |99 117|AVP gene precursorc aspects of neona
P09402088A2250 |6 13|defects606T007
P09402088A2250 |81 91|processingT0000 Phar
P09402139A1121 |0 12|SimilaritiesP00001606T00
P09402139A1121 |113 120|insulineonatal
P09402139A1121 |25 33|hIGFBP-1 with al
P09402139A1121 |94 101|regionsologic 
P09402139A1121 |270 288|glucose metabolismred to controls bu
P09402139A1121 |122 136|glucocorticoidyperbilirubine
P09402139A1121 |233 240|IGFBP-1ts are 
P09402139A1121 |73 82|promoters00008171T
P09402139A1121 |256 266|regulationced when c
P09402139A1121 |217 227|hypothesisof K-deple
P09402139A1121 |66 71|PEPCKidase
P09402139A1121 |173 182|responsesis shown 
P09402139A1121 |38 64|phosphoenolpyruvate kinasee phosphatases and 5-nucle
P09403059A0209 |139 146|element. P0000
P09403059A0209 |72 77|SINESP0000
P09403059A0209 |12 18|repeat76 Com
P09403059A0209 |39 51|DNA elements phosphatase
P09403059A0209 |79 115|medium reiteration frequency repeats71T0000 Pharmacologic aspects of neo
P09403059A0209 |65 70|LINEStidas
P09404725A0644 |103 112|exceptionpects of 
P09404725A0644 |62 69|femalesleotida
P09404725A0644 |15 21|amountCompar
P09404725A0644 |25 37|gangliosides with alkali
P09404725A0644 |78 83|males171T0
P09404725A0644 |6 10|days606T
P09405195A0320 |53 58|locusand 5
P09405195A0320 |105 114|sequencescts of ne
P09405195A0320 |160 163|DNA CS
P09405195A0320 |226 229|DNAete
P09405195A0320 |73 86|recombination00008171T0000
P09405195A0320 |14 24|constructs Compariso
P09405195A0320 |247 260|recombinationer displaced 
P09405195A0320 |128 137|stretcheslirubinem
P09405195A0320 |172 187|intron excision is shown as a 
P09405380A0800 |70 76|systeme P000
P09405380A0800 |41 48|strainshosphat
P09405380A0800 |90 100|propertiesrmacologic
P09405380A0800 |129 139|retrovirusirubinemia
P09405380A0800 |27 37|categoriesith alkali
P09405380A0800 |4 13|existence01606T007
P09405536A0777 |186 206|conditioning stimuli function of CSF PCO
P09405536A0777 |224 233|magnitudepleted ra
P09405536A0777 |261 268|plateauhen com
P09405536A0777 |11 33|conditioning procedure076 Comparison with al
P09405536A0777 |104 111|fashionects of
P09405536A0777 |241 250|responseso longer 
P09405536A0777 |155 166|application When CSF [
P09405536A0777 |39 46|C-fiber phosph
P09405536A0777 |136 143|animalsmia. P0
P09405685A0113 |152 161|GPyPyPy-3472 When 
P09405685A0113 |148 151|T/A97A
P09405685A0113 |91 106|consensus motifmacologic aspec
P09405685A0113 |110 117|PuPuPuCf neona
P09405685A0113 |128 142|GPyPyPyPuPuPuClirubinemia. P
P09405685A0113 |57 60|p535-n
P09405685A0113 |124 127|T/Aerb
P09405685A0113 |143 146|A/T000
P09405685A0113 |23 55|DNA binding transcription factoron with alkaline phosphatases an
P09405685A0113 |118 121|A/Tal 
P09407026A0426 |0 13|TSA treatmentP00001606T007
P09407026A0426 |80 91|positioning1T0000 Phar
P09407026A0426 |293 303|remodelingll have a 
P09407026A0426 |95 100|nuc-1logic
P09407026A0426 |124 143|chromatin templateserbilirubinemia. P0
P09407026A0426 |333 340|factors.21 +/-
P09407026A0426 |160 179|protein acetylation CSF [HCO3-] is sho
P09407026A0426 |221 226|steps-depl
P09407026A0426 |49 72|enhancer factor bindingses and 5-nucleotidase 
P09407026A0426 |184 204|chromatin remodeling a function of CSF P
P09407026A0426 |307 312|nuc-1ifica
P09407026A0426 |108 116|majority of neon
P09407026A0426 |274 283|templatesto contro
P09407031A0557 |16 20|Crb2ompa
P09407031A0557 |158 173|Cdc2 activationen CSF [HCO3-] 
P09407031A0557 |96 111|phosphorylationogic aspects of
P09407031A0557 |115 126|Chk1 kinasenatal hyper
P09407031A0557 |5 14|UV damage1606T0076
P09407031A0557 |86 92|timing Pharm
P09407031A0974 |19 33|overexpressionarison with al
P09407031A0974 |57 67|phenotypes5-nucleoti
P09407031A0974 |80 92|crb2 mutants1T0000 Pharm
P09407031A0974 |37 41|Chk1ne p
P09407031A0974 |71 75|cut5 P00
P09407036T0000 |0 11|Tcn1p/Crz1pP00001606T0
P09407036T0000 |88 103|gene expressionharmacologic as
P09407036T0000 |37 57|transcription factorne phosphatases and 
P09407090T0000 |0 9|StructureP00001606
P09407090T0000 |40 44|genephos
P09407090T0000 |14 26|localization Comparison 
P09407090T0000 |54 63|SR-BI/CLAnd 5-nucl
P09407642A0305 |18 31|gel techniqueparison with 
P09407642A0305 |78 92|identification171T0000 Pharm
P09407642A0305 |45 50|assayhatas
P09407642A0305 |55 73|antibody detectiond 5-nucleotidase P
P09408516T0000 |0 9|StabilityP00001606
P09408516T0000 |13 26|pyrimethamine6 Comparison 
P09408516T0000 |75 81|months008171
P09408516T0000 |39 57|dosage formulation phosphatases and 
P09408796A0648 |171 183|CVLT indices] is shown a
P09408796A0648 |9 28|regression analysesT0076 Comparison wi
P09408796A0648 |161 166|WMS-RCSF [
P09408796A0648 |89 96|Freedomarmacol
P09408796A0648 |149 157|variance7A0472 W
P09408796A0648 |140 141|% 
P09408796A0648 |43 84|WAIS-R factor scores Verbal Comprehensionsphatases and 5-nucleotidase P00008171T00
P09408796A0648 |102 117|Distractibilityspects of neona
P09409416A0111 |16 24|arteriesompariso
P09409416A0111 |60 68|approachucleotid
P09409416A0111 |109 121|TC-2 64B EMEof neonatal 
P09409416A0111 |89 107|Doppler instrumentarmacologic aspect
P09409416A0111 |78 81|MHz171
P09409774A0214 |218 229|polypeptidef K-deplete
P09409774A0214 |15 20|levelCompa
P09409774A0214 |43 50|memberssphatas
P09409774A0214 |177 187|VCSB1 genehown as a 
P09409774A0214 |26 35|sequenceswith alka
P09409774A0214 |151 167|polypeptide SMR10472 When CSF [H
P09409774A0214 |110 120|VCSA1 genef neonatal
P09409774A0214 |59 65|familynucleo
P09409774A0214 |83 104|rat Rattus norvegicus000 Pharmacologic asp
P09409821T0000 |116 125|functionsatal hype
P09409821T0000 |29 39|RAD30 geneh alkaline
P09409821T0000 |73 77|dinB0000
P09409821T0000 |91 101|DNA damagemacologic 
P09409821T0000 |43 52|homologuesphatases
P09409821T0000 |148 180|postreplication repair mechanism97A0472 When CSF [HCO3-] is show
P09409821T0000 |82 86|umuC0000
P09411459A0729 |18 28|experimentparison wi
P09411459A0729 |165 170|level[HCO3
P09411459A0729 |75 86|puppet game008171T0000
P09411459A0729 |97 108|pretraininggic aspects
P09411459A0729 |42 55|deletion taskosphatases an
P09411459A0729 |126 140|vowel deletionbilirubinemia.
P09411459A0729 |228 241|CVCC materialed rats are n
P09411459A0729 |113 122|selectioneonatal h
P09411459A0729 |202 210|children PCO2 th
P09411459A0729 |174 181|successs shown
P09412079T0001 |0 12|Diet therapyP00001606T00
P09412079T0001 |43 57|stomach ulcerssphatases and 
P09412079T0001 |18 30|soy proteinsparison with
P09413375A1486 |103 124|plasma concentrationspects of neonatal hyp
P09413375A1486 |128 137|cytokineslirubinem
P09413375A1486 |95 99|riselogi
P09413375A1486 |62 72|IL-6 levelleotidase 
P09413375A1486 |21 24|LISiso
P09413375A1486 |54 58|risend 5
P09413375A1486 |3 15|ICU patients001606T0076 
P09414074A0827 |0 19|Resistance trainingP00001606T0076 Comp
P09414074A0827 |76 88|measurements08171T0000 P
P09414074A0827 |213 216|SSPata
P09414074A0827 |57 66|direction5-nucleot
P09414074A0827 |31 42|power curvealkaline ph
P09414074A0827 |118 123|loadsal hy
P09414074A0827 |143 148|power00089
P09414074A0827 |187 203|performance taskfunction of CSF 
P09414287A0637 |0 16|Gel-shift assaysP00001606T0076 C
P09414287A0637 |62 69|elementleotida
P09414287A0637 |32 49|Sp1 binding siteslkaline phosphata
P09414319A1442 |0 6|Y15170P00001
P09414319A1442 |62 68|Y15172leotid
P09414319A1442 |33 39|Surf-3kaline
P09414319A1442 |25 31|Y15171 with 
P09414319A1442 |8 14|Surf-26T0076
P09414319A1442 |41 47|Surf-1hospha
P09414319A1442 |70 76|Surf-5e P000
P09414319A1442 |49 55|Surf-6ses an
P09414319A1442 |16 22|Surf-4ompari
P09415711A1348 |0 18|Gel mobility shiftP00001606T0076 Com
P09415711A1348 |62 70|extractsleotidas
P09415711A1348 |83 92|rat liver000 Pharm
P09415711A1348 |144 160|alpha 1B-AR gene008997A0472 When
P09415711A1348 |167 186|CRE binding proteinCO3-] is shown as a
P09415711A1348 |133 136|CREine
P09415711A1348 |48 53|liverases 
P09415711A1348 |96 110|DDT1MF-2 cellsogic aspects o
P09415711A1348 |35 41|assaysline p
P09416467A0959 |103 123|ischemia-reperfusionpects of neonatal hy
P09416467A0959 |209 213|rolehe d
P09416467A0959 |81 92|arrhythmiasT0000 Pharm
P09416467A0959 |234 240|effects are 
P09416467A0959 |6 13|results606T007
P09416467A0959 |56 70|ACE inhibitors 5-nucleotidas
P09416467A0959 |168 173|drugsO3-] 
P09416467A0959 |141 158|scavenging actionP00008997A0472 Wh
P09416467A0959 |49 54|modelses a
P09416898A1798 |35 45|componentsline phosp
P09416898A1798 |82 95|ARVD patients0000 Pharmaco
P09416898A1798 |108 116|subjects of neon
P09416898A1798 |4 15|mean values01606T0076 
P09417082A0127 |47 65|urokinase receptortases and 5-nucleo
P09417082A0127 |13 30|signaling cascade6 Comparison with
P09417108A0000 |94 102|promoterologic a
P09417108A0000 |29 41|Htf9-c genesh alkaline p
P09417108A0000 |11 24|Htf9-a/RanBP1076 Compariso
P09417493A0823 |51 59|decreases and 5-
P09417493A0823 |63 84|laboratory indicatorseotidase P00008171T00
P09417493A0823 |122 139|alpha 2-globulineyperbilirubinemia
P09417493A0823 |88 100|inflammationharmacologic
P09417493A0823 |28 39|improvementth alkaline
P09417493A0823 |141 157|prostaglandin E2P00008997A0472 W
P09417493A0823 |113 120|proteineonatal
P09417493A0823 |3 13|accordance001606T007
P09417870A0105 |119 137|phorbol dibutyratel hyperbilirubinem
P09417870A0105 |178 191|melanogenesisown as a func
P09417870A0105 |76 85|treatment08171T000
P09417870A0105 |89 113|B16 mouse melanoma cellsarmacologic aspects of n
P09417870A0105 |46 62|protein kinase Catases and 5-nuc
P09417870A0105 |155 159|cell Whe
P09417870A0105 |33 42|depletionkaline ph
P09417870A0105 |139 143|PDBu. P0
P09417928A0980 |0 11|ReplacementP00001606T0
P09417928A0980 |15 23|residuesComparis
P09417928A0980 |27 36|positionsith alkal
P09417928A0980 |56 58|+2 5
P09417928A0980 |41 50|His128Asnhosphatas
P09417928A0980 |60 69|Gln155Lysucleotida
P09417928A0980 |97 104|fingersgic asp
P09417928A0980 |78 93|reading helices171T0000 Pharma
P09417928A0980 |138 145|bindinga. P000
P09417941A1287 |51 73|spermadhesin moleculess and 5-nucleotidase P
P09417941A1287 |209 215|domainhe dat
P09417941A1287 |149 151|LG7A
P09417941A1287 |83 94|CUB domains000 Pharmac
P09417941A1287 |197 201|facef CS
P09417941A1287 |179 184|edgeswn as
P09417941A1287 |106 113|loop LAts of n
P09417941A1287 |118 129|strand betaal hyperbil
P09417941A1287 |4 22|disulphide bridges01606T0076 Compari
P09417941A1287 |136 144|loops LEmia. P00
P09418040T0000 |0 12|Mg-chelataseP00001606T00
P09418040T0000 |256 261|CHL Hced w
P09418040T0000 |249 254|CHL D disp
P09418040T0000 |82 89|subunit0000 Ph
P09418040T0000 |266 272|CHL I.ompare
P09418040T0000 |25 39|identification with alkaline
P09418040T0000 |179 193|reconstitutionwn as a functi
P09418040T0000 |91 99|analysismacologi
P09418040T0000 |150 155|yeastA0472
P09418040T0000 |132 140|subunitsbinemia.
P09418040T0000 |45 64|Chl D cDNA sequencehatases and 5-nucle
P09418040T0000 |220 233|co-expressionK-depleted ra
P09418040T0000 |16 23|tobaccoomparis
P09418040T0000 |167 173|systemCO3-] 
P09418040T0000 |107 118|interactions of neonat
P09418040T0000 |201 216|enzyme activityF PCO2 the data
P09418057A0684 |55 64|locationsd 5-nucle
P09418057A0684 |27 35|sequenceith alka
P09418057A0684 |4 9|R-EST01606
P09418861A0623 |51 56|motifs and
P09418861A0623 |125 151|pleckstrin homology domainrbilirubinemia. P00008997A
P09418861A0623 |98 109|n-chimaerinic aspects 
P09418861A0623 |77 93|protein kinase C8171T0000 Pharma
P09418861A0623 |16 25|structureomparison
P09418871A0620 |32 36|E2F1lkal
P09418871A0620 |24 27|DDBn w
P09418871A0620 |61 94|coimmunoprecipitation experimentscleotidase P00008171T0000 Pharmac
P09418871A0620 |4 15|interaction01606T0076 
P09418882A0760 |103 111|U1 snRNApects of
P09418882A0760 |60 67|versionucleoti
P09418882A0760 |71 77|Prp42p P0000
P09418882A0760 |14 24|antibodies Compariso
P09418882A0760 |117 131|yeast extractstal hyperbilir
P09418905A1396 |71 74|Ras P0
P09418905A1396 |149 162|S-phase entry7A0472 When C
P09418905A1396 |31 39|additionalkaline
P09418905A1396 |127 130|EGFili
P09418905A1396 |57 67|activation5-nucleoti
P09418905A1396 |215 218|PKCa o
P09418905A1396 |167 182|gene expressionCO3-] is shown 
P09418905A1396 |96 110|DAG productionogic aspects o
P09418905A1396 |6 13|results606T007
P09418905A1396 |201 211|activationF PCO2 the
P09419415A0236 |68 89|fibroblast cell linesase P00008171T0000 Ph
P09419415A0236 |31 46|STAT activationalkaline phosph
P09419415A0236 |8 13|study6T007
P09419415A0236 |126 138|oncoproteinsbilirubinemi
P09419415A0236 |52 57|panel and 
P09419421A0385 |54 58|TKC1nd 5
P09419421A0385 |91 98|plateaumacolog
P09419421A0385 |31 38|bindingalkalin
P09419421A0385 |42 50|NF-Y/CBFosphatas
P09419421A0385 |106 113|S phasets of n
P09419421A0385 |20 25|cellsrison
P09419680A1112 |0 10|CONCLUSIONP00001606T
P09419680A1112 |104 119|single-fractionects of neonata
P09419680A1112 |45 63|barrier disruptionhatases and 5-nucl
P09419680A1112 |93 100|findingcologic
P09419680A1112 |131 149|irradiation injuryubinemia. P0000899
P09419680A1112 |19 31|animal modelarison with 
P09420219A0284 |68 74|exportase P0
P09420219A0284 |319 325|genomeeater 
P09420219A0284 |284 287|ends b
P09420219A0284 |18 31|investigationparison with 
P09420219A0284 |295 310|adenovirus type have a signifi
P09420219A0284 |240 251|tumor virusno longer d
P09420219A0284 |314 317|Ad5ly 
P09420219A0284 |226 231|mouseeted 
P09420219A0284 |135 154|beta-actin minigeneemia. P00008997A047
P09420219A0284 |165 172|control[HCO3-]
P09420219A0284 |35 45|parametersline phosp
P09420219A0284 |98 103|cellsic as
P09420219A0284 |205 222|enhancer-promoterO2 the data of K-
P09420220A0070 |137 141|geneia. 
P09420220A0070 |143 145|J.00
P09420220A0070 |105 109|HCMVcts 
P09420220A0070 |87 97|expressionPharmacolo
P09420220A0070 |32 44|interactionslkaline phos
P09420220A0070 |0 4|CellP000
P09420234A0654 |0 9|MpB GroELP00001606
P09420234A0654 |88 95|membersharmaco
P09420234A0654 |47 48|%t
P09420234A0654 |24 43|sequence similarityn with alkaline pho
P09420234A0654 |72 77|GroELP0000
P09420234A0654 |103 123|chaperonin-60 familypects of neonatal hy
P09420239A1937 |100 102|TM a
P09420239A1937 |13 22|mutations6 Compari
P09420239A1937 |107 127|Nef coding sequencess of neonatal hyperb
P09420239A1937 |217 224|changesof K-de
P09420239A1937 |82 92|elongation0000 Pharm
P09420239A1937 |261 293|consensus neutralization epitopehen compared to controls but sti
P09420239A1937 |177 191|TATA box siteshown as a func
P09420239A1937 |245 247|SUng
P09420239A1937 |129 136|changesirubine
P09420239A1937 |197 206|Sp1 sitesf CSF PCO
P09420239A1937 |161 175|acceptor sitesCSF [HCO3-] is
P09420239A1937 |317 336|glycosylation sitesgreater slope (1.21
P09420239A1937 |140 156|RNA splice donor P00008997A0472 
P09420239A1937 |232 241|V2 regionats are n
P09420239A1937 |340 342|SU 0
P09420251A1363 |0 2|C.P0
P09420252A0092 |102 110|proteinsspects o
P09420252A0092 |225 243|auxiliary proteinsleted rats are no 
P09420252A0092 |134 142|promoternemia. P
P09420252A0092 |178 186|env geneown as a
P09420252A0092 |41 49|promoterhosphata
P09420252A0092 |167 170|endCO3
P09420252A0092 |28 34|repeatth alk
P09420252A0092 |36 39|LTRine
P09420252A0092 |67 77|expressiondase P0000
P09420252A0092 |201 211|expressionF PCO2 the
P09420269A0000 |239 242|RNA no
P09420269A0000 |301 310|synthesisa signifi
P09420269A0000 |288 296|promotert still 
P09420269A0000 |327 334|strandsope (1.
P09420269A0000 |48 51|RUBase
P09420269A0000 |185 195|complementa function
P09420269A0000 |249 251|SL d
P09420269A0000 |146 155|structure8997A0472
P09420269A0000 |26 29|RNAwit
P09420269A0000 |215 218|enda o
P09420269A0000 |162 164|SLSF
P09420269A0000 |79 81|nt71
P09420269A0000 |167 169|ntCO
P09420269A0000 |107 116|ss-leaders of neon
P09420269A0000 |99 105|leaderc aspe
P09420269A0000 |7 10|end06T
P09420269A0000 |33 46|rubella viruskaline phosph
P09420275A0682 |19 31|requirementsarison with 
P09420275A0682 |196 205|sequencesof CSF PC
P09420275A0682 |77 93|oligonucleotides8171T0000 Pharma
P09420275A0682 |161 174|core sequenceCSF [HCO3-] i
P09420275A0682 |67 73|seriesdase P
P09420275A0682 |110 132|transversion mutationsf neonatal hyperbiliru
P09420275A0682 |36 48|CBF2 bindingine phosphat
P09420275A1111 |17 27|affinitiesmparison w
P09420275A1111 |62 67|LMP-2leoti
P09420275A1111 |31 35|CBF2alka
P09420275A1111 |55 60|LMP-1d 5-n
P09420275A1111 |73 87|CD23 promoters00008171T0000 
P09420275A1111 |3 11|addition001606T0
P09420671A1190 |0 11|CONCLUSIONSP00001606T0
P09420671A1190 |135 143|exerciseemia. P0
P09420671A1190 |163 179|adenosine stressF [HCO3-] is sho
P09420671A1190 |145 157|dipyridamole08997A0472 W
P09420671A1190 |77 85|patients8171T000
P09420671A1190 |28 34|uptaketh alk
P09420671A1190 |64 72|subjectsotidase 
P09420671A1190 |38 53|99mTc sestamibie phosphatases 
P09420671A1190 |100 114|artery disease aspects of ne
P09421507A0000 |64 81|pre-mRNA splicingotidase P00008171
P09421507A0000 |144 153|organisms008997A04
P09421507A0000 |7 21|protein family06T0076 Compar
P09421508A0696 |87 95|presencePharmaco
P09421508A0696 |130 148|transfection assayrubinemia. P000089
P09421508A0696 |31 36|TCF11alkal
P09421508A0696 |99 103|MafGc as
P09421508A0696 |59 63|sitenucl
P09421508A0696 |19 27|activityarison w
P09421511A0827 |153 161|position72 When 
P09421511A0827 |49 58|evolutionses and 5
P09421511A0827 |99 128|telomerase RNA-gene promotersc aspects of neonatal hyperbi
P09421511A0827 |194 208|telomerase RNAn of CSF PCO2 
P09421511A0827 |16 27|comparisonsomparison w
P09421511A0827 |169 186|template sequence3-] is shown as a
P09421511A0827 |69 95|RNA-polymerase specificityse P00008171T0000 Pharmaco
P09421516A1516 |220 238|deadenylation stepK-depleted rats ar
P09421516A1516 |181 191|K562 cells as a func
P09421516A1516 |96 109|NIH 3T3 cellsogic aspects 
P09421516A1516 |161 177|beta-globin mRNACSF [HCO3-] is s
P09421516A1516 |27 43|beta-globin mRNAith alkaline pho
P09421516A1516 |47 57|K562 cellstases and 
P09421516A1516 |18 23|decayparis
P09421516A1516 |141 150|stabilityP00008997
P09421516A1516 |0 13|DeadenylationP00001606T007
P09421521T0000 |0 27|Holliday junction resolvaseP00001606T0076 Comparison w
P09421521T0000 |71 92|endonuclease activity P00008171T0000 Pharm
P09421521T0000 |100 119|CCE1 homologue YDC2 aspects of neonata
P09422351A0000 |0 3|Ca2P00
P09422351A0000 |26 40|protein kinasewith alkaline 
P09422351A0000 |122 134|ion channelsyperbilirubi
P09422351A0000 |75 106|serine/threonine protein kinase008171T0000 Pharmacologic aspec
P09422351A0000 |45 49|CaMKhata
P09422351A0000 |191 212|transcription factorstion of CSF PCO2 the 
P09422351A0000 |146 153|enzymes8997A04
P09422351A0000 |168 176|proteinsO3-] is 
P09422727A0196 |187 191|CREBfunc
P09422727A0196 |166 185|CRE binding proteinHCO3-] is shown as 
P09422727A0196 |132 141|inductionbinemia. 
P09422727A0196 |42 50|TGACGTGAosphatas
P09422727A0196 |264 271|process compar
P09422727A0196 |147 157|activation997A0472 W
P09422727A0196 |208 230|transcription factor-2the data of K-depleted
P09422727A0196 |52 69|promoter sequence and 5-nucleotida
P09422727A0196 |76 110|protein kinase A signaling pathway08171T0000 Pharmacologic aspects o
P09422727A0196 |232 237|ATF-2ats a
P09423123A0000 |0 4|IVOXP000
P09423123A0000 |47 57|oxygenatortases and 
P09423123A0000 |21 28|acronymison wi
P09423310A0251 |0 19|HistopathologicallyP00001606T0076 Comp
P09423310A0251 |165 172|antigen[HCO3-]
P09423310A0251 |30 42|lymphangioma alkaline ph
P09423310A0251 |145 151|Factor08997A
P09423310A0251 |227 232|cellsted r
P09423310A0251 |123 132|stainingsperbiliru
P09423310A0251 |240 245|cystsno lo
P09423310A0251 |86 94|features Pharmac
P09423310A0251 |202 211|reactions PCO2 the
P09423310A0251 |136 140|CD34mia.
P09423856A1098 |0 19|Protease activitiesP00001606T0076 Comp
P09423856A1098 |178 188|processingown as a f
P09423856A1098 |144 147|kDa008
P09423856A1098 |213 228|autoproteolysisata of K-deplet
P09423856A1098 |245 258|peptide bondsnger displace
P09423856A1098 |113 119|masseseonata
P09423856A1098 |53 60|strainsand 5-n
P09423856A1098 |23 31|cultureson with 
P09423856A1098 |82 89|species0000 Ph
P09423856A1098 |277 282|partscontr
P09423856A1098 |203 209|resultPCO2 t
P09423856A1098 |290 299|moleculesstill hav
P09423968A0039 |152 159|defense472 Whe
P09423968A0039 |226 237|nociceptioneted rats a
P09423968A0039 |166 170|painHCO3
P09423968A0039 |74 85|interaction0008171T000
P09423968A0039 |30 39|analgesia alkaline
P09423968A0039 |143 150|systems0008997
P09423968A0039 |282 290|ontogenyols but 
P09423968A0039 |214 221|defenseta of K
P09423968A0039 |245 254|processesnger disp
P09423968A0039 |4 13|mechanism01606T007
P09423968A0039 |294 298|ratsl ha
P09423968A0039 |204 210|courseCO2 th
P09424012A1774 |68 80|mm distancesase P0000817
P09424012A1774 |40 48|patientsphosphat
P09424012A1774 |12 34|field placement errors76 Comparison with alk
P09424012A1774 |226 232|errorseted r
P09424012A1774 |180 185|errorn as 
P09424012A1774 |162 168|degreeSF [HC
P09424012A1774 |145 152|patient08997A0
P09424012A1774 |113 122|isocentereonatal h
P09425036A0649 |86 97|cell kinase Pharmacolo
P09425036A0649 |144 157|Csk substrate008997A0472 W
P09425036A0649 |72 75|LckP00
P09425036A0649 |38 45|versione phosp
P09425036A0649 |53 70|Src family memberand 5-nucleotidas
P09425036A0649 |3 11|addition001606T0
P09425038A0752 |0 2|A.P0
P09425038A0752 |11 13|A.07
P09425038A0752 |4 9|Swift01606
P09425676A0000 |50 53|S-Res 
P09425676A0000 |9 19|mechanismsT0076 Comp
P09425676A0000 |133 140|monkeysinemia.
P09425676A0000 |31 48|stimulus-responsealkaline phosphat
P09425676A0000 |71 94|S-R compatibility tasks P00008171T0000 Pharmac
P09425676A0000 |55 67|associationsd 5-nucleoti
P09425676A0000 |116 127|experimentsatal hyperb
P09426068A0826 |4 24|c-myc/TGF-alpha HCCs01606T0076 Compariso
P09426068A0826 |74 84|expression0008171T00
P09426068A0826 |183 190|tissuess a fun
P09426068A0826 |88 97|TGF-alphaharmacolo
P09426068A0826 |195 205|c-myc HCCs of CSF PC
P09426068A0826 |121 126|indexhyper
P09426068A0826 |147 153|levels997A04
P09426068A0826 |130 138|contrastrubinemi
P09426068A0826 |157 166|apoptosishen CSF [
P09426143A1358 |171 182|competition] is shown 
P09426143A1358 |285 295|DNA region but still
P09426143A1358 |86 96|expression Pharmacol
P09426143A1358 |55 62|effectsd 5-nuc
P09426143A1358 |262 272|occupationen compare
P09426143A1358 |20 24|datariso
P09426143A1358 |303 315|target genessignificantl
P09426143A1358 |199 209|regulatorsCSF PCO2 t
P09426143A1358 |74 78|KdgR0008
P09426143A1358 |104 122|pectinolysis genesects of neonatal h
P09426143A1358 |225 234|repressorleted rat
P09426143A1358 |66 69|CRPida
P09426143A1358 |142 152|mechanisms00008997A0
P09426143A1358 |239 253|RNA polymerase no longer dis
P09426183A0000 |171 179|activity] is sho
P09426183A0000 |128 136|proteinslirubine
P09426183A0000 |147 150|DNA997
P09426183A0000 |208 216|locationthe data
P09426183A0000 |15 35|Rel/NF-kappaB familyComparison with alka
P09426183A0000 |154 160|dimers2 When
P09426183A0000 |39 71|vertebrate transcription factors phosphatases and 5-nucleotidase
P09426183A0000 |84 90|number00 Pha
P09426239A0386 |68 76|additionase P000
P09426239A0386 |42 48|operonosphat
P09426239A0386 |114 133|restriction enzymesonatal hyperbilirub
P09426239A0386 |82 87|genes0000 
P09426239A0386 |4 14|cglIM gene01606T0076
P09426595T0000 |35 61|saccharopine dehydrogenaseline phosphatases and 5-nu
P09426595T0000 |89 108|nucleotide sequencearmacologic aspects
P09426595T0000 |113 129|characterizationeonatal hyperbil
P09426595T0000 |67 87|Arabidopsis thalianadase P00008171T0000 
P09426595T0000 |21 30|reductaseison with
P09426907A0391 |71 90|silver sulfadiazine P00008171T0000 Pha
P09426907A0391 |96 101|waterogic 
P09426907A0391 |110 113|gelf n
P09426907A0391 |56 67|formulation 5-nucleoti
P09426907A0391 |4 11|purpose01606T0
P09426907A0391 |20 33|investigationrison with al
P09426907A0391 |115 124|poloxamernatal hyp
P09426958A0110 |81 101|corneal cDNA libraryT0000 Pharmacologic 
P09426958A0110 |61 66|CO-Agcleot
P09426958A0110 |46 51|cloneatase
P09426958A0110 |122 127|cloneyperb
P09426958A0110 |4 15|study goals01606T0076 
P09427544A0000 |118 129|DNA libraryal hyperbil
P09427544A0000 |89 97|activityarmacolo
P09427544A0000 |46 59|pectate lyaseatases and 5-
P09427544A0000 |61 63|ECcl
P09427544A0000 |21 33|Amycolata spison with al
P09427544A0000 |4 12|pel gene01606T00
P09427544A0000 |155 159|TK24 Whe
P09427551A0501 |49 59|kb intronsses and 5-
P09427551A0501 |22 27|exonsson w
P09427551A0501 |113 129|linkage analysiseonatal hyperbil
P09427551A0501 |97 107|chromosomegic aspect
P09427551A0501 |4 8|gene0160
P09427627A0802 |69 78|formationse P00008
P09427627A0802 |82 90|mesoderm0000 Pha
P09427627A0802 |108 116|explants of neon
P09427627A0802 |3 18|Xenopus embryos001606T0076 Com
P09427627A0802 |140 146|manner P0000
P09427627A0802 |35 56|PDGF receptor proteinline phosphatases and
P09427627A0930 |152 161|treatment472 When 
P09427627A0930 |27 34|proteinith alk
P09427627A0930 |167 173|FK1012CO3-] 
P09427627A0930 |123 126|S6kper
P09427627A0930 |12 19|variant76 Comp
P09427627A0930 |55 75|transphosphorylationd 5-nucleotidase P00
P09427627A0930 |131 141|MAP kinaseubinemia. 
P09427627A0930 |119 122|p70l h
P09427627T0000 |70 74|rolee P0
P09427627T0000 |15 22|controlCompari
P09427627T0000 |78 97|membrane attachment171T0000 Pharmacolo
P09427627T0000 |26 33|insulinwith al
P09427627T0000 |38 61|PDGF receptor signalinge phosphatases and 5-nu
P09427844A0739 |70 81|associatione P00008171
P09427844A0739 |96 107|dCK subunitogic aspect
P09427844A0739 |25 36|dAK subunit with alkal
P09427844A0739 |89 92|dGKarm
P09427844A0739 |166 170|dGuoHCO3
P09427844A0739 |156 162|affectWhen C
P09427844A0739 |174 178|dCyds sh
P09427844A0739 |201 208|subunitF PCO2 
P09428389A1805 |0 11|CONCLUSIONSP00001606T0
P09428389A1805 |226 237|monotherapyeted rats a
P09428389A1805 |209 213|drughe d
P09428389A1805 |164 169|doses [HCO
P09428389A1805 |96 101|agentogic 
P09428389A1805 |76 87|combination08171T0000 
P09428389A1805 |27 31|doseith 
P09428389A1805 |133 151|serum testosteroneinemia. P00008997A
P09428389A1805 |173 185|bicalutamideis shown as 
P09428389A1805 |113 119|LHRH-Aeonata
P09428389A1805 |35 47|bicalutamideline phospha
P09428787A0138 |49 51|kbse
P09428787A0138 |104 131|p69/71 2-5A synthetase geneects of neonatal hyperbilir
P09428787A0138 |92 96|exonacol
P09428787A0138 |10 15|clone0076 
P09428787A0138 |71 77|region P0000
P09428799A0897 |101 125|intron/exon organizationaspects of neonatal hype
P09428799A0897 |165 172|P450scc[HCO3-]
P09428799A0897 |88 95|enzymesharmaco
P09428799A0897 |13 17|gene6 Co
P09428799A0897 |58 63|genes-nucl
P09429913A0528 |152 161|disorders472 When 
P09429913A0528 |191 199|disordertion of 
P09429913A0528 |24 32|questionn with a
P09429913A0528 |40 48|benefitsphosphat
P09429913A0528 |124 132|efficacyerbiliru
P09429913A0528 |0 7|RESULTSP000016
P09429913A0528 |100 107|studies aspect
P09429913A0528 |137 141|EMDRia. 
P09430461A0742 |103 111|infarctspects of
P09430461A0742 |113 114|pe
P09430461A0742 |212 213|pd
P09430461A0742 |297 305|patientsave a si
P09430461A0742 |385 396|defect sizears to be a
P09430461A0742 |332 345|BMIPP imaging1.21 +/- 0.23
P09430461A0742 |27 38|defect sizeith alkalin
P09430461A0742 |418 437|threshold techniquerug with the optimu
P09430461A0742 |367 381|quantificationurazepam thus 
P09430461A0742 |224 234|CONCLUSIONpleted rat
P09430461A0742 |258 262|datad wh
P09430461A0742 |288 293|groupt sti
P09430461A0742 |16 21|studyompar
P09430461A0742 |153 162|risk area72 When C
P09430461A0742 |495 501|amount000126
P09430461A0742 |48 61|BMIPP imagingases and 5-nu
P09430461A0742 |459 464|phaseral p
P09430461A0742 |547 557|infarctionhen extrac
P09430461A0742 |505 515|myocardium045 Beta b
P09430461A0742 |202 203|r 
P09430461A0742 |400 405|meansfecti
P09430461A0742 |474 487|determinationing 15 mg at 
P09430461A0742 |175 200|contrast ventriculography shown as a function of C
P09430461A0742 |519 523|risking 
P09430661A0796 |35 50|EphB1 receptorsline phosphatas
P09430661A0796 |67 82|Nck recruitmentdase P00008171T
P09430661A0796 |52 57|Y594F and 
P09430661A0796 |10 24|overexpression0076 Compariso
P09430661A0796 |115 129|JNK activationnatal hyperbil
P09430661A0796 |143 168|cell attachment responses0008997A0472 When CSF [HC
P09430661A0796 |86 91|EphB1 Phar
P09430668A0172 |70 76|sterole P000
P09430668A0172 |56 61|sites 5-nu
P09430668A0172 |104 112|proteinsects of 
P09430668A0172 |114 120|SREBPsonatal
P09430668A0172 |5 13|promoter1606T007
P09430668A0172 |18 34|HMG-CoA synthaseparison with alk
P09430730A0374 |0 2|S.P0
P09430730A0374 |8 14|Walter6T0076
P09430730A0374 |16 18|P.om
P09431812A0576 |32 39|Patchedlkaline
P09431812A0576 |41 44|Ptchos
P09431812A0576 |149 157|S2 cells7A0472 W
P09431812A0576 |135 145|activationemia. P000
P09431812A0576 |97 102|levelgic a
P09431812A0576 |25 27|Hh w
P09431812A0576 |64 80|Ci binding sitesotidase P0000817
P09431828A1472 |35 52|cyclosporine DR/Cline phosphatases
P09431828A1472 |112 117|rangeneona
P09431828A1472 |91 96|l h-1macol
P09431828A1472 |53 62|SS troughand 5-nuc
P09431828A1472 |23 31|increaseon with 
P09431828A1472 |71 76|l h-1 P000
P09432752A0109 |137 148|applicationia. P000089
P09432752A0109 |166 173|patientHCO3-] 
P09432752A0109 |120 126|moment hyper
P09432752A0109 |19 28|relativesarison wi
P09432752A0109 |76 99|treatment possibilities08171T0000 Pharmacologi
P09432752A0109 |0 8|PatientsP0000160
P09434160A0767 |8 15|PTPases6T0076 
P09434160A0767 |62 84|bone marrow stem cellsleotidase P00008171T00
P09434160A2078 |0 10|ExpressionP00001606T
P09434160A2078 |105 115|stem cellscts of neo
P09434160A2078 |47 51|CD34tase
P09434160A2078 |14 19|PTPRO Comp
P09434160A2078 |53 70|bone marrow cellsand 5-nucleotidas
P09434185A0902 |152 159|regions472 Whe
P09434185A0902 |60 73|DNA packagingucleotidase P
P09434185A0902 |197 207|DNA phagesf CSF PCO2
P09434185A0902 |78 101|phage assembly proteins171T0000 Pharmacologic 
P09434185A0902 |132 137|genesbinem
P09434185A0902 |47 58|replicationtases and 5
P09434185A0902 |4 16|organization01606T0076 C
P09434185A0902 |20 30|SPP1 genesrison with
P09434185A0902 |116 128|organizationatal hyperbi
P09434979A0790 |168 177|isocenterO3-] is s
P09434979A0790 |229 235|filterd rats
P09434979A0790 |193 194|%o
P09434979A0790 |80 94|photon fluence1T0000 Pharmac
P09434979A0790 |159 160|%n
P09434979A0790 |142 148|filter000089
P09434979A0790 |112 122|collimatorneonatal h
P09434979A0790 |48 62|photon fluenceases and 5-nuc
P09434979A0790 |4 11|results01606T0
P09434979A0790 |155 156|% 
P09435056A0128 |32 44|pediocin AcHlkaline phos
P09435056A0128 |242 245|MBP lo
P09435056A0128 |46 49|Lysata
P09435056A0128 |209 216|proteinhe data
P09435056A0128 |165 170|frame[HCO3
P09435056A0128 |22 28|domainson wi
P09435056A0128 |178 191|COOH terminusown as a func
P09435056A0128 |126 135|periplasmbilirubin
P09435056A0128 |146 150|form8997
P09435056A0128 |233 240|proteints are 
P09435056A0128 |96 105|machineryogic aspe
P09435056A0128 |55 58|Cysd 5
P09435116A0437 |0 7|IsomersP000016
P09435116A0437 |41 51|MS-MS datahosphatase
P09435116A0437 |59 97|trofluoroacetyl-biphenylol derivativesnucleotidase P00008171T0000 Pharmacolo
P09435789A0961 |100 111|hydroxyurea aspects of
P09435789A0961 |113 115|HUeo
P09435789A0961 |144 153|viability008997A04
P09435789A0961 |27 31|MEC3ith 
P09435789A0961 |182 190|presenceas a fun
P09435789A0961 |241 247|repairo long
P09435789A0961 |17 22|RAD24mpari
P09435789A0961 |262 272|DNA damageen compare
P09435789A0961 |157 168|yeast cellshen CSF [HC
P09435789A0961 |53 70|cell cycle arrestand 5-nucleotidas
P09435789A0961 |10 15|RAD170076 
P09435789A0961 |194 196|HUn 
P09435789A0961 |76 83|S phase08171T0
P09435806T0001 |71 89|cancer recurrences P00008171T0000 Ph
P09435806T0001 |9 14|valueT0076
P09435806T0001 |108 112|time of 
P09435806T0001 |22 32|estimationson with a
P09435806T0001 |93 98|CA125colog
P09435806T0001 |36 51|growth kineticsine phosphatase
P09436657A0303 |186 195|knowledge function
P09436657A0303 |5 11|review1606T0
P09436657A0303 |97 101|waysgic 
P09436657A0303 |67 81|carcinogenesisdase P00008171
P09436657A0303 |129 141|risk factorsirubinemia. 
P09436657A0303 |168 173|basisO3-] 
P09436657A0303 |55 63|pathwaysd 5-nucl
P09436657A0303 |35 42|diseaseline ph
P09436706A0168 |274 288|gonadotrophinsto controls bu
P09436706A0168 |151 162|stimulation0472 When C
P09436706A0168 |134 141|mistakenemia. 
P09436706A0168 |43 65|sperm injection cyclessphatases and 5-nucleo
P09436706A0168 |89 100|spermatozoaarmacologic
P09436706A0168 |121 131|pharmacisthyperbilir
P09436706A0168 |211 250|gonadotrophin-releasing hormone agonist data of K-depleted rats are no longer 
P09436706A0168 |184 195|combination a function
P09436706A0168 |4 11|patient01606T0
P09436706A0168 |252 268|leuprolide depotsplaced when com
P09436795A0350 |0 20|Protein C deficiencyP00001606T0076 Compa
P09436795A0350 |93 101|patientscologic 
P09436795A0350 |111 112|% 
P09436795A0350 |24 44|protein S deficiencyn with alkaline phos
P09436795A0350 |88 89|%h
P09436795A0350 |69 80|risk factorse P0000817
P09436795A0350 |116 124|patientsatal hyp
P09436795A0350 |153 161|children72 When 
P09436989A1011 |102 127|cell cycle reset functionspects of neonatal hyperb
P09436989A1011 |79 83|MOB171T0
P09436989A1011 |11 19|addition076 Comp
P09436989A1011 |164 193|spindle pole body duplication [HCO3-] is shown as a functi
P09436989A1011 |30 34|part alk
P09436989A1011 |53 61|functionand 5-nu
P09436989A1011 |146 156|initiation8997A0472 
P09436989A1011 |70 77|mitosise P0000
P09437001A0769 |85 96|temperature0 Pharmacol
P09437001A0769 |13 27|overproduction6 Comparison w
P09437001A0769 |31 36|Der3palkal
P09437001A0769 |3 11|contrast001606T0
P09437001A0769 |52 66|sec61-2 strain and 5-nucleot
P09437001A0769 |103 113|degrees C.pects of n
P09438165A0405 |17 22|day-8mpari
P09438165A0405 |44 45|%p
P09438165A0405 |77 85|patients8171T000
P09438165A0405 |24 33|PC levelsn with al
P09438165A0405 |160 161|% 
P09438165A0405 |122 125|dayype
P09438165A0405 |7 15|baseline06T0076 
P09438165A0405 |93 97|timecolo
P09438165A0405 |101 118|VOD manifestationaspects of neonat
P09438427A0727 |54 70|Hoxa1 expressionnd 5-nucleotidas
P09438427A0727 |28 39|CE2 elementth alkaline
P09438427A0727 |91 95|micemaco
P09438427A0727 |15 19|roleComp
P09438427A0727 |198 209|CE2 element CSF PCO2 t
P09438427A0727 |182 190|mutationas a fun
P09438427A0727 |127 165|Hoxa1 beta-galactosidase reporter geneilirubinemia. P00008997A0472 When CSF 
P09438427T0000 |51 57|somites and 
P09438427T0000 |83 93|expression000 Pharma
P09438427T0000 |26 33|elementwith al
P09438427T0000 |101 111|Hoxa1 geneaspects of
P09440166A0857 |0 7|RESULTSP000016
P09440166A0857 |20 40|cDNA insert sequencerison with alkaline 
P09440166A0857 |191 197|regiontion o
P09440166A0857 |212 216|taildata
P09440166A0857 |145 151|region08997A
P09440166A0857 |209 210|Ah
P09440166A0857 |110 121|nucleotidesf neonatal 
P09440166A0857 |49 60|nucleotidesses and 5-n
P09440166A0857 |86 90|mRNA Pha
P09440166A0857 |156 167|nucleotidesWhen CSF [H
P09440166A0857 |64 70|lengthotidas
P09440166A0857 |98 104|regionic asp
P09440166A0857 |204 208|polyCO2 
P09440616A0422 |24 34|activitiesn with alk
P09440616A0422 |14 19|phase Comp
P09441664A0377 |69 74|HNF-6se P0
P09441664A0377 |47 67|transcription factortases and 5-nucleoti
P09441664A0377 |98 126|HNF-3 beta promoter activityic aspects of neonatal hyper
P09441664A0377 |162 168|regionSF [HC
P09441664A0377 |201 206|genesF PCO
P09441746A0546 |2 12|cDNA clone0001606T00
P09441746A0546 |60 64|geneucle
P09441746A0546 |66 71|GPR39idase
P09442017A0435 |7 14|Science06T0076
P09442024A0236 |0 2|P.P0
P09442024A0236 |12 14|J.76
P09442024A0236 |4 10|Peyron01606T
P09442024A0708 |170 184|Jacalin lectin-] is shown as
P09442024A0708 |88 110|fibroblasts MRC5 cellsharmacologic aspects o
P09442024A0708 |58 67|CEMLAI/NP-nucleoti
P09442024A0708 |43 49|fusionsphata
P09442024A0708 |199 208|O-glycansCSF PCO2 
P09442024A0708 |131 138|amountsubinemi
P09442024A0708 |2 17|hybridoma clone0001606T0076 Co
P09442024A0708 |142 145|P47000
P09442024A0708 |19 22|7H1ari
P09442031A0586 |50 54|sizees a
P09442031A0586 |225 232|residueleted r
P09442031A0586 |188 196|vicinityunction 
P09442031A0586 |158 178|places cleavage Siteen CSF [HCO3-] is sh
P09442031A0586 |79 86|subunit71T0000
P09442031A0586 |132 156|TSHR ectodomain variantsbinemia. P00008997A0472 
P09442031A0586 |101 107|seriesaspect
P09442031A0586 |5 16|information1606T0076 C
P09442031A0586 |32 42|estimationlkaline ph
P09442072A0716 |137 146|footprintia. P0000
P09442072A0716 |152 158|region472 Wh
P09442072A0716 |187 189|bpfu
P09442072A0716 |53 59|regionand 5-
P09442072A0716 |112 119|extractneonata
P09442072A0716 |264 270|region compa
P09442072A0716 |90 94|Heparmac
P09442072A0716 |67 75|promoterdase P00
P09442072A0716 |231 244|liver factorsrats are no l
P09442072A0716 |9 14|DNaseT0076
P09442072A0716 |17 29|footprintingmparison wit
P09442072A0716 |278 281|DNAont
P09442072A0716 |99 103|cellc as
P09442072A0716 |204 213|fVII geneCO2 the d
P09442080A0856 |137 169|glutathione S-transferase fusionia. P00008997A0472 When CSF [HCO
P09442080A0856 |108 113|SHP-2 of n
P09442080A0856 |123 128|SHP-1perbi
P09442080A0856 |13 26|binding assay6 Comparison 
P09442080A0856 |241 247|fusiono long
P09442080A0856 |33 43|IM-9 cellskaline pho
P09442080A0856 |200 215|domain residuesSF PCO2 the dat
P09442080A0856 |93 104|associationcologic asp
P09442080A0856 |59 64|SHP-1nucle
P09442080A0856 |184 187|GHR a 
P09442080A0856 |49 55|sourceses an
P09442080A0856 |69 74|SHP-2se P0
P09442172A0908 |85 103|gonadotrophin dose0 Pharmacologic as
P09442172A0908 |149 163|pregnancy rate7A0472 When CS
P09442172A0908 |30 33|age al
P09442172A0908 |22 25|FSHson
P09442172A0908 |127 134|oocytesilirubi
P09442172A0908 |117 123|numbertal hy
P09443948A0000 |186 189|IIF fu
P09443948A0000 |76 85|technique08171T000
P09443948A0000 |161 184|immunofluorescence testCSF [HCO3-] is shown as
P09443948A0000 |14 19|study Comp
P09443948A0000 |231 245|trichinellosisrats are no lo
P09443948A0000 |212 221|outbreaksdata of K
P09443948A0000 |129 143|trichinellosisirubinemia. P0
P09443948A0000 |110 119|diagnosisf neonata
P09443948A0000 |249 258|Argentina displace
P09443948A0000 |202 206|sera PCO
P09443948A0000 |87 90|EITPha
P09443972A1145 |50 70|transcription factores and 5-nucleotidas
P09443972A1145 |104 114|expressionects of ne
P09443972A1145 |90 100|regulationrmacologic
P09443972A1145 |22 26|GKLFson 
P09443972A1145 |129 134|genesirubi
P09443972A1145 |4 11|results01606T0
P09443973A1028 |51 60|tif1-A79Vs and 5-n
P09443973A1028 |20 27|plasmidrison w
P09443973A1028 |0 4|CES4P000
P09443978A0262 |32 37|cellslkali
P09443978A0262 |99 112|transcriptionc aspects of 
P09443978A0262 |128 137|promoterslirubinem
P09443978A0262 |149 159|TATA boxes7A0472 Whe
P09443978A0262 |73 76|Sp1000
P09443978A0262 |200 209|initiatorSF PCO2 t
P09443978A0262 |174 183|promoterss shown a
P09443978A0262 |223 231|TATA boxepleted 
P09444316A0388 |50 58|toxicityes and 5
P09444316A0388 |108 111|sex of
P09444316A0388 |21 26|signsison 
P09444316A0388 |80 82|F01T
P09444316A0388 |87 97|F1 animalsPharmacolo
P09445056A0215 |115 127|architecturenatal hyperb
P09445056A0215 |135 148|gp41 oligomeremia. P000089
P09445056A0215 |91 94|BS3mac
P09445056A0215 |31 53|chemical cross-linkingalkaline phosphatases 
P09445056A0215 |59 62|bisnuc
P09445056A0215 |63 80|sulfosuccinimidyleotidase P0000817
P09445056A0215 |81 89|suberateT0000 Ph
P09445488A0230 |118 129|chromosomesal hyperbil
P09445488A0230 |29 47|USH1C disease geneh alkaline phospha
P09445488A0230 |90 97|markersrmacolo
P09445488A0230 |6 12|effort606T00
P09445488A0230 |145 156|combination08997A0472 
P09445488A0230 |131 135|YACsubin
P09445488A0230 |160 179|STS content mapping CSF [HCO3-] is sho
P09445488A0230 |184 205|Alu-PCR hybridization a function of CSF PC
P09445488A0230 |101 106|yeastaspec
P09445488A0230 |69 75|regionse P00
P09445488A1169 |0 19|PowerBLAST analysisP00001606T0076 Comp
P09445488A1169 |89 94|genesarmac
P09445488A1169 |72 76|ESTsP000
P09445488A1169 |96 99|BIRogi
P09445488A1169 |196 210|DNA binding/EFof CSF PCO2 th
P09445488A1169 |57 70|sequence tags5-nucleotidas
P09445488A1169 |133 139|regioninemia
P09445488A1169 |185 194|gene NEFAa functio
P09445488A1169 |101 105|SUR1aspe
P09445488A1169 |35 43|clustersline pho
P09446600A0260 |137 143|manneria. P0
P09446600A0260 |107 114|nucleuss of ne
P09446600A0260 |90 99|cytoplasmrmacologi
P09446600A0260 |64 67|Ahroti
P09446600A0260 |29 47|beta-galactosidaseh alkaline phospha
P09446600A0260 |2 16|fusion protein0001606T0076 C
P09446616A0780 |0 14|ReconstitutionP00001606T0076
P09446616A0780 |56 62|kinase 5-nuc
P09446616A0780 |18 32|Raf-1 activityparison with a
P09446616A0780 |83 93|cell lines000 Pharma
P09446616A0780 |70 74|Jak1e P0
P09446815A1021 |35 41|regionline p
P09446815A1021 |72 74|bpP0
P09446815A1021 |3 11|addition001606T0
P09447917A0000 |18 25|Geislerparison
P09447917A0000 |27 36|Brain Resith alkal
P09447917A0000 |4 14|hypothesis01606T0076
P09447962A0452 |23 29|rhis4lon wit
P09447962A0452 |11 21|transcript076 Compar
P09447962A1027 |170 180|rhis4 mRNA-] is show
P09447962A1027 |228 239|mRNA levelsed rats are
P09447962A1027 |46 50|formatas
P09447962A1027 |203 211|increasePCO2 the
P09447962A1027 |82 93|exonuclease0000 Pharma
P09447962A1027 |266 281|HIS4 mRNA levelompared to cont
P09447962A1027 |127 137|suppressorilirubinem
P09447962A1027 |157 166|half-lifehen CSF [
P09447962A1027 |54 58|XRN1nd 5
P09447962A1027 |21 35|interpretationison with alka
P09447963A0223 |0 4|Sip1P000
P09447963A0223 |72 87|splicing factorP00008171T0000 
P09447963A0223 |47 58|interactiontases and 5
P09447963A0223 |98 104|familyic asp
P09447963A0223 |64 68|SC35otid
P09447963A0223 |33 39|virtuekaline
P09447973A0168 |152 167|mSos C terminus472 When CSF [H
P09447973A0168 |213 221|activityata of K
P09447973A0168 |73 78|mSos100008
P09447973A0168 |169 183|MyrSos1-deltaC3-] is shown a
P09447973A0168 |48 69|myristoylation signalases and 5-nucleotida
P09447973A0168 |80 87|MyrSos11T0000 
P09447973A0168 |25 32|reports with a
P09447973A0168 |136 144|deletionmia. P00
P09447973A0168 |118 131|NIH 3T3 cellsal hyperbilir
P09447973A0168 |34 42|additionaline ph
P09447979A1430 |85 119|guanine nucleotide exchange factor0 Pharmacologic aspects of neonata
P09447979A1430 |121 125|GNEFhype
P09447979A1430 |64 77|sequestrationotidase P0000
P09447979A1430 |5 14|mutations1606T0076
P09447979A1430 |51 60|phenotypes and 5-n
P09447994A0000 |102 110|elementsspects o
P09447994A0000 |8 15|studies6T0076 
P09447994A0000 |210 218|responsee data o
P09447994A0000 |224 231|varietypleted 
P09447994A0000 |134 138|cAMPnemi
P09447994A0000 |249 256|stimuli displa
P09447994A0000 |159 163|CREsn CS
P09447994A0000 |129 132|AMPiru
P09447994A0000 |59 65|regionnucleo
P09447994A0000 |69 74|c-fosse P0
P09447994A0000 |140 157|response elements P00008997A0472 W
P09447994A0000 |187 206|c-fos transcriptionfunction of CSF PCO
P09448268A0186 |17 23|kinasemparis
P09448268A0186 |47 54|homologtases a
P09448268A0186 |25 28|Nlk wi
P09448268A0186 |79 82|nmo71T
P09448268A0186 |84 88|gene00 P
P09448574A0964 |171 185|system atrophy] is shown as 
P09448574A0964 |56 61|RACLO 5-nu
P09448574A0964 |148 156|patients97A0472 
P09448574A0964 |90 98|measuresrmacolog
P09448574A0964 |4 12|findings01606T00
P09448574A0964 |111 119|function neonata
P09448574A0964 |35 38|FDGlin
P09449018T0000 |0 21|Childhood misbehaviorP00001606T0076 Compar
P09449018T0000 |30 34|risk alk
P09449018T0000 |48 56|drug useases and
P09450932A0142 |116 122|arrestatal h
P09450932A0142 |45 56|subpathwayshatases and
P09450932A0142 |8 16|analysis6T0076 C
P09450932A0142 |126 139|DNA synthesisbilirubinemia
P09450932A0142 |64 89|DNA structure checkpointsotidase P00008171T0000 Ph
P09451003A0894 |50 57|proteines and 
P09451003A0894 |165 173|Esigma54[HCO3-] 
P09451003A0894 |145 156|interaction08997A0472 
P09451003A0894 |43 46|CRPsph
P09451003A0894 |182 198|CRP-cAMP complexas a function of
P09451003A0894 |132 138|resultbinemi
P09451003A0894 |99 109|repressionc aspects 
P09451003A0894 |6 24|Esigma54 promoters606T0076 Compariso
P09451003A0894 |71 89|sigma54 activators P00008171T0000 Ph
P09451016A1037 |102 107|cellsspect
P09451016A1037 |212 216|genedata
P09451016A1037 |12 44|GlcNAc2-PP-Dolichol biosynthesis76 Comparison with alkaline phos
P09451016A1037 |180 193|transcriptionn as a functi
P09451016A1037 |134 141|plasmidnemia. 
P09451016A1037 |87 96|membranesPharmacol
P09451016A1037 |155 162|glucose When C
P09451016A1037 |0 6|GlcNAcP00001
P09451857T0001 |17 31|tissue lesionsmparison with 
P09451857T0001 |82 97|creatine kinase0000 Pharmacolo
P09451857T0001 |52 61|injection and 5-nu
P09451857T0001 |101 106|bloodaspec
P09451857T0001 |65 78|determinationtidase P00008
P09451857T0001 |0 13|DemonstrationP00001606T007
P09452421A1042 |0 10|AntibodiesP00001606T
P09452421A1042 |120 123|Tyr hy
P09452421A1042 |26 36|GST mSH2-Bwith alkal
P09452421A1042 |73 76|kDa000
P09452421A1042 |59 66|proteinnucleot
P09452444A0000 |0 13|Interleukin-6P00001606T007
P09452444A0000 |131 144|hematopoiesisubinemia. P00
P09452444A0000 |15 19|IL-6Comp
P09452444A0000 |110 125|phase reactionsf neonatal hype
P09452444A0000 |93 102|responsescologic a
P09452444A0000 |38 46|cytokinee phosph
P09452444A0450 |5 13|analysis1606T007
P09452444A0450 |106 119|reporter genets of neonata
P09452444A0450 |74 92|IL-6 gene promoter0008171T0000 Pharm
P09452444A0450 |52 60|variants and 5-n
P09452444A0450 |25 33|deletion with al
P09452444A0450 |158 179|transcription factorsen CSF [HCO3-] is sho
P09453537A0863 |100 117|recognition sites aspects of neona
P09453537A0863 |59 69|complementnucleotida
P09453537A0863 |122 125|SP1ype
P09453537A0863 |5 11|region1606T0
P09453537A0863 |82 90|GC boxes0000 Pha
P09453537A0863 |33 43|CCAATC boxkaline pho
P09453689A0000 |136 147|cord injurymia. P00008
P09453689A0000 |79 94|bulbocavernosus71T0000 Pharmac
P09453689A0000 |149 152|SCI7A0
P09453689A0000 |4 11|purpose01606T0
P09453689A0000 |96 100|S2-4ogic
P09453689A0000 |172 197|bladder function recovery is shown as a function o
P09453689A0000 |110 113|BCRf n
P09453689A0000 |49 53|S4-5ses 
P09453689A0000 |55 68|pin sensationd 5-nucleotid
P09453689A0000 |70 73|PPSe P
P09454719A0181 |118 147|AAUAAA polyadenylation signalal hyperbilirubinemia. P00008
P09454719A0181 |196 228|polyadenylation signal sequencesof CSF PCO2 the data of K-deplet
P09454719A0181 |281 287|vectorrols b
P09454719A0181 |12 23|termination76 Comparis
P09454719A0181 |60 77|LTR R/U5 junctionucleotidase P0000
P09454719A0181 |38 49|transcriptse phosphata
P09454719A0181 |173 179|effectis sho
P09454719A0181 |236 246|propertiesare no lon
P09454735A1782 |0 6|LevelsP00001
P09454735A1782 |134 154|adhesion disassemblynemia. P00008997A047
P09454735A1782 |75 101|MAP kinase phosphorylation008171T0000 Pharmacologic 
P09454735A1782 |59 70|mitogenesisnucleotidas
P09454735A1782 |14 35|MEK inhibitor PD98059 Comparison with alka
P09454735A1782 |159 172|cell motilityn CSF [HCO3-]
P09455695A0762 |0 10|ALT levelsP00001606T
P09455695A0762 |78 79|%1
P09455695A0762 |89 94|weeksarmac
P09455695A0762 |14 24|responders Compariso
P09455695A0762 |98 117|vitamin E treatmentic aspects of neona
P09455695A0762 |43 44|%s
P09455695A0762 |49 59|AST levelsses and 5-
P09456312A1064 |85 104|localization signal0 Pharmacologic asp
P09456312A1064 |42 49|RanGAP1osphata
P09456312A1064 |32 38|domainlkalin
P09458021A1373 |4 5|%0
P09458021A1373 |7 8|P0
P09458021A1373 |24 27|MMFn w
P09458021A1373 |39 49|AZA groups phosphata
P09458030A0192 |4 9|study01606
P09458030A0192 |52 55|MMF an
P09458030A0192 |42 48|effectosphat
P09458030A0192 |67 90|bone mineral metabolismdase P00008171T0000 Pha
P09459241A0707 |0 4|Pao2P000
P09459241A0707 |72 75|kPaP00
P09459241A0707 |88 93|mm Hgharma
P09459241A0707 |33 36|kPakal
P09459241A0707 |96 97|Po
P09459241A0707 |49 54|mm Hgses a
P09459685T0001 |85 93|children0 Pharma
P09459685T0001 |39 53|stress factors phosphatases 
P09459685T0001 |8 22|configurations6T0076 Compari
P09459685T0001 |98 109|adolescentsic aspects 
P09459835A0297 |19 23|PMEAaris
P09459835A0297 |42 59|mg/kg body weightosphatases and 5-
P09459835A0297 |29 35|dosageh alka
P09459835A0297 |104 121|mg/kg body weightects of neonatal 
P09459835A0297 |91 97|dosagemacolo
P09459835A0297 |5 9|cats1606
P09459835A0297 |66 70|catsidas
P09459835A0297 |80 85|FPMPA1T000
P09460171T0000 |0 10|ResistanceP00001606T
P09460171T0000 |31 43|implicationsalkaline pho
P09460171T0000 |14 29|thyroid hormone Comparison wit
P09460171T0000 |67 75|researchdase P00
P09460171T0000 |94 120|thyroid hormone disruptorsologic aspects of neonatal
P09460171T0000 |83 90|effects000 Pha
P09461594A0000 |102 105|EMFspe
P09461594A0000 |183 193|PLC-gamma2s a functi
P09461594A0000 |31 39|exposurealkaline
P09461594A0000 |120 128|tyrosine hyperbi
P09461594A0000 |146 156|activation8997A0472 
P09461594A0000 |95 100|fieldlogic
P09461594A0000 |160 181|phospholipase Cgamma2 CSF [HCO3-] is shown
P09461594A0000 |72 78|energyP00008
P09461594A0000 |216 246|inositol phospholipid turnover of K-depleted rats are no lon
P09461594A0000 |43 64|DT40 lymphoma B cellssphatases and 5-nucle
P09461594A0000 |17 25|evidencemparison
P09463174A0670 |103 109|monthspects 
P09463174A0670 |27 34|resultsith alk
P09463174A0670 |90 96|periodrmacol
P09463174A0670 |50 58|patientses and 5
P09463380A1050 |34 44|expressionaline phos
P09463380A1050 |56 77|mesoderm marker genes 5-nucleotidase P0000
P09463380A1050 |89 94|Smad1armac
P09463380A1050 |10 17|xTAK1KN0076 Co
P09463560A0124 |0 8|PATIENTSP0000160
P09463560A0124 |13 19|METHOD6 Comp
P09463560A0124 |36 44|patientsine phos
P09463964A0243 |4 9|assay01606
P09463964A0243 |46 60|micrograms l-1atases and 5-n
P09463964A0243 |29 34|rangeh alk
P09463964A0243 |166 175|antiserumHCO3-] is
P09463964A0243 |130 136|mg l-1rubine
P09463964A0243 |109 123|micrograms l-1of neonatal hy
P09463964A0243 |80 88|antibody1T0000 P
P09463991T0000 |13 18|audit6 Com
P09464248A0289 |12 20|TATA box76 Compa
P09464525T0000 |0 10|ExpressionP00001606T
P09464525T0000 |60 62|Fvuc
P09464525T0000 |15 31|characterizationComparison with 
P09464525T0000 |67 79|Fv fragmentsdase P000081
P09464525T0000 |95 98|setlog
P09464525T0000 |112 122|antibodiesneonatal h
P09465035A1032 |86 87|L 
P09465035A1032 |88 93|alphaharma
P09465035A1032 |60 68|fractionucleotid
P09465035A1032 |95 103|activitylogic as
P09465035A1032 |11 20|inhibitor076 Compa
P09465035A1032 |21 22|si
P09465783A0449 |0 20|Platelet aggregationP00001606T0076 Compa
P09465783A0449 |94 103|treatmentologic as
P09465783A0449 |79 87|parallel71T0000 
P09465783A0449 |24 32|responsen with a
P09465783A0449 |109 112|ASAof 
P09465783A0449 |39 61|micrograms collagen/ml phosphatases and 5-nu
P09466267A1192 |50 54|rolees a
P09466267A1192 |82 92|regulation0000 Pharm
P09466267A1192 |96 116|dmsA-lacZ expressionogic aspects of neon
P09466267A1192 |6 18|himA mutants606T0076 Com
P09466267A1192 |38 41|IHFe p
P09466931T0000 |68 84|response elementase P00008171T00
P09466931T0000 |92 96|ng-1acol
P09466931T0000 |101 121|ng-2 intermolt genesaspects of neonatal 
P09466931T0000 |39 48|receptors phosphat
P09466931T0000 |0 13|Cross-talkingP00001606T007
P09467044A0973 |16 41|breast tumor relapse rateomparison with alkaline p
P09467044A0973 |75 87|MGDET groups008171T0000 
P09467044A0973 |66 70|PALPidas
P09467707T0000 |0 19|Sibling aggregationP00001606T0076 Comp
P09467707T0000 |73 90|apolipoproteins B00008171T0000 Pha
P09467707T0000 |45 68|lipoprotein cholesterolhatases and 5-nucleotid
P09467707T0000 |125 133|childrenrbilirub
P09467707T0000 |95 105|A-I levelslogic aspe
P09467707T0000 |139 159|Bogalusa Heart Study. P00008997A0472 Whe
P09467900A0701 |204 214|EF-hand CaCO2 the da
P09467900A0701 |219 233|binding domain K-depleted ra
P09467900A0701 |77 84|stretch8171T00
P09467900A0701 |125 133|X domainrbilirub
P09467900A0701 |94 113|amino acid residuesologic aspects of n
P09467900A0701 |156 166|N-terminusWhen CSF [
P09467900A0701 |4 18|CAPLC1 protein01606T0076 Com
P09467900A0701 |49 57|featuresses and 
P09467955A0468 |117 121|PEA3tal 
P09467955A0468 |144 152|promoter008997A0
P09467955A0468 |79 92|PEA3 promoter71T0000 Pharm
P09467955A0468 |106 113|abilityts of n
P09467955A0468 |5 15|hypothesis1606T0076 
P09467955A0468 |53 71|PEA3 binding sitesand 5-nucleotidase
P09467955A0468 |39 49|occurrence phosphata
P09468386A0594 |0 5|Pet-1P0000
P09468386A0594 |147 153|manner997A04
P09468386A0594 |104 123|promoter constructsects of neonatal hy
P09468386A0594 |54 59|motifnd 5-
P09468386A0594 |77 90|transcription8171T0000 Pha
P09468386A0594 |33 41|PEA3 ETSkaline p
P09468509A0463 |51 60|COS cellss and 5-n
P09468509A0463 |4 11|protein01606T0
P09468509A0463 |25 35|F2771 cDNA with alka
P09468509A0463 |81 90|cytoplasmT0000 Pha
P09468514A1065 |0 17|Northern analysisP00001606T0076 Co
P09468514A1065 |75 85|expression008171T000
P09468514A1065 |93 98|heartcolog
P09468514A1065 |41 51|expressionhosphatase
P09468514A1065 |55 61|tissued 5-nu
P09468515A0621 |17 25|deletionmparison
P09468515A0621 |93 110|SF-1 binding sitecologic aspects o
P09468515A0621 |131 138|abilityubinemi
P09468515A0621 |52 62|nucleotide and 5-nuc
P09468515A0621 |163 167|SF-1F [H
P09468515A0621 |33 48|promoter regionkaline phosphat
P09469415A1337 |85 106|CTL target structures0 Pharmacologic aspec
P09469415A1337 |127 140|possibilitiesilirubinemia.
P09469415A1337 |211 227|DNA immunization data of K-deple
P09469415A1337 |4 15|observation01606T0076 
P09469415A1337 |157 166|inductionhen CSF [
P09469415A1337 |54 61|peptidend 5-nu
P09469415A1337 |231 240|injectionrats are 
P09469415A1337 |272 279|beta 2md to co
P09469415A1337 |21 28|beta 2mison wi
P09469415A1337 |187 200|CTL responsesfunction of C
P09469820A0151 |137 147|modulationia. P00008
P09469820A0151 |51 60|YAP1 uORFs and 5-n
P09469820A0151 |255 266|translationaced when c
P09469820A0151 |19 24|genesariso
P09469820A0151 |86 91|uORF2 Phar
P09469820A0151 |209 212|UTRhe 
P09469820A0151 |235 242|control are no
P09469820A0151 |279 289|mRNA decayntrols but
P09469820A0151 |198 204|region CSF P
P09469820A0151 |107 121|reading framess of neonatal 
P09469820A0151 |168 174|eventsO3-] i
P09469820A0151 |4 9|mRNAs01606
P09469820A0151 |71 81|YAP2 uORF1 P00008171
P09469833A0533 |67 83|deletion mutantsdase P00008171T0
P09469833A0533 |60 63|setucl
P09469833A0533 |27 33|natureith al
P09469833A0533 |41 57|site specificityhosphatases and 
P09469833A0533 |95 106|bp sequencelogic aspec
P09469933A1060 |53 61|CLIP-170and 5-nu
P09469933A1060 |30 35|brain alka
P09469933A1060 |94 100|Restinologic
P09469933A1060 |41 48|messagehosphat
P09469933A1060 |7 14|tissues06T0076
P09471984A0000 |85 103|contact dermatitis0 Pharmacologic as
P09471984A0000 |59 66|abilitynucleot
P09471984A0000 |12 21|Chemicals76 Compar
P09471984A0000 |0 10|BACKGROUNDP00001606T
P09472038T0000 |86 96|activation Pharmacol
P09472038T0000 |13 25|polarization6 Comparison
P09472038T0000 |56 70|immunoreceptor 5-nucleotidas
P09472038T0000 |29 36|T cellsh alkal
P09472038T0000 |113 122|mechanismeonatal h
P09472608A0253 |204 210|JurkatCO2 th
P09472608A0253 |133 142|cell lineinemia. P
P09472608A0253 |164 173|cell line [HCO3-] 
P09472608A0253 |75 88|transcription008171T0000 P
P09472608A0253 |197 202|cellsf CSF
P09472608A0253 |144 150|U-87MG008997
P09472608A0253 |215 233|transfection assaya of K-depleted ra
P09472608A0253 |26 33|abilitywith al
P09472608A0253 |175 182|SK-N-MC shown 
P09472608A0253 |96 110|HIV-1 promoterogic aspects o
P09472608A0253 |50 62|protein YB-1es and 5-nuc
P09472616A1004 |119 127|lineagesl hyperb
P09472616A1004 |58 59|B-
P09472616A1004 |47 54|regionstases a
P09472616A1004 |18 29|amino acidsparison wit
P09472616A1004 |64 65|Co
P09472616A1004 |69 72|VP7se 
P09473040A1303 |55 84|siderophore system activitiesd 5-nucleotidase P00008171T00
P09473040A1303 |92 99|mutantsacologi
P09473040A1303 |12 21|alcR gene76 Compar
P09473040A1303 |12 21|alcR gene76 Compar
P09473040A1303 |55 84|siderophore system activitiesd 5-nucleotidase P00008171T00
P09473040A1303 |92 99|mutantsacologi
P09473317X2131 |0 9|CopyrightP00001606
P09473317X2131 |15 29|Academic PressComparison wit
P09473483A0953 |205 210|HIV-IO2 th
P09473483A0953 |215 221|HTLV-1a of K
P09473483A0953 |41 45|carehosp
P09473483A0953 |89 99|Rev mutantarmacologi
P09473483A0953 |138 145|therapya. P000
P09473483A0953 |174 185|individualss shown as 
P09473483A0953 |154 169|HIV-I infection2 When CSF [HCO
P09473755A0318 |0 8|PATIENTSP0000160
P09473755A0318 |30 37|January alkali
P09473755A0318 |13 20|METHODS6 Compa
P09473755A0318 |60 63|St.ucl
P09473755A0318 |47 51|Junetase
P09474001A0825 |17 20|SPsmpa
P09474001A0825 |165 170|MMFCV[HCO3
P09474001A0825 |181 182|% 
P09474001A0825 |54 60|groupsnd 5-n
P09474001A0825 |129 130|pi
P09474001A0825 |146 150|arms8997
P09474001A0825 |122 127|MMFCVyperb
P09474001A0825 |191 193|SPti
P09474001A0825 |99 107|patientsc aspect
P09474001A0825 |4 13|frequency01606T007
P09474648A0298 |16 23|P-SAECGomparis
P09474648A0298 |88 96|controlsharmacol
P09474648A0298 |31 35|timealka
P09474648A0298 |40 56|frequency domainphosphatases and
P09474648A0298 |63 71|patientseotidase
P09474648A0298 |77 80|Paf817
P09475378A1449 |64 77|HPLC analysisotidase P0000
P09475378A1449 |132 146|splice variantbinemia. P0000
P09475378A1449 |90 101|RUSH-1alpharmacologic 
P09475378A1449 |20 59|transcription-polymerase chain reactionrison with alkaline phosphatases and 5-
P09475724T0000 |0 4|TOR2P000
P09475724T0000 |28 46|signaling pathwaysth alkaline phosph
P09475724T0000 |60 71|cell growthucleotidase
P09475724T0000 |8 12|part6T00
P09475898T0000 |14 27|amnioinfusion Comparison w
P09476399A0141 |49 54|Kandyses a
P09476399A0141 |31 45|tea plantationalkaline phosp
P09476399A0141 |11 19|division076 Comp
P09476520A1326 |152 162|complexity472 When C
P09476520A1326 |134 141|hybridsnemia. 
P09476520A1326 |230 239|molecules rats are
P09476520A1326 |177 186|existencehown as a
P09476520A1326 |79 87|profiles71T0000 
P09476520A1326 |29 40|interactionh alkaline 
P09476520A1326 |115 125|antibodiesnatal hype
P09476520A1326 |7 13|models06T007
P09476520A1326 |207 220|heterogeneity the data of 
P09477316A0140 |3 8|order00160
P09477316A0140 |122 165|leucine zipper transcription factor MafB/Kryperbilirubinemia. P00008997A0472 When CSF 
P09477316A0140 |47 65|Hox gene inductiontases and 5-nucleo
P09477316A0140 |25 32|pathway with a
P09477316A0140 |226 233|signalseted ra
P09477316A0140 |98 116|Hox gene regulatoric aspects of neon
P09478921A0126 |0 10|SubstratesP00001606T
P09478921A0126 |15 19|p210Comp
P09478921A0126 |78 81|CML171
P09478921A0126 |62 74|pathogenesisleotidase P0
P09478921A0126 |20 27|bcr-ablrison w
P09478971A1896 |85 88|AhR0 P
P09478971A1896 |129 139|expressionirubinemia
P09478971A1896 |43 49|mannersphata
P09478971A1896 |73 77|role0000
P09478971A1896 |153 177|mouse embryo fibroblasts72 When CSF [HCO3-] is s
P09478971A1896 |143 149|Cyp1B1000899
P09478971A1896 |0 19|Reporter constructsP00001606T0076 Comp
P09478976A0718 |0 20|Transfection studiesP00001606T0076 Compa
P09478976A0718 |41 49|deletionhosphata
P09478976A0718 |134 137|OSMnem
P09478976A0718 |97 107|start sitegic aspect
P09478976A0718 |144 153|induction008997A04
P09478976A0718 |53 62|sequencesand 5-nuc
P09478976T0000 |0 12|Oncostatin MP00001606T00
P09478976T0000 |24 29|c-Fosn wit
P09478976T0000 |113 141|metalloproteinase-1 promotereonatal hyperbilirubinemia. 
P09478976T0000 |93 109|tissue inhibitorcologic aspects 
P09478976T0000 |69 81|AP-1 elementse P00008171
P09479498A0000 |83 90|protein000 Pha
P09479498A0000 |47 51|RNF4tase
P09479498A0000 |29 45|RING-finger geneh alkaline phosp
P09480831A0272 |102 108|regionspects
P09480831A0272 |161 166|cellsCSF [
P09480831A0272 |78 86|elements171T0000
P09480831A0272 |28 37|mechanismth alkali
P09480831A0272 |168 172|HAECO3-]
P09480831A0272 |112 119|AM geneneonata
P09480831A0272 |50 65|gene expressiones and 5-nucleo
P09480843A0848 |84 91|alanine00 Phar
P09480843A0848 |79 82|GCT71T
P09480843A0848 |167 175|rat RL14CO3-] is
P09480843A0848 |62 77|triplet repeatsleotidase P0000
P09480843A0848 |18 24|regionpariso
P09480843A0848 |96 106|nucleotideogic aspec
P09480843A0848 |32 43|transcriptslkaline pho
P09480929T0000 |102 110|proteinsspects o
P09480929T0000 |28 34|domainth alk
P09480929T0000 |121 151|baculovirus/insect cell systemhyperbilirubinemia. P00008997A
P09480929T0000 |8 12|FasR6T00
P09480929T0000 |47 57|productiontases and 
P09480929T0000 |68 74|fusionase P0
P09481826T0000 |17 31|liver syndromemparison with 
P09481826T0000 |54 60|changend 5-n
P09481826T0000 |37 48|Jersey herdne phosphat
P09481826T0000 |77 80|use817
P09481826T0000 |103 116|somatotrophinpects of neon
P09481826T0000 |64 68|dietotid
P09481826T0000 |0 7|ControlP000016
P09482107A0551 |220 225|cellsK-dep
P09482107A0551 |161 169|survivalCSF [HCO
P09482107A0551 |243 257|plasmid vectorlonger displac
P09482107A0551 |132 141|C3G cellsbinemia. 
P09482107A0551 |62 65|C3Gleo
P09482107A0551 |18 33|focus formationparison with al
P09482107A0551 |98 112|cell viabilityic aspects of 
P09482107A0551 |4 14|inhibition01606T0076
P09482107A0551 |174 186|growth ratess shown as a
P09482107A0551 |50 58|presencees and 5
P09482107A0551 |87 94|effectsPharmac
P09482107A0551 |204 216|NIH3T3 cellsCO2 the data
P09482902A0423 |0 8|C.D2-ChrP0000160
P09482902A0423 |112 119|allelesneonata
P09482902A0423 |127 151|CDK4/CDK6 inhibitors p16ilirubinemia. P00008997A
P09482902A0423 |94 99|DBA/2ologi
P09482902A0423 |72 83|Pctr1 locusP00008171T0
P09482902A0423 |38 51|DBA/2 allelese phosphatase
P09482902A0423 |20 27|strainsrison w
P09482902A0423 |156 159|p15Whe
P09482902A0942 |35 38|p16lin
P09482902A0942 |332 354|plasmacytoma induction1.21 +/- 0.23 vs. P000
P09482902A0942 |298 312|susceptibilityve a significa
P09482902A0942 |89 92|p16arm
P09482902A0942 |28 33|DBA/2th al
P09482902A0942 |45 50|A134Chatas
P09482902A0942 |119 126|abilityl hyper
P09482902A0942 |154 168|cyclin D2/CDK42 When CSF [HC
P09482902A0942 |252 258|allelesplace
P09482902A0942 |55 60|G232Ad 5-n
P09482902A0942 |191 213|retinoblastoma proteintion of CSF PCO2 the d
P09482902A0942 |387 396|candidates to be a
P09482902A0942 |364 367|p16 Fl
P09482902A0942 |172 185|kinase assays is shown as 
P09482902A0942 |77 85|variants8171T000
P09482902A0942 |316 327|BALB/c mice greater sl
P09482902A0942 |405 416|Pctr1 locusve hypnotic
P09482902A0942 |278 282|roleontr
P09482902A0942 |142 150|activity00008997
P09482902A0942 |368 373|INK4arazep
P09483596A0626 |139 150|excellent/3. P00008997
P09483596A0626 |26 36|differencewith alkal
P09483596A0626 |88 99|excellent/5harmacologi
P09483596A0626 |73 79|minute000081
P09483596A0626 |112 131|suxamethonium groupneonatal hyperbilir
P09483596A0626 |163 179|rocuronium groupF [HCO3-] is sho
P09483596A0626 |55 65|conditionsd 5-nucleo
P09484463T0000 |0 7|CloningP000016
P09484463T0000 |30 35|genes alka
P09484463T0000 |12 22|expression76 Compari
P09484463T0000 |73 80|tobacco0000817
P09484463T0000 |59 67|proteinsnucleoti
P09484781A1233 |103 110|PKB/Aktpects o
P09484781A1233 |37 62|D3 phosphatidylinositidesne phosphatases and 5-nuc
P09484781A1233 |89 99|activationarmacologi
P09484781A1233 |20 31|associationrison with 
P09485308A1165 |51 58|subunits and 5
P09485308A1165 |90 98|reactionrmacolog
P09485308A1165 |36 43|clusterine pho
P09485308A1165 |28 34|3Fe-4Sth alk
P09485308A1165 |4 14|FMN moiety01606T0076
P09485790T0000 |0 26|Alison Bell Memorial AwardP00001606T0076 Comparison 
P09486035A0051 |119 128|blindnessl hyperbi
P09486035A0051 |109 115|causesof neo
P09486035A0051 |11 28|population survey076 Comparison wi
P09486035A0051 |132 139|Lebanonbinemia
P09486035A0051 |81 91|prevalenceT0000 Phar
P09486035A0051 |54 65|individualsnd 5-nucleo
P09486035A0051 |0 7|METHODSP000016
P09486531A0638 |102 114|gut endodermspects of ne
P09486531A0638 |182 199|gut morphogenesisas a function of 
P09486531A0638 |22 38|HFH-8 expressionson with alkalin
P09486531A0638 |7 20|organogenesis06T0076 Compa
P09486531A0638 |129 133|roleirub
P09486531A0638 |160 169|induction CSF [HCO
P09486531A0638 |173 177|lungis s
P09486531A0638 |66 74|mesodermidase P0
P09486531A0638 |84 94|apposition00 Pharmac
P09486890A0234 |71 87|carcinoma spread P00008171T0000 
P09486890A0234 |62 67|casesleoti
P09486890A0234 |91 96|areasmacol
P09486890A0234 |9 20|laparoscopyT0076 Compa
P09486890A0234 |41 54|inoperabilityhosphatases a
P09486890A0234 |128 141|visualizationlirubinemia. 
P09487130A0383 |17 32|telomere lengthmparison with a
P09487130A0383 |157 166|telomereshen CSF [
P09487130A0383 |83 87|Cdc2000 
P09487130A0383 |109 127|DNA repair mutantsof neonatal hyperb
P09487130A0383 |45 52|mutantshatases
P09487130A0383 |185 189|typea fu
P09487130A0383 |3 13|difference001606T007
P09487130A0383 |69 79|regulationse P000081
P09487590A0657 |21 32|pain reliefison with a
P09487590A0657 |41 46|weekshosph
P09487590A0657 |4 17|mean duration01606T0076 Co
P09487841A0132 |50 68|sample preparationes and 5-nucleotid
P09487841A0132 |4 8|ESEM0160
P09487841A0132 |104 111|changesects of
P09487841A0132 |35 38|SEMlin
P09488441A0615 |0 3|Sp1P00
P09488441A0615 |115 129|p50 homodimersnatal hyperbil
P09488441A0615 |261 268|concerthen com
P09488441A0615 |182 198|site competitionas a function of
P09488441A0615 |243 253|expressionlonger dis
P09488441A0615 |151 170|P-selectin promoter0472 When CSF [HCO3
P09488441A0615 |66 74|enhanceridase P0
P09488441A0615 |78 113|P-selectin promoter NF-kappaB sites171T0000 Pharmacologic aspects of n
P09488441A0615 |17 30|transcriptionmparison with
P09488441A0615 |291 301|expressiontill have 
P09488441A0615 |138 141|Sp1a. 
P09488441A0615 |39 53|immunoglobulin phosphatases 
P09488441A0615 |274 279|Bcl-3to co
P09488466A0695 |117 147|precursor-product relationshiptal hyperbilirubinemia. P00008
P09488466A0695 |75 86|actinomycin008171T0000
P09488466A0695 |97 102|cellsgic a
P09488466A0695 |7 15|fragment06T0076 
P09488466A0695 |55 59|mRNAd 5-
P09488486A0000 |154 157|III2 W
P09488486A0000 |30 33|TBP al
P09488486A0000 |54 58|rolend 5
P09488486A0000 |125 136|polymerasesrbilirubine
P09488486A0000 |108 123|RNA polymerases of neonatal hy
P09488486A0000 |62 75|transcriptionleotidase P00
P09488486A0000 |21 28|proteinison wi
P09488486A0000 |4 8|TATA0160
P09488486A0000 |138 141|Pola. 
P09488486A0906 |16 19|TBPomp
P09488486A0906 |37 42|R239Sne ph
P09488486A0906 |77 110|yeast U6 snRNA gene transcription8171T0000 Pharmacologic aspects o
P09488486A0906 |29 34|R235Eh alk
P09488486A0906 |151 164|transcription0472 When CSF
P09488486A0906 |64 72|activityotidase 
P09488486A0906 |21 26|R231Eison 
P09488486A0906 |138 141|Pola. 
P09488491A0000 |0 12|E2F activityP00001606T00
P09488491A0000 |41 62|retinoblastoma familyhosphatases and 5-nuc
P09488491A0000 |29 33|parth al
P09488491A0000 |66 91|tumor suppressor proteinsidase P00008171T0000 Phar
P09488713A0886 |42 57|Site-1 cleavageosphatases and 
P09488713A0886 |121 125|SCAPhype
P09488713A0886 |91 105|overexpressionmacologic aspe
P09488713A0886 |28 38|inhibitionth alkalin
P09488725A0904 |32 40|identitylkaline 
P09488725A0904 |44 47|SFDpha
P09488725A0904 |73 85|polypeptides00008171T000
P09488725T0000 |49 57|subunitsses and 
P09488725T0000 |10 26|characterization0076 Comparison 
P09488725T0000 |81 92|proton pumpT0000 Pharm
P09489670A1157 |102 107|yeastspect
P09489670A1157 |57 63|levels5-nucl
P09489670A1157 |109 115|hyphaeof neo
P09489670A1157 |319 330|C. albicanseater slope
P09489670A1157 |3 14|C. albicans001606T0076
P09489670A1157 |81 91|cell typesT0000 Phar
P09489670A1157 |298 315|Hst6p transporterve a significantl
P09489670A1157 |281 289|functionrols but
P09489670A1157 |207 212|yeast the 
P09489670A1157 |155 173|HST6 transcription When CSF [HCO3-] 
P09489670A1157 |16 20|HST6ompa
P09490676A0800 |103 109|excesspects 
P09490676A0800 |129 150|oligodeoxynucleotidesirubinemia. P00008997
P09490676A0800 |13 20|binding6 Compa
P09490676A0800 |210 215|sitese dat
P09490676A0800 |44 57|Ets-2 proteinphatases and 
P09490676A0800 |36 39|Mybine
P09490676A0800 |67 76|fragmentsdase P000
P09490676A0800 |190 193|Mybcti
P09490727A1041 |38 46|tripletse phosph
P09490727A1041 |60 66|bodiesucleot
P09490727A1041 |124 133|apparatuserbilirub
P09490727A1041 |89 96|bundlesarmacol
P09490727A1041 |5 28|structure interconnects1606T0076 Comparison wi
P09491074A0104 |55 65|expressiond 5-nucleo
P09491074A0104 |73 84|temperature00008171T00
P09491074A0104 |90 105|promoter regionrmacologic aspe
P09491074A0104 |29 38|mechanismh alkalin
P09492038A0352 |152 163|mutagenesis472 When CS
P09492038A0352 |26 31|roleswith 
P09492038A0352 |106 110|exonts o
P09492038A0352 |90 96|regionrmacol
P09492038A0352 |15 20|studyCompa
P09492038A0352 |113 130|promoter activityeonatal hyperbili
P09492038A0352 |59 67|elementsnucleoti
P09492038A0352 |188 202|binding assaysunction of CSF
P09494078A1362 |39 48|yohimbine phosphat
P09494078A1362 |8 22|5HT5A receptor6T0076 Compari
P09494078A1362 |27 35|additionith alka
P09494078A1362 |83 89|effect000 Ph
P09495283A0000 |17 30|reporter genemparison with
P09495283A0000 |42 52|expressionosphatases
P09495283A0000 |131 141|HeLa cellsubinemia. 
P09495283A0000 |149 154|yeast7A047
P09495283A0000 |122 126|HSF2yper
P09495283A0000 |71 103|heat shock transcription factors P00008171T0000 Pharmacologic as
P09495283A0000 |113 117|HSF1eona
P09495283A0000 |32 40|beta-gallkaline 
P09495771A0379 |157 162|stagehen C
P09495771A0379 |166 175|septationHCO3-] is
P09495771A0379 |73 93|midcell constriction00008171T0000 Pharma
P09495771A0379 |10 22|fluorescence0076 Compari
P09495771A0379 |46 51|cellsatase
P09495771A0379 |111 115|FtsK neo
P09498553A0702 |68 76|GC boxesase P000
P09498553A0702 |38 53|promoter regione phosphatases 
P09498553A0702 |99 108|cap sitesc aspects
P09498553A0702 |158 164|natureen CSF
P09498553A0702 |213 243|transcription initiation sitesata of K-depleted rats are no 
P09498553A0702 |168 178|CYP51 geneO3-] is sh
P09498553A0702 |3 11|TATA box001606T0
P09498553A0702 |187 196|existencefunction 
P09498553T0000 |114 116|I.on
P09498553T0000 |28 35|studiesth alka
P09498553T0000 |61 65|P450cleo
P09498553T0000 |67 72|CYP51dase 
P09498553T0000 |94 112|P450 monooxygenaseologic aspects of 
P09498553T0000 |39 45|sterol phosp
P09498769A0095 |49 50|Bs
P09498769A0095 |203 215|plasma cellsPCO2 the dat
P09498769A0095 |162 169|B cellsSF [HCO
P09498769A0095 |26 40|representativewith alkaline 
P09498769A0095 |122 132|activationyperbiliru
P09498769A0095 |99 117|B cell developmentc aspects of neona
P09498769A0095 |65 73|proteinstidase P
P09498769A0095 |4 22|expression pattern01606T0076 Compari
P09499031A0000 |187 197|transcriptfunction o
P09499031A0000 |47 63|stomatitis virustases and 5-nucl
P09499031A0000 |225 238|transcriptionleted rats ar
P09499031A0000 |129 144|polyadenylationirubinemia. P00
P09499031A0000 |209 221|reinitiationhe data of K
P09499031A0000 |149 174|transcription termination7A0472 When CSF [HCO3-] i
P09499031A0000 |88 105|sequence elementsharmacologic aspe
P09499031A0000 |253 263|transcriptplaced whe
P09499031A0000 |65 68|VSVtid
P09499031A0000 |19 33|gene junctionsarison with al
P09499048A1003 |18 31|virus progenyparison with 
P09499048A1003 |104 106|gKec
P09499048A1003 |140 157|replication cycle P00008997A0472 W
P09499048A1003 |124 132|functionerbiliru
P09499048A1003 |81 86|cellsT0000
P09499061A0000 |0 8|CleavageP0000160
P09499061A0000 |13 16|DNA6 C
P09499061A0000 |25 34|reactions with alk
P09499061A0000 |95 104|integraselogic asp
P09499061A0000 |57 84|immunodeficiency virus type5-nucleotidase P00008171T00
P09499061A0000 |88 93|HIV-1harma
P09499061A0000 |156 165|HIV-1 DNAWhen CSF 
P09499061A0000 |143 152|insertion0008997A0
P09499061A0000 |175 186|host genome shown as a
P09499254A1309 |4 15|DSF regimen01606T0076 
P09499254A1309 |193 206|investigationon of CSF PCO
P09499254A1309 |122 139|patient toleranceyperbilirubinemia
P09499254A1309 |44 52|activityphatases
P09499254A1309 |147 154|regimen997A047
P09499254A1309 |56 64|patients 5-nucle
P09499254A1309 |96 116|islet-cell carcinomaogic aspects of neon
P09501093A0071 |85 99|Ras activation0 Pharmacologi
P09501093A0071 |45 48|MAPhat
P09501093A0071 |116 120|roleatal
P09501093A0071 |18 25|mitogenparison
P09501093A0071 |36 43|proteinine pho
P09501093A0071 |134 157|Ras signal transductionnemia. P00008997A0472 W
P09501093A0071 |50 56|kinasees and
P09501093A0071 |70 81|consequencee P00008171
P09501093A0071 |0 10|ActivationP00001606T
P09501169A0000 |0 26|Histone acetylation levelsP00001606T0076 Comparison 
P09501169A0000 |30 35|cells alka
P09501169A0000 |58 69|equilibrium-nucleotida
P09501169A0000 |88 106|histone acetylasesharmacologic aspec
P09501169A0000 |111 123|deacetylases neonatal hy
P09501982A1178 |0 11|CONCLUSIONSP00001606T0
P09501982A1178 |328 338|commitmentpe (1.21 +
P09501982A1178 |108 123|Xenopus embryos of neonatal hy
P09501982A1178 |199 208|potentialCSF PCO2 
P09501982A1178 |382 397|differentiationppears to be an
P09501982A1178 |13 18|XCoe26 Com
P09501982A1178 |164 169|XCoe2 [HCO
P09501982A1178 |221 237|progenitor cells-depleted rats a
P09501982A1178 |251 259|X-ngnr-1isplaced
P09501982A1178 |300 310|competence a signifi
P09501982A1178 |412 430|XNeuroD expressionotic drug with the
P09501982A1178 |66 73|cascadeidase P
P09501982A1178 |97 104|neuronsgic asp
P09501982A1178 |351 355|fate0001
P09501982A1178 |38 42|rolee ph
P09501982A1178 |140 162|Delta-Notch signalling P00008997A0472 When C
P09501982A1178 |274 284|transitionto control
P09502627A0705 |305 306|pg
P09502627A0705 |257 274|ejection fractioned when compared 
P09502627A0705 |21 28|Group Aison wi
P09502627A0705 |188 215|peak creatine kinase levelsunction of CSF PCO2 the dat
P09502627A0705 |218 219|pf
P09502627A0705 |124 140|ventriculographyerbilirubinemia.
P09502627A0705 |330 338|Group B. (1.21 +
P09502627A0705 |151 163|infarct area0472 When CS
P09502627A0705 |276 280|LVEF con
P09502627A0705 |42 51|incidenceosphatase
P09502627A0705 |9 17|PatientsT0076 Co
P09502627A0705 |285 303|hospital discharge but still have a 
P09502627A0705 |70 95|wall motion abnormalitiese P00008171T0000 Pharmaco
P09502627A0705 |97 98|pg
P09502627A0705 |0 7|RESULTSP000016
P09502720A0214 |0 19|CyIIa transcriptionP00001606T0076 Comp
P09502720A0214 |73 86|specification00008171T0000
P09502720A0214 |106 113|domainsts of n
P09502720T0000 |118 128|CyIIa geneal hyperbi
P09502720T0000 |132 150|sea urchin embryosbinemia. P00008997
P09502720T0000 |92 110|complex expressionacologic aspects o
P09502720T0000 |29 52|cell type specificationh alkaline phosphatases
P09502720T0000 |71 78|element P00008
P09503017A1021 |186 211|lung carcinoma cell lines function of CSF PCO2 the
P09503017A1021 |77 81|gene8171
P09503017A1021 |105 111|otherscts of
P09503017A1021 |117 134|chromosome 3p21.3tal hyperbilirubi
P09503017A1021 |36 41|HYAL1ine p
P09503017A1021 |16 24|evidenceompariso
P09503526A0614 |17 24|myalgiampariso
P09503526A0614 |26 33|Raynaudwith al
P09503526A0614 |46 61|skin vasculitisatases and 5-nu
P09503526A0614 |75 103|diseases WFAg concentrations008171T0000 Pharmacologic as
P09503526A0614 |36 44|syndromeine phos
P09503526A0614 |124 132|patientserbiliru
P09503526A0614 |3 11|patients001606T0
P09504423A0114 |238 247|pGEX-4T-2e no long
P09504423A0114 |188 191|GSTunc
P09504423A0114 |218 236|gene fusion vectorf K-depleted rats 
P09504423A0114 |321 329|proteaseter slop
P09504423A0114 |267 280|gene sequencempared to con
P09504423A0114 |124 128|BL21erbi
P09504423A0114 |331 345|alpha-thrombin(1.21 +/- 0.23
P09504423A0114 |31 42|4E-BP1 genealkaline ph
P09504423A0114 |193 197|geneon o
P09504423A0114 |13 23|expression6 Comparis
P09504423A0114 |84 88|gene00 P
P09504423A0114 |292 305|cleavage siteill have a si
P09504423A0114 |129 132|DE3iru
P09504423A0114 |161 186|glutathione-S-transferaseCSF [HCO3-] is shown as a
P09504423A0114 |140 151|fusion gene P00008997A
P09504514T0000 |139 148|remission. P000089
P09504514T0000 |120 129|leukaemia hyperbil
P09504514T0000 |161 168|MRC AMLCSF [HC
P09504514T0000 |11 21|comparison076 Compar
P09504514T0000 |89 101|chemotherapyarmacologic 
P09504514T0000 |150 157|resultsA0472 W
P09504514T0000 |172 177|trial is s
P09504514T0000 |25 33|addition with al
P09504514T0000 |48 75|bone-marrow transplantationases and 5-nucleotidase P00
P09504553T0000 |19 27|cannabisarison w
P09504553T0000 |12 15|use76 
P09504906A0099 |0 8|AnalysisP0000160
P09504906A0099 |74 84|amino acid0008171T00
P09504906A0099 |151 156|Hap1p0472 
P09504906A0099 |105 121|cysteine residuects of neonatal 
P09504906A0099 |141 147|domainP00008
P09504906A0099 |23 33|revertantson with al
P09504906A0099 |50 58|functiones and 5
P09505135A0182 |70 77|targetse P0000
P09505135A0182 |18 25|stimuliparison
P09505135A0182 |49 56|stimulises and
P09505733A0246 |85 92|factors0 Pharm
P09505733A0246 |52 57|shows and 
P09505733A0246 |12 19|studies76 Comp
P09505733A0246 |183 191|patientss a func
P09505733A0246 |122 130|distressyperbili
P09505733A0246 |174 179|groups sho
P09505733A0246 |157 168|limitationshen CSF [HC
P09505733A0246 |2 8|review000160
P09506439A2179 |0 9|PKC-gammaP00001606
P09506439A2179 |74 89|gene expression0008171T0000 Ph
P09506439A2179 |140 150|SVHK cells P00008997
P09506439A2179 |111 117|manner neona
P09506439A2179 |35 48|keratinocytesline phosphat
P09506959T0000 |0 14|IdentificationP00001606T0076
P09506959T0000 |135 145|regulatorsemia. P000
P09506959T0000 |60 69|complexesucleotida
P09506959T0000 |81 88|membersT0000 P
P09506959T0000 |96 115|Myc/Max/Mad networkogic aspects of neo
P09506959T0000 |19 35|characterizationarison with alka
P09506962A1000 |118 121|YY1al 
P09506962A1000 |46 53|calpainatases 
P09506962A1000 |65 75|proteasometidase P00
P09506962A1000 |106 114|elementsts of ne
P09506962A1000 |33 42|targetingkaline ph
P09506983A0304 |0 7|PrimersP000016
P09506983A0304 |82 95|RACE products0000 Pharmaco
P09506983A0304 |64 68|endsotid
P09506983A0304 |23 29|roundson wit
P09506983A0304 |33 37|RACEkali
P09506990T0000 |6 18|ZFM1 protein606T0076 Com
P09506990T0000 |124 141|activator proteinerbilirubinemia. 
P09506990T0000 |74 105|transcription activation domain0008171T0000 Pharmacologic aspe
P09506990T0000 |40 49|repressorphosphata
P09507032A1144 |101 106|cellsaspec
P09507032A1144 |134 143|apoptosisnemia. P0
P09507032A1144 |81 97|CSF-1 protectionT0000 Pharmacolo
P09507032A1144 |59 67|CSF1R/IRnucleoti
P09507032A1144 |18 34|CSF1R/IRDelta960parison with alk
P09508119A0498 |34 46|presentationaline phosph
P09508119A0498 |54 58|casend 5
P09508119A0498 |71 78|Gardner P00008
P09508119A0498 |81 89|syndromeT0000 Ph
P09508119A0498 |0 11|CONCLUSIONSP00001606T0
P09508377A0863 |273 281|melanoma to cont
P09508377A0863 |79 91|phaeomelanin71T0000 Phar
P09508377A0863 |122 127|pointyperb
P09508377A0863 |135 163|eumelanin/phaeomelanin ratioemia. P00008997A0472 When CS
P09508377A0863 |248 252|riskr di
P09508377A0863 |6 13|results606T007
P09508377A0863 |40 54|UV sensitivityphosphatases a
P09508377A0863 |228 239|individualsed rats are
P09508377A0863 |257 268|skin cancered when com
P09508377A0863 |175 193|chemical parameter shown as a functi
P09508377A0863 |100 116|eumelanin levels aspects of neon
P09508511A0588 |84 96|fluorofamide00 Pharmacol
P09508511A0588 |128 134|ureaselirubi
P09508511A0588 |77 79|os81
P09508511A0588 |57 61|dose5-nu
P09508511A0588 |3 10|ferrets001606T
P09508511A0588 |66 71|mg/kgidase
P09508511A0588 |35 46|H. mustelaeline phosph
P09508775A0293 |207 243|protooncogenes/transcription factors the data of K-depleted rats are no 
P09508775A0293 |89 114|protein kinase activationarmacologic aspects of ne
P09508775A0293 |29 36|pathwayh alkal
P09508775A0293 |132 138|growthbinemi
P09508775A0293 |156 164|pathwaysWhen CSF
P09508775A0293 |172 177|level is s
P09508775A0293 |185 195|expressiona function
P09509226A1235 |137 141|unitia. 
P09509226A1235 |106 109|ICUts 
P09509226A1235 |183 190|methodss a fun
P09509226A1235 |13 16|Use6 C
P09509226A1235 |30 36|method alkal
P09509226A1235 |76 89|time patients08171T0000 Ph
P09509226A1235 |59 68|reductionnucleotid
P09509226A1235 |146 153|savings8997A04
P09509226A1235 |228 236|outcomesed rats 
P09509226A1235 |117 125|transfertal hype
P09509226A1235 |157 169|nursing timehen CSF [HCO
P09509226A1235 |0 11|CONCLUSIONSP00001606T0
P09510189A0192 |137 140|DNAia.
P09510189A0192 |107 116|kilobasess of neon
P09510189A0192 |118 120|kbal
P09510189A0192 |35 47|organizationline phospha
P09510189A0192 |68 77|CD58 genease P0000
P09510398A1138 |34 42|patientsaline ph
P09510398A1138 |75 84|elevation008171T00
P09510398A1138 |54 66|hypouricemiand 5-nucleot
P09510398A1138 |96 115|urate concentrationogic aspects of neo
P09510398A1138 |145 154|Secretion08997A047
P09510398A1138 |124 132|subtypeserbiliru
P09510398A1138 |21 30|hematuriaison with
P09510398A1138 |4 16|risk factors01606T0076 C
P09510398A1138 |136 140|Postmia.
P09510582A0157 |117 120|geGtal
P09510582A0157 |164 169|agent [HCO
P09510582A0157 |105 111|geG-25cts of
P09510582A0157 |129 135|geG-50irubin
P09510582A0157 |125 127|mgrb
P09510582A0157 |148 150|mg97
P09510582A0157 |46 50|DCBMatas
P09510582A0157 |141 144|HBBP00
P09510582A0157 |23 31|patientson with 
P09510582A0157 |101 103|mgas
P09510925A0389 |85 96|week course0 Pharmacol
P09510925A0389 |108 116|sulphate of neon
P09510925A0389 |55 61|g dL-1d 5-nu
P09510925A0389 |7 32|haemoglobin concentration06T0076 Comparison with a
P09510925A0389 |34 36|Hbal
P09511724A0483 |103 110|calciumpects o
P09511724A0483 |7 12|cells06T00
P09511724A0483 |122 124|mMyp
P09511724A0483 |126 131|mediabilir
P09511724A0483 |39 57|Dsg protein levels phosphatases and 
P09511724A0483 |67 74|calciumdase P0
P09511724A0483 |18 30|accumulationparison with
P09511760A0221 |186 196|cHO-1 gene function 
P09511760A0221 |93 107|DNA sequencingcologic aspect
P09511760A0221 |9 36|restriction enzyme analysisT0076 Comparison with alkal
P09511760A0221 |245 252|regionsnger di
P09511760A0221 |226 228|kbet
P09511760A0221 |54 88|polymerase chain reaction analysisnd 5-nucleotidase P00008171T0000 P
P09511760A0221 |261 265|endshen 
P09511760A0221 |38 52|Southern blotse phosphatases
P09511760A0221 |153 159|clones72 Whe
P09512416A0460 |205 213|featuresO2 the d
P09512416A0460 |15 26|informationComparison 
P09512416A0460 |140 147|protein P00008
P09512416A0460 |232 245|7TM receptorsats are no lo
P09512416A0460 |92 117|Arabidopsis thaliana geneacologic aspects of neona
P09512416A0460 |62 75|sequence tagsleotidase P00
P09512416A0460 |0 7|RESULTSP000016
P09512416A0460 |187 194|domainsfunctio
P09512416A0460 |34 48|dbEST databasealine phosphat
P09512416A0460 |119 123|GCR1l hy
P09512550T0000 |0 3|E1AP00
P09512550T0000 |14 49|apolipoprotein AI enhancer activity Comparison with alkaline phosphata
P09512550T0000 |75 78|pRb008
P09512550T0000 |53 64|liver cellsand 5-nucle
P09512550T0000 |100 107|pathway aspect
P09512559T0000 |117 134|chromosome vectortal hyperbilirubi
P09512559T0000 |43 87|nerve growth factor-luciferase reporter genesphatases and 5-nucleotidase P00008171T0000 
P09512559T0000 |21 31|expressionison with 
P09512559T0000 |100 105|yeast aspe
P09513759A0716 |0 18|Calcitriol therapyP00001606T0076 Com
P09513759A0716 |41 49|decreasehosphata
P09513759A0716 |53 70|serum iPTH levelsand 5-nucleotidas
P09514156A1147 |0 11|AlterationsP00001606T0
P09514156A1147 |53 67|element regionand 5-nucleoti
P09514156A1147 |23 33|reactivityon with al
P09514156A1147 |199 204|stateCSF P
P09514156A1147 |15 20|DNaseCompa
P09514156A1147 |81 83|GCT0
P09514156A1147 |96 105|complexesogic aspe
P09514156A1147 |136 142|mannermia. P
P09514156A1147 |153 161|promoter72 When 
P09514159A0562 |62 66|Ptx1leot
P09514159A0562 |15 44|hormone-coding gene promotersComparison with alkaline phos
P09514260A1083 |137 143|originia. P0
P09514260A1083 |219 227|findings K-deple
P09514260A1083 |246 251|rolesger d
P09514260A1083 |265 266|Cc
P09514260A1083 |148 160|relationship97A0472 When
P09514260A1083 |51 64|pseudo inteins and 5-nucle
P09514260A1083 |255 263|intein Naced whe
P09514260A1083 |19 26|inteinsarison 
P09514260A1083 |114 121|inteinsonatal 
P09514260A1083 |272 281|EN motifsd to cont
P09514260A1083 |97 109|architecturegic aspects 
P09514260A1083 |71 78|results P00008
P09514260A1083 |170 186|protein families-] is shown as a
P09514272A0482 |119 122|P16l h
P09514272A0482 |76 80|mass0817
P09514272A0482 |111 114|P15 ne
P09514272A0482 |95 98|kDalog
P09514272A0482 |16 20|MvaTompa
P09514272A0482 |38 50|polypeptidese phosphatas
P09514272A0482 |84 87|kDa00 
P09514272A0482 |0 12|PurificationP00001606T00
P09514962A0841 |0 4|M-66P000
P09514962A0841 |27 34|proteinith alk
P09514962A0841 |46 50|MMTVatas
P09514962A0841 |59 74|T-cell lymphomanucleotidase P0
P09514962A0841 |76 80|EL-40817
P09515031A1020 |54 63|c-fos SREnd 5-nucl
P09515031A1020 |77 80|PKC817
P09515031A1020 |28 37|TGF-betafth alkali
P09515031A1020 |93 109|SRF binding sitecologic aspects 
P09515031A1020 |6 13|results606T007
P09515032A1230 |0 6|RT-PCRP00001
P09515032A1230 |22 30|p21 mRNAson with
P09515032A1230 |168 173|stageO3-] 
P09515032A1230 |117 123|stagestal hy
P09515665T0000 |51 72|CMV polyradiculopathys and 5-nucleotidase 
P09515665T0000 |16 34|foscarnet efficacyomparison with alk
P09515665T0000 |0 11|GanciclovirP00001606T0
P09515858A0000 |0 10|BACKGROUNDP00001606T
P09515858A0000 |12 21|Defensins76 Compar
P09515858A0000 |43 62|neutrophil peptidessphatases and 5-nuc
P09515858A0000 |106 124|azurophil granulests of neonatal hyp
P09515858A0000 |128 139|neutrophilslirubinemia
P09515858A0000 |82 90|peptides0000 Pha
P09515921A1662 |34 53|pca gene expressionaline phosphatases 
P09515921A1662 |90 100|pca operonrmacologic
P09515921A1662 |73 81|promoter00008171
P09515921A1662 |16 24|mutationompariso
P09515924A0104 |69 77|activityse P0000
P09515924A0104 |41 52|PDH complexhosphatases
P09515924A0104 |14 19|cells Comp
P09515924A0104 |9 10|gT
P09515924A0104 |94 101|proteinologic 
P09515924A0104 |86 90|U/mg Pha
P09515924A0104 |35 37|mgli
P09515924A0553 |50 75|hybridization experimentses and 5-nucleotidase P00
P09515924A0553 |25 30|genes with
P09515924A0553 |134 140|genomenemia.
P09515924A0553 |80 97|sequence analysis1T0000 Pharmacolo
P09515924A0553 |144 154|Z. mobilis008997A047
P09515924A0553 |114 126|gene regionsonatal hyper
P09515924A0553 |4 7|PDH016
P09516472A0292 |102 123|Id4 promoter activityspects of neonatal hy
P09516472A0292 |77 87|TATA motif8171T0000 
P09516472A0292 |34 42|elementsaline ph
P09517646A0149 |0 12|AzithromycinP00001606T00
P09517646A0149 |161 176|pylori regimensCSF [HCO3-] is 
P09517646A0149 |132 137|agentbinem
P09517646A0149 |22 42|generation macrolideson with alkaline ph
P09517646A0149 |81 97|pharmacokineticsT0000 Pharmacolo
P09517989A0476 |55 58|HIVd 5
P09517989A0476 |47 50|CMVtas
P09517989A0476 |111 118|cells/l neonat
P09517989A0476 |78 87|CD4 count171T0000 
P09517989A0476 |23 29|peopleon wit
P09517989A0476 |4 9|study01606
P09518383A0000 |0 10|BACKGROUNDP00001606T
P09518383A0000 |219 229|medication K-deplete
P09518383A0000 |52 60|diseases and 5-n
P09518383A0000 |189 195|smearsnction
P09518383A0000 |94 105|sex workersologic aspe
P09518383A0000 |62 65|STDleo
P09518383A0000 |121 125|Peruhype
P09518383A0000 |241 248|condomso longe
P09518383A0000 |107 110|FSWs o
P09518383A0000 |15 25|OBJECTIVESComparison
P09518383A0000 |115 119|Limanata
P09518383A0000 |157 162|testshen C
P09518383A0000 |67 82|control programdase P00008171T
P09518383A0000 |167 175|syphilisCO3-] is
P09518383A0000 |200 209|gonococciSF PCO2 t
P09518383A0000 |234 237|STDs a
P09518808T0000 |0 22|National certificationP00001606T0076 Compari
P09518808T0000 |45 62|quality assurancehatases and 5-nuc
P09518808T0000 |32 41|componentlkaline p
P09519757A0482 |119 122|NBFl h
P09519757A0482 |150 156|regionA0472 
P09519757A0482 |15 24|mutationsCompariso
P09519757A0482 |56 60|exon 5-n
P09519757A0482 |26 31|D811Nwith 
P09519757A0482 |192 205|heterozygotesion of CSF PC
P09519757A0482 |47 52|R835Ctases
P09519757A0482 |113 117|foldeona
P09519757A0482 |160 164|SUR1 CSF
P09519757A0482 |173 180|patientis show
P09519757A0482 |35 39|exonline
P09519828A0809 |137 162|E2 transactivation domainia. P00008997A0472 When C
P09519828A0809 |10 27|VP16-E2 molecules0076 Comparison w
P09519828A0809 |99 117|BPV-4 LCR promoterc aspects of neona
P09519828A0809 |81 91|activationT0000 Phar
P09519830A0282 |288 309|thymidine kinase genet still have a signif
P09519830A0282 |58 67|silencing-nucleoti
P09519830A0282 |167 172|ICP34CO3-]
P09519830A0282 |175 184|promoters shown as
P09519830A0282 |115 122|virusesnatal h
P09519830A0282 |323 329|genomer slop
P09519830A0282 |217 264|chloramphenicol acetyltransferase reporter geneof K-depleted rats are no longer displaced when
P09519830A0282 |3 8|order00160
P09519830A0282 |201 211|expressionF PCO2 the
P09519830A0282 |86 101|HSV-1 infection Pharmacologic 
P09519830A0282 |34 38|rolealin
P09520398A0124 |6 13|changes606T007
P09520398A0124 |88 101|core histonesharmacologic 
P09520398A0124 |41 49|increasehosphata
P09520398A0124 |57 75|acetylation levels5-nucleotidase P00
P09521907A0190 |85 104|expression patterns0 Pharmacologic asp
P09521907A0190 |42 51|Otx genesosphatase
P09521907A0190 |26 29|otdwit
P09521907A0190 |76 81|terms08171
P09521907A0190 |116 126|phenotypesatal hyper
P09521909A0081 |102 118|stamen primordiaspects of neonat
P09521909A0081 |58 64|region-nucle
P09521909A0081 |124 134|expressionerbilirubi
P09521909A0081 |182 193|developmentas a functi
P09521909A0081 |203 209|organsPCO2 t
P09521909A0081 |92 97|petalacolo
P09521909A0081 |157 163|regionhen CS
P09521909A0081 |0 20|APETALA3 transcriptsP00001606T0076 Compa
P09521913A0400 |35 43|60A geneline pho
P09521913A0400 |83 89|factor000 Ph
P09521913A0400 |18 27|mutationsparison w
P09522297A0744 |0 10|Cell linesP00001606T
P09522297A0744 |107 116|karyotypes of neon
P09522297A0744 |91 99|analysismacologi
P09522297A0744 |56 62|tumors 5-nuc
P09522297A0744 |71 75|mice P00
P09522979T0000 |84 94|population00 Pharmac
P09522979T0000 |41 51|predictionhosphatase
P09522979T0000 |22 33|fibronectinson with al
P09522979T0000 |55 69|preterm labourd 5-nucleotida
P09523478A0572 |34 42|childrenaline ph
P09523478A0572 |13 16|IgM6 C
P09523478A0572 |76 84|subjects08171T00
P09523478A0572 |59 72|toxoplasmosisnucleotidase 
P09523478A0572 |3 11|addition001606T0
P09523478A0572 |100 112|reactivation aspects of 
P09523551A0367 |5 13|variants1606T007
P09523551A0367 |75 76|G0
P09523551A0367 |46 54|topologyatases a
P09523551A0367 |93 102|receptorscologic a
P09524122A0336 |25 29|GPA2 wit
P09524122A0336 |46 52|growthatases
P09524122A0336 |15 21|alleleCompar
P09524122A0336 |78 87|RAS genes171T0000 
P09524122A0336 |58 64|strain-nucle
P09524222A0769 |100 108|sequence aspects
P09524222A0769 |223 229|MARCKSeplete
P09524222A0769 |58 62|beta-nuc
P09524222A0769 |213 219|regionata of
P09524222A0769 |245 256|actin-crossnger displa
P09524222A0769 |265 272|proteincompare
P09524222A0769 |30 37|isoform alkali
P09524222A0769 |167 175|subunitsCO3-] is
P09524222A0769 |376 401|calmodulin binding domainthus appears to be an eff
P09524222A0769 |286 302|protein kinase Cbut still have a
P09524222A0769 |327 341|beta 4-adducinope (1.21 +/- 
P09524222A0769 |4 17|COOH-terminus01606T0076 Co
P09524222A0769 |77 87|amino acid8171T0000 
P09524222A0769 |138 148|cell alphaa. P000089
P09524222A0769 |307 325|calcium/calmodulinificantly greater 
P09524222A1113 |137 142|cellsia. P
P09524222A1113 |37 57|beta-adducin isoformne phosphatases and 
P09524222A1113 |181 188|tissues as a f
P09524222A1113 |90 95|liverrmaco
P09524222A1113 |80 85|brain1T000
P09524222A1113 |97 108|bone marrowgic aspects
P09524222A1113 |114 118|NT-2onat
P09524222A1113 |0 12|PCR analysisP00001606T00
P09524229A0000 |171 182|hypoviruses] is shown 
P09524229A0000 |217 228|mycovirusesof K-deplet
P09524229A0000 |297 311|concentrationsave a signific
P09524229A0000 |333 356|inhibitor cycloheximide.21 +/- 0.23 vs. P00010
P09524229A0000 |29 43|enzyme laccaseh alkaline pho
P09524229A0000 |123 147|Cryphonectria parasiticaperbilirubinemia. P00008
P09524229A0000 |186 191|group func
P09524229A0000 |358 361|CHX3A0
P09524229A0000 |392 406|cyclosporin A.be an effectiv
P09524229A0000 |86 91|genes Phar
P09524229A0000 |76 82|number08171T
P09524229A0000 |230 235|lac-1 rats
P09524229A0000 |99 121|chestnut blight fungusc aspects of neonatal 
P09524229A0000 |4 14|gene lac-101606T0076
P09524250A0767 |47 50|AP1tas
P09524250A0767 |14 22|elements Compari
P09524259A0301 |152 168|insulin receptor472 When CSF [HC
P09524259A0301 |198 204|system CSF P
P09524259A0301 |61 66|IGFIRcleot
P09524259A0301 |181 186|yeast as a
P09524259A0301 |100 115|mutant receptor aspects of neo
P09524259A0301 |4 22|hp55 gamma protein01606T0076 Compari
P09524259A0301 |117 127|hp55 gammatal hyperb
P09524259A0301 |170 172|IR-]
P09524267A1023 |102 121|localization signalspects of neonatal 
P09524267A1023 |74 82|proteins0008171T
P09524267A1023 |282 293|plant cellsols but sti
P09524267A1023 |146 161|helicase motifs8997A0472 When 
P09524267A1023 |47 54|domainstases a
P09524267A1023 |135 141|domainemia. 
P09524267A1023 |200 204|partSF P
P09524267A1023 |212 239|RNA transcription apparatusdata of K-depleted rats are
P09524267A1023 |4 17|plant protein01606T0076 Co
P09524267A1023 |252 278|nucleotide excision repairsplaced when compared to c
P09524273A0205 |70 86|characterizatione P00008171T0000
P09524273A0205 |5 10|paper1606T
P09524273A0205 |106 112|regionts of 
P09524273A0205 |33 45|organizationkaline phosp
P09524273A0205 |49 61|mouse gC1qBPses and 5-nu
P09524276A0939 |152 172|bacterium protection472 When CSF [HCO3-]
P09524276A0939 |42 48|ureaseosphat
P09524276A0939 |192 198|damageion of
P09524276A0939 |74 77|NAC000
P09524276A0939 |114 118|OxyRonat
P09524276A0939 |52 72|Klebsiella aerogenes and 5-nucleotidase 
P09524276A0939 |84 92|catalase00 Pharm
P09524276A0939 |0 13|LysR proteinsP00001606T007
P09525105A0298 |64 80|Buddleia cordataotidase P0000817
P09525105A0298 |28 38|activitiesth alkalin
P09525105A0298 |53 60|extractand 5-n
P09525105A0298 |99 116|glycoside linarinc aspects of neon
P09525598A0325 |152 160|activity472 When
P09525598A0325 |125 128|Rafrbi
P09525598A0325 |120 123|Raf hy
P09525598A0325 |80 90|cell lines1T0000 Pha
P09525598A0325 |53 61|findingsand 5-nu
P09525598A0325 |129 140|delta26-303irubinemia.
P09525598A0325 |110 116|domainf neon
P09525598A0325 |32 39|T cellslkaline
P09525598A0325 |18 28|Raf kinaseparison wi
P09525598A0325 |69 76|varietyse P000
P09525598A0325 |0 10|RegulationP00001606T
P09525888A1482 |12 23|FLAP clones76 Comparis
P09525888A1482 |45 50|mousehatas
P09525888A1482 |60 79|muscle cDNA libraryucleotidase P000081
P09525891T0000 |0 7|MembersP000016
P09525891T0000 |15 20|meis1Compa
P09525891T0000 |123 128|CYP17perbi
P09525891T0000 |105 109|CRS1cts 
P09525891T0000 |95 103|sequencelogic as
P09525891T0000 |25 57|pbx homeodomain protein families with alkaline phosphatases and 
P09527921A1178 |205 220|initiation siteO2 the data of 
P09527921A1178 |269 282|transcriptionared to contr
P09527921A1178 |127 139|core elementilirubinemia
P09527921A1178 |92 96|siteacol
P09527921A1178 |44 63|electron microscopyphatases and 5-nucl
P09527921A1178 |31 40|complexesalkaline 
P09527921A1178 |291 299|TATA boxtill hav
P09527921A1178 |234 244|start sites are no l
P09527921A1178 |100 115|WDV Rep protein aspects of neo
P09527921A1178 |184 186|bp a
P09528758T0000 |0 5|Rex-1P0000
P09528758T0000 |151 158|protein0472 Wh
P09528758T0000 |9 13|geneT007
P09528758T0000 |160 165|Rox-1 CSF 
P09528758T0000 |94 99|Oct-3ologi
P09528758T0000 |106 119|Oct-6 bindingts of neonata
P09528758T0000 |25 45|transcription factor with alkaline phosp
P09528758T0000 |126 138|octamer sitebilirubinemi
P09528758T0000 |190 194|sitectio
P09528758T0000 |69 75|embryose P00
P09528766A0915 |68 76|pathwaysase P000
P09528766A0915 |110 138|CREB Ser-133 phosphorylationf neonatal hyperbilirubinemi
P09528766A0915 |9 19|inhibitionT0076 Comp
P09528766A0915 |48 65|p38/MAPKAP kinaseases and 5-nucleo
P09528766A0915 |32 39|ERK/RSKlkaline
P09528768A0000 |85 87|ER0 
P09528768A0000 |46 54|proteinsatases a
P09528768A0000 |107 120|transcriptions of neonatal
P09528768A0000 |74 83|reticulum0008171T0
P09528768A0000 |21 33|accumulationison with al
P09528768A0000 |128 133|geneslirub
P09528768A0000 |155 173|chaperone proteins When CSF [HCO3-] 
P09528768A0000 |0 5|CellsP0000
P09528770A1379 |171 187|activators Msn2p] is shown as a 
P09528770A1379 |29 56|protein kinase cAPK pathwayh alkaline phosphatases and
P09528770A1379 |192 197|Msn4pion o
P09528770A1379 |210 222|UAS activitye data of K-
P09528770A1379 |231 237|repeatrats a
P09528770A1379 |110 117|glucosef neona
P09528770A1379 |245 253|presencenger dis
P09528770A1379 |130 143|carbon sourcerubinemia. P0
P09528770A1379 |86 90|IREu Pha
P09528770A1379 |98 106|presenceic aspec
P09528770A1379 |257 264|acetateed when
P09528770A1379 |70 82|UAS activitye P00008171T
P09528784A0000 |87 102|complementationPharmacologic a
P09528784A0000 |10 14|gene0076
P09528784A0000 |22 35|fission yeastson with alka
P09528784A0000 |4 8|mei40160
P09528792A0000 |190 196|mannerction 
P09528792A0000 |12 20|splicing76 Compa
P09528792A0000 |210 220|cell typese data of 
P09528792A0000 |61 67|FGF-R2cleoti
P09528792A0000 |75 82|example008171T
P09528792A0000 |148 152|IIIc97A0
P09528792A0000 |133 143|exons IIIbinemia. P0
P09528792A0000 |24 57|fibroblast growth factor receptorn with alkaline phosphatases and 
P09528792A0000 |115 123|splicingnatal hy
P09528858A0205 |103 116|gene activitypects of neon
P09528858A0205 |28 39|methylationth alkaline
P09528858A0205 |43 47|CpGsspha
P09528858A0205 |88 99|suppressionharmacologi
P09528858A0205 |8 13|cases6T007
P09528858A0205 |69 76|regionsse P000
P09528950A0716 |49 73|luciferase reporter geneses and 5-nucleotidase P
P09528950A0716 |12 21|fragments76 Compar
P09528987A1348 |0 23|Cotransfection analysesP00001606T0076 Comparis
P09528987A1348 |73 96|T/EBP expression vector00008171T0000 Pharmacol
P09528987A1348 |31 65|T/EBP promoter-reporter constructsalkaline phosphatases and 5-nucleo
P09528987A1348 |164 178|autoregulation [HCO3-] is sh
P09528987A1348 |108 119|HepG2 cells of neonata
P09528987A1348 |215 218|rata o
P09528987A1348 |229 250|T/EBP gene expressiond rats are no longer 
P09528987A1348 |142 147|T/EBP00008
P09529156A1238 |0 8|DeletionP0000160
P09529156A1238 |79 92|receptor tail71T0000 Pharm
P09529156A1238 |149 164|desensitization7A0472 When CSF
P09529156A1238 |25 37|Ser residues with alkali
P09529156A1238 |109 129|phorbol 12-myristateof neonatal hyperbil
P09529156A1238 |53 71|PKC consensus siteand 5-nucleotidase
P09529156A1238 |170 171|%-
P09529216A0644 |0 13|Flap survivalP00001606T007
P09529216A0644 |29 40|developmenth alkaline 
P09529216A0644 |91 98|vesselsmacolog
P09529216A0644 |52 58|number and 5
P09529216A0644 |147 154|vessels997A047
P09529216A0644 |71 82|connections P00008171T
P09529216A0644 |116 123|pedicleatal hy
P09529649A0307 |0 9|Jean KligP00001606
P09529649A0307 |60 75|tract infectionucleotidase P00
P09529649A0307 |79 87|children71T0000 
P09529649A0307 |25 35|literature with alka
P09529721A0000 |273 283|assessment to contro
P09529721A0000 |218 226|hospitalf K-depl
P09529721A0000 |127 137|managementilirubinem
P09529721A0000 |297 308|counsellingave a signi
P09529721A0000 |241 247|weighto long
P09529721A0000 |10 20|indicators0076 Compa
P09529721A0000 |167 179|malnutritionCO3-] is sho
P09529721A0000 |47 62|classificationstases and 5-nuc
P09529721A0000 |81 93|malnutritionT0000 Pharma
P09529721A0000 |141 158|childhood illnessP00008997A0472 Wh
P09529721A0000 |313 322|follow-uptly great
P09529721A0000 |206 214|referral2 the da
P09529721A0000 |101 111|guidelinesaspects of
P09530251A0766 |0 4|SNACP000
P09530251A0766 |59 67|ischemianucleoti
P09530251A0766 |8 11|PBS6T0
P09530251A0766 |98 106|durationic aspec
P09530251A0766 |110 121|reperfusionf neonatal 
P09530251A0766 |48 51|minase
P09530251A0766 |32 33|hl
P09531538A0983 |79 96|dU2AF38 RS domain71T0000 Pharmacol
P09531538A0983 |47 64|splicing activitytases and 5-nucle
P09531538A0983 |12 23|requirement76 Comparis
P09531549A0658 |136 151|yAP180 proteinsmia. P00008997A
P09531549A0658 |198 205|patches CSF PC
P09531549A0658 |104 111|yAP180Aects of
P09531549A0658 |31 50|GST fusion proteinsalkaline phosphatas
P09531549A0658 |55 69|yeast extractsd 5-nucleotida
P09531549A0658 |126 134|clathrinbilirubi
P09531549A0658 |9 24|binding studiesT0076 Compariso
P09531549A0658 |95 100|siteslogic
P09531549A0658 |216 231|plasma membrane of K-depleted 
P09531549A0658 |156 161|Pan1pWhen 
P09531549A0658 |116 121|Pan1patal 
P09531549A0658 |168 173|actinO3-] 
P09531559A1153 |154 158|ZO-22 Wh
P09531559A1153 |121 127|domainhyperb
P09531559A1153 |9 26|affinity analysesT0076 Comparison 
P09531559A1153 |131 139|occludinubinemia
P09531559A1153 |96 100|ZO-1ogic
P09531559A1153 |64 71|proteinotidase
P09533030T0000 |0 12|Cytochrome bP00001606T00
P09533030T0000 |22 29|complexson wit
P09533030T0000 |92 102|componentsacologic a
P09533030T0000 |179 183|SDHCwn a
P09533030T0000 |214 218|1q21ta o
P09533030T0000 |106 124|liver mitochondriats of neonatal hyp
P09533030T0000 |223 228|11q23eplet
P09533030T0000 |55 69|oxidoreductased 5-nucleotida
P09533030T0000 |158 163|genesen CS
P09533030T0000 |196 200|SDHDof C
P09533030T0000 |72 84|cDNA cloningP00008171T00
P09533030T0000 |129 150|chromosome assignmentirubinemia. P00008997
P09533030T0000 |202 210|subunits PCO2 th
P09533109A0449 |207 208|p 
P09533109A0449 |66 70|daysidas
P09533109A0449 |23 35|theophyllineon with alka
P09533109A0449 |11 19|decrease076 Comp
P09533109A0449 |193 205|significanceon of CSF PC
P09533109A0449 |38 44|volumee phos
P09533109A0449 |99 113|administrationc aspects of n
P09533109A0449 |48 60|distributionases and 5-n
P09533109A0449 |117 128|chloroquinetal hyperbi
P09535082A0537 |103 119|target sequencespects of neonata
P09535082A0537 |261 268|complexhen com
P09535082A0537 |127 134|absenceilirubi
P09535082A0537 |213 225|DNA fragmentata of K-dep
P09535082A0537 |270 272|CIre
P09535082A0537 |206 208|bp2 
P09535082A0537 |4 12|addition01606T00
P09535082A0537 |160 167|complex CSF [H
P09535082A0537 |189 193|PrfAncti
P09535082A0537 |33 40|extractkaline 
P09535082A0537 |138 142|PrfAa. P
P09535082A0537 |169 173|CIII3-] 
P09535082A0537 |70 85|protein bindinge P00008171T000
P09535579A1105 |156 158|kJWh
P09535579A1105 |132 136|EPOCbine
P09535579A1105 |88 102|interpretationharmacologic a
P09535579A1105 |20 31|assumptionsrison with 
P09535579A1105 |106 124|energy expenditurets of neonatal hyp
P09535579A1105 |140 141|l 
P09535579A1105 |55 61|uptaked 5-nu
P09535833A0228 |140 146|factor P0000
P09535833A0228 |90 128|selenocysteine tRNA gene transcriptionrmacologic aspects of neonatal hyperbi
P09535833A0228 |150 164|Xenopus laevisA0472 When CSF
P09535833A0228 |14 33|amino acid sequence Comparison with al
P09535833A0228 |76 80|Staf0817
P09535833A0228 |37 43|m-Stafne pho
P09535835A0279 |0 6|ROCK-IP00001
P09535835A0279 |46 56|type formsatases and
P09535835A0279 |74 79|Cdc4200081
P09535835A0279 |22 27|mDia2son w
P09535835A0279 |8 16|Kinectin6T0076 C
P09535835A0279 |65 69|RhoAtida
P09535835A0279 |99 105|mannerc aspe
P09535851A0591 |84 101|P kinase activity00 Pharmacologic 
P09535851A0591 |12 20|isoforms76 Compa
P09535851A0591 |75 81|PtdIns008171
P09535851A0591 |56 66|Vmax value 5-nucleot
P09535851A0591 |26 38|beta isoformwith alkalin
P09535851A0591 |110 123|gamma isoformf neonatal hy
P09535851A0591 |168 172|acidO3-]
P09535892A0000 |84 99|plasma membrane00 Pharmacologi
P09535892A0000 |195 197|WD o
P09535892A0000 |199 206|Trp-AspCSF PCO
P09535892A0000 |146 153|segment8997A04
P09535892A0000 |208 215|repeatsthe dat
P09535892A0000 |182 187|unitsas a 
P09535892A0000 |65 72|signalstidase 
P09535892A0000 |39 49|G proteins phosphata
P09535892A0000 |4 16|beta subunit01606T0076 C
P09535892A0000 |250 258|proteinsdisplace
P09535908A0321 |113 116|LNXeon
P09535908A0321 |29 41|LNX messagesh alkaline p
P09535908A0321 |61 69|proteinscleotida
P09535908A0321 |95 101|masseslogic 
P09535908A0321 |130 135|LNX-brubin
P09535908A0321 |108 111|kDa of
P09535908A0321 |125 128|kDarbi
P09536028A0945 |51 55|acids an
P09536028A0945 |148 151|EGF97A
P09536028A0945 |72 94|cyclooxygenase productP00008171T0000 Pharmac
P09536028A0945 |183 214|signal pathway probe inhibitorss a function of CSF PCO2 the da
P09536028A0945 |141 143|TFP0
P09536028A0945 |113 125|contractionseonatal hype
P09536028A0945 |3 11|contrast001606T0
P09536028A0945 |17 35|contractile actionmparison with alka
P09536440A0000 |7 14|studies06T0076
P09536440A0000 |44 52|myosin Vphatases
P09536440A0000 |122 130|movementyperbili
P09536440A0000 |94 99|motorologi
P09536901A0362 |119 127|relationl hyperb
P09536901A0362 |43 45|T2sp
P09536901A0362 |27 29|T1it
P09536901A0362 |14 22|occasion Compari
P09536901A0362 |55 63|sagittald 5-nucl
P09536901A0362 |143 153|assessment0008997A04
P09536901A0362 |86 95|sequences Pharmaco
P09536901A0362 |68 70|T2as
P09537295A0951 |50 52|bpes
P09537295A0951 |147 157|P1 primers997A0472 W
P09537295A0951 |94 133|transcriptase-polymerase chain reactionologic aspects of neonatal hyperbilirub
P09537295A0951 |75 79|site0081
P09537295A0951 |176 192|primer extensionshown as a funct
P09537295A0951 |198 210|cDNA cloning CSF PCO2 th
P09537295A0951 |159 173|primer walkingn CSF [HCO3-] 
P09537295A0951 |21 31|start siteison with 
P09537295T0000 |0 8|AnalysisP0000160
P09537295T0000 |12 20|promoter76 Compa
P09537295T0000 |45 54|sequenceshatases a
P09537295T0000 |76 89|transcription08171T0000 Ph
P09537295T0000 |25 33|androgen with al
P09537295T0000 |97 100|ratgic
P09537295T0000 |118 130|protein geneal hyperbili
P09537361A0149 |206 215|depletion2 the dat
P09537361A0149 |41 51|expressionhosphatase
P09537361A0149 |112 115|cvineo
P09537361A0149 |77 106|transporter accessory protein8171T0000 Pharmacologic aspec
P09537361A0149 |177 187|conditionshown as a 
P09537361A0149 |130 156|colicin V immunity proteinrubinemia. P00008997A0472 
P09537361A0149 |191 202|iron excesstion of CSF
P09537361A0149 |23 36|transcriptionon with alkal
P09537361A0149 |4 19|iron dependence01606T0076 Comp
P09537361A0149 |55 59|cvaAd 5-
P09537375A0198 |65 76|lacZ fusiontidase P000
P09537375A0198 |124 128|GntRerbi
P09537375A0198 |31 41|expressionalkaline p
P09537375A0198 |59 63|gntTnucl
P09537375A0198 |145 154|regulator08997A047
P09537375A0198 |158 162|gntTen C
P09537375A0198 |5 25|gntR deletion mutant1606T0076 Comparison
P09537378A1227 |17 25|deletionmparison
P09537378A1227 |29 32|bcph a
P09537378A1227 |60 66|effectucleot
P09537378A1227 |42 52|chromosomeosphatases
P09537378A1227 |70 89|gcv-lacZ expressione P00008171T0000 Ph
P09537651A0366 |16 20|PEA3ompa
P09537651A0366 |58 67|induction-nucleoti
P09537651A0366 |9 14|sitesT0076
P09537651A0366 |131 140|inductionubinemia.
P09537651A0366 |148 187|phorbol ester phorbol myristate acetate97A0472 When CSF [HCO3-] is shown as a 
P09537651A0366 |189 192|PMAnct
P09537651A0366 |25 29|STAT wit
P09537651A0366 |71 76|v-src P000
P09537651A0366 |100 108|elements aspects
P09538156A0130 |0 13|BRCA1 proteinP00001606T007
P09538156A0130 |89 95|regionarmaco
P09538156A0130 |41 58|zinc finger motifhosphatases and 5
P09538220A0000 |37 40|mrrne 
P09538220A0000 |105 108|DNActs
P09538220A0000 |62 69|tRNAPheleotida
P09538220A0000 |74 87|tRNAPro genes0008171T0000 
P09538220A0000 |164 177|transcription [HCO3-] is s
P09538220A0000 |134 144|regulationnemia. P00
P09538220A0000 |148 159|replication97A0472 Whe
P09538220A0000 |29 35|regionh alka
P09538220A0000 |199 205|genomeCSF PC
P09538220A0000 |110 115|mtDNAf neo
P09538258A0200 |137 142|cellsia. P
P09538258A0200 |8 14|report6T0076
P09538258A0200 |56 70|Ras activation 5-nucleotidas
P09538258A0200 |110 119|receptorsf neonata
P09538258A0200 |76 87|stimulation08171T0000 
P09538258A0200 |101 106|typesaspec
P09538258A0200 |35 44|mechanismline phos
P09539421A0970 |39 44|roles phos
P09539421A0970 |24 33|K. lactisn with al
P09539421A0970 |67 94|telomere length maintenancedase P00008171T0000 Pharmac
P09539421A0970 |128 134|themeslirubi
P09539421A0970 |6 18|Sir proteins606T0076 Com
P09539421A0970 |53 62|silencingand 5-nuc
P09539721A0599 |87 97|activationPharmacolo
P09539721A0599 |28 32|DnaAth a
P09539721A0599 |105 116|pR promotercts of neon
P09539721A0599 |65 79|RNA polymerasetidase P000081
P09539721A0599 |49 61|beta subunitses and 5-nu
P09539746A0781 |85 90|cells0 Pha
P09539746A0781 |14 20|Bcl-XL Compa
P09539746A0781 |35 46|associationline phosph
P09539746A0781 |62 71|caspase-9leotidase
P09539746A0781 |50 56|Apaf-1es and
P09539746A0781 |0 10|ExpressionP00001606T
P09539779A0621 |152 162|expression472 When C
P09539779A0621 |166 170|All1HCO3
P09539779A0621 |105 120|Arp1 expressioncts of neonatal
P09539779A0621 |43 56|mouse embryossphatases and
P09539779A0621 |94 101|patternologic 
P09539779A0621 |20 33|hybridizationrison with al
P09539779A0621 |69 73|daysse P
P09540062A0755 |152 160|activity472 When
P09540062A0755 |176 209|H4 promoter/CAT fusion constructsshown as a function of CSF PCO2 t
P09540062A0755 |133 135|H4in
P09540062A0755 |74 82|proteins0008171T
P09540062A0755 |30 37|ability alkali
P09540062A0755 |6 13|mutants606T007
P09540062A0755 |58 62|Site-nuc
P09540062A0755 |115 122|abilitynatal h
P09540062A0755 |223 233|cell typesepleted ra
P09541280A0404 |102 118|plasma IgE levelspects of neonat
P09541280A0404 |75 89|FK506 ointment008171T0000 Ph
P09541280A0404 |60 69|treatmentucleotida
P09541280A0404 |47 54|NC micetases a
P09541280A0404 |10 20|plasma IgE0076 Compa
P09541636T0000 |85 91|tumors0 Phar
P09541636T0000 |61 69|patientscleotida
P09541636T0000 |38 57|artery embolizatione phosphatases and 
P09541636T0000 |0 23|Creatine kinase releaseP00001606T0076 Comparis
P09541721A0894 |119 124|LVEDPl hyp
P09541721A0894 |53 62|AHF modeland 5-nuc
P09541721A0894 |109 117|pressureof neona
P09541721A0894 |20 41|ischemia/angiotensionrison with alkaline p
P09541721A0894 |64 67|NICoti
P09543227A0815 |0 7|Group AP000016
P09543227A0815 |75 76|B0
P09543227A0815 |40 48|patientsphosphat
P09543227A0815 |109 121|risk factorsof neonatal 
P09543227A0815 |89 94|yearsarmac
P09543227A0815 |61 73|risk factorscleotidase P
P09543227A0815 |20 25|yearsrison
P09543227A0815 |127 128|Ci
P09543227A0815 |141 146|yearsP0000
P09543227A0815 |169 181|risk factors3-] is shown
P09544987A1583 |65 69|NCoRtida
P09544987A1583 |28 38|RU486-PR-Bth alkalin
P09544991A0483 |0 12|PRL receptorP00001606T00
P09544991A0483 |28 33|SHP-2th al
P09544991A0483 |47 67|tyrosine phosphatasetases and 5-nucleoti
P09544991A0750 |254 262|m-Stat5alaced wh
P09544991A0750 |63 72|inductioneotidase 
P09544991A0750 |192 208|m-Stat5adelta749ion of CSF PCO2 
P09544991A0750 |225 250|transactivation potentialleted rats are no longer 
P09544991A0750 |22 28|mutantson wi
P09544991A0750 |129 137|m-Stat5airubinem
P09544991A0750 |76 100|tyrosine phosphorylation08171T0000 Pharmacologic
P09544991A0750 |267 275|m-Stat5bmpared t
P09544991A0750 |32 37|SHP-2lkali
P09544991A0750 |175 183|deletion shown a
P09544991A0750 |117 125|activitytal hype
P09544991A0750 |139 147|m-Stat5b. P00008
P09545146A0884 |0 11|CONCLUSIONSP00001606T0
P09545146A0884 |150 154|Cl/FA047
P09545146A0884 |90 98|CBZ Cl/Frmacolog
P09545146A0884 |79 86|changes71T0000
P09545146A0884 |167 187|regression equationsCO3-] is shown as a 
P09545146A0884 |106 118|comedicationts of neonat
P09545146A0884 |209 223|concentrationshe data of K-d
P09545146A0884 |39 43|data pho
P09545146A0884 |66 75|estimatesidase P00
P09545146A0884 |138 146|decreasea. P0000
P09545146A0884 |238 252|validation sete no longer di
P09545293A0590 |17 24|lumicanmpariso
P09545293A0590 |29 38|keratocanh alkalin
P09545293A0590 |59 67|locationnucleoti
P09545293A0590 |0 5|SitesP0000
P09545312A1197 |98 111|transcriptionic aspects of
P09545312A1197 |45 57|HMG-I familyhatases and 
P09545312A1197 |30 37|members alkali
P09545312A1197 |76 80|role0817
P09545312A1197 |177 188|interactionhown as a f
P09545312A1197 |127 133|effectilirub
P09545312A1197 |4 16|observations01606T0076 C
P09545323T0000 |101 128|MLH1-PMS1 protein complexesaspects of neonatal hyperbi
P09545323T0000 |14 22|assembly Compari
P09545323T0000 |60 72|DNA mismatchucleotidase 
P09545323T0000 |36 43|complexine pho
P09545323T0000 |81 96|yeast MSH2-MSH6T0000 Pharmacol
P09545332A0137 |34 37|Pheali
P09545332A0137 |24 30|Tyr497n with
P09545332A0137 |161 165|IL-4CSF 
P09545332A0137 |149 157|response7A0472 W
P09545332A0137 |132 145|proliferationbinemia. P000
P09545332A0137 |81 107|insulin receptor substrateT0000 Pharmacologic aspect
P09545332A0137 |111 115|IRS1 neo
P09545332A0137 |49 73|tyrosine phosphorylationses and 5-nucleotidase P
P09545332A0137 |0 8|MutationP0000160
P09545353A1071 |33 48|kappaB elementskaline phosphat
P09545353A1071 |226 236|expressioneted rats 
P09545353A1071 |147 152|sites997A0
P09545353A1071 |63 121|activating transcription factor/cAMP response element siteeotidase P00008171T0000 Pharmacologic aspects of neonatal 
P09545353A1071 |160 175|E-selectin gene CSF [HCO3-] is
P09545353A1071 |198 207|TNF-alpha CSF PCO2
P09545638A0330 |36 65|yeast hnRNP methyltransferaseine phosphatases and 5-nucleo
P09545638A0330 |67 71|HMT1dase
P09545638A0330 |36 65|yeast hnRNP methyltransferaseine phosphatases and 5-nucleo
P09545638A0330 |67 71|HMT1dase
P09545638A0836 |76 102|methyltransferase activity08171T0000 Pharmacologic a
P09545638A0836 |12 27|HRMT1L2 protein76 Comparison w
P09545638A1181 |51 58|diseases and 5
P09545638A1181 |13 18|roles6 Com
P09545638A1181 |22 29|HRMT1L1son wit
P09545638A1181 |34 41|HRMT1L2aline p
P09545638T0000 |0 14|IdentificationP00001606T0076
P09545638T0000 |99 106|HRMT1L2c aspec
P09545638T0000 |58 85|arginine methyltransferases-nucleotidase P00008171T000
P09545638T0000 |19 35|characterizationarison with alka
P09545638T0000 |87 94|HRMT1L1Pharmac
P09546424A1550 |70 82|Crk proteinse P00008171T
P09546424A1550 |29 47|PDGF beta-receptorh alkaline phospha
P09547311A1394 |170 176|domain-] is 
P09547311A1394 |195 203|evidence of CSF 
P09547311A1394 |61 71|E-cadherincleotidase
P09547311A1394 |80 87|chimera1T0000 
P09547311A1394 |143 153|desmoglein0008997A04
P09547311A1394 |128 134|domainlirubi
P09547311A1394 |13 25|interactions6 Comparison
P09547311A1394 |253 263|E-cadherinplaced whe
P09547311A1394 |278 285|domainsontrols
P09547311A1394 |237 249|interactionsre no longer
P09547311A1394 |103 113|E-cadherinpects of n
P09547349A0000 |4 76|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine01606T0076 Comparison with alkaline phosphatases and 5-nucleotidase P000
P09547349A0000 |90 100|edelfosinermacologic
P09547349A0000 |125 134|apoptosisrbilirubi
P09547349A0000 |78 88|ET-18-OCH3171T0000 P
P09547349A0000 |144 155|tumor cells008997A0472
P09547349A0000 |114 121|induceronatal 
P09548481A0000 |118 133|IL-5Ralpha geneal hyperbilirub
P09548481A0000 |73 82|existence00008171T
P09548481A0000 |42 50|promoterosphatas
P09548481A0000 |95 103|promoterlogic as
P09548481A0000 |52 54|P1 a
P09548481A0000 |3 11|addition001606T0
P09549179A0774 |0 12|Serum levelsP00001606T00
P09549179A0774 |81 82|pT
P09549179A0774 |67 75|exposuredase P00
P09549179A0774 |79 80|p7
P09549179A0774 |56 63|changes 5-nucl
P09549179A0774 |117 122|studytal h
P09549179A0774 |98 108|conditionsic aspects
P09549179A0774 |16 28|testosteroneomparison wi
P09549179A0774 |84 87|DDE00 
P09549398A1463 |222 223|%d
P09549398A1463 |76 88|SPET studies08171T0000 P
P09549398A1463 |8 17|agreement6T0076 Co
P09549398A1463 |214 215|%t
P09549398A1463 |26 63|rest/postnitroglycerin technetium-99mwith alkaline phosphatases and 5-nucl
P09549398A1463 |197 206|viabilityf CSF PCO
P09549398A1463 |93 112|rest/redistributioncologic aspects of 
P09549398A1463 |174 182|presences shown 
P09549398A1463 |116 158|rest/reinjection thallium-201 SPET studiesatal hyperbilirubinemia. P00008997A0472 Wh
P09549632A1189 |49 60|specificityses and 5-n
P09549632A1189 |24 35|sensitivityn with alka
P09549632A1189 |41 42|%h
P09549632A1189 |73 79|regard000081
P09549632A1189 |134 139|trialnemia
P09549632A1189 |66 67|%i
P09549632A1189 |6 9|use606
P09549632A1189 |83 97|predictability000 Pharmacolo
P09549632A1189 |101 111|ALT levelsaspects of
P09549660A0782 |85 98|data scenario0 Pharmacolog
P09549660A0782 |22 31|data setsson with 
P09549660A0782 |39 47|subjects phospha
P09549783T0000 |82 90|patients0000 Pha
P09549783T0000 |56 64|saccades 5-nucle
P09549783T0000 |8 16|accuracy6T0076 C
P09550591A0454 |137 151|blood pressureia. P00008997A
P09550591A0454 |11 20|treatment076 Compa
P09550591A0454 |120 128|decrease hyperbi
P09550591A0454 |52 67|airway pressure and 5-nucleoti
P09550591A0454 |94 98|daysolog
P09550591A0454 |81 86|cmH2OT0000
P09550591A0454 |155 159|OSAS Whe
P09550919A0365 |136 140|PSVTmia.
P09550919A0365 |148 156|episodes97A0472 
P09550919A0365 |220 221|%K
P09550919A0365 |186 194|episodes functio
P09550919A0365 |53 61|responseand 5-nu
P09550919A0365 |179 180|%w
P09550919A0365 |95 97|mglo
P09550919A0365 |124 132|episodeserbiliru
P09550919A0365 |208 216|episodesthe data
P09550919A0365 |89 91|mgar
P09550919A0365 |198 199|% 
P09550919A0365 |41 47|mannerhospha
P09550919A0365 |160 161|% 
P09550919A0365 |167 175|episodesCO3-] is
P09550919A0365 |77 86|adenosine8171T0000
P09550919A0365 |111 113|mg n
P09550919A0365 |5 9|data1606
P09550919A0365 |101 103|mgas
P09551096A0108 |0 4|RNAsP000
P09551096A0108 |57 65|subunits5-nucleo
P09551096A0108 |28 38|componentsth alkalin
P09551096A0108 |99 106|factorsc aspec
P09551096A0108 |114 132|particle formationonatal hyperbiliru
P09551182A0212 |100 109|retinoids aspects 
P09551182A0212 |121 128|embryoshyperbi
P09551182A0212 |214 227|acid receptorta of K-deple
P09551182A0212 |177 199|transactivation domainhown as a function of 
P09551182A0212 |160 166|ligand CSF [
P09551182A0212 |72 78|methodP00008
P09551182A0212 |247 265|DNA binding domainer displaced when 
P09551182A0212 |9 28|retinoid signallingT0076 Comparison wi
P09551182A0212 |138 152|fusion proteina. P00008997A0
P09551182A0212 |32 49|zebrafish embryoslkaline phosphata
P09551938A0318 |91 109|CCR5 gene promotermacologic aspects 
P09551938A0318 |31 38|factorsalkalin
P09551972A1033 |0 12|FluorescenceP00001606T00
P09551972A1033 |130 143|cosmid c101F1rubinemia. P0
P09551972A1033 |191 197|8q24.3tion o
P09551972A1033 |59 69|chromosomenucleotida
P09551972A1033 |179 187|telomerewn as a 
P09551972A1033 |161 171|gene closeCSF [HCO3-
P09551972A1033 |38 55|metaphase spreadse phosphatases an
P09551972A1033 |21 34|hybridizationison with alk
P09551972A1033 |84 113|hybrid cell line 706-B6 clone00 Pharmacologic aspects of n
P09551972A1033 |118 123|CL-17al hy
P09552469A0225 |171 181|dispersion] is shown
P09552469A0225 |210 217|mixturee data 
P09552469A0225 |105 117|spectroscopycts of neona
P09552469A0225 |4 15|interaction01606T0076 
P09552469A0225 |143 151|analysis0008997A
P09552469A0225 |24 33|piroxicamn with al
P09552469A0225 |63 83|x-ray diffractometryeotidase P00008171T0
P09552469A0225 |101 103|IRas
P09552469A0225 |38 47|poloxamere phospha
P09552469A0225 |153 156|DTA72 
P09552469A0225 |85 88|XRD0 P
P09553040A0651 |17 20|Epompa
P09553040A0651 |123 128|Statsperbi
P09553040A0651 |63 81|signaling pathwayseotidase P00008171
P09553040A0651 |105 114|PLC-gammacts of ne
P09553040A0651 |37 47|activationne phospha
P09553040A0651 |92 103|PI-3 kinaseacologic as
P09553040A0651 |116 119|Rasata
P09553040A0651 |0 13|Cell survivalP00001606T007
P09553134A0596 |25 42|neurite outgrowth with alkaline ph
P09553134A0596 |107 110|PP1s o
P09553134A0596 |63 102|tyrosine kinase inhibitors herbimycin Aeotidase P00008171T0000 Pharmacologic a
P09553143A0729 |171 175|H2O2] is
P09553143A0729 |11 27|ZAP-70 substrate076 Comparison w
P09553143A0729 |29 35|SLP-76h alka
P09553143A0729 |156 165|treatmentWhen CSF 
P09553143A0729 |114 126|Jurkat cellsonatal hyper
P09553143A0729 |139 149|P116 cells. P0000899
P09553143A0729 |51 65|Erk activations and 5-nucleo
P09553686A0000 |239 259|absorption enhancers no longer displaced
P09553686A0000 |220 226|matrixK-depl
P09553686A0000 |20 28|patternsrison wi
P09553686A0000 |159 170|applicationn CSF [HCO3
P09553686A0000 |330 338|patch 7D (1.21 +
P09553686A0000 |63 70|estroneeotidas
P09553686A0000 |180 189|estradioln as a fu
P09553686A0000 |43 46|CASsph
P09553686A0000 |109 114|womenof ne
P09553686A0000 |72 75|CASP00
P09553686A0000 |286 298|applicationsbut still ha
P09553686A0000 |138 147|menopausea. P00008
P09553686A0000 |202 207|patch PCO2
P09553686A0000 |32 41|estradiollkaline p
P09553686A0000 |304 308|daysigni
P09555046A1617 |34 45|base changealine phosp
P09555046A1617 |135 143|sequenceemia. P0
P09555046A1617 |90 96|intronrmacol
P09555046A1617 |53 83|branchpoint consensus sequenceand 5-nucleotidase P00008171T0
P09555046A1617 |167 174|mammalsCO3-] i
P09555046A1617 |113 120|diseaseeonatal
P09555046A1617 |4 11|results01606T0
P09556557A1238 |24 31|regionsn with 
P09556561A0671 |137 143|guidesia. P0
P09556561A0671 |10 23|H/ACA snoRNAs0076 Comparis
P09556561A0671 |148 171|pseudouridine synthesis97A0472 When CSF [HCO3-
P09556561A0671 |75 80|group00817
P09556561A0671 |190 198|moleculection of
P09556561A0671 |40 45|Gar1pphosp
P09556561A0671 |84 91|snoRNAs00 Phar
P09556561A0671 |118 123|yeastal hy
P09556566A0174 |32 35|VDRlka
P09556566A0174 |76 84|RXRalpha08171T00
P09556566A0174 |12 30|vitamin D receptor76 Comparison with
P09556566A0174 |54 74|acid Xalpha receptornd 5-nucleotidase P0
P09556566A0174 |99 120|T cell line MT2 cellsc aspects of neonatal
P09556573A1062 |84 88|acid00 P
P09556573A1062 |57 58|S5
P09556573A1062 |145 165|co-activator RIP-14008997A0472 When CSF 
P09556573A1062 |126 135|PPARalphabilirubin
P09556573A1062 |111 122|interaction neonatal h
P09556573A1062 |199 208|PPARalphaCSF PCO2 
P09556573A1062 |231 235|SMRTrats
P09556573A1062 |8 15|studies6T0076 
P09556573A1062 |38 54|PPARalpha ligande phosphatases a
P09556573A1062 |184 195|interaction a function
P09556861A1018 |171 180|depletion] is show
P09556861A1018 |184 187|ATP a 
P09556861A1018 |21 31|literatureison with 
P09556861A1018 |113 123|inhibitioneonatal hy
P09556861A1018 |248 265|protein synthesisr displaced when 
P09556861A1018 |37 47|mechanismsne phospha
P09556861A1018 |76 78|OA08
P09556861A1018 |193 203|inhibitionon of CSF 
P09556861A1018 |284 302|lipid peroxidations but still have a
P09556861A1018 |64 72|toxicityotidase 
P09556861A1018 |141 152|respirationP00008997A0
P09556861A1018 |207 222|tRNA-synthetase the data of K-
P09556861A1018 |100 107|effects aspect
P09557678A0140 |86 90|BPV1 Pha
P09557678A0140 |129 149|carcinoma cell linesirubinemia. P0000899
P09557678A0140 |92 102|E2 proteinacologic a
P09557678A0140 |106 110|HeLats o
P09557678A0140 |63 82|papillomavirus typeeotidase P00008171T
P09557678A0140 |38 48|expressione phosphat
P09557678A0140 |212 236|G1/S phase growth arrestdata of K-depleted rats 
P09557678A0140 |115 119|HT-3nata
P09557678A0140 |175 188|proliferation shown as a f
P09557682A0490 |119 128|splicingsl hyperbi
P09557682A0490 |14 22|isoforms Compari
P09557682A0490 |75 87|combinations008171T0000 
P09557682A0490 |43 48|gammasphat
P09557682A0490 |24 35|hGli2 alphan with alka
P09557682A0490 |167 176|DNA motifCO3-] is 
P09557682A0490 |192 195|LTRion
P09557682A0490 |37 41|betane p
P09557682A0490 |178 183|TRE2Sown a
P09557682A0490 |142 150|isoforms00008997
P09557682A0490 |54 59|deltand 5-
P09557708A1426 |152 157|cells472 W
P09557708A1426 |57 66|periphery5-nucleot
P09557708A1426 |130 135|cellsrubin
P09557708A1426 |36 49|IEV particlesine phosphata
P09557708A1426 |172 181|vA33delta is shown
P09557708A1426 |84 94|microvilli00 Pharmac
P09557708A1426 |0 23|Specialized actin tailsP00001606T0076 Comparis
P09557912A0699 |33 37|mmHgkali
P09557912A0699 |250 252|SDdi
P09557912A0699 |25 27|SD w
P09557912A0699 |360 371|respiration0733 Fluraz
P09557912A0699 |183 192|cessations a funct
P09557912A0699 |303 305|SDsi
P09557912A0699 |269 278|cessationared to c
P09557912A0699 |60 70|anesthesiaucleotidas
P09557912A0699 |11 14|IOP076
P09557912A0699 |130 139|injectionrubinemia
P09557912A0699 |47 56|inductiontases and
P09557912A0699 |105 112|eyelashcts of 
P09557912A0699 |164 166|SD [
P09557912A0699 |326 336|resumptionlope (1.21
P09557912A0699 |258 262|mmHgd wh
P09557912A0699 |86 90|mmHg Pha
P09557912A0699 |282 292|convulsionols but st
P09557912A0699 |196 217|muscle fasciculationsof CSF PCO2 the data 
P09557912A0699 |229 242|suxamethoniumd rats are no
P09557912A0699 |78 80|SD17
P09557912A0699 |97 101|lossgic 
P09557912A0699 |172 176|mmHg is 
P09557912A0699 |143 156|methohexitone0008997A0472 
P09557912A0699 |311 315|mmHgantl
P09560221A0282 |169 180|animal CAKs3-] is show
P09560221A0282 |107 131|fission yeast CAK mutants of neonatal hyperbilir
P09560221A0282 |73 78|yeast00008
P09560221A0282 |150 157|proteinA0472 W
P09560221A0282 |8 14|cak1At6T0076
P09560221A0282 |133 139|cak1Atinemia
P09560221A0282 |2 6|cDNA0001
P09560221A0282 |49 61|CAK mutationses and 5-nu
P09560325A1285 |19 32|modificationsarison with a
P09560325A1285 |41 54|glycosylationhosphatases a
P09560325A1285 |106 118|explanationsts of neonat
P09560325A1285 |59 74|phosphorylationnucleotidase P0
P09560325A1285 |127 148|protein heterogeneityilirubinemia. P000089
P09560390A0771 |3 11|addition001606T0
P09560390A0771 |45 59|overexpressionhatases and 5-
P09560390A0771 |63 67|sum1eoti
P09560390A0771 |120 126|stress hyper
P09560390A0771 |89 108|cell cycle responsearmacologic aspects
P09560390A0771 |25 43|checkpoint control with alkaline pho
P09560430A0000 |0 4|Ime1P000
P09560430A0000 |74 79|cells00081
P09560430A0000 |58 65|a/alpha-nucleo
P09560430A0000 |47 54|meiosistases a
P09560430A0000 |21 25|roleison
P09560430A0000 |33 43|initiationkaline pho
P09561560A0579 |0 15|Rhesus macaquesP00001606T0076 
P09561560A0579 |125 142|SIV gene productsrbilirubinemia. P
P09561560A0579 |52 80|Mengo virus SIV recombinants and 5-nucleotidase P0000817
P09561560A0579 |197 209|CTL responsef CSF PCO2 t
P09561560A0579 |213 217|miceata 
P09561560A0579 |161 181|HIV-Nef recombinantsCSF [HCO3-] is shown
P09561560A0579 |20 31|BALB/c micerison with 
P09561560A0579 |233 249|HIV1 Nef peptidets are no longer
P09561560A0579 |99 112|CTL responsesc aspects of 
P09561560A0579 |259 268|positions when com
P09561616A0142 |0 12|DeltamethrinP00001606T00
P09561616A0142 |91 110|culicifacies adultsmacologic aspects o
P09561616A0142 |120 125|weeks hype
P09561616A0142 |159 163|dosen CS
P09561616A0142 |72 83|% mortalityP00008171T0
P09561616A0142 |48 55|surfaceases an
P09561616A0142 |170 175|mg/m2-] is
P09562398A0848 |137 143|valuesia. P0
P09562398A0848 |42 45|AUCosp
P09562398A0848 |92 94|.4ac
P09562398A0848 |57 59|.45-
P09562398A0848 |148 156|n-hexane97A0472 
P09562398A0848 |172 174|.1 i
P09562398A0848 |22 26|turnson 
P09562398A0848 |206 208|.92 
P09562398A0848 |0 17|TrichloroethyleneP00001606T0076 Co
P09562558T0000 |0 18|Solution structureP00001606T0076 Com
P09562558T0000 |44 50|domainphatas
P09562558T0000 |60 68|subgroupucleotid
P09562558T0000 |26 31|IRF-2with 
P09562558T0000 |100 106|family aspec
P09564860A2139 |139 147|proteins. P00008
P09564860A2139 |78 93|loop 3i domains171T0000 Pharma
P09564860A2139 |132 133|Gb
P09564860A2139 |13 40|receptor/G protein coupling6 Comparison with alkaline 
P09564860A2139 |134 137|i/onem
P09564860A2139 |189 198|receptorsnction of
P09564860A2139 |111 120|receptors neonatal
P09564860A2139 |64 74|expressionotidase P0
P09564860A2139 |3 11|contrast001606T0
P09564860A2315 |152 155|GGH472
P09564860A2315 |243 261|Gs protein pathwaylonger displaced w
P09564860A2315 |104 120|protein couplingects of neonatal
P09564860A2315 |61 71|rat GnRH-Rcleotidase
P09564860A2315 |202 221|signal transduction PCO2 the data of K
P09564860A2315 |128 139|selectivitylirubinemia
P09564860A2315 |161 170|cell lineCSF [HCO3
P09564860A2315 |177 181|loophown
P09564860A2315 |98 102|q/11ic a
P09564860A2315 |6 10|data606T
P09564860A2315 |49 53|loopses 
P09564860A2315 |87 97|receptor GPharmacolo
P09564917A0900 |101 102|pa
P09564917A0900 |95 99|U/mLlogi
P09564917A0900 |10 16|levels0076 C
P09564917A0900 |20 38|alpha2-antiplasminrison with alkalin
P09564917A0900 |65 76|mediastinumtidase P000
P09565576T0000 |33 53|DNA topoisomerase I.kaline phosphatases 
P09565576T0000 |12 18|domain76 Com
P09565584A0770 |186 187|H 
P09565584A0770 |2 9|cluster0001606
P09565584A0770 |66 75|sequencesidase P00
P09565584A0770 |132 136|exonbine
P09565584A0770 |104 108|exonects
P09565584A0770 |32 36|KKKRlkal
P09565584A0770 |19 30|amino acidsarison with
P09565584A0770 |222 242|mutagenesis analysisdepleted rats are no
P09565584A0770 |170 179|targeting-] is sho
P09565606A0520 |51 54|ends a
P09565606A0520 |95 103|sequencelogic as
P09565606A0520 |134 138|sitenemi
P09565606A0520 |25 34|structure with alk
P09565606A0520 |58 62|repY-nuc
P09565606A0520 |112 116|repZneon
P09565606A0520 |86 93|rCGCC-3 Pharma
P09566731A0458 |169 175|clones3-] is
P09566731A0458 |10 15|genes0076 
P09566731A0458 |110 126|mouse chromosomef neonatal hyper
P09566731A0458 |145 157|cell hybrids08997A0472 W
P09566731A0458 |54 60|regionnd 5-n
P09566731A0458 |70 94|chromosome 16p12.1-p11.2e P00008171T0000 Pharmac
P09566871A0343 |169 178|integrase3-] is sh
P09566871A0343 |164 167|TyA [H
P09566871A0343 |75 85|processing008171T000
P09566871A0343 |40 57|protein synthesisphosphatases and 
P09566871A0343 |124 136|FUS3 strainserbilirubine
P09566871A0343 |192 214|transcriptase proteinsion of CSF PCO2 the da
P09566871A0343 |31 38|Ty1 RNAalkalin
P09566871A0343 |21 27|levelsison w
P09566871A0343 |219 227|Ty1 cDNA K-deple
P09566871A0343 |3 15|fus3 mutants001606T0076 
P09566871A0343 |154 160|levels2 When
P09566871T0000 |32 54|Ty1 retrotranspositionlkaline phosphatases a
P09566871T0000 |76 95|protein kinase Fus308171T0000 Pharmaco
P09566871T0000 |18 28|regulationparison wi
P09566876A0000 |119 143|transcription activationl hyperbilirubinemia. P0
P09566876A0000 |12 36|transcription factor IIA76 Comparison with alkal
P09566876A0000 |38 43|TFIIAe pho
P09566876A0000 |95 107|promoter DNAlogic aspect
P09566876A0000 |64 84|TATA binding proteinotidase P00008171T00
P09566876A0000 |86 89|TBP Ph
P09566882A0693 |84 91|binding00 Phar
P09566882A0693 |95 99|Pho4logi
P09566882A0693 |114 118|Pho2onat
P09566882A0693 |6 14|function606T0076
P09566882A0693 |38 42|Pho2e ph
P09566882A0693 |50 58|promoteres and 5
P09566918A1115 |0 12|SubstitutionP00001606T00
P09566918A1115 |104 109|IRF-3ects 
P09566918A1115 |58 61|Asp-nu
P09566918A1115 |177 188|PRDI-PRDIIIhown as a f
P09566918A1115 |208 216|elementsthe data
P09566918A1115 |192 196|ISREion 
P09566918A1115 |143 152|activator0008997A0
P09566918A1115 |96 100|formogic
P09566918A1115 |20 33|Ser-Thr sitesrison with al
P09566918A1115 |156 165|promotersWhen CSF 
P09568445T0000 |83 103|contractile recovery000 Pharmacologic as
P09568445T0000 |44 54|infarctionphatases a
P09568445T0000 |10 16|angina0076 C
P09568445T0000 |110 122|thrombolysisf neonatal h
P09568549A0188 |119 123|ratsl hy
P09568549A0188 |61 66|dosescleot
P09568549A0188 |143 152|histamine0008997A0
P09568549A0188 |127 139|serum levelsilirubinemia
P09568549A0188 |110 114|micef ne
P09568549A0188 |8 13|study6T007
P09568549A0188 |70 79|malathione P000081
P09568549A0188 |19 25|effectarison
P09568549A0188 |100 106|routes aspec
P09568549A0188 |35 49|administrationline phosphata
P09570030T0000 |6 24|growth retardation606T0076 Compariso
P09570030T0000 |30 35|cause alka
P09570030T0000 |56 67|development 5-nucleoti
P09570107A0355 |32 35|ESPlka
P09570107A0355 |63 69|boilereotida
P09570107A0355 |11 28|PCDFs/PCDDs ratio076 Comparison wi
P09570133A0474 |139 147|proteins. P00008
P09570133A0474 |109 114|rolesof ne
P09570133A0474 |75 91|partner proteins008171T0000 Phar
P09570133A0474 |27 39|interactionsith alkaline
P09570133A0474 |160 169|promoters CSF [HCO
P09570133A0474 |57 69|interactions5-nucleotida
P09570133A0474 |3 11|addition001606T0
P09570944T0000 |0 12|LocalizationP00001606T00
P09570944T0000 |30 40|YAC contig alkaline 
P09570944T0000 |110 127|chromosome 7q21.1f neonatal hyperb
P09570944T0000 |78 100|resistance gene region171T0000 Pharmacologic
P09570944T0000 |54 56|Mbnd
P09570944T0000 |19 24|exonsariso
P09570952A0000 |66 75|M-proteinidase P00
P09570952A0000 |25 37|organization with alkali
P09570952A0000 |90 97|proteinrmacolo
P09570952A0000 |52 56|gene and
P09570952A0000 |112 122|myofibrilsneonatal h
P09571563A0000 |0 7|PURPOSEP000016
P09571563A0000 |73 84|keratectomy00008171T00
P09571563A0000 |47 53|corneatases 
P09571563A0000 |181 187|cornea as a 
P09571563A0000 |164 173|condition [HCO3-] 
P09571563A0000 |149 156|changes7A0472 
P09571563A0000 |132 145|determinationbinemia. P000
P09571563A0000 |25 39|image analysis with alkaline
P09571563A0000 |86 89|PRK Ph
P09572428A0526 |0 4|MeanP000
P09572428A0526 |88 91|PCOhar
P09572428A0526 |77 82|women8171T
P09572428A0526 |161 166|womenCSF [
P09572428A0526 |198 203|ng/ml CSF 
P09572428A0526 |63 64|Pe
P09572428A0526 |127 132|ng/mliliru
P09572428A0526 |179 186|ovarieswn as a
P09572428A0526 |7 35|SD serum VEGF concentrations06T0076 Comparison with alka
P09572428A0526 |96 100|PCOSogic
P09572491A1044 |34 51|missense mutationaline phosphatase
P09572491A1044 |111 118|alanine neonat
P09572491A1044 |123 130|glycineperbili
P09572491A1044 |82 85|p53000
P09572491A1044 |59 67|p53 genenucleoti
P09572491A1044 |18 23|cellsparis
P09572491A1044 |71 76|codon P000
P09572511A0148 |80 86|RBI-EM1T0000
P09572511A0148 |60 65|blockucleo
P09572511A0148 |26 33|RBI-MAPwith al
P09572511A0148 |88 97|algorithmharmacolo
P09572511A0148 |8 17|algorithm6T0076 Co
P09572511A0148 |76 78|EM08
P09572965A1235 |102 111|mechanismspects of
P09572965A1235 |161 168|speciesCSF [HC
P09572965A1235 |133 152|virulence phenotypeinemia. P00008997A0
P09572965A1235 |13 17|ORF56 Co
P09572965A1235 |25 33|homology with al
P09572965A1235 |8 11|ORF6T0
P09572965A1235 |39 48|gene agrB phosphat
P09572965A1235 |115 125|regulationnatal hype
P09572990A0630 |103 109|Stat-3pects 
P09572990A0630 |180 187|agarosen as a 
P09572990A0630 |150 160|hSIE probeA0472 When
P09572990A0630 |45 59|MHC-I ligationhatases and 5-
P09572990A0630 |23 27|hSIEon w
P09572990A0630 |123 131|extractsperbilir
P09572990A0630 |3 14|association001606T0076
P09572990A0630 |32 38|Stat-3lkalin
P09573187T0000 |16 26|repressionomparison 
P09573187T0000 |82 95|binding sites0000 Pharmaco
P09573187T0000 |49 63|regulator CatRses and 5-nucl
P09573202A0900 |170 176|domain-] is 
P09573202A0900 |97 104|glycinegic asp
P09573202A0900 |122 134|acid residueyperbilirubi
P09573202A0900 |138 146|positiona. P0000
P09573202A0900 |81 93|substitutionT0000 Pharma
P09573202A0900 |49 62|alpha subunitses and 5-nuc
P09573202A0900 |35 41|levelsline p
P09573244A0523 |52 78|polyadenylation site usage and 5-nucleotidase P00008
P09573244A0523 |10 22|mRNA species0076 Compari
P09573374A0687 |102 115|cosmid clonesspects of neo
P09573374A0687 |215 224|structurea of K-de
P09573374A0687 |33 52|restriction mappingkaline phosphatases
P09573374A0687 |175 184|IRF1 gene shown as
P09573374A0687 |64 67|YACoti
P09573374A0687 |6 28|Southern blot analysis606T0076 Comparison wi
P09573374A0687 |138 146|RIL genea. P0000
P09573374A0687 |86 96|chromosome Pharmacol
P09573374A0687 |155 157|kb W
P09573374A0687 |69 74|yeastse P0
P09573378A0761 |0 3|U73P00
P09573378A0761 |61 76|complementaritycleotidase P000
P09573378A0761 |22 30|D' boxesson with
P09573378A0761 |13 14|C6
P09573378A0761 |98 101|RNAic 
P09573378A0761 |16 17|Do
P09573884A0392 |84 93|retrusive00 Pharma
P09573884A0392 |133 141|subjectsinemia. 
P09573884A0392 |30 35|S-N-B alka
P09573884A0392 |125 130|Classrbili
P09573884A0392 |40 47|S-N-Pogphospha
P09573884A0392 |97 102|Classgic a
P09573884A0392 |20 28|positionrison wi
P09574799A1072 |186 196|sanitation function 
P09574799A1072 |47 54|factorstases a
P09574799A1072 |242 252|conditions longer di
P09574799A1072 |148 163|food inspection97A0472 When CS
P09574799A1072 |72 84|malnutritionP00008171T00
P09574799A1072 |63 70|povertyeotidas
P09574799A1072 |204 217|helminthiasesCO2 the data 
P09574799A1072 |129 133|lackirub
P09574799A1072 |0 15|EchinostomiasisP00001606T0076 
P09574799A1072 |119 125|marketl hype
P09575143A1189 |34 45|cell cortexaline phosp
P09575143A1189 |213 216|TCRata
P09575143A1189 |78 86|activity171T0000
P09575143A1189 |133 140|abilityinemia.
P09575143A1189 |90 108|SRC-family kinasesrmacologic aspects
P09575143A1189 |188 205|activation motifsunction of CSF PC
P09575143A1189 |158 172|immunoreceptoren CSF [HCO3-]
P09575143A1189 |20 26|ZAP-70rison 
P09575143A1189 |4 16|localization01606T0076 C
P09575187A1558 |65 83|ER calcium releasetidase P00008171T0
P09575187A1558 |122 131|sAPPalphayperbilir
P09575187A1558 |104 108|dataects
P09575187A1558 |44 53|apoptosisphatases 
P09575187A1558 |194 210|kappaB decoy DNAn of CSF PCO2 th
P09575187A1558 |176 182|effectshown 
P09575187A1558 |11 15|role076 
P09575187A1558 |162 171|apoptosisSF [HCO3-
P09575187A1558 |20 29|NF-kappaBrison wit
P09575217A0000 |5 23|cytokine receptors1606T0076 Comparis
P09575217A0000 |63 67|Jakseoti
P09575217A0000 |73 91|signal transducers00008171T0000 Phar
P09575217A0000 |31 61|Janus protein tyrosine kinasesalkaline phosphatases and 5-nu
P09575217A0000 |110 123|transcriptionf neonatal hy
P09575217A0000 |125 130|Statsrbili
P09575217A0000 |144 153|signaling008997A04
P09575217A0000 |96 106|activatorsogic aspec
P09575217A0971 |69 84|phosphorylationse P00008171T00
P09575217A0971 |88 92|Jak2harm
P09575217A0971 |134 160|Stat5 hyperphosphorylationnemia. P00008997A0472 When
P09575217A0971 |116 126|C terminusatal hyper
P09575217A0971 |38 54|Stat5 SH2 domaine phosphatases a
P09575217A0971 |100 108|deletion aspects
P09575217A0971 |16 30|R618K mutationomparison with
P09576230T0000 |49 67|reperfusion injuryses and 5-nucleoti
P09576230T0000 |111 117|arrest neona
P09576230T0000 |75 80|brain00817
P09576230T0000 |4 10|effect01606T
P09576230T0000 |21 45|oxide synthase inhibitorison with alkaline phosp
P09576915A0269 |85 94|silencers0 Pharmac
P09576915A0269 |31 34|HMRalk
P09576915A0269 |14 27|recombination Comparison w
P09576915A0269 |77 78|E8
P09576915A0269 |55 60|ringsd 5-n
P09577365A0747 |222 240|muscularis mucosaedepleted rats are 
P09577365A0747 |209 214|levelhe da
P09577365A0747 |74 87|collagen type0008171T0000 
P09577365A0747 |42 48|mucosaosphat
P09577365A0747 |179 184|caseswn as
P09577365A0747 |27 34|vesselsith alk
P09577365A0747 |193 201|stainingon of CS
P09577365A0747 |112 119|vesselsneonata
P09577365A0747 |127 136|submucosailirubine
P09577365A0747 |3 17|angiodysplasia001606T0076 Co
P09577365A0747 |154 161|vessels2 When 
P09577395A0000 |157 170|low-amplitudehen CSF [HCO3
P09577395A0000 |72 80|impulsesP0000817
P09577395A0000 |46 49|VORata
P09577395A0000 |192 201|rotationsion of CS
P09577395A0000 |178 185|degreesown as 
P09577395A0000 |144 154|degrees/s2008997A047
P09577395A0000 |83 88|brief000 P
P09577395A0000 |54 62|responsend 5-nuc
P09578042A0363 |34 42|patternsaline ph
P09578042A0363 |130 138|patientsrubinemi
P09578042A0363 |121 126|grouphyper
P09578042A0363 |168 171|TLEO3-
P09578042A0363 |98 107|SEEG/ECoGic aspect
P09578042A0363 |70 85|seizure outcomee P00008171T000
P09578042A0363 |153 166|lobe epilepsy72 When CSF [
P09578570A0200 |35 39|geneline
P09578570A0200 |107 118|combinations of neonat
P09578570A0200 |44 53|protein Zphatases 
P09578570A0200 |8 13|study6T007
P09578570A0200 |161 170|isolationCSF [HCO3
P09578570A0200 |208 215|librarythe dat
P09578570A0200 |122 139|PCR amplificationyperbilirubinemia
P09578570A0200 |76 85|structure08171T000
P09578570A0200 |59 71|organizationnucleotidase
P09578570A0200 |143 156|leukocyte DNA0008997A0472 
P09578570A0200 |174 186|phage cloness shown as a
P09579602A1720 |102 111|reductionspects of
P09579602A1720 |150 157|resultsA0472 W
P09579602A1720 |135 146|calculationemia. P0000
P09579602A1720 |6 19|modifications606T0076 Comp
P09579602A1720 |52 67|reproducibility and 5-nucleoti
P09579602A1720 |115 130|sample handlingnatal hyperbili
P09579602A1720 |71 90|CD34 determinations P00008171T0000 Pha
P09579789A0974 |139 159|discrimination tasks. P00008997A0472 Whe
P09579789A0974 |12 19|results76 Comp
P09579789A0974 |120 134|odor detection hyperbilirubi
P09579789A0974 |90 94|bulbrmac
P09579789A0974 |37 41|ratsne p
P09579789A0974 |109 116|varietyof neon
P09579789A0974 |189 197|controlsnction o
P09579789A0974 |64 72|remnantsotidase 
P09579808A0000 |0 10|UDP-GlcNAcP00001606T
P09579808A0000 |40 71|N-acetylglucosaminyltransferasephosphatases and 5-nucleotidase
P09579808A0000 |11 37|alpha-6-D-mannoside beta-1076 Comparison with alkali
P09579808A0000 |76 79|GnT081
P09579808A0000 |126 134|assemblybilirubi
P09579808A0000 |157 164|glycanshen CSF
P09579808A0000 |84 86|EC00
P09580062A0100 |137 141|doseia. 
P09580062A0100 |147 156|mg/kg/day997A0472 
P09580062A0100 |48 64|cyclophosphamideases and 5-nucle
P09580062A0100 |6 14|patients606T0076
P09580062A0100 |116 130|cyclosporine Aatal hyperbili
P09580062A0100 |69 77|steroidsse P0000
P09580563A0331 |152 160|nidulans472 When
P09580563A0331 |41 42|%h
P09580563A0331 |72 78|dyneinP00008
P09580563A0331 |14 33|amino acid sequence Comparison with al
P09580563A0331 |117 118|%t
P09580563A0331 |94 111|Neurospora crassaologic aspects of
P09580563A0331 |169 170|%3
P09580563A0331 |85 90|chain0 Pha
P09580700A0841 |103 107|CIRspect
P09580700A0841 |145 151|region08997A
P09580700A0841 |40 62|repressor preparationsphosphatases and 5-nuc
P09580700A0841 |177 189|footprintinghown as a fu
P09580700A0841 |109 118|CIR3-CIR6of neonat
P09580700A0841 |4 26|DNA binding activities01606T0076 Comparison 
P09580700A0841 |82 91|fragments0000 Phar
P09580700A0841 |155 164|templates When CSF
P09580700A0841 |169 174|DNase3-] i
P09581552A1323 |101 113|interactionsaspects of n
P09581552A1323 |10 19|modelling0076 Comp
P09581552A1323 |79 85|bundle71T000
P09581552A1323 |142 153|amino acids00008997A04
P09581552A1323 |39 61|tetramerization domain phosphatases and 5-nu
P09581775A0185 |205 214|signalingO2 the da
P09581775A0185 |130 134|U937rubi
P09581775A0185 |181 186|cells as a
P09581775A0185 |15 20|studyCompa
P09581775A0185 |136 143|U9-IIIBmia. P0
P09581775A0185 |162 169|PLB-985SF [HCO
P09581775A0185 |68 86|NF-kappaB activityase P00008171T0000
P09581775A0185 |171 179|PLB-IIIB] is sho
P09581834A2578 |238 247|G1 arreste no long
P09581834A2578 |104 107|PCAect
P09581834A2578 |89 95|effectarmaco
P09581834A2578 |183 200|signaling pathways a function of C
P09581834A2578 |122 128|effectyperbi
P09581834A2578 |150 160|impairmentA0472 When
P09581834A2578 |43 52|silymarinsphatases
P09581834A2578 |215 220|CDKIsa of 
P09581834A2578 |22 29|resultsson wit
P09581834A2578 |202 211|induction PCO2 the
P09581872A0000 |52 56|type and
P09581872A0000 |14 20|tissue Compa
P09581872A0000 |59 78|collagen expressionnucleotidase P00008
P09581872A0000 |22 36|cell structureson with alkal
P09582267A0326 |152 157|cells472 W
P09582267A0326 |15 23|functionComparis
P09582267A0326 |162 184|GM701 fibroblast cellsSF [HCO3-] is shown as
P09582267A0326 |199 212|growth arrestCSF PCO2 the 
P09582267A0326 |95 102|Siah-1Alogic a
P09582267A0326 |56 64|proteins 5-nucle
P09582267A0326 |234 243|apoptosiss are no 
P09582267A0326 |66 85|expression plasmidsidase P00008171T000
P09582267A0326 |50 54|Siahes a
P09582267A0326 |221 230|induction-depleted
P09582306T0000 |32 40|Galphai1lkaline 
P09582306T0000 |78 106|G protein signaling proteins171T0000 Pharmacologic aspec
P09582306T0000 |65 74|regulatortidase P0
P09582306T0000 |20 27|Galphaorison w
P09582306T0000 |48 59|interactionases and 5-
P09582306T0000 |2 16|point mutation0001606T0076 C
P09582308A1165 |118 130|heterodimersal hyperbili
P09582308A1165 |95 104|formationlogic asp
P09582308A1165 |41 50|formationhosphatas
P09582308A1165 |108 112|homo of 
P09582308A1165 |71 81|homodimers P00008171
P09582326A0151 |17 19|E.mp
P09582326A0151 |8 15|Fanning6T0076 
P09582326A0151 |0 2|N.P0
P09582327A0295 |373 384|stimulationam thus app
P09582327A0295 |112 122|expressionneonatal h
P09582327A0295 |93 98|cellscolog
P09582327A0295 |212 220|sequencedata of 
P09582327A0295 |271 277|regioned to 
P09582327A0295 |61 83|rat GnRH receptor cDNAcleotidase P00008171T0
P09582327A0295 |388 396|activity to be a
P09582327A0295 |30 39|GH3 cells alkaline
P09582327A0295 |345 357|GnRH agonist vs. P000109
P09582327A0295 |85 91|GGH3-10 Phar
P09582327A0295 |289 308|luciferase reporter still have a signi
P09582327A0295 |184 199|rat LHbeta gene a function of 
P09582327A0295 |142 153|fusion gene00008997A04
P09582327A0295 |317 326|LHbetaLUCgreater s
P09582327A0295 |237 247|base pairsre no long
P09582327A0295 |170 180|base pairs-] is show
P09582331A0506 |103 109|GATA-1pects 
P09582331A0506 |63 67|TATAeoti
P09582331A0506 |29 39|nucleotideh alkaline
P09582331A0506 |81 91|CAAT boxesT0000 Phar
P09582331A0506 |110 113|SP1f n
P09582331A0506 |155 163|elements When CS
P09582331A0506 |16 22|regionompari
P09582343A0000 |34 47|cell line SX9aline phospha
P09582343A0000 |61 85|carcinoma cell line FM3Acleotidase P00008171T000
P09582350A0165 |102 106|lossspec
P09582350A0165 |132 154|ketoacid dehydrogenasebinemia. P00008997A047
P09582350A0165 |165 175|activities[HCO3-] is
P09582350A0165 |110 112|E1f 
P09582350A0165 |56 71|E1alpha subunit 5-nucleotidase
P09582350A0165 |3 11|patients001606T0
P09582350A0165 |17 50|type IA maple syrup urine diseasemparison with alkaline phosphatas
P09582635A0523 |0 7|ResultsP000016
P09582635A0523 |46 62|H.T.V. specimensatases and 5-nuc
P09582635A0523 |88 94|kg/cm2harmac
P09582635A0523 |24 42|mean bond strengthn with alkaline ph
P09582635A0523 |106 124|mean bond strengthts of neonatal hyp
P09582635A0523 |128 144|R.T.V. specimenslirubinemia. P00
P09582635A0523 |170 176|kg/cm2-] is 
P09582953A0000 |0 10|OBJECTIVESP00001606T
P09582953A0000 |208 209|Xt
P09582953A0000 |389 396|changesto be a
P09582953A0000 |211 214|F.X da
P09582953A0000 |320 325|colicater 
P09582953A0000 |294 304|populationl have a s
P09582953A0000 |260 280|acute-phase responsewhen compared to con
P09582953A0000 |23 46|coagulation factor VIIIon with alkaline phosph
P09582953A0000 |58 64|F.VIII-nucle
P09582953A0000 |126 155|acute-phase reactant proteinsbilirubinemia. P00008997A0472
P09582953A0000 |95 101|C1-INHlogic 
P09582953A0000 |330 354|hemostasis abnormalities (1.21 +/- 0.23 vs. P000
P09582953A0000 |72 93|C1-esterase inhibitorP00008171T0000 Pharma
P09582953A0000 |47 56|coagulanttases and
P09582953A0000 |185 190|F.VIIa fun
P09582953A0000 |217 236|hemostasis proteinsof K-depleted rats 
P09582953A0000 |197 199|F.f 
P09582953A0000 |160 183|coagulation factors VII CSF [HCO3-] is shown a
P09582953A0000 |65 66|Ct
P09582953A0000 |308 314|horsesficant
P09582953A1097 |0 7|RESULTSP000016
P09582953A1097 |52 76|fibrinogen concentration and 5-nucleotidase P000
P09582953A1097 |162 168|horsesSF [HC
P09582953A1097 |9 15|HorsesT0076 
P09582953A1097 |133 135|PTin
P09582953A1097 |21 26|colicison 
P09582953A1097 |140 144|APTT P00
P09582953A1097 |86 95|alpha 2AP Pharmaco
P09582953A1097 |100 120|protein C activities aspects of neonatal
P09582953A1670 |50 56|C1-INHes and
P09582953A1670 |4 8|data0160
P09582953A1670 |22 33|plasminogenson with al
P09582953A1670 |86 106|acute-phase proteins Pharmacologic aspec
P09582953A1670 |35 44|alpha 2APline phos
P09583201A0759 |0 4|NoneP000
P09583201A0759 |12 20|patients76 Compa
P09583208A0171 |70 84|immunoglobuline P00008171T00
P09583208A0171 |7 16|elevation06T0076 C
P09583208A0171 |90 100|complementrmacologic
P09583208A0171 |20 35|creatine kinaserison with alka
P09583208A0171 |55 68|serum albumind 5-nucleotid
P09583592A0263 |0 6|DESIGNP00001
P09583592A0263 |11 18|METHODS076 Com
P09583592A0263 |20 30|Case studyrison with
P09583823A0238 |0 7|METHODSP000016
P09583823A0238 |150 157|holmiumA0472 W
P09583823A0238 |184 186|Ho a
P09583823A0238 |257 258|ne
P09583823A0238 |250 255|groupdispl
P09583823A0238 |23 27|pigson w
P09583823A0238 |83 99|infarction group000 Pharmacologi
P09583823A0238 |158 182|yttrium-aluminium garneten CSF [HCO3-] is shown 
P09583823A0238 |112 116|TMLRneon
P09583823A0238 |212 213|nd
P09583823A0238 |192 197|laserion o
P09583823A0238 |47 55|ligationtases an
P09583823A0238 |73 81|arteries00008171
P09583823A0238 |187 190|YAGfun
P09583823A0238 |199 210|laser groupCSF PCO2 th
P09583823A0238 |11 16|total076 C
P09583823A0238 |101 102|na
P09583823A0238 |137 141|wallia. 
P09584165T0000 |0 5|RACK1P0000
P09584165T0000 |47 54|homologtases a
P09584165T0000 |9 17|receptorT0076 Co
P09584165T0000 |146 159|NIH 3T3 cells8997A0472 Whe
P09584165T0000 |78 88|G proteins171T0000 P
P09584165T0000 |62 74|beta subunitleotidase P0
P09584165T0000 |99 107|activityc aspect
P09584165T0000 |111 131|src tyrosine kinases neonatal hyperbilir
P09584165T0000 |32 40|C kinaselkaline 
P09584165T0000 |136 142|growthmia. P
P09584179A0673 |0 17|Peptide sequencesP00001606T0076 Co
P09584179A0673 |57 83|transcription factor Adf-15-nucleotidase P00008171T0
P09584179A0673 |25 48|zinc finger protein Ttk with alkaline phosphat
P09584180A0701 |100 118|NF-kappaB proteins aspects of neonat
P09584180A0701 |90 95|Stat6rmaco
P09584180A0701 |24 37|reporter genen with alkali
P09584180A0701 |138 161|I.29mu B lymphoma cellsa. P00008997A0472 When 
P09584194A0000 |0 4|HEF1P000
P09584194A0000 |127 137|regulationilirubinem
P09584194A0000 |42 48|familyosphat
P09584194A0000 |11 14|Cas076
P09584194A0000 |21 28|Efs/Sinison wi
P09584194A0000 |6 10|p130606T
P09584194A0000 |64 80|docking proteinsotidase P0000817
P09584194A0000 |141 154|cell adhesionP00008997A047
P09584194A1305 |136 149|protein Dim1pmia. P0000899
P09584194A1305 |112 116|G2/Mneon
P09584194A1305 |212 215|p55dat
P09584194A1305 |182 188|regionas a f
P09584194A1305 |28 35|spindleth alka
P09584194A1305 |164 174|interactor [HCO3-] i
P09584194A1305 |16 20|roleompa
P09584194A1305 |48 65|library screeningases and 5-nucleo
P09584194A1305 |216 220|HEF1 of 
P09584194A1305 |97 104|homologgic asp
P09584194A1305 |192 196|HEF1ion 
P09584194A1305 |71 75|HEF1 P00
P09584194A1305 |3 10|support001606T
P09585253A1147 |206 222|MDA-MB-231 cells2 the data of K-
P09585253A1147 |62 72|activationleotidase 
P09585253A1147 |93 115|breast carcinoma cellscologic aspects of neo
P09585253A1147 |76 89|TF expression08171T0000 Ph
P09585253A1147 |167 174|pathwayCO3-] i
P09585253A1147 |148 158|activation97A0472 Wh
P09585253A1147 |39 54|raf-ERK pathway phosphatases a
P09585253A1147 |189 202|TF expressionnction of CSF
P09585253A1147 |4 8|data0160
P09585253A1147 |21 31|activationison with 
P09585540A0440 |101 126|agent 1,10-phenanthrolineaspects of neonatal hyper
P09585540A0440 |61 69|dialysiscleotida
P09585540A0440 |25 31|enzyme with 
P09586285A0551 |4 12|patients01606T00
P09586285A0551 |74 79|years00081
P09586285A0551 |26 56|H. influenza type b meningitiswith alkaline phosphatases and
P09586832A0229 |69 78|receptorsse P00008
P09586832A0229 |4 9|lines01606
P09587549T0001 |43 59|interferon alphasphatases and 5-
P09587549T0001 |28 37|treatmentth alkali
P09587549T0001 |11 18|seizure076 Com
P09587549T0001 |78 89|hepatitis C171T0000 Ph
P09588228A0370 |23 38|anticytokeratinon with alkalin
P09588228A0370 |111 122|MPM tissues neonatal h
P09588228A0370 |42 50|antibodyosphatas
P09588228A0370 |67 75|stainingdase P00
P09590294A0453 |8 15|studies6T0076 
P09590294A0453 |90 103|Notch pathwayrmacologic as
P09590294A0453 |46 60|identificationatases and 5-n
P09590294A0453 |72 82|componentsP00008171T
P09590540A0513 |32 34|kblk
P09590540A0513 |24 26|ntn 
P09590540A0513 |179 187|fragmentwn as a 
P09590540A0513 |244 264|lac operator controlonger displaced when
P09590540A0513 |270 283|pQE-30 vectorred to contro
P09590540A0513 |198 203|frame CSF 
P09590540A0513 |47 56|sequencestases and
P09590540A0513 |222 233|T5 promoterdepleted ra
P09590540A0513 |158 167|Sac1-Sal1en CSF [H
P09590540A0513 |128 134|domainlirubi
P09590540A0513 |79 94|signal sequence71T0000 Pharmac
P09590540A0513 |140 143|PCR P0
P09590540A0513 |4 13|bZP2 cDNA01606T007
P09591221A0137 |0 16|Control subjectsP00001606T0076 C
P09591221A0137 |25 35|potentials with alka
P09591221A0137 |75 85|positivity008171T000
P09591221A0137 |37 40|EPsne 
P09591221A0137 |110 112|P1f 
P09591221A0137 |100 108|ms range aspects
P09591221A0137 |139 143|site. P0
P09592125A0000 |0 5|ClassP0000
P09592125A0000 |8 29|alpha1,2-mannosidases6T0076 Comparison wit
P09592125A0000 |75 82|complex008171T
P09592125A0000 |60 71|elaborationucleotidase
P09592125A0000 |48 52|roleases
P09592125A0000 |97 104|glycansgic asp
P09592125A0000 |87 95|hybrid NPharmaco
P09592125A0000 |118 123|cellsal hy
P09592168T0000 |35 53|DNA binding domainline phosphatases 
P09592168T0000 |74 112|nucleotide excision repair protein XPA0008171T0000 Pharmacologic aspects of 
P09592168T0000 |11 19|features076 Comp
P09592168T0000 |55 63|M98-F219d 5-nucl
P09592208A0470 |140 144|data P00
P09592208A0470 |29 33|bookh al
P09592208A0470 |165 178|possibilities[HCO3-] is sh
P09592208A0470 |14 23|qualities Comparis
P09592208A0470 |108 120|construction of neonatal
P09592208A0470 |215 225|statisticsa of K-dep
P09592208A0470 |59 63|factnucl
P09592208A0470 |36 46|importanceine phosph
P09592219A0652 |4 11|results01606T0
P09592219A0652 |58 70|intervention-nucleotidas
P09592219A0652 |25 38|effectiveness with alkalin
P09593302A1165 |137 143|phenolia. P0
P09593302A1165 |41 59|non-responsivenesshosphatases and 5-
P09593302A1165 |121 128|abilityhyperbi
P09593302A1165 |86 94|A-domain Pharmac
P09593302A1165 |16 28|implicationsomparison wi
P09594299A0468 |119 128|reductionl hyperbi
P09594299A0468 |165 168|hip[HC
P09594299A0468 |104 108|yearects
P09594299A0468 |146 157|dislocation8997A0472 W
P09594299A0468 |62 66|timeleot
P09594299A0468 |20 25|indexrison
P09594299A0468 |0 7|RESULTSP000016
P09595496A0000 |35 47|endothelin-1line phospha
P09595496A0000 |88 93|fluidharma
P09595496A0000 |25 31|levels with 
P09595496A0000 |125 132|surgeryrbiliru
P09595496A0000 |97 105|patientsgic aspe
P09595496A0000 |49 53|ET-1ses 
P09596536A0219 |34 54|knee loading changesaline phosphatases a
P09596536A0219 |108 130|cartilage degeneration of neonatal hyperbili
P09596536A0219 |65 80|ACL transectiontidase P0000817
P09596542A0542 |17 25|surfacesmparison
P09596542A0542 |106 110|corets o
P09596542A0542 |38 54|cartilage matrixe phosphatases a
P09596638T0000 |71 82|Arabidopsis P00008171T
P09596638T0000 |12 19|mapping76 Comp
P09596638T0000 |27 50|Brassica S locus regionith alkaline phosphatas
P09596638T0000 |59 67|homeolognucleoti
P09596738T0000 |0 5|RolesP0000
P09596738T0000 |13 29|Candida albicans6 Comparison wit
P09596738T0000 |89 100|developmentarmacologic
P09596738T0000 |72 77|Cek1pP0000
P09596738T0000 |114 125|candidiasisonatal hype
P09596738T0000 |48 70|protein kinase homologases and 5-nucleotidas
P09598205A0430 |48 61|disaccharidesases and 5-nu
P09598205A0430 |12 20|reaction76 Compa
P09598205A0430 |24 39|monosaccharidesn with alkaline
P09598205A0430 |109 115|maltolof neo
P09598205A0430 |67 79|beta-alaninedase P000081
P09598205A0430 |96 105|formationogic aspe
P09598894A0732 |48 58|resorptionases and 5
P09598894A0732 |29 43|bone formationh alkaline pho
P09598894A0732 |8 16|subjects6T0076 C
P09598894A0732 |18 25|markersparison
P09599102A1191 |0 8|AnalysisP0000160
P09599102A1191 |60 70|repressionucleotidas
P09599102A1191 |28 38|refractileth alkalin
P09599102A1191 |14 26|Mac1p mutant Comparison 
P09599102A1191 |151 169|copper sensitivity0472 When CSF [HCO
P09599102A1191 |120 127|pattern hyperb
P09599102A1191 |131 146|CUP1 expressionubinemia. P0000
P09599102A1191 |78 80|Cu17
P09599102A1191 |81 82|IT
P09599102A1191 |84 99|transport genes00 Pharmacologi
P09599664A0881 |86 94|RXR beta Pharmac
P09599664A0881 |58 68|expression-nucleotid
P09599664A0881 |72 81|RXR alphaP00008171
P09599664A0881 |4 18|DNA sequencing01606T0076 Com
P09599664A0881 |38 44|clonese phos
P09599724A0193 |139 153|PCDF congeners. P00008997A04
P09599724A0193 |20 26|samplerison 
P09599724A0193 |157 169|blood lipidshen CSF [HCO
P09599724A0193 |320 326|cohortater s
P09599724A0193 |57 63|cohort5-nucl
P09599724A0193 |208 221|PCDF exposurethe data of K
P09599724A0193 |130 134|PCDDrubi
P09599724A0193 |254 262|exposurelaced wh
P09599724A0193 |184 190|extent a fun
P09599724A0193 |291 306|cancer findingstill have a sig
P09599724A0193 |40 49|employeesphosphata
P09599724A0193 |199 203|PCDDCSF 
P09599724A0193 |230 236|cohort rats 
P09599724A0193 |67 92|phenoxy herbicide workersdase P00008171T0000 Pharm
P09599897A0000 |202 205|WBC PC
P09599897A0000 |294 308|manifestationsl have a signi
P09599897A0000 |83 86|HSP000
P09599897A0000 |246 252|levelsger di
P09599897A0000 |264 267|PLT co
P09599897A0000 |57 81|Henoch-Schonlein purpura5-nucleotidase P00008171
P09599897A0000 |215 220|seruma of 
P09599897A0000 |241 244|CRPo l
P09599897A0000 |17 36|laboratory featuresmparison with alkal
P09599897A0000 |254 262|plateletlaced wh
P09599897A0000 |154 172|laboratory indices2 When CSF [HCO3-]
P09599897A0000 |190 200|blood cellction of C
P09599897A0000 |43 51|childrensphatase
P09599897A0000 |318 321|HSPrea
P09599897A0000 |129 141|associationsirubinemia. 
P09599897A0000 |232 239|proteinats are
P09601007A0223 |103 120|coral reef waterspects of neonatal
P09601007A0223 |31 35|dataalka
P09601007A0223 |208 221|calcificationthe data of K
P09601007A0223 |72 89|CO2 concentrationP00008171T0000 Ph
P09601007A0223 |195 206|respiration of CSF PCO
P09601007A0223 |61 68|changescleotid
P09601007A0223 |11 20|community076 Compa
P09601007A0223 |227 244|CaCO3 dissolutionted rats are no l
P09601007A0223 |179 193|photosynthesiswn as a functi
P09601007A0223 |140 149|processes P0000899
P09601510A0215 |84 95|transcripts00 Pharmaco
P09601510A0215 |45 57|FV pol geneshatases and 
P09601510A0215 |27 39|retrovirusesith alkaline
P09601510A0215 |3 11|contrast001606T0
P09601516A0695 |34 42|residuesaline ph
P09601516A0695 |56 64|residues 5-nucle
P09601516A0695 |89 104|fusion activityarmacologic asp
P09601516A0695 |72 76|PEP1P000
P09601516A0695 |140 150|processing P00008997
P09601516A0695 |112 121|S proteinneonatal 
P09601516A0695 |155 173|surface expression When CSF [HCO3-] 
P09601516A0695 |0 12|SubstitutionP00001606T00
P09601921A0000 |0 11|TributyltinP00001606T0
P09601921A0000 |209 215|Canadahe dat
P09601921A0000 |82 93|water birds0000 Pharma
P09601921A0000 |125 136|Great Lakesrbilirubine
P09601921A0000 |177 187|west coasthown as a 
P09601921A0000 |109 119|Lake Huronof neonata
P09601921A0000 |191 207|British Columbiation of CSF PCO2
P09601921A0000 |20 38|breakdown productsrison with alkalin
P09601921A0000 |154 167|United States2 When CSF [H
P09601921A0000 |50 61|di-butyltines and 5-nu
P09601940A0280 |118 126|NF-IL2-Aal hyper
P09601940A0280 |30 38|CD1 gene alkalin
P09601940A0280 |131 137|NF-IL6ubinem
P09601940A0280 |95 116|transcription factorslogic aspects of neon
P09601940A0280 |53 67|binding motifsand 5-nucleoti
P09601940A0280 |16 22|regionompari
P09602124A0127 |0 7|FregnacP000016
P09602124A0127 |9 11|M.T0
P09603345A1257 |0 7|GLRaV-2P000016
P09603345A1257 |189 208|genus Closterovirusnction of CSF PCO2 
P09603345A1257 |106 111|groupts of
P09603345A1257 |60 79|genome organizationucleotidase P000081
P09603345A1257 |20 33|closterovirusrison with al
P09603345A1257 |113 116|BYVeon
P09603345A1257 |175 181|member shown
P09603345A1257 |87 98|type memberPharmacolog
P09604052A0166 |51 64|control groups and 5-nucle
P09604052A0166 |134 148|wrist fracturenemia. P000089
P09604052A0166 |109 115|sampleof neo
P09604052A0166 |123 128|womenperbi
P09604052A0166 |92 97|womenacolo
P09604052A0166 |25 29|data wit
P09605137A0677 |71 84|IL-2 promoter P00008171T00
P09605137A0677 |161 173|Jurkat cellsCSF [HCO3-] 
P09605137A0677 |132 137|LFA-3binem
P09605137A0677 |104 123|reporter constructsects of neonatal hy
P09605137A0677 |23 28|c-Junon wi
P09605137A0677 |9 19|expressionT0076 Comp
P09605137A0677 |54 67|transcriptionnd 5-nucleoti
P09605137A0677 |33 36|p65kal
P09605930A1428 |103 118|rat hepatocytespects of neonat
P09605930A1428 |37 50|transfectionsne phosphatas
P09605930A1428 |10 17|results0076 Co
P09605930A1428 |143 151|ALS gene0008997A
P09605930A1428 |55 76|mobility shift assaysd 5-nucleotidase P000
P09605934A0801 |137 143|familyia. P0
P09605934A0801 |95 101|factorlogic 
P09605934A0801 |147 168|transcription factors997A0472 When CSF [HC
P09605934A0801 |106 112|memberts of 
P09605934A0801 |21 27|CACGTGison w
P09605934A0801 |5 19|E box sequence1606T0076 Comp
P09605934A0801 |49 64|binding elementses and 5-nucle
P09605934A0801 |69 72|USFse 
P09606633A0523 |0 23|Interferon beta therapyP00001606T0076 Comparis
P09606633A0523 |47 52|weekstases
P09606924T0000 |34 42|analysisaline ph
P09606924T0000 |23 29|methodon wit
P09606924T0000 |46 78|all-rac-alpha-tocopheryl acetateatases and 5-nucleotidase P00008
P09606924T0000 |115 129|infant formulanatal hyperbil
P09606924T0000 |83 100|retinyl palmitate000 Pharmacologic
P09606924T0000 |136 165|matrix solid-phase dispersionmia. P00008997A0472 When CSF 
P09606924T0000 |0 6|LiquidP00001
P09609342A0000 |154 165|performance2 When CSF 
P09609342A0000 |109 118|flow pumpof neonat
P09609342A0000 |79 88|flow pump71T0000 P
P09609342A0000 |120 123|AFP hy
P09609342A0000 |90 93|MFPrma
P09609342A0000 |23 28|typeson wi
P09609342A0000 |59 63|pumpnucl
P09609342A0000 |65 68|CFPtid
P09609342A0000 |32 43|turbo pumpslkaline pho
P09609705A0895 |0 11|ExaminationP00001606T0
P09609705A0895 |99 101|V.c 
P09609705A0895 |82 84|L.00
P09609705A0895 |75 80|Huang00817
P09609705A0895 |33 62|bc1 complex crystal structurekaline phosphatases and 5-nuc
P09609705A0895 |64 69|Zhangotida
P09609705A0895 |71 73|Z. P
P09609705A0895 |86 97|Shulmeister Pharmacolo
P09609720A0357 |119 128|proteasesl hyperbi
P09609720A0357 |46 47|Na
P09609720A0357 |166 172|regionHCO3-]
P09609720A0357 |146 153|protein8997A04
P09609720A0357 |78 86|nuclease171T0000
P09609720A0357 |23 32|fragmentson with a
P09609720A0357 |64 70|halvesotidas
P09610755A1731 |85 94|degrees/s0 Pharmac
P09610755A1731 |96 97|po
P09610755A1731 |61 64|EXTcle
P09610755A1731 |4 27|side-to-side difference01606T0076 Comparison w
P09610755A1731 |68 77|degrees/sase P0000
P09611016A0652 |119 126|pessaryl hyper
P09611016A0652 |149 158|pessaries7A0472 Wh
P09611016A0652 |132 141|placementbinemia. 
P09611016A0652 |15 20|womenCompa
P09611016A0652 |54 64|managementnd 5-nucle
P09611016A0652 |76 84|prolapse08171T00
P09611016A0652 |0 10|CONCLUSIONP00001606T
P09611016A0652 |68 73|gradease P
P09611229A1664 |85 94|existence0 Pharmac
P09611229A1664 |46 71|nmt1-451Dino2 Delta cellsatases and 5-nucleotidase
P09611229A1664 |146 165|expression/activity8997A0472 When CSF 
P09611229A1664 |131 138|factorsubinemi
P09611229A1664 |198 204|levels CSF P
P09611229A1664 |106 126|transcription factorts of neonatal hyper
P09611229A1664 |217 242|protein N-myristoy-lationof K-depleted rats are no
P09611229A1664 |24 34|expressionn with alk
P09611229A1664 |4 11|ability01606T0
P09611229A1664 |38 42|FAS1e ph
P09611234A0098 |0 18|Rev-erbAalpha/betaP00001606T0076 Com
P09611234A0098 |61 78|oncoproteins PLZFcleotidase P00008
P09611234A0098 |31 52|Mad bHLH-zip proteinsalkaline phosphatases
P09611234A0098 |112 130|corepressors N-CoRneonatal hyperbili
P09611234A0098 |135 139|SMRTemia
P09611234A0098 |83 92|LAZ3/BCL6000 Pharm
P09611234A0098 |21 26|Mxi-1ison 
P09611877A0455 |27 30|CSFith
P09611877A0455 |61 65|ECHOcleo
P09611877A0455 |15 23|isolatesComparis
P09611877A0455 |74 78|ECHO0008
P09611877A0455 |89 93|ECHOarma
P09612351A0386 |40 51|oscillationphosphatase
P09612351A0386 |13 21|evidence6 Compar
P09612351A0386 |63 71|ULF bandeotidase
P09612775A0726 |4 20|ParaSight-F test01606T0076 Compa
P09612775A0726 |90 98|patientsrmacolog
P09612775A0726 |74 83|treatment0008171T0
P09612775A0726 |47 67|serum antigen levelstases and 5-nucleoti
P09613574A0905 |99 112|methyl groupsc aspects of 
P09613574A0905 |225 228|minlet
P09613574A0905 |25 32|protein with a
P09613574A0905 |199 208|degrees CCSF PCO2 
P09613574A0905 |161 169|activityCSF [HCO
P09613574A0905 |122 135|substrate DNAyperbilirubin
P09613574A0905 |83 91|transfer000 Phar
P09613574A0905 |53 68|enzyme activityand 5-nucleotid
P09613574A0905 |96 98|3Hog
P09613574A0905 |143 155|MGMT protein0008997A0472
P09613946A0194 |2 28|deproteinization procedure0001606T0076 Comparison wi
P09613946A0194 |63 78|HPLC separationeotidase P00008
P09613946A0194 |95 102|mm I.D.logic a
P09614065A0966 |171 180|induction] is show
P09614065A0966 |29 37|responseh alkali
P09614065A0966 |104 112|presenceects of 
P09614065A0966 |60 68|mutationucleotid
P09614065A0966 |126 130|EpREbili
P09614065A0966 |77 86|sequences8171T0000
P09614065A0966 |144 153|AP-1 site008997A04
P09614065A0966 |0 11|EliminationP00001606T0
P09614106T0000 |127 137|expressionilirubinem
P09614106T0000 |11 19|mobility076 Comp
P09614106T0000 |31 40|sequencesalkaline 
P09614106T0000 |79 90|Col2a1 gene71T0000 Pha
P09614106T0000 |58 71|pair enhancer-nucleotidase
P09617765A0174 |100 106|region aspec
P09617765A0174 |132 133|Ab
P09617765A0174 |135 139|tailemia
P09617765A0174 |74 80|strand000817
P09617765A0174 |30 43|reading frame alkaline pho
P09617765A0174 |52 54|nt a
P09617765A0174 |127 131|polyilir
P09617765A0174 |4 12|sequence01606T00
P09617765A0174 |115 117|ntna
P09617807A0929 |138 145|elementa. P000
P09617807A0929 |215 223|elementsa of K-d
P09617807A0929 |94 104|assessmentologic asp
P09617807A0929 |123 126|peaper
P09617807A0929 |15 23|analysisComparis
P09617807A0929 |110 117|Cyclopsf neona
P09617807A0929 |229 235|plantsd rats
P09617807A0929 |163 175|relationshipF [HCO3-] is
P09617807A0929 |39 59|transcriptase domain phosphatases and 5-
P09618150A0127 |274 283|treatmentto contro
P09618150A0127 |251 259|increaseisplaced
P09618150A0127 |179 180|hw
P09618150A0127 |125 131|dbcAMPrbilir
P09618150A0127 |147 175|UCP1 gene transcription rate997A0472 When CSF [HCO3-] is
P09618150A0127 |61 66|IGF-Icleot
P09618150A0127 |17 22|dosesmpari
P09618150A0127 |291 293|h.ti
P09618150A0127 |191 213|UCP1 mRNA accumulationtion of CSF PCO2 the d
P09618150A0127 |217 218|ho
P09618150A0127 |109 123|dibutyryl cAMPof neonatal hy
P09618150A0127 |44 59|growth factor Iphatases and 5-
P09618150A0127 |235 241|effect are n
P09618150A0127 |71 78|insulin P00008
P09618150A1464 |3 11|addition001606T0
P09618150A1464 |61 67|effectcleoti
P09618150A1464 |29 54|AP-1 DNA binding activityh alkaline phosphatases a
P09618150A1464 |13 20|insulin6 Compa
P09618150A1464 |111 126|MEK-1 inhibitor neonatal hyper
P09618150A1464 |99 107|presencec aspect
P09618164A0709 |51 57|OMeRNAs and 
P09618164A0709 |20 47|methyl oligoribonucleotidesrison with alkaline phospha
P09618164A0709 |81 87|nucleiT0000 
P09618164A0709 |99 112|mdx myoblastsc aspects of 
P09618164A0709 |116 123|cultureatal hy
P09618164A0709 |17 18|Om
P09618475A0747 |49 64|down-regulationses and 5-nucle
P09618475A0747 |8 16|deletion6T0076 C
P09618475A0747 |111 115|Nrd1 neo
P09618475A0747 |36 41|motifine p
P09618475A0747 |99 107|functionc aspect
P09618481T0000 |0 10|RegulationP00001606T
P09618481T0000 |107 126|Smad family memberss of neonatal hyper
P09618481T0000 |24 46|p21/WAF1/Cip1 promotern with alkaline phosph
P09618481T0000 |78 90|interactions171T0000 Pha
P09618481T0000 |58 63|cells-nucl
P09618481T0000 |99 102|Sp1c a
P09619631A0344 |0 7|RESULTSP000016
P09619631A0344 |126 138|p120 Ras-GAPbilirubinemi
P09619631A0344 |23 38|C. elegans cDNAon with alkalin
P09619631A0344 |54 61|proteinnd 5-nu
P09619777A1583 |102 107|Fluidspect
P09619777A1583 |187 192|statefunct
P09619777A1583 |116 122|pepsinatal h
P09619777A1583 |257 262|hoursed wh
P09619777A1583 |217 227|conditionsof K-deple
P09619777A1583 |124 129|SGFsperbil
P09619777A1583 |276 292|state conditions controls but st
P09619777A1583 |9 26|base ketoconazoleT0076 Comparison 
P09619777A1583 |43 54|dissolutionsphatases a
P09619777A1583 |152 165|% dissolution472 When CSF 
P09619777A1583 |238 251|% dissolutione no longer d
P09619777A1583 |141 148|minutesP000089
P09619777A1583 |69 80|formulationse P0000817
P09619777A1583 |171 176|hours] is 
P09620273A0189 |84 102|cell proliferation00 Pharmacologic a
P09620273A0189 |62 69|cyclinsleotida
P09620273A0189 |129 154|E2F transcription factorsirubinemia. P00008997A047
P09620273A0189 |106 113|bindingts of n
P09620273A0189 |3 10|mammals001606T
P09620273A0189 |16 26|Rb proteinomparison 
P09620606A0000 |100 107|signals aspect
P09620606A0000 |60 67|T cellsucleoti
P09620606A0000 |55 58|TCRd 5
P09620606A0000 |39 47|ligation phospha
P09620606A0000 |3 11|addition001606T0
P09620606A0000 |19 26|signalsarison 
P09620873A1710 |85 94|pregnancy0 Pharmac
P09620873A1710 |14 25|observation Comparison
P09620873A1710 |38 67|luteal HSP-27 phosphorylatione phosphatases and 5-nucleoti
P09620873A1710 |189 216|sHSP phosphorylation eventsnction of CSF PCO2 the data
P09620873A1710 |156 174|PKC family membersWhen CSF [HCO3-] i
P09620873A1710 |101 110|PKC-deltaaspects o
P09620955A0370 |171 181|lac operon] is shown
P09620955A0370 |39 50|leader mRNA phosphatas
P09620955A0370 |64 77|program Mfoldotidase P0000
P09620955A0370 |21 30|structureison with
P09620955A0370 |84 95|combination00 Pharmaco
P09620955A0370 |119 128|deletionsl hyperbi
P09621062A0810 |50 60|activationes and 5-n
P09621062A0810 |148 155|mutants97A0472
P09621062A0810 |90 101|mutagenesisrmacologic 
P09621062A0810 |163 212|chloramphenicol acetyltransferase reporter systemF [HCO3-] is shown as a function of CSF PCO2 the 
P09621062A0810 |24 29|sitesn wit
P09621062A0810 |114 140|promoter function analysisonatal hyperbilirubinemia.
P09621062A0810 |4 14|importance01606T0076
P09621372A0369 |103 110|enzymespects o
P09621372A0369 |47 63|thrombocytopeniatases and 5-nucl
P09621372A0369 |74 77|CRP000
P09621372A0369 |8 25|blood examination6T0076 Comparison
P09621372A0369 |33 45|leukocytosiskaline phosp
P09621893A0000 |68 82|responsivenessase P00008171T
P09621893A0000 |95 115|alpha2-adrenoceptorslogic aspects of neo
P09621893A0000 |9 16|studiesT0076 C
P09621893A0000 |54 63|increasesnd 5-nucl
P09622055A0207 |103 108|Sli-1pects
P09622055A0207 |57 64|mammals5-nucle
P09622055A0207 |133 138|D-Cblinemi
P09622055A0207 |91 101|C. elegansmacologic 
P09622055A0207 |66 71|c-Cblidase
P09622055A0207 |76 81|Cbl-b08171
P09622055A0207 |4 11|members01606T0
P09622055A0207 |19 29|Cbl familyarison wit
P09622121A0525 |51 54|PTBs a
P09622121A0525 |40 47|bindingphospha
P09622121A0525 |88 116|supershift RNA-PTB complexesharmacologic aspects of neon
P09622121A0525 |9 19|antibodiesT0076 Comp
P09622121A0525 |58 61|RNA-nu
P09622121T0000 |87 105|protein componentsPharmacologic aspe
P09622121T0000 |11 21|antibodies076 Compar
P09622121T0000 |29 65|polypyrimidine tract binding proteinh alkaline phosphatases and 5-nucleo
P09622121T0000 |67 70|PTBdas
P09622121T0000 |145 154|pre-mRNAs08997A047
P09622121T0000 |172 185|branch points is shown as 
P09622121T0000 |4 7|use016
P09623830A0000 |16 19|useomp
P09623830A0000 |40 45|Botoxphosp
P09623830A0000 |23 38|botulinum toxinon with alkalin
P09623830A0000 |64 74|popularityotidase P0
P09625762A0426 |50 65|transactivationes and 5-nucleo
P09625762A0426 |10 25|oncoprotein E1A0076 Comparison
P09625762A0426 |86 92|manner Pharm
P09625807A0000 |38 52|display methode phosphatases
P09625807A0000 |76 81|mRNAs08171
P09625807A0000 |134 147|cell culturesnemia. P00008
P09625807A0000 |172 192|carcinoma cell lines is shown as a funct
P09625807A0000 |20 24|mRNAriso
P09626662A1076 |71 82|RXR subunit P00008171T
P09626662A1076 |8 19|experiments6T0076 Comp
P09626662A1076 |57 63|RIP1405-nucl
P09626662A1076 |45 53|affinityhatases 
P09626662A1076 |127 145|TR/RXR heterodimerilirubinemia. P000
P09626662A1076 |25 27|TR w
P09626662A1076 |112 119|partnerneonata
P09626662A1076 |175 181|ligand shown
P09627285A0160 |0 7|SETTINGP000016
P09627285A0160 |45 68|care infertility centerhatases and 5-nucleotid
P09627285A0160 |9 19|UniversityT0076 Comp
P09627285A0554 |51 60|cycle days and 5-n
P09627285A0554 |7 8|S0
P09627285A0554 |131 138|ampulesubinemi
P09627285A0554 |121 127|numberhyperb
P09627285A0554 |14 22|patients Compari
P09627285A0554 |142 145|hMG000
P09627285A0554 |37 47|FSH levelsne phospha
P09627285A0554 |70 82|oocyte yielde P00008171T
P09627285A0554 |0 6|RESULTP00001
P09627598A0384 |0 7|RESULTSP000016
P09627598A0384 |179 187|subjectswn as a 
P09627598A0384 |131 155|otolith system imbalanceubinemia. P00008997A0472
P09627598A0384 |107 116|OVAR tests of neon
P09627598A0384 |120 127|measure hyperb
P09627598A0384 |64 70|valuesotidas
P09627598A0384 |36 37|%i
P09627598A0384 |86 99|preponderance Pharmacologi
P09627598A0384 |16 24|patientsompariso
P09628375A0700 |7 22|ePTFE specimens06T0076 Compari
P09628375A0700 |24 39|tissue coveragen with alkaline
P09628419A0812 |54 63|durationsnd 5-nucl
P09628419A0812 |29 48|Kristofferson modelh alkaline phosphat
P09628419A0812 |78 82|ISIs171T
P09628419A0812 |20 24|Wingriso
P09628821A1194 |68 73|genesase P
P09628821A1194 |88 93|rolesharma
P09628821A1194 |127 138|progressionilirubinemi
P09628821A1194 |43 53|candidatessphatases 
P09628821A1194 |22 38|KG1a EST datasetson with alkalin
P09628821A1194 |143 161|lineage commitment0008997A0472 When 
P09628890A0455 |33 42|mutationskaline ph
P09628890A0455 |13 22|following6 Compari
P09628890A0455 |106 115|HA trimerts of neo
P09628890A0455 |64 86|carbohydrate structureotidase P00008171T0000
P09629449A0540 |4 11|results01606T0
P09629449A0540 |89 102|concentrationarmacologic a
P09629449A0540 |47 58|spermatozoatases and 5
P09629449A0540 |127 133|numberilirub
P09629449A0540 |106 118|PMN elastasets of neonat
P09629449A0540 |22 36|ROS productionson with alkal
P09629449A0540 |172 177|cells is s
P09630245A0102 |119 124|yeastl hyp
P09630245A0102 |62 73|counterpartleotidase P
P09630245A0102 |129 136|metazoairubine
P09630245A0102 |146 161|splicing events8997A0472 When 
P09630245A0102 |99 110|differencesc aspects o
P09630245A0102 |0 14|Yeast U1 snRNPP00001606T0076
P09630245A0903 |0 14|Yeast U1 snRNPP00001606T0076
P09630245A0903 |73 92|snRNP core proteins00008171T0000 Pharm
P09630245A0903 |47 55|proteinstases an
P09630245A0903 |178 195|U1 snRNP proteinsown as a function
P09630245A0903 |145 153|proteins08997A04
P09630245A0903 |100 110|homologues aspects o
P09630245A0903 |118 129|metazoan U1al hyperbil
P09631366A0951 |16 21|cycleompar
P09631366A0951 |26 31|caseswith 
P09631366A0951 |77 82|cycle8171T
P09631366A0951 |109 119|dose levelof neonata
P09631366A0951 |48 58|dose levelases and 5
P09631366A0951 |87 92|casesPharm
P09632217A0477 |204 211|cocaineCO2 the
P09632217A0477 |11 32|antagonist naltrexone076 Comparison with a
P09632217A0477 |113 123|naltrexoneeonatal hy
P09632217A0477 |142 147|mg/kg00008
P09632217A0477 |127 132|dosesiliru
P09632217A0477 |43 48|mg/kgsphat
P09632217A0477 |101 107|heroinaspect
P09632217A0477 |81 97|stimulus effectsT0000 Pharmacolo
P09632217A0477 |155 161|effect When 
P09632217A0477 |184 200|stimulus effects a function of C
P09632637A0361 |204 208|CCl4CO2 
P09632637A0361 |43 58|cell regulationsphatases and 5
P09632637A0361 |182 202|carbon tetrachlorideas a function of CSF
P09632637A0361 |166 170|ratsHCO3
P09632637A0361 |62 83|M6P/IGFIIR expressionleotidase P00008171T0
P09632637A0361 |231 240|stimulantrats are 
P09632637A0361 |8 13|study6T007
P09632637A0361 |99 132|M6P/IGFIIR mRNA transcript levelsc aspects of neonatal hyperbiliru
P09632637A0361 |155 160|cells When
P09632709A0464 |170 185|gene expression-] is shown as 
P09632709A0464 |90 94|BX42rmac
P09632709A0464 |56 63|protein 5-nucl
P09632709A0464 |26 33|NCoA-62with al
P09632709A0464 |130 137|proteinrubinem
P09632709A0464 |4 14|cDNA clone01606T0076
P09632734A0081 |51 57|regions and 
P09632734A0081 |147 158|Rab3 family997A0472 Wh
P09632734A0081 |104 109|groupects 
P09632734A0081 |113 138|GDP/GTP exchange proteinseonatal hyperbilirubinemi
P09632734A0081 |23 31|proteinson with 
P09632734A0081 |81 98|sequence homologyT0000 Pharmacolog
P09632734A0081 |168 188|GTP binding proteinsO3-] is shown as a f
P09632734A0943 |65 68|p70tid
P09632734A0943 |30 36|effect alkal
P09632734A0943 |95 103|activitylogic as
P09632734A0943 |40 55|ERK2 activationphosphatases an
P09632734A0943 |8 22|p82 expression6T0076 Compari
P09632734A0943 |59 63|p126nucl
P09632785A0000 |35 37|U2li
P09632785A0000 |133 154|splice site selectioninemia. P00008997A047
P09632785A0000 |122 126|roleyper
P09632785A0000 |97 103|factorgic as
P09632785A0000 |52 78|ribonucleoprotein particle and 5-nucleotidase P00008
P09632785A0000 |80 85|snRNP1T000
P09632785A0000 |4 33|pre-mRNA splicing factor U2AF01606T0076 Comparison with al
P09633171A0321 |102 118|room temperaturespects of neonat
P09633171A0321 |78 85|storage171T000
P09633171A0321 |57 65|incisors5-nucleo
P09633171A0321 |89 98|tap waterarmacolog
P09633171A0321 |197 212|testing machinef CSF PCO2 the 
P09633171A0321 |126 131|hoursbilir
P09633171A0321 |4 12|brackets01606T00
P09633171A0321 |168 178|shear modeO3-] is sh
P09633274A0000 |0 17|Exercise trainingP00001606T0076 Co
P09633274A0000 |72 94|heart failure patientsP00008171T0000 Pharmac
P09633274A0000 |59 68|treatmentnucleotid
P09633630A0740 |51 66|lettuce extracts and 5-nucleot
P09633630A0740 |106 109|BMCts 
P09633630A0740 |180 183|v/vn a
P09633630A0740 |14 17|Aer Co
P09633630A0740 |4 10|growth01606T
P09633630A0740 |126 128|Psbi
P09633630A0740 |177 178|%h
P09633630A0740 |130 141|fluorescensrubinemia. 
P09633630A0740 |101 104|v/vasp
P09633630A0740 |98 99|%i
P09633630A0740 |185 188|BMCa f
P09633630A0740 |19 29|hydrophilaarison wit
P09633879A0246 |137 142|yearsia. P
P09633879A0246 |95 103|patientslogic as
P09633879A0246 |57 78|serum ferritin levels5-nucleotidase P00008
P09633879A0246 |121 126|grouphyper
P09633879A0246 |43 53|resurgencesphatases 
P09633879A0246 |146 148|L189
P09633879A0246 |112 119|veteranneonata
P09633879A0246 |19 29|compliancearison wit
P09635149A1148 |0 10|HematocritP00001606T
P09635149A1148 |15 19|PaO2Comp
P09635276A1608 |51 58|changess and 5
P09635276A1608 |62 82|subunit interactionsleotidase P00008171T
P09635276A1608 |14 41|myosin phosphatase activity Comparison with alkaline p
P09635276A1608 |103 113|mechanismspects of n
P09635276A1608 |0 10|RegulationP00001606T
P09636119T0000 |69 74|plantse P0
P09636119T0000 |80 87|pulleys1T0000 
P09636119T0000 |21 30|generatorison with
P09636358A0000 |171 180|infection] is show
P09636358A0000 |111 122|translation neonatal h
P09636358A0000 |72 75|RNAP00
P09636358A0000 |159 164|timesn CSF
P09636358A0000 |145 150|mRNAs08997
P09636358A0000 |21 28|VAI RNAison wi
P09636358A0000 |32 42|adenoviruslkaline ph
P09636670T0000 |17 21|genempar
P09636670T0000 |94 102|analysisologic a
P09636670T0000 |106 119|breast cancerts of neonata
P09636670T0000 |58 78|kinase inhibitor p18-nucleotidase P00008
P09636670T0000 |0 9|StructureP00001606
P09636708A0460 |118 125|proteinal hype
P09636708A0460 |63 69|mannereotida
P09636708A0460 |104 110|YccA11ects o
P09636708A0460 |229 240|degradationd rats are 
P09636708A0460 |199 205|domainCSF PC
P09636708A0460 |4 16|YccA protein01606T0076 C
P09636708A0460 |141 160|amino acid residuesP00008997A0472 When
P09637689A0150 |98 102|RNAPic a
P09637689A0150 |24 42|activator proteinsn with alkaline ph
P09637689A0150 |10 14|type0076
P09637689A0150 |56 59|DNA 5-
P09637689A0150 |104 114|holoenzymeects of ne
P09637689A0150 |82 96|RNA polymerase0000 Pharmacol
P09637689A0150 |162 166|RNAPSF [
P09637689A0150 |143 154|recruitment0008997A047
P09637689A0150 |174 182|promoters shown 
P09638342T0000 |21 23|L1is
P09638342T0000 |78 108|membrane cytoskeleton assembly171T0000 Pharmacologic aspects
P09638342T0000 |12 16|role76 C
P09638342T0000 |43 47|linkspha
P09638342T0000 |65 73|adhesiontidase P
P09638485A0111 |54 93|leukocyte alkaline phosphatase activitynd 5-nucleotidase P00008171T0000 Pharma
P09638485A0111 |95 99|LAPAlogi
P09638485A0111 |182 189|workersas a fu
P09638485A0111 |12 19|benzene76 Comp
P09638485A0111 |43 48|tt-MAsphat
P09638485A0111 |125 138|car mechanicsrbilirubinemi
P09638485A0111 |37 41|acidne p
P09638485A0111 |143 162|road tanker drivers0008997A0472 When C
P09638650A0169 |35 38|NCRlin
P09638650A0169 |298 302|OFR5ve a
P09638650A0169 |27 33|regionith al
P09638650A0169 |125 126|Mr
P09638650A0169 |270 274|ORF4red 
P09638650A0169 |134 137|kDanem
P09638650A0169 |85 89|ORFs0 Ph
P09638650A0169 |152 166|RNA polymerase472 When CSF [
P09638650A0169 |324 335|nucleotides slope (1.2
P09638650A0169 |246 266|kDa movement proteinger displaced when c
P09638650A0169 |212 232|kDa movement proteindata of K-depleted r
P09638650A0169 |127 128|ri
P09638650A0169 |178 198|kDa movement proteinown as a function of
P09638650A0169 |111 119|proteins neonata
P09638650A0169 |314 317|NCRly 
P09638650A0169 |280 296|kDa coat proteintrols but still 
P09638650A0169 |46 57|nucleotidesatases and 
P09638650A0169 |168 172|ORF1O3-]
P09638650A0169 |202 206|ORF2 PCO
P09638650A0169 |236 240|ORF3are 
P09638650A0169 |69 83|reading framesse P00008171T0
P09638793A1446 |50 61|superiorityes and 5-nu
P09638793A1446 |75 77|LV00
P09638793A1446 |126 137|oxygenationbilirubinem
P09638793A1446 |88 98|propertiesharmacolog
P09638793A1446 |47 48|%t
P09638793A1446 |28 40|hemodilutionth alkaline 
P09638793A1446 |42 45|Hctosp
P09638793A1446 |196 203|carrierof CSF 
P09638793A1446 |65 70|LV MCtidas
P09638793A1446 |155 179|i.v. perflubron emulsion When CSF [HCO3-] is sho
P09639074A0707 |0 3|Sp1P00
P09639074A0707 |12 24|Sp3 isoforms76 Compariso
P09639074A0707 |91 100|complexesmacologic
P09639074A0707 |63 75|constituentseotidase P00
P09639074A0707 |136 140|sitemia.
P09639410A3282 |38 45|targetse phosp
P09639410A3282 |6 11|genes606T0
P09639410A3282 |66 76|strategiesidase P000
P09639558A0957 |55 58|IgGd 5
P09639558A0957 |79 91|erythrocytes71T0000 Phar
P09639558A0957 |36 46|haemolysisine phosph
P09639565A0225 |111 124|SV40 promoter neonatal hyp
P09639565A0225 |46 63|enhancer activityatases and 5-nucl
P09639565A0225 |77 82|cells8171T
P09640162A0242 |69 78|treatmentse P00008
P09640162A0242 |11 18|patient076 Com
P09640162A0242 |160 162|yr C
P09640162A0242 |130 148|ventricle teratomarubinemia. P000089
P09640162A0242 |82 107|growth hormone deficiency0000 Pharmacologic aspect
P09640162A0242 |50 64|growth hormonees and 5-nucle
P09640802A0467 |116 127|flap choiceatal hyperb
P09640802A0467 |95 108|possibilitieslogic aspects
P09640802A0467 |43 55|consequencessphatases an
P09640802A0467 |71 75|flap P00
P09641167A1359 |0 10|CONCLUSIONP00001606T
P09641167A1359 |12 21|TNF alpha76 Compar
P09641167A1359 |61 81|LDLr gene expressioncleotidase P00008171
P09641167A1359 |23 31|TGF betaon with 
P09641167A1359 |42 50|IL-1betaosphatas
P09641167A1359 |143 161|gene transcription0008997A0472 When 
P09641167A1359 |33 37|PDGFkali
P09642042A0646 |119 140|beta-phosphate moietyl hyperbilirubinemia.
P09642042A0646 |58 71|triphosphates-nucleotidase
P09642042A0646 |157 174|substrate bindinghen CSF [HCO3-] i
P09642042A0646 |93 100|analogscologic
P09642042A0646 |32 47|nucleotide monolkaline phospha
P09642042A0646 |0 18|Binding affinitiesP00001606T0076 Com
P09642200A0956 |291 299|bacteriatill hav
P09642200A0956 |104 117|M. jannaschiiects of neona
P09642200A0956 |247 263|chemical natureser displaced whe
P09642200A0956 |77 99|M. thermoautotrophicum8171T0000 Pharmacologi
P09642200A0956 |133 137|ahaKinem
P09642200A0956 |47 51|sizetase
P09642200A0956 |59 71|proteolipidsnucleotidase
P09642200A0956 |267 273|lipidsmpared
P09642200A0956 |216 224|membrane of K-de
P09642200A0956 |279 286|archaeantrols 
P09642214A0244 |138 142|MAPKa. P
P09642214A0244 |122 136|protein kinaseyperbilirubine
P09642214A0244 |90 100|activationrmacologic
P09642214A0244 |30 34|role alk
P09642214A0244 |179 190|COS-7 cellswn as a fun
P09642214A0244 |162 175|SHP-2 mutantsSF [HCO3-] is
P09642214A0244 |8 14|report6T0076
P09642214A0244 |55 72|phosphatase SHP-2d 5-nucleotidase 
P09642227A0000 |0 12|OsteoadherinP00001606T00
P09642227A0000 |37 54|bone proteoglycanne phosphatases a
P09642227A0000 |66 81|keratan sulfateidase P00008171
P09642238A0532 |0 6|IntronP00001
P09642238A0532 |46 63|enhancer activityatases and 5-nucl
P09642238A1285 |136 147|involvementmia. P00008
P09642238A1285 |78 105|transactivation experiments171T0000 Pharmacologic aspe
P09642238A1285 |109 120|COS-1 cellsof neonatal
P09642238A1285 |13 28|enhancer region6 Comparison wi
P09642238A1285 |210 216|factore data
P09642238A1285 |4 10|intron01606T
P09642238A1285 |161 172|Sp1 proteinCSF [HCO3-]
P09642238A1285 |71 74|Sp1 P0
P09642238A1285 |50 56|GATA-1es and
P09642276A0881 |136 144|functionmia. P00
P09642276A0881 |59 63|rolenucl
P09642276A0881 |148 151|Fak97A
P09642276A0881 |88 103|suicide programharmacologic as
P09642276A0881 |4 12|cleavage01606T00
P09642276A0881 |23 31|caspaseson with 
P09642276A0881 |71 80|execution P0000817
P09642276A0881 |16 19|Fakomp
P09642764A0469 |256 259|QCMced
P09642764A0469 |90 94|massrmac
P09642764A0469 |144 154|techniques008997A047
P09642764A0469 |63 81|Sauerbrey equationeotidase P00008171
P09642764A0469 |14 18|mass Com
P09642764A0469 |181 186|assay as a
P09642764A0469 |217 221|massof K
P09642764A0469 |163 167|caseF [H
P09642764A0469 |38 50|QCM responsee phosphatas
P09642764A0469 |117 123|thankstal hy
P09643153T0000 |1 10|Treatment00001606T
P09643153T0000 |29 47|T2N breast cancersh alkaline phospha
P09643153T0000 |20 22|T1ri
P09643546A0436 |0 24|Transcription initiationP00001606T0076 Compariso
P09643546A0436 |143 160|stress conditions0008997A0472 When
P09643546A0436 |81 89|promoterT0000 Ph
P09643546A0436 |115 120|cellsnatal
P09643548A0000 |4 9|genes01606
P09643548A0000 |83 119|cyanobacterium Synechocystis PCC6803000 Pharmacologic aspects of neonata
P09643548A0000 |20 26|2Fe-2Srison 
P09643548A0000 |39 50|ferredoxins phosphatas
P09645576A0148 |0 3|RNAP00
P09645576A0148 |54 57|BMTnd 
P09645576A0148 |7 12|GBV-C06T00
P09645576A0148 |38 46|patientse phosph
P09645576A0148 |35 36|%l
P09645942A1164 |16 41|Dsg-plakoglobin complexesomparison with alkaline p
P09645942A1164 |56 58|8S 5
P09645942A1164 |79 92|stoichiometry71T0000 Pharm
P09645942A1164 |8 12|pool6T00
P09645961A1158 |4 11|results01606T0
P09645961A1158 |30 37|binding alkali
P09645961A1158 |111 121|activation neonatal 
P09645961A1158 |41 49|CBF/NF-Yhosphata
P09645961A1158 |129 138|nTPH geneirubinemi
P09645961A1158 |66 75|CCAAT boxidase P00
P09647233A0336 |117 130|binding sitestal hyperbili
P09647233A0336 |164 170|repeat [HCO3
P09647233A0336 |75 82|binding008171T
P09647233A0336 |30 51|HIV-1 gene expression alkaline phosphatase
P09647233A0336 |172 175|LTR is
P09647233A0336 |67 71|partdase
P09647233A0336 |3 14|macrophages001606T0076
P09647233A0336 |86 96|NF-kappa B Pharmacol
P09647240A0000 |186 199|Val135 mutant function of 
P09647240A0000 |43 70|Janus kinase-STAT signalingsphatases and 5-nucleotidas
P09647240A0000 |203 206|p53PCO
P09647240A0000 |97 122|hepatoma Hep3B cell linesgic aspects of neonatal h
P09647240A0000 |4 13|influence01606T007
P09647240A0000 |17 20|p53mpa
P09649069A0490 |39 59|laryngeal parameters phosphatases and 5-
P09649069A0490 |113 125|examinationseonatal hype
P09649265A1575 |0 11|CONCLUSIONSP00001606T0
P09649265A1575 |75 83|biopsies008171T0
P09649265A1575 |182 185|menas 
P09649265A1575 |29 33|setsh al
P09649265A1575 |122 134|office visityperbilirubi
P09649265A1575 |91 99|prostatemacologi
P09649265A1575 |162 177|biopsy strategySF [HCO3-] is s
P09649265A1575 |229 240|examinationd rats are 
P09649265A1575 |257 266|serum PSAed when c
P09649265A1575 |49 59|ultrasoundses and 5-
P09649315A0943 |152 157|range472 W
P09649315A0943 |161 168|abilityCSF [HC
P09649315A0943 |94 113|MIP-1 beta variantsologic aspects of n
P09649315A0943 |133 141|proteinsinemia. 
P09649315A0943 |61 67|seriescleoti
P09649315A0943 |48 55|spectraases an
P09649315A0943 |43 46|NMRsph
P09649315A0943 |32 41|resonancelkaline p
P09649315A0943 |0 11|ExaminationP00001606T0
P09649426A0636 |48 54|strainases a
P09649426A0636 |15 27|PKA activityComparison w
P09649426A0636 |73 87|Msn4p activity00008171T0000 
P09649426A0636 |63 68|Msn2peotid
P09649437A1140 |52 58|C/EBPs and 5
P09649437A1140 |132 164|eosinophil lineage determinationbinemia. P00008997A0472 When CSF
P09649437A1140 |31 43|interactionsalkaline pho
P09649437A1140 |72 90|Ets family membersP00008171T0000 Pha
P09649437A1140 |106 112|GATA-1ts of 
P09649438A0182 |171 185|Tat activation] is shown as 
P09649438A0182 |115 122|factorsnatal h
P09649438A0182 |202 209|extract PCO2 t
P09649438A0182 |189 193|HeLancti
P09649438A0182 |72 83|CDK9 kinaseP00008171T0
P09649438A0182 |18 56|transcription elongation factor P-TEFbparison with alkaline phosphatases and
P09649438A0182 |156 159|TatWhe
P09649438A0182 |222 228|P-TEFbdeplet
P09649438A0182 |85 93|cyclin T0 Pharma
P09649501A0358 |169 174|HSBP13-] i
P09649501A0358 |211 218|protein data o
P09649501A0358 |29 36|repeatsh alkal
P09649501A0358 |132 165|heat shock factor binding proteinbinemia. P00008997A0472 When CSF 
P09649501A0358 |268 275|repeatspared t
P09649501A0358 |44 69|HSF1 trimerization domainphatases and 5-nucleotida
P09649501A0358 |299 318|HSF1 heptad repeatse a significantly g
P09649501A0358 |94 119|protein interaction assayologic aspects of neonata
P09649501A0358 |77 82|yeast8171T
P09649501A0358 |246 252|arraysger di
P09649537A0000 |42 70|yeast GCN2 eIF-2alpha kinaseosphatases and 5-nucleotidas
P09649537A0000 |12 23|cDNA clones76 Comparis
P09649537A0000 |72 77|yGCN2P0000
P09650180A1130 |42 49|voltageosphata
P09650180A1130 |73 74|%0
P09650180A1130 |106 115|mGy min-1ts of neo
P09650180A1130 |12 25|recombination76 Comparison
P09650180A1130 |79 89|dose-rates71T0000 Ph
P09650180A1130 |57 58|V5
P09650186A1043 |115 122|regionsnatal h
P09650186A1043 |8 14|number6T0076
P09650186A1043 |24 33|positivesn with al
P09650186A1043 |82 93|radiologist0000 Pharma
P09650186A1043 |53 59|schemeand 5-
P09650275T0000 |52 64|implications and 5-nucle
P09650275T0000 |91 113|biotechnology industrymacologic aspects of n
P09650275T0000 |29 47|weapons conventionh alkaline phospha
P09650299A0000 |0 5|VirD2P0000
P09650299A0000 |24 58|Agrobacterium tumefaciens proteinsn with alkaline phosphatases and 5
P09650299A0000 |77 87|processing8171T0000 
P09650299A0000 |92 100|transferacologic
P09650299A1334 |97 108|integrationgic aspects
P09650299A1334 |45 50|VirD2hatas
P09650299A1334 |57 63|domain5-nucl
P09650299A1334 |22 26|datason 
P09650403A0868 |4 16|DHEAS levels01606T0076 C
P09650403A0868 |91 96|groupmacol
P09650403A0868 |44 47|BMDpha
P09650403A0868 |109 112|BMDof 
P09650403A0868 |24 30|stagesn with
P09650789A0185 |102 115|energy levelsspects of neo
P09650789A0185 |27 38|spin systemith alkalin
P09650789A0185 |136 142|degreemia. P
P09650789A0185 |154 165|orientation2 When CSF 
P09650789A0185 |0 11|OrientationP00001606T0
P09650789A0185 |68 84|Overhauser shiftase P00008171T00
P09651321A0000 |0 10|Cystatin AP00001606T
P09651321A0000 |14 43|cysteine proteinase inhibitor Comparison with alkaline pho
P09651321A0000 |164 192|keratinocyte differentiation [HCO3-] is shown as a funct
P09651321A0000 |108 121|keratinocytes of neonatal 
P09651321A0000 |91 104|cell envelopemacologic asp
P09651321A0000 |59 77|precursor proteinsnucleotidase P0000
P09651321A0000 |155 160|stage When
P09651367T0000 |2 6|role0001
P09651367T0000 |63 73|inhibitioneotidase P
P09651367T0000 |30 42|Ras effector alkaline ph
P09651367T0000 |11 17|RalGDS076 Co
P09651367T0000 |86 96|myogenesis Pharmacol
P09651375T0000 |0 6|GTPaseP00001
P09651375T0000 |96 102|PSD-95ogic a
P09651375T0000 |43 62|binding specificitysphatases and 5-nuc
P09651375T0000 |91 94|PDZmac
P09651375T0000 |18 29|specificityparison wit
P09651375T0000 |113 119|domaineonata
P09651375T0000 |33 38|RGS12kalin
P09651375T0000 |103 109|Dlg/ZOpects 
P09651383A0967 |98 109|HepG2 cellsic aspects 
P09651383A0967 |48 60|element CIIBases and 5-n
P09651383A0967 |26 44|HNF-4 binding sitewith alkaline phos
P09651383A0967 |123 139|HNF-4 constructsperbilirubinemia
P09651383A0967 |241 250|regulatoro longer 
P09651383A0967 |258 269|apoCII gened when comp
P09651383A0967 |187 188|%f
P09651383A0967 |221 226|HNF-4-depl
P09651383A0967 |154 178|apoCII promoter activity2 When CSF [HCO3-] is sh
P09651383A0967 |196 203|controlof CSF 
P09651383A0967 |79 94|HNF-4 synthesis71T0000 Pharmac
P09651383A0967 |9 18|mutationsT0076 Com
P09651383A0967 |65 75|inhibitiontidase P00
P09652736A1205 |119 131|co-activatorl hyperbilir
P09652736A1205 |195 200|E2F-1 of C
P09652736A1205 |42 51|apoptosisosphatase
P09652736A1205 |26 31|E2F-1with 
P09652736A1205 |183 191|activitys a func
P09652736A1205 |62 74|tumour cellsleotidase P0
P09652736A1205 |55 58|p53d 5
P09652736A1205 |140 158|E2F/DP heterodimer P00008997A0472 Wh
P09652736A1205 |3 11|addition001606T0
P09652736A1205 |87 91|p300Phar
P09652737A1244 |137 144|changesia. P00
P09652737A1244 |218 222|AP-1f K-
P09652737A1244 |158 184|Jun family member proteinsen CSF [HCO3-] is shown as
P09652737A1244 |97 102|Fra-2gic a
P09652737A1244 |25 33|analysis with al
P09652737A1244 |49 75|Fos family member proteinsses and 5-nucleotidase P00
P09652737A1244 |223 242|DNA binding complexepleted rats are no
P09652737A1244 |87 92|Fra-1Pharm
P09652737A1244 |118 129|progressional hyperbil
P09652742A0455 |38 41|p53e p
P09652742A0455 |88 94|glandsharmac
P09652742A0455 |145 151|strain08997A
P09652742A0455 |110 116|tumorsf neon
P09653182A1298 |34 44|virus RNAsaline phos
P09653182A1298 |111 124|transcription neonatal hyp
P09653182A1298 |46 50|BSMVatas
P09653182A1298 |6 10|data606T
P09653182A1298 |144 150|plants008997
P09653182A1298 |83 92|MStV mRNA000 Pharm
P09653182A1298 |65 78|primer donorstidase P00008
P09653641A0471 |65 76|start codontidase P000
P09653641A0471 |6 14|isoforms606T0076
P09653648A0445 |0 10|ComparisonP00001606T
P09653648A0445 |150 158|end exonA0472 Wh
P09653648A0445 |91 93|kbma
P09653648A0445 |31 40|sequencesalkaline 
P09653648A0445 |14 18|cDNA Com
P09653648A0445 |226 232|regioneted r
P09653648A0445 |183 201|zinc finger domains a function of CS
P09653648A0445 |56 67|ZNF189 gene 5-nucleoti
P09653648A0445 |130 135|exonsrubin
P09653745A0180 |0 7|MalariaP000016
P09653745A0180 |198 203|model CSF 
P09653745A0180 |177 185|projectshown as 
P09653745A0180 |231 236|worldrats 
P09653745A0180 |93 102|reductioncologic a
P09653745A0180 |244 251|malariaonger d
P09653745A0180 |265 278|problem todaycompared to c
P09653745A0180 |66 79|paper queriesidase P000081
P09653745A0180 |142 150|thirties00008997
P09653745A0180 |50 55|1940ses an
P09653745A0180 |118 134|control projectsal hyperbilirubi
P09655248A0000 |153 159|uptake72 Whe
P09655248A0000 |59 91|lipoprotein receptor gene familynucleotidase P00008171T0000 Phar
P09655248A0000 |24 31|proteinn with 
P09655248A0000 |191 198|ligandstion of
P09655248A0000 |163 175|lipoproteinsF [HCO3-] is
P09655248A0000 |4 21|gp330/Megalin/LRP01606T0076 Compar
P09655248A0000 |136 144|receptormia. P00
P09655916A0415 |152 155|Leu472
P09655916A0415 |57 60|Arg5-n
P09655916A0415 |124 133|histidineerbilirub
P09655916A0415 |88 92|sideharm
P09655916A0415 |159 162|Glnn C
P09655916A0415 |7 28|DNA recognition helix06T0076 Comparison wi
P09655916A0415 |64 72|positionotidase 
P09655916A0415 |32 38|fingerlkalin
P09656414A0220 |0 6|DosageP00001
P09656414A0220 |15 20|casesCompa
P09656414A0220 |29 33|g/m2h al
P09656485A0351 |16 22|copiesompari
P09656485A0351 |31 39|elementsalkaline
P09656485A0351 |65 86|restriction digestiontidase P00008171T0000
P09657003T0000 |201 205|RNAsF PC
P09657003T0000 |147 167|Ophiostoma novo-ulmi997A0472 When CSF [H
P09657003T0000 |56 71|RNA polymerases 5-nucleotidase
P09657003T0000 |243 249|genomelonger
P09657003T0000 |13 26|relationships6 Comparison 
P09657003T0000 |127 145|elm disease fungusilirubinemia. P000
P09657003T0000 |110 113|RNAf n
P09657003T0000 |178 185|virusesown as 
P09657003T0000 |217 228|Arabidopsisof K-deplet
P09658104T0000 |0 4|RoleP000
P09658104T0000 |53 77|transcription factor YY1and 5-nucleotidase P0000
P09658104T0000 |12 48|transcription start site core region76 Comparison with alkaline phosphat
P09658104T0000 |114 138|repeat promoter activityonatal hyperbilirubinemi
P09658104T0000 |81 99|Rous sarcoma virusT0000 Pharmacologi
P09658122T0000 |68 72|PC-1ase 
P09658122T0000 |56 66|alpha-SNAP 5-nucleot
P09658122T0000 |116 132|nematode proteinatal hyperbiliru
P09658122T0000 |94 101|homologologic 
P09658122T0000 |35 43|homologsline pho
P09658122T0000 |0 13|Fowlpox virusP00001606T007
P09658403A1207 |51 75|progesterone agonist Orgs and 5-nucleotidase P00
P09658403A1207 |111 123|CAT activity neonatal hy
P09658403A1207 |12 15|Rap76 
P09658403A1207 |88 94|effectharmac
P09658403A1207 |30 38|exposure alkalin
P09658403A1207 |98 107|inductionic aspect
P09658403A1207 |42 47|cellsospha
P09658403A1207 |19 23|KN62aris
P09658403A1207 |0 8|AdditionP0000160
P09658405A0000 |4 14|Dax-1 gene01606T0076
P09658405A0000 |25 32|protein with a
P09658405A0000 |95 115|receptor superfamilylogic aspects of neo
P09658405A0000 |65 72|memberstidase 
P09658405A0000 |80 86|orphan1T0000
P09658769A0058 |32 44|IFN alpha-2blkaline phos
P09658769A0058 |76 88|hepatitis C.08171T0000 P
P09658769A0058 |55 64|diagnosisd 5-nucle
P09660823A0934 |65 78|p70 S6 kinasetidase P00008
P09660823A0934 |47 60|molecules Akttases and 5-n
P09660823A0934 |9 32|Ser/Thr phosphorylationT0076 Comparison with a
P09660836A0983 |170 179|S222D MEK-] is sho
P09660836A0983 |80 89|compounds1T0000 Ph
P09660836A0983 |143 151|affinity0008997A
P09660836A0983 |56 70|MEK inhibition 5-nucleotidas
P09660836A0983 |13 23|evaluation6 Comparis
P09660836A0983 |156 169|deltaN3-S218EWhen CSF [HCO
P09660836A0983 |38 52|state kineticse phosphatases
P09660836A0983 |190 198|PD098059ction of
P09660836A0983 |103 108|U0126pects
P09660838A0920 |137 152|serine residuesia. P00008997A0
P09660838A0920 |118 133|phosphorylational hyperbilirub
P09660838A0920 |52 58|action and 5
P09660838A0920 |213 232|heat shock responseata of K-depleted r
P09660838A0920 |105 109|HSF1cts 
P09660838A0920 |0 10|RegulationP00001606T
P09660838A0920 |187 193|growthfuncti
P09660838A0920 |17 26|degrees Cmparison 
P09660838A0920 |68 91|protein kinase cascadesase P00008171T0000 Phar
P09661676T0000 |42 46|IL-5osph
P09661676T0000 |9 20|implicationT0076 Compa
P09661676T0000 |78 86|patients171T0000
P09661676T0000 |24 38|protein levelsn with alkalin
P09661676T0000 |58 64|sputum-nucle
P09662339A0744 |136 145|CD44 mRNAmia. P000
P09662339A0744 |28 38|transitionth alkalin
P09662339A0744 |150 157|proteinA0472 W
P09662339A0744 |9 14|cellsT0076
P09662339A0744 |122 132|expressionyperbiliru
P09662339A0744 |92 100|activityacologic
P09662339A0744 |66 75|inductionidase P00
P09662443A0402 |96 116|caveolin gene familyogic aspects of neon
P09662443A0402 |47 59|organizationtases and 5-
P09662443A0402 |78 88|expression171T0000 P
P09663062A0175 |0 22|Tensile bond strengthsP00001606T0076 Compari
P09663062A0175 |58 64|dentin-nucle
P09663062A0175 |215 223|dentistsa of K-d
P09663062A0175 |31 36|resinalkal
P09663062A0175 |120 122|LB h
P09663062A0175 |87 94|systemsPharmac
P09663062A0175 |157 172|bonding systemshen CSF [HCO3-]
P09663062A0175 |188 195|scatterunction
P09663062A0175 |127 151|Scotchbond Multi-Purposeilirubinemia. P00008997A
P09663062A0175 |202 210|students PCO2 th
P09663062A0175 |153 155|MP72
P09663062A0175 |96 118|Clearfil Liner Bond IIogic aspects of neonat
P09663062A0175 |71 77|dentin P0000
P09664033A1204 |186 192|bodies funct
P09664033A1204 |5 17|distribution1606T0076 Co
P09664033A1204 |151 169|processing pathway0472 When CSF [HCO
P09664033A1204 |141 147|importP00008
P09664033A1204 |80 89|nucleolus1T0000 Ph
P09664033A1204 |49 58|precursorses and 5
P09664033A1204 |119 126|snoRNAsl hyper
P09665361T0000 |24 39|thyroid nodulesn with alkaline
P09665361T0000 |12 19|therapy76 Comp
P09665503A0526 |22 32|volunteersson with a
P09665503A0526 |47 52|studytases
P09665720A0325 |18 21|Mg2par
P09665720A0325 |74 89|polymerase site0008171T0000 Ph
P09665720A0325 |7 14|absence06T0076
P09665720A0325 |94 104|possessionologic asp
P09665720A0325 |112 127|primer terminusneonatal hyperb
P09665720A0325 |38 54|exonuclease sitee phosphatases a
P09665720A1145 |21 24|Mg2iso
P09665720A1145 |90 106|exonuclease sitermacologic aspec
P09665720A1145 |133 143|polymeraseinemia. P0
P09665720A1145 |151 155|site0472
P09665720A1145 |26 39|binding siteswith alkaline
P09665720A1145 |56 71|primer terminus 5-nucleotidase
P09666103A0496 |171 180|phenotype] is show
P09666103A0496 |125 130|E274Krbili
P09666103A0496 |108 113|E225K of n
P09666103A0496 |149 160|temperature7A0472 When
P09666103A0496 |4 19|missense allele01606T0076 Comp
P09666103A0496 |65 73|degreesCtidase P
P09666103A0496 |83 99|missense alleles000 Pharmacologi
P09666103A0496 |42 46|lossosph
P09666103A0496 |115 120|S269Lnatal
P09666103A0496 |21 26|P236Sison 
P09666103A0496 |101 106|L173Faspec
P09666103A0496 |50 58|functiones and 5
P09666114A0389 |86 90|TATA Pha
P09666114A0389 |11 19|analysis076 Comp
P09666114A0389 |134 145|G-C contentnemia. P000
P09666114A0389 |94 107|CAAT elementsologic aspect
P09666114A0389 |41 47|regionhospha
P09666114A0389 |159 176|Sp1 binding sitesn CSF [HCO3-] is 
P09666114A0389 |65 79|c-met promotertidase P000081
P09667482A0978 |51 65|stress factorss and 5-nucleo
P09667482A0978 |189 223|stress system disorder perspectivenction of CSF PCO2 the data of K-d
P09667482A0978 |176 183|contextshown a
P09667482A0978 |131 138|resultsubinemi
P09667482A0978 |73 80|context0000817
P09667482A0978 |4 10|report01606T
P09667482A0978 |114 121|diseaseonatal 
P09667482A0978 |35 47|contributionline phospha
P09667482A0978 |84 91|therapy00 Phar
P09667795A0000 |48 56|disorderases and
P09667795A0000 |6 18|pancreatitis606T0076 Com
P09668063A0274 |171 177|NIH3T3] is s
P09668063A0274 |179 181|DTwn
P09668063A0274 |125 132|varietyrbiliru
P09668063A0274 |94 101|effectsologic 
P09668063A0274 |183 188|cellss a f
P09668063A0274 |33 45|Ets proteinskaline phosp
P09668063A0274 |25 29|role wit
P09668063A0274 |49 67|Ras transformationses and 5-nucleoti
P09668063A0274 |136 151|Ets2 constructsmia. P00008997A
P09668096A0806 |49 59|preferenceses and 5-
P09668096A0806 |13 17|site6 Co
P09668096A0806 |72 80|partnersP0000817
P09668098A0868 |139 149|base pairs. P0000899
P09668098A0868 |166 190|transcription start siteHCO3-] is shown as a fun
P09668098A0868 |79 82|TPA71T
P09668098A0868 |56 73|deletion analysis 5-nucleotidase P
P09668098A0868 |94 102|elementsologic a
P09668098A0868 |22 37|FGF-BP promoterson with alkali
P09668108A1017 |0 12|ManipulationP00001606T00
P09668108A1017 |123 137|cancer therapyperbilirubinem
P09668108A1017 |76 85|apoptosis08171T000
P09668108A1017 |111 119|strategy neonata
P09668108A1017 |20 41|checkpoint regulatorsrison with alkaline p
P09668108A1017 |54 71|cell cycle arrestnd 5-nucleotidase
P09668119A0496 |68 83|protein bindingase P00008171T0
P09668119A0496 |224 231|CTCCT-3pleted 
P09668119A0496 |198 203|bases CSF 
P09668119A0496 |107 122|point mutationss of neonatal h
P09668119A0496 |143 162|binding nucleotides0008997A0472 When C
P09668119A0496 |16 37|mobility shift assaysomparison with alkali
P09669641A0425 |27 37|serum PE-1ith alkali
P09669641A0425 |15 23|accuracyComparis
P09669641A0425 |60 67|amylaseucleoti
P09670034A0340 |20 25|Ddc1prison
P09670034A0340 |60 65|Mec3pucleo
P09670034A0340 |76 87|interaction08171T0000 
P09670034A0340 |97 103|Rad17pgic as
P09670912T0000 |18 26|seizuresparison 
P09670943T0000 |0 23|B cell antigen receptorP00001606T0076 Comparis
P09670943T0000 |25 28|BCR wi
P09670943T0000 |96 125|Fc gamma RIIB1-BCR coligationogic aspects of neonatal hype
P09670943T0000 |82 92|inhibition0000 Pharm
P09670943T0000 |39 48|formation phosphat
P09670943T0000 |54 73|SHP-2-pp120 complexnd 5-nucleotidase P
P09671313A0334 |0 5|Chem.P0000
P09671313A0334 |54 56|J.nd
P09671313A0334 |33 45|MT Hartsoughkaline phosp
P09671464A0316 |119 126|meiosisl hyper
P09671464A0316 |79 86|glucose71T0000
P09671464A0316 |104 111|glucoseects of
P09671464A0316 |24 31|meiosisn with 
P09671464A0316 |9 13|SNF1T007
P09671464A0316 |141 145|Snf1P000
P09671464A0316 |50 55|stepses an
P09671496A0557 |187 197|appearancefunction o
P09671496A0557 |41 52|developmenthosphatases
P09671496A0557 |89 99|disruptionarmacologi
P09671496A0557 |72 76|miceP000
P09671496A0557 |107 118|c-Cbl locuss of neonat
P09671496A0557 |24 28|rolen wi
P09671496A0557 |57 68|homeostasis5-nucleotid
P09671496A0557 |32 37|c-Cbllkali
P09671496A0557 |136 140|micemia.
P09671576A0900 |34 42|endodermaline ph
P09671576A0900 |61 81|streak morphogenesiscleotidase P00008171
P09671579A1168 |16 24|noi/pax2ompariso
P09671579A1168 |83 93|integrator000 Pharma
P09671579A1168 |54 73|signaling processesnd 5-nucleotidase P
P09671579A1168 |116 136|boundary developmentatal hyperbilirubine
P09671791T0000 |50 72|growth factor receptores and 5-nucleotidase 
P09671791T0000 |148 156|activity97A0472 
P09671791T0000 |88 100|intermediateharmacologic
P09671791T0000 |160 167|L cells CSF [H
P09671791T0000 |19 29|activationarison wit
P09673037A0358 |0 7|METHODSP000016
P09673037A0358 |133 139|methodinemia
P09673037A0358 |143 149|Gomori000899
P09673037A0358 |36 47|bone marrowine phospha
P09673037A0358 |18 25|changesparison
P09673037A0358 |103 131|reticulin fiber impregnationpects of neonatal hyperbilir
P09673436A0898 |69 85|sodium excretionse P00008171T000
P09673436A0898 |212 213|nd
P09673436A0898 |56 65|increases 5-nucleo
P09673436A0898 |28 40|ANP infusionth alkaline 
P09673436A0898 |209 210|%h
P09673436A0898 |87 91|FENAPhar
P09673436A0898 |22 26|ratsson 
P09673436A0898 |159 167|infusionn CSF [H
P09673436A0898 |127 128|%i
P09673436A0898 |232 242|hypocapniaats are no
P09673436A0898 |130 131|Pr
P09673436A0898 |140 141|n 
P09673436A0898 |169 173|FENA3-] 
P09675154A0690 |84 93|mutations00 Pharma
P09675154A0690 |199 216|missense mutationCSF PCO2 the data
P09675154A0690 |125 134|insertionrbilirubi
P09675154A0690 |40 48|familiesphosphat
P09675154A0690 |218 223|W118Rf K-d
P09675154A0690 |162 191|consensus splicing donor siteSF [HCO3-] is shown as a func
P09675154A0690 |54 60|GSD-Ibnd 5-n
P09675154A0690 |138 152|point mutationa. P00008997A0
P09675896A0959 |0 7|RemovalP000016
P09675896A0959 |15 30|carboxyl regionComparison with
P09675896A0959 |64 74|activationotidase P0
P09676349A0000 |3 10|Level A001606T
P09676349A0000 |73 93|release theophylline00008171T0000 Pharma
P09676349A0000 |121 134|Bronchoretardhyperbilirubi
P09676349A0000 |95 98|CASlog
P09676349A0000 |29 40|correlationh alkaline 
P09676349A0000 |108 119|preparation of neonata
P09676349A0000 |142 155|investigation00008997A0472
P09676419A0158 |0 6|METHODP00001
P09676419A0158 |86 91|study Phar
P09676419A0158 |320 344|solid-phase immunoassaysater slope (1.21 +/- 0.2
P09676419A0158 |23 31|childrenon with 
P09676419A0158 |219 226|CAP SX1 K-depl
P09676419A0158 |126 133|patientbilirub
P09676419A0158 |57 62|years5-nuc
P09676419A0158 |208 217|allergensthe data 
P09676419A0158 |108 122|questionnaires of neonatal h
P09676419A0158 |280 283|IgEtro
P09676419A0158 |44 50|monthsphatas
P09676419A0158 |256 278|serum immunoglobulin Eced when compared to c
P09676419A0158 |168 183|screening testsO3-] is shown a
P09676419A0158 |233 246|determinationts are no lon
P09676419A0158 |138 154|family historiesa. P00008997A047
P09676419A0158 |307 316|serum IgEificantly
P09677330A0584 |69 73|UCR2se P
P09677330A0584 |147 151|unit997A
P09677330A0584 |29 46|linker region LR1h alkaline phosph
P09677330A0584 |60 64|UCR1ucle
P09677330A0584 |125 129|UCR2rbil
P09677330A0584 |108 111|LR2 of
P09677330A0584 |176 180|exonshow
P09677330A0584 |93 98|exonscolog
P09677405A0856 |0 18|Pol32Delta strainsP00001606T0076 Com
P09677405A0856 |28 40|antimutatorsth alkaline 
P09677405A0856 |78 89|mutagenesis171T0000 Ph
P09677410A1059 |119 136|HBV core promoterl hyperbilirubine
P09677410A1059 |44 47|p53pha
P09677410A1059 |176 179|HBxsho
P09677410A1059 |160 168|enhancer CSF [HC
P09677410A1059 |79 82|HBV71T
P09677410A1059 |12 16|time76 C
P09677410A1059 |66 70|roleidas
P09677410A1059 |22 29|resultsson wit
P09677410A1059 |234 237|p53s a
P09677410A1059 |222 230|functiondepleted
P09678579A0768 |64 77|blot analysisotidase P0000
P09678579A0768 |43 53|AtCP1 genesphatases 
P09678579A0768 |8 15|insight6T0076 
P09678579A0768 |25 35|expression with alka
P09678837A0736 |84 96|methacholine00 Pharmacol
P09678837A0736 |15 20|studyCompa
P09678837A0736 |125 133|rhinitisrbilirub
P09678837A0736 |195 212|blood eosinophils of CSF PCO2 the 
P09678837A0736 |181 190|serum IgE as a fun
P09678837A0736 |60 78|bronchoprovocationucleotidase P00008
P09678837A0736 |4 7|aim016
P09678837A0736 |42 56|responsivenessosphatases and
P09678837A0736 |156 169|pollen seasonWhen CSF [HCO
P09678837A0736 |100 108|subjects aspects
P09679066A1352 |100 109|pre-mRNAs aspects 
P09679066A1352 |57 64|protein5-nucle
P09679066A1352 |79 87|splicing71T0000 
P09679066A1352 |6 13|results606T007
P09679066A1352 |32 45|demonstrationlkaline phosp
P09679750A0304 |137 143|NSAIDsia. P0
P09679750A0304 |165 174|attention[HCO3-] i
P09679750A0304 |33 64|prostate cancer chemopreventionkaline phosphatases and 5-nucle
P09679750A0304 |109 135|cyclo-oxygenase inhibitorsof neonatal hyperbilirubin
P09679750A0304 |19 28|potentialarison wi
P09679750A0304 |102 107|drugsspect
P09680994A0169 |186 207|P. hybrida orthologue function of CSF PCO2
P09680994A0169 |148 169|intron/exon structure97A0472 When CSF [HCO
P09680994A0169 |96 103|proteinogic as
P09680994A0169 |23 32|isolationon with a
P09680994A0169 |126 143|sequence homologybilirubinemia. P0
P09680994A0169 |215 230|Z. mays r genesa of K-depleted
P09680994A0169 |38 53|P. hybrida genee phosphatases 
P09680994A0169 |5 10|study1606T
P09680994A0169 |55 60|jaf13d 5-n
P09680994A0169 |117 122|basistal h
P09681822A0520 |70 77|tissuese P0000
P09681822A0520 |10 29|c-erbB3 transcripts0076 Comparison wit
P09682897A0218 |18 23|yearsparis
P09682897A0218 |58 76|electrocardiograms-nucleotidase P000
P09682897A0218 |104 115|QRS changesects of neo
P09682897A0218 |142 156|injury pattern00008997A0472 
P09682897A0218 |38 44|searche phos
P09683576A0542 |21 34|cleavage siteison with alk
P09683576A0542 |61 76|protease domaincleotidase P000
P09683576A0542 |106 116|processingts of neon
P09683576A0542 |78 93|Gln2526-Asp2527171T0000 Pharma
P09685021A0127 |0 7|METHODSP000016
P09685021A0127 |244 253|membranesonger dis
P09685021A0127 |182 188|micromas a f
P09685021A0127 |88 113|model lenticule materialsharmacologic aspects of n
P09685021A0127 |349 355|cornea P0001
P09685021A0127 |287 297|collagen Iut still h
P09685021A0127 |194 211|surface roughnessn of CSF PCO2 the
P09685021A0127 |326 332|pocketlope (
P09685021A0127 |155 161|microm When 
P09685021A0127 |365 369|catsFlur
P09685021A0127 |126 145|membrane pore sizesbilirubinemia. P000
P09685021A0127 |419 436|epithelializationug with the optim
P09685021A0127 |234 239|orders are
P09685021A0127 |278 283|layerontro
P09685021A0127 |471 481|attachment being 15 
P09685021A0127 |9 44|Millipore ultrafiltration membranesT0076 Comparison with alkaline phos
P09685021A0127 |64 74|pore sizesotidase P0
P09685021A0127 |445 456|persistenceor use in g
P09685021A0127 |168 174|micromO3-] i
P09685021A0127 |409 415|extentypnoti
P09685226A0000 |34 42|agonistsaline ph
P09685226A0000 |90 103|transcriptionrmacologic as
P09685226A0000 |161 165|geneCSF 
P09685226A0000 |12 22|calcitonin76 Compari
P09685226A0000 |62 74|cAMP pathwayleotidase P0
P09685226A0000 |194 215|lung cancer cell linen of CSF PCO2 the dat
P09685226A0000 |217 220|BENof 
P09685226A0000 |145 152|protein08997A0
P09685226A0000 |4 8|role0160
P09685226A0000 |154 159|PTHrP2 Whe
P09685346A0419 |19 24|Pitx2ariso
P09685346A0419 |95 105|activationlogic aspe
P09685346A0419 |135 154|transfection assaysemia. P00008997A047
P09685346A0419 |37 56|homeodomain proteinne phosphatases and
P09685346A0419 |58 63|Pit-1-nucl
P09685346A0419 |113 131|prolactin promotereonatal hyperbilir
P09685346A0419 |4 15|combination01606T0076 
P09686344T0000 |42 79|ornithine transcarbamylase deficiencyosphatases and 5-nucleotidase P000081
P09686344T0000 |30 38|spectrum alkalin
P09686603A0124 |170 192|TCR beta gene segments-] is shown as a funct
P09686603A0124 |45 53|elementshatases 
P09686603A0124 |26 30|rolewith
P09686603A0124 |74 84|mechanisms0008171T00
P09686603A0124 |147 166|germline expression997A0472 When CSF [
P09686603A0124 |126 134|promoterbilirubi
P09687498A1173 |70 76|v-erbAe P000
P09687498A1173 |4 11|results01606T0
P09687498A1173 |83 91|oncogene000 Phar
P09687498A1173 |37 41|rolene p
P09687498A1173 |107 113|c-ErbAs of n
P09687498A1173 |190 204|overexpressionction of CSF P
P09687498A1173 |115 122|TRalphanatal h
P09687498A1173 |155 167|conformation When CSF [H
P09687498A1173 |49 58|mutationsses and 5
P09687511A1091 |0 14|DownregulationP00001606T0076
P09687511A1091 |129 145|colony formationirubinemia. P000
P09687511A1091 |229 238|potentiald rats ar
P09687511A1091 |147 158|restoration997A0472 Wh
P09687511A1091 |88 99|suppressionharmacologi
P09687511A1091 |55 67|32Dcl3 cellsd 5-nucleoti
P09687511A1091 |189 204|differentiationnction of CSF P
P09687511A1091 |18 32|FUS expressionparison with a
P09687511A1091 |103 109|growthpects 
P09687514A0521 |49 69|transcription systemses and 5-nucleotida
P09687514A0521 |106 114|proteinsts of ne
P09687514A0521 |147 156|complexes997A0472 
P09687514A0521 |8 13|study6T007
P09688264A1029 |5 14|repressor1606T0076
P09688264A1029 |46 49|spiata
P09688264A1029 |106 121|rat hepatocytests of neonatal 
P09688264A1029 |57 76|UTR silencer action5-nucleotidase P000
P09689047A0253 |2 14|prerequisite0001606T0076
P09689047A0253 |109 122|monophosphateof neonatal h
P09689047A0253 |148 158|CMP-Neu5Ac97A0472 Wh
P09689047A0253 |192 216|Golgi sialyltransferasesion of CSF PCO2 the data
P09689047A0253 |47 62|glycoconjugatestases and 5-nuc
P09689047A0253 |142 146|acid0000
P09689047A0253 |178 187|substrateown as a 
P09689047A0253 |23 32|synthesison with a
P09689047A0253 |80 105|sugar-nucleotide cytidine1T0000 Pharmacologic aspe
P09689919A1192 |17 26|PEDF cDNAmparison 
P09689919A1192 |81 98|PEDF glycoproteinT0000 Pharmacolog
P09691031A1050 |113 121|pathwayseonatal 
P09691031A1050 |13 18|model6 Com
P09691031A1050 |61 70|targetingcleotidas
P09691031A1050 |28 41|Sro7 functionth alkaline p
P09691031A1050 |78 93|myosin proteins171T0000 Pharma
P09691037A0355 |69 78|N. crassase P00008
P09691037A0355 |9 18|sequencesT0076 Com
P09691037A0355 |89 107|Neurospora speciesarmacologic aspect
P09691037A0355 |58 65|strains-nucleo
P09691037A0355 |35 44|insertionline phos
P09692965A0904 |71 79|patterns P000081
P09692965A0904 |104 110|burialects o
P09692965A0904 |91 99|exposuremacologi
P09692965A0904 |37 44|helicesne phos
P09692965A0904 |5 13|cysteine1606T007
P09693035T0000 |138 148|assignmenta. P000089
P09693035T0000 |110 120|expressionf neonatal
P09693035T0000 |72 94|Caenorhabditis elegansP00008171T0000 Pharmac
P09693035T0000 |96 108|cDNA cloningogic aspects
P09693035T0000 |6 10|ULK1606T
P09693035T0000 |20 43|serine/threonine kinaserison with alkaline pho
P09693035T0000 |55 68|UNC-51 kinased 5-nucleotid
P09693134A0782 |259 269|identities when comp
P09693134A0782 |183 201|column neuroblastss a function of CS
P09693134A0782 |30 37|markers alkali
P09693134A0782 |92 103|neuroblastsacologic as
P09693134A0782 |147 150|DER997
P09693134A0782 |79 86|domains71T0000
P09693134A0782 |226 244|column neuroblastseted rats are no l
P09693134A0782 |294 302|positionl have a
P09693134A0782 |158 165|embryosen CSF 
P09693134A0782 |322 333|neuroblastser slope (1
P09693134A0782 |118 129|neuroblastsal hyperbil
P09693306T0000 |35 43|patientsline pho
P09693306T0000 |60 71|schwannomasucleotidase
P09693306T0000 |21 31|potentialsison with 
P09694034A0713 |19 28|clozapinearison wi
P09694034A0713 |225 230|drugsleted
P09694034A0713 |45 47|LIha
P09694034A0713 |6 13|results606T007
P09694034A0713 |163 173|test modelF [HCO3-] 
P09694034A0713 |146 151|value8997A
P09694034A0713 |109 115|actionof neo
P09694034A0713 |101 105|modeaspe
P09694034A0713 |64 78|antipsychoticsotidase P00008
P09694034A0713 |155 157|LI W
P09694034A0713 |206 215|potential2 the dat
P09694514A0000 |137 155|C3a peptide ligandia. P00008997A0472
P09694514A0000 |183 192|responsess a funct
P09694514A0000 |74 83|G-protein0008171T0
P09694514A0000 |246 264|muscle contractionger displaced when
P09694514A0000 |92 116|chemoattractant receptoracologic aspects of neon
P09694514A0000 |43 47|C3aRspha
P09694514A0000 |227 237|mast cellsted rats a
P09694514A0000 |296 307|eosinophilshave a sign
P09694514A0000 |283 292|migrationls but st
P09694514A0000 |4 41|complement C3a anaphylatoxin receptor01606T0076 Comparison with alkaline p
P09694514A0000 |204 221|histamine releaseCO2 the data of K
P09694599A1355 |0 11|CONCLUSIONSP00001606T0
P09694599A1355 |95 103|cystitislogic as
P09694599A1355 |120 129|hematuria hyperbil
P09694599A1355 |53 61|IL-1betaand 5-nu
P09694599A1355 |25 35|elevations with alka
P09694599A1355 |39 48|IL-1alpha phosphat
P09694599A1355 |71 79|patients P000081
P09694725A0500 |102 129|gamma interferon activationspects of neonatal hyperbil
P09694725A0500 |76 81|LILRE08171
P09694725A0500 |11 17|assays076 Co
P09694725A0500 |83 98|oligonucleotide000 Pharmacolog
P09694725A0500 |67 74|elementdase P0
P09694725A0500 |140 144|site P00
P09694725A0500 |174 191|IL-1beta promoters shown as a func
P09694860A0498 |123 130|proteinperbili
P09694860A0498 |75 81|region008171
P09694860A0498 |15 21|regionCompar
P09694860A0498 |44 50|domainphatas
P09694860A0498 |91 99|homologymacologi
P09694869A0932 |136 151|cytokine effectmia. P00008997A
P09694869A0932 |20 27|supportrison w
P09694869A0932 |114 119|Stat3onata
P09694869A0932 |294 309|cytokine effectl have a signif
P09694869A0932 |82 94|p21 promoter0000 Pharmac
P09694869A0932 |159 171|p21 promotern CSF [HCO3-
P09694869A0932 |213 221|mutationata of K
P09694869A0932 |43 47|rolespha
P09694869A0932 |229 250|STAT response elementd rats are no longer 
P09694869A0932 |258 266|promoterd when c
P09694869A0932 |51 56|STATss and
P09694869A0932 |201 206|Stat3F PCO
P09694869A0932 |96 110|overexpressionogic aspects o
P09694869A0932 |64 74|activationotidase P0
P09694869A0932 |3 11|addition001606T0
P09694897T0000 |69 71|U1se
P09694897T0000 |151 156|motif0472 
P09694897T0000 |26 62|ribonucleoprotein C protein tetramerwith alkaline phosphatases and 5-nuc
P09694897T0000 |73 75|U200
P09694897T0000 |108 135|affinity RNA binding domain of neonatal hyperbilirubin
P09694897T0000 |81 90|U6 snRNAsT0000 Pha
P09695194T0000 |32 43|proportionslkaline pho
P09695194T0000 |58 62|data-nuc
P09695194T0000 |7 17|comparison06T0076 Co
P09696164A0000 |33 42|detectionkaline ph
P09696164A0000 |76 80|SIDS0817
P09696164A0000 |53 74|infant death syndromeand 5-nucleotidase P0
P09696164A0000 |18 24|systempariso
P09696819A0450 |98 107|formationic aspect
P09696819A0450 |135 137|ERem
P09696819A0450 |44 46|gEph
P09696819A0450 |14 21|mutants Compar
P09696819A0450 |75 88|vTF7-3 system008171T0000 P
P09696819A0450 |148 157|transport97A0472 W
P09696819A0450 |183 190|complexs a fun
P09696819A0450 |124 133|reticulumerbilirub
P09696819A0450 |54 62|vacciniand 5-nuc
P09698457A0778 |35 50|Cux/CDPDeltaCR1line phosphatas
P09698457A0778 |95 104|vibrissaelogic asp
P09698457A0778 |62 71|phenotypeleotidase
P09698457A0778 |114 118|haironat
P09698457A0778 |18 22|micepari
P09698457A0976 |239 243|date no 
P09698457A0976 |166 174|affinityHCO3-] i
P09698457A0976 |213 216|DNAata
P09698457A0976 |128 135|proteinlirubin
P09698457A0976 |95 114|tissue distributionlogic aspects of ne
P09698457A0976 |11 18|protein076 Com
P09698457A0976 |262 272|cut repeaten compare
P09698457A0976 |277 284|bindingcontrol
P09698457A0976 |33 39|levelskaline
P09698457A0976 |185 201|target sequencesa function of CS
P09698512A0296 |0 7|METHODSP000016
P09698512A0296 |63 84|transplant recipientseotidase P00008171T00
P09700644T0000 |4 12|spectrum01606T00
P09700644T0000 |31 50|brain abnormalitiesalkaline phosphatas
P09700644T0000 |58 69|measurement-nucleotida
P09700644T0000 |92 102|correlatesacologic a
P09701609A0116 |86 92|PhLOP2 Pharm
P09701609A0116 |75 81|PhLOP1008171
P09701609A0116 |108 115|ability of neo
P09701609A0116 |133 143|Gbetagammainemia. P0
P09701609A0116 |58 73|orphan proteins-nucleotidase P
P09701609A0116 |4 14|laboratory01606T0076
P09701616A0108 |100 103|DNA as
P09701616A0108 |111 140|sand shrimp Metapenaeus ensis neonatal hyperbilirubinemia.
P09701616A0108 |77 85|eyestalk8171T000
P09701616A0108 |8 47|transcriptase-polymerase chain reaction6T0076 Comparison with alkaline phospha
P09701616A0108 |49 55|RT-PCRses an
P09701821A1108 |70 80|proportione P0000817
P09701821A1108 |13 26|transcription6 Comparison 
P09701821A1108 |135 141|levelsemia. 
P09701821A1108 |97 107|osmolaritygic aspect
P09701821A1108 |43 51|opuE P-1sphatase
P09701821A1108 |53 60|sigma Aand 5-n
P09701821A1108 |3 11|contrast001606T0
P09701895A0119 |85 89|year0 Ph
P09701895A0119 |105 115|prevalencects of neo
P09701895A0119 |22 30|childrenson with
P09701895A0119 |131 138|anaemiaubinemi
P09701895A0119 |38 49|months-3 yre phosphata
P09701895A0119 |71 77|period P0000
P09703021A0000 |259 263|step whe
P09703021A0000 |124 138|sclerotizationerbilirubinemi
P09703021A0000 |12 47|arylalkylamine N-acetyltransferases76 Comparison with alkaline phospha
P09703021A0000 |164 181|neurotransmitters [HCO3-] is shown
P09703021A0000 |203 211|functionPCO2 the
P09703021A0000 |267 289|melatonin biosynthesismpared to controls but
P09703021A0000 |228 237|catalysised rats a
P09703021A0000 |215 226|vertebratesa of K-depl
P09703021A0000 |3 10|insects001606T
P09703021A0000 |140 152|inactivation P00008997A0
P09703021A0000 |49 55|AANATsses an
P09703021A0000 |103 112|processespects of 
P09703213A0280 |71 81|depression P00008171
P09703213A0280 |24 41|D1 antagonist SCHn with alkaline p
P09703213A0280 |112 124|facilitationneonatal hyp
P09703213A0280 |3 14|experiments001606T0076
P09703276A2346 |68 83|carcinogenicityase P00008171T0
P09703276A2346 |29 42|hydroquinonesh alkaline ph
P09703276A2346 |6 13|results606T007
P09703276A2346 |51 63|mutagenicitys and 5-nucl
P09703816A0139 |0 5|IA-CTP0000
P09703816A0139 |73 84|shot method00008171T00
P09703816A0139 |31 42|doxorubicinalkaline ph
P09703816A0139 |46 48|mgat
P09703816A0139 |107 121|iliac arteriess of neonatal 
P09703816A0139 |11 20|cisplatin076 Compa
P09703816A0139 |24 26|mgn 
P09704006A0224 |0 10|Arnt3 mRNAP00001606T
P09704006A0224 |44 50|musclephatas
P09704006A0224 |74 83|P19 cells0008171T0
P09704006A0224 |61 68|embryoscleotid
P09704006A0224 |28 33|brainth al
P09704006A0224 |106 110|acidts o
P09704296T0000 |34 41|purpuraaline p
P09704296T0000 |75 91|immunoglobulin E008171T0000 Phar
P09704296T0000 |60 71|serum levelucleotidase
P09704296T0000 |123 130|patientperbili
P09704296T0000 |96 108|eosinophiliaogic aspects
P09704569T0000 |38 46|locatione phosph
P09704569T0000 |12 21|structure76 Compar
P09704569T0000 |60 79|TR2 orphan receptorucleotidase P000081
P09704569T0000 |97 125|steroid receptor superfamilygic aspects of neonatal hype
P09704569T0000 |83 89|member000 Ph
P09704857T0000 |0 11|CorrelationP00001606T0
P09704857T0000 |60 68|patientsucleotid
P09704857T0000 |15 29|skin disordersComparison wit
P09704857T0000 |74 82|HIV/AIDS0008171T
P09704857T0000 |35 49|CD4 lymphocyteline phosphata
P09704927A0479 |84 102|heterodimerization00 Pharmacologic a
P09704927A0479 |25 33|homology with al
P09704927A0479 |39 43|E2Fs pho
P09704927A0479 |6 12|shares606T00
P09704927A0479 |114 125|box domainsonatal hype
P09704927A0479 |71 82|DNA binding P00008171T
P09705258A0837 |117 126|insertiontal hyper
P09705258A0837 |151 160|lacZ gene0472 When
P09705258A0837 |95 99|genelogi
P09705258A0837 |78 84|copies171T00
P09705258A0837 |58 63|virus-nucl
P09705258A0837 |4 20|IE13.1 cell line01606T0076 Compa
P09705324A0213 |0 5|DNaseP0000
P09705324A0213 |289 296|rat Std still 
P09705324A0213 |257 259|bped
P09705324A0213 |190 223|thyroid hormone response elementsction of CSF PCO2 the data of K-d
P09705324A0213 |245 255|base pairsnger displ
P09705324A0213 |268 285|promoter sequencepared to controls
P09705324A0213 |78 88|hepatocyte171T0000 P
P09705324A0213 |41 64|mobility shift analyseshosphatases and 5-nucle
P09705324A0213 |107 111|HNF1s of
P09705324A0213 |152 157|C/EBP472 W
P09705324A0213 |97 105|factor-1gic aspe
P09705324A0213 |8 20|footprinting6T0076 Compa
P09705324A0213 |143 150|protein0008997
P09705324A0213 |168 177|consensusO3-] is s
P09705324A1602 |102 119|liver specificityspects of neonata
P09705324A1602 |363 375|interference3 Flurazepam
P09705324A1602 |424 442|DNA-AR interactionth the optimum dos
P09705324A1602 |216 221|OCT-1 of K
P09705324A1602 |157 167|repressionhen CSF [H
P09705324A1602 |23 48|rat Std promoter functionon with alkaline phosphat
P09705324A1602 |321 327|effectter sl
P09705324A1602 |249 258|positions displace
P09705324A1602 |127 139|rat Std geneilirubinemia
P09705324A1602 |389 394|C/EBPto be
P09705324A1602 |193 201|presenceon of CS
P09705324A1602 |226 240|C/EBP elementseted rats are 
P09705324A1602 |379 384|OCT-1s app
P09705324A1602 |284 286|ARs 
P09705324A1602 |76 81|C/EBP08171
P09705324A1602 |12 19|studies76 Comp
P09705324A1602 |67 71|HNF1dase
P09705324A1602 |175 179|gene sho
P09705352A0879 |33 38|Cdc19kalin
P09705352A0879 |46 53|subunitatases 
P09705352A0879 |40 44|Mcm2phos
P09705352A0879 |72 114|minichromosome maintenance protein complexP00008171T0000 Pharmacologic aspects of ne
P09705352A0879 |9 13|Hsk1T007
P09705352A0879 |129 142|fission yeastirubinemia. P
P09705497A0227 |64 99|methyl methanesulfonate sensitivityotidase P00008171T0000 Pharmacologi
P09705497A0227 |159 186|DNA post-replication repairn CSF [HCO3-] is shown as a
P09705497A0227 |107 120|mms2-1 mutants of neonatal
P09705497A0227 |4 19|yeast MMS2 gene01606T0076 Comp
P09705497A0227 |38 45|abilitye phosp
P09705564T0000 |68 72|E1E4ase 
P09705564T0000 |73 86|E5 transcript00008171T0000
P09705564T0000 |47 58|E5A proteintases and 5
P09705564T0000 |24 43|papillomavirus typen with alkaline pho
P09705564T0000 |0 10|ExpressionP00001606T
P09706565A1072 |51 65|immobilizations and 5-nucleo
P09706565A1072 |71 82|atipamezole P00008171T
P09706565A1072 |44 47|minpha
P09706565A1072 |16 19|M/Komp
P09706565A1072 |0 10|AnesthesiaP00001606T
P09706643A0206 |43 50|diseasesphatas
P09706643A0206 |30 35|agent alka
P09707498A0262 |0 21|MK-801 administrationP00001606T0076 Compar
P09707498A0262 |45 53|responsehatases 
P09707498A0262 |57 72|seizure latency5-nucleotidase 
P09707577A1047 |17 29|distributionmparison wit
P09707577A1047 |43 50|markerssphatas
P09707577A1047 |3 11|contrast001606T0
P09708450A0648 |0 8|ToxicityP0000160
P09708450A0648 |107 114|controls of ne
P09708450A0648 |138 145|regimena. P000
P09708450A0648 |66 77|study groupidase P0000
P09708450A0648 |32 38|periodlkalin
P09708450A0648 |154 159|G-CSF2 Whe
P09708565A0000 |275 292|commercializationo controls but st
P09708565A0000 |152 170|radioimmunotherapy472 When CSF [HCO3
P09708565A0000 |252 270|multicenter trialssplaced when compa
P09708565A0000 |20 27|articlerison w
P09708565A0000 |83 93|antibodies000 Pharma
P09708565A0000 |95 108|radionuclideslogic aspects
P09708565A0000 |122 129|methodsyperbil
P09708565A0000 |233 243|study sitets are no 
P09708565A0000 |172 175|RIT is
P09708565A0000 |46 53|factorsatases 
P09708565A0000 |195 203|lymphoma of CSF 
P09708565A0000 |70 79|selectione P000081
P09708565A0000 |4 11|purpose01606T0
P09708565A0000 |205 208|NHLO2 
P09708565A0000 |137 148|developmentia. P000089
P09710131A0374 |50 59|distanceses and 5-
P09710131A0374 |61 89|image intensifier tube modescleotidase P00008171T0000 Ph
P09710131A0374 |94 115|laser printer formatsologic aspects of neo
P09710131A0374 |5 12|methods1606T00
P09710582A0535 |138 145|PD98059a. P000
P09710582A0535 |66 88|protein kinase pathwayidase P00008171T0000 P
P09710582A0535 |123 136|MEK inhibitorperbilirubine
P09710582A0535 |14 17|Rho Co
P09710582A0535 |174 187|AP-1 activitys shown as a 
P09710582A0535 |113 116|MEKeon
P09710582A0535 |4 10|effect01606T
P09710582A0535 |21 25|AP-1ison
P09710589A1111 |54 58|R82And 5
P09710589A1111 |46 52|domainatases
P09710589A1111 |29 37|residuesh alkali
P09710589A1111 |14 25|mutagenesis Comparison
P09710589A1111 |60 64|K85Aucle
P09710589A1111 |76 80|V89A0817
P09710589A1111 |94 102|proteinsologic a
P09710589A1111 |142 152|HTLV-1 LTR00008997A0
P09710589A1111 |66 70|K88Aidas
P09710591A0981 |0 9|MutationsP00001606
P09710591A0981 |44 59|serine residuesphatases and 5-
P09710591A0981 |189 199|MAP kinasenction of 
P09710591A0981 |97 111|growth factorsgic aspects of
P09710591A0981 |147 162|transactivation997A0472 When C
P09710591A0981 |167 185|block potentiationCO3-] is shown as 
P09710591A0981 |116 126|MAP kinaseatal hyper
P09710591A0981 |21 31|C terminusison with 
P09710591A0981 |35 40|c-fosline 
P09710591A0981 |69 92|phosphorylation targetsse P00008171T0000 Pharm
P09710599A0310 |154 167|ets-2 protein2 When CSF [H
P09710599A0310 |89 94|ets-2armac
P09710599A0310 |121 122|hh
P09710599A0310 |14 19|cells Comp
P09710599A0310 |21 26|ets-2ison 
P09710599A0310 |140 150|expression P00008997
P09710599A0310 |55 68|response gened 5-nucleotid
P09710599A0310 |33 38|CSF-1kalin
P09710599T0000 |100 108|response aspects
P09710599T0000 |11 21|activation076 Compar
P09710599T0000 |75 96|ets-2 phosphorylation008171T0000 Pharmacol
P09710599T0000 |146 155|signaling8997A0472
P09710599T0000 |131 137|factorubinem
P09710599T0000 |43 62|protein kinases p42sphatases and 5-nuc
P09710599T0000 |67 70|p44das
P09710614T0000 |85 95|regulation0 Pharmaco
P09710614T0000 |65 71|domaintidase
P09710614T0000 |144 169|phosphoinositide 3-kinase008997A0472 When CSF [HCO
P09710614T0000 |130 140|activationrubinemia.
P09710614T0000 |49 52|CD2ses
P09710614T0000 |33 41|sequencekaline p
P09710614T0000 |117 125|adhesiontal hype
P09710614T0000 |0 14|IdentificationP00001606T0076
P09710615T0000 |0 5|Vam7pP0000
P09710615T0000 |63 71|functioneotidase
P09710615T0000 |45 61|syntaxin homologhatases and 5-nu
P09710615T0000 |36 41|Vam3pine p
P09710615T0000 |22 30|moleculeson with
P09710615T0000 |99 118|protein traffickingc aspects of neonat
P09710615T0000 |84 89|yeast00 Ph
P09710621A0598 |102 126|Neu juxtamembrane domainspects of neonatal hyper
P09710621A0598 |72 94|cysteine substitutionsP00008171T0000 Pharmac
P09710621A0598 |166 172|seriesHCO3-]
P09710621A0598 |62 68|seriesleotid
P09710621A0598 |176 189|interreceptorshown as a fu
P09710621A0598 |130 135|orderrubin
P09710621A0598 |145 157|dimerization08997A0472 W
P09710621A0598 |20 31|possibilityrison with 
P09710641A0000 |205 226|zeta-crystallin genesO2 the data of K-depl
P09710641A0000 |82 84|HD00
P09710641A0000 |57 63|domain5-nucl
P09710641A0000 |183 189|alphaAs a fu
P09710641A0000 |120 135|eye development hyperbilirubin
P09710641A0000 |41 46|Pax-6hosph
P09710641A0000 |192 198|delta1ion of
P09710641A0000 |86 106|transcription factor Pharmacologic aspec
P09710641A0000 |156 166|activationWhen CSF [
P09710641A0000 |174 180|alphaBs show
P09710641A0000 |234 238|lenss ar
P09710641A0000 |65 67|PDti
P09710641A0000 |69 80|homeodomainse P0000817
P09712037A0470 |0 15|Tctex-1 bindingP00001606T0076 
P09712037A0470 |106 114|sequencets of ne
P09712037A0470 |61 70|integritycleotidas
P09712037A0470 |53 56|Fynand
P09712037A0470 |247 270|lymphocyte Ag receptorser displaced when compa
P09712037A0470 |162 178|Fyn interactionsSF [HCO3-] is sh
P09712037A0470 |78 93|lysine residues171T0000 Pharma
P09712037A0470 |218 235|activation motifsf K-depleted rats
P09712037A0470 |188 202|immunoreceptorunction of CSF
P09712037A0470 |38 49|amino acidse phosphata
P09712037A0470 |237 242|ITAMsre no
P09712297T0000 |85 100|vein thrombosis0 Pharmacologic
P09712297T0000 |66 74|patientsidase P0
P09712297T0000 |113 124|individualseonatal hyp
P09712297T0000 |4 37|prothrombin gene G20210A mutation01606T0076 Comparison with alkali
P09712644T0000 |34 44|GluR2 genealine phos
P09712644T0000 |109 117|elementsof neona
P09712644T0000 |62 72|expressionleotidase 
P09712644T0000 |83 92|promoters000 Pharm
P09712644T0000 |16 26|regulationomparison 
P09712859A1110 |100 109|infection aspects 
P09712859A1110 |15 21|NF-ATpCompar
P09712859A1110 |52 60|enhancer and 5-n
P09712859A1110 |130 143|blood T-cellsrubinemia. P0
P09712859A1110 |36 42|NF-AT4ine ph
P09712859A1110 |4 11|binding01606T0
P09712898A0911 |87 90|GCKPha
P09712898A0911 |31 45|p38 activationalkaline phosp
P09712898A0911 |22 26|SAPKson 
P09712898A0911 |95 98|RIPlog
P09712898A0911 |6 11|TRAF2606T0
P09712898A0911 |70 85|protein kinasese P00008171T000
P09712898T0000 |68 72|SAPKase 
P09712898T0000 |91 97|kinasemacolo
P09712898T0000 |74 77|Jun000
P09712898T0000 |52 66|protein kinase and 5-nucleot
P09712898T0000 |108 111|p38 of
P09712898T0000 |99 102|JNKc a
P09712898T0000 |0 31|Tumor necrosis factor signalingP00001606T0076 Comparison with 
P09712915A0672 |69 80|combinationse P0000817
P09712915A0672 |88 98|activitiesharmacolog
P09712915A0672 |28 36|promoterth alkal
P09712915A0672 |133 136|Sp3ine
P09712915A0672 |106 131|transcription factors Sp1ts of neonatal hyperbilir
P09712915A0672 |142 146|NF-Y0000
P09712915A0672 |4 12|activity01606T00
P09712919A0307 |84 85|s0
P09712919A0307 |7 14|studies06T0076
P09712919A0307 |66 83|signaling pathwayidase P00008171T0
P09712919A0307 |112 127|CREB activationneonatal hyperb
P09712919A0307 |33 39|reportkaline
P09712919A0307 |138 145|T cellsa. P000
P09713584A1193 |0 11|RespondentsP00001606T0
P09713584A1193 |29 43|spouse/partnerh alkaline pho
P09713584A1193 |105 111|peoplects of
P09713584A1193 |89 99|BMI statusarmacologi
P09713584A1193 |129 135|groupsirubin
P09713990T0000 |0 9|IsolationP00001606
P09713990T0000 |45 67|colon cancer cell linehatases and 5-nucleoti
P09713990T0000 |106 128|TP53 expression systemts of neonatal hyperbi
P09713990T0000 |21 37|TP53 target geneison with alkali
P09713996A0262 |119 126|varietyl hyper
P09713996A0262 |92 102|cell linesacologic a
P09713996A0262 |147 153|agents997A04
P09713996A0262 |18 22|MDR1pari
P09713996A0262 |53 60|cancersand 5-n
P09713996A0262 |70 84|patient tumorse P00008171T00
P09713996A0262 |0 14|OverexpressionP00001606T0076
P09713996T0000 |170 178|patients-] is sh
P09713996T0000 |65 79|rearrangementstidase P000081
P09713996T0000 |95 115|drug resistance genelogic aspects of neo
P09713996T0000 |26 42|characterizationwith alkaline ph
P09713996T0000 |155 165|cell lines When CSF 
P09713996T0000 |200 203|ALLSF 
P09713996T0000 |117 136|MDR1/P-glycoproteintal hyperbilirubine
P09713996T0000 |184 188|drug a f
P09714109A0000 |0 10|BACKGROUNDP00001606T
P09714109A0000 |60 74|blood pressureucleotidase P0
P09714109A0000 |107 121|nerve activitys of neonatal 
P09714109A0000 |88 94|muscleharmac
P09714109A0000 |123 126|SNAper
P09714109A0000 |42 49|smokingosphata
P09714109A0785 |85 93|infusion0 Pharma
P09714109A0785 |9 32|blood pressure increaseT0076 Comparison with a
P09714109A0785 |36 44|responseine phos
P09714109A0785 |128 138|muscle SNAlirubinemi
P09714109A0785 |48 55|smokingases an
P09714109A0785 |116 124|increaseatal hyp
P09714835A0345 |222 229|Frickerdeplete
P09714835A0345 |11 17|report076 Co
P09714835A0345 |121 139|carboxypeptidase Ehyperbilirubinemia
P09714835A0345 |151 157|enzyme0472 W
P09714835A0345 |39 42|CPD ph
P09714835A0345 |218 220|L.f 
P09714835A0345 |231 235|L.D.rats
P09714835A0345 |212 216|Songdata
P09714835A0345 |141 144|CPEP00
P09714835A0345 |200 210|duck gp180SF PCO2 th
P09714835A0345 |19 37|carboxypeptidase Darison with alkali
P09714835A0345 |169 184|characteristics3-] is shown as
P09715278A1079 |152 158|manner472 Wh
P09715278A1079 |126 146|G1 cell cycle arrestbilirubinemia. P0000
P09715278A1079 |77 87|maturation8171T0000 
P09715278A1079 |89 96|changesarmacol
P09715278A1079 |22 35|transfectantsson with alka
P09715278A1079 |179 191|NT2/D1 cellswn as a func
P09715278A1079 |113 118|geneseonat
P09715278A1079 |0 12|RA-treatmentP00001606T00
P09715278A1526 |4 18|histopathology01606T0076 Com
P09715278A1526 |107 127|FGF4 over-expressings of neonatal hyperb
P09715278A1526 |135 156|control transfectantsemia. P00008997A0472 
P09715278A1526 |77 93|xenograft tumors8171T0000 Pharma
P09715278A1526 |23 41|neovascularizationon with alkaline p
P09715384A0235 |48 58|treatmentsases and 5
P09715384A0235 |90 97|resultsrmacolo
P09715384A0235 |72 77|J/cm2P0000
P09715384A0235 |12 19|vessels76 Comp
P09715384A0235 |28 36|diameterth alkal
P09715384A0235 |44 46|mmph
P09715384A0235 |146 148|mm89
P09715384A0235 |130 137|vesselsrubinem
P09715384A0235 |161 162|%C
P09715384A0235 |110 111|%f
P09716095T0000 |0 15|Pressure ulcersP00001606T0076 
P09716179A0974 |0 20|RXR-gamma expressionP00001606T0076 Compa
P09716179A0974 |79 84|genes71T00
P09716179A0974 |192 212|cdk2 kinase activityion of CSF PCO2 the 
P09716179A0974 |183 187|cdc2s a 
P09716179A0974 |151 158|p27Kip10472 Wh
P09716179A0974 |217 235|RB phosphorylationof K-depleted rats
P09716179A0974 |42 51|reductionosphatase
P09716179A0974 |55 61|levelsd 5-nu
P09716179A0974 |116 146|kinase inhibitors p21Cip1/WAF1atal hyperbilirubinemia. P0000
P09716183A1036 |0 3|TBPP00
P09716183A1036 |146 172|ERK kinase consensus sites8997A0472 When CSF [HCO3-]
P09716183A1036 |109 130|phosphorylation sitesof neonatal hyperbili
P09716183A1036 |180 183|TBPn a
P09716183A1036 |99 103|ERK2c as
P09716183A1036 |199 205|domainCSF PC
P09716183A1036 |38 46|extractse phosph
P09716183A1036 |50 60|U937 cellses and 5-n
P09716435A1004 |117 135|cortisol elevationtal hyperbilirubin
P09716435A1004 |106 112|vigourts of 
P09716435A1004 |31 42|HS subjectsalkaline ph
P09716435A1004 |75 79|rise0081
P09716435A1004 |95 102|declinelogic a
P09716435A1004 |11 21|CR/PP diet076 Compar
P09716435A1004 |163 173|PR/CP dietF [HCO3-] 
P09716435A1004 |83 93|depression000 Pharma
P09717246A0526 |170 175|day-1-] is
P09717246A0526 |56 69|exposure time 5-nucleotida
P09717246A0526 |149 152|ILC7A0
P09717246A0526 |180 184|ILVFn as
P09717246A0526 |75 89|rate constants008171T0000 Ph
P09717246A0526 |131 143|lipid weightubinemia. P0
P09717246A0526 |10 13|ILC007
P09717246A0526 |18 29|ILVF valuesparison wit
P09717246A0526 |116 121|day-1atal 
P09717835A0941 |69 79|IRS familyse P000081
P09717835A0941 |94 109|Xenopus homologologic aspects 
P09717835A0941 |37 43|xIRS-une pho
P09717835A0941 |125 131|memberrbilir
P09717835A0941 |6 23|sequence analyses606T0076 Comparis
P09717835A0941 |55 61|memberd 5-nu
P09717887A0239 |185 195|predictorsa function
P09717887A0239 |60 67|VO2peakucleoti
P09717887A0239 |199 206|VO2peakCSF PCO
P09717887A0239 |215 225|populationa of K-dep
P09717887A0239 |12 17|study76 Co
P09717887A0239 |91 108|occlusive diseasemacologic aspects
P09717887A0239 |143 155|claudication0008997A0472
P09717887A0239 |110 114|PAODf ne
P09717887A0239 |39 47|equation phospha
P09717887A0239 |116 124|patientsatal hyp
P09718372T0000 |0 8|EvidenceP0000160
P09718372T0000 |40 47|pathwayphospha
P09718372T0000 |105 118|fission yeastcts of neonat
P09718372T0000 |64 70|stressotidas
P09718372T0000 |81 101|Sty1/Spc1 MAP kinaseT0000 Pharmacologic 
P09718671A0000 |16 28|Injury Scaleomparison wi
P09718671A0000 |160 168|patients CSF [HC
P09718671A0000 |62 79|TRISS methodologyleotidase P000081
P09718671A0000 |30 33|AIS al
P09718671A0000 |112 118|systemneonat
P09718671A0000 |127 135|analysisilirubin
P09718671A0000 |36 57|Injury Severity Scaleine phosphatases and 
P09718671A0000 |139 147|injuries. P00008
P09719636A1134 |117 134|H411-X2-H414 pairtal hyperbilirubi
P09719636A1134 |228 232|gp17ed r
P09719636A1134 |198 204|region CSF P
P09719636A1134 |94 111|H382-X2-H385 pairologic aspects of
P09719636A1134 |73 88|histidine pairs00008171T0000 P
P09719636A1134 |42 51|mutationsosphatase
P09719636A1134 |214 224|C terminusta of K-de
P09719636A1134 |143 160|H430-X5-H436 pair0008997A0472 When
P09719636A1134 |5 15|hypothesis1606T0076 
P09721207A0637 |16 24|analysisompariso
P09721207A0637 |123 137|vacillans geneperbilirubinem
P09721207A0637 |31 36|exonsalkal
P09721207A0637 |66 72|regionidase 
P09721207A0637 |83 93|Chromosome000 Pharma
P09721798A1734 |70 83|HCV hepatitise P00008171T0
P09721798A1734 |13 20|percent6 Compa
P09721798A1734 |105 115|recurrencects of neo
P09721798A1734 |24 32|childrenn with a
P09721798A1734 |146 151|death8997A
P09721798A1734 |128 141|liver failurelirubinemia. 
P09721798A1734 |55 65|transplantd 5-nucleo
P09722043A2070 |83 90|enzymes000 Pha
P09722043A2070 |41 49|increasehosphata
P09722043A2070 |14 24|TPN groups Compariso
P09722043A2070 |67 72|liverdase 
P09722043A2070 |53 63|activitiesand 5-nucl
P09722161A3065 |0 10|RegulationP00001606T
P09722161A3065 |45 54|targetinghatases a
P09722161A3065 |72 85|Igf2/Mpr geneP00008171T000
P09722161A3065 |24 30|growthn with
P09722508A0953 |34 48|Galpha11 Q209Laline phosphat
P09722508A0953 |135 143|proteinsemia. P0
P09722508A0953 |60 86|Src family kinase activityucleotidase P00008171T0000
P09722508A0953 |147 160|HEK-293 cells997A0472 When
P09722508A0953 |99 123|tyrosine phosphorylationc aspects of neonatal hy
P09722766A0706 |115 119|ratsnata
P09722766A0706 |79 84|BUP-471T00
P09722766A0706 |4 24|micturition pressure01606T0076 Compariso
P09722766A0706 |64 73|injectionotidase P
P09723896A0000 |34 43|receptorsaline pho
P09723896A0000 |45 49|PPARhata
P09723896A0000 |212 215|RXRdat
P09723896A0000 |197 210|acid receptorf CSF PCO2 th
P09723896A0000 |130 138|elementsrubinemi
P09723896A0000 |60 73|transcriptionucleotidase P
P09723896A0000 |140 144|PPRE P00
P09723896A0000 |97 107|peroxisomegic aspect
P09723896A0000 |154 172|heterodimerization2 When CSF [HCO3-]
P09723896A0000 |0 10|PeroxisomeP00001606T
P09724654A0761 |136 147|recruitmentmia. P00008
P09724654A0761 |62 68|timingleotid
P09724654A0761 |120 126|timing hyper
P09724654A0761 |78 89|recruitment171T0000 Ph
P09724654A0761 |130 133|RPArub
P09724654A0761 |36 43|originsine pho
P09724654A0761 |96 107|Mcm proteinogic aspect
P09724654A1120 |68 75|originsase P00
P09724654A1120 |43 52|Dbf4/Cdc7sphatases
P09724654A1120 |13 21|presence6 Compar
P09724654A1120 |114 117|RPAona
P09724654A1120 |54 58|Mcmsnd 5
P09724654A1120 |32 38|S-CDKslkalin
P09724654A1120 |103 110|loadingpects o
P09724754A0173 |0 8|TyrosineP0000160
P09724754A0173 |24 29|STATsn wit
P09724754A0173 |93 98|genescolog
P09724754A0173 |64 71|nucleusotidase
P09724763T0000 |114 117|DNAona
P09724763T0000 |14 26|substitution Comparison 
P09724763T0000 |30 63|abalone sperm fertilization genes alkaline phosphatases and 5-nucl
P09724763T0000 |88 95|intronsharmaco
P09724763T0000 |72 84|substitutionP00008171T00
P09724772A0840 |0 22|Gel retardation assaysP00001606T0076 Compari
P09724772A0840 |74 95|zia operator-promoter0008171T0000 Pharmaco
P09724772A0840 |47 56|complexestases and
P09724772A0840 |150 164|metal-chelatorA0472 When CSF
P09724772A0840 |133 142|treatmentinemia. P
P09724772A0840 |100 116|ZiaR-DNA binding aspects of neon
P09725292A1473 |0 10|CONCLUSIONP00001606T
P09725292A1473 |97 99|CTgi
P09725292A1473 |80 85|liver1T000
P09725292A1473 |50 58|criteriaes and 5
P09725651A0077 |136 154|Pentium processorsmia. P00008997A047
P09725651A0077 |90 98|versionsrmacolog
P09725651A0077 |44 61|Microsoft Windowsphatases and 5-nu
P09725651A0077 |105 114|computerscts of ne
P09725651A0077 |13 17|RTPS6 Co
P09725651A0077 |67 78|environmentdase P00008
P09725854A1060 |153 160|alleles72 When
P09725854A1060 |164 180|maintainer lines [HCO3-] is show
P09725854A1060 |53 59|actionand 5-
P09725854A1060 |67 72|genesdase 
P09725854A1060 |94 105|differencesologic aspe
P09725854A1060 |227 255|urf209 processing activitiested rats are no longer displ
P09725854A1060 |216 222|orf107 of K-
P09725854A1060 |188 198|capabilityunction of
P09725854A1060 |19 29|similarityarison wit
P09725854A1060 |118 136|IS1112C Rf3 alleleal hyperbilirubine
P09726201T0000 |0 5|JCAHOP0000
P09726201T0000 |14 28|interpretation Comparison wi
P09726979T0000 |33 49|characterizationkaline phosphata
P09726979T0000 |60 78|sphingosine kinaseucleotidase P00008
P09726979T0000 |10 17|cloning0076 Co
P09726987T0000 |8 45|SPT3-TAFII31-GCN5-L acetylase complex6T0076 Comparison with alkaline phosp
P09726987T0000 |60 84|transcription factor IIDucleotidase P00008171T00
P09726988A0275 |0 6|OleateP00001
P09726988A0275 |28 34|levelsth alk
P09726988A0275 |38 50|M-CPT I mRNAe phosphatas
P09726991T0000 |0 7|MappingP000016
P09726991T0000 |15 33|DNA binding domainComparison with al
P09726991T0000 |59 84|transcription factor Mac1nucleotidase P00008171T00
P09727045A0817 |136 144|presencemia. P00
P09727045A0817 |157 170|AR N terminushen CSF [HCO3
P09727045A0817 |40 50|activationphosphatas
P09727045A0817 |10 19|mechanism0076 Comp
P09727045A0817 |175 196|ligand binding domain shown as a function 
P09727045A0817 |55 66|cooperationd 5-nucleot
P09727045A0817 |101 105|HREsaspe
P09727045A0817 |70 79|receptorse P000081
P09727046A0000 |189 192|Lamnct
P09727046A0000 |123 127|siteperb
P09727046A0000 |183 186|LCRs a
P09727046A0000 |149 181|beta-globin locus control region7A0472 When CSF [HCO3-] is shown
P09727046A0000 |194 196|L.n 
P09727046A0000 |131 134|HS2ubi
P09727046A0000 |94 100|regionologic
P09727046A0000 |43 50|proteinsphatas
P09727046A0000 |52 58|HS2NF5 and 5
P09727046A0784 |100 104|TAL1 asp
P09727046A0784 |89 94|NF-E2armac
P09727046A0784 |62 72|regulatorsleotidase 
P09727046A0784 |21 24|HS2iso
P09727046A0784 |4 13|CBF1 site01606T007
P09727046A0784 |38 43|sitese pho
P09727046A0784 |81 87|GATA-1T0000 
P09729481A0000 |152 169|Sp1 binding sites472 When CSF [HCO
P09729481A0000 |179 203|transcription start sitewn as a function of CSF 
P09729481A0000 |125 134|sequencesrbilirubi
P09729481A0000 |4 47|rat branched-chain-2-oxo-acid dehydrogenase01606T0076 Comparison with alkaline phospha
P09729481A0000 |99 107|promoterc aspect
P09729481A0000 |55 66|kinase mRNAd 5-nucleot
P09729481A0000 |49 53|BCODses 
P09729481A1177 |0 15|Co-transfectionP00001606T0076 
P09729481A1177 |146 152|kinase8997A0
P09729481A1177 |123 126|Sp1per
P09729481A1177 |209 213|sitehe d
P09729481A1177 |225 231|regionleted 
P09729481A1177 |93 108|Schneider cellscologic aspects
P09729481A1177 |58 76|promoter construct-nucleotidase P000
P09729481A1177 |159 176|promoter activityn CSF [HCO3-] is 
P09729481A1177 |23 45|Sp1 expression plasmidon with alkaline phosp
P09730413A0642 |187 194|cancersfunctio
P09730413A0642 |11 25|investigations076 Comparison
P09730413A0642 |62 66|roleleot
P09730413A0642 |80 89|treatment1T0000 Ph
P09730413A0642 |147 163|treatment option997A0472 When CS
P09730413A0642 |115 126|TME surgerynatal hyper
P09730413A0642 |168 179|Stage T1-T3O3-] is sho
P09731354A0963 |17 26|degrees Cmparison 
P09731354A0963 |43 58|surface densitysphatases and 5
P09731354A0963 |62 72|NH2 groupsleotidase 
P09731354A0963 |142 144|hr00
P09731354A0963 |97 99|hrgi
P09731354A0963 |83 90|maximum000 Pha
P09731354A0963 |33 34|%k
P09731513A1090 |152 162|HTLV-I Tax472 When C
P09731513A1090 |47 58|cooperationtases and 5
P09731513A1090 |120 135|transactivation hyperbilirubin
P09731513A1090 |22 29|resultsson wit
P09731513A1090 |62 93|transcription factors NF-kappaBleotidase P00008171T0000 Pharma
P09731513A1090 |98 102|AP-1ic a
P09731513A1090 |139 148|IL-8 gene. P000089
P09731704A0000 |100 108|estrogen aspects
P09731704A0000 |142 166|U2-OS osteosarcoma cells00008997A0472 When CSF [
P09731704A0000 |110 112|E2f 
P09731704A0000 |123 138|gene activationperbilirubinemi
P09731704A0000 |89 96|isoformarmacol
P09731704A0000 |5 10|study1606T
P09731704A0000 |36 43|effectsine pho
P09731704A0000 |80 87|ERalpha1T0000 
P09731704A0000 |55 78|estrogen receptor-alphad 5-nucleotidase P00008
P09731704A1472 |85 93|OS cells0 Pharma
P09731704A1472 |76 83|ERalpha08171T0
P09731704A1472 |27 34|amountsith alk
P09731704A1472 |106 118|potentiationts of neonat
P09731704A1472 |185 191|mannera func
P09731704A1472 |38 69|delta5ERalpha expression vectore phosphatases and 5-nucleotida
P09731704A1472 |136 151|ERELuc activitymia. P00008997A
P09731704A1472 |0 12|TransfectionP00001606T00
P09731705A2126 |0 7|StudiesP000016
P09731705A2126 |95 101|VDR-TRlogic 
P09731705A2126 |63 71|evidenceeotidase
P09731705A2126 |18 23|yeastparis
P09731705A2126 |80 89|formation1T0000 Ph
P09731705A2126 |35 41|systemline p
P09731705A2126 |118 129|interactional hyperbil
P09733493A0493 |138 146|solutiona. P0000
P09733493A0493 |90 107|hydroxyl radicalsrmacologic aspect
P09733493A0493 |58 67|melatonin-nucleoti
P09733493A0493 |46 56|standpointatases and
P09733493A0493 |4 11|results01606T0
P09733493A0493 |116 122|vacuumatal h
P09733647A1960 |70 76|B-loope P000
P09733647A1960 |58 62|part-nuc
P09733647A1960 |148 153|algae97A04
P09733647A1960 |104 111|varietyects of
P09733647A1960 |15 50|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-PheComparison with alkaline phosphatas
P09733647A1960 |5 13|sequence1606T007
P09733647A1960 |158 172|archeabacteriaen CSF [HCO3-]
P09733647A1960 |115 124|organismsnatal hyp
P09733647A1960 |138 146|bacteriaa. P0000
P09733794A1323 |34 39|Bcl-2aline
P09733794A1323 |57 65|proteins5-nucleo
P09733794A1323 |91 98|controlmacolog
P09733794A1323 |74 77|Bax000
P09733794A1323 |120 125|cells hype
P09733794A1323 |142 151|treatment00008997A
P09733794A1323 |67 72|Bcl-xdase 
P09733794A1323 |23 30|changeson with
P09733794A1323 |157 159|Tghe
P09733815T0000 |0 8|TyrosineP0000160
P09733815T0000 |123 136|virus latencyperbilirubine
P09733815T0000 |60 91|protein tyrosine kinase loadingucleotidase P00008171T0000 Phar
P09733815T0000 |23 42|membrane protein 2Aon with alkaline ph
P09733815T0000 |96 106|regulationogic aspec
P09733854A0198 |84 86|LR00
P09733854A0198 |88 91|RNAhar
P09733854A0198 |24 34|transcriptn with alk
P09733854A0198 |52 59|latency and 5-
P09734808A0000 |186 192|phases funct
P09734808A0000 |11 26|test efficiency076 Comparison 
P09734808A0000 |66 90|contrast/color card testidase P00008171T0000 Pha
P09734808A0000 |147 153|number997A04
P09734808A0000 |157 164|stimulihen CSF
P09734808A0000 |116 129|test stimulusatal hyperbil
P09735286A0599 |102 110|presencespects o
P09735286A0599 |82 94|Mu B protein0000 Pharmac
P09735286A0599 |122 132|target DNAyperbiliru
P09735286A0599 |114 117|ATPona
P09735286A0599 |20 28|proteinsrison wi
P09735286A0599 |4 10|defect01606T
P09735286A0599 |69 72|Mn2se 
P09735366A1180 |119 123|EPL1l hy
P09735366A1180 |194 200|humansn of C
P09735366A1180 |151 155|ESTs0472
P09735366A1180 |6 33|homology cloning techniques606T0076 Comparison with al
P09735366A1180 |92 105|yeast proteinacologic aspe
P09735366A1180 |161 183|Caenorhabditis elegansCSF [HCO3-] is shown a
P09735366A1180 |72 74|PcP0
P09735366A1180 |70 71|Ee
P09735366A1180 |185 189|micea fu
P09735366A1180 |84 88|Epc100 P
P09735366A1180 |51 66|mouse homologues and 5-nucleot
P09735368A0636 |102 110|activityspects o
P09735368A0636 |28 31|UTRth 
P09735368A0636 |129 144|K box sequencesirubinemia. P00
P09735368A0636 |78 89|transcripts171T0000 Ph
P09735368A0636 |22 24|m8so
P09735368A0636 |49 61|accumulationses and 5-nu
P09735371A0227 |138 157|homeodomain proteina. P00008997A0472 W
P09735371A0227 |94 105|touch cellsologic aspe
P09735371A0227 |41 60|homeodomain proteinhosphatases and 5-n
P09735371A0227 |76 86|production08171T0000
P09735371A0227 |196 207|touch cellsof CSF PCO2
P09735371A0227 |113 118|mec-3eonat
P09735371A0227 |173 188|differentiationis shown as a f
P09736239A0436 |275 287|accumulationo controls b
P09736239A0436 |298 310|excitotoxinsve a signifi
P09736239A0436 |242 243|% 
P09736239A0436 |210 223|resuscitatione data of K-d
P09736239A0436 |329 342|resuscitatione (1.21 +/- 0
P09736239A0436 |105 113|striatumcts of n
P09736239A0436 |50 59|aspartatees and 5-
P09736239A0436 |159 160|pn
P09736239A0436 |144 157|resuscitation008997A0472 W
P09736239A0436 |231 232|%r
P09736239A0436 |14 34|resuscitation period Comparison with alk
P09736239A0436 |173 174|pi
P09736239A0436 |64 88|glutamate concentrationsotidase P00008171T0000 P
P09736697A0783 |68 72|ERKsase 
P09736697A0783 |95 99|ERK2logi
P09736697A0783 |109 113|JNK1of n
P09736697A0783 |46 52|kinaseatases
P09736697A0783 |77 91|overexpression8171T0000 Phar
P09736697A0783 |125 141|Stat3 activationrbilirubinemia. 
P09736697A0783 |36 40|MEK1ine 
P09736697A0783 |0 10|ExpressionP00001606T
P09736697A1107 |0 4|MEKsP000
P09736697A1107 |256 263|pathwayced whe
P09736697A1107 |184 202|Janus kinases Jak1 a function of CSF
P09736697A1107 |24 39|IL-6 activationn with alkaline
P09736697A1107 |95 99|sitelogi
P09736697A1107 |61 69|mutationcleotida
P09736697A1107 |43 48|Stat3sphat
P09736697A1107 |73 83|serine-72700008171T0
P09736697A1107 |104 126|serine phosphorylationects of neonatal hyper
P09736697A1107 |224 229|Stat3plete
P09736697A1107 |163 168|Stat3F [HC
P09736697A1107 |9 13|ERKsT007
P09736697A1107 |207 211|Jak2 the
P09736697A1107 |139 149|inhibition. P0000899
P09736715A0729 |171 172|K]
P09736715A0729 |94 97|ILKolo
P09736715A0729 |183 186|ILKs a
P09736715A0729 |166 168|PiHC
P09736715A0729 |13 33|phosphatidylinositol6 Comparison with al
P09736715A0729 |125 133|membranerbilirub
P09736715A0729 |40 53|trisphosphatephosphatases 
P09736715A0729 |82 90|activity0000 Pha
P09736715A0729 |115 123|additionnatal hy
P09736770A0351 |68 76|promoterase P000
P09736770A0351 |26 41|binding studieswith alkaline p
P09736770A0351 |89 97|activityarmacolo
P09736770A0351 |60 65|HEFT1ucleo
P09736770A0351 |129 132|Sp1iru
P09736770A0351 |109 115|GC boxof neo
P09736770A0351 |136 139|Sp3mia
P09736770A0351 |0 12|TransfectionP00001606T00
P09737453A0557 |0 6|PlasmaP00001
P09737453A0557 |197 202|ELISAf CSF
P09737453A0557 |92 99|complexacologi
P09737453A0557 |58 65|surgery-nucleo
P09737453A0557 |120 126|factor hyper
P09737453A0557 |190 195|assayction
P09737453A0557 |52 56|days and
P09737453A0557 |48 50|SDas
P09737453A0557 |70 84|IgG antibodiese P00008171T00
P09737921T0000 |0 17|Genome plasticityP00001606T0076 Co
P09737921T0000 |63 76|bacteriophageeotidase P000
P09737921T0000 |131 142|specificityubinemia. P
P09737921T0000 |78 91|recombination171T0000 Phar
P09737921T0000 |110 122|motifs swapsf neonatal h
P09737921T0000 |32 48|tail fiber locuslkaline phosphat
P09738010A0305 |4 16|FAS promoter01606T0076 C
P09738010A0305 |129 147|base pair positionirubinemia. P00008
P09738010A0305 |106 117|E-box motifts of neona
P09738010A0305 |37 44|insulinne phos
P09738010A0305 |66 91|insulin response sequenceidase P00008171T0000 Phar
P09738087A0583 |117 126|illnessestal hyper
P09738087A0583 |26 36|predictorswith alkal
P09738087A0583 |93 103|adjustmentcologic as
P09738087A0583 |40 48|survivalphosphat
P09738087A0583 |67 87|Cox regression modeldase P00008171T0000 
P09738087A0583 |4 10|effect01606T
P09738693T0000 |0 7|EffectsP000016
P09738693T0000 |47 55|survivaltases an
P09738693T0000 |59 65|sepsisnucleo
P09738693T0000 |11 18|rhG-CSF076 Com
P09738693T0000 |22 42|neutrophil functionsson with alkaline ph
P09738693T0000 |83 87|rats000 
P09739401A0000 |0 9|OBJECTIVEP00001606
P09739401A0000 |31 38|articlealkalin
P09739401A0000 |15 22|purposeCompari
P09739401A0000 |52 71|balance instruments and 5-nucleotidase
P09739401A0000 |131 137|clinicubinem
P09739401A0000 |141 157|home environmentP00008997A0472 W
P09739401A0000 |101 106|yearsaspec
P09739913A0194 |0 11|CASE REPORTP00001606T0
P09739913A0194 |77 82|trunk8171T
P09739913A0194 |38 49|skin defecte phosphata
P09741391A0581 |33 41|body boxkaline p
P09741391A0581 |126 131|pausebilir
P09741391A0581 |43 53|PenH unitssphatases 
P09741391A0581 |90 99|breathingrmacologi
P09741391A0581 |140 151|inspiration P00008997A
P09741391A0581 |80 86|effort1T0000
P09741391A0581 |64 69|Pauseotida
P09741391A0581 |156 166|expirationWhen CSF [
P09741783A0000 |0 11|AnastrozoleP00001606T0
P09741783A0000 |148 161|breast cancer97A0472 When 
P09741783A0000 |25 44|aromatase inhibitor with alkaline phos
P09741783A0000 |128 133|womenlirub
P09741783A0000 |67 85|survival advantagedase P00008171T000
P09741783A0000 |101 108|acetateaspects
P09742129A0491 |0 2|W.P0
P09743128A0969 |0 7|MorittaP000016
P09743128A0969 |22 29|Bis-GMAson wit
P09743233A0526 |0 8|MutationP0000160
P09743233A0526 |57 61|site5-nu
P09743233A0526 |23 27|AP-1on w
P09743233A0526 |77 94|promoter activity8171T0000 Pharmac
P09743233A0526 |98 102|SMCsic a
P09743233A0526 |35 48|ets componentline phosphat
P09743720A0268 |0 7|ANIMALSP000016
P09743720A0268 |15 19|dogsComp
P09743720A0268 |46 48|DMat
P09744095A1016 |304 310|mutantignifi
P09744095A1016 |21 28|mutantsison wi
P09744095A1016 |82 93|mutants hy20000 Pharma
P09744095A1016 |247 263|level expressioner displaced whe
P09744095A1016 |95 98|hy3log
P09744095A1016 |215 233|inflorescence stema of K-depleted ra
P09744095A1016 |271 279|CAB geneed to co
P09744095A1016 |160 168|response CSF [HC
P09744095A1016 |195 204|hypocotyl of CSF P
P09744095A1016 |289 296|shy2-1D still 
P09744095A1016 |118 126|phyA-201al hyper
P09744095A1016 |172 180|darkness is show
P09744095A1016 |111 117|fre1-1 neona
P09744095A1016 |36 50|shy2-1D mutantine phosphatas
P09744095A1016 |99 105|phyB-1c aspe
P09745797A0943 |68 78|disruptionase P00008
P09745797A0943 |90 95|tasksrmaco
P09745797A0943 |45 49|painhata
P09745797A0943 |25 41|underpredictions with alkaline p
P09745797A0943 |114 120|impactonatal
P09747651A0000 |0 14|Laser ablationP00001606T0076
P09747651A0000 |80 89|emphysema1T0000 Ph
P09747651A0000 |50 57|measurees and 
P09747873T0000 |19 40|adapter protein GRB10arison with alkaline 
P09747873T0000 |56 63|BCR-ABL 5-nucl
P09748261A0000 |99 104|Faapsc asp
P09748261A0000 |45 65|acyl-CoA synthetaseshatases and 5-nucleo
P09748261A0000 |73 97|acid activation proteins00008171T0000 Pharmacolo
P09748286A0000 |100 104|LIFR asp
P09748286A0000 |106 110|genets o
P09748286A0000 |63 71|leukemiaeotidase
P09748286A0000 |166 179|pair enhancerHCO3-] is sho
P09748286A0000 |193 204|nucleotideson of CSF P
P09748286A0000 |133 149|characterizationinemia. P0000899
P09748286A0000 |41 49|enhancerhosphata
P09748286A0000 |83 98|factor receptor000 Pharmacolog
P09748513X1360 |0 9|CopyrightP00001606
P09748513X1360 |15 36|Elsevier Science B.V.Comparison with alkal
P09748669A0414 |51 53|ADs 
P09748669A0414 |10 14|time0076
P09748669A0414 |58 61|VaD-nu
P09748669A0414 |33 42|dichotomykaline ph
P09749533A0764 |0 5|CloneP0000
P09749533A0764 |15 22|homologCompari
P09749533A0764 |26 34|CONSTANSwith alk
P09749533A0764 |47 51|genetase
P09749533A0764 |80 94|flowering time1T0000 Pharmac
P09749533A0764 |98 109|Arabidopsisic aspects 
P09749988A0000 |0 7|BadcockP000016
P09749988A0000 |86 90|line Pha
P09749988A0000 |115 125|attractionnatal hype
P09749988A0000 |146 151|study8997A
P09749988A0000 |301 310|repulsiona signifi
P09749988A0000 |243 257|repulsion zonelonger displac
P09749988A0000 |12 22|Westheimer76 Compari
P09749988A0000 |46 50|3-11atas
P09749988A0000 |106 111|zonests of
P09749988A0000 |166 173|resultsHCO3-] 
P09749988A0000 |130 139|repulsionrubinemia
P09749988A0000 |228 235|extentsed rats
P09749988A0000 |283 290|contourls but 
P09749988A0000 |32 38|Visionlkalin
P09750325A0000 |205 207|H7O2
P09750325A0000 |74 102|power energization technique0008171T0000 Pharmacologic a
P09750325A0000 |140 151|populations P00008997A
P09750325A0000 |20 45|intensity light emissionsrison with alkaline phosp
P09750325A0000 |213 235|Listeria monocytogenesata of K-depleted rats
P09750325A0000 |104 108|PPETects
P09750325A0000 |4 11|effects01606T0
P09750325A0000 |191 199|serotypetion of 
P09750325A0000 |237 248|serotype 4bre no longe
P09750325A0000 |118 126|survivalal hyper
P09750540A0000 |68 76|symptomsase P000
P09750540A0000 |41 49|syndromehosphata
P09750540A0000 |31 34|MCSalk
P09750540A0000 |109 126|chemical exposureof neonatal hyper
P09750540A0000 |9 29|chemical sensitivityT0076 Comparison wit
P09751061A0000 |85 103|homeodomain family0 Pharmacologic as
P09751061A0000 |271 281|expressioned to cont
P09751061A0000 |107 115|proteinss of neo
P09751061A0000 |294 299|genesl hav
P09751061A0000 |52 64|factor Pit-1 and 5-nucle
P09751061A0000 |196 204|responseof CSF P
P09751061A0000 |208 236|signal-transduction pathwaysthe data of K-depleted rats 
P09751061A0000 |70 77|memberse P0000
P09751061A0000 |155 166|homeostasis When CSF [
P09751061A0000 |139 150|development. P00008997
P09751061A0000 |0 19|POU-domain proteinsP00001606T0076 Comp
P09751114A0967 |21 25|MyoDison
P09751114A0967 |47 52|cellstases
P09751114A0967 |62 64|E1le
P09751114A0967 |88 94|vectorharmac
P09751114A1987 |102 112|conditionsspects of 
P09751114A1987 |56 60|role 5-n
P09751114A1987 |121 132|mitogenesishyperbiliru
P09751114A1987 |82 95|MyoD function0000 Pharmaco
P09751114A1987 |27 33|Thr115ith al
P09751114A1987 |6 13|results606T007
P09751114A1987 |68 78|regulationase P00008
P09751166A1460 |51 59|Sp1 sites and 5-
P09751166A1460 |89 105|TH transcriptionarmacologic aspe
P09751166A1460 |111 119|promoter neonata
P09751166A1460 |43 46|CREsph
P09751166A1460 |18 25|resultsparison
P09751166A1460 |138 144|mannera. P00
P09751458A0845 |0 20|desmethyltrimebutineP00001606T0076 Compa
P09753241A0524 |206 217|% DSS model2 the data 
P09753241A0524 |130 142|colon mucosarubinemia. P
P09753241A0524 |11 23|examinations076 Comparis
P09753241A0524 |107 110|MPOs o
P09753241A0524 |81 105|myeloperoxidase activityT0000 Pharmacologic aspe
P09753241A0524 |54 57|WBCnd 
P09753241A0524 |42 52|blood cellosphatases
P09753241A0524 |198 203|weeks CSF 
P09753241A0524 |175 186|% DSS model shown as a
P09753241A0524 |115 126|homogenatesnatal hyper
P09753241A0524 |71 77|assays P0000
P09753241A0524 |168 172|weekO3-]
P09753730A0881 |0 16|T7 transcriptionP00001606T0076 C
P09753730A0881 |59 65|levelsnucleo
P09753730A0881 |106 109|usets 
P09753730A0881 |82 92|expression0000 Pharm
P09753730A0881 |113 131|promoter mutationseonatal hyperbilir
P09753769A0362 |100 114|PBAN precursor aspects of ne
P09753769A0362 |72 92|amino acid sequencesP00008171T0000 Pharm
P09753769A0362 |28 32|setsth a
P09753769A0362 |36 52|oligonucleotidesine phosphatases
P09753769A0362 |4 11|primers01606T0
P09753774A1642 |0 6|PlantsP00001
P09753774A1642 |108 111|GF3 of
P09753774A1642 |95 106|1,1-nystoselogic aspec
P09753774A1642 |89 92|GF2arm
P09753774A1642 |64 87|oligofructans 1-kestoseotidase P00008171T0000 
P09753774A1642 |38 47|constructe phospha
P09753774A1642 |141 144|GF4P00
P09753774A1642 |117 139|1,1,1-fructosylnystosetal hyperbilirubinemia
P09753774A2246 |101 134|plant fructosyl transferase genesaspects of neonatal hyperbilirubi
P09753774A2246 |13 23|comparison6 Comparis
P09753774A2246 |75 80|1-fft00817
P09753774A2246 |197 218|plant invertase genesf CSF PCO2 the data o
P09753774A2246 |41 61|amino acid sequenceshosphatases and 5-nu
P09753774A2246 |159 178|plant fructan genesn CSF [HCO3-] is sh
P09753774A2246 |65 70|1-ssttidas
P09753775A0734 |49 63|ICK1 inductionses and 5-nucl
P09753775A0734 |9 13|ICK1T007
P09753775A0734 |29 32|ABAh a
P09753775A0734 |76 84|decrease08171T00
P09753775A0734 |98 124|histone H1 kinase activityic aspects of neonatal hyp
P09754571A0169 |49 69|display amplicon 3G1ses and 5-nucleotida
P09754571A0169 |107 127|RAG1 mRNA expressions of neonatal hyperb
P09754571A0169 |9 19|transcriptT0076 Comp
P09754571A0169 |145 155|cell lines08997A0472
P09754571A1257 |48 58|chromosomeases and 5
P09754571A1257 |63 68|10q26eotid
P09754571A1257 |41 44|armhos
P09754571A1257 |4 14|hBRAG gene01606T0076
P09755191A0553 |100 106|chc1-5 aspec
P09755191A0553 |59 65|allelenucleo
P09755191A0553 |125 144|frameshift mutationrbilirubinemia. P00
P09755191A0553 |88 98|chain geneharmacolog
P09755191A0553 |73 81|clathrin00008171
P09755191A0553 |157 160|endhen
P09755191A0553 |178 191|reading frameown as a func
P09755191A0553 |21 27|swa5-1ison w
P09755191A0553 |168 172|CHC1O3-]
P09755199A0373 |49 52|Scmses
P09755199A0373 |121 128|domainshyperbi
P09755199A0373 |60 67|allelesucleoti
P09755199A0373 |95 107|requirementslogic aspect
P09755199A0373 |33 40|lesionskaline 
P09755199A0559 |32 45|Scm mutationslkaline phosp
P09755199A0559 |129 132|Scmiru
P09755199A0559 |93 106|PcG mutationscologic aspec
P09755199A0559 |67 77|mbt repeatdase P0000
P09755199A0559 |138 145|allelesa. P000
P09755478A0366 |119 125|larvael hype
P09755478A0366 |41 51|expressionhosphatase
P09755478A0366 |73 81|diapause00008171
P09755478A0366 |136 152|trace expressionmia. P00008997A0
P09755478A0366 |59 69|transcriptnucleotida
P09755478A0366 |170 175|pupae-] is
P09755478A0366 |0 17|Northern analysisP00001606T0076 Co
P09756687A0981 |33 43|discussionkaline pho
P09756687A0981 |146 152|values8997A0
P09756687A0981 |12 28|characterization76 Comparison wi
P09756687A0981 |80 94|rate constants1T0000 Pharmac
P09756687A0981 |64 69|setupotida
P09756895A0322 |17 23|chCTCFmparis
P09756895A0322 |89 94|exonsarmac
P09756895A0322 |105 111|introncts of
P09756895A0322 |56 60|exon 5-n
P09756895A0322 |8 13|locus6T007
P09757012A0942 |16 19|PDZomp
P09757012A0942 |24 35|SAM domainsn with alka
P09757012A0942 |95 102|adaptorlogic a
P09757012A0942 |127 138|informationilirubinemi
P09757012A0942 |43 54|KS5 proteinsphatases a
P09757012A0942 |144 171|signal transduction pathway008997A0472 When CSF [HCO3-
P09757012A0942 |4 12|presence01606T00
P09759180A0000 |0 10|BACKGROUNDP00001606T
P09759180A0000 |30 32|FQ a
P09759180A0000 |89 105|cartilage damagearmacologic aspe
P09759180A0000 |12 28|Fluoroquinolones76 Comparison wi
P09759180A0000 |57 65|children5-nucleo
P09759180A0000 |81 85|riskT000
P09759691A1051 |205 207|SDO2
P09759691A1051 |367 377|nonsmokersurazepam t
P09759691A1051 |268 276|1.0-mmolpared to
P09759691A1051 |356 363|smokers943A073
P09759691A1051 |17 24|controlmpariso
P09759691A1051 |119 129|microg/minl hyperbil
P09759691A1051 |218 232|blood pressuref K-depleted r
P09759691A1051 |189 194|mm Hgnctio
P09759691A1051 |93 110|albumin excretioncologic aspects o
P09759691A1051 |297 321|plasma cholesterol levelave a significantly grea
P09759691A1051 |58 62|risk-nuc
P09759691A1051 |419 424|kg/m2ug wi
P09759691A1051 |142 147|women00008
P09759691A1051 |432 447|body mass indexptimum dose for
P09759691A1051 |283 288|mg/dLls bu
P09759691A1051 |134 137|mennem
P09759691A1051 |277 278|Lc
P09759691A1051 |67 83|microalbuminuriadase P00008171T0
P09759691A1051 |38 47|variablese phospha
P09759691A1051 |3 11|analyses001606T0
P09759865A0673 |304 315|PDGF-Ralphaignificantl
P09759865A0673 |59 66|bindingnucleot
P09759865A0673 |144 160|gel shift assays008997A0472 When
P09759865A0673 |95 98|p65log
P09759865A0673 |182 193|degradationas a functi
P09759865A0673 |28 37|TNF-alphath alkali
P09759865A0673 |210 225|NF-kappaB-alphae data of K-dep
P09759865A0673 |15 23|IL-1betaComparis
P09759865A0673 |105 140|NF-kappaB consensus oligonucleotidects of neonatal hyperbilirubinemia.
P09759865A0673 |262 276|myofibroblastsen compared to
P09759865A0673 |249 258|cytoplasm displace
P09759865A0673 |227 240|IkappaB-alphated rats are 
P09759865A0673 |74 90|Rel proteins p500008171T0000 Pha
P09759865A0673 |197 206|inhibitorf CSF PCO
P09759865A0673 |283 291|IL-1betals but s
P09760243A0970 |0 15|CotransfectionsP00001606T0076 
P09760243A0970 |78 93|transactivation171T0000 Pharma
P09760243A0970 |31 56|HNF-4 expression plasmidsalkaline phosphatases and
P09760243A0970 |21 26|ATF-2ison 
P09760243A0970 |101 117|apoCIII promoteraspects of neona
P09760341T0000 |0 26|Phosphocreatine hydrolysisP00001606T0076 Comparison 
P09760341T0000 |45 53|exercisehatases 
P09760341T0000 |59 65|effectnucleo
P09760341T0000 |69 73|FIO2se P
P09761711A0000 |85 93|coupling0 Pharma
P09761711A0000 |124 130|nucleierbili
P09761711A0000 |62 69|averageleotida
P09761711A0000 |111 119|electron neonata
P09761711A0000 |160 185|susceptibility anisotropy CSF [HCO3-] is shown as 
P09761711A0000 |139 147|presence. P00008
P09761711A0000 |0 20|Pseudocontact shiftsP00001606T0076 Compa
P09761723A0226 |0 6|GETS-1P00001
P09761723A0226 |28 35|tissuesth alka
P09761723A0226 |56 62|retina 5-nuc
P09761723A0226 |67 72|braindase 
P09761791A0489 |35 47|SRZ proteinsline phospha
P09761791A0489 |4 15|interaction01606T0076 
P09761791A0489 |86 104|blot overlay assay Pharmacologic asp
P09761791A0489 |19 25|U1-70Karison
P09763421A1199 |36 61|Fab1p kinase inactivationine phosphatases and 5-nu
P09763421A1199 |167 171|sizeCO3-
P09763421A1199 |10 20|phenotypes0076 Compa
P09763421A1199 |109 130|acidification defectsof neonatal hyperbili
P09763421A1199 |92 98|growthacolog
P09763421A1199 |145 154|increases08997A047
P09763446A0000 |21 35|Ypt/Rab familyison with alka
P09763446A0000 |56 66|regulation 5-nucleot
P09763446A0000 |6 13|GTPases606T007
P09763446A0000 |80 89|transport1T0000 Ph
P09763446A1234 |70 79|fractionse P000081
P09763446A1234 |31 36|Ypt1palkal
P09763446A1234 |12 26|GAP activities76 Comparison 
P09763446A1234 |4 7|GEF016
P09763470A0000 |0 25|Dopamine beta-hydroxylaseP00001606T0076 Comparison
P09763470A0000 |46 56|conversionatases and
P09763470A0000 |60 68|dopamineucleotid
P09763470A0000 |147 154|neurons997A047
P09763470A0000 |72 85|noradrenalineP00008171T000
P09763470A0000 |27 30|DBHith
P09763470A0000 |159 179|neuroendocrine cellsn CSF [HCO3-] is sho
P09763470A1756 |153 156|Sp172 
P09763470A1756 |195 203|DBH gene of CSF 
P09763470A1756 |177 187|activationhown as a 
P09763470A1756 |109 130|transcription factorsof neonatal hyperbili
P09763470A1756 |88 97|synergismharmacolo
P09763470A1756 |47 51|roletase
P09763470A1756 |55 61|Phox2ad 5-nu
P09763470A1756 |144 147|AP2008
P09763470A1756 |138 142|CREBa. P
P09763470A1756 |19 24|studyariso
P09763522A2545 |136 143|studiesmia. P0
P09763522A2545 |147 156|apoptosis997A0472 
P09763522A2545 |56 62|Ox-LDL 5-nuc
P09763522A2545 |18 26|antibodyparison 
P09763522A2545 |173 180|animalsis show
P09763522A2545 |86 95|apoptosis Pharmaco
P09763522A2545 |35 42|N-SMaseline ph
P09763607A0521 |23 34|Ngo strainson with alk
P09763607A0521 |62 72|activationleotidase 
P09763607A0521 |91 101|p38 kinasemacologic 
P09763607A0521 |42 57|phosphorylationosphatases and 
P09763607A0521 |76 79|JNK081
P09764741A0092 |127 132|basisiliru
P09764741A0092 |106 112|heartsts of 
P09764741A0092 |40 48|elementsphosphat
P09764741A0092 |56 79|cell division machinery 5-nucleotidase P000081
P09764741A0092 |95 102|beatinglogic a
P09764741A0092 |8 13|beams6T007
P09765261A0000 |307 333|cAMP response element coreificantly greater slope (1
P09765261A0000 |155 192|cAMP response element binding protein When CSF [HCO3-] is shown as a funct
P09765261A0000 |354 363|sequences10943A073
P09765261A0000 |57 72|trans-activator5-nucleotidase 
P09765261A0000 |146 153|protein8997A04
P09765261A0000 |30 45|retrovirus type alkaline phosp
P09765261A0000 |281 293|pair repeatsrols but sti
P09765261A0000 |74 77|Tax000
P09765261A0000 |194 198|CREBn of
P09765261A0000 |49 55|HTLV-Ises an
P09765261A0000 |111 138|basic-domain/leucine-zipper neonatal hyperbilirubinemi
P09765261A0000 |10 16|T cell0076 C
P09765261A0000 |140 144|bZip P00
P09765261A0000 |235 242|element are no
P09765271A1108 |103 108|genespects
P09765271A1108 |265 272|proteincompare
P09765271A1108 |133 140|insulininemia.
P09765271A1108 |243 249|growthlonger
P09765271A1108 |164 197|phosphoenolpyruvate carboxykinase [HCO3-] is shown as a function o
P09765271A1108 |37 62|insulin response sequencene phosphatases and 5-nuc
P09765271A1108 |199 224|tyrosine aminotransferaseCSF PCO2 the data of K-de
P09765271A1108 |5 13|sequence1606T007
P09765271A1108 |87 93|regionPharma
P09765277A0000 |138 150|trophoblastsa. P00008997
P09765277A0000 |24 51|glucose transporter isoformn with alkaline phosphatase
P09765277A0000 |126 133|neuronsbilirub
P09765277A0000 |55 59|Glutd 5-
P09765285A0998 |102 107|AaUSPspect
P09765285A0998 |146 150|time8997
P09765285A0998 |214 221|IRper-0ta of K
P09765285A0998 |182 207|spacer length requirementas a function of CSF PCO2
P09765285A0998 |121 128|IRhsp-1hyperbi
P09765285A0998 |164 174|stringency [HCO3-] i
P09765285A0998 |85 92|binding0 Pharm
P09765285A0998 |252 259|bindingsplaced
P09765285A0998 |22 31|half-siteson with 
P09765285A0998 |96 101|AaEcRogic 
P09765285A0998 |225 232|IRper-5leted r
P09765285A0998 |66 73|IRper-1idase P
P09765285A0998 |39 64|consensus sequence AGGTCA phosphatases and 5-nucle
P09765285A1763 |4 10|levels01606T
P09765285A1763 |14 29|transactivation Comparison wit
P09765285A1763 |120 124|DR-4 hyp
P09765285A1763 |110 117|IRper-1f neona
P09765285A1763 |91 108|response elementsmacologic aspects
P09765285A1763 |127 134|IRhsp-1ilirubi
P09765285A1763 |65 83|binding affinitiestidase P00008171T0
P09765372A0669 |51 55|halfs an
P09765372A0669 |9 16|densityT0076 C
P09765372A0669 |63 67|bodyeoti
P09765372A0669 |166 176|C. armatusHCO3-] is 
P09765372A0669 |31 37|spinesalkali
P09765372A0669 |76 88|distribution08171T0000 P
P09765372A0669 |92 96|typeacol
P09765372A0669 |112 126|dorsal surfaceneonatal hyper
P09765372A0669 |100 108|papillae aspects
P09765388T0000 |0 12|InactivationP00001606T00
P09765388T0000 |28 31|p73th 
P09765388T0000 |75 77|E400
P09765388T0000 |53 56|E1Band
P09765388T0000 |92 104|oncoproteinsacologic asp
P09765388T0000 |16 19|p53omp
P09765388T0000 |35 50|adenovirus typeline phosphatas
P09765394A0000 |119 125|originl hype
P09765394A0000 |57 72|gene expression5-nucleotidase 
P09765394A0000 |94 105|replicationologic aspe
P09765394A0000 |127 133|oriLytilirub
P09765394A0000 |17 41|virus transactivator Ztamparison with alkaline p
P09765394A1590 |0 14|CotransfectionP00001606T0076
P09765394A1590 |149 163|CAT expression7A0472 When CS
P09765394A1590 |90 107|activation domainrmacologic aspect
P09765394A1590 |130 145|superactivationrubinemia. P000
P09765394A1590 |39 47|proteins phospha
P09765411A0991 |0 20|Sequence comparisonsP00001606T0076 Compa
P09765411A0991 |149 153|mRNA7A04
P09765411A0991 |47 51|S27atase
P09765411A0991 |165 179|hybrid protein[HCO3-] is sho
P09765411A0991 |60 69|ubiquitinucleotida
P09765411A0991 |110 116|CP Ritf neon
P09765411A0991 |77 86|sequences8171T0000
P09765411A0991 |189 222|structure NH2-ubiquitin-S27a-COOHnction of CSF PCO2 the data of K-
P09765411A0991 |100 106|genome aspec
P09765466A0231 |0 2|J.P0
P09765754A1727 |25 32|studies with a
P09765754A1727 |12 17|trend76 Co
P09765754A1727 |43 46|PVIsph
P09767504A1371 |84 98|administration00 Pharmacolog
P09767504A1371 |56 69|concentration 5-nucleotida
P09767504A1371 |27 32|mg/kgith a
P09767504A1371 |79 80|h7
P09767504A1371 |127 129|h.il
P09767504A1371 |16 20|doseompa
P09767575A0657 |141 147|domainP00008
P09767575A0657 |41 45|edgehosp
P09767575A0657 |53 64|SD sequenceand 5-nucle
P09767575A0657 |131 137|regionubinem
P09767575A0657 |83 99|ribosome binding000 Pharmacologi
P09767575A0657 |5 11|domain1606T0
P09767593A0130 |100 108|proteins aspects
P09767593A0130 |134 141|p130Casnemia. 
P09767593A0130 |112 122|host cellsneonatal h
P09767593A0130 |9 13|YopHT007
P09767593A0130 |66 72|subsetidase 
P09767593A0130 |33 36|PTPkal
P09767687T0000 |82 90|analysis0000 Pha
P09767687T0000 |13 21|position6 Compar
P09767687T0000 |29 40|Phacotaceaeh alkaline 
P09767687T0000 |107 121|rbcL sequencess of neonatal 
P09767687T0000 |94 102|18S rDNAologic a
P09767687T0000 |52 69|Chlamydophyceaeas and 5-nucleotida
P09769209A0100 |85 107|nasF operon expression0 Pharmacologic aspect
P09769209A0100 |36 46|conclusionine phosph
P09769209A0100 |72 81|inductionP00008171
P09769209A0100 |143 168|antitermination mechanism0008997A0472 When CSF [HC
P09769209A0100 |17 24|studiesmpariso
P09769910A1700 |19 25|injuryarison
P09769910A1700 |88 97|cytokinesharmacolo
P09769910A1700 |121 128|effectshyperbi
P09769910A1700 |58 61|TNF-nu
P09769910A1700 |41 46|cellshosph
P09769910A1700 |4 14|activation01606T0076
P09769910A1700 |138 147|mediatorsa. P00008
P09770241A0000 |2 11|technique0001606T0
P09770241A0000 |95 101|systemlogic 
P09770241A0000 |56 68|brain cortex 5-nucleotid
P09770241A0000 |24 31|imagingn with 
P09770241A0000 |39 45|animal phosp
P09770378A0641 |0 11|EGFR levelsP00001606T0
P09770415A0139 |51 66|KRxxxxxxxxxKTKKs and 5-nucleot
P09770415A0139 |44 49|motifphata
P09770415A0139 |146 165|localization signal8997A0472 When CSF 
P09770415A0139 |167 170|NLSCO3
P09770415A0139 |25 32|THOV NP with a
P09770415A0139 |71 91|amino acid positions P00008171T0000 Phar
P09770493A0499 |17 22|rangempari
P09770493A0499 |174 190|postimplantations shown as a fun
P09770493A0499 |143 150|embryos0008997
P09770493A0499 |209 212|dayhe 
P09770493A0499 |81 104|cell fate determinationT0000 Pharmacologic asp
P09770493A0499 |55 76|cell cycle regulationd 5-nucleotidase P000
P09770493A0499 |3 7|PP2A0016
P09770493A0499 |35 44|functionsline phos
P09770686A0484 |48 60|hypertensionases and 5-n
P09770686A0484 |18 29|risk factorparison wit
P09771555A0499 |4 11|results01606T0
P09771555A0499 |26 51|anthraquinone sennoside Bwith alkaline phosphatase
P09771555A0499 |56 61|rhein 5-nu
P09771967A1052 |32 48|chromosome 13q14lkaline phosphat
P09771967A1052 |52 58|region and 5
P09771967A1052 |13 21|LB1 gene6 Compar
P09771967A1052 |113 117|DLBLeona
P09771967A1052 |99 109|breakpointc aspects 
P09771985A0238 |17 24|repatchmpariso
P09771985A0238 |58 64|EtHgCl-nucle
P09771985A0238 |94 100|EtHgClologic
P09771985A0238 |73 82|solutions00008171T
P09771985A0238 |112 122|L-cysteineneonatal h
P09771985A0238 |127 138|glutathioneilirubinemi
P09771985A0238 |3 11|subjects001606T0
P09771985A0238 |35 56|ethylmercury chlorideline phosphatases and
P09773975A1873 |137 142|levelia. P
P09773975A1873 |312 316|t1/2ntly
P09773975A1873 |47 66|hamster ovary cellstases and 5-nucleot
P09773975A1873 |224 237|substitutionspleted rats a
P09773975A1873 |288 291|mint s
P09773975A1873 |255 258|minace
P09773975A1873 |359 363|YmaxA073
P09773975A1873 |115 119|t1/2nata
P09773975A1873 |191 200|receptorstion of C
P09773975A1873 |293 297|Ymaxll h
P09773975A1873 |354 357|min109
P09773975A1873 |246 250|t1/2ger 
P09773975A1873 |124 127|minerb
P09773975A1873 |302 303|% 
P09773975A1873 |335 336|%1
P09773975A1873 |146 161|internalization8997A0472 When 
P09773975A1873 |95 113|Ang II stimulationlogic aspects of n
P09773975A1873 |269 270|%a
P09773975A1873 |239 244|T332E no l
P09773975A1873 |305 310|T336Egnifi
P09773975A1873 |368 369|%r
P09773975A1873 |173 174|%i
P09773975A1873 |163 167|YmaxF [H
P09773975A1873 |345 349|t1/2 vs.
P09773975A1873 |326 330|Ymaxlope
P09773975A1873 |260 264|Ymaxwhen
P09773975A1873 |321 324|minter
P09773975A1873 |338 343|S338D/- 0.
P09773975A1873 |10 24|AT1A receptors0076 Compariso
P09773975A1873 |279 283|t1/2ntro
P09773975A1873 |272 277|S335Dd to 
P09773981A0415 |110 119|inductionf neonata
P09773981A0415 |15 38|glucocorticoid receptorComparison with alkalin
P09773981A0415 |60 65|Stat5ucleo
P09773981A0415 |47 54|complextases a
P09774403A0107 |0 2|T.P0
P09774403A0107 |28 30|G.th
P09774403A0107 |14 16|A. C
P09774403A0107 |22 26|Coteson 
P09774403A0107 |4 12|Mahasneh01606T00
P09774444A0351 |33 37|UKLFkali
P09774444A0351 |73 87|Cys2-His2 type00008171T0000 
P09774444A0351 |165 189|Sp1 recognition sequence[HCO3-] is shown as a fu
P09774444A0351 |22 29|portionson wit
P09774444A0351 |133 153|beta-globin promoterinemia. P00008997A04
P09774444A0351 |53 65|zinc fingersand 5-nucleo
P09774444A0351 |114 125|CACCC motifonatal hype
P09774450A0000 |50 78|gamma-glutamyl leukotrienasees and 5-nucleotidase P00008
P09774450A0000 |124 138|leukotriene D4erbilirubinemi
P09774450A0000 |30 42|mouse enzyme alkaline ph
P09774450A0000 |99 113|leukotriene C4c aspects of n
P09774450A0000 |80 83|GGL1T0
P09774450A0000 |140 144|LTD4 P00
P09774450A0000 |115 119|LTC4nata
P09774484T0000 |0 18|UGA codon positionP00001606T0076 Com
P09774484T0000 |45 73|selenocysteine incorporationhatases and 5-nucleotidase P
P09774484T0000 |31 41|efficiencyalkaline p
P09774484T0000 |79 103|glutathione peroxidase-171T0000 Pharmacologic as
P09774641A0824 |68 76|cyclin Dase P000
P09774641A0824 |54 64|expressionnd 5-nucle
P09774641A0824 |104 131|retinoblastoma gene productects of neonatal hyperbilir
P09774641A0824 |81 96|phosphorylationT0000 Pharmacol
P09774641A0824 |0 9|ForskolinP00001606
P09774662A0958 |116 125|RNA levelatal hype
P09774662A0958 |59 74|E2F1 expressionnucleotidase P0
P09774662A0958 |4 16|ARF promoter01606T0076 C
P09774662A0958 |101 108|resultsaspects
P09776293A0777 |102 103|%s
P09776293A0777 |13 20|binding6 Compa
P09776293A0777 |75 76|%0
P09776293A0777 |110 112|mlf 
P09776293A0777 |93 94|%c
P09776293A0777 |24 31|99mTc dn with 
P09776293A0777 |122 130|solutionyperbili
P09776293A0777 |50 58|placentaes and 5
P09776293A0777 |33 40|1-HMPAOkaline 
P09776293A0777 |84 85|%0
P09776293A0777 |0 7|RESULTSP000016
P09776360A0620 |0 2|CMP0
P09776360A0620 |43 68|transcription factor AP-1sphatases and 5-nucleotid
P09776360A0620 |23 39|binding activityon with alkaline
P09776360A1781 |0 9|NF-kappaBP00001606
P09776360A1781 |123 131|effectorperbilir
P09776360A1781 |135 137|CMem
P09776360A1781 |141 152|DLD-1 cellsP00008997A0
P09776360A1781 |78 86|promoter171T0000
P09776360A1781 |71 74|NOS P0
P09776360A1781 |49 57|activityses and 
P09777477A0000 |0 9|ObserversP00001606
P09777477A0000 |143 146|air000
P09777477A0000 |160 170|peppermint CSF [HCO3
P09777477A0000 |15 27|brain injuryComparison w
P09777477A0000 |116 122|whiffsatal h
P09777477A0000 |65 79|vigilance tasktidase P000081
P09777477A0000 |32 52|control participantslkaline phosphatases
P09777477A0000 |136 139|airmia
P09777600A0000 |68 82|chromatographyase P00008171T
P09777600A0000 |31 40|l-mentholalkaline 
P09777600A0000 |112 120|detectorneonatal
P09777600A0000 |20 26|methodrison 
P09777999A0796 |0 7|RESULTSP000016
P09777999A0796 |62 74|PaCO2 levelsleotidase P0
P09777999A0796 |91 92|%m
P09777999A0796 |109 110|%o
P09777999A0796 |94 105|hypercapniaologic aspe
P09777999A0796 |76 86|hypocapnia08171T0000
P09777999A0796 |21 26|indexison 
P09778006A0718 |274 279|valueto co
P09778006A0718 |89 94|PaCO2armac
P09778006A0718 |118 122|meanal h
P09778006A0718 |185 189|mmHga fu
P09778006A0718 |55 69|carbon dioxided 5-nucleotida
P09778006A0718 |295 313|baseline Vmca/mmHg have a significan
P09778006A0718 |82 87|blood0000 
P09778006A0718 |112 116|mmHgneon
P09778006A0718 |127 129|SDil
P09778006A0718 |247 248|se
P09778006A0718 |242 244|cm l
P09778006A0718 |132 144|measurementsbinemia. P00
P09778006A0718 |164 168|PaCO [HC
P09778006A0718 |255 259|mmHgaced
P09778006A0718 |16 29|baseline Vmcaomparison wit
P09778006A0718 |281 291|percentagerols but s
P09778006A0718 |199 224|carbon dioxide reactivityCSF PCO2 the data of K-de
P09778006A0718 |43 51|pressuresphatase
P09778006A0718 |235 240|value are 
P09778068A1129 |254 259|deathlaced
P09778068A1129 |13 34|Cox survival analysis6 Comparison with alk
P09778068A1129 |240 250|predictorsno longer 
P09778068A1129 |195 200|month of C
P09778068A1129 |67 68|%d
P09778068A1129 |178 189|performanceown as a fu
P09778068A1129 |128 136|ablationlirubine
P09778068A1129 |46 57|baseline EFatases and 
P09778068A1129 |101 114|regurgitationaspects of ne
P09778068A1129 |142 149|failure0000899
P09778068A1129 |70 78|presencee P00008
P09778068A1129 |207 215|ablation the dat
P09778191A0000 |35 45|estimationline phosp
P09778191A0000 |89 105|reserve capacityarmacologic aspe
P09778191A0000 |63 67|rCBFeoti
P09778191A0000 |180 183|MRIn a
P09778191A0000 |135 140|meansemia.
P09778191A0000 |24 30|methodn with
P09778191A0000 |161 178|resonance imagingCSF [HCO3-] is sh
P09778191A0000 |58 61|CBF-nu
P09778191A0000 |126 131|basisbilir
P09778197A0415 |0 27|Cost-effectiveness analysisP00001606T0076 Comparison w
P09778197A0415 |114 124|comparisononatal hyp
P09778197A0415 |293 308|atherosclerosisll have a signi
P09778197A0415 |265 272|statinscompare
P09778197A0415 |243 263|reductase inhibitorslonger displaced whe
P09778197A0415 |180 187|therapyn as a 
P09778197A0415 |345 356|cholesterol vs. P00010
P09778197A0415 |284 289|costss but
P09778197A0415 |48 53|meansases 
P09778197A0415 |156 163|therapyWhen CS
P09778197A0415 |193 229|beta-hydroxy-beta-methylglutaryl-CoAon of CSF PCO2 the data of K-deplete
P09778197A0415 |132 137|costsbinem
P09778197A0415 |231 241|coenzyme Arats are n
P09778197A0415 |76 97|health care resources08171T0000 Pharmacolo
P09780002A0996 |117 122|E2F-1tal h
P09780002A0996 |26 48|transactivation domainwith alkaline phosphat
P09780002A0996 |83 96|transcription000 Pharmacol
P09780002A0996 |9 15|E2FBP1T0076 
P09780002A0996 |64 67|E2Foti
P09780002A0996 |100 111|cooperation aspects of
P09780228A0122 |0 10|SequencingP00001606T
P09780228A0122 |41 59|FK506 gene clusterhosphatases and 5-
P09780228A0122 |22 33|DNA segmentson with al
P09780228A0613 |35 39|FkbBline
P09780228A0613 |74 78|FkbA0008
P09780228A0613 |44 48|FkbCphat
P09780228A0613 |14 31|domain structures Comparison with 
P09780228A0613 |95 114|fatty-acid-synthaselogic aspects of ne
P09780228A0613 |147 154|modules997A047
P09780228A0613 |125 132|domainsrbiliru
P09780228A0613 |115 118|FASnat
P09780336A0771 |0 8|AnalysisP0000160
P09780336A0771 |88 99|populationsharmacologi
P09780336A0771 |58 70|mouse testes-nucleotidas
P09780336A0771 |131 141|expressionubinemia. 
P09780336A0771 |177 186|cell typehown as a
P09780336A0771 |12 32|Msy2 mRNA expression76 Comparison with a
P09780336A0771 |157 173|round spermatidshen CSF [HCO3-] 
P09780336A0771 |219 247|messenger ribonucleoproteins K-depleted rats are no long
P09780336A0771 |201 208|amountsF PCO2 
P09780336A0771 |103 113|germ cellspects of n
P09781761A0384 |118 123|fluidal hy
P09781761A0384 |93 98|fluidcolog
P09781761A0384 |72 77|bloodP0000
P09781761A0384 |5 21|Ho Chi Minh City1606T0076 Compar
P09781761A0384 |37 44|culturene phos
P09781761A0384 |49 68|latex agglutinationses and 5-nucleotid
P09781761A0384 |100 105|urine aspe
P09781871A0404 |0 18|Glycogen synthesisP00001606T0076 Com
P09781871A0404 |263 266|Eccn c
P09781871A0404 |23 33|catabolismon with al
P09781871A0404 |52 62|glycolysis and 5-nuc
P09781871A0404 |219 224|plant K-de
P09781871A0404 |331 335|rsmA(1.2
P09781871A0404 |302 313|metabolites significan
P09781871A0404 |240 262|response elicitor HrpNno longer displaced wh
P09781871A0404 |129 133|csrAirub
P09781871A0404 |196 213|virulence factorsof CSF PCO2 the d
P09781871A0404 |74 97|cell surface properties0008171T0000 Pharmacolo
P09781871A0404 |165 175|production[HCO3-] is
P09781871A0404 |339 357|Erwinia carotovora- 0.23 vs. P000109
P09781871A0404 |64 72|motilityotidase 
P09781871A0404 |35 50|gluconeogenesisline phosphatas
P09781871A0404 |102 111|adherencespects of
P09781874A1061 |51 71|adenine substitutions and 5-nucleotidase
P09781874A1061 |104 110|regionects o
P09781874A1061 |75 85|nucleotide008171T000
P09781874A1061 |40 47|guaninephospha
P09781874A1061 |148 153|cwg2p97A04
P09781874A1061 |128 140|change A202Tlirubinemia.
P09781874A1061 |4 19|cwg2-1 mutation01606T0076 Comp
P09784063A0621 |0 17|Deletion analysisP00001606T0076 Co
P09784063A0621 |46 52|domainatases
P09784063A0621 |61 69|promotercleotida
P09784063A0621 |125 136|nucleotidesrbilirubine
P09784063A0621 |82 113|ORF5/deltaX transcript promoter0000 Pharmacologic aspects of n
P09784192A1027 |20 31|MBP fusionsrison with 
P09784192A1027 |12 19|peptide76 Comp
P09784192A1027 |57 82|surface plasmon resonance5-nucleotidase P00008171T
P09784245T0000 |34 40|MyBP-Caline 
P09784245T0000 |43 57|identificationsphatases and 
P09784245T0000 |61 77|protein kinase Acleotidase P0000
P09784245T0000 |82 120|protein kinase C phosphorylation sites0000 Pharmacologic aspects of neonatal
P09784245T0000 |23 32|protein Con with a
P09785114A1026 |71 77|groups P0000
P09785114A1026 |45 56|CORT levelshatases and
P09785114A1026 |12 15|PND76 
P09786197A0322 |0 8|AnalysisP0000160
P09786197A0322 |166 185|sequence similarityHCO3-] is shown as 
P09786197A0322 |135 139|csrRemia
P09786197A0322 |224 231|systemspleted 
P09786197A0322 |24 36|DNA sequencen with alkal
P09786197A0322 |108 122|reading frames of neonatal h
P09786197A0322 |144 148|csrS0089
P09786197A0322 |67 87|transposon insertiondase P00008171T0000 
P09786404A0541 |34 35|Pa
P09786404A0541 |29 32|rpmh a
P09786404A0541 |10 23|aggregates/ml0076 Comparis
P09786926A0095 |254 257|ratlac
P09786926A0095 |135 154|fatty-acid synthaseemia. P00008997A047
P09786926A0095 |196 204|activityof CSF P
P09786926A0095 |161 165|geneCSF 
P09786926A0095 |27 33|regionith al
P09786926A0095 |41 69|fatty-acid synthase promoterhosphatases and 5-nucleotida
P09786926A0095 |156 159|FASWhe
P09786926A0095 |113 127|overexpressioneonatal hyperb
P09786926A0095 |262 267|cellsen co
P09786926A0095 |223 231|promoterepleted 
P09786926A1372 |84 103|ADD1/SREBP1 binding00 Pharmacologic as
P09786926A1372 |131 138|elementubinemi
P09786926A1372 |56 62|SREBP2 5-nuc
P09786926A1372 |145 149|site0899
P09786926A1372 |24 39|binding studiesn with alkaline
P09786926A1372 |113 119|steroleonata
P09786926A1372 |140 143|SRE P0
P09786932A1042 |32 42|similaritylkaline ph
P09786932A1042 |46 51|IRF-3atase
P09786932A1042 |122 131|cell typeyperbilir
P09786932A1042 |147 151|IFNA997A
P09786932A1042 |79 89|expression71T0000 Ph
P09786932A1042 |193 197|roleon o
P09786932A1042 |167 172|IRF-7CO3-]
P09786932A1042 |93 98|IRF-7colog
P09786932A1042 |111 116|cells neon
P09786932A1042 |6 11|IRF-7606T0
P09786932A1042 |216 236|IFNA gene expression of K-depleted rats 
P09786949A0114 |0 2|J.P0
P09787323A0000 |0 7|PURPOSEP000016
P09787323A0000 |46 55|treatmentatases an
P09787323A0000 |13 31|role interleukin-66 Comparison with 
P09787323A0000 |33 37|IL-6kali
P09787323A0000 |70 87|thrombocytopeniase P00008171T0000 
P09788739A1096 |157 183|MDA231 breast cancer cellshen CSF [HCO3-] is shown a
P09788739A1096 |90 107|signaling cascadermacologic aspect
P09788739A1096 |124 131|varietyerbilir
P09788739A1096 |26 39|serine kinasewith alkaline
P09788739A1096 |76 84|molecule08171T00
P09788739A1096 |144 153|responses008997A04
P09789025A0149 |0 7|GalphaqP000016
P09789025A0149 |41 48|Galphaihosphat
P09789025A0149 |59 62|SRFnuc
P09789025A0149 |9 17|Galpha12T0076 Co
P09789025A0149 |23 31|Galpha13on with 
P09789025A0149 |71 75|RhoA P00
P09789795A0607 |69 83|concentrationsse P00008171T0
P09789795A0607 |22 30|subjectsson with
P09789795A0607 |43 44|As
P09789795A0607 |65 67|NAti
P09789795A0607 |50 63|noradrenalinees and 5-nucl
P09790499A0545 |0 22|Northern blot analysesP00001606T0076 Compari
P09790499A0545 |37 53|hBub1 mRNA levelne phosphatases 
P09790499A0545 |92 97|cellsacolo
P09790499A0545 |81 88|tissuesT0000 P
P09790499A0545 |118 123|indexal hy
P09790767A0372 |103 111|band q31pects of
P09790767A0372 |73 79|contig000081
P09790767A0372 |89 99|chromosomearmacologi
P09790767A0372 |36 55|sequence tag clonesine phosphatases an
P09790768A0621 |0 11|Htra2-beta3P00001606T0
P09790768A0621 |107 113|kidneys of n
P09790768A0621 |72 77|brainP0000
P09790768A0621 |79 91|liver testis71T0000 Phar
P09790771A0956 |0 18|Gng3lg transcriptsP00001606T0076 Com
P09790771A0956 |82 88|testes0000 P
P09790771A0956 |72 77|brainP0000
P09790771A0956 |38 45|varietye phosp
P09790771A0956 |49 56|tissuesses and
P09790771A1032 |86 91|locus Phar
P09790771A1032 |58 62|Gng3-nuc
P09790771A1032 |95 105|chromosomelogic aspe
P09790771A1032 |67 73|Gng3lgdase P
P09790771A1032 |23 38|backcross panelon with alkalin
P09790986A0689 |49 89|glutathione S-transferase fusion proteinses and 5-nucleotidase P00008171T0000 Ph
P09790986A0689 |121 132|amino acidshyperbiliru
P09790986A0689 |28 36|antibodyth alkal
P09790986A0689 |142 148|NRAMP2000089
P09792439T0000 |0 10|InhibitionP00001606T
P09792439T0000 |66 82|hnRNP C1 proteinidase P00008171T
P09792439T0000 |18 47|apolipoprotein B mRNA editingparison with alkaline phospha
P09792439T0000 |87 106|40S hnRNP complexesPharmacologic aspec
P09792627A0441 |0 5|SRC-1P0000
P09792627A0441 |41 51|repressionhosphatase
P09792627A0441 |55 66|GR activityd 5-nucleot
P09792630A1127 |70 74|TTCCe P0
P09792630A1127 |127 137|nucleosideilirubinem
P09792630A1127 |146 163|initiator element8997A0472 When CS
P09792630A1127 |94 108|consensus CTCAologic aspects
P09792630A1127 |182 209|deoxynucleotidyltransferaseas a function of CSF PCO2 t
P09792630A1127 |118 119|Na
P09792630A1127 |216 222|number of K-
P09792630A1127 |112 116|NTCTneon
P09792630A1127 |249 254|genes disp
P09792630A1127 |109 111|+1of
P09792630A1127 |12 20|sequence76 Compa
P09792630A1127 |67 69|+1da
P09792630A1127 |37 66|transcription start site CTCAne phosphatases and 5-nucleot
P09792682A0713 |48 57|subunit cases and 
P09792682A0713 |61 63|F0cl
P09792682A0713 |6 13|results606T007
P09792682A0713 |38 44|numbere phos
P09792702A0754 |34 40|mutantaline 
P09792702A0754 |120 141|HSP70 gene expression hyperbilirubinemia. 
P09792702A0754 |93 108|JNK1 activationcologic aspects
P09792702A0754 |44 48|JNK1phat
P09792702A0754 |65 72|glucosetidase 
P09792702A0754 |0 10|ExpressionP00001606T
P09792714A1408 |70 83|transcriptione P00008171T0
P09792714A1408 |157 161|AF-1hen 
P09792714A1408 |124 134|activationerbilirubi
P09792714A1408 |29 37|proteinsh alkali
P09792714A1408 |61 66|stepscleot
P09792714A1408 |98 107|mechanismic aspect
P09792714A1408 |4 15|interaction01606T0076 
P09792714A1408 |138 153|gene expressiona. P00008997A04
P09792714A1408 |19 23|AF-1aris
P09794414T0000 |4 8|role0160
P09794414T0000 |12 38|protein kinase C signaling76 Comparison with alkalin
P09794414T0000 |52 69|DRA transcription and 5-nucleotida
P09794795A0183 |0 14|Ligand bindingP00001606T0076
P09794795A0183 |255 282|transcription factors STAT3aced when compared to contr
P09794795A0183 |48 72|tyrosine phosphorylationases and 5-nucleotidase 
P09794795A0183 |322 325|SH2er 
P09794795A0183 |22 38|receptor complexson with alkalin
P09794795A0183 |112 127|phosphorylationneonatal hyperb
P09794795A0183 |242 251|activator longer d
P09794795A0183 |301 320|src homology domaina significantly gre
P09794795A0183 |91 104|Janus kinasesmacologic asp
P09794795A0183 |181 192|recruitment as a funct
P09794795A0183 |287 292|STAT1ut st
P09794795A0183 |106 109|Jakts 
P09794795A0183 |135 167|signal transducing subunit gp130emia. P00008997A0472 When CSF [H
P09794795A0183 |220 237|signal transducerK-depleted rats a
P09794795A0183 |197 212|phosphorylationf CSF PCO2 the 
P09794795A0183 |77 87|activation8171T0000 
P09794795A0183 |338 366|protein tyrosine phosphatase/- 0.23 vs. P00010943A0733 F
P09794795A0183 |368 372|SHP2raze
P09795130A0742 |18 26|increaseparison 
P09795130A0742 |30 38|distance alkalin
P09795130A0742 |73 79|effect000081
P09795130A0742 |83 105|translation efficiency000 Pharmacologic aspe
P09795170A0774 |65 68|TGAtid
P09795170A0774 |74 79|codon00081
P09795170A0774 |104 122|kb transcript sizeects of neonatal h
P09795170A0774 |20 40|polyadenylation siterison with alkaline 
P09795213A0129 |0 13|RBP56 proteinP00001606T007
P09795213A0129 |176 181|Heardshown
P09795213A0129 |208 210|L.th
P09795213A0129 |183 187|D.J.s a 
P09795213A0129 |31 39|hTAFII68alkaline
P09795213A0129 |151 164|Bertolotti A.0472 When CSF
P09795213A0129 |166 170|LutzHCO3
P09795213A0129 |104 107|TAFect
P09795213A0129 |134 149|TFIID complexesnemia. P0000899
P09795213A0129 |254 261|proteinlaced w
P09795213A0129 |116 130|sub-populationatal hyperbili
P09795213A0129 |352 366|RNA polymerase0010943A0733 F
P09795213A0129 |218 226|hTAFII68f K-depl
P09795213A0129 |189 196|Chambonnction 
P09795213A0129 |267 275|homologympared t
P09795213A0129 |283 309|proto-oncoproteins TLS/FUSls but still have a signif
P09795213A0129 |77 84|protein8171T00
P09795213A0129 |314 317|EWSly 
P09795213A0129 |198 200|P. C
P09795213A0129 |202 206|Tora PCO
P09795213A0129 |172 174|Y. i
P09795213A0129 |96 102|factorogic a
P09795213A0129 |342 347|TFIID.23 v
P09795341A0806 |19 39|mobility shift assayarison with alkaline
P09795341A0806 |74 90|binding property0008171T0000 Pha
P09795341A0806 |94 97|TR2olo
P09795341A0806 |116 123|isoformatal hy
P09797189A0559 |55 66|CCAAT motifd 5-nucleot
P09797189A0559 |13 27|shift analysis6 Comparison w
P09797456A0000 |68 73|rolesase P
P09797456A0000 |77 95|cell proliferation8171T0000 Pharmaco
P09797456A0000 |133 142|apoptosisinemia. P
P09797456A0000 |114 128|transformationonatal hyperbi
P09797456A0000 |97 112|differentiationgic aspects of 
P09797456A0000 |16 36|c-myc proto-oncogeneomparison with alkal
P09797456A0000 |0 10|BACKGROUNDP00001606T
P09797456A0883 |0 5|AMY-1P0000
P09797456A0883 |89 96|nucleusarmacol
P09797456A0883 |104 109|cellsects 
P09797456A0883 |164 169|cells [HCO
P09797456A0883 |120 136|c-myc expression hyperbilirubine
P09797456A0883 |40 45|cellsphosp
P09797456A0883 |27 36|cytoplasmith alkal
P09797456A0883 |57 62|c-myc5-nuc
P09797456A0883 |70 76|levelse P000
P09798068A0290 |0 7|RESULTSP000016
P09798068A0290 |109 116|proteinof neon
P09798068A0290 |183 186|rats a
P09798068A0290 |163 173|% homologyF [HCO3-] 
P09798068A0290 |77 79|bp81
P09798068A0290 |214 219|GABABta of
P09798068A0290 |124 135|amino acidserbilirubin
P09798068A0290 |55 68|reading framed 5-nucleotid
P09798068A0290 |37 41|cDNAne p
P09798068A0290 |206 212|acid B2 the 
P09798068A0290 |221 229|receptor-deplete
P09798100A0705 |3 6|Day001
P09798100A0705 |75 77|IM00
P09798100A0705 |14 20|CIDR-B Compa
P09798100A0705 |41 64|micrograms cloprostenolhosphatases and 5-nucle
P09798263T0000 |70 97|calcium channel antagonistse P00008171T0000 Pharmacolo
P09798263T0000 |20 30|propertiesrison with
P09798263T0000 |123 136|swimming testperbilirubine
P09798263T0000 |39 65|serotonin receptor ligands phosphatases and 5-nucleo
P09798263T0000 |140 144|mice P00
P09799086A0725 |136 138|Gsmi
P09799086A0725 |59 70|frame shiftnucleotidas
P09799086A0725 |199 210|LN patientsCSF PCO2 th
P09799086A0725 |122 128|repeatyperbi
P09799086A0725 |83 105|G nucleotide insertion000 Pharmacologic aspe
P09799086A0725 |142 151|HPRT exon00008997A
P09799086A0725 |18 34|hotspot mutationparison with alk
P09799086A0725 |48 55|patientases an
P09799237A0624 |46 65|gastrulation defectatases and 5-nucleo
P09799237A0624 |14 21|embryos Compar
P09799237A0624 |88 92|termharm
P09799362A0507 |100 119|Zinc Finger protein aspects of neonata
P09799362A0507 |65 82|abbreviation AZF1tidase P00008171T
P09799362A0507 |32 40|featureslkaline 
P09799362A1463 |152 161|influence472 When 
P09799362A1463 |219 240|RNA polymerase mutant K-depleted rats are 
P09799362A1463 |178 189|suppressionown as a fu
P09799362A1463 |165 170|Azf1p[HCO3
P09799362A1463 |104 130|transcription factor Mtf1pects of neonatal hyperbili
P09799362A1463 |19 24|Azf1pariso
P09799362A1463 |66 82|expression levelidase P00008171T
P09799362A1463 |32 42|yeast celllkaline ph
P09799362A1463 |0 15|Over-expressionP00001606T0076 
P09799634A0161 |136 143|proteinmia. P0
P09799634A0161 |94 111|crystal structureologic aspects of
P09799634A0161 |53 59|domainand 5-
P09799634A0161 |130 134|UmuDrubi
P09799634A0161 |20 34|computer modelrison with alk
P09799634A0161 |71 80|repressor P0000817
P09799793T0000 |64 72|analysisotidase 
P09799793T0000 |12 22|sequencing76 Compari
P09799793T0000 |122 132|CUTL1 lociyperbiliru
P09799793T0000 |47 62|chromosome 7q22tases and 5-nuc
P09799793T0000 |30 37|regions alkali
P09799793T0000 |144 149|genes00899
P09799793T0000 |94 102|sequenceologic a
P09799793T0000 |80 82|kb1T
P09799793T0000 |114 117|EPOona
P09800187A0100 |237 246|mutationsre no lon
P09800187A0100 |124 133|responseserbilirub
P09800187A0100 |209 229|mouse lymphoma cellshe data of K-deplete
P09800187A0100 |64 67|Tk1oti
P09800187A0100 |144 152|exposure008997A0
P09800187A0100 |42 46|TP53osph
P09800187A0100 |8 13|Trp536T007
P09800187A0100 |250 255|Trp53displ
P09800187A0100 |156 175|DNA damaging agentsWhen CSF [HCO3-] is
P09800187A0100 |71 81|chromosome P00008171
P09800187A0100 |19 32|mouse homologarison with a
P09801156A0220 |103 111|gene E75pects of
P09801156A0220 |13 22|fragments6 Compari
P09801156A0220 |41 69|amino acid sequence homologyhosphatases and 5-nucleotida
P09801156A0220 |84 92|ecdysone00 Pharm
P09801333A0174 |16 22|N geneompari
P09801333A0174 |40 53|reading framephosphatases 
P09801333A0174 |98 102|PA-8ic a
P09801333A0174 |86 96|PRRS virus Pharmacol
P09802206A1058 |32 37|geneslkali
P09802206A1058 |57 60|TEF5-n
P09802206A1058 |113 117|RPS7eona
P09802206A1058 |9 26|sequence homologyT0076 Comparison 
P09802206A1058 |71 108|translation elongation factor-1 alpha P00008171T0000 Pharmacologic aspects
P09802206A1058 |138 148|protein S7a. P000089
P09802902A0225 |102 126|ARF6 nucleotide exchangespects of neonatal hyper
P09802902A0225 |30 34|ARNO alk
P09802902A0225 |52 67|plasma membrane and 5-nucleoti
P09803081T0000 |6 15|pathology606T0076 
P09803081T0000 |30 37|outcome alkali
P09803081T0000 |41 54|childhood SLEhosphatases a
P09804779A0000 |0 21|Transcription factorsP00001606T0076 Compar
P09804779A0000 |29 40|Stat familyh alkaline 
P09804779A0000 |59 74|protein kinasesnucleotidase P0
P09804779A1163 |38 66|Stat5 serine phosphorylatione phosphatases and 5-nucleot
P09804779A1163 |209 215|Stat5ahe dat
P09804779A1163 |20 28|pathwaysrison wi
P09804836A0000 |98 124|mouse BAC1.2F5 macrophagesic aspects of neonatal hyp
P09804836A0000 |86 94|response Pharmac
P09804836A0000 |223 224|Pe
P09804836A0000 |157 162|CSF-1hen C
P09804836A0000 |251 280|size exclusion chromatographyisplaced when compared to con
P09804836A0000 |297 302|phaseave a
P09804836A0000 |226 249|affinity chromatographyeted rats are no longer
P09804836A0000 |286 288|C4bu
P09804836A0000 |165 169|pp37[HCO
P09804836A0000 |324 338|chromatography slope (1.21 +
P09804836A0000 |202 210|fraction PCO2 th
P09804836A0000 |128 155|colony stimulating factor-1lirubinemia. P00008997A0472
P09804836A0000 |36 43|proteinine pho
P09804836A0000 |308 316|pressureficantly
P09805052A0119 |0 4|DoseP000
P09805052A0119 |166 170|doseHCO3
P09805052A0119 |62 68|monthsleotid
P09805052A0119 |91 105|immunogenicitymacologic aspe
P09805052A0119 |11 13|ig07
P09805052A0119 |72 77|orderP0000
P09805052A0119 |41 47|schemehospha
P09805052A0119 |143 149|months000899
P09805977A0143 |70 76|origine P000
P09805977A0143 |166 176|substancesHCO3-] is 
P09805977A0143 |22 26|datason 
P09805977A0143 |182 195|xenoestrogensas a function
P09805977A0143 |157 162|classhen C
P09805977A0143 |86 96|sperm fall Pharmacol
P09806516A1212 |51 59|patientss and 5-
P09806516A1212 |5 16|association1606T0076 C
P09806516A1212 |87 97|recurrencePharmacolo
P09806516A1689 |0 10|CONCLUSIONP00001606T
P09806516A1689 |111 117|Postop neona
P09806516A1689 |43 48|Preopsphat
P09806516A1689 |121 129|patientshyperbil
P09806516A1689 |52 60|patients and 5-n
P09806516A1689 |93 100|diseasecologic
P09806516A1689 |173 181|excisionis shown
P09806516A1689 |18 25|controlparison
P09806546A1270 |68 79|RFX complexase P000081
P09806546A1270 |30 35|RFXAP alka
P09806546A1270 |83 99|MHC-II promoters000 Pharmacologi
P09806546A1270 |53 60|bindingand 5-n
P09806546A1270 |4 15|interaction01606T0076 
P09806546A1270 |21 25|RFX5ison
P09806826A0244 |103 106|Chrpec
P09806826A0244 |90 99|Vwf locusrmacologi
P09806826A0244 |30 36|defect alkal
P09806826A0244 |40 47|RIIIS/Jphospha
P09806826A0244 |58 67|mouse Chr-nucleoti
P09806826A1773 |103 107|genepect
P09806826A1773 |6 10|data606T
P09806826A1773 |133 141|syndromeinemia. 
P09806826A1773 |165 179|susceptibility[HCO3-] is sho
P09806826A1773 |31 43|localizationalkaline pho
P09806826A1773 |203 214|lung injuryPCO2 the da
P09806826A1773 |53 65|disease lociand 5-nucleo
P09806826A1773 |81 87|regionT0000 
P09806826A1773 |155 160|locus When
P09806830X1174 |0 9|CopyrightP00001606
P09806830X1174 |15 29|Academic PressComparison wit
P09806857A0854 |33 40|proteinkaline 
P09806857A0854 |79 89|invertases71T0000 Ph
P09806857A0854 |145 162|Pac25I R-M operon08997A0472 When C
P09806857A0854 |94 104|resolvasesologic asp
P09806857A0854 |8 21|reading frame6T0076 Compar
P09806857A0854 |65 75|similaritytidase P00
P09806858T0000 |68 77|rnaI genease P0000
P09806858T0000 |24 28|genen wi
P09806858T0000 |50 62|plasmid pLS1es and 5-nuc
P09806858T0000 |0 14|IdentificationP00001606T0076
P09806919A0447 |119 133|ecdysone pulsel hyperbilirub
P09806919A0447 |8 11|usp6T0
P09806919A0447 |148 166|puparium formation97A0472 When CSF [
P09806919A0447 |38 51|instar larvaee phosphatase
P09806919A0447 |102 111|responsesspects of
P09807755A0146 |67 78|muscle flapdase P00008
P09807755A0146 |24 30|supplyn with
P09807755A0146 |52 61|viability and 5-nu
P09808155A0813 |0 11|ExaminationP00001606T0
P09808155A0813 |194 196|bpn 
P09808155A0813 |90 97|factorsrmacolo
P09808155A0813 |15 18|DNACom
P09808155A0813 |58 66|analysis-nucleot
P09808155A0813 |161 173|DNA fragmentCSF [HCO3-] 
P09808155A0813 |142 147|cells00008
P09808155A0813 |19 44|protein binding complexesarison with alkaline phos
P09808216A0000 |85 87|FB0 
P09808216A0000 |120 126|ratios hyper
P09808216A0000 |42 52|regulationosphatases
P09808216A0000 |56 62|energy 5-nuc
P09808216A0000 |12 19|Studies76 Comp
P09808216A0000 |28 31|menth 
P09808216A0000 |96 108|manipulationogic aspects
P09808216A0000 |76 83|balance08171T0
P09808216A0000 |64 66|EBot
P09808216A0000 |0 10|BACKGROUNDP00001606T
P09808366A0828 |153 160|animals72 When
P09808366A0828 |44 54|conditionsphatases a
P09808366A0828 |105 122|KA microinjectioncts of neonatal h
P09808366A0828 |142 149|VRG-Apa0000899
P09808366A0828 |130 134|siderubi
P09808366A0828 |6 14|apneusis606T0076
P09808366A0828 |71 76|apnea P000
P09808441A0320 |185 196|coexistencea function 
P09808441A0320 |149 157|melanoma7A0472 W
P09808441A0320 |132 141|characterbinemia. 
P09808441A0320 |14 22|analysis Compari
P09808441A0320 |90 101|singularityrmacologic 
P09808441A0320 |163 176|lymphotropismF [HCO3-] is 
P09808441A0320 |109 113|caseof n
P09808441A0320 |218 232|cell carcinomaf K-depleted r
P09808441A0320 |65 74|melanomastidase P0
P09810087A0379 |0 7|RESULTSP000016
P09810087A0379 |109 114|acidsof ne
P09810087A0379 |94 99|HSV Iologi
P09810087A0379 |72 92|herpes simplex virusP00008171T0000 Pharm
P09810087A0379 |53 61|presenceand 5-nu
P09810087A0379 |142 147|humor00008
P09810087A0379 |65 69|typetida
P09810087A0379 |21 35|seroconversionison with alka
P09811695A1146 |102 125|MuLV TM Env protein p15spects of neonatal hype
P09811695A1146 |126 127|Eb
P09811695A1146 |28 47|HIV-1 Gag sequencesth alkaline phospha
P09811695A1146 |6 13|results606T007
P09811695A1146 |84 94|processing00 Pharmac
P09811718A0979 |38 49|associatione phosphata
P09811718A0979 |61 70|HIV-2 nefcleotidas
P09811718A0979 |53 56|SIVand
P09811718A0979 |7 14|results06T0076
P09811718A0979 |96 103|TCRzetaogic as
P09811718A0979 |80 89|HIV-1 nef1T0000 Ph
P09811730A1396 |0 16|Competition EMSAP00001606T0076 C
P09811730A1396 |111 139|KCS protein binding activity neonatal hyperbilirubinemia
P09811730A1396 |191 218|transfection reporter assaytion of CSF PCO2 the data o
P09811730A1396 |67 75|proteinsdase P00
P09811730A1396 |156 173|promoter activityWhen CSF [HCO3-] 
P09811730A1396 |86 97|KCS element Pharmacolo
P09811730T0000 |0 9|MechanismP00001606
P09811730T0000 |13 30|interferon action6 Comparison with
P09811730T0000 |60 69|positionsucleotida
P09811730T0000 |141 151|activationP00008997A
P09811730T0000 |173 196|protein kinase pkr geneis shown as a function 
P09811730T0000 |32 46|identificationlkaline phosph
P09811730T0000 |100 111|KCS element aspects of
P09813041A1122 |0 2|GHP0
P09813041A1122 |88 98|conditionsharmacolog
P09813041A1122 |42 52|activationosphatases
P09813041A1122 |56 59|Jun 5-
P09813041A1122 |23 38|phosphorylationon with alkalin
P09813041A1122 |71 77|kinase P0000
P09813063T0000 |0 10|ExpressionP00001606T
P09813063T0000 |29 52|phospholipase D homologh alkaline phosphatases
P09813063T0000 |82 93|development0000 Pharma
P09813063T0000 |101 110|forebrainaspects o
P09813093A0624 |34 41|YCL024Waline p
P09813093A0624 |91 95|GIN4maco
P09813093A0624 |15 21|effectCompar
P09813093A0624 |62 73|combinationleotidase P
P09813093A0624 |79 87|deletion71T0000 
P09813098A0521 |0 10|ParalemminP00001606T
P09813098A0521 |125 131|mannerrbilir
P09813098A0521 |43 47|mRNAspha
P09813110A0982 |119 125|domainl hype
P09813110A0982 |60 70|similarityucleotidas
P09813110A0982 |144 150|region008997
P09813110A0982 |12 31|amino acid sequence76 Comparison with 
P09813110A0982 |35 40|CBP90line 
P09813110A0982 |84 91|protein00 Phar
P09813203T0000 |115 131|envelope proteinnatal hyperbilir
P09813203T0000 |26 46|serine substitutionswith alkaline phosph
P09813203T0000 |54 61|V3 loopnd 5-nu
P09813203T0000 |93 107|immunogenicitycologic aspect
P09813203T0000 |65 85|HIV-1 gp120 IIIB/LAItidase P00008171T000
P09813203T0000 |4 10|effect01606T
P09813207A0434 |0 32|Transcription start site mappingP00001606T0076 Comparison with a
P09813207A0434 |325 328|ATGslo
P09813207A0434 |244 255|nucleotidesonger displ
P09813207A0434 |332 336|lef21.21
P09813207A0434 |90 100|transcriptrmacologic
P09813207A0434 |289 300|nucleotides still have
P09813207A0434 |222 232|TTGT motifdepleted r
P09813207A0434 |48 56|presenceases and
P09813207A0434 |116 126|TAAG motifatal hyper
P09813207A0434 |143 154|nucleotides0008997A047
P09813207A0434 |192 202|transcription of CSF
P09813207A0434 |272 280|TATA boxd to con
P09813207A0434 |307 314|respectificant
P09813254A0000 |68 85|family interferonase P00008171T000
P09813254A0000 |39 50|synthetases phosphatas
P09813254A0000 |113 121|proteinseonatal 
P09813254A0000 |33 37|2-5Akali
P09813254A0000 |55 62|membersd 5-nuc
P09813254A0000 |87 90|IFNPha
P09813254A0000 |17 31|oligoadenylatemparison with 
P09813259A1097 |69 80|sensitivityse P0000817
P09813259A1097 |121 124|GBPhyp
P09813259A1097 |42 50|blockadeosphatas
P09813259A1097 |106 112|injuryts of 
P09813259A1097 |129 132|IBGiru
P09813259A1097 |4 12|findings01606T00
P09813635A0678 |32 39|contactlkaline
P09813635A0678 |91 93|P3ma
P09813635A0678 |58 62|edge-nuc
P09813635A0678 |125 132|complexrbiliru
P09813635A0678 |76 82|canine08171T
P09813635A0678 |6 16|striations606T0076 C
P09814637A1214 |4 18|PbrO2 readings01606T0076 Com
P09814637A1214 |88 90|CTha
P09814637A1214 |94 97|MRIolo
P09814637A1214 |54 70|microhemorrhagesnd 5-nucleotidas
P09814905A0598 |101 110|nutritionaspects o
P09814905A0598 |30 46|swine production alkaline phosph
P09814905A0598 |92 97|meansacolo
P09814905A0598 |79 88|solutions71T0000 P
P09814905A0598 |54 65|environmentnd 5-nucleo
P09814905A0598 |4 16|consequences01606T0076 C
P09815578A1245 |102 117|prostate cancerspects of neona
P09815578A1245 |29 39|alterationh alkaline
P09815578A1245 |5 10|study1606T
P09815578A1245 |43 48|CDKN2sphat
P09815578A1245 |140 163|prostate carcinogenesis P00008997A0472 When CS
P09815578A1245 |85 98|abnormalities0 Pharmacolog
P09815948A1065 |103 120|peak plasma levelpects of neonatal
P09815948A1065 |58 68|toxicities-nucleotid
P09815948A1065 |78 82|area171T
P09815948A1065 |93 98|curvecolog
P09815948A1065 |20 30|parametersrison with
P09817131A0296 |63 82|translation processeotidase P00008171T
P09817131A0296 |15 32|SF-36 survey formComparison with a
P09817190A0074 |80 92|hypertension1T0000 Pharm
P09817190A0074 |66 76|prevalenceidase P000
P09817190A0074 |13 16|use6 C
P09817190A0074 |96 124|kidney transplant recipientsogic aspects of neonatal hyp
P09817190A0074 |20 33|cyclosporin Arison with al
P09817373A0000 |0 7|PURPOSEP000016
P09817373A0000 |149 160|muscle tone7A0472 When
P09817373A0000 |114 127|insufficiencyonatal hyperb
P09817373A0000 |37 57|hypercholesterolemiane phosphatases and 
P09817373A0000 |214 230|tissue synthesista of K-depleted
P09817373A0000 |26 33|effectswith al
P09817373A0000 |190 198|activityction of
P09817373A0000 |234 257|constrictor eicosanoidss are no longer displac
P09817373A0000 |185 188|NOSa f
P09817373A0000 |169 183|oxide synthase3-] is shown a
P09817601T0000 |0 16|CharacterizationP00001606T0076 C
P09817601T0000 |56 65|aromatase 5-nucleo
P09817601T0000 |67 75|P450aromdase P00
P09817601T0000 |77 81|gene8171
P09817601T0000 |112 122|expressionneonatal h
P09817601T0000 |35 42|regionsline ph
P09819038A0448 |103 119|body temperaturepects of neonata
P09819038A0448 |62 66|daysleot
P09819038A0448 |36 49|infusion pumpine phosphata
P09819038A0448 |12 17|FVIIa76 Co
P09819038A0448 |98 99|hi
P09819038A0448 |70 86|room temperaturee P00008171T0000
P09819110A0703 |0 14|CD4 lymphocyteP00001606T0076
P09819110A0703 |58 66|response-nucleot
P09819110A0703 |89 96|time LDarmacol
P09819110A0703 |25 36|load levels with alkal
P09819110A0703 |70 81|ARV therapye P00008171
P09819216A0220 |7 19|Biochemistry06T0076 Comp
P09819288A0578 |0 6|LevelsP00001
P09819288A0578 |88 91|endhar
P09819288A0578 |77 83|height8171T0
P09819288A0578 |10 19|serum IgE0076 Comp
P09819288A0578 |53 56|IgEand
P09819288A0578 |99 105|seasonc aspe
P09819377A1209 |119 131|accumulationl hyperbilir
P09819377A1209 |77 86|mutations8171T0000
P09819377A1209 |40 57|underaccumulationphosphatases and 
P09819377A1209 |177 182|rangehown 
P09819377A1209 |61 67|snR13Fcleoti
P09819377A1209 |97 108|C2U4 repeatgic aspects
P09819377A1209 |145 149|RNAs0899
P09819377A1209 |21 32|C2U4 repeatison with a
P09819377A1209 |2 10|mutation0001606T
P09819391A1123 |34 38|Arfsalin
P09819391A1123 |43 59|tyrosine kinasessphatases and 5-
P09819391A1123 |149 175|membrane remodeling events7A0472 When CSF [HCO3-] is
P09819391A1123 |112 124|organizationneonatal hyp
P09819391A1123 |126 131|ASAP1bilir
P09819391A1123 |83 94|cell growth000 Pharmac
P09819391A1123 |187 196|processesfunction 
P09819411A0897 |103 115|CTTCCCTGGAAGpects of neo
P09819411A0897 |11 29|footprint analysis076 Comparison wit
P09819411A0897 |52 62|palindrome and 5-nuc
P09819411A0897 |37 48|PNR elementne phosphat
P09819411A0897 |96 101|sitesogic 
P09819411A0897 |3 8|DNase00160
P09819414A1103 |51 58|isoforms and 5
P09819414A1103 |14 20|nexins Compa
P09819414A1103 |109 124|medium isoformsof neonatal hyp
P09819414A1103 |66 81|leptin receptoridase P00008171
P09819421A0000 |0 12|CyclophilinsP00001606T00
P09819421A0000 |125 128|CsArbi
P09819421A0000 |43 53|isomerasessphatases 
P09819421A0000 |110 123|cyclosporin Af neonatal hy
P09819422A0768 |119 123|Cns1l hy
P09819422A0768 |9 38|protein retention experimentsT0076 Comparison with alkalin
P09819422A0768 |48 69|Hsp90 heterocomplexesases and 5-nucleotida
P09819422A0768 |100 115|coprecipitation aspects of neo
P09819430A0000 |16 23|GTPasesomparis
P09819430A0000 |64 69|cycleotida
P09819430A0000 |129 134|stateirubi
P09819430A0000 |49 57|proteinsses and 
P09819430A0000 |100 104|form asp
P09819440A0000 |119 126|varietyl hyper
P09819440A0000 |12 25|transcription76 Comparison
P09819440A0000 |38 45|factorse phosp
P09819440A0000 |130 134|waysrubi
P09819440A0000 |98 113|RNA polymerasesic aspects of n
P09819440A0000 |69 90|transcription factorsse P00008171T0000 Pha
P09819440A0783 |71 75|RPB5 P00
P09819440A0783 |107 112|cellss of 
P09819440A0783 |11 14|RMP076
P09819440A0783 |79 93|RNA polymerase71T0000 Pharma
P09819507A0000 |136 140|daysmia.
P09819507A0000 |15 22|rabbitsCompari
P09819507A0000 |8 13|study6T007
P09819507A0000 |77 82|Dexon8171T
P09819507A0000 |57 71|wound reaction5-nucleotidase
P09819507A0000 |147 169|trabeculectomy surgery997A0472 When CSF [HCO
P09819507A0000 |112 116|flapneon
P09819507A0000 |197 208|mitomycin-Cf CSF PCO2 
P09819507A0000 |190 193|usecti
P09819507A0000 |86 91|nylon Phar
P09820163A0565 |4 11|mapping01606T0
P09820163A0565 |31 48|Southern blottingalkaline phosphat
P09820163A0565 |53 73|restriction analysisand 5-nucleotidase P
P09820205A0000 |117 135|gamete interactiontal hyperbilirubin
P09820205A0000 |43 53|glycocalyxsphatases 
P09820205A0000 |73 79|oocyte000081
P09820205A0000 |20 22|ZPri
P09820205A0000 |4 18|zona pellucida01606T0076 Com
P09820611T0000 |43 51|infusionsphatase
P09820611T0000 |104 115|predialysisects of neo
P09820611T0000 |12 15|use76 
P09820611T0000 |73 87|erythropoietin00008171T0000 
P09820611T0000 |123 131|patientsperbilir
P09820611T0000 |146 157|nephropathy8997A0472 W
P09820621A0067 |118 127|influenceal hyperb
P09820621A0067 |131 144|leptin levelsubinemia. P00
P09820621A0067 |53 60|changesand 5-n
P09820621A0067 |22 38|thyroid functionson with alkalin
P09820621A0067 |64 82|energy expenditureotidase P00008171T
P09820621A0067 |87 103|body compositionPharmacologic as
P09821978A1255 |16 24|deficitsompariso
P09821978A1255 |78 80|SE17
P09821978A1255 |43 50|animalssphatas
P09821978A1255 |64 70|MK-801otidas
P09822602A0237 |254 257|CBPlac
P09822602A0237 |56 66|HIF-1alpha 5-nucleot
P09822602A0237 |29 38|mechanismh alkalin
P09822602A0237 |132 138|importbinemi
P09822602A0237 |42 52|activationosphatases
P09822602A0237 |213 224|recruitmentata of K-de
P09822602A0237 |176 198|transactivation domainshown as a function of
P09822602A0237 |245 252|proteinnger di
P09822602A0237 |143 153|activation0008997A04
P09822602A0237 |83 90|process000 Pha
P09822602A0237 |155 167|derepression When CSF [H
P09822602A0237 |259 275|p300 coactivator when compared t
P09822602A1172 |32 38|importlkalin
P09822602A1172 |146 151|roles8997A
P09822602A1172 |62 73|recruitmentleotidase P
P09822602A1172 |77 80|CBP817
P09822602A1172 |43 58|transactivationsphatases and 5
P09822602A1172 |178 188|HIF-1alphaown as a f
P09822602A1172 |155 174|signal transduction When CSF [HCO3-] i
P09822647A0000 |4 23|rat aldolase C gene01606T0076 Comparis
P09822647A0000 |45 51|enzymehatase
P09822647A0000 |80 85|brain1T000
P09822652A1118 |85 88|Sp10 P
P09822652A1118 |14 20|effect Compa
P09822652A1118 |24 45|HCK promoter activityn with alkaline phosp
P09822652A1118 |67 81|concentrationsdase P00008171
P09822661T0073 |16 22|domainompari
P09822661T0073 |27 46|amino acid residuesith alkaline phosph
P09822661T0073 |59 74|quinone bindingnucleotidase P0
P09822685A0596 |119 132|reading framel hyperbiliru
P09822685A0596 |90 96|regionrmacol
P09822685A0596 |8 16|analyses6T0076 C
P09822685A0596 |46 64|Lu-ECAM-1 peptidesatases and 5-nucle
P09822685A0596 |163 176|size proteinsF [HCO3-] is 
P09822685A0596 |22 30|antiserason with
P09822690A0000 |69 99|protein phosphorylation eventsse P00008171T0000 Pharmacologi
P09822690A0000 |10 24|sperm motility0076 Compariso
P09822690A0000 |43 50|cascadesphatas
P09822690A0000 |112 129|protein kinase A.neonatal hyperbil
P09822825A0141 |34 38|BAP2alin
P09822825A0141 |44 54|expressionphatases a
P09822825A0141 |134 145|amino acidsnemia. P000
P09822825A0141 |107 115|additions of neo
P09822825A0141 |62 71|BAP3 geneleotidase
P09822825A0141 |8 13|paper6T007
P09822825A0141 |153 159|medium72 Whe
P09823014T0000 |0 6|EffectP00001
P09823014T0000 |76 83|indices08171T0
P09823014T0000 |124 132|patientserbiliru
P09823014T0000 |104 120|lipid metabolismects of neonatal
P09823014T0000 |30 38|products alkalin
P09823014T0000 |138 143|NIDDMa. P0
P09823014T0000 |52 64|carbohydrate and 5-nucle
P09823014T0000 |87 99|carbohydratePharmacologi
P09823014T0000 |69 72|fatse 
P09823561T0001 |18 31|MALT lymphomaparison with 
P09823561T0001 |61 84|Gastrospirillum hominiscleotidase P00008171T00
P09823561T0001 |36 59|helicobacter heilmanniiine phosphatases and 5-
P09823775A1122 |138 147|mechanisma. P00008
P09823775A1122 |120 128|insights hyperbi
P09823775A1122 |26 30|viewwith
P09823775A1122 |74 97|HLA-DRA gene activation0008171T0000 Pharmacolo
P09823775A1122 |61 69|cofactorcleotida
P09823775A1122 |151 157|action0472 W
P09823775A1122 |6 13|studies606T007
P09823775A1122 |42 43|Yo
P09823775A1122 |36 41|HMG Iine p
P09823775A1122 |101 107|Oct-2Aaspect
P09824001A1665 |49 59|predictorsses and 5-
P09824001A1665 |73 76|vWF000
P09824001A1665 |106 116|techniquests of neon
P09824001A1665 |63 71|survivaleotidase
P09824001A1665 |77 79|Ag81
P09824001A1665 |3 11|contrast001606T0
P09824021A1263 |51 58|diseases and 5
P09824021A1263 |149 159|parameters7A0472 Whe
P09824021A1263 |128 138|NO therapylirubinemi
P09824021A1263 |108 116|response of neon
P09824021A1263 |39 47|features phospha
P09824021A1263 |0 10|CONCLUSIONP00001606T
P09824158A1336 |84 88|SMRT00 P
P09824158A1336 |13 39|BCL-6 POZ domain mutations6 Comparison with alkaline
P09824158A1336 |74 79|N-CoR00081
P09824158A1336 |107 120|transcriptions of neonatal
P09824158A1336 |57 68|interaction5-nucleotid
P09826434T0000 |50 81|platelet cAMP phosphodiesterasees and 5-nucleotidase P00008171
P09826434T0000 |8 24|characterization6T0076 Compariso
P09826434T0000 |107 118|mutagenesiss of neonat
P09826434T0000 |83 88|PDE3A000 P
P09826434T0000 |39 43|site pho
P09826658A0691 |156 171|BPV-1 pre-mRNAsWhen CSF [HCO3-
P09826658A0691 |104 115|suppressionects of neo
P09826658A0691 |144 152|splicing008997A0
P09826658A0691 |131 139|assemblyubinemia
P09826658A0691 |5 18|core sequence1606T0076 Com
P09826658A0691 |65 76|nucleotidestidase P000
P09826778A0943 |0 15|Over-expressionP00001606T0076 
P09826778A0943 |88 101|transcriptionharmacologic 
P09826778A0943 |59 70|coactivatornucleotidas
P09826778A0943 |128 135|COUP-TFlirubin
P09826778A0943 |23 36|cofactor p300on with alkal
P09826778A0943 |114 124|repressiononatal hyp
P09827446T0001 |34 47|C4 deficiencyaline phospha
P09827446T0001 |20 29|hepatitisrison wit
P09827724A1362 |3 12|mutations001606T00
P09827724A1362 |38 46|adenomase phosph
P09827878A0091 |119 126|defencel hyper
P09827878A0091 |6 28|glutathione peroxidase606T0076 Comparison wi
P09827878A0091 |93 104|erythrocytecologic asp
P09827878A0091 |61 64|SODcle
P09827878A0091 |30 33|GPX al
P09827878A0091 |39 59|superoxide dismutase phosphatases and 5-
P09827878A0091 |203 210|workersPCO2 th
P09827878A0091 |168 176|activityO3-] is 
P09827878A0091 |85 89|role0 Ph
P09827993A0000 |34 38|NCPsalin
P09827993A0000 |134 153|retrovirus assemblynemia. P00008997A04
P09827993A0000 |166 183|RNA encapsidationHCO3-] is shown a
P09827993A0000 |88 117|virion RNA binding activitiesharmacologic aspects of neona
P09827993A0000 |11 32|nucleocapsid proteins076 Comparison with a
P09827993A0000 |54 74|zinc finger proteinsnd 5-nucleotidase P0
P09828137A0000 |87 94|S-phasePharmac
P09828137A0000 |131 141|DNA damageubinemia. 
P09828137A0000 |30 34|rad1 alk
P09828137A0000 |99 110|G2/M arrestc aspects o
P09828137A0000 |36 70|cell cycle checkpoint control geneine phosphatases and 5-nucleotidas
P09828137A0000 |114 122|responseonatal h
P09828137A0000 |157 172|DNA replicationhen CSF [HCO3-]
P09829836A0000 |154 158|CDKs2 Wh
P09829836A0000 |145 152|kinases08997A0
P09829836A0000 |95 107|oscillationslogic aspect
P09829836A0000 |67 77|cell cycledase P0000
P09829836A0000 |127 133|cyclinilirub
P09829836A0000 |115 123|activitynatal hy
P09829836A0000 |32 43|progressionlkaline pho
P09829836A0815 |17 27|selectionsmparison w
P09829836A0815 |46 65|cyclin/CDK functionatases and 5-nucleo
P09829836A0815 |111 127|yeast LEU2 genes neonatal hyperb
P09829836A0815 |32 42|inhibitionlkaline ph
P09829843A0119 |204 210|cancerCO2 th
P09829843A0119 |215 226|neutropeniaa of K-depl
P09829843A0119 |46 49|CSFata
P09829843A0119 |149 158|incidence7A0472 Wh
P09829843A0119 |120 128|measures hyperbi
P09829843A0119 |173 186|complicationsis shown as a
P09829843A0119 |37 44|factorsne phos
P09829843A0119 |190 198|patientsction of
P09829843A0119 |86 94|practice Pharmac
P09829843A0819 |369 393|chemiluminescence systemazepam thus appears to b
P09829843A0819 |250 255|leveldispl
P09829843A0819 |320 339|neutrophil functionater slope (1.21 +/
P09829843A0819 |93 103|occurrencecologic as
P09829843A0819 |57 68|neutropenia5-nucleotid
P09829843A0819 |214 217|dayta 
P09829843A0819 |299 315|neutrophil counte a significantl
P09829843A0819 |242 245|day lo
P09829843A0819 |228 237|microg kged rats a
P09829843A0819 |119 138|neutrophil recoveryl hyperbilirubinemi
P09829843A0819 |18 21|CSFpar
P09829843A0819 |155 164|rHu G-CSF When CSF
P09829843A0819 |140 150|rHu GM-CSF P00008997
P09829843A0819 |43 53|initiationsphatases 
P09829843A0819 |201 209|microg mF PCO2 t
P09829843A0819 |4 14|injections01606T0076
P09829916T0000 |0 10|ExpressionP00001606T
P09829916T0000 |14 18|lacZ Com
P09829916T0000 |105 109|W205cts 
P09829916T0000 |65 71|operontidase
P09829916T0000 |28 36|promoterth alkal
P09829916T0000 |84 91|vectors00 Phar
P09829916T0000 |118 124|fusional hyp
P09832099A0000 |136 157|color kinesis imagingmia. P00008997A0472 W
P09832099A0000 |40 51|wall motionphosphatase
P09832099A0000 |104 113|tetralogyects of n
P09832099A0000 |59 66|systolenucleot
P09832099A0000 |125 128|TOFrbi
P09832099A0000 |70 78|patientse P00008
P09832099A0000 |117 123|Fallottal hy
P09832436A0738 |0 15|RT-PCR analysisP00001606T0076 
P09832436A0738 |120 133|PLP diversity hyperbilirub
P09832436A0738 |45 50|PLP-Chatas
P09832436A0738 |82 93|rat strains0000 Pharma
P09832436A0738 |28 33|PLP-Hth al
P09832436A0738 |55 60|PLP-Dd 5-n
P09832436A0738 |155 166|differences When CSF [
P09832436T0000 |87 90|PRLPha
P09832436T0000 |10 17|cloning0076 Co
P09832436T0000 |109 119|protein H.of neonata
P09832436T0000 |62 65|ratleo
P09832436T0000 |76 85|prolactin08171T000
P09832436T0000 |92 98|familyacolog
P09832436T0000 |22 38|characterizationson with alkalin
P09832436T0000 |48 54|memberases a
P09832504A0596 |102 119|cysteine residuesspects of neonata
P09832504A0596 |60 66|hCycT1ucleot
P09832504A0596 |76 80|zinc0817
P09832504A0596 |128 136|proteinslirubine
P09832504A0596 |52 55|Tat an
P09832504A0596 |32 43|interactionlkaline pho
P09832505A0903 |68 73|Oct-1ase P
P09832505A0903 |28 45|activation targetth alkaline phosp
P09832505A0903 |57 66|activator5-nucleot
P09832505A0903 |100 121|transcription complex aspects of neonatal 
P09832511A0269 |136 143|patternmia. P0
P09832511A0269 |13 25|neurogenesis6 Comparison
P09832511A0269 |147 154|neurons997A047
P09832511A0269 |89 100|neuroblastsarmacologic
P09832511A0269 |27 38|Vnd proteinith alkalin
P09832511A0269 |64 84|column neuroectodermotidase P00008171T00
P09832518A0615 |4 21|repression domain01606T0076 Compar
P09832518A0615 |167 173|lactisCO3-] 
P09832518A0615 |181 198|database searches as a function of
P09832518A0615 |45 58|Cdc68 proteinhatases and 5
P09832518A0615 |147 152|yeast997A0
P09832518A0615 |130 137|homologrubinem
P09832518A0615 |97 105|sequencegic aspe
P09832518A0615 |113 118|Cdc68eonat
P09833610A0626 |33 49|affinity hormonekaline phosphata
P09833610A0626 |105 111|signalcts of
P09833610A0626 |58 62|site-nuc
P09833610A0626 |4 13|exodomain01606T007
P09833740A1112 |0 27|Pyrrolidine dithiocarbamateP00001606T0076 Comparison w
P09833740A1112 |123 125|U1pe
P09833740A1112 |261 277|provirus latencyhen compared to 
P09833740A1112 |77 80|LTR817
P09833740A1112 |198 207|mechanism CSF PCO2
P09833740A1112 |130 141|ACH-2 cellsrubinemia. 
P09833740A1112 |54 63|inhibitornd 5-nucl
P09833740A1112 |96 114|cytokine responsesogic aspects of ne
P09833740A1112 |217 227|cell typesof K-deple
P09833740A1112 |252 257|modessplac
P09834070A0793 |139 164|protein kinase C activity. P00008997A0472 When CSF
P09834070A0793 |60 67|absenceucleoti
P09834070A0793 |96 99|Ca2ogi
P09834070A0793 |25 35|activation with alka
P09834070A0793 |125 135|inhibitionrbilirubin
P09834070A0793 |208 212|CD19the 
P09834070A0793 |191 198|pathwaytion of
P09834070A0793 |39 43|ERK2 pho
P09834070A0793 |71 78|changes P00008
P09834070A0793 |223 238|B cell functionepleted rats ar
P09834521A0000 |17 29|hydatid cystmparison wit
P09834521A0000 |45 49|sitehata
P09835615A0574 |51 58|proteins and 5
P09835615A0574 |90 107|repressor domainsrmacologic aspect
P09835615A0574 |109 111|R1of
P09835615A0574 |12 20|analysis76 Compa
P09835615A0574 |116 118|R2at
P09835615A0574 |34 37|KS1ali
P09836881A0441 |117 126|Bruininkstal hyper
P09836881A0441 |13 22|BCH group6 Compari
P09836881A0441 |45 62|motor performancehatases and 5-nuc
P09836881A0441 |98 115|Motor Proficiencyic aspects of neo
P09836881A0441 |70 94|Bruininks-Oseretsky Teste P00008171T0000 Pharmac
P09837714A1068 |69 82|modificationsse P00008171T
P09837714A1068 |39 41|pH p
P09837714A1068 |22 33|possibilityson with al
P09837714A1068 |125 143|cell proliferationrbilirubinemia. P0
P09837714A1068 |108 114|events of ne
P09837714A1068 |4 11|results01606T0
P09837714A1068 |174 187|Dictyosteliums shown as a 
P09837714A1068 |86 91|DdRPA Phar
P09837714A1068 |155 170|differentiation When CSF [HCO3
P09837715A0581 |205 208|MLVO2 
P09837715A0581 |58 61|DNA-nu
P09837715A0581 |210 242|SL3-3 LTR-CAT reporter constructe data of K-depleted rats are no
P09837715A0581 |189 203|leukemia virusnction of CSF 
P09837715A0581 |67 72|leveldase 
P09837715A0581 |76 109|chloramphenicol acetyltransferase08171T0000 Pharmacologic aspects 
P09837715A0581 |111 114|CAT ne
P09837715A0581 |116 120|mRNAatal
P09837715A0581 |36 42|amountine ph
P09837715A0581 |152 157|cells472 W
P09837715A0581 |171 176|HIV-1] is 
P09837824A0419 |205 208|A2GO2 
P09837824A0419 |104 110|telSMNects o
P09837824A0419 |14 30|telSMN mutations Comparison with
P09837824A0419 |96 100|copyogic
P09837824A0419 |130 150|frameshift mutationsrubinemia. P00008997
P09837824A0419 |210 215|S262Ie dat
P09837824A0419 |165 173|542delGT[HCO3-] 
P09837824A0419 |185 203|missense mutationsa function of CSF 
P09837824A0419 |65 76|individualstidase P000
P09837824A0419 |221 226|T274I-depl
P09837824A0419 |152 160|800ins11472 When
P09837907A0857 |16 29|TNF receptorsomparison wit
P09837907A0857 |88 98|activitiesharmacolog
P09837907A0857 |181 186|c-Jun as a
P09837907A0857 |57 72|down-regulation5-nucleotidase 
P09837907A0857 |198 214|kinase induction CSF PCO2 the da
P09837907A0857 |160 175|AP-1 activation CSF [HCO3-] is
P09837907A0857 |124 144|caspase-3 activationerbilirubinemia. P00
P09837907A0857 |110 122|cytotoxicityf neonatal h
P09837907A0857 |146 155|NF-kappaB8997A0472
P09837907A0857 |4 12|decrease01606T00
P09837907A0857 |33 37|IL-4kali
P09837913A0000 |0 4|TypeP000
P09837913A0000 |56 65|thyroxine 5-nucleo
P09837913A0000 |7 17|deiodinase06T0076 Co
P09837913A0000 |40 52|deiodinationphosphatases
P09837913A0000 |81 97|triiodothyronineT0000 Pharmacolo
P09837913A0000 |19 21|D2ar
P09837913A0419 |119 121|D2l 
P09837913A0419 |123 126|hD2per
P09837913A0419 |45 64|sequence tag cloneshatases and 5-nucle
P09837913A0419 |128 132|cDNAliru
P09837913A0419 |102 105|UTRspe
P09837914A0844 |0 4|BiolP000
P09837920A0222 |85 100|phosphorylation0 Pharmacologic
P09837920A0222 |41 53|requirementshosphatases 
P09837920A0222 |58 70|consequences-nucleotidas
P09837920A0222 |109 120|interactionof neonatal
P09837920A0222 |129 134|c-Junirubi
P09837920A0222 |139 142|JNK. P
P09837933T0000 |68 83|peptidylglycinease P00008171T0
P09837933T0000 |134 143|endosomesnemia. P0
P09837933T0000 |100 113|monooxygenase aspects of n
P09837933T0000 |58 64|domain-nucle
P09837933T0000 |16 23|proteinomparis
P09837933T0000 |0 6|P-CIP1P00001
P09837945A0820 |171 179|fraction] is sho
P09837945A0820 |197 205|materialf CSF PC
P09837945A0820 |133 138|Sop1pinemi
P09837945A0820 |121 129|fractionhyperbil
P09837945A0820 |0 18|ImmunolocalizationP00001606T0076 Com
P09837945A0820 |22 27|Sop1pson w
P09837945A0820 |51 63|distributions and 5-nucl
P09837945A0820 |68 94|cell fractionation studiesase P00008171T0000 Pharmac
P09837978T0093 |81 89|JNK/SAPKT0000 Ph
P09837978T0093 |10 20|activation0076 Compa
P09837978T0093 |24 29|c-Junn wit
P09837978T0093 |65 79|protein kinasetidase P000081
P09838122A0489 |59 74|mouse homologuenucleotidase P0
P09838122A0489 |31 51|coding cDNA sequencealkaline phosphatase
P09838122A0489 |78 82|MPP3171T
P09840822A0462 |55 62|concernd 5-nuc
P09840822A0462 |27 34|taggingith alk
P09840822A0462 |80 110|magnetization transfer effects1T0000 Pharmacologic aspects o
P09840822A0462 |4 10|method01606T
P09840928A0884 |68 71|H2Aase
P09840928A0884 |92 102|substratesacologic a
P09840928A0884 |132 145|kinase assaysbinemia. P000
P09840928A0884 |31 34|Dlkalk
P09840928A0884 |159 167|extractsn CSF [H
P09840928A0884 |76 78|H408
P09840928A0884 |50 66|core histones H3es and 5-nucleot
P09840928A0884 |118 128|histone H3al hyperbi
P09840932A0365 |71 77|target P0000
P09840932A0365 |25 33|evidence with al
P09840932A0365 |8 13|study6T007
P09840932A0365 |82 95|cyclin A/Cdk20000 Pharmaco
P09840932A0365 |39 44|B-Myb phos
P09840934A0435 |239 244|cells no l
P09840934A0435 |189 196|effectsnction 
P09840934A0435 |92 98|Ha-Rasacolog
P09840934A0435 |29 41|Ha-RasV12S35h alkaline p
P09840934A0435 |148 162|RalGDS pathway97A0472 When C
P09840934A0435 |16 20|G12Vompa
P09840934A0435 |218 227|apoptosisf K-deple
P09840934A0435 |22 26|T35Sson 
P09840934A0435 |112 124|Ha-RasV12G37neonatal hyp
P09840934A0435 |8 14|Ha-Ras6T0076
P09840934A0435 |105 109|E37Gcts 
P09840934A0435 |99 103|G12Vc as
P09840934A0435 |64 86|Rafl signaling pathwayotidase P00008171T0000
P09840943A0144 |39 48|cyclin E2 phosphat
P09840943A0144 |31 37|cyclinalkali
P09840943A0144 |88 97|cyclin E.harmacolo
P09840943A0144 |76 84|homology08171T00
P09842517A0497 |117 120|MRItal
P09842517A0497 |94 101|methodsologic 
P09842517A0497 |8 18|experience6T0076 Com
P09842517A0497 |58 66|SieScape-nucleot
P09842517A0497 |110 112|CTf 
P09842517A0497 |32 42|technologylkaline ph
P09843378A0187 |100 119|SH3 binding domains aspects of neonata
P09843378A0187 |65 74|receptorstidase P0
P09843378A0187 |4 24|dopamine D4 receptor01606T0076 Compariso
P09843412A0130 |51 58|Abeta42s and 5
P09843412A0130 |73 80|species0000817
P09843412A0130 |44 49|Abetaphata
P09843412A0130 |127 129|ADil
P09843412A0130 |36 40|formine 
P09843572A0944 |117 129|cell lysatestal hyperbil
P09843572A0944 |109 113|Wee1of n
P09843572A0944 |149 153|Wee17A04
P09843572A0944 |52 67|Cdr2 associates and 5-nucleoti
P09843572A0944 |27 38|experimentsith alkalin
P09843572A0944 |5 10|model1606T
P09843572A0944 |99 105|domainc aspe
P09843577A0000 |52 63|deprivation and 5-nucl
P09843577A0000 |26 31|cellswith 
P09843577A0000 |76 98|G2/M cell size control08171T0000 Pharmacolog
P09843944A0976 |152 171|UP element function472 When CSF [HCO3-
P09843944A0976 |90 94|turnrmac
P09843944A0976 |58 65|hexamer-nucleo
P09843944A0976 |0 8|A-tractsP0000160
P09844106A0835 |49 52|FLGses
P09844106A0835 |67 78|fibronectindase P00008
P09844106A0835 |58 63|cells-nucl
P09844106A0835 |5 20|phosphorylation1606T0076 Compa
P09844106A0835 |36 45|adherenceine phosp
P09844106A0835 |98 103|cellsic as
P09844106A0835 |86 89|ST2 Ph
P09844921A0000 |0 3|RafP00
P09844921A0000 |114 138|differentiation messagesonatal hyperbilirubinemi
P09844921A0000 |13 44|serine-threonine protein kinase6 Comparison with alkaline phos
P09844921A0000 |71 83|transmission P00008171T0
P09844921A0000 |87 93|growthPharma
P09845043A0000 |102 110|drinkingspects o
P09845043A0000 |121 134|alcohol abusehyperbilirubi
P09845043A0000 |151 158|problem0472 Wh
P09845043A0000 |59 64|NIAAAnucle
P09845043A0000 |29 42|Alcohol Abuseh alkaline ph
P09845043A0000 |47 57|Alcoholismtases and 
P09845043A0000 |165 183|alcohol dependence[HCO3-] is shown a
P09845043A0000 |81 86|formsT0000
P09845043A0000 |4 25|US National Institute01606T0076 Comparison
P09845043A0000 |201 209|disorderF PCO2 t
P09845043A0000 |236 245|componentare no lo
P09845662A0085 |137 156|gel electrophoresisia. P00008997A0472 
P09845662A0085 |158 166|SDS-PAGEen CSF [
P09845662A0085 |63 71|collageneotidase
P09845662A0085 |46 50|lackatas
P09845662A0085 |90 95|meansrmaco
P09845662A0085 |99 113|sodium dodecylc aspects of n
P09845662A0085 |54 58|typend 5
P09845662A0085 |32 36|skinlkal
P09845662A0085 |0 8|CollagenP0000160
P09845856A0560 |0 7|RESULTSP000016
P09845856A0560 |63 77|ulcer diseaseseotidase P0000
P09845856A0560 |27 33|periodith al
P09846033A0488 |34 46|pretreatmentaline phosph
P09846033A0488 |21 28|changesison wi
P09846033A0488 |79 80|p7
P09846033A0488 |50 63|posttreatmentes and 5-nucl
P09846033A0488 |0 7|RESULTSP000016
P09846482A0441 |3 7|turn0016
P09846482A0441 |122 142|actin polymerizationyperbilirubinemia. P
P09846482A0441 |26 33|complexwith al
P09846482A0441 |89 103|protein kinasearmacologic as
P09846482A0441 |57 67|activation5-nucleoti
P09846482A0441 |9 17|assemblyT0076 Co
P09846927A0227 |85 90|death0 Pha
P09846927A0227 |60 72|stomach wallucleotidase 
P09846927A0227 |15 21|buttonCompar
P09846927A0227 |31 42|perforationalkaline ph
P09846927A0227 |4 7|tip016
P09847371A0000 |0 22|Jembrana disease virusP00001606T0076 Compari
P09847371A0000 |131 134|BIVubi
P09847371A0000 |107 129|immunodeficiency viruss of neonatal hyperbil
P09847371A0000 |24 27|JDVn w
P09847371A0000 |58 68|lentivirus-nucleotid
P09847397A0935 |16 17|%o
P09847397A0935 |177 188|CCAAT boxeshown as a f
P09847397A0935 |133 148|glucocorticoidsinemia. P000089
P09847397A0935 |89 96|virusesarmacol
P09847397A0935 |25 33|residues with al
P09847397A0935 |111 128|response elements neonatal hyperbi
P09847397A0935 |217 227|TATA boxesof K-deple
P09847397A0935 |64 73|sequencesotidase P
P09848653A0597 |0 5|Nhp2pP0000
P09848653A0597 |24 31|proteinn with 
P09848653A0597 |81 89|proteinsT0000 Ph
P09848653A0597 |50 56|familyes and
P09849421A0332 |103 115|Organizationpects of neo
P09849421A0332 |211 215|mail dat
P09849421A0332 |120 128|Research hyperbi
P09849421A0332 |146 165|Cancer Core Quality8997A0472 When CSF 
P09849421A0332 |133 142|Treatmentinemia. P
P09849421A0332 |73 76|age000
P09849421A0332 |44 54|Norwegiansphatases a
P09849421A0332 |5 11|survey1606T0
P09849421A0332 |189 202|EORTC QLQ-C30nction of CSF
P09849421A0332 |64 69|yearsotida
P09849421A0332 |169 187|Life Questionnaire3-] is shown as a 
P09849722A0797 |220 233|brain regionsK-depleted ra
P09849722A0797 |213 218|gyrusata o
P09849722A0797 |182 188|cortexas a f
P09849722A0797 |63 78|signal increaseeotidase P00008
P09849722A0797 |151 165|cingulate gyri0472 When CSF 
P09849722A0797 |276 300|emotion processing tasks controls but still have
P09849722A0797 |7 19|presentation06T0076 Comp
P09849722A0797 |36 47|expressionsine phospha
P09849722A0797 |114 129|cingulate gyrusonatal hyperbil
P09849961A0387 |0 15|Down-regulationP00001606T0076 
P09849961A0387 |124 139|differentiationerbilirubinemia
P09849961A0387 |227 245|myoblast cell lineted rats are no lo
P09849961A0387 |42 64|serine phosphorylationosphatases and 5-nucle
P09849961A0387 |78 98|PI 3-kinase activity171T0000 Pharmacolog
P09849961A0387 |19 24|IRS-1ariso
P09849961A0387 |153 158|IRS-172 Wh
P09849965A0000 |5 10|study1606T
P09849965A0000 |75 81|ligand008171
P09849965A0000 |45 51|systemhatase
P09849965A0000 |89 101|dimerizationarmacologic 
P09849965A0000 |134 137|hPRnem
P09849965A0000 |111 132|progesterone receptor neonatal hyperbiliru
P09849965A0000 |67 71|roledase
P09851614A0109 |170 175|mRNAs-] is
P09851614A0109 |146 160|cap structures8997A0472 When
P09851614A0109 |109 112|ntsof 
P09851614A0109 |132 139|absencebinemia
P09851614A0109 |96 107|nucleotidesogic aspect
P09851614A0109 |77 84|regions8171T00
P09851614A0109 |18 26|featuresparison 
P09851614A0109 |86 89|UTR Ph
P09851700A0000 |102 108|mannerspects
P09851700A0000 |24 57|tissue-type plasminogen activatorn with alkaline phosphatases and 
P09851700A0000 |59 63|t-PAnucl
P09851700A0000 |4 8|gene0160
P09851988A0085 |34 46|anaerobiosisaline phosph
P09851988A0085 |21 29|arginineison wit
P09851988A0085 |9 17|presenceT0076 Co
P09851988A0085 |86 93|pathway Pharma
P09851988A0085 |69 78|inductionse P00008
P09852005A1287 |254 263|complexeslaced whe
P09852005A1287 |197 218|serum response factorf CSF PCO2 the data o
P09852005A1287 |161 192|MADS box consensus binding siteCSF [HCO3-] is shown as a funct
P09852005A1287 |130 139|gene PEP1rubinemia
P09852005A1287 |28 59|MADS box consensus binding siteth alkaline phosphatases and 5-
P09852005A1287 |291 303|OP4 sequencetill have a 
P09852005A1287 |141 145|SAP1P000
P09852005A1287 |69 77|promoterse P0000
P09852005A1287 |0 11|CompetitionP00001606T0
P09852068A0150 |50 55|DNasees an
P09852068A0150 |130 137|FP1-FP6rubinem
P09852068A0150 |11 15|SHBG076 
P09852068A0150 |121 128|regionshyperbi
P09852068A0150 |91 103|significancemacologic as
P09852068A0150 |25 33|promoter with al
P09852068A0150 |58 70|footprinting-nucleotidas
P09852068A0150 |159 167|promotern CSF [H
P09852068A0150 |189 215|HepG2 hepatoblastoma cellsnction of CSF PCO2 the dat
P09852109A1475 |137 149|efficienciesia. P0000899
P09852109A1475 |9 20|translationT0076 Compa
P09852109A1475 |240 247|regionsno long
P09852109A1475 |74 87|transcripts C0008171T0000 
P09852109A1475 |194 206|transcript Dn of CSF PCO
P09852109A1475 |42 58|profile analysisosphatases and 5
P09852109A1475 |92 93|Ea
P09852109A1475 |277 284|controlcontrol
P09852109A1475 |255 259|roleaced
P09852136A0174 |171 178|protein] is sh
P09852136A0174 |31 36|Ser36alkal
P09852136A0174 |90 97|abilityrmacolo
P09852136A0174 |56 62|domain 5-nuc
P09852136A0174 |41 44|Asnhos
P09852136A0174 |182 191|COS cellsas a func
P09852136A0174 |106 124|guanine nucleotidets of neonatal hyp
P09852136A0174 |145 158|hemagglutinin08997A0472 Wh
P09852136A0174 |160 162|HA C
P09852136A0174 |66 70|p190idas
P09852136A0174 |21 29|mutationison wit
P09852136A0507 |0 17|Wild type HA-p190P00001606T0076 Co
P09852136A0507 |28 37|phenotypeth alkali
P09852136A0507 |110 122|Rho functionf neonatal h
P09852136A0507 |73 83|extensions00008171T0
P09852136A0507 |49 54|cellsses a
P09852136A0507 |139 155|ADP-ribosylation. P00008997A0472
P09852752A0950 |34 44|vasculitisaline phos
P09852752A0950 |82 84|RA00
P09852752A0950 |66 78|complicationidase P00008
P09854034A0536 |109 121|mRNA speciesof neonatal 
P09854034A0536 |44 55|G+C contentphatases an
P09854034A0536 |61 68|exon 1bcleotid
P09854034A0536 |26 34|promoterwith alk
P09855111A0905 |308 316|synthaseficantly
P09855111A0905 |299 306|HMG CoAe a sig
P09855111A0905 |63 70|domainseotidas
P09855111A0905 |330 340|cell lines (1.21 +/-
P09855111A0905 |211 221|regulation data of K
P09855111A0905 |113 123|regulationeonatal hy
P09855111A0905 |127 143|SREBP processingilirubinemia. P0
P09855111A0905 |27 41|overexpressionith alkaline p
P09855111A0905 |244 255|mRNA levelsonger displ
P09855111A0905 |287 297|coenzyme Aut still h
P09855111A0905 |378 384|mannerus app
P09855111A0905 |161 171|disruptionCSF [HCO3-
P09855111A0905 |233 238|genests ar
P09856397A0099 |0 17|Dry matter intakeP00001606T0076 Co
P09856397A0099 |28 52|nutrient digestibilitiesth alkaline phosphatases
P09856397A0099 |135 142|tissuesemia. P
P09856397A0099 |113 124|persistencyeonatal hyp
P09856397A0099 |128 131|FB1lir
P09856397A0099 |54 78|serum chemistry profilesnd 5-nucleotidase P00008
P09856397A0099 |80 107|sphingolipid concentrations1T0000 Pharmacologic aspect
P09856732A0114 |100 109|lidocaine aspects 
P09856732A0114 |90 96|effectrmacol
P09856732A0114 |12 19|studies76 Comp
P09857038A1374 |0 2|E.P0
P09857038A1374 |11 13|J.07
P09857038A1374 |4 9|Scott01606
P09857197A0289 |0 5|Yap1pP0000
P09857197A0289 |37 48|crm1 mutantne phosphat
P09857197A0289 |131 139|presenceubinemia
P09857197A0289 |79 94|export sequence71T0000 Pharmac
P09857197A0289 |106 114|sequencets of ne
P09857197A0289 |143 149|RanGTP000899
P09857197A0289 |96 99|NESogi
P09857197A0289 |54 59|Crm1pnd 5-
P09857197A0289 |118 123|Yap1pal hy
P09857265A0669 |0 11|Mean intakeP00001606T0
P09857265A0669 |134 144|vegetablesnemia. P00
P09857265A0669 |119 123|fatsl hy
P09857265A0669 |187 188|%f
P09857265A0669 |49 58|mg RE/dayses and 5
P09857265A0669 |113 117|meateona
P09857265A0669 |63 66|meneot
P09857265A0669 |149 163|dairy products7A0472 When CS
P09857265A0669 |197 198|%f
P09857265A0669 |128 132|oilsliru
P09857265A0669 |192 193|%i
P09857265A0669 |15 24|vitamin ACompariso
P09857265A0669 |96 109|contributionsogic aspects 
P09857265A0669 |173 179|intakeis sho
P09857265A0669 |71 76|women P000
P09857265A0669 |206 207|%2
P09858094A0583 |51 53|O1s 
P09858094A0583 |60 62|O4uc
P09858094A0583 |57 59|O35-
P09858094A0583 |10 19|amplitude0076 Comp
P09858094A0583 |39 49|potentials phosphata
P09858094A0583 |117 123|periodtal hy
P09858531A1017 |98 103|c-fosic as
P09858531A1017 |13 33|RING1 overexpression6 Comparison with al
P09858531A1017 |72 93|proto-oncogenes c-junP00008171T0000 Pharma
P09858531A1017 |54 64|expressionnd 5-nucle
P09858571T0000 |136 154|dolichol synthesismia. P00008997A047
P09858571T0000 |126 132|enzymebiliru
P09858571T0000 |47 87|reticulum protein localization mutationstases and 5-nucleotidase P00008171T0000 
P09858571T0000 |97 118|cis-prenyltransferasegic aspects of neonat
P09858571T0000 |4 19|yeast RER2 gene01606T0076 Comp
P09858572A0000 |4 29|yeast retrotransposon Ty501606T0076 Comparison wit
P09858572A0000 |61 68|regionscleotid
P09858572A0000 |79 88|chromatin71T0000 P
P09858577A1186 |138 143|Sko1pa. P0
P09858577A1186 |160 168|effector CSF [HC
P09858577A1186 |12 16|SKO176 C
P09858577A1186 |107 125|stress sensitivitys of neonatal hype
P09858577A1186 |58 69|hog1 mutant-nucleotida
P09858577A1186 |176 187|HOG pathwayshown as a 
P09858577A1186 |37 52|ENA1 expressionne phosphatases
P09858577A1186 |4 8|loss0160
P09858581A0183 |52 56|gene and
P09858581A0183 |149 151|Ts7A
P09858581A0183 |104 120|splicing defectsects of neonatal
P09858581A0183 |9 19|expressionT0076 Comp
P09858581A0183 |160 167|prp38-1 CSF [H
P09858581A0183 |58 64|SPP381-nucle
P09858581A0183 |93 99|growthcologi
P09858588A1046 |102 107|cellsspect
P09858588A1046 |44 47|p68pha
P09858588A1046 |36 40|formine 
P09858588A1046 |77 81|G1/S8171
P09858588A1046 |116 120|G2/Matal
P09858588A1046 |68 73|cellsase P
P09858593A0334 |102 125|insulin gene expressionspects of neonatal hype
P09858593A0334 |57 78|Xenopus NeuroD1/BETA25-nucleotidase P00008
P09858593A0334 |138 150|neurogenesisa. P00008997
P09858593A0334 |19 39|amino acid sequencesarison with alkaline
P09858599A0392 |68 82|transformationase P00008171T
P09858599A0392 |130 145|PBX interactionrubinemia. P000
P09858599A0392 |5 25|NUP98-HOXA9 chimeras1606T0076 Comparison
P09858599A0392 |96 109|HOXA9 domainsogic aspects 
P09858599A0392 |114 125|DNA bindingonatal hype
P09858599A0392 |38 57|NIH 3T3 fibroblastse phosphatases and 
P09858619A0356 |35 39|Y319line
P09858619A0356 |7 14|studies06T0076
P09858619A0356 |65 80|ZAP-70 functiontidase P0000817
P09858713A1174 |51 54|Pans a
P09858713A1174 |162 165|ciDSF 
P09858713A1174 |242 245|CiD lo
P09858713A1174 |194 205|enhancementn of CSF PC
P09858713A1174 |260 267|mutantswhen co
P09858713A1174 |22 26|datason 
P09858713A1174 |59 62|CiDnuc
P09858713A1174 |213 238|gain-of-function activityata of K-depleted rats ar
P09858713A1174 |116 128|transductionatal hyperbi
P09858713A1174 |86 89|Arm Ph
P09858713A1174 |168 175|animalsO3-] is
P09858713A1174 |136 145|Wg signalmia. P000
P09858714A1171 |35 39|modAline
P09858714A1171 |44 47|ddapha
P09858714A1171 |105 108|srdcts
P09858714A1171 |8 11|ORF6T0
P09858714A1171 |13 18|dda.26 Com
P09858714A1171 |81 88|sigma70T0000 P
P09858714A1171 |49 75|shares sequence similarityses and 5-nucleotidase P00
P09858745A1350 |51 55|genes an
P09858745A1350 |145 148|IBS089
P09858745A1350 |61 74|cooperativitycleotidase P0
P09858745A1350 |120 127|studies hyperb
P09858745A1350 |169 180|interaction3-] is show
P09858745A1350 |87 107|footprinting studiesPharmacologic aspect
P09858745A1350 |4 12|location01606T00
P09858745A1350 |20 23|IBSris
P09858745A1350 |207 220|binding sites the data of 
P09858745A1350 |184 188|CatR a f
P09858745A1350 |252 255|DNAspl
P09858745A1350 |35 39|catBline
P09858745A2033 |141 156|clcA transcriptP00008997A0472 
P09858745A2033 |61 73|intermediatecleotidase P
P09858745A2033 |75 83|fumarate008171T0
P09858745A2033 |124 133|formationerbilirub
P09858745A2033 |9 29|transcription assaysT0076 Comparison wit
P09858883A1106 |68 72|N-A3ase 
P09858883A1106 |45 48|M-1hat
P09858883A1106 |24 28|Kaffn wi
P09858883A1106 |57 64|binding5-nucle
P09858883A1106 |130 133|T84rub
P09858883A1106 |122 126|N-A3yper
P09858883A1106 |76 81|T84.108171
P09858883A1106 |111 118|binding neonat
P09858883A1106 |99 102|M-1c a
P09858883A1106 |0 16|BIAcore analysisP00001606T0076 C
P09860979A0521 |0 10|ExpressionP00001606T
P09860979A0521 |147 150|Crk997
P09860979A0521 |63 77|Crk SH2-domaineotidase P0000
P09860979A0521 |14 18|p130 Com
P09860979A0521 |25 28|Cas wi
P09860979A0521 |92 106|JNK activationacologic aspec
P09860979A0521 |39 54|binding protein phosphatases a
P09860979A0521 |19 22|Casari
P09861099A1011 |140 151|differences P00008997A
P09861099A1011 |159 165|g/kg/dn CSF 
P09861099A1011 |179 190|kcal/kg/daywn as a fun
P09861099A1011 |95 108|energy intakelogic aspects
P09861099A1011 |61 75|protein intakecleotidase P00
P09861099A1011 |192 194|SDio
P09861099A1011 |44 56|measurementsphatases and
P09861099A1011 |85 86|P0
P09861099A1011 |118 119|Pa
P09861099A1011 |77 78|r8
P09861099A1011 |167 169|SDCO
P09861099A1011 |9 21|correlationsT0076 Compar
P09861099A1011 |110 111|rf
P09861365A0000 |38 43|assaye pho
P09861365A0000 |45 50|ELISAhatas
P09861365A0000 |95 102|antigenlogic a
P09861365A0000 |121 126|serumhyper
P09861365A0000 |111 117|microL neona
P09861365A0000 |4 9|Og4C301606
P09862343A0225 |51 55|IL-4s an
P09862343A0225 |180 189|moleculesn as a fu
P09862343A0225 |104 113|influenceects of n
P09862343A0225 |148 161|up-regulation97A0472 When 
P09862343A0225 |132 138|systembinemi
P09862343A0225 |193 206|B lymphocyteson of CSF PCO
P09862343A0225 |17 35|gp200-MR6 ligationmparison with alka
P09862481A0000 |4 18|Mig1 repressor01606T0076 Com
P09862481A0000 |24 43|zinc finger proteinn with alkaline pho
P09862481A0000 |58 76|glucose repression-nucleotidase P000
P09862481A0000 |80 85|yeast1T000
P09862496A0187 |0 8|EthyleneP0000160
P09862496A0187 |24 41|endosperm rupturen with alkaline p
P09862496A0187 |57 77|betaGLU I expression5-nucleotidase P0000
P09862496A0187 |128 135|patternlirubin
P09862496A0187 |139 159|betaGLU I expression. P00008997A0472 Whe
P09863624A0629 |48 58|sheep CRF1ases and 5
P09863624A0629 |133 138|aminoinemi
P09863624A0629 |83 88|CRF1s000 P
P09863624A0629 |162 170|receptorSF [HCO3
P09863624A0629 |26 35|structurewith alka
P09863624A0629 |148 154|domain97A047
P09863624A0629 |4 14|divergence01606T0076
P09863624A0629 |191 199|residuestion of 
P09863624A0629 |201 206|ovineF PCO
P09863624A0629 |216 220|CRF1 of 
P09863624A2301 |84 93|Tyr0-oCRF00 Pharma
P09863624A2301 |193 196|minon 
P09863624A2301 |182 186|timeas a
P09863624A2301 |60 67|percentucleoti
P09863624A2301 |78 82|125I171T
P09863624A2301 |245 250|oCRF1nger 
P09863624A2301 |160 165|cells CSF 
P09863624A2301 |130 138|fractionrubinemi
P09863624A2301 |71 76|total P000
P09863624A2301 |203 212|degrees CPCO2 the 
P09863624A2301 |154 157|Cos2 W
P09863624A2301 |16 40|receptor internalizationomparison with alkaline 
P09863720T0000 |57 77|protein S deficiency5-nucleotidase P0000
P09863720T0000 |30 37|disease alkali
P09863720T0000 |47 52|onsettases
P09864141A0528 |100 104|Y744 asp
P09864141A0528 |15 20|Stat3Compa
P09864141A0528 |40 48|affinityphosphat
P09864141A0528 |91 95|Y704maco
P09864141A0528 |194 198|Y764n of
P09864141A0528 |134 151|peptide analoguesnemia. P00008997A
P09864141A0528 |158 173|phosphopeptidesen CSF [HCO3-] 
P09864141A0528 |25 34|Stat3beta with alk
P09864141A0528 |64 79|phosphopeptidesotidase P000081
P09864141A0528 |185 189|Y729a fu
P09864335A1226 |20 27|resultsrison w
P09864335A1226 |91 106|drug resistancemacologic aspec
P09864335A1226 |147 155|evidence997A0472
P09864335A1226 |46 55|FCR1 geneatases an
P09864335A1226 |240 245|Fcr1pno lo
P09864335A1226 |225 231|factorleted 
P09864335A1226 |161 175|FCZ resistanceCSF [HCO3-] is
P09864335A1226 |78 87|regulator171T0000 
P09864335A1226 |196 208|inactivationof CSF PCO2 
P09864335A1226 |110 121|C. albicansf neonatal 
P09864689A1408 |86 92|effect Pharm
P09864689A1408 |130 133|DCMrub
P09864689A1408 |109 122|heart failureof neonatal h
P09864689A1408 |6 14|findings606T0076
P09864689A1408 |59 71|washout ratenucleotidase
P09864689A1408 |96 105|treatmentogic aspe
P09864689A1408 |33 38|MYO/Mkalin
P09865775A0162 |103 113|propertiespects of n
P09865775A0162 |42 50|couplersosphatas
P09865775A0162 |61 70|placementcleotidas
P09865775A0162 |82 87|ALGO20000 
P09865775A0162 |5 10|study1606T
P09866068A1058 |0 11|CONCLUSIONSP00001606T0
P09866068A1058 |13 25|Pretreatment6 Comparison
P09866068A1058 |150 156|effectA0472 
P09866068A1058 |31 34|OCsalk
P09866068A1058 |90 95|phasermaco
P09866068A1058 |197 212|pregnancy ratesf CSF PCO2 the 
P09866068A1058 |182 193|recruitmentas a functi
P09866068A1058 |54 65|suppressionnd 5-nucleo
P09866068A1058 |114 128|cyst formationonatal hyperbi
P09867159A1444 |139 140|%.
P09867159A1444 |93 94|%c
P09867159A1444 |127 128|%i
P09867159A1444 |27 43|threshold valuesith alkaline pho
P09867159A1444 |61 72|specificitycleotidase 
P09867159A1444 |104 111|FDG PETects of
P09867159A1444 |45 56|sensitivityhatases and
P09867159A1444 |85 86|%0
P09867159A1444 |81 82|%T
P09867159A1444 |97 98|%g
P09867159A1444 |131 132|%u
P09867159A1444 |143 144|%0
P09867159A1444 |5 11|regard1606T0
P09867253A0229 |51 67|protooncoproteins and 5-nucleoti
P09867253A0229 |109 134|transcription factor AP-1of neonatal hyperbilirubi
P09867253A0229 |91 96|c-Junmacol
P09867253A0229 |36 41|c-Fosine p
P09867253A0229 |5 19|c-Jun activity1606T0076 Comp
P09867855T0000 |0 19|Dorsal root gangliaP00001606T0076 Comp
P09867855T0000 |61 117|rabbit beta-galactoside alpha1,2-fucosyltransferase genecleotidase P00008171T0000 Pharmacologic aspects of neona
P09867855T0000 |36 53|promoter activityine phosphatases 
P09868412A1628 |0 10|CONCLUSIONP00001606T
P09868412A1628 |223 226|BMDepl
P09868412A1628 |188 205|swimming exerciseunction of CSF PC
P09868412A1628 |213 219|effectata of
P09868412A1628 |245 253|swimmingnger dis
P09868412A1628 |148 157|exercises97A0472 W
P09868412A1628 |43 51|body BMDsphatase
P09868412A1628 |106 117|study groupts of neona
P09868412A1628 |316 324|shoulder greater
P09868412A1628 |16 21|studyompar
P09868412A1628 |277 285|exercisecontrols
P09868412A1628 |336 356|grip muscle strength +/- 0.23 vs. P00010
P09868412A1628 |174 182|subjectss shown 
P09868412A1628 |64 72|neck BMDotidase 
P09869297A1807 |68 89|Hoxb1 gene expressionase P00008171T0000 Ph
P09869297A1807 |41 53|CE2 elementshosphatases 
P09869297A1807 |14 19|roles Comp
P09869297A1807 |97 108|developmentgic aspects
P09869297A1807 |33 36|CE1kal
P09869356A0926 |0 8|CAL gainP0000160
P09869356A0926 |31 33|mmal
P09869356A0926 |46 53|defectsatases 
P09869356A0926 |62 70|CAL gainleotidas
P09869356A0926 |79 81|mm71
P09869356A0926 |37 38|%n
P09869400A0203 |0 11|ComparisonsP00001606T0
P09869400A0203 |126 138|wheat germinbilirubinemi
P09869400A0203 |29 36|germinsh alkal
P09869400A0203 |82 109|Arabidopsis GLP subfamilies0000 Pharmacologic aspects 
P09869400A0203 |53 61|proteinsand 5-nu
P09869528T0000 |17 21|dogsmpar
P09869528T0000 |36 45|RF energyine phosp
P09869528T0000 |5 13|fixation1606T007
P09871353A0174 |118 122|fishal h
P09871353A0174 |131 135|lochubin
P09871353A0174 |44 69|A. salmonicida infectionsphatases and 5-nucleotida
P09871353A0174 |32 40|evidencelkaline 
P09871353A0174 |84 96|furunculosis00 Pharmacol
P09872326A0566 |68 71|CBFase
P09872326A0566 |104 122|heat shock proteinects of neonatal h
P09872326A0566 |41 49|CBF/cdc2hosphata
P09872326A0566 |126 134|promoterbilirubi
P09872337A0000 |171 198|clindamycin phosphate ester] is shown as a function of
P09872337A0000 |294 303|Dalacin Tl have a 
P09872337A0000 |124 129|% w/verbil
P09872337A0000 |147 152|% w/v997A0
P09872337A0000 |31 42|clindamycinalkaline ph
P09872337A0000 |131 140|tretinoinubinemia.
P09872337A0000 |17 27|absorptionmparison w
P09872337A0000 |154 158|gels2 Wh
P09872337A0000 |248 276|clindamycin phosphate lotionr displaced when compared to
P09872337A0000 |203 218|clindamycin HClPCO2 the data o
P09872337A0000 |111 122|clindamycin neonatal h
P09872337A0000 |279 292|% clindamycinntrols but st
P09872337A0000 |71 81|volunteers P00008171
P09872832A1262 |171 180|TNF-alpha] is show
P09872832A1262 |187 203|interferon gammafunction of CSF 
P09872832A1262 |86 91|lungs Phar
P09872832A1262 |248 249|pr
P09872832A1262 |122 126|IL-6yper
P09872832A1262 |142 169|tumor necrosis factor-alpha00008997A0472 When CSF [HCO
P09872832A1262 |129 133|IL-8irub
P09872832A1262 |107 120|interleukin-6s of neonatal
P09872832A1262 |135 140|IL-12emia.
P09872832A1262 |4 22|BAL concentrations01606T0076 Compari
P09872832A1262 |235 246|differences are no lon
P09872832A1262 |35 44|cytokinesline phos
P09872832A1262 |205 214|IFN-gammaO2 the da
P09873060A0901 |0 24|Phosphorylation analysesP00001606T0076 Compariso
P09873060A0901 |122 126|FosByper
P09873060A0901 |40 50|inhibitionphosphatas
P09873060A0901 |94 109|phosphorylationologic aspects 
P09873060A0901 |113 117|JunDeona
P09873060A0901 |54 59|ERK-1nd 5-
P09873291A0620 |69 84|knowledge scorese P00008171T00
P09873291A0620 |8 16|analysis6T0076 C
P09873291A0620 |20 28|variancerison wi
P09873291A0620 |100 114|patient groups aspects of ne
P09874803A0000 |190 206|disease episodesction of CSF PCO
P09874803A0000 |134 138|SpeBnemi
P09874803A0000 |79 96|cysteine protease71T0000 Pharmacol
P09874803A0000 |122 132|exotoxin Byperbiliru
P09874803A0000 |160 176|virulence factor CSF [HCO3-] is 
P09874803A0000 |21 52|bacterium group A Streptococcusison with alkaline phosphatases
P09875541A0210 |153 157|SELF72 W
P09875541A0210 |133 151|hand movement taskinemia. P00008997A
P09875541A0210 |47 51|parttase
P09875541A0210 |59 80|dorsal premotor areasnucleotidase P0000817
P09875541A0210 |4 17|orbitofrontal01606T0076 Co
P09876794T0000 |0 9|ImprovingP00001606
P09876794T0000 |14 27|evidence base Comparison w
P09876794T0000 |32 43|anaesthesialkaline pho
P09877417A0704 |0 17|Plasma CCK levelsP00001606T0076 Co
P09877417A0704 |45 54|intervalshatases a
P09878256A0000 |119 131|deficienciesl hyperbilir
P09878256A0000 |145 158|abnormalities08997A0472 Wh
P09878256A0000 |167 178|retardationCO3-] is sh
P09878256A0000 |194 199|deathn of 
P09878256A0000 |4 35|peroxisome biogenesis disorders01606T0076 Comparison with alka
P09878256A0000 |37 41|PBDsne p
P09878256A0000 |71 79|diseases P000081
P09878256A0000 |49 52|setses
P09878437A0967 |53 57|siteand 
P09878437A0967 |61 76|phosphorylationcleotidase P000
P09878437A0967 |11 15|site076 
P09878437A0967 |89 93|Glu9arma
P09878437A0967 |79 84|Asp1071T00
P09878437A0967 |36 47|triad Asp53ine phospha
P09878542A1151 |115 131|osteopontin VDREnatal hyperbilir
P09878542A1151 |88 91|VDRhar
P09878542A1151 |22 30|findingsson with
P09878542A1151 |64 73|silencingotidase P
P09879766A0402 |3 8|PAV-300160
P09879766A0402 |14 24|E1A region Compariso
P09879766A0402 |56 65|map units 5-nucleo
P09880029A0703 |102 121|amino acid identityspects of neonatal 
P09880029A0703 |216 218|C3 o
P09880029A0703 |147 161|FBNYV proteins997A0472 When 
P09880029A0703 |181 193|Rep proteins as a functi
P09880029A0703 |269 276|SCSV-C2ared to
P09880029A0703 |281 283|C6ro
P09880029A0703 |227 228|%t
P09880029A0703 |13 32|MDV genome products6 Comparison with a
P09880029A0703 |48 51|Repase
P09880029A0703 |237 238|%r
P09880029A0703 |99 100|%c
P09880029A0703 |69 77|proteinsse P0000
P09880029A0703 |205 211|MDV-C2O2 the
P09880103A0387 |0 3|MPOP00
P09880103A0387 |90 109|M hydrogen peroxidermacologic aspects 
P09880103A0387 |23 31|mCi 125Ion with 
P09880103A0387 |37 46|techniquene phosph
P09880103A0387 |71 79|presence P000081
P09880103A0387 |50 63|self-labelinges and 5-nucl
P09880327A0322 |103 110|proteinpects o
P09880327A0322 |164 172|vesicles [HCO3-]
P09880327A0322 |57 65|proteins5-nucleo
P09880327A0322 |123 130|dockingperbili
P09880327A0322 |77 88|yeast Uso1p8171T0000 P
P09880327A0322 |19 26|varietyarison 
P09880512A1251 |87 90|Sp1Pha
P09880512A1251 |73 82|receptors00008171T
P09880512A1251 |23 27|Bmp2on w
P09880512A1251 |4 8|data0160
P09880513A1013 |5 13|proteins1606T007
P09880513A1013 |62 69|tubulinleotida
P09880543A0570 |0 4|HEEDP000
P09880543A0570 |26 36|MA proteinwith alkal
P09880543A0570 |76 87|yeast cells08171T0000 
P09880544A0693 |118 140|recombination knockoutal hyperbilirubinemia.
P09880544A0693 |195 206|DT-40 cells of CSF PCO
P09880544A0693 |14 36|DT-40 lymphoma B-cells Comparison with alkal
P09880544A0693 |224 235|DT-40 cellspleted rats
P09880544A0693 |151 160|apoptosis0472 When
P09880544A0693 |167 179|Fas ligationCO3-] is sho
P09880544A0693 |271 279|btk geneed to co
P09880544A0693 |95 103|btk genelogic as
P09880544A0693 |77 87|disruption8171T0000 
P09881666A0535 |35 44|CREB siteline phos
P09881666A0535 |9 17|TGATGTCAT0076 Co
P09881666A0535 |95 98|ER2log
P09881666A0535 |66 75|AP-1 siteidase P00
P09881666A0535 |2 7|motif00016
P09881692A0094 |49 51|b4se
P09881692A0094 |120 138|Ckappa1 gene locus hyperbilirubinemi
P09881692A0094 |53 55|b5an
P09881692A0094 |57 59|b65-
P09881692A0094 |39 47|variants phospha
P09881692A0094 |64 66|b9ot
P09881692A1109 |103 105|b6pe
P09881692A1109 |45 50|geneshatas
P09881692A1109 |78 94|oligonucleotides171T0000 Pharmac
P09881692A1109 |167 174|rabbitsCO3-] i
P09881692A1109 |148 150|T.97
P09881692A1109 |14 19|order Comp
P09881692A1109 |178 195|Southern blottingown as a function
P09881692A1109 |110 112|b9f 
P09881692A1109 |99 101|b5c 
P09881692A1109 |116 126|probe DNAsatal hyper
P09882303A1413 |0 5|TRAF2P0000
P09882303A1413 |44 54|expressionphatases a
P09882303A1413 |177 182|cellshown 
P09882303A1413 |89 110|deletion TRAF2 mutantarmacologic aspects o
P09882303A1413 |33 38|TRADDkalin
P09882303A1413 |155 169|JNK activation When CSF [HCO
P09882303A1984 |102 123|signalling mechanismsspects of neonatal hy
P09882303A1984 |56 70|JNK activation 5-nucleotidas
P09882303A1984 |88 92|LMP1harm
P09882303A1984 |47 52|TRAF2tases
P09882303A1984 |28 32|roleth a
P09882303A1984 |6 10|data606T
P09882303A1984 |37 42|TRADDne ph
P09882303A1984 |136 160|TNF receptor/CD40 familymia. P00008997A0472 When
P09882303A1984 |187 197|activitiesfunction o
P09882303T0000 |34 50|membrane proteinaline phosphatas
P09882303T0000 |146 151|TRAF28997A
P09882303T0000 |99 109|C terminusc aspects 
P09882303T0000 |67 78|JNK pathwaydase P00008
P09882303T0000 |116 125|mechanismatal hype
P09882303T0000 |136 141|TRADDmia. 
P09882321A0948 |3 11|contrast001606T0
P09882321A0948 |92 117|EBNA-3 protein expressionacologic aspects of neona
P09882321A0948 |135 146|EBNA-3 geneemia. P0000
P09882321A0948 |159 170|EBNA-3 cDNAn CSF [HCO3
P09882321A0948 |37 42|cellsne ph
P09882321A0948 |54 60|EBNA-3nd 5-n
P09882321A0948 |80 88|increase1T0000 P
P09882334A0822 |34 45|lamb kidneyaline phosp
P09882334A0822 |145 153|mutation08997A04
P09882334A0822 |166 182|tyrosine residueHCO3-] is shown 
P09882334A0822 |47 50|FLKtas
P09882334A0822 |232 243|propagationats are no 
P09882334A0822 |97 100|BLVgic
P09882334A0822 |82 91|infection0000 Phar
P09882334A0822 |52 57|cells and 
P09882334A0822 |201 206|motifF PCO
P09882334A0822 |251 256|virusispla
P09882334A0822 |16 24|passagesompariso
P09882334A0822 |118 130|transfectional hyperbili
P09882337A0000 |0 22|Varicella-zoster virusP00001606T0076 Compari
P09882337A0000 |131 153|gI Fc receptor complexubinemia. P00008997A04
P09882337A0000 |57 83|transmembrane glycoprotein5-nucleotidase P00008171T0
P09882337A0000 |29 44|glycoprotein gIh alkaline phos
P09882337A0000 |128 130|gEli
P09882337A0000 |24 27|VZVn w
P09882337A0000 |97 106|componentgic aspec
P09882337A0000 |50 54|typees a
P09882348A0611 |168 176|oncogeneO3-] is 
P09882348A0611 |135 146|fibroblastsemia. P0000
P09882348A0611 |111 130|Shc adapter protein neonatal hyperbili
P09882348A0611 |29 51|phosphorylation statush alkaline phosphatase
P09882348A0611 |8 11|end6T0
P09882348A0611 |67 92|tyrosine kinase substratedase P00008171T0000 Pharm
P09882451A0195 |6 11|genes606T0
P09882451A0195 |88 107|ferrochelatase geneharmacologic aspect
P09882451A0195 |160 173|transformants CSF [HCO3-] 
P09882451A0195 |109 114|HEM15of ne
P09882451A0195 |57 63|mutant5-nucl
P09882451A0195 |142 152|phenotypes00008997A0
P09882489A0451 |119 124|arrayl hyp
P09882489A0451 |15 23|evidenceComparis
P09882489A0451 |199 206|signalsCSF PCO
P09882489A0451 |150 157|modulesA0472 W
P09882489A0451 |8 13|study6T007
P09882489A0451 |76 91|mef2 expression08171T0000 Phar
P09882499A0231 |87 95|elementsPharmaco
P09882499A0231 |30 46|mouse technology alkaline phosph
P09882499A0231 |128 138|expressionlirubinemi
P09882499A0231 |142 146|Pax60000
P09882593A0996 |51 55|61Nis an
P09882593A0996 |192 206|pompholyx typeion of CSF PCO
P09882593A0996 |149 155|groups7A0472
P09882593A0996 |14 24|experiment Compariso
P09882593A0996 |134 142|controlsnemia. P
P09882593A0996 |173 184|hand eczemais shown as
P09882593A0996 |109 114|womenof ne
P09882593A0996 |70 84|drinking watere P00008171T00
P09882593A0996 |35 49|nickel isotopeline phosphata
P09882638A0235 |49 65|tunica albugineases and 5-nucleo
P09882638A0235 |94 102|erectionologic a
P09882638A0235 |26 41|collagen fiberswith alkaline p
P09882638A0235 |77 86|expansion8171T0000
P09882638A0235 |7 13|tissue06T007
P09883639A0000 |102 107|yearsspect
P09883639A0000 |10 18|patients0076 Com
P09883639A0000 |62 65|NTMleo
P09883639A0000 |48 60|mycobacteriaases and 5-n
P09883639A0000 |0 6|NumberP00001
P09884232A0286 |0 10|ComparisonP00001606T
P09884232A0286 |31 35|attPalka
P09884232A0286 |181 195|integrase gene as a function
P09884232A0286 |151 156|place0472 
P09884232A0286 |83 87|attR000 
P09884232A0286 |37 41|attBne p
P09884232A0286 |110 123|core sequencef neonatal hy
P09884232A0286 |131 144|recombinationubinemia. P00
P09884232A0286 |18 27|sequencesparison w
P09884232A0286 |64 78|junctions attLotidase P00008
P09884232A0286 |100 102|bp a
P09884232A0286 |170 173|end-] 
P09884275T0000 |0 26|Interferon-alpha treatmentP00001606T0076 Comparison 
P09884275T0000 |77 87|recipients8171T0000 
P09884275T0000 |97 114|organ transplantsgic aspects of ne
P09884275T0000 |65 73|disordertidase P
P09884747A0477 |68 86|control volunteersase P00008171T0000
P09884747A0477 |183 192|allergenss a funct
P09884747A0477 |135 149|yeast antigensemia. P0000899
P09884747A0477 |14 21|testing Compar
P09884747A0477 |43 58|brewery workerssphatases and 5
P09884747A0477 |123 129|barleyperbil
P09884747A0477 |93 111|skin prick testingcologic aspects of
P09884747A0477 |219 235|serum IgE levels K-depleted rats
P09885431A0000 |102 105|mixspe
P09885431A0000 |175 180|types show
P09885431A0000 |67 86|bridge restorationsdase P00008171T0000
P09885431A0000 |57 62|crown5-nuc
P09885431A0000 |27 35|accuracyith alka
P09885431A0000 |117 125|siliconetal hype
P09885431A0000 |138 158|impression materialsa. P00008997A0472 Wh
P09885431A0000 |184 194|stock tray a functio
P09885431A0000 |0 9|OBJECTIVEP00001606
P09886602A0000 |0 10|OBJECTIVESP00001606T
P09886602A0000 |208 218|recurrencethe data o
P09886602A0000 |150 161|Gleason sumA0472 When 
P09886602A0000 |281 284|XRTrol
P09886602A0000 |222 237|prostate cancerdepleted rats a
P09886602A0000 |87 94|antigenPharmac
P09886602A0000 |257 279|beam radiation therapyed when compared to co
P09886602A0000 |321 333|tumor markerter slope (1
P09886602A0000 |296 308|introductionhave a signi
P09886602A0000 |178 192|radiation doseown as a funct
P09886602A0000 |26 33|abilitywith al
P09886602A0000 |124 135|tumor stageerbilirubin
P09886602A0000 |37 49|pretreatmentne phosphata
P09886602A0000 |163 167|raceF [H
P09886602A0000 |350 361|care centerP00010943A0
P09886602A0000 |312 315|PSAntl
P09886602A0000 |101 113|measurementsaspects of n
P09886602A0000 |96 99|PSAogi
P09886602A0000 |169 172|age3-]
P09886602A0000 |137 148|tumor gradeia. P000089
P09886843A0339 |118 122|NRGNal h
P09886843A0339 |45 51|targethatase
P09886843A0339 |30 34|gene alk
P09886843A0339 |167 171|geneCO3-
P09886843A0339 |106 114|elementsts of ne
P09886843A0339 |55 70|thyroid hormoned 5-nucleotidas
P09886843A0339 |138 147|fragmentsa. P00008
P09886850A0145 |69 83|ligand bindingse P00008171T0
P09886850A0145 |112 127|phosphorylationneonatal hyperb
P09886850A0145 |144 169|MEK/ERK signaling pathway008997A0472 When CSF [HCO
P09886850A0145 |20 28|activityrison wi
P09886850A0145 |32 41|PPARgammalkaline p
P09887544A0000 |0 10|BACKGROUNDP00001606T
P09887544A0000 |12 20|Diazepam76 Compa
P09887544A0000 |148 157|treatment97A0472 W
P09887544A0000 |133 140|anxietyinemia.
P09887544A0000 |123 129|reliefperbil
P09887544A0000 |106 114|sedationts of ne
P09887544A0000 |161 169|epilepsyCSF [HCO
P09887544A0000 |57 70|tranquilizers5-nucleotidas
P09887544A0000 |97 101|druggic 
P09887544A0000 |33 53|benzodiazepine groupkaline phosphatases 
P09888711A0781 |0 22|Bioplastique granulomaP00001606T0076 Compari
P09888711A0781 |226 230|sizeeted
P09888711A0781 |157 175|Artecoll granulomahen CSF [HCO3-] is
P09888711A0781 |321 327|bodiester sl
P09888711A0781 |142 148|bodies000089
P09888711A0781 |63 69|spaceseotida
P09888711A0781 |251 256|roundispla
P09888711A0781 |191 205|round vacuolestion of CSF PC
P09888711A0781 |81 85|sizeT000
P09888711A0781 |235 240|shape are 
P09888994A0858 |85 98|somitogenesis0 Pharmacolog
P09888994A0858 |62 80|mesoderm formationleotidase P0000817
P09888994A0858 |108 114|embryo of ne
P09888994A0858 |20 24|generiso
P09889202T0000 |49 62|domain Zalphases and 5-nuc
P09889202T0000 |167 175|proteinsCO3-] is
P09889202T0000 |107 117|similaritys of neona
P09889202T0000 |134 138|betanemi
P09889202T0000 |66 96|dsRNA adenosine deaminase typeidase P00008171T0000 Pharmacol
P09889202T0000 |126 131|alphabilir
P09889202T0000 |140 146|family P0000
P09889202T0000 |19 27|analysisarison w
P09889306A0321 |17 27|regulationmparison w
P09889306A0321 |73 85|applications00008171T000
P09889306A0321 |31 53|Glvr-1 gene expressionalkaline phosphatases 
P09889306A0321 |194 207|gene deliveryn of CSF PCO2
P09889306A0321 |120 127|vectors hyperb
P09889306A0321 |144 180|ape leukemia virus envelope proteins008997A0472 When CSF [HCO3-] is show
P09889306A0321 |89 101|gene therapyarmacologic 
P09889306A0321 |3 11|addition001606T0
P09889306A0321 |223 233|cell typesepleted ra
P09890778T0000 |0 13|CarbohydratesP00001606T007
P09890778T0000 |46 53|methodsatases 
P09890778T0000 |18 33|glycoconjugatesparison with al
P09891009T0000 |21 44|mouse glycolate oxidaseison with alkaline phos
P09891009T0000 |10 17|cloning0076 Co
P09891046A0269 |84 94|disruption00 Pharmac
P09891046A0269 |28 31|PKRth 
P09891046A0269 |105 118|PKR signalingcts of neonat
P09891046A0269 |10 16|manner0076 C
P09891046A0269 |41 52|cell growthhosphatases
P09891046A0269 |142 153|cell growth00008997A04
P09891046A0269 |65 74|apoptosistidase P0
P09891046A0554 |39 50|interaction phosphatas
P09891046A0554 |56 59|PKR 5-
P09891046A0554 |24 35|protein L18n with alka
P09891049A0761 |51 60|nucleasess and 5-n
P09891049A0761 |78 93|rRNA processing171T0000 Pharma
P09891049A0761 |101 106|Rnt1paspec
P09891049A0761 |111 116|Rat1p neon
P09891049A0761 |32 41|precursorlkaline p
P09891049A0761 |0 10|ProcessingP00001606T
P09891061A0373 |68 81|SpHE promoterase P00008171
P09891061A0373 |30 40|regulators alkaline 
P09891061A0373 |183 194|cis elements a functio
P09891061A0373 |149 153|bait7A04
P09891061A0373 |52 60|fragment and 5-n
P09891061A0373 |112 120|elementsneonatal
P09891061A1240 |119 129|expressionl hyperbil
P09891061A1240 |63 69|timingeotida
P09891061A1240 |73 95|SpEts4 gene expression00008171T0000 Pharmaco
P09891061A1240 |27 31|SpHEith 
P09891061A1240 |133 137|SpHEinem
P09891061A1240 |156 175|sea urchin blastulaWhen CSF [HCO3-] is
P09891061A1240 |48 57|regulatorases and 
P09891065A1493 |86 95|PKC-alpha Pharmaco
P09891065A1493 |75 82|mutants008171T
P09891065A1493 |27 41|SRE activationith alkaline p
P09891065A1493 |99 110|PKC-epsilonc aspects o
P09891085A0815 |102 116|27S precursorsspects of neon
P09891085A0815 |15 20|cellsCompa
P09891085A0815 |40 47|defectsphospha
P09891085A0815 |66 71|cellsidase
P09891092A1000 |51 61|structuress and 5-nu
P09891092A1000 |91 104|end formationmacologic asp
P09891092A1000 |28 32|siteth a
P09891092A1000 |37 46|stem-loopne phosph
P09891707A0000 |48 51|SpAase
P09891707A0000 |15 23|subtypesComparis
P09891707A0000 |27 46|spondyloarthropathyith alkaline phosph
P09892017A2151 |70 74|ELE1e P0
P09892017A2151 |62 66|roleleot
P09892017A2151 |8 19|experiments6T0076 Comp
P09892017A2151 |86 106|receptor functioning Pharmacologic aspec
P09892021A0712 |102 126|fibroblast growth factorspects of neonatal hyper
P09892021A0712 |38 51|NIH 3T3 cellse phosphatase
P09892021A0712 |83 92|secretion000 Pharm
P09892021A0712 |146 151|tumor8997A
P09892021A0712 |170 176|factor-] is 
P09892021A0712 |18 22|PTTGpari
P09892021A0712 |0 14|OverexpressionP00001606T0076
P09892021A0712 |68 78|expressionase P00008
P09892422A1096 |186 193|impulse functi
P09892422A1096 |166 178|transmissionHCO3-] is sh
P09892422A1096 |225 239|purkinje fibreleted rats are
P09892422A1096 |75 86|contraction008171T0000
P09892422A1096 |30 43|tissue sheath alkaline pho
P09892422A1096 |127 133|spreadilirub
P09892422A1096 |94 104|myocardiumologic asp
P09892422A1096 |206 217|termination2 the data 
P09892422A1096 |137 147|conductionia. P00008
P09892642A0172 |0 2|E1P0
P09892642A0172 |74 85|replication0008171T000
P09892642A0172 |42 56|HPV E2 proteinosphatases and
P09892642A0172 |6 18|DNA helicase606T0076 Com
P09892662A0334 |87 97|activationPharmacolo
P09892662A0334 |143 150|cyclase0008997
P09892662A0334 |121 130|regulatorhyperbili
P09892662A0334 |101 103|Gsas
P09892662A0334 |19 39|mutant alpha subunitarison with alkaline
P09892736A0343 |116 135|signal transductionatal hyperbilirubin
P09892736A0343 |9 15|searchT0076 
P09892736A0343 |72 84|% similarityP00008171T00
P09892736A0343 |46 55|CDED/LIORatases an
P09892736A0343 |166 170|ORC1HCO3
P09892736A0343 |96 104|proteinsogic asp
P09892736A0343 |36 42|regionine ph
P09892736A0343 |140 156|cell replication P00008997A0472 
P09892736A0343 |175 178|KSR sh
P09893060A0767 |51 61|expressions and 5-nu
P09893060A0767 |69 71|kbse
P09893060A0767 |0 22|Northern blot analysisP00001606T0076 Compari
P09893262A1272 |16 23|varietyomparis
P09893262A1272 |96 114|TGF-beta responsesogic aspects of ne
P09893262A1272 |38 45|schemese phosp
P09893262A1272 |81 92|restrictionT0000 Pharm
P09893913A0656 |0 9|InductionP00001606
P09893913A0656 |43 51|fentanylsphatase
P09893913A0656 |94 104|atracuriumologic asp
P09893913A0656 |13 24|anaesthesia6 Compariso
P09893913A0656 |55 68|micrograms/kgd 5-nucleotid
P09893913A0656 |110 115|mg/kgf neo
P09893913A0656 |71 82|thiopentone P00008171T
P09893913A0656 |86 91|mg/kg Phar
P09894962T0000 |50 63|malformationses and 5-nucl
P09894962T0000 |29 36|profileh alkal
P09894962T0000 |99 112|malformationsc aspects of 
P09894962T0000 |2 12|comparison0001606T00
P09895323T0000 |32 40|kreislerlkaline 
P09895323T0000 |73 78|Hoxa300008
P09895323T0000 |44 54|regulationphatases a
P09895323T0000 |23 28|roleson wi
P09895323T0000 |83 94|Hoxb3 genes000 Pharmac
P09897032T0000 |57 66|resonator5-nucleot
P09897032T0000 |29 41|self-pulsingh alkaline p
P09900679T0000 |0 16|Wave cyberneticsP00001606T0076 C
P09900679T0000 |27 32|modelith a
P09900679T0000 |87 96|phenomenaPharmacol
P09903722T0000 |0 20|Autoionization ratesP00001606T0076 Compa
P09903722T0000 |25 38|energy levels with alkalin
P09903722T0000 |58 72|Rydberg states-nucleotidase 
P09903722T0000 |42 52|triplet nfosphatases
P09903722T0000 |76 78|H208
P09904139T0000 |41 50|operatorshosphatas
P09904139T0000 |14 22|approach Compari
P09911328T0000 |21 31|scatteringison with 
P09911328T0000 |9 17|approachT0076 Co
P09911328T0000 |53 60|problemand 5-n
P09913308T0000 |66 72|energyidase 
P09913308T0000 |61 62|Jc
P09913308T0000 |11 17|lasing076 Co
P09913308T0000 |89 101|laser pulsesarmacologic 
P09913308T0000 |26 28|nmwi
P09913308T0000 |40 47|Ti ionsphospha
P09914156A1496 |170 187|promoter activity-] is shown as a 
P09914156A1496 |249 251|bp d
P09914156A1496 |76 106|tenascin-C promoter constructs08171T0000 Pharmacologic aspec
P09914156A1496 |215 227|pair elementa of K-deple
P09914156A1496 |268 282|RNA start sitepared to contr
P09914156A1496 |115 124|deletionsnatal hyp
P09914156A1496 |66 72|seriesidase 
P09914156A1496 |18 25|regionsparison
P09914156A1496 |33 41|promoterkaline p
P09914500A0000 |51 71|transcription factors and 5-nucleotidase
P09914500A0000 |181 202|tumor necrosis factor as a function of CSF
P09914500A0000 |111 119|proteins neonata
P09914500A0000 |24 33|NF-kappaBn with al
P09914500A0000 |208 213|alphathe d
P09914500A0000 |241 251|conditionso longer d
P09914500A0000 |80 85|genes1T000
P09914500A0000 |8 22|factor kappa B6T0076 Compari
P09914500A0000 |153 176|cytokines interleukin-172 When CSF [HCO3-] is 
P09914500A0000 |204 207|TNFCO2
P09914518A1217 |170 172|E2-]
P09914518A1217 |95 124|AF-1 transactivation functionlogic aspects of neonatal hyp
P09914518A1217 |46 56|activationatases and
P09914518A1217 |60 68|COUP-TFIucleotid
P09914518A1217 |15 26|enhancementComparison 
P09914518A1217 |128 130|ERli
P09914518A1217 |176 194|4-hydroxytamoxifenshown as a functio
P09914518A1217 |158 166|presenceen CSF [
P09914518A1217 |203 206|ICIPCO
P09914525A0890 |39 41|tm p
P09914525A0890 |30 35|point alka
P09914525A0890 |47 55|degreesCtases an
P09914525A0890 |12 15|Ffh76 
P09915118T0000 |35 48|rat accessoryline phosphat
P09915118T0000 |11 26|naris occlusion076 Comparison 
P09915118T0000 |59 63|bulbnucl
P09915798A1077 |153 181|steroid receptor interaction72 When CSF [HCO3-] is shown
P09915798A1077 |15 20|hsp90Compa
P09915798A1077 |79 104|hsp90 dimerization domain71T0000 Pharmacologic asp
P09915798A1077 |46 64|chaperone activityatases and 5-nucle
P09915798A1077 |130 138|elementsrubinemi
P09915798A1077 |5 11|region1606T0
P09915860A0000 |98 107|mdr genesic aspect
P09915860A0000 |62 68|pgp2GCleotid
P09915860A0000 |20 39|rat pgp2/mdr1b generison with alkaline
P09915860A0000 |124 142|consensus Sp1 siteerbilirubinemia. P
P09915860A0000 |54 60|regionnd 5-n
P09915860A0000 |4 12|promoter01606T00
P09915860A0119 |0 3|Sp1P00
P09915860A0119 |37 56|pgp2/mdr1b promoterne phosphatases and
P09915860A0119 |14 29|transactivation Comparison wit
P09915860A0119 |82 97|Schneider cells0000 Pharmacolo
P09915860A0119 |6 10|role606T
P09916786A0811 |0 12|MeasurementsP00001606T00
P09916786A0811 |208 219|immunoassaythe data of
P09916786A0811 |224 247|urine deoxypyridinolinepleted rats are no long
P09916786A0811 |164 169|serum [HCO
P09916786A0811 |22 42|bone mineral densityson with alkaline ph
P09916786A0811 |76 81|femur08171
P09916786A0811 |57 62|spine5-nuc
P09916786A0811 |147 162|bone remodeling997A0472 When C
P09916786A0811 |272 286|chromatographyd to controls 
P09916786A0811 |98 118|X-ray absorptiometryic aspects of neonat
P09916786A0811 |184 204|alkaline phosphatase a function of CSF P
P09916786A0811 |136 143|markersmia. P0
P09916809A0405 |118 146|transmembrane signal peptideal hyperbilirubinemia. P0000
P09916809A0405 |44 50|matrixphatas
P09916809A0405 |52 55|ECM an
P09916809A0405 |57 64|protein5-nucle
P09916809A0405 |6 9|MGP606
P09916809A0405 |98 105|proteinic aspe
P09917064T0000 |5 10|roles1606T
P09917064T0000 |91 98|maskingmacolog
P09917064T0000 |14 17|p82 Co
P09917064T0000 |57 72|polyadenylation5-nucleotidase 
P09917064T0000 |23 40|clam CPEB homologon with alkaline 
P09917387T0000 |34 47|factor TFIIIBaline phospha
P09917387T0000 |58 66|DNA bend-nucleot
P09917387T0000 |79 87|TATA box71T0000 
P09917387T0000 |112 122|start siteneonatal h
P09917387T0000 |4 18|RNA polymerase01606T0076 Com
P09917389A1239 |4 11|pattern01606T0
P09917389A1239 |62 66|FinPleot
P09917389A1239 |15 32|RNase E digestionComparison with a
P09917389A1239 |97 108|finP305 RNAgic aspects
P09917389A1239 |72 80|GST-FinOP0000817
P09917389A1239 |36 47|finP305 RNAine phospha
P09917389A1239 |114 122|cleavageonatal h
P09917391A0380 |0 25|Transcription readthroughP00001606T0076 Comparison
P09917391A0380 |44 51|repeatsphatase
P09917391A0380 |63 69|effecteotida
P09917391A0380 |78 83|event171T0
P09917555T0001 |0 8|AnalysisP0000160
P09917555T0001 |26 53|growth factor prescriptionswith alkaline phosphatases 
P09917555T0001 |67 81|cancer centersdase P00008171
P09918096A0520 |33 37|cystkali
P09918096A0520 |14 18|case Com
P09918715A0304 |34 42|MotA boxaline ph
P09918715A0304 |57 65|position5-nucleo
P09918715A0304 |18 30|DNA sequenceparison with
P09918715A0304 |0 4|MotAP000
P09918715A1158 |152 165|transcription472 When CSF 
P09918715A1158 |73 93|TATA binding protein00008171T0000 Pharma
P09918715A1158 |25 29|AsiA wit
P09918715A1158 |126 133|bindingbilirub
P09918715A1158 |111 118|factors neonat
P09918715A1158 |95 98|TBPlog
P09918715A1158 |175 198|core promoter sequences shown as a function of
P09918715A1158 |67 71|TAFsdase
P09918715A1158 |16 20|MotAompa
P09918715A1158 |137 148|TBP resultsia. P000089
P09918720A0998 |184 191|adenine a func
P09918720A0998 |43 48|basessphat
P09918720A0998 |161 168|contactCSF [HC
P09918720A0998 |141 147|Ser229P00008
P09918720A0998 |4 17|S229A variant01606T0076 Co
P09918720A0998 |87 91|basePhar
P09918720A0998 |117 123|pockettal hy
P09918842A0184 |117 127|initiationtal hyperb
P09918842A0184 |91 99|proteinsmacologi
P09918842A0184 |60 66|regionucleot
P09918842A0184 |131 146|RNA replicationubinemia. P0000
P09918842A0184 |79 87|assembly71T0000 
P09918842A0184 |9 21|conservationT0076 Compar
P09918842A0184 |32 40|terminuslkaline 
P09920539A0272 |4 16|stimulations01606T0076 C
P09920539A0272 |79 87|protocol71T0000 
P09920539A0272 |62 65|dayleo
P09920539A0272 |95 119|gonadotropin stimulationlogic aspects of neonata
P09920539A0272 |42 48|GnRH-aosphat
P09920775A0075 |4 12|sequence01606T00
P09920775A0075 |166 175|P19 cellsHCO3-] is
P09920775A0075 |147 162|differentiation997A0472 When C
P09920775A0075 |94 118|reporter gene expressionologic aspects of neonat
P09920775A0075 |24 26|bpn 
P09920775A0075 |43 67|transcription start sitesphatases and 5-nucleoti
P09920882A0287 |0 4|ChemP000
P09920896A1230 |137 144|proteinia. P00
P09920896A1230 |15 26|differencesComparison 
P09920896A1230 |194 204|structuresn of CSF P
P09920896A1230 |60 73|type peptidesucleotidase P
P09920896A1230 |110 122|substitutionf neonatal h
P09920896A1230 |155 165|disruption When CSF 
P09920903A1045 |6 13|results606T007
P09920903A1045 |31 41|c-met genealkaline p
P09920903A1045 |62 81|p53 gene regulationleotidase P00008171
P09920903A1045 |52 58|target and 5
P09920930A0521 |119 135|c-Fos expressionl hyperbilirubin
P09920930A0521 |30 43|RhoA function alkaline pho
P09920930A0521 |65 68|SREtid
P09920930A0521 |94 100|effectologic
P09920930A0521 |69 81|Luc activityse P00008171
P09920930A0521 |0 8|C3 toxinP0000160
P09920930A0959 |186 200|co-stimulation function of C
P09920930A0959 |47 61|growth factorstases and 5-nu
P09920930A0959 |225 235|Ro-31-8220leted rats
P09920930A0959 |30 41|combination alkaline p
P09920930A0959 |174 182|responses shown 
P09920930A0959 |80 84|AP-11T00
P09920930A0959 |158 161|Lucen 
P09920930A0959 |9 17|C3 toxinT0076 Co
P09920930A0959 |139 149|activation. P0000899
P09920930A0959 |206 220|growth factors2 the data of 
P09920930A0959 |153 157|AP-172 W
P09920930A0959 |85 97|Luc activity0 Pharmacolo
P09920982A0253 |136 138|P.mi
P09920982A0253 |125 132|strainsrbiliru
P09920982A0253 |62 76|susceptibilityleotidase P000
P09920982A0253 |195 214|Rap ID ANA II panel of CSF PCO2 the da
P09920982A0253 |159 171|acne lesionsn CSF [HCO3-
P09920982A0253 |112 118|agentsneonat
P09920982A0253 |23 28|studyon wi
P09920982A0253 |4 7|aim016
P09921179T0001 |4 8|role0160
P09921179T0001 |62 67|heartleoti
P09921179T0001 |47 54|surgerytases a
P09921179T0001 |27 43|echocardiographyith alkaline pho
P09921179T0001 |78 85|vessels171T000
P09922230A1482 |119 130|C. albicansl hyperbili
P09922230A1482 |75 85|resistance008171T000
P09922230A1482 |45 49|CAP1hata
P09922230A1482 |20 27|resultsrison w
P09922230A1482 |100 115|stress response aspects of neo
P09922856A0459 |0 10|TrinipatchP00001606T
P09922856A0459 |108 122|dose-strengths of neonatal h
P09922856A0459 |57 62|patch5-nuc
P09922856A0459 |141 148|mg/24 hP000089
P09922856A0459 |126 133|mg/24 hbilirub
P09922856A0459 |71 90|absorption promoter P00008171T0000 Pha
P09922856A0459 |153 176|Laboratoires Synthelabo72 When CSF [HCO3-] is 
P09923245A0482 |4 8|RMRI0160
P09923245A0482 |24 46|interrater reliabilityn with alkaline phosph
P09923245A0482 |83 91|patients000 Phar
P09924675A0412 |239 246|process no lon
P09924675A0412 |26 39|considerationwith alkaline
P09924675A0412 |270 282|interventionred to contr
P09924675A0412 |13 18|point6 Com
P09924675A0412 |260 265|basiswhen 
P09924675A0412 |113 121|mainstayeonatal 
P09924675A0412 |127 132|modeliliru
P09924675A0412 |76 81|ICIDH08171
P09924675A0412 |137 148|diagnosticsia. P000089
P09924675A0412 |49 60|conceptionsses and 5-n
P09924675A0412 |152 166|rehabilitation472 When CSF [
P09924675A0412 |205 220|characteristicsO2 the data of 
P09924987A0000 |0 8|PokeweedP0000160
P09924987A0000 |19 26|proteinarison 
P09924987A0000 |80 93|N-glycosidase1T0000 Pharma
P09924987A0000 |28 31|PAPth 
P09924987A0000 |121 126|A4324hyper
P09924987A0000 |143 148|A266000089
P09924987A0000 |130 138|28S rRNArubinemi
P09924987A0000 |192 202|eukaryotesion of CSF
P09924987A0000 |152 160|23S rRNA472 When
P09924987A0000 |38 58|Phytolacca americanae phosphatases and 5
P09924987A0000 |174 183|ribosomess shown a
P09924987A0000 |207 218|prokaryotes the data o
P09924987A0000 |103 119|adenine residuespects of neonata
P09925120A0074 |0 9|OBJECTIVEP00001606
P09925120A0074 |47 53|trialstases 
P09925120A0074 |105 111|effectcts of
P09925120A0074 |129 135|fibersirubin
P09925120A0074 |16 29|meta-analysisomparison wit
P09925372A0458 |16 20|ZFPsompa
P09925372A0458 |45 49|HFHZhata
P09925372A0458 |30 38|ZFP cDNA alkalin
P09925372A0458 |63 72|heart ZFPeotidase 
P09925372A0458 |121 124|boxhyp
P09925372A0458 |79 96|sequence homology71T0000 Pharmacol
P09925372A0458 |126 130|KRABbili
P09925372A1063 |68 73|heartase P
P09925372A1063 |44 49|heartphata
P09925372A1063 |122 129|processyperbil
P09925372A1063 |88 97|HFHZ mRNAharmacolo
P09925372A1063 |133 144|developmentinemia. P00
P09925372A1063 |20 30|expressionrison with
P09925777A1195 |67 87|beta-globin reporterdase P00008171T0000 
P09925777A1195 |150 155|mRNAsA0472
P09925777A1195 |14 31|affinity hnRNP A1 Comparison with 
P09925777A1195 |130 136|levelsrubine
P09925777A1195 |89 92|Revarm
P09925777A1195 |40 44|sitephos
P09925777A1195 |161 162|%C
P09927193A0107 |18 26|proteinsparison 
P09927193A0107 |74 85|oncogenesis0008171T000
P09927193A0107 |43 48|BCL-6sphat
P09927193A0107 |28 32|PLZFth a
P09927193A0107 |37 42|LAZ-3ne ph
P09927193A0107 |3 7|date0016
P09927449A0421 |0 14|OverexpressionP00001606T0076
P09927449A0421 |110 120|CLN2 genesf neonatal
P09927449A0421 |83 93|repression000 Pharma
P09927449A0421 |53 62|G1 arrestand 5-nuc
P09927449A0421 |18 22|POG1pari
P09927449A0421 |101 105|CLN1aspe
P09927570A0507 |17 31|RNU2 fragilitymparison with 
P09927570A0507 |208 211|kDathe
P09927570A0507 |134 143|E1 vectornemia. P0
P09927570A0507 |157 168|E1 productshen CSF [HC
P09927570A0507 |219 231|kDa proteins K-depleted 
P09927570A0507 |172 184|E1A proteins is shown as
P09927570A0507 |110 113|kDaf n
P09927570A0507 |201 204|E1BF P
P09927570A0507 |98 106|Ad12 E1Bic aspec
P09927570A0507 |71 88|expression vector P00008171T0000 P
P09927570A0507 |50 62|transfectiones and 5-nuc
P09927585A0796 |152 162|factor Sp1472 When C
P09927585A0796 |83 110|bandshift complex formation000 Pharmacologic aspects o
P09927585A0796 |57 65|proteins5-nucleo
P09927585A0796 |116 119|KCSata
P09927585A0796 |0 33|Competitionsupershift EMSA assaysP00001606T0076 Comparison with al
P09927589T0000 |0 10|SimilarityP00001606T
P09927589T0000 |46 56|regulationatases and
P09927589T0000 |14 25|DNA binding Comparison
P09927589T0000 |60 88|Caenorhabditis elegans MAB-3ucleotidase P00008171T0000 P
P09927589T0000 |146 149|sex899
P09927589T0000 |130 142|conservationrubinemia. P
P09927589T0000 |162 172|mechanismsSF [HCO3-]
P09927589T0000 |117 120|DSXtal
P09929088A0000 |0 7|CONTEXTP000016
P09929088A0000 |113 129|cancer screeningeonatal hyperbil
P09929088A0000 |96 100|costogic
P09929088A0000 |9 17|ThinPrepT0076 Co
P09929088A0000 |19 26|AutoPaparison 
P09929088A0000 |80 91|sensitivity1T0000 Phar
P09929088A0000 |32 38|Papnetlkalin
P09929088A0000 |49 61|technologiesses and 5-nu
P09929811A0000 |0 11|ExperimentsP00001606T0
P09929811A0000 |323 329|branchr slop
P09929811A0000 |53 64|derivativesand 5-nucle
P09929811A0000 |261 272|electrogramhen compare
P09929811A0000 |214 221|segmentta of K
P09929811A0000 |26 30|catswith
P09929811A0000 |182 188|CM-345as a f
P09929811A0000 |351 357|artery000109
P09929811A0000 |162 168|CM-251SF [HC
P09929811A0000 |107 117|propertiess of neona
P09929811A0000 |286 295|occlusionbut still
P09929811A0000 |201 210|mean riseF PCO2 th
P09929811A0000 |142 148|agents000089
P09929811A0000 |237 242|leadsre no
P09929811A0000 |170 176|CM-266-] is 
P09931118A1072 |69 77|IL-1betase P0000
P09931118A1072 |12 18|p42/4476 Com
P09931118A1072 |27 38|JNK pathwayith alkalin
P09931118A1072 |59 65|actionnucleo
P09931191A0434 |50 53|Cones 
P09931191A0434 |109 124|muscle ischemiaof neonatal hyp
P09931191A0434 |31 39|subjectsalkaline
P09931191A0434 |75 82|fatigue008171T
P09931191A0434 |58 71|Ecc arm curls-nucleotidase
P09931191A0434 |161 169|protocolCSF [HCO
P09931191A0434 |144 154|resistance008997A047
P09931191A0434 |3 11|protocol001606T0
P09931216A0566 |0 7|AirflowP000016
P09931216A0566 |106 112|modulets of 
P09931216A0566 |44 51|turbinephatase
P09931216A0566 |58 63|45-ft-nucl
P09931216A0566 |70 75|cablee P00
P09931252A1055 |102 111|abilitiesspects of
P09931252A1055 |135 154|scaffolding proteinemia. P00008997A047
P09931252A1055 |60 72|coat proteinucleotidase 
P09931252A1055 |22 46|amino acid substitutionsson with alkaline phosph
P09931252A1055 |5 14|mutations1606T0076
P09931391A0944 |21 35|liver functionison with alka
P09931391A0944 |47 54|surgerytases a
P09931391A0944 |9 17|recoveryT0076 Co
P09931435A0357 |119 123|exonl hy
P09931435A0357 |105 109|exoncts 
P09931435A0357 |128 133|ZIS-1lirub
P09931435A0357 |147 151|size997A
P09931435A0357 |47 52|exonstases
P09931435A0357 |14 25|transcripts Comparison
P09931435A0357 |54 58|exonnd 5
P09931435A0357 |178 181|UTRown
P09931435A0357 |65 70|ZIS-2tidas
P09931435A0357 |85 90|ZIS-10 Pha
P09932288A0378 |0 10|ExpressionP00001606T
P09932288A0378 |31 34|XT3alk
P09932288A0378 |126 138|cDNA librarybilirubinemi
P09932288A0378 |91 99|sequencemacologi
P09932288A0378 |25 29|gene wit
P09932288A0378 |71 77|kidney P0000
P09933428A0351 |0 9|IFN-gammaP00001606
P09933428A0351 |104 113|treatmentects of n
P09933428A0351 |37 39|TBne
P09933428A0351 |67 75|controlsdase P00
P09933641A0241 |85 93|analysis0 Pharma
P09933641A0241 |175 188|amplification shown as a f
P09933641A0241 |113 118|cloneeonat
P09933641A0241 |192 201|cDNA endsion of CS
P09933641A0241 |15 24|sequencesCompariso
P09933641A0241 |139 148|sequences. P000089
P09933641A0241 |100 104|NHE5 asp
P09933641A0241 |51 64|amplifications and 5-nucle
P09933641A0241 |68 77|cDNA endsase P0000
P09933848A1008 |64 68|roleotid
P09933848A1008 |89 103|autoantibodiesarmacologic as
P09933848A1008 |72 76|drugP000
P09933848A1008 |43 51|analysissphatase
P09933848A1008 |6 20|alloantibodies606T0076 Compa
P09934611A1054 |87 91|meanPhar
P09934611A1054 |53 59|extentand 5-
P09934611A1054 |72 83|min LVdP/dtP00008171T0
P09934611A1054 |5 15|dependence1606T0076 
P09934611A1054 |99 107|pressurec aspect
P09935377T0108 |0 5|GenoaP0000
P09935377T0108 |7 12|Italy06T00
P09935377T0108 |20 26|Augustrison 
P09936001T0000 |84 89|delta00 Ph
P09936001T0000 |11 20|structure076 Compa
P09936001T0000 |91 100|plutoniummacologic
P09936001T0000 |31 40|plutoniumalkaline 
P09936001T0000 |59 61|Ganu
P09936001T0000 |24 29|deltan wit
P09936001T0000 |67 80|Sc impuritiesdase P0000817
P09936001T0000 |55 57|Ald 
P09938097T0000 |68 77|acceptorsase P0000
P09938097T0000 |14 22|transfer Compari
P09938097T0000 |27 63|photoluminescence undulation spectraith alkaline phosphatases and 5-nucl
P09938097T0000 |81 85|ZnTeT000
P09940132T0000 |76 86|properties08171T0000
P09940132T0000 |43 65|charge-transfer solidssphatases and 5-nucleo
P09940132T0000 |8 14|theory6T0076
P09943651T0000 |20 27|solitonrison w
P09943651T0000 |9 14|modesT0076
P09944066T0073 |0 2|IIP0
P09945838T0000 |51 53|Gas 
P09945838T0000 |42 46|GaAsosph
P09945838T0000 |57 72|heterojunctions5-nucleotidase 
P09945838T0000 |18 37|matching conditionsparison with alkali
P09945838T0000 |48 50|Alas
P09947191T0000 |68 70|Z2as
P09947191T0000 |79 94|antiferromagnet71T0000 Pharmac
P09947191T0000 |44 53|exponentsphatases 
P09947191T0000 |57 64|CsMnBr35-nucle
P09947191T0000 |0 31|Neutron scattering measurementsP00001606T0076 Comparison with 
P09949160A0600 |238 241|Epoe n
P09949160A0600 |53 61|bulk PKCand 5-nu
P09949160A0600 |93 103|expressioncologic as
P09949160A0600 |212 217|betaIdata 
P09949160A0600 |267 272|cellsmpare
P09949160A0600 |245 251|growthnger d
P09949160A0600 |165 177|upregulation[HCO3-] is s
P09949160A0600 |195 203|isoforms of CSF 
P09949160A0600 |224 234|readditionpleted rat
P09949160A0600 |119 135|eta PKC isoformsl hyperbilirubin
P09949160A0600 |14 28|32D Epo1 cells Comparison wi
P09949160A0600 |44 49|levelphata
P09949160A0600 |107 114|epsilons of ne
P09949160A0600 |72 80|activityP0000817
P09949178A0264 |102 112|pre-B-cellspects of 
P09949178A0264 |8 18|expression6T0076 Com
P09949178A0264 |121 125|linehype
P09949178A0264 |90 96|growthrmacol
P09949178A0264 |67 73|factordase P
P09949178A0264 |127 132|1A9-Miliru
P09949178A0264 |39 52|interleukin-6 phosphatases
P09949178A0264 |54 58|IL-6nd 5
P09949312A0524 |0 7|AirflowP000016
P09949312A0524 |52 63|vacuum pump and 5-nucl
P09949312A0524 |20 29|dust traprison wit
P09950213A1660 |137 150|participationia. P00008997
P09950213A1660 |52 59|TbetaRI and 5-
P09950213A1660 |64 72|TbetaRIIotidase 
P09950213A1660 |38 50|goblet cellse phosphatas
P09950213A1660 |116 124|TGF-betaatal hyp
P09950213A1660 |154 163|TbetaRIII2 When CS
P09950394A0336 |70 79|physiciane P000081
P09950394A0336 |28 52|carboxyhemoglobin levelsth alkaline phosphatases
P09950394A0336 |15 23|exposureComparis
P09950394A0336 |88 97|diagnosisharmacolo
P09950394A0336 |4 11|history01606T0
P09952378A0529 |35 56|% confidence intervalline phosphatases and
P09952378A0529 |130 140|adjustmentrubinemia.
P09952378A0529 |109 123|IgG antibodiesof neonatal hy
P09952378A0529 |4 14|odds ratio01606T0076
P09952378A0529 |145 155|covariates08997A0472
P09952378A0529 |86 96|serostatus Pharmacol
P09952378A0529 |19 22|CHDari
P09952425A0893 |258 264|degreed when
P09952425A0893 |63 68|taskseotid
P09952425A0893 |226 230|roleeted
P09952425A0893 |120 124|type hyp
P09952425A0893 |175 185|structures shown as 
P09952425A0893 |8 13|group6T007
P09952425A0893 |40 47|animalsphospha
P09952425A0893 |79 85|lesion71T000
P09952425A0893 |204 210|lesionCO2 th
P09952425A0893 |101 112|impairmentsaspects of 
P09952425A0893 |238 249|hippocampuse no longer
P09952425A0893 |17 21|HIPPmpar
P09959737T0000 |4 8|case0160
P09959737T0000 |13 22|neutrinos6 Compari
P09959737T0000 |28 36|SN 1987Ath alkal
P09961326T0000 |65 71|modelstidase
P09961326T0000 |11 23|fluctuations076 Comparis
P09961326T0000 |43 52|interfacesphatases
P09961682T0000 |0 5|ModelP0000
P09961682T0000 |24 32|dynamicsn with a
P09961682T0000 |36 53|stick-slip motionine phosphatases 
P09964171T0000 |17 22|atomsmpari
P09964171T0000 |58 66|presence-nucleot
P09964171T0000 |44 50|mediumphatas
P09964171T0000 |92 97|fieldacolo
P09964171T0000 |0 3|NMRP00
P09964770T0000 |0 14|MicrostructureP00001606T0076
P09964770T0000 |48 67|laminate compositesases and 5-nucleoti
P09964770T0000 |19 31|conductivityarison with 
P09965234T0000 |34 52|octylcyanobiphenylaline phosphatases
P09965234T0000 |12 26|heat transport76 Comparison 
P09965234T0000 |59 73|liquid crystalnucleotidase P
P09965234T0000 |54 57|8CBnd 
P09965909T0000 |32 53|soliton perturbationslkaline phosphatases 
P09965909T0000 |7 15|approach06T0076 
P09965909T0000 |23 28|studyon wi
P09971776A0838 |102 105|Nefspe
P09971776A0838 |209 218|dipeptidehe data o
P09971776A0838 |132 135|W57bin
P09971776A0838 |91 98|bindingmacolog
P09971776A0838 |140 143|L58 P0
P09971776A0838 |114 122|receptoronatal h
P09971776A0838 |25 39|CD4 regulation with alkaline
P09971776A0838 |176 191|dileucine motifshown as a func
P09971776A0838 |237 243|regionre no 
P09971776A0838 |251 258|proteinisplace
P09971776A0838 |50 58|residueses and 5
P09971776A0838 |0 9|MutationsP00001606
P09971790A0856 |49 68|helicase activitiesses and 5-nucleotid
P09971790A0856 |88 117|amino-terminal-charge clusterharmacologic aspects of neona
P09971790A0856 |134 148|D40A-D42A-D44Anemia. P000089
P09971790A0856 |125 132|proteinrbiliru
P09971790A0856 |166 198|AAV hairpin DNA binding activityHCO3-] is shown as a function of
P09971790A0856 |8 17|mutations6T0076 Co
P09971790A0856 |32 44|endonucleaselkaline phos
P09971806A1585 |19 23|KSHVaris
P09971806A1585 |10 15|cycle0076 
P09971806A1585 |109 127|tumor pathogenesisof neonatal hyperb
P09971806A1585 |52 59|control and 5-
P09971806A1585 |67 80|KSHV/Rta genedase P0000817
P09971815A2094 |238 243|sitese no 
P09971815A2094 |48 71|candidate latency genesases and 5-nucleotidase
P09971815A2094 |397 415|gammaherpesviruses effective hypnoti
P09971815A2094 |82 91|gammaHV680000 Phar
P09971815A2094 |112 117|genesneona
P09971815A2094 |295 307|v-bcl-2 gene have a sign
P09971815A2094 |266 273|regionsompared
P09971815A2094 |247 254|latencyer disp
P09971815A2094 |125 132|latencyrbiliru
P09971815A2094 |196 212|latency programsof CSF PCO2 the 
P09971815A2094 |287 293|genomeut sti
P09971815A2094 |357 364|latency43A0733
P09971815A2094 |325 329|geneslop
P09971815A2094 |309 319|v-GCR geneicantly gr
P09971815A2094 |163 169|organsF [HCO
P09971815A2094 |98 108|expressionic aspects
P09971815A2094 |375 384|gammaHV68 thus app
P09971822A1542 |33 37|rolekali
P09971822A1542 |61 80|splicing inhibitioncleotidase P0000817
P09971822A1542 |42 44|U1os
P09971822A1542 |6 10|data606T
P09973351A1522 |23 39|DcuS-DcuR systemon with alkaline
P09973351A1522 |61 71|substratescleotidase
P09973607A0254 |68 80|Sp100 splicease P0000817
P09973607A0254 |40 56|characterizationphosphatases and
P09973607A0254 |89 97|proteinsarmacolo
P09973607A0254 |151 154|end047
P09973607A0254 |129 140|elucidationirubinemia.
P09973607A0254 |162 172|Sp100 geneSF [HCO3-]
P09973607A0254 |21 35|identificationison with alka
P09973607A0254 |116 125|existenceatal hype
P09974642T0000 |0 9|CrossoverP00001606
P09974642T0000 |26 30|heatwith
P09974642T0000 |41 48|magnetshosphat
P09974642T0000 |79 87|dynamics71T0000 
P09976626T0000 |0 7|ErratumP000016
P09976626T0000 |60 74|transformationucleotidase P0
P09976626T0000 |20 37|precursor effectsrison with alkali
P09976626T0000 |9 16|AbsenceT0076 C
P09976626T0000 |98 106|Li metalic aspec
P09976626T0000 |87 94|crystalPharmac
P09980944T0000 |0 19|Interplane couplingP00001606T0076 Comp
P09980944T0000 |90 99|resonancermacologi
P09980944T0000 |27 53|superconductor Y2Ba4Cu7O15ith alkaline phosphatases 
P09980944T0000 |69 82|NQR spin-echose P00008171T
P09982923T0000 |33 38|NiSi2kalin
P09982923T0000 |11 20|structure076 Compa
P09982923T0000 |57 64|bulk Si5-nucle
P09982923T0000 |42 53|CoSi2 layerosphatases 
P09983871T0000 |0 19|Raman investigationP00001606T0076 Comp
P09983871T0000 |23 46|YBa2-xLaxCu3O7 ceramicson with alkaline phosph
P09984526T0000 |0 7|EffectsP000016
P09984526T0000 |28 46|lattice parametersth alkaline phosph
P09984526T0000 |11 24|point defects076 Compariso
P09984526T0000 |50 64|semiconductorses and 5-nucle
P09985302T0000 |8 25|electron dynamics6T0076 Comparison
P09985302T0000 |62 69|antidotleotida
P09986796A1761 |9 18|deletionsT0076 Com
P09986796A1761 |46 57|amino acidsatases and 
P09986796A1761 |26 27|Cw
P09986796A1761 |79 86|effects71T0000
P09987176A0260 |119 127|anti-HAVl hyperb
P09987176A0260 |31 42|vaccinationalkaline ph
P09987176A0260 |78 87|follow-up171T0000 
P09987176A0260 |109 115|levelsof neo
P09987176A0260 |6 12|months606T00
P09987176A0260 |48 57|vaccineesases and 
P09987634A1265 |100 110|PRK effect aspects o
P09987634A1265 |15 18|PRKCom
P09987634A1265 |24 29|weeksn wit
P09987634A1265 |46 57|retreatmentatases and 
P09987634A1265 |82 92|regression0000 Pharm
P09987634A1265 |33 36|agekal
P09987961A0093 |54 66|vasculopathynd 5-nucleot
P09987961A0093 |72 85|proliferationP00008171T000
P09987961A0093 |106 117|fibroblaststs of neona
P09987961A0093 |89 101|synoviocytesarmacologic 
P09987961A0093 |10 17|lesions0076 Co
P09987961A0093 |40 52|angiomatosisphosphatases
P09988682T0033 |49 88|beta1,6-N-acetylglucosaminyltransferaseses and 5-nucleotidase P00008171T0000 P
P09988682T0033 |27 31|cDNAith 
P09988682T0033 |10 17|cloning0076 Co
P09988682T0033 |108 112|core of 
P09988682T0033 |97 101|coregic 
P09988767A1496 |64 80|mouse 3Ost genesotidase P0000817
P09988767A1496 |94 105|assignmentsologic aspe
P09988767A1496 |14 39|mouse back-cross analysis Comparison with alkaline
P09988767A1496 |159 173|identificationn CSF [HCO3-] 
P09988767A1496 |129 136|isologsirubine
P09988767A1496 |200 212|site markersSF PCO2 the 
P09988767A1496 |55 59|locid 5-
P09988850A0000 |69 76|SCIRFIRse P000
P09988850A0000 |296 302|coursehave a
P09988850A0000 |24 34|Impairmentn with alk
P09988850A0000 |244 251|purposeonger d
P09988850A0000 |60 67|Recordsucleoti
P09988850A0000 |81 88|batteryT0000 P
P09988850A0000 |112 139|dementia rating instrumentsneonatal hyperbilirubinemia
P09988850A0000 |159 166|recordsn CSF [
P09988850A0000 |212 234|schizophrenia patientsdata of K-depleted rat
P09988850A0000 |316 322|change great
P09988850A0000 |326 339|schizophrenialope (1.21 +/
P09988850A0000 |369 386|autopsy materialsazepam thus appea
P09988850A0000 |4 10|Scales01606T
P09989334A0964 |156 162|intronWhen C
P09989334A0964 |29 47|processing signalsh alkaline phospha
P09989334A0964 |104 124|polyadenylation siteects of neonatal hyp
P09989334A0964 |77 95|donor splice sites8171T0000 Pharmaco
P09989334A0964 |55 65|transcriptd 5-nucleo
P09989339A0968 |19 22|useari
P09989339A0968 |30 37|product alkali
P09989339A0968 |41 53|brain weighthosphatases 
P09989339A0968 |58 67|clearance-nucleoti
P09990057T0000 |0 13|RecombinationP00001606T007
P09990057T0000 |99 104|chainc asp
P09990057T0000 |142 149|absence0000899
P09990057T0000 |59 70|chain locusnucleotidas
P09990057T0000 |90 92|Igrm
P09990057T0000 |157 182|matrix attachment regionshen CSF [HCO3-] is shown 
P09990057T0000 |114 134|enhancer core regiononatal hyperbilirubi
P09990057T0000 |18 31|transcriptionparison with 
P09990057T0000 |50 52|Iges
P09990060A0803 |65 86|dyad symmetry elementtidase P00008171T0000
P09990060A0803 |124 137|IL-2 enhancererbilirubinem
P09990060A0803 |13 19|motifs6 Comp
P09990060A0803 |146 159|CD18 promoter8997A0472 Whe
P09990060A0803 |24 28|partn wi
P09990060A0937 |168 177|inductionO3-] is s
P09990060A0937 |181 195|IL-16 promoter as a function
P09990060A0937 |95 102|bindinglogic a
P09990060A0937 |133 154|dyad symmetry elementinemia. P00008997A047
P09990060A0937 |106 115|GABPalphats of neo
P09990060A0937 |121 125|betahype
P09990060A0937 |20 57|coactivator CREB binding protein/p300rison with alkaline phosphatases and 
P09990060A0937 |199 206|T cellsCSF PCO
P09990060A0937 |80 89|GABPalpha1T0000 Ph
P09990060A0937 |3 10|concert001606T
P09990315A0205 |0 3|TPOP00
P09990315A0205 |118 128|activational hyperbi
P09990315A0205 |154 162|agonists2 When C
P09990315A0205 |248 256|agonistsr displa
P09990315A0205 |31 35|ERK1alka
P09990315A0205 |46 62|protein kinase Catases and 5-nuc
P09990315A0205 |132 136|ERKsbine
P09990315A0205 |224 238|PKC activationpleted rats ar
P09990315A0205 |186 200|phorbol esters function of C
P09990315A0205 |37 41|ERK2ne p
P09990315A0205 |78 81|TPO171
P09990315A0205 |173 181|thrombinis shown
P09990315A0205 |64 67|PKCoti
P09990507A0000 |0 10|BACKGROUNDP00001606T
P09990507A0000 |129 135|timingirubin
P09990507A0000 |62 78|ubiquitin ligaseleotidase P00008
P09990507A0000 |39 58|proteolysis pathway phosphatases and 5
P09990507A0000 |113 124|selectivityeonatal hyp
P09990507A0000 |80 82|E31T
P09990507A0000 |139 150|degradation. P00008997
P09990507A0763 |0 11|CONCLUSIONSP00001606T0
P09990507A0763 |46 50|Pop1atas
P09990507A0763 |13 30|Fission yeast SCF6 Comparison with
P09990507A0763 |55 59|Pop2d 5-
P09990507A0763 |115 139|F-box/WD-repeat proteinsnatal hyperbilirubinemia
P09994942T0000 |4 15|NMR studies01606T0076 
P09994942T0000 |37 53|antiferromagnetsne phosphatases 
P09995847T0000 |0 26|Optical-absorption spectraP00001606T0076 Comparison 
P09995847T0000 |61 86|transition line strengthscleotidase P00008171T0000
P09995847T0000 |90 97|holmiumrmacolo
P09995847T0000 |42 55|energy levelsosphatases an
P09995847T0000 |110 113|Na3f n
P09995897T0000 |0 11|ObservationP00001606T0
P09995897T0000 |44 55|Pb0 defectsphatases an
P09995897T0000 |23 35|interactionson with alka
P09995897T0000 |69 86|Si/SiO2 interfacese P00008171T0000
P09999256T0000 |20 26|theoryrison 
P09999256T0000 |41 60|transport phenomenahosphatases and 5-n
P09999742T0000 |0 3|NH3P00
P09999742T0000 |44 52|surfacesphatases
P09999742T0000 |28 30|Sith
P09999742T0000 |8 22|NO interaction6T0076 Compari
P10000253T0000 |0 15|Chirality-glassP00001606T0076 
P10000253T0000 |79 87|XY model71T0000 
P10000253T0000 |20 43|spin-glass correlationsrison with alkaline pho
P10001333T0038 |0 15|Echo modulationP00001606T0076 
P10001333T0038 |24 29|YAlO3n wit
P10001333T0038 |19 22|Pr3ari
P10001541T0000 |0 10|MechanismsP00001606T
P10001541T0000 |28 36|emissionth alkal
P10001541T0000 |66 73|siliconidase P
P10002245T0000 |71 80|YBa2Cu3O7 P0000817
P10002245T0000 |41 51|CuO chainshosphatase
P10002245T0000 |82 95|delta crystal0000 Pharmaco
P10002245T0000 |21 33|conductivityison with al
P10006319T0000 |0 18|Surface spin wavesP00001606T0076 Com
P10006319T0000 |24 46|Heisenberg ferrimagnetn with alkaline phosph
P10006319T0000 |65 75|anisotropytidase P00
P10007469T0000 |19 26|libronsarison 
P10007469T0000 |31 38|phononsalkalin
P10007469T0000 |54 57|C60nd 
P10007564T0000 |68 75|surfacease P00
P10007564T0000 |61 62|Wc
P10007564T0000 |46 55|structureatases an
P10007564T0000 |22 30|geometryson with
P10008261T0000 |0 22|Temperature dependenceP00001606T0076 Compari
P10008261T0000 |30 40|sublattice alkaline 
P10008261T0000 |53 66|magnetizationand 5-nucleot
P10008261T0000 |70 79|YBa2Cu3O6e P000081
P10009565T0000 |0 22|GW Gamma approximationP00001606T0076 Compari
P10009565T0000 |72 82|insulatorsP00008171T
P10009565T0000 |27 49|electron self-energiesith alkaline phosphata
P10009565T0000 |53 67|semiconductorsand 5-nucleoti
P10013227T0000 |0 21|Precision measurementP00001606T0076 Compar
P10013227T0000 |29 54|pion mass difference m pih alkaline phosphatases a
P10013227T0000 |57 61|m pi5-nu
P10019841T0000 |8 15|gravity6T0076 
P10019841T0000 |63 71|approacheotidase
P10019841T0000 |41 46|orderhosph
P10021333A0674 |85 96|interaction0 Pharmacol
P10021333A0674 |111 116|genes neon
P10021333A0674 |26 33|mutantswith al
P10021333A0674 |8 19|experiments6T0076 Comp
P10021333A0674 |59 64|brunonucle
P10021350A0093 |103 109|nucleipects 
P10021350A0093 |163 184|transcription factorsF [HCO3-] is shown as
P10021350A0093 |241 246|geneso lon
P10021350A0093 |120 143|TCF/LEF family proteins hyperbilirubinemia. P0
P10021350A0093 |15 20|modelCompa
P10021350A0093 |200 213|transcriptionSF PCO2 the d
P10021350A0093 |53 75|Armadillo/beta-cateninand 5-nucleotidase P00
P10021350A0093 |217 229|Wingless/Wntof K-deplete
P10021350A0093 |35 41|signalline p
P10022032A0000 |186 219|calcium channel blocker diltiazem function of CSF PCO2 the data of
P10022032A0000 |72 75|NICP00
P10022032A0000 |3 10|support001606T
P10022032A0000 |115 147|receptor antagonists propranololnatal hyperbilirubinemia. P00008
P10022032A0000 |158 166|atenololen CSF [
P10022032A0000 |280 292|interactionstrols but st
P10022032A0000 |168 171|ATNO3-
P10022032A0000 |48 70|vasodilator nicorandilases and 5-nucleotidas
P10022032A0000 |35 42|studiesline ph
P10022032A0000 |221 224|DTZ-de
P10022210A0620 |0 7|FactorsP000016
P10022210A0620 |42 54|SPME processosphatases a
P10022210A0620 |20 36|direct-immersionrison with alkal
P10022210A0620 |38 40|DIe 
P10022850A0929 |102 119|Zta transcriptionspects of neonata
P10022850A0929 |31 39|fragmentalkaline
P10022850A0929 |55 66|C/H1 domaind 5-nucleot
P10022850A0929 |130 151|reactivation functionrubinemia. P00008997A
P10022850A0929 |3 11|contrast001606T0
P10022850A0929 |86 98|coactivation Pharmacolog
P10022858A0985 |3 11|addition001606T0
P10022858A0985 |106 113|proteints of n
P10022858A0985 |22 48|splicing enhancer sequenceson with alkaline phosphat
P10022858A0985 |65 74|selectiontidase P0
P10022867A1069 |136 145|reversionmia. P000
P10022867A1069 |16 20|ETH1ompa
P10022867A1069 |1 12|Elimination00001606T00
P10022867A1069 |64 78|mutation ratesotidase P00008
P10022867A1069 |114 118|typeonat
P10022867A1069 |24 36|apn1 strainsn with alkal
P10022867A1069 |160 178|lysine prototrophy CSF [HCO3-] is sh
P10022867A1069 |149 156|adenine7A0472 
P10022867A1069 |24 36|apn1 strainsn with alkal
P10022867A1069 |160 178|lysine prototrophy CSF [HCO3-] is sh
P10022867A1069 |149 156|adenine7A0472 
P10022867A1069 |136 145|reversionmia. P000
P10022867A1069 |64 78|mutation ratesotidase P00008
P10022867A1069 |114 118|typeonat
P10022867A1069 |1 12|Elimination00001606T00
P10022867A1069 |16 20|ETH1ompa
P10022875A1265 |65 76|PI 3-kinasetidase P000
P10022875A1265 |30 43|Ras effectors alkaline pho
P10022875A1265 |109 112|Pakof 
P10022875A1265 |6 10|data606T
P10022880A0000 |172 200|signal transduction pathways is shown as a function of C
P10022880A0000 |121 133|Ras proteinshyperbilirub
P10022880A0000 |91 104|downregulatormacologic asp
P10022880A0000 |151 155|role0472
P10022880A0000 |41 44|GAPhos
P10022880A0000 |47 59|p120 Ras-GAPtases and 5-
P10022880A0000 |109 117|effectorof neona
P10022880A0000 |10 39|Ras GTPase-activating protein0076 Comparison with alkaline
P10022905A0446 |98 115|missense mutationic aspects of neo
P10022905A0446 |76 83|alleles08171T0
P10022905A0446 |213 220|tissuesata of 
P10022905A0446 |149 157|activity7A0472 W
P10022905A0446 |6 19|mog-1 alleles606T0076 Comp
P10022905A0446 |159 169|mog-1 mRNAn CSF [HCO
P10022905A0446 |191 200|germ linetion of C
P10022905A0446 |38 49|stop codonse phosphata
P10022921A0608 |84 98|cell viability00 Pharmacolog
P10022921A0608 |59 63|pst1nucl
P10022921A0608 |20 29|SIN3 generison wit
P10022925A0870 |64 70|motifsotidas
P10022925A0870 |80 88|function1T0000 P
P10022925A0870 |4 25|Nmd3 protein sequence01606T0076 Comparison
P10022978A1261 |32 39|repeatslkaline
P10022978A1261 |105 112|regionscts of 
P10022978A1261 |53 65|organizationand 5-nucleo
P10022978A1261 |122 126|baseyper
P10022978A1261 |140 155|chromosome arms P00008997A0472
P10022978A1261 |4 16|distribution01606T0076 C
P10024383T0000 |0 10|CalcitoninP00001606T
P10024383T0000 |52 64|hyperostosis and 5-nucle
P10024383T0000 |125 132|twy/twyrbiliru
P10024383T0000 |80 90|osteopenia1T0000 Pha
P10024383T0000 |118 123|mouseal hy
P10024498A0783 |69 76|Y sitesse P000
P10024498A0783 |31 37|assaysalkali
P10024498A0783 |129 139|HNF-3alphairubinemia
P10024498A0783 |57 64|HNF-3 X5-nucle
P10024498A0783 |144 153|HNF-3beta008997A04
P10024498A0783 |100 105|sites aspe
P10024882A0541 |3 11|addition001606T0
P10024882A0541 |120 136|promoter opening hyperbilirubine
P10024882A0541 |75 81|domain008171
P10024882A0541 |91 98|RNA polmacolog
P10024882A0541 |31 35|cdk7alka
P10024882A0541 |109 116|absenceof neon
P10024882A0541 |83 86|CTD000
P10025050A1052 |4 11|therapy01606T0
P10025050A1052 |31 41|antagonistalkaline p
P10025050A1052 |105 117|lansoprazolects of neona
P10025050A1052 |91 101|omeprazolemacologic 
P10025050A1052 |76 85|therapies08171T000
P10025506A0079 |33 49|plastin isoformskaline phosphata
P10025506A0079 |3 9|humans001606
P10025506A1078 |3 7|TATA0016
P10025506A1078 |11 23|Inr sequence076 Comparis
P10026146A0680 |136 140|PrKXmia.
P10026146A0680 |22 37|RIalpha subunitson with alkali
P10026146A0680 |93 97|cAMPcolo
P10026146A0680 |246 256|holoenzymeger displa
P10026146A0680 |266 280|Calpha subunitompared to con
P10026146A0680 |299 313|protein kinasee a significan
P10026146A0680 |75 89|concentrations008171T0000 Ph
P10026146A0680 |153 157|type72 W
P10026146A0680 |217 236|cAMP concentrationsof K-depleted rats 
P10026146A0680 |53 61|additionand 5-nu
P10026146A0680 |99 101|Kac 
P10026146A0680 |107 109|nMs 
P10026146A0680 |175 189|protein kinase shown as a fu
P10026146A0680 |4 14|inhibition01606T0076
P10026211A0136 |0 8|ProteinsP0000160
P10026211A0136 |27 36|PEPCK CREith alkal
P10026211A0136 |61 68|proteincleotid
P10026211A0136 |134 140|familynemia.
P10026211A0136 |80 87|members1T0000 
P10026211A0136 |127 132|C/EBPiliru
P10026211A0136 |70 74|CREBe P0
P10026211A0136 |118 125|proteinal hype
P10026211A0543 |170 194|H4IIE rat hepatoma cells-] is shown as a functio
P10026211A0543 |60 64|betaucle
P10026211A0543 |45 55|C/EBPalphahatases an
P10026211A0543 |112 135|glucocorticoid responseneonatal hyperbilirubin
P10026211A0543 |73 77|CREB0000
P10026211A0543 |23 37|pDeltaCREC/EBPon with alkali
P10026211A0543 |5 14|construct1606T0076
P10026229A0950 |186 194|fragment functio
P10026229A0950 |147 158|enhancement997A0472 Wh
P10026229A0950 |56 66|Pbx1 sites 5-nucleot
P10026229A0950 |22 33|mutagenesisson with al
P10026229A0950 |42 51|Engrailedosphatase
P10026229A0950 |3 11|addition001606T0
P10026229A0950 |101 106|sitesaspec
P10026275A0549 |18 36|structure elementsparison with alkal
P10026784A0331 |68 89|transcription factorsase P00008171T0000 Ph
P10026784A0331 |9 17|evidenceT0076 Co
P10026784A0331 |41 50|functionshosphatas
P10026784A0331 |111 132|POU DNA binding motif neonatal hyperbiliru
P10026784A0331 |58 64|family-nucle
P10026784A0331 |159 170|developmentn CSF [HCO3
P10026784A0331 |140 145|roles P000
P10026784A0929 |115 130|POU-homeodomainnatal hyperbili
P10026784A0929 |28 39|DNA bindingth alkaline
P10026784A0929 |43 75|POU domain transcription factorssphatases and 5-nucleotidase P00
P10026784A2166 |153 157|GTAT72 W
P10026784A2166 |59 73|GCAT half-sitenucleotidase P
P10026784A2166 |145 151|domain08997A
P10026784A2166 |126 131|Pit-1bilir
P10026784A2166 |7 20|Oct-1 crystal06T0076 Compa
P10026784A2166 |178 184|strandown as
P10026784A2166 |39 45|domain phosp
P10026784A2166 |99 107|sequencec aspect
P10026824A0309 |34 57|V1a/V2 hybrid receptorsaline phosphatases and 
P10026824A0309 |224 235|V2 receptorpleted rats
P10026824A0309 |267 275|couplingmpared t
P10026824A0309 |161 169|couplingCSF [HCO
P10026824A0309 |95 99|looplogi
P10026824A0309 |107 119|V1a receptors of neonata
P10026824A0309 |22 30|analysisson with
P10026824A0309 |212 216|loopdata
P10026824A0309 |173 178|Gq/11is sh
P10026824A0309 |279 281|Gsnt
P10027498A0536 |51 56|deaths and
P10027498A0536 |122 123|py
P10027498A0536 |89 101|U.S. programarmacologic 
P10027498A0536 |11 21|end points076 Compar
P10027904A0768 |61 67|regioncleoti
P10029337A0406 |169 173|days3-] 
P10029337A0406 |94 95|lo
P10029337A0406 |147 155|activity997A0472
P10029337A0406 |180 182|SDn 
P10029337A0406 |120 141|serum creatine kinase hyperbilirubinemia. 
P10029337A0406 |192 193|li
P10029337A0406 |44 71|blood lactate concentrationphatases and 5-nucleotidase
P10029337A0406 |87 91|mmolPhar
P10029337A0406 |188 189|Uu
P10029337A0406 |108 116|increase of neon
P10029337A0406 |79 81|SD71
P10029337A0406 |143 145|CK00
P10029337A0406 |4 20|fatigue exercise01606T0076 Compa
P10029860A0605 |51 61|categoriess and 5-nu
P10029860A0605 |104 111|fillingects of
P10029860A0605 |66 70|typeidas
P10029860A0605 |19 26|aspectsarison 
P10029917A0366 |0 7|ResultsP000016
P10029917A0366 |90 94|casermac
P10029917A0366 |30 38|presence alkalin
P10029917A0366 |128 150|muscle cell dispersionlirubinemia. P00008997
P10029917A0366 |195 215|portal vein branches of CSF PCO2 the dat
P10029917A0366 |42 56|myofibroblastsosphatases and
P10029917A0366 |82 86|case0000
P10031854T0000 |0 22|New Langevin equationsP00001606T0076 Compari
P10031854T0000 |80 83|top1T0
P10032519T0000 |68 78|generationase P00008
P10032519T0000 |44 55|possibilityphatases an
P10032519T0000 |10 21|corrections0076 Compar
P10032519T0000 |25 35|beta decay with alka
P10032581T0000 |17 46|grazing-incidence diffractionmparison with alkaline phosph
P10032581T0000 |64 73|radiationotidase P
P10032581T0000 |50 61|synchrotrones and 5-nu
P10033973T0000 |55 71|Bose condensatesd 5-nucleotidase
P10033973T0000 |12 20|exchange76 Compa
P10033973T0000 |24 29|atomsn wit
P10033973T0000 |38 43|trapse pho
P10034615T0000 |0 23|Structure determinationP00001606T0076 Comparis
P10034615T0000 |78 79|x1
P10034615T0000 |59 73|reconstructionnucleotidase P
P10034615T0000 |83 87|H/Ni000 
P10035841T0000 |43 51|hydrogensphatase
P10035841T0000 |9 17|trappingT0076 Co
P10036181A0603 |102 119|rat brain regionsspects of neonata
P10036181A0603 |26 48|hybridization analyseswith alkaline phosphat
P10036181A0603 |58 80|GPR34 mRNA transcripts-nucleotidase P0000817
P10036181A0603 |0 13|Northern blotP00001606T007
P10036191A0000 |136 140|TFECmia.
P10036191A0000 |124 128|TFE3erbi
P10036191A0000 |29 38|subfamilyh alkalin
P10036191A0000 |209 224|gene expressionhe data of K-de
P10036191A0000 |91 112|transcription factorsmacologic aspects of 
P10036191A0000 |81 89|bHLH-ZIPT0000 Ph
P10036191A0000 |24 27|MiTn w
P10036191A0000 |179 189|regulationwn as a fu
P10036191A0000 |146 150|Mitf8997
P10036191A0000 |65 79|leucine zippertidase P000081
P10036191A0000 |130 134|TFEBrubi
P10036191A0000 |4 22|microphthalmia-TFE01606T0076 Compari
P10036191A0000 |236 249|cell lineagesare no longer
P10037004A0000 |113 120|relapseeonatal
P10037004A0000 |12 20|patients76 Compa
P10037004A0000 |149 156|therapy7A0472 
P10037004A0000 |62 70|leukemialeotidas
P10037004A0000 |31 36|yearsalkal
P10037004A0000 |109 111|BMof
P10037004A0000 |72 75|ALLP00
P10037004A0000 |197 202|studyf CSF
P10037004A0000 |96 107|bone marrowogic aspect
P10037378A0176 |4 17|dorsal nerves01606T0076 Co
P10037378A0176 |25 30|penis with
P10037378A0176 |66 75|lidocaineidase P00
P10037460A0221 |53 68|memory functionand 5-nucleotid
P10037460A0221 |72 83|interactionP00008171T0
P10037460A0221 |43 48|motorsphat
P10037460A0221 |95 115|ligand acetylcholinelogic aspects of neo
P10037460A0221 |25 34|receptors with alk
P10037460A0221 |7 12|brain06T00
P10037576T0000 |35 41|iodineline p
P10037576T0000 |20 28|necrosisrison wi
P10037576T0000 |48 67|plaque radiotherapyases and 5-nucleoti
P10037576T0000 |87 95|melanomaPharmaco
P10037681A0494 |34 43|PKC-alphaaline pho
P10037681A0494 |164 168|RhoA [HC
P10037681A0494 |11 22|interaction076 Compari
P10037681A0494 |89 97|fragmentarmacolo
P10037681A0494 |122 124|D4yp
P10037681A0494 |107 111|PLD1s of
P10037681A0494 |49 53|PLD1ses 
P10037681A0494 |26 29|ARFwit
P10037681A0494 |154 160|mutant2 When
P10037681A0494 |170 180|RhoAVal-14-] is show
P10037774A0366 |35 63|signal transduction pathwaysline phosphatases and 5-nucl
P10037774A0366 |8 13|study6T007
P10037774A0366 |96 114|LDLR transcriptionogic aspects of ne
P10041728T0000 |0 21|Vacuum Rabi splittingP00001606T0076 Compar
P10041728T0000 |27 34|featureith alk
P10041728T0000 |90 102|observationsrmacologic a
P10041728T0000 |38 62|linear-dispersion theorye phosphatases and 5-nuc
P10041728T0000 |64 72|Analysisotidase 
P10043466T0000 |70 91|polydiacetylene 4BCMUe P00008171T0000 Phar
P10043466T0000 |14 21|effects Compar
P10043466T0000 |46 54|kineticsatases a
P10043466T0000 |58 66|excitons-nucleot
P10044519T0000 |5 14|reduction1606T0076
P10044519T0000 |28 33|flowsth al
P10044519T0000 |37 45|polymersne phosp
P10046849T0000 |23 45|structure calculationson with alkaline phosp
P10046849T0000 |6 11|scale606T0
P10047970T0013 |8 24|world literature6T0076 Compariso
P10049357A0608 |50 62|HDAC complexes and 5-nuc
P10049357A0608 |24 27|Skin w
P10049357A0608 |72 75|SkiP00
P10049357A0608 |6 13|results606T007
P10049357A0608 |112 122|repressionneonatal h
P10049357A0608 |140 147|complex P00008
P10049357A0608 |33 42|componentkaline ph
P10049359A1073 |100 115|rhinovirus IRES aspects of neo
P10049359A1073 |12 15|unr76 
P10049359A1073 |54 57|PTBnd 
P10049359A1073 |71 82|translation P00008171T
P10049742T0000 |0 8|AnalysisP0000160
P10049742T0000 |73 76|ZF5000
P10049742T0000 |63 69|domaineotida
P10049742T0000 |16 42|consensus binding sequenceomparison with alkaline ph
P10049775T0000 |0 7|MappingP000016
P10049775T0000 |39 61|Anion Channel isoforms phosphatases and 5-nu
P10049912T0000 |0 14|IdentificationP00001606T0076
P10049912T0000 |41 51|suppressorhosphatase
P10049912T0000 |104 130|DNA exonuclease deficiencyects of neonatal hyperbili
P10049912T0000 |59 73|UV sensitivitynucleotidase P
P10049912T0000 |18 25|RNase Tparison
P10050883A0967 |0 10|InhibitionP00001606T
P10050883A0967 |134 140|effectnemia.
P10050883A0967 |157 166|viabilityhen CSF [
P10050883A0967 |14 43|phosphatidylinositol-3 kinase Comparison with alkaline pho
P10050883A0967 |81 97|p53 conformationT0000 Pharmacolo
P10050883A0967 |71 77|effect P0000
P10051030A1080 |17 27|percentagemparison w
P10051030A1080 |31 36|malesalkal
P10051030A1080 |75 82|strains008171T
P10051030A1080 |40 56|semen productionphosphatases and
P10051030A1080 |106 114|regimensts of ne
P10051030A1080 |3 13|difference001606T007
P10051030A1080 |84 93|CP levels00 Pharma
P10051400A0000 |84 103|cranio-rachischisis00 Pharmacologic as
P10051400A0000 |78 81|NTD171
P10051400A0000 |31 36|modelalkal
P10051400A0000 |65 76|tube defecttidase P000
P10051400A0000 |4 12|Lp mouse01606T00
P10051488A1293 |116 139|mobility AP-1 complexesatal hyperbilirubinemia
P10051488A1293 |82 86|HSCs0000
P10051488A1293 |8 16|analysis6T0076 C
P10051488A1293 |64 71|cultureotidase
P10051488A1293 |20 47|AP-1 DNA binding activitiesrison with alkaline phospha
P10051488A1293 |98 107|discoveryic aspect
P10051488A1293 |141 147|HMAP-1P00008
P10051488A1610 |34 49|TIMP-1 promoteraline phosphata
P10051488A1610 |96 102|% lossogic a
P10051488A1610 |78 84|HMAP-1171T00
P10051488A1610 |106 114|activityts of ne
P10051488A1610 |140 144|HSCs P00
P10051488A1610 |65 74|formationtidase P0
P10051488A1610 |0 9|MutationsP00001606
P10051488A1610 |17 26|AP-1 sitemparison 
P10052371A0171 |137 144|smokingia. P00
P10052371A0171 |91 100|occasionsmacologic
P10052371A0171 |61 69|subjectscleotida
P10052371A0171 |23 46|immunoglobulin A levelson with alkaline phosph
P10052371A0171 |208 211|daythe
P10052371A0171 |167 176|cessationCO3-] is 
P10052371A0171 |180 187|smokingn as a 
P10052371A0171 |156 160|daysWhen
P10052371A0171 |218 227|cessationf K-deple
P10052371A0171 |0 12|STUDY DESIGNP00001606T00
P10052371A0171 |119 126|subjectl hyper
P10052878A0135 |16 31|set-up accuracyomparison with 
P10052878A0135 |36 51|reproducibilityine phosphatase
P10053852T0000 |0 4|RoleP000
P10053852T0000 |41 72|Gerasimov-Drell-Hearn sum ruleshosphatases and 5-nucleotidase 
P10053852T0000 |27 36|Schwingerith alkal
P10053852T0000 |8 10|g26T
P10054976T0000 |68 89|Raman coupling regimease P00008171T0000 Ph
P10054976T0000 |25 29|ions wit
P10054976T0000 |52 62|detachment and 5-nuc
P10054976T0000 |0 12|SpectroscopyP00001606T00
P10055173T0000 |0 22|Band structure effectsP00001606T0076 Compari
P10055173T0000 |62 75|quasicrystalsleotidase P00
P10055173T0000 |26 46|transport propertieswith alkaline phosph
P10059496T0000 |37 52|Penrose latticene phosphatases
P10059496T0000 |9 29|transmission spectraT0076 Comparison wit
P10063122T0000 |0 25|Two-Channel Kondo LatticeP00001606T0076 Comparison
P10063122T0000 |41 46|Metalhosph
P10063739A0601 |119 127|controlsl hyperb
P10063739A0601 |75 86|study group008171T0000
P10063739A0601 |26 55|esophageal sphincter pressurewith alkaline phosphatases an
P10063739A0601 |192 195|EVLion
P10063739A0601 |88 92|meanharm
P10063739A0601 |151 159|pressure0472 Whe
P10063739A0601 |109 113|mmHgof n
P10063739A0601 |94 96|SDol
P10063739A0601 |140 144|mmHg P00
P10063739A0601 |185 188|EVSa f
P10064604A0824 |0 4|CPDsP000
P10064604A0824 |20 25|sitesrison
P10064604A0824 |80 86|repair1T0000
P10064604A0824 |49 55|TFIIIAses an
P10065176A0657 |152 167|macrometastases472 When CSF [H
P10065176A0657 |31 54|hormone receptor statusalkaline phosphatases a
P10065176A0657 |67 72|casesdase 
P10065176A0657 |13 23|difference6 Comparis
P10065176A0657 |112 133|lymph node metastasesneonatal hyperbilirub
P10065176A0657 |81 102|lymph node metastasesT0000 Pharmacologic a
P10065684A0916 |204 214|sarcomeresCO2 the da
P10065684A0916 |302 308|microm signi
P10065684A0916 |13 17|hand6 Co
P10065684A0916 |74 87|lung capacity0008171T0000 
P10065684A0916 |19 27|subjectsarison w
P10065684A0916 |184 185|p 
P10065684A0916 |262 273|abnormalityen compared
P10065684A0916 |216 217|L 
P10065684A0916 |218 221|sarf K
P10065684A0916 |56 62|volume 5-nuc
P10065684A0916 |89 92|TLCarm
P10065684A0916 |128 129|nl
P10065684A0916 |229 237|subjectsd rats a
P10065684A0916 |130 133|mitrub
P10065684A0916 |167 178|mt x micromCO3-] is sh
P10065684A0916 |310 311|pc
P10065684A0916 |97 98|%g
P10065684A0916 |64 66|RVot
P10065684A0916 |33 45|air trappingkaline phosp
P10066790A0497 |254 261|epsilonlaced w
P10066790A0497 |44 75|immunoprecipitation experimentsphatases and 5-nucleotidase P00
P10066790A0497 |241 248|mu-ARP2o longe
P10066790A0497 |90 95|beta4rmaco
P10066790A0497 |138 142|AP-4a. P
P10066790A0497 |101 110|componentaspects o
P10066790A0497 |129 136|complexirubine
P10066790A0497 |167 185|sigma4 polypeptideCO3-] is shown as 
P10066790A0497 |16 38|sedimentation velocityomparison with alkalin
P10066790A0497 |236 239|mu4are
P10066790A0497 |0 14|Gel filtrationP00001606T0076
P10066790A0497 |205 229|adaptor subunit homologsO2 the data of K-deplete
P10066798A0391 |0 6|CyclinP00001
P10066798A0391 |41 55|protein levelshosphatases an
P10066798A0391 |148 152|mice97A0
P10066798A0391 |126 135|c-src527Fbilirubin
P10066798A0391 |109 125|tumor virus-pp60of neonatal hype
P10066798A0391 |82 88|tumors0000 P
P10066798A0391 |21 36|kinase activityison with alkal
P10066815T0000 |85 110|phosphoinositide 3-kinase0 Pharmacologic aspects o
P10066815T0000 |4 7|SH2016
P10066815T0000 |140 150|inhibition P00008997
P10066815T0000 |26 34|inositolwith alk
P10066815T0000 |70 81|p85 subunite P00008171
P10066815T0000 |38 49|phosphatasee phosphata
P10066815T0000 |154 179|B cell receptor signaling2 When CSF [HCO3-] is sho
P10066815T0000 |51 55|SHIPs an
P10068040A0136 |17 29|mouse genomemparison wit
P10068040A0136 |44 50|copiesphatas
P10068040A0136 |58 68|ubc-9 gene-nucleotid
P10068418A1194 |71 75|body P00
P10068418A1194 |56 59|hip 5-
P10068418A1194 |151 159|estrogen0472 Whe
P10068418A1194 |15 35|bone mineral densityComparison with alka
P10068418A1194 |163 182|alendronate therapyF [HCO3-] is shown 
P10068418A1194 |43 48|spinesphat
P10068418A1194 |99 109|raloxifenec aspects 
P10068418A1194 |3 11|increase001606T0
P10068446A0124 |69 85|PKC preparationsse P00008171T000
P10068446A0124 |113 116|BPOeon
P10068446A0124 |37 45|presencene phosp
P10068446A0124 |135 152|cysteine residuesemia. P00008997A0
P10068446A0124 |18 25|studiesparison
P10068446A0124 |156 159|PKCWhe
P10068446A0124 |101 109|reactionaspects 
P10068446A0124 |49 61|thiol agentsses and 5-nu
P10068637A1320 |15 23|Csx/Nkx2Comparis
P10068674A0644 |50 57|Lyp RNAes and 
P10068674A0644 |42 46|formosph
P10068674A0644 |59 63|Lyp2nucl
P10068834A0713 |51 53|VRs 
P10068834A0713 |31 33|PEal
P10068834A0713 |15 17|DMCo
P10068834A0713 |58 60|DM-n
P10068834A0713 |73 76|MR.000
P10068834A0713 |4 9|costs01606
P10068834A0713 |35 37|DMli
P10069815A0285 |85 95|proteasome0 Pharmaco
P10069815A0285 |15 23|evidenceComparis
P10069815A0285 |72 76|Doa4P000
P10069815A0285 |52 63|interaction and 5-nucl
P10070158A0573 |128 148|transmembrane domainlirubinemia. P000089
P10070158A0573 |12 27|splicing events76 Comparison w
P10070158A0573 |63 77|cassette exonseotidase P0000
P10071205A0833 |49 52|ORFses
P10071205A0833 |120 127|cistron hyperb
P10071205A0833 |60 64|STA2ucle
P10071205A0833 |14 19|genes Comp
P10071205A0833 |93 103|AUG codonscologic as
P10071212A0399 |22 38|O. australiensisson with alkalin
P10071761A2374 |154 164|regulation2 When CSF
P10071761A2374 |13 20|mapping6 Compa
P10071761A2374 |121 128|insighthyperbi
P10071761A2374 |202 208|anyone PCO2 
P10071761A2374 |52 66|identification and 5-nucleot
P10071761A2374 |79 87|promoter71T0000 
P10071761A2374 |28 43|promoter regionth alkaline pho
P10071761A2374 |99 108|sequencesc aspects
P10071761A2374 |232 239|factorsats are
P10071761A2374 |3 11|addition001606T0
P10071761A2374 |168 183|UCP2 expressionO3-] is shown a
P10071806A0377 |4 8|rate0160
P10071806A0377 |44 52|survivalphatases
P10071806A0377 |12 25|resectability76 Comparison
P10072205A0167 |85 95|conditions0 Pharmaco
P10072205A0167 |59 72|MAP estimatesnucleotidase 
P10072205A0167 |109 128|point approximationof neonatal hyperbi
P10072205A0167 |166 178|distributionHCO3-] is sh
P10072205A0167 |132 146|density valuesbinemia. P0000
P10072205A0167 |36 48|distributionine phosphat
P10072205A0167 |52 54|ML a
P10072205A0167 |3 8|order00160
P10072205A0167 |187 196|estimatesfunction 
P10072774A0537 |0 6|RT-PCRP00001
P10072774A0537 |89 110|ligand binding domainarmacologic aspects o
P10072774A0537 |126 148|beta integrin subunitsbilirubinemia. P000089
P10072774A0537 |58 81|oligonucleotide primers-nucleotidase P00008171
P10072774A0537 |112 115|LBDneo
P10072774A0537 |153 161|Bge cDNA72 When 
P10073899A0740 |101 104|CVSasp
P10073899A0740 |11 31|culture failure rate076 Comparison with 
P10073899A0740 |90 94|centrmac
P10073899A0740 |43 47|centspha
P10073899A0740 |64 67|EAFoti
P10073940A0335 |48 57|signalingases and 
P10073940A0335 |8 18|expression6T0076 Com
P10073940A0335 |22 28|d-axinson wi
P10073947A1110 |33 38|FVIIakalin
P10073947A1110 |43 48|PAI-1sphat
P10073947A1110 |18 29|differencesparison wit
P10074135T0000 |68 74|barleyase P0
P10074135T0000 |82 93|dwarf virus0000 Pharma
P10074135T0000 |105 109|RNA1cts 
P10074135T0000 |55 64|synthesisd 5-nucle
P10074135T0000 |33 41|elementskaline p
P10074282A0236 |35 39|ringline
P10074282A0236 |58 63|L-NNA-nucl
P10074282A0236 |13 17|side6 Co
P10074282A0236 |65 87|NO-synthesis inhibitortidase P00008171T0000 
P10074282A0236 |92 106|methylene blueacologic aspec
P10074282A0236 |140 147|changes P00008
P10074282A0236 |116 133|cGMPase inhibitoratal hyperbilirub
P10074425A0729 |137 145|deletionia. P000
P10074425A0729 |109 113|MEFsof n
P10074425A0729 |14 26|inactivation Comparison 
P10074425A0729 |71 89|mitogen starvation P00008171T0000 Ph
P10074425A0729 |59 67|responsenucleoti
P10074425A0729 |153 161|p27 gene72 When 
P10074425A0729 |34 55|cyclin E-Cdk2 complexaline phosphatases an
P10074520T0000 |0 14|IdentificationP00001606T0076
P10074520T0000 |94 103|detectionologic as
P10074520T0000 |133 136|PCRine
P10074520T0000 |107 129|Mycobacterium ulceranss of neonatal hyperbil
P10074520T0000 |80 89|sequences1T0000 Ph
P10074520T0000 |39 45|IS2404 phosp
P10074520T0000 |19 35|characterizationarison with alka
P10074520T0000 |50 56|IS2606es and
P10074903A0915 |103 135|cell growth retardation activitypects of neonatal hyperbilirubin
P10074903A0915 |161 165|partCSF 
P10074903A0915 |181 199|p21 protein levels as a function of 
P10074903A0915 |143 147|IFNs0008
P10074903A0915 |22 29|resultsson wit
P10074903A0915 |54 65|possibilitynd 5-nucleo
P10074903A0915 |71 83|p202 protein P00008171T0
P10074921A1169 |85 88|p530 P
P10074921A1169 |8 15|results6T0076 
P10074921A1169 |42 72|HepG2 hepatoblastoma cell lineosphatases and 5-nucleotidase 
P10075415A1178 |64 72|homologyotidase 
P10075415A1178 |47 54|ORF-Ptotases a
P10075415A1178 |105 118|UV resistancects of neonat
P10075415A1178 |125 138|plasmid pPSR1rbilirubinemi
P10075415A1178 |26 32|regionwith a
P10075415A1178 |8 18|sequencing6T0076 Com
P10075415A1178 |80 91|ru/AB genes1T0000 Phar
P10076007A0656 |34 47|casein kinasealine phospha
P10076007A0656 |131 137|kinaseubinem
P10076007A0656 |88 95|mRNP3+4harmaco
P10076007A0656 |99 106|oocytesc aspec
P10076007A0656 |20 26|kinaserison 
P10076007A0656 |4 8|MSY20160
P10076007A0656 |55 61|kinased 5-nu
P10077188A1172 |119 124|genesl hyp
P10077188A1172 |219 223|mRNA K-d
P10077188A1172 |163 173|heat shockF [HCO3-] 
P10077188A1172 |228 235|proteined rats
P10077188A1172 |62 74|biosynthesisleotidase P0
P10077188A1172 |33 38|geneskalin
P10077188A1172 |96 104|proteinsogic asp
P10077188A1172 |86 91|acids Phar
P10077188A1172 |206 215|synthesis2 the dat
P10077533A0976 |87 96|MUL genesPharmacol
P10077533A0976 |6 10|data606T
P10077533A0976 |75 78|MKS008
P10077533A0976 |53 67|identificationand 5-nucleoti
P10077533A0976 |33 38|toolskalin
P10078734A0480 |86 91|elbow Phar
P10078734A0480 |13 27|recovery curve6 Comparison w
P10078734A0480 |73 78|nerve00008
P10078734A0480 |47 58|stimulationtases and 5
P10078734A0480 |96 105|recordingogic aspe
P10078734A0480 |115 136|flexor carpi radialisnatal hyperbilirubine
P10078876A0000 |201 210|flowmetryF PCO2 th
P10078876A0000 |241 265|hemoglobin concentrationo longer displaced when 
P10078876A0000 |224 231|changespleted 
P10078876A0000 |82 89|signals0000 Ph
P10078876A0000 |270 281|oxygenationred to cont
P10078876A0000 |150 157|imagingA0472 W
P10078876A0000 |31 38|changesalkalin
P10078876A0000 |159 181|microspectrophotometryn CSF [HCO3-] is shown
P10078876A0000 |112 136|rat somatosensory cortexneonatal hyperbilirubine
P10078876A0000 |4 11|origins01606T0
P10078876A0000 |64 72|activityotidase 
P10079173A0000 |81 85|RRMsT000
P10079173A0000 |57 79|RNA recognition motifs5-nucleotidase P000081
P10079173A0000 |25 33|proteins with al
P10080436T0000 |0 10|ComparisonP00001606T
P10080436T0000 |14 25|frequencies Comparison
P10080436T0000 |131 137|bypassubinem
P10080436T0000 |108 111|use of
P10080436T0000 |36 48|fibrillationine phosphat
P10080436T0000 |64 77|artery bypassotidase P0000
P10080875A0772 |69 90|transcription factorsse P00008171T0000 Pha
P10080875A0772 |15 34|supershift analysisComparison with alk
P10080875A0772 |119 128|complexesl hyperbi
P10080875A0772 |258 263|c-Fosd whe
P10080875A0772 |50 60|antibodieses and 5-n
P10080875A0772 |223 226|p52epl
P10080875A0772 |292 298|NF-IL6ill ha
P10080875A0772 |265 270|C-Juncompa
P10080875A0772 |243 256|AP-1 proteinslonger displa
P10080875A0772 |203 221|NF-kappaB proteinsPCO2 the data of K
P10080875A0772 |172 175|p65 is
P10080875A0772 |281 290|C/EBPbetarols but 
P10080875A0772 |228 233|c-Reled ra
P10080875A0772 |235 240|Rel B are 
P10080875A0772 |143 167|NF-kappaB components p500008997A0472 When CSF [H
P10080875A0772 |4 11|results01606T0
P10080875A0772 |273 277|CREB to 
P10080901A0271 |50 58|elementses and 5
P10080901A0271 |134 144|protein L9nemia. P00
P10080901A0271 |9 17|peptidesT0076 Co
P10080901A0271 |72 81|structureP00008171
P10080901A0271 |110 116|domainf neon
P10080901A0271 |2 5|set000
P10082137A0262 |100 103|IRF as
P10082137A0262 |178 205|procollagen mRNA expressionown as a function of CSF PC
P10082137A0262 |24 33|IFN-gamman with al
P10082137A0262 |92 98|factoracolog
P10082137A0262 |209 225|skin fibroblastshe data of K-dep
P10082137A0262 |107 111|mRNAs of
P10082137A0262 |154 164|inhibition2 When CSF
P10082137A0262 |55 67|accumulationd 5-nucleoti
P10082137A0262 |249 255|donors displ
P10082137A0262 |4 11|results01606T0
P10082137A0262 |175 176|I 
P10082137A0262 |168 174|alpha1O3-] i
P10082137A0262 |71 81|interferon P00008171
P10082554T0000 |98 120|cell growth regulationic aspects of neonatal
P10082554T0000 |11 18|domains076 Com
P10082554T0000 |22 52|c-myc promoter binding proteinson with alkaline phosphatases
P10082554T0000 |83 93|repression000 Pharma
P10082570A0440 |30 40|gene UBP43 alkaline 
P10082573A1015 |152 163|holocomplex472 When CS
P10082573A1015 |225 230|DNaseleted
P10082573A1015 |210 219|formatione data of
P10082573A1015 |121 146|globin gene transcriptionhyperbilirubinemia. P0000
P10082573A1015 |54 57|HS2nd 
P10082573A1015 |248 259|holocomplexr displaced
P10082573A1015 |6 13|results606T007
P10082573A1015 |59 62|HS3nuc
P10082573A1015 |98 102|unitic a
P10082573A1015 |38 48|hypothesise phosphat
P10082573A1015 |309 334|globin gene transcriptionicantly greater slope (1.
P10082573A1015 |68 71|HS4ase
P10082585A0512 |51 65|rDNA silencings and 5-nucleo
P10082585A0512 |194 198|rDNAn of
P10082585A0512 |90 96|screenrmacol
P10082585A0512 |143 153|expression0008997A04
P10082585A0512 |31 38|factorsalkalin
P10082585A0512 |157 171|reporter geneshen CSF [HCO3-
P10082585A0512 |117 126|mutationstal hyper
P10084294A0219 |103 117|serum ferritinpects of neona
P10084294A0219 |182 194|microg/literas a functio
P10084294A0219 |122 151|transferrin saturation levelsyperbilirubinemia. P00008997A
P10084294A0219 |201 202|%F
P10084294A0219 |23 27|needon w
P10084294A0219 |32 36|ironlkal
P10084294A0219 |69 80|progenitorsse P0000817
P10085088A0918 |103 120|protein synthesispects of neonatal
P10085088A0918 |146 152|domain8997A0
P10085088A0918 |177 185|activityhown as 
P10085088A0918 |47 51|eIF3tase
P10085088A0918 |83 99|initiation phase000 Pharmacologi
P10085088A0918 |6 13|results606T007
P10085088A0918 |71 75|role P00
P10085088A0918 |32 43|p33 subunitlkaline pho
P10085120A0000 |71 78|therapy P00008
P10085120A0000 |28 46|signaling pathwaysth alkaline phosph
P10085120A0000 |90 99|hypericinrmacologi
P10085120A0000 |8 13|study6T007
P10085120A0000 |80 83|PDT1T0
P10085140A1004 |50 54|rolees a
P10085140A1004 |107 113|targets of n
P10085140A1004 |28 33|ATF-2th al
P10085140A1004 |131 144|TAK1 pathwaysubinemia. P00
P10085140A1004 |122 126|Smadyper
P10085140A1004 |58 76|TGF-beta signaling-nucleotidase P000
P10085140A1004 |6 13|results606T007
P10085383A1367 |4 9|WORDS01606
P10085383A1367 |11 20|Melaleuca076 Compa
P10085383A1367 |67 86|Regulation scheduledase P00008171T0000
P10085383A1367 |22 37|Lake Okeechobeeson with alkali
P10085383A1367 |39 52|Littoral zone phosphatases
P10085383A1367 |54 65|Water levelnd 5-nucleo
P10085505A1184 |87 92|casesPharm
P10085505A1184 |31 35|veinalka
P10085505A1184 |13 17|peak6 Co
P10085505A1184 |66 70|peakidas
P10085605A0239 |0 9|SpecimensP00001606
P10085605A0239 |94 97|hCGolo
P10085605A0239 |73 82|alpha hCG00008171T
P10085605A0239 |27 44|alpha-fetoproteinith alkaline phos
P10085605A0239 |59 66|estriolnucleot
P10085697T0000 |0 45|FASEB Federal Funding Consensus Conference FYP00001606T0076 Comparison with alkaline phosp
P10086544A0504 |477 491|catecholamines 15 mg at nigh
P10086544A0504 |522 532|furosemide agents. P
P10086544A0504 |493 504|epinephrine P00012653T
P10086544A0504 |116 119|CPBata
P10086544A0504 |190 212|temperature differencection of CSF PCO2 the 
P10086544A0504 |300 307|lactate a sign
P10086544A0504 |121 131|heart ratehyperbilir
P10086544A0504 |61 70|care unitcleotidas
P10086544A0504 |389 397|fractionto be an
P10086544A0504 |238 266|oxygen saturation differencee no longer displaced when c
P10086544A0504 |101 112|terminationaspects of 
P10086544A0504 |36 43|arrivaline pho
P10086544A0504 |370 377|factorszepam t
P10086544A0504 |507 516|enoximone5 Beta bl
P10086544A0504 |312 338|neutrophil elastase levelsntly greater slope (1.21 +
P10086544A0504 |161 169|pressureCSF [HCO
P10086544A0504 |438 451|ejection time dose for use
P10086544A0504 |14 18|data Com
P10086544A0504 |344 351|Doppler3 vs. P
P10086544A0504 |89 94|hoursarmac
P10086544A0504 |268 280|urine outputpared to con
P10086544A0504 |468 473|dosesice b
P10086544A0504 |133 147|blood pressureinemia. P00008
P10086544A0504 |282 298|serum creatinineols but still ha
P10086544A0504 |402 413|preejectionctive hypno
P10086725A0000 |0 9|MDS1/EVI1P00001606
P10086725A0000 |79 102|transcription activator71T0000 Pharmacologic a
P10086725A0000 |22 32|chromosomeson with a
P10086725A0000 |178 185|tissuesown as 
P10086725A0000 |140 145|cells P000
P10086725A0000 |35 43|band q26line pho
P10087213A0878 |0 8|AnalysisP0000160
P10087213A0878 |47 57|replicasestases and 
P10087213A0878 |151 160|formation0472 When
P10087213A0878 |175 180|class show
P10087213A0878 |98 136|H. pylori plasmid replication proteinsic aspects of neonatal hyperbilirubine
P10087213A0878 |184 210|H. pylori plasmid proteins a function of CSF PCO2 th
P10087213A0878 |16 33|protein sequencesomparison with al
P10087549A0720 |4 13|JTc delta01606T007
P10087549A0720 |146 150|msec8997
P10087549A0720 |94 96|msol
P10087549A0720 |61 70|JTc deltacleotidas
P10087549A0720 |210 212|mse 
P10087549A0720 |30 36|groups alkal
P10087549A0720 |220 223|ms.K-d
P10087549A0720 |158 162|msecen C
P10087549A0720 |112 121|JTc deltaneonatal 
P10087549A0720 |189 202|control groupnction of CSF
P10087549A0720 |78 86|VT group171T0000
P10087549A0720 |104 106|msec
P10087549A0720 |129 138|PVC groupirubinemi
P10087549A0720 |172 181|JTc delta is shown
P10087993A0782 |85 93|decrease0 Pharma
P10087993A0782 |13 21|deletion6 Compar
P10087993A0782 |53 67|delta promoterand 5-nucleoti
P10087993A0782 |97 107|expressiongic aspect
P10087993A0782 |38 45|portione phosp
P10087993A0782 |3 11|contrast001606T0
P10087993A1352 |51 73|repressor proteins BP1s and 5-nucleotidase P
P10087993A1352 |176 193|promoter activityshown as a functi
P10087993A1352 |78 81|BP2171
P10087993A1352 |14 25|mutagenesis Comparison
P10087993A1352 |164 172|increase [HCO3-]
P10087993A1352 |113 129|beta globin geneeonatal hyperbil
P10087993A1352 |37 42|sitesne ph
P10087993A1352 |98 105|portionic aspe
P10087993A1352 |139 145|region. P000
P10090125A0750 |68 69|Ma
P10090125A0750 |75 85|relaxation008171T000
P10090125A0750 |18 44|alpha1 antagonist prazosinparison with alkaline phos
P10090146T0000 |68 80|chick retinaase P0000817
P10090146T0000 |41 49|AP-2betahosphata
P10090146T0000 |13 23|expression6 Comparis
P10090146T0000 |27 36|AP-2alphaith alkal
P10090146T0000 |124 128|AP-2erbi
P10090146T0000 |82 92|repression0000 Pharm
P10090146T0000 |96 120|R-FABP promoter activityogic aspects of neonatal
P10090535A1194 |68 70|Lpas
P10090535A1194 |27 29|TGit
P10090535A1194 |61 62|%c
P10090535A1194 |45 49|apoBhata
P10090535A1194 |42 43|%o
P10090535A1194 |111 117|groups neona
P10090535A1194 |4 13|algorithm01606T007
P10090535A1194 |86 87|% 
P10090943A1426 |84 86|SD00
P10090943A1426 |9 14|valueT0076
P10090943A1426 |122 124|SDyp
P10090943A1426 |135 136|Pe
P10090943A1426 |60 65|ratioucleo
P10090943A1426 |22 27|CD79bson w
P10090943A1426 |128 133|B-CLLlirub
P10090943A1426 |97 103|donorsgic as
P10090943A1426 |35 40|CD79bline 
P10090943A1976 |117 133|activation stagetal hyperbilirub
P10090943A1976 |166 171|B-CLLHCO3-
P10090943A1976 |88 98|regulationharmacolog
P10090943A1976 |62 67|CD79bleoti
P10090943A1976 |10 17|B cells0076 Co
P10090943A1976 |148 154|B cell97A047
P10090943A1976 |36 43|variantine pho
P10090943A1976 |49 58|mechanismses and 5
P10091594A0284 |66 68|CDid
P10091594A0284 |167 174|epitopeCO3-] i
P10091594A0284 |149 159|propensity7A0472 Whe
P10091594A0284 |73 89|NMR spectroscopy00008171T0000 Ph
P10091594A0284 |104 116|ELISA assaysects of neon
P10091594A0284 |15 22|studiesCompari
P10091594A0284 |43 64|structure predictionssphatases and 5-nucle
P10091594A0284 |228 237|anti-K159ed rats a
P10091594A0284 |179 194|helix formationwn as a functio
P10091594A0284 |213 224|recognitionata of K-de
P10091619A0104 |68 69|%a
P10091619A0104 |43 48|statesphat
P10091619A0104 |11 29|England ADL scores076 Comparison wit
P10091619A0104 |86 91|state Phar
P10091619A0104 |96 102|scoresogic a
P10091619A0104 |116 117|%a
P10091619A0104 |0 6|SchwabP00001
P10092132A0285 |186 191|13q34 func
P10092132A0285 |90 95|casesrmaco
P10092132A0285 |77 82|11q138171T
P10092132A0285 |161 168|11p11.2CSF [HC
P10092132A0285 |108 112|case of 
P10092132A0285 |11 16|gains076 C
P10092132A0285 |148 150|.297
P10092132A0285 |18 22|HLGspari
P10092132A0285 |38 57|gene amplificationse phosphatases and 
P10092132A0285 |170 180|12p11.2-12-] is show
P10092132A0285 |152 159|7q21-22472 Whe
P10092847A0455 |20 32|distributionrison with a
P10092847A0455 |78 90|hMT-IIA gene171T0000 Pha
P10092847A0455 |57 72|promoter region5-nucleotidase 
P10092847A0455 |167 182|MRE arrangementCO3-] is shown 
P10092847A0455 |121 149|mouse metallothionein-I genehyperbilirubinemia. P0000899
P10092847A0455 |43 47|MREsspha
P10092847A0455 |214 230|metal regulationta of K-depleted
P10092847A0455 |203 209|factorPCO2 t
P10092847A0455 |5 12|respect1606T00
P10092856A0798 |4 8|cDNA0160
P10092856A0798 |61 68|controlcleotid
P10092856A0798 |89 117|phosphate isomerase promoterarmacologic aspects of neona
P10092856A0798 |76 81|yeast08171
P10094314A0935 |170 175|SRp20-] is
P10094314A0935 |162 165|9G8SF 
P10094314A0935 |57 81|zinc knuckle 9G8 variant5-nucleotidase P00008171
P10094314A0935 |122 131|agreementyperbilir
P10094314A0935 |141 145|factP000
P10094314A0935 |112 117|SRp20neona
P10094314A0935 |155 158|RBD Wh
P10094314A0935 |19 32|RNA sequencesarison with a
P10094396A0000 |0 16|Topoisomerase IIP00001606T0076 C
P10094396A0000 |74 80|PK CK2000817
P10094396A0000 |28 34|targetth alk
P10094396A0000 |42 70|protein kinase casein kinaseosphatases and 5-nucleotidas
P10094701A0000 |50 54|genees a
P10094701A0000 |145 165|phosphate limitation08997A0472 When CSF 
P10094701A0000 |133 141|responseinemia. 
P10094701A0000 |91 113|Sinorhizobium melilotimacologic aspects of n
P10094701A0000 |82 86|ackA0000
P10094701A0000 |7 11|work06T0
P10094701A0000 |66 80|acetate kinaseidase P0000817
P10094701A0000 |20 30|laboratoryrison with
P10095059A1003 |21 41|nucleotide positionsison with alkaline p
P10095059A1003 |59 75|HIV-1 transcriptnucleotidase P00
P10095059A1003 |4 11|numbers01606T0
P10095061A0592 |186 196|structures function 
P10095061A0592 |36 48|MEMA proteinine phosphat
P10095061A0592 |111 114|DRS ne
P10095061A0592 |146 157|nucleoplasm8997A0472 W
P10095061A0592 |73 76|kDa000
P10095061A0592 |101 108|serinesaspects
P10095061A0592 |86 92|domain Pharm
P10095061A0592 |116 123|proteinatal hy
P10095061A0592 |0 17|Sequence analysisP00001606T0076 Co
P10095062A0558 |101 106|exonsaspec
P10095062A0558 |121 123|kbhy
P10095062A0558 |29 38|structureh alkalin
P10095062A0558 |52 78|topoisomerase IIalpha gene and 5-nucleotidase P00008
P10096469T0000 |53 62|cat motorand 5-nuc
P10096469T0000 |13 23|modulation6 Comparis
P10096469T0000 |72 79|neuronsP000081
P10096469T0000 |41 49|activityhosphata
P10096573A0207 |84 108|kappaB consensus element00 Pharmacologic aspects
P10096573A0207 |72 78|factorP00008
P10096573A0207 |181 183|bp a
P10096573A0207 |80 82|NF1T
P10096573A0207 |9 16|studiesT0076 C
P10096573A0207 |140 146|region P0000
P10096573A0207 |154 173|MGSA/GRO-alpha gene2 When CSF [HCO3-] 
P10097120T0000 |3 7|exon0016
P10097120T0000 |44 48|mRNAphat
P10097120T0000 |22 31|transportson with 
P10097932A0915 |68 75|mg/24 hase P00
P10097932A0915 |162 166|UAERSF [
P10097932A0915 |77 78|n8
P10097932A0915 |58 62|UAER-nuc
P10097932A0915 |199 208|follow-upCSF PCO2 
P10097932A0915 |88 104|microalbuminuriaharmacologic asp
P10097932A0915 |173 180|mg/24 his show
P10097932A0915 |142 150|patients00008997
P10097932A0915 |190 195|yearsction
P10097932A0915 |17 25|patientsmparison
P10098601A1320 |85 89|site0 Ph
P10098601A1320 |11 19|analysis076 Comp
P10098601A1320 |65 73|proteinstidase P
P10098601A1320 |128 141|SF-1 sequencelirubinemia. 
P10098601A1320 |35 38|DNAlin
P10098601A1320 |51 56|JEG-3s and
P10098744A0630 |69 75|clonesse P00
P10098744A0630 |159 175|serum-dependencen CSF [HCO3-] is
P10098744A0630 |126 144|proliferation ratebilirubinemia. P00
P10098744A0630 |148 157|monolayer97A0472 W
P10098744A0630 |180 193|proliferationn as a functi
P10098744A0630 |43 52|phenotypesphatases
P10098744A0630 |16 22|changeompari
P10098744A0630 |263 286|differentiation markersn compared to controls 
P10098744A0630 |114 124|parametersonatal hyp
P10098744A0630 |82 89|respect0000 Ph
P10098744A0630 |232 242|morphologyats are no
P10098744A0630 |197 205|survivalf CSF PC
P10098744A0630 |3 11|contrast001606T0
P10098744A0630 |207 221|tumorigenicity the data of K
P10099247A1051 |102 116|SRB populationspects of neon
P10099247A1051 |40 54|retention timephosphatases a
P10099247A1051 |215 217|MBa 
P10099247A1051 |124 132|inoculumerbiliru
P10099247A1051 |61 65|dayscleo
P10099247A1051 |76 84|presence08171T00
P10099247A1051 |161 165|timeCSF 
P10099247A1051 |197 200|SRBf C
P10099247A1051 |7 17|reactor pH06T0076 Co
P10099576A0666 |102 110|geometryspects o
P10099576A0666 |26 29|aimwit
P10099576A0666 |14 20|valves Compa
P10099576A0666 |60 65|shearucleo
P10099576A0666 |71 80|parameter P0000817
P10099576A0666 |141 151|conditionsP00008997A
P10099576A0666 |50 56|effectes and
P10099576A0666 |118 123|valveal hy
P10100605A0392 |140 149|rhodamine P0000899
P10100605A0392 |24 29|burstn wit
P10100605A0392 |78 92|transformation171T0000 Pharm
P10100605A0392 |96 112|dihydrorhodamineogic aspects of 
P10100605A0392 |158 172|flow cytometryen CSF [HCO3-]
P10101159A0742 |68 77|mutationsase P0000
P10101159A0742 |25 34|SOC1 gene with alk
P10101159A0742 |92 107|cbp1 ts allelesacologic aspect
P10101159A0742 |141 146|mRNAsP0000
P10101159A0742 |2 10|mutation0001606T
P10101198A0632 |2 28|deletion mutation analysis0001606T0076 Comparison wi
P10101198A0632 |143 150|binding0008997
P10101198A0632 |105 120|leucine zipperscts of neonatal
P10101198A0632 |48 55|proteinases an
P10101198A0632 |86 92|region Pharm
P10101198A0946 |171 174|DNA] i
P10101198A0946 |2 17|database search0001606T0076 Co
P10101198A0946 |246 258|interactionsger displace
P10101198A0946 |57 65|homology5-nucleo
P10101198A0946 |147 154|protein997A047
P10101198A0946 |180 187|monomern as a 
P10101198A0946 |103 135|transcription termination factorpects of neonatal hyperbilirubin
P10101198A0946 |207 222|leucine zippers the data of K-
P10101198A0946 |68 73|matchase P
P10101198A0946 |137 142|mTERFia. P
P10101744A0917 |7 13|trials06T007
P10101744A0917 |15 32|antigen challengeComparison with a
P10101744A0917 |44 45|hp
P10101744A0917 |61 70|treatmentcleotidas
P10102000A1206 |68 81|ERA-III groupase P00008171
P10102000A1206 |42 54|ERA-II grouposphatases a
P10102000A1206 |13 21|patients6 Compar
P10102000A1206 |96 110|mortality rateogic aspects o
P10102000A1206 |117 118|%t
P10102136A0220 |86 90|sera Pha
P10102136A0220 |74 75|%0
P10102136A0220 |47 58|cyst fluidstases and 5
P10102136A0220 |20 23|PSAris
P10102136A0646 |34 39|ratioaline
P10102136A0646 |76 80|Type0817
P10102136A0646 |26 27|Kw
P10102136A0646 |30 32|Na a
P10102136A0646 |67 70|PSAdas
P10102136A0646 |7 12|cysts06T00
P10102136A0646 |84 89|cysts00 Ph
P10102136A0646 |0 4|TypeP000
P10102627A0217 |35 57|AP-1 reporter activityline phosphatases and 
P10102627A0217 |13 33|DNA binding activity6 Comparison with al
P10102627A0217 |82 87|cells0000 
P10103002A0705 |101 122|carbohydrate analysisaspects of neonatal h
P10103002A0705 |192 196|siteion 
P10103002A0705 |166 183|type glycan chainHCO3-] is shown a
P10103002A0705 |91 99|proteinsmacologi
P10103002A0705 |9 29|N-glycosylation siteT0076 Comparison wit
P10103002A0705 |41 53|chicken gp42hosphatases 
P10103002A0705 |126 130|gp42bili
P10103002A0705 |144 152|presence008997A0
P10103057A0251 |38 54|characterizatione phosphatases a
P10103057A0251 |151 158|studies0472 Wh
P10103057A0251 |97 108|Runt domaingic aspects
P10103057A0251 |72 80|fragmentP0000817
P10103057A0251 |112 116|AML1neon
P10103057A0251 |21 33|optimizationison with al
P10119827T0000 |0 14|Judge OKs docsP00001606T0076
P10119827T0000 |24 40|Chicago hospitaln with alkaline 
P10119827T0000 |16 19|bidomp
P10120952T0000 |0 5|HANYSP0000
P10120952T0000 |30 53|gall bladder guidelines alkaline phosphatases 
P10125354T0000 |0 13|Groups dickerP00001606T007
P10125354T0000 |45 48|gashat
P10125354T0000 |18 30|price breaksparison with
P10132730T0000 |9 20|CareNetworkT0076 Compa
P10132730T0000 |44 57|teacher unionphatases and 
P10132730T0000 |61 65|Wis.cleo
P10132730T0000 |26 30|pactwith
P10134977T0000 |0 5|JCAHOP0000
P10134977T0000 |15 24|hospitalsCompariso
P10134977T0000 |26 34|patiencewith alk
P10146207A0223 |0 15|UltrasonographyP00001606T0076 
P10146207A0223 |71 82|cord injury P00008171T
P10146207A0223 |50 60|evaluationes and 5-n
P10153759A0360 |0 4|UPMCP000
P10153759A0360 |54 76|NHBC organ procurementnd 5-nucleotidase P000
P10153759A0360 |21 33|organizationison with al
P10171173A0955 |69 76|diseasese P000
P10171173A0955 |11 19|concerns076 Comp
P10171173A0955 |208 218|hemorrhagethe data o
P10171173A0955 |122 127|non-Ayperb
P10171173A0955 |135 144|hepatitisemia. P00
P10171173A0955 |30 35|blood alka
P10171173A0955 |173 188|research effortis shown as a f
P10171173A0955 |246 252|bypassger di
P10171173A0955 |98 117|deficiency syndromeic aspects of neona
P10171173A0955 |273 284|circulation to control
P10181397A0641 |137 150|United Statesia. P00008997
P10181397A0641 |91 100|countriesmacologic
P10181397A0641 |14 20|trends Compa
P10181397A0641 |24 33|fertilityn with al
P10181397A0641 |63 81|gender differenceseotidase P00008171
P10181397A0641 |35 57|life expectancy ratiosline phosphatases and 
P10181397A0641 |119 129|populationl hyperbil
P10184191T0045 |0 6|HolgerP00001
P10187317T0000 |0 8|HospitalP0000160
P10187317T0000 |24 40|AHERF physiciansn with alkaline 
P10187798A1098 |152 156|U2OS472 
P10187798A1098 |25 30|DAP-1 with
P10187798A1098 |128 150|osteosarcoma cell linelirubinemia. P00008997
P10187798A1098 |49 58|apoptosisses and 5
P10187798A1098 |76 101|L929 fibroblast cell line08171T0000 Pharmacologic 
P10187798A1098 |0 14|OverexpressionP00001606T0076
P10187798A1098 |34 41|sentrinaline p
P10187842A1155 |141 146|sitesP0000
P10187842A1155 |105 110|motifcts o
P10187842A1155 |11 19|contrast076 Comp
P10187842A1155 |164 173|PPARalpha [HCO3-] 
P10187842A1155 |95 99|sitelogi
P10187842A1155 |23 33|PPARgamma2on with al
P10187864A1372 |84 94|regulation00 Pharmac
P10187864A1372 |22 26|KCC3son 
P10187864A1372 |36 42|memberine ph
P10187864A1372 |6 13|results606T007
P10187864A1372 |100 104|KCC1 asp
P10187864A1372 |50 60|KCC familyes and 5-n
P10190324A0000 |85 93|stenosis0 Pharma
P10190324A0000 |177 181|SVAShown
P10190324A0000 |21 33|elastin geneison with al
P10190324A0000 |95 99|SVASlogi
P10190324A0000 |38 47|mutationse phospha
P10190324A0000 |139 147|families. P00008
P10191090A0000 |71 82|development P00008171T
P10191090A0000 |15 25|expressionComparison
P10191090A0000 |33 42|PAX3 genekaline ph
P10192134A1088 |0 8|25-OH-D3P0000160
P10192134A1088 |41 47|healthhospha
P10192134A1088 |80 98|micrograms/kg feed1T0000 Pharmacolog
P10192134A1088 |128 142|turkey rationslirubinemia. P
P10192134A1088 |114 124|vitamin D3onatal hyp
P10192134A1088 |64 73|use levelotidase P
P10192432A0214 |2 6|list0001
P10192432A0214 |176 184|criteriashown as
P10192432A0214 |27 34|diseaseith alk
P10192432A0214 |13 18|names6 Com
P10192432A0214 |164 172|core set [HCO3-]
P10192432A0214 |53 61|criteriaand 5-nu
P10192432A0214 |111 118|experts neonat
P10192432A0214 |81 96|Consensus PanelT0000 Pharmacol
P10192432A0214 |138 143|ordera. P0
P10192638T0000 |0 24|Methanesulfonyl fluorideP00001606T0076 Compariso
P10192638T0000 |76 82|safety08171T
P10192638T0000 |26 29|MSFwit
P10192638T0000 |123 131|dementiaperbilir
P10192638T0000 |87 95|efficacyPharmaco
P10192638T0000 |67 72|studydase 
P10192638T0000 |139 153|Alzheimer type. P00008997A04
P10192638T0000 |103 112|treatmentpects of 
P10193950A0478 |0 7|METHODSP000016
P10193950A0478 |112 116|boneneon
P10193950A0478 |92 110|prostate carcinomaacologic aspects o
P10193950A0478 |149 153|risk7A04
P10193950A0478 |72 74|T3P0
P10193950A0478 |17 23|Augustmparis
P10193950A0478 |87 90|TNMPha
P10193950A0478 |48 51|menase
P10193950A0478 |157 179|lymph node involvementhen CSF [HCO3-] is sho
P10193950A0478 |66 68|T2id
P10193950A0478 |231 254|staging lymphadenectomyrats are no longer disp
P10193950A0478 |33 37|Junekali
P10193950A0478 |207 216|pendetide the data
P10194225A1132 |102 113|glycerol Raspects of n
P10194225A1132 |10 15|wheel0076 
P10194225A1132 |76 89|pyruvate Gneo08171T0000 Ph
P10194225A1132 |65 72|alaninetidase 
P10194230A0817 |18 25|surgeryparison
P10194230A0817 |104 106|nMec
P10194230A0817 |46 70|adenosine concentrationsatases and 5-nucleotidas
P10194230A0817 |27 41|dialysate PGE2ith alkaline p
P10194451A0000 |238 253|p210 substratese no longer dis
P10194451A0000 |209 213|goalhe d
P10194451A0000 |31 43|relationshipalkaline pho
P10194451A0000 |65 69|p210tida
P10194451A0000 |178 181|CMLown
P10194451A0000 |297 313|progenitor cellsave a significan
P10194451A0000 |265 282|chronic-phase CMLcompared to contr
P10194451A0000 |79 111|protein tyrosine kinase activity71T0000 Pharmacologic aspects of
P10194451A0000 |116 130|manifestationsatal hyperbili
P10194451A0000 |191 200|expansiontion of C
P10194451A0000 |168 176|leukemiaO3-] is 
P10194451A0000 |70 77|bcr/able P0000
P10194762A0648 |262 269|alanineen comp
P10194762A0648 |240 246|STAT5ano lon
P10194762A0648 |165 171|ERK1/2[HCO3-
P10194762A0648 |150 161|associationA0472 When 
P10194762A0648 |181 195|fusion protein as a function
P10194762A0648 |30 70|glutathione-S-transferase-fusion protein alkaline phosphatases and 5-nucleotidas
P10194762A0648 |123 129|STAT5aperbil
P10194762A0648 |226 232|serineeted r
P10194762A0648 |9 22|precipitationT0076 Compari
P10194762A0648 |97 119|transactivation domaingic aspects of neonata
P10194769A0146 |51 54|rats a
P10194769A0146 |65 88|cDNA expression librarytidase P00008171T0000 P
P10194769A0146 |173 180|proteinis show
P10194769A0146 |97 122|417-amino acid WD proteingic aspects of neonatal h
P10194769A0146 |9 16|elementT0076 C
P10194769A0146 |135 139|PREBemia
P10194769A0146 |141 144|PRLP00
P10194769A0146 |38 43|clonee pho
P10194769A0146 |156 171|element bindingWhen CSF [HCO3-
P10194769A0146 |18 20|1Ppa
P10195425T0000 |0 16|CharacterizationP00001606T0076 C
P10195425T0000 |24 50|transcription factor MTF-1n with alkaline phosphatas
P10195425T0000 |117 129|conservationtal hyperbil
P10195425T0000 |81 94|Fugu rubripesT0000 Pharmac
P10195425T0000 |139 160|metal stress response. P00008997A0472 When
P10195425T0000 |69 79|pufferfishse P000081
P10195690A0000 |49 54|PPARsses a
P10195690A0000 |83 111|hormone receptor superfamily000 Pharmacologic aspects of
P10195690A0000 |60 67|membersucleoti
P10195690A0000 |4 14|peroxisome01606T0076
P10195690A0000 |38 47|receptorse phospha
P10195697A0456 |71 89|enhancing activity P00008171T0000 Ph
P10195697A0456 |9 23|F-SRC-1 mutantT0076 Comparis
P10195697A0456 |48 54|domainases a
P10196127A1059 |69 77|residuesse P0000
P10196127A1059 |14 18|site Com
P10196127A1059 |26 35|S1 pocketwith alka
P10196127A1059 |97 117|pyroglutamyl residuegic aspects of neona
P10196248A0482 |51 59|sequences and 5-
P10196248A0482 |67 69|ntda
P10196248A0482 |22 32|TTV genomeson with a
P10196248A0482 |129 133|armsirub
P10196248A0482 |160 167|stretch CSF [H
P10196248A0482 |71 73|nt P
P10196248A0482 |190 192|ntct
P10196248A0482 |185 186|%a
P10196248A0482 |169 179|GC content3-] is sho
P10196266A0000 |100 103|MCF as
P10196266A0000 |74 98|mink cell focus-inducing0008171T0000 Pharmacolog
P10196266A0000 |105 113|subgroupcts of n
P10196266A0000 |124 140|leukemia viruseserbilirubinemia.
P10196266A0000 |46 55|infectionatases an
P10196266A0000 |10 29|mouse Mus castaneus0076 Comparison wit
P10196266A0000 |142 147|MuLVs00008
P10196316A0715 |17 25|functionmparison
P10196316A0715 |39 51|virus growth phosphatase
P10196316A0715 |29 35|VZV gKh alka
P10196316A0715 |107 110|VZVs o
P10196316A0715 |55 61|seriesd 5-nu
P10196316A0715 |65 84|gK deletion mutantstidase P00008171T00
P10196316A0715 |139 149|Oka strain. P0000899
P10196316A0715 |118 121|DNAal 
P10196318T0000 |0 26|CCAAT displacement proteinP00001606T0076 Comparison 
P10196318T0000 |93 95|E7co
P10196318T0000 |89 91|E6ar
P10196318T0000 |67 86|papillomavirus typedase P00008171T0000
P10196318T0000 |101 113|E1 promotersaspects of n
P10196597A0510 |38 45|studiese phosp
P10196597A0510 |12 20|findings76 Compa
P10196597A0510 |80 95|characteristics1T0000 Pharmaco
P10196597A0510 |99 112|drink driversc aspects of 
P10197763A0580 |54 74|AMP response elementnd 5-nucleotidase P0
P10197763A0580 |30 39|mutations alkaline
P10197763A0580 |125 126|%r
P10197763A0580 |92 118|nerve growth factor effectacologic aspects of neonat
P10197985A0145 |171 174|U11] i
P10197985A0145 |264 282|pre-mRNA substrate compared to contr
P10197985A0145 |56 72|oligonucleotides 5-nucleotidase 
P10197985A0145 |124 126|sser
P10197985A0145 |154 157|BPS2 W
P10197985A0145 |251 256|sitesispla
P10197985A0145 |159 167|elementsn CSF [H
P10197985A0145 |179 189|U12 snRNPswn as a fu
P10197985A0145 |297 314|complex formationave a significant
P10197985A0145 |221 234|cooperativity-depleted rat
P10197985A0145 |87 98|recognitionPharmacolog
P10197985A0145 |132 152|branchpoint sequencebinemia. P00008997A0
P10197985A0145 |9 33|RNase H protection assayT0076 Comparison with al
P10198003A1505 |0 8|AnalysisP0000160
P10198003A1505 |12 16|lacZ76 C
P10198003A1505 |97 107|expressiongic aspect
P10198003A1505 |111 115|rsmB neo
P10198003A1505 |33 40|fusionskaline 
P10198003A1505 |69 74|sitesse P0
P10198056A0000 |16 37|cell surface proteinsomparison with alkali
P10198056A0000 |58 71|lipid bilayer-nucleotidase
P10198056A0000 |110 113|GPIf n
P10198056A0000 |80 108|glycosylphosphatidylinositol1T0000 Pharmacologic aspects
P10198061A0339 |17 29|import assaymparison wit
P10198061A0339 |121 124|Ranhyp
P10198061A0339 |31 43|beta-cateninalkaline pho
P10198061A0339 |112 119|cytosolneonata
P10198061A0339 |129 136|ATP/GTPirubine
P10198061A0339 |70 77|nucleuse P0000
P10198061A0339 |100 108|addition aspects
P10199539A1353 |101 104|VO2asp
P10199539A1353 |72 75|cytP00
P10199539A1353 |134 141|hypoxianemia. 
P10199539A1353 |24 31|hypoxian with 
P10199539A1353 |78 96|a3 oxidation level171T0000 Pharmacol
P10199539A1353 |42 53|correlationosphatases 
P10199539A1353 |143 145|r200
P10200473A0171 |136 143|FLAME-1mia. P0
P10200473A0171 |121 127|Casperhyperb
P10200473A0171 |151 158|I-FLICE0472 Wh
P10200473A0171 |129 134|CLARPirubi
P10200473A0171 |42 49|processosphata
P10200473A0171 |145 149|FLIP0899
P10200473A0171 |24 33|regulatorn with al
P10200473A0171 |57 64|Usurpin5-nucle
P10200473A0171 |99 106|Usurpinc aspec
P10200473A0171 |163 167|MRITF [H
P10200473A0171 |115 119|CASHnata
P10200473A0171 |87 94|aliasesPharmac
P10201468A0297 |0 14|Plasma glucoseP00001606T0076
P10201468A0297 |40 43|IRIpho
P10201468A0297 |46 55|C-peptideatases an
P10201468A0297 |31 38|insulinalkalin
P10201468A0297 |92 102|time pointacologic a
P10201468A0297 |57 65|glucagon5-nucleo
P10201468A0297 |110 114|OGTTf ne
P10201468A0297 |71 83|GLP-1 levels P00008171T0
P10202006A0546 |17 24|productmpariso
P10202006A0546 |91 94|SPAmac
P10202006A0546 |31 45|fusion proteinalkaline phosp
P10202006A0546 |53 61|B domainand 5-nu
P10202006A0546 |80 89|protein A1T0000 Ph
P10202006A1266 |0 14|PolypyrimidineP00001606T0076
P10202006A1266 |177 184|bindinghown as
P10202006A1266 |209 224|polypyrimidineshe data of K-de
P10202006A1266 |268 280|immunizationpared to con
P10202006A1266 |19 32|ssDNA bindingarison with a
P10202006A1266 |49 58|VH domainses and 5
P10202006A1266 |190 196|ligandction 
P10202006A1266 |244 260|B cell selectiononger displaced 
P10202006A1266 |94 96|Abol
P10202006A1266 |131 145|autoantibodiesubinemia. P000
P10202006A1266 |286 291|Z-DNAbut s
P10202006A1266 |111 119|activity neonata
P10202006A1266 |236 240|roleare 
P10203611T0000 |0 56|Technetium-99m methylene diphosphonate scintimammographyP00001606T0076 Comparison with alkaline phosphatases and
P10203611T0000 |61 71|evaluationcleotidase
P10203611T0000 |84 97|breast masses00 Pharmacolo
P10205099A0377 |0 13|INTERVENTIONSP00001606T007
P10205099A0377 |186 189|day fu
P10205099A0377 |252 254|I4sp
P10205099A0377 |117 120|daytal
P10205099A0377 |156 159|T16Whe
P10205099A0377 |112 114|mgne
P10205099A0377 |212 217|weeksdata 
P10205099A0377 |181 183|mg a
P10205099A0377 |231 236|weeksrats 
P10205099A0377 |196 200|weekof C
P10205099A0377 |15 29|Study patientsComparison wit
P10205099A0377 |134 139|weeksnemia
P10205099A0377 |164 176|itraconazole [HCO3-] is 
P10205099A0377 |141 151|groups T12P00008997A
P10205099A0377 |96 107|terbinafineogic aspect
P10205099A0377 |71 77|groups P0000
P10205099A0377 |238 247|groups I3e no long
P10205176A0000 |19 22|NRsari
P10205176A0000 |56 71|transregulators 5-nucleotidase
P10205176A0000 |133 141|featuresinemia. 
P10205176A0000 |161 168|controlCSF [HC
P10205176A0000 |94 105|yeast cellsologic aspe
P10205176A0000 |8 17|receptors6T0076 Co
P10205176A0000 |200 209|evolutionSF PCO2 t
P10205176A0704 |70 83|transcriptione P00008171T0
P10205176A0704 |44 50|domainphatas
P10205176A0704 |52 56|PSU1 and
P10205588A0000 |68 77|infectionase P0000
P10205588A0000 |99 111|streptococcic aspects of
P10205588A0000 |172 187|characteristics is shown as a 
P10205588A0000 |52 61|arthritis and 5-nu
P10205588A0000 |135 143|beta HSAemia. P0
P10205588A0000 |151 159|emphasis0472 Whe
P10205588A0000 |115 133|Lancefield group Anatal hyperbilirub
P10205588A0000 |38 46|patientse phosph
P10205588A0000 |204 212|featuresCO2 the 
P10205588A0000 |0 9|OBJECTIVEP00001606
P10205933A0699 |0 8|BacteriaP0000160
P10205933A0699 |196 208|Lyme Diseaseof CSF PCO2 
P10205933A0699 |26 39|labyrinthitiswith alkaline
P10205933A0699 |135 143|syphilisemia. P0
P10205933A0699 |172 183|spirochaete is shown a
P10205933A0699 |110 121|spirochaetef neonatal 
P10205933A0699 |87 106|Treponemas PallidumPharmacologic aspec
P10205933A0699 |69 72|earse 
P10206152A1024 |71 78|minimum P00008
P10206152A1024 |82 84|G100
P10206152A1024 |59 66|mitosisnucleot
P10206152A1024 |130 143|messenger RNArubinemia. P0
P10206152A1024 |36 43|proteinine pho
P10206152A1024 |112 122|expressionneonatal h
P10206152A1024 |18 28|expressionparison wi
P10206152A1024 |48 55|maximumases an
P10206698A2041 |49 60|mutagenesisses and 5-n
P10206698A2041 |104 109|genesects 
P10206698A2041 |130 137|abilityrubinem
P10206698A2041 |73 81|approach00008171
P10206698A2041 |160 165|tract CSF 
P10206698A2041 |6 14|findings606T0076
P10206959A0368 |0 6|PatholP00001
P10207041A0065 |99 115|protein productsc aspects of neo
P10207041A0065 |15 25|cell cycleComparison
P10207041A0065 |41 45|parthosp
P10207041A0065 |62 75|transcriptionleotidase P00
P10207041A0065 |79 91|cyclin genes71T0000 Phar
P10207041A0065 |176 183|kinasesshown a
P10207049A0693 |51 55|types an
P10207049A0693 |37 44|subunitne phos
P10207049A0693 |58 101|serine/threonine phosphoprotein phosphatase-nucleotidase P00008171T0000 Pharmacologic 
P10207049A0693 |4 13|GAC1 gene01606T007
P10207049A0693 |103 107|Glc7pect
P10207049A1001 |33 49|Glc7 phosphatasekaline phosphata
P10207049A1001 |74 86|subunit play0008171T0000
P10207049A1001 |105 119|HSF activationcts of neonata
P10207049A1001 |58 62|Gac1-nuc
P10207049A1001 |123 141|CUP1 transcriptionperbilirubinemia. 
P10207049A1001 |96 101|rolesogic 
P10207049A1001 |4 11|results01606T0
P10207087A0956 |0 3|MEFP00
P10207087A0956 |62 94|promoter reporter gene constructleotidase P00008171T0000 Pharmac
P10207087A0956 |150 153|MEFA04
P10207087A0956 |104 123|activating activityects of neonatal hy
P10207087A0956 |127 130|MEFili
P10207087A0956 |8 13|AML1B6T007
P10207087A0956 |175 183|AML1/ETO shown a
P10207087A0956 |48 59|interleukinases and 5-
P10207090A0801 |21 29|presenceison wit
P10207090A0801 |37 40|GRRne 
P10207090A0801 |105 113|moleculects of n
P10207090A0801 |65 76|degradationtidase P000
P10207090A0801 |80 83|p501T0
P10207092A0924 |85 108|protein kinase activity0 Pharmacologic aspects
P10207092A0924 |5 20|phosphorylation1606T0076 Compa
P10207092A0924 |118 136|sea urchin nucleusal hyperbilirubine
P10207115A0389 |34 39|levelaline
P10207115A0389 |95 104|mechanismlogic asp
P10207115A0389 |43 46|p21sph
P10208865A1246 |49 56|mrIhh-Nses and
P10208865A1246 |94 109|resorption pitsologic aspects 
P10208865A1246 |28 47|osteoclast culturesth alkaline phospha
P10208865A1246 |113 127|dentine sliceseonatal hyperb
P10208865A1246 |81 90|formationT0000 Pha
P10208893A0839 |70 89|WAD goat populatione P00008171T0000 Ph
P10208893A0839 |44 53|genotypesphatases 
P10208893A0839 |13 20|results6 Compa
P10209021A0212 |85 96|mRNA export0 Pharmacol
P10209021A0212 |14 23|mechanism Comparis
P10209021A0212 |61 81|interaction functioncleotidase P00008171
P10209021A0212 |33 38|Gle2pkalin
P10209031A0832 |141 156|phosphorylationP00008997A0472 
P10209031A0832 |195 221|zeta ITAM phosphotyrosines of CSF PCO2 the data of K
P10209031A0832 |104 115|SH2 domainsects of neo
P10209031A0832 |75 79|zeta0081
P10209031A0832 |160 179|zeta ITAM tyrosines CSF [HCO3-] is sho
P10209031A0832 |89 99|Fyn kinasearmacologi
P10209031A0832 |58 69|interaction-nucleotida
P10209031A0832 |4 20|Fyn NH2 terminus01606T0076 Compa
P10209119A0076 |220 231|proteolysisK-depleted 
P10209119A0076 |22 35|protein Skp1pson with alka
P10209119A0076 |78 107|F-box/WD-repeat protein Cdc4p171T0000 Pharmacologic aspect
P10209119A0076 |11 16|yeast076 C
P10209119A0076 |195 198|Cdk of
P10209119A0076 |55 68|member Cdc53pd 5-nucleotid
P10209119A0076 |200 215|inhibitor Sic1pSF PCO2 the dat
P10209119A0076 |117 150|SCFCdc4p ubiquitin ligase complextal hyperbilirubinemia. P00008997
P10209119A0076 |187 193|kinasefuncti
P10209119A0594 |239 250|proteolysis no longer 
P10209119A0594 |226 235|functionseted rats
P10209119A0594 |59 71|similaritiesnucleotidase
P10209119A0594 |77 81|pop18171
P10209119A0594 |129 148|deletion phenotypesirubinemia. P000089
P10209119A0594 |86 96|pop2 genes Pharmacol
P10209759T0000 |0 16|Antithrombin IIIP00001606T0076 C
P10209759T0000 |29 32|minh a
P10209759T0000 |80 84|rats1T00
P10209759T0000 |49 76|ischemia reperfusion injuryses and 5-nucleotidase P000
P10210952A0261 |19 28|diagnosesarison wi
P10210952A0261 |63 71|criteriaeotidase
P10210952A0261 |3 13|retrospect001606T007
P10211329A0457 |138 149|involvementa. P0000899
P10211329A0457 |92 100|evidenceacologic
P10211329A0457 |104 114|malignancyects of ne
P10211329A0457 |31 43|serum lipasealkaline pho
P10211329A0457 |75 83|syndrome008171T0
P10211329A0457 |158 166|disorderen CSF [
P10211329A0457 |6 18|observations606T0076 Com
P10211329A0457 |65 72|Sjogrentidase 
P10211329A0457 |48 56|serum CAases and
P10211422T0000 |6 18|pancreatitis606T0076 Com
P10211422T0000 |40 60|polyarteritis nodosaphosphatases and 5-n
P10211422T0000 |24 36|complicationn with alkal
P10211919A0846 |220 238|CGI Severity scaleK-depleted rats ar
P10211919A0846 |105 109|weekcts 
P10211919A0846 |98 101|endic 
P10211919A0846 |52 68|sertraline group and 5-nucleotid
P10211919A0846 |22 33|improvementson with al
P10211919A0846 |211 215|NIMH dat
P10211919A0846 |134 155|CGI Improvement scalenemia. P00008997A0472
P10211919A0846 |168 171|endO3-
P10211919A0846 |175 180|weeks show
P10211919A0846 |35 36|pl
P10211919A0846 |119 125|Y-BOCSl hype
P10212278A0387 |17 32|protein kinasesmparison with a
P10212278A0387 |212 216|MAPKdata
P10212278A0387 |129 143|protein kinaseirubinemia. P0
P10212278A0387 |196 210|protein kinaseof CSF PCO2 th
P10212278A0387 |145 153|SAPK/JNK08997A04
P10212278A0387 |243 252|moleculeslonger di
P10212278A0387 |159 170|p38 membersn CSF [HCO3
P10212278A0387 |97 117|protein kinase/c-Jungic aspects of neona
P10212278A0387 |218 229|superfamilyf K-deplete
P10212278A0387 |55 71|c-jun expressiond 5-nucleotidase
P10212284A0000 |33 38|beta1kalin
P10212284A0000 |61 78|matrix depositioncleotidase P00008
P10212284A0000 |28 31|TGFth 
P10212284A0000 |13 26|growth factor6 Comparison 
P10212284A0000 |112 117|cellsneona
P10212284A0000 |83 96|proliferation000 Pharmacol
P10212332T0000 |0 18|ChronotherapeuticsP00001606T0076 Com
P10212332T0000 |37 44|diseasene phos
P10212426A1067 |0 5|GroupP0000
P10212426A1067 |114 120|valuesonatal
P10212426A1067 |124 129|deltaerbil
P10212426A1067 |149 154|study7A047
P10212426A1067 |75 83|decrease008171T0
P10212426A1067 |48 60|hearing lossases and 5-n
P10212426A1067 |33 42|listenerskaline ph
P10212426A1067 |19 28|functionsarison wi
P10212426A1067 |87 98|performancePharmacolog
P10212969A0470 |0 12|UroflowmetryP00001606T00
P10212969A0470 |24 31|dysurian with 
P10212969A0470 |86 94|subjects Pharmac
P10214610A0900 |39 50|percentiles phosphatas
P10214610A0900 |14 23|variation Comparis
P10214610A0900 |66 69|ageida
P10215485A0837 |117 119|NAta
P10215485A0837 |107 112|mI/Crs of 
P10215485A0837 |40 46|statusphosph
P10215485A0837 |12 24|correlations76 Compariso
P10215485A0837 |78 95|State Examination171T0000 Pharmaco
P10215485A0837 |100 105|NA/mI aspe
P10215594A1728 |0 8|GlucagonP0000160
P10215594A1728 |111 115|CRE1 neo
P10215594A1728 |58 62|CRE1-nuc
P10215594A1728 |176 179|pO2sho
P10215594A1728 |123 143|2SV40-LUC constructsperbilirubinemia. P0
P10215594A1728 |22 34|LUC activityson with alk
P10215594A1728 |93 102|inductioncologic a
P10215594A1728 |67 77|CRE2 sitesdase P0000
P10215594A1728 |118 122|CRE2al h
P10215608A0161 |85 93|rGST Yc10 Pharma
P10215608A0161 |74 83|rat GSTA30008171T0
P10215608A0161 |95 107|subunit genelogic aspect
P10215608A0161 |29 38|isolationh alkalin
P10215608A0161 |43 59|characterizationsphatases and 5-
P10215608A0161 |8 13|study6T007
P10215803T0000 |51 68|calcium gluconates and 5-nucleotid
P10215803T0000 |39 47|infusion phospha
P10215811A0635 |19 27|bleedingarison w
P10215811A0635 |91 94|EVLmac
P10215811A0635 |44 55|eradicationphatases an
P10215811A0635 |77 85|sessions8171T000
P10215811A0635 |8 15|control6T0076 
P10215850A0754 |118 120|kbal
P10215850A0754 |61 71|TrxR2 genecleotidase
P10215850A0754 |142 154|localization00008997A047
P10215850A0754 |94 99|exonsologi
P10215850A0754 |158 174|position 22q11.2en CSF [HCO3-] i
P10215850A0754 |35 47|organizationline phospha
P10216052A0105 |372 381|questionspam thus 
P10216052A0105 |360 368|subgroup0733 Flu
P10216052A0105 |88 98|disabilityharmacolog
P10216052A0105 |183 195|disabilitiess a function
P10216052A0105 |108 113|tasks of n
P10216052A0105 |161 174|interrelationCSF [HCO3-] i
P10216052A0105 |317 327|field lossgreater sl
P10216052A0105 |17 22|studympari
P10216052A0105 |399 407|validityffective
P10216052A0105 |54 63|frequencynd 5-nucl
P10216052A0105 |127 144|glaucoma patientsilirubinemia. P00
P10216052A0105 |266 276|difficultyompared to
P10216052A0105 |298 306|severityve a sig
P10216052A0105 |67 71|selfdase
P10216052A0105 |202 217|factor analysis PCO2 the data 
P10216052A0105 |232 240|relationats are 
P10216052A0105 |432 440|subgroupptimum d
P10216052A0105 |283 290|measurels but 
P10216052A0105 |4 8|aims0160
P10216052A0105 |412 423|reliabilityotic drug w
P10216052A0105 |444 453|questionsfor use i
P10216052A0105 |342 350|glaucoma.23 vs. 
P10216052A1682 |237 245|glaucomare no lo
P10216052A1682 |178 188|field lossown as a f
P10216052A1682 |267 276|questionsmpared to
P10216052A1682 |215 224|variablesa of K-de
P10216052A1682 |149 157|severity7A0472 W
P10216052A1682 |17 25|validitymparison
P10216052A1682 |255 263|subgroupaced whe
P10216052A1682 |87 88|rP
P10216052A1682 |48 57|questionsases and 
P10216052A1682 |112 123|correlationneonatal hy
P10216052A1682 |202 207|score PCO2
P10216052A1682 |134 141|measurenemia. 
P10216052A1682 |96 97|po
P10216052A1682 |38 44|subsete phos
P10216161A1530 |102 110|proteinsspects o
P10216161A1530 |225 229|typelete
P10216161A1530 |48 56|homologsases and
P10216161A1530 |23 37|cytochromes bdon with alkali
P10216161A1530 |244 272|B. stearothermophilus enzymeonger displaced when compare
P10216161A1530 |301 305|typea si
P10216161A1530 |192 194|bdio
P10216161A1530 |70 79|organismse P000081
P10216161A1530 |138 149|subfamiliesa. P0000899
P10216161A1530 |169 173|type3-] 
P10216161A1530 |0 19|Sequence comparisonP00001606T0076 Comp
P10217683A0509 |0 22|Canalith repositioningP00001606T0076 Compari
P10217683A0509 |30 38|mainstay alkalin
P10217683A0509 |42 51|treatmentosphatase
P10218109T0000 |0 18|Solution structureP00001606T0076 Com
P10218109T0000 |40 65|MutT pyrophosphohydrolasephosphatases and 5-nucleo
P10218109T0000 |23 32|mechanismon with a
P10218200A0534 |6 10|eyes606T
P10218200A0534 |47 57|microgramstases and 
P10218200A0534 |73 101|tissue plasminogen activator00008171T0000 Pharmacologic 
P10218200A0534 |132 135|hrsbin
P10218357A0486 |102 115|cuff-pressurespects of neo
P10218357A0486 |41 51|cuff-tubeshosphatase
P10218357A0486 |123 134|anaesthesiaperbilirubi
P10218357A0486 |12 23|CONCLUSIONS76 Comparis
P10218357A0486 |90 98|increasermacolog
P10218357A0486 |53 55|G2an
P10218357A0486 |25 31|Brandt with 
P10218357A0486 |140 143|N2O P0
P10218357A0486 |0 7|RESULTSP000016
P10219091A0246 |51 57|enzymes and 
P10219091A0246 |32 41|gene CTL1lkaline p
P10220275A0694 |4 11|binding01606T0
P10220275A0694 |134 141|Gialphanemia. 
P10220275A0694 |15 25|PH domainsComparison
P10220275A0694 |29 39|Gbetagammah alkaline
P10220275A0694 |74 84|Gbetagamma0008171T00
P10220275A0694 |57 70|preincubation5-nucleotidas
P10220275A0694 |126 130|formbili
P10220364A0087 |35 45|supernovaeline phosp
P10220364A0087 |6 16|afterglows606T0076 C
P10220364A0087 |71 81|hypernovae P00008171
P10221467T0000 |70 94|dopamine agonist therapye P00008171T0000 Pharmac
P10221467T0000 |13 25|pericarditis6 Comparison
P10221467T0000 |125 132|diseaserbiliru
P10221467T0000 |46 53|diseaseatases 
P10221467T0000 |96 107|cabergolineogic aspect
P10221467T0000 |113 122|Parkinsoneonatal h
P10221820A0902 |21 25|APBDison
P10221820A0902 |133 144|coexistenceinemia. P00
P10221820A0902 |13 17|type6 Co
P10221820A0902 |56 59|AMT 5-
P10221820A0902 |148 152|APBD97A0
P10221820A0902 |92 102|cliniciansacologic a
P10221820A0902 |157 160|AMThen
P10223338A1601 |85 94|HIV-2 gag0 Pharmac
P10223338A1601 |147 154|HIV-1RF997A047
P10223338A1601 |56 70|fusion protein 5-nucleotidas
P10223338A1601 |134 142|HIV-1SF2nemia. P
P10223338A1601 |114 123|HIV-1IIIBonatal hy
P10223338A1601 |125 132|HIV-1MNrbiliru
P10223338A1601 |3 11|addition001606T0
P10223338A1601 |100 110|V3 domains aspects o
P10223338A2186 |117 133|HIV/AIDS vaccinetal hyperbilirub
P10223338A2186 |63 68|HIV-1eotid
P10223338A2186 |53 59|cladesand 5-
P10223338A2186 |26 37|V3 peptideswith alkali
P10223338A2186 |80 89|HIV-2 gag1T0000 Ph
P10223338A2186 |4 11|results01606T0
P10223498A0479 |171 188|Erectile Function] is shown as a f
P10223498A0479 |52 59|ability and 5-
P10223498A0479 |27 36|responsesith alkal
P10223498A0479 |123 131|erectionperbilir
P10223498A0479 |88 96|questionharmacol
P10223498A0479 |74 82|erection0008171T
P10223498A0479 |190 194|IIEFctio
P10223498A0479 |140 167|15-item International Index P00008997A0472 When CSF [H
P10223498A0479 |100 107|ability aspect
P10223498A0479 |0 8|EfficacyP0000160
P10224244T0000 |17 28|involvementmparison wi
P10224244T0000 |90 100|regulationrmacologic
P10224244T0000 |36 57|Glc7-Reg1 phosphataseine phosphatases and 
P10224244T0000 |104 122|INO1 transcriptionects of neonatal h
P10224244T0000 |66 82|Snf1-Snf4 kinaseidase P00008171T
P10224244T0000 |0 8|EvidenceP0000160
P10224257A0079 |137 139|P2ia
P10224257A0079 |125 131|regionrbilir
P10224257A0079 |94 96|P1ol
P10224257A0079 |41 47|her-1bhospha
P10224257A0079 |30 36|her-1a alkal
P10224257A0079 |3 11|XO males001606T0
P10224257A0079 |83 92|promoters000 Pharm
P10224257A0079 |169 175|intron3-] is
P10224257A0079 |17 28|her-1 mRNAsmparison wi
P10224289T0000 |0 9|InductionP00001606
P10224289T0000 |13 34|Fas ligand expression6 Comparison with alk
P10224289T0000 |38 41|HIVe p
P10224289T0000 |83 109|T cell receptor zeta chain000 Pharmacologic aspects 
P10224289T0000 |55 66|interactiond 5-nucleot
P10224289T0000 |70 73|Nefe P
P10224293A0000 |171 177|motifs] is s
P10224293A0000 |40 45|RPTPsphosp
P10224293A0000 |104 123|phosphatase domainsects of neonatal hy
P10224293A0000 |58 64|family-nucle
P10224293A0000 |131 141|ectodomainubinemia. 
P10224293A0000 |0 38|Receptor protein tyrosine phosphatasesP00001606T0076 Comparison with alkalin
P10224293A0000 |68 76|proteinsase P000
P10224293A2021 |70 77|studiese P0000
P10224293A2021 |25 38|brain regions with alkalin
P10224293A2021 |53 58|basisand 5
P10224293A2021 |81 100|RPTP-kappa functionT0000 Pharmacologic
P10224513A0240 |35 46|arithmeticsline phosph
P10224513A0240 |122 132|interviewsyperbiliru
P10224513A0240 |107 117|videotapess of neona
P10224513A0240 |14 23|stressors Comparis
P10224513A0240 |66 77|Stroop testidase P0000
P10224513A0240 |79 96|videogame playing71T0000 Pharmacol
P10224513A0240 |98 103|filmsic as
P10224513A0240 |48 60|speech tasksases and 5-n
P10224758A0202 |4 17|control group01606T0076 Co
P10224758A0202 |29 47|afterbirth samplesh alkaline phospha
P10224758A0202 |77 88|pregnancies8171T0000 P
P10225279A0450 |153 157|gene72 W
P10225279A0450 |25 29|gene wit
P10225279A0450 |94 97|ORFolo
P10225279A0450 |56 66|UL55 genes 5-nucleot
P10225279A0450 |72 80|homologyP0000817
P10225279A0450 |172 190|pseudorabies virus is shown as a fun
P10225279A0450 |42 51|MDV2 UL54osphatase
P10225279A0450 |99 104|ORF-1c asp
P10225279A0450 |116 132|herpesvirus typeatal hyperbiliru
P10225945A0436 |17 21|lossmpar
P10225945A0436 |42 49|meiosisosphata
P10225945A0436 |25 38|MAD2 staining with alkalin
P10225945A0436 |131 138|measureubinemi
P10225945A0436 |193 205|kinetochoreson of CSF PC
P10225945A0436 |210 217|meiosise data 
P10225945A0436 |142 149|tension0000899
P10225945A0436 |82 104|microtubule attachment0000 Pharmacologic asp
P10225945A0436 |3 11|contrast001606T0
P10225945A0436 |155 163|distance When CS
P10226029A0905 |156 161|serumWhen 
P10226029A0905 |94 101|contactologic 
P10226029A0905 |123 131|contactsperbilir
P10226029A0905 |14 19|cells Comp
P10226029A0905 |25 34|PH domain with alk
P10226029A0905 |145 152|absence08997A0
P10226029A0905 |59 64|sitesnucle
P10226029A0905 |38 45|Akt/PKBe phosp
P10226074A0637 |127 131|exonilir
P10226074A0637 |31 38|regionsalkalin
P10226074A0637 |63 68|exonseotid
P10226074A0637 |79 101|translation start site71T0000 Pharmacologic 
P10226838A1011 |137 143|energyia. P0
P10226838A1011 |90 101|stimulationrmacologic 
P10226838A1011 |57 67|electrodes5-nucleoti
P10226838A1011 |106 109|60sts 
P10226838A1011 |4 12|motility01606T00
P10226838A1011 |16 21|spermompar
P10228009A0600 |34 39|IL-17aline
P10228009A0600 |59 62|TNFnuc
P10228009A0600 |43 54|IEC-6 cellssphatases a
P10228009A0600 |109 114|TRAF2of ne
P10228009A0600 |83 91|factor-6000 Phar
P10228009A0600 |93 98|TRAF6colog
P10228009A0600 |0 9|InductionP00001606
P10228009A0600 |17 30|CINC promotermparison with
P10228155A1293 |0 7|SCFFWD1P000016
P10228155A1293 |70 80|regulatione P0000817
P10228155A1293 |28 45|tumor developmentth alkaline phosp
P10228155A1293 |50 61|suppressiones and 5-nu
P10228155A1293 |84 114|beta-catenin protein stability00 Pharmacologic aspects of ne
P10228157T0000 |18 44|spindle checkpoint pathwayparison with alkaline phos
P10228157T0000 |59 71|Dbf2p kinasenucleotidase
P10228157T0000 |83 88|yeast000 P
P10228561A0539 |142 149|modules0000899
P10228561A0539 |75 83|residues008171T0
P10228561A0539 |104 118|DNA phosphatesects of neonat
P10228561A0539 |91 98|contactmacolog
P10228561A0539 |40 59|DNA polymerase betaphosphatases and 5-
P10228561A0539 |24 36|organizationn with alkal
P10228795A0842 |0 7|RESULTSP000016
P10228795A0842 |77 92|nerve responses8171T0000 Pharm
P10228795A0842 |114 117|IASona
P10228795A0842 |96 99|EFSogi
P10228795A0842 |21 27|nervesison w
P10228795A0842 |55 65|regulationd 5-nucleo
P10229084A0000 |275 279|pp43o co
P10229084A0000 |297 325|protein tyrosine kinase Pyk2ave a significantly greater 
P10229084A0000 |176 191|protein complexshown as a func
P10229084A0000 |391 399|SLAP-130 be an e
P10229084A0000 |362 378|adaptor proteins33 Flurazepam th
P10229084A0000 |51 69|immunoprecipitatess and 5-nucleotida
P10229084A0000 |258 273|phosphoproteinsd when compared
P10229084A0000 |16 35|gel electrophoresisomparison with alka
P10229084A0000 |114 127|T lymphocytesonatal hyperb
P10229084A0000 |144 158|identification008997A0472 Wh
P10229084A0000 |281 285|pp72rols
P10229084A0000 |287 291|pp85ut s
P10229084A0000 |380 386|SKAP55 appea
P10229084A0000 |231 234|Fynrat
P10229668A0190 |19 32|cdc33 mutantsarison with a
P10229668A0190 |48 50|G1as
P10229668A0560 |49 56|Cln3-1pses and
P10229668A0560 |126 136|dependencebilirubine
P10229668A0560 |95 106|translationlogic aspec
P10229668A0560 |78 87|CLN3 mRNA171T0000 
P10229668A0560 |63 74|hybrid UBI4eotidase P0
P10229668A0560 |172 182|cell cycle is shown 
P10229668A0560 |42 47|Cln3pospha
P10229668A0560 |140 145|eIF4E P000
P10229668A0560 |2 16|cdc33-1 strain0001606T0076 C
P10229682A1151 |170 182|NF-IL-6 site-] is shown 
P10229682A1151 |11 17|motifs076 Co
P10229682A1151 |225 231|regionleted 
P10229682A1151 |22 37|gene expressionson with alkali
P10229682A1151 |160 168|sequence CSF [HC
P10229682A1151 |96 107|kappaB siteogic aspect
P10229682A1151 |86 94|sequence Pharmac
P10231026A0253 |38 40|kbe 
P10231026A0253 |77 84|introns8171T00
P10231026A0253 |63 68|exonseotid
P10231026A0253 |22 26|Elk1son 
P10231026A0253 |4 18|gene structure01606T0076 Com
P10231454A0731 |158 165|U/literen CSF 
P10231454A0731 |59 66|calciumnucleot
P10231454A0731 |124 144|alkaline phosphataseerbilirubinemia. P00
P10231454A0731 |90 100|phosphorusrmacologic
P10231454A0731 |36 41|mg/dline p
P10231454A0731 |6 19|serum calcium606T0076 Comp
P10231454A0731 |83 88|mg/dl000 P
P10231454A0731 |113 118|mg/dleonat
P10231485A0342 |0 17|Sequence analysisP00001606T0076 Co
P10231485A0342 |121 125|TtrBhype
P10231485A0342 |99 105|4Fe-4Sc aspe
P10231485A0342 |146 154|clusters8997A047
P10231485A0342 |215 236|quinol oxidation sitea of K-depleted rats 
P10231485A0342 |107 114|clusters of ne
P10231485A0342 |165 169|TtrC[HCO
P10231485A0342 |138 144|4Fe-4Sa. P00
P10231485A0342 |48 91|molybdopterin guanine dinucleotide cofactorases and 5-nucleotidase P00008171T0000 Phar
P10231485A0342 |185 201|membrane proteina function of CS
P10231485A0342 |32 36|TtrAlkal
P10231513T0000 |29 57|granulation tissue formationh alkaline phosphatases and 
P10231513T0000 |75 80|study00817
P10231513T0000 |14 25|differences Comparison
P10231513T0000 |88 91|rathar
P10231581A1125 |51 60|SP1 sitess and 5-n
P10231581A1125 |14 25|mutagenesis Comparison
P10231581A1125 |73 77|exon0000
P10231581A1125 |123 140|promoter activityperbilirubinemia.
P10231862A1117 |19 26|infantsarison 
P10231862A1117 |128 140|contributionlirubinemia.
P10231862A1117 |106 110|weekts o
P10231862A1117 |75 80|acids00817
P10231862A1117 |212 216|pooldata
P10231862A1117 |178 184|plasmaown as
P10231862A1117 |114 118|lifeonat
P10231862A1117 |155 164|synthesis When CSF
P10232078A0552 |0 8|IschemiaP0000160
P10232078A0552 |59 76|6-keto-PGF1 alphanucleotidase P000
P10232078A0552 |13 24|reperfusion6 Compariso
P10232078A0552 |81 85|TXB2T000
P10232078A0552 |48 55|releaseases an
P10232600T0000 |18 25|antigenparison
P10232600T0000 |108 134|prostate cancer cell lines of neonatal hyperbilirubi
P10232600T0000 |27 30|PSAith
P10232600T0000 |67 77|expressiondase P0000
P10232600T0000 |81 104|sodium iodide symporterT0000 Pharmacologic asp
P10232872A0081 |83 93|population000 Pharma
P10232872A0081 |60 68|subgroupucleotid
P10232872A0081 |40 42|CDph
P10233147A0218 |0 5|Ras2pP0000
P10233147A0218 |127 134|cascadeilirubi
P10233147A0218 |25 31|growth with 
P10233147A0218 |63 81|signaling pathwayseotidase P00008171
P10233147A0218 |107 125|Cdc42p/Ste20p/MAPKs of neonatal hype
P10233147A0218 |173 187|Cyr1p/cAMP/PKAis shown as a 
P10233147A0218 |189 196|pathwaynction 
P10233147A0218 |157 171|protein kinasehen CSF [HCO3-
P10233147A0218 |87 105|filamentation MAPKPharmacologic aspe
P10233885A0899 |154 157|p322 W
P10233885A0899 |162 174|p30 isoformsSF [HCO3-] i
P10233885A0899 |132 146|mim-1 promoterbinemia. P0000
P10233885A0899 |21 31|predictionison with 
P10233885A0899 |114 124|activationonatal hyp
P10233885A0899 |33 46|transfectionskaline phosph
P10233885A0899 |70 86|cell line Jurkate P00008171T0000
P10233946A0000 |71 78|repeats P00008
P10233946A0000 |166 184|leukemia virus RNAHCO3-] is shown as
P10233946A0000 |202 212|hypothesis PCO2 the 
P10233946A0000 |52 55|SNV an
P10233946A0000 |145 155|expression08997A0472
P10233946A0000 |9 13|workT007
P10233946A0000 |29 50|spleen necrosis virush alkaline phosphatas
P10233946A0000 |248 255|elementr displ
P10233946A0000 |218 225|SNV RNAf K-dep
P10233946A0000 |294 302|proteinsl have a
P10233946A0000 |80 84|LTRs1T00
P10234698A0728 |33 40|effectskaline 
P10234698A0728 |73 87|animal studies00008171T0000 
P10234698A0728 |104 116|pretreatmentects of neon
P10234698A0728 |44 59|CNS developmentphatases and 5-
P10234698A0728 |224 233|treatmentpleted ra
P10234698A0728 |63 69|numbereotida
P10234698A0728 |122 137|corticosteroidsyperbilirubinem
P10234698A0728 |163 168|brainF [HC
P10234698A0728 |191 197|injurytion o
P10235265A0197 |64 70|systemotidas
P10235265A0197 |7 16|mechanism06T0076 C
P10235265A0197 |147 161|cyclin subunit997A0472 When 
P10235265A0197 |97 118|proteolysis machinerygic aspects of neonat
P10235265A0197 |142 145|Clb000
P10236651T0000 |0 10|PredictorsP00001606T
P10236651T0000 |57 75|admission criteria5-nucleotidase P00
P10236651T0000 |14 21|success Compar
P10236651T0000 |25 40|pharmacy school with alkaline 
P10236651T0000 |42 46|PCATosph
P10240361T0000 |35 50|dissatisfactionline phosphatas
P10240361T0000 |57 67|physicians5-nucleoti
P10240361T0000 |9 15|surveyT0076 
P10243927A0000 |184 190|spread a fun
P10243927A0000 |41 54|investigatorshosphatases a
P10243927A0000 |29 39|fire testsh alkaline
P10243927A0000 |62 84|IIT Research Instituteleotidase P00008171T00
P10243927A0000 |210 215|gasese dat
P10243927A0000 |135 139|roomemia
P10243927A0000 |5 11|series1606T0
P10243927A0000 |143 154|fire origin0008997A047
P10243927A0000 |200 205|smokeSF PC
P10243927A0000 |115 127|door controlnatal hyperb
P10271171A0458 |82 86|unit0000
P10271171A0458 |105 120|resource centercts of neonatal
P10271171A0458 |59 66|librarynucleot
P10271171A0458 |28 33|shiftth al
P10271171A0458 |7 12|LATCH06T00
P10271171A0458 |37 51|identificationne phosphatase
P10281637A0000 |0 9|ReportingP00001606
P10281637A0000 |91 98|complexmacolog
P10281637A0000 |80 85|drugs1T000
P10281637A0000 |54 60|trialsnd 5-n
P10281637A0000 |21 27|eventsison w
P10281637A0000 |117 122|issuetal h
P10304090T0000 |0 21|Medicare SNF benefitsP00001606T0076 Compar
P10308312A0203 |170 177|effects-] is s
P10308312A0203 |41 54|understandinghosphatases a
P10308312A0203 |88 98|ultrasoundharmacolog
P10308312A0203 |62 84|interaction mechanismsleotidase P00008171T00
P10308312A0203 |8 13|paper6T007
P10308312A0203 |27 33|statusith al
P10308312A0203 |129 136|factorsirubine
P10308312A0203 |115 120|medianatal
P10318806A0000 |0 7|MembersP000016
P10318806A0000 |154 160|kinase2 When
P10318806A0000 |93 99|kinasecologi
P10318806A0000 |247 256|cytokineser displa
P10318806A0000 |183 191|elementss a func
P10318806A0000 |211 217|signal data 
P10318806A0000 |47 60|kinase familytases and 5-n
P10318806A0000 |166 169|p38HCO
P10318806A0000 |135 140|c-Junemia.
P10318806A0000 |15 22|mitogenCompari
P10318806A0000 |118 134|protein kinase-1al hyperbilirubi
P10318806A0000 |42 45|MAPosp
P10318806A0000 |231 245|growth factorsrats are no lo
P10318806A0000 |33 40|proteinkaline 
P10318806A0000 |272 278|agentsd to c
P10318806A0476 |114 123|responsesonatal hy
P10318806A0476 |15 20|studyCompa
P10318806A0476 |58 62|role-nuc
P10318806A0476 |76 87|MAP kinases08171T0000 
P10318806A0918 |0 8|AnalysesP0000160
P10318806A0918 |259 280|phospholipase C-gamma when compared to con
P10318806A0918 |359 362|p38A07
P10318806A0918 |114 132|Src family kinasesonatal hyperbiliru
P10318806A0918 |95 103|proteinslogic as
P10318806A0918 |62 74|Src homologyleotidase P0
P10318806A0918 |240 257|phosphatase SHP-2no longer displac
P10318806A0918 |12 20|tyrosine76 Compa
P10318806A0918 |286 289|Crkbut
P10318806A0918 |345 355|activation vs. P0001
P10318806A0918 |134 163|phosphatidylinositol 3-kinasenemia. P00008997A0472 When CS
P10318806A0918 |187 194|proteinfunctio
P10318806A0918 |37 51|PDGF receptorsne phosphatase
P10318806A0918 |198 201|Ras CS
P10318806A0918 |310 314|rolecant
P10318806A0918 |207 219|Src homology the data of
P10318859A0535 |70 94|tyrosine phosphorylatione P00008171T0000 Pharmac
P10318859A0535 |111 119|paxillin neonata
P10318859A0535 |37 58|tyrosine phosphatasesne phosphatases and 5
P10318859A0535 |18 27|calpeptinparison w
P10318900A0637 |239 247|particle no long
P10318900A0637 |131 143|conformationubinemia. P0
P10318900A0637 |167 177|efficiencyCO3-] is s
P10318900A0637 |29 36|studiesh alkal
P10318900A0637 |181 196|mRNA production as a function 
P10318900A0637 |151 157|capsid0472 W
P10318900A0637 |83 90|binding000 Pha
P10318900A0637 |43 66|electron cryomicroscopysphatases and 5-nucleot
P10318900A0637 |98 101|Fabic 
P10318900A0637 |103 109|8H2/G5pects 
P10318918A0824 |87 92|motifPharm
P10318918A0824 |124 137|HCV genotypeserbilirubinem
P10318918A0824 |62 68|regionleotid
P10318918A0824 |20 28|analysisrison wi
P10318918A0824 |32 36|NS5Alkal
P10319320A1022 |171 178|control] is sh
P10319320A1022 |41 49|16K hPRLhosphata
P10319320A1022 |182 194|angiogenesisas a functio
P10319320A1022 |22 30|findingsson with
P10319320A1022 |76 90|Ras activation08171T0000 Pha
P10319320A1022 |97 107|antagonismgic aspect
P10319320A1022 |153 162|mechanism72 When C
P10319327A1237 |137 140|SRFia.
P10319327A1237 |177 192|protein E12/E47hown as a funct
P10319327A1237 |12 57|SRE oligonucleotide gel mobility shift assays76 Comparison with alkaline phosphatases and 
P10319327A1237 |71 79|extracts P000081
P10319327A1237 |93 98|cellscolog
P10319327A1237 |116 124|presenceatal hyp
P10319327A1237 |0 8|AnalysisP0000160
P10319955A0941 |34 49|occlusion ratesaline phosphata
P10319955A0941 |14 25|differences Comparison
P10319955A0941 |75 79|test0081
P10319955A0941 |57 61|chi25-nu
P10319955A0941 |63 73|chi-squareeotidase P
P10319955A0941 |127 128|Pi
P10319955A0941 |97 108|differencesgic aspects
P10320177A0487 |0 29|Baseline electrocorticographyP00001606T0076 Comparison wit
P10320177A0487 |267 276|microg/kgmpared to
P10320177A0487 |63 67|lobeeoti
P10320177A0487 |241 250|microg/kgo longer 
P10320177A0487 |72 98|depth electrode recordingsP00008171T0000 Pharmacolog
P10320177A0487 |106 114|amygdalats of ne
P10320177A0487 |227 237|alfentanilted rats a
P10320177A0487 |119 130|hippocampusl hyperbili
P10320177A0487 |255 263|fentanylaced whe
P10320177A0487 |161 164|minCSF
P10320177A0487 |199 218|i.v. administrationCSF PCO2 the data o
P10320177A0487 |39 46|surface phosph
P10320177A0487 |168 177|recordingO3-] is s
P10320480A0451 |98 110|beta subunitic aspects o
P10320480A0451 |122 136|RNA polymeraseyperbilirubine
P10320480A0451 |60 64|roleucle
P10320480A0451 |22 28|systemson wi
P10320480A0451 |80 90|C-terminus1T0000 Pha
P10320579A1831 |16 20|FlgNompa
P10320579A1831 |110 114|HAPsf ne
P10320579A1831 |25 29|FliT wit
P10320579A1831 |143 150|domains0008997
P10320579A1831 |53 73|flagellar chaperonesand 5-nucleotidase P
P10320579A1831 |158 164|exporten CSF
P10320579A1831 |87 102|oligomerizationPharmacologic a
P10321158T0000 |68 72|corease 
P10321158T0000 |40 46|canalsphosph
P10321158T0000 |93 98|dowelcolog
P10321158T0000 |9 25|core fabricationT0076 Comparison
P10321158T0000 |54 63|cast postnd 5-nucl
P10321158T0000 |0 4|PostP000
P10322022A0263 |0 6|Rep63AP00001
P10322022A0263 |54 57|ORFnd 
P10322022A0263 |25 27|aa w
P10322022A0263 |90 100|% identityrmacologic
P10322022A0263 |12 23|amino acids76 Comparis
P10322022A0263 |166 174|pSM19035HCO3-] i
P10322022A0263 |226 241|pAMbeta1 familyeted rats are n
P10322022A0263 |135 152|plasmids pAMbeta1emia. P00008997A0
P10322022A0263 |154 160|pIP5012 When
P10322022A0263 |196 210|pAW63 repliconof CSF PCO2 th
P10322022A0263 |109 129|replication proteinsof neonatal hyperbil
P10322022A0263 |76 86|similarity08171T0000
P10322022A0263 |277 285|plasmidscontrols
P10322629A0198 |51 64|Xenopus Pax-5s and 5-nucle
P10322629A0198 |109 120|gene familyof neonatal
P10322629A0198 |31 47|characterizationalkaline phospha
P10322629A0198 |99 104|Pax-2c asp
P10322629A0198 |80 91|orthologues1T0000 Phar
P10322629A0198 |19 26|cloningarison 
P10322629A0198 |69 74|Pax-8se P0
P10323225A0244 |0 9|Km valuesP00001606
P10323225A0244 |14 22|ammonium Compari
P10323225A0244 |60 63|NADucl
P10323225A0244 |40 44|NADHphos
P10323225A0244 |46 55|glutamateatases an
P10323225A0244 |24 38|2-oxoglutaraten with alkalin
P10323225A0244 |101 103|mMas
P10323463T0000 |1 17|Interferon-alpha00001606T0076 Co
P10323463T0000 |67 81|manifestationsdase P00008171
P10323463T0000 |144 152|activity008997A0
P10323463T0000 |94 100|effectologic
P10323463T0000 |94 100|effectologic
P10323463T0000 |1 17|Interferon-alpha00001606T0076 Co
P10323463T0000 |144 152|activity008997A0
P10323463T0000 |67 81|manifestationsdase P00008171
P10323863A0852 |102 128|rabbit reticulocyte lysatespects of neonatal hyperbi
P10323863A0852 |92 98|factoracolog
P10323863A0852 |143 169|ribonucleoprotein assembly0008997A0472 When CSF [HCO
P10323863A0852 |37 47|productionne phospha
P10323863A0852 |3 11|addition001606T0
P10323863A0852 |70 80|telomerasee P0000817
P10325413A1211 |103 113|propensitypects of n
P10325413A1211 |128 133|helixlirub
P10325413A1211 |24 29|c-Abln wit
P10325413A1211 |13 20|binding6 Compa
P10325413A1211 |216 227|interaction of K-deple
P10325413A1211 |202 206|base PCO
P10325413A1211 |33 73|DNA containing 5-methylcytosine residueskaline phosphatases and 5-nucleotidase P
P10325413A1211 |185 194|reductiona functio
P10326221A0531 |77 86|fulminans8171T0000
P10326221A0531 |27 35|childrenith alka
P10326221A0531 |11 19|mutation076 Comp
P10326221A0531 |57 61|legs5-nu
P10326221A0531 |43 53|amputationsphatases 
P10326654A0351 |368 378|differencerazepam th
P10326654A0351 |185 190|groupa fun
P10326654A0351 |115 122|minutesnatal h
P10326654A0351 |216 228|fibrillation of K-deplet
P10326654A0351 |262 273|arrhythmiasen compared
P10326654A0351 |398 406|ischemiaeffectiv
P10326654A0351 |386 394|durationrs to be
P10326654A0351 |176 183|minutesshown a
P10326654A0351 |56 65|durations 5-nucleo
P10326654A0351 |328 330|VFpe
P10326654A0351 |13 30|pilot experiments6 Comparison with
P10326654A0351 |166 171|studyHCO3-
P10326654A0351 |254 258|formlace
P10326654A0351 |84 92|ischemia00 Pharm
P10326654A0351 |291 296|grouptill 
P10326654A0351 |282 289|minutesols but
P10326654A0351 |314 324|prevalencely greater
P10326654A0351 |230 232|VF r
P10326654A0351 |128 137|durationslirubinem
P10326856T0000 |56 75|purse-string device 5-nucleotidase P00
P10326856T0000 |14 36|pancreaticojejunostomy Comparison with alkal
P10327051A0688 |103 108|Thr71pects
P10327051A0688 |178 185|complexown as 
P10327051A0688 |93 98|Thr69colog
P10327051A0688 |151 163|p300/CBP-ATF0472 When CS
P10327051A0688 |134 143|formationnemia. P0
P10327051A0688 |71 83|target sites P00008171T0
P10327051A0688 |65 69|SAPKtida
P10327051A0688 |32 63|Stress-Activated-Protein-Kinaselkaline phosphatases and 5-nucl
P10327051A0688 |87 91|ATF2Phar
P10328351A0443 |0 13|Blood samplesP00001606T007
P10328351A0443 |75 76|d0
P10328351A0443 |46 68|supplementation periodatases and 5-nucleotid
P10328351A0443 |89 90|da
P10329135A1326 |6 13|results606T007
P10329135A1326 |72 80|mt-hsp70P0000817
P10329135A1326 |41 53|presequenceshosphatases 
P10329135A1326 |111 125|protein import neonatal hype
P10329566A0610 |71 80|structure P0000817
P10329566A0610 |178 185|featureown as 
P10329566A0610 |92 108|valine anticodonacologic aspects
P10329566A0610 |160 174|aminoacyl stem CSF [HCO3-] i
P10329566A0610 |124 133|structureerbilirub
P10329566A0610 |211 223|tetraviruses data of K-d
P10329566A0610 |142 152|pseudoknot00008997A0
P10329566A0610 |7 15|terminus06T0076 
P10329566A0610 |23 29|genomeon wit
P10329566A0610 |201 207|generaF PCO2
P10329574A1733 |0 2|O.P0
P10329574A1733 |13 18|RNA-76 Com
P10329574A1733 |148 157|deletions97A0472 W
P10329574A1733 |63 66|RNAeot
P10329574A1733 |95 98|RNAlog
P10329574A1733 |113 126|OnuMV4-Ld RNAeonatal hyper
P10329586A0414 |141 143|FNP0
P10329586A0414 |28 30|FNth
P10329586A0414 |15 26|fibronectinComparison 
P10329586A0414 |123 137|overexpressionperbilirubinem
P10329586A0414 |72 85|LNCaP-r cellsP00008171T000
P10329586A0414 |147 162|prostate cancer997A0472 When C
P10329586A0414 |9 13|geneT007
P10329625A0715 |154 159|cells2 Whe
P10329625A0715 |166 170|FTOCHCO3
P10329625A0715 |47 50|CD3tas
P10329625A0715 |76 85|TCR genes08171T000
P10329625A0715 |41 44|CD8hos
P10329625A0715 |22 38|cell surface CD4son with alkalin
P10329625A0715 |54 59|cellsnd 5-
P10329736A0681 |81 92|p85 subunitT0000 Pharm
P10329736A0681 |28 33|yeastth al
P10329736A0681 |45 51|systemhatase
P10329736A0681 |53 58|mIRS3and 5
P10329736A0681 |96 125|phosphatidylinositol 3-kinaseogic aspects of neonatal hype
P10329736A1106 |0 19|Insulin stimulationP00001606T0076 Comp
P10329736A1106 |59 62|p85nuc
P10329736A1106 |79 82|Shc71T
P10329736A1106 |33 44|associationkaline phos
P10329736A1106 |64 68|SHP2otid
P10329736A1106 |48 53|mIRS3ases 
P10329736A1106 |70 73|Ncke P
P10330134A0765 |4 19|mRNA expression01606T0076 Comp
P10330134A0765 |78 107|transient-transfection assays171T0000 Pharmacologic aspect
P10330134A0765 |160 168|promoter CSF [HC
P10330134A0765 |29 33|RFX2h al
P10330134A0765 |226 232|mannereted r
P10330134A0765 |122 139|RFX binding sitesyperbilirubinemia
P10330134A0765 |23 27|RFX1on w
P10330134A0765 |197 203|tissuef CSF 
P10330134A0765 |143 148|front00089
P10330134A0765 |39 43|RFX3 pho
P10330146A0730 |32 38|intronlkalin
P10330146A0730 |109 118|sequencesof neonat
P10330146A0730 |183 188|sitess a f
P10330146A0730 |165 173|deletion[HCO3-] 
P10330146A0730 |126 147|luciferase expressionbilirubinemia. P00008
P10330146A0730 |40 50|repressionphosphatas
P10330146A0730 |7 11|case06T0
P10330146A0730 |54 75|luciferase expressionnd 5-nucleotidase P00
P10330159A1258 |152 156|site472 
P10330159A1258 |6 9|VDR606
P10330159A1258 |189 196|Jun-Fosnction 
P10330159A1258 |62 72|activationleotidase 
P10330159A1258 |81 98|promoter/enhancerT0000 Pharmacolog
P10330159A1258 |38 48|componentse phosphat
P10330159A1258 |117 122|NFAT1tal h
P10330159A1258 |204 207|DNACO2
P10330168A0135 |98 103|Cdc7pic as
P10330168A0135 |29 36|kinasesh alkal
P10330168A0135 |166 168|G1HC
P10330168A0135 |74 80|kinase000817
P10330168A0135 |181 196|DNA replication as a function 
P10330168A0135 |42 50|cyclin Bosphatas
P10330168A0135 |131 143|factor Dbf4pubinemia. P0
P10330168A0135 |52 55|Clb an
P10330168A0135 |82 92|Cdk/Cdc28p0000 Pharm
P10330396A0387 |51 55|CRM1s an
P10330396A0387 |143 154|p62 complex0008997A047
P10330396A0387 |159 169|Can/Nup214n CSF [HCO
P10330396A0387 |122 133|associationyperbilirub
P10330396A0387 |75 84|periphery008171T00
P10330396A0387 |4 25|RanQ69L preincubation01606T0076 Comparison
P10330396A0387 |114 117|NPCona
P10330396A0387 |100 112|pore complex aspects of 
P10330396A0387 |35 47|accumulationline phospha
P10331276A0298 |40 49|structurephosphata
P10331276A0298 |11 19|elements076 Comp
P10331646A0595 |3 11|contrast001606T0
P10331646A0595 |188 202|amino terminusunction of CSF
P10331646A0595 |25 44|amino acid sequence with alkaline phos
P10331646A0595 |144 153|abundance008997A04
P10331646A0595 |57 63|family5-nucl
P10331646A0595 |74 86|transferases0008171T0000
P10331646A0595 |222 237|signal sequencedepleted rats a
P10331646A0595 |325 332|proteinslope (
P10331646A0595 |157 163|testishen CS
P10331646A0595 |263 278|signal sequencen compared to c
P10331646A0595 |107 121|lymphoma cellss of neonatal 
P10331646A0595 |286 303|carboxyl terminusbut still have a 
P10331646A0595 |349 355|export P0001
P10331646A0595 |65 69|ART5tida
P10331730A0504 |0 7|RESULTSP000016
P10331730A0504 |82 83|%0
P10331730A0504 |52 60|Sardinia and 5-n
P10331730A0504 |126 138|study periodbilirubinemi
P10331730A0504 |14 18|year Com
P10331730A0504 |38 43|casese pho
P10331730A0504 |97 105|patientsgic aspe
P10331730A0504 |175 182|centres shown 
P10331730A0504 |33 34|%k
P10331875A0523 |152 165|cooperativity472 When CSF 
P10331875A0523 |88 96|affinityharmacol
P10331875A0523 |121 124|HSFhyp
P10331875A0523 |72 83|specificityP00008171T0
P10331875A0523 |183 190|trimerss a fun
P10331875A0523 |113 117|formeona
P10331875A0523 |5 20|dimer interface1606T0076 Compa
P10332733A0000 |4 24|paramyxovirus fusion01606T0076 Compariso
P10332733A0000 |29 36|proteinh alkal
P10332733A0000 |46 61|membrane fusionatases and 5-nu
P10332733A0000 |26 27|Fw
P10333481A1102 |118 135|promoter activityal hyperbilirubin
P10333481A1102 |39 43|UCP2 pho
P10333481A1102 |96 102|regionogic a
P10333481A1102 |58 68|constructs-nucleotid
P10333481A1102 |14 31|deletion analysis Comparison with 
P10333481A1102 |156 158|ntWh
P10333481A1102 |191 199|enhancertion of 
P10333481A1102 |223 225|bpep
P10333481A1102 |236 251|promoter regionare no longer d
P10333526A0459 |4 14|hTERT gene01606T0076
P10333526A0459 |61 66|exonscleot
P10333529A0277 |5 17|betaAPP mRNA1606T0076 Co
P10333529A0277 |22 34|Abeta levelsson with alk
P10333529A0277 |52 59|trisomy and 5-
P10334888A0960 |69 77|increasese P0000
P10334888A0960 |129 141|nondiabeticsirubinemia. 
P10334888A0960 |113 116|mineon
P10334888A0960 |36 41|groupine p
P10334888A0960 |81 100|IL-8 concentrationsT0000 Pharmacologic
P10334888A0960 |3 16|reperfusion B001606T0076 C
P10336495A0547 |84 95|interaction00 Pharmaco
P10336495A0547 |146 155|complexes8997A0472
P10336495A0547 |123 131|RXRalphaperbilir
P10336495A0547 |29 37|agonistsh alkali
P10336495A0547 |104 108|NCoRects
P10336495A0547 |5 15|repression1606T0076 
P10336495A0547 |113 122|PPARalphaeonatal h
P10336495A0547 |48 56|receptorases and
P10336495A0547 |169 174|cells3-] i
P10339552A0361 |35 45|SRm160/300line phosp
P10339552A0361 |15 20|studyCompa
P10339552A0361 |95 103|splicinglogic as
P10339552A0361 |109 117|pre-mRNAof neona
P10339552A0361 |76 79|ESE081
P10339552A0361 |156 160|geneWhen
P10339566A0602 |85 97|Spc94p/Nud1p0 Pharmacolo
P10339566A0602 |111 117|Spc42p neona
P10339566A0602 |99 105|Cnm67pc aspe
P10339566A0602 |59 73|SPB subcomplexnucleotidase P
P10339566A0602 |32 41|componentlkaline p
P10339566A0602 |0 6|Spc42pP00001
P10340447A0424 |71 74|QMF P0
P10340447A0424 |28 39|correlationth alkaline
P10340447A0424 |12 24|coefficients76 Compariso
P10340447A0424 |83 93|QIT system000 Pharma
P10340883A1266 |18 28|stage IIIBparison wi
P10340883A1266 |11 13|OS07
P10340883A1266 |61 66|stagecleot
P10340883A1266 |37 38|%n
P10340883A1266 |55 56|%d
P10341219A0481 |141 156|mass aggregatesP00008997A0472 
P10341219A0481 |13 36|heparin lyase treatment6 Comparison with alkal
P10341219A0481 |52 57|cells and 
P10341219A0481 |40 48|extractsphosphat
P10341219A0481 |113 120|proteineonatal
P10341219A0481 |81 98|YD-repeat proteinT0000 Pharmacolog
P10342511A0909 |51 57|scoress and 
P10342511A0909 |4 15|coefficient01606T0076 
P10342511A0909 |19 32|determinationarison with a
P10342511A0909 |34 36|r2al
P10342536A0954 |50 58|formulaees and 5
P10342536A0954 |73 84|information00008171T00
P10342536A0954 |172 184|whey formula is shown as
P10342536A0954 |129 133|milkirub
P10342536A0954 |27 42|protein contentith alkaline ph
P10342536A0954 |228 253|soy/pork collagen formulaed rats are no longer dis
P10342536A0954 |123 126|cowper
P10342536A0954 |263 281|amino acid formulan compared to cont
P10342536A0954 |6 19|determination606T0076 Comp
P10342536A0954 |86 106|RAST/EAST inhibition Pharmacologic aspec
P10342536A0954 |207 226|whey/casein formula the data of K-depl
P10342829A0236 |51 61|mechanismss and 5-nu
P10342829A0236 |179 191|reproductionwn as a func
P10342829A0236 |124 130|hGnRHRerbili
P10342829A0236 |132 136|genebine
P10342829A0236 |150 155|issueA0472
P10342829A0236 |30 35|GnRHR alka
P10342829A0236 |3 8|light00160
P10342829A0236 |93 103|regulationcologic as
P10342829A0236 |117 122|GnRHRtal h
P10342829A0236 |16 26|importanceomparison 
P10342829A1370 |65 72|extracttidase 
P10342829A1370 |47 56|alphaT3-1tases and
P10342829A1370 |12 33|mobility shift assays76 Comparison with al
P10342829A1370 |88 100|SF-1 proteinharmacologic
P10342829A1370 |124 128|SF-1erbi
P10342829A1370 |172 183|GSE element is shown a
P10343189A0911 |0 5|GradeP0000
P10343189A0911 |8 17|mucositis6T0076 Co
P10343189A0911 |36 43|patientine pho
P10344736A0796 |0 22|CDK4 kinase activitiesP00001606T0076 Compari
P10344736A0796 |52 58|levels and 5
P10344736A0796 |66 87|CDK inhibitor p21Cip1idase P00008171T0000 
P10344736A0796 |99 123|cyclin E immunocomplexesc aspects of neonatal hy
P10347144A0516 |50 68|baculovirus systemes and 5-nucleotid
P10347144A0516 |106 109|kDats 
P10347144A0516 |25 32|protein with a
P10347144A0516 |130 138|sequencerubinemi
P10347144A0516 |142 147|AVQGP00008
P10347144A0516 |98 102|sizeic a
P10347197A0502 |119 123|Grb2l hy
P10347197A0502 |82 95|co-expression0000 Pharmaco
P10347197A0502 |128 153|Sos1 expression constructlirubinemia. P00008997A04
P10347197A0502 |54 66|Met receptornd 5-nucleot
P10347197A0502 |39 45|HGF/SF phosp
P10347197A0502 |0 9|InductionP00001606
P10347197A0502 |17 35|urokinase promotermparison with alka
P10347203A0832 |171 184|proliferation] is shown as
P10347203A0832 |56 78|somatostatin treatment 5-nucleotidase P00008
P10347203A0832 |26 31|STAT3with 
P10347203A0832 |100 115|pertussis toxin aspects of neo
P10347203A0832 |158 167|increasesen CSF [H
P10347203A0832 |0 22|Serine phosphorylationP00001606T0076 Compari
P10347203A0832 |119 121|PDl 
P10347220A1477 |100 103|RNA as
P10347220A1477 |61 66|yeastcleot
P10347220A1477 |75 84|apparatus008171T00
P10347220A1477 |131 154|RNA guanylyltransferaseubinemia. P00008997A047
P10347220A1477 |270 310|triphosphatase-guanylyltransferase Mce1pred to controls but still have a signifi
P10347220A1477 |123 128|Cet1pperbi
P10347220A1477 |107 121|triphosphatases of neonatal 
P10347220A1477 |319 341|methyltransferase Hcm1eater slope (1.21 +/- 
P10347220A1477 |231 240|apparatusrats are 
P10347220A1477 |350 352|p.P0
P10347220A1477 |156 161|Ceg1pWhen 
P10347220A1477 |168 173|Abd1pO3-] 
P10347839A0434 |85 86|M0
P10347839A0434 |28 31|dogth 
P10347839A0434 |66 67|Mi
P10347839A0434 |40 47|bladderphospha
P10347839A0434 |20 23|ratris
P10347839A0434 |4 15|IC50 values01606T0076 
P10348859A0292 |137 143|Cys117ia. P0
P10348859A0292 |148 154|Cys12697A047
P10348859A0292 |88 90|Hgha
P10348859A0292 |30 43|binding sites alkaline pho
P10348859A0292 |125 132|monomerrbiliru
P10348859A0292 |95 98|ionlog
P10348859A0292 |58 72|MerR homodimer-nucleotidase 
P10348859A0292 |110 115|Cys82f neo
P10349084T0000 |139 146|purpura. P0000
P10349084T0000 |30 50|virus seropositivity alkaline phosphatas
P10349084T0000 |58 66|efficacy-nucleot
P10349084T0000 |89 97|globulinarmacolo
P10349084T0000 |4 13|influence01606T007
P10349084T0000 |101 109|childrenaspects 
P10349443A0358 |137 138|%i
P10349443A0358 |77 83|larvae8171T0
P10349443A0358 |27 38|field testsith alkalin
P10349443A0358 |89 95|valuesarmaco
P10349443A0358 |62 73|infestationleotidase P
P10349443A0358 |4 11|results01606T0
P10349443A0358 |52 58|levels and 5
P10349443A0358 |19 22|labari
P10349443A0358 |118 119|%a
P10350027A0942 |102 113|performancespects of n
P10350027A0942 |127 130|dayili
P10350027A0942 |16 18|mgom
P10350027A0942 |39 46|effects phosph
P10350027A0942 |50 61|psychomotores and 5-nu
P10350027A0942 |0 11|AmisulprideP00001606T0
P10350454A0000 |0 4|MutYP000
P10350454A0000 |109 112|G.Aof 
P10350454A0000 |56 66|mismatches 5-nucleot
P10350454A0000 |91 93|oGma
P10350454A0000 |77 89|8-oxoguanine8171T0000 Ph
P10350454A0000 |40 51|specificityphosphatase
P10350454A0000 |23 34|glycosylaseon with alk
P10350454A0000 |100 107|guanine aspect
P10350484A0346 |16 31|kinase activityomparison with 
P10350484A0346 |149 157|increase7A0472 W
P10350484A0346 |165 169|Vmax[HCO
P10350484A0346 |105 115|% decreasects of neo
P10350484A0346 |45 54|complexeshatases a
P10350484A0346 |130 133|ATPrub
P10350484A0346 |123 125|KMpe
P10350484A0346 |67 71|CheAdase
P10350484A0346 |4 12|kinetics01606T00
P10350638A0000 |0 7|LatexinP000016
P10350638A0000 |11 39|carboxypeptidase A inhibitor076 Comparison with alkaline
P10350638A0000 |78 84|manner171T00
P10350638A0000 |124 131|systemserbilir
P10350638A0000 |59 63|cellnucl
P10350638A0000 |139 142|rat. P
P10353073A0118 |0 19|Regression analysesP00001606T0076 Comp
P10353073A0118 |55 62|factorsd 5-nuc
P10353073A0118 |33 37|riskkali
P10353880A0257 |102 111|diagnosisspects of
P10353880A0257 |89 95|birthsarmaco
P10353880A0257 |120 121|P 
P10353880A0257 |64 71|infantsotidase
P10353880A0257 |115 118|HSVnat
P10355085A1119 |0 7|SubsetsP000016
P10355085A1119 |124 138|injury patternerbilirubinemi
P10355085A1119 |11 19|patients076 Comp
P10355085A1119 |72 75|ISSP00
P10355085A1119 |144 153|survivors008997A04
P10355085A1119 |161 173|nonsurvivorsCSF [HCO3-] 
P10355085A1119 |52 60|severity and 5-n
P10355085A1119 |64 70|traumaotidas
P10355536A0172 |22 27|yearsson w
P10355536A0172 |29 34|rangeh alk
P10355536A0172 |11 14|age076
P10355536A0172 |41 46|yearshosph
P10355910A0369 |33 38|yearskalin
P10355910A0369 |14 23|follow-up Comparis
P10355910A0369 |27 30|ageith
P10357751A0866 |140 144|risk P00
P10357751A0866 |243 251|childrenlonger d
P10357751A0866 |301 306|scorea sig
P10357751A0866 |31 39|childrenalkaline
P10357751A0866 |269 276|diseaseared to
P10357751A0866 |164 168|risk [HC
P10357751A0866 |59 64|scorenucle
P10357751A0866 |365 369|riskFlur
P10357751A0866 |89 92|FFMarm
P10357751A0866 |148 153|death97A04
P10357751A0866 |13 18|group6 Com
P10357751A0866 |74 80|weight000817
P10357751A0866 |172 176|% CI is 
P10357751A0866 |311 317|weightantly 
P10358031A0303 |102 110|divisionspects o
P10358031A0303 |132 143|cytokinesisbinemia. P0
P10358031A0303 |122 128|defectyperbi
P10358031A0303 |151 166|cell separation0472 When CSF [
P10358031A0303 |80 90|G2/M delay1T0000 Pha
P10358031A0303 |57 63|nuclei5-nucl
P10358031A0303 |3 11|addition001606T0
P10358031A0303 |19 24|cellsariso
P10358075A0984 |0 5|DAF16P0000
P10358075A0984 |177 180|PKBhow
P10358075A0984 |147 155|receptor997A0472
P10358075A0984 |133 144|insulin/IGFinemia. P00
P10358075A0984 |157 172|PtdIns 3-kinasehen CSF [HCO3-]
P10358075A0984 |23 32|componenton with a
P10358075A0984 |38 55|signaling pathwaye phosphatases an
P10358075A0984 |115 125|homologuesnatal hype
P10358079A0391 |70 75|ErbB4e P00
P10358079A0391 |44 56|heterodimersphatases and
P10358079A0391 |60 65|ErbB2ucleo
P10358079A0391 |9 28|neu differentiationT0076 Comparison wi
P10358079A0391 |86 91|Stat5 Phar
P10358080A1114 |152 156|role472 
P10358080A1114 |172 196|HSF1 binding preferences is shown as a function 
P10358080A1114 |9 23|linker regionsT0076 Comparis
P10358080A1114 |131 142|HSF1 linkerubinemia. P
P10358080A1114 |27 48|transcription factorsith alkaline phosphat
P10358080A1114 |223 234|determinantepleted rat
P10358080A1114 |71 94|DNA binding specificity P00008171T0000 Pharmac
P10358080A1114 |253 284|HSF1 monomer-trimer equilibriumplaced when compared to control
P10358080A1114 |100 107|studies aspect
P10358080T0000 |0 10|ModulationP00001606T
P10358080T0000 |59 72|linker domainnucleotidase 
P10358080T0000 |20 51|heat shock factor trimerizationrison with alkaline phosphatase
P10358083A0263 |186 190|GATA fun
P10358083A0263 |202 222|transcription factor PCO2 the data of K-
P10358083A0263 |231 236|sitesrats 
P10358083A0263 |77 93|characterization8171T0000 Pharma
P10358083A0263 |109 118|complexesof neonat
P10358083A0263 |148 170|sequence motifs GTGACT97A0472 When CSF [HCO3
P10358083A0263 |175 180|ATTGT show
P10358083A0263 |64 72|F9 cellsotidase 
P10358083A0263 |16 24|analysesompariso
P10358083A0263 |171 172|C]
P10358138A0672 |101 105|SLAMaspe
P10358138A0672 |74 83|signaling0008171T0
P10358138A0672 |44 47|XLPpha
P10358138A0672 |31 40|phenotypealkaline 
P10358138A0672 |167 192|signaling adaptor proteinCO3-] is shown as a funct
P10358138A0672 |122 144|cell surface moleculesyperbilirubinemia. P00
P10358138A0672 |6 13|results606T007
P10358138A0672 |158 161|SAPen 
P10359014A1077 |87 102|serine residuesPharmacologic a
P10359014A1077 |67 76|threoninedase P000
P10359014A1077 |22 49|Fra-2 phosphorylation sitesson with alkaline phosphata
P10359014A1077 |124 130|regionerbili
P10359014A1077 |134 139|meansnemia
P10359014A1077 |53 57|MAPKand 
P10359014A1077 |189 207|threonine residuesnction of CSF PCO2
P10359014A1077 |233 237|MAPKts a
P10359014A1077 |157 168|mutagenesishen CSF [HC
P10359575A0317 |154 158|hIgA2 Wh
P10359575A0317 |123 133|bFcgamma2Rperbilirub
P10359575A0317 |107 112|bIgG2s of 
P10359575A0317 |75 78|IgA008
P10359575A0317 |80 84|hIgA1T00
P10359575A0317 |53 62|FcalphaRIand 5-nuc
P10359575A0317 |140 145|bIgG2 P000
P10359575A0317 |101 105|IgG2aspe
P10359603A0430 |0 5|Vac1pP0000
P10359603A0430 |28 50|Sec1p homologue Vps45pth alkaline phosphatas
P10359663A0425 |239 271|oIFNtau-SV40-CAT transactivation no longer displaced when compar
P10359663A0425 |74 81|oIFNtau0008171
P10359663A0425 |161 166|basesCSF [
P10359663A0425 |131 139|promoterubinemia
P10359663A0425 |125 129|SV40rbil
P10359663A0425 |63 70|regionseotidas
P10359663A0425 |210 225|enhancer regione data of K-dep
P10359663A0425 |99 104|frontc asp
P10359663A0425 |145 152|regions08997A0
P10359663A0425 |115 120|virusnatal
P10359663A0425 |34 40|systemaline 
P10359663A1280 |137 143|GATA-2ia. P0
P10359663A1280 |76 91|transactivation08171T0000 Phar
P10359663A1280 |95 106|oIFNtau-CATlogic aspec
P10359663A1280 |57 62|c-Fos5-nuc
P10359663A1280 |147 153|GATA-3997A04
P10359663A1280 |46 51|c-Junatase
P10359663A1280 |115 125|expressionnatal hype
P10359663A1280 |129 135|GATA-1irubin
P10359663A1280 |3 26|co-transfection studies001606T0076 Comparison 
P10359663A1280 |32 42|expressionlkaline ph
P10359664A0579 |70 88|lysyl endoproteasee P00008171T0000 P
P10359664A0579 |45 51|MARCKShatase
P10359664A0579 |105 121|electrospray MS.cts of neonatal 
P10359664A0579 |18 23|sitesparis
P10359673A0000 |4 19|yeast LPD1 gene01606T0076 Comp
P10359673A0000 |29 52|lipoamide dehydrogenaseh alkaline phosphatases
P10359673A0000 |90 113|amino acid biosynthesisrmacologic aspects of n
P10359673A0000 |79 86|control71T0000
P10359673A0000 |130 155|GCN4 transcription factorrubinemia. P00008997A0472
P10359792A0610 |102 128|dCtBP corepressor proteinsspects of neonatal hyperbi
P10359792A0610 |90 97|Grouchormacolo
P10359792A0610 |40 52|Rpd3 mutantsphosphatases
P10359792A0610 |164 175|recruitment [HCO3-] is
P10359792A0610 |179 199|histone deacetylaseswn as a function of 
P10359792A0610 |20 27|defectsrison w
P10360454A0916 |85 99|pentoxifylline0 Pharmacologi
P10360454A0916 |177 190|control grouphown as a fun
P10360454A0916 |13 38|serum TNF-a concentration6 Comparison with alkalin
P10360454A0916 |151 152|p0
P10360454A0916 |144 149|pg/ml00899
P10360454A0916 |128 133|monthlirub
P10360454A0916 |66 74|patientsidase P0
P10360454A0916 |117 122|pg/mltal h
P10360839A1338 |70 79|subfamilye P000081
P10360839A1338 |30 40|expression alkaline 
P10360839A1338 |83 105|KRAB zinc finger genes000 Pharmacologic aspe
P10360839A1338 |146 159|cell lineages8997A0472 Whe
P10360839A1338 |55 62|membersd 5-nuc
P10360839A1338 |3 11|addition001606T0
P10360947A1113 |139 146|changes. P0000
P10360947A1113 |10 35|fluorescence spectroscopy0076 Comparison with alka
P10360947A1113 |79 86|binding71T0000
P10360947A1113 |90 93|Ca2rma
P10360947A1113 |98 103|ALG-2ic as
P10360947A1113 |200 207|proteinSF PCO2
P10360947A1113 |185 192|domainsa funct
P10360947A1113 |49 58|dichroismses and 5
P10361038A0281 |81 94|protein genesT0000 Pharmac
P10361038A0281 |44 53|promotersphatases 
P10361038A0281 |27 36|locationsith alkal
P10362652A0350 |32 35|EGFlka
P10362652A0350 |52 66|Ras activation and 5-nucleot
P10362652A0350 |40 42|nMph
P10362652A0350 |5 14|carbachol1606T0076
P10362652A0350 |20 26|microMrison 
P10362652A1456 |119 120|%l
P10362652A1456 |62 69|HA-ERK2leotida
P10362652A1456 |37 58|carbachol stimulationne phosphatases and 5
P10362652A1456 |110 113|EGFf n
P10362652A1456 |18 21|Sospar
P10362652A1456 |100 106|effect aspec
P10362897A0545 |0 7|RESULTSP000016
P10362897A0545 |24 31|passagen with 
P10362897A0545 |107 121|Doppler signals of neonatal 
P10362897A0545 |90 99|intensityrmacologi
P10362897A0545 |162 168|effectSF [HC
P10362897A0545 |145 153|duration08997A04
P10362897A0545 |67 74|amountsdase P0
P10362897A0545 |35 43|contrastline pho
P10363517A0401 |35 40|casesline 
P10363517A0401 |8 13|paper6T007
P10363517A0401 |59 74|ultrasonographynucleotidase P0
P10363517A0401 |20 27|lesionsrison w
P10364076A0429 |6 13|regions606T007
P10364076A0429 |31 36|E-boxalkal
P10364076A0429 |105 115|affinitiescts of neo
P10364076A0429 |59 72|repeat motifsnucleotidase 
P10364076A0429 |82 89|SREBP-10000 Ph
P10364159A0813 |17 26|questionsmparison 
P10364159A0813 |151 157|4E-BP10472 W
P10364159A0813 |120 133|kinase assays hyperbilirub
P10364159A0813 |42 59|FRAP/mTOR proteinosphatases and 5-
P10364159A0813 |66 93|FRAP/mTOR immunoprecipitateidase P00008171T0000 Pharma
P10364163A0092 |0 3|HrsP00
P10364163A0092 |160 167|traffic CSF [H
P10364163A0092 |91 100|phosphatemacologic
P10364163A0092 |129 137|proteinsirubinem
P10364163A0092 |10 14|FYVE0076
P10364163A0092 |22 40|zinc finger domainson with alkaline 
P10364163A0092 |67 87|phosphatidylinositoldase P00008171T0000 
P10364202A0646 |118 126|increaseal hyper
P10364202A0646 |198 209|involvement CSF PCO2 t
P10364202A0646 |130 140|activationrubinemia.
P10364202A0646 |79 94|leukemia factor71T0000 Pharmac
P10364202A0646 |63 66|DBPeot
P10364202A0646 |225 236|coactivatorleted rats 
P10364202A0646 |157 181|GAL4-DBP fusion proteinshen CSF [HCO3-] is shown
P10364202A0646 |245 252|processnger di
P10364202A0646 |4 16|coexpression01606T0076 C
P10364202A0646 |32 53|expression constructslkaline phosphatases 
P10364314A0919 |85 93|NS2 gene0 Pharma
P10364314A0919 |73 77|part0000
P10364314A0919 |41 52|nucleotideshosphatases
P10364314A0919 |6 16|subgenomes606T0076 C
P10364319A0109 |0 2|CpP0
P10364319A0109 |24 32|promotern with a
P10364319A0109 |78 84|EBNA3C171T00
P10364319A0109 |126 138|control loopbilirubinemi
P10364319A0109 |37 57|EBNA mRNA initiationne phosphatases and 
P10364425A0610 |51 58|absences and 5
P10364425A0610 |121 126|STAT3hyper
P10364425A0610 |107 117|activations of neona
P10364425A0610 |62 70|tyrosineleotidas
P10364425A0610 |6 17|indications606T0076 Co
P10364425A0610 |33 43|signallingkaline pho
P10364523A0826 |152 160|vicinity472 When
P10364523A0826 |52 57|exons and 
P10364523A0826 |93 99|regioncologi
P10364523A0826 |5 18|exon trapping1606T0076 Com
P10364523A0826 |67 77|YAC 946E12dase P0000
P10364523A0826 |138 144|contiga. P00
P10364523A0826 |168 179|breakpointsO3-] is sho
P10364523T0000 |68 70|Mbas
P10364523T0000 |11 46|dysplasia translocation breakpoints076 Comparison with alkaline phosph
P10364523T0000 |89 97|evidencearmacolo
P10364523T0000 |83 87|SOX9000 
P10364523T0000 |114 128|control regiononatal hyperbi
P10365883A1355 |35 47|VRE patientsline phospha
P10365883A1355 |164 173|pathogens [HCO3-] 
P10365883A1355 |120 129|infection hyperbil
P10365883A1355 |197 206|infectionf CSF PCO
P10365883A1355 |131 142|coinfectionubinemia. P
P10365883A1355 |66 80|vancomycin useidase P0000817
P10365883A1355 |16 31|characteristicsomparison with 
P10366446A0893 |83 100|interaction motif000 Pharmacologic
P10366446A0893 |105 112|FLI LRRcts of 
P10366446A0893 |14 20|domain Compa
P10366446A0893 |52 59|protein and 5-
P10366503A0812 |119 130|gp17 columnl hyperbili
P10366503A0812 |209 215|naturehe dat
P10366503A0812 |99 106|His-tagc aspec
P10366503A0812 |230 237|protein rats a
P10366503A0812 |176 185|terminaseshown as 
P10366503A0812 |40 46|phagesphosph
P10366503A0812 |242 269|terminase interaction sites longer displaced when comp
P10366503A0812 |139 161|co-immunoprecipitation. P00008997A0472 When 
P10366503A0812 |87 93|phagesPharma
P10366503A0812 |0 18|Binding affinitiesP00001606T0076 Com
P10366503A0812 |68 77|retentionase P0000
P10366503A1506 |275 281|portalo cont
P10366503A1506 |219 223|gp17 K-d
P10366503A1506 |246 263|terminase regionsger displaced whe
P10366503A1506 |210 214|gp20e da
P10366503A1506 |164 173|structure [HCO3-] 
P10366503A1506 |289 306|packasome complex still have a sig
P10366503A1506 |86 94|antibody Pharmac
P10366503A1506 |54 58|gp20nd 5
P10366503A1506 |114 121|peptideonatal 
P10366503A1506 |13 22|terminase6 Compari
P10366503A1506 |195 206|association of CSF PCO
P10366503A1506 |66 73|peptideidase P
P10366503A1506 |140 146|access P0000
P10366559A0605 |71 77|plants P0000
P10366559A0605 |94 101|virionsologic 
P10366559A0605 |52 58|levels and 5
P10366559A0605 |4 18|hybrid viruses01606T0076 Com
P10366722T0000 |0 4|cDNAP000
P10366722T0000 |59 87|mouse DNA polymerase epsilonnucleotidase P00008171T0000 
P10366722T0000 |40 50|gene Pole1phosphatas
P10366722T0000 |20 32|organizationrison with a
P10366722T0000 |98 105|subunitic aspe
P10367240A1354 |50 56|mediumes and
P10367240A1354 |94 104|substancesologic asp
P10367240A1354 |242 257|sperm injection longer displac
P10367240A1354 |149 160|spermatozoa7A0472 When
P10367240A1354 |13 29|cryopreservation6 Comparison wit
P10367240A1354 |76 78|SP08
P10367240A1354 |131 145|cryoprotectionubinemia. P000
P10367240A1354 |33 44|spermatozoakaline phos
P10367240A1354 |184 208|fertilization procedures a function of CSF PCO2 
P10367385A0000 |49 57|analysisses and 
P10367385A0000 |61 74|beta-carotenecleotidase P0
P10367385A0000 |25 31|method with 
P10367385A0000 |86 90|food Pha
P10367460A0191 |84 111|V maximum capacitor voltage00 Pharmacologic aspects of
P10367460A0191 |180 192|Hz frequencyn as a funct
P10367460A0191 |61 78|power consumptioncleotidase P00008
P10367460A0191 |164 168|time [HC
P10367460A0191 |39 49|kW maximum phosphata
P10367460A0191 |146 158|microseconds8997A0472 Wh
P10367460A0191 |4 19|FCMS conditions01606T0076 Comp
P10367460A0191 |117 129|microsecondstal hyperbil
P10367646A0569 |170 177|calcium-] is s
P10367646A0569 |215 222|albumina of K-
P10367646A0569 |242 243|P 
P10367646A0569 |183 198|serum globulinss a function of
P10367646A0569 |133 142|increasesinemia. P
P10367646A0569 |107 115|additions of neo
P10367646A0569 |55 62|changesd 5-nuc
P10367646A0569 |144 168|alanine aminotransferase008997A0472 When CSF [HC
P10367646A0569 |95 103|analyteslogic as
P10367646A0569 |233 240|proteints are 
P10367646A0569 |7 16|hemolysis06T0076 C
P10367646A0569 |200 201|PS
P10367646A0569 |70 81|mean valuese P00008171
P10369418A0644 |102 121|NF-kappaB complexesspects of neonatal 
P10369418A0644 |89 98|inductionarmacolog
P10369418A0644 |153 168|NF-kappaB sites72 When CSF [HC
P10369418A0644 |237 240|p65re 
P10369418A0644 |196 199|p50of 
P10369418A0644 |24 32|extractsn with a
P10369418A0644 |227 232|c-Relted r
P10369418A0644 |0 4|EMSAP000
P10369418A0644 |204 208|RelBCO2 
P10369418A0644 |51 62|stimulations and 5-nuc
P10369418A0644 |68 73|CD40Lase P
P10369625A0942 |22 25|ODAson
P10369625A0942 |8 18|monitoring6T0076 Com
P10369757A0000 |306 319|transcriptionnificantly gr
P10369757A0000 |215 224|complexesa of K-de
P10369757A0000 |333 338|genes.21 +
P10369757A0000 |88 105|Bacillus subtilisharmacologic aspe
P10369757A0000 |181 182|l 
P10369757A0000 |107 111|ArgRs of
P10369757A0000 |44 63|arginine metabolismphatases and 5-nucl
P10369757A0000 |116 120|AhrCatal
P10369757A0000 |247 260|transcriptioner displaced 
P10369757A0000 |367 391|plasmid dimer resolutionurazepam thus appears to
P10369757A0000 |10 31|transcription factors0076 Comparison with 
P10369757A0000 |281 286|genesrols 
P10369757A0000 |162 170|proteinsSF [HCO3
P10369757A0000 |340 344|AhrC 0.2
P10369775A0178 |84 106|residues Lys438-Gln52000 Pharmacologic aspec
P10369775A0178 |41 63|residues Arg183-His267hosphatases and 5-nucl
P10369775A0178 |12 29|protein fragments76 Comparison wit
P10369775A0178 |77 79|ER81
P10369775A0178 |114 120|rat GRonatal
P10369926A0251 |137 156|CXC chemokine genesia. P00008997A0472 
P10369926A0251 |9 25|intron structureT0076 Comparison
P10369926A0251 |29 40|chicken IL8h alkaline 
P10369926A0251 |4 8|exon0160
P10369926A0251 |85 88|IL80 P
P10369965A0000 |48 75|basidiocarp differentiationases and 5-nucleotidase P00
P10369965A0000 |83 109|mushroom Agrocybe aegerita000 Pharmacologic aspects 
P10369965A0000 |4 16|Aa-Pri2 gene01606T0076 C
P10370675A0649 |138 141|HCVa. 
P10370675A0649 |63 80|hepatitis C viruseotidase P0000817
P10370675A0649 |123 134|combinationperbilirubi
P10370675A0649 |90 91|%r
P10370675A0649 |19 32|liver diseasearison with a
P10370675A0649 |54 57|HCCnd 
P10370675A0649 |82 85|HCV000
P10370675A0649 |146 159|alcohol abuse8997A0472 Whe
P10370675A0649 |94 107|alcohol abuseologic aspect
P10370675A0649 |111 112|% 
P10370675A0649 |40 48|patientsphosphat
P10370675A0649 |9 15|causesT0076 
P10370675A0649 |163 164|%F
P10370778A0000 |103 116|breast cancerpects of neon
P10370778A0000 |55 60|phased 5-n
P10370778A0000 |263 271|vorozolen compar
P10370778A0000 |249 257|Novartis displac
P10370778A0000 |179 196|tamoxifen therapywn as a function 
P10370778A0000 |148 155|disease97A0472
P10370778A0000 |211 219|ARIMIDEX data of
P10370778A0000 |241 247|FEMARAo long
P10370778A0000 |230 239|letrozole rats are
P10370778A0000 |10 30|aromatase inhibitors0076 Comparison with
P10370778A0000 |79 88|treatment71T0000 P
P10370778A0000 |198 209|anastrozole CSF PCO2 t
P10370778A0000 |221 227|Zeneca-deple
P10370778A0000 |65 75|evaluationtidase P00
P10370778A0000 |282 289|Janssenols but
P10370778A0000 |273 280|RIVIZOR to con
P10370778A0000 |136 141|womenmia. 
P10371097A0963 |0 11|CONCLUSIONSP00001606T0
P10371097A0963 |158 168|Turbuhaleren CSF [HC
P10371097A0963 |37 41|toolne p
P10371097A0963 |132 152|inhalation techniquebinemia. P00008997A0
P10371097A0963 |13 22|Turbutest6 Compari
P10371097A0963 |55 63|patientsd 5-nucl
P10371097A0963 |65 73|trainingtidase P
P10371097A0963 |84 98|identification00 Pharmacolog
P10371097A0963 |103 114|improvementpects of ne
P10372627A0530 |34 43|snowboardaline pho
P10372627A0530 |60 65|casesucleo
P10372627A0530 |9 17|injuriesT0076 Co
P10372627A0530 |23 28|caseson wi
P10373029A0204 |32 38|soleuslkalin
P10373029A0204 |12 23|artery/vein76 Comparis
P10373029A0204 |43 64|gastrocnemius musclessphatases and 5-nucle
P10373029A0204 |101 111|volunteersaspects of
P10373507A0680 |152 163|alpha-actin472 When CS
P10373507A0680 |180 223|SRF promoter-luciferase reporter activitiesn as a function of CSF PCO2 the data of K-d
P10373507A0680 |165 174|SM22alpha[HCO3-] i
P10373507A0680 |111 122|alpha-actin neonatal h
P10373507A0680 |132 143|alpha-actinbinemia. P0
P10373507A0680 |69 75|mutantse P00
P10373507A0680 |0 9|SRFDelta5P00001606
P10373523A0924 |21 27|p50E4Fison w
P10373523A0924 |14 19|media Comp
P10373523A0924 |52 61|apoptosis and 5-nu
P10374632A0818 |19 25|effectarison
P10374632A0818 |75 78|NBP008
P10374632A0818 |83 90|mg.kg-1000 Pha
P10374632A0818 |29 32|Nimh a
P10374632A0818 |4 11|potency01606T0
P10374632A0818 |38 45|mg.kg-1e phosp
P10374632A0897 |0 10|CONCLUSIONP00001606T
P10374632A0897 |12 29|NBP pre-treatment76 Comparison wit
P10374632A0897 |90 100|RMCAO ratsrmacologic
P10374632A0897 |78 86|striatum171T0000
P10374632A0897 |70 74|rCBFe P0
P10375107A1138 |0 11|ProgressionP00001606T0
P10375107A1138 |109 119|metastasisof neonata
P10375107A1138 |29 41|chemotherapyh alkaline p
P10375107A1138 |95 103|patientslogic as
P10375107A1138 |82 90|survival0000 Pha
P10375638A0859 |119 124|cellsl hyp
P10375638A0859 |93 103|efficiencycologic as
P10375638A0859 |74 78|mRNA0008
P10375638A0859 |37 53|NRF-1 expressionne phosphatases 
P10375638A0859 |144 162|translation system008997A0472 When C
P10375638A0859 |23 27|UTR1on w
P10375638A0859 |0 9|MutationsP00001606
P10375640A0153 |50 54|cDNAes a
P10375640A0153 |79 92|reading frame71T0000 Pharm
P10375640A0153 |56 61|CBS-1 5-nu
P10375640A0153 |23 42|nucleotide sequenceon with alkaline ph
P10375640A0153 |111 122|amino acids neonatal h
P10375640A0153 |141 147|weightP00008
P10375640A0153 |155 158|kDa Wh
P10375694T0000 |103 109|monkeypects 
P10375694T0000 |166 176|motor areaHCO3-] is 
P10375694T0000 |77 87|motor area8171T0000 
P10375694T0000 |131 142|input zonesubinemia. P
P10375694T0000 |111 121|comparison neonatal 
P10375694T0000 |39 50|input zones phosphatas
P10375718A0000 |87 100|animal modelsPharmacologic
P10375718A0000 |121 135|administrationhyperbilirubin
P10375718A0000 |110 117|methodsf neona
P10375718A0000 |63 75|angiogenesiseotidase P00
P10375718A0000 |6 30|fibroblast growth factor606T0076 Comparison with
P10375718A0000 |32 36|bFGFlkal
P10376065A0881 |115 128|spring filternatal hyperbi
P10376065A0881 |133 144|RF02 filterinemia. P00
P10376065A0881 |72 78|medianP00008
P10376065A0881 |62 70|pressureleotidas
P10376065A0881 |36 45|elevationine phosp
P10376065A0881 |92 97|mm Hgacolo
P10376065A0881 |5 12|filters1606T00
P10376065A0881 |99 100|nc
P10376446A0000 |68 74|methodase P0
P10376446A0000 |165 170|cycle[HCO3
P10376446A0000 |134 136|LPne
P10376446A0000 |98 101|PLRic 
P10376446A0000 |59 65|2-hournucleo
P10376446A0000 |126 132|lutealbiliru
P10376446A0000 |11 16|women076 C
P10376446A0000 |28 33|yearsth al
P10376446A0000 |86 89|leg Ph
P10376446A0000 |18 21|agepar
P10376446A0000 |138 144|phasesa. P00
P10376446A0000 |118 120|FPal
P10376873A0706 |36 39|UTRine
P10376873A0706 |6 12|sgRNA2606T00
P10376874A0759 |205 212|supportO2 the 
P10376874A0759 |246 257|interactionger displac
P10376874A0759 |178 185|proteinown as 
P10376874A0759 |24 31|defectsn with 
P10376874A0759 |98 111|protein eRF3Cic aspects of
P10376874A0759 |39 60|eRF1-eRF3 interaction phosphatases and 5-n
P10376874A0759 |136 149|eRF1 proteinsmia. P0000899
P10376874A0759 |221 229|presence-deplete
P10376877A0611 |0 7|RemovalP000016
P10376877A0611 |36 44|segmentsine phos
P10376877A0611 |112 119|Ss rRNAneonata
P10376877A0611 |213 221|18S rRNAata of K
P10376877A0611 |199 209|productionCSF PCO2 t
P10376877A0611 |161 167|regionCSF [H
P10376877A0611 |65 69|halftida
P10376877A0611 |96 105|formationogic aspe
P10376877A0611 |175 182|protein shown 
P10376877A0611 |138 142|parta. P
P10376991A0977 |0 3|RasP00
P10376991A0977 |31 39|tegumentalkaline
P10377345A0740 |0 5|GreenP0000
P10377345A0740 |126 133|regionsbilirub
P10377345A0740 |45 61|UNC-49C subunitshatases and 5-nu
P10377345A0740 |81 93|muscle cellsT0000 Pharma
P10377345A0740 |33 40|UNC-49Bkaline 
P10377438A0647 |58 61|TEL-nu
P10377438A0647 |15 22|proteinCompari
P10377438A0647 |24 28|UBC9n wi
P10378989A0000 |16 21|studyompar
P10378989A0000 |122 130|patientsyperbili
P10378989A0000 |165 170|Italy[HCO3
P10378989A0000 |140 145|years P000
P10378989A0000 |197 204|Januaryf CSF P
P10378989A0000 |57 64|reports5-nucle
P10378989A0000 |183 189|periods a fu
P10378989A0000 |149 152|age7A0
P10378989A0000 |4 7|aim016
P10378989A0000 |157 163|Sicilyhen CS
P10378989A0000 |216 224|December of K-de
P10378989A0000 |86 100|drug reactions Pharmacologic
P10379547A0000 |0 9|MoleculesP00001606
P10379547A0000 |13 16|NH36 C
P10379547A0000 |63 68|MASEReotid
P10379547A0000 |52 61|radiation and 5-nu
P10379899A0446 |77 84|signals8171T00
P10379899A0446 |130 154|theca cell layer markersrubinemia. P00008997A047
P10379899A0446 |26 33|studieswith al
P10379899A0446 |10 18|findings0076 Com
P10379899A0446 |108 117|follicles of neona
P10379942A0956 |101 118|MDV2 UL10 proteinaspects of neonat
P10379942A0956 |30 38|residues alkalin
P10379942A0956 |89 93|partarma
P10379942T0000 |0 14|IdentificationP00001606T0076
P10379942T0000 |106 126|glycoprotein M genests of neonatal hyper
P10379942T0000 |44 66|disease virus serotypephatases and 5-nucleot
P10379942T0000 |90 100|comparisonrmacologic
P10379942T0000 |36 41|Marekine p
P10379942T0000 |130 150|Herpesviridae familyrubinemia. P00008997
P10379942T0000 |19 28|structurearison wi
P10379942T0000 |69 88|glycoprotein M genese P00008171T0000 P
P10380232A0000 |0 9|OBJECTIVEP00001606
P10380232A0000 |214 220|emesista of 
P10380232A0000 |88 110|regimen-chlorpromazineharmacologic aspects o
P10380232A0000 |183 187|TROPs a 
P10380232A0000 |301 313|perspectivesa significan
P10380232A0000 |328 336|patientspe (1.21
P10380232A0000 |53 56|CEAand
P10380232A0000 |113 126|dexamethasoneeonatal hyper
P10380232A0000 |144 181|5-HT3 receptor antagonist-tropisetron008997A0472 When CSF [HCO3-] is shown
P10380232A0000 |266 274|childrenompared 
P10380232A0000 |24 51|cost-effectiveness analysisn with alkaline phosphatase
P10380232A0000 |315 323|hospitaly greate
P10380232A0000 |250 262|chemotherapydisplaced wh
P10380232A0000 |128 135|CPM-DEXlirubin
P10380232A0000 |197 204|controlf CSF P
P10380659A0545 |0 13|Baseline dataP00001606T007
P10380659A0545 |36 42|adultsine ph
P10380800A0194 |252 260|ancestorsplaced 
P10380800A0194 |177 183|dsRNAshown a
P10380800A0194 |227 237|host plantted rats a
P10380800A0194 |149 155|dsRNAs7A0472
P10380800A0194 |105 127|RNA polymerase domainscts of neonatal hyperb
P10380800A0194 |20 30|nucleotiderison with
P10380800A0194 |43 63|amino acid sequencessphatases and 5-nucl
P10380800A0194 |71 83|core regions P00008171T0
P10380800A0194 |2 12|comparison0001606T00
P10380878A0542 |136 155|histone deacetylasemia. P00008997A0472
P10380878A0542 |44 50|regionphatas
P10380878A0542 |54 58|Bin1nd 5
P10380878A0542 |110 113|DNAf n
P10380878A0542 |21 32|possibilityison with a
P10380878A0542 |87 106|repression functionPharmacologic aspec
P10380890A0619 |102 104|IRsp
P10380890A0619 |12 21|sequences76 Compar
P10381257A0000 |68 93|preprotein import complexase P00008171T0000 Pharma
P10381257A0000 |30 37|metaxin alkali
P10381257A0000 |133 146|mitochondrioninemia. P0000
P10381257A0000 |107 115|membranes of neo
P10381257A0000 |53 62|componentand 5-nuc
P10381257A0000 |21 28|proteinison wi
P10381377T0000 |64 69|SHIP2otida
P10381377T0000 |91 101|regulationmacologic 
P10381377T0000 |105 122|insulin signalingcts of neonatal h
P10381377T0000 |10 17|cloning0076 Co
P10381377T0000 |79 83|role71T0
P10381377T0000 |40 60|inositol phosphatasephosphatases and 5-n
P10381377T0000 |21 24|ratiso
P10381570A1355 |0 4|Slp1P000
P10381570A1355 |54 65|yeast cellsnd 5-nucleo
P10381570A1355 |132 151|interstripe regionsbinemia. P00008997A
P10381570A1355 |104 113|repressorects of n
P10381570A1355 |164 170|stages [HCO3
P10381570A1355 |15 28|transcriptionComparison wi
P10381570A1355 |38 50|binding sitee phosphatas
P10381570A1355 |174 187|embryogenesiss shown as a 
P10381570A1355 |87 91|rolePhar
P10381570A1355 |117 128|ftz stripestal hyperbi
P10383764A1809 |70 83|homomultimerse P00008171T0
P10383764A1809 |106 117|informationts of neona
P10383764A1809 |271 278|channeled to c
P10383764A1809 |54 66|VirB4 dimersnd 5-nucleot
P10383764A1809 |39 44|model phos
P10383764A1809 |294 308|export machinel have a signi
P10383764A1809 |126 134|assemblybilirubi
P10383764A1809 |229 237|activityd rats a
P10383764A1809 |4 11|results01606T0
P10383764A1809 |140 161|transenvelope channel P00008997A0472 When 
P10383764A1809 |21 28|studiesison wi
P10383764A1809 |190 202|DNA transferction of CSF
P10383966A0000 |119 128|cell walll hyperbi
P10383966A0000 |92 101|componentacologic 
P10383966A0000 |62 75|peptidoglycanleotidase P00
P10383966A0000 |4 31|penicillin binding proteins01606T0076 Comparison with 
P10383966A0000 |33 37|PBPskali
P10384129A0000 |137 148|individualsia. P000089
P10384129A0000 |94 97|CD4olo
P10384129A0000 |79 90|populations71T0000 Pha
P10384129A0000 |11 15|TCRA076 
P10384129A0000 |61 65|PBMCcleo
P10384129A0000 |44 55|RNA samplesphatases an
P10384129A0000 |100 103|CD8 as
P10384129A0000 |113 120|T cellseonatal
P10384129A0000 |0 9|TCR alphaP00001606
P10384129A0000 |17 27|expressionmparison w
P10385384A0654 |35 42|xylitolline ph
P10385384A0654 |47 56|activatortases and
P10385384A0654 |8 15|results6T0076 
P10385384A0654 |64 89|pentose phosphate pathwayotidase P00008171T0000 Ph
P10385395A0000 |171 176|gland] is 
P10385395A0000 |30 33|HDL al
P10385395A0000 |83 101|cholesteryl esters000 Pharmacologic 
P10385395A0000 |67 78|cholesteroldase P00008
P10385395A0000 |9 28|density lipoproteinT0076 Comparison wi
P10385395A0000 |57 63|uptake5-nucl
P10385395A0000 |181 187|gonads as a 
P10385395A0000 |35 43|receptorline pho
P10385395A0000 |143 155|HDL particle0008997A0472
P10385395A0000 |103 113|substratespects of n
P10385395A0000 |118 133|steroidogenesisal hyperbilirub
P10385915A1341 |0 7|D3S1261P000016
P10385915A1341 |120 122|cM h
P10385915A1341 |75 82|D3S1766008171T
P10385915A1341 |45 55|MITF locushatases an
P10385915A1341 |131 139|distanceubinemia
P10385915A1341 |63 70|D3S2465eotidas
P10385915A1341 |145 149|side0899
P10385915A1341 |100 105|locus aspe
P10388670A1976 |154 162|adhesion2 When C
P10388670A1976 |82 92|dispersant0000 Pharm
P10388670A1976 |43 55|storage timesphatases an
P10388670A1976 |116 123|storageatal hy
P10388670A1976 |4 15|percentages01606T0076 
P10388670A1976 |19 27|recoveryarison w
P10388670A1976 |70 78|additione P00008
P10390158A1150 |0 15|Point mutationsP00001606T0076 
P10390158A1150 |44 57|Pit-1 bindingphatases and 
P10390158A1150 |23 27|siteon w
P10390158A1150 |81 103|tiGH promoter activityT0000 Pharmacologic as
P10390538T0000 |23 42|zinc-finger proteinon with alkaline ph
P10390538T0000 |67 76|sequencesdase P000
P10391075A0000 |116 127|brain tumoratal hyperb
P10391075A0000 |62 71|sclerosisleotidase
P10391075A0000 |131 143|MRI findingsubinemia. P0
P10391075A0000 |20 32|autopsy caserison with a
P10391246A0756 |69 86|kinase activitiesse P00008171T0000
P10391246A0756 |13 18|MOM-46 Com
P10391246A0756 |41 49|proteinshosphata
P10391246A0756 |23 27|TAK1on w
P10391277A0000 |0 10|BACKGROUNDP00001606T
P10391277A0000 |93 105|fibrillationcologic aspe
P10391277A0000 |41 50|treatmenthosphatas
P10391277A0000 |54 60|choicend 5-n
P10391277A0000 |16 24|MAZE-IIIompariso
P10391903T0000 |0 4|Gab2P000
P10391903T0000 |12 31|pleckstrin homology76 Comparison with 
P10391903T0000 |99 109|ERK kinasec aspects 
P10391903T0000 |113 118|Elk-1eonat
P10391903T0000 |50 65|adapter proteines and 5-nucleo
P10391903T0000 |84 93|signaling00 Pharma
P10392266A0111 |101 109|activityaspects 
P10392266A0111 |128 142|immunoglobulinlirubinemia. P
P10392266A0111 |26 35|xanthomaswith alka
P10392266A0111 |4 12|presence01606T00
P10392266A0111 |48 66|serum lipid levelsases and 5-nucleot
P10392669A0935 |141 175|prostaglandin analogue misoprostolP00008997A0472 When CSF [HCO3-] is
P10392669A0935 |589 599|preventiond CO2 prod
P10392669A0935 |318 327|reductionreater sl
P10392669A0935 |439 449|ranitidinedose for u
P10392669A0935 |252 262|preventionsplaced wh
P10392669A0935 |667 677|omeprazoletravenous 
P10392669A0935 |417 431|H2 antagonistsdrug with the 
P10392669A0935 |900 911|gastropathynd decrease
P10392669A0935 |301 307|ulcersa sign
P10392669A0935 |362 375|complications33 Flurazepam
P10392669A0935 |539 545|ulcers3A0210
P10392669A0935 |625 631|ulcersntilat
P10392669A0935 |95 105|approacheslogic aspe
P10392669A0935 |451 461|cimetidine in genera
P10392669A0935 |639 661|proton pump inhibitorsst ceased. P00015731A0
P10392669A0935 |28 37|incidenceth alkali
P10392669A0935 |791 805|barrier agentsame) induced a
P10392669A0935 |855 874|prophylactic agentsnot dependent on in
P10392669A0935 |502 512|prevention3T0045 Bet
P10392669A0935 |382 415|histamine H2 receptor antagonistsppears to be an effective hypnoti
P10392669A0935 |130 133|userub
P10392669A0935 |743 749|ulcersolamid
P10392669A0935 |72 79|lesionsP000081
P10392669A0935 |466 476|famotidinectice bein
P10392669A0935 |703 711|efficacyof carbo
P10392669A0935 |558 572|term treatmentrporeal CO2 re
P10392669A0935 |199 203|drugCSF 
P10392669A0935 |6 13|attempt606T007
P10392669A0935 |683 695|pantoprazolestration (25
P10392710A1000 |0 15|Lung mesenchymeP00001606T0076 
P10392710A1000 |29 37|compleath alkali
P10392710A1000 |90 112|peptide growth factorsrmacologic aspects of 
P10392710A1000 |39 46|inducer phosph
P10392710A1000 |50 68|lung morphogenesises and 5-nucleotid
P10392900A1020 |117 141|tyrosine phosphorylationtal hyperbilirubinemia. 
P10392900A1020 |72 77|c-AblP0000
P10392900A1020 |145 159|RNA polymerase08997A0472 Whe
P10392900A1020 |56 68|localization 5-nucleotid
P10392900A1020 |22 34|HIV promoterson with alk
P10392900A1020 |4 14|activation01606T0076
P10392903A0000 |154 173|papillomavirus type2 When CSF [HCO3-] 
P10392903A0000 |106 125|carcinoma cell linets of neonatal hype
P10392903A0000 |177 180|DNAhow
P10392903A0000 |11 36|papillomavirus E2 protein076 Comparison with alkal
P10392903A0000 |53 66|proliferationand 5-nucleot
P10392903A0000 |70 80|HT-3 cellse P0000817
P10392903A0889 |0 16|E2 point mutantsP00001606T0076 C
P10392903A0889 |105 138|cell cycle inhibitors hydroxyureacts of neonatal hyperbilirubinemi
P10392903A0889 |63 69|cdc25Aeotida
P10392903A0889 |74 91|cdc25B expression0008171T0000 Phar
P10392903A0889 |143 151|mimosine0008997A
P10392903A0889 |35 46|cell growthline phosph
P10392914A0000 |68 72|ductase 
P10392914A0000 |30 41|arrangement alkaline p
P10392914A0000 |122 132|dilatationyperbiliru
P10392914A0000 |74 79|AAPBD00081
P10392914A0000 |172 188|tract malignancy is shown as a f
P10392914A0000 |0 18|BACKGROUND/PURPOSEP00001606T0076 Com
P10393192A0792 |0 24|Neurospora crassa CYT-18P00001606T0076 Compariso
P10393192A0792 |57 71|intron mutants5-nucleotidase
P10393192A0792 |97 103|defectgic as
P10393192A0792 |48 52|trapases
P10393197A0543 |0 4|DDP1P000
P10393197A0543 |42 59|interphase nucleiosphatases and 5-
P10393197A0543 |23 38|heterochromatinon with alkalin
P10393197A0543 |70 81|neuroblastse P00008171
P10393201A0654 |170 175|break-] is
P10393201A0654 |208 219|exonucleasethe data of
P10393201A0654 |192 200|additionion of C
P10393201A0654 |25 42|DNA repair system with alkaline ph
P10393201A0654 |78 98|DNA ligase III-XRCC1171T0000 Pharmacolog
P10393201A0654 |54 73|DNA polymerase betand 5-nucleotidase P
P10393201A0654 |138 150|base residuea. P00008997
P10393251A0283 |70 90|restriction analysise P00008171T0000 Pha
P10393251A0283 |22 33|insert sizeson with al
P10393251A0283 |37 42|120kbne ph
P10393251A0283 |4 13|PAC clone01606T007
P10393251T0000 |0 8|SequenceP0000160
P10393251T0000 |94 109|T-ALL cell lineologic aspects 
P10393251T0000 |12 23|10q24 locus76 Comparis
P10393251T0000 |40 54|HOX11 oncogenephosphatases a
P10393251T0000 |69 78|gene HUG1se P00008
P10393422A0476 |24 29|LAMB2n wit
P10393422A0476 |41 45|genehosp
P10393422A0476 |107 113|LAMB2Ls of n
P10393422A0476 |95 105|pseudogenelogic aspe
P10393422A0476 |9 11|kbT0
P10393910A0705 |116 120|siteatal
P10393910A0705 |97 101|partgic 
P10393910A0705 |128 140|endonucleaselirubinemia.
P10393910A0705 |14 25|mutagenesis Comparison
P10393910A0705 |157 164|elementhen CSF
P10393910A0705 |83 88|motif000 P
P10393910A0705 |64 72|evidenceotidase 
P10393910A0705 |33 43|R2 proteinkaline pho
P10393969A0000 |118 128|expressional hyperbi
P10393969A0000 |177 189|transfectionhown as a fu
P10393969A0000 |132 137|genesbinem
P10393969A0000 |13 29|cell protein no.6 Comparison wit
P10393969A0000 |164 173|infection [HCO3-] 
P10393969A0000 |82 96|transactivator0000 Pharmacol
P10393969A0000 |42 62|herpes simplex virusosphatases and 5-nuc
P10393969A0000 |33 37|ICP0kali
P10393969A0000 |155 160|cells When
P10394116T0000 |51 58|remarkss and 5
P10394116T0000 |62 74|oscillometryleotidase P0
P10394116T0000 |21 35|blood pressureison with alka
P10394116T0000 |0 17|Wrist measurementP00001606T0076 Co
P10394900A1166 |49 57|presenceses and 
P10394900A1166 |121 133|35S promoterhyperbilirub
P10394900A1166 |15 25|expressionComparison
P10394900A1166 |89 113|cauliflower mosaic virusarmacologic aspects of n
P10394900A1166 |29 35|leavesh alka
P10394900A1166 |64 79|enhancer regionotidase P000081
P10394900A1166 |115 119|CaMVnata
P10394919A1058 |8 15|element6T0076 
P10394919A1058 |45 54|amplitudehatases a
P10394919A1058 |62 73|oscillationleotidase P
P10395199A0792 |273 285|Virone-Oddos to controls
P10395199A0792 |314 318|W.H.ly g
P10395199A0792 |255 257|M.ac
P10395199A0792 |291 297|Multontill h
P10395199A0792 |191 207|tumor regressiontion of CSF PCO2
P10395199A0792 |355 361|Tocque0943A0
P10395199A0792 |299 303|M.C.e a 
P10395199A0792 |243 253|Kenigsberglonger dis
P10395199A0792 |363 365|B.3 
P10395199A0792 |320 333|Schweighofferater slope (1
P10395199A0792 |159 170|Ras pathwayn CSF [HCO3
P10395199A0792 |335 337|F.1 
P10395199A0792 |269 271|I.ar
P10395199A0792 |239 241|O. n
P10395199A0792 |305 312|Fridmangnifica
P10395199A0792 |32 39|controllkaline
P10395199A0792 |231 237|Cochetrats a
P10395199A0792 |43 54|experimentssphatases a
P10395199A0792 |287 289|A.ut
P10395199A0792 |134 145|mAb Y13-259nemia. P000
P10395199A0792 |84 93|Y259 scFv00 Pharma
P10395199A0792 |259 267|Delumeau when co
P10395199A0792 |218 229|mouse modelf K-deplete
P10395199A0792 |78 82|scFv171T
P10395199A0792 |349 353|J.L. P00
P10395199A0792 |5 9|scFv1606
P10395199A0792 |339 347|Teillaud- 0.23 v
P10395283A0960 |33 42|activin Akaline ph
P10395283A0960 |72 77|Smad4P0000
P10395283A0960 |47 51|OP-1tase
P10395283A0960 |13 24|competition6 Compariso
P10395283A0960 |128 145|signal transducerlirubinemia. P000
P10395283A0960 |56 68|availability 5-nucleotid
P10395283A0960 |99 112|concentrationc aspects of 
P10395283A0960 |201 210|responsesF PCO2 th
P10395378A1198 |155 170|fusion activity When CSF [HCO3
P10395378A1198 |99 106|ligandsc aspec
P10395378A1198 |129 132|endiru
P10395378A1198 |4 8|data0160
P10395378A1198 |64 88|HA envelope glycoproteinotidase P00008171T0000 P
P10395827A1297 |117 136|parallel beta sheettal hyperbilirubine
P10395827A1297 |61 65|coilcleo
P10395827A1297 |92 104|beta strandsacologic asp
P10395827A1297 |22 47|parallel beta helix modelson with alkaline phospha
P10395908A0236 |87 94|regionsPharmac
P10395908A0236 |104 135|amino acid motif characteristicects of neonatal hyperbilirubin
P10395908A0236 |143 153|R7G family0008997A04
P10395908A0236 |42 49|proteinosphata
P10395908A0236 |157 166|G-proteinhen CSF [
P10395908A0236 |190 199|receptorsction of 
P10395911A0288 |68 74|regionase P0
P10395911A0288 |24 55|chicken apolipoprotein A-I genen with alkaline phosphatases an
P10395911A0288 |0 16|CharacterisationP00001606T0076 C
P10395920A1424 |117 125|KGF genetal hype
P10395920A1424 |6 13|results606T007
P10395920A1424 |129 137|responseirubinem
P10395920A1424 |42 52|ATF familyosphatases
P10395920A1424 |27 34|membersith alk
P10395920A1424 |175 178|CRE sh
P10395920A1424 |99 109|regulationc aspects 
P10395920A1424 |190 197|elementction o
P10395920A1424 |155 162|stimuli When C
P10396343A0754 |85 93|suspects0 Pharma
P10396343A0754 |151 152|%0
P10396343A0754 |59 65|samplenucleo
P10396343A0754 |73 77|rest0000
P10396343A0754 |135 138|DNAemi
P10396343A0754 |31 44|blood samplesalkaline phos
P10396343A0754 |181 182|% 
P10396343A0754 |157 172|T. b. gambiensehen CSF [HCO3-]
P10396343A0754 |142 145|PCR000
P10396343A0754 |187 204|T. b. rhodesiensefunction of CSF P
P10396343A0754 |17 27|proportionmparison w
P10396343T0000 |87 101|TrypTect CIATTPharmacologic 
P10396343T0000 |47 65|agglutination testtases and 5-nucleo
P10396343T0000 |15 25|evaluationComparison
P10396343T0000 |33 37|cardkali
P10396343T0000 |70 85|trypanosomiasise P00008171T000
P10396793A0815 |0 7|ResultsP000016
P10396793A0815 |105 115|reductionscts of neo
P10396793A0815 |146 156|indicators8997A0472 
P10396793A0815 |160 178|alcohol dependence CSF [HCO3-] is sh
P10396793A0815 |123 133|prevalenceperbilirub
P10396793A0815 |12 15|men76 
P10396793A0815 |47 50|daytas
P10396793A0815 |36 42|drinksine ph
P10396793A0815 |199 200|%C
P10396793A0815 |71 90|dependence criteria P00008171T0000 Pha
P10396793A0815 |207 208|% 
P10397257A1142 |0 11|MutagenesisP00001606T0
P10397257A1142 |40 49|Sp1 sitesphosphata
P10397257A1142 |160 165|cells CSF 
P10397257A1142 |132 133|%b
P10397257A1142 |180 202|cell cycle periodicityn as a function of CSF
P10397257A1142 |224 229|cellsplete
P10397257A1142 |58 64|region-nucle
P10397257A1142 |78 89|combination171T0000 Ph
P10397257A1142 |115 123|activitynatal hy
P10397257A1142 |19 35|CDE/CHR elementsarison with alka
P10398286A0678 |16 25|procedureomparison
P10398286A0678 |46 57|comparisonsatases and 
P10398286A0678 |135 141|natureemia. 
P10398286A0678 |76 95|sample size methods08171T0000 Pharmaco
P10398286A0678 |145 148|S2p089
P10398286A0678 |6 13|Scheffe606T007
P10398286A0678 |32 44|illustrationlkaline phos
P10398682A0365 |68 78|resolutionase P00008
P10398682A0365 |29 38|VP16 coreh alkalin
P10398682A0365 |4 21|crystal structure01606T0076 Compar
P10399136A0389 |0 7|OzagrelP000016
P10399136A0389 |111 114|HPC ne
P10399136A0389 |9 19|ifenprodilT0076 Comp
P10399136A0389 |99 103|rCBFc as
P10399136A0389 |37 44|dilazepne phos
P10399136A0389 |21 32|cinnarizineison with a
P10399136A0389 |70 84|pentoxifyllinee P00008171T00
P10400032A0304 |119 129|managementl hyperbil
P10400032A0304 |11 17|method076 Co
P10400032A0304 |76 87|hypotension08171T0000 
P10400032A0304 |48 57|vena cavaases and 
P10400593A1084 |3 11|contrast001606T0
P10400593A1084 |13 18|PvirE6 Com
P10400593A1084 |22 46|Plac promoter constructsson with alkaline phosph
P10400593A1084 |107 112|virE2s of 
P10400593A1084 |66 71|VirE2idase
P10400593A1084 |80 85|virE11T000
P10400712A0000 |7 26|parainfluenza virus06T0076 Comparison 
P10400712A0000 |40 49|prototypephosphata
P10400712A0000 |30 33|SV5 al
P10400712A0000 |57 79|Paramyxoviridae family5-nucleotidase P000081
P10400712A0000 |111 122|RNA viruses neonatal h
P10400712A0577 |32 34|GElk
P10400712A0577 |135 145|SV5 genomeemia. P000
P10400712A0577 |259 261|HN w
P10400712A0577 |19 28|functionsarison wi
P10400712A0577 |184 186|GE a
P10400712A0577 |188 190|IGun
P10400712A0577 |159 182|gene junction sequencesn CSF [HCO3-] is shown 
P10400712A0577 |271 281|polymeraseed to cont
P10400712A0577 |60 73|transcriptionucleotidase P
P10400712A0577 |90 98|plasmidsrmacolog
P10400712A0577 |230 257|hemagglutinin-neuraminidase rats are no longer displac
P10400712A0577 |315 336|counterpart sequencesy greater slope (1.21
P10400712A0577 |348 362|gene junctions. P00010943A07
P10400712A0577 |286 291|genesbut s
P10400712A0577 |44 56|GS sequencesphatases and
P10400712A0577 |110 115|cDNAsf neo
P10400712A0577 |196 208|GS sequencesof CSF PCO2 
P10400712A0577 |283 284|Ll
P10400712A0577 |36 38|IGin
P10400757A0000 |0 5|CXCR4P0000
P10400757A0000 |11 29|chemokine receptor076 Comparison wit
P10400757A0000 |135 140|HIV-1emia.
P10400757A0000 |104 131|immunodeficiency virus typeects of neonatal hyperbilir
P10400757A0000 |142 150|isolates00008997
P10400757A0000 |92 96|R5X4acol
P10400757A0000 |36 46|coreceptorine phosph
P10400757A0000 |71 73|X4 P
P10400757A1498 |34 40|detailaline 
P10400757A1498 |218 223|HIV-1f K-d
P10400757A1498 |6 10|data606T
P10400757A1498 |196 201|CXCR4of CS
P10400757A1498 |62 74|requirementsleotidase P0
P10400757A1498 |45 50|CXCR4hatas
P10400757A1498 |185 192|domainsa funct
P10400757A1498 |98 111|HIV-1 strainsic aspects of
P10400757A1498 |237 251|fusion processre no longer d
P10400757A1498 |136 155|mutagenesis effortsmia. P00008997A0472
P10400760A0663 |70 99|amino acid residues E960-A961e P00008171T0000 Pharmacologi
P10400760A0663 |157 176|cleavage efficiencyhen CSF [HCO3-] is 
P10400760A0663 |114 125|E1345-T1346onatal hype
P10400760A0663 |131 142|E1419-G1420ubinemia. P
P10400760A0663 |21 29|analysesison wit
P10400760A0663 |4 11|results01606T0
P10400760A0663 |48 58|proteinaseases and 5
P10400760A0663 |101 112|E1071-S1072aspects of 
P10400774A0240 |0 2|y.P0
P10400785A0912 |0 2|SMP0
P10400785A0912 |132 154|nucleoporin CAN/Nup214binemia. P00008997A047
P10400785A0912 |53 63|componentsand 5-nucl
P10400785A0912 |77 91|export pathway8171T0000 Phar
P10400785A0912 |113 123|GTPase Raneonatal hy
P10400785A0912 |71 74|CRM P0
P10400794T0000 |102 114|similaritiesspects of ne
P10400794T0000 |125 142|membrane proteinsrbilirubinemia. P
P10400794T0000 |89 96|proteinarmacol
P10400794T0000 |149 151|2A7A
P10400794T0000 |28 32|geneth a
P10400794T0000 |38 44|Kaposie phos
P10400794T0000 |66 77|herpesvirusidase P0000
P10400794T0000 |168 173|virusO3-] 
P10400794T0000 |0 14|IdentificationP00001606T0076
P10402022A0432 |32 36|ratelkal
P10402022A0432 |9 15|clicksT0076 
P10402022A0432 |43 44|ss
P10402467T0000 |0 6|MyosinP00001
P10402467T0000 |130 135|cellsrubin
P10402467T0000 |13 25|chain kinase6 Comparison
P10402467T0000 |97 108|plasminogengic aspects
P10402467T0000 |161 167|mannerCSF [H
P10402467T0000 |50 57|Ras/ERKes and 
P10402467T0000 |69 78|migrationse P00008
P10403575A1401 |102 116|control levelsspects of neon
P10403575A1401 |45 50|DAX-1hatas
P10403575A1401 |97 98|%g
P10403575A1401 |79 92|transcription71T0000 Pharm
P10403575A1401 |4 14|inhibition01606T0076
P10403575A1401 |18 41|StAR gene transcriptionparison with alkaline p
P10403690A0000 |275 286|IEP regimeno controls 
P10403690A0000 |97 107|stage IIIbgic aspect
P10403690A0000 |500 504|days653T
P10403690A0000 |315 334|mesna uroprotectiony greater slope (1.
P10403690A0000 |434 439|mg/m2imum 
P10403690A0000 |288 298|ifosfamidet still ha
P10403690A0000 |119 142|ECOG performance statusl hyperbilirubinemia. P
P10403690A0000 |488 493|mg/m2ight.
P10403690A0000 |249 273|combination chemotherapy displaced when compared
P10403690A0000 |301 306|gm/m2a sig
P10403690A0000 |420 431|mitomycin-Cg with the 
P10403690A0000 |362 365|day33 
P10403690A0000 |144 146|PS00
P10403690A0000 |214 218|careta o
P10403690A0000 |385 390|mg/m2ars t
P10403690A0000 |28 33|studyth al
P10403690A0000 |90 95|NSCLCrmaco
P10403690A0000 |239 243|care no 
P10403690A0000 |372 381|cisplatinpam thus 
P10403690A0000 |441 450|cisplatinse for us
P10403690A0000 |39 47|patients phospha
P10403690A0000 |467 470|daytic
P10403690A0000 |407 418|MVP regimen hypnotic d
P10403690A0000 |220 223|BSCK-d
P10403690A0000 |397 400|day ef
P10403690A0000 |455 460|mg/m2gener
P10403690A0000 |350 355|mg/m2P0001
P10403690A0000 |72 88|cell lung cancerP00008171T0000 P
P10403690A0000 |336 346|epirubicin +/- 0.23 
P10403690A0000 |474 485|vinblastineing 15 mg a
P10403839A0140 |154 169|splice variants2 When CSF [HCO
P10403839A0140 |6 26|sequence information606T0076 Comparison 
P10403839A0140 |198 202|gene CSF
P10403839A0140 |177 188|mouse BMAL1hown as a f
P10403839A0140 |133 138|cDNAsinemi
P10403839A0140 |45 51|hBMAL1hatase
P10403839A0140 |38 43|BMAL1e pho
P10403839A0140 |53 58|cDNAsand 5
P10403839A0140 |190 196|mBMAL1ction 
P10403839A0140 |86 96|laboratory Pharmacol
P10403839A1459 |0 10|ComparisonP00001606T
P10403839A1459 |242 246|gene lon
P10403839A1459 |166 169|AhrHCO
P10403839A1459 |90 96|mBMAL1rmacol
P10403839A1459 |60 86|intron/exon splice patternucleotidase P00008171T0000
P10403839A1459 |189 197|subclassnction o
P10403839A1459 |130 134|mAhrrubi
P10403839A1459 |20 41|bHLH/PAS family genesrison with alkaline p
P10403839A1459 |156 161|BMAL1When 
P10405635A0374 |50 58|promoteres and 5
P10405635A0374 |181 186|cells as a
P10405635A0374 |20 30|activitiesrison with
P10405635A0374 |86 105|deletion constructs Pharmacologic aspe
P10406047A1244 |102 108|heightspects
P10406047A1244 |114 124|complianceonatal hyp
P10406047A1244 |334 347|lung function21 +/- 0.23 v
P10406047A1244 |144 150|system008997
P10406047A1244 |92 98|weightacolog
P10406047A1244 |241 248|infantso longe
P10406047A1244 |193 204|ILD infantson of CSF P
P10406047A1244 |285 289|PFTs but
P10406047A1244 |164 170|weight [HCO3
P10406047A1244 |356 365|age group943A0733 
P10406047A1244 |257 261|PPHNed w
P10406047A1244 |174 185|lung volumes shown as 
P10406047A1244 |229 237|controlsd rats a
P10406047A1244 |70 78|capacitye P00008
P10406047A1244 |35 46|differencesline phosph
P10406122T0000 |102 116|responsivenessspects of neon
P10406122T0000 |146 162|methyl jasmonate8997A0472 When C
P10406122T0000 |120 134|tissue culture hyperbilirubi
P10406122T0000 |23 30|elementon with
P10406122T0000 |58 86|tobacco retrotransposon Tto1-nucleotidase P00008171T0000
P10406122T0000 |174 183|elicitorss shown a
P10406122T0000 |38 50|LTR promotere phosphatas
P10406459A0000 |221 230|magnitude-depleted
P10406459A0000 |181 204|Ser-133 phosphorylation as a function of CSF P
P10406459A0000 |134 138|CREBnemi
P10406459A0000 |172 179|protein is sho
P10406459A0000 |8 13|study6T007
P10406459A0000 |247 260|NIH 3T3 cellser displaced 
P10406459A0000 |106 109|TPAts 
P10406459A0000 |63 67|PDGFeoti
P10406459A0000 |48 61|growth factorases and 5-nu
P10406459A0000 |235 243|kinetics are no 
P10406459A0000 |116 125|forskolinatal hype
P10406459A0000 |70 104|12-O-tetradecanoyl-phorbol-acetatee P00008171T0000 Pharmacologic asp
P10406462A1127 |17 25|evidencemparison
P10406462A1127 |79 89|activation71T0000 Ph
P10406462A1127 |41 45|rolehosp
P10406462A1127 |93 105|OR1/RXRalphacologic aspe
P10406462A1127 |49 54|SRC-1ses a
P10406464A0687 |3 11|contrast001606T0
P10406464A0687 |13 36|mTRAP100 coprecipitates6 Comparison with alkal
P10406464A0687 |134 152|vitamin D receptornemia. P00008997A0
P10406464A0687 |75 87|TRAP complex008171T0000 
P10406464A0687 |58 67|component-nucleoti
P10406464A0687 |89 96|TRAP220armacol
P10406464A0687 |114 125|contacts TRonatal hype
P10406464A0687 |175 181|manner shown
P10406465A0589 |35 59|vitamin D responsivenessline phosphatases and 5-
P10406465A0589 |27 30|VDRith
P10406465A0589 |78 86|promoter171T0000
P10406465A0589 |5 13|sequence1606T007
P10406466A0000 |51 75|thyroid hormone receptors and 5-nucleotidase P00
P10406466A0000 |86 99|acid receptor Pharmacologi
P10406466A0000 |117 126|receptorstal hyper
P10406466A0000 |35 44|receptorsline phos
P10406843A1265 |0 10|ExpressionP00001606T
P10406843A1265 |14 28|GlcNAc-TI mRNA Comparison wi
P10406843A1265 |66 72|RT-PCRidase 
P10406843A1265 |32 39|tobaccolkaline
P10406954A0715 |0 24|Chemical stability testsP00001606T0076 Compariso
P10406954A0715 |43 54|mutagenesissphatases a
P10406954A0715 |94 98|RegSolog
P10406954A0715 |66 82|amino acids H219idase P00008171T
P10406954A0715 |145 153|residues08997A04
P10406954A0715 |87 90|D63Pha
P10406954A0715 |103 107|RegRpect
P10407184A0149 |49 54|areasses a
P10407184A0149 |123 137|neuropathologyperbilirubinem
P10407184A0149 |62 70|AD brainleotidas
P10407184A0149 |25 37|betaAPP gene with alkali
P10407184A0149 |109 115|factorof neo
P10407184A0149 |141 143|ADP0
P10407184A0149 |3 17|overexpression001606T0076 Co
P10407184A0520 |228 231|UREed 
P10407184A0520 |297 312|promoter regionave a significa
P10407184A0520 |124 127|CATerb
P10407184A0520 |242 252|prhbetaE-B longer di
P10407184A0520 |28 44|promoter regionsth alkaline phos
P10407184A0520 |88 122|chloramphenicol acetyl transferaseharmacologic aspects of neonatal h
P10407184A0520 |183 184|hs
P10407184A0520 |362 379|hbetaAPP promoter33 Flurazepam thu
P10407184A0520 |150 157|plasmidA0472 W
P10407184A0520 |134 143|phbetaE-Bnemia. P0
P10407184A0520 |186 201|promoter region function of CS
P10407184A0520 |259 266|plasmid when c
P10407184A0520 |323 326|UREr s
P10407184A0520 |293 295|rhll
P10407184A0520 |285 291|rhesus but s
P10407184A0520 |15 22|studiesCompari
P10407184A0520 |345 354|bp region vs. P000
P10407184A0520 |73 86|reporter gene00008171T0000
P10407269A0000 |139 143|part. P0
P10407269A0000 |82 85|arm000
P10407269A0000 |25 28|DNA wi
P10407269A0000 |8 10|bp6T
P10407269A0000 |89 113|fission yeast chromosomearmacologic aspects of n
P10407269A0000 |63 68|cdc14eotid
P10407269A0000 |192 217|genome sequencing projection of CSF PCO2 the data 
P10407269A0000 |151 165|European Union0472 When CSF 
P10407269A0000 |45 58|markers cdc18hatases and 5
P10407269A0000 |63 68|cdc14eotid
P10407269A0000 |192 217|genome sequencing projection of CSF PCO2 the data 
P10407269A0000 |151 165|European Union0472 When CSF 
P10407269A0000 |45 58|markers cdc18hatases and 5
P10407269A0000 |139 143|part. P0
P10407269A0000 |8 10|bp6T
P10407269A0000 |89 113|fission yeast chromosomearmacologic aspects of n
P10407269A0000 |25 28|DNA wi
P10407269A0000 |82 85|arm000
P10407985A0574 |0 5|G-CSFP0000
P10407985A0574 |11 21|micrograms076 Compar
P10407985A0574 |65 71|GM-CSFtidase
P10407985A0574 |77 92|micrograms s.c.8171T0000 Pharm
P10407985A0574 |38 42|s.c.e ph
P10407985A0574 |117 123|cyclestal hy
P10409656A1016 |0 14|OverexpressionP00001606T0076
P10409656A1016 |131 135|H411ubin
P10409656A1016 |182 185|LPSas 
P10409656A1016 |88 99|growth rateharmacologi
P10409656A1016 |165 178|cell response[HCO3-] is sh
P10409656A1016 |45 65|macrophage cell linehatases and 5-nucleo
P10409656A1016 |117 127|expressiontal hyperb
P10409656A1016 |18 27|H411 cDNAparison w
P10409656A1016 |139 143|part. P0
P10409656A1016 |35 38|RAWlin
P10409699A0292 |289 314|polymerase chain reaction still have a significant
P10409699A0292 |268 277|cDNA endspared to 
P10409699A0292 |189 208|mannosidase homolognction of CSF PCO2 
P10409699A0292 |159 172|coding regionn CSF [HCO3-]
P10409699A0292 |92 97|yeastacolo
P10409699A0292 |125 137|mannosidasesrbilirubinem
P10409699A0292 |227 238|combinationted rats ar
P10409699A0292 |251 264|amplificationisplaced when
P10409699A0292 |336 340|cDNA +/-
P10409699A0292 |55 74|sequence similarityd 5-nucleotidase P0
P10409699A0292 |16 35|sequence tag clonesomparison with alka
P10409724A1021 |0 10|ActivationP00001606T
P10409724A1021 |14 20|ERK1/2 Compa
P10409724A1021 |73 87|response genes00008171T0000 
P10409724A1021 |40 49|inductionphosphata
P10409730A0597 |87 89|bpPh
P10409730A0597 |122 135|transcriptionyperbilirubin
P10409730A0597 |108 118|initiation of neonat
P10409730A0597 |26 34|RP geneswith alk
P10409730A0597 |4 17|transcription01606T0076 Co
P10409730A0597 |55 74|Rap1p binding sitesd 5-nucleotidase P0
P10409741A0382 |69 76|cdc4-16se P000
P10409741A0382 |105 120|division defectcts of neonatal
P10409741A0382 |30 37|alleles alkali
P10409741A0382 |41 45|CDC4hosp
P10409741A0382 |47 54|cdc4-10tases a
P10409741A0382 |56 63|cdc4-11 5-nucl
P10409741A0382 |124 137|cdc20-1 cellserbilirubinem
P10409749T0000 |0 4|RoleP000
P10409749T0000 |31 45|discriminationalkaline phosp
P10409749T0000 |81 91|activatorsT0000 Phar
P10409749T0000 |18 27|structureparison w
P10409755A1846 |3 10|summary001606T
P10409755A1846 |29 39|activationh alkaline
P10409755A1846 |12 14|Ca76
P10409755A1846 |82 93|TG exposure0000 Pharma
P10409755A1846 |43 56|NO productionsphatases and
P10409755A1846 |97 109|JT/Neo cellsgic aspects 
P10409755A1846 |66 75|apoptosisidase P00
P10411139A0887 |0 12|AccumulationP00001606T00
P10411139A0887 |77 83|Prp44p8171T0
P10411139A0887 |20 32|U4/U6 duplexrison with a
P10411139A0887 |49 63|overexpressionses and 5-nucl
P10411139A1344 |4 11|results01606T0
P10411139A1344 |88 92|roleharm
P10411139A1344 |62 69|resultsleotida
P10411139A1344 |124 135|U4/U6 helixerbilirubin
P10411139A1344 |97 103|Prp44pgic as
P10411140A0499 |102 107|mRNAsspect
P10411140A0499 |88 94|regionharmac
P10411140A0499 |120 130|terminator hyperbili
P10411140A0499 |26 29|RNAwit
P10411140A0499 |50 66|RNase E cleavagees and 5-nucleot
P10411160T0000 |55 76|skin cancer incidenced 5-nucleotidase P000
P10411160T0000 |28 39|variabilityth alkaline
P10411160T0000 |4 13|mysteries01606T007
P10413604A0063 |157 170|DNA synthesishen CSF [HCO3
P10413604A0063 |123 132|mechanismperbiliru
P10413604A0063 |47 54|kinasestases a
P10413604A0063 |56 60|PKAs 5-n
P10413604A0063 |82 88|growth0000 P
P10413607A0085 |170 180|cell types-] is show
P10413607A0085 |133 146|DNA synthesisinemia. P0000
P10413607A0085 |226 245|signal transductioneted rats are no lo
P10413607A0085 |114 117|CVIona
P10413607A0085 |65 81|matrix moleculestidase P00008171
P10413607A0085 |33 41|contrastkaline p
P10413607A0085 |101 112|collagen VIaspects of 
P10413662A0193 |102 109|plasmidspects 
P10413662A0193 |125 148|iron acquisition systemrbilirubinemia. P000089
P10413662A0193 |94 98|pJM1olog
P10413662A0193 |166 175|virulenceHCO3-] is
P10413662A0193 |39 64|pMJ101 replication region phosphatases and 5-nucle
P10413662A0193 |179 193|V. anguillarumwn as a functi
P10413662A0193 |217 225|pathogenof K-dep
P10413662A0193 |238 247|vibriosise no long
P10413676A0000 |17 22|sitesmpari
P10413676A0000 |26 68|transmembrane integrin receptor clusteringwith alkaline phosphatases and 5-nucleotid
P10413676A0000 |99 115|signaling eventsc aspects of neo
P10413676A0000 |0 3|FAKP00
P10413676A0595 |0 10|ExpressionP00001606T
P10413676A0595 |292 308|paxillin bindingill have a signi
P10413676A0595 |190 196|domainction 
P10413676A0595 |251 254|FAKisp
P10413676A0595 |22 33|FAK mutantsson with al
P10413676A0595 |89 96|Tyr-397armacol
P10413676A0595 |149 167|SH3 binding region7A0472 When CSF [H
P10413676A0595 |312 315|FAKntl
P10413676A0595 |41 44|FAKhos
P10413676A0595 |46 51|cellsatase
P10413676A0595 |256 270|cell migrationced when compa
P10413676A0595 |116 120|siteatal
P10413676A0595 |175 178|FAK sh
P10413676A0595 |97 107|SH2 domaingic aspect
P10413676A0595 |64 83|FAK kinase activityotidase P00008171T0
P10413676A0595 |274 276|FNto
P10413676A1193 |84 87|Ser00 
P10413676A1193 |132 145|contact sitesbinemia. P000
P10413676A1193 |105 122|FRNK localizationcts of neonatal h
P10413676A1193 |56 70|point mutation 5-nucleotidas
P10413676A1193 |72 80|Leu-1034P0000817
P10413676A1193 |23 29|effecton wit
P10413676A1193 |33 37|FRNKkali
P10414451A0093 |34 36|yral
P10414451A0093 |216 225|protein C of K-dep
P10414451A0093 |58 61|DVT-nu
P10414451A0093 |26 29|agewit
P10414451A0093 |124 133|protein Cerbilirub
P10414451A0093 |88 96|presenceharmacol
P10414451A0093 |227 236|protein Sted rats 
P10414451A0093 |135 140|APC-Remia.
P10414451A0093 |164 166|LA [
P10414451A0093 |16 24|patientsompariso
P10414451A0093 |185 195|antibodiesa function
P10414451A0093 |200 212|deficienciesSF PCO2 the 
P10414451A0093 |143 162|lupus anticoagulant0008997A0472 When C
P10414451A0093 |100 110|resistance aspects o
P10414451A0093 |238 254|ATIII activitiese no longer disp
P10416429A0221 |0 6|DESIGNP00001
P10416429A0221 |22 28|numberson wi
P10416429A0221 |8 18|Comparison6T0076 Com
P10416429A0221 |58 63|years-nucl
P10416429A0221 |43 46|PKUsph
P10416429A0221 |120 126|number hyper
P10416429A0221 |98 104|numberic asp
P10416429A0221 |140 155|population data P00008997A0472
P10416429A0221 |71 87|NSW PKU database P00008171T0000 
P10416429A0221 |32 37|womenlkali
P10416558A0000 |0 7|PURPOSEP000016
P10416558A0000 |191 204|health statustion of CSF P
P10416558A0000 |245 256|individualsnger displa
P10416558A0000 |331 347|exercise relapse(1.21 +/- 0.23 v
P10416558A0000 |62 69|effectsleotida
P10416558A0000 |13 21|purposes6 Compar
P10416558A0000 |284 290|degrees but 
P10416558A0000 |152 166|CD4 cell count472 When CSF [
P10416558A0000 |258 259|Nd
P10416558A0000 |81 91|laboratoryT0000 Phar
P10416558A0000 |142 150|function00008997
P10416558A0000 |106 122|exercise programts of neonatal h
P10416558A0000 |37 42|studyne ph
P10416558A0000 |304 310|healthignifi
P10417331A1008 |50 61|mM pantoatees and 5-nu
P10417331A1008 |28 36|activityth alkal
P10417331A1008 |75 76|s0
P10417331A1008 |89 91|pHar
P10417331A1008 |63 64|ke
P10417331A1008 |65 68|cattid
P10417331A1008 |4 10|enzyme01606T
P10417703A1326 |51 53|RPs 
P10417703A1326 |162 180|plant RPT subunitsSF [HCO3-] is show
P10417703A1326 |193 211|yeast counterpartson of CSF PCO2 the
P10417703A1326 |22 29|resultsson wit
P10417703A1326 |129 139|eukaryotesirubinemia
P10417703A1326 |232 241|functionsats are n
P10417703A1326 |64 78|20S proteasomeotidase P00008
P10419006A0378 |38 66|estrogen replacement therapye phosphatases and 5-nucleot
P10419006A0378 |14 22|evidence Compari
P10419006A0378 |73 82|menopause00008171T
P10419006A0378 |93 111|breast cancer riskcologic aspects of
P10419521A0136 |136 155|polymerase activitymia. P00008997A0472
P10419521A0136 |40 43|ELLpho
P10419521A0136 |177 190|transcriptionhown as a fun
P10419521A0136 |61 65|typecleo
P10419521A0136 |19 38|elongation activityarison with alkalin
P10419521A0136 |3 11|addition001606T0
P10419521A0136 |87 105|interaction domainPharmacologic aspe
P10419521A0136 |69 83|RNA polymerasese P00008171T0
P10422291A0572 |35 42|myelomaline ph
P10422291A0572 |15 25|IgA lambdaComparison
P10422291A0572 |59 70|involvementnucleotidas
P10422291A0572 |2 11|diagnosis0001606T0
P10422342A0535 |238 242|131Ie no
P10422342A0535 |260 265|111Inwhen 
P10422342A0535 |244 249|201Tlonger
P10422342A0535 |177 189|examinationshown as a fu
P10422342A0535 |41 49|majorityhosphata
P10422342A0535 |220 232|preparationsK-depleted r
P10422342A0535 |251 255|67Gaispl
P10422342A0535 |53 65|examinationsand 5-nucleo
P10422342A0535 |113 117|doseeona
P10422342A0535 |202 216|administration PCO2 the data
P10422342A0535 |77 85|medicine8171T000
P10422342A0535 |141 157|radiation burdenP00008997A0472 W
P10422342A0535 |4 20|radiation burden01606T0076 Compa
P10422468A0524 |238 242|casee no
P10422468A0524 |217 229|Y chromosomeof K-deplete
P10422468A0524 |261 270|mutationshen compa
P10422468A0524 |126 139|abnormalitiesbilirubinemia
P10422468A0524 |57 61|ICSI5-nu
P10422468A0524 |176 190|sex chromosomeshown as a fun
P10422468A0524 |151 154|NOA047
P10422468A0524 |13 17|risk6 Co
P10422468A0524 |285 298|fibrosis gene but still ha
P10422468A0524 |195 209|microdeletions of CSF PCO2 t
P10422468A0524 |257 259|OAed
P10422468A0524 |21 33|malformationison with al
P10422468A0524 |143 147|case0008
P10422468A0524 |37 45|childrenne phosp
P10422468A0524 |168 172|rateO3-]
P10422468A0524 |101 105|riskaspe
P10423156A0265 |0 13|TaV particlesP00001606T007
P10423156A0265 |107 110|kDas o
P10423156A0265 |46 51|g/cm3atase
P10423156A0265 |29 36|densityh alkal
P10423156A0265 |79 94|capsid proteins71T0000 Pharmac
P10423156A0265 |55 59|CsCld 5-
P10423193A1309 |0 10|CONCLUSIONP00001606T
P10423193A1309 |64 75|involvementotidase P00
P10423193A1309 |140 143|CTS P0
P10423193A1309 |115 125|neuropathynatal hype
P10423193A1309 |18 25|resultsparison
P10423292A0782 |35 40|Spam1line 
P10423292A0782 |133 136|CREine
P10423292A0782 |13 15|bp6 
P10423292A0782 |115 120|sitesnatal
P10423292A0782 |25 31|region with 
P10423292A0782 |86 106|transcription factor Pharmacologic aspec
P10423292A0782 |154 161|element2 When 
P10425094A1006 |48 49|sa
P10425094A1006 |31 38|complexalkalin
P10425094A1006 |13 23|relaxivity6 Comparis
P10425094A1006 |54 56|mMnd
P10425445T0000 |0 9|StructureP00001606
P10425445T0000 |14 24|expression Compariso
P10425445T0000 |32 97|mouse growth hormone receptor/growth hormone binding protein genelkaline phosphatases and 5-nucleotidase P00008171T0000 Pharmacolo
P10426450A1458 |34 46|liver/spleenaline phosph
P10426450A1458 |22 24|SAso
P10426450A1458 |126 129|ILKbil
P10426450A1458 |10 18|recovery0076 Com
P10426450A1458 |61 67|tonsilcleoti
P10426450A1458 |90 92|SGrm
P10426450A1458 |98 112|contact chicksic aspects of 
P10426450A1458 |203 209|chicksPCO2 t
P10426450A1458 |71 85|contact poults P00008171T000
P10426450A1458 |184 198|contact poults a function of
P10426878A0367 |19 31|ISIS-2 trialarison with 
P10426878A0367 |131 139|patientsubinemia
P10426878A0367 |78 91|Collaboration171T0000 Phar
P10426878A0367 |40 44|dataphos
P10426878A0367 |107 114|aspirins of ne
P10426878A0367 |67 76|Trialistsdase P000
P10426878A0367 |162 172|infarctionSF [HCO3-]
P10426878A0367 |191 201|preventiontion of CS
P10426878A0367 |4 11|results01606T0
P10427654A0000 |69 80|laparoscopyse P0000817
P10427654A0000 |189 195|cancernction
P10427654A0000 |112 120|patientsneonatal
P10427654A0000 |126 140|adenocarcinomabilirubinemia.
P10427654A0000 |167 173|cancerCO3-] 
P10427654A0000 |148 157|esophagus97A0472 W
P10427654A0000 |39 43|role pho
P10427654A0000 |5 10|study1606T
P10427654A0000 |101 108|stagingaspects
P10427654A0000 |223 230|surgeryepleted
P10428091A0322 |137 142|womenia. P
P10428091A0322 |36 40|MMRsine 
P10428091A0322 |79 90|disparities71T0000 Pha
P10428091A0322 |5 11|report1606T0
P10428091A0322 |103 112|mortalitypects of 
P10428294A0227 |0 25|Preheparin LPL mass levelP00001606T0076 Comparison
P10428294A0227 |58 69|individuals-nucleotida
P10428294A0227 |104 107|menect
P10428294A0227 |112 117|womenneona
P10428294A0227 |84 89|years00 Ph
P10428759A0743 |2 10|decrease0001606T
P10428759A0743 |30 54|receptor kinase activity alkaline phosphatases a
P10428759A0743 |93 102|receptorscologic a
P10428811A0628 |0 5|Cat-1P0000
P10428811A0628 |46 61|binding partneratases and 5-nu
P10428811A0628 |86 101|receptor kinase Pharmacologic 
P10428811A0628 |114 119|GRK-2onata
P10428811A0628 |154 162|activity2 When C
P10428811A0628 |103 110|betaARKpects o
P10428811A1067 |0 12|Cat proteinsP00001606T00
P10428811A1067 |62 67|cellsleoti
P10428811A1067 |107 110|Srcs o
P10428811A1067 |83 102|adhesion kinase Fak000 Pharmacologic a
P10428862A0834 |0 31|Immunoprecipitation experimentsP00001606T0076 Comparison with 
P10428862A0834 |75 86|interaction008171T0000
P10428862A0834 |106 110|DokRts o
P10428862A0834 |183 194|BaF/3 cellss a functio
P10428862A0834 |125 132|proteinrbiliru
P10428862A0834 |52 62|antibodies and 5-nuc
P10429184A0000 |0 9|ExpansinsP00001606
P10429184A0000 |135 144|mechanismemia. P00
P10429184A0000 |59 68|extensionnucleotid
P10429184A0000 |26 34|proteinswith alk
P10429184A0000 |81 97|plant cell wallsT0000 Pharmacolo
P10429184A0000 |16 22|familyompari
P10429740A0000 |103 106|IBSpec
P10429740A0000 |5 11|review1606T0
P10429740A0000 |36 44|evidenceine phos
P10429740A0000 |64 73|therapiesotidase P
P10429740A0000 |87 101|bowel syndromePharmacologic 
P10429946A0473 |138 147|sequencesa. P00008
P10429946A0473 |15 21|regionCompar
P10429946A0473 |125 127|bprb
P10429946A0473 |108 116|promoter of neon
P10429946A0473 |40 53|collagen genephosphatases 
P10429946A0473 |29 34|alphah alk
P10429946A0473 |73 81|fragment00008171
P10429946A0473 |178 186|elementsown as a
P10429946A0473 |131 135|exonubin
P10429946A0473 |37 38|Vn
P10429946A0473 |96 98|bpog
P10429946A0988 |84 101|complex formation00 Pharmacologic 
P10429946A0988 |13 21|addition6 Compar
P10429946A0988 |25 73|B-Myb-glutathionine S-transferase fusion protein with alkaline phosphatases and 5-nucleotidase P
P10430421T0000 |85 103|Cache County Study0 Pharmacologic as
P10430421T0000 |52 64|AD increases and 5-nucle
P10430421T0000 |29 32|ageh a
P10430421T0000 |38 48|prevalencee phosphat
P10430421T0000 |0 19|APOE-epsilon4 countP00001606T0076 Comp
P10430580A0000 |0 6|RepairP00001
P10430580A0000 |10 30|double-strand breaks0076 Comparison with
P10430580A0000 |74 85|end-joining0008171T000
P10430580A0000 |53 56|DNAand
P10430580A0000 |126 131|yeastbilir
P10430580A0000 |32 36|DSBslkal
P10430580A0000 |87 91|NHEJPhar
P10430583A0000 |70 74|RecAe P0
P10430583A0000 |58 66|homology-nucleot
P10430583A0000 |6 21|DNA repair gene606T0076 Compar
P10430883A0000 |71 77|glands P0000
P10430883A0000 |218 223|mucinf K-d
P10430883A0000 |22 27|cellsson w
P10430883A0000 |298 326|sodium borohydride reductionve a significantly greater s
P10430883A0000 |89 95|glandsarmaco
P10430883A0000 |208 213|classthe d
P10430883A0000 |328 333|Con Ape (1
P10430883A0000 |61 68|Brunnercleotid
P10430883A0000 |165 175|metaplasia[HCO3-] is
P10430883A0000 |118 123|tractal hy
P10430883A0000 |256 264|stainingced when
P10430883A0000 |250 253|Condis
P10430883A0000 |54 59|cellsnd 5-
P10430883A0000 |41 46|glandhosph
P10430883A0000 |287 296|oxidationut still 
P10430883A0000 |140 145|ducts P000
P10430883A0000 |339 370|horseradish peroxidase reaction- 0.23 vs. P00010943A0733 Flura
P10430886A0838 |51 55|TraRs an
P10430886A0838 |15 22|mutantsCompari
P10430886A0838 |122 131|activatoryperbilir
P10430886A0838 |87 102|heteromultimersPharmacologic a
P10430890A1059 |6 15|elongin C606T0076 
P10430890A1059 |135 151|partner proteinsemia. P00008997A
P10430890A1059 |90 104|rearrangementsrmacologic asp
P10430890A1059 |43 51|solutionsphatase
P10430890A1059 |110 117|bindingf neona
P10430944A1298 |68 80|malignanciesase P0000817
P10430944A1298 |45 49|rolehata
P10430944A1298 |20 38|JAK/STAT signalingrison with alkalin
P10430944A1298 |4 8|data0160
P10430980A0465 |26 31|womenwith 
P10430980A0465 |14 17|men Co
P10433729A1559 |0 2|A.P0
P10433729A1559 |12 15|K.E76 
P10433729A1559 |31 33|C.al
P10433729A1559 |4 10|Bowers01606T
P10433729A1559 |21 29|Matthewsison wit
P10433970A0279 |34 47|reading framealine phospha
P10433970A0279 |66 84|DNA binding domainidase P00008171T00
P10433970A0279 |94 113|localization signalologic aspects of n
P10433970A0279 |118 140|transactivation domainal hyperbilirubinemia.
P10433970A0279 |0 6|Spfkh1P00001
P10435595A0203 |40 56|trans-activationphosphatases and
P10435595A0203 |14 23|mechanism Comparis
P10436016A0337 |0 14|Gel filtrationP00001606T0076
P10436016A0337 |131 136|Mad1pubine
P10436016A0337 |63 68|Mad2peotid
P10436016A0337 |101 129|spindle checkpoint componentaspects of neonatal hyperbil
P10436016A0337 |19 50|co-immunoprecipitation analysesarison with alkaline phosphatas
P10437043A0164 |51 59|biopsiess and 5-
P10437043A0164 |23 28|caseson wi
P10437043A0164 |0 7|METHODSP000016
P10437043A0164 |34 36|SSal
P10438540A1185 |102 120|transport activityspects of neonatal
P10438540A1185 |60 62|Cduc
P10438540A1185 |128 135|proteinlirubin
P10438540A1185 |91 97|strainmacolo
P10438540A1185 |67 76|tolerancedase P000
P10438540A1185 |36 50|domain mutantsine phosphatas
P10438593A0000 |70 83|transcriptione P00008171T0
P10438593A0000 |10 39|immunodeficiency virus type-10076 Comparison with alkaline
P10438593A0000 |41 46|HIV-1hosph
P10438593A0000 |99 126|RNA polymerase processivityc aspects of neonatal hyper
P10438593A0000 |48 59|Tat proteinases and 5-
P10438607A0330 |71 85|gene fork head P00008171T000
P10438607A0330 |13 18|SEBPs6 Com
P10438607A0330 |47 54|producttases a
P10438607A0330 |20 25|SEBP2rison
P10438627A0885 |0 17|Identity elementsP00001606T0076 Co
P10438627A0885 |122 136|T7 transcriptsyperbilirubine
P10438627A0885 |30 34|mono alk
P10438627A0885 |173 176|Pheis 
P10438627A0885 |143 151|variants0008997A
P10438627A0885 |83 90|pfTrm1p000 Pha
P10438627A0885 |160 163|Asp CS
P10438627A0885 |182 187|yeastas a 
P10438627A0885 |21 25|tRNAison
P10438627A0885 |54 63|reactionsnd 5-nucl
P10438627A0885 |155 159|tRNA Whe
P10438627A0885 |168 172|tRNAO3-]
P10438924A1009 |68 118|serine/threonine kinase glycogen synthase kinase-3ase P00008171T0000 Pharmacologic aspects of neonat
P10438924A1009 |120 125|GSK-3 hype
P10438924A1009 |29 32|Akth a
P10438924A1009 |22 27|cellsson w
P10438924T0000 |4 27|B cell antigen receptor01606T0076 Comparison w
P10438924T0000 |42 45|Aktosp
P10438924T0000 |47 63|protein kinase Btases and 5-nucl
P10438924T0000 |65 109|glycogen synthase kinase-3 signaling pathwaytidase P00008171T0000 Pharmacologic aspects 
P10438924T0000 |114 143|phosphatidylinositol 3-kinaseonatal hyperbilirubinemia. P0
P10438941A1197 |138 143|genesa. P0
P10438941A1197 |97 117|switch recombinationgic aspects of neona
P10438941A1197 |58 59|B-
P10438941A1197 |6 26|recombination events606T0076 Comparison 
P10438941A1197 |64 76|T cell linesotidase P000
P10438950A0580 |0 4|IL-1P000
P10438950A0580 |95 116|fibroblast cell lineslogic aspects of neon
P10438950A0580 |9 46|TNF increase AND-34 transcript levelsT0076 Comparison with alkaline phosph
P10438950A0580 |84 89|nurse00 Ph
P10439040A0658 |87 93|regionPharma
P10439040A0658 |122 135|CAT reportersyperbilirubin
P10439040A0658 |165 175|constructs[HCO3-] is
P10439040A0658 |43 59|c-myc expressionsphatases and 5-
P10439040A0658 |95 98|UTRlog
P10439040A0658 |65 70|c-myctidas
P10439040A0658 |18 28|role eIF4Eparison wi
P10440923A0684 |0 8|AnalysisP0000160
P10440923A0684 |263 269|levelsn comp
P10440923A0684 |80 93|control cells1T0000 Pharma
P10440923A0684 |52 72|lovastatin treatment and 5-nucleotidase 
P10440923A0684 |213 219|cyclinata of
P10440923A0684 |121 127|levelshyperb
P10440923A0684 |180 190|inhibitionn as a fun
P10440923A0684 |12 31|cell cycle proteins76 Comparison with 
P10440923A0684 |47 48|ht
P10440923A0684 |104 113|elevationects of n
P10440923A0684 |152 172|kinase inhibitor p27472 When CSF [HCO3-]
P10440923A0684 |293 315|retinoblastoma proteinll have a significantl
P10440923A0684 |199 207|cyclin ECSF PCO2
P10440923A0684 |317 320|pRbgre
P10440923A0684 |232 247|kinase activityats are no long
P10440923A0684 |173 177|kip1is s
P10441243A0443 |0 7|RESULTSP000016
P10441243A0443 |21 42|leptin concentrationsison with alkaline ph
P10441243A0443 |81 86|ng/mlT0000
P10441243A0443 |98 106|subjectsic aspec
P10441449X1212 |0 9|CopyrightP00001606
P10441449X1212 |15 29|Academic PressComparison wit
P10441483A0454 |0 22|Oligonucleotide probesP00001606T0076 Compari
P10441483A0454 |61 75|EpRE sequencescleotidase P00
P10441483A0454 |115 123|analysesnatal hy
P10441483A0454 |136 144|proteinsmia. P00
P10441506A0098 |0 7|PKNbetaP000016
P10441506A0098 |17 34|sequence homologymparison with alk
P10441506A0098 |255 273|amino acid stretchaced when compared
P10441506A0098 |222 228|domaindeplet
P10441506A0098 |112 117|aminoneona
P10441506A0098 |93 100|repeatscologic
P10441506A0098 |338 344|domain/- 0.2
P10441506A0098 |140 154|leucine-zipper P00008997A047
P10441506A0098 |128 134|regionlirubi
P10441506A0098 |40 48|PKNalphaphosphat
P10441506A0098 |160 169|sequences CSF [HCO
P10441506A0098 |70 73|PKNe P
P10441506A0098 |306 319|CZ region/HR1nificantly gr
P10441506A0098 |275 287|D region/HR2o controls b
P10441506A0098 |171 184|CZ region/HR1] is shown as
P10442493A0815 |117 143|plasma cyclosporine levelstal hyperbilirubinemia. P0
P10442493A0815 |72 82|serum FLOPP00008171T
P10442493A0815 |29 37|lycopeneh alkali
P10442493A0815 |13 25|serum levels6 Comparison
P10442493A0815 |42 46|FLOPosph
P10442493A0815 |145 146|r0
P10442493A0815 |156 157|pW
P10442493A0815 |3 11|baseline001606T0
P10443990A0000 |0 10|BACKGROUNDP00001606T
P10443990A0000 |83 94|bone health000 Pharmac
P10443990A0000 |20 39|alcohol consumptionrison with alkaline
P10444597A0586 |168 175|nucleusO3-] is
P10444597A0586 |25 34|induction with alk
P10444597A0586 |111 122|mRNA export neonatal h
P10444597A0586 |135 140|Npl3pemia.
P10444597A0586 |74 81|ethanol0008171
P10444597A0586 |65 69|salttida
P10444597A0586 |83 93|conditions000 Pharma
P10444597A0586 |38 44|stresse phos
P10444597A0586 |48 58|heat shockases and 5
P10444813A0448 |16 22|reliefompari
P10444813A0448 |27 37|inhibitionith alkali
P10444813A0448 |45 51|growthhatase
P10444813A0448 |59 82|metastases interferon-anucleotidase P00008171T
P10444813A0448 |87 109|somatostatin analoguesPharmacologic aspects 
P10445161A1565 |49 54|studyses a
P10445161A1565 |176 181|sexesshown
P10445161A1565 |147 167|organ weight changes997A0472 When CSF [H
P10445161A1565 |105 116|weight gaincts of neon
P10445161A1565 |81 84|ppmT00
P10445161A1565 |127 131|ratsilir
P10445161A1565 |190 193|ppmcti
P10445161A1565 |3 10|summary001606T
P10445506A0073 |65 76|body lengthtidase P000
P10445506A0073 |30 35|sperm alka
P10445506A0073 |44 49|timesphata
P10445945T0000 |0 19|John leonard dawsonP00001606T0076 Comp
P10446131A0132 |0 19|PDGF A-chain levelsP00001606T0076 Comp
P10446131A0132 |88 92|ATIIharm
P10446131A0132 |71 75|SMCs P00
P10446131A0132 |50 69|smooth muscle cellses and 5-nucleotida
P10446149A0809 |100 105|A-Raf aspe
P10446149A0809 |46 51|assayatase
P10446149A0809 |29 34|yeasth alk
P10446149A0809 |107 112|B-Rafs of 
P10446149A0809 |91 98|c-Raf-1macolog
P10446149A0809 |66 79|Ras effectorsidase P000081
P10446149A0809 |146 152|RalGDS8997A0
P10446149A0809 |158 162|Rin1en C
P10446149A0809 |114 144|phosphoinositol-3 kinase deltaonatal hyperbilirubinemia. P00
P10446206A0000 |171 176|study] is 
P10446206A0000 |218 238|hepatoma HepG2 cellsf K-depleted rats ar
P10446206A0000 |131 155|transcription start siteubinemia. P00008997A0472
P10446206A0000 |192 213|neuroblastoma SK-N-SHion of CSF PCO2 the d
P10446206A0000 |44 47|PS1pha
P10446206A0000 |30 42|presenilin-1 alkaline ph
P10446206A0000 |49 57|promoterses and 
P10446206A0000 |115 123|relationnatal hy
P10446206A0000 |0 16|Deletion mappingP00001606T0076 C
P10446206A0000 |85 93|fragment0 Pharma
P10446833T0000 |17 28|oxygenationmparison wi
P10446833T0000 |45 51|sepsishatase
P10446833T0000 |56 61|shock 5-nu
P10446833T0000 |33 41|shuntingkaline p
P10446910A0147 |0 8|AnalysisP0000160
P10446910A0147 |87 104|E2-responsivenessPharmacologic asp
P10446910A0147 |295 297|E2 h
P10446910A0147 |276 291|transactivation controls but s
P10446910A0147 |63 69|regioneotida
P10446910A0147 |252 257|sitessplac
P10446910A0147 |154 180|deletion/mutation analysis2 When CSF [HCO3-] is show
P10446910A0147 |16 34|E2F1 gene promoteromparison with alk
P10446910A0147 |118 137|transfection assaysal hyperbilirubinem
P10446912A0883 |35 45|mechanismsline phosp
P10446912A0883 |77 98|CYP11A1 transcription8171T0000 Pharmacolog
P10446912A0883 |147 158|JEG-3 cells997A0472 Wh
P10446912A0883 |63 66|OF3eot
P10446912A0883 |132 135|Sp1bin
P10446912A0883 |122 125|OF3ype
P10446912A0883 |114 117|OF5ona
P10446912A0883 |7 13|course06T007
P10446912A0883 |140 143|Sp3 P0
P10446912A0883 |55 58|OF5d 5
P10446998A0375 |17 32|differentiationmparison with a
P10446998A0375 |122 140|c-fos inducibilityyperbilirubinemia.
P10446998A0375 |96 110|responsivenessogic aspects o
P10446998A0375 |63 68|cellseotid
P10446998A0375 |114 118|junBonat
P10446998A0375 |3 11|contrast001606T0
P10446998A0955 |0 25|Adipocyte differentiationP00001606T0076 Comparison
P10446998A0955 |44 49|cellsphata
P10446998A0955 |108 116|junB SRE of neon
P10446998A0955 |78 85|ability171T000
P10446998A0955 |89 92|SRFarm
P10446998A0955 |166 180|mobility shiftHCO3-] is show
P10446998A0955 |122 131|c-fos SREyperbilir
P10446998A0955 |143 147|SREs0008
P10446998A0955 |230 257|DNA binding characteristics rats are no longer displac
P10446998A0955 |185 206|gel supershift assaysa function of CSF PCO
P10446998A0955 |273 285|protein SP-1 to controls
P10446998T0000 |0 14|TransformationP00001606T0076
P10446998T0000 |60 94|serum response factor interactionsucleotidase P00008171T0000 Pharmac
P10446998T0000 |46 56|inhibitionatases and
P10446998T0000 |100 123|serum response elements aspects of neonatal hy
P10447593A0144 |137 150|sigma factorsia. P00008997
P10447593A0144 |109 121|similaritiesof neonatal 
P10447593A0144 |61 63|T7cl
P10447593A0144 |4 15|core enzyme01606T0076 
P10447593A0144 |42 59|bacteriophages T3osphatases and 5-
P10447593A0144 |84 102|specificity factor00 Pharmacologic a
P10447593A0144 |68 71|SP6ase
P10447597A1004 |4 17|Cr.psbA-4 ORF01606T0076 Co
P10447597A1004 |58 71|GIY-YIG motif-nucleotidase
P10447597A1004 |36 41|motifine p
P10448036A0748 |170 176|finger-] is 
P10448036A0748 |44 49|S RNAphata
P10448036A0748 |203 211|affinityPCO2 the
P10448036A0748 |127 132|zf4-7iliru
P10448036A0748 |244 259|RNA interactiononger displaced
P10448036A0748 |89 113|competitor concentrationarmacologic aspects of n
P10448036A0748 |135 152|S RNA interactionemia. P00008997A0
P10448036A0748 |216 227|specificity of K-deple
P10448036A0748 |4 15|interaction01606T0076 
P10448036A0748 |236 243|proteinare no 
P10448036A0748 |19 24|zf4-6ariso
P10448095A0865 |103 113|conversionpects of n
P10448095A0865 |132 142|adipocytesbinemia. P
P10448095A0865 |45 61|C/EBP expressionhatases and 5-nu
P10448095A0865 |218 228|adipocytesf K-deplet
P10448095A0865 |161 179|expression profileCSF [HCO3-] is sho
P10448095A0865 |4 29|STAT protein accumulation01606T0076 Comparison wit
P10448095A0865 |117 128|fibroblaststal hyperbi
P10448285A1035 |103 109|monthspects 
P10448285A1035 |88 94|monthsharmac
P10448285A1035 |73 78|trial00008
P10448285A1035 |25 33|response with al
P10448285A1035 |11 20|durations076 Compa
P10448285A1035 |38 51|survival timee phosphatase
P10448285A1035 |64 69|phaseotida
P10448440T0020 |4 8|role0160
P10448440T0020 |24 34|psychiatryn with alk
P10448440T0020 |75 88|schizophrenia008171T0000 P
P10448440T0020 |39 61|understanding patients phosphatases and 5-nu
P10448440T0020 |99 119|personality disorderc aspects of neonata
P10448902A0921 |69 89|superoxide dismutasese P00008171T0000 Ph
P10448902A0921 |42 64|glutathione peroxidaseosphatases and 5-nucle
P10448902A0921 |23 30|enzymeson with
P10448902A0921 |110 114|ratsf ne
P10448902A0921 |32 40|catalaselkaline 
P10448902A0921 |154 158|rats2 Wh
P10449072A0560 |68 71|GPiase
P10449072A0560 |75 77|PD00
P10449072A0560 |11 15|goal076 
P10449072A0560 |49 60|arrangementses and 5-n
P10449899A0881 |59 68|PERV copynucleotid
P10449899A0881 |14 21|results Compar
P10449899A0881 |73 89|integration site00008171T0000 Ph
P10450815A0180 |274 280|genderto con
P10450815A0180 |253 260|factorsplaced 
P10450815A0180 |93 102|age rangecologic a
P10450815A0180 |147 159|relationship997A0472 Whe
P10450815A0180 |269 272|ageare
P10450815A0180 |109 114|yearsof ne
P10450815A0180 |12 25|investigation76 Comparison
P10450815A0180 |287 294|hygieneut stil
P10450815A0180 |74 85|individuals0008171T000
P10450815A0180 |224 231|accountpleted 
P10450815A0180 |202 210|calculus PCO2 th
P10450815A0180 |41 51|populationhosphatase
P10450815A0180 |308 320|inflammationficantly gre
P10450815A0180 |168 183|tobacco smokingO3-] is shown a
P10451209A0000 |0 9|OBJECTIVEP00001606
P10451209A0000 |124 129|doseserbil
P10451209A0000 |79 89|hemorrhage71T0000 Ph
P10451209A0000 |133 168|methylprednisolone sodium succinateinemia. P00008997A0472 When CSF [HC
P10451209A0000 |32 46|administrationlkaline phosph
P10451209A0000 |101 105|dogsaspe
P10451209A0000 |50 61|misoprostoles and 5-nu
P10451209A0000 |170 174|MPSS-] i
P10452306A0502 |0 8|PatientsP0000160
P10452306A0502 |106 111|x-rayts of
P10452306A0502 |192 224|heart catheterization parametersion of CSF PCO2 the data of K-de
P10452306A0502 |134 140|M-modenemia.
P10452306A0502 |90 94|LVEFrmac
P10452306A0502 |60 88|norepinephrine concentrationucleotidase P00008171T0000 P
P10452306A0502 |127 132|ratioiliru
P10452306A0502 |167 175|diameterCO3-] is
P10452306A0502 |96 104|peak Vo2ogic asp
P10452306A0502 |35 46|MIBG uptakeline phosph
P10452951A0000 |115 122|speciesnatal h
P10452951A0000 |8 25|hormone receptors6T0076 Comparison
P10452951A0000 |27 30|NRsith
P10452951A0000 |97 106|functionsgic aspec
P10452951A0000 |53 74|transcription factorsand 5-nucleotidase P0
P10452991A0331 |33 58|influenza virus particleskaline phosphatases and 5
P10452991A0331 |6 11|cells606T0
P10452991A0331 |81 94|T cell clonesT0000 Pharmac
P10453006A0000 |0 10|SequencingP00001606T
P10453006A0000 |25 36|Danio rerio with alkal
P10453006A0000 |59 69|chromosomenucleotida
P10453006A0000 |88 98|chromosomeharmacolog
P10453006A0000 |14 23|zebrafish Comparis
P10453006A0000 |74 76|P100
P10453006A0000 |184 188|loci a f
P10453006A0000 |157 171|identificationhen CSF [HCO3-
P10453006A0000 |217 228|proteasomesof K-deplet
P10453006A0000 |130 141|cDNA clonesrubinemia. 
P10453006A0000 |107 122|clone fragmentss of neonatal h
P10453006A0000 |230 234|PSMB rat
P10453006A0000 |200 213|beta subunitsSF PCO2 the d
P10453006A0478 |168 174|humansO3-] i
P10453006A0478 |59 64|PSMB9nucle
P10453006A0478 |92 98|PSMB12acolog
P10453006A0478 |74 79|genes00081
P10453006A0478 |15 25|homologuesComparison
P10453006A0478 |39 50|genes PSMB5 phosphatas
P10453006A0478 |159 164|genesn CSF
P10453006A0478 |81 87|PSMB11T0000 
P10453006A0478 |3 11|addition001606T0
P10453248A0094 |101 107|modelsaspect
P10453248A0094 |28 39|perspectiveth alkaline
P10453248A0094 |11 15|Udry076 
P10453248A0094 |146 155|behaviour8997A0472
P10453371A0640 |0 6|WeightP00001
P10453371A0640 |62 74|BMD z-scoresleotidase P0
P10453371A0640 |11 26|height z-scores076 Comparison 
P10453721A0445 |96 100|partogic
P10453721A0445 |10 27|sampling strategy0076 Comparison w
P10453721A0445 |57 87|parameter estimation algorithm5-nucleotidase P00008171T0000 
P10453721A0445 |108 133|ADAPT II software package of neonatal hyperbilirub
P10454533A0859 |51 65|transformations and 5-nucleo
P10454533A0859 |24 29|Hsc70n wit
P10454533A0859 |108 112|acid of 
P10454533A0859 |166 178|conformationHCO3-] is sh
P10454533A0859 |15 18|HRICom
P10454533A0859 |138 141|HRIa. 
P10454533A0859 |81 97|Hsc70 antagonistT0000 Pharmacolo
P10454533A0859 |69 72|HRIse 
P10454533A0859 |0 11|InteractionP00001606T0
P10454540A0392 |33 38|D208Akalin
P10454540A0392 |60 71|combinationucleotidase
P10454540A0392 |76 96|exonuclease activity08171T0000 Pharmacol
P10454540A0392 |4 28|amino acid changes D206A01606T0076 Comparison wi
P10454550A0960 |68 72|Glc7ase 
P10454550A0960 |22 30|evidenceson with
P10454550A0960 |107 126|Snf1 kinase complexs of neonatal hyper
P10454550A0960 |50 54|Reg1es a
P10454550A0960 |84 94|substrates00 Pharmac
P10454557A0000 |85 95|chromosome0 Pharmaco
P10454557A0000 |228 242|HML locus showed rats are no
P10454557A0000 |124 132|sequenceerbiliru
P10454557A0000 |165 175|chromosome[HCO3-] is
P10454557A0000 |134 137|ARSnem
P10454557A0000 |15 20|yeastCompa
P10454557A0000 |189 193|ARSsncti
P10454557A0000 |246 273|replication origin activityger displaced when compared
P10454557A0000 |48 59|replicatorsases and 5-
P10454557A0000 |139 147|elements. P00008
P10454557A0975 |221 231|components-depleted 
P10454557A0975 |73 79|ARS302000081
P10454557A0975 |61 67|ARS320cleoti
P10454557A0975 |82 92|inactivity0000 Pharm
P10454557A0975 |144 153|silencing008997A04
P10454557A0975 |179 188|silencerswn as a f
P10454557A0975 |199 202|cisCSF
P10454557A0975 |167 174|originsCO3-] i
P10454557A0975 |36 51|HML ARS clusterine phosphatase
P10454557A0975 |6 13|results606T007
P10454557A0975 |53 59|ARS303and 5-
P10454557A0975 |96 103|originsogic as
P10454561A0594 |305 320|TD-IkappaBalphagnificantly gre
P10454561A0594 |15 20|studyCompa
P10454561A0594 |297 300|p65ave
P10454561A0594 |128 149|tumor necrosis factorlirubinemia. P0000899
P10454561A0594 |56 71|TD-IkappaBalpha 5-nucleotidase
P10454561A0594 |210 240|NF-kappaB DNA binding activitye data of K-depleted rats are 
P10454561A0594 |164 195|IkappaBalpha gene transcription [HCO3-] is shown as a function
P10454561A0594 |80 124|phorbol myristate acetate-phytohemagglutinin1T0000 Pharmacologic aspects of neonatal hyp
P10454561A0594 |42 52|expressionosphatases
P10454561A0594 |292 296|RelAill 
P10454561A0594 |275 288|sequestrationo controls bu
P10454568A0815 |35 39|cDNAline
P10454568A0815 |13 29|Grb10 expression6 Comparison wit
P10454568A0815 |127 134|insulinilirubi
P10454568A0815 |77 94|expression system8171T0000 Pharmac
P10454568A0815 |227 234|fashionted rat
P10454568A0815 |182 195|DNA synthesisas a function
P10454568A0815 |106 113|PDGF-BBts of n
P10454568A0815 |116 121|IGF-Iatal 
P10454568A0815 |202 210|ecdysone PCO2 th
P10454568A0815 |154 167|growth factor2 When CSF [H
P10454568A0815 |169 172|EGF3-]
P10454570A0846 |274 283|inductionto contro
P10454570A0846 |345 361|ERK-2 activation vs. P00010943A0
P10454570A0846 |184 189|ATF-2 a fu
P10454570A0846 |324 330|kinase slope
P10454570A0846 |191 196|c-Juntion 
P10454570A0846 |334 339|ERK-121 +/
P10454570A0846 |416 427|stimulation drug with 
P10454570A0846 |381 384|TPAapp
P10454570A0846 |129 146|kinase activationirubinemia. P0000
P10454570A0846 |435 447|uPA enhancermum dose for
P10454570A0846 |47 70|protein kinase pathwaystases and 5-nucleotidas
P10454570A0846 |165 180|phosphorylation[HCO3-] is show
P10454570A0846 |99 117|protein kinase-Junc aspects of neona
P10454570A0846 |202 206|JunD PCO
P10454570A0846 |4 12|analysis01606T00
P10454570A0846 |237 241|IL-1re n
P10455087A1400 |0 11|CONCLUSIONSP00001606T0
P10455087A1400 |24 35|individualsn with alka
P10455087A1400 |43 67|body insulin sensitivitysphatases and 5-nucleoti
P10455087A1400 |112 121|thresholdneonatal 
P10455143T0000 |0 21|Interdomain signalingP00001606T0076 Compar
P10455143T0000 |60 83|glucocorticoid receptorucleotidase P00008171T0
P10455143T0000 |38 46|fragmente phosph
P10455183A0530 |17 22|xtRNAmpari
P10455183A0530 |43 50|bindingsphatas
P10455183A0530 |28 32|geneth a
P10455183A0530 |91 96|Oct-1macol
P10455183A0530 |23 26|Secon 
P10455183A0530 |126 134|capacitybilirubi
P10455183A0530 |64 81|Staf zinc fingersotidase P00008171
P10455183A0530 |3 11|contrast001606T0
P10455183A0930 |70 86|Staf zinc fingere P00008171T0000
P10455183A0930 |193 196|Secon 
P10455183A0930 |180 192|Xenopus tRNAn as a funct
P10455183A0930 |151 171|activation mechanism0472 When CSF [HCO3-
P10455183A0930 |20 27|resultsrison w
P10455183A0930 |208 222|U6 snRNA genesthe data of K-
P10455183A0930 |55 66|utilizationd 5-nucleot
P10455183A0930 |116 127|determinantatal hyperb
P10455189A0104 |3 10|B cells001606T
P10455189A0104 |12 16|HEF176 C
P10455189A0104 |63 72|mechanismeotidase 
P10455189A0104 |94 111|integrin ligationologic aspects of
P10455189A0427 |51 55|HEF1s an
P10455189A0427 |23 47|tyrosine phosphorylationon with alkaline phospha
P10455189A0427 |96 102|mannerogic a
P10455189A0427 |71 75|time P00
P10457075A1198 |51 53|VIs 
P10457075A1198 |105 110|Pcritcts o
P10457075A1198 |76 77|%0
P10457075A1198 |126 128|Rnbi
P10457075A1198 |130 143|peak decreaserubinemia. P0
P10457075A1198 |79 80|P7
P10457075A1198 |150 151|%A
P10457075A1198 |64 72|increaseotidase 
P10457075A1198 |54 57|maxnd 
P10457075A1198 |153 154|P7
P10457075A1198 |0 40|Independent protrudor muscle stimulationP00001606T0076 Comparison with alkaline 
P10458905A0000 |69 89|YAC/BAC clone contigse P00008171T0000 Ph
P10458905A0000 |14 26|construction Comparison 
P10458905A0000 |93 101|8p22-p23cologic 
P10458907A0543 |21 50|mouse Rad30b mRNA transcriptsison with alkaline phosphatas
P10458907A0543 |62 77|repair proteinsleotidase P0000
P10458907A0543 |107 113|testiss of n
P10458907A0543 |10 16|RAD30B0076 C
P10458914A0674 |102 108|regionspects
P10458914A0674 |58 65|library-nucleo
P10458914A0674 |120 122|kb h
P10458914A0674 |16 31|mouse STAP geneomparison with 
P10458914A0674 |143 148|exons00089
P10458914A0674 |84 93|STAP gene00 Pharma
P10458914A0674 |0 8|AnalysisP0000160
P10459809A1262 |77 84|biofilm8171T00
P10459809A1262 |10 29|matrix distribution0076 Comparison wit
P10459809A1262 |43 55|cell densitysphatases an
P10460015A0465 |68 74|heightase P0
P10460015A0465 |93 104|improvementcologic asp
P10460015A0465 |9 15|monthsT0076 
P10460015A0465 |79 85|weight71T000
P10460015A0465 |116 136|bone mineral densityatal hyperbilirubine
P10460015A0465 |141 149|bone ageP0000899
P10460015A0465 |19 28|treatmentarison wi
P10460015A0465 |49 57|estrogenses and 
P10460171A0842 |0 21|Viscosity experimentsP00001606T0076 Compar
P10460171A0842 |96 115|phosphoryl transferogic aspects of neo
P10460171A0842 |86 94|chemical Pharmac
P10460171A0842 |39 63|fragment kinase reaction phosphatases and 5-nucl
P10460171A0842 |117 121|steptal 
P10460171A0842 |136 140|ratemia.
P10460172A0823 |0 22|Velocity sedimentationP00001606T0076 Compari
P10460172A0823 |135 151|kDa polypeptidesemia. P00008997A
P10460172A0823 |24 37|cross-linkingn with alkali
P10460172A0823 |166 181|heterotetramersHCO3-] is shown
P10460172A0823 |43 71|immunoprecipitation analysessphatases and 5-nucleotidase
P10460172A0823 |97 106|rat braingic aspec
P10463057A0534 |9 26|expression levelsT0076 Comparison 
P10463057A0534 |44 52|plasmidsphatases
P10463242A0316 |50 56|regiones and
P10463242A0316 |24 29|wavesn wit
P10463242A0316 |3 6|EEG001
P10464185T0000 |53 86|polysaccharide biosynthesis genesand 5-nucleotidase P00008171T0000
P10464185T0000 |90 122|Streptococcus agalactiae type Iarmacologic aspects of neonatal h
P10464185T0000 |10 26|characterization0076 Comparison 
P10464250A0275 |7 15|FASEB J.06T0076 
P10464291A0597 |85 98|protein delta0 Pharmacolog
P10464291A0597 |129 133|timeirub
P10464291A0597 |47 57|PDGFalphaRtases and 
P10464291A0597 |13 18|ng/ml6 Com
P10464291A0597 |112 123|mRNA levelsneonatal hy
P10464291A0597 |144 150|manner008997
P10464291A0597 |100 110|C/EBPdelta aspects o
P10464291A0597 |0 8|IL-1betaP0000160
P10464302A1109 |258 278|growth factor signald when compared to c
P10464302A1109 |225 232|pathwayleted r
P10464302A1109 |173 178|modelis sh
P10464302A1109 |199 207|assemblyCSF PCO2
P10464302A1109 |242 254|transmission longer disp
P10464302A1109 |286 298|cytoskeletonbut still ha
P10464302A1109 |88 104|pathway proteinsharmacologic asp
P10464302A1109 |55 58|neud 5
P10464302A1109 |5 16|recruitment1606T0076 C
P10464302A1109 |50 54|p185es a
P10464302A1109 |136 152|interaction sitemia. P00008997A0
P10464310A0218 |289 295|FGFR-1 still
P10464310A0218 |122 152|juxtamembrane tyrosine residueyperbilirubinemia. P00008997A0
P10464310A0218 |45 62|fibroblast growthhatases and 5-nuc
P10464310A0218 |281 284|Crkrol
P10464310A0218 |95 100|cellslogic
P10464310A0218 |10 34|tyrosine phosphorylation0076 Comparison with alk
P10464310A0218 |228 235|Tyr-463ed rats
P10464310A0218 |160 166|FGFR-1 CSF [
P10464310A0218 |174 188|Crk SH2 domains shown as a f
P10464310A0218 |202 208|FGFR-1 PCO2 
P10464310A0218 |38 41|Crke p
P10464310A0218 |255 272|complex formationaced when compare
P10466306A0000 |64 73|techniqueotidase P
P10466306A0000 |110 118|functionf neonat
P10466306A0000 |96 105|perfusionogic aspe
P10466306A0000 |21 51|Technetium-99m sestamibi SPECTison with alkaline phosphatase
P10466825T0000 |0 4|RoleP000
P10466825T0000 |73 83|expression00008171T0
P10466825T0000 |28 34|regionth alk
P10466825T0000 |95 100|geneslogic
P10466825T0000 |38 58|baculovirus p10 mRNAe phosphatases and 5
P10467004A0116 |32 43|nucleotideslkaline pho
P10467004A0116 |146 153|introns8997A04
P10467004A0116 |4 14|intron RNA01606T0076
P10467004A0116 |113 128|sequence motifseonatal hyperbi
P10467004A0116 |81 90|structureT0000 Pha
P10467004A0116 |155 161|Michel When 
P10467004A0683 |4 10|intron01606T
P10467004A0683 |46 50|factatas
P10467004A0683 |183 185|bps 
P10467004A0683 |25 33|splicing with al
P10467004A0683 |146 154|splicing8997A047
P10467004A0683 |83 108|EBS2/IBS2 sequence motifs000 Pharmacologic aspects
P10467004A0683 |65 74|EBS1/IBS1tidase P0
P10467403A0000 |4 36|Trk/Nerve Growth Factor receptor01606T0076 Comparison with alkal
P10467403A0000 |72 78|numberP00008
P10467403A0000 |126 155|phosphatidylinositol 3-kinasebilirubinemia. P00008997A0472
P10467403A0000 |56 66|activation 5-nucleot
P10467403A0000 |96 114|signaling proteinsogic aspects of ne
P10467403A0000 |157 168|PI 3-kinasehen CSF [HC
P10467465T0000 |19 39|significance testingarison with alkaline
P10467465T0000 |60 72|alternativesucleotidase 
P10467465T0000 |41 55|misconceptionshosphatases an
P10467465T0000 |4 15|controversy01606T0076 
P10468033T0000 |0 15|Chemical uptakeP00001606T0076 
P10468033T0000 |27 42|stratum corneumith alkaline ph
P10468033T0000 |82 90|solvents0000 Pha
P10468585A0980 |34 45|enhancementaline phosp
P10468585A0980 |147 152|Hap46997A0
P10468585A0980 |5 16|DNA binding1606T0076 C
P10468585A0980 |177 194|hsp70 interactionhown as a functio
P10468585A0980 |86 105|amino acid residues Pharmacologic aspe
P10468585A0980 |136 143|portionmia. P0
P10469140A0336 |204 221|mutation analysesCO2 the data of K
P10469140A0336 |127 135|TNFalphailirubin
P10469140A0336 |109 123|responsivenessof neonatal hy
P10469140A0336 |60 65|sitesucleo
P10469140A0336 |96 104|promoterogic asp
P10469140A0336 |142 199|chloramphenicol acetyl transferase reporter gene deletion00008997A0472 When CSF [HCO3-] is shown as a function of 
P10469140A0336 |81 86|PAI-2T0000
P10469140A0336 |19 27|functionarison w
P10469174A0678 |69 77|fragmentse P0000
P10469174A0678 |11 28|sequence analysis076 Comparison wi
P10469174A0678 |167 173|domainCO3-] 
P10469174A0678 |183 190|MBF1CTDs a fun
P10469174A0678 |177 181|MBF1hown
P10469174A0678 |124 128|MBF1erbi
P10469174A0678 |112 120|residuesneonatal
P10469174A0678 |33 49|NMR measurementskaline phosphata
P10469656T0000 |16 24|responseompariso
P10469656T0000 |121 125|MSK1hype
P10469656T0000 |159 165|kinasen CSF 
P10469656T0000 |57 71|gene induction5-nucleotidase
P10469656T0000 |141 155|histone H3/HMGP00008997A0472
P10469656T0000 |100 119|MAP kinase cascades aspects of neonata
P10470220A1011 |4 15|arrangement01606T0076 
P10470220A1011 |127 130|RIAili
P10470220A1011 |182 183|%a
P10470220A1011 |91 92|%m
P10470220A1011 |74 85|specificity0008171T000
P10470220A1011 |165 176|specificity[HCO3-] is 
P10470220A1011 |50 61|sensitivityes and 5-nu
P10470220A1011 |158 159|%e
P10470220A1011 |25 38|cutoff-levels with alkalin
P10470220A1011 |67 68|%d
P10470220A1011 |97 109|Protein S100gic aspects 
P10470220A1011 |201 204|LIAF P
P10470220A1011 |141 152|sensitivityP00008997A0
P10471587A0239 |289 300|amoxicillin still have
P10471587A0239 |158 172|antimicrobialsen CSF [HCO3-]
P10471587A0239 |196 200|MICsof C
P10471587A0239 |9 16|strainsT0076 C
P10471587A0239 |215 221|RT-PCRa of K
P10471587A0239 |134 143|techniquenemia. P0
P10471587A0239 |38 55|triplicate assayse phosphatases an
P10471587A0239 |20 34|C. trachomatisrison with alk
P10471587A0239 |70 83|RT-PCR methode P00008171T0
P10471587A0239 |252 264|erythromycinsplaced when
P10471696A0734 |16 20|SAS4ompa
P10471696A0734 |25 29|SAS5 wit
P10471696A0734 |43 47|rolespha
P10471696A0734 |108 112|role of 
P10471696A0734 |120 123|ACS hy
P10471696A0734 |5 12|alleles1606T00
P10471696A0734 |127 145|Rap1p binding siteilirubinemia. P000
P10471696A0734 |55 73|Abf1p binding sited 5-nucleotidase P
P10471696A0734 |81 95|HMR-E silencerT0000 Pharmaco
P10471721A0141 |17 25|analysismparison
P10471721A0141 |146 159|pollen S gene8997A0472 Whe
P10471721A0141 |160 161|s 
P10471721A0141 |181 186|genes as a
P10471721A0141 |99 104|genesc asp
P10471721A0141 |112 115|SLGneo
P10471721A0141 |48 55|S locusases an
P10471721A0141 |117 120|SRKtal
P10471743A0000 |2 6|cDNA0001
P10471743A0000 |74 109|Arabidopsis thaliana cDNA libraries0008171T0000 Pharmacologic aspects 
P10471743A0000 |27 30|RNAith
P10471743A0000 |38 50|DNA helicasee phosphatas
P10471746A1102 |116 138|Myogenin transcriptionatal hyperbilirubinemi
P10471746A1102 |9 13|MyoDT007
P10471746A1102 |28 44|tryptophan motifth alkaline phos
P10471746A1102 |82 99|Myogenin promoter0000 Pharmacologi
P10471746A1102 |54 74|chromatin remodelingnd 5-nucleotidase P0
P10472314A0717 |68 73|womenase P
P10472314A0717 |31 35|PUNPalka
P10472314A0717 |24 27|TTPn w
P10472314A0717 |13 20|Periods6 Compa
P10472314A0717 |53 56|menand
P10472314A0717 |0 7|RESULTSP000016
P10472836A0189 |0 11|Feed intakeP00001606T0
P10472836A0189 |41 42|Ph
P10472836A0189 |62 72|treatmentsleotidase 
P10472836A0189 |16 24|BW gainsompariso
P10472836A0189 |84 86|M.00
P10473589A0189 |18 22|betapari
P10473589A0189 |62 78|integrase domainleotidase P00008
P10473589A0189 |47 52|alphatases
P10473589A0189 |95 105|C terminuslogic aspe
P10473589A0189 |27 30|kDaith
P10473589A0189 |110 113|kDaf n
P10473589A0189 |4 14|N terminus01606T0076
P10473598A0691 |137 152|transactivationia. P00008997A0
P10473598A0691 |163 169|Skn-1aF [HCO
P10473598A0691 |30 36|region alkal
P10473598A0691 |173 191|competition assaysis shown as a func
P10473598A0691 |53 76|transactivation abilityand 5-nucleotidase P000
P10473598A0691 |98 106|promoteric aspec
P10473598A0691 |0 6|Skn-1aP00001
P10473623A0081 |119 128|formationl hyperbi
P10473623A0081 |89 99|gene Mix.2armacologi
P10473623A0081 |183 186|ARFs a
P10473623A0081 |9 24|Xenopus embryosT0076 Compariso
P10473623A0081 |147 154|complex997A047
P10473623A0081 |43 76|growth factor-beta member activinsphatases and 5-nucleotidase P000
P10473623A0081 |175 181|factor shown
P10474898A0629 |207 215|primates the dat
P10474898A0629 |125 129|FISHrbil
P10474898A0629 |167 173|assaysCO3-] 
P10474898A0629 |72 88|CMT1A-REP repeatP00008171T0000 P
P10474898A0629 |28 37|structureth alkali
P10474898A0629 |110 123|hybridizationf neonatal hy
P10474898A0629 |131 139|analysisubinemia
P10474898A0629 |197 203|seriesf CSF 
P10474898A0629 |55 64|synthesisd 5-nucle
P10475610A1289 |0 5|Natl.P0000
P10475972A0269 |19 27|outbreakarison w
P10475972A0269 |7 11|face06T0
P10475972A0269 |41 46|delayhosph
P10475972A0269 |83 89|deaths000 Ph
P10475972A0269 |54 65|vaccinationnd 5-nucleo
P10476970A0542 |140 146|family P0000
P10476970A0542 |165 175|G-proteins[HCO3-] is
P10476970A0542 |135 136|Ge
P10476970A0542 |60 67|proteinucleoti
P10476970A0542 |76 85|rap1GAPII08171T000
P10476970A0542 |26 33|isoformwith al
P10476970A0542 |37 41|Raplne p
P10476970A0542 |113 127|alpha-subunitseonatal hyperb
P10477545T0000 |18 33|pertussis toxinparison with al
P10477545T0000 |99 112|HIV-1 strainsc aspects of 
P10477545T0000 |46 67|CC chemokine receptoratases and 5-nucleoti
P10477545T0000 |4 14|B-oligomer01606T0076
P10477545T0000 |81 86|entryT0000
P10477583A0000 |19 37|B cell Ag receptorarison with alkali
P10477583A0000 |77 87|Fc gamma R8171T0000 
P10477583A0000 |123 132|mechanismperbiliru
P10477583A0000 |106 117|progressionts of neona
P10477583A0000 |72 75|IgGP00
P10477583A0000 |106 117|progressionts of neona
P10477583A0000 |72 75|IgGP00
P10477583A0000 |19 37|B cell Ag receptorarison with alkali
P10477583A0000 |55 67|Fc receptorsd 5-nucleoti
P10477583A0000 |39 42|BCR ph
P10477583A0000 |77 87|Fc gamma R8171T0000 
P10477583A0000 |123 132|mechanismperbiliru
P10477583A0000 |39 42|BCR ph
P10477583A0000 |55 67|Fc receptorsd 5-nucleoti
P10477597A0126 |0 5|TRAF2P0000
P10477597A0126 |129 133|KHS1irub
P10477597A0126 |40 63|serine/threonine kinasephosphatases and 5-nucl
P10477597A0126 |150 160|activationA0472 When
P10477597A0126 |18 27|activatorparison w
P10477597A0126 |80 93|center kinase1T0000 Pharma
P10477597A0126 |168 180|SAPK pathwayO3-] is show
P10477597A0126 |103 107|GCKRpect
P10477599T0000 |80 84|site1T00
P10477599T0000 |25 32|element with a
P10477599T0000 |43 52|C motif-1sphatases
P10477599T0000 |178 184|T cellown as
P10477599T0000 |127 139|interactionsilirubinemia
P10477599T0000 |53 74|lymphotactin promoterand 5-nucleotidase P0
P10477599T0000 |158 164|factoren CSF
P10477620A0580 |171 179|activity] is sho
P10477620A0580 |78 105|I kappa B alpha degradation171T0000 Pharmacologic aspe
P10477620A0580 |148 164|I kappa B kinase97A0472 When CSF
P10477620A0580 |63 76|translocationeotidase P000
P10477620A0580 |166 169|IKKHCO
P10477620A0580 |107 123|I kappa B serines of neonatal hy
P10477620A0580 |127 142|phosphorylationilirubinemia. P
P10477620A0580 |196 214|curcumin treatmentof CSF PCO2 the da
P10477620A0580 |50 54|RelAes a
P10477620A0580 |17 48|NF-kappa B DNA binding activitymparison with alkaline phosphat
P10477748A1076 |2 9|portion0001606
P10477748A1076 |13 17|p1936 Co
P10477748A1076 |58 65|spindle-nucleo
P10478275A1230 |221 229|contrast-deplete
P10478275A1230 |24 28|needn wi
P10478275A1230 |9 15|issuesT0076 
P10478275A1230 |106 110|dietts o
P10478275A1230 |164 169|foods [HCO
P10478275A1230 |189 199|technologynction of 
P10478275A1230 |42 48|numberosphat
P10478275A1230 |66 76|mechanismsidase P000
P10478275A1230 |141 145|riskP000
P10478844A1604 |0 14|CotransfectionP00001606T0076
P10478844A1604 |113 124|PPARalphatreonatal hyp
P10478844A1604 |232 244|coactivatorsats are no l
P10478844A1604 |22 33|coactivatorson with al
P10478844A1604 |47 54|proteintases a
P10478844A1604 |164 170|effect [HCO3
P10478844A1604 |98 109|PPARalphawtic aspects 
P10478844A1604 |174 185|PPARalphatrs shown as 
P10478844A1604 |206 217|competition2 the data 
P10478844A1604 |84 94|repression00 Pharmac
P10478848A0331 |0 4|SF-1P000
P10478848A0331 |33 43|AF1 domainkaline pho
P10479025A0528 |137 146|responsesia. P0000
P10479025A0528 |104 115|spectrogramects of neo
P10479025A0528 |46 64|TF-MUSIC algorithmatases and 5-nucle
P10479025A0528 |29 36|sourcesh alkal
P10479025A0528 |83 96|target region000 Pharmacol
P10479025A0528 |16 25|locationsomparison
P10479382A1098 |17 24|resultsmpariso
P10479382A1098 |28 33|termsth al
P10479382A1098 |105 125|development patternscts of neonatal hype
P10479382A1098 |56 60|time 5-n
P10479382A1098 |41 50|influencehosphatas
P10479382A1098 |130 137|fitnessrubinem
P10479382A1098 |77 88|constraints8171T0000 P
P10479492A0000 |0 9|OBJECTIVEP00001606
P10479492A0000 |67 71|datadase
P10479492A0000 |88 89|%h
P10479492A0000 |61 65|SEERcleo
P10479492A0000 |30 42|Epidemiology alkaline ph
P10479492A0000 |115 153|corpus uteri adenocarcinoma FIGO stagenatal hyperbilirubinemia. P00008997A04
P10479492A0000 |97 110|survival rategic aspects o
P10479492A0000 |48 59|End Resultsases and 5-
P10479492A0000 |16 28|Surveillanceomparison wi
P10480937A0000 |187 189|Cafu
P10480937A0000 |181 185|cAMP as 
P10480937A0000 |8 42|Drosophila A kinase anchor protein6T0076 Comparison with alkaline ph
P10480937A0000 |230 232|E. r
P10480937A0000 |162 169|signalsSF [HCO
P10480937A0000 |199 213|diacylglycerolCSF PCO2 the d
P10480937A0000 |215 217|Lia 
P10480937A0000 |55 78|A kinase anchor proteind 5-nucleotidase P00008
P10480937A0000 |219 221|Z. K
P10480937A0000 |223 228|Rossieplet
P10480937A0000 |84 92|DAKAP20000 Pharm
P10482516A1158 |157 182|transcription readthroughhen CSF [HCO3-] is shown 
P10482516A1158 |125 134|stem-looprbilirubi
P10482516A1158 |109 117|deletionof neona
P10482516A1158 |145 153|increase08997A04
P10482516A1158 |9 30|transcription resultsT0076 Comparison with
P10482516A1158 |53 72|structure functionsand 5-nucleotidase 
P10482516A1158 |80 101|attenuation mechanism1T0000 Pharmacologic 
P10482516T0000 |39 74|transcription attenuation mechanism phosphatases and 5-nucleotidase P0
P10482516T0000 |107 141|Bacillus subtilis trpEDCFBA operons of neonatal hyperbilirubinemia. 
P10482516T0000 |89 99|expressionarmacologi
P10482516T0000 |5 18|RNA stem-loop1606T0076 Com
P10482565A0469 |93 99|fusioncologi
P10482565A0469 |28 37|mutationsth alkali
P10482565A0469 |59 66|effectsnucleot
P10482620A1009 |103 109|Stat5apects 
P10482620A1009 |113 133|transcription factoreonatal hyperbilirub
P10482620A1009 |92 99|absenceacologi
P10482620A1009 |56 60|MMTV 5-n
P10482620A1009 |33 46|transcriptionkaline phosph
P10482620A1009 |64 67|LTRoti
P10482620A1009 |184 197|transcription a function o
P10482620A1009 |207 215|MMTV LTR the dat
P10483124T0000 |0 8|RegionalP0000160
P10483124T0000 |146 157|combination8997A0472 W
P10483124T0000 |167 187|cDNA scanning methodCO3-] is shown as a 
P10483124T0000 |45 50|geneshatas
P10483124T0000 |126 142|Ac/Ds transposonbilirubinemia. P
P10483124T0000 |58 78|CIC5F11/CIC2B9 locus-nucleotidase P00008
P10483124T0000 |82 113|Arabidopsis thaliana chromosome0000 Pharmacologic aspects of n
P10483124T0000 |21 32|mutagenesisison with a
P10483945A0641 |68 72|1-3xase 
P10483945A0641 |45 53|patientshatases 
P10483945A0641 |83 87|3-5x000 
P10483945A0641 |59 60|%n
P10483945A0641 |9 24|CK-MB elevationT0076 Compariso
P10483945A0641 |94 95|%o
P10483945A0641 |122 130|patientsyperbili
P10483945A0641 |101 103|5xas
P10483945A0641 |80 81|%1
P10483945A0641 |117 118|%t
P10483945A0641 |0 7|RESULTSP000016
P10484695A0791 |6 24|NART-R performance606T0076 Compariso
P10484695A0791 |44 52|estimatephatases
P10484695A0791 |72 80|patientsP0000817
P10484695A0791 |122 141|language impairmentyperbilirubinemia. 
P10484695A0791 |56 67|baseline IQ 5-nucleoti
P10484695A0791 |97 106|disordersgic aspec
P10484818A0292 |49 75|cross-correlation analysisses and 5-nucleotidase P00
P10484818A0292 |10 15|areas0076 
P10484818A0292 |40 45|meansphosp
P10485353T0000 |137 143|Franceia. P0
P10485353T0000 |92 100|childrenacologic
P10485353T0000 |106 117|West Africats of neona
P10485353T0000 |47 72|polysaccharide antibodiestases and 5-nucleotidase 
P10485353T0000 |163 173|serosurveyF [HCO3-] 
P10485353T0000 |8 37|Haemophilus influenzae type b6T0076 Comparison with alkali
P10485353T0000 |80 87|infants1T0000 
P10485353T0000 |119 131|Burkina-Fasol hyperbilir
P10485470A0242 |50 57|factorses and 
P10485470A0242 |29 32|Sp1h a
P10485470A0242 |73 82|Sp1 sites00008171T
P10485470A0242 |224 242|binding activitiespleted rats are no
P10485470A0242 |151 172|mobility shift assays0472 When CSF [HCO3-]
P10485470A0242 |90 112|p21/WAF1/Cip1 promoterrmacologic aspects of 
P10485470A0242 |37 40|Sp3ne 
P10485470A0242 |8 13|study6T007
P10485470A0242 |189 202|TSA treatmentnction of CSF
P10485470A0242 |116 126|MG63 cellsatal hyper
P10485585A0175 |68 81|neurohormonesase P00008171
P10485585A0175 |27 34|resultsith alk
P10485585A0175 |42 51|discoveryosphatase
P10485585A0175 |0 7|GaloyanP000016
P10486210A0126 |81 89|promoterT0000 Ph
P10486210A0126 |31 41|expressionalkaline p
P10486210A0126 |13 23|regulation6 Comparis
P10486210A0126 |53 76|aldehyde reductase geneand 5-nucleotidase P000
P10487040A0453 |34 39|MIB-1aline
P10487040A0453 |44 58|p53 antibodiesphatases and 5
P10487040A0453 |90 98|reactionrmacolog
P10487040A0453 |74 75|%0
P10487040A0453 |20 28|stainingrison wi
P10487217A0735 |102 108|signalspects
P10487217A0735 |134 144|N-terminusnemia. P00
P10487217A0735 |46 57|amino acidsatases and 
P10487217A0735 |28 38|preproteinth alkalin
P10487217A0735 |4 11|C2C-Prx01606T0
P10487217A0735 |115 126|amino acidsnatal hyper
P10487307A0768 |19 35|surgery patientsarison with alka
P10487307A0768 |89 96|placeboarmacol
P10487307A0768 |121 126|orderhyper
P10487307A0768 |83 85|mg00
P10487307A0768 |64 78|hydrocortisoneotidase P00008
P10487744T0000 |17 31|sorting signalmparison with 
P10487744T0000 |66 72|domainidase 
P10487744T0000 |156 165|migrationWhen CSF 
P10487744T0000 |39 53|beta2 integrin phosphatases 
P10487744T0000 |86 95|recycling Pharmaco
P10487744T0000 |103 118|plasma membranepects of neonat
P10487753A0788 |17 30|XDRP1 proteinmparison with
P10487753A0788 |47 59|Xenopus eggstases and 5-
P10487753A0788 |78 91|cell division171T0000 Phar
P10487753A0788 |4 13|injection01606T007
P10487759A0630 |17 32|Xenopus embryosmparison with a
P10487759A0630 |124 134|expressionerbilirubi
P10487759A0630 |162 175|reporter geneSF [HCO3-] is
P10487759A0630 |58 67|integrity-nucleoti
P10487759A0630 |140 145|Xbra2 P000
P10487759A0630 |81 90|sequencesT0000 Pha
P10487760A0336 |3 8|order00160
P10487760A0336 |28 37|cofactorsth alkali
P10487760A0336 |91 104|Xenopus MEF2Dmacologic asp
P10487760A0336 |110 115|yeastf neo
P10487760A0336 |12 18|screen76 Com
P10487760A0336 |127 133|screenilirub
P10487760A0336 |81 87|mutantT0000 
P10487762A0252 |0 4|NuA4P000
P10487762A0252 |31 35|massalka
P10487762A0252 |43 46|MDasph
P10487921A0132 |0 18|ATF1 transcriptionP00001606T0076 Com
P10487921A0132 |74 80|oxygen000817
P10487921A0132 |64 69|acidsotida
P10487953A0765 |4 12|patients01606T00
P10487953A0765 |44 61|S-phase fractionsphatases and 5-nu
P10487953A0765 |89 98|specimensarmacolog
P10487953A0765 |28 34|tumorsth alk
P10487953A0765 |110 114|timef ne
P10487953A0765 |129 138|operationirubinemi
P10488087A0340 |0 8|MutationP0000160
P10488087A0340 |112 116|SP-Aneon
P10488087A0340 |26 31|siteswith 
P10488087A0340 |182 201|SP-A gene sequencesas a function of CS
P10488087A0340 |53 64|combinationand 5-nucle
P10488087A0340 |142 170|acetyltransferase constructs00008997A0472 When CSF [HCO3
P10488087A0340 |33 36|TBEkal
P10488087A0340 |100 108|activity aspects
P10488088T0000 |115 122|proteinnatal h
P10488088T0000 |13 28|growth factor-I6 Comparison wi
P10488088T0000 |37 51|bcl-2 promoterne phosphatase
P10488088T0000 |64 84|transcription factorotidase P00008171T00
P10488129T0058 |0 9|SynthesisP00001606
P10488129T0058 |60 73|E2F complexesucleotidase P
P10488129T0058 |77 83|intron8171T0
P10488129T0058 |31 32|Sa
P10488129T0058 |23 26|RNAon 
P10488129T0058 |49 56|bindingses and
P10488147A1176 |85 107|eosinophil trafficking0 Pharmacologic aspect
P10488147A1176 |74 81|control0008171
P10488147A1176 |143 152|phenomena0008997A0
P10488147A1176 |53 66|understandingand 5-nucleot
P10488147A1176 |18 27|eotaxin-3parison w
P10488147A1176 |0 14|IdentificationP00001606T0076
P10488148A0111 |0 9|NF-kappaBP00001606
P10488148A0111 |111 139|signal transduction pathways neonatal hyperbilirubinemia
P10488148A0111 |27 31|roleith 
P10488148A0111 |94 101|stimuliologic 
P10488148A0111 |74 83|cytokines0008171T0
P10488148A0111 |191 200|infectiontion of C
P10488148A0111 |158 164|switchen CSF
P10488148A0111 |49 70|HIV-1 gene expressionses and 5-nucleotidas
P10488148A0111 |35 45|activationline phosp
P10488148A1267 |98 109|interactionic aspects 
P10488148A1267 |27 31|MAPKith 
P10488148A1267 |123 132|NF-kappaBperbiliru
P10488148A1267 |149 156|complex7A0472 
P10488148A1267 |52 56|AP-1 and
P10488148A1267 |197 206|HIV-1 LTRf CSF PCO
P10488148A1267 |6 13|studies606T007
P10488148A1267 |113 117|AP-1eona
P10488148T0000 |0 37|ERK MAP kinase links cytokine signalsP00001606T0076 Comparison with alkali
P10488148T0000 |62 77|HIV-1 infectionleotidase P0000
P10488148T0000 |122 126|AP-1yper
P10488148T0000 |107 118|interactions of neonat
P10488148T0000 |41 51|activationhosphatase
P10488148T0000 |131 140|NF-kappaBubinemia.
P10488337T0000 |51 63|dimerizations and 5-nucl
P10488337T0000 |110 123|bZIP proteinsf neonatal hy
P10488337T0000 |26 35|chaperonewith alka
P10488337T0000 |65 76|DNA bindingtidase P000
P10488337T0000 |98 106|activityic aspec
P10488875A0000 |65 70|palsytidas
P10488875A0000 |91 102|toe walkingmacologic a
P10488875A0000 |28 36|patientsth alkal
P10488875A0000 |104 107|ITWect
P10488875A0000 |72 74|CPP0
P10488875A0000 |9 24|differentiationT0076 Compariso
P10489680A0927 |0 11|Sputum IL-8P00001606T0
P10489680A0927 |95 96|Pl
P10489680A0927 |67 70|TDIdas
P10489680A0927 |76 93|grain dust-asthma08171T0000 Pharma
P10489680A0927 |55 58|BPTd 5
P10489680A0927 |16 19|MPOomp
P10489822T0000 |0 11|MontelukastP00001606T0
P10489822T0000 |56 62|asthma 5-nuc
P10489822T0000 |89 94|trialarmac
P10489822T0000 |40 52|inflammationphosphatases
P10489822T0000 |20 26|airwayrison 
P10490065T0000 |0 9|TreatmentP00001606
P10490065T0000 |30 34|role alk
P10490065T0000 |22 28|anginason wi
P10490065T0000 |53 60|therapyand 5-n
P10490604A0601 |70 73|Lcke P
P10490604A0601 |26 37|kinase-deadwith alkali
P10490604A0601 |79 95|ZAP-70 block 70Z71T0000 Pharmaco
P10490604A0601 |56 61|forms 5-nu
P10490604A0601 |109 124|NFAT activationof neonatal hyp
P10490604A0601 |65 68|Fyntid
P10490609A0413 |220 232|ARS activityK-depleted r
P10490609A0413 |75 83|sequence008171T0
P10490609A0413 |144 152|thymines008997A0
P10490609A0413 |162 174|interruptionSF [HCO3-] i
P10490609A0413 |95 102|repeatslogic a
P10490609A0413 |41 50|sequenceshosphatas
P10490609A0413 |132 140|adeninesbinemia.
P10490609A0413 |189 197|cytosinenction o
P10490609A0413 |178 185|guanineown as 
P10490609A0413 |0 13|SubstitutionsP00001606T007
P10490609A0413 |17 23|regionmparis
P10490639A0000 |186 201|cyclin partners function of CS
P10490639A0000 |78 81|Cdk171
P10490639A0000 |29 34|PHO85h alk
P10490639A0000 |62 76|protein kinaseleotidase P000
P10490639A0000 |93 100|subunitcologic
P10490639A0000 |126 131|rolesbilir
P10490639A0000 |159 170|associationn CSF [HCO3
P10490639A0000 |203 207|PclsPCO2
P10490662A0431 |0 7|MutantsP000016
P10490662A0431 |46 52|adultsatases
P10490662A0431 |76 88|morphologies08171T0000 P
P10490662A0431 |108 120|compound eye of neonatal
P10490662A0431 |96 106|appendagesogic aspec
P10490662A0431 |18 30|lace allelesparison with
P10490662A0819 |3 7|fact0016
P10490662A0819 |9 21|SPT activityT0076 Compar
P10490662A0819 |29 32|flyh a
P10490662A0819 |59 63|Lacenucl
P10490662A0819 |97 105|antibodygic aspe
P10490816A0000 |17 25|RET genemparison
P10490816A0000 |132 138|MEN 2Bbinemi
P10490816A0000 |104 127|cancer syndromes MEN 2Aects of neonatal hyperb
P10490816A0000 |38 62|receptor tyrosine kinasee phosphatases and 5-nuc
P10490816A0000 |0 9|MutationsP00001606
P10490822A1167 |80 88|approach1T0000 P
P10490822A1167 |24 33|targetingn with al
P10490822A1167 |37 44|Ras-GAPne phos
P10490822A1167 |6 13|results606T007
P10490826T0000 |0 4|EB-1P000
P10490826T0000 |88 89|th
P10490826T0000 |8 48|tyrosine kinase signal transduction gene6T0076 Comparison with alkaline phosphat
P10490826T0000 |131 151|oncoprotein E2a-Pbx1ubinemia. P00008997A
P10490826T0000 |112 115|ALLneo
P10490826T0000 |96 102|subsetogic a
P10490835T0000 |51 61|inhibitions and 5-nu
P10490835T0000 |108 141|tyrosine kinase signaling pathway of neonatal hyperbilirubinemia. 
P10490835T0000 |73 91|cancer cell growth00008171T0000 Phar
P10490835T0000 |93 102|crosstalkcologic a
P10490835T0000 |0 23|Protein kinase A-IalphaP00001606T0076 Comparis
P10490843A0159 |0 4|BCL6P000
P10490843A0159 |167 177|malignancyCO3-] is s
P10490843A0159 |15 36|POZ/Zn finger proteinComparison with alkal
P10490843A0159 |125 132|proteinrbiliru
P10490843A0159 |40 49|structurephosphata
P10490843A0159 |179 183|PLZFwn a
P10490843A0159 |99 109|regulatorsc aspects 
P10490955T0000 |0 4|BetaP000
P10490955T0000 |133 149|thrombospondin-1inemia. P0000899
P10490955T0000 |105 129|protein kinase signalingcts of neonatal hyperbil
P10490955T0000 |58 82|T lymphoma cell adhesion-nucleotidase P00008171T
P10490955T0000 |43 54|stimulationsphatases a
P10490955T0000 |7 15|integrin06T0076 
P10490955T0000 |154 179|thrombospondin-1 peptides2 When CSF [HCO3-] is sho
P10491133A0365 |68 78|reactivityase P00008
P10491133A0365 |122 131|NO donorsyperbilir
P10491133A0365 |82 93|HO isozymes0000 Pharma
P10491133A0365 |29 46|activity analysesh alkaline phosph
P10491133A0365 |99 109|NO speciesc aspects 
P10491133A0365 |0 10|Optical CDP00001606T
P10491187T0000 |4 29|phosphotransferase system01606T0076 Comparison wit
P10491187T0000 |31 34|PTSalk
P10491187T0000 |94 102|analysisologic a
P10491187T0000 |63 77|identificationeotidase P0000
P10491187T0000 |160 169|gene ptsH CSF [HCO
P10491187T0000 |108 144|histidine phosphocarrier protein HPr of neonatal hyperbilirubinemia. P00
P10491213A0263 |0 20|Serum concentrationsP00001606T0076 Compa
P10491213A0263 |167 171|DpyrCO3-
P10491213A0263 |186 196|tomography function 
P10491213A0263 |290 297|densitystill h
P10491213A0263 |358 374|material density3A0733 Flurazepa
P10491213A0263 |429 433|boyse op
P10491213A0263 |115 121|levelsnatal 
P10491213A0263 |251 260|vertebraeisplaced 
P10491213A0263 |125 137|pyridinolinerbilirubinem
P10491213A0263 |60 64|BALPucle
P10491213A0263 |387 391|bones to
P10491213A0263 |24 28|bonen wi
P10491213A0263 |148 165|deoxypyridinoline97A0472 When CSF 
P10491213A0263 |449 453|agesse i
P10491213A0263 |269 275|femursared t
P10491213A0263 |238 243|arease no 
P10491213A0263 |442 447|girlse for
P10491213A0263 |101 104|BGPasp
P10491213A0263 |38 58|alkaline phosphatasee phosphatases and 5
P10491213A0263 |312 316|bonently
P10491213A0263 |198 200|CT C
P10491213A0263 |324 333|vertebrae slope (1
P10491213A0263 |459 464|yearsral p
P10491213A0263 |399 405|femursffecti
P10491213A0263 |83 99|bone Gla protein000 Pharmacologi
P10491213A0263 |70 81|osteocalcine P00008171
P10491213A0263 |202 214|measurements PCO2 the da
P10491213A0263 |139 142|Pyr. P
P10491213A0263 |343 349|volume23 vs.
P10492127A0914 |207 209|hr t
P10492127A0914 |127 135|mg/kg/hrilirubin
P10492127A0914 |11 16|study076 C
P10492127A0914 |149 152|min7A0
P10492127A0914 |30 44|administration alkaline phos
P10492127A0914 |115 119|dosenata
P10492127A0914 |173 186|saline intakeis shown as a
P10492127A0914 |48 58|devazepideases and 5
P10492127A0914 |71 108|cholecystokinin-A receptor antagonist P00008171T0000 Pharmacologic aspects
P10492169A0939 |155 162|EST-YD1 When C
P10492169A0939 |111 117|PAPP-A neona
P10492169A0939 |131 135|geneubin
P10492169A0939 |52 56|ESTs and
P10492169A0939 |93 109|plasma protein-Acologic aspects 
P10492169A0939 |5 12|cluster1606T00
P10492169A0939 |65 70|genestidas
P10493203T0000 |118 121|ECGal 
P10493203T0000 |11 16|value076 C
P10493203T0000 |62 70|patientsleotidas
P10493203T0000 |93 106|abnormalitiescologic aspec
P10493203T0000 |22 46|treadmill exercise scoreson with alkaline phosph
P10493575T0000 |51 60|rat S100Bs and 5-n
P10493575T0000 |148 151|p5397A
P10493575T0000 |62 71|beta betaleotidase
P10493575T0000 |91 98|peptidemacolog
P10493575T0000 |26 36|C-terminuswith alkal
P10493575T0000 |11 18|changes076 Com
P10493575T0000 |40 43|Ca2pho
P10493575T0000 |138 144|domaina. P00
P10493580A1126 |16 21|Gly84ompar
P10493580A1126 |25 29|part wit
P10493580A1126 |45 58|oxyanion holehatases and 5
P10493580A1126 |129 136|C groupirubine
P10493580A1126 |76 89|stabilization08171T0000 Ph
P10493580A1126 |144 166|esterase/lipase family008997A0472 When CSF [
P10493580A1126 |97 113|transition stategic aspects of n
P10493876A0000 |275 286|residue dA6o controls 
P10493876A0000 |599 607|NMR datauction (
P10493876A0000 |531 537|duplexP00013
P10493876A0000 |248 259|amino groupr displaced
P10493876A0000 |419 420|Bu
P10493876A0000 |244 245|No
P10493876A0000 |421 422|g 
P10493876A0000 |63 70|bondingeotidas
P10493876A0000 |423 424|Ci
P10493876A0000 |652 664|calculations0015731A0090
P10493876A0000 |517 519|dAck
P10493876A0000 |511 512|Bt
P10493876A0000 |101 104|12Rasp
P10493876A0000 |648 650|MD. 
P10493876A0000 |513 514|g 
P10493876A0000 |96 99|11Sogi
P10493876A0000 |515 516|Cl
P10493876A0000 |447 448|d 
P10493876A0000 |380 402|DNA sequence context d appears to be an effe
P10493876A0000 |111 114|14S ne
P10493876A0000 |160 168|epoxy-11 CSF [HC
P10493876A0000 |106 109|13Rts 
P10493876A0000 |521 523|dTg 
P10493876A0000 |318 319|Br
P10493876A0000 |425 444|A6-C7-T8-T9-C10-C11h the optimum dose 
P10493876A0000 |116 128|stereoisomeratal hyperbi
P10493876A0000 |489 496|A21-G22ght. P0
P10493876A0000 |352 372|thymine residue dT170010943A0733 Fluraze
P10493876A0000 |324 327|dA6 sl
P10493876A0000 |322 323|Ce
P10493876A0000 |218 219|Bf
P10493876A0000 |320 321|ga
P10493876A0000 |144 156|dihydroxy-13008997A0472 
P10493876A0000 |574 585|informationval approxi
P10493876A0000 |638 646|dynamicsost ceas
P10493876A0000 |449 484|G12-G13-A14-A15-G16-T17-G18-A19-G20se in general practice being 15 mg 
P10493876A0000 |30 36|adduct alkal
P10493876A0000 |305 315|trans-antignificantl
P10493876A0000 |403 417|C1-T2-C3-T4-C5tive hypnotic 
P10493876A0000 |78 90|fjord region171T0000 Pha
P10493876A0000 |195 196|g 
P10493876A0000 |220 221|gK
P10493876A0000 |222 225|CDEdep
P10493876A0000 |4 22|solution structure01606T0076 Compari
P10493876A0000 |197 205|chrysenef CSF PC
P10493876A0000 |341 349|opposite0.23 vs.
P10493876A0000 |611 622|combination), alveolar
P10495573A0365 |100 107|studies aspect
P10495573A0365 |194 204|acceptancen of CSF P
P10495573A0365 |120 127|results hyperb
P10495573A0365 |6 16|sildenafil606T0076 C
P10495573A0365 |163 164|%F
P10495573A0365 |148 152|MUSE97A0
P10495573A0365 |29 35|marketh alka
P10495573A0365 |132 142|sildenafilbinemia. P
P10495573A0365 |55 60|placed 5-n
P10495573A0365 |173 179|courseis sho
P10495573A0365 |64 68|MUSEotid
P10495573A0365 |156 157|%W
P10496161A0503 |0 16|Serum antibodiesP00001606T0076 C
P10496161A0503 |45 46|%h
P10496161A0503 |63 74|guinea pigseotidase P0
P10496161A0503 |88 91|WPIhar
P10496161A0503 |96 100|ratsogic
P10496161A0503 |114 117|WPIona
P10496284A0115 |118 127|IgG indexal hyperb
P10496284A0115 |131 149|IgG synthesis rateubinemia. P0000899
P10496284A0115 |27 35|episodesith alka
P10496284A0115 |37 48|CSF proteinne phosphat
P10496284A0115 |76 82|levels08171T
P10496284A0115 |53 69|immunoglobulin Gand 5-nucleotida
P10496284A0115 |71 74|IgG P0
P10496303A1968 |171 176|mg/kg] is 
P10496303A1968 |53 67|valganciclovirand 5-nucleoti
P10496303A1968 |93 104|ganciclovircologic asp
P10496303A1968 |106 111|AUC24ts of
P10496303A1968 |156 167|ganciclovirWhen CSF [H
P10496303A1968 |80 89|exposures1T0000 Ph
P10496303A1968 |19 26|resultsarison 
P10496303A1968 |0 11|CONCLUSIONSP00001606T0
P10496388A1956 |119 126|concernl hyper
P10496388A1956 |12 24|nonperfusion76 Compariso
P10496388A1956 |104 110|eventsects o
P10496388A1956 |104 110|eventsects o
P10496388A1956 |119 126|concernl hyper
P10496388A1956 |68 72|dosease 
P10496388A1956 |49 56|vesselsses and
P10496388A1956 |80 85|J/cm21T000
P10496388A1956 |80 85|J/cm21T000
P10496388A1956 |12 24|nonperfusion76 Compariso
P10496388A1956 |49 56|vesselsses and
P10496388A1956 |68 72|dosease 
P10496553A1004 |49 56|percentses and
P10496553A1004 |66 71|weeksidase
P10496553A1004 |97 102|weeksgic a
P10496553A1004 |197 204|percentf CSF P
P10496553A1004 |122 129|figuresyperbil
P10496553A1004 |134 142|patientsnemia. P
P10496553A1004 |157 182|immunodeficiency syndromehen CSF [HCO3-] is shown 
P10496553A1004 |80 87|percent1T0000 
P10496553A1004 |4 16|healing rate01606T0076 C
P10496553A1004 |33 41|patientskaline p
P10497117A0358 |33 36|ORFkal
P10497117A0358 |45 54|V proteinhatases a
P10497117A0358 |99 102|ORFc a
P10497117A0358 |4 10|P mRNA01606T
P10497199A0559 |175 184|COUP-TFII shown as
P10497199A0559 |10 16|screen0076 C
P10497199A0559 |164 170|factor [HCO3
P10497199A0559 |20 25|yeastrison
P10497199A0559 |77 91|factor binding8171T0000 Phar
P10497199A0559 |99 103|GlREc as
P10497199A0559 |114 131|chicken ovalbuminonatal hyperbilir
P10497262A0000 |64 72|U5 snRNAotidase 
P10497262A0000 |31 35|genealka
P10497262A0000 |132 157|U5 RNA affinity selectionbinemia. P00008997A0472 W
P10497262A0000 |44 49|transphata
P10497262A0000 |162 174|cDNA cloningSF [HCO3-] i
P10497262A0000 |82 124|trypanosomatid species Leptomonas seymouri0000 Pharmacologic aspects of neonatal hyp
P10497800A0000 |119 126|bulimial hyper
P10497800A0000 |106 114|anorexiats of ne
P10497800A0000 |12 19|Butcher76 Comp
P10497800A0000 |67 75|McKinleydase P00
P10497800A0000 |56 64|Hathaway 5-nucle
P10497800A0000 |4 10|MMPI-A01606T
P10497800A0000 |50 54|MMPIes a
P10497874A0925 |19 40|phosphatidyl inositolarison with alkaline 
P10497874A0925 |13 17|hand6 Co
P10497874A0925 |135 153|PLC-gamma1 isozymeemia. P00008997A04
P10497874A0925 |45 57|bisphosphatehatases and 
P10497874A0925 |111 127|tyrosine residue neonatal hyperb
P10497874A0925 |92 107|phosphorylationacologic aspect
P10497874A0925 |59 63|PIP2nucl
P10497874A0925 |65 75|hydrolysistidase P00
P10498616A0157 |204 210|growthCO2 th
P10498616A0157 |214 218|IL-4ta o
P10498616A0157 |177 184|absencehown as
P10498616A0157 |89 93|IL-3arma
P10498616A0157 |74 87|interleukin-30008171T0000 
P10498616A0157 |105 138|mast cell/megakaryocyte cell linects of neonatal hyperbilirubinemi
P10498616A0157 |17 22|M-Rasmpari
P10498616A0157 |188 192|IL-3unct
P10498616A0157 |57 67|expression5-nucleoti
P10498616A0157 |233 250|expression levelsts are no longer 
P10498616A0157 |161 169|survivalCSF [HCO
P10498616A0157 |2 13|G22V mutant0001606T007
P10498616A0157 |274 280|growthto con
P10498616A1280 |186 194|parallel functio
P10498616A1280 |127 137|activationilirubinem
P10498616A1280 |10 15|M-Ras0076 
P10498616A1280 |56 63|exhibit 5-nucl
P10498616A1280 |218 225|p21 Rasf K-dep
P10498616A1280 |22 44|Caenorhabditis elegansson with alkaline phos
P10498616A1280 |153 168|signaling paths72 When CSF [HC
P10498616A1280 |85 93|features0 Pharma
P10498706A1219 |38 42|PecSe ph
P10498706A1219 |63 78|pelE expressioneotidase P00008
P10498706A1219 |108 117|repressor of neona
P10498706A1219 |123 127|KdgRperb
P10498706A1219 |20 24|datariso
P10498706A1219 |54 58|pelDnd 5
P10498717A1048 |102 117|RsmA productionspects of neona
P10498717A1048 |60 78|rsmB transcriptionucleotidase P00008
P10498717A1048 |6 18|observations606T0076 Com
P10498717A1048 |34 38|RsmCalin
P10499121A0542 |55 74|Class D instrumentsd 5-nucleotidase P0
P10499121A0542 |147 152|study997A0
P10499121A0542 |80 97|input compression1T0000 Pharmacolo
P10499121A0542 |128 138|enrollmentlirubinemi
P10499121A0542 |114 118|timeonat
P10499121A0542 |21 38|hearing aid usersison with alkalin
P10499357A0439 |0 12|SCOB testingP00001606T00
P10499357A0439 |179 187|behaviorwn as a 
P10499357A0439 |95 103|schedulelogic as
P10499357A0439 |146 154|exposure8997A047
P10499357A0439 |245 253|evidencenger dis
P10499357A0439 |91 93|FIma
P10499357A0439 |110 115|FI120f neo
P10499357A0439 |193 197|dataon o
P10499357A0439 |105 109|FR20cts 
P10499357A0439 |257 270|neurotoxicityed when compa
P10499357A0439 |81 89|intervalT0000 Ph
P10499357A0439 |64 69|ratiootida
P10499357A0439 |203 208|WeeksPCO2 
P10499357A0439 |71 73|FR P
P10499357A0439 |32 39|animalslkaline
P10501034A0839 |0 30|Ribonuclease protection assaysP00001606T0076 Comparison with
P10501034A0839 |134 140|mannernemia.
P10501034A0839 |45 49|hmg1hata
P10501034A0839 |198 212|pigment glands CSF PCO2 the 
P10501034A0839 |148 161|morphogenesis97A0472 When 
P10501034A0839 |54 58|hmg2nd 5
P10501034A0839 |216 223|embryos of K-d
P10501656A1415 |94 110|tumor cell linesologic aspects o
P10501656A1415 |13 23|expression6 Comparis
P10501656A1415 |41 63|Northern blot analysishosphatases and 5-nucl
P10501936T0000 |171 181|morphology] is shown
P10501936T0000 |20 37|Neurospora crassarison with alkali
P10501936T0000 |127 134|defectsilirubi
P10501936T0000 |58 80|membrane protein TOM70-nucleotidase P0000817
P10501936T0000 |115 118|RIPnat
P10501936T0000 |99 113|point mutationc aspects of n
P10501936T0000 |0 12|InactivationP00001606T00
P10501936T0000 |152 166|protein import472 When CSF [
P10501965A0879 |207 215|receptor the dat
P10501965A0879 |8 13|genes6T007
P10501965A0879 |147 152|genes997A0
P10501965A0879 |73 76|end000
P10501965A0879 |90 99|s6 kinasermacologi
P10501965A0879 |158 163|Gpr31en CS
P10501965A0879 |189 198|G-proteinnction of
P10501965A0879 |33 38|unitskalin
P10501965A0879 |101 105|Rsk3aspe
P10501969A1329 |4 11|results01606T0
P10501969A1329 |78 84|GATA-4171T00
P10501969A1329 |61 68|targetscleotid
P10501969A1329 |145 158|cardiogenesis08997A0472 Wh
P10501969A1329 |25 31|GATA-5 with 
P10502216A0289 |51 60|efegatrans and 5-n
P10502216A0289 |159 170|reperfusionn CSF [HCO3
P10502216A0289 |142 145|TPA000
P10502216A0289 |112 140|tissue plasminogen activatorneonatal hyperbilirubinemia.
P10502216A0289 |180 182|MIn 
P10502216A0289 |5 10|study1606T
P10502216A0289 |66 79|streptokinaseidase P000081
P10502216A0289 |39 47|efficacy phospha
P10502216A0289 |87 94|heparinPharmac
P10502402A0129 |116 127|possibilityatal hyperb
P10502402A0129 |160 161|T 
P10502402A0129 |133 138|TRAILinemi
P10502402A0129 |23 28|TRAILon wi
P10502402A0129 |176 188|cytotoxicityshown as a f
P10502402A0129 |83 102|mouse T lymphocytes000 Pharmacologic a
P10502402A0129 |203 213|regulationPCO2 the d
P10502402A0533 |136 159|T lymphocyte activationmia. P00008997A0472 Whe
P10502402A0533 |25 35|inhibitors with alka
P10502402A0533 |105 125|TRAIL gene inductioncts of neonatal hype
P10502402A0533 |64 92|signal transduction pathwaysotidase P00008171T0000 Pharm
P10502402A0533 |2 7|panel00016
P10502434A0367 |65 74|carcinomatidase P0
P10502434A0367 |132 151|vault brachytherapybinemia. P00008997A
P10502434A0367 |173 182|treatmentis shown 
P10502434A0367 |22 28|Augustson wi
P10502434A0367 |5 13|February1606T007
P10502434A0367 |39 47|patients phospha
P10502434A0604 |51 55|ICG2s an
P10502434A0604 |67 79|ICG3 diseasedase P000081
P10502434A0604 |7 15|patients06T0076 
P10502434A0604 |20 30|stage IBG3rison with
P10502434A0604 |39 43|ICG1 pho
P10502522A0000 |118 129|individualsal hyperbil
P10502522A0000 |146 156|cell lines8997A0472 
P10502522A0000 |10 26|provirus genomes0076 Comparison 
P10502522A0000 |92 103|lymphocytesacologic as
P10502522A0000 |36 62|T-cell leukemia virus typeine phosphatases and 5-nuc
P10503540A0602 |2 7|total00016
P10503540A0602 |15 27|primer pairsComparison w
P10503540A0602 |72 73|%P
P10503540A0602 |47 63|banding patternstases and 5-nucl
P10503540A0602 |106 113|allelests of n
P10503540A0602 |124 143|polyacrylamide gelserbilirubinemia. P0
P10503812A1450 |137 140|ageia.
P10503812A1450 |53 78|organ transplant patientsand 5-nucleotidase P00008
P10503812A1450 |159 162|agen C
P10503812A1450 |128 133|yearslirub
P10503812A1450 |29 34|studyh alk
P10503812A1450 |38 49|cyclosporine phosphata
P10503812A1450 |191 219|cyclosporin pharmacokineticstion of CSF PCO2 the data of
P10503812A1450 |98 118|allograft recipientsic aspects of neonat
P10503812A1450 |2 12|population0001606T00
P10504332A0701 |0 22|Immunofluoresence dataP00001606T0076 Compari
P10504332A0701 |247 254|markerser disp
P10504332A0701 |161 166|cellsCSF [
P10504332A0701 |63 71|receptoreotidase
P10504332A0701 |192 200|receptorion of C
P10504332A0701 |202 218|RAP fluorescence PCO2 the data o
P10504332A0701 |93 96|RAPcol
P10504332A0701 |140 147|pathway P00008
P10504332A0701 |115 122|markersnatal h
P10505694A0000 |85 89|PBMC0 Ph
P10505694A0000 |60 65|blooducleo
P10505694A0000 |78 83|cells171T0
P10505694A0000 |147 158|enhancement997A0472 Wh
P10505694A0000 |132 142|productionbinemia. P
P10505694A0000 |28 36|cytokineth alkal
P10505694A0000 |121 130|IFN-gammahyperbili
P10505694A0000 |16 21|IL-12ompar
P10505694A0000 |176 188|cytotoxicityshown as a f
P10505694A0000 |103 119|interferon-gammapects of neonata
P10505694A0000 |0 14|Interleukin-12P00001606T0076
P10505694A0739 |0 16|IL-12 productionP00001606T0076 C
P10505694A0739 |110 118|dialysisf neonat
P10505694A0739 |130 131|Pr
P10505694A0739 |120 121|r 
P10505694A0739 |81 93|hemodialyzerT0000 Pharma
P10505694A0739 |37 54|C3a concentrationne phosphatases a
P10505694A0739 |71 77|outlet P0000
P10505694A0739 |103 106|minpec
P10506143A0610 |169 172|EGF3-]
P10506143A0610 |112 116|JNK1neon
P10506143A0610 |213 218|MEKK1ata o
P10506143A0610 |147 157|activators997A0472 W
P10506143A0610 |230 255|GTP binding proteins Rac1 rats are no longer displ
P10506143A0610 |135 142|stimuliemia. P
P10506143A0610 |19 44|JNKK2-JNK1 fusion proteinarison with alkaline phos
P10506143A0610 |185 195|anisomycina function
P10506143A0610 |260 267|Cdc42Hswhen co
P10506143A0610 |174 183|TNF-alphas shown a
P10506143A0610 |197 211|UV irradiationf CSF PCO2 the
P10506143A0610 |64 76|JNK activityotidase P000
P10506143A0610 |3 13|HeLa cells001606T007
P10506160A0297 |0 2|J.P0
P10508522A1598 |4 11|results01606T0
P10508522A1598 |47 53|targettases 
P10508522A1598 |57 65|EWS-FLI15-nucleo
P10508522A1598 |22 34|TGF-beta RIIson with alk
P10509768A1118 |68 73|groupase P
P10509768A1118 |94 100|mmol/lologic
P10509768A1118 |105 106|%c
P10509768A1118 |127 150|serum cholesterol levelilirubinemia. P00008997
P10509768A1118 |108 117|reduction of neona
P10509768A1118 |4 13|reduction01606T007
P10509768A1118 |33 45|acids intakekaline phosp
P10510295A0606 |48 51|ERAase
P10510295A0606 |148 157|GLK1 gene97A0472 W
P10510295A0606 |13 46|ethanol repression autoregulation6 Comparison with alkaline phosph
P10510295A0606 |76 79|TAB081
P10510295A0606 |125 140|promoter regionrbilirubinemia.
P10510295A0606 |65 74|TA repeattidase P0
P10510295A0606 |81 98|repressor elementT0000 Pharmacolog
P10510379A0105 |50 55|STAT6es an
P10510379A0105 |83 94|DNA element000 Pharmac
P10510379A0105 |10 30|transcription factor0076 Comparison with
P10510379A0105 |39 46|process phosph
P10510379A0105 |100 119|cytokine activation aspects of neonata
P10511216A0654 |0 11|CONCLUSIONSP00001606T0
P10511216A0654 |63 68|causeeotid
P10511216A0654 |42 46|kinkosph
P10511554T0000 |66 100|clone Caenorhabditis elegans cdf-1idase P00008171T0000 Pharmacologic
P10511554T0000 |41 57|polymorphism maphosphatases and 
P10512699A0364 |155 159|opal Whe
P10512699A0364 |47 60|SECIS elementtases and 5-n
P10512699A0364 |161 164|UGACSF
P10512699A0364 |108 132|selenocysteine insertion of neonatal hyperbiliru
P10512699A0364 |208 219|translationthe data of
P10512699A0364 |193 204|terminationon of CSF P
P10512699A0364 |166 171|codonHCO3-
P10512699A0364 |36 45|structureine phosp
P10512699A0364 |92 96|mRNAacol
P10512699A0364 |5 14|machinery1606T0076
P10512699A0364 |140 148|position P000089
P10512699T0000 |170 183|co-expression-] is shown a
P10512699T0000 |193 197|selAon o
P10512699T0000 |107 119|gene fusionss of neonata
P10512699T0000 |151 165|SECIS elements0472 When CSF 
P10512699T0000 |11 21|expression076 Compar
P10512699T0000 |208 218|selC genesthe data o
P10512699T0000 |199 203|selBCSF 
P10512699T0000 |71 96|rat thioredoxin reductase P00008171T0000 Pharmacol
P10512857A0000 |35 46|plakoglobinline phosph
P10512857A0000 |72 79|nucleusP000081
P10512857A0000 |88 100|interactionsharmacologic
P10512857A0000 |115 136|transcription factorsnatal hyperbilirubine
P10512857A0000 |57 64|signals5-nucle
P10512857A0000 |3 16|Wnt signaling001606T0076 C
P10512857A0000 |18 30|beta-cateninparison with
P10512882A0137 |119 127|activityl hyperb
P10512882A0137 |160 167|kinases CSF [H
P10512882A0137 |88 100|localizationharmacologic
P10512882A0137 |14 21|complex Compar
P10512882A0137 |30 33|FAK al
P10512882A0137 |146 156|Src family8997A0472 
P10512882A0137 |131 138|membersubinemi
P10512882A0137 |38 49|Src kinasese phosphata
P10512882A0137 |0 8|AssemblyP0000160
P10513756A0584 |119 138|selection criterionl hyperbilirubinemi
P10513756A0584 |149 154|alpha7A047
P10513756A0584 |42 43|%o
P10513756A0584 |26 30|biaswith
P10513756A0584 |67 84|8-predictor modeldase P00008171T00
P10513756A0584 |4 7|EPV016
P10513922A1237 |85 91|fibers0 Phar
P10513922A1237 |167 168|pC
P10513922A1237 |120 130|comparison hyperbili
P10513922A1237 |105 116|repair sitects of neon
P10513922A1237 |57 63|number5-nucl
P10513922A1237 |40 49|increasesphosphata
P10513922A1237 |159 165|groupsn CSF 
P10513922A1237 |4 9|study01606
P10514493A0199 |25 40|differentiation with alkaline 
P10514493A0199 |120 130|Ntr-1 gene hyperbili
P10514493A0199 |91 101|expressionmacologic 
P10514493A0199 |44 71|N1E-115 neuroblastoma cellsphatases and 5-nucleotidase
P10514493A0199 |135 149|reporter genesemia. P0000899
P10514493A0199 |160 184|NTR-1 promoter sequences CSF [HCO3-] is shown as
P10514808T0000 |35 50|epileptogenesisline phosphatas
P10514808T0000 |9 19|dysplasiasT0076 Comp
P10514808T0000 |21 29|geneticsison wit
P10516011A0471 |35 50|peptide mappingline phosphatas
P10516011A0471 |89 100|mutagenesisarmacologic
P10516011A0471 |7 11|work06T0
P10516011A0471 |125 150|pAP phosphorylation sitesrbilirubinemia. P00008997
P10516011A0471 |52 69|mass spectrometry and 5-nucleotida
P10516011A0471 |117 121|setstal 
P10516026A0270 |5 16|HERV-K type1606T0076 C
P10516026A0270 |25 31|clones with 
P10516072A0146 |0 4|DuchP000
P10516072A0146 |10 12|F.00
P10516738A0925 |7 18|time-points06T0076 Com
P10516738A0925 |40 41|%p
P10516738A0925 |58 73|irbesartan/HCTZ-nucleotidase P
P10516738A0925 |25 33|patients with al
P10516878T0000 |0 12|ModificationP00001606T00
P10516878T0000 |62 71|Parkinsonleotidase
P10516878T0000 |74 81|disease0008171
P10516878T0000 |49 58|pergolideses and 5
P10516878T0000 |94 99|studyologi
P10516878T0000 |16 45|dopamine D2 receptor activityomparison with alkaline phosp
P10516878T0000 |103 106|PETpec
P10517666A1069 |112 116|nGREneon
P10517666A1069 |44 63|AP-1 nucleoproteinsphatases and 5-nucl
P10517666A1069 |14 27|binding sites Comparison w
P10517666A1069 |92 100|elementsacologic
P10517666A1069 |37 39|GRne
P10517672A1417 |204 212|proteinsCO2 the 
P10517672A1417 |214 230|trans-activationta of K-depleted
P10517672A1417 |40 76|alpha1-globin promoter-CAT constructphosphatases and 5-nucleotidase P000
P10517672A1417 |130 134|CTF1rubi
P10517672A1417 |15 23|fragmentComparis
P10517672A1417 |234 246|CAT activitys are no lon
P10517672A1417 |145 182|Drosophila Schneider SL2 insect cells08997A0472 When CSF [HCO3-] is shown 
P10517672A1417 |100 126|CCAAT transcription factor aspects of neonatal hyper
P10517672A1417 |136 139|NF1mia
P10517675A0809 |119 125|memberl hype
P10517675A0809 |63 83|p21WAF1/CIP1 proteineotidase P00008171T0
P10517675A0809 |150 173|kinase inhibitor familyA0472 When CSF [HCO3-] 
P10517675A0809 |175 182|p27kip1 shown 
P10517675A0809 |93 107|protein levelscologic aspect
P10517675A0809 |0 21|Western blot analysisP00001606T0076 Compar
P10517675A0809 |51 59|increases and 5-
P10518496A0952 |0 11|AggregationP00001606T0
P10518496A0952 |151 177|periimplantation lethality0472 When CSF [HCO3-] is s
P10518496A0952 |134 141|tissuesnemia. 
P10518496A0952 |78 85|embryos171T000
P10518496A0952 |41 51|stem cellshosphatase
P10518496A0952 |189 200|developmentnction of C
P10518496A0952 |222 235|organogenesisdepleted rats
P10518502T0000 |102 110|survivalspects o
P10518502T0000 |10 15|nos-20076 
P10518502T0000 |114 136|Caenorhabditis elegansonatal hyperbilirubine
P10518502T0000 |76 97|germ cell development08171T0000 Pharmacolo
P10518502T0000 |21 26|genesison 
P10518502T0000 |0 5|nos-1P0000
P10518561A0261 |139 146|enzymes. P0000
P10518561A0261 |120 129|effectors hyperbil
P10518561A0261 |18 28|regulatorsparison wi
P10518561A0261 |32 50|Tec family kinaseslkaline phosphatas
P10518561A0885 |55 57|PHd 
P10518561A0885 |62 73|SH2 domainsleotidase P
P10518561A0885 |89 102|kinase domainarmacologic a
P10518561A0885 |29 34|BRDG1h alk
P10518561A0885 |10 25|phosphorylation0076 Comparison
P10518561A0885 |38 41|Tece p
P10518822A1037 |0 10|CONCLUSIONP00001606T
P10518822A1037 |112 121|biomarkerneonatal 
P10518822A1037 |126 134|activitybilirubi
P10518822A1037 |90 96|asthmarmacol
P10518822A1037 |203 209|asthmaPCO2 t
P10518822A1037 |142 169|CCR3 receptor ligand system00008997A0472 When CSF [HCO
P10518822A1037 |38 45|eotaxine phosp
P10518822A1037 |18 26|findingsparison 
P10518937A0572 |204 213|K. lactisCO2 the d
P10518937A0572 |129 133|Bas2irub
P10518937A0572 |78 92|adenine supply171T0000 Pharm
P10518937A0572 |121 125|Bas1hype
P10518937A0572 |104 111|factorsects of
P10518937A0572 |31 42|KlHIS4 genealkaline ph
P10518937A0572 |157 164|controlhen CSF
P10518937A0572 |197 200|wayf C
P10518937A0572 |4 23|expression analysis01606T0076 Comparis
P10518937A0572 |49 69|phosphate starvationses and 5-nucleotida
P10518956A0137 |154 159|gland2 Whe
P10518956A0137 |196 213|deiodinase systemof CSF PCO2 the d
P10518956A0137 |57 66|cytokines5-nucleot
P10518956A0137 |89 98|mediatorsarmacolog
P10518956A0137 |165 178|thyroid gland[HCO3-] is sh
P10518956A0137 |6 29|thyroid hormone changes606T0076 Comparison wit
P10518956A0137 |127 139|hypothalamusilirubinemia
P10518956A0137 |114 119|levelonata
P10518956A0137 |49 53|partses 
P10518956A1212 |17 20|FT3mpa
P10518956A1212 |37 40|TSHne 
P10518956A1212 |29 32|FT4h a
P10518956A1212 |70 74|forme P0
P10518956A1212 |0 8|ESS typeP0000160
P10520800A0307 |0 7|METHODSP000016
P10520800A0307 |114 123|reductiononatal hy
P10520800A0307 |83 88|years000 P
P10520800A0307 |58 61|men-nu
P10520800A0307 |130 146|echocardiographyrubinemia. P0000
P10520800A0307 |151 168|electrocardiogram0472 When CSF [HC
P10520800A0307 |35 43|patientsline pho
P10520800A0307 |49 53|HOCMses 
P10520800A0307 |69 72|agese 
P10520800A0307 |170 173|ECG-] 
P10521345A0202 |275 281|systemo cont
P10521345A0202 |217 226|centuriesof K-depl
P10521345A0202 |189 196|Ice Agenction 
P10521345A0202 |58 63|proxy-nucl
P10521345A0202 |243 249|notionlonger
P10521345A0202 |105 131|surface slope waters northcts of neonatal hyperbilir
P10521345A0202 |32 46|Laurentian Fanlkaline phosph
P10521345A0202 |18 22|datapari
P10521345A0202 |139 150|Gulf Stream. P00008997
P10521345A0202 |68 91|sea surface temperaturease P00008171T0000 Phar
P10521443A0486 |256 279|NF-kappaB c-Rel subunitced when compared to co
P10521443A0486 |113 133|NF-kappaB activationeonatal hyperbilirub
P10521443A0486 |25 38|IR activation with alkalin
P10521443A0486 |196 209|IkappaB-alphaof CSF PCO2 t
P10521443A0486 |160 174|overexpression CSF [HCO3-] i
P10521443A0486 |210 216|A32/36e data
P10521443A0486 |65 76|IR mutationtidase P000
P10521443A0486 |5 11|effect1606T0
P10521443A0486 |80 89|tyrosines1T0000 Ph
P10521443A0486 |234 248|overexpressions are no longe
P10521447A0606 |116 156|AML/CBFalpha transcription factor familyatal hyperbilirubinemia. P00008997A0472 
P10521447A0606 |57 72|sequence TGTGGT5-nucleotidase 
P10521447A0606 |22 23|Bs
P10521447A0606 |76 86|core motif08171T0000
P10521447A0606 |4 10|factor01606T
P10521447A0606 |101 108|membersaspects
P10521447A1190 |63 82|AML1-ETO repressioneotidase P00008171T
P10521447A1190 |31 45|AML3/CBFalpha1alkaline phosp
P10521447A1190 |13 27|overexpression6 Comparison w
P10521450A0437 |87 90|LynPha
P10521450A0437 |74 81|B cells0008171
P10521450A0437 |30 33|Lyn al
P10521450A0437 |59 69|DT40 cellsnucleotida
P10521450A0437 |12 26|Akt activation76 Comparison 
P10521450A0437 |36 39|Sykine
P10521450A0437 |96 100|miceogic
P10521509A0000 |0 10|RegulatorsP00001606T
P10521509A0000 |87 97|pleckstrinPharmacolo
P10521509A0000 |216 220|RGS9 of 
P10521509A0000 |191 208|RGS proteins RGS6tion of CSF PCO2 
P10521509A0000 |62 65|DEPleo
P10521509A0000 |210 214|RGS7e da
P10521509A0000 |108 123|G protein gamma of neonatal hy
P10521509A0000 |79 85|EGL-1071T000
P10521509A0000 |226 231|RGS11eted 
P10521509A0000 |14 33|G protein signaling Comparison with al
P10521509A0000 |153 162|subfamily72 When C
P10521509A0000 |138 145|domainsa. P000
P10521509A0000 |40 48|proteinsphosphat
P10521509A0000 |103 106|GGLpec
P10521509A0000 |35 38|RGSlin
P10521544T0000 |0 7|CloningP000016
P10521544T0000 |91 111|Man8GlcNAc2 isomer Bmacologic aspects of
P10521544T0000 |43 64|alpha 1,2-mannosidasesphatases and 5-nucle
P10521544T0000 |12 22|expression76 Compari
P10521544T0000 |128 140|biosynthesislirubinemia.
P10521544T0000 |76 87|Man9GlcNAc208171T0000 
P10521796A0872 |309 317|subjectsicantly 
P10521796A0872 |165 167|IM[H
P10521796A0872 |195 197|IM o
P10521796A0872 |225 241|neck hyperplasialeted rats are n
P10521796A0872 |119 129|metaplasial hyperbil
P10521796A0872 |187 190|DYSfun
P10521796A0872 |335 344|gastritis1 +/- 0.2
P10521796A0872 |213 220|atrophyata of 
P10521796A0872 |176 185|dysplasiashown as 
P10521796A0872 |28 31|ageth 
P10521796A0872 |389 397|baselineto be an
P10521796A0872 |131 133|IMub
P10521796A0872 |11 13|GC07
P10521796A0872 |287 290|DYSut 
P10521796A0872 |346 348|SGvs
P10521796A0872 |74 92|baseline diagnoses0008171T0000 Pharm
P10521796A0872 |370 379|gastritiszepam thu
P10521796A0872 |381 384|CAGapp
P10521796A0872 |36 39|sexine
P10521796A0872 |4 7|ORs016
P10523319A0209 |69 76|domainsse P000
P10523319A0209 |30 35|Rat7p alka
P10523319A0209 |20 25|Dbp5prison
P10523520A0986 |50 62|Hh moleculeses and 5-nuc
P10523520A0986 |72 77|phylaP0000
P10523520A0986 |10 24|nematode genes0076 Compariso
P10523520A0986 |38 46|homologse phosph
P10523634A1404 |84 98|Cbf5p proteins00 Pharmacolog
P10523634A1404 |57 68|association5-nucleotid
P10523634A1404 |29 48|Psi synthase domainh alkaline phosphat
P10523634A1404 |12 21|mutations76 Compar
P10523634A1404 |113 130|box H/ACA snoRNAseonatal hyperbili
P10523634A1404 |202 213|interaction PCO2 the d
P10523634A1404 |173 179|domainis sho
P10523634A1404 |2 8|subset000160
P10523640A0367 |187 192|Stat3funct
P10523640A0367 |148 156|tyrosine97A0472 
P10523640A0367 |89 99|activationarmacologi
P10523640A0367 |13 32|Src tyrosine kinase6 Comparison with a
P10523640A0367 |161 183|serine phosphorylationCSF [HCO3-] is shown a
P10523640A0367 |79 87|tyrosine71T0000 
P10523640A0367 |54 75|Stat3 phosphorylationnd 5-nucleotidase P00
P10523640A0367 |118 133|gene regulational hyperbilirub
P10523647A0000 |102 109|stimulispects 
P10523647A0000 |176 187|cell growthshown as a 
P10523647A0000 |130 146|stress responsesrubinemia. P0000
P10523647A0000 |91 98|varietymacolog
P10523647A0000 |31 36|C/EBPalkal
P10523647A0000 |65 77|bZIP proteintidase P0000
P10523647A0000 |214 224|cell deathta of K-de
P10523647A0000 |4 29|transcription factor CHOP01606T0076 Comparison wit
P10523647A0000 |48 55|proteinases an
P10523647A1001 |48 57|regulatorases and 
P10523647A1001 |61 79|C/EBP target genescleotidase P000081
P10523647A1001 |134 151|AP-1 target genesnemia. P00008997A
P10523647A1001 |107 119|AP-1 factorss of neonata
P10523647A1001 |6 10|CHOP606T
P10523663A0404 |5 10|motif1606T
P10523663A0404 |47 72|homeobox activator DEAF-1tases and 5-nucleotidase 
P10523663A0404 |131 141|modulatorsubinemia. 
P10523663A0404 |97 102|groupgic a
P10523674A0000 |137 154|S rRNA processingia. P00008997A047
P10523674A0000 |106 121|DNA replicationts of neonatal 
P10523674A0000 |15 49|ribonucleoprotein endoribonucleaseComparison with alkaline phosphata
P10523674A0000 |78 83|roles171T0
P10523674A0000 |0 9|RNase MRPP00001606
P10524258A0286 |21 31|regulationison with 
P10524258A0286 |89 108|immunocytochemistryarmacologic aspects
P10524258A0286 |52 57|cek-1 and 
P10524258A0286 |77 85|cultures8171T000
P10524258A0286 |113 135|Northern blot analysiseonatal hyperbilirubin
P10524258A0286 |39 50|FGFR-1 gene phosphatas
P10524258T0000 |0 10|RegulationP00001606T
P10524258T0000 |97 119|muscle differentiationgic aspects of neonata
P10524258T0000 |57 63|FGFR-15-nucl
P10524258T0000 |20 53|fibroblast growth factor receptorrison with alkaline phosphatases 
P10524258T0000 |65 80|gene expressiontidase P0000817
P10525413A1408 |69 73|LIM2se P
P10525413A1408 |56 60|part 5-n
P10525413A1408 |74 79|R122A00081
P10525413A1408 |25 33|residues with al
P10525413A1408 |126 144|N NMR spectroscopybilirubinemia. P00
P10525413A1408 |4 21|backbone dynamics01606T0076 Compar
P10525413A1408 |64 68|CRP2otid
P10526670A0236 |0 3|RacP00
P10526670A0236 |24 39|actin filamentsn with alkaline
P10526670A0236 |57 66|plus-ends5-nucleot
P10526670A0236 |41 48|F-actinhosphat
P10526670A0236 |11 20|uncapping076 Compa
P10526670A0236 |76 96|phosphatidylinositol08171T0000 Pharmacol
P10526670A0236 |145 162|membrane ruffling08997A0472 When C
P10526670A0236 |115 119|PIP2nata
P10526670A0236 |101 113|bisphosphateaspects of n
P10526670A1828 |119 122|PKBl h
P10526670A1828 |176 194|Ras transformationshown as a functio
P10526670A1828 |161 172|suppressionCSF [HCO3-]
P10526670A1828 |20 31|ICE/caspaserison with 
P10526670A1828 |93 102|apoptosiscologic a
P10526670A1828 |34 43|inhibitoraline pho
P10526670A1828 |51 56|N1445s and
P10527106A0384 |0 9|OBJECTIVEP00001606
P10527106A0384 |131 138|deficitubinemi
P10527106A0384 |56 63|support 5-nucl
P10527106A0384 |41 49|findingshosphata
P10527106A0384 |142 146|need0000
P10527106A0384 |24 37|preponderancen with alkali
P10527106A0384 |168 177|depictionO3-] is s
P10527106A0384 |185 192|deficita funct
P10527158T0000 |4 12|AL-R8 SI01606T00
P10527158T0000 |56 70|plutonium pits 5-nucleotidas
P10527158T0000 |78 96|USDOE Pantex Plant171T0000 Pharmacol
P10527158T0000 |23 51|generation staging containeron with alkaline phosphatase
P10527180A0869 |610 614|% CI2), 
P10527180A0869 |301 318|hormone receptorsa significantly g
P10527180A0869 |181 202|% confidence interval as a function of CSF
P10527180A0869 |714 721|disease anhydr
P10527180A0869 |368 380|chemotherapyrazepam thus
P10527180A0869 |785 793|responsesulthiam
P10527180A0869 |96 99|Coxogi
P10527180A0869 |507 511|% CI5 Be
P10527180A0869 |525 535|metastasesents. P000
P10527180A0869 |165 171|hazard[HCO3-
P10527180A0869 |669 673|boneaven
P10527180A0869 |290 297|absencestill h
P10527180A0869 |833 837|% CIrtic
P10527180A0869 |731 735|% CItors
P10527180A0869 |594 600|system produ
P10527180A0869 |48 49|Pa
P10527180A0869 |352 355|use001
P10527180A0869 |429 446|survival intervale optimum dose fo
P10527180A0869 |113 121|analysiseonatal 
P10527180A0869 |491 497|monthst. P00
P10527180A0869 |661 667|tissue090 In
P10527180A0869 |543 548|liver10 Wh
P10527180A0869 |627 650|approaches significanceilation almost ceased. 
P10527180A0869 |221 248|Karnofsky performance score-depleted rats are no longe
P10527180A0869 |462 471|treatment practice
P10527180A0869 |764 772|responsee, dichl
P10527180A0869 |261 262|%h
P10527180A0869 |694 699|sites5 mg/
P10527180A0869 |149 154|years7A047
P10527180A0869 |390 394|% CIo be
P10527180A0869 |328 332|% CIpe (
P10527180A0869 |811 823|chemotherapyy important 
P10527180A0869 |558 562|% CIrpor
P10527180A0869 |678 682|lungdmin
P10527180A0869 |9 16|FactorsT0076 C
P10527180A0869 |131 134|ageubi
P10527180A0869 |73 90|treatment failure00008171T0000 Pha
P10527180A0869 |272 276|% CId to
P10527180A0869 |65 69|risktida
P10527180A0869 |204 206|CICO
P10527180A0869 |0 7|RESULTSP000016
P10527426A0521 |171 180|exclusion] is show
P10527426A0521 |73 98|exon I+II+III combination00008171T0000 Pharmacolog
P10527426A0521 |159 165|intronn CSF 
P10527426A0521 |128 133|formslirub
P10527426A0521 |146 155|inclusion8997A0472
P10527426A0521 |109 112|endof 
P10527426A0521 |192 201|sequencesion of CS
P10527426A0521 |184 188|exon a f
P10527426A0521 |4 8|form0160
P10527426A0521 |16 36|SBEI gene transcriptomparison with alkal
P10527426A0521 |51 58|kernelss and 5
P10527475A0643 |50 57|grooveses and 
P10527475A0643 |12 17|MNGCs76 Co
P10527475A0643 |3 5|PC00
P10527475A0643 |35 45|inclusionsline phosp
P10528035A1102 |3 10|percent001606T
P10528035A1102 |95 102|percentlogic a
P10528035A1102 |12 13|P7
P10528035A1102 |36 49|normalizationine phosphata
P10528035A1102 |53 90|serum alanine aminotransferase levelsand 5-nucleotidase P00008171T0000 Pha
P10529198A0068 |101 104|Sosasp
P10529198A0068 |88 95|ras-GRFharmaco
P10529198A0068 |72 87|homologues p140P00008171T0000 
P10529198A0068 |25 31|domain with 
P10529354A0375 |103 116|P28 complexespects of neon
P10529354A0375 |93 98|PA700colog
P10529354A0375 |26 33|complexwith al
P10529354A0375 |89 92|19Sarm
P10529354A0375 |65 75|structurestidase P00
P10529354A0375 |143 156|26S particles0008997A0472 
P10529354A0375 |4 14|proteasome01606T0076
P10529354A0375 |81 84|20ST00
P10531334A0525 |51 60|PTPS-S19As and 5-n
P10531334A0525 |130 134|typerubi
P10531334A0525 |109 123|protein kinaseof neonatal hy
P10531334A0525 |24 31|enzymesn with 
P10531334A0525 |125 128|cGKrbi
P10531334A0525 |76 85|substrate08171T000
P10531334A0525 |3 9|assays001606
P10531340A1275 |17 19|R.mp
P10531340A1275 |4 15|Fleischmann01606T0076 
P10531340A1275 |29 31|J.h 
P10531340A1275 |21 27|Venterison w
P10531340A1275 |0 2|R.P0
P10531342A0348 |102 110|homologyspects o
P10531342A0348 |15 21|domainCompar
P10531342A0348 |114 148|promastigote surface glycoproteinsonatal hyperbilirubinemia. P000089
P10531342A0348 |42 45|kDaosp
P10531342A0348 |156 173|psa2/gp46 complexWhen CSF [HCO3-] 
P10531342A0348 |68 86|amino acid repeatsase P00008171T0000
P10531342A1111 |3 11|contrast001606T0
P10531342A1111 |148 173|promastigote cell surface97A0472 When CSF [HCO3-] 
P10531342A1111 |40 60|proteophosphoglycansphosphatases and 5-n
P10531342A1111 |66 83|ppg1 gene productidase P00008171T0
P10531360A0958 |118 127|VEGF mRNAal hyperb
P10531360A0958 |134 144|conditionsnemia. P00
P10531360A0958 |105 114|inductioncts of ne
P10531360A0958 |156 163|hypoxiaWhen CS
P10531360A0958 |58 67|construct-nucleoti
P10531360A0958 |33 38|cellskalin
P10531360A0958 |16 25|infectionomparison
P10531446A0203 |0 10|NeuregulinP00001606T
P10531446A0203 |62 73|ErbB familyleotidase P
P10531446A0203 |47 54|memberstases a
P10531446A0203 |40 45|ErbB4phosp
P10531446A0203 |29 34|ErbB3h alk
P10531446A0203 |77 102|receptor tyrosine kinases8171T0000 Pharmacologic a
P10531446A0203 |22 27|ErbB2son w
P10532354A1374 |138 146|blockagea. P0000
P10532354A1374 |195 205|alteration of CSF PC
P10532354A1374 |67 78|epsilon-COPdase P00008
P10532354A1374 |25 30|Anu2p with
P10532354A1374 |160 185|protein transport pathway CSF [HCO3-] is shown as 
P10532354A1374 |94 106|accumulationologic aspec
P10532354A1374 |243 254|yeast cellslonger disp
P10532354A1374 |217 227|morphologyof K-deple
P10532354A1374 |114 125|ER membraneonatal hype
P10532354A1374 |4 11|results01606T0
P10532354A1374 |38 53|yeast homologuee phosphatases 
P10532805A0792 |3 13|PC12 cells001606T007
P10532805A0792 |52 67|differentiation and 5-nucleoti
P10532805A0792 |15 34|nerve growth factorComparison with alk
P10532805A0792 |82 92|expression0000 Pharm
P10532805A0792 |96 101|nrg-1ogic 
P10532805A1084 |70 72|ABe 
P10532805A1084 |43 68|protein kinase A activitysphatases and 5-nucleotid
P10532805A1084 |104 110|agentsects o
P10532805A1084 |5 21|PC12 cell mutant1606T0076 Compar
P10532805A1084 |140 150|nrg-1 mRNA P00008997
P10533066A0758 |0 14|TSC1 mutationsP00001606T0076
P10533066A0758 |74 90|splice mutations0008171T0000 Pha
P10533066A0758 |52 62|insertions and 5-nuc
P10533066A0758 |36 45|mutationsine phosp
P10533066A1197 |103 107|TSC2pect
P10533066A1197 |24 37|abnormalitiesn with alkali
P10533066A1197 |45 48|PTThat
P10533066A1197 |7 15|patients06T0076 
P10533066A1197 |71 89|missense mutations P00008171T0000 Ph
P10534048A0297 |137 140|ACFia.
P10534048A0297 |10 19|algorithm0076 Comp
P10534048A0297 |182 194|transmissionas a functio
P10534048A0297 |284 294|projections but stil
P10534048A0297 |105 135|attenuation correction factorscts of neonatal hyperbilirubin
P10534048A0297 |234 249|attenuation maps are no longer
P10534048A0297 |82 93|calculation0000 Pharma
P10534048A0297 |21 29|FOREPROJison wit
P10534048A0297 |49 69|projection algorithmses and 5-nucleotida
P10534402A0126 |139 147|proteins. P00008
P10534402A0126 |89 108|sequence similarityarmacologic aspects
P10534402A0126 |122 129|domainsyperbil
P10534402A0126 |15 19|cDNAComp
P10534402A0126 |64 71|proteinotidase
P10534402A0126 |42 52|mouse geneosphatases
P10534402A0126 |155 168|Spo11p family When CSF [HC
P10534402A0126 |32 35|DNAlka
P10534402A0659 |0 6|RT-PCRP00001
P10534402A0659 |203 215|accumulationPCO2 the dat
P10534402A0659 |219 223|mRNA K-d
P10534402A0659 |145 153|Prophase08997A04
P10534402A0659 |47 58|time coursetases and 5
P10534402A0659 |104 120|Spo11 expressionects of neonatal
P10534402A0659 |236 251|pachytene stageare no longer d
P10534402A0659 |71 89|testis development P00008171T0000 Ph
P10534402A0659 |19 41|hybridization analysesarison with alkaline p
P10534402A0659 |170 185|pachytene stage-] is shown as 
P10534691A0542 |0 7|AnimalsP000016
P10534691A0542 |143 153|procedures0008997A04
P10534691A0542 |111 118|culture neonat
P10534691A0542 |28 33|weeksth al
P10534691A0542 |20 25|deathrison
P10534691A0542 |158 166|evidenceen CSF [
P10534691A0542 |48 54|graftsases a
P10534691A0542 |170 179|infection-] is sho
P10535715A0268 |35 40|phaseline 
P10535715A0268 |111 118|kJ/24 h neonat
P10535715A0268 |150 156|phasesA0472 
P10535715A0268 |66 67|Fi
P10535715A0268 |128 134|luteallirubi
P10535715A0268 |4 7|RMR016
P10535715A0268 |141 148|kJ/24 hP000089
P10536125A0093 |0 11|OseltamivirP00001606T0
P10536125A0093 |105 114|inhibitorcts of ne
P10536125A0093 |13 19|GS41046 Comp
P10536125A0093 |74 80|GS4071000817
P10536125A0093 |63 70|prodrugeotidas
P10536125A0093 |118 147|influenzavirus neuraminidasesal hyperbilirubinemia. P00008
P10536369A0662 |102 109|elementspects 
P10536369A0662 |42 50|evidenceosphatas
P10536369A0662 |55 85|VDR-TR heterodimer interactiond 5-nucleotidase P00008171T000
P10536369A0662 |3 28|gel mobility shift assays001606T0076 Comparison wi
P10536369A1280 |37 47|mechanismsne phospha
P10536369A1280 |13 23|importance6 Comparis
P10536369A1280 |62 70|responseleotidas
P10536369A1280 |88 94|mannerharmac
P10536788A0931 |103 117|control liverspects of neona
P10536788A0931 |9 10|dT
P10536788A0931 |73 79|breeds000081
P10536788A0931 |14 25|overfeeding Comparison
P10536788A0931 |138 140|PLa.
P10536788A0931 |157 158|%h
P10536788A0931 |168 170|PLO3
P10536788A0931 |35 46|PL profilesline phosph
P10540015A0664 |68 76|controlsase P000
P10540015A0664 |43 55|ALS patientssphatases an
P10540015A0664 |155 156|% 
P10540015A0664 |126 139|MEP thresholdbilirubinemia
P10540015A0664 |84 105|stimulation intensity00 Pharmacologic aspe
P10540015A0664 |0 13|C-SP durationP00001606T007
P10540292A1179 |200 206|inputsSF PCO
P10540292A1179 |78 86|regulons171T0000
P10540292A1179 |94 98|cellolog
P10540292A1179 |165 173|response[HCO3-] 
P10540292A1179 |129 143|spv expressionirubinemia. P0
P10540292A1179 |25 44|spv virulence genes with alkaline phos
P10540292A1179 |112 123|possibilityneonatal hy
P10540292A1179 |6 10|data606T
P10540553A0980 |34 39|cellsaline
P10540553A0980 |165 178|proliferation[HCO3-] is sh
P10540553A0980 |97 105|activitygic aspe
P10540553A0980 |128 131|DNAlir
P10540553A0980 |57 61|wall5-nu
P10540553A0980 |10 19|synthesis0076 Comp
P10540553A0980 |180 184|i.g.n as
P10540553A0980 |115 124|synthesisnatal hyp
P10540553A0980 |23 26|PNAon 
P10540553A0980 |190 196|growthction 
P10540553A0980 |153 160|ability72 When
P10540915A0697 |87 88|%P
P10540915A0697 |90 94|n.s.rmac
P10540915A0697 |42 50|ligationosphatas
P10540915A0697 |9 21|transsectionT0076 Compar
P10540915A0697 |52 57|TL&PL and 
P10540915A0697 |70 79|reductione P000081
P10541432A0185 |17 30|erbB proteinsmparison with
P10541432A0185 |77 101|tyrosine phosphorylation8171T0000 Pharmacologic 
P10541432A0185 |182 201|ERK MAPK activitiesas a function of CS
P10541432A0185 |211 229|glioblastoma cells data of K-deplete
P10541432A0185 |64 67|EGFoti
P10541432A0185 |246 265|ERK MAPK activitiesger displaced when 
P10541432A0185 |116 128|Shc proteinsatal hyperbi
P10541432A0185 |49 62|growth factorses and 5-nuc
P10541550A0487 |119 132|amplificationl hyperbiliru
P10541550A0487 |57 72|chorion element5-nucleotidase 
P10541550A0487 |164 178|follicle cells [HCO3-] is sh
P10541550A0487 |142 160|DmORC localization00008997A0472 When
P10541550A0487 |42 46|ACE3osph
P10541550A0487 |6 24|immunolocalization606T0076 Compariso
P10541550A0487 |87 98|informationPharmacolog
P10541865A1301 |68 77|mutationsase P0000
P10541865A1301 |148 154|tumors97A047
P10541865A1301 |99 110|transcriptsc aspects o
P10541865A1301 |22 34|co-deletionsson with alk
P10541865A1301 |38 44|CDKN2Ae phos
P10541865A1301 |49 55|CDKN2Bses an
P10542237A0357 |154 157|LPS2 W
P10542237A0357 |26 34|explantswith alk
P10542237A0357 |134 152|lipopolysaccharidenemia. P00008997A0
P10542237A0357 |189 203|IL-6 secretionnction of CSF 
P10542237A0357 |92 100|responseacologic
P10542237A0357 |64 68|miceotid
P10542237A0357 |117 124|stimulital hyp
P10542249A0415 |51 62|combinations and 5-nuc
P10542249A0415 |111 115|CAAT neo
P10542249A0415 |40 45|liverphosp
P10542249A0415 |148 153|alpha97A04
P10542249A0415 |133 140|proteininemia.
P10542249A0415 |158 167|C/EBPbetaen CSF [H
P10542249A0415 |142 147|C/EBP00008
P10542249A0415 |81 102|transcription factorsT0000 Pharmacologic a
P10542249A0415 |0 18|Albumin expressionP00001606T0076 Com
P10542260A0832 |49 54|FVIIases a
P10542260A0832 |96 105|receptorsogic aspe
P10542260A0832 |59 62|FXanuc
P10542260A0832 |4 15|requirement01606T0076 
P10542260A0832 |32 40|activitylkaline 
P10542269A0000 |0 20|Amyloid beta-proteinP00001606T0076 Compa
P10542269A0000 |88 95|plaquesharmaco
P10542269A0000 |120 129|Alzheimer hyperbil
P10542269A0000 |163 174|proteolysisF [HCO3-] i
P10542269A0000 |109 116|vesselsof neon
P10542269A0000 |56 71|amyloid fibrils 5-nucleotidase
P10542269A0000 |41 52|constituenthosphatases
P10542269A0000 |132 139|diseasebinemia
P10542269A0000 |141 143|ADP0
P10542269A0000 |22 27|Abetason w
P10542269A0000 |216 219|APP of
P10542269A0000 |184 214|beta-amyloid precursor protein a function of CSF PCO2 the da
P10542274A1376 |50 53|PKAes 
P10542274A1376 |130 147|promoter activityrubinemia. P00008
P10542274A1376 |55 64|signalingd 5-nucle
P10542274A1376 |96 125|caveolin-1 protein expressionogic aspects of neonatal hype
P10542274A1376 |18 28|activationparison wi
P10542274A1376 |32 48|protein kinase Alkaline phosphat
P10542277A0000 |19 35|beta heterodimerarison with alka
P10542277A0000 |53 59|importand 5-
P10542277A0000 |63 71|proteinseotidase
P10542277A0000 |4 18|importin alpha01606T0076 Com
P10542277A0000 |101 121|localization signalsaspects of neonatal 
P10542281A0382 |152 161|G1 domain472 When 
P10542281A0382 |132 144|repeat loopsbinemia. P00
P10542281A0382 |14 19|G1-G2 Comp
P10542281A0382 |49 61|link proteinses and 5-nu
P10542281A0382 |112 124|proteoglycanneonatal hyp
P10542281A0382 |34 44|hyaluronanaline phos
P10542281A0382 |102 107|motifspect
P10542281A2021 |85 90|G1-G20 Pha
P10542281A2021 |123 134|atrolysin Cperbilirubi
P10542281A2021 |29 37|presenceh alkali
P10542281A2021 |150 155|sitesA0472
P10542281A2021 |111 119|activity neonata
P10542281A2021 |41 48|absencehosphat
P10542281A2021 |59 74|keratan sulfatenucleotidase P0
P10542281A2021 |4 11|results01606T0
P10543270A1054 |67 75|recoverydase P00
P10543270A1054 |88 91|ppbhar
P10543270A1054 |135 136|pe
P10543270A1054 |31 36|NOexhalkal
P10543270A1054 |108 117|discharge of neona
P10543270A1054 |130 133|ppbrub
P10543270A1054 |8 28|i.v. steroid therapy6T0076 Comparison wi
P10543270A1054 |93 94|pc
P10543727A0282 |171 176|H2TF1] is 
P10543727A0282 |428 435|EnA-TREhe opti
P10543727A0282 |20 25|sitesrison
P10543727A0282 |295 308|H2TF1 element have a signi
P10543727A0282 |212 223|kappaB sitedata of K-d
P10543727A0282 |423 426|endith
P10543727A0282 |180 195|kappaB1 elementn as a function
P10543727A0282 |388 412|ATF recognition sequence to be an effective hypn
P10543727A0282 |162 165|endSF 
P10543727A0282 |383 387|AP-1pear
P10543727A0282 |229 244|kappaB2 elementd rats are no l
P10543727A0282 |358 368|HLA system3A0733 Flu
P10543727A0282 |116 151|rel/NF-kappaB transcription factorsatal hyperbilirubinemia. P00008997A
P10543727A0282 |99 111|binding sitec aspects of
P10543727A0282 |336 344|p65/relA +/- 0.2
P10543727A0282 |65 72|exampletidase 
P10543727A0282 |38 59|transcription factorse phosphatases and 5-
P10543728A0358 |16 19|E1Aomp
P10543728A0358 |79 101|DNA binding activities71T0000 Pharmacologic 
P10543728A0358 |105 109|AP-1cts 
P10543728A0358 |114 122|contrastonatal h
P10543728A0358 |22 35|cHa-ras cellsson with alka
P10543728A0358 |141 146|cellsP0000
P10543728A0358 |155 164|E1A cells When CSF
P10543730A0000 |17 36|cyclin Ume3p/Srb11pmparison with alkal
P10543730A0000 |107 117|repressions of neona
P10543730A0000 |62 68|kinaseleotid
P10543730A0000 |121 126|geneshyper
P10543730A0000 |75 80|Ume5p00817
P10543730A0000 |143 158|stress response0008997A0472 Wh
P10543730A0000 |162 169|meiosisSF [HCO
P10543730A0000 |4 9|yeast01606
P10543730A0000 |70 73|Cdke P
P10543949A0686 |19 21|S1ar
P10543949A0686 |73 79|cavity000081
P10543949A0686 |23 39|specificity siteon with alkaline
P10544037A0617 |0 4|FZD4P000
P10544037A0617 |125 126|%r
P10544037A0617 |147 148|%9
P10544037A0617 |31 36|FZD10alkal
P10544037A0617 |85 89|FZD40 Ph
P10544037A0617 |50 69|amino acid identityes and 5-nucleotida
P10544037A0617 |114 119|FZD10onata
P10544037A0617 |22 26|FZD9son 
P10544037A0617 |93 97|FZD9colo
P10544037A0617 |128 132|FZD9liru
P10544037A0617 |106 110|FZD4ts o
P10544037A0617 |136 141|FZD10mia. 
P10544037A0617 |103 104|%p
P10544088A0308 |81 94|transcriptionT0000 Pharmac
P10544088A0308 |133 136|Tatine
P10544088A0308 |46 51|PRDIIatase
P10544088A0308 |25 43|reporter construct with alkaline pho
P10544088A0308 |56 59|CAT 5-
P10544088A0308 |110 119|NF-kappaBf neonata
P10544088A0308 |4 13|NF-kappaB01606T007
P10544089A1208 |206 213|MP-CP-32 the d
P10544089A1208 |116 117|Ha
P10544089A1208 |52 58|sgRNAs and 5
P10544089A1208 |214 217|UTRta 
P10544089A1208 |176 183|MP-CP-3shown a
P10544089A1208 |245 252|MP genenger di
P10544089A1208 |148 150|MP97
P10544089A1208 |62 68|TMV U1leotid
P10544089A1208 |172 174|CR i
P10544089A1208 |162 164|MPSF
P10544089A1208 |73 78|crTMV00008
P10544089A1208 |195 197|MP o
P10544089A1208 |184 187|UTR a 
P10544089A1208 |202 204|U1 P
P10544089A1208 |97 114|hairpin structuregic aspects of ne
P10544089A1208 |143 147|IRES0008
P10544089A1208 |4 19|RNA transcripts01606T0076 Comp
P10544113A0293 |0 29|EIAV LTR sequence variabilityP00001606T0076 Comparison wit
P10544113A0293 |75 83|enhancer008171T0
P10544113A0293 |60 67|portionucleoti
P10544113A0293 |95 105|U3 segmentlogic aspe
P10544113A0293 |113 116|LTReon
P10545192T0000 |137 158|agent vanadyl sulfateia. P00008997A0472 Wh
P10545192T0000 |91 94|s6kmac
P10545192T0000 |75 82|MEK/ERK008171T
P10545192T0000 |45 55|activationhatases an
P10545192T0000 |96 113|signaling cascadeogic aspects of n
P10545192T0000 |63 72|ras/C-rafeotidase 
P10545192T0000 |87 90|p70Pha
P10545192T0000 |0 41|Phosphatidylinositol 3-kinase requirementP00001606T0076 Comparison with alkaline p
P10545248A0567 |17 25|enhancermparison
P10545248A0567 |114 117|Tinona
P10545248A0567 |64 77|binding sitesotidase P0000
P10545248A0567 |4 8|core0160
P10545248A0567 |175 190|muscle lineages shown as a fun
P10545248A0567 |86 112|homeodomain protein Tinman Pharmacologic aspects of 
P10545281A0836 |4 11|example01606T0
P10545281A0836 |45 71|purification tag sequenceshatases and 5-nucleotidase
P10545281A0836 |148 168|protein accumulation97A0472 When CSF [HC
P10545281A0836 |13 25|introduction6 Comparison
P10545281A0836 |130 143|bop gene mRNArubinemia. P0
P10545281A0836 |92 105|coding regionacologic aspe
P10548434A1549 |155 168|p38 signaling When CSF [HC
P10548434A1549 |131 134|ERKubi
P10548434A1549 |26 33|abilitywith al
P10548434A1549 |37 44|polyomane phos
P10548434A1549 |144 151|JNK/SPK008997A
P10548434A1549 |52 62|T antigens and 5-nuc
P10548434A1549 |96 111|differentiationogic aspects of
P10548622A0906 |119 133|egg collectionl hyperbilirub
P10548622A0906 |202 207|TUGOR PCO2
P10548622A0906 |42 52|lignocaineosphatases
P10548622A0906 |88 111|i.v. sedation/analgesiaharmacologic aspects of
P10548622A0906 |31 36|blockalkal
P10548622A0906 |181 200|ultrasound guidance as a function of C
P10548622A0906 |71 82|conjunction P00008171T
P10548622A0906 |235 244|procedure are no l
P10548622A0906 |223 227|paineple
P10548622A0906 |169 174|route3-] i
P10548722A0099 |49 53|H1.8ses 
P10548722A0099 |24 36|organizationn with alkal
P10548722A0099 |245 249|genenger
P10548722A0099 |193 200|elementon of C
P10548722A0099 |4 8|loci0160
P10548722A0099 |157 161|SIREhen 
P10548722A0099 |141 149|sequenceP0000899
P10548722A0099 |71 85|TcP2beta genes P00008171T000
P10549354A1782 |102 124|beta-catenin complexesspects of neonatal hyp
P10549354A1782 |149 158|mutations7A0472 Wh
P10549354A1782 |180 192|beta-cateninn as a funct
P10549354A1782 |30 46|colon carcinomas alkaline phosph
P10549354A1782 |241 244|APCo l
P10549354A1782 |51 60|melanomass and 5-n
P10549354A1782 |16 19|APComp
P10549354A1782 |223 237|downregulationepleted rats a
P10549354A1782 |261 275|Axin/Conductinhen compared t
P10549354A1782 |246 255|GSK3 betager displ
P10549354A1782 |130 136|resultrubine
P10549354A1782 |166 176|N terminusHCO3-] is 
P10549354A1782 |96 101|Tcf-4ogic 
P10549354A1782 |2 12|proportion0001606T00
P10549354A2371 |119 124|formsl hyp
P10549354A2371 |30 42|deregulation alkaline ph
P10549354A2371 |128 134|cancerlirubi
P10549354A2371 |46 70|Tcf target gene activityatases and 5-nucleotidas
P10549354A2371 |8 18|mechanisms6T0076 Com
P10549354A2371 |100 108|melanoma aspects
P10549912A0136 |238 246|branchese no lon
P10549912A0136 |181 186|V1-V4 as a
P10549912A0136 |162 179|segment elevationSF [HCO3-] is sho
P10549912A0136 |24 31|patientn with 
P10549912A0136 |299 305|arterye a si
P10549912A0136 |265 276|angioplastycompared to
P10549912A0136 |74 84|infarction0008171T00
P10549912A0136 |5 11|report1606T0
P10549912A0136 |202 206|loss PCO
P10549912A0136 |117 127|infarctiontal hyperb
P10549912A0136 |154 158|lead2 Wh
P10550139A0191 |0 8|PATIENTSP0000160
P10550139A0191 |96 101|sidesogic 
P10550139A0191 |13 20|METHODS6 Compa
P10550139A0191 |115 120|crestnatal
P10550139A0191 |64 85|bone marrow aspiratesotidase P00008171T000
P10550139A0191 |141 149|patientsP0000899
P10550139A0191 |49 62|prostatectomyses and 5-nuc
P10550571A0000 |0 7|PURPOSEP000016
P10550571A0000 |189 195|thiolsnction
P10550571A0000 |167 174|WR-2721CO3-] i
P10550571A0000 |123 132|compoundsperbiliru
P10550571A0000 |89 97|patientsarmacolo
P10550571A0000 |72 85|plasma levelsP00008171T000
P10550571A0000 |18 25|WR-2721parison
P10550571A0000 |156 163|effectsWhen CS
P10550571A0000 |48 55|studiesases an
P10550571A0000 |138 142|nonea. P
P10550574A1038 |139 140|%.
P10550574A1038 |105 110|gradects o
P10550574A1038 |75 101|serum alkaline phosphatase008171T0000 Pharmacologic 
P10550574A1038 |30 40|toxicities alkaline 
P10550574A1038 |144 150|cycles008997
P10550574A1038 |42 50|diarrheaosphatas
P10550574A1038 |52 61|infection and 5-nu
P10550574A1038 |5 11|regard1606T0
P10551788A0229 |0 6|LHbetaP00001
P10551788A0229 |88 105|trophoblast cellsharmacologic aspe
P10551788A0229 |55 61|CGbetad 5-nu
P10551788A0229 |33 50|gonadotrope cellskaline phosphatas
P10551796T0000 |0 10|RegulationP00001606T
P10551796T0000 |14 33|HIV-1 transcription Comparison with al
P10551816A0162 |6 12|LTBP-1606T00
P10551816A0162 |44 49|formsphata
P10551848A0000 |51 55|Tadas an
P10551848A0000 |57 59|M.5-
P10551848A0000 |29 31|Y.h 
P10551848A0000 |47 49|K.ta
P10551848A0000 |14 19|study Comp
P10551848A0000 |65 74|MacLennantidase P0
P10551848A0000 |76 78|D.08
P10551848A0000 |21 27|Kimuraison w
P10551848A0000 |33 45|Kurzydlowskikaline phosp
P10551867A0350 |20 39|amino acid residuesrison with alkaline
P10551867A0350 |131 149|rat cDNA librariesubinemia. P0000899
P10551867A0350 |53 73|9-kilobase pair mRNAand 5-nucleotidase P
P10551867A0350 |83 98|splice variants000 Pharmacolog
P10551879T0000 |154 177|protein fusion proteins2 When CSF [HCO3-] is s
P10551879T0000 |94 132|fluorescence resonance energy transferologic aspects of neonatal hyperbiliru
P10551879T0000 |47 74|A-kinase anchoring proteinstases and 5-nucleotidase P0
P10551879T0000 |78 90|living cells171T0000 Pha
P10551879T0000 |21 43|protein kinase bindingison with alkaline pho
P10552357A1936 |0 11|CONCLUSIONSP00001606T0
P10552357A1936 |150 154|OCTAA047
P10552357A1936 |269 272|AIRare
P10552357A1936 |235 242|effects are no
P10552357A1936 |251 263|echogenicityisplaced whe
P10552357A1936 |99 111|microspheresc aspects of
P10552357A1936 |72 84|microspheresP00008171T00
P10552357A1936 |192 203|LV functionion of CSF 
P10552357A1936 |138 146|efficacya. P0000
P10552357A1936 |116 132|LV opacificationatal hyperbiliru
P10552357A1936 |32 43|superioritylkaline pho
P10552357A1936 |16 24|additionompariso
P10553551A0000 |51 59|disorders and 5-
P10553551A0000 |84 91|pathway00 Phar
P10553551A0000 |0 20|Factor XI deficiencyP00001606T0076 Compa
P10553959A0812 |4 19|Ishasha samples01606T0076 Comp
P10553959A0812 |60 66|levelsucleot
P10553959A0812 |27 32|rangeith a
P10554946A0082 |102 107|drugsspect
P10554946A0082 |28 46|clomiphene citrateth alkaline phosph
P10554946A0082 |180 186|uterusn as a
P10554946A0082 |172 178|breast is sh
P10554946A0082 |197 203|lipidsf CSF 
P10554946A0082 |126 134|faslodexbilirubi
P10554946A0082 |111 121|raloxifene neonatal 
P10554946A0082 |161 168|actionsCSF [HC
P10554946A0082 |21 26|SERMSison 
P10554946A0082 |188 192|boneunct
P10554946A0082 |141 149|emphasisP0000899
P10554946A0082 |51 60|tamoxifens and 5-n
P10555079A0254 |0 2|TiP0
P10555079A0254 |28 38|morphologyth alkalin
P10555285A1065 |32 50|duplication eventslkaline phosphatas
P10555285A1065 |83 105|FUT3-FUT5-FUT6 cluster000 Pharmacologic aspe
P10555285A1065 |176 185|mechanismshown as 
P10555285A1065 |233 247|globin clusterts are no long
P10555285A1065 |5 17|organization1606T0076 Co
P10555964A0778 |0 2|S.P0
P10555964A0778 |9 11|S.T0
P10555964A0778 |4 7|Kim016
P10556028A0292 |184 188|BD-2 a f
P10556028A0292 |110 123|repA promoterf neonatal hy
P10556028A0292 |125 129|Preprbil
P10556028A0292 |95 104|structurelogic asp
P10556028A0292 |40 63|plasmid incompatibilityphosphatases and 5-nucl
P10556028A0292 |30 36|region alkal
P10556028A0292 |4 14|cop region01606T0076
P10556028A0292 |65 68|inctid
P10556028A0292 |175 179|BD-1 sho
P10556028A0292 |155 173|RepA binding sites When CSF [HCO3-] 
P10556029A0852 |0 13|WA constructsP00001606T007
P10556029A0852 |44 55|topoisomersphatases an
P10556029A0852 |97 112|interconversiongic aspects of 
P10556029A0852 |61 81|cyclization kineticscleotidase P00008171
P10556029A0852 |116 126|precursorsatal hyper
P10556029A0852 |138 149|topoisomersa. P0000899
P10556033A0000 |32 39|memberslkaline
P10556033A0000 |132 138|domainbinemi
P10556033A0000 |45 50|yeasthatas
P10556033A0000 |54 60|humansnd 5-n
P10556033A0000 |166 172|regionHCO3-]
P10556033A0000 |99 106|systemsc aspec
P10556033A0000 |4 22|RFX protein family01606T0076 Compari
P10556044A0913 |0 7|BindingP000016
P10556044A0913 |31 58|alpha-dystroglycan receptoralkaline phosphatases and 5
P10556044A0913 |11 22|sulphatides076 Compari
P10556044A0913 |103 113|LG modulespects of n
P10556046A0328 |103 107|sidepect
P10556046A0328 |62 79|signaling pathwayleotidase P000081
P10556046A0328 |115 129|Xenopus embryonatal hyperbil
P10556063A0092 |55 68|Trk subfamilyd 5-nucleotid
P10556063A0092 |30 39|subfamily alkaline
P10556063A0092 |6 13|kinases606T007
P10556089A0901 |239 245|CUG-bp no lo
P10556089A0901 |214 227|gene functionta of K-deple
P10556089A0901 |198 210|conservation CSF PCO2 th
P10556089A0901 |130 140|processingrubinemia.
P10556089A0901 |46 64|muscle developmentatases and 5-nucle
P10556089A0901 |149 165|muscle component7A0472 When CSF 
P10556089A0901 |4 8|data0160
P10556089A0901 |23 28|etr-1on wi
P10556089A0901 |101 105|roleaspe
P10556089A0901 |68 78|C. elegansase P00008
P10556145A1034 |0 10|GentamicinP00001606T
P10556145A1034 |105 110|ordercts o
P10556145A1034 |60 78|sputum Psa densityucleotidase P00008
P10556145A1034 |20 23|DPIris
P10556145A1034 |28 31|SVNth 
P10556145A1034 |80 81|p1
P10556145A1034 |114 123|magnitudeonatal hy
P10556263A1035 |0 11|CONCLUSIONSP00001606T0
P10556263A1035 |89 91|ACar
P10556263A1035 |44 49|spacephata
P10556263A1035 |25 30|value with
P10556263A1035 |98 103|spaceic as
P10556595A0391 |70 82|transversione P00008171T
P10556595A0391 |59 60|Gn
P10556595A0391 |95 98|endlog
P10556595A0391 |61 62|Cc
P10556595A0391 |15 23|sequenceComparis
P10556595A0391 |113 119|regioneonata
P10556595A0391 |66 67|Ti
P10556595A0391 |38 47|recN genee phospha
P10556595A0391 |3 11|analysis001606T0
P10556751A0758 |186 191|staff func
P10556751A0758 |91 103|immunizationmacologic as
P10556751A0758 |61 64|HGVcle
P10556751A0758 |105 108|HGVcts
P10556751A0758 |39 57|transmission rates phosphatases and 
P10556751A0758 |73 77|lack0000
P10556751A0758 |156 162|hazardWhen C
P10556751A0758 |17 21|viewmpar
P10557008T0000 |0 9|DetectionP00001606
P10557008T0000 |13 22|poisoning6 Compari
P10557008T0000 |60 66|motherucleot
P10557008T0000 |26 32|Impilawith a
P10557008T0000 |71 76|child P000
P10557072A0127 |81 85|ULK1T000
P10557072A0127 |30 35|mouse alka
P10557072A0127 |73 79|kinase000081
P10557072A0127 |46 51|cDNAsatase
P10557072A0418 |152 153|C4
P10557072A0418 |116 118|PSat
P10557072A0418 |9 15|UNC-51T0076 
P10557072A0418 |95 109|proline/serinelogic aspects 
P10557072A0418 |120 126|domain hyper
P10557072A0418 |32 48|domain structurelkaline phosphat
P10557072A0418 |155 161|domain When 
P10557072A0418 |70 83|kinase domaine P00008171T0
P10557072A0418 |0 4|ULKsP000
P10557072A1218 |6 13|results606T007
P10557072A1218 |107 112|cellss of 
P10557072A1218 |27 31|ULK2ith 
P10557072A1218 |76 93|signaling pathway08171T0000 Pharma
P10557308A0000 |0 18|Connector enhancerP00001606T0076 Com
P10557308A0000 |22 25|KSRson
P10557308A0000 |27 30|CNKith
P10557308A0000 |49 56|proteinses and
P10557308A0000 |70 83|RAS signalinge P00008171T0
P10559207A0207 |186 192|course funct
P10559207A0207 |125 130|genesrbili
P10559207A0207 |26 41|ATP sulfurylasewith alkaline p
P10559207A0207 |11 20|organisms076 Compa
P10559207A0207 |46 66|APS kinase reactionsatases and 5-nucleot
P10559207A0207 |150 156|fusionA0472 
P10559207A0207 |93 100|enzymescologic
P10559207A0207 |196 205|evolutionof CSF PC
P10559207A0207 |233 239|enzymets are
P10559207A0207 |169 174|genes3-] i
P10559303A0000 |32 48|membrane proteinlkaline phosphat
P10559303A0000 |13 18|virus6 Com
P10559303A0000 |52 56|LMP1 and
P10559303A0000 |88 102|transformationharmacologic a
P10559303A0000 |20 23|EBVris
P10559303A0000 |114 127|B lymphocytesonatal hyperb
P10559320A0080 |136 140|RNAsmia.
P10559320A0080 |79 91|protein nsP171T0000 Phar
P10559320A0080 |43 50|homologsphatas
P10559320A0080 |27 29|1ait
P10559320A0080 |54 64|alphavirusnd 5-nucle
P10559320A0080 |19 23|halfaris
P10559324A0716 |38 50|Ad5 E4orf6/7e phosphatas
P10559324A0716 |24 26|Adn 
P10559324A0716 |72 81|rat cellsP00008171
P10559324A0716 |128 130|Adli
P10559324A0716 |59 68|apoptosisnucleotid
P10559364A0846 |3 7|HCMV0016
P10559364A0846 |24 32|HF cellsn with a
P10559364A0846 |215 218|SSBa o
P10559364A0846 |302 306|BrdU sig
P10559364A0846 |91 119|DNA replication compartmentsmacologic aspects of neonata
P10559364A0846 |135 165|polymerase processivity factoremia. P00008997A0472 When CSF 
P10559364A0846 |45 46|hh
P10559364A0846 |194 213|DNA binding proteinn of CSF PCO2 the d
P10559364A0846 |220 224|UL57K-de
P10559364A0846 |48 51|IE2ase
P10559364A0846 |283 300|bromodeoxyuridinels but still have
P10559364A0846 |167 171|UL44CO3-
P10559364A0846 |231 258|UL112-113 accessory proteinrats are no longer displace
P10559364A0846 |8 13|Towne6T007
P10560014A0000 |108 114|system of ne
P10560014A0000 |72 89|angioarchitectureP00008171T0000 Ph
P10560014A0000 |26 47|heart vascularizationwith alkaline phospha
P10560014A0000 |147 157|myocardium997A0472 W
P10560997A1072 |0 10|CONCLUSIONP00001606T
P10560997A1072 |59 65|methodnucleo
P10560997A1072 |11 12|S0
P10560997A1072 |82 91|ovulation0000 Phar
P10560997A1072 |33 42|LH levelskaline ph
P10561095A2141 |154 172|hypoparathyroidism2 When CSF [HCO3-]
P10561095A2141 |40 47|diseasephospha
P10561095A2141 |9 20|reoperationT0076 Compa
P10561095A2141 |131 140|incidenceubinemia.
P10561095A2141 |83 100|calcitonin levels000 Pharmacologic
P10561095A2141 |49 54|groupses a
P10561153A0225 |153 158|month72 Wh
P10561153A0225 |74 77|SSc000
P10561153A0225 |13 17|case6 Co
P10561153A0225 |135 142|failureemia. P
P10561153A0225 |21 30|carcinomaison with
P10561153A0225 |38 44|breaste phos
P10561251A0000 |0 7|PURPOSEP000016
P10561251A0000 |263 267|HDCTn co
P10561251A0000 |249 261|chemotherapy displaced w
P10561251A0000 |212 228|modality therapydata of K-deplet
P10561251A0000 |146 156|stage IIIB8997A0472 
P10561251A0000 |122 131|mortalityyperbilir
P10561251A0000 |91 98|factorsmacolog
P10561251A0000 |285 310|stem-cell transplantation but still have a signifi
P10561251A0000 |135 140|womenemia.
P10561251A0000 |75 77|OS00
P10561251A0000 |48 51|DFSase
P10561251A0000 |185 188|IBCa f
P10561251A0000 |65 73|survivaltidase P
P10561251A0000 |230 233|CMT ra
P10561251A0000 |38 46|survivale phosph
P10561251A0000 |170 183|breast cancer-] is shown a
P10561460A0615 |137 151|signal peptideia. P00008997A
P10561460A0615 |108 112|cDNA of 
P10561460A0615 |4 21|GPI anchor moiety01606T0076 Compar
P10561460A0615 |77 88|polypeptide8171T0000 P
P10561460A0615 |64 69|levelotida
P10561460A0615 |156 176|GPI signal sequencesWhen CSF [HCO3-] is 
P10561546A0000 |137 156|localization signalia. P00008997A0472 
P10561546A0000 |90 98|antibodyrmacolog
P10561546A0000 |41 48|proteinhosphat
P10561546A0000 |160 181|NF-kappaB p65 subunit CSF [HCO3-] is shown
P10562418A0238 |48 53|cellsases 
P10562418A0238 |18 24|eventspariso
P10562456T0000 |117 124|walbaumtal hyp
P10562456T0000 |11 18|regions076 Com
P10562456T0000 |45 51|intronhatase
P10562456T0000 |59 78|growth hormone genenucleotidase P00008
P10562456T0000 |26 34|promoterwith alk
P10562456T0000 |82 95|rainbow trout0000 Pharmaco
P10562456T0000 |97 109|Oncorhynchusgic aspects 
P10562495A0188 |100 104|gene asp
P10562495A0188 |122 132|productionyperbiliru
P10562495A0188 |14 23|SFV genes Comparis
P10562495A0188 |160 165|virus CSF 
P10562495A0188 |29 37|homologsh alkali
P10562495A0188 |77 87|SFV genome8171T0000 
P10562495A0188 |55 71|Chordopoxvirinaed 5-nucleotidase
P10563212A0514 |54 57|QoLnd 
P10563212A0514 |123 131|controlsperbilir
P10563212A0514 |24 43|SF-36 questionnairen with alkaline pho
P10563605A0773 |48 52|IENFases
P10563605A0773 |12 17|trend76 Co
P10563605A0773 |28 39|associationth alkaline
P10563605A0773 |109 110|po
P10563605A0773 |63 68|nerveeotid
P10563605A0773 |82 97|fiber densities0000 Pharmacolo
P10563605A0773 |99 100|rc
P10563789A1951 |3 11|addition001606T0
P10563789A1951 |91 93|CGma
P10563789A1951 |30 50|F beta alpha/CG beta alkaline phosphatas
P10563789A1951 |13 18|media6 Com
P10563789A1951 |98 111|FSH receptorsic aspects of
P10563836A1234 |3 11|contrast001606T0
P10563836A1234 |13 34|AP-2 binding activity6 Comparison with alk
P10563836A1234 |80 93|Western blots1T0000 Pharma
P10563836A1234 |143 148|cells00089
P10563836A1234 |114 133|AP-2 protein levelsonatal hyperbilirub
P10563836A1234 |64 74|T47D cellsotidase P0
P10564231A0315 |17 19|M.mp
P10564231A0315 |0 11|N. van HoekP00001606T0
P10564280A0140 |186 199|Src substrate function of 
P10564280A0140 |61 68|YT521-Bcleotid
P10564280A0140 |131 169|component scaffold attachment factor Bubinemia. P00008997A0472 When CSF [HCO
P10564280A0140 |227 232|Sam68ted r
P10564280A0140 |52 59|protein and 5-
P10564280A0140 |218 225|mitosisf K-dep
P10564472A0853 |6 13|mutants606T007
P10564472A0853 |46 57|TraR fusionatases and 
P10564472A0853 |76 82|system08171T
P10564474T0000 |10 20|homologues0076 Compa
P10564474T0000 |74 101|outer-membrane protein OprH0008171T0000 Pharmacologic 
P10564474T0000 |106 128|polymyxin B resistancets of neonatal hyperbi
P10564474T0000 |56 66|expression 5-nucleot
P10564479A0384 |0 8|DeletionP0000160
P10564479A0384 |44 50|effectphatas
P10564479A0384 |106 115|activatorts of neo
P10564479A0384 |12 16|fdsR76 C
P10564479A0384 |166 173|absenceHCO3-] 
P10564479A0384 |149 158|repressor7A0472 Wh
P10564479A0384 |135 142|formateemia. P
P10564479A0384 |177 184|formatehown as
P10564479A0384 |123 131|presenceperbilir
P10564479A0384 |66 76|fds operonidase P000
P10564479A0384 |54 58|FdsRnd 5
P10564484A0859 |51 55|genes an
P10564484A0859 |180 184|siten as
P10564484A0859 |31 43|binding sitealkaline pho
P10564484A0859 |194 202|promotern of CSF
P10564484A0859 |128 140|requirementslirubinemia.
P10564484A0859 |147 155|function997A0472
P10564484A0859 |5 15|constructs1606T0076 
P10564484A0859 |69 77|promoterse P0000
P10564495A0444 |137 140|CEAia.
P10564495A0444 |250 255|cellsdispl
P10564495A0444 |216 221|CD66d of K
P10564495A0444 |23 35|Opa proteinson with alka
P10564495A0444 |93 97|cDNAcolo
P10564495A0444 |209 213|CGM1he d
P10564495A0444 |150 158|subgroupA0472 Wh
P10564495A0444 |142 147|CD66e00008
P10564495A0444 |197 204|tropismf CSF P
P10564495A0444 |128 135|antigenlirubin
P10564495A0444 |227 230|NCAted
P10564495A0444 |166 177|CD66 familyHCO3-] is s
P10564495A0444 |65 75|HeLa cellstidase P00
P10564495A0444 |232 237|CD66cats a
P10564495A0444 |39 43|C751 pho
P10564495A0444 |3 11|addition001606T0
P10564593A0428 |85 95|chromosome0 Pharmaco
P10564593A0428 |101 115|MCF-7 AdVp3000aspects of neo
P10564593A0428 |180 193|translocationn as a functi
P10564593A0428 |120 128|MCF-7 MX hyperbi
P10564593A0428 |60 74|rearrangementsucleotidase P0
P10564593A0428 |32 37|paintlkali
P10564593A0428 |19 29|chromosomearison wit
P10564593A0428 |136 144|S1-M1-80mia. P00
P10564593A0428 |0 4|FISHP000
P10564593A1618 |71 79|evidence P000081
P10564593A1618 |108 115|regions of neo
P10564593A1618 |228 242|drug transported rats are no
P10564593A1618 |182 202|MXR half-transporteras a function of CSF
P10564593A1618 |132 139|partnerbinemia
P10564593A1618 |83 98|coamplification000 Pharmacolog
P10564593A1618 |23 39|half-transporteron with alkaline
P10564593A1618 |4 12|MXR gene01606T00
P10564593A1618 |48 55|absenceases an
P10564939A0981 |4 10|effect01606T
P10564939A0981 |14 21|smoking Compar
P10564939A0981 |47 52|studytases
P10564939A0981 |62 66|dataleot
P10566630A0371 |0 5|SerumP0000
P10566630A0371 |43 51|SD scoresphatase
P10566630A0371 |164 170|months [HCO3
P10566630A0371 |134 140|monthsnemia.
P10566630A0371 |36 41|IGF-Iine p
P10566630A0371 |92 97|womenacolo
P10566630A0371 |19 34|growth factor Iarison with alk
P10566630A0371 |84 87|men00 
P10566862A0000 |51 60|distancess and 5-n
P10566862A0000 |127 137|evaluationilirubinem
P10566862A0000 |27 39|stereoacuityith alkaline
P10566862A0000 |12 23|Measurement76 Comparis
P10566862A0000 |165 174|imbalance[HCO3-] i
P10566862A0000 |83 107|depth stereoacuity tests000 Pharmacologic aspect
P10566862A0000 |178 188|strabismusown as a f
P10566862A0000 |141 149|patientsP0000899
P10566862A0000 |0 10|BACKGROUNDP00001606T
P10567430A0785 |170 176|Galpha-] is 
P10567430A0785 |53 57|q/11and 
P10567430A0785 |212 216|GRK5data
P10567430A0785 |92 101|constructacologic 
P10567430A0785 |145 151|Galpha08997A
P10567430A0785 |120 127|binding hyperb
P10567430A0785 |198 208|constructs CSF PCO2 
P10567430A0785 |105 109|GRK2cts 
P10567430A0785 |220 224|GRK6K-de
P10567430A0785 |152 153|s4
P10567430A0785 |156 162|GalphaWhen C
P10567430A0785 |131 137|Galphaubinem
P10567430A0785 |11 18|studies076 Com
P10567430A0785 |40 52|brain Galphaphosphatases
P10567430A0785 |138 142|q/11a. P
P10567524T0000 |68 73|yeastase P
P10567524T0000 |39 56|signaling network phosphatases and
P10567524T0000 |4 25|elm1 kinase functions01606T0076 Comparison
P10567533A0818 |23 25|RTon
P10567533A0818 |130 146|tyrosine kinasesrubinemia. P0000
P10567533A0818 |77 84|primers8171T00
P10567533A0818 |27 39|PCR productsith alkaline
P10567533A0818 |8 21|transcription6T0076 Compar
P10567533A0818 |112 118|motifsneonat
P10567538A1028 |17 43|acetyltransferase activitymparison with alkaline pho
P10567538A1028 |134 137|CH3nem
P10567538A1028 |107 126|activation functions of neonatal hyper
P10567538A1028 |47 51|p300tase
P10567538A1028 |157 163|regionhen CS
P10567538A1028 |3 11|addition001606T0
P10567581A0119 |205 215|expressionO2 the dat
P10567581A0119 |240 256|hepatocyte entryno longer displa
P10567581A0119 |195 200|liver of C
P10567581A0119 |64 71|HFH-11Botidase
P10567581A0119 |99 102|Winc a
P10567581A0119 |27 32|HNF-3ith a
P10567581A0119 |109 122|family memberof neonatal h
P10567581A0119 |148 174|head transcription factors97A0472 When CSF [HCO3-] i
P10567581A0119 |279 286|S phasentrols 
P10567581A0119 |262 277|DNA replicationen compared to 
P10567581A0119 |33 62|fork head homolog-11B proteinkaline phosphatases and 5-nuc
P10567581A0119 |87 94|TridentPharmac
P10567582A1334 |38 44|embryoe phos
P10567582A1334 |92 105|embryogenesisacologic aspe
P10567582A1334 |14 19|CtBP1 Comp
P10567582A1334 |59 64|CtBP2nucle
P10567582A1334 |7 12|mouse06T00
P10567589A1268 |102 119|Pmt3p conjugationspects of neonata
P10567589A1268 |13 22|functions6 Compari
P10567589A1268 |26 31|Pmt3pwith 
P10567589A1268 |76 84|proteins08171T00
P10568275A0679 |4 8|role0160
P10568275A0679 |12 21|transport76 Compar
P10568275A0679 |60 72|Arctic Oceanucleotidase 
P10568275A0679 |25 32|sea ice with a
P10568275A0679 |109 115|GEOMARof neo
P10568275A0679 |42 50|Kara Seaosphatas
P10568275A0679 |97 105|subgroupgic aspe
P10568455A0000 |174 176|CLs 
P10568455A0000 |44 73|slow-release estradiol-17betaphatases and 5-nucleotidase P
P10568455A0000 |31 40|injectionalkaline 
P10568455A0000 |181 196|pseudopregnancy as a function 
P10568455A0000 |75 79|SRE20081
P10568455A0000 |131 140|PGF2alphaubinemia.
P10568455A0000 |94 109|pseudopregnancyologic aspects 
P10568455A0000 |159 172|corpora lutean CSF [HCO3-]
P10568455A0000 |113 118|giltseonat
P10568728A1445 |100 104|week asp
P10568728A1445 |13 34|serum creatine kinase6 Comparison with alk
P10568728A1445 |60 64|daysucle
P10568728A1445 |4 9|level01606
P10568728A1445 |71 76|ESWIB P000
P10568744A0728 |99 104|sitesc asp
P10568744A0728 |135 139|roleemia
P10568744A0728 |45 54|promotershatases a
P10568744A0728 |159 168|directionn CSF [HC
P10568744A0728 |79 84|genes71T00
P10568744A0728 |172 193|mating type switching is shown as a functi
P10568744A0728 |23 28|siteson wi
P10570262A0000 |0 10|ActivationP00001606T
P10570262A0000 |30 33|TCR al
P10570262A0000 |89 107|signaling cascadesarmacologic aspect
P10570262A0000 |14 21|T cells Compar
P10570262A0000 |79 85|number71T000
P10570262A0000 |58 67|receptors-nucleoti
P10570996A1213 |220 227|insulinK-deple
P10570996A1213 |92 105|scavenger RTKacologic aspe
P10570996A1213 |245 254|receptorsnger disp
P10570996A1213 |132 141|signaturebinemia. 
P10570996A1213 |150 158|TK classA0472 Wh
P10570996A1213 |15 23|analysisComparis
P10570996A1213 |162 171|receptorsSF [HCO3-
P10570996A1213 |111 118|domains neonat
P10570996A1213 |55 64|sequencesd 5-nucle
P10570996A1213 |33 43|TK domainskaline pho
P10571047A1009 |101 118|HindIII fragmentsaspects of neonat
P10571047A1009 |8 11|7SL6T0
P10571047A1009 |58 65|spacers-nucleo
P10571047A1009 |25 34|sequences with alk
P10571047A1009 |140 142|kb P
P10571474A0571 |0 7|ResultsP000016
P10571474A0571 |53 60|atrophyand 5-n
P10571474A0571 |23 29|stresson wit
P10571474A0571 |39 42|CA3 ph
P10571474A0571 |65 75|tianeptinetidase P00
P10572087A0326 |102 111|screeningspects of
P10572087A0326 |19 34|binding partnerarison with alk
P10572087A0326 |75 80|FANCC00817
P10572087A0326 |51 73|anemia group C proteins and 5-nucleotidase P
P10572087A0326 |85 90|yeast0 Pha
P10572130A1623 |137 141|roleia. 
P10572130A1623 |106 120|RNA polymerasets of neonatal
P10572130A1623 |165 177|DNA geometry[HCO3-] is s
P10572130A1623 |145 154|formation08997A047
P10572130A1623 |94 102|subunitsologic a
P10572130A1623 |6 13|results606T007
P10572130A1623 |32 56|transcription activatorslkaline phosphatases and
P10572131A0000 |0 18|Klebsiella oxytocaP00001606T0076 Com
P10572131A0000 |63 70|enzymeseotidas
P10572131A0000 |86 102|nasFEDCBA operon Pharmacologic a
P10572866A0481 |69 79|phosphorusse P000081
P10572866A0481 |41 54|plasma valueshosphatases a
P10572866A0481 |7 16|hemolysis06T0076 C
P10572866A0481 |58 67|potassium-nucleoti
P10572866A0481 |87 94|proteinPharmac
P10572866A0481 |100 126|aspartate aminotransferase aspects of neonatal hyper
P10573781A0631 |0 7|StudiesP000016
P10573781A0631 |31 42|involvementalkaline ph
P10573781A0631 |71 82|chromosomes P00008171T
P10573781A0631 |55 59|locid 5-
P10573781A0631 |87 93|excessPharma
P10573781A0631 |100 111|chromosomes aspects of
P10574913A1108 |87 96|processesPharmacol
P10574913A1108 |105 120|Src recruitmentcts of neonatal
P10574913A1108 |143 158|internalization0008997A0472 Wh
P10574913A1108 |197 211|ERK activationf CSF PCO2 the
P10574913A1108 |251 265|ERK activationisplaced when 
P10574913A1108 |38 62|receptor phosphorylatione phosphatases and 5-nuc
P10574929A0583 |21 34|fractionationison with alk
P10574929A0583 |47 61|P-CIP2 proteintases and 5-nu
P10574982A1075 |0 16|Supershift EMSAsP00001606T0076 C
P10574982A1075 |104 113|complexesects of n
P10574982A1075 |90 94|partrmac
P10574982A1075 |54 62|factor-1nd 5-nuc
P10574982A1075 |71 76|USF-1 P000
P10574992A0901 |137 148|irradiationia. P000089
P10574992A0901 |108 133|cell death susceptibility of neonatal hyperbilirub
P10574992A0901 |12 23|E1A binding76 Comparis
P10574992A0901 |191 231|PARP chemical inhibitor 3-aminobenzamidetion of CSF PCO2 the data of K-depleted 
P10574992A0901 |67 87|PARP enzyme activitydase P00008171T0000 
P10574992A0901 |55 63|increased 5-nucl
P10574992A0901 |32 40|p300/CBPlkaline 
P10575231A0355 |0 8|AnalysisP0000160
P10575231A0355 |96 103|intronsogic as
P10575231A0355 |24 30|regionn with
P10575231A0355 |55 64|Cdc6 gened 5-nucle
P10575231A0355 |84 89|exons00 Ph
P10575545A0147 |18 23|CACCCparis
P10575545A0147 |28 39|CAAT motifsth alkaline
P10575642T0000 |0 15|Skin pH changesP00001606T0076 
P10575642T0000 |32 45|iontophoresislkaline phosp
P10576177A0308 |81 86|rangeT0000
P10576177A0308 |44 53|diagnosisphatases 
P10576177A0308 |90 99|prognosesrmacologi
P10576177A0308 |125 136|implicationrbilirubine
P10576177A0308 |5 16|distinction1606T0076 C
P10576545A0926 |38 51|DNA cassettese phosphatase
P10576545A0926 |131 141|expressionubinemia. 
P10576545A0926 |73 90|D1A gene promoter00008171T0000 Pha
P10576545A0926 |145 155|transgenes08997A0472
P10576545A0926 |4 16|availability01606T0076 C
P10578528A0730 |80 89|character1T0000 Ph
P10578528A0730 |94 107|manifestationologic aspect
P10578528A0730 |145 159|symptomatology08997A0472 Whe
P10578528A0730 |57 60|EEG5-n
P10578528A0730 |37 42|focusne ph
P10578528A0730 |23 31|locationon with 
P10579331A1225 |50 81|rat HDL receptor SR-BI promoteres and 5-nucleotidase P00008171
P10579331A1225 |130 134|dSRErubi
P10579331A1225 |150 158|SREBP-1aA0472 Wh
P10579331A1225 |121 125|pSREhype
P10579331A1225 |181 194|transcription as a functio
P10579331A1225 |203 207|genePCO2
P10579331A1225 |95 119|sterol response elementslogic aspects of neonata
P10579331A1225 |4 11|results01606T0
P10579331A1225 |21 28|studiesison wi
P10579722T0000 |51 69|myosin phosphatases and 5-nucleotida
P10579722T0000 |43 46|MBSsph
P10579722T0000 |73 83|Rho-kinase00008171T0
P10579722T0000 |0 15|PhosphorylationP00001606T0076 
P10579722T0000 |34 41|subunitaline p
P10580071A0436 |119 129|transplantl hyperbil
P10580071A0436 |60 75|transplantationucleotidase P00
P10580071A0436 |9 17|patientsT0076 Co
P10580071A0436 |51 55|lists an
P10580438A0508 |136 149|preadipocytesmia. P0000899
P10580438A0508 |41 45|EMSAhosp
P10580438A0508 |122 130|extractsyperbili
P10580438A0508 |164 174|adipocytes [HCO3-] i
P10580438A0508 |53 76|GLUT4 repressor elementand 5-nucleotidase P000
P10580438A0508 |78 82|G4RE171T
P10580438A0508 |19 39|mobility shift assayarison with alkaline
P10580438A0508 |103 108|bandspects
P10582831T0000 |85 93|patients0 Pharma
P10582831T0000 |26 40|redistributionwith alkaline 
P10582831T0000 |55 68|complicationsd 5-nucleotid
P10582831T0000 |0 9|SyndromesP00001606
P10584138T0001 |34 46|radiotherapyaline phosph
P10584138T0001 |72 76|headP000
P10584138T0001 |81 92|neck tumorsT0000 Pharm
P10584138T0001 |20 30|amifostinerison with
P10584138T0001 |50 68|radio-chemotherapyes and 5-nucleotid
P10584138T0001 |0 14|CytoprotectionP00001606T0076
P10584704A0913 |220 228|sectionsK-deplet
P10584704A0913 |131 142|cytokeratinubinemia. P
P10584704A0913 |89 95|HMB-45armaco
P10584704A0913 |46 51|S-100atase
P10584704A0913 |104 105|%e
P10584704A0913 |61 66|casescleot
P10584704A0913 |20 28|stainingrison wi
P10584704A0913 |199 204|blockCSF P
P10584704A0913 |174 182|melanomas shown 
P10584704A0913 |152 157|cases472 W
P10585311A0494 |152 158|biopsy472 Wh
P10585311A0494 |120 125|onset hype
P10585311A0494 |30 34|MPGN alk
P10585311A0494 |53 56|ageand
P10585311A0494 |97 105|intervalgic aspe
P10585311A0494 |129 137|symptomsirubinem
P10585311A0494 |76 79|age081
P10585311A0494 |14 19|types Comp
P10585311A0494 |141 150|diagnosisP00008997
P10585311A0494 |83 92|diagnosis000 Pharm
P10585311A0494 |69 74|onsetse P0
P10585311A0494 |0 8|PatientsP0000160
P10585311A1542 |102 106|MPGNspec
P10585311A1542 |67 75|patientsdase P00
P10585311A1542 |95 99|typelogi
P10585311A1542 |81 85|typeT000
P10585311A1542 |17 30|abnormalitiesmparison with
P10585417A1412 |16 27|differencesomparison w
P10585417A1412 |45 62|tissue expressionhatases and 5-nuc
P10585417A1412 |148 156|function97A0472 
P10585417A1412 |31 40|signalingalkaline 
P10585417A1412 |126 130|PRLrbili
P10585417A1412 |99 103|PRLrc as
P10585440A0204 |102 105|armspe
P10585440A0204 |43 56|FAK homologuesphatases and
P10585440A0204 |120 130|chromosome hyperbili
P10585440A0204 |58 64|DFak56-nucle
P10585440A0204 |80 88|band 56D1T0000 P
P10585453A1029 |187 194|hGH LCRfunctio
P10585453A1029 |165 169|role[HCO
P10585453A1029 |31 50|hGH-N gene promoteralkaline phosphatas
P10585453A1029 |108 112|data of 
P10585453A1029 |12 23|Pit-1 sites76 Comparis
P10585453A1029 |77 92|gene activation8171T0000 Pharm
P10585453A1029 |174 179|Pit-1s sho
P10585463A0859 |51 84|baculovirus-Sf9 expression systems and 5-nucleotidase P00008171T00
P10585463A0859 |12 32|prenylcysteine lyase76 Comparison with a
P10585480A0157 |102 105|Racspe
P10585480A0157 |94 97|Rasolo
P10585480A0157 |28 38|SH3 domainth alkalin
P10585480A0157 |55 89|guanine nucleotide exchange factord 5-nucleotidase P00008171T0000 Ph
P10585480A0157 |48 51|Sosase
P10585480A0265 |0 15|Point mutationsP00001606T0076 
P10585480A0265 |29 39|SH3 domainh alkaline
P10585480A0265 |66 77|interactionidase P0000
P10585491A0945 |373 382|seedlingsam thus a
P10585491A0945 |54 57|CBFnd 
P10585491A0945 |397 406|seedlings effectiv
P10585491A0945 |249 265|binding activity displaced when 
P10585491A0945 |124 132|extractserbiliru
P10585491A0945 |300 307|tissues a sign
P10585491A0945 |420 429|cytokining with th
P10585491A0945 |183 191|extractss a func
P10585491A0945 |286 294|extractsbut stil
P10585491A0945 |225 234|seedlingsleted rat
P10585491A0945 |75 97|AtpC promoter sequence008171T0000 Pharmacolo
P10585491A0945 |318 340|AtpC expression levelsreater slope (1.21 +/-
P10585491A0945 |154 176|AtpC expression levels2 When CSF [HCO3-] is 
P10585491A0945 |138 144|tissuea. P00
P10585491A0945 |347 355|extractss. P0001
P10585491A0945 |3 28|gel mobility shift assays001606T0076 Comparison wi
P10585491A0945 |34 50|binding activityaline phosphatas
P10585808A0000 |0 29|Mycoplasma hominis infectionsP00001606T0076 Comparison wit
P10585808A0000 |91 100|detectionmacologic
P10585808A0000 |69 76|methodsse P000
P10586074A0129 |38 56|plasmid constructse phosphatases and
P10586074A0129 |28 34|seriesth alk
P10586074A0129 |120 130|flavivirus hyperbili
P10586074A0129 |9 16|purposeT0076 C
P10586074A0129 |89 112|envelope glycoprotein Earmacologic aspects of 
P10586074A0129 |76 81|forms08171
P10586074A0129 |142 160|encephalitis virus00008997A0472 When
P10586107A0160 |85 107|cell surface receptors0 Pharmacologic aspect
P10586107A0160 |29 34|typesh alk
P10586107A0160 |49 70|transduction pathwaysses and 5-nucleotidas
P10586115A0477 |85 93|IL-1beta0 Pharma
P10586115A0477 |120 124|IL-6 hyp
P10586115A0477 |203 210|inducerPCO2 th
P10586115A0477 |95 104|TNF-alphalogic asp
P10586115A0477 |245 250|% FCSnger 
P10586115A0477 |109 113|IL-6of n
P10586115A0477 |74 83|IL-1alpha0008171T0
P10586115A0477 |54 63|cytokinesnd 5-nucl
P10586115A0477 |233 241|culturests are n
P10586115A0477 |174 179|cellss sho
P10586115A0477 |155 161|PKCeta When 
P10586626A0607 |152 156|ADEM472 
P10586626A0607 |90 98|presencermacolog
P10586626A0607 |123 134|involvementperbilirubi
P10586626A0607 |14 22|diseases Compari
P10586626A0607 |42 48|matterosphat
P10586626A0607 |138 146|patientsa. P0000
P10587460A0302 |99 111|hVDR mutantsc aspects of
P10587460A0302 |57 61|hVDR5-nu
P10587460A0302 |214 222|bacteriata of K-
P10587460A0302 |123 131|Delta113perbilir
P10587460A0302 |133 141|Delta102inemia. 
P10587460A0302 |152 159|Delta84472 Whe
P10587460A0302 |113 121|Delta134eonatal 
P10587460A0302 |22 41|VDRE binding domainson with alkaline p
P10587460A0302 |52 55|VDR an
P10587460A0302 |143 150|Delta900008997
P10587460A0302 |161 168|Delta80CSF [HC
P10587460A0302 |66 72|seriesidase 
P10587460A0302 |174 181|Delta60s shown
P10587461A0341 |70 79|formatione P000081
P10587461A0341 |47 56|anticodontases and
P10587461A0341 |92 108|transition stateacologic aspects
P10587461A0341 |29 37|contactsh alkali
P10587461A0341 |114 118|siteonat
P10587461A0341 |18 27|mechanismparison w
P10587576A0596 |55 57|kbd 
P10587576A0596 |105 121|SH3GL pseudogenects of neonatal 
P10587576A0596 |15 23|clustersComparis
P10587576A0596 |6 10|REPs606T
P10587576A0596 |62 68|harborleotid
P10587576A0596 |83 87|ESTs000 
P10587576A0596 |38 42|locie ph
P10588946A0432 |50 58|proteinses and 5
P10588946A0432 |80 85|ORP-61T000
P10588946A0432 |71 76|ORP-1 P000
P10588946A0432 |16 23|minimumomparis
P10589562A1208 |69 81|BB resonatorse P00008171
P10589562A1208 |27 36|inabilityith alkal
P10589562A1208 |13 19|result6 Comp
P10589562A1208 |3 7|part0016
P10589562A1208 |100 121|RF power requirements aspects of neonatal 
P10589711A1228 |119 124|cellsl hyp
P10589711A1228 |213 219|milieuata of
P10589711A1228 |13 28|narZ expression6 Comparison wi
P10589711A1228 |3 11|addition001606T0
P10589711A1228 |82 93|Madin-Darby0000 Pharma
P10589711A1228 |101 107|kidneyaspect
P10589711A1228 |154 166|salts medium2 When CSF [
P10590092A0124 |9 19|mechanismsT0076 Comp
P10590092A0124 |60 63|CNSucl
P10590092A0124 |31 52|HIV-1 gene expressionalkaline phosphatases
P10590368X0000 |32 43|alternativelkaline pho
P10590368X0000 |247 261|survival rateser displaced w
P10590368X0000 |214 220|cervixta of 
P10590368X0000 |122 132|BACKGROUNDyperbiliru
P10590368X0000 |164 174|lymph node [HCO3-] i
P10590368X0000 |86 106|stage IA-B carcinoma Pharmacologic aspec
P10590368X0000 |55 67|hysterectomyd 5-nucleoti
P10590368X0000 |114 120|cervixonatal
P10590368X0000 |191 206|stage carcinomation of CSF PCO
P10590368X0000 |11 24|trachelectomy076 Compariso
P10590368X0000 |72 80|patientsP0000817
P10590368X0000 |277 278|%c
P10590368X0000 |138 147|prognosisa. P00008
P10591633A0138 |87 94|vesiclePharmac
P10591633A0138 |196 207|recognitionof CSF PCO2
P10591633A0138 |111 115|view neo
P10591633A0138 |215 230|membrane fusiona of K-depleted
P10591633A0138 |124 150|SNARE protein interactionserbilirubinemia. P00008997
P10591633A0138 |45 56|recognitionhatases and
P10591633A0138 |173 177|roleis s
P10591633A0138 |6 11|event606T0
P10591633A0138 |20 27|processrison w
P10591633A0138 |64 79|target membraneotidase P000081
P10591933A0798 |16 20|Typeompa
P10591933A0798 |60 66|valuesucleot
P10591933A0798 |179 187|distancewn as a 
P10591933A0798 |90 95|anglermaco
P10591933A0798 |23 36|configurationon with alkal
P10591933A0798 |100 108|coracoid aspects
P10591976A0317 |0 12|MeasurementsP00001606T00
P10591976A0317 |91 99|patientsmacologi
P10591976A0317 |31 38|LWS latalkalin
P10591976A0317 |78 83|total171T0
P10591976A0317 |47 51|Wardtase
P10591976A0317 |20 28|LWS p.a.rison wi
P10591976A0317 |54 62|trianglend 5-nuc
P10591990A0178 |2 7|group00016
P10591990A0178 |104 108|BPRSects
P10591990A0178 |44 55|in-patientsphatases an
P10591990A0178 |14 20|DSM-IV Compa
P10591990A0178 |76 81|times08171
P10591990A0178 |92 96|SAPSacol
P10591990A0178 |113 116|PASeon
P10591990A0178 |98 102|SANSic a
P10592791A0370 |408 415|abilityhypnoti
P10592791A0370 |455 466|SET-EIA kitgeneral pra
P10592791A0370 |94 102|SET-RPLAologic a
P10592791A0370 |376 391|test proceduresthus appears to
P10592791A0370 |107 122|RIDASCREEN kitss of neonatal h
P10592791A0370 |439 451|practicalitydose for use
P10592791A0370 |284 294|backgrounds but stil
P10592791A0370 |19 28|TECRA kitarison wi
P10592791A0370 |156 169|investigationWhen CSF [HCO
P10592791A0370 |262 274|SET-RPLA kiten compared 
P10592791A0370 |80 87|strains1T0000 
P10592791A0370 |191 195|lacktion
P10592791A0370 |249 256|testing displa
P10592791A0370 |500 517|research purposes653T0045 Beta blo
P10592791A0370 |470 479|screeninge being 1
P10592791A0370 |231 235|timerats
P10592791A0370 |400 404|lackfect
P10592791A0370 |199 206|abilityCSF PCO
P10592791A0370 |173 181|SE typesis shown
P10592791A0370 |67 69|SEda
P10592791A0370 |3 13|conclusion001606T007
P10592791A0370 |306 320|RIDASCREEN kitnificantly gre
P10592791T0001 |0 10|ComparisonP00001606T
P10592791T0001 |14 30|immunoassay kits Comparison with
P10592791T0001 |63 75|enterotoxinseotidase P00
P10592791T0001 |35 44|detectionline phos
P10592824A1157 |170 171|%-
P10592824A1157 |153 154|%7
P10592824A1157 |292 302|Chi-squareill have a
P10592824A1157 |127 134|vaccineilirubi
P10592824A1157 |212 220|childrendata of 
P10592824A1157 |246 250|doseger 
P10592824A1157 |183 184|%s
P10592824A1157 |198 199|% 
P10592824A1157 |75 87|JEV antibody008171T0000 
P10592824A1157 |17 26|frequencymparison 
P10592824A1157 |119 123|dosel hy
P10592824A1157 |254 265|JE vaccineslaced when 
P10592824A1157 |66 71|ratesidase
P10592824A1157 |281 282|Pr
P10592824A1157 |38 47|infectione phospha
P10592824A1157 |307 317|trend testificantly 
P10593939A0747 |170 177|members-] is s
P10593939A0747 |189 194|SRZ22nctio
P10593939A0747 |179 184|SRZ21wn as
P10593939A0747 |134 146|SR45 proteinnemia. P0000
P10593939A0747 |90 102|SR33 proteinrmacologic a
P10593939A0747 |206 212|family2 the 
P10593939A0747 |249 260|Arabidopsis displaced 
P10593939A0747 |273 278|U-70K to c
P10593939A0747 |50 73|interaction experimentses and 5-nucleotidase P
P10593950A1113 |3 10|summary001606T
P10593950A1113 |108 120|protein p116 of neonatal
P10593950A1113 |41 55|chromatographyhosphatases an
P10593950A1113 |12 15|WT176 
P10593950A1113 |76 78|U508
P10593950A1113 |125 133|hnRNP A1rbilirub
P10593950A1113 |37 39|dTne
P10593950A1113 |64 70|U2AF65otidas
P10594130A0652 |70 77|degreese P0000
P10594130A0652 |15 21|heartsCompar
P10594130A0652 |90 98|stainingrmacolog
P10594130A0652 |47 54|infantstases a
P10594239A0614 |186 193|alleles functi
P10594239A0614 |20 29|mouse Chrrison wit
P10594239A0614 |42 50|Chr 1q31osphatas
P10594239A0614 |92 100|evidenceacologic
P10594239A0614 |124 132|contrasterbiliru
P10594239A0614 |141 145|Tih1P000
P10594239A0614 |64 71|regionsotidase
P10594239A0614 |136 139|Iplmia
P10594239A0614 |0 9|Tih1 mapsP00001606
P10594239T0000 |70 76|TDAG51e P000
P10594239T0000 |128 136|locationlirubine
P10594239T0000 |104 114|expressionects of ne
P10594239T0000 |59 68|Ipl/Tssc3nucleotid
P10594239T0000 |8 18|pleckstrin6T0076 Com
P10594239T0000 |82 86|Tih10000
P10594239T0000 |36 47|gene familyine phospha
P10594903A0000 |34 47|nanoparticlesaline phospha
P10594903A0000 |197 207|laboratoryf CSF PCO2
P10594903A0000 |111 121|substances neonatal 
P10594903A0000 |164 166|VX [
P10594903A0000 |134 151|warfare agents GAnemia. P00008997A
P10594903A0000 |4 13|potential01606T007
P10594903A0000 |157 159|HDhe
P10594903A0000 |49 52|RNPses
P10594903A0000 |153 155|GB72
P10595315A0344 |87 98|blood gasesPharmacolog
P10595315A0344 |75 81|status008171
P10595315A0344 |28 35|effectsth alka
P10595315A0344 |53 63|parametersand 5-nucl
P10596955A1032 |137 143|Immunoia. P0
P10596955A1032 |122 130|microg/lyperbili
P10596955A1032 |44 52|troponinphatases
P10596955A1032 |23 39|failure patientson with alkaline
P10596955A1032 |79 91|Axsym method71T0000 Phar
P10596955A1032 |64 72|microg/lotidase 
P10596955A1032 |102 108|levelsspects
P10597222A1371 |64 78|HMBA signalingotidase P00008
P10597222A1371 |106 109|p21ts 
P10597222A1371 |27 30|p27ith
P10597222A1371 |52 60|molecule and 5-n
P10597223A0339 |220 241|transcription factorsK-depleted rats are n
P10597223A0339 |131 133|bpub
P10597223A0339 |150 179|transcription initiation siteA0472 When CSF [HCO3-] is sho
P10597223A0339 |61 71|activationcleotidase
P10597223A0339 |75 78|p21008
P10597223A0339 |22 36|Ras-expressionson with alkal
P10597223A0339 |111 123|p21 promoter neonatal hy
P10597223A0339 |191 204|binding sitestion of CSF P
P10597223A0339 |101 107|regionaspect
P10597232A0000 |4 26|RET/PTC3 rearrangement01606T0076 Comparison 
P10597232A0000 |40 46|fusionphosph
P10597232A0000 |63 72|RET geneseotidase 
P10597232A0000 |144 162|thyroid carcinomas008997A0472 When C
P10597232A0000 |54 58|ELE1nd 5
P10597317A1156 |0 9|ApoptosisP00001606
P10597317A1156 |88 96|additionharmacol
P10597317A1156 |243 247|LMP1long
P10597317A1156 |151 157|masses0472 W
P10597317A1156 |19 24|cellsariso
P10597317A1156 |49 64|co-transfectionses and 5-nucle
P10597317A1156 |256 264|RS cellsced when
P10597317A1156 |113 125|HD-MyZ cellseonatal hype
P10597317A1156 |212 215|JNKdat
P10597317A1156 |230 239|apoptosis rats are
P10597317A1156 |198 208|inhibition CSF PCO2 
P10597317A1156 |76 80|LMP10817
P10597317A1156 |68 71|JBDase
P10598101A0000 |117 120|boxtal
P10598101A0000 |62 77|maize endospermleotidase P0000
P10598101A0000 |3 11|addition001606T0
P10598101A0000 |127 150|kDa zein gene promotersilirubinemia. P00008997
P10598101A0000 |86 94|proteins Pharmac
P10598101A0000 |19 39|bZIP protein Opaque2arison with alkaline
P10598101A0754 |86 94|pentamer Pharmac
P10598101A0754 |113 124|yeast cellseonatal hyp
P10598101A0754 |213 229|expression assayata of K-deplete
P10598101A0754 |245 266|maize endosperm cellsnger displaced when c
P10598101A0754 |180 197|kDa zein promotern as a function o
P10598101A0754 |105 109|sitects 
P10598101A0754 |4 19|mEmBP-1 protein01606T0076 Comp
P10598101A0754 |158 171|transcriptionen CSF [HCO3-
P10598101A0754 |64 72|promoterotidase 
P10598101A0754 |33 46|transcriptionkaline phosph
P10598316A1534 |0 3|GHBP00
P10598316A1534 |11 14|HMB076
P10598316A1534 |41 51|substanceshosphatase
P10598316A1534 |7 9|CB06
P10599013A0505 |14 20|deaths Compa
P10599727A1567 |17 43|estrogen treatment regimenmparison with alkaline pho
P10599727A1567 |61 63|TScl
P10599727A1567 |128 133|peerslirub
P10599727A1567 |10 12|GH00
P10599727A1567 |98 108|conformityic aspects
P10599727A1567 |50 55|girlses an
P10600171A1066 |83 90|binding000 Pha
P10600171A1066 |60 66|resultucleot
P10600171A1066 |46 52|CYP3A2atases
P10600171A1066 |28 42|responsivenessth alkaline ph
P10600171A1066 |94 101|COUP-TFologic 
P10600171A1066 |109 128|CYP3A2 DexRE-1 siteof neonatal hyperbi
P10600171A1432 |21 29|activityison wit
P10600171A1432 |63 72|3A23SiteAeotidase 
P10600171A1432 |7 14|CYP3A2306T0076
P10600171A1432 |93 97|USF1colo
P10600171A1432 |112 152|bHLH/leucine zipper transcription factorneonatal hyperbilirubinemia. P00008997A0
P10600171A1432 |54 59|E-boxnd 5-
P10601280A0674 |34 41|elementaline p
P10601280A0674 |120 130|activation hyperbili
P10601280A0674 |70 91|ST3 promoter activitye P00008171T0000 Phar
P10601290A0742 |119 130|differencesl hyperbili
P10601290A0742 |161 164|I1YCSF
P10601290A0742 |228 233|classed ra
P10601290A0742 |89 96|peptidearmacol
P10601290A0742 |192 216|x-ray crystal structuresion of CSF PCO2 the data
P10601290A0742 |134 152|T cell recognitionnemia. P00008997A0
P10601290A0742 |18 23|basisparis
P10601290A0742 |42 64|cell surface stabilityosphatases and 5-nucle
P10601290A0742 |236 257|MHC-peptide complexesare no longer displac
P10601290A0742 |169 172|I1F3-]
P10601335A0892 |0 14|RedistributionP00001606T0076
P10601335A0892 |75 85|degrees C.008171T000
P10601335A0892 |53 58|cellsand 5
P10601335A0892 |18 29|mannosidaseparison wit
P10601344A1653 |100 106|beta1A aspec
P10601344A1653 |31 46|activity assaysalkaline phosph
P10601344A1653 |60 67|GTPasesucleoti
P10601344A1653 |181 185|RhoA as 
P10601344A1653 |108 114|beta1D of ne
P10601344A1653 |134 138|GE11nemi
P10601344A1653 |119 130|IL2R-beta1Al hyperbili
P10601344A1653 |86 96|expression Pharmacol
P10601344A1653 |190 194|Rac1ctio
P10601344A1653 |142 152|GD25 cells00008997A0
P10601344A1653 |162 172|activationSF [HCO3-]
P10601344A1653 |3 11|addition001606T0
P10601344A1653 |207 212|Cdc42 the 
P10601410A0977 |136 151|conduction timemia. P00008997A
P10601410A0977 |41 45|rolehosp
P10601410A0977 |62 75|remyelinationleotidase P00
P10601410A0977 |3 13|conclusion001606T007
P10601410A0977 |95 112|sclerosis lesionslogic aspects of 
P10601410A0977 |19 23|dataaris
P10601410A0977 |50 54|IVIges a
P10601606A0152 |4 24|rhabdomyosarcoma R1H01606T0076 Compariso
P10601606A0152 |60 72|WAG/Rij ratsucleotidase 
P10601606A0152 |104 113|degrees Cects of n
P10601606A0152 |120 130|degrees C. hyperbili
P10601606A0152 |46 51|flankatase
P10601606A0152 |96 97|ho
P10601747A0482 |85 94|anomalies0 Pharmac
P10601747A0482 |112 123|N400 effectneonatal hy
P10601747A0482 |166 176|word onsetHCO3-] is 
P10601747A0482 |21 34|control wordsison with alk
P10601747A0482 |155 159|msec Whe
P10602419A1253 |18 25|effectsparison
P10602502A0422 |69 74|G0/G1se P0
P10602502A0422 |9 20|Tob proteinT0076 Compa
P10602502A0422 |78 86|S phases171T0000
P10602502A0422 |22 26|Tob2son 
P10602502A0422 |37 59|cell cycle progressionne phosphatases and 5-
P10602507A0652 |116 130|cyclin D1/cdk4atal hyperbili
P10602507A0652 |27 36|cyclin D1ith alkal
P10602507A0652 |41 44|p21hos
P10602507A0652 |132 135|p53bin
P10602507A0652 |104 112|activityects of 
P10602507A0652 |15 23|increaseComparis
P10602507A0652 |159 174|CSF-1 inductionn CSF [HCO3-] i
P10602507A0652 |178 181|p21own
P10602507A0652 |53 59|effectand 5-
P10602507A0652 |218 232|p53 expressionf K-depleted r
P10602516A0182 |87 92|M-NAPPharm
P10602516A0182 |122 130|functionyperbili
P10602516A0182 |13 16|SLK6 C
P10602516A0182 |31 39|homologyalkaline
P10602516A0182 |43 54|microtubulesphatases a
P10602516A0182 |78 85|protein171T000
P10602516A0182 |98 104|AT1-46ic asp
P10602516A0182 |3 11|addition001606T0
P10602838A0127 |17 25|patientsmparison
P10602838A0127 |30 37|females alkali
P10602838A0127 |44 49|malesphata
P10602838A0127 |8 13|study6T007
P10603349A1667 |68 78|activationase P00008
P10603349A1667 |173 195|Myf5 expression domainis shown as a function
P10603349A1667 |82 86|Myf50000
P10603349A1667 |40 48|hedgehogphosphat
P10603349A1667 |123 129|somiteperbil
P10603349A1667 |99 115|progenitor cellsc aspects of neo
P10603349A1667 |203 216|mesencephalonPCO2 the data
P10603349A1667 |4 29|signalling molecules Wnt101606T0076 Comparison wit
P10603349A1667 |156 165|viscinityWhen CSF 
P10604246A0523 |0 12|STUDY DESIGNP00001606T00
P10604246A0523 |250 258|patientsdisplace
P10604246A0523 |212 214|V4da
P10604246A0523 |127 128|Vi
P10604246A0523 |178 181|MNCown
P10604246A0523 |63 73|collectioneotidase P
P10604246A0523 |271 277|donorsed to 
P10604246A0523 |28 33|studyth al
P10604246A0523 |108 116|AutoPBSC of neon
P10604246A0523 |228 243|cell tubing seted rats are no 
P10604246A0523 |195 199|cell of 
P10604246A0523 |17 24|METHODSmpariso
P10604246A0523 |118 125|versional hype
P10604246A0523 |96 102|deviceogic a
P10604246A0523 |77 82|PBPCs8171T
P10604246A0523 |201 210|procedureF PCO2 th
P10604246A0523 |138 157|AutoPBSC tubing seta. P00008997A0472 W
P10604583T0000 |51 58|patients and 5
P10604583T0000 |28 35|removalth alka
P10604583T0000 |165 176|elimination[HCO3-] is 
P10604583T0000 |74 88|Wilson disease0008171T0000 P
P10604583T0000 |194 200|toxinsn of C
P10604583T0000 |39 45|copper phosp
P10604583T0000 |145 156|possibility08997A0472 
P10604583T0000 |116 137|liver transplantationatal hyperbilirubinem
P10604583T0000 |0 16|Albumin dialysisP00001606T0076 C
P10604945A0731 |205 211|factorO2 the
P10604945A0731 |92 99|ethanolacologi
P10604945A0731 |56 65|Sp1 sites 5-nucleo
P10604945A0731 |105 111|otherscts of
P10604945A0731 |142 154|organization00008997A047
P10604945A0731 |230 246|ethanol response rats are no lon
P10604945A0731 |16 35|promoter constructsomparison with alka
P10604945A0731 |171 186|promoter region] is shown as a
P10606245A0906 |0 14|OverexpressionP00001606T0076
P10606245A0906 |40 58|osteosarcoma cellsphosphatases and 5
P10606245A0906 |147 156|OC box I.997A0472 
P10606245A0906 |29 32|ROSh a
P10606245A0906 |18 25|CDP/cutparison
P10606245A0906 |111 121|repression neonatal 
P10606245A0906 |70 80|repressione P0000817
P10606245A0906 |84 104|OC promoter activity00 Pharmacologic asp
P10606272A1241 |0 9|InjectionP00001606
P10606272A1241 |29 32|RNAh a
P10606272A1241 |91 99|SF1 genemacologi
P10606272A1241 |38 48|C. eleganse phosphat
P10606272A1241 |125 130|yeastrbili
P10606272A1241 |156 164|metazoanWhen CSF
P10606272A1241 |70 79|lethalitye P000081
P10606515A0389 |153 159|strand72 Whe
P10606515A0389 |73 94|acid receptor element00008171T0000 Pharmac
P10606515A0389 |108 113|DNase of n
P10606515A0389 |40 51|DNA bindingphosphatase
P10606515A0389 |5 12|domains1606T00
P10606515A0389 |116 125|footprintatal hype
P10606664A0000 |0 21|Snail family proteinsP00001606T0076 Compar
P10606664A0000 |125 148|cell fate determinationrbilirubinemia. P000089
P10606664A0000 |26 37|zinc fingerwith alkali
P10606664A0000 |54 64|regulatorsnd 5-nucle
P10606664A0000 |116 121|rolesatal 
P10607566A0880 |85 88|RAR0 P
P10607566A0880 |188 191|TCFunc
P10607566A0880 |196 216|beta-catenin bindingof CSF PCO2 the data
P10607566A0880 |160 163|RXR CS
P10607566A0880 |72 83|RA receptorP00008171T0
P10607566A0880 |30 42|beta-catenin alkaline ph
P10607566A0880 |21 28|findingison wi
P10607566A0880 |114 120|manneronatal
P10607566A0880 |139 158|retinoid X receptor. P00008997A0472 Wh
P10607566A0880 |170 173|RAR-] 
P10607899A0605 |137 167|estrogen receptor binding siteia. P00008997A0472 When CSF [H
P10607899A0605 |109 113|CREBof n
P10607899A0605 |104 107|Sp1ect
P10607899A0605 |75 99|consensus binding motifs008171T0000 Pharmacologi
P10607899A0605 |0 17|Sequence analysisP00001606T0076 Co
P10607899A0605 |25 40|promoter region with alkaline 
P10607899A0605 |51 59|TATA boxs and 5-
P10607899A0605 |119 129|half sitesl hyperbil
P10607900T0000 |0 25|Sak kinase gene structureP00001606T0076 Comparison
P10607900T0000 |46 56|regulationatases and
P10608053A0923 |0 12|ThrombolysisP00001606T00
P10608053A0923 |214 218|p NSta o
P10608053A0923 |149 154|Group7A047
P10608053A0923 |121 127|groupshyperb
P10608053A0923 |108 112|hour of 
P10608053A0923 |51 68|platelet activitys and 5-nucleotid
P10608053A0923 |184 185|p 
P10608053A0923 |191 209|001versus baselinetion of CSF PCO2 t
P10608053A0923 |82 88|values0000 P
P10608053A0923 |140 145|IU/ml P000
P10608053A0923 |231 237|groupsrats a
P10608053A0923 |39 47|increase phospha
P10608053A0923 |175 180|Group show
P10608893A0727 |38 41|DNAe p
P10608893A0727 |75 86|specificity008171T0000
P10608893A0727 |11 16|Hp140076 C
P10608893A0727 |123 126|DNAper
P10608893A0727 |56 64|strength 5-nucle
P10608893A0727 |27 31|Hp55ith 
P10610716A1127 |19 37|missense mutationsarison with alkali
P10610716A1127 |46 51|R254Gatase
P10610716A1127 |57 62|P362R5-nuc
P10610716A1127 |106 117|FD patientsts of neona
P10610716A1127 |93 100|AC genecologic
P10610716A1127 |39 44|E138V phos
P10611225A1127 |100 111|translation aspects of
P10611225A1127 |125 136|interactionrbilirubine
P10611225A1127 |29 40|interactionh alkaline 
P10611225A1127 |192 196|roleion 
P10611225A1127 |166 172|regionHCO3-]
P10611225A1127 |44 49|eIF4Aphata
P10611225A1127 |6 10|data606T
P10611225A1127 |76 82|eIF4GI08171T
P10611225A1127 |66 72|regionidase 
P10611225A1127 |140 145|eIF4A P000
P10611228A1388 |49 57|DAP5/p97ses and 
P10611228A1388 |78 84|assays171T00
P10611228A1388 |23 27|formon w
P10611228A1388 |4 12|DAP5/p8601606T00
P10611235A1927 |139 157|Ste5p-MAPK cascade. P00008997A0472 W
P10611235A1927 |40 45|modelphosp
P10611235A1927 |27 31|stepith 
P10611235A1927 |94 95|Go
P10611235A1927 |165 180|plasma membrane[HCO3-] is show
P10611235A1927 |96 105|betagammaogic aspe
P10611235A1927 |53 63|activationand 5-nucl
P10611235A1927 |71 81|MAPK Fus3p P00008171
P10611235A1927 |117 131|relocalizationtal hyperbilir
P10611242A0541 |103 107|SAGApect
P10611242A0541 |124 128|Spt8erbi
P10611242A0541 |73 86|HIS3 promoter00008171T0000
P10611242A0541 |54 65|TBP bindingnd 5-nucleo
P10611242A0541 |40 44|SAGAphos
P10611242A0541 |21 28|findingison wi
P10611242A0541 |116 120|Spt3atal
P10611320A0816 |83 87|CAK1000 
P10611320A0816 |121 134|Cak1p proteinhyperbilirubi
P10611320A0816 |73 81|CAK gene00008171
P10611320A0816 |148 152|Cdk797A0
P10611353A0458 |0 13|Northern blotP00001606T007
P10611353A0458 |128 134|retinalirubi
P10611353A0458 |92 95|RNRaco
P10611353A0458 |228 250|Northern blot analysised rats are no longer 
P10611353A0458 |26 52|transcription-PCR analyseswith alkaline phosphatases
P10611353A0458 |62 74|mRNA samplesleotidase P0
P10611353A0458 |174 176|kbs 
P10611353A0458 |196 198|kbof
P10611353A0458 |141 152|transcriptsP00008997A0
P10611353A0458 |222 224|kbde
P10612044A1180 |49 66|AP-4 binding siteses and 5-nucleot
P10612044A1180 |30 42|conservation alkaline ph
P10612044A1180 |78 89|nucleotides171T0000 Ph
P10612044A1180 |106 135|transcription initiation sitets of neonatal hyperbilirubin
P10612044A1180 |144 153|Aal-rpL34008997A04
P10612044A1180 |158 172|Aal-rpL8 genesen CSF [HCO3-]
P10612505A1317 |169 170|%3
P10612505A1317 |37 42|studyne ph
P10612505A1317 |162 163|%S
P10612505A1317 |94 111|group differencesologic aspects of
P10612505A1317 |11 15|type076 
P10612505A1317 |115 131|treatment effectnatal hyperbilir
P10612505A1317 |82 83|%0
P10612505A1317 |18 23|errorparis
P10612505A1317 |49 54|powerses a
P10612773A1210 |0 11|CONCLUSIONSP00001606T0
P10612773A1210 |13 25|Serum levels6 Comparison
P10612773A1210 |106 113|surgeryts of n
P10612773A1210 |29 38|S-100betah alkalin
P10612773A1210 |52 59|markers and 5-
P10612773A1210 |83 91|outcomes000 Phar
P10612805A0716 |20 30|alterationrison with
P10612805A0716 |58 65|cancers-nucleo
P10612918A0318 |4 12|problems01606T00
P10612918A0318 |52 58|screws and 5
P10613816X0000 |0 7|StatinsP000016
P10613816X0000 |211 221|treatments data of K
P10613816X0000 |15 21|lipidsCompar
P10613816X0000 |113 118|studyeonat
P10613816X0000 |97 102|drugsgic a
P10613816X0000 |163 170|effectsF [HCO3
P10613816X0000 |265 277|osteoporosiscompared to 
P10613816X0000 |243 256|bone diseaseslonger displa
P10613816X0000 |33 38|boneskalin
P10613816X0000 |174 178|bones sh
P10613816X0000 |49 56|statinsses and
P10613816X0000 |139 148|compounds. P000089
P10613843A0107 |16 24|productsompariso
P10613843A0107 |89 94|genesarmac
P10613843A0107 |122 124|Cayp
P10613843A0107 |129 141|ion channelsirubinemia. 
P10613843A0107 |36 54|duplication eventsine phosphatases a
P10613863T0000 |101 108|repeatsaspects
P10613863T0000 |133 146|pfoA promoterinemia. P0000
P10613863T0000 |4 27|VirR response regulator01606T0076 Comparison w
P10613863T0000 |33 56|Clostridium perfringenskaline phosphatases and
P10613874A0663 |0 7|CloningP000016
P10613874A0663 |105 107|bpct
P10613874A0663 |67 75|presencedase P00
P10613874A0663 |145 153|proteins08997A04
P10613874A0663 |176 180|GlnRshow
P10613874A0663 |12 22|sequencing76 Compari
P10613874A0663 |164 172|homology [HCO3-]
P10613874A0663 |39 45|region phosp
P10613874A0663 |83 87|ORFs000 
P10613874A0663 |185 198|GlnA proteinsa function of
P10613874A0663 |49 53|pepXses 
P10614676A0000 |0 9|ObjectiveP00001606
P10614676A0000 |120 128|tibolone hyperbi
P10614676A0000 |161 173|mg estradiolCSF [HCO3-] 
P10614676A0000 |133 135|mgin
P10614676A0000 |180 205|mg norethisterone acetaten as a function of CSF PC
P10614676A0000 |74 82|bleeding0008171T
P10614676A0000 |224 251|hormone replacement therapypleted rats are no longer d
P10614676A0000 |101 106|womenaspec
P10614676A0000 |53 62|incidenceand 5-nuc
P10614676A0000 |207 213|E+NETA the d
P10614676A0000 |35 44|thicknessline phos
P10614857A0584 |0 18|Leukocyte culturesP00001606T0076 Com
P10614857A0584 |149 157|children7A0472 W
P10614857A0584 |240 241|Pn
P10614857A0584 |180 190|adenovirusn as a fun
P10614857A0584 |60 68|childrenucleotid
P10614857A0584 |74 80|months000817
P10614857A0584 |104 110|yieldsects o
P10614857A0584 |84 87|age00 
P10614857A0584 |216 217|P 
P10614857A0584 |114 117|IFNona
P10614857A0584 |228 238|rhinovirused rats ar
P10614857A0584 |192 193|Pi
P10614857A0584 |203 214|coronavirusPCO2 the da
P10614857A0584 |34 39|bloodaline
P10616948A0998 |34 38|dosealin
P10616948A0998 |90 113|seizure threshold levelrmacologic aspects of n
P10616948A0998 |7 19|BF ECT group06T0076 Comp
P10617126A1005 |254 259|grouplaced
P10617126A1005 |47 51|losstase
P10617126A1005 |13 21|analysis6 Compar
P10617126A1005 |200 203|CA3SF 
P10617126A1005 |140 144|rats P00
P10617126A1005 |123 126|CA1per
P10617126A1005 |72 77|groupP0000
P10617126A1005 |192 195|CA1ion
P10617126A1005 |117 121|areatal 
P10617126A1005 |156 169|dentate gyrusWhen CSF [HCO
P10617126A1005 |186 190|area fun
P10617126A1005 |220 224|ratsK-de
P10617144A0386 |119 120|%l
P10617144A0386 |15 30|phosphorylationComparison with
P10617144A0386 |92 97|sitesacolo
P10617144A0386 |44 49|Ser64phata
P10617144A0386 |4 11|extents01606T0
P10617144A0386 |34 39|Ser44aline
P10617232A0393 |137 145|patientsia. P000
P10617232A0393 |121 130|treatmenthyperbili
P10617232A0393 |21 29|serologyison wit
P10617232A0393 |77 92|liver histology8171T0000 Pharm
P10617232A0393 |35 48|liver enzymesline phosphat
P10617232A0393 |0 13|Serum HBV-DNAP00001606T007
P10617613A1192 |0 4|ChemP000
P10618645A0750 |0 17|Maximum inductionP00001606T0076 Co
P10618645A0750 |43 56|concentrationsphatases and
P10618645A0750 |74 78|CalC0008
P10618645A0750 |21 25|AP-1ison
P10618645A0750 |64 70|nmol/Lotidas
P10619062T0000 |0 27|Haycocknema perplexum n. g.P00001606T0076 Comparison w
P10619062T0000 |29 34|n. sph alk
P10619169A0411 |51 61|orchimetrys and 5-nu
P10619169A0411 |22 33|testis sizeson with al
P10619169A0411 |70 81|time periode P00008171
P10619169A0411 |0 4|RamsP000
P10619254A1055 |0 14|Animal studiesP00001606T0076
P10619254A1055 |27 44|beam equalizationith alkaline phos
P10619254A1055 |98 111|image qualityic aspects of
P10619353T0000 |119 148|promoter transcription factorl hyperbilirubinemia. P000089
P10619353T0000 |150 157|COUP-TFA0472 W
P10619353T0000 |75 86|interaction008171T0000
P10619353T0000 |8 32|estrogen receptor ligand6T0076 Comparison with a
P10619353T0000 |92 109|chicken ovalbuminacologic aspects 
P10619353T0000 |37 71|estrogen response element sequencene phosphatases and 5-nucleotidase
P10619353T0000 |0 4|RoleP000
P10620010A1155 |119 125|kinasel hype
P10620010A1155 |59 83|tyrosine phosphorylationnucleotidase P00008171T0
P10620010A1155 |199 209|activationCSF PCO2 t
P10620010A1155 |47 57|cell cycletases and 
P10620010A1155 |105 115|activationcts of neo
P10620010A1155 |15 19|CdksComp
P10620010A1155 |175 181|T-loop shown
P10620010A1155 |158 167|threonineen CSF [H
P10620010A1155 |139 154|phosphorylation. P00008997A047
P10620010A1155 |0 10|CONCLUSIONP00001606T
P10620335A0749 |39 46|COUP-TF phosph
P10620335A0749 |62 72|CV-1 cellsleotidase 
P10620335A0749 |20 23|AHRris
P10620777A1399 |0 8|AB004534P0000160
P10622574A0000 |18 35|hepatitis C virusparison with alka
P10622574A0000 |42 51|infectionosphatase
P10622574A0000 |125 126|%r
P10622574A0000 |73 82|childhood00008171T
P10622574A0000 |142 147|world00008
P10622574A0000 |37 40|HCVne 
P10622574A0000 |4 14|prevalence01606T0076
P10622574A0000 |98 114|prevalence ratesic aspects of ne
P10622576A0552 |136 147|risk groupsmia. P00008
P10622576A0552 |88 98|preventionharmacolog
P10622576A0552 |60 68|patientsucleotid
P10622576A0552 |79 84|means71T00
P10622576A0552 |26 37|informationwith alkali
P10622576A0552 |112 121|attentionneonatal 
P10622576A0552 |159 171|drug abusersn CSF [HCO3-
P10623758A0947 |136 141|cellsmia. 
P10623758A0947 |43 50|gangliasphatas
P10623758A0947 |176 182|monthsshown 
P10623758A0947 |27 28|%i
P10623758A0947 |88 106|beta-galactosidaseharmacologic aspec
P10623758A0947 |32 39|neuronslkaline
P10623758A0947 |7 14|latency06T0076
P10623758A0947 |70 77|footpade P0000
P10623758A0947 |117 123|numbertal hy
P10623804A0808 |153 177|Fc gamma RIIB1 signaling72 When CSF [HCO3-] is s
P10623804A0808 |65 72|effectstidase 
P10623804A0808 |135 149|decoy proteinsemia. P0000899
P10623804A0808 |104 109|SHP-1ects 
P10623804A0808 |98 102|SHIPic a
P10623804A0808 |114 119|SHP-2onata
P10623804A0808 |18 26|approachparison 
P10623804A0808 |35 43|questionline pho
P10624787A0432 |170 174|case-] i
P10624787A0432 |53 61|patientsand 5-nu
P10624787A0432 |178 182|Typeown 
P10624787A0432 |146 147|P8
P10624787A0432 |134 135|Pn
P10624787A0432 |220 221|PK
P10624787A0432 |117 132|blood pressurestal hyperbiliru
P10624787A0432 |185 187|DMa 
P10624787A0432 |253 254|Pp
P10624787A0432 |203 218|body mass indexPCO2 the data o
P10624787A0432 |74 75|P0
P10624787A0432 |36 45|functionsine phosp
P10624787A0432 |236 251|waist-hip ratioare no longer d
P10625438A1429 |238 253|control samplese no longer dis
P10625438A1429 |7 14|tissues06T0076
P10625438A1429 |177 187|transcripthown as a 
P10625438A1429 |124 134|conditionserbilirubi
P10625438A1429 |148 155|% level97A0472
P10625438A1429 |29 40|transcriptsh alkaline 
P10625438A1429 |54 60|insertnd 5-n
P10625438A1429 |159 165|insertn CSF 
P10625438A1429 |86 92|repeat Pharm
P10625438A1429 |70 82|bp insertione P00008171T
P10625494A1059 |6 13|results606T007
P10625494A1059 |28 39|CAAT-regionth alkaline
P10625494A1059 |72 85|MDR1 promoterP00008171T000
P10625494A1059 |89 103|HL60/VCR cellsarmacologic as
P10625683A0091 |100 109|molecules aspects 
P10625683A0091 |163 172|receptorsF [HCO3-]
P10625683A0091 |146 154|function8997A047
P10625683A0091 |63 78|phosphorylationeotidase P00008
P10625683A0091 |113 120|processeonatal
P10625683A0091 |23 47|protein tyrosine kinaseson with alkaline phospha
P10625683A0091 |5 14|receptors1606T0076
P10625683A0091 |49 53|PTKsses 
P10625721T0101 |34 38|HACAalin
P10625721T0101 |26 32|Arrestwith a
P10625721T0101 |40 51|Study Groupphosphatase
P10625721T0101 |0 11|HypothermiaP00001606T0
P10627518A0544 |102 115|contributionsspects of neo
P10627518A0544 |91 94|summac
P10627518A0544 |134 138|UTRsnemi
P10627518A0544 |40 51|cooperationphosphatase
P10627518A0544 |16 22|effectompari
P10627532A0739 |103 106|p38pec
P10627532A0739 |31 32|Za
P10627532A0739 |25 26|R 
P10627532A0739 |111 114|JNK ne
P10627532A0739 |94 101|kinasesologic 
P10627532A0739 |89 92|MAParm
P10627532A0739 |150 160|activationA0472 When
P10627532A0739 |178 203|transcription factor ATF2own as a function of CSF 
P10627532A0739 |129 144|phosphorylationirubinemia. P00
P10627532A0739 |80 87|protein1T0000 
P10627532A0739 |55 61|stressd 5-nu
P10627834A0178 |100 104|G120 asp
P10627834A0178 |115 137|New Zealand selectionsnatal hyperbilirubinem
P10627834A0178 |144 150|Dublin008997
P10627834A0178 |179 186|Stanleywn as a
P10627834A0178 |29 35|Tehamah alka
P10627834A0178 |160 166|Meyric CSF [
P10627834A0178 |73 82|cultivars00008171T
P10627834A0178 |84 93|Esterhazy00 Pharma
P10627834A0178 |153 158|Glory72 Wh
P10627834A0178 |18 27|cultivarsparison w
P10627834A0178 |4 6|US01
P10627834A0178 |40 44|Vinaphos
P10627834A0178 |168 177|McKinsterO3-] is s
P10627834A0178 |139 142|Rex. P
P10628490T0000 |0 7|AnatomyP000016
P10628490T0000 |23 29|arteryon wit
P10628748A0344 |68 92|inhibin alpha expressionase P00008171T0000 Pharm
P10628748A0344 |9 19|activationT0076 Comp
P10628748A0344 |27 39|cAMP pathwayith alkaline
P10628748A0344 |126 130|SF-1bili
P10628748A0344 |115 122|actionsnatal h
P10628748A0746 |0 8|DeletionP0000160
P10628748A0746 |130 151|cAMP-response elementrubinemia. P00008997A
P10628748A0746 |73 80|element0000817
P10628748A0746 |57 61|SF-15-nu
P10628748A0746 |27 38|mutagenesisith alkalin
P10628748A0746 |82 92|TCA GGGCCA0000 Pharm
P10628748A0746 |153 156|CRE72 
P10628750A0298 |102 110|enhancerspects o
P10628750A0298 |41 49|cytokinehosphata
P10628750A0298 |182 185|Relas 
P10628750A0298 |148 161|factor-kappaB97A0472 When 
P10628750A0298 |31 35|APREalka
P10628750A0298 |188 200|x NF-kappaB1unction of C
P10628750A0298 |163 172|NF-kappaBF [HCO3-]
P10628750A0298 |80 88|TNFalpha1T0000 P
P10628750A0298 |51 78|tumor necrosis factor-alphas and 5-nucleotidase P00008
P10628750T0000 |0 11|AngiotensinP00001606T0
P10628750T0000 |72 121|angiotensinogen gene acute-phase response elementP00008171T0000 Pharmacologic aspects of neonatal 
P10628750T0000 |31 37|factoralkali
P10628750T0000 |143 150|pathway0008997
P10628750T0000 |43 59|kappaB1 isoformssphatases and 5-
P10628750T0000 |39 41|NF p
P10628750T0000 |155 175|NF-kappaB activation When CSF [HCO3-] is
P10628755A0000 |85 97|GH secretion0 Pharmacolo
P10628755A0000 |10 17|ligands0076 Co
P10628755A0000 |122 153|orphan GH-secretagogue receptoryperbilirubinemia. P00008997A04
P10628755A0000 |66 71|cycleidase
P10628755A0000 |155 160|GHS-R When
P10628971A0824 |49 56|defectsses and
P10628971A0824 |146 149|VPS899
P10628971A0824 |79 88|mutations71T0000 P
P10628971A0824 |123 144|protein sorting genesperbilirubinemia. P00
P10628971A0824 |166 192|dynamin family member VPS1HCO3-] is shown as a funct
P10628971A0824 |66 73|membersidase P
P10628971A0824 |37 40|TGNne 
P10628971A0824 |4 14|collection01606T0076
P10628971A0824 |18 25|mutantsparison
P10628971A1165 |103 107|RIC1pect
P10628971A1165 |49 56|defectsses and
P10628971A1165 |248 272|microtubule organizationr displaced when compare
P10628971A1165 |24 31|mutantsn with 
P10628971A1165 |92 101|followingacologic 
P10628971A1165 |61 69|isolatescleotida
P10628971A1165 |120 127|product hyperb
P10628971A1165 |314 350|inositol polyphosphate 5-phosphatasely greater slope (1.21 +/- 0.23 vs. 
P10628971A1165 |12 20|spectrum76 Compa
P10628971A1165 |166 185|ribosome biogenesisHCO3-] is shown as 
P10628971A1165 |75 84|mutations008171T00
P10628971A1165 |187 191|LUV1func
P10628971A1165 |278 283|INP53ontro
P10628971A1165 |37 40|TGNne 
P10628971A1165 |236 243|vacuoleare no 
P10628971A1165 |204 211|productCO2 the
P10629035A0827 |153 171|cdc17/pol1 mutants72 When CSF [HCO3-
P10629035A0827 |125 135|telomeraserbilirubin
P10629035A0827 |11 23|strandedness076 Comparis
P10629035A0827 |180 187|defectsn as a 
P10629035A0827 |52 61|extension and 5-nu
P10629035A0827 |76 82|strand08171T
P10629035A0827 |216 225|synthesis of K-dep
P10629035A0827 |84 91|G tails00 Phar
P10629176A0887 |3 11|addition001606T0
P10629176A0887 |88 97|FBP1 geneharmacolo
P10629176A0887 |13 19|CaMig16 Comp
P10629176A0887 |36 45|complexesine phosp
P10629176A0887 |55 66|URS1 regiond 5-nucleot
P10629938A1352 |169 180|development3-] is show
P10629938A1352 |124 128|toolerbi
P10629938A1352 |94 103|apparatusologic as
P10629938A1352 |151 161|cell cycle0472 When 
P10629938A1352 |22 34|distributionson with alk
P10629938A1352 |42 58|GFP-POLO proteinosphatases and 5
P10629938A1352 |66 78|compartmentsidase P00008
P10629938A1352 |140 147|studies P00008
P10630471T0000 |3 12|ASIC-chip001606T00
P10630471T0000 |30 44|depth analysis alkaline phos
P10630471T0000 |89 102|cell behaviorarmacologic a
P10630630A0614 |34 43|inhibitoraline pho
P10630630A0614 |47 50|PKCtas
P10630630A0614 |90 105|CFI mRNA levelsrmacologic aspe
P10630630A0614 |78 86|increase171T0000
P10630630A0614 |9 21|calphostin CT0076 Compar
P10633075A1111 |51 59|polymerss and 5-
P10633075A1111 |10 13|IgG007
P10633075A1111 |74 93|N-acetylglucosamine0008171T0000 Pharma
P10633075A1111 |25 38|Fab fragments with alkalin
P10633075A1111 |101 107|effectaspect
P10633499A1306 |0 24|Arhythmacanthus YamagutiP00001606T0076 Compariso
P10633499A1306 |120 130|hook types hyperbili
P10633499A1306 |158 168|transitionen CSF [HC
P10633499A1306 |202 207|hooks PCO2
P10633499A1306 |86 97|distinction Pharmacolo
P10633499A1306 |50 57|synonymes and 
P10634007A0202 |86 88|HD P
P10634007A0202 |14 18|case Com
P10634007A0202 |134 148|drug clearancenemia. P000089
P10634007A0202 |94 97|NAColo
P10634007A0202 |72 84|hemodialysisP00008171T00
P10634007A0202 |22 44|acetaminophen overdoseson with alkaline phos
P10634007A0202 |112 124|intoxicationneonatal hyp
P10635209A0419 |33 37|coatkali
P10635209A0419 |41 49|adhesivehosphata
P10635209A0419 |10 22|conditioning0076 Compari
P10637149A0806 |100 103|REF as
P10637149A0806 |39 41|RD p
P10637149A0806 |43 45|CCsp
P10637149A0806 |47 48|Et
P10637149A0806 |18 33|G-A anastomosisparison with al
P10637149A0806 |55 65|loop areasd 5-nucleo
P10637149A0806 |138 141|A-Aa. 
P10637149A0806 |49 50|ps
P10637230A0332 |87 92|cellsPharm
P10637230A0332 |108 112|IFNs of 
P10637230A0332 |59 72|proliferationnucleotidase 
P10637230A0332 |8 18|expression6T0076 Com
P10637230A0332 |22 27|c-mycson w
P10637230A0332 |96 104|responseogic asp
P10637238A0291 |0 46|Eastern Cooperative Oncology Group trial E3186P00001606T0076 Comparison with alkaline phosph
P10637238A0291 |77 85|question8171T000
P10637337A0545 |18 28|DNA repairparison wi
P10637337A0545 |44 48|TFA1phat
P10637337A0545 |61 70|mutationscleotidas
P10638607A0000 |205 219|adenocarcinomaO2 the data of
P10638607A0000 |75 80|phase00817
P10638607A0000 |83 89|trials000 Ph
P10638607A0000 |6 14|articles606T0076
P10638607A0000 |111 119|patients neonata
P10638607A0000 |150 160|esophagealA0472 When
P10638607A0000 |31 38|resultsalkalin
P10638607A0000 |141 148|N0-1 M0P000089
P10638607A0000 |98 107|treatmentic aspect
P10638607A0000 |170 184|cell carcinoma-] is shown as
P10638607A0000 |186 189|SCC fu
P10639585A0157 |0 7|StudiesP000016
P10639585A0157 |11 30|MPO gene regulation076 Comparison with
P10639585A0157 |57 66|mechanism5-nucleot
P10639585A0157 |98 113|differentiationic aspects of n
P10640683A0204 |51 57|lysates and 
P10640683A0204 |121 133|NDRF/NeuroD2hyperbilirub
P10640683A0204 |61 72|COS-7 cellscleotidase 
P10640683A0204 |38 41|PKNe p
P10640683A0204 |95 116|expression constructslogic aspects of neon
P10640683A0204 |138 141|PKNa. 
P10640683A0204 |0 12|NDRF/NeuroD2P00001606T00
P10640683A0670 |101 116|transactivationaspects of neon
P10640683A0670 |209 222|co-expressionhe data of K-
P10640683A0670 |363 376|transcription3 Flurazepam 
P10640683A0670 |60 70|expressionucleotidas
P10640683A0670 |329 337|increasee (1.21 
P10640683A0670 |285 295|derivative but still
P10640683A0670 |255 258|PKNace
P10640683A0670 |156 161|RIPE3When 
P10640683A0670 |247 251|former d
P10640683A0670 |124 152|rat insulin promoter elementerbilirubinemia. P00008997A0
P10640683A0670 |10 29|transfection assays0076 Comparison wit
P10640683A0670 |74 86|NDRF/NeuroD20008171T0000
P10640683A0670 |163 171|enhancerF [HCO3-
P10640683A0670 |36 45|P19 cellsine phosp
P10640701T0000 |21 26|sitesison 
P10640701T0000 |30 40|Engrailed2 alkaline 
P10640701T0000 |104 114|expressionects of ne
P10640701T0000 |65 75|initiationtidase P00
P10640734A0190 |68 71|SH2ase
P10640734A0190 |126 148|tyrosine phosphatase-1bilirubinemia. P000089
P10640734A0190 |90 102|phosphatasesrmacologic a
P10640734A0190 |173 186|cell activityis shown as a
P10640734A0190 |37 42|ITIMsne ph
P10640734A0190 |5 29|tyrosine phosphorylation1606T0076 Comparison wit
P10640734A0190 |50 59|moleculeses and 5-
P10641037A1371 |0 8|AF154055P0000160
P10641688A0341 |0 9|AlignmentP00001606
P10641688A0341 |62 74|disc changesleotidase P0
P10641688A0341 |26 31|spinewith 
P10641688A0341 |43 56|abnormalitiessphatases and
P10642524A0156 |16 27|interactionomparison w
P10642524A0156 |42 47|hsp70ospha
P10642524A0156 |145 151|motifs08997A
P10642524A0156 |161 168|regionsCSF [HC
P10642524A0156 |31 36|mSTI1alkal
P10642524A0156 |65 66|Nt
P10642524A0156 |52 57|hsp90 and 
P10642524A0156 |114 138|tetratricopeptide repeatonatal hyperbilirubinemi
P10642524A0156 |140 143|TPR P0
P10642531A2322 |85 106|RGD recognition sites0 Pharmacologic aspec
P10642531A2322 |58 70|relationship-nucleotidas
P10642531A2322 |0 23|Competition experimentsP00001606T0076 Comparis
P10642889A0393 |0 17|Sequence analysisP00001606T0076 Co
P10642889A0393 |46 52|regionatases
P10642889A0393 |110 118|TATA boxf neonat
P10642889A0393 |69 78|ATG codonse P00008
P10643313A0345 |118 121|BSSal 
P10643313A0345 |131 137|ml SF6ubinem
P10643313A0345 |74 85|conjunctiva0008171T000
P10643313A0345 |90 106|micrograms rt-PArmacologic aspec
P10643313A0345 |54 66|disinfectionnd 5-nucleot
P10643313A0345 |6 25|i.v. administration606T0076 Comparison
P10643313A0345 |114 116|mlon
P10643313A0345 |33 49|mg acetazolamidekaline phosphata
P10644357A0935 |138 141|VP2a. 
P10644357A0935 |27 30|VP1ith
P10644357A0935 |6 13|results606T007
P10644357A0935 |146 149|VP3899
P10644357A0935 |66 73|nucleusidase P
P10644357A0935 |115 122|regionsnatal h
P10644414T0000 |64 95|mosquito ultraspiracle isoformsotidase P00008171T0000 Pharmaco
P10644414T0000 |13 23|expression6 Comparis
P10644414T0000 |28 38|regulationth alkalin
P10644414T0000 |42 60|20-hydroxyecdysoneosphatases and 5-n
P10644753A0725 |136 154|glycosaminoglycansmia. P00008997A047
P10644753A0725 |91 106|heparan sulfatemacologic aspec
P10644753A0725 |43 67|antibody affinity columnsphatases and 5-nucleoti
P10644753A0725 |10 18|isoforms0076 Com
P10644753A0725 |111 118|heparin neonat
P10644753A0725 |80 87|sulfate1T0000 
P10644760A0000 |85 96|interaction0 Pharmacol
P10644760A0000 |41 67|neurotransmitter phenotypehosphatases and 5-nucleoti
P10644760A0000 |110 114|cuesf ne
P10644760A0000 |24 35|maintenancen with alka
P10644760A0000 |4 19|differentiation01606T0076 Comp
P10644760A0000 |138 147|machinerya. P00008
P10644760A0956 |34 38|Arixalin
P10644760A0956 |23 30|domainson with
P10644760A0956 |61 78|activation domaincleotidase P00008
P10644760A0956 |96 113|repression domainogic aspects of n
P10644760A0956 |0 8|AnalysisP0000160
P10645921A0000 |0 10|BACKGROUNDP00001606T
P10645921A0000 |60 68|disorderucleotid
P10645921A0000 |29 40|hypertrophyh alkaline 
P10645921A0000 |83 95|morphologies000 Pharmaco
P10645921A1320 |119 121|SDl 
P10645921A1320 |200 210|odds ratioSF PCO2 th
P10645921A1320 |52 53|P 
P10645921A1320 |40 50|remodelingphosphatas
P10645921A1320 |62 72|odds ratioleotidase 
P10645921A1320 |13 23|predictors6 Comparis
P10645921A1320 |190 191|Pc
P10645921A1320 |98 115|ejection fractionic aspects of neo
P10645921A1320 |136 137|Pm
P10645921A1320 |170 188|circumflex disease-] is shown as a f
P10646820T0000 |4 8|case0160
P10646820T0000 |28 43|lymphadenectomyth alkaline pho
P10646820T0000 |121 130|carcinomahyperbili
P10646820T0000 |95 107|hysterectomylogic aspect
P10646820T0000 |58 69|lymph nodes-nucleotida
P10646863A0838 |0 14|OverexpressionP00001606T0076
P10646863A0838 |72 82|expressionP00008171T
P10646863A0838 |46 51|cellsatase
P10646863A0838 |97 118|topoisomerase IIalphagic aspects of neonat
P10646863A0838 |18 24|ICBP90pariso
P10647177A0599 |69 75|bulgesse P00
P10647177A0599 |135 140|sitesemia.
P10647177A0599 |105 109|foldcts 
P10647177A0599 |52 56|pair and
P10647177A0599 |162 166|baseSF [
P10647177A0599 |174 183|formations shown a
P10647177A0599 |4 15|RNA aptamer01606T0076 
P10647633A1685 |49 58|sphincterses and 5
P10647633A1685 |146 152|rectum8997A0
P10647633A1685 |109 115|stoolsof neo
P10647633A1685 |133 138|coloninemi
P10647633A1685 |66 69|RSJida
P10647633A1685 |23 31|presenceon with 
P10647633A1685 |4 9|study01606
P10647633A1685 |98 105|passageic aspe
P10647817T0000 |0 9|IsolationP00001606
P10647817T0000 |13 18|cDNAs6 Com
P10647817T0000 |88 92|PTA1harm
P10647817T0000 |28 34|gibbonth alk
P10647817T0000 |59 84|T cell activation antigennucleotidase P00008171T00
P10647817T0000 |39 54|monkey platelet phosphatases a
P10647859A0000 |274 280|levelsto con
P10647859A0000 |257 259|QBed
P10647859A0000 |322 327|cmH2Oer sl
P10647859A0000 |292 300|pressureill have
P10647859A0000 |353 354|P0
P10647859A0000 |355 358|CO2094
P10647859A0000 |417 420|gasdru
P10647859A0000 |246 255|breathingger displ
P10647859A0000 |385 393|eucapniaars to b
P10647859A0000 |182 190|subjectsas a fun
P10647859A0000 |302 307|Pappl sign
P10647859A0000 |198 207|occasions CSF PCO2
P10647859A0000 |135 144|diaphragmemia. P00
P10647859A0000 |395 398|CO2an 
P10647859A0000 |119 127|activityl hyperb
P10647859A0000 |223 228|rateseplet
P10647859A0000 |98 102|IPPVic a
P10647859A0000 |76 96|pressure ventilation08171T0000 Pharmacol
P10647859A0000 |38 44|effecte phos
P10647859A0000 |341 351|hypocapnia0.23 vs. P
P10648020A0151 |0 7|METHODSP000016
P10648020A0151 |58 94|factors tissue plasminogen activator-nucleotidase P00008171T0000 Pharmac
P10648020A0151 |215 222|markersa of K-
P10648020A0151 |243 251|patientslonger d
P10648020A0151 |9 30|Von Willebrand factorT0076 Comparison with
P10648020A0151 |167 172|PAI-1CO3-]
P10648020A0151 |132 163|plasminogen activator inhibitorbinemia. P00008997A0472 When CS
P10648020A0151 |186 196|fibrinogen function 
P10648020A0151 |114 126|tPA capacityonatal hyper
P10648020A0151 |96 99|tPAogi
P10648020A0151 |277 279|RAco
P10648020A0151 |175 184|platelets shown as
P10648020A0151 |32 35|vWFlka
P10648211A0000 |9 29|signaling propertiesT0076 Comparison wit
P10648211A0000 |60 68|quantityucleotid
P10648211A0000 |73 84|combination00008171T00
P10648211A0000 |88 100|ion channelsharmacologic
P10648489A1117 |68 71|sumase
P10648489A1117 |78 96|segment depression171T0000 Pharmacol
P10648489A1117 |105 111|troughcts of
P10648489A1117 |116 135|peak concentrationsatal hyperbilirubin
P10648489A1117 |36 40|doseine 
P10648489A1117 |0 9|TreatmentP00001606
P10648489A1117 |51 60|reductions and 5-n
P10648619A0000 |102 119|promoter activityspects of neonata
P10648619A0000 |164 165|C 
P10648619A0000 |259 276|promoter activity when compared to
P10648619A0000 |25 37|contribution with alkali
P10648619A0000 |63 70|proteineotidas
P10648619A0000 |209 213|lackhe d
P10648619A0000 |302 306|tRNA sig
P10648619A0000 |150 163|silkworm tRNAA0472 When CS
P10648619A0000 |282 286|silkols 
P10648619A0000 |72 75|TBPP00
P10648619A0000 |167 170|AlaCO3
P10648619A0000 |316 320|gene gre
P10648619A0000 |225 246|interactions accountsleted rats are no lon
P10648619A0000 |172 176|gene is 
P10648619A0000 |77 94|TATA interactions8171T0000 Pharmac
P10648619A0000 |311 314|Alaant
P10648619A0000 |307 309|SGif
P10649449A0413 |185 192|domainsa funct
P10649449A0413 |47 70|squalene synthase genestases and 5-nucleotidas
P10649449A0413 |31 41|homologiesalkaline p
P10649449A0413 |90 96|numberrmacol
P10649449A0413 |75 82|enzymes008171T
P10649449A0413 |128 151|amino acid conservationlirubinemia. P00008997A
P10649449A0413 |106 115|organismsts of neo
P10649449A0413 |163 170|bindingF [HCO3
P10649449A0413 |4 13|sequences01606T007
P10649456A1061 |100 109|Frankfurt aspects 
P10649456A1061 |15 22|strainsCompari
P10649456A1061 |89 98|EUROSCARFarmacolog
P10649456A1061 |75 87|stock centre008171T0000 
P10649456A1061 |59 66|EUROFANnucleot
P10649456A1061 |4 10|clones01606T
P10649738A0953 |84 98|patient-months00 Pharmacolog
P10649738A0953 |47 54|patienttases a
P10649738A0953 |4 12|episodes01606T00
P10649738A0953 |72 81|episode/3P00008171
P10649738A0953 |64 68|CAPDotid
P10649738A0953 |16 27|peritonitisomparison w
P10650104X0284 |0 9|CopyrightP00001606
P10650104X0284 |36 48|Radiologistsine phosphat
P10650104X0284 |19 32|Royal Collegearison with a
P10650938T0000 |51 72|estrogen dependenciess and 5-nucleotidase 
P10650938T0000 |23 25|ERon
P10650938T0000 |27 35|isoformsith alka
P10650938T0000 |96 109|trout ER geneogic aspects 
P10650938T0000 |4 21|estrogen receptor01606T0076 Compar
P10650939A0789 |0 9|InductionP00001606
P10650939A0789 |72 76|AP-1P000
P10650939A0789 |26 38|coexpressionwith alkalin
P10650939A0789 |42 47|A-Fosospha
P10650939A1542 |118 127|PGDH-2368al hyperb
P10650939A1542 |63 67|PR-Beoti
P10650939A1542 |104 114|activationects of ne
P10650939A1542 |14 17|SMC Co
P10650939A1542 |40 61|progesterone receptorphosphatases and 5-nu
P10650939A1542 |72 76|PR-AP000
P10650939A1542 |24 32|isoformsn with a
P10650939A1542 |128 132|luc3liru
P10650958A1315 |171 191|mobility shift assay] is shown as a func
P10650958A1315 |105 114|complexescts of ne
P10650958A1315 |40 50|% homologyphosphatas
P10650958A1315 |56 79|consensus c-myb element 5-nucleotidase P000081
P10650958A1315 |142 147|c-myb00008
P10650958A1315 |0 9|Element BP00001606
P10651076T0000 |5 15|resolution1606T0076 
P10651076T0000 |77 86|arthritis8171T0000
P10651076T0000 |43 48|lungssphat
P10651076T0000 |25 35|tomography with alka
P10651076T0000 |52 60|patients and 5-n
P10651805A1600 |70 96|mouse L1210 leukemia cellse P00008171T0000 Pharmacol
P10651805A1600 |108 127|folate accumulation of neonatal hyperb
P10651805A1600 |227 239|methotrexateted rats are
P10651805A1600 |166 190|acid growth requirementsHCO3-] is shown as a fun
P10651805A1600 |212 223|sensitivitydata of K-d
P10651805A1600 |145 155|leucovorin08997A0472
P10651805A1600 |7 19|transfection06T0076 Comp
P10651805A1600 |52 64|carrier cDNA and 5-nucle
P10651805T0000 |0 16|CharacterizationP00001606T0076 C
P10651805T0000 |75 82|carrier008171T
P10651805T0000 |94 113|folate accumulationologic aspects of n
P10651805T0000 |126 140|leukemia cellsbilirubinemia.
P10652093A0139 |0 8|ElectronP0000160
P10652093A0139 |129 139|collectionirubinemia
P10652093A0139 |62 73|A118 genomeleotidase P
P10652093A0139 |159 172|DNA moleculesn CSF [HCO3-]
P10652093A0139 |35 43|analysesline pho
P10652102A0620 |85 102|Ty1 transposition0 Pharmacologic a
P10652102A0620 |25 31|dosage with 
P10652102A0620 |45 49|Fus3hata
P10652102A0620 |66 76|inhibitionidase P000
P10652102A0620 |116 122|growthatal h
P10652228A0759 |66 76|Rho familyidase P000
P10652228A0759 |45 51|kinasehatase
P10652228A0759 |121 124|Dblhyp
P10652228A0759 |14 24|activation Compariso
P10652228A0759 |28 33|c-Junth al
P10652228A0759 |89 97|proteinsarmacolo
P10652324A0177 |13 26|participation6 Comparison 
P10652324A0177 |30 46|collagen binding alkaline phosph
P10652362A0933 |16 20|dataompa
P10652362A0933 |227 235|vesiclested rats
P10652362A0933 |192 197|entryion o
P10652362A0933 |90 112|internalization signalrmacologic aspects of 
P10652362A0933 |59 63|CFTRnucl
P10652362A0933 |147 167|adaptor complex AP-2997A0472 When CSF [H
P10652362A0933 |38 55|carboxyl terminuse phosphatases an
P10652362A0933 |201 205|CFTRF PC
P10652800A0984 |171 185|insulin dosage] is shown as 
P10652800A0984 |47 56|evolutiontases and
P10652800A0984 |211 217|height data 
P10652800A0984 |143 151|duration0008997A
P10652800A0984 |92 104|relationshipacologic asp
P10652800A0984 |199 206|controlCSF PCO
P10652800A0984 |125 128|agerbi
P10652800A0984 |132 141|diagnosisbinemia. 
P10652800A0984 |64 72|patientsotidase 
P10652800A0984 |4 27|insulin therapy regimen01606T0076 Comparison w
P10652800A0984 |155 163|diabetes When CS
P10652800A0984 |221 224|BMI-de
P10653359A1297 |0 10|Scmh1 mapsP00001606T
P10653359A1297 |14 22|4D1-D2.1 Compari
P10653359A1297 |26 30|micewith
P10653400A0000 |34 51|donor nephrectomyaline phosphatase
P10653400A0000 |93 98|donorcolog
P10653400A0000 |53 56|LDNand
P10653400A0000 |4 17|applicability01606T0076 Co
P10653550A1120 |0 20|Hyaluronan treatmentP00001606T0076 Compa
P10653550A1120 |138 144|regiona. P00
P10653550A1120 |107 115|meniscuss of neo
P10653550A1120 |32 51|collagen remodelinglkaline phosphatase
P10653550A1120 |70 76|regione P000
P10653693A0429 |115 125|componentsnatal hype
P10653693A0429 |72 76|KRABP000
P10653693A0429 |24 30|issuesn with
P10653693A0429 |77 99|KAP-1-RBCC interaction8171T0000 Pharmacologi
P10653693A0903 |17 23|B2 boxmparis
P10653693A0903 |65 80|oligomerizationtidase P0000817
P10653693A0903 |173 182|functionsis shown 
P10653693A0903 |41 47|regionhospha
P10653693A0903 |135 142|domainsemia. P
P10653693A0903 |4 15|RING finger01606T0076 
P10653693A0903 |99 111|KRAB bindingc aspects of
P10653693A0903 |116 125|mutationsatal hype
P10653693A0903 |84 94|KAP-1-RBCC00 Pharmac
P10653697A0133 |0 6|ActinsP00001
P10653697A0133 |46 56|processingatases and
P10653697A0133 |26 31|formswith 
P10653697A0133 |87 95|sequencePharmaco
P10653733A0596 |9 16|domainsT0076 C
P10653733A0596 |56 64|peptides 5-nucle
P10654032A1133 |0 4|JPEGP000
P10654032A1133 |24 41|compression ration with alkaline p
P10654032A1133 |86 97|performance Pharmacolo
P10655164A0546 |153 154|H7
P10655164A0546 |147 152|solm0997A0
P10655164A0546 |165 166|p[
P10655164A0546 |121 127|limitshyperb
P10655164A0546 |181 187|x10-10 as a 
P10655164A0546 |134 139|parl0nemia
P10655164A0546 |159 164|parr0n CSF
P10655164A0546 |40 53|uncertaintiesphosphatases 
P10655164A0546 |83 95|Li abundance000 Pharmaco
P10655164A0546 |140 142|Li P
P10655230A0685 |34 53|mouse GCN2 isoformsaline phosphatases 
P10655230A0685 |121 127|domainhyperb
P10655230A0685 |104 110|kinaseects o
P10655230A0685 |11 28|yeast counterpart076 Comparison wi
P10655230A0685 |76 85|sequences08171T000
P10656154A0722 |16 17|%o
P10656154A0722 |23 31|criteriaon with 
P10656154A0722 |36 39|PMSine
P10656154A0722 |5 10|women1606T
P10656161A0316 |0 3|MBIP00
P10656161A0316 |131 141|AUC valuesubinemia. 
P10656161A0316 |28 39|Cmax valuesth alkaline
P10656161A0316 |8 12|MMBI6T00
P10656161A0316 |82 87|serum0000 
P10656802A1724 |113 117|siteeona
P10656802A1724 |30 61|cathepsin X amino acid sequence alkaline phosphatases and 5-nu
P10656802A1724 |13 22|insertion6 Compari
P10657238A0541 |152 161|construct472 When 
P10657238A0541 |123 140|mouse NMuMG cellsperbilirubinemia.
P10657238A0541 |106 119|transcriptionts of neonata
P10657238A0541 |88 98|mStaf geneharmacolog
P10657238A0541 |175 183|fragment shown a
P10657238A0541 |59 65|regionnucleo
P10657238A0541 |236 244|activityare no l
P10657238A0541 |0 24|Transfection experimentsP00001606T0076 Compariso
P10657658A0165 |220 226|mannerK-depl
P10657658A0165 |110 121|degradationf neonatal 
P10657658A0165 |8 15|studies6T0076 
P10657658A0165 |199 207|NF-kappaCSF PCO2
P10657658A0165 |123 128|kappaperbi
P10657658A0165 |74 105|I kappa B alpha phosphorylation0008171T0000 Pharmacologic aspe
P10657658A0165 |138 162|reporter gene expressiona. P00008997A0472 When C
P10657658A0165 |48 60|HA fragmentsases and 5-n
P10657658A0165 |168 192|ICAM-1 promoter activityO3-] is shown as a funct
P10657658A0165 |19 29|T-24 cellsarison wit
P10657899A0685 |51 67|oligonucleotidess and 5-nucleoti
P10657899A0685 |113 117|AP-1eona
P10657899A0685 |172 176|mice is 
P10657899A0685 |25 35|mouse skin with alka
P10657899A0685 |121 130|JB6 cellshyperbili
P10657899A0685 |71 78|PKCzeta P00008
P10657899A0685 |99 109|activationc aspects 
P10657899A0685 |16 21|cellsompar
P10657899A0685 |0 12|PretreatmentP00001606T00
P10658425A1567 |4 9|level01606
P10658425A1567 |62 66|dogsleot
P10658425A1567 |41 42|%h
P10658425A1567 |25 34|infection with alk
P10658445A0208 |0 7|METHODSP000016
P10658445A0208 |142 146|year0000
P10658445A0208 |213 227|prostaglandinsata of K-deple
P10658445A0208 |121 137|treatment cycleshyperbilirubinem
P10658445A0208 |181 196|reference group as a function 
P10658445A0208 |157 163|latterhen CS
P10658445A0208 |20 25|grouprison
P10658445A0208 |35 43|patientsline pho
P10658445A0208 |84 108|PGE1 alpha-ciclodestrina00 Pharmacologic aspects
P10658588A0304 |0 28|Desmethylferrochloroquine 1aP00001606T0076 Comparison wi
P10658588A0304 |145 148|HB3089
P10658588A0304 |92 106|schizontocidesacologic aspec
P10658588A0304 |161 182|Plasmodium falciparumCSF [HCO3-] is shown 
P10658588A0304 |33 60|didesmethylferrochloroquinekaline phosphatases and 5-n
P10658588A0304 |112 114|CQne
P10658588A0304 |136 143|strainsmia. P0
P10658588A0304 |153 156|Dd272 
P10660069A0819 |116 125|RRD genesatal hype
P10660069A0819 |72 76|PBS2P000
P10660069A0819 |134 167|Hog1p signal transduction pathwaynemia. P00008997A0472 When CSF [H
P10660069A0819 |4 22|rrd1,2delta mutant01606T0076 Compari
P10660069A0819 |92 103|interactionacologic as
P10660069A0819 |64 68|HOG1otid
P10660069A0819 |48 60|inactivationases and 5-n
P10660304A0522 |254 261|contextlaced w
P10660304A0522 |228 236|stimulused rats 
P10660304A0522 |15 29|JAK/Tyk familyComparison wit
P10660304A0522 |86 92|Tyr705 Pharm
P10660304A0522 |33 49|tyrosine kinaseskaline phosphata
P10660304A0522 |129 135|kinaseirubin
P10660304A0522 |77 82|STAT38171T
P10660304A0522 |58 73|phosphorylation-nucleotidase P
P10660304A0522 |0 7|MembersP000016
P10660304A0522 |100 114|CNTF signaling aspects of ne
P10660304A0522 |152 167|phosphorylation472 When CSF [H
P10660304A0522 |171 183|STAT3 Tyr727] is shown a
P10660604A0748 |36 49|transcriptionine phosphata
P10660604A0748 |9 25|CARbeta/RXRalphaT0076 Comparison
P10660604A0748 |58 95|HD-PPRE luciferase reporter construct-nucleotidase P00008171T0000 Pharmaco
P10660676A0000 |0 17|Zebrafish cyclopsP00001606T0076 Co
P10660676A0000 |47 65|Growth Factor betatases and 5-nucleo
P10660676A0000 |67 74|TGFbetadase P0
P10660676A0000 |76 92|signaling factor08171T0000 Pharm
P10660676A0000 |112 123|mouse Nodalneonatal hy
P10660676A0000 |19 22|cycari
P10662550A0679 |21 35|candidate geneison with alka
P10662550A0679 |63 84|retardation phenotypeeotidase P00008171T00
P10662550A0679 |93 108|ATR-16 patientscologic aspects
P10662550A0679 |6 10|SOX8606T
P10662614A0000 |153 160|genomes72 When
P10662614A0000 |124 135|Potyviridaeerbilirubin
P10662614A0000 |109 116|membersof neon
P10662614A0000 |75 79|WSMV0081
P10662614A0000 |4 23|genome organization01606T0076 Comparis
P10662614A0000 |188 214|amino acid dissimilaritiesunction of CSF PCO2 the da
P10662614A0000 |48 73|wheat streak mosaic virusases and 5-nucleotidase P
P10662614A0000 |236 248|polyproteinsare no longe
P10662614A0972 |71 77|HC-Pro P0000
P10662614A0972 |79 81|P171
P10662614A0972 |91 93|CPma
P10662614A0972 |15 20|assayCompa
P10662614A0972 |67 69|CIda
P10662614A0972 |58 63|genes-nucl
P10662614A0972 |83 85|P300
P10662614A0972 |115 127|interactionsnatal hyperb
P10663558T0000 |137 142|chainia. P
P10663558T0000 |92 96|miceacol
P10663558T0000 |46 74|basement membrane reactivityatases and 5-nucleotidase P0
P10663558T0000 |128 130|Igli
P10663558T0000 |19 31|light chainsarison with 
P10664876A0000 |0 10|Patch testP00001606T
P10664876A0000 |223 230|group Aepleted
P10664876A0000 |263 273|acetonidesn compared
P10664876A0000 |57 65|patients5-nucleo
P10664876A0000 |333 339|esters.21 +/
P10664876A0000 |148 172|corticosteroid molecules97A0472 When CSF [HCO3-]
P10664876A0000 |181 187|groups as a 
P10664876A0000 |130 144|classificationrubinemia. P00
P10664876A0000 |285 307|betamethasone type-non but still have a sign
P10664876A0000 |254 261|group Blaced w
P10664876A0000 |324 331|group D slope 
P10664876A0000 |86 107|corticosteroid series Pharmacologic aspect
P10664876A0000 |232 251|hydrocortisone typeats are no longer d
P10664876A0000 |276 283|group C contro
P10664876A0000 |206 215|molecules2 the dat
P10664876A0000 |33 47|corticosteroidkaline phospha
P10665308T0001 |0 10|MechanismsP00001606T
P10665308T0001 |14 27|tachyphylaxis Comparison w
P10665308T0001 |40 50|anesthesiaphosphatas
P10665308T0001 |59 67|durationnucleoti
P10665798A0598 |51 73|aspartate transaminases and 5-nucleotidase P
P10665798A0598 |75 95|alkaline phosphatase008171T0000 Pharmaco
P10665798A0598 |209 213|cellhe d
P10665798A0598 |149 176|D. russelli venom injection7A0472 When CSF [HCO3-] is 
P10665798A0598 |28 41|serum enzymesth alkaline p
P10665798A0598 |180 191|albino ratsn as a func
P10665798A0598 |121 142|lactate dehydrogenasehyperbilirubinemia. P
P10665798A0598 |217 230|tissue damageof K-depleted
P10665798A0598 |97 119|creatine phosphokinasegic aspects of neonata
P10665798A0598 |3 11|increase001606T0
P10665798A0598 |19 24|levelariso
P10665949A1131 |76 83|lesions08171T0
P10665949A1131 |12 23|farm budget76 Comparis
P10665949A1131 |89 96|feedlotarmacol
P10665949A1131 |40 50|importancephosphatas
P10666222A0330 |35 55|survivin cDNA clonesline phosphatases an
P10666222A0330 |110 127|survivin proteinsf neonatal hyperb
P10666222A0330 |86 95|existence Pharmaco
P10666238A1322 |71 78|protein P00008
P10666238A1322 |10 19|induction0076 Comp
P10666238A1322 |132 155|E2F-1 promoter activitybinemia. P00008997A0472
P10666238A1322 |23 34|E2F bindingon with alk
P10666238A1322 |42 56|E2F-1 promoterosphatases and
P10666238A1322 |113 128|transactivationeonatal hyperbi
P10666238A1322 |64 68|E4-6otid
P10666253A1291 |34 41|hairpinaline p
P10666253A1291 |54 60|amountnd 5-n
P10666253A1291 |13 26|stabilization6 Comparison 
P10666253A1291 |64 75|tRNA primerotidase P00
P10666253A1291 |100 103|PBS as
P10666509A0494 |78 96|propranolol groups171T0000 Pharmacol
P10666509A0494 |62 73|zatebradineleotidase P
P10666509A0494 |26 37|arrhythmiaswith alkali
P10667597A0668 |0 3|ZK7P00
P10667597A0668 |79 83|gene71T0
P10667597A0668 |8 19|HZF16 genes6T0076 Comp
P10667597A0668 |37 52|splice variantsne phosphatases
P10668701A1311 |0 10|CONCLUSIONP00001606T
P10668701A1311 |108 114|effect of ne
P10668701A1311 |12 20|Presence76 Compa
P10668701A1311 |62 66|riskleot
P10668701A1311 |135 148|atherogenesisemia. P000089
P10668701A1311 |71 79|dementia P000081
P10668701A1311 |24 37|APOE epsilon4n with alkali
P10668701A1311 |84 86|AD00
P10668701A1311 |118 130|dyslipidemiaal hyperbili
P10669319A1722 |68 76|patientsase P000
P10669319A1722 |94 99|phaseologi
P10669319A1722 |12 23|conclusions76 Comparis
P10669319A1722 |58 64|number-nucle
P10669319A1722 |103 108|trialpects
P10669594A0000 |34 38|AgfAalin
P10669594A0000 |43 47|SefAspha
P10669594A0000 |24 32|fimbrinsn with a
P10669594A0000 |181 220|16-amino acid Leishmania T-cell epitope as a function of CSF PCO2 the data of 
P10669594A0000 |159 162|PT3n C
P10669594A0000 |77 91|fimbriae SEF178171T0000 Phar
P10669594A0000 |96 101|SEF14ogic 
P10669594A0000 |238 258|metalloprotease gp63e no longer displace
P10669594A0969 |49 62|SefA proteinsses and 5-nuc
P10669594A0969 |10 18|contrast0076 Com
P10669594A0969 |28 32|noneth a
P10669594A0969 |22 26|AgfAson 
P10669594A0969 |96 104|fimbriaeogic asp
P10669596A0430 |221 227|nature-deple
P10669596A0430 |140 145|level P000
P10669596A0430 |99 103|Abc2c as
P10669596A0430 |163 180|nuclease activityF [HCO3-] is show
P10669596A0430 |245 269|RecBCD nuclease activitynger displaced when comp
P10669596A0430 |11 17|growth076 Co
P10669596A0430 |21 30|phage P22ison with
P10669596A0430 |293 299|enzymell hav
P10669596A0430 |87 95|presencePharmaco
P10669596A0430 |207 213|change the d
P10669633A0391 |81 91|expressionT0000 Phar
P10669633A0391 |45 55|mechanismshatases an
P10669633A0391 |135 146|THP-1 cellsemia. P0000
P10669633A0391 |121 131|activationhyperbilir
P10669633A0391 |8 13|study6T007
P10669633A0391 |99 109|flt-1 genec aspects 
P10669736A0903 |118 127|abundanceal hyperb
P10669736A0903 |74 84|HeLa cells0008171T00
P10669736A0903 |59 70|transcriptsnucleotidas
P10669736A0903 |131 134|PTBubi
P10669736A0903 |21 31|differenceison with 
P10669736A0903 |35 38|CATlin
P10669751T0000 |96 110|c-jun promoterogic aspects o
P10669751T0000 |73 88|cot oncoprotein00008171T0000 P
P10669751T0000 |27 60|protein kinase signaling pathwaysith alkaline phosphatases and 5-n
P10669751T0000 |127 141|transformationilirubinemia. 
P10670358A0143 |0 11|DermatologyP00001606T0
P10670358A0143 |18 27|exceptionparison w
P10671224A0254 |71 87|CD95L expression P00008171T0000 
P10671224A0254 |15 20|studyCompa
P10671224A0254 |57 66|mechanism5-nucleot
P10671519A0641 |0 25|Protein sequence analysisP00001606T0076 Comparison
P10671519A0641 |215 221|emerina of K
P10671519A0641 |130 140|LEM modulerubinemia.
P10671519A0641 |72 78|domainP00008
P10671519A0641 |197 208|polypeptidef CSF PCO2 
P10671519A0641 |161 178|membrane proteinsCSF [HCO3-] is sh
P10671519A0641 |39 50|MAN1 shares phosphatas
P10671519A0641 |99 110|amino acidsc aspects o
P10671520T0000 |35 40|I-mfaline 
P10671520T0000 |10 17|cloning0076 Co
P10671520T0000 |133 149|HIV-1 expressioninemia. P0000899
P10671520T0000 |59 66|proteinnucleot
P10671520T0000 |100 126|T-cell leukemia virus type aspects of neonatal hyper
P10671554A0492 |174 182|sequences shown 
P10671554A0492 |12 32|amino acid sequences76 Comparison with a
P10671554A0492 |111 130|amino acid residues neonatal hyperbili
P10671554A0492 |63 76|porcine cDNAseotidase P000
P10671554A0492 |197 214|Edman degradationf CSF PCO2 the da
P10671554A0492 |52 58|bovine and 5
P10671606A0884 |154 162|patients2 When C
P10671606A0884 |109 117|patientsof neona
P10671606A0884 |123 126|APAper
P10671606A0884 |106 107|%t
P10671606A0884 |151 152|%0
P10671606A0884 |80 86|images1T0000
P10671606A0884 |5 27|chemical shift imaging1606T0076 Comparison w
P10671606A0884 |33 49|signal intensitykaline phosphata
P10671606A0884 |168 171|BAHO3-
P10672433A0199 |201 211|percentageF PCO2 the
P10672433A0199 |73 82|wake time00008171T
P10672433A0199 |186 195|awakening function
P10672433A0199 |84 88|time00 P
P10672433A0199 |153 164|sleep onset72 When CSF
P10672433A0199 |49 60|measurementses and 5-n
P10672433A0199 |20 25|diaryrison
P10672433A0199 |246 252|personger di
P10672433A0199 |92 95|bedaco
P10672433A0199 |215 222|morninga of K-
P10672433A0199 |121 127|numberhyperb
P10672433A0199 |142 146|wake0000
P10672433A0199 |9 14|nightT0076
P10672433A0199 |131 138|minutesubinemi
P10672433A0199 |109 119|efficiencyof neonata
P10672433A0199 |166 170|WASOHCO3
P10672433A0199 |173 182|alertnessis shown 
P10672433A0199 |97 100|TIBgic
P10672433A0199 |234 239|alarms are
P10672433A0199 |64 71|bedtimeotidase
P10672899A0078 |0 4|AcadP000
P10673335X0782 |0 9|CopyrightP00001606
P10673335X0782 |15 29|Academic PressComparison wit
P10673426A0168 |16 22|domainompari
P10673426A0168 |13 14|R6
P10673426A0168 |59 67|activitynucleoti
P10673426A0168 |111 124|translocation neonatal hyp
P10673426A0168 |92 93|Ta
P10673426A0168 |95 101|domainlogic 
P10673426A0168 |130 137|processrubinem
P10673426A0168 |172 178|domain is sh
P10673426A0168 |231 243|cytotoxicityrats are no 
P10673426A0168 |219 223|site K-d
P10673426A0168 |203 211|receptorPCO2 the
P10674395A0262 |152 179|signal transduction pathway472 When CSF [HCO3-] is sho
P10674395A0262 |203 217|protein kinasePCO2 the data 
P10674395A0262 |37 47|expressionne phospha
P10674395A0262 |146 150|cGMP8997
P10674395A0262 |95 99|GnRHlogi
P10674395A0262 |81 93|neuropeptideT0000 Pharma
P10674395A0262 |55 59|gened 5-
P10674395A0262 |141 144|GMPP00
P10674395A0262 |262 277|cell line GT1-7en compared to 
P10674484A0633 |33 40|lesionskaline 
P10674484A0633 |121 131|perceptionhyperbilir
P10674484A0633 |88 97|rat brainharmacolo
P10674484A0633 |73 80|neurons0000817
P10674484A0633 |6 10|data606T
P10674484A0633 |156 162|memoryWhen C
P10675154T0000 |19 34|botulinum toxinarison with alk
P10675154T0000 |8 15|potency6T0076 
P10675331A0600 |152 161|cortactin472 When 
P10675331A0600 |53 77|tyrosine phosphorylationand 5-nucleotidase P0000
P10675331A0600 |124 148|tyrosine phosphorylationerbilirubinemia. P000089
P10675331A0600 |13 18|c-Src6 Com
P10675331A0600 |165 170|Stat3[HCO3
P10675331A0600 |3 11|contrast001606T0
P10675331A0600 |81 84|ShcT00
P10675331A0600 |32 45|isoproterenollkaline phosp
P10675331A0600 |100 114|Erk activation aspects of ne
P10675610A0279 |0 5|MSSPsP0000
P10675610A0279 |31 46|DNA replicationalkaline phosph
P10675610A0279 |78 100|cell cycle progression171T0000 Pharmacologic
P10675610A0279 |63 73|apopotosiseotidase P
P10675610A0279 |125 138|C-MYC proteinrbilirubinemi
P10675610A0279 |48 61|transcriptionases and 5-nu
P10677214A1045 |102 107|slopespect
P10677214A1045 |241 247|valueso long
P10677214A1045 |320 333|acid catalystater slope (1
P10677214A1045 |189 191|pHnc
P10677214A1045 |296 300|basehave
P10677214A1045 |59 62|lognuc
P10677214A1045 |386 393|dGTP-Mgrs to b
P10677214A1045 |27 31|E53Dith 
P10677214A1045 |146 150|hump8997
P10677214A1045 |176 183|maximumshown a
P10677214A1045 |208 215|plateauthe dat
P10677214A1045 |63 64|ke
P10677214A1045 |9 18|type MutTT0076 Com
P10677214A1045 |78 80|pH17
P10677214A1045 |130 134|limbrubi
P10677214A1045 |50 55|plotses an
P10677214A1045 |398 405|complexeffecti
P10677214A1045 |65 68|cattid
P10677214A1045 |36 48|E44D mutantsine phosphat
P10677214A1045 |235 237|pK a
P10677214A1045 |374 381|MutT-Mgm thus 
P10677214A2842 |51 55|E44Ds an
P10677214A2842 |11 18|changes076 Com
P10677214A2842 |165 171|Glu-44[HCO3-
P10677214A2842 |194 205|site regionn of CSF PC
P10677214A2842 |127 139|loop I-helixilirubinemia
P10677214A2842 |78 79|H1
P10677214A2842 |142 147|motif00008
P10677214A2842 |84 98|N HSQC spectra00 Pharmacolog
P10677297A0933 |170 175|cells-] is
P10677297A0933 |134 142|locationnemia. P
P10677297A0933 |9 19|expressionT0076 Comp
P10677297A0933 |150 157|proteinA0472 W
P10677297A0933 |58 66|nonsense-nucleot
P10677297A0933 |71 89|missense mutations P00008171T0000 Ph
P10678144A0509 |6 10|i.v.606T
P10678968A1096 |220 226|seasonK-depl
P10678968A1096 |181 187|period as a 
P10678968A1096 |33 46|I. scapulariskaline phosph
P10678968A1096 |55 63|activityd 5-nucl
P10678968A1096 |21 25|miceison
P10678968A1096 |198 206|activity CSF PCO
P10678968A1096 |73 79|summer000081
P10678968A1096 |118 134|mouse populational hyperbilirubi
P10678968A1096 |100 110|proportion aspects o
P10678968A1096 |0 8|ImmunityP0000160
P10678968A1096 |152 169|E. phagocytophila472 When CSF [HCO
P10679015A0216 |98 101|setic 
P10679015A0216 |13 17|view6 Co
P10679015A0216 |105 113|proteinscts of n
P10679015A0216 |57 62|class5-nuc
P10679015A0216 |27 34|studiesith alk
P10679015A0216 |66 73|snoRNPsidase P
P10679015A0216 |38 43|yeaste pho
P10679065A0711 |239 250|CREB serine no longer 
P10679065A0711 |155 171|protein kinase-2 When CSF [HCO3-
P10679065A0711 |55 80|protein kinase-2 activityd 5-nucleotidase P0000817
P10679065A0711 |179 188|complexeswn as a f
P10679065A0711 |130 138|p38 MAPKrubinemi
P10679065A0711 |255 276|phosphoacceptor motifaced when compared to
P10679065A0711 |206 223|peptide substrate2 the data of K-d
P10679065A0711 |0 17|BCR cross-linkingP00001606T0076 Co
P10679065A0711 |85 91|enzyme0 Phar
P10679065A1217 |0 10|ActivationP00001606T
P10679065A1217 |30 77|junB promoter/chloramphenicol acetyltransferase alkaline phosphatases and 5-nucleotidase P0000
P10679065A1217 |79 82|CAT71T
P10679065A1217 |105 108|BCRcts
P10679065A1217 |129 137|SB203580irubinem
P10679065A1217 |84 97|reporter gene00 Pharmacolo
P10679190A0693 |119 132|reading framel hyperbiliru
P10679190A0693 |134 138|mORFnemi
P10679190A0693 |78 89|translation171T0000 Ph
P10679190A0693 |11 19|evidence076 Comp
P10679190A0693 |43 56|reading framesphatases and
P10679190A0693 |58 62|uORF-nuc
P10679649A0311 |0 7|METHODSP000016
P10679649A0311 |54 65|outpatientsnd 5-nucleo
P10679649A0311 |209 214|yearshe da
P10679649A0311 |180 192|chemotherapyn as a funct
P10679649A0311 |135 147|methotrexateemia. P00008
P10679649A0311 |194 204|median agen of CSF P
P10679649A0311 |153 167|5-fluorouracil72 When CSF [H
P10679649A0311 |117 133|cyclophosphamidetal hyperbilirub
P10679649A0311 |216 221|range of K
P10679649A0311 |9 25|TBN measurementsT0076 Comparison
P10679649A0311 |230 235|years rats
P10679649A0311 |71 87|breast carcinoma P00008171T0000 
P10679649A0311 |169 172|CMF3-]
P10679781A1183 |136 150|phorbol estersmia. P00008997
P10679781A1183 |6 37|bp Glucocorticoid Response Unit606T0076 Comparison with alkali
P10679781A1183 |106 120|dibutyryl-cAMPts of neonatal
P10679781A1183 |39 42|GRU ph
P10679781A1183 |65 89|glucocorticoid inductiontidase P00008171T0000 Ph
P10679922A1110 |85 113|tumor suppressor gene target0 Pharmacologic aspects of n
P10679922A1110 |46 53|samplesatases 
P10679922A1110 |126 137|neck cancerbilirubinem
P10679922A1110 |11 20|mutations076 Compa
P10679922A1110 |71 75|ING1 P00
P10679922A1110 |117 121|headtal 
P10681520A0525 |0 8|Ras-GRF1P0000160
P10681520A0525 |183 193|Gbetagammas a functi
P10681520A0525 |134 139|Cdc42nemia
P10681520A0525 |93 105|GEF activitycologic aspe
P10681520A0525 |126 129|Rhobil
P10681520A0525 |36 41|v-Srcine p
P10681520A0525 |113 116|Raceon
P10681562A0263 |144 160|PPARgamma action008997A0472 When
P10681562A0263 |15 36|PPARgamma antagonistsComparison with alkal
P10681562A0263 |107 122|mutant receptors of neonatal h
P10681588A0899 |1 5|EMSA0000
P10681588A0899 |40 44|PC12phos
P10681588A0899 |199 203|PC12CSF 
P10681588A0899 |79 82|CRE71T
P10681588A0899 |224 232|extractspleted r
P10681588A0899 |255 264|CCAAT-boxaced when
P10681588A0899 |118 138|transcription factoral hyperbilirubinemi
P10681588A0899 |53 55|C6an
P10681588A0899 |59 69|Rat2 cellsnucleotida
P10681588A0899 |297 306|factor Y.ave a sig
P10681588A0899 |26 34|proteinswith alk
P10681588A0899 |270 277|complexred to 
P10681588A0899 |208 215|C6 cellthe dat
P10681588A0899 |88 95|complexharmaco
P10681588A0899 |151 156|CCAAT0472 
P10681588A0899 |59 69|Rat2 cellsnucleotida
P10681588A0899 |297 306|factor Y.ave a sig
P10681588A0899 |26 34|proteinswith alk
P10681588A0899 |270 277|complexred to 
P10681588A0899 |208 215|C6 cellthe dat
P10681588A0899 |88 95|complexharmaco
P10681588A0899 |151 156|CCAAT0472 
P10681588A0899 |1 5|EMSA0000
P10681588A0899 |140 143|ATF P0
P10681588A0899 |174 186|protein betas shown as a
P10681588A0899 |79 82|CRE71T
P10681588A0899 |224 232|extractspleted r
P10681588A0899 |255 264|CCAAT-boxaced when
P10681588A0899 |118 138|transcription factoral hyperbilirubinemi
P10681588A0899 |53 55|C6an
P10681588A0899 |40 44|PC12phos
P10681588A0899 |199 203|PC12CSF 
P10681588A0899 |174 186|protein betas shown as a
P10681588A0899 |140 143|ATF P0
P10681679A0220 |32 39|portionlkaline
P10681679A0220 |72 83|enlargementP00008171T0
P10681679A0220 |47 52|tumortases
P10681679A0220 |135 144|diagnosisemia. P00
P10681679A0220 |110 115|yearsf neo
P10681679A0220 |8 18|resolution6T0076 Com
P10681679A0220 |97 107|tumor cystgic aspect
P10681679A0220 |54 64|serial MRInd 5-nucle
P10682570A0453 |0 3|LPOP00
P10682570A0453 |41 47|pointshospha
P10682570A0453 |8 18|SOD levels6T0076 Com
P10682570A0453 |70 79|operatione P000081
P10683072T0000 |53 64|prophylaxisand 5-nucle
P10683072T0000 |131 145|cell carcinomaubinemia. P000
P10683072T0000 |22 33|tachycardiason with al
P10683072T0000 |82 109|bolus interleukin-2 therapy0000 Pharmacologic aspects 
P10683244A0939 |17 21|NBF1mpar
P10683244A0939 |22 31|R proteinson with 
P10683244A0939 |212 216|NBF2data
P10683244A0939 |76 84|proteins08171T00
P10683244A0939 |57 64|mixture5-nucle
P10683244A0939 |134 153|sieve chomatographynemia. P00008997A04
P10683244A0939 |159 166|mixturen CSF [
P10683244A0939 |37 49|NBF2 proteinne phosphata
P10683244A0939 |202 206|NBF1 PCO
P10683244A0939 |207 208|R 
P10683244A1860 |186 197|interaction function o
P10683244A1860 |61 69|R regioncleotida
P10683244A1860 |128 133|unitslirub
P10683244A1860 |78 89|NBF2 domain171T0000 Ph
P10683244A1860 |215 222|absencea of K-
P10683244A1860 |56 60|NBF1 5-n
P10683244A1860 |149 159|propensity7A0472 Whe
P10683244A1860 |232 243|nucleotidesats are no 
P10683244A1860 |267 282|phosphorylationmpared to contr
P10683244A1860 |20 31|experimentsrison with 
P10683244A1860 |49 53|CFTRses 
P10683244X2359 |0 9|CopyrightP00001606
P10683244X2359 |15 29|Academic PressComparison wit
P10683259A0774 |0 20|Sulfhydryl titrationP00001606T0076 Compa
P10683259A0774 |194 200|valuesn of C
P10683259A0774 |161 171|differenceCSF [HCO3-
P10683259A0774 |109 129|maleimide derivativeof neonatal hyperbil
P10683259A0774 |26 39|iodoacetamidewith alkaline
P10683259A0774 |208 217|cysteinesthe data 
P10683259A0774 |133 139|biotininemia
P10683259A0774 |93 101|reactioncologic 
P10683259A0774 |229 245|splice junctionsd rats are no lo
P10683259A0774 |188 190|pKun
P10683259A0774 |80 86|thiols1T0000
P10683989A0251 |35 42|resultsline ph
P10683989A0251 |127 141|Qs/Q tau ratioilirubinemia. 
P10683989A0251 |59 68|increasesnucleotid
P10683989A0251 |72 76|PaO2P000
P10683989A0251 |13 29|oxide inhalation6 Comparison wit
P10683989A0251 |81 85|SaO2T000
P10683989A0251 |143 144|P0
P10683989A0251 |115 123|decreasenatal hy
P10683989A0251 |87 88|PP
P10684069A0508 |35 38|FIClin
P10684069A0508 |47 51|P0.1tase
P10684069A0508 |24 27|MIPn w
P10684069A0508 |40 45|Wimaxphosp
P10684069A0508 |56 74|minute ventilation 5-nucleotidase P0
P10684069A0508 |133 149|methylphenidatuminemia. P0000899
P10684069A0508 |29 33|MMIFh al
P10684069A0508 |4 11|results01606T0
P10684069A0508 |76 78|Vr08
P10684069A0508 |115 129|administrationnatal hyperbil
P10684069A0508 |154 167|aminophylline2 When CSF [H
P10684097A0175 |119 130|ovariectomyl hyperbili
P10684097A0175 |106 117|ovariectomyts of neona
P10684097A0175 |28 32|ratsth a
P10684097A0175 |150 167|ethinyl estradiolA0472 When CSF [H
P10684097A0175 |80 94|sham operation1T0000 Pharmac
P10684097A0175 |65 71|groupstidase
P10684097A0175 |18 20|SDpa
P10684097A0175 |187 191|g B.func
P10684111A1411 |55 62|factorsd 5-nuc
P10684111A1411 |30 37|variety alkali
P10684111A1411 |108 127|MAPK family members of neonatal hyperb
P10684111A1411 |75 79|pair0081
P10684111A1411 |83 91|MAPK p44000 Phar
P10684111A1411 |96 104|MAPK p42ogic asp
P10684265T0000 |69 84|cytomegalovirusse P00008171T00
P10684265T0000 |88 99|conjugationharmacologi
P10684265T0000 |148 154|hSMT3b97A047
P10684265T0000 |29 59|transactivator protein IE2-p86h alkaline phosphatases and 5-
P10684265T0000 |9 21|modificationT0076 Compar
P10684265T0000 |128 143|proteins SUMO-1lirubinemia. P0
P10684304A1242 |4 15|interaction01606T0076 
P10684304A1242 |26 27|Lw
P10684304A1242 |24 25|Un
P10684534A0634 |0 9|ProtamineP00001606
P10684534A0634 |14 27|heparin doses Comparison w
P10684534A0634 |82 87|doses0000 
P10684534A0634 |40 50|Sigma-dosephosphatas
P10684534A0634 |35 38|sumlin
P10684534A0634 |103 117|clotting timespects of neona
P10684646A0224 |97 107|expressiongic aspect
P10684646A0224 |24 33|mechanismn with al
P10684646A0224 |72 78|growthP00008
P10684646A0224 |111 119|caveolin neonata
P10684646A0224 |8 13|study6T007
P10684660A1266 |0 10|ComparisonP00001606T
P10684660A1266 |40 57|processing enzymephosphatases and 
P10684660A1266 |135 142|enzymesemia. P
P10684660A1266 |67 72|plantdase 
P10684660A1266 |110 120|activitiesf neonatal
P10684660A1266 |18 23|plantparis
P10684660A1266 |32 36|tRNAlkal
P10684941A0722 |4 15|requirement01606T0076 
P10684941A0722 |132 136|sidebine
P10684941A0722 |44 61|ligation reactionphatases and 5-nu
P10684941A0722 |94 107|nt insertionsologic aspect
P10684941A0722 |79 86|results71T0000
P10684941A0722 |144 148|nick0089
P10684941A0722 |22 37|complementarityson with alkali
P10684967A0000 |0 6|NKX2.1P00001
P10684967A0000 |26 36|NK2 familywith alkal
P10684967A0000 |63 84|transcription factorseotidase P00008171T00
P10684967A0000 |12 18|member76 Com
P10684967A0000 |135 142|absenceemia. P
P10684967A0000 |114 119|mouseonata
P10684967A0000 |146 160|thyroid tissue8997A0472 When
P10684967A0000 |185 199|lung phenotypea function of 
P10684967A0000 |100 110|disruption aspects o
P10687366A0000 |0 22|National abortion lawsP00001606T0076 Compari
P10687366A0000 |44 52|abortionphatases
P10687366A0000 |60 66|foetusucleot
P10687366A0000 |132 137|weeksbinem
P10687366A0000 |116 119|ageata
P10687855A1197 |85 90|Zn-160 Pha
P10687855A1197 |104 108|roleects
P10687855A1197 |30 39|pituitary alkaline
P10687855A1197 |65 70|cellstidas
P10687855A1197 |122 133|developmentyperbilirub
P10687855A1197 |155 170|differentiation When CSF [HCO3
P10687855A1197 |0 10|ExpressionP00001606T
P10687855T0000 |0 47|Mouse growth hormone transcription factor Zn-16P00001606T0076 Comparison with alkaline phospha
P10687855T0000 |105 124|zinc finger domainscts of neonatal hyp
P10687855T0000 |66 75|structureidase P00
P10687855T0000 |141 150|rat Zn-15P00008997
P10687862A1980 |55 61|CI/CIId 5-nu
P10687862A1980 |46 50|CIIIatas
P10687862A1980 |97 114|promoter activitygic aspects of ne
P10687862A1980 |4 31|CCAAT core sequence mutants01606T0076 Comparison with 
P10687945A0000 |0 11|DeglutitionP00001606T0
P10687945A0000 |44 51|infantsphatase
P10688639A1310 |100 115|p300 expression aspects of neo
P10688639A1310 |61 73|PEST domainscleotidase P
P10688639A1310 |37 57|PU.1 transactivationne phosphatases and 
P10688639A1310 |5 15|repression1606T0076 
P10688646A0535 |101 113|alpha-globinaspects of n
P10688646A0535 |192 211|expression analysision of CSF PCO2 the
P10688646A0535 |23 33|K562 cellson with al
P10688646A0535 |130 149|hormone hybrid generubinemia. P0000899
P10688646A0535 |65 82|HS-40 mutants cistidase P00008171T
P10688646A0535 |175 187|footprinting shown as a 
P10688660A0992 |98 110|progesteroneic aspects o
P10688660A0992 |198 201|PRE CS
P10688660A0992 |167 196|progesterone response elementCO3-] is shown as a function 
P10688660A0992 |210 231|reporter DNA templatee data of K-depleted 
P10688660A0992 |15 23|additionComparis
P10688660A0992 |67 77|T47D cellsdase P0000
P10688660A0992 |129 142|transcriptionirubinemia. P
P10688660A0992 |36 39|CBPine
P10688660A0992 |55 63|extractsd 5-nucl
P10688661A0237 |154 161|mutants2 When 
P10688661A0237 |29 38|REST/NRSFh alkalin
P10688661A0237 |12 27|binding protein76 Comparison w
P10688661A0237 |209 214|geneshe da
P10688661A0237 |179 189|expressionwn as a fu
P10688661A0237 |56 76|transcription factor 5-nucleotidase P000
P10688661A0237 |87 96|mutationsPharmacol
P10688661A0237 |117 126|lethalitytal hyper
P10688663A0207 |0 7|RemovalP000016
P10688663A0207 |94 112|core histone tailsologic aspects of 
P10688663A0207 |75 86|acetylation008171T0000
P10688663A0207 |15 40|core histone tail domainsComparison with alkaline 
P10688663A0207 |52 71|trypsin proteolysis and 5-nucleotidase
P10688663A0207 |163 169|TFIIIAF [HCO
P10688663A0207 |218 221|DNAf K
P10688663A0207 |141 151|inhibitionP00008997A
P10688666A1010 |55 59|partd 5-
P10688666A1010 |61 81|homo-oligomerizationcleotidase P00008171
P10688666A1010 |13 22|mechanism6 Compari
P10688666A1010 |26 41|ASK1 activationwith alkaline p
P10690702A0065 |0 7|OUTCOMEP000016
P10690702A0065 |107 124|myasthenia graviss of neonatal hyp
P10690702A0065 |60 74|electromyogramucleotidase P0
P10690702A0065 |94 103|diagnosisologic as
P10690702A0065 |9 42|Acetylcholine receptor antibodiesT0076 Comparison with alkaline ph
P10690725A1037 |10 18|patients0076 Com
P10690725A1037 |29 33|PRFRh al
P10690866A0783 |49 75|TSH frequency distributionses and 5-nucleotidase P00
P10690866A0783 |79 86|mothers71T0000
P10690866A0783 |91 99|neonatesmacologi
P10690866A0783 |39 45|shifts phosp
P10690866A0783 |4 14|variations01606T0076
P10691972T0000 |0 16|CharacterizationP00001606T0076 C
P10691972T0000 |94 98|geneolog
P10691972T0000 |107 117|regulations of neona
P10691972T0000 |88 92|MRP2harm
P10691972T0000 |150 168|resistance proteinA0472 When CSF [HC
P10691972T0000 |121 139|comparison withthehyperbilirubinemia
P10691972T0000 |172 176|MRP3 is 
P10691972T0000 |178 182|geneown 
P10691972T0000 |36 42|regionine ph
P10691972T0000 |66 84|resistance proteinidase P00008171T00
P10692167A0364 |16 25|mechanismomparison
P10692167A0364 |74 85|M. synoviae0008171T000
P10692167A0364 |58 70|observations-nucleotidas
P10692374A1873 |254 257|PANlac
P10692374A1873 |128 131|PANlir
P10692374A1873 |73 88|20S proteasomes00008171T0000 P
P10692374A1873 |195 203|proteins of CSF 
P10692374A1873 |31 44|M. jannaschiialkaline phos
P10692374A1873 |164 174|hydrolysis [HCO3-] i
P10692374A1873 |295 303|reaction have a 
P10692374A1873 |231 250|amino acid residuesrats are no longer 
P10692374A1873 |6 13|results606T007
P10692374A1873 |99 119|nucleotidase complexc aspects of neonata
P10692433A0000 |48 52|roleases
P10692433A0000 |108 118|cell cycle of neonat
P10692433A0000 |56 57|G 
P10692433A0000 |4 28|transcription factor E2F01606T0076 Comparison wi
P10692433A0000 |64 82|S phase transitionotidase P00008171T
P10693246A0252 |35 45|componentsline phosp
P10693246A0252 |124 134|dissectionerbilirubi
P10693246A0252 |193 204|mediastinumon of CSF P
P10693246A0252 |157 179|laryngeal nerve chainshen CSF [HCO3-] is sho
P10693246A0252 |19 29|dissectionarison wit
P10693314A0521 |69 77|patientsse P0000
P10693314A0521 |11 19|patients076 Comp
P10693314A0521 |29 42|CK-MB resultsh alkaline ph
P10693314A0521 |105 106|%c
P10693314A0521 |108 116|patients of neon
P10693314A0521 |79 82|ECG71T
P10693314A0521 |92 95|AMIaco
P10693314A0521 |66 67|%i
P10694189A0469 |4 10|effect01606T
P10694189A0469 |14 17|MIB Co
P10694189A0469 |67 80|noradrenalinedase P0000817
P10694189A0469 |39 44|curve phos
P10694210A0385 |87 105|cingulate corticesPharmacologic aspe
P10694210A0385 |213 216|H1Rata
P10694210A0385 |145 163|d-chlorpheniramine08997A0472 When CS
P10694210A0385 |208 209|%t
P10694210A0385 |13 21|blockade6 Compar
P10694210A0385 |181 185|dose as 
P10694210A0385 |127 141|administrationilirubinemia. 
P10694210A0385 |25 28|H1R wi
P10694210A0385 |189 191|mgnc
P10694210A0385 |232 240|corticesats are 
P10694511A0570 |136 138|Cami
P10694511A0570 |42 46|mid1osph
P10694511A0570 |124 132|increaseerbiliru
P10694511A0570 |89 98|phenotypearmacolog
P10694511A0570 |30 34|cDNA alk
P10694511A0570 |143 158|uptake activity0008997A0472 Wh
P10694511A0570 |22 26|yam8son 
P10694511A0570 |54 59|cellsnd 5-
P10694511A0570 |4 14|expression01606T0076
P10694605A1327 |19 34|infection ratesarison with alk
P10694605A1327 |125 126|Pr
P10694605A1327 |112 123|double-lungneonatal hy
P10694605A1327 |129 131|NSir
P10694605A1327 |36 59|events/100 patient-daysine phosphatases and 5-
P10694605A1327 |138 144|monthsa. P00
P10694609A0309 |205 210|hoursO2 th
P10694609A0309 |49 58|inductionses and 5
P10694609A0309 |19 29|compliancearison wit
P10694609A0309 |142 146|hour0000
P10694609A0309 |62 72|anesthesialeotidase 
P10694609A0309 |121 138|operating theaterhyperbilirubinemi
P10694609A0309 |153 159|return72 Whe
P10694609A0309 |103 113|filtrationpects of n
P10694609A0309 |187 196|care unitfunction 
P10694609A0309 |221 230|operation-depleted
P10695685T0000 |33 42|rationalekaline ph
P10695685T0000 |12 19|therapy76 Comp
P10695685T0000 |82 94|consequences0000 Pharmac
P10695685T0000 |55 67|implicationsd 5-nucleoti
P10696007A1325 |32 53|C2-C3 disk morphologylkaline phosphatases 
P10696007A1325 |88 96|responseharmacol
P10696007A1325 |12 23|correlation76 Comparis
P10698516T0000 |0 3|KFCP00
P10698516T0000 |54 64|capabilitynd 5-nucle
P10698516T0000 |81 97|SAPK/JNK pathwayT0000 Pharmacolo
P10698516T0000 |18 24|kinasepariso
P10698937T0000 |0 5|TIP30P0000
P10698937T0000 |52 65|up-regulation and 5-nucleo
P10698937T0000 |91 96|genesmacol
P10698937T0000 |23 38|kinase activityon with alkalin
P10698937T0000 |71 77|subset P0000
P10698974A0951 |48 54|regionases a
P10698974A0951 |25 35|STAG3 gene with alka
P10698974A0951 |58 68|chromosome-nucleotid
P10698974A0951 |298 306|deletionve a sig
P10698974A0951 |226 237|breakpointseted rats a
P10698974A0951 |96 101|genesogic 
P10698974A0951 |283 291|syndromels but s
P10698974A0951 |157 161|genehen 
P10698974A0951 |293 296|WBSll 
P10699354A0557 |0 13|Reaction timeP00001606T007
P10699354A0557 |15 17|RTCo
P10699354A0557 |23 27|P300on w
P10699653A0967 |34 40|accessaline 
P10699653A0967 |20 24|ratsriso
P10699653A0967 |143 150|sucrose0008997
P10699653A0967 |125 132|ethanolrbiliru
P10699653A0967 |135 136|%e
P10699653A0967 |3 13|experiment001606T007
P10699653A0967 |156 164|solutionWhen CSF
P10699653A0967 |80 89|tap water1T0000 Ph
P10699653A0967 |48 55|bottlesases an
P10699653A0967 |153 154|%7
P10699684A0661 |51 57|numbers and 
P10699684A0661 |61 69|patientscleotida
P10699684A0661 |123 125|M.pe
P10699684A0661 |13 18|Zelen6 Com
P10699684A0661 |91 97|groupsmacolo
P10699684A0661 |110 121|institutionf neonatal 
P10699684A0661 |21 27|methodison w
P10699896A0455 |17 22|groupmpari
P10699896A0455 |41 47|genderhospha
P10699896A0455 |26 34|patientswith alk
P10699896A0455 |49 50|Ps
P10699896A0455 |0 7|RESULTSP000016
P10700262A0000 |102 118|brain structuresspects of neonat
P10700262A0000 |44 53|interplayphatases 
P10700262A0000 |74 89|control systems0008171T0000 Ph
P10700262A0000 |17 26|attentionmparison 
P10701534A0164 |118 123|yearsal hy
P10701534A0164 |127 130|ageili
P10701534A0164 |62 74|hemidystonialeotidase P0
P10701534A0164 |90 101|head traumarmacologic 
P10701534A0164 |37 57|low-frequency tremorne phosphatases and 
P10701534A0164 |4 11|patient01606T0
P10702241A0357 |70 72|a2e 
P10702241A0357 |124 129|brainerbil
P10702241A0357 |63 68|hearteotid
P10702241A0357 |13 23|a1 isoform6 Comparis
P10702241A0357 |104 109|liverects 
P10702241A0357 |117 122|hearttal h
P10702241A0357 |86 92|kidney Pharm
P10702241A0357 |53 58|brainand 5
P10702241A0357 |76 81|liver08171
P10702241A0357 |111 115|lung neo
P10702241A0357 |131 137|spleenubinem
P10702241A0357 |143 149|kidney000899
P10702241A0357 |98 100|a3ic
P10702253A0357 |119 130|cDNA clonesl hyperbili
P10702253A0357 |165 173|splicing[HCO3-] 
P10702253A0357 |181 196|HIF-1alpha gene as a function 
P10702253A0357 |30 69|transcriptase-polymerase chain reaction alkaline phosphatases and 5-nucleotida
P10702253A0357 |11 18|cloning076 Com
P10702253A0357 |83 101|HIF-1alpha subunit000 Pharmacologic 
P10702285A0855 |35 36|Gl
P10702285A0855 |245 246|qn
P10702285A0855 |243 244|Gl
P10702285A0855 |150 153|p85A04
P10702285A0855 |104 111|pathwayects of
P10702285A0855 |165 172|subunit[HCO3-]
P10702285A0855 |185 205|wortmannin treatmenta function of CSF PC
P10702285A0855 |113 123|expressioneonatal hy
P10702285A0855 |265 289|GLUT4-EGFP translocationcompared to controls but
P10702285A0855 |40 41|Gp
P10702285A0855 |46 54|functionatases a
P10702285A0855 |14 26|relationship Comparison 
P10702285A0855 |37 38|qn
P10702285A0855 |64 93|phosphatidylinositol 3-kinaseotidase P00008171T0000 Pharma
P10702389A1148 |103 112|cytoplasmpects of 
P10702389A1148 |11 13|BL07
P10702389A1148 |74 81|protein0008171
P10702389A1148 |59 64|casesnucle
P10702389A1148 |19 32|RB2/p130 genearison with a
P10702794A1495 |171 189|feedback mechanism] is shown as a fu
P10702794A1495 |161 165|partCSF 
P10702794A1495 |60 66|targetucleot
P10702794A1495 |30 34|ERK2 alk
P10702794A1495 |117 122|HePTPtal h
P10702794A1495 |70 75|HePTPe P00
P10702794A1495 |144 157|ERK2 activity008997A0472 W
P10702794A1495 |16 20|dataompa
P10702794A1495 |102 107|modelspect
P10702926T0089 |0 14|Cross-reactionP00001606T0076
P10702926T0089 |36 44|antibodyine phos
P10702926T0089 |53 80|alpha beta T cell receptorsand 5-nucleotidase P0000817
P10703633A0747 |0 17|Strontium nitrateP00001606T0076 Co
P10703633A0747 |256 270|mean magnitudeced when compa
P10703633A0747 |116 124|durationatal hyp
P10703633A0747 |212 215|mindat
P10703633A0747 |94 95|po
P10703633A0747 |177 180|SEMhow
P10703633A0747 |182 185|minas 
P10703633A0747 |278 298|irritation sensationontrols but still ha
P10703633A0747 |200 204|meanSF P
P10703633A0747 |72 76|acidP000
P10703633A0747 |47 57|comparisontases and 
P10703633A0747 |132 152|irritation sensationbinemia. P00008997A0
P10703633A0747 |306 317|time pointsnificantly 
P10703633A0747 |236 237|pa
P10703633A0747 |38 42|acide ph
P10703633A0747 |207 210|SEM th
P10703633A0747 |170 174|mean-] i
P10704196A1051 |19 36|sulfhydryl groupsarison with alkal
P10704196A1051 |161 165|sideCSF 
P10704196A1051 |79 83|half71T0
P10704196A1051 |91 106|plasma membranemacologic aspec
P10704196A1051 |173 180|helicesis show
P10704196A1051 |140 145|model P000
P10704283A0649 |69 76|syntenyse P000
P10704283A0649 |31 39|sequencealkaline
P10704283A0649 |120 135|gene candidates hyperbilirubin
P10704283A0649 |15 17|MbCo
P10704283A0649 |86 105|chromosome 5q31-q33 Pharmacologic aspe
P10704283A0649 |179 205|IL-4 cytokine gene clusterwn as a function of CSF PC
P10704283A0649 |160 165|genes CSF 
P10704283A0649 |49 55|regionses an
P10704283A0649 |1 9|Analysis00001606
P10704285A0536 |118 132|AP-2alpha geneal hyperbiliru
P10704285A0536 |6 13|AP-2rep606T007
P10704285A0536 |29 48|reporter expressionh alkaline phosphat
P10704285A0536 |80 98|AP-2alpha promoter1T0000 Pharmacolog
P10704285A0536 |175 184|AP-2alpha shown as
P10704338A0354 |68 74|domainase P0
P10704338A0354 |242 251|structure longer d
P10704338A0354 |271 286|leucine residueed to controls 
P10704338A0354 |90 97|proteinrmacolo
P10704338A0354 |181 186|turns as a
P10704338A0354 |288 300|P-position-Lt still have
P10704338A0354 |86 88|CA P
P10704338A0354 |82 85|p24000
P10704338A0354 |24 31|insightn with 
P10704338A0354 |147 163|proline residues997A0472 When CS
P10704338A0354 |111 122|replication neonatal h
P10704338A0354 |229 232|p24d r
P10704338A0354 |41 45|rolehosp
P10704338A0354 |3 8|order00160
P10704338A0354 |204 217|alpha-helicesCO2 the data 
P10704410T0000 |34 40|exportaline 
P10704410T0000 |48 85|replication initiator proteins Mcm2-7ases and 5-nucleotidase P00008171T000
P10704410T0000 |0 17|Clb/Cdc28 kinasesP00001606T0076 Co
P10704499A0682 |171 174|fyn] i
P10704499A0682 |177 180|PLChow
P10704499A0682 |182 185|PKCas 
P10704499A0682 |62 72|antibodiesleotidase 
P10704499A0682 |121 131|inhibitorshyperbilir
P10704499A0682 |151 170|tyrosine kinase p590472 When CSF [HCO3
P10704499A0682 |252 255|PMAspl
P10704499A0682 |190 193|MEKcti
P10704499A0682 |80 104|fibroblast growth factor1T0000 Pharmacologic asp
P10704499A0682 |219 250|phorbol-12-myristate-13-acetate K-depleted rats are no longer 
P10704499A0682 |214 217|PKCta 
P10704499A0682 |106 109|FGFts 
P10704499A0682 |47 56|treatmenttases and
P10704499A0682 |15 28|PC12-E2 cellsComparison wi
P10704499A0682 |111 119|receptor neonata
P10704499A0682 |201 210|activatorF PCO2 th
P10704853T0000 |0 17|Cooperative rolesP00001606T0076 Co
P10704853T0000 |21 35|Bozozok/Dharmaison with alka
P10704853T0000 |54 62|proteinsnd 5-nuc
P10704853T0000 |107 116|zebrafishs of neon
P10704853T0000 |70 79|formatione P000081
P10704853T0000 |87 103|dorsal organizerPharmacologic as
P10704975A0479 |0 18|Thiopentone sodiumP00001606T0076 Com
P10704975A0479 |45 48|minhat
P10704975A0479 |82 90|exposure0000 Pha
P10704975A0479 |94 99|NOC-5ologi
P10704975A0479 |72 75|minP00
P10704975A0479 |157 170|neurotoxicityhen CSF [HCO3
P10704975A0479 |185 193|controlsa functi
P10705380A0629 |127 141|UV-irradiationilirubinemia. 
P10705380A0629 |40 59|Xretpos transcriptsphosphatases and 5-
P10705380A0629 |104 111|regionsects of
P10705380A0629 |194 197|wayn o
P10705380A0629 |146 166|BMP-4 overexpression8997A0472 When CSF [
P10705380A0629 |199 206|genesisCSF PCO
P10705783A0433 |85 90|means0 Pha
P10705783A0433 |45 53|chemicalhatases 
P10705783A0433 |112 136|concentration gentamicinneonatal hyperbilirubine
P10705783A0433 |13 18|cases6 Com
P10705783A0433 |31 41|neurectomyalkaline p
P10705783A0433 |65 80|labyrinthectomytidase P0000817
P10705783A0433 |141 146|mg/mLP0000
P10706475A0644 |33 37|DSPPkali
P10706475A0644 |62 65|DPPleo
P10706475A0644 |54 57|DSPnd 
P10706513A0843 |50 56|monthses and
P10706513A0843 |15 24|prognosisCompariso
P10706513A0843 |77 88|ventilation8171T0000 P
P10706513A0843 |33 44|% mortalitykaline phos
P10706688A0376 |80 102|fasl promoter function1T0000 Pharmacologic a
P10706688A0376 |108 115|fashion of neo
P10706688A0376 |57 61|site5-nu
P10706688A0376 |14 27|TCR signaling Comparison w
P10706688A0376 |129 146|NF-kappaB bindingirubinemia. P0000
P10706688A0376 |36 48|AP-1 bindingine phosphat
P10706736A1091 |100 107|T cells aspect
P10706736A1091 |167 175|epitopesCO3-] is
P10706736A1091 |31 39|melanomaalkaline
P10706736A1091 |82 91|detection0000 Phar
P10706736A1091 |95 98|CD8log
P10706736A1091 |130 135|HLA-Arubin
P10706736A1091 |6 14|patients606T0076
P10706736A1091 |66 68|Agid
P10706887A0281 |16 17|%o
P10706887A0281 |21 26|ALCLsison 
P10706887A0281 |40 43|ALKpho
P10706887A0281 |63 64|te
P10706887A0281 |101 114|abnormalitiesaspects of ne
P10706887A0281 |138 152|ALK expressiona. P00008997A0
P10706887A1457 |50 58|functiones and 5
P10706887A1457 |145 150|drugs08997
P10706887A1457 |109 115|tumorsof neo
P10706887A1457 |159 171|methotrexaten CSF [HCO3-
P10706887A1457 |82 91|lymphomas0000 Phar
P10706887A1457 |22 31|decreasesson with 
P10706887A1457 |3 11|addition001606T0
P10706887A1457 |35 39|ATICline
P10708243A0000 |50 60|antibodieses and 5-n
P10708243A0000 |97 109|preeclampsiagic aspects 
P10708243A0000 |78 92|pregnancy loss171T0000 Pharm
P10708243A0000 |14 25|observation Comparison
P10708243A0000 |115 119|rolenata
P10708243A0000 |138 148|antibodiesa. P000089
P10708424A0800 |69 74|BGLF4se P0
P10708424A0800 |10 14|ions0076
P10708424A0800 |46 65|autophosphorylationatases and 5-nucleo
P10708424A0800 |108 116|activity of neon
P10708424A0800 |80 89|magnesium1T0000 Ph
P10708769A0433 |103 112|inductionpects of 
P10708769A0433 |71 78|element P00008
P10708769A0433 |21 27|regionison w
P10708769A0433 |4 8|Mif10160
P10708769A0433 |116 127|tunicamycinatal hyperb
P10708769A0433 |50 52|ERes
P10709705T0000 |6 32|point feature registration606T0076 Comparison with a
P10709705T0000 |46 57|informationatases and 
P10710499A0000 |0 12|MethysergideP00001606T00
P10710499A0000 |75 91|wound blood flow008171T0000 Phar
P10710499A0000 |96 111|edema formationogic aspects of
P10710499A0000 |18 38|serotonin antagonistparison with alkalin
P10710742T0000 |0 27|Serum leptin concentrationsP00001606T0076 Comparison w
P10710742T0000 |31 36|womenalkal
P10710742T0000 |44 75|gonadotropin stimulation cyclesphatases and 5-nucleotidase P00
P10710985T0000 |25 38|work practice with alkalin
P10710985T0000 |60 81|strengths perspectiveucleotidase P00008171
P10710985T0000 |44 52|familiesphatases
P10710985T0000 |8 16|families6T0076 C
P10711674A0000 |51 57|familys and 
P10711674A0000 |133 144|keratoconusinemia. P00
P10711674A0000 |116 119|MIMata
P10711674A0000 |83 88|Leber000 P
P10711674A0000 |111 114|LCA ne
P10711674A0000 |100 109|amaurosis aspects 
P10711674A0000 |0 7|PURPOSEP000016
P10712512A0506 |0 6|Ste18pP00001
P10712512A0506 |66 77|prenylationidase P0000
P10712512A0506 |27 42|plasma membraneith alkaline ph
P10712512A0506 |55 62|absenced 5-nuc
P10712512A0506 |81 94|thioacylationT0000 Pharmac
P10712599A0349 |19 24|IRF-1ariso
P10712599A0349 |66 73|pathwayidase P
P10712618A0181 |185 195|aspartasesa function
P10712618A0181 |83 93|% homology000 Pharma
P10712618A0181 |133 134|%i
P10712618A0181 |14 33|sequence comparison Comparison with al
P10712618A0181 |99 126|Bacillus subtilis aspartasec aspects of neonatal hyper
P10712618A0181 |48 73|Bacillus YM55-1 aspartaseases and 5-nucleotidase P
P10713083A0170 |39 43|TraR pho
P10713083A0170 |15 21|systemCompar
P10713083A0170 |27 35|activityith alka
P10713083A0170 |95 99|TraMlogi
P10713083A0560 |87 100|TraR functionPharmacologic
P10713083A0560 |160 180|DNA recognition site CSF [HCO3-] is show
P10713083A0560 |72 76|TraMP000
P10713083A0560 |122 142|transcription factoryperbilirubinemia. P
P10713083A0560 |25 30|assay with
P10713083A0560 |59 70|DNA bindingnucleotidas
P10713155A0151 |187 195|extractsfunction
P10713155A0151 |132 137|cellsbinem
P10713155A0151 |139 144|Ad-NE. P00
P10713155A0151 |18 40|IIIa pre-mRNA splicingparison with alkaline 
P10713155A0151 |197 204|HeLa-NEf CSF P
P10713155A0151 |169 178|HeLa cell3-] is sh
P10713155A0151 |84 92|extracts00 Pharm
P10713161A0985 |0 12|InactivationP00001606T00
P10713161A0985 |45 49|ulp1hata
P10713161A0985 |54 61|defectsnd 5-nu
P10713161A0985 |107 130|Smt3-protein conjugatess of neonatal hyperbili
P10713161A0985 |150 156|mutantA0472 
P10713161A0985 |16 20|Ulp2ompa
P10713161A0985 |50 52|tses
P10713175A1399 |118 124|importal hyp
P10713175A1399 |132 148|ARF-Mdm2 complexbinemia. P000089
P10713175A1399 |54 58|Mdm2nd 5
P10713175A1399 |39 50|ARF binding phosphatas
P10713175A1399 |167 184|cell cycle arrestCO3-] is shown as
P10713175A1399 |18 25|resultsparison
P10713175A1399 |84 90|change00 Pha
P10713176A0422 |0 19|Cyclin A expressionP00001606T0076 Comp
P10713176A0422 |90 116|pocket protein partners Rbrmacologic aspects of neon
P10713176A0422 |196 198|Rbof
P10713176A0422 |128 132|p130liru
P10713176A0422 |46 51|cellsatase
P10713176A0422 |226 244|E2F-p107 complexeseted rats are no l
P10713176A0422 |164 171|control [HCO3-
P10713176A0422 |262 280|mitogen withdrawalen compared to con
P10713176A0422 |55 58|E2Fd 5
P10713176A0422 |143 148|v-Jun00089
P10713176A0422 |69 80|conjunctionse P0000817
P10713176A0422 |118 122|p107al h
P10713176A0885 |0 21|D-cyclin-cdk activityP00001606T0076 Compar
P10713176A0885 |176 189|DNA synthesisshown as a fu
P10713176A0885 |78 83|cells171T0
P10713176A0885 |194 212|cell proliferationn of CSF PCO2 the 
P10713176A0885 |141 154|inhibitor p16P00008997A047
P10713176A0885 |38 56|Rb phosphorylatione phosphatases and
P10713176A0885 |99 109|expressionc aspects 
P10713176A0885 |155 160|INK4A When
P10713176A0885 |117 121|cdk4tal 
P10713239A0988 |0 10|CONCLUSIONP00001606T
P10713239A0988 |92 101|IOL opticacologic 
P10713239A0988 |25 34|mechanism with alk
P10713239A0988 |49 66|capsulorhexis rimses and 5-nucleot
P10713453A0172 |152 158|Hrb57A472 Wh
P10713453A0172 |76 80|gene0817
P10713453A0172 |92 95|57Aaco
P10713453A0172 |47 59|antibody Q18tases and 5-
P10713453A0172 |99 119|polytene chromosomesc aspects of neonata
P10713453A0172 |4 11|protein01606T0
P10714985A1057 |49 58|structureses and 5
P10714985A1057 |3 27|RNA boundary experiments001606T0076 Comparison w
P10714985A1057 |82 85|G/U000
P10714985A1057 |126 148|leader RNA associationbilirubinemia. P000089
P10714985A1057 |71 77|number P0000
P10714985A1057 |86 96|AG repeats Pharmacol
P10715322A0000 |0 14|Gene silencingP00001606T0076
P10715322A0000 |40 53|DNA sequencesphosphatases 
P10715322A0000 |81 91|eukaryotesT0000 Phar
P10715322A0000 |103 109|plantspects 
P10715325A0834 |170 174|EIN2-] i
P10715325A0834 |73 90|stress conditions00008171T0000 Pha
P10715325A0834 |121 129|salinityhyperbil
P10715325A0834 |134 141|droughtnemia. 
P10715325A0834 |4 15|AtERF genes01606T0076 
P10715325A0834 |202 210|pathways PCO2 th
P10715325A0834 |147 168|ETHYLENE-INSENSITIVE2997A0472 When CSF [HC
P10715325A0834 |49 57|ethyleneses and 
P10715325A0834 |100 108|wounding aspects
P10715602A0149 |0 7|AnimalsP000016
P10715602A0149 |45 50|mg/kghatas
P10715602A0149 |27 40|dexamethasoneith alkaline 
P10715602A0149 |198 203|rSP-C CSF 
P10715602A0149 |183 190|Germanys a fun
P10715602A0149 |210 220|surfactante data of 
P10715602A0149 |120 133|phospholipids hyperbilirub
P10715602A0149 |83 113|surfactant preparation Exosurf000 Pharmacologic aspects of n
P10715602A0149 |172 181|Burgwedel is shown
P10715602A0149 |145 155|surfactant08997A0472
P10715602A0149 |157 170|Wellcome GmbHhen CSF [HCO3
P10715602A0149 |19 23|dosearis
P10717612A0000 |0 10|BACKGROUNDP00001606T
P10717612A0000 |188 201|interleukin-2unction of CS
P10717612A0000 |28 33|studyth al
P10717612A0000 |90 98|regimensrmacolog
P10717612A0000 |74 82|toxicity0008171T
P10717612A0000 |16 19|aimomp
P10717612A0000 |55 69|response ratesd 5-nucleotida
P10717612A0000 |216 225|treatment of K-dep
P10717612A0000 |260 274|cell carcinomawhen compared 
P10717612A0000 |203 207|IL-2PCO2
P10717612A0000 |229 237|patientsd rats a
P10717612A0000 |160 166|GM-CSF CSF [
P10717612A0000 |140 158|stimulating factor P00008997A0472 Wh
P10717612A0000 |171 182|combination] is shown 
P10720434A0291 |137 140|UTRia.
P10720434A0291 |12 21|injection76 Compar
P10720434A0291 |88 98|repressionharmacolog
P10720434A0291 |62 71|sequencesleotidase
P10720434A0291 |35 40|mRNAsline 
P10720434A0291 |102 116|cyclin B1 mRNAspects of neon
P10721698A1195 |184 188|CSTB a f
P10721698A1195 |95 99|CSTBlogi
P10721698A1195 |167 180|transcriptionCO3-] is show
P10721698A1195 |122 130|functionyperbili
P10721698A1195 |6 10|data606T
P10721698A1195 |42 58|dodecamer repeatosphatases and 5
P10721698A1195 |25 34|expansion with alk
P10721698A1195 |83 91|promoter000 Phar
P10721698A1195 |138 146|promotera. P0000
P10721704A1155 |221 231|cell types-depleted 
P10721704A1155 |198 206|activity CSF PCO
P10721704A1155 |160 177|sequence analysis CSF [HCO3-] is s
P10721704A1155 |96 107|Elav familyogic aspect
P10721704A1155 |24 36|organizationn with alkal
P10721704A1155 |40 44|mHuAphos
P10721704A1155 |113 129|promoter elementeonatal hyperbil
P10721704A1155 |81 88|membersT0000 P
P10721704X0000 |0 8|AnalysisP0000160
P10721704X0000 |19 22|endari
P10721704X0000 |155 161|Elavl1 When 
P10721704X0000 |262 273|cell growthen compared
P10721704X0000 |92 99|elementacologi
P10721704X0000 |149 153|mHuA7A04
P10721704X0000 |30 42|mouse Elavl1 alkaline ph
P10721704X0000 |44 48|mHuAphat
P10721704X0000 |104 112|evidenceects of 
P10721704X0000 |135 147|organizationemia. P00008
P10721704X0000 |318 332|mRNA stabilityreater slope (
P10721704X0000 |50 54|genees a
P10721704X0000 |203 208|genesPCO2 
P10721704X0000 |230 238|proteins rats ar
P10721704X0000 |193 199|familyon of 
P10721704X0000 |278 291|proliferationontrols but s
P10721704X0000 |304 314|regulationignificant
P10721714A1087 |103 111|promoterpects of
P10721714A1087 |52 55|Sp1 an
P10721714A1087 |79 86|regions71T0000
P10721714A1087 |123 131|Sp1 siteperbilir
P10721714A1087 |169 175|region3-] is
P10721714A1087 |16 37|mobility shift assaysomparison with alkali
P10721717A0676 |0 4|Fgd3P000
P10721717A0676 |9 13|FGD1T007
P10721717A0676 |27 33|degreeith al
P10721717A0676 |37 54|sequence identityne phosphatases a
P10721717A0676 |82 101|amino acid residues0000 Pharmacologic 
P10721726T0000 |21 49|mouse thioredoxin reductasesison with alkaline phosphata
P10721726T0000 |10 17|cloning0076 Co
P10722063A0328 |70 77|mixturee P0000
P10722063A0328 |148 153|phase97A04
P10722063A0328 |133 136|v/vine
P10722063A0328 |28 50|octadecylsilane columnth alkaline phosphatas
P10722063A0328 |4 15|HPLC method01606T0076 
P10722063A0328 |158 167|detectionen CSF [H
P10722063A0328 |57 66|degrees C5-nucleot
P10722063A0328 |175 177|nm s
P10722063A0328 |116 120|acidatal
P10722509A0392 |84 92|patients00 Pharm
P10722509A0392 |28 30|mgth
P10722509A0392 |135 137|kgem
P10722509A0392 |121 130|dipivoxilhyperbili
P10722509A0392 |57 59|kg5-
P10722509A0392 |106 108|mgts
P10722509A0392 |63 74|body weighteotidase P0
P10722509A0392 |43 52|dipivoxilsphatases
P10722509A0392 |6 14|patients606T0076
P10722661A0146 |0 4|CYC2P000
P10722661A0146 |22 29|proteinson wit
P10722661A0146 |110 122|PHO80 cyclinf neonatal h
P10722661A0146 |39 56|sequence identity phosphatases and
P10722661A0146 |64 87|Neurospora crassa PREG1otidase P00008171T0000 
P10722661A0406 |35 42|complexline ph
P10722661A0406 |95 102|kinaseslogic a
P10722661A0406 |228 235|controled rats
P10722661A0406 |104 108|CRKsects
P10722661A0406 |115 124|CYC2 genenatal hyp
P10722661A0406 |142 156|TY epitope tag00008997A0472 
P10722661A0406 |178 196|trypanosome genomeown as a function 
P10722661A0406 |70 81|trypanosomee P00008171
P10722661A0406 |16 20|CYC2ompa
P10722737A1726 |54 57|Inrnd 
P10722737A1726 |79 89|regulation71T0000 Ph
P10722737A1726 |183 189|S genes a fu
P10722737A1726 |28 39|involvementth alkaline
P10722737A1726 |134 137|Sp1nem
P10722737A1726 |43 46|Sp1sph
P10722737A1726 |177 180|LTChow
P10722737A1726 |109 129|transcription factorof neonatal hyperbil
P10722737A1726 |159 169|regulationn CSF [HCO
P10722737A1726 |6 14|findings606T0076
P10722969A0510 |40 44|areaphos
P10722969A0510 |15 23|progressComparis
P10722969A0510 |27 31|dateith 
P10723723A0781 |18 32|mouse promoterparison with a
P10723723A0781 |124 128|exonerbi
P10723723A0781 |45 51|copieshatase
P10723723A0781 |57 88|CT dinucleotide repeat sequence5-nucleotidase P00008171T0000 P
P10723723A0781 |115 117|bpna
P10723727A0713 |18 24|regionpariso
P10723727A0713 |88 120|polyadenylation signal sequencesharmacologic aspects of neonatal
P10723727A0713 |37 43|intronne pho
P10724436A0085 |83 89|system000 Ph
P10724436A0085 |22 26|U3O8son 
P10724436A0085 |36 55|reference materialsine phosphatases an
P10724483A0540 |96 107|HOG pathwayogic aspect
P10724483A0540 |61 72|HEM13 genescleotidase 
P10724483A0540 |24 36|cAMP controln with alkal
P10724483A0540 |52 56|SRP1 and
P10724519A1185 |77 85|elements8171T000
P10724519A1185 |44 48|RNAsphat
P10725017A0673 |170 200|Healthcare Record Architecture-] is shown as a function of C
P10725017A0673 |60 67|CEN ENVucleoti
P10725017A0673 |5 10|paper1606T
P10725017A0673 |144 151|CEN ENV008997A
P10725017A0673 |40 48|approachphosphat
P10725017A0673 |117 134|healthcare recordtal hyperbilirubi
P10725017A0673 |84 98|specialisation00 Pharmacolog
P10725382A0398 |0 17|Sequence analysesP00001606T0076 Co
P10725382A0398 |83 89|domain000 Ph
P10725382A0398 |130 134|SOS2rubi
P10725382A0398 |120 126|domain hyper
P10725382A0398 |21 25|sos2ison
P10725382A0398 |33 40|alleleskaline 
P10725433A0543 |186 194|sequence functio
P10725433A0543 |163 172|consensusF [HCO3-]
P10725433A0543 |125 133|mutationrbilirub
P10725433A0543 |215 232|promoter functiona of K-depleted r
P10725433A0543 |31 38|bindingalkalin
P10725433A0543 |101 113|B cell linesaspects of n
P10725433A0543 |48 55|factorsases an
P10725433A0543 |64 84|Wp reporter activityotidase P00008171T00
P10725433A0543 |2 10|mutation0001606T
P10725433A0543 |153 157|site72 W
P10727247A0461 |141 151|TEF-1gammaP00008997A
P10727247A0461 |127 136|TEF-1betailirubine
P10727247A0461 |111 125|TEF-1 isoforms neonatal hype
P10727247A0461 |46 64|expression patternatases and 5-nucle
P10727247A0461 |21 28|cloningison wi
P10727247A0461 |81 97|characterizationT0000 Pharmacolo
P10727413A1244 |71 85|hamster CYP7A1 P00008171T000
P10727413A1244 |14 27|binding sites Comparison w
P10727413A1244 |95 103|promoterlogic as
P10727413A1244 |177 181|unithown
P10727413A1244 |47 54|factorstases a
P10727413A1244 |225 243|tissue restrictionleted rats are no 
P10727413A1244 |210 220|expressione data of 
P10727413A1244 |113 121|vicinityeonatal 
P10727413A1244 |261 269|hormoneshen comp
P10727413A1244 |144 151|species008997A
P10727413A1244 |251 257|actionisplac
P10727413A1244 |278 285|insulinontrols
P10727426A1280 |68 78|olomoucinease P00008
P10727426A1280 |23 28|PfPK6on wi
P10727426A1280 |45 59|CDK inhibitorshatases and 5-
P10727426A1280 |83 94|roscovitine000 Pharmac
P10727426A1280 |4 19|kinase activity01606T0076 Comp
P10727428A0000 |32 39|proteinlkaline
P10727428A0000 |130 134|rolerubi
P10727428A0000 |41 48|kinaseshosphat
P10727428A0000 |90 105|differentiationrmacologic aspe
P10727428A0000 |67 85|cell proliferationdase P00008171T000
P10727428A0000 |9 12|MAPT00
P10727428A0000 |161 172|hypertrophyCSF [HCO3-]
P10727428A0000 |114 124|cell typesonatal hyp
P10727428A0000 |138 149|MAP kinasesa. P0000899
P10727433A0560 |239 242|ras no
P10727433A0560 |131 148|activator proteinubinemia. P000089
P10727433A0560 |167 179|uPA promoterCO3-] is sho
P10727433A0560 |72 82|activationP00008171T
P10727433A0560 |122 129|Ets/AP1yperbil
P10727433A0560 |90 108|signalling pathwayrmacologic aspects
P10727433A0560 |20 45|CSF-1R expression plasmidrison with alkaline phosp
P10727433A0560 |219 225|target K-dep
P10727433A0560 |247 272|protein kinase C pathwayser displaced when compare
P10727433A0560 |0 12|TransfectionP00001606T00
P10727433A0560 |152 159|element472 Whe
P10727433T0000 |0 10|RegulationP00001606T
P10727433T0000 |148 153|CSF-197A04
P10727433T0000 |72 78|RAW264P00008
P10727433T0000 |14 64|urokinase plasminogen activator gene transcription Comparison with alkaline phosphatases and 5-nucle
P10727433T0000 |110 120|macrophagef neonatal
P10727433T0000 |199 207|receptorCSF PCO2
P10727433T0000 |177 182|levelhown 
P10727433T0000 |140 146|factor P0000
P10727433T0000 |86 106|macrophage cell line Pharmacologic aspec
P10727511A0294 |0 8|MoleculeP0000160
P10727511A0294 |61 70|inductioncleotidas
P10727511A0294 |111 129|signaling pathways neonatal hyperbil
P10727511A0294 |9 10|sT
P10727511A0294 |74 79|GLT-100081
P10727511A0294 |145 155|regulation08997A0472
P10727511A0294 |33 41|cultureskaline p
P10727515A1202 |85 93|receptor0 Pharma
P10727515A1202 |126 133|PLCbetabilirub
P10727515A1202 |40 41|Gp
P10727515A1202 |183 198|pertussis toxins a function of
P10727515A1202 |53 62|receptorsand 5-nuc
P10727515A1202 |110 122|stimulationsf neonatal h
P10727515A1202 |42 43|qo
P10727515A1202 |143 152|responses0008997A0
P10727515A1202 |0 12|CoactivationP00001606T00
P10728945A0233 |0 8|PatientsP0000160
P10728945A0233 |82 95|Thrombosis-II0000 Pharmaco
P10728945A0233 |25 35|Integrilin with alka
P10728945A0233 |108 113|trial of n
P10728945A0233 |97 106|IMPACT-IIgic aspec
P10728945A0233 |48 68|Platelet Aggregationases and 5-nucleotid
P10728986A0000 |87 106|cell fate decisionsPharmacologic aspec
P10728986A0000 |57 75|animal development5-nucleotidase P00
P10728986A0000 |4 25|Wnt signaling pathway01606T0076 Comparison
P10729151A1160 |38 44|HPV-11e phos
P10729151A1160 |83 102|reporter expression000 Pharmacologic a
P10729151A1160 |5 13|mutation1606T007
P10729155A0653 |103 108|betaIpects
P10729155A0653 |57 68|carboxy end5-nucleotid
P10729155A0653 |88 101|beta-strand Iharmacologic 
P10729155A0653 |173 177|faceis s
P10729155A0653 |202 209|subunit PCO2 t
P10729155A0653 |129 137|residuesirubinem
P10729155A0653 |20 31|MVMi capsidrison with 
P10729155A0653 |38 46|sequencee phosph
P10729220A0000 |19 23|IGF2aris
P10729220A0000 |44 57|growth factorphatases and 
P10729220A0000 |121 126|mousehyper
P10729220A0000 |66 75|H19 genesidase P00
P10729220A1569 |77 80|H19817
P10729220A1569 |15 26|methylationComparison 
P10729220A1569 |63 73|disruptioneotidase P
P10729220A1569 |109 114|brainof ne
P10729221A0798 |55 73|Kv4 family membersd 5-nucleotidase P
P10729221A0798 |22 41|expression patternsson with alkaline p
P10729221A0798 |80 99|subtype specificity1T0000 Pharmacologi
P10729221A0798 |4 14|comparison01606T0076
P10730292T0000 |33 50|Class II divisionkaline phosphatas
P10730292T0000 |6 25|treatment mechanics606T0076 Comparison
P10730292T0000 |53 65|malocclusionand 5-nucleo
P10730763A1491 |136 152|disease severitymia. P00008997A0
P10730763A1491 |122 132|assessmentyperbiliru
P10730763A1491 |95 108|research toollogic aspects
P10730763A1491 |78 89|development171T0000 Ph
P10730763A1491 |12 15|use76 
P10730763A1491 |23 55|Nottingham Eczema Severity Scoreon with alkaline phosphatases an
P10730763A1491 |191 198|studiestion of
P10731411A0958 |187 194|residuefunctio
P10731411A0958 |43 51|residuessphatase
P10731411A0958 |29 39|importanceh alkaline
P10731411A0958 |73 79|motifs000081
P10731411A0958 |165 175|importance[HCO3-] is
P10731411A0958 |4 13|consensus01606T007
P10731411A0958 |213 218|motifata o
P10731411A0958 |111 133|DEAD-box RNA helicases neonatal hyperbilirub
P10731411A0958 |184 185|A 
P10731411A0958 |207 211|DEAD the
P10731926A0775 |0 16|Advanced adenomaP00001606T0076 C
P10731926A0775 |58 60|mm-n
P10731926A0775 |122 131|dysplasiayperbilir
P10731926A0775 |82 86|size0000
P10731926A0775 |67 74|adenomadase P0
P10731926A0775 |144 153|carcinoma008997A04
P10731926A0775 |100 109|component aspects 
P10731926A0775 |35 42|adenomaline ph
P10732669A0510 |174 198|reporter gene constructss shown as a function of
P10732669A0510 |13 19|assays6 Comp
P10732669A0510 |121 127|Oshox1hyperb
P10732669A0510 |162 170|activitySF [HCO3
P10732669A0510 |27 31|riceith 
P10732669A0510 |73 93|particle bombardment00008171T0000 Pharma
P10732669A0510 |213 233|HD-Zip binding sitesata of K-depleted ra
P10732669A0510 |52 57|cells and 
P10732669A1336 |0 7|ResultsP000016
P10732669A1336 |213 219|familyata of
P10732669A1336 |192 200|proteinsion of C
P10732669A1336 |104 112|proteinsects of 
P10732669A1336 |143 153|homodimers0008997A04
P10732669A1336 |22 28|assaysson wi
P10732669A1336 |163 175|heterodimersF [HCO3-] is
P10732669A1336 |116 124|familiesatal hyp
P10732669A1336 |49 70|mobility shift assaysses and 5-nucleotidas
P10733569A0364 |16 20|HSFsompa
P10733569A0364 |62 72|regulationleotidase 
P10733569A0364 |129 137|functionirubinem
P10733569A0364 |93 115|stress gene expressioncologic aspects of neo
P10733569A0364 |149 164|stress response7A0472 When CSF
P10733569A0364 |22 26|HSF1son 
P10733569A0364 |141 145|HSF2P000
P10733581A1391 |70 80|V12N38 Rase P0000817
P10733581A1391 |108 112|loss of 
P10733581A1391 |62 65|Rafleo
P10733581A1391 |25 35|expression with alka
P10733581A1391 |116 130|TTF-1 activityatal hyperbili
P10733591A0146 |102 104|S6sp
P10733591A0146 |184 202|cell proliferation a function of CSF
P10733591A0146 |27 34|targetsith alk
P10733591A0146 |166 179|transcriptionHCO3-] is sho
P10733591A0146 |134 140|kinasenemia.
P10733591A0146 |152 162|regulation472 When C
P10733591A0146 |84 94|activation00 Pharmac
P10733591A0146 |117 122|c-juntal h
P10733591A0146 |142 145|JNK000
P10733591A0146 |46 56|remodelingatases and
P10733591A0146 |106 112|kinasets of 
P10733591A0146 |98 101|p70ic 
P10733591A0146 |64 82|actin cytoskeletonotidase P00008171T
P10733591A0533 |0 10|ExpressionP00001606T
P10733591A0533 |149 164|plasma membrane7A0472 When CSF
P10733591A0533 |62 71|PKClambdaleotidase
P10733591A0533 |121 130|PKClambdahyperbili
P10733591A0533 |45 58|translocationhatases and 5
P10733591A0533 |111 116|Cdc42 neon
P10733591A0533 |24 37|Cdc42 resultsn with alkali
P10733591A0533 |176 185|cytoplasmshown as 
P10733591A0533 |81 88|nucleusT0000 P
P10733591A0533 |98 105|cytosolic aspe
P10733880X1783 |0 9|CopyrightP00001606
P10733880X1783 |15 29|Academic PressComparison wit
P10734312A0503 |141 172|Ras membrane localization motifP00008997A0472 When CSF [HCO3-]
P10734312A0503 |22 38|Shc localizationson with alkalin
P10734312A0503 |42 56|membrane raftsosphatases and
P10734312A0503 |180 190|C-terminusn as a fun
P10734312A0503 |83 95|Shc function000 Pharmaco
P10734312A0503 |114 125|Shc chimeraonatal hype
P10735272A0649 |119 123|genel hy
P10735272A0649 |161 171|expressionCSF [HCO3-
P10735272A0649 |227 270|chromosome 19q glioma tumor suppressor geneted rats are no longer displaced when compa
P10735272A0649 |29 70|strand conformation polymorphism analysesh alkaline phosphatases and 5-nucleotidas
P10735272A0649 |210 215|ANOVAe dat
P10735272A0649 |175 192|glioma cell lines shown as a funct
P10735272A0649 |99 110|alterationsc aspects o
P10735272A0649 |127 134|gliomasilirubi
P10735272A0649 |139 153|RT-PCR studies. P00008997A04
P10735272A0649 |0 17|Southern blottingP00001606T0076 Co
P10735848A1440 |0 4|RegAP000
P10735848A1440 |36 45|regulatorine phosp
P10735848A1440 |49 68|tol-oprL expressionses and 5-nucleotid
P10736161T0000 |0 8|Enzyme IP0000160
P10736161T0000 |36 67|sugar phosphotransferase systemine phosphatases and 5-nucleoti
P10736161T0000 |16 35|phosphoenolpyruvateomparison with alka
P10736223A1227 |206 220|mRNA stability2 the data of 
P10736223A1227 |107 111|PrgXs of
P10736223A1227 |180 191|readthroughn as a func
P10736223A1227 |15 19|dataComp
P10736223A1227 |97 101|prgQgic 
P10736223A1227 |82 93|Qa promoter0000 Pharma
P10736223A1227 |130 143|transcriptionrubinemia. P0
P10736223A1227 |38 51|transcriptione phosphatase
P10736223A1227 |55 59|prgXd 5-
P10737366A0280 |86 95|threshold Pharmaco
P10737366A0280 |126 139|formalin testbilirubinemia
P10737366A0280 |111 118|stimuli neonat
P10737366A0280 |143 147|rats0008
P10737366A0280 |55 59|PTFLd 5-
P10738139A0681 |40 71|cytokine response pathway genesphosphatases and 5-nucleotidase
P10738139A0681 |75 79|KSHV0081
P10738139A0681 |10 17|mimicry0076 Co
P10738139A0681 |27 35|cytokineith alka
P10739408A0896 |0 18|Family environmentP00001606T0076 Com
P10739408A0896 |63 76|relationshipseotidase P000
P10739408A0896 |104 111|supportects of
P10739408A0896 |78 91|substance use171T0000 Phar
P10739408A0896 |36 45|influenceine phosp
P10739671A0136 |207 220|fibroblast WI the data of 
P10739671A0136 |188 199|leukemia HLunction of 
P10739671A0136 |294 302|fragmentl have a
P10739671A0136 |112 124|c-myb intronneonatal hyp
P10739671A0136 |127 153|transcription pause regionilirubinemia. P00008997A04
P10739671A0136 |367 371|IRFsuraz
P10739671A0136 |47 53|probestases 
P10739671A0136 |166 174|extractsHCO3-] i
P10739671A0136 |224 229|cellsplete
P10739671A0136 |358 365|factors3A0733 
P10739671A0136 |81 89|segmentsT0000 Ph
P10739671A0136 |336 346|interferon +/- 0.23 
P10739671A0136 |381 389|proteinsappears 
P10739671A0136 |314 327|binding sitesly greater sl
P10739671A0136 |272 279|complexd to co
P10739671A0136 |3 40|electrophoresis mobility shift assays001606T0076 Comparison with alkaline 
P10740602A0141 |0 12|STUDY DESIGNP00001606T00
P10740602A0141 |47 53|smearstases 
P10740602A0141 |14 36|Fine needle aspiration Comparison with alkal
P10740602A0141 |107 113|breasts of n
P10740602A0141 |88 97|carcinomaharmacolo
P10740602A0141 |62 67|casesleoti
P10740602A0141 |99 102|ILCc a
P10740602A0141 |157 165|analysishen CSF 
P10741850A0452 |85 89|GCSh0 Ph
P10741850A0452 |63 72|sequenceseotidase 
P10741850A0452 |197 205|exposuref CSF PC
P10741850A0452 |161 175|gene inductionCSF [HCO3-] is
P10741850A0452 |94 112|GCSl subunit genesologic aspects of 
P10741850A0452 |32 37|EpREslkali
P10741850A0452 |0 30|Electrophile Response ElementsP00001606T0076 Comparison with
P10741947T0000 |6 15|technique606T0076 
P10741947T0000 |75 83|hemoclip008171T0
P10741947T0000 |63 66|LADeot
P10741947T0000 |40 48|stenosisphosphat
P10742114A0486 |0 4|Dll3P000
P10742114A0486 |72 79|varietyP000081
P10742114A0486 |98 105|defectsic aspe
P10742114A0486 |37 42|mousene ph
P10742114A0486 |57 59|pu5-
P10742114A0486 |117 130|SD phenotypestal hyperbili
P10742114A0486 |50 55|pudgyes an
P10742216A0555 |0 8|SchlegelP0000160
P10742216A0555 |10 12|J.00
P10743608A1154 |137 144|mitosisia. P00
P10743608A1154 |58 65|TbRAB31-nucleo
P10743608A1154 |215 219|bodya of
P10743608A1154 |193 199|manneron of 
P10743608A1154 |46 56|cell cycleatases and
P10743608A1154 |224 235|kinetoplastpleted rats
P10743608A1154 |97 106|structuregic aspec
P10743608A1154 |267 279|microtubulesmpared to co
P10743608A1154 |162 176|daughter cellsSF [HCO3-] is 
P10743608A1154 |252 263|involvementsplaced whe
P10743608A1154 |0 17|TbRAB31 behaviourP00001606T0076 Co
P10743719A0223 |17 26|rejectionmparison 
P10743719A0223 |10 12|dg00
P10743719A0223 |123 144|rejection nephropathyperbilirubinemia. P00
P10743719A0223 |73 83|management00008171T0
P10743719A0223 |95 99|risklogi
P10743719A0223 |48 57|rejectionases and 
P10744026A0000 |0 10|InvertasesP00001606T
P10744026A0000 |59 67|fructosenucleoti
P10744026A0000 |72 79|glucoseP000081
P10744026A0000 |48 55|sucroseases an
P10744026A0000 |35 44|breakdownline phos
P10744749A0315 |119 127|activityl hyperb
P10744749A0315 |61 71|inhibitioncleotidase
P10744749A0315 |89 95|effectarmaco
P10744749A0315 |29 39|mechanismsh alkaline
P10744749A0315 |195 202|factors of CSF
P10744749A0315 |144 156|MyoD protein008997A0472 
P10744749A0315 |178 186|paradigmown as a
P10744749T0000 |137 147|KIX domainia. P00008
P10744749T0000 |10 16|T cell0076 C
P10744749T0000 |89 102|transcriptionarmacologic a
P10744749T0000 |151 155|p3000472
P10744749T0000 |52 63|Tax protein and 5-nucl
P10744749T0000 |39 49|virus type phosphata
P10744974T0000 |0 15|PhosphorylationP00001606T0076 
P10744974T0000 |110 115|yeastf neo
P10744974T0000 |58 64|Cdc15p-nucle
P10744974T0000 |20 50|spindle pole body localizationrison with alkaline phosphatas
P10744974T0000 |84 98|protein kinase00 Pharmacolog
P10745563A0409 |116 127|gold stentsatal hyperb
P10745563A0409 |150 158|capacityA0472 Wh
P10745563A0409 |164 169|steel [HCO
P10745563A0409 |15 26|hyperplasiaComparison 
P10745563A0409 |42 55|complicationsosphatases an
P10745563A0409 |197 212|neo-endotheliumf CSF PCO2 the 
P10747053A1102 |35 42|defectsline ph
P10747053A1102 |213 216|SBFata
P10747053A1102 |91 95|rolemaco
P10747053A1102 |199 209|activationCSF PCO2 t
P10747053A1102 |221 224|MBF-de
P10747053A1102 |53 58|taf17and 5
P10747053A1102 |59 65|slm7-1nucleo
P10747053A1102 |179 184|TAF17wn as
P10747053A1102 |141 151|activationP00008997A
P10747053A1102 |99 102|TAFc a
P10747053A1102 |111 121|modulators neonatal 
P10747053A1102 |4 14|cell cycle01606T0076
P10747053A1102 |170 174|role-] i
P10747099A0507 |32 35|ERKlka
P10747099A0507 |24 30|kinasen with
P10747099A0507 |126 129|CASbil
P10747099A0507 |62 70|couplingleotidas
P10747099A0507 |135 142|c-CrkIIemia. P
P10747099A0507 |115 124|substratenatal hyp
P10747099A0507 |263 278|collagen matrixn compared to c
P10747099A0507 |219 224|cells K-de
P10747099A0507 |144 147|Crk008
P10747099A0507 |230 239|apoptosis rats are
P10747099A0507 |78 99|adaptor proteins p130171T0000 Pharmacologi
P10747099A0507 |193 206|cell invasionon of CSF PCO
P10747099A0507 |172 180|pathways is show
P10747099A0507 |37 47|activationne phospha
P10747782A0390 |68 74|extentase P0
P10747782A0390 |41 50|complexeshosphatas
P10747782A0390 |121 130|moleculeshyperbili
P10747782A0390 |15 19|Mbp1Comp
P10747782A0390 |159 179|DNA binding activityn CSF [HCO3-] is sho
P10747782A0390 |196 208|core domainsof CSF PCO2 
P10747782A0390 |24 28|Swi4n wi
P10747782A0390 |84 93|sequences00 Pharma
P10747782A0390 |0 11|ProteolysisP00001606T0
P10747879A0607 |64 77|reading frameotidase P0000
P10747879A0607 |125 138|reading framerbilirubinemi
P10747879A0607 |41 47|regionhospha
P10747879A0607 |105 112|domainscts of 
P10747879A0607 |4 13|evolution01606T007
P10747879A0607 |21 25|CCR5ison
P10747890A1096 |171 178|lesions] is sh
P10747890A1096 |6 13|results606T007
P10747890A1096 |127 149|base pair interactionsilirubinemia. P0000899
P10747890A1096 |28 35|residueth alka
P10747890A1096 |53 67|protein sensorand 5-nucleoti
P10747890A1096 |86 105|groove interactions Pharmacologic aspe
P10747987A0658 |16 23|enzymesomparis
P10747987A0658 |33 41|monomerskaline p
P10748054T0048 |2 9|pathway0001606
P10748054T0048 |14 24|regulation Compariso
P10748054T0048 |28 48|B lymphocyte antigenth alkaline phosphat
P10748054T0048 |66 78|calcium fluxidase P00008
P10748113A0187 |117 122|braintal h
P10748113A0187 |45 49|RIM2hata
P10748113A0187 |25 36|RIM protein with alkal
P10748113A0187 |80 84|RIM11T00
P10748125A0000 |0 11|Inhibitor-1P00001606T0
P10748125A0000 |60 64|typeucle
P10748125A0000 |22 33|inhibitor-2son with al
P10748125A0000 |106 109|PP1ts 
P10748125A0000 |13 16|I-16 C
P10748125A0000 |67 104|protein serine/threonine phosphatasesdase P00008171T0000 Pharmacologic asp
P10748125A0000 |35 38|I-2lin
P10748164A1284 |34 44|AC elementaline phos
P10748164A1284 |61 70|inductioncleotidas
P10748164A1284 |134 141|factorsnemia. 
P10748164A1284 |162 168|probesSF [HC
P10748164A1284 |145 147|AC08
P10748164A1284 |193 200|factorson of C
P10748164A1284 |113 118|siteseonat
P10748164A1284 |0 18|Scanning mutationsP00001606T0076 Com
P10748175A0000 |153 165|transporters72 When CSF 
P10748175A0000 |56 61|Golgi 5-nu
P10748175A0000 |4 14|substrates01606T0076
P10748175A0000 |77 83|sugars8171T0
P10748175A0000 |43 48|lumensphat
P10748175A0000 |19 35|glycan synthesisarison with alka
P10748175A0000 |118 125|cytosolal hype
P10748194T0000 |39 61|density protein PSD-95 phosphatases and 5-nu
P10748194T0000 |91 109|trafficking signalmacologic aspects 
P10748194T0000 |9 18|targetingT0076 Com
P10748204A0238 |7 9|J.06
P10748672A0130 |0 5|BitesP0000
P10748672A0130 |110 117|failuref neona
P10748672A0130 |24 30|addersn with
P10748672A0130 |13 20|species6 Compa
P10748672A0130 |32 44|Vipera aspislkaline phos
P10748672A0130 |49 61|Vipera berusses and 5-nu
P10749145T0000 |171 182|kinase ERK1] is shown 
P10749145T0000 |29 42|PCPH proteinsh alkaline ph
P10749145T0000 |122 125|Rasype
P10749145T0000 |94 105|oncoproteinologic aspe
P10749145T0000 |58 80|diphosphatase activity-nucleotidase P0000817
P10749166A0991 |171 179|bacteria] is sho
P10749166A0991 |188 202|A. tumefaciensunction of CSF
P10749166A0991 |6 13|results606T007
P10749166A0991 |135 146|B. henselaeemia. P0000
P10749166A0991 |49 54|genesses a
P10749166A0991 |85 96|arrangement0 Pharmacol
P10749849A0000 |98 115|cell cycle arrestic aspects of neo
P10749849A0000 |180 189|WAF1/Cip1n as a fu
P10749849A0000 |75 84|stability008171T00
P10749849A0000 |159 179|kinase inhibitor p21n CSF [HCO3-] is sho
P10749849A0000 |124 134|activationerbilirubi
P10749849A0000 |13 22|mechanism6 Compari
P10749849A0000 |36 56|tumor suppressor p53ine phosphatases and
P10749849A0000 |191 195|genetion
P10749932A0000 |0 8|PaxillinP0000160
P10749932A0000 |40 58|integrin signalingphosphatases and 5
P10749932A0000 |20 36|adaptor moleculerison with alkal
P10750020A0843 |68 82|ER/Sp1 bindingase P00008171T
P10750020A0843 |123 130|pathwayperbili
P10750020A0843 |49 64|transactivationses and 5-nucle
P10750020A0843 |6 30|growth factor activation606T0076 Comparison with
P10750020A0843 |94 99|sitesologi
P10750020A0843 |154 163|ER action2 When CS
P10750020A0843 |34 36|ERal
P10750021A0728 |84 92|activity00 Pharm
P10750021A0728 |133 135|P2in
P10750021A0728 |123 129|regionperbil
P10750021A0728 |13 21|analysis6 Compar
P10750021A0728 |25 62|deletion promoter-reporter constructs with alkaline phosphatases and 5-nuc
P10750021A0728 |96 98|P2og
P10750524A0724 |0 7|RESULTSP000016
P10750524A0724 |146 147|p8
P10750524A0724 |87 97|proportionPharmacolo
P10750524A0724 |18 28|thresholdsparison wi
P10750524A0724 |58 63|tests-nucl
P10750524A0724 |139 144|group. P00
P10750524A0724 |103 106|agepec
P10751398A1135 |102 107|virusspect
P10751398A1135 |3 11|addition001606T0
P10751398A1135 |115 131|membrane proteinnatal hyperbilir
P10751398A1135 |81 85|CD40T000
P10751398A1135 |17 30|transcriptionmparison with
P10751398A1135 |34 49|c-IAP2 promoteraline phosphata
P10752450A0288 |2 9|variety0001606
P10752450A0288 |135 141|marketemia. 
P10752450A0288 |43 60|fluoride productssphatases and 5-n
P10752450A0288 |83 108|fluoride delivery systems000 Pharmacologic aspects
P10752475A1376 |137 145|ligationia. P000
P10752475A1376 |260 270|antibodieswhen compa
P10752475A1376 |333 345|mouse models.21 +/- 0.23
P10752475A1376 |149 153|CD207A04
P10752475A1376 |303 320|tumor regressionssignificantly gre
P10752475A1376 |220 225|cellsK-dep
P10752475A1376 |359 365|trialsA0733 
P10752475A1376 |185 193|presencea functi
P10752475A1376 |81 90|apoptosisT0000 Pha
P10752475A1376 |250 258|mouse Igdisplace
P10752475A1376 |6 13|studies606T007
P10752475A1376 |167 177|antibodiesCO3-] is s
P10752475A1376 |104 111|B cellsects of
P10752475A1376 |38 64|signal-transduction eventse phosphatases and 5-nucle
P10752475A1376 |239 243|goat no 
P10752807A1598 |0 10|CONCLUSIONP00001606T
P10752807A1598 |12 21|Treatment76 Compar
P10752807A1598 |122 130|survivalyperbili
P10752807A1598 |61 85|factor antagonist BB-882cleotidase P00008171T000
P10752807A1598 |164 172|function [HCO3-]
P10752807A1598 |25 31|sepsis with 
P10752807A1598 |111 118|placebo neonat
P10752807A1598 |177 197|organ failure scoreshown as a function o
P10752807A1598 |144 150|status008997
P10752807A1598 |96 105|advantageogic aspe
P10753553T0000 |0 9|PhenazoneP00001606
P10753553T0000 |44 50|effectphatas
P10753553T0000 |67 71|micedase
P10753553T0000 |54 63|lidocainend 5-nucl
P10754312A0798 |34 42|proteinsaline ph
P10754312A0798 |4 14|solubility01606T0076
P10756007A0575 |87 93|genomePharma
P10756007A0575 |20 33|RBE sequencesrison with al
P10756007A0575 |64 73|locationsotidase P
P10756007A1512 |0 11|EM analysisP00001606T0
P10756007A1512 |47 54|complextases a
P10756007A1512 |69 85|ch-19 target DNAse P00008171T000
P10756020A0571 |4 11|protein01606T0
P10756020A0571 |108 115|virions of neo
P10756020A0571 |41 65|vaccinia virus particleshosphatases and 5-nucleo
P10756020A0571 |75 84|membranes008171T00
P10756020A0571 |172 177|cells is s
P10756020A0571 |140 159|electron microscopy P00008997A0472 Whe
P10756032A0599 |152 157|cells472 W
P10756032A0599 |106 122|hypersensitivityts of neonatal h
P10756032A0599 |91 101|protectionmacologic 
P10756032A0599 |45 62|cyclin E promoterhatases and 5-nuc
P10756032A0599 |8 37|dimethyl sulfate footprinting6T0076 Comparison with alkali
P10756032A0599 |80 87|regions1T0000 
P10756094A0671 |68 85|marker resolutionase P00008171T000
P10756094A0671 |114 116|kbon
P10756094A0671 |46 48|Mbat
P10756094A0671 |15 19|STSsComp
P10756094A0671 |2 7|total00016
P10756094A0671 |32 40|intervallkaline 
P10756100A0457 |70 78|diabetese P00008
P10756100A0457 |28 42|amino-terminusth alkaline ph
P10756100A0457 |12 20|mutation76 Compa
P10756100A0457 |46 49|IB1ata
P10756225A1464 |102 110|responsespects o
P10756225A1464 |53 61|rhinitisand 5-nu
P10756225A1464 |24 25|%n
P10756225A1464 |29 37|patientsh alkali
P10756225A1464 |91 98|surgerymacolog
P10756225A1464 |141 146|cellsP0000
P10756225A1464 |158 167|IL-5 mRNAen CSF [H
P10756225A1464 |66 69|CRSida
P10756225A1464 |175 190|ethmoid sinuses shown as a fun
P10756225A1464 |0 10|CONCLUSIONP00001606T
P10757975A0509 |0 4|BiolP000
P10757983A0733 |16 20|sizeompa
P10757983A0733 |26 38|CRS sequencewith alkalin
P10757983A0733 |166 185|zinc finger proteinHCO3-] is shown as 
P10757983A0733 |189 211|mouse ZBP-89 homologuenction of CSF PCO2 the
P10757983A0733 |7 12|basis06T00
P10757983A0733 |76 90|identification08171T0000 Pha
P10757983A0733 |96 115|zinc finger proteinogic aspects of neo
P10757983A0733 |117 127|Adx factortal hyperb
P10758289A0141 |0 7|METHODSP000016
P10758289A0141 |144 153|specimens008997A04
P10758289A0141 |25 38|muscle fibres with alkalin
P10758289A0141 |114 127|pisiform boneonatal hyperb
P10758289A0141 |69 83|finger flexorsse P00008171T0
P10758489A0206 |35 39|ICK2line
P10758489A0206 |126 133|Cdc2bAtbilirub
P10758489A0206 |73 80|Cdc2aAt0000817
P10758489A0206 |104 107|CDKect
P10758489A0206 |22 31|isolationson with 
P10758489A0206 |113 124|Arabidopsiseonatal hyp
P10758726T0000 |32 44|arrangementslkaline phos
P10758726T0000 |9 15|impactT0076 
P10759693A0201 |0 7|METHODSP000016
P10759693A0201 |263 268|usersn com
P10759693A0201 |295 304|phenytoin have a s
P10759693A0201 |159 169|antagonistn CSF [HCO
P10759693A0201 |249 259|nizatidine displaced
P10759693A0201 |26 36|odds ratiowith alkal
P10759693A0201 |215 232|agents ranitidinea of K-depleted r
P10759693A0201 |234 244|famotidines are no l
P10759693A0201 |109 120|interactionof neonatal
P10759693A0201 |72 76|riskP000
P10759693A0201 |285 293|warfarin but sti
P10759693A0201 |48 55|measureases an
P10759693A0201 |273 281|nonusers to cont
P10759693A0201 |309 321|theophyllineicantly grea
P10759693A0201 |38 40|ORe 
P10759693A0201 |136 139|usemia
P10759693A0201 |171 181|cimetidine] is shown
P10760109A1050 |102 103|%s
P10760109A1050 |218 234|blood hemoglobinf K-depleted rat
P10760109A1050 |126 134|patientsbilirubi
P10760109A1050 |176 188|plasma IGF-1shown as a f
P10760109A1050 |208 211|SCrthe
P10760109A1050 |105 106|Pc
P10760109A1050 |164 168|tHcy [HC
P10760109A1050 |49 57|patientsses and 
P10760109A1050 |18 30|malnutritionparison with
P10760109A1050 |190 206|serum creatininection of CSF PCO
P10760109A1050 |140 143|CVD P0
P10760109A1050 |66 69|CVDida
P10760109A1050 |37 38|%n
P10760109A1050 |4 14|prevalence01606T0076
P10760109A1050 |170 174|SAlb-] i
P10760132A1169 |85 104|protein prenylation0 Pharmacologic asp
P10760132A1169 |133 153|vesicle polarizationinemia. P00008997A04
P10760132A1169 |72 77|levelP0000
P10760132A1169 |40 51|temperaturephosphatase
P10760132A1169 |4 8|data0160
P10760169A1142 |68 98|transcription initiation sitesase P00008171T0000 Pharmacolog
P10760169A1142 |30 40|CreA sites alkaline 
P10760169A1142 |22 26|pairson 
P10760950A1133 |36 46|N-utrophinine phosph
P10760950A1133 |11 27|staining pattern076 Comparison w
P10760950A1133 |111 130|actin stress fibers neonatal hyperbili
P10761263A1108 |16 21|modelompar
P10761263A1108 |145 162|prostate patients08997A0472 When C
P10761263A1108 |41 50|Hotellinghosphatas
P10761263A1108 |122 134|displacementyperbilirubi
P10761263A1108 |53 65|T2 statisticand 5-nucleo
P10761263A1108 |5 14|Newcastle1606T0076
P10762254A0954 |136 158|TMA methyltransferasesmia. P00008997A0472 Wh
P10762254A0954 |77 103|MMA methyltransferase gene8171T0000 Pharmacologic as
P10762254A0954 |9 12|DMAT00
P10762254A0954 |109 114|genesof ne
P10762254A0954 |190 201|amber codonction of CS
P10762254A0954 |4 7|MMA016
P10762254A0954 |128 131|DMAlir
P10762254A0954 |18 40|TMA methyltransferasesparison with alkaline 
P10762254A0954 |49 57|homologsses and 
P10762348A0269 |98 106|activityic aspec
P10762348A0269 |62 69|nucleusleotida
P10762348A0269 |6 21|phosphorylation606T0076 Compar
P10762348A0269 |23 36|STAT proteinson with alkal
P10763823A0824 |0 14|OverexpressionP00001606T0076
P10763823A0824 |74 86|transfection0008171T0000
P10763823A0824 |108 115|plasmid of neo
P10763823A0824 |57 66|apoptosis5-nucleot
P10763823A0824 |123 133|cell deathperbilirub
P10763823A0824 |92 97|mcl-1acolo
P10763823A0824 |18 23|mcl-1paris
P10763827A1158 |163 181|senescence programF [HCO3-] is shown
P10763827A1158 |75 87|ras oncogene008171T0000 
P10763827A1158 |89 101|inactivationarmacologic 
P10763827A1158 |61 69|responsecleotida
P10763827A1158 |105 123|TGFbeta1 secretioncts of neonatal hy
P10763827A1158 |24 43|senescence pathwaysn with alkaline pho
P10763827A1158 |127 135|responseilirubin
P10764150A0000 |19 28|abilitiesarison wi
P10764150A0000 |131 143|FDC-P1 cellsubinemia. P0
P10764150A0000 |108 127|cytokine dependency of neonatal hyperb
P10764150A0000 |61 66|formscleot
P10764150A0000 |8 13|study6T007
P10764150A0000 |80 91|Raf kinases1T0000 Phar
P10764574A0718 |0 11|ApplicationP00001606T0
P10764574A0718 |73 93|Arabidopsis thaliana00008171T0000 Pharma
P10764574A0718 |62 67|genesleoti
P10764574A0718 |128 147|prediction accuracylirubinemia. P00008
P10764574A0718 |177 194|alignment methodshown as a functio
P10764574A0718 |46 49|setata
P10764574A0718 |113 124|improvementeonatal hyp
P10764574A0718 |19 25|methodarison
P10764729A1846 |84 100|accession number00 Pharmacologic
P10764729A1846 |77 79|TM81
P10764729A1846 |13 26|cDNA sequence6 Comparison 
P10764729A1846 |36 50|betaV spectrinine phosphatas
P10764729A1846 |69 76|GenBankse P000
P10764760T0000 |0 15|TransactivationP00001606T0076 
P10764760T0000 |74 95|JNK signaling pathway0008171T0000 Pharmaco
P10764760T0000 |59 66|repeatsnucleot
P10764760T0000 |39 44|HIV-1 phos
P10764802A1258 |51 55|Kip2s an
P10764802A1258 |181 190|mechanism as a fun
P10764802A1258 |247 250|p57er 
P10764802A1258 |299 314|differentiatione a significant
P10764802A1258 |47 50|p57tas
P10764802A1258 |135 146|interactionemia. P0000
P10764802A1258 |224 232|activitypleted r
P10764802A1258 |251 255|Kip2ispl
P10764802A1258 |6 10|data606T
P10764802A1258 |37 43|domainne pho
P10764802A1258 |257 271|family membersed when compar
P10764802A1258 |84 100|Cip/Kip proteins00 Pharmacologic
P10764970A1009 |103 108|casespects
P10764970A1009 |26 51|quinupristin/dalfopristinwith alkaline phosphatase
P10764970A1009 |242 250|practice longer 
P10764970A1009 |12 22|resistance76 Compari
P10764970A1009 |181 193|introduction as a functi
P10764970A1009 |4 8|mode0160
P10764970A1009 |161 169|isolatesCSF [HCO
P10764970A1009 |124 133|existenceerbilirub
P10764970A1009 |216 221|class of K
P10764970A1009 |87 90|PCRPha
P10765095A0308 |235 248|PRL secretion are no longe
P10765095A0308 |225 230|testsleted
P10765095A0308 |135 141|L-Dopaemia. 
P10765095A0308 |105 115|conditionscts of neo
P10765095A0308 |66 90|prostate cancer patientsidase P00008171T0000 Pha
P10765095A0308 |146 160|metoclopramide8997A0472 When
P10765095A0308 |123 131|responseperbilir
P10765095A0308 |5 10|study1606T
P10765095A0308 |38 51|PRL secretione phosphatase
P10766246A0000 |0 27|Integrin adhesion receptorsP00001606T0076 Comparison w
P10766246A0000 |114 129|gene expressiononatal hyperbil
P10766246A0000 |67 81|cell functionsdase P00008171
P10766246A0000 |100 110|regulation aspects o
P10766246A0000 |38 45|signalse phosp
P10766246A0000 |174 182|survivals shown 
P10766246A0000 |139 152|proliferation. P00008997A0
P10766246A0000 |154 169|differentiation2 When CSF [HCO
P10766493T0000 |0 13|RecombinationP00001606T007
P10766493T0000 |28 34|repairth alk
P10766493T0000 |15 26|replicationComparison 
P10766493T0000 |41 51|complexityhosphatase
P10766493T0000 |55 62|harmonyd 5-nuc
P10766556T0000 |4 24|somatoform conundrum01606T0076 Compariso
P10766556T0000 |28 36|questionth alkal
P10766556T0000 |52 58|valves and 5
P10767091A0133 |16 26|ultrasoundomparison 
P10767091A0133 |28 32|IOUSth a
P10767091A0133 |61 68|attemptcleotid
P10767091A0133 |223 233|techniquesepleted ra
P10767091A0133 |175 193|image obliteration shown as a functi
P10767091A0133 |147 169|inter-user variability997A0472 When CSF [HCO
P10767091A0133 |87 99|difficultiesPharmacologi
P10767091A0133 |139 145|nature. P000
P10767251A1046 |171 180|pressures] is show
P10767251A1046 |62 69|sealantleotida
P10767251A1046 |121 136|lung resectionshyperbilirubine
P10767251A1046 |97 108|air leakagegic aspects
P10767251A1046 |46 54|Vivostatatases a
P10767251A1046 |29 34|studyh alk
P10767251A1046 |140 144|pigs P00
P10767251A1046 |0 11|CONCLUSIONSP00001606T0
P10767338T0000 |35 44|mutationsline phos
P10767338T0000 |72 74|CaP0
P10767338T0000 |14 21|disease Compar
P10767338T0000 |79 83|pump71T0
P10767338T0000 |48 54|ATP2C1ases a
P10767553A0100 |0 3|HexP00
P10767553A0100 |77 103|helix transcription factor8171T0000 Pharmacologic as
P10767553A0100 |124 136|Factor 3betaerbilirubine
P10767553A0100 |105 115|Hepatocytects of neo
P10767553A0100 |138 146|HNF3betaa. P0000
P10767553A0100 |35 40|liverline 
P10767560A0105 |34 50|characterizationaline phosphatas
P10767560A0105 |202 215|transcription PCO2 the dat
P10767560A0105 |149 174|mouse Pkr promoter region7A0472 When CSF [HCO3-] i
P10767560A0105 |90 104|mouse Pkr genermacologic asp
P10767560A0105 |6 15|extension606T0076 
P10767560A0105 |70 82|organizatione P00008171T
P10769144A0000 |51 69|consensus sequences and 5-nucleotida
P10769144A0000 |78 89|cis-element171T0000 Ph
P10769144A0000 |12 22|TGACGTCA-376 Compari
P10769144A0000 |4 7|CRE016
P10769144A0000 |118 133|gene expressional hyperbilirub
P10770041A0731 |51 56|rights and
P10770041A0731 |113 117|sizeeona
P10770041A0731 |76 88|kidney width08171T0000 P
P10770041A0731 |123 124|pp
P10770041A0731 |99 108|thicknessc aspects
P10770041A0731 |0 13|Kidney lengthP00001606T007
P10770065A0264 |68 89|lymph node dissectionase P00008171T0000 Ph
P10770065A0264 |26 32|T1N0M0with a
P10770065A0264 |13 18|stage6 Com
P10770065A0264 |91 92|Rm
P10770065A0264 |95 96|bl
P10770065A0264 |39 62|S2 sleeve segmentectomy phosphatases and 5-nuc
P10770471T0000 |0 11|BenztropineP00001606T0
P10770471T0000 |36 48|night sweatsine phosphat
P10771528T0036 |2 7|cause00016
P10771528T0036 |47 55|childrentases an
P10771528T0036 |11 19|increase076 Comp
P10771528T0036 |23 43|alkaline phosphataseon with alkaline pho
P10771709A0291 |32 40|patientslkaline 
P10771709A0291 |95 103|presencelogic as
P10771709A0291 |245 258|questionnairenger displace
P10771709A0291 |123 130|Q feverperbili
P10771709A0291 |107 110|IgMs o
P10771709A0291 |18 24|chargepariso
P10771709A0291 |190 207|Coxiella burnetiiction of CSF PCO2
P10771709A0291 |157 175|IgG antibody titerhen CSF [HCO3-] is
P10771709A0291 |179 186|phase Iwn as a
P10771709A0291 |142 149|disease0000899
P10771709A0291 |46 54|evidenceatases a
P10771709A0291 |73 87|seroconversion00008171T0000 
P10771709A0291 |64 71|Q feverotidase
P10771709A0291 |4 14|physicians01606T0076
P10772856X1492 |0 9|CopyrightP00001606
P10772856X1492 |15 29|Academic PressComparison wit
P10772977A0222 |19 27|movementarison w
P10772977A0222 |31 44|PVX CP mutantalkaline phos
P10772977A0222 |65 85|Nicotiana tabacum cvtidase P00008171T000
P10773351A0672 |152 160|elements472 When
P10773351A0672 |63 72|IFN-gammaeotidase 
P10773351A0672 |47 57|U937 cellstases and 
P10773351A0672 |13 28|CD86 expression6 Comparison wi
P10773351A0672 |32 43|stimulationlkaline pho
P10773351A0672 |86 94|presence Pharmac
P10773351A0672 |113 116|GASeon
P10773351A0672 |118 150|gamma-interferon activation siteal hyperbilirubinemia. P00008997
P10773351A0672 |0 9|InductionP00001606
P10773455A1268 |235 244|MEL cells are no l
P10773455A1268 |179 189|activationwn as a fu
P10773455A1268 |43 48|sitessphat
P10773455A1268 |315 320|ALAS2y gre
P10773455A1268 |79 85|region71T000
P10773455A1268 |123 143|mouse ALAS2 promoterperbilirubinemia. P0
P10773455A1268 |113 115|bpeo
P10773455A1268 |261 271|importancehen compar
P10773455A1268 |296 307|specificityhave a sign
P10773455A1268 |337 347|activation+/- 0.23 v
P10773455A1268 |216 231|differentiation of K-depleted 
P10773458A0000 |0 7|SNAP-23P000016
P10773458A0000 |53 72|vesicle traffickingand 5-nucleotidase 
P10773458A0000 |27 31|roleith 
P10773458A0000 |39 49|regulation phosphata
P10773458A0000 |86 91|cells Phar
P10773667A0351 |87 88|%P
P10773667A0351 |65 76|yeast NHP6Atidase P000
P10773667A0351 |23 37|HMG20 proteinson with alkali
P10773667A0351 |80 81|%1
P10773667A0351 |4 14|HMG domain01606T0076
P10773951A0000 |17 18|Am
P10773951A0000 |92 108|O group husbandsacologic aspects
P10773951A0000 |63 78|O group motherseotidase P00008
P10773951A0000 |28 45|B antibody statusth alkaline phosp
P10773951A0000 |8 11|IgG6T0
P10773951A0000 |0 3|IgMP00
P10775038A0142 |51 61|cell cycles and 5-nu
P10775038A0142 |28 43|Wee1 regulationth alkaline pho
P10775038A0142 |124 131|proteinerbilir
P10775038A0142 |63 68|yeasteotid
P10775038A0142 |132 133|sb
P10775038A0142 |6 13|attempt606T007
P10775038A0142 |80 89|screening1T0000 Ph
P10775267A0363 |170 180|pre-B-cell-] is show
P10775267A0363 |120 123|BMT hy
P10775267A0363 |125 130|modelrbili
P10775267A0363 |27 30|T/Tith
P10775267A0363 |11 23|transduction076 Comparis
P10775267A0363 |195 203|lymphoma of CSF 
P10775267A0363 |31 32|La
P10775267A0363 |96 118|bone marrow transplantogic aspects of neonat
P10775267A0363 |144 145|F0
P10775267A0363 |76 83|disease08171T0
P10775267A0363 |140 143|T/T P0
P10775267A0363 |156 168|long-latencyWhen CSF [HC
P10775585A0754 |205 219|kinase pathwayO2 the data of
P10775585A0754 |26 32|P70/S2with a
P10775585A0754 |122 138|signaling eventsyperbilirubinemi
P10775585A0754 |200 203|MAPSF 
P10775585A0754 |191 198|proteintion of
P10775585A0754 |53 66|NIH 3T3 cellsand 5-nucleot
P10775585A0754 |0 14|Ab-MLV strainsP00001606T0076
P10775585A0754 |102 110|capacityspects o
P10775623A0120 |4 15|codon usage01606T0076 
P10775623A0120 |61 70|env genescleotidas
P10775623A0120 |47 50|gagtas
P10775623A0120 |52 55|pol an
P10777217A0536 |118 126|residuesal hyper
P10777217A0536 |109 116|p73betaof neon
P10777217A0536 |165 178|PIG3 promoter[HCO3-] is sh
P10777217A0536 |65 73|contrasttidase P
P10777217A0536 |77 80|p53817
P10777217A0536 |43 56|PIG3 promotersphatases and
P10777217A0536 |99 105|domainc aspe
P10777217A0536 |4 23|p53-homolog p73beta01606T0076 Comparis
P10777499A0883 |0 7|ResultsP000016
P10777499A0883 |111 112|B 
P10777499A0883 |92 104|phytochromesacologic asp
P10777499A0883 |79 86|signals71T0000
P10777499A0883 |66 69|DE1ida
P10777499A0883 |23 29|assayson wit
P10777499A0883 |42 49|mutantsosphata
P10777499A0883 |175 182|element shown 
P10777499A0883 |138 145|elementa. P000
P10777586A1022 |0 22|Co-immunoprecipitationP00001606T0076 Compari
P10777586A1022 |66 69|Sp1ida
P10777586A1022 |247 264|band shift assayser displaced when
P10777586A1022 |27 54|DNA affinity chromatographyith alkaline phosphatases a
P10777586A1022 |91 97|ZBP-89macolo
P10777586A1022 |223 227|HeLaeple
P10777586A1022 |116 132|silencer elementatal hyperbiliru
P10777586A1022 |156 163|complexWhen CS
P10777586A1022 |236 243|extractare no 
P10777586A1022 |170 178|mobility-] is sh
P10777669A0582 |4 15|ZNF274 gene01606T0076 
P10777669A0582 |94 104|RH mappingologic asp
P10777669A0582 |36 49|marker RP S28ine phosphata
P10777669A0582 |65 89|chromosome 19qter regiontidase P00008171T0000 Ph
P10778740A1493 |102 110|activityspects o
P10778740A1493 |167 172|pho85CO3-]
P10778740A1493 |15 31|Cdk2 truncationsComparison with 
P10778740A1493 |191 196|locustion 
P10778740A1493 |174 178|HIS3s sh
P10778740A1493 |131 137|regionubinem
P10778740A1493 |71 78|strains P00008
P10778740A1493 |118 123|pho85al hy
P10778757A0000 |186 191|INCW2 func
P10778757A0000 |94 100|alleleologic
P10778757A0000 |165 184|cell wall invertase[HCO3-] is shown as
P10778757A0000 |120 123|Mn1 hy
P10778757A0000 |125 135|seed locusrbilirubin
P10778757A0000 |108 118|Miniature1 of neonat
P10778757A0000 |57 63|mutant5-nucl
P10778757A0000 |65 71|mn1-89tidase
P10778757A0000 |32 38|naturelkalin
P10779313A1842 |49 64|Xenopus oocytesses and 5-nucle
P10779313A1842 |209 213|betahe d
P10779313A1842 |121 134|GIRK channelshyperbilirubi
P10779313A1842 |141 148|pathwayP000089
P10779313A1842 |82 93|stimulation0000 Pharma
P10779313A1842 |177 192|phosphorylationhown as a funct
P10779313A1842 |216 218|AR o
P10779313A1842 |33 41|myocyteskaline p
P10779329T0000 |0 4|SlapP000
P10779329T0000 |26 29|Srcwit
P10779329T0000 |40 48|functionphosphat
P10779329T0000 |81 104|cell morphology changesT0000 Pharmacologic asp
P10779352T0000 |0 14|IdentificationP00001606T0076
P10779352T0000 |26 38|E2F3 productwith alkalin
P10779352T0000 |91 101|repressionmacologic 
P10779352T0000 |105 116|Rb proteinscts of neon
P10779352T0000 |76 87|specificity08171T0000 
P10779352T0000 |50 59|mechanismes and 5-
P10779508A0452 |50 54|SFREes a
P10779508A0452 |11 43|footprinting protection analysis076 Comparison with alkaline pho
P10779508A0452 |89 139|glutathione S-transferase-ERRalpha1 fusion proteinarmacologic aspects of neonatal hyperbilirubinemia
P10779508A0452 |59 70|ERE regionsnucleotidas
P10779508A0452 |3 8|DNase00160
P10779508A0897 |32 37|SRC1alkali
P10779508A0897 |41 46|GRIP1hosph
P10779508A0897 |99 107|activityc aspect
P10779508A0897 |19 30|coactivatorarison with
P10779508T0000 |0 8|EstrogenP0000160
P10779508T0000 |58 69|coactivator-nucleotida
P10779508T0000 |26 40|receptor alphawith alkaline 
P10779508T0000 |143 159|lactoferrin gene0008997A0472 Whe
P10779508T0000 |103 129|estrogen response elementspects of neonatal hyperbil
P10780018A0539 |19 25|modelsarison
P10780018A0539 |44 49|agingphata
P10780018A0539 |58 71|response time-nucleotidase
P10780018A0539 |33 40|effectskaline 
P10780518A1270 |34 50|protein functionaline phosphatas
P10780518A1270 |67 78|examinationdase P00008
P10780518A1270 |4 11|effects01606T0
P10780518A1270 |21 30|mutationsison with
P10780764A0722 |139 144|range. P00
P10780764A0722 |77 81|PM108171
P10780764A0722 |11 17|levels076 Co
P10780764A0722 |91 97|micrommacolo
P10780764A0722 |60 69|diametersucleotida
P10780764A0722 |21 30|particlesison with
P10780764A0722 |99 102|PM2c a
P10780764A0722 |159 164|x m-3n CSF
P10780764A0722 |38 39|%e
P10780764A0722 |116 121|rangeatal 
P10780883T0000 |119 125|effectl hype
P10780883T0000 |28 39|herpesvirusth alkaline
P10780883T0000 |83 93|resistance000 Pharma
P10780883T0000 |129 145|interferon-alphairubinemia. P000
P10780883T0000 |46 56|interferonatases and
P10780883T0000 |0 6|KaposiP00001
P10780883T0000 |68 74|factorase P0
P10781109T0000 |70 90|Arabidopsis thalianae P00008171T0000 Pha
P10781109T0000 |31 43|interferencealkaline pho
P10781109T0000 |63 66|RNAeot
P10781423A0993 |0 10|ComparisonP00001606T
P10781423A0993 |40 42|bpph
P10781423A0993 |14 23|sequences Comparis
P10781423A0993 |151 156|TTF-10472 
P10781423A0993 |54 77|consensus binding sitesnd 5-nucleotidase P0000
P10781423A0993 |86 149|homeodomain transcription factor thyroid transcription factor-1 Pharmacologic aspects of neonatal hyperbilirubinemia. P0000899
P10781541A1063 |115 119|rolenata
P10781541A1063 |26 35|sequenceswith alka
P10781541A1063 |74 83|promoters0008171T0
P10781541A1063 |197 206|promotersf CSF PCO
P10781541A1063 |59 65|regionnucleo
P10781541A1063 |130 139|sequencesrubinemia
P10781541A1063 |172 185|transcription is shown as 
P10781541A1063 |158 168|regulationen CSF [HC
P10781552A0000 |0 6|PurpleP00001
P10781552A0000 |121 132|respirationhyperbiliru
P10781552A0000 |105 119|photosynthesiscts of neonata
P10781552A0000 |143 152|oxidation0008997A0
P10781552A0000 |66 72|energyidase 
P10781552A0000 |22 30|bacteriason with
P10781552A0000 |86 93|sources Pharma
P10781552A0000 |138 139|Ha
P10781604A0827 |3 11|analysis001606T0
P10781604A0827 |107 121|Rsp5 WW domains of neonatal 
P10781604A0827 |123 131|Rsp5 WW2perbilir
P10781604A0827 |166 172|assaysHCO3-]
P10781604A0827 |149 154|yeast7A047
P10781604A0827 |25 33|peptides with al
P10781604A0827 |53 65|CTD sequenceand 5-nucleo
P10781611A1023 |33 44|macrophageskaline phos
P10781611A1023 |13 17|bone6 Co
P10781611A1023 |157 161|micehen 
P10781611A1023 |112 122|comparisonneonatal h
P10781611A1023 |130 141|macrophagesrubinemia. 
P10781611A1023 |64 68|miceotid
P10781611A1023 |98 108|efficiencyic aspects
P10781990A0455 |85 105|hyperintense lesions0 Pharmacologic aspe
P10781990A0455 |12 15|MRI76 
P10781990A0455 |42 45|dayosp
P10781990A0455 |113 128|globus palliduseonatal hyperbi
P10782640A0444 |119 130|astigmatisml hyperbili
P10782640A0444 |61 84|CM300 FEG/UT microscopecleotidase P00008171T00
P10782640A0444 |90 100|correctionrmacologic
P10782640A0444 |4 10|method01606T
P10782640A0444 |35 55|aberration constantsline phosphatases an
P10782989A0575 |137 155|DNA binding domainia. P00008997A0472
P10782989A0575 |173 184|amino acidsis shown as
P10782989A0575 |78 96|DNA binding domain171T0000 Pharmacol
P10782989A0575 |104 124|amino acid sequencesects of neonatal hyp
P10782989A0575 |39 47|presence phospha
P10782989A0575 |4 15|interaction01606T0076 
P10784367A0133 |0 6|METHODP00001
P10784367A0133 |145 153|subjects08997A04
P10784367A0133 |12 18|sample76 Com
P10784367A0133 |209 217|patientshe data 
P10784367A0133 |192 197|studyion o
P10784367A0133 |169 178|disorders3-] is sh
P10784367A0133 |117 122|studytal h
P10784367A0133 |22 30|subjectsson with
P10784367A0133 |237 246|disordersre no lon
P10784367A0133 |50 86|Suffolk County Mental Health Projectes and 5-nucleotidase P00008171T0000
P10784393A0000 |0 16|Marrow dysplasiaP00001606T0076 C
P10784393A0000 |28 42|characteristicth alkaline ph
P10784393A0000 |121 130|cytopeniahyperbili
P10784393A0000 |76 84|syndrome08171T00
P10784393A0000 |147 156|anomalies997A0472 
P10784393A0000 |46 54|patientsatases a
P10784393A0000 |86 89|MDS Ph
P10784393A0000 |103 119|marrow blastosispects of neonata
P10785294A0720 |65 77|restorationstidase P0000
P10785294A0720 |28 41|inlays/onlaysth alkaline p
P10785294A0720 |133 148|resin compositeinemia. P000089
P10785294A0720 |109 113|onesof n
P10785668A0000 |175 185|ecologists shown as 
P10785668A0000 |109 116|subjectof neon
P10785668A0000 |133 141|researchinemia. 
P10785668A0000 |60 69|pathogensucleotida
P10785668A0000 |45 55|herbivoreshatases an
P10785668A0000 |36 41|rangeine p
P10785668A0000 |22 28|attackson wi
P10785668A0000 |160 170|biologists CSF [HCO3
P10785668A0000 |96 101|fieldogic 
P10785668A0000 |4 10|plants01606T
P10785880A0947 |0 10|CONCLUSIONP00001606T
P10785880A0947 |107 112|classs of 
P10785880A0947 |47 60|complicationstases and 5-n
P10785880A0947 |90 98|patientsrmacolog
P10785880A0947 |115 129|HELLP syndromenatal hyperbil
P10785880A0947 |16 27|probabilityomparison w
P10786671A0182 |169 174|hTERT3-] i
P10786671A0182 |63 73|expressioneotidase P
P10786671A0182 |135 145|telomeraseemia. P000
P10786671A0182 |91 98|subunitmacolog
P10786671A0182 |176 180|geneshow
P10786671A0182 |27 46|telomerase activityith alkaline phosph
P10786671A0182 |106 112|enzymets of 
P10786671A0182 |18 22|steppari
P10786671A0182 |154 167|transcriptase2 When CSF [H
P10786742A0670 |51 52|hs
P10786742A0670 |59 66|surgerynucleot
P10786742A0670 |7 20|control group06T0076 Compa
P10786742A0670 |22 38|platelet markersson with alkalin
P10787437A1616 |82 87|SRE-10000 
P10787437A1616 |13 20|element6 Compa
P10787437A1616 |37 61|transcription start sitene phosphatases and 5-nu
P10787804T0000 |0 4|AMDAP000
P10787804T0000 |11 16|paper076 C
P10787804T0000 |28 32|waysth a
P10787804T0000 |59 63|carenucl
P10787804T0000 |67 71|SNFsdase
P10788320A1034 |190 202|U4/U6 snRNPsction of CSF
P10788320A1034 |183 185|U5s 
P10788320A1034 |90 102|interactionsrmacologic a
P10788320A1034 |124 137|102kD proteinerbilirubinem
P10788320A1034 |26 38|TPR elementswith alkalin
P10788320A1034 |226 235|particleseted rats
P10788320A1034 |159 168|tri-snRNPn CSF [HC
P10788320A1034 |6 14|proteins606T0076
P10788476A0891 |0 10|AntibodiesP00001606T
P10788476A0891 |143 163|stomatitis G protein0008997A0472 When CS
P10788476A0891 |181 191|cell assay as a func
P10788476A0891 |90 108|ER-Golgi transportrmacologic aspects
P10788476A0891 |39 46|portion phosph
P10788476A0891 |50 77|Sec31A co-precipitate Sec13es and 5-nucleotidase P0000
P10788480T0000 |0 10|RegulationP00001606T
P10788480T0000 |56 85|protein gene expression links 5-nucleotidase P00008171T000
P10788480T0000 |131 141|drosophilaubinemia. 
P10788480T0000 |112 127|DNA replicationneonatal hyperb
P10790390X0000 |305 320|gene expressiongnificantly gre
P10790390X0000 |255 280|gypsy insulator sequencesaced when compared to con
P10790390X0000 |187 201|gene silencingfunction of CS
P10790390X0000 |81 85|mdg4T000
P10790390X0000 |157 164|varietyhen CSF
P10790390X0000 |22 32|complexityson with a
P10790390X0000 |127 128|Ei
P10790390X0000 |244 251|controlonger d
P10790390X0000 |129 132|variru
P10790390X0000 |282 292|regulationols but st
P10790390X0000 |40 80|position effect variegation modifier modphosphatases and 5-nucleotidase P0000817
P10790390X0000 |106 110|mdg4ts o
P10790390X0000 |133 138|3-93Dinemi
P10790390X0000 |168 177|processesO3-] is s
P10790390X0000 |234 237|PEVs a
P10790390X0000 |337 347|cell death+/- 0.23 v
P10790390X0000 |205 232|position effect variegationO2 the data of K-depleted r
P10790390X0000 |102 105|modspe
P10791251A0110 |59 68|functionsnucleotid
P10791251A0110 |90 96|humansrmacol
P10791251A0110 |41 47|thingshospha
P10791251A0110 |25 30|kinds with
P10791819A0771 |5 13|tendency1606T007
P10791819A0771 |123 132|selectionperbiliru
P10791819A0771 |72 88|asparagus genomeP00008171T0000 P
P10791819A0771 |146 152|codons8997A0
P10791819A0771 |42 64|nucleotide compositionosphatases and 5-nucle
P10791901A0609 |68 90|MRP1-PG13 supernatantsase P00008171T0000 Pha
P10791901A0609 |143 144|%0
P10791901A0609 |231 239|presencerats are
P10791901A0609 |148 165|target K562 cells97A0472 When CSF 
P10791901A0609 |35 49|cell line K562line phosphata
P10791901A0609 |114 123|MRP1 geneonatal hy
P10791901A0609 |277 286|etoposidecontrols 
P10791901A0609 |259 273|concentrations when compared
P10791901A0609 |0 12|TransductionP00001606T00
P10792583A0000 |0 10|RegulationP00001606T
P10792583A0000 |125 129|ACTHrbil
P10792583A0000 |148 158|adaptation97A0472 Wh
P10792583A0000 |162 168|stressSF [HC
P10792583A0000 |24 49|vasopressin V1b receptorsn with alkaline phosphata
P10792583A0000 |131 140|secretionubinemia.
P10792583A0000 |67 71|roledase
P10792583A0000 |116 123|hormoneatal hy
P10792718T0000 |0 14|IdentificationP00001606T0076
P10792718T0000 |88 97|regulatorharmacolo
P10792718T0000 |21 35|AfsA homologueison with alka
P10792718T0000 |37 41|BarXne p
P10792718T0000 |110 136|autoregulator biosynthesisf neonatal hyperbilirubine
P10792718T0000 |138 164|virginiamycin biosynthesisa. P00008997A0472 When CSF
P10792718T0000 |169 196|virginiamycin M1 resistance3-] is shown as a function 
P10793143A1533 |68 77|Abf1 ARS1ase P0000
P10793143A1533 |182 192|initiationas a funct
P10793143A1533 |104 111|resultsects of
P10793143A1533 |90 98|activityrmacolog
P10793143A1533 |142 150|activity00008997
P10793143A1533 |196 211|DNA replicationof CSF PCO2 the
P10793143A1533 |125 129|Cdc6rbil
P10793143A1533 |32 43|DNA bindinglkaline pho
P10793143A1533 |170 174|role-] i
P10793991A0569 |19 28|longevityarison wi
P10793991A0569 |109 121|telemedicineof neonatal 
P10793991A0569 |79 87|position71T0000 
P10793991A0569 |41 56|TIE researchershosphatases and
P10793991A0569 |36 39|Webine
P10793991A0569 |99 105|trendsc aspe
P10794405A0000 |153 155|H172
P10794405A0000 |104 108|stepects
P10794405A0000 |120 133|understanding hyperbilirub
P10794405A0000 |15 20|studyCompa
P10794405A0000 |159 168|chromatinn CSF [HC
P10794405A0000 |59 66|domainsnucleot
P10794405A0000 |24 32|peptidesn with a
P10794405A0000 |141 149|functionP0000899
P10794405A0000 |70 80|histone H1e P0000817
P10794936A0241 |170 171|%-
P10794936A0241 |246 247|%g
P10794936A0241 |27 34|MB/BacTith alk
P10794936A0241 |130 144|recovery ratesrubinemia. P00
P10794936A0241 |56 61|media 5-nu
P10794936A0241 |286 298|mycobacteriabut still ha
P10794936A0241 |191 214|M. tuberculosis complextion of CSF PCO2 the da
P10794936A0241 |36 40|MGITine 
P10794936A0241 |112 124|mycobacterianeonatal hyp
P10794936A0241 |4 18|recovery rates01606T0076 Com
P10794936A0241 |87 88|%P
P10795098A0253 |33 38|Crohnkalin
P10795098A0253 |73 83|phenomenon00008171T0
P10795098A0253 |41 48|diseasehosphat
P10795098A0253 |9 19|vasculitisT0076 Comp
P10796465A0373 |68 79|acupuncturease P000081
P10796465A0373 |112 120|symptomsneonatal
P10796465A0373 |89 95|asthmaarmaco
P10796465A0373 |55 61|trialsd 5-nu
P10796465A0373 |0 18|SELECTION CRITERIAP00001606T0076 Com
P10796486A0817 |0 18|SELECTION CRITERIAP00001606T0076 Com
P10796486A0817 |130 147|asthma medicationrubinemia. P00008
P10796486A0817 |79 86|therapy71T0000
P10796486A0817 |31 37|trialsalkali
P10796486A0817 |154 162|children2 When C
P10796486A0817 |48 56|childrenases and
P10796486A0817 |113 124|conjunctioneonatal hyp
P10796486A0817 |103 109|familypects 
P10796486A0817 |170 187|asthma medication-] is shown as a 
P10797125A0000 |68 84|core temperaturease P00008171T00
P10797125A0000 |298 306|exerciseve a sig
P10797125A0000 |124 138|sweating onseterbilirubinemi
P10797125A0000 |245 260|passive heatingnger displaced 
P10797125A0000 |265 274|degrees Ccompared 
P10797125A0000 |186 191|women func
P10797125A0000 |291 294|mintil
P10797125A0000 |159 167|estrogenn CSF [H
P10797125A0000 |93 119|core temperature thresholdcologic aspects of neonata
P10797125A0000 |212 226|degrees C restdata of K-depl
P10797125A0000 |313 323|degrees C.tly greate
P10797125A0000 |12 22|hypothesis76 Compari
P10797125A0000 |47 56|increasestases and
P10797125A0000 |202 204|yr P
P10797125A0000 |238 241|mine n
P10797586A0402 |98 105|bladderic aspe
P10797586A0402 |82 88|signal0000 P
P10797586A0402 |41 49|responsehosphata
P10797586A0402 |53 65|disturbancesand 5-nucleo
P10797586A0402 |4 10|models01606T
P10798607A1359 |35 42|killingline ph
P10798607A1359 |46 58|meningococciatases and 5
P10798607A1359 |144 152|immunity008997A0
P10798607A1359 |182 190|patientsas a fun
P10798607A1359 |89 94|assayarmac
P10798607A1359 |4 8|data0160
P10798607A1359 |100 121|antibody titer levels aspects of neonatal 
P10799501A1391 |86 101|SPRK activation Pharmacologic 
P10799501A1391 |58 69|environment-nucleotida
P10799501A1391 |105 110|Cdc42cts o
P10799501A1391 |6 13|studies606T007
P10799501A1391 |36 45|componentine phosp
P10799576A0196 |0 2|M.P0
P10799590A0431 |0 6|JkappaP00001
P10799590A0431 |125 138|transcriptionrbilirubinemi
P10799590A0431 |108 114|Jkappa of ne
P10799590A0431 |270 276|Jkappared to
P10799590A0431 |167 174|EBNA-3CCO3-] i
P10799590A0431 |192 199|EBNA-3Cion of 
P10799590A0431 |52 62|activation and 5-nuc
P10799590A0431 |213 226|transcriptionata of K-depl
P10799590A0431 |77 92|EBNA-3C protein8171T0000 Pharm
P10799590A0431 |19 24|sitesariso
P10799590A0431 |237 246|mechanismre no lon
P10799595A1454 |87 104|HPV-6 E1 promoterPharmacologic asp
P10799595A1454 |121 135|HPV life cyclehyperbilirubin
P10799595A1454 |45 55|regulatorshatases an
P10799595A1454 |11 14|YY1076
P10799595A1454 |19 22|CDPari
P10799863T0000 |116 125|MHC classatal hype
P10799863T0000 |128 148|antigen presentationlirubinemia. P000089
P10799863T0000 |11 19|cleavage076 Comp
P10799863T0000 |45 56|proteasomeshatases and
P10799863T0000 |23 40|metallopeptidaseson with alkaline 
P10799863T0000 |83 100|HIV-1 ENV epitope000 Pharmacologic
P10799879T0000 |0 7|CloningP000016
P10799879T0000 |12 28|characterization76 Comparison wi
P10799879T0000 |91 103|Src homologymacologic as
P10799879T0000 |131 148|T cell activationubinemia. P000089
P10799879T0000 |106 113|domainsts of n
P10799879T0000 |46 61|adaptor proteinatases and 5-nu
P10799879T0000 |67 86|pleckstrin homologydase P00008171T0000
P10799879T0000 |38 41|Lnke p
P10801244A0578 |0 15|Vancomycin dataP00001606T0076 
P10801244A0578 |66 71|modelidase
P10801244A0578 |77 80|use817
P10801244A0578 |84 101|NONMEM population00 Pharmacologic 
P10801244A0578 |118 126|softwareal hyper
P10801330A1714 |154 157|FAK2 W
P10801330A1714 |90 95|statermaco
P10801330A1714 |43 74|membrane cytoskeleton fractionssphatases and 5-nucleotidase P0
P10801330A1714 |9 12|CasT00
P10801330A1714 |31 38|cytosolalkalin
P10801330A1714 |127 147|platelet aggregationilirubinemia. P00008
P10801330A1714 |191 199|fractiontion of 
P10801482A0968 |18 21|p65par
P10801482A0968 |37 44|targetsne phos
P10801482A0968 |63 71|affinityeotidase
P10801482A0968 |91 99|residuesmacologi
P10801482A0968 |114 119|rolesonata
P10801482A0968 |141 155|kappaB targetsP00008997A0472
P10801809T0000 |34 53|yeast PHO8 promoteraline phosphatases 
P10801809T0000 |57 67|comparison5-nucleoti
P10801809T0000 |87 100|PHO5 promoterPharmacologic
P10801809T0000 |16 26|regulationomparison 
P10801860A0000 |136 141|acidsmia. 
P10801860A0000 |4 11|Siglecs01606T0
P10801860A0000 |93 99|sugarscologi
P10801860A0000 |47 82|immunoglobulin superfamily proteinstases and 5-nucleotidase P00008171T
P10801860A0000 |38 45|lectinse phosp
P10801860A0000 |18 27|subfamilyparison w
P10802669A1434 |51 61|similaritys and 5-nu
P10802669A1434 |83 86|A-T000
P10802669A1434 |91 94|NBSmac
P10802669A1434 |31 42|explanationalkaline ph
P10802669A1434 |65 74|phenotypetidase P0
P10802669A1434 |4 8|data0160
P10802909A0478 |0 11|PATIENTS ORP00001606T0
P10802909A0478 |56 64|criteria 5-nucle
P10802909A0478 |39 47|children phospha
P10802909A0478 |18 30|PARTICIPANTSparison with
P10804379T0001 |0 6|UpdateP00001
P10804379T0001 |25 35|infections with alka
P10804379T0001 |60 75|cytomegalovirusucleotidase P00
P10804379T0001 |52 55|HIV an
P10804379T0001 |39 50|hepatitis C phosphatas
P10805286A0233 |220 228|androgenK-deplet
P10805286A0233 |133 144|HepG2 cellsinemia. P00
P10805286A0233 |122 131|cell lineyperbilir
P10805286A0233 |210 216|effecte data
P10805286A0233 |165 188|rat PCI mRNA expression[HCO3-] is shown as a f
P10805286A0233 |15 20|studyCompa
P10805286A0233 |39 51|cis-elements phosphatase
P10805286A0233 |249 256|tissues displa
P10805286A0233 |232 235|ratats
P10805286A0233 |65 73|PCI genetidase P
P10805286A0233 |87 97|expressionPharmacolo
P10805286A0914 |16 35|PCI mRNA expressionomparison with alka
P10805286A0914 |56 62|organs 5-nuc
P10805286A0914 |142 161|PCI mRNA expression00008997A0472 When 
P10805286A0914 |7 12|study06T00
P10805286A0914 |126 134|androgenbilirubi
P10805286A0914 |80 92|rat PCI cDNA1T0000 Pharm
P10805286A0914 |116 122|effectatal h
P10805390A0340 |68 96|GaAs/AlGaAs heterostructuresase P00008171T0000 Pharmacol
P10805390A0340 |31 43|measurementsalkaline pho
P10805390A0340 |47 64|photoluminescencetases and 5-nucle
P10805390A0340 |18 29|performanceparison wit
P10805729A0987 |68 76|C strandase P000
P10805729A0987 |179 200|acid binding surfaceswn as a function of C
P10805729A0987 |95 99|DDP1logi
P10805729A0987 |120 130|KH domains hyperbili
P10805729A0987 |25 34|complexes with alk
P10805729A0987 |4 17|stoichiometry01606T0076 Co
P10805737T0000 |138 151|eIF5 functiona. P00008997A
P10805737T0000 |73 77|role0000
P10805737T0000 |121 125|eIF2hype
P10805737T0000 |105 117|beta subunitcts of neona
P10805737T0000 |66 70|eIF5idas
P10805737T0000 |130 134|eIF5rubi
P10805737T0000 |11 19|analysis076 Comp
P10805737T0000 |81 92|interactionT0000 Pharm
P10805737T0000 |33 62|translation initiation factorkaline phosphatases and 5-nuc
P10805738A0799 |102 112|expressionspects of 
P10805738A0799 |429 436|embryose optim
P10805738A0799 |52 56|MyoD and
P10805738A0799 |261 271|activationhen compar
P10805738A0799 |296 305|reportershave a si
P10805738A0799 |215 239|Gal4-MyoD fusion proteina of K-depleted rats are
P10805738A0799 |29 32|p38h a
P10805738A0799 |390 401|fibroblastso be an eff
P10805738A0799 |62 81|p38 kinase activityleotidase P00008171
P10805738A0799 |39 48|activator phosphat
P10805738A0799 |349 359|conversion P00010943
P10805738A0799 |132 137|genesbinem
P10805738A0799 |166 169|p38HCO
P10805738A0799 |153 162|induction72 When C
P10805738A0799 |201 209|activityF PCO2 t
P10805738A0799 |415 423|p38alphac drug w
P10805738A0799 |5 13|evidence1606T007
P10805738A0799 |309 313|MyoDican
P10805738A0799 |374 379|mousem thu
P10805739A0343 |64 78|eIF2B subunitsotidase P00008
P10805739A0343 |31 48|complex formationalkaline phosphat
P10805739A0343 |5 13|activity1606T007
P10805739A0640 |68 80|eIF2Bepsilonase P0000817
P10805739A0640 |164 168|eIF2 [HC
P10805739A0640 |134 142|activitynemia. P
P10805739A0640 |54 64|C terminusnd 5-nucle
P10805739A0640 |82 90|residues0000 Pha
P10805739A0640 |147 158|interaction997A0472 Wh
P10805739A0640 |4 12|analysis01606T00
P10805739A0640 |16 34|nonsense mutationsomparison with alk
P10805747A0633 |136 155|septin organizationmia. P00008997A0472
P10805747A0633 |61 68|kinasescleotid
P10805747A0633 |97 102|Kcc4pgic a
P10805747A0633 |126 132|effectbiliru
P10805747A0633 |13 22|mutations6 Compari
P10805747A0633 |3 11|contrast001606T0
P10805747A0633 |87 92|Hsl1pPharm
P10805823A1920 |102 108|strokespects
P10805823A1920 |88 98|preventionharmacolog
P10805823A1920 |73 79|pacing000081
P10805823A1920 |140 146|causes P0000
P10805823A1920 |112 117|deathneona
P10805823A1920 |25 31|pacing with 
P10805823A1920 |48 55|benefitases an
P10805823A1920 |0 11|CONCLUSIONSP00001606T0
P10807900A0933 |168 177|diagnosisO3-] is s
P10807900A0933 |6 20|non-cirrhotics606T0076 Compa
P10807900A0933 |37 55|vein visualisationne phosphatases an
P10807900A0933 |22 26|lackson 
P10807900A0933 |133 134|%i
P10807900A0933 |120 125|value hype
P10807900A0933 |81 94|% specificityT0000 Pharmac
P10807900A0933 |64 77|% sensitivityotidase P0000
P10807900A0933 |203 215|hypertensionPCO2 the dat
P10807900A0933 |98 99|%i
P10807900A0933 |155 160|value When
P10807903A0362 |0 5|D5/D1P0000
P10807903A0362 |20 22|CTri
P10807903A0362 |24 49|tail substitution mutantsn with alkaline phosphata
P10807903A0362 |214 238|cAMP accumulation assaysta of K-depleted rats ar
P10807903A0362 |62 72|rank orderleotidase 
P10807903A0362 |88 106|agonist affinitiesharmacologic aspec
P10807903A0362 |349 357|agonists P000109
P10807903A0362 |281 297|exhibit receptorrols but still h
P10807903A0362 |13 19|D5/D1D6 Comp
P10807903A0362 |259 271|D1 receptors when compar
P10807903A0362 |323 337|responsivenessr slope (1.21 
P10807903A0362 |6 8|CT60
P10807903A0362 |142 154|D1 receptors00008997A047
P10807903A0362 |76 83|potency08171T0
P10807903A0362 |311 319|activityantly gr
P10807903A0362 |175 189|ligand binding shown as a fu
P10809233A0606 |0 8|ModelingP0000160
P10809233A0606 |122 125|H11ype
P10809233A0606 |104 108|loopects
P10809233A0606 |61 68|absencecleotid
P10809233A0606 |114 116|H4on
P10809233A0606 |42 49|surfaceosphata
P10809233A0606 |72 75|H12P00
P10809233A0606 |86 94|residues Pharmac
P10809233A0606 |100 102|H3 a
P10810083A1283 |21 32|kinase geneison with a
P10810083A1283 |67 84|zinc finger motifdase P00008171T00
P10810294A0730 |0 15|Stat activationP00001606T0076 
P10810294A0730 |61 84|reporter gene inductioncleotidase P00008171T00
P10810294A0730 |31 33|GHal
P10810294A0730 |38 42|IL-6e ph
P10810294A0730 |19 27|responsearison w
P10810745A0677 |0 8|HFA 134aP0000160
P10810745A0677 |43 51|moisturesphatase
P10810745A0677 |61 72|environmentcleotidase 
P10810745A0677 |82 85|HFA000
P10810745A0677 |23 31|tendencyon with 
P10811079A0555 |119 120|%l
P10811079A0555 |128 145|epilepsy patientslirubinemia. P000
P10811079A0555 |90 112|vigabatrin monotherapyrmacologic aspects of 
P10811079A0555 |18 34|color perceptionparison with alk
P10811079A0555 |159 184|carbamazepine monotherapyn CSF [HCO3-] is shown as
P10811079A0555 |59 76|epilepsy patientsnucleotidase P000
P10811079A0555 |50 51|%e
P10811079A0555 |0 7|RESULTSP000016
P10811079A1277 |34 40|platesaline 
P10811079A1277 |63 69|groupseotida
P10811079A1277 |7 26|SPP2 screening test06T0076 Comparison 
P10811804A0000 |32 52|kinase phosphatase-3lkaline phosphatases
P10811804A0000 |27 30|MAPith
P10811804A0000 |151 154|ERK047
P10811804A0000 |156 167|MAP kinasesWhen CSF [H
P10811804A0000 |54 59|MKP-3nd 5-
P10811804A0000 |143 149|kinase000899
P10811804A0000 |18 25|proteinparison
P10811804A0000 |71 94|specificity phosphatase P00008171T0000 Pharmac
P10811804A0800 |35 43|peptidesline pho
P10811804A0800 |57 70|docking sites5-nucleotidas
P10811804A0800 |114 117|rskona
P10811804A0800 |82 105|target substrates Elk-10000 Pharmacologic aspe
P10811804A0800 |110 113|p90f n
P10811804A0800 |141 151|activationP00008997A
P10811804A0800 |155 160|MKP-3 When
P10811908A0938 |0 27|HPLC phosphopeptide mappingP00001606T0076 Comparison w
P10811908A0938 |98 102|NCLKic a
P10811908A0938 |129 132|I-1iru
P10811908A0938 |29 50|amino acid sequencingh alkaline phosphatas
P10811908A0938 |70 81|mutagenesise P00008171
P10811908A0938 |118 121|Seral 
P10812294X0000 |34 37|SBFali
P10812294X0000 |115 121|poniesnatal 
P10812294X0000 |142 152|ingredient00008997A0
P10812294X0000 |90 93|SBFrma
P10812294X0000 |49 60|feed intakeses and 5-n
P10812294X0000 |16 20|dietompa
P10814989T0000 |0 27|Hepatitis C virus infectionP00001606T0076 Comparison w
P10814989T0000 |52 60|diseases and 5-n
P10814989T0000 |83 88|study000 P
P10814989T0000 |64 70|Franceotidas
P10815410A0000 |49 70|neuroendocrine systemses and 5-nucleotidas
P10815410A0000 |94 103|increasesologic as
P10815410A0000 |11 17|system076 Co
P10815410A0000 |107 116|cytokiness of neon
P10815410A0000 |189 195|systemnction
P10815410A0000 |131 135|IL-6ubin
P10815410A0000 |125 129|IL-1rbil
P10815410A0000 |158 165|effectsen CSF 
P10815410A0000 |140 143|TNF P0
P10815807A1271 |119 131|T-cell linesl hyperbilir
P10815807A1271 |61 75|c-Myb promotercleotidase P00
P10815807A1271 |27 40|transcriptionith alkaline 
P10815807A1271 |100 106|HTLV-I aspec
P10817754T0000 |0 3|H19P00
P10817754T0000 |104 110|regionects o
P10817754T0000 |25 35|expression with alka
P10817754T0000 |8 12|Igf26T00
P10817754T0000 |123 126|H19per
P10817754T0000 |82 85|cis000
P10817754T0000 |65 69|waystida
P10819327T0000 |0 17|C. elegans KLP-11P00001606T0076 Co
P10819327T0000 |24 29|KAP-1n wit
P10819327T0000 |31 40|orthologsalkaline 
P10819327T0000 |75 114|mouse KIF3A/KIFB/KAP3 kinesin complexes008171T0000 Pharmacologic aspects of ne
P10819327T0000 |18 23|OSM-3paris
P10819327T0000 |48 69|sea urchin kinesin-IIases and 5-nucleotida
P10820829T0000 |0 10|FlavonoidsP00001606T
P10820829T0000 |16 36|Brosimum acutifoliumomparison with alkal
P10820904A0000 |0 10|BACKGROUNDP00001606T
P10820904A0000 |57 65|syndrome5-nucleo
P10820904A0000 |123 136|liver diseaseperbilirubine
P10820904A0000 |88 101|liver failureharmacologic 
P10820904A0000 |20 34|encephalopathyrison with alk
P10820904A0000 |156 167|anastomosisWhen CSF [H
P10821836A0842 |24 37|S transcriptsn with alkali
P10821836A0842 |74 93|sense S transcripts0008171T0000 Pharma
P10822117A1386 |114 125|informationonatal hype
P10822117A1386 |12 22|adjustment76 Compari
P10822117A1386 |135 149|subject-modelsemia. P0000899
P10822117A1386 |52 57|model and 
P10822117A1386 |83 95|observations000 Pharmaco
P10823630A1124 |119 129|predictionl hyperbil
P10823630A1124 |13 21|presence6 Compar
P10823630A1124 |78 87|parameter171T0000 
P10823630A1124 |25 35|effacement with alka
P10823837A1213 |33 37|ideakali
P10823837A1213 |249 257|alpha1-4 displac
P10823837A1213 |295 305|GPI anchor have a si
P10823837A1213 |43 60|YLL031c transferssphatases and 5-n
P10823837A1213 |193 198|Mcd4pon of
P10823837A1213 |134 139|groupnemia
P10823837A1213 |116 123|mannoseatal hy
P10823837A1213 |155 171|GPI lipid anchor When CSF [HCO3-
P10823837A1213 |279 287|mannosesntrols b
P10823837A1213 |65 86|ethanolaminephosphatetidase P00008171T0000
P10823837A1213 |203 239|Gpi7p transfer ethanolaminephosphatePCO2 the data of K-depleted rats are
P10823837A1213 |175 183|proteins shown a
P10823837A1213 |4 8|data0160
P10823961A0664 |32 40|CBP/p300lkaline 
P10823961A0664 |165 177|interactions[HCO3-] is s
P10823961A0664 |151 156|means0472 
P10823961A0664 |134 147|transcriptionnemia. P00008
P10823961A0664 |45 52|DRIP130hatases
P10823961A0664 |4 14|C terminus01606T0076
P10823961A0664 |56 65|component 5-nucleo
P10823961A0664 |73 94|DRIP/TRAP/ARC complex00008171T0000 Pharmac
P10823961A0664 |18 22|TRBPpari
P10823961A0664 |116 120|TRBPatal
P10824485A0393 |4 12|patients01606T00
P10824485A0393 |128 137|illnesseslirubinem
P10824485A0393 |72 91|T lymphocyte countsP00008171T0000 Phar
P10824485A0393 |46 53|diseaseatases 
P10824485A0393 |67 70|CD4das
P10824485A0393 |114 118|AIDSonat
P10824958A1109 |68 70|COas
P10824958A1109 |145 148|age089
P10824958A1109 |47 50|usetas
P10824958A1109 |104 120|broiler breedersects of neonatal
P10824958A1109 |18 24|energypariso
P10824958A1109 |96 100|PSHLogic
P10824958A1109 |83 85|PF00
P10824958A1109 |139 141|wk. 
P10824958A1109 |35 38|PABlin
P10825000A1245 |32 40|Coquellelkaline 
P10825000A1245 |4 28|gene amplification model01606T0076 Comparison wi
P10825200T0000 |102 106|Jak3spec
P10825200T0000 |167 182|STAT activationCO3-] is shown 
P10825200T0000 |133 136|Lckine
P10825200T0000 |73 83|activation00008171T0
P10825200T0000 |62 71|signalingleotidase
P10825200T0000 |13 37|protein tyrosine kinases6 Comparison with alkali
P10825200T0000 |125 128|Sykrbi
P10825200T0000 |56 60|IL-2 5-n
P10825200T0000 |41 54|interleukin-2hosphatases a
P10825200T0000 |87 90|sykPha
P10825200T0000 |0 9|HierarchyP00001606
P10825293T0000 |68 90|cell contact formationase P00008171T0000 Pha
P10825293T0000 |92 104|contributionacologic asp
P10825293T0000 |12 18|dimers76 Com
P10825293T0000 |22 43|N-cadherin-Fc chimerason with alkaline pho
P10825293T0000 |139 146|signals. P0000
P10825294A0473 |186 200|AML C terminus function of C
P10825294A0473 |89 102|BSP promotersarmacologic a
P10825294A0473 |13 24|OC promoter6 Compariso
P10825294A0473 |135 145|mechanismsemia. P000
P10825294A0473 |76 79|MDR081
P10825294A0473 |43 53|C terminussphatases 
P10825294A0473 |245 263|pentapeptide VWRPYnger displaced whe
P10825294A0473 |64 70|mannerotidas
P10825294A0473 |81 84|LTRT00
P10826861A0000 |187 194|failurefunctio
P10826861A0000 |165 175|neuropathy[HCO3-] is
P10826861A0000 |134 145|amyloidosisnemia. P000
P10826861A0000 |15 38|immunoglobulin productsComparison with alkalin
P10826861A0000 |93 107|manifestationscologic aspect
P10826861A0000 |42 62|plasma cell neoplasmosphatases and 5-nuc
P10826861A0000 |147 163|cryoglobulinemia997A0472 When CS
P10826861A0000 |82 89|variety0000 Ph
P10826861A0000 |118 132|hyperviscosityal hyperbiliru
P10826946A1198 |0 13|InvestigationP00001606T007
P10826946A1198 |79 84|gp12071T00
P10826946A1198 |106 115|gp120 SAgts of neo
P10826946A1198 |164 167|Igs [H
P10826946A1198 |45 56|interactionhatases and
P10826946A1198 |141 147|subsetP00008
P10826946A1198 |157 158|Vh
P10826946A1198 |159 160|Hn
P10826946A1198 |71 74|Igs P0
P10826946A1198 |32 37|basislkali
P10827885T0059 |33 38|trialkalin
P10827952A0158 |83 102|bromodomain modules000 Pharmacologic a
P10827952A0158 |148 167|histone H4 peptides97A0472 When CSF [H
P10827952A0158 |45 52|subunithatases
P10827952A0158 |56 61|TFIID 5-nu
P10827952A0158 |23 31|TAFII250on with 
P10828022A0877 |0 20|Endostatin treatmentP00001606T0076 Compa
P10828022A0877 |28 35|minutesth alka
P10828022A0877 |42 47|hoursospha
P10828022A0877 |92 101|formationacologic 
P10828022A0877 |56 80|tyrosine phosphorylation 5-nucleotidase P0000817
P10828022A0877 |84 87|Shb00 
P10828022A0877 |118 127|complexesal hyperb
P10828319A0342 |101 110|psoriasisaspects o
P10828319A0342 |22 32|vitamin D3son with a
P10828319A0342 |11 18|analogs076 Com
P10828319A0342 |61 67|numbercleoti
P10828319A0342 |71 77|trials P0000
P10828319A0342 |86 97|improvement Pharmacolo
P10828591A0080 |136 152|markers D11S1765mia. P00008997A0
P10828591A0080 |210 217|diseasee data 
P10828591A0080 |121 127|regionhyperb
P10828591A0080 |74 80|course000817
P10828591A0080 |99 113|transcript mapc aspects of n
P10828591A0080 |53 66|cDNA sequenceand 5-nucleot
P10828591A0080 |192 196|geneion 
P10828591A0080 |157 168|uteroglobinhen CSF [HC
P10828591A0080 |4 14|transcript01606T0076
P10828751A2258 |102 111|treatmentspects of
P10828751A2258 |46 56|managementatases and
P10828751A2258 |60 68|patientsucleotid
P10828751A2258 |27 33|futureith al
P10828751A2258 |9 18|challengeT0076 Com
P10829973T0000 |0 27|Iodine deficiency disordersP00001606T0076 Comparison w
P10829973T0000 |31 41|Bangladeshalkaline p
P10830395A0408 |4 21|network evolution01606T0076 Compar
P10830395A0408 |44 52|approachphatases
P10830395A0408 |66 77|Flory modelidase P0000
P10831972A0744 |119 127|controlsl hyperb
P10831972A0744 |69 82|endometriosisse P00008171T
P10831972A0744 |58 63|women-nucl
P10831972A0744 |90 99|treatmentrmacologi
P10831972A0744 |0 7|RESULTSP000016
P10831972A0744 |17 28|CD23 levelsmparison wi
P10831972A1091 |119 126|danazoll hyper
P10831972A1091 |70 81|CD23 levelse P00008171
P10831972A1091 |38 51|endometriosise phosphatase
P10831972A1091 |130 158|leuprolide acetate injectionrubinemia. P00008997A0472 Wh
P10831972A1091 |16 24|findingsompariso
P10831972A1091 |0 10|CONCLUSIONP00001606T
P10833461A0603 |51 54|PACs a
P10833461A0603 |56 63|library 5-nucl
P10833461A0603 |148 154|length97A047
P10833461A0603 |89 108|length UGT2B7 probearmacologic aspects
P10833461A0603 |39 49|chromosome phosphata
P10833461A0603 |142 144|kb00
P10833461A0603 |24 27|P-1n w
P10833461A0603 |115 120|clonenatal
P10833461A0603 |16 20|geneompa
P10833486A0598 |0 3|AgeP00
P10833486A0598 |94 100|mmol/Lologic
P10833486A0598 |62 64|ORle
P10833486A0598 |149 151|2N7A
P10833486A0598 |30 32|OR a
P10833486A0598 |72 85|triglyceridesP00008171T000
P10833486A0598 |153 155|OR72
P10833486A0598 |18 28|odds ratioparison wi
P10833486A0598 |114 138|alanine aminotransferaseonatal hyperbilirubinemi
P10833486A0598 |53 57|kg/mand 
P10833486A0598 |140 143|ALT P0
P10833486A0598 |42 45|BMIosp
P10833486A0598 |11 16|years076 C
P10833486A0598 |204 212|fibrosisCO2 the 
P10833486A0598 |102 104|ORsp
P10834707A1533 |84 91|sorbent00 Phar
P10834707A1533 |25 32|amounts with a
P10834707A1533 |110 124|treatment timef neonatal hyp
P10834707A1533 |36 62|platelet activating factorine phosphatases and 5-nuc
P10834781A0693 |21 26|groupison 
P10834781A0693 |134 140|periodnemia.
P10834781A0693 |60 75|residence timesucleotidase P00
P10834781A0693 |93 109|plasma clearancecologic aspects 
P10834781A0693 |77 81|MRTs8171
P10834781A0693 |165 170|group[HCO3
P10834781A0693 |172 173|P 
P10834781A0693 |113 122|lidocaineeonatal h
P10835355A0225 |174 178|SSA3s sh
P10835355A0225 |23 47|zinc finger protein Gis1on with alkaline phospha
P10835355A0225 |93 110|rim15Delta defectcologic aspects o
P10835355A0225 |75 85|suppressor008171T000
P10835355A0225 |158 170|derepressionen CSF [HCO3
P10835355A0225 |114 122|nutrientonatal h
P10835485A0941 |119 138|amino acid residuesl hyperbilirubinemi
P10835485A0941 |178 183|mouseown a
P10835485A0941 |147 154|factors997A047
P10835485A0941 |15 18|SH3Com
P10835485A0941 |20 27|segmentrison w
P10835485A0941 |53 61|contrastand 5-nu
P10835485A0941 |159 165|cattlen CSF 
P10835485A0941 |86 103|sequence identity Pharmacologic as
P10835485A0941 |35 48|linker domainline phosphat
P10835732A0911 |3 14|differences001606T0076
P10835732A0911 |78 85|aymaras171T000
P10835732A0911 |24 42|cholesterol levelsn with alkaline ph
P10835732A0911 |65 73|mapuchestidase P
P10836542A0363 |54 67|UV-A wavebandnd 5-nucleoti
P10836542A0363 |77 79|nm81
P10836542A0363 |8 9|%6
P10836542A0363 |23 34|UV exposureon with alk
P10836786A0516 |156 169|RNase MRP RNAWhen CSF [HCO
P10836786A0516 |41 53|RNA subunitshosphatases 
P10836786A0516 |29 33|roleh al
P10836786A0516 |135 139|MRP3emia
P10836786A0516 |144 146|P300
P10836786A0516 |77 98|substrate specificity8171T0000 Pharmacolog
P10836786A0516 |57 72|enzyme function5-nucleotidase 
P10836786A0516 |174 185|RNase P RNAs shown as 
P10836786A0516 |115 133|hairpin structuresnatal hyperbilirub
P10837126A1004 |54 70|signaling factornd 5-nucleotidas
P10837126A1004 |44 50|Xwnt-8phatas
P10837126A1004 |108 120|marker genes of neonatal
P10837126A1004 |94 104|repertoireologic asp
P10837126A1004 |29 40|pMesogenin1h alkaline 
P10837126A1004 |144 153|phenotype008997A04
P10837126A1004 |6 11|genes606T0
P10838139A1447 |16 28|Ha-ras codonomparison wi
P10838139A1447 |80 86|tumors1T0000
P10838139A1447 |32 41|mutationslkaline p
P10838399A0525 |68 80|bone diseasease P0000817
P10838399A0525 |15 22|PET FDGCompari
P10838399A0525 |39 53|lung infection phosphatases 
P10838399A0525 |86 109|reconstruction artifact Pharmacologic aspects 
P10838531A0675 |0 12|Tumor stagesP00001606T00
P10838531A0675 |38 42|IIIAe ph
P10838531A0675 |65 66|%t
P10838531A0675 |23 28|T3 N0on wi
P10838531A0675 |48 49|%a
P10838531A0675 |18 21|IIBpar
P10838531A0675 |55 59|IIIBd 5-
P10838531A0675 |70 78|patientse P00008
P10838531A0675 |35 36|%l
P10839470A1148 |84 92|exercise00 Pharm
P10839470A1148 |11 21|comparison076 Compar
P10839470A1148 |133 139|Malaysinemia
P10839470A1148 |105 121|measure analysiscts of neonatal 
P10839470A1148 |201 202|pF
P10839470A1148 |64 70|supineotidas
P10839470A1148 |25 46|percentage reductions with alkaline phosph
P10839470A1148 |169 175|change3-] is
P10839470A1148 |50 60|heart ratees and 5-n
P10839547A0978 |20 25|modelrison
P10839547A0978 |56 71|DNA methylation 5-nucleotidase
P10839547A0978 |27 39|CTCF bindingith alkaline
P10839593A0000 |51 65|amphotericin Bs and 5-nucleo
P10839593A0000 |97 106|treatmentgic aspec
P10839593A0000 |110 121|fluconazolef neonatal 
P10839593A0000 |41 47|safetyhospha
P10839593A0000 |166 179|HIV infectionHCO3-] is sho
P10839593A0000 |28 36|efficacyth alkal
P10839593A0000 |138 149|candidiasisa. P0000899
P10839593A0000 |71 81|suspension P00008171
P10839593A0000 |83 87|ABOS000 
P10839593A0000 |153 160|persons72 When
P10839593A0000 |0 9|OBJECTIVEP00001606
P10840001A0188 |0 21|Mucin gene expressionP00001606T0076 Compar
P10840001A0188 |94 101|cancersologic 
P10840001A0188 |126 131|tractbilir
P10840001A0188 |70 78|diseasese P00008
P10841537A0669 |37 41|RPB5ne p
P10841537A0669 |60 72|interactionsucleotidase 
P10841537A0669 |26 33|regionswith al
P10841537A0669 |130 140|structuresrubinemia.
P10841593A0780 |32 43|% reductionlkaline pho
P10841593A0780 |108 124|nicotine patches of neonatal hyp
P10841593A0780 |47 68|cigarette consumptiontases and 5-nucleotid
P10841593A0780 |92 104|availabilityacologic asp
P10841593A0780 |4 9|model01606
P10841601T0000 |0 11|Paper alertP00001606T0
P10843716A0406 |84 90|mastin00 Pha
P10843716A0406 |128 134|humanslirubi
P10843716A0406 |94 98|geneolog
P10843716A0406 |61 72|pseudogenescleotidase 
P10843716A0406 |112 116|dogsneon
P10843716A0406 |4 18|tryptase locus01606T0076 Com
P10843810A0802 |64 72|homologyotidase 
P10843810A0802 |13 17|part6 Co
P10843810A0802 |120 124|gene hyp
P10843810A0802 |161 170|directionCSF [HCO3
P10843810A0802 |40 45|clonephosp
P10843810A0802 |79 83|exon71T0
P10843810A0802 |196 199|LTRof 
P10843810A0802 |97 117|tyrosine phosphatasegic aspects of neona
P10845522A0000 |68 101|99mTc-sestamibi scintimammographyase P00008171T0000 Pharmacologic 
P10845522A0000 |124 134|evaluationerbilirubi
P10845522A0000 |193 204|mammographyon of CSF P
P10845522A0000 |106 116|sonographyts of neon
P10845522A0000 |138 152|breast lesionsa. P00008997A0
P10845522A0000 |217 228|examinationof K-deplet
P10845522A0000 |59 64|rolesnucle
P10845522A0000 |16 21|studyompar
P10845522A0000 |0 9|OBJECTIVEP00001606
P10846054A0573 |170 173|RNA-] 
P10846054A0573 |11 19|analyses076 Comp
P10846054A0573 |89 93|ORFsarma
P10846054A0573 |46 52|codonsatases
P10846054A0573 |192 200|proteinsion of C
P10846054A0573 |215 235|LIYV RNA replicationa of K-depleted rats
P10846054A0573 |147 150|RNA997
P10846054A0573 |109 121|accumulationof neonatal 
P10846054A0573 |125 141|progeny LIYV RNArbilirubinemia. 
P10846054A0573 |83 86|RNA000
P10846069T0000 |0 4|RoleP000
P10846069T0000 |8 10|NH6T
P10846069T0000 |115 126|replicationnatal hyper
P10846069T0000 |97 110|transcriptiongic aspects o
P10846069T0000 |67 91|parainfluenza virus typedase P00008171T0000 Phar
P10846069T0000 |33 40|domainskaline 
P10846069T0000 |48 57|P proteinases and 
P10848605T0000 |0 15|PhosphorylationP00001606T0076 
P10848605T0000 |122 132|activitiesyperbiliru
P10848605T0000 |62 82|juxtamembrane regionleotidase P00008171T
P10848605T0000 |44 57|kinase domainphatases and 
P10848605T0000 |19 36|tyrosine residuesarison with alkal
P10848605T0000 |136 149|Eph receptorsmia. P0000899
P10848848A0413 |0 7|RESULTSP000016
P10848848A0413 |9 17|FournierT0076 Co
P10848848A0413 |20 28|gangrenerison wi
P10848993A0000 |187 191|genefunc
P10848993A0000 |162 170|sequenceSF [HCO3
P10848993A0000 |242 245|amk lo
P10848993A0000 |209 240|serine/threonine protein kinasehe data of K-depleted rats are 
P10848993A0000 |73 78|mutAB00008
P10848993A0000 |30 38|vicinity alkalin
P10848993A0000 |110 140|Amycolatopsis mediterranei U32f neonatal hyperbilirubinemia.
P10848993A0000 |42 71|methylmalonyl-CoA mutase geneosphatases and 5-nucleotidase
P10848993A0000 |8 22|DNA sequencing6T0076 Compari
P10848993A0000 |155 160|clone When
P10848993A0000 |87 96|rifamycinPharmacol
P10850329A0248 |0 4|IL-2P000
P10850329A0248 |135 143|melanomaemia. P0
P10850329A0248 |31 40|treatmentalkaline 
P10850329A0248 |59 70|combinationnucleotidas
P10850329A0248 |92 102|biotherapyacologic a
P10850329A0248 |165 179|cell carcinoma[HCO3-] is sho
P10850329A0248 |76 88|chemotherapy08171T0000 P
P10850329A0248 |110 120|managementf neonatal
P10850453A0713 |102 111|TGF-beta1spects of
P10850453A0713 |10 20|expression0076 Compa
P10850453A0713 |193 215|V12Ha-Ras transfectionon of CSF PCO2 the dat
P10850453A0713 |132 152|TGF-beta1 inhibitionbinemia. P00008997A0
P10850453A0713 |62 67|Raf-1leoti
P10850453A0713 |115 122|TSU-Pr1natal h
P10850453A0713 |178 189|stimulationown as a fu
P10850453A0713 |92 98|effectacolog
P10850453A0713 |156 161|DU145When 
P10850453A0713 |34 40|Ha-Rasaline 
P10850453A1292 |118 134|growth advantageal hyperbilirubi
P10850453A1292 |67 94|Ras/MAPK pathway activationdase P00008171T0000 Pharmac
P10850453A1292 |148 168|TGF-beta1 production97A0472 When CSF [HC
P10850453A1292 |20 24|datariso
P10850453A1292 |38 57|prostate carcinomase phosphatases and 
P10850719A0680 |152 164|Jbeta12-RSSs472 When CSF
P10850719A0680 |134 147|Vbeta 23-RSSsnemia. P00008
P10850719A0680 |79 84|Vbeta71T00
P10850719A0680 |88 93|Jbetaharma
P10850719A0680 |31 52|DJbeta rearrangementsalkaline phosphatases
P10850719A0680 |117 130|compatibilitytal hyperbili
P10850719A0680 |0 14|Vbeta segmentsP00001606T0076
P10850849A0730 |102 107|hoursspect
P10850849A0730 |59 72|microg x h/mlnucleotidase 
P10850849A0730 |176 180|Cmaxshow
P10850849A0730 |245 250|hoursnger 
P10850849A0730 |211 226|absorption time data of K-depl
P10850849A0730 |132 136|Cmaxbine
P10850849A0730 |74 82|t1/2beta0008171T
P10850849A0730 |256 271|bioavailabilityced when compar
P10850849A0730 |157 166|microg/mlhen CSF [
P10850849A0730 |25 38|AUC0-infinity with alkalin
P10850849A0730 |199 204|hoursCSF P
P10850849A0730 |109 130|maximum concentrationof neonatal hyperbili
P10850849A0730 |287 288|%u
P10850849A0730 |9 23|administrationT0076 Comparis
P10850849A0730 |168 172|timeO3-]
P10850942A0989 |71 80|% glucose P0000817
P10850942A0989 |42 50|emptyingosphatas
P10850942A0989 |56 65|% peptone 5-nucleo
P10850942A0989 |151 160|nutrition0472 When
P10850942A0989 |114 117|TPNona
P10850942A0989 |99 103|ratsc as
P10850942A0989 |20 30|differencerison with
P10850942A0989 |174 178|dayss sh
P10850942A0989 |3 13|experiment001606T007
P10850997A1016 |70 73|Fure P
P10850997A1016 |27 37|regulationith alkali
P10850997A1016 |13 17|H-NS6 Co
P10850997A1016 |59 66|absencenucleot
P10850997A1016 |3 11|contrast001606T0
P10851089A1248 |55 60|yeastd 5-n
P10851089A1248 |74 88|ubiquitination0008171T0000 P
P10851089A1248 |108 118|cell cycle of neonat
P10851089A1248 |130 138|proteinsrubinemi
P10851089A1248 |29 51|cell cycle progressionh alkaline phosphatase
P10851089A1248 |93 104|degradationcologic asp
P10851089A1248 |6 9|SAG606
P10851267A0000 |0 3|E2FP00
P10851267A0000 |12 32|transcription factor76 Comparison with a
P10851267A0000 |76 83|S-phase08171T0
P10851267A0000 |48 70|cell cycle progressionases and 5-nucleotidas
P10851745A0624 |34 39|moodsaline
P10851745A0624 |54 60|healthnd 5-n
P10851745A0624 |89 97|capacityarmacolo
P10851745A0624 |62 67|sleepleoti
P10851745A0624 |16 23|fatigueomparis
P10851745A0624 |69 75|safetyse P00
P10852221A0422 |103 110|surgerypects o
P10852221A0422 |79 85|period71T000
P10852221A0422 |23 32|treatmenton with a
P10852221A0422 |127 133|effectilirub
P10852221A0422 |40 45|graftphosp
P10852221A0422 |174 181|neuronss shown
P10852221A0422 |141 149|survivalP0000899
P10852460A0170 |69 77|seleniumse P0000
P10852460A0170 |24 44|blood concentrationsn with alkaline phos
P10852460A0170 |180 189|age rangen as a fu
P10852460A0170 |79 83|zinc71T0
P10852460A0170 |198 200|yr C
P10852460A0170 |85 92|retinol0 Pharm
P10852460A0170 |48 64|thyroid hormonesases and 5-nucle
P10852460A0170 |219 227|criteria K-deple
P10852460A0170 |98 114|alpha-tocopherolic aspects of ne
P10852460A0170 |235 251|SENIEUR protocol are no longer d
P10852460A0170 |142 150|Northern00008997
P10852460A0170 |4 17|relationships01606T0076 Co
P10852460A0170 |170 178|subjects-] is sh
P10852485A0477 |16 18|CSom
P10852485A0477 |8 14|Spring6T0076
P10852485A0477 |94 96|q5ol
P10852485A0477 |135 141|Q geneemia. 
P10852485A0477 |54 78|chromosome deletion linend 5-nucleotidase P00008
P10852485A0477 |112 113|%n
P10852485A0477 |82 84|CS00
P10852485A0477 |33 39|Q genekaline
P10852485A0477 |117 120|5ALtal
P10852953A0000 |0 14|InvestigationsP00001606T0076
P10852953A0000 |129 150|gamma frequency rangeirubinemia. P00008997
P10852953A0000 |213 218|rangeata o
P10852953A0000 |226 228|Hzet
P10852953A0000 |105 121|field potentialscts of neonatal 
P10852953A0000 |33 39|sliceskaline
P10852953A0000 |158 160|Hzen
P10852953A0000 |83 89|bursts000 Ph
P10852953A0000 |206 210|beta2 th
P10852953A0000 |187 198|oscillationfunction of
P10853059X0751 |0 9|Karger AGP00001606
P10853059X0751 |11 16|Basel076 C
P10853778A0316 |53 64|bone graftsand 5-nucle
P10853778A0316 |7 25|surgery bone cysts06T0076 Comparison
P10853850A1103 |34 44|challengesaline phos
P10853850A1103 |8 12|LTE46T00
P10853850A1103 |121 122|ph
P10853850A1103 |97 119|inhalation provocationgic aspects of neonata
P10853850A1103 |49 53|riseses 
P10854004A0788 |80 93|noradrenaline1T0000 Pharma
P10854004A0788 |41 42|%h
P10854004A0788 |63 76|FVR responseseotidase P000
P10854004A0788 |46 49|ERTata
P10854004A0788 |129 142|nitroprussideirubinemia. P
P10854004A0788 |111 124|acetylcholine neonatal hyp
P10854004A0788 |95 106|angiotensinlogic aspec
P10854004A0788 |6 9|FVR606
P10854004A0788 |54 57|HRTnd 
P10854699A0424 |137 152|FGF-AS sequenceia. P00008997A0
P10854699A0424 |6 18|FGF-AS cDNAs606T0076 Com
P10854699A0424 |82 97|splice variants0000 Pharmacolo
P10854699A0424 |106 110|exonts o
P10854699A0424 |116 121|exonsatal 
P10854699A0424 |50 61|FGF-AS mRNAes and 5-nu
P10855690A0870 |70 84|hPL-B enhancere P00008171T00
P10855690A0870 |44 54|MAP kinasephatases a
P10855690A0870 |109 116|pathwayof neon
P10855690A0870 |22 29|resultsson wit
P10855793A1418 |0 16|CharacterizationP00001606T0076 C
P10855793A1418 |123 137|identificationperbilirubinem
P10855793A1418 |61 66|genescleot
P10855793A1418 |196 205|disordersof CSF PC
P10855793A1418 |145 155|candidates08997A0472
P10855793A1418 |160 165|genes CSF 
P10855793A1418 |93 97|cordcolo
P10855793A1418 |32 36|TNRslkal
P10855796A1160 |68 75|patternase P00
P10855796A1160 |127 133|regionilirub
P10855796A1160 |146 152|tectum8997A0
P10855796A1160 |79 100|EphA8 gene expression71T0000 Pharmacologic
P10855796A1160 |170 181|development-] is shown
P10855796A1160 |17 42|RNA hybridization studiesmparison with alkaline ph
P10856298A0798 |220 226|enzymeK-depl
P10856298A0798 |178 183|levelown a
P10856298A0798 |125 131|growthrbilir
P10856298A0798 |109 114|levelof ne
P10856298A0798 |166 172|growthHCO3-]
P10856298A0798 |70 89|hamster ovary cellse P00008171T0000 Ph
P10856298A0798 |39 46|enzymes phosph
P10856298A0798 |143 148|T339I00089
P10856298A0798 |16 21|cDNAsompar
P10856298A0798 |0 12|TransfectionP00001606T00
P10856491A0178 |0 7|SETTINGP000016
P10856491A0178 |59 64|womennucle
P10856491A0178 |42 49|Patientosphata
P10856491A0178 |9 19|UniversityT0076 Comp
P10856491A0178 |98 103|myomaic as
P10856491A0178 |113 124|pregnancieseonatal hyp
P10856491A0178 |23 41|Paris VII hospitalon with alkaline p
P10856491A0178 |50 51|se
P10856491A0178 |69 81|embolizationse P00008171
P10856805T0000 |0 33|Improving fissure sealant qualityP00001606T0076 Comparison with al
P10856805T0000 |46 57|preparationatases and 
P10856805T0000 |70 75|levele P00
P10857215A0000 |4 26|Menopause-Rating-Scale01606T0076 Comparison 
P10857215A0000 |28 33|MRS Ith al
P10857215A0000 |56 64|practice 5-nucle
P10857215A0806 |85 95|population0 Pharmaco
P10857215A0806 |39 47|standard phospha
P10857215A0806 |54 64|instrumentnd 5-nucle
P10857215A0806 |4 10|MRS II01606T
P10857262A0186 |119 122|BTBl h
P10857262A0186 |27 42|fruA transcriptith alkaline ph
P10857262A0186 |147 153|domain997A04
P10857262A0186 |175 180|exons show
P10857262A0186 |4 11|protein01606T0
P10857262A0186 |200 201|%S
P10857262A0186 |86 100|type A protein Pharmacologic
P10857262A0186 |70 72|D.e 
P10857751A0304 |102 108|CEHARPspects
P10857751A0304 |33 47|Mharp/Smarcal1kaline phospha
P10857751A0304 |3 11|addition001606T0
P10857751A0304 |132 148|GenBank databasebinemia. P000089
P10857751A0304 |69 100|Caenorhabditis elegans orthologse P00008171T0000 Pharmacologic
P10857751A0304 |17 31|mouse orthologmparison with 
P10858355A0920 |17 30|clinafloxacinmparison with
P10858355A0920 |54 81|Enterococcus faecium SF2149nd 5-nucleotidase P00008171
P10858355A0920 |86 113|Enterococcus faecalis WH245 Pharmacologic aspects of n
P10858355A0920 |0 12|SparfloxacinP00001606T00
P10858988A0786 |0 3|ECPP00
P10858988A0786 |27 32|serumith a
P10858988A0786 |78 87|challenge171T0000 
P10858988A0786 |8 23|tryptase levels6T0076 Comparis
P10860131A0847 |0 17|Tolterodine usersP00001606T0076 Co
P10860131A0847 |27 32|timesith a
P10860131A0847 |88 90|RRha
P10860131A0847 |82 86|drug0000
P10860131A0847 |98 102|% CIic a
P10860196A0876 |33 38|costskalin
P10860196A0876 |108 113|years of n
P10860196A0876 |76 80|year0817
P10860196A0876 |20 27|programrison w
P10860752A1601 |32 35|RNAlka
P10860752A1601 |90 104|autoregulationrmacologic asp
P10860752A1601 |37 51|binding domainne phosphatase
P10860752A1601 |108 149|bacteriophage T4 DNA polymerase synthesis of neonatal hyperbilirubinemia. P0000899
P10860752A1601 |63 72|mechanismeotidase 
P10860752A1601 |172 176|mRNA is 
P10860752A1601 |4 12|presence01606T00
P10860827A0399 |0 8|DeletionP0000160
P10860827A0399 |87 93|regionPharma
P10860827A0399 |70 78|elementse P00008
P10860827A0399 |24 32|analysesn with a
P10860827A0399 |117 132|CSX1 expressiontal hyperbiliru
P10860827A0399 |136 150|cardiomyocytesmia. P00008997
P10860846A0480 |185 189|rolea fu
P10860846A0480 |11 18|studies076 Com
P10860846A0480 |89 115|cotransfection experimentsarmacologic aspects of neo
P10860846A0480 |197 223|HGF gene promoter activityf CSF PCO2 the data of K-d
P10860846A0480 |161 164|AP2CSF
P10860846A0480 |125 146|AP2 expression vectorrbilirubinemia. P0000
P10860846A0480 |54 77|AP2 core binding regionnd 5-nucleotidase P0000
P10860846A0480 |38 46|mutatione phosph
P10861080A0433 |17 25|transfermparison
P10861080A0433 |91 100|TNF-alphamacologic
P10861080A0433 |43 70|IkappaBalpha overexpressionsphatases and 5-nucleotidas
P10861080A0433 |146 147|%8
P10861080A0433 |29 41|IkappaBalphah alkaline p
P10861080A0433 |77 87|production8171T0000 
P10861080A0433 |118 121|GBSal 
P10861086A0259 |70 73|RAWe P
P10861086A0259 |52 62|expression and 5-nuc
P10861086A0259 |199 207|Fc gammaCSF PCO2
P10861086A0259 |243 255|phagocytosislonger displ
P10861086A0259 |104 114|Src kinaseects of ne
P10861086A0259 |164 184|gain-of-function Csk [HCO3-] is shown as
P10861086A0259 |278 284|mannerontrol
P10861086A0259 |80 89|cell line1T0000 Ph
P10861086A0259 |219 228|signaling K-deplet
P10861086A0259 |3 29|reconstitution experiments001606T0076 Comparison wit
P10861086A0259 |116 119|Cskata
P10861086A0904 |3 11|contrast001606T0
P10861086A0904 |89 98|membranesarmacolog
P10861086A0904 |132 154|phagocytosis signalingbinemia. P00008997A047
P10861086A0904 |122 128|seriesyperbi
P10861086A0904 |27 36|constructith alkal
P10861086A0904 |38 43|a-Srce pho
P10861906A0999 |118 126|mutational hyper
P10861906A0999 |160 164|IME1 CSF
P10861906A0999 |234 247|DNA synthesiss are no long
P10861906A0999 |140 156|transcript level P00008997A0472 
P10861906A0999 |99 103|IME1c as
P10861906A0999 |212 219|defectsdata of
P10861906A0999 |108 112|IME2 of 
P10861906A0999 |86 91|genes Phar
P10861906A0999 |48 65|transcript levelsases and 5-nucleo
P10861906A0999 |4 24|delta srb10 mutation01606T0076 Compariso
P10861906A0999 |185 189|IME2a fu
P10861906A0999 |252 259|meiosissplaced
P10861906A1479 |48 55|meiosisases an
P10861906A1479 |107 111|CCL1s of
P10861906A1479 |194 200|mediumn of C
P10861906A1479 |178 190|alkalizationown as a fun
P10861906A1479 |76 93|transcript levels08171T0000 Pharma
P10861906A1479 |123 142|nitrogen starvationperbilirubinemia. P
P10861906A1479 |97 102|KIN28gic a
P10861906A1479 |33 43|conditionskaline pho
P10861909A0502 |274 298|transcription efficiencyto controls but still ha
P10861909A0502 |153 157|ura472 W
P10861909A0502 |221 223|3X-d
P10861909A0502 |144 146|S.00
P10861909A0502 |386 403|restriction sitesrs to be an effec
P10861909A0502 |57 63|marker5-nucl
P10861909A0502 |90 93|LEUrma
P10861909A0502 |120 122|S. h
P10861909A0502 |96 100|geneogic
P10861909A0502 |336 348|cloning site +/- 0.23 vs
P10861909A0502 |163 167|his3F [H
P10861909A0502 |135 139|geneemia
P10861909A0502 |225 228|41Xlet
P10861909A0502 |4 15|pJR vectors01606T0076 
P10861909A0502 |371 376|sitesepam 
P10861909A0502 |233 236|81Xts 
P10861909A0502 |206 219|nmt1 promoter2 the data of
P10861909A0502 |169 174|genes3-] i
P10862289A0289 |16 23|montouxomparis
P10862289A0289 |110 116|bodiesf neon
P10862289A0289 |41 47|adultshospha
P10862289A0289 |120 131|A60 antigen hyperbilir
P10862289A0289 |101 104|IgGasp
P10862289A0289 |80 87|control1T0000 
P10862289A0289 |5 9|Sera1606
P10862289A0289 |49 56|age/sexses and
P10862289A0289 |1 4|GUT000
P10863048A0000 |117 125|stimulustal hype
P10863048A0000 |41 53|cord lesionshosphatases 
P10863048A0000 |167 168|sC
P10863048A0000 |150 153|CRDA04
P10863048A0000 |158 162|mmHgen C
P10863048A0000 |212 216|ratsdata
P10863048A0000 |77 85|activity8171T000
P10863048A0000 |4 10|effect01606T
P10863048A0000 |138 148|distensiona. P000089
P10863352T0001 |0 14|Franz SchubertP00001606T0076
P10863352T0001 |26 31|musicwith 
P10863352T0001 |36 44|diseasesine phos
P10863352T0001 |20 24|liferiso
P10864271A0504 |152 159|mammals472 Whe
P10864271A0504 |76 94|Trichinella larvae08171T0000 Pharmac
P10864271A0504 |59 72|disseminationnucleotidase 
P10864271A0504 |193 201|behavioron of CS
P10864271A0504 |29 33|roleh al
P10864271A0504 |165 174|scavenger[HCO3-] i
P10864271A0504 |98 104|natureic asp
P10864271A0504 |4 11|results01606T0
P10864271A0504 |37 51|S. argyrostomane phosphatase
P10864271A0504 |119 129|comparisonl hyperbil
P10864271A0504 |137 141|roleia. 
P10864496A0401 |69 73|TnrAse P
P10864496A0401 |54 65|interactionnd 5-nucleo
P10864496A0401 |83 106|nrgAB promoter fragment000 Pharmacologic aspec
P10864496A0401 |128 138|conditionslirubinemi
P10864496A0401 |4 36|equilibrium dissociation binding01606T0076 Comparison with alkal
P10864496A0401 |115 117|nMna
P10864641A1400 |153 159|glycan72 Whe
P10864641A1400 |106 116|regulatorsts of neon
P10864641A1400 |31 40|N-glycansalkaline 
P10864641A1400 |120 142|influenza virus growth hyperbilirubinemia. P
P10864641A1400 |6 13|results606T007
P10864641A1400 |197 203|Asn123f CSF 
P10864641A1400 |163 169|Asn149F [HCO
P10864641A1400 |83 94|HA molecule000 Pharmac
P10864641A1400 |71 75|site P00
P10864989A0484 |0 7|RESULTSP000016
P10864989A0484 |219 220|% 
P10864989A0484 |150 153|FIPA04
P10864989A0484 |107 113|medians of n
P10864989A0484 |132 139|numbersbinemia
P10864989A0484 |226 241|separation timeeted rats are n
P10864989A0484 |74 83|reduction0008171T0
P10864989A0484 |155 161|median When 
P10864989A0484 |65 66|pt
P10864989A0484 |196 215|separation efficacyof CSF PCO2 the dat
P10864989A0484 |13 25|introduction6 Comparison
P10864989A0484 |101 105|WBCsaspe
P10864989A0484 |33 37|PAIPkali
P10865422A0138 |86 95|histories Pharmaco
P10865422A0138 |57 62|level5-nuc
P10865422A0138 |41 51|hemoglobinhosphatase
P10865422A0138 |113 133|iron supplementationeonatal hyperbilirub
P10865422A0138 |53 55|Hban
P10865422A0138 |36 38|SFin
P10865422A0138 |20 34|serum ferritinrison with alk
P10865422A0138 |99 108|donationsc aspects
P10865838A0000 |102 111|migrationspects of
P10865838A0000 |149 154|cells7A047
P10865838A0000 |21 34|growth factorison with alk
P10865838A0000 |36 40|VEGFine 
P10865838A0000 |52 59|agonist and 5-
P10865838A0000 |86 91|cells Phar
P10865838A0000 |116 124|divisionatal hyp
P10865940A0000 |102 104|ECsp
P10865940A0000 |95 100|cellslogic
P10865940A0000 |160 180|NF-kappaB activation CSF [HCO3-] is show
P10865940A0000 |16 49|agent pyrrolidine dithiocarbamateomparison with alkaline phosphata
P10865940A0000 |51 55|PDTCs an
P10866323A0666 |34 56|SIE-1 hypermethylationaline phosphatases and
P10866323A0666 |60 77|p21WAF1 inductionucleotidase P0000
P10866323A0666 |23 30|effectson with
P10866323A0666 |81 96|STAT activationT0000 Pharmacol
P10866677A1839 |0 3|PhdP00
P10866677A1839 |28 36|peptidesth alkal
P10866677A1839 |63 68|mouseeotid
P10866677A1839 |99 107|extractsc aspect
P10866689A0295 |114 117|pRbona
P10866689A0295 |226 247|tal-1-E12 heterodimereted rats are no long
P10866689A0295 |62 78|reporter plasmidleotidase P00008
P10866689A0295 |14 30|SAOS-2 cell line Comparison with
P10866689A0295 |178 207|tal-1-E12-Lmo2-Ldb1 complexesown as a function of CSF PCO2
P10866689A0295 |147 155|activity997A0472
P10866689A0295 |94 112|tal-1 binding siteologic aspects of 
P10866689A0295 |7 10|pRb06T
P10866689A0295 |159 173|tal-1-E12-Lmo2n CSF [HCO3-] 
P10866886A1277 |5 11|effect1606T0
P10866886A1277 |45 54|oxycodonehatases a
P10866886A1277 |28 39|conjunctionth alkaline
P10866886A1277 |72 91|mu-receptor agonistP00008171T0000 Phar
P10867199A0230 |152 165|insect orders472 When CSF 
P10867199A0230 |78 85|studies171T000
P10867199A0230 |33 41|criteriakaline p
P10867199A0230 |3 11|contrast001606T0
P10867199A0230 |127 131|EPVsilir
P10867199A0230 |101 106|levelaspec
P10867199A0230 |51 55|datas an
P10867496T0001 |0 17|NeurofibromatosisP00001606T0076 Co
P10867496T0001 |25 31|breast with 
P10867496T0001 |37 44|patientne phos
P10867496T0001 |50 75|Morbus von Recklinghausenes and 5-nucleotidase P00
P10868488A0921 |17 23|periodmparis
P10868488A0921 |29 33|rateh al
P10868488A0921 |37 47|aggressionne phospha
P10868488A0921 |86 104|testosterone level Pharmacologic asp
P10869076A1384 |49 57|presenceses and 
P10869076A1384 |129 133|boxAirub
P10869076A1384 |76 84|ribosome08171T00
P10869076A1384 |109 112|Rhoof 
P10869076A1384 |26 36|hypothesiswith alkal
P10869076A1384 |61 71|tryptophancleotidase
P10869076A1384 |115 121|accessnatal 
P10869076A1384 |6 13|results606T007
P10869076A1384 |97 101|tnaCgic 
P10869076A1384 |138 147|rut sitesa. P00008
P10869076A1384 |168 193|transcription terminationO3-] is shown as a functi
P10869465A1054 |185 195|cell typesa function
P10869465A1054 |106 112|clonests of 
P10869465A1054 |74 92|expression changes0008171T0000 Pharm
P10869465A1054 |151 167|germ cell stages0472 When CSF [H
P10869465A1054 |8 21|hybridization6T0076 Compar
P10869465A1054 |131 138|changesubinemi
P10869465A1054 |41 51|RNA probeshosphatase
P10869465A1054 |197 204|Sertolif CSF P
P10869465A1054 |235 240|cells are 
P10870043A0621 |85 90|femur0 Pha
P10870043A0621 |98 99|%i
P10870043A0621 |4 18|administration01606T0076 Com
P10870043A0621 |26 38|GnRH agonistwith alkalin
P10870043A0621 |115 128|control groupnatal hyperbi
P10870043A0621 |51 71|bone mineral densitys and 5-nucleotidase
P10870391T0034 |0 10|PreventionP00001606T
P10870391T0034 |25 34|diagnosis with alk
P10870391T0034 |39 46|therapy phosph
P10870391T0034 |50 65|travel diarrheaes and 5-nucleo
P10871045A1221 |51 64|C/EBP isoforms and 5-nucle
P10871045A1221 |22 31|C/EBPbetason with 
P10871045A1221 |231 237|effectrats a
P10871045A1221 |198 206|promoter CSF PCO
P10871045A1221 |241 253|acetaldehydeo longer dis
P10871045A1221 |140 157|C/EBPbeta binding P00008997A0472 W
P10871045A1221 |5 10|study1606T
P10871045A1221 |172 190|C/EBP binding site is shown as a fun
P10871045A1221 |84 98|stellate cells00 Pharmacolog
P10871045A1221 |118 135|C/EBPbeta proteinal hyperbilirubin
P10871347A0477 |0 17|Mutation analysisP00001606T0076 Co
P10871347A0477 |40 52|motif TCCCCTphosphatases
P10871347A0477 |69 86|PyRo1 interactionse P00008171T0000
P10871379A0261 |18 42|transactivation functionparison with alkaline ph
P10871379A0261 |73 76|HCF000
P10871379A0261 |46 51|Lumanatase
P10871379A0261 |8 12|VP166T00
P10871412A0369 |21 27|roundsison w
P10871412A0369 |44 65|focus formation assayphatases and 5-nucleo
P10871412A0369 |31 40|selectionalkaline 
P10871412A0369 |92 97|Rz007acolo
P10871412A0369 |82 90|ribozyme0000 Pha
P10871615A0368 |0 2|G.P0
P10871615A0368 |14 16|C. C
P10871615A0368 |8 12|Hyde6T00
P10871842A0988 |81 88|membersT0000 P
P10871842A0988 |56 68|upregulation 5-nucleotid
P10871842A0988 |163 176|proliferationF [HCO3-] is 
P10871842A0988 |25 46|proteasome inhibition with alkaline phosph
P10871842A0988 |92 121|transcription factor familiesacologic aspects of neonatal 
P10871842A0988 |143 158|stress response0008997A0472 Wh
P10871842A0988 |4 11|results01606T0
P10872473A2286 |49 57|XH2 geneses and 
P10872473A2286 |74 86|X chromosome0008171T0000
P10872473A2286 |125 131|factorrbilir
P10872473A2286 |148 163|gene expression97A0472 When CS
P10872473A2286 |88 94|Xq13.3harmac
P10872473A2286 |4 18|ATR-X syndrome01606T0076 Com
P10872473A2286 |32 41|mutationslkaline p
P10872535A0000 |0 4|AIMSP000
P10872535A0000 |58 65|factors-nucleo
P10872535A0000 |177 186|responseshown as a
P10872535A0000 |122 136|susceptibilityyperbilirubine
P10872535A0000 |318 331|abnormalitiesreater slope 
P10872535A0000 |85 97|birthweights0 Pharmacolo
P10872535A0000 |223 227|OGTTeple
P10872535A0000 |253 264|associationplaced when
P10872535A0000 |22 26|roleson 
P10872535A0000 |140 148|diabetes P000089
P10872535A0000 |199 221|glucose tolerance testCSF PCO2 the data of K
P10872535A0000 |280 303|birthweight differencestrols but still have a 
P10872535A0000 |101 106|twinsaspec
P10872535A0000 |341 345|life0.23
P10872756A1325 |17 40|randomization imbalancemparison with alkaline 
P10872756A1325 |177 195|dose control grouphown as a function
P10872756A1325 |94 102|patientsologic a
P10872756A1325 |3 13|NASCIS III001606T007
P10872756A1325 |143 149|chance000899
P10872756A1325 |111 124|motor deficit neonatal hyp
P10872756A1325 |154 162|recovery2 When C
P10872756A1325 |84 90|number00 Pha
P10872827A0000 |0 18|Penicillin acylaseP00001606T0076 Com
P10872827A0000 |73 84|heterodimer00008171T00
P10872827A0000 |104 107|kDaect
P10872827A0000 |20 22|PAri
P10872827A0000 |131 134|kDaubi
P10872827A0000 |46 55|ATCC11105atases an
P10872827A0000 |114 121|subunitonatal 
P10872827A0000 |141 148|subunitP000089
P10872831A0000 |85 89|EPOR0 Ph
P10872831A0000 |113 125|EST databaseeonatal hype
P10872831A0000 |46 54|homologyatases a
P10872831A0000 |60 83|erythropoietin receptorucleotidase P00008171T0
P10872831A0000 |33 36|ESTkal
P10872831A0000 |19 31|sequence tagarison with 
P10872851A0714 |87 90|AoPPha
P10872851A0714 |125 127|SVrb
P10872851A0714 |164 165|P 
P10872851A0714 |129 130|Pi
P10872851A0714 |92 93|Pa
P10872851A0714 |9 12|LCxT00
P10872851A0714 |53 64|tachycardiaand 5-nucle
P10872851A0714 |143 148|LVEDP00089
P10873158A0000 |34 40|kappaBaline 
P10873158A0000 |72 87|gene expressionP00008171T0000 
P10873158A0000 |30 32|NF a
P10873158A0000 |97 103|airwaygic as
P10873158A0000 |22 28|factorson wi
P10873158A0000 |148 154|stress97A047
P10873158A0000 |115 120|cellsnatal
P10873158A0000 |0 10|ActivationP00001606T
P10873286X0000 |0 13|GAP JUNCTIONSP00001606T007
P10873286X0000 |28 35|PREFACEth alka
P10873286X0000 |21 26|BRAINison 
P10873386A0000 |71 81|C2 subunit P00008171
P10873386A0000 |89 103|20S proteasomearmacologic as
P10873386A0000 |52 62|mouse gene and 5-nuc
P10873387A0816 |156 160|Xp11When
P10873387A0816 |104 128|mouse synaptophysin geneects of neonatal hyperbi
P10873387A0816 |134 140|regionnemia.
P10873387A0816 |93 96|endcol
P10873387A0816 |42 45|endosp
P10873387A0816 |29 33|geneh al
P10873387A0816 |53 70|Cacna1f gene mapsand 5-nucleotidas
P10873387A0816 |80 82|kb1T
P10873388A0623 |34 39|probealine
P10873388A0623 |131 139|prostateubinemia
P10873388A0623 |41 63|Northern hybridizationhosphatases and 5-nucl
P10873388A0623 |122 127|levelyperb
P10873388A0623 |15 28|Rhotekin cDNAComparison wi
P10873388A0623 |156 161|levelWhen 
P10873388A0623 |174 181|tissuess shown
P10873388A0623 |231 243|lung tissuesrats are no 
P10873388A0623 |87 97|transcriptPharmacolo
P10873388A0623 |221 226|liver-depl
P10874044A0647 |85 89|ERK20 Ph
P10874044A0647 |11 24|co-expression076 Compariso
P10874044A0647 |91 95|JNK1maco
P10874044A0647 |140 156|pE1-luc activity P00008997A0472 
P10874044A0647 |58 66|p38alpha-nucleot
P10874044A0647 |79 83|ERK171T0
P10874044A0647 |48 54|mutantases a
P10874044A0647 |100 104|JNK2 asp
P10874151A0000 |0 10|BACKGROUNDP00001606T
P10874151A0000 |67 78|alternativedase P00008
P10874151A0000 |12 36|Gamma knife radiosurgery76 Comparison with alkal
P10874151A0000 |107 114|lesionss of ne
P10874151A0000 |82 89|surgery0000 Ph
P10874151A0000 |38 41|GKRe p
P10878398A0542 |137 142|groupia. P
P10878398A0542 |121 124|Epohyp
P10878398A0542 |42 47|groupospha
P10878398A0542 |26 29|Epowit
P10878398A0542 |106 119|CAPD patientsts of neonata
P10878398A0542 |49 62|leptin levelsses and 5-nuc
P10878398A0542 |16 24|patientsompariso
P10878606A0876 |35 45|structuresline phosp
P10878606A0876 |111 123|interactions neonatal hy
P10878606A0876 |64 70|organsotidas
P10878675A1278 |137 145|subjectsia. P000
P10878675A1278 |92 100|activityacologic
P10878675A1278 |109 127|energy expenditureof neonatal hyperb
P10878675A1278 |0 10|CONCLUSIONP00001606T
P10878675A1278 |34 53|antagonist idazoxanaline phosphatases 
P10878944A0000 |87 98|SwitzerlandPharmacolog
P10878944A0000 |9 42|diphtheria toxin polymer particleT0076 Comparison with alkaline ph
P10878944A0000 |180 183|St.n a
P10878944A0000 |143 152|Institute0008997A0
P10878944A0000 |129 139|laboratoryirubinemia
P10878944A0000 |76 85|DiaMed AG08171T000
P10878944A0000 |54 59|agentnd 5-
P10878944A0000 |156 176|Childhood InfectionsWhen CSF [HCO3-] is 
P10880486A0790 |35 44|mutationsline phos
P10880486A0790 |92 98|zipperacolog
P10880486A0790 |99 102|Ebrc a
P10880486A0790 |117 127|RhoA locustal hyperb
P10880702A0966 |117 126|componenttal hyper
P10880702A0966 |195 203|behavior of CSF 
P10880702A0966 |15 22|resultsCompari
P10880702A0966 |130 143|sensitizationrubinemia. P0
P10880702A0966 |46 54|exposureatases a
P10880702A0966 |73 84|apomorphine00008171T00
P10880702A0966 |147 158|amphetamine997A0472 Wh
P10880702A0966 |58 69|amphetamine-nucleotida
P10881275T0000 |33 48|GM1 gangliosidekaline phosphat
P10881275T0000 |61 69|practicecleotida
P10881275T0000 |12 29|serum IgM binding76 Comparison wit
P10882163A1077 |0 19|Objective responsesP00001606T0076 Comp
P10882163A1077 |148 154|mg/day97A047
P10882163A1077 |210 220|exemestanee data of 
P10882163A1077 |105 122|aminoglutethimidects of neonatal h
P10882163A1077 |224 230|mg/daypleted
P10882163A1077 |178 198|aromatase inhibitorsown as a function of
P10882163A1077 |126 127|%b
P10882163A1077 |94 101|failureologic 
P10882163A1077 |37 44|studiesne phos
P10882163A1077 |77 87|exemestane8171T0000 
P10882163A1077 |133 143|exemestaneinemia. P0
P10882163A1077 |203 204|%P
P10882163A1077 |70 73|usee P
P10882213A0163 |0 6|TopicsP00001
P10882213A0163 |427 434|factorsthe opt
P10882213A0163 |292 307|classificationsill have a sign
P10882213A0163 |353 361|myositis010943A0
P10882213A0163 |189 197|patientsnction o
P10882213A0163 |122 132|malignancyyperbiliru
P10882213A0163 |333 342|childhood.21 +/- 0
P10882213A0163 |30 34|data alk
P10882213A0163 |388 396|entities to be a
P10882213A0163 |238 248|usefulnesse no longe
P10882213A0163 |175 185|assessment shown as 
P10882213A0163 |504 514|approaches0045 Beta 
P10882213A0163 |311 321|discussionantly grea
P10882213A0163 |525 536|limitationsents. P0001
P10882213A0163 |106 117|evaluationsts of neona
P10882213A0163 |50 61|associationes and 5-nu
P10882213A0163 |400 406|reviewfectiv
P10882213A0163 |79 85|cancer71T000
P10882213A0163 |463 473|managementpractice b
P10882213A0163 |159 167|approachn CSF [H
P10882213A0163 |572 578|damagemoval 
P10882213A0163 |477 494|myositis patients 15 mg at night. 
P10882213A0163 |65 73|myositistidase P
P10882213A0163 |203 232|dermatomyositis sine myositisPCO2 the data of K-depleted r
P10882213A0163 |138 154|myositis patienta. P00008997A047
P10882213A0163 |551 567|disease activityextracorporeal C
P10882462T0000 |4 11|science01606T0
P10882462T0000 |15 33|tissue engineeringComparison with al
P10882850A0000 |102 126|pyrimidine base residuesspects of neonatal hyper
P10882850A0000 |18 21|Nthpar
P10882850A0000 |82 89|removal0000 Ph
P10882850A0000 |132 135|DNAbin
P10882850A0000 |48 63|DNA glycosylaseases and 5-nucl
P10882850A0000 |0 12|EndonucleaseP00001606T00
P10884978A0633 |84 89|males00 Ph
P10884978A0633 |94 101|femalesologic 
P10884978A0633 |65 75|differencetidase P00
P10884978A0633 |129 132|ageiru
P10884978A0633 |25 34|hyperemia with alk
P10884978A0633 |4 12|duration01606T00
P10884978A0633 |50 55|aginges an
P10885708T0000 |52 57|agent and 
P10885708T0000 |29 34|entryh alk
P10885708T0000 |79 86|abscess71T0000
P10885708T0000 |9 27|bile duct blockageT0076 Comparison w
P10885731A0915 |71 83|block length P00008171T0
P10885731A0915 |161 171|solubilityCSF [HCO3-
P10885731A0915 |88 101|crystallinityharmacologic 
P10885731A0915 |47 67|synthesis conditionstases and 5-nucleoti
P10885731A0915 |37 43|impactne pho
P10885731A0915 |179 187|polymerswn as a 
P10885731A0915 |111 117|impact neona
P10885731A0915 |143 156|crystallinity0008997A0472 
P10885731A0915 |18 23|studyparis
P10885750A0236 |48 56|functionases and
P10885750A0236 |60 66|CREB-2ucleot
P10885750A0236 |95 111|organ physiologylogic aspects of
P10885750A0236 |80 91|development1T0000 Phar
P10886067A0520 |66 68|mmid
P10886067A0520 |10 18|diameter0076 Com
P10886067A0520 |44 49|rotorphata
P10886067A0520 |27 36|thicknessith alkal
P10886067A0520 |57 59|mm5-
P10887912A0740 |87 105|temporalis musclesPharmacologic aspe
P10887912A0740 |56 64|masseter 5-nucle
P10887912A0740 |22 42|maximum EMG activityson with alkaline ph
P10887912A0740 |163 175|subjects bitF [HCO3-] is
P10887912A0740 |9 13|MVBFT007
P10887912A0740 |142 153|muscle pain00008997A04
P10887912A0740 |191 195|sidetion
P10887921A0718 |0 11|CONCLUSIONSP00001606T0
P10887921A0718 |24 32|relationn with a
P10887921A0718 |131 139|rim areaubinemia
P10887921A0718 |40 50|topographyphosphatas
P10887921A0718 |90 94|SWAPrmac
P10887921A0718 |184 193|follow-up a functi
P10887921A0718 |158 162|roleen C
P10887921A0718 |66 77|field areasidase P0000
P10887921A0718 |207 215|glaucoma the dat
P10887921A0718 |170 179|diagnosis-] is sho
P10888570A0678 |118 124|limitsal hyp
P10888570A0678 |92 98|Pueblaacolog
P10888570A0678 |10 19|alkaloids0076 Comp
P10888570A0678 |61 69|Marcianacleotida
P10888570A0678 |45 52|Atzimbahatases
P10888570A0678 |81 86|MurcaT0000
P10888570A0678 |54 59|Lopeznd 5-
P10888570A0678 |37 41|peelne p
P10888570A0678 |141 152|food safetyP00008997A0
P10888570A0678 |71 79|Montsama P000081
P10889399A0243 |4 26|detection success rate01606T0076 Comparison 
P10889399A0243 |75 78|MEK008
P10889399A0243 |56 63|markers 5-nucl
P10890911A0470 |136 149|transcriptionmia. P0000899
P10890911A0470 |89 96|TGFbetaarmacol
P10890911A0470 |75 79|LEF10081
P10890911A0470 |21 26|Smad3ison 
P10890911A0470 |157 183|Xenopus homeobox gene twinhen CSF [HCO3-] is shown a
P10890911A0470 |57 71|HMG box domain5-nucleotidase
P10890911A0470 |101 113|Wnt pathwaysaspects of n
P10890911A0470 |185 189|Xtwna fu
P10891093A0000 |4 26|transmembrane topology01606T0076 Comparison 
P10891093A0000 |30 32|Na a
P10891093A0000 |130 144|fusion vectorsrubinemia. P00
P10891093A0000 |41 55|exchanger NHE3hosphatases an
P10891093A0000 |88 113|transcription/translationharmacologic aspects of n
P10891093A0000 |195 209|cDNA sequences of CSF PCO2 t
P10891093A0000 |121 126|typeshyper
P10891093A0000 |36 37|Hi
P10891093A0000 |162 191|membrane insertion propertiesSF [HCO3-] is shown as a func
P10891093A0000 |228 241|NHE3 membraneed rats are n
P10891093A0000 |260 264|msdswhen
P10891093A0000 |251 258|domainsisplace
P10891266A0421 |0 5|ACE-2P0000
P10891266A0421 |24 34|C terminusn with alk
P10891266A0421 |38 44|H typee phos
P10891286A0000 |34 53|chain kinase familyaline phosphatases 
P10891286A0000 |104 129|actin/myosin cytoskeletonects of neonatal hyperbil
P10891286A0000 |15 27|titin/myosinComparison w
P10891286A0000 |168 176|functionO3-] is 
P10891286A0000 |155 163|assembly When CS
P10891286A0000 |72 76|roleP000
P10891286A0000 |84 96|organization00 Pharmacol
P10891286A0000 |0 7|MembersP000016
P10891399A1185 |32 39|c-fosERlkaline
P10891399A1185 |131 140|AP-1 siteubinemia.
P10891399A1185 |79 82|p2171T
P10891399A1185 |192 199|controlion of 
P10891399A1185 |225 230|genesleted
P10891399A1185 |165 169|role[HCO
P10891399A1185 |65 75|inhibitiontidase P00
P10891399A1185 |203 213|cell cyclePCO2 the d
P10891399A1185 |83 92|Cip1/WAF1000 Pharm
P10891399A1185 |174 179|c-foss sho
P10891399A1185 |18 28|activationparison wi
P10891441A0871 |71 75|Sos1 P00
P10891441A0871 |106 126|phosphatidylinositolts of neonatal hyper
P10891441A0871 |91 102|p85 subunitmacologic a
P10891441A0871 |15 41|pTyr317 Shc phosphopeptideComparison with alkaline p
P10891441A0871 |142 152|mast cells00008997A0
P10891441A0871 |77 81|SHIP8171
P10891441A0871 |130 136|kinaserubine
P10891441A0871 |65 69|Grb2tida
P10891441A0871 |174 191|mass spectrometrys shown as a func
P10891489A0152 |169 177|proteins3-] is s
P10891489A0152 |82 95|proliferation0000 Pharmaco
P10891489A0152 |37 53|HMG-I/Y proteinsne phosphatases 
P10891489A0152 |108 122|transformation of neonatal h
P10891489A0152 |155 159|role Whe
P10891489A0152 |201 211|malignancyF PCO2 the
P10891489A0152 |142 149|cancers0000899
P10891489A0152 |185 197|pathogenesisa function o
P10891489A0152 |19 29|expressionarison wit
P10891632A0435 |185 194|increasesa functio
P10891632A0435 |198 217|withdrawal symptoms CSF PCO2 the data 
P10891632A0435 |233 245|side-effectsts are no lo
P10891632A0435 |96 115|withdrawal syndromeogic aspects of neo
P10891632A0435 |145 163|treatment schedule08997A0472 When CS
P10891632A0435 |4 37|naltrexone/lofexidine combination01606T0076 Comparison with alkali
P10891632A0435 |71 81|resolution P00008171
P10892300A0268 |85 89|cows0 Ph
P10892300A0268 |56 61|March 5-nu
P10892300A0268 |31 41|calcinosisalkaline p
P10892300A0268 |10 18|symptoms0076 Com
P10892300A0268 |100 123|locomotor abnormalities aspects of neonatal hy
P10892823A1040 |0 9|ScreeningP00001606
P10892823A1040 |90 100|componentsrmacologic
P10892823A1040 |41 48|alcoholhosphat
P10892823A1040 |11 21|counseling076 Compar
P10892823A1040 |61 69|drug usecleotida
P10892823A1040 |27 36|treatmentith alkal
P10892823A1040 |118 126|HBP careal hyper
P10893243T0000 |34 39|mousealine
P10893243T0000 |156 190|factor family zinc finger proteinsWhen CSF [HCO3-] is shown as a fun
P10893243T0000 |106 144|selenocysteine tRNA gene transcriptionts of neonatal hyperbilirubinemia. P00
P10893243T0000 |16 26|regulationomparison 
P10893243T0000 |50 100|chaperonin subunit gene Ccta/t-complex polypeptidees and 5-nucleotidase P00008171T0000 Pharmacologic
P10893258T0000 |118 143|reticulum quality controlal hyperbilirubinemia. P0
P10893258T0000 |74 101|membrane protein biogenesis0008171T0000 Pharmacologic 
P10893258T0000 |13 29|protein response6 Comparison wit
P10893258T0000 |49 56|aspectsses and
P10894149T0000 |51 58|proteins and 5
P10894149T0000 |177 183|factorhown a
P10894149T0000 |29 37|receptorh alkali
P10894149T0000 |121 130|receptorshyperbili
P10894149T0000 |90 100|activationrmacologic
P10894149T0000 |191 200|ERRalpha1tion of C
P10894149T0000 |219 235|receptor alpha-1 K-depleted rats
P10894149T0000 |202 210|estrogen PCO2 th
P10894149T0000 |141 161|orphan receptors SF1P00008997A0472 When 
P10894149T0000 |0 4|PNRCP000
P10894816A0836 |0 7|StudiesP000016
P10894816A0836 |140 144|IL-6 P00
P10894816A0836 |128 136|responselirubine
P10894816A0836 |90 93|SRErma
P10894816A0836 |81 88|elementT0000 P
P10894816A0836 |16 32|reporter plasmidomparison with a
P10894886A0375 |36 42|tumorsine ph
P10894886A0375 |61 68|changescleotid
P10894886A0375 |26 32|subsetwith a
P10894886A0375 |78 83|genes171T0
P10895417A0000 |153 162|clearance72 When C
P10895417A0000 |166 174|morphineHCO3-] i
P10895417A0000 |90 99|liposomesrmacologi
P10895417A0000 |33 36|EPIkal
P10895417A0000 |38 46|deliverye phosph
P10895417A0000 |191 200|analgesiation of C
P10895417A0000 |101 130|DepoFoam drug delivery systemaspects of neonatal hyperbili
P10895417A0000 |50 58|morphinees and 5
P10895417A0669 |119 126|arousall hyper
P10895417A0669 |10 19|EPI-C04010076 Comp
P10895417A0669 |29 35|salineh alka
P10895417A0669 |101 117|food consumptionaspects of neona
P10895417A0669 |39 55|DepoFoam vehicle phosphatases an
P10895417A0669 |128 148|hindlimb muscle tonelirubinemia. P000089
P10895417A0669 |154 170|body temperature2 When CSF [HCO3
P10895417A0669 |84 86|hr00
P10895851A0696 |102 103|gs
P10895851A0696 |110 112|g.f 
P10895851A0696 |77 78|%8
P10895851A0696 |23 45|Owen Mumford filamentson with alkaline phosp
P10895851A0696 |0 18|Bailey InstrumentsP00001606T0076 Com
P10896008A0531 |0 12|PARTICIPANTSP00001606T00
P10896008A0531 |26 32|samplewith a
P10896008A0531 |47 58|outpatientstases and 5
P10896008A0531 |150 151|nA
P10896008A0531 |105 109|typects 
P10896008A0531 |75 80|motor00817
P10896008A0531 |175 183|controls shown a
P10896008A0531 |113 114|ne
P10896008A0531 |93 103|neuropathycologic as
P10896008A0531 |185 186|na
P10896008A0531 |139 148|dystrophy. P000089
P10896859A0000 |170 178|cortisol-] is sh
P10896859A0000 |142 150|infusion00008997
P10896859A0000 |94 97|ADXolo
P10896859A0000 |193 206|steroid sheepon of CSF PCO
P10896859A0000 |14 31|water deprivation Comparison with 
P10896859A0000 |4 10|effect01606T
P10896859A0000 |99 104|sheepc asp
P10896859A0000 |39 40|h 
P10896859A0000 |154 165|aldosterone2 When CSF 
P10896859A0000 |50 62|Na excretiones and 5-nuc
P10896859A0838 |22 27|causeson w
P10896859A0838 |57 69|Na retention5-nucleotida
P10897233A1057 |0 10|CONCLUSIONP00001606T
P10897233A1057 |22 27|feverson w
P10897233A1057 |35 48|Nazareth arealine phosphat
P10897973T0001 |51 58|heparins and 5
P10897973T0001 |83 87|role000 
P10897973T0001 |91 103|antithrombinmacologic as
P10897973T0001 |60 74|Thrombosis ABCucleotidase P0
P10897973T0001 |0 27|Antithrombin III deficiencyP00001606T0076 Comparison w
P10897973T0001 |34 44|substitutealine phos
P10898795A0527 |97 101|BCoRgic 
P10898795A0527 |75 79|BCoR0081
P10898795A0527 |9 14|classT0076
P10898795A0527 |46 51|HDACsatase
P10898795A0527 |134 141|classesnemia. 
P10898795A0527 |24 44|histone deacetylasesn with alkaline phos
P10898795A0527 |145 150|HDACs08997
P10899128A0661 |18 25|exampleparison
P10899128A0661 |164 174|regulation [HCO3-] i
P10899128A0661 |42 70|transcription factor complexosphatases and 5-nucleotidas
P10899128A0661 |89 97|MADS-boxarmacolo
P10899128A0661 |104 120|forkhead proteinects of neonatal
P10899128A0661 |143 155|implications0008997A0472
P10899128A0661 |188 203|gene expressionunction of CSF 
P10899142A0000 |137 138|Gi
P10899142A0000 |40 63|Genome Project databasephosphatases and 5-nucl
P10899142A0000 |245 251|DLGR-2nger d
P10899142A0000 |268 272|cDNApare
P10899142A0000 |240 243|LGRno 
P10899142A0000 |165 168|LGR[HC
P10899142A0000 |155 163|receptor When CS
P10899142A0000 |20 28|Berkeleyrison wi
P10899142A0000 |219 223|gene K-d
P10899142A0000 |69 78|sequencesse P00008
P10899142A0000 |187 193|DLGR-1functi
P10900129A0138 |0 18|Degenerate primersP00001606T0076 Com
P10900129A0138 |105 112|RT-PCRscts of 
P10900129A0138 |67 82|CYP3A sequencesdase P00008171T
P10900129A0138 |50 57|regionses and 
P10900269A0396 |119 132|recombinationl hyperbiliru
P10900269A0396 |178 179|%o
P10900269A0396 |109 117|TK genesof neona
P10900269A0396 |149 160|frequencies7A0472 When
P10900269A0396 |168 173|rangeO3-] 
P10900269A0396 |5 10|cells1606T
P10900269A0396 |202 212|background PCO2 the 
P10900269A0396 |35 39|TFOsline
P10900269A0396 |68 83|polypurine sitease P00008171T0
P10901133A0381 |0 16|MethyllevamisoleP00001606T0076 C
P10901133A0381 |42 50|standardosphatas
P10902348A0566 |0 17|Resistance ratiosP00001606T0076 Co
P10902348A0566 |78 87|R5 strain171T0000 
P10902348A0566 |124 135|applicationerbilirubin
P10902348A0566 |164 180|glass jar method [HCO3-] is show
P10902348A0566 |58 68|comparison-nucleotid
P10902348A0566 |32 45|field strainslkaline phosp
P10903440A0515 |102 109|pupariaspects 
P10903440A0515 |63 77|testes tissueseotidase P0000
P10903440A0515 |30 36|TSGF-2 alkal
P10903440A0515 |5 16|transcripts1606T0076 C
P10903440A0515 |53 58|ovaryand 5
P10903440A0515 |125 129|generbil
P10903440A0515 |81 87|adultsT0000 
P10903440A0515 |175 181|stages shown
P10903495A0533 |33 38|HepG2kalin
P10903495A0533 |73 81|sequence00008171
P10903495A0533 |47 55|extractstases an
P10903495A0533 |5 26|gel retardation assay1606T0076 Comparison 
P10903495A0533 |115 119|bandnata
P10903583T0000 |0 11|ReliabilityP00001606T0
P10903583T0000 |33 39|motionkaline
P10903583T0000 |24 29|rangen wit
P10903583T0000 |62 83|spine motion analyserleotidase P00008171T0
P10903583T0000 |116 124|subjectsatal hyp
P10903583T0000 |50 56|OSI CAes and
P10903733A0540 |0 33|Coimmunoprecipitation experimentsP00001606T0076 Comparison with al
P10903733A0540 |122 126|TRAFyper
P10903733A0540 |59 64|cellsnucle
P10903733A0540 |77 81|BCMA8171
P10903733A0540 |131 136|TRAF2ubine
P10903733A0540 |142 164|TRAF3 adaptor proteins00008997A0472 When CSF
P10903733A0540 |114 120|factoronatal
P10903837A1208 |87 91|VSX1Phar
P10903837A1208 |10 19|RINX gene0076 Comp
P10903837A1208 |105 132|Gene Nomenclature Committeects of neonatal hyperbiliru
P10903837A1208 |33 41|orthologkaline p
P10903837A1208 |49 67|goldfish Vsx1 geneses and 5-nucleoti
P10903843A0447 |16 28|localizationomparison wi
P10903843A0447 |67 74|clusterdase P0
P10903843A0447 |131 136|Tapa1ubine
P10903843A0447 |88 93|genesharma
P10903843A0447 |39 49|chromosome phosphata
P10903843A0447 |141 152|Kcnq1 genesP00008997A0
P10903877A0879 |119 127|decreasel hyperb
P10903877A0879 |131 143|3TP activityubinemia. P0
P10903877A0879 |79 91|calphostin C71T0000 Phar
P10903877A0879 |72 75|PKCP00
P10903877A0879 |14 17|PKA Co
P10903877A0879 |164 183|ERK kinase activity [HCO3-] is shown a
P10903877A0879 |36 39|AMPine
P10903877A0879 |58 68|inhibition-nucleotid
P10903877A0879 |43 52|forskolinsphatases
P10903877A0879 |187 191|CRACfunc
P10903877A0879 |0 10|ActivationP00001606T
P10904191A0000 |110 119|San Diegof neonata
P10904191A0000 |63 74|specificityeotidase P0
P10904191A0000 |121 123|CAhy
P10904191A0000 |211 214|FVU da
P10904191A0000 |216 225|specimens of K-dep
P10904191A0000 |144 153|specimens008997A04
P10904191A0000 |244 252|patientsonger di
P10904191A0000 |125 128|USArbi
P10904191A0000 |177 185|patientshown as 
P10904191A0000 |12 17|study76 Co
P10904191A0000 |47 58|sensitivitytases and 5
P10904191A0000 |86 108|Gen-Probe Incorporated Pharmacologic aspects
P10904191A0000 |199 209|void urineCSF PCO2 t
P10904191A0000 |78 84|AMP CT171T00
P10905349A0329 |0 6|Mus81pP00001
P10905349A0329 |53 81|XPF endonuclease superfamilyand 5-nucleotidase P00008171
P10905349A0329 |33 39|motifskaline
P10905349A0329 |19 27|homologyarison w
P10905349A0609 |48 54|Mus81pases a
P10905349A0609 |14 22|analysis Compari
P10905349A0609 |82 88|repair0000 P
P10905349A0609 |37 43|Rad54pne pho
P10905349A0609 |121 131|DNA damagehyperbilir
P10905349A0609 |66 73|pathwayidase P
P10905349A0609 |96 105|toleranceogic aspe
P10905352A0000 |119 125|helperl hype
P10905352A0000 |11 24|plasmid pCLU1076 Compariso
P10905352A0000 |133 146|plasmid pGKL2inemia. P0000
P10905352A0000 |88 97|cytoplasmharmacolo
P10905352A0000 |181 187|primer as a 
P10905352A0000 |172 174|TP i
P10905352A0000 |163 170|proteinF [HCO3
P10905352A0000 |108 111|aid of
P10905352A0000 |54 60|lactisnd 5-n
P10905352A0000 |34 39|yeastaline
P10906176A0000 |103 115|mouse genomepects of neo
P10906176A0000 |38 44|familye phos
P10906176A0000 |26 36|transposonwith alkal
P10906176A0000 |15 18|ETnCom
P10906176A0000 |48 57|sequencesases and 
P10906176A0000 |87 94|mutagenPharmac
P10906317A0351 |152 153|%4
P10906317A0351 |26 35|variableswith alka
P10906317A0351 |88 98|proportionharmacolog
P10906317A0351 |73 78|right00008
P10906317A0351 |121 126|shifthyper
P10906317A0351 |65 69|lefttida
P10906317A0351 |54 63|hemifieldnd 5-nucl
P10906317A0351 |159 160|%n
P10906317A0351 |139 148|hemifield. P000089
P10906317A0351 |102 108|trialsspects
P10906999T0000 |50 67|chemiluminescencees and 5-nucleoti
P10906999T0000 |36 43|systemsine pho
P10906999T0000 |4 15|measurement01606T0076 
P10906999T0000 |19 21|NOar
P10907348A0508 |119 127|activityl hyperb
P10907348A0508 |149 151|AP7A
P10907348A0508 |47 57|metabolismtases and 
P10907348A0508 |76 94|PTH concentrations08171T0000 Pharmac
P10907348A0508 |131 145|bone isoenzymeubinemia. P000
P10907348A0508 |12 24|examinations76 Compariso
P10907348A0508 |67 71|ionsdase
P10907348A0508 |98 109|blood serumic aspects 
P10907971A0806 |0 12|AtorvastatinP00001606T00
P10907971A0806 |41 68|HMG-CoA reductase inhibitorhosphatases and 5-nucleotid
P10907971T0000 |17 27|assessmentmparison w
P10907971T0000 |31 66|HMG-CoA reductase inhibitor therapyalkaline phosphatases and 5-nucleot
P10907971T0000 |93 105|CURVES studycologic aspe
P10907971T0000 |71 79|analysis P000081
P10908317A1459 |102 108|domainspects
P10908317A1459 |24 33|E domainsn with al
P10908317A1459 |161 182|estradiol sensitivityCSF [HCO3-] is shown 
P10908317A1459 |130 141|counterpartrubinemia. 
P10908317A1459 |47 56|receptorstases and
P10908317A1459 |219 234|transactivation K-depleted rat
P10908317A1459 |112 116|rtERneon
P10908317A1459 |82 93|replacement0000 Pharma
P10908317A1459 |190 198|increasection of
P10908317A1459 |206 215|magnitude2 the dat
P10908364A0000 |0 5|G-DNAP0000
P10908364A0000 |72 77|rolesP0000
P10908364A0000 |25 38|DNA structure with alkalin
P10908462A3159 |21 24|NRTiso
P10908462A3159 |66 75|intensityidase P00
P10908462A3159 |90 97|supportrmacolo
P10908462A3159 |114 120|smokeronatal
P10908462A3159 |4 17|effectiveness01606T0076 Co
P10908478A0717 |85 94|illnesses0 Pharmac
P10908478A0717 |114 124|quetiapineonatal hyp
P10908478A0717 |126 133|placebobilirub
P10908478A0717 |60 73|schizophreniaucleotidase P
P10908478A0717 |155 160|drugs When
P10908478A0717 |48 54|adultsases a
P10908478A0717 |191 199|outcomestion of 
P10908478A0717 |35 41|trialsline p
P10908478A0717 |0 18|SELECTION CRITERIAP00001606T0076 Com
P10908822A0519 |1 2|%0
P10908822A0519 |6 10|% CI606T
P10908822A0519 |19 22|.3%ari
P10909973A1508 |152 161|substrate472 When 
P10909973A1508 |95 102|isoformlogic a
P10909973A1508 |40 43|CREpho
P10909973A1508 |27 32|GLP-1ith a
P10909973A1508 |63 77|cotransfectioneotidase P0000
P10909973A1508 |3 11|contrast001606T0
P10909973A1508 |83 90|M1-CREB000 Pha
P10909973A1508 |179 194|phosphorylationwn as a functio
P10909973A1508 |116 140|consensus serine residueatal hyperbilirubinemia.
P10909973A1508 |17 23|actionmparis
P10910073A0876 |155 166|patient RNA When CSF [
P10910073A0876 |12 29|PDGFbetaR fusions76 Comparison wit
P10910073A0876 |121 134|amplificationhyperbilirubi
P10910073A0876 |93 97|genecolo
P10910073A0876 |59 67|splicingnucleoti
P10910073A0876 |148 151|PCR97A
P10910073A0876 |80 84|exon1T00
P10910073A0876 |138 142|cDNAa. P
P10910439A1196 |0 11|CONCLUSIONSP00001606T0
P10910439A1196 |83 86|GFR000
P10910439A1196 |129 138|treatmentirubinemi
P10910439A1196 |26 38|hypertensionwith alkalin
P10910439A1196 |48 60|protein loadases and 5-n
P10910439A1196 |71 79|decrease P000081
P10910908A0767 |32 59|PI3K-Akt activation pathwaylkaline phosphatases and 5-
P10910908A0767 |97 103|effectgic as
P10910908A0767 |107 110|EPOs o
P10910908A0767 |5 12|finding1606T00
P10910908A0767 |71 75|role P00
P10913094A0424 |117 146|gel mobility shift-PCR methodtal hyperbilirubinemia. P0000
P10913094A0424 |105 111|cyclescts of
P10913094A0424 |83 87|AdpA000 
P10913094A0424 |5 18|DNA fragments1606T0076 Com
P10913172A0442 |101 107|lysineaspect
P10913172A0442 |129 134|motifirubi
P10913172A0442 |60 74|Rad24 functionucleotidase P0
P10913172A0442 |37 42|motifne ph
P10913172A0442 |113 120|residueeonatal
P10913276A0510 |69 80|interactionse P0000817
P10913276A0510 |45 49|SOS1hata
P10913276A0510 |90 111|PLC-gamma1 SH3 domainrmacologic aspects of
P10913276A0510 |35 41|domainline p
P10913276A0684 |65 75|SH3 domaintidase P00
P10913276A0684 |79 89|PLC-gamma171T0000 Ph
P10913276A0684 |15 33|expression studiesComparison with al
P10913276A0684 |111 122|association neonatal h
P10913276A0684 |128 132|SOS1liru
P10913304A0894 |69 73|Elk1se P
P10913304A0894 |13 22|Ets mRNAs6 Compari
P10913304A0894 |79 82|PE171T
P10913304A0894 |63 67|SAP1eoti
P10913304A0894 |46 50|Fli1atas
P10913304A0894 |40 44|Ets2phos
P10913304A0894 |52 61|GABPalpha and 5-nu
P10913304A1180 |153 156|PE172 
P10913304A1180 |36 41|brainine p
P10913304A1180 |180 186|domainn as a
P10913304A1180 |74 85|kDa protein0008171T000
P10913304A1180 |101 108|proteinaspects
P10913304A1180 |4 17|kb transcript01606T0076 Co
P10913304A1180 |203 211|homologyPCO2 the
P10913304A1180 |139 149|Ets domain. P0000899
P10913304A1180 |222 225|ERFdep
P10915728A0216 |16 24|patientsompariso
P10915728A0216 |76 84|patients08171T00
P10915728A0216 |125 133|IFN-betarbilirub
P10915728A0216 |108 113|units of n
P10915728A0216 |30 39|cirrhosis alkaline
P10915728A0216 |168 176|patientsO3-] is 
P10915728A0216 |65 71|groupstidase
P10915728A0216 |142 146|week0000
P10915728A0216 |185 196|IFN therapya function 
P10915728A0216 |154 160|months2 When
P10915780A1063 |85 99|overexpression0 Pharmacologi
P10915780A1063 |124 129|glanderbil
P10915780A1063 |181 197|cyclin D1 levels as a function o
P10915780A1063 |164 176|ILK activity [HCO3-] is 
P10915780A1063 |144 148|mice0089
P10915780A1063 |43 48|cellssphat
P10915780A1063 |57 71|cyclin D1 mRNA5-nucleotidase
P10915780A1063 |103 108|Wnt-1pects
P10915780A1063 |0 20|Wnt-1 overexpressionP00001606T0076 Compa
P10917402T0000 |59 67|patientsnucleoti
P10917402T0000 |79 89|depression71T0000 Ph
P10917402T0000 |24 38|administrationn with alkalin
P10917402T0000 |42 55|amitriptylineosphatases an
P10918059A0569 |0 8|DeletionP0000160
P10918059A0569 |39 43|loss pho
P10918059A0569 |47 49|Cata
P10918059A0569 |64 74|activationotidase P0
P10918059A0569 |16 26|RVH domainomparison 
P10918164A0878 |157 178|% confidence intervalhen CSF [HCO3-] is sh
P10918164A0878 |199 200|PC
P10918164A0878 |182 186|% CIas a
P10918164A0878 |63 68|timeseotid
P10918164A0878 |144 153|detectors008997A04
P10918164A0878 |43 53|physicianssphatases 
P10918164A0878 |9 28|regression analysisT0076 Comparison wi
P10918164A0878 |96 103|lesionsogic as
P10918164A0878 |113 115|mmeo
P10918440T0000 |0 31|Erythema exsudativum multiformeP00001606T0076 Comparison with 
P10918440T0000 |74 80|factor000817
P10918440T0000 |109 130|blood stem cell donorof neonatal hyperbili
P10918440T0000 |43 54|granulocytesphatases a
P10918572A0794 |0 3|VaIP00
P10918572A0794 |77 82|ErbB48171T
P10918572A0794 |40 45|ErbB2phosp
P10918572A0794 |60 65|ErbB1ucleo
P10918572A0794 |8 12|VaII6T00
P10918572A0794 |67 72|ErbB3dase 
P10918572A1547 |170 190|TGF-alpha precursors-] is shown as a fun
P10918572A1547 |215 229|ErbB signalinga of K-deplete
P10918572A1547 |56 61|ErbBs 5-nu
P10918572A1547 |22 24|WTso
P10918572A1547 |76 92|ErbB2 activation08171T0000 Pharm
P10918572A1547 |128 140|consequenceslirubinemia.
P10918572A1547 |37 46|TGF-alphane phosph
P10918572A1547 |6 18|interactions606T0076 Com
P10918596A0000 |33 47|p53 C-terminuskaline phospha
P10918596A0000 |88 96|activityharmacol
P10918596A0000 |114 122|moleculeonatal h
P10918596A0000 |64 68|roleotid
P10918599A0071 |3 11|contrast001606T0
P10918599A0071 |27 32|E2F-3ith a
P10918599A0071 |135 141|levelsemia. 
P10918599A0071 |65 78|G1/S boundarytidase P00008
P10918599A0071 |145 147|GO08
P10918599A0071 |176 178|Rbsh
P10918599A0071 |80 86|E2F-3B1T0000
P10918599A0071 |114 124|cell cycleonatal hyp
P10918612A0000 |117 125|patternstal hype
P10918612A0000 |79 93|growth signals71T0000 Pharma
P10918612A0000 |30 35|c-Jun alka
P10918612A0000 |129 144|gene expressionirubinemia. P00
P10918612A0000 |4 28|transcription factor Jun01606T0076 Comparison wi
P10918943T0000 |55 71|agent almokalantd 5-nucleotidase
P10918943T0000 |30 35|class alka
P10918943T0000 |75 79|mice0081
P10918943T0000 |14 22|toxicity Compari
P10918948A0110 |137 145|diseasesia. P000
P10918948A0110 |66 74|Debridatidase P0
P10918948A0110 |36 46|metaboliteine phosph
P10918948A0110 |76 79|CAS081
P10918948A0110 |5 13|compound1606T007
P10918948A0110 |50 61|trimebutinees and 5-nu
P10919971A0606 |87 96|vitamin EPharmacol
P10919971A0606 |77 85|exercise8171T000
P10919971A0606 |44 63|neutrophil responsephatases and 5-nucl
P10919971A0606 |3 11|addition001606T0
P10919971A0606 |114 122|increaseonatal h
P10919971A0606 |202 215|muscle repair PCO2 the dat
P10919971A0606 |138 162|creatine kinase activitya. P00008997A0472 When C
P10919971A0606 |19 25|effectarison
P10920186A0528 |119 122|usel h
P10920186A0528 |88 98|transcriptharmacolog
P10920186A0528 |151 154|PCR047
P10920186A0528 |126 137|MLL primersbilirubinem
P10920186A0528 |40 49|templatesphosphata
P10920186A0528 |106 110|loopts o
P10920186A0528 |59 71|fusion pointnucleotidase
P10920186A0528 |17 26|formationmparison 
P10920906A0759 |119 125|marginl hype
P10920906A0759 |16 23|authorsomparis
P10920906A0759 |138 140|cma.
P10920906A0759 |73 76|STS000
P10920906A0759 |0 10|CONCLUSIONP00001606T
P10920906A0759 |51 61|managements and 5-nu
P10921197A0179 |0 12|MeasurementsP00001606T00
P10921197A0179 |115 117|b.na
P10921197A0179 |96 113|ADAC Pinnacle3 V4ogic aspects of n
P10921197A0179 |49 75|treatment planning systemsses and 5-nucleotidase P00
P10921197A0179 |87 91|VO5BPhar
P10924061A0588 |0 10|ActivationP00001606T
P10924061A0588 |60 69|treatmentucleotida
P10924061A0588 |41 44|minhos
P10924061A0588 |52 53|h 
P10925159A1353 |115 123|extractsnatal hy
P10925159A1353 |125 131|MARTA2rbilir
P10925159A1353 |89 98|fractionsarmacolog
P10925159A1353 |46 53|lysatesatases 
P10925159A1353 |8 14|MARTA16T0076
P10925159A1353 |173 194|salt-wash preparationis shown as a functio
P10925207A0634 |37 50|kb transcriptne phosphatas
P10925207A0634 |15 20|exonsCompa
P10925207A0634 |134 138|UTRsnemi
P10925207A0634 |125 132|regionsrbiliru
P10926776A0731 |69 80|amino acidsse P0000817
P10926776A0731 |56 65|insertion 5-nucleo
P10926776A0731 |12 25|PDP1 isoforms76 Comparison
P10926776A0731 |40 52|substitutionphosphatases
P10926776A0731 |114 121|proteinonatal 
P10928179A0101 |101 107|debateaspect
P10928179A0101 |43 54|examinationsphatases a
P10928179A0101 |12 21|technique76 Compar
P10928179A0101 |58 78|sentinel lymph nodes-nucleotidase P00008
P10928179A0101 |80 84|SLNs1T00
P10928337A0590 |99 103|massc as
P10928337A0590 |8 18|correction6T0076 Com
P10928337A0590 |108 114|volume of ne
P10928337A0590 |22 28|anemiason wi
P10928337A0590 |52 66|erythropoietin and 5-nucleot
P10928477A0764 |86 103|platelet function Pharmacologic as
P10928477A0764 |173 192|patient populationsis shown as a funct
P10928477A0764 |149 161|shear stress7A0472 When 
P10928477A0764 |121 137|platelet defectshyperbilirubinem
P10928477A0764 |5 10|study1606T
P10928477A0764 |33 49|PFA-100 analyzerkaline phosphata
P10930526A0174 |35 42|cloningline ph
P10930526A0174 |72 80|HuPLSCR1P0000817
P10930526A0174 |48 61|PL scramblaseases and 5-nu
P10930526A0174 |86 98|mouse origin Pharmacolog
P10931524A0313 |87 95|sequencePharmaco
P10931524A0313 |26 34|activitywith alk
P10931524A0313 |126 131|assaybilir
P10931524A0313 |38 41|Gtxe p
P10931927A0655 |68 83|template-primerase P00008171T0
P10931927A0655 |28 29|At
P10931927A0655 |268 272|sizepare
P10931927A0655 |30 36|GGGTTA alkal
P10931927A0655 |164 167|HIV [H
P10931927A0655 |48 54|TAACCCases a
P10931927A0655 |58 61|T-3-nu
P10931927A0655 |176 189|transcriptaseshown as a fu
P10931927A0655 |242 250|products longer 
P10931927A0655 |9 24|oligomer duplexT0076 Compariso
P10931927A0655 |280 292|template DNAtrols but st
P10931927A0655 |107 122|Klenow fragments of neonatal h
P10931927A0655 |203 225|telomere DNA sequencesPCO2 the data of K-dep
P10931927A0655 |143 157|DNA polymerase0008997A0472 W
P10931950A0869 |0 4|Cdk2P000
P10931950A0869 |9 13|MAPKT007
P10931950A0869 |109 121|T187A mutantof neonatal 
P10931950A0869 |42 55|tumor lysatesosphatases an
P10931950A0869 |93 96|p27col
P10931960A0630 |117 125|additiontal hype
P10931960A0630 |12 31|avirulence activity76 Comparison with 
P10931960A0630 |181 193|protein VP16 as a functi
P10931960A0630 |43 52|mutationssphatases
P10931960A0630 |160 174|herpes simplex CSF [HCO3-] i
P10931960A0630 |133 150|activation domaininemia. P00008997
P10931960A0630 |83 100|activation domain000 Pharmacologic
P10931960A0630 |4 8|loss0160
P10932196A0359 |17 26|RP2 locusmparison 
P10932196A0359 |66 67|%i
P10932196A0359 |104 119|linkage studiesects of neonata
P10932196A0359 |30 36|Xp11.3 alkal
P10932196A0359 |71 84|XLRP patients P00008171T00
P10932196A0359 |0 9|MutationsP00001606
P10932329A0597 |81 108|sulcus cecocolicus dorsalisT0000 Pharmacologic aspects
P10932329A0597 |22 27|cecumson w
P10932329A0597 |46 51|colonatase
P10932329A0597 |113 122|ventraliseonatal h
P10932329A0597 |4 9|limit01606
P10932527A0947 |68 85|epithelializationase P00008171T000
P10932527A0947 |14 16|HD C
P10932527A0947 |27 34|healingith alk
P10932527A0947 |108 120|inflammation of neonatal
P10932527T0000 |100 106|ponies aspec
P10932527T0000 |89 95|horsesarmaco
P10932527T0000 |72 85|wound healingP00008171T000
P10932527T0000 |25 50|haemodialysate Solcoseryl with alkaline phosphatas
P10932527T0000 |4 17|effectiveness01606T0076 Co
P10932679A0049 |85 89|role0 Ph
P10932679A0049 |111 122|expenditure neonatal h
P10932679A0049 |167 178|food intakeCO3-] is sh
P10932679A0049 |97 107|absorptiongic aspect
P10932679A0049 |25 33|evidence with al
P10932679A0049 |126 132|energybiliru
P10932679A0049 |159 163|rolen CS
P10932679A0049 |39 55|diet composition phosphatases an
P10933154A1118 |6 14|findings606T0076
P10933154A1118 |108 117|rejection of neona
P10933154A1118 |76 93|donor transplants08171T0000 Pharma
P10933154A1118 |37 45|analysisne phosp
P10933728A1398 |273 287|responsiveness to controls b
P10933728A1398 |182 190|evidenceas a fun
P10933728A1398 |6 13|results606T007
P10933728A1398 |52 56|CBF2 and
P10933728A1398 |111 129|hnRNP protein AUF1 neonatal hyperbil
P10933728A1398 |43 47|rolespha
P10933728A1398 |229 249|CBF1 binding elementd rats are no longer
P10933728A1398 |70 91|EBNA2 transactivatione P00008171T0000 Phar
P10933728A1398 |291 296|EBNA2till 
P10933728A1398 |141 150|componentP00008997
P10933728A1398 |154 158|CBF22 Wh
P10933728A1398 |207 215|sequence the dat
P10933732A0000 |207 213|family the d
P10933732A0000 |57 64|cluster5-nucle
P10933732A0000 |89 93|ORFsarma
P10933732A0000 |73 87|reading frames00008171T0000 
P10933732A0000 |104 112|proteinsects of 
P10933732A0000 |194 200|factorn of C
P10933732A0000 |118 126|homologyal hyper
P10933732A0000 |24 35|herpesvirusn with alka
P10933732A0000 |143 164|transcription factors0008997A0472 When CSF
P10933732A0000 |172 182|interferon is shown 
P10933732A0000 |202 205|IRF PC
P10933732A0000 |39 44|HHV-8 phos
P10933732A0000 |4 10|genome01606T
P10934073A1433 |127 131|homeilir
P10934073A1433 |14 25|limitations Comparison
P10934073A1433 |30 43|CHIME monitor alkaline pho
P10934073A1433 |56 67|opportunity 5-nucleoti
P10934073A1433 |92 96|dataacol
P10934310A0698 |85 95|weaknesses0 Pharmaco
P10934310A0698 |30 40|ultrasound alkaline 
P10934310A0698 |108 119|angiography of neonata
P10934310A0698 |0 14|DATA SYNTHESISP00001606T0076
P10934640A1114 |85 91|menses0 Phar
P10934640A1114 |26 32|heightwith a
P10934640A1114 |62 68|colonyleotid
P10934640A1114 |14 15|p 
P10934640A1114 |45 50|yearshatas
P10934640A1114 |70 71|pe
P10934640A1114 |113 119|TB BMCeonata
P10934640A1114 |93 94|pc
P10934640A1114 |0 12|TB bone areaP00001606T00
P10934640A1114 |34 35|pa
P10934751T0001 |0 14|CREST syndromeP00001606T0076
P10934751T0001 |36 48|significanceine phosphat
P10935488A1033 |119 125|A-FABPl hype
P10935488A1033 |132 142|expressionbinemia. P
P10935488A1033 |65 74|T24 cellstidase P0
P10935488A1033 |97 117|acid binding proteingic aspects of neona
P10935488A1033 |40 61|PPARgamma target genephosphatases and 5-nu
P10935488A1033 |168 198|bladder cancer differentiationO3-] is shown as a function of
P10935488A1033 |0 12|TroglitazoneP00001606T00
P10935880A1049 |0 7|VirusesP000016
P10935880A1049 |57 70|NCP BVDV type5-nucleotidas
P10935880A1049 |29 34|lungsh alk
P10935880A1049 |90 96|BVHV-1rmacol
P10935880A1049 |43 48|PI-3Vsphat
P10935880A1049 |101 105|BVDVaspe
P10936051T0000 |16 29|megasatelliteomparison wit
P10936051T0000 |4 9|RS44701606
P10936051T0000 |90 96|enzymermacol
P10936051T0000 |115 123|promoternatal hy
P10936051T0000 |48 56|sequenceases and
P10936920A0105 |35 39|cuesline
P10936920A0105 |97 107|predictiongic aspect
P10936920A0105 |9 19|experienceT0076 Comp
P10936920A0105 |54 62|elementsnd 5-nuc
P10936920A0105 |70 80|generatione P0000817
P10938102A0265 |21 27|effectison w
P10938102A0265 |43 50|targetssphatas
P10938102A0265 |97 116|translation factorsgic aspects of neon
P10938102A0265 |54 81|NS1 influenza virus proteinnd 5-nucleotidase P00008171
P10938102A1359 |85 91|eIF4GI0 Phar
P10938102A1359 |72 75|NS1P00
P10938102A1359 |60 65|modelucleo
P10938102A1359 |45 49|datahata
P10938102A1359 |212 238|influenza virus messengersdata of K-depleted rats ar
P10938102A1359 |128 134|regionlirubi
P10938102A1359 |193 204|translationon of CSF P
P10938102A1359 |157 161|mRNAhen 
P10938102A1359 |139 142|UTR. P
P10938102T0000 |70 81|NS1 proteine P00008171
P10938102T0000 |59 65|targetnucleo
P10938102T0000 |11 44|translation initiation factor 4GI076 Comparison with alkaline phos
P10938102T0000 |112 127|influenza virusneonatal hyperb
P10938102T0000 |99 108|activatorc aspects
P10938105A0000 |34 38|exonalin
P10938105A0000 |177 188|splice sitehown as a f
P10938105A0000 |46 79|fibroblast growth factor receptoratases and 5-nucleotidase P000081
P10938105A0000 |122 135|sequence IAS1yperbilirubin
P10938105A0000 |82 86|gene0000
P10938105A0000 |0 8|SplicingP0000160
P10938109A1361 |22 29|PKCbetason wit
P10938109A1361 |15 20|cellsCompa
P10938109A1361 |79 86|insulin71T0000
P10938109A1361 |132 139|signalsbinemia
P10938109A1361 |61 65|rolecleo
P10938109A1361 |95 98|EGFlog
P10938109A1361 |108 121|growth factor of neonatal 
P10938113A0388 |184 196|Vav isoforms a function 
P10938113A0388 |226 236|activitieseted rats 
P10938113A0388 |134 141|classesnemia. 
P10938113A0388 |75 79|Vav30081
P10938113A0388 |57 70|isoforms Vav25-nucleotidas
P10938113A0388 |145 154|receptors08997A047
P10938120A1093 |102 105|PKAspe
P10938120A1093 |30 54|fbp1 promoter constructs alkaline phosphatases a
P10938120A1093 |110 125|MAPK regulationf neonatal hype
P10938120A1093 |146 151|sites8997A
P10938120A1093 |79 83|UAS271T0
P10938120A1093 |71 75|UAS1 P00
P10938120A1093 |16 26|regulationomparison 
P10938130A0338 |0 5|X-rayP0000
P10938130A0338 |42 61|PLZF BTB/POZ domainosphatases and 5-nu
P10938130A0338 |107 116|interfaces of neon
P10938130A0338 |23 27|dataon w
P10938130A0338 |80 89|homodimer1T0000 Ph
P10938135A0259 |139 173|tyrosine kinase signaling pathways. P00008997A0472 When CSF [HCO3-] 
P10938135A0259 |15 19|SMRTComp
P10938135A0259 |125 135|activationrbilirubin
P10938135A0259 |89 99|repressionarmacologi
P10938135A0259 |44 65|transcription factorsphatases and 5-nucleo
P10938135A0259 |217 239|growth factor receptorof K-depleted rats are
P10938135A0259 |4 11|ability01606T0
P10938556A0248 |34 38|ratsalin
P10938556A0248 |66 71|cellsidase
P10938556A0248 |88 98|ventriclesharmacolog
P10938556A0248 |3 11|addition001606T0
P10938556A0248 |48 55|neuronsases an
P10939030A0986 |100 110|survival p aspects o
P10939030A0986 |123 128|gradeperbi
P10939030A0986 |132 150|granulocytopenia pbinemia. P00008997
P10939030A0986 |45 60|response rate phatases and 5-n
P10939030A0986 |4 15|differences01606T0076 
P10939030A0986 |174 187|neutropenia ps shown as a 
P10939030A0986 |93 94|%c
P10939030A0986 |81 82|pT
P10939030A0986 |70 75|powere P00
P10939785A0540 |0 8|PatientsP0000160
P10939785A0540 |174 183|treatments shown a
P10939785A0540 |54 79|ACE inhibitor perindoprilnd 5-nucleotidase P000081
P10939785A0540 |213 220|placeboata of 
P10939785A0540 |35 44|treatmentline phos
P10939785A0540 |154 170|contraindication2 When CSF [HCO3
P10939785A0540 |98 108|indapamideic aspects
P10939785A0540 |136 146|indicationmia. P0000
P10939785A0540 |221 222|s-
P10940413A1153 |184 190|defect a fun
P10940413A1153 |74 83|stiffness0008171T0
P10940413A1153 |159 163|bonen CS
P10940413A1153 |43 49|effectsphata
P10940413A1153 |88 116|stress concentration effectsharmacologic aspects of neon
P10940413A1153 |140 148|strength P000089
P10940413A1153 |4 11|results01606T0
P10940553A0912 |85 95|regulation0 Pharmaco
P10940553A0912 |110 134|hPer1 gene transcriptionf neonatal hyperbilirubi
P10940553A0912 |6 13|regions606T007
P10940553A0912 |48 66|tissue-specificityases and 5-nucleot
P10940557A1687 |35 81|Broad Complex Z2 transcription factor elementsline phosphatases and 5-nucleotidase P00008171
P10940557A1687 |134 139|genesnemia
P10940557A1687 |120 123|MIH hy
P10940557A1687 |109 116|regionsof neon
P10940557A1687 |23 30|CF1/USPon with
P10940562A0379 |0 17|Sequence analysisP00001606T0076 Co
P10940562A0379 |76 86|pseudogene08171T0000
P10940562A0379 |52 62|oasA2 gene and 5-nuc
P10940562T0000 |103 110|enzymespects o
P10940562T0000 |88 93|thiolharma
P10940562T0000 |47 62|oas gene familytases and 5-nuc
P10940562T0000 |165 185|Arabidopsis thaliana[HCO3-] is shown as 
P10940562T0000 |95 101|lyaseslogic 
P10940562T0000 |72 86|O-acetylserineP00008171T0000
P10940562T0000 |132 136|stepbine
P10940562T0000 |23 39|characterizationon with alkaline
P10940562T0000 |140 161|cysteine biosynthesis P00008997A0472 When 
P10940892A0573 |85 88|Chr0 P
P10940892A0573 |47 57|vasculitistases and 
P10940892A0573 |124 133|progenieserbilirub
P10940892A0573 |107 115|D4Mit147s of neo
P10940892A0573 |73 83|chromosome00008171T0
P10940892A0573 |95 102|D4Mit89logic a
P10940892A0573 |23 42|susceptibility locion with alkaline ph
P10942587A0981 |220 222|RbK-
P10942587A0981 |149 156|changes7A0472 
P10942587A0981 |88 92|mRNAharm
P10942587A0981 |47 49|Rbta
P10942587A0981 |210 216|levelse data
P10942587A0981 |164 174|E7 protein [HCO3-] i
P10942587A0981 |82 86|form0000
P10942587A0981 |22 43|phosphorylation stateson with alkaline pho
P10942587A0981 |7 16|treatment06T0076 C
P10942587A0981 |101 116|HPV E6/E7 genesaspects of neon
P10942587A0981 |255 265|antibodiesaced when 
P10942599A1298 |175 188|embryogenesis shown as a f
P10942599A1298 |108 122|Hoxa-1 protein of neonatal h
P10942599A1298 |130 155|differentiation processesrubinemia. P00008997A0472
P10942599A1298 |91 100|functionsmacologic
P10942599A1298 |43 62|Hoxa-1 target genessphatases and 5-nuc
P10942599A1298 |8 24|characterization6T0076 Compariso
P10943891A1062 |184 188|site a f
P10943891A1062 |199 210|spliceosomeCSF PCO2 th
P10943891A1062 |160 169|formation CSF [HCO
P10943891A1062 |47 55|fidelitytases an
P10943891A1062 |15 29|U6-U57 mutantsComparison wit
P10943891A1062 |83 106|splice site recognition000 Pharmacologic aspec
P10943891A1062 |189 190|sn
P10943891A1062 |126 136|nucleotidebilirubine
P10943891A1062 |4 11|ability01606T0
P10943891A1062 |64 75|branch siteotidase P00
P10944466A0451 |23 32|structureon with a
P10944466A0451 |40 51|WNT-2B genephosphatase
P10945010T0001 |70 78|leukemiae P00008
P10945010T0001 |28 45|induction therapyth alkaline phosp
P10945010T0001 |12 24|daunorubicin76 Compariso
P10945010T0001 |4 8|role0160
P10945781A0412 |77 97|enterotoxin activity8171T0000 Pharmacolo
P10945781A0412 |12 29|Aeromonas strains76 Comparison wit
P10945781A0412 |41 58|V cholerae non-O1hosphatases and 5
P10946303A0000 |0 9|TNF-alphaP00001606
P10946303A0000 |121 129|NCI-H292hyperbil
P10946303A0000 |75 80|COX-200817
P10946303A0000 |45 53|increasehatases 
P10946303A0000 |97 111|PGE2 formationgic aspects of
P10946303A0000 |82 92|expression0000 Pharm
P10946303A0000 |57 73|cyclooxygenase-25-nucleotidase P
P10946303A0000 |20 24|doseriso
P10946303A0000 |141 146|cellsP0000
P10947274A0839 |32 35|NCSlka
P10947274A0839 |120 123|10B hy
P10947274A0839 |77 82|times8171T
P10947274A0839 |95 100|157Gdlogic
P10947274A0839 |62 69|RBE-cGyleotida
P10947274A0839 |4 16|therapy time01606T0076 C
P10947274A0839 |48 52|doseases
P10947840A0762 |0 4|Mis3P000
P10947840A0762 |23 32|formationon with a
P10947840A0762 |79 84|level71T00
P10947840A0762 |88 96|proteinsharmacol
P10947840A0762 |36 52|18S ribosome RNAine phosphatases
P10947840A0762 |114 122|couplingonatal h
P10950398T0100 |0 21|Losartan InterventionP00001606T0076 Compar
P10950398T0100 |26 34|Endpointwith alk
P10950415A0866 |0 10|CONCLUSIONP00001606T
P10950415A0866 |90 99|procedurermacologi
P10950415A0866 |147 153|vision997A04
P10950415A0866 |12 22|Vitrectomy76 Compari
P10950415A0866 |132 143|improvementbinemia. P0
P10950415A0866 |36 46|hemorrhageine phosph
P10950415A0866 |50 65|Terson syndromees and 5-nucleo
P10950924A0393 |0 3|RNAP00
P10950924A0393 |60 67|embryosucleoti
P10950924A0393 |109 114|areasof ne
P10950924A0393 |29 43|brain sectionsh alkaline pho
P10950924A0393 |12 25|hybridization76 Comparison
P10950924A0393 |131 137|cortexubinem
P10950924A0393 |86 94|labeling Pharmac
P10950935A0111 |70 76|methode P000
P10950935A0111 |135 139|PACsemia
P10950935A0111 |44 53|sequencesphatases 
P10950935A0111 |14 26|manipulation Comparison 
P10950935A0111 |146 151|yeast8997A
P10950935A0111 |108 110|P1 o
P10950935A0111 |122 133|chromosomesyperbilirub
P10950935A0111 |176 180|YACsshow
P10950935A0111 |163 174|chromosomesF [HCO3-] i
P10951579A1238 |119 134|gene expressionl hyperbilirubi
P10951579A1238 |41 49|F9 cellshosphata
P10951579A1238 |29 37|majorityh alkali
P10951579A1238 |150 155|cellsA0472
P10951579A1238 |6 23|gamma-irradiation606T0076 Comparis
P10951579A1238 |82 88|wt-p530000 P
P10951579A1238 |58 67|apoptosis-nucleoti
P10951579A1238 |96 104|triggersogic asp
P10951579A1238 |138 141|DNAa. 
P10951848A0230 |0 12|MobilizationP00001606T00
P10951848A0230 |58 76|stimulating factor-nucleotidase P000
P10951848A0230 |109 119|cell shiftof neonata
P10951848A0230 |94 99|termsologi
P10951848A0230 |134 139|bloodnemia
P10951848A0230 |18 34|cyclophosphamideparison with alk
P10951848A0230 |216 232|megachemotherapy of K-depleted r
P10951848A0230 |201 209|recoveryF PCO2 t
P10951848A0230 |103 107|CD34pect
P10951848A0230 |153 170|quality autograft72 When CSF [HCO3
P10952828A2638 |220 233|image qualityK-depleted ra
P10952828A2638 |95 123|ejection fraction estimationlogic aspects of neonatal hy
P10952828A2638 |166 177|3D approachHCO3-] is s
P10952828A2638 |127 149|heart failure patientsilirubinemia. P0000899
P10952828A2638 |196 206|ventriclesof CSF PCO
P10952828A2638 |43 52|resonancesphatases
P10952828A2638 |70 79|techniquee P000081
P10952828A2638 |84 90|volume00 Pha
P10954093A0000 |85 92|strains0 Pharm
P10954093A0000 |29 32|Path a
P10954093A0000 |13 27|DNA transposon6 Comparison w
P10954093A0000 |56 63|genomes 5-nucl
P10954093A0000 |112 137|fungus Podospora anserinaneonatal hyperbilirubinem
P10954525A1161 |68 75|profilease P00
P10954525A1161 |79 87|proteins71T0000 
P10954525A1161 |13 21|presence6 Compar
P10954525A1161 |45 51|extenthatase
P10954525A1161 |25 28|Tax wi
P10954525A1161 |96 101|TRE-2ogic 
P10954564A1262 |51 54|ORFs a
P10954564A1262 |58 65|protein-nucleo
P10954564A1262 |125 128|ORFrbi
P10954564A1262 |37 43|domainne pho
P10954564A1262 |86 98|gene product Pharmacolog
P10954913A0152 |38 62|Atlantic halibut Mx genee phosphatases and 5-nuc
P10954913A0152 |83 101|liver cDNA library000 Pharmacologic 
P10954913A0152 |21 31|cDNA cloneison with 
P10955313A0000 |0 6|PLUS-3P00001
P10955313A0000 |44 50|speechphatas
P10955313A0000 |24 32|protocoln with a
P10955313A0000 |65 73|childrentidase P
P10955913A0827 |5 11|HIT II1606T0
P10955913A0827 |60 68|heparinsucleotid
P10955913A0827 |26 33|heparinwith al
P10955998A1124 |115 128|DNA mutationsnatal hyperbi
P10955998A1124 |12 22|efficiency76 Compari
P10955998A1124 |30 50|glycosylase activity alkaline phosphatas
P10955998A1124 |93 103|S120K MutYcologic as
P10955998A1124 |82 89|ability0000 Ph
P10958271A0365 |0 7|METHODSP000016
P10958271A0365 |244 248|ERNAonge
P10958271A0365 |333 341|patients.21 +/- 
P10958271A0365 |94 111|ejection fractionologic aspects of
P10958271A0365 |123 130|volumesperbili
P10958271A0365 |61 73|measurementscleotidase P
P10958271A0365 |256 264|patientsced when
P10958271A0365 |156 166|TechnetiumWhen CSF [
P10958271A0365 |113 117|LVEFeona
P10958271A0365 |296 304|functionhave a s
P10958271A0365 |179 194|perfusion SPECTwn as a functio
P10958271A0365 |310 326|echocardiographycantly greater s
P10958271A0365 |172 177|Tc99m is s
P10958271A0365 |12 19|RESULTS76 Comp
P10958271A0365 |200 242|equilibrium radionuclide angiocardiographySF PCO2 the data of K-depleted rats are no
P10958271A0365 |273 283|assessment to contro
P10958456A0529 |87 89|bpPh
P10958456A0529 |93 95|Cpco
P10958456A0529 |148 170|polyadenylation signal97A0472 When CSF [HCO3
P10958456A0529 |106 108|bpts
P10958456A0529 |28 34|lengthth alk
P10958456A0529 |96 98|F6og
P10958456A0529 |6 11|cDNAs606T0
P10958456A0529 |112 114|Cpne
P10958456A0529 |115 118|F10nat
P10958456A0529 |71 78|regions P00008
P10958673A0142 |70 73|UPRe P
P10958673A0142 |52 68|protein response and 5-nucleotid
P10958673A0142 |106 132|ER stress response elementts of neonatal hyperbiliru
P10958673A0142 |134 138|ERSEnemi
P10958673A0142 |143 150|mammals0008997
P10958673A0142 |19 28|signalingarison wi
P10958688A0265 |2 28|Y. lipolytica Kar2p mutant0001606T0076 Comparison wi
P10958688A0265 |56 67|interaction 5-nucleoti
P10958688A0265 |110 121|interactionf neonatal 
P10958688A0265 |76 88|Sls1p mutant08171T0000 P
P10958688A0265 |160 172|conformation CSF [HCO3-]
P10958688A0265 |127 132|Sls1piliru
P10958688A0265 |142 152|nucleotide00008997A0
P10958698A0280 |102 110|functionspects o
P10958698A0280 |70 86|Cse4p N terminuse P00008171T0000
P10958698A0280 |51 62|mutagenesiss and 5-nuc
P10958698A0485 |69 72|HFDse 
P10958698A0485 |40 46|domainphosph
P10958698A0485 |132 146|Cse4p functionbinemia. P0000
P10958698A0485 |122 128|effectyperbi
P10958698A0485 |4 11|spacing01606T0
P10958698A0485 |48 51|ENDase
P10959676A0200 |18 28|comparisonparison wi
P10959676A0200 |4 9|bases01606
P10959838A0153 |18 22|Fhitpari
P10959838A0153 |39 53|fusion protein phosphatases 
P10959838A0153 |66 72|memberidase 
P10959838A0153 |59 62|Nitnuc
P10959838A0153 |80 101|nitrilase superfamily1T0000 Pharmacologic 
P10959838A0153 |3 16|invertebrates001606T0076 C
P10961046A0342 |0 15|Platelet countsP00001606T0076 
P10961046A0342 |40 50|fibrinogenphosphatas
P10961046A0342 |20 28|functionrison wi
P10961046A0342 |83 89|levels000 Ph
P10961046A0342 |78 81|vWF171
P10961046A0342 |114 120|sampleonatal
P10961046A0342 |55 76|von Willebrand factord 5-nucleotidase P000
P10961585A0273 |81 90|hemolysisT0000 Pha
P10961585A0273 |44 60|thrombocytopeniaphatases and 5-n
P10961585A0273 |4 18|manifestations01606T0076 Com
P10962564A0883 |69 78|cytosinesse P00008
P10962564A0883 |194 200|mannern of C
P10962564A0883 |86 98|sense strand Pharmacolog
P10962564A0883 |141 145|lossP000
P10962564A0883 |149 157|activity7A0472 W
P10962564A0883 |116 123|thymineatal hy
P10962564A0883 |2 31|beta2 RARE reporter construct0001606T0076 Comparison with 
P10962593A0580 |18 26|AFP rateparison 
P10962738A0000 |51 57|memorys and 
P10962738A0000 |62 72|perceptionleotidase 
P10962738A0000 |32 41|attentionlkaline p
P10962738A0000 |0 13|ConsciousnessP00001606T007
P10962881A0900 |51 55|risks an
P10962881A0900 |29 35|effecth alka
P10962881A0900 |59 63|% CInucl
P10962881A0900 |0 11|MultiparityP00001606T0
P10963577T0016 |0 7|PictureP000016
P10963577T0016 |12 17|smell76 Co
P10963735A0193 |221 252|polyacrylonitrile membrane AN69-depleted rats are no longer di
P10963735A0193 |107 110|CRFs o
P10963735A0193 |88 91|CTLhar
P10963735A0193 |60 66|stressucleot
P10963735A0193 |15 20|studyCompa
P10963735A0193 |78 86|controls171T0000
P10963735A0193 |41 46|levelhosph
P10963735A0193 |167 183|dialysis sessionCO3-] is shown a
P10963735A0193 |4 7|aim016
P10963735A0193 |115 126|HD patientsnatal hyper
P10963735A0651 |35 44|vitamin Eline phos
P10963735A0651 |61 72|acid levelscleotidase 
P10963735A0651 |46 51|thiolatase
P10963735A0651 |9 26|plasma parametersT0076 Comparison 
P10964833A1696 |49 53|POAGses 
P10964833A1696 |158 162|mmHgen C
P10964833A1696 |105 106|%c
P10964833A1696 |15 27|participantsComparison w
P10964833A1696 |141 144|IOPP00
P10964833A1696 |32 33|%l
P10964995A2152 |71 78|cancers P00008
P10964995A2152 |165 170|HER-2[HCO3
P10964995A2152 |54 59|womennd 5-
P10964995A2152 |124 133|treatmenterbilirub
P10964995A2152 |41 48|concernhosphat
P10964995A2152 |65 67|ERti
P10964995A2152 |141 147|tumorsP00008
P10965135A0735 |0 17|Promoter activityP00001606T0076 Co
P10965135A0735 |230 247|inhibitor PD98059 rats are no long
P10965135A0735 |79 82|ras71T
P10965135A0735 |225 228|MKKlet
P10965135A0735 |105 124|oncogene inhibitioncts of neonatal hyp
P10965135A0735 |86 99|mos oncogenes Pharmacologi
P10965135A0735 |52 66|cotransfection and 5-nucleot
P10965135A0735 |178 183|cellsown a
P10965135A0735 |206 223|MAP kinase kinase2 the data of K-d
P10965135A0735 |154 162|activity2 When C
P10965135A1207 |136 146|MKK levelsmia. P0000
P10965135A1207 |181 211|transcription factor complexes as a function of CSF PCO2 the
P10965135A1207 |30 40|expression alkaline 
P10965135A1207 |83 94|development000 Pharmac
P10965135A1207 |56 60|gene 5-n
P10965135A1207 |44 52|Cktsf1b1phatases
P10965135A1207 |99 118|cell transformationc aspects of neonat
P10965135A1207 |4 11|results01606T0
P10965830A0305 |0 13|INTERVENTIONSP00001606T007
P10965830A0305 |134 144|volunteersnemia. P00
P10965830A0305 |43 56|PCO2 tensionssphatases and
P10965830A0305 |109 118|fasciitisof neonat
P10965830A0305 |28 38|tissue PO2th alkalin
P10965830A0305 |178 188|conditionsown as a f
P10965830A0305 |83 91|patients000 Phar
P10965905A1618 |102 110|LY294002spects o
P10965905A1618 |391 396|cells be a
P10965905A1618 |360 381|MAP kinase activation0733 Flurazepam thus 
P10965905A1618 |328 332|PI3Kpe (
P10965905A1618 |303 309|targetsignif
P10965905A1618 |85 98|concentration0 Pharmacolog
P10965905A1618 |118 126|findingsal hyper
P10965905A1618 |19 33|Akt activationarison with al
P10965905A1618 |262 270|activityen compa
P10965905A1618 |145 167|wortmannin sensitivity08997A0472 When CSF [H
P10965905A1618 |336 345|mediation +/- 0.23
P10965905A1618 |316 324|addition greater
P10965905A1618 |224 245|MAP kinase activationpleted rats are no lo
P10965905A1618 |310 311|sc
P10965905A1618 |67 72|cellsdase 
P10965905T0000 |0 16|Insulin receptorP00001606T0076 C
P10965905T0000 |94 119|protein kinase activationologic aspects of neonata
P10965905T0000 |53 59|growthand 5-
P10965905T0000 |38 49|enhancemente phosphata
P10967361A0000 |153 163|resolution72 When CS
P10967361A0000 |128 135|featurelirubin
P10967361A0000 |90 104|brain functionrmacologic asp
P10967361A0000 |20 37|resonance imagingrison with alkali
P10967361A0000 |39 43|fMRI pho
P10967531A1025 |205 211|micromO2 the
P10967531A1025 |67 81|fibre necrosisdase P00008171
P10967531A1025 |178 182|typeown 
P10967531A1025 |24 29|aortan wit
P10967531A1025 |164 170|microm [HCO3
P10967531A1025 |99 109|leucocytesc aspects 
P10967531A1025 |54 59|edemand 5-
P10967531A1025 |219 223|type K-d
P10967531A1025 |87 95|adhesionPharmaco
P10967531A1025 |119 137|muscle fibre areasl hyperbilirubinem
P10967890A1120 |51 64|comprehensions and 5-nucle
P10967890A1120 |4 11|results01606T0
P10967890A1120 |106 112|stagests of 
P10967890A1120 |30 42|relationship alkaline ph
P10967890A1120 |116 127|developmentatal hyperb
P10967890A1120 |69 79|productionse P000081
P10970048A0352 |34 42|RH levelaline ph
P10970048A0352 |76 82|orders08171T
P10970048A0352 |161 165|dropCSF 
P10970048A0352 |62 68|valuesleotid
P10970048A0352 |150 155|timesA0472
P10970048A0352 |115 129|voltage valuesnatal hyperbil
P10970048A0352 |173 175|RHis
P10970048A0352 |97 109|contrariwisegic aspects 
P10970048A0352 |18 26|increaseparison 
P10970048A0352 |86 95|magnitude Pharmaco
P10972688A1272 |49 59|differenceses and 5-
P10972688A1272 |13 22|follow-up6 Compari
P10972688A1272 |67 76|incidencedase P000
P10972688A1272 |80 96|hospitalizations1T0000 Pharmacol
P10972894A0488 |200 207|librarySF PCO2
P10972894A0488 |40 48|culturesphosphat
P10972894A0488 |62 68|formatleotid
P10972894A0488 |113 121|colonieseonatal 
P10972894A0488 |8 17|libraries6T0076 Co
P10972894A0488 |126 132|platesbiliru
P10972894A0488 |143 150|library0008997
P10972894A0488 |173 180|libraryis show
P10972980A0295 |136 137|Cm
P10972980A0295 |23 27|mTORon w
P10972980A0295 |219 230|amino acids K-depleted
P10972980A0295 |11 21|cell lines076 Compar
P10972980A0295 |46 53|targetsatases 
P10972980A0295 |74 94|phosphatidylinositol0008171T0000 Pharmac
P10972980A0295 |186 192|kinase funct
P10972980A0295 |154 164|G-proteins2 When CSF
P10972980A0295 |110 127|protein kinases Af neonatal hyperb
P10972980A0295 |129 130|Bi
P10972980A0295 |196 203|calciumof CSF 
P10972980A0295 |96 98|PIog
P10972980A0295 |100 108|3-kinase aspects
P10972990A0196 |68 77|stabilityase P0000
P10972990A0196 |21 32|protein p53ison with a
P10972990A0526 |171 210|hypoxanthine phosphoribosyl transferase] is shown as a function of CSF PCO2 th
P10972990A0526 |212 216|HPRTdata
P10972990A0526 |76 96|mutation frequencies08171T0000 Pharmacol
P10972990A0526 |135 137|TKem
P10972990A0526 |14 26|p53 function Comparison 
P10972990A0526 |30 32|E6 a
P10972990A0526 |117 133|thymidine kinasetal hyperbilirub
P10972990A0526 |48 56|increaseases and
P10972990A0526 |218 223|locusf K-d
P10972990A0526 |139 144|locus. P00
P10972990A0526 |0 10|AbrogationP00001606T
P10972990A0966 |169 183|amplifications3-] is shown a
P10972990A0966 |24 35|LOH mutantsn with alka
P10972990A0966 |198 212|translocations CSF PCO2 the 
P10972990A0966 |147 167|chromosome deletions997A0472 When CSF [H
P10972990A0966 |12 20|analysis76 Compa
P10972990A0966 |115 125|chromosomenatal hype
P10972990A0966 |39 58|chromosome painting phosphatases and 5
P10972990A0966 |93 104|aberrationscologic asp
P10972990A0966 |250 256|mutantdispla
P10972990A0966 |71 77|mosaic P0000
P10972990A1518 |70 81|maintenancee P00008171
P10972990A1518 |127 133|repairilirub
P10972990A1518 |93 102|integritycologic a
P10972990A1518 |24 29|modeln wit
P10972990A1518 |6 13|results606T007
P10972990A1518 |39 50|p53 protein phosphatas
P10973151A0883 |86 96|Pernambuco Pharmacol
P10973151A0883 |43 50|profilesphatas
P10973151A0883 |182 193|environmentas a functi
P10973151A0883 |162 174|interferenceSF [HCO3-] i
P10973151A0883 |111 115|fact neo
P10973151A0883 |77 82|State8171T
P10973151A0883 |54 69|schistosomiasisnd 5-nucleotida
P10973151A0883 |4 14|importance01606T0076
P10973385A1423 |186 202|survival benefit function of CSF
P10973385A1423 |37 44|patternne phos
P10973385A1423 |25 31|tumors with 
P10973385A1423 |58 64|spread-nucle
P10973385A1423 |161 174|esophagectomyCSF [HCO3-] i
P10973385A1423 |147 159|artery nodes997A0472 Whe
P10973385A1423 |238 246|patientse no lon
P10973385A1423 |3 11|patients001606T0
P10973385A1423 |217 228|gastrectomyof K-deplet
P10973385A1423 |17 21|typempar
P10973385A1423 |119 128|curvaturel hyperbi
P10973400A0664 |0 7|RESULTSP000016
P10973400A0664 |106 114|injuriests of ne
P10973400A0664 |156 163|flexionWhen CS
P10973400A0664 |24 35|deformationn with alka
P10973400A0664 |78 103|flexion-distraction Stage171T0000 Pharmacologic as
P10973400A0664 |138 143|rangea. P0
P10973400A0664 |49 60|artery flowses and 5-n
P10974541A0389 |66 71|MZF1Bidase
P10974541A0389 |14 31|K562 cDNA library Comparison with 
P10974541A0389 |76 81|MZF1C08171
P10974541A0389 |53 64|transcriptsand 5-nucle
P10975465A0134 |50 58|KIAA0170es and 5
P10975465A0134 |164 176|BRCT domains [HCO3-] is 
P10975465A0134 |134 138|massnemi
P10975465A0134 |105 111|lengthcts of
P10975465A0134 |90 101|amino acidsrmacologic 
P10975465A0134 |76 83|protein08171T0
P10975465A0134 |10 26|cDNA clone NFBD10076 Comparison 
P10975465A0134 |147 148|D9
P10975465A0134 |202 221|amino acid residues PCO2 the data of K
P10975465A0134 |184 200|carboxy terminus a function of C
P10976413A0514 |0 7|RESULTSP000016
P10976413A0514 |95 105|predictorslogic aspe
P10976413A0514 |149 152|day7A0
P10976413A0514 |48 57|FSH levelases and 
P10976413A0514 |155 164|FSH level When CSF
P10976413A0514 |250 259|pregnancydisplaced
P10976413A0514 |23 32|FSH levelon with a
P10976413A0514 |219 225|mIU/ml K-dep
P10976413A0514 |109 120|IVF successof neonatal
P10976413A0514 |195 198|day of
P10976413A0514 |134 141|patientnemia. 
P10976413A0514 |202 211|FSH level PCO2 the
P10976413A0514 |172 178|mIU/ml is sh
P10980416T0000 |34 51|bone sialoproteinaline phosphatase
P10980416T0000 |12 30|hormone regulation76 Comparison with
P10980416T0000 |149 154|motif7A047
P10980416T0000 |142 147|Pit-100008
P10980416T0000 |162 183|rat BSP gene promoterSF [HCO3-] is shown a
P10980416T0000 |58 76|gene transcription-nucleotidase P000
P10980416T0000 |53 56|BSPand
P10980416T0000 |118 140|transcription factor-1al hyperbilirubinemia.
P10981094A0779 |115 122|premisenatal h
P10981094A0779 |183 192|magnitudes a funct
P10981094A0779 |132 141|intensitybinemia. 
P10981094A0779 |90 96|JNC VIrmacol
P10981094A0779 |42 54|Sixth Reportosphatases a
P10981094A0779 |196 213|pretreatment riskof CSF PCO2 the d
P10981094A0779 |145 154|treatment08997A047
P10981094A0779 |7 22|target BP goals06T0076 Compari
P10981094A0779 |64 88|Joint National Committeeotidase P00008171T0000 P
P10982076A0000 |170 180|indicators-] is show
P10982076A0000 |104 112|samplingects of 
P10982076A0000 |82 85|ILI000
P10982076A0000 |196 214|influenza activityof CSF PCO2 the da
P10982076A0000 |73 80|illness0000817
P10982076A0000 |141 146|valueP0000
P10982076A0000 |35 54|morbidity recordingline phosphatases a
P10982143A0346 |4 10|muskox01606T
P10982143A0346 |36 45|T. gondiiine phosp
P10982143A0346 |20 31|host recordrison with 
P10982391A0425 |324 332|elements slope (
P10982391A0425 |29 36|leucineh alkal
P10982391A0425 |44 50|repeatphatas
P10982391A0425 |14 25|NPF repeats Comparison
P10982391A0425 |269 277|segmentsared to 
P10982391A0425 |134 138|sitenemi
P10982391A0425 |157 163|domainhen CS
P10982391A0425 |188 201|membrane coreunction of CS
P10982391A0425 |227 246|transmembrane spansted rats are no lon
P10982391A0425 |71 79|residues P000081
P10982391A0425 |116 118|WWat
P10982825A0363 |48 56|presenceases and
P10982825A0363 |62 79|Mot3 binding siteleotidase P000081
P10982825A0363 |23 33|differenceon with al
P10982825A0363 |83 86|OpA000
P10983344A0000 |4 11|article01606T0
P10983344A0000 |42 52|correctionosphatases
P10983344A0000 |27 37|diagnosingith alkali
P10983344A0000 |67 75|ischemiadase P00
P10983344A0000 |83 92|intestine000 Pharm
P10983857A0923 |153 160|stomach72 When
P10983857A0923 |8 19|application6T0076 Comp
P10983857A0923 |56 68|PD reduction 5-nucleotid
P10983857A0923 |193 197|ratson o
P10983857A0923 |81 82|HT
P10983857A0923 |23 31|NCX-4016on with 
P10983857A0923 |112 121|hyperemianeonatal 
P10983857A0923 |139 145|damage. P000
P10983857A0923 |84 88|loss00 P
P10983979T0000 |50 62|U5 tri-snRNPes and 5-nuc
P10983979T0000 |29 40|splice siteh alkaline 
P10983979T0000 |107 127|spliceosome assemblys of neonatal hyperb
P10983979T0000 |44 49|U4/U6phata
P10983979T0000 |11 22|recognition076 Compari
P10983979T0000 |93 97|stepcolo
P10984122A0911 |85 91|mU6-C20 Phar
P10984122A0911 |3 10|control001606T
P10984122A0911 |44 56|DNA mixturesphatases and
P10984122A0911 |16 21|cellsompar
P10984122A0911 |68 81|vector mU6-C1ase P00008171
P10987280A0604 |153 163|matrilysin72 When CS
P10987280A0604 |142 149|feature0000899
P10987280A0604 |27 39|matrilysin-2ith alkaline
P10987280A0604 |56 73|threonine residue 5-nucleotidase P
P10987280A0604 |4 23|amino acid sequence01606T0076 Comparis
P10987280A0604 |101 105|siteaspe
P10987301A0332 |372 383|developmentpam thus ap
P10987301A0332 |387 393|Kaposis to b
P10987301A0332 |297 301|VEGFave 
P10987301A0332 |89 97|receptorarmacolo
P10987301A0332 |148 160|herpes virus97A0472 When
P10987301A0332 |330 340|stimulator (1.21 +/-
P10987301A0332 |120 126|Kaposi hyper
P10987301A0332 |282 295|growth factorols but still
P10987301A0332 |356 363|mitogen943A073
P10987301A0332 |217 229|angiogenesisof K-deplete
P10987301A0332 |248 257|secretionr displac
P10987301A0332 |396 403|sarcoman effec
P10987301A0332 |174 186|herpes viruss shown as a
P10987301A0332 |8 14|regard6T0076
P10987301A0332 |162 166|KSHVSF [
P10987301A0332 |99 103|GPCRc as
P10987301A0332 |71 72|G 
P10989777A1286 |103 113|assignmentpects of n
P10989777A1286 |24 31|clientsn with 
P10989777A1286 |161 166|groupCSF [
P10989777A1286 |12 20|subgroup76 Compa
P10989777A1286 |52 55|URD an
P10989777A1286 |80 85|study1T000
P10991383A0289 |49 50|%s
P10991383A0289 |58 63|atoms-nucl
P10991383A0289 |27 32|sitesith a
P10991383A0289 |149 154|state7A047
P10991383A0289 |134 136|3Dne
P10991383A0289 |114 115|%o
P10991383A0289 |82 88|energy0000 P
P10991383A0289 |7 14|lattice06T0076
P10991383A0289 |98 106|sublevelic aspec
P10991383A0289 |18 19|%p
P10991648T0000 |45 59|half syndromeshatases and 5-
P10992299A0745 |85 100|PI12 expression0 Pharmacologic
P10992299A0745 |166 189|brain cancer cell linesHCO3-] is shown as a fu
P10992299A0745 |135 154|tumor brain tissuesemia. P00008997A047
P10992299A0745 |203 205|H4PC
P10992299A0745 |36 51|gene expressionine phosphatase
P10992299A0745 |22 29|membersson wit
P10992299A0745 |191 198|U-87 MGtion of
P10992299A0745 |70 83|tumorigenesise P00008171T0
P10992983T0000 |55 66|penile sized 5-nucleot
P10992983T0000 |15 23|relationComparis
P10992983T0000 |72 74|A.P0
P10992983T0000 |39 50|orientation phosphatas
P10993773A0717 |171 183|min ischemia] is shown a
P10993773A0717 |199 210|microm/mmHgCSF PCO2 th
P10993773A0717 |5 10|slope1606T
P10993773A0717 |113 127|control valueseonatal hyperb
P10993773A0717 |52 64|min ischemia and 5-nucle
P10993773A0717 |80 91|microm/mmHg1T0000 Phar
P10993773A0717 |154 164|myocardium2 When CSF
P10993787A0369 |51 61|transitions and 5-nu
P10993787A0369 |74 77|PHI000
P10993787A0369 |110 119|reductionf neonata
P10993787A0369 |42 45|SHGosp
P10993787A0369 |193 200|factorson of C
P10993787A0369 |123 126|MAPper
P10993787A0369 |13 16|MAP6 C
P10993787A0369 |21 34|MSNA increaseison with alk
P10993787A0369 |173 183|separationis shown a
P10993787A0369 |67 70|SHGdas
P10993787A0369 |141 150|elevationP00008997
P10993787A0369 |154 158|MSNA2 Wh
P10995121A0569 |0 8|AnalysisP0000160
P10995121A0569 |46 60|Infant Formulaatases and 5-n
P10995121A0569 |12 44|Standard Reference Material 184676 Comparison with alkaline phos
P10995121A0569 |74 79|value00081
P10995121A0569 |120 122|K1 h
P10995121A0569 |115 116|Kn
P10995121A0569 |98 113|mg vitamin K/kgic aspects of n
P10995121A0569 |126 127|nb
P10995121A0569 |141 152|coefficientP00008997A0
P10995121A0569 |156 165|variationWhen CSF 
P10995751A0093 |71 81|C/EBP-beta P00008171
P10995751A0093 |91 109|gene transcriptionmacologic aspects 
P10995751A0093 |194 201|elementn of CS
P10995751A0093 |57 69|protein-beta5-nucleotida
P10995751A0093 |126 146|IFN response elementbilirubinemia. P0000
P10997330A0361 |0 22|Northern blot analysisP00001606T0076 Compari
P10997330A0361 |73 80|pattern0000817
P10997330A0361 |45 55|STORP genehatases an
P10997330A0361 |84 94|expression00 Pharmac
P10997330A0361 |118 126|PML geneal hyper
P10997863A0753 |137 150|seizure focusia. P00008997
P10997863A0753 |24 27|NAAn w
P10997863A0753 |88 100|FLE patientsharmacologic
P10997863A0753 |60 73|seizure focusucleotidase P
P10997863A0753 |7 19|TLE patients06T0076 Comp
P10997863A0753 |33 39|ratioskaline
P10997904A1258 |153 161|residues72 When 
P10997904A1258 |181 212|response regulator-kinase pairs as a function of CSF PCO2 the 
P10997904A1258 |75 94|response regulators008171T0000 Pharmac
P10997904A1258 |45 50|patchhatas
P10997904A1258 |4 18|Spo0F residues01606T0076 Com
P10997904A1258 |115 122|bindingnatal h
P10998679A0500 |35 38|wthlin
P10998679A0500 |65 74|prognosestidase P0
P10998679A0500 |158 162|painen C
P10998679A0500 |47 54|illnesstases a
P10998679A0500 |101 109|scenarioaspects 
P10998679A0500 |16 23|factorsomparis
P10999205A0607 |117 120|VOItal
P10999205A0607 |24 34|resolutionn with alk
P10999205A0607 |131 142|acquisitionubinemia. P
P10999205A0607 |91 95|areamaco
P10999205A0607 |163 170|spectraF [HCO3
P10999205A0607 |55 63|interestd 5-nucl
P10999301A0000 |186 191|scale func
P10999301A0000 |131 141|technologyubinemia. 
P10999301A0000 |125 129|SNOMrbil
P10999301A0000 |149 154|study7A047
P10999301A0000 |13 23|evaluation6 Comparis
P10999301A0000 |158 167|magnetismen CSF [H
P10999301A0000 |113 123|microscopeeonatal hy
P10999301A0000 |43 53|parameterssphatases 
P10999301A0000 |70 75|ordere P00
P10999301A0000 |85 93|scanning0 Pharma
P10999369A0192 |119 125|microVl hype
P10999369A0192 |63 72|amplitudeeotidase 
P10999369A0192 |150 156|microVA0472 
P10999369A0192 |80 90|N2/P2 peak1T0000 Pha
P10999369A0192 |163 165|mAF 
P10999369A0192 |131 133|mAub
P10999369A0192 |18 27|amplitudeparison w
P10999369A0192 |51 61|potentialss and 5-nu
P11000203A0752 |252 262|RNA exportsplaced wh
P11000203A0752 |210 220|activitiese data of 
P11000203A0752 |164 168|type [HC
P11000203A0752 |126 139|K-Rev mutantsbilirubinemia
P11000203A0752 |58 68|properties-nucleotid
P11000203A0752 |106 116|RNA exportts of neon
P11000203A0752 |6 15|mutations606T0076 
P11000203A0752 |19 24|K-Revariso
P11000250A0200 |0 5|LMP-1P0000
P11000250A0200 |57 61|TRAF5-nu
P11000250A0200 |63 68|TRADDeotid
P11000250A0200 |74 87|JAK molecules0008171T0000 
P11000250A0200 |138 146|pathwaysa. P0000
P11000250A0200 |112 116|AP-1neon
P11000250A0200 |25 40|plasma membrane with alkaline 
P11000250A0200 |155 159|CD40 Whe
P11000250A0200 |100 109|NF-kappaB aspects 
P11000266T0000 |85 107|alpha-fetoprotein gene0 Pharmacologic aspect
P11000266T0000 |71 77|intron P0000
P11000266T0000 |21 29|enhancerison wit
P11000266T0000 |49 57|promoterses and 
P11000266T0000 |0 14|IdentificationP00001606T0076
P11000521A0588 |255 284|phosphatidylinositol 3-kinaseaced when compared to control
P11000521A0588 |321 328|PKB/AKTter slo
P11000521A0588 |78 92|transformation171T0000 Pharm
P11000521A0588 |286 297|PI 3-kinasebut still h
P11000521A0588 |303 319|protein kinase Bsignificantly gr
P11000521A0588 |241 251|activationo longer d
P11000521A0588 |115 127|NIH3T3 cellsnatal hyperb
P11000521A0588 |217 222|IRS-2of K-
P11000521A0588 |23 41|signaling pathwayson with alkaline p
P11000521A0588 |168 183|phosphorylationO3-] is shown a
P11000521A0588 |187 215|insulin receptor substrate-2function of CSF PCO2 the dat
P11002236A0328 |34 41|authorsaline p
P11002236A0328 |125 137|Associationsrbilirubinem
P11002236A0328 |167 183|Oncology centersCO3-] is shown a
P11002236A0328 |54 63|PPB casesnd 5-nucl
P11002236A0328 |142 162|Pediatric Hematology00008997A0472 When C
P11002236A0328 |24 29|studyn wit
P11002236A0328 |80 100|retrospective search1T0000 Pharmacologic
P11002236A0328 |0 7|METHODSP000016
P11003471A1149 |81 86|groupT0000
P11003471A1149 |131 136|Indiaubine
P11003471A1149 |13 21|analysis6 Compar
P11003471A1149 |90 97|virusesrmacolo
P11003471A1149 |58 67|Bangalore-nucleoti
P11003471A1149 |38 52|ToLCV isolatese phosphatases
P11003641A0811 |169 176|ability3-] is 
P11003641A0811 |60 67|subunitucleoti
P11003641A0811 |198 211|transcription CSF PCO2 the
P11003641A0811 |147 154|mutants997A047
P11003641A0811 |130 139|fcp1 tfg1rubinemia
P11003641A0811 |46 51|RAP74atase
P11003641A0811 |180 185|Fcp1pn as 
P11003641A0811 |53 58|Tfg1pand 5
P11003641A0811 |108 118|phenotypes of neonat
P11003641A0811 |27 38|motif KEFGKith alkalin
P11003641A0811 |250 258|promoterdisplace
P11003641A0811 |71 76|TFIIF P000
P11003652A0961 |139 143|role. P0
P11003652A0961 |107 117|PAK Ste20ps of neona
P11003652A0961 |58 76|pheromone response-nucleotidase P000
P11003652A0961 |40 44|factphos
P11003652A0961 |27 33|Cdc42pith al
P11003652A0961 |6 13|results606T007
P11003652A0961 |86 97|interaction Pharmacolo
P11003653A0198 |0 8|DeletionP0000160
P11003653A0198 |126 131|gammabilir
P11003653A0198 |198 209|PYR complex CSF PCO2 t
P11003653A0198 |73 100|beta-globin locus construct00008171T0000 Pharmacologic
P11003653A0198 |233 239|switchts are
P11003653A0198 |172 176|mice is 
P11003653A0198 |52 59|complex and 5-
P11003653A0198 |38 42|sitee ph
P11003653A0198 |136 157|beta-globin switchingmia. P00008997A0472 W
P11003669A0000 |137 151|kinase domainsia. P00008997A
P11003669A0000 |15 23|rat geneComparis
P11003669A0000 |112 132|ErbB-2 juxtamembraneneonatal hyperbiliru
P11003669A0000 |67 74|proteindase P0
P11003669A0000 |91 97|screenmacolo
P11003669A0000 |4 11|product01606T0
P11003669A0000 |155 159|bait Whe
P11003805A0443 |0 7|StudiesP000016
P11003805A0443 |64 72|symptomsotidase 
P11003805A0443 |38 49|acid refluxe phosphata
P11003805A0443 |25 29|DGOR wit
P11003805A0443 |141 153|oesophagitisP00008997A04
P11003805A0443 |84 95|acid reflux00 Pharmaco
P11003807A0303 |51 63|oesophagitiss and 5-nucl
P11003807A0303 |121 139|oesophageal damagehyperbilirubinemia
P11003807A0303 |79 87|symptoms71T0000 
P11003807A0303 |0 8|SymptomsP0000160
P11004369A0000 |0 9|OBJECTIVEP00001606
P11004369A0000 |27 39|relationshipith alkaline
P11004369A0000 |192 201|carcinomaion of CS
P11004369A0000 |156 176|growth factor levelsWhen CSF [HCO3-] is 
P11004369A0000 |66 71|tumoridase
P11004369A0000 |110 129|microvessel densityf neonatal hyperbil
P11004369A0000 |48 58|blood flowases and 5
P11004369A0000 |84 108|color Doppler ultrasound00 Pharmacologic aspects
P11005808A1082 |51 70|ERK MAPK activations and 5-nucleotidas
P11005808A1082 |26 29|Raswit
P11005808A1082 |106 116|heat shockts of neon
P11005808A1082 |6 13|results606T007
P11005808A1082 |81 95|cell viabilityT0000 Pharmaco
P11005831A0242 |187 210|element binding proteinfunction of CSF PCO2 th
P11005831A0242 |43 47|bZIPspha
P11005831A0242 |27 41|leucine zipperith alkaline p
P11005831A0242 |147 152|AREB1997A0
P11005831A0242 |165 170|AREB3[HCO3
P11005831A0242 |120 126|system hyper
P11005831A0242 |49 53|typeses 
P11005831A0242 |6 11|cDNAs606T0
P11005831A0242 |67 75|proteinsdase P00
P11005831A0242 |154 159|AREB22 Whe
P11005831A0242 |103 108|yeastpects
P11006283A1180 |71 75|poly P00
P11006283A1180 |63 66|DNAeot
P11006283A1180 |12 20|AROM-p6476 Compa
P11006283A1180 |134 138|rolenemi
P11006283A1180 |142 168|mRNA maturation/metabolism00008997A0472 When CSF [HC
P11006283A1180 |76 77|A0
P11006283A1180 |79 91|homopolymers71T0000 Phar
P11006283A1180 |36 43|bindingine pho
P11006283A1180 |113 120|proteineonatal
P11006284T0000 |21 31|kinase ferison with 
P11006284T0000 |79 107|insulin receptor substrate-171T0000 Pharmacologic aspect
P11006284T0000 |58 67|complexes-nucleoti
P11006284T0000 |112 141|phosphatidylinositol 3-kinaseneonatal hyperbilirubinemia. 
P11006331A0319 |84 97|abnormalities00 Pharmacolo
P11006331A0319 |30 45|allotetraploids alkaline phosp
P11006331A0319 |13 22|phenotype6 Compari
P11007509A1271 |49 53|areases 
P11007509A1271 |7 22|PMR target area06T0076 Compari
P11007509A1271 |92 104|flow reserveacologic asp
P11007509A1271 |57 68|improvement5-nucleotid
P11007509A1271 |115 128|wall segmentsnatal hyperbi
P11007509A1271 |175 191|stress perfusion shown as a func
P11007777A0813 |0 8|AnalysisP0000160
P11007777A0813 |12 34|intron/exon boundaries76 Comparison with alk
P11007777A0813 |151 159|splicing0472 Whe
P11007777A0813 |101 126|aspartyl beta-hydroxylaseaspects of neonatal hyper
P11007777A0813 |172 176|gene is 
P11007777A0813 |78 85|junctin171T000
P11007777A0813 |87 95|junctatePharmaco
P11007777A0813 |50 60|BAC cloneses and 5-n
P11007949A1395 |49 53|PTENses 
P11007949A1395 |89 95|tumorsarmaco
P11007949A1395 |74 79|forms00081
P11007949A1395 |25 45|inactivation mutants with alkaline phosp
P11007949A1395 |65 66|%t
P11007949A1607 |76 80|PTEN0817
P11007949A1607 |30 38|activity alkalin
P11007949A1607 |88 93|cellsharma
P11007949A1607 |42 45|ILKosp
P11007954A0170 |33 40|proteinkaline 
P11007954A0170 |216 219|Sos of
P11007954A0170 |260 263|Raswhe
P11007954A0170 |83 86|Son000
P11007954A0170 |246 256|activationger displa
P11007954A0170 |125 128|Rasrbi
P11007954A0170 |227 235|membraneted rats
P11007954A0170 |106 121|exchange factorts of neonatal 
P11007954A0170 |44 48|Grb2phat
P11007954A0170 |186 194|receptor functio
P11007954A0170 |50 57|adaptores and 
P11007954A0170 |78 81|Sos171
P11007954A0170 |160 168|tyrosine CSF [HC
P11007954A0170 |198 201|Ras CS
P11007954A0170 |142 148|signal000089
P11007954A0170 |4 17|growth factor01606T0076 Co
P11007961A0930 |0 9|MutationsP00001606
P11007961A0930 |13 18|genes6 Com
P11007961A0930 |131 141|fostriecinubinemia. 
P11007961A0930 |108 122|PP2A inhibitor of neonatal h
P11007961A0930 |28 43|PR65/A subunitsth alkaline pho
P11007961A0930 |176 180|drugshow
P11007961A0930 |92 99|cancersacologi
P11007968A0255 |101 104|PCRasp
P11007968A0255 |31 34|dxralk
P11007968A0255 |93 96|DNAcol
P11007968A0255 |111 127|oligonucleotides neonatal hyperb
P11007968A0255 |9 16|purposeT0076 C
P11007968A0255 |142 149|regions0000899
P11007968A0255 |20 27|segmentrison w
P11008139T0000 |26 53|pattern discrimination taskwith alkaline phosphatases 
P11008139T0000 |11 19|learning076 Comp
P11008420A0580 |85 100|complex changes0 Pharmacologic
P11008420A0580 |21 30|advantageison with
P11008420A0580 |4 12|detector01606T00
P11008420A0580 |127 143|characterizationilirubinemia. P0
P11008420A0580 |50 68|segment deviationses and 5-nucleotid
P11008420A0580 |170 176|events-] is 
P11011139A0000 |169 173|Sin43-] 
P11011139A0000 |74 90|mediator complex0008171T0000 Pha
P11011139A0000 |181 191|alteration as a func
P11011139A0000 |134 141|studiesnemia. 
P11011139A0000 |59 68|componentnucleotid
P11011139A0000 |208 227|chromatin structurethe data of K-deple
P11011139A0000 |107 121|RNA polymerases of neonatal 
P11011139A0000 |36 53|SIN4 gene productine phosphatases 
P11011139A0000 |154 165|involvement2 When CSF 
P11012568A0192 |50 57|obesityes and 
P11012568A0192 |36 46|ACTH driveine phosph
P11012568A0192 |16 32|hypersensitivityomparison with a
P11012671A0576 |85 94|C/EBPbeta0 Pharmac
P11012671A0576 |42 46|siteosph
P11012671A0576 |58 78|Gadd45gamma promoter-nucleotidase P00008
P11012671A0576 |99 109|C/EBPdeltac aspects 
P11012671A0576 |188 210|reporter gene analysisunction of CSF PCO2 th
P11012671A0576 |178 182|EMSAown 
P11012671A0576 |156 176|mobility shift assayWhen CSF [HCO3-] is 
P11012671A0576 |3 11|addition001606T0
P11012680A0676 |0 14|Src activationP00001606T0076
P11012680A0676 |88 97|inhibitorharmacolo
P11012680A0676 |64 67|Srcoti
P11012680A0676 |26 30|FGF1with
P11012680A0676 |72 75|PP2P00
P11012680A0676 |101 104|Srcasp
P11012680A0676 |50 60|SH2 domaines and 5-n
P11012680A1020 |137 144|PDGF-BBia. P00
P11012680A1020 |122 133|stimulationyperbilirub
P11012680A1020 |61 86|calcium chelator BAPTA-AMcleotidase P00008171T0000
P11012680A1020 |90 97|oocytesrmacolo
P11012680A1020 |227 231|GVBDted 
P11012680A1020 |44 52|neomycinphatases
P11012680A1020 |15 23|PLCgammaComparis
P11012680A1020 |194 215|PLCgamma binding siten of CSF PCO2 the dat
P11012680A1020 |148 155|oocytes97A0472
P11012680A1020 |4 7|use016
P11012680A1020 |109 114|FGFR1of ne
P11012680A1020 |167 178|PDGFR-FGFR1CO3-] is sh
P11012680A1020 |236 256|ERK2 phosphorylationare no longer displa
P11012680A1020 |35 42|peptideline ph
P11013079A0927 |152 160|promoter472 When
P11013079A0927 |9 34|transcription start sitesT0076 Comparison with alk
P11013079A0927 |222 235|SV40 promoterdepleted rats
P11013079A0927 |101 124|transfection constructsaspects of neonatal hyp
P11013079A0927 |52 77|primer extension analysis and 5-nucleotidase P0000
P11013079A0927 |187 195|activityfunction
P11013079A0927 |85 95|mouse gene0 Pharmaco
P11014197A0339 |70 80|inhibitorse P0000817
P11014197A0339 |123 134|subfamiliesperbilirubi
P11014197A0339 |9 28|inhibitor scaffoldsT0076 Comparison wi
P11014197A0339 |96 103|kinasesogic as
P11014213A1019 |275 300|transcription factor GAL4o controls but still have
P11014213A1019 |233 240|ERalphats are 
P11014213A1019 |36 44|arseniteine phos
P11014213A1019 |261 267|domainhen co
P11014213A1019 |109 120|COS-1 cellsof neonatal
P11014213A1019 |88 107|receptor activationharmacologic aspect
P11014213A1019 |70 76|domaine P000
P11014213A1019 |223 229|domaineplete
P11014213A1019 |21 32|interactionison with a
P11014213A1019 |324 341|CAT reporter gene slope (1.21 +/- 
P11014213A1019 |170 186|receptors GAL-ER-] is shown as a
P11014215A1092 |152 158|region472 Wh
P11014215A1092 |226 241|down-regulationeted rats are n
P11014215A1092 |251 274|GnRHR promoter activityisplaced when compared 
P11014215A1092 |172 182|GnRHR gene is shown 
P11014215A1092 |109 131|translation start siteof neonatal hyperbilir
P11014215A1092 |64 76|DNA fragmentotidase P000
P11014215A1092 |18 34|deletion studiesparison with alk
P11014465A0479 |16 25|diagnosisomparison
P11014465A0479 |109 112|PVLof 
P11014465A0479 |122 126|daysyper
P11014465A0479 |88 92|daysharm
P11014465A0479 |45 58|echodensitieshatases and 5
P11014465A0479 |128 133|rangelirub
P11014465A0479 |77 82|range8171T
P11014465A0479 |9 12|dayT00
P11014465A0479 |71 75|days P00
P11014465A0479 |139 143|days. P0
P11014821T0000 |4 25|LAMMER protein kinase01606T0076 Comparison
P11014821T0000 |161 169|isoformsCSF [HCO
P11014821T0000 |41 50|Doa locushosphatas
P11014821T0000 |181 192|development as a funct
P11014821T0000 |97 111|germline cellsgic aspects of
P11014821T0000 |54 64|Drosophiland 5-nucle
P11015197A0310 |87 90|TM4Pha
P11015197A0310 |82 85|TMS000
P11015197A0310 |59 67|residuesnucleoti
P11015197A0310 |38 42|timee ph
P11015197A0310 |19 27|cysteinearison w
P11015200A0156 |7 9|J.06
P11016014A0181 |152 160|patients472 When
P11016014A0181 |67 81|susceptibilitydase P00008171
P11016014A0181 |28 33|studyth al
P11016014A0181 |210 225|angina pectorise data of K-dep
P11016014A0181 |181 190|syndromes as a fun
P11016014A0181 |16 19|aimomp
P11016014A0181 |113 125|lipoproteinseonatal hype
P11016014A0181 |142 148|status000089
P11016014A0181 |0 10|HYPOTHESISP00001606T
P11016014A0181 |85 99|apolipoprotein0 Pharmacologi
P11016724A0536 |35 56|99mTc-HSA nanocolloidline phosphatases and
P11016724A0536 |14 17|MBq Co
P11016724A0536 |25 31|microL with 
P11016724A0536 |109 116|surgeryof neon
P11016724A0536 |122 130|aliquotsyperbili
P11016724A0536 |3 10|group B001606T
P11016724A0536 |100 101|h 
P11016737A0275 |26 33|outcomewith al
P11016737A0275 |73 79|status000081
P11016850A0423 |84 94|similarity00 Pharmac
P11016850A0423 |59 66|proteinnucleot
P11016850A0423 |12 24|DNA fragment76 Compariso
P11016850A0423 |98 105|membersic aspe
P11016850A0423 |113 124|LysR familyeonatal hyp
P11016850A0423 |144 154|regulators008997A047
P11016850A0423 |156 161|LTTRsWhen 
P11016850A0423 |49 53|partses 
P11016954A0438 |51 56|RDE-1s and
P11016954A0438 |19 24|QDE-2ariso
P11016954A0438 |70 74|RNAie P0
P11016954A0438 |0 4|AGO1P000
P11017876A0787 |138 144|mDAP-3a. P00
P11017876A0787 |45 51|mDAP-3hatase
P11017876A0787 |166 172|matrixHCO3-]
P11017876A0787 |73 91|cell fractionation00008171T0000 Phar
P11017876A0787 |14 34|localization studies Comparison with alk
P11017876A0787 |52 71|EGFP fusion protein and 5-nucleotidase
P11017876A0787 |96 127|protease protection experimentsogic aspects of neonatal hyperb
P11018028A0263 |102 109|CDC25Mmspects 
P11018028A0263 |25 36|involvement with alkal
P11018028A0263 |145 151|RasGEF08997A
P11018028A0263 |166 177|mouse brainHCO3-] is s
P11018028A0263 |191 200|membranestion of C
P11018028A0263 |113 124|fibroblastseonatal hyp
P11018028A0263 |83 98|phosphorylation000 Pharmacolog
P11018028A0263 |55 69|protein kinased 5-nucleotida
P11018028A0263 |71 74|PKA P0
P11018264A0397 |0 33|Reporter gene expression analysesP00001606T0076 Comparison with al
P11018264A0397 |78 84|levels171T00
P11018264A0397 |88 98|expressionharmacolog
P11018264A0397 |126 136|cell linesbilirubine
P11018264A0397 |53 67|WASP promotersand 5-nucleoti
P11019257A0159 |84 94|decay rate00 Pharmac
P11019257A0159 |13 20|3T1-3T26 Compa
P11019257A0159 |210 221|distortionse data of K
P11019257A0159 |45 51|effecthatase
P11019257A0159 |98 106|emissionic aspec
P11019257A0159 |59 69|line shapenucleotida
P11019257A0159 |182 191|magnitudeas a func
P11019257A0159 |116 125|3T2 stateatal hype
P11019257A0159 |139 145|extent. P000
P11020375A0134 |2 7|total00016
P11020375A0134 |187 190|CLIfun
P11020375A0134 |25 44|Ross broiler chicks with alkaline phos
P11020375A0134 |144 149|parts00899
P11020375A0134 |126 130|g kgbili
P11020375A0134 |208 214|ppb AFthe da
P11020375A0134 |196 202|ppb AFof CSF
P11020375A0134 |109 116|controlof neon
P11020375A0134 |134 138|dietnemi
P11020375A0134 |220 223|CLIK-d
P11020375A0134 |118 121|CLIal 
P11020375A0134 |175 181|ppb AF shown
P11020375A0134 |233 237|daysts a
P11020375A0134 |163 166|ppbF [
P11020375A0134 |64 80|treatment groupsotidase P0000817
P11020375A0134 |168 170|AFO3
P11023074A1105 |4 8|cost0160
P11023074A1105 |13 17|test6 Co
P11023074A1105 |45 49|kEIAhata
P11023074A1105 |41 43|CCho
P11023074A1105 |54 59|PACE2nd 5-
P11023832A1038 |17 24|resultsmpariso
P11023832A1038 |161 175|protein kinaseCSF [HCO3-] is
P11023832A1038 |177 187|MAP kinasehown as a 
P11023832A1038 |193 213|NF-kappaB signallingon of CSF PCO2 the d
P11023832A1038 |89 95|PC-PLCarmaco
P11023832A1038 |54 62|TNFalphand 5-nuc
P11023832A1038 |42 52|KG1a cellsosphatases
P11023832A1038 |111 125|lipid products neonatal hype
P11023832A1038 |138 142|turna. P
P11023832A1038 |100 103|PLD as
P11023853A0188 |304 312|activityignifica
P11023853A0188 |267 280|energy budgetmpared to con
P11023853A0188 |27 45|weather conditionsith alkaline phosp
P11023853A0188 |244 253|partitiononger dis
P11023853A0188 |211 229|energy expenditure data of K-deplete
P11023853A0188 |106 121|laboratory datats of neonatal 
P11023853A0188 |192 201|estimatesion of CS
P11023853A0188 |258 265|verdinsd when 
P11023853A0188 |187 190|TALfun
P11023853A0188 |323 333|componentsr slope (1
P11023853A0188 |96 101|birdsogic 
P11023853A0188 |143 147|rate0008
P11023853A0188 |231 234|DEErat
P11023853A0188 |175 185|laboratory shown as 
P11023853A0188 |69 80|budget datase P0000817
P11023934A0855 |0 3|L/HP00
P11023934A0855 |107 117|predictorss of neona
P11023934A0855 |121 127|eventshyperb
P11023934A0855 |52 67|filling pattern and 5-nucleoti
P11023934A0855 |24 25|Pn
P11023934A0855 |11 14|chi076
P11023934A0855 |81 82|PT
P11023934A0855 |69 72|chise 
P11024026A0133 |103 110|bindingpects o
P11024026A0133 |24 33|arrestinsn with al
P11024026A0133 |9 20|selectivityT0076 Compa
P11024026A0133 |73 81|receptor00008171
P11024026A0133 |65 69|formtida
P11024026A0133 |115 127|dissociationnatal hyperb
P11024036A0984 |136 146|constructsmia. P0000
P11024036A0984 |72 96|reporter gene expressionP00008171T0000 Pharmacol
P11024036A0984 |41 70|C/EBP alpha expression vectorhosphatases and 5-nucleotidas
P11024036A0984 |22 33|fibroblastsson with al
P11024047A0626 |34 39|Smad2aline
P11024047A0626 |121 130|treatmenthyperbili
P11024047A0626 |75 103|luciferase reporter activity008171T0000 Pharmacologic as
P11024047A0626 |66 71|levelidase
P11024047A0626 |0 10|ExpressionP00001606T
P11024182A0781 |68 70|ARas
P11024182A0781 |14 15|I 
P11024182A0781 |7 13|alpha106T007
P11024182A0781 |214 217|pCIta 
P11024182A0781 |160 169|reduction CSF [HCO
P11024182A0781 |182 190|ribozymeas a fun
P11024182A0781 |74 76|IR00
P11024182A0781 |141 142|%P
P11024182A0781 |218 228|neo vectorf K-deplet
P11024182A0781 |53 62|reductionand 5-nuc
P11024182A0781 |100 122|pHbetaAPr-1-neo vector aspects of neonatal h
P11024182A0781 |17 30|collagen mRNAmparison with
P11024300A1579 |186 194|portions functio
P11024300A1579 |215 228|reading framea of K-deplet
P11024300A1579 |122 130|proteinsyperbili
P11024300A1579 |88 99|polypeptideharmacologi
P11024300A1579 |164 167|ARC [H
P11024300A1579 |30 50|amino acid sequences alkaline phosphatas
P11024300A1579 |143 162|chromatin structure0008997A0472 When C
P11024300A1579 |232 242|TIG-1 mRNAats are no
P11024300A1579 |111 118|complex neonat
P11024300A1579 |54 71|peptide fragmentsnd 5-nucleotidase
P11024300A1579 |0 6|NatureP00001
P11025367A1009 |17 39|plasma cholecystokininmparison with alkaline
P11025367A1009 |62 70|patientsleotidas
P11025367A1009 |92 100|emptyingacologic
P11025367A1009 |0 13|AbnormalitiesP00001606T007
P11027027A0061 |85 90|LC/MS0 Pha
P11027027A0061 |97 120|electrospray ionizationgic aspects of neonatal
P11027027A0061 |3 20|Sunset Yellow FCF001606T0076 Compa
P11027027A0061 |51 83|chromatography/mass spectrometrys and 5-nucleotidase P00008171T0
P11027267A0752 |0 8|PolysomeP0000160
P11027267A0752 |13 35|40S ribosome fractions6 Comparison with alka
P11027267A0752 |67 78|krr1 mutantdase P00008
P11027267A0752 |98 103|cellsic as
P11027274A1682 |34 45|PI 3-kinasealine phosp
P11027274A1682 |126 135|structurebilirubin
P11027274A1682 |56 64|activity 5-nucle
P11027274A1682 |144 151|isoform008997A
P11027274A1682 |82 89|extents0000 Ph
P11027280A0536 |0 10|Cam kinaseP00001606T
P11027280A0536 |59 64|Smad4nucle
P11027280A0536 |90 95|Smad3rmaco
P11027280A0536 |30 45|phosphorylation alkaline phosp
P11027280A0536 |82 88|extent0000 P
P11027280A0536 |49 54|Smad2ses a
P11027289A0000 |254 260|regionlaced 
P11027289A0000 |94 113|RNA binding proteinologic aspects of n
P11027289A0000 |148 164|RNA accumulation97A0472 When CSF
P11027289A0000 |28 38|suppressorth alkalin
P11027289A0000 |210 231|transposon insertionse data of K-depleted 
P11027289A0000 |194 199|genesn of 
P11027289A0000 |115 117|SUna
P11027289A0000 |57 58|s5
P11027289A0000 |177 184|alleleshown as
P11027289A0000 |48 52|geneases
P11027289A0000 |118 119|Sa
P11027289A0321 |87 107|RNA binding activityPharmacologic aspect
P11027289A0321 |47 53|motifstases 
P11027289A0321 |114 115|So
P11027289A0321 |5 11|result1606T0
P11027289A0321 |111 113|SU n
P11027289A0321 |55 59|ARM1d 5-
P11027289A0321 |64 68|ARM2otid
P11027294A0483 |68 72|p300ase 
P11027294A0483 |30 64|histone acetyltransferase activity alkaline phosphatases and 5-nucle
P11027294A0483 |144 154|alteration008997A047
P11027294A0483 |95 104|reductionlogic asp
P11027294A0483 |120 139|histone acetylation hyperbilirubinemia
P11027294A0483 |158 177|chromatin structureen CSF [HCO3-] is s
P11027294A0483 |5 16|interaction1606T0076 C
P11027724A0335 |50 53|Seres 
P11027724A0335 |75 83|residues008171T0
P11027724A0335 |42 48|serineosphat
P11027724A0335 |89 94|p-Serarmac
P11027724A0335 |12 19|BRI1-KD76 Comp
P11027724A0335 |59 68|threoninenucleotid
P11027724A0335 |70 73|Thre P
P11027833A0362 |0 13|Flow cytomeryP00001606T007
P11027833A0362 |27 46|cell cycle analysisith alkaline phosph
P11028131A1374 |119 124|costsl hyp
P11028131A1374 |8 16|research6T0076 C
P11028131A1374 |128 139|IFN beta-1blirubinemia
P11028131A1374 |66 78|modificationidase P00008
P11028131A1374 |82 84|MS00
P11028131A1374 |93 100|historycologic
P11028131A1374 |143 147|RRMS0008
P11028131A1374 |39 64|measure treatment effects phosphatases and 5-nucle
P11028131T0000 |0 18|Cost-effectivenessP00001606T0076 Com
P11028131T0000 |61 93|sclerosis disability progressioncleotidase P00008171T0000 Pharma
P11028131T0000 |22 40|interferon beta-1bson with alkaline 
P11028944A1020 |18 28|AUC valuesparison wi
P11028944A1020 |9 13|CmaxT007
P11028944A1020 |67 71|dosedase
P11029045A0000 |0 15|HyperactivationP00001606T0076 
P11029045A0000 |48 53|cellsases 
P11029045A0000 |27 40|fission yeastith alkaline 
P11029045A0000 |107 118|catastrophes of neonat
P11029045A0000 |19 23|Cdc2aris
P11029045A0000 |84 91|mitosis00 Phar
P11029262T0000 |0 5|DiaryP0000
P11029458A0000 |0 5|CellsP0000
P11029458A0000 |57 64|stimuli5-nucle
P11029458A0000 |23 31|responseon with 
P11029459A0000 |34 43|TGF-beta1aline pho
P11029459A0000 |145 149|cell0899
P11029459A0000 |58 74|tumor suppressor-nucleotidase P0
P11029459A0000 |13 32|growth factor-beta16 Comparison with a
P11029459A0000 |112 127|characteristicsneonatal hyperb
P11029459A0000 |80 94|tumor promoter1T0000 Pharmac
P11029467T0000 |184 199|cell line THP-1 a function of 
P11029467T0000 |44 53|adenylatephatases 
P11029467T0000 |22 29|peptideson wit
P11029467T0000 |126 141|gene activationbilirubinemia. 
P11029467T0000 |73 84|polypeptide00008171T00
P11029467T0000 |101 113|factor-kappaaspects of n
P11029467T0000 |154 160|levels2 When
P11029656A0640 |0 3|Mn2P00
P11029656A0640 |79 87|proteins71T0000 
P11029656A0640 |24 40|junction bindingn with alkaline 
P11029656A0640 |54 64|activitiesnd 5-nucle
P11029700A0295 |20 22|Osri
P11029700A0295 |74 85|transcripts0008171T000
P11029700A0295 |52 59|tissues and 5-
P11029700A0295 |9 13|cycHT007
P11029700A0295 |121 126|cellshyper
P11029700A0295 |6 8|Pt60
P11029700A0295 |23 27|cycHon w
P11029700A0746 |102 111|rice CDKsspects of
P11029700A0746 |53 57|CycHand 
P11029700A0746 |82 84|R200
P11029700A0746 |32 37|assaylkali
P11029700A0746 |50 52|Oses
P11029704A0378 |342 346|ABI3.23 
P11029704A0378 |93 103|distB ABREcologic as
P11029704A0378 |244 256|RY/G complexonger displa
P11029704A0378 |148 163|transactivation97A0472 When CS
P11029704A0378 |28 48|particle bombardmentth alkaline phosphat
P11029704A0378 |269 279|RY repeatsared to co
P11029704A0378 |13 21|analysis6 Compar
P11029704A0378 |323 338|transactivationr slope (1.21 +
P11029704A0378 |191 199|responsetion of 
P11029704A0378 |218 226|tetramerf K-depl
P11029704A0378 |52 73|tobacco leaf sections and 5-nucleotidase P
P11029704A0378 |130 137|elementrubinem
P11029704A0378 |167 171|ABI3CO3-
P11029704A0378 |286 291|G-boxbut s
P11029704A0378 |77 85|tetramer8171T000
P11029704A0378 |203 206|ABAPCO
P11030066A0142 |23 37|manifestationson with alkali
P11030066A0142 |63 69|babieseotida
P11030066A0142 |41 53|brain injuryhosphatases 
P11030066A0142 |82 96|motor deficits0000 Pharmacol
P11030476A0685 |0 6|SporesP00001
P11030476A0685 |60 65|waterucleo
P11030476A0685 |12 31|Rhizopus stolonifer76 Comparison with 
P11030476A0685 |77 86|spores/mL8171T0000
P11030744A0763 |0 14|OverexpressionP00001606T0076
P11030744A0763 |30 34|dpm1 alk
P11030744A0763 |52 54|S. a
P11030744A0763 |110 131|DPM synthase activityf neonatal hyperbilir
P11030744A0763 |89 97|increasearmacolo
P11030744A0763 |39 48|his7/dpm1 phosphat
P11030744A0763 |18 24|Trdpm1pariso
P11031252A0646 |170 176|amount-] is 
P11031252A0646 |180 189|PKC deltan as a fu
P11031252A0646 |31 49|PKC epsilon levelsalkaline phosphata
P11031252A0646 |110 115|levelf neo
P11031252A0646 |124 135|PKC isotypeerbilirubin
P11031252A0646 |79 90|HMW isoform71T0000 Pha
P11031252A0646 |66 74|contrastidase P0
P11031252A0646 |4 13|LMW FGF-201606T007
P11031366T0001 |0 19|Helicobacter pyloriP00001606T0076 Comp
P11031366T0001 |24 40|stomach diseasesn with alkaline 
P11031366T0001 |55 60|pointd 5-n
P11031366T0001 |64 68|viewotid
P11031773A0174 |51 72|formalin induced-pains and 5-nucleotidase 
P11031773A0174 |9 16|purposeT0076 C
P11031773A0174 |31 35|testalka
P11031773A0174 |76 80|mice0817
P11031773A0174 |37 46|capsaicinne phosph
P11032599T0000 |39 42|use ph
P11032599T0000 |15 30|recommendationsComparison with
P11032599T0000 |79 86|factors71T0000
P11032599T0000 |113 132|practice guidelineseonatal hyperbiliru
P11032677A0230 |68 73|plugsase P
P11032677A0230 |165 172|atrophy[HCO3-]
P11032677A0230 |120 129|steatitis hyperbil
P11032677A0230 |212 221|glossitisdata of K
P11032677A0230 |144 152|myopathy008997A0
P11032677A0230 |10 18|findings0076 Com
P11032677A0230 |174 185|candidiasiss shown as 
P11032677A0230 |32 44|pancreatitislkaline phos
P11034392A1072 |48 65|survival pathwaysases and 5-nucleo
P11034392A1072 |160 173|proliferation CSF [HCO3-] 
P11034392A1072 |89 97|receptorarmacolo
P11034392A1072 |107 120|NF-kappaB/Rels of neonatal
P11034392A1072 |125 130|PI-3Krbili
P11034392A1072 |20 24|datariso
P11034547A0674 |139 168|homeodomain recognition sites. P00008997A0472 When CSF [HC
P11034547A0674 |47 56|multimerstases and
P11034547A0674 |96 99|DB1ogi
P11034547A0674 |111 118|element neonat
P11034547A0674 |10 14|Arix0076
P11034547A0674 |81 88|bindingT0000 P
P11034547A0674 |19 25|NBPhoxarison
P11034547A1355 |136 148|DBH promotermia. P000089
P11034547A1355 |22 27|studyson w
P11034547A1355 |42 48|NBPhoxosphat
P11034547A1355 |33 37|Arixkali
P11034547A1355 |118 128|propertiesal hyperbi
P11034933A0389 |119 131|prolongationl hyperbilir
P11034933A0389 |165 183|nmol/L domperidone[HCO3-] is shown a
P11034933A0389 |143 157|repolarization0008997A0472 W
P11034933A0389 |59 76|guinea pig heartsnucleotidase P000
P11034933A0389 |12 19|RESULTS76 Comp
P11034933A0389 |21 28|Studiesison wi
P11034933A0389 |0 7|METHODSP000016
P11035037A0183 |32 44|yeast TAF145lkaline phos
P11035037A0183 |89 101|TBP functionarmacologic 
P11035037A0183 |46 53|yTAF145atases 
P11035037A0183 |21 28|segmentison wi
P11035037A0183 |64 67|TBPoti
P11035867A0000 |0 9|OBJECTIVEP00001606
P11035867A0000 |335 356|blood pressure curves1 +/- 0.23 vs. P00010
P11035867A0000 |123 133|Braun GmbHperbilirub
P11035867A0000 |290 311|blood pressure valuesstill have a signific
P11035867A0000 |223 227|dataeple
P11035867A0000 |263 272|algorithmn compare
P11035867A0000 |246 255|selectionger displ
P11035867A0000 |145 152|Germany08997A0
P11035867A0000 |100 121|Braun PrecisionSensor aspects of neonatal 
P11035867A0000 |172 202|ANSI/AAMI SP10-1992 guidelines is shown as a function of CSF
P11035867A0000 |135 143|Kronbergemia. P0
P11035867A0000 |70 98|wrist blood pressure monitore P00008171T0000 Pharmacolog
P11035867A0000 |35 46|performanceline phosph
P11036786A0628 |117 124|Animalstal hyp
P11036786A0628 |88 112|Drinking Water Standardsharmacologic aspects of 
P11036786A0628 |14 21|results Compar
P11036786A0628 |58 72|target animals-nucleotidase 
P11036786A0628 |39 50|experiments phosphatas
P11036938A1162 |206 211|surge2 the
P11036938A1162 |28 38|expressionth alkalin
P11036938A1162 |134 151|steroid secretionnemia. P00008997A
P11036938A1162 |176 179|daysho
P11036938A1162 |215 228|gonadotropinsa of K-deplet
P11036938A1162 |62 76|erbB receptorsleotidase P000
P11036938A1162 |110 122|augmentationf neonatal h
P11036938A1162 |3 11|increase001606T0
P11036939A2149 |34 42|pathwaysaline ph
P11036939A2149 |64 87|planar polarity pathwayotidase P00008171T0000 
P11036939A2149 |48 59|Wnt pathwayases and 5-
P11036939A2149 |0 3|DshP00
P11037759T0000 |0 15|Catch-up growthP00001606T0076 
P11037759T0000 |54 68|administrationnd 5-nucleotid
P11037759T0000 |91 108|agent vincristinemacologic aspects
P11037759T0000 |33 43|dimensionskaline pho
P11037759T0000 |118 122|ratsal h
P11037823A1134 |0 11|CONCLUSIONSP00001606T0
P11037823A1134 |13 30|LSCC malformation6 Comparison with
P11037823A1134 |180 184|SNHLn as
P11037823A1134 |120 128|deafness hyperbi
P11037823A1134 |144 150|gusher008997
P11037823A1134 |196 203|hearingof CSF 
P11037823A1134 |92 100|aqueductacologic
P11037823A1134 |175 178|CHL sh
P11037823A1134 |49 66|ear malformationsses and 5-nucleot
P11038042A0948 |102 122|platelet nadir countspects of neonatal h
P11038042A0948 |55 77|blood cell nadir countd 5-nucleotidase P0000
P11038042A0948 |96 97|lo
P11038042A0948 |18 23|mg/m2paris
P11038042A0948 |0 10|EscalationP00001606T
P11038118A0000 |0 14|Methyl formateP00001606T0076
P11038118A0000 |76 87|fabrication08171T0000 
P11038118A0000 |56 67|oligoesters 5-nucleoti
P11038118A0000 |91 103|microspheresmacologic as
P11038118A0000 |129 142|serum albuminirubinemia. P
P11038118A0000 |144 147|BSA008
P11038317A0000 |152 157|cells472 W
P11038317A0000 |81 89|elementsT0000 Ph
P11038317A0000 |97 106|machinerygic aspec
P11038317A0000 |121 137|membrane traffichyperbilirubinem
P11038317A0000 |48 61|RAB subfamilyases and 5-nu
P11038317A0000 |32 40|proteinslkaline 
P11038366A1322 |103 108|Rts1ppects
P11038366A1322 |58 69|association-nucleotida
P11038366A1322 |94 101|subunitologic 
P11038366A1322 |13 17|loss6 Co
P11038366A1322 |21 32|methylationison with a
P11038366A1322 |81 86|yeastT0000
P11038366A1417 |84 93|complexes00 Pharma
P11038366A1417 |6 17|methylation606T0076 Co
P11038366A1417 |58 62|PP2A-nuc
P11038366A1417 |45 54|formationhatases a
P11038366A1417 |21 27|Pph21pison w
P11038366A1417 |117 130|PP2A functiontal hyperbili
P11039341A0180 |185 189|taska fu
P11039341A0180 |113 123|componentseonatal hy
P11039341A0180 |4 11|purpose01606T0
P11039341A0180 |54 69|characteristicsnd 5-nucleotida
P11039341A0180 |20 25|studyrison
P11039341A0180 |86 93|mapping Pharma
P11039341A0180 |138 141|ICAa. 
P11039780A0770 |119 131|gene therapyl hyperbilir
P11039780A0770 |81 94|animal modelsT0000 Pharmac
P11039780A0770 |4 11|authors01606T0
P11039780A0770 |218 242|osteoarthritis treatmentf K-depleted rats are no
P11039780A0770 |202 214|gene therapy PCO2 the da
P11039780A0770 |148 156|overview97A0472 
P11039780A0770 |33 40|studieskaline 
P11039780A0770 |250 256|futuredispla
P11039780A0770 |98 112|osteoarthritisic aspects of 
P11039780A0770 |168 178|strategiesO3-] is sh
P11039780A0770 |187 198|developmentfunction of
P11040101A1180 |16 23|resultsomparis
P11040101A1180 |233 242|VEGF genets are no
P11040101A1180 |212 225|transcriptiondata of K-dep
P11040101A1180 |126 132|levelsbiliru
P11040101A1180 |56 76|VEGF gene expression 5-nucleotidase P000
P11040101A1180 |193 197|turnon o
P11040101A1180 |138 147|IL-1 betaa. P00008
P11040101A1180 |38 47|IL-1 betae phospha
P11040101A1180 |263 268|sitesn com
P11040101A1180 |155 163|p38 MAPK When CS
P11040101A1180 |168 182|JNK signalingsO3-] is shown 
P11040219A0548 |51 52|Ns
P11040219A0548 |11 15|NusA076 
P11040219A0548 |30 38|presence alkalin
P11040219A0548 |141 145|NusAP000
P11040219A0548 |80 98|S1 homology region1T0000 Pharmacolog
P11040219A0548 |42 47|alphaospha
P11040219A0548 |19 22|RNAari
P11040219A0548 |0 7|BindingP000016
P11041308A0156 |119 145|South Oaks Gambling Screenl hyperbilirubinemia. P000
P11041308A0156 |44 50|DSM-IVphatas
P11041308A0156 |4 12|subjects01606T00
P11041308A0156 |108 115|Version of neo
P11041308A0156 |147 151|SOGS997A
P11041308A0156 |64 81|gambling criteriaotidase P00008171
P11041308A0156 |35 40|basisline 
P11042197A0386 |0 3|LysP00
P11042197A0386 |59 61|HDnu
P11042197A0386 |13 16|Arg6 C
P11042197A0386 |52 55|end an
P11042197A0386 |81 93|dimerizationT0000 Pharma
P11042199A0572 |0 9|ElevationP00001606
P11042199A0572 |157 163|mediumhen CS
P11042199A0572 |27 29|Cait
P11042199A0572 |123 128|MK801perbi
P11042199A0572 |201 218|calcium elevationF PCO2 the data o
P11042199A0572 |67 76|treatmentdase P000
P11042199A0572 |111 121|nifedipine neonatal 
P11042199A0572 |130 137|removalrubinem
P11042199A0572 |251 255|CREBispl
P11042199A0572 |237 247|activationre no long
P11042199A0572 |168 178|dantroleneO3-] is sh
P11042199A0572 |141 143|CaP0
P11042199A0572 |102 109|proteinspects 
P11042199A0572 |34 40|levelsaline 
P11042204A0186 |69 90|p38 kinase activationse P00008171T0000 Pha
P11042204A0186 |125 133|activityrbilirub
P11042204A0186 |29 49|phosphatidylinositolh alkaline phosphata
P11042204A0186 |12 17|study76 Co
P11042204A0186 |143 154|neutrophils0008997A047
P11042204A0186 |101 120|Akt phosphorylationaspects of neonatal
P11042703A0875 |116 118|moat
P11042703A0875 |122 126|boysyper
P11042703A0875 |104 109|girlsects 
P11042703A0875 |95 100|birthlogic
P11042703A0875 |78 88|increments171T0000 P
P11042703A0875 |27 36|referenceith alkal
P11042703A0875 |5 9|BFDS1606
P11042703A0875 |38 50|W/A Z scorese phosphatas
P11043469A0440 |118 126|pTiChry5al hyper
P11043469A0440 |135 142|T-rightemia. P
P11043469A0440 |15 31|border sequencesComparison with 
P11043469A0440 |162 172|productionSF [HCO3-]
P11043469A0440 |106 114|T-regionts of ne
P11043469A0440 |180 193|Amadoriopinesn as a functi
P11043469A0440 |76 85|T-regions08171T000
P11043469A0440 |144 146|TR00
P11044097A0422 |113 133|transcription factoreonatal hyperbilirub
P11044097A0422 |27 30|HMGith
P11044097A0422 |142 147|sites00008
P11044097A0422 |83 88|sites000 P
P11044097T0000 |54 75|transcription factorsnd 5-nucleotidase P00
P11044097T0000 |145 153|promoter08997A04
P11044097T0000 |43 50|bindingsphatas
P11044097T0000 |106 133|immunodeficiency virus typets of neonatal hyperbilirub
P11044097T0000 |83 92|U5 region000 Pharm
P11044097T0000 |20 27|proteinrison w
P11044105A0616 |35 54|splicing suppressorline phosphatases a
P11044105A0616 |97 108|splice sitegic aspects
P11044105A0616 |58 62|ESS1-nuc
P11044105A0616 |75 78|use008
P11044105A0616 |86 88|nt P
P11044105A0616 |19 26|elementarison 
P11045180A1892 |0 11|LeptinaemiaP00001606T0
P11045180A1892 |96 108|hypertensionogic aspects
P11045180A1892 |130 144|classificationrubinemia. P00
P11045180A1892 |55 77|blood pressure readingd 5-nucleotidase P0000
P11045180A1892 |87 92|stagePharm
P11045607A0239 |70 72|bpe 
P11045607A0239 |105 115|start sitects of neo
P11045607A0239 |36 65|transcription initiation siteine phosphatases and 5-nucleo
P11045607A0239 |3 16|RACE analysis001606T0076 C
P11046146A1202 |35 43|extractsline pho
P11046146A1202 |254 259|cellslaced
P11046146A1202 |117 131|concentrationstal hyperbilir
P11046146A1202 |230 238|extracts rats ar
P11046146A1202 |161 169|extractsCSF [HCO
P11046146A1202 |135 149|dithiothreitolemia. P0000899
P11046146A1202 |186 191|cells func
P11046146A1202 |220 226|levelsK-depl
P11046146A1202 |65 72|bindingtidase 
P11046146A1202 |6 23|diamide treatment606T0076 Comparis
P11046146A1202 |76 88|NFI proteins08171T0000 P
P11046146A1202 |201 216|NFI-DNA bindingF PCO2 the data
P11046146A1202 |98 106|additionic aspec
P11046148A0716 |0 5|LMP2AP0000
P11046148A0716 |95 115|Nedd4 family memberslogic aspects of neo
P11046148A0716 |15 18|LynCom
P11046148A0716 |83 91|activity000 Phar
P11046148A0716 |23 41|Syk ubiquitinationon with alkaline p
P11046148A0716 |159 178|Lyn tyrosine kinasen CSF [HCO3-] is sh
P11046148A0716 |55 62|fashiond 5-nuc
P11046148A0716 |136 151|destabilizationmia. P00008997A
P11046153A1052 |69 79|expressionse P000081
P11046153A1052 |22 31|apoptosisson with 
P11046153A1052 |87 103|p300 coactivatorPharmacologic as
P11046517A0619 |4 11|results01606T0
P11046517A0619 |62 63|Zl
P11046517A0619 |40 41|Zp
P11048832A0271 |0 6|FisherP00001
P11048832A0271 |23 30|Pearsonon with
P11048832A0271 |15 19|testComp
P11048832A0271 |33 42|chi2 testkaline ph
P11048832A0271 |69 77|analysisse P0000
P11049241A0659 |0 7|RESULTSP000016
P11049241A0659 |110 120|differencef neonatal
P11049241A0659 |25 30|group with
P11049241A0659 |208 209|pt
P11049241A0659 |88 90|ETha
P11049241A0659 |168 173|groupO3-] 
P11049241A0659 |189 193|daysncti
P11049241A0659 |142 147|group00008
P11049241A0659 |32 57|serum PP14 concentrationslkaline phosphatases and 
P11049241A0659 |204 206|ETCO
P11049889A1271 |0 19|ThromboelastographyP00001606T0076 Comp
P11049889A1271 |124 138|weight heparinerbilirubinemi
P11049889A1271 |72 78|degreeP00008
P11049889A1271 |25 29|test wit
P11049889A1271 |82 97|anticoagulation0000 Pharmacolo
P11050084A0000 |5 15|expression1606T0076 
P11050084A0000 |105 108|fatcts
P11050084A0000 |160 175|lipid oxidation CSF [HCO3-] is
P11050084A0000 |148 156|capacity97A0472 
P11050084A0000 |73 82|PPARalpha00008171T
P11050084A0000 |57 71|receptor alpha5-nucleotidase
P11050084A0000 |23 33|peroxisomeon with al
P11050084A0888 |17 24|elementmpariso
P11050084A0888 |45 54|PPARgammahatases a
P11050084A0888 |31 40|PPARalphaalkaline 
P11050084A0888 |70 76|nucleie P000
P11050168A1185 |187 209|stability determinantsfunction of CSF PCO2 t
P11050168A1185 |164 171|protein [HCO3-
P11050168A1185 |6 13|results606T007
P11050168A1185 |95 105|mRNA decaylogic aspe
P11050168A1185 |29 37|evidenceh alkali
P11050168A1185 |55 69|susceptibilityd 5-nucleotida
P11050168A1185 |138 146|affinitya. P0000
P11051364A0890 |51 58|group As and 5
P11051364A0890 |23 24|%o
P11051364A0890 |93 113|variceal eradicationcologic aspects of n
P11051364A0890 |26 34|patientswith alk
P11051364A0890 |115 122|group Bnatal h
P11051364A0890 |39 42|PHG ph
P11051364A0890 |83 86|PHG000
P11051364A0890 |70 71|%e
P11051364A0890 |0 7|RESULTSP000016
P11051370A1906 |0 8|ResponseP0000160
P11051370A1906 |39 48|Americans phosphat
P11051370A1906 |64 76|HCV genotypeotidase P000
P11053009A0000 |0 7|AspirinP000016
P11053009A0000 |22 28|ulcersson wi
P11053009A0000 |92 100|activityacologic
P11053009A0000 |105 128|prostaglandin synthesiscts of neonatal hyperbi
P11053009A0000 |71 85|cyclooxygenase P00008171T000
P11053009A0000 |87 90|COXPha
P11053263A0200 |68 71|endase
P11053263A0200 |2 7|total00016
P11053263A0200 |16 22|clonesompari
P11053263A0200 |50 60|sequencinges and 5-n
P11053370A0708 |0 10|ExpressionP00001606T
P11053370A0708 |91 116|glutathione S-transferasemacologic aspects of neon
P11053370A0708 |16 30|hybrid proteinomparison with
P11053370A0708 |144 157|Uhp signaling008997A0472 W
P11053370A0708 |77 81|UhpB8171
P11053370A0708 |69 73|halfse P
P11053370A0708 |118 121|GSTal 
P11054011A1685 |0 11|CONCLUSIONSP00001606T0
P11054011A1685 |124 132|survivalerbiliru
P11054011A1685 |148 156|patients97A0472 
P11054011A1685 |224 231|Ecuadorpleted 
P11054011A1685 |81 101|locoregional controlT0000 Pharmacologic 
P11054011A1685 |114 115|%o
P11054011A1685 |217 222|Quitoof K-
P11054011A1685 |56 60|MSGT 5-n
P11054011A1685 |172 191|oncology department is shown as a func
P11054011A1685 |43 52|treatmentsphatases
P11054011A1685 |105 106|%c
P11054011A1685 |138 144|seriesa. P00
P11054011A1685 |205 213|hospitalO2 the d
P11054341A0599 |0 7|RESULTSP000016
P11054341A0599 |105 123|SWAP abnormalitiescts of neonatal hy
P11054341A0599 |75 79|SWAP0081
P11054341A0599 |94 98|riskolog
P11054341A0599 |133 137|riskinem
P11054341A0599 |151 162|SWAP result0472 When C
P11054341A0599 |9 26|Glaucoma suspectsT0076 Comparison 
P11054341A0599 |49 55|groupsses an
P11054539A0114 |118 120|bpal
P11054539A0114 |164 183|amino acid residues [HCO3-] is shown a
P11054539A0114 |75 88|reading frame008171T0000 P
P11054539A0114 |53 60|intronsand 5-n
P11054539A0114 |144 155|polypeptide008997A0472
P11054539A0114 |106 116|base pairsts of neon
P11054539A0114 |4 8|gene0160
P11054539A0114 |32 37|exonslkali
P11054565A0654 |171 181|GAP domain] is shown
P11054565A0654 |104 110|GTPaseects o
P11054565A0654 |9 20|p190-B exonT0076 Compa
P11054565A0654 |131 139|residuesubinemia
P11054565A0654 |40 46|p190-Aphosph
P11054565A0654 |122 129|domainsyperbil
P11054565A0654 |225 234|structureleted rat
P11054565A0654 |201 213|conservationF PCO2 the d
P11054565A0654 |247 257|p190 geneser displac
P11054565A0654 |77 83|length8171T0
P11054565A0654 |71 73|kb P
P11054565A0654 |32 36|exonlkal
P11054571A0230 |17 27|teneurin-1mparison w
P11054571A0230 |110 120|locus Xq25f neonatal
P11054571A0230 |29 33|TEN1h al
P11054571A0230 |62 72|PAC clonesleotidase 
P11054571A0230 |86 90|part Pha
P11054571A0230 |35 39|geneline
P11054970A0282 |50 63|neurofibromases and 5-nucl
P11054970A0282 |4 26|plexiform neurofibroma01606T0076 Comparison 
P11054970A0282 |86 89|NF1 Ph
P11055513A0564 |112 119|testingneonata
P11055513A0564 |11 19|lookback076 Comp
P11055513A0564 |47 52|bloodtases
P11055513A0564 |77 88|hepatitis C8171T0000 P
P11055513A0564 |25 33|patients with al
P11055786A0306 |43 48|stepssphat
P11055786A0306 |13 22|algorithm6 Compari
P11056007A0224 |137 140|SETia.
P11056007A0224 |210 214|rMTMe da
P11056007A0224 |60 67|stretchucleoti
P11056007A0224 |104 107|Glnect
P11056007A0224 |194 200|domainn of C
P11056007A0224 |152 169|Enhancer-of-zeste472 When CSF [HCO
P11056007A0224 |117 120|Phetal
P11056007A0224 |25 36|amino acids with alkal
P11056007A0224 |202 205|SID PC
P11056007A0224 |77 85|sequence8171T000
P11056007A0224 |40 47|FVVLNLQphospha
P11056007A0224 |142 150|Suvar3-900008997
P11056007A0224 |171 180|Trithorax] is show
P11056019A0926 |119 134|ethyl carbamatel hyperbilirubi
P11056019A0926 |54 60|adductnd 5-n
P11056019A0926 |63 64|Ne
P11056019A0926 |16 36|glycosylase activityomparison with alkal
P11056019A0926 |100 114|vinyl chloride aspects of ne
P11056019A0926 |86 96|metabolite Pharmacol
P11056019A0926 |0 4|MED1P000
P11056019A0926 |68 82|ethenocytosinease P00008171T
P11058008A0159 |33 46|flap necrosiskaline phosph
P11058008A0159 |60 65|flapsucleo
P11058008A0159 |14 23|instances Comparis
P11058008A0159 |73 86|tip ischaemia00008171T0000
P11058119A0957 |98 101|XPAic 
P11058119A0957 |82 94|localization0000 Pharmac
P11058119A0957 |27 31|XAB1ith 
P11058119A0957 |6 13|results606T007
P11058119A0957 |55 61|GTPased 5-nu
P11058120A0256 |84 89|IRF-100 Ph
P11058120A0256 |13 20|factors6 Compa
P11058120A0256 |105 114|potentialcts of ne
P11058120A0256 |22 27|IRF-2son w
P11058120A0256 |69 80|counterpartse P0000817
P11058132A0264 |69 86|Bacillus subtilisse P00008171T0000
P11058132A0264 |182 192|B.subtilisas a funct
P11058132A0264 |46 54|proteinsatases a
P11058132A0264 |121 131|comparisonhyperbilir
P11058132A0264 |25 42|% match sequences with alkaline ph
P11058132A0264 |161 170|organismsCSF [HCO3
P11058132A0264 |95 96|%l
P11058132A0264 |141 149|proteinsP0000899
P11058132A0264 |16 20|CDSsompa
P11058406A0447 |35 39|i.v.line
P11058406A0447 |59 75|circulation timenucleotidase P00
P11058406A0447 |92 96|i.v.acol
P11058406A0447 |110 129|tobramycin solutionf neonatal hyperbil
P11058406A0447 |18 21|SLNpar
P11059492A0376 |0 9|BacteriolP00001606
P11059777A0813 |206 216|expression2 the data
P11059777A0813 |95 105|activationlogic aspe
P11059777A0813 |147 156|apoptosis997A0472 
P11059777A0813 |47 71|nick end labeling assaystases and 5-nucleotidase
P11059777A0813 |197 202|BCL-Xf CSF
P11059777A0813 |178 193|down-regulationown as a functi
P11059777A0813 |9 25|deoxynucleotidylT0076 Comparison
P11059777A0813 |113 128|PAX3 repressorseonatal hyperbi
P11059777A0813 |203 204|LP
P11059786A0682 |0 22|VEGF promoter activityP00001606T0076 Compari
P11059786A0682 |161 163|PICS
P11059786A0682 |167 173|kinaseCO3-] 
P11059786A0682 |121 124|Rashyp
P11059786A0682 |115 119|EGFRnata
P11059786A0682 |36 49|transfectionsine phosphata
P11059786A0682 |129 149|phosphatidylinositolirubinemia. P0000899
P11059786A0682 |101 111|inhibitionaspects of
P11059786A0682 |153 159|kinase72 Whe
P11059786T0000 |186 192|kinase funct
P11059786T0000 |227 234|hypoxiated rat
P11059786T0000 |144 151|pathway008997A
P11059786T0000 |162 182|phosphatidylinositolSF [HCO3-] is shown 
P11059786T0000 |10 32|growth factor receptor0076 Comparison with a
P11059786T0000 |85 109|growth factor expression0 Pharmacologic aspects 
P11059786T0000 |119 137|glioblastoma cellsl hyperbilirubinem
P11062047A1208 |34 46|densovirusesaline phosph
P11062047A1208 |6 11|IHHNV606T0
P11062047A1208 |144 181|virus Penaeus stylirostris densovirus008997A0472 When CSF [HCO3-] is shown
P11062047A1208 |183 189|PstDNVs a fu
P11062047A1208 |83 102|family Parvoviridae000 Pharmacologic a
P11062047A1208 |54 75|genus Brevidensovirusnd 5-nucleotidase P00
P11062067A0000 |17 31|protein kinasemparison with 
P11062067A0000 |72 78|kinaseP00008
P11062067A0000 |166 174|stressesHCO3-] i
P11062067A0000 |55 60|c-Jund 5-n
P11062067A0000 |80 83|JNK1T0
P11062067A0000 |144 153|cytokines008997A04
P11062067A0000 |115 123|responsenatal hy
P11062067A0000 |35 40|SAPK1line 
P11062068T0000 |51 54|MAPs a
P11062068T0000 |56 76|kinase phosphatase-1 5-nucleotidase P000
P11062068T0000 |166 176|regulationHCO3-] is 
P11062068T0000 |91 105|p38 MAP kinasemacologic aspe
P11062068T0000 |42 49|proteinosphata
P11062068T0000 |128 131|p38lir
P11062068T0000 |10 20|activation0076 Compa
P11062068T0000 |143 149|domain000899
P11062068T0000 |116 120|roleatal
P11062257A0977 |68 75|dockingase P00
P11062257A0977 |193 210|transport processon of CSF PCO2 th
P11062257A0977 |47 56|reactionstases and
P11062257A0977 |90 98|vesiclesrmacolog
P11062257A0977 |158 169|specificityen CSF [HCO
P11062257A0977 |108 115|vacuole of neo
P11062257A0977 |10 29|class C-Vps complex0076 Comparison wit
P11062257A0977 |80 86|fusion1T0000
P11062257A0977 |174 184|efficiencys shown as
P11062274T0000 |99 105|strokec aspe
P11062274T0000 |52 80|tissue plasminogen activator and 5-nucleotidase P0000817
P11062705A0658 |68 84|cancer cell linease P00008171T00
P11062705A0658 |28 32|roleth a
P11062705A0658 |51 56|ATF-2s and
P11063127A0000 |0 19|Signal transductionP00001606T0076 Comp
P11063127A0000 |157 161|acidhen 
P11063127A0000 |163 165|OAF 
P11063127A0000 |24 34|modulationn with alk
P11063127A0000 |176 183|effectsshown a
P11063127A0000 |105 107|PPct
P11063127A0000 |70 80|inhibitione P0000817
P11063127A0000 |141 145|roleP000
P11063127A0000 |38 53|phosphorylatione phosphatases 
P11063127A0000 |84 103|protein phosphatase00 Pharmacologic as
P11063127A0000 |118 122|PP2Aal h
P11063169T0000 |0 17|Botulinum toxin AP00001606T0076 Co
P11063169T0000 |57 66|foot drop5-nucleot
P11063169T0000 |92 100|outcomesacologic
P11063169T0000 |25 34|treatment with alk
P11063252A0437 |34 36|kbal
P11063252A0437 |47 73|HSL translation start sitetases and 5-nucleotidase P
P11063252A0437 |0 6|Exon AP00001
P11063742A0000 |0 9|NF-kappaBP00001606
P11063742A0000 |31 51|transcription factoralkaline phosphatase
P11063742A0000 |105 113|chemicalcts of n
P11063742A0000 |129 139|reductantsirubinemia
P11063742A0000 |87 93|stressPharma
P11064829T0058 |0 27|Cardiovascular risk factorsP00001606T0076 Comparison w
P11064829T0058 |49 58|treatmentses and 5
P11066245T0000 |55 63|mistakesd 5-nucl
P11066245T0000 |72 76|SNFsP000
P11066245T0000 |26 43|compliance reviewwith alkaline pho
P11067797A1306 |102 110|functionspects o
P11067797A1306 |151 166|BV distribution0472 When CSF [
P11067797A1306 |191 201|componentstion of CS
P11067797A1306 |123 133|assessmentperbilirub
P11067797A1306 |13 28|EBCT technology6 Comparison wi
P11067797A1306 |55 65|evaluationd 5-nucleo
P11067797A1306 |0 11|CONCLUSIONSP00001606T0
P11067928A0532 |87 99|Jkappa genesPharmacologi
P11067928A0532 |29 30|Vh
P11067928A0532 |31 32|Ha
P11067928A0532 |75 81|Vkappa008171
P11067928A0532 |40 41|Hp
P11067928A0532 |10 14|mAbs0076
P11067928A0532 |72 73|DP
P11067928A0532 |43 56|gene segmentssphatases and
P11067928A0532 |38 39|Je
P11069011A0224 |0 15|SSF experimentsP00001606T0076 
P11069011A0224 |75 78|CO2008
P11069011A0224 |176 185|pesticideshown as 
P11069011A0224 |147 156|materials997A0472 
P11069011A0224 |120 127|mixture hyperb
P11069011A0224 |48 59|bioreactorsases and 5-
P11069011A0224 |100 105|traps aspe
P11069075T0000 |0 16|CharacterizationP00001606T0076 C
P11069075T0000 |94 110|cell developmentologic aspects o
P11069075T0000 |63 75|implicationseotidase P00
P11069075T0000 |22 59|Xenopus laevis CXC chemokine receptorson with alkaline phosphatases and 5-
P11069075T0000 |118 135|vertebrate embryoal hyperbilirubin
P11069223A0593 |0 8|PatientsP0000160
P11069223A0593 |30 35|liver alka
P11069223A0593 |48 64|marrow functionsases and 5-nucle
P11069307A0546 |0 10|InhibitionP00001606T
P11069307A0546 |54 60|effectnd 5-n
P11069307A0546 |96 107|translationogic aspect
P11069307A0546 |128 149|replication factor 1alirubinemia. P0000899
P11069307A0546 |111 114|BMV ne
P11069307A0546 |14 30|RNA2 translation Comparison with
P11069307A0546 |190 200|antagonistction of C
P11069307A0546 |81 92|translationT0000 Pharm
P11069307A0546 |174 177|p20s s
P11069307A0546 |204 217|DED1 functionCO2 the data 
P11069307A0546 |221 232|translation-depleted r
P11069756A2618 |478 480|PS15
P11069756A2618 |168 182|GRK interacterO3-] is shown 
P11069756A2618 |233 236|GRKts 
P11069756A2618 |432 454|paxillin kinase linkerptimum dose for use in
P11069756A2618 |163 166|GITF [
P11069756A2618 |313 316|ERKtly
P11069756A2618 |585 587|SHma
P11069756A2618 |501 517|phosphothreonine53T0045 Beta blo
P11069756A2618 |108 133|Papillomavirus E6 protein of neonatal hyperbilirub
P11069756A2618 |46 48|CHat
P11069756A2618 |497 499|PT01
P11069756A2618 |104 106|E6ec
P11069756A2618 |523 538|phosphotyrosineagents. P000136
P11069756A2618 |378 387|subdomainus appear
P11069756A2618 |318 321|p38rea
P11069756A2618 |356 359|PBS943
P11069756A2618 |427 430|PKLthe
P11069756A2618 |184 188|GPCR a f
P11069756A2618 |540 543|RTKA02
P11069756A2618 |297 311|protein kinaseave a signific
P11069756A2618 |602 608|domainion (V
P11069756A2618 |482 495|phosphoserineg at night. P
P11069756A2618 |462 469|partner practi
P11069756A2618 |223 231|receptorepleted 
P11069756A2618 |323 326|JNKr s
P11069756A2618 |456 460|POR1ener
P11069756A2618 |92 102|SRC kinaseacologic a
P11069756A2618 |146 161|adhesion kinase8997A0472 When 
P11069756A2618 |389 392|PIXto 
P11069756A2618 |329 332|PAKe (
P11069756A2618 |35 44|substrateline phos
P11069756A2618 |238 271|G-protein-coupled-receptor kinasee no longer displaced when compar
P11069756A2618 |519 521|PYin
P11069756A2618 |473 476|Racein
P11069756A2618 |76 79|CSK081
P11069756A2618 |348 354|kinase. P000
P11069756A2618 |135 138|FAKemi
P11069756A2618 |15 18|CASCom
P11069756A2618 |0 13|AbbreviationsP00001606T007
P11069756A2618 |273 277|MAPK to 
P11069756A2618 |545 583|growth factor receptor tyrosine kinase When extracorporeal CO2 removal appro
P11069756A2618 |68 74|domainase P0
P11069756A2618 |410 425|exchange factorpnotic drug wit
P11069788A0531 |107 110|Pgas o
P11069788A0531 |210 214|cm He da
P11069788A0531 |181 185|PEEP as 
P11069788A0531 |82 97|difference PEEP0000 Pharmacolo
P11069788A0531 |189 196|dyn refnction 
P11069788A0531 |125 129|meanrbil
P11069788A0531 |28 30|SBth
P11069788A0531 |150 154|cm HA047
P11069788A0531 |54 62|patientsnd 5-nuc
P11069788A0531 |157 158|Oh
P11069788A0531 |217 218|Oo
P11069788A0531 |118 123|decayal hy
P11069788A0531 |134 136|SDne
P11069791A0226 |70 72|mge 
P11069791A0226 |58 62|dose-nuc
P11069791A0226 |92 94|moac
P11069791A0226 |208 211|IPTthe
P11069791A0226 |133 136|IPTine
P11069791A0226 |167 176|Regimen BCO3-] is 
P11069791A0226 |16 24|subjectsompariso
P11069791A0226 |49 52|IPTses
P11069791A0226 |216 218|mg o
P11069791A0226 |96 105|Regimen Aogic aspe
P11069791A0226 |163 165|moF 
P11069791A0226 |231 233|mora
P11069791A0226 |141 143|mgP0
P11069791A0226 |235 244|Regimen C are no l
P11069825A0530 |64 73|follow-upotidase P
P11069825A0530 |88 97|incidenceharmacolo
P11069825A0530 |15 20|casesCompa
P11069825A0530 |24 36|tuberculosisn with alkal
P11069825A0530 |58 60|yr-n
P11069897A1112 |6 13|results606T007
P11069897A1112 |29 35|BACH1th alka
P11069897A1112 |74 77|BTB000
P11069897A1112 |45 50|BACH1hatas
P11069897A1112 |94 105|interactionologic aspe
P11069897A1112 |58 65|nucleus-nucleo
P11069999A1602 |4 11|U17/U1601606T0
P11069999A1602 |58 65|HIV LTR-nucleo
P11069999A1602 |25 38|gene products with alkalin
P11069999A1602 |20 23|U16ris
P11070007A0136 |85 92|B cells0 Pharm
P11070007A0136 |161 164|endCSF
P11070007A0136 |135 137|Wpem
P11070007A0136 |178 184|genomeown as
P11070007A0136 |25 35|EBNA genes with alka
P11070007A0136 |128 130|Cpli
P11070007A0136 |117 126|promoterstal hyper
P11070007A0136 |0 13|TranscriptionP00001606T007
P11070056A0704 |64 72|Lian-Aa1otidase 
P11070056A0704 |76 84|mosquito08171T00
P11070056A0704 |29 39|similarityh alkaline
P11070056A0704 |47 60|RNaseH domaintases and 5-n
P11070056A0704 |93 108|retrotransposoncologic aspects
P11070056A0704 |4 20|Cili-2 sequences01606T0076 Compa
P11070078A1153 |239 244|cells no l
P11070078A1153 |120 130|repression hyperbili
P11070078A1153 |57 85|Rb tumor suppressor pathways5-nucleotidase P00008171T000
P11070078A1153 |13 21|response6 Compar
P11070078A1153 |224 231|signalspleted 
P11070078A1153 |164 172|pathways [HCO3-]
P11070078A1153 |134 140|HPV E6nemia.
P11070078A1153 |49 52|p53ses
P11070078A1153 |206 212|growth2 the 
P11070078A1153 |145 147|E708
P11070078A1153 |100 110|HeLa cells aspects o
P11070078A1153 |187 194|fashionfunctio
P11071651A1308 |38 45|pathwaye phosp
P11071651A1308 |105 123|retinoid inductioncts of neonatal hy
P11071651A1308 |127 145|FR-beta expressionilirubinemia. P000
P11071651A1308 |66 81|differentiationidase P00008171
P11071789T0000 |37 51|ACE inhibitorsne phosphatase
P11071789T0000 |63 76|heart failureeotidase P000
P11071789T0000 |22 33|dose levelsson with al
P11071852A0297 |71 77|SOCS-3 P0000
P11071852A0297 |23 29|SOCS-3on wit
P11071852A0297 |149 160|muscle mRNA7A0472 When
P11071852A0297 |114 128|chain reactiononatal hyperbi
P11071852A0297 |48 53|IGFIRases 
P11071924A0588 |184 192|activity a funct
P11071924A0588 |163 170|domainsF [HCO3
P11071924A0588 |57 65|activity5-nucleo
P11071924A0588 |130 135|SLI-1rubin
P11071924A0588 |107 126|RING finger domainss of neonatal hyper
P11071924A0588 |30 49|RING finger domains alkaline phosphata
P11071924A0588 |99 102|SH2c a
P11071924A0588 |82 89|protein0000 Ph
P11071924A0588 |22 25|SH2son
P11071924A0588 |174 179|c-Cbls sho
P11071924A0588 |2 9|protein0001606
P11071974A0155 |16 23|effectsomparis
P11071974A0155 |120 133|lipid profile hyperbilirub
P11071974A0155 |177 203|plasma homocysteine levelshown as a function of CSF 
P11071974A0155 |109 116|changesof neon
P11071974A0155 |210 219|treatmente data of
P11071974A0155 |135 146|coagulationemia. P0000
P11071974A0155 |151 171|fibrinolysis markers0472 When CSF [HCO3-
P11071974A0155 |76 80|ESRD0817
P11071974A0155 |40 47|factorsphospha
P11071974A0155 |27 30|HRTith
P11071974A0155 |67 74|diseasedase P0
P11071974A0155 |82 90|patients0000 Pha
P11072155A0764 |49 57|TGF betases and 
P11072155A0764 |29 40|correlationh alkaline 
P11072155A0764 |60 66|levelsucleot
P11072155A0764 |78 99|cell radiosensitivity171T0000 Pharmacologi
P11072155A0764 |101 115|lymphocyte SF2aspects of neo
P11072388T0000 |34 60|smoking reduction strategyaline phosphatases and 5-n
P11072388T0000 |22 28|safetyson wi
P11072388T0000 |78 91|schizophrenia171T0000 Phar
P11072388T0000 |6 17|feasibility606T0076 Co
P11072388T0000 |65 72|smokerstidase 
P11073163A0131 |155 168|cell survival When CSF [HC
P11073163A0131 |28 39|degradationth alkaline
P11073163A0131 |94 98|roleolog
P11073163A0131 |106 116|proteasomets of neon
P11073163A0131 |132 150|cell proliferationbinemia. P00008997
P11073163A0131 |43 51|proteinssphatase
P11073163A0131 |65 83|cell cycle controltidase P00008171T0
P11073218A0800 |95 101|regionlogic 
P11073218A0800 |62 70|U.G pairleotidas
P11073218A0800 |10 20|nucleotide0076 Compa
P11073539A0866 |34 40|desminaline 
P11073539A0866 |56 61|cells 5-nu
P11073539A0866 |11 19|analysis076 Comp
P11073539A0866 |44 48|SW13phat
P11073539A0866 |100 106|clumps aspec
P11073539A0866 |126 134|materialbilirubi
P11073539A0866 |160 169|cytoplasm CSF [HCO
P11073539A0866 |50 53|vimes 
P11073539A0866 |69 80|aggregationse P0000817
P11073870A0375 |102 105|PRCspe
P11073870A0375 |14 21|lesions Compar
P11073870A0375 |213 215|s.at
P11073870A0375 |128 138|oculomotorlirubinemi
P11073870A0375 |147 160|response task997A0472 When
P11073870A0375 |79 86|lesions71T0000
P11073870A0375 |56 59|PHC 5-
P11073870A0375 |65 73|patientstidase P
P11073870A0375 |36 39|PRCine
P11073870A0375 |110 113|PHCf n
P11073870A0375 |187 200|memory delaysfunction of C
P11073870A0375 |0 8|PatientsP0000160
P11073919A0631 |343 362|dimer stabilization23 vs. P00010943A07
P11073919A0631 |160 164|D361 CSF
P11073919A0631 |106 110|E274ts o
P11073919A0631 |47 50|E94tas
P11073919A0631 |166 170|D364HCO3
P11073919A0631 |118 122|R277al h
P11073919A0631 |251 260|formationisplaced 
P11073919A0631 |188 192|F397unct
P11073919A0631 |52 56|D134 and
P11073919A0631 |112 116|G276neon
P11073919A0631 |296 302|domainhave a
P11073919A0631 |178 182|Y389own 
P11073919A0631 |58 62|R154-nuc
P11073919A0631 |124 128|Y278erbi
P11073919A0631 |154 158|C3602 Wh
P11073919A0631 |82 86|G2350000
P11073919A0631 |94 98|G237olog
P11073919A0631 |148 152|D33297A0
P11073919A0631 |88 92|G236harm
P11073919A0631 |329 335|domaine (1.2
P11073919A0631 |100 104|F238 asp
P11073919A0631 |172 176|G387 is 
P11073919A0631 |37 40|K69ne 
P11073919A0631 |42 45|D88osp
P11073919A0631 |383 387|ODCspear
P11073919A0631 |142 146|Y3310000
P11073919A0631 |76 80|D2330817
P11073919A0631 |130 134|K294rubi
P11073919A0631 |194 213|mouse ODC numberingn of CSF PCO2 the d
P11073919A0631 |16 35|amino acid residuesomparison with alka
P11073919A0631 |3 11|addition001606T0
P11073919A0631 |64 68|K169otid
P11073919A0631 |412 430|S. ruminantium LDCotic drug with the
P11073919A0631 |70 74|H197e P0
P11073919A0631 |136 140|Y323mia.
P11073954A0337 |32 45|reading framelkaline phosp
P11073954A0337 |60 79|CP2 family proteinsucleotidase P000081
P11073954A0337 |4 13|Psc2 cDNA01606T007
P11074003A0741 |85 90|CGNPs0 Pha
P11074003A0741 |26 29|Shhwit
P11074003A0741 |4 11|results01606T0
P11074003A0741 |50 57|cyclinges and 
P11074210A0623 |103 122|insulin sensitivitypects of neonatal h
P11074210A0623 |96 98|BPog
P11074210A0623 |57 84|insulin resistance syndrome5-nucleotidase P00008171T00
P11074210A0623 |39 49|components phosphata
P11074210A0623 |4 15|QT interval01606T0076 
P11075678A0298 |4 15|wavenumbers01606T0076 
P11075678A0298 |89 92|DFTarm
P11075678A0298 |209 220|force fieldhe data of 
P11075678A0298 |104 105|Ge
P11075678A0298 |44 49|modesphata
P11075678A0298 |109 122|approximationof neonatal h
P11075678A0298 |94 101|B3LYP/6ologic 
P11075678A0298 |133 142|agreementinemia. P
P11075678A0298 |161 167|valuesCSF [H
P11075678A0298 |53 62|vibrationand 5-nuc
P11075929A1657 |98 107|formationic aspect
P11075929A1657 |62 72|metabolismleotidase 
P11075929A1657 |135 143|functionemia. P0
P11075929A1657 |4 8|data0160
P11075929A1657 |24 32|evidencen with a
P11075929A1657 |147 151|ThlB997A
P11075929A1657 |38 42|ThlAe ph
P11075929A1657 |81 85|acidT000
P11075944A0691 |100 109|androgens aspects 
P11075944A0691 |53 57|fgf8and 
P11075944A0691 |13 17|npm36 Co
P11075944A0691 |61 75|MMTV insertioncleotidase P00
P11075944A0691 |113 123|SC-3 cellseonatal hy
P11075944A0691 |3 11|addition001606T0
P11076860A0872 |51 56|UEV1As and
P11076860A0872 |202 214|localization PCO2 the da
P11076860A0872 |92 95|Kuaaco
P11076860A0872 |132 142|structuresbinemia. P
P11076860A0872 |164 174|Kua domain [HCO3-] i
P11076860A0872 |70 77|proteine P0000
P11076860A0872 |32 40|proteinslkaline 
P11076860A0872 |218 225|Kua-UEVf K-dep
P11076860A0872 |100 107|Kua-UEV aspect
P11076860A0872 |0 11|ExperimentsP00001606T0
P11078726X0000 |259 266|enzymes when c
P11078726X0000 |15 30|phosphorylationComparison with
P11078726X0000 |227 233|domainted ra
P11078726X0000 |47 53|Ser315tases 
P11078726X0000 |302 306|role sig
P11078726X0000 |284 290|domains but 
P11078726X0000 |120 140|transcription factor hyperbilirubinemia.
P11078726X0000 |40 43|p53pho
P11078726X0000 |94 114|p53 protein activityologic aspects of ne
P11078726X0000 |79 92|transcription71T0000 Pharm
P11078726X0000 |336 351|gene expression +/- 0.23 vs. P
P11078726X0000 |169 179|antibodies3-] is sho
P11080796A0883 |85 93|IKKgamma0 Pharma
P11080796A0883 |27 36|cell lineith alkal
P11080796A0883 |61 64|IKKcle
P11080796A0883 |43 53|expressionsphatases 
P11080796A0883 |76 83|protein08171T0
P11080796A1277 |171 174|Tax] i
P11080796A1277 |82 90|IKKalpha0000 Pha
P11080796A1277 |58 61|IKK-nu
P11080796A1277 |95 102|IKKbetalogic a
P11080796A1277 |72 80|subunitsP0000817
P11080796A1277 |47 50|Taxtas
P11080796A1277 |4 28|Tax/IKKgamma interaction01606T0076 Comparison wi
P11080796A1277 |113 124|recruitmenteonatal hyp
P11080796A1277 |202 205|IKK PC
P11080796A1277 |190 198|activityction of
P11080796A1277 |152 161|mechanism472 When 
P11081962T0000 |59 64|Avenanucle
P11081962T0000 |44 47|mappha
P11081962T0000 |12 16|AFLP76 C
P11082185A0415 |35 39|typeline
P11082185A0415 |97 102|IRF-1gic a
P11082185A0415 |82 93|amino acids0000 Pharma
P11082185A0415 |147 155|activity997A0472
P11082185A0415 |54 60|domainnd 5-n
P11082185A0415 |3 11|addition001606T0
P11082587X0000 |0 7|EffectsP000016
P11082587X0000 |195 199|SBBS of 
P11082587X0000 |121 130|influencehyperbili
P11082587X0000 |134 154|laser beam smoothingnemia. P00008997A047
P11082587X0000 |105 116|model limitcts of neon
P11082587X0000 |261 271|spot modelhen compar
P11082587X0000 |232 237|limitats a
P11082587X0000 |56 76|brillouin scattering 5-nucleotidase P000
P11082587X0000 |32 41|smoothinglkaline p
P11082587X0000 |169 193|Brillouin backscattering3-] is shown as a functi
P11082715X0001 |205 216|metabolitesO2 the data
P11082715X0001 |30 42|theophylline alkaline ph
P11082715X0001 |120 126|method hyper
P11082715X0001 |51 62|metabolitess and 5-nuc
P11082715X0001 |184 196|theophylline a function 
P11082715X0001 |223 231|caffeineepleted 
P11082715X0001 |114 118|HPLConat
P11082715X0001 |240 251|metabolitesno longer d
P11082715X0001 |79 90|performance71T0000 Pha
P11082715X0001 |167 180|determinationCO3-] is show
P11082715X0001 |13 26|determination6 Comparison 
P11082715X0001 |66 70|HPLCidas
P11082715X0001 |98 112|chromatographyic aspects of 
P11083154A0881 |64 74|heart rateotidase P0
P11083154A0881 |45 62|oxygen uptake VO2hatases and 5-nuc
P11083154A0881 |76 97|minute ventilation VE08171T0000 Pharmacolo
P11083154A0881 |25 40|test conditions with alkaline 
P11083154A0881 |109 117|exertionof neona
P11083154A0881 |129 138|shrinkageirubinemi
P11083154A0881 |4 9|males01606
P11083358A1071 |0 10|CONCLUSIONP00001606T
P11083358A1071 |59 67|patientsnucleoti
P11083358A1071 |12 15|SPT76 
P11083358A1071 |36 39|WSTine
P11083358A1071 |83 93|aspiration000 Pharma
P11083432A0332 |34 41|controlaline p
P11083432A0332 |61 62|nc
P11083432A0332 |43 44|ns
P11083432A0332 |78 79|n1
P11083432A0332 |72 76|FK-3P000
P11083432A0332 |8 14|groups6T0076
P11083432A0332 |55 59|FK-1d 5-
P11083868A0386 |0 11|DNA bindingP00001606T0
P11083868A0386 |129 151|transactivation domainirubinemia. P00008997A
P11083868A0386 |93 98|Elk-1colog
P11083868A0386 |76 83|binding08171T0
P11083868A0386 |52 58|assays and 5
P11083868A0386 |16 41|glutathione S-transferaseomparison with alkaline p
P11084022A1178 |51 57|changes and 
P11084022A1178 |94 109|cell flatteningologic aspects 
P11084022A1178 |61 76|cell morphologycleotidase P000
P11084022A1178 |14 28|ALK7 signaling Comparison wi
P11084022A1178 |142 156|cell processes00008997A0472 
P11084022A1178 |114 125|elaborationonatal hype
P11084334A0590 |220 228|proteinsK-deplet
P11084334A0590 |126 131|motifbilir
P11084334A0590 |111 114|TPR ne
P11084334A0590 |63 77|point mutationeotidase P0000
P11084334A0590 |46 52|screenatases
P11084334A0590 |192 203|interactionion of CSF 
P11084334A0590 |4 17|swa2-1 allele01606T0076 Co
P11084334A0590 |172 180|proteins is show
P11084334A0590 |145 152|auxilin08997A0
P11084334A0590 |116 122|domainatal h
P11084334A0590 |85 109|tetratricopeptide repeat0 Pharmacologic aspects 
P11084556T0000 |0 11|AssociationP00001606T0
P11084556T0000 |15 21|stressCompar
P11084556T0000 |128 138|cord bloodlirubinemi
P11084556T0000 |29 37|deliveryh alkali
P11084556T0000 |74 79|cells00081
P11084556T0000 |53 60|numbersand 5-n
P11084556T0000 |98 114|progenitor cellsic aspects of ne
P11084649A0497 |186 194|mesoderm functio
P11084649A0497 |60 64|sideucle
P11084649A0497 |108 120|gastrulation of neonatal
P11084649A0497 |72 78|embryoP00008
P11084649A0497 |149 157|epiblast7A0472 W
P11084649A0497 |122 132|expressionyperbiliru
P11084649A0497 |31 41|expressionalkaline p
P11084649A0497 |18 25|embryosparison
P11084649A0497 |99 104|onsetc asp
P11084649A0497 |214 220|streakta of 
P11084649A0497 |86 88|E6 P
P11084649A0497 |168 176|endodermO3-] is 
P11085267A0562 |0 14|TransformationP00001606T0076
P11085267A0562 |41 46|sconBhosph
P11085267A0562 |22 35|sconC3 mutantson with alka
P11085267A0562 |71 80|phenotype P0000817
P11085600A0123 |48 54|inputsases a
P11085600A0123 |94 100|regionologic
P11085600A0123 |73 79|cortex000081
P11085600A0123 |160 171|information CSF [HCO3-
P11085600A0123 |4 11|authors01606T0
P11086872A0000 |0 9|InfluenceP00001606
P11086872A0000 |13 26|oil emulsions6 Comparison 
P11086872A0000 |31 39|diphenylalkaline
P11086872A0000 |75 82|changes008171T
P11086872A0000 |99 118|Citrus aurantifoliac aspects of neonat
P11086872A0000 |86 97|Kagzi limes Pharmacolo
P11087141A0977 |136 144|evidencemia. P00
P11087141A0977 |9 17|analysisT0076 Co
P11087141A0977 |29 43|GT transcriptsh alkaline pho
P11087141A0977 |75 92|splicing patterns008171T0000 Pharm
P11087141A0977 |116 122|regionatal h
P11087141A0977 |21 27|alpha1ison w
P11087141A0977 |127 130|UTRili
P11087141A0977 |155 172|splicing activity When CSF [HCO3-]
P11087141A0977 |206 212|manner2 the 
P11088635A0200 |141 155|usage patternsP00008997A0472
P11088635A0200 |104 110|sourceects o
P11088635A0200 |74 82|computer0008171T
P11088635A0200 |60 68|couplingucleotid
P11088635A0200 |10 41|Kubo-Martin-Schwinger condition0076 Comparison with alkaline p
P11088635A0200 |163 169|systemF [HCO
P11089911A1267 |137 150|ATLN elementsia. P00008997
P11089911A1267 |111 129|retrotransposition neonatal hyperbil
P11089911A1267 |90 103|transcriptionrmacologic as
P11089911A1267 |52 59|regions and 5-
P11089911A1267 |19 28|sequencesarison wi
P11090172A0612 |19 35|RNA1 replicationarison with alka
P11090172A0612 |40 54|RNA3 synthesisphosphatases a
P11090172A0612 |122 136|FHV virion RNAyperbilirubine
P11090172A0612 |91 96|yeastmacol
P11090172A0612 |66 71|yeastidase
P11090172A0612 |4 15|time course01606T0076 
P11090272A1240 |34 42|splicingaline ph
P11090272A1240 |61 65|GAIPcleo
P11090272A1240 |52 56|ORL1 and
P11090272A1240 |4 17|transcription01606T0076 Co
P11090762A0527 |171 185|power increase] is shown as 
P11090762A0527 |28 39|muscle painth alkaline
P11090762A0527 |65 76|stimulationtidase P000
P11090762A0527 |113 121|increaseeonatal 
P11090762A0527 |125 130|deltarbili
P11090762A0527 |167 169|HzCO
P11090762A0527 |209 223|parietal locushe data of K-d
P11090762A0527 |136 138|Hzmi
P11090762A0527 |18 24|effectpariso
P11090762A0527 |140 145|power P000
P11090762A0527 |153 160|alpha-172 When
P11090762A0527 |0 7|RESULTSP000016
P11092770A0238 |153 154|%7
P11092770A0238 |123 133|extractionperbilirub
P11092770A0238 |135 146|specificityemia. P0000
P11092770A0238 |96 105|predictorogic aspe
P11092770A0238 |83 90|class C000 Pha
P11092770A0238 |159 170|sensitivityn CSF [HCO3
P11092770A0238 |4 14|extraction01606T0076
P11092770A0238 |184 185|% 
P11092809A0823 |17 24|resultsmpariso
P11092809A0823 |89 97|mesodermarmacolo
P11092809A0823 |44 49|PI3Ksphata
P11092809A0823 |75 83|ectoderm008171T0
P11092809A0823 |3 11|addition001606T0
P11092809A0823 |35 39|ERKsline
P11092850A1023 |68 77|tuf genesase P0000
P11092850A1023 |180 187|lineagen as a 
P11092850A1023 |120 127|species hyperb
P11092850A1023 |96 104|ancestorogic asp
P11092850A1023 |144 148|copy0089
P11092850A1023 |9 40|16S rRNA gene sequence analysisT0076 Comparison with alkaline 
P11092850A1023 |49 56|speciesses and
P11092850A1023 |207 215|ancestor the dat
P11092886A0341 |51 60|CREMalphas and 5-n
P11092886A0341 |14 42|protein kinase A stimulation Comparison with alkaline ph
P11092886A0341 |77 84|complex8171T00
P11092886A0341 |108 141|phosphoenolpyruvate carboxykinase of neonatal hyperbilirubinemia. 
P11092886A0341 |150 154|geneA047
P11092886A0341 |92 100|promoteracologic
P11092886A0341 |143 148|PEPCK00089
P11093745A0563 |17 26|HNF3 sitemparison 
P11093745A0563 |109 116|elementof neon
P11093745A0563 |52 64|NF1/CTF site and 5-nucle
P11093745A0563 |36 46|appositionine phosph
P11094066A0505 |21 31|regulationison with 
P11094066A0505 |160 166|manner CSF [
P11094066A0505 |123 139|FKHR-L1 activityperbilirubinemia
P11094066A0505 |47 57|modulationtases and 
P11094066A0505 |108 112|IL-3 of 
P11094066A0505 |65 102|forkhead transcription factor FKHR-L1tidase P00008171T0000 Pharmacologic a
P11094066A1194 |204 217|proliferationCO2 the data 
P11094066A1194 |63 66|p27eot
P11094066A1194 |149 158|mechanism7A0472 Wh
P11094066A1194 |73 86|transcription00008171T0000
P11094066A1194 |67 71|KIP1dase
P11094066A1194 |22 34|observationsson with alk
P11094066A1194 |108 131|FKHR-L1 phosphorylation of neonatal hyperbilir
P11094066A1194 |191 199|survivaltion of 
P11094066A1194 |49 59|inhibitionses and 5-
P11094072A0842 |0 5|DNaseP0000
P11094072A0842 |91 98|fashionmacolog
P11094072A0842 |47 57|c-Myb sitetases and 
P11094072A0842 |16 28|footprintingomparison wi
P11094072A1234 |17 22|c-Mybmpari
P11094072A1234 |37 51|RAG-2 promoterne phosphatase
P11094072A1234 |106 110|sitets o
P11094072A1234 |82 97|consensus c-Myb0000 Pharmacolo
P11094072A1234 |55 62|T cellsd 5-nuc
P11094073A0000 |156 161|yeastWhen 
P11094073A0000 |24 30|membern with
P11094073A0000 |89 125|Ros receptor protein tyrosine kinasearmacologic aspects of neonatal hype
P11094073A0000 |127 131|RPTKilir
P11094073A0000 |59 63|Vav3nucl
P11094073A0000 |145 152|protein08997A0
P11094073A0000 |173 182|screeningis shown 
P11094073A0000 |38 57|Vav family proteinse phosphatases and 
P11094075A0257 |85 102|rat thyroid cells0 Pharmacologic a
P11094075A0257 |31 43|reexpressionalkaline pho
P11094075A0257 |154 172|v-ras-Ki oncogenes2 When CSF [HCO3-]
P11094075A0257 |200 209|phenotypeSF PCO2 t
P11094075A0257 |144 149|v-mos00899
P11094075A0257 |118 130|retrovirusesal hyperbili
P11094075A0257 |51 64|r-PTPeta genes and 5-nucle
P11094087T0000 |137 151|kinase pathwayia. P00008997A
P11094087T0000 |8 18|expression6T0076 Com
P11094087T0000 |46 60|transformationatases and 5-n
P11094087T0000 |22 26|Rnd3son 
P11094087T0000 |85 90|cells0 Pha
P11094091A0000 |103 118|phosphorylationpects of neonat
P11094091A0000 |76 83|stimuli08171T0
P11094091A0000 |133 147|serine residueinemia. P00008
P11094091A0000 |149 155|Ser1337A0472
P11094091A0000 |20 45|transcription factor CREBrison with alkaline phosp
P11094091A0000 |4 12|activity01606T00
P11094109A0600 |17 20|agempa
P11094109A0600 |47 52|yearstases
P11094109A0600 |24 37|symptom onsetn with alkali
P11094109A0600 |0 7|RESULTSP000016
P11094590A0617 |139 142|VAP. P
P11094590A0617 |86 94|bacteria Pharmac
P11094590A0617 |156 159|PTCWhe
P11094590A0617 |297 298|%a
P11094590A0617 |126 135|diagnosisbilirubin
P11094590A0617 |148 151|PSB97A
P11094590A0617 |243 248|valuelonge
P11094590A0617 |198 209|specificity CSF PCO2 t
P11094590A0617 |74 82|presence0008171T
P11094590A0617 |195 196|% 
P11094590A0617 |220 221|%K
P11094590A0617 |259 260|% 
P11094590A0617 |174 185|sensitivitys shown as 
P11094590A0617 |8 14|fields6T0076
P11094590A0617 |282 287|valueols b
P11094590A0617 |39 51|relationship phosphatase
P11094590A0617 |98 111|Gram stainingic aspects of
P11095248A0423 |21 29|proteinsison wit
P11095248A0423 |181 185|gp27 as 
P11095248A0423 |90 94|gp31rmac
P11095248A0423 |76 88|glycoprotein08171T0000 P
P11095248A0423 |124 132|cleavageerbiliru
P11095248A0423 |31 36|XFGF3alkal
P11095248A0423 |172 179|product is sho
P11095248A0423 |66 68|Mrid
P11095248A1523 |25 32|Xenopus with a
P11095248A1523 |47 52|FGF3stases
P11095248A1523 |107 115|activitys of neo
P11095248A1523 |72 84|prerequisiteP00008171T00
P11095981A0254 |52 63|replication and 5-nucl
P11095981A0254 |26 38|cis-elementswith alkalin
P11095981A0254 |123 131|plasmidsperbilir
P11095981A0254 |149 158|mutations7A0472 Wh
P11095981A0254 |79 90|bp promoter71T0000 Pha
P11095981A0254 |163 172|deletionsF [HCO3-]
P11096662T0000 |17 24|Therapympariso
P11096662T0000 |37 51|Artery Diseasene phosphatase
P11096662T0000 |0 9|TranilastP00001606
P11097040A0000 |137 145|freezingia. P000
P11097040A0000 |266 281|dog spermatozoaompared to cont
P11097040A0000 |57 64|effects5-nucle
P11097040A0000 |183 188|ratess a f
P11097040A0000 |30 35|study alka
P11097040A0000 |75 80|Equex00817
P11097040A0000 |288 298|degrees C.t still ha
P11097040A0000 |254 262|survivallaced wh
P11097040A0000 |86 99|TRIS-extender Pharmacologi
P11097040A0000 |114 119|semenonata
P11097040A0000 |130 135|stepsrubin
P11097040A0000 |198 210|interactions CSF PCO2 th
P11097040A0000 |225 235|treatmentsleted rats
P11097040A0000 |161 168|methodsCSF [HC
P11097040A0000 |4 14|objectives01606T0076
P11097079A0525 |5 10|study1606T
P11097079A0525 |61 70|cliniciancleotidas
P11097079A0525 |43 53|validationsphatases 
P11097079A0525 |77 87|NIMH-LCM-p8171T0000 
P11098217A0674 |4 14|Aie1 locus01606T0076
P11098217A0674 |29 52|mouse chromosome 7A2-A3h alkaline phosphatases
P11098217A0674 |76 89|hybridization08171T0000 Ph
P11098420A0175 |137 144|suicideia. P00
P11098420A0175 |12 21|disorders76 Compar
P11098420A0175 |38 49|adolescentse phosphata
P11098420A0175 |25 33|children with al
P11098420A0175 |124 133|mortalityerbilirub
P11098420A0175 |87 98|developmentPharmacolog
P11098420A0175 |69 78|morbidityse P00008
P11099377T0000 |55 106|proteoglycan core protein beta-d-xylosyltransferased 5-nucleotidase P00008171T0000 Pharmacologic aspec
P11099377T0000 |10 17|cloning0076 Co
P11099377T0000 |121 134|isoform XT-IIhyperbilirubi
P11099377T0000 |42 54|UDP-d-Xyloseosphatases a
P11099377T0000 |22 32|expressionson with a
P11100515A0282 |0 14|ThyrotoxicosisP00001606T0076
P11100515A0282 |22 32|amiodaroneson with a
P11100515A0282 |162 168|effectSF [HC
P11100515A0282 |104 113|potentialects of n
P11100515A0282 |175 196|amiodarone withdrawal shown as a function 
P11100515A0282 |117 131|thyrotoxicosistal hyperbilir
P11101008A0649 |0 15|Chaperones/HSPsP00001606T0076 
P11101008A0649 |36 41|rolesine p
P11101008A0649 |49 69|cell cycle processesses and 5-nucleotida
P11101847A0159 |116 120|refsatal
P11101847A0159 |57 70|stabilization5-nucleotidas
P11101847A0159 |10 20|signalling0076 Compa
P11101847A0159 |75 85|activation008171T000
P11101847A0159 |24 28|E2F1n wi
P11101847A0159 |93 114|tumour suppressor p53cologic aspects of ne
P11102367A1170 |51 59|identitys and 5-
P11102367A1170 |29 40|conclusionsh alkaline 
P11102367A1170 |126 136|Drosophilabilirubine
P11102367A1170 |176 184|approachshown as
P11102367A1170 |228 237|mutationsed rats a
P11102367A1170 |89 100|developmentarmacologic
P11102367A1170 |63 71|proteinseotidase
P11102367A1170 |116 122|systematal h
P11102367A1170 |5 10|study1606T
P11102367A1170 |260 267|screenswhen co
P11102367A1170 |153 160|example72 When
P11102367A1170 |204 209|masseCO2 t
P11102458A0000 |170 172|nm-]
P11102458A0000 |182 186|typeas a
P11102458A0000 |122 125|kDaype
P11102458A0000 |107 114|proteins of ne
P11102458A0000 |16 30|identificationomparison with
P11102458A0000 |155 159|site Whe
P11102458A0000 |212 228|protein kinase Adata of K-deplet
P11102458A0000 |63 75|neurobeachineotidase P00
P11102458A0000 |43 59|characterizationsphatases and 5-
P11102458A0000 |230 237|PKA RII rats a
P11102458A0000 |161 162|KC
P11102458A0000 |163 164|dF
P11102458A0000 |201 208|subunitF PCO2 
P11103472A0802 |119 129|amplitudesl hyperbil
P11103472A0802 |14 17|ADD Co
P11103472A0802 |69 74|trendse P0
P11103472A0802 |93 98|CNV-1colog
P11103472A0802 |47 62|CNV-1 amplitudetases and 5-nuc
P11103472A0802 |103 108|CNV-2pects
P11103472A0802 |0 8|ChildrenP0000160
P11103601T0025 |6 11|UMDNJ606T0
P11103792A0755 |0 14|OverexpressionP00001606T0076
P11103792A0755 |224 232|bax-nullpleted r
P11103792A0755 |66 71|cellsidase
P11103792A0755 |129 137|presenceirubinem
P11103792A0755 |264 269|mouse comp
P11103792A0755 |280 291|fibroblaststrols but s
P11103792A0755 |166 171|serumHCO3-
P11103792A0755 |18 23|c-Mycparis
P11103792A0755 |141 147|growthP00008
P11103792A0755 |81 90|apoptosisT0000 Pha
P11103792A0755 |50 55|mousees an
P11103792A0755 |187 196|apoptosisfunction 
P11105129T0000 |32 42|Klebsiellalkaline ph
P11105129T0000 |54 96|Producing Extended-Spectrum beta-lactamasend 5-nucleotidase P00008171T0000 Pharmacol
P11105129T0000 |129 135|Brazilirubin
P11105129T0000 |14 28|Susceptibility Comparison wi
P11105129T0000 |98 102|ESBLic a
P11105129T0000 |116 125|Hospitalsatal hype
P11105716A0782 |0 10|CONCLUSIONP00001606T
P11105716A0782 |121 124|CBVhyp
P11105716A0782 |104 117|determinationects of neona
P11105716A0782 |91 96|errormacol
P11105716A0782 |129 139|CBF valuesirubinemia
P11105716A0782 |215 235|MR perfusion studiesa of K-depleted rats
P11105716A0782 |177 184|accounthown as
P11105716A0782 |37 56|AIF peak saturationne phosphatases and
P11105716A0782 |16 23|resultsomparis
P11105717A0123 |0 7|METHODSP000016
P11105717A0123 |165 175|hemoglobin[HCO3-] is
P11105717A0123 |9 11|T2T0
P11105717A0123 |199 215|microvasculatureCSF PCO2 the dat
P11105717A0123 |183 194|vasculatures a functio
P11105717A0123 |55 61|imagesd 5-nu
P11105717A0123 |103 128|susceptibility differencepects of neonatal hyperbi
P11106216A0918 |87 94|FOT RrsPharmac
P11106216A0918 |7 20|COPD patients06T0076 Compa
P11106216A0918 |59 60|%n
P11106216A0918 |26 37|variabilitywith alkali
P11106216A0918 |52 55|Rrs an
P11106216A0918 |98 99|%i
P11106428A0635 |84 89|FAP-100 Ph
P11106428A0635 |165 190|glutathione-S-transferase[HCO3-] is shown as a fun
P11106428A0635 |135 139|formemia
P11106428A0635 |74 80|domain000817
P11106428A0635 |151 154|Ser047
P11106428A0635 |106 117|amino acidsts of neona
P11106428A0635 |12 15|end76 
P11106428A0635 |192 195|GSTion
P11106428A0635 |39 47|proteins phospha
P11106428A0635 |141 148|Cys2408P000089
P11106667A1061 |84 99|Cox2p synthesis00 Pharmacologi
P11106667A1061 |107 119|mitochondrias of neonata
P11106667A1061 |44 65|membrane localizationphatases and 5-nucleo
P11106667A1061 |30 35|roles alka
P11106667A1061 |6 13|Pet111p606T007
P11106667A1061 |70 80|regulatione P0000817
P11106668A0875 |139 145|c-IAP1. P000
P11106668A0875 |44 62|spacer-RING domainphatases and 5-nuc
P11106668A0875 |125 135|BIR domainrbilirubin
P11106668A0875 |29 34|cellsh alk
P11106668A0875 |13 25|transfection6 Comparison
P11106668A0875 |158 167|apoptosisen CSF [H
P11106668A0875 |98 106|functionic aspec
P11107637X0001 |32 38|boundslkalin
P11107637X0001 |222 230|patientsdepleted
P11107637X0001 |155 161|method When 
P11107637X0001 |294 307|heart diseasel have a sign
P11107637X0001 |246 254|diseasesger disp
P11107637X0001 |265 280|atherosclerosiscompared to con
P11107637X0001 |331 336|ozone(1.21
P11107637X0001 |121 133|significancehyperbilirub
P11107637X0001 |90 105|pathophysiologyrmacologic aspe
P11107637X0001 |197 203|lipidsf CSF 
P11107637X0001 |314 327|use titrationly greater sl
P11107637X0001 |79 84|ozone71T00
P11107637X0001 |165 175|definition[HCO3-] is
P11107637X0001 |186 193|binders functi
P11107637X0001 |64 73|titrationotidase P
P11107637X0001 |143 150|article0008997
P11107637X0001 |42 60|blood serum lipidsosphatases and 5-n
P11107637X0001 |4 17|determination01606T0076 Co
P11107637X0001 |207 218|blood serum the data o
P11108151A0560 |171 188|tyrphostin AG1478] is shown as a f
P11108151A0560 |52 66|PKC inhibitors and 5-nucleot
P11108151A0560 |212 228|fibronectin mRNAdata of K-deplet
P11108151A0560 |199 208|inductionCSF PCO2 
P11108151A0560 |15 31|fibronectin mRNAComparison with 
P11108151A0560 |154 166|EGF-R mutant2 When CSF [
P11108151A0560 |70 83|PKC depletione P00008171T0
P11108151A0560 |116 130|EGF-R functionatal hyperbili
P11108151A0560 |0 3|AngP00
P11108151A0560 |102 112|inhibitionspects of 
P11108374A1466 |0 6|AcoustP00001
P11108523A0326 |0 12|Video imagesP00001606T00
P11108523A0326 |82 90|centroid0000 Pha
P11108523A0326 |159 169|anisometryn CSF [HCO
P11108523A0326 |148 151|I1197A
P11108523A0326 |142 146|axes0000
P11108523A0326 |108 115|moments of neo
P11108523A0326 |198 216|internostril angle CSF PCO2 the data
P11108523A0326 |153 156|I2272 
P11108523A0326 |20 28|nostrilsrison wi
P11108523A0326 |71 80|perimeter P0000817
P11108523A0326 |65 69|areatida
P11108523A0326 |233 238|anglets ar
P11108523A0326 |171 180|bulkiness] is show
P11108523A0326 |102 106|axisspec
P11108548A0710 |0 18|MS characteristicsP00001606T0076 Com
P11108548A0710 |133 138|basisinemi
P11108548A0710 |88 109|substitution patternsharmacologic aspects 
P11108548A0710 |173 187|APcI interfaceis shown as a 
P11108548A0710 |22 31|coumarinsson with 
P11108548A0710 |146 154|response8997A047
P11108548A0710 |64 72|flavonesotidase 
P11108548A0710 |33 42|psoralenskaline ph
P11108616A0000 |0 10|Young fishP00001606T
P11108616A0000 |12 35|Oreochromis mossambicus76 Comparison with alka
P11108616A0000 |88 92|daysharm
P11108616A0000 |73 74|g0
P11108616A0000 |164 168|days [HC
P11108616A0000 |140 152|hypergravity P00008997A0
P11108616A0000 |53 65|microgravityand 5-nucleo
P11108616A0000 |126 132|STS-84biliru
P11108616A0000 |100 121|space missions STS-55 aspects of neonatal 
P11108616A0000 |154 156|hg2 
P11108720A0124 |254 258|S6K2lace
P11108720A0124 |130 137|regionsrubinem
P11108720A0124 |41 52|core kinasehosphatases
P11108720A0124 |29 33|S6K1h al
P11108720A0124 |224 243|localization signalpleted rats are no 
P11108720A0124 |75 82|domains008171T
P11108720A0124 |100 104|S6K1 asp
P11108720A0124 |112 113|Nn
P11108720A0124 |57 63|linker5-nucl
P11108720A0124 |184 191|nucleus a func
P11108720A0124 |0 4|S6K2P000
P11108720A1130 |0 12|PretreatmentP00001606T00
P11108720A1130 |88 101|kinase kinaseharmacologic 
P11108720A1130 |134 149|S6K2 activationnemia. P0000899
P11108720A1130 |175 179|S6K1 sho
P11108720A1130 |163 169|extentF [HCO
P11108720A1130 |108 123|inhibitor U0126 of neonatal hy
P11108720A1130 |16 21|cellsompar
P11108720A1130 |103 106|MEKpec
P11108839A0401 |0 7|T cellsP000016
P11108839A0401 |43 46|kDasph
P11108839A0401 |20 28|isoformsrison wi
P11108839A0401 |76 87|kDa isoform08171T0000 
P11108839A0401 |59 65|kinasenucleo
P11108839A0401 |115 127|localisationnatal hyperb
P11108839A0401 |32 36|S6k1lkal
P11110040A0000 |0 10|KetanserinP00001606T
P11110040A0000 |241 251|metaboliteo longer d
P11110040A0000 |128 135|corneallirubin
P11110040A0000 |92 100|infusionacologic
P11110040A0000 |26 30|drugwith
P11110040A0000 |193 201|pressureon of CS
P11110040A0000 |148 160|applications97A0472 When
P11110040A0000 |36 61|5-HT2 receptor antagonismine phosphatases and 5-nu
P11110040A0000 |212 217|timesdata 
P11110040A0000 |110 124|% w/v solutionf neonatal hyp
P11110040A0000 |223 231|activityepleted 
P11110040A0000 |253 265|ketanserinolplaced when 
P11110528A0414 |83 92|direction000 Pharm
P11110528A0414 |45 62|velocity encodinghatases and 5-nuc
P11110528A0414 |109 115|regionof neo
P11110528A0414 |148 152|cm/s97A0
P11110528A0414 |31 39|sequencealkaline
P11110528A0414 |129 137|velocityirubinem
P11110528A0414 |22 24|2Dso
P11111051A0051 |68 71|HATase
P11111051A0051 |31 36|Tip60alkal
P11111051A0051 |73 81|activity00008171
P11111051A0051 |41 66|histone acetyltransferasehosphatases and 5-nucleot
P11112417A1126 |4 8|data0160
P11112417A1126 |28 45|MLSN1 transcriptsth alkaline phosp
P11112417A1126 |159 175|MLSN1 expressionn CSF [HCO3-] is
P11112417A1126 |126 140|melanoma cellsbilirubinemia.
P11112417A1126 |214 227|transcriptionta of K-deple
P11112417A1126 |232 247|mRNA processingats are no long
P11112417A1126 |200 205|levelSF PC
P11112438X0847 |0 9|CopyrightP00001606
P11112438X0847 |15 29|Academic PressComparison wit
P11112700A1936 |0 7|PlectinP000016
P11112700A1936 |61 70|C-terminicleotidas
P11112700A1936 |44 51|domainsphatase
P11112700A1936 |149 160|desmoplakin7A0472 When
P11112700A1936 |132 139|plectinbinemia
P11112700A1936 |122 128|domainyperbi
P11112700A1936 |12 23|desmoplakin76 Comparis
P11112700A1936 |174 177|MTss s
P11112700T0000 |0 16|CharacterizationP00001606T0076 C
P11112700T0000 |24 50|microtubule binding domainn with alkaline phosphatas
P11112700T0000 |135 146|microtubuleemia. P0000
P11112700T0000 |158 166|proteinsen CSF [
P11112700T0000 |93 97|MACFcolo
P11112700T0000 |126 131|groupbilir
P11112700T0000 |54 91|microtubule actin crosslinking factornd 5-nucleotidase P00008171T0000 Phar
P11112700T0000 |100 114|identification aspects of ne
P11112790A0989 |6 13|results606T007
P11112790A0989 |31 42|involvementalkaline ph
P11112790A0989 |73 76|UPR000
P11112790A0989 |57 65|elements5-nucleo
P11113179A0541 |137 144|adaptoria. P00
P11113179A0541 |63 80|estrogen receptoreotidase P0000817
P11113179A0541 |28 32|SRC1th a
P11113179A0541 |164 168|p300 [HC
P11113179A0541 |52 55|CBP an
P11113179A0541 |41 48|bindinghosphat
P11113179A0541 |106 120|SRC1 functionsts of neonatal
P11113179A0541 |156 159|CBPWhe
P11113179A0541 |16 24|contrastompariso
P11113179A1020 |171 177|assays] is s
P11113179A1020 |14 23|construct Comparis
P11113179A1020 |41 49|residueshosphata
P11113179A1020 |107 117|AD1 regions of neona
P11113179A1020 |121 125|SRC1hype
P11113179A1020 |143 163|coactivator activity0008997A0472 When CS
P11113179A1020 |86 98|LXXLL motifs Pharmacolog
P11113199A0800 |32 38|anchorlkalin
P11113199A0800 |132 155|ERK2-Delta19-25 mutantsbinemia. P00008997A0472
P11113199A0800 |47 51|ERKstase
P11113199A0800 |6 9|MEK606
P11113199A0800 |67 82|MEK interactiondase P00008171T
P11113199A0800 |57 61|lack5-nu
P11113199A0800 |173 178|cellsis sh
P11113199A0800 |116 128|localizationatal hyperbi
P11113201A1114 |102 117|target proteinsspects of neona
P11113201A1114 |75 79|step0081
P11113201A1114 |22 40|six-protein familyson with alkaline 
P11113201A1114 |10 16|member0076 C
P11113201A1114 |44 49|yeastphata
P11113201A1114 |83 98|O mannosylation000 Pharmacolog
P11113201A1114 |0 4|Pmt2P000
P11113546A0728 |50 53|endes 
P11113546A0728 |6 13|samples606T007
P11113546A0728 |132 144|Giardia cystbinemia. P00
P11113546A0728 |62 74|trial periodleotidase P0
P11113546A0728 |36 45|beginningine phosp
P11113546A0728 |114 127|nematode eggsonatal hyperb
P11113692A0169 |102 105|PDRspe
P11113692A0169 |158 162|typeen C
P11113692A0169 |93 96|BDRcol
P11113692A0169 |244 249|entryonger
P11113692A0169 |208 216|mean agethe data
P11113692A0169 |60 70|backgrounducleotidas
P11113692A0169 |165 173|diabetes[HCO3-] 
P11113692A0169 |194 199|yearsn of 
P11113692A0169 |16 21|studyompar
P11113692A0169 |257 262|mm Hged wh
P11113692A0169 |80 91|retinopathy1T0000 Phar
P11113692A0169 |43 55|risk factorssphatases an
P11113692A0169 |226 240|blood pressureeted rats are 
P11113692A0169 |132 140|patientsbinemia.
P11113692A0169 |203 206|agePCO
P11113692A0169 |4 7|aim016
P11113822A0999 |36 44|controlsine phos
P11113822A0999 |90 102|jaw pathosesrmacologic a
P11113822A0999 |10 19|quadrants0076 Comp
P11113823A0197 |5 10|cases1606T
P11113823A0197 |23 37|chondromatosison with alkali
P11114294A0075 |207 211|CFTR the
P11114294A0075 |124 134|expressionerbilirubi
P11114294A0075 |226 235|T84 cellseted rats
P11114294A0075 |149 193|fibrosis transmembrane conductance regulator7A0472 When CSF [HCO3-] is shown as a functi
P11114294A0075 |195 199|CFTR of 
P11114294A0075 |54 91|cytokines tumor necrosis factor alphand 5-nucleotidase P00008171T0000 Phar
P11114294A0075 |96 112|interferon gammaogic aspects of 
P11114294A0075 |9 16|studiesT0076 C
P11114294A0075 |201 205|geneF PC
P11114294A0075 |216 221|HT-29 of K
P11114521A0282 |0 10|RegulationP00001606T
P11114521A0282 |66 71|cellsidase
P11114521A0282 |43 51|adhesionsphatase
P11114521A0282 |14 18|RhoA Com
P11114521A0282 |98 112|cell spreadingic aspects of 
P11114521A0282 |117 126|migrationtal hyper
P11114718A0349 |16 33|mouse fibroblastsomparison with al
P11114718A0349 |94 97|p21olo
P11114718A0349 |56 61|v-Src 5-nu
P11114718A0349 |76 90|protein levels08171T0000 Pha
P11114718A0349 |126 134|cyclin Ebilirubi
P11114718A0349 |111 120|cyclin D1 neonatal
P11114718A0349 |67 71|mRNAdase
P11114718A0349 |99 108|WAF1/CIP1c aspects
P11114924A0808 |0 4|ORFAP000
P11114924A0808 |9 13|ccdAT007
P11114924A0808 |65 90|primer extension analysistidase P00008171T0000 Pha
P11116084A0000 |0 12|Mouse ImpactP00001606T00
P11116084A0000 |39 43|gene pho
P11116084A0000 |81 88|proteinT0000 P
P11116084A0000 |100 108|function aspects
P11116131A0863 |21 24|P2Yiso
P11116131A0863 |29 33|mRNAh al
P11116131A0863 |41 48|culturehosphat
P11116131A0863 |6 11|cells606T0
P11116148A0741 |0 20|Coexpression studiesP00001606T0076 Compa
P11116148A0741 |47 50|PKBtas
P11116148A0741 |60 75|transactivationucleotidase P00
P11116148A0741 |157 166|C/EBPbetahen CSF [
P11116148A0741 |130 153|transactivation domainsrubinemia. P00008997A04
P11116148A0741 |79 88|C/EBPbeta71T0000 P
P11116148A0741 |98 108|C/EBPalphaic aspects
P11116148A0741 |35 42|insulinline ph
P11117263A0570 |171 175|acid] is
P11117263A0570 |177 180|DMAhow
P11117263A0570 |242 248|epiHMA longe
P11117263A0570 |122 129|cerealeyperbil
P11117263A0570 |91 96|rootsmacol
P11117263A0570 |285 289|acid but
P11117263A0570 |291 294|HMAtil
P11117263A0570 |250 260|H. vulgaredisplaced 
P11117263A0570 |296 306|S. cerealehave a sig
P11117263A0570 |25 32|species with a
P11117263A0570 |236 240|acidare 
P11117263A0570 |201 205|acidF PC
P11117263A0570 |41 56|Ids3 expressionhosphatases and
P11117263A0570 |207 209|MA t
P11117263A0570 |100 110|H. vulgare aspects o
P11117523A0650 |118 131|cell culturesal hyperbilir
P11117523A0650 |78 87|P19 cells171T0000 
P11117523A0650 |3 11|contrast001606T0
P11117523A0650 |140 147|neurons P00008
P11117523A0650 |59 74|differentiationnucleotidase P0
P11117523A0650 |18 37|COUP-TFI expressionparison with alkali
P11117523A0650 |101 103|RAas
P11117826A0788 |35 47|pretreatmentline phospha
P11117826A0788 |111 119|patients neonata
P11117826A0788 |78 81|use171
P11117826A0788 |177 181|datahown
P11117826A0788 |143 153|comparison0008997A04
P11117826A0788 |52 72|follow-up evaluation and 5-nucleotidase 
P11117826A0788 |8 11|PET6T0
P11117826A0788 |98 101|PETic 
P11117826A0788 |207 211|data the
P11118062A1691 |156 165|phenotypeWhen CSF 
P11118062A1691 |74 84|K-ras gene0008171T00
P11118062A1691 |58 66|mutation-nucleot
P11118062A1691 |27 32|modelith a
P11118062A1691 |121 135|aggressivenesshyperbilirubin
P11118062A1691 |112 117|levelneona
P11118062A1691 |38 50|localizatione phosphatas
P11118438A0411 |69 88|plant species applese P00008171T0000 P
P11118438A0411 |208 215|juglonethe dat
P11118438A0411 |90 105|Malus domesticarmacologic aspe
P11118438A0411 |45 59|Pin1 homologuehatases and 5-
P11118438A0411 |22 31|isolationson with 
P11118438A0411 |162 183|substrate specificitySF [HCO3-] is shown a
P11118438A0411 |245 249|Pin1nger
P11118438A0411 |236 240|caseare 
P11118438A0411 |35 41|MdPin1line p
P11118440T0000 |71 102|candidate tumor suppressor ING1 P00008171T0000 Pharmacologic a
P11118440T0000 |40 63|alternative transcriptsphosphatases and 5-nucl
P11118440T0000 |28 36|productsth alkal
P11118440T0000 |13 24|association6 Compariso
P11118440T0000 |112 123|mSin3/HDAC1neonatal hy
P11118440T0000 |140 159|corepressor complex P00008997A0472 Whe
P11118619A0835 |16 20|dataompa
P11118619A0835 |60 91|host cell transcription factorsucleotidase P00008171T0000 Phar
P11118619A0835 |52 58|models and 5
P11118619A0835 |121 130|infectionhyperbili
P11118619A0835 |44 47|TAgpha
P11118619A0835 |189 203|transformationnction of CSF 
P11118619A0835 |154 159|event2 Whe
P11118712A1296 |205 220|within-herd PTBO2 the data of 
P11118712A1296 |52 58|limits and 5
P11118712A1296 |299 304|herdse a s
P11118712A1296 |97 101|testgic 
P11118712A1296 |226 236|prevalenceeted rats 
P11118712A1296 |254 260|reasonlaced 
P11118712A1296 |117 127|estimationtal hyperb
P11118712A1296 |323 332|herd sizer slope (
P11118712A1296 |174 191|confidence limitss shown as a func
P11118712A1296 |278 294|herd specificityontrols but stil
P11118712A1296 |66 74|accuracyidase P0
P11118712A1296 |140 155|herd prevalence P00008997A0472
P11118712A1296 |5 25|sensitivity analysis1606T0076 Comparison
P11119611A0428 |0 6|ORFK10P00001
P11119611A0428 |124 131|tissueserbilir
P11119611A0428 |151 153|CD04
P11119611A0428 |143 146|PEL000
P11119611A0428 |66 71|LANA2idase
P11119611A0428 |162 172|KS lesionsSF [HCO3-]
P11119611A0428 |55 62|antigend 5-nuc
P11119611A0428 |19 26|proteinarison 
P11120441A1193 |17 26|believersmparison 
P11120441A1193 |105 114|asymmetrycts of ne
P11120441A1193 |129 139|complexityirubinemia
P11120441A1193 |70 80|activatione P0000817
P11121043A0074 |34 42|inducersaline ph
P11121043A0074 |78 90|neurogenesis171T0000 Pha
P11121043A0074 |12 16|BMPs76 C
P11121043A0074 |64 74|regulatorsotidase P0
P11121043A0074 |3 10|Xenopus001606T
P11121118A0075 |49 62|GAF sequencesses and 5-nuc
P11121118A0075 |22 30|variantsson with
P11121118A0075 |81 87|regionT0000 
P11121118T0000 |34 63|phosphodiesterase PDE11A genealine phosphatases and 5-nucl
P11121118T0000 |8 20|organization6T0076 Compa
P11121397A0587 |136 146|initiationmia. P0000
P11121397A0587 |12 20|findings76 Compa
P11121397A0587 |165 180|heparan sulfate[HCO3-] is show
P11121397A0587 |151 161|elongation0472 When 
P11121397A0587 |66 106|alpha1,4-N-acetylglucosaminyltransferaseidase P00008171T0000 Pharmacologic aspec
P11121397A0587 |39 52|rib-2 protein phosphatases
P11121434A0915 |0 10|InhibitionP00001606T
P11121434A0915 |121 129|recoveryhyperbil
P11121434A0915 |37 51|Rat1/ras cellsne phosphatase
P11121434A0915 |78 85|PD98059171T000
P11121434A0915 |63 76|Mek inhibitoreotidase P000
P11121434A0915 |18 33|Mek/Erk pathwayparison with al
P11121434A0915 |170 174|HR12-] i
P11121490A0000 |102 111|apoptosisspects of
P11121490A0000 |66 72|stressidase 
P11121490A0000 |4 42|transcription factor CHOP/GADD153 gene01606T0076 Comparison with alkaline ph
P11122381A0908 |0 8|AdditionP0000160
P11122381A0908 |147 157|activation997A0472 W
P11122381A0908 |46 54|peptidesatases a
P11122381A0908 |105 123|GM-CSF stimulationcts of neonatal hy
P11122381A0908 |161 166|STAT5CSF [
P11122381A0908 |86 95|tyrosines Pharmaco
P11122588A0549 |0 21|MAIN OUTCOME MEASURESP00001606T0076 Compar
P11122588A0549 |218 223|sleepf K-d
P11122588A0549 |23 40|Percentage changeon with alkaline 
P11122588A0549 |63 68|indexeotid
P11122588A0549 |210 214|houre da
P11122588A0549 |90 105|hypopnea eventsrmacologic aspe
P11122588A0549 |167 170|SDBCO3
P11122588A0549 |75 87|apnea events008171T0000 
P11122588A0549 |186 189|AHI fu
P11122588A0549 |118 123|sleepal hy
P11122588A0549 |252 258|weightsplace
P11122588A0549 |110 114|hourf ne
P11122588A0549 |129 133|oddsirub
P11122588A0549 |199 205|eventsCSF PC
P11122588A0549 |231 238|respectrats ar
P11122588A0549 |70 73|AHIe P
P11123054T0000 |25 34|syndromes with alk
P11123089A0362 |117 129|vasculitidestal hyperbil
P11123089A0362 |47 56|frequencytases and
P11123089A0362 |28 39|informationth alkaline
P11123089A0362 |143 151|patients0008997A
P11123089A0362 |58 73|characteristics-nucleotidase P
P11123089A0362 |177 192|tissue diseaseshown as a funct
P11123089A0362 |5 12|article1606T00
P11123089A0362 |99 109|mechanismsc aspects 
P11123316T0000 |0 20|Tec kinase signalingP00001606T0076 Compa
P11123316T0000 |24 31|T cellsn with 
P11123316T0000 |48 77|phosphatidylinositol 3-kinaseases and 5-nucleotidase P0000
P11123316T0000 |86 116|Tec pleckstrin homology domain Pharmacologic aspects of neon
P11123701A0442 |34 37|DNAali
P11123701A0442 |77 85|coupling8171T000
P11123701A0442 |198 219|transcription complex CSF PCO2 the data of
P11123701A0442 |130 139|promotersrubinemia
P11123701A0442 |26 30|typewith
P11123701A0442 |164 178|DNA constructs [HCO3-] is sh
P11123701A0442 |321 331|DNA duplexter slope 
P11123701A0442 |296 305|diffusionhave a si
P11123701A0442 |8 16|evidence6T0076 C
P11123701A0442 |260 274|DNA supercoilswhen compared 
P11123701A0442 |116 126|activitiesatal hyper
P11123912A0306 |154 163|T antigen2 When CS
P11123912A0306 |134 146|polyomavirusnemia. P0000
P11123912A0306 |113 120|peptideeonatal
P11123912A0306 |26 36|SH2 domainwith alkal
P11123912A0306 |165 167|MT[H
P11123912A0306 |4 13|structure01606T007
P11123912A0306 |70 73|SH2e P
P11124024A1098 |85 91|repeat0 Phar
P11124024A1098 |43 60|protein complexessphatases and 5-n
P11124024A1098 |33 38|siteskalin
P11124024A1098 |64 74|palindromeotidase P0
P11124024A1098 |99 111|C+T sequencec aspects of
P11124024A1098 |138 149|GAGA motifsa. P0000899
P11124024A1098 |169 175|strand3-] is
P11124902X1337 |0 9|CopyrightP00001606
P11124902X1337 |15 29|Academic PressComparison wit
P11125151T0000 |0 19|Nucleotide sequenceP00001606T0076 Comp
P11125151T0000 |58 66|analysis-nucleot
P11125151T0000 |105 112|virus-2cts of 
P11125151T0000 |21 40|genome organizationison with alkaline 
P11125151T0000 |70 88|pineapple mealybuge P00008171T0000 P
P11125363A0525 |0 8|PatientsP0000160
P11125363A0525 |105 114|cisplatincts of ne
P11125363A0525 |163 167|daysF [H
P11125363A0525 |145 159|5-fluorouracil08997A0472 Whe
P11125363A0525 |130 132|gmru
P11125363A0525 |56 69|tumor mapping 5-nucleotida
P11125363A0525 |134 136|m.ne
P11125363A0525 |101 103|m.as
P11125363A0525 |190 202|radiotherapyction of CSF
P11125363A0525 |96 98|mgog
P11125363A0525 |19 42|pretreatment cystoscopyarison with alkaline ph
P11125363A0525 |118 121|dayal 
P11125411A0857 |35 46|laparoscopyline phosph
P11125411A0857 |109 115|testesof neo
P11125411A0857 |132 138|testisbinemi
P11125411A0857 |155 160|canal When
P11125411A0857 |16 24|patientsompariso
P11125872A0133 |69 86|phosphodiesterasese P00008171T0000
P11125872A0133 |90 99|inhibitorrmacologi
P11125872A0133 |5 15|philosophy1606T0076 
P11125872A0133 |145 153|delivery08997A04
P11125872A0133 |181 187|routes as a 
P11125872A0133 |39 50|compound RP phosphatas
P11125872A0133 |191 205|administrationtion of CSF PC
P11126275A1068 |68 76|bleedingase P000
P11126275A1068 |10 16|levels0076 C
P11126275A1068 |20 52|anticardiolipin immunoglobulin Grison with alkaline phosphatases
P11126353A0582 |51 52|%s
P11126353A0582 |56 65|diagnosis 5-nucleo
P11126353A0582 |91 93|3yma
P11126353A0582 |86 87|% 
P11126353A0582 |23 30|obesityon with
P11126353A0582 |9 19|PrevalenceT0076 Comp
P11126353A0582 |32 39|BMI SDSlkaline
P11126353A0582 |0 7|RESULTSP000016
P11126806A0206 |85 96|circulation0 Pharmacol
P11126806A0206 |11 19|sequelae076 Comp
P11126806A0206 |27 54|antiphospholipid-antibodiesith alkaline phosphatases a
P11127161T0000 |17 34|smoking cessationmparison with alk
P11127161T0000 |0 9|BupropionP00001606
P11127200A1024 |71 74|ROS P0
P11127200A1024 |82 87|cells0000 
P11127200A1024 |59 67|activitynucleoti
P11127200A1024 |145 154|TGF-beta108997A047
P11127200A1024 |176 186|expressionshown as a
P11127200A1024 |280 287|hormonetrols b
P11127200A1024 |195 201|alpha1 of CS
P11127200A1024 |289 292|PTH st
P11127200A1024 |322 330|receptorer slope
P11127200A1024 |250 260|expressiondisplaced 
P11127200A1024 |203 218|collagen I genePCO2 the data o
P11127200A1024 |315 320|PTHrPy gre
P11127200A1024 |109 135|AP-1 transcription factorsof neonatal hyperbilirubin
P11127200A1024 |38 42|AP-1e ph
P11127200A1024 |306 313|peptidenifican
P11127250A1111 |0 2|PMP0
P11127250A1111 |125 129|curerbil
P11127250A1111 |40 44|dosephos
P11127250A1111 |148 150|VL97
P11127250A1111 |12 17|mg/kg76 Co
P11127250A1111 |134 142|patientsnemia. P
P11127250A1111 |48 50|SBas
P11127250A1111 |58 62|days-nuc
P11127250A1111 |161 166|IndiaCSF [
P11127250A1111 |101 103|SBas
P11127250A1111 |154 159|Bihar2 Whe
P11127955X0001 |35 42|Surgeryline ph
P11127955X0001 |9 16|therapyT0076 C
P11127955X0001 |108 121|colon cancers of neonatal 
P11127955X0001 |21 33|colon cancerison with al
P11127955X0001 |81 87|numberT0000 
P11128312A1238 |101 110|femur BMDaspects o
P11128312A1238 |56 64|fracture 5-nucle
P11128312A1238 |147 153|radius997A04
P11128312A1238 |156 157|%W
P11128312A1238 |114 115|%o
P11128312A1238 |23 34|differenceson with alk
P11128312A1238 |213 214|%a
P11128312A1238 |176 185|dimensionshown as 
P11128312A1238 |129 132|BMDiru
P11128312A1238 |193 204|radiographson of CSF P
P11128312A1238 |81 87|groupsT0000 
P11128312A1238 |36 37|pi
P11128312A1238 |206 209|FD22 t
P11128925A0000 |0 10|BACKGROUNDP00001606T
P11128925A0000 |28 33|studyth al
P11128925A0000 |121 124|GCFhyp
P11128925A0000 |151 159|findings0472 Whe
P11128925A0000 |84 90|levels00 Pha
P11128925A0000 |114 119|fluidonata
P11128925A0000 |188 197|arthritisunction o
P11128925A0000 |213 226|periodontitisata of K-depl
P11128925A0000 |63 76|interleukin-6eotidase P000
P11128925A0000 |199 201|RACS
P11128925A0000 |228 230|APed
P11128925A0000 |16 19|aimomp
P11128925A0000 |78 82|IL-6171T
P11128925A0000 |163 171|patientsF [HCO3-
P11129515A0000 |152 155|PMS472
P11129515A0000 |142 150|syndrome00008997
P11129515A0000 |40 48|efficacyphosphat
P11129515A0000 |30 35|trial alka
P11129515A0000 |114 122|patientsonatal h
P11129515A0000 |55 86|Vitex agnus castus L extract Zed 5-nucleotidase P00008171T0000
P11129724A0904 |0 7|StudiesP000016
P11129724A0904 |46 59|contaminationatases and 5-
P11129724A0904 |74 78|role0008
P11129724A0904 |36 42|sourceine ph
P11129724A0904 |112 124|transmissionneonatal hyp
P11129724A0904 |128 132|MRSAliru
P11129724A0904 |100 104|milk asp
P11129724A0904 |136 144|neonatesmia. P00
P11131321T0000 |0 7|EffectsP000016
P11131321T0000 |78 107|homidum chloride chemotherapy171T0000 Pharmacologic aspect
P11131321T0000 |11 28|Trypanosoma vivax076 Comparison wi
P11131321T0000 |45 58|Yankasa sheephatases and 5
P11131321T0000 |67 74|resultsdase P0
P11131321T0000 |32 41|pregnancylkaline p
P11131634A0955 |0 10|NF kappa BP00001606T
P11131634A0955 |89 97|Y8 cellsarmacolo
P11131634A0955 |75 80|cells00817
P11131634A0955 |43 49|extentsphata
P11131634A0955 |53 64|roscovitineand 5-nucle
P11132063A0250 |221 228|effects-deplet
P11132063A0250 |13 32|treatment exposures6 Comparison with a
P11132063A0250 |135 146|hepatitis Cemia. P0000
P11132063A0250 |95 102|effectslogic a
P11132063A0250 |183 197|cardiomyopathys a function o
P11132063A0250 |47 57|populationtases and 
P11132063A0250 |112 121|cirrhosisneonatal 
P11132063A0250 |248 259|dysfunctionr displaced
P11132148A0162 |4 12|presence01606T00
P11132148A0162 |62 77|promoter regionleotidase P0000
P11132148A0162 |31 39|residuesalkaline
P11132148A0162 |125 129|locirbil
P11132148A0162 |113 122|HLA classeonatal h
P11132195A0000 |205 222|input/output dataO2 the data of K-
P11132195A0000 |91 97|lengthmacolo
P11132195A0000 |120 125|order hype
P11132195A0000 |248 255|systemsr displ
P11132195A0000 |22 32|parametersson with a
P11132195A0000 |189 201|measurementsnction of CS
P11132195A0000 |147 154|methods997A047
P11132195A0000 |177 183|modelshown a
P11132195A0000 |133 145|nonlinearityinemia. P000
P11132195A0000 |47 62|Volterra seriestases and 5-nuc
P11132195A0000 |105 111|memorycts of
P11132195A0000 |12 18|number76 Com
P11132195A0000 |278 286|memoriesontrols 
P11132790A0609 |50 55|scorees an
P11132790A0609 |63 66|S-Beot
P11132790A0609 |13 19|method6 Comp
P11132790A0609 |180 193|risk childrenn as a functi
P11132790A0609 |79 87|subtests71T0000 
P11132790A0609 |99 104|scorec asp
P11133741A0617 |0 4|NiClP000
P11133741A0617 |144 148|loss0089
P11133741A0617 |162 179|promoter activitySF [HCO3-] is sho
P11133741A0617 |41 51|activationhosphatase
P11133741A0617 |71 79|mutation P000081
P11133741A0617 |55 64|NF-kappaBd 5-nucle
P11133741A0617 |114 122|promoteronatal h
P11133741A0617 |101 106|sitesaspec
P11133741A0617 |16 31|MCP-1 synthesisomparison with 
P11133830A0174 |0 10|EngagementP00001606T
P11133830A0174 |37 42|pairsne ph
P11133830A0174 |146 164|kDa phosphoprotein8997A0472 When CSF
P11133830A0174 |121 129|proteinshyperbil
P11133830A0174 |189 209|proto-oncogene c-Cblnction of CSF PCO2 t
P11133830A0174 |97 103|numbergic as
P11133830A0174 |67 91|tyrosine phosphorylationdase P00008171T0000 Phar
P11133830A0174 |20 23|CD2ris
P11133830A0174 |55 58|mAbd 5
P11133927T0000 |85 89|rate0 Ph
P11133927T0000 |58 64|muscle-nucle
P11133927T0000 |12 28|NIR spectroscopy76 Comparison wi
P11133927T0000 |93 101|exercisecologic 
P11133927T0000 |0 8|ValidityP0000160
P11133986A0350 |171 176|c-Jun] is 
P11133986A0350 |215 224|3T3 cellsa of K-de
P11133986A0350 |160 165|c-Fos CSF 
P11133986A0350 |130 138|functionrubinemi
P11133986A0350 |194 201|kappaE3n of CS
P11133986A0350 |90 94|PU.1rmac
P11133986A0350 |58 79|transcription factors-nucleotidase P000081
P11133986A0350 |9 16|studiesT0076 C
P11133986A0350 |125 128|PIPrbi
P11133986A0350 |203 211|enhancerPCO2 the
P11133986A0350 |99 123|PU.1 interaction partnerc aspects of neonatal hy
P11134033A0000 |69 74|mousese P0
P11134033A0000 |83 96|tumor viruses000 Pharmacol
P11134033A0000 |11 22|int-6 locus076 Compari
P11134033A0000 |134 168|translation initiation factor eIF3nemia. P00008997A0472 When CSF [HC
P11134033A0000 |49 65|integration siteses and 5-nucleo
P11134033A0000 |117 130|eIF3e subunittal hyperbili
P11134033A0639 |18 27|int6Deltaparison w
P11134033A0639 |74 80|medium000817
P11134033A0639 |29 35|mutanth alka
P11134033A0639 |3 16|int6 deletion001606T0076 C
P11134351A1405 |33 44|cell growthkaline phos
P11134351A1405 |14 20|MIP-2A Compa
P11134351A1405 |56 60|role 5-n
P11134351A1405 |64 69|MBP-1otida
P11134508A0317 |71 76|AtHD1 P000
P11134508A0317 |78 82|gene171T
P11134508A0317 |23 29|plantson wit
P11134508A0317 |55 69|Arabidopsis HDd 5-nucleotida
P11134822A0629 |29 49|accelerations/30 minh alkaline phosphata
P11134822A0629 |12 13|P7
P11137296A0923 |205 231|transcription-PCR analysisO2 the data of K-depleted 
P11137296A0923 |298 311|mouse tissuesve a signific
P11137296A0923 |331 337|levels(1.21 
P11137296A0923 |115 124|cDNA endsnatal hyp
P11137296A0923 |156 158|bpWh
P11137296A0923 |263 274|PFK-C genesn compared 
P11137296A0923 |246 251|PFK-Ager d
P11137296A0923 |126 134|RLM-RACEbilirubi
P11137296A0923 |5 35|transcription initiation sites1606T0076 Comparison with alka
P11137296A0923 |72 75|RNAP00
P11137296A0923 |253 258|PFK-Bplace
P11137296A0923 |98 111|amplificationic aspects of
P11137296A0923 |168 196|translation initiation codonO3-] is shown as a function 
P11137296A1216 |0 10|PFK-A mRNAP00001606T
P11137296A1216 |80 91|PFK-C genes1T0000 Phar
P11137296A1216 |48 55|tissuesases an
P11137296A1216 |70 75|PFK-Be P00
P11137367A0297 |102 109|circuitspects 
P11137367A0297 |12 31|Toshiba IIDR system76 Comparison with 
P11137367A0297 |57 72|X-ray TV system5-nucleotidase 
P11137367A0297 |87 92|imagePharm
P11137551A0437 |25 29|acid wit
P11137551A0437 |88 93|limitharma
P11137551A0437 |46 52|levelsatases
P11137551A0437 |9 16|sardineT0076 C
P11138009A1032 |84 96|USH1 patient00 Pharmacol
P11138009A1032 |42 53|Delta M1281osphatases 
P11138009A1032 |58 63|IVS51-nucl
P11138009A1032 |31 40|mutationsalkaline 
P11138009A1032 |65 66|Gt
P11138009A1032 |3 11|addition001606T0
P11138231T0000 |0 7|CloseupP000016
P11138231T0000 |11 19|resource076 Comp
P11138231T0000 |24 30|nursesn with
P11138694A0000 |254 261|ganglialaced w
P11138694A0000 |188 194|ligandunctio
P11138694A0000 |82 107|acetylcholine transporter0000 Pharmacologic aspect
P11138694A0000 |267 270|PETmpa
P11138694A0000 |11 33|fluorobenzyltrozamicol076 Comparison with al
P11138694A0000 |139 145|neuron. P000
P11138694A0000 |233 240|densityts are 
P11138694A0000 |203 208|studyPCO2 
P11138694A0000 |1 4|18F000
P11138694A0000 |35 38|FBTlin
P11139148A0421 |153 161|activity72 When 
P11139148A0421 |57 62|SAF-A5-nuc
P11139148A0421 |107 111|MARss of
P11139148A0421 |44 53|homologuephatases 
P11139148A0421 |24 31|proteinn with 
P11139148A0421 |185 194|fractionsa functio
P11139336A0257 |37 52|INCENP behaviorne phosphatases
P11139336A0257 |60 67|mitosisucleoti
P11139336A0257 |14 26|associations Comparison 
P11139469A0402 |119 146|protein kinase C inhibitorsl hyperbilirubinemia. P0000
P11139469A0402 |29 52|Ang2 mRNA accumulationsh alkaline phosphatases
P11139469A0402 |168 170|CaO3
P11139469A0402 |71 75|Ang1 P00
P11139469A0402 |79 94|Tie2 expression71T0000 Pharmac
P11139469A0402 |185 191|agentsa func
P11139469A0402 |0 6|Ang IIP00001
P11139473A0696 |0 17|Promoter analysisP00001606T0076 Co
P11139473A0696 |62 71|consensusleotidase
P11139473A0696 |125 139|SMemb promoterrbilirubinemia
P11139473A0696 |40 48|sequencephosphat
P11139473A0696 |88 95|elementharmaco
P11139473A0696 |97 100|CREgic
P11139473A0696 |157 175|Hex responsivenesshen CSF [HCO3-] is
P11139567A1440 |0 25|LH/CG receptor activationP00001606T0076 Comparison
P11139567A1440 |53 63|activationand 5-nucl
P11139567A1440 |67 96|phosphatidylinositol 3-kinasedase P00008171T0000 Pharmacol
P11139567A1440 |29 33|ARNOh al
P11139567A1440 |98 109|PI 3-kinaseic aspects 
P11139567A1440 |117 146|G protein beta gamma subunitstal hyperbilirubinemia. P0000
P11139605A0811 |0 17|Deletion analysisP00001606T0076 Co
P11139605A0811 |214 217|Sp1ta 
P11139605A0811 |226 232|regioneted r
P11139605A0811 |151 172|mobility shift assays0472 When CSF [HCO3-]
P11139605A0811 |188 199|interactionunction of 
P11139605A0811 |93 110|promoter activitycologic aspects o
P11139605A0811 |43 51|sequencesphatase
P11139605A0811 |203 209|C/EBPsPCO2 t
P11139605A0811 |115 130|auto-activationnatal hyperbili
P11139974A0762 |0 11|TerminationP00001606T0
P11139974A0762 |107 108|%s
P11139974A0762 |82 83|%0
P11139974A0762 |67 76|BV pacingdase P000
P11139974A0762 |92 101|RV pacingacologic 
P11139974A0762 |23 25|VTon
P11139974A0762 |39 46|attempt phosph
P11140472A0497 |205 210|noiseO2 th
P11140472A0497 |106 115|algorithmts of neo
P11140472A0497 |31 40|algorithmalkaline 
P11140472A0497 |120 131|monochannel hyperbilir
P11140472A0497 |15 22|resultsCompari
P11140472A0497 |169 178|algorithm3-] is sh
P11140472A0497 |82 92|algorithms0000 Pharm
P11140472A0497 |147 152|noise997A0
P11140472A0497 |237 254|cases improvementre no longer disp
P11140472A0497 |50 57|resultses and 
P11141003T0000 |0 7|ChangesP000016
P11141003T0000 |54 62|cochlearnd 5-nuc
P11141003T0000 |43 50|nucleussphatas
P11141003T0000 |11 29|stimulation levels076 Comparison wit
P11141003T0000 |71 76|users P000
P11141003T0000 |35 39|timeline
P11142380A0389 |0 8|NucleaseP0000160
P11142380A0389 |40 51|mutagenesisphosphatase
P11142380A0389 |142 149|helices0000899
P11142380A0389 |179 186|regionswn as a
P11142380A0389 |77 79|TE81
P11142380A0389 |81 86|TE105T0000
P11142380A0389 |116 125|structureatal hype
P11143384A0267 |0 9|Tele-TalkP00001606
P11143384A0267 |24 34|capabilityn with alk
P11143384A0267 |56 77|conference situations 5-nucleotidase P0000
P11143384A0267 |38 47|operatinge phospha
P11143384A0267 |84 100|microphone input00 Pharmacologic
P11145562A0000 |175 180|state show
P11145562A0000 |9 17|decreaseT0076 Co
P11145562A0000 |75 81|IGF-IR008171
P11145562A0000 |60 63|IGFucl
P11145562A0000 |45 58|growth factorhatases and 5
P11145562A0000 |93 101|prostatecologic 
P11145562A0000 |25 29|type wit
P11145562A0000 |126 140|transformationbilirubinemia.
P11145562A0000 |113 118|cellseonat
P11145562A0000 |65 73|receptortidase P
P11145562A0468 |86 91|cells Phar
P11145562A0468 |113 122|T antigeneonatal h
P11145562A0468 |66 74|prostateidase P0
P11145562A0468 |4 17|P69 cell line01606T0076 Co
P11145562A0468 |33 48|immortalizationkaline phosphat
P11145563A0202 |32 45|StAR promoterlkaline phosp
P11145563A0202 |107 113|SREBPss of n
P11145563A0202 |63 69|steroleotida
P11145563A0202 |97 105|proteinsgic aspe
P11145563A0303 |34 56|StAR promoter activityaline phosphatases and
P11145563A0303 |97 119|granulosa-lutein cellsgic aspects of neonata
P11145563A0303 |14 22|SREBP-1a Compari
P11145563A0303 |75 86|COS-1 cells008171T0000
P11145563A0303 |64 71|contextotidase
P11145563A0303 |0 10|ExpressionP00001606T
P11145566A0000 |185 201|HDL-R regulationa function of CS
P11145566A0000 |47 52|HDL-Rtases
P11145566A0000 |74 97|cholesterol homeostasis0008171T0000 Pharmacolo
P11145566A0000 |25 45|lipoprotein receptor with alkaline phosp
P11145566A0000 |126 132|targetbiliru
P11145566A0000 |63 70|elementeotidas
P11145566A0000 |158 163|drugsen CS
P11145566A0000 |168 181|understandingO3-] is shown
P11145571A0788 |85 101|response element0 Pharmacologic 
P11145571A0788 |15 28|gene factor-3Comparison wi
P11145571A0788 |33 49|STAT1 homodimerskaline phosphata
P11145571A0788 |144 151|element008997A
P11145571A0788 |129 137|sequenceirubinem
P11145571A0788 |139 142|GAS. P
P11145571A0788 |103 107|ISREpect
P11145590A0217 |138 158|TGF-beta1 regulationa. P00008997A0472 Wh
P11145590A0217 |89 91|TGar
P11145590A0217 |74 87|thyroglobulin0008171T0000 
P11145590A0217 |179 200|transcription factorswn as a function of C
P11145590A0217 |125 134|attentionrbilirubi
P11145590A0217 |40 50|mechanismsphosphatas
P11145590A0217 |93 108|gene expressioncologic aspects
P11145590A0217 |54 70|TGF-beta1 actionnd 5-nucleotidas
P11145717A0936 |117 121|K713tal 
P11145717A0936 |89 99|sequencingarmacologi
P11145717A0936 |30 31|K 
P11145717A0936 |56 68|TPO fragment 5-nucleotid
P11145717A0936 |22 28|lysineson wi
P11145743A0170 |118 123|TTF-1al hy
P11145743A0170 |199 207|activityCSF PCO2
P11145743A0170 |57 70|thyroid cells5-nucleotidas
P11145743A0170 |215 235|deiodinase promotersa of K-depleted rats
P11145743A0170 |28 38|regulationth alkalin
P11145743A0170 |48 53|genesases 
P11145743A0170 |158 165|proteinen CSF 
P11145743A0170 |76 82|effect08171T
P11145743A0170 |86 114|thyroid transcription factor Pharmacologic aspects of ne
P11145743A0170 |169 174|Pax-83-] i
P11145813A0668 |0 19|Regional blood blowP00001606T0076 Comp
P11145813A0668 |45 57|microsphereshatases and 
P11145813A0668 |36 41|meansine p
P11145813A0668 |72 79|regionsP000081
P11145813A0668 |91 94|T11mac
P11145813A0668 |87 89|C6Ph
P11145813A0668 |100 112|L6 vertebrae aspects of 
P11145887A1393 |0 10|ActivationP00001606T
P11145887A1393 |97 102|c-Jungic a
P11145887A1393 |40 49|AP-1 sitephosphata
P11145887A1393 |193 196|Taxon 
P11145887A1393 |104 108|JunBects
P11145887A1393 |14 27|transcription Comparison w
P11145887A1393 |157 162|levelhen C
P11145887A1393 |114 130|c-Fos activationonatal hyperbili
P11145887A1393 |53 65|Jurkat cellsand 5-nucleo
P11145887A1393 |81 86|Fra-2T0000
P11145887A1393 |69 73|JunDse P
P11145955A0189 |34 57|estrogen receptor alphaaline phosphatases and 
P11145955A0189 |59 66|ERalphanucleot
P11145955A0189 |92 107|gene expressionacologic aspect
P11145955A0189 |179 187|analysiswn as a 
P11145955A0189 |209 223|protein kinasehe data of K-d
P11145955A0189 |120 123|SRE hy
P11145955A0189 |225 229|MAPKlete
P11145955A0189 |153 161|analysis72 When 
P11145955A0189 |253 255|E2pl
P11145955A0189 |320 327|controlater sl
P11145955A0189 |295 304|TGF-alpha have a s
P11145955A0189 |4 13|mechanism01606T007
P11145955A0189 |231 249|pathway activationrats are no longer
P11145955A0189 |78 88|activation171T0000 P
P11145955A0189 |169 177|promoter3-] is s
P11145955A0189 |274 293|growth factor alphato controls but sti
P11146961T0000 |0 19|Perfusion techniqueP00001606T0076 Comp
P11146961T0000 |74 80|PADCAB000817
P11146961T0000 |59 72|artery bypassnucleotidase 
P11148042A1258 |113 134|peptide immiscibilityeonatal hyperbilirubi
P11148042A1258 |146 164|gel state bilayers8997A0472 When CSF
P11148042A1258 |46 55|chain PEsatases an
P11148042A1258 |90 100|variationsrmacologic
P11148042A1258 |9 17|mixturesT0076 Co
P11148042A1258 |22 24|LAso
P11148589A1124 |0 11|CONCLUSIONSP00001606T0
P11148589A1124 |27 49|immunization practicesith alkaline phosphata
P11148589A1124 |198 204|future CSF P
P11148589A1124 |141 160|United States todayP00008997A0472 When
P11148589A1124 |55 62|authorsd 5-nuc
P11148589A1124 |233 255|liver carcinoma deathsts are no longer displ
P11148589A1124 |101 126|Pacific Islander childrenaspects of neonatal hyper
P11148589A1124 |187 190|HBVfun
P11149472A1257 |50 61|osteoblastses and 5-nu
P11149472A1257 |67 79|chondrocytesdase P000081
P11149472A1257 |12 34|NP/NMP4/CIZ expression76 Comparison with alk
P11149472A1257 |83 91|rat bone000 Phar
P11149472A1257 |38 48|osteocytese phosphat
P11150114T0000 |0 9|ChlamydiaP00001606
P11150114T0000 |23 29|canceron wit
P11150114T0000 |38 49|associatione phosphata
P11150315A0226 |187 210|DNA recognition libraryfunction of CSF PCO2 th
P11150315A0226 |133 142|signalinginemia. P
P11150315A0226 |47 78|transcription factor activitiestases and 5-nucleotidase P00008
P11150315A0226 |231 251|DNA binding proteinsrats are no longer d
P11150315A0226 |8 16|approach6T0076 C
P11150315A0226 |270 278|extractsred to c
P11150315A0226 |157 179|oligonucleotide cloneshen CSF [HCO3-] is sho
P11150315A0226 |257 261|PC12ed w
P11150315A0844 |0 3|NGFP00
P11150315A0844 |41 60|ERK phosphorylationhosphatases and 5-n
P11150315A0844 |66 69|EGFida
P11150315A0844 |96 103|reportsogic as
P11150315A1126 |0 3|NGFP00
P11150315A1126 |13 16|EGF6 C
P11150315A1126 |76 81|Fra-208171
P11150315A1126 |37 42|bandsne ph
P11150439A0701 |0 18|Energy expenditureP00001606T0076 Com
P11150439A0701 |127 158|isotope ratio mass spectroscopyilirubinemia. P00008997A0472 Wh
P11150439A0701 |93 95|COco
P11150439A0701 |74 76|CO00
P11150439A0701 |194 213|regression equationn of CSF PCO2 the d
P11150439A0701 |99 123|enrichment determinationc aspects of neonatal hy
P11150439A0701 |82 88|breath0000 P
P11150439A0701 |67 70|NaHdas
P11150439A0701 |55 63|infusiond 5-nucl
P11150439A0701 |168 179|applicationO3-] is sho
P11151826T0000 |0 8|WorkloadP0000160
P11151826T0000 |10 14|UAPs0076
P11152070A0573 |49 55|genomeses an
P11152070A0573 |37 41|copyne p
P11152070A0573 |59 73|A. chrysogenumnucleotidase P
P11152070A0573 |122 141|cefEF cephalosporinyperbilirubinemia. 
P11152070A0573 |180 206|cephalosporin fermentationn as a function of CSF PCO
P11152070A0573 |113 117|pcbCeona
P11152070A0573 |83 99|expression level000 Pharmacologi
P11152070A0573 |232 242|transcriptats are no
P11152070A0573 |4 13|actA gene01606T007
P11152070A0573 |155 160|genes When
P11152081A0413 |38 48|inhibitione phosphat
P11152081A0413 |92 108|sulfur oxidationacologic aspects
P11152081A0413 |10 20|mmol SDS/l0076 Compa
P11152081A0413 |52 65|acidification and 5-nucleo
P11152081A0413 |67 87|metal solubilizationdase P00008171T0000 
P11152283A0223 |51 69|gene transcriptions and 5-nucleotida
P11152283A0223 |73 77|PC120000
P11152283A0223 |98 103|orderic as
P11152283A0223 |82 93|INS-1 cells0000 Pharma
P11152283A0223 |25 29|role wit
P11152283A0223 |141 146|genesP0000
P11152283A0223 |33 36|NGFkal
P11152344A0416 |205 209|cordO2 t
P11152344A0416 |123 132|placementperbiliru
P11152344A0416 |183 190|surfaces a fun
P11152344A0416 |31 38|animalsalkalin
P11152344A0416 |159 165|spongen CSF 
P11152344A0416 |76 90|arachnoid scar08171T0000 Pha
P11152344A0416 |94 99|C1-C2ologi
P11152344A0416 |5 12|animals1606T00
P11152344A0416 |51 58|animalss and 5
P11152451A0529 |35 42|SmSmad2line ph
P11152451A0529 |130 140|antibodiesrubinemia.
P11152451A0529 |79 102|Sj26-GST fusion protein71T0000 Pharmacologic a
P11152451A0529 |65 73|bacteriatidase P
P11152451A0529 |4 33|Schistosoma mansoni homologue01606T0076 Comparison with al
P11152451A1580 |254 269|TGF-beta effectlaced when comp
P11152451A1580 |73 84|interaction00008171T00
P11152451A1580 |90 100|receptor Irmacologic
P11152451A1580 |162 169|nucleusSF [HCO
P11152451A1580 |193 218|target gene transcriptionon of CSF PCO2 the data o
P11152451A1580 |29 36|SmSmad2h alkal
P11152451A1580 |6 10|data606T
P11152451A1580 |53 69|TGF-beta signalsand 5-nucleotida
P11152521A0181 |19 35|protein productsarison with alka
P11152521A0181 |76 94|expression vectors08171T0000 Pharmac
P11152521A0181 |109 128|ORF40/41 transcriptof neonatal hyperbi
P11152521A0181 |202 208|intron PCO2 
P11152521A0181 |157 166|componenthen CSF [
P11152963A0000 |34 37|SH3ali
P11152963A0000 |144 151|culture008997A
P11152963A0000 |92 96|geneacol
P11152963A0000 |176 181|brainshown
P11152963A0000 |74 84|astrocytes0008171T00
P11152963A0000 |86 90|SETA Pha
P11152963A0000 |18 30|src homologyparison with
P11152963A0000 |156 162|tumorsWhen C
P11152963A0000 |116 140|astrocyte transformationatal hyperbilirubinemia.
P11152963A0000 |0 10|ExpressionP00001606T
P11153302A0000 |0 24|Naltrexone hydrochlorideP00001606T0076 Compariso
P11153302A0000 |40 66|opioid receptor antagonistphosphatases and 5-nucleot
P11153302A0000 |116 130|detoxificationatal hyperbili
P11153302A0000 |84 91|efforts00 Phar
P11154491A0322 |186 193|needles functi
P11154491A0322 |93 99|massescologi
P11154491A0322 |42 50|patientsosphatas
P11154491A0322 |57 60|age5-n
P11154491A0322 |113 115|CTeo
P11154491A0322 |159 172|echoendoscopen CSF [HCO3-]
P11154491A0322 |127 134|EUS-FNAilirubi
P11154491A0322 |64 69|yearsotida
P11154491A0322 |0 7|METHODSP000016
P11155096A0222 |0 7|METHODSP000016
P11155096A0222 |211 215|mU/l dat
P11155096A0222 |241 243|T4o 
P11155096A0222 |218 239|serum thyroxin levelsf K-depleted rats are
P11155096A0222 |82 98|serum antibodies0000 Pharmacolog
P11155096A0222 |145 150|IU/ml08997
P11155096A0222 |122 129|TPO-Absyperbil
P11155096A0222 |180 183|TSHn a
P11155096A0222 |9 23|Thyroid statusT0076 Comparis
P11155096A0222 |40 48|baselinephosphat
P11155096A0222 |153 169|serum TSH levels72 When CSF [HCO
P11155096A0222 |102 120|thyroid peroxidasespects of neonatal
P11155096A0222 |68 78|assessmentase P00008
P11156303A1098 |119 127|childrenl hyperb
P11156303A1098 |107 115|drainages of neo
P11156303A1098 |81 92|alternativeT0000 Pharm
P11156303A1098 |198 207|infection CSF PCO2
P11156303A1098 |149 158|adhesions7A0472 Wh
P11156303A1098 |169 176|history3-] is 
P11156303A1098 |34 42|shuntingaline ph
P11156413T0000 |119 126|utilityl hyper
P11156413T0000 |88 100|polyomavirusharmacologic
P11156413T0000 |134 145|developmentnemia. P000
P11156413T0000 |45 50|mousehatas
P11156413T0000 |23 39|characterizationon with alkaline
P11156413T0000 |59 74|tumor cell linenucleotidase P0
P11156413T0000 |108 117|T antigen of neona
P11156413T0000 |155 174|cancer therapeutics When CSF [HCO3-] i
P11156413T0000 |0 10|DerivationP00001606T
P11156484A0223 |0 12|TBARS levelsP00001606T00
P11156484A0223 |145 154|existence08997A047
P11156484A0223 |58 69|AFR release-nucleotida
P11156484A0223 |104 113|resonanceects of n
P11156484A0223 |39 53|capacity assay phosphatases 
P11156484A0223 |82 90|electron0000 Pha
P11156484A0223 |178 186|diabetesown as a
P11156484A0223 |115 118|EPRnat
P11156484A0223 |168 174|stressO3-] i
P11156618T0000 |35 49|mouse SCL lociline phosphata
P11156618T0000 |61 68|regionscleotid
P11156618T0000 |168 177|sequencesO3-] is s
P11156618T0000 |11 21|comparison076 Compar
P11156618T0000 |72 83|sensitivityP00008171T0
P11156618T0000 |87 112|restriction endonucleasesPharmacologic aspects of 
P11156618T0000 |139 144|peaks. P00
P11156789A1669 |338 341|CSF/- 
P11156789A1669 |145 165|oxygen concentration08997A0472 When CSF 
P11156789A1669 |179 187|propofolwn as a 
P11156789A1669 |125 132|changesrbiliru
P11156789A1669 |90 98|childrenrmacolog
P11156789A1669 |48 54|causesases a
P11156789A1669 |20 31|observationrison with 
P11156789A1669 |263 281|CSF protein levelsn compared to cont
P11156789A1669 |293 309|propofol bindingll have a signif
P11156789A1669 |219 225|oxygen K-dep
P11156789A1669 |73 86|CSF pulsation00008171T0000
P11156789A1669 |326 332|uptakelope (
P11156789A1669 |252 259|changessplaced
P11156789A1669 |108 123|motion artifact of neonatal hy
P11156789A1669 |313 321|proteinstly grea
P11157035A1405 |168 175|therapyO3-] is
P11157035A1405 |30 35|study alka
P11157035A1405 |125 137|IFN alpha-2brbilirubinem
P11157035A1405 |79 93|determinations71T0000 Pharma
P11157035A1405 |106 112|trialsts of 
P11157035A1405 |157 164|benefithen CSF
P11157035A1405 |4 13|utilities01606T007
P11157334A1107 |0 9|Serum PTHP00001606
P11157334A1107 |60 68|WM groupucleotid
P11157334A1107 |36 44|WL groupine phos
P11157334A1107 |70 71|Pe
P11157763T0000 |17 30|EMAPII domainmparison with
P11157763T0000 |40 73|aminoacyl-tRNA synthetase complexphosphatases and 5-nucleotidase P
P11157763T0000 |95 108|dimer mimicrylogic aspects
P11157763T0000 |0 9|StructureP00001606
P11157774A0789 |71 80|sterility P0000817
P11157774A0789 |12 25|dSLBP alleles76 Comparison
P11157774A0789 |42 53|developmentosphatases 
P11157784A0141 |158 163|locusen CS
P11157784A0141 |78 82|sc11171T
P11157784A0141 |123 127|geneperb
P11157784A0141 |28 44|chromosome 22q11th alkaline phos
P11157784A0141 |14 24|DGCR6 gene Compariso
P11157784A0141 |129 135|DGCR6Lirubin
P11157784A0141 |111 115|copy neo
P11157784A0141 |58 69|copy repeat-nucleotida
P11157784A0141 |178 180|b.ow
P11157784A0141 |172 176|sc11 is 
P11157879A0192 |0 7|METHODSP000016
P11157879A0192 |101 112|fluorometryaspects of 
P11157879A0192 |13 20|passive6 Compa
P11157879A0192 |45 56|fluoresceinhatases and
P11157879A0192 |32 41|transportlkaline p
P11157879A0192 |69 72|BRBse 
P11158236A0000 |0 19|Nerve growth factorP00001606T0076 Comp
P11158236A0000 |39 43|acid pho
P11158236A0000 |76 86|PC12 cells08171T0000
P11158236A0000 |45 47|RAha
P11158236A0000 |65 72|actionstidase 
P11158236A0000 |21 24|NGFiso
P11158288T0000 |0 11|RecruitmentP00001606T0
P11158288T0000 |97 101|CREBgic 
P11158288T0000 |76 93|activation domain08171T0000 Pharma
P11158288T0000 |120 140|CREB phosphorylation hyperbilirubinemia.
P11158288T0000 |36 43|complexine pho
P11158288T0000 |18 32|RNA polymeraseparison with a
P11158290A0728 |101 105|betaaspe
P11158290A0728 |112 119|epsilonneonata
P11158290A0728 |67 82|destruction boxdase P00008171T
P11158290A0728 |27 34|serinesith alk
P11158290A0728 |4 10|region01606T
P11158290A0728 |86 98|IkappaBalpha Pharmacolog
P11158295A0158 |87 90|SH3Pha
P11158295A0158 |96 107|SH2 regionsogic aspect
P11158295A0158 |53 56|Cskand
P11158295A0158 |36 49|kinase domainine phosphata
P11158295A0158 |5 13|function1606T007
P11158295A0158 |71 83|Src homology P00008171T0
P11158310A0993 |69 73|betase P
P11158310A0993 |52 61|ATF6alpha and 5-nu
P11158310A0993 |43 47|NF-Yspha
P11158310A0993 |28 32|ERSFth a
P11158310A0993 |140 143|UPR P0
P11158310A0993 |100 104|ERSE asp
P11158324A1073 |547 572|anion transporter proteinhen extracorporeal CO2 re
P11158324A1073 |191 220|triglyceride transfer proteintion of CSF PCO2 the data of 
P11158324A1073 |323 343|lipoprotein receptorr slope (1.21 +/- 0.
P11158324A1073 |159 175|apolipoprotein Bn CSF [HCO3-] is
P11158324A1073 |144 149|genes00899
P11158324A1073 |416 421|liver drug
P11158324A1073 |91 112|lipoprotein secretionmacologic aspects of 
P11158324A1073 |60 70|disruptionucleotidas
P11158324A1073 |286 296|expressionbut still 
P11158324A1073 |345 366|scavenger receptor BI vs. P00010943A0733 F
P11158324A1073 |392 408|bile acid uptakebe an effective 
P11158324A1073 |429 444|down-regulatione optimum dose 
P11158324A1073 |250 268|cholesterol uptakedisplaced when com
P11158324A1073 |380 388|decrease appears
P11158324A1073 |130 140|expressionrubinemia.
P11158324A1073 |13 23|phenotypes6 Comparis
P11158324A1073 |230 238|increase rats ar
P11158324A1073 |470 534|bile acid transporters sodium taurocholate cotransporter proteine being 15 mg at night. P00012653T0045 Beta blocking agents. P00
P11158326A1032 |68 78|SH2 domainase P00008
P11158326A1032 |6 13|effects606T007
P11158326A1032 |52 60|mutation and 5-n
P11158326A1032 |80 84|R47G1T00
P11158326A1032 |33 38|SHIP2kalin
P11158337A0000 |275 279|SF-1o co
P11158337A0000 |80 84|gene1T00
P11158337A0000 |57 70|GnRH receptor5-nucleotidas
P11158337A0000 |265 273|factor-1compared
P11158337A0000 |196 200|GRASof C
P11158337A0000 |281 293|binding siterols but sti
P11158337A0000 |228 232|AP-1ed r
P11158337A0000 |72 78|GnRH-RP00008
P11158337A0000 |186 194|sequence functio
P11158337A0000 |39 49|expression phosphata
P11158337A0000 |234 241|elements are n
P11158337A0000 |110 131|transcription factorsf neonatal hyperbilir
P11158337A0000 |168 174|GnRH-RO3-] i
P11158337A0000 |207 226|activator protein-1 the data of K-depl
P11158456A0223 |0 7|METHODSP000016
P11158456A0223 |185 193|sequelaea functi
P11158456A0223 |54 58|timend 5
P11158456A0223 |22 31|interviewson with 
P11158456A0223 |215 218|agea o
P11158456A0223 |128 132|typeliru
P11158456A0223 |108 117|intervals of neona
P11158456A0223 |195 209|family history of CSF PCO2 t
P11158456A0223 |222 233|terminationdepleted ra
P11158456A0223 |154 160|spells2 When
P11158456A0223 |70 82|consultatione P00008171T
P11158456A0223 |141 150|frequencyP00008997
P11158456A0223 |173 183|phenomenonis shown a
P11158456A0223 |237 243|spellsre no 
P11158456A0223 |136 139|BHSmia
P11159081A1155 |84 89|tumor00 Ph
P11159081A1155 |9 14|casesT0076
P11159081A1155 |107 113|seromas of n
P11159081A1155 |28 38|MR imagingth alkalin
P11159081A1155 |20 21|%r
P11159081A1155 |117 127|reexcisiontal hyperb
P11159363A1251 |0 11|MethylationP00001606T0
P11159363A1251 |61 63|CGcl
P11159363A1251 |45 56|E2F elementhatases and
P11159363A1251 |66 68|CGid
P11159363A1251 |59 60|mn
P11159363A1251 |122 129|complexyperbil
P11159363A1251 |20 37|cytosine residuesrison with alkali
P11159363A1251 |64 65|mo
P11160096A1067 |6 15|mutations606T0076 
P11160096A1067 |75 84|phenotype008171T00
P11160096A1067 |44 59|fliF backgroundphatases and 5-
P11160280A1275 |70 81|IRF elemente P00008171
P11160280A1275 |41 46|IRF-1hosph
P11160280A1275 |27 37|expressionith alkali
P11160280A1275 |55 62|bindingd 5-nuc
P11160307A0394 |254 260|regionlaced 
P11160307A0394 |15 24|wH22xeGFPCompariso
P11160307A0394 |300 309|FcgammaRI a signif
P11160307A0394 |208 214|Fc endthe da
P11160307A0394 |268 271|Fabpar
P11160307A0394 |74 81|mAb H220008171
P11160307A0394 |194 200|regionn of C
P11160307A0394 |140 150|CH3 domain P00008997
P11160307A0394 |5 13|molecule1606T007
P11160307A0394 |128 131|endlir
P11160307A0394 |87 91|eGFPPhar
P11160307A0394 |152 161|wH22xeGFP472 When 
P11160656A0000 |0 10|InactivityP00001606T
P11160656A0000 |144 150|region008997
P11160656A0000 |297 313|NTera2 carcinomaave a significan
P11160656A0000 |24 39|cytomegalovirusn with alkaline
P11160656A0000 |88 93|MIERRharma
P11160656A0000 |180 184|lackn as
P11160656A0000 |156 165|modulatorWhen CSF 
P11160656A0000 |80 86|region1T0000
P11160656A0000 |320 325|cellsater 
P11160656A0000 |188 204|HCMV replicationunction of CSF P
P11160656A0000 |127 135|enhancerilirubin
P11160656A0000 |226 231|cellseted 
P11160656A0000 |259 269|cell types when comp
P11160656A0000 |117 125|promotertal hype
P11160656A0000 |41 45|HCMVhosp
P11160656A0000 |315 318|NT2y g
P11160683A1220 |70 80|C/EBP sitee P0000817
P11160683A1220 |5 16|interaction1606T0076 C
P11160683A1220 |161 165|CREBCSF 
P11160683A1220 |121 135|ATF/CREB siteshyperbilirubin
P11160683A1220 |99 117|CREB-1 recruitmentc aspects of neona
P11160683A1220 |38 57|C/EBP dimer bindinge phosphatases and 
P11160688A1726 |71 80|cyclin D3 P0000817
P11160688A1726 |91 104|translocationmacologic asp
P11160688A1726 |14 20|events Compa
P11160688A1726 |120 129|cytoplasm hyperbil
P11160688A1726 |47 56|structuretases and
P11160688A1726 |108 112|ICP0 of 
P11160721A0932 |71 93|TBLV enhancer activity P00008171T0000 Pharma
P11160721A0932 |10 23|transfections0076 Comparis
P11160721A0932 |45 53|mutationhatases 
P11160721A0932 |128 140|T-cell lineslirubinemia.
P11160721A0932 |55 59|556Md 5-
P11160732A0464 |0 13|Vector stocksP00001606T007
P11160732A0464 |131 140|SIVmac316ubinemia.
P11160732A0464 |177 187|SIVmac1A11hown as a 
P11160732A0464 |64 77|SIVmac clonesotidase P0000
P11160732A0464 |142 159|macrophage tropic00008997A0472 Whe
P11160732A0464 |25 42|envelope proteins with alkaline ph
P11160732A0464 |98 117|T-lymphocyte tropicic aspects of neona
P11160732A0464 |87 96|SIVmac239Pharmacol
P11160732A1199 |272 278|importd to c
P11160732A1199 |246 259|transcriptionger displaced
P11160732A1199 |209 228|SIVmac239 infectionhe data of K-deplet
P11160732A1199 |13 24|PCR studies6 Compariso
P11160732A1199 |288 291|DNAt s
P11160732A1199 |87 94|nucleusPharmac
P11160732A1199 |54 63|transportnd 5-nucl
P11160732A1199 |112 123|macrophagesneonatal hy
P11160732A1199 |40 49|synthesisphosphata
P11160732A1199 |160 171|pseudotypes CSF [HCO3-
P11160732A1199 |193 204|restrictionon of CSF P
P11160732A1199 |142 147|clone00008
P11160732A1199 |67 77|vector DNAdase P0000
P11160738A1414 |68 81|establishmentase P00008171
P11160738A1414 |105 114|infectioncts of ne
P11160738A1414 |26 35|functionswith alka
P11160738A1414 |39 45|vIRF-2 phosp
P11160742A0696 |5 6|Z1
P11160742A0696 |11 23|R expression076 Comparis
P11160742A0696 |67 72|cellsdase 
P11160742A0696 |36 50|PML dispersionine phosphatas
P11160860A0662 |207 235|IkappaBalpha phosphorylation the data of K-depleted rats
P11160860A0662 |31 45|IkappaB kinasealkaline phosp
P11160860A0662 |120 143|IkappaB phosphorylation hyperbilirubinemia. P0
P11160860A0662 |83 87|role000 
P11160860A0662 |47 55|IKK-betatases an
P11160860A0662 |91 111|NF-kappaB activationmacologic aspects of
P11160860A0662 |188 193|cellsuncti
P11160860A0662 |19 27|activityarison w
P11160896A0713 |0 26|Immunofluorescence studiesP00001606T0076 Comparison 
P11160896A0713 |30 44|C2C12 myotubes alkaline phos
P11160896A0713 |65 82|MEF2A co-localisetidase P00008171T
P11160896A0713 |130 145|differentiationrubinemia. P000
P11160896A0713 |90 97|nucleusrmacolo
P11160896A0713 |114 122|myotubesonatal h
P11160896A0713 |55 60|Smad2d 5-n
P11160902A0962 |84 94|expression00 Pharmac
P11160902A0962 |45 54|potentialhatases a
P11160902A0962 |176 186|expressionshown as a
P11160902A0962 |148 156|settings97A0472 
P11160902A0962 |195 199|gene of 
P11160902A0962 |98 125|c-sis/PDGF-B proto-oncogeneic aspects of neonatal hype
P11160902A0962 |16 20|TFOsompa
P11160929T0000 |35 39|siteline
P11160929T0000 |60 73|endonucleasesucleotidase P
P11160929T0000 |43 52|LAGLIDADGsphatases
P11160929T0000 |6 15|evolution606T0076 
P11161455A1286 |51 63|cell hybridss and 5-nucl
P11161455A1286 |101 110|cDNA mapsaspects o
P11161455A1286 |114 124|chromosomeonatal hyp
P11161455A1286 |0 22|Southern blot analysisP00001606T0076 Compari
P11161455A1286 |34 37|DNAali
P11161720X1294 |0 9|CopyrightP00001606
P11161720X1294 |15 29|Academic PressComparison wit
P11161793A1033 |55 62|speciesd 5-nuc
P11161793A1033 |142 155|EGFR activity00008997A0472
P11161793A1033 |26 43|receptor isoformswith alkaline pho
P11161793A1033 |122 127|rolesyperb
P11161793A1033 |83 91|proteins000 Phar
P11161793A1033 |4 12|presence01606T00
P11161816A0851 |19 31|similaritiesarison with 
P11161816A0851 |166 172|actionHCO3-]
P11161816A0851 |78 86|sequence171T0000
P11161816A0851 |94 107|SH3GLB familyologic aspect
P11161816A0851 |41 60|endophilin proteinshosphatases and 5-n
P11161816A0851 |129 133|foldirub
P11161816A0851 |158 162|modeen C
P11162278A0629 |86 92|lobule Pharm
P11162278A0629 |122 127|gyrusyperb
P11162278A0629 |45 55|activationhatases an
P11162278A0629 |26 33|figureswith al
P11162278A0629 |7 15|rotation06T0076 
P11162576A0213 |21 35|identificationison with alka
P11162576A0213 |77 82|exons8171T
P11162576A0213 |121 131|PDE5A genehyperbilir
P11162576A0213 |59 70|alternativenucleotidas
P11162576A0213 |99 107|promoterc aspect
P11162666A0442 |87 92|acidsPharm
P11162666A0442 |53 61|additionand 5-nu
P11162666A0442 |4 31|glucose/insulin stimulation01606T0076 Comparison with 
P11162936A2727 |137 155|tissue selectivityia. P00008997A0472
P11162936A2727 |15 26|developmentComparison 
P11162936A2727 |96 103|ERalphaogic as
P11162936A2727 |78 91|antiestrogens171T0000 Phar
P11162936A2727 |107 113|ERbetas of n
P11162936A2727 |165 171|agents[HCO3-
P11162936A2727 |30 37|ligands alkali
P11162936A2727 |223 232|treatmentepleted r
P11162936A2727 |251 264|breast cancerisplaced when
P11162936A2727 |65 74|estrogenstidase P0
P11162936A2727 |237 247|preventionre no long
P11162936A2727 |187 214|hormone replacement therapyfunction of CSF PCO2 the da
P11163932A0000 |152 161|pulmonate472 When 
P11163932A0000 |12 17|tests76 Co
P11163932A0000 |192 203|temperatureion of CSF 
P11163932A0000 |211 221|substratum data of K
P11163932A0000 |126 143|thermopreferendumbilirubinemia. P0
P11163932A0000 |43 78|roman garden snail Helix pomatia L.sphatases and 5-nucleotidase P00008
P11163932A0000 |27 35|specimenith alka
P11163932A0000 |97 102|ordergic a
P11163932A0000 |234 249|air temperatures are no longer
P11163968A0152 |34 50|genome sequencesaline phosphatas
P11163968A0152 |80 97|Pyrococcus abyssi1T0000 Pharmacolo
P11163968A0152 |54 75|Pyrococcus horikoshiind 5-nucleotidase P00
P11163968A0152 |143 151|archaeon0008997A
P11163968A0152 |15 19|workComp
P11163968A0152 |116 121|genusatal 
P11163968A0152 |201 221|genome polymorphismsF PCO2 the data of K
P11163968A0152 |234 272|restriction-modification gene homologss are no longer displaced when compare
P11163968A0152 |103 110|speciespects o
P11163968A0152 |153 168|archaebacterium72 When CSF [HC
P11164078A0833 |55 58|NADd 5
P11164078A0833 |75 84|viewpoint008171T00
P11164078A0833 |46 51|modelatase
P11164078A0833 |88 106|treatment-responseharmacologic aspec
P11164078A0833 |62 65|manleo
P11164078A0833 |5 17|animal model1606T0076 Co
P11164078A0833 |21 29|dystoniaison wit
P11166478T0000 |69 79|pain modelse P000081
P11166478T0000 |54 59|mousend 5-
P11166478T0000 |33 48|antinociceptionkaline phosphat
P11166863A0167 |85 89|RTOG0 Ph
P11166863A0167 |75 83|toxicity008171T0
P11166863A0167 |61 66|gradecleot
P11166863A0167 |31 32|%a
P11166863A0167 |14 15|% 
P11166863A0167 |20 24|% CIriso
P11166863A0167 |34 42|patientsaline ph
P11167019A1249 |4 8|TATA0160
P11167019A1249 |60 95|ATPsynCF6 transcription start sitesucleotidase P00008171T0000 Pharmaco
P11167019A1249 |47 56|GABPalphatases and
P11167019A1249 |10 15|motif0076 
P11167111A0957 |87 90|LPDPha
P11167111A0957 |110 115|weeksf neo
P11167111A0957 |122 124|TXyp
P11167111A0957 |73 83|recipients00008171T0
P11167111A0957 |21 45|lung function parametersison with alkaline phosp
P11167111A0957 |101 107|graftsaspect
P11167778T0000 |36 42|sepsisine ph
P11167778T0000 |9 32|antithrombin deficiencyT0076 Comparison with a
P11168366A0569 |102 110|GGT mRNAspects o
P11168366A0569 |40 48|fragmentphosphat
P11168366A0569 |79 88|sequences71T0000 P
P11168366A0569 |114 125|HepG2 cellsonatal hype
P11168366A0569 |3 11|addition001606T0
P11168422A0248 |50 69|metal fluoride ionses and 5-nucleotida
P11168422A0248 |7 13|Nature06T007
P11168422A0248 |125 137|iron proteinrbilirubinem
P11168422A0248 |79 88|phosphate71T0000 P
P11168422A0248 |112 117|sitesneona
P11168422A0248 |139 142|Kp2. P
P11168446T0000 |38 46|patientse phosph
P11168446T0000 |93 104|alterationscologic asp
P11168446T0000 |10 34|erythropoietin synthesis0076 Comparison with alk
P11168446T0000 |65 78|heart failuretidase P00008
P11168446T0000 |114 127|haemodynamicsonatal hyperb
P11168588T0000 |0 10|ExpressionP00001606T
P11168588T0000 |108 125|kinase activation of neonatal hype
P11168588T0000 |91 96|c-Junmacol
P11168588T0000 |14 39|herpes simplex virus type Comparison with alkaline
P11168588T0000 |58 75|Cdc42/Rac pathway-nucleotidase P00
P11168588T0000 |42 45|US3osp
P11169080T0000 |52 55|Bok an
P11169080T0000 |13 22|education6 Compari
P11169080T0000 |41 50|ignorancehosphatas
P11169080T0000 |58 61|Law-nu
P11169113A0555 |38 50|phi29 mutante phosphatas
P11169113A0555 |89 93|genearma
P11169113A0555 |29 32|p16h a
P11169113A0555 |77 85|mutation8171T000
P11169113A0555 |21 25|roleison
P11169149A0097 |19 28|knowledgearison wi
P11169149A0097 |30 35|SNTCS alka
P11170476A1546 |171 180|molecules] is show
P11170476A1546 |40 54|gp96 complexesphosphatases a
P11170476A1546 |63 73|plasticityeotidase P
P11170476A1546 |195 206|recognition of CSF PCO
P11170476A1546 |31 38|peptidealkalin
P11170476A1546 |142 150|peptides00008997
P11170476A1546 |97 103|pocketgic as
P11170476A1546 |125 130|relayrbili
P11170476A1546 |18 27|stabilityparison w
P11170476A1546 |154 157|MHC2 W
P11171118A0836 |102 114|interactionsspects of ne
P11171118A0836 |14 21|binding Compar
P11171118A0836 |75 86|competition008171T0000
P11171118A0836 |25 29|NF-1 wit
P11171118A0836 |146 156|antibodies8997A0472 
P11171118A0836 |124 141|NF-1 DNA elementserbilirubinemia. 
P11171118A0836 |33 38|PSE-Bkalin
P11171118A0836 |51 56|PSE-As and
P11171320A0894 |0 12|CoexpressionP00001606T00
P11171320A0894 |25 28|ctn wi
P11171320A0894 |57 65|deletion5-nucleo
P11171320A0894 |30 37|protein alkali
P11171320A0894 |160 183|amino acid substitution CSF [HCO3-] is shown a
P11171320A0894 |290 304|EalphaCL cellsstill have a s
P11171320A0894 |185 193|tyrosinea functi
P11171320A0894 |250 261|aggregationdisplaced w
P11171320A0894 |20 24|p120riso
P11171320A0894 |99 129|tyrosine phosphorylation sitesc aspects of neonatal hyperbil
P11171320A0894 |234 242|increases are no
P11171320A0894 |283 285|ELls
P11171320A0894 |138 145|proteina. P000
P11171320A0894 |204 217|phenylalanineCO2 the data 
P11172610A0508 |49 55|numberses an
P11172610A0508 |13 16|p736 C
P11172610A0508 |78 87|promoters171T0000 
P11172944A0548 |0 7|RESULTSP000016
P11172944A0548 |67 72|Gradedase 
P11172944A0548 |43 54|pneumonitissphatases a
P11172944A0548 |75 86|pneumonitis008171T0000
P11172944A0548 |19 27|patientsarison w
P11172944A0548 |35 40|Gradeline 
P11172944A0826 |85 106|radiation pneumonitis0 Pharmacologic aspec
P11172944A0826 |45 56|correlationhatases and
P11172944A0826 |65 80|plasma TNFalphatidase P0000817
P11172944A0826 |3 11|contrast001606T0
P11175333A0336 |21 45|co-precipitation methodsison with alkaline phosp
P11175333A0336 |74 82|proteins0008171T
P11176098A0342 |17 21|pigsmpar
P11176098A0342 |60 72|shock groupsucleotidase 
P11176098A0342 |0 7|METHODSP000016
P11176290T0000 |102 105|MRIspe
P11176290T0000 |83 95|fibrillation000 Pharmaco
P11176290T0000 |28 41|vein stenosisth alkaline p
P11176290T0000 |48 71|radiofrequency ablationases and 5-nucleotidase
P11176290T0000 |0 14|IdentificationP00001606T0076
P11177538A0655 |34 37|MOIali
P11177538A0655 |64 90|% gene transfer efficiencyotidase P00008171T0000 Pha
P11177538A0655 |49 53|daysses 
P11177538A0655 |0 16|Tumor cell linesP00001606T0076 C
P11177686A0243 |0 9|TreatmentP00001606
P11177686A0243 |45 52|optionshatases
P11177686A0243 |130 138|dilationrubinemi
P11177686A0243 |67 74|therapydase P0
P11178248A1042 |119 128|positivesl hyperbi
P11178248A1042 |38 58|screening techniquese phosphatases and 5
P11178248A1042 |99 109|occurrencec aspects 
P11178248A1042 |62 67|termsleoti
P11178248A1042 |71 82|sensitivity P00008171T
P11178248A1042 |84 94|efficiency00 Pharmac
P11178696A0301 |114 123|injectiononatal hy
P11178696A0301 |94 95|so
P11178696A0301 |181 186|PD US as a
P11178696A0301 |134 148|contrast agentnemia. P000089
P11178696A0301 |129 130|gi
P11178696A0301 |7 16|US images06T0076 C
P11178765A0642 |51 55|acids an
P11178765A0642 |61 72|developmentcleotidase 
P11178765A0642 |86 96|metastasis Pharmacol
P11178765A0642 |156 161|cellsWhen 
P11178765A0642 |147 152|colon997A0
P11178765A0642 |116 136|mouse adenocarcinomaatal hyperbilirubine
P11178765A0642 |19 26|effectsarison 
P11179272T0000 |17 26|Chlamydiamparison 
P11179272T0000 |82 92|restenosis0000 Pharm
P11179272T0000 |43 77|Helicobacter pylori IgG antibodiessphatases and 5-nucleotidase P0000
P11179272T0000 |105 117|implantationcts of neona
P11179272T0000 |153 169|ultrasound study72 When CSF [HCO
P11179272T0000 |0 15|CytomegalovirusP00001606T0076 
P11179400T0000 |0 9|ResponsesP00001606
P11179400T0000 |62 66|ratsleot
P11179400T0000 |25 52|carotid body chemoreceptors with alkaline phosphatases
P11179664T0000 |85 116|transcription factor RUNX1/AML10 Pharmacologic aspects of neon
P11179664T0000 |40 45|locusphosp
P11179664T0000 |0 12|ArchitectureP00001606T00
P11179664T0000 |17 24|anatomympariso
P11179668A0869 |34 42|proteinsaline ph
P11179668A0869 |63 74|PLTP familyeotidase P0
P11179687A0280 |138 149|subfamiliesa. P0000899
P11179687A0280 |89 93|PTPsarma
P11179687A0280 |75 87|phosphatases008171T0000 
P11179687A0280 |45 52|enzymeshatases
P11179687A0280 |163 167|PTPsF [H
P11179687A0280 |8 13|paper6T007
P11179687A0280 |176 189|receptor PTPsshown as a fu
P11179687A0280 |191 196|RPTPstion 
P11179687A0280 |18 26|tyrosineparison 
P11179687A1118 |34 40|modulealine 
P11179687A1118 |148 153|group97A04
P11179687A1118 |133 139|memberinemia
P11179687A1118 |62 72|disulphideleotidase 
P11179687A1118 |24 32|metazoann with a
P11179687A1118 |81 91|Ig membersT0000 Phar
P11179689A0000 |100 106|domain aspec
P11179689A0000 |164 172|sequence [HCO3-]
P11179689A0000 |30 42|HMG box gene alkaline ph
P11179689A0000 |127 138|amino acidsilirubinemi
P11179689A0000 |76 88|DNA sequence08171T0000 P
P11179689A0000 |182 193|DNA bindingas a functi
P11179689A0000 |4 19|Sox gene family01606T0076 Comp
P11179689A0000 |21 24|Sryiso
P11179956A1818 |86 92|domain Pharm
P11179956A1818 |60 67|effectsucleoti
P11179956A1818 |176 183|domainsshown a
P11179956A1818 |12 19|results76 Comp
P11179956A1818 |209 225|proton transporthe data of K-dep
P11179956A1818 |96 114|nucleotide bindingogic aspects of ne
P11179956A1818 |143 155|interactions0008997A0472
P11180027A1306 |68 78|depressionase P00008
P11180027A1306 |12 22|parameters76 Compari
P11180027A1306 |38 41|M6Ge p
P11180027A1306 |84 92|morphine00 Pharm
P11180255A0776 |69 76|effectsse P000
P11180255A0776 |166 171|spaceHCO3-
P11180255A0776 |105 114|mechanismcts of ne
P11180255A0776 |23 32|argumentson with a
P11180255A0776 |145 151|energy08997A
P11180255A0776 |41 54|improbabilityhosphatases a
P11180255A0776 |80 95|UHF frequencies1T0000 Pharmaco
P11180255A0776 |157 161|timehen 
P11180688A0000 |68 76|childrenase P000
P11180688A0000 |178 181|MFTown
P11180688A0000 |125 134|illnessesrbilirubi
P11180688A0000 |164 176|Fitness Test [HCO3-] is 
P11180688A0000 |50 59|Hong Konges and 5-
P11180688A0000 |191 198|shuttletion of
P11180688A0000 |251 256|yearsispla
P11180688A0000 |218 232|schoolchildrenf K-depleted r
P11180688A0000 |37 38|Vn
P11180688A0000 |42 45|maxosp
P11180688A0000 |14 35|maximum oxygen uptake Comparison with alka
P11180688A0000 |203 207|testPCO2
P11180688A0000 |96 107|associationogic aspect
P11181516A0119 |153 160|regions72 When
P11181516A0119 |229 237|elementsd rats a
P11181516A0119 |243 245|E2lo
P11181516A0119 |75 88|transfections008171T0000 P
P11181516A0119 |251 255|Flatispl
P11181516A0119 |99 115|INS-1 beta-cellsc aspects of neo
P11181516A0119 |172 194|rat insulin I promoter is shown as a functio
P11181516A0119 |257 262|A2/A3ed wh
P11181516A0119 |16 61|deletion insulin promoter-reporter constructsomparison with alkaline phosphatases and 5-nu
P11181525T0000 |68 78|regulationase P00008
P11181525T0000 |23 25|ARon
P11181525T0000 |82 100|AR gene expression0000 Pharmacologic
P11181525T0000 |27 41|amino-terminusith alkaline p
P11181525T0000 |4 21|androgen receptor01606T0076 Compar
P11181525T0000 |115 123|enhancernatal hy
P11181531A0464 |84 97|transcription00 Pharmacolo
P11181531A0464 |160 183|cytokines interleukin-6 CSF [HCO3-] is shown a
P11181531A0464 |45 57|osteoporosishatases and 
P11181531A0464 |188 201|interleukin-1unction of CS
P11181531A0464 |8 17|mechanism6T0076 Co
P11181531A0464 |27 36|estrogensith alkal
P11181531A0464 |101 124|NF-kappa B target genesaspects of neonatal hyp
P11181531A0464 |70 80|repressione P0000817
P11181548A0214 |81 87|regionT0000 
P11181548A0214 |45 52|elementhatases
P11181548A0214 |108 118|expression of neonat
P11181548A0214 |72 78|tissueP00008
P11181548A0214 |149 161|DNA fragment7A0472 When 
P11181548A0214 |126 138|mE-RABP genebilirubinemi
P11181548A0214 |53 54|sa
P11181564A0733 |19 24|genesariso
P11181564A0733 |62 72|chromosomeleotidase 
P11181564A0733 |7 12|mouse06T00
P11181564A0733 |48 58|region 8E1ases and 5
P11181995A1093 |0 8|AnalysisP0000160
P11181995A1093 |240 248|evidenceno longe
P11181995A1093 |201 214|mouse matchesF PCO2 the da
P11181995A1093 |190 195|genesction
P11181995A1093 |65 76|transcriptstidase P000
P11181995A1093 |16 31|genome sequenceomparison with 
P11181995A1093 |118 126|evidenceal hyper
P11182520A0889 |49 60|restrictionses and 5-n
P11182520A0889 |74 79|assay00081
P11182520A0889 |18 26|genotypeparison 
P11182746A0872 |16 24|patientsompariso
P11182746A0872 |41 47|levelshospha
P11182746A0872 |64 76|drug therapyotidase P000
P11185475T0034 |3 10|Caveman001606T
P11187016T0000 |48 60|implicationsases and 5-n
P11187016T0000 |11 17|models076 Co
P11187016T0000 |26 46|A-bomb survivor datawith alkaline phosph
P11187016T0000 |78 88|mechanisms171T0000 P
P11188971A0000 |34 43|Parkinsonaline pho
P11188971A0000 |122 128|targetyperbi
P11188971A0000 |96 107|methodologyogic aspect
P11188971A0000 |22 29|surgeryson wit
P11188971A0000 |46 53|diseaseatases 
P11188971A0000 |55 57|PDd 
P11188971A0000 |70 80|discussione P0000817
P11188993A0298 |0 7|CornealP000016
P11188993A0298 |134 140|Gomorinemia.
P11188993A0298 |143 168|methenamine silver stains0008997A0472 When CSF [HC
P11188993A0298 |109 120|acid-Schiffof neonatal
P11188993A0298 |122 128|Giemsayperbi
P11188993A0298 |35 41|biopsyline p
P11188993A0298 |84 94|evaluation00 Pharmac
P11189314A1000 |6 13|results606T007
P11189314A1000 |90 94|GLCMrmac
P11189314A1000 |28 32|BACMth a
P11189314A1000 |77 84|effects8171T00
P11191208A0000 |275 285|PDR3 geneso controls
P11191208A0000 |166 199|ABC binding cassette transportersHCO3-] is shown as a function of 
P11191208A0000 |73 87|overexpression00008171T0000 
P11191208A0000 |91 96|genesmacol
P11191208A0000 |211 218|control data o
P11191208A0000 |145 157|facilitators08997A0472 W
P11191208A0000 |10 20|resistance0076 Compa
P11191208A0000 |226 250|transcription regulatorseted rats are no longer 
P11191208A0000 |266 270|PDR1ompa
P11191208A0000 |112 133|membrane efflux pumpsneonatal hyperbilirub
P11191365A0682 |0 14|SusceptibilityP00001606T0076
P11191365A0682 |153 154|%7
P11191365A0682 |222 224|VTde
P11191365A0682 |86 87|% 
P11191365A0682 |295 296|P 
P11191365A0682 |189 201|fibrillationnction of CS
P11191365A0682 |264 266|VF c
P11191365A0682 |270 271|%r
P11191365A0682 |241 242|%o
P11191365A0682 |142 144|VT00
P11191365A0682 |129 140|tachycardiairubinemia.
P11191365A0682 |229 230|%d
P11191365A0682 |280 293|non-diabeticstrols but sti
P11191365A0682 |165 173|episodes[HCO3-] 
P11191365A0682 |235 237|VF a
P11191365A0682 |203 205|VFPC
P11191365A0682 |67 76|diabeticsdase P000
P11191365A0682 |100 106|hearts aspec
P11191365A0682 |35 46|arrhythmiasline phosph
P11193045A1193 |69 72|p63se 
P11193045A1193 |107 118|developments of neonat
P11193045A1193 |44 52|functionphatases
P11193045A1193 |86 103|tumor suppression Pharmacologic as
P11193045A1193 |64 67|p73oti
P11193045A1193 |59 62|p53nuc
P11193045A1193 |2 9|picture0001606
P11193045A1193 |32 40|gradientlkaline 
P11193666A1269 |98 102|herdic a
P11193666A1269 |30 39|outbreaks alkaline
P11193666A1269 |43 66|Babesia carrier animalssphatases and 5-nucleot
P11193704A0000 |18 33|pleuropneumoniaparison with al
P11193704A0000 |45 51|threathatase
P11193704A0000 |56 62|cattle 5-nuc
P11193704A0000 |66 72|Africaidase 
P11194101A0532 |0 19|Baseline BMD valuesP00001606T0076 Comp
P11194101A0532 |282 293|user groupsols but sti
P11194101A0532 |145 149|view0899
P11194101A0532 |92 98|othersacolog
P11194101A0532 |106 111|levelts of
P11194101A0532 |122 127|spineyperb
P11194101A0532 |233 234|Pt
P11194101A0532 |370 375|femurzepam
P11194101A0532 |335 339|bone1 +/
P11194101A0532 |70 75|groupe P00
P11194101A0532 |221 227|g x cm-deple
P11194147A1496 |4 16|distribution01606T0076 C
P11194147A1496 |44 53|Sri Lankaphatases 
P11194147A1496 |24 40|rice cultivationn with alkaline 
P11194147A1496 |77 90|HIDD villages8171T0000 Pha
P11194183A0866 |35 40|hairsline 
P11194183A0866 |262 292|placebo control group subjectsen compared to controls but st
P11194183A0866 |397 398|P 
P11194183A0866 |294 309|procyanidin B-2l have a signif
P11194183A0866 |82 88|microm0000 P
P11194183A0866 |335 337|SD1 
P11194183A0866 |92 100|diameteracologic
P11194183A0866 |213 218|trialata o
P11194183A0866 |418 424|t testrug wi
P11194183A0866 |147 155|cm2 area997A0472
P11194183A0866 |63 68|hairseotid
P11194183A0866 |120 124|area hyp
P11194183A0866 |344 347|cm23 v
P11194183A0866 |164 194|procyanidin B-2 group subjects [HCO3-] is shown as a functio
P11194183A0866 |326 330|meanlope
P11194183A0866 |16 22|numberompari
P11194183A0866 |392 395|cm2be 
P11194183A0866 |383 385|SDpe
P11194183A0866 |349 356|placebo P00010
P11194183A0866 |130 139|cm squarerubinemia
P11194183A0866 |4 12|increase01606T00
P11194183A0866 |374 378|meanm th
P11195338A0494 |42 52|Lg3 alleleosphatases
P11195338A0494 |78 87|phenotype171T0000 
P11195338A0494 |8 18|expression6T0076 Com
P11195401A1030 |5 22|plasma AVP levels1606T0076 Compari
P11195401A1030 |109 114|SIADHof ne
P11195401A1030 |62 67|SSRIsleoti
P11195401A1030 |78 91|AVP secretion171T0000 Phar
P11195401A1030 |43 48|casessphat
P11196191A1789 |51 58|synergys and 5
P11196191A1789 |38 42|IL-6e ph
P11196191A1789 |9 36|T47D breast carcinoma cellsT0076 Comparison with alkal
P11196191A1789 |64 95|EGF receptor autocrine activityotidase P00008171T0000 Pharmaco
P11196191A1789 |118 136|MAPK/PI3K pathwaysal hyperbilirubine
P11196199T0000 |100 104|CREB asp
P11196199T0000 |106 121|binding proteints of neonatal 
P11196199T0000 |83 98|element binding000 Pharmacolog
P11196199T0000 |6 15|homologue606T0076 
P11196199T0000 |167 170|p53CO3
P11196199T0000 |155 163|activity When CS
P11196199T0000 |19 40|yeast Rad23 protein Aarison with alkaline 
P11196340A1046 |50 58|antigenses and 5
P11196340A1046 |113 127|aescin analogseonatal hyperb
P11196340A1046 |27 41|identificationith alkaline p
P11196340A1046 |79 90|variability71T0000 Pha
P11196340A1046 |143 151|validity0008997A
P11196340A1046 |18 25|methodsparison
P11197288A0855 |68 75|strainsase P00
P11197288A0855 |130 138|regimensrubinemi
P11197288A0855 |104 108|rateects
P11197288A0855 |24 37|metronidazolen with alkali
P11197288A0855 |5 13|patients1606T007
P11197328T0000 |0 7|BindingP000016
P11197328T0000 |164 179|mesophyll cells [HCO3-] is sho
P11197328T0000 |76 121|maize C4 phosphoenolpyruvate carboxylase gene08171T0000 Pharmacologic aspects of neonatal 
P11197328T0000 |147 160|transcription997A0472 When
P11197328T0000 |11 15|cell076 
P11197328T0000 |66 72|regionidase 
P11197328T0000 |38 46|proteinse phosph
P11197549A0748 |85 96|arrhythmias0 Pharmacol
P11197549A0748 |75 80|mm Hg00817
P11197549A0748 |20 40|stabilization periodrison with alkaline 
P11197549A0748 |42 47|PaCO2ospha
P11197549A0748 |58 60|SD-n
P11197549A0748 |49 53|meanses 
P11197549A0748 |0 7|RESULTSP000016
P11197926A0000 |0 10|BACKGROUNDP00001606T
P11197926A0000 |79 87|versions71T0000 
P11197926A0000 |151 158|effects0472 Wh
P11197926A0000 |95 123|General Health Questionnairelogic aspects of neonatal hy
P11197926A0000 |215 224|intervalsa of K-de
P11197926A0000 |198 203|times CSF 
P11197926A0000 |125 128|GHQrbi
P11197926A0000 |21 28|studiesison wi
P11198053T0000 |137 140|ratia.
P11198053T0000 |58 65|St John-nucleo
P11198053T0000 |89 101|constituentsarmacologic 
P11198053T0000 |120 129|responses hyperbil
P11198053T0000 |36 56|Hypericum perforatumine phosphatases and
P11198053T0000 |6 13|effects606T007
P11198053T0000 |25 32|extract with a
P11198053T0000 |17 19|LImp
P11198053T0000 |68 72|wortase 
P11198289T0000 |34 47|copper levelsaline phospha
P11198289T0000 |60 68|dystoniaucleotid
P11198289T0000 |10 29|serum ceruloplasmin0076 Comparison wit
P11198385A0000 |85 91|adults0 Phar
P11198385A0000 |25 38|algerae Vavra with alkalin
P11198385A0000 |74 80|larvae000817
P11198385A0000 |151 170|Gharbia Governorate0472 When CSF [HCO3
P11198385A0000 |97 114|laboratory colonygic aspects of ne
P11198385A0000 |118 134|Culex pipiens L.al hyperbilirubi
P11198424T0000 |51 55|genes an
P11198424T0000 |10 17|cloning0076 Co
P11198424T0000 |67 76|precursordase P000
P11198424T0000 |22 38|characterizationson with alkalin
P11198424T0000 |42 47|OsPSKospha
P11198424T0000 |81 101|phytosulfokine-alphaT0000 Pharmacologic 
P11198424T0000 |116 139|rice cell proliferationatal hyperbilirubinemia
P11200568A0830 |102 116|IgG antibodiesspects of neon
P11200568A0830 |79 90|measurement71T0000 Pha
P11200568A0830 |11 15|dams076 
P11200568A0830 |120 131|M. pulmonis hyperbilir
P11200568A0830 |66 74|necropsyidase P0
P11200568A0830 |58 62|time-nuc
P11200568A0830 |94 97|IgMolo
P11200568A0830 |39 50|inoculation phosphatas
P11200568A0830 |0 5|BloodP0000
P11201250A0849 |0 24|Plasma DHE concentrationP00001606T0076 Compariso
P11201250A0849 |108 112|skin of 
P11201250A0849 |63 74|applicationeotidase P0
P11201250A0849 |47 52|ng/mltases
P11201250A0849 |125 128|ratrbi
P11201250A0849 |82 90|PSA tape0000 Pha
P11202434T0000 |103 108|ACBP2pects
P11202434T0000 |78 99|palmitoyl-CoA binding171T0000 Pharmacologi
P11202434T0000 |56 62|domain 5-nuc
P11202434T0000 |142 149|protein0000899
P11202434T0000 |7 31|amino acid substitutions06T0076 Comparison with 
P11202434T0000 |76 77|C0
P11202434T0000 |113 124|Arabidopsiseonatal hyp
P11202434T0000 |155 170|ankyrin repeats When CSF [HCO3
P11202705A1112 |0 12|ImplicationsP00001606T00
P11202705A1112 |108 126|Posidonia oceanica of neonatal hyper
P11202705A1112 |46 67|accumulation patternsatases and 5-nucleoti
P11202705A1112 |97 104|tissuesgic asp
P11202705A1112 |16 29|biomonitoringomparison wit
P11203702A1307 |222 228|Xlim-1deplet
P11203702A1307 |167 176|mechanismCO3-] is 
P11203702A1307 |210 218|activitye data o
P11203702A1307 |54 71|activation domainnd 5-nucleotidase
P11203702A1307 |6 12|Xlim-1606T00
P11203702A1307 |124 133|CT239-403erbilirub
P11203702A1307 |114 120|domainonatal
P11203702A1307 |236 245|organizerare no lo
P11204897A0797 |36 48|participantsine phosphat
P11204897A0797 |15 19|timeComp
P11204897A0797 |61 82|bridge simulator taskcleotidase P00008171T
P11204897A0797 |24 34|absorptionn with alk
P11207216A0296 |87 101|chain reactionPharmacologic 
P11207216A0296 |106 128|cDNA library screeningts of neonatal hyperbi
P11207216A0296 |11 22|PGHS-2 cDNA076 Compari
P11207216A0296 |39 50|combination phosphatas
P11207216A0719 |34 41|proteinaline p
P11207216A0719 |122 153|phorbol 12-myristate 13-acetateyperbilirubinemia. P00008997A04
P11207216A0719 |164 166|nM [
P11207216A0719 |18 29|PGHS-2 mRNAparison wit
P11207216A0719 |4 14|regulation01606T0076
P11207216A0719 |65 73|culturestidase P
P11207216A0719 |155 158|PMA Wh
P11207216A0719 |100 105|cells aspe
P11207261A1421 |305 315|coligationgnificantl
P11207261A1421 |11 19|analysis076 Comp
P11207261A1421 |347 355|receptors. P0001
P11207261A1421 |192 204|phosphatasesion of CSF P
P11207261A1421 |319 330|BCR complexeater slope
P11207261A1421 |45 62|DT40 B cell lineshatases and 5-nuc
P11207261A1421 |206 211|SHP-12 the
P11207261A1421 |216 221|SHP-2 of K
P11207261A1421 |159 171|Src homologyn CSF [HCO3-
P11207261A1421 |100 131|Fc gamma RIIB1-PECAM-1 receptor aspects of neonatal hyperbilir
P11207261A1421 |289 299|regulation still hav
P11207269A0745 |53 63|propertiesand 5-nucl
P11207269A0745 |15 18|mAbCom
P11207269A0745 |72 85|p95 componentP00008171T000
P11207282A0729 |205 225|IgH gene transcriptsO2 the data of K-dep
P11207282A0729 |58 62|form-nuc
P11207282A0729 |192 201|reductionion of CS
P11207282A0729 |121 136|down-regulationhyperbilirubine
P11207282A0729 |20 30|expressionrison with
P11207282A0729 |96 107|B cell lineogic aspect
P11207282A0729 |66 80|chicken Notch1idase P0000817
P11207282A0729 |140 162|surface IgM expression P00008997A0472 When C
P11207282A0729 |84 90|Notch200 Pha
P11207288A0897 |0 13|SubstitutionsP00001606T007
P11207288A0897 |125 132|bindingrbiliru
P11207288A0897 |44 47|ABRpha
P11207288A0897 |21 24|YFViso
P11207288A0897 |36 42|regionine ph
P11207288A0897 |93 101|residuescologic 
P11207288A0897 |154 172|class Ia molecules2 When CSF [HCO3-]
P11207288A0897 |136 146|peptide-Agmia. P0000
P11207308A0999 |170 187|kinase activation-] is shown as a 
P11207308A0999 |62 67|agentleoti
P11207308A0999 |224 230|ERK1/2pleted
P11207308A0999 |153 158|c-Jun72 Wh
P11207308A0999 |21 38|diferuloylmethaneison with alkalin
P11207308A0999 |218 222|JAK3f K-
P11207308A0999 |212 216|JAK2data
P11207308A0999 |95 116|STAT1 phosphorylationlogic aspects of neon
P11207308A0999 |142 147|STAT100008
P11207308A0999 |11 19|curcumin076 Comp
P11207308A0999 |130 138|activityrubinemi
P11207308A0999 |236 255|p38 phosphorylationare no longer displ
P11207308A0999 |206 210|JAK12 th
P11207609A0994 |171 175|HeLa] is
P11207609A0994 |180 189|NRK cellsn as a fu
P11207609A0994 |153 157|VSVG72 W
P11207609A0994 |217 228|differencesof K-deplet
P11207609A0994 |248 259|traffickingr displaced
P11207609A0994 |159 167|chimerasn CSF [H
P11207609A0994 |93 108|ER localizationcologic aspects
P11207609A0994 |122 151|stomatitis virus glycoproteinyperbilirubinemia. P00008997A
P11207609A0994 |65 69|tailtida
P11207609A0994 |47 52|TGN46tases
P11207609A0994 |17 24|failurempariso
P11207609A0994 |3 11|contrast001606T0
P11207609A0994 |32 42|QKTT motiflkaline ph
P11208017A0070 |2 12|cDNA clone0001606T00
P11208017A0070 |79 86|soybean71T0000
P11208017A0070 |22 51|C2H2-type zinc finger proteinson with alkaline phosphatase
P11208017A0070 |53 59|SCOF-1and 5-
P11208814A0673 |102 120|sequence alignmentspects of neonatal
P11208814A0673 |92 100|proteinsacologic
P11208814A0673 |49 60|interactionses and 5-n
P11208814A0673 |184 199|phosphorylation a function of 
P11208814A0673 |20 31|specificityrison with 
P11208814A0673 |217 226|subdomainof K-depl
P11208814A0673 |249 257|proteins displac
P11208814A0673 |144 146|m700
P11208814A0673 |203 207|CKIIPCO2
P11208814A0673 |165 179|consensus site[HCO3-] is sho
P11208814A0673 |152 154|m847
P11208814A0673 |140 142|m5 P
P11208814A0673 |64 75|DmCKIIalphaotidase P00
P11209100A0069 |96 103|effectsogic as
P11209100A0069 |107 118|stimulations of neonat
P11209100A0069 |44 48|dataphat
P11209100A0069 |134 154|cytokine antagonistsnemia. P00008997A047
P11209100A0069 |198 204|IL-1ra CSF P
P11209100A0069 |123 130|releaseperbili
P11209100A0069 |63 66|PMNeot
P11209100A0069 |25 35|properties with alka
P11209100A0069 |163 196|interleukin-1 receptor antagonistF [HCO3-] is shown as a function 
P11209814A0243 |205 216|bioceramicsO2 the data
P11209814A0243 |20 33|investigationrison with al
P11209814A0243 |96 110|tissue capsuleogic aspects o
P11209814A0243 |146 172|aluminum calcium phosphate8997A0472 When CSF [HCO3-]
P11209814A0243 |130 142|implantationrubinemia. P
P11209814A0243 |4 11|purpose01606T0
P11209814A0243 |174 179|ALCAPs sho
P11209814A0243 |65 80|characteristicstidase P0000817
P11209814A0243 |201 203|HAF 
P11209814A0243 |185 199|hydroxyapetitea function of 
P11210401A0000 |0 23|Sevelamer hydrochlorideP00001606T0076 Comparis
P11210401A0000 |134 142|patientsnemia. P
P11210401A0000 |25 32|Renagel with a
P11210401A0000 |94 103|treatmentologic as
P11210401A0000 |107 124|hyperphosphatemias of neonatal hyp
P11210401A0000 |69 76|polymerse P000
P11210401A0000 |153 165|hemodialysis72 When CSF 
P11210401A0544 |32 39|digoxinlkaline
P11210401A0544 |104 118|administrationects of neonat
P11210401A0544 |44 52|warfarinphatases
P11210401A0544 |122 131|sevelameryperbilir
P11210401A0544 |20 28|profilesrison wi
P11210839A0282 |103 108|drugspects
P11210839A0282 |126 137|ethionamidebilirubinem
P11210839A0282 |57 65|patients5-nucleo
P11210839A0282 |47 48|%t
P11210839A0282 |37 41|halfne p
P11210839A0282 |7 25|PO3 administration06T0076 Comparison
P11210839A0282 |110 121|ethambutolef neonatal 
P11210839A0282 |157 169|oprofloxacinhen CSF [HCO
P11210839A0282 |141 152|ethambutoleP00008997A0
P11210988T0000 |4 12|survival01606T00
P11210988T0000 |30 38|patients alkalin
P11210988T0000 |62 77|prostate cancerleotidase P0000
P11211759A0165 |152 173|humidification system472 When CSF [HCO3-] 
P11211759A0165 |126 147|transtracheal heatingbilirubinemia. P00008
P11211759A0165 |177 192|ANAMED HUMITUBEhown as a funct
P11211759A0165 |107 114|group Bs of ne
P11211759A0165 |31 36|groupalkal
P11211759A0165 |38 53|Control group Ae phosphatases 
P11211759A0165 |65 74|hot-watertidase P0
P11211759A0165 |218 234|cancer operationf K-depleted rat
P11211759A0165 |87 93|systemPharma
P11211759A0165 |0 8|PatientsP0000160
P11211936A1490 |99 102|JNKc a
P11211936A1490 |104 119|SAPK activationects of neonata
P11211936A1490 |61 65|blr1cleo
P11211936A1490 |182 195|growth arrestas a function
P11211936A1490 |12 16|data76 C
P11211936A1490 |47 57|expressiontases and 
P11211936A1490 |162 177|differentiationSF [HCO3-] is s
P11211936A1490 |76 93|JNK/SAPK activity08171T0000 Pharma
P11212249A0993 |103 111|activitypects of
P11212249A0993 |76 93|activator protein08171T0000 Pharma
P11212249A0993 |62 72|antagonismleotidase 
P11212249A0993 |31 40|receptorsalkaline 
P11212249A0993 |97 101|AP-1gic 
P11212249A0993 |4 11|effects01606T0
P11212327A1564 |207 218|interaction the data o
P11212327A1564 |130 143|p59Lyn kinaserubinemia. P0
P11212327A1564 |72 85|PIG compoundsP00008171T000
P11212327A1564 |224 232|caveolinpleted r
P11212327A1564 |151 155|site0472
P11212327A1564 |30 44|rat adipocytes alkaline phos
P11212327A1564 |159 169|cross-talkn CSF [HCO
P11212327A1564 |7 14|studies06T0076
P11212327A1564 |95 126|IRS1/3 tyrosine phosphorylationlogic aspects of neonatal hyper
P11212327A1564 |260 263|PIGwhe
P11212327A1564 |184 194|regulation a functio
P11213342A0492 |85 96|test period0 Pharmacol
P11213342A0492 |13 27|parameters SF26 Comparison w
P11213342A0492 |40 50|efficiencyphosphatas
P11213342A0492 |0 7|RESULTSP000016
P11214177A1125 |50 57|nt RNAses and 
P11214177A1125 |121 130|satellitehyperbili
P11214177A1125 |13 18|sense6 Com
P11214177A1125 |76 82|satRNA08171T
P11214354A1104 |137 140|I-Ria.
P11214354A1104 |41 42|ph
P11214354A1104 |72 90|lipid peroxidationP00008171T0000 Pha
P11214354A1104 |157 168|CON animalshen CSF [HC
P11214354A1104 |112 126|protein thiolsneonatal hyper
P11214354A1104 |7 14|animals06T0076
P11214354A1104 |51 57|levelss and 
P11214354A1104 |102 103|ps
P11215622A0949 |0 8|GrippersP0000160
P11215622A0949 |72 78|strainP00008
P11215622A0949 |40 53|force sensorsphosphatases 
P11216247T0000 |4 9|child01606
P11218739A0811 |0 10|TransitionP00001606T
P11218739A0811 |26 32|H-BPPVwith a
P11218739A0811 |48 53|casesases 
P11218739A0811 |19 20|Pa
P11220166A0616 |16 23|effectsomparis
P11220166A0616 |281 293|cortex loopsrols but sti
P11220166A0616 |229 241|interventiond rats are n
P11220166A0616 |40 51|stimulationphosphatase
P11220166A0616 |317 326|behaviourgreater s
P11220166A0616 |133 142|existenceinemia. P
P11220166A0616 |89 96|aspectsarmacol
P11220166A0616 |59 76|motor performancenucleotidase P000
P11220166A0616 |297 302|motorave a
P11220166A0616 |196 220|brain dopamine receptorsof CSF PCO2 the data of 
P11220166A0616 |110 120|processingf neonatal
P11220166A0616 |154 166|interactions2 When CSF [
P11220306A0911 |0 6|HexA71P00001
P11220306A0911 |122 126|HexAyper
P11220306A0911 |97 101|HexAgic 
P11220306A0911 |128 134|strainlirubi
P11220306A0911 |26 30|RpoSwith
P11220306A0911 |66 78|sigma factoridase P00008
P11220306A0911 |39 45|levels phosp
P11220306A1753 |69 79|productionse P000081
P11220306A1753 |131 135|copyubin
P11220306A1753 |106 113|effectsts of n
P11220306A1753 |25 28|DNA wi
P11220306A1753 |43 47|handspha
P11220306A1753 |9 15|copiesT0076 
P11220306A1753 |19 23|rsmBaris
P11220306A1753 |139 143|hexA. P0
P11220486A0686 |1 2|%0
P11220486A0686 |8 13|IL-126T007
P11220486A0686 |19 20|%a
P11220487T0000 |50 64|trichomoniasises and 5-nucle
P11220487T0000 |11 17|review076 Co
P11220487T0000 |32 37|testslkali
P11220857T0000 |0 4|CHAPP000
P11220857T0000 |13 23|Department6 Comparis
P11220857T0000 |27 43|Veterans Affairsith alkaline pho
P11221836A0981 |23 29|fusionon wit
P11221836A0981 |91 98|potencymacolog
P11221836A0981 |57 64|vaccine5-nucle
P11221836A0981 |144 150|tumors008997
P11221845A0295 |139 159|Restriction Landmark. P00008997A0472 Whe
P11221845A0295 |27 45|methylation statusith alkaline phosp
P11221845A0295 |225 235|loci/spotsleted rats
P11221845A0295 |121 131|MT-D2 micehyperbilir
P11221845A0295 |61 66|livercleot
P11221845A0295 |194 200|RLGS-Mn of C
P11221845A0295 |181 192|Methylation as a funct
P11221845A0295 |71 83|liver tumors P00008171T0
P11221845A0295 |115 119|micenata
P11221845A0295 |281 293|liver tumorsrols but sti
P11221845A0295 |168 176|ScanningO3-] is 
P11221845A0295 |87 103|SV40 T/t antigenPharmacologic as
P11221845A0800 |170 190|SNAG repressor motif-] is shown as a fun
P11221845A0800 |227 255|C2H2-type zinc finger motifsted rats are no longer displ
P11221845A0800 |132 154|493-amino acid proteinbinemia. P00008997A047
P11221845A0800 |211 217|region data 
P11221845A0800 |39 52|reading frame phosphatases
P11221845A0800 |277 281|halfcont
P11221845A0800 |77 81|gene8171
P11221845A0800 |4 20|Genescan program01606T0076 Compa
P11221845A0800 |98 107|B236 spotic aspect
P11221845A1370 |68 73|brainase P
P11221845A1370 |97 102|livergic a
P11221845A1370 |37 40|mltne 
P11221845A1370 |75 81|spleen008171
P11221845A1370 |83 91|stom ach000 Phar
P11221845A1370 |0 22|Northern blot analysisP00001606T0076 Compari
P11221845A1713 |0 9|TreatmentP00001606
P11221845A1713 |146 149|mlt899
P11221845A1713 |91 101|expressionmacologic 
P11221845A1713 |105 108|mltcts
P11221845A1713 |290 304|SV40 T antigenstill have a s
P11221845A1713 |48 53|agentases 
P11221845A1713 |257 276|liver tumorigenesised when compared to
P11221845A1713 |55 74|5-aza-deoxycytidined 5-nucleotidase P0
P11221845A1713 |189 192|mltnct
P11221845A1713 |206 217|target gene2 the data 
P11221845A1713 |13 26|N18TG-2 cells6 Comparison 
P11221845A1713 |132 142|repressionbinemia. P
P11221845A1713 |238 249|methylatione no longer
P11221845A1713 |171 182|methylation] is shown 
P11222387A1497 |50 56|actiones and
P11222387A1497 |130 137|promiserubinem
P11222387A1497 |79 109|ABL tyrosine kinase inhibition71T0000 Pharmacologic aspects 
P11222387A1497 |37 46|mechanismne phosph
P11222387A1497 |111 123|FTI SCH66336 neonatal hy
P11222387A1497 |146 155|treatment8997A0472
P11222387A1497 |21 29|compoundison wit
P11222387A1497 |175 183|leukemia shown a
P11222639A1273 |35 39|roleline
P11222639A1273 |73 83|regulation00008171T0
P11222639A1273 |44 60|tyrosine residuephatases and 5-n
P11222639A1273 |6 13|results606T007
P11222639A1273 |87 101|L1 endocytosisPharmacologic 
P11222720A1699 |17 21|RPMSmpar
P11222720A1699 |129 148|corepressor complexirubinemia. P000089
P11222720A1699 |41 50|regulatorhosphatas
P11222720A1699 |91 103|interactionsmacologic as
P11222720A1699 |54 59|EBNA2nd 5-
P11222720A1699 |64 78|Notch activityotidase P00008
P11223131A0000 |0 17|Folate metabolismP00001606T0076 Co
P11223131A0000 |159 164|classn CSF
P11223131A0000 |180 186|agentsn as a
P11223131A0000 |31 69|malaria parasite Plasmodium falciparumalkaline phosphatases and 5-nucleotida
P11223131A0000 |201 204|useF P
P11223131A0000 |115 126|replicationnatal hyper
P11223131A0000 |99 110|cell growthc aspects o
P11223131A0000 |86 94|activity Pharmac
P11223131A0000 |136 142|targetmia. P
P11223153A0533 |71 92|microsphere technique P00008171T0000 Pharm
P11223153A0533 |23 32|text fileon with a
P11223153A0533 |142 148|pixels000089
P11223153A0533 |161 166|flowsCSF [
P11223153A0533 |4 14|BFA System01606T0076
P11223153A0533 |174 186|color schemas shown as a
P11223153A0533 |113 125|lung anatomyeonatal hype
P11223153A0533 |38 43|flowse pho
P11223153A0533 |98 108|constructsic aspects
P11223164A0000 |0 9|RetinoidsP00001606
P11223164A0000 |73 83|inhibition00008171T0
P11223164A0000 |104 111|varietyects of
P11223164A0000 |55 64|apoptosisd 5-nucle
P11223164A0000 |38 53|differentiatione phosphatases 
P11223164A0000 |29 34|onseth alk
P11223164A0000 |87 93|growthPharma
P11223164A0000 |136 141|cellsmia. 
P11223186A1095 |119 123|GATAl hy
P11223186A1095 |147 148|s9
P11223186A1095 |89 96|regionsarmacol
P11223186A1095 |142 146|site0000
P11223186A1095 |129 137|sequenceirubinem
P11223186A1095 |108 117|AP-1 site of neona
P11223186A1095 |19 55|oIFNtau enhancer-reporter constructsarison with alkaline phosphatases an
P11223186A1095 |0 15|TransactivationP00001606T0076 
P11223199A0751 |68 79|WB analysisase P000081
P11223199A0751 |28 38|evaluationth alkalin
P11223199A0751 |83 88|serum000 P
P11223199A0751 |6 13|results606T007
P11223199A0751 |42 50|exposureosphatas
P11223199A0751 |54 64|S. neuronand 5-nucle
P11223199A0751 |116 122|horsesatal h
P11223240A0655 |51 72|polyadenylation sitess and 5-nucleotidase 
P11223240A0655 |11 34|Menin1 gene transcripts076 Comparison with alk
P11223240A0655 |99 107|messagesc aspect
P11223246A0359 |0 17|Sequence analysisP00001606T0076 Co
P11223246A0359 |147 153|region997A04
P11223246A0359 |89 97|proteinsarmacolo
P11223246A0359 |33 54|RBP21 shares homologykaline phosphatases a
P11223246A0359 |117 128|motif LxCxEtal hyperbi
P11223255A1034 |17 43|consensus amino acid motifmparison with alkaline pho
P11223255A1034 |3 11|addition001606T0
P11223255A1034 |48 81|serine threonine receptor kinasesases and 5-nucleotidase P00008171
P11223256A1212 |51 57|regions and 
P11223256A1212 |65 79|pea 33RNP genetidase P000081
P11223257A0404 |0 6|OsBBPIP00001
P11223257A0404 |248 254|mannerr disp
P11223257A0404 |261 270|inductionhen compa
P11223257A0404 |189 198|endothallnction of
P11223257A0404 |126 148|protein phosphatase 2Abilirubinemia. P000089
P11223257A0404 |333 344|requirement.21 +/- 0.2
P11223257A0404 |299 312|cycloheximidee a significa
P11223257A0404 |150 154|PP2AA047
P11223257A0404 |210 220|light/darke data of 
P11223257A0404 |181 183|CN a
P11223257A0404 |382 391|inductionppears to
P11223257A0404 |314 317|CHXly 
P11223257A0404 |106 108|JAts
P11223257A0404 |357 374|protein synthesis43A0733 Flurazepa
P11223257A0404 |223 227|timeeple
P11223257A0404 |156 166|inhibitorsWhen CSF [
P11223257A0404 |64 72|responseotidase 
P11223257A0404 |200 202|ENSF
P11223257A0404 |42 60|rice seedling leafosphatases and 5-n
P11223257A0404 |168 179|cantharidinO3-] is sho
P11223257A0404 |100 104|acid asp
P11223938X1218 |34 38|Ltd.alin
P11223938X1218 |15 25|John WileyComparison
P11223938X1218 |28 32|Sonsth a
P11223938X1218 |0 9|CopyrightP00001606
P11224226A0000 |4 11|effects01606T0
P11224226A0000 |211 219|paradigm data of
P11224226A0000 |15 31|chlordiazepoxideComparison with 
P11224226A0000 |131 162|benzodiazepine receptor agonistubinemia. P00008997A0472 When C
P11224226A0000 |56 87|benzodiazepine receptor agonist 5-nucleotidase P00008171T0000 
P11224226A0000 |41 46|mg/kghosph
P11224226A0000 |93 103|bretazenilcologic as
P11224226A0000 |113 118|mg/kgeonat
P11226228A0899 |43 47|genespha
P11226228A0899 |31 36|yeastalkal
P11226228A0899 |9 17|plasmidsT0076 Co
P11226752A0750 |171 178|protein] is sh
P11226752A0750 |231 235|formrats
P11226752A0750 |245 251|Notch1nger d
P11226752A0750 |122 130|activityyperbili
P11226752A0750 |13 33|tissue culture cells6 Comparison with al
P11226752A0750 |134 137|E47nem
P11226752A0750 |185 191|mannera func
P11226752A0750 |203 214|suppressionPCO2 the da
P11226752A0750 |261 265|DTX1hen 
P11226752A0750 |35 49|overexpressionline phosphata
P11226752A0750 |69 90|mouse deltex homologsse P00008171T0000 Pha
P11227039A0953 |35 38|BMIlin
P11227039A0953 |12 17|women76 Co
P11227039A0953 |59 60|Pn
P11227039A0953 |40 41|Pp
P11227039A0953 |106 112|groupsts of 
P11227039A0953 |83 88|primi000 P
P11227039A0953 |54 57|PBFnd 
P11227182A1475 |64 74|parametersotidase P0
P11227182A1475 |108 121|leptin levels of neonatal 
P11227182A1475 |135 146|bone marrowemia. P0000
P11227182A1475 |92 103|bone marrowacologic as
P11227182A1475 |43 55|correlationssphatases an
P11227182A1475 |125 130|serumrbili
P11227182A1475 |82 88|lipids0000 P
P11227182A1475 |4 11|authors01606T0
P11227484T0000 |50 73|ion-association complexes and 5-nucleotidase P
P11227484T0000 |79 90|rhodamine B71T0000 Pha
P11227484T0000 |13 26|determination6 Comparison 
P11227484T0000 |30 43|methylmercury alkaline pho
P11227484T0000 |110 116|iodidef neon
P11227484T0000 |98 106|presenceic aspec
P11228700T0000 |4 12|position01606T00
P11228700T0000 |53 58|todayand 5
P11228700T0000 |31 37|expertalkali
P11228700T0000 |20 27|analystrison w
P11228700T0000 |39 48|yesterday phosphat
P11230145A0732 |49 59|Notch-CBF1ses and 5-
P11230145A0732 |182 192|conversionas a funct
P11230145A0732 |60 88|RBP-Jkappa signaling pathwayucleotidase P00008171T0000 P
P11230145A0732 |4 11|results01606T0
P11230145A0732 |37 41|rolene p
P11230145A0732 |92 111|cell fate decisionsacologic aspects of
P11230145A0732 |156 167|replicationWhen CSF [H
P11230145A0732 |138 146|pathwaysa. P0000
P11230169A0480 |137 147|DNA domainia. P00008
P11230169A0480 |14 20|method Compa
P11230169A0480 |211 214|20p da
P11230169A0480 |203 209|invdupPCO2 t
P11230169A0480 |73 92|array hybridization00008171T0000 Pharm
P11230169A0480 |31 60|chromatin immunoprecipitationalkaline phosphatases and 5-n
P11230169A0480 |184 196|20p12 region a function 
P11230169A0480 |222 239|marker chromosomedepleted rats are
P11230534A0688 |55 62|speciesd 5-nuc
P11230534A0688 |14 19|total Comp
P11230534A0688 |26 40|DEAH helicaseswith alkaline 
P11230889A1151 |119 125|monthsl hype
P11230889A1151 |30 45|arm lymphoedema alkaline phosp
P11230889A1151 |92 102|arm volumeacologic a
P11230889A1151 |147 151|HBO2997A
P11230889A1151 |132 141|treatmentbinemia. 
P11230889A1151 |76 88|improvements08171T0000 P
P11230889A1151 |4 9|cases01606
P11231287A0158 |85 97|thapsigargin0 Pharmacolo
P11231287A0158 |25 52|neuroblastoma cells SK-N-SH with alkaline phosphatases
P11231287A0158 |4 15|sensitivity01606T0076 
P11231287A0158 |64 73|apoptosisotidase P
P11232947A1451 |69 74|chainse P0
P11232947A1451 |94 104|recurrenceologic asp
P11232947A1451 |13 34|lymph node dissection6 Comparison with alk
P11232947A1451 |146 154|survival8997A047
P11232947A1451 |38 55|radiation therapye phosphatases an
P11233643A0000 |119 122|PDTl h
P11233643A0000 |178 183|mg/kgown a
P11233643A0000 |110 117|therapyf neona
P11233643A0000 |24 27|usen w
P11233643A0000 |165 173|ALA dose[HCO3-] 
P11233643A0000 |49 53|acidses 
P11233643A0000 |55 58|ALAd 5
P11233643A0000 |142 149|maximum0000899
P11233643A0000 |87 91|PPIXPhar
P11233643A0000 |68 82|protoporphyrinase P00008171T
P11234223A1451 |205 209|MEPMO2 t
P11234223A1451 |173 176|IPMis 
P11234223A1451 |37 43|groupsne pho
P11234223A1451 |231 238|killingrats ar
P11234223A1451 |110 115|classf neo
P11234223A1451 |74 82|activity0008171T
P11234223A1451 |181 185|PAPM as 
P11234223A1451 |16 27|antibioticsomparison w
P11234223A1451 |168 171|AMKO3-
P11234223A1451 |200 203|CAZSF 
P11234223A1451 |119 130|antibioticsl hyperbili
P11234223A1451 |152 159|killing472 Whe
P11235335T0000 |9 12|HIVT00
P11235777A0878 |17 25|syndromemparison
P11235777A0878 |106 132|dihydrotestosterone levelsts of neonatal hyperbiliru
P11235777A0878 |96 101|rangeogic 
P11235777A0878 |78 81|end171
P11235777A0878 |27 32|47XXYith a
P11235777A0878 |3 14|Klinefelter001606T0076
P11235777A0878 |35 60|serum testosterone levelsline phosphatases and 5-n
P11235817A0000 |201 207|adultsF PCO2
P11235817A0000 |106 112|reliefts of 
P11235817A0000 |72 77|classP0000
P11235817A0000 |164 174|conditions [HCO3-] i
P11235817A0000 |39 53|antihistamines phosphatases 
P11235817A0000 |188 196|childrenunction 
P11235817A0000 |123 131|symptomsperbilir
P11235817A0000 |4 37|histamine H1 receptor antagonists01606T0076 Comparison with alkali
P11235817A0000 |81 92|medicationsT0000 Pharm
P11236056A0374 |0 10|ConclusionP00001606T
P11236056A0374 |22 28|levelsson wi
P11236056A0374 |38 46|childrene phosph
P11236056A0374 |16 18|Lpom
P11237038A0889 |51 72|pressure flow studiess and 5-nucleotidase 
P11237038A0889 |110 114|HIFUf ne
P11237038A0889 |123 150|bladder outflow obstructionperbilirubinemia. P00008997
P11237038A0889 |12 20|patients76 Compa
P11237038A0889 |22 23|ns
P11237038A0889 |2 8|subset000160
P11237491A0000 |0 4|AIMSP000
P11237491A0000 |181 201|serum concentrations as a function of CS
P11237491A0000 |258 272|concentrationsd when compare
P11237491A0000 |288 299|individualst still hav
P11237491A0000 |50 62|fluctuationses and 5-nuc
P11237491A0000 |222 234|fluctuationsdepleted rat
P11237491A0000 |21 29|baselineison wit
P11237491A0000 |90 92|CArm
P11237491A0000 |141 147|cancerP00008
P11237491A0000 |110 118|patientsf neonat
P11237491A0000 |165 175|hypothesis[HCO3-] is
P11237491A0000 |100 102|CA a
P11237491A0000 |70 88|tumour markers CEAe P00008171T0000 P
P11237598A0962 |68 78|structuresase P00008
P11237598A0962 |27 36|frameworkith alkal
P11237598A0962 |46 53|enzymesatases 
P11237598A0962 |131 140|mechanismubinemia.
P11237598A0962 |99 108|evolutionc aspects
P11238105A0959 |102 109|alpha-2spects 
P11238105A0959 |197 202|Jak-2f CSF
P11238105A0959 |240 244|CD86no l
P11238105A0959 |150 157|abilityA0472 W
P11238105A0959 |61 67|term-3cleoti
P11238105A0959 |211 221|substrates data of K
P11238105A0959 |169 193|tyrosine phosphorylation3-] is shown as a functi
P11238105A0959 |117 123|domaintal hy
P11238105A0959 |53 59|domainand 5-
P11238105A0959 |0 5|CellsP0000
P11238105A0959 |17 31|alpha subunitsmparison with 
P11238375A0617 |85 89|ERK60 Ph
P11238375A0617 |91 100|p38 gammamacologic
P11238375A0617 |14 18|RhoA Com
P11238375A0617 |71 81|activation P00008171
P11238375A0617 |125 131|memberrbilir
P11238375A0617 |41 55|kinase cascadehosphatases an
P11238375A0617 |139 149|p38 family. P0000899
P11238375A0617 |153 158|MAPKs72 Wh
P11238402A0191 |68 91|DAN/TIR gene expressionase P00008171T0000 Phar
P11238402A0191 |37 47|mechanismsne phospha
P11238405A0817 |19 24|tup11ariso
P11238405A0817 |40 49|atf1-pcr1phosphata
P11238405A0817 |208 218|activationthe data o
P11238405A0817 |29 34|tup12h alk
P11238405A0817 |104 108|roleects
P11238405A0817 |66 75|activatoridase P00
P11238405A0817 |172 176|atf1 is 
P11238405A0817 |112 132|fbp1-lacZ expressionneonatal hyperbiliru
P11238405A0817 |143 168|spc1 MAPK phosphorylation0008997A0472 When CSF [HC
P11238405A0817 |3 10|strains001606T
P11238447A0524 |186 191|nup98 func
P11238447A0524 |42 48|eIF-5Aosphat
P11238447A0524 |9 24|binding studiesT0076 Compariso
P11238447A0524 |90 97|Rev-NESrmacolo
P11238447A0524 |75 86|interaction008171T0000
P11238447A0524 |197 202|nup62f CSF
P11238447A0524 |178 184|nup153own as
P11238447A0524 |127 133|eIF-5Ailirub
P11238447A0524 |103 117|CRM1/exportin1pects of neona
P11238447A0524 |153 176|nucleoporins CAN/nup21472 When CSF [HCO3-] is 
P11238586A0000 |35 40|classline 
P11238586A0000 |209 212|MHChe 
P11238586A0000 |259 271|interactions when compar
P11238586A0000 |49 75|histocompatibility complexses and 5-nucleotidase P00
P11238586A0000 |158 166|contactsen CSF [
P11238586A0000 |127 130|TCRili
P11238586A0000 |297 304|bindingave a s
P11238586A0000 |176 182|alpha1shown 
P11238586A0000 |11 18|studies076 Com
P11238586A0000 |132 143|alpha/betasbinemia. P0
P11238586A0000 |187 201|alpha2 helicesfunction of CS
P11238586A0000 |77 80|MHC817
P11238586A0000 |110 125|T cell receptorf neonatal hype
P11238882A0157 |72 76|geneP000
P11238882A0157 |29 33|eIF6h al
P11238884A0892 |0 4|MiceP000
P11238884A0892 |24 36|dlg mutationn with alkal
P11238884A0892 |79 89|hypoplasia71T0000 Ph
P11238884A0892 |45 63|growth retardationhatases and 5-nucl
P11238884A0892 |67 72|uterodase 
P11238884A0892 |129 134|cleftirubi
P11238884A0892 |145 151|palate08997A
P11238884A0892 |97 107|premaxillagic aspect
P11238884A0892 |112 120|mandibleneonatal
P11238916A0838 |204 212|paxillinCO2 the 
P11238916A0838 |40 48|paxillinphosphat
P11238916A0838 |130 148|macrophage lysatesrubinemia. P000089
P11238916A0838 |12 19|complex76 Comp
P11238916A0838 |31 38|PTP phialkalin
P11238916A0838 |178 185|PTP phiown as 
P11238916A0838 |93 97|Pyk2colo
P11238916A0838 |76 91|tyrosine kinase08171T0000 Phar
P11238916A0838 |217 221|Pyk2of K
P11238916A0838 |168 174|domainO3-] i
P11238947A0636 |54 70|hnRNP A2 bindingnd 5-nucleotidas
P11238947A0636 |91 97|A2RE-2macolo
P11238947A0636 |22 25|A8Gson
P11238947A0636 |9 20|base changeT0076 Compa
P11238947A0636 |108 121|RNA transport of neonatal 
P11238947A0636 |37 45|sequencene phosp
P11238947A0636 |83 87|case000 
P11239184A1340 |0 18|Baseline variablesP00001606T0076 Com
P11239184A1340 |180 191|artery signn as a func
P11239184A1340 |134 139|edemanemia
P11239184A1340 |120 130|CT changes hyperbili
P11239184A1340 |80 87|aspirin1T0000 
P11239184A1340 |143 154|mass effect0008997A047
P11239184A1340 |63 66|useeot
P11239184A1340 |101 110|incidenceaspects o
P11239184A1340 |35 37|CDli
P11239529A0981 |0 8|IL-1betaP0000160
P11239529A0981 |75 88|localizations008171T0000 P
P11239529A0981 |58 65|lesions-nucleo
P11239529A0981 |37 49|endometriomane phosphata
P11240600A0523 |64 72|durationotidase 
P11240600A0523 |11 23|drug history076 Comparis
P11240600A0523 |76 90|VGB medication08171T0000 Pha
P11240600A0523 |53 59|amountand 5-
P11241166A0677 |170 180|regulators-] is show
P11241166A0677 |266 274|sequenceompared 
P11241166A0677 |247 255|cytokineer displ
P11241166A0677 |126 130|Ob-Rbili
P11241166A0677 |145 153|increase08997A04
P11241166A0677 |208 219|suppressorsthe data of
P11241166A0677 |132 136|mRNAbine
P11241166A0677 |19 34|gene expressionarison with alk
P11241166A0677 |184 199|STAT signalling a function of 
P11241166A0677 |223 242|cytokine signallingepleted rats are no
P11241166A0677 |53 65|FA treatmentand 5-nucleo
P11241166A0677 |83 91|decrease000 Phar
P11241166A0677 |276 279|CIS co
P11241166A0677 |7 15|analysis06T0076 
P11241166A0677 |109 124|leptin receptorof neonatal hyp
P11241166A0677 |99 105|amountc aspe
P11241166A0677 |201 206|SOCS3F PCO
P11241215A0566 |153 164|performance72 When CSF
P11241215A0566 |142 147|phase00008
P11241215A0566 |82 93|thioredoxin0000 Pharma
P11241215A0566 |11 20|receptors076 Compa
P11241215A0566 |61 76|fusion proteinscleotidase P000
P11241215A0566 |203 212|digestionPCO2 the 
P11241215A0566 |188 195|RP-HPLCunction
P11241215A0566 |172 186|chromatography is shown as a
P11241215A0566 |218 230|enterokinasef K-depleted
P11241215A0566 |33 41|sBMPR-IAkaline p
P11241243A0693 |118 127|componental hyperb
P11241243A0693 |65 79|quantificationtidase P000081
P11241243A0693 |129 134|% PSCirubi
P11241243A0693 |38 46|analysise phosph
P11241243A0693 |4 11|authors01606T0
P11241243A0693 |140 154|p53 expression P00008997A047
P11241243A0693 |87 97|percentagePharmacolo
P11241243A0693 |50 59|pathologyes and 5-
P11241332A0393 |205 210|foamsO2 th
P11241332A0393 |147 153|anchor997A04
P11241332A0393 |89 99|variationsarmacologi
P11241332A0393 |63 81|fixation strengthseotidase P00008171
P11241332A0393 |9 16|purposeT0076 C
P11241332A0393 |229 233|boned ra
P11241332A0393 |160 172|screw anchor CSF [HCO3-]
P11241332A0393 |250 259|densitiesdisplaced
P11241332A0393 |117 136|bone anchor designstal hyperbilirubine
P11241356T0000 |142 156|stellate cells00008997A0472 
P11241356T0000 |41 53|localizationhosphatases 
P11241356T0000 |13 28|phosphorylation6 Comparison wi
P11241356T0000 |57 62|Smad35-nuc
P11241356T0000 |93 120|collagen gene transcriptioncologic aspects of neonatal
P11241672T0000 |51 73|integrin gene promoters and 5-nucleotidase P
P11241672T0000 |12 28|characterization76 Comparison wi
P11241672T0000 |121 128|elementhyperbi
P11241672T0000 |75 89|identification008171T0000 Ph
P11241672T0000 |36 47|murine betaine phospha
P11241672T0000 |147 153|STAT-6997A04
P11241672T0000 |133 143|regulationinemia. P0
P11241672T0000 |96 109|interleukin-4ogic aspects 
P11241672T0000 |0 7|CloningP000016
P11243306A0961 |0 11|CONCLUSIONSP00001606T0
P11243306A0961 |26 32|levelswith a
P11243306A0961 |150 158|presenceA0472 Wh
P11243306A0961 |36 52|oxLDL antibodiesine phosphatases
P11243306A0961 |202 208|levels PCO2 
P11243306A0961 |162 174|hypertensionSF [HCO3-] i
P11243306A0961 |80 92|hypertension1T0000 Pharm
P11243306A0961 |117 131|artery diseasetal hyperbilir
P11243336A0000 |34 38|filmalin
P11243336A0000 |12 19|MD-55-276 Comp
P11243336A0000 |128 151|brachytherapy dosimetrylirubinemia. P00008997A
P11243336A0000 |83 95|applications000 Pharmaco
P11243494A0833 |0 7|RESULTSP000016
P11243494A0833 |75 78|CRF008
P11243494A0833 |82 87|rates0000 
P11243494A0833 |62 68|heroinleotid
P11243494A0833 |28 34|groupsth alk
P11243494A0833 |18 22|dayspari
P11243494A0833 |116 127|performanceatal hyperb
P11243777A0000 |11 25|CCAAT elements076 Comparison
P11243777A0000 |61 77|promoter regionscleotidase P0000
P11243980A0510 |35 51|PET examinationsline phosphatase
P11243980A0510 |12 20|patients76 Compa
P11243980A0510 |63 81|staging procedureseotidase P00008171
P11244568A0506 |118 124|larvaeal hyp
P11244568A0506 |95 101|amountlogic 
P11244568A0506 |28 32|geneth a
P11244568A0506 |74 85|development0008171T000
P11244568A0506 |58 62|mRNA-nuc
P11244568A0506 |4 10|Gap69C01606T
P11244733A0782 |0 5|CasesP0000
P11244733A0782 |41 51|metastasishosphatase
P11244733A0782 |9 20|lung cancerT0076 Compa
P11244733A0782 |96 101|deathogic 
P11245986T0000 |58 86|rat aldolase B gene promoter-nucleotidase P00008171T0000
P11245986T0000 |31 38|proteinalkalin
P11246679A0000 |0 9|OBJECTIVEP00001606
P11246679A0000 |83 87|CCHB000 
P11246679A0000 |112 119|diseaseneonata
P11246679A0000 |30 41|association alkaline p
P11246679A0000 |96 101|fetusogic 
P11246679A0000 |70 81|heart blocke P00008171
P11246887A0000 |102 106|CETPspec
P11246887A0000 |159 167|activityn CSF [H
P11246887A0000 |247 255|subjectser displ
P11246887A0000 |24 28|rolen wi
P11246887A0000 |332 335|CAC1.2
P11246887A0000 |208 228|artery calcificationthe data of K-deplet
P11246887A0000 |302 306|loss sig
P11246887A0000 |60 63|CETucl
P11246887A0000 |230 233|CAC ra
P11246887A0000 |108 116|activity of neon
P11246887A0000 |314 328|sex differencely greater slo
P11246887A0000 |135 151|transfer proteinemia. P00008997A
P11246887A0000 |153 157|PLTP72 W
P11246887A0000 |185 195|prevalencea function
P11246887A0000 |5 10|study1606T
P11246887A0000 |66 100|cholesteryl ester transfer proteinidase P00008171T0000 Pharmacologic
P11246887A0000 |282 290|subjectsols but 
P11246887A0000 |339 347|diabetes- 0.23 v
P11246887A0000 |32 58|cholesteryl ester transferlkaline phosphatases and 5
P11247663A1447 |70 81|individualse P00008171
P11247663A1447 |44 57|DNAH9 allelesphatases and 
P11247663A1447 |29 40|inheritanceh alkaline 
P11247663A1447 |4 12|families01606T00
P11248463A0187 |4 16|blood levels01606T0076 C
P11248463A0187 |29 37|pyruvateh alkali
P11248463A0187 |42 53|amino acidsosphatases 
P11248463A0187 |20 27|lactaterison w
P11248626T0000 |0 8|EfficacyP0000160
P11248626T0000 |61 69|functioncleotida
P11248626T0000 |105 118|prostatectomycts of neonat
P11248626T0000 |83 89|nerves000 Ph
P11248626T0000 |142 152|evaluation00008997A0
P11248626T0000 |29 37|Cavermaph alkali
P11248626T0000 |48 56|locationases and
P11248626T0000 |168 176|surgeonsO3-] is 
P11250196A0455 |16 27|domain foldomparison w
P11250196A0455 |166 176|Protein S.HCO3-] is 
P11250196A0455 |47 68|calcium binding sitestases and 5-nucleotid
P11250196A0455 |125 164|betagamma-crystallin fold family memberrbilirubinemia. P00008997A0472 When CSF
P11250196A0455 |39 43|pair pho
P11250942A0626 |101 105|AF-2aspe
P11250942A0626 |42 47|GRIP1ospha
P11250942A0626 |128 139|interactionlirubinemia
P11250942A0626 |11 19|analyses076 Comp
P11250942A0626 |107 113|domains of n
P11250942A0626 |23 26|VDRon 
P11250942A0626 |52 56|RAC3 and
P11250942A0626 |76 99|VDR activation function08171T0000 Pharmacologi
P11250942A0626 |175 182|regions shown 
P11250942A0626 |190 193|VDRcti
P11251083T0000 |0 9|MechanismP00001606
P11251083T0000 |39 54|cell morphology phosphatases a
P11251083T0000 |59 72|S phase entrynucleotidase 
P11251083T0000 |28 35|controlth alka
P11251083T0000 |86 99|growth factor Pharmacologi
P11251083T0000 |118 137|MEK/ERK activationsal hyperbilirubinem
P11251104A0526 |116 119|GA.ata
P11251104A0526 |61 87|transcription factor GAMybcleotidase P00008171T0000 
P11251104A0526 |4 14|expression01606T0076
P11251104A0526 |18 31|alpha-amylaseparison with 
P11251252A0494 |0 19|3D image-processingP00001606T0076 Comp
P11251252A0494 |127 135|3D viewsilirubin
P11251252A0494 |147 151|mode997A
P11251252A0494 |89 95|planesarmaco
P11251252A0494 |97 109|section modegic aspects 
P11251252A0494 |39 54|ultrasound data phosphatases a
P11251276A0793 |32 39|surgerylkaline
P11251276A0793 |10 18|patients0076 Com
P11251697T0000 |96 119|electron spin resonanceogic aspects of neonata
P11251697T0000 |79 92|determination71T0000 Pharm
P11251697T0000 |72 77|drugsP0000
P11251697T0000 |130 146|spin trap methodrubinemia. P0000
P11251697T0000 |7 37|superoxide scavenging activity06T0076 Comparison with alkali
P11251951A0000 |102 114|skin lesionsspects of ne
P11251951A0000 |40 49|techniquephosphata
P11251951A0000 |198 202|CMIS CSF
P11251951A0000 |12 22|Dermoscopy76 Compari
P11251951A0000 |180 188|melanoman as a f
P11251951A0000 |156 164|patientsWhen CSF
P11251951A0000 |80 88|accuracy1T0000 P
P11251951A0000 |143 152|diagnosis0008997A0
P11251951A0000 |223 231|melanomaepleted 
P11251951A0000 |0 10|BACKGROUNDP00001606T
P11254134A0648 |84 92|sequence00 Pharm
P11254134A0648 |59 62|PTFnuc
P11254134A0648 |10 14|PTax0076
P11254134A0648 |121 127|regionhyperb
P11254134A0648 |142 159|background levels00008997A0472 Whe
P11254134A0648 |32 53|background activitieslkaline phosphatases 
P11254504A0766 |139 143|MyoD. P0
P11254504A0766 |88 91|Sp1har
P11254504A0766 |220 228|homeoboxK-deplet
P11254504A0766 |118 137|activator protein-2al hyperbilirubinem
P11254504A0766 |159 172|factor-kappaBn CSF [HCO3-]
P11254504A0766 |145 149|p3000899
P11254504A0766 |247 274|Cdx protein-2 binding siteser displaced when compared 
P11254504A0766 |182 203|zinc finger protein-1as a function of CSF 
P11254504A0766 |99 116|growth response-1c aspects of neon
P11254504A0766 |230 233|Cdx ra
P11254504A0766 |13 28|promoter region6 Comparison wi
P11254504A0766 |235 241|gene A are n
P11254504A0766 |71 79|elements P000081
P11254713A1029 |38 48|componentse phosphat
P11254713A1029 |10 21|interaction0076 Compar
P11254713A1029 |130 141|alterationsrubinemia. 
P11254713A1029 |150 157|complexA0472 W
P11254713A1029 |211 234|IL-2 gene transcription data of K-depleted rat
P11254713A1029 |199 207|decreaseCSF PCO2
P11254713A1029 |161 171|activationCSF [HCO3-
P11254713A1029 |57 64|rel/AP15-nucle
P11254713A1029 |77 84|complex8171T00
P11254713A1029 |25 28|Tat wi
P11254864T0000 |38 51|breast cancere phosphatase
P11254864T0000 |25 34|treatment with alk
P11255035A0331 |37 42|brainne ph
P11255035A0331 |44 65|SVZa progenitor cellsphatases and 5-nucleo
P11255035A0331 |75 83|capacity008171T0
P11255035A0331 |13 29|progenitor cells6 Comparison wit
P11255035A0331 |130 139|phenotyperubinemia
P11255252A0961 |10 22|ER3 sequence0076 Compari
P11255252A0961 |121 135|yeast extractshyperbilirubin
P11255252A0961 |72 79|FXR HREP000081
P11255252A0961 |26 29|DNAwit
P11255423A0211 |0 9|OBJECTIVEP00001606
P11255423A0211 |28 39|associationth alkaline
P11255423A0211 |105 119|CD4 lymphocytects of neonata
P11255423A0211 |144 147|HIV008
P11255423A0211 |94 101|declineologic 
P11255423A0211 |133 138|womeninemi
P11255423A0211 |54 62|symptomsnd 5-nuc
P11255423A0211 |80 89|mortality1T0000 Ph
P11256845A0340 |35 69|Scotland Coronary Prevention Studyline phosphatases and 5-nucleotida
P11256845A0340 |27 31|Westith 
P11256845A0340 |146 152|events8997A0
P11256845A0340 |208 215|WOSCOPSthe dat
P11256845A0340 |104 120|statin treatmentects of neonatal
P11256845A0340 |164 172|patients [HCO3-]
P11256845A0340 |262 267|eventen co
P11256845A0340 |80 88|findings1T0000 P
P11256845A0340 |321 327|poundster sl
P11256845A0340 |178 188|populationown as a f
P11256845A0340 |228 229|%e
P11256845A0340 |12 20|analysis76 Compa
P11256845A0340 |285 289|cost but
P11256845A0340 |71 78|WOSCOPS P00008
P11256845A0340 |237 241|riskre n
P11256944A1144 |34 38|ATF6alin
P11256944A1144 |126 152|ER stress response elementbilirubinemia. P00008997A0
P11256944A1144 |94 107|point mutantsologic aspect
P11256944A1144 |47 63|G13 gene producttases and 5-nucl
P11256944A1144 |25 30|forms with
P11256944A1144 |185 194|ER stressa functio
P11256962A0233 |254 261|portionlaced w
P11256962A0233 |199 203|exonCSF 
P11256962A0233 |146 170|GlyR alpha subunit genes8997A0472 When CSF [HCO3
P11256962A0233 |269 283|GlyR beta mRNAared to contro
P11256962A0233 |120 127|regions hyperb
P11256962A0233 |80 97|beta subunit gene1T0000 Pharmacolo
P11256962A0233 |39 50|differences phosphatas
P11256962A0233 |66 72|regionidase 
P11256962A0233 |0 17|Sequence analysisP00001606T0076 Co
P11256962A0233 |205 209|exonO2 t
P11257870A0000 |274 277|HRTto 
P11257870A0000 |62 68|hybridleotid
P11257870A0000 |151 154|ASP047
P11257870A0000 |135 149|sludge processemia. P0000899
P11257870A0000 |258 272|retention timed when compare
P11257870A0000 |117 119|TFta
P11257870A0000 |223 234|temperatureepleted rat
P11257870A0000 |80 87|reactor1T0000 
P11257870A0000 |188 205|trichloroethyleneunction of CSF PC
P11257870A0000 |12 17|study76 Co
P11257870A0000 |47 56|potentialtases and
P11257870A0000 |166 176|wastewaterHCO3-] is 
P11257870A0000 |109 115|filterof neo
P11257870A0000 |207 210|TCE th
P11258906A0743 |71 75|Rec2 P00
P11258906A0743 |126 130|RecAbili
P11258906A0743 |88 100|pairing biasharmacologic
P11258906A0743 |39 55|oligonucleotides phosphatases an
P11258906A0743 |3 32|DNA strand exchange reactions001606T0076 Comparison with a
P11259347A0000 |48 58|literatureases and 5
P11259347A0000 |121 128|abilityhyperbi
P11259347A0000 |10 22|observations0076 Compari
P11259347A0000 |147 156|chemicals997A0472 
P11259347A0000 |79 84|clues71T00
P11259347A0000 |113 119|humanseonata
P11259347A0000 |99 109|variationsc aspects 
P11259503A0212 |51 56|cellss and
P11259503A0212 |66 67|hi
P11259503A0212 |24 30|microMn with
P11259503A0212 |86 96|luciferase Pharmacol
P11259503A0212 |0 19|Forskolin treatmentP00001606T0076 Comp
P11259593A1094 |0 8|AnalysisP0000160
P11259593A1094 |63 78|cell separationeotidase P00008
P11259593A1094 |12 27|ace2Delta cells76 Comparison w
P11259593A1094 |41 46|Ace2phosph
P11259593A1094 |101 107|growthaspect
P11260468A1179 |155 167|protein H-NS When CSF [H
P11260468A1179 |37 40|AR1ne 
P11260468A1179 |127 134|absenceilirubi
P11260468A1179 |95 114|papBA transcriptionlogic aspects of ne
P11260468A1179 |66 77|CAP subunitidase P0000
P11260468A1179 |4 11|results01606T0
P11260662X0000 |0 2|A.P0
P11260662X0000 |13 15|D.6 
P11260662X0000 |4 11|Slatkin01606T0
P11263622A0683 |137 138|ri
P11263622A0683 |88 104|vessel wall areaharmacologic asp
P11263622A0683 |150 151|rA
P11263622A0683 |121 135|histopathologyhyperbilirubin
P11263622A0683 |113 116|MRIeon
P11263622A0683 |36 37|pi
P11263622A0683 |23 34|correlationon with alk
P11263622A0683 |69 83|wall thicknessse P00008171T0
P11263622A0683 |0 7|RESULTSP000016
P11263664A1085 |51 71|XBra gene expressions and 5-nucleotidase
P11263664A1085 |79 87|mesoderm71T0000 
P11263664A1085 |23 27|SIP1on w
P11263664A1085 |4 8|data0160
P11263664T0000 |0 4|SIP1P000
P11263664T0000 |6 30|Smad interacting protein606T0076 Comparison with
P11263664T0000 |131 141|repressorsubinemia. 
P11263664T0000 |65 88|enhancer binding factortidase P00008171T0000 P
P11263664T0000 |38 46|deltaEF1e phosph
P11264176A0181 |0 5|B-mybP0000
P11264176A0181 |23 38|G1/S transitionon with alkalin
P11264176A0181 |86 108|cyclin A2/cdk2 complex Pharmacologic aspects
P11264177T0000 |0 19|Nucleotide sequenceP00001606T0076 Comp
P11264177T0000 |105 111|B-cellcts of
P11264177T0000 |21 38|transcription mapison with alkalin
P11264177T0000 |132 140|leukemiabinemia.
P11264177T0000 |44 61|mutation analysisphatases and 5-nu
P11264177T0000 |87 93|regionPharma
P11264177T0000 |69 74|13q14se P0
P11264182A0000 |207 222|T-cell leukemia the data of K-
P11264182A0000 |44 47|Taxpha
P11264182A0000 |76 85|regulator08171T000
P11264182A0000 |133 138|genesinemi
P11264182A0000 |183 197|leukemogenesiss a function o
P11264182A0000 |6 32|T-cell leukemia virus type606T0076 Comparison with a
P11264182A0000 |36 42|HTLV-Iine ph
P11264372T0000 |85 105|herpes simplex virus0 Pharmacologic aspe
P11264372T0000 |41 54|translocationhosphatases a
P11264372T0000 |58 79|infected-cell protein-nucleotidase P000081
P11264372T0000 |0 12|RequirementsP00001606T00
P11264375A0000 |55 66|protein IE2d 5-nucleot
P11264375A0000 |27 31|HCMVith 
P11264375A0000 |10 25|cytomegalovirus0076 Comparison
P11264375A0000 |124 133|regulatorerbilirub
P11264375A0000 |159 169|infectionsn CSF [HCO
P11264375A0000 |80 94|phosphoprotein1T0000 Pharmac
P11264561A0167 |85 94|occlusion0 Pharmac
P11264561A0167 |55 62|anatomyd 5-nuc
P11264561A0167 |32 36|RSTDlkal
P11264561A0167 |0 9|OBJECTIVEP00001606
P11265853A0000 |51 63|Novacor Corps and 5-nucl
P11265853A0000 |44 48|LVASphat
P11265853A0000 |65 72|Oaklandtidase 
P11265853A0000 |29 42|Assist Systemh alkaline ph
P11265853A0000 |74 76|CA00
P11265853A0000 |4 11|Novacor01606T0
P11265853A0000 |154 167|configuration2 When CSF [H
P11266184A0000 |0 8|AtheromaP0000160
P11266184A0000 |188 190|SEun
P11266184A0000 |111 113|MR n
P11266184A0000 |131 141|componentsubinemia. 
P11266184A0000 |177 186|spin-echohown as a
P11266184A0000 |192 198|imagesion of
P11266184A0000 |31 52|signal intensity areaalkaline phosphatases
P11266184A0000 |155 173|signal intensities When CSF [HCO3-] 
P11266184A0000 |86 89|TOF Ph
P11266184A0000 |115 121|imagesnatal 
P11266184A0000 |70 84|time-of-flighte P00008171T00
P11266184A0000 |100 109|resonance aspects 
P11266194A0743 |0 4|BodyP000
P11266194A0743 |9 21|distributionT0076 Compar
P11266194A0743 |59 69|tomographynucleotida
P11266227A0295 |18 29|p-toluidineparison wit
P11266227A0295 |47 55|pH valuetases an
P11266227A0295 |63 77|donor solutioneotidase P0000
P11266227A0295 |4 14|flux rates01606T0076
P11266540A0328 |39 61|Groucho family members phosphatases and 5-nu
P11266540A0328 |121 143|Tcf/Lef family membershyperbilirubinemia. P0
P11266540A0328 |72 79|abilityP000081
P11266558A1470 |152 177|recruiting RNA polymerase472 When CSF [HCO3-] is s
P11266558A1470 |106 123|initiator elementts of neonatal hy
P11266558A1470 |31 52|transcription extractalkaline phosphatases
P11266558A1470 |188 208|SL RNA gene promoterunction of CSF PCO2 
P11266558A1470 |64 80|binding activityotidase P0000817
P11266615A0258 |4 11|protein01606T0
P11266615A0258 |72 85|linker regionP00008171T000
P11266615A0258 |92 111|amino acid residuesacologic aspects of
P11266615A0258 |37 44|domainsne phos
P11267679A0102 |119 126|proteinl hyper
P11267679A0102 |89 102|reading framearmacologic a
P11267679A0102 |134 145|amino acidsnemia. P000
P11267679A0102 |8 25|bp EcoRI fragment6T0076 Comparison
P11267679A0102 |49 71|Southern hybridizationses and 5-nucleotidase
P11268459A0167 |116 124|responseatal hyp
P11268459A0167 |177 190|tissue tumorshown as a fun
P11268459A0167 |227 236|prognosisted rats 
P11268459A0167 |46 58|relationshipatases and 5
P11268459A0167 |210 222|chemotherapye data of K-
P11268459A0167 |134 142|decreasenemia. P
P11268459A0167 |126 130|ratebili
P11268459A0167 |92 95|%DBaco
P11268459A0167 |146 158|tumor volume8997A0472 Wh
P11268459A0167 |25 30|study with
P11268459A0167 |71 90|DOX binding ability P00008171T0000 Pha
P11268887A1174 |116 119|FVCata
P11268887A1174 |9 27|misinterpretationsT0076 Comparison w
P11268887A1174 |124 128|FEV1erbi
P11268887A1174 |106 112|regardts of 
P11268887A1174 |76 90|preadolescents08171T0000 Pha
P11268887A1174 |37 53|reference valuesne phosphatases 
P11271297T0000 |0 14|NephrotoxicityP00001606T0076
P11271297T0000 |90 98|patientsrmacolog
P11271297T0000 |75 77|FK00
P11271297T0000 |57 70|cyclosporin A5-nucleotidas
P11271297T0000 |32 53|liver transplantationlkaline phosphatases 
P11273995A1148 |142 157|relaxation time00008997A0472 W
P11273995A1148 |107 117|velocitiess of neona
P11273995A1148 |29 37|subjectsh alkali
P11273995A1148 |46 58|TOF patientsatases and 5
P11274109A0129 |0 7|AcetoinP000016
P11274109A0129 |73 87|carbon sources00008171T0000 
P11274109A0129 |29 37|bacteriah alkali
P11274109A0129 |56 61|phase 5-nu
P11274149A0625 |102 107|basisspect
P11274149A0625 |73 81|proteins00008171
P11274149A0625 |52 63|RING finger and 5-nucl
P11274149A0625 |11 19|analysis076 Comp
P11274149A0625 |133 143|E2 enzymesinemia. P0
P11274149A0625 |36 41|U-boxine p
P11274149A0625 |116 127|interactionatal hyperb
P11274179A0610 |80 90|activation1T0000 Pha
P11274179A0610 |106 116|disruptionts of neon
P11274179A0610 |63 68|Raf-1eotid
P11274179A0610 |44 50|modulephatas
P11274179A0610 |10 17|studies0076 Co
P11274179A0610 |25 38|Rac/Cdc42/Pak with alkalin
P11274184A0000 |0 4|Nrf2P000
P11274184A0000 |75 91|heme oxygenase-1008171T0000 Phar
P11274184A0000 |15 25|expressionComparison
P11274184A0000 |57 68|antioxidant5-nucleotid
P11274184A0000 |29 34|genesh alk
P11274184A0000 |44 51|enzymesphatase
P11274184A0000 |93 97|HO-1colo
P11274184A0000 |114 128|detoxificationonatal hyperbi
P11274184A1068 |69 79|expressionse P000081
P11274184A1068 |6 13|results606T007
P11274184A1068 |28 32|ATF4th a
P11274184A1068 |116 122|manneratal h
P11274184A1068 |141 148|complexP000089
P11274184A1068 |53 57|CdCland 
P11274184A1068 |87 96|ho-1 genePharmacol
P11274184A1068 |154 158|Nrf22 Wh
P11274357A0724 |204 242|nucleoside diphosphate kinase activityCO2 the data of K-depleted rats are no
P11274357A0724 |302 306|form sig
P11274357A0724 |90 96|mutantrmacol
P11274357A0724 |53 57|typeand 
P11274357A0724 |158 162|RhoAen C
P11274357A0724 |248 254|nm23H1r disp
P11274357A0724 |26 40|overexpressionwith alkaline 
P11274357A0724 |147 152|Cdc42997A0
P11274357A0724 |182 187|formsas a 
P11274357A0724 |316 323|GTPases greate
P11274357A0724 |13 17|hand6 Co
P11274357A0724 |132 137|formsbinem
P11274357A0724 |141 145|Rac1P000
P11274357A0724 |100 106|nm23H1 aspec
P11274368A0469 |51 68|protein synthesiss and 5-nucleotid
P11274368A0469 |92 120|histone deacetylase activityacologic aspects of neonatal
P11274368A0469 |5 11|effect1606T0
P11274368A0469 |32 39|absencelkaline
P11274368A0818 |0 8|DeletionP0000160
P11274368A0818 |26 43|initiator elementwith alkaline pho
P11274368A0818 |60 70|repressionucleotidas
P11274368A0818 |94 99|c-Mycologi
P11274368A0818 |78 90|p21 promoter171T0000 Pha
P11274563T0000 |19 29|estimationarison wit
P11274563T0000 |52 59|results and 5-
P11274563T0000 |6 17|lung volume606T0076 Co
P11274563T0000 |33 35|MRka
P11275986A0091 |50 78|p53 tumor suppressor proteines and 5-nucleotidase P00008
P11275986A0091 |7 20|gene products06T0076 Compa
P11275986A0091 |22 24|E6so
P11275986A0091 |113 124|degradationeonatal hyp
P11276426A0501 |68 87|% sequence identityase P00008171T0000 
P11276426A0501 |10 15|Mmip10076 
P11276426A0501 |60 65|shareucleo
P11276426A0501 |3 8|mouse00160
P11276426A0501 |96 104|productsogic asp
P11276426A0501 |40 47|proteinphospha
P11276426A0501 |117 121|genetal 
P11276426A0501 |17 27|Mad membermparison w
P11277913T0000 |101 117|mRNA translationaspects of neona
P11277913T0000 |54 64|Hsp70 mRNAnd 5-nucle
P11277913T0000 |89 97|enhancerarmacolo
P11277913T0000 |38 44|regione phos
P11277913T0000 |3 10|element001606T
P11278286A0456 |139 149|regulation. P0000899
P11278286A0456 |157 167|rat 5-HT1Ahen CSF [H
P11278286A0456 |298 306|promoterve a sig
P11278286A0456 |269 279|inhibitionared to co
P11278286A0456 |79 91|inactivation71T0000 Phar
P11278286A0456 |226 235|inclusioneted rats
P11278286A0456 |49 65|5-HT1A receptorsses and 5-nucleo
P11278286A0456 |184 193|promoters a functi
P11278286A0456 |18 23|cellsparis
P11278286A0456 |114 117|GREona
P11278286A0456 |67 75|deletiondase P00
P11278286A0456 |197 212|corticosteroidsf CSF PCO2 the 
P11278286A0456 |41 43|GRho
P11278286A0456 |37 39|MRne
P11278286A0456 |99 103|nGREc as
P11278286A1083 |103 105|GRpe
P11278286A1083 |76 87|combination08171T0000 
P11278286A1083 |40 50|inhibitionphosphatas
P11278286A1083 |67 72|MR/GRdase 
P11278286A1083 |97 99|MRgi
P11278290A1220 |81 91|activationT0000 Phar
P11278290A1220 |123 128|cellsperbi
P11278290A1220 |44 52|TGF-betaphatases
P11278290A1220 |95 109|Agc expressionlogic aspects 
P11278290A1220 |198 212|Agc expression CSF PCO2 the 
P11278290A1220 |130 146|Smad2 activationrubinemia. P0000
P11278290A1220 |8 13|Smad26T007
P11278290A1220 |189 194|levelnctio
P11278310A1516 |69 90|caspase-3 stimulationse P00008171T0000 Pha
P11278310A1516 |122 133|cell numberyperbilirub
P11278310A1516 |110 118|decreasef neonat
P11278310A1516 |35 41|mutantline p
P11278390A0632 |137 143|levelsia. P0
P11278390A0632 |67 77|PKRDeltaE7dase P0000
P11278390A0632 |8 54|transcriptase-polymerase chain reaction assays6T0076 Comparison with alkaline phosphatases a
P11278390A0632 |117 124|tissuestal hyp
P11278390A0632 |102 107|rangespect
P11278400A0668 |81 92|OCT bindingT0000 Pharm
P11278400A0668 |76 79|POU081
P11278400A0668 |94 114|homeodomain proteinsologic aspects of ne
P11278400A0668 |31 41|cell linesalkaline p
P11278400A0668 |66 72|numberidase 
P11278400A0668 |143 163|mobility shift assay0008997A0472 When CS
P11278440A0095 |0 3|SV1P00
P11278440A0095 |82 84|S100
P11278440A0095 |93 107|hydrophobicitycologic aspect
P11278440A0095 |123 135|S0-S1 linkerperbilirubin
P11278440A0095 |38 61|S1 transmembrane domaine phosphatases and 5-nu
P11278440A0095 |19 30|acid insertarison with
P11278461A0637 |51 62|amino acidss and 5-nuc
P11278461A0637 |120 152|rainbow trout HIF-1alpha protein hyperbilirubinemia. P00008997A0
P11278461A0637 |90 94|partrmac
P11278461A0637 |45 49|parthata
P11278461A0637 |11 21|antibodies076 Compar
P11278461A0637 |182 215|chinook salmon HIF-1alpha proteinas a function of CSF PCO2 the dat
P11278461A0637 |164 177|rainbow trout [HCO3-] is s
P11278461A0637 |219 240|Western blot analysis K-depleted rats are 
P11278461A0637 |96 107|amino acidsogic aspect
P11278488T0000 |84 99|adhesion kinase00 Pharmacologi
P11278488T0000 |61 72|associationcleotidase 
P11278488T0000 |4 20|v-Src SH3 domain01606T0076 Compa
P11278488T0000 |35 39|cellline
P11278521A0849 |169 177|promoter3-] is s
P11278521A0849 |183 206|lacZ reporter constructs a function of CSF PCO
P11278521A0849 |47 54|nonamertases a
P11278521A0849 |10 30|pair oligonucleotide0076 Comparison with
P11278521A0849 |124 129|acidserbil
P11278521A0849 |63 76|up-regulationeotidase P000
P11278521A0849 |92 102|inhibitionacologic a
P11278521A0849 |80 87|hypoxia1T0000 
P11278563A0917 |0 17|Deletion analysesP00001606T0076 Co
P11278563A0917 |72 87|ankyrin repeatsP00008171T0000 
P11278563A0917 |62 67|Grb14leoti
P11278563A0917 |47 58|amino acidstases and 5
P11278563A0917 |127 138|interactionilirubinemi
P11278563A0917 |97 106|tankyrasegic aspec
P11278583A0873 |0 11|MutagenesisP00001606T0
P11278583A0873 |55 70|effector motifsd 5-nucleotidas
P11278583A0873 |263 274|recruitmentn compared 
P11278583A0873 |20 23|IRSris
P11278583A0873 |24 26|CXn 
P11278583A0873 |214 218|Grb2ta o
P11278583A0873 |78 81|SNT171
P11278583A0873 |199 210|recruitmentCSF PCO2 th
P11278583A0873 |347 350|Soss. 
P11278583A0873 |227 249|phosphotyrosine motifsted rats are no longer
P11278583A0873 |44 51|classesphatase
P11278583A0873 |15 19|SNT1Comp
P11278583A0873 |278 282|Shp2ontr
P11278583A0873 |110 124|ERK activationf neonatal hyp
P11278583A0873 |163 185|phosphotyrosine motifsF [HCO3-] is shown as 
P11278583A0873 |138 153|differentiationa. P00008997A04
P11278583A0873 |304 309|motifignif
P11278594A0618 |153 160|chimera72 When
P11278594A0618 |214 230|MIC-1 propeptideta of K-depleted
P11278594A0618 |40 47|chimeraphospha
P11278594A0618 |242 249|peptide longer
P11278594A0618 |21 31|propeptideison with 
P11278594A0618 |80 100|TGF-beta1 propeptide1T0000 Pharmacologic
P11278594A0618 |113 122|secretioneonatal h
P11278594A0618 |71 76|MIC-1 P000
P11278594A0618 |184 195|interaction a function
P11278604A0300 |136 145|CHO cellsmia. P000
P11278604A0300 |194 201|abilityn of CS
P11278604A0300 |151 170|Lec20 cell extracts0472 When CSF [HCO3
P11278604A0300 |214 217|Galta 
P11278604A0300 |56 62|5Lec20 5-nuc
P11278604A0300 |240 249|acceptorsno longer
P11278604A0300 |25 34|N-glycans with alk
P11278604A0300 |114 121|speciesonatal 
P11278610A0902 |18 26|SOCS boxparison 
P11278610A0902 |43 51|Cullin-2sphatase
P11278610A0902 |83 91|TEL-JAK2000 Phar
P11278610A0902 |65 79|ubiquitinationtidase P000081
P11278671T0000 |16 30|Bcl-2 homologyomparison with
P11278671T0000 |88 95|neuronsharmaco
P11278671T0000 |45 59|splice varianthatases and 5-
P11278671T0000 |63 66|Bakeot
P11278671T0000 |131 136|cellsubine
P11278713A1054 |67 71|sitedase
P11278713A1054 |89 109|instability elementsarmacologic aspects 
P11278713A1054 |166 191|coding region determinantHCO3-] is shown as a func
P11278713A1054 |44 48|exonphat
P11278713A1054 |24 30|regionn with
P11278713A1054 |128 139|transcriptslirubinemia
P11278819A0565 |0 19|Sequence comparisonP00001606T0076 Comp
P11278819A0565 |24 39|binding studiesn with alkaline
P11278819A0565 |148 161|half sequence97A0472 When 
P11278819A0565 |66 71|sitesidase
P11278819A0565 |196 208|MOK2 bindingof CSF PCO2 
P11278819A0565 |179 191|core elementwn as a func
P11278819A0565 |83 89|intron000 Ph
P11278819A0565 |114 130|mouse IRBP genesonatal hyperbili
P11278848A1316 |99 104|cellsc asp
P11278848A1316 |44 54|activationphatases a
P11278848A1316 |147 169|Sp1 consensus sequence997A0472 When CSF [HCO
P11278848A1316 |124 131|plasmiderbilir
P11278848A1316 |13 21|SB2035806 Compar
P11278848A1316 |78 95|promoter activity171T0000 Pharmaco
P11278848A1316 |58 61|Sp1-nu
P11278855A0205 |17 28|interactionmparison wi
P11278855A0205 |45 48|p65hat
P11278855A0205 |135 147|Western blotemia. P00008
P11278855A0205 |164 168|cell [HC
P11278855A0205 |90 122|coimmunoprecipitation experimentrmacologic aspects of neonatal h
P11278855A0205 |37 40|TLSne 
P11278855A0205 |66 71|assayidase
P11278870A0123 |0 8|AnalysisP0000160
P11278870A0123 |182 189|elementas a fu
P11278870A0123 |89 102|fission yeastarmacologic a
P11278870A0123 |62 85|copper transporter geneleotidase P00008171T000
P11278870A0123 |225 250|transcription factor Cuf1leted rats are no longer 
P11278870A0123 |191 195|CuSEtion
P11278870A0123 |54 58|ctr4nd 5
P11278870A0123 |23 30|regionson with
P11278870A0123 |38 46|promotere phosph
P11278870A0123 |141 149|identityP0000899
P11278928A1634 |137 158|C/EBPepsilon isoformsia. P00008997A0472 Wh
P11278928A1634 |160 163|p32 CS
P11278928A1634 |90 104|mRNA structurermacologic asp
P11278928A1634 |80 86|effect1T0000
P11278928A1634 |20 24|datariso
P11278928A1634 |108 119|translation of neonata
P11278928A1634 |38 52|mRNA structuree phosphatases
P11278928A1634 |168 171|p30O3-
P11279038A0194 |0 12|WRN helicaseP00001606T00
P11279038A0194 |88 106|Holliday junctionsharmacologic aspec
P11279038A0194 |79 82|DNA71T
P11279038A0194 |32 46|DNA structureslkaline phosph
P11279086A1350 |139 147|activity. P00008
P11279086A1350 |189 199|regulationnction of 
P11279086A1350 |43 48|rolessphat
P11279086A1350 |24 33|ADAM-TS12n with al
P11279086A1350 |62 67|cellsleoti
P11279086A1350 |99 114|tumor processesc aspects of ne
P11279086A1350 |203 216|cell adhesionPCO2 the data
P11279086A1350 |6 10|data606T
P11279086A1350 |81 92|developmentT0000 Pharm
P11279086A1350 |156 164|moleculeWhen CSF
P11279108T0000 |0 7|BindingP000016
P11279108T0000 |11 32|serum response factor076 Comparison with a
P11279108T0000 |134 146|muscle cellsnemia. P0000
P11279108T0000 |36 54|CArG box sequencesine phosphatases a
P11279108T0000 |99 114|gene expressionc aspects of ne
P11279207A0904 |16 23|resultsomparis
P11279207A0904 |60 73|TCR signalingucleotidase P
P11279207A0904 |47 56|componenttases and
P11279207A0904 |33 37|HPK1kali
P11279217A0273 |0 4|BiolP000
P11279324A0710 |16 23|infarctomparis
P11279324A0710 |74 80|method000817
P11279324A0710 |4 8|size0160
P11279324A0710 |49 64|creatine kinaseses and 5-nucle
P11279385A3917 |221 227|method-deple
P11279385A3917 |24 33|techniquen with al
P11279385A3917 |134 141|abilitynemia. 
P11279385A3917 |168 176|pathwaysO3-] is 
P11279385A3917 |189 199|conductionnction of 
P11279385A3917 |67 73|M modedase P
P11279385A3917 |87 89|2DPh
P11279385A3917 |103 110|Dopplerpects o
P11279720A0844 |0 18|SELECTION CRITERIAP00001606T0076 Com
P11279720A0844 |131 140|Parkinsonubinemia.
P11279720A0844 |182 198|levodopa therapyas a function of
P11279720A0844 |107 116|diagnosiss of neon
P11279720A0844 |165 178|complications[HCO3-] is sh
P11279720A0844 |82 90|patients0000 Pha
P11279720A0844 |52 63|cabergoline and 5-nucl
P11279720A0844 |42 48|trialsosphat
P11279720A0844 |143 150|disease0008997
P11279720A0844 |71 78|placebo P00008
P11280495A1330 |0 11|CONCLUSIONSP00001606T0
P11280495A1330 |107 122|Amadori albumins of neonatal h
P11280495A1330 |61 70|PD fluidscleotidas
P11280495A1330 |94 103|formationologic as
P11280495A1330 |127 131|AGEsilir
P11280799A1025 |171 175|IL-8] is
P11280799A1025 |42 50|peptidesosphatas
P11280799A1025 |126 136|antibodiesbilirubine
P11280799A1025 |157 167|productionhen CSF [H
P11280799A1025 |80 95|IL-8 production1T0000 Pharmaco
P11280799A1025 |23 32|PTHrP1-34on with a
P11280799A1025 |191 196|PTHrPtion 
P11280799A1025 |3 11|contrast001606T0
P11281201T0000 |14 21|effects Compar
P11281268A0000 |154 189|sea anemone Anthopleurura japonicus2 When CSF [HCO3-] is shown as a fu
P11281268A0000 |131 134|AKsubi
P11281268A0000 |75 80|times00817
P11281268A0000 |203 235|clam Pseudocardium sachalinensisPCO2 the data of K-depleted rats
P11281268A0000 |37 40|AKsne 
P11281268A0000 |111 129|phosphagen kinases neonatal hyperbil
P11281268A0000 |98 107|evolutionic aspect
P11281268A0000 |19 35|arginine kinasesarison with alka
P11282029A0075 |48 70|beta-receptor promoterases and 5-nucleotidas
P11282029A0075 |123 127|roleperb
P11282029A0075 |135 148|transcriptionemia. P000089
P11282029A0075 |82 93|CCAAT motif0000 Pharma
P11282029A0075 |42 46|PDGFosph
P11282029A0075 |27 40|growth factorith alkaline 
P11282029A0075 |99 103|NF-Yc as
P11282029A0075 |4 9|mouse01606
P11282088A0837 |0 12|Baseline MBFP00001606T00
P11282088A0837 |43 44|Ps
P11282088A0837 |67 72|malesdase 
P11282088A0837 |16 23|femalesomparis
P11282394A0841 |69 89|antigen reactivitiesse P00008171T0000 Ph
P11282394A0841 |127 145|cross-reactivitiesilirubinemia. P000
P11282394A0841 |100 104|mAbs asp
P11282394A0841 |16 28|VH/VL-chainsomparison wi
P11282395A0530 |100 108|activity aspects
P11282395A0530 |37 52|RAG1/2 proteinsne phosphatases
P11282395A0530 |134 149|protein complexnemia. P0000899
P11282395A0530 |157 193|DNA repair proteins Nbs1/Mre11/Rad50hen CSF [HCO3-] is shown as a functi
P11282395A0530 |64 76|DNA hairpinsotidase P000
P11282395A1073 |102 124|kappaL chain gene locispects of neonatal hyp
P11282395A1073 |199 210|individualsCSF PCO2 th
P11282395A1073 |148 165|blood lymphocytes97A0472 When CSF 
P11282395A1073 |172 183|NBS patient is shown a
P11282395A1073 |58 72|CDR3 sequences-nucleotidase 
P11282395A1073 |43 54|differencessphatases a
P11282395A1073 |3 11|addition001606T0
P11282395A1073 |87 97|Ig lambdaLPharmacolo
P11282433T0000 |51 59|patientss and 5-
P11282433T0000 |38 47|etoposidee phospha
P11282433T0000 |9 14|studyT0076
P11282433T0000 |106 122|cell lung cancerts of neonatal h
P11282433T0000 |18 28|paclitaxelparison wi
P11282433T0000 |0 5|PhaseP0000
P11282761A0531 |5 20|supplementation1606T0076 Compa
P11282761A0531 |111 124|NO production neonatal hyp
P11282761A0531 |24 34|L-argininen with alk
P11282761A0531 |59 78|plasma L-citrullinenucleotidase P00008
P11282761A0531 |96 107|enhancementogic aspect
P11283010A0701 |5 15|activation1606T0076 
P11283010A0701 |36 46|CGS 12066Aine phosph
P11283014A0921 |119 123|rolel hy
P11283014A0921 |40 53|transcriptionphosphatases 
P11283014A0921 |4 11|results01606T0
P11283014A0921 |143 163|actin polymerization0008997A0472 When CS
P11283014A0921 |25 29|WASP wit
P11283014A0921 |64 79|TCR stimulationotidase P000081
P11283014A0921 |85 91|manner0 Phar
P11283168A0738 |64 74|expressionotidase P0
P11283168A0738 |166 167|dH
P11283168A0738 |128 143|mid-developmentlirubinemia. P0
P11283168A0738 |111 120|endosperm neonatal
P11283168A0738 |27 32|linesith a
P11283168A0738 |82 90|Gus gene0000 Pha
P11283168A0738 |174 182|anthesiss shown 
P11283256A0258 |69 78|complexesse P00008
P11283256A0258 |32 36|MRCKlkal
P11283354A0548 |6 10|data606T
P11283354A0548 |150 174|heterochromatin assemblyA0472 When CSF [HCO3-] i
P11283354A0548 |135 146|inheritanceemia. P0000
P11283354A0548 |30 37|pathway alkali
P11283354A0548 |57 78|histone modifications5-nucleotidase P00008
P11283354A0548 |92 104|histone codeacologic asp
P11285054A0781 |0 19|Regression analysesP00001606T0076 Comp
P11285054A0781 |91 97|amountmacolo
P11285054A0781 |101 110|REM sleepaspects o
P11285054A0781 |158 166|arousalsen CSF [
P11285054A0781 |172 182|NREM sleep is shown 
P11285054A0781 |32 56|SOREMP dream occurrenceslkaline phosphatases and
P11285054A0781 |118 141|NREMP dream occurrencesal hyperbilirubinemia. 
P11285235A0466 |96 108|GATA factorsogic aspects
P11285235A0466 |9 14|TRPS1T0076
P11285235A0466 |67 77|activationdase P0000
P11285329A0682 |39 44|women phos
P11285329A0682 |46 47|Pa
P11285329A0682 |7 11|% CI06T0
P11285329A0682 |22 32|micromol/Lson with a
P11286833A0959 |171 176|range] is 
P11286833A0959 |64 74|leucovorinotidase P0
P11286833A0959 |6 14|patients606T0076
P11286833A0959 |78 102|maintenance chemotherapy171T0000 Pharmacologic a
P11286833A0959 |132 139|femalesbinemia
P11286833A0959 |164 169|years [HCO
P11286833A0959 |45 59|5-fluorouracilhatases and 5-
P11286833A0959 |35 41|cyclesline p
P11286833A0959 |184 189|years a fu
P11286833A0959 |154 157|age2 W
P11286833A0959 |103 110|RESULTSpects o
P11286833A0959 |119 124|malesl hyp
P11287555A1057 |101 108|CEMx174aspects
P11287555A1057 |113 122|MT4 cellseonatal h
P11287555A1057 |82 96|infectiousness0000 Pharmacol
P11287555A1057 |4 19|Delta6CCI virus01606T0076 Comp
P11287555A1057 |48 68|replication capacityases and 5-nucleotid
P11287578A1311 |0 9|SecretionP00001606
P11287578A1311 |13 26|interleukin-86 Comparison 
P11287578A1311 |60 74|protein 1alphaucleotidase P0
P11287578A1311 |36 46|macrophageine phosph
P11287578A1311 |111 118|protein neonat
P11287578A1311 |28 34|RANTESth alk
P11287578A1311 |153 166|keratinocytes72 When CSF [
P11287578A1311 |170 172|E6-]
P11287579A1084 |16 21|T255Aompar
P11287579A1084 |80 100|late-gene expression1T0000 Pharmacologic
P11287579A1084 |8 14|mutant6T0076
P11287579A1084 |48 54|E4orf6ases a
P11287579A1084 |32 39|abilitylkaline
P11287611A0802 |141 151|expressionP00008997A
P11287611A0802 |91 99|BRL49653macologi
P11287611A0802 |61 64|PGDcle
P11287611A0802 |7 16|PPARgamma06T0076 C
P11287611A0802 |46 53|15d-PGJatases 
P11287611A0802 |104 116|troglitazoneects of neon
P11287611A0802 |82 89|ligands0000 Ph
P11287611A0802 |159 173|cyclin D1 genen CSF [HCO3-] 
P11287623A0286 |190 197|varietyction o
P11287623A0286 |90 93|ERKrma
P11287623A0286 |95 112|signaling pathwaylogic aspects of 
P11287623A0286 |167 184|integrin subunitsCO3-] is shown as
P11287623A0286 |211 227|mouse cell lines data of K-deple
P11287623A0286 |82 88|kinase0000 P
P11287623A0286 |142 152|expression00008997A0
P11287654A0150 |85 95|C terminus0 Pharmaco
P11287654A0150 |60 67|domainsucleoti
P11287654A0150 |18 25|proteinparison
P11287654A0150 |0 4|PABPP000
P11288208A0712 |0 8|ChildrenP0000160
P11288208A0712 |61 64|PCPcle
P11288208A0712 |134 140|monthsnemia.
P11288208A0712 |79 84|rates71T00
P11288208A0712 |41 57|tract infectionshosphatases and 
P11288208A0712 |88 95|declineharmaco
P11288208A0712 |144 148|life0089
P11288208A0712 |99 114|CD4 cell countsc aspects of ne
P11288930A0000 |17 24|effectsmpariso
P11288930A0000 |174 180|matings show
P11288930A0000 |96 100|ratsogic
P11288930A0000 |128 139|generationslirubinemia
P11288930A0000 |199 208|lactationCSF PCO2 
P11288930A0000 |185 194|gestationa functio
P11288930A0000 |155 161|mating When 
P11288930A0000 |81 85|acidT000
P11288930A0000 |32 46|administrationlkaline phosph
P11288930A0000 |87 91|MCPAPhar
P11289135A0975 |102 116|protein kinasespects of neon
P11289135A0975 |332 341|apoptosis1.21 +/- 
P11289135A0975 |227 234|pathwayted rat
P11289135A0975 |208 218|disruptionthe data o
P11289135A0975 |316 328|potentiation greater slo
P11289135A0975 |14 16|FP C
P11289135A0975 |284 299|inhibitor U0126s but still hav
P11289135A0975 |155 177|protein kinase cascade When CSF [HCO3-] is s
P11289135A0975 |260 281|protein kinase kinasewhen compared to cont
P11289135A0975 |66 76|activationidase P000
P11289135A0975 |184 197|PMA treatment a function o
P11289135A0975 |0 10|CoexposureP00001606T
P11289149A0658 |138 141|CBPa. 
P11289149A0658 |77 99|transactivation domain8171T0000 Pharmacologi
P11289149A0658 |10 21|EWS protein0076 Compar
P11289149A0658 |107 115|cofactors of neo
P11289149A0658 |129 136|proteinirubine
P11289149A0658 |33 46|transcriptionkaline phosph
P11290415A0288 |70 79|screeninge P000081
P11290415A0288 |120 132|PCR analysis hyperbiliru
P11290415A0288 |45 66|ICBP90 gene structurehatases and 5-nucleot
P11290415A0288 |15 20|studyCompa
P11290415A0288 |91 99|placentamacologi
P11290415A0288 |108 115|library of neo
P11290906T0000 |27 39|Tl-201 SPECTith alkaline
P11290906T0000 |73 83|infarction00008171T0
P11290906T0000 |11 23|accumulation076 Comparis
P11291552A0156 |0 7|METHODSP000016
P11291552A0156 |13 21|patients6 Compar
P11291552A0156 |52 55|MFH an
P11292335A0852 |70 91|sequence substitutione P00008171T0000 Phar
P11292335A0852 |22 29|dnaE173son wit
P11292335A0852 |40 56|mutator mutationphosphatases and
P11292335A0852 |147 156|frequency997A0472 
P11292335A0852 |173 192|frameshift mutationis shown as a funct
P11292335A0852 |115 125|frameshiftnatal hype
P11292839A0531 |139 148|construct. P000089
P11292839A0531 |30 33|pol al
P11292839A0531 |193 196|TBPon 
P11292839A0531 |184 191|protein a func
P11292839A0531 |56 63|factors 5-nucl
P11292839A0531 |94 103|exceptionologic as
P11292839A0531 |122 130|TATA-boxyperbili
P11292839A0531 |243 248|TBPwtlonge
P11292839A0531 |4 17|transcription01606T0076 Co
P11292839A0531 |198 204|mutant CSF P
P11292839A0531 |228 231|TBPed 
P11292839A0531 |206 213|TBP-DR22 the d
P11292839A0531 |71 78|U6 gene P00008
P11292844A0081 |0 3|HSFP00
P11292844A0081 |42 49|trimersosphata
P11292844A0081 |10 13|DNA007
P11292844A0081 |59 62|DNAnuc
P11292844A0081 |19 25|trimerarison
P11294895A0292 |38 50|gene producte phosphatas
P11294895A0292 |106 111|Sec14ts of
P11294895A0292 |29 34|spo20h alk
P11294895A0292 |123 160|phosphatidylinositol transfer proteinperbilirubinemia. P00008997A0472 When
P11294895A0292 |172 177|yeast is s
P11295470A0954 |84 90|B cell00 Pha
P11295470A0954 |25 47|linkage disequilibrium with alkaline phospha
P11295470A0954 |72 76|siteP000
P11295470A0954 |13 21|evidence6 Compar
P11295470A0954 |129 132|UTRiru
P11295470A0954 |100 108|promoter aspects
P11295523A0218 |49 58|mid-1970sses and 5
P11295523A0218 |6 13|numbers606T007
P11295760A1374 |0 23|Specimen mass reductionP00001606T0076 Comparis
P11295760A1374 |95 99|W/cmlogi
P11295760A1374 |63 64|%e
P11295760A1374 |39 49|irradiance phosphata
P11295760A1374 |80 84|mass1T00
P11296288A1107 |103 112|sequencespects of 
P11296288A1107 |89 94|orf-xarmac
P11296288A1107 |75 78|gag008
P11296288A1107 |45 60|pCMVJS21DeltaGPhatases and 5-n
P11296288A1107 |21 31|derivativeison with 
P11296288A1107 |80 83|pol1T0
P11296288A1107 |148 152|foci97A0
P11296288A1107 |3 11|addition001606T0
P11296288A1107 |35 43|pCMVJS21line pho
P11296442A0565 |102 111|tube sizespects of
P11296442A0565 |45 52|formulahatases
P11296442A0565 |15 24|tube sizeCompariso
P11296442A0565 |38 42|Colee ph
P11296442A0565 |199 208|tube sizeCSF PCO2 
P11296442A0565 |134 144|anesthesianemia. P00
P11296442A0565 |175 182|formula shown 
P11296442A0565 |3 13|conclusion001606T007
P11297419A0894 |3 8|F222W00160
P11297419A0894 |78 85|changes171T000
P11297419A0894 |56 74|fluorescence probe 5-nucleotidase P0
P11297419A0894 |123 130|residueperbili
P11297419A0894 |9 23|W21F rGST A1-1T0076 Comparis
P11297419A0894 |93 104|environmentcologic asp
P11297514A0218 |153 158|genes72 Wh
P11297514A0218 |44 53|inductionphatases 
P11297514A0218 |14 27|hos1 mutation Comparison w
P11297514A0218 |61 86|CBF transcription factorscleotidase P00008171T0000
P11297514A0218 |94 105|temperatureologic aspe
P11297545A0948 |221 224|p38-de
P11297545A0948 |7 19|transfection06T0076 Comp
P11297545A0948 |212 215|hGHdat
P11297545A0948 |111 119|mediator neonata
P11297545A0948 |29 38|CHOP cDNAh alkalin
P11297545A0948 |240 246|mannerno lon
P11297545A0948 |190 199|apoptosisction of 
P11297545A0948 |174 184|protections shown as
P11297545A0948 |52 67|carcinoma cells and 5-nucleoti
P11297545A0948 |86 90|CHOP Pha
P11297545A0948 |138 149|mitogenesisa. P0000899
P11297866A0484 |3 11|contrast001606T0
P11297866A0484 |89 99|propulsionarmacologi
P11297866A0484 |72 74|BFP0
P11297866A0484 |62 68|effectleotid
P11297866A0484 |21 33|I. argentinaison with al
P11297866A0484 |38 49|I. theezanse phosphata
P11298326A0677 |2 12|comparison0001606T00
P11298326A0677 |107 114|regionss of ne
P11298326A0677 |62 71|selectionleotidase
P11298326A0677 |31 43|Vkappa genesalkaline pho
P11298326A0677 |133 138|genesinemi
P11298326A0677 |142 157|point mutations00008997A0472 W
P11301189A1396 |3 11|contrast001606T0
P11301189A1396 |46 51|INK4datase
P11301189A1396 |28 38|expressionth alkalin
P11301189A1396 |106 121|B-lineage cellsts of neonatal 
P11301189A1396 |42 45|p19osp
P11302072A0508 |32 43|stimulationlkaline pho
P11302072A0508 |134 146|interventionnemia. P0000
P11302072A0508 |97 123|Word List Recognition Taskgic aspects of neonatal hy
P11302072A0508 |72 90|Boston Naming TestP00008171T0000 Pha
P11302072A0508 |183 195|significances a function
P11302072A0508 |53 64|performanceand 5-nucle
P11302072A0508 |4 11|results01606T0
P11302566A1318 |19 29|flatteningarison wit
P11302566A1318 |89 108|psychomotor slowingarmacologic aspects
P11302566A1318 |55 84|dopamine receptor sensitivityd 5-nucleotidase P00008171T00
P11302704T0000 |0 20|Homo-oligomerisationP00001606T0076 Compa
P11302704T0000 |33 45|localisationkaline phosp
P11302704T0000 |49 74|mouse histone deacetylaseses and 5-nucleotidase P0
P11303027A0954 |119 128|potentiall hyperbi
P11303027A0954 |75 85|ARF family008171T000
P11303027A0954 |60 67|GTPasesucleoti
P11303027A0954 |6 10|data606T
P11303027A0954 |133 143|cross-talkinemia. P0
P11303027A0954 |28 35|networkth alka
P11303027A0954 |96 105|effectorsogic aspe
P11303027A0954 |39 51|interactions phosphatase
P11303638A0559 |5 23|NEU overexpression1606T0076 Comparis
P11303638A0559 |63 64|%e
P11303638A0559 |31 38|controlalkalin
P11303638A0559 |56 57|% 
P11303638A0559 |66 67|pi
P11303890A0996 |51 57|valuess and 
P11303890A0996 |79 87|microg/l71T0000 
P11303890A0996 |7 11|time06T0
P11303890A0996 |37 42|dosesne ph
P11305129T0000 |68 75|coursesase P00
P11305129T0000 |29 43|tetanus toxoidh alkaline pho
P11305129T0000 |13 25|booster dose6 Comparison
P11305129T0000 |126 134|globulinbilirubi
P11305129T0000 |92 104|implicationsacologic asp
P11305129T0000 |79 90|vaccination71T0000 Pha
P11305129T0000 |112 115|useneo
P11305129T0000 |0 7|EffectsP000016
P11306101A0000 |191 213|3alpha-hydroxysteroidstion of CSF PCO2 the d
P11306101A0000 |163 186|17beta-hydroxy-steroidsF [HCO3-] is shown as a
P11306101A0000 |145 153|alcohols08997A04
P11306101A0000 |62 75|hamster liverleotidase P00
P11306101A0000 |6 21|RACE techniques606T0076 Compar
P11306101A0000 |99 113|dehydrogenasesc aspects of n
P11306463A0383 |34 39|L901Qaline
P11306463A0383 |18 26|C domainparison 
P11306463A0383 |127 135|C domainilirubin
P11306463A0383 |30 32|Rb a
P11306463A0383 |2 10|mutation0001606T
P11306463A0383 |87 110|cdk4/D1 phosphorylationPharmacologic aspects o
P11306511A1476 |3 14|association001606T0076
P11306511A1476 |123 144|progesterone receptorperbilirubinemia. P00
P11306511A1476 |44 54|expressionphatases a
P11306511A1476 |98 108|mdm2 mRNAsic aspects
P11306511A1476 |115 119|lacknata
P11306845A0168 |64 81|blister formationotidase P00008171
P11306845A0168 |13 24|examination6 Compariso
P11306845A0168 |42 49|changesosphata
P11306845A0168 |96 109|keratinocytesogic aspects 
P11308851A0333 |17 34|response functionmparison with alk
P11308851A0333 |127 146|material parametersilirubinemia. P0000
P11308851A0333 |93 108|frequency rangecologic aspects
P11308851A0333 |63 67|GSEReoti
P11308851A0333 |159 163|beadn CS
P11308851A0333 |172 179|network is sho
P11308877A0213 |84 96|input phases00 Pharmacol
P11308877A0213 |112 127|discharge timesneonatal hyperb
P11308877A0213 |67 75|relationdase P00
P11308877A0213 |46 49|mapata
P11308877A0213 |173 206|orientation preserving circle mapis shown as a function of CSF PCO
P11308877A0213 |35 40|inputline 
P11309077A0953 |50 56|jejunies and
P11309077A0953 |36 42|jejuniine ph
P11309077A0953 |94 104|biotype I.ologic asp
P11309077A0953 |30 34|Camp alk
P11309077A0953 |5 12|strains1606T00
P11309077A0953 |86 90|ones Pha
P11309373A0783 |0 8|AnalysisP0000160
P11309373A0783 |78 82|rise171T
P11309373A0783 |63 72|promoterseotidase 
P11309373A0783 |12 22|mCTR mRNAs76 Compari
P11309373A0783 |173 180|regionsis show
P11309373A0783 |199 206|lengthsCSF PCO
P11309373A0783 |125 131|regionrbilir
P11309373A0783 |101 114|mCTR isoformsaspects of ne
P11309373A0783 |139 143|gene. P0
P11309389A0273 |288 303|down-regulationt still have a 
P11309389A0273 |124 127|PMAerb
P11309389A0273 |193 197|GHBPon o
P11309389A0273 |31 42|proteolysisalkaline ph
P11309389A0273 |224 227|GHRple
P11309389A0273 |325 337|GH signalingslope (1.21 
P11309389A0273 |144 168|metalloprotease activity008997A0472 When CSF [HC
P11309389A0273 |77 122|phorbol ester phorbol 12-myristate 13-acetate8171T0000 Pharmacologic aspects of neonatal h
P11309389A0273 |307 320|GHR abundanceificantly gre
P11309389A0273 |254 268|domain remnantlaced when com
P11309400T0000 |0 7|EffectsP000016
P11309400T0000 |56 61|decay 5-nu
P11309400T0000 |14 36|terminus modifications Comparison with alkal
P11309400T0000 |40 44|mRNAphos
P11309400T0000 |78 95|protein synthesis171T0000 Pharmaco
P11309677A0000 |136 140|GV-Fmia.
P11309677A0000 |127 134|fatigueilirubi
P11309677A0000 |167 171|GV-HCO3-
P11309677A0000 |157 165|veteranshen CSF 
P11309677A0000 |80 96|Gulf War Illness1T0000 Pharmacol
P11309677A0000 |66 74|veteransidase P0
P11309677A0000 |98 101|GWIic 
P11309677A0000 |35 42|batteryline ph
P11309678A0489 |117 125|splicingtal hype
P11309678A0489 |38 42|mRNAe ph
P11309678A0489 |8 34|transcription-PCR analysis6T0076 Comparison with alk
P11309678A0489 |48 56|patientsases and
P11309678A0489 |87 96|mutationsPharmacol
P11310937A0548 |119 122|CRPl h
P11310937A0548 |56 60|time 5-n
P11310937A0548 |242 250|tertiles longer 
P11310937A0548 |167 174|tertileCO3-] i
P11310937A0548 |107 114|tertiles of ne
P11310937A0548 |194 203|TNF-alphan of CSF 
P11310937A0548 |67 73|monthsdase P
P11310937A0548 |127 131|IL-6ilir
P11310937A0548 |179 189|fibrinogenwn as a fu
P11310937A0548 |18 27|mortalityparison w
P11310937A0548 |0 7|RESULTSP000016
P11311153T0000 |117 123|enzymetal hy
P11311153T0000 |74 86|polymorphism0008171T0000
P11311153T0000 |4 16|relationship01606T0076 C
P11311153T0000 |24 48|factor V Leiden mutationn with alkaline phosphat
P11311153T0000 |94 105|angiotensinologic aspe
P11311153T0000 |141 162|thromboembolic eventsP00008997A0472 When C
P11311153T0000 |185 197|arthroplastya function o
P11311464A0362 |68 76|sciaticaase P000
P11311464A0362 |150 169|bladder dysfunctionA0472 When CSF [HCO
P11311464A0362 |134 144|paraplegianemia. P00
P11311464A0362 |83 97|motor weakness000 Pharmacolo
P11311464A0362 |6 15|disorders606T0076 
P11311464A0362 |111 122|extremities neonatal h
P11311464A0362 |39 56|saddle anesthesia phosphatases and
P11311464A0362 |33 37|painkali
P11311480A0079 |154 158|loss2 Wh
P11311480A0079 |126 137|perineuriumbilirubinem
P11311480A0079 |71 82|alterations P00008171T
P11311480A0079 |6 18|nerve biopsy606T0076 Com
P11311480A0079 |189 195|fibersnction
P11311480A0079 |101 118|cell infiltrationaspects of neonat
P11311480A0079 |49 60|perineuriumses and 5-n
P11311550A0253 |220 235|rat cardiocytesK-depleted rats
P11311550A0253 |145 153|elements08997A04
P11311550A0253 |27 37|regulationith alkali
P11311550A0253 |208 216|culturesthe data
P11311550A0253 |120 132|contribution hyperbiliru
P11311550A0253 |75 100|rat eIF4E promoter region008171T0000 Pharmacologic
P11311550A0253 |45 59|rat eIF4E genehatases and 5-
P11311550A0253 |168 181|transcriptionO3-] is shown
P11311550A0253 |262 280|myoblast cell lineen compared to con
P11311550A0253 |65 67|kBti
P11311550A0253 |252 253|Cs
P11311550A0253 |256 257|Cc
P11311563A0423 |113 122|CCAAT boxeonatal h
P11311563A0423 |73 85|OA induction00008171T000
P11311563A0423 |10 19|CCAAT box0076 Comp
P11311563A0423 |53 71|promoter constructand 5-nucleotidase
P11311687A0231 |34 41|studiesaline p
P11311687A0231 |107 115|relations of neo
P11311687A0231 |142 151|morbidity00008997A
P11311687A0231 |52 64|RLS severity and 5-nucle
P11311687A0231 |126 134|measuresbilirubi
P11311687A0231 |4 10|JHRLSS01606T
P11311687A0231 |168 171|RLSO3-
P11311909A0938 |17 21|casempar
P11311909A0938 |27 35|aneurysmith alka
P11311909A0938 |65 68|endtid
P11311909A0938 |87 102|A1 fenestrationPharmacologic a
P11311980A1049 |0 4|GABAP000
P11311980A1049 |5 6|B1
P11311980A1049 |7 10|R1g06T
P11311980A1049 |54 61|tissuesnd 5-nu
P11311980A1049 |33 38|brainkalin
P11312108A2853 |0 4|RaesP000
P11312108A2853 |6 8|P.60
P11312120A1311 |0 28|NF-kappaB pathway activationP00001606T0076 Comparison wi
P11312120A1311 |121 124|Rashyp
P11312120A1311 |91 100|oncogenesmacologic
P11312120A1311 |112 119|Bcr/Ablneonata
P11312120A1311 |129 132|Raciru
P11312120A1311 |43 57|transformationsphatases and 
P11312120A1311 |173 182|potentialis shown 
P11312120A1311 |71 77|number P0000
P11312326A0169 |207 213|genome the d
P11312326A0169 |10 13|rev007
P11312326A0169 |62 67|cloneleoti
P11312326A0169 |135 144|isolationemia. P00
P11312326A0169 |241 258|virus replicationo longer displace
P11312326A0169 |45 50|HIV-1hatas
P11312326A0169 |114 120|methodonatal
P11312326A0169 |231 237|rescuerats a
P11312326A0169 |179 187|elementswn as a 
P11312326A0169 |33 41|HIV typekaline p
P11312326A0169 |71 98|complementation experiments P00008171T0000 Pharmacolog
P11312584X1846 |0 9|CopyrightP00001606
P11312584X1846 |15 29|Academic PressComparison wit
P11313249T0000 |98 115|activation domainic aspects of neo
P11313249T0000 |60 67|proteinucleoti
P11313249T0000 |27 36|zebrafishith alkal
P11313342A0224 |65 86|center cleft residuestidase P00008171T0000
P11313342A0224 |161 164|PAPCSF
P11313342A0224 |29 50|alanine substitutionsh alkaline phosphatas
P11313342A0224 |149 157|activity7A0472 W
P11313342A0224 |129 137|ribosomeirubinem
P11313342A0224 |112 124|depurinatingneonatal hyp
P11313386A0704 |0 21|SH2D1A protein levelsP00001606T0076 Compar
P11313386A0704 |42 60|CD40 cross-linkingosphatases and 5-n
P11313386A0704 |83 107|B cell receptor ligation000 Pharmacologic aspect
P11313398A0687 |0 22|Cross-linking FcalphaRP00001606T0076 Compari
P11313398A0687 |109 117|PKBalphaof neona
P11313398A0687 |26 33|wt-ITAMwith al
P11313398A0687 |73 75|PI00
P11313398A0687 |95 105|activationlogic aspe
P11313398A0687 |37 51|IIA-ITAM cellsne phosphatase
P11313946A0449 |85 90|M-Ras0 Pha
P11313946A0449 |95 102|p21 Raslogic a
P11313946A0449 |28 33|Nore1th al
P11313946A0449 |19 23|AF-6aris
P11313946A0449 |0 8|RPM/RGL3P0000160
P11313946T0000 |69 72|p21se 
P11313946T0000 |40 47|p21 Rasphospha
P11313946T0000 |105 116|cell growthcts of neon
P11313946T0000 |30 35|M-Ras alka
P11313946T0000 |18 26|effectorparison 
P11313946T0000 |86 100|gene induction Pharmacologic
P11313961A1323 |85 88|age0 P
P11313961A1323 |151 159|p53 gene0472 Whe
P11313961A1323 |66 72|tumorsidase 
P11313961A1323 |93 101|contrastcologic 
P11313961A1323 |126 133|strainsbilirub
P11313961A1323 |4 8|mice0160
P11313961A1323 |116 119|p53ata
P11314030A1264 |119 122|FAKl h
P11314030A1264 |111 114|Abl ne
P11314030A1264 |40 46|regionphosph
P11314030A1264 |208 211|SH3the
P11314030A1264 |133 148|signal pathwaysinemia. P000089
P11314030A1264 |194 200|regionn of C
P11314030A1264 |83 91|elements000 Phar
P11314030A1264 |163 171|paradigmF [HCO3-
P11314030A1264 |230 240|SH3 domain rats are 
P11314030A1264 |4 11|results01606T0
P11314030A1264 |50 53|Crkes 
P11314046A0000 |0 7|CyclinsP000016
P11314046A0000 |31 43|determinantsalkaline pho
P11314046A0000 |55 77|cell cycle progressiond 5-nucleotidase P0000
P11314373T0000 |27 34|formulaith alk
P11314373T0000 |15 19|careComp
P11314373T0000 |46 53|problematases 
P11314428A0651 |170 171|P-
P11314428A0651 |29 36|abilityh alkal
P11314428A0651 |122 146|months width differencesyperbilirubinemia. P0000
P11314428A0651 |44 58|hydroxyapatitephatases and 5
P11314428A0651 |181 184|LHS as
P11314428A0651 |98 110|significanceic aspects o
P11314428A0651 |66 73|socketsidase P
P11314428A0651 |162 168|regionSF [HC
P11314428A0651 |190 191|Pc
P11314428A0651 |201 204|RHSF P
P11315633A0920 |34 37|RNAali
P11315633A0920 |26 29|VPgwit
P11315633A0920 |106 134|amino acid sequence analysists of neonatal hyperbilirubi
P11315633A0920 |4 17|cleavage site01606T0076 Co
P11315633A0920 |83 92|E445-T446000 Pharm
P11315633A0920 |142 153|polyprotein00008997A04
P11315633A0920 |48 62|RNA polymeraseases and 5-nuc
P11315633A0920 |169 182|sobemoviruses3-] is shown 
P11316127A0485 |64 70|valuesotidas
P11316127A0485 |89 103|Control groupsarmacologic as
P11316127A0485 |14 19|HCM-I Comp
P11316127A0485 |78 84|HCM-II171T00
P11316127A0485 |4 10|%SVend01606T
P11317256A0361 |136 143|abscessmia. P0
P11317256A0361 |47 55|isolatestases an
P11317256A0361 |23 37|S. intermediuson with alkali
P11317256A0361 |59 74|S. constellatusnucleotidase P0
P11317256A0361 |11 19|isolates076 Comp
P11317256A0361 |101 113|S. anginosusaspects of n
P11317256A0361 |87 88|%P
P11318363A0085 |0 6|DESIGNP00001
P11318363A0085 |22 27|studyson w
P11318608A0669 |48 61|amplificationases and 5-nu
P11318608A0669 |133 146|reading frameinemia. P0000
P11318608A0669 |183 190|proteins a fun
P11318608A0669 |241 245|NLSso lo
P11318608A0669 |219 239|localization signals K-depleted rats are
P11318608A0669 |267 274|regionsmpared 
P11318608A0669 |95 105|DENTT cDNAlogic aspe
P11318608A0669 |6 34|brain cDNA library screening606T0076 Comparison with alk
P11318608A0669 |65 69|cDNAtida
P11318608A1155 |0 12|TransfectionP00001606T00
P11318608A1155 |28 57|DENTT NLS deletion constructsth alkaline phosphatases and 
P11318608A1155 |109 118|nucleolusof neonat
P11318608A1155 |80 85|NLS-11T000
P11319098A0164 |154 162|addition2 When C
P11319098A0164 |209 225|LacI-GalR familyhe data of K-dep
P11319098A0164 |166 170|PkwRHCO3
P11319098A0164 |44 78|protein translocase component SecEphatases and 5-nucleotidase P00008
P11319098A0164 |194 201|proteinn of CS
P11319098A0164 |6 11|genes606T0
P11319098A0164 |131 143|proteins L11ubinemia. P0
P11319098A0164 |148 150|L197
P11319098A0164 |99 111|protein NusGc aspects of
P11319098A0164 |21 38|tryptophanyl tRNAison with alkalin
P11319880A1108 |0 9|RapamycinP00001606
P11319880A1108 |11 30|FRAP/mTOR inhibitor076 Comparison with
P11319880A1108 |73 85|predominance00008171T000
P11319880A1108 |120 124|band hyp
P11319880A1108 |40 62|4E-BP1 phosphorylationphosphatases and 5-nuc
P11319880A1108 |93 98|alphacolog
P11321187A0355 |70 79|synthesise P000081
P11321187A0355 |31 42|MS patientsalkaline ph
P11321187A0355 |83 85|C.00
P11321187A0355 |142 150|controls00008997
P11321187A0355 |106 109|IgGts 
P11321187A0355 |48 49|%a
P11321187A0355 |155 156|% 
P11323411A0505 |0 25|Far Western blot analysisP00001606T0076 Comparison
P11323411A0505 |67 71|SHP2dase
P11323411A0505 |52 63|SH2 domains and 5-nucl
P11323411A0505 |125 137|N-SH2 domainrbilirubinem
P11323411A0505 |147 162|phosphotyrosine997A0472 When C
P11323411A0505 |210 211|Pe
P11323411A0505 |164 167|Tyr [H
P11323411A0505 |168 169|PO
P11323411A0505 |99 110|orientationc aspects o
P11323411A0505 |80 84|Gab11T00
P11323411A0505 |206 209|Tyr2 t
P11323411A0505 |184 196|C-SH2 domain a function 
P11323419T0000 |143 167|mouse uterine epithelium0008997A0472 When CSF [H
P11323419T0000 |90 114|fucosyltransferase genesrmacologic aspects of ne
P11323419T0000 |40 50|expressionphosphatas
P11323419T0000 |27 34|mappingith alk
P11323419T0000 |10 17|cloning0076 Co
P11323419T0000 |67 84|blood group alphadase P00008171T00
P11323419T0000 |189 194|tractnctio
P11323716A0413 |19 24|RAD23ariso
P11323716A0413 |29 33|DDI1h al
P11323716A0413 |57 69|interactions5-nucleotida
P11323716A0413 |4 15|UBA domains01606T0076 
P11324516A0159 |87 121|D1/D2 receptor agonist apomorphinePharmacologic aspects of neonatal 
P11324516A0159 |30 44|administration alkaline phos
P11324516A0159 |46 50|i.t.atas
P11324516A0159 |132 146|pain thresholdbinemia. P0000
P11324516A0159 |180 182|AAn 
P11324516A0159 |157 176|potentiating effecthen CSF [HCO3-] is 
P11324516A0159 |55 83|D2 receptor agonist LY171555d 5-nucleotidase P00008171T0
P11325195A0661 |68 72|lambase 
P11325195A0661 |77 93|pork longissimus8171T0000 Pharma
P11325195A0661 |15 18|MFICom
P11325195A0661 |39 45|muscle phosp
P11325195A0661 |4 6|R201
P11325391A0498 |69 79|saline keyse P000081
P11325391A0498 |91 100|schedulesmacologic
P11325391A0498 |10 15|doses0076 
P11325391A0498 |19 32|d-amphetaminearison with a
P11325685A1624 |103 110|fatiguepects o
P11325685A1624 |12 33|L-carnitine treatment76 Comparison with al
P11325685A1624 |132 139|declinebinemia
P11325685A1624 |44 75|plasma carnitine concentrationsphatases and 5-nucleotidase P00
P11325685A1624 |148 165|exercise capacity97A0472 When CSF 
P11325685A1624 |169 190|hemodialysis patients3-] is shown as a fun
P11325944A0511 |35 39|UhpBline
P11325944A0511 |9 19|expressionT0076 Comp
P11325944A0511 |56 70|hybrid protein 5-nucleotidas
P11325944A0511 |227 230|uhpted
P11325944A0511 |89 114|glutathione S-transferasearmacologic aspects of ne
P11325944A0511 |72 78|GST-BcP00008
P11325944A0511 |194 202|blockagen of CSF
P11325944A0511 |116 119|GSTata
P11325944A0511 |234 240|strains are 
P11325944A0511 |157 164|portionhen CSF
P11325944A0511 |168 172|UhpBO3-]
P11325944A0511 |206 221|uhpT expression2 the data of K
P11327292A0190 |68 72|riskase 
P11327292A0190 |98 104|visionic asp
P11327292A0190 |12 20|location76 Compa
P11327292A0190 |86 90|loss Pha
P11327292A0190 |34 46|malformationaline phosph
P11327698A0191 |445 450|U0126or us
P11327698A0191 |252 263|HepG2 cellssplaced whe
P11327698A0191 |18 21|PKCpar
P11327698A0191 |459 478|Sp1 phosphorylationral practice being 
P11327698A0191 |158 161|PMAen 
P11327698A0191 |355 366|IGF-II mRNA0943A0733 F
P11327698A0191 |386 397|HepG2 cellsrs to be an
P11327698A0191 |95 104|IGF-II P4logic asp
P11327698A0191 |26 48|p44/p42MAPK signalingswith alkaline phosphat
P11327698A0191 |270 284|PKC inhibitionred to control
P11327698A0191 |480 491|P4 activity mg at nigh
P11327698A0191 |121 129|activityhyperbil
P11327698A0191 |496 507|IGF-II mRNA0012653T004
P11327698A0191 |317 336|Sp1 phosphorylationgreater slope (1.21
P11327698A0191 |165 186|PKC expression vector[HCO3-] is shown as a
P11327698A0191 |288 308|PKC inhibitor Go6976t still have a signi
P11327698A0191 |221 232|P4 activity-depleted r
P11327698A0191 |427 441|MEK activationthe optimum do
P11327698A0191 |413 423|inhibitiontic drug w
P11327698A0191 |197 216|Sp1 phosphorylationf CSF PCO2 the data
P11327698A0191 |527 538|HepG2 cellsts. P000136
P11327698A0191 |140 154|PKC activation P00008997A047
P11327698A0191 |338 349|P4 activity/- 0.23 vs.
P11327858A0087 |18 28|mechanismsparison wi
P11327858A0087 |47 63|oncoprotein Hdm2tases and 5-nucl
P11327858A0087 |30 33|Arf al
P11327858A0087 |89 92|p53arm
P11327858A0087 |76 85|regulator08171T000
P11328699A0000 |85 89|wall0 Ph
P11328699A0000 |58 62|time-nuc
P11328699A0000 |72 77|closeP0000
P11328699A0000 |30 39|test mice alkaline
P11328699A0000 |145 159|test situation08997A0472 Whe
P11328699A0000 |97 106|containergic aspec
P11328853A0644 |0 11|ExaminationP00001606T0
P11328853A0644 |95 110|promoter regionlogic aspects o
P11328853A0644 |124 142|promoter sequenceserbilirubinemia. P
P11328853A0644 |23 48|promoter deletion mutantson with alkaline phosphat
P11328853A0644 |64 68|SF-1otid
P11331589A0113 |49 66|male X chromosomeses and 5-nucleot
P11331589A0113 |83 93|expression000 Pharma
P11331589A0113 |4 15|MSL complex01606T0076 
P11331596A0710 |0 4|PrrpP000
P11331596A0710 |33 44|EVH1 domainkaline phos
P11331596A0710 |48 52|Menaases
P11331596A0710 |87 94|proteinPharmac
P11331604A0267 |0 5|Srb10P0000
P11331604A0267 |121 134|srb10 mutantshyperbilirubi
P11331604A0267 |38 52|Gcn4 stabilitye phosphatases
P11331604A0267 |66 81|phosphorylationidase P00008171
P11331604A0267 |25 34|regulator with alk
P11331604A0267 |98 102|Gcn4ic a
P11331604A0267 |86 94|turnover Pharmac
P11331613A0827 |80 88|subclass1T0000 P
P11331613A0827 |11 18|effects076 Com
P11331613A0827 |58 67|mutations-nucleoti
P11331613A0827 |22 35|pVHL functionson with alka
P11333263A0240 |48 54|middleases a
P11333263A0240 |78 93|leader sequence171T0000 Pharma
P11333263A0240 |132 149|promoter activitybinemia. P0000899
P11333263A0240 |6 12|intron606T00
P11333263A0240 |20 30|base pairsrison with
P11333268A1521 |205 208|RasO2 
P11333268A1521 |246 252|switchger di
P11333268A1521 |212 215|Sosdat
P11333268A1521 |264 274|disruption compared 
P11333268A1521 |95 102|regionslogic a
P11333268A1521 |301 305|sitea si
P11333268A1521 |60 63|Sosucl
P11333268A1521 |192 201|anchoringion of CS
P11333268A1521 |14 22|analysis Compari
P11333268A1521 |44 56|interactionsphatases and
P11333268A1521 |135 147|consequencesemia. P00008
P11333268A1521 |153 164|interaction72 When CSF
P11333268A1521 |86 92|switch Pharm
P11333268A1521 |229 240|interactiond rats are 
P11333268A1521 |106 109|Rasts 
P11333268A1521 |73 79|switch000081
P11333268A1521 |310 326|GDP dissociationcantly greater s
P11333268A1521 |170 176|switch-] is 
P11334124A0903 |119 129|dose rangel hyperbil
P11334124A0903 |56 64|increase 5-nucle
P11334124A0903 |13 26|dose-response6 Comparison 
P11334124A0903 |84 92|AUC0-6 h00 Pharm
P11334124A0903 |81 82|hT
P11334124A0903 |146 154|Respimat8997A047
P11334124A0903 |103 107|FEV1pect
P11334124A0903 |68 72|FEV1ase 
P11335116A1099 |0 21|Bandshift experimentsP00001606T0076 Compar
P11335116A1099 |211 217|BmHR3A data 
P11335116A1099 |202 206|role PCO
P11335116A1099 |282 296|vitellogenesisols but still 
P11335116A1099 |135 144|sequencesemia. P00
P11335116A1099 |152 161|promoters472 When 
P11335116A1099 |250 260|BmGATAbetadisplaced 
P11335116A1099 |265 274|ESP genescompared 
P11335116A1099 |236 246|expressionare no lon
P11335116A1099 |39 45|BmHR3A phosp
P11335116A1099 |96 128|Orphan receptor Response Elementogic aspects of neonatal hyperbi
P11335116A1099 |170 175|genes-] is
P11335116A1099 |68 72|ROREase 
P11335710A0320 |53 67|Erk activationand 5-nucleoti
P11335710A0320 |44 49|phasephata
P11336211A0132 |33 42|Bengtssonkaline ph
P11336211A0132 |14 20|method Compa
P11336211A0132 |44 48|Applphat
P11336698A0075 |70 97|yeast remodeler RSC complexe P00008171T0000 Pharmacolo
P11336698A0075 |27 32|Rsc30ith a
P11336698A0075 |42 52|componentsosphatases
P11336698A0075 |18 22|Rsc3pari
P11337859A0651 |49 50|%s
P11337859A0651 |56 61|FeCl3 5-nu
P11337859A0651 |12 26|color removals76 Comparison 
P11337859A0651 |226 237|H2O2 dosageeted rats a
P11337859A0651 |180 220|hydrogen peroxide oxidation pretreatmentn as a function of CSF PCO2 the data of 
P11337859A0651 |91 98|dosagesmacolog
P11337859A0651 |144 149|mol/L00899
P11337859A0651 |111 122|coagulation neonatal h
P11337859A0651 |78 89|coagulation171T0000 Ph
P11337859A0651 |246 251|mol/Lger d
P11337859A0651 |4 7|COD016
P11340048A0432 |50 64|flux densitieses and 5-nucle
P11340048A0432 |95 102|sensorslogic a
P11340048A0432 |26 37|correlationwith alkali
P11340048A0432 |135 149|flux densitiesemia. P0000899
P11340048A0432 |173 180|sensorsis show
P11340048A0432 |116 127|differencesatal hyperb
P11340080A0096 |34 54|checkpoint signalingaline phosphatases a
P11340080A0096 |13 21|proteins6 Compar
P11340080A0096 |150 157|studiesA0472 W
P11340080A0096 |133 138|yeastinemi
P11340080A0096 |72 76|Rad9P000
P11340080A0096 |62 66|Hus1leot
P11340080A0096 |56 60|Rad1 5-n
P11340080A0096 |109 128|immunoprecipitationof neonatal hyperbi
P11340085A0211 |205 209|frogO2 t
P11340085A0211 |196 203|speciesof CSF 
P11340085A0211 |147 166|amino acid sequence997A0472 When CSF [
P11340085A0211 |286 308|transactivation domainbut still have a signi
P11340085A0211 |13 23|hypothesis6 Comparis
P11340085A0211 |257 264|regionsed when
P11340085A0211 |54 61|regionsnd 5-nu
P11340085A0211 |266 273|CR1-CR4ompared
P11340085A0211 |117 129|coactivatorstal hyperbil
P11340085A0211 |170 180|C/EBPalpha-] is show
P11340516A0509 |0 9|ToleranceP00001606
P11340516A0509 |74 80|ADAL-2000817
P11340516A0509 |61 70|tolerancecleotidas
P11340516A0509 |105 114|Tisuacrylcts of ne
P11340516A0509 |13 19|ADAL-26 Comp
P11340516A0509 |43 56|Vicryl suturesphatases and
P11340525A0737 |119 128|regimen Bl hyperbi
P11340525A0737 |146 147|%8
P11340525A0737 |108 109|% 
P11340525A0737 |74 75|%0
P11340525A0737 |44 60|study end pointsphatases and 5-n
P11340525A0737 |157 166|regimen Chen CSF [
P11340525A0737 |7 15|patients06T0076 
P11340525A0737 |24 31|regimenn with 
P11340525A0737 |175 202|treatment success criterion shown as a function of CSF
P11340525A0737 |85 94|regimen A0 Pharmac
P11341349T0000 |83 88|women000 P
P11341349T0000 |24 30|effectn with
P11341349T0000 |6 16|indicators606T0076 C
P11341349T0000 |36 67|breast cancer screening programine phosphatases and 5-nucleoti
P11341405A0146 |19 22|MCBari
P11341405A0146 |7 17|POPULATION06T0076 Co
P11341405A0146 |30 47|racing Greyhounds alkaline phospha
P11341405A0146 |65 72|reasonstidase 
P11341405A0146 |86 103|MCB abnormalities Pharmacologic as
P11341405A1154 |0 11|CONCLUSIONSP00001606T0
P11341405A1154 |249 258|responses displace
P11341405A1154 |25 34|RELEVANCE with alk
P11341405A1154 |335 341|tracks1 +/- 
P11341405A1154 |177 184|osteonshown as
P11341405A1154 |149 157|turnover7A0472 W
P11341405A1154 |316 322|racing great
P11341405A1154 |192 208|dorsal quadrantsion of CSF PCO2 
P11341405A1154 |55 64|thicknessd 5-nucle
P11341405A1154 |115 125|Greyhoundsnatal hype
P11341405A1154 |293 300|loadingll have
P11341405A1154 |217 220|MCBof 
P11341405A1154 |110 111|Vf
P11341405A1154 |162 173|orientationSF [HCO3-] 
P11341405A1154 |79 89|properties71T0000 Ph
P11341405A1154 |98 104|MCB-IVic asp
P11341405A1154 |306 312|resultnifica
P11341828A0744 |94 103|moleculesologic as
P11341828A0744 |30 40|D-peptides alkaline 
P11341828A0744 |73 79|domain000081
P11342479A0430 |152 163|evaporation472 When CS
P11342479A0430 |63 73|paclitaxeleotidase P
P11342479A0430 |12 19|RESULTS76 Comp
P11342479A0430 |21 41|Palmaz-Schatz stentsison with alkaline p
P11342479A0430 |114 123|immersiononatal hy
P11342479A0430 |94 109|microgram/stentologic aspects 
P11342479A0430 |0 7|METHODSP000016
P11342479A0430 |137 147|paclitaxelia. P00008
P11344530A0320 |0 11|PercentagesP00001606T0
P11344530A0320 |28 36|overloadth alkal
P11344530A0320 |15 23|recoveryComparis
P11344530A0320 |41 55|dilution testshosphatases an
P11344530A0320 |79 80|%7
P11345435A0199 |48 50|P3as
P11345435A0199 |107 119|localizations of neonata
P11345435A0199 |21 35|RNA subdomainsison with alka
P11345445A0533 |187 201|concentrationsfunction of CS
P11345445A0533 |108 119|springtails of neonata
P11345445A0533 |13 22|OECD soil6 Compari
P11345445A0533 |163 165|ZnF 
P11345445A0533 |77 94|Cd concentrations8171T0000 Pharmac
P11345445A0533 |146 152|levels8997A0
P11345445A0533 |156 158|CuWh
P11345445A0533 |33 42|Cd levelskaline ph
P11347201X0001 |68 78|BACKGROUNDase P00008
P11347201X0001 |110 119|vitamin Df neonata
P11347201X0001 |131 134|n-3ubi
P11347201X0001 |62 66|dietleot
P11347201X0001 |80 90|Plant food1T0000 Pha
P11347201X0001 |97 108|vitamin B12gic aspects
P11347201X0001 |22 28|adultsson wi
P11347201X0001 |157 162|acidshen C
P11347201X0001 |0 18|Nutritional statusP00001606T0076 Com
P11348318A0940 |51 59|patientss and 5-
P11348318A0940 |88 95|breastsharmaco
P11348318A0940 |104 120|characterizationects of neonatal
P11348318A0940 |30 41|mammography alkaline p
P11348318A0940 |133 139|massesinemia
P11348318A0940 |19 26|adjunctarison 
P11349796A0950 |0 12|MeasurementsP00001606T00
P11349796A0950 |79 83|days71T0
P11349796A0950 |132 136|daysbine
P11349796A0950 |67 69|D0da
P11349796A0950 |144 147|D30008
P11349796A0950 |57 65|exposure5-nucleo
P11349796A0950 |114 116|D3on
P11349796A0950 |101 112|measurementaspects of 
P11350038A0459 |84 98|stem structure00 Pharmacolog
P11350038A0459 |47 51|Stemtase
P11350038A0459 |142 146|role0000
P11350038A0459 |112 119|hY RNAsneonata
P11350038A0459 |41 45|halfhosp
P11350038A0459 |154 168|export process2 When CSF [HC
P11350038A0459 |16 24|evidenceompariso
P11350165A1606 |0 7|ChangesP000016
P11350165A1606 |60 74|stem structureucleotidase P0
P11350165A1606 |15 26|DB sequenceComparison 
P11350165A1606 |90 96|lossesrmacol
P11350165A1606 |100 122|translation efficiency aspects of neonatal h
P11350175A0173 |92 110|chaperone activityacologic aspects o
P11350175A0173 |27 34|membersith alk
P11350175A0173 |78 87|isomerase171T0000 
P11350175A0173 |43 57|protein familysphatases and 
P11350812A0829 |152 174|stress fiber formation472 When CSF [HCO3-] i
P11350812A0829 |105 119|ERK activationcts of neonata
P11350812A0829 |43 46|MEKsph
P11350812A0829 |79 87|Rp-cAMPS71T0000 
P11350812A0829 |121 146|caldesmon phosphorylationhyperbilirubinemia. P0000
P11350812A0829 |18 41|Raf-1 target ERK kinaseparison with alkaline p
P11350812A0829 |0 10|InhibitionP00001606T
P11350957A0457 |0 10|PACAP mRNAP00001606T
P11350957A0457 |77 82|PACAP8171T
P11350957A0457 |46 53|tissuesatases 
P11350957A0457 |114 123|cytoplasmonatal hy
P11350957A0457 |70 75|cellse P00
P11350982A0560 |83 93|activation000 Pharma
P11350982A0560 |43 54|involvementsphatases a
P11350982A0560 |26 34|evidencewith alk
P11350982A0560 |58 79|GCN1-GCN2 interaction-nucleotidase P000081
P11350982A0560 |97 101|GCN2gic 
P11352423A0084 |87 91|flapPhar
P11352423A0084 |95 101|choicelogic 
P11352423A0084 |11 23|forearm flap076 Comparis
P11352423A0084 |67 75|arm flapdase P00
P11352423A0084 |113 123|situationseonatal hy
P11352663A0138 |119 126|bindingl hyper
P11352663A0138 |89 96|bindingarmacol
P11352663A0138 |44 49|classphata
P11352663A0138 |3 13|comparison001606T007
P11352663A0138 |52 62|expression and 5-nuc
P11352663A0138 |130 139|NF-kappaBrubinemia
P11352663A0138 |33 42|Ad5 cellskaline ph
P11352663A0138 |100 107|COUP-TF aspect
P11352671A0492 |169 179|hPIV2 cDNA3-] is sho
P11352671A0492 |131 135|siteubin
P11352671A0492 |57 74|nucleotide change5-nucleotidase P0
P11352671A0492 |215 222|virusesa of K-
P11352671A0492 |29 37|geneticsh alkali
P11352671A0492 |224 230|rPIV2Vpleted
P11352671A0492 |6 17|application606T0076 Co
P11352671A0492 |76 79|UCU081
P11352671A0492 |244 248|cDNAonge
P11352671A0492 |83 86|ACU000
P11352671A0492 |143 149|V gene000899
P11353392A1127 |4 14|frameshift01606T0076
P11353392A1127 |28 33|ADEx2th al
P11353392A1127 |67 82|coding sequencedase P00008171T
P11353392A1127 |113 126|ASIP mutationeonatal hyper
P11353770A0085 |186 192|places funct
P11353770A0085 |79 101|N-glycosylase activity71T0000 Pharmacologic 
P11353770A0085 |121 142|8-oxoguanine residueshyperbilirubinemia. P
P11353770A0085 |25 33|activity with al
P11353770A0085 |58 60|S3-n
P11353770A0085 |146 149|DNA899
P11353770A0085 |110 117|removalf neona
P11353770A0085 |171 176|sites] is 
P11353774A0255 |139 149|hepatocyte. P0000899
P11353774A0255 |246 253|proteinger dis
P11353774A0255 |229 231|NRd 
P11353774A0255 |125 131|memberrbilir
P11353774A0255 |57 75|forkhead homologue5-nucleotidase P00
P11353774A0255 |79 95|rhabdomyosarcoma71T0000 Pharmaco
P11353774A0255 |211 227|hormone receptor data of K-deple
P11353774A0255 |33 49|characterizationkaline phosphata
P11353774A0255 |158 175|factor 3/forkheaden CSF [HCO3-] is
P11353774A0255 |97 101|FKHRgic 
P11353774A0255 |185 196|gene familya function 
P11353774A0255 |19 28|isolationarison wi
P11354406A1373 |112 124|ICP waveformneonatal hyp
P11354406A1373 |13 36|CSF outflow conductance6 Comparison with alkal
P11354406A1373 |67 77|compliancedase P0000
P11354975A0850 |17 28|Euspondylusmparison wi
P11354975A0850 |107 112|Sucres of 
P11354975A0850 |6 13|species606T007
P11354975A0850 |127 136|Venezuelailirubine
P11354975A0850 |76 85|bromeliad08171T000
P11354975A0850 |53 59|femaleand 5-
P11354975A0850 |98 105|El Humoic aspe
P11355576A1125 |102 126|tumor suppressor proteinspects of neonatal hyper
P11355576A1125 |244 269|E2F transcription factorsonger displaced when comp
P11355576A1125 |133 156|pRb controls commitmentinemia. P00008997A0472 
P11355576A1125 |287 305|cell proliferationut still have a si
P11355576A1125 |184 191|S phase a func
P11355576A1125 |83 93|inhibition000 Pharma
P11355576A1125 |178 180|G1ow
P11355576A1125 |57 72|phosphorylation5-nucleotidase 
P11355576A1125 |37 40|CDKne 
P11355576A1125 |128 131|pRblir
P11355576A1125 |228 236|activityed rats 
P11355576A1125 |4 11|cyclins01606T0
P11355576A1125 |205 209|partO2 t
P11355615A0766 |113 121|practiceeonatal 
P11355615A0766 |94 107|incorporationologic aspect
P11355615A0766 |11 20|education076 Compa
P11355615A0766 |63 72|directioneotidase 
P11355615A0766 |77 89|intervention8171T0000 Ph
P11355615A0766 |25 33|research with al
P11355668T0000 |128 142|syndrome viruslirubinemia. P
P11355668T0000 |91 98|porcinemacolog
P11355668T0000 |14 26|vasculopathy Comparison 
P11355668T0000 |41 52|hemorrhageshosphatases
P11355668T0000 |56 72|porcine neonates 5-nucleotidase 
P11356214A0794 |50 59|specimenses and 5-
P11356214A0794 |212 218|cavitydata o
P11356214A0794 |147 162|resin specimens997A0472 When C
P11356214A0794 |79 106|Knoop hardness measurements71T0000 Pharmacologic aspec
P11356214A0794 |135 143|surfacesemia. P0
P11356214A0794 |194 204|dimensionsn of CSF P
P11356214A0794 |4 14|difference01606T0076
P11356214A0794 |173 184|Teflon moldis shown as
P11356214A0794 |231 237|dentinrats a
P11356214A0794 |18 26|hardnessparison 
P11356214A0794 |32 36|timelkal
P11356716A0372 |17 22|clonempari
P11356716A0372 |64 78|GHS-R variantsotidase P00008
P11356716A0372 |33 42|sequenceskaline ph
P11356835A0000 |48 55|networkases an
P11356835A0000 |131 149|protein precursorsubinemia. P0000899
P11356835A0000 |72 79|controlP000081
P11356835A0000 |120 127|amounts hyperb
P11356835A0000 |99 103|cellc as
P11356835A0000 |157 178|amino acid starvationhen CSF [HCO3-] is sh
P11356853A0429 |85 92|control0 Pharm
P11356853A0429 |15 19|CoClComp
P11356853A0429 |50 74|luciferase reporter genees and 5-nucleotidase P0
P11356853A0429 |3 13|Ka13 cells001606T007
P11356853A0429 |110 134|pair mouse ho-1 promoterf neonatal hyperbilirubi
P11356853A0429 |136 144|pHO15lucmia. P00
P11356853A0429 |34 44|expressionaline phos
P11356853A0554 |51 60|sequencess and 5-n
P11356853A0554 |94 99|StREsologi
P11356853A0554 |84 92|elements00 Pharm
P11356853A0554 |0 17|Mutation analysesP00001606T0076 Co
P11356853A0873 |0 7|MembersP000016
P11356853A0873 |15 31|AP-1 superfamilyComparison with 
P11356853A0873 |76 80|StRE0817
P11356853A0873 |35 63|basic-leucine zipper factorsline phosphatases and 5-nucl
P11357063A0138 |0 12|DescriptionsP00001606T00
P11357063A0138 |95 103|featureslogic as
P11357063A0138 |133 137|lociinem
P11357063A0138 |21 26|locusison 
P11357063A0138 |39 49|comparison phosphata
P11357063A0138 |113 120|specieseonatal
P11357063A0138 |201 233|LHbeta-CGbeta gene cluster locusF PCO2 the data of K-depleted ra
P11357063A0138 |170 184|LH/CGbeta gene-] is shown as
P11357063A1053 |143 166|translation start codon0008997A0472 When CSF [
P11357063A1053 |107 120|TATA sequences of neonatal
P11357063A1053 |124 126|bper
P11357063A1053 |72 88|gpLH/CGbeta geneP00008171T0000 P
P11357063A1053 |29 40|LHbeta geneh alkaline 
P11357063A1053 |9 18|consensusT0076 Com
P11357063A1053 |58 64|region-nucle
P11358801A1046 |51 66|NHEJ deficiencys and 5-nucleot
P11358801A1046 |19 29|situationsarison wit
P11358801A1046 |43 49|breakssphata
P11358801A1046 |130 137|studiesrubinem
P11358801A1046 |84 98|rearrangements00 Pharmacolog
P11358801A1046 |103 112|agreementpects of 
P11358958A0878 |0 10|ExpressionP00001606T
P11358958A0878 |134 143|apoptosisnemia. P0
P11358958A0878 |105 116|tumor cellscts of neon
P11358958A0878 |60 77|growth inhibitionucleotidase P0000
P11358958A0878 |20 25|RACK1rison
P11358958A0878 |81 85|HF7cT000
P11358962A0344 |0 5|Foxp1P0000
P11358962A0344 |78 95|mouse development171T0000 Pharmaco
P11358962A0344 |10 15|Foxp20076 
P11358962A0344 |101 117|Foxp2 expressionaspects of neona
P11358962A0344 |38 44|levelse phos
P11358962A0344 |52 56|lung and
P11358962A0344 |69 72|E12se 
P11358962A0344 |136 153|airway epitheliummia. P00008997A04
P11359568T0000 |103 124|nucleoprotein complexpects of neonatal hyp
P11359568T0000 |134 156|plasmid partition sitenemia. P00008997A0472 
P11359568T0000 |52 56|ParB and
P11359568T0000 |10 18|analysis0076 Com
P11359568T0000 |26 50|pRA2 partitioning regionwith alkaline phosphatas
P11359568T0000 |158 162|parSen C
P11359568T0000 |71 90|parAB transcription P00008171T0000 Pha
P11359827T0000 |103 108|SPE-Jpects
P11359827T0000 |90 91|Jr
P11359827T0000 |30 46|characterization alkaline phosph
P11359827T0000 |74 83|exotoxins0008171T0
P11359827T0000 |93 98|SPE-Icolog
P11359907A0099 |103 107|VEGFpect
P11359907A0099 |88 101|growth factorharmacologic 
P11359907A0099 |8 27|dozen HIF-1 targets6T0076 Comparison w
P11359907A0099 |53 57|geneand 
P11360190A0178 |68 79|G0/G1 phasease P000081
P11360190A0178 |28 31|Taxth 
P11360190A0178 |40 62|cell cycle progressionphosphatases and 5-nuc
P11360190A0178 |130 135|cellsrubin
P11360190A0178 |89 100|G2/M phasesarmacologic
P11360190A0178 |110 125|T-cell line Kitf neonatal hype
P11360190A0178 |83 84|S0
P11361338A0093 |49 53|typeses 
P11361338A0093 |23 38|matrix proteinson with alkalin
P11361338A0093 |78 94|targeting signal171T0000 Pharmac
P11361338A0093 |120 134|tripeptide SKL hyperbilirubi
P11361338A0093 |96 100|PTS1ogic
P11361338A0093 |5 10|yeast1606T
P11361338A0447 |103 112|constructpects of 
P11361338A0447 |125 140|Pex5p chimaerasrbilirubinemia.
P11361338A0447 |10 26|PEX5-TPR domains0076 Comparison 
P11361338A0447 |91 96|yeastmacol
P11361338A0447 |52 60|nematode and 5-n
P11361338A0447 |39 46|tobacco phosph
P11361493T0000 |0 5|HIV-1P0000
P11361493T0000 |42 53|adolescentsosphatases 
P11361493T0000 |10 38|hepatitis B virus infections0076 Comparison with alkalin
P11361493T0000 |64 83|security institutesotidase P00008171T0
P11361493T0000 |87 99|Buenos AiresPharmacologi
P11367523A1684 |0 26|Immunofixation experimentsP00001606T0076 Comparison 
P11367523A1684 |59 68|allotypesnucleotid
P11367523A1684 |91 99|proteinsmacologi
P11367523A1684 |30 33|C4A al
P11367523A1684 |80 87|classes1T0000 
P11367523A1684 |38 41|C4Be p
P11367523A2624 |51 56|geness and
P11367523A2624 |120 129|C4A genes hyperbil
P11367523A2624 |9 21|C4B proteinsT0076 Compar
P11367523A2624 |84 98|concentrations00 Pharmacolog
P11368363A0129 |100 103|MPO as
P11368363A0129 |181 184|DNA as
P11368363A0129 |105 113|promotercts of n
P11368363A0129 |164 168|cDNA [HC
P11368363A0129 |253 267|mobility groupplaced when co
P11368363A0129 |83 98|myeloperoxidase000 Pharmacolog
P11368363A0129 |295 303|proteins have a 
P11368363A0129 |31 52|transcription factorsalkaline phosphatases
P11368363A0129 |7 13|course06T007
P11368363A0129 |132 136|timebine
P11368363A0129 |195 199|HBP1 of 
P11368363A0129 |234 240|members are 
P11368363A0129 |201 227|HMG-Box containing proteinF PCO2 the data of K-deple
P11368363A1103 |191 202|rat proteintion of CSF
P11368363A1103 |90 98|rat HBP1rmacolog
P11368363A1103 |59 65|domainnucleo
P11368363A1103 |10 26|protein sequence0076 Comparison 
P11368363A1103 |109 117|homologyof neona
P11368363A1103 |127 137|activationilirubinem
P11368363A1103 |142 159|repressor domains00008997A0472 Whe
P11368787A0180 |0 8|PromoterP0000160
P11368787A0180 |106 108|bpts
P11368787A0180 |63 70|portioneotidas
P11368787A0180 |166 192|transcription start pointsHCO3-] is shown as a funct
P11368787A0180 |25 33|activity with al
P11368787A0180 |84 99|annexin A5 gene00 Pharmacologi
P11368901A0327 |3 11|contrast001606T0
P11368901A0327 |58 69|repeat unit-nucleotida
P11368901A0327 |26 31|mousewith 
P11368901A0327 |37 45|proteinsne phosp
P11368901A0327 |97 104|portiongic asp
P11368911T0000 |69 79|C. elegansse P000081
P11368911T0000 |28 33|smg-4th al
P11368911T0000 |10 24|identification0076 Compariso
P11368911T0000 |48 65|mRNA surveillanceases and 5-nucleo
P11368914T0071 |118 125|controlal hype
P11368914T0071 |22 27|exonsson w
P11368914T0071 |145 153|promoter08997A04
P11368914T0071 |104 107|ORFect
P11368914T0071 |39 63|complement C3 gene locus phosphatases and 5-nucl
P11368914T0071 |87 90|endPha
P11369066A1210 |171 191|radiation dermatitis] is shown as a func
P11369066A1210 |20 23|MMFris
P11369066A1210 |42 56|corticosteroidosphatases and
P11369066A1210 |74 79|cream00081
P11369066A1210 |141 146|creamP0000
P11369066A1210 |0 11|CONCLUSIONSP00001606T0
P11369106A0428 |53 59|resultand 5-
P11369106A0428 |135 144|food websemia. P00
P11369106A0428 |91 115|transformation processesmacologic aspects of neo
P11369106A0428 |74 86|interactions0008171T0000
P11369106A0428 |41 47|sulfurhospha
P11369106A0428 |7 15|advances06T0076 
P11369410A0949 |137 147|processingia. P00008
P11369410A0949 |53 73|stimulus differencesand 5-nucleotidase P
P11369410A0949 |42 47|senseospha
P11369410A0949 |10 20|hypothesis0076 Compa
P11369410A0949 |158 170|participantsen CSF [HCO3
P11369410A0949 |87 96|behaviourPharmacol
P11369453A1083 |51 58|elements and 5
P11369453A1083 |13 21|increase6 Compar
P11369453A1083 |25 40|protein binding with alkaline 
P11369453A1083 |70 87|peptide treatmente P00008171T0000 
P11369700A0074 |34 48|chain isotypesaline phosphat
P11369700A0074 |66 83|B cell activatorsidase P00008171T0
P11369700A0074 |52 61|cytokines and 5-nu
P11369700A0074 |146 148|GL89
P11369700A0074 |151 152|C0
P11369700A0074 |136 144|germlinemia. P00
P11369700A0074 |156 168|region genesWhen CSF [HC
P11369700A0074 |96 109|transcriptionogic aspects 
P11369700A0074 |153 154|H7
P11369700A0074 |0 3|CSRP00
P11369700A0616 |50 59|Ets siteses and 5-
P11369700A0616 |176 186|expressionshown as a
P11369700A0616 |192 216|luciferase reporter geneion of CSF PCO2 the data
P11369700A0616 |132 136|PU.1bine
P11369700A0616 |67 90|mouse GL alpha promoterdase P00008171T0000 Pha
P11369700A0616 |231 248|GL alpha promoterrats are no longe
P11369700A0616 |8 18|manuscript6T0076 Com
P11369700A0616 |100 127|transcription factors Elf-1 aspects of neonatal hyperb
P11369700A0616 |154 158|site2 Wh
P11369759A0605 |0 4|CellP000
P11370174A0447 |66 72|monthsidase 
P11370174A0447 |79 89|withdrawal71T0000 Ph
P11370174A0447 |9 31|serum creatinine levelT0076 Comparison with 
P11370174A0447 |93 96|MMFcol
P11371115A0962 |4 14|proportion01606T0076
P11371115A0962 |22 30|biopsiesson with
P11371115A0962 |107 110|MGNs o
P11371115A0962 |60 71|HBs antigenucleotidase
P11371115A0962 |80 81|%1
P11371115A0962 |114 126|MPGN patternonatal hyper
P11371160A0193 |19 30|nucleotidesarison with
P11371160A0193 |66 88|discriminator base A73idase P00008171T0000 P
P11371160A0193 |130 138|moleculerubinemi
P11371160A0193 |45 61|base-pair C1-G72hatases and 5-nu
P11371160A0193 |96 101|aminoogic 
P11371160A0193 |116 122|branchatal h
P11371160A0854 |34 48|anticodon loopaline phosphat
P11371160A0854 |135 145|efficiencyemia. P000
P11371160A0854 |75 79|acts0081
P11371160A0854 |97 114|TyrRS interactiongic aspects of ne
P11371160A0854 |56 64|tyrosine 5-nucle
P11371160A0854 |149 161|tyrosylation7A0472 When 
P11371160A0854 |5 11|domain1606T0
P11371160A0854 |86 92|anchor Pharm
P11371343A0125 |85 92|protein0 Pharm
P11371343A0125 |31 39|separasealkaline
P11371343A0125 |19 29|cell cyclearison wit
P11371343A0125 |100 107|securin aspect
P11371417A0744 |340 359|preventilation data 0.23 vs. P00010943
P11371417A0744 |421 423|LA w
P11371417A0744 |122 143|tumor necrosis factoryperbilirubinemia. P0
P11371417A0744 |169 174|pg/ml3-] i
P11371417A0744 |100 118|lung lavage levels aspects of neonat
P11371417A0744 |308 314|levelsficant
P11371417A0744 |368 374|changerazepa
P11371417A0744 |225 235|macrophageleted rats
P11371417A0744 |318 327|cytokinesreater sl
P11371417A0744 |378 388|percentageus appears
P11371417A0744 |190 192|ILct
P11371417A0744 |53 63|% decreaseand 5-nucl
P11371417A0744 |249 258|protein-2 displace
P11371417A0744 |177 188|interleukinhown as a f
P11371417A0744 |260 265|MIP-2when 
P11371417A0744 |145 148|TNF089
P11371417A0744 |213 218|pg/mlata o
P11371417A0744 |26 39|control lungswith alkaline
P11371417A0744 |88 96|increaseharmacol
P11371417A0744 |150 155|alphaA0472
P11371417A0744 |11 22|ventilation076 Compari
P11371417A0744 |280 285|pg/mltrols
P11371417A0744 |195 199|beta of 
P11371417A0744 |67 83|chord compliancedase P00008171T0
P11371417A0744 |409 419|aggregatesypnotic dr
P11372882A1143 |71 77|levels P0000
P11372882A1143 |13 16|DDE6 C
P11372882A1143 |93 97|PCBscolo
P11372882A1143 |9 10|pT
P11372882A1143 |11 12|p0
P11372882A1143 |83 89|levels000 Ph
P11372882A1143 |21 36|beta-HCH levelsison with alkal
P11372959A1447 |206 207|%2
P11372959A1447 |131 143|relationshipubinemia. P0
P11372959A1447 |228 242|tick abundanceed rats are no
P11372959A1447 |215 224|variationa of K-de
P11372959A1447 |91 100|abundancemacologic
P11372959A1447 |172 188|habitat category is shown as a f
P11372959A1447 |145 160|R2 coefficients08997A0472 When
P11372959A1447 |9 28|regression analysisT0076 Comparison wi
P11372959A1447 |113 118|siteseonat
P11372959A1447 |71 78|factors P00008
P11373277A0812 |238 255|corepressor CtBP1e no longer displ
P11373277A0812 |123 129|effectperbil
P11373277A0812 |180 198|AP-2alpha promotern as a function of
P11373277A0812 |104 118|AP-2alpha geneects of neonat
P11373277A0812 |44 59|oncoprotein E1Aphatases and 5-
P11373277A0812 |217 220|E1Aof 
P11373277A0812 |202 213|interaction PCO2 the d
P11373277A0812 |160 172|derepression CSF [HCO3-]
P11373277A0812 |3 10|summary001606T
P11373277A0812 |70 83|transcriptione P00008171T0
P11374051A0437 |169 173|risk3-] 
P11374051A0437 |11 18|factors076 Com
P11374051A0437 |135 143|diseasesemia. P0
P11374051A0437 |60 75|corticosteroidsucleotidase P00
P11374051A0437 |36 39|ageine
P11374051A0437 |177 185|bleedinghown as 
P11374051A0437 |79 93|anticoagulants71T0000 Pharma
P11374051A0437 |53 56|useand
P11374051A0437 |101 120|ulcer complicationsaspects of neonatal
P11374559A0103 |0 12|SERS spectraP00001606T00
P11374559A0103 |82 94|island films0000 Pharmac
P11374559A0103 |110 136|colloidal silver solutionsf neonatal hyperbilirubine
P11374559A0103 |30 48|vacuum evaporation alkaline phosphat
P11374559A0103 |53 60|castingand 5-n
P11374559A0103 |64 69|p-NTPotida
P11374866X0914 |0 9|CopyrightP00001606
P11374866X0914 |15 29|Academic PressComparison wit
P11375392T0000 |98 101|Sp1ic 
P11375392T0000 |27 48|thioredoxin reductaseith alkaline phosphat
P11375392T0000 |107 118|Sp3 bindings of neonat
P11375392T0000 |91 96|Oct-1macol
P11375392T0000 |52 59|cloning and 5-
P11375392T0000 |77 85|activity8171T000
P11375392T0000 |146 154|promoter8997A047
P11375392T0000 |189 193|genencti
P11375392T0000 |4 17|core promoter01606T0076 Co
P11376007A0584 |185 207|protein phosphatase 2Aa function of CSF PCO2
P11376007A0584 |298 309|microcystinve a signif
P11376007A0584 |229 241|reactivationd rats are n
P11376007A0584 |160 179|protein phosphatase CSF [HCO3-] is sho
P11376007A0584 |209 213|PP2Ahe d
P11376007A0584 |107 115|additions of neo
P11376007A0584 |142 149|subunit0000899
P11376007A0584 |42 46|lossosph
P11376007A0584 |267 296|protein phosphatase inhibitormpared to controls but still 
P11376007A0584 |54 77|protein kinase activitynd 5-nucleotidase P0000
P11376007A0584 |81 87|DNA-PKT0000 
P11376119A0346 |103 105|bppe
P11376119A0346 |120 124|exon hyp
P11376119A0346 |66 72|regionidase 
P11376119A0346 |10 14|exon0076
P11376119A0346 |134 142|GHR genenemia. P
P11376119A0346 |80 91|GHR 1A mRNA1T0000 Phar
P11376119A0346 |16 23|exon 1Aomparis
P11376134A1506 |68 88|transcription factorase P00008171T0000 P
P11376134A1506 |97 102|sitesgic a
P11376134A1506 |6 17|corrections606T0076 Co
P11376134A1506 |33 42|sequenceskaline ph
P11376165T0000 |0 3|FLPP00
P11376165T0000 |8 32|Cre recombinase function6T0076 Comparison with a
P11376165T0000 |36 51|Xenopus embryosine phosphatase
P11376279A0000 |68 79|angiographyase P000081
P11376279A0000 |53 62|resonanceand 5-nuc
P11376279A0000 |93 104|extremitiescologic asp
P11376279A0000 |120 138|volume acquisition hyperbilirubinemi
P11376279A0000 |64 66|MRot
P11376279A0000 |2 8|method000160
P11376687A0344 |34 37|SNPali
P11376687A0344 |146 149|AUG899
P11376687A0344 |160 170|MTH1 mRNAs CSF [HCO3
P11376687A0344 |89 100|GTG83/ATG83armacologic
P11376687A0344 |209 212|p26he 
P11376687A0344 |191 207|MTH1 polypeptidetion of CSF PCO2
P11376687A0344 |42 46|exonosph
P11376687A0344 |9 32|nucleotide polymorphismT0076 Comparison with a
P11376687A0344 |256 272|targeting signalced when compare
P11376687A0344 |84 87|SNP00 
P11376946A0000 |85 96|phosphatase0 Pharmacol
P11376946A0000 |146 154|lineages8997A047
P11376946A0000 |123 128|cellsperbi
P11376946A0000 |46 49|SH2ata
P11376946A0000 |13 20|studies6 Compa
P11376946A0000 |191 196|cellstion 
P11376946A0000 |249 257|promoter displac
P11376946A0000 |37 42|SHP-1ne ph
P11376946A0000 |207 214|control the da
P11376946A0000 |259 261|P1 w
P11377975A0898 |141 151|conditionsP00008997A
P11377975A0898 |63 82|proteinase activityeotidase P00008171T
P11377975A0898 |30 40|COS1 cells alkaline 
P11377975A0898 |106 116|substratests of neon
P11377975A0898 |160 165|study CSF 
P11378898A0164 |0 4|ORF1P000
P11378898A0164 |15 28|EMBL databankComparison wi
P11378898A0164 |30 43|Accession No. alkaline pho
P11378898A0164 |11 13|bp07
P11379106A0372 |52 78|deammonification processes and 5-nucleotidase P00008
P11379106A0372 |95 99|flowlogi
P11379106A0372 |111 122|pilot plant neonatal h
P11379106A0372 |7 15|meantime06T0076 
P11380028A0000 |4 11|purpose01606T0
P11380028A0000 |145 153|131I-OIH08997A04
P11380028A0000 |105 114|pentetatects of ne
P11380028A0000 |119 137|orthoiodohippuratel hyperbilirubinem
P11380028A0000 |184 188|cats a f
P11380028A0000 |155 171|plasma clearance When CSF [HCO3-
P11380028A0000 |20 25|studyrison
P11380028A0000 |53 60|methodsand 5-n
P11380028A0000 |65 75|estimationtidase P00
P11380028A0000 |202 215|blood samples PCO2 the dat
P11380028A0000 |79 92|Technetium Tc71T0000 Pharm
P11380028A0000 |175 179|dogs sho
P11380028A0000 |98 103|99mTcic as
P11380370A0000 |70 72|KSe 
P11380370A0000 |28 40|skin lesionsth alkaline 
P11380370A0000 |61 68|sarcomacleotid
P11380370A0000 |52 58|Kaposi and 5
P11380370A0000 |2 9|patient0001606
P11380837A1505 |0 13|InterventionsP00001606T007
P11380837A1505 |132 137|costsbinem
P11380837A1505 |150 168|access dysfunctionA0472 When CSF [HC
P11380837A1505 |52 61|processes and 5-nu
P11380837A1505 |38 47|mediatorse phospha
P11381094A0797 |50 64|synaptotagminses and 5-nucle
P11381094A0797 |13 19|stonin6 Comp
P11381094A0797 |3 11|addition001606T0
P11381094A0797 |35 46|C2B domainsline phosph
P11382701A0688 |68 76|responsease P000
P11382701A0688 |89 93|risearma
P11382701A0688 |13 24|transection6 Compariso
P11382701A0688 |97 124|plasma sodium concentrationgic aspects of neonatal hyp
P11382701A0688 |38 49|vasopressine phosphata
P11382948A0793 |171 176|USPIO] is 
P11382948A0793 |30 38|MRI data alkalin
P11382948A0793 |140 152|permeability P00008997A0
P11382948A0793 |208 219|tumor gradethe data of
P11382948A0793 |105 124|breast cancer modelcts of neonatal hyp
P11382948A0793 |3 13|conclusion001606T007
P11382948A0793 |68 96|tumor microvessel propertiesase P00008171T0000 Pharmacol
P11383860A0661 |100 105|brain aspe
P11383860A0661 |47 56|excretiontases and
P11383860A0661 |60 79|99mTc ciprofloxacinucleotidase P000081
P11383860A0661 |143 155|liver uptake0008997A0472
P11383860A0661 |160 169|excretion CSF [HCO
P11383860A0661 |107 111|lungs of
P11383860A0661 |4 10|images01606T
P11383860A0661 |116 134|bone marrow uptakeatal hyperbilirubi
P11384225A0634 |16 35|expression cassetteomparison with alka
P11384225A0634 |160 169|sequences CSF [HCO
P11384225A0634 |83 90|protein000 Pha
P11384225A0634 |8 11|end6T0
P11384225A0634 |92 95|GFPaco
P11384225A0634 |54 58|genend 5
P11384225A0634 |115 118|endnat
P11384229A1669 |137 143|factoria. P0
P11384229A1669 |73 84|interaction00008171T00
P11384229A1669 |13 26|N63S mutation6 Comparison 
P11384229A1669 |44 58|VP5 backgroundphatases and 5
P11384229A1669 |103 130|beta-galactosidase activitypects of neonatal hyperbili
P11384229A1669 |170 182|PR7 mutation-] is shown 
P11384576A1132 |49 59|interferonses and 5-
P11384576A1132 |79 90|retinopathy71T0000 Pha
P11384576A1132 |20 31|vision lossrison with 
P11384576A1132 |3 11|addition001606T0
P11384880A0719 |51 66|gene expressions and 5-nucleot
P11384880A0719 |4 13|mechanism01606T007
P11384880A0719 |96 103|ZR-75-1ogic as
P11384880A0719 |110 129|breast cancer cellsf neonatal hyperbil
P11384880A0719 |21 30|inductionison with
P11384880A0719 |34 48|3beta-HSD typealine phosphat
P11385840A1684 |42 59|wastewater systemosphatases and 5-
P11385840A1684 |134 155|optimization routinesnemia. P00008997A0472
P11385840A1684 |14 27|RTC algorithm Comparison w
P11385840A1684 |79 89|parameters71T0000 Ph
P11387208T0000 |0 37|SKP1-SnRK protein kinase interactionsP00001606T0076 Comparison with alkali
P11387208T0000 |58 65|binding-nucleo
P11387208T0000 |71 97|plant SCF ubiquitin ligase P00008171T0000 Pharmacolo
P11387351A0092 |0 8|PATIENTSP0000160
P11387351A0092 |121 126|2-CDAhyper
P11387351A0092 |44 52|Decemberphatases
P11387351A0092 |224 227|MDSple
P11387351A0092 |134 142|childrennemia. P
P11387351A0092 |90 119|analog 2-chlorodeoxyadenosinermacologic aspects of neonata
P11387351A0092 |30 34|June alk
P11387351A0092 |214 222|syndrometa of K-
P11387351A0092 |167 175|childrenCO3-] is
P11387351A0092 |13 20|METHODS6 Compa
P11387351A0092 |191 194|AMLtio
P11387351A0092 |156 159|AMLWhe
P11387940A0647 |4 12|severity01606T00
P11387940A0647 |27 34|changesith alk
P11387940A0647 |67 77|percussiondase P0000
P11387940A0647 |54 63|magnitudend 5-nucl
P11387950X0001 |136 141|studymia. 
P11387950X0001 |344 355|lung injury3 vs. P0001
P11387950X0001 |118 128|objectivesal hyperbi
P11387950X0001 |359 362|ANPA07
P11387950X0001 |459 472|TNF secretionral practice 
P11387950X0001 |396 402|effectn effe
P11387950X0001 |22 33|ta chengchison with al
P11387950X0001 |333 340|changes.21 +/-
P11387950X0001 |177 199|leukocyte adhesivenesshown as a function of 
P11387950X0001 |245 250|stagenger 
P11387950X0001 |63 74|lung injuryeotidase P0
P11387950X0001 |423 432|Decoctionith the o
P11387950X0001 |436 454|leukocyte adhesionum dose for use in
P11387950X0001 |406 417|ta chengchie hypnotic 
P11387950X0001 |227 230|TNFted
P11387950X0001 |286 289|ANPbut
P11387950X0001 |13 18|study6 Com
P11387950X0001 |166 173|changesHCO3-] 
P11387950X0001 |272 284|pancreatitisd to control
P11387950X0001 |39 48|decoction phosphat
P11387950X0001 |315 323|relationy greate
P11387950X0001 |100 112|pancreatitis aspects of 
P11387950X0001 |204 225|tumor necrosis factorCO2 the data of K-dep
P11389077A0000 |2 9|variety0001606
P11389077A0000 |31 49|signaling pathwaysalkaline phosphata
P11389077A0000 |109 119|regulatorsof neonata
P11389085A0290 |0 8|TT cellsP0000160
P11389085A0290 |110 117|nucleusf neona
P11389085A0290 |93 97|RelAcolo
P11389085A0290 |43 58|MEN 2A type RETsphatases and 5
P11389085A0290 |98 101|p65ic 
P11389085A0290 |18 31|MTC cell lineparison with 
P11389085A1032 |137 140|RETia.
P11389085A1032 |27 45|NF-kappaB activityith alkaline phosp
P11389085A1032 |91 106|focus formationmacologic aspec
P11389085A1032 |144 157|NIH 3T3 cells008997A0472 W
P11389085A1032 |128 133|formslirub
P11389085A1032 |57 67|cell death5-nucleoti
P11389085A1032 |71 79|TT cells P000081
P11389085A1032 |0 10|InhibitionP00001606T
P11390395A1018 |104 119|transactivationects of neonata
P11390395A1018 |14 31|HMGI-C expression Comparison with 
P11390395A1018 |74 84|repression0008171T00
P11390581A1203 |53 61|sequenceand 5-nu
P11390581A1203 |10 17|finding0076 Co
P11390581A1203 |182 190|promoteras a fun
P11390581A1203 |166 174|activityHCO3-] i
P11390581A1203 |77 86|Cp region8171T0000
P11390581A1203 |25 39|identification with alkaline
P11390650A0562 |102 108|regionspects
P11390650A0562 |145 155|P-1 domain08997A0472
P11390650A0562 |11 29|deletion mutations076 Comparison wit
P11390650A0562 |112 118|SLP-76neonat
P11390650A0562 |71 77|domain P0000
P11390663A1400 |102 120|Gcn4p target genesspects of neonatal
P11390663A1400 |24 33|gcn4Deltan with al
P11390663A1400 |9 18|profilingT0076 Com
P11390663A1400 |142 147|cells00008
P11390663A1400 |66 93|induction pathway operatingidase P00008171T0000 Pharma
P11390684A1170 |0 8|EvidenceP0000160
P11390684A1170 |89 110|jadomycin B synthesisarmacologic aspects o
P11390684A1170 |54 69|jadM expressionnd 5-nucleotida
P11390684A1170 |16 38|Northern hybridizationomparison with alkalin
P11391303A0807 |54 83|intraobserver reproducibilitynd 5-nucleotidase P00008171T0
P11391303A0807 |11 16|R-LHR076 C
P11391303A0807 |6 9|LHR606
P11391303A0807 |36 49|interobserverine phosphata
P11391303A1023 |102 131|Tl-201 lung uptake evaluationspects of neonatal hyperbilir
P11391303A1023 |32 47|LHR measurementlkaline phospha
P11391303A1023 |86 98|contribution Pharmacolog
P11391303A1023 |0 11|CONCLUSIONSP00001606T0
P11391303A1023 |17 28|methodologymparison wi
P11391531A1157 |0 8|MutationP0000160
P11391531A1157 |66 75|inductionidase P00
P11391531A1157 |79 88|TNF-alpha71T0000 P
P11391531A1157 |38 52|Mdr1b promotere phosphatases
P11391531A1157 |16 30|NF-kappaB siteomparison with
P11391793A0856 |205 211|clonesO2 the
P11391793A0856 |188 198|chromosomeunction of
P11391793A0856 |25 35|complexity with alka
P11391793A0856 |120 123|SRO hy
P11391793A0856 |103 106|mappec
P11391793A0856 |71 77|tumors P0000
P11391793A0856 |200 203|PACSF 
P11391793A0856 |51 57|regions and 
P11391793A0856 |152 165|bacteriophage472 When CSF 
P11392306T0000 |17 23|designmparis
P11392306T0000 |28 38|techniquesth alkalin
P11392306T0000 |7 15|teaching06T0076 
P11392772A0182 |4 15|application01606T0076 
P11392772A0182 |208 215|Dnieperthe dat
P11392772A0182 |134 138|citynemi
P11392772A0182 |187 192|waterfunct
P11392772A0182 |55 64|treatmentd 5-nucle
P11392772A0182 |23 36|biotechnologyon with alkal
P11392772A0182 |113 126|zone Telychkaeonatal hyper
P11392772A0182 |248 253|timesr dis
P11392772A0182 |163 170|contentF [HCO3
P11392772A0182 |72 92|surface storm watersP00008171T0000 Pharm
P11392772A0182 |44 50|plantsphatas
P11392772A0182 |142 146|Kyiv0000
P11392772A0182 |174 183|petroleums shown a
P11393463A0274 |0 4|DataP000
P11393463A0274 |268 277|occasionspared to 
P11393463A0274 |181 196|informant group as a function 
P11393463A0274 |165 173|interval[HCO3-] 
P11393463A0274 |220 227|ratingsK-deple
P11393463A0274 |253 262|relativesplaced wh
P11393463A0274 |295 309|month interval have a signif
P11393463A0274 |127 136|occasionsilirubine
P11393463A0274 |242 249|friends longer
P11393463A0274 |40 55|student samplesphosphatases an
P11393463A0274 |78 79|n1
P11393463A0274 |198 199|n 
P11393463A0274 |71 76|group P000
P11393463A0274 |100 121|NEO-PI-R self-ratings aspects of neonatal 
P11393791A1153 |0 22|Northern blot analysisP00001606T0076 Compari
P11393791A1153 |145 155|expression08997A0472
P11393791A1153 |111 122|osteoclasts neonatal h
P11393791A1153 |26 30|RNAswith
P11393791A1153 |195 220|polymerase chain reaction of CSF PCO2 the data of 
P11393791A1153 |75 80|Atp6i00817
P11393791A1153 |38 44|numbere phos
P11393791A1153 |260 268|analysiswhen com
P11393791A1153 |230 235|assay rats
P11393791A1153 |48 61|mouse tissuesases and 5-nu
P11393791A1153 |222 228|RT-PCRdeplet
P11395469A1373 |33 39|motifskaline
P11395469A1373 |133 137|ironinem
P11395469A1373 |8 16|mutation6T0076 C
P11395469A1373 |111 121|regulation neonatal 
P11395469A1373 |125 129|sid2rbil
P11395469A1373 |66 76|regulationidase P000
P11395469A1373 |80 84|sid11T00
P11396685A0477 |220 227|cheesesK-deple
P11396685A0477 |132 134|mgbi
P11396685A0477 |107 113|samples of n
P11396685A0477 |14 21|results Compar
P11396685A0477 |97 103|amountgic as
P11396685A0477 |162 173|informationSF [HCO3-] 
P11396685A0477 |199 208|compoundsCSF PCO2 
P11396685A0477 |189 195|groupsnction
P11396685A0477 |32 35|DTDlka
P11397652A0381 |137 149|difficultiesia. P0000899
P11397652A0381 |80 92|test methods1T0000 Pharm
P11397652A0381 |36 48|spiral assayine phosphat
P11397652A0381 |211 221|volatility data of K
P11397652A0381 |223 227|etc.eple
P11397652A0381 |116 123|varietyatal hy
P11397652A0381 |191 207|sample viscositytion of CSF PCO2
P11397652A0381 |170 189|sample availability-] is shown as a fu
P11397652A0381 |0 10|GuidelinesP00001606T
P11398134A1565 |137 150|hyperuricemiaia. P00008997
P11398134A1565 |15 22|obesityCompari
P11398134A1565 |59 68|disordersnucleotid
P11398134A1565 |24 38|alcohol intaken with alkalin
P11398134A1565 |122 133|developmentyperbilirub
P11398134A1565 |3 13|conclusion001606T007
P11398134A1565 |103 113|predictorspects of n
P11398899A1183 |0 4|FansP000
P11398899A1183 |89 99|likelihoodarmacologi
P11398899A1183 |25 32|windows with a
P11398899A1183 |8 15|tunnels6T0076 
P11398899A1183 |108 126|PH3 concentrations of neonatal hyper
P11398899A1183 |48 57|locationsases and 
P11398899A1183 |139 144|areas. P00
P11399064T0000 |102 115|transcriptionspects of neo
P11399064T0000 |53 88|CCAAT/enhancer binding protein betaand 5-nucleotidase P00008171T0000 P
P11399064T0000 |90 100|C/EBP betarmacologic
P11399064T0000 |33 41|pathwayskaline p
P11399064T0000 |0 14|AutoregulationP00001606T0076
P11399834T0000 |18 36|HCV seroconversionparison with alkal
P11399834T0000 |10 14|case0076
P11399834T0000 |75 92|HCV NAT screening008171T0000 Pharm
P11399834T0000 |40 48|Portugalphosphat
P11399834T0000 |59 71|introductionnucleotidase
P11400644A0435 |19 32|uncertaintiesarison with a
P11400644A0435 |40 49|estimatesphosphata
P11400644A0435 |65 72|sourcestidase 
P11400644A0435 |5 15|reflection1606T0076 
P11400644A0435 |83 94|percentiles000 Pharmac
P11400644A0435 |140 149|g I-TEQ/y P0000899
P11400644A0435 |98 113|PCDD/F releasesic aspects of n
P11401105T0000 |0 10|GabapentinP00001606T
P11401105T0000 |29 38|myoclonush alkalin
P11401105T0000 |42 57|cancer patientsosphatases and 
P11401611A1703 |17 30|meta-analysismparison with
P11401611A1703 |130 139|fracturesrubinemia
P11401611A1703 |56 62|trials 5-nuc
P11401611A1703 |104 113|reductionects of n
P11401611A1703 |66 69|HRTida
P11401611A1703 |0 11|CONCLUSIONSP00001606T0
P11402674T0000 |0 32|Newcastle disease antibody titreP00001606T0076 Comparison with a
P11402674T0000 |49 76|serum calcium concentrationses and 5-nucleotidase P000
P11403173A0192 |2 7|total00016
P11403173A0192 |14 22|patients Compari
P11403173A0192 |38 51|brain tumourse phosphatase
P11403663A0359 |38 46|bearingse phosph
P11403663A0359 |111 121|2-D theory neonatal 
P11403663A0359 |63 71|impellereotidase
P11403663A0359 |90 101|predictionsrmacologic 
P11403663A0359 |22 26|dragson 
P11403663A0359 |4 8|lift0160
P11403719A1257 |50 57|controles and 
P11403719A1257 |91 98|insulinmacolog
P11403719A1257 |61 77|egr-1 expressioncleotidase P0000
P11403719A1257 |26 30|Gab1with
P11403719A1257 |4 11|results01606T0
P11404010A0235 |51 57|repeats and 
P11404010A0235 |13 22|triplexes6 Compari
P11404010A0235 |37 43|lengthne pho
P11404016A1922 |136 142|numbermia. P
P11404016A1922 |46 50|PKSsatas
P11404016A1922 |183 200|peptide synthasess a function of C
P11404016A1922 |104 110|TE IIsects o
P11404016A1922 |99 102|TEsc a
P11404016A1922 |20 30|TE domainsrison with
P11404016A1922 |202 206|NRPS PCO
P11404016A1922 |4 16|co-existence01606T0076 C
P11404016A1922 |154 164|polyketide2 When CSF
P11404019A0532 |32 49|mGSTM2 regulationlkaline phosphata
P11404019A0532 |88 103|promoter regionharmacologic as
P11404019A0532 |11 24|understanding076 Compariso
P11404312A0660 |24 25|Pn
P11404312A0660 |13 22|pmol/24 h6 Compari
P11406007A0292 |0 18|SELECTION CRITERIAP00001606T0076 Com
P11406007A0292 |46 52|trialsatases
P11406007A0292 |180 185|yearsn as 
P11406007A0292 |146 154|outcomes8997A047
P11406007A0292 |79 84|forms71T00
P11406007A0292 |63 67|IUSseoti
P11406007A0292 |158 163|womenen CS
P11406007A0292 |99 113|contraceptivesc aspects of n
P11406025A0204 |34 40|reviewaline 
P11406025A0204 |75 81|safety008171
P11406025A0204 |60 73|effectivenessucleotidase P
P11406025A0204 |86 99|acceptability Pharmacologi
P11406025A0204 |107 116|diaphragms of neon
P11406025A0204 |134 144|spermicidenemia. P00
P11406025A0204 |16 25|objectiveomparison
P11406025A0204 |0 10|OBJECTIVESP00001606T
P11406277A0598 |34 42|elementsaline ph
P11406277A0598 |166 174|elementsHCO3-] i
P11406277A0598 |180 188|activityn as a f
P11406277A0598 |60 77|promoter activityucleotidase P0000
P11406277A0598 |95 123|reporter expression activitylogic aspects of neonatal hy
P11406277A0598 |147 156|mutations997A0472 
P11406277A0598 |12 22|hypothesis76 Compari
P11406277A0598 |196 224|parent Hlx promoter sequenceof CSF PCO2 the data of K-de
P11406277A0598 |127 135|segmentsilirubin
P11406642A0792 |16 21|casesompar
P11406642A0792 |52 57|genes and 
P11406642A0792 |23 33|expressionon with al
P11407289A1507 |85 94|BIS index0 Pharmac
P11407289A1507 |183 189|agentss a fu
P11407289A1507 |43 53|anesthesiasphatases 
P11407289A1507 |0 11|CONCLUSIONSP00001606T0
P11407448A0815 |289 304|speech training still have a s
P11407448A0815 |59 67|patientsnucleoti
P11407448A0815 |4 11|results01606T0
P11407448A0815 |200 216|voice prosthesisSF PCO2 the data
P11407448A0815 |143 166|tract voice restoration0008997A0472 When CSF [
P11407448A0815 |256 264|punctureced when
P11407448A0815 |84 111|jejunum flap reconstruction00 Pharmacologic aspects of
P11407650A0661 |0 13|HypercalcemiaP00001606T007
P11407650A0661 |131 132|%u
P11407650A0661 |166 174|patientsHCO3-] i
P11407650A0661 |180 194|thyroid cancern as a functio
P11407650A0661 |157 162|womenhen C
P11407650A0661 |39 62|serum PTH concentration phosphatases and 5-nuc
P11407650A0661 |82 101|hyperparathyroidism0000 Pharmacologic 
P11407650A0661 |141 145|noneP000
P11407650A0661 |117 128|BC patientstal hyperbi
P11408099A0518 |84 93|Se levels00 Pharma
P11408099A0518 |25 37|correlations with alkali
P11408099A0518 |61 66|weekscleot
P11408099A0518 |134 135|rn
P11408099A0518 |105 106|rc
P11408099A0518 |143 144|P0
P11408099A0518 |97 103|kidneygic as
P11408099A0518 |127 132|heartiliru
P11408099A0518 |114 115|Po
P11408099A0518 |70 79|pregnancye P000081
P11408338A1686 |5 10|study1606T
P11408338A1686 |25 28|PSP wi
P11408338A1686 |122 127|casesyperb
P11408338A1686 |110 118|majorityf neonat
P11408338A1686 |158 170|neurologistsen CSF [HCO3
P11408575A0000 |138 142|forma. P
P11408575A0000 |122 125|Clbype
P11408575A0000 |57 67|activation5-nucleoti
P11408575A0000 |40 47|mitosisphospha
P11408575A0000 |29 34|entryh alk
P11408575A0000 |92 104|kinase Cdc28acologic asp
P11408575A0000 |112 120|cyclin Bneonatal
P11408591A0000 |85 90|cells0 Pha
P11408591A0000 |46 48|HAat
P11408591A0000 |20 30|productionrison with
P11408591A0000 |58 64|effect-nucle
P11408591A0000 |106 119|v-src mutantsts of neonata
P11408591A0000 |34 44|hyaluronanaline phos
P11408591A0000 |68 81|cell motilityase P00008171
P11408604A1440 |186 194|pathways functio
P11408604A1440 |37 39|2Lne
P11408604A1440 |162 172|activationSF [HCO3-]
P11408604A1440 |176 182|ERK1/2shown 
P11408604A1440 |41 50|receptorshosphatas
P11408604A1440 |26 27|Dw
P11408604A1440 |120 133|PDGF receptor hyperbilirub
P11408604A1440 |216 240|receptor tyrosine kinase of K-depleted rats are 
P11408604A1440 |64 82|ERK kinase cascadeotidase P00008171T
P11408604A1440 |4 11|results01606T0
P11408604A1440 |35 36|Dl
P11408604A1440 |103 112|signalingpects of 
P11408774X0893 |0 9|Karger AGP00001606
P11408774X0893 |11 16|Basel076 C
P11409425A0000 |304 308|riskigni
P11409425A0000 |118 146|tissue plasminogen activatoral hyperbilirubinemia. P0000
P11409425A0000 |154 166|Stroke Trial2 When CSF [
P11409425A0000 |222 225|Apodep
P11409425A0000 |292 298|strokeill ha
P11409425A0000 |55 73|National Instituted 5-nucleotidase P
P11409425A0000 |148 152|t-PA97A0
P11409425A0000 |182 194|relationshipas a functio
P11409425A0000 |269 276|outcomeared to
P11409425A0000 |90 98|Diseasesrmacolog
P11409425A0000 |370 382|t-PA therapyzepam thus a
P11409425A0000 |111 116|NINDS neon
P11409425A0000 |227 229|E2te
P11409425A0000 |346 354|responsevs. P000
P11409425A0000 |15 29|plasma samplesComparison wit
P11409425A0000 |326 336|hemorrhagelope (1.21
P11409425A0000 |206 220|apolipoprotein2 the data of 
P11409425A0000 |279 285|monthsntrols
P11409425A0000 |39 47|patients phospha
P11409425A0000 |236 252|Apo E4 phenotypeare no longer di
P11409425A0000 |103 109|Strokepects 
P11410110A0190 |0 4|NIRSP000
P11410110A0190 |88 106|forearm blood flowharmacologic aspec
P11410110A0190 |62 73|consumptionleotidase P
P11410110A0190 |75 77|mV00
P11410110A0190 |127 135|subjectsilirubin
P11410110A0190 |108 111|FBF of
P11410110A0190 |78 79|O1
P11410110A0190 |35 46|measurementline phosph
P11410110A0190 |50 58|muscle Oes and 5
P11410563A0363 |115 125|valve sizenatal hype
P11410563A0363 |91 94|agemac
P11410563A0363 |31 35|riskalka
P11410563A0363 |181 193|risk factors as a functi
P11410563A0363 |60 79|regression analysisucleotidase P000081
P11410563A0363 |96 113|body surface areaogic aspects of n
P11410563A0363 |127 151|shop order fracture rateilirubinemia. P00008997A
P11410563A0363 |198 201|OSF CS
P11410563A0363 |157 177|manufacturing periodhen CSF [HCO3-] is s
P11410563A0363 |21 27|factorison w
P11410664A0963 |136 149|up-regulationmia. P0000899
P11410664A0963 |112 117|orderneona
P11410664A0963 |267 284|repair activitiesmpared to control
P11410664A0963 |215 218|BERa o
P11410664A0963 |51 83|breast carcinoma MDA-MB231 cellss and 5-nucleotidase P00008171T0
P11410664A0963 |220 225|hOGG1K-dep
P11410664A0963 |20 29|techniquerison wit
P11410664A0963 |251 259|reversalisplaced
P11410664A0963 |188 196|activityunction 
P11410664A0963 |261 265|MGMThen 
P11410664A0963 |230 237|APE/ref rats a
P11410664A0963 |165 169|step[HCO
P11410664A0963 |105 108|MPGcts
P11410664A0963 |8 14|report6T0076
P11410664A0963 |173 176|BERis 
P11410679A0000 |152 155|use472
P11410679A0000 |92 97|genesacolo
P11410679A0000 |109 134|LOX recognition sequencesof neonatal hyperbilirubi
P11410679A0000 |180 190|constructsn as a fun
P11410679A0000 |14 24|alteration Compariso
P11410679A0000 |75 88|rearrangement008171T0000 P
P11410679A0000 |45 60|Cre recombinasehatases and 5-n
P11410679A0000 |216 219|cre of
P11410679A0000 |277 286|LOX sitescontrols 
P11410679A0000 |249 253|gene dis
P11410679A0000 |257 265|interested when 
P11410679A0000 |32 38|genomelkalin
P11411198A0711 |139 153|stomach cancer. P00008997A04
P11411198A0711 |106 110|riskts o
P11411198A0711 |61 75|Ashkenazi Jewscleotidase P00
P11411198A0711 |11 17|cancer076 Co
P11411198A0711 |173 181|lymphomais shown
P11411623T0000 |0 9|InfluenceP00001606
P11411623T0000 |13 32|compression therapy6 Comparison with a
P11411623T0000 |60 73|tissue injuryucleotidase P
P11411623T0000 |97 105|exercisegic aspe
P11411623T0000 |36 44|symptomsine phos
P11411961A0735 |0 26|Keratoconjunctivitis siccaP00001606T0076 Comparison 
P11411961A0735 |92 95|JRAaco
P11411961A0735 |78 86|children171T0000
P11411961A0735 |57 69|complication5-nucleotida
P11411961A0735 |143 150|battery0008997
P11411961A0735 |154 159|tests2 Whe
P11413148A0573 |0 16|STAT5A mutationsP00001606T0076 C
P11413148A0573 |24 36|Src homologyn with alkal
P11413148A0573 |40 43|SH2pho
P11413148A0573 |92 116|tyrosine phosphorylationacologic aspects of neon
P11413148A0573 |49 60|SH3 domainsses and 5-n
P11413277A1121 |50 58|dose MTXes and 5
P11413277A1121 |92 97|PCNSLacolo
P11413277A1121 |63 68|ara-Ceotid
P11413277A1121 |23 35|chemotherapyon with alka
P11413277A1121 |3 13|conclusion001606T007
P11413310A0148 |0 6|RANTESP00001
P11413310A0148 |244 257|RSV infectiononger displac
P11413310A0148 |161 172|eosinophilsCSF [HCO3-]
P11413310A0148 |133 142|monocytesinemia. P
P11413310A0148 |91 103|CC chemokinemacologic as
P11413310A0148 |44 50|T-cellphatas
P11413310A0148 |23 33|activationon with al
P11413310A0148 |178 188|cell typesown as a f
P11413310A0148 |144 155|lymphocytes008997A0472
P11413310A0148 |222 232|infiltratedepleted r
P11413310A0148 |204 208|lungCO2 
P11413319A0000 |0 14|Reovirus mRNAsP00001606T0076
P11413319A0000 |72 79|absenceP000081
P11413319A0000 |101 106|tailsaspec
P11413319A0000 |49 59|host cellsses and 5-
P11413641A0373 |68 80|quadrat areaase P0000817
P11413641A0373 |58 64|effect-nucle
P11413641A0373 |23 36|scale matterson with alkal
P11413641A0373 |0 8|AnalysesP0000160
P11413760A0000 |0 10|MyastheniaP00001606T
P11413760A0000 |76 86|antibodies08171T0000
P11413760A0000 |62 72|productionleotidase 
P11413760A0000 |134 141|synapsenemia. 
P11413760A0000 |99 112|ACh receptorsc aspects of 
P11413760A0000 |35 42|diseaseline ph
P11414754X1099 |0 9|CopyrightP00001606
P11414754X1099 |15 29|Academic PressComparison wit
P11415633A1253 |96 107|compressionogic aspect
P11415633A1253 |37 42|inputne ph
P11415633A1253 |23 33|force dataon with al
P11415633A1253 |66 71|modelidase
P11415952A0369 |0 6|AnginaP00001
P11415952A0369 |11 22|persistence076 Compari
P11415952A0369 |105 131|electrocardiogram ischemiacts of neonatal hyperbilir
P11415952A0369 |75 85|infarction008171T000
P11415952A0369 |37 49|associationsne phosphata
P11415952A0369 |163 183|heart disease eventsF [HCO3-] is shown a
P11415952A0369 |8 9|Q6
P11415952A0369 |97 103|anginagic as
P11415952A0369 |189 191|Q5nc
P11415958A0000 |119 123|datal hy
P11415958A0000 |61 64|usecle
P11415958A0000 |45 53|advanceshatases 
P11415958A0000 |93 101|analysiscologic 
P11415958A0000 |77 88|methodology8171T0000 P
P11415958A0000 |12 18|decade76 Com
P11415958A0000 |158 168|advantagesen CSF [HC
P11415958A0000 |185 193|approacha functi
P11416012A1982 |51 53|LHs 
P11416012A1982 |128 130|bpli
P11416012A1982 |228 231|PKIed 
P11416012A1982 |56 68|contribution 5-nucleotid
P11416012A1982 |132 148|reporter plasmidbinemia. P000089
P11416012A1982 |90 95|drivermaco
P11416012A1982 |38 47|mediatione phospha
P11416012A1982 |233 241|minigenets are n
P11416012A1982 |188 226|rabbit muscle protein kinase inhibitorunction of CSF PCO2 the data of K-depl
P11416012A1982 |101 113|LDL receptoraspects of n
P11416012A1982 |274 296|sarcoma virus promoterto controls but still 
P11416012A2511 |305 311|microMgnific
P11416012A2511 |427 437|derivativethe optimu
P11416012A2511 |393 399|microMe an e
P11416012A2511 |223 233|inhibitorsepleted ra
P11416012A2511 |291 293|LYti
P11416012A2511 |267 277|wortmanninmpared to 
P11416012A2511 |94 105|stimulationologic aspe
P11416012A2511 |361 363|PD73
P11416012A2511 |449 455|microMse in 
P11416012A2511 |30 34|role alk
P11416012A2511 |172 177|cells is s
P11416012A2511 |42 72|insulin/IGF-I effector pathwayosphatases and 5-nucleotidase 
P11416012A2511 |283 285|nMls
P11416012A2511 |383 388|U0126pears
P11416012A2511 |109 141|LDL receptor promoter expressionof neonatal hyperbilirubinemia. 
P11416012A2511 |439 444|U0124dose 
P11416012A2511 |374 380|microMm thus
P11416012A2511 |201 204|minF P
P11416012A2511 |338 359|protein kinase kinase/- 0.23 vs. P00010943
P11416012A2511 |409 415|latterypnoti
P11416012A2511 |237 265|phophatidylinositol 3-kinasere no longer displaced when 
P11416012T0000 |85 92|insulin0 Pharm
P11416012T0000 |203 232|phosphatidylinositol 3-kinasePCO2 the data of K-depleted r
P11416012T0000 |129 136|porcineirubine
P11416012T0000 |109 116|hormoneof neon
P11416012T0000 |26 36|activationwith alkal
P11416012T0000 |154 159|cells2 Whe
P11416012T0000 |185 199|protein kinasea function of 
P11416012T0000 |48 81|density lipoprotein receptor geneases and 5-nucleotidase P00008171
P11416012T0000 |256 289|protein kinase signaling pathwaysced when compared to controls but
P11416012T0000 |170 181|convergence-] is shown
P11416132A1351 |84 109|repeat binding activities00 Pharmacologic aspects 
P11416132A1351 |75 76|d0
P11416132A1351 |45 56|recognitionhatases and
P11416132A1351 |6 13|studies606T007
P11416132A1351 |77 79|GA81
P11416132A1351 |133 142|silencinginemia. P
P11416132A1351 |64 71|bxd PREotidase
P11416132A1351 |81 82|nT
P11416144A1324 |102 111|mechanismspects of
P11416144A1324 |125 136|p53 proteinrbilirubine
P11416144A1324 |63 81|cell proliferationeotidase P00008171
P11416144A1324 |46 52|ZBP-89atases
P11416144A1324 |25 38|understanding with alkalin
P11416144A1324 |4 12|findings01606T00
P11416260A0000 |172 185|data analysis is shown as 
P11416260A0000 |47 52|pointtases
P11416260A0000 |15 21|methodCompar
P11416260A0000 |108 116|patients of neon
P11416260A0000 |67 75|activitydase P00
P11416393A0000 |548 551|dayen 
P11416393A0000 |481 486|drugsmg at
P11416393A0000 |301 319|sodium restrictiona significantly gr
P11416393A0000 |180 191|body weightn as a func
P11416393A0000 |210 214|riske da
P11416393A0000 |442 449|numberse for u
P11416393A0000 |505 524|alcohol consumption045 Beta blocking a
P11416393A0000 |36 46|approachesine phosph
P11416393A0000 |105 112|controlcts of 
P11416393A0000 |352 361|assurance0010943A0
P11416393A0000 |431 437|dosageoptimu
P11416393A0000 |491 501|moderationt. P000126
P11416393A0000 |540 545|ounceA0210
P11416393A0000 |600 609|cessationction (VC
P11416393A0000 |125 149|blood pressure elevationrbilirubinemia. P0000899
P11416393A0000 |394 402|pressure an effe
P11416393A0000 |154 170|weight reduction2 When CSF [HCO3
P11416393A0000 |218 230|hypertensionf K-depleted
P11416393A0000 |575 591|exercise programal approximated 
P11416393A0000 |335 336|g1
P11416393A0000 |265 274|morbiditycompared 
P11416393A0000 |5 15|modalities1606T0076 
P11416393A0000 |613 632|tobacco consumption alveolar ventilati
P11416393A0000 |78 100|lifestyle modification171T0000 Pharmacologic
P11416393A0000 |339 342|day- 0
P11416393A0000 |279 288|mortalityntrols bu
P11416650T0000 |35 41|Updateline p
P11416650T0000 |18 30|Hypertensionparison with
P11416737T0000 |0 5|Ga-67P0000
P11416737T0000 |10 29|Tl-201 scintigraphy0076 Comparison wit
P11416737T0000 |64 75|case reportotidase P00
P11416737T0000 |48 60|plasmacytomaases and 5-n
P11416879A1589 |52 69|ventilation modes and 5-nucleotida
P11416879A1589 |9 27|blood gas tensionsT0076 Comparison w
P11418130A0499 |24 38|loxP sequencesn with alkalin
P11418130A0499 |74 87|recombination0008171T0000 
P11418662A0917 |119 128|NF-kappaBl hyperbi
P11418662A0917 |15 22|portionCompari
P11418662A0917 |95 106|p50 subunitlogic aspec
P11418662A0917 |26 31|Notchwith 
P11418662A0917 |46 61|p50 DNA bindingatases and 5-nu
P11418662A0917 |112 115|p65neo
P11418662A0917 |32 34|IClk
P11419938T0000 |68 84|metal activationase P00008171T00
P11419938T0000 |15 22|changesCompari
P11419938T0000 |108 116|evidence of neon
P11419938T0000 |89 100|DNA bindingarmacologic
P11419938T0000 |151 177|diphtheria toxin repressor0472 When CSF [HCO3-] is s
P11419938T0000 |131 141|homologiesubinemia. 
P11419938T0000 |37 62|uptake regulation proteinne phosphatases and 5-nuc
P11420612A0303 |153 161|interest72 When 
P11420612A0303 |31 38|mappingalkalin
P11420612A0303 |142 149|regions0000899
P11420612A0303 |43 61|sequencing effortssphatases and 5-nu
P11420612A0303 |106 110|mapsts o
P11420612A0303 |5 15|complement1606T0076 
P11420612A0303 |115 128|sequence datanatal hyperbi
P11422200A0000 |0 11|GranulocyteP00001606T0
P11422200A0000 |31 37|factoralkali
P11422200A0000 |126 135|infectionbilirubin
P11422200A0000 |46 60|administrationatases and 5-n
P11422200A0000 |149 157|microbes7A0472 W
P11422200A0000 |39 44|G-CSF phos
P11422200A0000 |99 117|defence mechanismsc aspects of neona
P11422757A0737 |80 88|baseline1T0000 P
P11422757A0737 |28 35|changesth alka
P11422757A0737 |6 17|individuals606T0076 Co
P11422757A0737 |66 76|ACR levelsidase P000
P11423991A1393 |136 145|responsesmia. P000
P11423991A1393 |10 16|screen0076 C
P11423991A1393 |67 79|p53 variantsdase P000081
P11423991A1393 |42 47|yeastospha
P11423991A1393 |27 38|p53 mutantsith alkalin
P11423991A1393 |113 116|p53eon
P11423991A1393 |174 190|cancer therapiess shown as a fun
P11424992A0712 |33 42|diagnoseskaline ph
P11424992A0712 |111 119|criteria neonata
P11425076A0364 |49 54|flowsses a
P11425076A0364 |165 172|inertia[HCO3-]
P11425076A0364 |194 221|perturbation theory resultsn of CSF PCO2 the data of K
P11425076A0364 |75 80|alpha00817
P11425076A0364 |60 66|resultucleot
P11425076A0364 |109 115|valuesof neo
P11425076A0364 |123 138|Reynolds numberperbilirubinemi
P11425076A0364 |225 235|comparisonleted rats
P11425076A0364 |277 282|modelcontr
P11425076A0364 |253 264|integrationplaced when
P11425877A1026 |0 5|CellsP0000
P11425877A1026 |176 184|decreaseshown as
P11425877A1026 |14 18|p116 Com
P11425877A1026 |258 273|F-actin contentd when compared
P11425877A1026 |86 96|structures Pharmacol
P11425877A1026 |218 229|aggregationf K-deplete
P11425877A1026 |52 61|formation and 5-nu
P11425877A1026 |112 121|reductionneonatal 
P11425877A1026 |38 44|defecte phos
P11425877A1026 |129 133|rateirub
P11425877A1026 |192 202|efficiencyion of CSF
P11425877A1026 |237 245|decreasere no lo
P11425877A1026 |137 160|fluid phase pinocytosisia. P00008997A0472 When
P11427329A1077 |152 158|sample472 Wh
P11427329A1077 |129 130|Ni
P11427329A1077 |94 95|ro
P11427329A1077 |89 92|VASarm
P11427329A1077 |121 122|rh
P11427329A1077 |4 12|validity01606T00
P11427329A1077 |20 25|FPS-Rrison
P11427329A1077 |67 79|correlationsdase P000081
P11427329A1077 |116 119|CASata
P11427329A1077 |102 103|Ns
P11427611A0000 |34 43|fumigatusaline pho
P11427611A0000 |195 200|NCCLS of C
P11427611A0000 |114 120|agentsonatal
P11427611A0000 |263 275|phenyl-aminon compared t
P11427611A0000 |83 91|compound000 Phar
P11427611A0000 |391 401|microscopy be an eff
P11427611A0000 |276 284|carbonyl control
P11427611A0000 |312 315|XTTntl
P11427611A0000 |347 360|determinations. P00010943A
P11427611A0000 |287 310|H-tetrazolium hydroxideut still have a signifi
P11427611A0000 |376 387|alterationsthus appear
P11427611A0000 |47 60|mulundocandintases and 5-n
P11427611A0000 |173 193|Laboratory Standardsis shown as a functi
P11427611A0000 |336 341|assay +/- 
P11427611A0000 |202 214|M38-P method PCO2 the da
P11427611A0000 |141 159|National CommitteeP00008997A0472 Whe
P11427611A0000 |4 18|susceptibility01606T0076 Com
P11428276A0352 |69 81|calcium saltse P00008171
P11428276A0352 |95 103|increaselogic as
P11428276A0352 |12 17|Hoeve76 Co
P11428276A0352 |107 117|phosphatess of neona
P11428276A0352 |20 36|syndrome lesionsrison with alkal
P11428276A0352 |4 7|Van016
P11428283A0228 |48 55|stridorases an
P11428283A0228 |14 20|infant Compa
P11428283A0228 |78 86|distress171T0000
P11428435A0446 |0 6|DESIGNP00001
P11428435A0446 |24 36|chart reviewn with alkal
P11428435A0446 |46 54|patientsatases a
P11428435A0446 |75 85|procedures008171T000
P11428435A0446 |93 107|period Januarycologic aspect
P11428435A0446 |116 124|Decemberatal hyp
P11428487T0000 |24 35|associationn with alka
P11428487T0000 |61 74|vein stenosiscleotidase P0
P11428487T0000 |10 20|vein varix0076 Compa
P11428897A0318 |259 263|CopG whe
P11428897A0318 |231 237|repeatrats a
P11428897A0318 |78 88|target DNA171T0000 P
P11428897A0318 |40 44|CopGphos
P11428897A0318 |12 23|experiments76 Comparis
P11428897A0318 |104 114|DNA ratiosects of ne
P11428897A0318 |151 156|turns0472 
P11428897A0318 |188 193|helixuncti
P11428897A0318 |96 103|proteinogic as
P11428897A0318 |202 212|directions PCO2 the 
P11428897A0318 |272 278|targetd to c
P11428897A0318 |169 173|face3-] 
P11429702A0917 |190 205|K650E receptorsction of CSF PC
P11429702A0917 |162 172|activationSF [HCO3-]
P11429702A0917 |270 294|receptor phosphorylationred to controls but stil
P11429702A0917 |227 238|aFGF ligandted rats ar
P11429702A0917 |122 135|FGFR3 mutantsyperbilirubin
P11429702A0917 |180 185|Y373Cn as 
P11429702A0917 |211 219|addition data of
P11429702A0917 |261 266|levelhen c
P11429702A0917 |97 103|levelsgic as
P11429702A0917 |42 52|conditionsosphatases
P11429702A0917 |54 60|KMS-11nd 5-n
P11429702A0917 |65 76|OPM-2 cellstidase P000
P11430042A0000 |153 159|liquid72 Whe
P11430042A0000 |13 17|text6 Co
P11430042A0000 |98 115|tetrafluoroborateic aspects of neo
P11430042A0000 |23 47|Stille coupling reactionon with alkaline phospha
P11430042A0000 |161 165|RTILCSF 
P11430042A0000 |117 125|BMIM BF4tal hype
P11430042A0000 |1 7|figure000016
P11430976X0000 |82 92|substances0000 Pharm
P11430976X0000 |30 42|biosynthesis alkaline ph
P11430976X0000 |46 69|woody plant biopolymersatases and 5-nucleotida
P11430976X0000 |8 14|issues6T0076
P11431348A0000 |152 164|MAPK pathway472 When CSF
P11431348A0000 |189 196|varietynction 
P11431348A0000 |25 52|checkpoint abrogator UCN-01 with alkaline phosphatases
P11431348A0000 |147 150|MEK997
P11431348A0000 |133 137|MAPKinem
P11431348A0000 |117 131|protein kinasetal hyperbilir
P11431348A0000 |206 225|leukemia cell lines2 the data of K-dep
P11431348A0000 |81 91|inhibitorsT0000 Phar
P11431348A0000 |139 145|kinase. P000
P11431348A0000 |0 12|InteractionsP00001606T00
P11431472A0540 |55 56|dd
P11431472A0540 |105 106|Ac
P11431472A0540 |53 54|Ka
P11431472A0540 |24 33|Rab6A-GTPn with al
P11431472A0540 |63 69|micromeotida
P11431472A0540 |80 85|Rab1B1T000
P11431472A0540 |4 20|affinity binding01606T0076 Compa
P11431857A0186 |4 12|students01606T00
P11431857A0186 |149 163|urine analysis7A0472 When CS
P11431857A0186 |90 104|urine analysisrmacologic asp
P11431857A0186 |30 45|urine screening alkaline phosp
P11431857A0186 |67 71|timedase
P11431857A0186 |114 118|daysonat
P11432112A0000 |85 86|h0
P11432112A0000 |57 72|embryo cleavage5-nucleotidase 
P11432112A0000 |13 22|objective6 Compari
P11432112A0000 |74 77|FEC000
P11432112A0000 |31 36|studyalkal
P11432112A0000 |156 180|embryo selection processWhen CSF [HCO3-] is show
P11432112A0000 |127 131|ICSIilir
P11432112A0000 |110 125|sperm injectionf neonatal hype
P11432112A0000 |138 147|parametera. P00008
P11432112A0000 |0 7|PURPOSEP000016
P11432748T0000 |0 10|RegulationP00001606T
P11432748T0000 |14 49|laminin beta2 chain gene expression Comparison with alkaline phosphata
P11432748T0000 |59 76|cancer cell linesnucleotidase P000
P11432776A0421 |0 8|NorthernP0000160
P11432776A0421 |109 119|expressionof neonata
P11432776A0421 |132 138|musclebinemi
P11432776A0421 |13 34|Western blot analyses6 Comparison with alk
P11432776A0421 |53 58|Graf2and 5
P11432776A0421 |83 90|tissues000 Pha
P11433014A0683 |54 70|core histone H2And 5-nucleotidas
P11433014A0683 |109 112|MCBof 
P11433014A0683 |74 77|H2B000
P11433014A0683 |44 50|fusionphatas
P11433014A0683 |95 99|taillogi
P11433014A0683 |162 169|proteinSF [HCO
P11433018A0756 |136 145|stabilitymia. P000
P11433018A0756 |58 71|H/ACA snoRNAs-nucleotidase
P11433018A0756 |104 117|H/ACA snoRNPsects of neona
P11433018A0756 |6 10|data606T
P11433018A0756 |163 173|componentsF [HCO3-] 
P11433018A0756 |92 100|assemblyacologic
P11433018A0756 |38 45|bindinge phosp
P11433018A0756 |49 54|Nhp2pses a
P11433024A0260 |0 10|TelomeraseP00001606T
P11433024A0260 |117 125|templatetal hype
P11433024A0260 |100 113|RNA component aspects of n
P11433024A0260 |78 89|chromosomes171T0000 Ph
P11433024A0260 |16 41|ribonucleoprotein complexomparison with alkaline p
P11433024A0260 |69 72|DNAse 
P11433379A0000 |0 3|SITP00
P11433379A0000 |131 142|lymphocytesubinemia. P
P11433379A0000 |92 107|adaptor proteinacologic aspect
P11433379A0000 |36 51|adaptor proteinine phosphatase
P11434084A0508 |85 92|d-dimer0 Pharm
P11434084A0508 |15 26|patients DDComparison 
P11434084A0508 |50 66|microlatex testses and 5-nucleot
P11435428A0000 |51 58|acetates and 5
P11435428A0000 |99 114|lipid synthesisc aspects of ne
P11435428A0000 |10 31|acetyl-CoA synthetase0076 Comparison with 
P11435428A0000 |73 78|cells00008
P11435428A0000 |33 39|AceCS1kaline
P11435428A0000 |84 94|acetyl-CoA00 Pharmac
P11435517A0396 |102 103|Ps
P11435517A0396 |125 130|dietsrbili
P11435517A0396 |29 31|OMh 
P11435517A0396 |86 88|GE P
P11435517A0396 |116 120|dogsatal
P11435517A0396 |155 160|fiber When
P11435517A0396 |188 200|control dietunction of C
P11435517A0396 |25 27|DM w
P11435517A0396 |58 61|TDF-nu
P11435517A0396 |6 21|digestibilities606T0076 Compar
P11435517A0396 |78 84|energy171T00
P11435517A0396 |51 56|fibers and
P11435517A0396 |175 179|dogs sho
P11435517A0396 |33 35|CPka
P11435560A1322 |102 117|target HFV mRNAspects of neona
P11435560A1322 |60 67|nucleusucleoti
P11435560A1322 |15 19|dataComp
P11435560A1322 |94 98|fateolog
P11435560A1322 |35 47|HFV R regionline phospha
P11435578A0760 |51 54|CREs a
P11435578A0760 |79 87|TGACGTCA71T0000 
P11435578A0760 |41 49|elementshosphata
P11435578A0760 |89 98|consensusarmacolog
P11435578A0760 |173 181|TGACCTCAis shown
P11435578A0760 |6 10|TxRE606T
P11435578A0760 |163 171|TGACGGCAF [HCO3-
P11435578A0760 |140 146|strain P0000
P11435578A0760 |153 161|AGACGTCA72 When 
P11435578A2231 |171 184|transcription] is shown as
P11435578A2231 |75 84|enhancers008171T00
P11435578A2231 |43 56|consensus CREsphatases and
P11435578A2231 |95 102|bindinglogic a
P11435578A2231 |106 123|CREB/ATF proteinsts of neonatal hy
P11435578A2231 |144 154|repression008997A047
P11435578A2231 |23 37|reconstitutionon with alkali
P11435605A0587 |137 142|Tyr83ia. P
P11435605A0587 |29 32|CARh a
P11435605A0587 |104 120|contact residuesects of neonatal
P11435605A0587 |84 90|Lys12300 Pha
P11435605A0587 |217 221|Ad12of K
P11435605A0587 |127 132|Tyr80iliru
P11435605A0587 |178 197|binding interactionown as a function o
P11435605A0587 |212 215|Ad9dat
P11435605A0587 |227 244|Ad41L fiber knobsted rats are no l
P11435605A0587 |47 65|CAR residues Leu73tases and 5-nucleo
P11435605A0587 |14 25|mutagenesis Comparison
P11435605A0587 |207 210|Ad5 th
P11435605A0587 |70 76|Lys121e P000
P11435688A0262 |68 78|N-terminusase P00008
P11435688A0262 |54 60|domainnd 5-n
P11435688A0262 |5 14|subfamily1606T0076
P11435688A0262 |110 132|transmembrane segmentsf neonatal hyperbiliru
P11435688A0262 |18 23|genesparis
P11435688A0262 |103 106|setpec
P11435983T0000 |0 9|ToleranceP00001606
P11435983T0000 |52 63|bone marrow and 5-nucl
P11435983T0000 |19 34|transplantationarison with alk
P11435983T0000 |87 96|follow-upPharmacol
P11437439A0201 |87 101|prestalk cellsPharmacologic 
P11437439A0201 |77 83|subset8171T0
P11437439A0201 |4 21|promoter activity01606T0076 Compar
P11437439A0201 |38 44|regione phos
P11437660A1219 |0 12|SubstitutionP00001606T00
P11437660A1219 |73 94|phosphorylation sites00008171T0000 Pharmac
P11437660A1219 |150 161|replicationA0472 When 
P11437660A1219 |39 49|C-terminus phosphata
P11437660A1219 |132 145|transcriptionbinemia. P000
P11437660A1219 |122 128|effectyperbi
P11437660A1219 |65 69|losstida
P11437660A1219 |16 31|serine residuesomparison with 
P11438651A1365 |137 142|Orc2pia. P
P11438651A1365 |60 66|originucleot
P11438651A1365 |163 184|replication initiatorF [HCO3-] is shown as
P11438651A1365 |146 155|component8997A0472
P11438651A1365 |90 112|replication initiationrmacologic aspects of 
P11438651A1365 |37 40|HMLne 
P11438651A1365 |6 31|replication fork movement606T0076 Comparison with 
P11438654A1237 |32 44|adapter Gab1lkaline phos
P11438654A1237 |82 86|PI3K0000
P11438654A1237 |58 73|c-Met signaling-nucleotidase P
P11438654A1237 |6 14|findings606T0076
P11438654A1237 |99 131|c-Akt/Pak1 cell survival pathwayc aspects of neonatal hyperbilir
P11438666A0555 |169 184|TFIID component3-] is shown as
P11438666A0555 |131 150|immunoprecipitationubinemia. P00008997
P11438666A0555 |74 91|plant homeodomain0008171T0000 Phar
P11438666A0555 |38 41|TAFe p
P11438666A0555 |23 36|mouse proteinon with alkal
P11438666A0555 |93 96|PHDcol
P11438666A0555 |64 67|HFDoti
P11438666A0555 |98 104|fingeric asp
P11438838A0788 |33 42|TAR decoykaline ph
P11438838A0788 |89 93|U6-Parma
P11438838A0788 |75 87|RNA promoter008171T0000 
P11438838A0788 |10 19|inhibitor0076 Comp
P11438838A0788 |58 60|U6-n
P11439343A0785 |3 11|contrast001606T0
P11439343A0785 |44 58|Pc protein M33phatases and 5
P11439343A0785 |15 19|MPc3Comp
P11439343A0785 |82 85|AF9000
P11439343A0785 |21 25|dataison
P11441163T0000 |0 10|ForeignersP00001606T
P11441311X0001 |205 208|NHLO2 
P11441311X0001 |10 17|results0076 Co
P11441311X0001 |79 89|BACKGROUND71T0000 Ph
P11441311X0001 |132 153|chemotherapy regimensbinemia. P00008997A04
P11441311X0001 |194 203|lymphomasn of CSF 
P11441311X0001 |169 176|factors3-] is 
P11441311X0001 |101 108|resultsaspects
P11441311X0001 |23 30|MACOP-Bon with
P11441311X0001 |35 52|radiation therapyline phosphatases
P11441311X0001 |68 77|lymphomasase P0000
P11441952A0414 |140 150|difference P00008997
P11441952A0414 |183 184|bs
P11441952A0414 |83 93|percentage000 Pharma
P11441952A0414 |52 56|rats and
P11441952A0414 |112 120|controlsneonatal
P11441952A0414 |24 30|monthsn with
P11441952A0414 |215 219|testa of
P11441952A0414 |245 248|TBInge
P11441952A0414 |12 13|D7
P11441952A0414 |166 181|months post-TBIHCO3-] is shown
P11441952A0414 |194 208|avoidance testn of CSF PCO2 
P11441952A0414 |97 106|avoidancegic aspec
P11441952A0414 |6 10|days606T
P11441974A0320 |50 63|hemolymph PO2es and 5-nucl
P11441974A0320 |26 35|migrationwith alka
P11441974A0320 |149 156|reserve7A0472 
P11441974A0320 |83 86|kPa000
P11441974A0320 |189 197|mmol x lnction o
P11441974A0320 |7 10|end06T
P11441974A0320 |96 106|hemocyaninogic aspec
P11441974A0320 |19 22|dayari
P11443509A0293 |0 6|DESIGNP00001
P11443509A0293 |93 111|Examination Surveycologic aspects of
P11443509A0293 |43 44|ys
P11443509A0293 |147 152|Study997A0
P11443509A0293 |20 32|cohort studyrison with a
P11443509A0293 |113 119|NHANESeonata
P11443509A0293 |67 88|First National Healthdase P00008171T0000 P
P11443509A0293 |55 61|periodd 5-nu
P11443509A0293 |154 159|NHEFS2 Whe
P11443999A0573 |0 22|Mean Hg concentrationsP00001606T0076 Compari
P11443999A0573 |40 44|micephos
P11443999A0573 |62 73|Isle Royaleleotidase P
P11443999A0573 |30 36|livers alkal
P11443999A0573 |155 174|government agencies When CSF [HCO3-] i
P11443999A0573 |201 212|consumptionF PCO2 the 
P11443999A0573 |53 58|sitesand 5
P11443999A0573 |103 104|Pp
P11443999A0573 |118 135|Hg concentrationsal hyperbilirubin
P11444762A0373 |100 106|action aspec
P11444762A0373 |25 34|proposals with alk
P11444762A0373 |91 96|onsetmacol
P11444762A0373 |67 71|datadase
P11444762A0373 |55 63|analysisd 5-nucl
P11445008A0816 |38 48|comparisone phosphat
P11445008A0816 |61 83|FGFR expression levelscleotidase P00008171T0
P11445008A0816 |134 150|RNA pool samplesnemia. P00008997
P11445008A0816 |106 114|RNA poolts of ne
P11445008A0816 |4 9|assay01606
P11447490A0598 |49 54|fluidses a
P11447490A0598 |79 89|assessment71T0000 Ph
P11447490A0598 |22 30|effusionson with
P11447490A0598 |4 10|amount01606T
P11448051A0093 |222 229|polymerdeplete
P11448051A0093 |231 245|Eudragit RS100rats are no lo
P11448051A0093 |145 151|matrix08997A
P11448051A0093 |182 186|NaClas a
P11448051A0093 |62 84|intestine transit timeleotidase P00008171T00
P11448051A0093 |4 10|system01606T
P11448051A0093 |188 196|mannitolunction 
P11448051A0093 |202 207|Emdex PCO2
P11448051A0093 |175 180|agent show
P11448051A0093 |116 120|coreatal
P11449014A0000 |0 15|STUDY OBJECTIVEP00001606T0076 
P11449014A0000 |124 130|trialserbili
P11449014A0000 |209 212|E/Bhe 
P11449014A0000 |132 136|CCTsbine
P11449014A0000 |60 67|aspectsucleoti
P11449014A0000 |83 90|quality000 Pha
P11449014A0000 |22 27|studyson w
P11449014A0000 |177 207|epidemiologist/biostatisticianhown as a function of CSF PCO2
P11449014A0000 |157 170|participationhen CSF [HCO3
P11449014A0000 |141 149|relationP0000899
P11450490A0565 |186 191|range func
P11450490A0565 |110 115|linesf neo
P11450490A0565 |46 52|acuityatases
P11450490A0565 |62 82|range hand motions/0leotidase P00008171T
P11450490A0565 |170 176|acuity-] is 
P11450490A0565 |204 205|PC
P11450776T0000 |23 28|groupon wi
P11450776T0000 |45 56|peritonitishatases and
P11450776T0000 |7 11|case06T0
P11451447A0205 |0 5|GimplP0000
P11451447A0205 |7 9|F.06
P11451682A0190 |65 100|benzimidazole carbamate derivativestidase P00008171T0000 Pharmacologic
P11451682A0190 |12 24|chemotherapy76 Compariso
P11451682A0190 |47 61|administrationtases and 5-nu
P11451682A0190 |28 30|AEth
P11451682A0190 |126 137|albendazolebilirubinem
P11451682A0190 |110 121|mebendazolef neonatal 
P11451995T0000 |81 87|memberT0000 
P11451995T0000 |27 35|analysisith alka
P11451995T0000 |95 146|isoprenylcysteine carboxyl methyltransferase familylogic aspects of neonatal hyperbilirubinemia. P0000
P11451995T0000 |64 70|Ste14potidas
P11454004T0000 |136 160|hormone-response elementmia. P00008997A0472 When
P11454004T0000 |108 122|identification of neonatal h
P11454004T0000 |67 106|glycerol-3-phosphate dehydrogenase genedase P00008171T0000 Pharmacologic aspec
P11454004T0000 |179 190|promoter B.wn as a fun
P11454004T0000 |9 19|regulationT0076 Comp
P11454004T0000 |32 41|promoterslkaline p
P11454004T0000 |49 52|ratses
P11454190A0000 |17 28|Hepatitis Cmparison wi
P11454190A0000 |46 65|fatty liver diseaseatases and 5-nucleo
P11454190A0000 |67 71|NAFLdase
P11454190A0000 |127 140|United Statesilirubinemia.
P11454190A0000 |106 119|liver diseasets of neonata
P11454190A0000 |97 102|formsgic a
P11454190A0000 |0 15|BACKGROUND/AIMSP00001606T0076 
P11454239A0478 |279 284|alphantrol
P11454239A0478 |89 118|Principal Components Analysisarmacologic aspects of neonat
P11454239A0478 |123 153|Discriminant Function Analysisperbilirubinemia. P00008997A04
P11454239A0478 |30 35|ANOVA alka
P11454239A0478 |195 200|alpha of C
P11454239A0478 |216 227|Sensitivity of K-deple
P11454239A0478 |188 193|alphauncti
P11454239A0478 |267 276|Chronbachmpared to
P11454239A0478 |299 304|scalee a s
P11454239A0478 |177 185|Cronbachhown as 
P11454239A0478 |162 173|calculationSF [HCO3-] 
P11454239A0478 |41 87|Pearson Product Moment Correlation Coefficienthosphatases and 5-nucleotidase P00008171T0000 
P11454239A0478 |12 20|Analysis76 Compa
P11454239A0478 |232 243|specificityats are no 
P11454239A0478 |202 209|RESULTS PCO2 t
P11454703A0000 |51 62|maintenances and 5-nuc
P11454703A0000 |228 241|tumorigenesised rats are n
P11454703A0000 |150 155|cellsA0472
P11454703A0000 |83 98|chromosome ends000 Pharmacolog
P11454703A0000 |76 79|DNA081
P11454703A0000 |27 34|complexith alk
P11454703A0000 |4 14|telomerase01606T0076
P11454703A0000 |201 216|immortalizationF PCO2 the data
P11456259A0142 |51 55|TBIIs an
P11456259A0142 |13 49|TSH binding inhibitor immunoglobulin6 Comparison with alkaline phosphata
P11456259A0142 |76 77|%0
P11456259A0142 |89 101|presentationarmacologic 
P11456259A0142 |122 127|weeksyperb
P11456259A0142 |4 9|titer01606
P11456259A0142 |115 116|%n
P11457139A0604 |119 125|GlcNAcl hype
P11457139A0604 |22 25|CVNson
P11457139A0604 |80 86|GlcNAc1T0000
P11457139A0604 |65 77|affinity Mantidase P0000
P11457139A0604 |113 116|Maneon
P11457139A0604 |4 11|results01606T0
P11457139A0604 |98 109|D1D3 isomeric aspects 
P11459048A0485 |33 46|uncertaintieskaline phosph
P11459048A0485 |93 103|atmospherecologic as
P11459048A0485 |109 114|Venusof ne
P11459048A0485 |74 81|planets0008171
P11459048A0485 |54 60|modelsnd 5-n
P11459048A0485 |157 172|rotation stateshen CSF [HCO3-]
P11459304T0078 |0 21|Enantiomer separationP00001606T0076 Compar
P11459304T0078 |73 79|plasma000081
P11459304T0078 |41 63|O-desmethylvenlafaxinehosphatases and 5-nucl
P11459304T0078 |25 36|venlafaxine with alkal
P11459794A1172 |0 12|TE-671 cellsP00001606T00
P11459794A1172 |128 144|GnRH-II promoterlirubinemia. P00
P11459794A1172 |40 61|cAMP response elementphosphatases and 5-nu
P11459794A1172 |112 120|activityneonatal
P11459794A1172 |69 79|constructsse P000081
P11459960A1109 |81 92|heat labileT0000 Pharm
P11459960A1109 |39 49|components phosphata
P11459960A1109 |55 59|heatd 5-
P11459962A0785 |220 226|growthK-depl
P11459962A0785 |158 167|degrees Cen CSF [H
P11459962A0785 |67 81|repair pathwaydase P00008171
P11459962A0785 |192 201|degrees Cion of CS
P11459962A0785 |45 50|Rad52hatas
P11459962A0785 |115 134|rad27 Delta strainsnatal hyperbilirubi
P11459962A0785 |203 215|temperaturesPCO2 the dat
P11459962A0785 |173 187|semipermissiveis shown as a 
P11459962A0785 |32 37|geneslkali
P11459962A0785 |103 111|survivalpects of
P11460035A0548 |86 98|imputability Pharmacolog
P11460035A0548 |12 16|case76 C
P11460035A0548 |61 72|fluvoxaminecleotidase 
P11460035A0548 |43 56|carbamazepinesphatases and
P11460035A0548 |23 41|hydroxychloroquineon with alkaline p
P11461595A0000 |118 121|B+Bal 
P11461595A0000 |88 104|coalescence typeharmacologic asp
P11461595A0000 |164 169|flows [HCO
P11461595A0000 |108 116|reaction of neon
P11461595A0000 |124 125|Be
P11461595A0000 |56 65|particles 5-nucleo
P11461595A0000 |71 78|inertia P00008
P11461595A0000 |19 36|reaction kineticsarison with alkal
P11462004A0886 |68 77|advantagease P0000
P11462004A0886 |31 40|infectionalkaline 
P11462004A0886 |4 8|role0160
P11462004A0886 |113 115|N.eo
P11462004A0886 |96 111|complementationogic aspects of
P11462004A0886 |81 84|NLST00
P11462004A0886 |16 23|Vp1 DBDomparis
P11462004A1500 |205 208|Vp1O2 
P11462004A1500 |92 95|Vp2aco
P11462004A1500 |77 84|nucleus8171T00
P11462004A1500 |33 37|Vp1skali
P11462004A1500 |189 201|localizationnction of CS
P11462004A1500 |162 168|signalSF [HC
P11462004A1500 |100 103|Vp3 as
P11462004A1500 |137 141|NLS1ia. 
P11462024A0306 |0 3|ZhuP00
P11462024A0306 |5 7|V.16
P11462952A1040 |69 73|mU/Lse P
P11462952A1040 |94 98|mU/Lolog
P11462952A1040 |31 36|rangealkal
P11462952A1040 |45 49|mU/Lhata
P11462952A1040 |8 22|gastrin levels6T0076 Compari
P11462952A1040 |82 86|mean0000
P11463359A0167 |23 40|phorbol ester PMAon with alkaline 
P11463359A0167 |193 213|H4IIE hepatoma cellson of CSF PCO2 the d
P11463359A0167 |150 165|G6Pase promoterA0472 When CSF 
P11463359A0167 |135 142|controlemia. P
P11463359A0167 |109 124|luciferase geneof neonatal hyp
P11463359A0167 |93 103|expressioncologic as
P11463834A0606 |137 143|regionia. P0
P11463834A0606 |106 112|regionts of 
P11463834A0606 |42 53|amino acidsosphatases 
P11463834A0606 |8 28|deletion mutagenesis6T0076 Comparison wi
P11463834A0606 |148 163|Tax interaction97A0472 When CS
P11463834A0606 |116 119|CR2ata
P11463834A0606 |70 73|CBPe P
P11464997A0566 |99 105|familyc aspe
P11464997A0566 |72 82|counselingP00008171T
P11464997A0566 |29 38|diagnosish alkalin
P11464997A0566 |60 67|patientucleoti
P11464997A0566 |43 52|treatmentsphatases
P11464997A0566 |5 14|knowledge1606T0076
P11465518A0000 |0 10|BACKGROUNDP00001606T
P11465518A0000 |56 69|investigators 5-nucleotida
P11465518A0000 |195 206|individuals of CSF PCO
P11465518A0000 |105 109|wayscts 
P11465518A0000 |48 52|partases
P11465518A0000 |131 141|treatmentsubinemia. 
P11465518A0000 |78 84|public171T00
P11465518A0000 |32 40|interestlkaline 
P11465518A0000 |222 227|risksdeple
P11465655A0439 |119 125|mg/dayl hype
P11465655A0439 |93 99|mg/daycologi
P11465655A0439 |12 16|week76 C
P11465655A0439 |135 139|weekemia
P11465655A0439 |82 86|dose0000
P11465655A0439 |38 57|antagonist atenolole phosphatases and 
P11465844T0000 |85 101|Rickettsia typhi0 Pharmacologic 
P11465844T0000 |124 154|Ehrlichia phagocytophila grouperbilirubinemia. P00008997A047
P11465844T0000 |28 45|Kawasaki syndrometh alkaline phosp
P11465844T0000 |50 59|infectiones and 5-
P11465844T0000 |65 83|Rickettsia conoriitidase P00008171T0
P11465844T0000 |8 19|association6T0076 Comp
P11465844T0000 |103 120|Coxiella burnetiipects of neonatal
P11465844T0000 |0 4|LackP000
P11466227A1665 |85 87|EB0 
P11466227A1665 |89 106|mTf-CAT constructarmacologic aspec
P11466227A1665 |67 77|activationdase P0000
P11466227A1665 |40 46|effectphosph
P11466227A1665 |133 143|activationinemia. P0
P11466227A1665 |4 12|presence01606T00
P11466227A1665 |16 24|AS-oligoompariso
P11467349A0452 |22 26|taskson 
P11467349A0452 |45 53|measureshatases 
P11467349A0452 |57 68|ISF glucose5-nucleotid
P11468958A0122 |171 180|donations] is show
P11468958A0122 |267 275|concernsmpared t
P11468958A0122 |94 100|recallologic
P11468958A0122 |104 109|bloodects 
P11468958A0122 |186 197|individuals function o
P11468958A0122 |153 161|decision72 When 
P11468958A0122 |117 122|donortal h
P11468958A0122 |295 298|CJD ha
P11468958A0122 |213 227|travel historyata of K-deple
P11468958A0122 |36 51|policy analysisine phosphatase
P11468958A0122 |76 85|decisions08171T000
P11468958A0122 |14 21|results Compar
P11468958A0122 |235 237|UK a
P11468958A0122 |136 139|CJDmia
P11469701A0377 |87 102|insulin therapyPharmacologic a
P11469701A0377 |104 109|CIIITects 
P11469701A0377 |120 127|insulin hyperb
P11469701A0377 |178 199|insulin concentrationown as a function of 
P11469701A0377 |214 218|veinta o
P11469701A0377 |10 18|approach0076 Com
P11469701A0377 |22 44|insulin administrationson with alkaline phos
P11469701A0377 |143 150|fashion0008997
P11469737A1791 |87 88|%P
P11469737A1791 |107 111|tests of
P11469737A1791 |80 81|%1
P11469737A1791 |131 139|recoveryubinemia
P11469737A1791 |27 31|testith 
P11469737A1791 |3 8|visit00160
P11469737A1791 |48 72|muscle function recoveryases and 5-nucleotidase 
P11469853A0702 |124 129|yeasterbil
P11469853A0702 |15 21|systemCompar
P11469853A0702 |26 42|domain shufflingwith alkaline ph
P11469853A0702 |72 82|C1 domainsP00008171T
P11469853A0702 |60 68|functionucleotid
P11469853A0702 |94 104|Raf kinaseologic asp
P11469853A0702 |109 120|rat PKC etaof neonatal
P11469853A1053 |35 43|evidenceline pho
P11469853A1053 |120 129|C1 domain hyperbil
P11469853A1053 |133 138|yeastinemi
P11469853A1053 |104 112|functionects of 
P11469853A1053 |74 80|GTPase000817
P11469853A1053 |19 23|dataaris
P11469853A1053 |49 60|interactionses and 5-n
P11469926T0000 |51 63|crystal balls and 5-nucl
P11469926T0000 |0 29|Breast cancer risk assessmentP00001606T0076 Comparison wit
P11469970A0873 |0 8|PatientsP0000160
P11469970A0873 |149 156|ampulla7A0472 
P11469970A0873 |61 66|trialcleot
P11469970A0873 |14 18|type Com
P11469970A0873 |45 57|hyperalgesiahatases and 
P11469970A0873 |114 139|botulinum toxin injectiononatal hyperbilirubinemia
P11469970A0873 |23 26|SODon 
P11469970A0873 |212 219|therapydata of
P11469970A0873 |70 85|antidepressantse P00008171T000
P11469970A0873 |103 108|trialpects
P11470914A0305 |16 20|Rac1ompa
P11470914A0305 |57 64|nucleus5-nucle
P11470914A0305 |30 49|STAT3 translocation alkaline phosphata
P11470914A0305 |97 112|gene expressiongic aspects of 
P11470914A0305 |4 12|activity01606T00
P11471077A0382 |85 89|TRA20 Ph
P11471077A0382 |106 113|resultsts of n
P11471077A0382 |149 155|survey7A0472
P11471077A0382 |122 125|TRAype
P11471077A0382 |65 72|resultstidase 
P11471077A0382 |76 80|TRA10817
P11471077A0382 |43 52|variationsphatases
P11471077A0382 |33 39|amountkaline
P11471077A0382 |0 7|RESULTSP000016
P11471231A0964 |187 197|proceduresfunction o
P11471231A0964 |115 123|spectrumnatal hy
P11471231A0964 |67 78|differencesdase P00008
P11471231A0964 |3 11|addition001606T0
P11471231A0964 |19 27|patientsarison w
P11472523A0535 |51 63|inactivations and 5-nucl
P11472523A0535 |12 29|Extrusion cooking76 Comparison wit
P11472523A0535 |113 127|metabisulphiteeonatal hyperb
P11472523A0535 |67 70|DONdas
P11472523A0535 |89 94|valuearmac
P11472523A0535 |99 103|AFB1c as
P11472523A0535 |0 10|CONCLUSIONP00001606T
P11472696A0387 |4 15|differences01606T0076 
P11472696A0387 |93 96|ACScol
P11472696A0387 |60 68|patientsucleotid
P11472696A0387 |30 33|CRP al
P11472696A0387 |23 28|CPIgGon wi
P11472696A0387 |39 56|fibrinogen levels phosphatases and
P11473254A0000 |0 4|NaeIP000
P11473254A0000 |38 51|topoisomerasee phosphatase
P11473254A0000 |56 78|recombinase activities 5-nucleotidase P00008
P11473254A0000 |14 30|DNA endonuclease Comparison with
P11473254A0000 |86 97|Lys residue Pharmacolo
P11473254A0000 |117 120|Leutal
P11473261A0587 |0 4|Mss4P000
P11473261A0587 |79 82|GEF71T
P11473261A0587 |43 77|guanine nucleotide exchange factorsphatases and 5-nucleotidase P0000
P11474642A1451 |34 44|resistancealine phos
P11474642A1451 |108 115|control of neo
P11474642A1451 |56 69|hexamethonium 5-nucleotida
P11474642A1451 |74 82|mm Hg ml0008171T
P11474642A1451 |4 14|decrements01606T0076
P11474642A1451 |87 90|minPha
P11478627A0573 |103 117|transformationpects of neona
P11478627A0573 |78 80|Y117
P11478627A0573 |177 186|criterionhown as a
P11478627A0573 |62 69|optimumleotida
P11478627A0573 |91 93|Ynma
P11478627A0573 |134 142|propertynemia. P
P11478627A0573 |82 84|Y200
P11478627A0573 |42 48|searchosphat
P11478627A0573 |162 167|scaleSF [H
P11478627A0573 |4 25|desirability function01606T0076 Comparison
P11478627A0573 |71 72|D 
P11479104A0446 |191 196|womantion 
P11479104A0446 |280 285|causetrols
P11479104A0446 |133 143|CONCLUSIONinemia. P0
P11479104A0446 |149 157|presence7A0472 W
P11479104A0446 |90 98|criteriarmacolog
P11479104A0446 |52 60|antibody and 5-n
P11479104A0446 |178 185|diseaseown as 
P11479104A0446 |230 239|clinician rats are
P11479104A0446 |112 131|lupus erythematosisneonatal hyperbilir
P11479104A0446 |202 205|POF PC
P11479501A0744 |0 7|RESULTSP000016
P11479501A0744 |147 148|%9
P11479501A0744 |72 81|variationP00008171
P11479501A0744 |156 177|St Jude Medical valveWhen CSF [HCO3-] is s
P11479501A0744 |83 92|SD/mean x000 Pharm
P11479501A0744 |113 124|valve sizeseonatal hyp
P11479501A0744 |189 190|%n
P11479501A0744 |57 68|coefficient5-nucleotid
P11479501A0744 |140 141|% 
P11479501A0744 |96 97|%o
P11479501A0744 |196 197|%o
P11479501A0744 |35 47|distributionline phospha
P11479501A0744 |205 221|Omnicarbon valveO2 the data of K
P11480490A0443 |85 92|current0 Pharm
P11480490A0443 |79 80|I7
P11480490A0443 |113 123|occurrenceeonatal hy
P11480490A0443 |67 75|blockadedase P00
P11480490A0443 |127 137|arrhythmiailirubinem
P11480490A0443 |81 83|KrT0
P11480490A0443 |33 38|signskalin
P11480497T0000 |0 7|EffectsP000016
P11480497T0000 |97 103|memorygic as
P11480497T0000 |25 38|JP-8 jet fuel with alkalin
P11480497T0000 |111 114|rat ne
P11480497T0000 |71 78|battery P00008
P11480497T0000 |84 92|learning00 Pharm
P11480555A0928 |18 26|ceramideparison 
P11480555A0928 |44 51|fixturephatase
P11480555A0928 |66 76|cell deathidase P000
P11480555A0928 |4 14|production01606T0076
P11481625A0202 |119 122|MIUl h
P11481625A0202 |148 169|peginterferon alfa-2b97A0472 When CSF [HCO
P11481625A0202 |144 146|QW00
P11481625A0202 |92 115|interferon alfa-2b doseacologic aspects of neo
P11481625A0202 |27 35|subjectsith alka
P11481625A0202 |188 197|microg/kgunction o
P11481625A0202 |87 90|TIWPha
P11484028T0000 |3 17|cross purposes001606T0076 Co
P11484578A1132 |0 10|CONCLUSIONP00001606T
P11484578A1132 |44 60|measurement dataphatases and 5-n
P11484578A1132 |79 85|method71T000
P11484578A1132 |166 180|design programHCO3-] is show
P11484578A1132 |122 128|objectyperbi
P11484578A1132 |25 36|differences with alkal
P11484578A1132 |97 113|measurement datagic aspects of n
P11486032A1261 |85 90|RUNX10 Pha
P11486032A1261 |124 131|E2A-HLFerbilir
P11486032A1261 |10 31|transcription factors0076 Comparison with 
P11486032A1261 |71 78|protein P00008
P11486141A0424 |84 89|power00 Ph
P11486141A0424 |150 157|sourcesA0472 W
P11486141A0424 |53 61|studentsand 5-nu
P11486141A0424 |42 49|outcomeosphata
P11486141A0424 |161 166|errorCSF [
P11486141A0424 |5 12|factors1606T00
P11486141A0424 |99 112|meta analysisc aspects of 
P11486399A0000 |118 125|diseaseal hype
P11486399A0000 |31 41|epirubicinalkaline p
P11486399A0000 |78 93|salvage regimen171T0000 Pharma
P11486399A0000 |57 60|IEV5-n
P11486399A0000 |46 55|etoposideatases an
P11486399A0000 |4 15|combination01606T0076 
P11486399A0000 |19 29|ifosfamidearison wit
P11486476A0147 |234 244|proportions are no l
P11486476A0147 |147 156|myoglobin997A0472 
P11486476A0147 |331 340|admission(1.21 +/-
P11486476A0147 |61 76|characteristicscleotidase P000
P11486476A0147 |262 265|ACSen 
P11486476A0147 |80 88|patients1T0000 P
P11486476A0147 |248 256|patientsr displa
P11486476A0147 |127 145|markers troponin Tilirubinemia. P000
P11486476A0147 |214 224|chest painta of K-de
P11486476A0147 |94 104|chest painologic asp
P11486476A0147 |280 287|markerstrols b
P11486476A0147 |316 327|information greater sl
P11486476A0147 |14 19|trial Comp
P11486476A0147 |161 171|CK-MB massCSF [HCO3-
P11486476A0147 |110 115|valuef neo
P11486476A1512 |86 95|diagnosis Pharmaco
P11486476A1512 |43 52|myoglobinsphatases
P11486476A1512 |125 128|ECGrbi
P11486476A1512 |28 38|CK-MB massth alkalin
P11486476A1512 |8 26|markers troponin T6T0076 Comparison 
P11486476A1512 |99 109|chest painc aspects 
P11489597A0379 |137 144|fetusesia. P00
P11489597A0379 |43 50|femalessphatas
P11489597A0379 |123 130|outcomeperbili
P11489597A0379 |3 14|termination001606T0076
P11489597A0379 |65 70|grouptidas
P11489597A0379 |196 209|malformationsof CSF PCO2 t
P11489597A0379 |100 106|status aspec
P11489597A0379 |16 18|gdom
P11489597A0561 |53 64|weight gainand 5-nucle
P11489597A0561 |134 135|%n
P11489597A0561 |28 39|body weightth alkaline
P11489597A0561 |13 18|death6 Com
P11489597A0561 |104 119|pregnancy ratesects of neonata
P11489597A0561 |88 92|doseharm
P11489597A0561 |145 150|group08997
P11490862A0141 |139 146|support. P0000
P11490862A0141 |104 116|bone anchorsects of neon
P11490862A0141 |30 53|bladder neck suspension alkaline phosphatases 
P11490862A0141 |15 26|developmentComparison 
P11490862A0141 |67 81|Stamey-Pereyradase P00008171
P11490862A0141 |87 90|usePha
P11494391A0579 |49 71|artery-alone ALT graftses and 5-nucleotidase
P11494391A0579 |93 102|structurecologic a
P11494391A0579 |123 128|monthperbi
P11494391A0579 |150 164|bile secretionA0472 When CSF
P11494391A0579 |4 11|results01606T0
P11494391A0579 |32 33|%l
P11495833T0000 |78 83|model171T0
P11495833T0000 |15 21|impactCompar
P11495833T0000 |104 114|propertiesects of ne
P11495833T0000 |46 51|meansatase
P11495920A0504 |48 54|regionases a
P11495920A0504 |62 73|CYP3A4 geneleotidase P
P11495920A0504 |108 125|enhancer activity of neonatal hype
P11495920A0504 |9 22|pair mismatchT0076 Compari
P11496495A0000 |50 60|conditionses and 5-n
P11496495A0000 |20 28|analysisrison wi
P11496495A0000 |124 132|childrenerbiliru
P11496495A0000 |74 87|possibilities0008171T0000 
P11496495A0000 |4 11|authors01606T0
P11496495A0000 |116 120|careatal
P11496617A0301 |0 7|METHODSP000016
P11496617A0301 |324 335|anaesthesia slope (1.2
P11496617A0301 |353 359|mg DHB010943
P11496617A0301 |387 396|inductions to be a
P11496617A0301 |212 219|minutesdata of
P11496617A0301 |182 195|mg dolasetronas a function
P11496617A0301 |242 253|anaesthesia longer dis
P11496617A0301 |270 283|mg dolasetronred to contro
P11496617A0301 |31 39|patientsalkaline
P11496617A0301 |229 238|inductiond rats ar
P11496617A0301 |436 441|groupum do
P11496617A0301 |12 18|female76 Com
P11496617A0301 |51 66|thyroid surgerys and 5-nucleot
P11496617A0301 |255 260|groupaced 
P11496617A0301 |427 434|placebothe opt
P11496617A0301 |311 320|inductionantly gre
P11496617A0301 |413 418|grouptic d
P11496617A0301 |400 411|anaesthesiafective hyp
P11496617A0301 |337 342|group+/- 0
P11496617A0301 |170 177|regimes-] is s
P11498795A0716 |71 86|phosphorylation P00008171T0000
P11498795A0716 |94 104|RB proteinologic asp
P11498795A0716 |135 153|S phase transitionemia. P00008997A04
P11498795A0716 |120 125|delay hype
P11498795A0716 |10 21|progression0076 Compar
P11498795A0716 |40 48|G1-phasephosphat
P11500377A0518 |50 61|Wnt pathwayes and 5-nu
P11500377A0518 |3 10|mammals001606T
P11500377A0518 |32 42|repressorslkaline ph
P11500512A0000 |87 107|transporter proteinsPharmacologic aspect
P11500512A0000 |135 146|macrophagesemia. P0000
P11500512A0000 |31 37|memberalkali
P11500512A0000 |10 20|ABCG1 gene0076 Compa
P11500512A0000 |72 83|superfamilyP00008171T0
P11500512A0000 |166 176|oxysterolsHCO3-] is 
P11500512A0000 |57 65|cassette5-nucleo
P11500512A0000 |67 70|ABCdas
P11500571A0976 |17 27|expressionmparison w
P11500571A0976 |61 67|pollencleoti
P11500571A0976 |31 50|NtmybAS transcriptsalkaline phosphatas
P11500571A0976 |110 116|pollenf neon
P11500571A0976 |69 86|gPAL1 transcriptsse P00008171T0000
P11500913A1238 |0 13|C/EBPbeta LIPP00001606T007
P11500913A1238 |56 72|beta-casein mRNA 5-nucleotidase 
P11500913A1238 |148 156|hormones97A0472 
P11500913A1238 |29 39|HC11 cellsh alkaline
P11500913A1238 |125 133|responserbilirub
P11500913A1238 |93 120|cell differentiation markercologic aspects of neonatal
P11502738A1457 |70 77|mutantse P0000
P11502738A1457 |10 17|effects0076 Co
P11502738A1457 |109 118|bp regionof neonat
P11502738A1457 |126 144|cyclin D1 promoterbilirubinemia. P00
P11502738A1457 |37 47|inhibitorsne phospha
P11502758A0869 |51 55|roles an
P11502758A0869 |60 65|LAD-1ucleo
P11502758A0869 |77 91|FGFR signaling8171T0000 Phar
P11502758A0869 |6 14|findings606T0076
P11502778A0941 |236 246|pmol/literare no lon
P11502778A0941 |126 131|ratesbilir
P11502778A0941 |78 88|pmol/liter171T0000 P
P11502778A0941 |40 56|estradiol levelsphosphatases and
P11502778A0941 |149 155|levels7A0472
P11502778A0941 |210 226|estradiol levelse data of K-depl
P11502778A0941 |135 144|bone lossemia. P00
P11502778A0941 |159 182|bone resorption markersn CSF [HCO3-] is shown 
P11502778A0941 |67 73|mediandase P
P11502778A0941 |93 98|pg/mlcolog
P11502778A0941 |188 191|menunc
P11502778A0941 |18 21|menpar
P11504545A0393 |0 11|CompetitionP00001606T0
P11504545A0393 |47 65|immunoshift assaystases and 5-nucleo
P11504545A0393 |28 42|mobility shiftth alkaline ph
P11504545A0393 |112 120|extractsneonatal
P11504545A0393 |124 128|HeLaerbi
P11504545A0393 |133 143|CV-1 cellsinemia. P0
P11504545A0393 |81 92|NF1 factorsT0000 Pharm
P11504545A0393 |156 163|BKV-MLPWhen CS
P11504709A0981 |184 194|activation a functio
P11504709A0981 |79 82|TPO71T
P11504709A0981 |72 75|PMAP00
P11504709A0981 |132 140|promoterbinemia.
P11504709A0981 |107 115|Ets sites of neo
P11504709A0981 |5 10|study1606T
P11504709A0981 |53 61|responseand 5-nu
P11504709A0981 |144 148|GPIX0089
P11504709A0981 |39 49|expression phosphata
P11504709A0981 |234 240|kinases are 
P11505407A0461 |0 7|RESULTSP000016
P11505407A0461 |74 79|cells00081
P11505407A0461 |144 152|TNFalpha008997A0
P11505407A0461 |59 64|EpCAMnucle
P11505407A0461 |47 55|activitytases an
P11505407A0461 |22 30|fragmentson with
P11505407A0461 |115 142|tumor necrosis factor alphanatal hyperbilirubinemia. P
P11509266A0955 |84 87|BPF00 
P11509266A0955 |110 111|Pf
P11509266A0955 |196 204|survivalof CSF P
P11509266A0955 |182 192|predictorsas a funct
P11509266A0955 |89 90|Pa
P11509266A0955 |149 150|P7
P11509266A0955 |105 108|agects
P11509266A0955 |55 56|Pd
P11509266A0955 |20 53|hazards regression adenocarcinomarison with alkaline phosphatases 
P11509266A0955 |142 147|stage00008
P11509266A0955 |3 6|Cox001
P11509266A0955 |69 80|developmentse P0000817
P11509615T0000 |102 115|IL-2 receptorspects of neo
P11509615T0000 |65 85|T cell proliferationtidase P00008171T000
P11509615T0000 |0 29|Phosphatidylinositol 3-kinaseP00001606T0076 Comparison wit
P11509673A0574 |184 186|AA a
P11509673A0574 |29 38|BM3 cellsh alkalin
P11509673A0574 |91 99|F87V BM3macologi
P11509673A0574 |14 27|transfectants Comparison w
P11509673A0574 |173 182|14,15-EETis shown 
P11509673A0574 |202 211|apoptosis PCO2 the
P11509673A0574 |160 164|acid CSF
P11509673A0574 |250 259|apoptosisdisplaced
P11509673A0574 |70 89|P450 AA epoxygenasee P00008171T0000 Ph
P11511544T0000 |103 114|heat stresspects of ne
P11511544T0000 |74 85|specificity0008171T000
P11511544T0000 |90 99|responsesrmacologi
P11511544T0000 |4 15|loop domain01606T0076 
P11511544T0000 |19 50|heat shock transcription factorarison with alkaline phosphatas
P11512925A0000 |0 18|EXAFS measurementsP00001606T0076 Com
P11512925A0000 |130 139|structurerubinemia
P11512925A0000 |79 85|alloys71T000
P11512925A0000 |149 156|Ge atom7A0472 
P11512925A0000 |100 104|time asp
P11512925A0000 |35 39|edgeline
P11513121T0000 |155 160|PCOCs When
P11513121T0000 |61 88|quantum chemical parameterscleotidase P00008171T0000 P
P11513121T0000 |41 51|QSAR modelhosphatase
P11513121T0000 |12 17|study76 Co
P11513121T0000 |104 107|BCFect
P11513121T0000 |144 153|compounds008997A04
P11513121T0000 |22 37|robustness testson with alkali
P11513180A1257 |68 70|CTas
P11513180A1257 |11 16|cases076 C
P11513180A1257 |30 39|polyposis alkaline
P11513180A1257 |41 45|nonehosp
P11513180A1257 |109 114|bowelof ne
P11513579A0372 |21 27|systemison w
P11513579A0372 |88 95|Rho-GDIharmaco
P11513579A0372 |165 182|complex formation[HCO3-] is shown 
P11513579A0372 |150 161|interactionA0472 When 
P11513579A0372 |56 60|Rac1 5-n
P11513579A0372 |125 129|rolerbil
P11516890A0236 |51 57|systems and 
P11516890A0236 |46 49|CYPata
P11516890A0236 |28 44|cytochrome P-450th alkaline phos
P11516890A0236 |59 70|venlafaxinenucleotidas
P11516890A0236 |92 95|3A4aco
P11516890A0236 |131 136|SSRIsubine
P11516890A0236 |112 118|extentneonat
P11516890A0236 |80 87|CYP 2D61T0000 
P11517190A0352 |0 8|AnalysisP0000160
P11517190A0352 |176 186|expressionshown as a
P11517190A0352 |107 115|TATA boxs of neo
P11517190A0352 |47 55|presencetases an
P11517190A0352 |144 152|elements008997A0
P11517190A0352 |129 132|cisiru
P11517190A0352 |214 221|elementta of K
P11517190A0352 |83 93|start site000 Pharma
P11517190A0352 |16 33|promoter sequenceomparison with al
P11517190T0000 |79 92|transcription71T0000 Pharm
P11517190T0000 |15 23|promoterComparis
P11517190T0000 |31 48|rat ER alpha genealkaline phosphat
P11517190T0000 |106 114|receptorts of ne
P11517269A0472 |0 5|Pitx2P0000
P11517269A0472 |28 50|differentiation defectth alkaline phosphatas
P11517269A0472 |225 230|genesleted
P11517269A0472 |127 134|mutantsilirubi
P11517269A0472 |77 90|axon guidance8171T0000 Pha
P11517269A0472 |106 116|phenotypests of neon
P11517269A0472 |175 187|conservation shown as a 
P11517269A0472 |154 160|degree2 When
P11517399A0858 |187 199|splice sitesfunction of 
P11517399A0858 |229 236|speciesd rats 
P11517399A0858 |208 218|generationthe data o
P11517399A0858 |226 227|Te
P11517399A0858 |31 49|protein expressionalkaline phosphata
P11517399A0858 |164 175|utilization [HCO3-] is
P11517399A0858 |134 147|acceptor sitenemia. P00008
P11517399A0858 |22 26|mRNAson 
P11517399A0858 |110 118|mutationf neonat
P11517399A0858 |126 127|Tb
P11517399A0858 |65 72|mutantstidase 
P11517399A0858 |4 12|patterns01606T00
P11517445A0221 |19 26|choleraarison 
P11517445A0221 |10 15|cases0076 
P11517445A0221 |42 56|V. cholerae O1osphatases and
P11518505A0107 |85 91|organs0 Phar
P11518505A0107 |73 80|tissues0000817
P11518868A0559 |51 64|risk behaviors and 5-nucle
P11518868A0559 |76 85|knowledge08171T000
P11518868A0559 |30 37|history alkali
P11518868A0559 |93 110|hepatitis C viruscologic aspects o
P11518868A0559 |116 149|healthcare provider communicationatal hyperbilirubinemia. P0000899
P11519466A0196 |43 49|impactsphata
P11519466A0196 |13 17|diet6 Co
P11520436A0705 |102 112|connectionspects of 
P11520436A0705 |62 66|miceleot
P11520436A0705 |121 130|infectionhyperbili
P11520436A0705 |6 17|BALB/c mice606T0076 Co
P11520436A0705 |52 58|strain and 5
P11520436A0705 |78 85|studies171T000
P11520436A0705 |158 164|asthmaen CSF
P11520436A0705 |136 144|T. canismia. P00
P11521191A0000 |168 183|phosphorylationO3-] is shown a
P11521191A0000 |75 97|phosphorylation status008171T0000 Pharmacolo
P11521191A0000 |45 60|12S E1A proteinhatases and 5-n
P11521191A0000 |110 114|p107f ne
P11521191A0000 |147 157|cell cycle997A0472 W
P11521191A0000 |132 139|changesbinemia
P11521191A0000 |191 213|retinoblastoma proteintion of CSF PCO2 the d
P11521191A0000 |101 105|p130aspe
P11522431A0673 |18 36|tobacco dependenceparison with alkal
P11522431A0673 |162 170|drinkersSF [HCO3
P11522431A0673 |176 177|%s
P11522431A0673 |140 151|nondrinkers P00008997A
P11522431A0673 |112 123|individualsneonatal hy
P11522431A0673 |129 130|%i
P11522431A0673 |4 14|prevalence01606T0076
P11522431A0673 |64 79|ICD-10 criteriaotidase P000081
P11522584A0882 |69 79|MMF lesionse P000081
P11522584A0882 |106 107|Pt
P11522584A0882 |91 104|muscle biopsymacologic asp
P11522584A0882 |8 16|myalgias6T0076 C
P11522584A0882 |39 47|patients phospha
P11522626A1374 |36 37|Gi
P11522626A1374 |134 152|estrogen receptorsnemia. P00008997A0
P11522626A1374 |94 104|activationologic asp
P11522626A1374 |41 59|gene transcriptionhosphatases and 5-
P11522626A1374 |123 130|pathwayperbili
P11522626A1374 |22 32|regulationson with a
P11522626A1374 |112 120|Mek-Erk1neonatal
P11522658A0086 |139 145|BT-474. P000
P11522658A0086 |92 122|ErbB kinase inhibitor AG1478inacologic aspects of neonatal h
P11522658A0086 |29 50|ErbB1/ErbB2 signalingh alkaline phosphatas
P11522658A0086 |150 156|SKBR-3A0472 
P11522658A0086 |163 182|breast cancer cellsF [HCO3-] is shown 
P11522658A0086 |71 78|process P00008
P11522658A0870 |48 52|MAPKases
P11522658A0870 |79 82|p2771T
P11522658A0870 |41 44|p27hos
P11522658A0870 |112 116|Cdk2neon
P11522658A0870 |22 37|phosphorylationson with alkali
P11522658A0870 |125 138|stoichiometryrbilirubinemi
P11522658A0870 |66 75|stabilityidase P00
P11522658A0870 |157 172|kinase activityhen CSF [HCO3-]
P11523446A0523 |51 53|LCs 
P11523446A0523 |11 29|reference solution076 Comparison wit
P11523446A0523 |74 77|TOF000
P11523446A0523 |120 138|nitrogen detection hyperbilirubinemi
P11523446A0523 |140 147|LC-CLND P00008
P11523446A0523 |58 72|time-of-flight-nucleotidase 
P11523446A0523 |79 81|MS71
P11523446A0523 |100 102|LC a
P11523446A0523 |0 3|ICAP00
P11524015A0937 |48 59|H4 promoterases and 5-
P11524015A0937 |76 102|CAT reporter gene activity08171T0000 Pharmacologic a
P11524015A0937 |61 63|ntcl
P11524015A0937 |7 17|expression06T0076 Co
P11524015A0937 |21 27|BZAP45ison w
P11524815A0753 |101 112|2N0M0 casesaspects of 
P11524815A0753 |91 92|%m
P11524815A0753 |44 55|lung cancerphatases an
P11524815A0753 |59 60|%n
P11524815A0753 |27 28|%i
P11524815A0753 |73 84|lung cancer00008171T00
P11524815A0753 |97 99|T1gi
P11524815A0753 |6 19|control rates606T0076 Comp
P11524823X0001 |0 7|UtilityP000016
P11524823X0001 |25 28|GSI wi
P11524823X0001 |146 153|ability8997A04
P11524823X0001 |41 51|evaluationhosphatase
P11524823X0001 |226 233|infantseted ra
P11524823X0001 |117 122|studytal h
P11524823X0001 |86 95|emissions Pharmaco
P11524823X0001 |55 73|distortion productd 5-nucleotidase P
P11524823X0001 |216 224|neonates of K-de
P11524823X0001 |196 212|cochlea functionof CSF PCO2 the 
P11524823X0001 |161 177|OAE screener GSICSF [HCO3-] is s
P11524823X0001 |11 23|OAE screener076 Comparis
P11524823X0001 |101 108|purposeaspects
P11524823X0001 |238 244|adultse no l
P11525102A0970 |48 64|ACP Journal Clubases and 5-nucle
P11525102A0970 |124 125|%e
P11525102A0970 |133 134|%i
P11525102A0970 |29 36|reviewsh alkal
P11525102A0970 |107 118|sensitivitys of neonat
P11525102A0970 |66 67|ni
P11525102A0970 |127 129|CIil
P11525102A0970 |8 14|sample6T0076
P11525102A0970 |80 95|PubMed strategy1T0000 Pharmaco
P11525102A0970 |140 141|% 
P11525486A0350 |16 25|CaCO3-CO2omparison
P11525486A0350 |75 77|pH00
P11525486A0350 |26 28|N2wi
P11525486A0350 |38 46|solutione phosph
P11525640A0560 |0 10|InhibitionP00001606T
P11525640A0560 |158 161|ERKen 
P11525640A0560 |23 44|ERK kinase activitieson with alkaline phos
P11525640A0560 |163 171|PD098059F [HCO3-
P11525640A0560 |109 118|treatmentof neonat
P11525640A0560 |14 18|JNK1 Com
P11525640A0560 |201 213|UV inductionF PCO2 the d
P11525640A0560 |98 102|JNK1ic a
P11525640A0560 |55 65|expressiond 5-nucleo
P11525640A0560 |136 154|chemical inhibitormia. P00008997A047
P11525640A0560 |221 236|GADD45 promoter-depleted rats 
P11528127A1402 |117 121|% GCtal 
P11528127A1402 |145 150|L1/L208997
P11528127A1402 |125 130|mouserbili
P11528127A1402 |89 96|segmentarmacol
P11528127A1402 |33 40|segmentkaline 
P11528127A1402 |23 24|%o
P11528127A1402 |7 17|GC content06T0076 Co
P11528127A1402 |71 73|H1 P
P11528127A1402 |100 104|% GC asp
P11528253X1211 |0 9|CopyrightP00001606
P11528253X1211 |15 17|S.Co
P11528500A0571 |19 27|NRL genearison w
P11528500A0571 |56 64|families 5-nucle
P11528500A0571 |3 11|mutation001606T0
P11529914T0000 |0 9|NF-kappaBP00001606
P11529914T0000 |63 73|expressioneotidase P
P11529914T0000 |29 39|regulationh alkaline
P11529914T0000 |91 98|T cellsmacolog
P11529914T0000 |43 48|CD154sphat
P11529914T0000 |50 61|CD40 ligandes and 5-nu
P11530684A0667 |103 132|drive NK1-receptor mechanismspects of neonatal hyperbiliru
P11530684A0667 |61 68|neuronscleotid
P11530684A0667 |363 393|drive NMDA-receptor mechanisms3 Flurazepam thus appears to b
P11530684A0667 |90 98|C-fibersrmacolog
P11530684A0667 |241 249|C-fiberso longer
P11530684A0667 |349 357|A-fibers P000109
P11530684A0667 |254 284|drive NMDA receptor-mechanismslaced when compared to control
P11530684A0667 |292 296|typeill 
P11530684A0667 |54 58|typend 5
P11530684A0667 |215 219|onesa of
P11530684A0667 |301 305|onesa si
P11530684A0667 |36 45|responsesine phosp
P11530684A0667 |143 160|pain transmission0008997A0472 When
P11530684A0667 |196 203|changesof CSF 
P11530684A0667 |6 18|nerve injury606T0076 Com
P11530684A0667 |207 211|type the
P11530829A0000 |153 162|equipment72 When C
P11530829A0000 |36 47|developmentine phospha
P11530829A0000 |25 31|design with 
P11530829A0000 |92 99|testingacologi
P11530829A0000 |81 84|useT00
P11530829A0000 |54 67|ECG simulatornd 5-nucleoti
P11530829A0000 |5 12|article1606T00
P11530829A0000 |101 112|calibrationaspects of 
P11530829A0000 |117 128|maintenancetal hyperbi
P11532556A0000 |69 76|diseasese P000
P11532556A0000 |43 47|SDAEspha
P11532556A0000 |88 96|etiologyharmacol
P11532556A0000 |22 41|angioencephalopathyson with alkaline p
P11532556A0000 |115 122|thalaminatal h
P11532856A1175 |0 5|ThirdP0000
P11532856A1175 |243 251|p38 MAPKlonger d
P11532856A1175 |150 156|kinaseA0472 
P11532856A1175 |255 271|HIF-1 activationaced when compar
P11532856A1175 |86 89|HGF Ph
P11532856A1175 |158 162|MAPKen C
P11532856A1175 |93 117|stress kinase activitiescologic aspects of neona
P11532856A1175 |125 139|p42/44 mitogenrbilirubinemia
P11532856A1175 |29 33|datah al
P11532856A1175 |76 82|effect08171T
P11532856A1175 |226 232|kinaseeted r
P11532856A1175 |194 205|involvementn of CSF PC
P11532856A1175 |234 237|JNKs a
P11532856A1175 |35 51|N-acetylcysteineline phosphatase
P11533238A1137 |0 8|MutationP0000160
P11533238A1137 |63 70|abilityeotidas
P11533238A1137 |74 79|HDAC100081
P11533238A1137 |90 100|repressionrmacologic
P11533238A1137 |114 141|HLA-DRA promoter activationonatal hyperbilirubinemia. 
P11533238A1137 |16 31|octamer elementomparison with 
P11533340A1285 |71 77|months P0000
P11533340A1285 |25 35|difference with alka
P11533340A1285 |88 99|PDF infantsharmacologi
P11533340A1285 |121 136|point advantagehyperbilirubine
P11533340A1285 |53 59|scoresand 5-
P11533340A1285 |140 165|Bayley motor score scales P00008997A0472 When CSF 
P11533863A0125 |80 94|presupposition1T0000 Pharmac
P11533863A0125 |57 64|routine5-nucle
P11533863A0125 |14 18|case Com
P11533863A0125 |111 118|therapy neonat
P11533863A0125 |23 34|restorationon with alk
P11534132A0219 |87 94|expertsPharmac
P11534132A0219 |14 28|search engines Comparison wi
P11534132A0219 |58 65|results-nucleo
P11534132A0219 |71 77|domain P0000
P11534900A0000 |155 157|PB W
P11534900A0000 |215 232|Lymnaea acuminataa of K-depleted r
P11534900A0000 |135 153|piperonyl butoxideemia. P00008997A04
P11534900A0000 |91 109|Cedrus deodara oilmacologic aspects 
P11534900A0000 |163 175|fruit powderF [HCO3-] is
P11534900A0000 |179 192|Embelia ribeswn as a funct
P11534900A0000 |24 36|combinationsn with alkal
P11534900A0000 |54 86|molluscicides Azadirachta indicand 5-nucleotidase P00008171T0000
P11534900A0000 |115 133|synergists MGK-264natal hyperbilirub
P11535014A1157 |48 60|seizure typeases and 5-n
P11535014A1157 |79 88|frequency71T0000 P
P11535014A1157 |194 202|patientsn of CSF
P11535014A1157 |15 22|resultsCompari
P11535014A1157 |159 168|latenciesn CSF [HC
P11535014A1157 |126 145|precipitate factorsbilirubinemia. P000
P11535014A1157 |92 99|seizureacologi
P11535014A1157 |172 176|P300 is 
P11535014A1157 |64 67|TLEoti
P11535140T0000 |25 34|pregnancy with alk
P11535140T0000 |13 21|findings6 Compar
P11535532A0189 |48 56|responseases and
P11535532A0189 |60 64|IL-2ucle
P11535532A0189 |80 88|function1T0000 P
P11535532A0189 |21 33|enzyme DUB-2ison with al
P11535832A0586 |4 11|isoform01606T0
P11535832A0586 |57 67|C terminus5-nucleoti
P11535832A0586 |73 78|HDAC900008
P11535832A0586 |24 30|HDAC9an with
P11535832A0586 |39 41|aa p
P11536063A0178 |87 105|heart-lung-machinePharmacologic aspe
P11536063A0178 |26 46|lung transplantationwith alkaline phosph
P11536063A0178 |60 71|indicationsucleotidase
P11536063A0178 |10 21|embolectomy0076 Compar
P11536063A0178 |80 83|use1T0
P11538437A0568 |206 207|C2
P11538437A0568 |90 92|N2rm
P11538437A0568 |239 240|X 
P11538437A0568 |103 105|N2pe
P11538437A0568 |236 238|N2ar
P11538437A0568 |232 234|M2at
P11538437A0568 |97 98|Vg
P11538437A0568 |110 112|N2f 
P11538437A0568 |42 51|reactionsosphatase
P11538437A0568 |106 107|Xt
P11538437A0568 |226 227|Ve
P11538437A0568 |224 225|Bp
P11538437A0568 |255 257|N2ac
P11538437A0568 |118 120|N2al
P11538437A0568 |248 250|CNr 
P11538437A0568 |188 191|CH4unc
P11538437A0568 |113 114|Ae
P11538437A0568 |123 124|Vp
P11538437A0568 |183 184|As
P11538437A0568 |121 122|Xh
P11538437A0568 |180 182|N2n 
P11538437A0568 |241 242|Vo
P11538437A0568 |263 265|CNn 
P11538437A0568 |80 82|N21T
P11538437A0568 |157 175|N2 post-dischargeshen CSF [HCO3-] is
P11538437A0568 |83 84|A0
P11538437A0568 |266 267|Bo
P11538437A0568 |93 94|Cc
P11538437A0568 |145 146|V0
P11538437A0568 |214 216|M2ta
P11538437A0568 |95 96|Bl
P11538437A0568 |270 271|Vr
P11538437A0568 |268 269|Ap
P11538437A0568 |210 211|Ne
P11538437A0568 |72 74|N2P0
P11538437A0568 |132 134|N2bi
P11538437A0568 |135 136|Xe
P11538437A0568 |75 76|A0
P11538437A0568 |258 259|Xd
P11538437A0568 |221 223|CN-d
P11538437A0568 |8 18|conditions6T0076 Com
P11538437A0568 |282 303|% CH4 post-dischargesols but still have a 
P11538437A0568 |196 204|productsof CSF P
P11538437A0568 |143 144|B0
P11538437A0568 |140 142|N2 P
P11539522A0612 |33 42|knowledgekaline ph
P11539522A0612 |72 76|timeP000
P11539522A0612 |46 57|LET spectraatases and 
P11539522A0612 |80 95|space dosimetry1T0000 Pharmaco
P11539522A0612 |4 19|NAUSICAA system01606T0076 Comp
P11540991A0127 |3 8|order00160
P11540991A0127 |149 154|space7A047
P11540991A0127 |164 176|EASE program [HCO3-] is 
P11540991A0127 |134 140|flightnemia.
P11540991A0127 |36 41|testsine p
P11540991A0127 |27 34|effectsith alk
P11540991A0127 |109 120|NASA KC-135of neonatal
P11540991A0127 |188 217|Shuttle Atlantis mission 61-Bunction of CSF PCO2 the data 
P11540991A0127 |64 100|NASA MSFC Neutral Buoyancy Simulatorotidase P00008171T0000 Pharmacologic
P11542677A0411 |98 124|composting facility designic aspects of neonatal hyp
P11542677A0411 |129 136|controlirubine
P11542677A0411 |42 57|Generic Systemsosphatases and 
P11542677A0411 |82 94|alternatives0000 Pharmac
P11542677A0411 |5 12|article1606T00
P11542780A0086 |220 234|energy tranferK-depleted rat
P11542780A0086 |28 37|detectorsth alkali
P11542780A0086 |74 86|contribution0008171T0000
P11542780A0086 |241 250|componento longer 
P11542780A0086 |194 198|PNTDn of
P11542780A0086 |105 130|energy transfer componentcts of neonatal hyperbili
P11542780A0086 |39 42|TLD ph
P11542780A0086 |177 192|track detectorshown as a funct
P11542780A0086 |132 135|LETbin
P11542780A0086 |141 155|keV/micrometerP00008997A0472
P11542780A0086 |236 239|LETare
P11543154T0000 |0 9|ResponsesP00001606
P11543154T0000 |77 86|particles8171T0000
P11543154T0000 |13 24|TLD Mg2SiO46 Compariso
P11543154T0000 |91 106|space radiationmacologic aspec
P11543154T0000 |25 27|Tb w
P11543154T0000 |54 59|glassnd 5-
P11543317A0203 |34 45|combinationaline phosp
P11543317A0203 |122 126|TDMSyper
P11543317A0203 |13 17|dose6 Co
P11543317A0203 |164 168|PNTD [HC
P11543317A0203 |96 105|dosemeterogic aspe
P11543317A0203 |109 116|Mg2SiO4of neon
P11543317A0203 |148 162|track detector97A0472 When C
P11543317A0203 |65 74|detectorstidase P0
P11543317A0203 |118 120|Tbal
P11543662A0562 |17 24|mutantsmpariso
P11543662A0562 |62 63|Cl
P11543662A0562 |108 117|L protein of neona
P11543662A0562 |78 84|defect171T00
P11543662A0562 |11 15|gstC076 
P11543662A0562 |92 99|abilityacologi
P11543662A0562 |54 58|halfnd 5
P11545594A1556 |117 136|amino acid residuestal hyperbilirubine
P11545594A1556 |29 40|Myb domainsh alkaline 
P11545594A1556 |91 101|Myb domainmacologic 
P11545594A1556 |74 82|function0008171T
P11545594A1556 |177 184|proteinhown as
P11545594A1556 |161 168|surfaceCSF [HC
P11547819A0532 |0 7|METHODSP000016
P11547819A0532 |296 320|tissue penetration rateshave a significantly gre
P11547819A0532 |245 251|tissuenger d
P11547819A0532 |149 160|divergences7A0472 When
P11547819A0532 |121 144|laser output beam sizeshyperbilirubinemia. P00
P11547819A0532 |79 87|catheter71T0000 
P11547819A0532 |166 176|evaluationHCO3-] is 
P11547819A0532 |192 209|matter generationion of CSF PCO2 t
P11547819A0532 |379 397|vessel wall injurys appears to be an
P11547819A0532 |257 268|measuremented when com
P11547819A0532 |217 225|ablationof K-dep
P11547819A0532 |272 291|ablation hole sizesd to controls but s
P11547819A0532 |37 45|catheterne phosp
P11547819A0532 |9 20|ExperimentsT0076 Compa
P11547819A0532 |342 353|examination.23 vs. P00
P11547819A0532 |102 113|measurementspects of n
P11548027A0163 |220 230|indicatorsK-depleted
P11548027A0163 |158 184|service quality indicatorsen CSF [HCO3-] is shown as
P11548027A0163 |112 122|indicatorsneonatal h
P11548027A0163 |148 153|water97A04
P11548027A0163 |17 39|performance indicatorsmparison with alkaline
P11548027A0163 |136 146|indicatorsmia. P0000
P11548027A0163 |2 10|proposal0001606T
P11548027A0163 |68 74|groupsase P0
P11548027A0163 |186 206|personnel indicators function of CSF PCO
P11550795A2583 |0 14|OverexpressionP00001606T0076
P11550795A2583 |78 87|apoptosis171T0000 
P11550795A2583 |91 108|T cell hybridomasmacologic aspects
P11550795A2583 |141 151|Fas-ligandP00008997A
P11550795A2583 |53 59|T celland 5-
P11550795A2583 |128 137|inductionlirubinem
P11550795A2583 |156 167|interleukinWhen CSF [H
P11550795A2583 |18 26|RORgammaparison 
P11552058A0235 |86 90|days Pha
P11552058A0235 |26 32|valueswith a
P11552058A0235 |45 55|herniationhatases an
P11552058A0235 |5 8|ICP160
P11552058A0235 |38 43|mm Hge pho
P11552058A0833 |136 148|barbituratesmia. P000089
P11552058A0833 |6 15|therapies606T0076 
P11552058A0833 |57 72|saline solution5-nucleotidase 
P11552058A0833 |74 78|THAM0008
P11552058A0833 |80 112|Tris-hydroxy-methyl-aminomethane1T0000 Pharmacologic aspects of 
P11552058A0833 |114 120|bufferonatal
P11552724A0527 |254 261|failurelaced w
P11552724A0527 |142 149|disease0000899
P11552724A0527 |82 94|vessel lumen0000 Pharmac
P11552724A0527 |163 173|blood flowF [HCO3-] 
P11552724A0527 |265 272|allergycompare
P11552724A0527 |287 290|useut 
P11552724A0527 |60 70|blood flowucleotidas
P11552724A0527 |234 242|patientss are no
P11552724A0527 |217 230|interventionsof K-depleted
P11552724A0527 |294 308|contrast medial have a signi
P11552724A0527 |32 36|IVUSlkal
P11552724A0527 |0 11|CONCLUSIONSP00001606T0
P11552922A0361 |0 16|CYP2C19 genotypeP00001606T0076 C
P11552922A0361 |39 112|polymerase chain reaction-restriction fragment length polymorphism method phosphatases and 5-nucleotidase P00008171T0000 Pharmacologic aspects of 
P11553091A1472 |153 165|relationship72 When CSF 
P11553091A1472 |48 57|diagnosisases and 
P11553091A1472 |4 11|results01606T0
P11553091A1472 |124 134|correctionerbilirubi
P11553091A1472 |71 83|relationship P00008171T0
P11553091A1472 |138 143|Classa. P0
P11553704A0674 |8 12|data6T00
P11553704A0674 |121 136|MAPK activationhyperbilirubine
P11553704A0674 |62 72|EGFR-CD533leotidase 
P11553704A0674 |94 101|Ras N17ologic 
P11554469A1386 |70 89|cellulose synthasese P00008171T0000 Ph
P11554469A1386 |195 201|plants of CS
P11554469A1386 |27 35|questionith alka
P11554469A1386 |182 191|synthasesas a func
P11554469A1386 |123 130|membersperbili
P11554469A1386 |52 62|CesA genes and 5-nuc
P11554469A1386 |6 14|analyses606T0076
P11554566A0668 |4 22|hatcher incubators01606T0076 Compari
P11554566A0668 |31 40|companiesalkaline 
P11554566A0668 |135 144|company Aemia. P00
P11554566A0668 |180 190|company B.n as a fun
P11554566A0833 |8 23|companies sites6T0076 Comparis
P11554566A0833 |74 79|Tr10400081
P11554566A0833 |125 134|locationsrbilirubi
P11554727A0890 |86 89|PTH Ph
P11554727A0890 |97 111|GGGGGAGGGGAG-3gic aspects of
P11554727A0890 |128 133|PTHSRlirub
P11554727A0890 |72 82|repressionP00008171T
P11554727A0890 |4 24|mutation experiments01606T0076 Compariso
P11554727A0890 |55 63|sequenced 5-nucl
P11555516A0639 |39 43|COAT pho
P11555516A0639 |75 87|cutoff value008171T0000 
P11555516A0639 |56 61|L/min 5-nu
P11555516A0639 |28 37|thresholdth alkali
P11555516A0639 |150 154|riskA047
P11555516A0639 |125 139|artery diseaserbilirubinemia
P11555516A0639 |8 14|output6T0076
P11555669A0464 |0 10|ExperienceP00001606T
P11555669A0464 |28 36|sectionsth alkal
P11555669A0464 |55 72|Vrinnevi Hospitald 5-nucleotidase 
P11555669A0983 |49 56|tissuesses and
P11555669A0983 |89 94|pairsarmac
P11555669A0983 |13 16|mix6 C
P11555669A0983 |61 67|stainscleoti
P11555669A0983 |24 32|sectionsn with a
P11555669A0983 |37 44|samplesne phos
P11556809A2085 |184 195|P450 enzyme a function
P11556809A2085 |107 123|1-deoxycapsidiols of neonatal hy
P11556809A2085 |211 225|hydroxylations data of K-dep
P11556809A2085 |36 51|enzyme activityine phosphatase
P11556809A2085 |127 136|capsidiolilirubine
P11556809A2085 |167 173|notionCO3-] 
P11556809A2085 |83 102|5-epi-aristolochene000 Pharmacologic a
P11556809A2085 |233 254|hydrocarbon substratets are no longer disp
P11557127A0991 |3 13|conclusion001606T007
P11557127A0991 |15 19|NF-YComp
P11557127A0991 |24 41|Sp1 binding sitesn with alkaline p
P11557127A0991 |125 134|MRP2 generbilirubi
P11557127A0991 |94 107|rat mrp2 geneologic aspect
P11557127A0991 |58 62|role-nuc
P11557127A0991 |76 86|expression08171T0000
P11559366T0000 |87 91|genePhar
P11559366T0000 |30 40|inhibition alkaline 
P11559366T0000 |48 84|plasminogen activator inhibitor typeases and 5-nucleotidase P00008171T00
P11559547T0000 |119 128|receptorsl hyperbi
P11559547T0000 |90 100|ERR familyrmacologic
P11559547T0000 |53 82|pS2 breast cancer marker geneand 5-nucleotidase P00008171T
P11559547T0000 |16 26|regulationomparison 
P11559564A0459 |0 6|NB-506P00001
P11559564A0459 |127 142|splicing factorilirubinemia. P
P11559564A0459 |43 56|topoisomerasesphatases and
P11559564A0459 |31 39|capacityalkaline
P11559564A0459 |144 151|SF2/ASF008997A
P11559564A0459 |97 112|splicing factorgic aspects of 
P11559789A0314 |273 280|inducer to con
P11559789A0314 |230 248|producer cell line rats are no longe
P11559789A0314 |213 218|levelata o
P11559789A0314 |106 118|progesteronets of neonat
P11559789A0314 |75 98|ASF/SF2 splicing factor008171T0000 Pharmacolog
P11559789A0314 |140 153|gene cassette P00008997A04
P11559789A0314 |54 59|virusnd 5-
P11559789A0314 |20 24|workriso
P11559789A0314 |174 181|ASF/SF2s shown
P11559789A0314 |262 269|absenceen comp
P11559821A1315 |0 18|DNA binding assaysP00001606T0076 Com
P11559821A1315 |78 91|CREB-Tax-p300171T0000 Phar
P11559821A1315 |109 118|complexesof neonat
P11559821A1315 |66 74|assemblyidase P0
P11559821A1315 |128 151|repeat oligonucleotideslirubinemia. P00008997A
P11559821A1315 |92 95|CBPaco
P11559821A1315 |33 45|interferencekaline phosp
P11559821A1315 |49 52|p30ses
P11560292A0557 |32 41|structurelkaline p
P11560292A0557 |45 57|domain modelhatases and 
P11560292A0557 |60 73|prototype DSSucleotidase P
P11560292A0557 |78 101|dipslide urine cultures171T0000 Pharmacologic 
P11560509T0000 |0 15|DNA recognitionP00001606T0076 
P11560509T0000 |61 68|bindingcleotid
P11560509T0000 |88 91|DNAhar
P11560509T0000 |19 34|F factor TraI36arison with alk
P11560990A0272 |0 18|E47 protein levelsP00001606T0076 Com
P11560990A0272 |71 76|stage P000
P11560990A0272 |203 208|stagePCO2 
P11560990A0272 |126 132|levelsbiliru
P11560990A0272 |87 92|pointPharm
P11560990A0272 |169 179|transition3-] is sho
P11560992A0000 |69 75|kinasese P00
P11560992A0000 |178 193|protein kinasesown as a functi
P11560992A0000 |146 160|stress kinases8997A0472 When
P11560992A0000 |63 67|MAPKeoti
P11560992A0000 |228 232|JNKsed r
P11560992A0000 |47 61|protein kinasetases and 5-nu
P11560992A0000 |195 200|SAPKs of C
P11560992A0000 |105 114|moleculescts of ne
P11560992A0000 |87 91|MKK4Phar
P11560992A0000 |219 226|kinases K-depl
P11560992A0000 |202 207|c-Jun PCO2
P11560992A0000 |9 28|specificity kinasesT0076 Comparison wi
P11560992A0000 |77 80|MKK817
P11560992A0000 |276 283|stimuli contro
P11560992A0000 |237 245|responsere no lo
P11560992A0651 |0 19|SAPK/JNK activationP00001606T0076 Comp
P11560992A0651 |178 182|MKK4own 
P11560992A0651 |128 132|mkk7liru
P11560992A0651 |95 99|MKK4logi
P11560992A0651 |63 67|MKK7eoti
P11560992A0651 |225 239|stress stimulileted rats are
P11560992A0651 |81 91|expressionT0000 Phar
P11560992A0651 |159 174|phosphorylationn CSF [HCO3-] i
P11560992A0651 |52 59|absence and 5-
P11560992A0651 |138 153|mast cell linesa. P00008997A04
P11560992A0651 |204 212|responseCO2 the 
P11560992A1184 |205 210|cellsO2 th
P11560992A1184 |132 145|growth factorbinemia. P000
P11560992A1184 |150 157|antigenA0472 W
P11560992A1184 |91 101|mast cellsmacologic 
P11560992A1184 |6 10|MKK7606T
P11560992A1184 |40 49|regulatorphosphata
P11560992A1184 |106 110|MKK7ts o
P11560992A1184 |174 187|proliferations shown as a 
P11560992A1184 |68 87|SAPK/JNK activationase P00008171T0000 
P11561623A0897 |190 197|biomassction o
P11561623A0897 |120 124|fall hyp
P11561623A0897 |10 45|copepod Pseudonychocamptus proximus0076 Comparison with alkaline phosp
P11561623A0897 |79 92|Tisbe furcata71T0000 Pharm
P11561623A0897 |167 175|increaseCO3-] is
P11561623A0897 |213 219|springata of
P11561623A0897 |96 108|sand filtersogic aspects
P11561626A0197 |239 242|Pb2 no
P11561626A0197 |249 252|Zn2 di
P11561626A0197 |219 223|nH2O K-d
P11561626A0197 |93 100|cadmiumcologic
P11561626A0197 |24 33|solutionsn with al
P11561626A0197 |176 182|Cd-TMTshown 
P11561626A0197 |210 216|S3C3N3e data
P11561626A0197 |231 232|Mr
P11561626A0197 |314 317|airly 
P11561626A0197 |198 204|Pb-TMT CSF P
P11561626A0197 |258 259|nd
P11561626A0197 |87 91|zincPhar
P11561626A0197 |53 62|solutionsand 5-nuc
P11561626A0197 |233 236|Cd2ts 
P11561626A0197 |37 43|TMT-55ne pho
P11561626A0197 |110 115|saltsf neo
P11561626A0197 |141 147|Zn-TMTP00008
P11561626A0197 |207 209|M3 t
P11562278A0169 |171 181|cell death] is shown
P11562278A0169 |88 92|roleharm
P11562278A0169 |44 57|G1 regulationphatases and 
P11562278A0169 |22 27|genesson w
P11562278A0169 |111 126|differentiation neonatal hyper
P11562278A0169 |183 192|apoptosiss a funct
P11562278A0169 |96 109|proliferationogic aspects 
P11562278A0169 |141 155|transformationP00008997A0472
P11562870A0892 |34 45|lamotriginealine phosp
P11562870A0892 |131 132|%u
P11562870A0892 |123 128|yearsperbi
P11562870A0892 |107 108|%s
P11562870A0892 |71 77|months P0000
P11562870A0892 |98 104|monthsic asp
P11562870A0892 |4 15|probability01606T0076 
P11562870A0892 |19 28|treatmentarison wi
P11562870A0892 |84 85|%0
P11564871A1184 |139 143|need. P0
P11564871A1184 |179 189|eukaryoteswn as a fu
P11564871A1184 |27 35|presenceith alka
P11564871A1184 |208 221|TATA elementsthe data of K
P11564871A1184 |148 151|TBP97A
P11564871A1184 |165 169|Pols[HCO
P11564871A1184 |90 100|eukaryotesrmacologic
P11564871A1184 |6 13|results606T007
P11564871A1184 |52 73|transcription systems and 5-nucleotidase P
P11564871A1184 |231 240|promotersrats are 
P11564871A1184 |113 120|insighteonatal
P11564871A1184 |200 204|lackSF P
P11564893A1068 |186 193|respond functi
P11564893A1068 |197 205|mutagensf CSF PC
P11564893A1068 |58 68|6RG lesion-nucleotid
P11564893A1068 |161 165|cellCSF 
P11564893A1068 |26 38|conformationwith alkalin
P11564893A1068 |91 108|DNA repair factormacologic aspects
P11564893A1068 |44 50|repairphatas
P11564893A1068 |139 145|R-MGMT. P000
P11564893A1068 |70 74|MGMTe P0
P11564893A1068 |114 137|transcription regulatoronatal hyperbilirubinem
P11564893A1068 |169 174|sense3-] i
P11564893A1068 |16 22|changeompari
P11565747A1020 |68 91|competition experimentsase P00008171T0000 Phar
P11565747A1020 |111 122|correlation neonatal h
P11565747A1020 |215 223|splicinga of K-d
P11565747A1020 |227 241|P element IVS3ted rats are n
P11565747A1020 |195 202|ability of CSF
P11565747A1020 |135 153|binding affinitiesemia. P00008997A04
P11565747A1020 |19 34|splicing assaysarison with alk
P11565747A1020 |157 160|PSIhen
P11565747A1020 |36 51|UV crosslinkingine phosphatase
P11565747A1020 |169 184|SELEX sequences3-] is shown as
P11565747A1020 |0 4|DataP000
P11566874T0000 |38 44|dyneine phos
P11566874T0000 |8 20|motor domain6T0076 Compa
P11566948A1217 |16 31|nephrosclerosisomparison with 
P11566948A1217 |129 135|eventsirubin
P11566948A1217 |110 119|incidencef neonata
P11566948A1217 |72 83|combinationP00008171T0
P11566948A1217 |55 59|ACEId 5-
P11566948A1217 |33 40|therapykaline 
P11566961A0472 |0 21|Body weight reductionP00001606T0076 Compar
P11566961A0472 |88 110|blood pressure controlharmacologic aspects o
P11566961A0472 |32 51|insulin sensitivitylkaline phosphatase
P11566961A0472 |70 83|blood glucosee P00008171T0
P11566996A1391 |34 68|nucleotide excision repair pathwayaline phosphatases and 5-nucleotid
P11566996A1391 |89 95|repairarmaco
P11566996A1391 |189 192|pH.nct
P11566996A1391 |172 181|S. mutans is shown
P11566996A1391 |112 122|DNA damageneonatal h
P11566996A1391 |158 168|adaptationen CSF [HC
P11566996A1391 |21 25|uvrAison
P11568988A0960 |70 74|timee P0
P11568988A0960 |105 119|antibody titercts of neonata
P11568988A0960 |124 135|Pa elastaseerbilirubin
P11568988A0960 |56 60|WCXR 5-n
P11568988A0960 |41 48|changeshosphat
P11568988A0960 |9 25|regression modelT0076 Comparison
P11568988A0960 |93 100|culturecologic
P11569800T0000 |0 23|Temperature measurementP00001606T0076 Comparis
P11569800T0000 |40 47|systemsphospha
P11569900A0660 |0 14|APC-resistanceP00001606T0076
P11569900A0660 |81 92|specificityT0000 Pharm
P11569900A0660 |65 76|sensitivitytidase P000
P11569900A0660 |48 54|methodases a
P11569900A0660 |101 125|factor V Leiden mutationaspects of neonatal hype
P11569949A2087 |0 5|ZarixP0000
P11569949A2087 |15 33|patient enrollmentComparison with al
P11569949A2087 |73 79|Spring000081
P11569949A2087 |55 60|sitesd 5-n
P11570735A1097 |275 282|controlo contr
P11570735A1097 |208 217|reductionthe data 
P11570735A1097 |167 176|reductionCO3-] is 
P11570735A1097 |286 301|feedback groupsbut still have 
P11570735A1097 |13 21|subjects6 Compar
P11570735A1097 |39 53|feedback group phosphatases 
P11570735A1097 |96 117|ground reaction forceogic aspects of neona
P11570735A1097 |82 86|peak0000
P11570735A1097 |136 146|conditionsmia. P0000
P11570735A1097 |0 7|RESULTSP000016
P11570820T0000 |69 76|nucleusse P000
P11570820T0000 |5 18|casein kinase1606T0076 Com
P11570820T0000 |21 29|isoformsison wit
P11570820T0000 |81 90|cytoplasmT0000 Pha
P11572377T0000 |0 3|UseP00
P11572377T0000 |73 89|cavitation field00008171T0000 Ph
P11572377T0000 |20 32|lithotripterrison with a
P11572388A0000 |114 119|LSERsonata
P11572388A0000 |128 138|predictionlirubinemi
P11572388A0000 |160 169|compounds CSF [HCO
P11572388A0000 |47 52|studytases
P11572388A0000 |60 71|applicationucleotidase
P11572388A0000 |82 112|solvation energy relationships0000 Pharmacologic aspects of 
P11572388A0000 |212 216|RPLCdata
P11572388A0000 |25 32|results with a
P11572388A0000 |218 236|method developmentf K-depleted rats 
P11572388A0000 |5 10|paper1606T
P11572467A0658 |80 84|t-PA1T00
P11572467A0658 |135 139|clotemia
P11572467A0658 |67 76|injectiondase P000
P11572467A0658 |9 19|blood clotT0076 Comp
P11572467A0658 |46 52|cavityatases
P11572467A0658 |97 108|plasminogengic aspects
P11572467A0658 |112 119|plasminneonata
P11572467T0000 |0 10|ManagementP00001606T
P11572467T0000 |63 91|tissue plasminogen activatoreotidase P00008171T0000 Phar
P11572467T0000 |47 57|hemorrhagetases and 
P11572467T0000 |134 143|exchangernemia. P0
P11572467T0000 |93 97|t-PAcolo
P11572467T0000 |103 109|volumepects 
P11573771T0000 |0 6|EffectP00001
P11573771T0000 |10 25|heat treatments0076 Comparison
P11573771T0000 |33 44|meltabilitykaline phos
P11573771T0000 |48 55|cheesesases an
P11573891A0525 |0 7|RESULTSP000016
P11573891A0525 |149 158|exposures7A0472 Wh
P11573891A0525 |121 127|whiteshyperb
P11573891A0525 |19 23|centaris
P11573891A0525 |116 117|%a
P11573891A0525 |59 78|community outbreaksnucleotidase P00008
P11573891A0525 |35 44|Americansline phos
P11573891A0525 |84 87|TST00 
P11574088A1687 |17 21|timempar
P11574088A1687 |95 109|PAK recipientslogic aspects 
P11574088A1687 |74 77|SPK000
P11574088A1687 |65 69|daystida
P11574088A1687 |37 56|pancreas transplantne phosphatases and
P11574088A1687 |111 112|P 
P11574088A1687 |4 8|mean0160
P11574088A1687 |86 90|days Pha
P11574105A0727 |373 388|antibody titersam thus appears
P11574105A0727 |144 147|GBS008
P11574105A0727 |300 306|damage a sig
P11574105A0727 |208 211|GBSthe
P11574105A0727 |60 68|increaseucleotid
P11574105A0727 |269 287|IgM antibody peaksared to controls b
P11574105A0727 |160 177|disability scores CSF [HCO3-] is s
P11574105A0727 |72 86|antibody titerP00008171T0000
P11574105A0727 |14 28|antibody peaks Comparison wi
P11574105A0727 |318 336|IgM antibody peaksreater slope (1.21
P11574105A0727 |134 140|coursenemia.
P11574105A0727 |251 254|IgGisp
P11574105A0727 |351 359|patients00010943
P11574105A0727 |110 124|antibody titerf neonatal hyp
P11574105A0727 |199 204|weeksCSF P
P11574105A0727 |233 240|outcomets are 
P11574105A0727 |0 8|PatientsP0000160
P11575109A0214 |64 71|therapyotidase
P11575109A0214 |180 187|gingivan as a 
P11575109A0214 |134 140|graftsnemia.
P11575109A0214 |10 18|baseline0076 Com
P11575109A0214 |107 114|surgerys of ne
P11575109A0214 |28 39|examinationth alkaline
P11575109A0214 |145 154|treatment08997A047
P11575109A0214 |76 84|patients08171T00
P11575977A1133 |32 51|office hypertensionlkaline phosphatase
P11575977A1133 |9 17|patientsT0076 Co
P11575977A1133 |86 99|complications Pharmacologi
P11576158A1371 |33 48|skin blood flowkaline phosphat
P11576158A1371 |88 96|controlsharmacol
P11576158A1371 |7 19|TVD-patients06T0076 Comp
P11576776T0081 |25 51|microcrystalline cellulose with alkaline phosphatase
P11576776T0081 |15 21|moduliCompar
P11577094A1226 |50 63|HSAL2 pathwayes and 5-nucl
P11577094A1226 |6 14|findings606T0076
P11577094A1226 |75 79|role0081
P11577094A1226 |45 49|WT-1hata
P11577094A1226 |83 94|development000 Pharmac
P11577094A1226 |99 112|hematopoiesisc aspects of 
P11578685A0077 |0 6|ICAM-1P00001
P11578685A0077 |45 50|onsethatas
P11578685A0077 |28 37|predictorth alkali
P11578685A0077 |54 56|GOnd
P11579100T0000 |0 23|Phosphotyrosyl peptidesP00001606T0076 Comparis
P11579100T0000 |45 65|DNA binding activityhatases and 5-nucleo
P11579100T0000 |88 107|cell transformationharmacologic aspect
P11579100T0000 |67 82|gene regulationdase P00008171T
P11580173A0181 |0 19|Plane wave geometryP00001606T0076 Comp
P11580173A0181 |60 67|resultsucleoti
P11580173A0181 |76 80|work0817
P11580173A0181 |179 184|paperwn as
P11580173A0181 |151 159|geometry0472 Whe
P11580173A0181 |48 51|usease
P11580173A0181 |118 134|P3 approximational hyperbilirubi
P11580301A1161 |68 74|factorase P0
P11580301A1161 |100 113|polyarthritis aspects of n
P11580301A1161 |4 13|diagnosis01606T007
P11580301A1161 |17 30|HCV arthritismparison with
P11580301A1161 |34 42|patientsaline ph
P11580757A0304 |68 75|surgeryase P00
P11580757A0304 |40 53|TFCD patientsphosphatases 
P11580757A0304 |243 253|recordingslonger dis
P11580757A0304 |165 171|lesion[HCO3-
P11580757A0304 |150 152|MRA0
P11580757A0304 |197 201|zonef CS
P11580757A0304 |110 113|aimf n
P11580757A0304 |92 100|epilepsyacologic
P11580757A0304 |139 148|resonance. P000089
P11580757A0304 |0 7|METHODSP000016
P11580941A0815 |102 109|therapyspects 
P11580941A0815 |37 45|UPDRS IIne phosp
P11580941A0815 |79 80|%7
P11580941A0815 |148 152|time97A0
P11580941A0815 |123 134|% reductionperbilirubi
P11580941A0815 |50 60|III scoreses and 5-n
P11580941A0815 |19 30|examinationarison with
P11580941A0815 |116 120|meanatal
P11580941A0815 |0 7|RESULTSP000016
P11580941A0815 |85 96|stimulation0 Pharmacol
P11583428A0191 |3 6|Exp001
P11583621A0301 |102 107|deltaspect
P11583621A0301 |91 95|hTAFmaco
P11583621A0301 |181 185|hTAF as 
P11583621A0301 |134 138|hTAFnemi
P11583621A0301 |120 125|delta hype
P11583621A0301 |79 87|cleavage71T0000 
P11583621A0301 |46 56|expressionatases and
P11583621A0301 |165 172|complex[HCO3-]
P11583621A0301 |109 113|hTAFof n
P11583621A0301 |27 34|stimuliith alk
P11583880T0000 |38 56|AneuRx stent-grafte phosphatases and
P11583880T0000 |13 28|aneurysm repair6 Comparison wi
P11584107T0000 |54 64|assessmentnd 5-nucle
P11584107T0000 |78 83|field171T0
P11584107T0000 |43 49|originsphata
P11584107T0000 |20 28|diseasesrison wi
P11584328A0532 |0 17|Drug interactionsP00001606T0076 Co
P11584328A0532 |92 99|statinsacologi
P11584328A0532 |39 44|drugs phos
P11584328A0532 |71 88|CYP450 isoenzymes P00008171T0000 P
P11585856A0285 |0 7|METHODSP000016
P11585856A0285 |132 154|photon energy recoverybinemia. P00008997A047
P11585856A0285 |75 77|AC00
P11585856A0285 |60 62|RRuc
P11585856A0285 |33 40|benefitkaline 
P11585856A0285 |156 159|PERWhe
P11585856A0285 |112 130|scatter correctionneonatal hyperbili
P11585856A0285 |86 106|scanning line source Pharmacologic aspec
P11585856A0285 |185 199|backprojectiona function of 
P11586096A0699 |51 71|control measurementss and 5-nucleotidase
P11586096A0699 |26 49|patient characteristicswith alkaline phosphata
P11586096A0699 |11 22|differences076 Compari
P11586096A0699 |112 120|patientsneonatal
P11586096A0699 |98 104|muscleic asp
P11587514A0758 |54 69|ABA suppressionnd 5-nucleotida
P11587514A0758 |13 32|abi1-1 gene product6 Comparison with a
P11587514A0758 |89 107|alpha-amylase genearmacologic aspect
P11587514A0758 |40 46|effectphosph
P11587980A1039 |68 71|FOTase
P11587980A1039 |59 60|nn
P11587980A1039 |133 141|subgroupinemia. 
P11587980A1039 |89 110|interrupter techniquearmacologic aspects o
P11587980A1039 |73 81|contrary00008171
P11587980A1039 |151 159|children0472 Whe
P11587980A1039 |3 11|children001606T0
P11587980A1039 |191 199|baselinetion of 
P11587980A1039 |232 247|bronchodilationats are no long
P11587980A1039 |48 57|maneuversases and 
P11587980A1039 |170 187|resistance values-] is shown as a 
P11589568A0744 |152 164|kinetochores472 When CSF
P11589568A0744 |30 49|checkpoint response alkaline phosphata
P11589568A0744 |93 97|Bub3colo
P11589568A0744 |11 16|yeast076 C
P11589568A0744 |63 76|proteins Mad1eotidase P000
P11589568A0744 |116 128|counterpartsatal hyperbi
P11589568A0744 |84 88|Bub100 P
P11589779T0000 |17 25|Th2 typemparison
P11589779T0000 |36 44|responseine phos
P11589779T0000 |62 78|strongyloidiasisleotidase P00008
P11589779T0000 |48 56|patientsases and
P11589779T0000 |0 6|HTLV-1P00001
P11590364A1056 |57 63|retina5-nucl
P11590364A1056 |13 34|beta5L splice variant6 Comparison with alk
P11592315A0325 |0 9|PROCEDUREP00001606
P11592315A0325 |11 19|Cannulas076 Comp
P11592315A0325 |63 67|bodyeoti
P11592315A0325 |95 99|calflogi
P11592315A0325 |80 86|antrum1T0000
P11592532A0188 |85 92|degrees0 Pharm
P11592532A0188 |151 157|method0472 W
P11592532A0188 |97 109|degrees gridgic aspects 
P11592532A0188 |9 38|Humphrey Field Analyzer modelT0076 Comparison with alkalin
P11592532A0188 |44 47|HFApha
P11592532A0188 |0 7|METHODSP000016
P11592532A0188 |51 58|programs and 5
P11593394A0000 |68 73|cellsase P
P11593394A0000 |212 215|p15dat
P11593394A0000 |120 121|D 
P11593394A0000 |227 230|p27ted
P11593394A0000 |13 31|growth factor-beta6 Comparison with 
P11593394A0000 |134 157|cyclin kinase complexesnemia. P00008997A0472 W
P11593394A0000 |51 64|growth arrests and 5-nucle
P11593394A0000 |216 221|Ink4b of K
P11593394A0000 |83 93|regulation000 Pharma
P11593394A0000 |101 111|activitiesaspects of
P11593394A0000 |231 235|Kip1rats
P11593394A0000 |198 208|regulation CSF PCO2 
P11593394A0000 |33 41|TGF-betakaline p
P11593394A0000 |237 261|cyclin kinase inhibitorsre no longer displaced w
P11595170A0582 |186 191|exons func
P11595170A0582 |23 28|cDNAson wi
P11595170A0582 |213 220|intronsata of 
P11595170A0582 |126 138|organizationbilirubinemi
P11595170A0582 |43 47|hB1Fspha
P11595170A0582 |161 163|kbCS
P11595170A0582 |71 79|sequence P000081
P11595170A0582 |96 107|delineationogic aspect
P11595170A0582 |36 41|NR5A2ine p
P11595170A0582 |49 53|geneses 
P11595170A0582 |0 9|AlignmentP00001606
P11595176T0000 |35 45|SPEC1 geneline phosp
P11595176T0000 |62 70|splicingleotidas
P11595176T0000 |75 99|close promoter proximity008171T0000 Pharmacologi
P11595176T0000 |107 130|AF1q translocation genes of neonatal hyperbili
P11595176T0000 |12 21|structure76 Compar
P11595478A1014 |0 2|HpP0
P11595478A1014 |62 72|prevalenceleotidase 
P11595478A1014 |76 83|atrophy08171T0
P11595478A1014 |12 21|relatives76 Compar
P11595478A1014 |122 138|cancer relativesyperbilirubinemi
P11595478A1014 |33 39|cancerkaline
P11595478A1014 |100 113|Hp negativity aspects of n
P11595813A0633 |136 146|activitiesmia. P0000
P11595813A0633 |161 177|5alpha-reductaseCSF [HCO3-] is s
P11595813A0633 |41 46|placehosph
P11595813A0633 |11 21|metabolism076 Compar
P11595813A0633 |89 93|unitarma
P11595813A0633 |150 159|aromataseA0472 Whe
P11595813A0633 |25 34|androgens with alk
P11595813A0633 |196 204|presenceof CSF P
P11595813A0633 |58 63|areas-nucl
P11595813A0633 |212 230|androgen receptorsdata of K-depleted
P11595813A0633 |117 128|differencestal hyperbi
P11595840A0000 |71 76|tumor P000
P11595840A0000 |26 44|fluorodeoxyglucosewith alkaline phos
P11595840A0000 |46 54|F-18 FDGatases a
P11595840A0000 |92 111|blood glucose levelacologic aspects of
P11595840A0000 |4 10|uptake01606T
P11596104A0614 |0 22|Northern blot analysisP00001606T0076 Compari
P11596104A0614 |112 114|kbne
P11596104A0614 |131 141|cell linesubinemia. 
P11596104A0614 |73 79|signal000081
P11596104A0614 |39 45|PARNAs phosp
P11596104A0614 |101 110|kilobasesaspects o
P11596838A1357 |34 56|fluticasone propionatealine phosphatases and
P11596838A1357 |106 114|patientsts of ne
P11596838A1357 |60 66|microgucleot
P11596838A1357 |93 102|treatmentcologic a
P11596838A1357 |131 137|asthmaubinem
P11596838A1357 |27 30|useith
P11596838A1357 |5 13|analysis1606T007
P11596838A1357 |175 188|beta2-agonist shown as a f
P11597185A0477 |69 89|computer simulationsse P00008171T0000 Ph
P11597185A0477 |143 150|regimes0008997
P11597185A0477 |58 64|models-nucle
P11597185A0477 |154 177|metapopulation dynamics2 When CSF [HCO3-] is s
P11597185A0477 |35 49|metapopulationline phosphata
P11597936A0570 |51 59|patientss and 5-
P11597936A0570 |212 217|drugsdata 
P11597936A0570 |95 114|density lipoproteinlogic aspects of ne
P11597936A0570 |133 146|triglyceridesinemia. P0000
P11597936A0570 |121 126|mg/dLhyper
P11597936A0570 |74 79|years00081
P11597936A0570 |64 67|ageoti
P11597936A0570 |6 18|CAD patients606T0076 Com
P11597936A0570 |82 90|baseline0000 Pha
P11597936A0570 |235 243|controls are no 
P11597936A0570 |154 159|mg/dL2 Whe
P11599079A1040 |49 60|instrumentsses and 5-n
P11599079A1040 |78 81|API171
P11599079A1040 |75 76|V0
P11599079A1040 |98 99|Vi
P11599079A1040 |128 131|APIlir
P11599079A1040 |125 126|Vr
P11599079A1040 |18 34|orifice voltagesparison with alk
P11599079A1040 |101 104|APIasp
P11599797A0732 |17 21|genempar
P11599797A0732 |0 7|RESULTSP000016
P11599840A0813 |69 72|kPase 
P11599840A0813 |151 154|kPa047
P11599840A0813 |211 214|kPa da
P11599840A0813 |74 78|mean0008
P11599840A0813 |134 141|sectionnemia. 
P11599840A0813 |117 120|kPatal
P11599840A0813 |188 195|sectionunction
P11599840A0813 |249 256|section displa
P11599840A0813 |92 101|deviationacologic 
P11599840A0813 |229 232|kPad r
P11599840A0813 |47 53|mattertases 
P11599840A0813 |14 24|elasticity Compariso
P11599840A0813 |4 10|moduli01606T
P11599840A0813 |169 172|kPa3-]
P11600252A0795 |141 150|mortalityP00008997
P11600252A0795 |131 137|changeubinem
P11600252A0795 |74 80|series000817
P11600252A0795 |4 6|LA01
P11600252A0795 |38 42|datae ph
P11600314A0000 |137 145|analysisia. P000
P11600314A0000 |15 27|polarographyComparison w
P11600314A0000 |161 163|B2CS
P11600314A0000 |149 159|vitamin B17A0472 Whe
P11600314A0000 |45 50|pulsehatas
P11600314A0000 |65 72|methodstidase 
P11600314A0000 |168 170|B6O3
P11600365A0471 |152 171|reference compounds472 When CSF [HCO3-
P11600365A0471 |106 118|tosufloxacints of neonat
P11600365A0471 |44 50|E-5065phatas
P11600365A0471 |22 31|organismsson with 
P11600365A0471 |33 39|E-4767kaline
P11600467A1436 |35 45|alterationline phosp
P11600467A1436 |66 78|permeabilityidase P00008
P11602353A0770 |34 39|HFH-2aline
P11602353A0770 |151 155|gene0472
P11602353A0770 |15 25|HNF-3 betaComparison
P11602353A0770 |27 32|HFH-1ith a
P11602353A0770 |124 143|expression profileserbilirubinemia. P0
P11602353A0770 |41 46|HFH-3hosph
P11602353A0770 |59 69|C/EBP betanucleotida
P11602353A0770 |48 53|C/EBPases 
P11603271T0001 |21 38|vertigo syndromesison with alkalin
P11603271T0001 |9 16|vertigoT0076 C
P11604152A0526 |239 245|effect no lo
P11604152A0526 |259 269|bandwidths when comp
P11604152A0526 |83 86|VLF000
P11604152A0526 |125 127|LFrb
P11604152A0526 |215 222|purposea of K-
P11604152A0526 |183 185|Hzs 
P11604152A0526 |203 206|CCFPCO
P11604152A0526 |76 81|range08171
P11604152A0526 |162 167|rangeSF [H
P11604152A0526 |287 296|mean CCFsut still 
P11604152A0526 |13 26|MCBFV signals6 Comparison 
P11604152A0526 |104 123|low-frequency rangeects of neonatal hy
P11604152A0526 |169 171|HF3-
P11604152A0526 |4 8|MABP0160
P11604152A0526 |99 101|Hzc 
P11604152A0526 |139 141|Hz. 
P11604152A0526 |32 40|bandpasslkaline 
P11605207T0001 |0 9|TreatmentP00001606
P11605207T0001 |22 35|heart diseaseson with alka
P11605598A0785 |0 11|Hepatitis BP00001606T0
P11605598A0785 |146 153|climate8997A04
P11605598A0785 |80 87|El Paso1T0000 
P11605598A0785 |158 177|prevention programsen CSF [HCO3-] is s
P11605598A0785 |110 124|US populationsf neonatal hyp
P11605598A0785 |55 66|adolescentsd 5-nucleot
P11605598A0785 |16 38|C seroprevalence ratesomparison with alkalin
P11606538A1002 |33 38|geneskalin
P11606538A1002 |40 43|Nrkpho
P11606538A1002 |10 19|insertion0076 Comp
P11606538A1002 |63 87|receptor tyrosine kinaseeotidase P00008171T0000 
P11606538A1002 |93 96|Tppcol
P11606538A1002 |114 128|neuropeptidaseonatal hyperbi
P11614398T0000 |49 58|Mormonismses and 5
P11614398T0000 |11 17|people076 Co
P11614398T0000 |38 45|aspectse phosp
P11639485A0478 |93 102|languagescologic a
P11639485A0478 |12 16|work76 C
P11639485A0478 |151 159|scholars0472 Whe
P11639485A0478 |134 146|day studentsnemia. P0000
P11639485A0478 |78 82|Urdu171T
P11639485A0478 |111 118|benefit neonat
P11642687T0000 |0 10|ComparisonP00001606T
P11642687T0000 |74 82|outcomes0008171T
P11642687T0000 |21 38|language versionsison with alkalin
P11642687T0000 |57 62|SF-365-nuc
P11642687T0000 |46 52|QWB-SAatases
P11642687T0000 |101 117|prostate diseaseaspects of neona
P11642687T0000 |87 95|patientsPharmaco
P11653491T0000 |24 37|DNA violationn with alkali
P11653491T0000 |13 19|action6 Comp
P11669281A0653 |70 78|evidencee P00008
P11669281A0653 |82 93|competition0000 Pharma
P11669281A0653 |11 23|cytotoxicity076 Comparis
P11669281A0653 |97 106|synergismgic aspec
P11669281A0653 |36 47|antibioticsine phospha
P11669476A0346 |17 25|cytokinemparison
P11669476A0346 |90 97|tissuesrmacolo
P11669476A0346 |148 152|role97A0
P11669476A0346 |107 115|subjectss of neo
P11669476A0346 |165 183|insulin resistance[HCO3-] is shown a
P11669476A0346 |56 65|TNF-alpha 5-nucleo
P11669476A0346 |27 54|tumor necrosis factor-alphaith alkaline phosphatases a
P11675912A0131 |34 38|weekalin
P11675912A0131 |107 120|acetaminophens of neonatal
P11675912A0131 |126 137|alleviationbilirubinem
P11675912A0131 |95 102|aspirinlogic a
P11675912A0131 |10 17|alcohol0076 Co
P11675912A0131 |141 150|headachesP00008997
P11675912A0131 |71 82|preparation P00008171T
P11676899A0704 |19 31|risk factorsarison with 
P11676899A0704 |83 96|mononucleosis000 Pharmacol
P11676899A0704 |126 142|immunodeficiencybilirubinemia. P
P11676899A0704 |160 168|exposure CSF [HC
P11676899A0704 |65 70|virustidas
P11676899A0704 |174 187|wood industrys shown as a 
P11677363A0775 |87 89|PPPh
P11677363A0775 |124 131|measureerbilir
P11677363A0775 |46 56|IMT valuesatases and
P11677363A0775 |150 164|PP variabilityA0472 When CSF
P11677363A0775 |143 146|SBP000
P11677363A0775 |110 111|Pf
P11677363A0775 |78 83|h SBP171T0
P11677363A0775 |99 108|deviationc aspects
P11677363A0775 |19 26|findingarison 
P11677839A0876 |84 85|p0
P11677839A0876 |44 52|controlsphatases
P11677839A0876 |27 35|patientsith alka
P11677839A0876 |4 14|difference01606T0076
P11678437A0000 |171 200|petroleum development company] is shown as a function of C
P11678437A0000 |20 32|oil spillagerison with a
P11678437A0000 |36 42|growthine ph
P11678437A0000 |150 165|manifold sampleA0472 When CSF 
P11678437A0000 |61 76|nutrient uptakecleotidase P000
P11678437A0000 |44 56|productivityphatases and
P11678437A0000 |223 230|gravityepleted
P11678437A0000 |4 10|effect01606T
P11678437A0000 |80 85|maize1T000
P11678437A0000 |87 98|Zea mays L.Pharmacolog
P11678437A0000 |118 132|pot experimental hyperbiliru
P11679441A0429 |137 141|cGMPia. 
P11679441A0429 |53 68|nitrate/nitriteand 5-nucleotid
P11679441A0429 |112 135|guanosine monophosphateneonatal hyperbilirubin
P11679441A0429 |179 184|urinewn as
P11679441A0429 |75 99|micromol/mmol creatinine008171T0000 Pharmacologi
P11679441A0429 |168 174|plasmaO3-] i
P11679441A0429 |38 49|measuremente phosphata
P11679441A0429 |143 163|nmol/mmol creatinine0008997A0472 When CS
P11679441A0429 |70 73|NOxe P
P11679441A0429 |0 14|NO metabolitesP00001606T0076
P11680835A0756 |17 25|analysismparison
P11680835A0756 |83 87|acid000 
P11680835A0756 |40 45|costsphosp
P11680835A0756 |101 112|pamidronateaspects of 
P11680835A0756 |50 57|patientes and 
P11683558A0446 |4 8|diet0160
P11683558A0446 |89 100|differencesarmacologic
P11683558A0446 |12 20|migrants76 Compa
P11683558A0446 |73 87|micronutrients00008171T0000 
P11683558A0446 |124 128|dieterbi
P11683558A0446 |43 57|macronutrientssphatases and 
P11684665A0000 |51 59|sequences and 5-
P11684665A0000 |74 88|cell divisions0008171T0000 P
P11684665A0000 |139 157|nematode body plan. P00008997A0472 W
P11684665A0000 |0 24|C. elegans embryogenesisP00001606T0076 Compariso
P11685047A0301 |49 68|thrombin inhibitionses and 5-nucleotid
P11685047A0301 |77 93|substrate S-22388171T0000 Pharma
P11685047A0301 |23 29|methodon wit
P11685284X0000 |35 42|B37-B44line ph
P11685284X0000 |25 30|Suppl with
P11685284X0000 |1 13|Diabetologia00001606T007
P11686239A0464 |16 24|sequenceompariso
P11686239A0464 |149 168|sequence similarity7A0472 When CSF [HC
P11686239A0464 |91 100|stretchesmacologic
P11686239A0464 |82 85|G/C000
P11686239A0464 |176 183|G boxesshown a
P11686239A0464 |57 58|T5
P11686239A0464 |234 253|Dictyostelium geness are no longer dis
P11686239A0464 |32 39|3B genelkaline
P11686378A0326 |304 314|phenomenonignificant
P11686378A0326 |91 97|valuesmacolo
P11686378A0326 |180 193|E coli/cfu mLn as a functi
P11686378A0326 |21 28|reactorison wi
P11686378A0326 |80 84|LD501T00
P11686378A0326 |246 254|Pn decayger disp
P11686378A0326 |387 392|cellss to 
P11686378A0326 |330 335|cells (1.2
P11686378A0326 |61 70|dischargecleotidas
P11686378A0326 |280 288|coloniestrols bu
P11686378A0326 |132 146|concentrationsbinemia. P0000
P11686378A0326 |154 159|range2 Whe
P11686378A0326 |400 403|EHDfec
P11686378A0326 |369 376|numbersazepam 
P11687083A0218 |34 40|reviewaline 
P11687083A0218 |123 129|labourperbil
P11687083A0218 |70 100|prophylactic prostaglandin usee P00008171T0000 Pharmacologic
P11687083A0218 |114 119|stageonata
P11687083A0218 |59 66|effectsnucleot
P11687083A0218 |16 25|objectiveomparison
P11687083A0218 |0 10|OBJECTIVESP00001606T
P11687180A3209 |68 75|rHu EPOase P00
P11687180A3209 |107 112|onsets of 
P11687180A3209 |96 102|delaysogic a
P11687180A3209 |83 89|speeds000 Ph
P11687180A3209 |12 16|term76 C
P11687180A3209 |18 27|questionsparison w
P11687180A3209 |116 124|dialysisatal hyp
P11687352A0215 |0 7|METHODSP000016
P11687352A0215 |97 106|Septembergic aspec
P11687352A0215 |78 87|September171T0000 
P11687352A0215 |28 34|reviewth alk
P11687352A0215 |64 69|LASIKotida
P11687352A0215 |50 54|eyeses a
P11687517A1619 |3 8|ISREs00160
P11687517A1619 |36 50|mouse promoterine phosphatas
P11687737A0000 |0 10|BACKGROUNDP00001606T
P11687737A0000 |73 82|mortality00008171T
P11687737A0000 |143 146|age000
P11687737A0000 |59 68|morbiditynucleotid
P11687737A0000 |89 98|diabeticsarmacolog
P11687737A0000 |21 34|heart diseaseison with alk
P11687737A0000 |50 55|causees an
P11687869A0000 |36 43|colitisine pho
P11687869A0000 |14 19|woman Comp
P11687869A0000 |67 78|sarcoidosisdase P00008
P11689217T0000 |0 34|Cholesteryl ester transfer proteinP00001606T0076 Comparison with alk
P11689217T0000 |67 75|subjectsdase P00
P11689217T0000 |79 84|study71T00
P11689217T0000 |39 54|atherosclerosis phosphatases a
P11689217T0000 |103 114|angiographypects of ne
P11691585A1174 |85 89|homo0 Ph
P11691585A1174 |42 71|coimmunoprecipitation studiesosphatases and 5-nucleotidase
P11691585A1174 |95 113|heterodimerizationlogic aspects of n
P11691585A1174 |129 149|cKrox family membersirubinemia. P0000899
P11691585A1174 |16 37|mobility shift assaysomparison with alkali
P11691585T0000 |4 22|hcKrox gene family01606T0076 Compari
P11691585T0000 |56 68|matrix genes 5-nucleotid
P11692004A1200 |16 26|literatureomparison 
P11692004A1200 |108 120|relationship of neonatal
P11692004A1200 |63 70|studieseotidas
P11692004A1200 |150 159|aneurysmsA0472 Whe
P11692004A1200 |129 132|NF1iru
P11692004A1200 |2 8|review000160
P11693461A1649 |116 118|RAat
P11693461A1649 |79 81|US71
P11693461A1649 |133 143|populationinemia. P0
P11693461A1649 |96 111|TNF antagonistsogic aspects of
P11693461A1649 |36 46|drug costsine phosph
P11693461A1649 |6 22|utilisation data606T0076 Compari
P11693461A1649 |54 59|rangend 5-
P11693461A1649 |64 66|USot
P11695481A0310 |64 80|degradation rateotidase P0000817
P11695481A0310 |26 43|combination O3/UVwith alkaline pho
P11695481A0310 |10 20|conditions0076 Compa
P11695481A0310 |93 102|ozonationcologic a
P11697760A0000 |85 87|E20 
P11697760A0000 |160 168|OVX rats CSF [HC
P11697760A0000 |56 63|ability 5-nucl
P11697760A0000 |104 111|hormoneects of
P11697760A0000 |113 116|PTHeon
P11697760A0000 |67 83|17beta-estradioldase P00008171T0
P11697760A0000 |129 141|bone qualityirubinemia. 
P11697760A0000 |5 10|study1606T
P11697760A0000 |32 37|boronlkali
P11703464A0560 |51 58|regionss and 5
P11703464A0560 |128 136|responselirubine
P11703464A0560 |24 37|subjects rCBFn with alkali
P11703464A0560 |177 190|reinforcementhown as a fun
P11703464A0560 |116 124|circuitsatal hyp
P11703464A0560 |154 160|reward2 When
P11703558A0000 |0 11|DoxorubicinP00001606T0
P11703558A0000 |13 16|DOX6 C
P11703558A0000 |43 52|treatmentsphatases
P11703558A0000 |80 86|tumors1T0000
P11704380A1608 |119 128|Sta-nrMFPl hyperbi
P11704380A1608 |52 60|Un-nrMFP and 5-n
P11704380A1608 |40 48|Irr-rMFPphosphat
P11704380A1608 |107 115|Rev-rMFPs of neo
P11704380A1608 |4 14|event rate01606T0076
P11704380A1608 |18 26|patientsparison 
P11704829A0312 |0 25|Subtraction hybridizationP00001606T0076 Comparison
P11704829A0312 |134 141|changesnemia. 
P11704829A0312 |94 98|geneolog
P11704829A0312 |73 79|gene-7000081
P11704829A0312 |151 165|melanoma cells0472 When CSF 
P11704829A0312 |37 61|melanoma differentiationne phosphatases and 5-nu
P11704829A0312 |81 86|mda-7T0000
P11705093A2016 |65 71|effecttidase
P11705093A2016 |11 31|vitamin D3 analogues076 Comparison with 
P11706668A0000 |0 10|HydrocoeleP00001606T
P11706668A0000 |24 27|menn w
P11706668A0000 |60 65|areasucleo
P11706668A0000 |113 125|interventioneonatal hype
P11706668A0000 |71 80|treatment P0000817
P11706949T0000 |0 14|Growth hormoneP00001606T0076
P11706949T0000 |83 88|joint000 P
P11706949T0000 |96 99|ratogi
P11706949T0000 |32 57|growth factor I receptorslkaline phosphatases and 
P11707977A0750 |66 74|survivalidase P0
P11707977A0750 |13 17|hand6 Co
P11707977A0750 |78 89|H3 patients171T0000 Ph
P11707977A0750 |36 52|infusion therapyine phosphatases
P11708032A0183 |69 81|levoforinatese P00008171
P11708032A0183 |214 225|medicationsta of K-dep
P11708032A0183 |116 120|5-FUatal
P11708032A0183 |83 87|l-LV000 
P11708032A0183 |159 169|metastasesn CSF [HCO
P11708032A0183 |93 95|mgco
P11708032A0183 |126 128|mgbi
P11708032A0183 |57 65|infusion5-nucleo
P11708032A0183 |3 11|addition001606T0
P11708032A0183 |196 199|dayof 
P11708032A0183 |252 257|hourssplac
P11708032A0183 |273 285|infuser pump to controls
P11708032A0183 |100 114|5-fluorouracil aspects of ne
P11708362A0889 |32 39|payloadlkaline
P11708362A0889 |58 67|operation-nucleoti
P11708362A0889 |4 18|astronaut crew01606T0076 Com
P11708431A0904 |69 83|oligoarthritisse P00008171T0
P11708431A0904 |87 92|onsetPharm
P11708431A0904 |23 35|introductionon with alka
P11708431A0904 |10 18|patients0076 Com
P11708431A0904 |139 153|patient groups. P00008997A04
P11708431A0904 |50 58|categoryes and 5
P11708761A1388 |70 84|ACE inhibitorse P00008171T00
P11708761A1388 |113 130|diabetes mellituseonatal hyperbili
P11708761A1388 |63 66|useeot
P11708761A1388 |29 35|numberh alka
P11708761A1388 |39 48|arguments phosphat
P11708761A1388 |99 107|patientsc aspect
P11709561T0000 |0 5|PhaseP0000
P11709561T0000 |9 14|trialT0076
P11709561T0000 |29 31|D2h 
P11709561T0000 |44 56|antibody 3F8phatases and
P11709561T0000 |114 127|neuroblastomaonatal hyperb
P11709561T0000 |103 109|factorpects 
P11709890T0000 |0 11|Hepatitis AP00001606T0
P11709890T0000 |21 33|food handlerison with al
P11709890T0000 |65 78|food facilitytidase P00008
P11709890T0000 |40 48|Edmontonphosphat
P11709890T0000 |87 115|health protection strategiesPharmacologic aspects of neo
P11709890T0000 |50 57|Albertaes and 
P11710233T0000 |0 9|HydrogelsP00001606
P11710233T0000 |14 32|tissue engineering Comparison with a
P11710685A0994 |17 23|subsetmparis
P11710685A0994 |118 135|Papanicolaou testal hyperbilirubin
P11710685A0994 |99 110|sensitivityc aspects o
P11710685A0994 |27 32|ASCUSith a
P11710685A0994 |45 60|ASCUS/SIL ratiohatases and 5-n
P11710685A0994 |27 32|ASCUSith a
P11710685A0994 |45 60|ASCUS/SIL ratiohatases and 5-n
P11710685A0994 |17 23|subsetmparis
P11710685A0994 |99 110|sensitivityc aspects o
P11710685A0994 |118 135|Papanicolaou testal hyperbilirubin
P11711701A0602 |237 242|hoursre no
P11711701A0602 |179 184|hourswn as
P11711701A0602 |147 154|minutes997A047
P11711701A0602 |56 64|findings 5-nucle
P11711701A0602 |12 31|medicine physicians76 Comparison with 
P11711701A0602 |165 172|minutes[HCO3-]
P11711701A0602 |91 97|imagesmacolo
P11711701A0602 |203 208|hoursPCO2 
P11711701A0602 |189 196|minutesnction 
P11711701A0602 |110 140|Tc-99m MIBI image combinationsf neonatal hyperbilirubinemia.
P11711701A0602 |277 306|pertechnetate thyroid imagingcontrols but still have a sig
P11711701A0602 |217 224|minutesof K-de
P11714429X0000 |3 14|clopidogrel001606T0076
P11714429X0000 |84 95|cornerstone00 Pharmaco
P11714429X0000 |48 58|preventionases and 5
P11714429X0000 |145 160|thienopyridines08997A0472 When
P11714429X0000 |27 34|aspirinith alk
P11714429X0000 |300 304|Risk a s
P11714429X0000 |243 250|diseaselonger 
P11714429X0000 |133 141|efficacyinemia. 
P11714429X0000 |195 202|aspirin of CSF
P11714429X0000 |318 330|Events trialreater slope
P11714429X0000 |288 296|Patientst still 
P11714429X0000 |258 269|Clopidogreld when comp
P11714429X0000 |220 230|preventionK-depleted
P11714429X0000 |277 284|Aspirincontrol
P11714429X0000 |162 173|clopidogrelSF [HCO3-] 
P11714429X0000 |108 116|evidence of neon
P11714429X0000 |175 186|ticlopidine shown as a
P11714429X0000 |71 78|disease P00008
P11715079A1016 |154 164|mismatches2 When CSF
P11715079A1016 |261 264|eyehen
P11715079A1016 |247 253|motioner dis
P11715079A1016 |298 304|organsve a s
P11715079A1016 |224 231|commandpleted 
P11715079A1016 |105 113|responsects of n
P11715079A1016 |64 78|efference copyotidase P00008
P11715079A1016 |20 34|proprioceptionrison with alk
P11715079A1016 |173 197|eye movement informationis shown as a function o
P11715079A1016 |86 97|development Pharmacolo
P11715079A1016 |117 130|perturbationstal hyperbili
P11716043A0380 |100 136|Helsinki University Central Hospital aspects of neonatal hyperbilirubine
P11716043A0380 |27 35|patientsith alka
P11716043A0380 |46 53|surgeryatases 
P11716043A0380 |91 98|Surgerymacolog
P11716043A0380 |77 87|Department8171T0000 
P11716043A0380 |66 69|PTCida
P11716441A0585 |85 94|admission0 Pharmac
P11716441A0585 |41 58|health evaluationhosphatases and 5
P11716441A0585 |60 66|APACHEucleot
P11716441A0585 |18 28|physiologyparison wi
P11716441A0585 |0 3|ISSP00
P11718197A1282 |4 13|procedure01606T007
P11722993A0276 |0 12|Paul MonagleP00001606T00
P11722993A0276 |27 39|epidemiologyith alkaline
P11722993A0276 |94 100|systemologic
P11722993A0276 |164 169|utero [HCO
P11722993A0276 |129 138|locationsirubinemi
P11722993A0276 |52 62|thrombosis and 5-nuc
P11723500X0000 |102 112|BACKGROUNDspects of 
P11723500X0000 |95 100|womenlogic
P11723500X0000 |123 137|cell carcinomaperbilirubinem
P11723500X0000 |30 45|characteristics alkaline phosp
P11723500X0000 |156 162|cavityWhen C
P11723500X0000 |189 199|populationnction of 
P11723500X0000 |58 72|cell carcinoma-nucleotidase 
P11723500X0000 |139 142|SCC. P
P11723500X0000 |85 91|cavity0 Phar
P11723511A0780 |152 162|category D472 When C
P11723511A0780 |126 136|category Cbilirubine
P11723511A0780 |146 147|%8
P11723511A0780 |63 78|category A riskeotidase P00008
P11723511A0780 |91 92|%m
P11723511A0780 |181 192|category X. as a funct
P11723511A0780 |120 121|% 
P11723511A0780 |175 176|% 
P11723511A0780 |97 107|category Bgic aspect
P11723511A0780 |22 26|riskson 
P11723511A0780 |48 49|%a
P11723511A0780 |34 39|drugsaline
P11723675A1022 |170 177|group A-] is s
P11723675A1022 |249 254|point disp
P11723675A1022 |219 224|point K-de
P11723675A1022 |25 31|course with 
P11723675A1022 |58 68|SOFA score-nucleotid
P11723675A1022 |95 102|group Blogic a
P11723675A1022 |122 129|group Cyperbil
P11723675A1022 |241 243|.2o 
P11723675A1022 |135 137|.3em
P11723675A1022 |85 93|.3 point0 Pharma
P11723675A1022 |153 168|APACHE II score72 When CSF [HC
P11723675A1022 |49 54|meansses a
P11723675A1022 |190 195|pointction
P11723675A1022 |115 120|pointnatal
P11723675A1022 |142 147|point00008
P11723675A1022 |197 204|group Bf CSF P
P11723675A1022 |226 233|group Ceted ra
P11723675A1022 |4 12|severity01606T00
P11723675A1022 |70 77|group Ae P0000
P11723928A0294 |4 11|process01606T0
P11723928A0294 |57 72|Yangpu District5-nucleotidase 
P11723928A0294 |91 96|Chinamacol
P11723928A0294 |76 89|Shanghai City08171T0000 Ph
P11723928A0294 |36 53|river reclamationine phosphatases 
P11724510T0000 |35 44|apheresisline phos
P11724510T0000 |9 19|principlesT0076 Comp
P11726022A0909 |50 61|penetrationes and 5-nu
P11726022A0909 |166 171|modelHCO3-
P11726022A0909 |6 13|results606T007
P11726022A0909 |37 46|estimatesne phosph
P11726022A0909 |109 126|time calculationsof neonatal hyper
P11726022A0909 |80 92|calculations1T0000 Pharm
P11726022A0909 |101 105|rootaspe
P11726068A0539 |0 4|RindP000
P11726068A0539 |14 19|study Comp
P11726068A0539 |74 78|data0008
P11726068A0539 |27 38|conclusionsith alkalin
P11726164A0215 |102 110|residuesspects o
P11726164A0215 |72 85|food productsP00008171T000
P11726164A0215 |189 201|food allergynction of CS
P11726164A0215 |163 172|reactionsF [HCO3-]
P11726164A0215 |9 16|concernT0076 C
P11726164A0215 |20 35|food processorsrison with alka
P11726164A0215 |55 68|cross-contactd 5-nucleotid
P11726262A0692 |0 25|Lactate accumulation peakP00001606T0076 Comparison
P11726262A0692 |44 59|supplementationphatases and 5-
P11726262A0692 |120 122|mM h
P11726262A0692 |82 85|LEU000
P11726262A0692 |78 80|mM17
P11726262A0692 |61 64|HMBcle
P11726262A0692 |99 101|mMc 
P11726262A0692 |103 106|CONpec
P11726413A1756 |42 49|infantsosphata
P11726413A1756 |14 23|clearance Comparis
P11726413A1756 |74 81|opioids0008171
P11726413A1756 |56 64|contrast 5-nucle
P11726574A1304 |6 13|results606T007
P11726574A1304 |44 64|baseline assumptionsphatases and 5-nucle
P11726574A1304 |29 36|changesh alkal
P11726574A1304 |72 77|modelP0000
P11727073A0842 |0 10|CONCLUSIONP00001606T
P11727073A0842 |42 56|MIST-VR yieldsosphatases and
P11727073A0842 |126 130|taskbili
P11727073A0842 |28 35|novicesth alka
P11727073A0842 |70 77|changese P0000
P11727073A0842 |81 86|skillT0000
P11727073A0842 |189 197|trainingnction o
P11727073A0842 |154 161|results2 When 
P11727073A0842 |16 24|trainingompariso
P11727209A0502 |98 102|testic a
P11727209A0502 |107 118|orthostasias of neonat
P11727209A0502 |75 86|examination008171T0000
P11727209A0502 |23 31|familieson with 
P11727209A0502 |4 12|patients01606T00
P11728771A0187 |61 78|contrast materialcleotidase P00008
P11728771A0187 |44 52|reactionphatases
P11730182A0984 |136 140|Acermia.
P11730182A0984 |250 257|Poaceaedisplac
P11730182A0984 |189 190|pn
P11730182A0984 |179 185|Betulawn as 
P11730182A0984 |123 134|Cherry Hillperbilirubi
P11730182A0984 |301 306|Rumexa sig
P11730182A0984 |144 145|p0
P11730182A0984 |208 209|rt
P11730182A0984 |210 211|pe
P11730182A0984 |103 115|Philadelphiapects of neo
P11730182A0984 |238 239|pe
P11730182A0984 |236 237|ra
P11730182A0984 |38 49|correlatione phosphata
P11730182A0984 |308 309|rf
P11730182A0984 |310 311|pc
P11730182A0984 |167 168|pC
P11730182A0984 |165 166|r[
P11730182A0984 |187 188|rf
P11730182A0984 |259 260|r 
P11730182A0984 |222 234|Cupressaceaedepleted rat
P11730182A0984 |86 99|pollen levels Pharmacologi
P11730182A0984 |322 323|Pe
P11730182A0984 |156 163|QuercusWhen CS
P11730182A0984 |261 262|ph
P11730182A0984 |142 143|r0
P11730182A0984 |283 284|rl
P11730182A0984 |285 286|p 
P11730182A0984 |201 206|PinusF PCO
P11730182A0984 |273 281|Ambrosia to cont
P11730262A0874 |34 53|etidronate/fluoridealine phosphatases 
P11730262A0874 |22 27|studyson w
P11730262A0874 |122 125|menype
P11730262A0874 |104 115|pilot studyects of neo
P11730262A0874 |224 232|fluoridepleted r
P11730262A0874 |75 87|osteoporosis008171T0000 
P11730262A0874 |263 267|daysn co
P11730262A0874 |158 170|osteoporosisen CSF [HCO3
P11730262A0874 |189 199|etidronatenction of 
P11730262A0874 |207 211|days the
P11730262A0874 |238 255|calcium/vitamin De no longer displ
P11730712A0416 |34 39|weeksaline
P11730712A0416 |106 107|Pt
P11730712A0416 |91 104|MCA occlusionmacologic asp
P11730712A0416 |75 80|edema00817
P11730712A0416 |55 70|infarction sized 5-nucleotidas
P11730712A0416 |0 18|Treadmill trainingP00001606T0076 Com
P11732088A0471 |153 158|SSEUS72 Wh
P11732088A0471 |110 118|secretinf neonat
P11732088A0471 |40 48|readingsphosphat
P11732088A0471 |215 221|methoda of K
P11732088A0471 |141 151|ultrasoundP00008997A
P11732088A0471 |248 257|diagnosisr displac
P11732088A0471 |189 197|responsenction o
P11732088A0471 |3 8|order00160
P11732088A0471 |70 89|sphincter manometrye P00008171T0000 Ph
P11732417A0571 |116 129|serum samplesatal hyperbil
P11732417A0571 |12 39|percentage positivity value76 Comparison with alkaline
P11732417A0571 |194 203|ELISA kitn of CSF 
P11732417A0571 |146 155|reference8997A0472
P11732417A0571 |163 174|sample dataF [HCO3-] i
P11736254A0000 |169 179|structures3-] is sho
P11736254A0000 |61 67|modelscleoti
P11736254A0000 |115 127|partitioningnatal hyperb
P11736254A0000 |147 156|landscape997A0472 
P11736254A0000 |91 98|glassesmacolog
P11736254A0000 |3 11|analysis001606T0
P11736254A0000 |19 27|dynamicsarison w
P11736792A0204 |156 166|morphologyWhen CSF [
P11736792A0204 |46 51|studyatase
P11736792A0204 |109 143|World Health Organization criteriaof neonatal hyperbilirubinemia. P0
P11736792A0204 |208 216|criteriathe data
P11736792A0204 |72 74|G1P0
P11736792A0204 |10 23|semen samples0076 Comparis
P11736792A0204 |96 98|G2og
P11737056A0680 |49 58|ET mucosases and 5
P11737056A0680 |24 34|leucocytesn with alk
P11737056A0680 |76 80|BrdU0817
P11737056A0680 |42 44|MEos
P11737056A0680 |8 17|timepoint6T0076 Co
P11737056A0680 |112 119|subsetsneonata
P11737056A0680 |99 100|%c
P11737158A1517 |68 78|Broca BA44ase P00008
P11737158A1517 |126 138|computationsbilirubinemi
P11737158A1517 |94 99|gyrusologi
P11737158A1517 |158 165|contacten CSF 
P11737158A1517 |52 66|fusiform gyrus and 5-nucleot
P11737158A1517 |37 45|Wernickene phosp
P11737158A1517 |191 201|dimensionstion of CS
P11737158A1517 |18 23|areasparis
P11737900A0700 |87 88|PP
P11737900A0700 |76 78|r208
P11737900A0700 |12 23|correlation76 Comparis
P11737900A0700 |47 58|body weighttases and 5
P11737900A0700 |71 74|age P0
P11737900A0700 |32 42|plasma COPlkaline ph
P11738404A0120 |205 227|alpha-diacetoxy-8 betaO2 the data of K-deple
P11738404A0120 |255 296|alpha-benzoyloxy-13-isobutanoyloxy-4 betaaced when compared to controls but still 
P11738404A0120 |117 129|alpha-methyltal hyperbil
P11738404A0120 |459 471|analyses NMRral practice
P11738404A0120 |55 92|alpha-diacetoxy-8 beta-isobutanoyloxyd 5-nucleotidase P00008171T0000 Pharm
P11738404A0120 |488 492|dataight
P11738404A0120 |365 444|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuranFlurazepam thus appears to be an effective hypnotic drug with the optimum dose 
P11738404A0120 |300 337|beta-dihydroxy-beta-dihydroagarofuran a significantly greater slope (1.21 
P11738404A0120 |229 233|betad ra
P11738404A0120 |348 353|alpha. P00
P11738404A0120 |130 148|butanoyloxy-4 betarubinemia. P000089
P11738404A0120 |47 52|alphatases
P11738404A0120 |152 189|beta-dihydroxy-beta-dihydroagarofuran472 When CSF [HCO3-] is shown as a fu
P11738404A0120 |357 361|beta43A0
P11738404A0120 |6 25|chemical structures606T0076 Comparison
P11738404A0120 |96 115|alpha-benzoyloxy-13ogic aspects of neo
P11738404A0120 |197 202|alphaf CSF
P11738404A0120 |235 251|furancarbonyloxy are no longer d
P11738404A0120 |476 478|MSg 
P11740571A0114 |17 21|dosempar
P11740571A0114 |127 139|brain tissueilirubinemia
P11740571A0114 |89 97|activityarmacolo
P11740571A0114 |243 252|processeslonger di
P11740571A0114 |151 158|toluene0472 Wh
P11740571A0114 |45 52|maximumhatases
P11740571A0114 |216 226|activation of K-depl
P11740571A0114 |65 78|concentrationtidase P00008
P11740571A0114 |5 11|toxins1606T0
P11740571A0114 |101 123|glutathione peroxidaseaspects of neonatal hy
P11740571A0114 |169 196|chemiluminescence intensity3-] is shown as a function 
P11740806X0810 |0 16|Saunders CompanyP00001606T0076 C
P11741259A1233 |118 122|partal h
P11741259A1233 |88 92|drugharm
P11741259A1233 |4 15|performance01606T0076 
P11741259A1233 |65 72|abilitytidase 
P11741259A1233 |130 139|intestinerubinemia
P11741259A1233 |168 172|formO3-]
P11741259A1233 |32 41|particleslkaline p
P11741554T0000 |0 10|ComparisonP00001606T
P11741554T0000 |67 72|womendase 
P11741554T0000 |27 48|lipoprotein particlesith alkaline phosphat
P11741554T0000 |121 124|menhyp
P11741554T0000 |99 113|artery diseasec aspects of n
P11741554T0000 |139 153|artery disease. P00008997A04
P11742432A0798 |103 111|patientspects of
P11742432A0798 |396 408|cells/microLn effective 
P11742432A0798 |364 374|CD4 counts Flurazepa
P11742432A0798 |296 311|discontinuationhave a signific
P11742432A0798 |61 69|efficacycleotida
P11742432A0798 |315 336|macrolide prophylaxisy greater slope (1.21
P11742432A0798 |344 357|AIDS patients3 vs. P000109
P11742432A0798 |134 145|combinationnemia. P000
P11742432A0798 |84 99|MAC prophylaxis00 Pharmacologi
P11742432A0798 |263 268|tractn com
P11742432A0798 |188 197|incidenceunction o
P11742432A0798 |8 15|results6T0076 
P11742432A0798 |231 243|colonizationrats are no 
P11742432A0798 |161 168|therapyCSF [HC
P11742432A0798 |37 43|trialsne pho
P11742432A0798 |277 282|trialcontr
P11743360A2491 |137 139|mlia
P11743360A2491 |133 135|pgin
P11743360A2491 |91 92|%m
P11743360A2491 |42 53|mean amountosphatases 
P11743360A2491 |78 83|urine171T0
P11743360A2491 |57 61|IL-65-nu
P11743360A2491 |6 12|stress606T00
P11743360A2491 |18 22|ratspari
P11743612A1179 |0 8|PatientsP0000160
P11743612A1179 |75 84|diagnosis008171T00
P11743612A1179 |97 110|survival rategic aspects o
P11743612A1179 |135 148|CF populationemia. P000089
P11743612A1179 |14 16|CF C
P11743612A1179 |65 71|statustidase
P11743612A1179 |21 35|meconium ileusison with alka
P11744290T0045 |1 10|Cactaceae00001606T
P11744290T0045 |12 24|waste matter76 Compariso
P11744953A0878 |0 12|Skin cancersP00001606T00
P11744953A0878 |95 107|age patientslogic aspect
P11744953A0878 |43 48|tractsphat
P11744953A0878 |66 72|systemidase 
P11752821A1365 |0 10|CONCLUSIONP00001606T
P11752821A1365 |53 58|signsand 5
P11752821A1365 |76 95|Adamantiades-Behcet08171T0000 Pharmaco
P11752821A1365 |12 15|MMF76 
P11752821A1365 |21 26|g/dayison 
P11752821A1365 |98 105|diseaseic aspe
P11755894A0466 |139 149|management. P0000899
P11755894A0466 |122 124|mgyp
P11755894A0466 |106 109|ADLts 
P11755894A0466 |167 172|ileusCO3-]
P11755894A0466 |220 234|bowel functionK-depleted rat
P11755894A0466 |252 265|hospital staysplaced when 
P11755894A0466 |95 99|painlogi
P11755894A0466 |56 63|surgery 5-nucl
P11755894A0466 |7 16|treatment06T0076 C
P11755894A0466 |197 201|timef CS
P11755894A0466 |77 84|opioids8171T00
P11755894A0466 |174 177|POIs s
P11755894A0466 |33 41|patientskaline p
P11760398A0553 |119 127|presencel hyperb
P11760398A0553 |158 160|BSen
P11760398A0553 |25 33|patients with al
P11760398A0553 |146 154|features8997A047
P11760398A0553 |131 138|absenceubinemi
P11760398A0553 |226 238|ISG criteriaeted rats ar
P11760398A0553 |164 169|means [HCO
P11760398A0553 |184 188|form a f
P11760398A0553 |86 96|conditions Pharmacol
P11760398A0553 |39 41|BS p
P11760398A0553 |50 58|patientses and 5
P11760398A0553 |0 7|METHODSP000016
P11760796A0698 |0 8|EvidenceP0000160
P11760796A0698 |78 90|phakomatosis171T0000 Pha
P11760796A0698 |55 66|associationd 5-nucleot
P11760796A0698 |23 38|PHACES syndromeon with alkalin
P11760796A0698 |128 133|lightlirub
P11760796A0698 |156 166|backgroundWhen CSF [
P11760796A0698 |100 107|studies aspect
P11761601A0133 |102 128|contaminant concentrationsspects of neonatal hyperbi
P11761601A0133 |61 76|airflow patterncleotidase P000
P11761601A0133 |159 179|inhalation exposuresn CSF [HCO3-] is sho
P11761601A0133 |82 94|time history0000 Pharmac
P11761601A0133 |145 149|zone0899
P11761601A0133 |20 30|ACCESS-IAQrison with
P11761601A0133 |2 18|computer program0001606T0076 Com
P11763176A0918 |100 110|experiment aspects o
P11763176A0918 |146 147|%8
P11763176A0918 |31 52|antithrombin activityalkaline phosphatases
P11763176A0918 |80 91|experiments1T0000 Phar
P11763176A0918 |19 27|decreasearison w
P11764062A0000 |136 144|childrenmia. P00
P11764062A0000 |124 132|tendencyerbiliru
P11764062A0000 |208 216|Chorpitathe data
P11764062A0000 |225 230|Behavleted
P11764062A0000 |201 206|worryF PCO
P11764062A0000 |4 34|Penn State Worry Questionnaire01606T0076 Comparison with alk
P11764062A0000 |39 47|Children phospha
P11764062A0000 |49 55|PSWQ-Cses an
P11764062A0000 |70 95|self-report questionnairee P00008171T0000 Pharmaco
P11764226A0798 |0 14|ClassificationP00001606T0076
P11764226A0798 |121 127|monthshyperb
P11764226A0798 |66 74|patientsidase P0
P11764226A0798 |95 111|disease durationlogic aspects of
P11764226A0798 |165 179|EULAR criteria[HCO3-] is sho
P11764226A0798 |80 88|patients1T0000 P
P11764226A0798 |32 45|ILAR criterialkaline phosp
P11765448A0588 |48 56|patientsases and
P11765448A0588 |10 26|X-ray projection0076 Comparison 
P11766747A0000 |85 93|teratoma0 Pharma
P11766747A0000 |39 45|review phosp
P11766747A0000 |54 62|patientsnd 5-nuc
P11768467A0000 |0 23|Pyrethroid insecticidesP00001606T0076 Comparis
P11768467A0000 |43 54|agriculturesphatases a
P11768467A0000 |67 77|householdsdase P0000
P11769229A0357 |68 75|processase P00
P11769229A0357 |37 47|adsorptionne phospha
P11769229A0357 |91 99|sorptionmacologi
P11769229A0357 |4 23|sorption mechanisms01606T0076 Comparis
P11769229A0357 |51 60|partitions and 5-n
P11771979A1141 |34 45|variabilityaline phosp
P11771979A1141 |112 117|rangeneona
P11771979A1141 |161 164|LDFCSF
P11771979A1141 |132 139|methodsbinemia
P11771979A1141 |181 188|mapping as a f
P11771979A1141 |237 250|heterogeneityre no longer 
P11771979A1141 |87 96|microflowPharmacol
P11771979A1141 |49 60|LDF signalsses and 5-n
P11771979A1141 |153 159|organs72 Whe
P11771979A1141 |274 285|vasculatureto controls
P11773168A0915 |137 138|Pi
P11773168A0915 |149 150|P7
P11773168A0915 |19 27|survivalarison w
P11773168A0915 |54 62|survivalnd 5-nuc
P11773168A0915 |114 115|%o
P11773168A0915 |94 95|%o
P11773168A0915 |124 125|%e
P11773168A0915 |29 31|OSh 
P11773168A0915 |64 67|PFSoti
P11773168A0915 |130 135|arm Brubin
P11773168A0915 |84 85|%0
P11773168A0915 |100 105|arm A aspe
P11773168A0915 |69 74|ratesse P0
P11773921A0397 |0 7|METHODSP000016
P11773921A0397 |406 408|mge 
P11773921A0397 |167 171|daysCO3-
P11773921A0397 |395 399|dosean e
P11773921A0397 |220 228|patientsK-deplet
P11773921A0397 |259 270|clopidogrel when compa
P11773921A0397 |253 255|mgpl
P11773921A0397 |81 85|flowT000
P11773921A0397 |178 186|patientsown as a
P11773921A0397 |121 132|clopidogrelhyperbiliru
P11773921A0397 |303 311|patientssignific
P11773921A0397 |232 237|groupats a
P11773921A0397 |283 295|implantationls but still
P11773921A0397 |433 439|groupstimum 
P11773921A0397 |350 361|clopidogrelP00010943A0
P11773921A0397 |9 30|P-selectin expressionT0076 Comparison with
P11773921A0397 |315 320|groupy gre
P11773921A0397 |412 423|clopidogrelotic drug w
P11773921A0397 |370 374|dosezepa
P11773921A0397 |67 76|plateletsdase P000
P11773921A0397 |201 215|artery diseaseF PCO2 the dat
P11773921A0397 |141 145|doseP000
P11775180A0379 |49 55|surveyses an
P11775180A0379 |63 84|gamma-detecting probeeotidase P00008171T00
P11775180A0379 |21 32|explorationison with a
P11775301A0797 |17 29|interventionmparison wit
P11775301A0797 |3 9|effect001606
P11775301A0797 |33 50|depression scoreskaline phosphatas
P11776922A0830 |68 73|groupase P
P11776922A0830 |90 95|grouprmaco
P11776922A0830 |45 55|skull basehatases an
P11776922A0830 |59 64|casesnucle
P11776922A0830 |27 37|resorptionith alkali
P11776922A0830 |13 22|sclerosis6 Compari
P11776922A0830 |76 83|lesions08171T0
P11776922A0830 |99 106|lesionsc aspec
P11777575A0363 |155 163|networks When CS
P11777575A0363 |36 46|bulgaricusine phosph
P11777575A0363 |165 169|ANNs[HCO
P11777575A0363 |91 97|pelletmacolo
P11777575A0363 |115 119|datanata
P11777575A0363 |21 31|populationison with 
P11777575A0363 |4 12|quantity01606T00
P11777575A0363 |48 63|S. thermophilusases and 5-nucl
P11777575A0363 |101 105|PyMSaspe
P11777632A1678 |0 2|AFP0
P11777632A1678 |128 134|breastlirubi
P11777632A1678 |146 153|lesions8997A04
P11777632A1678 |177 181|losshown
P11777632A1678 |104 113|componentects of n
P11777632A1678 |185 198|AF expressiona function of
P11777632A1678 |38 45|patterne phosp
P11777632A1678 |233 246|breast cancerts are no lon
P11777632A1678 |49 59|expressionses and 5-
P11777632A1678 |259 265|stroma when 
P11778044A0000 |258 278|climate observationsd when compared to c
P11778044A0000 |160 171|simulations CSF [HCO3-
P11778044A0000 |74 84|properties0008171T00
P11778044A0000 |191 215|complexity climate modeltion of CSF PCO2 the dat
P11778044A0000 |92 106|climate systemacologic aspec
P11778044A0000 |125 148|fingerprinting approachrbilirubinemia. P000089
P11778044A0000 |236 247|diagnosticsare no long
P11778044A0000 |16 49|probability density distributionsomparison with alkaline phosphata
P11778804A0179 |0 9|FrequencyP00001606
P11778804A0179 |72 75|FDTP00
P11778804A0179 |20 26|curvesrison 
P11778804A0179 |49 55|methodses an
P11781615A0000 |35 40|cGVHDline 
P11781615A0000 |26 33|diseasewith al
P11781615A0000 |94 114|cell transplantationologic aspects of ne
P11781615A0000 |53 65|complicationand 5-nucleo
P11782218A0349 |33 42|perimetrykaline ph
P11782218A0349 |147 163|media absorption997A0472 When CS
P11782218A0349 |12 26|white-on-white76 Comparison 
P11782218A0349 |28 31|W-Wth 
P11782218A0349 |44 48|SWAPphat
P11782218A0349 |83 94|variability000 Pharmac
P11782218A0349 |129 138|thresholdirubinemi
P11782218A0349 |214 229|learning effectta of K-deplete
P11782218A0349 |115 125|estimationnatal hype
P11782218A0349 |175 195|examination duration shown as a function
P11783457A0000 |0 13|PreservativesP00001606T007
P11783457A0000 |31 40|componentalkaline 
P11783457A0000 |93 101|activitycologic 
P11783457A0000 |131 144|decompositionubinemia. P00
P11783457A0000 |109 115|bottleof neo
P11783457A0000 |55 67|preparationsd 5-nucleoti
P11783457A0000 |155 159|drug Whe
P11785085X0001 |68 76|patientsase P000
P11785085X0001 |240 248|PVM-R-01no longe
P11785085X0001 |12 20|analysis76 Compa
P11785085X0001 |119 127|efficacyl hyperb
P11785085X0001 |220 238|pneumovibromassageK-depleted rats ar
P11785085X0001 |189 202|Introl-4 unitnction of CSF
P11785085X0001 |56 64|drainage 5-nucle
P11785085X0001 |271 279|patientsed to co
P11785085X0001 |170 187|vacuum aspiration-] is shown as a 
P11785085X0001 |32 42|techniqueslkaline ph
P11785085X0001 |141 149|drainageP0000899
P11785085X0001 |305 316|prostatitisgnificantly
P11785085X0001 |102 113|prostatitisspects of n
P11785827A0986 |205 221|transmissibilityO2 the data of K
P11785827A0986 |52 58|models and 5
P11785827A0986 |231 244|communicationrats are no l
P11785827A0986 |182 200|selection pressureas a function of C
P11785827A0986 |29 37|relationh alkali
P11785827A0986 |138 149|degradationa. P0000899
P11785827A0986 |4 11|results01606T0
P11785827A0986 |159 165|forestn CSF 
P11785827A0986 |84 94|physiology00 Pharmac
P11785827A0986 |68 79|propagationase P000081
P11786248A1162 |0 11|ConsumptionP00001606T0
P11786248A1162 |58 65|lesions-nucleo
P11786248A1162 |132 133|%b
P11786248A1162 |73 77|PPTg0000
P11786248A1162 |140 149|% sucrose P0000899
P11786248A1162 |83 87|PPTg000 
P11786248A1162 |97 101|ratsgic 
P11786248A1162 |155 168|sham controls When CSF [HC
P11786248A1162 |16 25|% sucroseomparison
P11786945A0958 |35 46|arrhythmiasline phosph
P11786945A0958 |10 17|freedom0076 Co
P11786945A0958 |88 95|group Aharmaco
P11786945A0958 |57 66|follow-up5-nucleot
P11786945A0958 |83 84|%0
P11787041A0167 |7 18|development06T0076 Com
P11787322X0001 |0 9|InfluenceP00001606
P11787322X0001 |330 338|diseases (1.21 +
P11787322X0001 |121 132|instrumentshyperbiliru
P11787322X0001 |210 221|impressionse data of K
P11787322X0001 |303 315|transmissionsignificantl
P11787322X0001 |72 82|propertiesP00008171T
P11787322X0001 |166 180|prosthodonticsHCO3-] is show
P11787322X0001 |291 299|vehiclestill hav
P11787322X0001 |86 90|type Pha
P11787322X0001 |190 195|stonection
P11787322X0001 |23 30|methodson with
P11787322X0001 |237 244|recordsre no l
P11787322X0001 |98 106|V gypsumic aspec
P11787322X0001 |276 286|literature controls 
P11787322X0001 |137 146|materialsia. P0000
P11787322X0001 |34 55|chemical disinfectionaline phosphatases an
P11787720A1313 |137 138|%i
P11787720A1313 |129 131|n6ir
P11787720A1313 |59 63|acidnucl
P11787720A1313 |78 79|%1
P11787720A1313 |124 127|C20erb
P11787720A1313 |91 92|Pm
P11787720A1313 |14 18|milk Com
P11787720A1313 |38 46|decreasee phosph
P11787720A1313 |140 141|P 
P11787720A1313 |65 68|C18tid
P11787720A1313 |70 72|n6e 
P11787720A1313 |118 122|acidal h
P11787746A0374 |0 10|VitrectomyP00001606T
P11787746A0374 |15 22|removalCompari
P11787746A0374 |116 124|majorityatal hyp
P11787746A0374 |71 77|acuity P0000
P11787746A0374 |128 136|patientslirubine
P11787746A0374 |100 108|glaucoma aspects
P11787746A0374 |35 49|lens fragmentsline phosphata
P11789206A1182 |17 26|mechanismmparison 
P11789206A1182 |121 123|Qihy
P11789206A1182 |90 100|principlesrmacologic
P11789206A1182 |30 34|MIRI alk
P11789206A1182 |38 51|Qi deficiencye phosphatase
P11789206A1182 |56 68|blood stasis 5-nucleotid
P11789206A1182 |72 75|TCMP00
P11789206A1182 |141 153|blood stasisP00008997A04
P11789206A1182 |0 11|CONCLUSIONSP00001606T0
P11789216T0001 |0 7|EffectsP000016
P11789216T0001 |66 80|barrier actionidase P0000817
P11789216T0001 |22 39|blood circulationson with alkaline
P11789216T0001 |92 96|wallacol
P11789216T0001 |117 126|gastritistal hyper
P11789216T0001 |50 62|blood stasises and 5-nuc
P11790897T0000 |68 77|potentialase P0000
P11790897T0000 |10 18|patterns0076 Com
P11790897T0000 |124 137|breast cancererbilirubinem
P11790897T0000 |22 28|nippleson wi
P11790897T0000 |111 120|diagnosis neonatal
P11790897T0000 |57 66|SELDI-TOF5-nucleot
P11790897T0000 |38 44|fluidse phos
P11790897T0000 |86 96|biomarkers Pharmacol
P11791292A0193 |85 92|problem0 Pharm
P11791292A0193 |63 70|networkeotidas
P11791292A0193 |41 52|applicationhosphatases
P11791292A0193 |17 27|laboratorymparison w
P11791571T0000 |68 83|electrophoresisase P00008171T0
P11791571T0000 |108 132|plasma mass spectrometry of neonatal hyperbiliru
P11791571T0000 |2 53|high-efficiency cross-flow micronebulizer interface0001606T0076 Comparison with alkaline phosphatases 
P11791585A0287 |68 71|usease
P11791585A0287 |145 152|surface08997A0
P11791585A0287 |4 14|electrodes01606T0076
P11791853A0532 |17 24|resultsmpariso
P11791853A0532 |107 112|colors of 
P11791853A0532 |121 124|CODhyp
P11791853A0532 |148 158|wastewater97A0472 Wh
P11791853A0532 |41 77|coagulation-electrooxidation processhosphatases and 5-nucleotidase P0000
P11792586A0290 |101 114|tissue matrixaspects of ne
P11792586A0290 |78 89|microcracks171T0000 Ph
P11792586A0290 |7 14|loading06T0076
P11792586A0290 |126 130|bonebili
P11792586A0290 |43 51|activitysphatase
P11792586A0290 |65 74|formationtidase P0
P11792586A0290 |18 22|bonepari
P11793172A0545 |34 41|PE headaline p
P11793172A0545 |160 167|PE head CSF [H
P11793172A0545 |63 67|timeeoti
P11793172A0545 |74 77|THA000
P11793172A0545 |19 26|surfacearison 
P11793172A0545 |87 107|friction coefficientPharmacologic aspect
P11793614A0000 |0 9|OBJECTIVEP00001606
P11793614A0000 |28 32|lackth a
P11793614A0000 |210 225|anticoagulatione data of K-dep
P11793614A0000 |181 188|disease as a f
P11793614A0000 |120 129|inhibitor hyperbil
P11793614A0000 |36 42|effectine ph
P11793614A0000 |59 73|concentrationsnucleotidase P
P11793614A0000 |77 87|cilomilast8171T0000 
P11793614A0000 |138 147|treatmenta. P00008
P11793614A0000 |100 117|phosphodiesterase aspects of neona
P11796977T0000 |0 8|PostdocsP0000160
P11796977T0000 |30 45|mainland Europe alkaline phosp
P11796977T0000 |14 22|hardship Compari
P11800119A0814 |4 20|design principle01606T0076 Compa
P11800119A0814 |40 54|vibration modephosphatases a
P11800586A1090 |152 161|diagnosis472 When 
P11800586A1090 |165 177|tuberculosis[HCO3-] is s
P11800586A1090 |127 131|toolilir
P11800586A1090 |56 63|bacilli 5-nucl
P11800586A1090 |12 21|DPPD gene76 Compar
P11800586A1090 |97 105|moleculegic aspe
P11800586A1090 |71 78|results P00008
P11800878T0000 |0 15|Dynamic imagingP00001606T0076 
P11800878T0000 |47 73|ultrashort UV laser pulsestases and 5-nucleotidase P
P11800878T0000 |27 41|wave functionsith alkaline p
P11801459T0000 |0 8|EfficacyP0000160
P11801459T0000 |62 78|atherothrombosisleotidase P00008
P11801459T0000 |13 19|safety6 Comp
P11801459T0000 |23 30|aspirinon with
P11801459T0000 |48 58|managementases and 5
P11802580A0000 |118 133|patient recordsal hyperbilirub
P11802580A0000 |147 155|practice997A0472
P11802580A0000 |53 58|worldand 5
P11802580A0000 |179 199|health research toolwn as a function of 
P11802580A0000 |40 44|GPRDphos
P11802580A0000 |4 38|General Practice Research Database01606T0076 Comparison with alkalin
P11802580A0000 |69 90|computerized databasese P00008171T0000 Pha
P11802601A0107 |5 10|paper1606T
P11802601A0107 |91 107|aldicarb sulfonemacologic aspect
P11802601A0107 |112 130|aldicarb sulfoxideneonatal hyperbili
P11802601A0107 |78 89|metabolites171T0000 Ph
P11802601A0107 |56 64|aldicarb 5-nucle
P11802601A0107 |23 30|resultson with
P11802601A0107 |36 52|laboratory studyine phosphatases
P11803325A0868 |99 101|DCc 
P11803325A0868 |9 25|DC cardioversionT0076 Comparison
P11803325A0868 |109 118|GIK groupof neonat
P11803325A0868 |46 55|HBS groupatases an
P11803325A0868 |77 86|CBC group8171T0000
P11803325A0868 |67 69|DCda
P11804081A0552 |102 112|Evergladesspects of 
P11804081A0552 |6 12|August606T00
P11804081A0552 |61 63|TPcl
P11804081A0552 |23 27|ENRPon w
P11804081A0552 |53 57|tonsand 
P11804100A0365 |49 54|NH3-Nses a
P11804100A0365 |49 54|NH3-Nses a
P11804100A0365 |113 121|kineticseonatal 
P11804100A0365 |23 36|disappearanceon with alkal
P11804100A0365 |125 135|TP removalrbilirubin
P11804100A0365 |95 103|kineticslogic as
P11804100A0365 |40 44|BOD5phos
P11804100A0365 |125 135|TP removalrbilirubin
P11804100A0365 |95 103|kineticslogic as
P11804100A0365 |40 44|BOD5phos
P11804100A0365 |23 36|disappearanceon with alkal
P11804100A0365 |113 121|kineticseonatal 
P11804510A0730 |0 6|LossesP00001
P11804510A0730 |27 28|%i
P11804510A0730 |10 23|dichlofluanid0076 Comparis
P11804510A0730 |227 237|processingted rats a
P11804510A0730 |132 138|applesbinemi
P11804510A0730 |47 48|%t
P11804510A0730 |31 43|chlozolinatealkaline pho
P11804510A0730 |175 181|levels shown
P11804510A0730 |55 66|etridiazoled 5-nucleot
P11804510A0730 |197 198|%f
P11804510A0730 |70 71|%e
P11804510A0730 |118 128|processingal hyperbi
P11806132A0253 |32 36|arealkal
P11806132A0253 |25 30|AIRIN with
P11806132A0253 |94 98|rateolog
P11806132A0253 |52 65|% TB patients and 5-nucleo
P11806132A0253 |4 16|TB incidence01606T0076 C
P11810685A0147 |155 156|q 
P11810685A0147 |126 141|long-wavelengthbilirubinemia. 
P11810685A0147 |177 179|3Dho
P11810685A0147 |89 101|displacementarmacologic 
P11810685A0147 |226 232|DT-MRIeted r
P11810685A0147 |158 164|limitsen CSF
P11810685A0147 |189 214|displacement distributionnction of CSF PCO2 the da
P11810685A0147 |67 70|MRIdas
P11810685A0147 |21 46|displacement distributionison with alkaline phosph
P11810685A0147 |115 116|rn
P11811743A0800 |69 81|Class III FIse P00008171
P11811743A0800 |4 13|procedure01606T007
P11811743A0800 |133 142|clinicianinemia. P
P11811743A0800 |30 39|retention alkaline
P11811743A0800 |87 93|mannerPharma
P11811743A0800 |117 124|patienttal hyp
P11811825A0972 |4 11|results01606T0
P11811825A0972 |88 94|systemharmac
P11811825A0972 |28 56|cross-validation experimentsth alkaline phosphatases and
P11811825A0972 |75 82|average008171T
P11811825A0972 |109 120|specificityof neonatal
P11811825A0972 |158 175|sensitivity levelen CSF [HCO3-] is
P11815644A0081 |139 157|muscle recruitment. P00008997A0472 W
P11815644A0081 |165 177|echolocation[HCO3-] is s
P11815644A0081 |104 110|timingects o
P11815644A0081 |75 85|variations008171T000
P11815644A0081 |38 43|callse pho
P11815644A0081 |66 69|batida
P11815644A0081 |13 28|characteristics6 Comparison wi
P11815644A0081 |55 62|speciesd 5-nuc
P11815644A0081 |115 123|patternsnatal hy
P11816458A0319 |118 132|review articleal hyperbiliru
P11816458A0319 |26 38|Explanationswith alkalin
P11816458A0319 |63 74|help systemeotidase P0
P11816458A0319 |13 21|Examples6 Compar
P11816458A0319 |104 112|sectionsects of 
P11816458A0319 |134 149|journal articlenemia. P0000899
P11816458A0319 |163 173|experimentF [HCO3-] 
P11816458A0319 |42 50|APA Formosphatas
P11816458A0319 |215 226|experimentsa of K-depl
P11816458A0319 |178 193|journal articleown as a functi
P11816458A0319 |80 88|examples1T0000 P
P11816779A0343 |4 16|drug packets01606T0076 C
P11816779A0343 |61 76|chloramphenicolcleotidase P000
P11816779A0343 |27 41|acetyl aspirinith alkaline p
P11816779A0343 |43 56|acetaminophensphatases and
P11818675X0897 |0 9|Karger AGP00001606
P11818675X0897 |11 16|Basel076 C
P11819326A0000 |119 122|PSEl h
P11819326A0000 |188 191|PSEunc
P11819326A0000 |22 26|roleson 
P11819326A0000 |42 48|statusosphat
P11819326A0000 |124 131|METHODSerbilir
P11819326A0000 |62 70|patientsleotidas
P11819326A0000 |103 117|encephalopathypects of neona
P11819326A0000 |156 164|patientsWhen CSF
P11819326A0000 |248 258|volunteersr displace
P11819326A0000 |170 179|cirrhosis-] is sho
P11819326A0000 |0 3|AIMP00
P11821098A0269 |68 70|B.as
P11821098A0269 |46 48|LHat
P11821098A0269 |54 63|inhibin And 5-nucl
P11821098A0269 |25 37|Serum levels with alkali
P11821098A0269 |41 44|FSHhos
P11821098A0269 |21 22|Si
P11821098A0269 |0 20|MAIN OUTCOME MEASUREP00001606T0076 Compa
P11822790A0907 |49 56|patientses and
P11822790A0907 |22 31|SIP scoreson with 
P11822790A0907 |197 202|itemsf CSF
P11822790A0907 |125 141|study populationrbilirubinemia. 
P11822790A0907 |215 226|improvementa of K-depl
P11822790A0907 |88 95|exampleharmaco
P11822790A0907 |4 12|instance01606T00
P11822790A0907 |234 255|reproducibility noises are no longer displ
P11822790A0907 |112 117|scoreneona
P11822790A0907 |64 65|%o
P11822790A0907 |175 176|% 
P11822811A0319 |0 5|GroupP0000
P11822811A0319 |132 144|intoxicationbinemia. P00
P11822811A0319 |61 86|microg/kg ivermectin p.o.cleotidase P00008171T0000
P11822811A0319 |120 125|hours hype
P11822811A0319 |26 33|Collieswith al
P11822811A0319 |113 117|VMTHeona
P11824701A0894 |34 39|eventaline
P11824701A0894 |149 154|event7A047
P11824701A0894 |92 106|Bortner scoresacologic aspec
P11824701A0894 |56 60|Type 5-n
P11824701A0894 |63 80|behavior patternseotidase P0000817
P11824701A0894 |112 120|patientsneonatal
P11824701A0894 |0 8|PatientsP0000160
P11824801A0661 |137 145|minorityia. P000
P11824801A0661 |61 69|presencecleotida
P11824801A0661 |15 27|continuationComparison w
P11824801A0661 |92 104|exacerbationacologic asp
P11824801A0661 |108 119|sarcoidosis of neonata
P11824801A0661 |149 157|patients7A0472 W
P11824801A0661 |175 192|organ involvement shown as a funct
P11824801A0661 |35 53|interferon therapyline phosphatases 
P11825801A1212 |27 36|mortalityith alkal
P11825801A1212 |63 72|follow-upeotidase 
P11825801A1212 |79 85|months71T000
P11826141T0000 |84 92|amygdala00 Pharm
P11826141T0000 |12 19|effects76 Comp
P11826141T0000 |149 157|behavior7A0472 W
P11826141T0000 |53 60|rostraland 5-n
P11826141T0000 |23 45|lidocaine inactivationon with alkaline phosp
P11826141T0000 |161 165|ratsCSF 
P11826141T0000 |116 129|reinstatementatal hyperbil
P11826141T0000 |100 111|maintenance aspects of
P11828186A0239 |68 73|yearsase P
P11828186A0239 |92 105|heart diseaseacologic aspe
P11828186A0239 |195 205|NHANES III of CSF PC
P11828186A0239 |165 193|Nutrition Examination Survey[HCO3-] is shown as a functi
P11828186A0239 |115 131|CRP measurementsnatal hyperbilir
P11828186A0239 |38 41|mene p
P11828186A0239 |4 14|population01606T0076
P11828186A0239 |139 160|Third National Health. P00008997A0472 When
P11828186A0239 |51 56|womens and
P11830544A0335 |137 150|WIBC-9 tumorsia. P00008997
P11830544A0335 |66 70|sizeidas
P11830544A0335 |176 195|control MC-5 tumorsshown as a function
P11830544A0335 |75 77|nm00
P11830544A0335 |32 37|HER-2lkali
P11830544A0335 |86 93|1B4M-Gd Pharma
P11830544A0335 |38 49|neu antigene phosphata
P11830544A0335 |222 234|angiogenesisdepleted rat
P11830544A0335 |0 9|HerceptinP00001606
P11831512A0468 |239 246|lactose no lon
P11831512A0468 |92 102|treatmentsacologic a
P11831512A0468 |177 181|gramhown
P11831512A0468 |120 127|lactose hyperb
P11831512A0468 |45 46|dh
P11831512A0468 |186 190|gram fun
P11831512A0468 |50 53|agees 
P11831512A0468 |223 225|DEep
P11831512A0468 |261 266|DE-42hen c
P11831512A0468 |159 166|lactosen CSF [
P11831512A0468 |12 16|pigs76 C
P11831512A0468 |107 114|controls of ne
P11831512A0468 |135 154|carbohydrate sourceemia. P00008997A047
P11831512A0468 |197 200|CSSf C
P11831512A0468 |202 221|dextrose equivalent PCO2 the data of K
P11832019A0668 |51 68|emergency diseases and 5-nucleotid
P11832019A0668 |13 17|AMVT6 Co
P11832019A0668 |0 11|CONCLUSIONSP00001606T0
P11833863A0987 |71 80|positions P0000817
P11833863A0987 |13 23|difference6 Comparis
P11833863A0987 |27 41|apnea durationith alkaline p
P11833863A0987 |54 60|supinend 5-n
P11834476A1187 |274 284|protectionto control
P11834476A1187 |22 34|animal modelson with alk
P11834476A1187 |94 97|minolo
P11834476A1187 |72 83|transfusionP00008171T0
P11834476A1187 |104 112|ischemiaects of 
P11834476A1187 |138 160|hemoglobin transfusiona. P00008997A0472 When
P11834476A1187 |54 62|ischemiand 5-nuc
P11834476A1187 |173 189|oxygen transportis shown as a fu
P11834476A1187 |206 212|cortex2 the 
P11834476A1187 |222 230|increasedepleted
P11835109A0000 |117 121|lifetal 
P11835109A0000 |166 175|disordersHCO3-] is
P11835109A0000 |132 140|patientsbinemia.
P11835109A0000 |197 203|trialsf CSF 
P11835109A0000 |123 127|HRQLperb
P11835109A0000 |106 113|qualityts of n
P11835109A0000 |65 75|importancetidase P00
P11835109A0000 |48 57|awarenessases and 
P11836046A0549 |239 247|estrogen no long
P11836046A0549 |80 82|mg1T
P11836046A0549 |112 115|endneo
P11836046A0549 |297 302|monthave a
P11836046A0549 |145 152|group A08997A0
P11836046A0549 |57 74|calcium carbonate5-nucleotidase P0
P11836046A0549 |121 125|mealhype
P11836046A0549 |211 217|mg/day data 
P11836046A0549 |163 180|calcium carbonateF [HCO3-] is show
P11836046A0549 |193 199|manneron of 
P11836046A0549 |132 137|timesbinem
P11836046A0549 |254 277|mg medrogestone acetatelaced when compared to 
P11836046A0549 |51 53|mgs 
P11836046A0549 |154 155|n2
P11836046A0549 |96 103|calciumogic as
P11836046A0549 |313 314|nt
P11836046A0549 |283 286|dayls 
P11836046A0549 |140 143|day P0
P11836046A0549 |304 311|group Bignific
P11836303A0518 |0 8|TNFalphaP0000160
P11836303A0518 |13 24|IL-6 levels6 Compariso
P11836303A0518 |48 68|culture supernatantsases and 5-nucleotid
P11836303A1191 |16 21|studyompar
P11836303A1191 |53 64|disturbanceand 5-nucle
P11836303A1191 |162 167|stageSF [H
P11836303A1191 |96 112|cytokine biologyogic aspects of 
P11836303A1191 |86 92|change Pharm
P11837409A0584 |102 116|symptomatologyspects of neon
P11837409A0584 |24 51|National Longitudinal Studyn with alkaline phosphatase
P11837409A0584 |135 143|intervalemia. P0
P11837409A0584 |80 87|measure1T0000 
P11837409A0584 |55 72|Adolescent Healthd 5-nucleotidase 
P11838058A0084 |0 7|METHODSP000016
P11838058A0084 |46 62|tissue expansionatases and 5-nuc
P11838058A0084 |134 138|CPTEnemi
P11838058A0084 |76 81|cases08171
P11838058A0084 |160 165|study CSF 
P11838058A0084 |11 16|cases076 C
P11838058A0084 |64 68|CITEotid
P11838058A0084 |116 132|tissue expansionatal hyperbiliru
P11838102T0001 |0 7|WegenerP000016
P11838102T0001 |10 24|granulomatosis0076 Compariso
P11840365A0949 |34 44|hematocritaline phos
P11840365A0949 |52 72|General Health scale and 5-nucleotidase 
P11840365A0949 |24 30|effectn with
P11840365A0949 |80 85|SF-361T000
P11840365A0949 |87 88|PP
P11842037A0327 |86 91|value Phar
P11842037A0327 |37 62|% urine-plasma differencene phosphatases and 5-nuc
P11842037A0327 |18 28|precisionsparison wi
P11842728X0001 |85 97|blood flukes0 Pharmacolo
P11842728X0001 |37 51|Schistosomosisne phosphatase
P11842728X0001 |105 122|Schistosoma genuscts of neonatal h
P11842728X0001 |66 74|diseasesidase P0
P11842728X0001 |20 35|schistosomiasisrison with alka
P11843252A0907 |34 55|% confidence intervalaline phosphatases an
P11843252A0907 |9 22|response rateT0076 Compari
P11843252A0907 |29 30|%h
P11843252A0907 |97 105|survivalgic aspe
P11843252A0907 |67 68|%d
P11843252A0907 |59 63|% CInucl
P11843252A0907 |113 119|monthseonata
P11843252A0907 |71 72|% 
P11844591A0329 |68 71|APTase
P11844591A0329 |22 31|parameterson with 
P11844591A0329 |38 43|anglee pho
P11844591A0329 |55 66|peak torqued 5-nucleot
P11844812A0915 |137 143|PSA-TZia. P0
P11844812A0915 |126 127|Pb
P11844812A0915 |199 200|PC
P11844812A0915 |160 171|PSA density CSF [HCO3-
P11844812A0915 |182 197|prostate volumeas a function o
P11844812A0915 |121 124|PSAhyp
P11844812A0915 |45 58|ANN ROC curvehatases and 5
P11844812A0915 |17 28|ng/mL modelmparison wi
P11844812A0915 |93 97|AUCscolo
P11844812A0915 |145 146|P0
P11844812A0915 |34 37|AUCali
P11844812A0915 |102 112|percentagespects of 
P11845547A0449 |70 86|21-aminosteroidse P00008171T0000
P11845547A0449 |29 39|dobutamineh alkaline
P11845547A0449 |41 64|KATP channel activatorshosphatases and 5-nucle
P11845547A0449 |10 20|treatments0076 Compa
P11846167A0000 |0 8|SeleniumP0000160
P11846167A0000 |73 87|microorganisms00008171T0000 
P11846167A0000 |62 69|speciesleotida
P11846167A0000 |45 52|animalshatases
P11846167A0000 |25 32|element with a
P11846167A0000 |37 43|humansne pho
P11846187A0894 |4 23|GT-foreign-pictures01606T0076 Comparis
P11846187A0894 |94 117|permeability directionsologic aspects of neona
P11846187A0894 |40 48|judgmentphosphat
P11846187A0894 |58 66|subjects-nucleot
P11847580T0000 |41 49|findingshosphata
P11847580T0000 |14 27|cholecystitis Comparison w
P11849417A0900 |171 182|HD patients] is shown 
P11849417A0900 |67 74|RESULTSdase P0
P11849417A0900 |30 36|groups alkal
P11849417A0900 |139 144|years. P00
P11849417A0900 |83 93|initiation000 Pharma
P11849417A0900 |97 117|dialysis PD patientsgic aspects of neona
P11849417A0900 |154 155|P2
P11849417A0900 |0 3|AgeP00
P11849796A0452 |0 7|RESULTSP000016
P11849796A0452 |122 133|IMRT fieldsyperbilirub
P11849796A0452 |47 53|3D-CRTtases 
P11849796A0452 |13 24|target dose6 Compariso
P11849796A0452 |79 91|improvements71T0000 Phar
P11849796A0452 |58 68|IMRT plans-nucleotid
P11851941A0372 |70 82|blood volumee P00008171T
P11851941A0372 |211 214|HES da
P11851941A0372 |134 145|haemoglobinnemia. P000
P11851941A0372 |37 56|serumalbumin methodne phosphatases and
P11851941A0372 |89 102|haemodilutionarmacologic a
P11851941A0372 |150 160|comparisonA0472 When
P11851941A0372 |190 209|hydroxyethyl starchction of CSF PCO2 t
P11851941A0372 |168 186|reference solutionO3-] is shown as a
P11852907A0871 |136 141|ordermia. 
P11852907A0871 |88 99|SRP contentharmacologi
P11852907A0871 |45 57|surface soilhatases and 
P11852907A0871 |36 40|EPC0ine 
P11852907A0871 |145 154|magnitude08997A047
P11852907A0871 |126 130|farmbili
P11852907A0871 |4 34|equilibrium phosphorus content01606T0076 Comparison with alk
P11852907A0871 |103 117|drainage waterpects of neona
P11853943A0122 |54 77|R-R interval estimationnd 5-nucleotidase P0000
P11853943A0122 |14 24|prediction Compariso
P11853943A0122 |40 49|algorithmphosphata
P11858256A0102 |34 45|explanationaline phosp
P11858256A0102 |54 60|effectnd 5-n
P11858256A0102 |21 29|researchison wit
P11858548A0241 |4 13|structure01606T007
P11858548A0241 |77 88|NMR spectra8171T0000 P
P11858548A0241 |40 45|studyphosp
P11858548A0241 |93 110|mass spectrometrycologic aspects o
P11858548A0241 |53 57|monoand 
P11858635A0896 |34 42|propertyaline ph
P11858635A0896 |74 94|LOO cross-validation0008171T0000 Pharmac
P11858635A0896 |46 57|QSAR modelsatases and 
P11859400A0229 |16 24|efficacyompariso
P11859400A0229 |209 218|acyclovirhe data o
P11859400A0229 |149 153|APCT7A04
P11859400A0229 |88 91|HSVhar
P11859400A0229 |225 240|HSV prophylaxisleted rats are 
P11859400A0229 |180 188|controlsn as a f
P11859400A0229 |38 50|valacyclovire phosphatas
P11859400A0229 |65 81|HSV reactivationtidase P00008171
P11859400A0229 |29 34|costsh alk
P11859400A0229 |116 147|progenitor cell transplantationatal hyperbilirubinemia. P00008
P11859400A0229 |155 163|patients When CS
P11859943A0150 |118 146|General Health Questionnaireal hyperbilirubinemia. P0000
P11859943A0150 |25 43|outpatient clinics with alkaline pho
P11859943A0150 |90 94|daysrmac
P11859943A0150 |4 10|adults01606T
P11859943A0150 |64 72|hospitalotidase 
P11860097A1695 |119 135|prosthesis usersl hyperbilirubin
P11860097A1695 |8 22|prosthesis use6T0076 Compari
P11860097A1695 |107 114|outcomes of ne
P11860097A1695 |61 66|studycleot
P11860097A1695 |140 149|non-users P0000899
P11860097A1695 |0 4|DataP000
P11860723A0182 |17 32|Georgia membersmparison with a
P11860723A0182 |40 56|American Collegephosphatases and
P11860723A0182 |60 73|Obstetriciansucleotidase P
P11860723A0182 |78 91|Gynecologists171T0000 Phar
P11860723A0182 |2 13|mail survey0001606T007
P11860876A0409 |0 15|HIV-1 C subtypeP00001606T0076 
P11860876A0409 |42 43|%o
P11860876A0409 |19 23|IDUsaris
P11861092A0730 |305 320|HDI5000 scannergnificantly gre
P11861092A0730 |325 335|C5-2 probeslope (1.2
P11861092A0730 |291 294|Pimtil
P11861092A0730 |18 29|enhancementparison wit
P11861092A0730 |158 161|FGSen 
P11861092A0730 |52 58|lesion and 5
P11861092A0730 |176 190|colour Dopplershown as a fun
P11861092A0730 |210 223|power Dopplere data of K-d
P11861092A0730 |151 156|scale0472 
P11861092A0730 |351 353|WA00
P11861092A0730 |192 195|FCDion
P11861092A0730 |225 228|FPDlet
P11861092A0730 |118 132|scanning modesal hyperbiliru
P11861092A0730 |259 262|HGS wh
P11861092A0730 |252 257|scalesplac
P11861092A0730 |337 340|ATL+/-
P11861092A0730 |7 14|plateau06T0076
P11861092A0730 |67 74|patientdase P0
P11861092A0730 |342 349|Bothell.23 vs.
P11861092A0730 |275 289|inversion modeo controls but
P11862350T0000 |153 160|traffic72 When
P11862350T0000 |60 95|NMDA receptor antagonist remacemideucleotidase P00008171T0000 Pharmaco
P11862350T0000 |131 142|performanceubinemia. P
P11862350T0000 |27 34|effectsith alk
P11862350T0000 |14 19|study Comp
P11862350T0000 |99 112|road trackingc aspects of 
P11862350T0000 |38 51|carbamazepinee phosphatase
P11863811A0259 |70 75|rangee P00
P11863811A0259 |79 81|Pr71
P11863811A0259 |26 40|Nusselt numberwith alkaline 
P11863811A0259 |59 60|%n
P11863811A0259 |97 107|experimentgic aspect
P11864173T0000 |32 38|causeslkalin
P11864173T0000 |80 90|bronchitis1T0000 Pha
P11864173T0000 |42 46|typeosph
P11864173T0000 |55 68|exacerbationsd 5-nucleotid
P11864173T0000 |19 28|pathogensarison wi
P11865218A0069 |0 9|TreatmentP00001606
P11865218A0069 |53 66|wax softeningand 5-nucleot
P11865218A0069 |44 47|usepha
P11865218A0069 |81 86|agentT0000
P11865218A0069 |19 28|conditionarison wi
P11866130A0419 |3 11|addition001606T0
P11866130A0419 |13 23|benzocaine6 Comparis
P11866130A0419 |109 128|quinaldine sulphateof neonatal hyperbi
P11866130A0419 |79 91|phagocytosis71T0000 Phar
P11866130A0419 |28 44|2-phenoxyethanolth alkaline phos
P11866130A0419 |99 104|MS222c asp
P11866130A0419 |55 74|complement activityd 5-nucleotidase P0
P11867388A0502 |237 238|Pr
P11867388A0502 |52 65|concentration and 5-nucleo
P11867388A0502 |95 112|fear conditioninglogic aspects of 
P11867388A0502 |89 90|%a
P11867388A0502 |182 199|fear conditioningas a function of 
P11867388A0502 |149 150|%7
P11867388A0502 |40 46|memoryphosph
P11867388A0502 |132 133|%b
P11867388A0502 |15 26|suppressionComparison 
P11867388A0502 |152 156|mean472 
P11867388A0502 |116 123|contextatal hy
P11867388A0502 |216 217|% 
P11867388A0502 |233 234|%t
P11867388A0502 |203 207|tonePCO2
P11867388A0502 |77 83|memory8171T0
P11867388A0502 |4 6|EC01
P11867388A0502 |168 171|SEMO3-
P11870646A0668 |4 11|utility01606T0
P11870646A0668 |127 133|damageilirub
P11870646A0668 |92 102|resistanceacologic a
P11870646A0668 |46 79|ceramic/substrate bilayer systemsatases and 5-nucleotidase P000081
P11870646A0668 |36 42|designine ph
P11870646A0668 |20 28|analysesrison wi
P11872359A0000 |152 155|CVD472
P11872359A0000 |215 226|Australiansa of K-depl
P11872359A0000 |26 44|insulin resistancewith alkaline phos
P11872359A0000 |46 48|IRat
P11872359A0000 |88 95|diseaseharmaco
P11872359A0000 |62 69|clusterleotida
P11872359A0000 |141 149|syndromeP0000899
P11872359A0000 |188 197|mortalityunction o
P11872359A0000 |97 100|CVDgic
P11872359A0000 |169 174|cause3-] i
P11872359A0000 |102 114|risk factorsspects of ne
P11872570T0000 |0 8|DementiaP0000160
P11872570T0000 |44 48|carephat
P11872570T0000 |29 32|NHSh a
P11873003X0000 |0 15|HIV-1 infectionP00001606T0076 
P11873003X0000 |188 203|HIV-1 infectionunction of CSF 
P11873003X0000 |82 90|survival0000 Pha
P11873003X0000 |25 31|Africa with 
P11873003X0000 |300 306|Uganda a sig
P11873003X0000 |209 223|seroconversionhe data of K-d
P11873003X0000 |167 184|progression timesCO3-] is shown as
P11873003X0000 |227 231|AIDSted 
P11873003X0000 |73 77|AIDS0000
P11873003X0000 |285 290|death but 
P11873003X0000 |44 54|differencephatases a
P11873003X0000 |250 254|timedisp
P11873003X0000 |65 69|timetida
P11873003X0000 |277 281|AIDScont
P11873003X0000 |128 137|countrieslirubinem
P11873003X0000 |139 149|OBJECTIVES. P0000899
P11873003X0000 |239 244|death no l
P11874637A0212 |84 96|improvements00 Pharmacol
P11874637A0212 |144 152|decrease008997A0
P11874637A0212 |40 47|therapyphospha
P11874637A0212 |245 257|malignanciesnger displac
P11874637A0212 |160 169|incidence CSF [HCO
P11874637A0212 |210 229|deficiency syndromee data of K-deplete
P11874637A0212 |104 113|treatmentects of n
P11874637A0212 |4 7|use016
P11874637A0212 |174 182|severitys shown 
P11874637A0212 |231 235|AIDSrats
P11874637A0212 |49 54|HAARTses a
P11874637A0212 |117 130|HIV infectiontal hyperbili
P11875695A0718 |0 4|TimeP000
P11875695A0718 |104 108|% CIects
P11875695A0718 |74 86|registration0008171T0000
P11875695A0718 |60 68|survivalucleotid
P11875695A0718 |8 19|progression6T0076 Comp
P11875695A0718 |94 100|monthsologic
P11875695A0718 |26 32|monthswith a
P11875695A0718 |114 120|monthsonatal
P11875695A0718 |38 44|monthse phos
P11876937A0261 |17 19|kgmp
P11876937A0261 |26 29|daywit
P11876937A0261 |133 136|dayine
P11876937A0261 |13 14|U6
P11876937A0261 |70 74|ratse P0
P11876937A0261 |99 105|salinec aspe
P11876937A0261 |78 85|H group171T000
P11876937A0261 |118 125|N groupal hype
P11876937A0261 |0 7|HeparinP000016
P11879108A0719 |0 20|MAIN OUTCOME MEASUREP00001606T0076 Compa
P11879108A0719 |183 205|immunodeficiency viruss a function of CSF PC
P11879108A0719 |91 118|ligase chain reaction assaymacologic aspects of neonat
P11879108A0719 |74 83|infection0008171T0
P11879108A0719 |22 23|As
P11879108A0719 |161 172|test resultCSF [HCO3-]
P11879108A0719 |130 145|outcome measurerubinemia. P000
P11879108A0719 |33 44|test resultkaline phos
P11879108A0719 |207 210|HIV th
P11881268A0000 |4 11|purpose01606T0
P11881268A0000 |78 114|exercise self-efficacy questionnaire171T0000 Pharmacologic aspects of ne
P11881268A0000 |142 147|women00008
P11881268A0000 |20 25|studyrison
P11881923A1256 |137 149|POST periodsia. P0000899
P11881923A1256 |11 27|lymphocyte ratio076 Comparison w
P11881923A1256 |29 47|plasma haptoglobinh alkaline phospha
P11881923A1256 |107 113|periods of n
P11881923A1256 |78 79|P1
P11881923A1256 |177 187|treatmentshown as a 
P11881923A1256 |130 133|PRErub
P11881923A1256 |53 63|CBG levelsand 5-nucl
P11881923A1256 |0 10|NeutrophilP00001606T
P11882054A0568 |152 156|ROIs472 
P11882054A0568 |231 244|lesion volumerats are no l
P11882054A0568 |59 69|structuresnucleotida
P11882054A0568 |131 138|regionsubinemi
P11882054A0568 |104 109|pairsects 
P11882054A0568 |18 25|lesionsparison
P11882054A0568 |191 197|slicestion o
P11882054A0568 |142 150|interest00008997
P11882054A0568 |71 82|FMZ binding P00008171T
P11882054A0568 |253 266|mirror regionplaced when c
P11882054A1250 |254 264|epilepsieslaced when
P11882054A1250 |209 219|mechanismshe data of
P11882054A1250 |132 142|epilepsiesbinemia. P
P11882054A1250 |74 90|spiking activity0008171T0000 Pha
P11882054A1250 |45 54|decreaseshatases a
P11882054A1250 |58 69|FMZ binding-nucleotida
P11882054A1250 |193 201|relationon of CS
P11882054A1250 |167 178|FMZ bindingCO3-] is sh
P11882054A1250 |223 238|epileptogenesisepleted rats ar
P11882054A1250 |16 27|correlationomparison w
P11882747A0354 |0 2|CDP0
P11882747A0354 |28 50|Farnsworth D-15 methodth alkaline phosphatas
P11883682A0162 |51 56|spills and
P11883682A0162 |91 97|metalsmacolo
P11883682A0162 |105 124|estuarine sedimentscts of neonatal hyp
P11883682A0162 |22 32|monitoringson with a
P11883682A0162 |69 81|distributionse P00008171
P11883763A1062 |205 217|Pu transportO2 the data 
P11883763A1062 |10 16|fluxes0076 C
P11883763A1062 |124 129|slopeerbil
P11883763A1062 |149 154|layer7A047
P11883763A1062 |250 264|East China Seadisplaced when
P11883763A1062 |83 92|particles000 Pharm
P11883763A1062 |27 29|Puit
P11883763A1062 |70 79|transporte P000081
P11883763A1062 |237 242|slopere no
P11884014A0665 |33 46|diet deliverykaline phosph
P11884014A0665 |74 81|effects0008171
P11884014A0665 |63 65|GIeo
P11884014A0665 |9 28|treatment protocolsT0076 Comparison wi
P11885053A1897 |65 72|objectstidase 
P11885053A1897 |135 142|objectsemia. P
P11885053A1897 |164 179|memorial shrine [HCO3-] is sho
P11885053A1897 |47 53|groupstases 
P11885053A1897 |37 43|Volkanne pho
P11885737A1713 |4 9|range01606
P11885737A1713 |29 47|spermatozoa/microlh alkaline phospha
P11885737A1713 |76 86|compromise08171T0000
P11885737A1713 |96 104|criteriaogic asp
P11886473A0796 |0 15|Gastritis scoreP00001606T0076 
P11886473A0796 |83 84|p0
P11886473A0796 |93 96|nodcol
P11886473A0796 |123 127|CagAperb
P11886473A0796 |130 131|pr
P11886473A0796 |105 106|pc
P11886473A0796 |152 158|antrum472 Wh
P11886473A0796 |118 121|nodal 
P11886473A0796 |48 52|CagAases
P11886473A0796 |54 62|childrennd 5-nuc
P11886473A0796 |163 169|corpusF [HCO
P11886473A0796 |76 80|CagA0817
P11886473A0796 |43 46|nodsph
P11886473A0796 |98 102|CagAic a
P11886473A0796 |71 74|nod P0
P11887803A1455 |239 240|p 
P11887803A1455 |178 182|CAPDown 
P11887803A1455 |230 237|Balance rats a
P11887803A1455 |162 166|ratsSF [
P11887803A1455 |79 86|animals71T0000
P11887803A1455 |148 158|peritoneum97A0472 Wh
P11887803A1455 |122 130|fibrosisyperbili
P11887803A1455 |223 227|CAPDeple
P11887803A1455 |4 18|mean thickness01606T0076 Com
P11887803A1455 |202 209|animals PCO2 t
P11887803A1455 |35 45|peritoneumline phosp
P11887803A1455 |69 75|groupsse P00
P11888183A0541 |86 94|duration Pharmac
P11888183A0541 |58 75|maximum intensity-nucleotidase P00
P11888183A0541 |10 18|analysis0076 Com
P11888183A0541 |134 140|maximanemia.
P11888183A0541 |112 115|hrsneo
P11888183A0541 |48 54|seriesases a
P11888867A0000 |205 213|survivalO2 the d
P11888867A0000 |217 225|patientsof K-dep
P11888867A0000 |173 184|correlationis shown as
P11888867A0000 |66 73|TA90-ICidase P
P11888867A0000 |245 254|melanomasnger disp
P11888867A0000 |122 129|antigenyperbil
P11888867A0000 |0 10|BACKGROUNDP00001606T
P11888867A0000 |138 146|antibodya. P0000
P11888867A0000 |190 200|recurrencection of C
P11888867A0000 |51 62|serum levels and 5-nuc
P11888867A0000 |85 92|complex0 Pharm
P11890354A0000 |0 18|Genetics InstituteP00001606T0076 Com
P11890354A0000 |46 56|oprelvekinatases and
P11890354A0000 |91 95|formmaco
P11890354A0000 |105 110|IL-11cts o
P11890354A0000 |58 65|rhIL-11-nucleo
P11890354A0000 |67 74|Neumegadase P0
P11890438A0838 |0 8|PatientsP0000160
P11890438A0838 |53 57|daysand 
P11890438A0838 |89 98|dressingsarmacolog
P11890438A0838 |38 44|clinice phos
P11890438A0838 |70 76|woundse P000
P11893403A0252 |85 93|exposure0 Pharma
P11893403A0252 |148 158|toxicology97A0472 Wh
P11893403A0252 |106 113|analogyts of n
P11893403A0252 |37 54|safety evaluationne phosphatases a
P11893403A0252 |127 143|pharmacokineticsilirubinemia. P0
P11893403A0252 |58 76|flavor ingredients-nucleotidase P000
P11893403A0252 |115 125|metabolismnatal hype
P11893403A0252 |0 8|ElementsP0000160
P11893767A0356 |85 86|O0
P11893767A0356 |26 44|minute ventilationwith alkaline phos
P11893767A0356 |46 47|Ea
P11893767A0356 |197 200|dayf C
P11893767A0356 |144 161|breathing pattern008997A0472 When 
P11893767A0356 |131 135|agesubin
P11893767A0356 |81 83|VET0
P11893767A0356 |69 79|equivalentse P000081
P11894605A1429 |0 14|INTERPRETATIONP00001606T0076
P11894605A1429 |232 243|advertisingats are no 
P11894605A1429 |77 95|health information8171T0000 Pharmaco
P11894605A1429 |210 216|amounte data
P11894605A1429 |195 202|changes of CSF
P11894605A1429 |138 148|motivationa. P000089
P11894605A1429 |175 181|result shown
P11894605A1429 |99 106|smokingc aspec
P11894605A1429 |50 60|dissonancees and 5-n
P11894605A1429 |221 228|content-deplet
P11895024A1054 |5 10|cases1606T
P11895024A1054 |14 17|GBS Co
P11895024A1054 |30 32|TM a
P11895024A1054 |56 72|AFP surveillance 5-nucleotidase 
P11895024A1054 |95 112|hospital searcheslogic aspects of 
P11895184A0000 |68 80|object-placease P0000817
P11895184A0000 |149 175|cheeseboard maze apparatus7A0472 When CSF [HCO3-] is
P11895184A0000 |15 19|ratsComp
P11895184A0000 |82 92|odor-place0000 Pharm
P11895184A0000 |25 32|control with a
P11895184A0000 |126 130|taskbili
P11895184A0000 |4 11|ability01606T0
P11895184A0000 |48 55|lesionsases an
P11897449A0566 |205 209|meanO2 t
P11897449A0566 |26 41|activation sitewith alkaline p
P11897449A0566 |108 111|RFA of
P11897449A0566 |194 203|beats/minn of CSF 
P11897449A0566 |220 229|beats/minK-deplete
P11897449A0566 |48 62|administrationases and 5-nuc
P11897449A0566 |113 120|RESULTSeonatal
P11897449A0566 |126 136|heart ratebilirubine
P11897449A0566 |66 73|esmololidase P
P11897449A0566 |96 101|shiftogic 
P11897449A0566 |162 167|stateSF [H
P11897449A0566 |140 144|rest P00
P11897449A0566 |4 9|shift01606
P11897888A0590 |34 48|administrationaline phosphat
P11897888A0590 |58 69|supplements-nucleotida
P11897888A0590 |0 13|Urine samplesP00001606T007
P11897950A0617 |0 11|CONCLUSIONSP00001606T0
P11897950A0617 |134 141|eyelidsnemia. 
P11897950A0617 |92 109|drainage pathwaysacologic aspects 
P11897950A0617 |183 189|eyelids a fu
P11897950A0617 |13 31|Lymphoscintigraphy6 Comparison with 
P11897950A0617 |39 64|cynomolgus monkey eyelids phosphatases and 5-nucle
P11897950A0617 |153 160|pathway72 When
P11898018T0000 |34 42|researchaline ph
P11898018T0000 |0 15|Data managementP00001606T0076 
P11898797A0124 |205 216|innervationO2 the data
P11898797A0124 |107 115|patientss of neo
P11898797A0124 |176 180|lossshow
P11898797A0124 |133 144|head injuryinemia. P00
P11898797A0124 |46 80|choline acetyltransferase activityatases and 5-nucleotidase P0000817
P11898797A0124 |97 103|cortexgic as
P11898797A0124 |36 42|levelsine ph
P11899479A0122 |69 75|palatese P00
P11899479A0122 |25 32|lesions with a
P11899479A0122 |61 67|cheekscleoti
P11899479A0122 |186 203|CHROMagar Candida function of CSF 
P11899479A0122 |115 132|cotton wool swabsnatal hyperbiliru
P11899479A0122 |216 229|yeast species of K-deplete
P11899479A0122 |323 336|kit AuxaColorr slope (1.21
P11899479A0122 |251 260|germ tubeisplaced 
P11899479A0122 |53 59|tongueand 5-
P11899479A0122 |96 111|denture surfaceogic aspects of
P11899479A0122 |13 19|smears6 Comp
P11899479A0122 |45 51|mucosahatase
P11899479A0122 |279 297|assimilation testsntrols but still h
P11899479A0122 |169 181|glucose agar3-] is shown
P11899489A0119 |4 11|effects01606T0
P11899489A0119 |58 62|care-nuc
P11899489A0119 |125 130|stagerbili
P11899489A0119 |31 40|treatmentalkaline 
P11899489A0119 |92 100|dementiaacologic
P11899489A0119 |67 74|supportdase P0
P11900770T0000 |33 44|attenuationkaline phos
P11900770T0000 |75 103|dopamine receptor antagonism008171T0000 Pharmacologic as
P11900770T0000 |61 67|impactcleoti
P11900770T0000 |21 31|incentivesison with 
P11902068T0000 |18 25|journeyparison
P11902068T0000 |4 15|CKD patient01606T0076 
P11902738A0185 |0 8|PATIENTSP0000160
P11902738A0185 |52 64|cohort study and 5-nucle
P11902738A0185 |131 136|feverubine
P11902738A0185 |27 32|studyith a
P11902738A0185 |177 193|neutrophil counthown as a functi
P11902738A0185 |72 80|childrenP0000817
P11902738A0185 |13 20|METHODS6 Compa
P11902738A0185 |141 152|neutropeniaP00008997A0
P11902738A0185 |200 209|cells/mm3SF PCO2 t
P11902738A0185 |114 125|institutiononatal hype
P11902738A0185 |86 92|cancer Pharm
P11902738A0185 |223 229|periodeplete
P11902781A0550 |0 14|ConcentrationsP00001606T0076
P11902781A0550 |128 134|seasonlirubi
P11902781A0550 |43 52|Deoprayagsphatases
P11902781A0550 |95 99|mg/Llogi
P11902781A0550 |31 32|Na
P11902781A0550 |38 39|Ne
P11902781A0550 |20 22|O3ri
P11902781A0550 |25 26|N 
P11902781A0550 |18 19|Np
P11902781A0550 |33 35|H3ka
P11904017A0000 |102 105|bedspe
P11904017A0000 |147 153|region997A04
P11904017A0000 |130 134|flowrubi
P11904017A0000 |30 37|process alkali
P11904017A0000 |177 183|systemhown a
P11904017A0000 |57 67|blood flow5-nucleoti
P11907691A0214 |51 60|locationss and 5-n
P11907691A0214 |96 100|massogic
P11907691A0214 |77 83|object8171T0
P11907691A0214 |24 40|contact surfacesn with alkaline 
P11907691A0214 |4 16|orientations01606T0076 C
P11907691A0214 |86 92|center Pharm
P11908529A0553 |32 38|numberlkalin
P11908529A0553 |26 30|fluxwith
P11908529A0553 |183 190|objectss a fun
P11908529A0553 |120 133|AgCl crystals hyperbilirub
P11908529A0553 |110 118|plasticsf neonat
P11908529A0553 |77 87|comparison8171T0000 
P11908529A0553 |135 138|LiFemi
P11908529A0553 |158 164|regionen CSF
P11908529A0553 |52 55|cm3 an
P11908529A0553 |57 63|charge5-nucl
P11908529A0553 |141 152|energy lossP00008997A0
P11908529A0553 |99 108|detectorsc aspects
P11908529A0553 |42 47|starsospha
P11908529A0553 |4 11|results01606T0
P11908529A0553 |71 75|ions P00
P11909404A0000 |34 42|functionaline ph
P11909404A0000 |56 60|sign 5-n
P11909404A0000 |6 13|domains606T007
P11909404A0000 |18 25|regionsparison
P11910310A0279 |0 6|DESIGNP00001
P11910310A0279 |58 63|trial-nucl
P11910344A1119 |0 11|CONCLUSIONSP00001606T0
P11910344A1119 |79 83|type71T0
P11910344A1119 |45 50|studyhatas
P11910344A1119 |65 73|patientstidase P
P11910344A1119 |158 166|increaseen CSF [
P11910344A1119 |127 135|functionilirubin
P11910344A1119 |86 89|HRS Ph
P11910344A1119 |170 178|survival-] is sh
P11911552A0776 |102 111|remissionspects of
P11911552A0776 |124 129|rangeerbil
P11911552A0776 |82 86|dose0000
P11911552A0776 |144 148|mg/d0089
P11911552A0776 |27 37|quetiapineith alkali
P11911552A0776 |39 46|therapy phosph
P11911552A0776 |3 11|patients001606T0
P11912261A0284 |85 93|receptor0 Pharma
P11912261A0284 |13 19|agents6 Comp
P11912261A0284 |134 144|experiencenemia. P00
P11912261A0284 |37 50|PTH secretionne phosphatas
P11912261A0284 |113 119|glandseonata
P11912677A0281 |101 109|data setaspects 
P11912677A0281 |10 18|analysis0076 Com
P11912677A0281 |74 85|variability0008171T000
P11912677A0281 |54 63|structurend 5-nucl
P11912677A0281 |33 43|hypotheseskaline pho
P11913427A0290 |115 120|errornatal
P11913427A0290 |133 135|g.in
P11913427A0290 |75 88|accelerations008171T0000 P
P11913427A0290 |66 71|valueidase
P11913427A0290 |4 12|subjects01606T00
P11915436A0491 |55 60|ratesd 5-n
P11915436A0491 |13 28|incidence rates6 Comparison wi
P11915436A0491 |76 86|population08171T0000
P11917061A0922 |171 172|P]
P11917061A0922 |72 83|cyclosporinP00008171T0
P11917061A0922 |132 141|remissionbinemia. 
P11917061A0922 |88 98|prednisoneharmacolog
P11917061A0922 |60 68|responseucleotid
P11917061A0922 |22 30|responseson with
P11917061A0922 |9 18|predictorT0076 Com
P11917061A0922 |160 161|% 
P11917061A0922 |143 157|remission rate0008997A0472 W
P11917061A0922 |34 44|tacrolimusaline phos
P11917882A0326 |84 91|dentine00 Phar
P11917882A0326 |140 157|adhesion-strategy P00008997A0472 W
P11917882A0326 |52 61|interface and 5-nu
P11917882A0326 |25 30|study with
P11917882A0326 |71 80|selection P0000817
P11917882A0326 |101 108|systemsaspects
P11920455X1195 |0 9|CopyrightP00001606
P11920455X1195 |15 38|American Cancer SocietyComparison with alkalin
P11920455X1195 |39 42|DOI ph
P11920455X1195 |55 61|.10318d 5-nu
P11920896A0298 |153 156|FPR72 
P11920896A0298 |121 126|womenhyper
P11920896A0298 |61 65|testcleo
P11920896A0298 |38 40|DRe 
P11920896A0298 |8 13|study6T007
P11920896A0298 |147 151|rate997A
P11920896A0298 |168 169|%O
P11920896A0298 |84 94|population00 Pharmac
P11921126A1196 |68 75|aspectsase P00
P11921126A1196 |27 34|STN-DBSith alk
P11921126A1196 |109 111|PDof
P11921126A1196 |79 82|QoL71T
P11921126A1196 |86 94|patients Pharmac
P11921126A1196 |19 25|PDQ-39arison
